{"drugbank": {"@xmlns": "http://www.drugbank.ca", "@xmlns:xsi": "http://www.w3.org/2001/XMLSchema-instance", "@xsi:schemaLocation": "http://www.drugbank.ca http://www.drugbank.ca/docs/drugbank.xsd", "@version": "4.3", "drug": [{"@type": "biotech", "@created": "2005-06-13", "@updated": "2015-02-23", "drugbank-id": [{"@primary": "true", "#text": "DB00001"}, "BIOD00024", "BTD00024"], "name": "Lepirudin", "description": "Lepirudin is identical to natural hirudin except for substitution of leucine for isoleucine at the N-terminal end of the molecule and the absence of a sulfate group on the tyrosine at position 63. It is produced via yeast cells. Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.", "cas-number": "120993-53-5", "groups": {"group": "approved"}, "general-references": "# Smythe MA, Stephens JL, Koerber JM, Mattson JC: A comparison of lepirudin and argatroban outcomes. Clin Appl Thromb Hemost. 2005 Oct;11(4):371-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16244762\n# Tardy B, Lecompte T, Boelhen F, Tardy-Poncet B, Elalamy I, Morange P, Gruel Y, Wolf M, Francois D, Racadot E, Camarasa P, Blouch MT, Nguyen F, Doubine S, Dutrillaux F, Alhenc-Gelas M, Martin-Toutain I, Bauters A, Ffrench P, de Maistre E, Grunebaum L, Mouton C, Huisse MG, Gouault-Heilmann M, Lucke V: Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood. 2006 Sep 1;108(5):1492-6. Epub 2006 May 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16690967\n# Lubenow N, Eichler P, Lietz T, Greinacher A: Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost. 2005 Nov;3(11):2428-36. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16241940\n# Askari AT, Lincoff AM: Antithrombotic Drug Therapy in Cardiovascular Disease. 2009 Oct; pp. 440\u2013. ISBN 9781603272346. \"Google books\":http://books.google.com/books?id=iadLoXoQkWEC&pg=PA440.", "synthesis-reference": null, "indication": "For the treatment of heparin-induced thrombocytopenia", "pharmacodynamics": "Lepirudin is used to break up clots and to reduce thrombocytopenia. It binds to thrombin and prevents thrombus or clot formation. It is a highly potent, selective, and essentially irreversible inhibitor of thrombin and clot-bond thrombin. Lepirudin requires no cofactor for its anticoagulant action. Lepirudin is a recombinant form of hirudin, an endogenous anticoagulant found in medicinal leeches.", "mechanism-of-action": "Lepirudin forms a stable non-covalent complex with alpha-thrombin, thereby abolishing its ability to cleave fibrinogen and initiate the clotting cascade. The inhibition of thrombin prevents the blood clotting cascade.", "toxicity": "In case of overdose (eg, suggested by excessively high aPTT values) the risk of bleeding is increased.", "metabolism": "Lepirudin is thought to be metabolized by release of amino acids via catabolic hydrolysis of the parent drug. However, con-clusive data are not available. About 48% of the administration dose is excreted in the urine which consists of unchanged drug (35%) and other fragments of the parent drug.", "absorption": "Bioavailability is 100% following injection.", "half-life": "Approximately 1.3 hours", "protein-binding": null, "route-of-elimination": "Lepirudin is thought to be metabolized by release of amino acids via catabolic hydrolysis of the parent drug. About 48% of the administration dose is excreted in the urine which consists of unchanged drug (35%) and other fragments of the parent drug.", "volume-of-distribution": "* 12.2 L [Healthy young subjects (n = 18, age 18-60 years)]\n* 18.7 L [Healthy elderly subjects (n = 10, age 65-80 years)]\n* 18 L [Renally impaired patients (n = 16, creatinine clearance below 80 mL/min)]\n* 32.1 L [HIT patients (n = 73)]", "clearance": "* 164 ml/min [Healthy 18-60 yrs]\n* 139 ml/min [Healthy 65-80 yrs]\n* 61 ml/min [renal impaired]\n* 114 ml/min [HIT (Heparin-induced thrombocytopenia)]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": {"@language": "", "@coder": "", "#text": "Hirudin variant-1"}}, "products": {"product": {"name": "Refludan", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02240996", "started-marketing-on": "2000-01-31", "ended-marketing-on": "2013-07-26", "dosage-form": "powder for solution", "strength": "50 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}}, "international-brands": null, "mixtures": {"mixture": {"name": "Refludan", "ingredients": "Lepirudin"}}, "packagers": {"packager": [{"name": "Bayer Healthcare", "url": "http://www.bayerhealthcare.com"}, {"name": "Berlex Labs", "url": "http://www.berlex.com"}]}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Bayer healthcare pharmaceuticals inc"}}, "prices": {"price": {"description": "Refludan 50 mg vial", "cost": {"@currency": "USD", "#text": "273.19"}, "unit": "vial"}}, "categories": {"category": [{"category": "Antithrombins", "mesh-id": null}, {"category": "Fibrinolytic Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": {"form": "Powder for solution", "route": "intravenous", "strength": "50 mg"}}, "atc-codes": {"atc-code": {"@code": "B01AE02", "level": [{"@code": "B", "#text": "BLOOD AND BLOOD FORMING ORGANS"}, {"@code": "B01", "#text": "ANTITHROMBOTIC AGENTS"}, {"@code": "B01A", "#text": "ANTITHROMBOTIC AGENTS"}, {"@code": "B01AE", "#text": "Direct thrombin inhibitors"}]}}, "ahfs-codes": {"ahfs-code": "20:12.04.12"}, "patents": {"patent": [{"number": "1339104", "country": "Canada", "approved": "1997-07-29", "expires": "2014-07-29"}, {"number": "5180668", "country": "United States", "approved": "1993-01-19", "expires": "2010-01-19"}]}, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00001 sequence\nLVYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIP\nEEYLQ"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "65 \u00b0C", "source": "Otto, A. & Seckler, R. Eur. J. Biochem. 202:67-73 (1991)"}, {"kind": "Hydrophobicity", "value": "-0.777", "source": null}, {"kind": "Isoelectric Point", "value": "4.04", "source": null}, {"kind": "Molecular Weight", "value": "6963.4250", "source": null}, {"kind": "Molecular Formula", "value": "C287H440N80O110S6", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "11916"}, {"resource": "KEGG Drug", "identifier": "D06880"}, {"resource": "National Drug Code Directory", "identifier": "50419-150-57"}, {"resource": "PharmGKB", "identifier": "PA450195"}, {"resource": "UniProtKB", "identifier": "P01050"}, {"resource": "Wikipedia", "identifier": "Lepirudin"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/lepirudin.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/lepirudin.html"}]}, "pathways": {"pathway": {"smpdb-id": "SMP00278", "name": "Lepirudin Action Pathway", "drugs": {"drug": [{"drugbank-id": "DB00001", "name": "Lepirudin"}, {"drugbank-id": "DB01022", "name": "Phylloquinone"}, {"drugbank-id": "DB01373", "name": "Calcium"}]}, "enzymes": {"uniprot-id": ["P00734", "P00748", "P02452", "P03952", "P03951", "P00740", "P00451", "P12259", "P00742", "P02671", "P02675", "P02679", "P00488", "P05160", "P00747", "P00750", "P08709", "P13726", "Q9BQB6", "P38435"]}}}, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0000048", "name": "Prothrombin", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Turpie AG: Anticoagulants in acute coronary syndromes. Am J Cardiol. 1999 Sep 2;84(5A):2M-6M. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10505536\n# Warkentin TE: Venous thromboembolism in heparin-induced thrombocytopenia. Curr Opin Pulm Med. 2000 Jul;6(4):343-51. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10912644\n# Eriksson BI: New therapeutic options in deep vein thrombosis prophylaxis. Semin Hematol. 2000 Jul;37(3 Suppl 5):7-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11055889\n# Fabrizio MC: Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass. J Extra Corpor Technol. 2001 May;33(2):117-25. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11467439\n# Szaba FM, Smiley ST: Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood. 2002 Feb 1;99(3):1053-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11807012\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P00734", "@source": "Swiss-Prot", "name": "Prothrombin", "general-function": "Involved in blood clotting cascade", "specific-function": "Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C", "gene-name": "F2", "locus": "11p11-q12", "cellular-location": "Secreted protein; extracellular space", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.7", "molecular-weight": "70037.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3535"}, {"resource": "GenAtlas", "identifier": "F2"}, {"resource": "GeneCards", "identifier": "F2"}, {"resource": "GenBank Gene Database", "identifier": "M17262"}, {"resource": "GenBank Protein Database", "identifier": "339641"}, {"resource": "UniProtKB", "identifier": "P00734"}, {"resource": "UniProt Accession", "identifier": "THRB_HUMAN"}]}, "synonyms": {"synonym": ["Activated Factor II [IIa]", "Coagulation factor II", "EC 3.4.21.5", "Prothrombin precursor", "Thrombin"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Prothrombin precursor\nMAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC\nVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV\nNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE\nCSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA\nQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG\nDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI\nDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN\nDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP\nVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST\nRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY\nGFYTHVFRLKKWIQKVIDQFGE"}, "gene-sequence": {"@format": "FASTA", "#text": ">1869 bp\nATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC\nCTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG\nGTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTAGAGCGAGAGTGC\nGTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG\nGATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT\nGCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG\nAACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT\nGAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC\nGACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA\nTGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA\nGGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG\nTACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA\nCAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC\nTTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT\nGGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA\nGATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC\nCAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT\nCTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC\nGACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG\nCTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG\nGTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT\nGACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACAAGGTACGAGCGAAACATTGAAAAG\nATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC\nCGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT\nGTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG\nGTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC\nAGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC\nCGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA\nGGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC\nCGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT\nGGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT\nGGAGAGTAG"}, "pfams": {"pfam": [{"identifier": "PF00594", "name": "Gla"}, {"identifier": "PF00051", "name": "Kringle"}, {"identifier": "PF00089", "name": "Trypsin"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "thrombin activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "binding"}, {"category": "process", "description": "hemostasis"}, {"category": "process", "description": "blood coagulation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "physiological process"}]}}}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2015-11-10", "drugbank-id": [{"@primary": "true", "#text": "DB00002"}, "BIOD00071", "BTD00071"], "name": "Cetuximab", "description": "Epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.", "cas-number": "205923-56-4", "groups": {"group": "approved"}, "general-references": null, "synthesis-reference": null, "indication": "For treatment of EGFR-expressing metastatic colorectal cancer in patients who are refractory to other irinotecan-based chemotherapy regimens. Cetuximab is also indicated for treatment of squamous cell carcinoma of the head and neck in conjucntion with radiation therapy.", "pharmacodynamics": "Used in the treatment of colorectal cancer, cetuximab binds specifically to the epidermal growth factor receptor (EGFr, HER1, c-ErbB-1) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor\u2013alpha. Binding of cetuximab to the EGFr blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased matrix metalloproteinase secretion and reduced vascular endothelial growth factor production.", "mechanism-of-action": "Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.", "toxicity": "Single doses of cetuximab higher than 500 mg/m<sup>2</sup> have not been tested. There is no experience with overdosage in human clinical trials.", "metabolism": null, "absorption": null, "half-life": "114 hrs", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Anti EGFR"}, {"@language": "", "@coder": "", "#text": "IMC-C225"}]}, "products": {"product": [{"name": "Erbitux", "ndc-id": "66733-948_8518fcc5-91cf-46e6-8fd2-b7d8418200a1", "ndc-product-code": "66733-948", "dpd-id": null, "started-marketing-on": "2004-02-12", "ended-marketing-on": null, "dosage-form": "solution", "strength": "2 mg/mL", "route": "intravenous", "fda-application-number": "BLA125084", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Erbitux", "ndc-id": "66733-958_8518fcc5-91cf-46e6-8fd2-b7d8418200a1", "ndc-product-code": "66733-958", "dpd-id": null, "started-marketing-on": "2007-10-02", "ended-marketing-on": null, "dosage-form": "solution", "strength": "2 mg/mL", "route": "intravenous", "fda-application-number": "BLA125084", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Erbitux", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02271249", "started-marketing-on": "2008-10-28", "ended-marketing-on": null, "dosage-form": "solution", "strength": "2 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Erbitux", "ingredients": "Cetuximab"}, {"name": "Erbitux", "ingredients": "Cetuximab"}, {"name": "Erbitux", "ingredients": "Cetuximab"}]}, "packagers": {"packager": [{"name": "Cardinal Health", "url": "http://www.cardinal.com"}, {"name": "Catalent Pharma Solutions", "url": "http://www.catalent.com"}, {"name": "ImClone Systems Inc.", "url": "http://www.imclone.com"}, {"name": "Oso Biopharmaceuticals Manufacturing LLC", "url": null}]}, "manufacturers": null, "prices": null, "categories": {"category": {"category": "Antineoplastic Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Solution", "route": "intravenous", "strength": "2 mg"}, {"form": "Solution", "route": "intravenous", "strength": "2 mg/mL"}]}, "atc-codes": {"atc-code": {"@code": "L01XC06", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L01", "#text": "ANTINEOPLASTIC AGENTS"}, {"@code": "L01X", "#text": "OTHER ANTINEOPLASTIC AGENTS"}, {"@code": "L01XC", "#text": "Monoclonal antibodies"}]}}, "ahfs-codes": null, "patents": {"patent": {"number": "1340417", "country": "Canada", "approved": "1999-03-02", "expires": "2016-03-02"}}, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">Cetuximab heavy chain\nQVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYN\nTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAA\nSTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG\nLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSPKSCDKTHTCPPCPAPELL\nGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ\nYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR\nDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS\nRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK"}, {"@format": "FASTA", "#text": ">Cetuximab light chain\nDILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPS\nRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPP\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT\nLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGA"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "61 \u00b0C (FAB fragment), 71 \u00b0C (whole mAb)", "source": "Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)"}, {"kind": "Hydrophobicity", "value": "-0.413", "source": null}, {"kind": "Isoelectric Point", "value": "8.48", "source": null}, {"kind": "Molecular Weight", "value": "145781.6000", "source": null}, {"kind": "Molecular Formula", "value": "C6484H10042N1732O2023S36", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "13175"}, {"resource": "National Drug Code Directory", "identifier": "66733-948-23"}, {"resource": "GenBank", "identifier": "J00228"}, {"resource": "PharmGKB", "identifier": "PA10040"}, {"resource": "Wikipedia", "identifier": "Cetuximab"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/erbitux.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/cetuximab.html"}]}, "pathways": {"pathway": {"smpdb-id": "SMP00474", "name": "Cetuximab Action Pathway", "drugs": {"drug": {"drugbank-id": "DB00002", "name": "Cetuximab"}}, "enzymes": {"uniprot-id": "P00533"}}}, "reactions": null, "snp-effects": {"effect": [{"protein-name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "gene-symbol": "FCGR2A", "uniprot-id": "P12318", "rs-id": "rs1801274", "allele": null, "defining-change": "H allelle", "description": "Increased progression free survival", "pubmed-id": "17704420"}, {"protein-name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "gene-symbol": "FCGR3A", "uniprot-id": "P08637", "rs-id": "rs396991", "allele": null, "defining-change": "A > C", "description": "Better response to drug therapy (longer progression free survival) with the F allele", "pubmed-id": "17704420"}]}, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000767", "name": "Epidermal growth factor receptor", "organism": "Human", "actions": {"action": "antagonist"}, "references": "# Hosokawa N, Yamamoto S, Uehara Y, Hori M, Tsuchiya KS: Effect of thiazinotrienomycin B, an ansamycin antibiotic, on the function of epidermal growth factor receptor in human stomach tumor cells. J Antibiot (Tokyo). 1999 May;52(5):485-90. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10480573\n# Wakita H, Takigawa M: Activation of epidermal growth factor receptor promotes late terminal differentiation of cell-matrix interaction-disrupted keratinocytes. J Biol Chem. 1999 Dec 24;274(52):37285-91. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10601294\n# Suwa T, Ueda M, Jinno H, Ozawa S, Kitagawa Y, Ando N, Kitajima M: Epidermal growth factor receptor-dependent cytotoxic effect of anti-EGFR antibody-ribonuclease conjugate on human cancer cells. Anticancer Res. 1999 Sep-Oct;19(5B):4161-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10628369\n# Burke P, Schooler K, Wiley HS: Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell. 2001 Jun;12(6):1897-910. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11408594\n# Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS: Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001 Jul 1;61(13):5090-101. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11431346\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P00533", "@source": "Swiss-Prot", "name": "Epidermal growth factor receptor", "general-function": "Involved in transmembrane receptor protein tyrosine kinase activity", "specific-function": "Isoform 2/truncated isoform may act as an antagonist", "gene-name": "EGFR", "locus": "7p12", "cellular-location": "Cell membrane; single-pass type I membrane protein. Isoform 2:Secreted protein", "transmembrane-regions": "646-668", "signal-regions": null, "theoretical-pi": "6.67", "molecular-weight": "134279.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3236"}, {"resource": "GenAtlas", "identifier": "EGFR"}, {"resource": "GeneCards", "identifier": "EGFR"}, {"resource": "GenBank Gene Database", "identifier": "X00588"}, {"resource": "GenBank Protein Database", "identifier": "757924"}, {"resource": "UniProtKB", "identifier": "P00533"}, {"resource": "UniProt Accession", "identifier": "EGFR_HUMAN"}]}, "synonyms": {"synonym": ["EC 2.7.10.1", "Epidermal growth factor receptor precursor", "Receptor tyrosine-protein kinase ErbB-1"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Epidermal growth factor receptor precursor\nMRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEV\nVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALA\nVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDF\nQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGC\nTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYV\nVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFK\nNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAF\nENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKL\nFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCN\nLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM\nGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVV\nALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGS\nGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGI\nCLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAA\nRNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSY\nGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPK\nFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQ\nQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTED\nSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLN\nTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRV\nAPQSSEFIGA"}, "gene-sequence": {"@format": "FASTA", "#text": ">3633 bp\nATGCGACCCTCCGGGACGGCCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCG\nGCGAGTCGGGCTCTGGAGGAAAAGAAAGTTTGCCAAGGCACGAGTAACAAGCTCACGCAG\nTTGGGCACTTTTGAAGATCATTTTCTCAGCCTCCAGAGGATGTTCAATAACTGTGAGGTG\nGTCCTTGGGAATTTGGAAATTACCTATGTGCAGAGGAATTATGATCTTTCCTTCTTAAAG\nACCATCCAGGAGGTGGCTGGTTATGTCCTCATTGCCCTCAACACAGTGGAGCGAATTCCT\nTTGGAAAACCTGCAGATCATCAGAGGAAATATGTACTACGAAAATTCCTATGCCTTAGCA\nGTCTTATCTAACTATGATGCAAATAAAACCGGACTGAAGGAGCTGCCCATGAGAAATTTA\nCAGGAAATCCTGCATGGCGCCGTGCGGTTCAGCAACAACCCTGCCCTGTGCAACGTGGAG\nAGCATCCAGTGGCGGGACATAGTCAGCAGTGACTTTCTCAGCAACATGTCGATGGACTTC\nCAGAACCACCTGGGCAGCTGCCAAAAGTGTGATCCAAGCTGTCCCAATGGGAGCTGCTGG\nGGTGCAGGAGAGGAGAACTGCCAGAAACTGACCAAAATCATCTGTGCCCAGCAGTGCTCC\nGGGCGCTGCCGTGGCAAGTCCCCCAGTGACTGCTGCCACAACCAGTGTGCTGCAGGCTGC\nACAGGCCCCCGGGAGAGCGACTGCCTGGTCTGCCGCAAATTCCGAGACGAAGCCACGTGC\nAAGGACACCTGCCCCCCACTCATGCTCTACAACCCCACCACGTACCAGATGGATGTGAAC\nCCCGAGGGCAAATACAGCTTTGGTGCCACCTGCGTGAAGAAGTGTCCCCGTAATTATGTG\nGTGACAGATCACGGCTCGTGCGTCCGAGCCTGTGGGGCCGACAGCTATGAGATGGAGGAA\nGACGGCGTCCGCAAGTGTAAGAAGTGCGAAGGGCCTTGCCGCAAAGTGTGTAACGGAATA\nGGTATTGGTGAATTTAAAGACTCACTCTCCATAAATGCTACGAATATTAAACACTTCAAA\nAACTGCACCTCCATCAGTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCC\nTTCACACATACTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAA\nATCACAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCTTT\nGAGAACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTCTTGCAGTC\nGTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGATAAGTGATGGAGAT\nGTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATACAATAAACTGGAAAAAACTG\nTTTGGGACCTCCGGTCAGAAAACCAAAATTATAAGCAACAGAGGTGAAAACAGCTGCAAG\nGCCACAGGCCAGGTCTGCCATGCCTTGTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCC\nAGGGACTGCGTCTCTTGCCGGAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAAG\nCTTCTGGAGGGTGAGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCA\nGAGTGCCTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATC\nCAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGAGTCATG\nGGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGTGTGCCACCTGTGC\nCATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGAAGGCTGTCCAACGAATGGG\nCCTAAGATCCCGTCCATCGCCACTGGGATGGTGGGGGCCCTCCTCTTGCTGCTGGTGGTG\nGCCCTGGGGATCGGCCTCTTCATGCGAAGGCGCCACATCGTTCGGAAGCGCACGCTGCGG\nAGGCTGCTGCAGGAGAGGGAGCTTGTGGAGCCTCTTACACCCAGTGGAGAAGCTCCCAAC\nCAAGCTCTCTTGAGGATCTTGAAGGAAACTGAATTCAAAAAGATCAAAGTGCTGGGCTCC\nGGTGCGTTCGGCACGGTGTATAAGGGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATT\nCCCGTCGCTATCAAGGAATTAAGAGAAGCAACATCTCCGAAAGCCAACAAGGAAATCCTC\nGATGAAGCCTACGTGATGGCCAGCGTGGACAACCCCCACGTGTGCCGCCTGCTGGGCATC\nTGCCTCACCTCCACCGTGCAACTCATCACGCAGCTCATGCCCTTCGGCTGCCTCCTGGAC\nTATGTCCGGGAACACAAAGACAATATTGGCTCCCAGTACCTGCTCAACTGGTGTGTGCAG\nATCGCAAAGGGCATGAACTACTTGGAGGACCGTCGCTTGGTGCACCGCGACCTGGCAGCC\nAGGAACGTACTGGTGAAAACACCGCAGCATGTCAAGATCACAGATTTTGGGCTGGCCAAA\nCTGCTGGGTGCGGAAGAGAAAGAATACCATGCAGAAGGAGGCAAAGTGCCTATCAAGTGG\nATGGCATTGGAATCAATTTTACACAGAATCTATACCCACCAGAGTGATGTCTGGAGCTAC\nGGGGTGACCGTTTGGGAGTTGATGACCTTTGGATCCAAGCCATATGACGGAATCCCTGCC\nAGCGAGATCTCCTCCATCCTGGAGAAAGGAGAACGCCTCCCTCAGCCACCCATATGTACC\nATCGATGTCTACATGATCATGGTCAAGTGCTGGATGATAGACGCAGATAGTCGCCCAAAG\nTTCCGTGAGTTGATCATCGAATTCTCCAAAATGGCCCGAGACCCCCAGCGCTACCTTGTC\nATTCAGGGGGATGAAAGAATGCATTTGCCAAGTCCTACAGACTCCAACTTCTACCGTGCC\nCTGATGGATGAAGAAGACATGGACGACGTGGTGGATGCCGACGAGTACCTCATCCCACAG\nCAGGGCTTCTTCAGCAGCCCCTCCACGTCACGGACTCCCCTCCTGAGCTCTCTGAGTGCA\nACCAGCAACAATTCCACCGTGGCTTGCATTGATAGAAATGGGCTGCAAAGCTGTCCCATC\nAAGGAAGACAGCTTCTTGCAGCGATACAGCTCAGACCCCACAGGCGCCTTGACTGAGGAC\nAGCATAGACGACACCTTCCTCCCAGTGCCTGAATACATAAACCAGTCCGTTCCCAAAAGG\nCCCGCTGGCTCTGTGCAGAATCCTGTCTATCACAATCAGCCTCTGAACCCCGCGCCCAGC\nAGAGACCCACACTACCAGGACCCCCACAGCACTGCAGTGGGCAACCCCGAGTATCTCAAC\nACTGTCCAGCCCACCTGTGTCAACAGCACATTCGACAGCCCTGCCCACTGGGCCCAGAAA\nGGCAGCCACCAAATTAGCCTGGACAACCCTGACTACCAGCAGGACTTCTTTCCCAAGGAA\nGCCAAGCCAAATGGCATCTTTAAGGGCTCCACAGCTGAAAATGCAGAATACCTAAGGGTC\nGCGCCACAAAGCAGTGAATTTATTGGAGCATGA"}, "pfams": {"pfam": [{"identifier": "PF07714", "name": "Pkinase_Tyr"}, {"identifier": "PF00757", "name": "Furin-like"}, {"identifier": "PF01030", "name": "Recep_L_domain"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "transmembrane receptor protein tyrosine kinase activity"}, {"category": "function", "description": "epidermal growth factor receptor activity"}, {"category": "function", "description": "protein-tyrosine kinase activity"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "transferase activity, transferring phosphorus-containing groups"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "function", "description": "kinase activity"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "transferase activity"}, {"category": "function", "description": "protein kinase activity"}, {"category": "process", "description": "protein amino acid phosphorylation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "enzyme linked receptor protein signaling pathway"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "transmembrane receptor protein tyrosine kinase signaling pathway"}, {"category": "process", "description": "biopolymer metabolism"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "biopolymer modification"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "protein modification"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "2", "id": "BE0000901", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "organism": "Human", "actions": null, "references": "# Snyder LC, Astsaturov I, Weiner LM: Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S71-80. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16336752", "known-action": "unknown", "polypeptide": {"@id": "O75015", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "general-function": null, "specific-function": "Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils", "gene-name": "FCGR3B", "locus": "1q23", "cellular-location": "Cell membrane; lipid-anchor; GPI-anchor. Secreted protein. Note=Secreted after cleavage", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.71", "molecular-weight": "26216.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3620"}, {"resource": "GenAtlas", "identifier": "FCGR3B"}, {"resource": "GeneCards", "identifier": "FCGR3B"}, {"resource": "GenBank Gene Database", "identifier": "X16863"}, {"resource": "GenBank Protein Database", "identifier": "31322"}, {"resource": "UniProtKB", "identifier": "O75015"}, {"resource": "UniProt Accession", "identifier": "FCG3B_HUMAN"}]}, "synonyms": {"synonym": ["CD16b antigen", "Fc-gamma RIII", "Fc-gamma RIII-beta", "Fc-gamma RIIIb", "FcR-10", "FcRIII", "FcRIIIb", "IgG Fc receptor III-1", "Low affinity immunoglobulin gamma Fc region receptor III-B precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-B precursor\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI"}, "gene-sequence": {"@format": "FASTA", "#text": ">702 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "3", "id": "BE0002093", "name": "Complement C1r subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P00736", "@source": "Swiss-Prot", "name": "Complement C1r subcomponent", "general-function": null, "specific-function": "C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system", "gene-name": "C1R", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.24", "molecular-weight": "80174.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1246"}, {"resource": "GenAtlas", "identifier": "C1R"}, {"resource": "GeneCards", "identifier": "C1R"}, {"resource": "GenBank Gene Database", "identifier": "X04701"}, {"resource": "GenBank Protein Database", "identifier": "29539"}, {"resource": "UniProtKB", "identifier": "P00736"}, {"resource": "UniProt Accession", "identifier": "C1R_HUMAN"}]}, "synonyms": {"synonym": ["Complement C1r subcomponent precursor", "Complement component 1, r subcomponent", "EC 3.4.21.41"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1r subcomponent\nMWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF\nQQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF\nSNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY\nELQEDRHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF\nDIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL\nRYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD\nDGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR\nESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF\nTNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV\nSVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME\nEKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV\nRDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2118 bp\nATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC\nATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC\nAACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC\nCAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT\nGATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG\nGGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC\nTCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT\nGTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG\nTGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT\nGAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG\nGCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC\nAACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT\nGATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC\nGGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC\nAATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG\nCGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC\nATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA\nGGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT\nGATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA\nAACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC\nCGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG\nGAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG\nGGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG\nAGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC\nACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT\nGCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC\nCTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC\nAGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG\nCTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC\nAACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG\nGAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT\nGAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT\nGGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA\nAGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC\nAGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG\nATGGAGGAGGAGGACTGA"}, "pfams": {"pfam": [{"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF07645", "name": "EGF_CA"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "4", "id": "BE0002094", "name": "Complement C1q subcomponent subunit A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02745", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit A", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QA", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.45", "molecular-weight": "26017.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1241"}, {"resource": "GenAtlas", "identifier": "C1QA"}, {"resource": "GeneCards", "identifier": "C1QA"}, {"resource": "GenBank Gene Database", "identifier": "AF135157"}, {"resource": "GenBank Protein Database", "identifier": "4894854"}, {"resource": "UniProtKB", "identifier": "P02745"}, {"resource": "UniProt Accession", "identifier": "C1QA_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit A precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit A\nMEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR\nTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI\nRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR\nGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL\nIFPSA"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG\nGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC\nAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG\nACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC\nAAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGGGCCCGTGGCATCCCGGGAATTAAA\nGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT\nCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG\nGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC\nTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG\nGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG\nGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC\nCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC\nATCTTCCCATCTGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "5", "id": "BE0002095", "name": "Complement C1q subcomponent subunit B", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02746", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit B", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QB", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.87", "molecular-weight": "26460.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1242"}, {"resource": "GenAtlas", "identifier": "C1QB"}, {"resource": "GeneCards", "identifier": "C1QB"}, {"resource": "GenBank Gene Database", "identifier": "X03084"}, {"resource": "GenBank Protein Database", "identifier": "573114"}, {"resource": "UniProtKB", "identifier": "P02746"}, {"resource": "UniProt Accession", "identifier": "C1QB_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit B precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit B\nMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEK\nGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKI\nAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCV\nNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANSIF\nSGFLLFPDMEA"}, "gene-sequence": {"@format": "FASTA", "#text": ">688 bp\nCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGG\nGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCC\nAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAA\nTCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGCCCAGGGGCCCCTGG\nAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAGAAAATCGCCTTCTC\nTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATCCGCTTCGACCACGT\nGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTCACCTGCAAGGTGCC\nCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTGTGCGTGAACCTCAT\nGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTATGCCTACAACACCTT\nCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAGAACGTCTTCCTGCA\nGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGCATCTTTTCCGGGTT\nCCTGCTCTTTCCAGATATGGAGGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "6", "id": "BE0002096", "name": "Complement C1q subcomponent subunit C", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02747", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit C", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QC", "locus": "1p36.11", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.58", "molecular-weight": "25774.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1245"}, {"resource": "GenAtlas", "identifier": "C1QC"}, {"resource": "GeneCards", "identifier": "C1QC"}, {"resource": "GenBank Gene Database", "identifier": "AF087892"}, {"resource": "GenBank Protein Database", "identifier": "33150626"}, {"resource": "UniProtKB", "identifier": "P02747"}, {"resource": "UniProt Accession", "identifier": "C1QC_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit C precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit C\nMDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP\nGIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS\nVFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV\nLLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF\nLLFPD"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG\nCTGCTGCCCCTCAGGGCCAAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC\nCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA\nGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA\nCCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC\nCCCATGGGATTCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA\nGTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC\nAACGCGGTCCTCACCAACCCGCAGGAGGATTATGACACGAGCACTGGCAAGTTCACCTGC\nAAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG\nCTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT\nCAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT\nGTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC\nCTGCTCTTCCCCGACTAG"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "7", "id": "BE0002097", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17704420", "known-action": "unknown", "polypeptide": {"@id": "P08637", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "general-function": null, "specific-function": "Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis", "gene-name": "FCGR3A", "locus": "1q23", "cellular-location": "Cell membrane", "transmembrane-regions": "209-229", "signal-regions": null, "theoretical-pi": "8.21", "molecular-weight": "29089.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3619"}, {"resource": "GenAtlas", "identifier": "FCGR3A"}, {"resource": "GeneCards", "identifier": "FCGR3A"}, {"resource": "GenBank Gene Database", "identifier": "X52645"}, {"resource": "GenBank Protein Database", "identifier": "31324"}, {"resource": "UniProtKB", "identifier": "P08637"}, {"resource": "UniProt Accession", "identifier": "FCG3A_HUMAN"}]}, "synonyms": {"synonym": ["CD16a antigen", "Fc-gamma RIII", "Fc-gamma RIII-alpha", "Fc-gamma RIIIa", "FcR-10", "FcRIII", "FcRIIIa", "IgG Fc receptor III-2", "Low affinity immunoglobulin gamma Fc region receptor III-A precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK"}, "gene-sequence": {"@format": "FASTA", "#text": ">765 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCGACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCA\nAAAGCCACACTCAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTTTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGG\nAAGGACCATAAATTTAAATGGAGAAAGGACCCTCAAGACAAATGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "8", "id": "BE0001529", "name": "Complement C1s subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P09871", "@source": "Swiss-Prot", "name": "Complement C1s subcomponent", "general-function": "Involved in calcium ion binding", "specific-function": "C1s B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4", "gene-name": "C1S", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "4.59", "molecular-weight": "76685.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1247"}, {"resource": "GenAtlas", "identifier": "C1S"}, {"resource": "GeneCards", "identifier": "C1S"}, {"resource": "GenBank Gene Database", "identifier": "X06596"}, {"resource": "GenBank Protein Database", "identifier": "763110"}, {"resource": "UniProtKB", "identifier": "P09871"}, {"resource": "UniProt Accession", "identifier": "C1S_HUMAN"}]}, "synonyms": {"synonym": ["C1 esterase", "Complement C1s subcomponent precursor", "EC 3.4.21.42"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1s subcomponent precursor\nMWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIE\nLSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERF\nTGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVF\nTALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVF\nVAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTP\nNSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCG\nIPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPK\nCVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGN\nREPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVK\nMGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKV\nEKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCG\nTYGLYTRVKNYVDWIMKTMQENSTPRED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2067 bp\nATGTGGTGCATTGTCCTGTTTTCACTTTTGGCATGGGTTTATGCTGAGCCTACCATGTAT\nGGGGAGATCCTGTCCCCTAACTATCCTCAGGCATATCCCAGTGAGGTAGAGAAATCTTGG\nGACATAGAAGTTCCTGAAGGGTATGGGATTCACCTCTACTTCACCCATCTGGACATTGAG\nCTGTCAGAGAACTGTGCGTATGACTCAGTGCAGATAATCTCAGGAGACACTGAAGAAGGG\nAGGCTCTGTGGACAGAGGAGCAGTAACAATCCCCACTCTCCAATTGTGGAAGAGTTCCAA\nGTCCCATACAACAAACTCCAGGTGATCTTTAAGTCAGACTTTTCCAATGAAGAGCGTTTT\nACGGGGTTTGCTGCATACTATGTTGCCACAGACATAAATGAATGCACAGATTTTGTAGAT\nGTCCCTTGTAGCCACTTCTGCAACAATTTCATTGGTGGTTACTTCTGCTCCTGCCCCCCG\nGAATATTTCCTCCATGATGACATGAAGAATTGCGGAGTTAATTGCAGTGGGGATGTATTC\nACTGCACTGATTGGGGAGATTGCAAGTCCCAATTATCCCAAACCATATCCAGAGAACTCA\nAGGTGTGAATACCAGATCCGGTTGGAGAAAGGGTTCCAAGTGGTGGTGACCTTGCGGAGA\nGAAGATTTTGATGTGGAAGCAGCTGACTCAGCGGGAAACTGCCTTGACAGTTTAGTTTTT\nGTTGCAGGAGATCGGCAATTTGGTCCTTACTGTGGTCATGGATTCCCTGGGCCTCTAAAT\nATTGAAACCAAGAGTAATGCTCTTGATATCATCTTCCAAACTGATCTAACAGGGCAAAAA\nAAGGGCTGGAAACTTCGCTATCATGGAGATCCAATGCCCTGCCCTAAGGAAGACACTCCC\nAATTCTGTTTGGGAGCCTGCGAAGGCAAAATATGTCTTTAGAGATGTGGTGCAGATAACC\nTGTCTGGATGGGTTTGAAGTTGTGGAGGGACGTGTTGGTGCAACATCTTTCTATTCGACT\nTGTCAAAGCAATGGAAAGTGGAGTAATTCCAAACTGAAATGTCAACCTGTGGACTGTGGC\nATTCCTGAATCCATTGAGAATGGTAAAGTTGAAGACCCAGAGAGCACTTTGTTTGGTTCT\nGTCATCCGCTACACTTGTGAGGAGCCATATTACTACATGGAAAATGGAGGAGGTGGGGAG\nTATCACTGTGCTGGTAACGGGAGCTGGGTGAATGAGGTGCTGGGCCCGGAGCTGCCGAAA\nTGTGTTCCAGTCTGTGGAGTCCCCAGAGAACCCTTTGAAGAAAAACAGAGGATAATTGGA\nGGATCCGATGCAGATATTAAAAACTTCCCCTGGCAAGTCTTCTTTGACAACCCATGGGCT\nGGTGGAGCGCTCATTAATGAGTACTGGGTGCTGACGGCTGCTCATGTTGTGGAGGGAAAC\nAGGGAGCCAACAATGTATGTTGGGTCCACCTCAGTGCAGACCTCACGGCTGGCAAAATCC\nAAGATGCTCACTCCTGAGCATGTGTTTATTCATCCGGGATGGAAGCTGCTGGAAGTCCCA\nGAAGGACGAACCAATTTTGATAATGACATTGCACTGGTGCGGCTGAAAGACCCAGTGAAA\nATGGGACCCACCGTCTCTCCCATCTGCCTACCAGGCACCTCTTCCGACTACAACCTCATG\nGATGGGGACCTGGGACTGATCTCAGGCTGGGGCCGAACAGAGAAGAGAGATCGTGCTGTT\nCGCCTCAAGGCGGCAAGGTTACCTGTAGCTCCTTTAAGAAAATGCAAAGAAGTGAAAGTG\nGAGAAACCCACAGCAGATGCAGAGGCCTATGTTTTCACTCCTAACATGATCTGTGCTGGA\nGGAGAGAAGGGCATGGATAGCTGTAAAGGGGACAGTGGTGGGGCCTTTGCTGTACAGGAT\nCCCAATGACAAGACCAAATTCTACGCAGCTGGCCTGGTGTCCTGGGGGCCCCAGTGTGGG\nACCTATGGGCTCTACACACGGGTAAAGAACTATGTTGACTGGATAATGAAGACTATGCAG\nGAAAATAGCACCCCCCGTGAGGACTAA"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "9", "id": "BE0000710", "name": "High affinity immunoglobulin gamma Fc receptor I", "organism": "Human", "actions": null, "references": "# Negri DR, Tosi E, Valota O, Ferrini S, Cambiaggi A, Sforzini S, Silvani A, Ruffini PA, Colnaghi MI, Canevari S: In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody. Br J Cancer. 1995 Oct;72(4):928-33. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7547242", "known-action": "unknown", "polypeptide": {"@id": "P12314", "@source": "Swiss-Prot", "name": "High affinity immunoglobulin gamma Fc receptor I", "general-function": "Involved in receptor signaling protein activity", "specific-function": "Binds to the Fc region of immunoglobulins gamma. High affinity receptor", "gene-name": "FCGR1A", "locus": "1q21.2-q21.3", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "293-313", "signal-regions": null, "theoretical-pi": "8.08", "molecular-weight": "42632.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3613"}, {"resource": "GenAtlas", "identifier": "FCGR1A"}, {"resource": "GeneCards", "identifier": "FCGR1A"}, {"resource": "GenBank Gene Database", "identifier": "X14356"}, {"resource": "GenBank Protein Database", "identifier": "31332"}, {"resource": "UniProtKB", "identifier": "P12314"}, {"resource": "UniProt Accession", "identifier": "FCGR1_HUMAN"}]}, "synonyms": {"synonym": ["CD64 antigen", "Fc-gamma RI", "FcRI", "High affinity immunoglobulin gamma Fc receptor I precursor", "IgG Fc receptor I"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">High affinity immunoglobulin gamma Fc receptor I precursor\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1125 bp\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCTCTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAACTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "10", "id": "BE0002098", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17704420", "known-action": "unknown", "polypeptide": {"@id": "P12318", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "general-function": null, "specific-function": "Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens", "gene-name": "FCGR2A", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.78", "molecular-weight": "34990.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3616"}, {"resource": "GenAtlas", "identifier": "FCGR2A"}, {"resource": "GeneCards", "identifier": "FCGR2A"}, {"resource": "GenBank Gene Database", "identifier": "M31932"}, {"resource": "GenBank Protein Database", "identifier": "182474"}, {"resource": "UniProtKB", "identifier": "P12318"}, {"resource": "UniProt Accession", "identifier": "FCG2A_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-a", "Fc-gamma-RIIa", "FcRII-a", "IgG Fc receptor II-a", "Low affinity immunoglobulin gamma Fc region receptor II-a precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-a\nMAMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSRLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">954 bp\nATGGCTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "11", "id": "BE0002099", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31994", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "general-function": null, "specific-function": "Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B- cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis", "gene-name": "FCGR2B", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.12", "molecular-weight": "34044.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3618"}, {"resource": "GenAtlas", "identifier": "FCGR2B"}, {"resource": "GeneCards", "identifier": "FCGR2B"}, {"resource": "GenBank Gene Database", "identifier": "U87560"}, {"resource": "GenBank Protein Database", "identifier": "4099445"}, {"resource": "UniProtKB", "identifier": "P31994"}, {"resource": "UniProt Accession", "identifier": "FCG2B_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-b", "Fc-gamma-RIIb", "FcRII-b", "IgG Fc receptor II-b", "Low affinity immunoglobulin gamma Fc region receptor II-b precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI"}, "gene-sequence": {"@format": "FASTA", "#text": ">930 bp\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCTCTCCCAGGATACCCTGAG\nTGCAGGGAAATGGGAGAGACCCTCCCTGAGAAACCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATT"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "12", "id": "BE0002100", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31995", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "general-function": null, "specific-function": "Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells", "gene-name": "FCGR2C", "locus": "1q23.3", "cellular-location": "Cell membrane", "transmembrane-regions": "224-246", "signal-regions": null, "theoretical-pi": "6.9", "molecular-weight": "35578.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:15626"}, {"resource": "GenAtlas", "identifier": "FCGR2C"}, {"resource": "GeneCards", "identifier": "FCGR2C"}, {"resource": "GenBank Gene Database", "identifier": "X17652"}, {"resource": "GenBank Protein Database", "identifier": "32074"}, {"resource": "UniProtKB", "identifier": "P31995"}, {"resource": "UniProt Accession", "identifier": "FCG2C_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-c", "Fc-gamma-RIIc", "FcRII-c", "IgG Fc receptor II-c", "Low affinity immunoglobulin gamma Fc region receptor II-c precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-c\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR\nAPTDDDKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">972 bp\nATGGGAATCCTGTCATTTTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACAGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCATTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCTGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG\nAAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT\nGAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG\nGCACCTACTGACGATGATAAAAACATCTACTTGACTCTTCCTCCCAACGACCATGTCAAC\nAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-11-16", "drugbank-id": [{"@primary": "true", "#text": "DB00003"}, "BIOD00001", "BTD00001"], "name": "Dornase alfa", "description": "Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. The 260-amino acid sequence of dornase alfa is identical to the endogenous human enzyme. Dornase alfa cleaves extracellular DNA to 5\u00b4-phosphodinucleotide and 5\u00b4-phosphooligonucleotide end products without affecting intracellular DNA. In individuals with cystic fibrosis, extracellular DNA, which is an extremely viscous anion, is released by degenerating leukocytes that accumulate during inflammatory responses to infections. Enzymatic breakdown of this extracellular DNA appears to reduce sputum viscosity and viscoelasticity.", "cas-number": "9003-98-9", "groups": {"group": "approved"}, "general-references": "# Cramer GW, Bosso JA: The role of dornase alfa in the treatment of cystic fibrosis. Ann Pharmacother. 1996 Jun;30(6):656-61. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8792953 \n# Jones AP, Wallis C: Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2010 Mar 17;3:CD001127. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20238314 \n# Riethmueller J, Kumpf M, Borth-Bruhns T, Brehm W, Wiskirchen J, Sieverding L, Ankele C, Hofbeck M, Baden W: Clinical and in vitro effect of dornase alfa in mechanically ventilated pediatric non-cystic fibrosis patients with atelectases. Cell Physiol Biochem. 2009;23(1-3):205-10. Epub 2009 Feb 18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19255515 \n# Roche Products Limited. Pulmozyme. 1st ed. Newmarket, Auckland: N.p., 2014. Web. 11 Nov. 2014.\n#Glowm.com,. 'Dornase Alfa'. N.p., 2014. Web. 11 Nov. 2014.", "synthesis-reference": null, "indication": "Used as adjunct therapy in the treatment of cystic fibrosis.", "pharmacodynamics": "Cystic fibrosis (CF) is a disease characterized by the retention of viscous purulent secretions in the airways. These thick secretions contribute both to reduced pulmonary function and to frequent pulmonary infection. Purulent pulmonary secretions of individuals with cystic fibrosis contain very high concentrations of extracellular DNA released by degenerating leukocytes that accumulate in response to these infections. Dornase alfa hydrolyzes the DNA in sputum of CF patients and reduces sputum viscosity and viscoelasticity. The enzyme does not appear to affect sputum in the absence of an inflammatory response to infection, nor does it affect the sputum of healthy individuals.", "mechanism-of-action": "Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5\u00b4-phosphodinucleotide and 5\u00b4-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Extracellular DNA is a viscous anionic polymer and its breakdown appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF, thus reducing airflow obstruction. Dornase alfa does not seem to have any effect on non-purulent sputum.", "toxicity": "Adverse reactions occur at a frequency of < 1/1000 and are usually mild and transient in nature. Reported adverse effects include chest pain (pleuritic/non-cardiac), fever, dyspepsia, voice alteration (hoarseness), pharyngitis, dyspnea, laryngitis, rhinitis, decreased lung function, rash, urticaria, and conjunctivitis. There is no evidence of carcinogenic or mutagenic properties. The safety of dornase alfa has not been studied in pregnant women, nursing women and children under the age of 5 years old.", "metabolism": "While no conclusive studies have yet been published, dornase alfa is expected to be metabolized by proteases in biofluids.", "absorption": "Studies in rats and monkeys after inhalation of dornase alfa shows very little systemic absorption (less than 15% for rats and less than 2% for monkeys). The results were also witnessed in patients. Dornase alfa is also associated with very low accumulation with no serum concentration greater than 10ng/mL observed no matter the dose administered. Bioavailability: mean sputum concentrations of dornase alfa can be measured after 15 minutes. Onset is achieved within 3 to 7 days. Peak concentrations are achieved after 9 days.", "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": "In studies in rats and monkeys, the initial volume of distribution is similar to the serum volume. Concentrations in sputum decline rapidly after inhalation.", "clearance": "Studies in rats indicate that, following aerosol administration, the disappearance half-life of dornase alfa from the lungs is 11 hours. In humans, sputum DNase levels declined below half of those detected immediately post-administration within 2 hours but effects on sputum rheology persisted beyond 12 hours.", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Deoxyribonuclease I"}, {"@language": "", "@coder": "", "#text": "Deoxyribonuclease-1 precursor"}, {"@language": "", "@coder": "", "#text": "DNase"}, {"@language": "", "@coder": "", "#text": "DNase I"}, {"@language": "", "@coder": "", "#text": "rhDNase"}]}, "products": {"product": [{"name": "Pulmozyme", "ndc-id": "50242-100_1f306717-b937-4efc-a269-bcadda447cce", "ndc-product-code": "50242-100", "dpd-id": null, "started-marketing-on": "1993-12-30", "ended-marketing-on": null, "dosage-form": "solution", "strength": "1 mg/mL", "route": "respiratory (inhalation)", "fda-application-number": "BLA103532", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Pulmozyme 1mg/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02046733", "started-marketing-on": "1994-12-31", "ended-marketing-on": null, "dosage-form": "solution", "strength": "1 mg", "route": "inhalation", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": {"name": "Viscozyme", "company": "Roche (Chile)"}}, "mixtures": {"mixture": [{"name": "Pulmozyme", "ingredients": "Dornase alfa"}, {"name": "Pulmozyme 1mg/ml", "ingredients": "Dornase alfa"}]}, "packagers": {"packager": [{"name": "Cardinal Health", "url": "http://www.cardinal.com"}, {"name": "Catalent Pharma Solutions", "url": "http://www.catalent.com"}, {"name": "F Hoffmann-La Roche Ltd.", "url": "http://www.roche.com"}, {"name": "Genentech Inc.", "url": "http://www.gene.com"}, {"name": "Meda AB", "url": "http://www.meda.se"}, {"name": "Medpointe Pharmaceuticals", "url": null}]}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Genentech, Inc"}}, "prices": {"price": [{"description": "Lufyllin 200 mg tablet", "cost": {"@currency": "USD", "#text": "3.21"}, "unit": "tablet"}, {"description": "Lufyllin-gg tablet", "cost": {"@currency": "USD", "#text": "3.84"}, "unit": "tablet"}, {"description": "Lufyllin-GG 200-200 mg tablet", "cost": {"@currency": "USD", "#text": "3.99"}, "unit": "tablet"}, {"description": "Lufyllin-400 tablet", "cost": {"@currency": "USD", "#text": "4.62"}, "unit": "tablet"}, {"description": "Lufyllin 400 mg tablet", "cost": {"@currency": "USD", "#text": "4.81"}, "unit": "tablet"}, {"description": "Pulmozyme 1 mg/ml ampul", "cost": {"@currency": "USD", "#text": "37.05"}, "unit": "ml"}, {"description": "Pulmozyme 1 mg/ml Solution 2.5ml Plastic Container", "cost": {"@currency": "USD", "#text": "77.06"}, "unit": "plastic"}, {"description": "Lufyllin-GG 100-100 mg/15ml Elixir", "cost": {"@currency": "USD", "#text": "0.6"}, "unit": "ml"}]}, "categories": {"category": {"category": "Enzymes", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Solution", "route": "respiratory (inhalation)", "strength": "1 mg/mL"}, {"form": "Solution", "route": "inhalation", "strength": "1 mg"}]}, "atc-codes": null, "ahfs-codes": {"ahfs-code": "44:00"}, "patents": {"patent": [{"number": "2137237", "country": "Canada", "approved": "2004-10-26", "expires": "2013-05-28"}, {"number": "2184581", "country": "Canada", "approved": "2005-02-22", "expires": "2015-02-28"}]}, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": {"@format": "FASTA", "#text": ">Dornase alfa sequence\nLKIAAFNIQTFGETKMSNATLVSYIVQILSRYDIALVQEVRDSHLTAVGKLLDNLNQDAP\nDTYHYVVSEPLGRNSYKERYLFVYRPDQVSAVDSYYYDDGCEPCGNDTFNREPAIVRFFS\nRFTEVREFAIVPLHAAPGDAVAEIDALYDVYLDVQEKWGLEDVMLMGDFNAGCSYVRPSQ\nWSSIRLWTSPTFQWLIPDSADTTATPTHCAYDRIVVAGMLLRGAVVPDSALPFNFQAAYG\nLSDQLAQAISDHYPVEVMLK"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "67 \u00b0C", "source": "Chan, H.K. et al., Pharm Res. 13:756-761 (1996)"}, {"kind": "Hydrophobicity", "value": "-0.083", "source": null}, {"kind": "Isoelectric Point", "value": "4.58", "source": null}, {"kind": "Molecular Weight", "value": "29253.9000", "source": null}, {"kind": "Molecular Formula", "value": "C1321H1999N339O396S9", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "650"}, {"resource": "GenBank", "identifier": "M55983"}, {"resource": "PharmGKB", "identifier": "PA10318"}, {"resource": "UniProtKB", "identifier": "P24855"}, {"resource": "Wikipedia", "identifier": "Dornase_alfa"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/pulmozyme.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/dornase-alfa.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0004796", "name": "DNA", "organism": "Human", "actions": null, "references": "# Cramer GW, Bosso JA: The role of dornase alfa in the treatment of cystic fibrosis. Ann Pharmacother. 1996 Jun;30(6):656-61. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8792953", "known-action": "yes"}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-01-14", "drugbank-id": [{"@primary": "true", "#text": "DB00004"}, "BIOD00084", "BTD00084"], "name": "Denileukin diftitox", "description": "A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.", "cas-number": "173146-27-5", "groups": {"group": ["approved", "investigational"]}, "general-references": "# Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17187516\n# Park M, Liu GT, Piltz-Seymour J, Wisda CL, Rook AH, Junkins-Hopkins JM, Nasta SD, Kim EJ: Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy. Leuk Lymphoma. 2007 Apr;48(4):808-11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17454642", "synthesis-reference": null, "indication": "For treatment of cutaneous T-cell lymphoma", "pharmacodynamics": "Denileukin diftitox (Ontak) directs the cytocidal action of diphtheria toxin to cells which express the IL-2 receptor. The human IL-2 receptor exists in three forms, low (CD25), intermediate (CD122/CD132) and high (CD25/CD122/CD132) affinity. Malignant cells expressing one or more of the subunits of the IL-2 receptor are found in certain leukemias and lymphomas including cutaneous T-cell lymphoma (CTCL). Ontak interacts with the high affinity IL-2 receptor on the cell surface and inhibits cellular protein synthesis, resulting in cell death within hours.", "mechanism-of-action": "Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": "70-80 min", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": "* 0.06 to 0.09 L/kg", "clearance": "* 0.6 - 2.0 mL/min/kg [Lymphoma]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Diphtheria toxin precursor"}, {"@language": "", "@coder": "", "#text": "DT"}, {"@language": "", "@coder": "", "#text": "NAD(+--diphthamide ADP- ribosyltransferase)"}]}, "products": {"product": {"name": "Ontak", "ndc-id": "62856-603_f2eba925-c3a4-45db-a391-23e7a11bdb24", "ndc-product-code": "62856-603", "dpd-id": null, "started-marketing-on": "2008-10-15", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "150 ug/mL", "route": "intravenous", "fda-application-number": "BLA103767", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}}, "international-brands": null, "mixtures": {"mixture": {"name": "Ontak", "ingredients": "Denileukin diftitox"}}, "packagers": {"packager": [{"name": "Eisai Inc.", "url": "http://www.eisai.com"}, {"name": "Hollister-Stier Laboratories LLC", "url": "http://www.hollisterstier.com"}, {"name": "Ligand Pharmaceuticals Inc.", "url": "http://www.ligand.com"}]}, "manufacturers": null, "prices": {"price": {"description": "Ontak 150 mcg/ml vial", "cost": {"@currency": "USD", "#text": "878.4"}, "unit": "ml"}}, "categories": {"category": {"category": "Antineoplastic Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": {"form": "Injection, solution", "route": "intravenous", "strength": "150 ug/mL"}}, "atc-codes": {"atc-code": {"@code": "L01XX29", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L01", "#text": "ANTINEOPLASTIC AGENTS"}, {"@code": "L01X", "#text": "OTHER ANTINEOPLASTIC AGENTS"}, {"@code": "L01XX", "#text": "Other antineoplastic agents"}]}}, "ahfs-codes": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00004 sequence\nMGADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKGFYSTDNK\nYDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVG\nTEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDAMY\nEYMAQACAGNRVRRSVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIKNKMSESPNKTVS\nEEKAKQYLEEFHQTALEHPELSELKTVTGTNPVFAGANYAAWAVNVAQVIDSETADNLEK\nTTAALSILPGIGSVMGIADGAVHHNTEEIVAQSIALSSLMVAQAIPLVGELVDIGFAAYN\nFVESIINLFQVVHNSYNRPAYSPGHKTHAPTSSSTKKTQLQLEHLLLDLQMILNGINNYK\nNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVI\nVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.301", "source": null}, {"kind": "Isoelectric Point", "value": "5.45", "source": null}, {"kind": "Molecular Weight", "value": "57647.3000", "source": null}, {"kind": "Molecular Formula", "value": "C2560H4042N678O799S17", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "National Drug Code Directory", "identifier": "62856-603-01"}, {"resource": "GenBank", "identifier": "V01536"}, {"resource": "PharmGKB", "identifier": "PA164750594"}, {"resource": "UniProtKB", "identifier": "P00587"}, {"resource": "Wikipedia", "identifier": "Denileukin_diftitox"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic2/denileukin.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/denileukin-diftitox.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000658", "name": "Interleukin-2 receptor subunit alpha", "organism": "Human", "actions": {"action": "binder"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Kiyokawa T, Shirono K, Hattori T, Nishimura H, Yamaguchi K, Nichols JC, Strom TB, Murphy JR, Takatsuki K: Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia. Cancer Res. 1989 Jul 15;49(14):4042-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2786749\n# Murphy JR, Kelley VE, Strom TB: Interleukin 2 toxin: a step toward selective immunomodulation. Am J Kidney Dis. 1988 Feb;11(2):159-62. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/3124610\n# Duvic M, Talpur R: Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18684057\n# Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17187516\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P01589", "@source": "Swiss-Prot", "name": "Interleukin-2 receptor subunit alpha", "general-function": "Involved in interleukin-2 receptor activity", "specific-function": "Receptor for interleukin-2", "gene-name": "IL2RA", "locus": "10p15-p14", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "241-259", "signal-regions": null, "theoretical-pi": "6.49", "molecular-weight": "30819.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6008"}, {"resource": "GenAtlas", "identifier": "IL2RA"}, {"resource": "GeneCards", "identifier": "IL2RA"}, {"resource": "GenBank Gene Database", "identifier": "X01057"}, {"resource": "GenBank Protein Database", "identifier": "33813"}, {"resource": "UniProtKB", "identifier": "P01589"}, {"resource": "UniProt Accession", "identifier": "IL2RA_HUMAN"}]}, "synonyms": {"synonym": ["CD25 antigen", "IL-2 receptor alpha subunit", "IL-2-RA", "IL2-RA", "Interleukin-2 receptor alpha chain precursor", "p55", "TAC antigen"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interleukin-2 receptor alpha chain precursor\nMDSYLLMWGLLTFIMVPGCQAELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKS\nGSLYMLCTGNSSHSSWDNQCQCTSSATRNTTKQVTPQPEEQKERKTTEMQSPMQPVDQAS\nLPGHCREPPPWENEATERIYHFVVGQMVYYQCVQGYRALHRGPAESVCKMTHGKTRWTQP\nQLICTGEMETSQFPGEEKPQASPEGRPESETSCLVTTTDFQIQTEMAATMETSIFTTEYQ\nVAVAGCVFLLISVLLLSGLTWQRRQRKSRRTI"}, "gene-sequence": {"@format": "FASTA", "#text": ">819 bp\nATGGATTCATACCTGCTGATGTGGGGACTGCTCACGTTCATCATGGTGCCTGGCTGCCAG\nGCAGAGCTCTGTGACGATGACCCGCCAGAGATCCCACACGCCACATTCAAAGCCATGGCC\nTACAAGGAAGGAACCATGTTGAACTGTGAATGCAAGAGAGGTTTCCGCAGAATAAAAAGC\nGGGTCACTCTATATGCTCTGTACAGGAAACTCTAGCCACTCGTCCTGGGACAACCAATGT\nCAATGCACAAGCTCTGCCACTCGGAACACAACGAAACAAGTGACACCTCAACCTGAAGAA\nCAGAAAGAAAGGAAAACCACAGAAATGCAAAGTCCAATGCAGCCAGTGGACCAAGCGAGC\nCTTCCAGGTCACTGCAGGGAACCTCCACCATGGGAAAATGAAGCCACAGAGAGAATTTAT\nCATTTCGTGGTGGGGCAGATGGTTTATTATCAGTGCGTCCAGGGATACAGGGCTCTACAC\nAGAGGTCCTGCTGAGAGCGTCTGCAAAATGACCCACGGGAAGACAAGGTGGACCCAGCCC\nCAGCTCATATGCACAGGTGAAATGGAGACCAGTCAGTTTCCAGGTGAAGAGAAGCCTCAG\nGCAAGCCCCGAAGGCCGTCCTGAGAGTGAGACTTCCTGCCTCGTCACAACAACAGATTTT\nCAAATACAGACAGAAATGGCTGCAACCATGGAGACGTCCATATTTACAACAGAGTACCAG\nGTAGCAGTGGCCGGCTGTGTTTTCCTGCTGATCAGCGTCCTCCTCCTGAGTGGGCTCACC\nTGGCAGCGGAGACAGAGGAAGAGTAGAAGAACAATCTAG"}, "pfams": {"pfam": {"identifier": "PF00084", "name": "Sushi"}}, "go-classifiers": null}}, {"@position": "2", "id": "BE0000651", "name": "Interleukin-2 receptor subunit beta", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Foss F, Demierre MF, DiVenuti G: A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2005 Jul 15;106(2):454-7. Epub 2005 Apr 5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15811959\n# Foss F: Clinical experience with denileukin diftitox (ONTAK). Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16516670\n# Duvic M, Talpur R: Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18684057\n# Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17187516\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P14784", "@source": "Swiss-Prot", "name": "Interleukin-2 receptor subunit beta", "general-function": "Involved in hematopoietin/interferon-class (D200-domain) cytokine receptor activity", "specific-function": "Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2", "gene-name": "IL2RB", "locus": "22q13|22q13.1", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "241-265", "signal-regions": null, "theoretical-pi": "4.68", "molecular-weight": "61118.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6009"}, {"resource": "GenAtlas", "identifier": "IL2RB"}, {"resource": "GeneCards", "identifier": "IL2RB"}, {"resource": "GenBank Gene Database", "identifier": "M26062"}, {"resource": "GenBank Protein Database", "identifier": "307048"}, {"resource": "UniProtKB", "identifier": "P14784"}, {"resource": "UniProt Accession", "identifier": "IL2RB_HUMAN"}]}, "synonyms": {"synonym": ["CD122 antigen", "High affinity IL-2 receptor subunit beta", "IL-2 receptor", "Interleukin-2 receptor subunit beta precursor", "P70-75", "p75"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interleukin-2 receptor beta chain precursor\nMAAPALSWRLPLLILLLPLATSWASAAVNGTSQFTCFYNSRANISCVWSQDGALQDTSCQ\nVHAWPDRRRWNQTCELLPVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMA\nIQDFKPFENLRLMAPISLQVVHVETHRCNISWEISQASHYFERHLEFEARTLSPGHTWEE\nAPLLTLKQKQEWICLETLTPDTQYEFQVRVKPLQGEFTTWSPWSQPLAFRTKPAALGKDT\nIPWLGHLLVGLSGAFGFIILVYLLINCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDV\nQKWLSSPFPSSSFSPGGLAPEISPLEVLERDKVTQLLLQQDKVPEPASLSSNHSLTSCFT\nNQGYFFFHLPDALEIEACQVYFTYDPYSEEDPDEGVAGAPTGSSPQPLQPLSGEDDAYCT\nFPSRDDLLLFSPSLLGGPSPPSTAPGGSGAGEERMPPSLQERVPRDWDPQPLGPPTPGVP\nDLVDFQPPPELVLREAGEEVPDAGPREGVSFPWSRPPGQGEFRALNARLPLNTDAYLSLQ\nELQGQDPTHLV"}, "gene-sequence": {"@format": "FASTA", "#text": ">1656 bp\nATGGCGGCCCCTGCTCTGTCCTGGCGTCTGCCCCTCCTCATCCTCCTCCTGCCCCTGGCT\nACCTCTTGGGCATCTGCAGCGGTGAATGGCACTTCCCAGTTCACATGCTTCTACAACTCG\nAGAGCCAACATCTCCTGTGTCTGGAGCCAAGATGGGGCTCTGCAGGACACTTCCTGCCAA\nGTCCATGCCTGGCCGGACAGACGGCGGTGGAACCAAACCTGTGAGCTGCTCCCCGTGAGT\nCAAGCATCCTGGGCCTGCAACCTGATCCTCGGAGCCCCAGATTCTCAGAAACTGACCACA\nGTTGACATCGTCACCCTGAGGGTGCTGTGCCGTGAGGGGGTGCGATGGAGGGTGATGGCC\nATCCAGGACTTCAAGCCCTTTGAGAACCTTCGCCTGATGGCCCCCATCTCCCTCCAAGTT\nGTCCACGTGGAGACCCACAGATGCAACATAAGCTGGGAAATCTCCCAAGCCTCCCACTAC\nTTTGAAAGACACCTGGAGTTCGAGGCCCGGACGCTGTCCCCAGGCCACACCTGGGAGGAG\nGCCCCCCTGCTGACTCTCAAGCAGAAGCAGGAATGGATCTGCCTGGAGACGCTCACCCCA\nGACACCCAGTATGAGTTTCAGGTGCGGGTCAAGCCTCTGCAAGGCGAGTTCACGACCTGG\nAGCCCCTGGAGCCAGCCCCTGGCCTTCAGGACAAAGCCTGCAGCCCTTGGGAAGGACACC\nATTCCGTGGCTCGGCCACCTCCTCGTGGGCCTCAGCGGGGCTTTTGGCTTCATCATCTTA\nGTGTACTTGCTGATCAACTGCAGGAACACCGGGCCATGGCTGAAGAAGGTCCTGAAGTGT\nAACACCCCAGACCCCTCGAAGTTCTTTTCCCAGCTGAGCTCAGAGCATGGAGGAGACGTC\nCAGAAGTGGCTCTCTTCGCCCTTCCCCTCATCGTCCTTCAGCCCTGGCGGCCTGGCACCT\nGAGATCTCGCCACTAGAAGTGCTGGAGAGGGACAAGGTGACGCAGCTGCTCCTGCAGCAG\nGACAAGGTGCCTGAGCCCGCATCCTTAAGCAGCAACCACTCGCTGACCAGCTGCTTCACC\nAACCAGGGTTACTTCTTCTTCCACCTCCCGGATGCCTTGGAGATAGAGGCCTGCCAGGTG\nTACTTTACTTACGACCCCTACTCAGAGGAAGACCCTGATGAGGGTGTGGCCGGGGCACCC\nACAGGGTCTTCCCCCCAACCCCTGCAGCCTCTGTCAGGGGAGGACGACGCCTACTGCACC\nTTCCCCTCCAGGGATGACCTGCTGCTCTTCTCCCCCAGTCTCCTCGGTGGCCCCAGCCCC\nCCAAGCACTGCCCCTGGGGGCAGTGGGGCCGGTGAAGAGAGGATGCCCCCTTCTTTGCAA\nGAAAGAGTCCCCAGAGACTGGGACCCCCAGCCCCTGGGGCCTCCCACCCCAGGAGTCCCA\nGACCTGGTGGATTTTCAGCCACCCCCTGAGCTGGTGCTGCGAGAGGCTGGGGAGGAGGTC\nCCTGACGCTGGCCCCAGGGAGGGAGTCAGTTTCCCCTGGTCCAGGCCTCCTGGGCAGGGG\nGAGTTCAGGGCCCTTAATGCTCGCCTGCCCCTGAACACTGATGCCTACTTGTCCCTCCAA\nGAACTCCAGGGTCAGGACCCAACTCACTTGGTGTAG"}, "pfams": null, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "hematopoietin/interferon-class (D200-domain) cytokine receptor activity"}]}}}, {"@position": "3", "id": "BE0002102", "name": "Cytokine receptor common subunit gamma", "organism": "Human", "actions": null, "references": "# Foss F, Demierre MF, DiVenuti G: A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2005 Jul 15;106(2):454-7. Epub 2005 Apr 5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15811959\n# Foss F: Clinical experience with denileukin diftitox (ONTAK). Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16516670\n# Foss FM: DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Clin Lymphoma. 2000 Nov;1 Suppl 1:S27-31. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11707860", "known-action": "unknown", "polypeptide": {"@id": "P31785", "@source": "Swiss-Prot", "name": "Cytokine receptor common subunit gamma", "general-function": null, "specific-function": "Common subunit for the receptors for a variety of interleukins", "gene-name": "IL2RG", "locus": "Xq13.1", "cellular-location": "Membrane", "transmembrane-regions": "263-283", "signal-regions": null, "theoretical-pi": "6.31", "molecular-weight": "42287.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6010"}, {"resource": "GenAtlas", "identifier": "IL2RG"}, {"resource": "GeneCards", "identifier": "IL2RG"}, {"resource": "GenBank Gene Database", "identifier": "D11086"}, {"resource": "GenBank Protein Database", "identifier": "219890"}, {"resource": "UniProtKB", "identifier": "P31785"}, {"resource": "UniProt Accession", "identifier": "IL2RG_HUMAN"}]}, "synonyms": {"synonym": ["CD132 antigen", "Cytokine receptor common gamma chain precursor", "Gamma-C", "IL-2R gamma chain", "Interleukin- 2 receptor gamma chain", "p64"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytokine receptor common gamma chain\nMLKPSLPFTSLLFLQLPLLGVGLNTTILTPNGNEDTTADFFLTTMPTDSLSVSTLPLPEV\nQCFVFNVEYMNCTWNSSSEPQPTNLTLHYWYKNSDNDKVQKCSHYLFSEEITSGCQLQKK\nEIHLYQTFVVQLQDPREPRRQATQMLKLQNLVIPWAPENLTLHKLSESQLELNWNNRFLN\nHCLEHLVQYRTDWDHSWTEQSVDYRHKFSLPSVDGQKRYTFRVRSRFNPLCGSAQHWSEW\nSHPIHWGSNTSKENPFLFALEAVVISVGSMGLIISLLCVYFWLERTMPRIPTLKNLEDLV\nTEYHGNFSAWSGVSKGLAESLQPDYSERLCLVSEIPPKGGALGEGPGASPCNQHSPYWAP\nPCYTLKPET"}, "gene-sequence": {"@format": "FASTA", "#text": ">1110 bp\nATGTTGAAGCCATCATTACCATTCACATCCCTCTTATTCCTGCAGCTGCCCCTGCTGGGA\nGTGGGGCTGAACACGACAATTCTGACGCCCAATGGGAATGAAGACACCACAGCTGATTTC\nTTCCTGACCACTATGCCCACTGACTCCCTCAGTGTTTCCACTCTGCCCCTCCCAGAGGTT\nCAGTGTTTTGTGTTCAATGTCGAGTACATGAATTGCACTTGGAACAGCAGCTCTGAGCCC\nCAGCCTACCAACCTCACTCTGCATTATTGGTACAAGAACTCGGATAATGATAAAGTCCAG\nAAGTGCAGCCACTATCTATTCTCTGAAGAAATCACTTCTGGCTGTCAGTTGCAAAAAAAG\nGAGATCCACCTCTACCAAACATTTGTTGTTCAGCTCCAGGACCCACGGGAACCCAGGAGA\nCAGGCCACACAGATGCTAAAACTGCAGAATCTGGTGATCCCCTGGGCTCCAGAGAACCTA\nACACTTCACAAACTGAGTGAATCCCAGCTAGAACTGAACTGGAACAACAGATTCTTGAAC\nCACTGTTTGGAGCACTTGGTGCAGTACCGGACTGACTGGGACCACAGCTGGACTGAACAA\nTCAGTGGATTATAGACATAAGTTCTCCTTGCCTAGTGTGGATGGGCAGAAACGCTACACG\nTTTCGTGTTCGGAGCCGCTTTAACCCACTCTGTGGAAGTGCTCAGCATTGGAGTGAATGG\nAGCCACCCAATCCACTGGGGGAGCAATACTTCAAAAGAGAATCCTTTCCTGTTTGCATTG\nGAAGCCGTGGTTATCTCTGTTGGCTCCATGGGATTGATTATCAGCCTTCTCTGTGTGTAT\nTTCTGGCTGGAACGGACGATGCCCCGAATTCCCACCCTGAAGAACCTAGAGGATCTTGTT\nACTGAATACCACGGGAACTTTTCGGCCTGGAGTGGTGTGTCTAAGGGACTGGCTGAGAGT\nCTGCAGCCAGACTACAGTGAACGACTCTGCCTCGTCAGTGAGATTCCCCCAAAAGGAGGG\nGCCCTTGGGGAGGGGCCTGGGGCCTCCCCATGCAACCAGCATAGCCCCTACTGGGCCCCC\nCCATGTTACACCCTAAAGCCTGAAACCTGA"}, "pfams": null, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "hematopoietin/interferon-class (D200-domain) cytokine receptor activity"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-11-11", "drugbank-id": [{"@primary": "true", "#text": "DB00005"}, "BIOD00052", "BTD00052"], "name": "Etanercept", "description": "Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids", "cas-number": "185243-69-0", "groups": {"group": ["approved", "investigational"]}, "general-references": "# http://www.genome.jp/dbget-bin/www_bget?D00742\n#American Society of Health System Pharmacists, Inc., DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995. Etanercept; [updated 2014 Sept 24 cited 2014 Nov 11]. Available from http://web.b.ebscohost.com.login.ezproxy.library.ualberta.ca/dynamed/detail?vid=4&sid=eeea413d-1490-4efa-bf5d-71f40e1986a1%40sessionmgr111&hid=123&bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BlPXNpdGU%3d#db=dme&AN=232781", "synthesis-reference": "Timothy D. Osslund, Christi L. Clogston, Shon Lee Crampton, Randal B. Bass, \"Crystals of etanercept and methods of making thereof.\" U.S. Patent US07276477, issued October 02, 2007.", "indication": "For treatment of severe active rheumatoid arthritis in adults, severe juvenile idiopathic arthritis, ankylosing spondylitis, and severe plaque psoriasis.", "pharmacodynamics": "Tumor necrosis factor TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated levels of TNF are found in tissues and fluids of patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (AS), and plaque psoriasis. Etanercept binds specifically to tumor necrosis factor (TNF) and blocks its interaction with cell surface TNF receptors.", "mechanism-of-action": "There are two distinct receptors for TNF (TNFRs), a 55 kilodalton protein (p55) and a 75 kilodalton protein (p75). The biological activity of TNF is dependent upon binding to either cell surface receptor (p75 or p55). Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation.", "toxicity": null, "metabolism": null, "absorption": "Bioavailability following sub-Q administration is approximately 60%. Peak plasma concentrations achieved within 69 hours.", "half-life": "102 +/- 30 hrs in individuals with rheumatoid arthritis and 68 hours in healthy adults", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": "* 160 +/- 80 mL/hr [RA patients]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "CD120b"}, {"@language": "", "@coder": "", "#text": "p75"}, {"@language": "", "@coder": "", "#text": "p80 TNF-alpha receptor"}, {"@language": "", "@coder": "", "#text": "TNF-R2"}, {"@language": "", "@coder": "", "#text": "Tumor necrosis factor receptor 2"}, {"@language": "", "@coder": "", "#text": "Tumor necrosis factor receptor superfamily member 1B precursor"}, {"@language": "", "@coder": "", "#text": "Tumor necrosis factor receptor type II"}]}, "products": {"product": [{"name": "Enbrel", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02242903", "started-marketing-on": "2001-03-14", "ended-marketing-on": null, "dosage-form": "kit; liquid; powder for solution", "strength": "25 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Enbrel", "ndc-id": "58406-435_a4b46c16-aa8a-4789-98db-0df4d9eb5110", "ndc-product-code": "58406-435", "dpd-id": null, "started-marketing-on": "2005-10-06", "ended-marketing-on": null, "dosage-form": "solution", "strength": "50 mg/mL", "route": "subcutaneous", "fda-application-number": "BLA103795", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Enbrel", "ndc-id": "58406-445_a4b46c16-aa8a-4789-98db-0df4d9eb5110", "ndc-product-code": "58406-445", "dpd-id": null, "started-marketing-on": "2005-11-10", "ended-marketing-on": null, "dosage-form": "solution", "strength": "50 mg/mL", "route": "subcutaneous", "fda-application-number": "BLA103795", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Enbrel", "ndc-id": "58406-455_a4b46c16-aa8a-4789-98db-0df4d9eb5110", "ndc-product-code": "58406-455", "dpd-id": null, "started-marketing-on": "2005-11-10", "ended-marketing-on": null, "dosage-form": "solution", "strength": "25 mg/.5mL", "route": "subcutaneous", "fda-application-number": "BLA103795", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Enbrel", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02274728", "started-marketing-on": "2005-12-21", "ended-marketing-on": null, "dosage-form": "solution", "strength": "50 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": {"name": "Enbrel Sureclick", "company": null}}, "mixtures": {"mixture": [{"name": "Enbrel", "ingredients": "Etanercept"}, {"name": "Enbrel", "ingredients": "Etanercept"}, {"name": "Enbrel", "ingredients": "Etanercept"}, {"name": "Enbrel", "ingredients": "Etanercept + Water"}, {"name": "Enbrel", "ingredients": "Etanercept"}]}, "packagers": {"packager": [{"name": "Amgen Inc.", "url": "http://www.amgen.com"}, {"name": "Boehringer Ingelheim Ltd.", "url": "http://www.boehringer-ingelheim.com"}, {"name": "DSM Corp.", "url": "http://www.dsm.com"}, {"name": "Immunex Corp.", "url": null}, {"name": "Physicians Total Care Inc.", "url": "http://www.physicianstotalcare.com"}, {"name": "Vetter Pharma Fertigung GmbH and Co. KG", "url": "http://www.vetter-pharma.com"}]}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Amgen Inc. + Wyeth + Takeda"}}, "prices": {"price": [{"description": "Enbrel 25 mg kit", "cost": {"@currency": "USD", "#text": "250.37"}, "unit": "each"}, {"description": "Enbrel 50 mg/ml sureclick syr", "cost": {"@currency": "USD", "#text": "488.74"}, "unit": "syringe"}, {"description": "Enbrel 4 25 mg Kit (1 Box = 1 Kit = Four 25 mg Vials)", "cost": {"@currency": "USD", "#text": "1016.57"}, "unit": "box"}, {"description": "Enbrel (1 Box = 1 Kit = Four 50 mg Syringes) 3.92ml Box", "cost": {"@currency": "USD", "#text": "2033.14"}, "unit": "box"}, {"description": "Enbrel SureClick (1 Box Contains Four 50 mg Prefilled Autoinjectors)", "cost": {"@currency": "USD", "#text": "2033.14"}, "unit": "box"}]}, "categories": {"category": {"category": "Immunosuppressive Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Kit; liquid; powder for solution", "route": "subcutaneous", "strength": "25 mg"}, {"form": "Solution", "route": "subcutaneous", "strength": "25 mg/.5mL"}, {"form": "Solution", "route": "subcutaneous", "strength": "50 mg"}, {"form": "Solution", "route": "subcutaneous", "strength": "50 mg/mL"}]}, "atc-codes": {"atc-code": {"@code": "L04AB01", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L04", "#text": "IMMUNOSUPPRESSANTS"}, {"@code": "L04A", "#text": "IMMUNOSUPPRESSANTS"}, {"@code": "L04AB", "#text": "Tumor necrosis factor alpha (TNF-\u03b1) inhibitors"}]}}, "ahfs-codes": {"ahfs-code": "92:00.00"}, "patents": {"patent": [{"number": "2123593", "country": "Canada", "approved": "2000-03-14", "expires": "2013-09-14"}, {"number": "2476934", "country": "Canada", "approved": "2009-06-16", "expires": "2023-02-27"}, {"number": "36755", "country": "United States", "approved": "2000-06-27", "expires": "2012-10-23"}, {"number": "7276477", "country": "United States", "approved": "2007-10-02", "expires": "2024-07-29"}]}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB01281", "name": "Abatacept", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported."}, {"drugbank-id": "DB00026", "name": "Anakinra", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported."}, {"drugbank-id": "DB08879", "name": "Belimumab", "description": "Etanercept may enhance the adverse/toxic effect of Belimumab."}, {"drugbank-id": "DB06168", "name": "Canakinumab", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased."}, {"drugbank-id": "DB08904", "name": "Certolizumab pegol", "description": "Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab pegol."}, {"drugbank-id": "DB00531", "name": "Cyclophosphamide", "description": "Etanercept may enhance the adverse/toxic effect of Cyclophosphamide. An increased risk of solid cancer development may be present."}, {"drugbank-id": "DB06643", "name": "Denosumab", "description": "May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased."}, {"drugbank-id": "DB00065", "name": "Infliximab", "description": "Etanercept may enhance the immunosuppressive effect of Infliximab."}, {"drugbank-id": "DB01097", "name": "Leflunomide", "description": "Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased."}, {"drugbank-id": "DB00108", "name": "Natalizumab", "description": "Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased."}, {"drugbank-id": "DB00337", "name": "Pimecrolimus", "description": "May enhance the adverse/toxic effect of Immunosuppressants."}, {"drugbank-id": "DB06372", "name": "Rilonacept", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept."}, {"drugbank-id": "DB01656", "name": "Roflumilast", "description": "May enhance the immunosuppressive effect of Immunosuppressants."}, {"drugbank-id": "DB06688", "name": "Sipuleucel-T", "description": "Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T."}, {"drugbank-id": "DB06273", "name": "Tocilizumab", "description": "May enhance the immunosuppressive effect of Anti-TNF Agents."}, {"drugbank-id": "DB08895", "name": "Tofacitinib", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib."}, {"drugbank-id": "DB08895", "name": "Tofacitinib", "description": "Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib."}, {"drugbank-id": "DB00072", "name": "Trastuzumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB09033", "name": "Vedolizumab", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": "> Etanercept Sequence\nLPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDST\nYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRK\nCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTS\nTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSC\nDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD\nGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK\nGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS\nDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "71 \u00b0C (whole mAb)", "source": "Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)"}, {"kind": "Hydrophobicity", "value": "-0.529", "source": null}, {"kind": "Isoelectric Point", "value": "7.89", "source": null}, {"kind": "Molecular Weight", "value": "51234.9000", "source": null}, {"kind": "Molecular Formula", "value": "C2224H3475N621O698S36", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "12032"}, {"resource": "KEGG Compound", "identifier": "C07897"}, {"resource": "KEGG Drug", "identifier": "D00742"}, {"resource": "National Drug Code Directory", "identifier": "58406-455-04"}, {"resource": "GenBank", "identifier": "M32315"}, {"resource": "PharmGKB", "identifier": "PA449515"}, {"resource": "UniProtKB", "identifier": "P20333"}, {"resource": "Wikipedia", "identifier": "Etanercept"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/etanercept.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/etanercept.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000704", "name": "Tumor necrosis factor", "organism": "Human", "actions": {"action": "antibody"}, "references": "# Park YC, Burkitt V, Villa AR, Tong L, Wu H: Structural basis for self-association and receptor recognition of human TRAF2. Nature. 1999 Apr 8;398(6727):533-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10206649\n# Sandborn WJ, Hanauer SB: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999 May;5(2):119-33. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10338381\n# Grell M, Zimmermann G, Gottfried E, Chen CM, Grunwald U, Huang DC, Wu Lee YH, Durkop H, Engelmann H, Scheurich P, Wajant H, Strasser A: Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J. 1999 Jun 1;18(11):3034-43. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10357816\n# Moreland LW: Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis. Cleve Clin J Med. 1999 Jun;66(6):367-74. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10375846\n# Calabrese LH: Rheumatoid arthritis and primary care: the case for early diagnosis and treatment. J Am Osteopath Assoc. 1999 Jun;99(6):313-21. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10405518\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P01375", "@source": "Swiss-Prot", "name": "Tumor necrosis factor", "general-function": "Involved in tumor necrosis factor receptor binding", "specific-function": "Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin 1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation", "gene-name": "TNF", "locus": "6p21.3", "cellular-location": "Cell membrane; single-pass type II membrane protein. Processed form:Secreted protein. Also exists as", "transmembrane-regions": "36-56", "signal-regions": null, "theoretical-pi": "6.92", "molecular-weight": "25645.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:11892"}, {"resource": "GenAtlas", "identifier": "TNF"}, {"resource": "GeneCards", "identifier": "TNF"}, {"resource": "GenBank Gene Database", "identifier": "M16441"}, {"resource": "GenBank Protein Database", "identifier": "339741"}, {"resource": "UniProtKB", "identifier": "P01375"}, {"resource": "UniProt Accession", "identifier": "TNFA_HUMAN"}]}, "synonyms": {"synonym": ["Cachectin", "TNF-a", "TNF-alpha", "Tumor necrosis factor ligand superfamily member 2", "Tumor necrosis factor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Tumor necrosis factor precursor\nMSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQR\nEEFPRDLSLISPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELR\nDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRE\nTPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL"}, "gene-sequence": {"@format": "FASTA", "#text": ">702 bp\nATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAG\nACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATC\nGTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGG\nGAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCT\nTCTCGAACCCCGAGTGACAAGCCTGTAGCCCATGTTGTAGCAAACCCTCAAGCTGAGGGG\nCAGCTCCAGTGGCTGAACCGCCGGGCCAATGCCCTCCTGGCCAATGGCGTGGAGCTGAGA\nGATAACCAGCTGGTGGTGCCATCAGAGGGCCTGTACCTCATCTACTCCCAGGTCCTCTTC\nAAGGGCCAAGGCTGCCCCTCCACCCATGTGCTCCTCACCCACACCATCAGCCGCATCGCC\nGTCTCCTACCAGACCAAGGTCAACCTCCTCTCTGCCATCAAGAGCCCCTGCCAGAGGGAG\nACCCCAGAGGGGGCTGAGGCCAAGCCCTGGTATGAGCCCATCTATCTGGGAGGGGTCTTC\nCAGCTGGAGAAGGGTGACCGACTCAGCGCTGAGATCAATCGGCCCGACTATCTCGACTTT\nGCCGAGTCTGGGCAGGTCTACTTTGGGATCATTGCCCTGTGA"}, "pfams": {"pfam": {"identifier": "PF00229", "name": "TNF"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor binding"}, {"category": "function", "description": "cytokine activity"}, {"category": "function", "description": "tumor necrosis factor receptor binding"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "immune response"}]}}}, {"@position": "2", "id": "BE0000949", "name": "Tumor necrosis factor receptor superfamily member 1B", "organism": "Human", "actions": null, "references": "# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "unknown", "polypeptide": {"@id": "P20333", "@source": "Swiss-Prot", "name": "Tumor necrosis factor receptor superfamily member 1B", "general-function": "Involved in tumor necrosis factor receptor activity", "specific-function": "Receptor with high affinity for TNFSF2/TNF-alpha and approximately 5-fold lower affinity for homotrimeric TNFSF1/lymphotoxin-alpha. The TRAF1/TRAF2 complex recruits the apoptotic suppressors BIRC2 and BIRC3 to TNFRSF1B/TNFR2. This receptor mediates most of the metabolic effects of TNF-alpha. Isoform 2 blocks TNF-alpha-induced apoptosis, which suggests that it regulates TNF-alpha function by antagonizing its biological activity", "gene-name": "TNFRSF1B", "locus": "1p36.3-p36.2", "cellular-location": "Isoform 1:Cell membrane; single-pass type I membrane protein. Isoform 2:Secreted protein. TBP-II:Sec", "transmembrane-regions": "258-287", "signal-regions": null, "theoretical-pi": "6.22", "molecular-weight": "48291.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:11917"}, {"resource": "GenAtlas", "identifier": "TNFRSF1B"}, {"resource": "GeneCards", "identifier": "TNFRSF1B"}, {"resource": "GenBank Gene Database", "identifier": "M32315"}, {"resource": "GenBank Protein Database", "identifier": "189186"}, {"resource": "UniProtKB", "identifier": "P20333"}, {"resource": "UniProt Accession", "identifier": "TNR1B_HUMAN"}]}, "synonyms": {"synonym": ["CD120b antigen", "Etanercept", "p75", "p80 TNF-alpha receptor", "TNF-R2", "Tumor necrosis factor receptor 2", "Tumor necrosis factor receptor superfamily member 1B precursor", "Tumor necrosis factor receptor type II"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Tumor necrosis factor receptor superfamily member 1B precursor\nMAPVAVWAALAVGLELWAAAHALPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPG\nQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTC\nRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICR\nPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTS\nFLLPMGPSPPAEGSTGDFALPVGLIVGVTALGLLIIGVVNCVIMTQVKKKPLCLQREAKV\nPHLPADKARGTQGPEQQHLLITAPSSSSSSLESSASALDRRAPTRNQPQAPGVEASGAGE\nARASTGSSDSSPGGHGTQVNVTCIVNVCSSSDHSSQCSSQASSTMGDTDSSPSESPKDEQ\nVPFSKEECAFRSQLETPETLLGSTEEKPLPLGVPDAGMKPS"}, "gene-sequence": {"@format": "FASTA", "#text": ">1386 bp\nATGGCGCCCGTCGCCGTCTGGGCCGCGCTGGCCGTCGGACTGGAGCTCTGGGCTGCGGCG\nCACGCCTTGCCCGCCCAGGTGGCATTTACACCCTACGCCCCGGAGCCCGGGAGCACATGC\nCGGCTCAGAGAATACTATGACCAGACAGCTCAGATGTGCTGCAGCAAATGCTCGCCGGGC\nCAACATGCAAAAGTCTTCTGTACCAAGACCTCGGACACCGTGTGTGACTCCTGTGAGGAC\nAGCACATACACCCAGCTCTGGAACTGGGTTCCCGAGTGCTTGAGCTGTGGCTCCCGCTGT\nAGCTCTGACCAGGTGGAAACTCAAGCCTGCACTCGGGAACAGAACCGCATCTGCACCTGC\nAGGCCCGGCTGGTACTGCGCGCTGAGCAAGCAGGAGGGGTGCCGGCTGTGCGCGCCGCTG\nCGCAAGTGCCGCCCGGGCTTCGGCGTGGCCAGACCAGGAACTGAAACATCAGACGTGGTG\nTGCAAGCCCTGTGCCCCGGGGACGTTCTCCAACACGACTTCATCCACGGATATTTGCAGG\nCCCCACCAGATCTGTAACGTGGTGGCCATCCCTGGGAATGCAAGCATGGATGCAGTCTGC\nACGTCCACGTCCCCCACCCGGAGTATGGCCCCAGGGGCAGTACACTTACCCCAGCCAGTG\nTCCACACGATCCCAACACACGCAGCCAACTCCAGAACCCAGCACTGCTCCAAGCACCTCC\nTTCCTGCTCCCAATGGGCCCCAGCCCCCCAGCTGAAGGGAGCACTGGCGACTTCGCTCTT\nCCAGTTGGACTGATTGTGGGTGTGACAGCCTTGGGTCTACTAATAATAGGAGTGGTGAAC\nTGTGTCATCATGACCCAGGTGAAAAAGAAGCCCTTGTGCCTGCAGAGAGAAGCCAAGGTG\nCCTCACTTGCCTGCCGATAAGGCCCGGGGTACACAGGGCCCCGAGCAGCAGCACCTGCTG\nATCACAGCGCCGAGCTCCAGCAGCAGCTCCCTGGAGAGCTCGGCCAGTGCGTTGGACAGA\nAGGGCGCCCACTCGGAACCAGCCACAGGCACCAGGCGTGGAGGCCAGTGGGGCCGGGGAG\nGCCCGGGCCAGCACCGGGAGCTCAGATTCTTCCCCTGGTGGCCATGGGACCCAGGTCAAT\nGTCACCTGCATCGTGAACGTCTGTAGCAGCTCTGACCACAGCTCACAGTGCTCCTCCCAA\nGCCAGCTCCACAATGGGAGACACAGATTCCAGCCCCTCGGAGTCCCCGAAGGACGAGCAG\nGTCCCCTTCTCCAAGGAGGAATGTGCCTTTCGGTCACAGCTGGAGACGCCAGAGACCCTG\nCTGGGGAGCACCGAAGAGAAGCCCCTGCCCCTTGGAGTGCCTGATGCTGGGATGAAGCCC\nAGTTAA"}, "pfams": {"pfam": {"identifier": "PF00020", "name": "TNFR_c6"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "function", "description": "tumor necrosis factor receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "death receptor activity"}, {"category": "process", "description": "cytokine and chemokine mediated signaling pathway"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}]}}}, {"@position": "3", "id": "BE0000710", "name": "High affinity immunoglobulin gamma Fc receptor I", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P12314", "@source": "Swiss-Prot", "name": "High affinity immunoglobulin gamma Fc receptor I", "general-function": "Involved in receptor signaling protein activity", "specific-function": "Binds to the Fc region of immunoglobulins gamma. High affinity receptor", "gene-name": "FCGR1A", "locus": "1q21.2-q21.3", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "293-313", "signal-regions": null, "theoretical-pi": "8.08", "molecular-weight": "42632.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3613"}, {"resource": "GenAtlas", "identifier": "FCGR1A"}, {"resource": "GeneCards", "identifier": "FCGR1A"}, {"resource": "GenBank Gene Database", "identifier": "X14356"}, {"resource": "GenBank Protein Database", "identifier": "31332"}, {"resource": "UniProtKB", "identifier": "P12314"}, {"resource": "UniProt Accession", "identifier": "FCGR1_HUMAN"}]}, "synonyms": {"synonym": ["CD64 antigen", "Fc-gamma RI", "FcRI", "High affinity immunoglobulin gamma Fc receptor I precursor", "IgG Fc receptor I"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">High affinity immunoglobulin gamma Fc receptor I precursor\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1125 bp\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCTCTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAACTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "4", "id": "BE0002097", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "organism": "Human", "actions": null, "references": "# Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15457442\n# Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15526004", "known-action": "unknown", "polypeptide": {"@id": "P08637", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "general-function": null, "specific-function": "Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis", "gene-name": "FCGR3A", "locus": "1q23", "cellular-location": "Cell membrane", "transmembrane-regions": "209-229", "signal-regions": null, "theoretical-pi": "8.21", "molecular-weight": "29089.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3619"}, {"resource": "GenAtlas", "identifier": "FCGR3A"}, {"resource": "GeneCards", "identifier": "FCGR3A"}, {"resource": "GenBank Gene Database", "identifier": "X52645"}, {"resource": "GenBank Protein Database", "identifier": "31324"}, {"resource": "UniProtKB", "identifier": "P08637"}, {"resource": "UniProt Accession", "identifier": "FCG3A_HUMAN"}]}, "synonyms": {"synonym": ["CD16a antigen", "Fc-gamma RIII", "Fc-gamma RIII-alpha", "Fc-gamma RIIIa", "FcR-10", "FcRIII", "FcRIIIa", "IgG Fc receptor III-2", "Low affinity immunoglobulin gamma Fc region receptor III-A precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK"}, "gene-sequence": {"@format": "FASTA", "#text": ">765 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCGACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCA\nAAAGCCACACTCAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTTTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGG\nAAGGACCATAAATTTAAATGGAGAAAGGACCCTCAAGACAAATGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "5", "id": "BE0002098", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "organism": "Human", "actions": null, "references": "# Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15457442\n# Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15526004", "known-action": "unknown", "polypeptide": {"@id": "P12318", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "general-function": null, "specific-function": "Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens", "gene-name": "FCGR2A", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.78", "molecular-weight": "34990.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3616"}, {"resource": "GenAtlas", "identifier": "FCGR2A"}, {"resource": "GeneCards", "identifier": "FCGR2A"}, {"resource": "GenBank Gene Database", "identifier": "M31932"}, {"resource": "GenBank Protein Database", "identifier": "182474"}, {"resource": "UniProtKB", "identifier": "P12318"}, {"resource": "UniProt Accession", "identifier": "FCG2A_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-a", "Fc-gamma-RIIa", "FcRII-a", "IgG Fc receptor II-a", "Low affinity immunoglobulin gamma Fc region receptor II-a precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-a\nMAMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSRLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">954 bp\nATGGCTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "6", "id": "BE0002099", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31994", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "general-function": null, "specific-function": "Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B- cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis", "gene-name": "FCGR2B", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.12", "molecular-weight": "34044.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3618"}, {"resource": "GenAtlas", "identifier": "FCGR2B"}, {"resource": "GeneCards", "identifier": "FCGR2B"}, {"resource": "GenBank Gene Database", "identifier": "U87560"}, {"resource": "GenBank Protein Database", "identifier": "4099445"}, {"resource": "UniProtKB", "identifier": "P31994"}, {"resource": "UniProt Accession", "identifier": "FCG2B_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-b", "Fc-gamma-RIIb", "FcRII-b", "IgG Fc receptor II-b", "Low affinity immunoglobulin gamma Fc region receptor II-b precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI"}, "gene-sequence": {"@format": "FASTA", "#text": ">930 bp\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCTCTCCCAGGATACCCTGAG\nTGCAGGGAAATGGGAGAGACCCTCCCTGAGAAACCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATT"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "7", "id": "BE0002100", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "organism": "Human", "actions": null, "references": "# Hart SP, Ross JA, Ross K, Haslett C, Dransfield I: Molecular characterization of the surface of apoptotic neutrophils: implications for functional downregulation and recognition by phagocytes. Cell Death Differ. 2000 May;7(5):493-503. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10800083\n# Ranheim EA, Kipps TJ: Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Cell Immunol. 1995 Apr 1;161(2):226-35. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7535196", "known-action": "unknown", "polypeptide": {"@id": "P31995", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "general-function": null, "specific-function": "Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells", "gene-name": "FCGR2C", "locus": "1q23.3", "cellular-location": "Cell membrane", "transmembrane-regions": "224-246", "signal-regions": null, "theoretical-pi": "6.9", "molecular-weight": "35578.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:15626"}, {"resource": "GenAtlas", "identifier": "FCGR2C"}, {"resource": "GeneCards", "identifier": "FCGR2C"}, {"resource": "GenBank Gene Database", "identifier": "X17652"}, {"resource": "GenBank Protein Database", "identifier": "32074"}, {"resource": "UniProtKB", "identifier": "P31995"}, {"resource": "UniProt Accession", "identifier": "FCG2C_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-c", "Fc-gamma-RIIc", "FcRII-c", "IgG Fc receptor II-c", "Low affinity immunoglobulin gamma Fc region receptor II-c precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-c\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR\nAPTDDDKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">972 bp\nATGGGAATCCTGTCATTTTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACAGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCATTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCTGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG\nAAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT\nGAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG\nGCACCTACTGACGATGATAAAAACATCTACTTGACTCTTCCTCCCAACGACCATGTCAAC\nAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "8", "id": "BE0001087", "name": "Lymphotoxin-alpha", "organism": "Human", "actions": null, "references": "# Johnson CJ, Reilly KM, Murray KM: Etanercept in juvenile rheumatoid arthritis. Ann Pharmacother. 2001 Apr;35(4):464-71. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11302411\n# Pennica D, Lam VT, Mize NK, Weber RF, Lewis M, Fendly BM, Lipari MT, Goeddel DV: Biochemical properties of the 75-kDa tumor necrosis factor receptor. Characterization of ligand binding, internalization, and receptor phosphorylation. J Biol Chem. 1992 Oct 15;267(29):21172-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1328224\n# Gudbrandsdottir S, Larsen R, Sorensen LK, Nielsen S, Hansen MB, Svenson M, Bendtzen K, Muller K: TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2004 Jan-Feb;22(1):118-24. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15005015\n# Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P: True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha? Ann Rheum Dis. 2004 Oct;63(10):1344-6. Epub 2004 Mar 19. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15033655\n# Kang CP, Lee KW, Yoo DH, Kang C, Bae SC: The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford). 2005 Apr;44(4):547-52. Epub 2005 Feb 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15695296", "known-action": "unknown", "polypeptide": {"@id": "P01374", "@source": "Swiss-Prot", "name": "Lymphotoxin-alpha", "general-function": "Involved in tumor necrosis factor receptor binding", "specific-function": "Cytokine that in its homotrimeric form binds to TNFRSF1A/TNFR1, TNFRSF1B/TNFBR and TNFRSF14/HVEM. In its heterotrimeric form with LTB binds to TNFRSF3/LTBR. Lymphotoxin is produced by lymphocytes and cytotoxic for a wide range of tumor cells in vitro and in vivo", "gene-name": "LTA", "locus": "6p21.3", "cellular-location": "Homotrimer:Secreted protein. Heterotrimer:Membrane", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.36", "molecular-weight": "22297.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6709"}, {"resource": "GenAtlas", "identifier": "LTA"}, {"resource": "GeneCards", "identifier": "LTA"}, {"resource": "GenBank Gene Database", "identifier": "X01393"}, {"resource": "GenBank Protein Database", "identifier": "34445"}, {"resource": "UniProtKB", "identifier": "P01374"}, {"resource": "UniProt Accession", "identifier": "TNFB_HUMAN"}]}, "synonyms": {"synonym": ["LT-alpha", "Lymphotoxin-alpha precursor", "TNF-beta", "Tumor necrosis factor ligand superfamily member 1"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Lymphotoxin-alpha precursor\nMTPPERLFLPRVCGTTLHLLLLGLLLVLLPGAQGLPGVGLTPSAAQTARQHPKMHLAHST\nLKPAAHLIGDPSKQNSLLWRANTDRAFLQDGFSLSNNSLLVPTSGIYFVYSQVVFSGKAY\nSPKATSSPLYLAHEVQLFSSQYPFHVPLLSSQKMVYPGLQEPWLHSMYHGAAFQLTQGDQ\nLSTHTDGIPHLVLSPSTVFFGAFAL"}, "gene-sequence": {"@format": "FASTA", "#text": ">618 bp\nATGACACCACCTGAACGTCTCTTCCTCCCAAGGGTGTGTGGCACCACCCTACACCTCCTC\nCTTCTGGGGCTGCTGCTGGTTCTGCTGCCTGGGGCCCAGGGGCTCCCTGGTGTTGGCCTC\nACACCTTCAGCTGCCCAGACTGCCCGTCAGCACCCCAAGATGCATCTTGCCCACAGCACC\nCTCAAACCTGCTGCTCACCTCATTGGAGACCCCAGCAAGCAGAACTCACTGCTCTGGAGA\nGCAAACACGGACCGTGCCTTCCTCCAGGATGGTTTCTCCTTGAGCAACAATTCTCTCCTG\nGTCCCCACCAGTGGCATCTACTTCGTCTACTCCCAGGTGGTCTTCTCTGGGAAAGCCTAC\nTCTCCCAAGGCCACCTCCTCCCCACTCTACCTGGCCCATGAGGTCCAGCTCTTCTCCTCC\nCAGTACCCCTTCCATGTGCCTCTCCTCAGCTCCCAGAAGATGGTGTATCCAGGGCTGCAG\nGAACCCTGGCTGCACTCGATGTACCACGGGGCTGCGTTCCAGCTCACCCAGGGAGACCAG\nCTATCCACCCACACAGATGGCATCCCCCACCTAGTCCTCAGCCCTAGTACTGTCTTCTTT\nGGAGCCTTCGCTCTGTAG"}, "pfams": {"pfam": {"identifier": "PF00229", "name": "TNF"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor binding"}, {"category": "function", "description": "cytokine activity"}, {"category": "function", "description": "tumor necrosis factor receptor binding"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "immune response"}]}}}, {"@position": "9", "id": "BE0000901", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "organism": "Human", "actions": null, "references": "# Hart SP, Ross JA, Ross K, Haslett C, Dransfield I: Molecular characterization of the surface of apoptotic neutrophils: implications for functional downregulation and recognition by phagocytes. Cell Death Differ. 2000 May;7(5):493-503. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10800083\n# Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F: Acute-phase response, clinical measures and disease activity in ankylosing spondylitis. Joint Bone Spine. 2007 May;74(3):249-53. Epub 2007 Mar 5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17387033\n# Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15457442\n# Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15526004", "known-action": "unknown", "polypeptide": {"@id": "O75015", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "general-function": null, "specific-function": "Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils", "gene-name": "FCGR3B", "locus": "1q23", "cellular-location": "Cell membrane; lipid-anchor; GPI-anchor. Secreted protein. Note=Secreted after cleavage", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.71", "molecular-weight": "26216.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3620"}, {"resource": "GenAtlas", "identifier": "FCGR3B"}, {"resource": "GeneCards", "identifier": "FCGR3B"}, {"resource": "GenBank Gene Database", "identifier": "X16863"}, {"resource": "GenBank Protein Database", "identifier": "31322"}, {"resource": "UniProtKB", "identifier": "O75015"}, {"resource": "UniProt Accession", "identifier": "FCG3B_HUMAN"}]}, "synonyms": {"synonym": ["CD16b antigen", "Fc-gamma RIII", "Fc-gamma RIII-beta", "Fc-gamma RIIIb", "FcR-10", "FcRIII", "FcRIIIb", "IgG Fc receptor III-1", "Low affinity immunoglobulin gamma Fc region receptor III-B precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-B precursor\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI"}, "gene-sequence": {"@format": "FASTA", "#text": ">702 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "10", "id": "BE0001529", "name": "Complement C1s subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P09871", "@source": "Swiss-Prot", "name": "Complement C1s subcomponent", "general-function": "Involved in calcium ion binding", "specific-function": "C1s B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4", "gene-name": "C1S", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "4.59", "molecular-weight": "76685.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1247"}, {"resource": "GenAtlas", "identifier": "C1S"}, {"resource": "GeneCards", "identifier": "C1S"}, {"resource": "GenBank Gene Database", "identifier": "X06596"}, {"resource": "GenBank Protein Database", "identifier": "763110"}, {"resource": "UniProtKB", "identifier": "P09871"}, {"resource": "UniProt Accession", "identifier": "C1S_HUMAN"}]}, "synonyms": {"synonym": ["C1 esterase", "Complement C1s subcomponent precursor", "EC 3.4.21.42"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1s subcomponent precursor\nMWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIE\nLSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERF\nTGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVF\nTALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVF\nVAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTP\nNSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCG\nIPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPK\nCVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGN\nREPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVK\nMGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKV\nEKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCG\nTYGLYTRVKNYVDWIMKTMQENSTPRED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2067 bp\nATGTGGTGCATTGTCCTGTTTTCACTTTTGGCATGGGTTTATGCTGAGCCTACCATGTAT\nGGGGAGATCCTGTCCCCTAACTATCCTCAGGCATATCCCAGTGAGGTAGAGAAATCTTGG\nGACATAGAAGTTCCTGAAGGGTATGGGATTCACCTCTACTTCACCCATCTGGACATTGAG\nCTGTCAGAGAACTGTGCGTATGACTCAGTGCAGATAATCTCAGGAGACACTGAAGAAGGG\nAGGCTCTGTGGACAGAGGAGCAGTAACAATCCCCACTCTCCAATTGTGGAAGAGTTCCAA\nGTCCCATACAACAAACTCCAGGTGATCTTTAAGTCAGACTTTTCCAATGAAGAGCGTTTT\nACGGGGTTTGCTGCATACTATGTTGCCACAGACATAAATGAATGCACAGATTTTGTAGAT\nGTCCCTTGTAGCCACTTCTGCAACAATTTCATTGGTGGTTACTTCTGCTCCTGCCCCCCG\nGAATATTTCCTCCATGATGACATGAAGAATTGCGGAGTTAATTGCAGTGGGGATGTATTC\nACTGCACTGATTGGGGAGATTGCAAGTCCCAATTATCCCAAACCATATCCAGAGAACTCA\nAGGTGTGAATACCAGATCCGGTTGGAGAAAGGGTTCCAAGTGGTGGTGACCTTGCGGAGA\nGAAGATTTTGATGTGGAAGCAGCTGACTCAGCGGGAAACTGCCTTGACAGTTTAGTTTTT\nGTTGCAGGAGATCGGCAATTTGGTCCTTACTGTGGTCATGGATTCCCTGGGCCTCTAAAT\nATTGAAACCAAGAGTAATGCTCTTGATATCATCTTCCAAACTGATCTAACAGGGCAAAAA\nAAGGGCTGGAAACTTCGCTATCATGGAGATCCAATGCCCTGCCCTAAGGAAGACACTCCC\nAATTCTGTTTGGGAGCCTGCGAAGGCAAAATATGTCTTTAGAGATGTGGTGCAGATAACC\nTGTCTGGATGGGTTTGAAGTTGTGGAGGGACGTGTTGGTGCAACATCTTTCTATTCGACT\nTGTCAAAGCAATGGAAAGTGGAGTAATTCCAAACTGAAATGTCAACCTGTGGACTGTGGC\nATTCCTGAATCCATTGAGAATGGTAAAGTTGAAGACCCAGAGAGCACTTTGTTTGGTTCT\nGTCATCCGCTACACTTGTGAGGAGCCATATTACTACATGGAAAATGGAGGAGGTGGGGAG\nTATCACTGTGCTGGTAACGGGAGCTGGGTGAATGAGGTGCTGGGCCCGGAGCTGCCGAAA\nTGTGTTCCAGTCTGTGGAGTCCCCAGAGAACCCTTTGAAGAAAAACAGAGGATAATTGGA\nGGATCCGATGCAGATATTAAAAACTTCCCCTGGCAAGTCTTCTTTGACAACCCATGGGCT\nGGTGGAGCGCTCATTAATGAGTACTGGGTGCTGACGGCTGCTCATGTTGTGGAGGGAAAC\nAGGGAGCCAACAATGTATGTTGGGTCCACCTCAGTGCAGACCTCACGGCTGGCAAAATCC\nAAGATGCTCACTCCTGAGCATGTGTTTATTCATCCGGGATGGAAGCTGCTGGAAGTCCCA\nGAAGGACGAACCAATTTTGATAATGACATTGCACTGGTGCGGCTGAAAGACCCAGTGAAA\nATGGGACCCACCGTCTCTCCCATCTGCCTACCAGGCACCTCTTCCGACTACAACCTCATG\nGATGGGGACCTGGGACTGATCTCAGGCTGGGGCCGAACAGAGAAGAGAGATCGTGCTGTT\nCGCCTCAAGGCGGCAAGGTTACCTGTAGCTCCTTTAAGAAAATGCAAAGAAGTGAAAGTG\nGAGAAACCCACAGCAGATGCAGAGGCCTATGTTTTCACTCCTAACATGATCTGTGCTGGA\nGGAGAGAAGGGCATGGATAGCTGTAAAGGGGACAGTGGTGGGGCCTTTGCTGTACAGGAT\nCCCAATGACAAGACCAAATTCTACGCAGCTGGCCTGGTGTCCTGGGGGCCCCAGTGTGGG\nACCTATGGGCTCTACACACGGGTAAAGAACTATGTTGACTGGATAATGAAGACTATGCAG\nGAAAATAGCACCCCCCGTGAGGACTAA"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "11", "id": "BE0002093", "name": "Complement C1r subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P00736", "@source": "Swiss-Prot", "name": "Complement C1r subcomponent", "general-function": null, "specific-function": "C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system", "gene-name": "C1R", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.24", "molecular-weight": "80174.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1246"}, {"resource": "GenAtlas", "identifier": "C1R"}, {"resource": "GeneCards", "identifier": "C1R"}, {"resource": "GenBank Gene Database", "identifier": "X04701"}, {"resource": "GenBank Protein Database", "identifier": "29539"}, {"resource": "UniProtKB", "identifier": "P00736"}, {"resource": "UniProt Accession", "identifier": "C1R_HUMAN"}]}, "synonyms": {"synonym": ["Complement C1r subcomponent precursor", "Complement component 1, r subcomponent", "EC 3.4.21.41"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1r subcomponent\nMWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF\nQQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF\nSNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY\nELQEDRHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF\nDIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL\nRYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD\nDGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR\nESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF\nTNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV\nSVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME\nEKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV\nRDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2118 bp\nATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC\nATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC\nAACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC\nCAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT\nGATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG\nGGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC\nTCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT\nGTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG\nTGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT\nGAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG\nGCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC\nAACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT\nGATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC\nGGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC\nAATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG\nCGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC\nATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA\nGGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT\nGATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA\nAACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC\nCGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG\nGAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG\nGGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG\nAGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC\nACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT\nGCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC\nCTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC\nAGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG\nCTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC\nAACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG\nGAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT\nGAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT\nGGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA\nAGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC\nAGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG\nATGGAGGAGGAGGACTGA"}, "pfams": {"pfam": [{"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF07645", "name": "EGF_CA"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "12", "id": "BE0002094", "name": "Complement C1q subcomponent subunit A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02745", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit A", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QA", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.45", "molecular-weight": "26017.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1241"}, {"resource": "GenAtlas", "identifier": "C1QA"}, {"resource": "GeneCards", "identifier": "C1QA"}, {"resource": "GenBank Gene Database", "identifier": "AF135157"}, {"resource": "GenBank Protein Database", "identifier": "4894854"}, {"resource": "UniProtKB", "identifier": "P02745"}, {"resource": "UniProt Accession", "identifier": "C1QA_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit A precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit A\nMEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR\nTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI\nRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR\nGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL\nIFPSA"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG\nGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC\nAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG\nACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC\nAAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGGGCCCGTGGCATCCCGGGAATTAAA\nGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT\nCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG\nGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC\nTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG\nGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG\nGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC\nCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC\nATCTTCCCATCTGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "13", "id": "BE0002095", "name": "Complement C1q subcomponent subunit B", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02746", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit B", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QB", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.87", "molecular-weight": "26460.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1242"}, {"resource": "GenAtlas", "identifier": "C1QB"}, {"resource": "GeneCards", "identifier": "C1QB"}, {"resource": "GenBank Gene Database", "identifier": "X03084"}, {"resource": "GenBank Protein Database", "identifier": "573114"}, {"resource": "UniProtKB", "identifier": "P02746"}, {"resource": "UniProt Accession", "identifier": "C1QB_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit B precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit B\nMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEK\nGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKI\nAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCV\nNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANSIF\nSGFLLFPDMEA"}, "gene-sequence": {"@format": "FASTA", "#text": ">688 bp\nCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGG\nGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCC\nAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAA\nTCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGCCCAGGGGCCCCTGG\nAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAGAAAATCGCCTTCTC\nTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATCCGCTTCGACCACGT\nGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTCACCTGCAAGGTGCC\nCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTGTGCGTGAACCTCAT\nGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTATGCCTACAACACCTT\nCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAGAACGTCTTCCTGCA\nGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGCATCTTTTCCGGGTT\nCCTGCTCTTTCCAGATATGGAGGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "14", "id": "BE0002096", "name": "Complement C1q subcomponent subunit C", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02747", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit C", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QC", "locus": "1p36.11", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.58", "molecular-weight": "25774.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1245"}, {"resource": "GenAtlas", "identifier": "C1QC"}, {"resource": "GeneCards", "identifier": "C1QC"}, {"resource": "GenBank Gene Database", "identifier": "AF087892"}, {"resource": "GenBank Protein Database", "identifier": "33150626"}, {"resource": "UniProtKB", "identifier": "P02747"}, {"resource": "UniProt Accession", "identifier": "C1QC_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit C precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit C\nMDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP\nGIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS\nVFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV\nLLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF\nLLFPD"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG\nCTGCTGCCCCTCAGGGCCAAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC\nCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA\nGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA\nCCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC\nCCCATGGGATTCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA\nGTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC\nAACGCGGTCCTCACCAACCCGCAGGAGGATTATGACACGAGCACTGGCAAGTTCACCTGC\nAAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG\nCTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT\nCAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT\nGTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC\nCTGCTCTTCCCCGACTAG"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}]}, "enzymes": {"enzyme": {"@position": "15", "id": "BE0000262", "name": "Prostaglandin G/H synthase 2", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Bawolak MT, Touzin K, Moreau ME, Desormeaux A, Adam A, Marceau F: Cardiovascular expression of inflammatory signaling molecules, the kinin B1 receptor and COX2, in the rabbit: effects of LPS, anti-inflammatory and anti-hypertensive drugs. Regul Pept. 2008 Feb 7;146(1-3):157-68. Epub 2007 Sep 14. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17931716\n# Genovese T, Mazzon E, Crisafulli C, Di Paola R, Muia C, Bramanti P, Cuzzocrea S: Immunomodulatory effects of etanercept in an experimental model of spinal cord injury. J Pharmacol Exp Ther. 2006 Mar;316(3):1006-16. Epub 2005 Nov 22. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16303916", "known-action": "unknown", "polypeptide": {"@id": "P35354", "@source": "Swiss-Prot", "name": "Prostaglandin G/H synthase 2", "general-function": "Involved in peroxidase activity", "specific-function": "May have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity", "gene-name": "PTGS2", "locus": "1q25.2-q25.3", "cellular-location": "Microsome; microsomal membrane; peripheral membrane protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.41", "molecular-weight": "68997.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9605"}, {"resource": "GenAtlas", "identifier": "PTGS2"}, {"resource": "GeneCards", "identifier": "PTGS2"}, {"resource": "GenBank Gene Database", "identifier": "L15326"}, {"resource": "GenBank Protein Database", "identifier": "291988"}, {"resource": "UniProtKB", "identifier": "P35354"}, {"resource": "UniProt Accession", "identifier": "PGH2_HUMAN"}]}, "synonyms": {"synonym": ["COX-2", "Cyclooxygenase- 2", "EC 1.14.99.1", "PGH synthase 2", "PGHS-2", "PHS II", "Prostaglandin G/H synthase 2 precursor", "Prostaglandin H2 synthase 2", "Prostaglandin-endoperoxide synthase 2"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Prostaglandin G/H synthase 2 precursor\nMLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL\nTRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY\nGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS\nNMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY\nQIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD\nVLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ\nNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV\nAGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL\nYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV\nGFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER\nSTEL"}, "gene-sequence": {"@format": "FASTA", "#text": ">1815 bp\nATGCTCGCCCGCGCCCTGCTGCTGTGCGCGGTCCTGGCGCTCAGCCATACAGCAAATCCT\nTGCTGTTCCCACCCATGTCAAAACCGAGGTGTATGTATGAGTGTGGGATTTGACCAGTAT\nAAGTGCGATTGTACCCGGACAGGATTCTATGGAGAAAACTGCTCAACACCGGAATTTTTG\nACAAGAATAAAATTATTTCTGAAACCCACTCCAAACACAGTGCACTACATACTTACCCAC\nTTCAAGGGATTTTGGAACGTTGTGAATAACATTCCCTTCCTTCGAAATGCAATTATGAGT\nTATGTGTTGACATCCAGATCACATTTGATTGACAGTCCACCAACTTACAATGCTGACTAT\nGGCTACAAAAGCTGGGAAGCCTTCTCTAACCTCTCCTATTATACTAGAGCCCTTCCTCCT\nGTGCCTGATGATTGCCCGACTCCCTTGGGTGTCAAAGGTAAAAAGCAGCTTCCTGATTCA\nAATGAGATTGTGGAAAAATTGCTTCTAAGAAGAAAGTTCATCCCTGATCCCCAGGGCTCA\nAACATGATGTTTGCATTCTTTGCCCAGCACTTCACGCATCAGTTTTTCAAGACAGATCAT\nAAGCGAGGGCCAGCTTTCACCAACGGGCTGGGCCATGGGGTGGACTTAAATCATATTTAC\nGGTGAAACTCTGGCTAGACAGCGTAAACTGCGCCTTTTCAAGGATGGAAAAATGAAATAT\nCAGATAATTGATGGAGAGATGTATCCTCCCACAGTCAAAGATACTCAGGCAGAGATGATC\nTACCCTCCTCAAGTCCCTGAGCATCTACGGTTTGCTGTGGGGCAGGAGGTCTTTGGTCTG\nGTGCCTGGTCTGATGATGTATGCCACAATCTGGCTGCGGGAACACAACAGAGTATGCGAT\nGTGCTTAAACAGGAGCATCCTGAATGGGGTGATGAGCAGTTGTTCCAGACAAGCAGGCTA\nATACTGATAGGAGAGACTATTAAGATTGTGATTGAAGATTATGTGCAACACTTGAGTGGC\nTATCACTTCAAACTGAAATTTGACCCAGAACTACTTTTCAACAAACAATTCCAGTACCAA\nAATCGTATTGCTGCTGAATTTAACACCCTCTATCACTGGCATCCCCTTCTGCCTGACACC\nTTTCAAATTCATGACCAGAAATACAACTATCAACAGTTTATCTACAACAACTCTATATTG\nCTGGAACATGGAATTACCCAGTTTGTTGAATCATTCACCAGGCAAATTGCTGGCAGGGTT\nGCTGGTGGTAGGAATGTTCCACCCGCAGTACAGAAAGTATCACAGGCTTCCACTGACCAG\nAGCAGGCAGATGAAATACCAGTCTTTTAATGAGTACCGCAAACGCTTTATGCTGAAGCCC\nTATGAATCATTTGAAGAACTTACAGGAGAAAAGGAAATGTCTGCAGAGTTGGAAGCACTC\nTATGGTGACATCGATGCTGTGGAGCTGTATCCTGCCCTTCTGGTAGAAAAGCCTCGGCCA\nGATGCCATCTTTGGTGAAACCATGGTAGAAGTTGGAGCACCATTCTCCTTGAAAGGACTT\nATGGGTAATGTTATATGTTCTCCTGCCTACTGGAAGCCAAGCACTTTTGGTGGAGAAGTG\nGGTTTTCAAATCATCAACACTGCCTCAATTCAGTCTCTCATCTGCAATAACGTGAAGGGC\nTGTCCCTTTACTTCATTCAGTGTTCCAGATCCAGAGCTCATTAAAACAGTCACCATCAAT\nGCAAGTTCTTCCCGCTCCGGACTAGATGATATCAATCCCACAGTACTACTAAAAGAACGT\nTCGACTGAACTGTAG"}, "pfams": {"pfam": [{"identifier": "PF03098", "name": "An_peroxidase"}, {"identifier": "PF00008", "name": "EGF"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "antioxidant activity"}, {"category": "function", "description": "peroxidase activity"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}}, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-09-13", "drugbank-id": [{"@primary": "true", "#text": "DB00006"}, "BIOD00076", "BTD00076"], "name": "Bivalirudin", "description": "Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.", "cas-number": "128270-60-0", "groups": {"group": ["approved", "investigational"]}, "general-references": "# Seybert AL, Coons JC, Zerumsky K: Treatment of heparin-induced thrombocytopenia: is there a role for bivalirudin? Pharmacotherapy. 2006 Feb;26(2):229-41. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16466327\n# Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA: Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy. 2007 Apr;27(4):564-87. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17381384\n# Dang CH, Durkalski VL, Nappi JM: Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy. 2006 Apr;26(4):461-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16553503\n# Robson R: The use of bivalirudin in patients with renal impairment. J Invasive Cardiol. 2000 Dec;12 Suppl F:33F-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11156732\n# Van De Car DA, Rao SV, Ohman EM: Bivalirudin: a review of the pharmacology and clinical application. Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1673-81. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/21108549\n# Shammas NW: Bivalirudin: pharmacology and clinical applications. Cardiovasc Drug Rev. 2005 Winter;23(4):345-60. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16614733\n# Gleason TG, Chengelis CP, Jackson CB, Lindstrom P: A 24-hour continuous infusion study of bivalirudin in the rat. Int J Toxicol. 2003 May-Jun;22(3):195-206. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12851152", "synthesis-reference": "Avi Tovi, Chaim Eidelman, Shimon Shushan, Alon Hagi, Alexander Ivchenko, Gabriel-Marcus Butilca, Leah Bar-Oz, Tehila Gadi, Gil Zaovi, \"Process for production of Bivalirudin.\" U.S. Patent US20070093423, issued April 26, 2007.", "indication": "For treatment of heparin-induced thrombocytopenia and for the\nprevention of thrombosis. Bivalirudin is indicated for use in\npatients undergoing percutaneous coronary intervention (PCI), in\npatients at moderate to high risk acute coronary syndromes due to\nunstable angina or non-ST segment elevation in whom a PCI is planned.", "pharmacodynamics": "Bivalirudin directly and reversibly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin.  The action of bivalirudin is reversible because thrombin will slowly cleave the thrombin-bivalirudin bond which recovers the active site of thrombin.", "mechanism-of-action": "Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.", "toxicity": "Based on a study by Gleason et al., the no-observed-adverse-effect level (NOAEL) for bivalirudin, administered to rats via intravenous infusion over a 24-hour period, was 2000 mg/kg/24 h.", "metabolism": "80% proteolytic cleavage", "absorption": "Following intravenous administration, bivalirudin exhibits linear\npharmacokinetics .  The mean steady state concentration is 12.3 +/-\n1.7mcg/mL after administration of an intravenous bolus of 1mg/kg\nfollowd by a 2.5mg/kg/hr intravenous infusion given over 4 hours.", "half-life": "* Normal renal function: 25 min (in normal conditions)\n* Creatinine clearance 10-29mL/min: 57min\n* Dialysis-dependant patients: 3.5h", "protein-binding": "Other than thrombin and red blood cells, bivalirudin does not bind to\nplasma proteins.", "route-of-elimination": "Bivalirudin is cleared from plasma by a combination of renal mechanisms (20%) and proteolytic cleavage.", "volume-of-distribution": "0.2L/kg", "clearance": "* 3.4 mL/min/kg [Normal renal function]\n* 3.4 mL/min/kg [mild renal function]\n* 2.7 mL/min/kg [moderate renal function]\n* 2.8 mL/min/kg [severe renal function]\n* 1 mL/min/kg [Dialysis-dependent patients]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": {"product": [{"name": "Angiomax", "ndc-id": "55154-2275_799d3b00-809b-4abc-989c-05faccec49f8", "ndc-product-code": "55154-2275", "dpd-id": null, "started-marketing-on": "2000-12-15", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "250 mg", "route": "intravenous", "fda-application-number": "NDA020873", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Angiomax", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02246533", "started-marketing-on": "2003-05-08", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "250 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Angiomax", "ndc-id": "65293-001_3ff32af9-cb93-41e5-99ef-a7c162b35d92", "ndc-product-code": "65293-001", "dpd-id": null, "started-marketing-on": "2000-12-15", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "250 mg", "route": "intravenous", "fda-application-number": "NDA020873", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Bivalirudin", "ndc-id": "0409-8300_4530ae1c-394e-44f4-89c0-bacb0e6991a0", "ndc-product-code": "0409-8300", "dpd-id": null, "started-marketing-on": "2015-07-14", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "250 mg", "route": "intravenous", "fda-application-number": "ANDA090811", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Bivalirudin", "ndc-id": "0409-8300_fa3b34fe-d666-42e6-a1d4-3dbcfab7a384", "ndc-product-code": "0409-8300", "dpd-id": null, "started-marketing-on": "2015-07-14", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "250 mg", "route": "intravenous", "fda-application-number": "ANDA090816", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Bivalirudin", "ndc-id": "0781-3158_def5f702-a45c-4a38-a49b-a017bb7f5f3c", "ndc-product-code": "0781-3158", "dpd-id": null, "started-marketing-on": "2015-06-15", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "250 mg", "route": "intravenous", "fda-application-number": "NDA020873", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}]}, "international-brands": {"international-brand": {"name": "Angiox", "company": null}}, "mixtures": {"mixture": [{"name": "Bivalirudin", "ingredients": "Bivalirudin"}, {"name": "Bivalirudin", "ingredients": "Bivalirudin"}, {"name": "Bivalirudin", "ingredients": "Bivalirudin"}, {"name": "Angiomax", "ingredients": "Bivalirudin"}, {"name": "Angiomax", "ingredients": "Bivalirudin"}, {"name": "Angiomax", "ingredients": "Bivalirudin"}]}, "packagers": {"packager": [{"name": "Ben Venue Laboratories Inc.", "url": "http://www.benvenue.com"}, {"name": "Oryx Pharmaceuticals Inc.", "url": null}, {"name": "Sepracor Pharmaceuticals Inc.", "url": "http://www.sepracor.com"}, {"name": "The Medicines Co.", "url": "http://www.themedicinescompany.com"}]}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "The medicines co"}}, "prices": {"price": {"description": "Angiomax 250 mg vial", "cost": {"@currency": "USD", "#text": "780.0"}, "unit": "vial"}}, "categories": {"category": {"category": "Antithrombins", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Powder for solution", "route": "intravenous", "strength": "250 mg"}, {"form": "Injection, powder, lyophilized, for solution", "route": "intravenous", "strength": "250 mg"}]}, "atc-codes": {"atc-code": {"@code": "B01AE06", "level": [{"@code": "B", "#text": "BLOOD AND BLOOD FORMING ORGANS"}, {"@code": "B01", "#text": "ANTITHROMBOTIC AGENTS"}, {"@code": "B01A", "#text": "ANTITHROMBOTIC AGENTS"}, {"@code": "B01AE", "#text": "Direct thrombin inhibitors"}]}}, "ahfs-codes": {"ahfs-code": "20:12.04.12"}, "patents": {"patent": [{"number": "2065150", "country": "Canada", "approved": "1999-12-14", "expires": "2010-08-17"}, {"number": "5196404", "country": "United States", "approved": "1993-05-23", "expires": "2010-05-23"}, {"number": "7582727", "country": "United States", "approved": "2009-01-27", "expires": "2029-01-27"}]}, "food-interactions": {"food-interaction": ["Dan shen, dong quai, evening primrose oil, gingko, policosanol, willow bark", "Echinacea"]}, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00054", "name": "Abciximab", "description": "May enhance the anticoagulant effect of other Anticoagulants."}, {"drugbank-id": "DB01418", "name": "Acenocoumarol", "description": "May enhance the anticoagulant effect of other Anticoagulants."}, {"drugbank-id": "DB00945", "name": "Acetylsalicylic acid", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00009", "name": "Alteplase", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00029", "name": "Anistreplase", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06605", "name": "Apixaban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB04272", "name": "Citric Acid", "description": "May enhance the anticoagulant effect of other Anticoagulants."}, {"drugbank-id": "DB06695", "name": "Dabigatran etexilate", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06779", "name": "Dalteparin", "description": "May enhance the anticoagulant effect of other Anticoagulants."}, {"drugbank-id": "DB01254", "name": "Dasatinib", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01609", "name": "Deferasirox", "description": "Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased."}, {"drugbank-id": "DB03619", "name": "Deoxycholic Acid", "description": "Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased."}, {"drugbank-id": "DB00304", "name": "Desogestrel", "description": "May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects."}, {"drugbank-id": "DB00266", "name": "Dicoumarol", "description": "May enhance the anticoagulant effect of other Anticoagulants."}, {"drugbank-id": "DB00378", "name": "Dydrogesterone", "description": "May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects."}, {"drugbank-id": "DB00974", "name": "Edetic Acid", "description": "May enhance the anticoagulant effect of other Anticoagulants."}, {"drugbank-id": "DB09075", "name": "Edoxaban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01225", "name": "Enoxaparin", "description": "May enhance the anticoagulant effect of other Anticoagulants."}, {"drugbank-id": "DB08794", "name": "Ethyl biscoumacetate", "description": "May enhance the anticoagulant effect of other Anticoagulants."}, {"drugbank-id": "DB00569", "name": "Fondaparinux sodium", "description": "May enhance the anticoagulant effect of other Anticoagulants."}, {"drugbank-id": "DB06730", "name": "Gestodene", "description": "May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects."}, {"drugbank-id": "DB01109", "name": "Heparin", "description": "May enhance the anticoagulant effect of other Anticoagulants."}, {"drugbank-id": "DB00078", "name": "Ibritumomab", "description": "Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}, {"drugbank-id": "DB09053", "name": "Ibrutinib", "description": "May enhance the adverse/toxic effect of Anticoagulants."}, {"drugbank-id": "DB09079", "name": "Nintedanib", "description": "Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased."}, {"drugbank-id": "DB08935", "name": "Obinutuzumab", "description": "Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased."}, {"drugbank-id": "DB00686", "name": "Pentosan Polysulfate", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00498", "name": "Phenindione", "description": "May enhance the anticoagulant effect of other Anticoagulants."}, {"drugbank-id": "DB00946", "name": "Phenprocoumon", "description": "May enhance the anticoagulant effect of other Anticoagulants."}, {"drugbank-id": "DB00396", "name": "Progesterone", "description": "May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects."}, {"drugbank-id": "DB00015", "name": "Reteplase", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01207", "name": "Ridogrel", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06228", "name": "Rivaroxaban", "description": "Anticoagulants may enhance the anticoagulant effect of Rivaroxaban."}, {"drugbank-id": "DB01398", "name": "Salicylate-sodium", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00086", "name": "Streptokinase", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06206", "name": "Sugammadex", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06271", "name": "Sulodexide", "description": "May enhance the anticoagulant effect of other Anticoagulants."}, {"drugbank-id": "DB00031", "name": "Tenecteplase", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB09070", "name": "Tibolone", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00932", "name": "Tipranavir", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00374", "name": "Treprostinil", "description": "May enhance the anticoagulant effect of other Anticoagulants."}, {"drugbank-id": "DB00013", "name": "Urokinase", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00163", "name": "Vitamin E", "description": "May enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding."}, {"drugbank-id": "DB09030", "name": "Vorapaxar", "description": "May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding."}, {"drugbank-id": "DB00682", "name": "Warfarin", "description": "May enhance the anticoagulant effect of other Anticoagulants."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">Bivalirudin sequence\nFPRPGGGGNGDFEEIPEEYL"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.985", "source": null}, {"kind": "Isoelectric Point", "value": "3.91", "source": null}, {"kind": "Molecular Weight", "value": "2180.2853", "source": null}, {"kind": "Molecular Formula", "value": "C98H138N24O33", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "12945"}, {"resource": "KEGG Drug", "identifier": "D03136"}, {"resource": "National Drug Code Directory", "identifier": "65293-001-01"}, {"resource": "PharmGKB", "identifier": "PA10032"}, {"resource": "Wikipedia", "identifier": "Bivalirudin"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/angiomax.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/bivalirudin.html"}]}, "pathways": {"pathway": {"smpdb-id": "SMP00277", "name": "Bivalirudin Action Pathway", "drugs": {"drug": [{"drugbank-id": "DB00006", "name": "Bivalirudin"}, {"drugbank-id": "DB01022", "name": "Phylloquinone"}, {"drugbank-id": "DB01373", "name": "Calcium"}]}, "enzymes": {"uniprot-id": ["P00734", "P00748", "P02452", "P03952", "P03951", "P00740", "P00451", "P12259", "P00742", "P02671", "P02675", "P02679", "P00488", "P05160", "P00747", "P00750", "P08709", "P13726", "Q9BQB6", "P38435"]}}}, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0000048", "name": "Prothrombin", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Scatena R: Bivalirudin: a new generation antithrombotic drug. Expert Opin Investig Drugs. 2000 May;9(5):1119-27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11060732\n# Bates ER: Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes. Curr Cardiol Rep. 2001 Sep;3(5):348-54. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11504570\n# Gladwell TD: Bivalirudin: a direct thrombin inhibitor. Clin Ther. 2002 Jan;24(1):38-58. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11833835\n# Kleiman NS, Klem J, Fernandes LS, Rubin H, Challa S, Solomon S, Maresh K, Arora U, Klem E, Buergler J, Mathew S, Browning A, DeLao T: Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J. 2002 Apr;143(4):585-93. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11923794\n# Carswell CI, Plosker GL: Bivalirudin: a review of its potential place in the management of acute coronary syndromes. Drugs. 2002;62(5):841-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11929334\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P00734", "@source": "Swiss-Prot", "name": "Prothrombin", "general-function": "Involved in blood clotting cascade", "specific-function": "Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C", "gene-name": "F2", "locus": "11p11-q12", "cellular-location": "Secreted protein; extracellular space", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.7", "molecular-weight": "70037.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3535"}, {"resource": "GenAtlas", "identifier": "F2"}, {"resource": "GeneCards", "identifier": "F2"}, {"resource": "GenBank Gene Database", "identifier": "M17262"}, {"resource": "GenBank Protein Database", "identifier": "339641"}, {"resource": "UniProtKB", "identifier": "P00734"}, {"resource": "UniProt Accession", "identifier": "THRB_HUMAN"}]}, "synonyms": {"synonym": ["Activated Factor II [IIa]", "Coagulation factor II", "EC 3.4.21.5", "Prothrombin precursor", "Thrombin"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Prothrombin precursor\nMAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC\nVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV\nNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE\nCSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA\nQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG\nDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI\nDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN\nDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP\nVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST\nRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY\nGFYTHVFRLKKWIQKVIDQFGE"}, "gene-sequence": {"@format": "FASTA", "#text": ">1869 bp\nATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC\nCTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG\nGTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTAGAGCGAGAGTGC\nGTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG\nGATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT\nGCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG\nAACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT\nGAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC\nGACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA\nTGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA\nGGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG\nTACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA\nCAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC\nTTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT\nGGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA\nGATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC\nCAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT\nCTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC\nGACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG\nCTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG\nGTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT\nGACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACAAGGTACGAGCGAAACATTGAAAAG\nATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC\nCGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT\nGTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG\nGTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC\nAGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC\nCGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA\nGGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC\nCGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT\nGGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT\nGGAGAGTAG"}, "pfams": {"pfam": [{"identifier": "PF00594", "name": "Gla"}, {"identifier": "PF00051", "name": "Kringle"}, {"identifier": "PF00089", "name": "Trypsin"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "thrombin activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "binding"}, {"category": "process", "description": "hemostasis"}, {"category": "process", "description": "blood coagulation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "physiological process"}]}}}}, "enzymes": {"enzyme": {"@position": "1", "id": "BE0001075", "name": "Myeloperoxidase", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Rudolph V, Rudolph TK, Schopfer FJ, Bonacci G, Lau D, Szocs K, Klinke A, Meinertz T, Freeman BA, Baldus S: Bivalirudin decreases NO bioavailability by vascular immobilization of myeloperoxidase. J Pharmacol Exp Ther. 2008 Nov;327(2):324-31. Epub 2008 Aug 13. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18701766[", "known-action": "unknown", "polypeptide": {"@id": "P05164", "@source": "Swiss-Prot", "name": "Myeloperoxidase", "general-function": "Involved in peroxidase activity", "specific-function": "Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity", "gene-name": "MPO", "locus": "17q23.1", "cellular-location": "Lysosome", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.14", "molecular-weight": "83870.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:7218"}, {"resource": "GenAtlas", "identifier": "MPO"}, {"resource": "GeneCards", "identifier": "MPO"}, {"resource": "GenBank Gene Database", "identifier": "J02694"}, {"resource": "GenBank Protein Database", "identifier": "189040"}, {"resource": "UniProtKB", "identifier": "P05164"}, {"resource": "UniProt Accession", "identifier": "PERM_HUMAN"}]}, "synonyms": {"synonym": ["EC 1.11.1.7", "MPO", "Myeloperoxidase precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Myeloperoxidase precursor\nMGVPFFSSLRCMVDLGPCWAGGLTAEMKLLLALAGLLAILATPQPSEGAAPAVLGEVDTS\nLVLSSMEEAKQLVDKAYKERRESIKQRLRSGSASPMELLSYFKQPVAATRTAVRAADYLH\nVALDLLERKLRSLWRRPFNVTDVLTPAQLNVLSKSSGCAYQDVGVTCPEQDKYRTITGMC\nNNRRSPTLGASNRAFVRWLPAEYEDGFSLPYGWTPGVKRNGFPVALARAVSNEIVRFPTD\nQLTPDQERSLMFMQWGQLLDHDLDFTPEPAARASFVTGVNCETSCVQQPPCFPLKIPPND\nPRIKNQADCIPFFRSCPACPGSNITIRNQINALTSFVDASMVYGSEEPLARNLRNMSNQL\nGLLAVNQRFQDNGRALLPFDNLHDDPCLLTNRSARIPCFLAGDTRSSEMPELTSMHTLLL\nREHNRLATELKSLNPRWDGERLYQEARKIVGAMVQIITYRDYLPLVLGPTAMRKYLPTYR\nSYNDSVDPRIANVFTNAFRYGHTLIQPFMFRLDNRYQPMEPNPRVPLSRVFFASWRVVLE\nGGIDPILRGLMATPAKLNRQNQIAVDEIRERLFEQVMRIGLDLPALNMQRSRDHGLPGYN\nAWRRFCGLPQPETVGQLGTVLRNLKLARKLMEQYGTPNNIDIWMGGVSEPLKRKGRVGPL\nLACIIGTQFRKLRDGDRFWWENEGVFSMQQRQALAQISLPRIICDNTGITTVSKNNIFMS\nNSYPRDFVNCSTLPALNLASWREAS"}, "gene-sequence": {"@format": "FASTA", "#text": ">2238 bp\nATGGGGGTTCCCTTCTTCTCTTCTCTCAGATGCATGGTGGACTTAGGACCTTGCTGGGCT\nGGGGGTCTCACTGCAGAGATGAAGCTGCTTCTGGCCCTAGCAGGGCTCCTGGCCATTCTG\nGCCACGCCCCAGCCCTCTGAAGGTGCTGCTCCAGCTGTCCTGGGGGAGGTGGACACCTCG\nTTGGTGCTGAGCTCCATGGAGGAGGCCAAGCAGCTGGTGGACAAGGCCTACAAGGAGCGG\nCGGGAAAGCATCAAGCAGCGGCTTCGCAGCGGCTCAGCCAGCCCCATGGAACTCCTATCC\nTACTTCAAGCAGCCGGTGGCAGCCACCAGGACGGCGGTGAGGGCCGCTGACTACCTGCAC\nGTGGCTCTAGACCTGCTGGAGAGGAAGCTGCGGTCCCTGTGGCGAAGGCCATTCAATGTC\nACTGATGTGCTGACGCCCGCCCAGCTGAATGTGTTGTCCAAGTCAAGCGGCTGCGCCTAC\nCAGGACGTGGGGGTGACTTGCCCGGAGCAGGACAAATACCGCACCATCACCGGGATGTGC\nAACAACAGACGCAGCCCCACGCTGGGGGCCTCCAACCGTGCCTTTGTGCGCTGGCTGCCG\nGCGGAGTATGAGGACGGCTTCTCTCTTCCCTACGGCTGGACGCCCGGGGTCAAGCGCAAC\nGGCTTCCCGGTGGCTCTGGCTCGCGCGGTCTCCAACGAGATCGTGCGCTTCCCCACTGAT\nCAGCTGACTCCGGACCAGGAGCGCTCACTCATGTTCATGCAATGGGGCCAGCTGTTGGAC\nCACGACCTCGACTTCACCCCTGAGCCGGCCGCCCGGGCCTCCTTCGTCACTGGCGTCAAC\nTGCGAGACCAGCTGCGTTCAGCAGCCGCCCTGCTTCCCGCTCAAGATCCCGCCCAATGAC\nCCCCGCATCAAGAACCAAGCCGACTGCATCCCGTTCTTCCGCTCCTGCCCGGCTTGCCCC\nGGGAGCAACATCACCATCCGCAACCAGATCAACGCGCTCACTTCCTTCGTGGACGCCAGC\nATGGTGTACGGCAGCGAGGAGCCCCTGGCCAGGAACCTGCGCAACATGTCCAACCAGCTG\nGGGCTGCTGGCCGTCAACCAGCGCTTCCAAGACAACGGCCGGGCCCTGCTGCCCTTTGAC\nAACCTGCACGATGACCCCTGTCTCCTCACCAACCGCTCAGCGCGCATCCCCTGCTTCCTG\nGCAGGGGACACCCGTTCCAGTGAGATGCCCGAGCTCACCTCCATGCACACCCTCTTACTT\nCGGGAGCACAACCGGCTGGCCACAGAGCTCAAGAGCCTGAACCCTAGGTGGGATGGGGAG\nAGGCTCTACCAGGAAGCCCGGAAGATCGTGGGGGCCATGGTCCAGATCATCACTTACCGG\nGACTACCTGCCCCTGGTGCTGGGGCCAACGGCCATGAGGAAGTACCTGCCCACGTACCGT\nTCCTACAATGACTCAGTGGACCCACGCATCGCCAACGTCTTCACCAATGCCTTCCGCTAC\nGGCCACACCCTCATCCAACCCTTCATGTTCCGCCTGGACAATCGGTACCAGCCCATGGAA\nCCCAACCCCCGTGTCCCCCTCAGCAGGGTCTTTTTTGCCTCCTGGAGGGTCGTGCTGGAA\nGGTGGCATTGACCCCATCCTCCGGGGCCTCATGGCCACCCCTGCCAAGCTGAATCGTCAG\nAACCAAATTGCAGTGGATGAGATCCGGGAGCGATTGTTTGAGCAGGTCATGAGGATTGGG\nCTGGACCTGCCTGCTCTGAACATGCAGCGCAGCAGGGACCACGGCCTCCCAGGATACAAT\nGCCTGGAGGCGCTTCTGTGGGCTCCCGCAGCCTGAAACTGTGGGCCAGCTGGGCACGGTG\nCTGAGGAACCTGAAATTGGCGAGGAAACTGATGGAGCAGTATGGCACGCCCAACAACATC\nGACATCTGGATGGGCGGCGTGTCCGAGCCTCTGAAGCGCAAAGGCCGCGTGGGCCCACTC\nCTCGCCTGCATCATCGGTACCCAGTTCAGGAAGCTCCGGGATGGTGATCGGTTTTGGTGG\nGAGAACGAGGGTGTGTTCAGCATGCAGCAGCGACAGGCCCTGGCCCAGATCTCATTGCCC\nCGGATCATCTGCGACAACACAGGCATCACCACCGTGTCTAAGAACAACATCTTCATGTCC\nAACTCATATCCCCGGGACTTTGTCAACTGCAGTACACTTCCTGCATTGAACCTGGCTTCC\nTGGAGGGAAGCCTCCTAG"}, "pfams": {"pfam": {"identifier": "PF03098", "name": "An_peroxidase"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "antioxidant activity"}, {"category": "function", "description": "peroxidase activity"}, {"category": "process", "description": "cellular metabolism"}, {"category": "process", "description": "oxygen and reactive oxygen species metabolism"}, {"category": "process", "description": "response to oxidative stress"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}}, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-09-13", "drugbank-id": [{"@primary": "true", "#text": "DB00007"}, "BIOD00009", "BTD00009"], "name": "Leuprolide", "description": "Leuprolide belongs to the general class of drugs known as hormones or hormone antagonists. It is a synthetic 9 residue peptide analog of gonadotropin releasing hormone. Leuprolide is used to treat advanced prostate cancer. It is also used to treat uterine fibroids and endometriosis. Leuprolide is also under investigation for possible use in the treatment of mild to moderate Alzheimer's disease.", "cas-number": "53714-56-0", "groups": {"group": ["approved", "investigational"]}, "general-references": "# Saleh FM, Niel T, Fishman MJ: Treatment of paraphilia in young adults with leuprolide acetate: a preliminary case report series. J Forensic Sci. 2004 Nov;49(6):1343-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15568711\n# Geier MR, Geier DA: The potential importance of steroids in the treatment of autistic spectrum disorders and other disorders involving mercury toxicity. Med Hypotheses. 2005;64(5):946-54. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15780490\n# Doraiswamy PM, Xiong GL: Pharmacological strategies for the prevention of Alzheimer's disease. Expert Opin Pharmacother. 2006 Jan;7(1):1-10. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16370917\n# Sequence Information \"Link\":http://www.freepatentsonline.com/EP1790656.html\n# \"RxMed\":http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20L)/LUPRON%20DEPOT.html", "synthesis-reference": "Daniel Kadzimirzs, Gerhard Jas, Volker Autze, \"Solution-Phase Synthesis of Leuprolide and Its Intermediates.\" U.S. Patent US20090005535, issued January 01, 2009.", "indication": "For treatment of prostate cancer, endometriosis, uterine fibroids and premature puberty", "pharmacodynamics": "Used in the palliative treatment of advanced prostate cancer. Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis.", "mechanism-of-action": "Leuprolide binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion.", "toxicity": "In rats subcutaneous administration of 250 to 500 times the recommended human dose, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a clinical counterpart of this phenomenon. In early clinical trials with leuprolide acetate doses as high as 20 mg/day for up to two years caused no adverse effects differing from those observed with the 1 mg/day dose.", "metabolism": "Primarily degraded by peptidase and not by cytochrome P450 enzymes.", "absorption": "Bioavailability by subcutaneous administration is comparable to that by intravenous administration.", "half-life": "~3 hours", "protein-binding": "43% to 49%", "route-of-elimination": "Excretion in urine", "volume-of-distribution": "* 27 L [intravenous bolus administration to healthy male volunteers]", "clearance": "* 8.34 L/h [healthy male receiving a 1-mg IV bolus]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": {"salt": {"drugbank-id": {"@primary": "true", "#text": "DBSALT000105"}, "name": "Leuprolide acetate", "cas-number": "74381-53-6", "inchikey": "InChIKey=RGLRXNKKBLIBQS-XNHQSDQCSA-N"}}, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "(D-Leu(6),des-gly-NH2(10),pro-ethylamide(9))-gonadotropin-releasing hormone"}, {"@language": "", "@coder": "", "#text": "L-Pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-proline ethylamide"}, {"@language": "", "@coder": "", "#text": "Leuprorelin"}, {"@language": "", "@coder": "", "#text": "Leuprorelina"}, {"@language": "", "@coder": "", "#text": "Leuproreline"}, {"@language": "", "@coder": "", "#text": "Leuprorelinum"}, {"@language": "", "@coder": "", "#text": "PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-NHC2H5"}, {"@language": "", "@coder": "", "#text": "PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-nhet"}]}, "products": {"product": [{"name": "Eligard 22.5mg", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02248240", "started-marketing-on": "2003-12-01", "ended-marketing-on": null, "dosage-form": "powder for suspension, sustained-release", "strength": "28.2 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Eligard 30 mg", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02248999", "started-marketing-on": "2004-04-29", "ended-marketing-on": null, "dosage-form": "powder for suspension, sustained-release", "strength": "35.8 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Eligard 45 mg", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02268892", "started-marketing-on": "2005-08-15", "ended-marketing-on": null, "dosage-form": "powder for suspension, sustained-release", "strength": "58.2 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Eligard 7.5mg", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02248239", "started-marketing-on": "2003-12-01", "ended-marketing-on": null, "dosage-form": "powder for suspension, sustained-release", "strength": "10.2 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Leuprolide Acetate", "ndc-id": "0185-7400_db12d309-92e5-47f0-84d7-aba74956f6e0", "ndc-product-code": "0185-7400", "dpd-id": null, "started-marketing-on": "1998-08-04", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "1 mg/.2mL", "route": "subcutaneous", "fda-application-number": "ANDA074728", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Leuprolide Acetate Injection", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02240264", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "liquid", "strength": "5 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Lupron", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00727695", "started-marketing-on": "1985-12-31", "ended-marketing-on": null, "dosage-form": "liquid", "strength": "5 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Lupron Depot", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00884502", "started-marketing-on": "1992-12-31", "ended-marketing-on": null, "dosage-form": "powder for suspension, sustained-release", "strength": "3.75 mg", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Lupron Depot", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02239833", "started-marketing-on": "1999-09-13", "ended-marketing-on": null, "dosage-form": "powder for suspension, sustained-release", "strength": "30 mg", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Lupron Depot", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02239834", "started-marketing-on": "1999-09-13", "ended-marketing-on": null, "dosage-form": "powder for suspension, sustained-release", "strength": "11.25 mg", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Lupron Depot", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00836273", "started-marketing-on": "1989-12-31", "ended-marketing-on": null, "dosage-form": "powder for suspension, sustained-release", "strength": "7.5 mg", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Lupron Depot", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02230248", "started-marketing-on": "1997-01-29", "ended-marketing-on": null, "dosage-form": "powder for suspension, sustained-release", "strength": "22.5 mg", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Lupron Depot", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02148722", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "powder for suspension, sustained-release", "strength": "11.25 mg", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Lupron Depot", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02148730", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "powder for suspension, sustained-release", "strength": "15 mg", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Zeulide Depot", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02429977", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "powder for suspension, sustained-release; kit", "strength": "5.06 mg", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": [{"name": "Enantone", "company": null}, {"name": "Leuplin", "company": "Takeda"}, {"name": "LeuProMaxx", "company": "Baxter/Teva"}, {"name": "Leupromer", "company": null}, {"name": "Lutrate", "company": null}, {"name": "Memryte", "company": "Curaxis"}, {"name": "Prostap 3", "company": "Takeda UK"}, {"name": "Prostap SR", "company": "Takeda UK"}, {"name": "Viadur", "company": "Bayer AG"}]}, "mixtures": {"mixture": [{"name": "Leuprolide Acetate", "ingredients": "Leuprolide"}, {"name": "Lupron Depot", "ingredients": "Leuprolide"}, {"name": "Lupron Depot", "ingredients": "Leuprolide"}, {"name": "Lupron Depot", "ingredients": "Leuprolide"}, {"name": "Lupron Depot", "ingredients": "Leuprolide"}, {"name": "Lupron Depot", "ingredients": "Leuprolide"}, {"name": "Eligard 7.5mg", "ingredients": "Leuprolide"}, {"name": "Eligard 22.5mg", "ingredients": "Leuprolide"}, {"name": "Eligard 30 mg", "ingredients": "Leuprolide"}, {"name": "Lupron", "ingredients": "Leuprolide"}, {"name": "Eligard 45 mg", "ingredients": "Leuprolide"}, {"name": "Lupron Depot", "ingredients": "Leuprolide"}, {"name": "Lupron Depot", "ingredients": "Leuprolide"}, {"name": "Leuprolide Acetate Injection", "ingredients": "Leuprolide"}, {"name": "Zeulide Depot", "ingredients": "Leuprolide"}]}, "packagers": {"packager": [{"name": "Abbott Laboratories Ltd.", "url": "http://www.abbott.com"}, {"name": "Cardinal Health", "url": "http://www.cardinal.com"}, {"name": "Eon Labs", "url": null}, {"name": "Hospira Inc.", "url": "http://www.hospira.com"}, {"name": "Oso Biopharmaceuticals Manufacturing LLC", "url": null}, {"name": "Physicians Total Care Inc.", "url": "http://www.physicianstotalcare.com"}, {"name": "Sanofi-Aventis Inc.", "url": "http://www.sanofi-aventis.com"}, {"name": "Sun Pharmaceutical Industries Ltd.", "url": "http://www.sunpharma.com"}, {"name": "Takeda Pharmaceutical Co. Ltd.", "url": "http://www.takeda.com"}, {"name": "Teva Pharmaceutical Industries Ltd.", "url": "http://www.tevapharm.com"}, {"name": "Tolmar Inc.", "url": "http://www.tolmar.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Leuprolide 2wk 1 mg/0.2 ml kit", "cost": {"@currency": "USD", "#text": "385.33"}, "unit": "kit"}, {"description": "Leuprolide Acetate 1 mg/0.2ml Kit 2.8ml 2-Week Kit", "cost": {"@currency": "USD", "#text": "400.74"}, "unit": "box"}, {"description": "Eligard 7.5 mg syringe", "cost": {"@currency": "USD", "#text": "493.2"}, "unit": "syringe"}, {"description": "Lupron 2-wk 1 mg/0.2 ml kit", "cost": {"@currency": "USD", "#text": "594.37"}, "unit": "kit"}, {"description": "Eligard 22.5 mg syringe", "cost": {"@currency": "USD", "#text": "1479.6"}, "unit": "syringe"}, {"description": "Eligard 30 mg syringe", "cost": {"@currency": "USD", "#text": "1972.8"}, "unit": "syringe"}, {"description": "Eligard 45 mg syringe", "cost": {"@currency": "USD", "#text": "2959.2"}, "unit": "syringe"}]}, "categories": {"category": [{"category": "Antineoplastic Agents, Hormonal", "mesh-id": null}, {"category": "Fertility Agents, Female", "mesh-id": null}, {"category": "Estrogen Antagonists", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Powder for suspension, sustained-release", "route": "subcutaneous", "strength": "28.2 mg"}, {"form": "Powder for suspension, sustained-release", "route": "subcutaneous", "strength": "35.8 mg"}, {"form": "Powder for suspension, sustained-release", "route": "subcutaneous", "strength": "58.2 mg"}, {"form": "Powder for suspension, sustained-release", "route": "subcutaneous", "strength": "10.2 mg"}, {"form": "Injection, solution", "route": "subcutaneous", "strength": "1 mg/.2mL"}, {"form": "Liquid", "route": "subcutaneous", "strength": "5 mg"}, {"form": "Powder for suspension, sustained-release", "route": "intramuscular", "strength": "11.25 mg"}, {"form": "Powder for suspension, sustained-release", "route": "intramuscular", "strength": "15 mg"}, {"form": "Powder for suspension, sustained-release", "route": "intramuscular", "strength": "22.5 mg"}, {"form": "Powder for suspension, sustained-release", "route": "intramuscular", "strength": "3.75 mg"}, {"form": "Powder for suspension, sustained-release", "route": "intramuscular", "strength": "30 mg"}, {"form": "Powder for suspension, sustained-release", "route": "intramuscular", "strength": "7.5 mg"}, {"form": "Powder for suspension, sustained-release; kit", "route": "intramuscular", "strength": "5.06 mg"}]}, "atc-codes": {"atc-code": {"@code": "L02AE02", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L02", "#text": "ENDOCRINE THERAPY"}, {"@code": "L02A", "#text": "HORMONES AND RELATED AGENTS"}, {"@code": "L02AE", "#text": "Gonadotropin releasing hormone analogues"}]}}, "ahfs-codes": {"ahfs-code": "10:00.00"}, "patents": null, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00414", "name": "Acetohexamide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06203", "name": "Alogliptin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB08907", "name": "Canagliflozin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00672", "name": "Chlorpropamide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB09066", "name": "Corifollitropin Alfa", "description": "Luteinizing Hormone-Releasing Hormone Analogs may enhance the therapeutic effect of Corifollitropin Alfa."}, {"drugbank-id": "DB01120", "name": "Gliclazide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00222", "name": "Glimepiride", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01251", "name": "Gliquidone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01016", "name": "Glyburide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01306", "name": "Insulin Aspart", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01307", "name": "Insulin Detemir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00047", "name": "Insulin Glargine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01309", "name": "Insulin Glulisine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00046", "name": "Insulin Lispro", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00030", "name": "Insulin Regular", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB08914", "name": "Insulin, isophane", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB09083", "name": "Ivabradine", "description": "May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents."}, {"drugbank-id": "DB08882", "name": "Linagliptin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00331", "name": "Metformin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00834", "name": "Mifepristone", "description": "May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents."}, {"drugbank-id": "DB00912", "name": "Repaglinide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06335", "name": "Saxagliptin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01124", "name": "Tolbutamide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB04876", "name": "Vildagliptin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">Leuprolide\nPHWSYLLR"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "0.1", "source": null}, {"kind": "Molecular Weight", "value": "1209.3983", "source": null}, {"kind": "Molecular Formula", "value": "C59H84N16O12", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "1756"}, {"resource": "ChEBI", "identifier": "6427"}, {"resource": "KEGG Compound", "identifier": "C07612"}, {"resource": "KEGG Drug", "identifier": "D08113"}, {"resource": "National Drug Code Directory", "identifier": "0024-0793-75"}, {"resource": "PharmGKB", "identifier": "PA450203"}, {"resource": "Wikipedia", "identifier": "Leuprolide"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/eligard.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/leuprolide.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0000203", "name": "Gonadotropin-releasing hormone receptor", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Castellon E, Clementi M, Hitschfeld C, Sanchez C, Benitez D, Saenz L, Contreras H, Huidobro C: Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest. 2006 Apr-May;24(3):261-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16809153\n# Borroni R, Di Blasio AM, Gaffuri B, Santorsola R, Busacca M, Vigano P, Vignali M: Expression of GnRH receptor gene in human ectopic endometrial cells and inhibition of their proliferation by leuprolide acetate. Mol Cell Endocrinol. 2000 Jan 25;159(1-2):37-43. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10687850\n# Imai A, Takagi A, Horibe S, Takagi H, Tamaya T: Fas and Fas ligand system may mediate antiproliferative activity of gonadotropin-releasing hormone receptor in endometrial cancer cells. Int J Oncol. 1998 Jul;13(1):97-100. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9625809\n# Murase M, Uemura T, Gao M, Inada M, Funabashi T, Hirahara F: GnRH antagonist-induced down-regulation of the mRNA expression of pituitary receptors: comparisons with GnRH agonist effects. Endocr J. 2005 Feb;52(1):131-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15758569\n# Khurana KK, Singh SB, Tatum AH, Schulz V, Badawy SZ: Maintenance of increased Bcl-2 expression in uterine leiomyomas after GnRH agonist therapy. J Reprod Med. 1999 Jun;44(6):487-92. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10394541", "known-action": "yes", "polypeptide": {"@id": "P30968", "@source": "Swiss-Prot", "name": "Gonadotropin-releasing hormone receptor", "general-function": "Involved in rhodopsin-like receptor activity", "specific-function": "Receptor for gonadotropin releasing hormone (GnRH) that mediate the action of GnRH to stimulate the secretion of the gonadotropic hormones (LH and FSH). This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Isoform 2 may act a an inhibitor of GnRH-R signaling", "gene-name": "GNRHR", "locus": "4q21.2", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "39-58\n78-97\n116-137\n165-184\n213-232\n282-300\n307-326", "signal-regions": null, "theoretical-pi": "9.93", "molecular-weight": "37731.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:4421"}, {"resource": "GenAtlas", "identifier": "GNRHR"}, {"resource": "GeneCards", "identifier": "GNRHR"}, {"resource": "GenBank Gene Database", "identifier": "L03380"}, {"resource": "GenBank Protein Database", "identifier": "183422"}, {"resource": "IUPHAR", "identifier": "256"}, {"resource": "Guide to Pharmacology", "identifier": "31"}, {"resource": "UniProtKB", "identifier": "P30968"}, {"resource": "UniProt Accession", "identifier": "GNRHR_HUMAN"}]}, "synonyms": {"synonym": ["GnRH receptor", "GnRH-R"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Gonadotropin-releasing hormone receptor\nMANSASPEQNQNHCSAINNSIPLMQGNLPTLTLSGKIRVTVTFFLFLLSATFNASFLLKL\nQKWTQKKEKGKKLSRMKLLLKHLTLANLLETLIVMPLDGMWNITVQWYAGELLCKVLSYL\nKLFSMYAPAFMMVVISLDRSLAITRPLALKSNSKVGQSMVGLAWILSSVFAGPQLYIFRM\nIHLADSSGQTKVFSQCVTHCSFSQWWHQAFYNFFTFSCLFIIPLFIMLICNAKIIFTLTR\nVLHQDPHELQLNQSKNNIPRARLKTLKMTVAFATSFTVCWTPYYVLGIWYWFDPEMLNRL\nSDPVNHFFFLFAFLNPCFDPLIYGYFSL"}, "gene-sequence": {"@format": "FASTA", "#text": ">987 bp\nATGGCAAACAGTGCCTCTCCTGAACAGAATCAAAATCACTGTTCAGCCATCAACAACAGC\nATCCCACTGATGCAGGGCAACCTCCCCACTCTGACCTTGTCTGGAAAGATCCGAGTGACG\nGTTACTTTCTTCCTTTTTCTGCTCTCTGCGACCTTTAATGCTTCTTTCTTGTTGAAACTT\nCAGAAGTGGACACAGAAGAAAGAGAAAGGGAAAAAGCTCTCAAGAATGAAGCTGCTCTTA\nAAACATCTGACCTTAGCCAACCTGTTGGAGACTCTGATTGTCATGCCACTGGATGGGATG\nTGGAACATTACAGTCCAATGGTATGCTGGAGAGTTACTCTGCAAAGTTCTCAGTTATCTA\nAAGCTTTTCTCCATGTATGCCCCAGCCTTCATGATGGTGGTGATCAGCCTGGACCGCTCC\nCTGGCTATCACGAGGCCCCTAGCTTTGAAAAGCAACAGCAAAGTCGGACAGTCCATGGTT\nGGCCTGGCCTGGATCCTCAGTAGTGTCTTTGCAGGACCACAGTTATACATCTTCAGGATG\nATTCATCTAGCAGACAGCTCTGGACAGACAAAAGTTTTCTCTCAATGTGTAACACACTGC\nAGTTTTTCACAATGGTGGCATCAAGCATTTTATAACTTTTTCACCTTCAGCTGCCTCTTC\nATCATCCCTCTTTTCATCATGCTGATCTGCAATGCAAAAATCATCTTCACCCTGACACGG\nGTCCTTCATCAGGACCCCCACGAACTACAACTGAATCAGTCCAAGAACAATATACCAAGA\nGCACGGCTGAAGACTCTAAAAATGACGGTTGCATTTGCCACTTCATTTACTGTCTGCTGG\nACTCCCTACTATGTCCTAGGAATTTGGTATTGGTTTGATCCTGAAATGTTAAACAGGTTG\nTCAGACCCAGTAAATCACTTCTTCTTTCTCTTTGCCTTTTTAAACCCATGCTTTGATCCA\nCTTATCTATGGATATTTTTCTCTGTGA"}, "pfams": {"pfam": {"identifier": "PF00001", "name": "7tm_1"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "function", "description": "protein-hormone receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "gonadotropin-releasing hormone receptor activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}]}}}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-01-14", "drugbank-id": [{"@primary": "true", "#text": "DB00008"}, "BIOD00043", "BTD00043"], "name": "Peginterferon alfa-2a", "description": "Human interferon 2a, is a covalent conjugate of recombinant alfa-2a interferon with a single branched bis-monomethoxy polyethylene glycol (PEG) chain. The PEG moiety is linked at a single site to the interferon alfa moiety via a stable amide bond to lysine. Peginterferon alfa-2a has an approximate molecular weight of 60,000 daltons. Interferon alfa-2a is produced using recombinant DNA technology in which a cloned human leukocyte interferon gene is inserted into and expressed in Escherichia coli. The resultant protein is 165 amino acids. The PEG strand protects the molecule in vivo from proteolytic breakdown, substantially increases its in vivo half-life, and reduces immunogenicity by wrapping around and physically hindering access to the protein portion of the molecule.", "cas-number": "198153-51-4", "groups": {"group": ["approved", "investigational"]}, "general-references": null, "synthesis-reference": null, "indication": "For treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.", "pharmacodynamics": "Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.", "mechanism-of-action": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": "Terminal half life is 80 hours (range 50 to 140 hours).", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": {"product": [{"name": "Pegasys", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02248077", "started-marketing-on": "2003-08-14", "ended-marketing-on": null, "dosage-form": "solution", "strength": "180 mcg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Pegasys", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02248078", "started-marketing-on": "2003-08-14", "ended-marketing-on": null, "dosage-form": "solution", "strength": "180 mcg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Pegasys", "ndc-id": "0004-0350_95a6b02c-0779-4ee8-966e-f31625cd7ab7", "ndc-product-code": "0004-0350", "dpd-id": null, "started-marketing-on": "2002-10-16", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "180 ug/mL", "route": "subcutaneous", "fda-application-number": "BLA103964", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Pegasys", "ndc-id": "0004-0357_95a6b02c-0779-4ee8-966e-f31625cd7ab7", "ndc-product-code": "0004-0357", "dpd-id": null, "started-marketing-on": "2011-03-29", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "180 ug/.5mL", "route": "subcutaneous", "fda-application-number": "BLA103964", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Pegasys", "ndc-id": "0004-0360_95a6b02c-0779-4ee8-966e-f31625cd7ab7", "ndc-product-code": "0004-0360", "dpd-id": null, "started-marketing-on": "2011-11-01", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "135 ug/.5mL", "route": "subcutaneous", "fda-application-number": "BLA103964", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Pegasys", "ndc-id": "0004-0365_95a6b02c-0779-4ee8-966e-f31625cd7ab7", "ndc-product-code": "0004-0365", "dpd-id": null, "started-marketing-on": "2011-11-01", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "180 ug/.5mL", "route": "subcutaneous", "fda-application-number": "BLA103964", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Pegasys Rbv", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02253410", "started-marketing-on": "2004-05-26", "ended-marketing-on": null, "dosage-form": "solution; tablet", "strength": "180 mcg", "route": "oral; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Pegasys Rbv", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02253429", "started-marketing-on": "2004-05-26", "ended-marketing-on": null, "dosage-form": "solution; tablet", "strength": "180 mcg", "route": "oral; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Pegasys", "ingredients": "Peginterferon alfa-2a"}, {"name": "Pegasys", "ingredients": "Peginterferon alfa-2a"}, {"name": "Pegasys", "ingredients": "Peginterferon alfa-2a"}, {"name": "Pegasys", "ingredients": "Peginterferon alfa-2a"}, {"name": "Pegasys", "ingredients": "Peginterferon alfa-2a"}, {"name": "Pegasys", "ingredients": "Peginterferon alfa-2a"}, {"name": "Pegasys Rbv", "ingredients": "Peginterferon alfa-2a + Ribavirin"}, {"name": "Pegasys Rbv", "ingredients": "Peginterferon alfa-2a + Ribavirin"}]}, "packagers": {"packager": [{"name": "F Hoffmann La Roche Ltd.", "url": "http://www.roche.com"}, {"name": "F Hoffmann-La Roche Ltd.", "url": "http://www.roche.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Pegasys 180 mcg/ml vial", "cost": {"@currency": "USD", "#text": "642.64"}, "unit": "ml"}, {"description": "Pegasys 180 mcg/0.5 ml conv.pk", "cost": {"@currency": "USD", "#text": "2533.2"}, "unit": "each"}, {"description": "Pegasys (1 Kit = Four 180 mcg/ml Vials Prefilled Syringes) Box", "cost": {"@currency": "USD", "#text": "2634.53"}, "unit": "box"}]}, "categories": {"category": {"category": "Immunosuppressive Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, solution", "route": "subcutaneous", "strength": "135 ug/.5mL"}, {"form": "Injection, solution", "route": "subcutaneous", "strength": "180 ug/.5mL"}, {"form": "Injection, solution", "route": "subcutaneous", "strength": "180 ug/mL"}, {"form": "Solution", "route": "subcutaneous", "strength": "180 mcg"}, {"form": "Solution; tablet", "route": "oral; subcutaneous", "strength": "180 mcg"}]}, "atc-codes": {"atc-code": {"@code": "L03AB11", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L03", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03A", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03AB", "#text": "Interferons"}]}}, "ahfs-codes": {"ahfs-code": "08:18.20"}, "patents": {"patent": [{"number": "2172664", "country": "Canada", "approved": "2000-10-03", "expires": "2016-03-26"}, {"number": "2203480", "country": "Canada", "approved": "2009-06-30", "expires": "2017-04-23"}]}, "food-interactions": {"food-interaction": "Recommended adequate hydration."}, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00041", "name": "Aldesleukin", "description": "Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination."}, {"drugbank-id": "DB00363", "name": "Clozapine", "description": "Myelosuppressive Agents may enhance the adverse/toxic effect of Clozapine. Specifically, the risk for agranulocytosis may be increased."}, {"drugbank-id": "DB04817", "name": "Metamizole", "description": "May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased"}, {"drugbank-id": "DB00333", "name": "Methadone", "description": "Interferons (Alfa) may increase the serum concentration of Methadone."}, {"drugbank-id": "DB00811", "name": "Ribavirin", "description": "Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin. Hemolytic anemia has been observed."}, {"drugbank-id": "DB01265", "name": "Telbivudine", "description": "Peginterferon alfa-2a may enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased."}, {"drugbank-id": "DB00697", "name": "Tizanidine", "description": "CYP1A2 Inhibitors (Weak) may increase the serum concentration of Tizanidine."}, {"drugbank-id": "DB00495", "name": "Zidovudine", "description": "Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">Peginterferon alfa-2a sequence\nCDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI\nQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR\nKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "61 \u00b0C", "source": "Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)"}, {"kind": "Isoelectric Point", "value": "5.99", "source": null}, {"kind": "Molecular Weight", "value": "60000.0000", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "13246"}, {"resource": "GenBank", "identifier": "J00207"}, {"resource": "PharmGKB", "identifier": "PA164749390"}, {"resource": "UniProtKB", "identifier": "P01563"}, {"resource": "Wikipedia", "identifier": "Peginterferon_alfa-2a"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/pegasys.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/peginterferon-alfa-2a.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000385", "name": "Interferon alpha/beta receptor 2", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15898717\n# Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16953837\n# Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19955815\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P48551", "@source": "Swiss-Prot", "name": "Interferon alpha/beta receptor 2", "general-function": "Involved in interferon-alpha/beta receptor activity", "specific-function": "Receptor for interferons alpha and beta. Isoform 1 and isoform 3 are directly involved in signal transduction due to their interaction with the TYR kinase, JAK1. Isoform 1 also interacts with the transcriptional factors, STAT1 and STAT2. Both forms are potent inhibitors of type I IFN activity", "gene-name": "IFNAR2", "locus": null, "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "244-264", "signal-regions": null, "theoretical-pi": "4.11", "molecular-weight": "57759.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5433"}, {"resource": "GenAtlas", "identifier": "IFNAR2"}, {"resource": "GeneCards", "identifier": "IFNAR2"}, {"resource": "GenBank Gene Database", "identifier": "L42243"}, {"resource": "GenBank Protein Database", "identifier": "995300"}, {"resource": "UniProtKB", "identifier": "P48551"}, {"resource": "UniProt Accession", "identifier": "INAR2_HUMAN"}]}, "synonyms": {"synonym": ["IFN-alpha-REC", "IFN-R", "Interferon alpha/beta receptor 2", "Interferon-alpha/beta receptor beta chain precursor", "Type I interferon receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interferon-alpha/beta receptor beta chain precursor\nMLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS\nIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF\nSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK\nHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE\nSAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD\nMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI\nDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR\nITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT\nFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR"}, "gene-sequence": {"@format": "FASTA", "#text": ">1548 bp\nATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT\nATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT\nTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC\nATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG\nGTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA\nAGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC\nAGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG\nATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA\nGAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG\nCATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA\nATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA\nATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA\nTCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC\nATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG\nAATTTTCATAACTTTTTAGCCTGGCCATTTCCTAACCTGCCACCGTTGGAAGCCATGGAT\nATGGTGGAGGTCATTTACATCAACAGAAAGAAGAAAGTGTGGGATTATAATTATGATGAT\nGAAAGTGATAGCGATACTGAGGCAGCGCCCAGGACAAGTGGCGGTGGCTATACCATGCAT\nGGACTGACTGTCAGGCCTCTGGGTCAGGCCTCTGCCACCTCTACAGAATCCCAGTTGATA\nGACCCGGAGTCCGAGGAGGAGCCTGACCTGCCTGAGGTTGATGTGGAGCTCCCCACGATG\nCCAAAGGACAGCCCTCAGCAGTTGGAACTCTTGAGTGGGCCCTGTGAGAGGAGAAAGAGT\nCCACTCCAGGACCCTTTTCCCGAAGAGGACTACAGCTCCACGGAGGGGTCTGGGGGCAGA\nATTACCTTCAATGTGGACTTAAACTCTGTGTTTTTGAGAGTTCTTGATGACGAGGACAGT\nGACGACTTAGAAGCCCCTCTGATGCTATCGTCTCATCTGGAAGAGATGGTTGACCCAGAG\nGATCCTGATAATGTGCAATCAAACCATTTGCTGGCCAGCGGGGAAGGGACACAGCCAACC\nTTTCCCAGCCCCTCTTCAGAGGGCCTGTGGTCCGAAGATGCTCCATCTGATCAAAGTGAC\nACTTCTGAGTCAGATGTTGACCTTGGGGATGGTTATATAATGAGATGA"}, "pfams": null, "go-classifiers": null}}, {"id": "BE0000661", "name": "Interferon alpha/beta receptor 1", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15898717\n# Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16953837\n# Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19955815\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P17181", "@source": "Swiss-Prot", "name": "Interferon alpha/beta receptor 1", "general-function": "Involved in interferon-alpha/beta receptor activity", "specific-function": "Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta- subunits themselves", "gene-name": "IFNAR1", "locus": null, "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "437-457", "signal-regions": null, "theoretical-pi": "5.56", "molecular-weight": "63526.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5432"}, {"resource": "GenAtlas", "identifier": "IFNAR1"}, {"resource": "GeneCards", "identifier": "IFNAR1"}, {"resource": "GenBank Gene Database", "identifier": "J03171"}, {"resource": "GenBank Protein Database", "identifier": "306914"}, {"resource": "UniProtKB", "identifier": "P17181"}, {"resource": "UniProt Accession", "identifier": "INAR1_HUMAN"}]}, "synonyms": {"synonym": ["IFN-alpha-REC", "Interferon-alpha/beta receptor alpha chain precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interferon-alpha/beta receptor alpha chain precursor\nMMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT\nFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF\nTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI\nENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ\nNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK\nGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP\nVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV\nFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE\nYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN\nEDESESKTSEELQQDFV"}, "gene-sequence": {"@format": "FASTA", "#text": ">1674 bp\nATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGGCCCATGGGTG\nTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC\nATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT\nTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG\nAATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT\nAAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT\nACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG\nGCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT\nTTAAGCTTTACATATAGCTTACTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT\nGAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA\nAAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT\nATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA\nAATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG\nTGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA\nCCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA\nGGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA\nGAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA\nTCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT\nGTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT\nGAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT\nGTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT\nTTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA\nGTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC\nTTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG\nTATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA\nAAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT\nGATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT\nGAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA"}, "pfams": null, "go-classifiers": null}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-01-09", "drugbank-id": [{"@primary": "true", "#text": "DB00009"}, "BIOD00050", "BTD00050"], "name": "Alteplase", "description": "Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells", "cas-number": "105857-23-6", "groups": {"group": "approved"}, "general-references": null, "synthesis-reference": null, "indication": "For management of acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli", "pharmacodynamics": "Alteplase binds to fibrin in a thrombus and converts the entrapped plasminogen to plasmin. It also produces limited conversion of plasminogen in the absence of fibrin.", "mechanism-of-action": "Alteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "t-PA"}, {"@language": "", "@coder": "", "#text": "t-plasminogen activator"}, {"@language": "", "@coder": "", "#text": "Tissue-type plasminogen activator precursor"}, {"@language": "", "@coder": "", "#text": "tPA"}]}, "products": {"product": [{"name": "Activase Rt-pa", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02225689", "started-marketing-on": "1998-04-12", "ended-marketing-on": null, "dosage-form": "liquid; powder for solution", "strength": "50 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Activase Rt-pa", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02147440", "started-marketing-on": "1996-12-31", "ended-marketing-on": null, "dosage-form": "liquid; powder for solution", "strength": "100 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Activase Rt-pa Inj", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00771473", "started-marketing-on": "1987-12-31", "ended-marketing-on": "1998-07-31", "dosage-form": "powder for solution", "strength": "29 m", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Cathflo", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02245859", "started-marketing-on": "2002-09-26", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "1 mg", "route": "instillation", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Cathflo Activase", "ndc-id": "50242-041_162fe6a5-4dc6-46b5-8206-24a0af55f2d1", "ndc-product-code": "50242-041", "dpd-id": null, "started-marketing-on": "2001-09-04", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "2.2 mg/2mL", "route": "intravenous", "fda-application-number": "BLA103172", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Lysatec Rt - Pa", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02009285", "started-marketing-on": "1993-12-31", "ended-marketing-on": "1997-08-26", "dosage-form": "powder for solution", "strength": "50 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Cathflo Activase", "ingredients": "Alteplase"}, {"name": "Activase Rt-pa", "ingredients": "Alteplase + Water"}, {"name": "Activase Rt-pa", "ingredients": "Alteplase + Water"}, {"name": "Cathflo", "ingredients": "Alteplase"}, {"name": "Lysatec Rt - Pa", "ingredients": "Alteplase + Water"}, {"name": "Activase Rt-pa Inj", "ingredients": "Alteplase"}]}, "packagers": {"packager": {"name": "Genentech Inc.", "url": "http://www.gene.com"}}, "manufacturers": null, "prices": {"price": [{"description": "Cathflo activase 2 mg vial", "cost": {"@currency": "USD", "#text": "106.33"}, "unit": "vial"}, {"description": "Activase 50 mg vial", "cost": {"@currency": "USD", "#text": "2389.85"}, "unit": "vial"}, {"description": "Activase 100 mg vial", "cost": {"@currency": "USD", "#text": "4779.71"}, "unit": "vial"}]}, "categories": {"category": {"category": "Thrombolytic Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Liquid; powder for solution", "route": "intravenous", "strength": "100 mg"}, {"form": "Liquid; powder for solution", "route": "intravenous", "strength": "50 mg"}, {"form": "Powder for solution", "route": "intravenous", "strength": "29 m"}, {"form": "Powder for solution", "route": "instillation", "strength": "1 mg"}, {"form": "Injection, powder, lyophilized, for solution", "route": "intravenous", "strength": "2.2 mg/2mL"}, {"form": "Powder for solution", "route": "intravenous", "strength": "50 mg"}]}, "atc-codes": {"atc-code": [{"@code": "B01AD02", "level": [{"@code": "B", "#text": "BLOOD AND BLOOD FORMING ORGANS"}, {"@code": "B01", "#text": "ANTITHROMBOTIC AGENTS"}, {"@code": "B01A", "#text": "ANTITHROMBOTIC AGENTS"}, {"@code": "B01AD", "#text": "Enzymes"}]}, {"@code": "S01XA13", "level": [{"@code": "S", "#text": "SENSORY ORGANS"}, {"@code": "S01", "#text": "OPHTHALMOLOGICALS"}, {"@code": "S01X", "#text": "OTHER OPHTHALMOLOGICALS"}, {"@code": "S01XA", "#text": "Other ophthalmologicals"}]}]}, "ahfs-codes": {"ahfs-code": "20:12.20"}, "patents": null, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00054", "name": "Abciximab", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01418", "name": "Acenocoumarol", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00945", "name": "Acetylsalicylic acid", "description": "May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB00233", "name": "Aminosalicylic Acid", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB00261", "name": "Anagrelide", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06605", "name": "Apixaban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06692", "name": "Aprotinin", "description": "May diminish the therapeutic effect of Thrombolytic Agents."}, {"drugbank-id": "DB00278", "name": "Argatroban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01294", "name": "Bismuth Subsalicylate", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB00006", "name": "Bivalirudin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06441", "name": "Cangrelor", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01166", "name": "Cilostazol", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00215", "name": "Citalopram", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB04272", "name": "Citric Acid", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00758", "name": "Clopidogrel", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06695", "name": "Dabigatran etexilate", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Dabigatran etexilate."}, {"drugbank-id": "DB06779", "name": "Dalteparin", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06754", "name": "Danaparoid", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06700", "name": "Desvenlafaxine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00586", "name": "Diclofenac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00266", "name": "Dicoumarol", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00861", "name": "Diflunisal", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01551", "name": "Dihydrocodeine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00975", "name": "Dipyridamole", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00476", "name": "Duloxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00974", "name": "Edetic Acid", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB09075", "name": "Edoxaban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01225", "name": "Enoxaparin", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01240", "name": "Epoprostenol", "description": "May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents."}, {"drugbank-id": "DB00063", "name": "Eptifibatide", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01175", "name": "Escitalopram", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB08794", "name": "Ethyl biscoumacetate", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00749", "name": "Etodolac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00573", "name": "Fenoprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB08976", "name": "Floctafenine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00472", "name": "Fluoxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00712", "name": "Flurbiprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00176", "name": "Fluvoxamine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00569", "name": "Fondaparinux sodium", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01109", "name": "Heparin", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01050", "name": "Ibuprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01088", "name": "Iloprost", "description": "May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents."}, {"drugbank-id": "DB00328", "name": "Indomethacin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01009", "name": "Ketoprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00465", "name": "Ketorolac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB08918", "name": "Levomilnacipran", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01397", "name": "Magnesium salicylate", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB00784", "name": "Mefenamic acid", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00814", "name": "Meloxicam", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB04896", "name": "Milnacipran", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00461", "name": "Nabumetone", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB08813", "name": "Nadroparin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00788", "name": "Naproxen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00727", "name": "Nitroglycerin", "description": "May decrease the serum concentration of Alteplase."}, {"drugbank-id": "DB00991", "name": "Oxaprozin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00715", "name": "Paroxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00498", "name": "Phenindione", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00946", "name": "Phenprocoumon", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00554", "name": "Piroxicam", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06209", "name": "Prasugrel", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06228", "name": "Rivaroxaban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01398", "name": "Salicylate-sodium", "description": "May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB01399", "name": "Salsalate", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB01104", "name": "Sertraline", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00605", "name": "Sulindac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06271", "name": "Sulodexide", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01600", "name": "Tiaprofenic acid", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB08816", "name": "Ticagrelor", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00208", "name": "Ticlopidine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06822", "name": "Tinzaparin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00775", "name": "Tirofiban", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00500", "name": "Tolmetin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00374", "name": "Treprostinil", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00285", "name": "Venlafaxine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06684", "name": "Vilazodone", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB09030", "name": "Vorapaxar", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB09068", "name": "Vortioxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00682", "name": "Warfarin", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">Alteplase sequence\nSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGG\nTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSA\nLAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDC\nYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAK\nPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRS\nPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVH\nKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEAL\nSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGG\nPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "60 \u00b0C", "source": "Novokhatny, V.V. et al., J. Biol. Chem. 266:12994-123002 (1991)"}, {"kind": "Hydrophobicity", "value": "-0.516", "source": null}, {"kind": "Isoelectric Point", "value": "7.61", "source": null}, {"kind": "Molecular Weight", "value": "59042.3000", "source": null}, {"kind": "Molecular Formula", "value": "C2569H3928N746O781S40", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "7297"}, {"resource": "KEGG Drug", "identifier": "D02837"}, {"resource": "GenBank", "identifier": "L00153"}, {"resource": "PharmGKB", "identifier": "PA164776730"}, {"resource": "UniProtKB", "identifier": "P00750"}, {"resource": "Wikipedia", "identifier": "Alteplase"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/alteplas.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/alteplase.html"}]}, "pathways": {"pathway": {"smpdb-id": "SMP00280", "name": "Alteplase Action Pathway", "drugs": {"drug": [{"drugbank-id": "DB00009", "name": "Alteplase"}, {"drugbank-id": "DB01022", "name": "Phylloquinone"}, {"drugbank-id": "DB01373", "name": "Calcium"}]}, "enzymes": {"uniprot-id": ["P00747", "P00748", "P02452", "P03952", "P03951", "P00740", "P00451", "P00734", "P12259", "P00742", "P02671", "P02675", "P02679", "P00488", "P05160", "P00750", "P08709", "P13726", "Q9BQB6", "P38435"]}}}, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000211", "name": "Plasminogen", "organism": "Human", "actions": {"action": "activator"}, "references": "# Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18673235\n# Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19436656\n# Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17963464\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P00747", "@source": "Swiss-Prot", "name": "Plasminogen", "general-function": "Involved in plasmin activity", "specific-function": "Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo", "gene-name": "PLG", "locus": "6q26", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.25", "molecular-weight": "90569.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9071"}, {"resource": "GenAtlas", "identifier": "PLG"}, {"resource": "GeneCards", "identifier": "PLG"}, {"resource": "GenBank Gene Database", "identifier": "X05199"}, {"resource": "GenBank Protein Database", "identifier": "387026"}, {"resource": "UniProtKB", "identifier": "P00747"}, {"resource": "UniProt Accession", "identifier": "PLMN_HUMAN"}]}, "synonyms": {"synonym": ["EC 3.4.21.7", "Plasminogen precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Plasminogen precursor\nMEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT\nCRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN\nGITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE\nCEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE\nLRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS\nAQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE\nQLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG\nLTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED\nCMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG\nPWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT\nRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE\nPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ\nLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW\nGLGCARPNKPGVYVRVSRFVTWIEGVMRNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">2433 bp\nATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG\nCCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG\nCTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC\nTGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG\nAAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC\nTCAGAGTGCAAGACTGGGAATGGAAAGAATTACAGAGGGACGATGTCCAAAACAAAAAAT\nGGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT\nACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG\nGGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG\nTGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC\nATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT\nCCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG\nCTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGCGACATCCCC\nCGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT\nGAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT\nGCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTTCCCTGCAAAAATTTGGAT\nGAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC\nCAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA\nCAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT\nGATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT\nTGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC\nCTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA\nGACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT\nGTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAAATGTAGAGACTCCTTCCGAAGAAGAC\nTGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG\nCCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA\nAATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT\nCCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT\nGCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG\nGTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA\nAGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT\nGCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC\nCAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG\nCCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA\nGTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC\nATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG\nCTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA\nTCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT\nGGAGGGCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG\nGGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT\nACTTGGATTGAGGGAGTGATGAGAAATAATTAA"}, "pfams": {"pfam": [{"identifier": "PF00051", "name": "Kringle"}, {"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00024", "name": "PAN_1"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "plasmin activity"}, {"category": "function", "description": "binding"}, {"category": "process", "description": "hemostasis"}, {"category": "process", "description": "blood coagulation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "2", "id": "BE0000538", "name": "Fibrinogen alpha chain", "organism": "Human", "actions": null, "references": "# Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18673235\n# Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19436656\n# Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17963464", "known-action": "yes", "polypeptide": {"@id": "P02671", "@source": "Swiss-Prot", "name": "Fibrinogen alpha chain", "general-function": "Carbohydrate transport and metabolism", "specific-function": "Fibrinogen has a double function:yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation", "gene-name": "FGA", "locus": "4q28", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.87", "molecular-weight": "94974.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3661"}, {"resource": "GenAtlas", "identifier": "FGA"}, {"resource": "GeneCards", "identifier": "FGA"}, {"resource": "GenBank Gene Database", "identifier": "AF361104"}, {"resource": "GenBank Protein Database", "identifier": "13591824"}, {"resource": "UniProtKB", "identifier": "P02671"}, {"resource": "UniProt Accession", "identifier": "FIBA_HUMAN"}]}, "synonyms": {"synonym": "Fibrinogen alpha chain precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Fibrinogen alpha chain precursor [Contains: Fibrinopeptide A]\nMFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW\nNYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA\nNNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC\nRGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQ\nLQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSS\nGPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTW\nNPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV\nSPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTK\nEVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEF\nVSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKS\nYKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFS\nVYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQR\nGSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSH\nNNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENG\nVVWVSFRGADYSLRAVRMKIRPLVTQ"}, "gene-sequence": {"@format": "FASTA", "#text": ">2601 bp\nATGTTTTCCATGAGGATCGTCTGCCTAGTTCTAAGTGTGGTGGGCACAGCATGGACTGCA\nGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTG\nGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGG\nAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGAT\nTTTACAAACAGAATAAATAAGCTCAAAAATTCACTATTTGAATATCAGAAGAACAATAAG\nGATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCGATTTTTCCTCAGCC\nAATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTGAAGTC\nCTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAGAAAAATGTTAGA\nGCTCAGTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGT\nCGAGGGTCATGCAGTAGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAG\nCAGAAGCAACTTGAACAGGTCATTGCCAAAGACTTACTTCCCTCTAGAGATAGGCAACAC\nTTACCACTGATAAAAATGAAACCAGTTCCAGACTTGGTTCCCGGAAATTTTAAGAGCCAG\nCTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCGCAGATGAGAATGGAG\nTTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAACCGGA\nTCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCT\nGGACCTGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACC\nTGGAAACCTGGGAGCTCTGGACCTGGAAGTACTGGAAGCTGGAACTCTGGGAGCTCTGGA\nACTGGAAGTACTGGAAACCAAAACCCTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGG\nAATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCACTGGACCTCTGAGAGCTCTGTATCT\nGGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCAGATAGCCCAGGCTCT\nGGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAAATGTA\nAGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAA\nGAGCTCAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCA\nTGCTCTAAAACCGTTACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAA\nGAAGTGGTGACCTCCGAAGATGGTTCTGACTGTCCCGAGGCAATGGATTTAGGCACATTG\nTCTGGCATAGGTACTCTGGATGGGTTCCGCCATAGGCACCCTGATGAAGCTGCCTTCTTC\nGACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCTATGTTAGGAGAGTTT\nGTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGGAATCC\nAGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGC\nAAACAATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGC\nTATAAAATGGCAGATGAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAG\nAGAGGCCATGCTAAATCTCGCCCTGTCAGAGACTGTGATGATGTCCTCCAAACACATCCT\nTCAGGTACCCAAAGTGGCATTTTCAATATCAAGCTACCGGGATCCAGTAAGATTTTTTCT\nGTTTATTGCGATCAAGAGACCAGTTTGGGAGGATGGCTTTTGATCCAGCAAAGAATGGAT\nGGATCACTGAATTTTAACCGGACCTGGCAAGACTACAAGAGAGGTTTCGGCAGCCTGAAT\nGACGAGGGGGAAGGAGAATTCTGGCTAGGCAATGACTACCTCCACTTACTAACCCAAAGG\nGGCTCTGTTCTTAGGGTTGAATTAGAGGACTGGGCTGGGAATGAAGCTTATGCAGAATAT\nCACTTCCGGGTAGGCTCTGAGGCTGAAGGCTATGCCCTCCAAGTCTCCTCCTATGAAGGC\nACTGCGGGTGATGCTCTGATTGAGGGTTCCGTAGAGGAAGGGGCAGAGTACACCTCTCAC\nAACAACATGCAGTTCAGCACCTTTGACAGGGATGCAGACCAGTGGGAAGAGAACTGTGCA\nGAAGTCTATGGGGGAGGCTGGTGGTATAATAACTGCCAAGCAGCCAATCTCAATGGAATC\nTACTACCCTGGGGGCTCCTATGACCCAAGGAATAACAGTCCTTATGAGATTGAGAATGGA\nGTGGTCTGGGTTTCCTTTAGAGGGGCAGATTATTCCCTCAGGGCTGTTCGCATGAAAATT\nAGGCCCCTTGTGACCCAATAG"}, "pfams": {"pfam": {"identifier": "PF00147", "name": "Fibrinogen_C"}}, "go-classifiers": null}}, {"@position": "3", "id": "BE0000717", "name": "Urokinase plasminogen activator surface receptor", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "Q03405", "@source": "Swiss-Prot", "name": "Urokinase plasminogen activator surface receptor", "general-function": "Involved in U-plasminogen activator receptor activity", "specific-function": "Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form", "gene-name": "PLAUR", "locus": "19q13", "cellular-location": "Isoform 1:Cell membrane; lipid-anchor; GPI- anchor. Isoform 2:Secreted protein (Probable)", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.64", "molecular-weight": "36978.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9053"}, {"resource": "GenAtlas", "identifier": "PLAUR"}, {"resource": "GeneCards", "identifier": "PLAUR"}, {"resource": "GenBank Gene Database", "identifier": "X51675"}, {"resource": "GenBank Protein Database", "identifier": "37605"}, {"resource": "UniProtKB", "identifier": "Q03405"}, {"resource": "UniProt Accession", "identifier": "UPAR_HUMAN"}]}, "synonyms": {"synonym": ["CD87 antigen", "Monocyte activation antigen Mo3", "U- PAR", "uPAR", "Urokinase plasminogen activator surface receptor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Urokinase plasminogen activator surface receptor precursor\nMGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEEL\nELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISC\nGSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNG\nFHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGP\nMNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDV\nQYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1008 bp\nATGGGTCACCCGCCGCTGCTGCCGCTGCTGCTGCTGCTCCACACCTGCGTCCCAGCCTCT\nTGGGGCCTGCGGTGCATGCAGTGTAAGACCAACGGGGATTGCCGTGTGGAAGAGTGCGCC\nCTGGGACAGGACCTCTGCAGGACCACGATCGTGCGCTTGTGGGAAGAAGGAGAAGAGCTG\nGAGCTGGTGGAGAAAAGCTGTACCCACTCAGAGAAGACCAACAGGACCCTGAGCTATCGG\nACTGGCTTGAAGATCACCAGCCTTACCGAGGTTGTGTGTGGGTTAGACTTGTGCAACCAG\nGGCAACTCTGGCCGGGCTGTCACCTATTCCCGAAGCCGTTACCTCGAATGCATTTCCTGT\nGGCTCATCAGACATGAGCTGTGAGAGGGGCCGGCACCAGAGCCTGCAGTGCCGCAGCCCT\nGAAGAACAGTGCCTGGATGTGGTGACCCACTGGATCCAGGAAGGTGAAGAAGGGCGTCCA\nAAGGATGACCGCCACCTCCGTGGCTGTGGCTACCTTCCCGGCTGCCCGGGCTCCAATGGT\nTTCCACAACAACGACACCTTCCACTTCCTGAAATGCTGCAACACCACCAAATGCAACGAG\nGGCCCAATCCTGGAGCTTGAAAATCTGCCGCAGAATGGCCGCCAGTGTTACAGCTGCAAG\nGGGAACAGCACCCATGGATGCTCCTCTGAAGAGACTTTCCTCATTGACTGCCGAGGCCCC\nATGAATCAATGTCTGGTAGCCACCGGCACTCACGAACCGAAAAACCAAAGCTATATGGTA\nAGAGGCTGTGCAACCGCCTCAATGTGCCAACATGCCCACCTGGGTGACGCCTTCAGCATG\nAACCACATTGATGTCTCCTGCTGTACTAAAAGTGGCTGTAACCACCCAGACCTGGATGTC\nCAGTACCGCAGTGGGGCTGCTCCTCAGCCTGGCCCTGCCCATCTCAGCCTCACCATCACC\nCTGCTAATGACTGCCAGACTGTGGGGAGGCACTCTCCTCTGGACCTAA"}, "pfams": {"pfam": {"identifier": "PF00021", "name": "UPAR_LY6"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "U-plasminogen activator receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}]}}}, {"@position": "4", "id": "BE0000240", "name": "Plasminogen activator inhibitor 1", "organism": "Human", "actions": null, "references": "# Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17963464", "known-action": "unknown", "polypeptide": {"@id": "P05121", "@source": "Swiss-Prot", "name": "Plasminogen activator inhibitor 1", "general-function": "Involved in serine-type endopeptidase inhibitor activity", "specific-function": "This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, and protein C. Its rapid interaction with TPA may function as a major control point in the regulation of fibrinolysis", "gene-name": "SERPINE1", "locus": "7q21.3-q22", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.22", "molecular-weight": "45061.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:8583"}, {"resource": "GenAtlas", "identifier": "SERPINE1"}, {"resource": "GeneCards", "identifier": "SERPINE1"}, {"resource": "GenBank Gene Database", "identifier": "X04429"}, {"resource": "GenBank Protein Database", "identifier": "35272"}, {"resource": "UniProtKB", "identifier": "P05121"}, {"resource": "UniProt Accession", "identifier": "PAI1_HUMAN"}]}, "synonyms": {"synonym": ["Endothelial plasminogen activator inhibitor", "PAI", "PAI-1", "Plasminogen activator inhibitor 1 precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Plasminogen activator inhibitor 1 precursor\nMQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY\nGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI\nFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV\nDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD\nGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK\nFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS\nSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP"}, "gene-sequence": {"@format": "FASTA", "#text": ">1209 bp\nATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA\nGGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG\nAGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT\nGGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG\nATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT\nCTGTACAAGGAGCTCATGGGGCCATGGAACAAGGACGAGATCAGCACCACAGACGCGATC\nTTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC\nCGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT\nGACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG\nGACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT\nCCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC\nTCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT\nGGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT\nGCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG\nCTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG\nTTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC\nATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC\nGCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA\nTCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC\nTTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG\nGAACCCTGA"}, "pfams": {"pfam": {"identifier": "PF00079", "name": "Serpin"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "protease inhibitor activity"}, {"category": "function", "description": "endopeptidase inhibitor activity"}, {"category": "function", "description": "serine-type endopeptidase inhibitor activity"}, {"category": "function", "description": "enzyme regulator activity"}, {"category": "function", "description": "enzyme inhibitor activity"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-01-20", "drugbank-id": [{"@primary": "true", "#text": "DB00010"}, "BIOD00033", "BTD00033"], "name": "Sermorelin", "description": "Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues", "cas-number": "86168-78-7", "groups": {"group": ["approved", "withdrawn"]}, "general-references": null, "synthesis-reference": null, "indication": "For the treatment of dwarfism, prevention of HIV-induced weight loss", "pharmacodynamics": "Sermorelin is used in the treatment of children with growth hormone deficiency or growth failure. Geref increases plasma growth hormone (GH) concentration by stimulating the pituitary gland to release GH. Geref is similar to the full-length native hormone (44 residues) in its ability to stimulate GH secretion in humans.", "mechanism-of-action": "Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": "11-12 min", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": null, "international-brands": {"international-brand": {"name": "Geref", "company": "Serono Pharma"}}, "mixtures": null, "packagers": {"packager": [{"name": "Chengdu Shengnuo Bio Pharmaceutical Co. Ltd.", "url": null}, {"name": "Letco Medical Inc.", "url": "http://www.letcomedical.com"}, {"name": "Live Well Drugstore LLC", "url": "http://www.livewelldrugstore.com"}]}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Emd serono inc"}}, "prices": null, "categories": {"category": {"category": "Hormone Replacement Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": null, "atc-codes": {"atc-code": [{"@code": "H01AC04", "level": [{"@code": "H", "#text": "SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS"}, {"@code": "H01", "#text": "PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES"}, {"@code": "H01A", "#text": "ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES"}, {"@code": "H01AC", "#text": "Somatropin and somatropin agonists"}]}, {"@code": "V04CD03", "level": [{"@code": "V", "#text": "VARIOUS"}, {"@code": "V04", "#text": "DIAGNOSTIC AGENTS"}, {"@code": "V04C", "#text": "OTHER DIAGNOSTIC AGENTS"}, {"@code": "V04CD", "#text": "Tests for pituitary function"}]}]}, "ahfs-codes": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00010 sequence\nYADAIFTNSYRKVLGQLSARKLLQDIMSRQ"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.330", "source": null}, {"kind": "Isoelectric Point", "value": "9.99", "source": null}, {"kind": "Molecular Weight", "value": "3357.8820", "source": null}, {"kind": "Molecular Formula", "value": "C149H246N44O42S", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "KEGG Compound", "identifier": "C08192"}, {"resource": "PharmGKB", "identifier": "PA164749110"}, {"resource": "Wikipedia", "identifier": "Sermorelin"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic2/sermorelin.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/sermorelin-acetate.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0000625", "name": "Growth hormone-releasing hormone receptor", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, Veronese FM: PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003 Sep 26;55(10):1279-91. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14499707\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "Q02643", "@source": "Swiss-Prot", "name": "Growth hormone-releasing hormone receptor", "general-function": "Involved in G-protein coupled receptor activity", "specific-function": "Receptor for GRF, coupled to G proteins which activate adenylyl cyclase. Stimulates somatotroph cell growth, growth hormone gene transcription and growth hormone secretion", "gene-name": "GHRHR", "locus": "7p14", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "133-152\n163-181\n205-227\n241-262\n281-304\n330-348\n362-381", "signal-regions": null, "theoretical-pi": "6.73", "molecular-weight": "47402.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:4266"}, {"resource": "GenAtlas", "identifier": "GHRHR"}, {"resource": "GeneCards", "identifier": "GHRHR"}, {"resource": "GenBank Gene Database", "identifier": "L01406"}, {"resource": "GenBank Protein Database", "identifier": "183173"}, {"resource": "IUPHAR", "identifier": "247"}, {"resource": "Guide to Pharmacology", "identifier": "29"}, {"resource": "UniProtKB", "identifier": "Q02643"}, {"resource": "UniProt Accession", "identifier": "GHRHR_HUMAN"}]}, "synonyms": {"synonym": ["GHRH receptor", "GRF receptor", "GRFR", "Growth hormone-releasing hormone receptor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Growth hormone-releasing hormone receptor precursor\nMDRRMWGAHVFCVLSPLPTVLGHMHPECDFITQLREDESACLQAAEEMPNTTLGCPATWD\nGLLCWPTAGSGEWVTLPCPDFFSHFSSESGAVKRDCTITGWSEPFPPYPVACPVPLELLA\nEEESYFSTVKIIYTVGHSISIVALFVAITILVALRRLHCPRNYVHTQLFTTFILKAGAVF\nLKDAALFHSDDTDHCSFSTVLCKVSVAASHFATMTNFSWLLAEAVYLNCLLASTSPSSRR\nAFWWLVLAGWGLPVLFTGTWVSCKLAFEDIACWDLDDTSPYWWIIKGPIVLSVGVNFGLF\nLNIIRILVRKLEPAQGSLHTQSQYWRLSKSTLFLIPLFGIHYIIFNFLPDNAGLGIRLPL\nELGLGSFQGFIVAILYCFLNQEVRTEISRKWHGHDPELLPAWRTRAKWTTPSRSAAKVLT\nSMC"}, "gene-sequence": {"@format": "FASTA", "#text": ">1272 bp\nATGGACCGCCGGATGTGGGGGGCCCACGTCTTCTGCGTGTTGAGCCCGTTACCGACCGTA\nTTGGGCCACATGCACCCAGAATGTGACTTCATCACCCAGCTGAGAGAGGATGAGAGTGCC\nTGTCTACAAGCAGCAGAGGAGATGCCCAACACCACCCTGGGCTGCCCTGCGACCTGGGAT\nGGGCTGCTGTGCTGGCCAACGGCAGGCTCTGGCGAGTGGGTCACCCTCCCCTGCCCGGAT\nTTCTTCTCTCACTTCAGCTCAGAGTCAGGGGCTGTGAAACGGGATTGTACTATCACTGGC\nTGGTCTGAGCCCTTTCCACCTTACCCTGTGGCCTGCCCTGTGCCTCTGGAGCTGCTGGCT\nGAGGAGGAATCTTACTTCTCCACAGTGAAGATTATCTACACCGTGGGCCATAGCATCTCT\nATTGTAGCCCTCTTCGTGGCCATCACCATCCTGGTTGCTCTCAGGAGGCTCCACTGCCCC\nCGGAACTACGTCCACACCCAGCTGTTCACCACTTTTATCCTCAAGGCGGGACGTGTGTTC\nCTGAAGGATGCTGCCCTTTTCCACAGCGACGACACTGACCACTGCAGCTTCTCCACTGTT\nCTATGCAAGGTCTCTGTGGCCGCCTCCCATTTCGCCACCATGACCAACTTCAGCTGGCTG\nTTGGCAGAAGCCGTCTACCTGAACTGCCTCCTGGCCTCCACCTCCCCCAGCTCAAGGAGA\nGCCTTCTGGTGGCTGGTTCTCGCTGGCTGGGGGCTGCCCGTGCTCTTCACTGGCACGTGG\nGTGAGCTGCAAACTGGCCTTCGAGGACATCGCGTGCTGGGACCTGGACGACACCTCCCCC\nTACTGGTGGATCATCAAAGGGCCCATTGTCCTCTCGGTCGGGGTGAACTTTGGGCTTTTT\nCTCAATATTATCCGCATCCTGGTGAGGAAACTGGAGCCAGCTCAGGGCAGCCTCCATACC\nCAGTCTCAGTATTGGCGTCTCTCCAAGTCGACACTTTTCCTGATCCCACTCTTTGGAATT\nCACTACATCATCTTCAACTTCCTGCCAGACAATGCTGGCCTGGGCATCCGCCTCCCCCTG\nGAGCTGGGACTGGGTTCCTTCCAGGGCTTCATTGTTGCCATCCTCTACTGCTTCCTCAAC\nCAAGAGGTGAGGACTGAGATCTCACGGAAGTGGCATGGCCATGACCCTGAGCTTCTGCCA\nGCCTGGAGGACCCGTGCTAAGTGGACCACGCCTTCCCGCTCGGCGGCAAAGGTGCTGACA\nTCTATGTGCTAG"}, "pfams": {"pfam": [{"identifier": "PF00002", "name": "7tm_2"}, {"identifier": "PF02793", "name": "HRM"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "vasoactive intestinal polypeptide receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "function", "description": "secretin-like receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}]}}}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2015-09-23", "drugbank-id": [{"@primary": "true", "#text": "DB00011"}, "BIOD00096", "BTD00096", "DB00084"], "name": "Interferon alfa-n1", "description": "Purified, natural (n is for natural) glycosylated human interferon alpha proteins 166 residues", "cas-number": "74899-72-2", "groups": {"group": "approved"}, "general-references": null, "synthesis-reference": "Vladimir G. Debabov, Jury D. Tsygankov, Andrei J. Chistoserdov, Evgeny D. Sverdlov, Lara S. Izotova, Sergei V. Kostrov, Viktor E. Sterkin, Vladimir P. Kuznetsov, Sergei V. Belyaev, Galina S. Monastyrskaya, Irina S. Salomatina, Grigory M. Dolganov, Sergei G. Arsenian, Sergei A. Tsarev, Jury I. Kozlov, Alexandr Y. Strongin, Vsevolod I. Ogarkov, Jury A. Ovchinnikov, \"Method for producing human leukocyte interferon alpha-2.\" U.S. Patent US4680260, issued January, 1982.", "indication": "For treatment of venereal or genital warts caused by the Human Papiloma Virus", "pharmacodynamics": "Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.", "mechanism-of-action": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": "1.2 hours (mammalian reticulocytes, in vitro); &gt;20 hours (yeast, in vivo); &gt;10 hours (Escherichia coli, in vivo).", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Interferon alpha-2"}, {"@language": "", "@coder": "", "#text": "Interferon alpha-A"}, {"@language": "", "@coder": "", "#text": "Interferon alpha-n1 (Ins)"}, {"@language": "", "@coder": "", "#text": "LeIF A"}]}, "products": {"product": [{"name": "Wellferon Inj 10 000 000unit/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01959069", "started-marketing-on": "1992-12-31", "ended-marketing-on": "2000-08-01", "dosage-form": "liquid", "strength": "10000000 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Wellferon Inj 3000000unit/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01959077", "started-marketing-on": "1992-12-31", "ended-marketing-on": "2000-08-01", "dosage-form": "liquid", "strength": "3000000 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": {"name": "Wellferon", "company": "GlaxoSmithKline"}}, "mixtures": {"mixture": [{"name": "Wellferon Inj 10 000 000unit/ml", "ingredients": "Interferon alfa-n1"}, {"name": "Wellferon Inj 3000000unit/ml", "ingredients": "Interferon alfa-n1"}]}, "packagers": null, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Antiviral Agents", "mesh-id": null}, {"category": "Immunologic Factors", "mesh-id": null}, {"category": "Immunosuppressive Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Liquid", "route": "intramuscular; subcutaneous", "strength": "10000000 unit"}, {"form": "Liquid", "route": "intramuscular; subcutaneous", "strength": "3000000 unit"}]}, "atc-codes": {"atc-code": {"@code": "L03AB06", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L03", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03A", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03AB", "#text": "Interferons"}]}}, "ahfs-codes": null, "patents": null, "food-interactions": {"food-interaction": "Avoid alcohol."}, "drug-interactions": null, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00011 sequence\nCDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI\nQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR\nKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "61 \u00b0C", "source": "Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)"}, {"kind": "Hydrophobicity", "value": "-0.336", "source": null}, {"kind": "Isoelectric Point", "value": "5.99", "source": null}, {"kind": "Molecular Weight", "value": "19241.1000", "source": null}, {"kind": "Molecular Formula", "value": "C860H1353N227O255S9", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "7651"}, {"resource": "GenBank", "identifier": "J00207"}, {"resource": "PharmGKB", "identifier": "PA164746538"}, {"resource": "UniProtKB", "identifier": "P01563"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000385", "name": "Interferon alpha/beta receptor 2", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Krown SE: Interferon treatment of renal cell carcinoma. Current status and future prospects. Cancer. 1987 Feb 1;59(3 Suppl):647-51. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10822464\n# Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19955815\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P48551", "@source": "Swiss-Prot", "name": "Interferon alpha/beta receptor 2", "general-function": "Involved in interferon-alpha/beta receptor activity", "specific-function": "Receptor for interferons alpha and beta. Isoform 1 and isoform 3 are directly involved in signal transduction due to their interaction with the TYR kinase, JAK1. Isoform 1 also interacts with the transcriptional factors, STAT1 and STAT2. Both forms are potent inhibitors of type I IFN activity", "gene-name": "IFNAR2", "locus": null, "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "244-264", "signal-regions": null, "theoretical-pi": "4.11", "molecular-weight": "57759.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5433"}, {"resource": "GenAtlas", "identifier": "IFNAR2"}, {"resource": "GeneCards", "identifier": "IFNAR2"}, {"resource": "GenBank Gene Database", "identifier": "L42243"}, {"resource": "GenBank Protein Database", "identifier": "995300"}, {"resource": "UniProtKB", "identifier": "P48551"}, {"resource": "UniProt Accession", "identifier": "INAR2_HUMAN"}]}, "synonyms": {"synonym": ["IFN-alpha-REC", "IFN-R", "Interferon alpha/beta receptor 2", "Interferon-alpha/beta receptor beta chain precursor", "Type I interferon receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interferon-alpha/beta receptor beta chain precursor\nMLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS\nIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF\nSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK\nHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE\nSAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD\nMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI\nDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR\nITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT\nFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR"}, "gene-sequence": {"@format": "FASTA", "#text": ">1548 bp\nATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT\nATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT\nTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC\nATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG\nGTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA\nAGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC\nAGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG\nATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA\nGAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG\nCATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA\nATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA\nATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA\nTCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC\nATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG\nAATTTTCATAACTTTTTAGCCTGGCCATTTCCTAACCTGCCACCGTTGGAAGCCATGGAT\nATGGTGGAGGTCATTTACATCAACAGAAAGAAGAAAGTGTGGGATTATAATTATGATGAT\nGAAAGTGATAGCGATACTGAGGCAGCGCCCAGGACAAGTGGCGGTGGCTATACCATGCAT\nGGACTGACTGTCAGGCCTCTGGGTCAGGCCTCTGCCACCTCTACAGAATCCCAGTTGATA\nGACCCGGAGTCCGAGGAGGAGCCTGACCTGCCTGAGGTTGATGTGGAGCTCCCCACGATG\nCCAAAGGACAGCCCTCAGCAGTTGGAACTCTTGAGTGGGCCCTGTGAGAGGAGAAAGAGT\nCCACTCCAGGACCCTTTTCCCGAAGAGGACTACAGCTCCACGGAGGGGTCTGGGGGCAGA\nATTACCTTCAATGTGGACTTAAACTCTGTGTTTTTGAGAGTTCTTGATGACGAGGACAGT\nGACGACTTAGAAGCCCCTCTGATGCTATCGTCTCATCTGGAAGAGATGGTTGACCCAGAG\nGATCCTGATAATGTGCAATCAAACCATTTGCTGGCCAGCGGGGAAGGGACACAGCCAACC\nTTTCCCAGCCCCTCTTCAGAGGGCCTGTGGTCCGAAGATGCTCCATCTGATCAAAGTGAC\nACTTCTGAGTCAGATGTTGACCTTGGGGATGGTTATATAATGAGATGA"}, "pfams": null, "go-classifiers": null}}, {"@position": "2", "id": "BE0000661", "name": "Interferon alpha/beta receptor 1", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Krown SE: Interferon treatment of renal cell carcinoma. Current status and future prospects. Cancer. 1987 Feb 1;59(3 Suppl):647-51. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10822464\n# Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19955815\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P17181", "@source": "Swiss-Prot", "name": "Interferon alpha/beta receptor 1", "general-function": "Involved in interferon-alpha/beta receptor activity", "specific-function": "Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta- subunits themselves", "gene-name": "IFNAR1", "locus": null, "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "437-457", "signal-regions": null, "theoretical-pi": "5.56", "molecular-weight": "63526.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5432"}, {"resource": "GenAtlas", "identifier": "IFNAR1"}, {"resource": "GeneCards", "identifier": "IFNAR1"}, {"resource": "GenBank Gene Database", "identifier": "J03171"}, {"resource": "GenBank Protein Database", "identifier": "306914"}, {"resource": "UniProtKB", "identifier": "P17181"}, {"resource": "UniProt Accession", "identifier": "INAR1_HUMAN"}]}, "synonyms": {"synonym": ["IFN-alpha-REC", "Interferon-alpha/beta receptor alpha chain precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interferon-alpha/beta receptor alpha chain precursor\nMMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT\nFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF\nTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI\nENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ\nNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK\nGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP\nVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV\nFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE\nYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN\nEDESESKTSEELQQDFV"}, "gene-sequence": {"@format": "FASTA", "#text": ">1674 bp\nATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGGCCCATGGGTG\nTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC\nATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT\nTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG\nAATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT\nAAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT\nACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG\nGCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT\nTTAAGCTTTACATATAGCTTACTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT\nGAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA\nAAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT\nATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA\nAATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG\nTGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA\nCCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA\nGGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA\nGAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA\nTCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT\nGTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT\nGAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT\nGTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT\nTTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA\nGTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC\nTTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG\nTATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA\nAAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT\nGATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT\nGAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA"}, "pfams": null, "go-classifiers": null}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2011-09-03", "drugbank-id": [{"@primary": "true", "#text": "DB00012"}, "BIOD00032", "BTD00032"], "name": "Darbepoetin alfa", "description": "Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.", "cas-number": "11096-26-7", "groups": {"group": ["approved", "investigational"]}, "general-references": null, "synthesis-reference": null, "indication": "For the treatment of anemia (from renal transplants or certain HIV treatment)", "pharmacodynamics": "Darbepoetin alfa is used in the treatment of anemia. It is involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass.", "mechanism-of-action": "Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with\nprogenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Epoetin"}, {"@language": "", "@coder": "", "#text": "Erythropoietin precursor"}]}, "products": {"product": [{"name": "Aranesp", "ndc-id": "55513-002_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668", "ndc-product-code": "55513-002", "dpd-id": null, "started-marketing-on": "2006-09-11", "ended-marketing-on": null, "dosage-form": "solution", "strength": "25 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103951", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Aranesp", "ndc-id": "55513-003_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668", "ndc-product-code": "55513-003", "dpd-id": null, "started-marketing-on": "2006-09-11", "ended-marketing-on": null, "dosage-form": "solution", "strength": "40 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103951", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Aranesp", "ndc-id": "55513-004_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668", "ndc-product-code": "55513-004", "dpd-id": null, "started-marketing-on": "2006-09-11", "ended-marketing-on": null, "dosage-form": "solution", "strength": "60 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103951", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Aranesp", "ndc-id": "55513-005_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668", "ndc-product-code": "55513-005", "dpd-id": null, "started-marketing-on": "2006-09-11", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103951", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Aranesp", "ndc-id": "55513-006_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668", "ndc-product-code": "55513-006", "dpd-id": null, "started-marketing-on": "2006-09-11", "ended-marketing-on": null, "dosage-form": "solution", "strength": "200 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103951", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Aranesp", "ndc-id": "55513-021_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668", "ndc-product-code": "55513-021", "dpd-id": null, "started-marketing-on": "2006-08-14", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "40 ug/.4mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103951", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Aranesp", "ndc-id": "55513-023_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668", "ndc-product-code": "55513-023", "dpd-id": null, "started-marketing-on": "2006-08-14", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "60 ug/.3mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103951", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Aranesp", "ndc-id": "55513-025_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668", "ndc-product-code": "55513-025", "dpd-id": null, "started-marketing-on": "2006-08-14", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 ug/.5mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103951", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Aranesp", "ndc-id": "55513-027_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668", "ndc-product-code": "55513-027", "dpd-id": null, "started-marketing-on": "2006-09-11", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "150 ug/.3mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103951", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Aranesp", "ndc-id": "55513-028_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668", "ndc-product-code": "55513-028", "dpd-id": null, "started-marketing-on": "2006-08-14", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "200 ug/.4mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103951", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Aranesp", "ndc-id": "55513-032_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668", "ndc-product-code": "55513-032", "dpd-id": null, "started-marketing-on": "2006-06-07", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "500 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103951", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Aranesp", "ndc-id": "55513-053_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668", "ndc-product-code": "55513-053", "dpd-id": null, "started-marketing-on": "2006-09-11", "ended-marketing-on": null, "dosage-form": "solution", "strength": "150 ug/.75mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103951", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Aranesp", "ndc-id": "55513-057_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668", "ndc-product-code": "55513-057", "dpd-id": null, "started-marketing-on": "2006-08-26", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "25 ug/.42mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103951", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Aranesp", "ndc-id": "55513-098_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668", "ndc-product-code": "55513-098", "dpd-id": null, "started-marketing-on": "2006-08-26", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "10 ug/.4mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103951", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Aranesp", "ndc-id": "55513-110_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668", "ndc-product-code": "55513-110", "dpd-id": null, "started-marketing-on": "2006-08-14", "ended-marketing-on": null, "dosage-form": "solution", "strength": "300 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103951", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Aranesp", "ndc-id": "55513-111_dc1f3c6a-a2bd-4375-928c-e1a0bbc52668", "ndc-product-code": "55513-111", "dpd-id": null, "started-marketing-on": "2006-08-14", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "300 ug/.6mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103951", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02391767", "started-marketing-on": "2014-01-27", "ended-marketing-on": null, "dosage-form": "solution", "strength": "200 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02391775", "started-marketing-on": "2014-03-26", "ended-marketing-on": null, "dosage-form": "solution", "strength": "200 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02391783", "started-marketing-on": "2014-02-10", "ended-marketing-on": null, "dosage-form": "solution", "strength": "200 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02391791", "started-marketing-on": "2014-04-21", "ended-marketing-on": null, "dosage-form": "solution", "strength": "500 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02391805", "started-marketing-on": "2014-05-05", "ended-marketing-on": null, "dosage-form": "solution", "strength": "500 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02391821", "started-marketing-on": "2013-11-04", "ended-marketing-on": null, "dosage-form": "solution", "strength": "500 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02392313", "started-marketing-on": "2013-08-16", "ended-marketing-on": null, "dosage-form": "solution", "strength": "25 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02392321", "started-marketing-on": "2014-03-12", "ended-marketing-on": null, "dosage-form": "solution", "strength": "40 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02392348", "started-marketing-on": "2014-03-03", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02392356", "started-marketing-on": "2014-04-03", "ended-marketing-on": null, "dosage-form": "solution", "strength": "200 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02392364", "started-marketing-on": "2014-02-24", "ended-marketing-on": null, "dosage-form": "solution", "strength": "500 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02246353", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "15 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02246356", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "60 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02246359", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "325 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02246354", "started-marketing-on": "2002-08-13", "ended-marketing-on": "2015-08-04", "dosage-form": "solution", "strength": "25 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02246355", "started-marketing-on": "2002-08-13", "ended-marketing-on": "2015-08-04", "dosage-form": "solution", "strength": "40 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02246357", "started-marketing-on": "2002-08-20", "ended-marketing-on": "2015-08-04", "dosage-form": "solution", "strength": "100 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02246358", "started-marketing-on": "2002-08-13", "ended-marketing-on": "2015-08-04", "dosage-form": "solution", "strength": "200 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02391732", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "40 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02246360", "started-marketing-on": "2002-08-13", "ended-marketing-on": "2015-08-04", "dosage-form": "solution", "strength": "500 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02391813", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "500 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02391848", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "500 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02391740", "started-marketing-on": "2013-12-11", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Aranesp        -(hsa-free)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02391759", "started-marketing-on": "2014-05-07", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Aranesp", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}, {"name": "Aranesp        -(hsa-free)", "ingredients": "Darbepoetin alfa"}]}, "packagers": {"packager": [{"name": "Amgen Inc.", "url": "http://www.amgen.com"}, {"name": "Physicians Total Care Inc.", "url": "http://www.physicianstotalcare.com"}]}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Amgen Inc."}}, "prices": {"price": [{"description": "Aranesp 25 mcg/ml vial", "cost": {"@currency": "USD", "#text": "156.36"}, "unit": "ml"}, {"description": "Aranesp (Albumin Free) 25 mcg/ml vial", "cost": {"@currency": "USD", "#text": "162.61"}, "unit": "vial"}, {"description": "Aranesp 40 mcg/ml vial", "cost": {"@currency": "USD", "#text": "250.2"}, "unit": "ml"}, {"description": "Aranesp 60 mcg/ml vial", "cost": {"@currency": "USD", "#text": "375.3"}, "unit": "ml"}, {"description": "Aranesp (Albumin Free) 60 mcg/ml vial", "cost": {"@currency": "USD", "#text": "390.31"}, "unit": "vial"}, {"description": "Aranesp 100 mcg/ml vial", "cost": {"@currency": "USD", "#text": "625.44"}, "unit": "ml"}, {"description": "Aranesp 200 mcg/ml vial", "cost": {"@currency": "USD", "#text": "1250.88"}, "unit": "ml"}, {"description": "Aranesp 300 mcg/ml vial", "cost": {"@currency": "USD", "#text": "1876.32"}, "unit": "ml"}, {"description": "Aranesp (Albumin Free) 300 mcg/ml vial", "cost": {"@currency": "USD", "#text": "1951.37"}, "unit": "vial"}, {"description": "Aranesp (Albumin Free) 100 mcg/0.5ml Solution (1 Box = Four 0.5ml Syringes)", "cost": {"@currency": "USD", "#text": "2601.83"}, "unit": "box"}, {"description": "Aranesp (Albumin Free) 100 mcg/ml Solution Four 1ml Vials Per Box", "cost": {"@currency": "USD", "#text": "2601.83"}, "unit": "box"}, {"description": "Aranesp (Albumin Free) 150 mcg/0.75ml Solution (1 Box = Four 0.75ml Vials)", "cost": {"@currency": "USD", "#text": "3902.75"}, "unit": "box"}]}, "categories": {"category": [{"category": "Hematinics", "mesh-id": null}, {"category": "Anti-anemic Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, solution", "route": "intravenous; subcutaneous", "strength": "10 ug/.4mL"}, {"form": "Injection, solution", "route": "intravenous; subcutaneous", "strength": "100 ug/.5mL"}, {"form": "Injection, solution", "route": "intravenous; subcutaneous", "strength": "150 ug/.3mL"}, {"form": "Injection, solution", "route": "intravenous; subcutaneous", "strength": "200 ug/.4mL"}, {"form": "Injection, solution", "route": "intravenous; subcutaneous", "strength": "25 ug/.42mL"}, {"form": "Injection, solution", "route": "intravenous; subcutaneous", "strength": "300 ug/.6mL"}, {"form": "Injection, solution", "route": "intravenous; subcutaneous", "strength": "40 ug/.4mL"}, {"form": "Injection, solution", "route": "intravenous; subcutaneous", "strength": "500 ug/mL"}, {"form": "Injection, solution", "route": "intravenous; subcutaneous", "strength": "60 ug/.3mL"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "100 ug/mL"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "150 ug/.75mL"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "200 ug/mL"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "25 ug/mL"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "300 ug/mL"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "40 ug/mL"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "60 ug/mL"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "100 mcg"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "15 mcg"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "200 mcg"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "25 mcg"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "325 mcg"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "40 mcg"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "500 mcg"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "60 mcg"}]}, "atc-codes": {"atc-code": {"@code": "B03XA02", "level": [{"@code": "B", "#text": "BLOOD AND BLOOD FORMING ORGANS"}, {"@code": "B03", "#text": "ANTIANEMIC PREPARATIONS"}, {"@code": "B03X", "#text": "OTHER ANTIANEMIC PREPARATIONS"}, {"@code": "B03XA", "#text": "Other antianemic preparations"}]}}, "ahfs-codes": {"ahfs-code": "20:16.00"}, "patents": {"patent": [{"number": "2147124", "country": "Canada", "approved": "2002-11-05", "expires": "2014-08-16"}, {"number": "2165694", "country": "Canada", "approved": "2003-03-18", "expires": "2010-10-15"}]}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00480", "name": "Lenalidomide", "description": "Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Lenalidomide."}, {"drugbank-id": "DB01041", "name": "Thalidomide", "description": "Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Thalidomide."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00012 sequence\nAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQA\nVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAIS\nPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "53 \u00b0C", "source": "Arakawa, T. et al., Biosci. Biotechnol. Biochem. 65:1321-1327 (2001)"}, {"kind": "Hydrophobicity", "value": "-0.188", "source": null}, {"kind": "Isoelectric Point", "value": "8.75", "source": null}, {"kind": "Molecular Weight", "value": "18396.1000", "source": null}, {"kind": "Molecular Formula", "value": "C815H1317N233O241S5", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "12550"}, {"resource": "GenBank", "identifier": "X02158"}, {"resource": "PharmGKB", "identifier": "PA164743138"}, {"resource": "UniProtKB", "identifier": "P01588"}, {"resource": "Wikipedia", "identifier": "Darbepoetin_alfa"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/aranesp.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/darbepoetin-alfa-albumin.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0000654", "name": "Erythropoietin receptor", "organism": "Human", "actions": {"action": "agonist"}, "references": "# LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, Hall C, Meshaw A, Farrell FX: Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther. 2006 Feb;5(2):347-55. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16505108\n# Kokhaei P, Abdalla AO, Hansson L, Mikaelsson E, Kubbies M, Haselbeck A, Jernberg-Wiklund H, Mellstedt H, Osterborg A: Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies. Clin Cancer Res. 2007 Jun 15;13(12):3536-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17575216\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P19235", "@source": "Swiss-Prot", "name": "Erythropoietin receptor", "general-function": "Involved in transmembrane receptor activity", "specific-function": "Isoform EPOR-T, missing the cytoplasmic tail, acts as a dominant-negative receptor of EPOR-mediated signaling", "gene-name": "EPOR", "locus": "19p13.3-p13.2", "cellular-location": "Cell membrane; single-pass type I membrane protein. Isoform EPOR-S:Secreted protein. Isoform EPOR-S", "transmembrane-regions": "251-273", "signal-regions": null, "theoretical-pi": "4.37", "molecular-weight": "55066.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3416"}, {"resource": "GenAtlas", "identifier": "EPOR"}, {"resource": "GeneCards", "identifier": "EPOR"}, {"resource": "GenBank Gene Database", "identifier": "M60459"}, {"resource": "GenBank Protein Database", "identifier": "182245"}, {"resource": "UniProtKB", "identifier": "P19235"}, {"resource": "UniProt Accession", "identifier": "EPOR_HUMAN"}]}, "synonyms": {"synonym": ["EPO-R", "Erythropoietin receptor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Erythropoietin receptor precursor\nMDHLGASLWPQVGSLCLLLAGAAWAPPPNLPDPKFESKAALLAARGPEELLCFTERLEDL\nVCFWEEAASAGVGPGNYSFSYQLEDEPWKLCRLHQAPTARGAVRFWCSLPTADTSSFVPL\nELRVTAASGAPRYHRVIHINEVVLLDAPVGLVARLADESGHVVLRWLPPPETPMTSHIRY\nEVDVSAGNGAGSVQRVEILEGRTECVLSNLRGRTRYTFAVRARMAEPSFGGFWSAWSEPV\nSLLTPSDLDPLILTLSLILVVILVLLTVLALLSHRRALKQKIWPGIPSPESEFEGLFTTH\nKGNFQLWLYQNDGCLWWSPCTPFTEDPPASLEVLSERCWGTMQAVEPGTDDEGPLLEPVG\nSEHAQDTYLVLDKWLLPRNPPSEDLPGPGGSVDIVAMDEGSEASSCSSALASKPSPEGAS\nAASFEYTILDPSSQLLRPWTLCPELPPTPPHLKYLYLVVSDSGISTDYSSGDSQGAQGGL\nSDGPYSNPYENSLIPAAEPLPPSYVACS"}, "gene-sequence": {"@format": "FASTA", "#text": ">1527 bp\nATGGACCACCTCGGGGCGTCCCTCTGGCCCCAGGTCGGCTCCCTTTGTCTCCTGCTCGCT\nGGGGCCGCCTGGGCGCCCCCGCCTAACCTCCCGGACCCCAAGTTCGAGAGCAAAGCGGCC\nTTGCTGGCGGCCCGGGGGCCCGAAGAGCTTCTGTGCTTCACCGAGCGGTTGGAGGACTTG\nGTGTGTTTCTGGGAGGAAGCGGCGAGCGCTGGGGTGGGCCCGGGCAACTACAGCTTCTCC\nTACCAGCTCGAGGATGAGCCATGGAAGCTGTGTCGCCTGCACCAGGCTCCCACGGCTCGT\nGGTGCGGTGCGCTTCTGGTGTTCGCTGCCTACAGCCGACACGTCGAGCTTCGTGCCCCTA\nGAGTTGCGCGTCACAGCAGCCTCCGGCGCTCCGCGATATCACCGTGTCATCCACATCAAT\nGAAGTAGTGCTCCTAGACGCCCCCGTGGGGCTGGTGGCGCGGTTGGCTGACGAGAGCGGC\nCACGTAGTGTTGCGCTGGCTCCCGCCGCCTGAGACACCCATGACGTCTCACATCCGCTAC\nGAGGTGGACGTCTCGGCCGGCAACGGCGCAGGGAGCGTACAGAGGGTGGAGATCCTGGAG\nGGCCGCACCGAGTGTGTGCTGAGCAACCTGCGGGGCCGGACGCGCTACACCTTCGCCGTC\nCGCGCGCGTATGGCTGAGCCGAGCTTCGGCGGCTTCTGGAGCGCCTGGTCGGAGCCTGTG\nTCGCTGCTGACGCCTAGCGACCTGGACCCCCTCATCCTGACGCTCTCCCTCATCCTCGTG\nGTCATCCTGGTGCTGCTGACCGTGCTCGCGCTGCTCTCCCACCGCCGGGCTCTGAAGCAG\nAAGATCTGGCCTGGCATCCCGAGCCCAGAGAGCGAGTTTGAAGGCCTCTTCACCACCCAC\nAAGGGTAACTTCCAGCTGTGGCTGTACCAGAATGATGGCTGCCTGTGGTGGAGCCCCTGC\nACCCCCTTCACGGAGGACCCACCTGCTTCCCTGGAAGTCCTCTCAGAGCGCTGCTGGGGG\nACGATGCAGGCAGTGGAGCCGGGGACAGATGATGAGGGCCCCCTGCTGGAGCCAGTGGGC\nAGTGAGCATGCCCAGGATACCTATCTGGTGCTGGACAAATGGTTGCTGCCCCGGAACCCG\nCCCAGTGAGGACCTCCCAGGGCCTGGTGGCAGTGTGGACATAGTGGCCATGGATGAAGGC\nTCAGAAGCATCCTCCTGCTCATCTGCTTTGGCCTCGAAGCCCAGCCCAGAGGGAGCCTCT\nGCTGCCAGCTTTGAGTACACTATCCTGGACCCCAGCTCCCAGCTCTTGCGTCCATGGACA\nCTGTGCCCTGAGCTGCCCCCTACCCCACCCCACCTAAAGTACCTGTACCTTGTGGTATCT\nGACTCTGGCATCTCAACTGACTACAGCTCAGGGGACTCCCAGGGAGCCCAAGGGGGCTTA\nTCCGATGGCCCCTACTCCAACCCTTATGAGAACAGCCTTATCCCAGCCGCTGAGCCTCTG\nCCCCCCAGCTATGTGGCTTGCTCTTAG"}, "pfams": {"pfam": {"identifier": "PF00041", "name": "fn3"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "hematopoietin/interferon-class (D200-domain) cytokine receptor activity"}]}}}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-01-20", "drugbank-id": [{"@primary": "true", "#text": "DB00013"}, "BIOD00030", "BTD00030"], "name": "Urokinase", "description": "Low molecular weight form of human urokinase, that consists of an A chain of 2,000 daltons linked by a sulfhydryl bond to a B chain of 30,400 daltons. Recombinant urokinase plasminogen activator", "cas-number": "9039-53-6", "groups": {"group": ["approved", "investigational", "withdrawn"]}, "general-references": "# Housley C: Contract purchasing means a buyer's market. Dimens Health Serv. 1976 Apr;53(4):16, 19-20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/5328", "synthesis-reference": "Koji Sasaki, Yasukazu Harada, \"Urokinase preparation for oral administration.\" U.S. Patent US4258030, issued November, 1975.", "indication": "Urokinase can be used for the treatment of pulminary embolism, coronary artery thrombosis, IV catheter clearance, and venous and arterial blood clots.", "pharmacodynamics": "Urokinase is used for the treatment of pulmonary embolisms. The low molecular weight form of human urokinase consists of an A chain of 2,000 daltons linked by a sulfhydryl bond to a B chain of 30,400 daltons. Urokinase is an enzyme (protein) produced by the kidney, and found in the urine. There are two forms of urokinase which differ in molecular weight but have similar clinical effects. Urokinase is the low molecular weight form. Urokinase acts on the endogenous fibrinolytic system. It converts plasminogen to the enzyme plasmin. Plasmin degrades fibrin clots as well as fibrinogen and some other plasma proteins.", "mechanism-of-action": "Urokinase acts on the endogenous fibrinolytic system. It cleaves the Arg-Val bond in plasminogen to produce active plasmin. Plasmin degrades fibrin clots as well as fibrinogen and other plasma proteins.", "toxicity": null, "metabolism": "Proteolysis", "absorption": null, "half-life": "12 minutes. Small fractions of the administered dose are excreted in bile and urine", "protein-binding": null, "route-of-elimination": "Urokinase administered by intravenous infusion is rapidly cleared by the liver. Small fractions of the administered dose are excreted in bile and urine", "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "U-plasminogen activator"}, {"@language": "", "@coder": "", "#text": "uPA"}, {"@language": "", "@coder": "", "#text": "Urokinase-type plasminogen activator precursor"}]}, "products": {"product": [{"name": "Kinlytic (urokinase for Injection)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00749702", "started-marketing-on": "1988-12-31", "ended-marketing-on": "2009-10-28", "dosage-form": "powder for solution", "strength": "250000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kinlytic Open-cath", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00886777", "started-marketing-on": "1991-12-31", "ended-marketing-on": "2009-10-28", "dosage-form": "powder for solution", "strength": "5000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": [{"name": "Abbokinase", "company": "Abbott Laboratories"}, {"name": "Kinlytic", "company": "Microbix Biosystems Inc."}]}, "mixtures": {"mixture": [{"name": "Kinlytic Open-cath", "ingredients": "Urokinase"}, {"name": "Kinlytic (urokinase for Injection)", "ingredients": "Urokinase"}]}, "packagers": {"packager": [{"name": "Hospira Inc.", "url": "http://www.hospira.com"}, {"name": "ImaRx Therapeutics", "url": "http://www.imarx.com"}, {"name": "Microbix Biosystems Inc.", "url": "http://www.microbix.com"}]}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Microbix biosystems inc"}}, "prices": null, "categories": {"category": {"category": "Thrombolytic Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Powder for solution", "route": "intravenous", "strength": "250000 unit"}, {"form": "Powder for solution", "route": "intravenous", "strength": "5000 unit"}]}, "atc-codes": {"atc-code": {"@code": "B01AD04", "level": [{"@code": "B", "#text": "BLOOD AND BLOOD FORMING ORGANS"}, {"@code": "B01", "#text": "ANTITHROMBOTIC AGENTS"}, {"@code": "B01A", "#text": "ANTITHROMBOTIC AGENTS"}, {"@code": "B01AD", "#text": "Enzymes"}]}}, "ahfs-codes": {"ahfs-code": "20:12.20"}, "patents": null, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00054", "name": "Abciximab", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB01418", "name": "Acenocoumarol", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00945", "name": "Acetylsalicylic acid", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00233", "name": "Aminosalicylic Acid", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB00261", "name": "Anagrelide", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB06605", "name": "Apixaban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06692", "name": "Aprotinin", "description": "Aprotinin may diminish the therapeutic effect of Thrombolytic Agents."}, {"drugbank-id": "DB00278", "name": "Argatroban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01294", "name": "Bismuth Subsalicylate", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB00006", "name": "Bivalirudin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06441", "name": "Cangrelor", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB01166", "name": "Cilostazol", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00215", "name": "Citalopram", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00758", "name": "Clopidogrel", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB06695", "name": "Dabigatran etexilate", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06779", "name": "Dalteparin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06754", "name": "Danaparoid", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06700", "name": "Desvenlafaxine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00586", "name": "Diclofenac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00861", "name": "Diflunisal", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB01551", "name": "Dihydrocodeine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00975", "name": "Dipyridamole", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00476", "name": "Duloxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB09075", "name": "Edoxaban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01225", "name": "Enoxaparin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01240", "name": "Epoprostenol", "description": "May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents."}, {"drugbank-id": "DB00063", "name": "Eptifibatide", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB01175", "name": "Escitalopram", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00749", "name": "Etodolac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00573", "name": "Fenoprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB08976", "name": "Floctafenine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00472", "name": "Fluoxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00712", "name": "Flurbiprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00176", "name": "Fluvoxamine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00569", "name": "Fondaparinux sodium", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01109", "name": "Heparin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01050", "name": "Ibuprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB01088", "name": "Iloprost", "description": "May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents."}, {"drugbank-id": "DB00328", "name": "Indomethacin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB01009", "name": "Ketoprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00465", "name": "Ketorolac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB08918", "name": "Levomilnacipran", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB01397", "name": "Magnesium salicylate", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB00784", "name": "Mefenamic acid", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00814", "name": "Meloxicam", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB04896", "name": "Milnacipran", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00461", "name": "Nabumetone", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB08813", "name": "Nadroparin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00788", "name": "Naproxen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00991", "name": "Oxaprozin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00715", "name": "Paroxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00554", "name": "Piroxicam", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB06209", "name": "Prasugrel", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB06228", "name": "Rivaroxaban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01399", "name": "Salsalate", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB01104", "name": "Sertraline", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00605", "name": "Sulindac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB01600", "name": "Tiaprofenic acid", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB08816", "name": "Ticagrelor", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00208", "name": "Ticlopidine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB06822", "name": "Tinzaparin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00775", "name": "Tirofiban", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00500", "name": "Tolmetin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00374", "name": "Treprostinil", "description": "May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents."}, {"drugbank-id": "DB00285", "name": "Venlafaxine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB06684", "name": "Vilazodone", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB09030", "name": "Vorapaxar", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB09068", "name": "Vortioxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00682", "name": "Warfarin", "description": "May enhance the anticoagulant effect of Anticoagulants."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00013 sequence\nKPSSPPEELKFQCGQKTLRPRFKIIGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLMS\nPCWVISATHCFIDYPKKEDYIVYLGRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHND\nIALLKIRSKEGRCAQPSRTIQTICLPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMT\nVVKLISHRECQQPHYYGSEVTTKMLCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVS\nWGRGCALKDKPGVYTRVSHFLPWIRSHTKEENGLAL"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "76 \u00b0C at pH 4.5", "source": "Nowak, U.K. et al., Biochemistry 33:2951-2960 (1994)"}, {"kind": "Hydrophobicity", "value": "-0.466", "source": null}, {"kind": "Isoelectric Point", "value": "8.66", "source": null}, {"kind": "Molecular Weight", "value": "31126.5000", "source": null}, {"kind": "Molecular Formula", "value": "C1376H2145N383O406S18", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "2012"}, {"resource": "National Drug Code Directory", "identifier": "24430-1003-1"}, {"resource": "GenBank", "identifier": "X02419"}, {"resource": "PharmGKB", "identifier": "PA451836"}, {"resource": "UniProtKB", "identifier": "P00749"}, {"resource": "Wikipedia", "identifier": "Urokinase"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/pharmclips2.cgi?keyword=%20Abbokinase%AE"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/mtm/urokinase.html"}]}, "pathways": {"pathway": {"smpdb-id": "SMP00284", "name": "Urokinase Action Pathway", "drugs": {"drug": [{"drugbank-id": "DB00013", "name": "Urokinase"}, {"drugbank-id": "DB01022", "name": "Phylloquinone"}, {"drugbank-id": "DB01373", "name": "Calcium"}]}, "enzymes": {"uniprot-id": ["P00747", "P00748", "P02452", "P03952", "P03951", "P00740", "P00451", "P00734", "P12259", "P00742", "P02671", "P02675", "P02679", "P00488", "P05160", "P00750", "P08709", "P13726", "Q9BQB6", "P38435"]}}}, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000211", "name": "Plasminogen", "organism": "Human", "actions": {"action": "activator"}, "references": "# Zhang X, Zhou H, Shen G, Liu Z, Hu Y, Wei W, Song S: Study on the mechanism of the annexin II-mediated co-assembly of t-PA and plasminogen. J Huazhong Univ Sci Technolog Med Sci. 2002;22(1):21-3, 76. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12658774\n# Lopez-Alemany R, Longstaff C, Hawley S, Mirshahi M, Fabregas P, Jardi M, Merton E, Miles LA, Felez J: Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against alpha-Enolase. Am J Hematol. 2003 Apr;72(4):234-42. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12666133\n# Hashimoto M, Oiwa K, Matsuo O, Ueshima S, Okada K, Okada Y, Okamoto S, Giddings JC, Yamamoto J: Suppression of argatroban-induced endogenous thrombolysis by PKSI-527, and antibodies to TPA and UPA, evaluated in a rat arterial thrombolysis model. Thromb Haemost. 2003 May;89(5):820-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12719778\n# Guda K, Claffey KP, Dong M, Nambiar PR, Rosenberg DW: Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors. Mol Carcinog. 2003 May;37(1):51-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12720300\n# Chang H, Shyu KG, Lin S, Wang BW, Liu YC, Lee CC: Cell adhesion induces the plasminogen activator inhibitor-1 gene expression through phosphatidylinositol 3-kinase/Akt activation in anchorage dependent cells. Cell Commun Adhes. 2002 Sep-Dec;9(5-6):239-47. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12745435\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P00747", "@source": "Swiss-Prot", "name": "Plasminogen", "general-function": "Involved in plasmin activity", "specific-function": "Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo", "gene-name": "PLG", "locus": "6q26", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.25", "molecular-weight": "90569.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9071"}, {"resource": "GenAtlas", "identifier": "PLG"}, {"resource": "GeneCards", "identifier": "PLG"}, {"resource": "GenBank Gene Database", "identifier": "X05199"}, {"resource": "GenBank Protein Database", "identifier": "387026"}, {"resource": "UniProtKB", "identifier": "P00747"}, {"resource": "UniProt Accession", "identifier": "PLMN_HUMAN"}]}, "synonyms": {"synonym": ["EC 3.4.21.7", "Plasminogen precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Plasminogen precursor\nMEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT\nCRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN\nGITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE\nCEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE\nLRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS\nAQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE\nQLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG\nLTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED\nCMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG\nPWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT\nRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE\nPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ\nLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW\nGLGCARPNKPGVYVRVSRFVTWIEGVMRNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">2433 bp\nATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG\nCCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG\nCTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC\nTGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG\nAAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC\nTCAGAGTGCAAGACTGGGAATGGAAAGAATTACAGAGGGACGATGTCCAAAACAAAAAAT\nGGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT\nACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG\nGGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG\nTGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC\nATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT\nCCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG\nCTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGCGACATCCCC\nCGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT\nGAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT\nGCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTTCCCTGCAAAAATTTGGAT\nGAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC\nCAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA\nCAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT\nGATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT\nTGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC\nCTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA\nGACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT\nGTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAAATGTAGAGACTCCTTCCGAAGAAGAC\nTGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG\nCCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA\nAATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT\nCCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT\nGCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG\nGTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA\nAGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT\nGCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC\nCAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG\nCCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA\nGTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC\nATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG\nCTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA\nTCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT\nGGAGGGCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG\nGGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT\nACTTGGATTGAGGGAGTGATGAGAAATAATTAA"}, "pfams": {"pfam": [{"identifier": "PF00051", "name": "Kringle"}, {"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00024", "name": "PAN_1"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "plasmin activity"}, {"category": "function", "description": "binding"}, {"category": "process", "description": "hemostasis"}, {"category": "process", "description": "blood coagulation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "2", "id": "BE0000717", "name": "Urokinase plasminogen activator surface receptor", "organism": "Human", "actions": null, "references": "# Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ: Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol. 2003 Mar 3;160(5):781-91. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12615913\n# Fuchs T, Allgayer H: Transcriptional regulation of the urokinase receptor (u-PAR)--a central molecule of invasion and metastasis. Biol Chem. 2003 May;384(5):755-61. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12817472\n# Kanse SM, Chavakis T, Al-Fakhri N, Hersemeyer K, Monard D, Preissner KT: Reciprocal regulation of urokinase receptor (CD87)-mediated cell adhesion by plasminogen activator inhibitor-1 and protease nexin-1. J Cell Sci. 2004 Jan 26;117(Pt 3):477-85. Epub 2003 Dec 16. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14679304\n# Beaufort N, Leduc D, Rousselle JC, Magdolen V, Luther T, Namane A, Chignard M, Pidard D: Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. J Immunol. 2004 Jan 1;172(1):540-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14688365\n# Guerrero J, Santibanez JF, Gonzalez A, Martinez J: EGF receptor transactivation by urokinase receptor stimulus through a mechanism involving Src and matrix metalloproteinases. Exp Cell Res. 2004 Jan 1;292(1):201-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14720519\n# Gutova M, Najbauer J, Gevorgyan A, Metz MZ, Weng Y, Shih CC, Aboody KS: Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS One. 2007 Feb 28;2(2):e243. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17327908", "known-action": "yes", "polypeptide": {"@id": "Q03405", "@source": "Swiss-Prot", "name": "Urokinase plasminogen activator surface receptor", "general-function": "Involved in U-plasminogen activator receptor activity", "specific-function": "Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form", "gene-name": "PLAUR", "locus": "19q13", "cellular-location": "Isoform 1:Cell membrane; lipid-anchor; GPI- anchor. Isoform 2:Secreted protein (Probable)", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.64", "molecular-weight": "36978.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9053"}, {"resource": "GenAtlas", "identifier": "PLAUR"}, {"resource": "GeneCards", "identifier": "PLAUR"}, {"resource": "GenBank Gene Database", "identifier": "X51675"}, {"resource": "GenBank Protein Database", "identifier": "37605"}, {"resource": "UniProtKB", "identifier": "Q03405"}, {"resource": "UniProt Accession", "identifier": "UPAR_HUMAN"}]}, "synonyms": {"synonym": ["CD87 antigen", "Monocyte activation antigen Mo3", "U- PAR", "uPAR", "Urokinase plasminogen activator surface receptor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Urokinase plasminogen activator surface receptor precursor\nMGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEEL\nELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISC\nGSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNG\nFHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGP\nMNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDV\nQYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1008 bp\nATGGGTCACCCGCCGCTGCTGCCGCTGCTGCTGCTGCTCCACACCTGCGTCCCAGCCTCT\nTGGGGCCTGCGGTGCATGCAGTGTAAGACCAACGGGGATTGCCGTGTGGAAGAGTGCGCC\nCTGGGACAGGACCTCTGCAGGACCACGATCGTGCGCTTGTGGGAAGAAGGAGAAGAGCTG\nGAGCTGGTGGAGAAAAGCTGTACCCACTCAGAGAAGACCAACAGGACCCTGAGCTATCGG\nACTGGCTTGAAGATCACCAGCCTTACCGAGGTTGTGTGTGGGTTAGACTTGTGCAACCAG\nGGCAACTCTGGCCGGGCTGTCACCTATTCCCGAAGCCGTTACCTCGAATGCATTTCCTGT\nGGCTCATCAGACATGAGCTGTGAGAGGGGCCGGCACCAGAGCCTGCAGTGCCGCAGCCCT\nGAAGAACAGTGCCTGGATGTGGTGACCCACTGGATCCAGGAAGGTGAAGAAGGGCGTCCA\nAAGGATGACCGCCACCTCCGTGGCTGTGGCTACCTTCCCGGCTGCCCGGGCTCCAATGGT\nTTCCACAACAACGACACCTTCCACTTCCTGAAATGCTGCAACACCACCAAATGCAACGAG\nGGCCCAATCCTGGAGCTTGAAAATCTGCCGCAGAATGGCCGCCAGTGTTACAGCTGCAAG\nGGGAACAGCACCCATGGATGCTCCTCTGAAGAGACTTTCCTCATTGACTGCCGAGGCCCC\nATGAATCAATGTCTGGTAGCCACCGGCACTCACGAACCGAAAAACCAAAGCTATATGGTA\nAGAGGCTGTGCAACCGCCTCAATGTGCCAACATGCCCACCTGGGTGACGCCTTCAGCATG\nAACCACATTGATGTCTCCTGCTGTACTAAAAGTGGCTGTAACCACCCAGACCTGGATGTC\nCAGTACCGCAGTGGGGCTGCTCCTCAGCCTGGCCCTGCCCATCTCAGCCTCACCATCACC\nCTGCTAATGACTGCCAGACTGTGGGGAGGCACTCTCCTCTGGACCTAA"}, "pfams": {"pfam": {"identifier": "PF00021", "name": "UPAR_LY6"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "U-plasminogen activator receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}]}}}, {"@position": "3", "id": "BE0000895", "name": "Urokinase-type plasminogen activator", "organism": "Human", "actions": null, "references": "# Bell WR: Present-day thrombolytic therapy: therapeutic agents--pharmacokinetics and pharmacodynamics. Rev Cardiovasc Med. 2002;3 Suppl 2:S34-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12556741\n# Gamberi G, Serra M, Ragazzini P, Magagnoli G, Pazzaglia L, Ponticelli F, Ferrari C, Zanasi M, Bertoni F, Picci P, Benassi MS: Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep. 2003 Mar-Apr;10(2):351-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12579271\n# Zhang G, Kim H, Cai X, Lopez-Guisa JM, Alpers CE, Liu Y, Carmeliet P, Eddy AA: Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephropathy. J Am Soc Nephrol. 2003 May;14(5):1254-71. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12707394\n# Chang H, Shyu KG, Lin S, Wang BW, Liu YC, Lee CC: Cell adhesion induces the plasminogen activator inhibitor-1 gene expression through phosphatidylinositol 3-kinase/Akt activation in anchorage dependent cells. Cell Commun Adhes. 2002 Sep-Dec;9(5-6):239-47. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12745435\n# Wielockx B, Libert C: Serine proteases of the fibrinolysis pathway are not involved in lethal hepatitis and fibrinogen breakdown induced by tumor necrosis factor. Cytokine. 2003 Mar 21;21(6):281-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12824001", "known-action": "yes", "polypeptide": {"@id": "P00749", "@source": "Swiss-Prot", "name": "Urokinase-type plasminogen activator", "general-function": "Involved in chemotaxis and signal transduction activity", "specific-function": "Specifically cleave the zymogen plasminogen to form the active enzyme plasmin", "gene-name": "PLAU", "locus": "10q24", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.48", "molecular-weight": "48526.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9052"}, {"resource": "GenAtlas", "identifier": "PLAU"}, {"resource": "GeneCards", "identifier": "PLAU"}, {"resource": "GenBank Gene Database", "identifier": "X02419"}, {"resource": "GenBank Protein Database", "identifier": "1834524"}, {"resource": "UniProtKB", "identifier": "P00749"}, {"resource": "UniProt Accession", "identifier": "UROK_HUMAN"}]}, "synonyms": {"synonym": ["EC 3.4.21.73", "U-plasminogen activator", "uPA", "Urokinase-type plasminogen activator precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Urokinase-type plasminogen activator precursor\nMRALLARLLLCVLVVSDSKGSNELHQVPSNCDCLNGGTCVSNKYFSNIHWCNCPKKFGGQ\nHCEIDKSKTCYEGNGHFYRGKASTDTMGRPCLPWNSATVLQQTYHAHRSDALQLGLGKHN\nYCRNPDNRRRPWCYVQVGLKPLVQECMVHDCADGKKPSSPPEELKFQCGQKTLRPRFKII\nGGEFTTIENQPWFAAIYRRHRGGSVTYVCGGSLMSPCWVISATHCFIDYPKKEDYIVYLG\nRSRLNSNTQGEMKFEVENLILHKDYSADTLAHHNDIALLKIRSKEGRCAQPSRTIQTICL\nPSMYNDPQFGTSCEITGFGKENSTDYLYPEQLKMTVVKLISHRECQQPHYYGSEVTTKML\nCAADPQWKTDSCQGDSGGPLVCSLQGRMTLTGIVSWGRGCALKDKPGVYTRVSHFLPWIR\nSHTKEENGLAL"}, "gene-sequence": {"@format": "FASTA", "#text": ">1296 bp\nATGAGAGCCCTGCTGGCGCGCCTGCTTCTCTGCGTCCTGGTCGTGAGCGACTCCAAAGGC\nAGCAATGAACTTCATCAAGTTCCATCGAACTGTGACTGTCTAAATGGAGGAACATGTGTG\nTCCAACAAGTACTTCTCCAACATTCACTGGTGCAACTGCCCAAAGAAATTCGGAGGGCAG\nCACTGTGAAATAGATAAGTCAAAAACCTGCTATGAGGGGAATGGTCACTTTTACCGAGGA\nAAGGCCAGCACTGACACCATGGGCCGGCCCTGCCTGCCCTGGAACTCTGCCACTGTCCTT\nCAGCAAACGTACCATGCCCACAGATCTGATGCTCTTCAGCTGGGCCTGGGGAAACATAAT\nTACTGCAGGAACCCAGACAACCGGAGGCGACCCTGGTGCTATGTGCAGGTGGGCCTAAAG\nCCGCTTGTCCAAGAGTGCATGGTGCATGACTGCGCAGATGGAAAAAAGCCCTCCTCTCCT\nCCAGAAGAATTAAAATTTCAGTGTGGCCAAAAGACTCTGAGGCCCCGCTTTAAGATTATT\nGGGGGAGAATTCACCACCATCGAGAACCAGCCCTGGTTTGCGGCCATCTACAGGAGGCAC\nCGGGGGGGCTCTGTCACCTACGTGTGTGGAGGCAGCCTCATGAGCCCTTGCTGGGTGATC\nAGCGCCACACACTGCTTCATTGATTACCCAAAGAAGGAGGACTACATCGTCTACCTGGGT\nCGCTCAAGGCTTAACTCCAACACGCAAGGGGAGATGAAGTTTGAGGTGGAAAACCTCATC\nCTACACAAGGACTACAGCGCTGACACGCTTGCTCACCACAACGACATTGCCTTGCTGAAG\nATCCGTTCCAAGGAGGGCAGGTGTGCGCAGCCATCCCGGACTATACAGACCATCTGCCTG\nCCCTCGATGTATAACGATCCCCAGTTTGGCACAAGCTGTGAGATCACTGGCTTTGGAAAA\nGAGAATTCTACCGACTATCTCTATCCGGAGCAGCTGAAAATGACTGTTGTGAAGCTGATT\nTCCCACCGGGAGTGTCAGCAGCCCCACTACTACGGCTCTGAAGTCACCACCAAAATGCTG\nTGTGCTGCTGACCCACAGTGGAAAACAGATTCCTGCCAGGGAGACTCAGGGGGACCCCTC\nGTCTGTTCCCTCCAAGGCCGCATGACTTTGACTGGAATTGTGAGCTGGGGCCGTGGATGT\nGCCCTGAAGGACAAGCCAGGCGTCTACACGAGAGTCTCACACTTCTTACCCTGGATCCGC\nAGTCACACCAAGGAAGAGAATGGCCTGGCCCTCTGA"}, "pfams": {"pfam": [{"identifier": "PF00051", "name": "Kringle"}, {"identifier": "PF00089", "name": "Trypsin"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "peptidase activity"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}]}}}, {"@position": "4", "id": "BE0001088", "name": "Tissue-type plasminogen activator", "organism": "Human", "actions": null, "references": "# Chang H, Shyu KG, Lin S, Wang BW, Liu YC, Lee CC: Cell adhesion induces the plasminogen activator inhibitor-1 gene expression through phosphatidylinositol 3-kinase/Akt activation in anchorage dependent cells. Cell Commun Adhes. 2002 Sep-Dec;9(5-6):239-47. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12745435\n# Lindholt JS, Jorgensen B, Shi GP, Henneberg EW: Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2003 Jun;25(6):546-51. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12787697\n# Aleman C, Alegre J, Monasterio J, Segura RM, Armadans L, Angles A, Varela E, Ruiz E, Fernandez de Sevilla T: Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions. Clin Sci (Lond). 2003 Nov;105(5):601-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12826021\n# Wells RG, Havens PL: Intrapleural fibrinolysis for parapneumonic effusion and empyema in children. Radiology. 2003 Aug;228(2):370-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12893898\n# Stief TW, Bunder R, Richter A, Maisch B, Renz H, Fareed J: In vitro simulation of therapeutic plasmatic fibrinolysis. Clin Appl Thromb Hemost. 2003 Jul;9(3):211-20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14507109", "known-action": "yes", "polypeptide": {"@id": "P00750", "@source": "Swiss-Prot", "name": "Tissue-type plasminogen activator", "general-function": "Involved in plasminogen activator activity", "specific-function": "Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Play a direct role in facilitating neuronal migration", "gene-name": "PLAT", "locus": "8p12", "cellular-location": "Secreted protein; extracellular space", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.81", "molecular-weight": "62917.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9051"}, {"resource": "GenAtlas", "identifier": "PLAT"}, {"resource": "GeneCards", "identifier": "PLAT"}, {"resource": "GenBank Gene Database", "identifier": "L00153"}, {"resource": "GenBank Protein Database", "identifier": "339834"}, {"resource": "UniProtKB", "identifier": "P00750"}, {"resource": "UniProt Accession", "identifier": "TPA_HUMAN"}]}, "synonyms": {"synonym": ["Alteplase", "EC 3.4.21.68", "Reteplase", "t- PA", "t-plasminogen activator", "Tissue-type plasminogen activator precursor", "tPA"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Tissue-type plasminogen activator precursor\nMDAMKRGLCCVLLLCGAVFVSPSQEIHARFRRGARSYQVICRDEKTQMIYQQHQSWLRPV\nLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCE\nIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCR\nNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWN\nSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCG\nLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQ\nERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCA\nQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQH\nLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQK\nDVPGVYTKVTNYLDWIRDNMRP"}, "gene-sequence": {"@format": "FASTA", "#text": ">1689 bp\nATGGATGCAATGAAGAGAGGGCTCTGCTGTGTGCTGCTGCTGTGTGGAGCAGTCTTCGTT\nTCGCCCAGCCAGGAAATCCATGCCCGATTCAGAAGAGGAGCCAGATCTTACCAAGTGATC\nTGCAGAGATGAAAAAACGCAGATGATATACCAGCAACATCAGTCATGGCTGCGCCCTGTG\nCTCAGAAGCAACCGGGTGGAATATTGCTGGTGCAACAGTGGCAGGGCACAGTGCCACTCA\nGTGCCTGTCAAAAGTTGCAGCGAGCCAAGGTGTTTCACCGGGGGCACCTGCCAGCAGGCC\nCTGTACTTCTCAGATTTCGTGTGCCAGTGCCCCGAAGGATTTGCTGGGAAGTGCTGTGAA\nATAGATACCAGGGCCACGTGCTACGAGGACCAGGGCATCAGCTACAGGGGCACGTGGAGC\nACAGCGGAGAGTGGCGCCGAGTGCACCAACTGGAACAGCAGCGCGTTGGCCCAGAAGCCC\nTACAGCGGGCGGAGGCCAGATGCCATCAGGCTGGGCCTGGGGAACCACAACTACTGCAGA\nAACCCAGATCGAGACTCAAAGCCCTGGTGCTACGTCTTTAAGGCGGGGAAGTACAGCTCA\nGAGTTCTGCAGCACCCCTGCCTGCTCTGAGGGAAACAGTGACTGCTACTTTGGGAATGGG\nTCAGCCTACCGTGGCACGCACAGCCTCACCGAGTCGGGTGCCTCCTGCCTCCCGTGGAAT\nTCCATGATCCTGATAGGCAAGGTTTACACAGCACAGAACCCCAGTGCCCAGGCACTGGGC\nCTGGGCAAACATAATTACTGCCGGAATCCTGATGGGGATGCCAAGCCCTGGTGCCACGTG\nCTGAAGAACCGCAGGCTGACGTGGGAGTACTGTGATGTGCCCTCCTGCTCCACCTGCGGC\nCTGAGACAGTACAGCCAGCCTCAGTTTCGCATCAAAGGAGGGCTCTTCGCCGACATCGCC\nTCCCACCCCTGGCAGGCTGCCATCTTTGCCAAGCACAGGAGGTCGCCCGGAGAGCGGTTC\nCTGTGCGGGGGCATACTCATCAGCTCCTGCTGGATTCTCTCTGCCGCCCACTGCTTCCAG\nGAGAGGTTTCCGCCCCACCACCTGACGGTGATCTTGGGCAGAACATACCGGGTGGTCCCT\nGGCGAGGAGGAGCAGAAATTTGAAGTCGAAAAATACATTGTCCATAAGGAATTCGATGAT\nGACACTTACGACAATGACATTGCGCTGCTGCAGCTGAAATCGGATTCGTCCCGCTGTGCC\nCAGGAGAGCAGCGTGGTCCGCACTGTGTGCCTTCCCCCGGCGGACCTGCAGCTGCCGGAC\nTGGACGGAGTGTGAGCTCTCCGGCTACGGCAAGCATGAGGCCTTGTCTCCTTTCTATTCG\nGAGCGGCTGAAGGAGGCTCATGTCAGACTGTACCCATCCAGCCGCTGCACATCACAACAT\nTTACTTAACAGAACAGTCACCGACAACATGCTGTGTGCTGGAGACACTCGGAGCGGCGGG\nCCCCAGGCAAACTTGCACGACGCCTGCCAGGGCGATTCGGGAGGCCCCCTGGTGTGTCTG\nAACGATGGCCGCATGACTTTGGTGGGCATCATCAGCTGGGGCCTGGGCTGTGGACAGAAG\nGATGTCCCGGGTGTGTACACCAAGGTTACCAACTACCTAGACTGGATTCGTGACAACATG\nCGACCGTGA"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF00051", "name": "Kringle"}, {"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00039", "name": "fn1"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "peptidase activity"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "plasminogen activator activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}]}}}, {"@position": "5", "id": "BE0000240", "name": "Plasminogen activator inhibitor 1", "organism": "Human", "actions": null, "references": "# Gamberi G, Serra M, Ragazzini P, Magagnoli G, Pazzaglia L, Ponticelli F, Ferrari C, Zanasi M, Bertoni F, Picci P, Benassi MS: Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep. 2003 Mar-Apr;10(2):351-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12579271\n# Shetty S, Bdeir K, Cines DB, Idell S: Induction of plasminogen activator inhibitor-1 by urokinase in lung epithelial cells. J Biol Chem. 2003 May 16;278(20):18124-31. Epub 2003 Mar 17. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12642587\n# Hellgren M: Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost. 2003 Apr;29(2):125-30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12709915\n# Chang H, Shyu KG, Lin S, Wang BW, Liu YC, Lee CC: Cell adhesion induces the plasminogen activator inhibitor-1 gene expression through phosphatidylinositol 3-kinase/Akt activation in anchorage dependent cells. Cell Commun Adhes. 2002 Sep-Dec;9(5-6):239-47. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12745435\n# Gerstein ES, Shcherbakov AM, Kaz'min AI, Ognerubov NA, Kushlinskii NE: [Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer] Vopr Onkol. 2003;49(2):165-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12785198", "known-action": "yes", "polypeptide": {"@id": "P05121", "@source": "Swiss-Prot", "name": "Plasminogen activator inhibitor 1", "general-function": "Involved in serine-type endopeptidase inhibitor activity", "specific-function": "This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, and protein C. Its rapid interaction with TPA may function as a major control point in the regulation of fibrinolysis", "gene-name": "SERPINE1", "locus": "7q21.3-q22", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.22", "molecular-weight": "45061.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:8583"}, {"resource": "GenAtlas", "identifier": "SERPINE1"}, {"resource": "GeneCards", "identifier": "SERPINE1"}, {"resource": "GenBank Gene Database", "identifier": "X04429"}, {"resource": "GenBank Protein Database", "identifier": "35272"}, {"resource": "UniProtKB", "identifier": "P05121"}, {"resource": "UniProt Accession", "identifier": "PAI1_HUMAN"}]}, "synonyms": {"synonym": ["Endothelial plasminogen activator inhibitor", "PAI", "PAI-1", "Plasminogen activator inhibitor 1 precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Plasminogen activator inhibitor 1 precursor\nMQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY\nGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI\nFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV\nDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD\nGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK\nFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS\nSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP"}, "gene-sequence": {"@format": "FASTA", "#text": ">1209 bp\nATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA\nGGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG\nAGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT\nGGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG\nATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT\nCTGTACAAGGAGCTCATGGGGCCATGGAACAAGGACGAGATCAGCACCACAGACGCGATC\nTTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC\nCGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT\nGACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG\nGACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT\nCCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC\nTCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT\nGGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT\nGCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG\nCTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG\nTTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC\nATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC\nGCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA\nTCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC\nTTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG\nGAACCCTGA"}, "pfams": {"pfam": {"identifier": "PF00079", "name": "Serpin"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "protease inhibitor activity"}, {"category": "function", "description": "endopeptidase inhibitor activity"}, {"category": "function", "description": "serine-type endopeptidase inhibitor activity"}, {"category": "function", "description": "enzyme regulator activity"}, {"category": "function", "description": "enzyme inhibitor activity"}]}}}, {"@position": "6", "id": "BE0000969", "name": "Plasminogen activator inhibitor 2", "organism": "Human", "actions": null, "references": "# Swartz JM, Bystrom J, Dyer KD, Nitto T, Wynn TA, Rosenberg HF: Plasminogen activator inhibitor-2 (PAI-2) in eosinophilic leukocytes. J Leukoc Biol. 2004 Oct;76(4):812-9. Epub 2004 Jul 26. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15277569\n# Wygrecka M, Markart P, Ruppert C, Kuchenbuch T, Fink L, Bohle RM, Grimminger F, Seeger W, Gunther A: Compartment- and cell-specific expression of coagulation and fibrinolysis factors in the murine lung undergoing inhalational versus intravenous endotoxin application. Thromb Haemost. 2004 Sep;92(3):529-40. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15351849\n# Iglesias D, Alegre J, Aleman C, Ruiz E, Soriano T, Armadans LI, Segura RM, Angles A, Monasterio J, de Sevilla TF: Metalloproteinases and tissue inhibitors of metalloproteinases in exudative pleural effusions. Eur Respir J. 2005 Jan;25(1):104-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15640330\n# Grebenchtchikov N, Maguire TM, Riisbro R, Geurts-Moespot A, O'Donovan N, Schmitt M, McGreal G, McDermott E, O'Higgins N, Brunner N, Sweep CG, Duffy MJ: Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. Oncol Rep. 2005 Jul;14(1):235-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15944795\n# Fernandez-Soria V, Lleonart ME, Diaz-Fuertes M, Villuendas R, Sanchez-Prieto R, Fabra A, Ramon Y Cajal S: Adenovirus E1A orchestrates the urokinase-plasminogen activator system and upregulates PAI-2 expression, supporting a tumor suppressor effect. Int J Oncol. 2006 Jan;28(1):143-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16327990", "known-action": "yes", "polypeptide": {"@id": "P05120", "@source": "Swiss-Prot", "name": "Plasminogen activator inhibitor 2", "general-function": "Involved in serine-type endopeptidase inhibitor activity", "specific-function": "Inhibits urokinase-type plasminogen activator. The monocyte derived PAI-2 is distinct from the endothelial cell- derived PAI-1", "gene-name": "SERPINB2", "locus": "18q21.3", "cellular-location": "Cytoplasm. Secreted protein; extracellular space", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.34", "molecular-weight": "46597.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:8584"}, {"resource": "GenAtlas", "identifier": "SERPINB2"}, {"resource": "GeneCards", "identifier": "SERPINB2"}, {"resource": "GenBank Gene Database", "identifier": "J02685"}, {"resource": "GenBank Protein Database", "identifier": "189545"}, {"resource": "UniProtKB", "identifier": "P05120"}, {"resource": "UniProt Accession", "identifier": "PAI2_HUMAN"}]}, "synonyms": {"synonym": ["Monocyte Arg-serpin", "PAI-2", "Placental plasminogen activator inhibitor", "Plasminogen activator inhibitor 2 precursor", "Urokinase inhibitor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Plasminogen activator inhibitor 2 precursor\nMEDLCVANTLFALNLFKHLAKASPTQNLFLSPWSISSTMAMVYMGSRGSTEDQMAKVLQF\nNEVGANAVTPMTPENFTSCGFMQQIQKGSYPDAILQAQAADKIHSSFRSLSSAINASTGN\nYLLESVNKLFGEKSASFREEYIRLCQKYYSSEPQAVDFLECAEEARKKINSWVKTQTKGK\nIPNLLPEGSVDGDTRMVLVNAVYFKGKWKTPFEKKLNGLYPFRVNSAQRTPVQMMYLREK\nLNIGYIEDLKAQILELPYAGDVSMFLLLPDEIADVSTGLELLESEITYDKLNKWTSKDKM\nAEDEVEVYIPQFKLEEHYELRSILRSMGMEDAFNKGRANFSGMSERNDLFLSEVFHQAMV\nDVNEEGTEAAAGTGGVMTGRTGHGGPQFVADHPFLFLIMHKITNCILFFGRFSSP"}, "gene-sequence": {"@format": "FASTA", "#text": ">1248 bp\nATGGAGGATCTTTGTGTGGCAAACACACTCTTTGCCCTCAATTTATTCAAGCATCTGGCA\nAAAGCAAGCCCCACCCAGAACCTCTTCCTCTCCCCATGGAGCATCTCGTCCACCATGGCC\nATGGTCTACATGGGCTCCAGGGGCAGCACCGAAGACCAGATGGCCAAGGTGCTTCAGTTT\nAATGAAGTGGGAGCCAATGCAGTTACCCCCATGACTCCAGAGAACTTTACCAGCTGTGGG\nTTCATGCAGCAGATCCAGAAGGGTAGTTATCCTGATGCGATTTTGCAGGCACAAGCTGCA\nGATAAAATCCATTCATCCTTCCGCTCTCTCAGCTCTGCAATCAATGCATCCACAGGGGAT\nTATTTACTGGAAAGTGTCAATAAGCTGTTTGGTGAGAAGTCTGCGAGCTTCCGGGAAGAA\nTATATTCGACTCTGTCAGAAATATTACTCCTCAGAACCCCAGGCAGTAGACTTCCTAGAA\nTGTGCAGAAGAAGCTAGAAAAAAGATTAATTCCTGGGTCAAGACTCAAACCAAAGGCAAA\nATCCCAAACTTGTTACCTGAAGGTTCTGTAGATGGGGATACCAGGATGGTCCTGGTGAAT\nGCTGTCTACTTCAAAGGAAAGTGGAAAACTCCATTTGAGAAGAAACTAAATGGGCTTTAT\nCCTTTCCGTGTAAACTCGGCTCAGCGCACACCTGTACAGATGATGTACTTGCGTGAAAAG\nCTAAACATTGGATACATAGAAGACCTAAAGGCTCAGATTCTAGAACTCCCATATGCTGGA\nGATGTTAGCATGTTCTTGTTGCTTCCAGATGAAATTGCCGATGTGTCCACTGGCTTGGAG\nCTGCTGGAAAGTGAAATAACCTATGACAAACTCAACAAGTGGACCAGCAAAGACAAAATG\nGCTGAAGATGAAGTTGAGGTATACATACCCCAGTTCAAATTAGAAGAGCATTATGAACTC\nAGATCCATTCTGAGAAGCATGGGCATGGAGGACGCCTTCAACAAGGGACGGGCCAATTTC\nTCAGGGATGTCGGAGAGGAATGACCTGTTTCTTTCTGAAGTGTTCCACCAAGCCATGGTG\nGATGTGAATGAGGAGGGCACTGAAGCAGCCGCTGGCACAGGAGGTGTTATGACAGGGAGA\nACTGGACATGGAGGCCCACAGTTTGTGGCAGATCATCCGTTTCTTTTTCTTATTATGCAT\nAAGATAACCAAGTGCATTTTATTTTTCGGCAGATTTTGCTCACCCTAA"}, "pfams": {"pfam": {"identifier": "PF00079", "name": "Serpin"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "enzyme regulator activity"}, {"category": "function", "description": "enzyme inhibitor activity"}, {"category": "function", "description": "protease inhibitor activity"}, {"category": "function", "description": "endopeptidase inhibitor activity"}, {"category": "function", "description": "serine-type endopeptidase inhibitor activity"}]}}}, {"@position": "7", "id": "BE0002112", "name": "Plasma serine protease inhibitor", "organism": "Human", "actions": null, "references": "# Uhrin P, Schofer C, Zaujec J, Ryban L, Hilpert M, Weipoltshammer K, Jerabek I, Pirtzkall I, Furtmuller M, Dewerchin M, Binder BR, Geiger M: Male fertility and protein C inhibitor/plasminogen activator inhibitor-3 (PCI): localization of PCI in mouse testis and failure of single plasminogen activator knockout to restore spermatogenesis in PCI-deficient mice. Fertil Steril. 2007 Oct;88(4S):1049-1057. Epub 2007 Apr 16. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17434507\n# Espana F, Navarro S, Medina P, Zorio E, Estelles A: The role of protein C inhibitor in human reproduction. Semin Thromb Hemost. 2007 Feb;33(1):41-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17253188\n# Odet F, Guyot R, Leduque P, Le Magueresse-Battistoni B: Evidence for similar expression of protein C inhibitor and the urokinase-type plasminogen activator system during mouse testis development. Endocrinology. 2004 Mar;145(3):1481-9. Epub 2003 Nov 26. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14645112", "known-action": "unknown", "polypeptide": {"@id": "P05154", "@source": "Swiss-Prot", "name": "Plasma serine protease inhibitor", "general-function": null, "specific-function": "Inhibits activated protein C as well as plasminogen activators", "gene-name": "SERPINA5", "locus": "14q32.1", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.76", "molecular-weight": "45702.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:8723"}, {"resource": "GenAtlas", "identifier": "SERPINA5"}, {"resource": "GeneCards", "identifier": "SERPINA5"}, {"resource": "GenBank Gene Database", "identifier": "J02639"}, {"resource": "GenBank Protein Database", "identifier": "180550"}, {"resource": "UniProtKB", "identifier": "P05154"}, {"resource": "UniProt Accession", "identifier": "IPSP_HUMAN"}]}, "synonyms": {"synonym": ["Acrosomal serine protease inhibitor", "PAI-3", "PAI3", "PCI", "Plasma serine protease inhibitor precursor", "Plasminogen activator inhibitor 3", "Protein C inhibitor", "Serpin A5"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Plasma serine protease inhibitor\nMQLFLLLCLVLLSPQGASLHRHHPREMKKRVEDLHVGATVAPSSRRDFTFDLYRALASAA\nPSQNIFFSPVSISMSLAMLSLGAGSSTKMQILEGLGLNLQKSSEKELHRGFQQLLQELNQ\nPRDGFQLSLGNALFTDLVVDLQDTFVSAMKTLYLADTFPTNFRDSAGAMKQINDYVAKQT\nKGKIVDLLKNLDSNAVVIMVNYIFFKAKWETSFNHKGTQEQDFYVTSETVVRVPMMSRED\nQYHYLLDRNLSCRVVGVPYQGNATALFILPSEGKMQQVENGLSEKTLRKWLKMFKKRQLE\nLYLPKFSIEGSYQLEKVLPSLGISNVFTSHADLSGISNHSNIQVSEMVHKAVVEVDESGT\nRAAAATGTIFTFRSARLNSQRLVFNRPFLMFIVDNNILFLGKVNRP"}, "gene-sequence": {"@format": "FASTA", "#text": ">1221 bp\nATGCAGCTCTTCCTCCTCTTGTGCCTGGTGCTTCTCAGCCCTCAGGGGGCCTCCCTTCAC\nCGCCACCACCCCCGGGAGATGAAGAAGAGAGTCGAGGACCTCCATGTAGGTGCCACGGTG\nGCCCCCAGCAGCAGAAGGGACTTTACCTTTGACCTCTACAGGGCCTTGGCTTCCGCTGCC\nCCCAGCCAGAACATCTTCTTCTCCCCTGTGAGCATCTCCATGAGCCTGGCCATGCTCTCC\nCTGGGGGCTGGGTCCAGCACAAAGATGCAGATCCTGGAGGGCCTGGGCCTCAACCTCCAG\nAAAAGCTCAGAGAAGGAGCTGCACAGAGGCTTTCAGCAGCTCCTTCAGGAACTCAACCAG\nCCCAGAGATGGCTTCCAGCTGAGCCTCGGCAATGCCCTTTTCACCGACCTGGTGGTAGAC\nCTGCAGGACACCTTCGTAAGTGCCATGAAGACGCTGTACCTGGCAGACACTTTCCCCACC\nAACTTTAGGGACTCTGCAGGGGCCATGAAGCAGATCAATGATTATGTGGCAAAGCAAACG\nAAGGGCAAGATTGTGGACTTGCTTAAGAACCTCGATAGCAATGCGGTCGTGATCATGGTG\nAATTACATCTTCTTTAAAGCTAAGTGGGAGACAAGCTTCAACCACAAAGGCACCCAAGAG\nCAAGACTTCTACGTGACCTCGGAGACTGTGGTGCGGGTACCCATGATGAGCCGCGAGGAT\nCAGTATCACTACCTCCTGGACCGGAACCTCTCCTGCAGGGTGGTGGGGGTCCCCTACCAA\nGGCAATGCCACGGCTTTGTTCATTCTCCCCAGTGAGGGAAAGATGCAGCAGGTGGAGAAT\nGGACTGAGTGAGAAAACGCTGAGGAAGTGGCTTAAGATGTTCAAAAAGAGGCAGCTCGAG\nCTTTACCTTCCCAAATTCTCCATTGAGGGCTCCTATCAGCTGGAGAAAGTCCTCCCCAGT\nCTGGGGATCAGTAACGTCTTCACCTCCCATGCTGATCTGTCCCGCATCAGCAACCACTCA\nAATATCCAGGTGTCTGAGATGGTGCACAAAGCTGTGGTGGAGGTGGACGAGTCGGGAACC\nAGAGCAGCGGCAGCCACGGGGACAATCTTCACTTTCAGGTCGGCCCGCCTGAACTCTCAG\nAGGCTAGTGTTCAACAGGCCCTTTCTGATGTTCATTGTGGATAACAACATCCTCTTCCTT\nGGCAAAGTGAACCGCCCCTGA"}, "pfams": {"pfam": {"identifier": "PF00079", "name": "Serpin"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "enzyme regulator activity"}, {"category": "function", "description": "enzyme inhibitor activity"}, {"category": "function", "description": "protease inhibitor activity"}, {"category": "function", "description": "endopeptidase inhibitor activity"}, {"category": "function", "description": "serine-type endopeptidase inhibitor activity"}]}}}, {"@position": "8", "id": "BE0000942", "name": "Low-density lipoprotein receptor-related protein 2", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Kanalas JJ: Effect of the nephritogenic autoantibody of Heymann's nephritis on plasminogen-binding to gp330 and activation by urokinase. Biochim Biophys Acta. 1993 Nov 25;1225(1):101-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8241286\n# Kanalas JJ: Analysis of plasmin binding and urokinase activation of plasminogen bound to the Heymann nephritis autoantigen, gp330. Arch Biochem Biophys. 1992 Dec;299(2):255-60. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1280065\n# Korenberg JR, Argraves KM, Chen XN, Tran H, Strickland DK, Argraves WS: Chromosomal localization of human genes for the LDL receptor family member glycoprotein 330 (LRP2) and its associated protein RAP (LRPAP1). Genomics. 1994 Jul 1;22(1):88-93. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7959795", "known-action": "unknown", "polypeptide": {"@id": "P98164", "@source": "Swiss-Prot", "name": "Low-density lipoprotein receptor-related protein 2", "general-function": "Involved in calcium ion binding", "specific-function": "May participate in regulation of parathyroid-hormone and para-thyroid-hormone-related protein release", "gene-name": "LRP2", "locus": "2q24-q31", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "4424-4446", "signal-regions": null, "theoretical-pi": "4.68", "molecular-weight": "521933.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6694"}, {"resource": "GenAtlas", "identifier": "LRP2"}, {"resource": "GeneCards", "identifier": "LRP2"}, {"resource": "GenBank Gene Database", "identifier": "U33837"}, {"resource": "GenBank Protein Database", "identifier": "1809240"}, {"resource": "UniProtKB", "identifier": "P98164"}, {"resource": "UniProt Accession", "identifier": "LRP2_HUMAN"}]}, "synonyms": {"synonym": ["Glycoprotein 330", "gp330", "Low-density lipoprotein receptor-related protein 2 precursor", "Megalin"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low-density lipoprotein receptor-related protein 2 precursor\nMDRGPAAVACTLLLALVACLAPASGQECDSAHFRCGSGHCIPADWRCDGTKDCSDDADEI\nGCAVVTCQQGYFKCQSEGQCIPSSWVCDQDQDCDDGSDERQDCSQSTCSSHQITCSNGQC\nIPSEYRCDHVRDCPDGADENDCQYPTCEQLTCDNGACYNTSQKCDWKVDCRDSSDEINCT\nEICLHNEFSCGNGECIPRAYVCDHDNDCQDGSDEHACNYPTCGGYQFTCPSGRCIYQNWV\nCDGEDDCKDNGDEDGCESGPHDVHKCSPREWSCPESGRCISIYKVCDGILDCPGREDENN\nTSTGKYCSMTLCSALNCQYQCHETPYGGACFCPPGYIINHNDSRTCVEFDDCQIWGICDQ\nKCESRPGRHLCHCEEGYILERGQYCKANDSFGEASIIFSNGRDLLIGDIHGRSFRILVES\nQNRGVAVGVAFHYHLQRVFWTDTVQNKVFSVDINGLNIQEVLNVSVETPENLAVDWVNNK\nIYLVETKVNRIDMVNLDGSYRVTLITENLGHPRGIAVDPTVGYLFFSDWESLSGEPKLER\nAFMDGSNRKDLVKTKLGWPAGVTLDMISKRVYWVDSRFDYIETVTYDGIQRKTVVHGGSL\nIPHPFGVSLFEGQVFFTDWTKMAVLKANKFTETNPQVYYQASLRPYGVTVYHSLRQPYAT\nNPCKDNNGGCEQVCVLSHRTDNDGLGFRCKCTFGFQLDTDERHCIAVQNFLIFSSQVAIR\nGIPFTLSTQEDVMVPVSGNPSFFVGIDFDAQDSTIFFSDMSKHMIFKQKIDGTGREILAA\nNRVENVESLAFDWISKNLYWTDSHYKSISVMRLADKTRRTVVQYLNNPRSVVVHPFAGYL\nFFTDWFRPAKIMRAWSDGSHLLPVINTTLGWPNGLAIDWAASRLYWVDAYFDKIEHSTFD\nGLDRRRLGHIEQMTHPFGLAIFGEHLFFTDWRLGAIIRVRKADGGEMTVIRSGIAYILHL\nKSYDVNIQTGSNACNQPTHPNGDCSHFCFPVPNFQRVCGCPYGMRLASNHLTCEGDPTNE\nPPTEQCGLFSFPCKNGRCVPNYYLCDGVDDCHDNSDEQLCGTLNNTCSSSAFTCGHGECI\nPAHWRCDKRNDCVDGSDEHNCPTHAPASCLDTQYTCDNHQCISKNWVCDTDNDCGDGSDE\nKNCNSTETCQPSQFNCPNHRCIDLSFVCDGDKDCVDGSDEVGCVLNCTASQFKCASGDKC\nIGVTNRCDGVFDCSDNSDEAGCPTRPPGMCHSDEFQCQEDGICIPNFWECDGHPDCLYGS\nDEHNACVPKTCPSSYFHCDNGNCIHRAWLCDRDNDCGDMSDEKDCPTQPFRCPSWQWQCL\nGHNICVNLSVVCDGIFDCPNGTDESPLCNGNSCSDFNGGCTHECVQEPFGAKCLCPLGFL\nLANDSKTCEDIDECDILGSCSQHCYNMRGSFRCSCDTGYMLESDGRTCKVTASESLLLLV\nASQNKIIADSVTSQVHNIYSLVENGSYIVAVDFDSISGRIFWSDATQGKTWSAFQNGTDR\nRVVFDSSIILTETIAIDWVGRNLYWTDYALETIEVSKIDGSHRTVLISKNLTNPRGLALD\nPRMNEHLLFWSDWGHHPRIERASMDGSMRTVIVQDKIFWPCGLTIDYPNRLLYFMDSYLD\nYMDFCDYNGHHRRQVIASDLIIRHPYALTLFEDSVYWTDRATRRVMRANKWHGGNQSVVM\nYNIQWPLGIVAVHPSKQPNSVNPCAFSRCSHLCLLSSQGPHFYSCVCPSGWSLSPDLLNC\nLRDDQPFLITVRQHIIFGISLNPEVKSNDAMVPIAGIQNGLDVEFDDAEQYIYWVENPGE\nIHRVKTDGTNRTVFASISMVGPSMNLALDWISRNLYSTNPRTQSIEVLTLHGDIRYRKTL\nIANDGTALGVGFPIGITVDPARGKLYWSDQGTDSGVPAKIASANMDGTSVKTLFTGNLEH\nLECVTLDIEEQKLYWAVTGRGVIERGNVDGTDRMILVHQLSHPWGIAVHDSFLYYTDEQY\nEVIERVDKATGANKIVLRDNVPNLRGLQVYHRRNAAESSNGCSNNMNACQQICLPVPGGL\nFSCACATGFKLNPDNRSCSPYNSFIVVSMLSAIRGFSLELSDHSETMVPVAGQGRNALHV\nDVDVSSGFIYWCDFSSSVASDNAIRRIKPDGSSLMNIVTHGIGENGVRGIAVDWVAGNLY\nFTNAFVSETLIEVLRINTTYRRVLLKVTVDMPRHIVVDPKNRYLFWADYGQRPKIERSFL\nDCTNRTVLVSEGIVTPRGLAVDRSDGYVYWVDDSLDIIARIRINGENSEVIRYGSRYPTP\nYGITVFENSIIWVDRNLKKIFQASKEPENTEPPTVIRDNINWLRDVTIFDKQVQPRSPAE\nVNNNPCLENNGGCSHLCFALPGLHTPKCDCAFGTLQSDGKNCAISTENFLIFALSNSLRS\nLHLDPENHSPPFQTINVERTVMSLDYDSVSDRIYFTQNLASGVGQISYATLSSGIHTPTV\nIASGIGTADGIAFDWITRRIYYSDYLNQMINSMAEDGSNRTVIARVPKPRAIVLDPCQGY\nLYWADWDTHAKIERATLGGNFRVPIVNSSLVMPSGLTLDYEEDLLYWVDASLQRIERSTL\nTGVDREVIVNAAVHAFGLTLYGQYIYWTDLYTQRIYRANKYDGSGQIAMTTNLLSQPRGI\nNTVVKNQKQQCNNPCEQFNGGCSHICAPGPNGAECQCPHEGNWYLANNRKHCIVDNGERC\nGASSFTCSNGRCISEEWKCDNDNDCGDGSDEMESVCALHTCSPTAFTCANGRCVQYSYRC\nDYYNDCGDGSDEAGCLFRDCNATTEFMCNNRRCIPREFICNGVDNCHDNNTSDEKNCPDR\nTCQSGYTKCHNSNICIPRVYLCDGDNDCGDNSDENPTYCTTHTCSSSEFQCASGRCIPQH\nWYCDQETDCFDASDEPASCGHSERTCLADEFKCDGGRCIPSEWICDGDNDCGDMSDEDKR\nHQCQNQNCSDSEFLCVNDRPPDRRCIPQSWVCDGDVDCTDGYDENQNCTRRTCSENEFTC\nGYGLCIPKIFRCDRHNDCGDYSDERGCLYQTCQQNQFTCQNGRCISKTFVCDEDNDCGDG\nSDELMHLCHTPEPTCPPHEFKCDNGRCIEMMKLCNHLDDCLDNSDEKGCGINECHDPSIS\nGCDHNCTDTLTSFYCSCRPGYKLMSDKRTCVDIDECTEMPFVCSQKCENVIGSYICKCAP\nGYLREPDGKTCRQNSNIEPYLIFSNRYYLRNLTIDGYFYSLILEGLDNVVALDFDRVEKR\nLYWIDTQRQVIERMFLNKTNKETIINHRLPAAESLAVDWVSRKLYWLDARLDGLFVSDLN\nGGHRRMLAQHCVDANNTFCFDNPRGLALHPQYGYLYWADWGHRAYIGRVGMDGTNKSVII\nSTKLEWPNGITIDYTNDLLYWADAHLGYIEYSDLEGHHRHTVYDGALPHPFAITIFEDTI\nYWTDWNTRTVEKGNKYDGSNRQTLVNTTHRPFDIHVYHPYRQPIVSNPCGTNNGGCSHLC\nLIKPGGKGFTCECPDDFRTLQLSGSTYCMPMCSSTQFLCANNEKCIPIWWKCDGQKDCSD\nGSDELALCPQRFCRLGQFQCSDGNCTSPQTLCNAHQNCPDGSDEDRLLCENHHCDSNEWQ\nCANKRCIPESWQCDTFNDCEDNSDEDSSHCASRTCRPGQFRCANGRCIPQAWKCDVDNDC\nGDHSDEPIEECMSSAHLCDNFTEFSCKTNYRCIPKWAVCNGVDDCRDNSDEQGCEERTCH\nPVGDFRCKNHHCIPLRWQCDGQNDCGDNSDEENCAPRECTESEFRCVNQQCIPSRWICDH\nYNDCGDNSDERDCEMRTCHPEYFQCTSGHCVHSELKCDGSADCLDASDEADCPTRFPDGA\nYCQATMFECKNHVCIPPYWKCDGDDDCGDGSDEELHLCLDVPCNSPNRFRCDNNRCIYSH\nEVCNGVDDCGDGTDETEEHCRKPTPKPCTEYEYKCGNGHCIPHDNVCDDADDCGDWSDEL\nGCNKGKERTCAENICEQNCTQLNEGGFICSCTAGFETNVFDRTSCLDINECEQFGTCPQH\nCRNTKGSYECVCADGFTSMSDRPGKRCAAEGSSPLLLLPDNVRIRKYNLSSERFSEYLQD\nEEYIQAVDYDWDPKDIGLSVVYYTVRGEGSRFGAIKRAYIPNFESGRNNLVQEVDLKLKY\nVMQPDGIAVDWVGRHIYWSDVKNKRIEVAKLDGRYRKWLISTDLDQPAAIAVNPKLGLMF\nWTDWGKEPKIESAWMNGEDRNILVFEDLGWPTGLSIDYLNNDRIYWSDFKEDVIETIKYD\nGTDRRVIAKEAMNPYSLDIFEDQLYWISKEKGEVWKQNKFGQGKKEKTLVVNPWLTQVRI\nFHQLRYNKSVPNLCKQICSHLCLLRPGGYSCACPQGSSFIEGSTTECDAAIELPINLPPP\nCRCMHGGNCYFDETDLPKCKCPSGYTGKYCEMAFSKGISPGTTAVAVLLTILLIVVIGAL\nAIAGFFHYRRTGSLLPALPKLPSLSSLVKPSENGNGVTFRSGADLNMDIGVSGFGPETAI\nDRSMAMSEDFVMEMGKQPIIFENPMYSARDSAVKVVQPIQVTVSENVDNKNYGSPINPSE\nIVPETNPTSPAADGTQVTKWNLFKRKSKQTTNFENPIYAQMENEQKESVAATPPPSPSLP\nAKPKPPSRRDPTPTYSATEDTFKDTANLVKEDSEV"}, "gene-sequence": {"@format": "FASTA", "#text": ">13968 bp\nATGGATCGCGGGCCGGCAGCAGTGGCGTGCACGCTGCTCCTGGCTCTCGTCGCCTGCCTA\nGCGCCGGCCAGTGGCCAAGAATGTGACAGTGCGCATTTTCGCTGTGGAAGTGGGCATTGC\nATCCCTGCAGACTGGAGGTGTGATGGGACCAAAGACTGTTCAGATGACGCGGATGAAATT\nGGCTGCGCTGTTGTGACCTGCCAGCAGGGCTATTTCAAGTGCCAGAGTGAGGGACAATGC\nATCCCCAGCTCCTGGGTGTGTGACCAAGATCAAGACTGTGATGATGGCTCAGATGAACGT\nCAAGATTGCTCACAAAGTACATGCTCAAGTCATCAGATAACATGCTCCAATGGTCAGTGT\nATCCCAAGTGAATACAGGTGCGACCACGTCAGAGACTGCCCCGATGGAGCTGATGAGAAT\nGACTGCCAGTACCCAACATGTGAGCAGCTTACTTGTGACAATGGGGCCTGCTATAACACC\nAGTCAGAAGTGTGATTGGAAAGTTGATTGCAGGGACTCCTCAGATGAAATCAACTGCACT\nGAGATATGCTTGCACAATGAGTTTTCATGTGGCAATGGAGAGTGTATCCCTCGTGCTTAT\nGTCTGTGACCATGACAATGATTGCCAAGACGGCAGTGATGAACATGCTTGCAACTATCCG\nACCTGCGGTGGTTACCAGTTCACTTGCCCCAGTGGCCGATGCATTTATCAAAACTGGGTT\nTGTGATGGAGAAGATGACTGTAAAGATAATGGAGATGAAGATGGATGTGAAAGCGGTCCT\nCATGATGTTCATAAATGTTCCCCAAGAGAATGGTCTTGCCCAGAGTCGGGACGATGCATC\nTCCATTTATAAAGTTTGTGATGGGATTTTAGATTGCCCAGGAAGAGAAGATGAAAACAAC\nACTAGTACCGGAAAATACTGTAGTATGACTCTGTGCTCTGCCTTGAACTGCCAGTACCAG\nTGCCATGAGACGCCGTATGGAGGAGCGTGTTTTTGTCCCCCAGGTTATATCATCAACCAC\nAATGACAGCCGTACCTGTGTTGAGTTTGATGATTGCCAGATATGGGGAATTTGTGACCAG\nAAGTGTGAAAGCCGACCTGGCCGTCACCTGTGCCACTGTGAAGAAGGGTATATCTTGGAG\nCGTGGACAGTATTGCAAAGCTAATGATTCCTTTGGCGAGGCCTCCATTATCTTCTCCAAT\nGGTCGGGATTTGTTAATTGGTGATATTCATGGAAGGAGCTTCCGGATCCTAGTGGAGTCT\nCAGAATCGTGGAGTGGCCGTGGGTGTGGCTTTCCACTATCACCTGCAAAGAGTTTTTTGG\nACAGACACCGTGCAAAATAAGGTTTTTTCAGTTGACATTAATGGTTTAAATATCCAAGAG\nGTTCTCAATGTTTCTGTTGAAACCCCAGAGAACCTGGCTGTGGACTGGGTTAATAATAAA\nATCTATCTAGTGGAAACCAAGGTCAACCGCATAGATATGGTAAATTTGGATGGAAGCTAT\nCGGGTTACCCTTATAACTGAAAACTTGGGGCATCCTAGAGGAATTGCCGTGGACCCAACT\nGTTGGTTATTTATTTTTCTCAGATTGGGAGAGCCTTTCTGGGGAACCTAAGCTGGAAAGG\nGCATTCATGGATGGCAGCAACCGTAAAGACTTGGTGAAAACAAAGCTGGGATGGCCTGCT\nGGGGTAACTCTGGATATGATATCGAAGCGTGTTTACTGGGTTGACTCTCGGTTTGATTAC\nATTGAAACTGTAACTTATGATGGAATTCAAAGGAAGACTGTAGTTCATGGAGGCTCCCTC\nATTCCTCATCCCTTTGGAGTAAGCTTATTTGAAGGTCAGGTGTTCTTTACAGATTGGACA\nAAGATGGCCGTGCTGAAGGCAAACAAGTTCACAGAGACCAACCCACAAGTGTACTACCAG\nGCTTCCCTGAGGCCCTATGGAGTGACTGTTTACCATTCCCTCAGACAGCCCTATGCTACC\nAATCCGTGTAAAGATAACAATGGGGGCTGTGAGCAGGTCTGTGTTCTCAGCCACAGAACA\nGATAATGATGGTTTGGGTTTCCGTTGCAAGTGCACATTCGGCTTCCAACTGGATACAGAT\nGAGCGCCACTGCATTGCTGTTCAGAATTTCCTCATTTTTTCATCCCAAGTTGCTATTCGT\nGGGATCCCGTTCACCTTGTCTACCCAGGAAGATGTCATGGTTCCAGTTTCGGGGAATCCT\nTCTTTCTTTGTCGGGATTGATTTTGACGCCCAGGACAGCACTATCTTTTTTTCAGATATG\nTCAAAACACATGATTTTTAAGCAAAAGATTGATGGCACAGGAAGAGAAATTCTCGCAGCT\nAACAGGGTGGAAAATGTTGAAAGTTTGGCTTTTGATTGGATTTCAAAGAATCTCTATTGG\nACAGACTCTCATTACAAGAGTATCAGTGTCATGAGGCTAGCTGATAAAACGAGACGCACA\nGTAGTTCAGTATTTAAATAACCCACGGTCGGTGGTAGTTCATCCTTTTGCCGGGTATCTA\nTTCTTCACTGATTGGTTCCGTCCTGCTAAAATTATGAGAGCATGGAGTGACGGATCTCAC\nCTCTTGCCTGTAATAAACACTACTCTTGGATGGCCCAATGGCTTGGCCATCGATTGGGCT\nGCTTCACGATTGTACTGGGTAGATGCCTATTTTGATAAAATTGAGCACAGCACCTTTGAT\nGGTTTAGACAGAAGAAGACTGGGCCATATAGAGCAGATGACACATCCGTTTGGACTTGCC\nATCTTTGGAGAGCATTTATTTTTTACTGACTGGAGACTGGGTGCCATTATTCGAGTCAGG\nAAAGCAGATGGTGGAGAAATGACAGTTATCCGAAGTGGCATTGCTTACATACTGCATTTG\nAAATCGTATGATGTCAACATCCAGACTGGTTCTAACGCCTGTAATCAACCCACGCATCCT\nAACGGTGACTGCAGCCACTTCTGCTTCCCGGTGCCAAATTTCCAGCGAGTGTGTGGGTGC\nCCTTATGGAATGAGGCTGGCTTCCAATCACTTGACATGCGAGGGGGACCCAACCAATGAA\nCCACCCACGGAGCAGTGTGGCTTATTTTCCTTCCCCTGTAAAAATGGCAGATGTGTGCCC\nAATTACTATCTCTGTGATGGAGTCGATGATTGTCATGATAACAGTGATGAGCAACTATGT\nGGCACACTTAATAATACCTGTTCATCTTCGGCGTTCACCTGTGGCCATGGGGAGTGCATT\nCCTGCACACTGGCGCTGTGACAAACGCAACGACTGTGTGGATGGCAGTGATGAGCACAAC\nTGCCCCACCCACGCACCTGCTTCCTGCCTTGACACCCAATACACCTGTGATAATCACCAG\nTGTATCTCAAAGAACTGGGTCTGTGACACAGACAATGATTGTGGGGATGGATCTGATGAA\nAAGAACTGCAATTCGACAGAGACATGCCAACCTAGTCAGTTTAATTGCCCCAATCATCGA\nTGTATTGACCTATCGTTTGTCTGTGATGGTGACAAGGATTGTGTTGATGGATCTGATGAG\nGTTGGTTGTGTATTAAACTGTACTGCTTCTCAATTCAAGTGTGCCAGTGGGGATAAATGT\nATTGGCGTCACAAATCGTTGTGATGGTGTTTTTGATTGCAGTGACAACTCGGATGAAGCG\nGGCTGTCCAACCAGGCCTCCTGGTATGTGCCACTCAGATGAATTTCAGTGCCAAGAAGAT\nGGTATCTGCATCCCGAACTTCTGGGAATGTGATGGGCATCCAGACTGCCTCTATGGATCT\nGATGAGCACAATGCCTGTGTCCCCAAGACTTGCCCTTCATCATATTTCCACTGTGACAAC\nGGAAACTGCATCCACAGGGCATGGCTCTGTGATCGGGACAATGACTGCGGGGATATGAGT\nGATGAGAAGGACTGCCCTACTCAGCCCTTTCGCTGTCCTAGTTGGCAATGGCAGTGTCTT\nGGCCATAACATCTGTGTGAATCTGAGTGTAGTGTGTGATGGCATCTTTGACTGCCCCAAT\nGGGACAGATGAGTCCCCACTTTGCAATGGGAACAGCTGCTCAGATTTCAATGGTGGTTGT\nACTCACGAGTGTGTTCAAGAGCCCTTTGGGGCTAAATGCCTATGTCCATTGGGATTCTTA\nCTTGCCAATGATTCTAAGACCTGTGAAGACATAGATGAATGTGATATTCTAGGCTCTTGT\nAGCCAGCACTGTTACAATATGAGAGGTTCTTTCCGGTGCTCGTGTGATACAGGCTACATG\nTTAGAAAGTGATGGGAGGACTTGCAAAGTTACAGCATCTGAGAGTCTGCTGTTACTTGTG\nGCAAGTCAGAACAAAATTATTGCCGACAGTGTCACCTCCCAGGTCCACAATATCTATTCA\nTTGGTCGAGAATGGTTCTTACATTGTAGCTGTTGATTTTGATTCAATTAGTGGTCGTATC\nTTTTGGTCTGATGCAACTCAGGGTAAAACCTGGAGTGCGTTTCAAAATGGAACGGACAGA\nAGAGTGGTATTTGACAGTAGCATCATCTTGACTGAAACTATTGCAATAGATTGGGTAGGT\nCGTAATCTTTACTGGACAGACTATGCTCTGGAAACAATTGAAGTCTCCAAAATTGATGGG\nAGCCACAGGACTGTGCTGATTAGTAAAAACCTAACAAATCCAAGAGGACTAGCATTAGAT\nCCCAGAATGAATGAGCATCTACTGTTCTGGTCTGACTGGGGCCACCACCCTCGCATCGAG\nCGAGCCAGCATGGACGGCAGCATGCGCACTGTCATTGTCCAGGACAAGATCTTCTGGCCC\nTGCGGCTTAACTATTGACTACCCCAACAGACTGCTCTACTTCATGGACTCCTATCTTGAT\nTACATGGACTTTTGCGATTATAATGGACACCATCGGAGACAGGTGATAGCCAGTGATTTG\nATTATACGGCACCCCTATGCCCTAACTCTCTTTGAAGACTCTGTGTACTGGACTGACCGT\nGCTACTCGTCGGGTTATGCGAGCCAACAAGTGGCATGGAGGGAACCAGTCAGTTGTAATG\nTATAATATTCAATGGCCCCTTGGGATTGTTGCGGTTCATCCTTCGAAACAACCAAATTCC\nGTGAATCCATGTGCCTTTTCCCGCTGCAGCCATCTCTGCCTGCTTTCCTCACAGGGGCCT\nCATTTTTACTCCTGTGTTTGTCCTTCAGGATGGAGTCTGTCTCCTGATCTCCTGAATTGC\nTTGAGAGATGATCAACCTTTCTTAATAACTGTAAGGCAACATATAATTTTTGGAATCTCC\nCTTAATCCTGAGGTGAAGAGCAATGATGCTATGGTCCCCATAGCAGGGATACAGAATGGT\nTTAGATGTTGAATTTGATGATGCTGAGCAATACATCTATTGGGTTGAAAATCCAGGTGAA\nATTCACAGAGTGAAGACAGATGGCACCAACAGGACAGTATTTGCTTCTATATCTATGGTG\nGGGCCTTCTATGAACCTGGCCTTAGATTGGATTTCAAGAAACCTTTATTCTACCAATCCT\nAGAACTCAGTCAATCGAGGTTTTGACACTCCACGGAGATATCAGATACAGAAAAACATTG\nATTGCCAATGATGGGACAGCTCTTGGAGTTGGCTTTCCAATTGGCATAACTGTTGATCCT\nGCTCGTGGGAAGCTGTACTGGTCAGACCAAGGAACTGACAGTGGGGTTCCTGCCAAGATC\nGCCAGTGCTAACATGGATGGCACATCTGTGAAAACTCTCTTTACTGGGAACCTCGAACAC\nCTGGAGTGTGTCACTCTTGACATCGAAGAGCAGAAACTCTACTGGGCAGTCACTGGAAGA\nGGAGTGATTGAAAGAGGAAACGTGGATGGAACAGATCGGATGATCCTGGTACACCAGCTT\nTCCCACCCCTGGGGAATTGCAGTCCATGATTCTTTCCTTTATTATACTGATGAACAGTAT\nGAGGTCATTGAAAGAGTTGATAAGGCCACTGGGGCCAACAAAATAGTCTTGAGAGATAAT\nGTTCCAAATCTGAGGGGTCTTCAAGTTTATCACAGACGCAATGCCGCCGAATCCTCAAAT\nGGCTGTAGCAACAACATGAATGCCTGTCAGCAGATTTGCCTGCCTGTACCAGGAGGATTG\nTTTTCCTGCGCCTGTGCCACTGGATTTAAACTCAATCCTGATAATCGGTCCTGCTCTCCA\nTATAACTCTTTCATTGTTGTTTCAATGCTGTCTGCAATCAGAGGCTTTAGCTTGGAATTG\nTCAGATCATTCAGAAACCATGGTGCCGGTGGCAGGCCAAGGACGAAACGCACTGCATGTG\nGATGTGGATGTGTCCTCTGGCTTTATTTATTGGTGTGATTTTAGCAGCTCAGTGGCATCT\nGATAATGCGATCCGTAGAATTAAACCAGATGGATCTTCTCTGATGAACATTGTGACACAT\nGGAATAGGAGAAAATGGAGTCCGGGGTATTGCAGTGGATTGGGTAGCAGGAAATCTTTAT\nTTCACCAATGCCTTTGTTTCTGAAACACTGATAGAAGTTCTGCGGATCAATACTACTTAC\nCGCCGTGTTCTTCTTAAAGTCACAGTGGACATGCCTAGGCATATTGTTGTAGATCCCAAG\nAACAGATACCTCTTCTGGGCTGACTATGGGCAGAGACCAAAGATTGAGCGTTCTTTCCTT\nGACTGTACCAATCGAACAGTGCTTGTGTCAGAGGGCATTGTCACACCACGGGGCTTGGCA\nGTGGACCGAAGTGATGGCTACGTTTATTGGGTTGATGATTCTTTAGATATAATTGCAAGG\nATTCGTATCAATGGAGAGAACTCTGAAGTGATTCGTTATGGCAGTCGTTACCCAACTCCT\nTATGGCATCACTGTTTTTGAAAATTCTATCATATGGGTAGATAGGAATTTGAAAAAGATC\nTTCCAAGCCAGCAAGGAACCAGAGAACACAGAGCCACCCACAGTGATAAGAGACAATATC\nAACTGGCTAAGAGATGTGACCATCTTTGACAAGCAAGTCCAGCCCCGGTCACCAGCAGAG\nGTCAACAACAACCCTTGCTTGGAAAACAATGGTGGGTGCTCTCATCTCTGCTTTGCTCTG\nCCTGGATTGCACACCCCAAAATGTGACTGTGCCTTTGGGACCCTGCAAAGTGATGGCAAG\nAATTGTGCCATTTCAACAGAAAATTTCCTCATCTTTGCCTTGTCTAATTCCTTGAGAAGC\nTTACACTTGGACCCTGAAAACCATAGCCCACCTTTCCAAACAATAAATGTGGAAAGAACT\nGTCATGTCTCTAGACTATGACAGTGTAAGTGATAGAATCTACTTCACACAAAATTTAGCC\nTCTGGAGTTGGACAGATTTCCTATGCCACCCTGTCTTCAGGGATCCATACTCCAACTGTC\nATTGCTTCAGGTATAGGGACTGCTGATGGCATTGCCTTTGACTGGATTACTAGAAGAATT\nTATTACAGTGACTACCTCAACCAGATGATTAATTCCATGGCTGAAGATGGGTCTAACCGC\nACTGTGATAGCCCGCGTTCCAAAACCAAGAGCAATTGTGTTAGATCCCTGCCAAGGGTAC\nCTGTACTGGGCTGACTGGGATACACATGCCAAAATCGAGAGAGCCACATTGGGAGGAAAC\nTTCCGGGTACCCATTGTGAACAGCAGTCTGGTCATGCCCAGTGGGCTGACTCTGGACTAT\nGAAGAGGACCTTCTCTACTGGGTGGATGCTAGTCTGCAGAGGATTGAACGCAGCACTCTG\nACGGGCGTGGATCGTGAAGTCATTGTCAATGCAGCCGTTCATGCTTTTGGCTTGACTCTC\nTATGGCCAGTATATTTACTGGACTGACTTGTACACACAAAGAATTTACCGAGCTAACAAA\nTATGACGGGTCAGGTCAGATTGCAATGACCACAAATTTGCTCTCCCAGCCCAGGGGAATC\nAACACTGTTGTGAAGAACCAGAAACAACAGTGTAACAATCCTTGTGAACAGTTTAATGGG\nGGCTGCAGCCATATCTGTGCACCAGGTCCAAATGGTGCCGAGTGCCAGTGTCCACATGAG\nGGCAACTGGTATTTGGCCAACAACAGGAAGCACTGCATTGTGGACAATGGTGAACGATGT\nGGTGCATCTTCCTTCACCTGCTCCAATGGGCGCTGCATCTCGGAAGAGTGGAAGTGTGAT\nAATGACAACGACTGTGGGGATGGCAGTGATGAGATGGAAAGTGTCTGTGCACTTCACACC\nTGCTCACCGACAGCCTTCACCTGTGCCAATGGGCGATGTGTCCAATACTCTTACCGCTGT\nGATTACTACAATGACTGTGGTGATGGCAGTGATGAGGCAGGGTGCCTGTTCAGGGACTGC\nAATGCCACCACGGAGTTTATGTGCAATAACAGAAGGTGCATACCTCGTGAGTTTATCTGC\nAATGGTGTAGACAACTGCCATGATAATAACACTTCAGATGAGAAAAATTGCCCTGATCGC\nACTTGCCAGTCTGGATACACAAAATGTCATAATTCAAATATTTGTATTCCTCGCGTTTAT\nTTGTGTGACGGAGACAATGACTGTGGAGATAACAGTGATGAAAACCCTACTTATTGCACC\nACTCACACATGCAGCAGCAGTGAGTTCCAATGCGCATCTGGGCGCTGTATTCCTCAACAT\nTGGTATTGTGATCAAGAAACAGATTGTTTTGATGCCTCTGATGAACCTGCCTCTTGTGGT\nCACTCTGAGCGAACATGCCTAGCTGATGAGTTCAAGTGTGATGGTGGGAGGTGCATCCCA\nAGCGAATGGATCTGTGACGGTGATAATGACTGTGGGGATATGAGTGACGAGGATAAAAGG\nCACCAGTGTCAGAATCAAAACTGCTCGGATTCCGAGTTTCTCTGTGTAAATGACAGACCT\nCCGGACAGGAGGTGCATTCCCCAGTCTTGGGTCTGTGATGGCGATGTGGATTGTACTGAC\nGGCTACGATGAGAATCAGAATTGCACCAGGAGAACTTGCTCTGAAAATGAATTCACCTGT\nGGTTACGGACTGTGTATCCCAAAGATATTCAGGTGTGACCGGCACAATGACTGTGGTGAC\nTATAGCGACGAGAGGGGCTGCTTATACCAGACTTGCCAACAGAATCAGTTTACCTGTCAG\nAACGGGCGCTGCATTAGTAAAACCTTCGTCTGTGATGAGGATAATGACTGTGGAGACGGA\nTCTGATGAGCTGATGCACCTGTGCCACACCCCAGAACCCACGTGTCCACCTCACGAGTTC\nAAGTGTGACAATGGGCGCTGCATCGAGATGATGAAACTCTGCAACCACCTAGATGACTGT\nTTGGACAACAGCGATGAGAAAGGCTGTGGCATTAATGAATGCCATGACCCTTCAATCAGT\nGGCTGCGATCACAACTGCACAGACACCTTAACCAGTTTCTATTGTTCCTGTCGTCCTGGT\nTACAAGCTCATGTCTGACAAGCGGACTTGTGTTGATATTGATGAATGCACAGAGATGCCT\nTTTGTCTGTAGCCAGAAGTGTGAGAATGTAATAGGCTCCTACATCTGTAAGTGTGCCCCA\nGGCTACCTCCGAGAACCAGATGGAAAGACCTGCCGGCAAAACAGTAACATCGAACCCTAT\nCTCATTTTTAGCAACCGTTACTATTTGAGAAATTTAACTATAGATGGCTATTTTTACTCC\nCTCATCTTGGAAGGACTGGACAATGTTGTGGCATTAGATTTTGACCGAGTAGAGAAGAGA\nTTGTATTGGATTGATACACAGAGGCAAGTCATTGAGAGAATGTTTCTGAATAAGACAAAC\nAAGGAGACAATCATAAACCACAGACTACCAGCTGCAGAAAGTCTGGCTGTAGACTGGGTT\nTCCAGAAAGCTCTACTGGTTGGATGCCCGCCTGGATGGCCTCTTTGTCTCTGACCTCAAT\nGGTGGACACCGCCGCATGCTGGCCCAGCACTGTGTGGATGCCAACAACACCTTCTGCTTT\nGATAATCCCAGAGGACTTGCCCTTCACCCTCAATATGGGTACCTCTACTGGGCAGACTGG\nGGTCACCGCGCATACATTGGGAGAGTAGGCATGGATGGAACCAACAAGTCTGTGATAATC\nTCCACCAAGTTAGAGTGGCCTAATGGCATCACCATTGATTACACCAATGATCTACTCTAC\nTGGGCAGATGCCCACCTGGGTTACATAGAGTACTCTGATTTGGAGGGCCACCATCGACAC\nACGGTGTATGATGGGGCACTGCCTCACCCTTTCGCTATTACCATTTTTGAAGACACTATT\nTATTGGACAGATTGGAATACAAGGACAGTGGAAAAGGGAAACAAATATGATGGATCAAAT\nAGACAGACACTGGTGAACACAACACACAGACCATTTGACATCCATGTGTACCATCCATAT\nAGGCAGCCCATTGTGAGCAATCCCTGTGGTACCAACAATGGTGGCTGTTCTCATCTCTGC\nCTCATCAAGCCAGGAGGAAAAGGGTTCACTTGCGAGTGTCCAGATGACTTCCGCACCCTT\nCAACTGAGTGGCAGCACCTACTGCATGCCCATGTGCTCCAGCACCCAGTTCCTGTGCGCT\nAACAATGAAAAGTGCATTCCTATCTGGTGGAAATGTGATGGACAGAAAGACTGCTCAGAT\nGGCTCTGATGAACTGGCCCTTTGCCCGCAGCGCTTCTGCCGACTGGGACAGTTCCAGTGC\nAGTGACGGCAACTGCACCAGCCCGCAGACTTTATGCAATGCTCACCAAAATTGCCCTGAT\nGGGTCTGATGAAGACCGTCTTCTTTGTGAGAATCACCACTGTGACTCCAATGAATGGCAG\nTGCGCCAACAAACGTTGCATCCCAGAATCCTGGCAGTGTGACACATTTAACGACTGTGAG\nGATAACTCAGATGAAGACAGTTCCCACTGTGCCAGCAGGACCTGCCGGCCGGGCCAGTTT\nCGGTGTGCTAATGGCCGCTGCATCCCGCAGGCCTGGAAGTGTGATGTGGATAATGATTGT\nGGAGACCACTCGGATGAGCCCATTGAAGAATGCATGAGCTCTGCCCATCTCTGTGACAAC\nTTCACAGAATTCAGCTGCAAAACAAATTACCGCTGCATCCCAAAGTGGGCCGTGTGCAAT\nGGTGTAGATGACTGCAGGGACAACAGTGATGAGCAAGGCTGTGAGGAGAGGACATGCCAT\nCCTGTGGGGGATTTCCGCTGTAAAAATCACCACTGCATCCCTCTTCGTTGGCAGTGTGAT\nGGGCAAAATGACTGTGGAGATAACTCAGATGAGGAAAACTGTGCTCCCCGGGAGTGCACA\nGAGAGCGAGTTTCGATGTGTCAATCAGCAGTGCATTCCCTCGCGATGGATCTGTGACCAT\nTACAACGACTGTGGGGACAACTCAGATGAACGGGACTGTGAGATGAGGACCTGCCATCCT\nGAATATTTTCAGTGTACAAGTGGACATTGTGTACACAGTGAACTGAAATGCGATGGATCC\nGCTGACTGTTTGGATGCGTCTGATGAAGCTGATTGTCCCACACGCTTTCCTGATGGTGCA\nTACTGCCAGGCTACTATGTTCGAATGCAAAAACCATGTTTGTATCCCGCCATATTGGAAA\nTGTGATGGCGATGATGACTGTGGCGATGGTTCAGATGAAGAACTTCACCTGTGCTTGGAT\nGTTCCCTGTAATTCACCAAACCGTTTCCGGTGTGACAACAATCGCTGCATTTATAGTCAT\nGAGGTGTGCAATGGTGTGGATGACTGTGGAGATGGAACTGATGAGACAGAGGAGCACTGT\nAGAAAACCGACCCCTAAACCTTGTACAGAATATGAATATAAGTGTGGCAATGGGCATTGC\nATTCCACATGACAATGTGTGTGATGATGCCGATGACTGTGGTGACTGGTCCGATGAACTG\nGGTTGCAATAAAGGAAAAGAAAGAACATGTGCTGAAAATATATGCGAGCAAAATTGTACC\nCAATTAAATGAAGGAGGATTTATCTGCTCCTGTACAGCTGGGTTCGAAACCAATGTTTTT\nGACAGAACCTCCTGTCTAGATATCAATGAATGTGAACAATTTGGGACTTGTCCCCAGCAC\nTGCAGAAATACCAAAGGAAGTTATGAGTGTGTCTGTGCTGATGGCTTCACGTCTATGAGT\nGACCGCCCTGGAAAACGATGTGCAGCTGAGGGTAGCTCTCCTTTGTTGCTACTGCCTGAC\nAATGTCCGAATTCGAAAATATAATCTCTCATCTGAGAGGTTCTCAGAGTATCTTCAAGAT\nGAGGAATATATCCAAGCTGTTGATTATGATTGGGATCCCAAGGACATAGGCCTCAGTGTT\nGTGTATTACACTGTGCGAGGGGAGGGCTCTAGGTTTGGTGCTATCAAACGTGCCTACATC\nCCCAACTTTGAATCCGGCCGCAATAATCTTGTGCAGGAAGTTGACCTGAAACTGAAATAC\nGTAATGCAGCCAGATGGAATAGCAGTGGACTGGGTTGGAAGGCATATTTACTGGTCAGAT\nGTCAAGAATAAACGCATTGAGGTGGCTAAACTTGATGGAAGGTACAGAAAGTGGCTGATT\nTCCACTGACCTGGACCAACCAGCTGCTATTGCTGTGAATCCCAAACTAGGGCTTATGTTC\nTGGACTGACTGGGGAAAGGAACCTAAAATCGAGTCTGCCTGGATGAATGGAGAGGACCGC\nAACATCCTGGTTTTCGAGGACCTTGGTTGGCCAACTGGCCTTTCTATCGATTATTTGAAC\nAATGACCGAATCTACTGGAGTGACTTCAAGGAGGACGTTATTGAAACCATAAAATATGAT\nGGGACTGATAGGAGAGTCATTGCAAAGGAAGCAATGAACCCTTACAGCCTGGACATCTTT\nGAAGACCAGTTATACTGGATATCTAAGGAAAAGGGAGAAGTATGGAAACAAAATAAATTT\nGGGCAAGGAAAGAAAGAGAAAACGCTGGTAGTGAACCCTTGGCTCACTCAAGTTCGAATC\nTTTCATCAACTCAGATACAATAAGTCAGTGCCCAACCTTTGCAAACAGATCTGCAGCCAC\nCTCTGCCTTCTGAGACCTGGAGGATACAGCTGTGCCTGTCCCCAAGGCTCCAGCTTTATA\nGAGGGGAGCACCACTGAGTGTGATGCAGCCATCGAACTGCCTATCAACCTGCCCCCCCCA\nTGCAGGTGCATGCACGGAGGAAATTGCTATTTTGATGAGACTGACCTCCCCAAATGCAAG\nTGTCCTAGCGGCTACACCGGAAAATATTGTGAAATGGCGTTTTCAAAAGGCATCTCTCCA\nGGAACAACCGCAGTAGCTGTGCTGTTGACAATCCTCTTGATCGTCGTAATTGGAGCTCTG\nGCAATTGCAGGATTCTTCCACTATAGAAGGACCGGCTCCCTTTTGCCTGCTCTGCCCAAG\nCTGCCAAGCTTAAGCAGTCTCGTCAAGCCCTCTGAAAATGGGAATGGGGTGACCTTCAGA\nTCAGGGGCAGATCTTAACATGGATATTGGAGTGTCTGGTTTTGGACCTGAGACTGCTATT\nGACAGGTCAATGGCAATGAGTGAAGACTTTGTCATGGAAATGGGGAAGCAGCCCATAATA\nTTTGAAAACCCAATGTACTCAGCCAGAGACAGTGCTGTCAAAGTGGTTCAGCCAATCCAG\nGTGACTGTATCTGAAAATGTGGATAATAAGAATTATGGAAGTCCCATAAACCCTTCTGAG\nATAGTTCCAGAGACAAACCCAACTTCACCAGCTGCTGATGGAACTCAGGTGACAAAATGG\nAATCTCTTCAAACGAAAATCTAAACAAACTACCAACTTTGAAAATCCAATCTATGCACAG\nATGGAGAACGAGCAAAAGGAAAGTGTTGCTGCGACACCACCTCCATCACCTTCGCTCCCT\nGCTAAGCCTAAGCCTCCTTCGAGAAGAGACCCAACTCCAACCTATTCTGCAACAGAAGAC\nACTTTTAAAGACACCGCAAATCTTGTTAAAGAAGACTCTGAAGTATAG"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF07645", "name": "EGF_CA"}, {"identifier": "PF00057", "name": "Ldl_recept_a"}, {"identifier": "PF00058", "name": "Ldl_recept_b"}, {"identifier": "PF07974", "name": "EGF_2"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}]}}}, {"@position": "9", "id": "BE0001656", "name": "Suppressor of tumorigenicity 14 protein", "organism": "Human", "actions": null, "references": "# Suzuki M, Kobayashi H, Kanayama N, Saga Y, Suzuki M, Lin CY, Dickson RB, Terao T: Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase. J Biol Chem. 2004 Apr 9;279(15):14899-908. Epub 2004 Jan 27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14747469\n# Kirchhofer D, Peek M, Li W, Stamos J, Eigenbrot C, Kadkhodayan S, Elliott JM, Corpuz RT, Lazarus RA, Moran P: Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1. J Biol Chem. 2003 Sep 19;278(38):36341-9. Epub 2003 Jun 18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12815039", "known-action": "unknown", "polypeptide": {"@id": "Q9Y5Y6", "@source": "Swiss-Prot", "name": "Suppressor of tumorigenicity 14 protein", "general-function": "Involved in protease activity", "specific-function": "Degrades extracellular matrix. Proposed to play a role in breast cancer invasion and metastasis. Exhibits trypsin-like activity as defined by cleavage of synthetic substrates with Arg or Lys as the P1 site", "gene-name": "ST14", "locus": "11q24-q25", "cellular-location": "Membrane; single-pass type II membrane protein (Probable)", "transmembrane-regions": "56-76", "signal-regions": null, "theoretical-pi": "6.53", "molecular-weight": "94770.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:11344"}, {"resource": "GenAtlas", "identifier": "ST14"}, {"resource": "GeneCards", "identifier": "ST14"}, {"resource": "GenBank Gene Database", "identifier": "AF118224"}, {"resource": "GenBank Protein Database", "identifier": "6647302"}, {"resource": "UniProtKB", "identifier": "Q9Y5Y6"}, {"resource": "UniProt Accession", "identifier": "ST14_HUMAN"}]}, "synonyms": {"synonym": ["EC 3.4.21.109", "Matriptase", "Membrane-type serine protease 1", "MT-SP1", "Prostamin", "Serine protease 14", "Serine protease TADG-15", "Tumor-associated differentially-expressed gene 15 protein"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Suppressor of tumorigenicity protein 14\nMGSDRARKGGGGPKDFGAGLKYNSRHEKVNGLEEGVEFLPVNNVKKVEKHGPGRWVVLAA\nVLIGLLLVLLGIGFLVWHLQYRDVRVQKVFNGYMRITNENFVDAYENSNSTEFVSLASKV\nKDALKLLYSGVPFLGPYHKESAVTAFSEGSVIAYYWSEFSIPQHLVEEAERVMAEERVVM\nLPPRARSLKSFVVTSVVAFPTDSKTVQRTQDNSCSFGLHARGVELMRFTTPGFPDSPYPA\nHARCQWALRGDADSVLSLTFRSFDLASCDERGSDLVTVYNTLSPMEPHALVQLCGTYPPS\nYNLTFHSSQNVLLITLITNTERRHPGFEATFFQLPRMSSCGGRLRKAQGTFNSPYYPGHY\nPPNIDCTWNIEVPNNQHVKVRFKFFYLLEPGVPAGTCPKDYVEINGEKYCGERSQFVVTS\nNSNKITVRFHSDQSYTDTGFLAEYLSYDSSDPCPGQFTCRTGRCIRKELRCDGWADCTDH\nSDELNCSCDAGHQFTCKNKFCKPLFWVCDSVNDCGDNSDEQGCSCPAQTFRCSNGKCLSK\nSQQCNGKDDCGDGSDEASCPKVNVVTCTKHTYRCLNGLCLSKGNPECDGKEDCSDGSDEK\nDCDCGLRSFTRQARVVGGTDADEGEWPWQVSLHALGQGHICGASLISPNWLVSAAHCYID\nDRGFRYSDPTQWTAFLGLHDQSQRSAPGVQERRLKRIISHPFFNDFTFDYDIALLELEKP\nAEYSSMVRPICLPDASHVFPAGKAIWVTGWGHTQYGGTGALILQKGEIRVINQTTCENLL\nPQQITPRMMCVGFLSGGVDSCQGDSGGPLSSVEADGRIFQAGVVSWGDGCAQRNKPGVYT\nRLPLFRDWIKENTGV"}, "gene-sequence": {"@format": "FASTA", "#text": ">2568 bp\nATGGGGAGCGATCGGGCCCGCAAGGGCGGAGGGGGCCCGAAGGACTTCGGCGCGGGACTC\nAAGTACAACTCCCGGCACGAGAAAGTGAATGGCTTGGAGGAAGGCGTGGAGTTCCTGCCA\nGTCAACAACGTCAAGAAGGTGGAAAAGCATGGCCCGGGGCGCTGGGTGGTGCTGGCAGCC\nGTGCTGATCGGCCTCCTCTTGGTCTTGCTGGGGATCGGCTTCCTGGTGTGGCATTTGCAG\nTACCGGGACGTGCGTGTCCAGAAGGTCTTCAATGGCTACATGAGGATCACAAATGAGAAT\nTTTGTGGATGCCTACGAGAACTCCAACTCCACTGAGTTTGTAAGCCTGGCCAGCAAGGTG\nAAGGACGCGCTGAAGCTGCTGTACAGCGGAGTCCCATTCCTGGGCCCCTACCACAAGGAG\nTCGGCTGTGACGGCCTTCAGCGAGGGCAGCGTCATCGCCTACTACTGGTCTGAGTTCAGC\nATCCCGCAGCACCTGGTGGAGGAGGCCGAGCGCGTCATGGCCGAGGAGCGCGTAGTCATG\nCTGCCCCCGCGGGCGCGCTCCCTGAAGTCCTTTGTGGTCACCTCAGTGGTGGCTTTCCCC\nACGGACTCCAAAACAGTACAGAGGACCCAGGACAACAGCTGCAGCTTTGGCCTGCACGCC\nCGCGGTGTGGAGCTGATGCGCTTCACCACGCCCGGCTTCCCTGACAGCCCCTACCCCGCT\nCATGCCCGCTGCCAGTGGGCCCTGCGGGGGGACGCCGACTCAGTGCTGAGCCTCACCTTC\nCGCAGCTTTGACCTTGCGTCCTGCGACGAGCGCGGCAGCGACCTGGTGACGGTGTACAAC\nACCCTGAGCCCCATGGAGCCCCACGCCCTGGTGCAGTTGTGTGGCACCTACCCTCCCTCC\nTACAACCTGACCTTCCACTCCTCCCAGAACGTCCTGCTCATCACACTGATAACCAACACT\nGAGCGGCGGCATCCCGGCTTTGAGGCCACCTTCTTCCAGCTGCCTAGGATGAGCAGCTGT\nGGAGGCCGCTTACGTAAAGCCCAGGGGACATTCAACAGCCCCTACTACCCAGGCCACTAC\nCCACCCAACATTGACTGCACATGGAACATTGAGGTGCCCAACAACCAGCATGTGAAGGTG\nCGCTTCAAATTCTTCTACCTGCTGGAGCCCGGCGTGCCTGCGGGCACCTGCCCCAAGGAC\nTACGTGGAGATCAATGGGGAGAAATACTGCGGAGAGAGGTCCCAGTTCGTCGTCACCAGC\nAACAGCAACAAGATCACAGTTCGCTTCCACTCAGATCAGTCCTACACCGACACCGGCTTC\nTTAGCTGAATACCTCTCCTACGACTCCAGTGACCCATGCCCGGGGCAGTTCACGTGCCGC\nACGGGGCGGTGTATCCGGAAGGAGCTGCGCTGTGATGGCTGGGCCGACTGCACCGACCAC\nAGCGATGAGCTCAACTGCAGTTGCGACGCCGGCCACCAGTTCACGTGCAAGAACAAGTTC\nTGCAAGCCCCTCTTCTGGGTCTGCGACAGTGTGAACGACTGCGGAGACAACAGCGACGAG\nCAGGGGTGCAGTTGTCCGGCCCAGACCTTCAGGTGTTCCAATGGGAAGTGCCTCTCGAAA\nAGCCAGCAGTGCAATGGGAAGGACGACTGTGGGGACGGGTCCGACGAGGCCTCCTGCCCC\nAAGGTGAACGTCGTCACTTGTACCAAACACACCTACCGCTGCCTCAATGGGCTCTGCTTG\nAGCAAGGGCAACCCTGAGTGTGACGGGAAGGAGGACTGTAGCGACGGCTCAGATGAGAAG\nGACTGCGACTGTGGGCTGCGGTCATTCACGAGACAGGCTCGTGTTGTTGGGGGCACGGAT\nGCGGATGAGGGCGAGTGGCCCTGGCAGGTAAGCCTGCATGCTCTGGGCCAGGGCCACATC\nTGCGGTGCTTCCCTCATCTCTCCCAACTGGCTGGTCTCTGCCGCACACTGCTACATCGAT\nGACAGAGGATTCAGGTACTCAGACCCCACGCAGTGGACGGCCTTCCTGGGCTTGCACGAC\nCAGAGCCAGCGCAGCGCCCCTGGGGTGCAGGAGCGCAGGCTCAAGCGCATCATCTCCCAC\nCCCTTCTTCAATGACTTCACCTTCGACTATGACATCGCGCTGCTGGAGCTGGAGAAACCG\nGCAGAGTACAGCTCCATGGTGCGGCCCATCTGCCTGCCGGACGCCTCCCATGTCTTCCCT\nGCCGGCAAGGCCATCTGGGTCACGGGCTGGGGACACACCCAGTATGGAGGCACTGGCGCG\nCTGATCCTGCAAAAGGGTGAGATCCGCGTCATCAACCAGACCACCTGCGAGAACCTCCTG\nCCGCAGCAGATCACGCCGCGCATGATGTGCGTGGGCTTCCTCAGCGGCGGCGTGGACTCC\nTGCCAGGGTGATTCCGGGGGACCCCTGTCCAGCGTGGAGGCGGATGGGCGGATCTTCCAG\nGCCGGTGTGGTGAGCTGGGGAGACGGCTGCGCTCAGAGGAACAAGCCAGGCGTGTACACA\nAGGCTCCCTCTGTTTCGGGACTGGATCAAAGAGAACACTGGGGTATAG"}, "pfams": {"pfam": [{"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00057", "name": "Ldl_recept_a"}, {"identifier": "PF00431", "name": "CUB"}, {"identifier": "PF01390", "name": "SEA"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "peptidase activity"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}]}}}, {"@position": "10", "id": "BE0002113", "name": "Nidogen-1", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Stephens RW, Aumailley M, Timpl R, Reisberg T, Tapiovaara H, Myohanen H, Murphy-Ullrich J, Vaheri A: Urokinase binding to laminin-nidogen. Structural requirements and interactions with heparin. Eur J Biochem. 1992 Aug 1;207(3):937-42. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1499567", "known-action": "unknown", "polypeptide": {"@id": "P14543", "@source": "Swiss-Prot", "name": "Nidogen-1", "general-function": null, "specific-function": "Sulfated glycoprotein widely distributed in basement membranes and tightly associated with laminin. Also binds to collagen IV and perlecan. It probably has a role in cell- extracellular matrix interactions", "gene-name": "NID1", "locus": "1q43", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "4.96", "molecular-weight": "136454.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:7821"}, {"resource": "GenAtlas", "identifier": "NID1"}, {"resource": "GeneCards", "identifier": "NID1"}, {"resource": "GenBank Gene Database", "identifier": "M30269"}, {"resource": "GenBank Protein Database", "identifier": "189209"}, {"resource": "UniProtKB", "identifier": "P14543"}, {"resource": "UniProt Accession", "identifier": "NID1_HUMAN"}]}, "synonyms": {"synonym": ["Entactin", "Nidogen-1 precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Nidogen-1\nMLASSSRIRAAWTRALLLPLLLAGPVGCLSRQELFPFGPGQGDLELEDGDDFVSPALELS\nGALRFYDRSDIDAVYVTTNGIIATSEPPAKESHPGLFPPTFGAVAPFLADLDTTDGLGKV\nYYREDLSPSITQRAAECVHRGFPEISFQPSSAVVVTWESVAPYQGPSRDPDQKGKRNTFQ\nAVLASSDSSSYAIFLYPEDGLQFHTTFSKKENNQVPAVVAFSQGSVGFLWKSNGAYNIFA\nNDRESIENLAKSSNSGQQGVWVFEIGSPATTNGVVPADVILGTEDGAEYDDEDEDYDLAT\nTRLGLEDVGTTPFSYKALRRGGADTYSVPSVLSPRRAATERPLGPPTERTRSFQLAVETF\nHQQHPQVIDVDEVEETGVVFSYNTDSRQTCANNRHQCSVHAECRDYATGFCCSCVAGYTG\nNGRQCVAEGSPQRVNGKVKGRIFVGSSQVPIVFENTDLHSYVVMNHGRSYTAISTIPETV\nGYSLLPLAPVGGIIGWMFAVEQDGFKNGFSITGGEFTRQAEVTFVGHPGNLVIKQRFSGI\nDEHGHLTIDTELEGRVPQIPFGSSVHIEPYTELYHYSTSVITSSSTREYTVTEPERDGAS\nPSRIYTYQWRQTITFQECVHDDSRPALPSTQQLSVDSVFVLYNQEEKILRYAFSNSIGPV\nREGSPDALQNPCYIGTHGCDTNAACRPGPRTQFTCECSIGFRGDGRTCYDIDECSEQPSV\nCGSHTICNNHPGTFRCECVEGYQFSDEGTCVAVVDQRPINYCETGLHNCDIPQRAQCIYT\nGGSSYTCSCLPGFSGDGQACQDVDECQPSRCHPDAFCYNTPGSFTCQCKPGYQGDGFRCV\nPGEVEKTRCQHEREHILGAAGATDPQRPIPPGLFVPECDAHGHYAPTQCHGSTGYCWCVD\nRDGREVEGTRTRPGMTPPCLSTVAPPIHQGPAVPTAVIPLPPGTHLLFAQTGKIERLPLE\nGNTMRKTEAKAFLHVPAKVIIGLAFDCVDKMVYWTDITEPSIGRASLHGGEPTTIIRQDL\nGSPEGIAVDHLGRNIFWTDSNLDRIEVAKLDGTQRRVLFETDLVNPRGIVTDSVRGNLYW\nTDWNRDNPKIETSYMDGTNRRILVQDDLGLPNGLTFDAFSSQLCWVDAGTNRAECLNPSQ\nPSRRKALEGLQYPFAVTSYGKNLYFTDWKMNSVVALDLAISKETDAFQPHKQTRLYGITT\nALSQCPQGHNYCSVNNGGCTHLCLATPGSRTCRCPDNTLGVDCIERK"}, "gene-sequence": {"@format": "FASTA", "#text": ">3744 bp\nATGTTGGCCTCGAGCAGCCGGATCCGGGCTGCGTGGACGCGGGCGCTGCTGCTGCCGCTG\nCTGCTGGCGGGGCCTGTGGGCTGCCTGAGCCGCCAGGAGCTCTTTCCCTTCGGCCCCGGA\nCAGGGGGACCTGGAGCTGGAGGACGGGGATGACTTCGTCTCTCCTGCCCTGGAGCTGAGT\nGGGGCGCTCCGCTTCTACGACAGATCCGACATCGACGCAGTCTACGTCACCACAAATGGC\nATCATTGCTACGAGTGAACCCCCGGCCAAAGAATCCCATCCCGGGCTCTTCCCACCAACA\nTTCGGTGCAGTCGCCCCTTTCCTGGCGGACTTGGACACGACCGATGGCCTGGGGAAGGTT\nTATTATCGAGAAGACTTATCCCCCTCCATCACTCAGCGAGCAGCAGAGTGTGTCCACAGA\nGGGTTCCCGGAGATCTCTTTCCAGCCTAGTAGCGCGGTGGTTGTCACTTGGGAATCCGTG\nGCCCCCTACCAAGGGCCCAGCAGGGACCCAGACCAGAAAGGCAAGAGAAACACGTTCCAG\nGCTGTTCTAGCCTCCTCTGATTCCAGCTCCTATGCCATTTTCCTTTATCCTGAGGATGGT\nCTGCAGTTCCATACGACATTCTCAAAGAAGGAAAACAACCAAGTTCCTGCCGTGGTTGCA\nTTCAGTCAAGGTTCAGTGGGATTCTTATGGAAGAGCAACGGAGCTTATAACATATTTGCT\nAATGACAGGGAATCAATTGAAAATTTGGCCAAGAGTAGTAACTCTGGGCAGCAGGGTGTC\nTGGGTGTTTGAGATTGGGAGTCCAGCCACCACCAATGGCGTGGTGCCTGCAGACGTGATC\nCTCGGAACTGAAGATGGGGCAGAGTATGATGATGAGGATGAAGATTATGACCTGGCGACC\nACTCGTCTGGGCCTGGAGGATGTGGGCACCACGCCCTTCTCCTACAAGGCTCTGAGAAGG\nGGAGGTGCTGACACATACAGTGTGCCCAGCGTCCTCTCCCCGCGCCGGGCAGCTACCGAA\nAGGCCCCTTGGACCTCCCACAGAGAGAACCAGGTCTTTCCAGTTGGCAGTGGAGACTTTT\nCACCAGCAGCACCCTCAGGTCATAGATGTGGATGAAGTTGAGGAAACAGGAGTTGTTTTC\nAGCTATAACACGGATTCCCGCCAGACGTGTGCTAACAACAGACACCAGTGCTCGGTGCAC\nGCAGAGTGCAGGGACTACGCCACGGGCTTCTGCTGCAGCTGTGTCGCTGGCTATACGGGC\nAATGGCAGGCAATGTGTTGCAGAAGGTTCCCCCCAGCGAGTCAATGGCAAGGTGAAAGGA\nAGGATCTTTGTGGGGAGCAGCCAGGTCCCCATTGTCTTTGAGAACACTGACCTCCACTCT\nTACGTAGTAATGAACCACGGGCGCTCCTACACAGCCATCAGCACCATTCCCGAGACCGTT\nGGATATTCTCTGCTTCCACTGGCCCCAGTTGGAGGCATCATTGGATGGATGTTTGCAGTG\nGAGCAGGACGGATTCAAGAATGGGTTCAGCATCACCGGGGGTGAGTTCACTCGCCAGGCT\nGAGGTGACCTTCGTGGGGCACCCGGGCAATCTGGTCATTAAGCAGCGGTTCAGCGGCATC\nGATGAGCATGGGCACCTGACCATCGACACGGAGCTGGAGGGCCGCGTGCCGCAGATTCCG\nTTCGGCTCCTCCGTGCACATTGAGCCCTACACGGAGCTGTACCACTACTCCACCTCAGTG\nATCACTTCCTCCTCCACCCGGGAGTACACGGTGACTGAGCCCGAGCGAGATGGGGCATCT\nCCTTCACGCATCTACACTTACCAGTGGCGCCAGACCATCACCTTCCAGGAATGCGTCCAC\nGATGACTCCCGGCCAGCCCTGCCCAGCACCCAGCAGCTCTCGGTGGACAGCGTGTTCGTC\nCTGTACAACCAGGAGGAGAAGATCTTGCGCTACGCTTTCAGCAACTCCATTGGGCCTGTG\nAGGGAAGGCTCCCCTGATGCTCTTCAGAATCCCTGCTACATCGGCACTCATGGGTGTGAC\nACCAACGCGGCCTGTCGCCCTGGTCCCAGGACACAGTTCACCTGCGAGTGCTCCATCGGC\nTTCCGAGGAGACGGGCGAACCTGCTATGATATTGATGAATGTTCAGAACAACCCTCAGTG\nTGTGGGAGCCACACAATCTGCAATAATCACCCAGGAACCTTCCGCTGCGAGTGTGTGGAG\nGGCTACCAGTTTTCAGATGAGGGAACGTGTGTGGCTGTCGTGGACCAGCGCCCCATCAAC\nTACTGTGAAACTGGCCTTCATAACTGCGACATACCCCAGCGGGCCCAGTGTATCTACACA\nGGAGGCTCCTCCTACACCTGTTCCTGCTTGCCAGGCTTTTCTGGGGATGGCCAAGCCTGC\nCAAGATGTAGATGAATGCCAGCCAAGCCGATGTCACCCTGACGCCTTCTGCTACAACACT\nCCAGGCTCTTTCACGTGCCAGTGCAAACCTGGTTATCAGGGAGACGGCTTCCGTTGCGTG\nCCCGGAGAGGTGGAGAAAACCCGGTGCCAGCACGAGCGAGAACACATTCTCGGGGCAGCG\nGGGGCGACAGACCCACAGCGACCCATTCCTCCGGGGCTGTTCGTTCCTGAGTGCGATGCG\nCACGGGCACTACGCGCCCACCCAGTGCCACGGCAGCACCGGCTACTGCTGGTGCGTGGAT\nCGCGACGGCCGCGAGGTGGAGGGCACCAGGACCAGGCCCGGGATGACGCCCCCGTGTCTG\nAGTACAGTGGCTCCCCCGATTCACCAAGGACCTGCGGTGCCTACCGCCGTGATCCCCTTG\nCCTCCTGGGACCCATTTACTCTTTGCCCAGACTGGGAAGATTGAGCGCCTGCCCCTGGAG\nGGAAATACCATGAGGAAGACAGAAGCAAAGGCGTTCCTTCATGTCCCGGCTAAAGTCATC\nATTGGACTGGCCTTTGACTGCGTGGACAAGATGGTTTACTGGACGGACATCACTGAGCCT\nTCCATTGGGAGAGCTAGTCTACATGGTGGAGAGCCAACCACCATCATTAGACAAGATCTT\nGGAAGTCCAGAAGGTATCGCTGTTGATCACCTTGGCCGCAACATCTTCTGGACAGACTCT\nAACCTGGATCGAATAGAAGTGGCGAAGCTGGACGGCACGCAGCGCCGGGTGCTCTTTGAG\nACTGACCTGGTGAATCCCAGAGGCATTGTAACGGATTCCGTGAGAGGGAACCTTTACTGG\nACAGACTGGAACAGAGATAACCCCAAGATTGAAACTTCCTACATGGACGGCACGAACCGG\nAGGATCCTTGTGCAGGATGACCTGGGCTTGCCCAATGGACTGCACTTCGATGCGTTCTCA\nTCTCAGCTCTGCTGGGTGGATGCAGGCACCAATCGGGCGGAATGCCTGAACCCCAGTCAG\nCCCAGCAGACGCAAGGCTCTCGAAGGGCTCCAGTATCCTTTTGCTGTGACGAGCTACGGG\nAAGAATCTGTATTTCACAGACTGGAAGATGAATTCCGTGGTTGCTCTCGATCTTGCAATT\nTCCAAGGAGACGGATGCTTTCCAACCCCACAAGCAGACCCGGCTGTATGGCATCACCACG\nGCCCTGTCTCAGTGTCCGCAAGGCCATAACTACTGCTCAGTGAACAATGGCGGCTGCACC\nCACCTATGCTTGGCCACCCCAGGGAGCAGGACCTGCCGTTGCCCTGACAACACCTTGGGA\nGTTGACTGTATCGAACGGAAATGA"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF07645", "name": "EGF_CA"}, {"identifier": "PF00058", "name": "Ldl_recept_b"}, {"identifier": "PF00086", "name": "Thyroglobulin_1"}, {"identifier": "PF06119", "name": "NIDO"}, {"identifier": "PF07474", "name": "G2F"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "cell adhesion"}, {"category": "process", "description": "cell-substrate adhesion"}, {"category": "process", "description": "cell-matrix adhesion"}, {"category": "process", "description": "cellular process"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2005-06-13", "@updated": "2013-09-16", "drugbank-id": [{"@primary": "true", "#text": "DB00014"}, "BIOD00113", "BTD00113"], "name": "Goserelin", "description": "Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.", "cas-number": "65807-02-5", "groups": {"group": "approved"}, "general-references": null, "synthesis-reference": "Kripa S. Srivastava, Matthew R. Davis, \"Solid Phase Peptide for the Production of Goserelin.\" U.S. Patent US20100311946, issued December 09, 2010.", "indication": "Used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty.", "pharmacodynamics": "The pharmacokinetics of goserelin have been determined in both male and female healthy volunteers and patients. In these studies, goserelin was administered as a single 250\u00b5g (aqueous solution) dose and as a single or multiple 3.6 mg depot dose by subcutaneous route.", "mechanism-of-action": "Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.", "toxicity": "No experience of overdosage from clinical trials.", "metabolism": "Hepatic", "absorption": "Inactive orally, rapidly absorbed following subcutaneous administration.", "half-life": "4-5 hours", "protein-binding": "27.3%", "route-of-elimination": "Clearance of goserelin following subcutaneous administration of a radiolabeled solution of goserelin was very rapid and occurred via a combination of hepatic and urinary excretion. More than 90% of a subcutaneous radiolabeled solution formulation dose of goserelin was excreted in urine.", "volume-of-distribution": "* 44.1 \u00b1 13.6 L [subcutaneous administration of 250 mcg]", "clearance": "* 121 +/- 42.4 mL/min [prostate cancer with 10.8 mg depot]", "classification": {"description": "This compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.", "direct-parent": "Peptides", "kingdom": "Organic compounds", "superclass": "Organic acids and derivatives", "class": "Carboxylic acids and derivatives", "subclass": "Amino acids, peptides, and analogues", "alternative-parent": ["Alpha amino acid amides", "Amphetamines and derivatives", "Azacyclic compounds", "Carbonyl compounds", "Carboximidamides", "Carboxylic acid hydrazides", "Dialkyl ethers", "Guanidines", "Heteroaromatic compounds", "Hydrazinecarboxamides", "Hydrocarbon derivatives", "Imidazoles", "Indoles", "Lactams", "N-acyl amines", "N-acyl-alpha amino acids and derivatives", "N-acylpyrrolidines", "Phenols and derivatives", "Phenylpropylamines", "Primary alcohols", "Propargyl-type 1,3-dipolar organic compounds", "Pyrrolidine-2-ones", "Pyrrolidinecarboxamides", "Secondary carboxylic acid amides", "Semicarbazides", "Substituted pyrroles", "Tertiary amines", "Tertiary carboxylic acid amides", "Tryptamines and derivatives"], "substituent": ["2-pyrrolidone", "Alcohol", "Alpha peptide", "Alpha-amino acid amide", "Amine", "Amphetamine or derivatives", "Aromatic heteropolycyclic compound", "Azacycle", "Azole", "Benzenoid", "Carbonyl group", "Carboxamide group", "Carboximidamide", "Carboxylic acid amide", "Carboxylic acid hydrazide", "Dialkyl ether", "Ether", "Fatty acyl", "Fatty amide", "Guanidine", "Heteroaromatic compound", "Hydrazinecarboxamide", "Hydrocarbon derivative", "Imidazole", "Indole", "Indole or derivatives", "Lactam", "Monocyclic benzene moiety", "N-acyl-alpha amino acid or derivatives", "N-acyl-amine", "N-acylpyrrolidine", "N-substituted-alpha-amino acid", "Organic 1,3-dipolar compound", "Organoheterocyclic compound", "Organonitrogen compound", "Organooxygen compound", "Phenol", "Phenylpropylamine", "Primary alcohol", "Propargyl-type 1,3-dipolar organic compound", "Pyrrole", "Pyrrolidine", "Pyrrolidine carboxylic acid or derivatives", "Pyrrolidine-2-carboxamide", "Pyrrolidone", "Secondary carboxylic acid amide", "Semicarbazide", "Substituted pyrrole", "Tertiary amine", "Tertiary carboxylic acid amide", "Triptan"]}, "salts": {"salt": {"drugbank-id": {"@primary": "true", "#text": "DBSALT000093"}, "name": "Goserelin acetate", "cas-number": null, "inchikey": "InChIKey=IKDXDQDKCZPQSZ-JHYYTBFNSA-N"}}, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Goserelin"}, {"@language": "", "@coder": "", "#text": "Goserelin acetate"}, {"@language": "", "@coder": "", "#text": "ICI-118630"}, {"@language": "", "@coder": "", "#text": "Zoladex"}]}, "products": {"product": [{"name": "Zoladex", "ndc-id": "0310-0950_51881b14-e43f-46f0-af20-93413460c37f", "ndc-product-code": "0310-0950", "dpd-id": null, "started-marketing-on": "2003-05-05", "ended-marketing-on": null, "dosage-form": "implant", "strength": "3.6 mg", "route": "subcutaneous", "fda-application-number": "NDA019726", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Zoladex", "ndc-id": "0310-0951_ed24c6da-3f20-4330-b813-cdc1d5d1df16", "ndc-product-code": "0310-0951", "dpd-id": null, "started-marketing-on": "2003-05-05", "ended-marketing-on": null, "dosage-form": "implant", "strength": "10.8 mg", "route": "subcutaneous", "fda-application-number": "NDA020578", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Zoladex Inj Depot 3.6mg", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02049325", "started-marketing-on": "1994-12-31", "ended-marketing-on": null, "dosage-form": "implant", "strength": "3.6 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Zoladex La Inj Depot 10.8mg", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02225905", "started-marketing-on": "1996-08-28", "ended-marketing-on": null, "dosage-form": "implant", "strength": "10.8 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Zoladex", "ingredients": "Goserelin"}, {"name": "Zoladex", "ingredients": "Goserelin"}, {"name": "Zoladex Inj Depot 3.6mg", "ingredients": "Goserelin"}, {"name": "Zoladex La Inj Depot 10.8mg", "ingredients": "Goserelin"}]}, "packagers": {"packager": {"name": "AstraZeneca Inc.", "url": "http://www.astrazeneca.ca"}}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Astrazeneca uk ltd"}}, "prices": {"price": [{"description": "Zoladex 3.6 mg implant syringe", "cost": {"@currency": "USD", "#text": "451.19"}, "unit": "syringe"}, {"description": "Zoladex 10.8 mg implant syringe", "cost": {"@currency": "USD", "#text": "1380.65"}, "unit": "syringe"}]}, "categories": null, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Implant", "route": "subcutaneous", "strength": "10.8 mg"}, {"form": "Implant", "route": "subcutaneous", "strength": "3.6 mg"}]}, "atc-codes": {"atc-code": {"@code": "L02AE03", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L02", "#text": "ENDOCRINE THERAPY"}, {"@code": "L02A", "#text": "HORMONES AND RELATED AGENTS"}, {"@code": "L02AE", "#text": "Gonadotropin releasing hormone analogues"}]}}, "ahfs-codes": {"ahfs-code": ["68:18.00", "92:00.00"]}, "patents": {"patent": [{"number": "7118552", "country": "United States", "approved": "2002-04-13", "expires": "2022-04-13"}, {"number": "7500964", "country": "United States", "approved": "2001-02-26", "expires": "2021-02-26"}]}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00414", "name": "Acetohexamide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06203", "name": "Alogliptin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB08907", "name": "Canagliflozin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00672", "name": "Chlorpropamide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB09066", "name": "Corifollitropin Alfa", "description": "Luteinizing Hormone-Releasing Hormone Analogs may enhance the therapeutic effect of Corifollitropin Alfa."}, {"drugbank-id": "DB01120", "name": "Gliclazide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00222", "name": "Glimepiride", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01251", "name": "Gliquidone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01016", "name": "Glyburide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01306", "name": "Insulin Aspart", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01307", "name": "Insulin Detemir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00047", "name": "Insulin Glargine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01309", "name": "Insulin Glulisine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00046", "name": "Insulin Lispro", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00030", "name": "Insulin Regular", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB08914", "name": "Insulin, isophane", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB09083", "name": "Ivabradine", "description": "May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents."}, {"drugbank-id": "DB08882", "name": "Linagliptin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00331", "name": "Metformin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00834", "name": "Mifepristone", "description": "May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents."}, {"drugbank-id": "DB00912", "name": "Repaglinide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06335", "name": "Saxagliptin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01124", "name": "Tolbutamide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB04876", "name": "Vildagliptin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}]}, "calculated-properties": {"property": [{"kind": "logP", "value": "0.3", "source": "ALOGPS"}, {"kind": "logS", "value": "-4.7", "source": "ALOGPS"}, {"kind": "Water Solubility", "value": "2.83e-02 g/l", "source": "ALOGPS"}, {"kind": "logP", "value": "-5.2", "source": "ChemAxon"}, {"kind": "IUPAC Name", "value": "(2S)-1-[(2S)-2-[(2S)-2-[(2R)-3-(tert-butoxy)-2-[(2S)-2-[(2S)-3-hydroxy-2-[(2S)-2-[(2S)-3-(1H-imidazol-5-yl)-2-{[(2S)-5-oxopyrrolidin-2-yl]formamido}propanamido]-3-(1H-indol-3-yl)propanamido]propanamido]-3-(4-hydroxyphenyl)propanamido]propanamido]-4-methylpentanamido]-5-[(diaminomethylidene)amino]pentanoyl]-N-(carbamoylamino)pyrrolidine-2-carboxamide", "source": "ChemAxon"}, {"kind": "Traditional IUPAC Name", "value": "(2S)-1-[(2S)-2-[(2S)-2-[(2R)-3-(tert-butoxy)-2-[(2S)-2-[(2S)-3-hydroxy-2-[(2S)-2-[(2S)-3-(3H-imidazol-4-yl)-2-{[(2S)-5-oxopyrrolidin-2-yl]formamido}propanamido]-3-(1H-indol-3-yl)propanamido]propanamido]-3-(4-hydroxyphenyl)propanamido]propanamido]-4-methylpentanamido]-5-[(diaminomethylidene)amino]pentanoyl]-N-(carbamoylamino)pyrrolidine-2-carboxamide", "source": "ChemAxon"}, {"kind": "Molecular Weight", "value": "1269.4105", "source": "ChemAxon"}, {"kind": "Monoisotopic Weight", "value": "1268.641439486", "source": "ChemAxon"}, {"kind": "SMILES", "value": "CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O", "source": "ChemAxon"}, {"kind": "Molecular Formula", "value": "C59H84N18O14", "source": "ChemAxon"}, {"kind": "InChI", "value": "InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1", "source": "ChemAxon"}, {"kind": "InChIKey", "value": "InChIKey=BLCLNMBMMGCOAS-URPVMXJPSA-N", "source": "ChemAxon"}, {"kind": "Polar Surface Area (PSA)", "value": "495.89", "source": "ChemAxon"}, {"kind": "Refractivity", "value": "325.84", "source": "ChemAxon"}, {"kind": "Polarizability", "value": "131.22", "source": "ChemAxon"}, {"kind": "Rotatable Bond Count", "value": "33", "source": "ChemAxon"}, {"kind": "H Bond Acceptor Count", "value": "18", "source": "ChemAxon"}, {"kind": "H Bond Donor Count", "value": "17", "source": "ChemAxon"}, {"kind": "pKa (strongest acidic)", "value": "9.27", "source": "ChemAxon"}, {"kind": "pKa (strongest basic)", "value": "10.82", "source": "ChemAxon"}, {"kind": "Physiological Charge", "value": "2", "source": "ChemAxon"}, {"kind": "Number of Rings", "value": "6", "source": "ChemAxon"}, {"kind": "Bioavailability", "value": "0", "source": "ChemAxon"}, {"kind": "Rule of Five", "value": "0", "source": "ChemAxon"}, {"kind": "Ghose Filter", "value": "0", "source": "ChemAxon"}, {"kind": "MDDR-Like Rule", "value": "1", "source": "ChemAxon"}]}, "experimental-properties": {"property": [{"kind": "Water Solubility", "value": "Soluble", "source": null}, {"kind": "logP", "value": "-2", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "11167"}, {"resource": "KEGG Drug", "identifier": "D00573"}, {"resource": "National Drug Code Directory", "identifier": "0310-0951-30"}, {"resource": "PharmGKB", "identifier": "PA164747674"}, {"resource": "Wikipedia", "identifier": "Goserelin"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/goserel.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/goserelin.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000134", "name": "Lutropin-choriogonadotropic hormone receptor", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Kirby RS, Fitzpatrick JM, Clarke N: Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int. 2009 Dec;104(11):1580-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20053189", "known-action": "yes", "polypeptide": {"@id": "P22888", "@source": "Swiss-Prot", "name": "Lutropin-choriogonadotropic hormone receptor", "general-function": "Involved in rhodopsin-like receptor activity", "specific-function": "Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase", "gene-name": "LHCGR", "locus": "2p21", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "364-385\n396-416\n440-462\n483-505\n526-549\n571-594\n606-627", "signal-regions": null, "theoretical-pi": "8.58", "molecular-weight": "78617.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6585"}, {"resource": "GenAtlas", "identifier": "LHCGR"}, {"resource": "GeneCards", "identifier": "LHCGR"}, {"resource": "GenBank Gene Database", "identifier": "M73746"}, {"resource": "GenBank Protein Database", "identifier": "903746"}, {"resource": "IUPHAR", "identifier": "254"}, {"resource": "Guide to Pharmacology", "identifier": "30"}, {"resource": "UniProtKB", "identifier": "P22888"}, {"resource": "UniProt Accession", "identifier": "LSHR_HUMAN"}]}, "synonyms": {"synonym": ["LH/CG-R", "LHR", "LSH- R", "Luteinizing hormone receptor", "Lutropin-choriogonadotropic hormone receptor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Lutropin-choriogonadotropic hormone receptor precursor\nMKQRFSALQLLKLLLLLQPPLPRALREALCPEPCNCVPDGALRCPGPTAGLTRLSLAYLP\nVKVIPSQAFRGLNEVIKIEISQIDSLERIEANAFDNLLNLSEILIQNTKNLRYIEPGAFI\nNLPRLKYLSICNTGIRKFPDVTKVFSSESNFILEICDNLHITTIPGNAFQGMNNESVTLK\nLYGNGFEEVQSHAFNGTTLTSLELKENVHLEKMHNGAFRGATGPKTLDISSTKLQALPSY\nGLESIQRLIATSSYSLKKLPSRETFVNLLEATLTYPSHCCAFRNLPTKEQNFSHSISENF\nSKQCESTVRKVSNKTLYSSMLAESELSGWDYEYGFCLPKTPRCAPEPDAFNPCEDIMGYD\nFLRVLIWLINILAIMGNMTVLFVLLTSRYKLTVPRFLMCNLSFADFCMGLYLLLIASVDS\nQTKGQYYNHAIDWQTGSGCSTAGFFTVFASELSVYTLTVITLERWHTITYAIHLDQKLRL\nRHAILIMLGGWLFSSLIAMLPLVGVSNYMKVSICFPMDVETTLSQVYILTILILNVVAFF\nIICACYIKIYFAVRNPELMATNKDTKIAKKMAILIFTDFTCMAPISFFAISAAFKVPLIT\nVTNSKVLLVLFYPINSCANPFLYAIFTKTFQRDFFLLLSKFGCCKRRAELYRRKDFSAYT\nSNCKNGFTGSNKPSQSTLKLSTLHCQGTALLDKTRYTEC"}, "gene-sequence": {"@format": "FASTA", "#text": ">2058 bp\nATGAAGCAGCGGTTCTCGCCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGGCGCCG\nCTGCCACGAGCGCTGCGCAGGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGCGCC\nCTGCGTGCCCCGGCCCCACGGCCGTCCACTCGACTATCACTTGCCTACCTCCCTGTCAAA\nGTGATCCCATCTCAAAGTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATCTCTCAG\nATTGATTCCCTGGAAAGGATAGAAGCTAATGCCTTTGACAACCTCCTCAATTTGTCTGAA\nATACTGATCCAGAACACCAAAAATCTGAGATACATTGAGCCCGGAGCATTTATAAATCTT\nCCCCGATTAAAATACTTGAGCATCTGTAACACAGGCATCAGAAAGTTTCCAGATGTTACG\nAAGGTCTTCTCCTCTGAATCAAATTTCATTCTGGAAATTTGTGATAACTTACACATAACC\nACCATACCAGGAAATGCTTTTCAAGGGATGAATAATGAATCTGTAACACTCAAACTATAT\nGGAAATGGATTTGAAGAAGTACAAAGTCATGCATTCAATGGGACGACACTGACTTCACTG\nGAGCTAAAGGAAAACGTACATCTGGAGAAGATGCACAATGGAGCCTTCCGTGGGGCCACA\nGGGCCGAAAACCTTGGATATTTCTTCCACCAAATTGCAGGCCCTGCCGAGCTATGGCCTA\nGAGTCCATTCAGAGGCTAATTGCCACGTCATCCTATTCTCTAAAAAAATTGCCATCAAAA\nCAAACATTTGTCAATCTCCTGAGGGCCACGCTTCATTACCCCAGCCACTGCTGTGCATTT\nAGAAACTTGCCAACGAAAGAGCTAAACTTCTCACATTCCATTTCTGAAAACTTTTCCAAA\nCAATGTGAAAGCACAGTAAGGAAAAGTGAACTGAGTGGCTGGGACTATGAATATGGTTTC\nTGCTTACCCAAGACACCCCGATGTGCTCCTGAACCAGATGCTTTTAATCCCTGTGAAGAC\nATTATGGGCTATGACTTCCTTAGGGTCCTGATTTGGCTGATTAATATTCTAGCCATCATG\nGGAAACATGACTGTTCTTTTTGTTCTCCTGACAAGTCGTTACAAACTTACAGTGCCTCGT\nTTTCTCATGTGCAATCTCTCCTTTGCAGACTTTTGCATGGGGCTCTATCTGCTGCTCATA\nGCCTCAGTTGATTCCCAAACCAAGGGCCAGTACTATAACCATGCCATAGACTGGCAGACA\nGGGAGTGGGTGCAGCACTGCTGGCTTTTTCACTGTATTAGCAAGTGAACTTTCTGTCTAC\nACCCTCACCGTCATCACTCTAGAAAGATGGCACACCATCACCTATGCTATTCACCTGGAC\nCAAAAGCTGCGATTAAGACATGCCATTCTGATTATGCTTGGAGGCTGGCTCTTTTCTTCT\nCTAATTGCTATGTTGCCCCTTGTCGGGGTCAGCAATTACATGAAGGTCAGTATTTGCTTC\nCCCATGGATGTGGAAACCACTCTCTCACAAGTCTATATATTAACCATCCTGATTCTCAAT\nGTGGTGGCCTTCTTAATAATTTGTGCTTGCTACATTAAAATTTATTTTGCAGTTCGAAAC\nCCAGAATTAATGGCTACCAATAAAGATACAAAGATTGCTAAGAAAATGGCAATCCTCATC\nTTCACCGATTTTACCTGCATGGCACCTATCTCTTTTTTTGCCATCTCAGCTGCCTTCAAA\nGTACCTCTTATCACAGTAACCAACTCTAAAGTTTTACTGGTTCTTTTTTATCCCATCAAT\nTCTTGTGCCAATCCATTTCTGTATGCAATATTCACTAAGACATTCCAAAGAGATTTCTTT\nCTTTTGCTGAGCAAATTTGGCTGCTGTAAACGTCGGGCTGATCCTCTTTATAGAAGGAAA\nGATTTTTCAGCTTACACCTCCAACTGCAAAAATGGCTTCACTGGATCAAATAAGCCTTCT\nCAATCCACCTTGAAGTTGTCCACATTGCACTGTCAAGGTACAGCTCTCCTAGACAAGACT\nCGCTACACAGAGTGTTAA"}, "pfams": {"pfam": {"identifier": "PF00001", "name": "7tm_1"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "function", "description": "lutropin-choriogonadotropic hormone receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "protein-hormone receptor activity"}, {"category": "function", "description": "receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}]}}}, {"@position": "1", "id": "BE0000203", "name": "Gonadotropin-releasing hormone receptor", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Kirby RS, Fitzpatrick JM, Clarke N: Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int. 2009 Dec;104(11):1580-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20053189", "known-action": "yes", "polypeptide": {"@id": "P30968", "@source": "Swiss-Prot", "name": "Gonadotropin-releasing hormone receptor", "general-function": "Involved in rhodopsin-like receptor activity", "specific-function": "Receptor for gonadotropin releasing hormone (GnRH) that mediate the action of GnRH to stimulate the secretion of the gonadotropic hormones (LH and FSH). This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Isoform 2 may act a an inhibitor of GnRH-R signaling", "gene-name": "GNRHR", "locus": "4q21.2", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "39-58\n78-97\n116-137\n165-184\n213-232\n282-300\n307-326", "signal-regions": null, "theoretical-pi": "9.93", "molecular-weight": "37731.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:4421"}, {"resource": "GenAtlas", "identifier": "GNRHR"}, {"resource": "GeneCards", "identifier": "GNRHR"}, {"resource": "GenBank Gene Database", "identifier": "L03380"}, {"resource": "GenBank Protein Database", "identifier": "183422"}, {"resource": "IUPHAR", "identifier": "256"}, {"resource": "Guide to Pharmacology", "identifier": "31"}, {"resource": "UniProtKB", "identifier": "P30968"}, {"resource": "UniProt Accession", "identifier": "GNRHR_HUMAN"}]}, "synonyms": {"synonym": ["GnRH receptor", "GnRH-R"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Gonadotropin-releasing hormone receptor\nMANSASPEQNQNHCSAINNSIPLMQGNLPTLTLSGKIRVTVTFFLFLLSATFNASFLLKL\nQKWTQKKEKGKKLSRMKLLLKHLTLANLLETLIVMPLDGMWNITVQWYAGELLCKVLSYL\nKLFSMYAPAFMMVVISLDRSLAITRPLALKSNSKVGQSMVGLAWILSSVFAGPQLYIFRM\nIHLADSSGQTKVFSQCVTHCSFSQWWHQAFYNFFTFSCLFIIPLFIMLICNAKIIFTLTR\nVLHQDPHELQLNQSKNNIPRARLKTLKMTVAFATSFTVCWTPYYVLGIWYWFDPEMLNRL\nSDPVNHFFFLFAFLNPCFDPLIYGYFSL"}, "gene-sequence": {"@format": "FASTA", "#text": ">987 bp\nATGGCAAACAGTGCCTCTCCTGAACAGAATCAAAATCACTGTTCAGCCATCAACAACAGC\nATCCCACTGATGCAGGGCAACCTCCCCACTCTGACCTTGTCTGGAAAGATCCGAGTGACG\nGTTACTTTCTTCCTTTTTCTGCTCTCTGCGACCTTTAATGCTTCTTTCTTGTTGAAACTT\nCAGAAGTGGACACAGAAGAAAGAGAAAGGGAAAAAGCTCTCAAGAATGAAGCTGCTCTTA\nAAACATCTGACCTTAGCCAACCTGTTGGAGACTCTGATTGTCATGCCACTGGATGGGATG\nTGGAACATTACAGTCCAATGGTATGCTGGAGAGTTACTCTGCAAAGTTCTCAGTTATCTA\nAAGCTTTTCTCCATGTATGCCCCAGCCTTCATGATGGTGGTGATCAGCCTGGACCGCTCC\nCTGGCTATCACGAGGCCCCTAGCTTTGAAAAGCAACAGCAAAGTCGGACAGTCCATGGTT\nGGCCTGGCCTGGATCCTCAGTAGTGTCTTTGCAGGACCACAGTTATACATCTTCAGGATG\nATTCATCTAGCAGACAGCTCTGGACAGACAAAAGTTTTCTCTCAATGTGTAACACACTGC\nAGTTTTTCACAATGGTGGCATCAAGCATTTTATAACTTTTTCACCTTCAGCTGCCTCTTC\nATCATCCCTCTTTTCATCATGCTGATCTGCAATGCAAAAATCATCTTCACCCTGACACGG\nGTCCTTCATCAGGACCCCCACGAACTACAACTGAATCAGTCCAAGAACAATATACCAAGA\nGCACGGCTGAAGACTCTAAAAATGACGGTTGCATTTGCCACTTCATTTACTGTCTGCTGG\nACTCCCTACTATGTCCTAGGAATTTGGTATTGGTTTGATCCTGAAATGTTAAACAGGTTG\nTCAGACCCAGTAAATCACTTCTTCTTTCTCTTTGCCTTTTTAAACCCATGCTTTGATCCA\nCTTATCTATGGATATTTTTCTCTGTGA"}, "pfams": {"pfam": {"identifier": "PF00001", "name": "7tm_1"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "function", "description": "protein-hormone receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "gonadotropin-releasing hormone receptor activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2010-09-29", "drugbank-id": [{"@primary": "true", "#text": "DB00015"}, "BIOD00013", "BTD00013"], "name": "Reteplase", "description": "Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a \"third-generation\" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).", "cas-number": "133652-38-7", "groups": {"group": "approved"}, "general-references": null, "synthesis-reference": null, "indication": "For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction", "pharmacodynamics": "Reteplase cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.", "mechanism-of-action": "Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "t- PA"}, {"@language": "", "@coder": "", "#text": "t-plasminogen activator"}, {"@language": "", "@coder": "", "#text": "Tissue-type plasminogen activator precursor"}, {"@language": "", "@coder": "", "#text": "tPA"}]}, "products": {"product": {"name": "Retavase", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02233013", "started-marketing-on": "1999-02-19", "ended-marketing-on": "2013-08-29", "dosage-form": "powder for solution", "strength": "10.4 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}}, "international-brands": null, "mixtures": {"mixture": {"name": "Retavase", "ingredients": "Reteplase"}}, "packagers": {"packager": [{"name": "EKR Therapeutics Inc.", "url": "http://www.ekrtx.com"}, {"name": "Hospira Inc.", "url": "http://www.hospira.com"}, {"name": "PDL BioPharma Inc.", "url": "http://www.pdl.com"}]}, "manufacturers": null, "prices": {"price": {"description": "Retavase vial half-kit", "cost": {"@currency": "USD", "#text": "2605.93"}, "unit": "vial"}}, "categories": {"category": [{"category": "Fibrinolytic Agents", "mesh-id": null}, {"category": "Thrombolytic Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": {"form": "Powder for solution", "route": "intravenous", "strength": "10.4 unit"}}, "atc-codes": {"atc-code": {"@code": "B01AD07", "level": [{"@code": "B", "#text": "BLOOD AND BLOOD FORMING ORGANS"}, {"@code": "B01", "#text": "ANTITHROMBOTIC AGENTS"}, {"@code": "B01A", "#text": "ANTITHROMBOTIC AGENTS"}, {"@code": "B01AD", "#text": "Enzymes"}]}}, "ahfs-codes": null, "patents": {"patent": {"number": "2107476", "country": "Canada", "approved": "2007-12-18", "expires": "2012-04-15"}}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00054", "name": "Abciximab", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01418", "name": "Acenocoumarol", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00945", "name": "Acetylsalicylic acid", "description": "May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB00233", "name": "Aminosalicylic Acid", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB00261", "name": "Anagrelide", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06605", "name": "Apixaban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06692", "name": "Aprotinin", "description": "May diminish the therapeutic effect of Thrombolytic Agents."}, {"drugbank-id": "DB00278", "name": "Argatroban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01294", "name": "Bismuth Subsalicylate", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB00006", "name": "Bivalirudin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06441", "name": "Cangrelor", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01166", "name": "Cilostazol", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00215", "name": "Citalopram", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB04272", "name": "Citric Acid", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00758", "name": "Clopidogrel", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06695", "name": "Dabigatran etexilate", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Dabigatran etexilate."}, {"drugbank-id": "DB06779", "name": "Dalteparin", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06754", "name": "Danaparoid", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06700", "name": "Desvenlafaxine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00586", "name": "Diclofenac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00266", "name": "Dicoumarol", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00861", "name": "Diflunisal", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01551", "name": "Dihydrocodeine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00975", "name": "Dipyridamole", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00476", "name": "Duloxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00974", "name": "Edetic Acid", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB09075", "name": "Edoxaban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01225", "name": "Enoxaparin", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01240", "name": "Epoprostenol", "description": "May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents."}, {"drugbank-id": "DB00063", "name": "Eptifibatide", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01175", "name": "Escitalopram", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB08794", "name": "Ethyl biscoumacetate", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00749", "name": "Etodolac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00573", "name": "Fenoprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB08976", "name": "Floctafenine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00472", "name": "Fluoxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00712", "name": "Flurbiprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00176", "name": "Fluvoxamine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00569", "name": "Fondaparinux sodium", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01109", "name": "Heparin", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01050", "name": "Ibuprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01088", "name": "Iloprost", "description": "May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents."}, {"drugbank-id": "DB00328", "name": "Indomethacin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01009", "name": "Ketoprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00465", "name": "Ketorolac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB08918", "name": "Levomilnacipran", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01397", "name": "Magnesium salicylate", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB00784", "name": "Mefenamic acid", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00814", "name": "Meloxicam", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB04896", "name": "Milnacipran", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00461", "name": "Nabumetone", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB08813", "name": "Nadroparin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00788", "name": "Naproxen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00991", "name": "Oxaprozin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00715", "name": "Paroxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00498", "name": "Phenindione", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00946", "name": "Phenprocoumon", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00554", "name": "Piroxicam", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06209", "name": "Prasugrel", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06228", "name": "Rivaroxaban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01398", "name": "Salicylate-sodium", "description": "May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB01399", "name": "Salsalate", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB01104", "name": "Sertraline", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00605", "name": "Sulindac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06271", "name": "Sulodexide", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01600", "name": "Tiaprofenic acid", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB08816", "name": "Ticagrelor", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00208", "name": "Ticlopidine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06822", "name": "Tinzaparin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00775", "name": "Tirofiban", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00500", "name": "Tolmetin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00374", "name": "Treprostinil", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00285", "name": "Venlafaxine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06684", "name": "Vilazodone", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB09030", "name": "Vorapaxar", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB09068", "name": "Vortioxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00682", "name": "Warfarin", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00015 sequence\nSYQGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYC\nRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAA\nIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKF\nEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELS\nGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHD\nACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "60 \u00b0C", "source": "Novokhatny, V.V. et al., J. Biol. Chem. 266:12994-123002 (1991)"}, {"kind": "Hydrophobicity", "value": "-0.435", "source": null}, {"kind": "Isoelectric Point", "value": "6.86", "source": null}, {"kind": "Molecular Weight", "value": "39589.6000", "source": null}, {"kind": "Molecular Formula", "value": "C1736H2671N499O522S22", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "11534"}, {"resource": "National Drug Code Directory", "identifier": "24477-041-02"}, {"resource": "GenBank", "identifier": "L00153"}, {"resource": "PharmGKB", "identifier": "PA164743728"}, {"resource": "UniProtKB", "identifier": "P00750"}, {"resource": "Wikipedia", "identifier": "Reteplase"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic2/reteplase.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/reteplase.html"}]}, "pathways": {"pathway": {"smpdb-id": "SMP00285", "name": "Reteplase Action Pathway", "drugs": {"drug": [{"drugbank-id": "DB00015", "name": "Reteplase"}, {"drugbank-id": "DB01022", "name": "Phylloquinone"}, {"drugbank-id": "DB01373", "name": "Calcium"}]}, "enzymes": {"uniprot-id": ["P00747", "P00748", "P02452", "P03952", "P03951", "P00740", "P00451", "P00734", "P12259", "P00742", "P02671", "P02675", "P02679", "P00488", "P05160", "P00750", "P08709", "P13726", "Q9BQB6", "P38435"]}}}, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000211", "name": "Plasminogen", "organism": "Human", "actions": {"action": "activator"}, "references": "# Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17963464\n# Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18673235\n# Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19436656\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P00747", "@source": "Swiss-Prot", "name": "Plasminogen", "general-function": "Involved in plasmin activity", "specific-function": "Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo", "gene-name": "PLG", "locus": "6q26", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.25", "molecular-weight": "90569.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9071"}, {"resource": "GenAtlas", "identifier": "PLG"}, {"resource": "GeneCards", "identifier": "PLG"}, {"resource": "GenBank Gene Database", "identifier": "X05199"}, {"resource": "GenBank Protein Database", "identifier": "387026"}, {"resource": "UniProtKB", "identifier": "P00747"}, {"resource": "UniProt Accession", "identifier": "PLMN_HUMAN"}]}, "synonyms": {"synonym": ["EC 3.4.21.7", "Plasminogen precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Plasminogen precursor\nMEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT\nCRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN\nGITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE\nCEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE\nLRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS\nAQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE\nQLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG\nLTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED\nCMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG\nPWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT\nRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE\nPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ\nLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW\nGLGCARPNKPGVYVRVSRFVTWIEGVMRNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">2433 bp\nATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG\nCCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG\nCTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC\nTGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG\nAAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC\nTCAGAGTGCAAGACTGGGAATGGAAAGAATTACAGAGGGACGATGTCCAAAACAAAAAAT\nGGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT\nACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG\nGGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG\nTGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC\nATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT\nCCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG\nCTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGCGACATCCCC\nCGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT\nGAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT\nGCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTTCCCTGCAAAAATTTGGAT\nGAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC\nCAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA\nCAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT\nGATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT\nTGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC\nCTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA\nGACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT\nGTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAAATGTAGAGACTCCTTCCGAAGAAGAC\nTGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG\nCCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA\nAATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT\nCCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT\nGCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG\nGTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA\nAGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT\nGCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC\nCAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG\nCCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA\nGTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC\nATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG\nCTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA\nTCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT\nGGAGGGCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG\nGGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT\nACTTGGATTGAGGGAGTGATGAGAAATAATTAA"}, "pfams": {"pfam": [{"identifier": "PF00051", "name": "Kringle"}, {"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00024", "name": "PAN_1"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "plasmin activity"}, {"category": "function", "description": "binding"}, {"category": "process", "description": "hemostasis"}, {"category": "process", "description": "blood coagulation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "2", "id": "BE0000538", "name": "Fibrinogen alpha chain", "organism": "Human", "actions": null, "references": "# Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18673235\n# Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19436656\n# Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17963464", "known-action": "yes", "polypeptide": {"@id": "P02671", "@source": "Swiss-Prot", "name": "Fibrinogen alpha chain", "general-function": "Carbohydrate transport and metabolism", "specific-function": "Fibrinogen has a double function:yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation", "gene-name": "FGA", "locus": "4q28", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.87", "molecular-weight": "94974.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3661"}, {"resource": "GenAtlas", "identifier": "FGA"}, {"resource": "GeneCards", "identifier": "FGA"}, {"resource": "GenBank Gene Database", "identifier": "AF361104"}, {"resource": "GenBank Protein Database", "identifier": "13591824"}, {"resource": "UniProtKB", "identifier": "P02671"}, {"resource": "UniProt Accession", "identifier": "FIBA_HUMAN"}]}, "synonyms": {"synonym": "Fibrinogen alpha chain precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Fibrinogen alpha chain precursor [Contains: Fibrinopeptide A]\nMFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW\nNYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA\nNNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC\nRGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQ\nLQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSS\nGPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTW\nNPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV\nSPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTK\nEVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEF\nVSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKS\nYKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFS\nVYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQR\nGSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSH\nNNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENG\nVVWVSFRGADYSLRAVRMKIRPLVTQ"}, "gene-sequence": {"@format": "FASTA", "#text": ">2601 bp\nATGTTTTCCATGAGGATCGTCTGCCTAGTTCTAAGTGTGGTGGGCACAGCATGGACTGCA\nGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTG\nGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGG\nAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGAT\nTTTACAAACAGAATAAATAAGCTCAAAAATTCACTATTTGAATATCAGAAGAACAATAAG\nGATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCGATTTTTCCTCAGCC\nAATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTGAAGTC\nCTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAGAAAAATGTTAGA\nGCTCAGTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGT\nCGAGGGTCATGCAGTAGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAG\nCAGAAGCAACTTGAACAGGTCATTGCCAAAGACTTACTTCCCTCTAGAGATAGGCAACAC\nTTACCACTGATAAAAATGAAACCAGTTCCAGACTTGGTTCCCGGAAATTTTAAGAGCCAG\nCTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCGCAGATGAGAATGGAG\nTTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAACCGGA\nTCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCT\nGGACCTGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACC\nTGGAAACCTGGGAGCTCTGGACCTGGAAGTACTGGAAGCTGGAACTCTGGGAGCTCTGGA\nACTGGAAGTACTGGAAACCAAAACCCTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGG\nAATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCACTGGACCTCTGAGAGCTCTGTATCT\nGGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCAGATAGCCCAGGCTCT\nGGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAAATGTA\nAGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAA\nGAGCTCAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCA\nTGCTCTAAAACCGTTACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAA\nGAAGTGGTGACCTCCGAAGATGGTTCTGACTGTCCCGAGGCAATGGATTTAGGCACATTG\nTCTGGCATAGGTACTCTGGATGGGTTCCGCCATAGGCACCCTGATGAAGCTGCCTTCTTC\nGACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCTATGTTAGGAGAGTTT\nGTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGGAATCC\nAGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGC\nAAACAATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGC\nTATAAAATGGCAGATGAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAG\nAGAGGCCATGCTAAATCTCGCCCTGTCAGAGACTGTGATGATGTCCTCCAAACACATCCT\nTCAGGTACCCAAAGTGGCATTTTCAATATCAAGCTACCGGGATCCAGTAAGATTTTTTCT\nGTTTATTGCGATCAAGAGACCAGTTTGGGAGGATGGCTTTTGATCCAGCAAAGAATGGAT\nGGATCACTGAATTTTAACCGGACCTGGCAAGACTACAAGAGAGGTTTCGGCAGCCTGAAT\nGACGAGGGGGAAGGAGAATTCTGGCTAGGCAATGACTACCTCCACTTACTAACCCAAAGG\nGGCTCTGTTCTTAGGGTTGAATTAGAGGACTGGGCTGGGAATGAAGCTTATGCAGAATAT\nCACTTCCGGGTAGGCTCTGAGGCTGAAGGCTATGCCCTCCAAGTCTCCTCCTATGAAGGC\nACTGCGGGTGATGCTCTGATTGAGGGTTCCGTAGAGGAAGGGGCAGAGTACACCTCTCAC\nAACAACATGCAGTTCAGCACCTTTGACAGGGATGCAGACCAGTGGGAAGAGAACTGTGCA\nGAAGTCTATGGGGGAGGCTGGTGGTATAATAACTGCCAAGCAGCCAATCTCAATGGAATC\nTACTACCCTGGGGGCTCCTATGACCCAAGGAATAACAGTCCTTATGAGATTGAGAATGGA\nGTGGTCTGGGTTTCCTTTAGAGGGGCAGATTATTCCCTCAGGGCTGTTCGCATGAAAATT\nAGGCCCCTTGTGACCCAATAG"}, "pfams": {"pfam": {"identifier": "PF00147", "name": "Fibrinogen_C"}}, "go-classifiers": null}}, {"@position": "3", "id": "BE0000717", "name": "Urokinase plasminogen activator surface receptor", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "Q03405", "@source": "Swiss-Prot", "name": "Urokinase plasminogen activator surface receptor", "general-function": "Involved in U-plasminogen activator receptor activity", "specific-function": "Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form", "gene-name": "PLAUR", "locus": "19q13", "cellular-location": "Isoform 1:Cell membrane; lipid-anchor; GPI- anchor. Isoform 2:Secreted protein (Probable)", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.64", "molecular-weight": "36978.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9053"}, {"resource": "GenAtlas", "identifier": "PLAUR"}, {"resource": "GeneCards", "identifier": "PLAUR"}, {"resource": "GenBank Gene Database", "identifier": "X51675"}, {"resource": "GenBank Protein Database", "identifier": "37605"}, {"resource": "UniProtKB", "identifier": "Q03405"}, {"resource": "UniProt Accession", "identifier": "UPAR_HUMAN"}]}, "synonyms": {"synonym": ["CD87 antigen", "Monocyte activation antigen Mo3", "U- PAR", "uPAR", "Urokinase plasminogen activator surface receptor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Urokinase plasminogen activator surface receptor precursor\nMGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEEL\nELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISC\nGSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNG\nFHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGP\nMNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDV\nQYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1008 bp\nATGGGTCACCCGCCGCTGCTGCCGCTGCTGCTGCTGCTCCACACCTGCGTCCCAGCCTCT\nTGGGGCCTGCGGTGCATGCAGTGTAAGACCAACGGGGATTGCCGTGTGGAAGAGTGCGCC\nCTGGGACAGGACCTCTGCAGGACCACGATCGTGCGCTTGTGGGAAGAAGGAGAAGAGCTG\nGAGCTGGTGGAGAAAAGCTGTACCCACTCAGAGAAGACCAACAGGACCCTGAGCTATCGG\nACTGGCTTGAAGATCACCAGCCTTACCGAGGTTGTGTGTGGGTTAGACTTGTGCAACCAG\nGGCAACTCTGGCCGGGCTGTCACCTATTCCCGAAGCCGTTACCTCGAATGCATTTCCTGT\nGGCTCATCAGACATGAGCTGTGAGAGGGGCCGGCACCAGAGCCTGCAGTGCCGCAGCCCT\nGAAGAACAGTGCCTGGATGTGGTGACCCACTGGATCCAGGAAGGTGAAGAAGGGCGTCCA\nAAGGATGACCGCCACCTCCGTGGCTGTGGCTACCTTCCCGGCTGCCCGGGCTCCAATGGT\nTTCCACAACAACGACACCTTCCACTTCCTGAAATGCTGCAACACCACCAAATGCAACGAG\nGGCCCAATCCTGGAGCTTGAAAATCTGCCGCAGAATGGCCGCCAGTGTTACAGCTGCAAG\nGGGAACAGCACCCATGGATGCTCCTCTGAAGAGACTTTCCTCATTGACTGCCGAGGCCCC\nATGAATCAATGTCTGGTAGCCACCGGCACTCACGAACCGAAAAACCAAAGCTATATGGTA\nAGAGGCTGTGCAACCGCCTCAATGTGCCAACATGCCCACCTGGGTGACGCCTTCAGCATG\nAACCACATTGATGTCTCCTGCTGTACTAAAAGTGGCTGTAACCACCCAGACCTGGATGTC\nCAGTACCGCAGTGGGGCTGCTCCTCAGCCTGGCCCTGCCCATCTCAGCCTCACCATCACC\nCTGCTAATGACTGCCAGACTGTGGGGAGGCACTCTCCTCTGGACCTAA"}, "pfams": {"pfam": {"identifier": "PF00021", "name": "UPAR_LY6"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "U-plasminogen activator receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}]}}}, {"@position": "4", "id": "BE0000240", "name": "Plasminogen activator inhibitor 1", "organism": "Human", "actions": null, "references": "# Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17963464", "known-action": "unknown", "polypeptide": {"@id": "P05121", "@source": "Swiss-Prot", "name": "Plasminogen activator inhibitor 1", "general-function": "Involved in serine-type endopeptidase inhibitor activity", "specific-function": "This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, and protein C. Its rapid interaction with TPA may function as a major control point in the regulation of fibrinolysis", "gene-name": "SERPINE1", "locus": "7q21.3-q22", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.22", "molecular-weight": "45061.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:8583"}, {"resource": "GenAtlas", "identifier": "SERPINE1"}, {"resource": "GeneCards", "identifier": "SERPINE1"}, {"resource": "GenBank Gene Database", "identifier": "X04429"}, {"resource": "GenBank Protein Database", "identifier": "35272"}, {"resource": "UniProtKB", "identifier": "P05121"}, {"resource": "UniProt Accession", "identifier": "PAI1_HUMAN"}]}, "synonyms": {"synonym": ["Endothelial plasminogen activator inhibitor", "PAI", "PAI-1", "Plasminogen activator inhibitor 1 precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Plasminogen activator inhibitor 1 precursor\nMQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY\nGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI\nFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV\nDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD\nGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK\nFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS\nSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP"}, "gene-sequence": {"@format": "FASTA", "#text": ">1209 bp\nATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA\nGGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG\nAGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT\nGGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG\nATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT\nCTGTACAAGGAGCTCATGGGGCCATGGAACAAGGACGAGATCAGCACCACAGACGCGATC\nTTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC\nCGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT\nGACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG\nGACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT\nCCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC\nTCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT\nGGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT\nGCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG\nCTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG\nTTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC\nATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC\nGCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA\nTCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC\nTTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG\nGAACCCTGA"}, "pfams": {"pfam": {"identifier": "PF00079", "name": "Serpin"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "protease inhibitor activity"}, {"category": "function", "description": "endopeptidase inhibitor activity"}, {"category": "function", "description": "serine-type endopeptidase inhibitor activity"}, {"category": "function", "description": "enzyme regulator activity"}, {"category": "function", "description": "enzyme inhibitor activity"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2011-08-02", "drugbank-id": [{"@primary": "true", "#text": "DB00016"}, "BIOD00103", "BTD00103"], "name": "Epoetin alfa", "description": "Human erythropoietin (recombinant), produced by CHO cells.", "cas-number": "113427-24-0", "groups": {"group": "approved"}, "general-references": null, "synthesis-reference": null, "indication": "For treatment of anemia (from renal transplants or certain HIV treatment)", "pharmacodynamics": "Used in the treatment of anemia. Involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass.", "mechanism-of-action": "Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": "* 20.2 +/- 15.9 mL/h/kg [150 Units/kg SC TIW, Week 1 when anemic cancer patients were receiving chemotherapy]\n* 23.6 +/- 9.5 mL/h/kg [150 Units/kg SC TIW, Week 3 when anemic cancer patients were not receiving chemotherapy]\n* 9.2 +/- 4.7 mL/h/kg [40,000 Units/kg SC TIW, Week 1 when anemic cancer patients were receiving chemotherapy]\n* 13.9 +/- 7.6 mL/h/kg [40,000 Units/kg SC TIW, Week 3 when anemic cancer patients were not receiving chemotherapy]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": {"@language": "", "@coder": "", "#text": "Erythropoietin precursor"}}, "products": {"product": [{"name": "Epogen", "ndc-id": "55513-126_89a8e8ee-9d7a-422f-9271-6563fabf6f69", "ndc-product-code": "55513-126", "dpd-id": null, "started-marketing-on": "1989-06-30", "ended-marketing-on": null, "dosage-form": "solution", "strength": "2000 [iU]/mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103234", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Epogen", "ndc-id": "55513-144_89a8e8ee-9d7a-422f-9271-6563fabf6f69", "ndc-product-code": "55513-144", "dpd-id": null, "started-marketing-on": "1993-08-16", "ended-marketing-on": null, "dosage-form": "solution", "strength": "10000 [iU]/mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103234", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Epogen", "ndc-id": "55513-148_89a8e8ee-9d7a-422f-9271-6563fabf6f69", "ndc-product-code": "55513-148", "dpd-id": null, "started-marketing-on": "1993-08-16", "ended-marketing-on": null, "dosage-form": "solution", "strength": "4000 [iU]/mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103234", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Epogen", "ndc-id": "55513-267_89a8e8ee-9d7a-422f-9271-6563fabf6f69", "ndc-product-code": "55513-267", "dpd-id": null, "started-marketing-on": "1990-04-30", "ended-marketing-on": null, "dosage-form": "solution", "strength": "3000 [iU]/mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103234", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Epogen", "ndc-id": "55513-283_89a8e8ee-9d7a-422f-9271-6563fabf6f69", "ndc-product-code": "55513-283", "dpd-id": null, "started-marketing-on": "1994-12-05", "ended-marketing-on": null, "dosage-form": "solution", "strength": "10000 [iU]/mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103234", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Epogen", "ndc-id": "55513-478_89a8e8ee-9d7a-422f-9271-6563fabf6f69", "ndc-product-code": "55513-478", "dpd-id": null, "started-marketing-on": "1997-03-03", "ended-marketing-on": null, "dosage-form": "solution", "strength": "20000 [iU]/mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103234", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Eprex Sterile Solution", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02243239", "started-marketing-on": "2005-08-24", "ended-marketing-on": null, "dosage-form": "solution", "strength": "20000 unit", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Eprex Sterile Solution", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02288680", "started-marketing-on": "2007-11-19", "ended-marketing-on": null, "dosage-form": "solution", "strength": "30000 unit", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Eprex Sterile Solution 10000iu/1.0ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02231587", "started-marketing-on": "1997-09-19", "ended-marketing-on": null, "dosage-form": "solution", "strength": "10000 unit", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Eprex Sterile Solution 10000iu/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02126591", "started-marketing-on": "1990-12-31", "ended-marketing-on": "2014-10-09", "dosage-form": "solution", "strength": "10000 unit", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Eprex Sterile Solution 1000iu/0.5ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02231583", "started-marketing-on": "1997-09-19", "ended-marketing-on": null, "dosage-form": "solution", "strength": "1000 unit", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Eprex Sterile Solution 20000iu/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02206072", "started-marketing-on": "1996-10-02", "ended-marketing-on": "2010-04-29", "dosage-form": "solution", "strength": "20000 unit", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Eprex Sterile Solution 2000iu/0.5ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02231584", "started-marketing-on": "1997-09-19", "ended-marketing-on": null, "dosage-form": "solution", "strength": "2000 unit", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Eprex Sterile Solution 2000iu/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02126575", "started-marketing-on": "1992-12-31", "ended-marketing-on": "2014-09-25", "dosage-form": "solution", "strength": "2000 unit", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Eprex Sterile Solution 3000iu/0.3ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02231585", "started-marketing-on": "1997-09-19", "ended-marketing-on": null, "dosage-form": "solution", "strength": "3000 unit", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Eprex Sterile Solution 40000iu/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02240722", "started-marketing-on": "1999-12-21", "ended-marketing-on": null, "dosage-form": "solution", "strength": "40000 unit", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Eprex Sterile Solution 4000iu/0.4ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02231586", "started-marketing-on": "1997-09-19", "ended-marketing-on": null, "dosage-form": "solution", "strength": "4000 unit", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Eprex Sterile Solution 4000iu/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02126583", "started-marketing-on": "1990-12-31", "ended-marketing-on": "2014-10-09", "dosage-form": "solution", "strength": "4000 unit", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Eprex Sterile Solution 5000iu/0.5ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02243400", "started-marketing-on": "2002-07-01", "ended-marketing-on": null, "dosage-form": "solution", "strength": "5000 unit", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Eprex Sterile Solution 6000 Iu/0.6 Ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02243401", "started-marketing-on": "2001-02-20", "ended-marketing-on": null, "dosage-form": "solution", "strength": "6000 unit", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Eprex Sterile Solution 8000 Iu/0.8 Ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02243403", "started-marketing-on": "2001-02-20", "ended-marketing-on": null, "dosage-form": "solution", "strength": "8000 unit", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": [{"name": "Binocrit", "company": "Sandoz"}, {"name": "Epocept", "company": "Lupin pharma"}, {"name": "Epofit", "company": "Intas pharma"}, {"name": "Epogin", "company": "Chugai"}, {"name": "Eprex", "company": "Janssen-Cilag. Ortho Biologics LLC"}, {"name": "Nanokine", "company": "Nanogen Pharmaceutical biotechnology, Vietnam)"}]}, "mixtures": {"mixture": [{"name": "Epogen", "ingredients": "Epoetin alfa"}, {"name": "Epogen", "ingredients": "Epoetin alfa"}, {"name": "Epogen", "ingredients": "Epoetin alfa"}, {"name": "Epogen", "ingredients": "Epoetin alfa"}, {"name": "Epogen", "ingredients": "Epoetin alfa"}, {"name": "Epogen", "ingredients": "Epoetin alfa"}, {"name": "Eprex Sterile Solution 1000iu/0.5ml", "ingredients": "Epoetin alfa"}, {"name": "Eprex Sterile Solution 2000iu/0.5ml", "ingredients": "Epoetin alfa"}, {"name": "Eprex Sterile Solution 3000iu/0.3ml", "ingredients": "Epoetin alfa"}, {"name": "Eprex Sterile Solution 4000iu/0.4ml", "ingredients": "Epoetin alfa"}, {"name": "Eprex Sterile Solution 10000iu/1.0ml", "ingredients": "Epoetin alfa"}, {"name": "Eprex Sterile Solution 40000iu/ml", "ingredients": "Epoetin alfa"}, {"name": "Eprex Sterile Solution", "ingredients": "Epoetin alfa"}, {"name": "Eprex Sterile Solution 5000iu/0.5ml", "ingredients": "Epoetin alfa"}, {"name": "Eprex Sterile Solution 6000 Iu/0.6 Ml", "ingredients": "Epoetin alfa"}, {"name": "Eprex Sterile Solution 8000 Iu/0.8 Ml", "ingredients": "Epoetin alfa"}, {"name": "Eprex Sterile Solution", "ingredients": "Epoetin alfa"}, {"name": "Eprex Sterile Solution 10000iu/ml", "ingredients": "Epoetin alfa"}, {"name": "Eprex Sterile Solution 4000iu/ml", "ingredients": "Epoetin alfa"}, {"name": "Eprex Sterile Solution 2000iu/ml", "ingredients": "Epoetin alfa"}, {"name": "Eprex Sterile Solution 20000iu/ml", "ingredients": "Epoetin alfa"}]}, "packagers": {"packager": [{"name": "Amgen Inc.", "url": "http://www.amgen.com"}, {"name": "Centocor Ortho Biotech Inc.", "url": "http://www.centocororthobiotech.com"}, {"name": "DSM Corp.", "url": "http://www.dsm.com"}, {"name": "Janssen-Ortho Inc.", "url": "http://www.janssen-ortho.com"}, {"name": "JHP Pharmaceuticals LLC", "url": "http://www.jhppharma.com"}, {"name": "Ortho-McNeil-Janssen Pharmaceuticals Inc.", "url": "http://www.ortho-mcneil.com"}, {"name": "Physicians Total Care Inc.", "url": "http://www.physicianstotalcare.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Epogen 2000 unit/ml vial", "cost": {"@currency": "USD", "#text": "34.14"}, "unit": "vial"}, {"description": "Procrit 2000 unit/ml vial", "cost": {"@currency": "USD", "#text": "37.09"}, "unit": "vial"}, {"description": "Epogen 3000 unit/ml vial", "cost": {"@currency": "USD", "#text": "47.53"}, "unit": "vial"}, {"description": "Procrit 3000 unit/ml vial", "cost": {"@currency": "USD", "#text": "55.63"}, "unit": "vial"}, {"description": "Epogen 4000 unit/ml vial", "cost": {"@currency": "USD", "#text": "61.34"}, "unit": "vial"}, {"description": "Procrit 4000 unit/ml vial", "cost": {"@currency": "USD", "#text": "74.17"}, "unit": "vial"}, {"description": "Epogen 10000 unit/ml vial", "cost": {"@currency": "USD", "#text": "151.8"}, "unit": "ml"}, {"description": "Epogen 20000 unit/ml vial", "cost": {"@currency": "USD", "#text": "303.6"}, "unit": "ml"}, {"description": "Epogen 10000 unit/ml Solution 2ml Vial", "cost": {"@currency": "USD", "#text": "315.74"}, "unit": "vial"}, {"description": "Procrit 10000 unit/ml Solution 2ml Vial", "cost": {"@currency": "USD", "#text": "358.02"}, "unit": "vial"}, {"description": "Procrit 20000 unit/ml Solution", "cost": {"@currency": "USD", "#text": "378.14"}, "unit": "ml"}, {"description": "Procrit 20000 unit/ml vial", "cost": {"@currency": "USD", "#text": "388.97"}, "unit": "ml"}, {"description": "Epogen 40000 unit/ml vial", "cost": {"@currency": "USD", "#text": "640.37"}, "unit": "ml"}, {"description": "Procrit 10000 unit/ml vial", "cost": {"@currency": "USD", "#text": "710.87"}, "unit": "vial"}, {"description": "Procrit 40000 unit/ml vial", "cost": {"@currency": "USD", "#text": "767.03"}, "unit": "vial"}, {"description": "Epogen 10000 unit/ml Solution 1 Box Contains Ten 1ml Vials", "cost": {"@currency": "USD", "#text": "1578.72"}, "unit": "box"}, {"description": "Epogen 20000 unit/ml Solution 1 Box Contains Ten 1ml Vials", "cost": {"@currency": "USD", "#text": "3157.44"}, "unit": "box"}, {"description": "Epogen 40000 unit/ml Solution 1 Box Contains Ten 1ml Vials", "cost": {"@currency": "USD", "#text": "6852.3"}, "unit": "box"}]}, "categories": {"category": [{"category": "Hematinics", "mesh-id": null}, {"category": "Anti-anemic Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Solution", "route": "intravenous; subcutaneous", "strength": "10000 [iU]/mL"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "2000 [iU]/mL"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "20000 [iU]/mL"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "3000 [iU]/mL"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "4000 [iU]/mL"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "20000 unit"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "30000 unit"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "10000 unit"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "1000 unit"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "2000 unit"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "3000 unit"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "40000 unit"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "4000 unit"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "5000 unit"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "6000 unit"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "8000 unit"}]}, "atc-codes": null, "ahfs-codes": {"ahfs-code": "20:16.00"}, "patents": {"patent": {"number": "1339047", "country": "Canada", "approved": "1997-05-27", "expires": "2014-05-27"}}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00480", "name": "Lenalidomide", "description": "Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Lenalidomide."}, {"drugbank-id": "DB01041", "name": "Thalidomide", "description": "Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Thalidomide."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00016 sequence\nAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQA\nVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAIS\nPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "53 \u00b0C", "source": "Arakawa, T. et al., Biosci. Biotechnol. Biochem. 65:1321-1327 (2001)"}, {"kind": "Isoelectric Point", "value": "8.75", "source": null}, {"kind": "Molecular Weight", "value": "18396.1000", "source": null}, {"kind": "Molecular Formula", "value": "C815H1317N233O241S5", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "299"}, {"resource": "National Drug Code Directory", "identifier": "55513-126-10"}, {"resource": "GenBank", "identifier": "X02158"}, {"resource": "PharmGKB", "identifier": "PA10072"}, {"resource": "UniProtKB", "identifier": "P01588"}, {"resource": "Wikipedia", "identifier": "Epoetin_alfa"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/epoetin.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/epoetin-alfa.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0000654", "name": "Erythropoietin receptor", "organism": "Human", "actions": {"action": "agonist"}, "references": "# LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, Hall C, Meshaw A, Farrell FX: Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther. 2006 Feb;5(2):347-55. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16505108\n# Kokhaei P, Abdalla AO, Hansson L, Mikaelsson E, Kubbies M, Haselbeck A, Jernberg-Wiklund H, Mellstedt H, Osterborg A: Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies. Clin Cancer Res. 2007 Jun 15;13(12):3536-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17575216\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P19235", "@source": "Swiss-Prot", "name": "Erythropoietin receptor", "general-function": "Involved in transmembrane receptor activity", "specific-function": "Isoform EPOR-T, missing the cytoplasmic tail, acts as a dominant-negative receptor of EPOR-mediated signaling", "gene-name": "EPOR", "locus": "19p13.3-p13.2", "cellular-location": "Cell membrane; single-pass type I membrane protein. Isoform EPOR-S:Secreted protein. Isoform EPOR-S", "transmembrane-regions": "251-273", "signal-regions": null, "theoretical-pi": "4.37", "molecular-weight": "55066.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3416"}, {"resource": "GenAtlas", "identifier": "EPOR"}, {"resource": "GeneCards", "identifier": "EPOR"}, {"resource": "GenBank Gene Database", "identifier": "M60459"}, {"resource": "GenBank Protein Database", "identifier": "182245"}, {"resource": "UniProtKB", "identifier": "P19235"}, {"resource": "UniProt Accession", "identifier": "EPOR_HUMAN"}]}, "synonyms": {"synonym": ["EPO-R", "Erythropoietin receptor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Erythropoietin receptor precursor\nMDHLGASLWPQVGSLCLLLAGAAWAPPPNLPDPKFESKAALLAARGPEELLCFTERLEDL\nVCFWEEAASAGVGPGNYSFSYQLEDEPWKLCRLHQAPTARGAVRFWCSLPTADTSSFVPL\nELRVTAASGAPRYHRVIHINEVVLLDAPVGLVARLADESGHVVLRWLPPPETPMTSHIRY\nEVDVSAGNGAGSVQRVEILEGRTECVLSNLRGRTRYTFAVRARMAEPSFGGFWSAWSEPV\nSLLTPSDLDPLILTLSLILVVILVLLTVLALLSHRRALKQKIWPGIPSPESEFEGLFTTH\nKGNFQLWLYQNDGCLWWSPCTPFTEDPPASLEVLSERCWGTMQAVEPGTDDEGPLLEPVG\nSEHAQDTYLVLDKWLLPRNPPSEDLPGPGGSVDIVAMDEGSEASSCSSALASKPSPEGAS\nAASFEYTILDPSSQLLRPWTLCPELPPTPPHLKYLYLVVSDSGISTDYSSGDSQGAQGGL\nSDGPYSNPYENSLIPAAEPLPPSYVACS"}, "gene-sequence": {"@format": "FASTA", "#text": ">1527 bp\nATGGACCACCTCGGGGCGTCCCTCTGGCCCCAGGTCGGCTCCCTTTGTCTCCTGCTCGCT\nGGGGCCGCCTGGGCGCCCCCGCCTAACCTCCCGGACCCCAAGTTCGAGAGCAAAGCGGCC\nTTGCTGGCGGCCCGGGGGCCCGAAGAGCTTCTGTGCTTCACCGAGCGGTTGGAGGACTTG\nGTGTGTTTCTGGGAGGAAGCGGCGAGCGCTGGGGTGGGCCCGGGCAACTACAGCTTCTCC\nTACCAGCTCGAGGATGAGCCATGGAAGCTGTGTCGCCTGCACCAGGCTCCCACGGCTCGT\nGGTGCGGTGCGCTTCTGGTGTTCGCTGCCTACAGCCGACACGTCGAGCTTCGTGCCCCTA\nGAGTTGCGCGTCACAGCAGCCTCCGGCGCTCCGCGATATCACCGTGTCATCCACATCAAT\nGAAGTAGTGCTCCTAGACGCCCCCGTGGGGCTGGTGGCGCGGTTGGCTGACGAGAGCGGC\nCACGTAGTGTTGCGCTGGCTCCCGCCGCCTGAGACACCCATGACGTCTCACATCCGCTAC\nGAGGTGGACGTCTCGGCCGGCAACGGCGCAGGGAGCGTACAGAGGGTGGAGATCCTGGAG\nGGCCGCACCGAGTGTGTGCTGAGCAACCTGCGGGGCCGGACGCGCTACACCTTCGCCGTC\nCGCGCGCGTATGGCTGAGCCGAGCTTCGGCGGCTTCTGGAGCGCCTGGTCGGAGCCTGTG\nTCGCTGCTGACGCCTAGCGACCTGGACCCCCTCATCCTGACGCTCTCCCTCATCCTCGTG\nGTCATCCTGGTGCTGCTGACCGTGCTCGCGCTGCTCTCCCACCGCCGGGCTCTGAAGCAG\nAAGATCTGGCCTGGCATCCCGAGCCCAGAGAGCGAGTTTGAAGGCCTCTTCACCACCCAC\nAAGGGTAACTTCCAGCTGTGGCTGTACCAGAATGATGGCTGCCTGTGGTGGAGCCCCTGC\nACCCCCTTCACGGAGGACCCACCTGCTTCCCTGGAAGTCCTCTCAGAGCGCTGCTGGGGG\nACGATGCAGGCAGTGGAGCCGGGGACAGATGATGAGGGCCCCCTGCTGGAGCCAGTGGGC\nAGTGAGCATGCCCAGGATACCTATCTGGTGCTGGACAAATGGTTGCTGCCCCGGAACCCG\nCCCAGTGAGGACCTCCCAGGGCCTGGTGGCAGTGTGGACATAGTGGCCATGGATGAAGGC\nTCAGAAGCATCCTCCTGCTCATCTGCTTTGGCCTCGAAGCCCAGCCCAGAGGGAGCCTCT\nGCTGCCAGCTTTGAGTACACTATCCTGGACCCCAGCTCCCAGCTCTTGCGTCCATGGACA\nCTGTGCCCTGAGCTGCCCCCTACCCCACCCCACCTAAAGTACCTGTACCTTGTGGTATCT\nGACTCTGGCATCTCAACTGACTACAGCTCAGGGGACTCCCAGGGAGCCCAAGGGGGCTTA\nTCCGATGGCCCCTACTCCAACCCTTATGAGAACAGCCTTATCCCAGCCGCTGAGCCTCTG\nCCCCCCAGCTATGTGGCTTGCTCTTAG"}, "pfams": {"pfam": {"identifier": "PF00041", "name": "fn3"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "hematopoietin/interferon-class (D200-domain) cytokine receptor activity"}]}}}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2015-08-07", "drugbank-id": [{"@primary": "true", "#text": "DB00017"}, "BIOD00025", "BTD00025"], "name": "Salmon Calcitonin", "description": "Synthetic peptide, 32 residues long formulated as a nasal spray.", "cas-number": "47931-85-1", "groups": {"group": ["approved", "investigational"]}, "general-references": "# Sanofi-Aventis Canada Inc. Calcimar Solution. Laval, Quebec: N.p., 2014. \n#Lexicomp. Calcitonin. N.p., 2014. Web. 11 Nov. 2014.", "synthesis-reference": "Marcos C. Poblet, Berta P. Obiols, Gemma J. Farres, \"Procedure for preparing salmon calcitonin.\" U.S. Patent US5527881, issued October, 1991.", "indication": "Used in the treatment of symptomatic Paget's disease for patients unresponsive to alternate treatments or intolerant to such treatments. In addition, it is used in emergency situations when serum calcium levels must be decreased quickly until the underlying condition is identified. It can also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents. Calcitonin can be used in patients with azotemia and cases where intravenous fluids would be contraindicated due to limited cardiac reserves. Also for the treatment of post-menopausal osteoporosis in women more than 5 years post-menopause.", "pharmacodynamics": "Calcitonin inhibits bone resorption by osteoclasts (bone remodeling cells) and promotes bone formation by osteoblasts. This leads to a net increase in bone mass and a reduction in plasma calcium levels. It also promotes the renal excretion of ions such as calcium, phosphate, sodium, magnesium, and potassium by decreasing tubular reabsorption. In consequence, there is an increase in the jejunal secretion of water, sodium, potassium, and chloride.", "mechanism-of-action": "Calcitonin binds to the calcitonin receptor (found primarily in osteoclasts) which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.", "toxicity": "Salmon calcitonin was shown to inhibit lactation in animals and is not recommend in nursing mothers. While research in animals have shown a decrease in fetal weight, no studies have yet shown similar results in humans. It is recommended however to proceed carefully when administering salmon calcitonin to pregnant women and consider if the benefits outweigh the risks. Because of its protein nature, salmon calcitonin may provoke an allergy reaction (bronchospams and swelling of the tongue/throat) that can turn into a full-blown anaphylactic response. The manufacturer also reports an increase in the risk of malignancies from oral route (0.7%) to intranasal route (2.4%) compared to placebo. The same may apply to IV, IM and SC routes since the systemic exposure is higher in those cases.\nNausea is noticeable in some patients but tends to decrease with continued administration. Rhinitis, headaches and back pain have also been reported among others.", "metabolism": "Salmon calcitonin is primarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule. It is also metabolized in the blood and the peripheral tissue.", "absorption": "Salmon calcitonin is rapidly absorbed and eliminated. Bioavailability following subcutaneous and intramuscular injection in humans is high and similar for the two routes of administration (71% and 66%, respectively). Via the nasal route, the bioavailability varies between 3 to 5% relative to IM.", "half-life": "Half-life elimination (terminal): I.M. 58 minutes; SubQ 59 to 64 minutes; Nasal: ~18 to 23 minutes", "protein-binding": "30 to 40%", "route-of-elimination": "Urine. Studies with injectable calcitonin show increases in the excretion of filtered phosphate, calcium, and sodium by decreasing their tubular reabsorption in the kidney.", "volume-of-distribution": "0.15 to 0.3 L/kg", "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Calcimar"}, {"@language": "", "@coder": "", "#text": "Calcitonin (Salmon Synthetic)"}, {"@language": "", "@coder": "", "#text": "Calcitonin 1 precursor"}, {"@language": "", "@coder": "", "#text": "Calcitonin Salmon"}, {"@language": "", "@coder": "", "#text": "Calcitonin-salmon"}, {"@language": "", "@coder": "", "#text": "Calcitonin, salmon"}, {"@language": "", "@coder": "", "#text": "Cibacalcin"}, {"@language": "", "@coder": "", "#text": "Fortical"}, {"@language": "", "@coder": "", "#text": "Miacalcin"}, {"@language": "", "@coder": "", "#text": "Salmon calcitonin"}, {"@language": "", "@coder": "", "#text": "Salmotonin"}]}, "products": {"product": [{"name": "Apo-calcitonin Injectable", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02246058", "started-marketing-on": "2003-05-01", "ended-marketing-on": "2013-08-02", "dosage-form": "liquid", "strength": "200 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "true", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Apo-calcitonin Nasal Spray", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02247585", "started-marketing-on": "2003-09-12", "ended-marketing-on": "2013-10-01", "dosage-form": "solution", "strength": "200 unit", "route": "nasal", "fda-application-number": null, "generic": "true", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Calcimar Solution Inj 200unit/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01926691", "started-marketing-on": "1983-12-31", "ended-marketing-on": null, "dosage-form": "solution", "strength": "200 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Calcitonin (salmon) Injection, BP", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02383233", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "200 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Calcitonin Salmon", "ndc-id": "54868-6323_495988fd-328f-485b-9dc8-cfc1a47baa05", "ndc-product-code": "54868-6323", "dpd-id": null, "started-marketing-on": "2011-12-09", "ended-marketing-on": null, "dosage-form": "spray, metered", "strength": "200 [iU]/.09mL", "route": "nasal", "fda-application-number": "ANDA076979", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Calcitonin Salmon", "ndc-id": "49884-161_35e3dd68-677f-45e9-b4bf-f30fa2a34367", "ndc-product-code": "49884-161", "dpd-id": null, "started-marketing-on": "2009-06-08", "ended-marketing-on": null, "dosage-form": "spray, metered", "strength": "200 [iU]/.09mL", "route": "nasal", "fda-application-number": "ANDA076979", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Calcitonin Salmon", "ndc-id": "0781-6320_99e9e62b-9796-42ec-8f69-551dabf92ec1", "ndc-product-code": "0781-6320", "dpd-id": null, "started-marketing-on": "1995-08-01", "ended-marketing-on": null, "dosage-form": "spray, metered", "strength": "200 [iU]", "route": "nasal", "fda-application-number": "NDA020313", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Calcitonin Salmon", "ndc-id": "60505-0823_af648eda-ff07-596c-b25a-d1d3d57a4890", "ndc-product-code": "60505-0823", "dpd-id": null, "started-marketing-on": "2008-12-09", "ended-marketing-on": null, "dosage-form": "spray, metered", "strength": "200 [iU]", "route": "nasal", "fda-application-number": "ANDA076396", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Caltine Inj 100 Unit/ml (1ml Amp)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02007134", "started-marketing-on": "1993-12-31", "ended-marketing-on": "2014-07-25", "dosage-form": "liquid", "strength": "100 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Caltine Inj 100unit/ml (0.5ml Amp)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01940376", "started-marketing-on": "1993-12-31", "ended-marketing-on": "2002-01-30", "dosage-form": "liquid", "strength": "100 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Fortical", "ndc-id": "54868-5499_5855b6df-3949-4d36-b210-0fa2e5db974d", "ndc-product-code": "54868-5499", "dpd-id": null, "started-marketing-on": "2005-12-30", "ended-marketing-on": null, "dosage-form": "spray, metered", "strength": "2200 [iU]/mL", "route": "nasal", "fda-application-number": "NDA021406", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Fortical", "ndc-id": "0245-0008_2905a738-af8b-4baa-9c2f-67769897220c", "ndc-product-code": "0245-0008", "dpd-id": null, "started-marketing-on": "2005-08-12", "ended-marketing-on": null, "dosage-form": "spray, metered", "strength": "2200 [iU]/mL", "route": "nasal", "fda-application-number": "NDA021406", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Miacalcin", "ndc-id": "54766-149_c83870aa-b4eb-49d4-8790-a78dd66b1d1b", "ndc-product-code": "54766-149", "dpd-id": null, "started-marketing-on": "1986-07-03", "ended-marketing-on": "2018-03-31", "dosage-form": "injection, solution", "strength": "200 [iU]/mL", "route": "intramuscular", "fda-application-number": "NDA017808", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Miacalcin", "ndc-id": "0078-0149_223dc129-c720-41ba-a4e6-d879ea89431d", "ndc-product-code": "0078-0149", "dpd-id": null, "started-marketing-on": "1986-07-03", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "200 [iU]/mL", "route": "intramuscular; subcutaneous", "fda-application-number": "NDA017808", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Miacalcin", "ndc-id": "0078-0311_bbd80843-5b89-4b66-b1d2-c5c5a28c346e", "ndc-product-code": "0078-0311", "dpd-id": null, "started-marketing-on": "1995-08-01", "ended-marketing-on": null, "dosage-form": "spray, metered", "strength": "200 [iU]", "route": "nasal", "fda-application-number": "NDA020313", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Miacalcin Injection 200iu/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02144301", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "liquid", "strength": "200 unit", "route": "intramuscular; intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Miacalcin Nasal Spray 200 Iu", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02240775", "started-marketing-on": "1999-09-08", "ended-marketing-on": "2013-10-01", "dosage-form": "spray", "strength": "200 unit", "route": "nasal", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Pro-calcitonin - 200", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02311046", "started-marketing-on": "2008-07-04", "ended-marketing-on": "2011-07-27", "dosage-form": "solution", "strength": "200 unit", "route": "nasal", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Sandoz-calcitonin Ns", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02261766", "started-marketing-on": "2004-12-01", "ended-marketing-on": "2013-10-01", "dosage-form": "liquid", "strength": "200 unit", "route": "nasal", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": {"name": "Calcimar", "company": null}}, "mixtures": {"mixture": [{"name": "Miacalcin", "ingredients": "Salmon Calcitonin"}, {"name": "Miacalcin", "ingredients": "Salmon Calcitonin"}, {"name": "Fortical", "ingredients": "Salmon Calcitonin"}, {"name": "Calcitonin Salmon", "ingredients": "Salmon Calcitonin"}, {"name": "Calcitonin Salmon", "ingredients": "Salmon Calcitonin"}, {"name": "Miacalcin", "ingredients": "Salmon Calcitonin"}, {"name": "Fortical", "ingredients": "Salmon Calcitonin"}, {"name": "Calcitonin Salmon", "ingredients": "Salmon Calcitonin"}, {"name": "Calcitonin Salmon", "ingredients": "Salmon Calcitonin"}, {"name": "Calcimar Solution Inj 200unit/ml", "ingredients": "Salmon Calcitonin"}, {"name": "Caltine Inj 100 Unit/ml (1ml Amp)", "ingredients": "Salmon Calcitonin"}, {"name": "Caltine Inj 100unit/ml (0.5ml Amp)", "ingredients": "Salmon Calcitonin"}, {"name": "Miacalcin Nasal Spray 200 Iu", "ingredients": "Salmon Calcitonin"}, {"name": "Apo-calcitonin Injectable", "ingredients": "Salmon Calcitonin"}, {"name": "Apo-calcitonin Nasal Spray", "ingredients": "Salmon Calcitonin"}, {"name": "Sandoz-calcitonin Ns", "ingredients": "Salmon Calcitonin"}, {"name": "Pro-calcitonin - 200", "ingredients": "Salmon Calcitonin"}, {"name": "Miacalcin Injection 200iu/ml", "ingredients": "Salmon Calcitonin"}, {"name": "Calcitonin (salmon) Injection, BP", "ingredients": "Salmon Calcitonin"}]}, "packagers": {"packager": [{"name": "Apotex Inc.", "url": "http://www.apotex.com"}, {"name": "Novartis AG", "url": "http://www.novartis.com"}, {"name": "Par Pharmaceuticals", "url": "http://www.parpharm.com"}, {"name": "Sandoz", "url": "http://www.sandoz.ca"}, {"name": "Upsher Smith Laboratories", "url": "http://www.upsher-smith.com"}]}, "manufacturers": {"manufacturer": [{"@generic": "false", "#text": "Sanofi aventis us llc"}, {"@generic": "false", "#text": "Astrazeneca lp"}, {"@generic": "false", "#text": "Novartis pharmaceuticals corp"}, {"@generic": "false", "#text": "Apotex inc"}, {"@generic": "false", "#text": "Par pharmaceutical inc"}, {"@generic": "false", "#text": "Upsher smith laboratories inc"}]}, "prices": {"price": [{"description": "Caltine 100 (100 Iu/Ml) 100 iu/ml", "cost": {"@currency": "USD", "#text": "8.81"}, "unit": "ml"}, {"description": "Calcimar 200 iu/ml", "cost": {"@currency": "USD", "#text": "29.94"}, "unit": "ml"}, {"description": "Miacalcin 200 unit/ml vial", "cost": {"@currency": "USD", "#text": "30.73"}, "unit": "ml"}, {"description": "Fortical 200 unit nasal spray", "cost": {"@currency": "USD", "#text": "34.3"}, "unit": "ml"}, {"description": "Calcitonin-salmon 200 unit sp", "cost": {"@currency": "USD", "#text": "39.51"}, "unit": "ml"}, {"description": "Miacalcin 200 unit nasal spray", "cost": {"@currency": "USD", "#text": "44.68"}, "unit": "ml"}, {"description": "Miacalcin For Inj, 2 unit = 1 Box 2ml Vial", "cost": {"@currency": "USD", "#text": "63.59"}, "unit": "vial"}, {"description": "Calcitonin (Salmon) 200 unit/act Solution 3.7ml Bottle", "cost": {"@currency": "USD", "#text": "123.28"}, "unit": "bottle"}, {"description": "Miacalcin 200 unit/act Solution 3.7ml Bottle", "cost": {"@currency": "USD", "#text": "139.39"}, "unit": "bottle"}]}, "categories": {"category": [{"category": "Bone Density Conservation Agents", "mesh-id": null}, {"category": "Antihypercalcemic Agents", "mesh-id": null}, {"category": "Anti-Osteporotic Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Liquid", "route": "intramuscular; subcutaneous", "strength": "200 unit"}, {"form": "Solution", "route": "nasal", "strength": "200 unit"}, {"form": "Solution", "route": "intramuscular; subcutaneous", "strength": "200 unit"}, {"form": "Spray, metered", "route": "nasal", "strength": "200 [iU]/.09mL"}, {"form": "Liquid", "route": "intramuscular; subcutaneous", "strength": "100 unit"}, {"form": "Spray, metered", "route": "nasal", "strength": "2200 [iU]/mL"}, {"form": "Injection, solution", "route": "intramuscular", "strength": "200 [iU]/mL"}, {"form": "Injection, solution", "route": "intramuscular; subcutaneous", "strength": "200 [iU]/mL"}, {"form": "Spray, metered", "route": "nasal", "strength": "200 [iU]"}, {"form": "Liquid", "route": "intramuscular; intravenous; subcutaneous", "strength": "200 unit"}, {"form": "Spray", "route": "nasal", "strength": "200 unit"}, {"form": "Liquid", "route": "nasal", "strength": "200 unit"}]}, "atc-codes": {"atc-code": {"@code": "H05BA01", "level": [{"@code": "H", "#text": "SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS"}, {"@code": "H05", "#text": "CALCIUM HOMEOSTASIS"}, {"@code": "H05B", "#text": "ANTI-PARATHYROID AGENTS"}, {"@code": "H05BA", "#text": "Calcitonin preparations"}]}}, "ahfs-codes": {"ahfs-code": "68:24.00"}, "patents": {"patent": [{"number": "5733569", "country": "United States", "approved": "1995-03-31", "expires": "2015-03-31"}, {"number": "6440392", "country": "United States", "approved": "2001-02-02", "expires": "2021-02-02"}]}, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00017 sequence\nCSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.537", "source": null}, {"kind": "Isoelectric Point", "value": "8.86", "source": null}, {"kind": "Molecular Weight", "value": "3431.8530", "source": null}, {"kind": "Molecular Formula", "value": "C145H240N44O48S2", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "13186"}, {"resource": "KEGG Compound", "identifier": "C06865"}, {"resource": "KEGG Drug", "identifier": "D00249"}, {"resource": "National Drug Code Directory", "identifier": "60505-0823-6"}, {"resource": "GenBank", "identifier": "Y00765"}, {"resource": "PharmGKB", "identifier": "PA448715"}, {"resource": "UniProtKB", "identifier": "P01263"}, {"resource": "Wikipedia", "identifier": "Calcitonin"}]}, "external-links": {"external-link": {"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic2/calcit.htm"}}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0000431", "name": "Calcitonin receptor", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Bouizar Z, Fouchereau-Peron M, Taboulet J, Moukhtar MS, Milhaud G: Purification and characterization of calcitonin receptors in rat kidney membranes by covalent cross-linking techniques. Eur J Biochem. 1986 Feb 17;155(1):141-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/3004987\n# Stroop SD, Moore EE: Intracellular calcium increases mediated by a recombinant human calcitonin receptor. J Bone Miner Res. 1995 Apr;10(4):524-32. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7610922\n# Sarkar A, Dickerson IM: Cloning, characterization, and expression of a calcitonin receptor from guinea pig brain. J Neurochem. 1997 Aug;69(2):455-64. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9231703\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "unknown", "polypeptide": {"@id": "P30988", "@source": "Swiss-Prot", "name": "Calcitonin receptor", "general-function": "Involved in calcitonin receptor activity", "specific-function": "This is a receptor for calcitonin. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. The calcitonin receptor is thought to couple to the heterotrimeric guanosine triphosphate-binding protein that is sensitive to cholera toxin", "gene-name": "CALCR", "locus": "7q21.3", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "154-173\n197-216\n237-259\n277-296\n313-336\n360-377\n390-411", "signal-regions": null, "theoretical-pi": "8.71", "molecular-weight": "57304.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1440"}, {"resource": "GenAtlas", "identifier": "CALCR"}, {"resource": "GeneCards", "identifier": "CALCR"}, {"resource": "GenBank Gene Database", "identifier": "L00587"}, {"resource": "GenBank Protein Database", "identifier": "179880"}, {"resource": "IUPHAR", "identifier": "43"}, {"resource": "Guide to Pharmacology", "identifier": "11"}, {"resource": "UniProtKB", "identifier": "P30988"}, {"resource": "UniProt Accession", "identifier": "CALCR_HUMAN"}]}, "synonyms": {"synonym": ["Calcitonin receptor precursor", "CT-R"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Calcitonin receptor precursor\nMRFTFTSRCLALFLLLNHPTPILPAFSNQTYPTIEPKPFLYVVGRKKMMDAQYKCYDRMQ\nQLPAYQGEGPYCNRTWDGWLCWDDTPAGVLSYQFCPDYFPDFDPSEKVTKYCDEKGVWFK\nHPENNRTWSNYTMCNAFTPEKLKNAYVLYYLAIVGHSLSIFTLVISLGIFVFFRKLTTIF\nPLNWKYRKALSLGCQRVTLHKNMFLTYILNSMIIIIHLVEVVPNGELVRRDPVSCKILHF\nFHQYMMACNYFWMLCEGIYLHTLIVVAVFTEKQRLRWYYLLGWGFPLVPTTIHAITRAVY\nFNDNCWLSVETHLLYIIHGPVMAALVVNFFFLLNIVRVLVTKMRETHEAESHMYLKAVKA\nTMILVPLLGIQFVVFPWRPSNKMLGKIYDYVMHSLIHFQGFFVATIYCFCNNEVQTTVKR\nQWAQFKIQWNQRWGRRPSNRSARAAAAAAEAGDIPIYICHQEPRNEPANNQGEESAEIIP\nLNIIEQESSA"}, "gene-sequence": {"@format": "FASTA", "#text": ">1473 bp\nATGAGGTTCACATTTACAAGCCGGTGCTTGGCACTGTTTCTTCTTCTAAATCACCCAACC\nCCAATTCTTCCTGCCTTTTCAAATCAAACCTATCCAACAATAGAGCCCAAGCCATTTCTT\nTACGTCGTAGGACGAAAGAAGATGATGGATGCACAGTACAAATGCTATGACCGAATGCAG\nCAGTTACCCGCATACCAAGGAGAAGGTCCATATTGCAATCGCACCTGGGATGGATGGCTG\nTGCTGGGATGACACACCGGCTGGAGTATTGTCCTATCAGTTCTGCCCAGATTATTTTCCG\nGATTTTGATCCATCAGAAAAGGTTACAAAATACTGTGATGAAAAAGGTGTTTGGTTTAAA\nCATCCTGAAAACAATCGAACCTGGTCCAACTATACTATGTGCAATGCTTTCACTCCTGAG\nAAACTGAAGAATGCATATGTTCTGTACTATTTGGCTATTGTGGGTCATTCTTTGTCAATT\nTTCACCCTAGTGATTTCCCTGGGGATTTTCGTGTTTTTCAGAAAATTGACAACTATTTTT\nCCTTTGAATTGGAAATATAGGAAGGCATTGAGCCTTGGCTGCCAAAGGGTAACCCTGCAC\nAAGAACATGTTTCTTACTTACATTCTGAATTCTATGATTATCATCATCCACCTGGTTGAA\nGTAGTACCCAATGGAGAGCTCGTGCGAAGGGACCCGGTGAGCTGCAAGATTTTGCATTTT\nTTCCACCAGTACATGATGGCCTGCAACTATTTCTGGATGCTCTGTGAAGGGATCTATCTT\nCATACACTCATTGTCGTGGCTGTGTTTACTGAGAAGCAACGCTTGCGGTGGTATTATCTC\nTTGGGCTGGGGGTTCCCGCTGGTGCCAACCACTATCCATGCTATTACCAGGGCCGTGTAC\nTTCAATGACAACTGCTGGCTGAGTGTGGAAACCCATTTGCTTTACATAATCCATGGACCT\nGTCATGGCGGCACTTGTGGTCAATTTCTTCTTTTTGCTCAACATTGTCCGGGTGCTTGTG\nACCAAAATGAGGGAAACCCATGAGGCGGAATCCCACATGTACCTGAAGGCTGTGAAGGCC\nACCATGATCCTTGTGCCCCTGCTGGGAATCCAGTTTGTCGTCTTTCCCTGGAGACCTTCC\nAACAAGATGCTTGGGAAGATATATGATTACGTGATGCACTCTCTGATTCATTTCCAGGGC\nTTCTTTGTTGCGACCATCTACTGCTTCTGCAACAATGAGGTCCAAACCACCGTGAAGCGC\nCAATGGGCCCAATTCAAAATTCAGTGGAACCAGCGTTGGGGGAGGCGCCCCTCCAACCGC\nTCTGCTCGCGCTGCAGCCGCTGCTGCGGAGGCTGGCGACATCCCAATTTACATCTGCCAT\nCAGGAGCCGAGGAATGAACCAGCCAACAACCAAGGCGAGGAGAGTGCTGAGATCATCCCT\nTTGAATATCATAGAGCAAGAGTCATCTGCTTGA"}, "pfams": {"pfam": [{"identifier": "PF00002", "name": "7tm_2"}, {"identifier": "PF02793", "name": "HRM"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "secretin-like receptor activity"}, {"category": "function", "description": "calcitonin receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}]}}}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2010-09-29", "drugbank-id": [{"@primary": "true", "#text": "DB00018"}, "BIOD00023", "BTD00023"], "name": "Interferon alfa-n3", "description": "Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).", "cas-number": null, "groups": {"group": ["approved", "investigational"]}, "general-references": "# Sturgill MG, Rashidbaigi A, Liao MJ, Zhao XX, Hua J, Trout R, Knill JR, Grasing KW: Extravascular administration of interferon alfa-N3 increases serum exposure and 2-5(A) synthetase activity. J Clin Pharmacol. 2000 Jun;40(6):606-15. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10868311", "synthesis-reference": null, "indication": "For the intralesional treatment of refractory or recurring external condylomata acuminata.", "pharmacodynamics": "Interferon alfa-n3 upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase), beta-2 microglobulin, neopterin and protein kinase R.", "mechanism-of-action": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": null, "international-brands": {"international-brand": [{"name": "Alferon", "company": "Interferon Sciences Inc."}, {"name": "Alferon LDO", "company": null}, {"name": "Alferon N Injection", "company": null}]}, "mixtures": null, "packagers": {"packager": {"name": "Hemispherx Biopharma Inc.", "url": "http://www.hemispherx.net"}}, "manufacturers": null, "prices": {"price": {"description": "Alferon n 5 million unit vial", "cost": {"@currency": "USD", "#text": "412.87"}, "unit": "ml"}}, "categories": {"category": {"category": "Immunosuppressive Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": null, "atc-codes": null, "ahfs-codes": null, "patents": null, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00041", "name": "Aldesleukin", "description": "Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination."}, {"drugbank-id": "DB00363", "name": "Clozapine", "description": "Myelosuppressive Agents may enhance the adverse/toxic effect of Clozapine. Specifically, the risk for agranulocytosis may be increased."}, {"drugbank-id": "DB04817", "name": "Metamizole", "description": "May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased"}, {"drugbank-id": "DB00333", "name": "Methadone", "description": "Interferons (Alfa) may increase the serum concentration of Methadone."}, {"drugbank-id": "DB00811", "name": "Ribavirin", "description": "Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin. Hemolytic anemia has been observed."}, {"drugbank-id": "DB00495", "name": "Zidovudine", "description": "Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine."}]}, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">DB00018 sequence (alpha-2A)\nCDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI\nQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR\nKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE"}, {"@format": "FASTA", "#text": ">DB00018 sequence (alpha-2B)\nCDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI\nQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVR\nKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE"}, {"@format": "FASTA", "#text": ">DB00018 sequence (alpha-2C)\nCDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRRDFGFPQEEFGNQFQKAETIPVLHEMI\nQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVR\nKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "61 \u00b0C", "source": "Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)"}, {"kind": "Isoelectric Point", "value": "5.99", "source": null}]}, "external-identifiers": {"external-identifier": {"resource": "PharmGKB", "identifier": "PA164746228"}}, "external-links": {"external-link": {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/interferon-alfa-n3-solution.html"}}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000661", "name": "Interferon alpha/beta receptor 1", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15898717\n# Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19955815\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P17181", "@source": "Swiss-Prot", "name": "Interferon alpha/beta receptor 1", "general-function": "Involved in interferon-alpha/beta receptor activity", "specific-function": "Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta- subunits themselves", "gene-name": "IFNAR1", "locus": null, "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "437-457", "signal-regions": null, "theoretical-pi": "5.56", "molecular-weight": "63526.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5432"}, {"resource": "GenAtlas", "identifier": "IFNAR1"}, {"resource": "GeneCards", "identifier": "IFNAR1"}, {"resource": "GenBank Gene Database", "identifier": "J03171"}, {"resource": "GenBank Protein Database", "identifier": "306914"}, {"resource": "UniProtKB", "identifier": "P17181"}, {"resource": "UniProt Accession", "identifier": "INAR1_HUMAN"}]}, "synonyms": {"synonym": ["IFN-alpha-REC", "Interferon-alpha/beta receptor alpha chain precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interferon-alpha/beta receptor alpha chain precursor\nMMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT\nFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF\nTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI\nENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ\nNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK\nGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP\nVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV\nFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE\nYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN\nEDESESKTSEELQQDFV"}, "gene-sequence": {"@format": "FASTA", "#text": ">1674 bp\nATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGGCCCATGGGTG\nTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC\nATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT\nTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG\nAATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT\nAAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT\nACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG\nGCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT\nTTAAGCTTTACATATAGCTTACTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT\nGAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA\nAAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT\nATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA\nAATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG\nTGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA\nCCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA\nGGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA\nGAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA\nTCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT\nGTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT\nGAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT\nGTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT\nTTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA\nGTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC\nTTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG\nTATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA\nAAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT\nGATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT\nGAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA"}, "pfams": null, "go-classifiers": null}}, {"id": "BE0000385", "name": "Interferon alpha/beta receptor 2", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15898717\n# Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19955815\n# Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16953837\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P48551", "@source": "Swiss-Prot", "name": "Interferon alpha/beta receptor 2", "general-function": "Involved in interferon-alpha/beta receptor activity", "specific-function": "Receptor for interferons alpha and beta. Isoform 1 and isoform 3 are directly involved in signal transduction due to their interaction with the TYR kinase, JAK1. Isoform 1 also interacts with the transcriptional factors, STAT1 and STAT2. Both forms are potent inhibitors of type I IFN activity", "gene-name": "IFNAR2", "locus": null, "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "244-264", "signal-regions": null, "theoretical-pi": "4.11", "molecular-weight": "57759.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5433"}, {"resource": "GenAtlas", "identifier": "IFNAR2"}, {"resource": "GeneCards", "identifier": "IFNAR2"}, {"resource": "GenBank Gene Database", "identifier": "L42243"}, {"resource": "GenBank Protein Database", "identifier": "995300"}, {"resource": "UniProtKB", "identifier": "P48551"}, {"resource": "UniProt Accession", "identifier": "INAR2_HUMAN"}]}, "synonyms": {"synonym": ["IFN-alpha-REC", "IFN-R", "Interferon alpha/beta receptor 2", "Interferon-alpha/beta receptor beta chain precursor", "Type I interferon receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interferon-alpha/beta receptor beta chain precursor\nMLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS\nIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF\nSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK\nHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE\nSAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD\nMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI\nDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR\nITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT\nFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR"}, "gene-sequence": {"@format": "FASTA", "#text": ">1548 bp\nATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT\nATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT\nTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC\nATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG\nGTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA\nAGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC\nAGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG\nATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA\nGAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG\nCATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA\nATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA\nATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA\nTCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC\nATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG\nAATTTTCATAACTTTTTAGCCTGGCCATTTCCTAACCTGCCACCGTTGGAAGCCATGGAT\nATGGTGGAGGTCATTTACATCAACAGAAAGAAGAAAGTGTGGGATTATAATTATGATGAT\nGAAAGTGATAGCGATACTGAGGCAGCGCCCAGGACAAGTGGCGGTGGCTATACCATGCAT\nGGACTGACTGTCAGGCCTCTGGGTCAGGCCTCTGCCACCTCTACAGAATCCCAGTTGATA\nGACCCGGAGTCCGAGGAGGAGCCTGACCTGCCTGAGGTTGATGTGGAGCTCCCCACGATG\nCCAAAGGACAGCCCTCAGCAGTTGGAACTCTTGAGTGGGCCCTGTGAGAGGAGAAAGAGT\nCCACTCCAGGACCCTTTTCCCGAAGAGGACTACAGCTCCACGGAGGGGTCTGGGGGCAGA\nATTACCTTCAATGTGGACTTAAACTCTGTGTTTTTGAGAGTTCTTGATGACGAGGACAGT\nGACGACTTAGAAGCCCCTCTGATGCTATCGTCTCATCTGGAAGAGATGGTTGACCCAGAG\nGATCCTGATAATGTGCAATCAAACCATTTGCTGGCCAGCGGGGAAGGGACACAGCCAACC\nTTTCCCAGCCCCTCTTCAGAGGGCCTGTGGTCCGAAGATGCTCCATCTGATCAAAGTGAC\nACTTCTGAGTCAGATGTTGACCTTGGGGATGGTTATATAATGAGATGA"}, "pfams": null, "go-classifiers": null}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2011-12-20", "drugbank-id": [{"@primary": "true", "#text": "DB00019"}, "BIOD00094", "BTD00094"], "name": "Pegfilgrastim", "description": "PEGylated (at N terminus) form of human G-CSF (Granulocyte colony stimulating factor), 175 residues, produced from E. coli via bacterial fermentation.", "cas-number": "208265-92-3", "groups": {"group": "approved"}, "general-references": "# Yang BB, Kido A: Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet. 2011 May 1;50(5):295-306. doi: 10.2165/11586040-000000000-00000. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/21456630", "synthesis-reference": null, "indication": "Increases leukocyte production, for treatment in non-myeloid cancer, neutropenia and bone marrow transplant", "pharmacodynamics": "Used in the treatment of chemotherapy-induced neutropenia by enhancing the production of neutrophils. Pegfilgrastim acts on hematopoietic cells by binding to specific cell surface receptors thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. Pegfilgrastim has reduced renal clearance and prolonged persistence in vivo as compared to Filgrastim.", "mechanism-of-action": "Pegfilgrastim binds to the G-CSF receptor. As a G-CSF analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Pegfilgrastim also stimulates the release of neutrophils from bone marrow storage pools and reduces their maturation time. Pegfilgrastim acts to increase the phagocytic activity of mature neutrophils. In patients receiving cytotoxic chemotherapy, pegfilgrastim can accelerate neutrophil recovery, leading to a reduction in duration of the neutropenic phase", "toxicity": null, "metabolism": null, "absorption": null, "half-life": "15-80 hrs", "protein-binding": null, "route-of-elimination": "Filgrastim is primarily eliminated by the kidney and neutrophils/neutrophil precursors; the latter presumably involves binding of the growth factor to the G-CSF receptor on the cell surface, internalization of the growth factor-receptor complexes via endocytosis, and subsequent degradation inside the cells. Pegylation of filgrastim renders renal clearance insignificant, which was demonstrated in bilaterally nephrectomized rats and confirmed in subjects with renal impairment. As a result, the neutrophil-mediated clearance is the predominant elimination pathway for pegfilgrastim. During chemotherapy-induced neutropenia, the clearance of pegfilgrastim is significantly reduced and the concentration of pegfilgrastim is sustained until onset of neutrophil recovery.", "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "G-CSF"}, {"@language": "", "@coder": "", "#text": "Granulocyte colony-stimulating factor precursor"}, {"@language": "", "@coder": "", "#text": "Lenograstim"}, {"@language": "", "@coder": "IUPAC", "#text": "N-(3-Hydroxypropyl)Methionylcolony-stimulating Factor (human), 1-Ether with .Alpha.-Methyl-.Omega.-Hydroxypoly(Oxyethylene)"}, {"@language": "", "@coder": "", "#text": "Pluripoietin"}]}, "products": {"product": [{"name": "Neulasta", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02249790", "started-marketing-on": "2004-03-12", "ended-marketing-on": null, "dosage-form": "solution", "strength": "10 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Neulasta", "ndc-id": "55513-190_46514a8d-2de6-484b-9f40-0f3bd19458c6", "ndc-product-code": "55513-190", "dpd-id": null, "started-marketing-on": "2002-04-01", "ended-marketing-on": null, "dosage-form": "injection", "strength": "6 mg/.6mL", "route": "subcutaneous", "fda-application-number": "BLA125031", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Neulasta", "ingredients": "Pegfilgrastim"}, {"name": "Neulasta", "ingredients": "Pegfilgrastim"}]}, "packagers": {"packager": [{"name": "Amgen Inc.", "url": "http://www.amgen.com"}, {"name": "Physicians Total Care Inc.", "url": "http://www.physicianstotalcare.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Neulasta 6 mg/0.6ml Solution 0.6ml Syringe", "cost": {"@currency": "USD", "#text": "4026.05"}, "unit": "syringe"}, {"description": "Neulasta 6 mg/0.6 ml syringe", "cost": {"@currency": "USD", "#text": "4102.37"}, "unit": "syringe"}]}, "categories": {"category": [{"category": "Immunosuppressive Agents", "mesh-id": null}, {"category": "Antineutropenic Agents", "mesh-id": null}]}, "affected-organisms": null, "dosages": {"dosage": [{"form": "Injection", "route": "subcutaneous", "strength": "6 mg/.6mL"}, {"form": "Solution", "route": "subcutaneous", "strength": "10 mg"}]}, "atc-codes": {"atc-code": {"@code": "L03AA13", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L03", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03A", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03AA", "#text": "Colony stimulating factors"}]}}, "ahfs-codes": {"ahfs-code": "20:16.00"}, "patents": {"patent": [{"number": "1339071", "country": "Canada", "approved": "1997-07-29", "expires": "2014-07-29"}, {"number": "1341537", "country": "Canada", "approved": "2007-07-31", "expires": "2024-07-31"}]}, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": {"@format": "FASTA", "#text": "> Pegfilgrastim sequence\nMTPLGPASSLPQSFLLKCLEQVRKIQGDGAALQEKLCATYKLCHPEELVLLGHSLGIPWA\nPLSSCPSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQ\nQMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLAQP"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "60 \u00b0C", "source": "Luo, P., Protein Science 11:1218-1226 (2002)"}, {"kind": "Hydrophobicity", "value": "0.209", "source": null}, {"kind": "Isoelectric Point", "value": "5.65", "source": null}, {"kind": "Molecular Weight", "value": "18802.8000", "source": null}, {"kind": "Molecular Formula", "value": "C845H1343N223O243S9", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "12313"}, {"resource": "KEGG Drug", "identifier": "D06889"}, {"resource": "National Drug Code Directory", "identifier": "55513-190-01"}, {"resource": "GenBank", "identifier": "X03438"}, {"resource": "PharmGKB", "identifier": "PA164781387"}, {"resource": "UniProtKB", "identifier": "P09919"}, {"resource": "Wikipedia", "identifier": "Pegfilgrastim"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/neulasta.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/pegfilgrastim.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000793", "name": "Granulocyte colony-stimulating factor receptor", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Erkeland SJ, Aarts LH, Irandoust M, Roovers O, Klomp A, Valkhof M, Gits J, Eyckerman S, Tavernier J, Touw IP: Novel role of WD40 and SOCS box protein-2 in steady-state distribution of granulocyte colony-stimulating factor receptor and G-CSF-controlled proliferation and differentiation signaling. Oncogene. 2007 Mar 29;26(14):1985-94. Epub 2006 Sep 25. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17001306\n# Elsasser A, Franzen M, Kohlmann A, Weisser M, Schnittger S, Schoch C, Reddy VA, Burel S, Zhang DE, Ueffing M, Tenen DG, Hiddemann W, Behre G: The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner. Oncogene. 2003 Aug 28;22(36):5646-57. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12944913\n# Ward AC: The role of the granulocyte colony-stimulating factor receptor (G-CSF-R) in disease. Front Biosci. 2007 Jan 1;12:608-18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17127322\n# Zhuang D, Qiu Y, Haque SJ, Dong F: Tyrosine 729 of the G-CSF receptor controls the duration of receptor signaling: involvement of SOCS3 and SOCS1. J Leukoc Biol. 2005 Oct;78(4):1008-15. Epub 2005 Jul 20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16033816\n# Cao YR, Shao ZH, Liu H, Shi J, Bai J, Tu MF, Wang HQ, Xing LM, Cui ZZ, Sun J, Jia HR, Yang TY: [The response of bone marrow hematopoietic cells to G-CSF in paroxysmal nocturnal hemoglobinuria patients] Zhonghua Xue Ye Xue Za Zhi. 2005 Apr;26(4):235-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15949269\n# Kotto-Kome AC, Fox SE, Lu W, Yang BB, Christensen RD, Calhoun DA: Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol Res. 2004 Jul;50(1):55-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15082029", "known-action": "yes", "polypeptide": {"@id": "Q99062", "@source": "Swiss-Prot", "name": "Granulocyte colony-stimulating factor receptor", "general-function": "Involved in hematopoietin/interferon-class (D200-domain) cytokine receptor activity", "specific-function": "Receptor for granulocyte colony-stimulating factor. In addition it may function in some adhesion or recognition events at the cell surface", "gene-name": "CSF3R", "locus": "1p35-p34.3", "cellular-location": "Cell membrane; single-pass type I membrane protein. Isoform GCSFR2:Secreted protein (Probable). Isof", "transmembrane-regions": "628-650", "signal-regions": null, "theoretical-pi": "6.14", "molecular-weight": "92157.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2439"}, {"resource": "GenAtlas", "identifier": "CSF3R"}, {"resource": "GeneCards", "identifier": "CSF3R"}, {"resource": "GenBank Gene Database", "identifier": "X55721"}, {"resource": "GenBank Protein Database", "identifier": "31697"}, {"resource": "UniProtKB", "identifier": "Q99062"}, {"resource": "UniProt Accession", "identifier": "CSF3R_HUMAN"}]}, "synonyms": {"synonym": ["CD114 antigen", "G-CSF-R", "Granulocyte colony-stimulating factor receptor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Granulocyte colony-stimulating factor receptor precursor\nMARLGNCSLTWAALIILLLPGSLEECGHISVSAPIVHLGDPITASCIIKQNCSHLDPEPQ\nILWRLGAELQPGGRQQRLSDGTQESIITLPHLNHTQAFLSCCLNWGNSLQILDQVELRAG\nYPPAIPHNLSCLMNLTTSSLICQWEPGPETHLPTSFTLKSFKSRGNCQTQGDSILDCVPK\nDGQSHCCIPRKHLLLYQNMGIWVQAENALGTSMSPQLCLDPMDVVKLEPPMLRTMDPSPE\nAAPPQAGCLQLCWEPWQPGLHINQKCELRHKPQRGEASWALVGPLPLEALQYELCGLLPA\nTAYTLQIRCIRWPLPGHWSDWSPSLELRTTERAPTVRLDTWWRQRQLDPRTVQLFWKPVP\nLEEDSGRIQGYVVSWRPSGQAGAILPLCNTTELSCTFHLPSEAQEVALVAYNSAGTSRPT\nPVVFSESRGPALTRLHAMARDPHSLWVGWEPPNPWPQGYVIEWGLGPPSASNSNKTWRME\nQNGRATGFLLKENIRPFQLYEIIVTPLYQDTMGPSQHVYAYSQEMAPSHAPELHLKHIGK\nTWAQLEWVPEPPELGKSPLTHYTIFWTNAQNQSFSAILNASSRGFVLHGLEPASLYHIHL\nMAASQAGATNSTVLTLMTLTPEGSELHIILGLFGLLLLLTCLCGTAWLCCSPNRKNPLWP\nSVPDPAHSSLGSWVPTIMEEDAFQLPGLGTPPITKLTVLEEDEKKPVPWESHNSSETCGL\nPTLVQTYVLQGDPRAVSTQPQSQSGTSDQVLYGQLLGSPTSPGPGHYLRCDSTQPLLAGL\nTPSPKSYENLWFQASPLGTLVTPAPSQEDDCVFGPLLNFPLLQGIRVHGMEALGSF"}, "gene-sequence": {"@format": "FASTA", "#text": ">2511 bp\nATGGCAAGGCTGGGAAACTGCAGCCTGACTTGGGCTGCCCTGATCATCCTGCTGCTCCCC\nGGAAGTCTGGAGGAGTGCGGGCACATCAGTGTCTCAGCCCCCATCGTCCACCTGGGGGAT\nCCCATCACAGCCTCCTGCATCATCAAGCAGAACTGCAGCCATCTGGACCCGGAGCCACAG\nATTCTGTGGAGACTGGGAGCAGAGCTTCAGCCCGGGGGCAGGCAGCAGCGTCTGTCTGAT\nGGGACCCAGGAATCTATCATCACCCTGCCCCACCTCAACCACACTCAGGCCTTTCTCTCC\nTGCTGCCTGAACTGGGGCAACAGCCTGCAGATCCTGGACCAGGTTGAGCTGCGCGCAGGC\nTACCCTCCAGCCATACCCCACAACCTCTCCTGCCTCATGAACCTCACAACCAGCAGCCTC\nATCTGCCAGTGGGAGCCAGGACCTGAGACCCACCTACCCACCAGCTTCACTCTGAAGAGT\nTTCAAGAGCCGGGGCAACTGTCAGACCCAAGGGGACTCCATCCTGGACTGCGTGCCCAAG\nGACGGGCAGAGCCACTGCTGCATCCCACGCAAACACCTGCTGTTGTACCAGAATATGGGC\nATCTGGGTGCAGGCAGAGAATGCGCTGGGGACCAGCATGTCCCCACAACTGTGTCTTGAT\nCCCATGGATGTTGTGAAACTGGAGCCCCCCATGCTGCGGACCATGGACCCCAGCCCTGAA\nGCGGCCCCTCCCCAGGCAGGCTGCCTACAGCTGTGCTGGGAGCCATGGCAGCCAGGCCTG\nCACATAAATCAGAAGTGTGAGCTGCGCCACAAGCCGCAGCGTGGAGAAGCCAGCTGGGCA\nCTGGTGGGCCCCCTCCCCTTGGAGGCCCTTCAGTATGAGCTCTGCGGGCTCCTCCCAGCC\nACGGCCTACACCCTGCAGATACGCTGCATCCGCTGGCCCCTGCCTGGCCACTGGAGCGAC\nTGGAGCCCCAGCCTGGAGCTGAGAACTACCGAACGGGCCCCCACTGTCAGACTGGACACA\nTGGTGGCGGCAGAGGCAGCTGGACCCCAGGACAGTGCAGCTGTTCTGGAAGCCAGTGCCC\nCTGGAGGAAGACAGCGGACGGATCCAAGGTTATGTGGTTTCTTGGAGACCCTCAGGCCAG\nGCTGGGGCCATCCTGCCCCTCTGCAACACCACAGAGCTCAGCTGCACCTTCCACCTGCCT\nTCAGAAGCCCAGGAGGTGGCCCTTGTGGCCTATAACTCAGCCGGGACCTCTCGCCCCACC\nCCGGTGGTCTTCTCAGAAAGCAGAGGCCCAGCTCTGACCAGACTCCATGCCATGGCCCGA\nGACCCTCACAGCCTCTGGGTAGGCTGGGAGCCCCCCAATCCATGGCCTCAGGGCTATGTG\nATTGAGTGGGGCCTGGGCCCCCCCAGCGCGAGCAATAGCAACAAGACCTGGAGGATGGAA\nCAGAATGGGAGAGCCACGGGGTTTCTGCTGAAGGAGAACATCAGGCCCTTTCAGCTCTAT\nGAGATCATCGTGACTCCCTTGTACCAGGACACCATGGGACCCTCCCAGCATGTCTATGCC\nTACTCTCAAGAAATGGCTCCCTCCCATGCCCCAGAGCTGCATCTAAAGCACATTGGCAAG\nACCTGGGCACAGCTGGAGTGGGTGCCTGAGCCCCCTGAGCTGGGGAAGAGCCCCCTTACC\nCACTACACCATCTTCTGGACCAACGCTCAGAACCAGTCCTTCTCCGCCATCCTGAATGCC\nTCCTCCCGTGGCTTTGTCCTCCATGGCCTGGAGCCCGCCAGTCTGTATCACATCCACCTC\nATGGCTGCCAGCCAGGCTGGGGCCACCAACAGTACAGTCCTCACCCTGATGACCTTGACC\nCCAGAGGGGTCGGAGCTACACATCATCCTGGGCCTGTTCGGCCTCCTGCTGTTGCTCACC\nTGCCTCTGTGGAACTGCCTGGCTCTGTTGCAGCCCCAACAGGAAGAATCCCCTCTGGCCA\nAGTGTCCCAGACCCAGCTCACAGCAGCCTGGGCTCCTGGGTGCCCACAATCATGGAGGAG\nGATGCCTTCCAGCTGCCCGGCCTTGGCACGCCACCCATCACCAAGCTCACAGTGCTGGAG\nGAGGATGAAAAGAAGCCGGTGCCCTGGGAGTCCCATAACAGCTCAGAGACCTGTGGCCTC\nCCCACTCTGGTCCAGACCTATGTGCTCCAGGGGGACCCAAGAGCAGTTTCCACCCAGCCC\nCAATCCCAGTCTGGCACCAGCGATCAGGTCCTTTATGGGCAGCTGCTGGGCAGCCCCACA\nAGCCCAGGGCCAGGGCACTATCTCCGCTGTGACTCCACTCAGCCCCTCTTGGCGGGCCTC\nACCCCCAGCCCCAAGTCCTATGAGAACCTCTGGTTCCAGGCCAGCCCCTTGGGGACCCTG\nGTAACCCCAGCCCCAAGCCAGGAGGACGACTGTGTCTTTGGGCCACTGCTCAACTTCCCC\nCTCCTGCAGGGGATCCGGGTCCATGGGATGGAGGCGCTGGGGAGCTTCTAG"}, "pfams": {"pfam": [{"identifier": "PF00041", "name": "fn3"}, {"identifier": "PF06328", "name": "Lep_receptor_Ig"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "hematopoietin/interferon-class (D200-domain) cytokine receptor activity"}]}}}, {"id": "BE0000394", "name": "Neutrophil elastase", "organism": "Human", "actions": null, "references": "# Carter CR, Whitmore KM, Thorpe R: The significance of carbohydrates on G-CSF: differential sensitivity of G-CSFs to human neutrophil elastase degradation. J Leukoc Biol. 2004 Mar;75(3):515-22. Epub 2003 Dec 4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14657210\n# Jian MY, Koizumi T, Tsushima K, Fujimoto K, Kubo K: Effects of granulocyte colony-stimulating factor (G-CSF) and neutrophil elastase inhibitor (ONO-5046) on acid-induced lung injury in rats. Inflammation. 2004 Dec;28(6):327-36. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16245075\n# Pelus LM, Bian H, King AG, Fukuda S: Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRObeta/CXCL2 and GRObetaT/CXCL2delta4. Blood. 2004 Jan 1;103(1):110-9. Epub 2003 Sep 4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12958067\n# Druhan LJ, Ai J, Massullo P, Kindwall-Keller T, Ranalli MA, Avalos BR: Novel mechanism of G-CSF refractoriness in patients with severe congenital neutropenia. Blood. 2005 Jan 15;105(2):584-91. Epub 2004 Sep 7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15353486\n# Schepers H, Wierenga AT, van Gosliga D, Eggen BJ, Vellenga E, Schuringa JJ: Reintroduction of C/EBPalpha in leukemic CD34+ stem/progenitor cells impairs self-renewal and partially restores myelopoiesis. Blood. 2007 Aug 15;110(4):1317-25. Epub 2007 May 2. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17475913", "known-action": "unknown", "polypeptide": {"@id": "P08246", "@source": "Swiss-Prot", "name": "Neutrophil elastase", "general-function": "Involved in elastase activity and cytokine binding", "specific-function": "Modifies the functions of natural killer cells, monocytes and granulocytes. Inhibits C5a-dependent neutrophil enzyme release and chemotaxis", "gene-name": "ELANE", "locus": "19p13.3", "cellular-location": "Cytoplasmic", "transmembrane-regions": "7-26", "signal-regions": null, "theoretical-pi": "9.41", "molecular-weight": "28518.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3309"}, {"resource": "GenAtlas", "identifier": "ELA2"}, {"resource": "GeneCards", "identifier": "ELA2"}, {"resource": "GenBank Gene Database", "identifier": "Y00477"}, {"resource": "GenBank Protein Database", "identifier": "296665"}, {"resource": "UniProtKB", "identifier": "P08246"}, {"resource": "UniProt Accession", "identifier": "ELNE_HUMAN"}]}, "synonyms": {"synonym": ["Bone marrow serine protease", "EC 3.4.21.37", "Elastase-2", "HLE", "Human leukocyte elastase", "Leukocyte elastase precursor", "Medullasin", "Neutrophil elastase", "PMN elastase"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Leukocyte elastase precursor\nMTLGRRLACLFLACVLPALLLGGTALASEIVGGRRARPHAWPFMVSLQLRGGHFCGATLI\nAPNFVMSAAHCVANVNVRAVRVVLGAHNLSRREPTRQVFAVQRIFENGYDPVNLLNDIVI\nLQLNGSATINANVQVAQLPAQGRRLGNGVQCLAMGWGLLGRNRGIASVLQELNVTVVTSL\nCRRSNVCTLVRGRQAGVCFGDSGSPLVCNGLIHGIASFVRGGCASGLYPDAFAPVAQFVN\nWIDSIIQRSEDNPCPHPRDPDPASRTH"}, "gene-sequence": {"@format": "FASTA", "#text": ">804 bp\nATGACCCTCGGCCGCCGACTCGCGTGTCTTTTCCTCGCCTGTGTCCTGCCGGCCTTGCTG\nCTGGGGGGCACCGCGCTGGCCTCGGAGATTGTGGGGGGCCGGCGAGCGCGGCCCCACGCG\nTGGCCCTTCATGGTGTCCCTGCAGCTGCGCGGAGGCCACTTCTGCGGCGCCACCCTGATT\nGCGCCCAACTTCGTCATGTCGGCCGCGCACTGCGTGGCGAATGTAAACGTCCGCGCGGTG\nCGGGTGGTCCTGGGAGCCCATAACCTCTCGCGGCGGGAGCCCACCCGGCAGGTGTTCGCC\nGTGCAGCGCATCTTCGAAAACGGCTACGACCCCGTAAACTTGCTCAACGACATCGTGATT\nCTCCAGCTCAACGGGTCGGCCACCATCAACGCCAACGTGCAGGTGGCCCAGCTGCCGGCT\nCAGGGACGCCGCCTGGGCAACGGGGTGCAGTGCCTGGCCATGGGCTGGGGCCTTCTGGGC\nAGGAACCGTGGGATCGCCAGCGTCCTGCAGGAGCTCAACGTGACGGTGGTGACGTCCCTC\nTGCCGTCGCAGCAACGTCTGCACTCTCGTGAGGGGCCGGCAGGCCGGCGTCTGTTTCGGG\nGACTCCGGCAGCCCCTTGGTCTGCAACGGGCTAATCCACGGAATTGCCTCCTTCGTCCGG\nGGAGGCTGCGCCTCAGGGCTCTACCCCGATGCCTTTGCCCCGGTGGCACAGTTTGTAAAC\nTGGATCGACTCTATCATCCAACGCTCCGAGGACAACCCCTGTCCCCACCCCCGGGACCCG\nGACCCGGCCAGCAGGACCCACTGA"}, "pfams": {"pfam": {"identifier": "PF00089", "name": "Trypsin"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-10-03", "drugbank-id": [{"@primary": "true", "#text": "DB00020"}, "BIOD00035", "BTD00035"], "name": "Sargramostim", "description": "Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.", "cas-number": "83869-56-1", "groups": {"group": ["approved", "investigational"]}, "general-references": null, "synthesis-reference": "Kaname Sugimoto, \"Process for the production of human colony-stimulating factor.\" U.S. Patent US4621050, issued May, 1983.", "indication": "For the treatment of cancer and bone marrow transplant", "pharmacodynamics": "Sargramostim is used in the treatment of bone marrow transplant recipients or those exposed to chemotherapy an recovering from acut myelogenous leukemia, Leukine or GM-CSF is a hematopoietic growth factor which stimulates the survival, clonal expansion (proliferation) and differentiation of hematopoietic progenitor cells. GM-CSF is also capable of activating mature granulocytes and macrophages. After a bone marrow transplant or chemotherapy, patients have a reduced capacity to produce red and white blood cells. Supplementing them with external sources of GM-CSF helps bring the level of neutrophils back to normal so that they can better fight infections.", "mechanism-of-action": "Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway. This leads to the production of hemopoietic cells and neutrophils", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": "* 420 mL/min/m2 [Normal people with liquid LEUKINE (IV)]\n* 431 mL/min/m2 [Normal people with lyophilized LEUKINE (IV)]\n* 549 mL/min/m2 [Normal people with liquid LEUKINE (SC)]\n* 529 mL/min/m2 [Normal people with lyophilized LEUKINE (SC)]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": {"@language": "", "@coder": "", "#text": "GM-CSF"}}, "products": {"product": [{"name": "Leukine", "ndc-id": "58468-0180_4c805287-5661-452a-91c6-da688bebc400", "ndc-product-code": "58468-0180", "dpd-id": null, "started-marketing-on": "2010-03-15", "ended-marketing-on": "2016-06-30", "dosage-form": "injection, powder, for solution", "strength": "250 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103362", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Leukine", "ndc-id": "0024-5843_95b04916-3ce2-4785-b102-35b1d3984d59", "ndc-product-code": "0024-5843", "dpd-id": null, "started-marketing-on": "1991-05-01", "ended-marketing-on": null, "dosage-form": "injection, powder, for solution", "strength": "250 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103362", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Leukine", "ndc-id": "0024-5844_95b04916-3ce2-4785-b102-35b1d3984d59", "ndc-product-code": "0024-5844", "dpd-id": null, "started-marketing-on": "1996-12-01", "ended-marketing-on": null, "dosage-form": "liquid", "strength": "500 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103362", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}]}, "international-brands": {"international-brand": {"name": "Leucomax", "company": "Novartis"}}, "mixtures": {"mixture": [{"name": "Leukine", "ingredients": "Sargramostim"}, {"name": "Leukine", "ingredients": "Sargramostim"}, {"name": "Leukine", "ingredients": "Sargramostim"}]}, "packagers": {"packager": [{"name": "Bayer Healthcare", "url": "http://www.bayerhealthcare.com"}, {"name": "Genzyme Inc.", "url": "http://www.genzyme.ca"}, {"name": "Hospira Inc.", "url": "http://www.hospira.com"}, {"name": "Kramer-Novis", "url": "http://www.kramernovis.com"}, {"name": "Physicians Total Care Inc.", "url": "http://www.physicianstotalcare.com"}, {"name": "Wyeth Pharmaceuticals", "url": "http://www.wyeth.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Leukine 250 mcg vial", "cost": {"@currency": "USD", "#text": "204.79"}, "unit": "vial"}, {"description": "Bio-immunex capsule", "cost": {"@currency": "USD", "#text": "0.42"}, "unit": "capsule"}]}, "categories": {"category": {"category": "Immunosuppressive Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, powder, for solution", "route": "intravenous; subcutaneous", "strength": "250 ug/mL"}, {"form": "Liquid", "route": "intravenous; subcutaneous", "strength": "500 ug/mL"}]}, "atc-codes": {"atc-code": {"@code": "L03AA09", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L03", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03A", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03AA", "#text": "Colony stimulating factors"}]}}, "ahfs-codes": null, "patents": {"patent": {"number": "1341150", "country": "Canada", "approved": "2000-12-05", "expires": "2017-12-05"}}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00290", "name": "Bleomycin", "description": "Sargramostim may enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased."}, {"drugbank-id": "DB00531", "name": "Cyclophosphamide", "description": "May enhance the adverse/toxic effect of Sargramostim. Specifically, the risk of pulmonary toxicity may be enhanced."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00020 sequence\nAPARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLE\nLYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFD\nCWEPVQE"}}, "experimental-properties": {"property": [{"kind": "Isoelectric Point", "value": "5.05", "source": null}, {"kind": "Molecular Weight", "value": "14434.5000", "source": null}, {"kind": "Molecular Formula", "value": "C639H1006N168O196S8", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "National Drug Code Directory", "identifier": "50419-002-33"}, {"resource": "GenBank", "identifier": "M13207"}, {"resource": "PharmGKB", "identifier": "PA164748631"}, {"resource": "UniProtKB", "identifier": "P04141"}, {"resource": "Wikipedia", "identifier": "Sargramostim"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/sargramostim.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/sargramostim.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000628", "name": "Granulocyte-macrophage colony-stimulating factor receptor subunit alpha", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW, Hochhaus A, Neubauer A, Burchert A: Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood. 2007 Mar 1;109(5):2147-55. Epub 2006 Nov 7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17090651\n# Chen J, Carcamo JM, Golde DW: The alpha subunit of the granulocyte-macrophage colony-stimulating factor receptor interacts with c-Kit and inhibits c-Kit signaling. J Biol Chem. 2006 Aug 4;281(31):22421-6. Epub 2006 Jun 7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16760463\n# Lencz T, Morgan TV, Athanasiou M, Dain B, Reed CR, Kane JM, Kucherlapati R, Malhotra AK: Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry. 2007 Jun;12(6):572-80. Epub 2007 Mar 20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17522711\n# Xiao R, Zhang R, Wang YL, Zhu ZL, Chen T, Yang JH: [Expression of soluble GM-CSF-Ralpha in patients with acute myeloid leukemia] Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Apr;14(2):225-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16638185\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P15509", "@source": "Swiss-Prot", "name": "Granulocyte-macrophage colony-stimulating factor receptor subunit alpha", "general-function": "Involved in hematopoietin/interferon-class (D200-domain) cytokine receptor activity", "specific-function": "Low affinity receptor for granulocyte-macrophage colony- stimulating factor. Transduces a signal that results in the proliferation, differentiation, and functional activation of hematopoietic cells", "gene-name": "CSF2RA", "locus": "Xp22.32 and Yp11.3", "cellular-location": "Cell membrane; single-pass type I membrane protein. Isoform 3:Secreted protein (Probable) protein. I", "transmembrane-regions": "321-346", "signal-regions": null, "theoretical-pi": "7.81", "molecular-weight": "46207.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2435"}, {"resource": "GenAtlas", "identifier": "CSF2RA"}, {"resource": "GeneCards", "identifier": "CSF2RA"}, {"resource": "GenBank Gene Database", "identifier": "X17648"}, {"resource": "GenBank Protein Database", "identifier": "32089"}, {"resource": "UniProtKB", "identifier": "P15509"}, {"resource": "UniProt Accession", "identifier": "CSF2R_HUMAN"}]}, "synonyms": {"synonym": ["CD116 antigen", "CDw116", "GM-CSF-R-alpha", "GMR", "Granulocyte-macrophage colony-stimulating factor receptor alpha chain precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Granulocyte-macrophage colony-stimulating factor receptor alpha chain precursor\nMLLLVTSLLLCELPHPAFLLIPEKSDLRTVAPASSLNVRFDSRTMNLSWDCQENTTFSKC\nFLTDKKNRVVEPRLSNNECSCTFREICLHEGVTFEVHVNTSQRGFQQKLLYPNSGREGTA\nAQNFSCFIYNADLMNCTWARGPTAPRDVQYFLYIRNSKRRREIRCPYYIQDSGTHVGCHL\nDNLSGLTSRNYFLVNGTSREIGIQFFDSLLDTKKIERFNPPSNVTVRCNTTHCLVRWKQP\nRTYQKLSYLDFQYQLDVHRKNTQPGTENLLINVSGDLENRYNFPSSEPRAKHSVKIRAAD\nVRILNWSSWSEAIEFGSDDGNLGSVYIYVLLIVGTLVCGIVLGFLFKRFLRIQRLFPPVP\nQIKDKLNDNHEVEDEIIWEEFTPEEGKGYREEVLTVKEIT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1203 bp\nATGCTTCTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCCTCCTG\nATCCCAGAGAAATCGGATCTGCGAACAGTGGCACCAGCCTCTAGTCTCAATGTGAGGTTT\nGACTCCAGGACGATGAATTTAAGCTGGGACTGCCAAGAAAACACAACCTTCAGCAAGTGT\nTTCTTAACTGACAAGAAGAACAGAGTCGTGGAACCCAGGCTCAGTAACAACGAATGTTCG\nTGCACATTTCGTGAAATTTGTCTGCATGAAGGAGTCACATTTGAGGTTCACGTGAATACT\nAGTCAAAGAGGATTTCAACAGAAACTGCTTTATCCAAATTCAGGAAGGGAGGGTACCGCT\nGCTCAGAATTTCTCCTGTTTCATCTACAATGCGGATTTAATGAACTGTACCTGGGCGAGG\nGGTCCGACGGCCCCCCGTGACGTCCAGTATTTTTTGTACATACGAAACTCAAAGAGAAGG\nAGGGAGATCCGGTGTCCTTATTACATACAAGACTCAGGAACCCATGTGGGATGTCACCTG\nGATAACCTGTCAGGATTAACGTCTCGCAATTACTTTCTGGTTAACGGAACCAGCCGAGAA\nATTGGCATCCAATTCTTTGATTCACTTTTGGACACAAAGAAAATAGAACGATTCAACCCT\nCCCAGCAATGTCACCGTACGTTGCAACACGACGCACTGCCTCGTACGGTGGAAACAGCCC\nAGGACCTATCAGAAGCTGTCGTACCTGGACTTTCAGTACCAGCTGGACGTCCACAGAAAG\nAATACCCAGCCTGGCACGGAAAACCTACTGATTAATGTTTCTGGTGATTTGGAAAATAGA\nTACAACTTTCCAAGCTCTGAGCCCAGAGCAAAACACAGTGTGAAGATCAGAGCTGCAGAC\nGTCCGCATCTTGAATTGGAGCTCCTGGAGTGAAGCCATTGAATTTGGTTCTGACGACGGG\nAACCTCGGCTCTGTGTACATTTATGTGCTCCTAATCGTGGGAACCCTTGTCTGTGGCATC\nGTCCTCGGCTTCCTCTTTAAAAGGTTCCTTAGGATACAGCGGCTGTTCCCGCCAGTTCCA\nCAGATCAAAGACAAACTGAATGATAACCATGAGGTGGAAGACGAGATCATCTGGGAGGAA\nTTCACCCCAGAGGAAGGGAAAGGCTACCGCGAAGAGGTCTTGACCGTGAAGGAAATTACC\nTGA"}, "pfams": null, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "hematopoietin/interferon-class (D200-domain) cytokine receptor activity"}]}}}, {"@position": "2", "id": "BE0001036", "name": "Interleukin-3 receptor subunit alpha", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Eksioglu EA, Mahmood SS, Chang M, Reddy V: GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinflammatory response. Exp Hematol. 2007 Aug;35(8):1163-71. Epub 2007 Jun 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17562355\n# Sakhno LV, Leplina OIu, Tikhonova MA, Raspai ZhM, Gileva IP, Nikonov SD, Zhdanov OA, Ostanin AA, Chernykh ER: [Characteristics of A-interferon-generated dendritic cells in patients with pulmonary tuberculosis] Probl Tuberk Bolezn Legk. 2007;(3):42-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17500228\n# Ward KA, Stewart LA, Schwarer AP: CD34+-derived CD11c+ + + BDCA-1+ + CD123+ + DC: expansion of a phenotypically undescribed myeloid DC1 population for use in adoptive immunotherapy. Cytotherapy. 2006;8(2):130-40. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16698686\n# Lencz T, Morgan TV, Athanasiou M, Dain B, Reed CR, Kane JM, Kucherlapati R, Malhotra AK: Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry. 2007 Jun;12(6):572-80. Epub 2007 Mar 20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17522711", "known-action": "yes", "polypeptide": {"@id": "P26951", "@source": "Swiss-Prot", "name": "Interleukin-3 receptor subunit alpha", "general-function": "Involved in hematopoietin/interferon-class (D200-domain) cytokine receptor activity", "specific-function": "This is a receptor for interleukin-3", "gene-name": "IL3RA", "locus": "Xp22.3 or Yp11.3", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "306-325", "signal-regions": null, "theoretical-pi": "8.32", "molecular-weight": "43330.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6012"}, {"resource": "GenAtlas", "identifier": "IL3RA"}, {"resource": "GeneCards", "identifier": "IL3RA"}, {"resource": "GenBank Gene Database", "identifier": "M74782"}, {"resource": "GenBank Protein Database", "identifier": "186331"}, {"resource": "UniProtKB", "identifier": "P26951"}, {"resource": "UniProt Accession", "identifier": "IL3RA_HUMAN"}]}, "synonyms": {"synonym": ["CD123 antigen", "IL-3R-alpha", "Interleukin-3 receptor alpha chain precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interleukin-3 receptor alpha chain precursor\nMVLLWLTLLLIALPCLLQTKEDPNPPITNLRMKAKAQQLTWDLNRNVTDIECVKDADYSM\nPAVNNSYCQFGAISLCEVTNYTVRVANPPFSTWILFPENSGKPWAGAENLTCWIHDVDFL\nSCSWAVGPGAPADVQYDLYLNVANRRQQYECLHYKTDAQGTRIGCRFDDISRLSSGSQSS\nHILVRGRSAAFGIPCTDKFVVFSQIEILTPPNMTAKCNKTHSFMHWKMRSHFNRKFRYEL\nQIQKRMQPVITEQVRDRTSFQLLNPGTYTVQIRARERVYEFLSAWSTPQRFECDQEEGAN\nTRAWRTSLLIALGTLLALVCVFVICRRYLVMQRLFPRIPHMKDPIGDSFQNDKLVVWEAG\nKAGLEECLVTEVQVVQKT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1137 bp\nATGGTCCTCCTTTGGCTCACGCTGCTCCTGATCGCCCTGCCCTGTCTCCTGCAAACGAAG\nGAAGATCCAAACCCACCAATCACGAACCTAAGGATGAAAGCAAAGGCTCAGCAGTTGACC\nTGGGACCTTAACAGAAATGTGACCGATATCGAGTGTGTTAAAGATGCCGACTATTCTATG\nCCGGCAGTGAACAATAGCTATTGCCAGTTTGGAGCAATTTCCTTATGTGAAGTGACCAAC\nTACACCGTCCGAGTGGCCAACCCACCATTCTCCACGTGGATCCTCTTCCCTGAGAACAGT\nGGGAAGCCTTGGGCAGGTGCGGAGAATCTGACCTGCTGGATTCATGACGTGGATTTCTTG\nAGCTGCAGCTGGGCGGTAGGCCCGGGGGCCCCCGCGGACGTCCAGTACGACCTGTACTTG\nAACGTTGCCAACAGGCGTCAACAGTACGAGTGTCTTCACTACAAAACGGATGCTCAGGGA\nACACGTATCGGGTGTCGTTTCGATGACATCTCTCGACTCTCCAGCGGTTCTCAAAGTTCC\nCACATCCTGGTGCGGGGCAGGAGCGCAGCCTTCGGTATCCCCTGCACAGATAAGTTTGTC\nGTCTTTTCACAGATTGAGATATTAACTCCACCCAACATGACTGCAAAGTGTAATAAGACA\nCATTCCTTTATGCACTGGAAAATGAGAAGTCATTTCAATCGCAAATTTCGCTATGAGCTT\nCAGATACAAAAGAGAATGCAGCCTGTAATCACAGAACAGGTCAGAGACAGAACCTCCTTC\nCAGCTACTCAATCCTGGAACGTACACAGTACAAATAAGAGCCCGGGAAAGAGTGTATGAA\nTTCTTGAGCGCCTGGAGCACCCCCCAGCGCTTCGAGTGCGACCAGGAGGAGGGCGCAAAC\nACACGTGCCTGGCGGACGTCGCTGCTGATCGCGCTGGGGACGCTGCTGGCCCTGGTCTGT\nGTCTTCGTGATCTGCAGAAGGTATCTGGTGATGCAGAGACTCTTTCCCCGCATCCCTCAC\nATGAAAGACCCCATCGGTGACAGCTTCCAAAACGACAAGCTGGTGGTCTGGGAGGCGGGC\nAAAGCCGGCCTGGAGGAGTGTCTGGTGACTGAAGTACAGGTCGTGCAGAAAACTTGA"}, "pfams": null, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "hematopoietin/interferon-class (D200-domain) cytokine receptor activity"}]}}}, {"@position": "3", "id": "BE0002115", "name": "Cytokine receptor common subunit beta", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Shen Y, Baker E, Callen DF, Sutherland GR, Willson TA, Rakar S, Gough NM: Localization of the human GM-CSF receptor beta chain gene (CSF2RB) to chromosome 22q12.2-->q13.1. Cytogenet Cell Genet. 1992;61(3):175-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1424804", "known-action": "yes", "polypeptide": {"@id": "P32927", "@source": "Swiss-Prot", "name": "Cytokine receptor common subunit beta", "general-function": null, "specific-function": "High affinity receptor for interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor", "gene-name": "CSF2RB", "locus": "22q13.1", "cellular-location": "Membrane", "transmembrane-regions": "444-460", "signal-regions": null, "theoretical-pi": "5.21", "molecular-weight": "97336.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2436"}, {"resource": "GenAtlas", "identifier": "CSF2RB"}, {"resource": "GeneCards", "identifier": "CSF2RB"}, {"resource": "GenBank Gene Database", "identifier": "M59941"}, {"resource": "GenBank Protein Database", "identifier": "487425"}, {"resource": "UniProtKB", "identifier": "P32927"}, {"resource": "UniProt Accession", "identifier": "IL3RB_HUMAN"}]}, "synonyms": {"synonym": ["CD131 antigen", "CDw131", "Cytokine receptor common beta chain precursor", "GM-CSF/IL-3/IL-5 receptor common beta-chain"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytokine receptor common beta chain\nMVLAQGLLSMALLALCWERSLAGAEETIPLQTLRCYNDYTSHITCRWADTQDAQRLVNVT\nLIRRVNEDLLEPVSCDLSDDMPWSACPHPRCVPRRCVIPCQSFVVTDVDYFSFQPDRPLG\nTRLTVTLTQHVQPPEPRDLQISTDQDHFLLTWSVALGSPQSHWLSPGDLEFEVVYKRLQD\nSWEDAAILLSNTSQATLGPEHLMPSSTYVARVRTRLAPGSRLSGRPSKWSPEVCWDSQPG\nDEAQPQNLECFFDGAAVLSCSWEVRKEVASSVSFGLFYKPSPDAGEEECSPVLREGLGSL\nHTRHHCQIPVPDPATHGQYIVSVQPRRAEKHIKSSVNIQMAPPSLNVTKDGDSYSLRWET\nMKMRYEHIDHTFEIQYRKDTATWKDSKTETLQNAHSMALPALEPSTRYWARVRVRTSRTG\nYNGIWSEWSEARSWDTESVLPMWVLALIVIFLTIAVLLALRFCGIYGYRLRRKWEEKIPN\nPSKSHLFQNGSAELWPPGSMSAFTSGSPPHQGPWGSRFPELEGVFPVGFGDSEVSPLTIE\nDPKHVCDPPSGPDTTPAASDLPTEQPPSPQPGPPAASHTPEKQASSFDFNGPYLGPPHSR\nSLPDILGQPEPPQEGGSQKSPPPGSLEYLCLPAGGQVQLVPLAQAMGPGQAVEVERRPSQ\nGAAGSPSLESGGGPAPPALGPRVGGQDQKDSPVAIPMSSGDTEDPGVASGYVSSADLVFT\nPNSGASSVSLVPSLGLPSDQTPSLCPGLASGPPGAPGPVKSGFEGYVELPPIEGRSPRSP\nRNNPVPPEAKSPVLNPGERPADVSPTSPQPEGLLVLQQVGDYCFLPGLGPGPLSLRSKPS\nSPGPGPEIKNLDQAFQVKKPPGQAVPQVPVIQLFKALKQQDYLSLPPWEVNKPGEVC"}, "gene-sequence": {"@format": "FASTA", "#text": ">2694 bp\nATGGTGCTGGCCCAGGGGCTGCTCTCCATGGCCCTGCTGGCCCTGTGCTGGGAGCGCAGC\nCTGGCAGGGGCAGAAGAAACCATCCCGCTGCAGACCCTGCGCTGCTACAACGACTACACC\nAGCCACATCACCTGCAGGTGGGCAGACACCCAGGATGCCCAGCGGCTCGTCAACGTGACC\nCTCATTCGCCGGGTGAATGAGGACCTCCTGGAGCCAGTGTCCTGTGACCTCAGTGATGAC\nATGCCCTGGTCAGCCTGCCCCCATCCCCGCTGCGTGCCCAGGAGATGTGTCATTCCCTGC\nCAGAGTTTTGTCGTCACTGACGTTGACTACTTCTCATTCCAACCAGACAGGCCTCTGGGC\nACCCGGCTCACCGTCACTCTGACCCAGCATGTCCAGCCTCCTGAGCCCAGGGACCTGCAG\nATCAGCACCGACCAGGACCACTTCCTGCTGACCTGGAGTGTGGCCCTTGGGAGTCCCCAG\nAGCCACTGGTTGTCCCCAGGGGATCTGGAGTTTGAGGTGGTCTACAAGCGGCTTCAGGAC\nTCTTGGGAGGACGCAGCCATCCTCCTCTCCAACACCTCCCAGGCCACCCTGGGGCCAGAG\nCACCTCATGCCCAGCAGCACCTACGTGGCCCGAGTACGGACCCGCCTGGCCCCAGGTTCT\nCGGCTCTCAGGACGTCCCAGCAAGTGGAGCCCAGAGGTTTGCTGGGACTCCCAGCCAGGG\nGATGAGGCCCAGCCCCAGAACCTGGAGTGCTTCTTTGACGGGGCCGCCGTGCTCAGCTGC\nTCCTGGGAGGTGAGGAAGGAGGTGGCCAGCTCGGTCTCCTTTGGCCTATTCTACAAGCCC\nAGCCCAGATGCAGGGGAGGAAGAGTGCTCCCCAGTGCTGAGGGAGGGGCTCGGCAGCCTC\nCACACCAGGCACCACTGCCAGATTCCCGTGCCCGACCCCGCGACCCACGGCCAATACATC\nGTCTCTGTTCAGCCAAGGAGGGCAGAGAAACACATAAAGAGCTCAGTGAACATCCAGATG\nGCCCCTCCATCCCTCAACGTGACCAAGGATGGAGACAGCTACAGCCTGCGCTGGGAAACA\nATGAAAATGCGATACGAACACATAGACCACACATTTGAGATCCAGTACAGGAAAGACACG\nGCCACGTGGAAGGACAGCAAGACCGAGACCCTCCAGAACGCCCACAGCATGGCCCTGCCA\nGCCCTGGAGCCCTCCACCAGGTACTGGGCCAGGGTGAGGGTCAGGACCTCCCGCACCGGC\nTACAACGGGATCTGGAGCGAGTGGAGTGAGGCGCGCTCCTGGGACACCGAGTCGGTGCTG\nCCTATGTGGGTGCTGGCCCTCATCGTGATCTTCCTCACCATCGCTGTGCTCCTGGCCCTC\nCGCTTCTGTGGCATCTACGGGTACAGGCTGCGCAGAAAGTGGGAGGAGAAGATCCCCAAC\nCCCAGCAAGAGCCACCTGTTCCAGAACGGGAGCGCAGAGCTTTGGCCCCCAGGCAGCATG\nTCGGCCTTCACTAGCGGGAGTCCCCCACACCAGGGGCCGTGGGGCAGCCGCTTCCCTGAG\nCTGGAGGGGGTGTTCCCTGTAGGATTCGGGGACAGCGAGGTGTCACCTCTCACCATAGAG\nGACCCCAAGCATGTCTGTGATCCACCATCTGGGCCTGACACGACTCCAGCTGCCTCAGAT\nCTACCCACAGAGCAGCCCCCCAGCCCCCAGCCAGGCCCGCCTGCCGCCTCCCACACACCT\nGAGAAACAGGCTTCCAGCTTTGACTTCAATGGGCCCTACCTGGGGCCGCCCCACAGCCGC\nTCCCTACCTGACATCCTGGGCCAGCCGGAGCCCCCACAGGAGGGTGGGAGCCAGAAGTCC\nCCACCTCCAGGGTCCCTGGAGTACCTGTGTCTGCCTGCTGGGGGGCAGGTGCAACTGGTC\nCCTCTGGCCCAGGCGATGGGACCGGGACAGGCCGTGGAAGTGGAGAGAAGGCCGAGCCAG\nGGGGCTGCAGGGAGTCCCTCCCTGGAGTCCGGGGGAGGCCCTGCCCCTCCTGCTCTTGGG\nCCAAGGGTGGGAGGACAGGACCAAAAGGACAGCCCTGTGGCTATACCCATGAGCTCTGGG\nGACACTGAGGACCCTGGAGTGGCCTCTGGTTATGTCTCCTCTGCAGACCTGGTATTCACC\nCCAAACTCAGGGGCCTCGTCTGTCTCCCTAGTTCCCTCTCTGGGCCTCCCCTCAGACCAG\nACCCCCAGCTTATGTCCTGGGCTGGCCAGTGGACCCCCTGGAGCCCCAGGCCCTGTGAAG\nTCAGGGTTTGAGGGCTATGTGGAGCTCCCTCCAATTGAGGGCCGGTCCCCCAGGTCACCA\nAGGAACAATCCTGTCCCCCCTGAGGCCAAAAGCCCTGTCCTGAACCCAGGGGAACGCCCG\nGCAGATGTGTCCCCAACATCCCCACAGCCCGAGGGCCTCCTTGTCCTGCAGCAAGTGGGC\nGACTATTGCTTCCTCCCCGGCCTGGGGCCCGGCCCTCTCTCGCTCCGGAGTAAACCTTCT\nTCCCCGGGACCCGGTCCTGAGATCAAGAACCTAGACCAGGCTTTTCAAGTCAAGAAGCCC\nCCAGGCCAGGCTGTGCCCCAGGTGCCCGTCATTCAGCTCTTCAAAGCCCTGAAGCAGCAG\nGACTACCTGTCTCTGCCCCCTTGGGAGGTCAACAAGCCTGGGGAGGTGTGTTGA"}, "pfams": {"pfam": {"identifier": "PF00041", "name": "fn3"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "hematopoietin/interferon-class (D200-domain) cytokine receptor activity"}, {"category": "function", "description": "interleukin receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "cytokine and chemokine mediated signaling pathway"}, {"category": "process", "description": "cellular process"}]}}}, {"@position": "4", "id": "BE0002116", "name": "Syndecan-2", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Modrowski D, Basle M, Lomri A, Marie PJ: Syndecan-2 is involved in the mitogenic activity and signaling of granulocyte-macrophage colony-stimulating factor in osteoblasts. J Biol Chem. 2000 Mar 31;275(13):9178-85. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10734053", "known-action": "unknown", "polypeptide": {"@id": "P34741", "@source": "Swiss-Prot", "name": "Syndecan-2", "general-function": null, "specific-function": "Cell surface proteoglycan that bears heparan sulfate", "gene-name": "SDC2", "locus": "8q22-q23", "cellular-location": "Membrane", "transmembrane-regions": "145-169", "signal-regions": null, "theoretical-pi": "4.48", "molecular-weight": "22174.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:10659"}, {"resource": "GenAtlas", "identifier": "SDC2"}, {"resource": "GeneCards", "identifier": "SDC2"}, {"resource": "GenBank Gene Database", "identifier": "J04621"}, {"resource": "GenBank Protein Database", "identifier": "386787"}, {"resource": "UniProtKB", "identifier": "P34741"}, {"resource": "UniProt Accession", "identifier": "SDC2_HUMAN"}]}, "synonyms": {"synonym": ["Fibroglycan", "Heparan sulfate proteoglycan core protein", "HSPG", "SYND2", "Syndecan-2 precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Syndecan-2\nMRRAWILLTLGLVACVSAESRAELTSDKDMYLDNSSIEEASGVYPIDDDDYASASGSGAD\nEDVESPELTTTRPLPKILLTSAAPKVETTTLNIQNKIPAQTKSPEETDKEKVHLSDSERK\nMDPAEEDTNVYTEKHSDSLFKRTEVLAAVIAGGVIGFLFAIFLILLLVYRMRKKDEGSYD\nLGERKPSSAAYQKAPTKEFYA"}, "gene-sequence": {"@format": "FASTA", "#text": ">606 bp\nATGCGGCGCGCGTGGATCCTGCTCACCTTGGGCTTGGTGGCCTGCGTGTCGGCGGAGTCG\nAGAGCAGAGCTGACATCTGATAAAGACATGTACCTTGACAACAGCTCCATTGAAGAAGCT\nTCAGGAGTGTATCCTATTGATGACGATGACTACGCTTCTGCGTCTGGCTCGGGAGCTGAT\nGAGGATGTAGAGAGTCCAGAGCTGACTACATCTCGACCACTTCCAAAGATACTGTTGACT\nAGTGCTGCTCCAAAAGTGGAAACCACGACGCTGAATATACAGAACAAGATACCTGCTCAG\nACAAAGTCACCTGAAGAAACTGATAAAGAGAAAGTTCACCTCTCTGACTCAGAAAGGAAA\nATGGACCCAGCCGAAGAGGATACAAATGTGTATACTGAGAAACACTCAGACAGTCTGTTT\nAAACGGACAGAAGTCCTAGCAGCTGTCACTGCTGGTGGAGTTATTGGCTTTCTCTTTGCA\nATTTTTCTTATCCTGCTGTTGGTGTATCGCATGAGAAAGAAGGATGAAGGAAGCTATGAC\nCTTGGAGAACGCAAACCATCCAGTGCTGCTTATCAGAAGGCACCTACTAAGGAGTTTTAT\nGCGTAA"}, "pfams": {"pfam": {"identifier": "PF01034", "name": "Syndecan"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "protein binding"}, {"category": "function", "description": "cytoskeletal protein binding"}]}}}, {"@position": "5", "id": "BE0002114", "name": "Bone marrow proteoglycan", "organism": "Human", "actions": null, "references": "# Menon K, Wu Y, Haas J, Sahu SK, Yang B, Zaheer A: Diminished degradation of myelin basic protein by anti-sulfatide antibody and interferon-gamma in myelin from glia maturation factor-deficient mice. Neurosci Res. 2007 Jun;58(2):156-63. Epub 2007 Feb 22. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17383764\n# Letuve S, Lajoie-Kadoch S, Audusseau S, Rothenberg ME, Fiset PO, Ludwig MS, Hamid Q: IL-17E upregulates the expression of proinflammatory cytokines in lung fibroblasts. J Allergy Clin Immunol. 2006 Mar;117(3):590-6. Epub 2006 Feb 8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16522458\n# Kang JH, Lee DH, Seo HM, Park JS, Nam KH, Shin SY, Park CS, Chung IY: Regulation of Functional Phenotypes of Cord-blood-derived Eosinophils by {gamma}-secretase Inhibitor. Am J Respir Cell Mol Biol. 2007 Jun 28;. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17600316", "known-action": "unknown", "polypeptide": {"@id": "P13727", "@source": "Swiss-Prot", "name": "Bone marrow proteoglycan", "general-function": null, "specific-function": "Cytotoxin and helminthotoxin. Also induces non-cytolytic histamine release from human basophils. Involved in antiparasitic defense mechanisms and immune hypersensitivity reactions. The proform acts as a proteinase inhibitor, reducing the activity of PAPPA", "gene-name": "PRG2", "locus": "11q12", "cellular-location": "Note=The proform is secreted", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.64", "molecular-weight": "25232.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9362"}, {"resource": "GenAtlas", "identifier": "PRG2"}, {"resource": "GeneCards", "identifier": "PRG2"}, {"resource": "GenBank Gene Database", "identifier": "Y00809"}, {"resource": "GenBank Protein Database", "identifier": "34476"}, {"resource": "UniProtKB", "identifier": "P13727"}, {"resource": "UniProt Accession", "identifier": "PRG2_HUMAN"}]}, "synonyms": {"synonym": ["BMPG", "Bone-marrow proteoglycan precursor", "Proteoglycan 2"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Bone-marrow proteoglycan\nMKLPLLLALLFGAVSALHLRSETSTFETPLGAKTLPEDEETPEQEMEETPCRELEEEEEW\nGSGSEDASKKDGAVESISVPDMVDKNLTCPEEEDTVKVVGIPGCQTCRYLLVRSLQTFSQ\nAWFTCRRCYRGNLVSIHNFNINYRIQCSVSALNQGQVWIGGRITGSGRCRRFQWVDGSRW\nNFAYWAAHQPWSRGGHCVALCTRGGYWRRAHCLRRLPFICSY"}, "gene-sequence": {"@format": "FASTA", "#text": ">669 bp\nATGAAACTCCCCCTACTTCTGGCTCTTCTATTTGGGGCAGTTTCTGCTCTTCATCTAAGG\nTCTGAGACTTCCACCTTTGAGACCCCTTTGGGTGCTAAGACGCTGCCTGAGGATGAGGAG\nACACCAGAGCAGGAGATGGAGGAGACCCCTTGCAGGGAGCTGGAGGAAGAGGAGGAGTGG\nGGCTCTGGAAGTGAAGATGCCTCCAAGAAAGATGGGGCTGTTGAGTCTATCTCAGTGCCA\nGATATGGTGGACAAAAACCTTACGTGTCCTGAGGAAGAGGACACAGTAAAAGTGGTGGGC\nATCCCTGGGTGCCAGACCTGCCGCTACCTCCTGGTGAGAAGTCTTCAGACGTTTAGTCAA\nGCTTGGTTTACTTGCCGGAGGTGCTACAGGGGCAACCTGGTTTCCATCCACAACTTCAAT\nATTAATTATCGAATCCAGTGTTCTGTCAGCGCGCTCAACCAGGGTCAAGTCTGGATTGGA\nGGCAGGATCACAGGCTCGGGTCGCTGCAGACGCTTTCAGTGGGTTGACGGCAGCCGCTGG\nAACTTTGCGTACTGGGCTGCTCACCAGCCCTGGTCCCGCGGTGGTCACTGCGTGGCCCTG\nTGTACCCGAGGAGGCTACTGGCGTCGAGCCCACTGCCTCAGAAGACTTCCTTTCATCTGT\nTCCTACTGA"}, "pfams": {"pfam": {"identifier": "PF00059", "name": "Lectin_C"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "binding"}, {"category": "function", "description": "carbohydrate binding"}, {"category": "function", "description": "sugar binding"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "immune response"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-09-13", "drugbank-id": [{"@primary": "true", "#text": "DB00021"}, "BIOD00039", "BTD00039"], "name": "Secretin", "description": "This drug is the synthetic form of natural secretin.  It is prepared using solid phase peptide synthesis.  Secretin is a peptide hormone produced in the S cells of the duodenum. Its main effect is to regulate the pH of the small  intestine\u2019s contents through the control of gastric acid secretion and buffering with bicarbonate. It was the first hormone to be discovered.", "cas-number": null, "groups": {"group": ["approved", "investigational"]}, "general-references": null, "synthesis-reference": "Martin Bickel, Rolf Geiger, Richard Leeb, Walter Petri, \"Secretin preparations with intensified and protracted action, process for their manufacture, their use as well as dihydroxybenzoyl-L-tyrosine.\" U.S. Patent US4302448, issued August, 1964.", "indication": "For diagnosis of pancreatic exocrine dysfunction and gastrinoma", "pharmacodynamics": "Used in the diagnosis of pancreatic dysfunction or gastrinoma (stomach cancer), secretin is a hormone produced in the S cells of the duodenum in response to low local pH. It stimulates the secretion of bicarbonate from bicarbonate producing organs(liver, pancreas, Brunner's glands) when the pH drops below a set value. This helps neutralize the gastric acid entering the duodenum from the stomach. It also inhibits acid secretion from the stomach by reducing gastrin release from the G cells of the stomach.", "mechanism-of-action": "Secretin binds to the secretin receptor found on the lining of S cells in the duodenum and G cells in the stomach. Binding leads to the secrection of bicarbonate or the reduction of the secretion of gastrin. Properly functioning organs (duodenum, pancreas and stomach) should be responsive to this hormone", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": {"product": {"name": "Secretin Inj 75unit/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00874000", "started-marketing-on": "1990-12-31", "ended-marketing-on": "1999-08-04", "dosage-form": "powder for solution", "strength": "75 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}}, "international-brands": {"international-brand": [{"name": "SecreFlo", "company": "Repligen Corp"}, {"name": "Secremax", "company": "Repligen Corp"}]}, "mixtures": {"mixture": {"name": "Secretin Inj 75unit/vial", "ingredients": "Secretin"}}, "packagers": {"packager": {"name": "Professional Co.", "url": null}}, "manufacturers": {"manufacturer": [{"@generic": "false", "#text": "Ferring pharmaceuticals inc"}, {"@generic": "false", "#text": "Chirhoclin inc"}]}, "prices": {"price": {"description": "Secretin-mannitol powder", "cost": {"@currency": "USD", "#text": "1.43"}, "unit": "g"}}, "categories": {"category": {"category": "Diagnostic Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": {"form": "Powder for solution", "route": "intravenous", "strength": "75 unit"}}, "atc-codes": {"atc-code": {"@code": "V04CK01", "level": [{"@code": "V", "#text": "VARIOUS"}, {"@code": "V04", "#text": "DIAGNOSTIC AGENTS"}, {"@code": "V04C", "#text": "OTHER DIAGNOSTIC AGENTS"}, {"@code": "V04CK", "#text": "Tests for pancreatic function"}]}}, "ahfs-codes": null, "patents": null, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB08897", "name": "Aclidinium", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00321", "name": "Amitriptyline", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00543", "name": "Amoxapine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00572", "name": "Atropine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00972", "name": "Azelastine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00245", "name": "Benzatropine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00835", "name": "Brompheniramine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00748", "name": "Carbinoxamine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00341", "name": "Cetirizine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01114", "name": "Chlorphenamine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00477", "name": "Chlorpromazine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00283", "name": "Clemastine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00771", "name": "Clidinium", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01242", "name": "Clomipramine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00363", "name": "Clozapine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00318", "name": "Codeine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01176", "name": "Cyclizine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00924", "name": "Cyclobenzaprine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00979", "name": "Cyclopentolate", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00434", "name": "Cyproheptadine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00496", "name": "Darifenacin", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01151", "name": "Desipramine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00967", "name": "Desloratadine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00405", "name": "Dexbrompheniramine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00804", "name": "Dicyclomine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01501", "name": "Difenoxin", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00985", "name": "Dimenhydrinate", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01075", "name": "Diphenhydramine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01081", "name": "Diphenoxylate", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00280", "name": "Disopyramide", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01142", "name": "Doxepin", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00366", "name": "Doxylamine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00450", "name": "Droperidol", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01288", "name": "Fenoterol", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB06702", "name": "Fesoterodine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00950", "name": "Fexofenadine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01148", "name": "Flavoxate", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00875", "name": "Flupentixol", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00623", "name": "Fluphenazine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00588", "name": "Fluticasone Propionate", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00986", "name": "Glycopyrrolate", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00502", "name": "Haloperidol", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00557", "name": "Hydroxyzine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00424", "name": "Hyoscyamine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00458", "name": "Imipramine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00332", "name": "Ipratropium bromide", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01247", "name": "Isocarboxazid", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01106", "name": "Levocabastine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB06282", "name": "Levocetirizine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00455", "name": "Loratadine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00408", "name": "Loxapine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00934", "name": "Maprotiline", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00737", "name": "Meclizine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB04843", "name": "Mepenzolate", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01403", "name": "Methotrimeprazine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01171", "name": "Moclobemide", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00540", "name": "Nortriptyline", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00334", "name": "Olanzapine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00768", "name": "Olopatadine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01173", "name": "Orphenadrine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01062", "name": "Oxybutynin", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00850", "name": "Perphenazine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00780", "name": "Phenelzine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01100", "name": "Pimozide", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB06153", "name": "Pizotifen", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00433", "name": "Prochlorperazine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00387", "name": "Procyclidine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00420", "name": "Promazine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01069", "name": "Promethazine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00782", "name": "Propantheline", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00344", "name": "Protriptyline", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01224", "name": "Quetiapine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00734", "name": "Risperidone", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00747", "name": "Scopolamine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01591", "name": "Solifenacin", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00679", "name": "Thioridazine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01623", "name": "Thiothixene", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01409", "name": "Tiotropium", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01036", "name": "Tolterodine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00752", "name": "Tranylcypromine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00831", "name": "Trifluoperazine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00376", "name": "Trihexyphenidyl", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00662", "name": "Trimethobenzamide", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00726", "name": "Trimipramine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00427", "name": "Triprolidine", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB00209", "name": "Trospium", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB09076", "name": "Umeclidinium", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}, {"drugbank-id": "DB01624", "name": "Zuclopenthixol", "description": "Anticholinergic Agents may diminish the therapeutic effect of Secretin."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00021 sequence\nHSDGTFTSELSRLRDSARLQRLLQGLV"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.463", "source": null}, {"kind": "Isoelectric Point", "value": "9.45", "source": null}, {"kind": "Molecular Weight", "value": "3056.4000", "source": null}, {"kind": "Molecular Formula", "value": "C130H219N43O42", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "2067"}, {"resource": "PharmGKB", "identifier": "PA164760844"}, {"resource": "Wikipedia", "identifier": "Secretin"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/secretin.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/human_secretin.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0000318", "name": "Secretin receptor", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P47872", "@source": "Swiss-Prot", "name": "Secretin receptor", "general-function": "Involved in G-protein coupled receptor activity", "specific-function": "This is a receptor for secretin. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase", "gene-name": "SCTR", "locus": "2q14.1", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "144-167\n175-194\n217-240\n255-276\n295-317\n344-362\n370-392", "signal-regions": null, "theoretical-pi": "7.77", "molecular-weight": "50207.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:10608"}, {"resource": "GenAtlas", "identifier": "SCTR"}, {"resource": "GeneCards", "identifier": "SCTR"}, {"resource": "GenBank Gene Database", "identifier": "U20178"}, {"resource": "GenBank Protein Database", "identifier": "662796"}, {"resource": "IUPHAR", "identifier": "252"}, {"resource": "Guide to Pharmacology", "identifier": "29"}, {"resource": "UniProtKB", "identifier": "P47872"}, {"resource": "UniProt Accession", "identifier": "SCTR_HUMAN"}]}, "synonyms": {"synonym": ["SCT-R", "Secretin receptor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Secretin receptor precursor\nMRPHLSPPLQQLLLPVLLACAAHSTGALPRLCDVLQVLWEEQDQCLQELSREQTGDLGTE\nQPVPGCEGMWDNISCWPSSVPGRMVEVECPRFLRMLTSRNGSLFRNCTQDGWSETFPRPN\nLACGVNVNDSSNEKRHSYLLKLKVMYTVGYSSSLVMLLVALGILCAFRRLHCTRNYIHMH\nLFVSFILRALSNFIKDAVLFSSDDVTYCDAHRAGCKLVMVLFQYCIMANYSWLLVEGLYL\nHTLLAISFFSERKYLQGFVAFGWGSPAIFVALWAIARHFLEDVGCWDINANASIWWIIRG\nPVILSILINFILFINILRILMRKLRTQETRGNEVSHYKRLARSTLLLIPLFGIHYIVFAF\nSPEDAMEIQLFFELALGSFQGLVVAVLYCFLNGEVQLEVQKKWQQWHLREFPLHPVASFS\nNSTKASHLEQSQGTCRTSII"}, "gene-sequence": {"@format": "FASTA", "#text": ">1323 bp\nATGCGTCCCCACCTGTCGCCGCCGCTGCAGCAGCTACTACTGCCGGTGCTGCTCGCCTGC\nGCCGCGCACTCGACTGGAGCCCTTCCCCGACTATGTGACGTGCTACAAGTGCTGTGGGAA\nGAGCAAGACCAGTGCCTGCAGGAACTCTCCAGAGAGCAGACAGGAGACCTGGGCACGGAG\nCAGCCAGTGCCAGGTTGTGAGGGGATGTGGGACAACATAAGCTGCTGGCCCTCTTCTGTG\nCCGGGCCGGATGGTGGAGGTGGAATGCCCGAGATTCCTCCGGATGCTCACCAGCAGAAAT\nGGTTCCTTGTTCCGAAACTGCACACAGGATGGCTGGTCAGAAACCTTCCCCAGGCCTAAT\nCTGGCCTGTGCGGTTAATGTGAACGACTCTTCCAACGAGAAGCGGCACTCCTACCTGCTG\nAAGCTGAAAGTCATGTACACCGTGGGCTACAGCTCCTCCCTGGTCATGCTCCTGGTCGCC\nCTTGGCATCCTCTGTGCTTTCCGGAGGCTCCACTGCACTCGCAACTACATCCACATGCAC\nCTGTTCGTGTCCTTCATCCTTCGTGCCCTGTCCAACTTCATCAAGGACGCCGTGCTCTTC\nTCCTCAGATGATGTCACCTACTGCGATGCCCACAGGGCGGGCTGCAAGCTGGTCATGGTG\nCTGTTCCAGTACTGCATCATGGCCAACTACTCCTGGCTGCTGGTGGAAGGCCTCTACCTT\nCACACACTCCTCGCCATCTCCTTCTTCTCTGAAAGAAAGTACCTCCAGGGATTTGTGGCA\nTTCGGATGGGGTTCTCCAGCCATTTTTGTTGCTTTGTGGGCTATTGCCAGACACTTTCTG\nGAAGATGTTGGGTGCTGGGACATCAATGCCAACGCATCCATCTGGTGGATCATTCGTGGT\nCCTGTGATCCTCTCCATCCTGATTAATTTCATCCTTTTCATAAACATTCTAAGAATCCTG\nATGAGAAAACTTAGAACCCAAGAAACAAGAGGAAATGAAGTCAGCCATTATAAGCGCCTG\nGCCAGGTCCACTCTCCTGCTGATCCCCCTCTTTGGCATCCACTACATCGTCTTCGCCTTC\nTCCCCAGAGGACGCTATGGAGATCCAGCTGTTTTTTGAACTAGCCCTTGCGTCATTCCAG\nGGACTGGTGGTGGCCGTCCTCTACTGCTTCCTCAACGGGGAGGTGCAGCTGGAGGTTCAG\nAAGAAGTGGCAGCAATGGCACCTCCGTGAGTTCCCACTGCACCCCGTGGCCTCCTTCAGC\nAACAGCACCAAGGCCAGCCACTTGGAGCAGAGCCAGGGCACCTGCAGGACCAGCATCATC\nTGA"}, "pfams": {"pfam": [{"identifier": "PF00002", "name": "7tm_2"}, {"identifier": "PF02793", "name": "HRM"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "secretin-like receptor activity"}, {"category": "function", "description": "vasoactive intestinal polypeptide receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}]}}}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2010-09-29", "drugbank-id": [{"@primary": "true", "#text": "DB00022"}, "BIOD00048", "BTD00048"], "name": "Peginterferon alfa-2b", "description": "Peginterferon alfa-2b is a covalent conjugate of recombinant alfa-2b interferon with monomethoxy polyethylene glycol (PEG). The average molecular weight of the PEG portion of the molecule is 12,000 daltons. The average molecular weight of the PEG-Intron molecule is approximately 31,000 daltons. The specific activity of peginterferon alfa-2b is approximately 0.7 x 108 IU/mg protein. Interferon alfa-2b is a water-soluble protein with a molecular weight of 19,271 daltons produced by recombinant DNA techniques. It is obtained from the bacterial fermentation of a strain of <i>Escherichia coli</i> bearing a genetically engineered plasmid containing an interferon gene from human leukocytes. The PEG strand protects the molecule in vivo from proteolytic breakdown, substantially increases its in vivo half-life, and reduces immunogenicity by wrapping around and physically hindering access to the protein portion of the molecule.", "cas-number": "99210-65-8", "groups": {"group": "approved"}, "general-references": null, "synthesis-reference": null, "indication": "For the treatment of chronic hepatitis C in patients not previously treated with interferon alpha who have compensated liver disease and are at least 18 years of age.", "pharmacodynamics": "Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.", "mechanism-of-action": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.", "toxicity": null, "metabolism": null, "absorption": "Following a single subcutaneous dose of peginterferon alfa-2b, the mean absorption half-life (t&frac12; k<sub>a</sub>) was 4.6 hours.", "half-life": "The mean elimination half-life is approximately 40 hours (range 22 to 60 hours) in patients with HCV infection.", "protein-binding": null, "route-of-elimination": "Renal elimination accounts for 30% of the clearance.", "volume-of-distribution": null, "clearance": "* Oral cl=22 mL/hr\u2219kg [patients with HCV infection]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": {"product": [{"name": "Pegetron", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02246026", "started-marketing-on": "2002-08-13", "ended-marketing-on": null, "dosage-form": "capsule; powder for solution", "strength": "50 mcg", "route": "oral; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Pegetron", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02246030", "started-marketing-on": "2002-08-13", "ended-marketing-on": null, "dosage-form": "capsule; powder for solution", "strength": "150 mcg", "route": "oral; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Pegetron", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02246027", "started-marketing-on": "2002-08-13", "ended-marketing-on": "2013-01-23", "dosage-form": "capsule; powder for solution", "strength": "80 mcg", "route": "oral; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Pegetron", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02246028", "started-marketing-on": "2002-08-13", "ended-marketing-on": "2013-01-23", "dosage-form": "capsule; powder for solution", "strength": "100 mcg", "route": "oral; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Pegetron", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02246029", "started-marketing-on": "2002-08-13", "ended-marketing-on": "2013-01-23", "dosage-form": "capsule; powder for solution", "strength": "120 mcg", "route": "oral; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Pegetron", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02254581", "started-marketing-on": "2004-09-17", "ended-marketing-on": null, "dosage-form": "capsule; powder for solution", "strength": "80 mcg", "route": "oral; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Pegetron", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02254603", "started-marketing-on": "2004-09-17", "ended-marketing-on": null, "dosage-form": "capsule; powder for solution", "strength": "100 mcg", "route": "oral; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Pegetron", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02254638", "started-marketing-on": "2004-09-17", "ended-marketing-on": null, "dosage-form": "capsule; powder for solution", "strength": "120 mcg", "route": "oral; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Pegetron", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02254646", "started-marketing-on": "2004-09-17", "ended-marketing-on": null, "dosage-form": "capsule; powder for solution", "strength": "150 mcg", "route": "oral; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Pegintron", "ndc-id": "0085-1297_b5ad295a-003e-438a-9932-d789ece6fe7a", "ndc-product-code": "0085-1297", "dpd-id": null, "started-marketing-on": "2001-01-19", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "120 ug/.5mL", "route": "subcutaneous", "fda-application-number": "BLA103949", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Pegintron", "ndc-id": "0085-1316_b5ad295a-003e-438a-9932-d789ece6fe7a", "ndc-product-code": "0085-1316", "dpd-id": null, "started-marketing-on": "2001-01-19", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "80 ug/.5mL", "route": "subcutaneous", "fda-application-number": "BLA103949", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Pegintron", "ndc-id": "0085-1323_b5ad295a-003e-438a-9932-d789ece6fe7a", "ndc-product-code": "0085-1323", "dpd-id": null, "started-marketing-on": "2001-01-19", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "50 ug/.5mL", "route": "subcutaneous", "fda-application-number": "BLA103949", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Pegintron", "ndc-id": "0085-1370_b5ad295a-003e-438a-9932-d789ece6fe7a", "ndc-product-code": "0085-1370", "dpd-id": null, "started-marketing-on": "2001-01-19", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "150 ug/.5mL", "route": "subcutaneous", "fda-application-number": "BLA103949", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Unitron Peg", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02242966", "started-marketing-on": "2001-03-27", "ended-marketing-on": "2012-02-01", "dosage-form": "powder for solution", "strength": "74 mcg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Unitron Peg", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02242967", "started-marketing-on": "2001-03-27", "ended-marketing-on": "2012-02-01", "dosage-form": "powder for solution", "strength": "118.4 mcg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Unitron Peg", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02242968", "started-marketing-on": "2001-03-27", "ended-marketing-on": "2012-02-01", "dosage-form": "powder for solution", "strength": "177.6 mcg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Unitron Peg", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02242969", "started-marketing-on": "2001-03-27", "ended-marketing-on": "2012-02-01", "dosage-form": "powder for solution", "strength": "222 mcg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Victrelis Triple", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02371448", "started-marketing-on": "2011-08-16", "ended-marketing-on": null, "dosage-form": "capsule; powder for solution", "strength": "80 mcg", "route": "oral; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Victrelis Triple", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02371456", "started-marketing-on": "2011-08-16", "ended-marketing-on": null, "dosage-form": "capsule; powder for solution", "strength": "100 mcg", "route": "oral; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Victrelis Triple", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02371464", "started-marketing-on": "2011-08-16", "ended-marketing-on": null, "dosage-form": "capsule; powder for solution", "strength": "120 mcg", "route": "oral; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Victrelis Triple", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02371472", "started-marketing-on": "2011-08-16", "ended-marketing-on": null, "dosage-form": "capsule; powder for solution", "strength": "150 mcg", "route": "oral; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": {"name": "PEG-Intron", "company": "Schering Corp"}}, "mixtures": {"mixture": [{"name": "Pegintron", "ingredients": "Peginterferon alfa-2b"}, {"name": "Pegintron", "ingredients": "Peginterferon alfa-2b"}, {"name": "Pegintron", "ingredients": "Peginterferon alfa-2b"}, {"name": "Pegintron", "ingredients": "Peginterferon alfa-2b"}, {"name": "Pegetron", "ingredients": "Peginterferon alfa-2b + Ribavirin"}, {"name": "Pegetron", "ingredients": "Peginterferon alfa-2b + Ribavirin"}, {"name": "Pegetron", "ingredients": "Peginterferon alfa-2b + Ribavirin"}, {"name": "Pegetron", "ingredients": "Peginterferon alfa-2b + Ribavirin"}, {"name": "Pegetron", "ingredients": "Peginterferon alfa-2b + Ribavirin"}, {"name": "Pegetron", "ingredients": "Peginterferon alfa-2b + Ribavirin"}, {"name": "Victrelis Triple", "ingredients": "Peginterferon alfa-2b + Boceprevir + Ribavirin"}, {"name": "Victrelis Triple", "ingredients": "Peginterferon alfa-2b + Boceprevir + Ribavirin"}, {"name": "Victrelis Triple", "ingredients": "Peginterferon alfa-2b + Boceprevir + Ribavirin"}, {"name": "Victrelis Triple", "ingredients": "Peginterferon alfa-2b + Boceprevir + Ribavirin"}, {"name": "Unitron Peg", "ingredients": "Peginterferon alfa-2b"}, {"name": "Unitron Peg", "ingredients": "Peginterferon alfa-2b"}, {"name": "Unitron Peg", "ingredients": "Peginterferon alfa-2b"}, {"name": "Unitron Peg", "ingredients": "Peginterferon alfa-2b"}, {"name": "Pegetron", "ingredients": "Peginterferon alfa-2b + Ribavirin"}, {"name": "Pegetron", "ingredients": "Peginterferon alfa-2b + Ribavirin"}, {"name": "Pegetron", "ingredients": "Peginterferon alfa-2b + Ribavirin"}]}, "packagers": {"packager": [{"name": "Physicians Total Care Inc.", "url": "http://www.physicianstotalcare.com"}, {"name": "Schering Corp.", "url": "http://www.schering.de"}, {"name": "Schering-Plough Inc.", "url": "http://www.schering-plough.ca"}, {"name": "Vetter Pharma Fertigung GmbH and Co. KG", "url": "http://www.vetter-pharma.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Peg-Intron 50 mcg kit", "cost": {"@currency": "USD", "#text": "553.4"}, "unit": "kit"}, {"description": "Peg-Intron redipen 50 mcg", "cost": {"@currency": "USD", "#text": "553.4"}, "unit": "redipen"}, {"description": "Peg-Intron redipen 80 mcg", "cost": {"@currency": "USD", "#text": "581.02"}, "unit": "redipen"}, {"description": "Peg-Intron 50 mcg/0.5ml Kit", "cost": {"@currency": "USD", "#text": "607.19"}, "unit": "kit"}, {"description": "Peg-Intron 80 mcg Kit", "cost": {"@currency": "USD", "#text": "609.26"}, "unit": "kit"}, {"description": "Peg-Intron redipen 120 mcg", "cost": {"@currency": "USD", "#text": "610.09"}, "unit": "redipen"}, {"description": "Peg-Intron Redipen 80 mcg/0.5ml Kit", "cost": {"@currency": "USD", "#text": "637.49"}, "unit": "kit"}, {"description": "Peg-Intron 120 mcg Kit", "cost": {"@currency": "USD", "#text": "639.74"}, "unit": "kit"}, {"description": "Peg-Intron redipen 150 mcg 4pk", "cost": {"@currency": "USD", "#text": "640.6"}, "unit": "redipen"}, {"description": "Peg-Intron redipen 150 mcg", "cost": {"@currency": "USD", "#text": "640.61"}, "unit": "redipen"}, {"description": "Peg-Intron Redipen 120 mcg/0.5ml Kit", "cost": {"@currency": "USD", "#text": "669.39"}, "unit": "kit"}, {"description": "Peg-Intron 150 mcg Kit", "cost": {"@currency": "USD", "#text": "671.74"}, "unit": "kit"}, {"description": "Peg-Intron Redipen 150 mcg/0.5ml Kit", "cost": {"@currency": "USD", "#text": "702.87"}, "unit": "kit"}, {"description": "Peg-Intron Redipen Pak 4 4 50 mcg/0.5ml Kit Box", "cost": {"@currency": "USD", "#text": "2428.8"}, "unit": "kit"}]}, "categories": {"category": {"category": "Immunosuppressive Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Capsule; powder for solution", "route": "oral; subcutaneous", "strength": "100 mcg"}, {"form": "Capsule; powder for solution", "route": "oral; subcutaneous", "strength": "120 mcg"}, {"form": "Capsule; powder for solution", "route": "oral; subcutaneous", "strength": "150 mcg"}, {"form": "Capsule; powder for solution", "route": "oral; subcutaneous", "strength": "50 mcg"}, {"form": "Capsule; powder for solution", "route": "oral; subcutaneous", "strength": "80 mcg"}, {"form": "Injection, powder, lyophilized, for solution", "route": "subcutaneous", "strength": "120 ug/.5mL"}, {"form": "Injection, powder, lyophilized, for solution", "route": "subcutaneous", "strength": "150 ug/.5mL"}, {"form": "Injection, powder, lyophilized, for solution", "route": "subcutaneous", "strength": "50 ug/.5mL"}, {"form": "Injection, powder, lyophilized, for solution", "route": "subcutaneous", "strength": "80 ug/.5mL"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "118.4 mcg"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "177.6 mcg"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "222 mcg"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "74 mcg"}]}, "atc-codes": {"atc-code": {"@code": "L03AB10", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L03", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03A", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03AB", "#text": "Interferons"}]}}, "ahfs-codes": {"ahfs-code": "08:18.20"}, "patents": {"patent": [{"number": "1341567", "country": "Canada", "approved": "2008-02-19", "expires": "2025-02-19"}, {"number": "2329474", "country": "Canada", "approved": "0002-02-26", "expires": "2016-10-31"}]}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB01418", "name": "Acenocoumarol", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB00041", "name": "Aldesleukin", "description": "Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination."}, {"drugbank-id": "DB00969", "name": "Alosetron", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB01223", "name": "Aminophylline", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB00321", "name": "Amitriptyline", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00543", "name": "Amoxapine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB01238", "name": "Aripiprazole", "description": "CYP2D6 Inhibitors (Weak) may increase the serum concentration of Aripiprazole."}, {"drugbank-id": "DB06216", "name": "Asenapine", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB00289", "name": "Atomoxetine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00195", "name": "Betaxolol", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB09128", "name": "Brexpiprazole", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB01558", "name": "Bromazepam", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB00241", "name": "Butalbital", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB00201", "name": "Caffeine", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB01197", "name": "Captopril", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB01136", "name": "Carvedilol", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00608", "name": "Chloroquine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB01114", "name": "Chlorphenamine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00477", "name": "Chlorpromazine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB01242", "name": "Clomipramine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB01242", "name": "Clomipramine", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB00363", "name": "Clozapine", "description": "Myelosuppressive Agents may enhance the adverse/toxic effect of Clozapine. Specifically, the risk for agranulocytosis may be increased."}, {"drugbank-id": "DB00318", "name": "Codeine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00924", "name": "Cyclobenzaprine", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB00851", "name": "Dacarbazine", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB01151", "name": "Desipramine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00514", "name": "Dextromethorphan", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB01551", "name": "Dihydrocodeine", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB01142", "name": "Doxepin", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00997", "name": "Doxorubicin", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00476", "name": "Duloxetine", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB09039", "name": "Eliglustat", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB01195", "name": "Flecainide", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00472", "name": "Fluoxetine", "description": "Peginterferon alfa-2b may decrease the serum concentration of Fluoxetine."}, {"drugbank-id": "DB00623", "name": "Fluphenazine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00499", "name": "Flutamide", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB00176", "name": "Fluvoxamine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00176", "name": "Fluvoxamine", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB00317", "name": "Gefitinib", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00502", "name": "Haloperidol", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB04946", "name": "Iloperidone", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00458", "name": "Imipramine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB06706", "name": "Isometheptene", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB00281", "name": "Lidocaine", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB00934", "name": "Maprotiline", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB04817", "name": "Metamizole", "description": "May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased"}, {"drugbank-id": "DB00333", "name": "Methadone", "description": "Interferons (Alfa) may increase the serum concentration of Methadone."}, {"drugbank-id": "DB01577", "name": "Methamphetamine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00264", "name": "Metoprolol", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00379", "name": "Mexiletine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00379", "name": "Mexiletine", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB00370", "name": "Mirtazapine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00370", "name": "Mirtazapine", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB01149", "name": "Nefazodone", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00540", "name": "Nortriptyline", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00334", "name": "Olanzapine", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB00715", "name": "Paroxetine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00850", "name": "Perphenazine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB01100", "name": "Pimozide", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB01100", "name": "Pimozide", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB01621", "name": "Pipotiazine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB08910", "name": "Pomalidomide", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB01087", "name": "Primaquine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB01035", "name": "Procainamide", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00420", "name": "Promazine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB01069", "name": "Promethazine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00571", "name": "Propranolol", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00571", "name": "Propranolol", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB00344", "name": "Protriptyline", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00980", "name": "Ramelteon", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB01367", "name": "Rasagiline", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB00811", "name": "Ribavirin", "description": "Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin. Hemolytic anemia has been observed."}, {"drugbank-id": "DB00734", "name": "Risperidone", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00268", "name": "Ropinirole", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB00296", "name": "Ropivacaine", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB09118", "name": "Stiripentol", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB00675", "name": "Tamoxifen", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB09071", "name": "Tasimelteon", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB01265", "name": "Telbivudine", "description": "Peginterferon alfa-2b may enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased."}, {"drugbank-id": "DB04844", "name": "Tetrabenazine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00277", "name": "Theophylline", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB00679", "name": "Thioridazine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB01623", "name": "Thiothixene", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB00373", "name": "Timolol", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00697", "name": "Tizanidine", "description": "CYP1A2 Inhibitors (Weak) may increase the serum concentration of Tizanidine."}, {"drugbank-id": "DB01036", "name": "Tolterodine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00831", "name": "Trifluoperazine", "description": "May increase the serum concentration of CYP1A2 Substrates."}, {"drugbank-id": "DB00726", "name": "Trimipramine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00285", "name": "Venlafaxine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB09068", "name": "Vortioxetine", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}, {"drugbank-id": "DB00495", "name": "Zidovudine", "description": "Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine."}, {"drugbank-id": "DB01624", "name": "Zuclopenthixol", "description": "May decrease the serum concentration of CYP2D6 Substrates. Peginterferon alfa-2b may increase the serum concentration of CYP2D6 Substrates."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00022 sequence\nCDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI\nQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR\nKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "61 \u00b0C", "source": "Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)"}, {"kind": "Isoelectric Point", "value": "5.99", "source": null}, {"kind": "Molecular Weight", "value": "31000.0000", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "12036"}, {"resource": "National Drug Code Directory", "identifier": "0085-1323-01"}, {"resource": "PharmGKB", "identifier": "PA164784024"}, {"resource": "UniProtKB", "identifier": "P01563"}, {"resource": "Wikipedia", "identifier": "Peginterferon_alfa-2b"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic2/peginterferon.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/peginterferon-alfa-2b.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000661", "name": "Interferon alpha/beta receptor 1", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15898717\n# Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19955815\n# Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16953837\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P17181", "@source": "Swiss-Prot", "name": "Interferon alpha/beta receptor 1", "general-function": "Involved in interferon-alpha/beta receptor activity", "specific-function": "Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta- subunits themselves", "gene-name": "IFNAR1", "locus": null, "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "437-457", "signal-regions": null, "theoretical-pi": "5.56", "molecular-weight": "63526.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5432"}, {"resource": "GenAtlas", "identifier": "IFNAR1"}, {"resource": "GeneCards", "identifier": "IFNAR1"}, {"resource": "GenBank Gene Database", "identifier": "J03171"}, {"resource": "GenBank Protein Database", "identifier": "306914"}, {"resource": "UniProtKB", "identifier": "P17181"}, {"resource": "UniProt Accession", "identifier": "INAR1_HUMAN"}]}, "synonyms": {"synonym": ["IFN-alpha-REC", "Interferon-alpha/beta receptor alpha chain precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interferon-alpha/beta receptor alpha chain precursor\nMMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT\nFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF\nTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI\nENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ\nNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK\nGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP\nVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV\nFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE\nYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN\nEDESESKTSEELQQDFV"}, "gene-sequence": {"@format": "FASTA", "#text": ">1674 bp\nATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGGCCCATGGGTG\nTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC\nATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT\nTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG\nAATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT\nAAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT\nACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG\nGCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT\nTTAAGCTTTACATATAGCTTACTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT\nGAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA\nAAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT\nATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA\nAATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG\nTGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA\nCCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA\nGGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA\nGAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA\nTCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT\nGTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT\nGAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT\nGTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT\nTTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA\nGTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC\nTTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG\nTATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA\nAAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT\nGATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT\nGAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA"}, "pfams": null, "go-classifiers": null}}, {"id": "BE0000385", "name": "Interferon alpha/beta receptor 2", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15898717\n# Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19955815\n# Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16953837\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P48551", "@source": "Swiss-Prot", "name": "Interferon alpha/beta receptor 2", "general-function": "Involved in interferon-alpha/beta receptor activity", "specific-function": "Receptor for interferons alpha and beta. Isoform 1 and isoform 3 are directly involved in signal transduction due to their interaction with the TYR kinase, JAK1. Isoform 1 also interacts with the transcriptional factors, STAT1 and STAT2. Both forms are potent inhibitors of type I IFN activity", "gene-name": "IFNAR2", "locus": null, "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "244-264", "signal-regions": null, "theoretical-pi": "4.11", "molecular-weight": "57759.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5433"}, {"resource": "GenAtlas", "identifier": "IFNAR2"}, {"resource": "GeneCards", "identifier": "IFNAR2"}, {"resource": "GenBank Gene Database", "identifier": "L42243"}, {"resource": "GenBank Protein Database", "identifier": "995300"}, {"resource": "UniProtKB", "identifier": "P48551"}, {"resource": "UniProt Accession", "identifier": "INAR2_HUMAN"}]}, "synonyms": {"synonym": ["IFN-alpha-REC", "IFN-R", "Interferon alpha/beta receptor 2", "Interferon-alpha/beta receptor beta chain precursor", "Type I interferon receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interferon-alpha/beta receptor beta chain precursor\nMLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS\nIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF\nSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK\nHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE\nSAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD\nMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI\nDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR\nITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT\nFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR"}, "gene-sequence": {"@format": "FASTA", "#text": ">1548 bp\nATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT\nATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT\nTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC\nATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG\nGTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA\nAGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC\nAGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG\nATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA\nGAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG\nCATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA\nATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA\nATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA\nTCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC\nATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG\nAATTTTCATAACTTTTTAGCCTGGCCATTTCCTAACCTGCCACCGTTGGAAGCCATGGAT\nATGGTGGAGGTCATTTACATCAACAGAAAGAAGAAAGTGTGGGATTATAATTATGATGAT\nGAAAGTGATAGCGATACTGAGGCAGCGCCCAGGACAAGTGGCGGTGGCTATACCATGCAT\nGGACTGACTGTCAGGCCTCTGGGTCAGGCCTCTGCCACCTCTACAGAATCCCAGTTGATA\nGACCCGGAGTCCGAGGAGGAGCCTGACCTGCCTGAGGTTGATGTGGAGCTCCCCACGATG\nCCAAAGGACAGCCCTCAGCAGTTGGAACTCTTGAGTGGGCCCTGTGAGAGGAGAAAGAGT\nCCACTCCAGGACCCTTTTCCCGAAGAGGACTACAGCTCCACGGAGGGGTCTGGGGGCAGA\nATTACCTTCAATGTGGACTTAAACTCTGTGTTTTTGAGAGTTCTTGATGACGAGGACAGT\nGACGACTTAGAAGCCCCTCTGATGCTATCGTCTCATCTGGAAGAGATGGTTGACCCAGAG\nGATCCTGATAATGTGCAATCAAACCATTTGCTGGCCAGCGGGGAAGGGACACAGCCAACC\nTTTCCCAGCCCCTCTTCAGAGGGCCTGTGGTCCGAAGATGCTCCATCTGATCAAAGTGAC\nACTTCTGAGTCAGATGTTGACCTTGGGGATGGTTATATAATGAGATGA"}, "pfams": null, "go-classifiers": null}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2015-11-13", "drugbank-id": [{"@primary": "true", "#text": "DB00023"}, "BIOD00011", "BTD00011"], "name": "Asparaginase", "description": "L-asparagine amidohydrolase from E. coli", "cas-number": "9015-68-3", "groups": {"group": "approved"}, "general-references": "# Appel IM, van Kessel-Bakvis C, Stigter R, Pieters R: Influence of two different regimens of concomitant treatment with asparaginase and dexamethasone on hemostasis in childhood acute lymphoblastic leukemia. Leukemia. 2007 Jun 7;. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17554375\n# http://www.google.com/patents/EP2046369A2", "synthesis-reference": "Masao Nambu, \"Process for producing immobilized L-asparaginase preparations for the therapy of leukemia.\" U.S. Patent US4617271, issued January, 1977.", "indication": "For treatment of acute lympocytic leukemia and non-Hodgkins lymphoma", "pharmacodynamics": "In a significant number of patients with acute leukemia, the malignant cells are dependent on an exogenous source of asparagine for survival. Normal cells, however, are able to synthesize asparagine and thus are affected less by the rapid depletion produced by treatment with the enzyme asparaginase. Elspar exploits a metabolic defect in asparagine synthesis of some malignant cells.", "mechanism-of-action": "Asparaginase converts asparagine to aspartic acid and ammonia. It facilitates production of oxaloacetate which is needed for general cellular metabolism. Some malignant cells lose the ability to produce asparagine and so the loss of exogenous sources of asparagine leads to cell death.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": "8-30 hrs", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Asparaginase (E. coli)"}, {"@language": "", "@coder": "", "#text": "L-asparagine amidohydrolase"}, {"@language": "", "@coder": "", "#text": "Putative L-asparaginase precursor"}]}, "products": {"product": [{"name": "Erwinase", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02237815", "started-marketing-on": "2009-07-01", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "10000 unit", "route": "intramuscular; intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kidrolase", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01926438", "started-marketing-on": "1974-12-31", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "10000 unit", "route": "intramuscular; intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": {"name": "Elspar", "company": "Merck & Co. Inc"}}, "mixtures": {"mixture": [{"name": "Kidrolase", "ingredients": "Asparaginase"}, {"name": "Erwinase", "ingredients": "Asparaginase"}]}, "packagers": {"packager": [{"name": "Lundbeck Inc.", "url": "http://www.lundbeckinc.com"}, {"name": "Merck & Co.", "url": "http://www.merck.com"}, {"name": "Prescript Pharmaceuticals", "url": "http://www.prescript.net"}]}, "manufacturers": null, "prices": {"price": {"description": "Elspar 10000 unit vial", "cost": {"@currency": "USD", "#text": "74.6"}, "unit": "vial"}}, "categories": {"category": {"category": "Antineoplastic Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Powder for solution", "route": "intramuscular; intravenous; subcutaneous", "strength": "10000 unit"}, {"form": "Powder for solution", "route": "intramuscular; intravenous", "strength": "10000 unit"}]}, "atc-codes": {"atc-code": {"@code": "L01XX02", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L01", "#text": "ANTINEOPLASTIC AGENTS"}, {"@code": "L01X", "#text": "OTHER ANTINEOPLASTIC AGENTS"}, {"@code": "L01XX", "#text": "Other antineoplastic agents"}]}}, "ahfs-codes": {"ahfs-code": "10:00.00"}, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": [{"@format": "FASTA", "#text": "> Elspar Sequence\nQMSLQQELRYIEALSAIVETGQKMLEAGESALDVVTEAVRLLEECPLFNAGIGAVFTRDE\nTHELDACVMDGNTLKAGAVAGVSHLRNPVLAARLVMEQSPHVMMIGEGAENFAFARGMER\nVSPEIFSTSLRYEQLLAARKEGATVLDHSGAPLDEKQKMGTVGAVALDLDGNLAAATSTG\nGMTNKLPGRVGDSPLVGAGCYANNASVAVSCTGTGEVFIRALAAYDIAALMDYGGLSLAE\nACERVVMEKLPTLGGSGGLIAIDHEGNVALPFNTEGMYRAWGYAGDTPTTGIYREKGDTV\nATQ"}, {"@format": "FASTA", "#text": ">sp|P00805|ASPG2_ECOLI L-asparaginase 2 OS=Escherichia coli (strain K12) GN=ansB PE=1 SV=2\nMEFFKKTALAALVMGFSGAALALPNITILATGGTIAGGGDSATKSNYTVGKVGVENLVNA\nVPQLKDIANVKGEQVVNIGSQDMNDNVWLTLAKKINTDCDKTDGFVITHGTDTMEETAYF\nLDLTVKCDKPVVMVGAMRPSTSMSADGPFNLYNAVVTAADKASANRGVLVVMNDTVLDGR\nDVTKTNTTDVATFKSVNYGPLGYIHNGKIDYQRTPARKHTSDTPFDVSKLNELPKVGIVY\nNYANASDLPAKALVDAGYDGIVSAGVGNGNLYKSVFDTLATAAKTGTAVVRSSRVPTGAT\nTQDAEVDDAKYGFVASGTLNPQKARVLLQLALTQTKDPQQIQQIFNQY"}]}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "0.059", "source": null}, {"kind": "Isoelectric Point", "value": "4.67", "source": null}, {"kind": "Molecular Weight", "value": "31731.9000", "source": null}, {"kind": "Molecular Formula", "value": "C1377H2208N382O442S17", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "2433"}, {"resource": "GenBank", "identifier": "U00096"}, {"resource": "PharmGKB", "identifier": "PA448492"}, {"resource": "UniProtKB", "identifier": "P37595"}, {"resource": "Wikipedia", "identifier": "Asparaginase"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/asparaginase.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/asparaginase.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0004798", "name": "L-asparagine", "organism": "Human", "actions": {"action": "other/unknown"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Wetzler M, Sanford BL, Kurtzberg J, DeOliveira D, Frankel SR, Powell BL, Kolitz JE, Bloomfield CD, Larson RA: Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood. 2007 May 15;109(10):4164-7. Epub 2007 Jan 30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17264295\n# Wenner KA, Vieira Pinheiro JP, Escherich G, Wessalowski R, Jorch N, Wolff J, Stehn M, Kohlschutter A, Boos J, Janka-Schaub GE: Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia. Klin Padiatr. 2005 Nov-Dec;217(6):321-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16307417\n# Appel IM, Pinheiro JP, den Boer ML, Lanvers C, Reniers NC, Boos J, Pieters R: Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL. Leukemia. 2003 Nov;17(11):2254-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14523472", "known-action": "yes"}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-10-14", "drugbank-id": [{"@primary": "true", "#text": "DB00024"}, "BIOD00020", "BTD00020"], "name": "Thyrotropin Alfa", "description": "Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer. It is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues containing one N-linked glycosylation site. The alpha subunit is nearly identical to that of human chorionic gonadotropin (hCG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). The alpha subunit is thought to be the effector region responsible for stimulation of adenylate cyclase (involved the generation of cAMP). The beta subunit (TSHB) is unique to TSH, and therefore determines its receptor specificity. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone.", "cas-number": "9002-71-5", "groups": {"group": "approved"}, "general-references": "# Lexicomp\n#Product label", "synthesis-reference": "19366632", "indication": "For detection of residueal or recurrent thyroid cancer", "pharmacodynamics": "Binding of thyrotropin alfa to TSH receptors on normal thyroid epithelial cells or on well-differentiated thyroid cancer tissue stimulates iodine uptake and organification. Thyrogen is an exogenous source of human TSH that offers an additional diagnostic tool in the follow-up of patients with a history of well-differentiated thyroid cancer.", "mechanism-of-action": "Thyrotropin Alfa binds to the thyrotropin receptors found on any residual thyroid cells or tissues. This stimulates radioactive iodine uptake for better radiodiagnostic imaging.", "toxicity": "No difference in efficacy and toxicity between adult and geriatric patients. No studies in lactating women, pregnant women and pediatrics. Cautionary administration is advised.", "metabolism": null, "absorption": "Time to peak: Median: 10 hours (range: 3-24 hours)\nAfter a single intramuscular injection of 0.9 mg of thyrotropin alfa: Cmax= 116+38mU/L, Tmax=22+8.5 hours. AUC=5088+1728 mU\u00b7hr/L.", "half-life": "25 \u00b1 10 hours", "protein-binding": null, "route-of-elimination": "kidney and liver", "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "rTSH"}, {"@language": "", "@coder": "", "#text": "Thyroid stimulating hormone"}, {"@language": "", "@coder": "", "#text": "Thyrotrophin-alfa"}, {"@language": "", "@coder": "", "#text": "Thyrotrophin-alpha"}, {"@language": "", "@coder": "", "#text": "Thyrotropin"}, {"@language": "", "@coder": "", "#text": "Thyrotropin-a"}, {"@language": "", "@coder": "", "#text": "Thyrotropin-alpha"}, {"@language": "", "@coder": "", "#text": "Thytrophin"}, {"@language": "", "@coder": "", "#text": "TSH"}]}, "products": {"product": [{"name": "Thyrogen", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02246016", "started-marketing-on": "2002-08-12", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "0.9 mg", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Thyrogen", "ndc-id": "58468-0030_b9da8016-40ba-4e81-85c8-911862339cee", "ndc-product-code": "58468-0030", "dpd-id": null, "started-marketing-on": "1998-11-30", "ended-marketing-on": null, "dosage-form": "injection, powder, for solution", "strength": ".9 mg/mL", "route": "intramuscular", "fda-application-number": "NDA020898", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Thyrogen", "ingredients": "Thyrotropin Alfa"}, {"name": "Thyrogen", "ingredients": "Thyrotropin Alfa"}]}, "packagers": {"packager": [{"name": "Genzyme Inc.", "url": "http://www.genzyme.ca"}, {"name": "Organon Pharmaceuticals", "url": "http://www.organonshop.com"}]}, "manufacturers": {"manufacturer": [{"@generic": "false", "#text": "Sanofi aventis us llc"}, {"@generic": "false", "#text": "Genzyme corp"}]}, "prices": {"price": {"description": "Thyrogen 1.1 mg vial", "cost": {"@currency": "USD", "#text": "1196.4"}, "unit": "vial"}}, "categories": {"category": {"category": "Diagnostic Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, powder, for solution", "route": "intramuscular", "strength": ".9 mg/mL"}, {"form": "Powder for solution", "route": "intramuscular", "strength": "0.9 mg"}]}, "atc-codes": {"atc-code": {"@code": "H01AB01", "level": [{"@code": "H", "#text": "SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS"}, {"@code": "H01", "#text": "PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES"}, {"@code": "H01A", "#text": "ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES"}, {"@code": "H01AB", "#text": "Thyrotropin"}]}}, "ahfs-codes": {"ahfs-code": "36:60.00"}, "patents": {"patent": {"number": "5840566", "country": "United States", "approved": "1995-11-24", "expires": "2015-11-24"}}, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">Alpha chain\nAPDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC\nVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS"}, {"@format": "FASTA", "#text": ">Beta chain\nFCIPTEYTMHIERRECAYCLTINTTICAGYCMTRDINGKLFLPKYALSQDVCTYRDFIYR\nTVEIPGCPLHVAPYFSYPVALSCKCGKCNTDYSDCIHEAIKTNYCTKPQKSY"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "55 \u00b0C", "source": null}, {"kind": "Hydrophobicity", "value": "-0.330", "source": null}, {"kind": "Isoelectric Point", "value": "7.50", "source": null}, {"kind": "Molecular Weight", "value": "22672.9000", "source": null}, {"kind": "Molecular Formula", "value": "C975H1513N267O304S26", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "12790"}, {"resource": "National Drug Code Directory", "identifier": "58468-1849-4"}, {"resource": "GenBank", "identifier": "M16647"}, {"resource": "PharmGKB", "identifier": "PA164746560"}, {"resource": "UniProtKB", "identifier": "P01225"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic2/thyrotropin.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/thyrotropin-alfa.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0000490", "name": "Thyrotropin receptor", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Szkudlinski MW: Recombinant human thyrotropins of the twenty-first century. Expert Opin Pharmacother. 2004 Dec;5(12):2435-40. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15571461\n# Conway GS: Clinical manifestations of genetic defects affecting gonadotrophins and their receptors. Clin Endocrinol (Oxf). 1996 Dec;45(6):657-63. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9039330\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P16473", "@source": "Swiss-Prot", "name": "Thyrotropin receptor", "general-function": "Involved in rhodopsin-like receptor activity", "specific-function": "Receptor for thyrothropin. Plays a central role in controlling thyroid cell metabolism. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Also acts as a receptor for thyrostimulin (GPA2+GPB5)", "gene-name": "TSHR", "locus": "14q31", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "414-441\n451-473\n495-517\n538-560\n581-602\n626-649\n661-682", "signal-regions": null, "theoretical-pi": "6.98", "molecular-weight": "86831.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:12373"}, {"resource": "GenAtlas", "identifier": "TSHR"}, {"resource": "GeneCards", "identifier": "TSHR"}, {"resource": "GenBank Gene Database", "identifier": "M73747"}, {"resource": "GenBank Protein Database", "identifier": "903760"}, {"resource": "IUPHAR", "identifier": "255"}, {"resource": "Guide to Pharmacology", "identifier": "30"}, {"resource": "UniProtKB", "identifier": "P16473"}, {"resource": "UniProt Accession", "identifier": "TSHR_HUMAN"}]}, "synonyms": {"synonym": ["Thyroid-stimulating hormone receptor", "Thyrotropin receptor precursor", "TSH-R"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Thyrotropin receptor precursor\nMRPADLLQLVLLLDLPRDLGGMGCSSPPCECHQEEDFRVTCKDIQRIPSLPPSTQTLKLI\nETHLRTIPSHAFSNLPNISRIYVSIDVTLQQLESHSFYNLSKVTHIEIRNTRNLTYIDPD\nALKELPLLKFLGIFNTGLKMFPDLTKVYSTDIFFILEITDNPYMTSIPVNAFQGLCNETL\nTLKLYNNGFTSVQGYAFNGTKLDAVYLNKNKYLTVIDKDAFGGVYSGPSLLDVSQTSVTA\nLPSKGLEHLKELIARNTWTLKKLPLSLSFLHLTRADLSYPSHCCAFKNQKKIRGILESLM\nCNESSMQSLRQRKSVNALNSPLHQEYEENLGDSIVGYKEKSKFQDTHNNAHYYVFFEEQE\nDEIIGFGQELKNPQEETLQAFDSHYDYTICGDSEDMVCTPKSDEFNPCEDIMGYKFLRIV\nVWFVSLLALLGNVFVLLILLTSHYKLNVPRFLMCNLAFADFCMGMYLLLIASVDLYTHSE\nYYNHAIDWQTGPGCNTAGFFTVFASELSVYTLTVITLERWYAITFAMRLDRKIRLRHACA\nIMVGGWVCCFLLALLPLVGISSYAKVSICLPMDTETPLALAYIVFVLTLNIVAFVIVCCC\nYVKIYITVRNPQYNPGDKDTKIAKRMAVLIFTDFICMAPISFYALSAILNKPLITVSNSK\nILLVLFYPLNSCANPFLYAIFTKAFQRDVFILLSKFGICKRQAQAYRGQRVPPKNSTDIQ\nVQKVTHDMRQGLHNMEDVYELIENSHLTPKKQGQISEEYMQTVL"}, "gene-sequence": {"@format": "FASTA", "#text": ">2292 bp\nATGAGGCCGGCGGACTTGCTGCAGCTGGTGCTGCTGCTCGACCTGCCCAGGGACCTGGGC\nGGAATGGGGTGTTCGTCTCCACCCTGCGAGTGCCATCAGGAGGAGGACTTCAGAGTCACC\nTGCAAGGATATTCAACGCATCCCCAGCTTACCGCCCAGTACGCAGACTCTGAAGCTTATT\nGAGACTCACCTGAGAACTATTCCAAGTCATGCATTTTCTAATCTGCCCAATATTTCCAGA\nATCTACGTATCTATAGATGTGACTCTGCAGCAGCTGGAATCACACTCCTTCTACAATTTG\nAGTAAAGTGACTCACATAGAAATTCGGAATACCAGGAACTTAACTTACATAGACCCTGAT\nGCCCTCAAAGAGCTCCCCCTCCTAAAGTCCTTGGCATTTTCAAACACTGGACTTAAAATG\nTTCCCTGACCTGACCAAAGTTTATTCCACTGATATATTCTTTATACTTGAAATTACAGAC\nAACCCTTACATGACGTCAATCCCTGTGAATGCTTTTCAGGGACTATGCAATGAAACCTTG\nACACTGAAGCTGTACAACAATGGCTTTACTTCAGTCCAAGGATATGATTTCTTTGGGACA\nAAGCTGGATGCTGTTTACCTAAACAAGAATAAATACCTGACAGTTATTGACAAAGATGCA\nTTTGGAGGAGTATACAGTGGACCAAGCTTGCTGGACGTGTCTCAAACCAGTGTCACTGCC\nCTTCCATCCAAAGGCCTGGAGCACCTGAAGGAACTGATAGCAAGAAACAGCTGGACTCTT\nAAGAAACTTGCACTTTCCTTGAGTTTCCTTCACCTCACACGGGCTGACCTTTCTTACCCA\nAGCCACTGCTGTGCTTTTAAGAATCAGAAGAAAATCAGAGGAATCCTTGAGTCCTTGATG\nTGTAATGAGAGCAGTATCGAGACGTTGCGCCAGAGAAAATCTGTGAATGCCTTGAATAGC\nCCCCTCCACCAGGAATATGAAGAGAATCTGGGTGACAGCATTGTTGGGTACAAGGAAAAG\nTCCAAGTTCCAGGATACTCATAACAACGCTCATTATTACGTCTTCTTTGAAGAACAAGAG\nGATGAGATCATTGGTTTTGGCCAGGAGCTCAAAAACCCCCAGGAAGAGACTCTACAAGCT\nTTTGACAGCCATTATGACTACACCATATGTGGGGACAGTGAAGACATGGTGTGTACCCCC\nAAGTCCGATGAGTTCAACCCGTGTGAAGACATAATGGGCTACAAGTTCCTGAGAATTGTG\nGTGTGGTTCGTTAGTCTGCTGGCTCTCCTGGGCAATGTCTTTGTCCTGCTTATTCTCCTC\nACCAGCCACTACAAACTGAACGTCCCCCGCTTTCTCATGTGCAACCTGGCCTTTGCGGAT\nTTCTGCATGGGGATGTACCTGCTCCTCATCGCCTCTGTAGACCTCTACACTCACTCTGAG\nTACTACAACCATGCCATCGACTGGCAGACAGGCCCTGGGTGCAACACGGCTGGTTTCTTC\nACTGTCTTTGCAAGCGAGTTATCGGTGTATACGCTGACGGTCATCACCCTGGAGCGCTGG\nTATGCCATCACCTTCGCCATGGCCCTGGACCGGAAGATCCGCCTCAGGCACGCATGTGCC\nATCATGGTTGGGGGCTGGGTTTGCTGCTTCCTTCTCGCCCTGCTTCCTTTGGTGGGAATA\nAGTAGCTATGCCAAAGTCAGTATCTGCCTGCCCATGGACACCGAGACCCCTCTTGCTCTG\nGCATATATTGTTTTTGTTCTGACGCTCAACATAGTTGCCTTCGTCATCGTCTGCTGCTGT\nTATGTGAAGATCTACATCACAGTCCGAAATCCGCACAACCCAGGGGACAAAGATACCAAA\nATTGCCAAGAGGATGGCTGTGTTGATCTTCACCGACTTCACGTGCATGGCCCCAATCTCA\nTTCTATGCTGTGTCAGCAATTCTGAACAAGCCTCTCATCACTGTTAGCAACTCCAAAATC\nTTGCTGGTACTCTTCTATCCAATTAACTCCTGTGCCAATCCATTCCTCTATGCTATTTTC\nACCAAGGCCTTCCAGAGGGATGTGTTCATCCTACTCAGCAAGTTTGGCATCTGTAAACGC\nCAGGCTCAGGCATACCGGGGGCAGAGGGTTCCTCCAAAGAACAGCACTGATATTCAGGTT\nCAAAAGGTTACCCACGACATGAGGCAGGGTCTCCACAACATGGAAGATGTCTATGAACTG\nATTGAAAACTCCCATCTAACCCCAAAGAAGCAAGGCCAAATCTCAGAAGAGTATATGCAA\nACGGTTTTGTAA"}, "pfams": {"pfam": [{"identifier": "PF00001", "name": "7tm_1"}, {"identifier": "PF00560", "name": "LRR_1"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "function", "description": "protein-hormone receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}]}}}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-09-13", "drugbank-id": [{"@primary": "true", "#text": "DB00025"}, "BIOD00029", "BTD00029"], "name": "Antihemophilic Factor", "description": "Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells", "cas-number": null, "groups": {"group": ["approved", "investigational"]}, "general-references": "# Titheradge MA, Coore HG: Initial rates of pyruvate transport in mitochondria determined by an \"inhibitor-stop\" technique. Biochem J. 1975 Sep;150(3):553-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2157", "synthesis-reference": "James W. Bloom, \"Warm ethanol method for preparation of low fibrinogen antihemophilic factor.\" U.S. Patent US4478825, issued June, 1955.", "indication": "For the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.", "pharmacodynamics": "Antihemophilic Factor binds factor IXa along with calcium and phospholipid, This complex converts factor X to factor Xa to facilitate clotting cascade.", "mechanism-of-action": "Antihemophilic factor (AHF) is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A (classical hemophilia).", "toxicity": null, "metabolism": null, "absorption": null, "half-life": "8.4-19.3 hrs", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": "* 4.1 mL/h\u2022kg [Previously treated pediatric patients]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "AHF"}, {"@language": "", "@coder": "", "#text": "Factor VIII"}]}, "products": {"product": [{"name": "Advate", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02284154", "started-marketing-on": "2006-10-06", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "1000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Advate", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02284162", "started-marketing-on": "2006-10-06", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "1500 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Advate", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02365944", "started-marketing-on": "2012-01-16", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "250 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Advate", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02365952", "started-marketing-on": "2012-03-05", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "500 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Advate", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02337193", "started-marketing-on": "2010-01-05", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "3000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Advate", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02365979", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "1000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Advate", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02365987", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "1500 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Advate", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02284138", "started-marketing-on": "2006-10-06", "ended-marketing-on": "2013-10-08", "dosage-form": "powder for solution", "strength": "250 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Advate", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02284146", "started-marketing-on": "2006-10-06", "ended-marketing-on": "2013-10-08", "dosage-form": "powder for solution", "strength": "500 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Advate", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02313111", "started-marketing-on": "2008-09-04", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "2000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Factorate Inj 15unit/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00611131", "started-marketing-on": "1984-12-31", "ended-marketing-on": "1999-12-15", "dosage-form": "powder for solution", "strength": "15 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Helixate Fs", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02308592", "started-marketing-on": "2009-09-07", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "2000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Helixate Fs", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02342723", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "3000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Helixate Fs", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02243186", "started-marketing-on": "2008-04-24", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "250 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Helixate Fs", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02243187", "started-marketing-on": "2008-04-24", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "500 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Helixate Fs", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02243188", "started-marketing-on": "2008-04-24", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "1000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Hemofil M", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00808709", "started-marketing-on": "1988-12-31", "ended-marketing-on": "2006-05-19", "dosage-form": "powder for solution", "strength": "1700 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Hyate C Inj Vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00738859", "started-marketing-on": "1986-12-31", "ended-marketing-on": "1996-09-25", "dosage-form": "powder for solution", "strength": "700 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Koate-hp - Pws IV 1000iu/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02187841", "started-marketing-on": "1997-01-23", "ended-marketing-on": "2000-08-01", "dosage-form": "powder for solution", "strength": "1000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Koate-hp Unj", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00836419", "started-marketing-on": "1989-12-31", "ended-marketing-on": "1998-09-25", "dosage-form": "liquid", "strength": "1800 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kogenate - Pws IV 1000I.U./vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02178834", "started-marketing-on": "1996-07-09", "ended-marketing-on": "2002-08-01", "dosage-form": "powder for solution", "strength": "1000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kogenate - Pws IV 250I.U./vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02178818", "started-marketing-on": "1996-11-20", "ended-marketing-on": "2002-08-01", "dosage-form": "powder for solution", "strength": "250 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kogenate - Pws IV 500I.U./vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02178826", "started-marketing-on": "1996-11-20", "ended-marketing-on": "2002-08-01", "dosage-form": "powder for solution", "strength": "500 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kogenate Fs", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02242489", "started-marketing-on": "2004-03-31", "ended-marketing-on": "2009-08-06", "dosage-form": "powder for solution", "strength": "250 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kogenate Fs", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02254476", "started-marketing-on": "2006-08-04", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "250 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kogenate Fs", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02242490", "started-marketing-on": "2000-09-29", "ended-marketing-on": "2009-08-06", "dosage-form": "powder for solution", "strength": "500 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kogenate Fs", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02254484", "started-marketing-on": "2005-09-26", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "500 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kogenate Fs", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02242491", "started-marketing-on": "2000-09-29", "ended-marketing-on": "2009-08-06", "dosage-form": "powder for solution", "strength": "1000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kogenate Fs", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02254492", "started-marketing-on": "2005-09-26", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "1000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kogenate Fs     -(with Bio-set)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02342758", "started-marketing-on": "2010-05-11", "ended-marketing-on": "2015-07-07", "dosage-form": "powder for solution", "strength": "3000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kogenate Fs     -(with Bio-set)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02302225", "started-marketing-on": "2008-08-06", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "2000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kogenate Fs     -(with Vial Adapter)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02291517", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "250 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kogenate Fs     -(with Vial Adapter)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02291525", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "500 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kogenate Fs     -(with Vial Adapter)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02291533", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "1000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kogenate Fs     -(with Vial Adapter)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02302217", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "2000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kogenate Fs     -(with Vial Adapter)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02342731", "started-marketing-on": "2015-07-07", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "3000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kogenate Pws 1000iu/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02042517", "started-marketing-on": "1993-12-31", "ended-marketing-on": "1998-09-25", "dosage-form": "powder for solution", "strength": "1000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kogenate Pws 250iu/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02042495", "started-marketing-on": "1993-12-31", "ended-marketing-on": "1998-09-25", "dosage-form": "powder for solution", "strength": "250 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kogenate Pws 500iu/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02042509", "started-marketing-on": "1993-12-31", "ended-marketing-on": "1998-09-25", "dosage-form": "powder for solution", "strength": "500 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kryobulin Vh 1000 Unit/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00719838", "started-marketing-on": "1988-12-31", "ended-marketing-on": "1998-08-13", "dosage-form": "powder for solution", "strength": "1000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kryobulin Vh 500 Unit/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00719811", "started-marketing-on": "1987-12-31", "ended-marketing-on": "1998-08-13", "dosage-form": "powder for solution", "strength": "500 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Monoclate-p  -  200-350iu/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02215144", "started-marketing-on": "2001-06-27", "ended-marketing-on": "2008-10-16", "dosage-form": "solution; kit", "strength": "2.5 ml", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Monoclate-p  -  400-700iu/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02215152", "started-marketing-on": "2001-06-27", "ended-marketing-on": "2008-10-16", "dosage-form": "solution; kit", "strength": "5 ml", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Monoclate-p  -  800-1500iu/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02215160", "started-marketing-on": "2001-06-27", "ended-marketing-on": "2008-10-16", "dosage-form": "solution; kit", "strength": "10 ml", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Profilate Heat Treated-wet Method Inj", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00740780", "started-marketing-on": "1988-12-31", "ended-marketing-on": "1997-11-12", "dosage-form": "liquid", "strength": "1000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Recombinate Pws Inj 1000I.U./vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02015137", "started-marketing-on": "1992-12-31", "ended-marketing-on": "2009-02-12", "dosage-form": "powder for solution", "strength": "1000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Recombinate Pws Inj 250I.U./vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02015129", "started-marketing-on": "1992-12-31", "ended-marketing-on": "2009-02-12", "dosage-form": "powder for solution", "strength": "250 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Recombinate Pws Inj 500I.U./vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02015145", "started-marketing-on": "1992-12-31", "ended-marketing-on": "2009-02-12", "dosage-form": "powder for solution", "strength": "500 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": [{"name": "Bioclate", "company": null}, {"name": "Helixate", "company": null}, {"name": "Hyate:C", "company": null}, {"name": "Koate-HP", "company": null}, {"name": "Kogenate", "company": null}, {"name": "Monarc-M", "company": null}, {"name": "ReFacto", "company": null}]}, "mixtures": {"mixture": [{"name": "Helixate Fs", "ingredients": "Antihemophilic Factor"}, {"name": "Helixate Fs", "ingredients": "Antihemophilic Factor"}, {"name": "Helixate Fs", "ingredients": "Antihemophilic Factor"}, {"name": "Kogenate Fs", "ingredients": "Antihemophilic Factor"}, {"name": "Kogenate Fs", "ingredients": "Antihemophilic Factor"}, {"name": "Kogenate Fs", "ingredients": "Antihemophilic Factor"}, {"name": "Advate", "ingredients": "Antihemophilic Factor"}, {"name": "Advate", "ingredients": "Antihemophilic Factor"}, {"name": "Kogenate Fs     -(with Bio-set)", "ingredients": "Antihemophilic Factor"}, {"name": "Helixate Fs", "ingredients": "Antihemophilic Factor"}, {"name": "Advate", "ingredients": "Antihemophilic Factor"}, {"name": "Advate", "ingredients": "Antihemophilic Factor"}, {"name": "Kogenate Fs     -(with Vial Adapter)", "ingredients": "Antihemophilic Factor"}, {"name": "Advate", "ingredients": "Antihemophilic Factor"}, {"name": "Advate", "ingredients": "Antihemophilic Factor"}, {"name": "Koate-hp Unj", "ingredients": "Antihemophilic Factor"}, {"name": "Kryobulin Vh 1000 Unit/vial", "ingredients": "Antihemophilic Factor"}, {"name": "Hyate C Inj Vial", "ingredients": "Antihemophilic Factor"}, {"name": "Recombinate Pws Inj 250I.U./vial", "ingredients": "Antihemophilic Factor"}, {"name": "Recombinate Pws Inj 1000I.U./vial", "ingredients": "Antihemophilic Factor"}, {"name": "Recombinate Pws Inj 500I.U./vial", "ingredients": "Antihemophilic Factor"}, {"name": "Kogenate Pws 250iu/vial", "ingredients": "Antihemophilic Factor"}, {"name": "Kogenate Pws 500iu/vial", "ingredients": "Antihemophilic Factor"}, {"name": "Kogenate Pws 1000iu/vial", "ingredients": "Antihemophilic Factor"}, {"name": "Koate-hp - Pws IV 1000iu/vial", "ingredients": "Antihemophilic Factor"}, {"name": "Monoclate-p  -  200-350iu/vial", "ingredients": "Water + Antihemophilic Factor"}, {"name": "Monoclate-p  -  400-700iu/vial", "ingredients": "Water + Antihemophilic Factor"}, {"name": "Monoclate-p  -  800-1500iu/vial", "ingredients": "Water + Antihemophilic Factor"}, {"name": "Kogenate - Pws IV 250I.U./vial", "ingredients": "Antihemophilic Factor"}, {"name": "Kogenate - Pws IV 500I.U./vial", "ingredients": "Antihemophilic Factor"}, {"name": "Kogenate - Pws IV 1000I.U./vial", "ingredients": "Antihemophilic Factor"}, {"name": "Factorate Inj 15unit/ml", "ingredients": "Antihemophilic Factor"}, {"name": "Kogenate Fs", "ingredients": "Antihemophilic Factor"}, {"name": "Kogenate Fs", "ingredients": "Antihemophilic Factor"}, {"name": "Kogenate Fs", "ingredients": "Antihemophilic Factor"}, {"name": "Advate", "ingredients": "Antihemophilic Factor"}, {"name": "Advate", "ingredients": "Antihemophilic Factor"}, {"name": "Kryobulin Vh 500 Unit/vial", "ingredients": "Antihemophilic Factor"}, {"name": "Kogenate Fs     -(with Bio-set)", "ingredients": "Antihemophilic Factor"}, {"name": "Profilate Heat Treated-wet Method Inj", "ingredients": "Antihemophilic Factor"}, {"name": "Hemofil M", "ingredients": "Antihemophilic Factor"}, {"name": "Kogenate Fs     -(with Vial Adapter)", "ingredients": "Antihemophilic Factor"}, {"name": "Kogenate Fs     -(with Vial Adapter)", "ingredients": "Antihemophilic Factor"}, {"name": "Kogenate Fs     -(with Vial Adapter)", "ingredients": "Antihemophilic Factor"}, {"name": "Kogenate Fs     -(with Vial Adapter)", "ingredients": "Antihemophilic Factor"}, {"name": "Helixate Fs", "ingredients": "Antihemophilic Factor"}, {"name": "Advate", "ingredients": "Antihemophilic Factor"}, {"name": "Advate", "ingredients": "Antihemophilic Factor"}]}, "packagers": {"packager": [{"name": "Baxter International Inc.", "url": "http://www.baxter.com"}, {"name": "Bayer Healthcare", "url": "http://www.bayerhealthcare.com"}, {"name": "CSL Behring LLC", "url": "http://www.cslbehring.com"}, {"name": "GlaxoSmithKline Inc.", "url": "http://www.gsk.com"}, {"name": "Grifols SA", "url": "http://www.grifols.com"}, {"name": "Ipsen Pharmaceuticals Inc.", "url": "http://www.ipsen.com"}, {"name": "Octapharma USA", "url": "http://www.octapharma.com"}, {"name": "Talecris Biotherapeutics", "url": "http://www.talecris.com"}, {"name": "Wyeth Pharmaceuticals", "url": "http://www.wyeth.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Monoclate-p 1000 unit kit", "cost": {"@currency": "USD", "#text": "1.01"}, "unit": "kit"}, {"description": "Monoclate-p 1500 unit kit", "cost": {"@currency": "USD", "#text": "1.01"}, "unit": "kit"}, {"description": "Monoclate-p 250 unit kit", "cost": {"@currency": "USD", "#text": "1.01"}, "unit": "kit"}, {"description": "Monoclate-p 500ahfu kit", "cost": {"@currency": "USD", "#text": "1.01"}, "unit": "kit"}, {"description": "Alphanate 1000-1500 unit vial", "cost": {"@currency": "USD", "#text": "1.2"}, "unit": "vial"}, {"description": "Alphanate 250-500 unit vial", "cost": {"@currency": "USD", "#text": "1.2"}, "unit": "vial"}, {"description": "Humate-p 1000 unit kit", "cost": {"@currency": "USD", "#text": "1.2"}, "unit": "kit"}, {"description": "Humate-p 1200 unit kit", "cost": {"@currency": "USD", "#text": "1.2"}, "unit": "kit"}, {"description": "Humate-p 2000 unit kit", "cost": {"@currency": "USD", "#text": "1.2"}, "unit": "kit"}, {"description": "Humate-p 2400 unit kit", "cost": {"@currency": "USD", "#text": "1.2"}, "unit": "kit"}, {"description": "Humate-p 500 unit kit", "cost": {"@currency": "USD", "#text": "1.2"}, "unit": "kit"}, {"description": "Humate-p 600 unit kit", "cost": {"@currency": "USD", "#text": "1.2"}, "unit": "kit"}, {"description": "Koate-dvi 1000 unit kit", "cost": {"@currency": "USD", "#text": "1.31"}, "unit": "kit"}, {"description": "Koate-dvi 250 unit kit", "cost": {"@currency": "USD", "#text": "1.31"}, "unit": "kit"}, {"description": "Koate-dvi 500 unit kit", "cost": {"@currency": "USD", "#text": "1.31"}, "unit": "kit"}, {"description": "Refacto 1000 unit vial", "cost": {"@currency": "USD", "#text": "1.31"}, "unit": "vial"}, {"description": "Refacto 2000 unit vial", "cost": {"@currency": "USD", "#text": "1.31"}, "unit": "vial"}, {"description": "Refacto 250 unit vial", "cost": {"@currency": "USD", "#text": "1.31"}, "unit": "vial"}, {"description": "Refacto 500 unit vial", "cost": {"@currency": "USD", "#text": "1.31"}, "unit": "vial"}, {"description": "Hemofil m 1701-2000 unit vial", "cost": {"@currency": "USD", "#text": "1.34"}, "unit": "vial"}, {"description": "Hemofil m 220-400 unit vial", "cost": {"@currency": "USD", "#text": "1.34"}, "unit": "vial"}, {"description": "Hemofil m 401-800 unit vial", "cost": {"@currency": "USD", "#text": "1.34"}, "unit": "vial"}, {"description": "Hemofil m 801-1700 unit vial", "cost": {"@currency": "USD", "#text": "1.34"}, "unit": "vial"}, {"description": "Wilate 450-450 unit kit", "cost": {"@currency": "USD", "#text": "1.38"}, "unit": "kit"}, {"description": "Wilate 900-900 unit kit", "cost": {"@currency": "USD", "#text": "1.38"}, "unit": "kit"}, {"description": "Helixate fs 1000 unit vial", "cost": {"@currency": "USD", "#text": "1.56"}, "unit": "vial"}, {"description": "Helixate fs 250 unit vial", "cost": {"@currency": "USD", "#text": "1.56"}, "unit": "vial"}, {"description": "Helixate fs 3000 unit vial", "cost": {"@currency": "USD", "#text": "1.56"}, "unit": "vial"}, {"description": "Helixate fs 500 unit vial", "cost": {"@currency": "USD", "#text": "1.56"}, "unit": "vial"}, {"description": "Xyntha 1000 unit kit", "cost": {"@currency": "USD", "#text": "1.66"}, "unit": "kit"}, {"description": "Xyntha 2000 unit kit", "cost": {"@currency": "USD", "#text": "1.66"}, "unit": "kit"}, {"description": "Xyntha 250 unit kit", "cost": {"@currency": "USD", "#text": "1.66"}, "unit": "kit"}, {"description": "Xyntha 500 unit kit", "cost": {"@currency": "USD", "#text": "1.66"}, "unit": "kit"}, {"description": "Advate 1201-1800 unit vial", "cost": {"@currency": "USD", "#text": "1.68"}, "unit": "vial"}, {"description": "Advate 1801-2400 unit vial", "cost": {"@currency": "USD", "#text": "1.68"}, "unit": "vial"}, {"description": "Advate 200-400 unit vial", "cost": {"@currency": "USD", "#text": "1.68"}, "unit": "vial"}, {"description": "Advate 2400-3600 unit vial", "cost": {"@currency": "USD", "#text": "1.68"}, "unit": "vial"}, {"description": "Advate 401-800 unit vial", "cost": {"@currency": "USD", "#text": "1.68"}, "unit": "vial"}, {"description": "Advate 801-1200 unit vial", "cost": {"@currency": "USD", "#text": "1.68"}, "unit": "vial"}, {"description": "Kogenate fs 1000 unit vial", "cost": {"@currency": "USD", "#text": "1.68"}, "unit": "vial"}, {"description": "Kogenate fs 250 unit vial", "cost": {"@currency": "USD", "#text": "1.68"}, "unit": "vial"}, {"description": "Kogenate fs 3000 unit vial", "cost": {"@currency": "USD", "#text": "1.68"}, "unit": "vial"}, {"description": "Kogenate fs 500 unit vial", "cost": {"@currency": "USD", "#text": "1.68"}, "unit": "vial"}]}, "categories": {"category": [{"category": "Coagulants", "mesh-id": null}, {"category": "Thrombotic Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Powder for solution", "route": "intravenous", "strength": "1500 unit"}, {"form": "Powder for solution", "route": "intravenous", "strength": "3000 unit"}, {"form": "Powder for solution", "route": "intravenous", "strength": "15 unit"}, {"form": "Powder for solution", "route": "intravenous", "strength": "1000 unit"}, {"form": "Powder for solution", "route": "intravenous", "strength": "250 unit"}, {"form": "Powder for solution", "route": "intravenous", "strength": "500 unit"}, {"form": "Powder for solution", "route": "intravenous", "strength": "1700 unit"}, {"form": "Powder for solution", "route": "intravenous", "strength": "700 unit"}, {"form": "Liquid", "route": "intravenous", "strength": "1800 unit"}, {"form": "Powder for solution", "route": "intravenous", "strength": "2000 unit"}, {"form": "Solution; kit", "route": "intravenous", "strength": "2.5 ml"}, {"form": "Solution; kit", "route": "intravenous", "strength": "5 ml"}, {"form": "Solution; kit", "route": "intravenous", "strength": "10 ml"}, {"form": "Liquid", "route": "intravenous", "strength": "1000 unit"}]}, "atc-codes": null, "ahfs-codes": {"ahfs-code": "20:28.16"}, "patents": {"patent": [{"number": "1339477", "country": "Canada", "approved": "1997-09-23", "expires": "2014-09-23"}, {"number": "2124690", "country": "Canada", "approved": "2007-09-11", "expires": "2013-10-01"}]}, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00025 sequence\nATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFN\nIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQ\nREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCR\nEGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNR\nSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLL\nMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRF\nDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIG\nRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGI\nTDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNME\nRDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAG\nVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKH\nKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYE\nDSYEDISAYLLSKNNAIEPRSFSQNSRHPSTRQKQFNATTIPENDIEKTDPWFAHRTPMP\nKIQNVSSSDLLMLLRQSPTPHGLSLSDLQEAKYETFSDDPSPGAIDSNNSLSEMTHFRPQ\nLHHSGDMVFTPESGLQLRLNEKLGTTAATELKKLDFKVSSTSNNLISTIPSDNLAAGTDN\nTSSLGPPSMPVHYDSQLDTTLFGKKSSPLTESGGPLSLSEENNDSKLLESGLMNSQESSW\nGKNVSSTESGRLFKGKRAHGPALLTKDNALFKVSISLLKTNKTSNNSATNRKTHIDGPSL\nLIENSPSVWQNILESDTEFKKVTPLIHDRMLMDKNATALRLNHMSNKTTSSKNMEMVQQK\nKEGPIPPDAQNPDMSFFKMLFLPESARWIQRTHGKNSLNSGQGPSPKQLVSLGPEKSVEG\nQNFLSEKNKVVVGKGEFTKDVGLKEMVFPSSRNLFLTNLDNLHENNTHNQEKKIQEEIEK\nKETLIQENVVLPQIHTVTGTKNFMKNLFLLSTRQNVEGSYDGAYAPVLQDFRSLNDSTNR\nTKKHTAHFSKKGEEENLEGLGNQTKQIVEKYACTTRISPNTSQQNFVTQRSKRALKQFRL\nPLEETELEKRIIVDDTSTQWSKNMKHLTPSTLTQIDYNEKEKGAITQSPLSDCLTRSHSI\nPQANRSPLPIAKVSSFPSIRPIYLTRVLFQDNSSHLPAASYRKKDSGVQESSHFLQGAKK\nNNLSLAILTLEMTGDQREVGSLGTSATNSVTYKKVENTVLPKPDLPKTSGKVELLPKVHI\nYQKDLFPTETSNGSPGHLDLVEGSLLQGTEGAIKWNEANRPGKVPFLRVATESSAKTPSK\nLLDPLAWDNHYGTQIPKEEWKSQEKSPEKTAFKKKDTILSLNACESNHAIAAINEGQNKP\nEIEVTWAKQGRTERLCSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIY\nDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTD\nGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGA\nEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHT\nNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHA\nINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYP\nGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITAS\nGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQ\nFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRS\nTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWR\nPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKV\nKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLY"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.533", "source": null}, {"kind": "Isoelectric Point", "value": "6.97", "source": null}, {"kind": "Molecular Weight", "value": "264725.5000", "source": null}, {"kind": "Molecular Formula", "value": "C11794H18314N3220O3553S83", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "745"}, {"resource": "Drugs Product Database (DPD)", "identifier": "9847"}, {"resource": "National Drug Code Directory", "identifier": "0026-3782-20"}, {"resource": "GenBank", "identifier": "M14113"}, {"resource": "PharmGKB", "identifier": "PA164750168"}, {"resource": "UniProtKB", "identifier": "P00451"}, {"resource": "Wikipedia", "identifier": "Antihemophilic_Factor"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic2/hemofilm.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/antihemophilic-factor-human.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000216", "name": "Coagulation factor X", "organism": "Human", "actions": {"action": "activator"}, "references": "# BLATRIX C, SOULIER JP: [Preparation of a fraction rich in prothrombin, proconvertin, Stuart factor and antihemophilic factor B (P.P.B. fraction)] Pathol Biol (Paris). 1959 Dec;7:2477-86. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/13801371\n# LUNDBLAD RL, DAVIE EW: THE ACTIVATION OF STUART FACTOR (FACTOR X) BY ACTIVATED ANTIHEMOPHILIC FACTOR (ACTIVATED FACTOR 8). Biochemistry. 1965 Jan;4:113-20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14285227\n# Radnoff OD, Saito H: Inhibition of Hageman factor, plasma thromboplastin antecedent, thrombin and other clotting factors by phenylglyoxal hydrate (38500). Proc Soc Exp Biol Med. 1975 Jan;148(1):177-82. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/236567\n# Orthner CL: Characterization of proteases in AHF concentrates: effect on factor VIII:von Willebrand protein as assessed by high-pressure gel permeation chromatography. J Lab Clin Med. 1984 Nov;104(5):816-28. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/6436416\n# Freedman J, Mody M, Lazarus AH, Dewar L, Song S, Blanchette VS, Garvey MB, Ofosu FA: Platelet activation and hypercoagulability following treatment with porcine factor VIII (HYATE:C). Am J Hematol. 2002 Mar;69(3):192-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11891806", "known-action": "yes", "polypeptide": {"@id": "P00742", "@source": "Swiss-Prot", "name": "Coagulation factor X", "general-function": "Involved in calcium ion binding", "specific-function": "Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting", "gene-name": "F10", "locus": "13q34", "cellular-location": "Cytoplasmic", "transmembrane-regions": "7-26", "signal-regions": null, "theoretical-pi": "5.74", "molecular-weight": "54732.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3528"}, {"resource": "GenAtlas", "identifier": "F10"}, {"resource": "GeneCards", "identifier": "F10"}, {"resource": "GenBank Gene Database", "identifier": "K03194"}, {"resource": "GenBank Protein Database", "identifier": "182841"}, {"resource": "UniProtKB", "identifier": "P00742"}, {"resource": "UniProt Accession", "identifier": "FA10_HUMAN"}]}, "synonyms": {"synonym": ["Coagulation factor X precursor", "EC 3.4.21.6", "Stuart factor", "Stuart- Prower factor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Coagulation factor X precursor\nMGRPLHLVLLSASLAGLLLLGESLFIRREQANNILARVTRANSFLEEMKKGHLERECMEE\nTCSYEEAREVFEDSDKTNEFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKN\nCELFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLERR\nKRSVAQATSSSGEAPDSITWKPYDAADLDPTENPFDLLDFNQTQPERGDNNLTRIVGGQE\nCKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGE\nAVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGI\nVSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSG\nGPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPE\nVITSSPLK"}, "gene-sequence": {"@format": "FASTA", "#text": ">1433 bp\nCCTCCCTGGCTGGCCTCCTGCTGCTCGGGGAAAGTCTGTTCATCCGCAGGGAGCAGGCCA\nACAACATCCTGGCGAGGGTCACGAGGGCCAATTCCTTTCTTGAAGAGATGAAGAAAGGAC\nACCTCGAAAGAGAGTGCATGGAAGAGACCTGCTCATACGAAGAGGCCCGCGAGGTCTTTG\nAGGACAGCGACAAGACGAATGAATTCTGGAATAAATACAAAGATGGCGACCAGTGTGAGA\nCCAGTCCTTGCCAGAACCAGGGCAAATGTAAAGACGGCCTCGGGGAATACACCTGCACCT\nGTTTAGAAGGATTCGAAGGCAAAAACTGTGAATTATTCACACGGAAGCTCTGCAGCCTGG\nACAACGGGGACTGTGACCAGTTCTGCCACGAGGAACAGAACTCTGTGGTGTGCTCCTGCG\nCCCGCGGGTACACCCTGGCTGACAACGGCAAGGCCTGCATTCCCACAGGGCCCTACCCCT\nGTGGGAAACAGACCCTGGAACGCAGGAAGAGGTCAGTGGCCCAGGCCACCAGCAGCAGCG\nGGGAGGCCCCTGACAGCATCACATGGAAGCCATATGATGCAGCCGACCTGGACCCCACCG\nAGAACCCCTTCGACCTGCTTGACTTCAACCAGACGCAGCCTGAGAGGGGCGACAACAACC\nTCACCAGGATCGTGGGAGGCCAGGAATGCAAGGACGGGGAGTGTCCCTGGCAGGCCCTGC\nTCATCAATGAGGAAAACGAGGGTTTCTGTGGTGGAACTATTCTGAGCGAGTTCTACATCC\nTAACGGCAGCCCACTGTCTCTACCAAGCCAAGAGATTCAAGGTGAGGGTAGGGGACCGGA\nACACGGAGCAGGAGGAGGGCGGTGAGGCGGTGCACGAGGTGGAGGTGGTCATCAAGCACA\nACCGGTTCACAAAGGAGACCTATGACTTCGACATCGCCGTGCTCCGGCTCAAGACCCCCA\nTCACCTTCCGCATGAACGTGGCGCCTGCCTGCCTCCCCGAGCGTGACTGGGCCGAGTCCA\nCGCTGATGACGCAGAAGACGGGGATTGTGAGCGGCTTCGGGCGCACCCACGAGAAGGGCC\nGGCAGTCCACCAGGCTCAAGATGCTGGAGGTGCCCTACGTGGACCGCAACAGCTGCAAGC\nTGTCCAGCAGCTTCATCATCACCCAGAACATGTTCTGTGCCGGCTACGACACCAAGCAGG\nAGGATGCCTGCCAGGGGGACAGCGGGGGCCCGCACGTCACCCGCTTCAAGGACACCTACT\nTCGTGACAGGCATCGTCAGCTGGGGAGAGAGCTGTGCCCGTAAGGGGAAGTACGGGATCT\nACACCAAGGTCACCGCCTTCCTCAAGTGGATCGACAGGTCCATGAAAACCAGGGGCTTGC\nCCAAGGCCAAGAGCCATGCCCCGGAGGTCATAACGTCCTCTCCATTAAAGTGA"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF00594", "name": "Gla"}, {"identifier": "PF00089", "name": "Trypsin"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "hemostasis"}, {"category": "process", "description": "blood coagulation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}]}}}, {"@position": "2", "id": "BE0000364", "name": "Coagulation factor IX", "organism": "Human", "actions": {"action": "cofactor"}, "references": "# Hule V: [Factor IX inhibitor (antihemophilic factor B, PTC) in a woman] Vnitr Lek. 1975 Mar;21(3):274-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1119107\n# Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K: Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry. 1985 Jul 2;24(14):3736-50. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2994716\n# LUNDBLAD RL, DAVIE EW: THE ACTIVATION OF ANTIHEMOPHILIC FACTOR (FACTOR 8) BY ACTIVATED CHRISTMAS FACTOR (ACTIVATED FACTOR9 9). Biochemistry. 1964 Nov;3:1720-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14240634\n# Hoofnagle JH, Gerety RJ, Thiel J, Barker LF: The prevalence of hepatitis B surface antigen in commercially prepared plasma products. J Lab Clin Med. 1976 Jul;88(1):102-13. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/932529\n# Prince AM, Horowitz B, Brotman B, Huima T, Richardson L, van den Ende MC: Inactivation of hepatitis B and Hutchinson strain non-A, non-B hepatitis viruses by exposure to Tween 80 and ether. Vox Sang. 1984;46(1):36-43. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/6422634", "known-action": "yes", "polypeptide": {"@id": "P00740", "@source": "Swiss-Prot", "name": "Coagulation factor IX", "general-function": "Involved in calcium ion binding", "specific-function": "Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca(2+) ions, phospholipids, and factor VIIIa", "gene-name": "F9", "locus": "Xq27.1-q27.2", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.16", "molecular-weight": "51779.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3551"}, {"resource": "GenAtlas", "identifier": "F9"}, {"resource": "GeneCards", "identifier": "F9"}, {"resource": "GenBank Gene Database", "identifier": "K02402"}, {"resource": "GenBank Protein Database", "identifier": "182609"}, {"resource": "UniProtKB", "identifier": "P00740"}, {"resource": "UniProt Accession", "identifier": "FA9_HUMAN"}]}, "synonyms": {"synonym": ["Christmas factor", "Coagulation factor IX precursor", "EC 3.4.21.22", "Plasma thromboplastin component", "PTC"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Coagulation factor IX precursor\nMQRVNMIMAESPGLITICLLGYLLSAECTVFLDHENANKILNRPKRYNSGKLEEFVQGNL\nERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCP\nFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGR\nVSVSQTSKLTRAETVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPW\nQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRII\nPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVF\nHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVE\nGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1389 bp\nATGCAGCGCGTGAACATGATCATGGCAGAATCACCAAGCCTCATCACCATCTGCCTTTTA\nGGATATCTACTCAGTGCTGAATGTACAGTTTTTCTTGATCATGAAAACGCCAACAAAATT\nCTGAATCGGCCAAAGAGGTATAATTCAGGTAAATTGGAAGAGTTTGTTCAAGGGAACCTT\nGAGAGAGAATGTATGGAAGAAAAGTGTAGTTTTGAAGAACCACGAGAAGTTTTTGAAAAC\nACTGAAAAGACAACTGAATTTTGGAAGCAGTATGTTGATGGAGATCAGTGTGAGTCCAAT\nCCATGTTTAAATGGCGGCAGTTGCAAGGATGACATTAATTCCTATGAATGTTGGTGTCCC\nTTTGGATTTGAAGGAAAGAACTGTGAATTAGATGTAACATGTAACATTAAGAATGGCAGA\nTGCGAGCAGTTTTGTAAAAATAGTGCTGATAACAAGGTGGTTTGCTCCTGTACTGAGGGA\nTATCGACTTGCAGAAAACCAGAAGTCCTGTGAACCAGCAGTGCCATTTCCATGTGGAAGA\nGTTTCTGTTTCACAAACTTCTAAGCTCACCCGTGCTGAGGCTGTTTTTCCTGATGTGGAC\nTATGTAAATCCTACTGAAGCTGAAACCATTTTGGATAACATCACTCAAGGCACCCAATCA\nTTTAATGACTTCACTCGGGTTGTTGGTGGAGAAGATGCCAAACCAGGTCAATTCCCTTGG\nCAGGTTGTTTTGAATGGTAAAGTTGATGCATTCTGTGGAGGCTCTATCGTTAATGAAAAA\nTGGATTGTAACTGCTGCCCACTGTGTTGAAACTGGTGTTAAAATTACAGTTGTCGCAGGT\nGAACATAATATTGAGGAGACAGAACATACAGAGCAAAAGCGAAATGTGATTCGAGCAATT\nATTCCTCACCACAACTACAATGCAGCTATTAATAAGTACAACCATGACATTGCCCTTCTG\nGAACTGGACGAACCCTTAGTGCTAAACAGCTACGTTACACCTATTTGCATTGCTGACAAG\nGAATACACGAACATCTTCCTCAAATTTGGATCTGGCTATGTAAGTGGCTGGGCAAGAGTC\nTTCCACAAAGGGAGATCAGCTTTAGTTCTTCAGTACCTTAGAGTTCCACTTGTTGACCGA\nGCCACATGTCTTCGATCTACAAAGTTCACCATCTATAACAACATGTTCTGTGCTGGCTTC\nCATGAAGGAGGTAGAGATTCATGTCAAGGAGATAGTGGGGGACCCCATGTTACTGAAGTG\nGAAGGGACCAGTTTCTTAACTGGAATTATTAGCTGGGGTGAAGAGTGTGCAATGAAAGGC\nAAATATGGAATATATACCAAGGTATCCCGGTATGTCAACTGGATTAAGGAAAAAACAAAG\nCTCACTTAA"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF00594", "name": "Gla"}, {"identifier": "PF00089", "name": "Trypsin"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "hemostasis"}, {"category": "process", "description": "blood coagulation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}]}}}, {"@position": "3", "id": "BE0001043", "name": "von Willebrand factor", "organism": "Human", "actions": {"action": "binder"}, "references": "# Shord SS, Lindley CM: Coagulation products and their uses. Am J Health Syst Pharm. 2000 Aug 1;57(15):1403-17; quiz 1418-20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10938981\n# Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA: Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost. 2002 Feb;87(2):224-30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11858481\n# Gill JC, Ewenstein BM, Thompson AR, Mueller-Velten G, Schwartz BA: Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia. 2003 Nov;9(6):688-95. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14750934\n# Smith KJ, Lusher JM, Cohen AR, Salzman P: Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC. Semin Hematol. 1990 Apr;27(2 Suppl 2):25-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2128855\n# Altieri DC, Capitanio AM, Mannucci PM: von Willebrand factor contaminating porcine factor VIII concentrate (Hyate:C) causes platelet aggregation. Br J Haematol. 1986 Aug;63(4):703-11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2942172", "known-action": "yes", "polypeptide": {"@id": "P04275", "@source": "Swiss-Prot", "name": "von Willebrand factor", "general-function": "Involved in chaperone binding", "specific-function": "Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma", "gene-name": "VWF", "locus": "12p13.3", "cellular-location": "Secreted protein. Note=Localized to storage granules", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.21", "molecular-weight": "309301.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:12726"}, {"resource": "GenAtlas", "identifier": "VWF"}, {"resource": "GeneCards", "identifier": "VWF"}, {"resource": "GenBank Gene Database", "identifier": "X04385"}, {"resource": "GenBank Protein Database", "identifier": "37947"}, {"resource": "UniProtKB", "identifier": "P04275"}, {"resource": "UniProt Accession", "identifier": "VWF_HUMAN"}]}, "synonyms": {"synonym": ["von Willebrand factor precursor", "vWF"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">von Willebrand factor precursor\nMIPARFAGVLLALALILPGTLCAEGTRGRSSTARCSLFGSDFVNTFDGSMYSFAGYCSYL\nLAGGCQKRSFSIIGDFQNGKRVSLSVYLGEFFDIHLFVNGTVTQGDQRVSMPYASKGLYL\nETEAGYYKLSGEAYGFVARIDGSGNFQVLLSDRYFNKTCGLCGNFNIFAEDDFMTQEGTL\nTSDPYDFANSWALSSGEQWCERASPPSSSCNISSGEMQKGLWEQCQLLKSTSVFARCHPL\nVDPEPFVALCEKTLCECAGGLECACPALLEYARTCAQEGMVLYGWTDHSACSPVCPAGME\nYRQCVSPCARTCQSLHINEMCQERCVDGCSCPEGQLLDEGLCVESTECPCVHSGKRYPPG\nTSLSRDCNTCICRNSQWICSNEECPGECLVTGQSHFKSFDNRYFTFSGICQYLLARDCQD\nHSFSIVIETVQCADDRDAVCTRSVTVRLPGLHNSLVKLKHGAGVAMDGQDIQLPLLKGDL\nRIQHTVTASVRLSYGEDLQMDWDGRGRLLVKLSPVYAGKTCGLCGNYNGNQGDDFLTPSG\nLAEPRVEDFGNAWKLHGDCQDLQKQHSDPCALNPRMTRFSEEACAVLTSPTFEACHRAVS\nPLPYLRNCRYDVCSCSDGRECLCGALASYAAACAGRGVRVAWREPGRCELNCPKGQVYLQ\nCGTPCNLTCRSLSYPDEECNEACLEGCFCPPGLYMDERGDCVPKAQCPCYYDGEIFQPED\nIFSDHHTMCYCEDGFMHCTMSGVPGSLLPDAVLSSPLSHRSKRSLSCRPPMVKLVCPADN\nLRAEGLECTKTCQNYDLECMSMGCVSGCLCPPGMVRHENRCVALERCPCFHQGKEYAPGE\nTVKIGCNTCVCRDRKWNCTDHVCDATCSTIGMAHYLTFDGLKYLFPGECQYVLVQDYCGS\nNPGTFRILVGNKGCSHPSVKCKKRVTILVEGGEIELFDGEVNVKRPMKDETHFEVVESGR\nYIILLLGKALSVVWDRHLSISVVLKQTYQEKVCGLCGNFDGIQNNDLTSSNLQVEEDPVD\nFGNSWKVSSQCADTRKVPLDSSPATCHNNIMKQTMVDSSCRILTSDVFQDCNKLVDPEPY\nLDVCIYDTCSCESIGDCACFCDTIAAYAHVCAQHGKVVTWRTATLCPQSCEERNLRENGY\nECEWRYNSCAPACQVTCQHPEPLACPVQCVEGCHAHCPPGKILDELLQTCVDPEDCPVCE\nVAGRRFASGKKVTLNPSDPEHCQICHCDVVNLTCEACQEPGGLVVPPTDAPVSPTTLYVE\nDISEPPLHDFYCSRLLDLVFLLDGSSRLSEAEFEVLKAFVVDMMERLRISQKWVRVAVVE\nYHDGSHAYIGLKDRKRPSELRRIASQVKYAGSQVASTSEVLKYTLFQIFSKIDRPEASRI\nALLLMASQEPQRMSRNFVRYVQGLKKKKVIVIPVGIGPHANLKQIRLIEKQAPENKAFVL\nSSVDELEQQRDEIVSYLCDLAPEAPPPTLPPHMAQVTVGPGLLGVSTLGPKRNSMVLDVA\nFVLEGSDKIGEADFNRSKEFMEEVIQRMDVGQDSIHVTVLQYSYMVTVEYPFSEAQSKGD\nILQRVREIRYQGGNRTNTGLALRYLSDHSFLVSQGDREQAPNLVYMVTGNPASDEIKRLP\nGDIQVVPIGVGPNANVQELERIGWPNAPILIQDFETLPREAPDLVLQRCCSGEGLQIPTL\nSPAPDCSQPLDVILLLDGSSSFPASYFDEMKSFAKAFISKANIGPRLTQVSVLQYGSITT\nIDVPWNVVPEKAHLLSLVDVMQREGGPSQIGDALGFAVRYLTSEMHGARPGASKAVVILV\nTDVSVDSVDAAADAARSNRVTVFPIGIGDRYDAAQLRILAGPAGDSNVVKLQRIEDLPTM\nVTLGNSFLHKLCSGFVRICMDEDGNEKRPGDVWTLPDQCHTVTCQPDGQTLLKSHRVNCD\nRGLRPSCPNSQSPVKVEETCGCRWTCPCVCTGSSTRHIVTFDGQNFKLTGSCSYVLFQNK\nEQDLEVILHNGACSPGARQGCMKSIEVKHSALSVELHSDMEVTVNGRLVSVPYVGGNMEV\nNVYGAIMHEVRFNHLGHIFTFTPQNNEFQLQLSPKTFASKTYGLCGICDENGANDFMLRD\nGTVTTDWKTLVQEWTVQRPGQTCQPILEEQCLVPDSSHCQVLLLPLFAECHKVLAPATFY\nAICQQDSCHQEQVCEVIASYAHLCRTNGVCVDWRTPDFCAMSCPPSLVYNHCEHGCPRHC\nDGNVSSCGDHPSEGCFCPPDKVMLEGSCVPEEACTQCIGEDGVQHQFLEAWVPDHQPCQI\nCTCLSGRKVNCTTQPCPTAKAPTCGLCEVARLRQNADQCCPEYECVCDPVSCDLPPVPHC\nERGLQPTLTNPGECRPNFTCACRKEECKRVSPPSCPPHRLPTLRKTQCCDEYECACNCVN\nSTVSCPLGYLASTATNDCGCTTTTCLPDKVCVHRSTIYPVGQFWEEGCDVCTCTDMEDAV\nMGLRVAQCSQKPCEDSCRSGFTYVLHEGECCGRCLPSACEVVTGSPRGDSQSSWKSVGSQ\nWASPENPCLINECVRVKEEVFIQQRNVSCPQLEVPVCPSGFQLSCKTSACCPSCRCERME\nACMLNGTVIGPGKTVMIDVCTTCRCMVQVGVISGFKLECRKTTCNPCPLGYKEENNTGEC\nCGRCLPTACTIQLRGGQIMTLKRDETLQDGCDTHFCKVNERGEYFWEKRVTGCPPFDEHK\nCLAEGGKIMKIPGTCCDTCEEPECNDITARLQYVKVGSCKSEVEVDIHYCQGKCASKAMY\nSIDINDVQDQCSCCSPTRTEPMQVALHCTNGSVVYHEVLNAMECKCSPRKCSK"}, "gene-sequence": {"@format": "FASTA", "#text": ">8442 bp\nATGATTCCTGCCAGATTTGCCGGGGTGCTGCTTGCTCTGGCCCTCATTTTGCCAGGGACC\nCTTTGTGCAGAAGGAACTCGCGGCAGGTCATCCACGGCCCGATGCAGCCTTTTCGGAAGT\nGACTTCGTCAACACCTTTGATGGGAGCATGTACAGCTTTGCGGGATACTGCAGTTACCTC\nCTGGCAGGGGGCTGCCAGAAACGCTCCTTCTCGATTATTGGGGACTTCCAGAATGGCAAG\nAGAGTGAGCCTCTCCGTGTATCTTGGGGAATTTTTTGACATCCATTTGTTTGTCAATGGT\nACCGTGACACAGGGGGACCAAAGAGTCTCCATGCCCTATGCCTCCAAAGGGCTGTATCTA\nGAAACTGAGGCTGGGTACTACAAGCTGTCCGGTGAGGCCTATGGCTTTGTGGCCAGGATC\nGATGGCAGCGGCAACTTTCAAGTCCTGCTGTCAGACAGATACTTCAACAAGACCTGCGGG\nCTGTGTGGCAACTTTAACATCTTTGCTGAAGATGACTTTATGACCCAAGAAGGGACCTTG\nACCTCGGACCCTTATGACTTTGCCAACTCATGGGCTCTGAGCAGTGGAGAACAGTGGTGT\nGAACGGGCATCTCCTCCCAGCAGCTCATGCAACATCTCCTCTGGGGAAATGCAGAAGGGC\nCTGTGGGAGCAGTGCCAGCTTCTGAAGAGCACCTCGGTGTTTGCCCGCTGCCACCCTCTG\nGTGGACCCCGAGCCTTTTGTGGCCCTGTGTGAGAAGACTTTGTGTGAGTGTGCTGGGGGG\nCTGGAGTGCGCCTGCCCTGCCCTCCTGGAGTACGCCCGGACCTGTGCCCAGGAGGGAATG\nGTGCTGTACGGCTGGACCGACCACAGCGCGTGCAGCCCAGTGTGCCCTGCTGGTATGGAG\nTATAGGCAGTGTGTGTCCCCTTGCGCCAGGACCTGCCAGAGCCTGCACATCAATGAAATG\nTGTCAGGAGCGATGCGTGGATGGCTGCAGCTGCCCTGAGGGACAGCTCCTGGATGAAGGC\nCTCTGCGTGGAGAGCACCGAGTGTCCCTGCGTGCATTCCGGAAAGCGCTACCCTCCCGGC\nACCTCCCTCTCTCGAGACTGCAACACCTGCATTTGCCGAAACAGCCAGTGGATCTGCAGC\nAATGAAGAATGTCCAGGGGAGTGCCTTGTCACAGGTCAATCACACTTCAAGAGCTTTGAC\nAACAGATACTTCACCTTCAGTGGGATCTGCCAGTACCTGCTGGCCCGGGATTGCCAGGAC\nCACTCCTTCTCCATTGTCATTGAGACTGTCCAGTGTGCTGATGACCGCGACGCTGTGTGC\nACCCGCTCCGTCACCGTCCGGCTGCCTGGCCTGCACAACAGCCTTGTGAAACTGAAGCAT\nGGGGCAGGAGTTGCCATGGATGGCCAGGACGTCCAGCTCCCCCTCCTGAAAGGTGACCTC\nCGCATCCAGCATACAGTGACGGCCTCCGTGCGCCTCAGCTACGGGGAGGACCTGCAGATG\nGACTGGGATGGCCGCGGGAGGCTGCTGGTGAAGCTGTCCCCCGTCTATGCCGGGAAGACC\nTGCGGCCTGTGTGGGAATTACAATGGCAACCAGGGCGACGACTTCCTTACCCCCTCTGGG\nCTGGCGGAGCCCCGGGTGGAGGACTTCGGGAACGCCTGGAAGCTGCACGGGGACTGCCAG\nGACCTGCAGAAGCAGCACAGCGATCCCTGCGCCCTCAACCCGCGCATGACCAGGTTCTCC\nGAGGAGGCGTGCGCGGTCCTGACGTCCCCCACATTCGAGGCCTGCCATCGTGCCGTCAGC\nCCGCTGCCCTACCTGCGGAACTGCCGCTACGACGTGTGCTCCTGCTCGGACGGCCGCGAG\nTGCCTGTGCGGCGCCCTGGCCAGCTATGCCGCGGCCTGCGCGGGGAGAGGCGTGCGCGTC\nGCGTGGCGCGAGCCAGGCCGCTGTGAGCTGAACTGCCCGAAAGGCCAGGTGTACCTGCAG\nTGCGGGACCCCCTGCAACCTGACCTGCCGCTCTCTCTCTTACCCGGATGAGGAATGCAAT\nGAGGCCTGCCTGGAGGGCTGCTTCTGCCCCCCAGGGCTCTACATGGATGAGAGGGGGGAC\nTGCGTGCCCAAGGCCCAGTGCCCCTGTTACTATGACGGTGAGATCTTCCAGCCAGAAGAC\nATCTTCTCAGACCATCACACCATGTGCTACTGTGAGGATGGCTTCATGCACTGTACCATG\nAGTGGAGTCCCCGGAAGCTTGCTGCCTGACGCTGTCCTCAGCAGTCCCCTGTCTCATCGC\nAGCAAAAGGAGCCTATCCTGTCGGCCCCCCATGGTCAAGCTGGTGTGTCCCGCTGACAAC\nCTGCGGGCTGAAGGGCTCGAGTGTACCAAAACGTGCCAGAACTATGACCTGGAGTGCATG\nAGCATGGGCTGTGTCTCTGGCTGCCTCTGCCCCCCGGGCATGGTCCGGCATGAGAACAGA\nTGTGTGGCCCTGGAAAGGTGTCCCTGCTTCCATCAGGGCAAGGAGTATGCCCCTGGAGAA\nACAGTGAAGATTGGCTGCAACACTTGTGTCTGTCGGGACCGGAAGTGGAACTGCACAGAC\nCATGTGTGTGATGCCACGTGCTCCACGATCGGCATGGCCCACTACCTCACCTTCGACGGG\nCTCAAATACCTGTTCCCCGGGGAGTGCCAGTACGTTCTGGTGCAGGATTACTGCGGCAGT\nAACCCTGGGACCTTTCGGATCCTAGTGGGGAATAAGGGATGCAGCCACCCCTCAGTGAAA\nTGCAAGAAACGGGTCACCATCCTGGTGGAGGGAGGAGAGATTGAGCTGTTTGACGGGGAG\nGTGAATGTGAAGAGGCCCATGAAGGATGAGACTCACTTTGAGGTGGTGGAGTCTGGCCGG\nTACATCATTCTGCTGCTGGGCAAAGCCCTCTCCGTGGTCTGGGACCGCCACCTGAGCATC\nTCCGTGGTCCTGAAGCAGACATACCAGGAGAAAGTGTGTGGCCTGTGTGGGAATTTTGAT\nGGCATCCAGAACAATGACCTCACCAGCAGCAACCTCCAAGTGGAGGAAGACCCTGTGGAC\nTTTGGGAACTCCTGGAAAGTGAGCTCGCAGTGTGCTGACACCAGAAAAGTGCCTCTGGAC\nTCATCCCCTGCCACCTGCCATAACAACATCATGAAGCAGACGATGGTGGATTCCTCCTGT\nAGAATCCTTACCAGTGACGTCTTCCAGGACTGCAACAAGCTGGTGGACCCCGAGCCATAT\nCTGGATGTCTGCATTTACGACACCTGCTCCTGTGAGTCCATTGGGGACTGCGCCTGCTTC\nTGCGACACCATTGCTGCCTATGCCCACGTGTGTGCCCAGCATGGCAAGGTGGTGACCTGG\nAGGACGGCCACATTGTGCCCCCAGAGCTGCGAGGAGAGGAATCTCCGGGAGAACGGGTAT\nGAGTGTGAGTGGCGCTATAACAGCTGTGCACCTGCCTGTCAAGTCACGTGTCAGCACCCT\nGAGCCACTGGCCTGCCCTGTGCAGTGTGTGGAGGGCTGCCATGCCCACTGCCCTCCAGGG\nAAAATCCTGGATGAGCTTTTGCAGACCTGCGTTGACCCTGAAGACTGTCCAGTGTGTGAG\nGTGGCTGGCCGGCGTTTTGCCTCAGGAAAGAAAGTCACCTTGAATCCCAGTGACCCTGAG\nCACTGCCAGATTTGCCACTGTGATGTTGTCAACCTCACCTGTGAAGCCTGCCAGGAGCCG\nGGAGGCCTGGTGGTGCCTCCCACAGATGCCCCGGTGAGCCCCACCACTCTGTATGTGGAG\nGACATCTCGGAACCGCCGTTGCACGATTTCTACTGCAGCAGGCTACTGGACCTGGTCTTC\nCTGCTGGATGGCTCCTCCAGGCTGTCCGAGGCTGAGTTTGAAGTGCTGAAGGCCTTTGTG\nGTGGACATGATGGAGCGGCTGCGCATCTCCCAGAAGTGGGTCCGCGTGGCCGTGGTGGAG\nTACCACGACGGCTCCCACGCCTACATCGGGCTCAAGGACCGGAAGCGACCGTCAGAGCTG\nCGGCGCATTGCCAGCCAGGTGAAGTATGCGGGCAGCCAGGTGGCCTCCACCAGCGAGGTC\nTTGAAATACACACTGTTCCAAATCTTCAGCAAGATCGACCGCCCTGAAGCCTCCCGCATC\nGCCCTGCTCCTGATGGCCAGCCAGGAGCCCCAACGGATGTCCCGGAACTTTGTCCGCTAC\nGTCCAGGGCCTGAAGAAGAAGAAGGTCATTGTGATCCCGGTGGGCATTGGGCCCCATGCC\nAACCTCAAGCAGATCCGCCTCATCGAGAAGCAGGCCCCTGAGAACAAGGCCTTCGTGCTG\nAGCAGTGTGGATGAGCTGGAGCAGCAAAGGGACGAGATCGTTAGCTACCTCTGTGACCTT\nGCCCCTGAAGCCCCTCCTCCTACTCTGCCCCCCCACATGGCACAAGTCACTGTGGGCCCG\nGGGCTCTTGGGGGTTTCGACCCTGGGGCCCAAGAGGAACTCCATGGTTCTGGATGTGGCG\nTTCGTCCTGGAAGGATCGGACAAAATTGGTGAAGCCGACTTCAACAGGAGCAAGGAGTTC\nATGGAGGAGGTGATTCAGCGGATGGATGTGGGCCAGGACAGCATCCACGTCACGGTGCTG\nCAGTACTCCTACATGGTGACCGTGGAGTACCCCTTCAGCGAGGCACAGTCCAAAGGGGAC\nATCCTGCAGCGGGTGCGAGAGATCCGCTACCAGGGCGGCAACAGGACCAACACTGGGCTG\nGCCCTGCGGTACCTCTCTGACCACAGCTTCTTGGTCAGCCAGGGTGACCGGGAGCAGGCG\nCCCAACCTGGTCTACATGGTCACCGGAAATCCTGCCTCTGATGAGATCAAGAGGCTGCCT\nGGAGACATCCAGGTGGTGCCCATTGGAGTGGGCCCTAATGCCAACGTGCAGGAGCTGGAG\nAGGATTGGCTGGCCCAATGCCCCTATCCTCATCCAGGACTTTGAGACGCTCCCCCGAGAG\nGCTCCTGACCTGGTGCTGCAGAGGTGCTGCTCCGGAGAGGGGCTGCAGATCCCCACCCTC\nTCCCCTGCACCTGACTGCAGCCAGCCCCTGGACGTGATCCTTCTCCTGGATGGCTCCTCC\nAGTTTCCCAGCTTCTTATTTTGATGAAATGAAGAGTTTCGCCAAGGCTTTCATTTCAAAA\nGCCAATATAGGGCCTCGTCTCACTCAGGTGTCAGTGCTGCAGTATGGAAGCATCACCACC\nATTGACGTGCCATGGAACGTGGTCCCGGAGAAAGCCCATTTGCTGAGCCTTGTGGACGTC\nATGCAGCGGGAGGGAGGCCCCAGCCAAATCGGGGATGCCTTGGGCTTTGCTGTGCGATAC\nTTGACTTCAGAAATGCATGGTGCCAGGCCGGGAGCCTCAAAGGCGGTGGTCATCCTGGTC\nACGGACGTCTCTGTGGATTCAGTGGATGCAGCAGCTGATGCCGCCAGGTCCAACAGAGTG\nACAGTGTTCCCTATTGGAATTGGAGATCGCTACGATGCAGCCCAGCTACGGATCTTGGCA\nGGCCCAGCAGGCGACTCCAACGTGGTGAAGCTCCAGCGAATCGAAGACCTCCCTACCATG\nGTCACCTTGGGCAATTCCTTCCTCCACAAACTGTGCTCTGGATTTGTTAGGATTTGCATG\nGATGAGGATGGGAATGAGAAGAGGCCCGGGGACGTCTGGACCTTGCCAGACCAGTGCCAC\nACCGTGACTTGCCAGCCAGATGGCCAGACCTTGCTGAAGACTCATCGGGTCAACTGTGAC\nCGGGGGCTGAGGCCTTCGTGCCCTAACAGCCAGTCCCCTGTTAAAGTGGAAGAGACCTGT\nGGCTGCCGCTGGACCTGCCCCTGCGTGTGCACAGGCAGCTCCACTCGGCACATCGTGACC\nTTTGATGGGCAGAATTTCAAGCTGACTGGCAGCTGTTCTTATGTCCTATTTCAAAACAAG\nGAGCAGGACCTGGAGGTGATTCTCCATAATGGTGCCTGCAGCCCTGGAGCAAGGCAGGGC\nTGCATGAAATCCATCGAGGTGAAGCACAGTGCCCTCTCCGTCGAGCTGCACAGTGACATG\nGAGGTGACGGTGAATGGGAGACTGGTCTCTGTTCCTTACGTGGGTGGGAACATGGAAGTC\nAACGTTTATGGTGCCATCATGCATGAGGTCAGATTCAATCACCTTGGTCACATCTTCACA\nTTCACTCCACAAAACAATGAGTTCCAACTGCAGCTCAGCCCCAAGACTTTTGCTTCAAAG\nACGTATGGTCTGTGTGGGATCTGTGATGAGAACGGAGCCAATGACTTCATGCTGAGGGAT\nGGCACAGTCACCACAGACTGGAAAACACTTGTTCAGGAATGGACTGTGCAGCGGCCAGGG\nCAGACGTGCCAGCCCATCCTGGAGGAGCAGTGTCTTGTCCCCGACAGCTCCCACTGCCAG\nGTCCTCCTCTTACCACTGTTTGCTGAATGCCACAAGGTCCTGGCTCCAGCCACATTCTAT\nGCCATCTGCCAGCAGGACAGTTGCCACCAGGAGCAAGTGTGTGAGGTGATCGCCTCTTAT\nGCCCACCTCTGTCGGACCAACGGGGTCTGCGTTGACTGGAGGACACCTGATTTCTGTGCT\nATGTCATGCCCACCATCTCTGGTCTACAACCACTGTGAGCATGGCTGTCCCCGGCACTGT\nGATGGCAACGTGAGCTCCTGTGGGGACCATCCCTCCGAAGGCTGTTTCTGCCCTCCAGAT\nAAAGTCATGTTGGAAGGCAGCTGTGTCCCTGAAGAGGCCTGCACTCAGTGCATTGGTGAG\nGATGGAGTCCAGCACCAGTTCCTGGAAGCCTGGGTCCCGGACCACCAGCCCTGTCAGATC\nTGCACATGCCTCAGCGGGCGGAAGGTCAACTGCACAACGCAGCCCTGCCCCACGGCCAAA\nGCTCCCACGTGTGGCCTGTGTGAAGTAGCCCGCCTCCGCCAGAATGCAGACCAGTGCTGC\nCCCGAGTATGAGTGTGTGTGTGACCCAGTGAGCTGTGACCTGCCCCCAGTGCCTCACTGT\nGAACGTGGCCTCCAGCCCACACTGACCAACCCTGGCGAGTGCAGACCCAACTTCACCTGC\nGCCTGCAGGAAGGAGGAGTGCAAAAGAGTGTCCCCACCCTCCTGCCCCCCGCACCGTTTG\nCCCACCCTTCGGAAGACCCAGTGCTGTGATGAGTATGAGTGTGCCTGCAACTGTGTCAAC\nTCCACAGTGAGCTGTCCCCTTGGGTACTTGGCCTCAACCGCCACCAATGACTGTGGCTGT\nACCACAACCACCTGCCTTCCCGACAAGGTGTGTGTCCACCGAAGCACCATCTACCCTGTG\nGGCCAGTTCTGGGAGGAGGGCTGCGATGTGTGCACCTGCACCGACATGGAGGATGCCGTG\nATGGGCCTCCGCGTGGCCCAGTGCTCCCAGAAGCCCTGTGAGGACAGCTGTCGGTCGGGC\nTTCACTTACGTTCTGCATGAAGGCGAGTGCTGTGGAAGGTGCCTGCCATCTGCCTGTGAG\nGTGGTGACTGGCTCACCGCGGGGGGACTCCCAGTCTTCCTGGAAGAGTGTCGGCTCCCAG\nTGGGCCTCCCCGGAGAACCCCTGCCTCATCAATGAGTGTGTCCGAGTGAAGGAGGAGGTC\nTTTATACAACAAAGGAACGTCTCCTGCCCCCAGCTGGAGGTCCCTGTCTGCCCCTCGGGC\nTTTCAGCTGAGCTGTAAGACCTCAGCGTGCTGCCCAAGCTGTCGCTGTGAGCGCATGGAG\nGCCTGCATGCTCAATGGCACTGTCATTGGGCCCGGGAAGACTGTGATGATCGATGTGTGC\nACGACCTGCCGCTGCATGGTGCAGGTGGGGGTCATCTCTGGATTCAAGCTGGAGTGCAGG\nAAGACCACCTGCAACCCCTGCCCCCTGGGTTACAAGGAAGAAAATAACACAGGTGAATGT\nTGTGGGAGATGTTTGCCTACGGCTTGCACCATTCAGCTAAGAGGAGGACAGATCATGACA\nCTGAAGCGTGATGAGACGCTCCAGGATGGCTGTGATACTCACTTCTGCAAGGTCAATGAG\nAGAGGAGAGTACTTCTGGGAGAAGAGGGTCACAGGCTGCCCACCCTTTGATGAACACAAG\nTGTCTGGCTGAGGGAGGTAAAATTATGAAAATTCCAGGCACCTGCTGTGACACATGTGAG\nGAGCCTGAGTGCAACGACATCACTGCCAGGCTGCAGTATGTCAAGGTGGGAAGCTGTAAG\nTCTGAAGTAGAGGTGGATATCCACTACTGCCAGGGCAAATGTGCCAGCAAAGCCATGTAC\nTCCATTGACATCAACGATGTGCAGGACCAGTGCTCCTGCTGCTCTCCGACACGGACGGAG\nCCCATGCAGGTGGCCCTGCACTGCACCAATGGCTCTGTTGTGTACCATGAGGTTCTCAAT\nGCCATGGAGTGCAAATGCTCCCCCAGGAAGTGCAGCAAGTGA"}, "pfams": {"pfam": [{"identifier": "PF00093", "name": "VWC"}, {"identifier": "PF00092", "name": "VWA"}, {"identifier": "PF00094", "name": "VWD"}, {"identifier": "PF08742", "name": "DUF1787"}, {"identifier": "PF01826", "name": "TIL"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular matrix"}, {"category": "component", "description": "extracellular matrix (sensu Metazoa)"}, {"category": "process", "description": "blood coagulation"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell adhesion"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "hemostasis"}]}}}, {"@position": "4", "id": "BE0002117", "name": "Phytanoyl-CoA dioxygenase, peroxisomal", "organism": "Human", "actions": {"action": "antagonist"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Chen C, Wang Q, Fang X, Xu Q, Chi C, Gu J: Roles of phytanoyl-CoA alpha-hydroxylase in mediating the expression of human coagulation factor VIII. J Biol Chem. 2001 Dec 7;276(49):46340-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11574539", "known-action": "unknown", "polypeptide": {"@id": "O14832", "@source": "Swiss-Prot", "name": "Phytanoyl-CoA dioxygenase, peroxisomal", "general-function": null, "specific-function": "Converts phytanoyl-CoA to 2-hydroxyphytanoyl-CoA", "gene-name": "PHYH", "locus": "10pter-p11.2", "cellular-location": "Peroxisome", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.65", "molecular-weight": "38539.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:8940"}, {"resource": "GenAtlas", "identifier": "PHYH"}, {"resource": "GeneCards", "identifier": "PHYH"}, {"resource": "GenBank Gene Database", "identifier": "AF023462"}, {"resource": "GenBank Protein Database", "identifier": "2564671"}, {"resource": "UniProtKB", "identifier": "O14832"}, {"resource": "UniProt Accession", "identifier": "PAHX_HUMAN"}]}, "synonyms": {"synonym": ["EC 1.14.11.18", "PhyH", "Phytanic acid oxidase", "Phytanoyl-CoA alpha-hydroxylase", "Phytanoyl-CoA dioxygenase, peroxisomal precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Phytanoyl-CoA dioxygenase, peroxisomal\nMEQLRAAARLQIVLGHLGRPSAGAVVAHPTSGTISSASFHPQQFQYTLDNNVLTLEQRKF\nYEENGFLVIKNLVPDADIQRFRNEFEKICRKEVKPLGLTVMRDVTISKSEYAPSEKMITK\nVQDFQEDKELFRYCTLPEILKYVECFTGPNIMAMHTMLINKPPDSGKKTSRHPLHQDLHY\nFPFRPSDLIVCAWTAMEHISRNNGCLVVLPGTHKGSLKPHDYPKWEGGVNKMFHGIQDYE\nENKARVHLVMEKGDTVFFHPLLIHGSGQNKTQGFRKAISCHFASADCHYIDVKGTSQENI\nEKEVVGIAHKFFGAENSVNLKDIWMFRARLVKGERTNL"}, "gene-sequence": {"@format": "FASTA", "#text": ">1017 bp\nATGGAGCAGCTTCGCGCCGCCGCCCGTCTGCAGATTGTTCTGGGCCACCTCGGCCGCCCC\nTCGGCCGGGGCTGTCGTAGCTCATCCCACTTCAGGGACTATTTCCTCTGCCAGTTTCCAT\nCCTCAACAATTCCAGTATACTCTGGATAATAATGTTCTAACCCTGGAACAGAGAAAATTT\nTATGAAGAAAATGGGTTTCTAGTAATCAAAAATCTTGTACCTGATGCCGATATTCAACGC\nTTTCGGAATGAGTTTGAAAAAATCTGCAGAAAGGAGGTGAAACCATTAGGATTAACAGTA\nATGAGAGATGTGACCATTTCGAAATCCGAATATGCTCCAAGTGAGAAGATGATCACGAAG\nGTCCAGGATTTCCAGGAAGATAAGGAGCTCTTCAGATACTGCACTCTCCCCGAGATTCTG\nAAATATGTGGAGTGCTTCACTGGACCTAATATTATGGCCATGCACACAATGTTGATAAAC\nAAACCTCCAGATTCTGGCAAGAAGACGTCCCGTCACCCCCTGCACCAGGACCTGCACTAT\nTTCCCCTTCAGGCCCAGCGATCTCATCGTTTGCGCCTGGACGGCGATGGAGCACATCAGC\nCGGAACAACGGCTGTCTGGTTGTGCTCCCAGGCACGCACAAGGGCTCCCTGAAGCCCCAC\nGATTACCCCAAGTGGGAGGGGGGAGTTAACAAAATGTTCCACGGGATCCAGGACTACGAG\nGAAAACAAGGCCCGGGTGCACCTGGTGATGGAGAAGGGCGACACTGTTTTCTTCCATCCT\nTTGCTCATCCACGGATCTGGTCAGAATAAAACCCAGGGATTCCGGAAGGCAATTTCCTGC\nCATTTCGCCAGTGCCGATTGCCACTACATTGACGTGAAGGGCACCAGTCAAGAAAACATC\nGAGAAGGAAGTTGTAGGAATAGCACATAAATTCTTTGGAGCTGAAAATAGCGTGAACTTG\nAAGGATATTTGGATGTTTCGAGCTCGACTTGTGAAAGGAGAAAGAACCAATCTTTGA"}, "pfams": {"pfam": {"identifier": "PF05721", "name": "PhyH"}}, "go-classifiers": null}}, {"@position": "6", "id": "BE0002118", "name": "Asialoglycoprotein receptor 2", "organism": "Human", "actions": {"action": "binder"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Bovenschen N, Rijken DC, Havekes LM, van Vlijmen BJ, Mertens K: The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J Thromb Haemost. 2005 Jun;3(6):1257-65. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15946216", "known-action": "unknown", "polypeptide": {"@id": "P07307", "@source": "Swiss-Prot", "name": "Asialoglycoprotein receptor 2", "general-function": null, "specific-function": "Mediates the endocytosis of plasma glycoproteins to which the terminal sialic acid residue on their complex carbohydrate moieties has been removed. The receptor recognizes terminal galactose and N-acetylgalactosamine units. After ligand binding to the receptor, the resulting complex is internalized and transported to a sorting organelle, where receptor and ligand are disassociated. The receptor then returns to the cell membrane surface", "gene-name": "ASGR2", "locus": "17p", "cellular-location": "Membrane", "transmembrane-regions": "59-79", "signal-regions": null, "theoretical-pi": "6.34", "molecular-weight": "35192.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:743"}, {"resource": "GenAtlas", "identifier": "ASGR2"}, {"resource": "GeneCards", "identifier": "ASGR2"}, {"resource": "GenBank Gene Database", "identifier": "M11025"}, {"resource": "GenBank Protein Database", "identifier": "179081"}, {"resource": "UniProtKB", "identifier": "P07307"}, {"resource": "UniProt Accession", "identifier": "ASGR2_HUMAN"}]}, "synonyms": {"synonym": ["ASGP-R 2", "ASGPR 2", "Hepatic lectin H2"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Asialoglycoprotein receptor 2\nMAKDFQDIQQLSSEENDHPFHQGEGPGTRRLNPRRGNPFLKGPPPAQPLAQRLCSMVCFS\nLLALSFNILLLVVICVTGSQSEGHRGAQLQAELRSLKEAFSNFSSSTLTEVQAISTHGGS\nVGDKITSLGAKLEKQQQDLKADHDALLFHLKHFPVDLRFVACQMELLHSNGSQRTCCPVN\nWVEHQGSCYWFSHSGKAWAEAEKYCQLENAHLVVINSWEEQKFIVQHTNPFNTWIGLTDS\nDGSWKWVDGTDYRHNYKNWAVTQPDNWHGHELGGSEDCVEVQPDGRWNDDFCLQVYRWVC\nEKRRNATGEVA"}, "gene-sequence": {"@format": "FASTA", "#text": ">936 bp\nATGGCCAAGGACTTTCAAGATATCCAGCAGCTGAGCTCGGAGGAAAATGACCATCCTTTC\nCATCAAGGTGAGGGGCCAGGCACTCGCAGGCTGAATCCCAGGAGAGGAAATCCATTTTTG\nAAAGGGCCACCTCCTGCCCAGCCCCTGGCACAGCGTCTCTGCTCCATGGTCTGCTTCAGT\nCTGCTTGCCCTGAGCTTCAACATCCTGCTGCTGGTGGTCATCTGTGTGACTGGGTCCCAA\nAGTGAGGGTCACAGAGGTGCACAGCTGCAAGCCGAGCTGCGGAGCCTGAAGGAAGCTTTC\nAGCAACTTCTCCTCGAGCACCCTGACGGAGGTCCAGGCAATCAGCACCCACGGAGGCAGC\nGTGGGTGACAAGATCACATCCCTAGGAGCCAAGCTGGAGAAACAGCAGCAGGACCTGAAA\nGCAGATCACGATGCCCTGCTCTTCCATCTGAAGCACTTCCCCGTGGACCTGCGCTTCGTG\nGCCTGCCAGATGGAGCTCCTCCACAGCAACGGCTCCCAAAGGACCTGCTGCCCCGTCAAC\nTGGGTGGAGCACCAAGGCAGCTGCTACTGGTTCTCTCACTCCGGGAAGGCCTGGGCTGAG\nGCGGAGAAGTACTGCCAGCTGGAGAACGCACACCTGGTGGTCATCAACTCCTGGGAGGAG\nCAGAAATTCATTGTACAACACACGAACCCCTTCAATACCTGGATAGGTCTCACGGACAGT\nGATGGCTCTTGGAAATGGGTGGATGGCACAGACTATAGGCACAACTACAAGAACTGGGCT\nGTCACTCAGCCAGATAATTGGCACGGGCACGAGCTGGGTGGAAGTGAAGACTGTGTTGAA\nGTCCAGCCGGATGGCCGCTGGAACGATGACTTCTGCCTGCAGGTGTACCGCTGGGTGTGT\nGAGAAAAGGCGGAATGCCACCGGCGAGGTGGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF00059", "name": "Lectin_C"}, {"identifier": "PF03954", "name": "Lectin_N"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "carbohydrate binding"}, {"category": "function", "description": "sugar binding"}]}}}, {"@position": "7", "id": "BE0001098", "name": "78 kDa glucose-regulated protein", "organism": "Human", "actions": {"action": "chaperone"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M: Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis. 1997 Dec;8 Suppl 2:S3-14. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9607108", "known-action": "unknown", "polypeptide": {"@id": "P11021", "@source": "Swiss-Prot", "name": "78 kDa glucose-regulated protein", "general-function": "Posttranslational modification, protein turnover, chaperones", "specific-function": "Probably plays a role in facilitating the assembly of multimeric protein complexes inside the ER", "gene-name": "HSPA5", "locus": "9q33-q34.1", "cellular-location": "Endoplasmic reticulum; endoplasmic reticulum lumen. Melanosome. Note=Identified by mass spectrometry", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "4.8", "molecular-weight": "72334.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5238"}, {"resource": "GenAtlas", "identifier": "HSPA5"}, {"resource": "GeneCards", "identifier": "HSPA5"}, {"resource": "GenBank Gene Database", "identifier": "M19645"}, {"resource": "GenBank Protein Database", "identifier": "386758"}, {"resource": "UniProtKB", "identifier": "P11021"}, {"resource": "UniProt Accession", "identifier": "GRP78_HUMAN"}]}, "synonyms": {"synonym": ["78 kDa glucose-regulated protein precursor", "BiP", "Endoplasmic reticulum lumenal Ca(2+)-binding protein grp78", "GRP 78", "Heat shock 70 kDa protein 5", "Immunoglobulin heavy chain-binding protein"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">78 kDa glucose-regulated protein precursor\nMKLSLVAAMLLLLSAARAEEEDKKEDVGTVVGIDLGTTYSCVGVFKNGRVEIIANDQGNR\nITPSYVAFTPEGERLIGDAAKNQLTSNPENTVFDAKRLIGRTWNDPSVQQDIKFLPFKVV\nEKKTKPYIQVDIGGGQTKTFAPEEISAMVLTKMKETAEAYLGKKVTHAVVTVPAYFNDAQ\nRQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREGEKNILVFDLGGGTFDVSLLTIDNG\nVFEVVATNGDTHLGGEDFDQRVMEHFIKLYKKKTGKDVRKDNRAVQKLRREVEKAKRALS\nSQHQARIEIESFYEGEDFSETLTRAKFEELNMDLFRSTMKPVQKVLEDSDLKKSDIDEIV\nLVGGSTRIPKIQQLVKEFFNGKEPSRGINPDEAVAYGAAVQAGVLSGDQDTGDLVLLDVC\nPLTLGIETVGGVMTKLIPRNTVVPTKKSQIFSTASDNQPTVTIKVYEGERPLTKDNHLLG\nTFDLTGIPPAPRGVPQIEVTFEIDVNGILRVTAEDKGTGNKNKITITNDQNRLTPEEIER\nMVNDAEKFAEEDKKLKERIDTRNELESYAYSLKNQIGDKEKLGGKLSSEDKETMEKAVEE\nKIEWLESHQDADIEDFKAKKKELEEIVQPIISKLYGSAGPPPTGEEDTAEKDEL"}, "gene-sequence": {"@format": "FASTA", "#text": ">1962 bp\nATGAAGCTCTCCCTGGTGGCCGCGATGCTGCTGCTGCTCAGCGCGGCGCGGGCCGAGGAG\nGAGGACAAGAAGGAGGACGTGGGCACGGTGGTCGGCATCGACTTGGGGACCACCTACTCC\nTGCGTCGGCGTGTTCAAGAACGGCCGCGTGGAGATCATCGCCAACGATCAGGGCAACCGC\nATCACGCCGTCCTATGTCGCCTTCACTCCTGAAGGGGAACGTCTGATTGGCGATGCCGCC\nAAGAACCAGCTCACCTCCAACCCCGAGAACACGGTCTTTGACGCCAAGCGGCTCATCGGC\nCGCACGTGGAATGACCCGTCTGTGCAGCAGGACATCAAGTTCTTGCCGTTCAAGGTGGTT\nGAAAAGAAAACTAAACCATACATTCAAGTTGATATTGGAGGTGGGCAAACAAAGACATTT\nGCTCCTGAAGAAATTTCTGCCATGGTTCTCACTAAAATGAAAGAAACCGCTGAGGCTTAT\nTTGGGAAAGAAGGTTACCCATGCAGTTGTTACTGTACCAGCCTATTTTAATGATGCCCAA\nCGCCAAGCAACCAAAGACGCTGGAACTATTGCTGGCCTAAATGTTATGAGGATCATCAAC\nGAGCCTACGGCAGCTGCTATTGCTTATGGCCTGGATAAGAGGGAGGGGGAGAAGAACATC\nCTGGTGTTTGACCTGGGTGGCGGAACCTTCGATGTGTCTCTTCTCACCATTGACAATGGT\nGTCTTCGAAGTTGTGGCCACTAATGGAGATACTCATCTGGGTGGAGAAGACTTTGACCAG\nCGTGTCATGGAACACTTCATCAAACTGTACAAAAAGAAGACGGGCAAAGATGTCAGGAAG\nGACAATAGAGCTGTGCAGAAACTCCGGCGCGAGGTAGAAAAGGCCAAGGCCCTGTCTTCT\nCAGCATCAAGCAAGAATTGAAATTGAGTCCTTCTATGAAGGAGAAGACTTTTCTGAGACC\nCTGACTCGGGCCAAATTTGAAGAGCTCAACATGGATCTGTTCCGGTCTACTATGAAGCCC\nGTCCAGAAAGTGTTGGAAGATTCTGATTTGAAGAAGTCTGATATTGATGAAATTGTTCTT\nGTTGGTGGCTCGACTCGAATTCCAAAGATTCAGCAACTGGTTAAAGAGTTCTTCAATGGC\nAAGGAACCATCCCGTGGCATAAACCCAGATGAAGCTGTAGCGTATGGTGCTGCTGTCCAG\nGCTGGTGTGCTCTCTGGTGATCAAGATACAGGTGACCTGGTACTGCTTCATGTATGTCCC\nCTTACACTTGGTATTGAAACTGTAGGAGGTGTCATGACCAAACTGATTCCAAGTAATACA\nGTGGTGCCTACCAAGAACTCTCAGATCTTTTCTACAGCTTCTGATAATCAACCAACTGTT\nACAATCAAGGTCTATGAAGGTGAAAGACCCCTGACAAAAGACAATCATCTTCTGGGTACA\nTTTGATCTGACTGGAATTCCTCCTGCTCCTCGTGGGGTCCCACAGATTGAAGTCACCTTT\nGAGATAGATGTGAATGGTATTCTTCGAGTGACAGCTGAAGACAAGGGTACAGGGAACAAA\nAATAAGATCACAATCACCAATGACCAGAATCGCCTGACACCTGAAGAAATCGAAAGGATG\nGTTAATGATGCTGAGAAGTTTGCTGAGGAAGACAAAAAGCTGAAGGAGCGCATTGATACT\nAGAAATGAGTTGGAAAGCTATGCCTATTCTCTAAAGAATCAGATTGGAGATAAAGAAAAG\nCTGGGAGGTAAACTTTCCTCTGAAGATAAGGAGACCATGGAAAAAGCTGTAGAAGAAAAG\nATTGAATGGCTGGAAAGCCACCAAGATGCTGACATTGAAGACTTCAAAGCTAAGAAGAAG\nGAACTGGAAGAAATTGTTCAACCAATTATCAGCAAACTCTATGGAAGTGCAGGCCCTCCC\nCCAACTGGTGAAGAGGATACAGCAGAAAAAGATGAGTTGTAG"}, "pfams": {"pfam": {"identifier": "PF00012", "name": "HSP70"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "binding"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "function", "description": "ATP binding"}]}}}, {"@position": "7", "id": "BE0002109", "name": "Calreticulin", "organism": "Human", "actions": {"action": "chaperone"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Pipe SW, Morris JA, Shah J, Kaufman RJ: Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem. 1998 Apr 3;273(14):8537-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9525969\n# Srour MA, Grupp J, Aburubaiha Z, Albert T, Brondke H, Oldenburg J, Schwaab R: Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein. Ann Hematol. 2007 Sep 26;. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17899080\n# Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M: Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis. 1997 Dec;8 Suppl 2:S3-14. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9607108\n# Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M: Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis. 1997 Dec;8 Suppl 2:S3-14. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9607108", "known-action": "unknown", "polypeptide": {"@id": "P27797", "@source": "Swiss-Prot", "name": "Calreticulin", "general-function": null, "specific-function": "Molecular calcium binding chaperone promoting folding, oligomeric assembly and quality control in the ER via the calreticulin/calnexin cycle. This lectin interacts transiently with almost all of the monoglucosylated glycoproteins that are synthesized in the ER. Interacts with the DNA-binding domain of NR3C1 and mediates its nuclear export", "gene-name": "CALR", "locus": "19p13.3-p13.2", "cellular-location": "Endoplasmic reticulum", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "4.04", "molecular-weight": "48142.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1455"}, {"resource": "GenAtlas", "identifier": "CALR"}, {"resource": "GeneCards", "identifier": "CALR"}, {"resource": "GenBank Gene Database", "identifier": "M32294"}, {"resource": "GenBank Protein Database", "identifier": "337487"}, {"resource": "UniProtKB", "identifier": "P27797"}, {"resource": "UniProt Accession", "identifier": "CALR_HUMAN"}]}, "synonyms": {"synonym": ["Calregulin", "Calreticulin precursor", "CRP55", "ERp60", "grp60", "HACBP"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Calreticulin\nMLLSVPLLLGLLGLAVAEPAVYFKEQFLDGDGWTSRWIESKHKSDFGKFVLSSGKFYGDE\nEKDKGLQTSQDARFYALSASFEPFSNKGQTLVVQFTVKHEQNIDCGGGYVKLFPNSLDQT\nDMHGDSEYNIMFGPDICGPGTKKVHVIFNYKGKNVLINKDIRCKDDEFTHLYTLIVRPDN\nTYEVKIDNSQVESGSLEDDWDFLPPKKIKDPDASKPEDWDERAKIDDPTDSKPEDWDKPE\nHIPDPDAKKPEDWDEEMDGEWEPPVIQNPEYKGEWKPRQIDNPDYKGTWIHPEIDNPEYS\nPDPSIYAYDNFGVLGLDLWQVKSGTIFDNFLITNDEAYAEEFGNETWGVTKAAEKQMKDK\nQDEEQRLKEEEEDKKRKEEEEAEDKEDDEDKDEDEEDEEDKEEDEEEDVPGQAKDEL"}, "gene-sequence": {"@format": "FASTA", "#text": ">1254 bp\nATGCTGCTATCCGTGCCGCTGCTGCTCGGCCTCCTCGGCCTGGCCGTCGCCGAGCCCGCC\nGTCTACTTCAAGGAGCAGTTTCTGGACGGAGACGGGTGGACTTCCCGCTGGATCGAATCC\nAAACACAAGTCAGATTTTGGCAAATTCGTTCTCAGTTCCGGCAAGTTCTACGGTGACGAG\nGAGAAAGATAAAGGTTTGCAGACAAGCCAGGATGCACGCTTTTATGCTCTGTCGGCCAGT\nTTCGAGCCTTTCAGCAACAAAGGCCAGACGCTGGTGGTGCAGTTCACGGTGAAACATGAG\nCAGAACATCGACTGTGGGGGCGGCTATGTGAAGCTGTTTCCTAATAGTTTGGACCAGACA\nGACATGCACGGAGACTCAGAATACAACATCATGTTTGGTCCCGACATCTGTGGCCCTGGC\nACCAAGAAGGTTCATGTCATCTTCAACTACAAGGGCAAGAACGTGCTGATCAACAAGGAC\nATCCGTTGCAAGGATGATGAGTTTACACACCTGTACACACTGATTGTGCGGCCAGACAAC\nACCTATGAGGTGAAGATTGACAACAGCCAGGTGGAGTCCGGCTCCTTGGAAGACGATTGG\nGACTTCCTGCCACCCAAGAAGATAAAGGATCCTGATGCTTCAAAACCGGAAGACTGGGAT\nGAGCGGGCCAAGATCGATGATCCCACAGACTCCAAGCCTGAGGACTGGGACAAGCCCGAG\nCATATCCCTGACCCTGATGCTAAGAAGCCCGAGGACTGGGATGAAGAGATGGACGGAGAG\nTGGGAACCCCCAGTGATTCAGAACCCTGAGTACAAGGGTGAGTGGAAGCCCCGGCAGATC\nGACAACCCAGATTACAAGGGCACTTGGATCCACCCAGAAATTGACAACCCCGAGTATTCT\nCCCGATCCCAGTATCTATGCCTATGATAACTTTGGCGTGCTGGGCCTGGACCTCTGGCAG\nGTCAAGTCTGGCACCATCTTTGACAACTTCCTCATCACCAACGATGAGGCATACGCTGAG\nGAGTTTGGCAACGAGACGTGGGGCGTAACAAAGGCAGCAGAGAAACAAATGAAGGACAAA\nCAGGACGAGGAGCAGAGGCTTAAGGAGGAGGAAGAAGACAAGAAACGCAAAGAGGAGGAG\nGAGGCAGAGGACAAGGAGGATGATGAGGACAAAGATGAGGATGAGGAGGATGAGGAGGAC\nAAGGAGGAAGATGAGGAGGAAGATGTCCCCGGCCAGGCCAAGGACGAGCTGTAG"}, "pfams": {"pfam": {"identifier": "PF00262", "name": "Calreticulin"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "membrane-bound organelle"}, {"category": "component", "description": "intracellular membrane-bound organelle"}, {"category": "component", "description": "endoplasmic reticulum"}, {"category": "component", "description": "organelle"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "unfolded protein binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "protein binding"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein folding"}]}}}, {"@position": "8", "id": "BE0001011", "name": "Calnexin", "organism": "Human", "actions": {"action": "chaperone"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Pipe SW, Morris JA, Shah J, Kaufman RJ: Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem. 1998 Apr 3;273(14):8537-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9525969\n# Becker S, Simpson JC, Pepperkok R, Heinz S, Herder C, Grez M, Seifried E, Tonn T: Confocal microscopy analysis of native, full length and B-domain deleted coagulation factor VIII trafficking in mammalian cells. Thromb Haemost. 2004 Jul;92(1):23-35. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15213841\n# Srour MA, Grupp J, Aburubaiha Z, Albert T, Brondke H, Oldenburg J, Schwaab R: Modified expression of coagulation factor VIII by addition of a glycosylation site at the N terminus of the protein. Ann Hematol. 2007 Sep 26;. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17899080\n# Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M: Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis. 1997 Dec;8 Suppl 2:S3-14. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9607108", "known-action": "unknown", "polypeptide": {"@id": "P27824", "@source": "Swiss-Prot", "name": "Calnexin", "general-function": "Involved in calcium ion binding", "specific-function": "Calcium-binding protein that interacts with newly synthesized glycoproteins in the endoplasmic reticulum. It may act in assisting protein assembly and/or in the retention within the ER of unassembled protein subunits. It seems to play a major role in the quality control apparatus of the ER by the retention of incorrectly folded proteins", "gene-name": "CANX", "locus": "5q35", "cellular-location": "Endoplasmic reticulum; endoplasmic reticulum membrane; single-pass type I membrane protein. Melanoso", "transmembrane-regions": "482-502", "signal-regions": null, "theoretical-pi": "4.21", "molecular-weight": "67569.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1473"}, {"resource": "GenAtlas", "identifier": "CANX"}, {"resource": "GeneCards", "identifier": "CANX"}, {"resource": "GenBank Gene Database", "identifier": "L10284"}, {"resource": "GenBank Protein Database", "identifier": "186523"}, {"resource": "UniProtKB", "identifier": "P27824"}, {"resource": "UniProt Accession", "identifier": "CALX_HUMAN"}]}, "synonyms": {"synonym": ["Calnexin precursor", "IP90", "Major histocompatibility complex class I antigen- binding protein p88", "p90"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Calnexin precursor\nMEGKWLLCMLLVLGTAIVEAHDGHDDDVIDIEDDLDDVIEEVEDSKPDTTAPPSSPKVTY\nKAPVPTGEVYFADSFDRGTLSGWILSKAKKDDTDDEIAKYDGKWEVEEMKESKLPGDKGL\nVLMSRAKHHAISAKLNKPFLFDTKPLIVQYEVNFQNGIECGGAYVKLLSKTPELNLDQFH\nDKTPYTIMFGPDKCGEDYKLHFIFRHKNPKTGIYEEKHAKRPDADLKTYFTDKKTHLYTL\nILNPDNSFEILVDQSVVNSGNLLNDMTPPVNPSREIEDPEDRKPEDWDERPKIPDPEAVK\nPDDWDEDAPAKIPDEEATKPEGWLDDEPEYVPDPDAEKPEDWDEDMDGEWEAPQIANPRC\nESAPGCGVWQRPVIDNPNYKGKWKPPMIDNPSYQGIWKPRKIPNPDFFEDLEPFRMTPFS\nAIGLELWSMTSDIFFDNFIICADRRIVDDWANDGWGLKKAADGAAEPGVVGQMIEAAEER\nPWLWVVYILTVALPVFLVILFCCSGKKQTSGMEYKKTDAPQPDVKEEEEEKEEEKDKGDE\nEEEGEEKLEEKQKSDAEEDGGTVSQEEEDRKPKAEEDEILNRSPRNRKPRRE"}, "gene-sequence": {"@format": "FASTA", "#text": ">1779 bp\nATGGAAGGGAAGTGGTTGCTGTGTATGTTACTGGTGCTTGGAACTGCTATTGTTGAGGCT\nCATGATGGACATGATGATGATGTGATTGATATTGAGGATGACCTTGACGATGTCATTGAA\nGAGGTAGAAGACTCAAAACCAGATACCACTGCTCCTCCTTCATCTCCCAAGGTTACTTAC\nAAAGCTCCAGTTCCAACAGGGGAAGTATATTTTGCTGATTCTTTTGACAGAGGAACTCTG\nTCAGGGTGGATTTTATCCAAAGCCAAGAAAGACGATACCGATGATGAAATTGCCAAATAT\nGATGGAAAGTGGGAGGTAGAGGAAATGAAGGAGTCAAAGCTTCCAGGTGATAAAGGACTT\nGTGTTGATGTCTCGGGCCAAGCATCATGCGATCTCTGCTAAACTGAACAAGCCCTTCCTG\nTTTGACACCAAGCCTCTCATTGTTCAGTATGAGGTTAATTTCCAAAATGGAATAGAATGT\nGGTGGTGCCTATGTGAAACTGCTTTCTAAAACACCAGAACTCAACCTGGATCAGTTCCAT\nGACAAGACCCCTTATACGATTATGTTTGGTCCAGATAAATGTGGAGAGGACTATAAACTG\nCACTTCATCTTCCGACACAAAAACCCCAAAACGGGTATCTATGAAGAAAAACATGCTAAG\nAGGCCAGATGCAGATCTGAAGACCTATTTTACTGATAAGAAAACACATCTTTACACACTA\nATCTTGAATCCAGATAATAGTTTTGAAATACTGGTTGACCAATCTGTGGTGAATAGTGGA\nAATCTGCTCAATGACATGACTCCTCCTGTAAATCCTTCACGTGAAATTGAGGACCCAGAA\nGACCGGAAGCCCGAGGATTGGGATGAAAGACCAAAAATCCCAGATCCAGAAGCTGTCAAG\nCCAGATGACTGGGATGAAGATGCCCCTGCTAAGATTCCAGATGAAGAGGCCACAAAACCC\nGAAGGCTGGTTAGATGATGAGCCTGAGTACGTACCTGATCCAGACGCAGAGAAACCTGAG\nGATTGGGATGAAGACATGGATGGAGAATGGGAGGCTCCTCAGATTGCCAACCCTAGATGT\nGAGTCAGCTCCTGGATGTGGTGTCTGGCAGCGACCTGTGATTGACAACCCCAATTATAAA\nGGCAAATGGAAGCCTCCTATGATTGACAATCCCAGTTACCAGGGAATCTGGAAACCCAGG\nAAAATACCAAATCCAGATTTCTTTGAAGATCTGGAACCTTTCAGAATGACTCCTTTTAGT\nGCTATTGGTTTGGAGCTGTGGTCCATGACCTCTGACATTTTTTTTGACAACTTTATCATT\nTGTGCTGATCGAAGAATAGTTGATGATTGGGCCAATGATGGATGGGGCCTGAAGAAAGCT\nGCTGATGGGGCTGCTGAGCCAGGCGTTGTGGGGCAGATGATCGAGGCAGCTGAAGAGCGC\nCCGTGGCTGTGGGTAGTCTATATTCTAACTGTAGCCCTTCCTGTGTTCCTGGTTATCCTC\nTTCTGCTGTTCTGGAAAGAAACAGACCAGTGGTATGGAGTATAAGAAAACTGATGCACCT\nCAACCGGATGTGAAGGAAGAGGAAGAAGAGAAGGAAGAGGAAAAGGACAAGGGAGATGAG\nGAGGAGGAAGGAGAAGAGAAACTTGAAGAGAAACAGAAAAGTGATGCTGAAGAAGATGGT\nGGCACTGTCAGTCAAGAGGAGGAAGACAGAAAACCTAAAGCAGAGGAGGATGAAATTTTG\nAACAGATCACCAAGAAACAGAAAGCCACGAAGAGAGTGA"}, "pfams": {"pfam": {"identifier": "PF00262", "name": "Calreticulin"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "binding"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}]}}}, {"@position": "9", "id": "BE0002119", "name": "Protein ERGIC-53", "organism": "Human", "actions": {"action": "chaperone"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Cunningham MA, Pipe SW, Zhang B, Hauri HP, Ginsburg D, Kaufman RJ: LMAN1 is a molecular chaperone for the secretion of coagulation factor VIII. J Thromb Haemost. 2003 Nov;1(11):2360-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14629470\n# Miao HZ, Sirachainan N, Palmer L, Kucab P, Cunningham MA, Kaufman RJ, Pipe SW: Bioengineering of coagulation factor VIII for improved secretion. Blood. 2004 May 1;103(9):3412-9. Epub 2004 Jan 15. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14726380", "known-action": "unknown", "polypeptide": {"@id": "P49257", "@source": "Swiss-Prot", "name": "Protein ERGIC-53", "general-function": null, "specific-function": "Mannose-specific lectin. May recognize sugar residues of glycoproteins, glycolipids, or glycosylphosphatidyl inositol anchors and may be involved in the sorting or recycling of proteins, lipids, or both. The LMAN1-MCFD2 complex forms a specific cargo receptor for the ER-to-Golgi transport of selected proteins", "gene-name": "LMAN1", "locus": "18q21.3-q22", "cellular-location": "Endoplasmic reticulum-Golgi intermediate compartment", "transmembrane-regions": "478-498", "signal-regions": null, "theoretical-pi": "6.76", "molecular-weight": "57550.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6631"}, {"resource": "GenAtlas", "identifier": "LMAN1"}, {"resource": "GeneCards", "identifier": "LMAN1"}, {"resource": "GenBank Gene Database", "identifier": "X71661"}, {"resource": "GenBank Protein Database", "identifier": "433938"}, {"resource": "UniProtKB", "identifier": "P49257"}, {"resource": "UniProt Accession", "identifier": "LMAN1_HUMAN"}]}, "synonyms": {"synonym": ["ER-Golgi intermediate compartment 53 kDa protein", "ERGIC-53 protein precursor", "Gp58", "Intracellular mannose- specific lectin MR60", "Lectin, mannose-binding 1"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">ERGIC-53 protein\nMAGSRQRGLRARVRPLFCALLLSLGRFVRGDGVGGDPAVALPHRRFEYKYSFKGPHLVQS\nDGTVPFWAHAGNAIPSSDQIRVAPSLKSQRGSVWTKTKAAFENWEVEVTFRVTGRGRIGA\nDGLAIWYAENQGLEGPVFGSADLWNGVGIFFDSFDNDGKKNNPAIVIIGNNGQIHYDHQN\nDGASQALASCQRDFRNKPYPVRAKITYYQNTLTVMINNGFTPDKNDYEFCAKVENMIIPA\nQGHFGISAATGGLADDHDVLSFLTFQLTEPGKEPPTPDKEISEKEKEKYQEEFEHFQQEL\nDKKKEEFQKGHPDLQGQPAEEIFESVGDRELRQVFEGQNRIHLEIKQLNRQLDMILDEQR\nRYVSSLTEEISKRGAGMPGQHGQITQQELDTVVKTQHEILRQVNEMKNSMSETVRLVSGM\nQHPGSAGGVYETTQHFIDIKEHLHIVKRDIDNLVQRNMPSNEKPKCPELPPFPSCLSTVH\nFIIFVVVQTVLFIGYIMYRSQQEAAAKKFF"}, "gene-sequence": {"@format": "FASTA", "#text": ">1533 bp\nATGGCGGGATCCAGGCAAAGGGGTCTCCGGGCCAGAGTTCGGCCGCTGTTCTGCGCCTTG\nCTGCTGTCACTCGGTCGCTTCGTCCGGGGCGACGGCGTGGGAGGAGACCCCGCGGTCGCG\nTTGCCACATCGCCGTTTCGAGTACAAATACAGCTTCAAGGGGCCGCACCTGGTGCAGAGC\nGACGGGACCGTGCCCTTCTGGGCCCACGCGGGGAATGCTATTCCAAGTTCAGATCAAATT\nCGAGTAGCACCATCTTTAAAAAGCCAAAGAGGCTCAGTGTGGACAAAGACAAAAGCGGCC\nTTTGAGAACTGGGAAGTTGAGGTGACATTTCGAGTGACTGGAAGAGGTCGAATTGGAGCT\nGATGGCCTAGCAATTTGGTATGCAGAAAATCAAGGCTTGGAGGGCCCTGTGTTTGGATCA\nGCTGATCTGTGGAATGGTGTTGGAATATTTTTTGATACTTTTGACAATGATGGAAAGAAA\nAATAATCCTGCTATAGTAATTATAGGCAACAATGGACAAATCCATTATGACCATCAAAAT\nGACGGGGCTAGTCAAGCTTTGGCAAGTTGCCAGAGGGACTTCCGCAACAAACCCTATCCT\nGTCCGAGCAAAGATTACCTATTACCAGAACACACTGACAGTAATGATCAATAATGGCTTT\nACACCAGATAAAAATGATTATGAATTTTGTGCCAAAGTGGAAAATATGATTATCCCTGCA\nCAAGGGCATTTTGGAATATCTGCTGCAACTGGAGGTCTTGCAGATGACCATGATGTCCTT\nTCTTTTCTGACTTTCCAGTTGACTGAACCTGGAAAAGAGCCGCCCACACCAGATAAAGAA\nATTTCGGAAAAGGAAAAAGAAAAGTATCAGGAGGAATTTGAGCACTTTCAACAAGAATTG\nGATAAAAAAAAAGAGGAATTCCAGAAGGGCCACCCCGACCTCCAAGGGCAGCCTGCGGAG\nGAAATATTTGAGAGTGTAGGAGATCGAGAGCTAAGACAAGTCTTTGAAGGACAGAATCGT\nATTCATCTTGAAATCAAGCAGCTGAACCGGCAGTTAGATATGATTCTTGATGAACAGAGA\nAGATATGTCTCTTCCTTAACAGAGGAAATCTCTAAAAGAGGAGCAGGAATGCCTGGGCAG\nCATGGGCAGATTACTCAACAAGAACTGGATACTGTTGTGAAAACTCAGCATGAGATTCTG\nAGACAAGTAAATGAAATGAAAAATTCCATGAGTGAAACCGTCAGACTGGTCAGTGGAATG\nCAGCACCCTGGCTCTGCTGGAGGCGTCTATGAGACAACACAGCACTTCATTGACATCAAA\nGAGCACCTGCACATAGTAAAGAGGGACATAGATAACTTAGTGCAGCGAAATATGCCATCA\nAATGAAAAGCCGAAATGCCCAGAACTACCACCATTTCCATCATGTTTGTCTACGGTCCAC\nTTCATTATATTTGTTGTGGTGCAAACTGTATTATTCATTGGTTATATCATGTATAGGTCT\nCAGCAAGAAGCAGCTGCCAAAAAATTCTTTTGA"}, "pfams": {"pfam": {"identifier": "PF03388", "name": "Lectin_leg-like"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}]}}}, {"@position": "10", "id": "BE0002110", "name": "Prolow-density lipoprotein receptor-related protein 1", "organism": "Human", "actions": {"action": "modulator"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Franchini M, Montagnana M: Low-density lipoprotein receptor-related protein 1: new functions for an old molecule. Clin Chem Lab Med. 2011 Jun;49(6):967-70. Epub 2011 Mar 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/21391865", "known-action": "unknown", "polypeptide": {"@id": "Q07954", "@source": "Swiss-Prot", "name": "Prolow-density lipoprotein receptor-related protein 1", "general-function": null, "specific-function": "Required for early embryonic development. Involved in the plasma clearance of chylomicron remnants and activated alpha 2-macroglobulin, as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. May modulate APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission", "gene-name": "LRP1", "locus": "12q13-q14", "cellular-location": "Cell membrane", "transmembrane-regions": "4420-4444", "signal-regions": null, "theoretical-pi": "5.02", "molecular-weight": "504578.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6692"}, {"resource": "GenAtlas", "identifier": "LRP1"}, {"resource": "GeneCards", "identifier": "LRP1"}, {"resource": "GenBank Gene Database", "identifier": "X13916"}, {"resource": "GenBank Protein Database", "identifier": "34339"}, {"resource": "UniProtKB", "identifier": "Q07954"}, {"resource": "UniProt Accession", "identifier": "LRP1_HUMAN"}]}, "synonyms": {"synonym": ["A2MR", "Alpha-2-macroglobulin receptor", "APOER", "Apolipoprotein E receptor", "CD91 antigen", "Low-density lipoprotein receptor-related protein 1 precursor", "LRP"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low-density lipoprotein receptor-related protein 1\nMLTPPLLLLLPLLSALVAAAIDAPKTCSPKQFACRDQITCISKGWRCDGERDCPDGSDEA\nPEICPQSKAQRCQPNEHNCLGTELCVPMSRLCNGVQDCMDGSDEGPHCRELQGNCSRLGC\nQHHCVPTLDGPTCYCNSSFQLQADGKTCKDFDECSVYGTCSQLCTNTDGSFICGCVEGYL\nLQPDNRSCKAKNEPVDRPPVLLIANSQNILATYLSGAQVSTITPTSTRQTTAMDFSYANE\nTVCWVHVGDSAAQTQLKCARMPGLKGFVDEHTINISLSLHHVEQMAIDWLTGNFYFVDDI\nDDRIFVCNRNGDTCVTLLDLELYNPKGIALDPAMGKVFFTDYGQIPKVERCDMDGQNRTK\nLVDSKIVFPHGITLDLVSRLVYWADAYLDYIEVVDYEGKGRQTIIQGILIEHLYGLTVFE\nNYLYATNSDNANAQQKTSVIRVNRFNSTEYQVVTRVDKGGALHIYHQRRQPRVRSHACEN\nDQYGKPGGCSDICLLANSHKARTCRCRSGFSLGSDGKSCKKPEHELFLVYGKGRPGIIRG\nMDMGAKVPDEHMIPIENLMNPRALDFHAETGFIYFADTTSYLIGRQKIDGTERETILKDG\nIHNVEGVAVDWMGDNLYWTDDGPKKTISVARLEKAAQTRKTLIEGKMTHPRAIVVDPLNG\nWMYWTDWEEDPKDSRRGRLERAWMDGSHRDIFVTSKTVLWPNGLSLDIPAGRLYWVDAFY\nDRIETILLNGTDRKIVYEGPELNHAFGLCHHGNYLFWTEYRSGSVYRLERGVGGAPPTVT\nLLRSERPPIFEIRMYDAQQQQVGTNKCRVNNGGCSSLCLATPGSRQCACAEDQVLDADGV\nTCLANPSYVPPPQCQPGEFACANSRCIQERWKCDGDNDCLDNSDEAPALCHQHTCPSDRF\nKCENNRCIPNRWLCDGDNDCGNSEDESNATCSARTCPPNQFSCASGRCIPISWTCDLDDD\nCGDRSDESASCAYPTCFPLTQFTCNNGRCININWRCDNDNDCGDNSDEAGCSHSCSSTQF\nKCNSGRCIPEHWTCDGDNDCGDYSDETHANCTNQATRPPGGCHTDEFQCRLDGLCIPLRW\nRCDGDTDCMDSSDEKSCEGVTHVCDPSVKFGCKDSARCISKAWVCDGDNDCEDNSDEENC\nESLACRPPSHPCANNTSVCLPPDKLCDGNDDCGDGSDEGELCDQCSLNNGGCSHNCSVAP\nGEGIVCSCPLGMELGPDNHTCQIQSYCAKHLKCSQKCDQNKFSVKCSCYEGWVLEPDGES\nCRSLDPFKPFIIFSNRHEIRRIDLHKGDYSVLVPGLRNTIALDFHLSQSALYWTDVVEDK\nIYRGKLLDNGALTSFEVVIQYGLATPEGLAVDWIAGNIYWVESNLDQIEVAKLDGTLRTT\nLLAGDIEHPRAIALDPRDGILFWTDWDASLPRIEAASMSGAGRRTVHRETGSGGWPNGLT\nVDYLEKRILWIDARSDAIYSARYDGSGHMEVLRGHEFLSHPFAVTLYGGEVYWTDWRTNT\nLAKANKWTGHNVTVVQRTNTQPFDLQVYHPSRQPMAPNPCEANGGQGPCSHLCLINYNRT\nVSCACPHLMKLHKDNTTCYEFKKFLLYARQMEIRGVDLDAPYYNYIISFTVPDIDNVTVL\nDYDAREQRVYWSDVRTQAIKRAFINGTGVETVVSADLPNAHGLAVDWVSRNLFWTSYDTN\nKKQINVARLDGSFKNAVVQGLEQPHGLVVHPLRGKLYWTDGDNISMANMDGSNRTLLFSG\nQKGPVGLAIDFPESKLYWISSGNHTINRCNLDGSGLEVIDAMRSQLGKATALAIMGDKLW\nWADQVSEKMGTCSKADGSGSVVLRNSTTLVMHMKVYDESIQLDHKGTNPCSVNNGDCSQL\nCLPTSETTRSCMCTAGYSLRSGQQACEGVGSFLLYSVHEGIRGIPLDPNDKSDALVPVSG\nTSLAVGIDFHAENDTIYWVDMGLSTISRAKRDQTWREDVVTNGIGRVEGIAVDWIAGNIY\nWTDQGFDVIEVARLNGSFRYVVISQGLDKPRAITVHPEKGYLFWTEWGQYPRIERSRLDG\nTERVVLVNVSISWPNGISVDYQDGKLYWCDARTDKIERIDLETGENREVVLSSNNMDMFS\nVSVFEDFIYWSDRTHANGSIKRGSKDNATDSVPLRTGIGVQLKDIKVFNRDRQKGTNVCA\nVANGGCQQLCLYRGRGQRACACAHGMLAEDGASCREYAGYLLYSERTILKSIHLSDERNL\nNAPVQPFEDPEHMKNVIALAFDYRAGTSPGTPNRIFFSDIHFGNIQQINDDGSRRITIVE\nNVGSVEGLAYHRGWDTLYWTSYTTSTITRHTVDQTRPGAFERETVITMSGDDHPRAFVLD\nECQNLMFWTNWNEQHPSIMRAALSGANVLTLIEKDIRTPNGLAIDHRAEKLYFSDATLDK\nIERCEYDGSHRYVILKSEPVHPFGLAVYGEHIFWTDWVRRAVQRANKHVGSNMKLLRVDI\nPQQPMGIIAVANDTNSCELSPCRINNGGCQDLCLLTHQGHVNCSCRGGRILQDDLTCRAV\nNSSCRAQDEFECANGECINFSLTCDGVPHCKDKSDEKPSYCNSRRCKKTFRQCSNGRCVS\nNMLWCNGADDCGDGSDEIPCNKTACGVGEFRCRDGTCIGNSSRCNQFVDCEDASDEMNCS\nATDCSSYFRLGVKGVLFQPCERTSLCYAPSWVCDGANDCGDYSDERDCPGVKRPRCPLNY\nFACPSGRCIPMSWTCDKEDDCEHGEDETHCNKFCSEAQFECQNHRCISKQWLCDGSDDCG\nDGSDEAAHCEGKTCGPSSFSCPGTHVCVPERWLCDGDKDCADGADESIAAGCLYNSTCDD\nREFMCQNRQCIPKHFVCDHDRDCADGSDESPECEYPTCGPSEFRCANGRCLSSRQWECDG\nENDCHDQSDEAPKNPHCTSPEHKCNASSQFLCSSGRCVAEALLCNGQDDCGDSSDERGCH\nINECLSRKLSGCSQDCEDLKIGFKCRCRPGFRLKDDGRTCADVDECSTTFPCSQRCINTH\nGSYKCLCVEGYAPRGGDPHSCKAVTDEEPFLIFANRYYLRKLNLDGSNYTLLKQGLNNAV\nALDFDYREQMIYWTDVTTQGSMIRRMHLNGSNVQVLHRTGLSNPDGLAVDWVGGNLYWCD\nKGRDTIEVSKLNGAYRTVLVSSGLREPRALVVDVQNGYLYWTDWGDHSLIGRIGMDGSSR\nSVIVDTKITWPNGLTLDYVTERIYWADAREDYIEFASLDGSNRHVVLSQDIPHIFALTLF\nEDYVYWTDWETKSINRAHKTTGTNKTLLISTLHRPMDLHVFHALRQPDVPNHPCKVNNGG\nCSNLCLLSPGGGHKCACPTNFYLGSDGRTCVSNCTASQFVCKNDKCIPFWWKCDTEDDCG\nDHSDEPPDCPEFKCRPGQFQCSTGICTNPAFICDGDNDCQDNSDEANCDIHVCLPSQFKC\nTNTNRCIPGIFRCNGQDNCGDGEDERDCPEVTCAPNQFQCSITKRCIPRVWVCDRDNDCV\nDGSDEPANCTQMTCGVDEFRCKDSGRCIPARWKCDGEDDCGDGSDEPKEECDERTCEPYQ\nFRCKNNRCVPGRWQCDYDNDCGDNSDEESCTPRPCSESEFSCANGRCIAGRWKCDGDHDC\nADGSDEKDCTPRCDMDQFQCKSGHCIPLRWRCDADADCMDGSDEEACGTGVRTCPLDEFQ\nCNNTLCKPLAWKCDGEDDCGDNSDENPEECARFVCPPNRPFRCKNDRVCLWIGRQCDGTD\nNCGDGTDEEDCEPPTAHTTHCKDKKEFLCRNQRCLSSSLRCNMFDDCGDGSDEEDCSIDP\nKLTSCATNASICGDEARCVRTEKAAYCACRSGFHTVPGQPGCQDINECLRFGTCSQLCNN\nTKGGHLCSCARNFMKTHNTCKAEGSEYQVLYIADDNEIRSLFPGHPHSAYEQAFQGDESV\nRIDAMDVHVKAGRVYWTNWHTGTISYRSLPPAAPPTTSNRHRRQIDRGVTHLNISGLKMP\nRGIAIDWVAGNVYWTDSGRDVIEVAQMKGENRKTLISGMIDEPHAIVVDPLRGTMYWSDW\nGNHPKIETAAMDGTLRETLVQDNIQWPTGLAVDYHNERLYWADAKLSVIGSIRLNGTDPI\nVAADSKRGLSHPFSIDVFEDYIYGVTYINNRVFKIHKFGHSPLVNLTGGLSHASDVVLYH\nQHKQPEVTNPCDRKKCEWLCLLSPSGPVCTCPNGKRLDNGTCVPVPSPTPPPDAPRPGTC\nNLQCFNGGSCFLNARRQPKCRCQPRYTGDKCELDQCWEHCRNGGTCAASPSGMPTCRCPT\nGFTGPKCTQQVCAGYCANNSTCTVNQGNQPQCRCLPGFLGDRCQYRQCSGYCENFGTCQM\nAADGSRQCRCTAYFEGSRCEVNKCSRCLEGACVVNKQSGDVTCNCTDGRVAPSCLTCVGH\nCSNGGSCTMNSKMMPECQCPPHMTGPRCEEHVFSQQQPGHIASILIPLLLLLLLVLVAGV\nVFWYKRRVQGAKGFQHQRMTNGAMNVEIGNPTYKMYEGGEPDDVGGLLDADFALDPDKPT\nNFTNPVYATLYMGGHGSRHSLASTDEKRELLGRGPEDEIGDPLA"}, "gene-sequence": {"@format": "FASTA", "#text": ">13635 bp\nATGCTGACCCCGCCGTTGCTCCTGCTGCTGCCCCTGCTCTCAGCTCTGGTCGCGGCGGCT\nATCGACGCCCCTAAGACTTGCAGCCCCAAGCAGTTTGCCTGCAGAGATCAAATAACCTGT\nATCTCAAAGGGCTGGCGGTGCGACGGTGAGAGGGACTGCCCAGACGGATCTGACGAGGCC\nCCTGAGATTTGTCCACAGAGTAAGGCCCAGCGATGCCAGCCAAACGAGCATAACTGCCTG\nGGTACTGAGCTGTGTGTTCCCATGTCCCGCCTCTGCAATGGGGTCCAGGACTGCATGGAC\nGGCTCAGATGAGGGGCCCCACTGCCGAGAGCTCCAAGGCAACTGCTCTCGCCTGGGCTGC\nCAGCACCATTGTGTCCCCACACTCGATGGGCCCACCTGCTACTGCAACAGCAGCTTTCAG\nCTTCAGGCAGATGGCAAGACCTGCAAAGATTTTGATGAGTGCTCAGTGTACGGCACCTGC\nAGCCAGCTATGCACCAACACAGACGGCTCCTTCATATGTGGCTGTGTTGAAGGATACCTC\nCTGCAGCCGGATAACCGCTCCTGCAAGGCCAAGAACGAGCCAGTAGACCGGCCCCCTGTG\nCTGTTGATAGCCAACTCCCAGAACATCTTGGCCACGTACCTGAGTGGGGCCCAGGTGTCT\nACCATCACACCTACGAGCACGCGGCAGACCACAGCCATGGACTTCAGCTATGCCAACGAG\nACCGTATGCTGGGTGCATGTTGGGGACAGTGCTGCTCAGACGCAGCTCAAGTGTGCCCGC\nATGCCTGGCCTAAAGGGCTTCGTGGATGAGCACACCATCAACATCTCCCTCAGTCTGCAC\nCACGTGGAACAGATGGCCATCGACTGGCTGACAGGCAACTTCTACTTTGTGGATGACATC\nGATGATAGGATCTTTGTCTGCAACAGAAATGGGGACACATGTGTCACATTGCTAGACCTG\nGAACTCTACAACCCCAAGGGCATTGCCCTGGACCCTGCCATGGGGAAGGTGTTTTTCACT\nGACTATGGGCAGATCCCAAAGGTGGAACGCTGTGACATGGATGGGCAGAACCGCACCAAG\nCTCGTCGACAGCAAGATTGTGTTTCCTCATGGCATCACGCTGGACCTGGTCAGCCGCCTT\nGTCTACTGGGCAGATGCCTATCTGGACTATATTGAAGTGGTGGACTATGAGGGCAAGGGC\nCGCCAGACCATCATCCAGGGCATCCTGATTGAGCACCTGTACGGCCTGACTGTGTTTGAG\nAATTATCTCTATGCCACCAACTCGGACAATGCCAATGCCCAGCAGAAGACGAGTGTGATC\nCGTGTGAACCGCTTTAACAGCACCGAGTACCAGGTTGTCACCCGGGTGGACAAGGGTGGT\nGCCCTCCACATCTACCACCAGAGGCGTCAGCCCCGAGTGAGGAGCCATGCCTGTGAAAAC\nGACCAGTATGGGAAGCCGGGTGGCTGCTCTGACATCTGCCTGCTGGCCAACAGCCACAAG\nGCGCGGACCTGCCGCTGCCGTTCCGGCTTCAGCCTGGGCAGTGACGGGAAGTCATGCAAG\nAAGCCGGAGCATGAGCTGTTCCTCGTGTATGGCAAGGGCCGGCCAGGCATCATCCGGGGC\nATGGATATGGGGGCCAAGGTCCCGGATGAGCACATGATCCCCATTGAAAACCTCATGAAC\nCCCCGAGCCCTGGACTTCCACGCTGAGACCGGCTTCATCTACTTTGCCGACACCACCAGC\nTACCTCATTGGCCGCCAGAAGATTGATGGCACTGAGCGGGAGACCATCCTGAAGGACGGC\nATCCACAATGTGGAGGGTGTGGCCGTGGACTGGATGGGAGACAATCTGTACTGGACGGAC\nGATGGGCCCAAAAAGACAATCAGCGTGGCCAGGCTGGAGAAAGCTGCTCAGACCCGCAAG\nACTTTAATCGAGGGCAAAATGACACACCCCAGGGCTATTGTGGTGGATCCACTCAATGGG\nTGGATGTACTGGACAGACTGGGAGGAGGACCCCAAGGACAGTCGGCGTGGGCGGCTGGAG\nAGGGCGTGGATGGATGGCTCACACCGAGACATCTTTGTCACCTCCAAGACAGTGCTTTGG\nCCCAATGGGCTAAGCCTGGACATCCCGGCTGGGCGCCTCTACTGGGTGGATGCCTTCTAC\nGACCGCATCGAGACGATACTGCTCAATGGCACAGACCGGAAGATTGTGTATGAAGGTCCT\nGAGCTGAACCACGCCTTTGGCCTGTGTCACCATGGCAACTACCTCTTCTGGACTGAGTAT\nCGGAGTGGCAGTGTCTACCGCTTGGAACGGGGTGTAGGAGGCGCACCCCCCACTGTGACC\nCTTCTGCGCAGTGAGCGGCCCCCCATCTTTGAGATCCGAATGTATGATGCCCAGCAGCAG\nCAAGTTGGCACCAACAAATGCCGGGTGAACAATGGCGGCTGCAGCAGCCTGTGCTTGGCC\nACCCCTGGGAGCCGCCAGTGCGCCTGTGCTGAGGACCAGGTGTTGGACGCAGACGGCGTC\nACTTGCTTGGCGAACCCATCCTACGTGCCTCCACCCCAGTGCCAGCCAGGCGAGTTTGCC\nTGTGCCAACAGCCGCTGCATCCAGGAGCGCTGGAAGTGTGACGGAGACAACGATTGCCTG\nGACAACAGTGATGAGGCCCCAGCCCTCTGCCATCAGCACACCTGCCCCTCGGACCGATTC\nAAGTGCGAGAACAACCGGTGCATCCCCAACCGCTGGCTCTGCGACGGGGACAATGACTGT\nGGGAACAGTGAAGATGAGTCCAATGCCACTTGTTCAGCCCGCACCTGCCCCCCCAACCAG\nTTCTCCTGTGCCAGTGGCCGCTGCATCCCCATCTCCTGGACGTGTGATCTGGATGACGAC\nTGTGGGGACCGCTCTGATGAGTCTGCTTCGTGTGCCTATCCCACCTGCTTCCCCCTGACT\nCAGTTTACCTGCAACAATGGCAGATGTATCAACATCAACTGGAGATGCGACAATGACAAT\nGACTGTGGGGACAACAGTGACGAAGCCGGCTGCAGCCACTCCTGTTCTAGCACCCAGTTC\nAAGTGCAACAGCGGGCGTTGCATCCCCGAGCACTGGACCTGCGATGGGGACAATGACTGC\nGGAGACTACAGTGATGAGACACACGCCAACTGCACCAACCAGGCCACGAGGCCCCCTGGT\nGGCTGCCACACTGATGAGTTCCAGTGCCGGCTGGATGGACTATGCATCCCCCTGCGGTGG\nCGCTGCGATGGGGACACTGACTGCATGGACTCCAGCGATGAGAAGAGCTGTGAGGGAGTG\nACCCACGTCTGCGATCCCAGTGTCAAGTTTGGCTGCAAGGACTCAGCTCGGTGCATCAGC\nAAAGCGTGGGTGTGTGATGGCGACAATGACTGTGAGGATAACTCGGACGAGGAGAACTGC\nGAGTCCCTGGCCTGCAGGCCACCCTCGCACCCTTGTGCCAACAACACCTCAGTCTGCCTG\nCCCCCTGACAAGCTGTGTGATGGCAACGACGACTGTGGCGACGGCTCAGATGAGGGCGAG\nCTCTGCGACCAGTGCTCTCTGAATAACGGTGGCTGCAGCCACAACTGCTCAGTGGCACCT\nGGCGAAGGCATTGTGTGTTCCTGCCCTCTGGGCATGGAGCTGGGGCCCGACAACCACACC\nTGCCAGATCCAGAGCTACTGTGCCAAGCATCTCAAATGCAGCCAAAAGTGCGACCAGAAC\nAAGTTCAGCGTGAAGTGCTCCTGCTACGAGGGCTGGGTCCTGGAACCTGACGGCGAGAGC\nTGCCGCAGCCTGGACCCCTTCAAGCCGTTCATCATTTTCTCCAACCGCCATGAAATCCGG\nCGCATCGATCTTCACAAAGGAGACTACAGCGTCCTGGTGCCCGGCCTGCGCAACACCATC\nGCCCTGGACTTCCACCTCAGCCAGAGCGCCCTCTACTGGACCGACGTGGTGGAGGACAAG\nATCTACCGCGGGAAGCTGCTGGACAACGGAGCCCTGACTAGTTTCGAGGTGGTGATTCAG\nTATGGCCTGGCCACACCCGAGGGCCTGGCTGTAGACTGGATTGCAGGCAACATCTACTGG\nGTGGAGAGTAACCTGGATCAGATCGAGGTGGCCAAGCTGGATGGGACCCTCCGGACCACC\nCTGCTGGCCGGTGACATTGAGCACCCAAGGGCAATCGCACTGGATCCCCGGGATGGGATC\nCTGTTTTGGACAGACTGGGATGCCAGCCTGCCCCGCATTGAGGCAGCCTCCATGAGTGGG\nGCTGGGCGCCGCACCGTGCACCGGGAGACCGGCTCTGGGGGCTGGCCCAACGGGCTCACC\nGTGGACTACCTGGAGAAGCGCATCCTTTGGATTGACGCCAGGTCAGATGCCATTTACTCA\nGCCCGTTACGACGGCTCTGGCCACATGGAGGTGCTTCGGGGACACGAGTTCCTGTCGCAC\nCCGTTTGCAGTGACGCTGTACGGGGGGGAGGTCTACTGGACTGACTGGCGAACAAACACA\nCTGGCTAAGGCCAACAAGTGGACCGGCCACAATGTCACCGTGGTACAGAGGACCAACACC\nCAGCCCTTTGACCTGCAGGTGTACCACCCCTCCCGCCAGCCCATGGCTCCCAATCCCTGT\nGAGGCCAATGGGGGCCAGGGCCCCTGCTCCCACCTGTGTCTCATCAACTACAACCGGACC\nGTGTCCTGCGCCTGCCCCCACCTCATGAAGCTCCACAAGGACAACACCACCTGCTATGAG\nTTTAAGAAGTTCCTGCTGTACGCACGTCAGATGGAGATCCGAGGTGTGGACCTGGATGCT\nCCCTACTACAACTACATCATCTCCTTCACGGTGCCCGACATCGACAACGTCACAGTGCTA\nGACTACGATGCCCGCGAGCAGCGTGTGTACTGGTCTGACGTGCGGACACAGGCCATCAAG\nCGGGCCTTCATCAACGGCACAGGCGTGGAGACAGTCGTCTCTGCAGACTTGCCAAATGCC\nCACGGGCTGGCTGTGGACTGGGTCTCCCGAAACCTGTTCTGGACAAGCTATGACACCAAT\nAAGAAGCAGATCAATGTGGCCCGGCTGGATGGCTCCTTCAAGAACGCAGTGGTGCAGGGC\nCTGGAGCAGCCCCATGGCCTTGTCGTCCACCCTCTGCGTGGGAAGCTCTACTGGACCGAT\nGGTGACAACATCAGCATGGCCAACATGGATGGCAGCAATCGCACCCTGCTCTTCAGTGGC\nCAGAAGGGCCCCGTGGGCCTGGCTATTGACTTCCCTGAAAGCAAACTCTACTGGATCAGC\nTCCGGGAACCATACCATCAACCGCTGCAACCTGGATGGGAGTGGGCTGGAGGTCATCGAT\nGCCATGCGGAGCCAGCTGGGCAAGGCCACCGCCCTGGCCATCATGGGGGACAAGCTGTGG\nTGGGCTGATCAGGTGTCGGAAAAGATGGGCACATGCAGCAAGGCTGACGGCTCGGGCTCC\nGTGGTCCTTCGGAACAGCACCACCCTGGTGATGCACATGAAGGTCTATGACGAGAGCATC\nCAGCTGGACCATAAGGGCACCAACCCCTGCAGTGTCAACAACGGTGACTGCTCCCAGCTC\nTGCCTGCCCACGTCAGAGACGACCCGCTCCTGCATGTGCACAGCCGGCTATAGCCTCCGG\nAGTGGCCAGCAGGCCTGCGAGGGCGTAGGTTCCTTTCTCCTGTACTCTGTGCATGAGGGA\nATCAGGGGAATTCCCCTGGATCCCAATGACAAGTCAGATGCCCTGGTCCCAGTGTCCGGG\nACCTCGCTGGCTGTCGGCATCGACTTCCACGCTGAAAATGACACCATCTACTGGGTGGAC\nATGGGCCTGAGCACGATCAGCCGGGCCAAGCGGGACCAGACGTGGCGTGAAGACGTGGTG\nACCAATGGCATTGGCCGTGTGGAGGGCATTGCAGTGGACTGGATCGCAGGCAACATCTAC\nTGGACAGACCAGGGCTTTGATGTCATCGAGGTCGCCCGGCTCAATGGCTCCTTCCGCTAC\nGTGGTGATCTCCCAGGGTCTAGACAAGCCCCGGGCCATCACCGTCCACCCGGAGAAAGGG\nTACTTGTTCTGGACTGAGTGGGGTCAGTATCCGCGTATTGAGCGGTCTCGGCTAGATGGC\nACGGAGCGTGTGGTGCTGGTCAACGTCAGCATCAGCTGGCCCAACGGCATCTCAGTGGAC\nTACCAGGATGGGAAGCTGTACTGGTGCGATGCACGGACAGACAAGATTGAACGGATCGAC\nCTGGAGACAGGTGAGAACCGCGAGGTGGTTCTGTCCAGCAACAACATGGACATGTTTTCA\nGTGTCTGTGTTTGAGGATTTCATCTACTGGAGTGACAGGACTCATGCCAACGGCTCTATC\nAAGCGCGGGAGCAAAGACAATGCCACAGACTCCGTGCCCCTGCGAACCGGCATCGGCGTC\nCAGCTTAAAGACATCAAAGTCTTCAACCGGGACCGGCAGAAAGGCACCAACGTGTGCGCG\nGTGGCCAATGGCGGGTGCCAGCAGCTGTGCCTGTACCGGGGCCGTGGGCAGCGGGCCTGC\nGCCTGTGCCCACGGGATGCTGGCTGAAGACGGAGCATCGTGCCGCGAGTATGCCGGCTAC\nCTGCTCTACTCAGAGCGCACCATTCTCAAGAGTATCCACCTGTCGGATGAGCGCAACCTC\nAATGCGCCCGTGCAGCCCTTCGAGGACCCTGAGCACATGAAGAACGTCATCGCCCTGGCC\nTTTGACTACCGGGCAGGCACCTCTCCGGGCACCCCCAATCGCATCTTCTTCAGCGACATC\nCACTTTGGGAACATCCAACAGATCAACGACGATGGCTCCAGGAGGATCACCATTGTGGAA\nAACGTGGGCTCCGTGGAAGGCCTGGCCTATCACCGTGGCTGGGACACTCTCTATTGGACA\nAGCTACACGACATCCACCATCACGCGCCACACAGTGGACCAGACCCGCCCAGGGGCCTTC\nGAGCGTGAGACCGTCATCACTATGTCTGGAGATGACCACCCACGGGCCTTCGTTTTGGAC\nGAGTGCCAGAACCTCATGTTCTGGACCAACTGGAATGAGCAGCATCCCAGCATCATGCGG\nGCGGCGCTCTCGGGAGCCAATGTCCTGACCCTTATCGAGAAGGACATCCGTACCCCCAAT\nGGCCTGGCCATCGACCACCGTGCCGAGAAGCTCTACTTCTCTGACGCCACCCTGGACAAG\nATCGAGCGGTGCGAGTATGACGGCTCCCACCGCTATGTGATCCTAAAGTCAGAGCCTGTC\nCACCCCTTCGGGCTGGCCGTGTATGGGGAGCACATTTTCTGGACTGACTGGGTGCGGCGG\nGCAGTGCAGCGGGCCAACAAGCACGTGGGCAGCAACATGAAGCTGCTGCGCGTGGACATC\nCCCCAGCAGCCCATGGGCATCATCGCCGTGGCCAACGACACCAACAGCTGTGAACTCTCT\nCCATGCCGAATCAACAACGGTGGCTGCCAGGACCTGTGTCTGCTCACTCACCAGGGCCAT\nGTCAACTGCTCATGCCGAGGGGGCCGAATCCTCCAGGATGACCTCACCTGCCGAGCGGTG\nAATTCCTCTTGCCGAGCACAAGATGAGTTTGAGTGTGCCAATGGCGAGTGCATCAACTTC\nAGCCTGACCTGCGACGGCGTCCCCCACTGCAAGGACAAGTCCGATGAGAAGCCATCCTAC\nTGCAACTCCCGCCGCTGCAAGAAGACTTTCCGGCAGTGCAGCAATGGGCGCTGTGTGTCC\nAACATGCTGTGGTGCAACGGGGCCGACGACTGTGGGGATGGCTCTGACGAGATCCCTTGC\nAACAAGACAGCCTGTGGTGTGGGCGAGTTCCGCTGCCGGGACGGGACCTGCATCGGGAAC\nTCCAGCCGCTGCAACCAGTTTGTGGATTGTGAGGACGCCTCAGATGAGATGAACTGCAGT\nGCCACCGACTGCAGCAGCTACTTCCGCCTGGGCGTGAAGGGCGTGCTCTTCCAGCCCTGC\nGAGCGGACCTCACTCTGCTACGCACCCAGCTGGGTGTGTGATGGCGCCAATGACTGTGGG\nGACTACAGTGATGAGCGCGACTGCCCAGGTGTGAAACGCCCCAGATGCCCTCTGAATTAC\nTTCGCCTGCCCTAGTGGGCGCTGCATCCCCATGAGCTGGACGTGTGACAAAGAGGATGAC\nTGTGAACATGGCGAGGACGAGACCCACTGCAACAAGTTCTGCTCAGAGGCCCAGTTTGAG\nTGCCAGAACCATCGCTGCATCTCCAAGCAGTGGCTGTGTGACGGCAGCGATGACTGTGGG\nGATGGCTCAGACGAGGCTGCTCACTGTGAAGGCAAGACGTGCGGCCCCTCCTCCTTCTCC\nTGCCCTGGCACCCACGTGTGCGTCCCCGAGCGCTGGCTCTGTGACGGTGACAAAGACTGT\nGCTGATGGTGCAGACGAGAGCATCGCAGCTGGTTGCTTGTACAACAGCACTTGTGACGAC\nCGTGAGTTCATGTGCCAGAACCGCCAGTGCATCCCCAAGCACTTCGTGTGTGACCACGAC\nCGTGACTGTGCAGATGGCTCTGATGAGTCCCCCGAGTGTGAGTACCCGACCTGCGGCCCC\nAGTGAGTTCCGCTGTGCCAATGGGCGCTGTCTGAGCTCCCGCCAGTGGGAGTGTGATGGC\nGAGAATGACTGCCACGACCAGAGTGACGAGGCTCCCAAGAACCCACACTGCACCAGCCCA\nGAGCACAAGTGCAATGCCTCGTCACAGTTCCTGTGCAGCAGTGGGCGCTGTGTGGCTGAG\nGCACTGCTCTGCAACGGCCAGGATGACTGTGGCGACAGCTCGGACGAGCGTGGCTGCCAC\nATCAATGAGTGTCTCAGCCGCAAGCTCAGTGGCTGCAGCCAGGACTGTGAGGACCTCAAG\nATCGGCTTCAAGTGCCGCTGTCGCCCTGGCTTCCGGCTGAAGGATGACGGCCGGACGTGT\nGCTGATGTGGACGAGTGCAGCACCACCTTCCCCTGCAGCCAGCGCTGCATCAACACCCAT\nGGCAGCTATAAGTGTCTGTGTGTGGAGGGCTATGCACCCCGCGGCGGCGACCCCCACAGC\nTGCAAGGCTGTGACTGACGAGGAACCGTTTCTGATCTTCGCCAACCGGTACTACCTGCGC\nAAGCTCAACCTGGACGGGTCCAACTACACGTTACTTAAGCAGGGCCTGAACAACGCCGTT\nGCCTTGGATTTTGACTACCGAGAGCAGATGATCTACTGGACAGATGTGACCACCCAGGGC\nAGCATGATCCGAAGGATGCACCTTAACGGGAGCAATGTGCAGGTCCTACACCGTACAGGC\nCTCAGCAACCCCGATGGGCTGGCTGTGGACTGGGTGGGTGGCAACCTGTACTGGTGCGAC\nAAAGGCCGGGACACCATCGAGGTGTCCAAGCTCAATGGGGCCTATCGGACGGTGCTGGTC\nAGCTCTGGCCTCCGTGAGCCCAGGGCTCTGGTGGTGGATGTGCAGAATGGGTACCTGTAC\nTGGACAGACTGGGGTGACCATTCACTGATCGGCCGCATCGGCATGGATGGGTCCAGCCGC\nAGCGTCATCGTGGACACCAAGATCACATGGCCCAATGGCCTGACGCTGGACTATGTCACT\nGAGCGCATCTACTGGGCCGACGCCCGCGAGGACTACATTGAATTTGCCAGCCTGGATGGC\nTCCAATCGCCACGTTGTGCTGAGCCAGGACATCCCGCACATCTTTGCACTGACCCTGTTT\nGAGGACTACGTCTACTGGACCGACTGGGAAACAAAGTCCATTAACCGAGCCCACAAGACC\nACGGGCACCAACAAAACGCTCCTCATCAGCACGCTGCACCGGCCCATGGACCTGCATGTC\nTTCCATGCCCTGCGCCAGCCAGACGTGCCCAATCACCCCTGCAAGGTCAACAATGGTGGC\nTGCAGCAACCTGTGCCTGCTGTCCCCCGGGGGAGGGCACAAATGTGCCTGCCCCACCAAC\nTTCTACCTGGGCAGCGATGGGCGCACCTGTGTGTCCAACTGCACGGCTAGCCAGTTTGTA\nTGCAAGAACGACAAGTGCATCCCCTTCTGGTGGAAGTGTGACACCGAGGACGACTGCGGG\nGACCACTCAGACGAGCCCCCGGACTGCCCTGAGTTCAAGTGCCGGCCCGGACAGTTCCAG\nTGCTCCACAGGTATCTGCACAAACCCTGCCTTCATCTGCGATGGCGACAATGACTGCCAG\nGACAACAGTGACGAGGCCAACTGTGACATCCACGTCTGCTTGCCCAGTCAGTTCAAATGC\nACCAACACCAACCGCTGTATTCCCGGCATCTTCCGCTGCAATGGGCAGGACAACTGCGGA\nGATGGGGAGGATGAGAGGGACTGCCCCGAGGTGACCTGCGCCCCCAACCAGTTCCAGTGC\nTCCATTACCAAACGGTGCATCCCCCGGGTCTGGGTCTGCGACCGGGACAATGACTGTGTG\nGATGGCAGTGATGAGCCCGCCAACTGCACCCAGATGACCTGTGGTGTGGACGAGTTCCGC\nTGCAAGGATTCGGGCCGCTGCATCCCAGCGCGTTGGAAGTGTGACGGAGAGGATGACTGT\nGGGGATGGCTCGGATGAGCCCAAGGAAGAGTGTGATGAACGCACCTGTGAGCCATACCAG\nTTCCGCTGCAAGAACAACCGCTGCGTGCCCGGCCGCTGGCAGTGCGACTACGACAACGAT\nTGCGGTGACAACTCCGATGAAGAGAGCTGCACCCCTCGGCCCTGCTCCGAGAGTGAGTTC\nTCCTGTGCCAACGGCCGCTGCATCGCGGGGCGCTGGAAATGCGATGGAGACCACGACTGC\nGCGGACGGCTCGGACGAGAAAGACTGCACCCCCCGCTGTGACATGGACCAGTTCCAGTGC\nAAGAGCGGCCACTGCATCCCCCTGCGCTGGCGCTGTGACGCAGACGCCGACTGCATGGAC\nGGCAGCGACGAGGAGGCCTGCGGCACTGGCGTGCGGACCTGCCCCCTGGACGAGTTCCAG\nTGCAACAACACCTTGTGCAAGCCGCTGGCCTGGAAGTGCGATGGCGAGGATGACTGTGGG\nGACAACTCAGATGAGAACCCCGAGGAGTGTGCCCGGTTCGTGTGCCCTCCCAACCGGCCC\nTTCCGTTGCAAGAATGACCGCGTCTGTCTGTGGATCGGGCGCCAATGCGATGGCACGGAC\nAACTGTGGGGATGGGACTGATGAAGAGGACTGTGAGCCCCCCACAGCCCACACCACCCAC\nTGCAAAGACAAGAAGGAGTTTCTGTGCCGGAACCAGCGCTGCCTCTCCTCCTCCCTGCGC\nTGCAACATGTTCGATGACTGCGGGGACGGCTCTGACGAGGAGGACTGCAGCATCGACCCC\nAAGCTGACCAGCTGCGCCACCAATGCCAGCATCTGTGGGGACGAGGCACGCTGCGTGCGC\nACCGAGAAAGCGGCCTACTGTGCCTGCCGCTCGGGCTTCCACACCGTGCCCGGCCAGCCC\nGGATGCCAAGACATCAACGAGTGCCTGCGCTTCGGCACCTGCTCCCAGCTCTGCAACAAC\nACCAAGGGCGGCCACCTCTGCAGCTGCGCTCGGAACTTCATGAAGACGCACAACACCTGC\nAAGGCCGAAGGCTCTGAGTACCAGGTCCTGTACATCGCTGATGACAATGAGATCCGCAGC\nCTGTTCCCCGGCCACCCCCATTCGGCTTACGAGCAGGCATTCCAGGGTGACGAGAGTGTC\nCGCATTGATGCTATGGATGTCCATGTCAAGGCTGGCCGTGTCTATTGGACCAACTGGCAC\nACGGGCACCATCTCCTACCGCAGCCTGCCACCTGCTGCGCCTCCTACCACTTCCAACCGC\nCACCGGCGACAGATTGACCGGGGTGTCACCCACCTCAACATTTCAGGGCTGAAGATGCCC\nAGAGGCATCGCCATCGACTGGGTGGCCGGAAACGTGTACTGGACCGACTCGGGCCGAGAT\nGTGATTGAGGTGGCGCAGATGAAGGGCGAGAACCGCAAGACGCTCATCTCGGGCATGATT\nGACGAGCCCCACGCCATTGTGGTGGACCCACTGAGGGGGACCATGTACTGGTCAGACTGG\nGGCAACCACCCCAAGATTGAGACGGCAGCGATGGATGGGACGCTTCGGGAGACACTGGTG\nCAGGACAACATTCAGTGGCCCACAGGCCTGGCCGTGGATTATCACAATGAGCGGCTGTAC\nTGGGCAGACGCCAAGCTTTCAGTCATCGGCAGCATCCGGCTCAATGGCACGGACCCCATT\nGTGGCTGCTGACAGCAAACGAGGCCTAAGTCACCCCTTCAGCATCGACGTCTTTGAGGAT\nTACATCTATGGTGTCACCTACATCAATAATCGTGTCTTCAAGATCCATAAGTTTGGCCAC\nAGCCCCTTGGTCAACCTGACAGGGGGCCTGAGCCACGCCTCTGACGTGGTCCTTTACCAT\nCAGCACAAGCAGCCCGAAGTGACCAACCCATGTGACCGCAAGAAATGCGAGTGGCTCTGC\nCTGCTGAGCCCCAGTGGGCCTGTCTGCACCTGTCCCAATGGGAAGCGGCTGGACAACGGC\nACATGCGTGCCTGTGCCCTCTCCAACGCCCCCCCCAGATGCTCCCCGGCCTGGAACCTGT\nAACCTGCAGTGCTTCAACGGTGGCAGCTGTTTCCTCAATGCACGGAGGCAGCCCAAGTGC\nCGCTGCCAACCCCGCTACACGGGTGACAAGTGTGAACTGGACCAGTGCTGGGAGCACTGT\nCGCAATGGGGGCACCTGTGCTGCCTCCCCCTCTGGCATGCCCACGTGCCGGTGCCCCACG\nGGCTTCACGGGCCCCAAATGCACCCAGCAGGTGTGTGCGGGCTACTGTGCCAACAACAGC\nACCTGCACTGTCAACCAGGGCAACCAGCCCCAGTGCCGATGCCTACCCGGCTTCCTGGGC\nGACCGCTGCCAGTACCGGCAGTGCTCTGGCTACTGTGAGAACTTTGGCACATGCCAGATG\nGCTGCTGATGGCTCCCGACAATGCCGCTGCACTGCCTACTTTGAGGGATCGAGGTGTGAG\nGTGAACAAGTGCAGCCGCTGTCTCGAAGGGGCCTGTGTGGTCAACAAGCAGAGTGGGGAT\nGTCACCTGCAACTGCACGGATGGCCGGGTGGCCCCCAGCTGTCTGACCTGCGTCGGCCAC\nTGCAGCAATGGCGGCTCCTGTACCATGAACAGCAAAATGATGCCTGAGTGCCAGTGCCCA\nCCCCACATGACAGGGCCCCGGTGTGAGGAGCACGTCTTCAGCCAGCAGCAGCCAGGACAT\nATAGCCTCCATCCTAATCCCTCTGCTGTTGCTGCTGCTGCTGGTTCTGGTGGCCGGAGTG\nGTATTCTGGTATAAGCGGCGAGTCCAAGGGGCTAAGGGCTTCCAGCACCAACGGATGACC\nAACGGGGCCATGAACGTGGAGATTGGAAACCCCACCTACAAGATGTACGAAGGCGGAGAG\nCCTGATGATGTGGGAGGCCTACTGGACGCTGACTTTGCCCTGGACCCTGACAAGCCCACC\nAACTTCACCAACCCCGTGTATGCCACACTCTACATGGGGGGCCATGGCAGTCGCCACTCC\nCTGGCCAGCACGGACGAGAAGCGAGAACTCCTGGGCCGGGGCCCTGAGGACGAGATAGGG\nGACCCCTTGGCATAG"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF07645", "name": "EGF_CA"}, {"identifier": "PF00057", "name": "Ldl_recept_a"}, {"identifier": "PF00058", "name": "Ldl_recept_b"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}]}}}, {"@position": "11", "id": "BE0002120", "name": "Multiple coagulation factor deficiency protein 2", "organism": "Human", "actions": {"action": "modulator"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# :   \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15886209", "known-action": "unknown", "polypeptide": {"@id": "Q8NI22", "@source": "Swiss-Prot", "name": "Multiple coagulation factor deficiency protein 2", "general-function": null, "specific-function": "The MCFD2-LMAN1 complex forms a specific cargo receptor for the ER-to-Golgi transport of selected proteins", "gene-name": "MCFD2", "locus": "2p21", "cellular-location": "Endoplasmic reticulum-Golgi intermediate compartment", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "4.25", "molecular-weight": "16391.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:18451"}, {"resource": "GenAtlas", "identifier": "MCFD2"}, {"resource": "GeneCards", "identifier": "MCFD2"}, {"resource": "GenBank Gene Database", "identifier": "AF475284"}, {"resource": "GenBank Protein Database", "identifier": "20799383"}, {"resource": "UniProtKB", "identifier": "Q8NI22"}, {"resource": "UniProt Accession", "identifier": "MCFD2_HUMAN"}]}, "synonyms": {"synonym": ["Multiple coagulation factor deficiency protein 2 precursor", "Neural stem cell-derived neuronal survival protein"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Multiple coagulation factor deficiency protein 2\nMTMRSLLRTPFLCGLLWAFCAPGARAEEPAASFSQPGSMGLDKNTVHDQEHIMEHLEGVI\nNKPEAEMSPQELQLHYFKMHDYDGNNLLDGLELSTAITHVHKEEGSEQAPLMSEDELINI\nIDGVLRDDDKNNDGYIDYAEFAKSLQ"}, "gene-sequence": {"@format": "FASTA", "#text": ">441 bp\nATGACCATGAGATCCCTGCTCAGAACCCCCTTCCTGTGTGGCCTGCTCTGGGCCTTTTGT\nGCCCCAGGCGCCAGGGCTGAGGAGCCTGCAGCCAGCTTCTCCCAACCCGGCAGCATGGGC\nCTGGATAAGAACACAGTGCACGACCAAGAGCATATCATGGAGCATCTAGAAGGTGTCATC\nAACAAACCAGAGGCGGAGATGTCGCCACAAGAATTGCAGCTCCATTACTTCAAAATGCAT\nGATTATGATGGCAATAATTTGCTTGATGGCTTAGAACTCTCCACAGCCATCACTCATGTC\nCATAAGGAGGAAGGGAGTGAACAGGCACCACTAATGAGTGAAGATGAACTGATTAACATA\nATAGATGGTGTTTTGAGAGATGATGACAAGAACAATGATGGATACATTGACTATGCTGAA\nTTTGCAAAATCACTGCAGTAG"}, "pfams": null, "go-classifiers": {"go-classifier": [{"category": "function", "description": "binding"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}]}}}]}, "enzymes": {"enzyme": [{"@position": "12", "id": "BE0000048", "name": "Prothrombin", "organism": "Human", "actions": {"action": "activator"}, "references": "# Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL: Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood. 2000 Mar 1;95(5):1694-702. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10688826\n# Ratnoff OD, Lewis JH: Heckathorn's disease: variable functional dificiency of antihemophilic factor (factor VIII). Blood. 1975 Aug;46(2):161-73. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1139038\n# Anderson DM, Shelley S, Crick N, Buraglio M: No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers. J Clin Pharmacol. 2002 Dec;42(12):1358-65. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12463731\n# Piet MP, Chin S, Prince AM, Brotman B, Cundell AM, Horowitz B: The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation. Transfusion. 1990 Sep;30(7):591-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2402772\n# Lazarchick J, Ashby MA, Lazarchick JJ, Sens DA: Mechanism of factor VIII inactivation by human antibodies. IV. Antibody binding prevents factor VIII proteolysis by thrombin. Ann Clin Lab Sci. 1986 Nov-Dec;16(6):497-501. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/3099625", "known-action": "unknown", "polypeptide": {"@id": "P00734", "@source": "Swiss-Prot", "name": "Prothrombin", "general-function": "Involved in blood clotting cascade", "specific-function": "Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C", "gene-name": "F2", "locus": "11p11-q12", "cellular-location": "Secreted protein; extracellular space", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.7", "molecular-weight": "70037.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3535"}, {"resource": "GenAtlas", "identifier": "F2"}, {"resource": "GeneCards", "identifier": "F2"}, {"resource": "GenBank Gene Database", "identifier": "M17262"}, {"resource": "GenBank Protein Database", "identifier": "339641"}, {"resource": "UniProtKB", "identifier": "P00734"}, {"resource": "UniProt Accession", "identifier": "THRB_HUMAN"}]}, "synonyms": {"synonym": ["Activated Factor II [IIa]", "Coagulation factor II", "EC 3.4.21.5", "Prothrombin precursor", "Thrombin"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Prothrombin precursor\nMAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC\nVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV\nNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE\nCSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA\nQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG\nDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI\nDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN\nDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP\nVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST\nRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY\nGFYTHVFRLKKWIQKVIDQFGE"}, "gene-sequence": {"@format": "FASTA", "#text": ">1869 bp\nATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC\nCTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG\nGTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTAGAGCGAGAGTGC\nGTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG\nGATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT\nGCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG\nAACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT\nGAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC\nGACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA\nTGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA\nGGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG\nTACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA\nCAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC\nTTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT\nGGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA\nGATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC\nCAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT\nCTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC\nGACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG\nCTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG\nGTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT\nGACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACAAGGTACGAGCGAAACATTGAAAAG\nATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC\nCGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT\nGTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG\nGTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC\nAGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC\nCGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA\nGGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC\nCGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT\nGGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT\nGGAGAGTAG"}, "pfams": {"pfam": [{"identifier": "PF00594", "name": "Gla"}, {"identifier": "PF00051", "name": "Kringle"}, {"identifier": "PF00089", "name": "Trypsin"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "thrombin activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "binding"}, {"category": "process", "description": "hemostasis"}, {"category": "process", "description": "blood coagulation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "physiological process"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}, {"@position": "13", "id": "BE0000380", "name": "Vitamin K-dependent protein C", "organism": "Human", "actions": {"action": "inactivator"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Bereczky Z, Kovacs KB, Muszbek L: Protein C and protein S deficiencies: similarities and differences between two brothers playing in the same game. Clin Chem Lab Med. 2010 Dec;48 Suppl 1:S53-66. Epub 2010 Nov 5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/21054189", "known-action": "unknown", "polypeptide": {"@id": "P04070", "@source": "Swiss-Prot", "name": "Vitamin K-dependent protein C", "general-function": "Involved in calcium ion binding", "specific-function": "Protein C is a vitamin K-dependent serine protease that regulates blood coagulation by inactivating factors Va and VIIIa in the presence of calcium ions and phospholipids", "gene-name": "PROC", "locus": "2q13-q14", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.23", "molecular-weight": "52072.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9451"}, {"resource": "GenAtlas", "identifier": "PROC"}, {"resource": "GeneCards", "identifier": "PROC"}, {"resource": "GenBank Gene Database", "identifier": "M11228"}, {"resource": "GenBank Protein Database", "identifier": "190334"}, {"resource": "UniProtKB", "identifier": "P04070"}, {"resource": "UniProt Accession", "identifier": "PROC_HUMAN"}]}, "synonyms": {"synonym": ["Anticoagulant protein C", "Autoprothrombin IIA", "Blood coagulation factor XIV", "EC 3.4.21.69", "Vitamin K-dependent protein C precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Vitamin K-dependent protein C precursor\nMWQLTSLLLFVATWGISGTPAPLDSVFSSSERAHQVLRIRKRANSFLEELRHSSLERECI\nEEICDFEEAKEIFQNVDDTLAFWSKHVDGDQCLVLPLEHPCASLCCGHGTCIDGIGSFSC\nDCRSGWEGRFCQREVSFLNCSLDNGGCTHYCLEEVGWRRCSCAPGYKLGDDLLQCHPAVK\nFPCGRPWKRMEKKRSHLKRDTEDQEDQVDPRLIDGKMTRRGDSPWQVVLLDSKKKLACGA\nVLIHPSWVLTAAHCMDESKKLLVRLGEYDLRRWEKWELDLDIKEVFVHPNYSKSTTDNDI\nALLHLAQPATLSQTIVPICLPDSGLAERELNQAGQETLVTGWGYHSSREKEAKRNRTFVL\nNFIKIPVVPHNECSEVMSNMVSENMLCAGILGDRQDACEGDSGGPMVASFHGTWFLVGLV\nSWGEGCGLLHNYGVYTKVSRYLDWIHGHIRDKEAPQKSWAP"}, "gene-sequence": {"@format": "FASTA", "#text": ">1386 bp\nATGTGGCAGCTCACAAGCCTCCTGCTGTTCGTGGCCACCTGGGGAATTTCCGGCACACCA\nGCTCCTCTTGACTCAGTGTTCTCCAGCAGCGAGCGTGCCCACCAGGTGCTGCGGATCCGC\nAAACGTGCCAACTCCTTCCTGGAGGAGCTCCGTCACAGCAGCCTGGAGCGGGAGTGCATA\nGAGGAGATCTGTGACTTCGAGGAGGCCAAGGAAATTTTCCAAAATGTGGATGACACACTG\nGCCTTCTGGTCCAAGCACGTCGACGGTGACCAGTGCTTGGTCTTGCCCTTGGAGCACCCG\nTGCGCCAGCCTGTGCTGCGGGCACGGCACGTGCATCGACGGCATCGGCAGCTTCAGCTGC\nGACTGCCGCAGCGGCTGGGAGGGCCGCTTCTGCCAGCGCGAGGTGAGCTTCCTCAATTGC\nTCTCTGGACAACGGCGGCTGCACGCATTACTGCCTAGAGGAGGTGGGCTGGCGGCGCTGT\nAGCTGTGCGCCTGGCTACAAGCTGGGGGACGACCTCCTGCAGTGTCACCCCGCAGTGAAG\nTTCCCTTGTGGGAGGCCCTGGAAGCGGATGGAGAAGAAGCGCAGTCACCTGAAACGAGAC\nACAGAAGACCAAGAAGACCAAGTAGATCCGCGGCTCATTGATGGGAAGATGACCAGGCGG\nGGAGACAGCCCCTGGCAGGTGGTCCTGCTGGACTCAAAGAAGAAGCTGGCCTGCGGGGCA\nGTGCTCATCCACCCCTCCTGGGTGCTGACAGCGGCCCACTGCATGGATGAGTCCAAGAAG\nCTCCTTGTCAGGCTTGGAGAGTATGACCTGCGGCGCTGGGAGAAGTGGGAGCTGGACCTG\nGACATCAAGGAGGTCTTCGTCCACCCCAACTACAGCAAGAGCACCACCGACAATGACATC\nGCACTGCTGCACCTGGCCCAGCCCGCCACCCTCTCGCAGACCATAGTGCCCATCTGCCTC\nCCGGACAGCGGCCTTGCAGAGCGCGAGCTCAATCAGGCCGGCCAGGAGACCCTCGTGACG\nGGCTGGGGCTACCACAGCAGCCGAGAGAAGGAGGCCAAGAGAAACCGCACCTTCGTCCTC\nAACTTCATCAAGATTCCCGTGGTCCCGCACAATGAGTGCAGCGAGGTCATGAGCAACATG\nGTGTCTGAGAACATGCTGTGTGCGGGCATCCTCGGGGACCGGCAGGATGCCTGCGAGGGC\nGACAGTGGGGGGCCCATGGTCGCCTCCTTCCACGGCACCTGGTTCCTGGTGGGCCTGGTG\nAGCTGGGGTGAGGGCTGTGGGCTCCTTCACAACTACGGCGTTTACACCAAAGTCAGCCGC\nTACCTCGACTGGATCCATGGGCACATCAGAGACAAGGAAGCCCCCCAGAAGAGCTGGGCA\nCCTTAG"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF00594", "name": "Gla"}, {"identifier": "PF00089", "name": "Trypsin"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "hemostasis"}, {"category": "process", "description": "blood coagulation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}]}, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-06-19", "drugbank-id": [{"@primary": "true", "#text": "DB00026"}, "BIOD00060", "BTD00060"], "name": "Anakinra", "description": "Anakinra is a recombinant, nonglycosylated human interleukin-1 receptor antagonist (IL-1Ra). The difference  between anakinra and the native human IL-1Ra is that anakinra has an extra methionine residue at the amino terminus. It is manufactured by using the E. coli expression system. Anakinra is composed of 153 amino acid residues. FDA approved on November 14, 2001.", "cas-number": "143090-92-0", "groups": {"group": "approved"}, "general-references": "# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352\n# Lequerr\u00e9 T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, Kone-Paut I, Michel M, Dernis E, Khellaf M, Limal N, Job-Deslandre C, Fautrel B, Le Lo\u00ebt X, Sibilia J; Soci\u00e9t\u00e9 Francophone pour la Rhumatologie et les Maladies Inflammatoires en P\u00e9diatrie (SOFREMIP); Club Rhumatismes et Inflammation (CRI): Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008 Mar;67(3):281-2.\n\"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17947302\n# FDA label", "synthesis-reference": null, "indication": "For the treatment of adult rheumatoid arthritis and treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID).", "pharmacodynamics": "Used to treat rheumatoid arthritis, Anakinra blocks the biologic activity of IL-1 by competitively inhibiting IL-1 binding to the interleukin-1 type I receptor (IL-1RI), which is expressed in a wide variety of tissues and organs. IL-1 production is induced in response to inflammatory stimuli and mediates various physiologic responses including inflammatory and immunological responses. Patients with rheumatoid arthritis have elevated levels of IL-1. The levels of the naturally occurring IL-1Ra in synovium and synovial fluid from rheumatoid arthritis (RA) patients are not sufficient to compete with the elevated amount of locally produced IL-1. Increasing the levels of IL-1Ra by artificial means reduces the negative effects (cartilage degradation, bone resorption) of IL-1.", "mechanism-of-action": "Anakinra binds competitively to the Interleukin-1 type I receptor (IL-1RI), thereby inhibiting the action of elevated levels IL-1 which normally can lead to cartilage degradation and bone resorption.", "toxicity": "Most common adverse reactions (incidence \u2265 5%) are injection site reaction, worsening of rheumatoid arthritis, upper respiratory tract infection, headache, nausea, diarrhea, sinusitis, arthralgia, flu like-symptoms, and abdominal pain when anakinra is used in RA patients. In NOMID patients, the most common AEs during the first 6 months of treatment (incidence >10%) are injection site reaction, headache, vomiting, arthralgia, pyrexia, and nasopharyngitis.", "metabolism": null, "absorption": "When a 70 mg subcutaneous bolus injection is given to healthy subjects, the absolute bioavailability is 95%. Accumulation does not occur following daily subcutaneous doses. \nTmax, SubQ, 1-2 mg/kg, healthy subjects = 3-7 hours;\nCmax, SubQ, 3 mg/kg once daily, NOMID patients = 3628 ng/mL.", "half-life": "Healthy subjects = 4 - 6 hours;\nNOMID patients = 5.7 hours (range of 3.1 - 28.2 hours).", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": "Clearance is variable and increases with increasing creatinine clearance and body weight. However, gender and age were not significant factors.", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "ICIL-1RA"}, {"@language": "", "@coder": "", "#text": "IL-1ra"}, {"@language": "", "@coder": "", "#text": "IL-1RN"}, {"@language": "", "@coder": "", "#text": "IL1 inhibitor"}, {"@language": "", "@coder": "", "#text": "Interleukin-1 receptor antagonist protein precursor"}, {"@language": "", "@coder": "", "#text": "IRAP"}]}, "products": {"product": [{"name": "Kineret", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02245913", "started-marketing-on": "2002-05-29", "ended-marketing-on": null, "dosage-form": "solution", "strength": "150 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kineret", "ndc-id": "66658-234_5888e955-91e4-4c46-95bb-46e7ba8d0aa1", "ndc-product-code": "66658-234", "dpd-id": null, "started-marketing-on": "2009-12-15", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 mg/.67mL", "route": "subcutaneous", "fda-application-number": "BLA103950", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Kineret", "ingredients": "Anakinra"}, {"name": "Kineret", "ingredients": "Anakinra"}]}, "packagers": {"packager": [{"name": "Amgen Inc.", "url": "http://www.amgen.com"}, {"name": "BioVitrum AB", "url": "http://www.biovitrum.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Kineret 100 mg/0.67 ml syr", "cost": {"@currency": "USD", "#text": "61.8"}, "unit": "syringe"}, {"description": "Kineret 1 Box = 7 Syringes, 4.69ml Box", "cost": {"@currency": "USD", "#text": "449.9"}, "unit": "box"}]}, "categories": {"category": [{"category": "Antirheumatic Agents", "mesh-id": null}, {"category": "Immunosuppressive Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, solution", "route": "subcutaneous", "strength": "100 mg/.67mL"}, {"form": "Solution", "route": "subcutaneous", "strength": "150 mg"}]}, "atc-codes": {"atc-code": {"@code": "L04AC03", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L04", "#text": "IMMUNOSUPPRESSANTS"}, {"@code": "L04A", "#text": "IMMUNOSUPPRESSANTS"}, {"@code": "L04AC", "#text": "Interleukin inhibitors"}]}}, "ahfs-codes": {"ahfs-code": "92:00.00"}, "patents": {"patent": [{"number": "1341322", "country": "Canada", "approved": "2001-11-27", "expires": "2018-11-27"}, {"number": "2141953", "country": "Canada", "approved": "2008-04-08", "expires": "2013-09-17"}]}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB01281", "name": "Abatacept", "description": "Anakinra may enhance the adverse/toxic effect of Abatacept."}, {"drugbank-id": "DB00051", "name": "Adalimumab", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported."}, {"drugbank-id": "DB06168", "name": "Canakinumab", "description": "Interleukin-1 Receptor Antagonist may enhance the adverse/toxic effect of Canakinumab. Whether such a combination will also alter the therapeutic response to one or both agents is unclear."}, {"drugbank-id": "DB08904", "name": "Certolizumab pegol", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported."}, {"drugbank-id": "DB06643", "name": "Denosumab", "description": "May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased."}, {"drugbank-id": "DB00005", "name": "Etanercept", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported."}, {"drugbank-id": "DB06674", "name": "golimumab", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported."}, {"drugbank-id": "DB00065", "name": "Infliximab", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported."}, {"drugbank-id": "DB01097", "name": "Leflunomide", "description": "Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased."}, {"drugbank-id": "DB00480", "name": "Lenalidomide", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported."}, {"drugbank-id": "DB00108", "name": "Natalizumab", "description": "Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased."}, {"drugbank-id": "DB00337", "name": "Pimecrolimus", "description": "May enhance the adverse/toxic effect of Immunosuppressants."}, {"drugbank-id": "DB08910", "name": "Pomalidomide", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported."}, {"drugbank-id": "DB01656", "name": "Roflumilast", "description": "May enhance the immunosuppressive effect of Immunosuppressants."}, {"drugbank-id": "DB06688", "name": "Sipuleucel-T", "description": "Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T."}, {"drugbank-id": "DB01041", "name": "Thalidomide", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported."}, {"drugbank-id": "DB08895", "name": "Tofacitinib", "description": "Anakinra may enhance the adverse/toxic effect of Tofacitinib."}, {"drugbank-id": "DB00072", "name": "Trastuzumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00026 sequence\nMRPSGRKSSKMQAFRIWDVNQKTFYLRNNQLVAGYLQGPNVNLEEKIDVVPIEPHALFLG\nIHGGKMCLSCVKSGDETRLQLEAVNITDLSENRKQDKRFAFIRSDSGPTTSFESAACPGW\nFLCTAMEADQPVSLTNMPDEGVMVTKFYFQEDE"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.412", "source": null}, {"kind": "Isoelectric Point", "value": "5.46", "source": null}, {"kind": "Molecular Weight", "value": "17257.6000", "source": null}, {"kind": "Molecular Formula", "value": "C759H1186N208O232S10", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "12604"}, {"resource": "KEGG Drug", "identifier": "D02934"}, {"resource": "National Drug Code Directory", "identifier": "66658-234-28"}, {"resource": "GenBank", "identifier": "M55646"}, {"resource": "PharmGKB", "identifier": "PA10799"}, {"resource": "UniProtKB", "identifier": "P18510"}, {"resource": "Wikipedia", "identifier": "Anakinra"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/anakinra.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/anakinra.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"@position": "1", "id": "BE0000565", "name": "Interleukin-1 receptor type 1", "organism": "Human", "actions": {"action": "antagonist"}, "references": "# Tang YH, Zhang SP, Liang Y, Deng CQ: [Effects of Panax notoginseng saponins on mRNA expressions of interleukin-1 beta, its correlative factors and cysteinyl-aspartate specific protease after cerebral ischemia-reperfusion in rats] Zhong Xi Yi Jie He Xue Bao. 2007 May;5(3):328-32. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17498496\n# Dayer JM: The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford). 2003 May;42 Suppl 2:ii3-10. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12817089\n# Vamvakopoulos J, Green C, Metcalfe S: Genetic control of IL-1beta bioactivity through differential regulation of the IL-1 receptor antagonist. Eur J Immunol. 2002 Oct;32(10):2988-96. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12355453\n# Do H, Vasilescu A, Carpentier W, Meyer L, Diop G, Hirtzig T, Coulonges C, Labib T, Spadoni JL, Therwath A, Lathrop M, Matsuda F, Zagury JF: Exhaustive genotyping of the interleukin-1 family genes and associations with AIDS progression in a French cohort. J Infect Dis. 2006 Dec 1;194(11):1492-504. Epub 2006 Oct 26. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17083033\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352\n# So A, De Smedt T, Revaz S, Tschopp J: A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17352828\n# Vannier E, Kaser A, Atkins MB, Fantuzzi G, Dinarello CA, Mier JW, Tilg H: Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy. Eur Cytokine Netw. 1999 Mar;10(1):37-42. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10210771", "known-action": "yes", "polypeptide": {"@id": "P14778", "@source": "Swiss-Prot", "name": "Interleukin-1 receptor type 1", "general-function": "Involved in transmembrane receptor activity", "specific-function": "Receptor for interleukin-1 alpha (IL-1A), beta (IL-1B), and interleukin-1 receptor antagonist protein (IL-1RA). Binding to the agonist leads to the activation of NF-kappa-B. Signaling involves formation of a ternary complex containing IL1RAP, TOLLIP, MYD88, and IRAK1 or IRAK2", "gene-name": "IL1R1", "locus": "2q12", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "337-356", "signal-regions": null, "theoretical-pi": "7.89", "molecular-weight": "65403.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5993"}, {"resource": "GenAtlas", "identifier": "IL1R1"}, {"resource": "GeneCards", "identifier": "IL1R1"}, {"resource": "GenBank Gene Database", "identifier": "X16896"}, {"resource": "GenBank Protein Database", "identifier": "33801"}, {"resource": "UniProtKB", "identifier": "P14778"}, {"resource": "UniProt Accession", "identifier": "IL1R1_HUMAN"}]}, "synonyms": {"synonym": ["CD121a antigen", "IL-1R- alpha", "IL-1R-1", "IL-1RT1", "Interleukin-1 receptor type I precursor", "p80"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interleukin-1 receptor type I precursor\nMKVLLRLICFIALLISSLEADKCKEREEKIILVSSANEIDVRPCPLNPNEHKGTITWYKD\nDSKTPVSTEQASRIHQHKEKLWFVPAKVEDSGHYYCVVRNSSYCLRIKISAKFVENEPNL\nCYNAQAIFKQKLPVAGDGGLVCPYMEFFKNENNELPKLQWYKDCKPLLLDNIHFSGVKDR\nLIVMNVAEKHRGNYTCHASYTYLGKQYPITRVIEFITLEENKPTRPVIVSPANETMEVDL\nGSQIQLICNVTGQLSDIAYWKWNGSVIDEDDPVLGEDYYSVENPANKRRSTLITVLNISE\nIESRFYKHPFTCFAKNTHGIDAAYIQLIYPVTNFQKHMIGICVTLTVIIVCSVFIYKIFK\nIDIVLWYRDSCYDFLPIKASDGKTYDAYILYPKTVGEGSTSDCDIFVFKVLPEVLEKQCG\nYKLFIYGRDDYVGEDIVEVINENVKKSRRLIIILVRETSGFSWLGGSSEEQIAMYNALVQ\nDGIKVVLLELEKIQDYEKMPESIKFIKQKHGAIRWSGDFTQGPQSAKTRFWKNVRYHMPV\nQRRSPSSKHQLLSPATKEKLQREAHVPLG"}, "gene-sequence": {"@format": "FASTA", "#text": ">1710 bp\nATGAAAGTGTTACTCAGACTTATTTGTTTCATAGCTCTACTGATTTCTTCTCTGGAGGCT\nGATAAATGCAAGGAACGTGAAGAAAAAATAATTTTAGTGTCATCTGCAAATGAAATTGAT\nGTTCGTCCCTGTCCTCTTAACCCAAATGAACACAAAGGCACTATAACTTGGTATAAAGAT\nGACAGCAAGACACCTGTATCTACAGAACAAGCCTCCAGGATTCATCAACACAAAGAGAAA\nCTTTGGTTTGTTCCTGCTAAGGTGGAGGATTCAGGACATTACTATTGCGTGGTAAGAAAT\nTCATCTTACTGCCTCAGAATTAAAATAAGTGCAAAATTTGTGGAGAATGAGCCTAACTTA\nTGTTATAATGCACAAGCCATATTTAAGCAGAAACTACCCGTTGCAGGAGACGGAGGACTT\nGTGTGCCCTTATATGGAGTTTTTTAAAAATGAAAATAATGAGTTACCTAAATTACAGTGG\nTATAAGGATTGCAAACCTCTACTTCTTGACAATATACACTTTAGTGGAGTCAAAGATAGG\nCTCATCGTGATGAATGTGGCTGAAAAGCATAGAGGGAACTATACTTGTCATGCATCCTAC\nACATACTTGGGCAAGCAATATCCTATTACCCGGGTAATAGAATTTATTACTCTAGAGGAA\nAACAAACCCACAAGGCCTGTGATTGTGAGCCCAGCTAATGAGACAATGGAAGTAGACTTG\nGGATCCCAGATACAATTGATCTGTAATGTCACCGGCCAGTTGAGTGACATTGCTTACTGG\nAAGTGGAATGGGTCAGTAATTGATGAAGATGACCCAGTGCTAGGGGAAGACTATTACAGT\nGTGGAAAATCCTGCAAACAAAAGAAGGAGTACCCTCATCACAGTGCTTAATATATCGGAA\nATTGAAAGTAGATTTTATAAACATCCATTTACCTGTTTTGCCAAGAATACACATGGTATA\nGATGCAGCATATATCCAGTTAATATATCCAGTCACTAATTTCCAGAAGCACATGATTGGT\nATATGTGTCACGTTGACAGTCATAATTGTGTGTTCTGTTTTCATCTATAAAATCTTCAAG\nATTGACATTGTGCTTTGGTACAGGGATTCCTGCTATGATTTTCTCCCAATAAAAGCTTCA\nGATGGAAAGACCTATGACGCATATATACTGTATCCAAAGACTGTTGGGGAAGGGTCTACC\nTCTGACTGTGATATTTTTGTGTTTAAAGTCTTGCCTGAGGTCTTGGAAAAACAGTGTGGA\nTATAAGCTGTTCATTTATGGAAGGGATGACTACGTTGGGGAAGACATTGTTGAGGTCATT\nAATGAAAACGTAAAGAAAAGCAGAAGACTGATTATCATTTTAGTCAGAGAAACATCAGGC\nTTCAGCTGGCTGGGTGGTTCATCTGAAGAGCAAATAGCCATGTATAATGCTCTTGTTCAG\nGATGGAATTAAAGTTGTCCTGCTTGAGCTGGAGAAAATCCAAGACTATGAGAAAATGCCA\nGAATCGATTAAATTCATTAAGCAGAAACATGGGGCTATCCGCTGGTCAGGGGACTTTACA\nCAGGGACCACAGTCTGCAAAGACAAGGTTCTGGAAGAATGTCAGGTACCACATGCCAGTC\nCAGCGACGGTCACCTTCATCTAAACACCAGTTACTGTCACCAGCCACTAAGGAGAAACTG\nCAAAGAGAGGCTCACGTGCCTCTCGGGTAG"}, "pfams": {"pfam": [{"identifier": "PF00047", "name": "ig"}, {"identifier": "PF01582", "name": "TIR"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "interleukin-1 receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "hematopoietin/interferon-class (D200-domain) cytokine receptor activity"}, {"category": "function", "description": "interleukin-1, Type I, activating receptor activity"}, {"category": "function", "description": "interleukin receptor activity"}]}}}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-07-31", "drugbank-id": [{"@primary": "true", "#text": "DB00027"}, "BIOD00036", "BTD00036"], "name": "Gramicidin D", "description": "Gramcidin D is a heterogeneous mixture of three antibiotic compounds, gramicidins A, B and C, making up 80%, 6%, and 14% respectively all of which are obtained from the soil bacterial species Bacillus brevis and called collectively gramicidin D.  Gramcidins are 15 residue peptides with alternating D and L amino acids.  The peptides assemble inside of the hydrophobic interior of the cellular lipid bilayer to form a \u03b2-helix. The helix itself is not long enough to span the membrane but it dimerizes to form the elongated channel needed to span the whole membrane. Gramicidin D is used primarily as a topical antibiotic and is one of the three constituents of consumer antibiotic polysporin ophthalmic solution.", "cas-number": "1405-97-6", "groups": {"group": "approved"}, "general-references": "# Ketchem RR, Lee KC, Huo S, Cross TA: Macromolecular structural elucidation with solid-state NMR-derived orientational constraints. J Biomol NMR. 1996 Jul;8(1):1-14. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8810522\n# Townsley LE, Tucker WA, Sham S, Hinton JF: Structures of gramicidins A, B, and C incorporated into sodium dodecyl sulfate micelles. Biochemistry. 2001 Oct 2;40(39):11676-86. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11570868\n# Burkhart BM, Gassman RM, Langs DA, Pangborn WA, Duax WL, Pletnev V: Gramicidin D conformation, dynamics and membrane ion transport. Biopolymers. 1999;51(2):129-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10397797", "synthesis-reference": "U.S.Patent 2,534,541.", "indication": "For treatment of skin lesions, surface wounds and eye infections", "pharmacodynamics": "Gramicidin is particularly effective against gram-positive bacteria. Because the drug is highly hemolytic, it cannot be administered internally and so is used only on the skin as a lotion or ointment. It is used primarily in the treatment of infected surface wounds, and in eye, nose, and throat infections. It is normally given with two other antibiotics (neomycin and polymixin B) as an ophthalmic solution", "mechanism-of-action": "Gramicidin D binds to and inserts itself into bacterial membranes (with a strong preference to gram-positive cell membranes). This results in membrane disruption and permeabilization (it acts as a channel). This leads to (i) loss of intracellular solutes (e.g., K+ and amino acids); (ii) dissipation of the transmembrane potential; (iii) inhibition of respiration; (iv) a reduction in ATP pools; and (v) inhibition of DNA, RNA, and protein synthesis, which leads to cell death.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Gramicidin"}, {"@language": "", "@coder": "", "#text": "Gramicidin A"}, {"@language": "", "@coder": "", "#text": "Gramicidin B"}, {"@language": "", "@coder": "", "#text": "Gramicidin C"}, {"@language": "", "@coder": "", "#text": "Gramicidine"}]}, "products": {"product": [{"name": "Ak Spor Liq", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00635065", "started-marketing-on": "1992-12-31", "ended-marketing-on": null, "dosage-form": "liquid", "strength": "10000 unit", "route": "ophthalmic", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Antibiotic Cream", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02311844", "started-marketing-on": "2009-12-23", "ended-marketing-on": null, "dosage-form": "cream", "strength": "10000 unit", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Antibiotic Cream", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02208288", "started-marketing-on": "1998-11-03", "ended-marketing-on": "2005-08-05", "dosage-form": "cream", "strength": "10000 unit", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Antibiotic Cream", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02372029", "started-marketing-on": "2012-03-22", "ended-marketing-on": null, "dosage-form": "cream", "strength": "10000 unit", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Antibiotic Cream for Kids", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02315033", "started-marketing-on": "2009-07-30", "ended-marketing-on": null, "dosage-form": "cream", "strength": "50 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Antibiotic Cream for Kids", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02317974", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "cream", "strength": "50 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Antibiotic Cream Plus Pain Relief", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02317834", "started-marketing-on": "2009-12-23", "ended-marketing-on": null, "dosage-form": "cream", "strength": "50 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Antibiotic Cream Plus Pain Relief", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02372045", "started-marketing-on": "2012-04-09", "ended-marketing-on": null, "dosage-form": "cream", "strength": "40 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Antibiotic Cream Plus Pain Relief for Kids", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02377187", "started-marketing-on": "2012-07-11", "ended-marketing-on": null, "dosage-form": "cream", "strength": "40 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Antibiotic Plus Pain Relief Cream", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02304457", "started-marketing-on": "2009-07-30", "ended-marketing-on": null, "dosage-form": "cream", "strength": "50 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kenacomb Cream", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01999850", "started-marketing-on": "1965-12-31", "ended-marketing-on": "2004-08-05", "dosage-form": "cream", "strength": "1 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kenacomb Mild Cream", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01999842", "started-marketing-on": "1968-12-31", "ended-marketing-on": "2004-08-05", "dosage-form": "cream", "strength": ".25 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kenacomb Mild Ointment", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01999834", "started-marketing-on": "1968-12-31", "ended-marketing-on": "2004-08-05", "dosage-form": "ointment", "strength": ".25 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kenacomb Ointment", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01999826", "started-marketing-on": "1996-07-31", "ended-marketing-on": "2004-08-05", "dosage-form": "ointment", "strength": "1 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kenacomb Ont", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00245267", "started-marketing-on": "1965-12-31", "ended-marketing-on": "1997-08-14", "dosage-form": "ointment", "strength": "1 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Lidecomb Cream", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00492442", "started-marketing-on": "1980-12-31", "ended-marketing-on": "1998-09-25", "dosage-form": "cream", "strength": "0.5 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Lidosporin Cream", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02230842", "started-marketing-on": "1998-07-08", "ended-marketing-on": "2000-11-27", "dosage-form": "cream", "strength": "50 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Lidosporin Cream", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01966006", "started-marketing-on": "1971-12-31", "ended-marketing-on": "2000-08-03", "dosage-form": "cream", "strength": "50 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Mecomb Crm 0.1%", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00464554", "started-marketing-on": "1979-12-31", "ended-marketing-on": "2003-07-17", "dosage-form": "cream", "strength": "1 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Neocidin", "ndc-id": "0904-3016_b7aa0bae-255b-4792-a963-6606370a175f", "ndc-product-code": "0904-3016", "dpd-id": null, "started-marketing-on": "2004-06-07", "ended-marketing-on": null, "dosage-form": "solution/ drops", "strength": "1.75; 10000; .025 mg/mL; [USP'U]/mL; mg/mL", "route": "ophthalmic", "fda-application-number": "ANDA064047", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Neomycin and Polymyxin B Sulfates and Gramicidin", "ndc-id": "54569-1188_dfc13b9e-15f1-40dd-bc59-b1eb48ee5dac", "ndc-product-code": "54569-1188", "dpd-id": null, "started-marketing-on": "1996-01-31", "ended-marketing-on": null, "dosage-form": "solution/ drops", "strength": "1.75; 10000; .025 mg/mL; [USP'U]/mL; mg/mL", "route": "ophthalmic", "fda-application-number": "ANDA064047", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Neomycin and Polymyxin B Sulfates and Gramicidin", "ndc-id": "24208-790_e0a6cfdc-12c3-471f-ad46-ad2868caf94b", "ndc-product-code": "24208-790", "dpd-id": null, "started-marketing-on": "1996-01-31", "ended-marketing-on": null, "dosage-form": "solution/ drops", "strength": "1.75; 10000; .025 mg/mL; [USP'U]/mL; mg/mL", "route": "ophthalmic", "fda-application-number": "ANDA064047", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Neomycin and Polymyxin B Sulfates and Gramicidin", "ndc-id": "55045-1194_07080003-b495-447a-bb9d-0efbe866e37a", "ndc-product-code": "55045-1194", "dpd-id": null, "started-marketing-on": "1996-01-31", "ended-marketing-on": null, "dosage-form": "solution/ drops", "strength": "1.75; 10000; .025 mg/mL; [USP'U]/mL; mg/mL", "route": "ophthalmic", "fda-application-number": "ANDA064047", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Neomycin and Polymyxin B Sulfates and Gramicidin", "ndc-id": "21695-528_65edc059-0806-4625-b583-0e36f04cf085", "ndc-product-code": "21695-528", "dpd-id": null, "started-marketing-on": "1996-01-31", "ended-marketing-on": null, "dosage-form": "solution/ drops", "strength": "1.75; 10000; .025 mg/mL; mg/mL; mg/mL", "route": "ophthalmic", "fda-application-number": "ANDA064047", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Neomycin and Polymyxin B Sulfates and Gramicidin", "ndc-id": "54868-6253_96b4ed40-9853-4ac2-8b3a-4548355d1c40", "ndc-product-code": "54868-6253", "dpd-id": null, "started-marketing-on": "2011-04-26", "ended-marketing-on": null, "dosage-form": "solution/ drops", "strength": "1.75; 10000; .025 mg/mL; [USP'U]/mL; mg/mL", "route": "ophthalmic", "fda-application-number": "ANDA064047", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Neosporin", "ndc-id": "61570-045_b8cd1d5a-9d3b-465e-9e5b-2f67af8dbeb2", "ndc-product-code": "61570-045", "dpd-id": null, "started-marketing-on": "1955-04-11", "ended-marketing-on": null, "dosage-form": "solution", "strength": "1.75; 10000; .025 mg/mL; [iU]/mL; mg/mL", "route": "ophthalmic", "fda-application-number": "ANDA060582", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Neosporin Antibiotic Cream", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00666203", "started-marketing-on": "1986-12-31", "ended-marketing-on": "2007-12-19", "dosage-form": "cream", "strength": "10000 unit", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Neosporin Eye-ear Solution", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00694371", "started-marketing-on": "1987-12-31", "ended-marketing-on": "2006-11-21", "dosage-form": "solution", "strength": "10000 unit", "route": "ophthalmic; otic", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Optimyxin Oto/opht Gtte", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00701785", "started-marketing-on": "1989-12-31", "ended-marketing-on": null, "dosage-form": "drops", "strength": "10000 unit", "route": "ophthalmic; otic", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Optimyxin Plus Oto-opht Gtte", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00807435", "started-marketing-on": "1989-12-31", "ended-marketing-on": null, "dosage-form": "drops", "strength": "10000 unit", "route": "ophthalmic; otic", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Original Antibiotic Cream", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02401002", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "cream", "strength": "10000 unit", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Original Antibiotic Cream", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02317656", "started-marketing-on": "2010-10-26", "ended-marketing-on": null, "dosage-form": "cream", "strength": "10000 unit", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Polycidin Eye, Ear Drops", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02229903", "started-marketing-on": "1997-01-30", "ended-marketing-on": "2002-09-10", "dosage-form": "liquid", "strength": "10000 unit", "route": "ophthalmic; otic", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Polysporin Antibiotic Burn Cream", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02230843", "started-marketing-on": "1998-07-08", "ended-marketing-on": "1999-06-18", "dosage-form": "cream", "strength": "50 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Polysporin Antibiotic Cream", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02230844", "started-marketing-on": "1997-08-07", "ended-marketing-on": null, "dosage-form": "cream", "strength": "10000 unit", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Polysporin Burn Formula Cream", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00068535", "started-marketing-on": "1991-12-31", "ended-marketing-on": "2000-08-03", "dosage-form": "cream", "strength": "50 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Polysporin Cream", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00035335", "started-marketing-on": "1971-12-31", "ended-marketing-on": "2000-08-03", "dosage-form": "cream", "strength": "10000 unit", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Polysporin Eye and Ear Drops Sterile", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00035343", "started-marketing-on": "1971-12-31", "ended-marketing-on": "2000-08-03", "dosage-form": "drops", "strength": "10000 unit", "route": "ophthalmic; otic", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Polysporin Eye and Ear Drops Sterile", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02239156", "started-marketing-on": "2000-02-12", "ended-marketing-on": null, "dosage-form": "drops", "strength": "10000 unit", "route": "ophthalmic; otic", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Polysporin for Kids", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02248189", "started-marketing-on": "2004-04-05", "ended-marketing-on": null, "dosage-form": "cream", "strength": "50 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Polysporin Plus Pain Relief", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02239201", "started-marketing-on": "1999-06-18", "ended-marketing-on": null, "dosage-form": "cream", "strength": "50 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Polysporin Triple Antibiotic Ointment", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02194104", "started-marketing-on": "1996-12-31", "ended-marketing-on": "2000-08-03", "dosage-form": "ointment", "strength": "500 unit", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Polysporin Triple Antibiotic Ointment", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02230847", "started-marketing-on": "1998-07-08", "ended-marketing-on": "1999-08-13", "dosage-form": "ointment", "strength": "500 unit", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Polytopic Cream", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00422908", "started-marketing-on": "1997-01-27", "ended-marketing-on": null, "dosage-form": "cream", "strength": "10000 unit", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Ratio-triacomb", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00550507", "started-marketing-on": "1992-12-31", "ended-marketing-on": null, "dosage-form": "cream", "strength": "1 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Sandoz Opticort", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02247920", "started-marketing-on": "2004-01-16", "ended-marketing-on": null, "dosage-form": "solution", "strength": "0.5 mg", "route": "ophthalmic; otic", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Sofracort Ear/eye Ointment", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00173606", "started-marketing-on": "1966-12-31", "ended-marketing-on": "1996-09-09", "dosage-form": "ointment", "strength": ".5 mg", "route": "ophthalmic; otic", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Sofracort Sterile Ear/eye Drops", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01987712", "started-marketing-on": "1966-12-31", "ended-marketing-on": "2004-07-30", "dosage-form": "drops", "strength": ".5 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Sofracort Sterile Ear/eye Drops", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02224623", "started-marketing-on": "2002-07-26", "ended-marketing-on": null, "dosage-form": "drops", "strength": "0.5 mg", "route": "ophthalmic; otic", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Sofracort Sterile Ear/eye Ointment", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02224631", "started-marketing-on": "1999-10-25", "ended-marketing-on": "2006-07-28", "dosage-form": "ointment", "strength": "0.5 mg", "route": "ophthalmic; otic", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Sofracort Sterile Ear/eye Ointment", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01987720", "started-marketing-on": "1966-12-31", "ended-marketing-on": "2001-07-20", "dosage-form": "ointment", "strength": ".5 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Soframycin Nasal Spray", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01987690", "started-marketing-on": "1994-12-31", "ended-marketing-on": "1998-08-12", "dosage-form": "spray", "strength": "2.5 mg", "route": "nasal", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Soframycin Nasal Spray", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02224860", "started-marketing-on": "2001-05-04", "ended-marketing-on": null, "dosage-form": "spray", "strength": "2.5 mg", "route": "nasal", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Soframycin Nasal Spray", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00173584", "started-marketing-on": "1959-12-31", "ended-marketing-on": "1996-09-09", "dosage-form": "spray", "strength": "2.5 mg", "route": "nasal", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Soframycin Ointment", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00026972", "started-marketing-on": "1961-12-31", "ended-marketing-on": "1997-08-05", "dosage-form": "ointment", "strength": ".05 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Soframycin Skin Ointment", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01987674", "started-marketing-on": "1995-12-31", "ended-marketing-on": "2000-07-28", "dosage-form": "ointment", "strength": "50 mcg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Soframycin Skin Ointment", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02224879", "started-marketing-on": "2001-05-04", "ended-marketing-on": null, "dosage-form": "ointment", "strength": "50 mcg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Theraderm Cream", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02022818", "started-marketing-on": "1993-12-31", "ended-marketing-on": null, "dosage-form": "cream", "strength": "1 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Triple Antibiotic Ointment", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02088339", "started-marketing-on": "1994-12-31", "ended-marketing-on": null, "dosage-form": "ointment", "strength": "500 unit", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "true", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Viaderm Kc Crm", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00717002", "started-marketing-on": "1983-12-31", "ended-marketing-on": null, "dosage-form": "cream", "strength": "1 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Viaderm Kc Ont", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00717029", "started-marketing-on": "1983-12-31", "ended-marketing-on": null, "dosage-form": "ointment", "strength": "1 mg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": {"name": "Sofradex", "company": "Sanofi"}}, "mixtures": {"mixture": [{"name": "Neocidin", "ingredients": "Neomycin + Polymyxin B Sulfate + Gramicidin D"}, {"name": "Neomycin and Polymyxin B Sulfates and Gramicidin", "ingredients": "Neomycin + Polymyxin B Sulfate + Gramicidin D"}, {"name": "Neomycin and Polymyxin B Sulfates and Gramicidin", "ingredients": "Neomycin + Polymyxin B Sulfate + Gramicidin D"}, {"name": "Neomycin and Polymyxin B Sulfates and Gramicidin", "ingredients": "Neomycin + Polymyxin B Sulfate + Gramicidin D"}, {"name": "Neomycin and Polymyxin B Sulfates and Gramicidin", "ingredients": "Neomycin + Polymyxin B Sulfate + Gramicidin D"}, {"name": "Neomycin and Polymyxin B Sulfates and Gramicidin", "ingredients": "Neomycin + Polymyxin B Sulfate + Gramicidin D"}, {"name": "Neosporin", "ingredients": "Neomycin + Polymyxin B Sulfate + Gramicidin D"}, {"name": "Optimyxin Oto/opht Gtte", "ingredients": "Polymyxin B Sulfate + Gramicidin D"}, {"name": "Optimyxin Plus Oto-opht Gtte", "ingredients": "Polymyxin B Sulfate + Gramicidin D + Neomycin"}, {"name": "Ratio-triacomb", "ingredients": "Triamcinolone + Nystatin + Gramicidin D + Neomycin"}, {"name": "Ak Spor Liq", "ingredients": "Polymyxin B Sulfate + Gramicidin D + Neomycin"}, {"name": "Theraderm Cream", "ingredients": "Triamcinolone + Nystatin + Gramicidin D + Neomycin"}, {"name": "Triple Antibiotic Ointment", "ingredients": "Bacitracin + Polymyxin B Sulfate + Gramicidin D"}, {"name": "Sofracort Sterile Ear/eye Drops", "ingredients": "Dexamethasone + Gramicidin D + Framycetin"}, {"name": "Soframycin Nasal Spray", "ingredients": "Phenylephrine + Gramicidin D + Framycetin"}, {"name": "Soframycin Skin Ointment", "ingredients": "Gramicidin D + Framycetin"}, {"name": "Polysporin Antibiotic Cream", "ingredients": "Polymyxin B Sulfate + Gramicidin D"}, {"name": "Polytopic Cream", "ingredients": "Polymyxin B Sulfate + Gramicidin D"}, {"name": "Polysporin Eye and Ear Drops Sterile", "ingredients": "Polymyxin B Sulfate + Gramicidin D"}, {"name": "Polysporin Plus Pain Relief", "ingredients": "Lidocaine + Polymyxin B Sulfate + Gramicidin D"}, {"name": "Sandoz Opticort", "ingredients": "Dexamethasone + Gramicidin D + Framycetin"}, {"name": "Polysporin for Kids", "ingredients": "Lidocaine + Polymyxin B Sulfate + Gramicidin D"}, {"name": "Antibiotic Plus Pain Relief Cream", "ingredients": "Lidocaine + Polymyxin B Sulfate + Gramicidin D"}, {"name": "Antibiotic Cream", "ingredients": "Polymyxin B Sulfate + Gramicidin D"}, {"name": "Antibiotic Cream for Kids", "ingredients": "Lidocaine + Polymyxin B Sulfate + Gramicidin D"}, {"name": "Original Antibiotic Cream", "ingredients": "Polymyxin B Sulfate + Gramicidin D"}, {"name": "Antibiotic Cream Plus Pain Relief", "ingredients": "Lidocaine + Polymyxin B Sulfate + Gramicidin D"}, {"name": "Antibiotic Cream", "ingredients": "Polymyxin B Sulfate + Gramicidin D"}, {"name": "Antibiotic Cream Plus Pain Relief", "ingredients": "Lidocaine + Polymyxin B Sulfate + Gramicidin D"}, {"name": "Antibiotic Cream Plus Pain Relief for Kids", "ingredients": "Lidocaine + Polymyxin B Sulfate + Gramicidin D"}, {"name": "Viaderm Kc Crm", "ingredients": "Triamcinolone + Nystatin + Gramicidin D + Neomycin"}, {"name": "Viaderm Kc Ont", "ingredients": "Triamcinolone + Nystatin + Gramicidin D + Neomycin"}, {"name": "Polysporin Eye and Ear Drops Sterile", "ingredients": "Polymyxin B Sulfate + Gramicidin D"}, {"name": "Polysporin Cream", "ingredients": "Polymyxin B Sulfate + Gramicidin D"}, {"name": "Lidosporin Cream", "ingredients": "Lidocaine + Polymyxin B Sulfate + Gramicidin D"}, {"name": "Polysporin Burn Formula Cream", "ingredients": "Lidocaine + Polymyxin B Sulfate + Gramicidin D"}, {"name": "Kenacomb Ont", "ingredients": "Triamcinolone + Nystatin + Gramicidin D + Neomycin"}, {"name": "Sofracort Sterile Ear/eye Drops", "ingredients": "Dexamethasone + Gramicidin D + Framycetin"}, {"name": "Soframycin Nasal Spray", "ingredients": "Phenylephrine + Gramicidin D + Framycetin"}, {"name": "Kenacomb Mild Cream", "ingredients": "Triamcinolone + Nystatin + Gramicidin D + Neomycin"}, {"name": "Sofracort Sterile Ear/eye Ointment", "ingredients": "Dexamethasone + Gramicidin D + Framycetin"}, {"name": "Kenacomb Cream", "ingredients": "Triamcinolone + Nystatin + Gramicidin D + Neomycin"}, {"name": "Soframycin Skin Ointment", "ingredients": "Gramicidin D + Framycetin"}, {"name": "Kenacomb Mild Ointment", "ingredients": "Triamcinolone + Nystatin + Gramicidin D + Neomycin"}, {"name": "Polysporin Triple Antibiotic Ointment", "ingredients": "Bacitracin + Polymyxin B Sulfate + Gramicidin D"}, {"name": "Kenacomb Ointment", "ingredients": "Triamcinolone + Nystatin + Gramicidin D + Neomycin"}, {"name": "Sofracort Ear/eye Ointment", "ingredients": "Dexamethasone + Gramicidin D + Framycetin"}, {"name": "Soframycin Nasal Spray", "ingredients": "Phenylephrine + Gramicidin D + Framycetin"}, {"name": "Mecomb Crm 0.1%", "ingredients": "Triamcinolone + Nystatin + Gramicidin D + Neomycin"}, {"name": "Antibiotic Cream", "ingredients": "Polymyxin B Sulfate + Gramicidin D"}, {"name": "Sofracort Sterile Ear/eye Ointment", "ingredients": "Dexamethasone + Gramicidin D + Framycetin"}, {"name": "Lidecomb Cream", "ingredients": "Fluocinonide + Nystatin + Gramicidin D + Neomycin"}, {"name": "Polycidin Eye, Ear Drops", "ingredients": "Polymyxin B Sulfate + Gramicidin D"}, {"name": "Polysporin Antibiotic Burn Cream", "ingredients": "Lidocaine + Polymyxin B Sulfate + Gramicidin D"}, {"name": "Polysporin Triple Antibiotic Ointment", "ingredients": "Bacitracin + Polymyxin B Sulfate + Gramicidin D"}, {"name": "Lidosporin Cream", "ingredients": "Lidocaine + Polymyxin B Sulfate + Gramicidin D"}, {"name": "Neosporin Antibiotic Cream", "ingredients": "Polymyxin B Sulfate + Gramicidin D + Neomycin"}, {"name": "Neosporin Eye-ear Solution", "ingredients": "Polymyxin B Sulfate + Gramicidin D + Neomycin"}, {"name": "Soframycin Ointment", "ingredients": "Gramicidin D + Framycetin"}, {"name": "Antibiotic Cream for Kids", "ingredients": "Lidocaine + Polymyxin B Sulfate + Gramicidin D"}, {"name": "Original Antibiotic Cream", "ingredients": "Polymyxin B Sulfate + Gramicidin D"}]}, "packagers": {"packager": [{"name": "Johnson & Johnson Healthcare", "url": "http://www.jnjcanada.com"}, {"name": "Monarch Pharmacy", "url": "http://www.monarch-pharmacy.co.uk"}, {"name": "Professional Co.", "url": null}]}, "manufacturers": null, "prices": {"price": [{"description": "Neosporin gu irr 40 mg/ml amp", "cost": {"@currency": "USD", "#text": "23.12"}, "unit": "ml"}, {"description": "Gramicidin d powder", "cost": {"@currency": "USD", "#text": "240.0"}, "unit": "g"}, {"description": "Neosporin + pain relief cream", "cost": {"@currency": "USD", "#text": "0.32"}, "unit": "g"}]}, "categories": {"category": [{"category": "Anti-Bacterial Agents", "mesh-id": null}, {"category": "Anti-Infective Agents", "mesh-id": null}, {"category": "Antibiotics", "mesh-id": null}, {"category": "Antibiotics, Topical", "mesh-id": null}]}, "affected-organisms": {"affected-organism": ["Pseudomonas aeruginosa", "Streptococcus pneumoniae", "Streptococcus agalactiae", "Neisseria meningitidis", "Haemophilus influenzae", "Neisseria gonorrhoeae", "Escherichia coli", "Staphylococcus aureus", "Klebsiella", "Enterobacter"]}, "dosages": {"dosage": [{"form": "Liquid", "route": "ophthalmic", "strength": "10000 unit"}, {"form": "Cream", "route": "topical", "strength": "40 mg"}, {"form": "Cream", "route": "topical", "strength": ".25 mg"}, {"form": "Ointment", "route": "topical", "strength": ".25 mg"}, {"form": "Cream", "route": "topical", "strength": "0.5 mg"}, {"form": "Solution/ drops", "route": "ophthalmic", "strength": "1.75; 10000; .025 mg/mL; [USP'U]/mL; mg/mL"}, {"form": "Solution/ drops", "route": "ophthalmic", "strength": "1.75; 10000; .025 mg/mL; mg/mL; mg/mL"}, {"form": "Solution", "route": "ophthalmic", "strength": "1.75; 10000; .025 mg/mL; [iU]/mL; mg/mL"}, {"form": "Solution", "route": "ophthalmic; otic", "strength": "10000 unit"}, {"form": "Drops", "route": "ophthalmic; otic", "strength": "10000 unit"}, {"form": "Liquid", "route": "ophthalmic; otic", "strength": "10000 unit"}, {"form": "Cream", "route": "topical", "strength": "10000 unit"}, {"form": "Cream", "route": "topical", "strength": "50 mg"}, {"form": "Cream", "route": "topical", "strength": "1 mg"}, {"form": "Solution", "route": "ophthalmic; otic", "strength": "0.5 mg"}, {"form": "Ointment", "route": "ophthalmic; otic", "strength": ".5 mg"}, {"form": "Drops", "route": "ophthalmic; otic", "strength": "0.5 mg"}, {"form": "Drops", "route": "topical", "strength": ".5 mg"}, {"form": "Ointment", "route": "ophthalmic; otic", "strength": "0.5 mg"}, {"form": "Ointment", "route": "topical", "strength": ".5 mg"}, {"form": "Spray", "route": "nasal", "strength": "2.5 mg"}, {"form": "Ointment", "route": "topical", "strength": ".05 mg"}, {"form": "Ointment", "route": "topical", "strength": "50 mcg"}, {"form": "Ointment", "route": "topical", "strength": "500 unit"}, {"form": "Ointment", "route": "topical", "strength": "1 mg"}]}, "atc-codes": {"atc-code": {"@code": "R02AB30", "level": [{"@code": "R", "#text": "RESPIRATORY SYSTEM"}, {"@code": "R02", "#text": "THROAT PREPARATIONS"}, {"@code": "R02A", "#text": "THROAT PREPARATIONS"}, {"@code": "R02AB", "#text": "Antibiotics"}]}}, "ahfs-codes": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "229 \u00b0C", "source": null}, {"kind": "Molecular Weight", "value": "1882.2947", "source": null}, {"kind": "Molecular Formula", "value": "C99H140N20O17", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "8523"}, {"resource": "KEGG Drug", "identifier": "D04369"}, {"resource": "PharmGKB", "identifier": "PA449808"}, {"resource": "Wikipedia", "identifier": "Gramicidin_D"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": {"transporter": {"@position": "1", "id": "BE0001032", "name": "Multidrug resistance protein 1", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14985103", "known-action": "unknown", "polypeptide": {"@id": "P08183", "@source": "Swiss-Prot", "name": "Multidrug resistance protein 1", "general-function": "Defense mechanisms and drug export", "specific-function": "Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells", "gene-name": "ABCB1", "locus": "7q21.1", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "52-72\n120-140\n189-209\n216-236\n297-317\n326-346\n711-731\n757-777\n833-853\n854-874\n937-957\n974-994", "signal-regions": null, "theoretical-pi": "9.44", "molecular-weight": "141464.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:40"}, {"resource": "GenAtlas", "identifier": "ABCB1"}, {"resource": "GeneCards", "identifier": "ABCB1"}, {"resource": "GenBank Gene Database", "identifier": "M14758"}, {"resource": "GenBank Protein Database", "identifier": "307180"}, {"resource": "UniProtKB", "identifier": "P08183"}, {"resource": "UniProt Accession", "identifier": "MDR1_HUMAN"}]}, "synonyms": {"synonym": ["ATP-binding cassette sub-family B member 1", "CD243 antigen", "EC 3.6.3.44", "P-glycoprotein 1"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Multidrug resistance protein 1\nMDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLYMVVGTLAAII\nHGAGLPLMMLVFGEMTDIFANAGNLEDLMSNITNRSDINDTGFFMNLEEDMTRYAYYYSG\nIGAGVLVAAYIQVSFWCLAAGRQIHKIRKQFFHAIMRQEIGWFDVHDVGELNTRLTDDVS\nKINEGIGDKIGMFFQSMATFFTGFIVGFTRGWKLTLVILAISPVLGLSAAVWAKILSSFT\nDKELLAYAKAGAVAEEVLAAIRTVIAFGGQKKELERYNKNLEEAKRIGIKKAITANISIG\nAAFLLIYASYALAFWYGTTLVLSGEYSIGQVLTVFFSVLIGAFSVGQASPSIEAFANARG\nAAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLEFRNVHFSYPSRKEVKILKGLNLKVQSG\nQTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVSQEPVLF\nATTIAENIRYGRENVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIA\nIARALVRNPKILLLDEATSALDTESEAVVQVALDKARKGRTTIVIAHRLSTVRNADVIAG\nFDDGVIVEKGNHDELMKEKGIYFKLVTMQTAGNEVELENAADESKSEIDALEMSSNDSRS\nSLIRKRSTRRSVRGSQAQDRKLSTKEALDESIPPVSFWRIMKLNLTEWPYFVVGVFCAII\nNGGLQPAFAIIFSKIIGVFTRIDDPETKRQNSNLFSLLFLALGIISFITFFLQGFTFGKA\nGEILTKRLRYMVFRSMLRQDVSWFDDPKNTTGALTTRLANDAAQVKGAIGSRLAVITQNI\nANLGTGIIISFIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGAGKIATEA\nIENFRTVVSLTQEQKFEHMYAQSLQVPYRNSLRKAHIFGITFSFTQAMMYFSYAGCFRFG\nAYLVAHKLMSFEDVLLVFSAVVFGAMAVGQVSSFAPDYAKAKISAAHIIMIIEKTPLIDS\nYSTEGLMPNTLEGNVTFGEVVFNYPTRPDIPVLQGLSLEVKKGQTLALVGSSGCGKSTVV\nQLLERFYDPLAGKVLLDGKEIKRLNVQWLRAHLGIVSQEPILFDCSIAENIAYGDNSRVV\nSQEEIVRAAKEANIHAFIESLPNKYSTKVGDKGTQLSGGQKQRIAIARALVRQPHILLLD\nEATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQL\nLAQKGIYFSMVSVQAGTKRQ"}, "gene-sequence": {"@format": "FASTA", "#text": ">3843 bp\nATGGATCTTGAAGGGGACCGCAATGGAGGAGCAAAGAAGAAGAACTTTTTTAAACTGAAC\nAATAAAAGTGAAAAAGATAAGAAGGAAAAGAAACCAACTGTCAGTGTATTTTCAATGTTT\nCGCTATTCAAATTGGCTTGACAAGTTGTATATGGTGGTGGGAACTTTGGCTGCCATCATC\nCATGGGGCTGGACTTCCTCTCATGATGCTGGTGTTTGGAGAAATGACAGATATCTTTGCA\nAATGCAGGAAATTTAGAAGATCTGATGTCAAACATCACTAATAGAAGTGATATCAATGAT\nACAGGGTTCTTCATGAATCTGGAGGAAGACATGACCAGGTATGCCTATTATTACAGTGGA\nATTGGTGCTGGGGTGCTGGTTGCTGCTTACATTCAGGTTTCATTTTGGTGCCTGGCAGCT\nGGAAGACAAATACACAAAATTAGAAAACAGTTTTTTCATGCTATAATGCGACAGGAGATA\nGGCTGGTTTGATGTGCACGATGTTGGGGAGCTTAACACCCGACTTACAGATGATGTCTCT\nAAGATTAATGAAGTTATTGGTGACAAAATTGGAATGTTCTTTCAGTCAATGGCAACATTT\nTTCACTGGGTTTATAGTAGGATTTACACGTGGTTGGAAGCTAACCCTTGTGATTTTGGCC\nATCAGTCCTGTTCTTGGACTGTCAGCTGCTGTCTGGGCAAAGATACTATCTTCATTTACT\nGATAAAGAACTCTTAGCGTATGCAAAAGCTGGAGCAGTAGCTGAAGAGGTCTTGGCAGCA\nATTAGAACTGTGATTGCATTTGGAGGACAAAAGAAAGAACTTGAAAGGTACAACAAAAAT\nTTAGAAGAAGCTAAAAGAATTGGGATAAAGAAAGCTATTACAGCCAATATTTCTATAGGT\nGCTGCTTTCCTGCTGATCTATGCATCTTATGCTCTGGCCTTCTGGTATGGGACCACCTTG\nGTCCTCTCAGGGGAATATTCTATTGGACAAGTACTCACTGTATTCTTTTCTGTATTAATT\nGGGGCTTTTAGTGTTGGACAGGCATCTCCAAGCATTGAAGCATTTGCAAATGCAAGAGGA\nGCAGCTTATGAAATCTTCAAGATAATTGATAATAAGCCAAGTATTGACAGCTATTCGAAG\nAGTGGGCACAAACCAGATAATATTAAGGGAAATTTGGAATTCAGAAATGTTCACTTCAGT\nTACCCATCTCGAAAAGAAGTTAAGATCTTGAAGGGCCTGAACCTGAAGGTGCAGAGTGGG\nCAGACGGTGGCCCTGGTTGGAAACAGTGGCTGTGGGAAGAGCACAACAGTCCAGCTGATG\nCAGAGGCTCTATGACCCCACAGAGGGGATGGTCAGTGTTGATGGACAGGATATTAGGACC\nATAAATGTAAGGTTTCTACGGGAAATCATTGGTGTGGTGAGTCAGGAACCTGTATTGTTT\nGCCACCACGATAGCTGAAAACATTCGCTATGGCCGTGAAAATGTCACCATGGATGAGATT\nGAGAAAGCTGTCAAGGAAGCCAATGCCTATGACTTTATCATGAAACTGCCTCATAAATTT\nGACACCCTGGTTGGAGAGAGAGGGGCCCAGTTGAGTGGTGGGCAGAAGCAGAGGATCGCC\nATTGCACGTGCCCTGGTTCGCAACCCCAAGATCCTCCTGCTGGATGAGGCCACGTCAGCC\nTTGGACACAGAAAGCGAAGCAGTGGTTCAGGTGGCTCTGGATAAGGCCAGAAAAGGTCGG\nACCACCATTGTGATAGCTCATCGTTTGTCTACAGTTCGTAATGCTGACGTCATCGCTGGT\nTTCGATGATGGAGTCATTGTGGAGAAAGGAAATCATGATGAACTCATGAAAGAGAAAGGC\nATTTACTTCAAACTTGTCACAATGCAGACAGCAGGAAATGAAGTTGAATTAGAAAATGCA\nGCTGATGAATCCAAAAGTGAAATTGATGCCTTGGAAATGTCTTCAAATGATTCAAGATCC\nAGTCTAATAAGAAAAAGATCAACTCGTAGGAGTGTCCGTGGATCACAAGCCCAAGACAGA\nAAGCTTAGTACCAAAGAGGCTCTGGATGAAAGTATACCTCCAGTTTCCTTTTGGAGGATT\nATGAAGCTAAATTTAACTGAATGGCCTTATTTTGTTGTTGGTGTATTTTGTGCCATTATA\nAATGGAGGCCTGCAACCAGCATTTGCAATAATATTTTCAAAGATTATAGGGGTTTTTACA\nAGAATTGATGATCCTGAAACAAAACGACAGAATAGTAACTTGTTTTCACTATTGTTTCTA\nGCCCTTGGAATTATTTCTTTTATTACATTTTTCCTTCAGGGTTTCACATTTGGCAAAGCT\nGGAGAGATCCTCACCAAGCGGCTCCGATACATGGTTTTCCGATCCATGCTCAGACAGGAT\nGTGAGTTGGTTTGATGACCCTAAAAACACCACTGGAGCATTGACTACCAGGCTCGCCAAT\nGATGCTGCTCAAGTTAAAGGGGCTATAGGTTCCAGGCTTGCTGTAATTACCCAGAATATA\nGCAAATCTTGGGACAGGAATAATTATATCCTTCATCTATGGTTGGCAACTAACACTGTTA\nCTCTTAGCAATTGTACCCATCATTGCAATAGCAGGAGTTGTTGAAATGAAAATGTTGTCT\nGGACAAGCACTGAAAGATAAGAAAGAACTAGAAGGTGCTGGGAAGATCGCTACTGAAGCA\nATAGAAAACTTCCGAACCGTTGTTTCTTTGACTCAGGAGCAGAAGTTTGAACATATGTAT\nGCTCAGAGTTTGCAGGTACCATACAGAAACTCTTTGAGGAAAGCACACATCTTTGGAATT\nACATTTTCCTTCACCCAGGCAATGATGTATTTTTCCTATGCTGGATGTTTCCGGTTTGGA\nGCCTACTTGGTGGCACATAAACTCATGAGCTTTGAGGATGTTCTGTTAGTATTTTCAGCT\nGTTGTCTTTGGTGCCATGGCCGTGGGGCAAGTCAGTTCATTTGCTCCTGACTATGCCAAA\nGCCAAAATATCAGCAGCCCACATCATCATGATCATTGAAAAAACCCCTTTGATTGACAGC\nTACAGCACGGAAGGCCTAATGCCGAACACATTGGAAGGAAATGTCACATTTGGTGAAGTT\nGTATTCAACTATCCCACCCGACCGGACATCCCAGTGCTTCAGGGACTGAGCCTGGAGGTG\nAAGAAGGGCCAGACGCTGGCTCTGGTGGGCAGCAGTGGCTGTGGGAAGAGCACAGTGGTC\nCAGCTCCTGGAGCGGTTCTACGACCCCTTGGCAGGGAAAGTGCTGCTTGATGGCAAAGAA\nATAAAGCGACTGAATGTTCAGTGGCTCCGAGCACACCTGGGCATCGTGTCCCAGGAGCCC\nATCCTGTTTGACTGCAGCATTGCTGAGAACATTGCCTATGGAGACAACAGCCGGGTGGTG\nTCACAGGAAGAGATCGTGAGGGCAGCAAAGGAGGCCAACATACATGCCTTCATCGAGTCA\nCTGCCTAATAAATATAGCACTAAAGTAGGAGACAAAGGAACTCAGCTCTCTGGTGGCCAG\nAAACAACGCATTGCCATAGCTCGTGCCCTTGTTAGACAGCCTCATATTTTGCTTTTGGAT\nGAAGCCACGTCAGCTCTGGATACAGAAAGTGAAAAGGTTGTCCAAGAAGCCCTGGACAAA\nGCCAGAGAAGGCCGCACCTGCATTGTGATTGCTCACCGCCTGTCCACCATCCAGAATGCA\nGACTTAATAGTGGTGTTTCAGAATGGCAGAGTCAAGGAGCATGGCACGCATCAGCAGCTG\nCTGGCACAGAAAGGCATCTATTTTTCAATGGTCAGTGTCCAGGCTGGAACAAAGCGCCAG\nTGA"}, "pfams": {"pfam": [{"identifier": "PF00005", "name": "ABC_tran"}, {"identifier": "PF00664", "name": "ABC_membrane"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "ATPase activity"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substances"}, {"category": "function", "description": "ATPase activity, coupled to transmembrane movement of substances"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "pyrophosphatase activity"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "nucleoside-triphosphatase activity"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}}}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-01-23", "drugbank-id": [{"@primary": "true", "#text": "DB00028"}, "BIOD00091", "BTD00091"], "name": "Intravenous Immunoglobulin", "description": "Intravenous immunoglobulin (IVIg) is a mixture of IgG1 and other antibodies derived from healthy human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and ion exchange chromatography. IVIg contains the same distribution of IgG antibody subclasses as is found in the general human population. IgG subclasses are fully represented in the following proportions: 70.3% IgG1, 24.7% IgG2, 3.1% IgG3, and 1.9% IgG4. IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders.", "cas-number": "9007-83-4", "groups": {"group": ["approved", "investigational"]}, "general-references": "# Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Siberil S, Dimitrov JD, Lacroix-Desmazes S, Berdah M, Crabol Y, Oksenhendler E, Levy Y, Mouthon L, Sautes-Fridman C, Hermine O, Kaveri SV: Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun. 2011 Feb;36(1):9-15. Epub 2010 Dec 9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20970960\n# Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17911465\n# Stangel M, Pul R: Basic principles of intravenous immunoglobulin (IVIg) treatment. J Neurol. 2006 Sep;253 Suppl 5:V18-24. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16998749\n# Emmi L, Chiarini F: The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol Sci. 2002 Apr;23 Suppl 1:S1-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12032582\n# http://www.path.cam.ac.uk/~mrc7/lecturenotes/handout1a.pdf", "synthesis-reference": "Wolfgang Stephan, \"Production of intravenously applicable native human immune globulin having a normal half-life.\" U.S. Patent US4082734, issued July, 1970.", "indication": "IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders. These indications includes idiopathic thrombocytopenic purpura, Kawasaki disease, hypogammaglobulinemia, B cell chronic lymphocytic leukemia, bone marrow transplant complications, Guillain-Barr\u00e9 syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), multiple sclerosis, rheumatoid arthritis, myesthenia gravis, Wiskott\u2013Aldrich syndrome and inflammatory skin diseases.", "pharmacodynamics": "Used as a replacement therapy in inherited humoral immunodeficiency disorders such as severe combined immunodeficiency syndrome, x-linked agammaglobulinemia, and Wiskott-Aldrich Syndrome. The immunoglobulins target, bind and kill bacterial cells as well as viral particles. IgG is the monomeric immunoglobulin of which there are four subclasses (IgG1, IgG2, IgG3 and IgG4) in differing abundances (66%, 23%, 7% and 4%). IgAs represent about 15% of the immunoglobulins in the blood. These target inhaled or ingested pathogens.", "mechanism-of-action": "IVIg interacts with a number of different components of the immune system, including cytokines, complement, Fc receptors and several cell surface immunocompetent molecules. IVIg also impacts different effector cells of the immune system (B and T lymphocytes, dendritic cells, etc.) and regulates a wide range of genes. Its main mechanism of actions are believed to be Fc-dependent and F(ab')2-dependent. IVIg competitively blocks gamma Fc receptors, preventing the binding and ingestion of phagocytes and suppressing platelet depletion. IVIg contains a number of different antobodies, which prevent infection by attaching to the surface of invading pathogens and aiding in their disposal before they can infect cells. Antibodies remove pathogens via complement activation, agglutination or precipitation, pathogen receptor blocking, macrophage \u201ctagging\u201d or neutralization (via binding) of pathogen toxins. Intact IVIg and F(ab\u2032)2 fragments of IVIg can also neutralize the activity of various autoantibodies. By triggering the production of interleukin-1 receptor antagonist, IVIg modulates of the production of cytokines and cytokine antagonists. It also prevents the generation of the C5b-9 membrane attack complex and subsequent complement-mediated tissue damage by binding active complement components.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": ">20 hours (mammalian reticulocytes, in vitro).", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Ig alpha-2 chain C region"}, {"@language": "", "@coder": "", "#text": "immune globulin"}, {"@language": "", "@coder": "", "#text": "Immunoglobulin G"}]}, "products": {"product": [{"name": "Gamastan", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00083259", "started-marketing-on": "1951-12-31", "ended-marketing-on": "1998-09-25", "dosage-form": "liquid", "strength": "16.5 %", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Gamastan S/d", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02230579", "started-marketing-on": "2004-03-04", "ended-marketing-on": null, "dosage-form": "solution", "strength": "18 %", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Gamimune N 10%  (iv)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02229695", "started-marketing-on": "2000-05-16", "ended-marketing-on": "2006-08-03", "dosage-form": "solution", "strength": "100 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Gamimune N 5%  (iv)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02178842", "started-marketing-on": "1997-01-17", "ended-marketing-on": "2006-08-03", "dosage-form": "solution", "strength": "50 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Gamimune N Inj 5%  (iv)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00559261", "started-marketing-on": "1986-12-31", "ended-marketing-on": "1998-09-25", "dosage-form": "liquid", "strength": "50 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Gammagard Liquid", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02279444", "started-marketing-on": "2007-08-08", "ended-marketing-on": null, "dosage-form": "solution", "strength": "10 %", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Gammagard S/d", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02231470", "started-marketing-on": "1997-08-22", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "5 g", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Gammagard S/d", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02231471", "started-marketing-on": "1997-08-22", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "10 g", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Gammagard S/d", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02231469", "started-marketing-on": "1997-08-22", "ended-marketing-on": "2015-05-12", "dosage-form": "powder for solution", "strength": "2.5 g", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Gammagard S/d  (iv)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02231468", "started-marketing-on": "1997-08-22", "ended-marketing-on": "2013-11-04", "dosage-form": "powder for solution", "strength": "0.5 g", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Gammar Inj 165mg/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01915312", "started-marketing-on": "1991-12-31", "ended-marketing-on": "1999-12-15", "dosage-form": "liquid", "strength": "165 mg", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Gamunex", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02247724", "started-marketing-on": "2003-10-22", "ended-marketing-on": null, "dosage-form": "solution", "strength": "10 g", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Hizentra", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02370352", "started-marketing-on": "2011-10-13", "ended-marketing-on": null, "dosage-form": "solution", "strength": "200 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Hyperrho S/d Full Dose", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02379457", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "1500 unit", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Hyperrho S/d Full Dose", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02243524", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "1500 unit", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Igivnex", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02277921", "started-marketing-on": "2006-05-24", "ended-marketing-on": null, "dosage-form": "solution", "strength": "10 g", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Immune Globulin Intravenous (human) 5%", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02185342", "started-marketing-on": "1996-12-31", "ended-marketing-on": "1998-09-28", "dosage-form": "liquid", "strength": "50 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Immune Globulin Intravenous (human), 10%", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02230920", "started-marketing-on": "2000-07-31", "ended-marketing-on": "2006-08-03", "dosage-form": "solution", "strength": "10 g", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Immune Globulin Intravenous (human), 5%", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02230919", "started-marketing-on": "1997-11-03", "ended-marketing-on": "2006-08-03", "dosage-form": "solution", "strength": "5 g", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Immune Serum Globulin (human)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02230647", "started-marketing-on": "1997-04-21", "ended-marketing-on": null, "dosage-form": "solution", "strength": "18 %", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Iveegam Immuno 5000mg  (iv)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01959301", "started-marketing-on": "1992-12-31", "ended-marketing-on": "2008-12-23", "dosage-form": "kit; liquid; powder for solution", "strength": "5 g", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Octagam 10%", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02380145", "started-marketing-on": "2013-04-04", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Octagam 5%", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02267713", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "50 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Privigen", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02304619", "started-marketing-on": "2009-01-08", "ended-marketing-on": null, "dosage-form": "solution", "strength": "10 %", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Sandoglobulin Nf Liquid", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02287994", "started-marketing-on": "2007-06-28", "ended-marketing-on": "2010-04-20", "dosage-form": "solution", "strength": "120 g", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Vivaglobin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02282518", "started-marketing-on": "2007-03-01", "ended-marketing-on": "2015-04-02", "dosage-form": "solution", "strength": "160 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": [{"name": "Civacir", "company": null}, {"name": "Flebogamma", "company": "Instituto Grifols SA"}]}, "mixtures": {"mixture": [{"name": "Gamastan S/d", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Immune Serum Globulin (human)", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Gammagard S/d", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Gammagard S/d", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Gamunex", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Igivnex", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Gammagard Liquid", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Privigen", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Hizentra", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Octagam 10%", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Gammar Inj 165mg/ml", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Iveegam Immuno 5000mg  (iv)", "ingredients": "Intravenous Immunoglobulin + Water"}, {"name": "Immune Globulin Intravenous (human) 5%", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Gamimune N 5%  (iv)", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Gamastan", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Gamimune N 10%  (iv)", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Immune Globulin Intravenous (human), 5%", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Immune Globulin Intravenous (human), 10%", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Gammagard S/d  (iv)", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Gammagard S/d", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Gamimune N Inj 5%  (iv)", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Vivaglobin", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Sandoglobulin Nf Liquid", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Hyperrho S/d Full Dose", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Octagam 5%", "ingredients": "Intravenous Immunoglobulin"}, {"name": "Hyperrho S/d Full Dose", "ingredients": "Intravenous Immunoglobulin"}]}, "packagers": {"packager": [{"name": "Alpha Therapeutic Corp.", "url": null}, {"name": "American Red Cross", "url": "http://www.redcross.org"}, {"name": "Baxter International Inc.", "url": "http://www.baxter.com"}, {"name": "Biotest Pharmaceuticals", "url": "http://www.biotestpharma.com"}, {"name": "Cangene Corp.", "url": "http://www.cangene.com"}, {"name": "CSL Behring LLC", "url": "http://www.cslbehring.com"}, {"name": "Grifols SA", "url": "http://www.grifols.com"}, {"name": "Massachusetts Public Health", "url": "http://www.mphaweb.org"}, {"name": "Massbiologics", "url": "http://www.massbio.org"}, {"name": "Medimmune Inc.", "url": "http://www.medimmune.com"}, {"name": "Novartis AG", "url": "http://www.novartis.com"}, {"name": "Octapharma USA", "url": "http://www.octapharma.com"}, {"name": "Talecris Biotherapeutics", "url": "http://www.talecris.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Flebogamma 5% vial", "cost": {"@currency": "USD", "#text": "4.84"}, "unit": "ml"}, {"description": "Flebogamma dif 5% vial", "cost": {"@currency": "USD", "#text": "4.84"}, "unit": "ml"}, {"description": "Immune globulin vial", "cost": {"@currency": "USD", "#text": "9.34"}, "unit": "ml"}, {"description": "Gamunex 10% vial", "cost": {"@currency": "USD", "#text": "11.6"}, "unit": "ml"}, {"description": "Gammagard liquid 10% vial", "cost": {"@currency": "USD", "#text": "13.79"}, "unit": "ml"}, {"description": "Gamastan s-d vial", "cost": {"@currency": "USD", "#text": "24.44"}, "unit": "ml"}, {"description": "Hizentra 1 gram/5 ml vial", "cost": {"@currency": "USD", "#text": "30.24"}, "unit": "ml"}, {"description": "Hizentra 2 gram/10 ml vial", "cost": {"@currency": "USD", "#text": "30.24"}, "unit": "ml"}, {"description": "Hizentra 4 gram/20 ml vial", "cost": {"@currency": "USD", "#text": "30.24"}, "unit": "ml"}, {"description": "Hyperhep b s-d vial", "cost": {"@currency": "USD", "#text": "165.04"}, "unit": "ml"}, {"description": "Nabi-hb vial", "cost": {"@currency": "USD", "#text": "176.34"}, "unit": "ml"}, {"description": "Hyperrab s-d vial", "cost": {"@currency": "USD", "#text": "224.07"}, "unit": "ml"}, {"description": "Hypertet s-d 250 unit syringe", "cost": {"@currency": "USD", "#text": "324.23"}, "unit": "syringe"}]}, "categories": {"category": [{"category": "Immunologic Factors", "mesh-id": null}, {"category": "Immunosuppressive Agents", "mesh-id": null}, {"category": "Anti-Infective Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": ["Humans and other mammals", "Bacteria and protozoa", "Various viruses"]}, "dosages": {"dosage": [{"form": "Liquid", "route": "intramuscular", "strength": "16.5 %"}, {"form": "Solution", "route": "intramuscular", "strength": "18 %"}, {"form": "Solution", "route": "intravenous", "strength": "50 mg"}, {"form": "Solution", "route": "intravenous", "strength": "10 %"}, {"form": "Powder for solution", "route": "intravenous", "strength": "10 g"}, {"form": "Powder for solution", "route": "intravenous", "strength": "2.5 g"}, {"form": "Powder for solution", "route": "intravenous", "strength": "5 g"}, {"form": "Powder for solution", "route": "intravenous", "strength": "0.5 g"}, {"form": "Liquid", "route": "intramuscular", "strength": "165 mg"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "10 g"}, {"form": "Solution", "route": "subcutaneous", "strength": "200 mg"}, {"form": "Solution", "route": "intramuscular", "strength": "1500 unit"}, {"form": "Liquid", "route": "intravenous", "strength": "50 mg"}, {"form": "Solution", "route": "intravenous", "strength": "10 g"}, {"form": "Solution", "route": "intravenous", "strength": "5 g"}, {"form": "Kit; liquid; powder for solution", "route": "intravenous", "strength": "5 g"}, {"form": "Solution", "route": "intravenous", "strength": "100 mg"}, {"form": "Solution", "route": "intravenous", "strength": "120 g"}, {"form": "Solution", "route": "subcutaneous", "strength": "160 mg"}]}, "atc-codes": null, "ahfs-codes": {"ahfs-code": "80:04.00"}, "patents": null, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00304", "name": "Desogestrel", "description": "Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin."}, {"drugbank-id": "DB01395", "name": "Drospirenone", "description": "Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin."}, {"drugbank-id": "DB00783", "name": "Estradiol", "description": "Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin."}, {"drugbank-id": "DB04574", "name": "Estropipate", "description": "Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin."}, {"drugbank-id": "DB00977", "name": "Ethinyl Estradiol", "description": "Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin."}, {"drugbank-id": "DB00823", "name": "Ethynodiol", "description": "Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin."}, {"drugbank-id": "DB01357", "name": "Mestranol", "description": "Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin."}, {"drugbank-id": "DB00957", "name": "Norgestimate", "description": "Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin."}, {"drugbank-id": "DB00592", "name": "Piperazine", "description": "Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin."}]}, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">IGG1\nPSALTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHAGKAPKVIIYEVNKRPSGV\nPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSDNFVFGTGTKVTVLGQPKANPTVT\nLFPPSSEELQANKATEVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASS\nYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSPLVLQESGPGLVKPSEALSLTCTV\nSGDSINTILYYWSWIRQPPGKGLEWIGYIYYSGSTYGNPSLKSRVTISVNTSKNQFYSKL\nSSVTAADTAVYYCARVPLVVNPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC\nLVKDYFPQPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH\nKPSNTKVDKRVAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPQVKFNWYV\nDGVQVHNAKTKPREQQYNSTYRVVSVLTVLHQNWLDGKEYKCKVSNKALPAPIEKTISKA\nKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD\nSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL"}, {"@format": "FASTA", "#text": ">IgA2\nELVMTQSPSSLSASVGDRVNIACRASQGISSALAWYQQKPGKAPRLLIYDASNLESGVPS\nRFSGSGSGTDFTLTISSLQPEDFAIYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPP\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT\nLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVKLLEQSGAEVKKPGASVKVSCKAS\nGYSFTSYGLHWVRQAPGQRLEWMGWISAGTGNTKYSQKFRGRVTFTRDTSATTAYMGLSS\nLRPEDTAVYYCARDPYGGGKSEFDYWGQGTLVTVSSASPTSPKVFPLSLDSTPQDGNVVV\nACLVQGFFPQEPLSVTWSESGQNVTARNFPPSQDASGDLYTTSSQLTLPATQCPDGKSVT\nCHVKHYTNPSQDVTVPCPVPPPPPCCHPRLSLHRPALEDLLLGSEANLTCTLTGLRDASG\nATFTWTPSSGKSAVQGPPERDLCGCYSVSSVLPGCAQPWNHGETFTCTAAHPELKTPLTA\nNITKSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYL\nTWASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLAGKPT\nHVNVSVVMAEVDGTCY"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "61 \u00b0C (FAB fragment), 71 \u00b0C (whole mAb)", "source": "Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)"}, {"kind": "Hydrophobicity", "value": "-0.331", "source": null}, {"kind": "Isoelectric Point", "value": "8.13", "source": null}, {"kind": "Molecular Weight", "value": "142682.3000", "source": null}, {"kind": "Molecular Formula", "value": "C6332H9826N1692O1980S42", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "7773"}, {"resource": "Drugs Product Database (DPD)", "identifier": "15161"}, {"resource": "National Drug Code Directory", "identifier": "67467-843-01"}, {"resource": "GenBank", "identifier": "J00221"}, {"resource": "PharmGKB", "identifier": "PA164754884"}, {"resource": "UniProtKB", "identifier": "P01877"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic2/baygam.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/immune-globulin-human.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000710", "name": "High affinity immunoglobulin gamma Fc receptor I", "organism": "Human", "actions": {"action": "antagonist"}, "references": "# Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17911465\n# Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20441428\n# Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17351760", "known-action": "yes", "polypeptide": {"@id": "P12314", "@source": "Swiss-Prot", "name": "High affinity immunoglobulin gamma Fc receptor I", "general-function": "Involved in receptor signaling protein activity", "specific-function": "Binds to the Fc region of immunoglobulins gamma. High affinity receptor", "gene-name": "FCGR1A", "locus": "1q21.2-q21.3", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "293-313", "signal-regions": null, "theoretical-pi": "8.08", "molecular-weight": "42632.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3613"}, {"resource": "GenAtlas", "identifier": "FCGR1A"}, {"resource": "GeneCards", "identifier": "FCGR1A"}, {"resource": "GenBank Gene Database", "identifier": "X14356"}, {"resource": "GenBank Protein Database", "identifier": "31332"}, {"resource": "UniProtKB", "identifier": "P12314"}, {"resource": "UniProt Accession", "identifier": "FCGR1_HUMAN"}]}, "synonyms": {"synonym": ["CD64 antigen", "Fc-gamma RI", "FcRI", "High affinity immunoglobulin gamma Fc receptor I precursor", "IgG Fc receptor I"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">High affinity immunoglobulin gamma Fc receptor I precursor\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1125 bp\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCTCTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAACTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "2", "id": "BE0004684", "name": "High affinity immunoglobulin gamma Fc receptor IB", "organism": "Human", "actions": {"action": "antagonist"}, "references": "# Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17911465\n# Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20441428\n# Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17351760", "known-action": "yes", "polypeptide": {"@id": "Q92637", "@source": "Swiss-Prot", "name": "High affinity immunoglobulin gamma Fc receptor IB", "general-function": "Involved in interferon-gamma-mediated signaling pathway", "specific-function": "May bind to the Fc region of immunoglobulins gamma with a low affinity compared to FCGR1A. May function in the humoral immune response.", "gene-name": "FCGR1B", "locus": null, "cellular-location": null, "transmembrane-regions": null, "signal-regions": null, "theoretical-pi": null, "molecular-weight": "32231.795", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "UniProtKB", "identifier": "Q92637"}, {"resource": "UniProt Accession", "identifier": "FCGRB_HUMAN"}]}, "synonyms": null, "amino-acid-sequence": {"@format": "FASTA", "#text": ">High affinity immunoglobulin gamma Fc receptor IB\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFMEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISQYTVKGLQLPTPVWFHVLFYLAVGIMFLVNTVLWVTIRKELKRKKKWNLEISLDSGHE\nKKVISSLQEDRHLEEELKCQEQKEEQLQEGVHRKEPQGAT"}, "gene-sequence": {"@format": "FASTA"}, "pfams": null, "go-classifiers": null}}, {"@position": "3", "id": "BE0002098", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "organism": "Human", "actions": {"action": "antagonist"}, "references": "# Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17911465\n# Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20441428\n# Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17351760", "known-action": "yes", "polypeptide": {"@id": "P12318", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "general-function": null, "specific-function": "Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens", "gene-name": "FCGR2A", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.78", "molecular-weight": "34990.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3616"}, {"resource": "GenAtlas", "identifier": "FCGR2A"}, {"resource": "GeneCards", "identifier": "FCGR2A"}, {"resource": "GenBank Gene Database", "identifier": "M31932"}, {"resource": "GenBank Protein Database", "identifier": "182474"}, {"resource": "UniProtKB", "identifier": "P12318"}, {"resource": "UniProt Accession", "identifier": "FCG2A_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-a", "Fc-gamma-RIIa", "FcRII-a", "IgG Fc receptor II-a", "Low affinity immunoglobulin gamma Fc region receptor II-a precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-a\nMAMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSRLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">954 bp\nATGGCTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "4", "id": "BE0002099", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "organism": "Human", "actions": {"action": "antagonist"}, "references": "# Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17911465\n# Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20441428\n# Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17351760", "known-action": "yes", "polypeptide": {"@id": "P31994", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "general-function": null, "specific-function": "Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B- cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis", "gene-name": "FCGR2B", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.12", "molecular-weight": "34044.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3618"}, {"resource": "GenAtlas", "identifier": "FCGR2B"}, {"resource": "GeneCards", "identifier": "FCGR2B"}, {"resource": "GenBank Gene Database", "identifier": "U87560"}, {"resource": "GenBank Protein Database", "identifier": "4099445"}, {"resource": "UniProtKB", "identifier": "P31994"}, {"resource": "UniProt Accession", "identifier": "FCG2B_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-b", "Fc-gamma-RIIb", "FcRII-b", "IgG Fc receptor II-b", "Low affinity immunoglobulin gamma Fc region receptor II-b precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI"}, "gene-sequence": {"@format": "FASTA", "#text": ">930 bp\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCTCTCCCAGGATACCCTGAG\nTGCAGGGAAATGGGAGAGACCCTCCCTGAGAAACCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATT"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "5", "id": "BE0002100", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "organism": "Human", "actions": {"action": "antagonist"}, "references": "# Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17911465\n# Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20441428\n# Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17351760", "known-action": "yes", "polypeptide": {"@id": "P31995", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "general-function": null, "specific-function": "Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells", "gene-name": "FCGR2C", "locus": "1q23.3", "cellular-location": "Cell membrane", "transmembrane-regions": "224-246", "signal-regions": null, "theoretical-pi": "6.9", "molecular-weight": "35578.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:15626"}, {"resource": "GenAtlas", "identifier": "FCGR2C"}, {"resource": "GeneCards", "identifier": "FCGR2C"}, {"resource": "GenBank Gene Database", "identifier": "X17652"}, {"resource": "GenBank Protein Database", "identifier": "32074"}, {"resource": "UniProtKB", "identifier": "P31995"}, {"resource": "UniProt Accession", "identifier": "FCG2C_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-c", "Fc-gamma-RIIc", "FcRII-c", "IgG Fc receptor II-c", "Low affinity immunoglobulin gamma Fc region receptor II-c precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-c\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR\nAPTDDDKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">972 bp\nATGGGAATCCTGTCATTTTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACAGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCATTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCTGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG\nAAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT\nGAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG\nGCACCTACTGACGATGATAAAAACATCTACTTGACTCTTCCTCCCAACGACCATGTCAAC\nAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "6", "id": "BE0002097", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "organism": "Human", "actions": {"action": "antagonist"}, "references": "# Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17911465\n# Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20441428\n# Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17351760", "known-action": "yes", "polypeptide": {"@id": "P08637", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "general-function": null, "specific-function": "Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis", "gene-name": "FCGR3A", "locus": "1q23", "cellular-location": "Cell membrane", "transmembrane-regions": "209-229", "signal-regions": null, "theoretical-pi": "8.21", "molecular-weight": "29089.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3619"}, {"resource": "GenAtlas", "identifier": "FCGR3A"}, {"resource": "GeneCards", "identifier": "FCGR3A"}, {"resource": "GenBank Gene Database", "identifier": "X52645"}, {"resource": "GenBank Protein Database", "identifier": "31324"}, {"resource": "UniProtKB", "identifier": "P08637"}, {"resource": "UniProt Accession", "identifier": "FCG3A_HUMAN"}]}, "synonyms": {"synonym": ["CD16a antigen", "Fc-gamma RIII", "Fc-gamma RIII-alpha", "Fc-gamma RIIIa", "FcR-10", "FcRIII", "FcRIIIa", "IgG Fc receptor III-2", "Low affinity immunoglobulin gamma Fc region receptor III-A precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK"}, "gene-sequence": {"@format": "FASTA", "#text": ">765 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCGACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCA\nAAAGCCACACTCAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTTTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGG\nAAGGACCATAAATTTAAATGGAGAAAGGACCCTCAAGACAAATGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "7", "id": "BE0000901", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "organism": "Human", "actions": {"action": "antagonist"}, "references": "# Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17911465\n# Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20441428\n# Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17351760", "known-action": "yes", "polypeptide": {"@id": "O75015", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "general-function": null, "specific-function": "Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils", "gene-name": "FCGR3B", "locus": "1q23", "cellular-location": "Cell membrane; lipid-anchor; GPI-anchor. Secreted protein. Note=Secreted after cleavage", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.71", "molecular-weight": "26216.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3620"}, {"resource": "GenAtlas", "identifier": "FCGR3B"}, {"resource": "GeneCards", "identifier": "FCGR3B"}, {"resource": "GenBank Gene Database", "identifier": "X16863"}, {"resource": "GenBank Protein Database", "identifier": "31322"}, {"resource": "UniProtKB", "identifier": "O75015"}, {"resource": "UniProt Accession", "identifier": "FCG3B_HUMAN"}]}, "synonyms": {"synonym": ["CD16b antigen", "Fc-gamma RIII", "Fc-gamma RIII-beta", "Fc-gamma RIIIb", "FcR-10", "FcRIII", "FcRIIIb", "IgG Fc receptor III-1", "Low affinity immunoglobulin gamma Fc region receptor III-B precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-B precursor\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI"}, "gene-sequence": {"@format": "FASTA", "#text": ">702 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "8", "id": "BE0003455", "name": "Complement C3", "organism": "Human", "actions": {"action": "binder"}, "references": "# Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20441428\n# Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17351760\n# Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17911465", "known-action": "yes", "polypeptide": {"@id": "P01024", "@source": "Swiss-Prot", "name": "Complement C3", "general-function": null, "specific-function": "Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes", "gene-name": "C3", "locus": null, "cellular-location": "Secreted", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.34", "molecular-weight": "187150.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1318"}, {"resource": "GenAtlas", "identifier": "C3"}, {"resource": "GenBank Gene Database", "identifier": "AY513239"}, {"resource": "UniProtKB", "identifier": "P01024"}, {"resource": "UniProt Accession", "identifier": "CO3_HUMAN"}]}, "synonyms": {"synonym": "Complement C3 precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C3\nMGPTSGPSLLLLLLTHLPLALGSPMYSIITPNILRLESEETMVLEAHDAQGDVPVTVTVH\nDFPGKKLVLSSEKTVLTPATNHMGNVTFTIPANREFKSEKGRNKFVTVQATFGTQVVEKV\nVLVSLQSGYLFIQTDKTIYTPGSTVLYRIFTVNHKLLPVGRTVMVNIENPEGIPVKQDSL\nSSQNQLGVLPLSWDIPELVNMGQWKIRAYYENSPQQVFSTEFEVKEYVLPSFEVIVEPTE\nKFYYIYNEKGLEVTITARFLYGKKVEGTAFVIFGIQDGEQRISLPESLKRIPIEDGSGEV\nVLSRKVLLDGVQNPRAEDLVGKSLYVSATVILHSGSDMVQAERSGIPIVTSPYQIHFTKT\nPKYFKPGMPFDLMVFVTNPDGSPAYRVPVAVQGEDTVQSLTQGDGVAKLSINTHPSQKPL\nSITVRTKKQELSEAEQATRTMQALPYSTVGNSNNYLHLSVLRTELRPGETLNVNFLLRMD\nRAHEAKIRYYTYLIMNKGRLLKAGRQVREPGQDLVVLPLSITTDFIPSFRLVAYYTLIGA\nSGQREVVADSVWVDVKDSCVGSLVVKSGQSEDRQPVPGQQMTLKIEGDHGARVVLVAVDK\nGVFVLNKKNKLTQSKIWDVVEKADIGCTPGSGKDYAGVFSDAGLTFTSSSGQQTAQRAEL\nQCPQPAARRRRSVQLTEKRMDKVGKYPKELRKCCEDGMRENPMRFSCQRRTRFISLGEAC\nKKVFLDCCNYITELRRQHARASHLGLARSNLDEDIIAEENIVSRSEFPESWLWNVEDLKE\nPPKNGISTKLMNIFLKDSITTWEILAVSMSDKKGICVADPFEVTVMQDFFIDLRLPYSVV\nRNEQVEIRAVLYNYRQNQELKVRVELLHNPAFCSLATTKRRHQQTVTIPPKSSLSVPYVI\nVPLKTGLQEVEVKAAVYHHFISDGVRKSLKVVPEGIRMNKTVAVRTLDPERLGREGVQKE\nDIPPADLSDQVPDTESETRILLQGTPVAQMTEDAVDAERLKHLIVTPSGCGEQNMIGMTP\nTVIAVHYLDETEQWEKFGLEKRQGALELIKKGYTQQLAFRQPSSAFAAFVKRAPSTWLTA\nYVVKVFSLAVNLIAIDSQVLCGAVKWLILEKQKPDGVFQEDAPVIHQEMIGGLRNNNEKD\nMALTAFVLISLQEAKDICEEQVNSLPGSITKAGDFLEANYMNLQRSYTVAIAGYALAQMG\nRLKGPLLNKFLTTAKDKNRWEDPGKQLYNVEATSYALLALLQLKDFDFVPPVVRWLNEQR\nYYGGGYGSTQATFMVFQALAQYQKDAPDHQELNLDVSLQLPSRSSKITHRIHWESASLLR\nSEETKENEGFTVTAEGKGQGTLSVVTMYHAKAKDQLTCNKFDLKVTIKPAPETEKRPQDA\nKNTMILEICTRYRGDQDATMSILDISMMTGFAPDTDDLKQLANGVDRYISKYELDKAFSD\nRNTLIIYLDKVSHSEDDCLAFKVHQYFNVELIQPGAVKVYAYYNLEESCTRFYHPEKEDG\nKLNKLCRDELCRCAEENCFIQKSDDKVTLEERLDKACEPGVDYVYKTRLVKVQLSNDFDE\nYIMAIEQTIKSGSDEVQVGQQRTFISPIKCREALKLEEKKHYLMWGLSSDFWGEKPNLSY\nIIGKDTWVEHWPEEDECQDEENQKQCQDLGAFTESMVVFGCPN"}, "gene-sequence": {"@format": "FASTA"}, "pfams": {"pfam": [{"identifier": "PF00207", "name": "A2M"}, {"identifier": "PF07678", "name": "A2M_comp"}, {"identifier": "PF01835", "name": "A2M_N"}, {"identifier": "PF07703", "name": "A2M_N_2"}, {"identifier": "PF07677", "name": "A2M_recep"}, {"identifier": "PF01821", "name": "ANATO"}, {"identifier": "PF01759", "name": "NTR"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase inhibitor activity"}, {"category": "function", "description": "enzyme regulator activity"}, {"category": "function", "description": "enzyme inhibitor activity"}, {"category": "function", "description": "protease inhibitor activity"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "inflammatory response"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "immune response"}]}}}, {"@position": "11", "id": "BE0004685", "name": "Complement C4-A", "organism": "Human", "actions": {"action": "binder"}, "references": "# Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20441428\n# Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17351760\n# Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17911465", "known-action": "yes", "polypeptide": {"@id": "P0C0L4", "@source": "Swiss-Prot", "name": "Complement C4-A", "general-function": "Involved in regulation of complement activation", "specific-function": "Non-enzymatic component of C3 and C5 convertases and thus essential for the propagation of the classical complement pathway. Covalently binds to immunoglobulins and immune complexes and enhances the solubilization of immune aggregates and the clearance of IC through CR1 on erythrocytes. C4A isotype is responsible for effective binding to form amide bonds with immune aggregates or protein antigens, while C4B isotype catalyzes the transacylation of the thioester carbonyl group to form ester bonds with carbohydrate antigens.Derived from proteolytic degradation of complement C4, C4a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.", "gene-name": "C4A", "locus": null, "cellular-location": null, "transmembrane-regions": null, "signal-regions": null, "theoretical-pi": null, "molecular-weight": "192783.805", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "UniProtKB", "identifier": "P0C0L4"}, {"resource": "UniProt Accession", "identifier": "CO4A_HUMAN"}]}, "synonyms": null, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C4-A\nMRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLRN\nPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLKDS\nLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMVEN\nSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPN\nFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE\nSQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAELTSW\nYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVPEVQD\nIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPDS\nRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPS\nFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA\nLGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAGLAFSDGDQW\nTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTRLPMMRSCEQRA\nARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLIDEDDIPVRSFFPE\nNWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLP\nMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS\nVVPTAAAAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNPLDHRGRTLEI\nPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASLLRLPRGCGEQTMIYLAP\nTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRKADGSYAAWLSRDSSTWLTA\nFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQDPCPVLDRSMQGGLVGNDETVA\nLTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKANSFLGEKASAGLLGAHAAAITAYAL\nTLTKAPVDLLGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNPSDPMPQAPAL\nWIETTAYALLHLLLHEGKAEMADQASAWLTRQGSFQGGFRSTQDTVIALDALSAYWIASH\nTTEERGLNVTLSSTGRNGFKSHALQLNNRQIRGLEEELQFSLGSKINVKVGGNSKGTLKV\nLRTYNVLDMKNTTCQDLQIEVTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTP\nLQLFEGRRNRRRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD\nLEKLTSLSDRYVSHFETEGPHVLLYFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYY\nNPERRCSVFYGAPSKSRLLATLCSAEVCQCAEGKCPRQRRALERGLQDEDGYRMKFACYY\nPRVEYGFQVKVLREDSRAAFRLFETKITQVLHFTKDVKAAANQMRNFLVRASCRLRLEPG\nKEYLIMGLDGATYDLEGHPQYLLDSNSWIEEMPSERLCRSTRQRAACAQLNDFLQEYGTQ\nGCQV"}, "gene-sequence": {"@format": "FASTA"}, "pfams": null, "go-classifiers": null}}, {"@position": "12", "id": "BE0004686", "name": "Complement C4-B", "organism": "Human", "actions": {"action": "binder"}, "references": "# Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20441428\n# Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17351760\n# Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17911465", "known-action": "yes", "polypeptide": {"@id": "P0C0L5", "@source": "Swiss-Prot", "name": "Complement C4-B", "general-function": "Involved in regulation of complement activation", "specific-function": "Non-enzymatic component of the C3 and C5 convertases and thus essential for the propagation of the classical complement pathway. Covalently binds to immunoglobulins and immune complexes and enhances the solubilization of immune aggregates and the clearance of IC through CR1 on erythrocytes. C4A isotype is responsible for effective binding to form amide bonds with immune aggregates or protein antigens, while C4B isotype catalyzes the transacylation of the thioester carbonyl group to form ester bonds with carbohydrate antigens.Derived from proteolytic degradation of complement C4, C4a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.", "gene-name": "C4B", "locus": null, "cellular-location": null, "transmembrane-regions": null, "signal-regions": null, "theoretical-pi": null, "molecular-weight": "192749.785", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "UniProtKB", "identifier": "P0C0L5"}, {"resource": "UniProt Accession", "identifier": "CO4B_HUMAN"}]}, "synonyms": null, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C4-B\nMRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQLQDVPRGQVVKGSVFLRN\nPSRNNVPCSPKVDFTLSSERDFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLKDS\nLSRTTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRVFALDQKMRPSTDTITVMVEN\nSHGLRVRKKEVYMPSSIFQDDFVIPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPN\nFEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVRFGLLDEDGKKTFFRGLE\nSQTKLVNGQSHISLSKAEFQDALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAELTSW\nYFVSSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASGIPVKVSATVSSPGSVPEVQD\nIQQNTDGSGQVSIPIIIPQTISELQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPDS\nRPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPKRTLTSVSVFVDHHLAPS\nFYFVAFYYHGDHPVANSLRVDVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVA\nLGALDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGGDSALQVFQAAGLAFSDGDQW\nTLSRKRLSCPKEKTTRKKRNVNFQKAINEKLGQYASPTAKRCCQDGVTRLPMMRSCEQRA\nARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQEEDLIDEDDIPVRSFFPE\nNWLWRVETVDRFQILTLWLPDSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLP\nMSVRRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGGGGLAQQVLVPAGSARPVAFS\nVVPTAATAVSLKVVARGSFEFPVGDAVSKVLQIEKEGAIHREELVYELNPLDHRGRTLEI\nPGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASLLRLPRGCGEQTMIYLAP\nTLAASRYLDKTEQWSTLPPETKDHAVDLIQKGYMRIQQFRKADGSYAAWLSRGSSTWLTA\nFVLKVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQDLSPVIHRSMQGGLVGNDETVA\nLTAFVTIALHHGLAVFQDEGAEPLKQRVEASISKASSFLGEKASAGLLGAHAAAITAYAL\nTLTKAPADLRGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSPTPAPRNPSDPMPQAPAL\nWIETTAYALLHLLLHEGKAEMADQAAAWLTRQGSFQGGFRSTQDTVIALDALSAYWIASH\nTTEERGLNVTLSSTGRNGFKSHALQLNNRQIRGLEEELQFSLGSKINVKVGGNSKGTLKV\nLRTYNVLDMKNTTCQDLQIEVTVKGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTP\nLQLFEGRRNRRRREAPKVVEEQESRVHYTVCIWRNGKVGLSGMAIADVTLLSGFHALRAD\nLEKLTSLSDRYVSHFETEGPHVLLYFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYY\nNPERRCSVFYGAPSKSRLLATLCSAEVCQCAEGKCPRQRRALERGLQDEDGYRMKFACYY\nPRVEYGFQVKVLREDSRAAFRLFETKITQVLHFTKDVKAAANQMRNFLVRASCRLRLEPG\nKEYLIMGLDGATYDLEGHPQYLLDSNSWIEEMPSERLCRSTRQRAACAQLNDFLQEYGTQ\nGCQV"}, "gene-sequence": {"@format": "FASTA"}, "pfams": null, "go-classifiers": null}}, {"@position": "12", "id": "BE0000855", "name": "Complement C5", "organism": "Human", "actions": {"action": "binder"}, "references": "# Baerenwaldt A, Biburger M, Nimmerjahn F: Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 May;6(3):425-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20441428\n# Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007 May;27(3):233-45. Epub 2007 Mar 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17351760\n# Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV: Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007 Sep;1110:497-506. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17911465", "known-action": "yes", "polypeptide": {"@id": "P01031", "@source": "Swiss-Prot", "name": "Complement C5", "general-function": "Involved in endopeptidase inhibitor activity", "specific-function": "Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes. C5a also stimulates the locomotion of polymorphonuclear leukocytes (chemokinesis) and direct their migration toward sites of inflammation (chemotaxis)", "gene-name": "C5", "locus": "9q33-q34", "cellular-location": null, "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.49", "molecular-weight": "188333.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1331"}, {"resource": "GenAtlas", "identifier": "C5"}, {"resource": "GeneCards", "identifier": "C5"}, {"resource": "GenBank Gene Database", "identifier": "M57729"}, {"resource": "GenBank Protein Database", "identifier": "179983"}, {"resource": "UniProtKB", "identifier": "P01031"}, {"resource": "UniProt Accession", "identifier": "CO5_HUMAN"}]}, "synonyms": {"synonym": "Complement C5 precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C5 precursor [Contains: Complement C5 beta chain; Complement C5 alpha chain; C5a anaphylatoxin; Complement C5 alpha' chain]\nMGLLGILCFLIFLGKTWGQEQTYVISAPKIFRVGASENIVIQVYGYTEAFDATISIKSYP\nDKKFSYSSGHVHLSSENKFQNSAILTIQPKQLPGGQNPVSYVYLEVVSKHFSKSKRMPIT\nYDNGFLFIHTDKPVYTPDQSVKVRVYSLNDDLKPAKRETVLTFIDPEGSEVDMVEEIDHI\nGIISFPDFKIPSNPRYGMWTIKAKYKEDFSTTGTAYFEVKEYVLPHFSVSIEPEYNFIGY\nKNFKNFEITIKARYFYNKVVTEADVYITFGIREDLKDDQKEMMQTAMQNTMLINGIAQVT\nFDSETAVKELSYYSLEDLNNKYLYIAVTVIESTGGFSEEAEIPGIKYVLSPYKLNLVATP\nLFLKPGIPYPIKVQVKDSLDQLVGGVPVILNAQTIDVNQETSDLDPSKSVTRVDDGVASF\nVLNLPSGVTVLEFNVKTDAPDLPEENQAREGYRAIAYSSLSQSYLYIDWTDNHKALLVGE\nHLNIIVTPKSPYIDKITHYNYLILSKGKIIHFGTREKFSDASYQSINIPVTQNMVPSSRL\nLVYYIVTGEQTAELVSDSVWLNIEEKCGNQLQVHLSPDADAYSPGQTVSLNMATGMDSWV\nALAAVDSAVYGVQRGAKKPLERVFQFLEKSDLGCGAGGGLNNANVFHLAGLTFLTNANAD\nDSQENDEPCKEILRPRRTLQKKIEEIAAKYKHSVVKKCCYDGACVNNDETCEQRAARISL\nGPRCIKAFTECCVVASQLRANISHKDMQLGRLHMKTLLPVSKPEIRSYFPESWLWEVHLV\nPRRKQLQFALPDSLTTWEIQGIGISNTGICVADTVKAKVFKDVFLEMNIPYSVVRGEQIQ\nLKGTVYNYRTSGMQFCVKMSAVEGICTSESPVIDHQGTKSSKCVRQKVEGSSSHLVTFTV\nLPLEIGLHNINFSLETWFGKEILVKTLRVVPEGVKRESYSGVTLDPRGIYGTISRRKEFP\nYRIPLDLVPKTEIKRILSVKGLLVGEILSAVLSQEGINILTHLPKGSAEAELMSVVPVFY\nVFHYLETGNHWNIFHSDPLIEKQKLKKKLKEGMLSIMSYRNADYSYSVWKGGSASTWLTA\nFALRVLGQVNKYVEQNQNSICNSLLWLVENYQLDNGSFKENSQYQPIKLQGTLPVEAREN\nSLYLTAFTVIGIRKAFDICPLVKIDTALIKADNFLLENTLPAQSTFTLAISAYALSLGDK\nTHPQFRSIVSALKREALVKGNPPIYRFWKDNLQHKDSSVPNTGTARMVETTAYALLTSLN\nLKDINYVNPVIKWLSEEQRYGGGFYSTQDTINAIEGLTEYSLLVKQLRLSMDIDVSYKHK\nGALHNYKMTDKNFLGRPVEVLLNDDLIVSTGFGSGLATVHVTTVVHKTSTSEEVCSFYLK\nIDTQDIEASHYRGYGNSDYKRIVACASYKPSREESSSGSSHAVMDISLPTGISANEEDLK\nALVEGVDQLFTDYQIKDGHVILQLNSIPSSDFLCVRFRIFELFEVGFLSPATFTVYEYHR\nPDKQCTMFYSTSNIKIQKVCEGAACKCVEADCGQMQEELDLTISAETRKQTACKPEIAYA\nYKVSITSITVENVFVKYKATLLDIYKTGEAVAEKDSEITFIKKVTCTNAELVKGRQYLIM\nGKEALQIKYNFSFRYIYPLDSLTWIEYWPRDTTCSSCQAFLANLDEFAEDIFLNGC"}, "gene-sequence": {"@format": "FASTA", "#text": ">5031 bp\nATGGGCCTTTTGGGAATACTTTGTTTTTTAATCTTCCTGGGGAAAACCTGGGGACAGGAG\nCAAACATATGTCATTTCAGCACCAAAAATATTCCGTGTTGGAGCATCTGAAAATATTGTG\nATTCAAGTTTATGGATACACTGAAGCATTTGATGCAACAATCTCTATTAAAAGTTATCCT\nGATAAAAAATTTAGTTACTCCTCAGGCCATGTTCATTTATCCTCAGAGAATAAATTCCAA\nAACTCTGCAATCTTAACAATACAACCAAAACAATTGCCTGGAGGACAAAACCCAGTTTCT\nTATGTGTATTTGGAAGTTGTATCAAAGCATTTTTCAAAATCAAAAAGAATGCCAATAACC\nTATGACAATGGATTTCTCTTCATTCATACAGACAAACCTGTTTATACTCCAGACCAGTCA\nGTAAAAGTTAGAGTTTATTCGTTGAATGACGACTTGAAGCCAGCCAAAAGAGAAACTGTC\nTTAACCTTCATAGATCCTGAAGGATCAGAAGTTGACATGGTAGAAGAAATTGATCATATT\nGGAATTATCTCTTTTCCTGACTTCAAGATTCCGTCTAATCCTAGATATGGTATGTGGACG\nATCAAGGCTAAATATAAAGAGGACTTTTCAACAACTGGAACCGCATATTTTGAAGTTAAA\nGAATATGTCTTGCCACATTTTTCTGTCTCAATCGAGCCAGAATATAATTTCATTGGTTAC\nAAGAACTTTAAGAATTTTGAAATTACTATAAAAGCAAGATATTTTTATAATAAAGTAGTC\nACTGAGGCTGACGTTTATATCACATTTGGAATAAGAGAAGACTTAAAAGATGATCAAAAA\nGAAATGATGCAAACAGCAATGCAAAACACAATGTTGATAAATGGAATTGCTCAAGTCACA\nTTTGATTCTGAAACAGCAGTCAAAGAACTGTCATACTACAGTTTAGAAGATTTAAACAAC\nAAGTACCTTTATATTGCTGTAACAGTCATAGAGTCTACAGGTGGATTTTCTGAAGAGGCA\nGAAATACCTGGCATCAAATATGTCCTCTCTCCCTACAAACTGAATTTGGTTGCTACTCCT\nCTTTTCCTGAAGCCTGGGATTCCATATCCCATCAAGGTGCAGGTTAAAGATTCGCTTGAC\nCAGTTGGTAGGAGGAGTCCCAGTAATACTGAATGCACAAACAATTGATGTAAACCAAGAG\nACATCTGACTTGGATCCAAGCAAAAGTGTAACACGTGTTGATGATGGAGTAGCTTCCTTT\nGTGCTTAATCTCCCATCTGGAGTGACGGTGCTGGAGTTTAATGTCAAAACTGATGCTCCA\nGATCTTCCAGAAGAAAATCAGGCCAGGGAAGGTTACCGAGCAATAGCATACTCATCTCTC\nAGCCAAAGTTACCTTTATATTGATTGGACTGATAACCATAAGGCTTTGCTAGTGGGAGAA\nCATCTGAATATTATTGTTACCCCCAAAAGCCCATATATTGACAAAATAACTCACTATAAT\nTACTTGATTTTATCCAAGGGCAAAATTATCCATTTTGGCACGAGGGAGAAATTTTCAGAT\nGCATCTTATCAAAGTATAAACATTCCAGTAACACAGAACATGGTTCCTTCATCCCGACTT\nCTGGTCTATTATATCGTCACAGGAGAACAGACAGCAGAATTAGTGTCTGATTCAGTCTGG\nTTAAATATTGAAGAAAAATGTGGCAACCAGCTCCAGGTTCATCTGTCTCCTGATGCAGAT\nGCATATTCTCCAGGCCAAACTGTGTCTCTTAATATGGCAACTGGAATGGATTCCTGGGTG\nGCATTAGCAGCAGTGGACAGTGCTGTGTATGGAGTCCAAAGAGGAGCCAAAAAGCCCTTG\nGAAAGAGTATTTCAATTCTTAGAGAAGAGTGATCTGGGCTGTGGGGCAGGTGGTGGCCTC\nAACAATGCCAATGTGTTCCACCTAGCTGGACTTACCTTCCTCACTAATGCAAATGCAGAT\nGACTCCCAAGAAAATGATGAACCTTGTAAAGAAATTCTCAGGCCAAGAAGAACGCTGCAA\nAAGAAGATAGAAGAAATAGCTGCTAAATATAAACATTCAGTAGTGAAGAAATGTTGTTAC\nGATGGAGCCTGCGTTAATAATGATGAAACCTGTGAGCAGCGAGCTGCACGGATTAGTTTA\nGGGCCAAGATGCATCAAAGCTTTCACTGAATGTTGTGTCGTCGCAAGCCAGCTCCGTGCT\nAATATCTCTCATAAAGACATGCAATTGGGAAGGCTACACATGAAGACCCTGTTACCAGTA\nAGCAAGCCAGAAATTCGGAGTTATTTTCCAGAAAGCTGGTTGTGGGAAGTTCATCTTGTT\nCCCAGAAGAAAACAGTTGCAGTTTGCCCTACCTGATTCTCTAACCACCTGGGAAATTCAA\nGGCATTGGCATTTCAAACACTGGTATATGTGTTGCTGATACTGTCAAGGCAAAGGTGTTC\nAAAGATGTCTTCCTGGAAATGAATATACCATATTCTGTTGTACGAGGAGAACAGATCCAA\nTTGAAAGGAACTGTTTACAACTATAGGACTTCTGGGATGCAGTTCTGTGTTAAAATGTCT\nGCTGTGGAGGGAATCTGCACTTCGGAAAGCCCAGTCATTGATCATCAGGGCACAAAGTCC\nTCCAAATGTGTGCGCCAGAAAGTAGAGGGCTCCTCCAGTCACTTGGTGACATTCACTGTG\nCTTCCTCTGGAAATTGGCCTTCACAACATCAATTTTTCACTGGAGACTTGGTTTGGAAAA\nGAAATCTTAGTAAAAACATTACGAGTGGTGCCAGAAGGTGTCAAAAGGGAAAGCTATTCT\nGGTGTTACTTTGGATCCTAGGGGTATTTATGGTACCATTAGCAGACGAAAGGAGTTCCCA\nTACAGGATACCCTTAGATTTGGTCCCCAAAACAGAAATCAAAAGGATTTTGAGTGTAAAA\nGGACTGCTTGTAGGTGAGATCTTGTCTGCAGTTCTAAGTCAGGAAGGCATCAATATCCTA\nACCCACCTCCCCAAAGGGAGTGCAGAGGCGGAGCTGATGAGCGTTGTCCCAGTATTCTAT\nGTTTTTCACTACCTGGAAACAGGAAATCATTGGAACATTTTTCATTCTGACCCATTAATT\nGAAAAGCAGAAACTGAAGAAAAAATTAAAAGAAGGGATGTTGAGCATTATGTCCTACAGA\nAATGCTGACTACTCTTACAGTGTGTGGAAGGGTGGAAGTGCTAGCACTTGGTTAACAGCT\nTTTGCTTTAAGAGTACTTGGACAAGTAAATAAATACGTAGAGCAGAACCAAAATTCAATT\nTGTAATTCTTTATTGTGGCTAGTTGAGAATTATCAATTAGATAATGGATCTTTCAAGGAA\nAATTCACAGTATCAACCAATAAAATTACAGGGTACCTTGCCTGTTGAAGCCCGAGAGAAC\nAGCTTATATCTTACAGCCTTTACTGTGATTGGAATTAGAAAGGCTTTCGATATATGCCCC\nCTGGTGAAAATCGACACAGCTCTAATTAAAGCTGACAACTTTCTGCTTGAAAATACACTG\nCCAGCCCAGAGCACCTTTACATTGGCCATTTCTGCGTATGCTCTTTCCCTGGGAGATAAA\nACTCACCCACAGTTTCGTTCAATTGTTTCAGCTTTGAAGAGAGAAGCTTTGGTTAAAGGT\nAATCCACCCATTTATCGTTTTTGGAAAGACAATCTTCAGCATAAAGACAGCTCTGTACCT\nAACACTGGTACGGCACGTATGGTAGAAACAACTGCCTATGCTTTACTCACCAGTCTGAAC\nTTGAAAGATATAAATTATGTTAACCCAGTCATCAAATGGCTATCAGAAGAGCAGAGGTAT\nGGAGGTGGCTTTTATTCAACCCAGGACACCATCAATGCCATTGAGGGCCTGACGGAATAT\nTCACTCCTGGTTAAACAACTCCGCTTGAGTATGGACATCGATGTTTCTTACAAGCATAAA\nGGTGCCTTACATAATTATAAAATGACAGACAAGAATTTCCTTGGGAGGCCAGTAGAGGTG\nCTTCTCAATGATGACCTCATTGTCAGTACAGGATTTGGCAGTGGCTTGGCTACAGTACAT\nGTAACAACTGTAGTTCACAAAACCAGTACCTCTGAGGAAGTTTGCAGCTTTTATTTGAAA\nATCGATACTCAGGATATTGAAGCATCCCACTACAGAGGCTACGGAAACTCTGATTACAAA\nCGCATAGTAGCATGTGCCAGCTACAAGCCCAGCAGGGAAGAATCATCATCTGGATCCTCT\nCATGCGGTGATGGACATCTCCTTGCCTACTGGAATCAGTGCAAATGAAGAAGACTTAAAA\nGCCCTTGTGGAAGGGGTGGATCAACTATTCACTGATTACCAAATCAAAGATGGACATGTT\nATTCTGCAACTGAATTCGATTCCCTCCAGTGATTTCCTTTGTGTACGATTCCGGATATTT\nGAACTCTTTGAAGTTGGGTTTCTCAGTCCTGCCACTTTCACAGTTTACGAATACCACAGA\nCCAGATAAACAGTGTACCATGTTTTATAGCACTTCCAATATCAAAATTCAGAAAGTCTGT\nGAAGGAGCCGCGTGCAAGTGTGTAGAAGCTGATTGTGGGCAAATGCAGGAAGAATTGGAT\nCTGACAATCTCTGCAGAGACAAGAAAACAAACAGCATGTAAACCAGAGATTGCATATGCT\nTATAAAGTTAGCATCACATCCATCACTGTAGAAAATGTTTTTGTCAAGTACAAGGCAACC\nCTTCTGGATATCTACAAAACTGGGGAAGCTGTTGCTGAGAAAGACTCTGAGATTACCTTC\nATTAAAAAGGTAACCTGTACTAACGCTGAGCTGGTAAAAGGAAGACAGTACTTAATTATG\nGGTAAAGAAGCCCTCCAGATAAAATACAATTTCAGTTTCAGGTACATCTACCCTTTAGAT\nTCCTTGACCTGGATTGAATACTGGCCTAGAGACACAACATGTTCATCGTGTCAAGCATTT\nTTAGCTAATTTAGATGAATTTGCCGAAGATATCTTTTTAAATGGATGCTAA"}, "pfams": {"pfam": [{"identifier": "PF00207", "name": "A2M"}, {"identifier": "PF07678", "name": "A2M_comp"}, {"identifier": "PF01835", "name": "A2M_N"}, {"identifier": "PF07703", "name": "A2M_N_2"}, {"identifier": "PF07677", "name": "A2M_recep"}, {"identifier": "PF01821", "name": "ANATO"}, {"identifier": "PF01759", "name": "NTR"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase inhibitor activity"}, {"category": "function", "description": "enzyme regulator activity"}, {"category": "function", "description": "enzyme inhibitor activity"}, {"category": "function", "description": "protease inhibitor activity"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "inflammatory response"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "immune response"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2010-09-29", "drugbank-id": [{"@primary": "true", "#text": "DB00029"}, "BIOD00102", "BTD00102"], "name": "Anistreplase", "description": "Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl group is chemically conjugated to a complex of bacterial-derived streptokinase and human Plasma-derived Lys-plasminogen proteins.", "cas-number": "81669-57-0", "groups": {"group": "approved"}, "general-references": null, "synthesis-reference": null, "indication": "For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction", "pharmacodynamics": "Anistreplase cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.", "mechanism-of-action": "Anistreplase cleaves the Arg/Val bond in plasminogen to form plasmin. This in turn leads to the degradation of blood clots.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "t- PA"}, {"@language": "", "@coder": "", "#text": "t-plasminogen activator"}, {"@language": "", "@coder": "", "#text": "Tissue-type plasminogen activator precursor"}, {"@language": "", "@coder": "", "#text": "tPA"}]}, "products": {"product": {"name": "Eminase 30 Units", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02229390", "started-marketing-on": "1997-12-15", "ended-marketing-on": "2009-02-23", "dosage-form": "powder for solution", "strength": "30 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}}, "international-brands": {"international-brand": {"name": "Eminase", "company": "Wulfing Pharma GmbH"}}, "mixtures": {"mixture": {"name": "Eminase 30 Units", "ingredients": "Anistreplase"}}, "packagers": {"packager": {"name": "Haupt Pharma", "url": "http://haupt-pharma.de"}}, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Fibrinolytic Agents", "mesh-id": null}, {"category": "Thrombolytic Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": {"form": "Powder for solution", "route": "intravenous", "strength": "30 unit"}}, "atc-codes": {"atc-code": {"@code": "B01AD03", "level": [{"@code": "B", "#text": "BLOOD AND BLOOD FORMING ORGANS"}, {"@code": "B01", "#text": "ANTITHROMBOTIC AGENTS"}, {"@code": "B01A", "#text": "ANTITHROMBOTIC AGENTS"}, {"@code": "B01AD", "#text": "Enzymes"}]}}, "ahfs-codes": {"ahfs-code": "20:12.20"}, "patents": null, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00054", "name": "Abciximab", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01418", "name": "Acenocoumarol", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00945", "name": "Acetylsalicylic acid", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00233", "name": "Aminosalicylic Acid", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB00261", "name": "Anagrelide", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06605", "name": "Apixaban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06692", "name": "Aprotinin", "description": "Aprotinin may diminish the therapeutic effect of Thrombolytic Agents."}, {"drugbank-id": "DB00278", "name": "Argatroban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01294", "name": "Bismuth Subsalicylate", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB00006", "name": "Bivalirudin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06441", "name": "Cangrelor", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01166", "name": "Cilostazol", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00215", "name": "Citalopram", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00758", "name": "Clopidogrel", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06695", "name": "Dabigatran etexilate", "description": "May enhance the anticoagulant effect of Dabigatran etexilate."}, {"drugbank-id": "DB06779", "name": "Dalteparin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06754", "name": "Danaparoid", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06700", "name": "Desvenlafaxine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00586", "name": "Diclofenac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00861", "name": "Diflunisal", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01551", "name": "Dihydrocodeine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00975", "name": "Dipyridamole", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00476", "name": "Duloxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB09075", "name": "Edoxaban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01225", "name": "Enoxaparin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01240", "name": "Epoprostenol", "description": "May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents."}, {"drugbank-id": "DB00063", "name": "Eptifibatide", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01175", "name": "Escitalopram", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00749", "name": "Etodolac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00573", "name": "Fenoprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB08976", "name": "Floctafenine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00472", "name": "Fluoxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00712", "name": "Flurbiprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00176", "name": "Fluvoxamine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00569", "name": "Fondaparinux sodium", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01109", "name": "Heparin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01050", "name": "Ibuprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01088", "name": "Iloprost", "description": "May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents."}, {"drugbank-id": "DB00328", "name": "Indomethacin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01009", "name": "Ketoprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00465", "name": "Ketorolac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB08918", "name": "Levomilnacipran", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01397", "name": "Magnesium salicylate", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB00784", "name": "Mefenamic acid", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00814", "name": "Meloxicam", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB04896", "name": "Milnacipran", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00461", "name": "Nabumetone", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB08813", "name": "Nadroparin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00788", "name": "Naproxen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00991", "name": "Oxaprozin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00715", "name": "Paroxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00554", "name": "Piroxicam", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06209", "name": "Prasugrel", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06228", "name": "Rivaroxaban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01399", "name": "Salsalate", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB01104", "name": "Sertraline", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00605", "name": "Sulindac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01600", "name": "Tiaprofenic acid", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB08816", "name": "Ticagrelor", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00208", "name": "Ticlopidine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06822", "name": "Tinzaparin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00775", "name": "Tirofiban", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00500", "name": "Tolmetin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00374", "name": "Treprostinil", "description": "May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents."}, {"drugbank-id": "DB00285", "name": "Venlafaxine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06684", "name": "Vilazodone", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB09030", "name": "Vorapaxar", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB09068", "name": "Vortioxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00682", "name": "Warfarin", "description": "May enhance the anticoagulant effect of Anticoagulants."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00029 sequence\nSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGG\nTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSA\nLAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDC\nYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAK\nPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRS\nPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVH\nKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEAL\nSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGG\nPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "60 \u00b0C", "source": "Novokhatny, V.V. et al., J. Biol. Chem. 266:12994-123002 (1991)"}, {"kind": "Hydrophobicity", "value": "-0.516", "source": null}, {"kind": "Isoelectric Point", "value": "7.61", "source": null}, {"kind": "Molecular Weight", "value": "59042.3000", "source": null}, {"kind": "Molecular Formula", "value": "C2569H3928N746O781S40", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "1199"}, {"resource": "GenBank", "identifier": "L00153"}, {"resource": "PharmGKB", "identifier": "PA164769075"}, {"resource": "UniProtKB", "identifier": "P00750"}, {"resource": "Wikipedia", "identifier": "Anistreplase"}]}, "external-links": null, "pathways": {"pathway": {"smpdb-id": "SMP00281", "name": "Anistreplase Action Pathway", "drugs": {"drug": [{"drugbank-id": "DB00029", "name": "Anistreplase"}, {"drugbank-id": "DB01022", "name": "Phylloquinone"}, {"drugbank-id": "DB01373", "name": "Calcium"}]}, "enzymes": {"uniprot-id": ["P00747", "P00748", "P02452", "P03952", "P03951", "P00740", "P00451", "P00734", "P12259", "P00742", "P02671", "P02675", "P02679", "P00488", "P05160", "P00750", "P08709", "P13726", "Q9BQB6", "P38435"]}}}, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000211", "name": "Plasminogen", "organism": "Human", "actions": {"action": "activator"}, "references": "# Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18673235\n# Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19436656\n# Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17963464\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P00747", "@source": "Swiss-Prot", "name": "Plasminogen", "general-function": "Involved in plasmin activity", "specific-function": "Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo", "gene-name": "PLG", "locus": "6q26", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.25", "molecular-weight": "90569.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9071"}, {"resource": "GenAtlas", "identifier": "PLG"}, {"resource": "GeneCards", "identifier": "PLG"}, {"resource": "GenBank Gene Database", "identifier": "X05199"}, {"resource": "GenBank Protein Database", "identifier": "387026"}, {"resource": "UniProtKB", "identifier": "P00747"}, {"resource": "UniProt Accession", "identifier": "PLMN_HUMAN"}]}, "synonyms": {"synonym": ["EC 3.4.21.7", "Plasminogen precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Plasminogen precursor\nMEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT\nCRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN\nGITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE\nCEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE\nLRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS\nAQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE\nQLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG\nLTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED\nCMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG\nPWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT\nRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE\nPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ\nLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW\nGLGCARPNKPGVYVRVSRFVTWIEGVMRNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">2433 bp\nATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG\nCCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG\nCTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC\nTGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG\nAAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC\nTCAGAGTGCAAGACTGGGAATGGAAAGAATTACAGAGGGACGATGTCCAAAACAAAAAAT\nGGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT\nACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG\nGGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG\nTGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC\nATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT\nCCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG\nCTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGCGACATCCCC\nCGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT\nGAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT\nGCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTTCCCTGCAAAAATTTGGAT\nGAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC\nCAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA\nCAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT\nGATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT\nTGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC\nCTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA\nGACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT\nGTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAAATGTAGAGACTCCTTCCGAAGAAGAC\nTGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG\nCCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA\nAATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT\nCCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT\nGCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG\nGTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA\nAGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT\nGCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC\nCAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG\nCCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA\nGTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC\nATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG\nCTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA\nTCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT\nGGAGGGCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG\nGGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT\nACTTGGATTGAGGGAGTGATGAGAAATAATTAA"}, "pfams": {"pfam": [{"identifier": "PF00051", "name": "Kringle"}, {"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00024", "name": "PAN_1"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "plasmin activity"}, {"category": "function", "description": "binding"}, {"category": "process", "description": "hemostasis"}, {"category": "process", "description": "blood coagulation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "2", "id": "BE0000538", "name": "Fibrinogen alpha chain", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "yes", "polypeptide": {"@id": "P02671", "@source": "Swiss-Prot", "name": "Fibrinogen alpha chain", "general-function": "Carbohydrate transport and metabolism", "specific-function": "Fibrinogen has a double function:yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation", "gene-name": "FGA", "locus": "4q28", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.87", "molecular-weight": "94974.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3661"}, {"resource": "GenAtlas", "identifier": "FGA"}, {"resource": "GeneCards", "identifier": "FGA"}, {"resource": "GenBank Gene Database", "identifier": "AF361104"}, {"resource": "GenBank Protein Database", "identifier": "13591824"}, {"resource": "UniProtKB", "identifier": "P02671"}, {"resource": "UniProt Accession", "identifier": "FIBA_HUMAN"}]}, "synonyms": {"synonym": "Fibrinogen alpha chain precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Fibrinogen alpha chain precursor [Contains: Fibrinopeptide A]\nMFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW\nNYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA\nNNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC\nRGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQ\nLQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSS\nGPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTW\nNPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV\nSPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTK\nEVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEF\nVSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKS\nYKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFS\nVYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQR\nGSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSH\nNNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENG\nVVWVSFRGADYSLRAVRMKIRPLVTQ"}, "gene-sequence": {"@format": "FASTA", "#text": ">2601 bp\nATGTTTTCCATGAGGATCGTCTGCCTAGTTCTAAGTGTGGTGGGCACAGCATGGACTGCA\nGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTG\nGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGG\nAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGAT\nTTTACAAACAGAATAAATAAGCTCAAAAATTCACTATTTGAATATCAGAAGAACAATAAG\nGATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCGATTTTTCCTCAGCC\nAATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTGAAGTC\nCTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAGAAAAATGTTAGA\nGCTCAGTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGT\nCGAGGGTCATGCAGTAGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAG\nCAGAAGCAACTTGAACAGGTCATTGCCAAAGACTTACTTCCCTCTAGAGATAGGCAACAC\nTTACCACTGATAAAAATGAAACCAGTTCCAGACTTGGTTCCCGGAAATTTTAAGAGCCAG\nCTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCGCAGATGAGAATGGAG\nTTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAACCGGA\nTCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCT\nGGACCTGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACC\nTGGAAACCTGGGAGCTCTGGACCTGGAAGTACTGGAAGCTGGAACTCTGGGAGCTCTGGA\nACTGGAAGTACTGGAAACCAAAACCCTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGG\nAATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCACTGGACCTCTGAGAGCTCTGTATCT\nGGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCAGATAGCCCAGGCTCT\nGGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAAATGTA\nAGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAA\nGAGCTCAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCA\nTGCTCTAAAACCGTTACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAA\nGAAGTGGTGACCTCCGAAGATGGTTCTGACTGTCCCGAGGCAATGGATTTAGGCACATTG\nTCTGGCATAGGTACTCTGGATGGGTTCCGCCATAGGCACCCTGATGAAGCTGCCTTCTTC\nGACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCTATGTTAGGAGAGTTT\nGTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGGAATCC\nAGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGC\nAAACAATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGC\nTATAAAATGGCAGATGAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAG\nAGAGGCCATGCTAAATCTCGCCCTGTCAGAGACTGTGATGATGTCCTCCAAACACATCCT\nTCAGGTACCCAAAGTGGCATTTTCAATATCAAGCTACCGGGATCCAGTAAGATTTTTTCT\nGTTTATTGCGATCAAGAGACCAGTTTGGGAGGATGGCTTTTGATCCAGCAAAGAATGGAT\nGGATCACTGAATTTTAACCGGACCTGGCAAGACTACAAGAGAGGTTTCGGCAGCCTGAAT\nGACGAGGGGGAAGGAGAATTCTGGCTAGGCAATGACTACCTCCACTTACTAACCCAAAGG\nGGCTCTGTTCTTAGGGTTGAATTAGAGGACTGGGCTGGGAATGAAGCTTATGCAGAATAT\nCACTTCCGGGTAGGCTCTGAGGCTGAAGGCTATGCCCTCCAAGTCTCCTCCTATGAAGGC\nACTGCGGGTGATGCTCTGATTGAGGGTTCCGTAGAGGAAGGGGCAGAGTACACCTCTCAC\nAACAACATGCAGTTCAGCACCTTTGACAGGGATGCAGACCAGTGGGAAGAGAACTGTGCA\nGAAGTCTATGGGGGAGGCTGGTGGTATAATAACTGCCAAGCAGCCAATCTCAATGGAATC\nTACTACCCTGGGGGCTCCTATGACCCAAGGAATAACAGTCCTTATGAGATTGAGAATGGA\nGTGGTCTGGGTTTCCTTTAGAGGGGCAGATTATTCCCTCAGGGCTGTTCGCATGAAAATT\nAGGCCCCTTGTGACCCAATAG"}, "pfams": {"pfam": {"identifier": "PF00147", "name": "Fibrinogen_C"}}, "go-classifiers": null}}, {"@position": "3", "id": "BE0000717", "name": "Urokinase plasminogen activator surface receptor", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "Q03405", "@source": "Swiss-Prot", "name": "Urokinase plasminogen activator surface receptor", "general-function": "Involved in U-plasminogen activator receptor activity", "specific-function": "Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form", "gene-name": "PLAUR", "locus": "19q13", "cellular-location": "Isoform 1:Cell membrane; lipid-anchor; GPI- anchor. Isoform 2:Secreted protein (Probable)", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.64", "molecular-weight": "36978.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9053"}, {"resource": "GenAtlas", "identifier": "PLAUR"}, {"resource": "GeneCards", "identifier": "PLAUR"}, {"resource": "GenBank Gene Database", "identifier": "X51675"}, {"resource": "GenBank Protein Database", "identifier": "37605"}, {"resource": "UniProtKB", "identifier": "Q03405"}, {"resource": "UniProt Accession", "identifier": "UPAR_HUMAN"}]}, "synonyms": {"synonym": ["CD87 antigen", "Monocyte activation antigen Mo3", "U- PAR", "uPAR", "Urokinase plasminogen activator surface receptor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Urokinase plasminogen activator surface receptor precursor\nMGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEEL\nELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISC\nGSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNG\nFHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGP\nMNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDV\nQYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1008 bp\nATGGGTCACCCGCCGCTGCTGCCGCTGCTGCTGCTGCTCCACACCTGCGTCCCAGCCTCT\nTGGGGCCTGCGGTGCATGCAGTGTAAGACCAACGGGGATTGCCGTGTGGAAGAGTGCGCC\nCTGGGACAGGACCTCTGCAGGACCACGATCGTGCGCTTGTGGGAAGAAGGAGAAGAGCTG\nGAGCTGGTGGAGAAAAGCTGTACCCACTCAGAGAAGACCAACAGGACCCTGAGCTATCGG\nACTGGCTTGAAGATCACCAGCCTTACCGAGGTTGTGTGTGGGTTAGACTTGTGCAACCAG\nGGCAACTCTGGCCGGGCTGTCACCTATTCCCGAAGCCGTTACCTCGAATGCATTTCCTGT\nGGCTCATCAGACATGAGCTGTGAGAGGGGCCGGCACCAGAGCCTGCAGTGCCGCAGCCCT\nGAAGAACAGTGCCTGGATGTGGTGACCCACTGGATCCAGGAAGGTGAAGAAGGGCGTCCA\nAAGGATGACCGCCACCTCCGTGGCTGTGGCTACCTTCCCGGCTGCCCGGGCTCCAATGGT\nTTCCACAACAACGACACCTTCCACTTCCTGAAATGCTGCAACACCACCAAATGCAACGAG\nGGCCCAATCCTGGAGCTTGAAAATCTGCCGCAGAATGGCCGCCAGTGTTACAGCTGCAAG\nGGGAACAGCACCCATGGATGCTCCTCTGAAGAGACTTTCCTCATTGACTGCCGAGGCCCC\nATGAATCAATGTCTGGTAGCCACCGGCACTCACGAACCGAAAAACCAAAGCTATATGGTA\nAGAGGCTGTGCAACCGCCTCAATGTGCCAACATGCCCACCTGGGTGACGCCTTCAGCATG\nAACCACATTGATGTCTCCTGCTGTACTAAAAGTGGCTGTAACCACCCAGACCTGGATGTC\nCAGTACCGCAGTGGGGCTGCTCCTCAGCCTGGCCCTGCCCATCTCAGCCTCACCATCACC\nCTGCTAATGACTGCCAGACTGTGGGGAGGCACTCTCCTCTGGACCTAA"}, "pfams": {"pfam": {"identifier": "PF00021", "name": "UPAR_LY6"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "U-plasminogen activator receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}]}}}, {"@position": "4", "id": "BE0000240", "name": "Plasminogen activator inhibitor 1", "organism": "Human", "actions": null, "references": "# Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17963464", "known-action": "unknown", "polypeptide": {"@id": "P05121", "@source": "Swiss-Prot", "name": "Plasminogen activator inhibitor 1", "general-function": "Involved in serine-type endopeptidase inhibitor activity", "specific-function": "This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, and protein C. Its rapid interaction with TPA may function as a major control point in the regulation of fibrinolysis", "gene-name": "SERPINE1", "locus": "7q21.3-q22", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.22", "molecular-weight": "45061.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:8583"}, {"resource": "GenAtlas", "identifier": "SERPINE1"}, {"resource": "GeneCards", "identifier": "SERPINE1"}, {"resource": "GenBank Gene Database", "identifier": "X04429"}, {"resource": "GenBank Protein Database", "identifier": "35272"}, {"resource": "UniProtKB", "identifier": "P05121"}, {"resource": "UniProt Accession", "identifier": "PAI1_HUMAN"}]}, "synonyms": {"synonym": ["Endothelial plasminogen activator inhibitor", "PAI", "PAI-1", "Plasminogen activator inhibitor 1 precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Plasminogen activator inhibitor 1 precursor\nMQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY\nGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI\nFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV\nDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD\nGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK\nFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS\nSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP"}, "gene-sequence": {"@format": "FASTA", "#text": ">1209 bp\nATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA\nGGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG\nAGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT\nGGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG\nATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT\nCTGTACAAGGAGCTCATGGGGCCATGGAACAAGGACGAGATCAGCACCACAGACGCGATC\nTTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC\nCGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT\nGACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG\nGACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT\nCCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC\nTCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT\nGGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT\nGCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG\nCTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG\nTTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC\nATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC\nGCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA\nTCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC\nTTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG\nGAACCCTGA"}, "pfams": {"pfam": {"identifier": "PF00079", "name": "Serpin"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "protease inhibitor activity"}, {"category": "function", "description": "endopeptidase inhibitor activity"}, {"category": "function", "description": "serine-type endopeptidase inhibitor activity"}, {"category": "function", "description": "enzyme regulator activity"}, {"category": "function", "description": "enzyme inhibitor activity"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-06-27", "drugbank-id": [{"@primary": "true", "#text": "DB00030"}, "BIOD00105", "BTD00105", "DB01383"], "name": "Insulin Regular", "description": "Insulin regular is a 51 residue peptide hormone, composed of two amino acid chains covalently linked by disulfide bonds. The structure is identical to native human insulin. Recombinant insulin is synthesized by recombinant DNA techncology. Inserting the human insulin gene into the Escherichia coli bacteria or Saccharomyces cerevisiae produces insulin for human use.", "cas-number": "11061-68-0", "groups": {"group": ["approved", "experimental", "investigational"]}, "general-references": "# Herrmann BL, Kasser C, Keuthage W, Huptas M, Dette H, Klute A: Comparison of insulin aspart vs. regular human insulin with or without insulin detemir concerning adipozytokines and metabolic effects in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2013 Apr;121(4):210-3. doi: 10.1055/s-0033-1334905. Epub 2013 Mar 19. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/23512415", "synthesis-reference": "Humulin is synthesized in a special non-disease-producing laboratory strain of Escherichia coli bacteria that has been genetically altered to produce human insulin.", "indication": "Indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 1 and type 2 diabetes mellitus.", "pharmacodynamics": "Insulin regular is a short-acting insulin. When subcutaneously administered, the onset of action (as evidenced by a decrease in glucose level) occurs 30 minutes post-dose. Maximal effect occurs between 1.5 and 3.5 hours post-dose. The glucose-lowering effect occurs 8 hours post-dose. Compared to other rapid-acting insulin analogs, insulin regular has a slower onset of action and longer duration of action.", "mechanism-of-action": "The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.\nInsulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.", "toxicity": "Hypoglycemia is one of the most frequent adverse events experienced by insulin users.", "metabolism": "Insulin is predominantly cleared by metabolic degradation via a receptor-mediated process.", "absorption": "Insulin is generally well absorbed.", "half-life": null, "protein-binding": "5% protein bound", "route-of-elimination": null, "volume-of-distribution": "0.15 L/kg", "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": {"@language": "", "@coder": "", "#text": "Insulin human"}}, "products": {"product": [{"name": "Afrezza", "ndc-id": "0024-5874_f222a734-081c-4098-a973-a3274e29e7ac", "ndc-product-code": "0024-5874", "dpd-id": null, "started-marketing-on": "2014-07-11", "ended-marketing-on": null, "dosage-form": "powder, metered", "strength": "4 1", "route": "respiratory (inhalation)", "fda-application-number": "NDA022472", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humalog 70/30", "ndc-id": "54868-2746_3457b3b5-976d-4240-bfad-e448294ec9cb", "ndc-product-code": "54868-2746", "dpd-id": null, "started-marketing-on": "1994-12-28", "ended-marketing-on": null, "dosage-form": "injection, suspension", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA019717", "generic": "false", "over-the-counter": "true", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humulin 70/30", "ndc-id": "0002-8715_003856b7-9100-4b23-bedb-3045b2e6f405", "ndc-product-code": "0002-8715", "dpd-id": null, "started-marketing-on": "1989-06-26", "ended-marketing-on": null, "dosage-form": "injection, suspension", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA019717", "generic": "false", "over-the-counter": "true", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humulin 70/30", "ndc-id": "0002-8770_003856b7-9100-4b23-bedb-3045b2e6f405", "ndc-product-code": "0002-8770", "dpd-id": null, "started-marketing-on": "1999-02-01", "ended-marketing-on": "2015-10-31", "dosage-form": "injection, suspension", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA019717", "generic": "false", "over-the-counter": "true", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humulin 70/30", "ndc-id": "0002-8803_003856b7-9100-4b23-bedb-3045b2e6f405", "ndc-product-code": "0002-8803", "dpd-id": null, "started-marketing-on": "2013-11-07", "ended-marketing-on": null, "dosage-form": "injection, suspension", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA019717", "generic": "false", "over-the-counter": "true", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humulin 70/30 70/30", "ndc-id": "52125-415_4db2dc6a-a89e-497b-bc23-4f3d57e899f4", "ndc-product-code": "52125-415", "dpd-id": null, "started-marketing-on": "2013-06-12", "ended-marketing-on": null, "dosage-form": "injection, suspension", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA019717", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humulin 70/30 70/30", "ndc-id": "52125-415_b1b49436-6e5c-4b36-8982-989d622f35ed", "ndc-product-code": "52125-415", "dpd-id": null, "started-marketing-on": "2015-09-01", "ended-marketing-on": null, "dosage-form": "injection, suspension", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA019717", "generic": "false", "over-the-counter": "true", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humulin N", "ndc-id": "0002-8730_ea9b211f-abbc-4a62-867a-596a24a5b419", "ndc-product-code": "0002-8730", "dpd-id": null, "started-marketing-on": "1999-02-01", "ended-marketing-on": "2015-10-31", "dosage-form": "injection, suspension", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA018781", "generic": "false", "over-the-counter": "true", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humulin N", "ndc-id": "0002-8805_ea9b211f-abbc-4a62-867a-596a24a5b419", "ndc-product-code": "0002-8805", "dpd-id": null, "started-marketing-on": "2013-11-07", "ended-marketing-on": null, "dosage-form": "injection, suspension", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA018781", "generic": "false", "over-the-counter": "true", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humulin N", "ndc-id": "54868-1429_2232ce07-e218-4907-8f20-1e8fe3277dde", "ndc-product-code": "54868-1429", "dpd-id": null, "started-marketing-on": "1994-10-24", "ended-marketing-on": null, "dosage-form": "injection, suspension", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA018781", "generic": "false", "over-the-counter": "true", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humulin R", "ndc-id": "0002-8215_08827443-2aa4-4cd9-9657-64a52085fd83", "ndc-product-code": "0002-8215", "dpd-id": null, "started-marketing-on": "1983-06-27", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 [iU]/mL", "route": "parenteral", "fda-application-number": "NDA018780", "generic": "false", "over-the-counter": "true", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humulin R", "ndc-id": "54868-3619_5ace7bf4-ae3d-4cc5-b5b6-a171d26d82a2", "ndc-product-code": "54868-3619", "dpd-id": null, "started-marketing-on": "1995-07-27", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA018780", "generic": "false", "over-the-counter": "true", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humulin R U-500", "ndc-id": "0002-8501_56852e9d-9832-4a7e-a19f-7ae855017bd6", "ndc-product-code": "0002-8501", "dpd-id": null, "started-marketing-on": "1997-01-06", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "500 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA018780", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Novolin 70/30", "ndc-id": "0169-1837_6748f022-4f9d-42ea-9f82-e39abad34324", "ndc-product-code": "0169-1837", "dpd-id": null, "started-marketing-on": "1991-06-25", "ended-marketing-on": null, "dosage-form": "injection, suspension", "strength": "100 [USP'U]/mL", "route": "subcutaneous", "fda-application-number": "NDA019991", "generic": "false", "over-the-counter": "true", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Novolin 70/30", "ndc-id": "54569-2918_8e7cb87c-79c5-46d0-88b7-5ccb6b66dd87", "ndc-product-code": "54569-2918", "dpd-id": null, "started-marketing-on": "1991-06-25", "ended-marketing-on": null, "dosage-form": "injection, suspension", "strength": "100 [USP'U]/mL", "route": "subcutaneous", "fda-application-number": "NDA019991", "generic": "false", "over-the-counter": "true", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Novolin 70/30", "ndc-id": "54868-3474_f8f7bdaf-47bb-43bc-8696-a6b844e21933", "ndc-product-code": "54868-3474", "dpd-id": null, "started-marketing-on": "1995-01-11", "ended-marketing-on": null, "dosage-form": "injection, suspension", "strength": "100 [USP'U]/mL", "route": "subcutaneous", "fda-application-number": "NDA019991", "generic": "false", "over-the-counter": "true", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Novolin 70/30", "ndc-id": "64725-1837_05dc7def-3137-4c5c-8d43-2baf9d7888df", "ndc-product-code": "64725-1837", "dpd-id": null, "started-marketing-on": "1991-06-25", "ended-marketing-on": null, "dosage-form": "injection, suspension", "strength": "100 [USP'U]/mL", "route": "subcutaneous", "fda-application-number": "NDA019991", "generic": "false", "over-the-counter": "true", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Novolin N", "ndc-id": "0169-1834_5ddfd50a-7a65-4658-85d6-500ae7aae946", "ndc-product-code": "0169-1834", "dpd-id": null, "started-marketing-on": "1991-07-01", "ended-marketing-on": null, "dosage-form": "injection, suspension", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA019959", "generic": "false", "over-the-counter": "true", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Novolin N", "ndc-id": "64725-1834_88240c8b-10c5-43b4-8a36-020380cea930", "ndc-product-code": "64725-1834", "dpd-id": null, "started-marketing-on": "1991-07-01", "ended-marketing-on": null, "dosage-form": "injection, suspension", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA019959", "generic": "false", "over-the-counter": "true", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Novolin R", "ndc-id": "0169-1833_6ede8238-f902-478d-8cee-997855045083", "ndc-product-code": "0169-1833", "dpd-id": null, "started-marketing-on": "1991-06-25", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA019938", "generic": "false", "over-the-counter": "true", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Novolin R", "ndc-id": "64725-1833_a2c745d7-1b63-4064-b6a1-e18e43b318ad", "ndc-product-code": "64725-1833", "dpd-id": null, "started-marketing-on": "1991-06-25", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA019938", "generic": "false", "over-the-counter": "true", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Novolin70/30 70/30", "ndc-id": "52125-414_4c714861-6964-4ecf-bf7e-2f353c9226c2", "ndc-product-code": "52125-414", "dpd-id": null, "started-marketing-on": "2014-07-29", "ended-marketing-on": null, "dosage-form": "injection, suspension", "strength": "100 [USP'U]/mL", "route": "subcutaneous", "fda-application-number": "NDA019991", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Novolin70/30 70/30", "ndc-id": "52125-414_ea917f6b-3e25-4236-93ae-9376d5282b27", "ndc-product-code": "52125-414", "dpd-id": null, "started-marketing-on": "2013-06-13", "ended-marketing-on": null, "dosage-form": "injection, suspension", "strength": "100 [USP'U]/mL", "route": "subcutaneous", "fda-application-number": "NDA019991", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Humulin R", "ingredients": "Insulin Regular"}, {"name": "Humulin R U-500", "ingredients": "Insulin Regular"}, {"name": "Humulin 70/30", "ingredients": "Insulin Regular"}, {"name": "Humulin N", "ingredients": "Insulin Regular"}, {"name": "Humulin 70/30", "ingredients": "Insulin Regular"}, {"name": "Humulin 70/30", "ingredients": "Insulin Regular"}, {"name": "Humulin N", "ingredients": "Insulin Regular"}, {"name": "Afrezza", "ingredients": "Insulin Regular"}, {"name": "Novolin R", "ingredients": "Insulin Regular"}, {"name": "Novolin N", "ingredients": "Insulin Regular"}, {"name": "Novolin 70/30", "ingredients": "Insulin Regular"}, {"name": "Novolin70/30 70/30", "ingredients": "Insulin Regular"}, {"name": "Novolin70/30 70/30", "ingredients": "Insulin Regular"}, {"name": "Humulin 70/30 70/30", "ingredients": "Insulin Regular"}, {"name": "Humulin 70/30 70/30", "ingredients": "Insulin Regular"}, {"name": "Novolin 70/30", "ingredients": "Insulin Regular"}, {"name": "Humulin N", "ingredients": "Insulin Regular"}, {"name": "Humalog 70/30", "ingredients": "Insulin Regular"}, {"name": "Novolin 70/30", "ingredients": "Insulin Regular"}, {"name": "Humulin R", "ingredients": "Insulin Regular"}, {"name": "Novolin R", "ingredients": "Insulin Regular"}, {"name": "Novolin N", "ingredients": "Insulin Regular"}, {"name": "Novolin 70/30", "ingredients": "Insulin Regular"}]}, "packagers": {"packager": [{"name": "A-S Medication Solutions LLC", "url": "http://orders.a-smeds.com"}, {"name": "DispenseXpress Inc.", "url": null}, {"name": "Eli Lilly & Co.", "url": "http://www.lilly.com"}, {"name": "Hospira Inc.", "url": "http://www.hospira.com"}, {"name": "Intervet International", "url": "http://www.intervet.ca"}, {"name": "Novo Nordisk Inc.", "url": "http://www.novonordisk.com"}, {"name": "Pfizer Inc.", "url": "http://www.pfizer.com"}, {"name": "Physicians Total Care Inc.", "url": "http://www.physicianstotalcare.com"}]}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Novo nordisk inc"}}, "prices": {"price": [{"description": "Novolin Ge Nph 100 unit/ml", "cost": {"@currency": "USD", "#text": "2.14"}, "unit": "cartridge"}, {"description": "Novolin Ge Toronto 100 unit/ml", "cost": {"@currency": "USD", "#text": "2.14"}, "unit": "cartridge"}, {"description": "Humulin N 100 unit/ml", "cost": {"@currency": "USD", "#text": "2.29"}, "unit": "cartridge"}, {"description": "Humulin R 100 unit/ml", "cost": {"@currency": "USD", "#text": "2.29"}, "unit": "cartridge"}, {"description": "Novolin Ge Nph Penfill 100 unit/ml Cartridge", "cost": {"@currency": "USD", "#text": "2.78"}, "unit": "cartridge"}, {"description": "Novolin Ge Toronto Penfill 100 unit/ml Cartridge", "cost": {"@currency": "USD", "#text": "2.8"}, "unit": "cartridge"}, {"description": "Humulin N Cartridge 100 unit/ml Cartridge", "cost": {"@currency": "USD", "#text": "2.99"}, "unit": "cartridge"}, {"description": "Humulin R Cartridge 100 unit/ml Cartridge", "cost": {"@currency": "USD", "#text": "2.99"}, "unit": "cartridge"}, {"description": "NovoLIN R InnoLet 100 unit/ml Solution 3ml Cartridge", "cost": {"@currency": "USD", "#text": "24.17"}, "unit": "cartridge"}, {"description": "Novolin r 100 unit/ml cartridg", "cost": {"@currency": "USD", "#text": "33.33"}, "unit": "ml"}, {"description": "NovoLIN R 100 unit/ml Solution 10ml Vial", "cost": {"@currency": "USD", "#text": "73.19"}, "unit": "vial"}, {"description": "NovoLIN R PenFill 100 unit/ml Solution Five 3ml Cartridges Per Box = 15ml", "cost": {"@currency": "USD", "#text": "162.26"}, "unit": "cartridge"}]}, "categories": {"category": {"category": "Antidiabetic Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Powder, metered", "route": "respiratory (inhalation)", "strength": "4 1"}, {"form": "Injection, suspension", "route": "subcutaneous", "strength": "100 [iU]/mL"}, {"form": "Injection, solution", "route": "parenteral", "strength": "100 [iU]/mL"}, {"form": "Injection, solution", "route": "subcutaneous", "strength": "500 [iU]/mL"}, {"form": "Injection, suspension", "route": "subcutaneous", "strength": "100 [USP'U]/mL"}, {"form": "Injection, solution", "route": "subcutaneous", "strength": "100 [iU]/mL"}]}, "atc-codes": null, "ahfs-codes": {"ahfs-code": ["68:20.08", "92:02.00*"]}, "patents": null, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00414", "name": "Acetohexamide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00945", "name": "Acetylsalicylic acid", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB06203", "name": "Alogliptin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01238", "name": "Aripiprazole", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01169", "name": "Arsenic trioxide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB09009", "name": "Articaine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06216", "name": "Asenapine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01072", "name": "Atazanavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00436", "name": "Bendroflumethiazide", "description": "Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00443", "name": "Betamethasone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB09128", "name": "Brexpiprazole", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00887", "name": "Bumetanide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06719", "name": "Buserelin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB08907", "name": "Canagliflozin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB09063", "name": "Ceritinib", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00880", "name": "Chlorothiazide", "description": "Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00672", "name": "Chlorpropamide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00310", "name": "Chlorthalidone", "description": "Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00363", "name": "Clozapine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01285", "name": "Corticotropin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01380", "name": "Cortisone acetate", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB04839", "name": "Cyproterone acetate", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB08912", "name": "Dabrafenib", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01406", "name": "Danazol", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01264", "name": "Darunavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00304", "name": "Desogestrel", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01234", "name": "Dexamethasone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01119", "name": "Diazoxide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB09123", "name": "Dienogest", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB02901", "name": "Dihydrotestosterone", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00280", "name": "Disopyramide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01395", "name": "Drospirenone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00974", "name": "Edetic Acid", "description": "May enhance the hypoglycemic effect of Insulin."}, {"drugbank-id": "DB00974", "name": "Edetic Acid", "description": "May enhance the hypoglycemic effect of Insulin."}, {"drugbank-id": "DB00668", "name": "Epinephrine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00783", "name": "Estradiol", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB04574", "name": "Estropipate", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00903", "name": "Ethacrynic acid", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00977", "name": "Ethinyl Estradiol", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00823", "name": "Ethynodiol", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00294", "name": "Etonogestrel", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01590", "name": "Everolimus", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00687", "name": "Fludrocortisone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01319", "name": "Fosamprenavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00695", "name": "Furosemide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01120", "name": "Gliclazide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00222", "name": "Glimepiride", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01067", "name": "Glipizide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01251", "name": "Gliquidone", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01016", "name": "Glyburide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00014", "name": "Goserelin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06788", "name": "Histrelin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00999", "name": "Hydrochlorothiazide", "description": "Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00741", "name": "Hydrocortisone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06789", "name": "Hydroxyprogesterone caproate", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB04946", "name": "Iloperidone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00808", "name": "Indapamide", "description": "Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00224", "name": "Indinavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB05278", "name": "inhaled insulin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01306", "name": "Insulin Aspart", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01307", "name": "Insulin Detemir", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00047", "name": "Insulin Glargine", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01309", "name": "Insulin Glulisine", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00046", "name": "Insulin Lispro", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB08914", "name": "Insulin, isophane", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB06791", "name": "Lanreotide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00007", "name": "Leuprolide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00367", "name": "Levonorgestrel", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB08882", "name": "Linagliptin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00166", "name": "Lipoic Acid", "description": "May enhance the hypoglycemic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06655", "name": "Liraglutide", "description": "May enhance the hypoglycemic effect of Insulin."}, {"drugbank-id": "DB01601", "name": "Lopinavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB08815", "name": "Lurasidone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01277", "name": "Mecasermin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00603", "name": "Medroxyprogesterone Acetate", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00351", "name": "Megestrol acetate", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01357", "name": "Mestranol", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00331", "name": "Metformin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01403", "name": "Methotrimeprazine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00232", "name": "Methyclothiazide", "description": "Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00959", "name": "Methylprednisolone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00524", "name": "Metolazone", "description": "Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB09046", "name": "Metreleptin", "description": "May enhance the hypoglycemic effect of Insulin."}, {"drugbank-id": "DB00834", "name": "Mifepristone", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00731", "name": "Nateglinide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00220", "name": "Nelfinavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00627", "name": "Niacin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB04868", "name": "Nilotinib", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00717", "name": "Norethindrone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00957", "name": "Norgestimate", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00104", "name": "Octreotide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00334", "name": "Olanzapine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00621", "name": "Oxandrolone", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB01267", "name": "Paliperidone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06663", "name": "Pasireotide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00082", "name": "Pegvisomant", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00738", "name": "Pentamidine", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01132", "name": "Pioglitazone", "description": "May enhance the adverse/toxic effect of Insulin. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination."}, {"drugbank-id": "DB00592", "name": "Piperazine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01621", "name": "Pipotiazine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01278", "name": "Pramlintide", "description": "May enhance the hypoglycemic effect of Insulin."}, {"drugbank-id": "DB00860", "name": "Prednisolone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00635", "name": "Prednisone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00396", "name": "Progesterone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01224", "name": "Quetiapine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00468", "name": "Quinine", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00912", "name": "Repaglinide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00734", "name": "Risperidone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00503", "name": "Ritonavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00412", "name": "Rosiglitazone", "description": "Insulin may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination."}, {"drugbank-id": "DB01398", "name": "Salicylate-sodium", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB01232", "name": "Saquinavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06335", "name": "Saxagliptin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00877", "name": "Sirolimus", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00359", "name": "Sulfadiazine", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01015", "name": "Sulfamethoxazole", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00263", "name": "Sulfisoxazole", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01268", "name": "Sunitinib", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00864", "name": "Tacrolimus", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06287", "name": "Temsirolimus", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00624", "name": "Testosterone", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00932", "name": "Tipranavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00839", "name": "Tolazamide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01124", "name": "Tolbutamide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00214", "name": "Torasemide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00620", "name": "Triamcinolone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06825", "name": "Triptorelin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB04876", "name": "Vildagliptin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB02546", "name": "Vorinostat", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00246", "name": "Ziprasidone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}]}, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">A chain\nGIVEQCCTSICSLYQLENYCN"}, {"@format": "FASTA", "#text": ">B chain\nFVNQHLCGSHLVEALYLVCGERGFFYTPKT"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "81 \u00b0C", "source": "Khachidze, D.G. et al., J. Biol. Phys. Chem. 1:64-67 (2001)"}, {"kind": "Hydrophobicity", "value": "0.218", "source": null}, {"kind": "Isoelectric Point", "value": "5.39", "source": null}, {"kind": "Molecular Weight", "value": "5808 Daltons", "source": null}, {"kind": "Molecular Formula", "value": "C257H383N65O77S6", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "ChEBI", "identifier": "5931"}, {"resource": "KEGG Compound", "identifier": "C00723"}, {"resource": "KEGG Drug", "identifier": "D03230"}, {"resource": "National Drug Code Directory", "identifier": "0002-8215-01"}, {"resource": "GenBank", "identifier": "AY137503"}, {"resource": "PharmGKB", "identifier": "PA164744571"}, {"resource": "UniProtKB", "identifier": "Q8HXV2"}, {"resource": "Wikipedia", "identifier": "Insulin"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/novolog.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/pro/humulin-r.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000033", "name": "Insulin receptor", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Desbuquois B, Chauvet G, Kouach M, Authier F: Cell itinerary and metabolic fate of proinsulin in rat liver: in vivo and in vitro studies. Endocrinology. 2003 Dec;144(12):5308-21. Epub 2003 Sep 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12970169\n# Chen LM, Yang XW, Tang JG: Acidic residues on the N-terminus of proinsulin C-Peptide are important for the folding of insulin precursor. J Biochem (Tokyo). 2002 Jun;131(6):855-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12038982\n# Bell DS: Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised? Drugs. 2007;67(13):1813-27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17722952\n# Tanti JF, Jager J: Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr Opin Pharmacol. 2009 Dec;9(6):753-62. Epub 2009 Aug 13. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19683471\n# Chiu SL, Cline HT: Insulin receptor signaling in the development of neuronal structure and function. Neural Dev. 2010 Mar 15;5:7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20230616\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P06213", "@source": "Swiss-Prot", "name": "Insulin receptor", "general-function": "Involved in transmembrane receptor protein tyrosine kinase activity", "specific-function": "This receptor binds insulin and has a tyrosine-protein kinase activity. Isoform Short has a higher affinity for insulin. Mediates the metabolic functions of insulin. Binding to insulin stimulates association of the receptor with downstream mediators including IRS1 and phosphatidylinositol 3'-kinase (PI3K). Can activate PI3K either directly by binding to the p85 regulatory subunit, or indirectly via IRS1", "gene-name": "INSR", "locus": "19p13.3-p13.2", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "957-979", "signal-regions": null, "theoretical-pi": "6.18", "molecular-weight": "156308.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6091"}, {"resource": "GenAtlas", "identifier": "INSR"}, {"resource": "GeneCards", "identifier": "INSR"}, {"resource": "GenBank Gene Database", "identifier": "M10051"}, {"resource": "GenBank Protein Database", "identifier": "307070"}, {"resource": "UniProtKB", "identifier": "P06213"}, {"resource": "UniProt Accession", "identifier": "INSR_HUMAN"}]}, "synonyms": {"synonym": ["CD220 antigen", "EC 2.7.10.1", "Insulin receptor precursor", "IR"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Insulin receptor precursor\nMGTGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHL\nQILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYAL\nVIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNE\nECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECL\nGNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQG\nCHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGC\nTVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETL\nEIGNYSFYALDNQNLRQLWDWSKHNLTTTQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQE\nRNDIALKTNGDKASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQ\nNVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFS\nDERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWE\nRQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQIL\nKELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAF\nPNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYV\nSARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCV\nSRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIG\nPLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSR\nEKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKG\nFTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMA\nAEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPV\nRWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDN\nCPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEME\nFEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSN\nPS"}, "gene-sequence": {"@format": "FASTA", "#text": ">4149 bp\nATGGGCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCG\nCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATC\nCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTG\nCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAA\nCTCATCATGATCACTGATTACTTGCTGCTCTTCCGGGTCTATGGGCTCGAGAGCCTGAAG\nGACCTGTTCCCCAACCTCACGGTCATCCGGGGATCACGACTGTTCTTTAACTACGCGCTG\nGTCATCTTCGAGATGGTTCACCTCAAGGAACTCGGCCTCTACAACCTGATGAACATCACC\nCGGGGTTCTGTCCGCATCGAGAAGAACAATGAGCTCTGTTACTTGGCCACTATCGACTGG\nTCCCGTATCCTGGATTCCGTGGAGGATAATCACATCGTGTTGAACAAAGATGACAACGAG\nGAGTGTGGAGACATCTGTCCGGGTACCGCGAAGGGCAAGACCAACTGCCCCGCCACCGTC\nATCAACGGGCAGTTTGTCGAACGATGTTGGACTCATAGTCACTGCCAGAAAGTTTGCCCG\nACCATCTGTAAGTCACACGGCTGCACCGCCGAAGGCCTCTGTTGCCACAGCGAGTGCCTG\nGGCAACTGTTCTCAGCCCGACGACCCCACCAAGTGCGTGGCCTGCCGCAACTTCTACCTG\nGACGGCAGGTGTGTGGAGACCTGCCCGCCCCCGTACTACCACTTCCAGGACTGGCGCTGT\nGTGAACTTCAGCTTCTGCCAGGACCTGCACCACAAATGCAAGAACTCGCGGAGGCAGGGC\nTGCCACCAATACGTCATTCACAACAACAAGTGCATCCCTGAGTGTCCCTCCGGGTACACG\nATGAATTCCAGCAACTTGCTGTGCACCCCATGCCTGGGTCCCTGTCCCAAGGTGTGCCAC\nCTCCTAGAAGGCGAGAAGACCATCGACTCGGTGACGTCTGCCCAGGAGCTCCGAGGATGC\nACCGTCATCAACGGGAGTCTGATCATCAACATTCGAGGAGGCAACAATCTGGCAGCTGAG\nCTAGAAGCCAACCTCGGCCTCATTGAAGAAATTTCAGGGTATCTAAAAATCCGCCGATCC\nTACGCTCTGGTGTCACTTTCCTTCTTCCGGAAGTTACGTCTGATTCGAGGAGAGACCTTG\nGAAATTGGGAACTACTCCTTCTATGCCTTGGACAACCAGAACCTAAGGCAGCTCTGGGAC\nTGGAGCAAACACAACCTCACCACCACTCAGGGGAAACTCTTCTTCCACTATAACCCCAAA\nCTCTGCTTGTCAGAAATCCACAAGATGGAAGAAGTTTCAGGAACCAAGGGGCGCCAGGAG\nAGAAACGACATTGCCCTGAAGACCAATGGGGACAAGGCATCCTGTGAAAATGAGTTACTT\nAAATTTTCTTACATTCGGACATCTTTTGACAAGATCTTGCTGAGATGGGAGCCGTACTGG\nCCCCCCGACTTCCGAGACCTCTTGGGGTTCATGCTGTTCTACAAAGAGGCCCCTTATCAG\nAATGTGACGGAGTTCGATGGGCAGGATGCGTGTGGTTCCAACAGTTGGACGGTGGTAGAC\nATTGACCCACCCCTGAGGTCCAACGACCCCAAATCACAGAACCACCCAGGGTGGCTGATG\nCGGGGTCTCAAGCCCTGGACCCAGTATGCCATCTTTGTGAAGACCCTGGTCACCTTTTCG\nGATGAACGCCGGACCTATGGGGCCAAGAGTGACATCATTTATGTCCAGACAGATGCCACC\nAACCCCTCTGTGCCCCTGGATCCAATCTCAGTGTCTAACTCATCATCCCAGATTATTCTG\nAAGTGGAAACCACCCTCCGACCCCAATGGCAACATCACCCACTACCTGGTTTTCTGGGAG\nAGGCAGGCGGAAGACAGTGAGCTGTTCGAGCTGGATTATTGCCTCAAAGGGCTGAAGCTG\nCCCTCGAGGACCTGGTCTCCACCATTCGAGTCTGAAGATTCTCAGAAGCACAACCAGAGT\nGAGTATGAGGATTCGGCCGGCGAATGCTGCTCCTGTCCAAAGACAGACTCTCAGATCCTG\nAAGGAGCTGGAGGAGTCCTCGTTTAGGAAGACGTTTGAGGATTACCTGCACAACGTGGTT\nTTCGTCCCCAGAAAAACCTCTTCAGGCACTGGTGCCGAGGACCCTAGGCCATCTCGGAAA\nCGCAGGTCCCTTGGCGATGTTGGGAATGTGACGGTGGCCGTGCCCACGGTGGCAGCTTTC\nCCCAACACTTCCTCGACCAGCGTGCCCACGAGTCCGGAGGAGCACAGGCCTTTTGAGAAG\nGTGGTGAACAAGGAGTCGCTGGTCATCTCCGGCTTGCGACACTTCACGGGCTATCGCATC\nGAGCTGCAGGCTTGCAACCAGGACACCCCTGAGGAACGGTGCAGTGTGGCAGCCTACGTC\nAGTGCGAGGACCATGCCTGAAGCCAAGGCTGATGACATTGTTGGCCCTGTGACGCATGAA\nATCTTTGAGAACAACGTCGTCCACTTGATGTGGCAGGAGCCGAAGGAGCCCAATGGTCTG\nATCGTGCTGTATGAAGTGAGTTATCGGCGATATGGTGATGAGGAGCTGCATCTCTGCGTC\nTCCCGCAAGCACTTCGCTCTGGAACGGGGCTGCAGGCTGCGTGGGCTGTCACCGGGGAAC\nTACAGCGTGCGAATCCGGGCCACCTCCCTTGCGGGCAACGGCTCTTGGACGGAACCCACC\nTATTTCTACGTGACAGACTATTTAGACGTCCCGTCAAATATTGCAAAAATTATCATCGGC\nCCCCTCATCTTTGTCTTTCTCTTCAGTGTTGTGATTGGAAGTATTTATCTATTCCTGAGA\nAAGAGGCAGCCAGATGGGCCGCTGGGACCGCTTTACGCTTCTTCAAACCCTGAGTATCTC\nAGTGCCAGTGATGTGTTTCCATGCTCTGTGTACGTGCCGGACGAGTGGGAGGTGTCTCGA\nGAGAAGATCACCCTCCTTCGAGAGCTGGGGCAGGGCTCCTTCGGCATGGTGTATGAGGGC\nAATGCCAGGGACATCATCAAGGGTGAGGCAGAGACCCGCGTGGCGGTGAAGACGGTCAAC\nGAGTCAGCCAGTCTCCGAGAGCGGATTGAGTTCCTCAATGAGGCCTCGGTCATGAAGGGC\nTTCACCTGCCATCACGTGGTGCGCCTCCTGGGAGTGGTGTCCAAGGGCCAGCCCACGCTG\nGTGGTGATGGAGCTGATGGCTCACGGAGACCTGAAGAGCTACCTCCGTTCTCTGCGGCCA\nGAGGCTGAGAATAATCCTGGCCGCCCTCCCCCTACCCTTCAAGAGATGATTCAGATGGCG\nGCAGAGATTGCTGACGGGATGGCCTACCTGAACGCCAAGAAGTTTGTGCATCGGGACCTG\nGCAGCGAGAAACTGCATGGTCGCCCATGATTTTACTGTCAAAATTGGAGACTTTGGAATG\nACCAGAGACATCTATGAAACGGATTACTACCGGAAAGGGGGCAAGGGTCTGCTCCCTGTA\nCGGTGGATGGCACCGGAGTCCCTGAAGGATGGGGTCTTCACCACTTCTTCTGACATGTGG\nTCCTTTGGCGTGGTCCTTTGGGAAATCACCAGCTTGGCAGAACAGCCTTACCAAGGCCTG\nTCTAATGAACAGGTGTTGAAATTTGTCATGGATGGAGGGTATCTGGATCAACCCGACAAC\nTGTCCAGAGAGAGTCACTGACCTCATGCGCATGTGCTGGCAATTCAACCCCAAGATGAGG\nCCAACCTTCCTGGAGATTGTCAACCTGCTCAAGGACGACCTGCACCCCAGCTTTCCAGAG\nGTGTCGTTCTTCCACAGCGAGGAGAACAAGGCTCCCGAGAGTGAGGAGCTGGAGATGGAG\nTTTGAGGACATGGAGAATGTGCCCCTGGACCGTTCCTCGCACTGTCAGAGGGAGGAGGCG\nGGGGGCCGGGATGGAGGGTCCTCGCTGGGTTTCAAGCGGAGCTACGAGGAACACATCCCT\nTACACACACATGAACGGAGGCAAGAAAAACGGGCGGATTCTGACCTTGCCTCGGTCCAAT\nCCTTCCTAA"}, "pfams": {"pfam": [{"identifier": "PF07714", "name": "Pkinase_Tyr"}, {"identifier": "PF00041", "name": "fn3"}, {"identifier": "PF00757", "name": "Furin-like"}, {"identifier": "PF01030", "name": "Recep_L_domain"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "protein-tyrosine kinase activity"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "transferase activity, transferring phosphorus-containing groups"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "function", "description": "kinase activity"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "transferase activity"}, {"category": "function", "description": "protein kinase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "transmembrane receptor protein tyrosine kinase activity"}, {"category": "function", "description": "epidermal growth factor receptor activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "protein amino acid phosphorylation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "enzyme linked receptor protein signaling pathway"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "transmembrane receptor protein tyrosine kinase signaling pathway"}, {"category": "process", "description": "biopolymer metabolism"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "biopolymer modification"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "protein modification"}]}}}, {"@position": "2", "id": "BE0000858", "name": "Insulin-like growth factor 1 receptor", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P08069", "@source": "Swiss-Prot", "name": "Insulin-like growth factor 1 receptor", "general-function": "Involved in transmembrane receptor protein tyrosine kinase activity", "specific-function": "This receptor binds insulin-like growth factor 1 (IGF1) with a high affinity and IGF2 with a lower affinity. It has a tyrosine-protein kinase activity, which is necessary for the activation of the IGF1-stimulated downstream signaling cascade", "gene-name": "IGF1R", "locus": "15q26.3", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "936-959", "signal-regions": null, "theoretical-pi": "5.54", "molecular-weight": "154795.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5465"}, {"resource": "GenAtlas", "identifier": "IGF1R"}, {"resource": "GeneCards", "identifier": "IGF1R"}, {"resource": "GenBank Gene Database", "identifier": "X04434"}, {"resource": "GenBank Protein Database", "identifier": "804990"}, {"resource": "UniProtKB", "identifier": "P08069"}, {"resource": "UniProt Accession", "identifier": "IGF1R_HUMAN"}]}, "synonyms": {"synonym": ["CD221 antigen", "EC 2.7.10.1", "IGF-I receptor", "Insulin-like growth factor 1 receptor precursor", "Insulin-like growth factor I receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Insulin-like growth factor 1 receptor precursor\nMKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLH\nILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIF\nEMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGD\nLCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCS\nAPDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHD\nGECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNL\nLINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSF\nYVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTR\nNNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDG\nQDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSE\nILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRH\nNYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRK\nVFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFES\nRVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTW\nEPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGN\nYTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHR\nKRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKG\nVVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIME\nLMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARN\nCMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGV\nVLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFL\nEIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRH\nSGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC"}, "gene-sequence": {"@format": "FASTA", "#text": ">4104 bp\nATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCC\nGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGC\nAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCAC\nATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTC\nATTACCGAGTACTTGCTGCTGTTCCGAGTGGCTGGCCTCGAGAGCCTCGGAGACCTCTTC\nCCCAACCTCACGGTCATCCGCGGCTGGAAACTCTTCTACAACTACGCCCTGGTCATCTTC\nGAGATGACCAATCTCAAGGATATTGGGCTTTACAACCTGAGGAACATTACTCGGGGGGCC\nATCAGGATTGAGAAAAATGCTGACCTCTGTTACCTCTCCACTGTGGACTGGTCCCTGATC\nCTGGATGCGGTGTCCAATAACTACATTGTGGGGAATAAGCCCCCAAAGGAATGTGGGGAC\nCTGTGTCCAGGGACCATGGAGGAGAAGCCGATGTGTGAGAAGACCACCATCAACAATGAG\nTACAACTACCGCTGCTGGACCACAAACCGCTGCCAGAAAATGTGCCCAAGCACGTGTGGG\nAAGCGGGCGTGCACCGAGAACAATGAGTGCTGCCACCCCGAGTGCCTGGGCAGCTGCAGC\nGCGCCTGACAACGACACGGCCTGTGTAGCTTGCCGCCACTACTACTATGCCGGTGTCTGT\nGTGCCTGCCTGCCCGCCCAACACCTACAGGTTTGAGGGCTGGCGCTGTGTGGACCGTGAC\nTTCTGCGCCAACATCCTCAGCGCCGAGAGCAGCGACTCCGAGGGGTTTGTGATCCACGAC\nGGCGAGTGCATGCAGGAGTGCCCCTCGGGCTTCATCCGCAACGGCAGCCAGAGCATGTAC\nTGCATCCCTTGTGAAGGTCCTTGCCCGAAGGTCTGTGAGGAAGAAAAGAAAACAAAGACC\nATTGATTCTGTTACTTCTGCTCAGATGCTCCAAGGATGCACCATCTTCAAGGGCAATTTG\nCTCATTAACATCCGACGGGGGAATAACATTGCTTCAGAGCTGGAGAACTTCATGGGGCTC\nATCGAGGTGGTGACGGGCTACGTGAAGATCCGCCATTCTCATGCCTTGGTCTCCTTGTCC\nTTCCTAAAAAACCTTCGCCTCATCCTAGGAGAGGAGCAGCTAGAAGGGAATTACTCCTTC\nTACGTCCTCGACAACCAGAACTTGCAGCAACTGTGGGACTGGGACCACCGCAACCTGACC\nATCAAAGCAGGGAAAATGTACTTTGCTTTCAATCCCAAATTATGTGTTTCCGAAATTTAC\nCGCATGGAGGAAGTGACGGGGACTAAAGGGCGCCAAAGCAAAGGGGACATAAACACCAGG\nAACAACGGGGAGAGAGCCTCCTGTGAAAGTGACGTCCTGCATTTCACCTCCACCACCACG\nTCGAAGAATCGCATCATCATAACCTGGCACCGGTACCGGCCCCCTGACTACAGGGATCTC\nATCAGCTTCACCGTTTACTACAAGGAAGCACCCTTTAAGAATGTCACAGAGTATGATGGG\nCAGGATGCCTGCGGCTCCAACAGCTGGAACATGGTGGACGTGGACCTCCCGCCCAACAAG\nGACGTGGAGCCCGGCATCTTACTACATGGGCTGAAGCCCTGGACTCAGTACGCCGTTTAC\nGTCAAGGCTGTGACCCTCACCATGGTGGAGAACGACCATATCCGTGGGGCCAAGAGTGAG\nATCTTGTACATTCGCACCAATGCTTCAGTTCCTTCCATTCCCTTGGACGTTCTTTCAGCA\nTCGAACTCCTCTTCTCAGTTAATCGTGAAGTGGAACCCTCCCTCTCTGCCCAACGGCAAC\nCTGAGTTACTACATTGTGCGCTGGCAGCGGCAGCCTCAGGACGGCTACCTTTACCGGCAC\nAATTACTGCTCCAAAGACAAAATCCCCATCAGGAAGTATGCCGACGGCACCATCGACATT\nGAGGAGGTCACAGAGAACCCCAAGACTGAGGTGTGTGGTGGGGAGAAAGGGCCTTGCTGC\nGCCTGCCCCAAAACTGAAGCCGAGAAGCAGGCCGAGAAGGAGGAGGCTGAATACCGCAAA\nGTCTTTGAGAATTTCCTGCACAACTCCATCTTCGTGCCCAGACCTGAAAGGAAGCGGAGA\nGATGTCATGCAAGTGGCCAACACCACCATGTCCAGCCGAAGCAGGAACACCACGGCCGCA\nGACACCTACAACATCACCGACCCGGAAGAGCTGGAGACAGAGTACCCTTTCTTTGAGAGC\nAGAGTGGATAACAAGGAGAGAACTGTCATTTCTAACCTTCGGCCTTTCACATTGTACCGC\nATCGATATCCACAGCTGCAACCACGAGGCTGAGAAGCTGGGCTGCAGCGCCTCCAACTTC\nGTCTTTGCAAGGACTATGCCCGCAGAAGGAGCAGATGACATTCCTGGGCCAGTGACCTGG\nGAGCCAAGGCCTGAAAACTCCATCTTTTTAAAGTGGCCGGAACCTGAGAATCCCAATGGA\nTTGATTCTAATGTATGAAATAAAATACGGATCACAAGTTGAGGATCAGCGAGAATGTGTG\nTCCAGACAGGAATACAGGAAGTATGGAGGGGCCAAGCTAAACCGGCTAAACCCGGGGAAC\nTACACAGCCCGGATTCAGGCCACATCTCTCTCTGGGAATGGGTCGTGGACAGATCCTGTG\nTTCTTCTATGTCCAGGCCAAAACAGGATATGAAAACTTCATCCATCTGATCATCGCTCTG\nCCCGTCGCTGTCCTGTTGATCGTGGGAGGGTTGGTGATTATGCTGTACGTCTTCCATAGA\nAAGAGAAATAACAGCAGGCTGGGGAATGGAGTGCTGTATGCCTCTGTGAACCCGGAGTAC\nTTCAGCGCTGCTGATGTGTACGTTCCTGATGAGTGGGAGGTGGCTCGGGAGAAGATCACC\nATGAGCCGGGAACTTGGGCAGGGGTCGTTTGGGATGGTCTATGAAGGAGTTGCCAAGGGT\nGTGGTGAAAGATGAACCTGAAACCAGAGTGGCCATTAAAACAGTGAACGAGGCCGCAAGC\nATGCGTGAGAGGATTGAGTTTCTCAACGAAGCTTCTGTGATGAAGGAGTTCAATTGTCAC\nCATGTGGTGCGATTGCTGGGTGTGGTGTCCCAAGGCCAGCCAACACTGGTCATCATGGAA\nCTGATGACACGGGGCGATCTCAAAAGTTATCTCCGGTCTCTGAGGCCAGAAATGGAGAAT\nAATCCAGTCCTAGCACCTCCAAGCCTGAGCAAGATGATTCAGATGGCCGGAGAGATTGCA\nGACGGCATGGCATACCTCAACGCCAATAAGTTCGTCCACAGAGACCTTGCTGCCCGGAAT\nTGCATGGTAGCCGAAGATTTCACAGTCAAAATCGGAGATTTTGGTATGACGCGAGATATC\nTATGAGACAGACTATTACCGGAAAGGAGGCAAAGGGCTGCTGCCCGTGCGCTGGATGTCT\nCCTGAGTCCCTCAAGGATGGAGTCTTCACCACTTACTCGGACGTCTGGTCCTTCGGGGTC\nGTCCTCTGGGAGATCGCCACACTGGCCGAGCAGCCCTACCAGGGCTTGTCCAACGAGCAA\nGTCCTTCGCTTCGTCATGGAGGGCGGCCTTCTGGACAAGCCAGACAACTGTCCTGACATG\nCTGTTTGAACTGATGCGCATGTGCTGGCAGTATAACCCCAAGATGAGGCCTTCCTTCCTG\nGAGATCATCAGCAGCATCAAAGAGGAGATGGAGCCTGGCTTCCGGGAGGTCTCCTTCTAC\nTACAGCGAGGAGAACAAGCTGCCCGAGCCGGAGGAGCTGGACCTGGAGCCAGAGAACATG\nGAGAGCGTCCCCCTGGACCCCTCGGCCTCCTCGTCCTCCCTGCCACTGCCCGACAGACAC\nTCAGGACACAAGGCCGAGAACGGCCCCGGCCCTGGGGTGCTGGTCCTCCGCGCCAGCTTC\nGACGAGAGACAGCCTTACGCCCACATGAACGGGGGCCGCAAGAACGAGCGGGCCTTGCCG\nCTGCCCCAGTCTTCGACCTGCTGA"}, "pfams": {"pfam": [{"identifier": "PF07714", "name": "Pkinase_Tyr"}, {"identifier": "PF00041", "name": "fn3"}, {"identifier": "PF00757", "name": "Furin-like"}, {"identifier": "PF01030", "name": "Recep_L_domain"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "protein-tyrosine kinase activity"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "transferase activity, transferring phosphorus-containing groups"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "function", "description": "kinase activity"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "transferase activity"}, {"category": "function", "description": "protein kinase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "transmembrane receptor protein tyrosine kinase activity"}, {"category": "function", "description": "epidermal growth factor receptor activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "protein amino acid phosphorylation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "enzyme linked receptor protein signaling pathway"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "transmembrane receptor protein tyrosine kinase signaling pathway"}, {"category": "process", "description": "biopolymer metabolism"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "biopolymer modification"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "protein modification"}]}}}, {"@position": "4", "id": "BE0002123", "name": "Retinoblastoma-associated protein", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P06400", "@source": "Swiss-Prot", "name": "Retinoblastoma-associated protein", "general-function": null, "specific-function": "Key regulator of entry into cell division that acts as a tumor suppressor. Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation. Recruits and targets histone methyltransferases SUV39H1, SUV420H1 and SUV420H2, leading to epigenetic transcriptional repression. Controls histone H4 'Lys-20' trimethylation. Also acts as a transcription repressor of E2F target genes by recruiting chromatin-modifying enzymes to promoters. Inhibits the intrinsic kinase activity of TAF1. Forms a complex with adenovirus E1A and with SV40 large T antigen. May bind and modulate functionally certain cellular proteins with which T and E1A compete for pocket binding", "gene-name": "RB1", "locus": "13q14.2", "cellular-location": "Nucleus", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.04", "molecular-weight": "106161.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9884"}, {"resource": "GenAtlas", "identifier": "RB1"}, {"resource": "GeneCards", "identifier": "RB1"}, {"resource": "GenBank Gene Database", "identifier": "M15400"}, {"resource": "GenBank Protein Database", "identifier": "190959"}, {"resource": "UniProtKB", "identifier": "P06400"}, {"resource": "UniProt Accession", "identifier": "RB_HUMAN"}]}, "synonyms": {"synonym": ["P105-RB", "PP110", "RB"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Retinoblastoma-associated protein\nMPPKTPRKTAATAAAAAAEPPAPPPPPPPEEDPEQDSGPEDLPLVRLEFEETEEPDFTAL\nCQKLKIPDHVRERAWLTWEKVSSVDGVLGGYIQKKKELWGICIFIAAVDLDEMSFTFTEL\nQKNIEISVHKFFNLLKEIDTSTKVDNAMSRLLKKYDVLFALFSKLERTCELIYLTQPSSS\nISTEINSALVLKVSWITFLLAKGEVLQMEDDLVISFQLMLCVLDYFIKLSPPMLLKEPYK\nTAVIPINGSPRTPRRGQNRSARIAKQLENDTRIIEVLCKEHECNIDEVKNVYFKNFIPFM\nNSLGLVTSNGLPEVENLSKRYEEIYLKNKDLDARLFLDHDKTLQTDSIDSFETQRTPRKS\nNLDEEVNVIPPHTPVRTVMNTIQQLMMILNSASDQPSENLISYFNNCTVNPKESILKRVK\nDIGYIFKEKFAKAVGQGCVEIGSQRYKLGVRLYYRVMESMLKSEEERLSIQNFSKLLNDN\nIFHMSLLACALEVVMATYSRSTSQNLDSGTDLSFPWILNVLNLKAFDFYKVIESFIKAEG\nNLTREMIKHLERCEHRIMESLAWLSDSPLFDLIKQSKDREGPTDHLESACPLNLPLQNNH\nTAADMYLSPVRSPKKKGSTTRVNSTANAETQATSAFQTQKPLKSTSLSLFYKKVYRLAYL\nRLNTLCERLLSEHPELEHIIWTLFQHTLQNEYELMRDRHLDQIMMCSMYGICKVKNIDLK\nFKIIVTAYKDLPHAVQETFKRVLIKEEEYDSIIVFYNSVFMQRLKTNILQYASTRPPTLS\nPIPHIPRSPYKFPSSPLRIPGGNIYISPLKSPYKISEGLPTPTKMTPRSRILVSIGESFG\nTSEKFQKINQMVCNSDRVLKRSAEGSNPPKPLKKLRFDIEGSDEADGSKHLPGESKFQQK\nLAEMTSTRTRMQKQKMNDSMDTSNKEEK"}, "gene-sequence": {"@format": "FASTA", "#text": ">2787 bp\nATGCCGCCCAAAACCCCCCGAAAAACGGCCGCCACCGCCGCCGCTGCCGCCGCGGAACCC\nCCGGCACCGCCGCCGCCGCCCCCTCCTGAGGAGGACCCAGAGCAGGACAGCGGCCCGGAG\nGACCTGCCTCTCGTCAGGCTTGAGTTTGAAGAAACAGAAGAACCTGATTTTACTGCATTA\nTGTCAGAAATTAAAGATACCAGATCATGTCAGAGAGAGAGCTTGGTTAACTTGGGAGAAA\nGTTTCATCTGTGGATGGAGTATTGGGAGGTTATATTCAAAAGAAAAAGGAACTGTGGGGA\nATCTGTATCTTTATTGCACGAGTTGACCTAGATGAGATGTCGTTCACTTTACTGAGCTAC\nAGAAAAACATACGAAATCAGTGTCCATAAATTCTTTAACTTACTAAAAGAAATTGATACC\nAGTACCAAAGTTGATAATGCTATGTCAAGACTGTTGAAGAAGTATGATGTATTGTTTGCA\nCTCTTCAGCAAATTGGAAAGGACATGTGAACTTATATATTTGACACAACCCAGCAGTTCG\nATATCTACTGAAATAAATTCTGCATTGGTGCTAAAAGTTTCTTGGATCACATTTTTATTA\nGCTAAAGGGGAAGTATTACAAATGGAAGATGATCTGGTGATTTCATTTCAGTTAATGCTA\nTGTGTCCTTGACTATTTTATTAAACTCTCACCTCCCATGTTGCTCAAAGAACCATATAAA\nACAGCTGTTATACCCATTAATGGTTCACCTCGAACACCCAGGCGAGGTCAGAACAGGAGT\nGCACGGATAGCAAAACAACTAGAAAATGATACAAGAATTATTGAAGTTCTCTGTAAAGAA\nCATGAATGTAATATAGATGAGGTGAAAAATGTTTATTTCAAAAATTTTATACCTTTTATG\nAATTCTCTTGGACTTGTAACATCTAATGGACTTCCAGAGGTTGAAAATCTTTCTAAACGA\nTACGAAGAAATTTATCTTAAAAATAAAGATCTAGATCGAAGATTATTTTTGGATCATGAT\nAAAACTCTTCAGACTGATTCTATAGACAGTTTTGAAACACAGAGAACACCACGAAAAAGT\nAACCTTGATGAAGAGGTGAATATAATTCCTCCACACACTCCAGTTAGGACTGTTATGAAC\nACTATCCAACAATTAATGATGATTTTAAATTCTGCAAGTGATCAACCTTCAGAAAATCTG\nATTTCCTATTTTAACAACTGCACAGTGAATCCAAAAGAAAGTATACTGAAAAGAGTGAAG\nGATATAGGATACATCTTTAAAGAGAAATTTGCTAAAGCTGTGGGACAGGGTTGTGTCGAA\nATTGGATCACAGCGATACAAACTTGGAGTTCGCTTGTATTACCGAGTAATGGAATCCATG\nCTTAAATCAGAAGAAGAACGATTATCCATTCAAAATTTTAGCAAACTTCTGAATGACAAC\nATTTTTCATATGTCTTTATTGGCGTGCGCTCTTGAGGTTGTAATGGCCACATATAGCAGA\nAGTACATCTCAGAATCTTGATTCTGGAACAGATTTGTCTTTCCCATGGATTCTGAATGTG\nCTTAATTTAAAAGCCTTTGATTTTTACAAAGTGATCGAAAGTTTTATCAAAGCAGAAGGC\nAACTTGACAAGAGAAATGATAAAACATTTAGAACGATGTGAACATCGAATCATGGAATCC\nCTTGCATGGCTCTCAGATTCACCTTTATTTGATCTTATTAAACAATCAAAGGACCGAGAA\nGGACCAACTGATCACCTTGAATCTGCTTGTCCTCTTAATCTTCCTCTCCAGAATAATCAC\nACTGCAGCAGATATGTATCTTTCTCCTGTAAGATCTCCAAAGAAAAAAGGTTCAACTACG\nCGTGTAAATTCTACTGCAAATGCAGAGACACAAGCAACCTCAGCCTTCCAGACCCAGAAG\nCCATTGAAATCTACCTCTCTTTCACTGTTTTATAAAAAAGTGTATCGGCTAGCCTATCTC\nCGGCTAAATACACTTTGTGAACGCCTTCTGTCTGAGCACCCAGAATTAGAACATATCATC\nTGGACCCTTTTCCAGCACACCCTGCAGAATGAGTATGAACTCATGAGAGACAGGCATTTG\nGACCAAATTATGATGTGTTCCATGTATGGCATATGCAAAGTGAAGAATATAGACCTTAAA\nTTCAAAATCATTGTAACAGCATACAAGGATCTTCCTCATGCTGTTCAGGAGACATTCAAA\nCGTGTTTTGATCAAAGAAGAGGAGTATGATTCTATTATAGTATTCTATAACTCGGTCTTC\nATGCAGAGACTGAAAACAAATATTTTGCAGTATGCTTCCACCAGGCCCCCTACCTTGTCA\nCCAATACCTCACATTCCTCGAAGCCCTTACAAGTTTCCTAGTTCACCCTTACGGATTCCT\nGGAGGGAACATCTATATTTCACCCCTGAAGAGTCCATATAAAATTTCAGAAGGTCTGCCA\nACACCAACAAAAATGACTCCAAGATCAAGAATCTTAGTATCAATTGGTGAATCATTCGGG\nACTTCTGAGAAGTTCCAGAAAATAAATCAGATGGTATGTAACAGCGACCGTGTGCTCAAA\nAGAAGTGCTGAAGGAAGCAACCCTCCTAAACCACTGAAAAAACTACGCTTTGATATTGAA\nGGATCAGATGAAGCAGATGGAAGTAAACATCTCCCAGGAGAGTCCAAATTTCAGCAGAAA\nCTGGCAGAAATGACTTCTACTCGAACACGAATGCAAAAGCAGAAAATGAATGATAGCATG\nGATACCTCAAACAAGGAAGAGAAATGA"}, "pfams": {"pfam": [{"identifier": "PF01858", "name": "RB_A"}, {"identifier": "PF01857", "name": "RB_B"}, {"identifier": "PF08934", "name": "Rb_C"}]}, "go-classifiers": null}}, {"@position": "4", "id": "BE0000941", "name": "Cathepsin D", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P07339", "@source": "Swiss-Prot", "name": "Cathepsin D", "general-function": "Involved in aspartic-type endopeptidase activity", "specific-function": "Acid protease active in intracellular protein breakdown. Involved in the pathogenesis of several diseases such as breast cancer and possibly Alzheimer disease", "gene-name": "CTSD", "locus": "11p15.5", "cellular-location": "Lysosome. Melanosome. Note=Identified by mass spectrometry in melanosome fractions from stage I to s", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.5", "molecular-weight": "44553.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2529"}, {"resource": "GenAtlas", "identifier": "CTSD"}, {"resource": "GeneCards", "identifier": "CTSD"}, {"resource": "GenBank Gene Database", "identifier": "M11233"}, {"resource": "GenBank Protein Database", "identifier": "181180"}, {"resource": "UniProtKB", "identifier": "P07339"}, {"resource": "UniProt Accession", "identifier": "CATD_HUMAN"}]}, "synonyms": {"synonym": ["Cathepsin D precursor", "EC 3.4.23.5"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cathepsin D precursor\nMQPSSLLPLALCLLAAPASALVRIPLHKFTSIRRTMSEVGGSVEDLIAKGPVSKYSQAVP\nAVTEGPIPEVLKNYMDAQYYGEIGIGTPPQCFTVVFDTGSSNLWVPSIHCKLLDIACWIH\nHKYNSDKSSTYVKNGTSFDIHYGSGSLSGYLSQDTVSVPCQSASSASALGGVKVERQVFG\nEATKQPGITFIAAKFDGILGMAYPRISVNNVLPVFDNLMQQKLVDQNIFSFYLSRDPDAQ\nPGGELMLGGTDSKYYKGSLSYLNVTRKAYWQVHLDQVEVASGLTLCKEGCEAIVDTGTSL\nMVGPVDEVRELQKAIGAVPLIQGEYMIPCEKVSTLPAITLKLGGKGYKLSPEDYTLKVSQ\nAGKTLCLSGFMGMDIPPPSGPLWILGDVFIGRYYTVFDRDNNRVGFAEAARL"}, "gene-sequence": {"@format": "FASTA", "#text": ">1239 bp\nATGCAGCCCTCCAGCCTTCTGCCGCTCGCCCTCTGCCTGCTGGCTGCACCCGCCTCCGCG\nCTCGTCAGGATCCCGCTGCACAAGTTCACGTCCATCCGCCGGACCATGTCGGAGGTTGGG\nGGCTCTGTGGAGGACCTGATTGCCAAAGGCCCCGTCTCAAAGTACTCCCAGGCGGTGCCA\nGCCGTGACCGAGGGGCCCATTCCCGAGGTGCTCAAGAACTACATGGACGCCCAGTACTAC\nGGGGAGATTGGCATCGGGACGCCCCCCCAGTGCTTCACAGTCGTCTTCGACACGGGCTCC\nTCCAACCTGTGGGTCCCCTCCATCCACTGCAAACTGCTGGACATCGCTTGCTGGATCCAC\nCACAAGTACAACAGCGACAAGTCCAGCACCTACGTGAAGAATGGTACCTCGTTTGACATC\nCACTATGGCTCGGGCAGCCTCTCCGGGTACCTGAGCCAGGACACTGTGTCGGTGCCCTGC\nCAGTCAGCGTCGTCAGCCTCTGCCCTGGGCGGTGTCAAAGTGGAGAGGCAGGTCTTTGGG\nGAGGCCACCAAGCAGCCAGGCATCACCTTCATCGCAGCCAAGTTCGATGGCATCCTGGGC\nATGGCCTACCCCCGCATCTCCGTCAACAACGTGCTGCCCGTCTTCGACAACCTGATGCAG\nCAGAAGCTGGTGGACCAGAACATCTTCTCCTTCTACCTGAGCAGGGACCCAGATGCGCAG\nCCTGGGGGTGAGCTGATGCTGGGTGGCACAGACTCCAAGTATTACAAGGGTTCTCTGTCC\nTACCTGAATGTCACCCGCAAGGCCTACTGGCAGGTCCACCTGGACCAGGTGGAGGTGGCC\nAGCGGGCTGACCCTGTGCAAGGAGGGCTGTGAGGCCATTGTGGACACAGGCACTTCCCTC\nATGGTGGGCCCGGTGGATGAGGTGCGCGAGCTGCAGAAGGCCATCGGGGCCGTGCCGCTG\nATTCAGGGCGAGTACATGATCCCCTGTGAGAAGGTGTCCACCCTGCCCGCGATCACACTG\nAAGCTGGGAGGCAAAGGCTACAAGCTGTCCCCAGAGGACTACACGCTCAAGGTGTCGCAG\nGCCGGGAAGACCCTCTGCCTGAGCGGCTTCATGGGCATGGACATCCCGCCACCCAGCGGG\nCCACTCTGGATCCTGGGCGACGTCTTCATCGGCCGCTACTACACTGTGTTTGACCGTGAC\nAACAACAGGGTGGGCTTCGCCGAGGCTGCCCGCCTCTAG"}, "pfams": {"pfam": [{"identifier": "PF07966", "name": "A1_Propeptide"}, {"identifier": "PF00026", "name": "Asp"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "pepsin A activity"}, {"category": "function", "description": "aspartic-type endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}]}}}, {"@position": "5", "id": "BE0001183", "name": "Insulin-degrading enzyme", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P14735", "@source": "Swiss-Prot", "name": "Insulin-degrading enzyme", "general-function": "Posttranslational modification, protein turnover, chaperones", "specific-function": "May play a role in the cellular processing of insulin. May be involved in intercellular peptide signaling", "gene-name": "IDE", "locus": "10q23-q25", "cellular-location": "Cytoplasm", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.74", "molecular-weight": "118023.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5381"}, {"resource": "GenAtlas", "identifier": "IDE"}, {"resource": "GeneCards", "identifier": "IDE"}, {"resource": "GenBank Gene Database", "identifier": "M21188"}, {"resource": "GenBank Protein Database", "identifier": "184556"}, {"resource": "UniProtKB", "identifier": "P14735"}, {"resource": "UniProt Accession", "identifier": "IDE_HUMAN"}]}, "synonyms": {"synonym": ["EC 3.4.24.56", "Insulin protease", "Insulinase", "Insulysin"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Insulin-degrading enzyme\nMRYRLAWLLHPALPSTFRSVLGARLPPPERLCGFQKKTYSKMNNPAIKRIGNHITKSPED\nKREYRGLELANGIKVLLMSDPTTDKSSAALDVHIGSLSDPPNIAGLSHFCEHMLFLGTKK\nYPKENEYSQFLSEHAGSSNAFTSGEHTNYYFDVSHEHLEGALDRFAQFFLCPLFDESCKD\nREVNAVDSEHEKNVMNDAWRLFQLEKATGNPKHPFSKFGTGNKYTLETRPNQEGIDVRQE\nLLKFHSAYYSSNLMAVCVLGRESLDDLTNLVVKLFSEVENKNVPLPEFPEHPFQEEHLKQ\nLYKIVPIKDIRNLYVTFPIPDLQKYYKSNPGHYLGHLIGHEGPGSLLSELKSKGWVNTLV\nGGQKEGARGFMFFIINVDLTEEGLLHVEDIILHMFQYIQKLRAEGPQEWVFQECKDLNAV\nAFRFKDKERPRGYTSKIAGILHYYPLEEVLTAEYLLEEFRPDLIEMVLDKLRPENVRVAI\nVSKSFEGKTDRTEEWYGTQYKQEAIPDEVIKKWQNADLNGKFKLPTKNEFIPTNFEILPL\nEKEATPYPALIKDTVMSKLWFKQDDKKKKPKACLNFEFFSPFAYVDPLHCNMAYLYLELL\nKDSLNEYAYAAELAGLSYDLQNTIYGMYLSVKGYNDKQPILLKKIIEKMATFEIDEKRFE\nIIKEAYMRSLNNFRAEQPHQHAMYYLRLLMTEVAWTKDELKEALDDVTLPRLKAFIPQLL\nSRLHIEALLHGNITKQAALGIMQMVEDTLIEHAHTKPLLPSQLVRYREVQLPDRGWFVYQ\nQRNEVHNNCGIEIYYQTDMQSTSENMFLELFCQIISEPCFNTLRTKEQLGYIVFSGPRRA\nNGIQSLRFIIQSEKPPHYLESRVEAFLITMEKSIEDMTEEAFQKHIQALAIRRLDKPKKL\nSAECAKYWGEIISQQYNFDRDNTEVAYLKTLTKEDIIKFYKEMLAVDAPRRHKVSVHVLA\nREMDSCPVVGEFPCQNDINLSQAPALPQPEVIQNMTEFKRGLPLFPLVKPHINFMAAKL"}, "gene-sequence": {"@format": "FASTA", "#text": ">3060 bp\nATGCGGTACCGGCTAGCGTGGCTTCTGCACCCCGCACTGCCCAGCACCTTCCGCTCAGTC\nCTCGGCGCCCGCCTGCCGCCTCCGGAGCGCCTGTGTGGTTTCCAAAAAAAGACTTACAGC\nAAAATGAATAATCCAGCCATCAAGAGAATAGGAAATCACATTACCAAGTCTCCTGAAGAC\nAAGCGAGAATATCGAGGGCTAGAGCTGGCCAATGGTATCAAAGTACTTCTTATGAGTGAT\nCCCACCACGGATAAGTCATCAGCAGCACTTGATGTGCACATAGGTTCATTGTCGGATCCT\nCCAAATATTGCTGGCTTAAGTCATTTTTGTGAACATATGCTTTTTTTGGGAACAAAGAAA\nTACCCTAAAGAAAATGAATACAGCCAGTTTCTCAGTGAGCATGCAGGAAGTTCAAATGCC\nTTTACTAGTGGAGAGCATACCAATTACTATTTTGATGTTTCTCATGAACACCTAGAAGGT\nGCCCTAGACAGGTTTGCACAGTTTTTTCTGTGCCCCTTGTTCGATGAAAGTTGCAAAGAC\nAGAGAGGTGAATGCAGTTGATTCAGAACATGAGAAGAATGTGATGAATGATGCCTGGAGA\nCTCTTTCAATTGGAAAAAGCTACAGGGAATCCTAAACACCCCTTCAGTAAATTTGGGACA\nGGTAACAAATATACTCTGGAGACTAGACCAAACCAAGAAGGCATTGATGTAAGACAAGAG\nCTACTGAAATTCCATTCTGCTTACTATTCATCCAACTTAATGGCTGTTTGTGTTTTAGGT\nCGAGAATCTTTAGATGACTTGACTAATCTGGTGGTAAAGTTATTTTCTGAAGTAGAGAAC\nAAAAATGTTCCATTGCCAGAATTTCCTGAACACCCTTTCCAAGAAGAACATCTTAAACAA\nCTTTACAAAATAGTACCCATTAAAGATATTAGGAATCTCTATGTGACATTTCCCATACCT\nGACCTTCAGAAATACTACAAATCAAATCCTGGTCATTATCTTGGTCATCTCATTGGGCAT\nGAAGGTCCTGGAAGTCTGTTATCAGAACTTAAGTCAAAGGGCTGGGTTAATACTCTTGTT\nGGTGGGCAGAAGGAAGGAGCCCGAGGTTTTATGTTTTTTATCATTAATGTGGACTTGACC\nGAGGAAGGATTATTACATGTTGAAGATATAATTTTGCACATGTTTCAATACATTCAGAAG\nTTACGTGCAGAAGGACCTCAAGAATGGGTTTTCCAAGAGTGCAAGGACTTGAATGCTGTT\nGCTTTTAGGTTTAAAGACAAAGAGAGGCCACGGGGCTATACATCTAAGATTGCAGGAATA\nTTGCATTATTATCCCCTAGAAGAGGTGCTCACAGCGGAATATTTACTGGAAGAATTTAGA\nCCTGACTTAATAGAGATGGTTCTCGATAAACTCAGACCAGAAAATGTCCGGGTTGCCATA\nGTTTCTAAATCTTTTGAAGGAAAAACTGATCGCACAGAAGAGTGGTATGGAACCCAGTAC\nAAACAAGAAGCTATACCGGATGAAGTCATCAAGAAATGGCAAAATGCTGACCTGAATGGG\nAAATTTAAACTTCCTACAAAGAATGAATTTATTCCTACGAATTTTGAGATTTTACCGTTA\nGAAAAAGAGGCGACACCATACCCTGCTCTTATTAAGGATACAGTCATGAGCAAACTTTGG\nTTCAAACAAGATGATAAGAAAAAAAAGCCGAAGGCTTGTCTCAACTTTGAATTTTTCAGC\nCCATTTGCTTATGTGGACCCCTTGCACTGTAACATGGCCTATTTGTACCTTGAGCTCCTC\nAAAGACTCACTCAACGAGTATGCATATGCAGCAGAGCTAGCAGGCTTGAGCTATGATCTC\nCAAAATACCATCTATGGGATGTATCTTTCAGTGAAAGGTTACAATGACAAGCAGCCAATT\nTTACTAAAGAAGATTATTGAGAAAATGGCTACCTTTGAGATTGATGAAAAAAGATTTGAA\nATTATCAAAGAAGCATATATGCGATCTCTTAACAATTTCCGGGCTGAACAGCCTCACCAG\nCATGCCATGTACTACCTCCGCTTGCTGATGACTGAAGTGGCCTGGACTAAAGATGAGTTA\nAAAGAAGCTCTGGATGATGTAACCCTTCCTCGCCTTAAGGCCTTCATACCTCAGCTCCTG\nTCACGGCTGCACATTGAAGCCCTTCTCCATGGAAACATAACAAAGCAGGCTGCATTAGGA\nATTATGCAGATGGTTGAAGACACCCTCATTGAACATGCTCATACCAAACCTCTCCTTCCA\nAGTCAGCTGGTTCGGTATAGAGAAGTTCAGCTCCCTGACAGAGGATGGTTTGTTTATCAG\nCAGAGAAATGAAGTTCACAATAACTGTGGCATCGAGATATACTACCAAACAGACATGCAA\nAGCACCTCAGAGAATATGTTTCTGGAGCTCTTCTGTCAGATTATCTCGGAACCTTGCTTC\nAACACCCTGCGCACCAAGGAGCAGTTGGGCTATATCGTCTTCAGCGGGCCACGTCGAGCT\nAATGGCATACAGAGCTTGAGATTCATCATCCAGTCAGAAAAGCCACCTCACTACCTAGAA\nAGCAGAGTGGAAGCTTTCTTAATTACCATGGAAAAGTCCATAGAGGACATGACAGAAGAG\nGCCTTCCAAAAACACATTCAGGCATTAGCAATTCGTCGACTAGACAAACCAAAGAAGCTA\nTCTGCTGAGTGTGCTAAATACTGGGGAGAAATCATCTCCCAGCAATATAATTTTGACAGA\nGATAACACTGAGGTTGCATATTTAAAGACACTTACCAAGGAAGATATCATCAAATTCTAC\nAAGGAAATGTTGGCAGTAGATGCTCCAAGGAGACATAAGGTATCCGTCCATGTTCTTGCC\nAGGGAAATGGATTCTTGTCCTGTTGTTGGAGAGTTCCCATGTCAAAATGACATAAATTTG\nTCACAAGCACCAGCCTTGCCACAACCTGAAGTGATTCAGAACATGACCGAATTCAAGCGT\nGGTCTGCCACTGTTTCCCCTTGTGAAACCACATATTAACTTCATGGCTGCAAAACTCTGA"}, "pfams": {"pfam": [{"identifier": "PF00675", "name": "Peptidase_M16"}, {"identifier": "PF05193", "name": "Peptidase_M16_C"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "metalloendopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}]}}}, {"@position": "6", "id": "BE0002124", "name": "Neuroendocrine convertase 2", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P16519", "@source": "Swiss-Prot", "name": "Neuroendocrine convertase 2", "general-function": "Posttranslational modification, protein turnover, chaperones", "specific-function": "Involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues", "gene-name": "PCSK2", "locus": "20p11.2", "cellular-location": "Cytoplasmic vesicle", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.47", "molecular-weight": "70566.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:8744"}, {"resource": "GenAtlas", "identifier": "PCSK2"}, {"resource": "GeneCards", "identifier": "PCSK2"}, {"resource": "GenBank Gene Database", "identifier": "J05252"}, {"resource": "GenBank Protein Database", "identifier": "189652"}, {"resource": "UniProtKB", "identifier": "P16519"}, {"resource": "UniProt Accession", "identifier": "NEC2_HUMAN"}]}, "synonyms": {"synonym": ["EC 3.4.21.94", "KEX2-like endoprotease 2", "NEC 2", "Neuroendocrine convertase 2 precursor", "PC2", "Prohormone convertase 2", "Proprotein convertase 2"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Neuroendocrine convertase 2\nMKGGCVSQWKAAAGFLFCVMVFASAERPVFTNHFLVELHKGGEDKARQVAAEHGFGVRKL\nPFAEGLYHFYHNGLAKAKRRRSLHHKQQLERDPRVKMALQQEGFDRKKRGYRDINEIDIN\nMNDPLFTKQWYLINTGQADGTPGLDLNVAEAWELGYTGKGVTIGIMDDGIDYLHPDLASN\nYNAEASYDFSSNDPYPYPRYTDDWFNSHGTRCAGEVSAAANNNICGVGVAYNSKVAGIRM\nLDQPFMTDIIEASSISHMPQLIDIYSASWGPTDNGKTVDGPRELTLQAMADGVNKGRGGK\nGSIYVWASGDGGSYDDCNCDGYASSMWTISINSAINDGRTALYDESCSSTLASTFSNGRK\nRNPEAGVATTDLYGNCTLRHSGTSAAAPEAAGVFALALEANLGLTWRDMQHLTVLTSKRN\nQLHDEVHQWRRNGVGLEFNHLFGYGVLDAGAMVKMAKDWKTVPERFHCVGGSVQDPEKIP\nSTGKLVLTLTTDACEGKENFVRYLEHVQAVITVNATRRGDLNINMTSPMGTKSILLSRRP\nRDDDSKVGFDKWPFMTTHTWGEDARGTWTLELGFVGSAPQKGVLKEWTLMLHGTQSAPYI\nDQVVRDYQSKLAMSKKEELEEELDEAVERSLKSILNKN"}, "gene-sequence": {"@format": "FASTA", "#text": ">1917 bp\nATGAAGGGTGGTTGTGTCTCCCAGTGGAAGGCGGCCGCCGGGTTCCTCTTCTGTGTCATG\nGTTTTTGCATCTGCTGAGCGACCGGTCTTCACGAATCATTTTCTTGTGGAGTTGCATAAA\nGGGGGAGAGGACAAAGCTCGCCAAGTTGCAGCAGAACACGGCTTTGGAGTCCGAAAGCTT\nCCCTTTGCTGAAGGTCTGTACCACTTTTATCACAATGGCCTTGCAAAGGCCAAGAGAAGA\nCGCAGCCTACACCACAAGCAGCAGCTGGAGAGAGACCCCAGGGTAAAGATGGCTTTGCAG\nCAGGAAGGATTTGACCGAAAAAAGCGAGGTTACAGAGACATCAATGAGATCGACATCAAC\nATGAACGATCCTCTTTTTACAAAGCAGTGGTATCTGATCAATACTGGGCAAGCTGATGGC\nACTCCTGGCCTTGATTTGAATGTGGCTGAAGCCTGGGAGCTGGGATACACAGGGAAAGGT\nGTTACCATTGGAATTATGGATGATGGGATTGACTATCTCCACCCGGACCTGGCCTCCAAC\nTATAATGCCGAAGCAAGTTACGACTTCAGCAGCAACGACCCCTATCCTTACCCTCGGTAC\nACAGATGACTGGTTTAACAGCCACGGGACCCGATGTGCAGGAGAAGTTTCTGCTGCCGCC\nAACAACAATATCTGTGGAGTTGGAGTAGCATACAACTCCAAGGTTGCAGGCATCCGGATG\nCTGGACCAGCCATTCATGACAGACATCATCGAGGCCTCCTCCATCAGTCATATGCCACAG\nCTGATTGACATCTACAGCGCCAGCTGGGGCCCCACAGACAACGGCAAGACAGTGGATGGG\nCCCCGGGACGTCACGCTGCAGGCCATGGCCGATGGCGTGAACAAGGGCCGCGGCGGCAAA\nGGCAGCATCTACGTGTGGGCCTCCGGGGACGGCGGCAGCTATGACGACTGCAACTGCGAC\nGGCTACGCCTCCAGCATGTGGACCATCTCCATCAACTCAGCCATCAACGACGGCAGGACT\nGCCCTGTACGACGAGAGCTGCTCTTCCACCTTGGCTTCCACCTTCAGCAACGGGAGGAAA\nAGGAACCCCGAGGCCGGTGTGGCAACCACAGATTTGTACGGCAACTGCACTCTGAGGCAT\nTCTGGGACATCTGCAGCTGCCCCCGAGGCAGCTGGTGTGTTTGCACTGGCTCTGGAGGCT\nAACCTGGGTCTGACCTGGCGGGACATGCAGCATCTGACTGTGCTCACCTCCAAACGGAAC\nCAGCTTCACGACGAGGTCCATCAGTGGCGGCGCAATGGGGTCGGCCTGGAATTTAATCAC\nCTCTTTGGCTACGGGGTCCTTGATGCAGGTGCCATGGTGAAAATGGCTAAAGACTGGAAA\nACCGTGCCTGAGAGATTCCACTGTGTGGGAGGCTCCGTGCAGGACCCTGAGAAAATACCA\nTCCACTGGCAAGTTGGTGCTGACACTCACAACCGACGCCTGTGAGGGGAAGGAAAATTTT\nGTCCGCTACCTGGAGCATGTCCAGGCTGTCATCACGGTCAACGCAACCAGAAGAGGAGAC\nCTGAACATCAACATGACTTCCCCTATGGGCACCAAGTCCATTTTGCTGAGCCGGCGTCCA\nAGGGATGACGACTCCAAGGTGGGCTTTGACAAGTGGCCTTTCATGACCACTCACACGTGG\nGGGGAAGACGCCCGAGGCACCTGGACCCTGGAGCTGGGATTTGTCGGCAGCGCCCCGCAG\nAAGGGGGTGCTGAAGGAGTGGACCCTGATGCTGCATGGCACTCAGAGTGCCCCGTACATC\nGACCAGGTGGTGCGGGATTACCAGTCCAAGTTGGCCATGTCCAAGAAAGAGGAGCTGGAG\nGAAGAGCTGGACGAAGCCGTGGAGAGAAGCCTGAAAAGCATCCTTAACAAGAACTAG"}, "pfams": {"pfam": [{"identifier": "PF00082", "name": "Peptidase_S8"}, {"identifier": "PF01483", "name": "P_proprotein"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "subtilase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}]}}}, {"@position": "7", "id": "BE0001123", "name": "Carboxypeptidase E", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P16870", "@source": "Swiss-Prot", "name": "Carboxypeptidase E", "general-function": "Amino acid transport and metabolism", "specific-function": "Removes residual C-terminal Arg or Lys remaining after initial endoprotease cleavage during prohormone processing. Processes proinsulin", "gene-name": "CPE", "locus": "4q32.3", "cellular-location": "Secreted protein. Note=Secretory granules of pancreatic islets, adrenal gland, pituitary and brain", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "4.78", "molecular-weight": "53151.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2303"}, {"resource": "GenAtlas", "identifier": "CPE"}, {"resource": "GeneCards", "identifier": "CPE"}, {"resource": "GenBank Gene Database", "identifier": "X51405"}, {"resource": "GenBank Protein Database", "identifier": "29667"}, {"resource": "UniProtKB", "identifier": "P16870"}, {"resource": "UniProt Accession", "identifier": "CBPE_HUMAN"}]}, "synonyms": {"synonym": ["Carboxypeptidase E precursor", "Carboxypeptidase H", "CPE", "CPH", "EC 3.4.17.10", "Enkephalin convertase", "Prohormone-processing carboxypeptidase"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Carboxypeptidase E precursor\nMAGRGGSALLALCGALAACGWLLGAEAQEPGAPAAGMRRRRRLQQEDGISFEYHRYPELR\nEALVSVWLQCTAISRIYTVGRSFEGRELLVIELSDNPGVHEPGEPEFKYIGNMHGNEAVG\nRELLIFLAQYLCNEYQKGNETIVNLIHSTRIHIMPSLNPDGFEKAASQPGELKDWFVGRS\nNAQGIDLNRNFPDLDRIVYVNEKEGGPNNHLLKNMKKIVDQNTKLAPETKAVIHWIMDIP\nFVLSANLHGGDLVANYPYDETRSGSAHEYSSSPDDAIFQSLARAYSSFNPAMSDPNRPPC\nRKNDDDSSFVDGTTNGGAWYSVPGGMQDFNYLSSNCFEITVELSCEKFPPEETLKTYWED\nNKNSLISYLEQIHRGVKGFVRDLQGNPIANATISVEGIDHDVTSAKDGDYWRLLIPGNYK\nLTASAPGYLAITKKVAVPYSPAAGVDFELESFSERKEEEKEELMEWWKMMSETLNF"}, "gene-sequence": {"@format": "FASTA", "#text": ">1431 bp\nATGGCCGGGCGAGGGGGCAGCGCGCTGCTGGCTCTGTGCGGGGCACTGGCTGCCTGCGGG\nTGGCTCCTGGGCGCCGAAGCCCAGGAGCCCGGGGCGCCCGCGGCGGGCATGAGGCGGCGC\nCGGCGGCTGCAGCAAGAGGACGGCATCTCCTTCGAGTACCACCGCTACCCCGAGCTGCGC\nGAGGCGCTCGTGTCCGTGTGGCTGCAGTGCACCGCCATCAGCAGGATTTACACGGTGGGG\nCGCAGCTTCGAGGGCCGGGAGCTCCTGGTCATCGAGCTGTCCGACAACCCTGGCGTCCAT\nGAGCCTGGTGAGCCTGAATTTAAATACATTGGGAATATGCATGGGAATGAGGCTGTTGGA\nCGAGAACTGCTCATTTTCTTGGCCCAGTACCTATGCAACGAATACCAGAAGGGGAACGAG\nACAATTGTCAACCTGATCCACAGTACCCGCATTCACATCATGCCTTCCCTGAACCCAGAT\nGGCTTTGAGAAGGCAGCGTCTCAGCCTGGTGAACTCAAGGACTGGTTTGTGGGTCGAAGC\nAATGCCCAGGGAATAGATCTGAACCGGAACTTTCCAGACCTGGATAGGATAGTGTACGTG\nAATGAGAAAGAAGGTGGTCCAAATAATCATCTGTTGAAAAATATGAAGAAAATTGTGGAT\nCAAAACACAAAGCTTGCTCCTGAGACCAAGGCTGTCATTCATTGGATTATGGATATTCCT\nTTTGTGCTTTCTGCCAATCTCCATGGAGGAGACCTTGTGGCCAATTATCCATATGATGAG\nACGCGGAGTGGTAGTGCTCACGAATACAGCTCCTCCCCAGATGACGCCATTTTCCAAAGC\nTTGGCCCGGGCATACTCTTCTTTCAACCCGGCCATGTCTGACCCCAATCGGCCACCATGT\nCGCAAGAATGATGATGACAGCAGCTTTGTAGATGGAACCACCAACGGTGGTGCTTGGTAC\nAGCGTACCTGGAGGGATGCAAGACTTCAATTACCTTAGCAGCAACTGTTTTGAGATCACC\nGTGGAGCTTAGCTGTGAGAAGTTCCCACCTGAAGAGACTCTGAAGACCTACTGGGAGGAT\nAACAAAAACTCCCTCATTAGCTACCTTGAGCAGATACACCGAGGAGTTAAAGGATTTGTC\nCGAGACCTTCAAGGTAACCCAATTGCGAATGCCACCATCTCCGTGGAAGGAATAGACCAC\nGATGTTACATCCGCAAAGGATGGTGATTACTGGAGATTGCTTATACCTGGAAACTATAAA\nCTTACAGCCTCAGCTCCAGGCTATCTGGCAATAACAAAGAAAGTGGCAGTTCCTTACAGC\nCCTGCTGCTGGGGTTGATTTTGAACTGGAGTCATTTTCTGAAAGGAAAGAAGAGGAGAAG\nGAAGAATTGATGGAATGGTGGAAAATGATGTCAGAAACTTTAAATTTTTAA"}, "pfams": {"pfam": {"identifier": "PF00246", "name": "Peptidase_M14"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "exopeptidase activity"}, {"category": "function", "description": "carboxypeptidase activity"}, {"category": "function", "description": "metallocarboxypeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "carboxypeptidase A activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}]}}}, {"@position": "8", "id": "BE0002125", "name": "Neuroendocrine convertase 1", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P29120", "@source": "Swiss-Prot", "name": "Neuroendocrine convertase 1", "general-function": "Posttranslational modification, protein turnover, chaperones", "specific-function": "Involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues. Substrates include POMC, renin, enkephalin, dynorphin, somatostatin and insulin", "gene-name": "PCSK1", "locus": "5q15-q21", "cellular-location": "Cytoplasmic vesicle", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.84", "molecular-weight": "84152.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:8743"}, {"resource": "GenAtlas", "identifier": "PCSK1"}, {"resource": "GeneCards", "identifier": "PCSK1"}, {"resource": "GenBank Gene Database", "identifier": "X64810"}, {"resource": "GenBank Protein Database", "identifier": "35318"}, {"resource": "UniProtKB", "identifier": "P29120"}, {"resource": "UniProt Accession", "identifier": "NEC1_HUMAN"}]}, "synonyms": {"synonym": ["EC 3.4.21.93", "NEC 1", "Neuroendocrine convertase 1 precursor", "PC1", "Prohormone convertase 1", "Proprotein convertase 1"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Neuroendocrine convertase 1\nMERRAWSLQCTAFVLFCAWCALNSAKAKRQFVNEWAAEIPGGPEAASAIAEELGYDLLGQ\nIGSLENHYLFKHKNHPRRSRRSAFHITKRLSDDDRVIWAEQQYEKERSKRSALRDSALNL\nFNDPMWNQQWYLQDTRMTAALPKLDLHVIPVWQKGITGKGVVITVLDDGLEWNHTDIYAN\nYDPEASYDFNDNDHDPFPRYDPTNENKHGTRCAGEIAMQANNHKCGVGVAYNSKVGGIRM\nLDGIVTDAIEASSIGFNPGHVDIYSASWGPNDDGKTVEGPGRLAQKAFEYGVKQGRQGKG\nSIFVWASGNGGRQGDNCDCDGYTDSIYTISISSASQQGLSPWYAEKCSSTLATSYSSGDY\nTDQRITSADLHNDCTETHTGTSASAPLAAGIFALALEANPNLTWRDMQHLVVWTSEYDPL\nANNPGWKKNGAGLMVNSRFGFGLLNAKALVDLADPRTWRSVPEKKECVVKDNDFEPRALK\nANGEVIIEIPTRACEGQENAIKSLEHVQFEATIEYSRRGDLHVTLTSAAGTSTVLLAERE\nRDTSPNGFKNWDFMSVHTWGENPIGTWTLRITDMSGRIQNEGRIVNWKLILHGTSSQPEH\nMKQPRVYTSYNTVQNDRRGVEKMVDPGEEQPTQENPKENTLVSKSPSSSSVGGRRDELEE\nGAPSQAMLRLLQSAFSKNSPPKQSPKKSPSAKLNIPYENFYEALEKLNKPSQLKDSEDSL\nYNDYVDVFYNTKPYKHRDDRLLQALVDILNEEN"}, "gene-sequence": {"@format": "FASTA", "#text": ">2262 bp\nATGGAGCGAAGAGCCTGGAGTCTGCAGTGCACTGCTTTCGTCCTCTTTTGCGCTTGGTGT\nGCACTGAACAGTGCAAAAGCGAAAAGGCAATTTGTCAATGAATGGGCAGCGGAGATCCCC\nGGGGGCCCGGAAGCAGCCTCGGCCATCGCCGAGGAGCTGGGCTATGACCTTTTGGGTCAG\nATTGGTTCACTTGAAAATCACTACTTATTCAAACATAAAAACCACCCCAGAAGGTCTCGA\nAGGAGTGCCTTTCATATCACTAAGAGATTATCTGATGATGATCGTGTGATATGGGCTGAA\nCAACAGTATGAAAAAGAAAGAAGTAAACGTTCAGCTCTAAGGGACTCAGCACTAAATCTC\nTTCAATGATCCCATGTGGAATCAGCAATGGTACTTGCAAGATACCAGGATGACGGCAGCC\nCTGCCCAAGCTGGACCTTCATGTGATACCTGTTTGGCAAAAAGGCATTACGGGCAAAGGA\nGTTGTTATCACCGTACTGGATGATGGTTTGGAGTGGAATCACACGGACATTTATGCCAAC\nTATGATCCAGAGGCTAGCTATGATTTTAATGATAATGACCATGATCCATTTCCCCGATAT\nGATCCCACAAACGAGAACAAACACGGGACCAGATGTGCAGGAGAAATTGCCATGCAAGCA\nAATAATCACAAATGCGGGGTTGGAGTTGCATACAATTCCAAAGTTGGAGGCATAAGAATG\nCTGGATGGCATTGTGACGGATGCTATTGAGGCCAGTTCAATTGGATTCAATCCTGGACAC\nGTGGATATTTACAGTGCAAGCTGGGGCCCTAATGATGATGGGAAAACTGTGGAGGGGCCT\nGGCCGGCTAGCCCAGAAGGCTTTTGAATATGGTGTCAAACAGGGGAGACAGGGGAAGGGG\nTCCATCTTCGTCTGGGCTTCGGGAAACGGGGGGCGTCAGGGAGATAATTGTGACTGTGAT\nGGCTACACAGACAGCATCTACACCATCTCCATCAGCAGTGCCTCCCAGCAAGGCCTATCC\nCCCTGGTACGCTGAGAAGTGCTCCTCCACACTGGCCACCTCTTACAGCGGCGGAGATTAC\nACCGACCAGAGAATCACGAGCGCTGACCTGCACAATGACTGCACGGAGACGCACACAGGC\nACCTCGGCCTCTGCACCTCTGGCTGCTGGCATCTTCGCTCTGGCCCTGGAAGCAAACCCA\nAATCTCACCTGGCGAGATATGCAGCACCTGGTTGTCTGGACCTCTGAGTATGACCCGCTG\nGCCAATAACCCTGGATGGAAAAAGAATGGAGCAGGCTTGATGGTGAATAGTCGATTTGGA\nTTTGGCTTGCTAAATGCCAAAGCTCTGGTGGATTTAGCTGACCCCAGGACCTGGAGGAGC\nGTGCCTGAGAAGAAAGAGTGTGTTGTAAAGGACAATGACTTTGAGCCCAGAGCCCTGAAA\nGCTAATGGAGAAGTTATCATTGAAATTCCAACAAGAGCTTGTGAAGGACAAGAAAATGCT\nATCAAGTCCCTGGAGCATGTACAATTTGAAGCAACAATTGAATATTCCCGAAGAGGAGAC\nCTTCATGTCACACTTACTTCTGCTGCTGGAACTAGCACTGTGCTCTTGGCTGAAAGAGAA\nCGGGATACATCTCCTAATGGCTTTAAGAACTGGGACTTCATGTCTGTTCACACATGGGGA\nGAGAACCCTATAGGTACTTGGACTTTGAGAATTACAGACATGTCTGGAAGAATTCAAAAT\nGAAGGAAGAATTGTGAACTGGAAGCTGATTTTGCACGGGACCTCTTCTCAGCCAGAGCAT\nATGAAGCAGCCTCGTGTGTACACGTCCTACAACACTGTTCAGAATGACAGAAGAGGGGTG\nGAGAAGATGGTGGATCCAGGGGAGGAGCAGCCCACACAAGAGAACCCTAAGGAGAACACC\nCTGGTGTCCAAAAGCCCCAGCAGCAGCAGCGTAGGGGGCCGGAGGGATGAGTTGGAGGAG\nGGAGCCCCTTCCCAGGCCATGCTGCGACTCCTGCAAAGTGCTTTCAGTAAAAACTCACCG\nCCAAAGCAATCACCAAAGAAGTCCCCAAGTGCAAAGCTCAACATCCCTTATGAAAACTTC\nTACGAAGCCCTGGAAAAGCTGAACAAACCTTCCCAGCTTAAAGACTCTGAAGACAGTCTG\nTATAATGACTATGTTGATGTTTTTTATAACACTAAACCTTACAAGCACAGAGACGACCGG\nCTGCTTCAAGCTCTGGTGGACATTCTGAATGAGGAAAATTAA"}, "pfams": {"pfam": [{"identifier": "PF00082", "name": "Peptidase_S8"}, {"identifier": "PF01483", "name": "P_proprotein"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "subtilase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}]}}}, {"@position": "9", "id": "BE0001147", "name": "Protein NOV homolog", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P48745", "@source": "Swiss-Prot", "name": "Protein NOV homolog", "general-function": "Involved in insulin-like growth factor binding", "specific-function": "Immediate-early protein likely to play a role in cell growth regulation", "gene-name": "NOV", "locus": "8q24.1", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.74", "molecular-weight": "39162.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:7885"}, {"resource": "GenAtlas", "identifier": "NOV"}, {"resource": "GeneCards", "identifier": "NOV"}, {"resource": "GenBank Gene Database", "identifier": "X78351"}, {"resource": "GenBank Protein Database", "identifier": "825696"}, {"resource": "UniProtKB", "identifier": "P48745"}, {"resource": "UniProt Accession", "identifier": "NOV_HUMAN"}]}, "synonyms": {"synonym": ["Nephroblastoma overexpressed gene protein homolog", "NovH", "Protein NOV homolog precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Protein NOV homolog precursor\nMQSVQSTSFCLRKQCLCLTFLLLHLLGQVAATQRCPPQCPGRCPATPPTCAPGVRAVLDG\nCSCCLVCARQRGESCSDLEPCDESSGLYCDRSADPSNQTGICTAVEGDNCVFDGVIYRSG\nEKFQPSCKFQCTCRDGQIGCVPRCQLDVLLPEPNCPAPRKVEVPGECCEKWICGPDEEDS\nLGGLTLAAYRPEATLGVEVSDSSVNCIEQTTEWTACSKSCGMGFSTRVTNRNRQCEMLKQ\nTRLCMVRPCEQEPEQPTDKKGKKCLRTKKSLKAIHLQFKNCTSLHTYKPRFCGVCSDGRC\nCTPHNTKTIQAEFQCSPGQIVKKPVMVIGTCTCHTNCPKNNEAFLQELELKTTRGKM"}, "gene-sequence": {"@format": "FASTA", "#text": ">1074 bp\nATGCAGAGTGTGCAGAGCACGAGCTTTTGTCTCCGAAAGCAGTGCCTTTGCCTGACCTTC\nCTGCTTCTCCATCTCCTGGGACAGGTCGCTGCGACTCAGCGCTGCCCTCCCCAGTGCCCG\nGGCCGGTGCCCTGCGACGCCGCCGACCTGCGCCCCCGGGGTGCGCGCGGTGCTGGACGGC\nTGCTCATGCTGTCTGGTGTGTGCCCGCCAGCGTGGCGAGAGCTGCTCAGATCTGGAGCCA\nTGCGACGAGAGCAGTGGCCTCTACTGTGATCGCAGCGCGGACCCCAGCAACCAGACTGGC\nATCTGCACGGCGGTAGAGGGAGATAACTGTGTGTTCGATGGGGTCATCTACCGCAGTGGA\nGAGAAATTTCAGCCAAGCTGCAAATTCCAGTGCACCTGCAGAGATGGGCAGATTGGCTGT\nGTGCCCCGCTGTCAGCTGGATGTGCTACTGCCTGAGCCTAACTGCCCAGCTCCAAGAAAA\nGTTGAGGTGCCTGGAGAGTGCTGTGAAAAGTGGATCTGTGGCCCAGATGAGGAGGATTCA\nCTGGGAGGCCTTACCCTTGCAGCTTACAGGCCAGAAGCCACCCTAGGAGTAGAAGTCTCT\nGACTCAAGTGTCAACTGCATTGAACAGACCACAGAGTGGACAGCATGCTCCAAGAGCTGT\nGGTATGGGGTTCTCCACCCGGGTCACCAATAGGAACCGTCAATGTGAGATGCTGAAACAG\nACTCGGCTCTGCATGGTGCGGCCCTGTGAACAAGAGCCAGAGCAGCCAACAGATAAGAAA\nGGAAAAAAGTGTCTCCGCACCAAGAAGTCACTCAAAGCCATCCACCTGCAGTTCAAGAAC\nTGCACCAGCCTGCACACCTACAAGCCCAGGTTCTGTGGGGTCTGCAGTGATGGCCGCTGC\nTGCACTCCCCACAATACCAAAACCATCCAGGCAGAGTTTCAGTGCTCCCCAGGGCAAATA\nGTCAAGAAGCCAGTGATGGTCATTGGGACCTGCACCTGTCACACCAACTGTCCTAAGAAC\nAATGAGGCCTTCCTCCAGGAGCTGGAGCTGAAGACTACCAGAGGGAAAATGTAA"}, "pfams": {"pfam": [{"identifier": "PF00093", "name": "VWC"}, {"identifier": "PF00219", "name": "IGFBP"}, {"identifier": "PF00007", "name": "Cys_knot"}, {"identifier": "PF00090", "name": "TSP_1"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "protein binding"}, {"category": "function", "description": "growth factor binding"}, {"category": "function", "description": "insulin-like growth factor binding"}, {"category": "process", "description": "regulation of biological process"}, {"category": "process", "description": "regulation of growth"}, {"category": "process", "description": "regulation of cell growth"}]}}}, {"@position": "10", "id": "BE0000942", "name": "Low-density lipoprotein receptor-related protein 2", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P98164", "@source": "Swiss-Prot", "name": "Low-density lipoprotein receptor-related protein 2", "general-function": "Involved in calcium ion binding", "specific-function": "May participate in regulation of parathyroid-hormone and para-thyroid-hormone-related protein release", "gene-name": "LRP2", "locus": "2q24-q31", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "4424-4446", "signal-regions": null, "theoretical-pi": "4.68", "molecular-weight": "521933.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6694"}, {"resource": "GenAtlas", "identifier": "LRP2"}, {"resource": "GeneCards", "identifier": "LRP2"}, {"resource": "GenBank Gene Database", "identifier": "U33837"}, {"resource": "GenBank Protein Database", "identifier": "1809240"}, {"resource": "UniProtKB", "identifier": "P98164"}, {"resource": "UniProt Accession", "identifier": "LRP2_HUMAN"}]}, "synonyms": {"synonym": ["Glycoprotein 330", "gp330", "Low-density lipoprotein receptor-related protein 2 precursor", "Megalin"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low-density lipoprotein receptor-related protein 2 precursor\nMDRGPAAVACTLLLALVACLAPASGQECDSAHFRCGSGHCIPADWRCDGTKDCSDDADEI\nGCAVVTCQQGYFKCQSEGQCIPSSWVCDQDQDCDDGSDERQDCSQSTCSSHQITCSNGQC\nIPSEYRCDHVRDCPDGADENDCQYPTCEQLTCDNGACYNTSQKCDWKVDCRDSSDEINCT\nEICLHNEFSCGNGECIPRAYVCDHDNDCQDGSDEHACNYPTCGGYQFTCPSGRCIYQNWV\nCDGEDDCKDNGDEDGCESGPHDVHKCSPREWSCPESGRCISIYKVCDGILDCPGREDENN\nTSTGKYCSMTLCSALNCQYQCHETPYGGACFCPPGYIINHNDSRTCVEFDDCQIWGICDQ\nKCESRPGRHLCHCEEGYILERGQYCKANDSFGEASIIFSNGRDLLIGDIHGRSFRILVES\nQNRGVAVGVAFHYHLQRVFWTDTVQNKVFSVDINGLNIQEVLNVSVETPENLAVDWVNNK\nIYLVETKVNRIDMVNLDGSYRVTLITENLGHPRGIAVDPTVGYLFFSDWESLSGEPKLER\nAFMDGSNRKDLVKTKLGWPAGVTLDMISKRVYWVDSRFDYIETVTYDGIQRKTVVHGGSL\nIPHPFGVSLFEGQVFFTDWTKMAVLKANKFTETNPQVYYQASLRPYGVTVYHSLRQPYAT\nNPCKDNNGGCEQVCVLSHRTDNDGLGFRCKCTFGFQLDTDERHCIAVQNFLIFSSQVAIR\nGIPFTLSTQEDVMVPVSGNPSFFVGIDFDAQDSTIFFSDMSKHMIFKQKIDGTGREILAA\nNRVENVESLAFDWISKNLYWTDSHYKSISVMRLADKTRRTVVQYLNNPRSVVVHPFAGYL\nFFTDWFRPAKIMRAWSDGSHLLPVINTTLGWPNGLAIDWAASRLYWVDAYFDKIEHSTFD\nGLDRRRLGHIEQMTHPFGLAIFGEHLFFTDWRLGAIIRVRKADGGEMTVIRSGIAYILHL\nKSYDVNIQTGSNACNQPTHPNGDCSHFCFPVPNFQRVCGCPYGMRLASNHLTCEGDPTNE\nPPTEQCGLFSFPCKNGRCVPNYYLCDGVDDCHDNSDEQLCGTLNNTCSSSAFTCGHGECI\nPAHWRCDKRNDCVDGSDEHNCPTHAPASCLDTQYTCDNHQCISKNWVCDTDNDCGDGSDE\nKNCNSTETCQPSQFNCPNHRCIDLSFVCDGDKDCVDGSDEVGCVLNCTASQFKCASGDKC\nIGVTNRCDGVFDCSDNSDEAGCPTRPPGMCHSDEFQCQEDGICIPNFWECDGHPDCLYGS\nDEHNACVPKTCPSSYFHCDNGNCIHRAWLCDRDNDCGDMSDEKDCPTQPFRCPSWQWQCL\nGHNICVNLSVVCDGIFDCPNGTDESPLCNGNSCSDFNGGCTHECVQEPFGAKCLCPLGFL\nLANDSKTCEDIDECDILGSCSQHCYNMRGSFRCSCDTGYMLESDGRTCKVTASESLLLLV\nASQNKIIADSVTSQVHNIYSLVENGSYIVAVDFDSISGRIFWSDATQGKTWSAFQNGTDR\nRVVFDSSIILTETIAIDWVGRNLYWTDYALETIEVSKIDGSHRTVLISKNLTNPRGLALD\nPRMNEHLLFWSDWGHHPRIERASMDGSMRTVIVQDKIFWPCGLTIDYPNRLLYFMDSYLD\nYMDFCDYNGHHRRQVIASDLIIRHPYALTLFEDSVYWTDRATRRVMRANKWHGGNQSVVM\nYNIQWPLGIVAVHPSKQPNSVNPCAFSRCSHLCLLSSQGPHFYSCVCPSGWSLSPDLLNC\nLRDDQPFLITVRQHIIFGISLNPEVKSNDAMVPIAGIQNGLDVEFDDAEQYIYWVENPGE\nIHRVKTDGTNRTVFASISMVGPSMNLALDWISRNLYSTNPRTQSIEVLTLHGDIRYRKTL\nIANDGTALGVGFPIGITVDPARGKLYWSDQGTDSGVPAKIASANMDGTSVKTLFTGNLEH\nLECVTLDIEEQKLYWAVTGRGVIERGNVDGTDRMILVHQLSHPWGIAVHDSFLYYTDEQY\nEVIERVDKATGANKIVLRDNVPNLRGLQVYHRRNAAESSNGCSNNMNACQQICLPVPGGL\nFSCACATGFKLNPDNRSCSPYNSFIVVSMLSAIRGFSLELSDHSETMVPVAGQGRNALHV\nDVDVSSGFIYWCDFSSSVASDNAIRRIKPDGSSLMNIVTHGIGENGVRGIAVDWVAGNLY\nFTNAFVSETLIEVLRINTTYRRVLLKVTVDMPRHIVVDPKNRYLFWADYGQRPKIERSFL\nDCTNRTVLVSEGIVTPRGLAVDRSDGYVYWVDDSLDIIARIRINGENSEVIRYGSRYPTP\nYGITVFENSIIWVDRNLKKIFQASKEPENTEPPTVIRDNINWLRDVTIFDKQVQPRSPAE\nVNNNPCLENNGGCSHLCFALPGLHTPKCDCAFGTLQSDGKNCAISTENFLIFALSNSLRS\nLHLDPENHSPPFQTINVERTVMSLDYDSVSDRIYFTQNLASGVGQISYATLSSGIHTPTV\nIASGIGTADGIAFDWITRRIYYSDYLNQMINSMAEDGSNRTVIARVPKPRAIVLDPCQGY\nLYWADWDTHAKIERATLGGNFRVPIVNSSLVMPSGLTLDYEEDLLYWVDASLQRIERSTL\nTGVDREVIVNAAVHAFGLTLYGQYIYWTDLYTQRIYRANKYDGSGQIAMTTNLLSQPRGI\nNTVVKNQKQQCNNPCEQFNGGCSHICAPGPNGAECQCPHEGNWYLANNRKHCIVDNGERC\nGASSFTCSNGRCISEEWKCDNDNDCGDGSDEMESVCALHTCSPTAFTCANGRCVQYSYRC\nDYYNDCGDGSDEAGCLFRDCNATTEFMCNNRRCIPREFICNGVDNCHDNNTSDEKNCPDR\nTCQSGYTKCHNSNICIPRVYLCDGDNDCGDNSDENPTYCTTHTCSSSEFQCASGRCIPQH\nWYCDQETDCFDASDEPASCGHSERTCLADEFKCDGGRCIPSEWICDGDNDCGDMSDEDKR\nHQCQNQNCSDSEFLCVNDRPPDRRCIPQSWVCDGDVDCTDGYDENQNCTRRTCSENEFTC\nGYGLCIPKIFRCDRHNDCGDYSDERGCLYQTCQQNQFTCQNGRCISKTFVCDEDNDCGDG\nSDELMHLCHTPEPTCPPHEFKCDNGRCIEMMKLCNHLDDCLDNSDEKGCGINECHDPSIS\nGCDHNCTDTLTSFYCSCRPGYKLMSDKRTCVDIDECTEMPFVCSQKCENVIGSYICKCAP\nGYLREPDGKTCRQNSNIEPYLIFSNRYYLRNLTIDGYFYSLILEGLDNVVALDFDRVEKR\nLYWIDTQRQVIERMFLNKTNKETIINHRLPAAESLAVDWVSRKLYWLDARLDGLFVSDLN\nGGHRRMLAQHCVDANNTFCFDNPRGLALHPQYGYLYWADWGHRAYIGRVGMDGTNKSVII\nSTKLEWPNGITIDYTNDLLYWADAHLGYIEYSDLEGHHRHTVYDGALPHPFAITIFEDTI\nYWTDWNTRTVEKGNKYDGSNRQTLVNTTHRPFDIHVYHPYRQPIVSNPCGTNNGGCSHLC\nLIKPGGKGFTCECPDDFRTLQLSGSTYCMPMCSSTQFLCANNEKCIPIWWKCDGQKDCSD\nGSDELALCPQRFCRLGQFQCSDGNCTSPQTLCNAHQNCPDGSDEDRLLCENHHCDSNEWQ\nCANKRCIPESWQCDTFNDCEDNSDEDSSHCASRTCRPGQFRCANGRCIPQAWKCDVDNDC\nGDHSDEPIEECMSSAHLCDNFTEFSCKTNYRCIPKWAVCNGVDDCRDNSDEQGCEERTCH\nPVGDFRCKNHHCIPLRWQCDGQNDCGDNSDEENCAPRECTESEFRCVNQQCIPSRWICDH\nYNDCGDNSDERDCEMRTCHPEYFQCTSGHCVHSELKCDGSADCLDASDEADCPTRFPDGA\nYCQATMFECKNHVCIPPYWKCDGDDDCGDGSDEELHLCLDVPCNSPNRFRCDNNRCIYSH\nEVCNGVDDCGDGTDETEEHCRKPTPKPCTEYEYKCGNGHCIPHDNVCDDADDCGDWSDEL\nGCNKGKERTCAENICEQNCTQLNEGGFICSCTAGFETNVFDRTSCLDINECEQFGTCPQH\nCRNTKGSYECVCADGFTSMSDRPGKRCAAEGSSPLLLLPDNVRIRKYNLSSERFSEYLQD\nEEYIQAVDYDWDPKDIGLSVVYYTVRGEGSRFGAIKRAYIPNFESGRNNLVQEVDLKLKY\nVMQPDGIAVDWVGRHIYWSDVKNKRIEVAKLDGRYRKWLISTDLDQPAAIAVNPKLGLMF\nWTDWGKEPKIESAWMNGEDRNILVFEDLGWPTGLSIDYLNNDRIYWSDFKEDVIETIKYD\nGTDRRVIAKEAMNPYSLDIFEDQLYWISKEKGEVWKQNKFGQGKKEKTLVVNPWLTQVRI\nFHQLRYNKSVPNLCKQICSHLCLLRPGGYSCACPQGSSFIEGSTTECDAAIELPINLPPP\nCRCMHGGNCYFDETDLPKCKCPSGYTGKYCEMAFSKGISPGTTAVAVLLTILLIVVIGAL\nAIAGFFHYRRTGSLLPALPKLPSLSSLVKPSENGNGVTFRSGADLNMDIGVSGFGPETAI\nDRSMAMSEDFVMEMGKQPIIFENPMYSARDSAVKVVQPIQVTVSENVDNKNYGSPINPSE\nIVPETNPTSPAADGTQVTKWNLFKRKSKQTTNFENPIYAQMENEQKESVAATPPPSPSLP\nAKPKPPSRRDPTPTYSATEDTFKDTANLVKEDSEV"}, "gene-sequence": {"@format": "FASTA", "#text": ">13968 bp\nATGGATCGCGGGCCGGCAGCAGTGGCGTGCACGCTGCTCCTGGCTCTCGTCGCCTGCCTA\nGCGCCGGCCAGTGGCCAAGAATGTGACAGTGCGCATTTTCGCTGTGGAAGTGGGCATTGC\nATCCCTGCAGACTGGAGGTGTGATGGGACCAAAGACTGTTCAGATGACGCGGATGAAATT\nGGCTGCGCTGTTGTGACCTGCCAGCAGGGCTATTTCAAGTGCCAGAGTGAGGGACAATGC\nATCCCCAGCTCCTGGGTGTGTGACCAAGATCAAGACTGTGATGATGGCTCAGATGAACGT\nCAAGATTGCTCACAAAGTACATGCTCAAGTCATCAGATAACATGCTCCAATGGTCAGTGT\nATCCCAAGTGAATACAGGTGCGACCACGTCAGAGACTGCCCCGATGGAGCTGATGAGAAT\nGACTGCCAGTACCCAACATGTGAGCAGCTTACTTGTGACAATGGGGCCTGCTATAACACC\nAGTCAGAAGTGTGATTGGAAAGTTGATTGCAGGGACTCCTCAGATGAAATCAACTGCACT\nGAGATATGCTTGCACAATGAGTTTTCATGTGGCAATGGAGAGTGTATCCCTCGTGCTTAT\nGTCTGTGACCATGACAATGATTGCCAAGACGGCAGTGATGAACATGCTTGCAACTATCCG\nACCTGCGGTGGTTACCAGTTCACTTGCCCCAGTGGCCGATGCATTTATCAAAACTGGGTT\nTGTGATGGAGAAGATGACTGTAAAGATAATGGAGATGAAGATGGATGTGAAAGCGGTCCT\nCATGATGTTCATAAATGTTCCCCAAGAGAATGGTCTTGCCCAGAGTCGGGACGATGCATC\nTCCATTTATAAAGTTTGTGATGGGATTTTAGATTGCCCAGGAAGAGAAGATGAAAACAAC\nACTAGTACCGGAAAATACTGTAGTATGACTCTGTGCTCTGCCTTGAACTGCCAGTACCAG\nTGCCATGAGACGCCGTATGGAGGAGCGTGTTTTTGTCCCCCAGGTTATATCATCAACCAC\nAATGACAGCCGTACCTGTGTTGAGTTTGATGATTGCCAGATATGGGGAATTTGTGACCAG\nAAGTGTGAAAGCCGACCTGGCCGTCACCTGTGCCACTGTGAAGAAGGGTATATCTTGGAG\nCGTGGACAGTATTGCAAAGCTAATGATTCCTTTGGCGAGGCCTCCATTATCTTCTCCAAT\nGGTCGGGATTTGTTAATTGGTGATATTCATGGAAGGAGCTTCCGGATCCTAGTGGAGTCT\nCAGAATCGTGGAGTGGCCGTGGGTGTGGCTTTCCACTATCACCTGCAAAGAGTTTTTTGG\nACAGACACCGTGCAAAATAAGGTTTTTTCAGTTGACATTAATGGTTTAAATATCCAAGAG\nGTTCTCAATGTTTCTGTTGAAACCCCAGAGAACCTGGCTGTGGACTGGGTTAATAATAAA\nATCTATCTAGTGGAAACCAAGGTCAACCGCATAGATATGGTAAATTTGGATGGAAGCTAT\nCGGGTTACCCTTATAACTGAAAACTTGGGGCATCCTAGAGGAATTGCCGTGGACCCAACT\nGTTGGTTATTTATTTTTCTCAGATTGGGAGAGCCTTTCTGGGGAACCTAAGCTGGAAAGG\nGCATTCATGGATGGCAGCAACCGTAAAGACTTGGTGAAAACAAAGCTGGGATGGCCTGCT\nGGGGTAACTCTGGATATGATATCGAAGCGTGTTTACTGGGTTGACTCTCGGTTTGATTAC\nATTGAAACTGTAACTTATGATGGAATTCAAAGGAAGACTGTAGTTCATGGAGGCTCCCTC\nATTCCTCATCCCTTTGGAGTAAGCTTATTTGAAGGTCAGGTGTTCTTTACAGATTGGACA\nAAGATGGCCGTGCTGAAGGCAAACAAGTTCACAGAGACCAACCCACAAGTGTACTACCAG\nGCTTCCCTGAGGCCCTATGGAGTGACTGTTTACCATTCCCTCAGACAGCCCTATGCTACC\nAATCCGTGTAAAGATAACAATGGGGGCTGTGAGCAGGTCTGTGTTCTCAGCCACAGAACA\nGATAATGATGGTTTGGGTTTCCGTTGCAAGTGCACATTCGGCTTCCAACTGGATACAGAT\nGAGCGCCACTGCATTGCTGTTCAGAATTTCCTCATTTTTTCATCCCAAGTTGCTATTCGT\nGGGATCCCGTTCACCTTGTCTACCCAGGAAGATGTCATGGTTCCAGTTTCGGGGAATCCT\nTCTTTCTTTGTCGGGATTGATTTTGACGCCCAGGACAGCACTATCTTTTTTTCAGATATG\nTCAAAACACATGATTTTTAAGCAAAAGATTGATGGCACAGGAAGAGAAATTCTCGCAGCT\nAACAGGGTGGAAAATGTTGAAAGTTTGGCTTTTGATTGGATTTCAAAGAATCTCTATTGG\nACAGACTCTCATTACAAGAGTATCAGTGTCATGAGGCTAGCTGATAAAACGAGACGCACA\nGTAGTTCAGTATTTAAATAACCCACGGTCGGTGGTAGTTCATCCTTTTGCCGGGTATCTA\nTTCTTCACTGATTGGTTCCGTCCTGCTAAAATTATGAGAGCATGGAGTGACGGATCTCAC\nCTCTTGCCTGTAATAAACACTACTCTTGGATGGCCCAATGGCTTGGCCATCGATTGGGCT\nGCTTCACGATTGTACTGGGTAGATGCCTATTTTGATAAAATTGAGCACAGCACCTTTGAT\nGGTTTAGACAGAAGAAGACTGGGCCATATAGAGCAGATGACACATCCGTTTGGACTTGCC\nATCTTTGGAGAGCATTTATTTTTTACTGACTGGAGACTGGGTGCCATTATTCGAGTCAGG\nAAAGCAGATGGTGGAGAAATGACAGTTATCCGAAGTGGCATTGCTTACATACTGCATTTG\nAAATCGTATGATGTCAACATCCAGACTGGTTCTAACGCCTGTAATCAACCCACGCATCCT\nAACGGTGACTGCAGCCACTTCTGCTTCCCGGTGCCAAATTTCCAGCGAGTGTGTGGGTGC\nCCTTATGGAATGAGGCTGGCTTCCAATCACTTGACATGCGAGGGGGACCCAACCAATGAA\nCCACCCACGGAGCAGTGTGGCTTATTTTCCTTCCCCTGTAAAAATGGCAGATGTGTGCCC\nAATTACTATCTCTGTGATGGAGTCGATGATTGTCATGATAACAGTGATGAGCAACTATGT\nGGCACACTTAATAATACCTGTTCATCTTCGGCGTTCACCTGTGGCCATGGGGAGTGCATT\nCCTGCACACTGGCGCTGTGACAAACGCAACGACTGTGTGGATGGCAGTGATGAGCACAAC\nTGCCCCACCCACGCACCTGCTTCCTGCCTTGACACCCAATACACCTGTGATAATCACCAG\nTGTATCTCAAAGAACTGGGTCTGTGACACAGACAATGATTGTGGGGATGGATCTGATGAA\nAAGAACTGCAATTCGACAGAGACATGCCAACCTAGTCAGTTTAATTGCCCCAATCATCGA\nTGTATTGACCTATCGTTTGTCTGTGATGGTGACAAGGATTGTGTTGATGGATCTGATGAG\nGTTGGTTGTGTATTAAACTGTACTGCTTCTCAATTCAAGTGTGCCAGTGGGGATAAATGT\nATTGGCGTCACAAATCGTTGTGATGGTGTTTTTGATTGCAGTGACAACTCGGATGAAGCG\nGGCTGTCCAACCAGGCCTCCTGGTATGTGCCACTCAGATGAATTTCAGTGCCAAGAAGAT\nGGTATCTGCATCCCGAACTTCTGGGAATGTGATGGGCATCCAGACTGCCTCTATGGATCT\nGATGAGCACAATGCCTGTGTCCCCAAGACTTGCCCTTCATCATATTTCCACTGTGACAAC\nGGAAACTGCATCCACAGGGCATGGCTCTGTGATCGGGACAATGACTGCGGGGATATGAGT\nGATGAGAAGGACTGCCCTACTCAGCCCTTTCGCTGTCCTAGTTGGCAATGGCAGTGTCTT\nGGCCATAACATCTGTGTGAATCTGAGTGTAGTGTGTGATGGCATCTTTGACTGCCCCAAT\nGGGACAGATGAGTCCCCACTTTGCAATGGGAACAGCTGCTCAGATTTCAATGGTGGTTGT\nACTCACGAGTGTGTTCAAGAGCCCTTTGGGGCTAAATGCCTATGTCCATTGGGATTCTTA\nCTTGCCAATGATTCTAAGACCTGTGAAGACATAGATGAATGTGATATTCTAGGCTCTTGT\nAGCCAGCACTGTTACAATATGAGAGGTTCTTTCCGGTGCTCGTGTGATACAGGCTACATG\nTTAGAAAGTGATGGGAGGACTTGCAAAGTTACAGCATCTGAGAGTCTGCTGTTACTTGTG\nGCAAGTCAGAACAAAATTATTGCCGACAGTGTCACCTCCCAGGTCCACAATATCTATTCA\nTTGGTCGAGAATGGTTCTTACATTGTAGCTGTTGATTTTGATTCAATTAGTGGTCGTATC\nTTTTGGTCTGATGCAACTCAGGGTAAAACCTGGAGTGCGTTTCAAAATGGAACGGACAGA\nAGAGTGGTATTTGACAGTAGCATCATCTTGACTGAAACTATTGCAATAGATTGGGTAGGT\nCGTAATCTTTACTGGACAGACTATGCTCTGGAAACAATTGAAGTCTCCAAAATTGATGGG\nAGCCACAGGACTGTGCTGATTAGTAAAAACCTAACAAATCCAAGAGGACTAGCATTAGAT\nCCCAGAATGAATGAGCATCTACTGTTCTGGTCTGACTGGGGCCACCACCCTCGCATCGAG\nCGAGCCAGCATGGACGGCAGCATGCGCACTGTCATTGTCCAGGACAAGATCTTCTGGCCC\nTGCGGCTTAACTATTGACTACCCCAACAGACTGCTCTACTTCATGGACTCCTATCTTGAT\nTACATGGACTTTTGCGATTATAATGGACACCATCGGAGACAGGTGATAGCCAGTGATTTG\nATTATACGGCACCCCTATGCCCTAACTCTCTTTGAAGACTCTGTGTACTGGACTGACCGT\nGCTACTCGTCGGGTTATGCGAGCCAACAAGTGGCATGGAGGGAACCAGTCAGTTGTAATG\nTATAATATTCAATGGCCCCTTGGGATTGTTGCGGTTCATCCTTCGAAACAACCAAATTCC\nGTGAATCCATGTGCCTTTTCCCGCTGCAGCCATCTCTGCCTGCTTTCCTCACAGGGGCCT\nCATTTTTACTCCTGTGTTTGTCCTTCAGGATGGAGTCTGTCTCCTGATCTCCTGAATTGC\nTTGAGAGATGATCAACCTTTCTTAATAACTGTAAGGCAACATATAATTTTTGGAATCTCC\nCTTAATCCTGAGGTGAAGAGCAATGATGCTATGGTCCCCATAGCAGGGATACAGAATGGT\nTTAGATGTTGAATTTGATGATGCTGAGCAATACATCTATTGGGTTGAAAATCCAGGTGAA\nATTCACAGAGTGAAGACAGATGGCACCAACAGGACAGTATTTGCTTCTATATCTATGGTG\nGGGCCTTCTATGAACCTGGCCTTAGATTGGATTTCAAGAAACCTTTATTCTACCAATCCT\nAGAACTCAGTCAATCGAGGTTTTGACACTCCACGGAGATATCAGATACAGAAAAACATTG\nATTGCCAATGATGGGACAGCTCTTGGAGTTGGCTTTCCAATTGGCATAACTGTTGATCCT\nGCTCGTGGGAAGCTGTACTGGTCAGACCAAGGAACTGACAGTGGGGTTCCTGCCAAGATC\nGCCAGTGCTAACATGGATGGCACATCTGTGAAAACTCTCTTTACTGGGAACCTCGAACAC\nCTGGAGTGTGTCACTCTTGACATCGAAGAGCAGAAACTCTACTGGGCAGTCACTGGAAGA\nGGAGTGATTGAAAGAGGAAACGTGGATGGAACAGATCGGATGATCCTGGTACACCAGCTT\nTCCCACCCCTGGGGAATTGCAGTCCATGATTCTTTCCTTTATTATACTGATGAACAGTAT\nGAGGTCATTGAAAGAGTTGATAAGGCCACTGGGGCCAACAAAATAGTCTTGAGAGATAAT\nGTTCCAAATCTGAGGGGTCTTCAAGTTTATCACAGACGCAATGCCGCCGAATCCTCAAAT\nGGCTGTAGCAACAACATGAATGCCTGTCAGCAGATTTGCCTGCCTGTACCAGGAGGATTG\nTTTTCCTGCGCCTGTGCCACTGGATTTAAACTCAATCCTGATAATCGGTCCTGCTCTCCA\nTATAACTCTTTCATTGTTGTTTCAATGCTGTCTGCAATCAGAGGCTTTAGCTTGGAATTG\nTCAGATCATTCAGAAACCATGGTGCCGGTGGCAGGCCAAGGACGAAACGCACTGCATGTG\nGATGTGGATGTGTCCTCTGGCTTTATTTATTGGTGTGATTTTAGCAGCTCAGTGGCATCT\nGATAATGCGATCCGTAGAATTAAACCAGATGGATCTTCTCTGATGAACATTGTGACACAT\nGGAATAGGAGAAAATGGAGTCCGGGGTATTGCAGTGGATTGGGTAGCAGGAAATCTTTAT\nTTCACCAATGCCTTTGTTTCTGAAACACTGATAGAAGTTCTGCGGATCAATACTACTTAC\nCGCCGTGTTCTTCTTAAAGTCACAGTGGACATGCCTAGGCATATTGTTGTAGATCCCAAG\nAACAGATACCTCTTCTGGGCTGACTATGGGCAGAGACCAAAGATTGAGCGTTCTTTCCTT\nGACTGTACCAATCGAACAGTGCTTGTGTCAGAGGGCATTGTCACACCACGGGGCTTGGCA\nGTGGACCGAAGTGATGGCTACGTTTATTGGGTTGATGATTCTTTAGATATAATTGCAAGG\nATTCGTATCAATGGAGAGAACTCTGAAGTGATTCGTTATGGCAGTCGTTACCCAACTCCT\nTATGGCATCACTGTTTTTGAAAATTCTATCATATGGGTAGATAGGAATTTGAAAAAGATC\nTTCCAAGCCAGCAAGGAACCAGAGAACACAGAGCCACCCACAGTGATAAGAGACAATATC\nAACTGGCTAAGAGATGTGACCATCTTTGACAAGCAAGTCCAGCCCCGGTCACCAGCAGAG\nGTCAACAACAACCCTTGCTTGGAAAACAATGGTGGGTGCTCTCATCTCTGCTTTGCTCTG\nCCTGGATTGCACACCCCAAAATGTGACTGTGCCTTTGGGACCCTGCAAAGTGATGGCAAG\nAATTGTGCCATTTCAACAGAAAATTTCCTCATCTTTGCCTTGTCTAATTCCTTGAGAAGC\nTTACACTTGGACCCTGAAAACCATAGCCCACCTTTCCAAACAATAAATGTGGAAAGAACT\nGTCATGTCTCTAGACTATGACAGTGTAAGTGATAGAATCTACTTCACACAAAATTTAGCC\nTCTGGAGTTGGACAGATTTCCTATGCCACCCTGTCTTCAGGGATCCATACTCCAACTGTC\nATTGCTTCAGGTATAGGGACTGCTGATGGCATTGCCTTTGACTGGATTACTAGAAGAATT\nTATTACAGTGACTACCTCAACCAGATGATTAATTCCATGGCTGAAGATGGGTCTAACCGC\nACTGTGATAGCCCGCGTTCCAAAACCAAGAGCAATTGTGTTAGATCCCTGCCAAGGGTAC\nCTGTACTGGGCTGACTGGGATACACATGCCAAAATCGAGAGAGCCACATTGGGAGGAAAC\nTTCCGGGTACCCATTGTGAACAGCAGTCTGGTCATGCCCAGTGGGCTGACTCTGGACTAT\nGAAGAGGACCTTCTCTACTGGGTGGATGCTAGTCTGCAGAGGATTGAACGCAGCACTCTG\nACGGGCGTGGATCGTGAAGTCATTGTCAATGCAGCCGTTCATGCTTTTGGCTTGACTCTC\nTATGGCCAGTATATTTACTGGACTGACTTGTACACACAAAGAATTTACCGAGCTAACAAA\nTATGACGGGTCAGGTCAGATTGCAATGACCACAAATTTGCTCTCCCAGCCCAGGGGAATC\nAACACTGTTGTGAAGAACCAGAAACAACAGTGTAACAATCCTTGTGAACAGTTTAATGGG\nGGCTGCAGCCATATCTGTGCACCAGGTCCAAATGGTGCCGAGTGCCAGTGTCCACATGAG\nGGCAACTGGTATTTGGCCAACAACAGGAAGCACTGCATTGTGGACAATGGTGAACGATGT\nGGTGCATCTTCCTTCACCTGCTCCAATGGGCGCTGCATCTCGGAAGAGTGGAAGTGTGAT\nAATGACAACGACTGTGGGGATGGCAGTGATGAGATGGAAAGTGTCTGTGCACTTCACACC\nTGCTCACCGACAGCCTTCACCTGTGCCAATGGGCGATGTGTCCAATACTCTTACCGCTGT\nGATTACTACAATGACTGTGGTGATGGCAGTGATGAGGCAGGGTGCCTGTTCAGGGACTGC\nAATGCCACCACGGAGTTTATGTGCAATAACAGAAGGTGCATACCTCGTGAGTTTATCTGC\nAATGGTGTAGACAACTGCCATGATAATAACACTTCAGATGAGAAAAATTGCCCTGATCGC\nACTTGCCAGTCTGGATACACAAAATGTCATAATTCAAATATTTGTATTCCTCGCGTTTAT\nTTGTGTGACGGAGACAATGACTGTGGAGATAACAGTGATGAAAACCCTACTTATTGCACC\nACTCACACATGCAGCAGCAGTGAGTTCCAATGCGCATCTGGGCGCTGTATTCCTCAACAT\nTGGTATTGTGATCAAGAAACAGATTGTTTTGATGCCTCTGATGAACCTGCCTCTTGTGGT\nCACTCTGAGCGAACATGCCTAGCTGATGAGTTCAAGTGTGATGGTGGGAGGTGCATCCCA\nAGCGAATGGATCTGTGACGGTGATAATGACTGTGGGGATATGAGTGACGAGGATAAAAGG\nCACCAGTGTCAGAATCAAAACTGCTCGGATTCCGAGTTTCTCTGTGTAAATGACAGACCT\nCCGGACAGGAGGTGCATTCCCCAGTCTTGGGTCTGTGATGGCGATGTGGATTGTACTGAC\nGGCTACGATGAGAATCAGAATTGCACCAGGAGAACTTGCTCTGAAAATGAATTCACCTGT\nGGTTACGGACTGTGTATCCCAAAGATATTCAGGTGTGACCGGCACAATGACTGTGGTGAC\nTATAGCGACGAGAGGGGCTGCTTATACCAGACTTGCCAACAGAATCAGTTTACCTGTCAG\nAACGGGCGCTGCATTAGTAAAACCTTCGTCTGTGATGAGGATAATGACTGTGGAGACGGA\nTCTGATGAGCTGATGCACCTGTGCCACACCCCAGAACCCACGTGTCCACCTCACGAGTTC\nAAGTGTGACAATGGGCGCTGCATCGAGATGATGAAACTCTGCAACCACCTAGATGACTGT\nTTGGACAACAGCGATGAGAAAGGCTGTGGCATTAATGAATGCCATGACCCTTCAATCAGT\nGGCTGCGATCACAACTGCACAGACACCTTAACCAGTTTCTATTGTTCCTGTCGTCCTGGT\nTACAAGCTCATGTCTGACAAGCGGACTTGTGTTGATATTGATGAATGCACAGAGATGCCT\nTTTGTCTGTAGCCAGAAGTGTGAGAATGTAATAGGCTCCTACATCTGTAAGTGTGCCCCA\nGGCTACCTCCGAGAACCAGATGGAAAGACCTGCCGGCAAAACAGTAACATCGAACCCTAT\nCTCATTTTTAGCAACCGTTACTATTTGAGAAATTTAACTATAGATGGCTATTTTTACTCC\nCTCATCTTGGAAGGACTGGACAATGTTGTGGCATTAGATTTTGACCGAGTAGAGAAGAGA\nTTGTATTGGATTGATACACAGAGGCAAGTCATTGAGAGAATGTTTCTGAATAAGACAAAC\nAAGGAGACAATCATAAACCACAGACTACCAGCTGCAGAAAGTCTGGCTGTAGACTGGGTT\nTCCAGAAAGCTCTACTGGTTGGATGCCCGCCTGGATGGCCTCTTTGTCTCTGACCTCAAT\nGGTGGACACCGCCGCATGCTGGCCCAGCACTGTGTGGATGCCAACAACACCTTCTGCTTT\nGATAATCCCAGAGGACTTGCCCTTCACCCTCAATATGGGTACCTCTACTGGGCAGACTGG\nGGTCACCGCGCATACATTGGGAGAGTAGGCATGGATGGAACCAACAAGTCTGTGATAATC\nTCCACCAAGTTAGAGTGGCCTAATGGCATCACCATTGATTACACCAATGATCTACTCTAC\nTGGGCAGATGCCCACCTGGGTTACATAGAGTACTCTGATTTGGAGGGCCACCATCGACAC\nACGGTGTATGATGGGGCACTGCCTCACCCTTTCGCTATTACCATTTTTGAAGACACTATT\nTATTGGACAGATTGGAATACAAGGACAGTGGAAAAGGGAAACAAATATGATGGATCAAAT\nAGACAGACACTGGTGAACACAACACACAGACCATTTGACATCCATGTGTACCATCCATAT\nAGGCAGCCCATTGTGAGCAATCCCTGTGGTACCAACAATGGTGGCTGTTCTCATCTCTGC\nCTCATCAAGCCAGGAGGAAAAGGGTTCACTTGCGAGTGTCCAGATGACTTCCGCACCCTT\nCAACTGAGTGGCAGCACCTACTGCATGCCCATGTGCTCCAGCACCCAGTTCCTGTGCGCT\nAACAATGAAAAGTGCATTCCTATCTGGTGGAAATGTGATGGACAGAAAGACTGCTCAGAT\nGGCTCTGATGAACTGGCCCTTTGCCCGCAGCGCTTCTGCCGACTGGGACAGTTCCAGTGC\nAGTGACGGCAACTGCACCAGCCCGCAGACTTTATGCAATGCTCACCAAAATTGCCCTGAT\nGGGTCTGATGAAGACCGTCTTCTTTGTGAGAATCACCACTGTGACTCCAATGAATGGCAG\nTGCGCCAACAAACGTTGCATCCCAGAATCCTGGCAGTGTGACACATTTAACGACTGTGAG\nGATAACTCAGATGAAGACAGTTCCCACTGTGCCAGCAGGACCTGCCGGCCGGGCCAGTTT\nCGGTGTGCTAATGGCCGCTGCATCCCGCAGGCCTGGAAGTGTGATGTGGATAATGATTGT\nGGAGACCACTCGGATGAGCCCATTGAAGAATGCATGAGCTCTGCCCATCTCTGTGACAAC\nTTCACAGAATTCAGCTGCAAAACAAATTACCGCTGCATCCCAAAGTGGGCCGTGTGCAAT\nGGTGTAGATGACTGCAGGGACAACAGTGATGAGCAAGGCTGTGAGGAGAGGACATGCCAT\nCCTGTGGGGGATTTCCGCTGTAAAAATCACCACTGCATCCCTCTTCGTTGGCAGTGTGAT\nGGGCAAAATGACTGTGGAGATAACTCAGATGAGGAAAACTGTGCTCCCCGGGAGTGCACA\nGAGAGCGAGTTTCGATGTGTCAATCAGCAGTGCATTCCCTCGCGATGGATCTGTGACCAT\nTACAACGACTGTGGGGACAACTCAGATGAACGGGACTGTGAGATGAGGACCTGCCATCCT\nGAATATTTTCAGTGTACAAGTGGACATTGTGTACACAGTGAACTGAAATGCGATGGATCC\nGCTGACTGTTTGGATGCGTCTGATGAAGCTGATTGTCCCACACGCTTTCCTGATGGTGCA\nTACTGCCAGGCTACTATGTTCGAATGCAAAAACCATGTTTGTATCCCGCCATATTGGAAA\nTGTGATGGCGATGATGACTGTGGCGATGGTTCAGATGAAGAACTTCACCTGTGCTTGGAT\nGTTCCCTGTAATTCACCAAACCGTTTCCGGTGTGACAACAATCGCTGCATTTATAGTCAT\nGAGGTGTGCAATGGTGTGGATGACTGTGGAGATGGAACTGATGAGACAGAGGAGCACTGT\nAGAAAACCGACCCCTAAACCTTGTACAGAATATGAATATAAGTGTGGCAATGGGCATTGC\nATTCCACATGACAATGTGTGTGATGATGCCGATGACTGTGGTGACTGGTCCGATGAACTG\nGGTTGCAATAAAGGAAAAGAAAGAACATGTGCTGAAAATATATGCGAGCAAAATTGTACC\nCAATTAAATGAAGGAGGATTTATCTGCTCCTGTACAGCTGGGTTCGAAACCAATGTTTTT\nGACAGAACCTCCTGTCTAGATATCAATGAATGTGAACAATTTGGGACTTGTCCCCAGCAC\nTGCAGAAATACCAAAGGAAGTTATGAGTGTGTCTGTGCTGATGGCTTCACGTCTATGAGT\nGACCGCCCTGGAAAACGATGTGCAGCTGAGGGTAGCTCTCCTTTGTTGCTACTGCCTGAC\nAATGTCCGAATTCGAAAATATAATCTCTCATCTGAGAGGTTCTCAGAGTATCTTCAAGAT\nGAGGAATATATCCAAGCTGTTGATTATGATTGGGATCCCAAGGACATAGGCCTCAGTGTT\nGTGTATTACACTGTGCGAGGGGAGGGCTCTAGGTTTGGTGCTATCAAACGTGCCTACATC\nCCCAACTTTGAATCCGGCCGCAATAATCTTGTGCAGGAAGTTGACCTGAAACTGAAATAC\nGTAATGCAGCCAGATGGAATAGCAGTGGACTGGGTTGGAAGGCATATTTACTGGTCAGAT\nGTCAAGAATAAACGCATTGAGGTGGCTAAACTTGATGGAAGGTACAGAAAGTGGCTGATT\nTCCACTGACCTGGACCAACCAGCTGCTATTGCTGTGAATCCCAAACTAGGGCTTATGTTC\nTGGACTGACTGGGGAAAGGAACCTAAAATCGAGTCTGCCTGGATGAATGGAGAGGACCGC\nAACATCCTGGTTTTCGAGGACCTTGGTTGGCCAACTGGCCTTTCTATCGATTATTTGAAC\nAATGACCGAATCTACTGGAGTGACTTCAAGGAGGACGTTATTGAAACCATAAAATATGAT\nGGGACTGATAGGAGAGTCATTGCAAAGGAAGCAATGAACCCTTACAGCCTGGACATCTTT\nGAAGACCAGTTATACTGGATATCTAAGGAAAAGGGAGAAGTATGGAAACAAAATAAATTT\nGGGCAAGGAAAGAAAGAGAAAACGCTGGTAGTGAACCCTTGGCTCACTCAAGTTCGAATC\nTTTCATCAACTCAGATACAATAAGTCAGTGCCCAACCTTTGCAAACAGATCTGCAGCCAC\nCTCTGCCTTCTGAGACCTGGAGGATACAGCTGTGCCTGTCCCCAAGGCTCCAGCTTTATA\nGAGGGGAGCACCACTGAGTGTGATGCAGCCATCGAACTGCCTATCAACCTGCCCCCCCCA\nTGCAGGTGCATGCACGGAGGAAATTGCTATTTTGATGAGACTGACCTCCCCAAATGCAAG\nTGTCCTAGCGGCTACACCGGAAAATATTGTGAAATGGCGTTTTCAAAAGGCATCTCTCCA\nGGAACAACCGCAGTAGCTGTGCTGTTGACAATCCTCTTGATCGTCGTAATTGGAGCTCTG\nGCAATTGCAGGATTCTTCCACTATAGAAGGACCGGCTCCCTTTTGCCTGCTCTGCCCAAG\nCTGCCAAGCTTAAGCAGTCTCGTCAAGCCCTCTGAAAATGGGAATGGGGTGACCTTCAGA\nTCAGGGGCAGATCTTAACATGGATATTGGAGTGTCTGGTTTTGGACCTGAGACTGCTATT\nGACAGGTCAATGGCAATGAGTGAAGACTTTGTCATGGAAATGGGGAAGCAGCCCATAATA\nTTTGAAAACCCAATGTACTCAGCCAGAGACAGTGCTGTCAAAGTGGTTCAGCCAATCCAG\nGTGACTGTATCTGAAAATGTGGATAATAAGAATTATGGAAGTCCCATAAACCCTTCTGAG\nATAGTTCCAGAGACAAACCCAACTTCACCAGCTGCTGATGGAACTCAGGTGACAAAATGG\nAATCTCTTCAAACGAAAATCTAAACAAACTACCAACTTTGAAAATCCAATCTATGCACAG\nATGGAGAACGAGCAAAAGGAAAGTGTTGCTGCGACACCACCTCCATCACCTTCGCTCCCT\nGCTAAGCCTAAGCCTCCTTCGAGAAGAGACCCAACTCCAACCTATTCTGCAACAGAAGAC\nACTTTTAAAGACACCGCAAATCTTGTTAAAGAAGACTCTGAAGTATAG"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF07645", "name": "EGF_CA"}, {"identifier": "PF00057", "name": "Ldl_recept_a"}, {"identifier": "PF00058", "name": "Ldl_recept_b"}, {"identifier": "PF07974", "name": "EGF_2"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}]}}}, {"@position": "11", "id": "BE0002126", "name": "Insulin-like growth factor-binding protein 7", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "Q16270", "@source": "Swiss-Prot", "name": "Insulin-like growth factor-binding protein 7", "general-function": null, "specific-function": "Binds IGF-I and IGF-II with a relatively low affinity. Stimulates prostacyclin (PGI2) production", "gene-name": "IGFBP7", "locus": "4q12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.94", "molecular-weight": "29131.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5476"}, {"resource": "GenAtlas", "identifier": "IGFBP7"}, {"resource": "GeneCards", "identifier": "IGFBP7"}, {"resource": "GenBank Gene Database", "identifier": "L19182"}, {"resource": "GenBank Protein Database", "identifier": "307151"}, {"resource": "UniProtKB", "identifier": "Q16270"}, {"resource": "UniProt Accession", "identifier": "IBP7_HUMAN"}]}, "synonyms": {"synonym": ["IBP- 7", "IGF-binding protein 7", "IGFBP-7", "IGFBP-rP1", "Insulin-like growth factor-binding protein 7 precursor", "MAC25 protein", "PGI2-stimulating factor", "Prostacyclin-stimulating factor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Insulin-like growth factor-binding protein 7\nMERPSLRALLLGAAGLLLLLLPLSSSSSSDTCGPCEPASCPPLPPLGCLLGETRDACGCC\nPMCARGEGEPCGGGGAGRGYCAPGMECVKSRKRRKGKAGAAAGGPGVSGVCVCKSRYPVC\nGSDGTTYPSGCQLRAASQRAESRGEKAITQVSKGTCEQGPSIVTPPKDIWNVTGAQVYLS\nCEVIGIPTPVLIWNKVKRGHYGVQRTELLPGDRDNLAIQTRGGPEKHEVTGWVLVSPLSK\nEDAGEYECHASNSQGQASASAKITVVDALHEIPVKKGEGAEL"}, "gene-sequence": {"@format": "FASTA", "#text": ">834 bp\nATGGAGCGCGCGTCGCTGCGCGCCCTGCTCTTCGGCCCCGCTGGGCTGCTGCTCCTGCTC\nCTGCCCCTCTCCTCTTCCTCCTCTTCGGACACCTGCGGCCCCTGCGAGCCGGCCTCCTGC\nCCGCCCCTGCCCCCGCTGGGCTGCCTGCTGGGCGAGACCCGCGACGCGTGCGGCTGCTGC\nCCTATGTGCGCCCGCGGCGAGGGCGAGCCGTGCGGGGGTGGCGGCGCCGGCAGGGGGTAC\nTGCGCGCCGGGCATGGAGTGCGTGAAGAGCCGCAAGAGGCGGAGGGGTAAAGCCGGGGCA\nGCAGCCGGCGGTCCGGGTGTAAGCGGCGTGTGCGTGTGCAAGAGCCGCTACCCGGTGTGC\nGGCAGCGACGGCACCACCTACCCGAGCGGCTGCCAGCTGCGCGCCGCCAGCCAGAGGGCC\nGAGAGCCGCGGGGAGAAGGCCATCACCCAGGTCAGCAAGGGCACCTGCGAGCAAGGTCCT\nTCCATAGTGACGCCCCCCAAGGACATCTGGAATGTCACTGGTGCCCAGGTGTACTTGAGC\nTGTGAGGTCATCGGAATCCCGACACCTGTCCTCATCTGGAACAAGGTAAAAAGGGGTCAC\nTATGGAGTTCAAAGGACAGAACTCCTGCCTGGTGACCGGGACAACCTGGCCATTCAGACC\nCGGGGTGGCCCAGAAAAGCATGAAGTAACTGGCTGGGTGCTGGTATCTCCTCTAAGTAAG\nGAAGATGCTGGAGAATATGAGTGCCATGCATCCAATTCCCAAGGACAGGCTTCAGCATCA\nGCAAAAATTACAGTGGTTGATGCCTTACATGAAATAGCCAGTGAAAAAAGGTGA"}, "pfams": {"pfam": [{"identifier": "PF07679", "name": "I-set"}, {"identifier": "PF07648", "name": "Kazal_2"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "protein binding"}, {"category": "function", "description": "growth factor binding"}, {"category": "function", "description": "insulin-like growth factor binding"}, {"category": "process", "description": "regulation of biological process"}, {"category": "process", "description": "regulation of growth"}, {"category": "process", "description": "regulation of cell growth"}]}}}, {"@position": "12", "id": "BE0002127", "name": "Synaptotagmin-like protein 4", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "Q96C24", "@source": "Swiss-Prot", "name": "Synaptotagmin-like protein 4", "general-function": null, "specific-function": "Modulates exocytosis of dense-core granules and secretion of hormones in the pancreas and the pituitary. Interacts with vesicles containing negatively charged phospholipids in a Ca(2+)-independent manner", "gene-name": "SYTL4", "locus": "-", "cellular-location": "Membrane", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.42", "molecular-weight": "76010.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:15588"}, {"resource": "GenAtlas", "identifier": "SYTL4"}, {"resource": "GeneCards", "identifier": "SYTL4"}, {"resource": "GenBank Gene Database", "identifier": "AK094110"}, {"resource": "GenBank Protein Database", "identifier": "21753104"}, {"resource": "UniProtKB", "identifier": "Q96C24"}, {"resource": "UniProt Accession", "identifier": "SYTL4_HUMAN"}]}, "synonyms": {"synonym": ["Exophilin-2", "Granuphilin"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Synaptotagmin-like protein 4\nMSELLDLSFLSEEEKDLILSVLQRDEEVRKADEKRIRRLKNELLEIKRKGAKRGSQHYSD\nRTCARCQESLGRLSPKTNTCRGCNHLVCRDCRIQESNGTWRCKVCAKEIELKKATGDWFY\nDQKVNRFAYRTGSEIIRMSLRHKPAVSKRETVGQSLLHQTQMGDIWPGRKIIQERQKEPS\nVLFEVPKLKSGKSALEAESESLDSFTADSDSTSRRDSLDKSGLFPEWKKMSAPKSQVEKE\nTQPGGQNVVFVDEGEMIFKKNTRKILRPSEYTKSVIDLRPEDVVHESGSLGDRSKSVPGL\nNVDMEEEEEEEDIDHLVKLHRQKLARSSMQSGSSMSTIGSMMSIYSEAGDFGNIFVTGRI\nAFSLKYEQQTQSLVVHVKECHQLAYADEAKKRSNPYVKTYLLPDKSRQGKRKTSIKRDTV\nNPLYDETLRYEIPESLLAQRTLQFSVWHHGRFGRNTFLGEAEIQMDSWKLDKKLDHCLPL\nHGKISAESPTGLPSHKGELVVSLKYIPASKTPVGGDRKKSKGGEGGELQVWIKEAKNLTA\nAKAGGTSDSFVKGYLLPMRNKASKRKTPVMKKTLNPHYNHTFVYNGVRLEDLQHMCLELT\nVWDREPLASNDFLGGVRLGVGTGISNGEVVDWMDSTGEEVSLWQKMRQYPGSWAEGTLQL\nRSSMAKQKLGL"}, "gene-sequence": {"@format": "FASTA", "#text": ">2016 bp\nATGTCGGAGTTACTGGACCTTTCTTTTCTGTCTGAGGAGGAAAAGGATTTGATTCTCAGT\nGTTCTACAGCGAGATGAAGAGGTCCGGAAAGCAGATGAGAAAAGGATTAGGCGACTAAAG\nAATGAGTTACTGGAGATAAAAAGGAAAGGGGCCAAGAGGGGCAGCCAACACTACAGTGAT\nCGGACCTGTGCCCGGTGCCAGGAGAGCCTGGGCCGTTTGAGTCCCAAAACCAATACTTGT\nCGGGGTTGTAATCACCTGGTGTGTCGGGACTGCCGCATACAGGAAAGCAATGGTACCTGG\nAGGTGCAAGGTGTGCGCCAAGGAAATAGAGTTGAAGAAAGCAACTGGGGACTGGTTTTAT\nGACCAGAAAGTGAATCGCTTTGCTTACCGCACAGGTAGTGAGATAATCAGGATGTCCCTG\nCGCCACAAACCTGCAGTGAGTAAAAGAGAGACAGTGGGACAGTCCCTCCTTCATCAGGCA\nCAGATGGGTGACATCTGGCCAGGAAGAAAGATCATTCAGGAGCGGCAGAAGGAGCCCAGT\nGTGCTATTTGAAGTGCCAAAGCTGAAAAGTGGAAAGAGTGCATTGGAAGCTGAGAGTGAG\nAGTCTGGATAGCTTCACAGCTGACTCGGATAGCACCTCCAGGAGAGACTCTCTGGATAAA\nTCTGGCCTCTTTCCAGAATGGAAGAAGATGTCTGCTCCCAAATCTCAAGTAGAAAAGGAA\nACTCAGCCTGGAGGTCAAAATGTGGTATTTGTGGATGAGGGTGAGATGATATTTAAGAAG\nAACACCAGAAAAATCCTCAGGCCTTCAGAGTACACTAAATCTGTGATAGATCTTCGCCCA\nGAAGATGTGGTACATGAAGGTGGCTCCTTGGGAGACAGAAGCAAATCCGTCCCAGGCCTC\nAATGTGGATATGGAAGAGGAAGAAGAAGAAGAAGACATTGACCACCTAGTGAAGTTACAT\nCGCCAGAAGCTAGCCAGAAGCAGCATGCAAAGTGGCTCCTCCATGAGTACGATCGGCAGC\nATGATGAGCATCTACAGTGAAGCTGGTGATTTCGGGAACATCTTTGTGACTGGCAGGATT\nGCCTTTTCCCTGAAGTATGAGCAGCAAACCCAGAGTCTGGTTGTCCATGTGAAGGAGTGC\nCATCAGCTGGCCTATGCTGATGAAGCCAAGAAGCGCTCTAACCCATATGTGAAGACTTAC\nCTTCTGCCTGACAAGTCCCGCCAAGGAAAAAGAAAAACCAGCATCAAGCGGGACACTGTT\nAATCCACTATATGATGAGACGCTGAGGTATGAGATCCCAGAATCTCTCCTGGCCCAGAGG\nACCCTGCAGTTCTCAGTTTGGCATCATGGTCGTTTTGGCAGAAACACTTTCCTTGGAGAG\nGCAGAGATCCAGATGGATTCCTGGAAGCTTGATAAGAAACTGGATCATTGCCTCCCTTTA\nCATGGAAAGATCAGTGCTGAGTCCCCGACTGGCTTGCCATCACACAAAGGCGAGTTGGTG\nGTTTCATTGAAATACATCCCAGCCTCCAAAACCCCTGTTGGAGGTGACCGGAAAAAGAGT\nAAAGGTGGGGAAGGGGGAGAGCTCCAGGTGTGGATCAAAGAAGCCAAGAACTTGACGGCT\nGCCAAAGCAGGAGGGACTTCAGACAGCTTTGTCAAGGGATACCTCCTTCCCATGAGGAAC\nAAGGCCAGTAAACGTAAAACTCCTGTGATGAAGAAGACCCTGAATCCTCACTACAACCAT\nACATTTGTCTACAATGGTGTGAGGCTGGAAGATCTACAGCATATGTGCCTGGAACTGACT\nGTGTGGGACCGGGAGCCCCTGGCCAGCAATGACTTCCTGGGAGGGGTCAGGCTGGGTGTT\nGGCACTGGGATCAGTAATGGGGAAGTGGTGGACTGGATGGACTCGACTGGGGAAGAAGTG\nAGCCTGTGGCAGAAGATGCGACAGTACCCAGGGTCTTGGGCAGAAGGGACTCTGCAGCTC\nCGTTCCTCAATGGCCAAGCAGAAGCTGGGTTTATGA"}, "pfams": {"pfam": [{"identifier": "PF00168", "name": "C2"}, {"identifier": "PF02318", "name": "RPH3A_effector"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "membrane"}, {"category": "component", "description": "vesicle"}, {"category": "component", "description": "protein complex"}, {"category": "component", "description": "cytoplasmic vesicle"}, {"category": "component", "description": "cytoplasmic membrane-bound vesicle"}, {"category": "component", "description": "coated vesicle"}, {"category": "component", "description": "clathrin-coated vesicle"}, {"category": "component", "description": "synaptic vesicle"}, {"category": "component", "description": "cell"}, {"category": "component", "description": "organelle"}, {"category": "component", "description": "ubiquitin ligase complex"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "ligase activity"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "transporter activity"}, {"category": "function", "description": "ligase activity, forming carbon-nitrogen bonds"}, {"category": "function", "description": "protein binding"}, {"category": "function", "description": "acid-amino acid ligase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "enzyme binding"}, {"category": "function", "description": "ubiquitin-protein ligase activity"}, {"category": "function", "description": "GTPase binding"}, {"category": "function", "description": "zinc ion binding"}, {"category": "function", "description": "small GTPase binding"}, {"category": "function", "description": "Rab GTPase binding"}, {"category": "process", "description": "protein modification"}, {"category": "process", "description": "protein transport"}, {"category": "process", "description": "intracellular protein transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "ubiquitin cycle"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein ubiquitination"}, {"category": "process", "description": "biopolymer metabolism"}, {"category": "process", "description": "biopolymer modification"}]}}}]}, "enzymes": {"enzyme": {"id": "BE0002433", "name": "Cytochrome P450 1A2", "organism": "Human", "actions": {"action": "inducer"}, "references": "# Flockhart DA. \"Drug Interactions: Cytochrome P450 Drug Interaction Table\":http://medicine.iupui.edu/clinpharm/ddis/table.asp. Indiana University School of Medicine (2007). Accessed May 28, 2010.", "known-action": "unknown", "polypeptide": {"@id": "P05177", "@source": "Swiss-Prot", "name": "Cytochrome P450 1A2", "general-function": "Involved in monooxygenase activity", "specific-function": "Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen", "gene-name": "CYP1A2", "locus": "15q24", "cellular-location": "Endoplasmic reticulum", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.43", "molecular-weight": "58295.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2596"}, {"resource": "GenAtlas", "identifier": "CYP1A2"}, {"resource": "GenBank Gene Database", "identifier": "Z00036"}, {"resource": "UniProtKB", "identifier": "P05177"}, {"resource": "UniProt Accession", "identifier": "CP1A2_HUMAN"}]}, "synonyms": {"synonym": ["CYPIA2", "EC 1.14.14.1", "P(3)450", "P450 4", "P450-P3"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytochrome P450 1A2\nMALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN\nPHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG\nQSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM\nAGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP\nILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN\nLIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS\nDRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL\nWEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE\nFSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN"}, "gene-sequence": {"@format": "FASTA", "#text": ">1548 bp\nATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCTGCCATC\nTTCTGCCTGGTATTCTGGGTGCTCAAGGGTTTGAGGCCTCGGGTCCCCAAAGGCCTGAAA\nAGTCCACCAGAGCCATGGGGCTGGCCCTTGCTCGGGCATGTGCTGACCCTGGGGAAGAAC\nCCGCACCTGGCACTGTCAAGGATGAGCCAGCGCTACGGGGACGTCCTGCAGATCCGCATT\nGGCTCCACGCCCGTGCTGGTGCTGAGCCGCCTGGACACCATCCGGCAGGCCCTGGTGCGG\nCAGGGCGACGATTTCAAGGGCCGGCCTGACCTCTACACCTCCACCCTCATCACTGATGGC\nCAGAGCTTGACCTTCAGCACAGACTCTGGACCGGTGTGGGCTGCCCGCCGGCGCCTGGCC\nCAGAATGCCCTCAACACCTTCTCCATCGCCTCTGACCCAGCTTCCTCATCCTCCTGCTAC\nCTGGAGGAGCATGTGAGCAAGGAGGCTAAGGCCCTGATCAGCAGGTTGCAGGAGCTGATG\nGCAGGGCCTGGGCACTTCGACCCTTACAATCAGGTGGTGGTGTCAGTGGCCAACGTCATT\nGGTGCCATGTGCTTCGGACAGCACTTCCCTGAGAGTAGCGATGAGATGCTCAGCCTCGTG\nAAGAACACTCATGAGTTCGTGGAGACTGCCTCCTCCGGGAACCCCCTGGACTTCTTCCCC\nATCCTTCGCTACCTGCCTAACCCTGCCCTGCAGAGGTTCAAGGCCTTCAACCAGAGGTTC\nCTGTGGTTCCTGCAGAAAACAGTCCAGGAGCACTATCAGGACTTTGACAAGAACAGTGTC\nCGGGACATCACGGGTGCCCTGTTCAAGCACAGCAAGAAGGGGCCTAGAGCCAGCGGCAAC\nCTCATCCCACAGGAGAAGATTGTCAACCTTGTCAATGACATCTTTGGAGCAGGATTTGAC\nACAGTCACCACAGCCATCTCCTGGAGCCTCATGTACCTTGTGACCAAGCCTGAGATACAG\nAGGAAGATCCAGAAGGAGCTGGACACTGTGATTGGCAGGGAGCGGCGGCCCCGGCTCTCT\nGACAGACCCCAGCTGCCCTACTTGGAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCC\nTTCTTGCCCTTCACCATCCCCCACAGCACAACAAGGGACACAACGCTGAATGGCTTCTAC\nATCCCCAAGAAATGCTGTGTCTTCGTAAACCAGTGGCAGGTCAACCATGACCCAGAGCTG\nTGGGAGGACCCCTCTGAGTTCCGGCCTGAGCGGTTCCTCACCGCCGATGGCACTGCCATT\nAACAAGCCCTTGAGTGAGAAGATGATGCTGTTTGGCATGGGCAAGCGCCGGTGTATCGGG\nGAAGTCCTGGCCAAGTGGGAGATCTTCCTCTTCCTGGCCATCCTGCTACAGCAACTGGAG\nTTCAGCGTGCCGCCGGGCGTGAAAGTCGACCTGACCCCCATCTACGGGCTGACCATGAAG\nCACGCCCGCTGTGAACATGTCCAGGCGCGGCGCTTCTCCATCAATTGA"}, "pfams": {"pfam": {"identifier": "PF00067", "name": "p450"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "iron ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "tetrapyrrole binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "heme binding"}, {"category": "function", "description": "monooxygenase activity"}, {"category": "function", "description": "oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "generation of precursor metabolites and energy"}, {"category": "process", "description": "electron transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}}, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2010-09-29", "drugbank-id": [{"@primary": "true", "#text": "DB00031"}, "BIOD00019", "BTD00019"], "name": "Tenecteplase", "description": "Tissue plasminogen activator (tPA). Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease domain.", "cas-number": "191588-94-0", "groups": {"group": "approved"}, "general-references": "# Gurbel PA, Hayes K, Bliden KP, Yoho J, Tantry US: The platelet-related effects of tenecteplase versus alteplase versus reteplase. Blood Coagul Fibrinolysis. 2005 Jan;16(1):1-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15650539\n# Melzer C, Richter C, Rogalla P, Borges AC, Theres H, Baumann G, Laule M: Tenecteplase for the treatment of massive and submassive pulmonary embolism. J Thromb Thrombolysis. 2004 Aug;18(1):47-50. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15744554\n# Ohman EM, Van de Werf F, Antman EM, Califf RM, de Lemos JA, Gibson CM, Oliverio RL, Harrelson L, McCabe C, DiBattiste P, Braunwald E: Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial. Am Heart J. 2005 Jul;150(1):79-88. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16084152\n# De Luca G, Suryapranata H, Chiariello M: Tenecteplase followed by immediate angioplasty is more effective than tenecteplase alone for people with STEMI. Commentary. Evid Based Cardiovasc Med. 2005 Dec;9(4):284-7. Epub 2005 Nov 2. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16380055\n# : Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006 Feb 18;367(9510):569-78. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16488800", "synthesis-reference": null, "indication": "For treatment of myocardial infarction and lysis of intracoronary emboli", "pharmacodynamics": "Tenecteplase is a fibrin-specific tissue-plasminogen activator. It binds to fibrin rich clots and cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.", "mechanism-of-action": "Tenecteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": "1.9 hours (mammalian reticulocytes, in vitro)\n>20 hours (yeast, in vivo)\n>10 hours (Escherichia coli, in vivo)", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": "* 99 - 119 mL/min [acute myocardial infarction patients]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "t- PA"}, {"@language": "", "@coder": "", "#text": "t-plasminogen activator"}, {"@language": "", "@coder": "", "#text": "Tissue-type plasminogen activator precursor"}, {"@language": "", "@coder": "", "#text": "tPA"}]}, "products": {"product": {"name": "Tnkase", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02244826", "started-marketing-on": "2001-10-18", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "50 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}}, "international-brands": null, "mixtures": {"mixture": {"name": "Tnkase", "ingredients": "Tenecteplase"}}, "packagers": {"packager": [{"name": "F Hoffmann-La Roche Ltd.", "url": "http://www.roche.com"}, {"name": "Genentech Inc.", "url": "http://www.gene.com"}]}, "manufacturers": null, "prices": {"price": {"description": "Tnkase 50 mg kit", "cost": {"@currency": "USD", "#text": "3238.76"}, "unit": "kit"}}, "categories": {"category": [{"category": "Fibrinolytic Agents", "mesh-id": null}, {"category": "Thrombolytic Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": {"form": "Powder for solution", "route": "intravenous", "strength": "50 mg"}}, "atc-codes": {"atc-code": {"@code": "B01AD11", "level": [{"@code": "B", "#text": "BLOOD AND BLOOD FORMING ORGANS"}, {"@code": "B01", "#text": "ANTITHROMBOTIC AGENTS"}, {"@code": "B01A", "#text": "ANTITHROMBOTIC AGENTS"}, {"@code": "B01AD", "#text": "Enzymes"}]}}, "ahfs-codes": {"ahfs-code": "20:12.20"}, "patents": {"patent": [{"number": "1341432", "country": "Canada", "approved": "2003-06-17", "expires": "2020-06-17"}, {"number": "2129660", "country": "Canada", "approved": "2005-06-28", "expires": "2013-05-28"}]}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00054", "name": "Abciximab", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01418", "name": "Acenocoumarol", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00945", "name": "Acetylsalicylic acid", "description": "May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB00233", "name": "Aminosalicylic Acid", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB00261", "name": "Anagrelide", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06605", "name": "Apixaban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06692", "name": "Aprotinin", "description": "May diminish the therapeutic effect of Thrombolytic Agents."}, {"drugbank-id": "DB00278", "name": "Argatroban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01294", "name": "Bismuth Subsalicylate", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB00006", "name": "Bivalirudin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06441", "name": "Cangrelor", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01166", "name": "Cilostazol", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00215", "name": "Citalopram", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB04272", "name": "Citric Acid", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00758", "name": "Clopidogrel", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06695", "name": "Dabigatran etexilate", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Dabigatran etexilate."}, {"drugbank-id": "DB06779", "name": "Dalteparin", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06754", "name": "Danaparoid", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06700", "name": "Desvenlafaxine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00586", "name": "Diclofenac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00266", "name": "Dicoumarol", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00861", "name": "Diflunisal", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01551", "name": "Dihydrocodeine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00975", "name": "Dipyridamole", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00476", "name": "Duloxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00974", "name": "Edetic Acid", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB09075", "name": "Edoxaban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01225", "name": "Enoxaparin", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01240", "name": "Epoprostenol", "description": "May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents."}, {"drugbank-id": "DB00063", "name": "Eptifibatide", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01175", "name": "Escitalopram", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB08794", "name": "Ethyl biscoumacetate", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00749", "name": "Etodolac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00573", "name": "Fenoprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB08976", "name": "Floctafenine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00472", "name": "Fluoxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00712", "name": "Flurbiprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00176", "name": "Fluvoxamine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00569", "name": "Fondaparinux sodium", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01109", "name": "Heparin", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01050", "name": "Ibuprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01088", "name": "Iloprost", "description": "May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents."}, {"drugbank-id": "DB00328", "name": "Indomethacin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01009", "name": "Ketoprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00465", "name": "Ketorolac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB08918", "name": "Levomilnacipran", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01397", "name": "Magnesium salicylate", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB00784", "name": "Mefenamic acid", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00814", "name": "Meloxicam", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB04896", "name": "Milnacipran", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00461", "name": "Nabumetone", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB08813", "name": "Nadroparin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00788", "name": "Naproxen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00991", "name": "Oxaprozin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00715", "name": "Paroxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00498", "name": "Phenindione", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00946", "name": "Phenprocoumon", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00554", "name": "Piroxicam", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06209", "name": "Prasugrel", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06228", "name": "Rivaroxaban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01398", "name": "Salicylate-sodium", "description": "May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB01399", "name": "Salsalate", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB01104", "name": "Sertraline", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00605", "name": "Sulindac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06271", "name": "Sulodexide", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01600", "name": "Tiaprofenic acid", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB08816", "name": "Ticagrelor", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00208", "name": "Ticlopidine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06822", "name": "Tinzaparin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00775", "name": "Tirofiban", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00500", "name": "Tolmetin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00374", "name": "Treprostinil", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00285", "name": "Venlafaxine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06684", "name": "Vilazodone", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB09030", "name": "Vorapaxar", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB09068", "name": "Vortioxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00682", "name": "Warfarin", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00031 sequence\nSYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGG\nTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGNWSTAESGAECTQWNSSA\nLAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDC\nYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAK\nPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAAAAKHRRS\nPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVH\nKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEAL\nSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGG\nPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "60 \u00b0C", "source": "Novokhatny, V.V. et al., J. Biol. Chem. 266:12994-123002 (1991)"}, {"kind": "Hydrophobicity", "value": "-0.528", "source": null}, {"kind": "Isoelectric Point", "value": "7.61", "source": null}, {"kind": "Molecular Weight", "value": "58951.2000", "source": null}, {"kind": "Molecular Formula", "value": "C2561H3919N747O781S40", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "12468"}, {"resource": "KEGG Drug", "identifier": "D06070"}, {"resource": "National Drug Code Directory", "identifier": "50242-038-61"}, {"resource": "GenBank", "identifier": "L00153"}, {"resource": "PharmGKB", "identifier": "PA164776757"}, {"resource": "UniProtKB", "identifier": "P00750"}, {"resource": "Wikipedia", "identifier": "Tenecteplase"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic2/tenecteplase.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/mtm/tenecteplase.html"}]}, "pathways": {"pathway": {"smpdb-id": "SMP00283", "name": "Tenecteplase Action Pathway", "drugs": {"drug": [{"drugbank-id": "DB00031", "name": "Tenecteplase"}, {"drugbank-id": "DB01022", "name": "Phylloquinone"}, {"drugbank-id": "DB01373", "name": "Calcium"}]}, "enzymes": {"uniprot-id": ["P00747", "P00748", "P02452", "P03952", "P03951", "P00740", "P00451", "P00734", "P12259", "P00742", "P02671", "P02675", "P02679", "P00488", "P05160", "P00750", "P08709", "P13726", "Q9BQB6", "P38435"]}}}, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000211", "name": "Plasminogen", "organism": "Human", "actions": {"action": "activator"}, "references": "# Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18673235\n# Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19436656\n# Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17963464\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P00747", "@source": "Swiss-Prot", "name": "Plasminogen", "general-function": "Involved in plasmin activity", "specific-function": "Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo", "gene-name": "PLG", "locus": "6q26", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.25", "molecular-weight": "90569.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9071"}, {"resource": "GenAtlas", "identifier": "PLG"}, {"resource": "GeneCards", "identifier": "PLG"}, {"resource": "GenBank Gene Database", "identifier": "X05199"}, {"resource": "GenBank Protein Database", "identifier": "387026"}, {"resource": "UniProtKB", "identifier": "P00747"}, {"resource": "UniProt Accession", "identifier": "PLMN_HUMAN"}]}, "synonyms": {"synonym": ["EC 3.4.21.7", "Plasminogen precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Plasminogen precursor\nMEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT\nCRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN\nGITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE\nCEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE\nLRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS\nAQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE\nQLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG\nLTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED\nCMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG\nPWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT\nRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE\nPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ\nLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW\nGLGCARPNKPGVYVRVSRFVTWIEGVMRNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">2433 bp\nATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG\nCCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG\nCTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC\nTGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG\nAAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC\nTCAGAGTGCAAGACTGGGAATGGAAAGAATTACAGAGGGACGATGTCCAAAACAAAAAAT\nGGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT\nACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG\nGGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG\nTGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC\nATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT\nCCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG\nCTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGCGACATCCCC\nCGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT\nGAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT\nGCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTTCCCTGCAAAAATTTGGAT\nGAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC\nCAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA\nCAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT\nGATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT\nTGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC\nCTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA\nGACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT\nGTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAAATGTAGAGACTCCTTCCGAAGAAGAC\nTGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG\nCCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA\nAATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT\nCCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT\nGCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG\nGTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA\nAGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT\nGCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC\nCAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG\nCCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA\nGTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC\nATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG\nCTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA\nTCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT\nGGAGGGCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG\nGGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT\nACTTGGATTGAGGGAGTGATGAGAAATAATTAA"}, "pfams": {"pfam": [{"identifier": "PF00051", "name": "Kringle"}, {"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00024", "name": "PAN_1"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "plasmin activity"}, {"category": "function", "description": "binding"}, {"category": "process", "description": "hemostasis"}, {"category": "process", "description": "blood coagulation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "2", "id": "BE0000538", "name": "Fibrinogen alpha chain", "organism": "Human", "actions": null, "references": "# Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19436656\n# Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18673235\n# Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17963464", "known-action": "yes", "polypeptide": {"@id": "P02671", "@source": "Swiss-Prot", "name": "Fibrinogen alpha chain", "general-function": "Carbohydrate transport and metabolism", "specific-function": "Fibrinogen has a double function:yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation", "gene-name": "FGA", "locus": "4q28", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.87", "molecular-weight": "94974.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3661"}, {"resource": "GenAtlas", "identifier": "FGA"}, {"resource": "GeneCards", "identifier": "FGA"}, {"resource": "GenBank Gene Database", "identifier": "AF361104"}, {"resource": "GenBank Protein Database", "identifier": "13591824"}, {"resource": "UniProtKB", "identifier": "P02671"}, {"resource": "UniProt Accession", "identifier": "FIBA_HUMAN"}]}, "synonyms": {"synonym": "Fibrinogen alpha chain precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Fibrinogen alpha chain precursor [Contains: Fibrinopeptide A]\nMFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDEDW\nNYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFSSA\nNNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKIRSC\nRGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGNFKSQ\nLQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSS\nGPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRPGSTGTW\nNPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEVSGNV\nSPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGPDGHKEVTK\nEVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPGFFSPMLGEF\nVSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYNRGDSTFESKS\nYKMADEAGSEADHEGTHSTKRGHAKSRPVRDCDDVLQTHPSGTQSGIFNIKLPGSSKIFS\nVYCDQETSLGGWLLIQQRMDGSLNFNRTWQDYKRGFGSLNDEGEGEFWLGNDYLHLLTQR\nGSVLRVELEDWAGNEAYAEYHFRVGSEAEGYALQVSSYEGTAGDALIEGSVEEGAEYTSH\nNNMQFSTFDRDADQWEENCAEVYGGGWWYNNCQAANLNGIYYPGGSYDPRNNSPYEIENG\nVVWVSFRGADYSLRAVRMKIRPLVTQ"}, "gene-sequence": {"@format": "FASTA", "#text": ">2601 bp\nATGTTTTCCATGAGGATCGTCTGCCTAGTTCTAAGTGTGGTGGGCACAGCATGGACTGCA\nGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTG\nGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGG\nAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGAT\nTTTACAAACAGAATAAATAAGCTCAAAAATTCACTATTTGAATATCAGAAGAACAATAAG\nGATTCTCATTCGTTGACCACTAATATAATGGAAATTTTGAGAGGCGATTTTTCCTCAGCC\nAATAACCGTGATAATACCTACAACCGAGTGTCAGAGGATCTGAGAAGCAGAATTGAAGTC\nCTGAAGCGCAAAGTCATAGAAAAAGTACAGCATATCCAGCTTCTGCAGAAAAATGTTAGA\nGCTCAGTTGGTTGATATGAAACGACTGGAGGTGGACATTGATATTAAGATCCGATCTTGT\nCGAGGGTCATGCAGTAGGGCTTTAGCTCGTGAAGTAGATCTGAAGGACTATGAAGATCAG\nCAGAAGCAACTTGAACAGGTCATTGCCAAAGACTTACTTCCCTCTAGAGATAGGCAACAC\nTTACCACTGATAAAAATGAAACCAGTTCCAGACTTGGTTCCCGGAAATTTTAAGAGCCAG\nCTTCAGAAGGTACCCCCAGAGTGGAAGGCATTAACAGACATGCCGCAGATGAGAATGGAG\nTTAGAGAGACCTGGTGGAAATGAGATTACTCGAGGAGGCTCCACCTCTTATGGAACCGGA\nTCAGAGACGGAAAGCCCCAGGAACCCTAGCAGTGCTGGAAGCTGGAACTCTGGGAGCTCT\nGGACCTGGAAGTACTGGAAACCGAAACCCTGGGAGCTCTGGGACTGGAGGGACTGCAACC\nTGGAAACCTGGGAGCTCTGGACCTGGAAGTACTGGAAGCTGGAACTCTGGGAGCTCTGGA\nACTGGAAGTACTGGAAACCAAAACCCTGGGAGCCCTAGACCTGGTAGTACCGGAACCTGG\nAATCCTGGCAGCTCTGAACGCGGAAGTGCTGGGCACTGGACCTCTGAGAGCTCTGTATCT\nGGTAGTACTGGACAATGGCACTCTGAATCTGGAAGTTTTAGGCCAGATAGCCCAGGCTCT\nGGGAACGCGAGGCCTAACAACCCAGACTGGGGCACATTTGAAGAGGTGTCAGGAAATGTA\nAGTCCAGGGACAAGGAGAGAGTACCACACAGAAAAACTGGTCACTTCTAAAGGAGATAAA\nGAGCTCAGGACTGGTAAAGAGAAGGTCACCTCTGGTAGCACAACCACCACGCGTCGTTCA\nTGCTCTAAAACCGTTACTAAGACTGTTATTGGTCCTGATGGTCACAAAGAAGTTACCAAA\nGAAGTGGTGACCTCCGAAGATGGTTCTGACTGTCCCGAGGCAATGGATTTAGGCACATTG\nTCTGGCATAGGTACTCTGGATGGGTTCCGCCATAGGCACCCTGATGAAGCTGCCTTCTTC\nGACACTGCCTCAACTGGAAAAACATTCCCAGGTTTCTTCTCACCTATGTTAGGAGAGTTT\nGTCAGTGAGACTGAGTCTAGGGGCTCAGAATCTGGCATCTTCACAAATACAAAGGAATCC\nAGTTCTCATCACCCTGGGATAGCTGAATTCCCTTCCCGTGGTAAATCTTCAAGTTACAGC\nAAACAATTTACTAGTAGCACGAGTTACAACAGAGGAGACTCCACATTTGAAAGCAAGAGC\nTATAAAATGGCAGATGAGGCCGGAAGTGAAGCCGATCATGAAGGAACACATAGCACCAAG\nAGAGGCCATGCTAAATCTCGCCCTGTCAGAGACTGTGATGATGTCCTCCAAACACATCCT\nTCAGGTACCCAAAGTGGCATTTTCAATATCAAGCTACCGGGATCCAGTAAGATTTTTTCT\nGTTTATTGCGATCAAGAGACCAGTTTGGGAGGATGGCTTTTGATCCAGCAAAGAATGGAT\nGGATCACTGAATTTTAACCGGACCTGGCAAGACTACAAGAGAGGTTTCGGCAGCCTGAAT\nGACGAGGGGGAAGGAGAATTCTGGCTAGGCAATGACTACCTCCACTTACTAACCCAAAGG\nGGCTCTGTTCTTAGGGTTGAATTAGAGGACTGGGCTGGGAATGAAGCTTATGCAGAATAT\nCACTTCCGGGTAGGCTCTGAGGCTGAAGGCTATGCCCTCCAAGTCTCCTCCTATGAAGGC\nACTGCGGGTGATGCTCTGATTGAGGGTTCCGTAGAGGAAGGGGCAGAGTACACCTCTCAC\nAACAACATGCAGTTCAGCACCTTTGACAGGGATGCAGACCAGTGGGAAGAGAACTGTGCA\nGAAGTCTATGGGGGAGGCTGGTGGTATAATAACTGCCAAGCAGCCAATCTCAATGGAATC\nTACTACCCTGGGGGCTCCTATGACCCAAGGAATAACAGTCCTTATGAGATTGAGAATGGA\nGTGGTCTGGGTTTCCTTTAGAGGGGCAGATTATTCCCTCAGGGCTGTTCGCATGAAAATT\nAGGCCCCTTGTGACCCAATAG"}, "pfams": {"pfam": {"identifier": "PF00147", "name": "Fibrinogen_C"}}, "go-classifiers": null}}, {"@position": "3", "id": "BE0000717", "name": "Urokinase plasminogen activator surface receptor", "organism": "Human", "actions": null, "references": "# Maupas-Schwalm F, Auge N, Robinet C, Cambus JP, Parsons SJ, Salvayre R, Negre-Salvayre A: The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue-type plasminogen activator. FASEB J. 2004 Sep;18(12):1398-400. Epub 2004 Jul 1. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15231724\n# Bankl HC, Samorapoompichit P, Pikula B, Latinovic L, Bankl H, Lechner K, Valent P: Characterization of human prostate mast cells and their increase in periprostatic vein thrombosis. Am J Clin Pathol. 2001 Jul;116(1):97-106. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11447759\n# Ferrier CM, Van Geloof WL, Straatman H, Van De Molengraft FJ, Van Muijen GN, Ruiter DJ: Spitz naevi may express components of the plasminogen activation system. J Pathol. 2002 Sep;198(1):92-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12210068", "known-action": "unknown", "polypeptide": {"@id": "Q03405", "@source": "Swiss-Prot", "name": "Urokinase plasminogen activator surface receptor", "general-function": "Involved in U-plasminogen activator receptor activity", "specific-function": "Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form", "gene-name": "PLAUR", "locus": "19q13", "cellular-location": "Isoform 1:Cell membrane; lipid-anchor; GPI- anchor. Isoform 2:Secreted protein (Probable)", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.64", "molecular-weight": "36978.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9053"}, {"resource": "GenAtlas", "identifier": "PLAUR"}, {"resource": "GeneCards", "identifier": "PLAUR"}, {"resource": "GenBank Gene Database", "identifier": "X51675"}, {"resource": "GenBank Protein Database", "identifier": "37605"}, {"resource": "UniProtKB", "identifier": "Q03405"}, {"resource": "UniProt Accession", "identifier": "UPAR_HUMAN"}]}, "synonyms": {"synonym": ["CD87 antigen", "Monocyte activation antigen Mo3", "U- PAR", "uPAR", "Urokinase plasminogen activator surface receptor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Urokinase plasminogen activator surface receptor precursor\nMGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEEL\nELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISC\nGSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNG\nFHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGP\nMNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDV\nQYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1008 bp\nATGGGTCACCCGCCGCTGCTGCCGCTGCTGCTGCTGCTCCACACCTGCGTCCCAGCCTCT\nTGGGGCCTGCGGTGCATGCAGTGTAAGACCAACGGGGATTGCCGTGTGGAAGAGTGCGCC\nCTGGGACAGGACCTCTGCAGGACCACGATCGTGCGCTTGTGGGAAGAAGGAGAAGAGCTG\nGAGCTGGTGGAGAAAAGCTGTACCCACTCAGAGAAGACCAACAGGACCCTGAGCTATCGG\nACTGGCTTGAAGATCACCAGCCTTACCGAGGTTGTGTGTGGGTTAGACTTGTGCAACCAG\nGGCAACTCTGGCCGGGCTGTCACCTATTCCCGAAGCCGTTACCTCGAATGCATTTCCTGT\nGGCTCATCAGACATGAGCTGTGAGAGGGGCCGGCACCAGAGCCTGCAGTGCCGCAGCCCT\nGAAGAACAGTGCCTGGATGTGGTGACCCACTGGATCCAGGAAGGTGAAGAAGGGCGTCCA\nAAGGATGACCGCCACCTCCGTGGCTGTGGCTACCTTCCCGGCTGCCCGGGCTCCAATGGT\nTTCCACAACAACGACACCTTCCACTTCCTGAAATGCTGCAACACCACCAAATGCAACGAG\nGGCCCAATCCTGGAGCTTGAAAATCTGCCGCAGAATGGCCGCCAGTGTTACAGCTGCAAG\nGGGAACAGCACCCATGGATGCTCCTCTGAAGAGACTTTCCTCATTGACTGCCGAGGCCCC\nATGAATCAATGTCTGGTAGCCACCGGCACTCACGAACCGAAAAACCAAAGCTATATGGTA\nAGAGGCTGTGCAACCGCCTCAATGTGCCAACATGCCCACCTGGGTGACGCCTTCAGCATG\nAACCACATTGATGTCTCCTGCTGTACTAAAAGTGGCTGTAACCACCCAGACCTGGATGTC\nCAGTACCGCAGTGGGGCTGCTCCTCAGCCTGGCCCTGCCCATCTCAGCCTCACCATCACC\nCTGCTAATGACTGCCAGACTGTGGGGAGGCACTCTCCTCTGGACCTAA"}, "pfams": {"pfam": {"identifier": "PF00021", "name": "UPAR_LY6"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "U-plasminogen activator receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}]}}}, {"@position": "4", "id": "BE0000240", "name": "Plasminogen activator inhibitor 1", "organism": "Human", "actions": null, "references": "# Lindberg P, Kinnby B, Lecander I, Lang NP, Matsson L: Increasing expression of tissue plasminogen activator and plasminogen activator inhibitor type 2 in dog gingival tissues with progressive inflammation. Arch Oral Biol. 2001 Jan;46(1):23-31. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11163592\n# Hattori M, Azami Y: Searching for preventive measures of cardiovascular events in aged Japanese taxi drivers--the daily rhythm of cardiovascular risk factors during a night duty day. J Hum Ergol (Tokyo). 2001 Dec;30(1-2):321-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14564902\n# Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17963464", "known-action": "unknown", "polypeptide": {"@id": "P05121", "@source": "Swiss-Prot", "name": "Plasminogen activator inhibitor 1", "general-function": "Involved in serine-type endopeptidase inhibitor activity", "specific-function": "This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, and protein C. Its rapid interaction with TPA may function as a major control point in the regulation of fibrinolysis", "gene-name": "SERPINE1", "locus": "7q21.3-q22", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.22", "molecular-weight": "45061.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:8583"}, {"resource": "GenAtlas", "identifier": "SERPINE1"}, {"resource": "GeneCards", "identifier": "SERPINE1"}, {"resource": "GenBank Gene Database", "identifier": "X04429"}, {"resource": "GenBank Protein Database", "identifier": "35272"}, {"resource": "UniProtKB", "identifier": "P05121"}, {"resource": "UniProt Accession", "identifier": "PAI1_HUMAN"}]}, "synonyms": {"synonym": ["Endothelial plasminogen activator inhibitor", "PAI", "PAI-1", "Plasminogen activator inhibitor 1 precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Plasminogen activator inhibitor 1 precursor\nMQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY\nGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI\nFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV\nDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD\nGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK\nFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS\nSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP"}, "gene-sequence": {"@format": "FASTA", "#text": ">1209 bp\nATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA\nGGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG\nAGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT\nGGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG\nATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT\nCTGTACAAGGAGCTCATGGGGCCATGGAACAAGGACGAGATCAGCACCACAGACGCGATC\nTTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC\nCGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT\nGACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG\nGACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT\nCCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC\nTCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT\nGGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT\nGCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG\nCTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG\nTTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC\nATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC\nGCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA\nTCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC\nTTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG\nGAACCCTGA"}, "pfams": {"pfam": {"identifier": "PF00079", "name": "Serpin"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "protease inhibitor activity"}, {"category": "function", "description": "endopeptidase inhibitor activity"}, {"category": "function", "description": "serine-type endopeptidase inhibitor activity"}, {"category": "function", "description": "enzyme regulator activity"}, {"category": "function", "description": "enzyme inhibitor activity"}]}}}, {"@position": "5", "id": "BE0000969", "name": "Plasminogen activator inhibitor 2", "organism": "Human", "actions": null, "references": "# Verkleij-Hagoort AC, Ursem NT, Hop WC, Geurts-Moespot A, Steegers EA, Sweep FC, Steegers-Theunissen RP: Complex congenital malformations and the impact of the plasminogen activator system and beta-hCG in amniotic fluid. Eur J Obstet Gynecol Reprod Biol. 2006 Nov 30;. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17141398\n# Bremer HA, Brommer EJ, Wallenburg HC: Effects of labor and delivery on fibrinolysis. Eur J Obstet Gynecol Reprod Biol. 1994 Jun 30;55(3):163-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7958159\n# Stump DC, Thienpont M, Collen D: Purification and characterization of a novel inhibitor of urokinase from human urine. Quantitation and preliminary characterization in plasma. J Biol Chem. 1986 Sep 25;261(27):12759-66. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/3091604", "known-action": "unknown", "polypeptide": {"@id": "P05120", "@source": "Swiss-Prot", "name": "Plasminogen activator inhibitor 2", "general-function": "Involved in serine-type endopeptidase inhibitor activity", "specific-function": "Inhibits urokinase-type plasminogen activator. The monocyte derived PAI-2 is distinct from the endothelial cell- derived PAI-1", "gene-name": "SERPINB2", "locus": "18q21.3", "cellular-location": "Cytoplasm. Secreted protein; extracellular space", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.34", "molecular-weight": "46597.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:8584"}, {"resource": "GenAtlas", "identifier": "SERPINB2"}, {"resource": "GeneCards", "identifier": "SERPINB2"}, {"resource": "GenBank Gene Database", "identifier": "J02685"}, {"resource": "GenBank Protein Database", "identifier": "189545"}, {"resource": "UniProtKB", "identifier": "P05120"}, {"resource": "UniProt Accession", "identifier": "PAI2_HUMAN"}]}, "synonyms": {"synonym": ["Monocyte Arg-serpin", "PAI-2", "Placental plasminogen activator inhibitor", "Plasminogen activator inhibitor 2 precursor", "Urokinase inhibitor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Plasminogen activator inhibitor 2 precursor\nMEDLCVANTLFALNLFKHLAKASPTQNLFLSPWSISSTMAMVYMGSRGSTEDQMAKVLQF\nNEVGANAVTPMTPENFTSCGFMQQIQKGSYPDAILQAQAADKIHSSFRSLSSAINASTGN\nYLLESVNKLFGEKSASFREEYIRLCQKYYSSEPQAVDFLECAEEARKKINSWVKTQTKGK\nIPNLLPEGSVDGDTRMVLVNAVYFKGKWKTPFEKKLNGLYPFRVNSAQRTPVQMMYLREK\nLNIGYIEDLKAQILELPYAGDVSMFLLLPDEIADVSTGLELLESEITYDKLNKWTSKDKM\nAEDEVEVYIPQFKLEEHYELRSILRSMGMEDAFNKGRANFSGMSERNDLFLSEVFHQAMV\nDVNEEGTEAAAGTGGVMTGRTGHGGPQFVADHPFLFLIMHKITNCILFFGRFSSP"}, "gene-sequence": {"@format": "FASTA", "#text": ">1248 bp\nATGGAGGATCTTTGTGTGGCAAACACACTCTTTGCCCTCAATTTATTCAAGCATCTGGCA\nAAAGCAAGCCCCACCCAGAACCTCTTCCTCTCCCCATGGAGCATCTCGTCCACCATGGCC\nATGGTCTACATGGGCTCCAGGGGCAGCACCGAAGACCAGATGGCCAAGGTGCTTCAGTTT\nAATGAAGTGGGAGCCAATGCAGTTACCCCCATGACTCCAGAGAACTTTACCAGCTGTGGG\nTTCATGCAGCAGATCCAGAAGGGTAGTTATCCTGATGCGATTTTGCAGGCACAAGCTGCA\nGATAAAATCCATTCATCCTTCCGCTCTCTCAGCTCTGCAATCAATGCATCCACAGGGGAT\nTATTTACTGGAAAGTGTCAATAAGCTGTTTGGTGAGAAGTCTGCGAGCTTCCGGGAAGAA\nTATATTCGACTCTGTCAGAAATATTACTCCTCAGAACCCCAGGCAGTAGACTTCCTAGAA\nTGTGCAGAAGAAGCTAGAAAAAAGATTAATTCCTGGGTCAAGACTCAAACCAAAGGCAAA\nATCCCAAACTTGTTACCTGAAGGTTCTGTAGATGGGGATACCAGGATGGTCCTGGTGAAT\nGCTGTCTACTTCAAAGGAAAGTGGAAAACTCCATTTGAGAAGAAACTAAATGGGCTTTAT\nCCTTTCCGTGTAAACTCGGCTCAGCGCACACCTGTACAGATGATGTACTTGCGTGAAAAG\nCTAAACATTGGATACATAGAAGACCTAAAGGCTCAGATTCTAGAACTCCCATATGCTGGA\nGATGTTAGCATGTTCTTGTTGCTTCCAGATGAAATTGCCGATGTGTCCACTGGCTTGGAG\nCTGCTGGAAAGTGAAATAACCTATGACAAACTCAACAAGTGGACCAGCAAAGACAAAATG\nGCTGAAGATGAAGTTGAGGTATACATACCCCAGTTCAAATTAGAAGAGCATTATGAACTC\nAGATCCATTCTGAGAAGCATGGGCATGGAGGACGCCTTCAACAAGGGACGGGCCAATTTC\nTCAGGGATGTCGGAGAGGAATGACCTGTTTCTTTCTGAAGTGTTCCACCAAGCCATGGTG\nGATGTGAATGAGGAGGGCACTGAAGCAGCCGCTGGCACAGGAGGTGTTATGACAGGGAGA\nACTGGACATGGAGGCCCACAGTTTGTGGCAGATCATCCGTTTCTTTTTCTTATTATGCAT\nAAGATAACCAAGTGCATTTTATTTTTCGGCAGATTTTGCTCACCCTAA"}, "pfams": {"pfam": {"identifier": "PF00079", "name": "Serpin"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "enzyme regulator activity"}, {"category": "function", "description": "enzyme inhibitor activity"}, {"category": "function", "description": "protease inhibitor activity"}, {"category": "function", "description": "endopeptidase inhibitor activity"}, {"category": "function", "description": "serine-type endopeptidase inhibitor activity"}]}}}, {"@position": "6", "id": "BE0002104", "name": "Tetranectin", "organism": "Human", "actions": null, "references": "# Westergaard UB, Andersen MH, Heegaard CW, Fedosov SN, Petersen TE: Tetranectin binds hepatocyte growth factor and tissue-type plasminogen activator. Eur J Biochem. 2003 Apr;270(8):1850-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12694198\n# Kamper EF, Kopeikina LT, Koutsoukos V, Stavridis J: Plasma tetranectin levels and disease activity in patients with rheumatoid arthritis. J Rheumatol. 1997 Feb;24(2):262-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9034981\n# Vuckovic B, Deric M: [Lipoprotein(a): a link between thrombogenesis and atherogenesis] Med Pregl. 2007 Jan-Feb;60(1-2):37-41. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17853709", "known-action": "unknown", "polypeptide": {"@id": "P05452", "@source": "Swiss-Prot", "name": "Tetranectin", "general-function": null, "specific-function": "Tetranectin binds to plasminogen and to isolated kringle 4. May be involved in the packaging of molecules destined for exocytosis", "gene-name": "CLEC3B", "locus": "3p22-p21.3", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.36", "molecular-weight": "22567.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:11891"}, {"resource": "GenAtlas", "identifier": "CLEC3B"}, {"resource": "GeneCards", "identifier": "CLEC3B"}, {"resource": "GenBank Gene Database", "identifier": "X64559"}, {"resource": "GenBank Protein Database", "identifier": "37409"}, {"resource": "UniProtKB", "identifier": "P05452"}, {"resource": "UniProt Accession", "identifier": "TETN_HUMAN"}]}, "synonyms": {"synonym": ["C-type lectin domain family 3 member B", "Plasminogen kringle 4-binding protein", "Tetranectin precursor", "TN"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Tetranectin\nMELWGAYLLLCLFSLLTQVTTEPPTQKPKKIVNAKKDVVNTKMFEELKSRLDTLAQEVAL\nLKEQQALQTVCLKGTKVHMKCFLAFTQTKTFHEASEDCISRGGTLSTPQTGSENDALYEY\nLRQSVGNEAEIWLGLNDMAAEGTWVDMTGARIAYKNWETEITAQPDGGKTENCAVLSGAA\nNGKWFDKRCRDQLPYICQFGIV"}, "gene-sequence": {"@format": "FASTA", "#text": ">609 bp\nATGGAGCTCTGGGGGGCCTACCTCCTCCTCTGCCTCTTCTCCCTCCTGACCCAGGTCACC\nACCGAGCCACCAACCCAGAAGCCCAAGAAGATTGTAAATGCCAAGAAAGATGTTGTGAAC\nACAAAGATGTTTGAGGAGCTCAAGAGCCGTCTGGACACCCTGGCCCAGGAGGTGGCCCTG\nCTGAAGGAGCAGCAGGCCCTGCAGACGGTCTGCCTGAAGGGGACCAAGGTGCACATGAAA\nTGCTTTCTGGCCTTCACCCAGACGAAGACCTTCCACGAGGCCAGCGAGGACTGCATCTCG\nCGCGGGGGCACCCTGAGCACCCCTCAGACTGGCTCGGAGAACGACGCCCTGTATGAGTAC\nCTGCGCCAGAGCGTGGGCAACGAGGCCGAGATCTGGCTGGGCCTCAACGACATGGCGGCC\nGAGGGCACCTGGGTGGACATGACCGGCGCCCGCATCGCCTACAAGAACTGGGAGACTGAG\nATCACCGCGCAACCCGATGGCGGCAAGACCGAGAACTGCGCGGTCCTGTCAGGCGCGGCC\nAACGGCAAGTGGTTCGACAAGCGCTGCCGCGATCAGCTGCCCTACATCTGCCAGTTCGGG\nATCGTGTAG"}, "pfams": {"pfam": {"identifier": "PF00059", "name": "Lectin_C"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "binding"}, {"category": "function", "description": "carbohydrate binding"}, {"category": "function", "description": "sugar binding"}]}}}, {"@position": "7", "id": "BE0002105", "name": "Keratin, type II cytoskeletal 8", "organism": "Human", "actions": null, "references": "# Kralovich KR, Li L, Hembrough TA, Webb DJ, Karns LR, Gonias SL: Characterization of the binding sites for plasminogen and tissue-type plasminogen activator in cytokeratin 8 and cytokeratin 18. J Protein Chem. 1998 Nov;17(8):845-54. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9988531\n# Hembrough TA, Kralovich KR, Li L, Gonias SL: Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation. Biochem J. 1996 Aug 1;317 ( Pt 3):763-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8760360\n# Hembrough TA, Li L, Gonias SL: Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator. J Biol Chem. 1996 Oct 11;271(41):25684-91. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8810346", "known-action": "unknown", "polypeptide": {"@id": "P05787", "@source": "Swiss-Prot", "name": "Keratin, type II cytoskeletal 8", "general-function": "Cell cycle control, cell division, chromosome partitioning", "specific-function": "Together with KRT19, helps to link the contractile apparatus to dystrophin at the costameres of striated muscle", "gene-name": "KRT8", "locus": "12q13", "cellular-location": null, "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.26", "molecular-weight": "53705.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6446"}, {"resource": "GenAtlas", "identifier": "KRT8"}, {"resource": "GeneCards", "identifier": "KRT8"}, {"resource": "GenBank Gene Database", "identifier": "M34482"}, {"resource": "GenBank Protein Database", "identifier": "181573"}, {"resource": "UniProtKB", "identifier": "P05787"}, {"resource": "UniProt Accession", "identifier": "K2C8_HUMAN"}]}, "synonyms": {"synonym": ["CK-8", "Cytokeratin-8", "K8", "Keratin-8"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Keratin, type II cytoskeletal 8\nMSIRVTQKSYKVSTSGPRAFSSRSYTSGPGSRISSSSFSRVGSSNFRGGLGGGYGGASGM\nGGITAVTVNQSLLSPLVLEVDPNIQAVRTQEKEQIKTLNNKFASFIDKVRFLEQQNKMLE\nTKWSLLQQQKTARSNMDNMFESYINNLRRQLETLGQEKLKLEAELGNMQGLVEDFKNKYE\nDEINKRTEMENEFVLIKKDVDEAYMNKVELESRLEGLTDEINFLRQLYEEEIRELQSQIS\nDTSVVLSMDNSRSLDMDSIIAEVKAQYEDIANRSRAEAESMYQIKYEELQSLAGKHGDDL\nRRTKTEISEMNRNISRLQAEIEGLKGQRASLEAAIADAEQRGELAIKDANAKLSELEAAL\nQRAKQDMARQLREYQELMNVKLALDIEIATYRKLLEGEESRLESGMQNMSIHTKTTSGYA\nGGLSSAYGGLTSPGLSYSLGSSFGSGAGSSSFSRTSSSRAVVVKKIETRDGKLVSESSDV\nLPK"}, "gene-sequence": {"@format": "FASTA", "#text": ">1449 bp\nATGTCCATCAGGGTGACCCAGAAGTCCTACAAGGTGTCCACCTCTGGCCCCCGGGCCTTC\nAGCAGCCGCTCCTACACGAGTGGGCCCGGTTCCCGCATCAGCTCCTCGAGCTTCTCCCGA\nGTGGGCAGCAGCAACTTTCGCGGTGGCCTGGGCGGCGGCTATGGTGGGGCCAGCGGCATG\nGGAGGCATCACCGCAGTTACGGTCAACCAGAGCCTGCTGAGCCCCCTTGTCCTGGAGGTG\nGACCCCAACATCCAGGCCGTGCGCACCCAGGAGAAGGAGCAGATCAAGACCCTCAACAAC\nAAGTTTGCCTCCTTCATAGACAAGGTACGGTTCCTGGAGCAGCAGAACAAGATGCTGGAG\nACCAAGTGGAGCCTCCTGCAGCAGCAGAAGACGGCTCGAAGCAACATGGACAACATGTTC\nGAGAGCTACATCAACAACCTTAGGCGGCAGCTGGAGACTCTGGGCCAGGAGAAGCTGAAG\nCTGGAGGCGGAGCTTGGCAACATGCAGGGGCTGGTGGAGGACTTCAAGAACAAGTATGAG\nGATGAGATCAATAAGCGTACAGAGATGGAGAACGAATTTGTCCTCATCAAGAAGGATGTG\nGATGAAGCTTACATGAACAAGGTAGAGCTGGAGTCTCGCCTGGAAGGGCTGACCGACGAG\nATCAACTTCCTCAGGCAGCTATATGAAGAGGAGATCCGGGAGCTGCAGTCCCAGATCTCG\nGACACATCTGTGGTGCTGTCCATGGACAACAGCCGCTCCCTGGACATGGACAGCATCATT\nGCTGAGGTCAAGGCACAGTACGAGGATATTGCCAACCGCAGCCGGGCTGAGGCTGAGAGC\nATGTACCAGATCAAGTATGAGGAGCTGCAGAGCCTGGCTGGGAAGCACGGGGATGACCTG\nCGGCGCACAAAGACTGAGATCTCTGAGATGAACCGGAACATCAGCCGGCTCCAGGCTGAG\nATTGAGGGCCTCAAAGGCCAGAGGGCTTCCCTGGAGGCCGCCATTGCAGATGCCGAGCAG\nCGTGGAGAGCTGGCCATTAAGGATGCCAACGCCAAGTTGTCCGAGCTGGAGGCCGCCCTG\nCAGCGGGCCAAGCAGGACATGGCGCGGCAGCTGCGTGAGTACCAGGAGCTGATGAACGTC\nAAGCTGGCCCTGGACATCGAGATCGCCACCTACAGGAAGCTGCTGGAGGGCGAGGAGAGC\nCGGCTGGAGTCTGGGATGCAGAACATGAGTATTCATACGAAGACCACCGGCGGCTATGCA\nGGTGGTCTGAGCTCGGCCTATGGGGGCTCACAAGCCGGCCTCAGCTACAGCCTGGGCTCC\nAGCTTTGGCTCTGGCGCGGGCTCCAGCTCCTTCAGCCGCACCAGCTCCTCCAGGGCCGTG\nGTTGTGAAGAAGATCGAGACACGTGATGGGAAGCTGGTGTCTGAGTCCTCTGACGTCCTG\nCCCAAGTGA"}, "pfams": {"pfam": {"identifier": "PF00038", "name": "Filament"}}, "go-classifiers": {"go-classifier": {"category": "function", "description": "structural molecule activity"}}}}, {"@position": "8", "id": "BE0001170", "name": "Annexin A2", "organism": "Human", "actions": null, "references": "# Diaz VM, Hurtado M, Thomson TM, Reventos J, Paciucci R: Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut. 2004 Jul;53(7):993-1000. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15194650\n# Kang HM, Choi KS, Kassam G, Fitzpatrick SL, Kwon M, Waisman DM: Role of annexin II tetramer in plasminogen activation. Trends Cardiovasc Med. 1999 Apr-May;9(3-4):92-102. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10578524\n# MacLeod TJ, Kwon M, Filipenko NR, Waisman DM: Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits: characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin. J Biol Chem. 2003 Jul 11;278(28):25577-84. Epub 2003 Apr 30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12730231", "known-action": "unknown", "polypeptide": {"@id": "P07355", "@source": "Swiss-Prot", "name": "Annexin A2", "general-function": "Involved in calcium ion binding", "specific-function": "Calcium-regulated membrane-binding protein whose affinity for calcium is greatly enhanced by anionic phospholipids. It binds two calcium ions with high affinity", "gene-name": "ANXA2", "locus": "15q21-q22", "cellular-location": "Secreted protein; extracellular space; extracellular matrix; basement membrane. Melanosome. Note=In", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.91", "molecular-weight": "38604.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:537"}, {"resource": "GenAtlas", "identifier": "ANXA2"}, {"resource": "GeneCards", "identifier": "ANXA2"}, {"resource": "GenBank Gene Database", "identifier": "D00017"}, {"resource": "GenBank Protein Database", "identifier": "219910"}, {"resource": "UniProtKB", "identifier": "P07355"}, {"resource": "UniProt Accession", "identifier": "ANXA2_HUMAN"}]}, "synonyms": {"synonym": ["Annexin II", "Calpactin I heavy chain", "Chromobindin-8", "Lipocortin II", "p36", "PAP-IV", "Placental anticoagulant protein IV", "Protein I"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Annexin A2\nMSTVHEILCKLSLEGDHSTPPSAYGSVKAYTNFDAERDALNIETAIKTKGVDEVTIVNIL\nTNRSNAQRQDIAFAYQRRTKKELASALKSALSGHLETVILGLLKTPAQYDASELKASMKG\nLGTDEDSLIEIICSRTNQELQEINRVYKEMYKTDLEKDIISDTSGDFRKLMVALAKGRRA\nEDGSVIDYELIDQDARDLYDAGVKRKGTDVPKWISIMTERSVPHLQKVFDRYKSYSPYDM\nLESIRKEVKGDLENAFLNLVQCIQNKPLYFADRLYDSMKGKGTRDKVLIRIMVSRSEVDM\nLKIRSEFKRKYGKSLYYYIQQDTKGDYQKALLYLCGGDD"}, "gene-sequence": {"@format": "FASTA", "#text": ">1020 bp\nATGTCTACTGTTCACGAAATCCTGTGCAAGCTCAGCTTGGAGGGTGATCACTCTACACCC\nCCAAGTGCATATGGGTCTGTCAAAGCCTATACTAACTTTGATGCTGAGCGGGATGCTTTG\nAACATTGAAACAGCCATCAAGACCAAAGGTGTGGATGAGGTCACCATTGTCAACATTTTG\nACCAACCGCAGCAATGCACAGAGACAGGATATTGCCTTCGCCTACCAGAGAAGGACCAAA\nAAGGAACTTGCATCAGCACTGAAGTCAGCCTTATCTGGCCACCTGGAGACGGTGATTTTG\nGGCCTATTGAAGACACCTGCTCAGTATGACGCTTCTGAGCTAAAAGCTTCCATGAAGGGG\nCTGGGAACCGACGAGGACTCTCTCATTGAGATCATCTGCTCCAGAACCAACCAGGAGCTG\nCAGGAAATTAACAGAGTCTACAAGGAAATGTACAAGACTGATCTGGAGAAGGACATTATT\nTCGGACACATCTGGTGACTTCCGCAAGCTGATGGTTGCCCTGGCAAAGGGTAGAAGAGCA\nGAGGATGGCTCTGTCATTGATTATGAACTGATTGACCAAGATGCTCGGGATCTCTATGAC\nGCTGGAGTGAAGAGGAAAGGAACTGATGTTCCCAAGTGGATCAGCATCATGACCGAGCGG\nAGCGTGCCCCACCTCCAGAAAGTATTTGATAGGTACAAGAGTTACAGCCCTTATGACATG\nTTGGAAAGCATCAGGAAAGAGGTTAAAGGAGACCTGGAAAATGCTTTCCTGAACCTGGTT\nCAGTGCATTCAGAACAAGCCCCTGTATTTTGCTGATCGGCTGTATGACTCCATGAAGGGC\nAAGGGGACGCGAGATAAGGTCCTGATCAGAATCATGGTCTCCCGCAGTGAAGTGGACATG\nTTGAAAATTAGGTCTGAATTCAAGAGAAAGTACGGCAAGTCCCTGTACTATTATATCCAG\nCAAGACACTAAGGGCGACTACCAGAAAGCGCTGCTGTACCTGTGTGGTGGAGATGACTGA"}, "pfams": {"pfam": {"identifier": "PF00191", "name": "Annexin"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "phospholipase inhibitor activity"}, {"category": "function", "description": "phospholipid binding"}, {"category": "function", "description": "calcium-dependent phospholipid binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "cytoskeletal protein binding"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "protein binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "enzyme regulator activity"}, {"category": "function", "description": "enzyme inhibitor activity"}, {"category": "function", "description": "lipid binding"}]}}}, {"@position": "9", "id": "BE0002109", "name": "Calreticulin", "organism": "Human", "actions": null, "references": "# Allen S, Bulleid NJ: Calnexin and calreticulin bind to enzymically active tissue-type plasminogen activator during biosynthesis and are not required for folding to the native conformation. Biochem J. 1997 Nov 15;328 ( Pt 1):113-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9359841", "known-action": "unknown", "polypeptide": {"@id": "P27797", "@source": "Swiss-Prot", "name": "Calreticulin", "general-function": null, "specific-function": "Molecular calcium binding chaperone promoting folding, oligomeric assembly and quality control in the ER via the calreticulin/calnexin cycle. This lectin interacts transiently with almost all of the monoglucosylated glycoproteins that are synthesized in the ER. Interacts with the DNA-binding domain of NR3C1 and mediates its nuclear export", "gene-name": "CALR", "locus": "19p13.3-p13.2", "cellular-location": "Endoplasmic reticulum", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "4.04", "molecular-weight": "48142.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1455"}, {"resource": "GenAtlas", "identifier": "CALR"}, {"resource": "GeneCards", "identifier": "CALR"}, {"resource": "GenBank Gene Database", "identifier": "M32294"}, {"resource": "GenBank Protein Database", "identifier": "337487"}, {"resource": "UniProtKB", "identifier": "P27797"}, {"resource": "UniProt Accession", "identifier": "CALR_HUMAN"}]}, "synonyms": {"synonym": ["Calregulin", "Calreticulin precursor", "CRP55", "ERp60", "grp60", "HACBP"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Calreticulin\nMLLSVPLLLGLLGLAVAEPAVYFKEQFLDGDGWTSRWIESKHKSDFGKFVLSSGKFYGDE\nEKDKGLQTSQDARFYALSASFEPFSNKGQTLVVQFTVKHEQNIDCGGGYVKLFPNSLDQT\nDMHGDSEYNIMFGPDICGPGTKKVHVIFNYKGKNVLINKDIRCKDDEFTHLYTLIVRPDN\nTYEVKIDNSQVESGSLEDDWDFLPPKKIKDPDASKPEDWDERAKIDDPTDSKPEDWDKPE\nHIPDPDAKKPEDWDEEMDGEWEPPVIQNPEYKGEWKPRQIDNPDYKGTWIHPEIDNPEYS\nPDPSIYAYDNFGVLGLDLWQVKSGTIFDNFLITNDEAYAEEFGNETWGVTKAAEKQMKDK\nQDEEQRLKEEEEDKKRKEEEEAEDKEDDEDKDEDEEDEEDKEEDEEEDVPGQAKDEL"}, "gene-sequence": {"@format": "FASTA", "#text": ">1254 bp\nATGCTGCTATCCGTGCCGCTGCTGCTCGGCCTCCTCGGCCTGGCCGTCGCCGAGCCCGCC\nGTCTACTTCAAGGAGCAGTTTCTGGACGGAGACGGGTGGACTTCCCGCTGGATCGAATCC\nAAACACAAGTCAGATTTTGGCAAATTCGTTCTCAGTTCCGGCAAGTTCTACGGTGACGAG\nGAGAAAGATAAAGGTTTGCAGACAAGCCAGGATGCACGCTTTTATGCTCTGTCGGCCAGT\nTTCGAGCCTTTCAGCAACAAAGGCCAGACGCTGGTGGTGCAGTTCACGGTGAAACATGAG\nCAGAACATCGACTGTGGGGGCGGCTATGTGAAGCTGTTTCCTAATAGTTTGGACCAGACA\nGACATGCACGGAGACTCAGAATACAACATCATGTTTGGTCCCGACATCTGTGGCCCTGGC\nACCAAGAAGGTTCATGTCATCTTCAACTACAAGGGCAAGAACGTGCTGATCAACAAGGAC\nATCCGTTGCAAGGATGATGAGTTTACACACCTGTACACACTGATTGTGCGGCCAGACAAC\nACCTATGAGGTGAAGATTGACAACAGCCAGGTGGAGTCCGGCTCCTTGGAAGACGATTGG\nGACTTCCTGCCACCCAAGAAGATAAAGGATCCTGATGCTTCAAAACCGGAAGACTGGGAT\nGAGCGGGCCAAGATCGATGATCCCACAGACTCCAAGCCTGAGGACTGGGACAAGCCCGAG\nCATATCCCTGACCCTGATGCTAAGAAGCCCGAGGACTGGGATGAAGAGATGGACGGAGAG\nTGGGAACCCCCAGTGATTCAGAACCCTGAGTACAAGGGTGAGTGGAAGCCCCGGCAGATC\nGACAACCCAGATTACAAGGGCACTTGGATCCACCCAGAAATTGACAACCCCGAGTATTCT\nCCCGATCCCAGTATCTATGCCTATGATAACTTTGGCGTGCTGGGCCTGGACCTCTGGCAG\nGTCAAGTCTGGCACCATCTTTGACAACTTCCTCATCACCAACGATGAGGCATACGCTGAG\nGAGTTTGGCAACGAGACGTGGGGCGTAACAAAGGCAGCAGAGAAACAAATGAAGGACAAA\nCAGGACGAGGAGCAGAGGCTTAAGGAGGAGGAAGAAGACAAGAAACGCAAAGAGGAGGAG\nGAGGCAGAGGACAAGGAGGATGATGAGGACAAAGATGAGGATGAGGAGGATGAGGAGGAC\nAAGGAGGAAGATGAGGAGGAAGATGTCCCCGGCCAGGCCAAGGACGAGCTGTAG"}, "pfams": {"pfam": {"identifier": "PF00262", "name": "Calreticulin"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "membrane-bound organelle"}, {"category": "component", "description": "intracellular membrane-bound organelle"}, {"category": "component", "description": "endoplasmic reticulum"}, {"category": "component", "description": "organelle"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "unfolded protein binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "protein binding"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein folding"}]}}}, {"@position": "10", "id": "BE0001011", "name": "Calnexin", "organism": "Human", "actions": null, "references": "# Allen S, Bulleid NJ: Calnexin and calreticulin bind to enzymically active tissue-type plasminogen activator during biosynthesis and are not required for folding to the native conformation. Biochem J. 1997 Nov 15;328 ( Pt 1):113-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9359841", "known-action": "unknown", "polypeptide": {"@id": "P27824", "@source": "Swiss-Prot", "name": "Calnexin", "general-function": "Involved in calcium ion binding", "specific-function": "Calcium-binding protein that interacts with newly synthesized glycoproteins in the endoplasmic reticulum. It may act in assisting protein assembly and/or in the retention within the ER of unassembled protein subunits. It seems to play a major role in the quality control apparatus of the ER by the retention of incorrectly folded proteins", "gene-name": "CANX", "locus": "5q35", "cellular-location": "Endoplasmic reticulum; endoplasmic reticulum membrane; single-pass type I membrane protein. Melanoso", "transmembrane-regions": "482-502", "signal-regions": null, "theoretical-pi": "4.21", "molecular-weight": "67569.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1473"}, {"resource": "GenAtlas", "identifier": "CANX"}, {"resource": "GeneCards", "identifier": "CANX"}, {"resource": "GenBank Gene Database", "identifier": "L10284"}, {"resource": "GenBank Protein Database", "identifier": "186523"}, {"resource": "UniProtKB", "identifier": "P27824"}, {"resource": "UniProt Accession", "identifier": "CALX_HUMAN"}]}, "synonyms": {"synonym": ["Calnexin precursor", "IP90", "Major histocompatibility complex class I antigen- binding protein p88", "p90"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Calnexin precursor\nMEGKWLLCMLLVLGTAIVEAHDGHDDDVIDIEDDLDDVIEEVEDSKPDTTAPPSSPKVTY\nKAPVPTGEVYFADSFDRGTLSGWILSKAKKDDTDDEIAKYDGKWEVEEMKESKLPGDKGL\nVLMSRAKHHAISAKLNKPFLFDTKPLIVQYEVNFQNGIECGGAYVKLLSKTPELNLDQFH\nDKTPYTIMFGPDKCGEDYKLHFIFRHKNPKTGIYEEKHAKRPDADLKTYFTDKKTHLYTL\nILNPDNSFEILVDQSVVNSGNLLNDMTPPVNPSREIEDPEDRKPEDWDERPKIPDPEAVK\nPDDWDEDAPAKIPDEEATKPEGWLDDEPEYVPDPDAEKPEDWDEDMDGEWEAPQIANPRC\nESAPGCGVWQRPVIDNPNYKGKWKPPMIDNPSYQGIWKPRKIPNPDFFEDLEPFRMTPFS\nAIGLELWSMTSDIFFDNFIICADRRIVDDWANDGWGLKKAADGAAEPGVVGQMIEAAEER\nPWLWVVYILTVALPVFLVILFCCSGKKQTSGMEYKKTDAPQPDVKEEEEEKEEEKDKGDE\nEEEGEEKLEEKQKSDAEEDGGTVSQEEEDRKPKAEEDEILNRSPRNRKPRRE"}, "gene-sequence": {"@format": "FASTA", "#text": ">1779 bp\nATGGAAGGGAAGTGGTTGCTGTGTATGTTACTGGTGCTTGGAACTGCTATTGTTGAGGCT\nCATGATGGACATGATGATGATGTGATTGATATTGAGGATGACCTTGACGATGTCATTGAA\nGAGGTAGAAGACTCAAAACCAGATACCACTGCTCCTCCTTCATCTCCCAAGGTTACTTAC\nAAAGCTCCAGTTCCAACAGGGGAAGTATATTTTGCTGATTCTTTTGACAGAGGAACTCTG\nTCAGGGTGGATTTTATCCAAAGCCAAGAAAGACGATACCGATGATGAAATTGCCAAATAT\nGATGGAAAGTGGGAGGTAGAGGAAATGAAGGAGTCAAAGCTTCCAGGTGATAAAGGACTT\nGTGTTGATGTCTCGGGCCAAGCATCATGCGATCTCTGCTAAACTGAACAAGCCCTTCCTG\nTTTGACACCAAGCCTCTCATTGTTCAGTATGAGGTTAATTTCCAAAATGGAATAGAATGT\nGGTGGTGCCTATGTGAAACTGCTTTCTAAAACACCAGAACTCAACCTGGATCAGTTCCAT\nGACAAGACCCCTTATACGATTATGTTTGGTCCAGATAAATGTGGAGAGGACTATAAACTG\nCACTTCATCTTCCGACACAAAAACCCCAAAACGGGTATCTATGAAGAAAAACATGCTAAG\nAGGCCAGATGCAGATCTGAAGACCTATTTTACTGATAAGAAAACACATCTTTACACACTA\nATCTTGAATCCAGATAATAGTTTTGAAATACTGGTTGACCAATCTGTGGTGAATAGTGGA\nAATCTGCTCAATGACATGACTCCTCCTGTAAATCCTTCACGTGAAATTGAGGACCCAGAA\nGACCGGAAGCCCGAGGATTGGGATGAAAGACCAAAAATCCCAGATCCAGAAGCTGTCAAG\nCCAGATGACTGGGATGAAGATGCCCCTGCTAAGATTCCAGATGAAGAGGCCACAAAACCC\nGAAGGCTGGTTAGATGATGAGCCTGAGTACGTACCTGATCCAGACGCAGAGAAACCTGAG\nGATTGGGATGAAGACATGGATGGAGAATGGGAGGCTCCTCAGATTGCCAACCCTAGATGT\nGAGTCAGCTCCTGGATGTGGTGTCTGGCAGCGACCTGTGATTGACAACCCCAATTATAAA\nGGCAAATGGAAGCCTCCTATGATTGACAATCCCAGTTACCAGGGAATCTGGAAACCCAGG\nAAAATACCAAATCCAGATTTCTTTGAAGATCTGGAACCTTTCAGAATGACTCCTTTTAGT\nGCTATTGGTTTGGAGCTGTGGTCCATGACCTCTGACATTTTTTTTGACAACTTTATCATT\nTGTGCTGATCGAAGAATAGTTGATGATTGGGCCAATGATGGATGGGGCCTGAAGAAAGCT\nGCTGATGGGGCTGCTGAGCCAGGCGTTGTGGGGCAGATGATCGAGGCAGCTGAAGAGCGC\nCCGTGGCTGTGGGTAGTCTATATTCTAACTGTAGCCCTTCCTGTGTTCCTGGTTATCCTC\nTTCTGCTGTTCTGGAAAGAAACAGACCAGTGGTATGGAGTATAAGAAAACTGATGCACCT\nCAACCGGATGTGAAGGAAGAGGAAGAAGAGAAGGAAGAGGAAAAGGACAAGGGAGATGAG\nGAGGAGGAAGGAGAAGAGAAACTTGAAGAGAAACAGAAAAGTGATGCTGAAGAAGATGGT\nGGCACTGTCAGTCAAGAGGAGGAAGACAGAAAACCTAAAGCAGAGGAGGATGAAATTTTG\nAACAGATCACCAAGAAACAGAAAGCCACGAAGAGAGTGA"}, "pfams": {"pfam": {"identifier": "PF00262", "name": "Calreticulin"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "binding"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}]}}}, {"@position": "11", "id": "BE0002110", "name": "Prolow-density lipoprotein receptor-related protein 1", "organism": "Human", "actions": null, "references": "# Moestrup SK, Nielsen S, Andreasen P, Jorgensen KE, Nykjaer A, Roigaard H, Gliemann J, Christensen EI: Epithelial glycoprotein-330 mediates endocytosis of plasminogen activator-plasminogen activator inhibitor type-1 complexes. J Biol Chem. 1993 Aug 5;268(22):16564-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8344937\n# Nykjaer A, Petersen CM, Moller B, Jensen PH, Moestrup SK, Holtet TL, Etzerodt M, Thogersen HC, Munch M, Andreasen PA, et al.: Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem. 1992 Jul 25;267(21):14543-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1378833\n# Hu K, Yang J, Tanaka S, Gonias SL, Mars WM, Liu Y: Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem. 2006 Jan 27;281(4):2120-7. Epub 2005 Nov 22. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16303771", "known-action": "unknown", "polypeptide": {"@id": "Q07954", "@source": "Swiss-Prot", "name": "Prolow-density lipoprotein receptor-related protein 1", "general-function": null, "specific-function": "Required for early embryonic development. Involved in the plasma clearance of chylomicron remnants and activated alpha 2-macroglobulin, as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. May modulate APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission", "gene-name": "LRP1", "locus": "12q13-q14", "cellular-location": "Cell membrane", "transmembrane-regions": "4420-4444", "signal-regions": null, "theoretical-pi": "5.02", "molecular-weight": "504578.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6692"}, {"resource": "GenAtlas", "identifier": "LRP1"}, {"resource": "GeneCards", "identifier": "LRP1"}, {"resource": "GenBank Gene Database", "identifier": "X13916"}, {"resource": "GenBank Protein Database", "identifier": "34339"}, {"resource": "UniProtKB", "identifier": "Q07954"}, {"resource": "UniProt Accession", "identifier": "LRP1_HUMAN"}]}, "synonyms": {"synonym": ["A2MR", "Alpha-2-macroglobulin receptor", "APOER", "Apolipoprotein E receptor", "CD91 antigen", "Low-density lipoprotein receptor-related protein 1 precursor", "LRP"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low-density lipoprotein receptor-related protein 1\nMLTPPLLLLLPLLSALVAAAIDAPKTCSPKQFACRDQITCISKGWRCDGERDCPDGSDEA\nPEICPQSKAQRCQPNEHNCLGTELCVPMSRLCNGVQDCMDGSDEGPHCRELQGNCSRLGC\nQHHCVPTLDGPTCYCNSSFQLQADGKTCKDFDECSVYGTCSQLCTNTDGSFICGCVEGYL\nLQPDNRSCKAKNEPVDRPPVLLIANSQNILATYLSGAQVSTITPTSTRQTTAMDFSYANE\nTVCWVHVGDSAAQTQLKCARMPGLKGFVDEHTINISLSLHHVEQMAIDWLTGNFYFVDDI\nDDRIFVCNRNGDTCVTLLDLELYNPKGIALDPAMGKVFFTDYGQIPKVERCDMDGQNRTK\nLVDSKIVFPHGITLDLVSRLVYWADAYLDYIEVVDYEGKGRQTIIQGILIEHLYGLTVFE\nNYLYATNSDNANAQQKTSVIRVNRFNSTEYQVVTRVDKGGALHIYHQRRQPRVRSHACEN\nDQYGKPGGCSDICLLANSHKARTCRCRSGFSLGSDGKSCKKPEHELFLVYGKGRPGIIRG\nMDMGAKVPDEHMIPIENLMNPRALDFHAETGFIYFADTTSYLIGRQKIDGTERETILKDG\nIHNVEGVAVDWMGDNLYWTDDGPKKTISVARLEKAAQTRKTLIEGKMTHPRAIVVDPLNG\nWMYWTDWEEDPKDSRRGRLERAWMDGSHRDIFVTSKTVLWPNGLSLDIPAGRLYWVDAFY\nDRIETILLNGTDRKIVYEGPELNHAFGLCHHGNYLFWTEYRSGSVYRLERGVGGAPPTVT\nLLRSERPPIFEIRMYDAQQQQVGTNKCRVNNGGCSSLCLATPGSRQCACAEDQVLDADGV\nTCLANPSYVPPPQCQPGEFACANSRCIQERWKCDGDNDCLDNSDEAPALCHQHTCPSDRF\nKCENNRCIPNRWLCDGDNDCGNSEDESNATCSARTCPPNQFSCASGRCIPISWTCDLDDD\nCGDRSDESASCAYPTCFPLTQFTCNNGRCININWRCDNDNDCGDNSDEAGCSHSCSSTQF\nKCNSGRCIPEHWTCDGDNDCGDYSDETHANCTNQATRPPGGCHTDEFQCRLDGLCIPLRW\nRCDGDTDCMDSSDEKSCEGVTHVCDPSVKFGCKDSARCISKAWVCDGDNDCEDNSDEENC\nESLACRPPSHPCANNTSVCLPPDKLCDGNDDCGDGSDEGELCDQCSLNNGGCSHNCSVAP\nGEGIVCSCPLGMELGPDNHTCQIQSYCAKHLKCSQKCDQNKFSVKCSCYEGWVLEPDGES\nCRSLDPFKPFIIFSNRHEIRRIDLHKGDYSVLVPGLRNTIALDFHLSQSALYWTDVVEDK\nIYRGKLLDNGALTSFEVVIQYGLATPEGLAVDWIAGNIYWVESNLDQIEVAKLDGTLRTT\nLLAGDIEHPRAIALDPRDGILFWTDWDASLPRIEAASMSGAGRRTVHRETGSGGWPNGLT\nVDYLEKRILWIDARSDAIYSARYDGSGHMEVLRGHEFLSHPFAVTLYGGEVYWTDWRTNT\nLAKANKWTGHNVTVVQRTNTQPFDLQVYHPSRQPMAPNPCEANGGQGPCSHLCLINYNRT\nVSCACPHLMKLHKDNTTCYEFKKFLLYARQMEIRGVDLDAPYYNYIISFTVPDIDNVTVL\nDYDAREQRVYWSDVRTQAIKRAFINGTGVETVVSADLPNAHGLAVDWVSRNLFWTSYDTN\nKKQINVARLDGSFKNAVVQGLEQPHGLVVHPLRGKLYWTDGDNISMANMDGSNRTLLFSG\nQKGPVGLAIDFPESKLYWISSGNHTINRCNLDGSGLEVIDAMRSQLGKATALAIMGDKLW\nWADQVSEKMGTCSKADGSGSVVLRNSTTLVMHMKVYDESIQLDHKGTNPCSVNNGDCSQL\nCLPTSETTRSCMCTAGYSLRSGQQACEGVGSFLLYSVHEGIRGIPLDPNDKSDALVPVSG\nTSLAVGIDFHAENDTIYWVDMGLSTISRAKRDQTWREDVVTNGIGRVEGIAVDWIAGNIY\nWTDQGFDVIEVARLNGSFRYVVISQGLDKPRAITVHPEKGYLFWTEWGQYPRIERSRLDG\nTERVVLVNVSISWPNGISVDYQDGKLYWCDARTDKIERIDLETGENREVVLSSNNMDMFS\nVSVFEDFIYWSDRTHANGSIKRGSKDNATDSVPLRTGIGVQLKDIKVFNRDRQKGTNVCA\nVANGGCQQLCLYRGRGQRACACAHGMLAEDGASCREYAGYLLYSERTILKSIHLSDERNL\nNAPVQPFEDPEHMKNVIALAFDYRAGTSPGTPNRIFFSDIHFGNIQQINDDGSRRITIVE\nNVGSVEGLAYHRGWDTLYWTSYTTSTITRHTVDQTRPGAFERETVITMSGDDHPRAFVLD\nECQNLMFWTNWNEQHPSIMRAALSGANVLTLIEKDIRTPNGLAIDHRAEKLYFSDATLDK\nIERCEYDGSHRYVILKSEPVHPFGLAVYGEHIFWTDWVRRAVQRANKHVGSNMKLLRVDI\nPQQPMGIIAVANDTNSCELSPCRINNGGCQDLCLLTHQGHVNCSCRGGRILQDDLTCRAV\nNSSCRAQDEFECANGECINFSLTCDGVPHCKDKSDEKPSYCNSRRCKKTFRQCSNGRCVS\nNMLWCNGADDCGDGSDEIPCNKTACGVGEFRCRDGTCIGNSSRCNQFVDCEDASDEMNCS\nATDCSSYFRLGVKGVLFQPCERTSLCYAPSWVCDGANDCGDYSDERDCPGVKRPRCPLNY\nFACPSGRCIPMSWTCDKEDDCEHGEDETHCNKFCSEAQFECQNHRCISKQWLCDGSDDCG\nDGSDEAAHCEGKTCGPSSFSCPGTHVCVPERWLCDGDKDCADGADESIAAGCLYNSTCDD\nREFMCQNRQCIPKHFVCDHDRDCADGSDESPECEYPTCGPSEFRCANGRCLSSRQWECDG\nENDCHDQSDEAPKNPHCTSPEHKCNASSQFLCSSGRCVAEALLCNGQDDCGDSSDERGCH\nINECLSRKLSGCSQDCEDLKIGFKCRCRPGFRLKDDGRTCADVDECSTTFPCSQRCINTH\nGSYKCLCVEGYAPRGGDPHSCKAVTDEEPFLIFANRYYLRKLNLDGSNYTLLKQGLNNAV\nALDFDYREQMIYWTDVTTQGSMIRRMHLNGSNVQVLHRTGLSNPDGLAVDWVGGNLYWCD\nKGRDTIEVSKLNGAYRTVLVSSGLREPRALVVDVQNGYLYWTDWGDHSLIGRIGMDGSSR\nSVIVDTKITWPNGLTLDYVTERIYWADAREDYIEFASLDGSNRHVVLSQDIPHIFALTLF\nEDYVYWTDWETKSINRAHKTTGTNKTLLISTLHRPMDLHVFHALRQPDVPNHPCKVNNGG\nCSNLCLLSPGGGHKCACPTNFYLGSDGRTCVSNCTASQFVCKNDKCIPFWWKCDTEDDCG\nDHSDEPPDCPEFKCRPGQFQCSTGICTNPAFICDGDNDCQDNSDEANCDIHVCLPSQFKC\nTNTNRCIPGIFRCNGQDNCGDGEDERDCPEVTCAPNQFQCSITKRCIPRVWVCDRDNDCV\nDGSDEPANCTQMTCGVDEFRCKDSGRCIPARWKCDGEDDCGDGSDEPKEECDERTCEPYQ\nFRCKNNRCVPGRWQCDYDNDCGDNSDEESCTPRPCSESEFSCANGRCIAGRWKCDGDHDC\nADGSDEKDCTPRCDMDQFQCKSGHCIPLRWRCDADADCMDGSDEEACGTGVRTCPLDEFQ\nCNNTLCKPLAWKCDGEDDCGDNSDENPEECARFVCPPNRPFRCKNDRVCLWIGRQCDGTD\nNCGDGTDEEDCEPPTAHTTHCKDKKEFLCRNQRCLSSSLRCNMFDDCGDGSDEEDCSIDP\nKLTSCATNASICGDEARCVRTEKAAYCACRSGFHTVPGQPGCQDINECLRFGTCSQLCNN\nTKGGHLCSCARNFMKTHNTCKAEGSEYQVLYIADDNEIRSLFPGHPHSAYEQAFQGDESV\nRIDAMDVHVKAGRVYWTNWHTGTISYRSLPPAAPPTTSNRHRRQIDRGVTHLNISGLKMP\nRGIAIDWVAGNVYWTDSGRDVIEVAQMKGENRKTLISGMIDEPHAIVVDPLRGTMYWSDW\nGNHPKIETAAMDGTLRETLVQDNIQWPTGLAVDYHNERLYWADAKLSVIGSIRLNGTDPI\nVAADSKRGLSHPFSIDVFEDYIYGVTYINNRVFKIHKFGHSPLVNLTGGLSHASDVVLYH\nQHKQPEVTNPCDRKKCEWLCLLSPSGPVCTCPNGKRLDNGTCVPVPSPTPPPDAPRPGTC\nNLQCFNGGSCFLNARRQPKCRCQPRYTGDKCELDQCWEHCRNGGTCAASPSGMPTCRCPT\nGFTGPKCTQQVCAGYCANNSTCTVNQGNQPQCRCLPGFLGDRCQYRQCSGYCENFGTCQM\nAADGSRQCRCTAYFEGSRCEVNKCSRCLEGACVVNKQSGDVTCNCTDGRVAPSCLTCVGH\nCSNGGSCTMNSKMMPECQCPPHMTGPRCEEHVFSQQQPGHIASILIPLLLLLLLVLVAGV\nVFWYKRRVQGAKGFQHQRMTNGAMNVEIGNPTYKMYEGGEPDDVGGLLDADFALDPDKPT\nNFTNPVYATLYMGGHGSRHSLASTDEKRELLGRGPEDEIGDPLA"}, "gene-sequence": {"@format": "FASTA", "#text": ">13635 bp\nATGCTGACCCCGCCGTTGCTCCTGCTGCTGCCCCTGCTCTCAGCTCTGGTCGCGGCGGCT\nATCGACGCCCCTAAGACTTGCAGCCCCAAGCAGTTTGCCTGCAGAGATCAAATAACCTGT\nATCTCAAAGGGCTGGCGGTGCGACGGTGAGAGGGACTGCCCAGACGGATCTGACGAGGCC\nCCTGAGATTTGTCCACAGAGTAAGGCCCAGCGATGCCAGCCAAACGAGCATAACTGCCTG\nGGTACTGAGCTGTGTGTTCCCATGTCCCGCCTCTGCAATGGGGTCCAGGACTGCATGGAC\nGGCTCAGATGAGGGGCCCCACTGCCGAGAGCTCCAAGGCAACTGCTCTCGCCTGGGCTGC\nCAGCACCATTGTGTCCCCACACTCGATGGGCCCACCTGCTACTGCAACAGCAGCTTTCAG\nCTTCAGGCAGATGGCAAGACCTGCAAAGATTTTGATGAGTGCTCAGTGTACGGCACCTGC\nAGCCAGCTATGCACCAACACAGACGGCTCCTTCATATGTGGCTGTGTTGAAGGATACCTC\nCTGCAGCCGGATAACCGCTCCTGCAAGGCCAAGAACGAGCCAGTAGACCGGCCCCCTGTG\nCTGTTGATAGCCAACTCCCAGAACATCTTGGCCACGTACCTGAGTGGGGCCCAGGTGTCT\nACCATCACACCTACGAGCACGCGGCAGACCACAGCCATGGACTTCAGCTATGCCAACGAG\nACCGTATGCTGGGTGCATGTTGGGGACAGTGCTGCTCAGACGCAGCTCAAGTGTGCCCGC\nATGCCTGGCCTAAAGGGCTTCGTGGATGAGCACACCATCAACATCTCCCTCAGTCTGCAC\nCACGTGGAACAGATGGCCATCGACTGGCTGACAGGCAACTTCTACTTTGTGGATGACATC\nGATGATAGGATCTTTGTCTGCAACAGAAATGGGGACACATGTGTCACATTGCTAGACCTG\nGAACTCTACAACCCCAAGGGCATTGCCCTGGACCCTGCCATGGGGAAGGTGTTTTTCACT\nGACTATGGGCAGATCCCAAAGGTGGAACGCTGTGACATGGATGGGCAGAACCGCACCAAG\nCTCGTCGACAGCAAGATTGTGTTTCCTCATGGCATCACGCTGGACCTGGTCAGCCGCCTT\nGTCTACTGGGCAGATGCCTATCTGGACTATATTGAAGTGGTGGACTATGAGGGCAAGGGC\nCGCCAGACCATCATCCAGGGCATCCTGATTGAGCACCTGTACGGCCTGACTGTGTTTGAG\nAATTATCTCTATGCCACCAACTCGGACAATGCCAATGCCCAGCAGAAGACGAGTGTGATC\nCGTGTGAACCGCTTTAACAGCACCGAGTACCAGGTTGTCACCCGGGTGGACAAGGGTGGT\nGCCCTCCACATCTACCACCAGAGGCGTCAGCCCCGAGTGAGGAGCCATGCCTGTGAAAAC\nGACCAGTATGGGAAGCCGGGTGGCTGCTCTGACATCTGCCTGCTGGCCAACAGCCACAAG\nGCGCGGACCTGCCGCTGCCGTTCCGGCTTCAGCCTGGGCAGTGACGGGAAGTCATGCAAG\nAAGCCGGAGCATGAGCTGTTCCTCGTGTATGGCAAGGGCCGGCCAGGCATCATCCGGGGC\nATGGATATGGGGGCCAAGGTCCCGGATGAGCACATGATCCCCATTGAAAACCTCATGAAC\nCCCCGAGCCCTGGACTTCCACGCTGAGACCGGCTTCATCTACTTTGCCGACACCACCAGC\nTACCTCATTGGCCGCCAGAAGATTGATGGCACTGAGCGGGAGACCATCCTGAAGGACGGC\nATCCACAATGTGGAGGGTGTGGCCGTGGACTGGATGGGAGACAATCTGTACTGGACGGAC\nGATGGGCCCAAAAAGACAATCAGCGTGGCCAGGCTGGAGAAAGCTGCTCAGACCCGCAAG\nACTTTAATCGAGGGCAAAATGACACACCCCAGGGCTATTGTGGTGGATCCACTCAATGGG\nTGGATGTACTGGACAGACTGGGAGGAGGACCCCAAGGACAGTCGGCGTGGGCGGCTGGAG\nAGGGCGTGGATGGATGGCTCACACCGAGACATCTTTGTCACCTCCAAGACAGTGCTTTGG\nCCCAATGGGCTAAGCCTGGACATCCCGGCTGGGCGCCTCTACTGGGTGGATGCCTTCTAC\nGACCGCATCGAGACGATACTGCTCAATGGCACAGACCGGAAGATTGTGTATGAAGGTCCT\nGAGCTGAACCACGCCTTTGGCCTGTGTCACCATGGCAACTACCTCTTCTGGACTGAGTAT\nCGGAGTGGCAGTGTCTACCGCTTGGAACGGGGTGTAGGAGGCGCACCCCCCACTGTGACC\nCTTCTGCGCAGTGAGCGGCCCCCCATCTTTGAGATCCGAATGTATGATGCCCAGCAGCAG\nCAAGTTGGCACCAACAAATGCCGGGTGAACAATGGCGGCTGCAGCAGCCTGTGCTTGGCC\nACCCCTGGGAGCCGCCAGTGCGCCTGTGCTGAGGACCAGGTGTTGGACGCAGACGGCGTC\nACTTGCTTGGCGAACCCATCCTACGTGCCTCCACCCCAGTGCCAGCCAGGCGAGTTTGCC\nTGTGCCAACAGCCGCTGCATCCAGGAGCGCTGGAAGTGTGACGGAGACAACGATTGCCTG\nGACAACAGTGATGAGGCCCCAGCCCTCTGCCATCAGCACACCTGCCCCTCGGACCGATTC\nAAGTGCGAGAACAACCGGTGCATCCCCAACCGCTGGCTCTGCGACGGGGACAATGACTGT\nGGGAACAGTGAAGATGAGTCCAATGCCACTTGTTCAGCCCGCACCTGCCCCCCCAACCAG\nTTCTCCTGTGCCAGTGGCCGCTGCATCCCCATCTCCTGGACGTGTGATCTGGATGACGAC\nTGTGGGGACCGCTCTGATGAGTCTGCTTCGTGTGCCTATCCCACCTGCTTCCCCCTGACT\nCAGTTTACCTGCAACAATGGCAGATGTATCAACATCAACTGGAGATGCGACAATGACAAT\nGACTGTGGGGACAACAGTGACGAAGCCGGCTGCAGCCACTCCTGTTCTAGCACCCAGTTC\nAAGTGCAACAGCGGGCGTTGCATCCCCGAGCACTGGACCTGCGATGGGGACAATGACTGC\nGGAGACTACAGTGATGAGACACACGCCAACTGCACCAACCAGGCCACGAGGCCCCCTGGT\nGGCTGCCACACTGATGAGTTCCAGTGCCGGCTGGATGGACTATGCATCCCCCTGCGGTGG\nCGCTGCGATGGGGACACTGACTGCATGGACTCCAGCGATGAGAAGAGCTGTGAGGGAGTG\nACCCACGTCTGCGATCCCAGTGTCAAGTTTGGCTGCAAGGACTCAGCTCGGTGCATCAGC\nAAAGCGTGGGTGTGTGATGGCGACAATGACTGTGAGGATAACTCGGACGAGGAGAACTGC\nGAGTCCCTGGCCTGCAGGCCACCCTCGCACCCTTGTGCCAACAACACCTCAGTCTGCCTG\nCCCCCTGACAAGCTGTGTGATGGCAACGACGACTGTGGCGACGGCTCAGATGAGGGCGAG\nCTCTGCGACCAGTGCTCTCTGAATAACGGTGGCTGCAGCCACAACTGCTCAGTGGCACCT\nGGCGAAGGCATTGTGTGTTCCTGCCCTCTGGGCATGGAGCTGGGGCCCGACAACCACACC\nTGCCAGATCCAGAGCTACTGTGCCAAGCATCTCAAATGCAGCCAAAAGTGCGACCAGAAC\nAAGTTCAGCGTGAAGTGCTCCTGCTACGAGGGCTGGGTCCTGGAACCTGACGGCGAGAGC\nTGCCGCAGCCTGGACCCCTTCAAGCCGTTCATCATTTTCTCCAACCGCCATGAAATCCGG\nCGCATCGATCTTCACAAAGGAGACTACAGCGTCCTGGTGCCCGGCCTGCGCAACACCATC\nGCCCTGGACTTCCACCTCAGCCAGAGCGCCCTCTACTGGACCGACGTGGTGGAGGACAAG\nATCTACCGCGGGAAGCTGCTGGACAACGGAGCCCTGACTAGTTTCGAGGTGGTGATTCAG\nTATGGCCTGGCCACACCCGAGGGCCTGGCTGTAGACTGGATTGCAGGCAACATCTACTGG\nGTGGAGAGTAACCTGGATCAGATCGAGGTGGCCAAGCTGGATGGGACCCTCCGGACCACC\nCTGCTGGCCGGTGACATTGAGCACCCAAGGGCAATCGCACTGGATCCCCGGGATGGGATC\nCTGTTTTGGACAGACTGGGATGCCAGCCTGCCCCGCATTGAGGCAGCCTCCATGAGTGGG\nGCTGGGCGCCGCACCGTGCACCGGGAGACCGGCTCTGGGGGCTGGCCCAACGGGCTCACC\nGTGGACTACCTGGAGAAGCGCATCCTTTGGATTGACGCCAGGTCAGATGCCATTTACTCA\nGCCCGTTACGACGGCTCTGGCCACATGGAGGTGCTTCGGGGACACGAGTTCCTGTCGCAC\nCCGTTTGCAGTGACGCTGTACGGGGGGGAGGTCTACTGGACTGACTGGCGAACAAACACA\nCTGGCTAAGGCCAACAAGTGGACCGGCCACAATGTCACCGTGGTACAGAGGACCAACACC\nCAGCCCTTTGACCTGCAGGTGTACCACCCCTCCCGCCAGCCCATGGCTCCCAATCCCTGT\nGAGGCCAATGGGGGCCAGGGCCCCTGCTCCCACCTGTGTCTCATCAACTACAACCGGACC\nGTGTCCTGCGCCTGCCCCCACCTCATGAAGCTCCACAAGGACAACACCACCTGCTATGAG\nTTTAAGAAGTTCCTGCTGTACGCACGTCAGATGGAGATCCGAGGTGTGGACCTGGATGCT\nCCCTACTACAACTACATCATCTCCTTCACGGTGCCCGACATCGACAACGTCACAGTGCTA\nGACTACGATGCCCGCGAGCAGCGTGTGTACTGGTCTGACGTGCGGACACAGGCCATCAAG\nCGGGCCTTCATCAACGGCACAGGCGTGGAGACAGTCGTCTCTGCAGACTTGCCAAATGCC\nCACGGGCTGGCTGTGGACTGGGTCTCCCGAAACCTGTTCTGGACAAGCTATGACACCAAT\nAAGAAGCAGATCAATGTGGCCCGGCTGGATGGCTCCTTCAAGAACGCAGTGGTGCAGGGC\nCTGGAGCAGCCCCATGGCCTTGTCGTCCACCCTCTGCGTGGGAAGCTCTACTGGACCGAT\nGGTGACAACATCAGCATGGCCAACATGGATGGCAGCAATCGCACCCTGCTCTTCAGTGGC\nCAGAAGGGCCCCGTGGGCCTGGCTATTGACTTCCCTGAAAGCAAACTCTACTGGATCAGC\nTCCGGGAACCATACCATCAACCGCTGCAACCTGGATGGGAGTGGGCTGGAGGTCATCGAT\nGCCATGCGGAGCCAGCTGGGCAAGGCCACCGCCCTGGCCATCATGGGGGACAAGCTGTGG\nTGGGCTGATCAGGTGTCGGAAAAGATGGGCACATGCAGCAAGGCTGACGGCTCGGGCTCC\nGTGGTCCTTCGGAACAGCACCACCCTGGTGATGCACATGAAGGTCTATGACGAGAGCATC\nCAGCTGGACCATAAGGGCACCAACCCCTGCAGTGTCAACAACGGTGACTGCTCCCAGCTC\nTGCCTGCCCACGTCAGAGACGACCCGCTCCTGCATGTGCACAGCCGGCTATAGCCTCCGG\nAGTGGCCAGCAGGCCTGCGAGGGCGTAGGTTCCTTTCTCCTGTACTCTGTGCATGAGGGA\nATCAGGGGAATTCCCCTGGATCCCAATGACAAGTCAGATGCCCTGGTCCCAGTGTCCGGG\nACCTCGCTGGCTGTCGGCATCGACTTCCACGCTGAAAATGACACCATCTACTGGGTGGAC\nATGGGCCTGAGCACGATCAGCCGGGCCAAGCGGGACCAGACGTGGCGTGAAGACGTGGTG\nACCAATGGCATTGGCCGTGTGGAGGGCATTGCAGTGGACTGGATCGCAGGCAACATCTAC\nTGGACAGACCAGGGCTTTGATGTCATCGAGGTCGCCCGGCTCAATGGCTCCTTCCGCTAC\nGTGGTGATCTCCCAGGGTCTAGACAAGCCCCGGGCCATCACCGTCCACCCGGAGAAAGGG\nTACTTGTTCTGGACTGAGTGGGGTCAGTATCCGCGTATTGAGCGGTCTCGGCTAGATGGC\nACGGAGCGTGTGGTGCTGGTCAACGTCAGCATCAGCTGGCCCAACGGCATCTCAGTGGAC\nTACCAGGATGGGAAGCTGTACTGGTGCGATGCACGGACAGACAAGATTGAACGGATCGAC\nCTGGAGACAGGTGAGAACCGCGAGGTGGTTCTGTCCAGCAACAACATGGACATGTTTTCA\nGTGTCTGTGTTTGAGGATTTCATCTACTGGAGTGACAGGACTCATGCCAACGGCTCTATC\nAAGCGCGGGAGCAAAGACAATGCCACAGACTCCGTGCCCCTGCGAACCGGCATCGGCGTC\nCAGCTTAAAGACATCAAAGTCTTCAACCGGGACCGGCAGAAAGGCACCAACGTGTGCGCG\nGTGGCCAATGGCGGGTGCCAGCAGCTGTGCCTGTACCGGGGCCGTGGGCAGCGGGCCTGC\nGCCTGTGCCCACGGGATGCTGGCTGAAGACGGAGCATCGTGCCGCGAGTATGCCGGCTAC\nCTGCTCTACTCAGAGCGCACCATTCTCAAGAGTATCCACCTGTCGGATGAGCGCAACCTC\nAATGCGCCCGTGCAGCCCTTCGAGGACCCTGAGCACATGAAGAACGTCATCGCCCTGGCC\nTTTGACTACCGGGCAGGCACCTCTCCGGGCACCCCCAATCGCATCTTCTTCAGCGACATC\nCACTTTGGGAACATCCAACAGATCAACGACGATGGCTCCAGGAGGATCACCATTGTGGAA\nAACGTGGGCTCCGTGGAAGGCCTGGCCTATCACCGTGGCTGGGACACTCTCTATTGGACA\nAGCTACACGACATCCACCATCACGCGCCACACAGTGGACCAGACCCGCCCAGGGGCCTTC\nGAGCGTGAGACCGTCATCACTATGTCTGGAGATGACCACCCACGGGCCTTCGTTTTGGAC\nGAGTGCCAGAACCTCATGTTCTGGACCAACTGGAATGAGCAGCATCCCAGCATCATGCGG\nGCGGCGCTCTCGGGAGCCAATGTCCTGACCCTTATCGAGAAGGACATCCGTACCCCCAAT\nGGCCTGGCCATCGACCACCGTGCCGAGAAGCTCTACTTCTCTGACGCCACCCTGGACAAG\nATCGAGCGGTGCGAGTATGACGGCTCCCACCGCTATGTGATCCTAAAGTCAGAGCCTGTC\nCACCCCTTCGGGCTGGCCGTGTATGGGGAGCACATTTTCTGGACTGACTGGGTGCGGCGG\nGCAGTGCAGCGGGCCAACAAGCACGTGGGCAGCAACATGAAGCTGCTGCGCGTGGACATC\nCCCCAGCAGCCCATGGGCATCATCGCCGTGGCCAACGACACCAACAGCTGTGAACTCTCT\nCCATGCCGAATCAACAACGGTGGCTGCCAGGACCTGTGTCTGCTCACTCACCAGGGCCAT\nGTCAACTGCTCATGCCGAGGGGGCCGAATCCTCCAGGATGACCTCACCTGCCGAGCGGTG\nAATTCCTCTTGCCGAGCACAAGATGAGTTTGAGTGTGCCAATGGCGAGTGCATCAACTTC\nAGCCTGACCTGCGACGGCGTCCCCCACTGCAAGGACAAGTCCGATGAGAAGCCATCCTAC\nTGCAACTCCCGCCGCTGCAAGAAGACTTTCCGGCAGTGCAGCAATGGGCGCTGTGTGTCC\nAACATGCTGTGGTGCAACGGGGCCGACGACTGTGGGGATGGCTCTGACGAGATCCCTTGC\nAACAAGACAGCCTGTGGTGTGGGCGAGTTCCGCTGCCGGGACGGGACCTGCATCGGGAAC\nTCCAGCCGCTGCAACCAGTTTGTGGATTGTGAGGACGCCTCAGATGAGATGAACTGCAGT\nGCCACCGACTGCAGCAGCTACTTCCGCCTGGGCGTGAAGGGCGTGCTCTTCCAGCCCTGC\nGAGCGGACCTCACTCTGCTACGCACCCAGCTGGGTGTGTGATGGCGCCAATGACTGTGGG\nGACTACAGTGATGAGCGCGACTGCCCAGGTGTGAAACGCCCCAGATGCCCTCTGAATTAC\nTTCGCCTGCCCTAGTGGGCGCTGCATCCCCATGAGCTGGACGTGTGACAAAGAGGATGAC\nTGTGAACATGGCGAGGACGAGACCCACTGCAACAAGTTCTGCTCAGAGGCCCAGTTTGAG\nTGCCAGAACCATCGCTGCATCTCCAAGCAGTGGCTGTGTGACGGCAGCGATGACTGTGGG\nGATGGCTCAGACGAGGCTGCTCACTGTGAAGGCAAGACGTGCGGCCCCTCCTCCTTCTCC\nTGCCCTGGCACCCACGTGTGCGTCCCCGAGCGCTGGCTCTGTGACGGTGACAAAGACTGT\nGCTGATGGTGCAGACGAGAGCATCGCAGCTGGTTGCTTGTACAACAGCACTTGTGACGAC\nCGTGAGTTCATGTGCCAGAACCGCCAGTGCATCCCCAAGCACTTCGTGTGTGACCACGAC\nCGTGACTGTGCAGATGGCTCTGATGAGTCCCCCGAGTGTGAGTACCCGACCTGCGGCCCC\nAGTGAGTTCCGCTGTGCCAATGGGCGCTGTCTGAGCTCCCGCCAGTGGGAGTGTGATGGC\nGAGAATGACTGCCACGACCAGAGTGACGAGGCTCCCAAGAACCCACACTGCACCAGCCCA\nGAGCACAAGTGCAATGCCTCGTCACAGTTCCTGTGCAGCAGTGGGCGCTGTGTGGCTGAG\nGCACTGCTCTGCAACGGCCAGGATGACTGTGGCGACAGCTCGGACGAGCGTGGCTGCCAC\nATCAATGAGTGTCTCAGCCGCAAGCTCAGTGGCTGCAGCCAGGACTGTGAGGACCTCAAG\nATCGGCTTCAAGTGCCGCTGTCGCCCTGGCTTCCGGCTGAAGGATGACGGCCGGACGTGT\nGCTGATGTGGACGAGTGCAGCACCACCTTCCCCTGCAGCCAGCGCTGCATCAACACCCAT\nGGCAGCTATAAGTGTCTGTGTGTGGAGGGCTATGCACCCCGCGGCGGCGACCCCCACAGC\nTGCAAGGCTGTGACTGACGAGGAACCGTTTCTGATCTTCGCCAACCGGTACTACCTGCGC\nAAGCTCAACCTGGACGGGTCCAACTACACGTTACTTAAGCAGGGCCTGAACAACGCCGTT\nGCCTTGGATTTTGACTACCGAGAGCAGATGATCTACTGGACAGATGTGACCACCCAGGGC\nAGCATGATCCGAAGGATGCACCTTAACGGGAGCAATGTGCAGGTCCTACACCGTACAGGC\nCTCAGCAACCCCGATGGGCTGGCTGTGGACTGGGTGGGTGGCAACCTGTACTGGTGCGAC\nAAAGGCCGGGACACCATCGAGGTGTCCAAGCTCAATGGGGCCTATCGGACGGTGCTGGTC\nAGCTCTGGCCTCCGTGAGCCCAGGGCTCTGGTGGTGGATGTGCAGAATGGGTACCTGTAC\nTGGACAGACTGGGGTGACCATTCACTGATCGGCCGCATCGGCATGGATGGGTCCAGCCGC\nAGCGTCATCGTGGACACCAAGATCACATGGCCCAATGGCCTGACGCTGGACTATGTCACT\nGAGCGCATCTACTGGGCCGACGCCCGCGAGGACTACATTGAATTTGCCAGCCTGGATGGC\nTCCAATCGCCACGTTGTGCTGAGCCAGGACATCCCGCACATCTTTGCACTGACCCTGTTT\nGAGGACTACGTCTACTGGACCGACTGGGAAACAAAGTCCATTAACCGAGCCCACAAGACC\nACGGGCACCAACAAAACGCTCCTCATCAGCACGCTGCACCGGCCCATGGACCTGCATGTC\nTTCCATGCCCTGCGCCAGCCAGACGTGCCCAATCACCCCTGCAAGGTCAACAATGGTGGC\nTGCAGCAACCTGTGCCTGCTGTCCCCCGGGGGAGGGCACAAATGTGCCTGCCCCACCAAC\nTTCTACCTGGGCAGCGATGGGCGCACCTGTGTGTCCAACTGCACGGCTAGCCAGTTTGTA\nTGCAAGAACGACAAGTGCATCCCCTTCTGGTGGAAGTGTGACACCGAGGACGACTGCGGG\nGACCACTCAGACGAGCCCCCGGACTGCCCTGAGTTCAAGTGCCGGCCCGGACAGTTCCAG\nTGCTCCACAGGTATCTGCACAAACCCTGCCTTCATCTGCGATGGCGACAATGACTGCCAG\nGACAACAGTGACGAGGCCAACTGTGACATCCACGTCTGCTTGCCCAGTCAGTTCAAATGC\nACCAACACCAACCGCTGTATTCCCGGCATCTTCCGCTGCAATGGGCAGGACAACTGCGGA\nGATGGGGAGGATGAGAGGGACTGCCCCGAGGTGACCTGCGCCCCCAACCAGTTCCAGTGC\nTCCATTACCAAACGGTGCATCCCCCGGGTCTGGGTCTGCGACCGGGACAATGACTGTGTG\nGATGGCAGTGATGAGCCCGCCAACTGCACCCAGATGACCTGTGGTGTGGACGAGTTCCGC\nTGCAAGGATTCGGGCCGCTGCATCCCAGCGCGTTGGAAGTGTGACGGAGAGGATGACTGT\nGGGGATGGCTCGGATGAGCCCAAGGAAGAGTGTGATGAACGCACCTGTGAGCCATACCAG\nTTCCGCTGCAAGAACAACCGCTGCGTGCCCGGCCGCTGGCAGTGCGACTACGACAACGAT\nTGCGGTGACAACTCCGATGAAGAGAGCTGCACCCCTCGGCCCTGCTCCGAGAGTGAGTTC\nTCCTGTGCCAACGGCCGCTGCATCGCGGGGCGCTGGAAATGCGATGGAGACCACGACTGC\nGCGGACGGCTCGGACGAGAAAGACTGCACCCCCCGCTGTGACATGGACCAGTTCCAGTGC\nAAGAGCGGCCACTGCATCCCCCTGCGCTGGCGCTGTGACGCAGACGCCGACTGCATGGAC\nGGCAGCGACGAGGAGGCCTGCGGCACTGGCGTGCGGACCTGCCCCCTGGACGAGTTCCAG\nTGCAACAACACCTTGTGCAAGCCGCTGGCCTGGAAGTGCGATGGCGAGGATGACTGTGGG\nGACAACTCAGATGAGAACCCCGAGGAGTGTGCCCGGTTCGTGTGCCCTCCCAACCGGCCC\nTTCCGTTGCAAGAATGACCGCGTCTGTCTGTGGATCGGGCGCCAATGCGATGGCACGGAC\nAACTGTGGGGATGGGACTGATGAAGAGGACTGTGAGCCCCCCACAGCCCACACCACCCAC\nTGCAAAGACAAGAAGGAGTTTCTGTGCCGGAACCAGCGCTGCCTCTCCTCCTCCCTGCGC\nTGCAACATGTTCGATGACTGCGGGGACGGCTCTGACGAGGAGGACTGCAGCATCGACCCC\nAAGCTGACCAGCTGCGCCACCAATGCCAGCATCTGTGGGGACGAGGCACGCTGCGTGCGC\nACCGAGAAAGCGGCCTACTGTGCCTGCCGCTCGGGCTTCCACACCGTGCCCGGCCAGCCC\nGGATGCCAAGACATCAACGAGTGCCTGCGCTTCGGCACCTGCTCCCAGCTCTGCAACAAC\nACCAAGGGCGGCCACCTCTGCAGCTGCGCTCGGAACTTCATGAAGACGCACAACACCTGC\nAAGGCCGAAGGCTCTGAGTACCAGGTCCTGTACATCGCTGATGACAATGAGATCCGCAGC\nCTGTTCCCCGGCCACCCCCATTCGGCTTACGAGCAGGCATTCCAGGGTGACGAGAGTGTC\nCGCATTGATGCTATGGATGTCCATGTCAAGGCTGGCCGTGTCTATTGGACCAACTGGCAC\nACGGGCACCATCTCCTACCGCAGCCTGCCACCTGCTGCGCCTCCTACCACTTCCAACCGC\nCACCGGCGACAGATTGACCGGGGTGTCACCCACCTCAACATTTCAGGGCTGAAGATGCCC\nAGAGGCATCGCCATCGACTGGGTGGCCGGAAACGTGTACTGGACCGACTCGGGCCGAGAT\nGTGATTGAGGTGGCGCAGATGAAGGGCGAGAACCGCAAGACGCTCATCTCGGGCATGATT\nGACGAGCCCCACGCCATTGTGGTGGACCCACTGAGGGGGACCATGTACTGGTCAGACTGG\nGGCAACCACCCCAAGATTGAGACGGCAGCGATGGATGGGACGCTTCGGGAGACACTGGTG\nCAGGACAACATTCAGTGGCCCACAGGCCTGGCCGTGGATTATCACAATGAGCGGCTGTAC\nTGGGCAGACGCCAAGCTTTCAGTCATCGGCAGCATCCGGCTCAATGGCACGGACCCCATT\nGTGGCTGCTGACAGCAAACGAGGCCTAAGTCACCCCTTCAGCATCGACGTCTTTGAGGAT\nTACATCTATGGTGTCACCTACATCAATAATCGTGTCTTCAAGATCCATAAGTTTGGCCAC\nAGCCCCTTGGTCAACCTGACAGGGGGCCTGAGCCACGCCTCTGACGTGGTCCTTTACCAT\nCAGCACAAGCAGCCCGAAGTGACCAACCCATGTGACCGCAAGAAATGCGAGTGGCTCTGC\nCTGCTGAGCCCCAGTGGGCCTGTCTGCACCTGTCCCAATGGGAAGCGGCTGGACAACGGC\nACATGCGTGCCTGTGCCCTCTCCAACGCCCCCCCCAGATGCTCCCCGGCCTGGAACCTGT\nAACCTGCAGTGCTTCAACGGTGGCAGCTGTTTCCTCAATGCACGGAGGCAGCCCAAGTGC\nCGCTGCCAACCCCGCTACACGGGTGACAAGTGTGAACTGGACCAGTGCTGGGAGCACTGT\nCGCAATGGGGGCACCTGTGCTGCCTCCCCCTCTGGCATGCCCACGTGCCGGTGCCCCACG\nGGCTTCACGGGCCCCAAATGCACCCAGCAGGTGTGTGCGGGCTACTGTGCCAACAACAGC\nACCTGCACTGTCAACCAGGGCAACCAGCCCCAGTGCCGATGCCTACCCGGCTTCCTGGGC\nGACCGCTGCCAGTACCGGCAGTGCTCTGGCTACTGTGAGAACTTTGGCACATGCCAGATG\nGCTGCTGATGGCTCCCGACAATGCCGCTGCACTGCCTACTTTGAGGGATCGAGGTGTGAG\nGTGAACAAGTGCAGCCGCTGTCTCGAAGGGGCCTGTGTGGTCAACAAGCAGAGTGGGGAT\nGTCACCTGCAACTGCACGGATGGCCGGGTGGCCCCCAGCTGTCTGACCTGCGTCGGCCAC\nTGCAGCAATGGCGGCTCCTGTACCATGAACAGCAAAATGATGCCTGAGTGCCAGTGCCCA\nCCCCACATGACAGGGCCCCGGTGTGAGGAGCACGTCTTCAGCCAGCAGCAGCCAGGACAT\nATAGCCTCCATCCTAATCCCTCTGCTGTTGCTGCTGCTGCTGGTTCTGGTGGCCGGAGTG\nGTATTCTGGTATAAGCGGCGAGTCCAAGGGGCTAAGGGCTTCCAGCACCAACGGATGACC\nAACGGGGCCATGAACGTGGAGATTGGAAACCCCACCTACAAGATGTACGAAGGCGGAGAG\nCCTGATGATGTGGGAGGCCTACTGGACGCTGACTTTGCCCTGGACCCTGACAAGCCCACC\nAACTTCACCAACCCCGTGTATGCCACACTCTACATGGGGGGCCATGGCAGTCGCCACTCC\nCTGGCCAGCACGGACGAGAAGCGAGAACTCCTGGGCCGGGGCCCTGAGGACGAGATAGGG\nGACCCCTTGGCATAG"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF07645", "name": "EGF_CA"}, {"identifier": "PF00057", "name": "Ldl_recept_a"}, {"identifier": "PF00058", "name": "Ldl_recept_b"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-10-03", "drugbank-id": [{"@primary": "true", "#text": "DB00032"}, "BIOD00018", "BTD00018"], "name": "Menotropins", "description": "Menotropins contains follicle stimulating hormone (FSH) and luteinizing hormone (LH) purified from the urine of postmenopausal women.  It is used as a fertility medication that is injected either subcutaneously or intramuscularly. It is composed of LH with 2 subunits, alpha = 92 residues, beta = 121 residues and FSH with 2 subunits, alpha = 92 residues, beta=111 residues.", "cas-number": "61489-71-2", "groups": {"group": "approved"}, "general-references": null, "synthesis-reference": null, "indication": "For the treatment of female infertility", "pharmacodynamics": "Used to treat female infertility, Menotropins stimulates late follicular maturation and resumption of oocyte meiosis, and initiates rupture of the pre-ovulatory ovarian follicle. Menotropins bind to the LH/hCG/FSH receptor of the granulosa and theca cells of the ovary to effect these changes in the absence of an endogenous LH surge.", "mechanism-of-action": "Being a combination drug, Menotropins bind to the follicle stimulating hormone receptor (FSH), which results in ovulation in the absence of sufficient endogenous luteinizing hormone (LH). It also binds the LH receptor, thereby stimulating proper hormone release. The drug contains both FSH and LH, therefore, it induces ovarian follicular growth and development as well as gonadal steroid production in women who do not have ovarian failure. FSH is the primary driver of follicular recruitment and growth in early folliculogenesis, while LH is important for ovarian steroidogenesis and is involved in the physiological events leading to development of a competent pre-ovulatory follicle.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": {"product": [{"name": "Menopur", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02283093", "started-marketing-on": "2006-09-19", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "75 unit", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Repronex", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02247790", "started-marketing-on": "2003-08-28", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "75 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Repronex", "ingredients": "Menotropins"}, {"name": "Menopur", "ingredients": "Menotropins"}]}, "packagers": {"packager": {"name": "Ferring Pharmaceuticals Inc.", "url": "http://www.ferring.com"}}, "manufacturers": null, "prices": {"price": [{"description": "Menopur 75 unit vial", "cost": {"@currency": "USD", "#text": "93.85"}, "unit": "vial"}, {"description": "Repronex 75 unit vial", "cost": {"@currency": "USD", "#text": "93.85"}, "unit": "vial"}, {"description": "Repronex 5 75 unit Solution 1 Box Contains Five 1ml Vials", "cost": {"@currency": "USD", "#text": "488.04"}, "unit": "box"}]}, "categories": {"category": [{"category": "Fertility Agents, Female", "mesh-id": null}, {"category": "Fertility Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Powder for solution", "route": "subcutaneous", "strength": "75 unit"}, {"form": "Powder for solution", "route": "intramuscular; subcutaneous", "strength": "75 unit"}]}, "atc-codes": null, "ahfs-codes": {"ahfs-code": "68:18.00"}, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">AlphaChain (LH)\nAPDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC\nVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS"}, {"@format": "FASTA", "#text": ">BetaChain (LH)\nSREPLRPWCHPINAILAVEKEGCPVCITVNTTICAGYCPTMMRVLQAVLPPLPQVVCTYR\nDVRFESIRLPGCPRGVDPVVSFPVALSCRCGPCRRSTSDCGGPKDHPLTCDHPQLSGLLF\nL"}, {"@format": "FASTA", "#text": ">AlphaChain (FSH)\nAPDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC\nVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS"}, {"@format": "FASTA", "#text": ">BetaChain (FSH)\nNSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYET\nVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "55 \u00b0C", "source": "Forastieri, H., Ingham, K.C. J. Biol. Chem. 257:7976-7981 (1982)"}, {"kind": "Hydrophobicity", "value": "-0.063", "source": null}, {"kind": "Isoelectric Point", "value": "8.44", "source": null}, {"kind": "Molecular Weight", "value": "23390.3000", "source": null}, {"kind": "Molecular Formula", "value": "C1014H1609N287O294S27", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "7369"}, {"resource": "GenBank", "identifier": "X00264"}, {"resource": "PharmGKB", "identifier": "PA164749406"}, {"resource": "UniProtKB", "identifier": "P01229"}, {"resource": "Wikipedia", "identifier": "Menotropins"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/menotropins.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/menotropins.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000387", "name": "Follicle-stimulating hormone receptor", "organism": "Human", "actions": {"action": "binder"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# van de Weijer BH, Mulders JW, Bos ES, Verhaert PD, van den Hooven HW: Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. Reprod Biomed Online. 2003 Nov;7(5):547-57. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14680547\n# Olive DL: The role of gonadotropins in ovulation induction. Am J Obstet Gynecol. 1995 Feb;172(2 Pt 2):759-65. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7872378\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P23945", "@source": "Swiss-Prot", "name": "Follicle-stimulating hormone receptor", "general-function": "Involved in follicle-stimulating hormone receptor activity", "specific-function": "Receptor for follicle-stimulating hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase", "gene-name": "FSHR", "locus": "2p21-p16", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "367-387\n399-421\n444-465\n486-508\n529-550\n574-597\n609-630", "signal-regions": null, "theoretical-pi": "7.19", "molecular-weight": "78296.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3969"}, {"resource": "GenAtlas", "identifier": "FSHR"}, {"resource": "GeneCards", "identifier": "FSHR"}, {"resource": "GenBank Gene Database", "identifier": "M65085"}, {"resource": "GenBank Protein Database", "identifier": "182771"}, {"resource": "IUPHAR", "identifier": "253"}, {"resource": "Guide to Pharmacology", "identifier": "30"}, {"resource": "UniProtKB", "identifier": "P23945"}, {"resource": "UniProt Accession", "identifier": "FSHR_HUMAN"}]}, "synonyms": {"synonym": ["Follicle-stimulating hormone receptor precursor", "Follitropin receptor", "FSH-R"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Follicle-stimulating hormone receptor precursor\nMALLLVSLLAFLSLGSGCHHRICHCSNRVFLCQESKVTEIPSDLPRNAIELRFVLTKLRV\nIQKGAFSGFGDLEKIEISQNDVLEVIEADVFSNLPKLHEIRIEKANNLLYINPEAFQNLP\nNLQYLLISNTGIKHLPDVHKIHSLQKVLLDIQDNINIHTIERNSFVGLSFESVILWLNKN\nGIQEIHNCAFNGTQLDELNLSDNNNLEELPNDVFHGASGPVILDISRTRIHSLPSYGLEN\nLKKLRARSTYNLKKLPTLEKLVALMEASLTYPSHCCAFANWRRQISELHPICNKSILRQE\nVDYMTQTRGQRSSLAEDNESSYSRGFDMTYTEFDYDLCNEVVDVTCSPKPDAFNPCEDIM\nGYNILRVLIWFISILAITGNIIVLVILTTSQYKLTVPRFLMCNLAFADLCIGIYLLLIAS\nVDIHTKSQYHNYAIDWQTGAGCDAAGFFTVFASELSVYTLTAITLERWHTITHAMQLDCK\nVQLRHAASVMVMGWIFAFAAALFPIFGISSYMKVSICLPMDIDSPLSQLYVMSLLVLNVL\nAFVVICGCYIHIYLTVRNPNIVSSSSDTRIAKRMAMLIFTDFLCMAPISFFAISASLKVP\nLITVSKAKILLVLFHPINSCANPFLYAIFTKNFRRDFFILLSKCGCYEMQAQIYRTETSS\nTVHNTHPRNGHCSSAPRVTNGSTYILVPLSHLAQN"}, "gene-sequence": {"@format": "FASTA", "#text": ">2088 bp\nATGGCCCTGCTCCTGGTCTCTTTGCTGGCATTCCTGAGCTTGGGCTCAGGATGTCATCAT\nCGGATCTGTCACTGCTCTAACAGGGTTTTTCTCTGCCAAGAGAGCAAGGTGACAGAGATT\nCCTTCTGACCTCCCGAGGAATGCCATTGAACTGAGGTTTGTCCTCACCAAGCTTCGAGTC\nATCCAAAAAGGTGCATTTTCAGGATTTGGGGACCTGGAGAAAATAGAGATCTCTCAGAAT\nGATGTCTTGGAGGTGATAGAGGCAGATGTGTTCTCCAACCTTCCCAAATTACATGAAATT\nAGAATTGAAAAGGCCAACAACCTGCTCTACATCACCCCTGAGGCCTTCCAGAACCTTCCC\nAACCTTCAATATCTGTTAATATCCAACACAGGTATTAAGCACCTTCCAGATGTTCACAAG\nATTCATTCTCTCCAAAAGGTTTTACTTGACATTCAAGATAACATAAACATCCACACAATT\nGAAAGAAATTCTTTCGTGGGGCTGAGCTTTGAAAGTGTGATTCTATGGCTGAATAAGAAT\nGGGATTCAAGAAATACACAACTGTGCATTCAATGGAACCCAACTAGATGCAGTGAATCTA\nAGCGATAATAATAATTTAGAAGAATTGCCTAATGATGTTTTCCACGGAGCCTCTGGACCA\nGTCATTCTAGATATTTCAAGAACAAGGATCCATTCCCTGCCTAGCTATGGCTTAGAAAAT\nCTTAAGAAGCTGAGGGCCAGGTCGACTTACAACTTAAAAAAGCTGCCTACTCTGGAAAAG\nCTTGTCGCCCTCATGGAAGCCAGCCTCACCTATCCCAGCCATTGCTGTGCCTTTGCAAAC\nTGGAGACGGCAAATCTCTGAGCTTCATCCAATTTGCAACAAATCTATTTTAAGGCAAGAA\nGTTGATTATATGACTCAGGCTAGGGGTCAGAGATCCTCTCTGGCAGAAGACAATGAGTCC\nAGCTACAGCAGAGGATTTGACATGACGTACACTGAGTTTGACTATGACTTATGCAATGAA\nGTGGTTGACGTGACCTGCTCCCCTAAGCCAGATGCATTCAACCCATGTGAAGATATCATG\nGGGTACAACATCCTCAGAGTCCTGATATGGTTTATCAGCATCCTGGCCATCACTGGGAAC\nATCATAGTGCTAGTGATCCTAACTACCAGCCAATATAAACTCACAGTCCCCAGGTTCCTT\nATGTGCAACCTGGCCTTTGCTGATCTCTGCATTGGAATCTACCTGCTGCTCATTGCATCA\nGTTGATATCCATACCAAGAGCCAATATCACAACTATGCCATTGACTGGCAAACTGGGGCA\nGGCTGTGATGCTGCTGGCTTTTTCACTGTCTTTGCCAGTGAGCTGTCAGTCTACACTCTG\nACAGCTATCACCTTGGAAAGATGGCATACCATCACGCATGCCATGCAGCTGGACTGCAAG\nGTGCAGCTCCGCCATGCTGCCAGTGTCATGGTGATGGGCTGGATTTTTGCTTTTGCAGCT\nGCCCTCTTTCCCATCTTTGGCATCAGCAGCTACATGAAGGTGAGCATCTGCCTGCCCATG\nGATATTGACAGCCCTTTGTCACAGCTGTATGTCATGTCCCTCCTTGTGCTCAATGTCCTG\nGCCTTTGTGGTCATCTGTGGCTGCTATATCCACATCTACCTCACAGTGCGGAACCCCAAC\nATCGTGTCCTCCTCTAGTGACACCAGGATCGCCAAGCGCATGGCCATGCTCATCTTCACT\nGACTTCCTCTGCATGGCACCCATTTCTTTCTTTGCCATTTCTGCCTCCCTCAAGGTGCCC\nCTCATCACTGTGTCCAAAGCAAAGATTCTGCTGGTTCTGTTTCACCCCATCAACTCCTGT\nGCCAACCCCTTCCTCTATGCCATCTTTACCAAAAACTTTCGCAGAGATTTCTTCATTCTG\nCTGAGCAAGTGTGGCTGCTATGAAATGCAAGCCCAAATTTATAGGACAGAAACTTCATCC\nACTGTCCACAACACCCATCCAAGGAATGGCCACTGCTCTTCAGCTCCCAGAGTCACCAGT\nGGTTCCACTTACATACTTGTCCCTCTAAGTCATTTAGCCCAAAACTAA"}, "pfams": {"pfam": [{"identifier": "PF00001", "name": "7tm_1"}, {"identifier": "PF00560", "name": "LRR_1"}, {"identifier": "PF01462", "name": "LRRNT"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "function", "description": "protein-hormone receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "follicle stimulating hormone receptor activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}]}}}, {"id": "BE0000134", "name": "Lutropin-choriogonadotropic hormone receptor", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# van de Weijer BH, Mulders JW, Bos ES, Verhaert PD, van den Hooven HW: Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. Reprod Biomed Online. 2003 Nov;7(5):547-57. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14680547\n# Olive DL: The role of gonadotropins in ovulation induction. Am J Obstet Gynecol. 1995 Feb;172(2 Pt 2):759-65. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7872378", "known-action": "yes", "polypeptide": {"@id": "P22888", "@source": "Swiss-Prot", "name": "Lutropin-choriogonadotropic hormone receptor", "general-function": "Involved in rhodopsin-like receptor activity", "specific-function": "Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase", "gene-name": "LHCGR", "locus": "2p21", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "364-385\n396-416\n440-462\n483-505\n526-549\n571-594\n606-627", "signal-regions": null, "theoretical-pi": "8.58", "molecular-weight": "78617.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6585"}, {"resource": "GenAtlas", "identifier": "LHCGR"}, {"resource": "GeneCards", "identifier": "LHCGR"}, {"resource": "GenBank Gene Database", "identifier": "M73746"}, {"resource": "GenBank Protein Database", "identifier": "903746"}, {"resource": "IUPHAR", "identifier": "254"}, {"resource": "Guide to Pharmacology", "identifier": "30"}, {"resource": "UniProtKB", "identifier": "P22888"}, {"resource": "UniProt Accession", "identifier": "LSHR_HUMAN"}]}, "synonyms": {"synonym": ["LH/CG-R", "LHR", "LSH- R", "Luteinizing hormone receptor", "Lutropin-choriogonadotropic hormone receptor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Lutropin-choriogonadotropic hormone receptor precursor\nMKQRFSALQLLKLLLLLQPPLPRALREALCPEPCNCVPDGALRCPGPTAGLTRLSLAYLP\nVKVIPSQAFRGLNEVIKIEISQIDSLERIEANAFDNLLNLSEILIQNTKNLRYIEPGAFI\nNLPRLKYLSICNTGIRKFPDVTKVFSSESNFILEICDNLHITTIPGNAFQGMNNESVTLK\nLYGNGFEEVQSHAFNGTTLTSLELKENVHLEKMHNGAFRGATGPKTLDISSTKLQALPSY\nGLESIQRLIATSSYSLKKLPSRETFVNLLEATLTYPSHCCAFRNLPTKEQNFSHSISENF\nSKQCESTVRKVSNKTLYSSMLAESELSGWDYEYGFCLPKTPRCAPEPDAFNPCEDIMGYD\nFLRVLIWLINILAIMGNMTVLFVLLTSRYKLTVPRFLMCNLSFADFCMGLYLLLIASVDS\nQTKGQYYNHAIDWQTGSGCSTAGFFTVFASELSVYTLTVITLERWHTITYAIHLDQKLRL\nRHAILIMLGGWLFSSLIAMLPLVGVSNYMKVSICFPMDVETTLSQVYILTILILNVVAFF\nIICACYIKIYFAVRNPELMATNKDTKIAKKMAILIFTDFTCMAPISFFAISAAFKVPLIT\nVTNSKVLLVLFYPINSCANPFLYAIFTKTFQRDFFLLLSKFGCCKRRAELYRRKDFSAYT\nSNCKNGFTGSNKPSQSTLKLSTLHCQGTALLDKTRYTEC"}, "gene-sequence": {"@format": "FASTA", "#text": ">2058 bp\nATGAAGCAGCGGTTCTCGCCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGGCGCCG\nCTGCCACGAGCGCTGCGCAGGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGCGCC\nCTGCGTGCCCCGGCCCCACGGCCGTCCACTCGACTATCACTTGCCTACCTCCCTGTCAAA\nGTGATCCCATCTCAAAGTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATCTCTCAG\nATTGATTCCCTGGAAAGGATAGAAGCTAATGCCTTTGACAACCTCCTCAATTTGTCTGAA\nATACTGATCCAGAACACCAAAAATCTGAGATACATTGAGCCCGGAGCATTTATAAATCTT\nCCCCGATTAAAATACTTGAGCATCTGTAACACAGGCATCAGAAAGTTTCCAGATGTTACG\nAAGGTCTTCTCCTCTGAATCAAATTTCATTCTGGAAATTTGTGATAACTTACACATAACC\nACCATACCAGGAAATGCTTTTCAAGGGATGAATAATGAATCTGTAACACTCAAACTATAT\nGGAAATGGATTTGAAGAAGTACAAAGTCATGCATTCAATGGGACGACACTGACTTCACTG\nGAGCTAAAGGAAAACGTACATCTGGAGAAGATGCACAATGGAGCCTTCCGTGGGGCCACA\nGGGCCGAAAACCTTGGATATTTCTTCCACCAAATTGCAGGCCCTGCCGAGCTATGGCCTA\nGAGTCCATTCAGAGGCTAATTGCCACGTCATCCTATTCTCTAAAAAAATTGCCATCAAAA\nCAAACATTTGTCAATCTCCTGAGGGCCACGCTTCATTACCCCAGCCACTGCTGTGCATTT\nAGAAACTTGCCAACGAAAGAGCTAAACTTCTCACATTCCATTTCTGAAAACTTTTCCAAA\nCAATGTGAAAGCACAGTAAGGAAAAGTGAACTGAGTGGCTGGGACTATGAATATGGTTTC\nTGCTTACCCAAGACACCCCGATGTGCTCCTGAACCAGATGCTTTTAATCCCTGTGAAGAC\nATTATGGGCTATGACTTCCTTAGGGTCCTGATTTGGCTGATTAATATTCTAGCCATCATG\nGGAAACATGACTGTTCTTTTTGTTCTCCTGACAAGTCGTTACAAACTTACAGTGCCTCGT\nTTTCTCATGTGCAATCTCTCCTTTGCAGACTTTTGCATGGGGCTCTATCTGCTGCTCATA\nGCCTCAGTTGATTCCCAAACCAAGGGCCAGTACTATAACCATGCCATAGACTGGCAGACA\nGGGAGTGGGTGCAGCACTGCTGGCTTTTTCACTGTATTAGCAAGTGAACTTTCTGTCTAC\nACCCTCACCGTCATCACTCTAGAAAGATGGCACACCATCACCTATGCTATTCACCTGGAC\nCAAAAGCTGCGATTAAGACATGCCATTCTGATTATGCTTGGAGGCTGGCTCTTTTCTTCT\nCTAATTGCTATGTTGCCCCTTGTCGGGGTCAGCAATTACATGAAGGTCAGTATTTGCTTC\nCCCATGGATGTGGAAACCACTCTCTCACAAGTCTATATATTAACCATCCTGATTCTCAAT\nGTGGTGGCCTTCTTAATAATTTGTGCTTGCTACATTAAAATTTATTTTGCAGTTCGAAAC\nCCAGAATTAATGGCTACCAATAAAGATACAAAGATTGCTAAGAAAATGGCAATCCTCATC\nTTCACCGATTTTACCTGCATGGCACCTATCTCTTTTTTTGCCATCTCAGCTGCCTTCAAA\nGTACCTCTTATCACAGTAACCAACTCTAAAGTTTTACTGGTTCTTTTTTATCCCATCAAT\nTCTTGTGCCAATCCATTTCTGTATGCAATATTCACTAAGACATTCCAAAGAGATTTCTTT\nCTTTTGCTGAGCAAATTTGGCTGCTGTAAACGTCGGGCTGATCCTCTTTATAGAAGGAAA\nGATTTTTCAGCTTACACCTCCAACTGCAAAAATGGCTTCACTGGATCAAATAAGCCTTCT\nCAATCCACCTTGAAGTTGTCCACATTGCACTGTCAAGGTACAGCTCTCCTAGACAAGACT\nCGCTACACAGAGTGTTAA"}, "pfams": {"pfam": {"identifier": "PF00001", "name": "7tm_1"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "function", "description": "lutropin-choriogonadotropic hormone receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "protein-hormone receptor activity"}, {"category": "function", "description": "receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-09-13", "drugbank-id": [{"@primary": "true", "#text": "DB00033"}, "BIOD00017", "BTD00017"], "name": "Interferon gamma-1b", "description": "Human Interferon gamma-1b (140 residues), produced from E. coli. Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatography. \nThe sequence displayed is a cDNA sequence which codes for human interferon gamma, as described by Gray et. al. and not specifically interferon gamma 1b.", "cas-number": "82115-62-6", "groups": {"group": ["approved", "investigational"]}, "general-references": "# Kantoch M, Dobrowolska H, Jarzabek Z, Jankowski M, Sadowski W, Janicki P: [Distribution and characteristics of Poliovirus strains circulating in Poland in 1968-1972. Genetic variation of strains isolated in various secretion periods and clones isolated from vaccines] Med Dosw Mikrobiol. 1975;27(4):353-63. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/55526\n# Ormas P, Pompa G, Beretta C, Faustini R: [The effects of some polypeptides on the systemic blood pressure of sheep (author's transl)] Folia Vet Lat. 1975 Jan-Mar;5(1):45-54. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/3458\n# Selitrennikoff CP, Sonneborn DR: Alkaline phosphatase of Blastocladiella emersonii: partial purification and characterization. J Bacteriol. 1977 Apr;130(1):249-56. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15978\n# Gray PW, Goeddel DV: Structure of the human immune interferon gene. Nature. 1982 Aug 26;298(5877):859-63. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/6180322\n# Ealick SE, Cook WJ, Vijay-Kumar S, Carson M, Nagabhushan TL, Trotta PP, Bugg CE: Three-dimensional structure of recombinant human interferon-gamma. Science. 1991 May 3;252(5006):698-702. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1902591\n# Ikeda H, Old LJ, Schreiber RD: The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002 Apr;13(2):95-109. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11900986\n# Chesler DA, Reiss CS: The role of IFN-gamma in immune responses to viral infections of the central nervous system. Cytokine Growth Factor Rev. 2002 Dec;13(6):441-54. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12401479\n# Dessein A, Kouriba B, Eboumbou C, Dessein H, Argiro L, Marquet S, Elwali NE, Rodrigues V, Li Y, Doumbo O, Chevillard C: Interleukin-13 in the skin and interferon-gamma in the liver are key players in immune protection in human schistosomiasis. Immunol Rev. 2004 Oct;201:180-90. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15361241\n# Joseph AM, Kumar M, Mitra D: Nef: \"necessary and enforcing factor\" in HIV infection. Curr HIV Res. 2005 Jan;3(1):87-94. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15638726\n# Copeland KF: Modulation of HIV-1 transcription by cytokines and chemokines. Mini Rev Med Chem. 2005 Dec;5(12):1093-101. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16375755\n# Schroder K, Hertzog PJ, Ravasi T, Hume DA: Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004 Feb;75(2):163-89. Epub 2003 Oct 2. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14525967", "synthesis-reference": "Irwin A. Braude, \"Production of human IFN-gamma (immune) interferon.\" U.S. Patent US4376821, issued December, 1975.", "indication": "Interferon gamma-1b is used for the treatment of Chronic granulomatous disease and Osteopetrosis.", "pharmacodynamics": "IFN gamma stimulates expression of the immunoglobulin heavy chain C gamma 3 and C gamma 2a germline transcripts in B cells. Many components of the antigen presentation pathways are also up-regulated by interferon gamma. It is also a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of type I interferons. Interferon gamma may also help the body regulate the activity of fibroblasts. By directly blocking the multiplication of fibroblasts and inhibiting the production and action of TGF-b, a potent scar-inducing molecule, Interferon gamma-1b may prevent excessive scarring.", "mechanism-of-action": "Binds directly to the type II interferon gamma receptor IFNGR1, leading to a complex of IFNGR1 and IFNGR2. This activates JAK1 and JAK2 kinases which form a STAT1 docking site. This leads to STAT1 phosphorylation, nuclear translocation and initiation of gene transcription of multiple immune-related genes.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "IFN-gamma"}, {"@language": "", "@coder": "", "#text": "Immune interferon"}, {"@language": "", "@coder": "", "#text": "Interferon gamma precursor"}]}, "products": {"product": {"name": "Actimmune", "ndc-id": "42238-111_bf71a33a-8d53-43f9-89c2-f39960eac1bc", "ndc-product-code": "42238-111", "dpd-id": null, "started-marketing-on": "2013-12-01", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 ug/.5mL", "route": "subcutaneous", "fda-application-number": "BLA103836", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}}, "international-brands": null, "mixtures": {"mixture": {"name": "Actimmune", "ingredients": "Interferon gamma-1b"}}, "packagers": {"packager": {"name": "InterMune Inc.", "url": "http://www.intermune.com"}}, "manufacturers": null, "prices": {"price": {"description": "Actimmune 2 million unit vial", "cost": {"@currency": "USD", "#text": "344.4"}, "unit": "vial"}}, "categories": {"category": {"category": "Immunosuppressive Agents", "mesh-id": null}}, "affected-organisms": null, "dosages": {"dosage": {"form": "Injection, solution", "route": "subcutaneous", "strength": "100 ug/.5mL"}}, "atc-codes": null, "ahfs-codes": null, "patents": {"patent": [{"number": "6936694", "country": "United States", "approved": "2005-08-30", "expires": "2022-08-30"}, {"number": "6936695", "country": "United States", "approved": "2005-08-30", "expires": "2022-08-30"}]}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00697", "name": "Tizanidine", "description": "CYP1A2 Inhibitors (Weak) may increase the serum concentration of Tizanidine."}, {"drugbank-id": "DB00495", "name": "Zidovudine", "description": "Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00033 sequence\nCYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQSQIVSFYFKLF\nKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVM\nAELSPAAKTGKRKRSQMLFRGRRASQ"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "61 \u00b0C", "source": "Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)"}, {"kind": "Hydrophobicity", "value": "-0.823", "source": null}, {"kind": "Isoelectric Point", "value": "9.54", "source": null}, {"kind": "Molecular Weight", "value": "17145.6000", "source": null}, {"kind": "Molecular Formula", "value": "C761H1206N214O225S6", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "GenBank", "identifier": "X13274"}, {"resource": "PharmGKB", "identifier": "PA164746386"}, {"resource": "UniProtKB", "identifier": "P01579"}, {"resource": "Wikipedia", "identifier": "Interferon_gamma-1b"}]}, "external-links": {"external-link": {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/interferon-gamma-1b.html"}}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000711", "name": "Interferon gamma receptor 1", "organism": "Human", "actions": {"action": "binder"}, "references": "# Matsuda A, Ebihara N, Kumagai N, Fukuda K, Ebe K, Hirano K, Sotozono C, Tei M, Hasegawa K, Shimizu M, Tamari M, Namba K, Ohno S, Mizuki N, Ikezawa Z, Shirakawa T, Hamuro J, Kinoshita S: Genetic polymorphisms in the promoter of the interferon gamma receptor 1 gene are associated with atopic cataracts. Invest Ophthalmol Vis Sci. 2007 Feb;48(2):583-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17251453\n# Yao X, Chen ZQ, Gong JQ, Chen M, Li AS, Liu J: The interferon-gamma receptor gene polymorphisms (Val14Met and Gln64Arg) are not associated with systemic lupus erythematosus in Chinese patients. Arch Dermatol Res. 2007 Oct;299(8):367-371. Epub 2007 Jul 6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17618444\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P15260", "@source": "Swiss-Prot", "name": "Interferon gamma receptor 1", "general-function": "Involved in cytokine binding", "specific-function": "Receptor for interferon gamma. Two receptors bind one interferon gamma dimer", "gene-name": "IFNGR1", "locus": "6q23-q24", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "246-266", "signal-regions": null, "theoretical-pi": "4.56", "molecular-weight": "54405.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5439"}, {"resource": "GenAtlas", "identifier": "IFNGR1"}, {"resource": "GeneCards", "identifier": "IFNGR1"}, {"resource": "GenBank Gene Database", "identifier": "J03143"}, {"resource": "GenBank Protein Database", "identifier": "306915"}, {"resource": "UniProtKB", "identifier": "P15260"}, {"resource": "UniProt Accession", "identifier": "INGR1_HUMAN"}]}, "synonyms": {"synonym": ["CD119 antigen", "CDw119", "IFN-gamma-R1", "Interferon-gamma receptor alpha chain precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interferon-gamma receptor alpha chain precursor\nMALLFLLPLVMQGVSRAEMGTADLGPSSVPTPTNVTIESYNMNPIVYWEYQIMPQVPVFT\nVEVKNYGVKNSEWIDACINISHHYCNISDHVGDPSNSLWVRVKARVGQKESAYAKSEEFA\nVCRDGKIGPPKLDIRKEEKQIMIDIFHPSVFVNGDEQEVDYDPETTCYIRVYNVYVRMNG\nSEIQYKILTQKEDDCDEIQCQLAIPVSSLNSQYCVSAEGVLHVWGVTTEKSKEVCITIFN\nSSIKGSLWIPVVAALLLFLVLSLVFICFYIKKINPLKEKSIILPKSLISVVRSATLETKP\nESKYVSLITSYQPFSLEKEVVCEEPLSPATVPGMHTEDNPGKVEHTEELSSITEVVTTEE\nNIPDVVPGSHLTPIERESSSPLSSNQSEPGSIALNSYHSRNCSESDHSRNGFDTDSSCLE\nSHSSLSDSEFPPNNKGEIKTEGQELITVIKAPTSFGYDKPHVLVDLLVDDSGKESLIGYR\nPTEDSKEFS"}, "gene-sequence": {"@format": "FASTA", "#text": ">1470 bp\nATGGCTCTCCTCTTTCTCCTACCCCTTGTCATGCAGGGTGTGAGCAGGGCTGAGATGGGC\nACCGCGGATCTGGGGCCGTCCTCAGTGCCTACACCAACTAATGTTACAATTGAATCCTAT\nAACATGAACCCTATCGTATATTGGGAGTACCAGATCATGCCACAGGTCCCTGTTTTTACC\nGTAGAGGTAAAGAACTATGGTGTTAAGAATTCAGAATGGATTGATGCCTGCATCAATATT\nTCTCATCATTATTGTAATATTTCTGATCATGTTGGTGATCCATCAAATTCTCTTTGGGTC\nAGAGTTAAAGCCAGGGTTGGACAAAAAGAATCTGCCTATGCAAAGTCAGAAGAATTTGCT\nGTATGCCGAGATGGAAAAATTGGACCACCTAAACTGGATATCAGAAAGGAGGAGAAGCAA\nATCATGATTGACATATTTCACCCTTCAGTTTTTGTAAATGGAGACGAGCAGGAAGTCGAT\nTATGATCCCGAAACTACCTGTTACATTAGGGTGTACAATGTGTATGTGAGAATGAACGGA\nAGTGAGATCCAGTATAAAATACTCACGCAGAAGGAAGATGATTGTGACGAGATTCAGTGC\nCAGTTAGCGATTCCAGTATCCTCACTGAATTCTCAGTACTGTGTTTCAGCAGAAGGAGTC\nTTACATGTGTGGGGTGTTACAACTGAAAAGTCAAAAGAAGTTTGTATTACCATTTTCAAT\nAGCAGTATAAAAGGTTCTCTTTGGATTCCAGTTGTTGCTGCTTTACTACTCTTTCTAGTG\nCTTAGCCTGGTATTCATCTGTTTTTATATTAAGAAAATTAATCCATTGAAGGAAAAAAGC\nATAATATTACCCAAGTCCTTGATCTCTGTGGTAAGAAGTGCTACTTTAGAGACAAAACCT\nGAATCAAAATATGTATCACTCATCACGTCATACCAGCCATTTTCCTTAGAAAAGGAGGTG\nGTCTGTGAAGAGCCGTTGTCTCCAGCAACAGTTCCAGGCATGCATACCGAAGACAATCCA\nGGAAAAGTGGAACATACAGAAGAACTTTCTAGTATAACAGAAGTGGTGACTACTGAAGAA\nAATATTCCTGACGTGGTCCCGGGCAGCCATCTGACTCCAATAGAGAGAGAGAGTTCTTCA\nCCTTTAAGTAGTAACCAGTCTGAACCTGGCAGCATCGCTTTAAACTCGTATCACTCCAGA\nAATTGTTCTGAGAGTGATCACTCCAGAAATGGTTTTGATACTGATTCCAGCTGTCTGGAA\nTCACATAGCTCCTTATCTGACTCAGAATTTCCCCCAAATAATAAAGGTGAAATAAAAACA\nGAAGGACAAGAGCTCATAACCGTAATAAAAGCCCCCACCTCCTTTGGTTATGATAAACCA\nCATGTGCTAGTGGATCTACTTGTGGATGATAGCGGTAAAGAGTCCTTGATTGGTTATAGA\nCCAACAGAAGATTCCAAAGAATTTTCATGA"}, "pfams": {"pfam": {"identifier": "PF07140", "name": "IFNGR1"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "protein binding"}, {"category": "function", "description": "cytokine binding"}]}}}, {"id": "BE0000467", "name": "Interferon gamma receptor 2", "organism": "Human", "actions": {"action": "binder"}, "references": "# Park-Min KH, Serbina NV, Yang W, Ma X, Krystal G, Neel BG, Nutt SL, Hu X, Ivashkiv LB: FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity. 2007 Jan;26(1):67-78. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17239631\n# Yao X, Chen ZQ, Gong JQ, Chen M, Li AS, Liu J: The interferon-gamma receptor gene polymorphisms (Val14Met and Gln64Arg) are not associated with systemic lupus erythematosus in Chinese patients. Arch Dermatol Res. 2007 Oct;299(8):367-371. Epub 2007 Jul 6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17618444\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P38484", "@source": "Swiss-Prot", "name": "Interferon gamma receptor 2", "general-function": "Involved in interferon-gamma receptor activity", "specific-function": "Part of the receptor for interferon gamma. Required for signal transduction. This accessory factor is an integral part of the IFN-gamma signal transduction pathway and is likely to interact with GAF, JAK1, and/or JAK2", "gene-name": "IFNGR2", "locus": null, "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "248-268", "signal-regions": null, "theoretical-pi": "5.35", "molecular-weight": "37835.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5440"}, {"resource": "GenAtlas", "identifier": "IFNGR2"}, {"resource": "GeneCards", "identifier": "IFNGR2"}, {"resource": "GenBank Gene Database", "identifier": "U05875"}, {"resource": "GenBank Protein Database", "identifier": "463550"}, {"resource": "UniProtKB", "identifier": "P38484"}, {"resource": "UniProt Accession", "identifier": "INGR2_HUMAN"}]}, "synonyms": {"synonym": ["AF-1", "Interferon-gamma receptor accessory factor 1", "Interferon-gamma receptor beta chain precursor", "Interferon-gamma transducer 1"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interferon-gamma receptor beta chain precursor\nMRPTLLWSLLLLLGVFAAAAAAPPDPLSQLPAPQHPKIRLYNAEQVLSWEPVALSNSTRP\nVVYRVQFKYTDSKWFTADIMSIGVNCTQITATECDFTAASPSAGFPMDFNVTLRLRAELG\nALHSAWVTMPWFQHYRNVTVGPPENIEVTPGEGSLIIRFSSPFDIADTSTAFFCYYVHYW\nEKGGIQQVKGPFRSNSISLDNLKPSRVYCLQVQAQLLWNKSNIFRVGHLSNISCYETMAD\nASTELQQVILISVGTFSLLSVLAGACFFLVLKYRGLIKYWFHTPPSIPLQIEEYLKDPTQ\nPILEALDKDSSPKDDVWDSVSIISFPEKEQEDVLQTL"}, "gene-sequence": {"@format": "FASTA", "#text": ">1014 bp\nATGCGACCGACGCTGCTGTGGTCGCTGCTGCTGCTGCTCGGAGTCTTCGCCGCCGCCGCC\nGCGGCCCCGCCAGACCCTCTTTCCCAGCTGCCCGCTCCTCAGCACCCGAAGATTCGCCTG\nTACAACGCAGAGCAGGTCCTGAGTTGGGAGCCAGTGGCCCTGAGCAATAGCACGAGGCCT\nGTTGTCTACCGAGTGCAGTTTAAATACACCGACAGTAAATGGTTCACGGCCGACATCATG\nTCCATAGGGGTGAATTGTACACAGATCACAGCAACAGAGTGTGACTTCACTGCCGCCAGT\nCCCTCAGCAGGCTTCCCAATGGATTTCAATGTCACTCTACGCCTTCGAGCTGAGCTGGGA\nGCACTCCATTCTGCCTGGGTGACAATGCCTTGGTTTCAACACTATCGGAATGTGACTGTC\nGGGCCTCCAGAAAACATTGAGGTGACCCCAGGAGAAGGCTCCCTCATCATCAGGTTCTCC\nTCTCCCTTTGACATCGCTGATACCTCCACGGCCTTTTTTTGTTATTATGTCCATTACTGG\nGAAAAAGGAGGAATCCAACAGGTCAAAGGCCCTTTCAGAAGCAACTCCATTTCATTGGAT\nAACTTAAAACCCTCCAGAGTGTACTGTTTACAAGTCCAGGCACAACTGCTTTGGAACAAA\nAGTAACATCTTTAGAGTCGGGCATTTAAGCAACATATCTTGCTACGAAACAATGGCAGAT\nGCCTCCACTGAGCTTCAGCAAGTCATCCTGATCTCCGTGGGAACATTTTCGTTGCTGTCG\nGTGCTGGCAGGAGCCTGTTTCTTCCTGGTCCTGAAATATAGAGGCCTGATTAAATACTGG\nTTTCACACTCCACCAAGCATCCCATTACAGATAGAAGAGTATTTAAAAGACCCAACTCAG\nCCCATCTTAGAGGCCTTGGACAAGGACAGCTCACCAAAGGATGACGTCTGGGACTCTGTG\nTCCATTATCTCGTTTCCGGAAAAGGAGCAAGAAGATGTTCTCCAAACGCTTTGA"}, "pfams": {"pfam": {"identifier": "PF00041", "name": "fn3"}}, "go-classifiers": null}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2015-09-23", "drugbank-id": [{"@primary": "true", "#text": "DB00034"}, "BIOD00012", "BIOD00095", "BTD00012", "BTD00095", "DB00037"], "name": "Interferon Alfa-2a, Recombinant", "description": "Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.", "cas-number": "77907-69-8", "groups": {"group": "approved"}, "general-references": null, "synthesis-reference": null, "indication": "For the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection.", "pharmacodynamics": "Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.", "mechanism-of-action": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.", "toxicity": "Interferon alfa-2 may cause serious adverse effects such as anemia; autoimmune diseases, including vasculitis, arthritis, hemolytic anemia, and erythematosus syndrome; cardiotoxicity; hepatotoxicity; hyperthyroidism or hypothyroidism; transient ischemic attacks; leukopenia; neurotoxicity; peripheral neuropathy; and thrombocytopenia. Some lesser side effects that may not need medical attention include blurred vision, change in taste or metallic taste, cold sores or stomatitis, diarrhea, dizziness, dry mouth, dry skin or itching, flu-like syndrome, increased sweating, leg cramps, loss of appetite, nausea or vomiting, skin rash, unusual tiredness, weight loss, and partial loss of hair.", "metabolism": null, "absorption": "Absorption is high (greater than 80%) when administered intramuscularly or subcutaneously.", "half-life": "The IM half-life of interferon alfa-2a is 6 hours to 8 hours; the half-life for IV infusion is 3.7 hours to 8.5 hours (mean 5.1 hours).", "protein-binding": null, "route-of-elimination": "Alpha-interferons are totally filtered through the glomeruli and undergo rapid proteolytic degradation during tubular reabsorption, rendering a negligible reappearance of intact alfa interferon in the systemic circulation.", "volume-of-distribution": "* 0.223 to 0.748 L/kg [healthy people]", "clearance": "* 2.14 - 3.62 mL/min/kg [healthy]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Interferon alfa-2a"}, {"@language": "", "@coder": "", "#text": "Interferon alpha-2a"}, {"@language": "", "@coder": "", "#text": "Oral interferon alfa"}, {"@language": "", "@coder": "", "#text": "rIFN-alpha-2a"}]}, "products": {"product": [{"name": "Roferon A Soln Inj 6 Million", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00812498", "started-marketing-on": "1989-12-31", "ended-marketing-on": "1997-08-26", "dosage-form": "liquid", "strength": "6000000 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Roferon A Sterile Pws 18m Unit/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01912003", "started-marketing-on": "1991-12-31", "ended-marketing-on": "1996-09-30", "dosage-form": "powder for solution", "strength": "18000000 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Roferon A Sterile Pws 3m Unit/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01911988", "started-marketing-on": "1991-12-31", "ended-marketing-on": "1996-09-30", "dosage-form": "powder for solution", "strength": "3000000 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Roferon A Sterile Pws 9m Unit/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01911996", "started-marketing-on": "1991-12-31", "ended-marketing-on": "1996-09-30", "dosage-form": "powder for solution", "strength": "9000000 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Roferon-a  Solution Inj. 9million I.U./0.9ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02019914", "started-marketing-on": "1993-12-31", "ended-marketing-on": "1997-08-26", "dosage-form": "solution", "strength": "9000000 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Roferon-a Sol Inj 3million Iu/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00812501", "started-marketing-on": "1989-12-31", "ended-marketing-on": "1997-08-25", "dosage-form": "liquid", "strength": "3000000 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Roferon-a Soln-liq Im Sc 4.5million I.u/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02217023", "started-marketing-on": "1997-04-25", "ended-marketing-on": "1999-11-02", "dosage-form": "liquid", "strength": "4.5 m", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Roferon-a Soln-liq Im Sc 9million I.U./ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02217058", "started-marketing-on": "1997-04-29", "ended-marketing-on": "2004-11-01", "dosage-form": "solution", "strength": "9 m", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Roferon-a Solution 18 Million I.U./3ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02217066", "started-marketing-on": "1997-01-15", "ended-marketing-on": "2005-07-14", "dosage-form": "solution", "strength": "18 m", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Roferon-a Solution 3 Million I.U./ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02217015", "started-marketing-on": "1997-02-25", "ended-marketing-on": "2005-07-14", "dosage-form": "solution", "strength": "3 m", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Roferon-a Solution 6 Million I.U./ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02217031", "started-marketing-on": "1997-02-24", "ended-marketing-on": "2000-07-27", "dosage-form": "solution", "strength": "6 m", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Roferon-a Solution Inj 36000000unit/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00891002", "started-marketing-on": "1992-12-31", "ended-marketing-on": "1997-06-18", "dosage-form": "solution", "strength": "36000000 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": [{"name": "Roferon A", "company": "Hoffmann-La Roche Inc"}, {"name": "Veldona", "company": "Amarillo Biosciences"}]}, "mixtures": {"mixture": [{"name": "Roferon A Sterile Pws 3m Unit/vial", "ingredients": "Interferon Alfa-2a, Recombinant"}, {"name": "Roferon A Sterile Pws 18m Unit/vial", "ingredients": "Interferon Alfa-2a, Recombinant"}, {"name": "Roferon A Sterile Pws 9m Unit/vial", "ingredients": "Interferon Alfa-2a, Recombinant"}, {"name": "Roferon-a Solution Inj 36000000unit/ml", "ingredients": "Interferon Alfa-2a, Recombinant"}, {"name": "Roferon-a  Solution Inj. 9million I.U./0.9ml", "ingredients": "Interferon Alfa-2a, Recombinant"}, {"name": "Roferon-a Solution 3 Million I.U./ml", "ingredients": "Interferon Alfa-2a, Recombinant"}, {"name": "Roferon-a Soln-liq Im Sc 4.5million I.u/ml", "ingredients": "Interferon Alfa-2a, Recombinant"}, {"name": "Roferon-a Solution 6 Million I.U./ml", "ingredients": "Interferon Alfa-2a, Recombinant"}, {"name": "Roferon-a Soln-liq Im Sc 9million I.U./ml", "ingredients": "Interferon Alfa-2a, Recombinant"}, {"name": "Roferon-a Solution 18 Million I.U./3ml", "ingredients": "Interferon Alfa-2a, Recombinant"}, {"name": "Roferon A Soln Inj 6 Million", "ingredients": "Interferon Alfa-2a, Recombinant"}, {"name": "Roferon-a Sol Inj 3million Iu/vial", "ingredients": "Interferon Alfa-2a, Recombinant"}]}, "packagers": {"packager": [{"name": "F Hoffmann La Roche Ltd.", "url": "http://www.roche.com"}, {"name": "F Hoffmann-La Roche Ltd.", "url": "http://www.roche.com"}]}, "manufacturers": null, "prices": null, "categories": null, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Liquid", "route": "intramuscular; subcutaneous", "strength": "6000000 unit"}, {"form": "Powder for solution", "route": "intramuscular; subcutaneous", "strength": "18000000 unit"}, {"form": "Powder for solution", "route": "intramuscular; subcutaneous", "strength": "3000000 unit"}, {"form": "Powder for solution", "route": "intramuscular; subcutaneous", "strength": "9000000 unit"}, {"form": "Solution", "route": "intramuscular; subcutaneous", "strength": "9000000 unit"}, {"form": "Liquid", "route": "intramuscular; subcutaneous", "strength": "3000000 unit"}, {"form": "Liquid", "route": "intramuscular; subcutaneous", "strength": "4.5 m"}, {"form": "Solution", "route": "intramuscular; subcutaneous", "strength": "9 m"}, {"form": "Solution", "route": "intramuscular; subcutaneous", "strength": "18 m"}, {"form": "Solution", "route": "intramuscular; subcutaneous", "strength": "3 m"}, {"form": "Solution", "route": "intramuscular; subcutaneous", "strength": "6 m"}, {"form": "Solution", "route": "intramuscular; subcutaneous", "strength": "36000000 unit"}]}, "atc-codes": {"atc-code": {"@code": "L03AB04", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L03", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03A", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03AB", "#text": "Interferons"}]}}, "ahfs-codes": null, "patents": {"patent": {"number": "2172664", "country": "Canada", "approved": "2000-10-03", "expires": "2016-03-26"}}, "food-interactions": {"food-interaction": "Avoid alcohol."}, "drug-interactions": null, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00034 sequence\nCDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI\nQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR\nKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE"}}, "experimental-properties": {"property": [{"kind": "Water Solubility", "value": "100 mg/ml", "source": null}, {"kind": "Hydrophobicity", "value": "-0.336", "source": null}, {"kind": "Isoelectric Point", "value": "5.99", "source": null}, {"kind": "Molecular Weight", "value": "19241.1000", "source": null}, {"kind": "Molecular Formula", "value": "C860H1353N227O255S9", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "1746"}, {"resource": "National Drug Code Directory", "identifier": "0004-2015-09"}, {"resource": "GenBank", "identifier": "J00207"}, {"resource": "PharmGKB", "identifier": "PA164779048"}, {"resource": "UniProtKB", "identifier": "P01563"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/roferon.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/interferon-alfa-2a-solution.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000661", "name": "Interferon alpha/beta receptor 1", "organism": "Human", "actions": null, "references": "# Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15898717\n# Cironi P, Swinburne IA, Silver PA: Enhancement of cell type specificity by quantitative modulation of a chimeric ligand. J Biol Chem. 2008 Mar 28;283(13):8469-76. Epub 2008 Jan 29. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18230610", "known-action": "yes", "polypeptide": {"@id": "P17181", "@source": "Swiss-Prot", "name": "Interferon alpha/beta receptor 1", "general-function": "Involved in interferon-alpha/beta receptor activity", "specific-function": "Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta- subunits themselves", "gene-name": "IFNAR1", "locus": null, "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "437-457", "signal-regions": null, "theoretical-pi": "5.56", "molecular-weight": "63526.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5432"}, {"resource": "GenAtlas", "identifier": "IFNAR1"}, {"resource": "GeneCards", "identifier": "IFNAR1"}, {"resource": "GenBank Gene Database", "identifier": "J03171"}, {"resource": "GenBank Protein Database", "identifier": "306914"}, {"resource": "UniProtKB", "identifier": "P17181"}, {"resource": "UniProt Accession", "identifier": "INAR1_HUMAN"}]}, "synonyms": {"synonym": ["IFN-alpha-REC", "Interferon-alpha/beta receptor alpha chain precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interferon-alpha/beta receptor alpha chain precursor\nMMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT\nFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF\nTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI\nENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ\nNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK\nGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP\nVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV\nFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE\nYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN\nEDESESKTSEELQQDFV"}, "gene-sequence": {"@format": "FASTA", "#text": ">1674 bp\nATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGGCCCATGGGTG\nTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC\nATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT\nTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG\nAATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT\nAAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT\nACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG\nGCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT\nTTAAGCTTTACATATAGCTTACTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT\nGAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA\nAAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT\nATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA\nAATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG\nTGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA\nCCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA\nGGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA\nGAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA\nTCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT\nGTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT\nGAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT\nGTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT\nTTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA\nGTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC\nTTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG\nTATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA\nAAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT\nGATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT\nGAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA"}, "pfams": null, "go-classifiers": null}}, {"id": "BE0000385", "name": "Interferon alpha/beta receptor 2", "organism": "Human", "actions": null, "references": "# Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15898717\n# Cironi P, Swinburne IA, Silver PA: Enhancement of cell type specificity by quantitative modulation of a chimeric ligand. J Biol Chem. 2008 Mar 28;283(13):8469-76. Epub 2008 Jan 29. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18230610", "known-action": "yes", "polypeptide": {"@id": "P48551", "@source": "Swiss-Prot", "name": "Interferon alpha/beta receptor 2", "general-function": "Involved in interferon-alpha/beta receptor activity", "specific-function": "Receptor for interferons alpha and beta. Isoform 1 and isoform 3 are directly involved in signal transduction due to their interaction with the TYR kinase, JAK1. Isoform 1 also interacts with the transcriptional factors, STAT1 and STAT2. Both forms are potent inhibitors of type I IFN activity", "gene-name": "IFNAR2", "locus": null, "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "244-264", "signal-regions": null, "theoretical-pi": "4.11", "molecular-weight": "57759.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5433"}, {"resource": "GenAtlas", "identifier": "IFNAR2"}, {"resource": "GeneCards", "identifier": "IFNAR2"}, {"resource": "GenBank Gene Database", "identifier": "L42243"}, {"resource": "GenBank Protein Database", "identifier": "995300"}, {"resource": "UniProtKB", "identifier": "P48551"}, {"resource": "UniProt Accession", "identifier": "INAR2_HUMAN"}]}, "synonyms": {"synonym": ["IFN-alpha-REC", "IFN-R", "Interferon alpha/beta receptor 2", "Interferon-alpha/beta receptor beta chain precursor", "Type I interferon receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interferon-alpha/beta receptor beta chain precursor\nMLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS\nIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF\nSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK\nHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE\nSAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD\nMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI\nDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR\nITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT\nFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR"}, "gene-sequence": {"@format": "FASTA", "#text": ">1548 bp\nATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT\nATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT\nTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC\nATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG\nGTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA\nAGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC\nAGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG\nATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA\nGAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG\nCATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA\nATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA\nATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA\nTCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC\nATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG\nAATTTTCATAACTTTTTAGCCTGGCCATTTCCTAACCTGCCACCGTTGGAAGCCATGGAT\nATGGTGGAGGTCATTTACATCAACAGAAAGAAGAAAGTGTGGGATTATAATTATGATGAT\nGAAAGTGATAGCGATACTGAGGCAGCGCCCAGGACAAGTGGCGGTGGCTATACCATGCAT\nGGACTGACTGTCAGGCCTCTGGGTCAGGCCTCTGCCACCTCTACAGAATCCCAGTTGATA\nGACCCGGAGTCCGAGGAGGAGCCTGACCTGCCTGAGGTTGATGTGGAGCTCCCCACGATG\nCCAAAGGACAGCCCTCAGCAGTTGGAACTCTTGAGTGGGCCCTGTGAGAGGAGAAAGAGT\nCCACTCCAGGACCCTTTTCCCGAAGAGGACTACAGCTCCACGGAGGGGTCTGGGGGCAGA\nATTACCTTCAATGTGGACTTAAACTCTGTGTTTTTGAGAGTTCTTGATGACGAGGACAGT\nGACGACTTAGAAGCCCCTCTGATGCTATCGTCTCATCTGGAAGAGATGGTTGACCCAGAG\nGATCCTGATAATGTGCAATCAAACCATTTGCTGGCCAGCGGGGAAGGGACACAGCCAACC\nTTTCCCAGCCCCTCTTCAGAGGGCCTGTGGTCCGAAGATGCTCCATCTGATCAAAGTGAC\nACTTCTGAGTCAGATGTTGACCTTGGGGATGGTTATATAATGAGATGA"}, "pfams": null, "go-classifiers": null}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2005-06-13", "@updated": "2013-09-16", "drugbank-id": [{"@primary": "true", "#text": "DB00035"}, "BIOD00061", "BIOD00112", "BTD00061", "BTD00112"], "name": "Desmopressin", "description": "Desmopressin is a chemical that is similar to Antidiuretic Hormone (ADH) which is found naturally in the body. It increases urine concentration and decreases urine production. Desmopressin is used to prevent and control excessive thirst, urination, and dehydration caused by injury, surgery, and certain medical conditions, allowing you to sleep through the night without awakening to urinate. It is also used to treat specific types of diabetes insipidus and conditions after head injury or pituitary surgery.", "cas-number": "16679-58-6", "groups": {"group": "approved"}, "general-references": "# Leissinger C, Becton D, Cornell C Jr, Cox Gill J: High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia. 2001 May;7(3):258-66. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11380629\n# Sequence Information \"Link\":http://www.ecplaza.net/tradeleads/seller/5605163/desmopressin_acetate.html", "synthesis-reference": "Krister Larsson, Thomas Mellbrand, Birgitta Mornstam, Jan Roschester, Jan-Ake Skoldback, \"High purity desmopressin produced in large single batches.\" U.S. Patent US5674850, issued November, 1991.", "indication": "Oral formulations may be used to manage primary nocturnal enuresis in adults and vasopressin sensitive diabetes insipidus, and for control of temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Intranasal and parenteral formulations may be used to manage spontaneous or trauma-induced bleeds (e.g. hemarthrosis, intramuscular hematoma, mucosal bleeding) in patients with hemophilia A or von Willebrand's disease Type I. May also be used parenterally to prevent or treat bleeding in patients with uremia.", "pharmacodynamics": "Desmopressin is a synthetic analogue of the natural antidiuretic hormone (ADH or vasopressin) that is produced by the hypothalamus and stored in the posterior pituitary gland. The main function of ADH is to regulate extracellular fluid volume in the body. ADH secretion is stimulated by angiotensin II, linking it to the renin-angiotensin-aldosterone system (RAAS). ADH stimulates water reabsorption in the kidneys by causing the insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. It also causes vasoconstriction through its action on vascular smooth muscle cells of the collecting tubules. The efficacy of desmopressin for managing bleeds in patients with hemophilia A or von Willebrand\u2019s disease Type I arises from its ability to elicit dose-dependent increases in plasma factor VIII (antihemophilic factor), plasminogen activator, and to a lesser extent, factor VIII-related antigen and ristocetin cofactor activities; these changes improve blood clotting.", "mechanism-of-action": "Desmopressin emulates the actions of endogenous human ADH (refer to Pharmacology section above). Desmpressin is a structural analogue of ADH modified by  deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. Compared to natural ADH, desmopressin elicits a great antidiuretic response on weight basis.", "toxicity": "Overdose may lead to increased duration of action and lead to symptoms such as fluid retention, headaches, abdominal cramps, nausea, and facial flushing. Adverse effects include headache, nausea, abdominal pain, facial flushing, dizziness, dry mouth, and hyponatremia. Nasal congestion and rhinitis have been reported with nasal spray formulations.", "metabolism": "Metabolic fate unknown. Is not affected by liver microsomal cytochrome P450 enzymes.", "absorption": "Minimally absorbed from the GI tract (average absolute bioavailability = 0.08-0.16%). 10-20% absorbed from nasal mucosa.", "half-life": "Oral t<sub>1/2</sub>=1.5-2.5 hours. Intranasal t<sub>1/2</sub>=3.3-3.5 hours. IV t<sub>1/2</sub> is biphasic: initial t<sub>1/2</sub>=7.8 minutes, terminal t<sub>1/2</sub>=0.4-4 hours.", "protein-binding": "50%", "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": "This compound belongs to the class of organic compounds known as cyclic peptides. These are compounds containing a cyclic moiety bearing a peptide backbone.", "direct-parent": "Cyclic peptides", "kingdom": "Organic compounds", "superclass": "Organic acids and derivatives", "class": "Carboxylic acids and derivatives", "subclass": "Amino acids, peptides, and analogues", "alternative-parent": ["Alpha amino acid amides", "Azacyclic compounds", "Carbonyl compounds", "Carboximidamides", "Cyclic alcohols and derivatives", "Guanidines", "Hydrocarbon derivatives", "Imines", "Lactams", "Macrolactams", "N-acyl amines", "N-acyl-alpha amino acids and derivatives", "N-acylpyrrolidines", "Organic disulfides", "Phenols and derivatives", "Primary carboxylic acid amides", "Pyrrolidinecarboxamides", "Secondary carboxylic acid amides", "Tertiary amines", "Tertiary carboxylic acid amides"], "substituent": ["Alpha-amino acid amide", "Amine", "Aromatic heteromonocyclic compound", "Azacycle", "Benzenoid", "Carbonyl group", "Carboxamide group", "Carboximidamide", "Carboxylic acid amide", "Cyclic alcohol", "Cyclic alpha peptide", "Fatty acyl", "Fatty amide", "Guanidine", "Hydrocarbon derivative", "Imine", "Lactam", "Macrolactam", "Monocyclic benzene moiety", "N-acyl-alpha amino acid or derivatives", "N-acyl-amine", "N-acylpyrrolidine", "N-substituted-alpha-amino acid", "Organic disulfide", "Organoheterocyclic compound", "Organonitrogen compound", "Organooxygen compound", "Phenol", "Primary carboxylic acid amide", "Pyrrolidine", "Pyrrolidine carboxylic acid or derivatives", "Pyrrolidine-2-carboxamide", "Secondary carboxylic acid amide", "Tertiary amine", "Tertiary carboxylic acid amide"]}, "salts": {"salt": [{"drugbank-id": {"@primary": "true", "#text": "DBSALT000044"}, "name": "Desmopressin acetate", "cas-number": null, "inchikey": "InChIKey=MLSVJHOYXJGGTR-IFHOVBQLSA-N"}, {"drugbank-id": {"@primary": "true", "#text": "DBSALT001154"}, "name": "Desmopressin acetate trihydrate", "cas-number": null, "inchikey": null}]}, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "1-(3-mercaptopropionic acid)-8-D-arginine-vasopressin"}, {"@language": "", "@coder": "", "#text": "1-deamino-8-D-arginine vasopressin"}, {"@language": "", "@coder": "", "#text": "1-Desamino-8-D-arginine vasopressin"}, {"@language": "", "@coder": "", "#text": "DDAVP"}, {"@language": "Spanish", "@coder": "INN", "#text": "Desmopresina"}, {"@language": "", "@coder": "", "#text": "Desmopressin"}, {"@language": "French", "@coder": "INN", "#text": "Desmopressine"}, {"@language": "Latin", "@coder": "INN", "#text": "Desmopressinum"}, {"@language": "", "@coder": "", "#text": "Minirin"}, {"@language": "", "@coder": "", "#text": "Stimate"}]}, "products": {"product": [{"name": "Apo-desmopressin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02284030", "started-marketing-on": "2007-01-31", "ended-marketing-on": null, "dosage-form": "tablet", "strength": "0.1 mg", "route": "oral", "fda-application-number": null, "generic": "true", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Apo-desmopressin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02284049", "started-marketing-on": "2007-01-31", "ended-marketing-on": null, "dosage-form": "tablet", "strength": "0.2 mg", "route": "oral", "fda-application-number": null, "generic": "true", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Ddavp", "ndc-id": "0075-0016_594ad44c-9c5d-47ad-b596-f667476a6b2f", "ndc-product-code": "0075-0016", "dpd-id": null, "started-marketing-on": "1995-09-06", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".1 mg", "route": "oral", "fda-application-number": "NDA019955", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Ddavp", "ndc-id": "0075-0026_594ad44c-9c5d-47ad-b596-f667476a6b2f", "ndc-product-code": "0075-0026", "dpd-id": null, "started-marketing-on": "1995-09-06", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".2 mg", "route": "oral", "fda-application-number": "NDA019955", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Ddavp", "ndc-id": "55566-2200_ebab4450-8a4b-49fc-8a2f-1e480a8b4f77", "ndc-product-code": "55566-2200", "dpd-id": null, "started-marketing-on": "1984-03-30", "ended-marketing-on": null, "dosage-form": "injection", "strength": "4 ug/mL", "route": "intravenous", "fda-application-number": "NDA018938", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Ddavp", "ndc-id": "55566-2300_ebab4450-8a4b-49fc-8a2f-1e480a8b4f77", "ndc-product-code": "55566-2300", "dpd-id": null, "started-marketing-on": "1984-03-30", "ended-marketing-on": null, "dosage-form": "injection", "strength": "4 ug/mL", "route": "intravenous", "fda-application-number": "NDA018938", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Ddavp", "ndc-id": "55566-2400_5a42e2bc-8ddf-4ae3-bec5-b5043a94fd7c", "ndc-product-code": "55566-2400", "dpd-id": null, "started-marketing-on": "1978-02-21", "ended-marketing-on": null, "dosage-form": "spray", "strength": ".1 ug/mL", "route": "nasal", "fda-application-number": "NDA017922", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Ddavp", "ndc-id": "55566-2500_8bc70011-b272-4f88-8707-85232a02f472", "ndc-product-code": "55566-2500", "dpd-id": null, "started-marketing-on": "1978-02-21", "ended-marketing-on": null, "dosage-form": "spray", "strength": ".1 ug/mL", "route": "nasal", "fda-application-number": "NDA021333", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Ddavp", "ndc-id": "55566-2600_f1879d97-af32-42a8-81f2-1374fea9592d", "ndc-product-code": "55566-2600", "dpd-id": null, "started-marketing-on": "1995-09-06", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".1 mg", "route": "oral", "fda-application-number": "NDA019955", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Ddavp", "ndc-id": "0075-2451_5e30ba6d-ebb3-4950-b03a-7f1e946da982", "ndc-product-code": "0075-2451", "dpd-id": null, "started-marketing-on": "1984-03-30", "ended-marketing-on": null, "dosage-form": "solution", "strength": "4 ug/mL", "route": "intravenous", "fda-application-number": "NDA018938", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Ddavp", "ndc-id": "55566-2700_f1879d97-af32-42a8-81f2-1374fea9592d", "ndc-product-code": "55566-2700", "dpd-id": null, "started-marketing-on": "1995-09-06", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".2 mg", "route": "oral", "fda-application-number": "NDA019955", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Ddavp", "ndc-id": "0075-2452_517c673f-db39-4b91-bd86-eb35db5bea7f", "ndc-product-code": "0075-2452", "dpd-id": null, "started-marketing-on": "1978-02-21", "ended-marketing-on": null, "dosage-form": "solution", "strength": ".1 mg/mL", "route": "nasal", "fda-application-number": "NDA017922", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Ddavp Inj 4mcg/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00873993", "started-marketing-on": "1993-12-31", "ended-marketing-on": null, "dosage-form": "liquid", "strength": "4 mcg", "route": "intramuscular; intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Ddavp Melt", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02284995", "started-marketing-on": "2006-11-02", "ended-marketing-on": null, "dosage-form": "tablet (orally disintegrating)", "strength": "60 mcg", "route": "sublingual", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Ddavp Melt", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02285002", "started-marketing-on": "2006-11-02", "ended-marketing-on": null, "dosage-form": "tablet (orally disintegrating)", "strength": "120 mcg", "route": "sublingual", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Ddavp Melt", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02285010", "started-marketing-on": "2009-05-05", "ended-marketing-on": null, "dosage-form": "tablet (orally disintegrating)", "strength": "240 mcg", "route": "sublingual", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Ddavp Rhinal Tube", "ndc-id": "0075-2450_b1b1e14c-afba-44c1-a384-5aae6a624046", "ndc-product-code": "0075-2450", "dpd-id": null, "started-marketing-on": "1978-02-21", "ended-marketing-on": null, "dosage-form": "solution", "strength": ".1 mg/mL", "route": "nasal", "fda-application-number": "NDA017922", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Ddavp Rhinyle", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00402516", "started-marketing-on": "1992-12-31", "ended-marketing-on": null, "dosage-form": "solution", "strength": "0.1 mg", "route": "nasal", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Ddavp Spray", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00836362", "started-marketing-on": "1989-12-31", "ended-marketing-on": null, "dosage-form": "metered-dose aerosol", "strength": "10 mcg", "route": "nasal", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Ddavp Tablets 0.1mg", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00824305", "started-marketing-on": "1995-12-31", "ended-marketing-on": null, "dosage-form": "tablet", "strength": "0.1 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Ddavp Tablets 0.2mg", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00824143", "started-marketing-on": "1995-12-31", "ended-marketing-on": null, "dosage-form": "tablet", "strength": "0.2 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Desmopressin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02346788", "started-marketing-on": "2011-07-27", "ended-marketing-on": "2014-06-25", "dosage-form": "tablet", "strength": "0.1 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Desmopressin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02346796", "started-marketing-on": "2011-07-27", "ended-marketing-on": "2014-06-25", "dosage-form": "tablet", "strength": "0.2 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Desmopressin Acetate", "ndc-id": "62756-529_b844ffe0-0b30-4d3b-8a16-1a6da45d9e28", "ndc-product-code": "62756-529", "dpd-id": null, "started-marketing-on": "2013-01-30", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "4 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA091280", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "62756-529_fe90dd4d-c54b-4fce-b5d0-b9f3fa69d2e3", "ndc-product-code": "62756-529", "dpd-id": null, "started-marketing-on": "2014-02-20", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "4 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA091280", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "0591-2464_c7c57f26-7675-44ad-93dd-ae9c757db230", "ndc-product-code": "0591-2464", "dpd-id": null, "started-marketing-on": "2011-08-15", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".1 mg", "route": "oral", "fda-application-number": "ANDA076470", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "0591-2465_c7c57f26-7675-44ad-93dd-ae9c757db230", "ndc-product-code": "0591-2465", "dpd-id": null, "started-marketing-on": "2011-08-15", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".2 mg", "route": "oral", "fda-application-number": "ANDA076470", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "24208-342_426fba34-8d84-4a3b-81a3-025ab9de95bf", "ndc-product-code": "24208-342", "dpd-id": null, "started-marketing-on": "1999-01-25", "ended-marketing-on": null, "dosage-form": "solution", "strength": ".1 mg/mL", "route": "nasal", "fda-application-number": "ANDA074830", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "68084-604_0f7ffbf3-8321-4c41-a4ba-7d2186e5cb7d", "ndc-product-code": "68084-604", "dpd-id": null, "started-marketing-on": "2012-10-08", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".2 mg", "route": "oral", "fda-application-number": "ANDA076470", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "68084-606_0f7ffbf3-8321-4c41-a4ba-7d2186e5cb7d", "ndc-product-code": "68084-606", "dpd-id": null, "started-marketing-on": "2012-10-08", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".1 mg", "route": "oral", "fda-application-number": "ANDA076470", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "68462-275_f0ae047c-4feb-4de2-876e-3d3e423c0c20", "ndc-product-code": "68462-275", "dpd-id": null, "started-marketing-on": "2015-05-28", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".1 mg", "route": "oral", "fda-application-number": "ANDA201831", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "68462-276_f0ae047c-4feb-4de2-876e-3d3e423c0c20", "ndc-product-code": "68462-276", "dpd-id": null, "started-marketing-on": "2015-05-28", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".2 mg", "route": "oral", "fda-application-number": "ANDA201831", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "0409-2265_72245812-5df9-43dd-bcc6-91ded8d829a4", "ndc-product-code": "0409-2265", "dpd-id": null, "started-marketing-on": "2000-08-28", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "4 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA075220", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "0409-2265_e2133b89-2a7d-4da7-a2ba-d2965275ae7e", "ndc-product-code": "0409-2265", "dpd-id": null, "started-marketing-on": "2015-01-01", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "4 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA075220", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "60687-109_a13b1439-215c-4305-aa26-4fc8469e298e", "ndc-product-code": "60687-109", "dpd-id": null, "started-marketing-on": "2015-09-15", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".1 mg", "route": "oral", "fda-application-number": "ANDA076470", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "0703-5051_ff87d1d1-98e4-42d0-afba-34cd1a7f2b2e", "ndc-product-code": "0703-5051", "dpd-id": null, "started-marketing-on": "1997-11-01", "ended-marketing-on": null, "dosage-form": "injection", "strength": "4 ug/mL", "route": "intravenous", "fda-application-number": "ANDA074888", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "0703-5054_ff87d1d1-98e4-42d0-afba-34cd1a7f2b2e", "ndc-product-code": "0703-5054", "dpd-id": null, "started-marketing-on": "1997-11-01", "ended-marketing-on": null, "dosage-form": "injection", "strength": "4 ug/mL", "route": "intravenous", "fda-application-number": "ANDA074888", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "54868-5602_983a15fb-e0d8-4e75-aa92-ade42e5e625a", "ndc-product-code": "54868-5602", "dpd-id": null, "started-marketing-on": "2006-05-22", "ended-marketing-on": null, "dosage-form": "solution", "strength": ".1 mg/mL", "route": "nasal", "fda-application-number": "ANDA074830", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "60687-120_a13b1439-215c-4305-aa26-4fc8469e298e", "ndc-product-code": "60687-120", "dpd-id": null, "started-marketing-on": "2015-09-15", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".2 mg", "route": "oral", "fda-application-number": "ANDA076470", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "54868-1129_01172abb-07b0-4cc9-ab0c-8922c8993c44", "ndc-product-code": "54868-1129", "dpd-id": null, "started-marketing-on": "2007-07-19", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".2 mg", "route": "oral", "fda-application-number": "ANDA077122", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "0093-7316_d90fa9b3-6dbb-402e-856e-008d26134ffd", "ndc-product-code": "0093-7316", "dpd-id": null, "started-marketing-on": "2006-01-27", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".1 mg", "route": "oral", "fda-application-number": "ANDA077122", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "68001-233_fd8867bb-e8f2-44e3-8443-d82a38e8a01b", "ndc-product-code": "68001-233", "dpd-id": null, "started-marketing-on": "2014-02-27", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".1 mg", "route": "oral", "fda-application-number": "ANDA076470", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "0093-7317_d90fa9b3-6dbb-402e-856e-008d26134ffd", "ndc-product-code": "0093-7317", "dpd-id": null, "started-marketing-on": "2006-01-27", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".2 mg", "route": "oral", "fda-application-number": "ANDA077122", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "50268-220_21174971-6cf2-c95c-1311-53db61b8fd62", "ndc-product-code": "50268-220", "dpd-id": null, "started-marketing-on": "2013-07-24", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".1 mg", "route": "oral", "fda-application-number": "ANDA076470", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "68001-234_fd8867bb-e8f2-44e3-8443-d82a38e8a01b", "ndc-product-code": "68001-234", "dpd-id": null, "started-marketing-on": "2014-02-27", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".2 mg", "route": "oral", "fda-application-number": "ANDA076470", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "50268-221_21174971-6cf2-c95c-1311-53db61b8fd62", "ndc-product-code": "50268-221", "dpd-id": null, "started-marketing-on": "2013-07-24", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".2 mg", "route": "oral", "fda-application-number": "ANDA076470", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "51079-446_4bb201e7-661f-4e39-97eb-09001b44b3bf", "ndc-product-code": "51079-446", "dpd-id": null, "started-marketing-on": "2007-12-26", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".2 mg", "route": "oral", "fda-application-number": "ANDA077122", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "60505-0257_59ba7fff-787d-4ba7-4078-b335868ed697", "ndc-product-code": "60505-0257", "dpd-id": null, "started-marketing-on": "2006-03-07", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".1 mg", "route": "oral", "fda-application-number": "ANDA077414", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "60505-0258_59ba7fff-787d-4ba7-4078-b335868ed697", "ndc-product-code": "60505-0258", "dpd-id": null, "started-marketing-on": "2006-03-07", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".2 mg", "route": "oral", "fda-application-number": "ANDA077414", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "68151-1281_7769db37-fb59-41a3-bce2-af11e382c104", "ndc-product-code": "68151-1281", "dpd-id": null, "started-marketing-on": "2006-01-27", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".1 mg", "route": "oral", "fda-application-number": "ANDA077122", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "0615-7549_321617aa-3c20-4330-8c8c-7d964d5cab39", "ndc-product-code": "0615-7549", "dpd-id": null, "started-marketing-on": "2011-01-17", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".2 mg", "route": "oral", "fda-application-number": "ANDA077122", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "55566-5020_dbfe4d67-5335-5333-debb-428f6f991de6", "ndc-product-code": "55566-5020", "dpd-id": null, "started-marketing-on": "1999-08-10", "ended-marketing-on": null, "dosage-form": "solution", "strength": ".1 mg/mL", "route": "nasal", "fda-application-number": "NDA017922", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "55566-5030_90bd1e51-06c1-61ab-fc0e-32c4dbd3b7a7", "ndc-product-code": "55566-5030", "dpd-id": null, "started-marketing-on": "1999-10-26", "ended-marketing-on": null, "dosage-form": "solution", "strength": "4 ug/mL", "route": "intravenous", "fda-application-number": "NDA018938", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "55566-5040_90bd1e51-06c1-61ab-fc0e-32c4dbd3b7a7", "ndc-product-code": "55566-5040", "dpd-id": null, "started-marketing-on": "1999-10-26", "ended-marketing-on": null, "dosage-form": "solution", "strength": "4 ug/mL", "route": "intravenous", "fda-application-number": "NDA018938", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "55566-5060_a3e1a3bc-b2d8-4947-87de-f1bb016fc8a3", "ndc-product-code": "55566-5060", "dpd-id": null, "started-marketing-on": "2008-05-05", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".1 mg", "route": "oral", "fda-application-number": "NDA021795", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "55566-5061_a3e1a3bc-b2d8-4947-87de-f1bb016fc8a3", "ndc-product-code": "55566-5061", "dpd-id": null, "started-marketing-on": "2008-05-05", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".2 mg", "route": "oral", "fda-application-number": "NDA021795", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "62756-161_7f3fe422-471d-4136-82ef-8a5c1c9451ef", "ndc-product-code": "62756-161", "dpd-id": null, "started-marketing-on": "2012-04-14", "ended-marketing-on": null, "dosage-form": "solution", "strength": ".1 mg/mL", "route": "nasal", "fda-application-number": "ANDA077212", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "63629-4816_33b4f5b2-d4ed-484b-a190-0b148c71a7ef", "ndc-product-code": "63629-4816", "dpd-id": null, "started-marketing-on": "2011-08-15", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".2 mg", "route": "oral", "fda-application-number": "ANDA076470", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "60505-0815_02785654-305c-82ab-08db-8ce8b0e42440", "ndc-product-code": "60505-0815", "dpd-id": null, "started-marketing-on": "2005-01-27", "ended-marketing-on": null, "dosage-form": "spray", "strength": "10 ug", "route": "nasal", "fda-application-number": "ANDA076703", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "66993-025_73f4ef96-b08d-43ee-9ef2-fc99894c2c00", "ndc-product-code": "66993-025", "dpd-id": null, "started-marketing-on": "2014-01-01", "ended-marketing-on": null, "dosage-form": "spray", "strength": "10 ug/.1mL", "route": "nasal", "fda-application-number": "NDA021333", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "47335-788_65420316-3251-490b-a0ef-e4cfec5cc384", "ndc-product-code": "47335-788", "dpd-id": null, "started-marketing-on": "2013-12-24", "ended-marketing-on": null, "dosage-form": "solution", "strength": ".1 mg/mL", "route": "nasal", "fda-application-number": "ANDA078271", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "68084-084_c1829c84-80f5-4513-af2e-fc7a0476a0ba", "ndc-product-code": "68084-084", "dpd-id": null, "started-marketing-on": "2010-01-12", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".1 mg", "route": "oral", "fda-application-number": "ANDA077414", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Acetate", "ndc-id": "68084-085_c1829c84-80f5-4513-af2e-fc7a0476a0ba", "ndc-product-code": "68084-085", "dpd-id": null, "started-marketing-on": "2010-01-12", "ended-marketing-on": null, "dosage-form": "tablet", "strength": ".2 mg", "route": "oral", "fda-application-number": "ANDA077414", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Desmopressin Spray", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02242465", "started-marketing-on": "2000-08-18", "ended-marketing-on": null, "dosage-form": "spray, metered dose", "strength": "10 mcg", "route": "nasal", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Desmopressin Tablets", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02257696", "started-marketing-on": "2005-02-18", "ended-marketing-on": "2012-08-03", "dosage-form": "tablet", "strength": "0.1 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Desmopressin Tablets", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02257718", "started-marketing-on": "2005-02-18", "ended-marketing-on": "2012-08-03", "dosage-form": "tablet", "strength": "0.2 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Minirin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02238598", "started-marketing-on": "2000-08-21", "ended-marketing-on": "2005-08-02", "dosage-form": "metered-dose aerosol", "strength": "10 mcg", "route": "nasal", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Minirin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02246500", "started-marketing-on": "2003-01-15", "ended-marketing-on": "2015-07-22", "dosage-form": "tablet", "strength": "0.1 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Nocdurna", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02431076", "started-marketing-on": "2014-11-17", "ended-marketing-on": null, "dosage-form": "tablet (orally disintegrating)", "strength": "50 mcg", "route": "sublingual", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Nocdurna", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02397927", "started-marketing-on": "2013-07-31", "ended-marketing-on": null, "dosage-form": "tablet (orally disintegrating)", "strength": "25 mcg", "route": "sublingual", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Nu-desmopressin Spray", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02336154", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "metered-dose pump", "strength": "0.1 g", "route": "nasal", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Octostim Liq Inj. 15mcg/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02024179", "started-marketing-on": "1995-12-31", "ended-marketing-on": null, "dosage-form": "liquid", "strength": "15 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Octostim Spray", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02237860", "started-marketing-on": "1998-12-01", "ended-marketing-on": null, "dosage-form": "spray", "strength": "150 mcg", "route": "nasal", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "PMS-desmopressin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02304368", "started-marketing-on": "2008-01-23", "ended-marketing-on": null, "dosage-form": "tablet", "strength": "0.1 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "PMS-desmopressin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02304376", "started-marketing-on": "2008-01-23", "ended-marketing-on": null, "dosage-form": "tablet", "strength": "0.2 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Stimate", "ndc-id": "0053-6871_288faa68-9d71-441c-8fd0-6b6aeda2070f", "ndc-product-code": "0053-6871", "dpd-id": null, "started-marketing-on": "2011-09-16", "ended-marketing-on": null, "dosage-form": "spray, metered", "strength": "1.5 mg/mL", "route": "nasal", "fda-application-number": "NDA020355", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Teva-desmopressin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02287730", "started-marketing-on": "2007-07-16", "ended-marketing-on": null, "dosage-form": "tablet", "strength": "0.1 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Teva-desmopressin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02287749", "started-marketing-on": "2007-07-16", "ended-marketing-on": null, "dosage-form": "tablet", "strength": "0.2 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": [{"name": "Adiuretin", "company": "Ferring"}, {"name": "DesmoMelt", "company": "Ferring"}]}, "mixtures": {"mixture": [{"name": "Stimate", "ingredients": "Desmopressin"}, {"name": "Ddavp", "ingredients": "Desmopressin"}, {"name": "Ddavp", "ingredients": "Desmopressin"}, {"name": "Ddavp Rhinal Tube", "ingredients": "Desmopressin"}, {"name": "Ddavp", "ingredients": "Desmopressin"}, {"name": "Ddavp", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Ddavp", "ingredients": "Desmopressin"}, {"name": "Ddavp", "ingredients": "Desmopressin"}, {"name": "Ddavp", "ingredients": "Desmopressin"}, {"name": "Ddavp", "ingredients": "Desmopressin"}, {"name": "Ddavp", "ingredients": "Desmopressin"}, {"name": "Ddavp", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Desmopressin Acetate", "ingredients": "Desmopressin"}, {"name": "Ddavp Inj 4mcg/ml", "ingredients": "Desmopressin"}, {"name": "Ddavp Rhinyle", "ingredients": "Desmopressin"}, {"name": "Octostim Liq Inj. 15mcg/ml", "ingredients": "Desmopressin"}, {"name": "Ddavp Tablets 0.1mg", "ingredients": "Desmopressin"}, {"name": "Ddavp Tablets 0.2mg", "ingredients": "Desmopressin"}, {"name": "Octostim Spray", "ingredients": "Desmopressin"}, {"name": "Desmopressin Spray", "ingredients": "Desmopressin"}, {"name": "Apo-desmopressin", "ingredients": "Desmopressin"}, {"name": "Apo-desmopressin", "ingredients": "Desmopressin"}, {"name": "Ddavp Melt", "ingredients": "Desmopressin"}, {"name": "Ddavp Melt", "ingredients": "Desmopressin"}, {"name": "Ddavp Melt", "ingredients": "Desmopressin"}, {"name": "Teva-desmopressin", "ingredients": "Desmopressin"}, {"name": "Teva-desmopressin", "ingredients": "Desmopressin"}, {"name": "PMS-desmopressin", "ingredients": "Desmopressin"}, {"name": "PMS-desmopressin", "ingredients": "Desmopressin"}, {"name": "Nocdurna", "ingredients": "Desmopressin"}, {"name": "Nocdurna", "ingredients": "Desmopressin"}, {"name": "Ddavp Spray", "ingredients": "Desmopressin"}, {"name": "Minirin", "ingredients": "Desmopressin"}, {"name": "Minirin", "ingredients": "Desmopressin"}, {"name": "Desmopressin Tablets", "ingredients": "Desmopressin"}, {"name": "Desmopressin Tablets", "ingredients": "Desmopressin"}, {"name": "Desmopressin", "ingredients": "Desmopressin"}, {"name": "Desmopressin", "ingredients": "Desmopressin"}, {"name": "Nu-desmopressin Spray", "ingredients": "Desmopressin"}]}, "packagers": {"packager": [{"name": "Amerisource Health Services Corp.", "url": "http://www.amerisourcebergen.com"}, {"name": "Apotex Inc.", "url": "http://www.apotex.com"}, {"name": "Arcola Laboratories", "url": null}, {"name": "Bachem Inc.", "url": "http://www.bachem.com"}, {"name": "Barr Pharmaceuticals", "url": null}, {"name": "Bausch & Lomb Inc.", "url": "http://www.bausch.com"}, {"name": "CSL Behring LLC", "url": "http://www.cslbehring.com"}, {"name": "Ferring Pharmaceuticals Inc.", "url": "http://www.ferring.com"}, {"name": "Hospira Inc.", "url": "http://www.hospira.com"}, {"name": "Kaiser Foundation Hospital", "url": null}, {"name": "Pharmacy Service Center", "url": null}, {"name": "Physicians Total Care Inc.", "url": "http://www.physicianstotalcare.com"}, {"name": "Promex Medical Inc.", "url": null}, {"name": "Rechon Life Science AB", "url": "http://www.rechon.com"}, {"name": "Sanofi-Aventis Inc.", "url": "http://www.sanofi-aventis.com"}, {"name": "Sicor Pharmaceuticals", "url": null}, {"name": "Sun Pharmaceutical Industries Ltd.", "url": "http://www.sunpharma.com"}, {"name": "Teva Pharmaceutical Industries Ltd.", "url": "http://www.tevapharm.com"}, {"name": "UDL Laboratories", "url": "http://www.udllabs.com"}, {"name": "Watson Pharmaceuticals", "url": "http://www.watson.com"}]}, "manufacturers": {"manufacturer": [{"@generic": "false", "#text": "Sanofi aventis us llc"}, {"@generic": "true", "#text": "Bedford laboratories div ben venue laboratories inc"}, {"@generic": "true", "#text": "Hospira inc"}, {"@generic": "true", "#text": "Teva parenteral medicines inc"}, {"@generic": "false", "#text": "Ferring pharmaceuticals inc"}, {"@generic": "true", "#text": "Bausch and lomb pharmaceuticals inc"}, {"@generic": "false", "#text": "Apotex inc richmond hill"}, {"@generic": "false", "#text": "Csl behring llc"}, {"@generic": "true", "#text": "Apotex inc etobicoke site"}, {"@generic": "true", "#text": "Teva pharmaceuticals usa"}, {"@generic": "true", "#text": "Watson laboratories inc"}]}, "prices": {"price": [{"description": "Apo-Desmopressin 10 mcg/dose Metered Dose Spray", "cost": {"@currency": "USD", "#text": "1.48"}, "unit": "dose"}, {"description": "Ddavp 0.1 mg Tablet", "cost": {"@currency": "USD", "#text": "1.49"}, "unit": "tablet"}, {"description": "Apo-Desmopressin 0.2 mg Tablet", "cost": {"@currency": "USD", "#text": "1.67"}, "unit": "tablet"}, {"description": "Novo-Desmopressin 0.2 mg Tablet", "cost": {"@currency": "USD", "#text": "1.67"}, "unit": "tablet"}, {"description": "Pms-Desmopressin 0.2 mg Tablet", "cost": {"@currency": "USD", "#text": "1.67"}, "unit": "tablet"}, {"description": "Ddavp 10 mcg/dose Metered Dose Spray", "cost": {"@currency": "USD", "#text": "2.13"}, "unit": "dose"}, {"description": "Ddavp 0.2 mg Tablet", "cost": {"@currency": "USD", "#text": "2.98"}, "unit": "tablet"}, {"description": "Desmopressin acetate 0.1 mg tablet", "cost": {"@currency": "USD", "#text": "3.08"}, "unit": "tablet"}, {"description": "Desmopressin acetate 0.2 mg tablet", "cost": {"@currency": "USD", "#text": "4.44"}, "unit": "tablet"}, {"description": "Ddavp 0.1 mg tablet", "cost": {"@currency": "USD", "#text": "4.47"}, "unit": "tablet"}, {"description": "Ddavp 0.2 mg tablet", "cost": {"@currency": "USD", "#text": "6.43"}, "unit": "tablet"}, {"description": "Desmopressin ac 4 mcg/ml vial", "cost": {"@currency": "USD", "#text": "7.08"}, "unit": "ml"}, {"description": "Desmopressin ac 4 mcg/ml amp", "cost": {"@currency": "USD", "#text": "7.28"}, "unit": "ml"}, {"description": "Ddavp 4 mcg/ml", "cost": {"@currency": "USD", "#text": "11.33"}, "unit": "ml"}, {"description": "Octostim 150 mcg/dose Metered Dose Spray", "cost": {"@currency": "USD", "#text": "17.39"}, "unit": "dose"}, {"description": "Ddavp 0.1 mg/ml Solution", "cost": {"@currency": "USD", "#text": "21.26"}, "unit": "ml"}, {"description": "Desmopressin 0.1 mg/ml spray", "cost": {"@currency": "USD", "#text": "39.6"}, "unit": "ml"}, {"description": "Ddavp 4 mcg/ml ampul", "cost": {"@currency": "USD", "#text": "43.27"}, "unit": "ml"}, {"description": "Ddavp 0.01% nasal spray", "cost": {"@currency": "USD", "#text": "50.76"}, "unit": "ml"}, {"description": "Stimate 1.5 mg/ml nasal spray", "cost": {"@currency": "USD", "#text": "334.2"}, "unit": "ml"}, {"description": "Apo-Desmopressin 0.1 mg Tablet", "cost": {"@currency": "USD", "#text": "0.83"}, "unit": "tablet"}, {"description": "Novo-Desmopressin 0.1 mg Tablet", "cost": {"@currency": "USD", "#text": "0.83"}, "unit": "tablet"}, {"description": "Pms-Desmopressin 0.1 mg Tablet", "cost": {"@currency": "USD", "#text": "0.83"}, "unit": "tablet"}]}, "categories": {"category": [{"category": "Antidiuretic Agents", "mesh-id": null}, {"category": "Hemostatics", "mesh-id": null}, {"category": "Renal Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Solution", "route": "intravenous", "strength": "4 ug/mL"}, {"form": "Spray", "route": "nasal", "strength": ".1 ug/mL"}, {"form": "Tablet", "route": "oral", "strength": ".1 mg"}, {"form": "Tablet", "route": "oral", "strength": ".2 mg"}, {"form": "Liquid", "route": "intramuscular; intravenous; subcutaneous", "strength": "4 mcg"}, {"form": "Tablet (orally disintegrating)", "route": "sublingual", "strength": "120 mcg"}, {"form": "Tablet (orally disintegrating)", "route": "sublingual", "strength": "240 mcg"}, {"form": "Tablet (orally disintegrating)", "route": "sublingual", "strength": "60 mcg"}, {"form": "Solution", "route": "nasal", "strength": ".1 mg/mL"}, {"form": "Solution", "route": "nasal", "strength": "0.1 mg"}, {"form": "Metered-dose aerosol", "route": "nasal", "strength": "10 mcg"}, {"form": "Tablet", "route": "oral", "strength": "0.1 mg"}, {"form": "Tablet", "route": "oral", "strength": "0.2 mg"}, {"form": "Injection", "route": "intravenous", "strength": "4 ug/mL"}, {"form": "Injection, solution", "route": "intravenous; subcutaneous", "strength": "4 ug/mL"}, {"form": "Spray", "route": "nasal", "strength": "10 ug"}, {"form": "Spray", "route": "nasal", "strength": "10 ug/.1mL"}, {"form": "Spray, metered dose", "route": "nasal", "strength": "10 mcg"}, {"form": "Tablet (orally disintegrating)", "route": "sublingual", "strength": "25 mcg"}, {"form": "Tablet (orally disintegrating)", "route": "sublingual", "strength": "50 mcg"}, {"form": "Metered-dose pump", "route": "nasal", "strength": "0.1 g"}, {"form": "Liquid", "route": "intravenous; subcutaneous", "strength": "15 mcg"}, {"form": "Spray", "route": "nasal", "strength": "150 mcg"}, {"form": "Spray, metered", "route": "nasal", "strength": "1.5 mg/mL"}]}, "atc-codes": {"atc-code": {"@code": "H01BA02", "level": [{"@code": "H", "#text": "SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS"}, {"@code": "H01", "#text": "PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES"}, {"@code": "H01B", "#text": "POSTERIOR PITUITARY LOBE HORMONES"}, {"@code": "H01BA", "#text": "Vasopressin and analogues"}]}}, "ahfs-codes": {"ahfs-code": "68:28.00"}, "patents": {"patent": [{"number": "2484724", "country": "Canada", "approved": "2007-01-16", "expires": "2023-05-07"}, {"number": "2486833", "country": "Canada", "approved": "2005-08-02", "expires": "2024-04-30"}, {"number": "5500413", "country": "United States", "approved": "1993-06-29", "expires": "2013-06-29"}, {"number": "7022340", "country": "United States", "approved": "2003-04-30", "expires": "2023-04-30"}]}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00802", "name": "Alfentanil", "description": "Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00321", "name": "Amitriptyline", "description": "Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00543", "name": "Amoxapine", "description": "Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00921", "name": "Buprenorphine", "description": "Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00611", "name": "Butorphanol", "description": "Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00564", "name": "Carbamazepine", "description": "May enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00482", "name": "Celecoxib", "description": "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00477", "name": "Chlorpromazine", "description": "May enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00215", "name": "Citalopram", "description": "Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB01242", "name": "Clomipramine", "description": "Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00318", "name": "Codeine", "description": "Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00618", "name": "Demeclocycline", "description": "May diminish the therapeutic effect of Desmopressin."}, {"drugbank-id": "DB01151", "name": "Desipramine", "description": "Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00586", "name": "Diclofenac", "description": "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00861", "name": "Diflunisal", "description": "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB01551", "name": "Dihydrocodeine", "description": "Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB01142", "name": "Doxepin", "description": "Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB01175", "name": "Escitalopram", "description": "Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00749", "name": "Etodolac", "description": "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00573", "name": "Fenoprofen", "description": "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00813", "name": "Fentanyl", "description": "Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB08976", "name": "Floctafenine", "description": "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00472", "name": "Fluoxetine", "description": "Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00712", "name": "Flurbiprofen", "description": "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00176", "name": "Fluvoxamine", "description": "Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00956", "name": "Hydrocodone", "description": "Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00327", "name": "Hydromorphone", "description": "Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB01050", "name": "Ibuprofen", "description": "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00458", "name": "Imipramine", "description": "Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00328", "name": "Indomethacin", "description": "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB01009", "name": "Ketoprofen", "description": "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00465", "name": "Ketorolac", "description": "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00555", "name": "Lamotrigine", "description": "May enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00854", "name": "Levorphanol", "description": "Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB01356", "name": "Lithium", "description": "May diminish the therapeutic effect of Desmopressin. Desmopressin may increase the serum concentration of Lithium."}, {"drugbank-id": "DB00784", "name": "Mefenamic acid", "description": "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00814", "name": "Meloxicam", "description": "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00333", "name": "Methadone", "description": "Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00295", "name": "Morphine", "description": "Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00461", "name": "Nabumetone", "description": "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00844", "name": "Nalbuphine", "description": "Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00788", "name": "Naproxen", "description": "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00540", "name": "Nortriptyline", "description": "Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00991", "name": "Oxaprozin", "description": "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00497", "name": "Oxycodone", "description": "Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB01192", "name": "Oxymorphone", "description": "Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00715", "name": "Paroxetine", "description": "Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00652", "name": "Pentazocine", "description": "Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00454", "name": "Pethidine", "description": "Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00554", "name": "Piroxicam", "description": "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00420", "name": "Promazine", "description": "ChlorPromazine may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00344", "name": "Protriptyline", "description": "Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00899", "name": "Remifentanil", "description": "Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB01104", "name": "Sertraline", "description": "Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00708", "name": "Sufentanil", "description": "Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00605", "name": "Sulindac", "description": "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB06204", "name": "Tapentadol", "description": "Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB01600", "name": "Tiaprofenic acid", "description": "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00500", "name": "Tolmetin", "description": "Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB06212", "name": "Tolvaptan", "description": "May diminish the therapeutic effect of Desmopressin."}, {"drugbank-id": "DB00193", "name": "Tramadol", "description": "Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB00726", "name": "Trimipramine", "description": "Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB06684", "name": "Vilazodone", "description": "Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin."}, {"drugbank-id": "DB09068", "name": "Vortioxetine", "description": "Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin."}]}, "calculated-properties": {"property": [{"kind": "logP", "value": "-1", "source": "ALOGPS"}, {"kind": "logS", "value": "-4", "source": "ALOGPS"}, {"kind": "Water Solubility", "value": "1.10e-01 g/l", "source": "ALOGPS"}, {"kind": "logP", "value": "-6.1", "source": "ChemAxon"}, {"kind": "IUPAC Name", "value": "(2S)-2-{[(2S)-1-[(4R,7S,10S,13S,16S)-13-benzyl-10-(2-carbamoylethyl)-7-(carbamoylmethyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl]pyrrolidin-2-yl]formamido}-5-carbamimidamido-N-(carbamoylmethyl)pentanamide", "source": "ChemAxon"}, {"kind": "Traditional IUPAC Name", "value": "desmopressin", "source": "ChemAxon"}, {"kind": "Molecular Weight", "value": "1069.217", "source": "ChemAxon"}, {"kind": "Monoisotopic Weight", "value": "1068.426954962", "source": "ChemAxon"}, {"kind": "SMILES", "value": "NC(=O)CC[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O", "source": "ChemAxon"}, {"kind": "Molecular Formula", "value": "C46H64N14O12S2", "source": "ChemAxon"}, {"kind": "InChI", "value": "InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29-,30-,31-,32-,33-,34-/m0/s1", "source": "ChemAxon"}, {"kind": "InChIKey", "value": "InChIKey=NFLWUMRGJYTJIN-NXBWRCJVSA-N", "source": "ChemAxon"}, {"kind": "Polar Surface Area (PSA)", "value": "435.41", "source": "ChemAxon"}, {"kind": "Refractivity", "value": "279.78", "source": "ChemAxon"}, {"kind": "Polarizability", "value": "106.19", "source": "ChemAxon"}, {"kind": "Rotatable Bond Count", "value": "19", "source": "ChemAxon"}, {"kind": "H Bond Acceptor Count", "value": "15", "source": "ChemAxon"}, {"kind": "H Bond Donor Count", "value": "14", "source": "ChemAxon"}, {"kind": "pKa (strongest acidic)", "value": "9.5", "source": "ChemAxon"}, {"kind": "pKa (strongest basic)", "value": "11.77", "source": "ChemAxon"}, {"kind": "Physiological Charge", "value": "1", "source": "ChemAxon"}, {"kind": "Number of Rings", "value": "4", "source": "ChemAxon"}, {"kind": "Bioavailability", "value": "0", "source": "ChemAxon"}, {"kind": "Rule of Five", "value": "0", "source": "ChemAxon"}, {"kind": "Ghose Filter", "value": "0", "source": "ChemAxon"}, {"kind": "MDDR-Like Rule", "value": "1", "source": "ChemAxon"}]}, "experimental-properties": {"property": {"kind": "logP", "value": "-4.2", "source": null}}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "2155"}, {"resource": "Drugs Product Database (DPD)", "identifier": "19910"}, {"resource": "Drugs Product Database (DPD)", "identifier": "20181"}, {"resource": "ChEBI", "identifier": "4450"}, {"resource": "KEGG Compound", "identifier": "C06944"}, {"resource": "KEGG Drug", "identifier": "D00291"}, {"resource": "National Drug Code Directory", "identifier": "55566-5020-1"}, {"resource": "PharmGKB", "identifier": "PA449237"}, {"resource": "Wikipedia", "identifier": "Desmopressin"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/desmoprt.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/desmopressin.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000293", "name": "Vasopressin V2 receptor", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Del Tredici AL, Vanover KE, Knapp AE, Bertozzi SM, Nash NR, Burstein ES, Lameh J, Currier EA, Davis RE, Brann MR, Mohell N, Olsson R, Piu F: Identification of novel selective V2 receptor non-peptide agonists. Biochem Pharmacol. 2008 Oct 30;76(9):1134-41. Epub 2008 Aug 12. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18761325\n# Slusarz MJ, Slusarz R, Ciarkowski J: Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system. Biopolymers. 2006 Apr 5;81(5):321-38. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16333859\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P30518", "@source": "Swiss-Prot", "name": "Vasopressin V2 receptor", "general-function": "Involved in rhodopsin-like receptor activity", "specific-function": "Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate adenylate cyclase", "gene-name": "AVPR2", "locus": "Xq28", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "39-63\n78-98\n114-135\n160-180\n201-220\n272-293\n309-328", "signal-regions": null, "theoretical-pi": "9.41", "molecular-weight": "40279.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:897"}, {"resource": "GenAtlas", "identifier": "AVPR2"}, {"resource": "GeneCards", "identifier": "AVPR2"}, {"resource": "GenBank Gene Database", "identifier": "U04357"}, {"resource": "GenBank Protein Database", "identifier": "28418"}, {"resource": "IUPHAR", "identifier": "368"}, {"resource": "Guide to Pharmacology", "identifier": "66"}, {"resource": "UniProtKB", "identifier": "P30518"}, {"resource": "UniProt Accession", "identifier": "V2R_HUMAN"}]}, "synonyms": {"synonym": ["Antidiuretic hormone receptor", "AVPR V2", "Renal-type arginine vasopressin receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Vasopressin V2 receptor\nMLMASTTSAVPGHPSLPSLPSNSSQERPLDTRDPLLARAELALLSIVFVAVALSNGLVLA\nALARRGRRGHWAPIHVFIGHLCLADLAVALFQVLPQLAWKATDRFRGPDALCRAVKYLQM\nVGMYASSYMILAMTLDRHRAICRPMLAYRHGSGAHWNRPVLVAWAFSLLLSLPQLFIFAQ\nRNVEGGSGVTDCWACFAEPWGRRTYVTWIALMVFVAPTLGIAACQVLIFREIHASLVPGP\nSERPGGRRRGRRTGSPGEGAHVSAAVAKTVRMTLVIVVVYVLCWAPFFLVQLWAAWDPEA\nPLEGAPFVLLMLLASLNSCTNPWIYASFSSSVSSELRSLLCCARGRTPPSLGPQDESCTT\nASSSLAKDTSS"}, "gene-sequence": {"@format": "FASTA", "#text": ">1116 bp\nATGCTCATGGCGTCCACCACTTCCGCTGTGCCTGGGCATCCCTCTCTGCCCAGCCTGCCC\nAGCAACAGCAGCCAGGAGAGGCCACTGGACACCCGGGACCCGCTGCTAGCCCGGGCGGAG\nCTGGCGCTGCTCTCCATAGTCTTTGTGGCTGTGGCCCTGAGCAATGGCCTGGTGCTGGCG\nGCCCTAGCTCGGCGGGGCCGGCGGGGCCACTGGGCACCCATACACGTCTTCATTGGCCAC\nTTGTGCCTGGCCGACCTGGCCGTGGCTCTGTTCCAAGTGCTGCCCCAGCTGGCCTGGAAG\nGCCACCGACCGCTTCCGTGGGCCAGATGCCCTGTGTCGGGCCGTGAAGTATCTGCAGATG\nGTGGGCATGTATGCCTCCTCCTACATGATCCTGGCCATGACGCTGGACCGCCACCGTGCC\nATCTGCCGTCCCATGCTGGCGTACCGCCATGGAAGTGGGGCTCACTGGAACCGGCCGGTG\nCTAGTGGCTTGGGCCTTCTCGCTCCTTCTCAGCCTGCCCCAGCTCTTCATCTTCGCCCAG\nCGCAACGTGGAAGGTGGCAGCGGGGTCACTGACTGCTGGGCCTGCTTTGCGGAGCCCTGG\nGGCCGTCGCACCTATGTCACCTGGATTGCCCTGATGGTGTTCGTGGCACCTACCCTGGGT\nATCGCCGCCTGCCAGGTGCTCATCTTCCGGGAGATTCATGCCAGTCTGGTGCCAGGGCCA\nTCAGAGAGGCCTGGGGGGCGCCGCAGGGGACGCCGGACAGGCAGCCCCGGTGAGGGAGCC\nCACGTGTCAGCAGCTGTGGCCAAGACTGTGAGGATGACGCTAGTGATTGTGGTCGTCTAT\nGTGCTGTGCTGGGCACCCTTCTTCCTGGTGCAGCTGTGGGCCGCGTGGGACCCGGAGGCA\nCCTCTGGAAGGGGCGCCCTTTGTGCTACTCATGTTGCTGGCCAGCCTCAACAGCTGCACC\nAACCCCTGGATCTATGCATCTTTCAGCAGCAGCGTGTCCTCAGAGCTGCGAAGCTTGCTC\nTGCTGTGCCCGGGGACGCACCCCACCCAGCCTGGGTCCCCAAGATGAGTCCTGCACCACC\nGCCAGCTCCTCCCTGGCCAAGGACACTTCATCGTGA"}, "pfams": {"pfam": {"identifier": "PF00001", "name": "7tm_1"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "function", "description": "peptide receptor activity, G-protein coupled"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "vasopressin-like receptor activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "vasopressin receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}]}}}, {"@position": "2", "id": "BE0000165", "name": "Vasopressin V1a receptor", "organism": "Human", "actions": null, "references": "# Loichot C, Cazaubon C, De Jong W, Helwig JJ, Nisato D, Imbs JL, Barthelmebs M: Nitric oxide, but not vasopressin V2 receptor-mediated vasodilation, modulates vasopressin-induced renal vasoconstriction in rats. Naunyn Schmiedebergs Arch Pharmacol. 2000 Mar;361(3):319-26. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10731046\n# Mechaly I, Laurent F, Portet K, Serrano J, Cros G: Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol. 1999 Nov 3;383(3):287-90. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10594321\n# Barthelmebs M, Krieger JP, Grima M, Nisato D, Imbs JL: Vascular effects of [Arg8]vasopressin in the isolated perfused rat kidney. Eur J Pharmacol. 1996 Oct 31;314(3):325-32. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8957254\n# Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004 Dec;11(4):871-85. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15613460", "known-action": "yes", "polypeptide": {"@id": "P37288", "@source": "Swiss-Prot", "name": "Vasopressin V1a receptor", "general-function": "Involved in rhodopsin-like receptor activity", "specific-function": "Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl- inositol-calcium second messenger system. Has been involved in social behaviors, including affiliation and attachment", "gene-name": "AVPR1A", "locus": "12q14-q15", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "53-76\n89-110\n126-147\n169-190\n219-239\n294-313\n332-351", "signal-regions": null, "theoretical-pi": "9.67", "molecular-weight": "46800.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:895"}, {"resource": "GenAtlas", "identifier": "AVPR1A"}, {"resource": "GeneCards", "identifier": "AVPR1A"}, {"resource": "GenBank Gene Database", "identifier": "L25615"}, {"resource": "GenBank Protein Database", "identifier": "667068"}, {"resource": "IUPHAR", "identifier": "366"}, {"resource": "Guide to Pharmacology", "identifier": "66"}, {"resource": "UniProtKB", "identifier": "P37288"}, {"resource": "UniProt Accession", "identifier": "V1AR_HUMAN"}]}, "synonyms": {"synonym": ["Antidiuretic hormone receptor 1a", "AVPR V1a", "V1aR", "Vascular/hepatic-type arginine vasopressin receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Vasopressin V1a receptor\nMRLSAGPDAGPSGNSSPWWPLATGAGNTSREAEALGEGNGPPRDVRNEELAKLEIAVLAV\nTFAVAVLGNSSVLLALHRTPRKTSRMHLFIRHLSLADLAVAFFQVLPQMCWDITYRFRGP\nDWLCRVVKHLQVFGMFASAYMLVVMTADRYIAVCHPLKTLQQPARRSRLMIAAAWVLSFV\nLSTPQYFVFSMIEVNNVTKARDCWATFIQPWGSRAYVTWMTGGIFVAPVVILGTCYGFIC\nYNIWCNVRGKTASRQSKGAEQAGVAFQKGFLLAPCVSSVKSISRAKIRTVKMTFVIVTAY\nIVCWAPFFIIQMWSVWDPMSVWTESENPTITITALLGSLNSCCNPWIYMFFSGHLLQDCV\nQSFPCCQNMKEKFNKEDTDSMSRRQTFYSNNRSPTNSTGMWKDSPKSSKSIKFIPVST"}, "gene-sequence": {"@format": "FASTA", "#text": ">1257 bp\nATGCGTCTCTCCGCCGGTCCCGACGCGGGGCCCTCGGGCAACTCCAGCCCATGGTGGCCT\nCTGGCCACCGGCGCTGGCAACACAAGCCGGGAGGCCGAAGCCCTCGGGGAGGGCAACGGC\nCCACCGAGGGACGTGCGCAACGAGGAGCTGGCCAAACTGGAGATCGCCGTGCTGGCGGTG\nACTTTCGCGGTGGCCGTGCTGGGCAACAGCAGCGTACTGCTGGCTCTGCACCGGACGCCG\nCGCAAGACGTCCCGCATGCACCTCTTCATCCGACACCTCAGCCTGGCCGACCTGGCCGTG\nGCATTCTTCCAGGTGCTGCCGCAAATGTGCTGGGACATCACCTACCGCTTCCGCGGCCCC\nGACTGGCTGTGCCGCGTGGTGAAGCACCTGCAGGTGTTCGGCATGTTTGCGTCGGCCTAC\nATGCTGGTAGTCATGACAGCCGACCGCTACATCGCGGTGTGCCACCCGCTCAAGACTCTG\nCAACAGCCCGCGCGCCGCTCGCGCCTCATGATCGCGGCCGCCTGGGTGCTGAGCTTCGTG\nCTGAGCACGCCGCAGTACTTCGTCTTCTCCATGATCGAGGTGAACAATGTCACCAAGGCC\nCGCGACTGCTGGGCCACCTTCATCCAGCCCTGGGGTTCTCGTGCCTACGTGACCTGGATG\nACGGGCGGCATCTTTGTGGCGCCCGTGGTCATCTTGGGTACCTGCTACGGCTTCATCTGC\nTACAACATCTGGTGCAACGTCCGCGGGAAGACGGCGTCGCGCCAGAGCAAGGGTGCAGAG\nCAAGCGGGTGTGGCCTTCCAAAAGGGGTTCCTGCTCGCACCCTGTGTCAGCAGCGTGAAG\nTCCATTTCCCGGGCCAAGATCCGCACGGTGAAGATGACTTTTGTGATCGTGACGGCTTAC\nATCGTCTGCTGGGCGCCTTTCTTCATCATCCAGATGTGGTCTGTCTGGGATCCCATGTCC\nGTCTGGACCGAATCGGAAAACCCTACCATCACCATCACTGCATTACTGGGTTCCTTGAAT\nAGCTGCTGTAATCCCTGGATATACATGTTTTTTAGTGGCCATCTCCTTCAAGACTGTGTT\nCAAAGCTTCCCATGCTGCCAAAACATGAAGGAAAAATTCAACAAAGAAGATACTGACAGT\nATGAGCAGAAGACAGACTTTTTATTCTAACAATCGAAGCCCAACAAACAGTACGGGTATG\nTGGAAGGACTCGCCTAAATCTTCCAAGTCCATCAAATTCATTCCTGTTTCAACTTGA"}, "pfams": {"pfam": {"identifier": "PF00001", "name": "7tm_1"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "function", "description": "peptide receptor activity, G-protein coupled"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "vasopressin-like receptor activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "vasopressin receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}]}}}, {"@position": "3", "id": "BE0000773", "name": "Vasopressin V1b receptor", "organism": "Human", "actions": null, "references": "# Pequeux C, Keegan BP, Hagelstein MT, Geenen V, Legros JJ, North WG: Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr Relat Cancer. 2004 Dec;11(4):871-85. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15613460\n# Dinan TG, O'Brien S, Lavelle E, Scott LV: Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression. Psychol Med. 2004 Jan;34(1):169-72. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14971638\n# Craighead M, Milne R, Campbell-Wan L, Watson L, Presland J, Thomson FJ, Marston HM, Macsweeney CP: Characterization of a novel and selective V1B receptor antagonist. Prog Brain Res. 2008;170:527-35. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18655906", "known-action": "yes", "polypeptide": {"@id": "P47901", "@source": "Swiss-Prot", "name": "Vasopressin V1b receptor", "general-function": "Involved in rhodopsin-like receptor activity", "specific-function": "Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl- inositol-calcium second messenger system", "gene-name": "AVPR1B", "locus": "1q32", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "36-59\n72-93\n109-130\n152-173\n202-222\n284-303\n322-341", "signal-regions": null, "theoretical-pi": "9.05", "molecular-weight": "46971.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:896"}, {"resource": "GenAtlas", "identifier": "AVPR1B"}, {"resource": "GeneCards", "identifier": "AVPR1B"}, {"resource": "GenBank Gene Database", "identifier": "D31833"}, {"resource": "GenBank Protein Database", "identifier": "563982"}, {"resource": "IUPHAR", "identifier": "367"}, {"resource": "Guide to Pharmacology", "identifier": "66"}, {"resource": "UniProtKB", "identifier": "P47901"}, {"resource": "UniProt Accession", "identifier": "V1BR_HUMAN"}]}, "synonyms": {"synonym": ["Antidiuretic hormone receptor 1b", "AVPR V1b", "AVPR V3", "V1bR", "Vasopressin V3 receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Vasopressin V1b receptor\nMDSGPLWDANPTPRGTLSAPNATTPWLGRDEELAKVEIGVLATVLVLATGGNLAVLLTLG\nQLGRKRSRMHLFVLHLALTDLAVALFQVLPQLLWDITYRFQGPDLLCRAVKYLQVLSMFA\nSTYMLLAMTLDRYLAVCHPLRSLQQPGQSTYLLIAAPWLLAAIFSLPQVFIFSLREVIQG\nSGVLDCWADFGFPWGPRAYLTWTTLAIFVLPVTMLTACYSLICHEICKNLKVKTQAWRVG\nGGGWRTWDRPSPSTLAATTRGLPSRVSSINTISRAKIRTVKMTFVIVLAYIACWAPFFSV\nQMWSVWDKNAPDEDSTNVAFTISMLLGNLNSCCNPWIYMGFNSHLLPRPLRHLACCGGPQ\nPRMRRRLSDGSLSSRHTTLLTRSSCPATLSLSLSLTLSGRPRPEESPRDLELADGEGTAE\nTIIF"}, "gene-sequence": {"@format": "FASTA", "#text": ">1275 bp\nATGGATTCTGGGCCTCTGTGGGATGCCAACCCCACCCCTCGGGGCACCCTCTCTGCCCCC\nAATGCCACAACACCCTGGCTGGGCCGGGATGAGGAGCTGGCCAAGGTGGAGATCGGAGTC\nCTGGCCACTGTCCTGGTGCTGGCGACCGGGGGCAACCTGGCTGTGCTGCTGACCCTGGGC\nCAGCTGGGCCGCAAGCGCTCCCGCATGCACCTGTTCGTGCTGCACTTAGCCCTGACAGAC\nCTGGCCGTGGCGCTCTTCCAGGTGCTGCCACAGCTGCTGTGGGACATCACCTACCGCTTC\nCAGGGCCCCGACCTCCTGTGCAGGGCCGTCAAGTACCTGCAGGTGCTCAGCATGTTTGCC\nTCCACCTACATGCTGCTGGCCATGACGCTGGACCGCTACCTGGCTGTCTGTCACCCCCTG\nCGCAGCCTCCAGCAGCCAGGCCAGTCCACCTACCTGCTCATCGCTGCTCCCTGGCTGCTG\nGCCGCCATCTTCAGCCTCCCTCAAGTCTTCATTTTTTCCCTGCGGGAGGTGATCCAGGGC\nTCAGGGGTGCTGGACTGCTGGGCAGACTTCGGCTTCCCTTGGGGGCCACGGGCCTACCTC\nACCTGGACCACCCTGGCTATCTTCGTTCTGCCGGTGACCATGCTCACGGCCTGCTACAGC\nCTCATCTGCCATGAGATCTGTAAAAACCTAAAAGTCAAGACACAGGCCTGGCGGGTGGGA\nGGAGGGGGCTGGAGGACTTGGGACAGGCCCTCACCTTCCACCTTAGCTGCCACCACTCGG\nGGGCTGCCATCTCGGGTCAGCAGCATCAACACCATCTCACGGGCCAAGATCCGAACAGTG\nAAGATGACCTTTGTCATCGTGCTGGCCTACATCGCTTGCTGGGCTCCCTTCTTCAGTGTC\nCAGATGTGGTCCGTGTGGGACAAGAATGCCCCTGATGAAGATTCCACCAATGTGGCTTTC\nACCATCTCTATGCTTTTGGGCAACCTCAACAGCTGCTGCAACCCCTGGATCTACATGGGC\nTTCAACAGCCACCTGTTACCGCGGCCCCTGCGTCACCTTGCCTGCTGTGGGGGTCCCCAG\nCCCAGGATGCGCCGGCGGCTCTCCGACGGCAGCCTCTCGAGCCGCCACACCACGCTGCTG\nACCCGCTCCAGCTGCCCGGCCACCCTCAGCCTCAGCCTCAGCCTAACCCTCAGTGGGAGG\nCCCAGGCCTGAAGAGTCACCAAGGGACTTGGAGCTGGCAGATGGGGAAGGCACCGCTGAG\nACCATCATCTTTTAG"}, "pfams": {"pfam": {"identifier": "PF00001", "name": "7tm_1"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "function", "description": "peptide receptor activity, G-protein coupled"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "vasopressin-like receptor activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "vasopressin receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}]}}}]}, "enzymes": {"enzyme": [{"@position": "4", "id": "BE0000017", "name": "Prostaglandin G/H synthase 1", "organism": "Human", "actions": {"action": "inducer"}, "references": "# Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, Nielsen S: Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol. 2005 May;288(5):F1053-68. Epub 2005 Jan 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15644490", "known-action": "unknown", "polypeptide": {"@id": "P23219", "@source": "Swiss-Prot", "name": "Prostaglandin G/H synthase 1", "general-function": "Involved in peroxidase activity", "specific-function": "May play an important role in regulating or promoting cell proliferation in some normal and neoplastically transformed cells", "gene-name": "PTGS1", "locus": "9q32-q33.3", "cellular-location": "Microsome; microsomal membrane; peripheral membrane protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.39", "molecular-weight": "68657.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9604"}, {"resource": "GenAtlas", "identifier": "PTGS1"}, {"resource": "GeneCards", "identifier": "PTGS1"}, {"resource": "GenBank Gene Database", "identifier": "M31822"}, {"resource": "GenBank Protein Database", "identifier": "387018"}, {"resource": "UniProtKB", "identifier": "P23219"}, {"resource": "UniProt Accession", "identifier": "PGH1_HUMAN"}]}, "synonyms": {"synonym": ["COX-1", "Cyclooxygenase- 1", "EC 1.14.99.1", "PGH synthase 1", "PGHS-1", "PHS 1", "Prostaglandin G/H synthase 1 precursor", "Prostaglandin H2 synthase 1", "Prostaglandin-endoperoxide synthase 1"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Prostaglandin G/H synthase 1 precursor\nMSRSLLLRFLLFLLLLPPLPVLLADPGAPTPVNPCCYYPCQHQGICVRFGLDRYQCDCTR\nTGYSGPNCTIPGLWTWLRNSLRPSPSFTHFLLTHGRWFWEFVNATFIREMLMRLVLTVRS\nNLIPSPPTYNSAHDYISWESFSNVSYYTRILPSVPKDCPTPMGTKGKKQLPDAQLLARRF\nLLRRKFIPDPQGTNLMFAFFAQHFTHQFFKTSGKMGPGFTKALGHGVDLGHIYGDNLERQ\nYQLRLFKDGKLKYQVLDGEMYPPSVEEAPVLMHYPRGIPPQSQMAVGQEVFGLLPGLMLY\nATLWLREHNRVCDLLKAEHPTWGDEQLFQTTRLILIGETIKIVIEEYVQQLSGYFLQLKF\nDPELLFGVQFQYRNRIAMEFNHLYHWHPLMPDSFKVGSQEYSYEQFLFNTSMLVDYGVEA\nLVDAFSRQIAGRIGGGRNMDHHILHVAVDVIRESREMRLQPFNEYRKRFGMKPYTSFQEL\nVGEKEMAAELEELYGDIDALEFYPGLLLEKCHPNSIFGESMIEIGAPFSLKGLLGNPICS\nPEYWKPSTFGGEVGFNIVKTATLKKLVCLNTKTCPYVSFRVPDASQDDGPAVERPSTEL"}, "gene-sequence": {"@format": "FASTA", "#text": ">1800 bp\nATGAGCCGGAGTCTCTTGCTCCGGTTCTTGCTGTTGCTGCTCCTGCTCCCGCCGCTCCCC\nGTCCTGCTCGCGGACCCAGGGGCGCCCACGCCAGTGAATCCCTGTTGTTACTATCCATGC\nCAGCACCAGGGCATCTGTGTCCGCTTCGGCCTTGACCGCTACCAGTGTGACTGCACCCGC\nACGGGCTATTCCGGCCCCAACTGCACCATCCCTGGCCTGTGGACCTGGCTCCGGAATTCA\nCTGCGGCCCAGCCCCTCTTTCACCCACTTCCTGCTCACTCACGGGCGCTGGTTCTGGGAG\nTTTGTCAATGCCACCTTCATCCGAGAGATGCTCATGCTCCTGGTACTCACAGTGCGCTCC\nAACCTTATCCCCAGTCCCCCCACCTACAACTCTGCACATGACTACATCAGCTGGGAGTCT\nTTCTCCAACGTGAGCTATTACACTCGTATTCTGCCCTCTGTGCCTAAAGATTGCCCCACA\nCCCATGGGAACCAAAGGGAAGAAGCAGTTGCCAGATGCCCAGCTCCTGGCCCGCCGCTTC\nCTGCTCAGGAGGAAGTTCATACCTGACCCCCAAGGCACCAACCTCATGTTTGCCTTCTTT\nGCACAACACTTCACCCACCAGTTCTTCAAAACTTCTGGCAAGATGGGTCCTGGCTTCACC\nAAGGCCTTGGGCCATGGGGTAGACCTCGGCCACATTTATGGAGACAATCTGGAGCGTCAG\nTATCAACTGCGGCTCTTTAAGGATGGGAAACTCAAGTACCAGGTGCTGGATGGAGAAATG\nTACCCGCCCTCGGTAGAAGAGGCGCCTGTGTTGATGCACTACCCCCGAGGCATCCCGCCC\nCAGAGCCAGATGGCTGTGGGCCAGGAGGTGTTTGGGCTGCTTCCTGGGCTCATGCTGTAT\nGCCACGCTCTGGCTACGTGAGCACAACCGTGTGTGTGACCTGCTGAAGGCTGAGCACCCC\nACCTGGGGCGATGAGCAGCTTTTCCAGACGACCCGCCTCATCCTCATAGGGGAGACCATC\nAAGATTGTCATCGAGGAGTACGTGCAGCAGCTGAGTGGCTATTTCCTGCAGCTGAAATTT\nGACCCAGAGCTGCTGTTCGGTGTCCAGTTCCAATACCGCAACCGCATTGCCACGGAGTTC\nAACCATCTCTACCACTGGCACCCCCTCATGCCTGACTCCTTCAAGGTGGGCTCCCAGGAG\nTACAGCTACGAGCAGTTCTTGTTCAACACCTCCATGTTGGTGGACTATGGGGTTGAGGCC\nCTGGTGGATGCCTTCTCTCGCCAGATTGCTGGCCGGATCGGTGGGGGCAGGAACATGGAC\nCACCACATCCTGCATGTGGCTGTGGATGTCATCAGGGAGTCTCGGGAGATGCGGCTGCAG\nCCCTTCAATGAGTACCGCAAGAGGTTTGGCATGAAACCCTACACCTCCTTCCAGGAGCTC\nGTAGGAGAGAAGGAGATGGCAGCAGAGTTGGAGGAATTGTATGGAGACATTGATGCGTTG\nGAGTTCTACCCTGGACTGCTTCTTGAAAAGTGCCATCCAAACTCTATCTTTGGGGAGAGT\nATGATAGAGATTGGGGCTCCCTTTTCCCTCAAGGGTCTCCTAGGGAATCCCATCTGTTCT\nCCGGAGTACTGGAAGCCGAGCACATTTGGCGGCGAGGTGGGCTTTAACATTGTCAAGACG\nGCCACACTGAAGAAGCTGGTCTGCCTCAACACCAAGACCTGTCCCTACGTTTCCTTCCGT\nGTGCCGGATGCCAGTCAGGATGATGGGCCTGCTGTGGAGCGACCATCCACAGAGCTCTGA"}, "pfams": {"pfam": [{"identifier": "PF03098", "name": "An_peroxidase"}, {"identifier": "PF00008", "name": "EGF"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "antioxidant activity"}, {"category": "function", "description": "peroxidase activity"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}, {"@position": "5", "id": "BE0000262", "name": "Prostaglandin G/H synthase 2", "organism": "Human", "actions": {"action": "inducer"}, "references": "# Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, Nielsen S: Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol. 2005 May;288(5):F1053-68. Epub 2005 Jan 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15644490", "known-action": "unknown", "polypeptide": {"@id": "P35354", "@source": "Swiss-Prot", "name": "Prostaglandin G/H synthase 2", "general-function": "Involved in peroxidase activity", "specific-function": "May have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity", "gene-name": "PTGS2", "locus": "1q25.2-q25.3", "cellular-location": "Microsome; microsomal membrane; peripheral membrane protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.41", "molecular-weight": "68997.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9605"}, {"resource": "GenAtlas", "identifier": "PTGS2"}, {"resource": "GeneCards", "identifier": "PTGS2"}, {"resource": "GenBank Gene Database", "identifier": "L15326"}, {"resource": "GenBank Protein Database", "identifier": "291988"}, {"resource": "UniProtKB", "identifier": "P35354"}, {"resource": "UniProt Accession", "identifier": "PGH2_HUMAN"}]}, "synonyms": {"synonym": ["COX-2", "Cyclooxygenase- 2", "EC 1.14.99.1", "PGH synthase 2", "PGHS-2", "PHS II", "Prostaglandin G/H synthase 2 precursor", "Prostaglandin H2 synthase 2", "Prostaglandin-endoperoxide synthase 2"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Prostaglandin G/H synthase 2 precursor\nMLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL\nTRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY\nGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS\nNMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY\nQIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD\nVLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ\nNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV\nAGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL\nYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV\nGFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER\nSTEL"}, "gene-sequence": {"@format": "FASTA", "#text": ">1815 bp\nATGCTCGCCCGCGCCCTGCTGCTGTGCGCGGTCCTGGCGCTCAGCCATACAGCAAATCCT\nTGCTGTTCCCACCCATGTCAAAACCGAGGTGTATGTATGAGTGTGGGATTTGACCAGTAT\nAAGTGCGATTGTACCCGGACAGGATTCTATGGAGAAAACTGCTCAACACCGGAATTTTTG\nACAAGAATAAAATTATTTCTGAAACCCACTCCAAACACAGTGCACTACATACTTACCCAC\nTTCAAGGGATTTTGGAACGTTGTGAATAACATTCCCTTCCTTCGAAATGCAATTATGAGT\nTATGTGTTGACATCCAGATCACATTTGATTGACAGTCCACCAACTTACAATGCTGACTAT\nGGCTACAAAAGCTGGGAAGCCTTCTCTAACCTCTCCTATTATACTAGAGCCCTTCCTCCT\nGTGCCTGATGATTGCCCGACTCCCTTGGGTGTCAAAGGTAAAAAGCAGCTTCCTGATTCA\nAATGAGATTGTGGAAAAATTGCTTCTAAGAAGAAAGTTCATCCCTGATCCCCAGGGCTCA\nAACATGATGTTTGCATTCTTTGCCCAGCACTTCACGCATCAGTTTTTCAAGACAGATCAT\nAAGCGAGGGCCAGCTTTCACCAACGGGCTGGGCCATGGGGTGGACTTAAATCATATTTAC\nGGTGAAACTCTGGCTAGACAGCGTAAACTGCGCCTTTTCAAGGATGGAAAAATGAAATAT\nCAGATAATTGATGGAGAGATGTATCCTCCCACAGTCAAAGATACTCAGGCAGAGATGATC\nTACCCTCCTCAAGTCCCTGAGCATCTACGGTTTGCTGTGGGGCAGGAGGTCTTTGGTCTG\nGTGCCTGGTCTGATGATGTATGCCACAATCTGGCTGCGGGAACACAACAGAGTATGCGAT\nGTGCTTAAACAGGAGCATCCTGAATGGGGTGATGAGCAGTTGTTCCAGACAAGCAGGCTA\nATACTGATAGGAGAGACTATTAAGATTGTGATTGAAGATTATGTGCAACACTTGAGTGGC\nTATCACTTCAAACTGAAATTTGACCCAGAACTACTTTTCAACAAACAATTCCAGTACCAA\nAATCGTATTGCTGCTGAATTTAACACCCTCTATCACTGGCATCCCCTTCTGCCTGACACC\nTTTCAAATTCATGACCAGAAATACAACTATCAACAGTTTATCTACAACAACTCTATATTG\nCTGGAACATGGAATTACCCAGTTTGTTGAATCATTCACCAGGCAAATTGCTGGCAGGGTT\nGCTGGTGGTAGGAATGTTCCACCCGCAGTACAGAAAGTATCACAGGCTTCCACTGACCAG\nAGCAGGCAGATGAAATACCAGTCTTTTAATGAGTACCGCAAACGCTTTATGCTGAAGCCC\nTATGAATCATTTGAAGAACTTACAGGAGAAAAGGAAATGTCTGCAGAGTTGGAAGCACTC\nTATGGTGACATCGATGCTGTGGAGCTGTATCCTGCCCTTCTGGTAGAAAAGCCTCGGCCA\nGATGCCATCTTTGGTGAAACCATGGTAGAAGTTGGAGCACCATTCTCCTTGAAAGGACTT\nATGGGTAATGTTATATGTTCTCCTGCCTACTGGAAGCCAAGCACTTTTGGTGGAGAAGTG\nGGTTTTCAAATCATCAACACTGCCTCAATTCAGTCTCTCATCTGCAATAACGTGAAGGGC\nTGTCCCTTTACTTCATTCAGTGTTCCAGATCCAGAGCTCATTAAAACAGTCACCATCAAT\nGCAAGTTCTTCCCGCTCCGGACTAGATGATATCAATCCCACAGTACTACTAAAAGAACGT\nTCGACTGAACTGTAG"}, "pfams": {"pfam": [{"identifier": "PF03098", "name": "An_peroxidase"}, {"identifier": "PF00008", "name": "EGF"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "antioxidant activity"}, {"category": "function", "description": "peroxidase activity"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}]}, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2010-09-14", "drugbank-id": [{"@primary": "true", "#text": "DB00036"}, "BIOD00006", "BTD00006"], "name": "Coagulation factor VIIa", "description": "Recombinant human coagulation Factor VIIa (rFVIIa), intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade.1 NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues. Cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.", "cas-number": "9001-25-6", "groups": {"group": "approved"}, "general-references": "# Blackshear PJ, Holloway PA, Alberti KG: Factors regulating amino acid release from extrasplanchnic tissues in the rat. Interactions of alanine and glutamine. Biochem J. 1975 Sep;150(3):379-87. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2155\n# Roberts HR, Monroe DM, White GC: The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood. 2004 Dec 15;104(13):3858-64. Epub 2004 Aug 24. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15328151\n# Kenet G, Walden R, Eldad A, Martinowitz U: Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999 Nov 27;354(9193):1879. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10584732\n# O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM: Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006 Jan 18;295(3):293-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16418464\n# Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T: Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005 Feb 24;352(8):777-85. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15728810", "synthesis-reference": null, "indication": "For treatment of hemorrhagic complications in hemophilia A and B", "pharmacodynamics": "Used in the treatment of bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and, when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.", "mechanism-of-action": "NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": "* 121 \u00b1 30 mL/kg [adults]\n* 153 \u00b1 29 mL/kg [children]\n* 280 to 290 mL/kg [congenital Factor VII deficiency]", "clearance": "* 33 - 37 mL/h x kg [healthy]\n* 1375 +/- 396 mL/hr [severe hemophilia A male children]\n* 57.3 +/- 9.5 mL/hr/kg [severe hemophilia A male children]\n* 2767 +/- 385 mL/hr [severe hemophilia A men]\n* 37.6 +/- 13.1 mL/hr/kg [severe hemophilia A men]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Coagulation factor VII precursor"}, {"@language": "", "@coder": "", "#text": "Eptacog alfa"}, {"@language": "", "@coder": "", "#text": "Proconvertin"}, {"@language": "", "@coder": "", "#text": "Serum prothrombin conversion accelerator"}, {"@language": "", "@coder": "", "#text": "SPCA"}]}, "products": {"product": [{"name": "Niastase", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02239659", "started-marketing-on": "1999-08-05", "ended-marketing-on": "2013-07-22", "dosage-form": "powder for solution", "strength": "1.2 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Niastase", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02239660", "started-marketing-on": "1999-08-05", "ended-marketing-on": "2013-07-22", "dosage-form": "powder for solution", "strength": "2.4 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Niastase", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02239661", "started-marketing-on": "1999-08-05", "ended-marketing-on": "2013-07-22", "dosage-form": "powder for solution", "strength": "4.8 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Niastase Rt", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02365669", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "kit; powder for solution", "strength": "8 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Niastase Rt", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02417146", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "kit; powder for solution", "strength": "8 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Niastase Rt", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02417103", "started-marketing-on": "2015-05-05", "ended-marketing-on": null, "dosage-form": "kit; powder for solution", "strength": "1 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Niastase Rt", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02417111", "started-marketing-on": "2015-05-05", "ended-marketing-on": null, "dosage-form": "kit; powder for solution", "strength": "2 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Niastase Rt", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02417138", "started-marketing-on": "2015-05-05", "ended-marketing-on": null, "dosage-form": "kit; powder for solution", "strength": "5 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Niastase Rt", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02347113", "started-marketing-on": "2010-08-25", "ended-marketing-on": null, "dosage-form": "kit; powder for solution", "strength": "1 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Niastase Rt", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02347121", "started-marketing-on": "2010-08-05", "ended-marketing-on": null, "dosage-form": "kit; powder for solution", "strength": "2 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Niastase Rt", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02347148", "started-marketing-on": "2010-08-25", "ended-marketing-on": null, "dosage-form": "kit; powder for solution", "strength": "5 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": {"name": "NovoSeven", "company": "Novo Nordisk"}}, "mixtures": {"mixture": [{"name": "Niastase Rt", "ingredients": "Coagulation factor VIIa"}, {"name": "Niastase Rt", "ingredients": "Coagulation factor VIIa"}, {"name": "Niastase Rt", "ingredients": "Coagulation factor VIIa"}, {"name": "Niastase Rt", "ingredients": "Coagulation factor VIIa"}, {"name": "Niastase Rt", "ingredients": "Coagulation factor VIIa"}, {"name": "Niastase Rt", "ingredients": "Coagulation factor VIIa"}, {"name": "Niastase", "ingredients": "Coagulation factor VIIa"}, {"name": "Niastase", "ingredients": "Coagulation factor VIIa"}, {"name": "Niastase", "ingredients": "Coagulation factor VIIa"}, {"name": "Niastase Rt", "ingredients": "Coagulation factor VIIa"}, {"name": "Niastase Rt", "ingredients": "Coagulation factor VIIa"}]}, "packagers": {"packager": {"name": "Novo Nordisk Inc.", "url": "http://www.novonordisk.com"}}, "manufacturers": null, "prices": {"price": [{"description": "Novoseven 1200 mcg vial", "cost": {"@currency": "USD", "#text": "1.64"}, "unit": "vial"}, {"description": "Novoseven 2400 mcg vial", "cost": {"@currency": "USD", "#text": "1.64"}, "unit": "vial"}, {"description": "Novoseven 4800 mcg vial", "cost": {"@currency": "USD", "#text": "1.64"}, "unit": "vial"}]}, "categories": {"category": [{"category": "Coagulants", "mesh-id": null}, {"category": "Thrombotic Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Powder for solution", "route": "intravenous", "strength": "1.2 mg"}, {"form": "Powder for solution", "route": "intravenous", "strength": "2.4 mg"}, {"form": "Powder for solution", "route": "intravenous", "strength": "4.8 mg"}, {"form": "Kit; powder for solution", "route": "intravenous", "strength": "1 mg"}, {"form": "Kit; powder for solution", "route": "intravenous", "strength": "2 mg"}, {"form": "Kit; powder for solution", "route": "intravenous", "strength": "5 mg"}, {"form": "Kit; powder for solution", "route": "intravenous", "strength": "8 mg"}]}, "atc-codes": null, "ahfs-codes": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00036 sequence\nANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGS\nCKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSL\nLADGVSCTPTVEYPCGKIPILEKRNASKPQGRIVGGKVCPKGECPWQVLLLVNGAQLCGG\nTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTN\nHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVL\nNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTG\nIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "58 \u00b0C", "source": "Petersen, L.C. et al., Eur. J. Biochem 261: 124-129 (1999)"}, {"kind": "Hydrophobicity", "value": "-0.311", "source": null}, {"kind": "Isoelectric Point", "value": "6.09", "source": null}, {"kind": "Molecular Weight", "value": "45079.1000", "source": null}, {"kind": "Molecular Formula", "value": "C1972H3076N560O597S28", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "13301"}, {"resource": "KEGG Compound", "identifier": "C03378"}, {"resource": "KEGG Drug", "identifier": "D00172"}, {"resource": "National Drug Code Directory", "identifier": "0169-7010-01"}, {"resource": "GenBank", "identifier": "M13232"}, {"resource": "PharmGKB", "identifier": "PA164748389"}, {"resource": "UniProtKB", "identifier": "P08709"}, {"resource": "Wikipedia", "identifier": "Factor_VII"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/novoseven.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/coagulation-factor-viia-recombinant.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000216", "name": "Coagulation factor X", "organism": "Human", "actions": null, "references": "# Malinvaud G: [Reflections on the use of PPSB fraction (Prothrombin-proconvertin-Stuart factor-antihemophilic factor B)] Transfusion (Paris). 1966;9(3):245-54. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/5969560\n# BLATRIX C, SOULIER JP: [Preparation of a fraction rich in prothrombin, proconvertin, Stuart factor and antihemophilic factor B (P.P.B. fraction)] Pathol Biol (Paris). 1959 Dec;7:2477-86. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/13801371\n# HERMANSKY F, VITEK J: The role of proconvertin and Stuart factor in the inactivation of tissue thromboplastin by serum. Experientia. 1960 Oct 15;16:455-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/13713641\n# GAERTNER H, CAEN J: [FUNCTIONAL RELATION BETWEEN ERYTHROPLASTIN (ERYTHROCYTE COAGULANT FACTOR) AND PLASMA FACTORS: PROACCELERIN (V), PROCONVERTIN (VII) AND STUART FACTOR(X).] Acta Physiol Pol. 1964 Mar-Apr;15:237-43. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14227143\n# DIDISHEIM P, LOEB J, BLATRIX C, SOULIER JP: Preparation of a human plasma fraction rich in prothrombin, proconvertin, Stuart factor, and PTC and a study of its activity and toxicity in rabbits and man. J Lab Clin Med. 1959 Feb;53(2):322-30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/13621053", "known-action": "unknown", "polypeptide": {"@id": "P00742", "@source": "Swiss-Prot", "name": "Coagulation factor X", "general-function": "Involved in calcium ion binding", "specific-function": "Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting", "gene-name": "F10", "locus": "13q34", "cellular-location": "Cytoplasmic", "transmembrane-regions": "7-26", "signal-regions": null, "theoretical-pi": "5.74", "molecular-weight": "54732.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3528"}, {"resource": "GenAtlas", "identifier": "F10"}, {"resource": "GeneCards", "identifier": "F10"}, {"resource": "GenBank Gene Database", "identifier": "K03194"}, {"resource": "GenBank Protein Database", "identifier": "182841"}, {"resource": "UniProtKB", "identifier": "P00742"}, {"resource": "UniProt Accession", "identifier": "FA10_HUMAN"}]}, "synonyms": {"synonym": ["Coagulation factor X precursor", "EC 3.4.21.6", "Stuart factor", "Stuart- Prower factor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Coagulation factor X precursor\nMGRPLHLVLLSASLAGLLLLGESLFIRREQANNILARVTRANSFLEEMKKGHLERECMEE\nTCSYEEAREVFEDSDKTNEFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKN\nCELFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLERR\nKRSVAQATSSSGEAPDSITWKPYDAADLDPTENPFDLLDFNQTQPERGDNNLTRIVGGQE\nCKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGE\nAVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGI\nVSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSG\nGPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPE\nVITSSPLK"}, "gene-sequence": {"@format": "FASTA", "#text": ">1433 bp\nCCTCCCTGGCTGGCCTCCTGCTGCTCGGGGAAAGTCTGTTCATCCGCAGGGAGCAGGCCA\nACAACATCCTGGCGAGGGTCACGAGGGCCAATTCCTTTCTTGAAGAGATGAAGAAAGGAC\nACCTCGAAAGAGAGTGCATGGAAGAGACCTGCTCATACGAAGAGGCCCGCGAGGTCTTTG\nAGGACAGCGACAAGACGAATGAATTCTGGAATAAATACAAAGATGGCGACCAGTGTGAGA\nCCAGTCCTTGCCAGAACCAGGGCAAATGTAAAGACGGCCTCGGGGAATACACCTGCACCT\nGTTTAGAAGGATTCGAAGGCAAAAACTGTGAATTATTCACACGGAAGCTCTGCAGCCTGG\nACAACGGGGACTGTGACCAGTTCTGCCACGAGGAACAGAACTCTGTGGTGTGCTCCTGCG\nCCCGCGGGTACACCCTGGCTGACAACGGCAAGGCCTGCATTCCCACAGGGCCCTACCCCT\nGTGGGAAACAGACCCTGGAACGCAGGAAGAGGTCAGTGGCCCAGGCCACCAGCAGCAGCG\nGGGAGGCCCCTGACAGCATCACATGGAAGCCATATGATGCAGCCGACCTGGACCCCACCG\nAGAACCCCTTCGACCTGCTTGACTTCAACCAGACGCAGCCTGAGAGGGGCGACAACAACC\nTCACCAGGATCGTGGGAGGCCAGGAATGCAAGGACGGGGAGTGTCCCTGGCAGGCCCTGC\nTCATCAATGAGGAAAACGAGGGTTTCTGTGGTGGAACTATTCTGAGCGAGTTCTACATCC\nTAACGGCAGCCCACTGTCTCTACCAAGCCAAGAGATTCAAGGTGAGGGTAGGGGACCGGA\nACACGGAGCAGGAGGAGGGCGGTGAGGCGGTGCACGAGGTGGAGGTGGTCATCAAGCACA\nACCGGTTCACAAAGGAGACCTATGACTTCGACATCGCCGTGCTCCGGCTCAAGACCCCCA\nTCACCTTCCGCATGAACGTGGCGCCTGCCTGCCTCCCCGAGCGTGACTGGGCCGAGTCCA\nCGCTGATGACGCAGAAGACGGGGATTGTGAGCGGCTTCGGGCGCACCCACGAGAAGGGCC\nGGCAGTCCACCAGGCTCAAGATGCTGGAGGTGCCCTACGTGGACCGCAACAGCTGCAAGC\nTGTCCAGCAGCTTCATCATCACCCAGAACATGTTCTGTGCCGGCTACGACACCAAGCAGG\nAGGATGCCTGCCAGGGGGACAGCGGGGGCCCGCACGTCACCCGCTTCAAGGACACCTACT\nTCGTGACAGGCATCGTCAGCTGGGGAGAGAGCTGTGCCCGTAAGGGGAAGTACGGGATCT\nACACCAAGGTCACCGCCTTCCTCAAGTGGATCGACAGGTCCATGAAAACCAGGGGCTTGC\nCCAAGGCCAAGAGCCATGCCCCGGAGGTCATAACGTCCTCTCCATTAAAGTGA"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF00594", "name": "Gla"}, {"identifier": "PF00089", "name": "Trypsin"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "hemostasis"}, {"category": "process", "description": "blood coagulation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}]}}}, {"id": "BE0002128", "name": "Serine protease hepsin", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P05981", "@source": "Swiss-Prot", "name": "Serine protease hepsin", "general-function": null, "specific-function": "Plays an essential role in cell growth and maintenance of cell morphology", "gene-name": "HPN", "locus": "19q11-q13.2", "cellular-location": "Membrane", "transmembrane-regions": "24-44", "signal-regions": null, "theoretical-pi": "7.66", "molecular-weight": "45012.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5155"}, {"resource": "GenAtlas", "identifier": "HPN"}, {"resource": "GeneCards", "identifier": "HPN"}, {"resource": "GenBank Gene Database", "identifier": "M18930"}, {"resource": "GenBank Protein Database", "identifier": "306886"}, {"resource": "UniProtKB", "identifier": "P05981"}, {"resource": "UniProt Accession", "identifier": "HEPS_HUMAN"}]}, "synonyms": {"synonym": ["EC 3.4.21.106", "Transmembrane protease, serine 1"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Serine protease hepsin\nMAQKEGGRTVPCCSRPKVAALTAGTLLLLTAIGAASWAIVAVLLRSDQEPLYPVQVSSAD\nARLMVFDKTEGTWRLLCSSRSNARVAGLSCEEMGFLRALTHSELDVRTAGANGTSGFFCV\nDEGRLPHTQRLLEVISVCDCPRGRFLAAICQDCGRRKLPVDRIVGGRDTSLGRWPWQVSL\nRYDGAHLCGGSLLSGDWVLTAAHCFPERNRVLSRWRVFAGAVAQASPHGLQLGVQAVVYH\nGGYLPFRDPNSEENSNDIALVHLSSPLPLTEYIQPVCLPAAGQALVDGKICTVTGWGNTQ\nYYGQQAGVLQEARVPIISNDVCNGADFYGNQIKPKMFCAGYPEGGIDACQGDSGGPFVCE\nDSISRTPRWRLCGIVSWGTGCALAQKPGVYTKVSDFREWIFQAIKTHSEASGMVTQL"}, "gene-sequence": {"@format": "FASTA", "#text": ">1254 bp\nATGGCGCAGAAGGAGGGTGGCCGGACTGTGCCATGCTGCTCCAGACCCAAGGTGGCAGCT\nCTCACTGCGGGGACCCTGCTACTTCTGACAGCCATCGGGGCGGCATCCTGGGCCATTGTG\nGCTGTTCTCCTCAGGAGTGACCAGGAGCCGCTGTACCCAGTGCAGGTCAGCTCTGCGGAC\nGCTCGGCTCATGGTCTTTGACAAGACGGAAGGGACGTGGCGGCTGCTGTGCTCCTCGCGC\nTCCAACGCCAGGGTAGCCGGACTCAGCTGCGAGGAGATGGGCTTCCTCAGGGCACTGACC\nCACTCCGAGCTGGACGTGCGAACGGCGGGCGCCAATGGCACGTCGGGCTTCTTCTGTGTG\nGACGAGGGGAGGCTGCCCCACACCCAGAGGCTGCTGGAGGTCATCTCCGTGTGTGATTGC\nCCCAGAGGCCGTTTCTTGGCCGCCATCTGCCAAGACTGTGGCCGCAGGAAGCTGCCCGTG\nGACCGCATCGTGGGAGGCCGGGACACCAGCTTGGGCCGGTGGCCGTGGCAAGTCAGCCTT\nCGCTATGATGGAGCACACCTCTGTGGGGGATCCCTGCTCTCCGGGGACTGGGTGCTGACA\nGCCGCCCACTGCTTCCCGGAGCGGAACCGGGTCCTGTCCCGATGGCGAGTGTTTGCCGGT\nGCCGTGGCCCAGGCCTCTCCCCACGGTCTGCAGCTGGGGGTGCAGGCTGTGGTCTACCAC\nGGGGGCTATCTTCCCTTTCGGGACCCCAACAGCGAGGAGAACAGCAACGATATTGCCCTG\nGTCCACCTCTCCAGTCCCCTGCCCCTCACAGAATACATCCAGCCTGTGTGCCTCCCAGCT\nGCCGGCCAGGCCCTGGTGGATGGCAAGATCTGTACCGTGACGGGCTGGGGCAACACGCAG\nTACTATGGCCAACAGGCCGGGGTACTCCAGGAGGCTCGAGTCCCCATAATCAGCAATGAT\nGTCTGCAATGGCGCTGACTTCTATGGAAACCAGATCAAGCCCAAGATGTTCTGTGCTGGC\nTACCCCGAGGGTGGCATTGATGCCTGCCAGGGCGACAGCGGTGGTCCCTTTGTGTGTGAG\nGACAGCATCTCTCGGACGCCACGTTGGCGGCTGTGTGGCATTGTGAGTTGGGGCACTGGC\nTGTGCCCTGGCCCAGAAGCCAGGCGTCTACACCAAAGTCAGTGACTTCCGGGAGTGGATC\nTTCCAGGCCATAAAGACTCACTCCGAAGCCAGCGGCATGGTGACCCAGCTCTGA"}, "pfams": {"pfam": [{"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF09272", "name": "Hepsin-SRCR"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "scavenger receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "proteolysis"}]}}}, {"id": "BE0000967", "name": "Tissue factor pathway inhibitor", "organism": "Human", "actions": null, "references": "# Mine S, Yamazaki T, Miyata T, Hara S, Kato H: Structural mechanism for heparin-binding of the third Kunitz domain of human tissue factor pathway inhibitor. Biochemistry. 2002 Jan 8;41(1):78-85. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11772005\n# Narita M, Bu G, Olins GM, Higuchi DA, Herz J, Broze GJ Jr, Schwartz AL: Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo. J Biol Chem. 1995 Oct 20;270(42):24800-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7559599\n# Stassens P, Bergum PW, Gansemans Y, Jespers L, Laroche Y, Huang S, Maki S, Messens J, Lauwereys M, Cappello M, Hotez PJ, Lasters I, Vlasuk GP: Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2149-54. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8700900\n# Lee AY, Vlasuk GP: Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor. J Intern Med. 2003 Oct;254(4):313-21. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12974870\n# Hansen CB, Pyke C, Petersen LC, Rao LV: Tissue factor-mediated endocytosis, recycling, and degradation of factor VIIa by a clathrin-independent mechanism not requiring the cytoplasmic domain of tissue factor. Blood. 2001 Mar 15;97(6):1712-20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11238112", "known-action": "unknown", "polypeptide": {"@id": "P10646", "@source": "Swiss-Prot", "name": "Tissue factor pathway inhibitor", "general-function": "Involved in serine-type endopeptidase inhibitor activity", "specific-function": "Inhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. It possesses an antithrombotic action and also the ability to associate with lipoproteins in plasma", "gene-name": "TFPI", "locus": "2q32", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.31", "molecular-weight": "35015.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:11760"}, {"resource": "GenAtlas", "identifier": "TFPI"}, {"resource": "GeneCards", "identifier": "TFPI"}, {"resource": "GenBank Gene Database", "identifier": "J03225"}, {"resource": "GenBank Protein Database", "identifier": "180546"}, {"resource": "UniProtKB", "identifier": "P10646"}, {"resource": "UniProt Accession", "identifier": "TFPI1_HUMAN"}]}, "synonyms": {"synonym": ["EPI", "Extrinsic pathway inhibitor", "LACI", "Lipoprotein- associated coagulation inhibitor", "TFPI", "Tissue factor pathway inhibitor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Tissue factor pathway inhibitor precursor\nMIYTMKKVHALWASVCLLLNLAPAPLNADSEEDEEHTIITDTELPPLKLMHSFCAFKADD\nGPCKAIMKRFFFNIFTRQCEEFIYGGCEGNQNRFESLEECKKMCTRDNANRIIKTTLQQE\nKPDFCFLEEDPGICRGYITRYFYNNQTKQCERFKYGGCLGNMNNFETLEECKNICEDGPN\nGFQVDNYGTQLNAVNNSLTPQSTKVPSLFEFHGPSWCLTPADRGLCRANENRFYYNSVIG\nKCRPFKYSGCGGNENNFTSKQECLRACKKGFIQRISKGGLIKTKRKRKKQRVKIAYEEIF\nVKNM"}, "gene-sequence": {"@format": "FASTA", "#text": ">915 bp\nATGATTTACACAATGAAGAAAGTACATGCACTTTGGGCTTCTGTATGCCTGCTGCTTAAT\nCTTGCCCCTGCCCCTCTTAATGCTGATTCTGAGGAAGATGAAGAACACACAATTATCACA\nGATACGGAGTTGCCACCACTGAAACTTATGCATTCATTTTGTGCATTCAAGGCGGATGAT\nGGCCCATGTAAAGCAATCATGAAAAGATTTTTCTTCAATATTTTCACTCGACAGTGCGAA\nGAATTTATATATGGGGGATGTGAAGGAAATCAGAATCGATTTGAAAGTCTGGAAGAGTGC\nAAAAAAATGTGTACAAGAGATAATGCAAACAGGATTATAAAGACAACATTGCAACAAGAA\nAAGCCAGATTTCTGCTTTTTGGAAGAAGATCCTGGAATATGTCGAGGTTATATTACCAGG\nTATTTTTATAACAATCAGACAAAACAGTGTGAACGTTTCAAGTATGGTGGATGCCTGGGC\nAATATGAACAATTTTGAGACACTGGAAGAATGCAAGAACATTTGTGAAGATGGTCCGAAT\nGGTTTCCAGGTGGATAATTATGGAACCCAGCTCAATGCTGTGAATAACTCCCTGACTCCG\nCAATCAACCAAGGTTCCCAGCCTTTTTGAATTTCACGGTCCCTCATGGTGTCTCACTCCA\nGCAGACAGAGGATTGTGTCGTGCCAATGAGAACAGATTCTACTACAATTCAGTCATTGGG\nAAATGCCGCCCATTTAAGTACAGTGGATGTGGGGGAAATGAAAACAATTTTACTTCCAAA\nCAAGAATGTCTGAGGGCATGTAAAAAAGGTTTCATCCAAAGAATATCAAAAGGAGGCCTA\nATTAAAACCAAAAGAAAAAGAAAGAAGCAGAGAGTGAAAATAGCATATGAAGAAATTTTT\nGTTAAAAATATGTGA"}, "pfams": {"pfam": {"identifier": "PF00014", "name": "Kunitz_BPTI"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "protease inhibitor activity"}, {"category": "function", "description": "endopeptidase inhibitor activity"}, {"category": "function", "description": "serine-type endopeptidase inhibitor activity"}, {"category": "function", "description": "enzyme regulator activity"}, {"category": "function", "description": "enzyme inhibitor activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "hemostasis"}, {"category": "process", "description": "blood coagulation"}]}}}, {"id": "BE0000403", "name": "Vitamin K-dependent gamma-carboxylase", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Bouwman CA, Van Dam E, Fase KM, Koppe JG, Seinen W, Thijssen HH, Vermeer C, Van den Berg M: Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin or 2,2',4,4',5,5'-hexachlorobiphenyl on vitamin K-dependent blood coagulation in male and female WAG/Rij-rats. Chemosphere. 1999 Feb;38(3):489-505. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10901669", "known-action": "unknown", "polypeptide": {"@id": "P38435", "@source": "Swiss-Prot", "name": "Vitamin K-dependent gamma-carboxylase", "general-function": "Involved in gamma-glutamyl carboxylase activity", "specific-function": "Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium binding gamma-carboxyglutamate (Gla) residues with the concomitant convertion of the reduced hydroquinone form of vitamin K to vitamin K epoxide", "gene-name": "GGCX", "locus": "2p12", "cellular-location": "Endoplasmic reticulum; endoplasmic reticulum membrane; multi-pass membrane protein", "transmembrane-regions": "61-81\n114-134\n137-157\n293-313\n362-382", "signal-regions": null, "theoretical-pi": "8.1", "molecular-weight": "87562.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:4247"}, {"resource": "GenAtlas", "identifier": "GGCX"}, {"resource": "GeneCards", "identifier": "GGCX"}, {"resource": "GenBank Gene Database", "identifier": "M81592"}, {"resource": "GenBank Protein Database", "identifier": "184028"}, {"resource": "UniProtKB", "identifier": "P38435"}, {"resource": "UniProt Accession", "identifier": "VKGC_HUMAN"}]}, "synonyms": {"synonym": ["EC 6.4.-.-", "Gamma-glutamyl carboxylase", "Vitamin K gamma glutamyl carboxylase"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Vitamin K-dependent gamma-carboxylase\nMAVSAGSARTSPSSDKVQKDKAELISGPRQDSRIGKLLGFEWTDLSSWRRLVTLLNRPTD\nPASLAVFRFLFGFLMVLDIPQERGLSSLDRKYLDGLDVCRFPLLDALRPLPLDWMYLVYT\nIMFLGALGMMLGLCYRISCVLFLLPYWYVFLLDKTSWNNHSYLYGLLAFQLTFMDANHYW\nSVDGLLNAHRRNAHVPLWNYAVLRGQIFIVYFIAGVKKLDADWVEGYSMEYLSRHWLFSP\nFKLLLSEELTSLLVVHWGGLLLDLSAGFLLFFDVSRSIGLFFVSYFHCMNSQLFSIGMFS\nYVMLASSPLFCSPEWPRKLVSYCPRRLQQLLPLKAAPQPSVSCVYKRSRGKSGQKPGLRH\nQLGAAFTLLYLLEQLFLPYSHFLTQGYNNWTNGLYGYSWDMMVHSRSHQHVKITYRDGRT\nGELGYLNPGVFTQSRRWKDHADMLKQYATCLSRLLPKYNVTEPQIYFDIWVSINDRFQQR\nIFDPRVDIVQAAWSPFQRTSWVQPLLMDLSPWRAKLQEIKSSLDNHTEVVFIADFPGLHL\nENFVSEDLGNTSIQLLQGEVTVELVAEQKNQTLREGEKMQLPAGEYHKVYTTSPSPSCYM\nYVYVNTTELALEQDLAYLQELKEKVENGSETGPLPPELQPLLEGEVKGGPEPTPLVQTFL\nRRQQRLQEIERRRNTPFHERFFRFLLRKLYVFRRSFLMTCISLRNLILGRPSLEQLAQEV\nTYANLRPFEAVGELNPSNTDSSHSNPPESNPDPVHSEF"}, "gene-sequence": {"@format": "FASTA", "#text": ">2277 bp\nATGGCGGTGTCTGCCGGGTCCGCGCGGACCTCGCCCAGCTCAGATAAAGTACAGAAAGAC\nAAGGCTGAACTGATCTCAGGGCCCAGGCAGGACAGCCGAATAGGGAAACTCTTGGGTTTT\nGAGTGGACAGATTTGTCCAGTTGGCGGAGGCTGGTGACCCTGCTGAATCGACCAACGGAC\nCCTGCAAGCTTAGCTGTCTTTCGTTTTCTTTTTGGGTTCTTGATGGTGCTAGACATTCCC\nCAGGAGCGGGGGCTCAGCTCTCTGGACCGGAAATACCTTGATGGGCTGGATGTGTGCCGC\nTTCCCCTTGCTGGATGCCCTACGCCCACTGCCACTTGACTGGATGTATCTTGTCTACACC\nATCATGTTTCTGGGGGCACTGGGCATGATGCTGGGCCTGTGCTACCGGATAAGCTGTGTG\nTTATTCCTGCTGCCATACTGGTATGTGTTTCTCCTGGACAAGACATCATGGAACAACCAC\nTCCTATCTGTATGGGTTGTTGGCCTTTCAGCTAACATTCATGGATGCAAACCACTACTGG\nTCTGTGGACGGTCTGCTGAATGCCCATAGGAGGAATGCCCACGTGCCCCTTTGGAACTAT\nGCAGTGCTCCGTGGCCAGATCTTCATTGTGTACTTCATTGCGGGTGTGAAAAAGCTGGAT\nGCAGACTGGGTTGAAGGCTATTCCATGGAATATTTGTCCCGGCACTGGCTCTTCAGTCCC\nTTCAAACTGCTGTTGTCTGAGGAGCTGACTAGCCTGCTGGTCGTGCACTGGGGTGGGCTG\nCTGCTTGACCTCTCAGCTGGTTTCCTGCTCTTTTTTGATGTCTCAAGATCCATTGGCCTG\nTTCTTTGTGTCCTACTTCCACTGCATGAATTCCCAGCTTTTCAGCATTGGTATGTTCTCC\nTACGTCATGCTGGCCAGCAGCCCTCTCTTCTGCTCCCCTGAGTGGCCTCGGAAGCTGGTG\nTCCTACTGCCCCCAAAGGTTGCAACAACTGTTGCCCCTCAAGGCAGCCCCTCAGCCCAGT\nGTTTCCTGTGTGTATAAGAGGAGCCGGGGCAAAAGTGGCCAGAAGCCAGGGCTGCGCCAT\nCAGCTGGGAGCTGCCTTCACCCTGCTCTACCTCCTGGAGCAGCTATTCCTGCCCTATTCT\nCATTTTCTCACCCAGGGCTATAACAACTGGACAAATGGGCTGTATGGCTATTCCTGGGAC\nATGATGGTGCACTCCCGTTCCCACCAGCACGTGAAGATCACCTACCGTGATGGCCGCACT\nGGCGAACTGGGCTACCTTAACCCTGGGGTATTTACACAGAGTCGGCGATGGAAGGATCAT\nGCAGACATGCTGAAGCAATATGCCACTTGCCTGAGCCGCCTGCTTCCCAAGTATAATGTC\nACTGAGCCCCAGATCTACTTTGATATTTGGGTCTCCATCAATGACCGCTTCCAGCAGAGG\nATTTTTGACCCTCGTGTGGACATCGTGCAGGCCGCTTGGTCACCCTTTCAGCGCACATCC\nTGGGTGCAACCACTCTTGATGGACCTGTCTCCCTGGAGGGCCAAGTTACAGGAAATCAAG\nAGCAGCCTAGACAACCACACTGAGGTGGTCTTCATTGCAGATTTCCCTGGACTGCACTTG\nGAGAATTTTGTGAGTGAAGACCTGGGCAACACTAGCATCCAGCTGCTGCAGGGGGAAGTG\nACTGTGGAGCTTGTGGCAGAACAGAAGAACCAGACTCTTCGAGAGGGAGAAAAAATGCAG\nTTGCCTGCTGGTGAGTACCATAAGGTGTATACGACATCACCTAGCCCTTCTTGCTACATG\nTACGTCTATGTCAACACTACAGAGCTTGCACTGGAGCAAGACCTGGCATATCTGCAAGAA\nTTAAAGGAAAAGGTGGAGAATGGAAGTGAAACAGGGCCTCTACCCCCAGAGCTGCAGCCT\nCTGTTGGAAGGGGAAGTAAAAGGGGGCCCTGAGCCAACACCTCTGGTTCAGACCTTTCTT\nAGACGCCAACAAAGGCTCCAGGAGATTGAACGCCGGCGAAATACTCCTTTCCATGAGCGA\nTTCTTCCGCTTCTTGTTGCGAAAGCTCTATGTCTTTCGCCGCAGCTTCCTGATGACTTGT\nATCTCACTTCGAAATCTGATATTAGGCCGTCCTTCCCTGGAGCAGCTGGCCCAGGAGGTG\nACTTATGCAAACTTGAGACCCTTTGAGGCAGTTGGAGAACTGAATCCCTCAAACACGGAT\nTCTTCACATTCTAATCCTCCTGAGTCAAATCCTGATCCTGTCCACTCAGAGTTCTGA"}, "pfams": {"pfam": {"identifier": "PF05090", "name": "VKG_Carbox"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "gamma-glutamyl carboxylase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "lyase activity"}, {"category": "function", "description": "carbon-carbon lyase activity"}, {"category": "function", "description": "carboxy-lyase activity"}, {"category": "process", "description": "biopolymer modification"}, {"category": "process", "description": "protein modification"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "peptidyl-amino acid modification"}, {"category": "process", "description": "peptidyl-glutamic acid modification"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "peptidyl-glutamic acid carboxylation"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "biopolymer metabolism"}]}}}, {"id": "BE0000333", "name": "Coagulation factor VII", "organism": "Human", "actions": null, "references": "# Perera L, Darden TA, Pedersen LG: Probing the structural changes in the light chain of human coagulation factor VIIa due to tissue factor association. Biophys J. 1999 Jul;77(1):99-113. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10388743\n# Shapiro A: Inhibitor treatment: state of the art. Semin Hematol. 2001 Oct;38(4 Suppl 12):26-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11735107\n# Shapiro A: Inhibitor treatment: state of the art. Dis Mon. 2003 Jan;49(1):22-38. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12525826\n# Siddiqui MA, Scott LJ: Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders. Drugs. 2005;65(8):1161-77. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15907148\n# Rizoli SB, Chughtai T: The emerging role of recombinant activated Factor VII (rFVIIa) in the treatment of blunt traumatic haemorrhage. Expert Opin Biol Ther. 2006 Jan;6(1):73-81. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16370916", "known-action": "unknown", "polypeptide": {"@id": "P08709", "@source": "Swiss-Prot", "name": "Coagulation factor VII", "general-function": "Involved in calcium ion binding", "specific-function": "Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X to factor Xa by limited proteolysis. Factor VIIa will also convert factor IX to factor IXa in the presence of tissue factor and calcium", "gene-name": "F7", "locus": "13q34", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.23", "molecular-weight": "51594.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3544"}, {"resource": "GenAtlas", "identifier": "F7"}, {"resource": "GeneCards", "identifier": "F7"}, {"resource": "GenBank Gene Database", "identifier": "M13232"}, {"resource": "GenBank Protein Database", "identifier": "182801"}, {"resource": "UniProtKB", "identifier": "P08709"}, {"resource": "UniProt Accession", "identifier": "FA7_HUMAN"}]}, "synonyms": {"synonym": ["Coagulation factor VII precursor", "EC 3.4.21.21", "Eptacog alfa", "Proconvertin", "Serum prothrombin conversion accelerator", "SPCA"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Coagulation factor VII precursor\nMVSQALRLLCLLLGLQGCLAAGGVAKASGGETRDMPWKPGPHRVFVTQEEAHGVLHRRRR\nANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGS\nCKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSL\nLADGVSCTPTVEYPCGKIPILEKRNASKPQGRIVGGKVCPKGECPWQVLLLVNGAQLCGG\nTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTN\nHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVL\nNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTG\nIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP"}, "gene-sequence": {"@format": "FASTA", "#text": ">1401 bp\nATGGTCTCCCAGGCCCTCAGGCTCCTCTGCCTTCTGCTTGGGCTTCAGGGCTGCCTGGCT\nGCAGGCGGGGTCGCTAAGGCCTCAGGAGGAGAAACACGGGACATGCCGTGGAAGCCGGGG\nCCTCACAGAGTCTTCGTAACCCAGGAGGAAGCCCACGGCGTCCTGCACCGGCGCCGGCGC\nGCCAACGCGTTCCTGGAGGAGCTGCGGCCGGGCTCCCTGGAGAGGGAGTGCAAGGAGGAG\nCAGTGCTCCTTCGAGGAGGCCCGGGAGATCTTCAAGGACGCGGAGAGGACGAAGCTGTTC\nTGGATTTCTTACAGTGATGGGGACCAGTGTGCCTCAAGTCCATGCCAGAATGGGGGCTCC\nTGCAAGGACCAGCTCCAGTCCTATATCTGCTTCTGCCTCCCTGCCTTCGAGGGCCGGAAC\nTGTGAGACGCACAAGGATGACCAGCTGATCTGTGTGAACGAGAACGGCGGCTGTGAGCAG\nTACTGCAGTGACCACACGGGCACCAAGCGCTCCTGTCGGTGCCACGAGGGGTACTCTCTG\nCTGGCAGACGGGGTGTCCTGCACACCCACAGTTGAATATCCATGTGGAAAAATACCTATT\nCTAGAAAAAAGAAATGCCAGCAAACCCCAAGGCCGAATTGTGGGGGGCAAGGTGTGCCCC\nAAAGGGGAGTGTCCATGGCAGGTCCTGTTGTTGGTGAATGGAGCTCAGTTGTGTGGGGGG\nACCCTGATCAACACCATCTGGGTGGTCTCCGCGGCCCACTGTTTCGACAAAATCAAGAAC\nTGGAGGAACCTGATCGCGGTGCTGGGCGAGCACGACCTCAGCGAGCACGACGGGGATGAG\nCAGAGCCGGCGGGTGGCGCAGGTCATCATCCCCAGCACGTACGTCCCGGGCACCACCAAC\nCACGACATCGCGCTGCTCCGCCTGCACCAGCCCGTGGTCCTCACTGACCATGTGGTGCCC\nCTCTGCCTGCCCGAACGGACGTTCTCTGAGAGGACGCTGGCCTTCGTGCGCTTCTCATTG\nGTCAGCGGCTGGGGCCAGCTGCTGGACCGTGGCGCCACGGCCCTGGAGCTCATGGTGCTC\nAACGTGCCCCGGCTGATGACCCAGGACTGCCTGCAGCAGTCACGGAAGGTGGGAGACTCC\nCCAAATATCACGGAGTACATGTTCTGTGCCGGCTACTCGGATGGCAGCAAGGACTCCTGC\nAAGGGGGACAGTGGAGGCCCACATGCCACCCACTACCGGGGCACGTGGTACCTGACGGGC\nATCGTCAGCTGGGGCCAGGGCTGCGCAACCGTGGGCCACTTTGGGGTGTACACCAGGGTC\nTCCCAGTACATCGAGTGGCTGCAAAAGCTCATGCGCTCAGAGCCACGCCCAGGAGTCCTC\nCTGCGAGCCCCATTTCCCTAG"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF00594", "name": "Gla"}, {"identifier": "PF00089", "name": "Trypsin"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "hemostasis"}, {"category": "process", "description": "blood coagulation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}]}}}, {"id": "BE0001178", "name": "Tissue factor", "organism": "Human", "actions": null, "references": "# HERMANSKY F, VITEK J: The role of proconvertin and Stuart factor in the inactivation of tissue thromboplastin by serum. Experientia. 1960 Oct 15;16:455-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/13713641\n# Rogers KS, Barton CL, Benson PA, Green RA: Effects of single-dose L-asparaginase on coagulation values in healthy dogs and dogs with lymphoma. Am J Vet Res. 1992 Apr;53(4):580-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1586032\n# Christensen NJ: Measurements of some blood clotting factors using a centrifugal analyser (Multistat III). Scand J Clin Lab Invest. 1983 Oct;43(6):521-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/6658368", "known-action": "unknown", "polypeptide": {"@id": "P13726", "@source": "Swiss-Prot", "name": "Tissue factor", "general-function": null, "specific-function": "Initiates blood coagulation by forming a complex with circulating factor VII or VIIa. The [TF:VIIa] complex activates factors IX or X by specific limited protolysis. TF plays a role in normal hemostasis by initiating the cell-surface assembly and propagation of the coagulation protease cascade", "gene-name": "F3", "locus": "1p22-p21", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "252-274", "signal-regions": null, "theoretical-pi": "7.09", "molecular-weight": "33068.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3541"}, {"resource": "GenAtlas", "identifier": "F3"}, {"resource": "GeneCards", "identifier": "F3"}, {"resource": "GenBank Gene Database", "identifier": "M16553"}, {"resource": "GenBank Protein Database", "identifier": "339504"}, {"resource": "UniProtKB", "identifier": "P13726"}, {"resource": "UniProt Accession", "identifier": "TF_HUMAN"}]}, "synonyms": {"synonym": ["CD142 antigen", "Coagulation factor III", "TF", "Thromboplastin", "Tissue factor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Tissue factor precursor\nMETPAWPRVPRPETAVARTLLLGWVFAQVAGASGTTNTVAAYNLTWKSTNFKTILEWEPK\nPVNQVYTVQISTKSGDWKSKCFYTTDTECDLTDEIVKDVKQTYLARVFSYPAGNVESTGS\nAGEPLYENSPEFTPYLETNLGQPTIQSFEQVGTKVNVTVEDERTLVRRNNTFLSLRDVFG\nKDLIYTLYYWKSSSSGKKTAKTNTNEFLIDVDKGENYCFSVQAVIPSRTVNRKSTDSPVE\nCMGQEKGEFREIFYIIGAVVFVVIILVIILAISLHKCRKAGVGQSWKENSPLNVS"}, "gene-sequence": {"@format": "FASTA", "#text": ">888 bp\nATGGAGACCCCTGCCTGGCCCCGGGTCCCGCGCCCCGAGACCGCCGTCGCTCGGACGCTC\nCTGCTCGGCTGGGTCTTCGCCCAGGTGGCCGGCGCTTCAGGCACTACAAATACTGTGGCA\nGCATATAATTTAACTTGGAAATCAACTAATTTCAAGACAATTTTGGAGTGGGAACCCAAA\nCCCGTCAATCAAGTCTACACTGTTCAAATAAGCACTAAGTCAGGAGATTGGAAAAGCAAA\nTGCTTTTACACAACAGACACAGAGTGTGACCTCACCGACGAGATTGTGAAGGATGTGAAG\nCAGACGTACTTGGCACGGGTCTTCTCCTACCCGGCAGGGAATGTGGAGAGCACCGGTTCT\nGCTGGGGAGCCTCTGTATGAGAACTCCCCAGAGTTCACACCTTACCTGGAGACAAACCTC\nGGACAGCCAACAATTCAGAGTTTTGAACAGGTGGGAACAAAAGTGAATGTGACCGTAGAA\nGATGAACGGACTTTAGTCAGAAGGAACAACACTTTCCTAAGCCTCCGGGATGTTTTTGGC\nAAGGACTTAATTTATACACTTTATTATTGGAAATCTTCAAGTTCAGGAAAGAAAACAGCC\nAAAACAAACACTAATGAGTTTTTGATTGATGTGGATAAAGGAGAAAACTACTGTTTCAGT\nGTTCAAGCAGTGATTCCCTCCCGAACAGTTAACCGGAAGAGTACAGACAGCCCGGTAGAG\nTGTATGGGCCAGGAGAAAGGGGAATTCAGAGAAATATTCTACATCATTGGAGCTGTGGCA\nTTTGTGGTCATCATCCTTGTCATCATCCTGGCTATATCTCTACACAAGTGTAGAAAGGCA\nGGAGTGGGGCAGAGCTGGAAGGAGAACTCCCCACTGAATGTTTCATAA"}, "pfams": {"pfam": {"identifier": "PF01108", "name": "Tissue_fac"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "process", "description": "blood coagulation"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "hemostasis"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2010-09-29", "drugbank-id": [{"@primary": "true", "#text": "DB00038"}, "BIOD00021", "BTD00021"], "name": "Oprelvekin", "description": "Oprelvekin, the active ingredient in Neumega\u00ae is recombinant Interleukin eleven, which is produced in Escherichia coli (E. coli) by recombinant DNA technology. The protein has a molecular mass of approximately 19,000 daltons, and is non-glycosylated. The polypeptide is 177 amino acids in length (the natural IL-11 has 178). This alteration has not resulted in measurable differences in bioactivity either in vitro or in vivo.\n\nThe primary hematopoietic activity of Neumega\u00ae is stimulation of megakaryocytopoiesis and thrombopoiesis. In mice and nonhuman primate studies Neumega\u00ae has shown potent thrombopoietic activity in compromised hematopoiesis, including moderately to severely myelosuppressed animals. In these studies, Neumega\u00ae improved platelet nadirs and accelerated platelet recoveries compared to controls.\n\nIn animal studies Oprelvekin also has non-hematopoetic activities. This includes the regulation of intestinal epithelium growth (enhanced healing of gastrointestinal lesions), the inhibition of adipogenesis, the induction of acute phase protein synthesis (e.g., fibrinogen), and inhibition of macrophageal released pro-inflammatory cytokines.", "cas-number": "145941-26-0", "groups": {"group": ["approved", "investigational"]}, "general-references": null, "synthesis-reference": null, "indication": "Increases reduced platelet levels due to chemotherapy", "pharmacodynamics": "Oprelvekin is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia. The primary hematopoietic activity of Oprelvekin is stimulation of megakaryocytopoiesis and thrombopoiesis. Oprelvekin has shown potent thrombopoietic activity in individuals with compromised hematopoiesis", "mechanism-of-action": "Oprelvekin binds to the interleukin 11 receptor which leads to a cascade of signal transduction events. IL-11 is a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production.", "toxicity": null, "metabolism": null, "absorption": "Absolute bioavailability is over 80%.", "half-life": "6.9 +/- 1.7 hrs", "protein-binding": null, "route-of-elimination": "The kidney is the primary route of elimination. The amount of intact Neumega in urine was low, indicating that the molecule was metabolized before excretion.", "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Adipogenesis inhibitory factor"}, {"@language": "", "@coder": "", "#text": "AGIF"}, {"@language": "", "@coder": "", "#text": "IL-11"}, {"@language": "", "@coder": "", "#text": "Interleukin-11 precursor"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": {"packager": [{"name": "Physicians Total Care Inc.", "url": "http://www.physicianstotalcare.com"}, {"name": "Wyeth Pharmaceuticals", "url": "http://www.wyeth.com"}]}, "manufacturers": null, "prices": {"price": {"description": "Neumega 5 mg vial", "cost": {"@currency": "USD", "#text": "352.9"}, "unit": "vial"}}, "categories": {"category": [{"category": "Antineoplastic Agents", "mesh-id": null}, {"category": "Coagulants", "mesh-id": null}, {"category": "Thrombotic Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": null, "atc-codes": {"atc-code": {"@code": "L03AC02", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L03", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03A", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03AC", "#text": "Interleukins"}]}}, "ahfs-codes": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00038 sequence\nGPPPGPPRVSPDPRAELDSTVLLTRSLLADTRQLAAQLRDKFPADGDHNLDSLPTLAMSA\nGALGALQLPGVLTRLRADLLSYLRHVQWLRRAGGSSLKTLEPELGTLQARLDRLLRRLQL\nLMSRLALPQPPPDPPAPPLAPPSSAWGGIRAAHAILGGLHLTLDWAVRGLLLLKTRL"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.070", "source": null}, {"kind": "Isoelectric Point", "value": "11.16", "source": null}, {"kind": "Molecular Weight", "value": "19047.2000", "source": null}, {"kind": "Molecular Formula", "value": "C854H1411N253O235S2", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "National Drug Code Directory", "identifier": "58394-004-01"}, {"resource": "GenBank", "identifier": "M57765"}, {"resource": "PharmGKB", "identifier": "PA164747991"}, {"resource": "UniProtKB", "identifier": "P20809"}, {"resource": "Wikipedia", "identifier": "Oprelvekin"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/oprelvek.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/oprelvekin.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0000416", "name": "Interleukin-11 receptor subunit alpha", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Nandurkar HH, Robb L, Begley CG: The role of IL-II in hematopoiesis as revealed by a targeted mutation of its receptor. Stem Cells. 1998;16 Suppl 2:53-65. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11012177\n# Li R, Hartley L, Robb L: Cloning of rat interleukin 11 and interleukin 11 receptor alpha chain and analysis of their expression in rat uterus in the peri-implantation period. Reproduction. 2001 Oct;122(4):593-600. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11570967\n# Nandurkar HH, Hilton DJ, Nathan P, Willson T, Nicola N, Begley CG: The human IL-11 receptor requires gp130 for signalling: demonstration by molecular cloning of the receptor. Oncogene. 1996 Feb 1;12(3):585-93. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8637716\n# Romas E, Udagawa N, Zhou H, Tamura T, Saito M, Taga T, Hilton DJ, Suda T, Ng KW, Martin TJ: The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J Exp Med. 1996 Jun 1;183(6):2581-91. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8676079\n# Nandurkar HH, Robb L, Tarlinton D, Barnett L, Kontgen F, Begley CG: Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis. Blood. 1997 Sep 15;90(6):2148-59. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9310465\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "Q14626", "@source": "Swiss-Prot", "name": "Interleukin-11 receptor subunit alpha", "general-function": "Involved in hematopoietin/interferon-class (D200-domain) cytokine receptor activity", "specific-function": "Receptor for interleukin-11. The receptor systems for IL6, LIF, OSM, CNTF, IL11 and CT1 can utilize IL6ST for initiating signal transmission. The IL11/IL11RA/IL6ST complex may be involved in the control of proliferation and/or differentiation of skeletogenic progenitor or other mesenchymal cells", "gene-name": "IL11RA", "locus": "9p13", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "371-391", "signal-regions": null, "theoretical-pi": "7.91", "molecular-weight": "45223.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5967"}, {"resource": "GenAtlas", "identifier": "IL11RA"}, {"resource": "GeneCards", "identifier": "IL11RA"}, {"resource": "GenBank Gene Database", "identifier": "Z38102"}, {"resource": "GenBank Protein Database", "identifier": "995654"}, {"resource": "UniProtKB", "identifier": "Q14626"}, {"resource": "UniProt Accession", "identifier": "I11RA_HUMAN"}]}, "synonyms": {"synonym": ["IL- 11RA", "IL-11R-alpha", "Interleukin-11 receptor alpha chain precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interleukin-11 receptor alpha chain precursor\nMSSSCSGLSRVLVAVATALVSASSPCPQAWGPPGVQYGQPGRSVKLCCPGVTAGDPVSWF\nRDGEPKLLQGPDSGLGHELVLAQADSTDEGTYICQTLDGALGGTVTLQLGYPPARPVVSC\nQAADYENFSCTWSPSQISGLPTRYLTSYRKKTVLGADSQRRSPSTGPWPCPQDPLGAARC\nVVHGAEFWSQYRINVTEVNPLGASTRLLDVSLQSILRPDPPQGLRVESVPGYPRRLRASW\nTYPASWPCQPHFLLKFRLQYRPAQHPAWSTVEPAGLEEVITDAVAGLPHAVRVSARDFLD\nAGTWSTWSPEAWGTPSTGTIPKEIPAWGQLHTQPEVEPQVDSPAPPRPSLQPHPRLLDHR\nDSVEQVAVLASLGILSFLGLVAGALALGLWLRLRRGGKDGSPKPGFLASVIPVDRRPGAP\nNL"}, "gene-sequence": {"@format": "FASTA", "#text": ">1269 bp\nATGAGCAGCAGCTGCTCAGGGCTGAGCAGGGTCCTGGTGGCCGTGGCTACAGCCCTGGTG\nTCTGCCTCCTCCCCCTGCCCCCAGGCCTGGGGCCCCCCAGGGGTCCAGTATGGGCAGCCA\nGGCAGGTCCGTGAAGCTGTGTTGTCCTGGAGTGACTGCCGGGGACCCAGTGTCCTGGTTT\nCGGGATGGGGAGCCAAAGCTGCTCCAGGGACCTGACTCTGGGCTAGGGCATGAACTGGTC\nCTGGCCCAGGCAGACAGCACTGATGAGGGCACCTACATCTGCCAGACCCTGGATGGTGCA\nCTTGGGGGCACAGTGACCCTGCAGCTGGGCTACCCTCCAGCCCGCCCTGTTGTCTCCTGC\nCAAGCAGCCGACTATGAGAACTTCTCTTGCACTTGGAGTCCCAGCCAGATCAGCGGTTTA\nCCCACCCGCTACCTCACCTCCTACAGGAAGAAGACAGTCCTAGGAGCTGATAGCCAGAGG\nAGGAGTCCATCCACAGGGCCCTGGCCATGCCCACAGGATCCCCTAGGGGCTGCCCGCTGT\nGTTGTCCACGGGGCTGAGTTCTGGAGCCAGTACCGGATTAATGTGACTGAGGTGAACCCA\nCTGGGTGCCAGCACACGCCTGCTGGATGTGAGCTTGCAGAGCATCTTGCGCCCTGACCCA\nCCCCAGGGCCTGCGGGTAGAGTCAGTACCAGGTTACCCCCGACGCCTGCGAGCCAGCTGG\nACATACCCTGCCTCCTGGCCGTGCCAGCCCCACTTCCTGCTCAAGTTCCGTTTGCAGTAC\nCGTCCGGCGCAGCATCCAGCCTGGTCCACGGTGGAGCCAGCTGGACTGGAGGAGGTGATC\nACAGATGCTGTGGCTGGGCTGCCCCATGCTGTACGAGTCAGTGCCCGGGACTTTCTAGAT\nGCTGGCACCTGGAGCACCTGGAGCCCGGAGGCCTGGGGAACTCCGAGCACTGGGACCATA\nCCAAAGGAGATACCAGCATGGGGCCAGCTACACACGCAGCCAGAGGTGGAGCCTCAGGTG\nGACAGCCCTGCTCCTCCAAGGCCCTCCCTCCAACCACACCCTCGGCTACTTGATCACAGG\nGACTCTGTGGAGCAGGTAGCTGTGCTGGCGTCTTTGGGAATCCTTTCTTTCCTGGGACTG\nGTGGCTGGGGCCCTGGCACTGGGGCTCTGGCTGAGGCTGAGACGGGGTGGGAAGGATGGA\nTCCCCAAAGCCTGGGTTCTTGGCCTCAGTGATTCCAGTGGACAGGCGTCCAGGAGCTCCA\nAACCTGTAG"}, "pfams": {"pfam": [{"identifier": "PF00047", "name": "ig"}, {"identifier": "PF00041", "name": "fn3"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "hematopoietin/interferon-class (D200-domain) cytokine receptor activity"}]}}}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-12-01", "drugbank-id": [{"@primary": "true", "#text": "DB00039"}, "BIOD00042", "BTD00042"], "name": "Palifermin", "description": "Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli.", "cas-number": "162394-19-6", "groups": {"group": "approved"}, "general-references": "#Lexicomp [Internet]. Palifermin. 2014 [cited 1 December 2014]. Available from: http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7429#f_interactions", "synthesis-reference": null, "indication": "For treatment of oral mucositis associated with chemotherapy and radiation therapy.", "pharmacodynamics": "Used in the prevention or treatment of oral mucoscitis (mouth ulcers arising from chemotherapy), Kepivance binds to the human keratinocyte growth factor (KGF) receptor on buccal cell surfaces. Kepivance acts as both a cell growth and survival factor by stimulating epithelial cell proliferation, differentiation, and migration around the tongue and mouth. The KGF receptor is found on many tissues particularly around the tongue, esophagus, salivary gland and other gastro-intestinal tract organs.", "mechanism-of-action": "Kepivance binds to the human keratinocyte growth factor (KGF) receptor found on buccal cell surfaces. The binding activates a Ras-MapK (Map kinase) signaling pathway which leads to the transcriptional activation of many proteins important for cell growth and survival.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": "Elimination half-life: 4.5 hours (range: 3.3-5.7 hours)", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "FGF-7"}, {"@language": "", "@coder": "", "#text": "Fibroblast growth factor- 7"}, {"@language": "", "@coder": "", "#text": "HBGF-7"}, {"@language": "", "@coder": "", "#text": "Keratinocyte growth factor precursor"}, {"@language": "", "@coder": "", "#text": "KGF"}]}, "products": {"product": [{"name": "Kepivance", "ndc-id": "66658-112_1cf1e381-844f-4c03-8c6f-581b0b79b3bf", "ndc-product-code": "66658-112", "dpd-id": null, "started-marketing-on": "2009-12-15", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "6.25 mg/1.2mL", "route": "intravenous", "fda-application-number": "BLA125103", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Kepivance", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02274221", "started-marketing-on": "2006-03-14", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "6.25 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Kepivance", "ingredients": "Palifermin"}, {"name": "Kepivance", "ingredients": "Palifermin"}]}, "packagers": {"packager": [{"name": "Amgen Inc.", "url": "http://www.amgen.com"}, {"name": "Baxter International Inc.", "url": "http://www.baxter.com"}, {"name": "BioVitrum AB", "url": "http://www.biovitrum.com"}]}, "manufacturers": null, "prices": {"price": {"description": "Kepivance 6.25 mg vial", "cost": {"@currency": "USD", "#text": "1650.0"}, "unit": "vial"}}, "categories": {"category": {"category": "Anti-Mucositis Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, powder, lyophilized, for solution", "route": "intravenous", "strength": "6.25 mg/1.2mL"}, {"form": "Powder for solution", "route": "intravenous", "strength": "6.25 mg"}]}, "atc-codes": {"atc-code": {"@code": "V03AF08", "level": [{"@code": "V", "#text": "VARIOUS"}, {"@code": "V03", "#text": "ALL OTHER THERAPEUTIC PRODUCTS"}, {"@code": "V03A", "#text": "ALL OTHER THERAPEUTIC PRODUCTS"}, {"@code": "V03AF", "#text": "Detoxifying agents for antineoplastic treatment"}]}}, "ahfs-codes": {"ahfs-code": "84:16.00"}, "patents": null, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB06779", "name": "Dalteparin", "description": "Heparin (Low Molecular Weight) may increase the serum concentration of Palifermin."}, {"drugbank-id": "DB01225", "name": "Enoxaparin", "description": "Heparin (Low Molecular Weight) may increase the serum concentration of Palifermin."}, {"drugbank-id": "DB01109", "name": "Heparin", "description": "May increase the serum concentration of Palifermin."}, {"drugbank-id": "DB08813", "name": "Nadroparin", "description": "Heparin (Low Molecular Weight) may increase the serum concentration of Palifermin."}, {"drugbank-id": "DB06822", "name": "Tinzaparin", "description": "Heparin (Low Molecular Weight) may increase the serum concentration of Palifermin."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">Palifermin sequence\nSYDYMEGGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNNYNIMEIRTVAVGIVAIKGVE\nSEFYLAMNKEGKLYAKKECNEDCNFKELILENHYNTYASAKWTHNGGEMFVALNQKGIPV\nRGKKTKKEQKTAHFLPMAIT"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.650", "source": null}, {"kind": "Isoelectric Point", "value": "9.47", "source": null}, {"kind": "Molecular Weight", "value": "16192.7000", "source": null}, {"kind": "Molecular Formula", "value": "C721H1142N202O204S9", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "17147"}, {"resource": "National Drug Code Directory", "identifier": "55513-520-06"}, {"resource": "GenBank", "identifier": "M60828"}, {"resource": "PharmGKB", "identifier": "PA164744014"}, {"resource": "UniProtKB", "identifier": "P21781"}, {"resource": "Wikipedia", "identifier": "Palifermin"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/kepivance.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/palifermin.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000748", "name": "Fibroblast growth factor receptor 2", "organism": "Human", "actions": {"action": "binder"}, "references": "# Beaven AW, Shea TC: Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant. Drugs Today (Barc). 2007 Jul;43(7):461-73. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17728847\n# Radtke ML, Kolesar JM: Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support. J Oncol Pharm Pract. 2005 Sep;11(3):121-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16390600\n# Huang YW, Wang LS, Chang HL, Ye W, Shu S, Sugimoto Y, Lin YC: Effect of keratinocyte growth factor on cell viability in primary cultured human prostate cancer stromal cells. J Steroid Biochem Mol Biol. 2006 Jul;100(1-3):24-33. Epub 2006 Jul 18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16854582\n# Patrie KM, Kudla AJ, Olwin BB, Chiu IM: Conservation of ligand specificity between the mammalian and amphibian fibroblast growth factor receptors. J Biol Chem. 1995 Dec 1;270(48):29018-24. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7499435\n# Cardoso WV, Itoh A, Nogawa H, Mason I, Brody JS: FGF-1 and FGF-7 induce distinct patterns of growth and differentiation in embryonic lung epithelium. Dev Dyn. 1997 Mar;208(3):398-405. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9056643\n# Berman B, Ostrovsky O, Shlissel M, Lang T, Regan D, Vlodavsky I, Ishai-Michaeli R, Ron D: Similarities and differences between the effects of heparin and glypican-1 on the bioactivity of acidic fibroblast growth factor and the keratinocyte growth factor. J Biol Chem. 1999 Dec 17;274(51):36132-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10593896\n# Zhu X, Lee K, Asa SL, Ezzat S: Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells. Am J Pathol. 2007 May;170(5):1618-28. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17456767\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P21802", "@source": "Swiss-Prot", "name": "Fibroblast growth factor receptor 2", "general-function": "Involved in protein kinase activity", "specific-function": "Receptor for acidic and basic fibroblast growth factors", "gene-name": "FGFR2", "locus": "10q26", "cellular-location": "Cell membrane; single-pass type I membrane protein. Isoform 14:Secreted protein. Isoform 19:Secreted", "transmembrane-regions": "378-398", "signal-regions": null, "theoretical-pi": "5.68", "molecular-weight": "92026.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3689"}, {"resource": "GenAtlas", "identifier": "FGFR2"}, {"resource": "GeneCards", "identifier": "FGFR2"}, {"resource": "GenBank Gene Database", "identifier": "X52832"}, {"resource": "GenBank Protein Database", "identifier": "31374"}, {"resource": "UniProtKB", "identifier": "P21802"}, {"resource": "UniProt Accession", "identifier": "FGFR2_HUMAN"}]}, "synonyms": {"synonym": ["CD332 antigen", "EC 2.7.10.1", "FGFR-2", "Fibroblast growth factor receptor 2 precursor", "Keratinocyte growth factor receptor 2"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Fibroblast growth factor receptor 2 precursor\nMVSWGRFICLVVVTMATLSLARPSFSLVEDTTLEPEEPPTKYQISQPEVYVAAPGESLEV\nRCLLKDAAVISWTKDGVHLGPNNRTVLIGEYLQIKGATPRDSGLYACTASRTVDSETWYF\nMVNVTDAISSGDDEDDTDGAEDFVSENSNNKRAPYWTNTEKMEKRLHAVPAANTVKFRCP\nAGGNPMPTMRWLKNGKEFKQEHRIGGYKVRNQHWSLIMESVVPSDKGNYTCVVENEYGSI\nNHTYHLDVVERSPHRPILQAGLPANASTVVGGDVEFVCKVYSDAQPHIQWIKHVEKNGSK\nYGPDGLPYLKVLKAAGVNTTDKEIEVLYIRNVTFEDAGEYTCLAGNSIGISFHSAWLTVL\nPAPGREKEITASPDYLEIAIYCIGVFLIACMVVTVILCRMKNTTKKPDFSSQPAVHKLTK\nRIPLRRQVTVSAESSSSMNSNTPLVRITTRLSSTADTPMLAGVSEYELPEDPKWEFPRDK\nLTLGKPLGEGCFGQVVMAEAVGIDKDKPKEAVTVAVKMLKDDATEKDLSDLVSEMEMMKM\nIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLRARRPPGMEYSYDINRVPEEQMTF\nKDLVSCTYQLARGMEYLASQKCIHRDLAARNVLVTENNVMKIADFGLARDINNIDYYKKT\nTNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLMWEIFTLGGSPYPGIPVEELFKLLKEGH\nRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLDLSQPLEQYS\nPSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSVKT"}, "gene-sequence": {"@format": "FASTA", "#text": ">2466 bp\nATGGTCAGCTGGGGTCGTTTCATCTGCCTGGTCGTGGTCACCATGGCAACCTTGTCCCTG\nGCCCGGCCCTCCTTCAGTTTAGTTGAGGATACCACATTAGAGCCAGAAGAGCCACCAACC\nAAATACCAAATCTCTCAACCAGAAGTGTACGTGGCTGCACCAGGGGAGTCGCTAGAGGTG\nCGCTGCCTGTTGAAAGATGCCGCCGTGATCAGTTGGACTAAGGATGGGGTGCACTTGGGG\nCCCAACAATAGGACAGTGCTTATTGGGGAGTACTTGCAGATAAAGGGCGCCACGCCTAGA\nGACTCCGGCCTCTATGCTTGTACTGCCAGTAGGACTGTAGACAGTGAAACTTGGTACTTC\nATGGTGAATGTCACAGATGCCATCTCATCCGGAGATGATGAGGATGACACCGATGGTGCG\nGAAGATTTTGTCAGTGAGAACAGTAACAACAAGAGAGCACCATACTGGACCAACACAGAA\nAAGATGGAAAAGCGGCTCCATGCTGTGCCTGCGGCCAACACTGTCAAGTTTCGCTGCCCA\nGCCGGGGGGAACCCAATGCCAACCATGCGGTGGCTGAAAAACGGGAAGGAGTTTAAGCAG\nGAGCATCGCATTGGAGGCTACAAGGTACGAAACCAGCACTGGAGCCTCATTATGGAAAGT\nGTGGTCCCATCTGACAAGGGAAATTATACCTGTGTGGTGGAGAATGAATACGGGTCCATC\nAATCACACGTACCACCTGGATGTTGTGGAGCGATCGCCTCACCGGCCCATCCTCCAAGCC\nGGACTGCCGGCAAATGCCTCCACAGTGGTCGGAGGAGACGTAGAGTTTGTCTGCAAGGTT\nTACAGTGATGCCCAGCCCCACATCCAGTGGATCAAGCACGTGGAAAAGAACGGCAGTAAA\nTACGGGCCCGACGGGCTGCCCTACCTCAAGGTTCTCAAGGCCGCCGGTGTTAACACCACG\nGACAAAGAGATTGAGGTTCTCTATATTCGGAATGTAACTTTTGAGGACGCTGGGGAATAT\nACGTGCTTGGCGGGTAATTCTATTGGGATATCCTTTCACTCTGCATGGTTGACAGTTCTG\nCCAGCGCCTGGAAGAGAAAAGGAGATTACAGCTTCCCCAGACTACCTGGAGATAGCCATT\nTACTGCATAGGGGTCTTCTTAATCGCCTGTATGGTGGTAACAGTCATCCTGTGCCGAATG\nAAGAACACGACCAAGAAGCCAGACTTCAGCAGCCAGCCGGCTGTGCACAAGCTGACCAAA\nCGTATCCCCCTGCGGAGACAGGTAACAGTTTCGGCTGAGTCCAGCTCCTCCATGAACTCC\nAACACCCCGCTGGTGAGGATAACAACACGCCTCTCTTCAACGGCAGACACCCCCATGCTG\nGCAGGGGTCTCCGAGTATGAACTTCCAGAGGACCCAAAATGGGAGTTTCCAAGAGATAAG\nCTGACACTGGGCAAGCCCCTGGGAGAAGGTTGCTTTGGGCAAGTGGTCATGGCGGAAGCA\nGTGGGAATTGACAAAGACAAGCCCAAGGAGGCGGTCACCGTGGCCGTGAAGATGTTGAAA\nGATGATGCCACAGAGAAAGACCTTTCTGATCTGGTGTCAGAGATGGAGATGATGAAGATG\nATTGGGAAACACAAGAATATCATAAATCTTCTTGGAGCCTGCACACAGGATGGGCCTCTC\nTATGTCATAGTTGAGTATGCCTCTAAAGGCAACCTCCGAGAATACCTCCGAGCCCGGAGG\nCCACCCGGGATGGAGTACTCCTATGACATTAACCGTGTTCCTGAGGAGCAGATGACCTTC\nAAGGACTTGGTGTCATGCACCTACCAGCTGGCCAGAGGCATGGAGTACTTGGCTTCCCAA\nAAATGTATTCATCGAGATTTAGCAGCCAGAAATGTTTTGGTAACAGAAAACAATGTGATG\nAAAATAGCAGACTTTGGACTCGCCAGAGATATCAACAATATAGACTATTACAAAAAGACC\nACCAATGGGCGGCTTCCAGTCAAGTGGATGGCTCCAGAAGCCCTGTTTGATAGAGTATAC\nACTCATCAGAGTGATGTCTGGTCCTTCGGGGTGTTAATGTGGGAGATCTTCACTTTAGGG\nGGCTCGCCCTACCCAGGGATTCCCGTGGAGGAACTTTTTAAGCTGCTGAAGGAAGGACAC\nAGAATGGATAAGCCAGCCAACTGCACCAACGAACTGTACATGATGATGAGGGACTGTTGG\nCATGCAGTGCCCTCCCAGAGACCAACGTTCAAGCAGTTGGTAGAAGACTTGGATCGAATT\nCTCACTCTCACAACCAATGAGGAATACTTGGACCTCAGCCAACCTCTCGAACAGTATTCA\nCCTAGTTACCCTGACACAAGAAGTTCTTGTTCTTCAGGAGATGATTCTGTTTTTTCTCCA\nGACCCCATGCCTTACGAACCATGCCTTCCTCAGTATCCACACATAAACGGCAGTGTTAAA\nACATGA"}, "pfams": {"pfam": [{"identifier": "PF07714", "name": "Pkinase_Tyr"}, {"identifier": "PF00047", "name": "ig"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "transferase activity"}, {"category": "function", "description": "protein-tyrosine kinase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "transferase activity, transferring phosphorus-containing groups"}, {"category": "function", "description": "kinase activity"}, {"category": "function", "description": "protein kinase activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "biopolymer metabolism"}, {"category": "process", "description": "biopolymer modification"}, {"category": "process", "description": "protein amino acid phosphorylation"}, {"category": "process", "description": "protein modification"}]}}}, {"id": "BE0002129", "name": "Neuropilin-1", "organism": "Human", "actions": null, "references": "# Beer HD, Vindevoghel L, Gait MJ, Revest JM, Duan DR, Mason I, Dickson C, Werner S: Fibroblast growth factor (FGF) receptor 1-IIIb is a naturally occurring functional receptor for FGFs that is preferentially expressed in the skin and the brain. J Biol Chem. 2000 May 26;275(21):16091-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10821861\n# Friedl A, Chang Z, Tierney A, Rapraeger AC: Differential binding of fibroblast growth factor-2 and -7 to basement membrane heparan sulfate: comparison of normal and abnormal human tissues. Am J Pathol. 1997 Apr;150(4):1443-55. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9094999\n# Wang F, Lu W, McKeehan K, Mohamedali K, Gabriel JL, Kan M, McKeehan WL: Common and specific determinants for fibroblast growth factors in the ectodomain of the receptor kinase complex. Biochemistry. 1999 Jan 5;38(1):160-71. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9890894", "known-action": "unknown", "polypeptide": {"@id": "O14786", "@source": "Swiss-Prot", "name": "Neuropilin-1", "general-function": null, "specific-function": "The soluble isoform 2 binds VEGF-165 and appears to inhibit its binding to cells. It may also induce apoptosis by sequestering VEGF-165. May bind as well various members of the semaphorin family. Its expression has an averse effect on blood vessel number and integrity", "gene-name": "NRP1", "locus": "10p12", "cellular-location": "Cell membrane", "transmembrane-regions": "857-879", "signal-regions": null, "theoretical-pi": "5.71", "molecular-weight": "103121.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:8004"}, {"resource": "GenAtlas", "identifier": "NRP1"}, {"resource": "GeneCards", "identifier": "NRP1"}, {"resource": "GenBank Gene Database", "identifier": "AF018956"}, {"resource": "GenBank Protein Database", "identifier": "2407641"}, {"resource": "UniProtKB", "identifier": "O14786"}, {"resource": "UniProt Accession", "identifier": "NRP1_HUMAN"}]}, "synonyms": {"synonym": ["CD304 antigen", "Neuropilin-1 precursor", "Vascular endothelial cell growth factor 165 receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Neuropilin-1\nMERGLPLLCAVLALVLAPAGAFRNDKCGDTIKIESPGYLTSPGYPHSYHPSEKCEWLIQA\nPDPYQRIMINFNPHFDLEDRDCKYDYVEVFDGENENGHFRGKFCGKIAPPPVVSSGPFLF\nIKFVSDYETHGAGFSIRYEIFKRGPECSQNYTTPSGVIKSPGFPEKYPNSLECTYIVFAP\nKMSEIILEFESFDLEPDSNPPGGMFCRYDRLEIWDGFPDVGPHIGRYCGQKTPGRIRSSS\nGILSMVFYTDSAIAKEGFSANYSVLQSSVSEDFKCMEALGMESGEIHSDQITASSQYSTN\nWSAERSRLNYPENGWTPGEDSYREWIQVDLGLLRFVTAVGTQGAISKETKKKYYVKTYKI\nDVSSNGEDWITIKEGNKPVLFQGNTNPTDVVVAVFPKPLITRFVRIKPATWETGISMRFE\nVYGCKITDYPCSGMLGMVSGLISDSQITSSNQGDRNWMPENIRLVTSRSGWALPPAPHSY\nINEWLQIDLGEEKIVRGIIIQGGKHRENKVFMRKFKIGYSNNGSDWKMIMDDSKRKAKSF\nEGNNNYDTPELRTFPALSTRFIRIYPERATHGGLGLRMELLGCEVEAPTAGPTTPNGNLV\nDECDDDQANCHSGTGDDFQLTGGTTVLATEKPTVIDSTIQSEFPTYGFNCEFGWGSHKTF\nCHWEHDNHVQLKWSVLTSKTGPIQDHTGDGNFIYSQADENQKGKVARLVSPVVYSQNSAH\nCMTFWYHMSGSHVGTLRVKLRYQKPEEYDQLVWMAIGHQGDHWKEGRVLLHKSLKLYQVI\nFEGEIGKGNLGGIAVDDISINNHISQEDCAKPADLDKKNPEIKIDETGSTPGYEGEGEGD\nKNISRKPGNVLKTLEPILITIIAMSALGVLLGAVCGVVLYCACWHNGMSERNLSALENYN\nFELVDGVKLKKDKLNTQSTYSEA"}, "gene-sequence": {"@format": "FASTA", "#text": ">2772 bp\nATGGAGAGGGGGCTGCCGCTCCTCTGCGCCGTGCTCGCCCTCGTCCTCGCCCCGGCCGGC\nGCTTTTCGCAACGATGAATGTGGCGATACTATAAAAATTGAAAGCCCCGGGTACCTTACA\nTCTCCTGGTTATCCTCATTCTTATCACCCAAGTGAAAAATGCGAATGGCTGATTCAGGCT\nCCGGACCCATACCAGAGAATTATGATCAACTTCAACCCTCACTTCGATTTGGAGGACAGA\nGACTGCAAGTATGACTACGTGGAAGTCTTCGATGGAGAAAATGAAAATGGACATTTTAGG\nGGAAAGTTCTGTGGAAAGATAGCCCCTCCTCCTGTTGTGTCTTCAGGGCCATTTCTTTTT\nATCAAATTTGTCTCTGACTACGAAACACATGGTGCAGGATTTTCCATACGTTATGAAATT\nTTCAAGAGAGGTCCTGAATGTTCCCAGAACTACACAACACCTAGTGGAGTGATAAAGTCC\nCCCGGATTCCCTGAAAAATATCCCAACAGCCTTGAATGCACTTATATTGTCTTTGCGCCA\nAAGATGTCAGAGATTATCCTGGAATTTGAAAGCTTTGACCTGGAGCCTGACTCAAATCCT\nCCAGGGGGGATGTTCTGTCGCTACGACCGGCTAGAAATCTGGGATGGATTCCCTGATGTT\nGGCCCTCACATTGGGCGTTACTGTGGACAGAAAACACCAGGTCGAATCCGATCCTCATCG\nGGCATTCTCTCCATGGTTTTTTACACCGACAGCGCGATAGCAAAAGAAGGTTTCTCAGCA\nAACTACAGTGTCTTGCAGAGCAGTGTCTCAGAAGATTTCAAATGTATGGAAGCTCTGGGC\nATGGAATCAGGAGAAATTCATTCTGACCAGATCACAGCTTCTTCCCAGTATAGCACCAAC\nTGGTCTGCAGAGCGCTCCCGCCTGAACTACCCTGAGAATGGGTGGACTCCCGGAGAGGAT\nTCCTACCGAGAGTGGATACAGGTAGACTTGGGCCTTCTGCGCTTTGTCACGGCTGTCGGG\nACACAGGGCGCCATTTCAAAAGAAACCAAGAAGAAATATTATGTCAAGACTTACAAGATC\nGACGTTAGCTCCAACGGGGAAGACTGGATCACCATAAAAGAAGGAAACAAACCTGTTCTC\nTTTCAGGGAAACACCAACCCCACAGATGTTGTGGTTGCAGTATTCCCCAAACCACTGATA\nACTCGATTTGTCCGAATCAAGCCTGCAACTTGGGAAACTGGCATATCTATGAGATTTGAA\nGTATACGGTTGCAAGATAACAGATTATCCTTGCTCTGGAATGTTGGGTATGGTGTCTGGA\nCTTATTTCTGACTCCCAGATCACATCATCCAACCAAGGAGACAGAAACTGGATGCCTGAA\nAACATCCGCCTGGTAACCAGTCGCTCTGGCTGGGCACTTCCACCCGCACCTCATTCCTAC\nATCAATGAGTGGCTCCAAATAGACCTGGGGGAGGAGAAGATCGTGAGGGGCATCATCATT\nCAGGGTGGGAAGCACCGAGAGAACAAGGTGTTCATGAGGAAGTTCAAGATCGGGTACAGC\nAACAACGGCTCGGACTGGAAGATGATCATGGATGACAGCAAACGCAAGGCGAAGTCTTTT\nGAGGGCAACAACAACTATGATACACCTGAGCTGCGGACTTTTCCAGCTCTCTCCACGCGA\nTTCATCAGGATCTACCCCGAGAGAGCCACTCATGGCGGACTGGGGCTCAGAATGGAGCTG\nCTGGGCTGTGAAGTGGAAGCCCCTACAGCTGGACCGACCACTCCCAACGGGAACTTGGTG\nGATGAATGTGATGACGACCAGGCCAACTGCCACAGTGGAACAGGTGATGACTTCCAGCTC\nACAGGTGGCACCACTGTGCTGGCCACAGAAAAGCCCACGGTCATAGACAGCACCATACAA\nTCAGAGTTTCCAACATATGGTTTTAACTGTGAATTTGGCTGGGGCTCTCACAAGACCTTC\nTGCCACTGGGAACATGACAATCACGTGCAGCTCAAGTGGAGTGTGTTGACCAGCAAGACG\nGGACCCATTCAGGATCACACAGGAGATGGCAACTTCATCTATTCCCAAGCTGACGAAAAT\nCAGAAGGGCAAAGTGGCTCGCCTGGTGAGCCCTGTGGTTTATTCCCAGAACTCTGCCCAC\nTGCATGACCTTCTGGTATCACATGTCTGGGTCCCACGTCGGCACACTCAGGGTCAAACTG\nCGCTACCAGAAGCCAGAGGAGTACGATCAGCTGGTCTGGATGGCCATTGGACACCAAGGT\nGACCACTGGAAGGAAGGGCGTGTCTTGCTCCACAAGTCTCTGAAACTTTATCAGGTGATT\nTTCGAGGGCGAAATCGGAAAAGGAAACCTTGGTGGGATTGCTGTGGATGACATTAGTATT\nAATAACCACATTTCACAAGAAGATTGTGCAAAACCAGCAGACCTGGATAAAAAGAACCCA\nGAAATTAAAATTGATGAAACAGGGAGCACGCCAGGATACGAAGGTGAAGGAGAAGGTGAC\nAAGAACATCTCCAGGAAGCCAGGCAATGTGTTGAAGACCTTAGAACCCATCCTCATCACC\nATCATAGCCATGAGCGCCCTGGGGGTCCTCCTGGGGGCTGTCTGTGGGGTCGTGCTGTAC\nTGTGCCTGTTGGCATAATGGGATGTCAGAAAGAAACTTGTCTGCCCTGGAGAACTATAAC\nTTTGAACTTGTGGATGGTGTGAAGTTGAAAAAAGACAAACTGAATACACAGAGTACTTAT\nTCGGAGGCATGA"}, "pfams": {"pfam": [{"identifier": "PF00754", "name": "F5_F8_type_C"}, {"identifier": "PF00629", "name": "MAM"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell adhesion"}]}}}, {"id": "BE0002131", "name": "Fibroblast growth factor receptor 1", "organism": "Human", "actions": null, "references": "# Ostrovsky O, Berman B, Gallagher J, Mulloy B, Fernig DG, Delehedde M, Ron D: Differential effects of heparin saccharides on the formation of specific fibroblast growth factor (FGF) and FGF receptor complexes. J Biol Chem. 2002 Jan 25;277(4):2444-53. Epub 2001 Nov 19. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11714710\n# Sher I, Lang T, Lubinsky-Mink S, Kuhn J, Adir N, Chatterjee S, Schomburg D, Ron D: Identification of residues important both for primary receptor binding and specificity in fibroblast growth factor-7. J Biol Chem. 2000 Nov 10;275(45):34881-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10950949\n# Matsubara A, Yasumoto H, Usui T: Hormone Refractory Prostate Cancer and Fibroblast Growth Factor Receptor. Breast Cancer. 1999 Oct 25;6(4):320-324. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11091737\n# Lu W, Luo Y, Kan M, McKeehan WL: Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem. 1999 Apr 30;274(18):12827-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10212269\n# Wang F, Lu W, McKeehan K, Mohamedali K, Gabriel JL, Kan M, McKeehan WL: Common and specific determinants for fibroblast growth factors in the ectodomain of the receptor kinase complex. Biochemistry. 1999 Jan 5;38(1):160-71. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9890894", "known-action": "unknown", "polypeptide": {"@id": "P11362", "@source": "Swiss-Prot", "name": "Fibroblast growth factor receptor 1", "general-function": null, "specific-function": "Receptor for basic fibroblast growth factor. A shorter form of the receptor could be a receptor for FGF1 (aFGF)", "gene-name": "FGFR1", "locus": "8p11.2-p11.1", "cellular-location": "Membrane", "transmembrane-regions": "377-397", "signal-regions": null, "theoretical-pi": "6.14", "molecular-weight": "91869.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3688"}, {"resource": "GenAtlas", "identifier": "FGFR1"}, {"resource": "GeneCards", "identifier": "FGFR1"}, {"resource": "GenBank Gene Database", "identifier": "X51803"}, {"resource": "GenBank Protein Database", "identifier": "31368"}, {"resource": "UniProtKB", "identifier": "P11362"}, {"resource": "UniProt Accession", "identifier": "FGFR1_HUMAN"}]}, "synonyms": {"synonym": ["Basic fibroblast growth factor receptor 1 precursor", "bFGF-R", "c-fgr", "CD331 antigen", "EC 2.7.10.1", "FGFR-1", "Fms-like tyrosine kinase 2"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Basic fibroblast growth factor receptor 1\nMWSWKCLLFWAVLVTATLCTARPSPTLPEQAQPWGAPVEVESFLVHPGDLLQLRCRLRDD\nVQSINWLRDGVQLAESNRTRITGEEVEVQDSVPADSGLYACVTSSPSGSDTTYFSVNVSD\nALPSSEDDDDDDDSSSEEKETDNTKPNRMPVAPYWTSPEKMEKKLHAVPAAKTVKFKCPS\nSGTPNPTLRWLKNGKEFKPDHRIGGYKVRYATWSIIMDSVVPSDKGNYTCIVENEYGSIN\nHTYQLDVVERSPHRPILQAGLPANKTVALGSNVEFMCKVYSDPQPHIQWLKHIEVNGSKI\nGPDNLPYVQILKTAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHSAWLTVLE\nALEERPAVMTSPLYLEIIIYCTGAFLISCMVGSVIVYKMKSGTKKSDFHSQMAVHKLAKS\nIPLRRQVTVSADSSASMNSGVLLVRPSRLSSSGTPMLAGVSEYELPEDPRWELPRDRLVL\nGKPLGEGCFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKDLSDLISEMEMMKMIGK\nHKNIINLLGACTQDGPLYVIVEYASKGNLREYLQARRPPGLEYCYNPSHNPEEQLSSKDL\nVSCAYQVARGMEYLASKKCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNG\nRLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPVEELFKLLKEGHRMD\nKPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQEYLDLSMPLDQYSPSF\nPDTRSSTCSSGEDSVFSHEPLPEEPCLPRHPAQLANGGLKRR"}, "gene-sequence": {"@format": "FASTA", "#text": ">2469 bp\nATGTGGAGCTGGAAGTGCCTCCTCTTCTGGGCTGTGCTGGTCACAGCCACACTCTGCACC\nGCTAGGCCGTCCCCGACCTTGCCTGAACAAGCCCAGCCCTGGGGAGCCCCTGTGGAAGTG\nGAGTCCTTCCTGGTCCACCCCGGTGACCTGCTGCAGCTTCGCTGTCGGCTGCGGGACGAT\nGTGCAGAGCATCAACTGGCTGCGGGACGGGGTGCAGCTGGCGGAAAGCAACCGCACCCGC\nATCACAGGGGAGGAGGTGGAGGTGCAGGACTCCGTGCCCGCAGACTCCGGCCTCTATGCT\nTGCGTAACCAGCAGCCCCTCGGGCAGTGACACCACCTACTTCTCCGTCAATGTTTCAGAT\nGCTCTCCCCTCCTCGGAGGATGATGATGATGATGATGACTCCTCTTCAGAGGAGAAAGAA\nACAGATAACACCAAACCAAACCGTATGCCCGTAGCTCCATATTGGACATCCCCAGAAAAG\nATGGAAAAGAAATTGCATGCAGTGCCGGCTGCCAAGACAGTGAAGTTCAAATGCCCTTCC\nAGTGGGACCCCAAACCCCACACTGCGCTGGTTGAAAAATGGCAAAGAATTCAAACCTGAC\nCACAGAATTGGAGGCTACAAGGTCCGTTATGCCACCTGGAGCATCATAATGGACTCTGTG\nGTGCCCTCTGACAAGGGCAACTACACCTGCATTGTGGAGAATGAGTACGGCAGCATCAAC\nCACACATACCAGCTGGATGTCGTGGAGCGGTCCCCTCACCGGCCCATCCTGCAAGCAGGG\nTTGCCCGCCAACAAAACAGTGGCCCTGGGTAGCAACGTGGAGTTCATGTGTAAGGTGTAC\nAGTGACCCGCAGCCGCACATCCAGTGGCTAAAGCACATCGAGGTGAATGGGAGCAAGATT\nGGCCCAGACAACCTGCCTTATGTCCAGATCTTGAAGACTGCTGGAGTTAATACCACCGAC\nAAAGAGATGGAGGTGCTTCACTTAAGAAATGTCTCCTTTGAGGACGCAGGGGAGTATACG\nTGCTTGGCGGGTAACTCTATCGGACTCTCCCATCACTCTGCATGGTTGACCGTTCTGGAA\nGCCCTGGAAGAGAGGCCGGCAGTGATGACCTCGCCCCTGTACCTGGAGATCATCATCTAT\nTGCACAGGGGCCTTCCTCATCTCCTGCATGGTGGGGTCGGTCATCGTCTACAAGATGAAG\nAGTGGTACCAAGAAGAGTGACTTCCACAGCCAGATGGCTGTGCACAAGCTGGCCAAGAGC\nATCCCTCTGCGCAGACAGGTAACAGTGTCTGCTGACTCCAGTGCATCCATGAACTCTGGG\nGTTCTTCTGGTTCGGCCATCACGGCTCTCCTCCAGTGGGACTCCCATGCTAGCAGGGGTC\nTCTGAGTATGAGCTTCCCGAAGACCCTCGCTGGGAGCTGCCTCGGGACAGACTGGTCTTA\nGGCAAACCCCTGGGAGAGGGCTGCTTTGGGCAGGTGGTGTTGGCAGAGGCTATCGGGCTG\nGACAAGGACAAACCCAACCGTGTGACCAAAGTGGCTGTGAAGATGTTGAAGTCGGACGCA\nACAGAGAAAGACTTGTCAGACCTGATCTCAGAAATGGAGATGATGAAGATGATCGGGAAG\nCATAAGAATATCATCAACCTGCTGGGGGCCTGCACGCAGGATGGTCCCTTGTATGTCATC\nGTGGAGTATGCCTCCAAGGGCAACCTGCGGGAGTACCTGCAGGCCCGGAGGCCCCCAGGG\nCTGGAATACTGCTACAACCCCAGCCACAACCCAGAGGAGCAGCTCTCCTCCAAGGACCTG\nGTGTCCTGCGCCTACCAGGTGGCCCGAGGCATGGAGTATCTGGCCTCCAAGAAGTGCATA\nCACCGAGACCTGGCAGCCAGGAATGTCCTGGTGACAGAGGACAATGTGATGAAGATAGCA\nGACTTTGGCCTCGCACGGGACATTCACCACATCGACTACTATAAAAAGACAACCAACGGC\nCGACTGCCTGTGAAGTGGATGGCACCCGAGGCATTATTTGACCGGATCTACACCCACCAG\nAGTGATGTGTGGTCTTTCGGGGTGCTCCTGTGGGAGATCTTCACTCTGGGCGGCTCCCCA\nTACCCCGGTGTGCCTGTGGAGGAACTTTTCAAGCTGCTGAAGGAGGGTCACCGCATGGAC\nAAGCCCAGTAACTGCACCAACGAGCTGTACATGATGATGCGGGACTGCTGGCATGCAGTG\nCCCTCACAGAGACCCACCTTCAAGCAGCTGGTGGAAGACCTGGACCGCATCGTGGCCTTG\nACCTCCAACCAGGAGTACCTGGACCTGTCCATGCCCCTGGACCAGTACTCCCCCAGCTTT\nCCCGACACCCGGAGCTCTACGTGCTCCTCAGGGGAGGATTCCGTCTTCTCTCATGAGCCG\nCTGCCCGAGGAGCCCTGCCTGCCCCGACACCCAGCCCAGCTTGCCAATCGGGGACTCAAA\nCGCCGCTGA"}, "pfams": {"pfam": [{"identifier": "PF07714", "name": "Pkinase_Tyr"}, {"identifier": "PF00047", "name": "ig"}, {"identifier": "PF07679", "name": "I-set"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "transferase activity"}, {"category": "function", "description": "protein-tyrosine kinase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "transferase activity, transferring phosphorus-containing groups"}, {"category": "function", "description": "kinase activity"}, {"category": "function", "description": "protein kinase activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "biopolymer metabolism"}, {"category": "process", "description": "biopolymer modification"}, {"category": "process", "description": "protein amino acid phosphorylation"}, {"category": "process", "description": "protein modification"}]}}}, {"id": "BE0001203", "name": "Fibroblast growth factor receptor 4", "organism": "Human", "actions": null, "references": "# Imagawa W, Cunha GR, Young P, Nandi S: Keratinocyte growth factor and acidic fibroblast growth factor are mitogens for primary cultures of mammary epithelium. Biochem Biophys Res Commun. 1994 Nov 15;204(3):1165-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7526860\n# Sher I, Lang T, Lubinsky-Mink S, Kuhn J, Adir N, Chatterjee S, Schomburg D, Ron D: Identification of residues important both for primary receptor binding and specificity in fibroblast growth factor-7. J Biol Chem. 2000 Nov 10;275(45):34881-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10950949\n# Sannes PL, Khosla J, Li CM, Pagan I: Sulfation of extracellular matrices modifies growth factor effects on type II cells on laminin substrata. Am J Physiol. 1998 Oct;275(4 Pt 1):L701-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9755102\n# Luo Y, Lu W, Mohamedali KA, Jang JH, Jones RB, Gabriel JL, Kan M, McKeehan WL: The glycine box: a determinant of specificity for fibroblast growth factor. Biochemistry. 1998 Nov 24;37(47):16506-15. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9843417\n# Yamanaka T, Sakamoto A, Tanaka Y, Zhang Y, Hayashido Y, Toratani S, Akagawa Y, Okamoto T: Isolation and serum-free culture of epithelial cells derived from epithelial rests of Malassez in human periodontal ligament. In Vitro Cell Dev Biol Anim. 2000 Sep;36(8):548-53. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11149756", "known-action": "unknown", "polypeptide": {"@id": "P22455", "@source": "Swiss-Prot", "name": "Fibroblast growth factor receptor 4", "general-function": "Involved in protein kinase activity", "specific-function": "Receptor for acidic fibroblast growth factor. Does not bind to basic fibroblast growth factor. Binds FGF19", "gene-name": "FGFR4", "locus": "5q35.1-qter", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "370-390", "signal-regions": null, "theoretical-pi": "6.81", "molecular-weight": "87955.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3691"}, {"resource": "GenAtlas", "identifier": "FGFR4"}, {"resource": "GeneCards", "identifier": "FGFR4"}, {"resource": "GenBank Gene Database", "identifier": "X57205"}, {"resource": "GenBank Protein Database", "identifier": "31372"}, {"resource": "UniProtKB", "identifier": "P22455"}, {"resource": "UniProt Accession", "identifier": "FGFR4_HUMAN"}]}, "synonyms": {"synonym": ["CD334 antigen", "EC 2.7.10.1", "FGFR-4", "Fibroblast growth factor receptor 4 precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Fibroblast growth factor receptor 4 precursor\nMRLLLALLGVLLSVPGPPVLSLEASEEVELEPCLAPSLEQQEQELTVALGQPVRLCCGRA\nERGGHWYKEGSRLAPAGRVRGWRGRLEIASFLPEDAGRYLCLARGSMIVLQNLTLITGDS\nLTSSNDDEDPKSHRDPSNRHSYPQQAPYWTHPQRMEKKLHAVPAGNTVKFRCPAAGNPTP\nTIRWLKDGQAFHGENRIGGIRLRHQHWSLVMESVVPSDRGTYTCLVENAVGSIRYNYLLD\nVLERSPHRPILQAGLPANTTAVVGSDVELLCKVYSDAQPHIQWLKHIVINGSSFGADGFP\nYVQVLKTADINSSEVEVLYLRNVSAEDAGEYTCLAGNSIGLSYQSAWLTVLPEEDPTWTA\nAAPEARYTDIILYASGSLALAVLLLLAGLYRGQALHGRHPRPPATVQKLSRFPLARQFSL\nESGSSGKSSSSLVRGVRLSSSGPALLAGLVSLDLPLDPLWEFPRDRLVLGKPLGEGCFGQ\nVVRAEAFGMDPARPDQASTVAVKMLKDNASDKDLADLVSEMEVMKLIGRHKNIINLLGVC\nTQEGPLYVIVECAAKGNLREFLRARRPPGPDLSPDGPRSSEGPLSFPVLVSCAYQVARGM\nQYLESRKCIHRDLAARNVLVTEDNVMKIADFGLARGVHHIDYYKKTSNGRLPVKWMAPEA\nLFDRVYTHQSDVWSFGILLWEIFTLGGSPYPGIPVEELFSLLREGHRMDRPPHCPPELYG\nLMRECWHAAPSQRPTFKQLVEALDKVLLAVSEEYLDLRLTFGPYSPSGGDASSTCSSSDS\nVFSHDPLPLGSSSFPFGSGVQT"}, "gene-sequence": {"@format": "FASTA", "#text": ">2409 bp\nATGCGGCTGCTGCTGGCCCTGTTGGGGGTCCTGCTGAGTGTGCCTGGGCCTCCAGTCTTG\nTCCCTGGAGGCCTCTGAGGAAGTGGAGCTTGAGCCCTGCCTGGCTCCCAGCCTGGAGCAG\nCAAGAGCAGGAGCTGACAGTAGCCCTTGGGCAGCCTGTGCGTCTGTGCTGTGGGCGGGCT\nGAGCGTGGTGGCCACTGGTACAAGGAGGGCAGTCGCCTGGCACCTGCTGGCCGTGTACGG\nGGCTGGAGGGGCCGCCTAGAGATTGCCAGCTTCCTACCTGAGGATGCTGGCCGCTACCTC\nTGCCTGGCACGAGGCTCCATGATCGTCCTGCAGAATCTCACCTTGATTACAGGTGACTCC\nTTGACCTCCAGCAACGATGATGAGGACCCCAAGTCCCATAGGGACCCCTCGAATAGGCAC\nAGTTACCCCCAGCAAGCACCCTACTGGACACACCCCCAGCGCATGGAGAAGAAACTGCAT\nGCAGTACCTGCGGGGAACACCGTCAAGTTCCGCTGTCCAGCTGCAGGCAACCCCACGCCC\nACCATCCGCTGGCTTAAGGATGGACAGGCCTTTCATGGGGAGAACCGCATTGGAGGCATT\nCGGCTGCGCCATCAGCACTGGAGTCTCGTGATGGAGAGCGTGGTGCCCTCGGACCGCGGC\nACATACACCTGCCTGGTAGAGAACGCTGTGGGCAGCATCCGCTATAACTACCTGCTAGAT\nGTGCTGGAGCGGTCCCCGCACCGGCCCATCCTGCAGGCCGGGCTCCCGGCCAACACCACA\nGCCGTGGTGGGCAGCGACGTGGAGCTGCTGTGCAAGGTGTACAGCGATGCCCAGCCCCAC\nATCCAGTGGCTGAAGCACATCGTCATCAACGGCAGCAGCTTCGGAGCCGTCGGTTTCCCC\nTATGTGCAAGTCCTAAAGACTGCAGACATCAATAGCTCAGAGGTGGAGGTCCTGTACCTG\nCGGAACGTGTCAGCCGAGGACGCAGGCGAGTACACCTGCCTCGCAGGCAATTCCATCGGC\nCTCTCCTACCAGTCTGCCTGGCTCACGGTGCTGCCAGAGGAGGACCCCACATGGACCGCA\nGCAGCGCCCGAGGCCAGGTATACGGACATCATCCTGTACGCGTCGGGCTCCCTGGCCTTG\nGCTGTGCTCCTGCTGCTGGCCGGGCTGTATCGAGGGCAGGCGCTCCACGGCCGGCACCCC\nCGCCCGCCCGCCACTGTGCAGAAGCTCTCCCGCTTCCCTCTGGCCCGACAGTTCTCCCTG\nGAGTCAGGCTCTTCCGGCAAGTCAAGCTCATCCCTGGTACGAGGCGTGCGTCTCTCCTCC\nAGCGGCCCCGCCTTGCTCGCCGGCCTCGTGAGTCTAGATCTACCTCTCGACCCACTATGG\nGAGTTCCCCCGGGACAGGCTGGTGCTTGGGAAGCCCCTAGGCGAGGGCTGCTTTGGCCAG\nGTAGTACGTGCAGAGGCCTTTGGCATGGACCCTGCCCGGCCTGACCAAGCCAGCACTGTG\nGCCGTCAAGATGCTCAAAGACAACGCCTCTGACAAGGACCTGGCCGACCTGGTCTCGGAG\nATGGAGGTGATGAAGCTGATCGGCCGACACAAGAACATCATCAACCTGCTTGGTGTCTGC\nACCCAGGAAGGGCCCCTGTACGTGATCGTGGAGTGCGCCGCCAAGGGAAACCTGCGGGAG\nTTCCTGCGGGCCCGGCGCCCCCCAGGCCCCGACCTCAGCCCCGACGGTCCTCGGAGCAGT\nGAGGGGCCGCTCTCCTTCCCAGTCCTGGTCTCCTGCGCCTACCAGGTGGCCCGAGGCATG\nCAGTATCTGGAGTCCCGGAAGTGTATCCACCGGGACCTGGCTGCCCGCAATGTGCTGGTG\nACTGAGGACAATGTGATGAAGATTGCTGACTTTGGGCTGGCCCGCGGCGTCCACCACATT\nGACTACTATAAGAAAACCAGCAACGGCCGCCTGCCTGTGAAGTGGATGGCGCCCGAGGCC\nTTGTTTGACCGGGTGTACACACACCAGAGTGACGTGTGGTCTTTTGGGATCCTGCTATGG\nGAGATCTTCACCCTCGGGGGCTCCCCGTATCCTGGCATCCCGGTGGAGGAGCTGTTCTCG\nCTGCTGCGGGAGGGACATCGGATGGACCGACCCCCACACTGCCCCCCAGAGCTGTACGGG\nCTGATGCGTGAGTGCTGGCACGCAGCGCCCTCCCAGAGGCCTACCTTCAAGCAGCTGGTG\nGAGGCGCTGGACAAGGTCCTGCTGGCCGTCTCTGAGGAGTACCTCGACCTCCGCCTGACC\nTTCGGACCCTATTCCCCCTCTGGTGGGGACGCCAGCAGCACCTGCTCCTCCAGCGATTCT\nGTCTTCAGCCACGACCCCCTGCCATTGGGATCCAGCTCCTTCCCCTTCGGGTCTGGGGTG\nCAGACATGA"}, "pfams": {"pfam": [{"identifier": "PF07714", "name": "Pkinase_Tyr"}, {"identifier": "PF00047", "name": "ig"}, {"identifier": "PF07679", "name": "I-set"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "transferase activity"}, {"category": "function", "description": "protein-tyrosine kinase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "transferase activity, transferring phosphorus-containing groups"}, {"category": "function", "description": "kinase activity"}, {"category": "function", "description": "protein kinase activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "biopolymer metabolism"}, {"category": "process", "description": "biopolymer modification"}, {"category": "process", "description": "protein amino acid phosphorylation"}, {"category": "process", "description": "protein modification"}]}}}, {"id": "BE0002133", "name": "Fibroblast growth factor receptor 3", "organism": "Human", "actions": null, "references": "# Cancilla B, Davies A, Cauchi JA, Risbridger GP, Bertram JF: Fibroblast growth factor receptors and their ligands in the adult rat kidney. Kidney Int. 2001 Jul;60(1):147-55. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11422746\n# Yamanaka T, Sakamoto A, Tanaka Y, Zhang Y, Hayashido Y, Toratani S, Akagawa Y, Okamoto T: Isolation and serum-free culture of epithelial cells derived from epithelial rests of Malassez in human periodontal ligament. In Vitro Cell Dev Biol Anim. 2000 Sep;36(8):548-53. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11149756\n# Beer HD, Vindevoghel L, Gait MJ, Revest JM, Duan DR, Mason I, Dickson C, Werner S: Fibroblast growth factor (FGF) receptor 1-IIIb is a naturally occurring functional receptor for FGFs that is preferentially expressed in the skin and the brain. J Biol Chem. 2000 May 26;275(21):16091-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10821861\n# Launay C, Fromentoux V, Thery C, Shi DL, Boucaut JC: Comparative analysis of the tissue distribution of three fibroblast growth factor receptor mRNAs during amphibian morphogenesis. Differentiation. 1994 Dec;58(2):101-11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7890137\n# Mummery CL, van Rooyen M, Bracke M, van den Eijnden-van Raaij J, van Zoelen EJ, Alitalo K: Fibroblast growth factor-mediated growth regulation and receptor expression in embryonal carcinoma and embryonic stem cells and human germ cell tumours. Biochem Biophys Res Commun. 1993 Feb 26;191(1):188-95. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7680555", "known-action": "unknown", "polypeptide": {"@id": "P22607", "@source": "Swiss-Prot", "name": "Fibroblast growth factor receptor 3", "general-function": null, "specific-function": "Receptor for acidic and basic fibroblast growth factors. Preferentially binds FGF1", "gene-name": "FGFR3", "locus": "4p16.3", "cellular-location": "Membrane", "transmembrane-regions": "376-396", "signal-regions": null, "theoretical-pi": "5.73", "molecular-weight": "87710.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3690"}, {"resource": "GenAtlas", "identifier": "FGFR3"}, {"resource": "GeneCards", "identifier": "FGFR3"}, {"resource": "GenBank Gene Database", "identifier": "M58051"}, {"resource": "GenBank Protein Database", "identifier": "182569"}, {"resource": "UniProtKB", "identifier": "P22607"}, {"resource": "UniProt Accession", "identifier": "FGFR3_HUMAN"}]}, "synonyms": {"synonym": ["CD333 antigen", "EC 2.7.10.1", "FGFR-3", "Fibroblast growth factor receptor 3 precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Fibroblast growth factor receptor 3\nMGAPACALALCVAVAIVAGASSESLGTEQRVVGRAAEVPGPEPGQQEQLVFGSGDAVELS\nCPPPGGGPMGPTVWVKDGTGLVPSERVLVGPQRLQVLNASHEDSGAYSCRQRLTQRVLCH\nFSVRVTDAPSSGDDEDGEDEAEDTGVDTGAPYWTRPERMDKKLLAVPAANTVRFRCPAAG\nNPTPSISWLKNGREFRGEHRIGGIKLRHQQWSLVMESVVPSDRGNYTCVVENKFGSIRQT\nYTLDVLERSPHRPILQAGLPANQTAVLGSDVEFHCKVYSDAQPHIQWLKHVEVNGSKVGP\nDGTPYVTVLKTAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHHSAWLVVLPAE\nEELVEADEAGSVYAGILSYGVGFFLFILVVAAVTLCRLRSPPKKGLGSPTVHKISRFPLK\nRQVSLESNASMSSNTPLVRIARLSSGEGPTLANVSELELPADPKWELSRARLTLGKPLGE\nGCFGQVVMAEAIGIDKDRAAKPVTVAVKMLKDDATDKDLSDLVSEMEMMKMIGKHKNIIN\nLLGACTQGGPLYVLVEYAAKGNLREFLRARRPPGLDYSFDTCKPPEEQLTFKDLVSCAYQ\nVARGMEYLASQKCIHRDLAARNVLVTEDNVMKIADFGLARDVHNLDYYKKTTNGRLPVKW\nMAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCT\nHDLYMIMRECWHAAPSQRPTFKQLVEDLDRVLTVTSTDEYLDLSAPFEQYSPGGQDTPSS\nSSSGDDSVFAHDLLPPAPPSSGGSRT"}, "gene-sequence": {"@format": "FASTA", "#text": ">2421 bp\nATGGGCGCCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCC\nTCCTCGGAGTCCTTGGGGACGGAGCAGCGCGTCGTGGGGCGAGCGGCAGAAGTCCCGGGC\nCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCGGGGATGCTGTGGAGCTGAGC\nTGTCCCCCGCCCGGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGG\nCTGGTGCCCTCGGAGCGTGTCCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCC\nCACGAGGACTCCGGGGCCTACAGCTGCCGGCAGCGGCTCACGCAGCGCGTACTGTGCCAC\nTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATGACGAAGACGGGGAGGACGAG\nGCTGAGGACACAGGTGTGGACACAGGGGCCCCTTACTGGACACGGCCCGAGCGGATGGAC\nAAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCCAGCCGCTGGC\nAACCCCACTCCCTCCATCTCCTGGCTGAAGAACGGCAGGGAGTTCCGCGGCGAGCACCGC\nATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGGTCATGGAAAGCGTGGTGCCC\nTCGGACCGCGGCAACTACACCTGCGTCGTGGAGAACAAGTTTGGCAGCATCCGGCAGACG\nTACACGCTGGACGTGCTGGAGCGCTCCCCGCACCGGCCCATCCTGCAGGCGGGGCTGCCG\nGCCAACCAGACGGCGGTGCTGGGCAGCGACGTGGAGTTCCACTGCAAGGTGTACAGTGAC\nGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGAACGGCAGCAAGGTGGGCCCG\nGACGGCACACCCTACGTTACCGTGCTCAAGACGGCGGGCGCTAACACCACCGACAAGGAG\nCTAGAGGTTCTCTCCTTGCACAACGTCACCTTTGAGGACGCCGGGGAGTACACCTGCCTG\nGCGGGCAATTCTATTGGGTTTTCTCATCACTCTGCGTGGCTGGTGGTGCTGCCAGCCGAG\nGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTGTGTATGCAGGCATCCTCAGCTACGGG\nGTGGGCTTCTTCCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCCTGCGCAGC\nCCCCCCAAGAAAGGCCTGGGCTCCCCCACCGTGCACAAGATCTCCCGCTTCCCGCTCAAG\nCGACAGGTGTCCCTGGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGCGCATC\nGCAAGGCTGTCCTCAGGGGAGGGCCCCACGCTGGCCAATGTCTCCGAGCTCGAGCTGCCT\nGCCGACCCCAAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCCTTGGGGAG\nGGCTGCTTCGGCCAGGTGGTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCC\nAAGCCTGTCACCGTAGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTCG\nGACCTGGTGTCTGAGATGGAGATGATGAAGATGATCGGGAAACACAAAAACATCATCAAC\nCTGCTGGGCGCCTGCACGCAGGGCGGGCCCCTGTACGTGCTGGTGGAGTACGCGGCCAAG\nGGTAACCTGCGGGAGTTTCTGCGGGCGCGGCGGCCCCCGGGCCTGGACTACTCCTTCGAC\nACCTGCAAGCCGCCCGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCCTGTGCCTACCAG\nGTGGCCCGGGGCATGGAGTACTTGGCCTCCCAGAAGTGCATCCACAGGGACCTGGCTGCC\nCGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTGGCCCGG\nGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGG\nATGGCGCCTGAGGCCTTGTTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCCTTT\nGGGGTCCTGCTCTGGGAGATCTTCACGCTGGGGGGCTCCCCGTACCCCGGCATCCCTGTG\nGAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAACTGCACA\nCACGACCTGTACATGATCATGCGGGAGTGCTGGCATGCCGCGCCCTCCCAGAGGCCCACC\nTTCAAGCAGCTGGTGGAGGACCTGGACCGTGTCCTTACCGTGACGTCCACCGACGAGTAC\nCTGGACCTGTCGGCGCCTTTCGAGCAGTACTCCCCGGGTGGCCAGGACACCCCCAGCTCC\nAGCTCCTCAGGGGACGACTCCGTGTTTGCCCACGACCTGCTGCCCCCGGCCCCACCCAGC\nAGTGGGGGCTCGCGGACGTGA"}, "pfams": {"pfam": [{"identifier": "PF07714", "name": "Pkinase_Tyr"}, {"identifier": "PF00047", "name": "ig"}, {"identifier": "PF07679", "name": "I-set"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "transferase activity"}, {"category": "function", "description": "protein-tyrosine kinase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "transferase activity, transferring phosphorus-containing groups"}, {"category": "function", "description": "kinase activity"}, {"category": "function", "description": "protein kinase activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "biopolymer metabolism"}, {"category": "process", "description": "biopolymer modification"}, {"category": "process", "description": "protein amino acid phosphorylation"}, {"category": "process", "description": "protein modification"}]}}}, {"id": "BE0001031", "name": "Basement membrane-specific heparan sulfate proteoglycan core protein", "organism": "Human", "actions": null, "references": "# Berman B, Ostrovsky O, Shlissel M, Lang T, Regan D, Vlodavsky I, Ishai-Michaeli R, Ron D: Similarities and differences between the effects of heparin and glypican-1 on the bioactivity of acidic fibroblast growth factor and the keratinocyte growth factor. J Biol Chem. 1999 Dec 17;274(51):36132-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10593896\n# Sharma B, Handler M, Eichstetter I, Whitelock JM, Nugent MA, Iozzo RV: Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest. 1998 Oct 15;102(8):1599-608. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9788974\n# Iwabuchi T, Goetinck PF: Syndecan-4 dependent FGF stimulation of mouse vibrissae growth. Mech Dev. 2006 Nov;123(11):831-41. Epub 2006 Aug 12. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16989989\n# Asada N, Tanaka Y, Hayashido Y, Toratani S, Kan M, Kitamoto M, Nakanishi T, Kajiyama G, Chayama K, Okamoto T: Expression of fibroblast growth factor receptor genes in human hepatoma-derived cell lines. In Vitro Cell Dev Biol Anim. 2003 Jul-Aug;39(7):321-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14753849", "known-action": "unknown", "polypeptide": {"@id": "P98160", "@source": "Swiss-Prot", "name": "Basement membrane-specific heparan sulfate proteoglycan core protein", "general-function": "Involved in protein binding and cell adhesion", "specific-function": "This protein is an integral component of basement membranes. It is responsible for the fixed negative electrostatic charge and is involved in the charge-selective ultrafiltration properties. It serves as an attachment substrate for cells", "gene-name": "HSPG2", "locus": "1p36.1-p34", "cellular-location": "Secreted protein; extracellular space", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.49", "molecular-weight": "468829.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5273"}, {"resource": "GenAtlas", "identifier": "HSPG2"}, {"resource": "GeneCards", "identifier": "HSPG2"}, {"resource": "GenBank Gene Database", "identifier": "X62515"}, {"resource": "GenBank Protein Database", "identifier": "29470"}, {"resource": "UniProtKB", "identifier": "P98160"}, {"resource": "UniProt Accession", "identifier": "PGBM_HUMAN"}]}, "synonyms": {"synonym": ["Basement membrane-specific heparan sulfate proteoglycan core protein precursor", "HSPG", "Perlecan", "PLC"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Basement membrane-specific heparan sulfate proteoglycan core protein precursor\nMGWRAPGALLLALLLHGRLLAVTHGLRAYDGLSLPEDIETVTASQMRWTHSYLSDDEDML\nADSISGDDLGSGDLGSGDFQMVYFRALVNFTRSIEYSPQLEDAGSREFREVSEAVVDTLE\nSEYLKIPGDQVVSVVFIKELDGWVFVELDVGSEGNADGAQIQEMLLRVISSGSVASYVTS\nPQGFQFRRLGTVPQFPRACTEAEFACHSYNECVALEYRCDRRPDCRDMSDELNCEEPVLG\nISPTFSLLVETTSLPPRPETTIMRQPPVTHAPQPLLPGSVRPLPCGPQEAACRNGHCIPR\nDYLCDGQEDCEDGSDELDCGPPPPCEPNEFPCGNGHCALKLWRCDGDFDCEDRTDEANCP\nTKRPEEVCGPTQFRCVSTNMCIPASFHCDEESDCPDRSDEFGCMPPQVVTPPRESIQASR\nGQTVTFTCVAIGVPTPIINWRLNWGHIPSHPRVTVTSEGGRGTLIIRDVKESDQGAYTCE\nAMNARGMVFGIPDGVLELVPQRGPCPDGHFYLEHSAACLPCFCFGITSVCQSTRRFRDQI\nRLRFDQPDDFKGVNVTMPAQPGTPPLSSTQLQIDPSLHEFQLVDLSRRFLVHDSFWALPE\nQFLGNKVDSYGGSLRYNVRYELARGMLEPVQRPDVVLVGAGYRLLSRGHTPTQPGALNQR\nQVQFSEEHWVHESGRPVQRAELLQVLQSLEAVLIQTVYNTKMASVGLSDIAMDTTVTHAT\nSHGRAHSVEECRCPIGYSGLSCESCDAHFTRVPGGPYLGTCSGCSCNGHASSCDPVYGHC\nLNCQHNTEGPQCNKCKAGFFGDAMKATATSCRPCPCPYIDASRRFSDTCFLDTDGQATCD\nACAPGYTGRRCESCAPGYEGNPIQPGGKCRPVNQEIVRCDERGSMGTSGEACRCKNNVVG\nRLCNECADGSFHLSTRNPDGCLKCFCMGVSRHCTSSSWSRAQLHGASEEPGHFSLTNAAS\nTHTTNEGIFSPTPGELGFSSFHRLLSGPYFWSLPSRFLGDKVTSYGGELRFTVTQRSQPG\nSTPLHGQPLVVLQGNNIILEHHVAQEPSPGQPSTFIVPFREQAWQRPDGQPATREHLLMA\nLAGIDTLLIRASYAQQPAESRVSGISMDVAVPEETGQDPALEVEQCSCPPGYRGPSCQDC\nDTGYTRTPSGLYLGTCERCSCHGHSEACEPETGACQGCQHHTEGPRCEQCQPGYYGDAQR\nGTPQDCQLCPCYGDPAAGQAAHTCFLDTDGHPTCDACSPGHSGRHCERCAPGYYGNPSQG\nQPCQRDSQVPGPIGCNCDPQGSVSSQCDAAGQCQCKAQVEGLTCSHCRPHHFHLSASNPD\nGCLPCFCMGITQQCASSAYTRHLISTHFAPGDFQGFALVNPQRNSRLTGEFTVEPVPEGA\nQLSFGNFAQLGHESFYWQLPETYQGDKVAAYGGKLRYTLSYTAGPQGSPLSDPDVQITGN\nNIMLVASQPALQGPERRSYEIMFREEFWRRPDGQPATREHLLMALADLDELLIRATFSSV\nPLVASISAVSLEVAQPGPSNRPRALEVEECRCPPGYIGLSCQDCAPGYTRTGSGLYLGHC\nELCECNGHSDLCHPETGACSQCQHNAAGEFCELCAPGYYGDATAGTPEDCQPCACPLTNP\nENMFSRTCESLGAGGYRCTACEPGYTGQYCEQCGPGYVGNPSVQGGQCLPETNQAPLVVE\nVHPARSIVPQGGSHSLRCQVSGSPPHYFYWSREDGRPVPSGTQQRHQGSELHFPSVQPSD\nAGVYICTCRNLHQSNTSRAELLVTEAPSKPITVTVEEQRSQSVRPGADVTFICTAKSKSP\nAYTLVWTRLHNGKLPTRAMDFNGILTIRNVQLSDAGTYVCTGSNMFAMDQGTATLHVQAS\nGTLSAPVVSIHPPQLTVQPGQLAEFRCSATGSPTPTLEWTGGPGGQLPAKAQIHGGILRL\nPAVEPTDQAQYLCRAHSSAGQQVARAVLHVHGGGGPRVQVSPERTQVHAGRTVRLYCRAA\nGVPSATITWRKEGGSLPPQARSERTDIATLLIPAITTADAGFYLCVATSPAGTAQARIQV\nVVLSASDASPPPVKIESSSPSVTEGQTLDLNCVVAGSAHAQVTWYRRGGSLPPHTQVHGS\nRLRLPQVSPADSGEYVCRVENGSGPKEASITVSVLHGTHSGPSYTPVPGSTRPIRIEPSS\nSHVAEGQTLDLNCVVPGQAHAQVTWHKRGGSLPARHQTHGSLLRLHQVTPADSGEYVCHV\nVGTSGPLEASVLVTIEASVIPGPIPPVRIESSSSTVAEGQTLDLSCVVAGQAHAQVTWYK\nRGGSLPARHQVRGSRLYIFQASPADAGQYVCRASNGMEASITVTVTGTQGANLAYPAGST\nQPIRIEPSSSQVAEGQTLDLNCVVPGQSHAQVTWHKRGGSLPVRHQTHGSLLRLYQASPA\nDSGEYVCRVLGSSVPLEASVLVTIEPAGSVPALGVTPTVRIESSSSQVAEGQTLDLNCLV\nAGQAHAQVTWHKRGGSLPARHQVHGSRLRLLQVTPADSGEYVCRVVGSSGTQEASVLVTI\nQQRLSGSHSQGVAYPVRIESSSASLANGHTLDLNCLVASQAPHTITWYKRGGSLPSRHQI\nVGSRLRIPQVTPADSGEYVCHVSNGAGSRETSLIVTIQGSGSSHVPSVSPPIRIESSSPT\nVVEGQTLDLNCVVARQPQAIITWYKRGGSLPSRHQTHGSHLRLHQMSVADSGEYVCRANN\nNIDALEASIVISVSPSAGSPSAPGSSMPIRIESSSSHVAEGETLDLNCVVPGQAHAQVTW\nHKRGGSLPSHHQTRGSRLRLHHVSPADSGEYVCRVMGSSGPLEASVLVTIEASGSSAVHV\nPAPGGAPPIRIEPSSSRVAEGQTLDLKCVVPGQAHAQVTWHKRGGNLPARHQVHGPLLRL\nNQVSPADSGEYSCQVTGSSGTLEASVLVTIEPSSPGPIPAPGLAQPIYIEASSSHVTEGQ\nTLDLNCVVPGQAHAQVTWYKRGGSLPARHQTHGSQLRLHLVSPADSGEYVCRAASGPGPE\nQEASFTVTVPPSEGSSYRLRSPVISIDPPSSTVQQGQDASFKCLIHDGAAPISLEWKTRN\nQELEDNVHISPNGSIITIVGTRPSNHGTYRCVASNAYGVAQSVVNLSVHGPPTVSVLPEG\nPVWVKVGKAVTLECVSAGEPRSSARWTRISSTPAKLEQRTYGLMDSHAVLQISSAKPSDA\nGTYVCLAQNALGTAQKQVEVIVDTGAMAPGAPQVQAEEAELTVEAGHTATLRCSATGSPA\nPTIHWSKLRSPLPWQHRLEGDTLIIPRVAQQDSGQYICNATSPAGHAEATIILHVESPPY\nATTVPEHASVQAGETVQLQCLAHGTPPLTFQWSRVGSSLPGRATARNELLHFERAAPEDS\nGRYRCRVTNKVGSAEAFAQLLVQGPPGSLPATSIPAGSTPTVQVTPQLETKSIGASVEFH\nCAVPSDRGTQLRWFKEGGQLPPGHSVQDGVLRIQNLDQSCQGTYICQAHGPWGKAQASAQ\nLVIQALPSVLINIRTSVQTVVVGHAVEFECLALGDPKPQVTWSKVGGHLRPGIVQSGGVV\nRIAHVELADAGQYRCTATNAAGTTQSHVLLLVQALPQISMPQEVRVPAGSAAVFPCIASG\nYPTPDISWSKLDGSLPPDSRLENNMLMLPSVRPQDAGTYVCTATNRQGKVKAFAHLQVPE\nRVVPYFTQTPYSFLPLPTIKDAYRKFEIKITFRPDSADGMLLYNGQKRVPGSPTNLANRQ\nPDFISFGLVGGRPEFRFDAGSGMATIRHPTPLALGHFHTVTLLRSLTQGSLIVGDLAPVN\nGTSQGKFQGLDLNEELYLGGYPDYGAIPKAGLSSGFIGCVRELRIQGEEIVFHDLNLTAH\nGISHCPTCRDRPCQNGGQCHDSESSSYVCVCPAGFTGSRCEHSQALHCHPEACGPDATCV\nNRPDGRGYTCRCHLGRSGLRCEEGVTVTTPSLSGAGSYLALPALTNTHHELRLDVEFKPL\nAPDGVLLFSGGKSGPVEDFVSLAMVGGHLEFRYELGSGLAVLRSAEPLALGRWHRVSAER\nLNKDGSLRVNGGRPVLRSSPGKSQGLNLHTLLYLGGVEPSVPLSPATNMSAHFRGCVGEV\nSVNGKRLDLTYSFLGSQGIGQCYDSSPCERQPCQHGATCMPAGEYEFQCLCRDGFKGDLC\nEHEENPCQLREPCLHGGTCQGTRCLCLPGFSGPRCQQGSGHGIAESDWHLEGSGGNDAPG\nQYGAYFHDDGFLAFPGHVFSRSLPEVPETIELEVRTSTASGLLLWQGVEVGEAGQGKDFI\nSLGLQDGHLVFRYQLGSGEARLVSEDPINDGEWHRVTALREGRRGSIQVDGEELVSGRSP\nGPNVAVNAKGSVYIGGAPDVATLTGGRFSSGITGCVKNLVLHSARPGAPPPQPLDLQHRA\nQAGANTRPCPS"}, "gene-sequence": {"@format": "FASTA", "#text": ">13182 bp\nATGGGGTGGCGGGCGCCGGGCGCGCTGCTGCTGGCGCTGCTGCTGCACGGGCGGCTGCTG\nGCGGTGACCCATGGGCTGAGGGCATACGATGGCTTGTCTCTGCCTGAGGACATAGAGACC\nGTCACAGCAAGCCAAATGCGCTGGACACATTCGTACCTTTCTGATGATGAGGACATGCTG\nGCTGACAGCATCTCAGGAGACGACCTGGGCAGTGGGGACCTGGGCAGCGGGGACTTCCAG\nATGGTTTATTTCCGAGCCCTGGTGAATTTCACTCGCTCCATCGAGTACAGCCCTCAGCTG\nGAGGATGCAGGCTCCAGAGAGTTTCGAGAGGTGTCCGAGGCTGTGGTAGACACGCTGGAG\nTCGGAGTACTTGAAAATTCCCGGAGACCAGGTTGTCAGTGTGGTGTTCATCAAGGAGCTG\nGATGGCTGGGTTTTTGTGGAGCTGGATGTGGGCTCGGAAGGGAATGCGGATGGGGCTCAG\nATTCAGGAGATGCTGCTCAGGGTCATCTCCAGCGGCTCTGTGGCCTCCTACGTCACCTCT\nCCCCAGGGATTCCAGTTCCGACGCCTGGGCACAGTGCCCCAGTTCCCAAGAGCCTGCACG\nGAGGCCGAGTTTGCCTGCCACAGCTACAATGAGTGTGTGGCCCTGGAGTATCGCTGTGAC\nCGGCGGCCCGACTGCAGGGACATGTCTGATGAGCTCAATTGTGAGGAGCCAGTCCTGGGT\nATCAGCCCCACATTCTCTCTCCTCGTGGAGACGACATCTTTACCGCCCCGGCCAGAGACA\nACCATCATGCGACAGCCACCAGTCACCCACGCTCCTCAGCCCCTGCTTCCCGGTTCCGTC\nAGGCCCCTGCCCTGTGGGCCCCAGGAGGCCGCATGCCGCAATGGGCACTGCATCCCCAGA\nGACTACCTCTGCGACGGACAGGAGGACTGCGAGGACGGCAGCGATGAGCTAGACTGTGGC\nCCCCCGCCACCCTGTGAGCCCAACGAGTTCCCCTGCGGGAATGGACATTGTGCCCTCAAG\nCTGTGGCGCTGCGATGGTGACTTTGACTGTGAGGACCGAACTGATGAAGCCAACTGCCCC\nACCAAGCGTCCTGAGGAAGTGTGCGGGCCCACACAGTTCCGATGCGTCTCTACCAACATG\nTGCATCCCAGCCAGCTTCCACTGTGACGAGGAGAGCGACTGTCCTGACCGGAGCGACGAG\nTTTGGCTGCATGCCCCCCCAGGTGGTGACACCTCCCCGGGAGTCCATCCAGGCTTCCCGG\nGGCCAGACAGTGACCTTCACCTGCGTGGCCATTGGCGTCCCCGCCCCCTTTCTCATCAAT\nTGGAGGCTCAACTGGGGCCACATCCCCTCTCAGCCCAGGGTGACAGTGACCAGCGAGGGT\nGGCCGTGGCACACTGATCATCCGTGATGTGAAGGAGTCAGACCAGGGTGCCTACACCTGT\nGAGGCCATGAACGCCCGGGGCATGGTGTTTGGCATTCCTGACGGTGTCCTTGAGCTCGTC\nCCACAACGAGCAGGCCCCTGCCCTGACGGCCACTTCTACCTGGAGCACAGCGCCGCCTGC\nCTGCCCTGCTTCTGCTTTGGCATCACCAGCGTGTGCCAGAGCACCCGCCGCTTCCGGGAC\nCAGATCAGGCTGCGCTTTGACCAACCCGATGACTTCAAGGGTGTGAATGTGACAATGCCT\nGCGCAGCCCGGCACGCCACCCCTCTCCTCCACGCAGCTGCAGATCGACCCATCCCTGCAC\nGAGTTCCAGCTAGTCGACCTGTCCCGCCGCTTCCTCGTCCACGACTCCTTCTGGGCTCTG\nCCTGAACAGTTCCTGGGCAACAAGGTGGACTCCTATGGCGGCTCCCTGCGTTACAACGTG\nCGCTACGAGTTGGCCCGTGGCATGCTGGAGCCAGTGCAGCGGCCGGACGTGGTCCTCGTG\nGGTGCCGGGTACCGCCTCCTCTCCCGAGGCCACACACCCACCCAACCTGGTGCTCTGAAC\nCAGCGCCAGGTCCAGTTCTCTGAGGAGCACTGGGTCCATGAGTCTGGCCGGCCGGTGCAG\nCGCGCGGAGCTGCTGCAGGTGCTGCAGAGCCTGGAGGCCGTGCTCATCCAGACCGTGTAC\nAACACCAAGATGGCTAGCGTGGGACTTAGCGACATCGCCATGGATACCACCGTCACCCAT\nGCCACCAGCCATGGCCGTGCCCACAGTGTGGAGGAGTGCAGATGCCCCATTGGCTATTCT\nGGCTTGTCCTGCGAGAGCTGTGATGCCCACTTCACTCGGGTGCCTGGTGGGCCCTACCTG\nGGCACCTGCTCTGGTTGCAGTTGCAATGGCCATGCCAGCTCCTGTGACCCTGTGTATGGC\nCACTGCCTGAATTGCCAGCACAACACGGAGGGGCCACAGTGCAAGAAGTGCAAGGCTGGC\nTTCTTTGGGGACGCCATGAAGGCCACGGCCACTTCCTGCCGGCCCTGCCCTTGCCCATAC\nATCGATGCCTCCCGCAGATTCTCAGACACTTGCTTCCTGGACACGGATGGCCAAGCCACA\nTGTGACGCCTGTGCCCCAGGCTACACTGGCCGCCGCTGTGAGAGCTGTGCCCCCGGATAC\nGAGGGCAACCCCATCCAGCCCGGCGGGAAGTGCAGGCCCGTCAACCAGGAGATTGTGCGC\nTGTGACGAGCGTGGCAGCATGGGGACCTCCGGGGAGGCCTGCCGCTGTAAGAACAATGTG\nGTGGGGCGCTTGTGCAATGAATGTGCTGACCGCTCTTTCCACCTGAGTACCCGAAACCCC\nGATGGCTGCCTCAAGTGCTTCTGCATGGGTGTCAGTCGCCACTGCACCAGCTCTTCATGG\nAGCCGTGCCCAGTTGCATGGGGCCTCTGAGGAGCCTGGTCACTTCAGCCTGACCAACGCC\nGCAAGCACCCACACCACCAACGAGGGCATCTTCTCCCCCACGCCCGGGGAACTGGGATTC\nTCCTCCTTCCACAGACTCTTATCTGGACCCTACTTCTGGAGCCTCCCTTCACGCTTCCTG\nGGGGACAAGGTGACCTCCTATGGAGGAGAGCTGCGCTTCACAGTGACCCAGAGGTCCCAG\nCCGGGCTCCACACCCCTGCACGGGCAGCCGTTGGTGGTGCTGCAAGGTAACAACATCATC\nCTAGAGCACCATGTGGCCCAGGAGCCCAGCCCCGGCCAGCCCAGCACCTTCATTGTGCCT\nTTCCGGGAGCAAGCATGGCAGCGGCCCGATGGGCAGCCAGCCACACGGGAGCACCTGCTG\nATGGCACTGGCAGGCATCGACACCCTCCTGATCCGAGCATCCTACGCCCAGCAGCCCGCT\nGAGAGCAGGGTCTCTGGCATCAGCATGGACGTGGCTGTGCCCGAGGAAACCGGCCAGGAC\nCCCGCGCTGGAAGTGGAACAGTGCTCCTGCCCACCCGGGTACCGTGGGCCGTCCTGCCAG\nGACTGTGACACAGGCTACACACGCACGCCCAGTGGCCTCTACCTGGGTACCTGTGAACGC\nTGCAGCTGCCATGGCCACTCAGAGGCCTGCGAGCCAGAAACAGGTGCCTGCCAGGGCTGC\nCAGCATCACACGGAGGGCCCTCGGTGTGAGCAGTGCCAGCCAGGATACTACGGGGACGCC\nCAGCGGGGGACACCACAGGACTGCCAGCTGTGCCCCTGCTACGGAGACCCTGCTGCCGGC\nCAGGCTGCCCACACTTGTTTTCTGGACACAGACGGCCACCCCACCTGTGATGCGTGCTCC\nCCAGGCCACAGTGGGCGTCACTGTGAGAGGTGCGCCCCTGGCTACTATGGCAACCCCAGC\nCAGGGCCAGCCATGCCAGAGAGACAGCCAGGTGCCAGGGCCCATAGGCTGCAACTGTGAC\nCCCCAAGGCAGCGTCAGCAGCCAGTGTGATGCTGCTGGTCAGTGCCAGTGCAAGGCCCAG\nGTGGAAGGCCTCACTTGCAGCCACTGCCGGCCCCACCACTTCCACCTGAGTGCCAGCAAC\nCCAGACGGCTGCCTGCCCTGCTTCTGTATGGGCATCACCCAGCAGTGCGCCAGCTCTGCC\nTACACACGCCACCTGATCTCCACCCACTTTGCCCCTGGGGACTTCCAAGGCTTTGCCCTG\nGTGAACCCACAGCGAAACAGCCGCCTGACAGGAGAATTCACTGTGGAACCCGTGCCCGAG\nGGTGCCCAGCTCTCTTTTGGCAACTTTGCCCAACTCGGCCATGAGTCCTTCTACTGGCAG\nCTGCCGGAGACATACCAGGGAGACAAGGTGGCGGCCTACGGTGGGAAGTTGCGATACACC\nCTCTCCTACACAGCAGGCCCACAGGGCAGCCCACTCTCTGACCCCGATGTGCAGATCACG\nGGCAACAACATCATGCTAGTGGCCTCCCAGCCAGCGCTGCAGGGCCCTGAGAGGAGGAGC\nTACGAGATCATGTTCCGAGAGGAATTCTGGCGCCGGCCCGATGGGCAGCCGGCCACACGC\nGAGCACCTCCTGATGGCACTGGCCGACCTGGATGAGCTCCTGATCCGGGCCACGTTCTCC\nTCCGTGCCGCTGGTGGCCAGCATCAGCGCAGTCAGCCTGGAGGTCGCCCAGCCGGGGCCC\nTCAAACAGACCCCGCGCCCTCGAGGTGGAGGAGTGCCGCTGCCCGCCAGGCTACATCGGT\nCTGTCCTGCCAGGACTGTGCCCCCGGCTACACGCGCACCGGGAGTGGGCTCTACCTCGGC\nCACTGCGAGCTATGTGAATGCAATGGCCACTCAGACCTGTGCCACCCAGAGACTGGGGCC\nTGCTCGCAATGCCAGCACAACGCCGCAGGGGAGTTCTGCGAGCTTTGTGCCCCTGGCTAC\nTACGGAGATGCCACAGCCGGGACGCCTGAGGACTGCCAGCCCTGTGCCTGCCCACTGACC\nAACCCAGAGAACATGTTTTCCCGCACCTGTGAGAGCCTGGGAGCCGGCGGGTACCGCTGC\nACGGCCTGCGAACCCGGCTACACTGGCCAGTACTGTGAGCAGTGTGGCCCAGGTTACGTG\nGGTAACCCCAGTGTGCAAGGGGGCCAGTGCCTGCCAGAGACAAACCAAGCCCCACTGGTG\nGTCGAGGTCCATCCTGCTCGAAGCATAGTGCCCCAAGGTGGCTCCCACTCCCTGCGGTGT\nCAGGTCAGTGGGAGGGGACCCCACTACTTCTATTGGTCCCGTGAGGATGGGCGGCCTGTG\nCCCAGCGGCACCCAGCAGCGACATCAAGGCTCCGAGCTCCACTTCCCCAGCGTCCAGCCC\nTCGGATGCTGGGGTCTACATTTGCACCTGCCGTAATCTCCACCGATCCAATACCAGCCGG\nGCAGAGCTGCTGGTCACTGAGGCTCCAAGCAAGCCCATCACAGTGACTGTGGAGGAGCAG\nCGGAGCCAGAGCGTGCGCCCCGGAGCTGACGTCACCTTCATCTGCACAGCCAAAAGCAAG\nTCCCCAGCCTATACCCTGGTGTGGACCCGCCTGCACAACGGGAAACTGCCCACCCGAGCC\nATGGATTTCAATGGCATCCTGACCATTCGCAACGTCCAGCTGAGTGATGCAGGCACCTAC\nGTGTGCACCGGCTCCAACATGTTTGCCATGGACCAGGGCACAGCCACTCTACATGTGCAG\nGCCTCGGGCACCTTGTCCGCCCCCGTGGTCTCCATCCATCCGCCACAGCTCACAGTGCAG\nCCCGGGCAACTGGCGGAGTTCCGCTGCAGCGCCACAGGGAGCCCCACGCCCACCCTCGAG\nTGGACAGGGGGCCCCGGCGGCCAGCTCCCTGCGAAGGCACAAATCCACGGCGGCATCCTG\nCGCCTGCCAGCTGTCGAGCCCACGGATCAGGCCCAGTACTTGTGCCGAGCCCACAGCAGC\nGCTGGGCAGCAGGTGGCCAGGGCTGTGCTCCACGTGCATGGGGGCGGTGGGCCCAGAGTC\nCAAGTGAGCCCAGAGAGGACCCAGGTCCACGCAGGCCGCACCGTCAGGCTGTACTGCAGG\nGCTGCAGGCGTGCCTAGCGCCACCATCACCTGGAGGAAGGAAGGGGGCAGCCTCCCACCA\nCAGGCCCGGTCAGAGCGCACAGACATCGCGACACTGCTCATCCCAGCCATCACGACTGCT\nGACGCCGGCTTCTACCTCTGCGTGGCCACCAGCCCTGCAGGCACTGCCCAGGCCCGGATC\nCAAGTGGTTGTCCTTTCAGCCTCAGATGCCAGCCAACCGCCGGTCAAGATTGAGTCCTCA\nTCGCCTTCTGTGACAGAAGGGCAAACACTCGACCTCAACTGTGTGGTGGCAGGGTCAGCC\nCATGCCCAGGTCACCTGGTACAGGCGAGGGGGTAGCCTGCCTCACCACACCCAGGTGCAC\nGGCTCCCGTCTGCGGCTCCCCCAGGTCTCACCAGCTGATTCTGGAGAGTATGTGTGCCGT\nGTGGAGAATGGATCGGGCCCCAAGGAGGCCTCCATTACTGTGTCTGTGCTCCACGGCACC\nCATTCTGGCCCCAGCTACACCCCAGTGCCCGGCAGCACCCGGCCCATCCGCATCGAGCCC\nTCCTCCTCACACGTGGCGGAAGGGCAGACCCTGGATCTGAACTGCGTGGTGCCCGGGCAG\nGCCCACGCCCAGGTCACGTGGCACAAGCGTGGGGGCAGCCTCCCTGCCCGGCACCAGACC\nCACGGCTCGCTGCTGCGGCTGCACCAGGTGACCCCGGCCGACTCAGGCGAGTATGTGTGC\nCATGTGGTGGGCACCTCCGGCCCCCTAGAGGCCTCAGTCCTGGTCACCATCGAAGCCTCT\nGTCATCCCTGGACCCATCCCACCTGTCAGGATCGAGTCTTCATCCTCCACAGTGGCCGAG\nGGCCAGACCCTGGATCTGAGCTGCGTGGTGGCAGGGCAGGCCCACGCCCAGGTCACATGG\nTACAAGCGTGGGGGCAGCCTCCCTGCCCGGCACCAGGTTCGTGGCTCCCGCCTGTACATC\nTTCCAGGCCTCACCTGCCGATGCGGGACAGTACGTCTGCCGGGCCAGCAACGGCATGGAG\nGCCTCCATCACGGTCACAGTAACTGGGACCCAGGGGGCCAACTTAGCCTACCCTGCCGGC\nAGCACCCAGCCCATCCGCATCGAGCCCTCCTCCTCGCAAGTGGCGGAAGGGCAGACCCTG\nGATCTGAACTGCGTGGTGCCCGGGCAGTCCCATGCCCAGGTCACGTGGCACAAGCGTGGG\nGGCAGCCTCCCTGTCCGGCACCAGACCCACGGCTCCCTGCTGAGACTCTACCAAGCGTCC\nCCCGCCGACTCGGGCGAGTACGTGTGCCGAGTGTTGGGCAGCTCCGTGCCTCTAGAGGCC\nTCTGTCCTGGTCACCATTGAGCCTGCGGGCTCAGTGCCTGCACTTGGGGTCACCCCCACG\nGTCCGGATCGAGTCATCGTCTTCGCAAGTGGCAGAGGGGCAGACCCTGGACCTGAACTGC\nCTCGTTGCTGGTCAGGCCCATGCCCAGGTCACGTGGCACAAGCGCGGGGGCAGCCTCCCG\nGCCCGGCACCAGGTGCATGGCTCGAGGCTACGCCTGCTCCAGGTGACCCCAGCTGATTCA\nGGGGAGTACGTGTGCCGTGTGGTCGGCAGCTCAGGTACCCAGGAAGCCTCAGTCCTTGTC\nACCATCCAGCAGCGCCTTAGTGGCTCCCACTCCCAGGGTGTGGCGTACCCCGTCCGCATC\nGAGTCCTCCTCAGCCTCCCTGGCCAATGGACACACCCTGGACCTCAACTGCCTGGTTGCC\nAGCCAGGCTCCCCACACCATCACCTGGTATAAGCGTGGAGGCAGCTTACCCAGCCGGCAC\nCAGATCGTGGGCTCCCGGCTGCGGATCCCTCAGGTGACTCCGGCAGACTCGGGCGAGTAC\nGTGTGTCACGTCAGTAACGGTGCAGGCTCCCGGGAGACCTCGCTCATCGTCACCATCCAG\nGGCAGCGGTTCCTCCCACGTGCCCAGAGTCTCCCCACCGATCAGGATCGAGTCGTCTTCC\nCCCACGGTGGTGGAAGGGCAGACCTTGGATCTGAACTGCGTGGTCGCCAGGCAGCCCCAG\nGCTATCATCACATGGTACAAGCGTGGGGGCAGCCTTCCCTCCCGACACCAGACCCATGGC\nTCCCACCTGCGGTTGCACCAAATGTCTGTGGCTGACTCGGGCGAGTATGTGTGCCGGGCC\nAACAACAACATCGATGCCCTGGAGGCCTCAATCGTCATCTCCGTCTCCCCTAGCGCCGGC\nAGCCCCTCCGCCCCTGGCAGCTCCATGCCCATCAGAATTGAGTCATCCTCCTCACACGTG\nGCCGAAGGGGAGACCCTGGATCTGAACTGCGTGGTCCCCGGGCAGGCCCATGCCCAGGTC\nACTTGGCACAAGCGTGGGGGCAGCCTCCCCAGTTACCATCAGACCCGCGGCTCACGGCTG\nCGGCTGCACCATGTGTCCCCGGCCGACTCGGGTGAATACGTGTGCCGGGTGATGGGCAGC\nTCTGGCCCCCTGGAGGCCTCAGTCCTCGTCACCATCGAAGCCTCTGGCTCAAGTGCTGTC\nCACGTCCCCGCCCCAGGTGGAGCCCCACCCATCCGCATCGAGCCCTCCTCCTCCCGAGTG\nGCAGAAGGGCAGACCCTGGATCTGAAGTGCGTGGTGCCCGGGCAGGCCCACGCCCAGGTC\nACGTGGCACAAGCGTGGAGGAAACCTCCCTGCCCGGCACCAGGTCCACGGCCCACTGCTG\nAGGCTGAACCAGGTGTCCCCGGCTGACTCTGGCGAGTACTCGTGCCAAGTGACCGGAAGC\nTCAGGCACCCTGGAGGCATCTGTCCTGGTCACAATTGAGCCCTCCAGCCCAGGACCCATT\nCCTGCTCCAGGACTGGCCCAGCCCATCTACATCGAGGCCTCCTCTTCACACGTGACTGAA\nGGGCAGACTCTGGATCTGAACTGTGTGGTGCCCGGGCAGGCCCATGCCCAGGTCACGTGG\nTACAAGCGCGGGGGCAGCCTCCCCGCCCGGCACCAGACCCATGGCTCCCAGCTGCGGCTC\nCACCACGTCTCCCCTGCCGACTCAGGCGAGTATGTGTGTCGTGCAGCCGGCGGCCCAGGC\nCCTGAGCAAGAAGCCTCCTTCACAGTCACCGTCCCGCCCAGTGAGGGGTCTTCCTACCGC\nCTTAGGAGCCCGGTCATCTCGATCGACCCGCCCAGCAGCACCGTGCAGCAGGGCCAGGAT\nGCCAGCTTCAAGTGCCTCATCCATGACGGGGCAGCCCCCATCAGCCTCGAGTGGAAGACC\nCGGAACCAGGAGCTGGAGGACAACGTCCACATCAGTCCCAATGGCTCCATCATCACCATC\nGTGGGCACCCGGCCCAGCAACCACGGTACCTACCGCTGCGTGGCCTCCAATGCCTACGGT\nGTGGCCCAGAGTGTGGTGAACCTCAGTGTGCACGGGCCCCCTACAGTGTCCGTGCTCCCC\nGAGGGCCCCGTGTGGGTGAAAGTGGGAAAGGCCGTCACCCTGGAGTGTGTCAGTGCCGGG\nGAGCCCCGCTCCTCTGCTCGTTGGACCCGGATCAGCAGCACCCCTGCCAAGTTGGAGCAG\nCGGACATATGGGCTCATGGACAGCCACACGGTGCTGCAGATTTCATCAGCTAAACCATCA\nGATGCGGGCACTTATGTGTGCCTTGCTCAGAATGCACTAGGCACAGCACAGAAGCAGGTG\nGAGGTGATCGTGGACACGGGCGCCATGGCCCCAGGGGCCCCTCAGGTCCAAGCTGAAGAA\nGCTGAGCTGACTGTGGAGGCTGGACACACGGCCACCTTGCGCTGCTCAGCCACAGGCAGC\nCCCGCGCGCACCATCCACTGGTCCAAGCTGCGTTCCCCACTGCCCTGGCAGCACCGGCTG\nGAAGGTGACACACTCATCATACCCCGGGTAGCCCAGCAGGACTCGGGCCAGTACATCTGC\nAATGCCACTAGCCCTGCCGGGCACGCTGAGGCCACCATCATCCTGCACGTGGAGAGCCCA\nCCATATGCCACCACGGTCCCAGAGCACGCTTCGGTGCAGGCAGGGGAGACGGTGCAGCTC\nCAGTGCCTGGCTCACGGGACACCCCCACTCACCTTCCAGTGGAGCCGCGTGGGCAGCAGC\nCTTCCTGGGAGGGCGACCGCCAGGAACGAGCTGCTGCACTTTGAGCGTGCAGCCCCTGAG\nGACTCAGGCCGCTACCGCTGCCGGGTCACCAACAAGGTGGGCTCAGCCGAGGCCTTTGCC\nCAGCTGCTCGTCCAAGGCCCTCCCGGCTCTCTCCCTGCCACCTCCATCCCAGCAGGGTCC\nACGCCCACCGTGCAGGTCACGCCTCAGCTAGAGACCAAGAGCATTGGGGCCAGCGTTGAG\nTTCCATTGTGCTGTGCCCAGCGACCGGGGTACCCAGCTCCGTTGGTTCAAGGAAGGGGGT\nCAGCTGCCTCCCGGTCACAGCGTGCAGGATGGGGTGCTCCGAATCCAGAACTTGGACCAG\nAGCTGCCAAGGGACGTATATATGCCAGGCCCATGGACCTTGGGGGAAGGCCCAGGCCAGT\nGCCCAGCTGGTTATCCAAGCCCTGCCCTCGGTGCTCATCAACATCCGGACCTCTGTGCAG\nACCGTGGTGGTTGGCCACGCCGTGGAGTTCGAATGCCTGGCACTGGGTGACCCCAAGCCT\nCAGGTGACATGGAGCAAAGTTGGAGGGCACCTGCGGCCAGGCATTGTGCAGAGCGGAGGT\nGTCGTCAGGATCGCCCACGTAGAGCTGGCTGATGCGGGACAGTATCGCTGCACTGCCACC\nAACGCAGCTGGCACCACACAATCCCACGTCCTGCTGCTTGTGCAAGCCTTGCCCCAGATC\nTCAATGCCCCAAGAAGTCCGTGTGCCTGCTGGTTCTGCAGCTGTCTTCCCCTGCATAGCC\nTCAGGCTACCCCACTCCTGACATCAGCTGGAGCAAGCTGGATGGCAGCCTGCCACCTGAC\nAGCCGCCTGGAGAACAACATGCTGATGCTGCCCTCAGTCCAACCCCAGGACGCAGGTACC\nTACGTCTGCACCGCCACTAACCGCCAGGGCAAGGTCAAAGCCTTTGCCCACCTGCAGGTG\nCCAGAGCGGGTGGTGCCCTACTTCACGCAGACCCCCTACTCCTTCCTACCGCTGCCCACC\nATCAAGGATGCCTACAGGAAGTTCGAGATCAAGATCACCTTCCGGCCTGACTCAGCCGAT\nGGGATGCTGCTGTACAATGGGCAGAAGCGAGTCCCAGGGAGCCCCACCAACCTGGCCAAC\nCGGCAGCCCGACTTCATCTCCTTCGGCCTCGTGGGGGGAAGGCCCGAGTTCCGGTTCGAT\nGCAGGCTCAGGCATGGCCACCATCCGCCATCCCACACCACTGGCCCTGGGCCATTTCCAC\nACCGTGACCCTGCTGCGCAGCCTCACCCAGGGCTCCCTGATTGTGGGTGACCTGGCCCCG\nGTCAACGGGACCTCCCAGGGCAAGTTCCAGGGCCTGGATCTGAACGAGGAACTCTACCTG\nGGTGGCTATCCTGACTATGGTGCCATCCCCAAGGCGGGGCTGAGCAGCGGCTTCATAGGC\nTGTGTCCGGGAGCTGCGCATCCAGGGCGAGGAGATCGTCTTCCATGACCTCAACCTCACG\nGCGCACGGCATCTCCCACTGCCCCACCTGTCGGGACCGGCCCTGCCAGAATGGCGGTCAG\nTGCCATGACTCTGAGAGCAGCAGCTATGTGTGCGTCTGCCCAGCTGGCTTCACCGGGAGC\nCGCTGTGAGCACTCGCAGGCCCTGCACTGCCATCCAGAGGCCTGTGGGCCCGACGCCACC\nTGTGTGAACCGGCCTGACGGTCGAGGCTACACCTGCCGCTGCCACCTGGGCCGCTCGGGG\nTTGCGGTGTGAGGAAGGTGTGACAGTGACCACCCCCTCGCTGTCGGGTGCTGGCTCCTAC\nCTGGCACTGCCCGCCCTCACCAACACACACCACGAGCTACGCCTGGACGTGGAGTTCAAG\nCCACTCGCCCCTGACGGGGTCCTGCTGTTCAGCGGGGGGAAGAGCGGGCCTGTGGAGGAC\nTTCGTGTCCCTGGCGATGGTGGGCGGCCACCTGGAGTTCCGCTATGAGTTGGGGTCAGGG\nCTGGCCGTTCTGCGGACGGCCGAGCCGCTGGCCCTGGGCCGCTGGCACCGTGTGTCTGCA\nGAGCGTCTCAACAAGGACGGCAGCCTGCGGGTGAATGGTGGACGCCCTGTGCTGCGCTCC\nTCGCCCGGCAAGAGCCAGGGCCTCAACCTGCACACCCTGCTCTACCTGGGGGGTGTGGAG\nCCTTCCGTGCCACTGTCCCCGGCCACCAACATGAGCGCTCACTTCCGCGGCTGTGTGGGC\nGAGGTGTCAGTGAATGGCAAACGGCTGGACCTCACCTACAGTTTCCTAGGCAGCCAGGGC\nATCGGGCAATGCTATGACAGCTCCCCATGTGAGCGCCAGCCTTGCCAACATGGTGCCACG\nTGCATGCCCGCTGGCGAGTATGAGTTCCAGTGCCTGTGTCGAGATGGAATCAAAGGAGAC\nCTGTGTGAGCACGAGGAGAACCCCTGCCAGCTCCGTGAACCCTGTCTGCATGGGGGCACC\nTGCCAGGGCACCCGCTGCCTCTGCCTCCCTGGCTTCTCTGGCCCACGCTGCCAACAAGGC\nTCTGGACATGGCATAGCAGAGTCCGACTGGCATCTTGAAGGCAGCGGGGGCAATGATGCC\nCCTGGGCAGTACGGAGCCTATTTCCACGATGATGGCTTCCTCGCCTTCCCTGGCCATGTC\nTTCTCCAGGAGCCTGCCCGAGGTGCCCGAGACCATCGAGCTGGAGGTTCGGACCAGCACA\nGCCAGTGGCCTCCTGCTCTGGCAGGGTGTGGAGGTGGGAGAGGCCGGCCAAGGCAAGGAC\nTTCATCAGCCTCGGGCTTCAAGACGGGCACCTTGTCTTCAGGTACCAGCTGGGTAGTGGG\nGAGGCCCGCCTGGTCTCTGAGGACCCCATCAATGACGGCGAGTGGCACCGGGTGACAGCA\nCTGCGGGAGGGCCGCAGAGGTTCCATCCAAGTCGACGGTGAGGAGCTGGTCAGCGGCCGG\nTCCCCAGGTCCCAACGTGGCAGTCAACGCCAAGGGCAGCATCTACATCGGCGGAGCCCCT\nGACGTGGCCACGCTGACCGGGGGCAGATTCTCCTCGGGCATCACAGGCTGTGTCAAGAAC\nCTGGTGCTGCACTCGGCCCGACCCGGCGCCCCGCCCCCACAGCCCCTGGACCTGCAGCAC\nCGCGCCCAGGCCGGGGCCAACACACGCCCCTGCCCCTCGTAG"}, "pfams": {"pfam": [{"identifier": "PF00047", "name": "ig"}, {"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF07679", "name": "I-set"}, {"identifier": "PF07686", "name": "V-set"}, {"identifier": "PF00057", "name": "Ldl_recept_a"}, {"identifier": "PF02210", "name": "Laminin_G_2"}, {"identifier": "PF01390", "name": "SEA"}, {"identifier": "PF00052", "name": "Laminin_B"}, {"identifier": "PF00053", "name": "Laminin_EGF"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular matrix"}, {"category": "function", "description": "structural molecule activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell adhesion"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-01-27", "drugbank-id": [{"@primary": "true", "#text": "DB00040"}, "BIOD00057", "BTD00057"], "name": "Glucagon recombinant", "description": "29 residue peptide hormone. Glucagon is synthesized in a special non- pathogenic laboratory strain of Escherichia coli bacteria that has been genetically altered by the addition of the gene for glucagons", "cas-number": "9007-92-5", "groups": {"group": "approved"}, "general-references": "# White CM: A review of potential cardiovascular uses of intravenous glucagon administration. J Clin Pharmacol. 1999 May;39(5):442-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10234590", "synthesis-reference": null, "indication": "For treatment of severe hypoglycemia, also used in gastrointestinal imaging", "pharmacodynamics": "Used in the treatment of hypoglycemia and in gastric imaging, glucagon increases blood glucose concentration and is used in the treatment of hypoglycemia. Glucagon acts only on liver glycogen, converting it to glucose through the release of insulin. It also relaxes the smooth muscles of the gastrointestinal tract.", "mechanism-of-action": "Glucagon binds the glucagon receptor, a G protein-coupled receptor located in the plasma membrane, which then initiates a dual signaling pathway using both adenylate cyclase activation and increased intracellular calcium. Adenylate cyclase manufactures cAMP (cyclic AMP), which activates protein kinase A (cAMP-dependent protein kinase). This enzyme, in turn, activates phosphorylase kinase, which, in turn, phosphorylates glycogen phosphorylase, converting into the active form called phosphorylase A. Phosphorylase A is the enzyme responsible for the release of glucose-1-phosphate from glycogen polymers. This yields glucose molecules to be released into the blood. Glucagon receptors are found in the liver, kidney, brain and pancreatic islet cells. The glucagon mediated signals lead to an increase in insulin excretion", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": "* 0.25 L/kg", "clearance": "* 13.5\u00a0 mL/min/kg [Adults with IV 1 mg]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Glucagon"}, {"@language": "", "@coder": "", "#text": "Glucagone"}, {"@language": "", "@coder": "", "#text": "Glucagonum"}, {"@language": "", "@coder": "", "#text": "His-ser-gln-gly-thr-phe-thr-ser-asp-tyr-ser-lys-tyr-leu-asp-ser-arg-arg-ala-gln-asp-phe-val-gln-trp-leu-met-asn-thr"}, {"@language": "", "@coder": "", "#text": "His-ser-glu(NH2)-gly-thr-phe-thr-ser-asp-tyr-ser-lys-tyr-leu-asp-ser-arg-arg-ala-glu(NH2)-asp-phe-val-glu(NH2)-trp-leu-met-asp(NH2)-thr"}, {"@language": "", "@coder": "", "#text": "HSQGTFTSDYSKYLDSRRAQDFVQWLMNT"}]}, "products": {"product": [{"name": "Glucagen", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02333619", "started-marketing-on": "2010-01-04", "ended-marketing-on": null, "dosage-form": "kit; powder for solution", "strength": "1 mg", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Glucagen Hypokit", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02333627", "started-marketing-on": "2009-12-23", "ended-marketing-on": null, "dosage-form": "kit; powder for solution", "strength": "1 mg", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Glucagon", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02243297", "started-marketing-on": "2002-05-27", "ended-marketing-on": null, "dosage-form": "kit; powder for solution", "strength": "1 mg", "route": "intramuscular; intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Glucagon", "ndc-id": "63323-596_a28fb798-125d-40fb-a8e4-c5423236cd8b", "ndc-product-code": "63323-596", "dpd-id": null, "started-marketing-on": "2015-05-08", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "1 mg/mL", "route": "intramuscular; intravenous", "fda-application-number": "NDA201849", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Glucagon Ampoule 666 1mg", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00015377", "started-marketing-on": "1961-12-31", "ended-marketing-on": "2002-05-27", "dosage-form": "powder for solution", "strength": "1 mg", "route": "intramuscular; intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Glucagon", "ingredients": "Glucagon recombinant"}, {"name": "Glucagon", "ingredients": "Glucagon recombinant"}, {"name": "Glucagen", "ingredients": "Glucagon recombinant"}, {"name": "Glucagen Hypokit", "ingredients": "Glucagon recombinant"}, {"name": "Glucagon Ampoule 666 1mg", "ingredients": "Glucagon recombinant"}]}, "packagers": {"packager": [{"name": "Bedford Labs", "url": "http://www.bedfordlabs.com"}, {"name": "Eli Lilly & Co.", "url": "http://www.lilly.com"}, {"name": "Novo Nordisk Inc.", "url": "http://www.novonordisk.com"}, {"name": "Physicians Total Care Inc.", "url": "http://www.physicianstotalcare.com"}]}, "manufacturers": {"manufacturer": [{"@generic": "false", "#text": "Eli lilly and co"}, {"@generic": "false", "#text": "Novo nordisk pharmaceuticals inc"}]}, "prices": {"price": [{"description": "Glucagen 1 mg vial", "cost": {"@currency": "USD", "#text": "84.0"}, "unit": "vial"}, {"description": "Glucagon 1 mg/vial", "cost": {"@currency": "USD", "#text": "94.98"}, "unit": "vial"}, {"description": "Glucagon 1 mg emergency kit", "cost": {"@currency": "USD", "#text": "119.28"}, "unit": "kit"}, {"description": "Glucagen 1 mg hypokit", "cost": {"@currency": "USD", "#text": "120.36"}, "unit": "kit"}, {"description": "GlucaGen HypoKit 1 mg Solution Box", "cost": {"@currency": "USD", "#text": "123.72"}, "unit": "box"}, {"description": "Glucagon Emergency 1 mg Kit Box", "cost": {"@currency": "USD", "#text": "124.05"}, "unit": "box"}, {"description": "Glucagon 1 mg kit", "cost": {"@currency": "USD", "#text": "128.34"}, "unit": "kit"}]}, "categories": {"category": {"category": "Hypoglycemic Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Kit; powder for solution", "route": "intramuscular", "strength": "1 mg"}, {"form": "Injection, powder, lyophilized, for solution", "route": "intramuscular; intravenous", "strength": "1 mg/mL"}, {"form": "Kit; powder for solution", "route": "intramuscular; intravenous; subcutaneous", "strength": "1 mg"}, {"form": "Powder for solution", "route": "intramuscular; intravenous; subcutaneous", "strength": "1 mg"}]}, "atc-codes": {"atc-code": {"@code": "H04AA01", "level": [{"@code": "H", "#text": "SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS"}, {"@code": "H04", "#text": "PANCREATIC HORMONES"}, {"@code": "H04A", "#text": "GLYCOGENOLYTIC HORMONES"}, {"@code": "H04AA", "#text": "Glycogenolytic hormones"}]}}, "ahfs-codes": {"ahfs-code": "68:22.12"}, "patents": null, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB01418", "name": "Acenocoumarol", "description": "May enhance the anticoagulant effect of Vitamin K Antagonists."}, {"drugbank-id": "DB08897", "name": "Aclidinium", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00321", "name": "Amitriptyline", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00543", "name": "Amoxapine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00572", "name": "Atropine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00972", "name": "Azelastine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00245", "name": "Benzatropine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00835", "name": "Brompheniramine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00748", "name": "Carbinoxamine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00341", "name": "Cetirizine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB01114", "name": "Chlorphenamine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00477", "name": "Chlorpromazine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00283", "name": "Clemastine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00771", "name": "Clidinium", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB01242", "name": "Clomipramine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00363", "name": "Clozapine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00318", "name": "Codeine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB01176", "name": "Cyclizine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00924", "name": "Cyclobenzaprine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00979", "name": "Cyclopentolate", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00434", "name": "Cyproheptadine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00496", "name": "Darifenacin", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB01151", "name": "Desipramine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00967", "name": "Desloratadine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00405", "name": "Dexbrompheniramine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00804", "name": "Dicyclomine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB01501", "name": "Difenoxin", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00985", "name": "Dimenhydrinate", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB01075", "name": "Diphenhydramine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB01081", "name": "Diphenoxylate", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00280", "name": "Disopyramide", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB01142", "name": "Doxepin", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00366", "name": "Doxylamine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00450", "name": "Droperidol", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB01288", "name": "Fenoterol", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB06702", "name": "Fesoterodine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00950", "name": "Fexofenadine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB01148", "name": "Flavoxate", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00875", "name": "Flupentixol", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00623", "name": "Fluphenazine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00588", "name": "Fluticasone Propionate", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00986", "name": "Glycopyrrolate", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00502", "name": "Haloperidol", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00557", "name": "Hydroxyzine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00424", "name": "Hyoscyamine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00458", "name": "Imipramine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00328", "name": "Indomethacin", "description": "Indomethacin may diminish the therapeutic effect of Glucagon."}, {"drugbank-id": "DB00332", "name": "Ipratropium bromide", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB01247", "name": "Isocarboxazid", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB01106", "name": "Levocabastine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB06282", "name": "Levocetirizine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00455", "name": "Loratadine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00408", "name": "Loxapine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00934", "name": "Maprotiline", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00737", "name": "Meclizine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB04843", "name": "Mepenzolate", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB01403", "name": "Methotrimeprazine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB01171", "name": "Moclobemide", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00540", "name": "Nortriptyline", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00334", "name": "Olanzapine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00768", "name": "Olopatadine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB01173", "name": "Orphenadrine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB01062", "name": "Oxybutynin", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00850", "name": "Perphenazine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00780", "name": "Phenelzine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB01100", "name": "Pimozide", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB06153", "name": "Pizotifen", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00433", "name": "Prochlorperazine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00387", "name": "Procyclidine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00420", "name": "Promazine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB01069", "name": "Promethazine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00782", "name": "Propantheline", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00344", "name": "Protriptyline", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB01224", "name": "Quetiapine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00734", "name": "Risperidone", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00747", "name": "Scopolamine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB01591", "name": "Solifenacin", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00679", "name": "Thioridazine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB01623", "name": "Thiothixene", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB01409", "name": "Tiotropium", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB01036", "name": "Tolterodine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00752", "name": "Tranylcypromine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00831", "name": "Trifluoperazine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00376", "name": "Trihexyphenidyl", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00662", "name": "Trimethobenzamide", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00726", "name": "Trimipramine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00427", "name": "Triprolidine", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00209", "name": "Trospium", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB09076", "name": "Umeclidinium", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}, {"drugbank-id": "DB00682", "name": "Warfarin", "description": "May enhance the anticoagulant effect of Vitamin K Antagonists."}, {"drugbank-id": "DB01624", "name": "Zuclopenthixol", "description": "Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">Glucagon for Injection Sequence \nHSQGTFTSDYSKYLDSRRAQDFVQWLMNT"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-1.197", "source": null}, {"kind": "Isoelectric Point", "value": "9.52", "source": null}, {"kind": "Molecular Weight", "value": "3767.1000", "source": null}, {"kind": "Molecular Formula", "value": "C165H249N49O51S1", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "12072"}, {"resource": "Drugs Product Database (DPD)", "identifier": "11363"}, {"resource": "KEGG Compound", "identifier": "C01501"}, {"resource": "KEGG Drug", "identifier": "D00116"}, {"resource": "National Drug Code Directory", "identifier": "0002-8031-01"}, {"resource": "GenBank", "identifier": "AF529185"}, {"resource": "PharmGKB", "identifier": "PA164779052"}, {"resource": "UniProtKB", "identifier": "Q8MJ25"}, {"resource": "Wikipedia", "identifier": "Glucagon_recombinant"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic2/gluca.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/glucagon.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000527", "name": "Glucagon receptor", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Katayama T, Shimamoto S, Oda H, Nakahara K, Kangawa K, Murakami N: Glucagon receptor expression and glucagon stimulation of ghrelin secretion in rat stomach. Biochem Biophys Res Commun. 2007 Jun 15;357(4):865-70. Epub 2007 Apr 9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17462598\n# Li P, Rogers T, Smiley D, DiMarchi RD, Zhang F: Design, synthesis and crystallization of a novel glucagon analog as a therapeutic agent. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Jul 1;63(Pt 7):599-601. Epub 2007 Jun 15. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17620721\n# Li XC, Zhuo JL: Targeting glucagon receptor signalling in treating metabolic syndrome and renal injury in Type 2 diabetes: theory versus promise. Clin Sci (Lond). 2007 Aug;113(4):183-93. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17623014\n# Fischer AJ, Stanke JJ, Ghai K, Scott M, Omar G: Development of bullwhip neurons in the embryonic chicken retina. J Comp Neurol. 2007 Aug 1;503(4):538-49. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17534934\n# Winzell MS, Brand CL, Wierup N, Sidelmann UG, Sundler F, Nishimura E, Ahren B: Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet. Diabetologia. 2007 Jul;50(7):1453-62. Epub 2007 May 4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17479245\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352\n# Menzel S, Stoffel M, Espinosa R 3rd, Fernald AA, Le Beau MM, Bell GI: Localization of the glucagon receptor gene to human chromosome band 17q25. Genomics. 1994 Mar 15;20(2):327-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8020989\n# Brubaker PL, Drucker DJ: Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels. 2002;8(3-4):179-88. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12529935\n# Lok S, Kuijper JL, Jelinek LJ, Kramer JM, Whitmore TE, Sprecher CA, Mathewes S, Grant FJ, Biggs SH, Rosenberg GB, et al.: The human glucagon receptor encoding gene: structure, cDNA sequence and chromosomal localization. Gene. 1994 Mar 25;140(2):203-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8144028", "known-action": "yes", "polypeptide": {"@id": "P47871", "@source": "Swiss-Prot", "name": "Glucagon receptor", "general-function": "Involved in glucagon receptor activity", "specific-function": "This is a receptor for glucagon which plays a central role in regulating the level of blood glucose by controlling the rate of hepatic glucose production and insulin secretion. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and also a phosphatidylinositol-calcium second messenger system", "gene-name": "GCGR", "locus": "17q25", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "143-166\n174-193\n226-249\n264-285\n304-326\n351-369\n382-404", "signal-regions": null, "theoretical-pi": "8.83", "molecular-weight": "54009.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:4192"}, {"resource": "GenAtlas", "identifier": "GCGR"}, {"resource": "GeneCards", "identifier": "GCGR"}, {"resource": "GenBank Gene Database", "identifier": "U03469"}, {"resource": "GenBank Protein Database", "identifier": "439690"}, {"resource": "IUPHAR", "identifier": "251"}, {"resource": "Guide to Pharmacology", "identifier": "29"}, {"resource": "UniProtKB", "identifier": "P47871"}, {"resource": "UniProt Accession", "identifier": "GLR_HUMAN"}]}, "synonyms": {"synonym": ["GL-R", "Glucagon receptor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Glucagon receptor precursor\nMPPCQPQRPLLLLLLLLACQPQVPSAQVMDFLFEKWKLYGDQCHHNLSLLPPPTELVCNR\nTFDKYSCWPDTPANTTANISCPWYLPWHHKVQHRFVFKRCGPDGQWVRGPRGQPWRDASQ\nCQMDGEEIEVQKEVAKMYSSFQVMYTVGYSLSLGALLLALAILGGLSKLHCTRNAIHANL\nFASFVLKASSVLVIDGLLRTRYSQKIGDDLSVSTWLSDGAVAGCRVAAVFMQYGIVANYC\nWLLVEGLYLHNLLGLATLPERSFFSLYLGIGWGAPMLFVVPWAVVKCLFENVQCWTSNDN\nMGFWWILRFPVFLAILINFFIFVRIVQLLVAKLRARQMHHTDYKFRLAKSTLTLIPLLGV\nHEVVFAFVTDEHAQGTLRSAKLFFDLFLSSFQGLLVAVLYCFLNKEVQSELRRRWHRWRL\nGKVLWEERNTSNHRASSSPGHGPPSKELQFGRGGGSQDSSAETPLAGGLPRLAESPF"}, "gene-sequence": {"@format": "FASTA", "#text": ">1434 bp\nATGCCCCCCTGCCAGCCACAGCGACCCCTGCTGCTGTTGCTGCTGCTGCTGGCCTGCCAG\nCCACAGGTCCCCTCCGCTCAGGTGATGGACTTCCTGTTTGAGAAGTGGAAGCTCTACGGT\nGACCAGTGTCACCACAACCTGAGCCTGCTGCCCCCTCCCACGGAGCTGGTGTGCAACAGA\nACCTTCGACAAGTATTCCTGCTGGCCGGACACCCCCGCCAATACCACGGCCAACATCTCC\nTGCCCCTGGTACCTGCCTTGGCACCACAAAGTGCAACACCGCTTCGTGTTCAAGAGATGC\nGGGCCCGACGGTCAGTGGGTGCGTGGACCCCGGGGGCAGCCTTGGCGTGATGCCTCCCAG\nTGCCAGATGGATGGCGAGGAGATTGAGGTCCAGAAGGAGGTGGCCAAGATGTACAGCAGC\nTTCCAGGTGATGTACACAGTGGGCTACAGCCTGTCCCTGGGGGCGCTGCTCCTCGCCTTG\nGCCATCCTGGGGGGCCTCAGCAAGCTGCACTGCACCCGCAATGCCATCCACGCGAATCTG\nTTTGCGTCCTTCGTGCTGAAAGCCAGCTCCGTGCTGGTCATTGATGGGCTGCTCAGGACC\nCGCTACAGCCAGAAAATTGGCGACGACCTCAGTGTCAGCACCTGGCTCAGTGATGGAGCG\nGTGGCTGGCTGCCGTGTGGCCGCGGTGTTCATGCAATATGGCATCGTGGCCAACTACTGC\nTGGCTGCTGGTGGAGGGCCTGTACCTGCACAACCTGCTGGGCCTGGCCACCCTCCCCGAG\nAGGAGCTTCTTCAGCCTCTACCTGGGCATCGGCTGGGGTGCCCCCATGCTGTTCGTCGTC\nCCCTGGGCAGTGGTCAAGTGTCTGTTCGAGAACGTCCAGTGCTGGACCAGCAATGACAAC\nATGGGCTTCTGGTGGATCCTGCGGTTCCCCGTCTTCCTGGCCATCCTGATCAACTTCTTC\nATCTTCGTCCGCATCGTTCAGCTGCTCGTGGCCAAGCTGCGGGCACGGCAGATGCACCAC\nACAGACTACAAGTTCCGGCTGGCCAAGTCCACGCTGACCCTCATCCCTCTGCTGGGCGTC\nCACGAAGTGGTCTTCGCCTTCGTGACGGACGAGCACGCCCAGGGCACCCTGCGCTCCGCC\nAAGCTCTTCTTCGACCTCTTCCTCAGCTCCTTCCAGGGCCTGCTGGTGGCTGTCCTCTAC\nTGCTTCCTCAACAAGGAGGTGCAGTCGGAGCTGCGGCGGCGTTGGCACCGCTGGCGCCTG\nGGCAAAGTGCTATGGGAGGAGCGGAACACCAGCAACCACAGGGCCTCATCTTCGCCCGGC\nCACGGCCCTCCCAGCAAGGAGCTGCAGTTTGGGAGGGGTGGTGGCAGCCAGGATTCATCT\nGCGGAGACCCCCTTGGCTGGTGGCCTCCCTAGATTGGCTGAGAGCCCCTTCTGA"}, "pfams": {"pfam": [{"identifier": "PF00002", "name": "7tm_2"}, {"identifier": "PF02793", "name": "HRM"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "secretin-like receptor activity"}, {"category": "function", "description": "glucagon receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}]}}}, {"id": "BE0002134", "name": "Glucagon-like peptide 2 receptor", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Boushey RP, Yusta B, Drucker DJ: Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res. 2001 Jan 15;61(2):687-93. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11212269\n# Munroe DG, Gupta AK, Kooshesh F, Vyas TB, Rizkalla G, Wang H, Demchyshyn L, Yang ZJ, Kamboj RK, Chen H, McCallum K, Sumner-Smith M, Drucker DJ, Crivici A: Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1569-73. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9990065\n# Estall JL, Koehler JA, Yusta B, Drucker DJ: The glucagon-like peptide-2 receptor C terminus modulates beta-arrestin-2 association but is dispensable for ligand-induced desensitization, endocytosis, and G-protein-dependent effector activation. J Biol Chem. 2005 Jun 10;280(23):22124-34. Epub 2005 Apr 6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15817468\n# Brubaker PL, Drucker DJ: Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels. 2002;8(3-4):179-88. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12529935", "known-action": "unknown", "polypeptide": {"@id": "O95838", "@source": "Swiss-Prot", "name": "Glucagon-like peptide 2 receptor", "general-function": null, "specific-function": "This is a receptor for glucagon-like peptide 2. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase", "gene-name": "GLP2R", "locus": "17p13.3", "cellular-location": "Membrane", "transmembrane-regions": "180-202\n211-230\n262-286\n299-322\n338-363\n386-406\n422-442", "signal-regions": null, "theoretical-pi": "9.03", "molecular-weight": "63002.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:4325"}, {"resource": "GenAtlas", "identifier": "GLP2R"}, {"resource": "GeneCards", "identifier": "GLP2R"}, {"resource": "GenBank Gene Database", "identifier": "AF105367"}, {"resource": "GenBank Protein Database", "identifier": "4324491"}, {"resource": "IUPHAR", "identifier": "250"}, {"resource": "Guide to Pharmacology", "identifier": "29"}, {"resource": "UniProtKB", "identifier": "O95838"}, {"resource": "UniProt Accession", "identifier": "GLP2R_HUMAN"}]}, "synonyms": {"synonym": ["GLP-2 receptor", "GLP-2-R", "GLP-2R", "Glucagon-like peptide 2 receptor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Glucagon-like peptide 2 receptor\nMKLGSSRAGPGRGSAGLLPGVHELPMGIPAPWGTSPLSFHRKCSLWAPGRPFLTLVLLVS\nIKQVTGSLLEETTRKWAQYKQACLRDLLKEPSGIFCNGTFDQYVCWPHSSPGNVSVPCPS\nYLPWWSEESSGRAYRHCLAQGTWQTIENATDIWQDDSECSENHSFKQNVDRYALLSTLQL\nMYTVGYSFSLISLFLALTLLLFLRKLHCTRNYIHMNLFASFILRTLAVLVKDVVFYNSYS\nKRPDNENGWMSYLSEMSTSCRSVQVLLHYFVGANYLWLLVEGLYLHTLLEPTVLPERRLW\nPRYLLLGWAFPVLFVVPWGFARAHLENTGCWTTNGNKKIWWIIRGPMMLCVTVNFFIFLK\nILKLLISKLKAHQMCFRDYKYRLAKSTLVLIPLLGVHEILFSFITDDQVEGFAKLIRLFI\nQLTLSSFHGFLVALQYGFANGEVKAELRKYWVRFLLARHSGCRACVLGKDFRFLGKCPKK\nLSEGDGAEKLRKLQPSLNSGRLLHLAMRGLGELGAQPQQDHARWPRGSSLSECSEGDVTM\nANTMEEILEESEI"}, "gene-sequence": {"@format": "FASTA", "#text": ">1662 bp\nATGAAGCTGGGATCGAGCAGGGCAGGGCCTGGGAGAGGAAGCGCGGGACTCCTGCCTGGC\nGTCCACGAGCTGCCCATGGGCATCCCTGCCCCCTGGGGGACCAGTCCTCTCTCCTTCCAC\nAGGAAGTGCTCTCTCTGGGCCCCTGGGAGGCCCTTCCTCACTCTGGTCCTGCTGGTTTCC\nATCAAGCAAGTTACAGGATCCCTCCTTGAGGAAACGACTCGGAAGTGGGCTCAGTACAAA\nCAGGCATGTCTGAGAGACTTACTCAAGGAACCTTCTGGCATATTTTGTAACGGGACATTT\nGATCAGTACGTGTGTTGGCCTCATTCTTCTCCTGGAAATGTCTCTGTACCCTGCCCTTCA\nTACTTACCTTGGTGGAGTGAAGAGAGCTCAGGAAGGGCCTACAGACACTGCTTGGCTCAG\nGGGACTTGGCAGACGATAGAGAACGCCACGGATATTTGGCAGGATGACTCCGAATGCTCC\nGAGAACCACAGCTTCAAGCAAAACGTGGACCGTTATGCCTTGCTGTCAACCTTGCAGCTG\nATGTACACCGTGGGATACTCCTTCTCTCTTATCTCCCTCTTCCTGGCTCTCACCCTCCTC\nTTGTTTCTTCGAAAACTCCACTGCACGCGCAACTACATCCACATGAACTTGTTTGCTTCT\nTTCATCCTGAGAACCCTGGCTGTACTGGTGAAGGACGTCGTCTTCTACAACTCTTACTCC\nAAGAGGCCTGACAATGAGAATGGGTGGATGTCCTACCTGTCAGAGATGTCCACCTCCTGC\nCGCTCAGTCCAGGTTCTCTTGCATTACTTTGTGGGTGCCAATTACTTATGGCTGCTGGTT\nGAAGGCCTCTACCTCCACACGCTGCTGGAGCCCACAGTGCTTCCTGAGAGGCGGCTGTGG\nCCCAGATACCTGCTGTTGGGTTGGGCCTTCCCTGTGCTATTTGTTGTACCCTGGGGTTTC\nGCCCGTGCACACCTGGAGAACACAGGGTGCTGGACAACAAATGGGAATAAGAAAATCTGG\nTGGATCATCCGAGGACCCATGATGCTCTGTGTAACAGTCAATTTCTTCATCTTCCTGAAA\nATTCTCAAGCTTCTCATTTCTAAGCTCAAAGCTCATCAAATGTGCTTCAGAGATTATAAA\nTACAGATTGGCAAAATCAACACTGGTCCTCATTCCTTTATTGGGCGTTCATGAGATCCTC\nTTCTCTTTCATCACTGATGATCAAGTTGAAGGATTTGCAAAACTTATACGACTTTTCATT\nCAGTTGACACTGAGCTCCTTTCATGGGTTCCTGGTGGCCTTGCAGTATGGTTTTGCCAAT\nGGAGAAGTGAAGGCTGAGCTGCGGAAATACTGGGTCCGCTTCTTGCTAGCCCGCCACTCA\nGGCTGCAGAGCCTGTGTCCTGGGGAAGGACTTCCGGTTCCTAGGAAAATGTCCCAAGAAG\nCTCTCGGAAGGAGATGGCGCTGAGAAGCTTCGGAAGCTGCAGCCCTCACTTAACAGTGGG\nCGGCTCCTACATCTAGCCATGCGAGGTCTTGGGGAGCTGGGCGCCCAGCCCCAACAGGAC\nCATGCACGCTGGCCCCGGGGCAGCAGCCTGTCCGAGTGCAGTGAGGGGGATGTCACCATG\nGCCAACACCATGGAGGAGATTCTGGAAGAGAGTGAGATCTAG"}, "pfams": {"pfam": [{"identifier": "PF00002", "name": "7tm_2"}, {"identifier": "PF02793", "name": "HRM"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}]}}}, {"id": "BE0000857", "name": "Glucagon-like peptide 1 receptor", "organism": "Human", "actions": null, "references": "# Korner M, Stockli M, Waser B, Reubi JC: GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007 May;48(5):736-43. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17475961\n# Baggio LL, Drucker DJ: Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007 May;132(6):2131-57. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17498508\n# Fischer AJ, Stanke JJ, Ghai K, Scott M, Omar G: Development of bullwhip neurons in the embryonic chicken retina. J Comp Neurol. 2007 Aug 1;503(4):538-49. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17534934\n# Brubaker PL, Drucker DJ: Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels. 2002;8(3-4):179-88. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12529935", "known-action": "unknown", "polypeptide": {"@id": "P43220", "@source": "Swiss-Prot", "name": "Glucagon-like peptide 1 receptor", "general-function": "Involved in peptide receptor activity, G-protein coupled", "specific-function": "This is a receptor for glucagon-like peptide 1. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase", "gene-name": "GLP1R", "locus": "6p21", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "146-168\n177-196\n228-252\n265-288\n304-329\n352-372\n388-408", "signal-regions": null, "theoretical-pi": "8.19", "molecular-weight": "53060.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:4324"}, {"resource": "GenAtlas", "identifier": "GLP1R"}, {"resource": "GeneCards", "identifier": "GLP1R"}, {"resource": "GenBank Gene Database", "identifier": "U01104"}, {"resource": "GenBank Protein Database", "identifier": "405082"}, {"resource": "IUPHAR", "identifier": "249"}, {"resource": "Guide to Pharmacology", "identifier": "29"}, {"resource": "UniProtKB", "identifier": "P43220"}, {"resource": "UniProt Accession", "identifier": "GLP1R_HUMAN"}]}, "synonyms": {"synonym": ["GLP-1 receptor", "GLP-1-R", "GLP-1R", "Glucagon-like peptide 1 receptor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Glucagon-like peptide 1 receptor precursor\nMAGAPGPLRLALLLLGMVGRAGPRPQGATVSLWETVQKWREYRRQCQRSLTEDPPPATDL\nFCNRTFDEYACWPDGEPGSFVNVSCPWYLPWASSVPQGHVYRFCTAEGLWLQKDNSSLPW\nRDLSECEESKRGERSSPEEQLLFLYIIYTVGYALSFSALVIASAILLGFRHLHCTRNYIH\nLNLFASFILRALSVFIKDAALKWMYSTAAQQHQWDGLLSYQDSLSCRLVFLLMQYCVAAN\nYYWLLVEGVYLYTLLAFSVFSEQWIFRLYVSIGWGVPLLFVVPWGIVKYLYEDEGCWTRN\nSNMNYWLIIRLPILFAIGVNFLIFVRVICIVVSKLKANLMCKTDIKCRLAKSTLTLIPLL\nGTHEVIFAFVMDEHARGTLRFIKLFTELSFTSFQGLMVAILYCFVNNEVQLEFRKSWERW\nRLEHLHIQRDSSMKPLKCPTSSLSSGATAGSSMYTATCQASCS"}, "gene-sequence": {"@format": "FASTA", "#text": ">1392 bp\nATGGCCGGCGCCCCCGGCCCGCTGCGCCTTGCCGTGCTGCTGCTCGGGATGGTGGGCAGG\nGCCGGCCCCCGCCCCCAGGGTGCCACTGTGTCCCTCTGGGAGACGGTGCAGAAATGGCGA\nGAATACCGACGCCAGTGCCAGCGCTCCCTGACTGAGGATCCACCTCCTGCCACAGACTTG\nTTCTGCAACCGGACCTTCGATGAATACGCCTGCTGGCCAGATGGGGAGCCAGGCTCGTTC\nGTGAATGTCAGCTGCCCCTGGTACCTGCCCTGGGCCAGCAGTGTGCCGCAGGGCCACGTG\nTACCGGTTCTGCACAGCTGAAGGCCTCTGGCTGCAGAAGGACAACTCCAGCCTGCCCTGG\nAGGGACTTGTCGGAGTGCGAGGAGTCCAAGCGAGGGGAGAGAAGCTGGGGGGAGGAGCAG\nCTCCTGTTCCTCTACATCATCTACACGGTGGCGTACGCACTCTCCTTCTCTGCTCTGGTT\nATCGCCTCTGCGATCCTCCTCGGCTTCAGACACCTGCACTGCACCAGGAACTACATCCAC\nCTGAACCTGTTTGCATCCTTCATCCTGCGAGCATTGTCCGTCTTCATCAAGGACGCAGCC\nCTGAAGTGGATGTATAGCACAGCCGCCCAGCAGCACCAGTGGGATGGGCTCCTCTCCTAC\nCAGGACTCTCTGAGCTGCCGCCTGGTGTTTCTGCTCATGCAGTACTGTGTGGCGGCCAAT\nTACTACTGGCTCTTGGTGGAGGGCGTGTACCTGTACACACTGCTGGCCTTCTCGGTCTTC\nTCTGAGCAATGGATCTTCAGGCTCTACGTGAGCATAGGCTGGGGTGTTCCCCTGCTGTTT\nGTTGTCCCCTGGGGCATTGTCAAGATCCTCTATGAGGACGAGGGCTGCTGGACCAGGAAC\nTCCAACATGAACTACTGGCTCATTATCCGGCTGCCCATTCTCTTTGCCATTGGGGTGAAC\nTTCCTCATCTTTGTTCGGGTCATCTGCATCGTGGTATCCAAACTGAAGGCCAATCTCATG\nTGCAAGACAGACATCAAATGCAGACTTGCCAAGTCCACGCTGACACTCATCCCCCTGCTG\nGGGACTCATGAGGTCATCTTTGCCTTTGTGATGGACGAGCACGCCCGGGGGACCCTGCGC\nTTCATCAAGCTGTTTACAGAGCTCTCCTTCACCTCCTTCCAGGGGCTGATGGTGGCCATC\nTTATACTGCTTTGTCAACAATGAGGTCCAGCTGGAATTTCGGAAGAGCTGGGAGCGCTGG\nCGGCTTGAGCACTTGCACATCCAGAGGGACAGCAGCATGAAGCCCCTCAAGTGTCCCACC\nAGCAGCCTGAGCAGTGGAGCCACGGCGGGCAGCAGCATGTACACAGCCACTTGCCAGGCC\nTCCTGCAGCTGA"}, "pfams": {"pfam": [{"identifier": "PF00002", "name": "7tm_2"}, {"identifier": "PF02793", "name": "HRM"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "peptide receptor activity, G-protein coupled"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "secretin-like receptor activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "glucagon receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}, {"category": "process", "description": "cellular process"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-09-13", "drugbank-id": [{"@primary": "true", "#text": "DB00041"}, "BIOD00082", "BTD00082"], "name": "Aldesleukin", "description": "Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.", "cas-number": "85898-30-2", "groups": {"group": "approved"}, "general-references": null, "synthesis-reference": "Hans-Ake Fabricius, Roland Stahn, \"Serum-free and mitogen-free T-cell growth factor and process for making same.\" U.S. Patent US4464355, issued May, 1971.", "indication": "For treatment of adults with metastatic renal cell carcinoma.", "pharmacodynamics": "Used to treat renal cell carcinoma, Aldesleukin induces the enhancement of lymphocyte mitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines, the enhancement of lymphocyte cytotoxicity, the induction of killer cell (lymphokine-activated (LAK) and natural (NK)) activity; and the induction of interferon-gamma production. IL-2 is normally produced by the body, secreted by T cells, and stimulates growth and differentiation of T cell response. It can be used in immunotherapy to treat cancer. It enhances the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor.", "mechanism-of-action": "Aldesleukin binds to the IL-2 receptor which leads to heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains, activation of the tyrosine kinase Jak3, and phosphorylation of tyrosine residues on the IL-2R beta chain. These events led to the creation of an activated receptor complex, to which various cytoplasmic signaling molecules are recruited and become substrates for regulatory enzymes (especially tyrosine kinases) that are associated with the receptor. These events stimulate growth and differentiation of T cells.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": "13 min-85 min", "protein-binding": null, "route-of-elimination": "The pharmacokinetic profile of Proleukin is characterized by high plasma concentrations following a short IV infusion, rapid distribution into the extravascular space and elimination from the body by metabolism in the kidneys with little or no bioactive protein excreted in the urine. Following the initial rapid organ distribution, the primary route of clearance of circulating proleukin is the kidney. Greater than 80% of the amount of Proleukin distributed to plasma, cleared from the circulation and presented to the kidney is metabolized to amino acids in the cells lining the proximal convoluted tubules.", "volume-of-distribution": "0.18 l/kg", "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "IL-2"}, {"@language": "", "@coder": "", "#text": "Interleukin-2 precursor"}, {"@language": "", "@coder": "", "#text": "T-cell growth factor"}, {"@language": "", "@coder": "", "#text": "TCGF"}]}, "products": {"product": [{"name": "Proleukin", "ndc-id": "0078-0495_d7232a34-b86b-47f3-b921-13a27fdf93a6", "ndc-product-code": "0078-0495", "dpd-id": null, "started-marketing-on": "1992-05-06", "ended-marketing-on": null, "dosage-form": "injection", "strength": "1.1 mg/mL", "route": "intravenous", "fda-application-number": "BLA103293", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Proleukin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02130181", "started-marketing-on": "1995-12-31", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "22000000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Proleukin", "ndc-id": "65483-116_b3294680-603d-42f9-a4c9-473213f6797a", "ndc-product-code": "65483-116", "dpd-id": null, "started-marketing-on": "1992-05-05", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "1.1 mg/mL", "route": "intravenous", "fda-application-number": "BLA103293", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Proleukin", "ingredients": "Aldesleukin"}, {"name": "Proleukin", "ingredients": "Aldesleukin"}, {"name": "Proleukin", "ingredients": "Aldesleukin"}]}, "packagers": {"packager": [{"name": "Bayer Healthcare", "url": "http://www.bayerhealthcare.com"}, {"name": "Chiron Corp.", "url": "http://www.chiron.com"}, {"name": "Novartis AG", "url": "http://www.novartis.com"}, {"name": "Physicians Total Care Inc.", "url": "http://www.physicianstotalcare.com"}, {"name": "Prometheus Laboratories Inc.", "url": "http://www.prometheuslabs.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Proleukin 22000000 unit Solution Vial", "cost": {"@currency": "USD", "#text": "976.66"}, "unit": "vial"}, {"description": "Proleukin 22 million unit vial", "cost": {"@currency": "USD", "#text": "1092.34"}, "unit": "each"}]}, "categories": {"category": [{"category": "Antineoplastic Agents", "mesh-id": null}, {"category": "Anti-HIV Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection", "route": "intravenous", "strength": "1.1 mg/mL"}, {"form": "Injection, powder, lyophilized, for solution", "route": "intravenous", "strength": "1.1 mg/mL"}, {"form": "Powder for solution", "route": "intravenous", "strength": "22000000 unit"}]}, "atc-codes": {"atc-code": {"@code": "L03AC01", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L03", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03A", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03AC", "#text": "Interleukins"}]}}, "ahfs-codes": {"ahfs-code": "10:00.00"}, "patents": null, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00240", "name": "Alclometasone", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB00288", "name": "Amcinonide", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB00394", "name": "Beclomethasone", "description": "May diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB00443", "name": "Betamethasone", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB01222", "name": "Budesonide", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB00237", "name": "Butabarbital", "description": "May enhance the hypotensive effect of Hypotensive Agents."}, {"drugbank-id": "DB01353", "name": "Butethal", "description": "May enhance the hypotensive effect of Hypotensive Agents."}, {"drugbank-id": "DB02300", "name": "Calcipotriol", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB01013", "name": "Clobetasol propionate", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB00838", "name": "Clocortolone", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB00363", "name": "Clozapine", "description": "Myelosuppressive Agents may enhance the adverse/toxic effect of Clozapine. Specifically, the risk for agranulocytosis may be increased."}, {"drugbank-id": "DB01285", "name": "Corticotropin", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB01380", "name": "Cortisone acetate", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB00547", "name": "Desoximetasone", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB01234", "name": "Dexamethasone", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB00271", "name": "Diatrizoate", "description": "May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents."}, {"drugbank-id": "DB00223", "name": "Diflorasone", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB00476", "name": "Duloxetine", "description": "Hypotensive Agents may enhance the orthostatic hypotensive effect of Duloxetine."}, {"drugbank-id": "DB00965", "name": "Ethiodized oil", "description": "May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents."}, {"drugbank-id": "DB00687", "name": "Fludrocortisone", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB00591", "name": "Fluocinolone Acetonide", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB01047", "name": "Fluocinonide", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB00324", "name": "Fluorometholone", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB00846", "name": "Flurandrenolide", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB08906", "name": "Fluticasone furoate", "description": "May diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB06786", "name": "Halcinonide", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB00596", "name": "Halobetasol Propionate", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB01354", "name": "Heptabarbital", "description": "May enhance the hypotensive effect of Hypotensive Agents."}, {"drugbank-id": "DB01355", "name": "Hexobarbital", "description": "May enhance the hypotensive effect of Hypotensive Agents."}, {"drugbank-id": "DB00769", "name": "Hydrocortamate", "description": "May diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB00741", "name": "Hydrocortisone", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB00018", "name": "Interferon alfa-n3", "description": "Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination."}, {"drugbank-id": "DB00069", "name": "Interferon alfacon-1", "description": "Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination."}, {"drugbank-id": "DB04711", "name": "Iodipamide", "description": "May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents."}, {"drugbank-id": "DB01249", "name": "Iodixanol", "description": "May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents."}, {"drugbank-id": "DB01362", "name": "Iohexol", "description": "May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents."}, {"drugbank-id": "DB08947", "name": "Iopamidol", "description": "May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents."}, {"drugbank-id": "DB09156", "name": "Iopromide", "description": "May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents."}, {"drugbank-id": "DB09134", "name": "Ioversol", "description": "May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents."}, {"drugbank-id": "DB09135", "name": "Ioxilan", "description": "May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents."}, {"drugbank-id": "DB01235", "name": "Levodopa", "description": "Hypotensive Agents may enhance the orthostatic hypotensive effect of Levodopa."}, {"drugbank-id": "DB04817", "name": "Metamizole", "description": "May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased"}, {"drugbank-id": "DB00474", "name": "Methohexital", "description": "May enhance the hypotensive effect of Hypotensive Agents."}, {"drugbank-id": "DB00959", "name": "Methylprednisolone", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB00764", "name": "Mometasone", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB00008", "name": "Peginterferon alfa-2a", "description": "Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination."}, {"drugbank-id": "DB00022", "name": "Peginterferon alfa-2b", "description": "Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination."}, {"drugbank-id": "DB00312", "name": "Pentobarbital", "description": "May enhance the hypotensive effect of Hypotensive Agents."}, {"drugbank-id": "DB01130", "name": "Prednicarbate", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB00860", "name": "Prednisolone", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB00635", "name": "Prednisone", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB00794", "name": "Primidone", "description": "May enhance the hypotensive effect of Hypotensive Agents."}, {"drugbank-id": "DB00896", "name": "Rimexolone", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB00734", "name": "Risperidone", "description": "Hypotensive Agents may enhance the hypotensive effect of Risperidone."}, {"drugbank-id": "DB00418", "name": "Secobarbital", "description": "May enhance the hypotensive effect of Hypotensive Agents."}, {"drugbank-id": "DB00620", "name": "Triamcinolone", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}, {"drugbank-id": "DB09082", "name": "Vilanterol", "description": "Corticosteroids may diminish the antineoplastic effect of Aldesleukin."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">Aldesleukin sequence\nMAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCL\nEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLN\nRWITFCQSIISTLT"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.192", "source": null}, {"kind": "Isoelectric Point", "value": "7.31", "source": null}, {"kind": "Molecular Weight", "value": "15314.8000", "source": null}, {"kind": "Molecular Formula", "value": "C690H1115N177O202S6", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "278"}, {"resource": "National Drug Code Directory", "identifier": "0078-0495-61"}, {"resource": "GenBank", "identifier": "M11144"}, {"resource": "PharmGKB", "identifier": "PA448081"}, {"resource": "UniProtKB", "identifier": "P60569"}, {"resource": "Wikipedia", "identifier": "Aldesleukin"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic2/aldesleukin.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/aldesleukin.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000651", "name": "Interleukin-2 receptor subunit beta", "organism": "Human", "actions": {"action": ["agonist", "modulator"]}, "references": "# Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA: Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2788-93. Epub 2006 Feb 13. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16477002\n# Steppan S, Eckart MR, Bajsarowicz K, Sternberg LR, Greve JM, Cassell DJ: Reduced secondary cytokine induction by BAY 50-4798, a high-affinity receptor-specific interleukin-2 analog. J Interferon Cytokine Res. 2006 Mar;26(3):171-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16542139\n# Cornish GH, Sinclair LV, Cantrell DA: Differential regulation of T-cell growth by IL-2 and IL-15. Blood. 2006 Jul 15;108(2):600-8. Epub 2006 Mar 28. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16569767\n# Lee KD, Chen HW, Chen CC, Shih YC, Liu HK, Cheng ML: Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2. Oncol Rep. 2006 May;15(5):1211-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16596189\n# Maclennan C, Hutchinson P, Holdsworth S, Bardin PG, Freezer NJ: Airway inflammation in asymptomatic children with episodic wheeze. Pediatr Pulmonol. 2006 Jun;41(6):577-83. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16617454\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P14784", "@source": "Swiss-Prot", "name": "Interleukin-2 receptor subunit beta", "general-function": "Involved in hematopoietin/interferon-class (D200-domain) cytokine receptor activity", "specific-function": "Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2", "gene-name": "IL2RB", "locus": "22q13|22q13.1", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "241-265", "signal-regions": null, "theoretical-pi": "4.68", "molecular-weight": "61118.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6009"}, {"resource": "GenAtlas", "identifier": "IL2RB"}, {"resource": "GeneCards", "identifier": "IL2RB"}, {"resource": "GenBank Gene Database", "identifier": "M26062"}, {"resource": "GenBank Protein Database", "identifier": "307048"}, {"resource": "UniProtKB", "identifier": "P14784"}, {"resource": "UniProt Accession", "identifier": "IL2RB_HUMAN"}]}, "synonyms": {"synonym": ["CD122 antigen", "High affinity IL-2 receptor subunit beta", "IL-2 receptor", "Interleukin-2 receptor subunit beta precursor", "P70-75", "p75"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interleukin-2 receptor beta chain precursor\nMAAPALSWRLPLLILLLPLATSWASAAVNGTSQFTCFYNSRANISCVWSQDGALQDTSCQ\nVHAWPDRRRWNQTCELLPVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMA\nIQDFKPFENLRLMAPISLQVVHVETHRCNISWEISQASHYFERHLEFEARTLSPGHTWEE\nAPLLTLKQKQEWICLETLTPDTQYEFQVRVKPLQGEFTTWSPWSQPLAFRTKPAALGKDT\nIPWLGHLLVGLSGAFGFIILVYLLINCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDV\nQKWLSSPFPSSSFSPGGLAPEISPLEVLERDKVTQLLLQQDKVPEPASLSSNHSLTSCFT\nNQGYFFFHLPDALEIEACQVYFTYDPYSEEDPDEGVAGAPTGSSPQPLQPLSGEDDAYCT\nFPSRDDLLLFSPSLLGGPSPPSTAPGGSGAGEERMPPSLQERVPRDWDPQPLGPPTPGVP\nDLVDFQPPPELVLREAGEEVPDAGPREGVSFPWSRPPGQGEFRALNARLPLNTDAYLSLQ\nELQGQDPTHLV"}, "gene-sequence": {"@format": "FASTA", "#text": ">1656 bp\nATGGCGGCCCCTGCTCTGTCCTGGCGTCTGCCCCTCCTCATCCTCCTCCTGCCCCTGGCT\nACCTCTTGGGCATCTGCAGCGGTGAATGGCACTTCCCAGTTCACATGCTTCTACAACTCG\nAGAGCCAACATCTCCTGTGTCTGGAGCCAAGATGGGGCTCTGCAGGACACTTCCTGCCAA\nGTCCATGCCTGGCCGGACAGACGGCGGTGGAACCAAACCTGTGAGCTGCTCCCCGTGAGT\nCAAGCATCCTGGGCCTGCAACCTGATCCTCGGAGCCCCAGATTCTCAGAAACTGACCACA\nGTTGACATCGTCACCCTGAGGGTGCTGTGCCGTGAGGGGGTGCGATGGAGGGTGATGGCC\nATCCAGGACTTCAAGCCCTTTGAGAACCTTCGCCTGATGGCCCCCATCTCCCTCCAAGTT\nGTCCACGTGGAGACCCACAGATGCAACATAAGCTGGGAAATCTCCCAAGCCTCCCACTAC\nTTTGAAAGACACCTGGAGTTCGAGGCCCGGACGCTGTCCCCAGGCCACACCTGGGAGGAG\nGCCCCCCTGCTGACTCTCAAGCAGAAGCAGGAATGGATCTGCCTGGAGACGCTCACCCCA\nGACACCCAGTATGAGTTTCAGGTGCGGGTCAAGCCTCTGCAAGGCGAGTTCACGACCTGG\nAGCCCCTGGAGCCAGCCCCTGGCCTTCAGGACAAAGCCTGCAGCCCTTGGGAAGGACACC\nATTCCGTGGCTCGGCCACCTCCTCGTGGGCCTCAGCGGGGCTTTTGGCTTCATCATCTTA\nGTGTACTTGCTGATCAACTGCAGGAACACCGGGCCATGGCTGAAGAAGGTCCTGAAGTGT\nAACACCCCAGACCCCTCGAAGTTCTTTTCCCAGCTGAGCTCAGAGCATGGAGGAGACGTC\nCAGAAGTGGCTCTCTTCGCCCTTCCCCTCATCGTCCTTCAGCCCTGGCGGCCTGGCACCT\nGAGATCTCGCCACTAGAAGTGCTGGAGAGGGACAAGGTGACGCAGCTGCTCCTGCAGCAG\nGACAAGGTGCCTGAGCCCGCATCCTTAAGCAGCAACCACTCGCTGACCAGCTGCTTCACC\nAACCAGGGTTACTTCTTCTTCCACCTCCCGGATGCCTTGGAGATAGAGGCCTGCCAGGTG\nTACTTTACTTACGACCCCTACTCAGAGGAAGACCCTGATGAGGGTGTGGCCGGGGCACCC\nACAGGGTCTTCCCCCCAACCCCTGCAGCCTCTGTCAGGGGAGGACGACGCCTACTGCACC\nTTCCCCTCCAGGGATGACCTGCTGCTCTTCTCCCCCAGTCTCCTCGGTGGCCCCAGCCCC\nCCAAGCACTGCCCCTGGGGGCAGTGGGGCCGGTGAAGAGAGGATGCCCCCTTCTTTGCAA\nGAAAGAGTCCCCAGAGACTGGGACCCCCAGCCCCTGGGGCCTCCCACCCCAGGAGTCCCA\nGACCTGGTGGATTTTCAGCCACCCCCTGAGCTGGTGCTGCGAGAGGCTGGGGAGGAGGTC\nCCTGACGCTGGCCCCAGGGAGGGAGTCAGTTTCCCCTGGTCCAGGCCTCCTGGGCAGGGG\nGAGTTCAGGGCCCTTAATGCTCGCCTGCCCCTGAACACTGATGCCTACTTGTCCCTCCAA\nGAACTCCAGGGTCAGGACCCAACTCACTTGGTGTAG"}, "pfams": null, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "hematopoietin/interferon-class (D200-domain) cytokine receptor activity"}]}}}, {"id": "BE0000658", "name": "Interleukin-2 receptor subunit alpha", "organism": "Human", "actions": {"action": ["agonist", "modulator"]}, "references": "# Waldmann TA: Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol. 2007 Jan;27(1):1-18. Epub 2007 Jan 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17216565\n# Recchia F, Cesta A, Rea S: Low dose interleukin-2 and 13-cis-retinoic acid as maintenance therapy in patients with solid tumors responsive to chemotherapy. J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):135-43. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16767920\n# Waldmann TA: Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene. 2007 May 28;26(25):3699-703. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17530023\n# Vlad G, Ho EK, Vasilescu ER, Fan J, Liu Z, Cai JW, Jin Z, Burke E, Deng M, Cadeiras M, Cortesini R, Itescu S, Marboe C, Mancini D, Suciu-Foca N: Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation. Transpl Immunol. 2007 Jul;18(1):13-21. Epub 2007 Apr 2. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17584597\n# Liu BY, Zhu P, Luo HB, Fu N: [Screening of short peptides binding to cell surface interleukin-2 receptor alpha chain] Nan Fang Yi Ke Da Xue Xue Bao. 2006 Jul;26(7):971-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16864089\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352\n# Ouyang Y, Kaminski NE: Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes. Arch Toxicol. 1999 Feb;73(1):1-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10207608", "known-action": "yes", "polypeptide": {"@id": "P01589", "@source": "Swiss-Prot", "name": "Interleukin-2 receptor subunit alpha", "general-function": "Involved in interleukin-2 receptor activity", "specific-function": "Receptor for interleukin-2", "gene-name": "IL2RA", "locus": "10p15-p14", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "241-259", "signal-regions": null, "theoretical-pi": "6.49", "molecular-weight": "30819.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6008"}, {"resource": "GenAtlas", "identifier": "IL2RA"}, {"resource": "GeneCards", "identifier": "IL2RA"}, {"resource": "GenBank Gene Database", "identifier": "X01057"}, {"resource": "GenBank Protein Database", "identifier": "33813"}, {"resource": "UniProtKB", "identifier": "P01589"}, {"resource": "UniProt Accession", "identifier": "IL2RA_HUMAN"}]}, "synonyms": {"synonym": ["CD25 antigen", "IL-2 receptor alpha subunit", "IL-2-RA", "IL2-RA", "Interleukin-2 receptor alpha chain precursor", "p55", "TAC antigen"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interleukin-2 receptor alpha chain precursor\nMDSYLLMWGLLTFIMVPGCQAELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKS\nGSLYMLCTGNSSHSSWDNQCQCTSSATRNTTKQVTPQPEEQKERKTTEMQSPMQPVDQAS\nLPGHCREPPPWENEATERIYHFVVGQMVYYQCVQGYRALHRGPAESVCKMTHGKTRWTQP\nQLICTGEMETSQFPGEEKPQASPEGRPESETSCLVTTTDFQIQTEMAATMETSIFTTEYQ\nVAVAGCVFLLISVLLLSGLTWQRRQRKSRRTI"}, "gene-sequence": {"@format": "FASTA", "#text": ">819 bp\nATGGATTCATACCTGCTGATGTGGGGACTGCTCACGTTCATCATGGTGCCTGGCTGCCAG\nGCAGAGCTCTGTGACGATGACCCGCCAGAGATCCCACACGCCACATTCAAAGCCATGGCC\nTACAAGGAAGGAACCATGTTGAACTGTGAATGCAAGAGAGGTTTCCGCAGAATAAAAAGC\nGGGTCACTCTATATGCTCTGTACAGGAAACTCTAGCCACTCGTCCTGGGACAACCAATGT\nCAATGCACAAGCTCTGCCACTCGGAACACAACGAAACAAGTGACACCTCAACCTGAAGAA\nCAGAAAGAAAGGAAAACCACAGAAATGCAAAGTCCAATGCAGCCAGTGGACCAAGCGAGC\nCTTCCAGGTCACTGCAGGGAACCTCCACCATGGGAAAATGAAGCCACAGAGAGAATTTAT\nCATTTCGTGGTGGGGCAGATGGTTTATTATCAGTGCGTCCAGGGATACAGGGCTCTACAC\nAGAGGTCCTGCTGAGAGCGTCTGCAAAATGACCCACGGGAAGACAAGGTGGACCCAGCCC\nCAGCTCATATGCACAGGTGAAATGGAGACCAGTCAGTTTCCAGGTGAAGAGAAGCCTCAG\nGCAAGCCCCGAAGGCCGTCCTGAGAGTGAGACTTCCTGCCTCGTCACAACAACAGATTTT\nCAAATACAGACAGAAATGGCTGCAACCATGGAGACGTCCATATTTACAACAGAGTACCAG\nGTAGCAGTGGCCGGCTGTGTTTTCCTGCTGATCAGCGTCCTCCTCCTGAGTGGGCTCACC\nTGGCAGCGGAGACAGAGGAAGAGTAGAAGAACAATCTAG"}, "pfams": {"pfam": {"identifier": "PF00084", "name": "Sushi"}}, "go-classifiers": null}}, {"id": "BE0002102", "name": "Cytokine receptor common subunit gamma", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA: Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2788-93. Epub 2006 Feb 13. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16477002\n# Shibata F, Toma T, Wada T, Inoue M, Tone Y, Ohta K, Kasahara Y, Sano F, Kimura M, Ikeno M, Koizumi S, Yachie A: Skin infiltration of CD56(bright) CD16(-) natural killer cells in a case of X-SCID with Omenn syndrome-like manifestations. Eur J Haematol. 2007 Jul;79(1):81-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17598841\n# Fonseca SG, Reis MM, Coelho V, Nogueira LG, Monteiro SM, Mairena EC, Bacal F, Bocchi E, Guilherme L, Zheng XX, Liew FY, Higuchi ML, Kalil J, Cunha-Neto E: Locally produced survival cytokines IL-15 and IL-7 may be associated to the predominance of CD8+ T cells at heart lesions of human chronic Chagas disease cardiomyopathy. Scand J Immunol. 2007 Aug-Sep;66(2-3):362-71. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17635814\n# Blank RB, Lamb EW, Tocheva AS, Crow ET, Lim KC, McKerrow JH, Davies SJ: The common gamma chain cytokines interleukin (IL)-2 and IL-7 indirectly modulate blood fluke development via effects on CD4+ T cells. J Infect Dis. 2006 Dec 1;194(11):1609-16. Epub 2006 Oct 23. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17083048\n# Smyth CM, Ginn SL, Deakin CT, Logan GJ, Alexander IE: Limiting {gamma}c expression differentially affects signaling via the interleukin (IL)-7 and IL-15 receptors. Blood. 2007 Jul 1;110(1):91-8. Epub 2007 Mar 15. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17363735", "known-action": "yes", "polypeptide": {"@id": "P31785", "@source": "Swiss-Prot", "name": "Cytokine receptor common subunit gamma", "general-function": null, "specific-function": "Common subunit for the receptors for a variety of interleukins", "gene-name": "IL2RG", "locus": "Xq13.1", "cellular-location": "Membrane", "transmembrane-regions": "263-283", "signal-regions": null, "theoretical-pi": "6.31", "molecular-weight": "42287.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6010"}, {"resource": "GenAtlas", "identifier": "IL2RG"}, {"resource": "GeneCards", "identifier": "IL2RG"}, {"resource": "GenBank Gene Database", "identifier": "D11086"}, {"resource": "GenBank Protein Database", "identifier": "219890"}, {"resource": "UniProtKB", "identifier": "P31785"}, {"resource": "UniProt Accession", "identifier": "IL2RG_HUMAN"}]}, "synonyms": {"synonym": ["CD132 antigen", "Cytokine receptor common gamma chain precursor", "Gamma-C", "IL-2R gamma chain", "Interleukin- 2 receptor gamma chain", "p64"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytokine receptor common gamma chain\nMLKPSLPFTSLLFLQLPLLGVGLNTTILTPNGNEDTTADFFLTTMPTDSLSVSTLPLPEV\nQCFVFNVEYMNCTWNSSSEPQPTNLTLHYWYKNSDNDKVQKCSHYLFSEEITSGCQLQKK\nEIHLYQTFVVQLQDPREPRRQATQMLKLQNLVIPWAPENLTLHKLSESQLELNWNNRFLN\nHCLEHLVQYRTDWDHSWTEQSVDYRHKFSLPSVDGQKRYTFRVRSRFNPLCGSAQHWSEW\nSHPIHWGSNTSKENPFLFALEAVVISVGSMGLIISLLCVYFWLERTMPRIPTLKNLEDLV\nTEYHGNFSAWSGVSKGLAESLQPDYSERLCLVSEIPPKGGALGEGPGASPCNQHSPYWAP\nPCYTLKPET"}, "gene-sequence": {"@format": "FASTA", "#text": ">1110 bp\nATGTTGAAGCCATCATTACCATTCACATCCCTCTTATTCCTGCAGCTGCCCCTGCTGGGA\nGTGGGGCTGAACACGACAATTCTGACGCCCAATGGGAATGAAGACACCACAGCTGATTTC\nTTCCTGACCACTATGCCCACTGACTCCCTCAGTGTTTCCACTCTGCCCCTCCCAGAGGTT\nCAGTGTTTTGTGTTCAATGTCGAGTACATGAATTGCACTTGGAACAGCAGCTCTGAGCCC\nCAGCCTACCAACCTCACTCTGCATTATTGGTACAAGAACTCGGATAATGATAAAGTCCAG\nAAGTGCAGCCACTATCTATTCTCTGAAGAAATCACTTCTGGCTGTCAGTTGCAAAAAAAG\nGAGATCCACCTCTACCAAACATTTGTTGTTCAGCTCCAGGACCCACGGGAACCCAGGAGA\nCAGGCCACACAGATGCTAAAACTGCAGAATCTGGTGATCCCCTGGGCTCCAGAGAACCTA\nACACTTCACAAACTGAGTGAATCCCAGCTAGAACTGAACTGGAACAACAGATTCTTGAAC\nCACTGTTTGGAGCACTTGGTGCAGTACCGGACTGACTGGGACCACAGCTGGACTGAACAA\nTCAGTGGATTATAGACATAAGTTCTCCTTGCCTAGTGTGGATGGGCAGAAACGCTACACG\nTTTCGTGTTCGGAGCCGCTTTAACCCACTCTGTGGAAGTGCTCAGCATTGGAGTGAATGG\nAGCCACCCAATCCACTGGGGGAGCAATACTTCAAAAGAGAATCCTTTCCTGTTTGCATTG\nGAAGCCGTGGTTATCTCTGTTGGCTCCATGGGATTGATTATCAGCCTTCTCTGTGTGTAT\nTTCTGGCTGGAACGGACGATGCCCCGAATTCCCACCCTGAAGAACCTAGAGGATCTTGTT\nACTGAATACCACGGGAACTTTTCGGCCTGGAGTGGTGTGTCTAAGGGACTGGCTGAGAGT\nCTGCAGCCAGACTACAGTGAACGACTCTGCCTCGTCAGTGAGATTCCCCCAAAAGGAGGG\nGCCCTTGGGGAGGGGCCTGGGGCCTCCCCATGCAACCAGCATAGCCCCTACTGGGCCCCC\nCCATGTTACACCCTAAAGCCTGAAACCTGA"}, "pfams": null, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "hematopoietin/interferon-class (D200-domain) cytokine receptor activity"}]}}}]}, "enzymes": {"enzyme": [{"@position": "1", "id": "BE0000262", "name": "Prostaglandin G/H synthase 2", "organism": "Human", "actions": {"action": "inducer"}, "references": "# Pyeon D, Diaz FJ, Splitter GA: Prostaglandin E(2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus. J Virol. 2000 Jun;74(12):5740-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10823885\n# Hamada T, Tsuchihashi S, Avanesyan A, Duarte S, Moore C, Busuttil RW, Coito AJ: Cyclooxygenase-2 deficiency enhances Th2 immune responses and impairs neutrophil recruitment in hepatic ischemia/reperfusion injury. J Immunol. 2008 Feb 1;180(3):1843-53. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18209082", "known-action": "unknown", "polypeptide": {"@id": "P35354", "@source": "Swiss-Prot", "name": "Prostaglandin G/H synthase 2", "general-function": "Involved in peroxidase activity", "specific-function": "May have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity", "gene-name": "PTGS2", "locus": "1q25.2-q25.3", "cellular-location": "Microsome; microsomal membrane; peripheral membrane protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.41", "molecular-weight": "68997.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9605"}, {"resource": "GenAtlas", "identifier": "PTGS2"}, {"resource": "GeneCards", "identifier": "PTGS2"}, {"resource": "GenBank Gene Database", "identifier": "L15326"}, {"resource": "GenBank Protein Database", "identifier": "291988"}, {"resource": "UniProtKB", "identifier": "P35354"}, {"resource": "UniProt Accession", "identifier": "PGH2_HUMAN"}]}, "synonyms": {"synonym": ["COX-2", "Cyclooxygenase- 2", "EC 1.14.99.1", "PGH synthase 2", "PGHS-2", "PHS II", "Prostaglandin G/H synthase 2 precursor", "Prostaglandin H2 synthase 2", "Prostaglandin-endoperoxide synthase 2"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Prostaglandin G/H synthase 2 precursor\nMLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL\nTRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY\nGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS\nNMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY\nQIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD\nVLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ\nNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV\nAGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL\nYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV\nGFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER\nSTEL"}, "gene-sequence": {"@format": "FASTA", "#text": ">1815 bp\nATGCTCGCCCGCGCCCTGCTGCTGTGCGCGGTCCTGGCGCTCAGCCATACAGCAAATCCT\nTGCTGTTCCCACCCATGTCAAAACCGAGGTGTATGTATGAGTGTGGGATTTGACCAGTAT\nAAGTGCGATTGTACCCGGACAGGATTCTATGGAGAAAACTGCTCAACACCGGAATTTTTG\nACAAGAATAAAATTATTTCTGAAACCCACTCCAAACACAGTGCACTACATACTTACCCAC\nTTCAAGGGATTTTGGAACGTTGTGAATAACATTCCCTTCCTTCGAAATGCAATTATGAGT\nTATGTGTTGACATCCAGATCACATTTGATTGACAGTCCACCAACTTACAATGCTGACTAT\nGGCTACAAAAGCTGGGAAGCCTTCTCTAACCTCTCCTATTATACTAGAGCCCTTCCTCCT\nGTGCCTGATGATTGCCCGACTCCCTTGGGTGTCAAAGGTAAAAAGCAGCTTCCTGATTCA\nAATGAGATTGTGGAAAAATTGCTTCTAAGAAGAAAGTTCATCCCTGATCCCCAGGGCTCA\nAACATGATGTTTGCATTCTTTGCCCAGCACTTCACGCATCAGTTTTTCAAGACAGATCAT\nAAGCGAGGGCCAGCTTTCACCAACGGGCTGGGCCATGGGGTGGACTTAAATCATATTTAC\nGGTGAAACTCTGGCTAGACAGCGTAAACTGCGCCTTTTCAAGGATGGAAAAATGAAATAT\nCAGATAATTGATGGAGAGATGTATCCTCCCACAGTCAAAGATACTCAGGCAGAGATGATC\nTACCCTCCTCAAGTCCCTGAGCATCTACGGTTTGCTGTGGGGCAGGAGGTCTTTGGTCTG\nGTGCCTGGTCTGATGATGTATGCCACAATCTGGCTGCGGGAACACAACAGAGTATGCGAT\nGTGCTTAAACAGGAGCATCCTGAATGGGGTGATGAGCAGTTGTTCCAGACAAGCAGGCTA\nATACTGATAGGAGAGACTATTAAGATTGTGATTGAAGATTATGTGCAACACTTGAGTGGC\nTATCACTTCAAACTGAAATTTGACCCAGAACTACTTTTCAACAAACAATTCCAGTACCAA\nAATCGTATTGCTGCTGAATTTAACACCCTCTATCACTGGCATCCCCTTCTGCCTGACACC\nTTTCAAATTCATGACCAGAAATACAACTATCAACAGTTTATCTACAACAACTCTATATTG\nCTGGAACATGGAATTACCCAGTTTGTTGAATCATTCACCAGGCAAATTGCTGGCAGGGTT\nGCTGGTGGTAGGAATGTTCCACCCGCAGTACAGAAAGTATCACAGGCTTCCACTGACCAG\nAGCAGGCAGATGAAATACCAGTCTTTTAATGAGTACCGCAAACGCTTTATGCTGAAGCCC\nTATGAATCATTTGAAGAACTTACAGGAGAAAAGGAAATGTCTGCAGAGTTGGAAGCACTC\nTATGGTGACATCGATGCTGTGGAGCTGTATCCTGCCCTTCTGGTAGAAAAGCCTCGGCCA\nGATGCCATCTTTGGTGAAACCATGGTAGAAGTTGGAGCACCATTCTCCTTGAAAGGACTT\nATGGGTAATGTTATATGTTCTCCTGCCTACTGGAAGCCAAGCACTTTTGGTGGAGAAGTG\nGGTTTTCAAATCATCAACACTGCCTCAATTCAGTCTCTCATCTGCAATAACGTGAAGGGC\nTGTCCCTTTACTTCATTCAGTGTTCCAGATCCAGAGCTCATTAAAACAGTCACCATCAAT\nGCAAGTTCTTCCCGCTCCGGACTAGATGATATCAATCCCACAGTACTACTAAAAGAACGT\nTCGACTGAACTGTAG"}, "pfams": {"pfam": [{"identifier": "PF03098", "name": "An_peroxidase"}, {"identifier": "PF00008", "name": "EGF"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "antioxidant activity"}, {"category": "function", "description": "peroxidase activity"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}, {"@position": "2", "id": "BE0000657", "name": "Cytosolic phospholipase A2", "organism": "Human", "actions": {"action": "inducer"}, "references": "# Wolbink GJ, Schalkwijk C, Baars JW, Wagstaff J, van den Bosch H, Hack CE: Therapy with interleukin-2 induces the systemic release of phospholipase-A2. Cancer Immunol Immunother. 1995 Nov;41(5):287-92. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8536274", "known-action": "unknown", "polypeptide": {"@id": "P47712", "@source": "Swiss-Prot", "name": "Cytosolic phospholipase A2", "general-function": "Involved in phospholipase activity", "specific-function": "Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory response", "gene-name": "PLA2G4A", "locus": "1q25", "cellular-location": "Cytoplasm. Cytoplasmic vesicle. Translocates to membrane vesicles in a calcium-dependent fashion", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.03", "molecular-weight": "85212.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9035"}, {"resource": "GenAtlas", "identifier": "PLA2G4A"}, {"resource": "GeneCards", "identifier": "PLA2G4A"}, {"resource": "GenBank Gene Database", "identifier": "M72393"}, {"resource": "GenBank Protein Database", "identifier": "190007"}, {"resource": "UniProtKB", "identifier": "P47712"}, {"resource": "UniProt Accession", "identifier": "PA24A_HUMAN"}]}, "synonyms": {"synonym": ["cPLA2", "EC 3.1.1.4", "Phospholipase A2 group IVA"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytosolic phospholipase A2\nMSFIDPYQHIIVEHQYSHKFTVVVLRATKVTKGAFGDMLDTPDPYVELFISTTPDSRKRT\nRHFNNDINPVWNETFEFILDPNQENVLEITLMDANYVMDETLGTATFTVSSMKVGEKKEV\nPFIFNQVTEMVLEMSLEVCSCPDLRFSMALCDQEKTFRQQRKEHIRESMKKLLGPKNSEG\nLHSARDVPVVAILGSGGGFRAMVGFSGVMKALYESGILDCATYVAGLSGSTWYMSTLYSH\nPDFPEKGPEEINEELMKNVSHNPLLLLTPQKVKRYVESLWKKKSSGQPVTFTDIFGMLIG\nETLIHNRMNTTLSSLKEKVNTAQCPLPLFTCLHVKPDVSELMFADWVEFSPYEIGMAKYG\nTFMAPDLFGSKFFMGTVVKKYEENPLHFLMGVWGSAFSILFNRVLGVSGSQSRGSTMEEE\nLENITTKHIVSNDSSDSDDESHEPKGTENEDAGSDYQSDNQASWIHRMIMALVSDSALFN\nTREGRAGKVHNFMLGLNLNTSYPLSPLSDFATQDSFDDDELDAAVADPDEFERIYEPLDV\nKSKKIHVVDSGLTFNLPYPLILRPQRGVDLIISFDFSARPSDSSPPFKELLLAEKWAKMN\nKLPFPKIDPYVFDREGLKECYVFKPKNPDMEKDCPTIIHFVLANINFRKYKAPGVPRETE\nEEKEIADFDIFDDPESPFSTFNFQYPNQAFKRLHDLMHFNTLNNIDVIKEAMVESIEYRR\nQNPSRCSVSLSNVEARRFFNKEFLSKPKA"}, "gene-sequence": {"@format": "FASTA", "#text": ">2250 bp\nATGTCATTTATAGATCCTTACCAGCACATTATAGTGGAGCACCAGTATTCCCACAAGTTT\nACGGTAGTGGTGTTACGTGCCACCAAAGTGACAAAGGGGGCCTTTGGTGACATGCTTGAT\nACTCCAGATCCCTATGTGGAACTTTTTATCTCTACAACCCCTGACAGCAGGAAGAGAACA\nAGACATTTCAATAATGACATAAACCCTGTGTGGAATGAGACCTTTGAATTTATTTTGGAT\nCCTAATCAGGAAAATGTTTTGGAGATTACGTTAATGGATGCCAATTATGTCATGGATGAA\nACTCTAGGGACAGCAACATTTACTGTATCTTCTATGAAGGTGGGAGAAAAGAAAGAAGTT\nCCTTTTATTTTCAACCAAGTCACTGAAATGGTTCTAGAAATGTCTCTTGAAGTTTGCTCA\nTGCCCAGACCTACGATTTAGTATGGCTCTGTGTGATCAGGAGAAGACTTTCAGACAACAG\nAGAAAAGAACACATAAGGGAGAGCATGAAGAAACTCTTGGGTCCAAAGAATAGTGAAGGA\nTTGCATTCTGCACGTGATGTGCCTGTGGTAGCCATATTGGGTTCAGGTGGGGGTTTCCGA\nGCCATGGTGGGATTCTCTGGTGTGATGAAGGCATTATACGAATCAGGAATTCTGGATTGT\nGCTACCTACGTTGCTGGTCTTTCTGGCTCCACCTGGTATATGTCAACCTTGTATTCTCAC\nCCTGATTTTCCAGAGAAAGGGCCAGAGGAGATTAATGAAGAACTAATGAAAAATGTTAGC\nCACAATCCCCTTTTACTTCTCACACCACAGAAAGTTAAAAGATATGTTGAGTCTTTATGG\nAAGAAGAAAAGCTCTGGACAACCTGTCACCTTTACTGATATCTTTGGGATGTTAATAGGA\nGAAACACTAATTCATAATAGAATGAATACTACTCTGAGCAGTTTGAAGGAAAAAGTTAAT\nACTGCACAATGCCCTTTACCTCTTTTCACCTGTCTTCATGTCAAACCTGACGTTTCAGAG\nCTGATGTTTGCAGATTGGGTTGAATTTAGTCCATACGAAATTGGCATGGCTAAATATGGT\nACTTTTATGGCTCCCGACTTATTTGGAAGCAAATTTTTTATGGGAACAGTCGTTAAGAAG\nTATGAAGAAAACCCCTTGCATTTCTTAATGGGTGTCTGGGGCAGTGCCTTTTCCATATTG\nTTCAACAGAGTTTTGGGCGTTTCTGGTTCACAAAGCAGAGGCTCCACAATGGAGGAAGAA\nTTAGAAAATATTACCACAAAGCATATTGTGAGTAATGATAGCTCGGACAGTGATGATGAA\nTCACACGAACCCAAAGGCACTGAAAATGAAGATGCTGGAAGTGACTATCAAAGTGATAAT\nCAAGCAAGTTGGATTCATCGTATGATAATGGCCTTGGTGAGTGATTCAGCTTTATTCAAT\nACCAGAGAAGGACGTGCTGGGAAGGTACACAACTTCATGCTGGGCTTGAATCTCAATACA\nTCTTATCCACTGTCTCCTTTGAGTGACTTTGCCACACAGGACTCCTTTGATGATGATGAA\nCTGGATGCAGCTGTAGCAGATCCTGATGAATTTGAGCGAATATATGAGCCTCTGGATGTC\nAAAAGTAAAAAGATTCATGTAGTGGACAGTGGGCTCACATTTAACCTGCCGTATCCCTTG\nATACTGAGACCTCAGAGAGGGGTTGATCTCATAATCTCCTTTGACTTTTCTGCAAGGCCA\nAGTGACTCTAGTCCTCCGTTCAAGGAACTTCTACTTGCAGAAAAGTGGGCTAAAATGAAC\nAAGCTCCCCTTTCCAAAGATTGATCCTTATGTGTTTGATCGGGAAGGGCTGAAGGAGTGC\nTATGTCTTTAAACCCAAGAATCCTGATATGGAGAAAGATTGCCCAACCATCATCCACTTT\nGTTCTGGCCAACATCAACTTCAGAAAGTACAAGGCTCCAGGTGTTCCAAGGGAAACTGAG\nGAAGAGAAAGAAATCGCTGACTTTGATATTTTTGATGACCCAGAATCACCATTTTCAACC\nTTCAATTTTCAATATCCAAATCAAGCATTCAAAAGACTACATGATCTTATGCACTTCAAT\nACTCTGAACAACATTGATGTGATAAAAGAAGCCATGGTTGAAAGCATTGAATATAGAAGA\nCAGAATCCATCTCGTTGCTCTGTTTCCCTTAGTAATGTTGAGGCAAGAAGATTTTTCAAC\nAAGGAGTTTCTAAGTAAACCCAAAGCATAG"}, "pfams": {"pfam": [{"identifier": "PF00168", "name": "C2"}, {"identifier": "PF01735", "name": "PLA2_B"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "carboxylic ester hydrolase activity"}, {"category": "function", "description": "lipase activity"}, {"category": "function", "description": "phospholipase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "hydrolase activity, acting on ester bonds"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "membrane lipid metabolism"}, {"category": "process", "description": "phospholipid metabolism"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "phospholipid catabolism"}, {"category": "process", "description": "primary metabolism"}, {"category": "process", "description": "lipid metabolism"}, {"category": "process", "description": "cellular lipid metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}, {"@position": "3", "id": "BE0002638", "name": "Cytochrome P450 3A4", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Elkahwaji J, Robin MA, Berson A, Tinel M, Letteron P, Labbe G, Beaune P, Elias D, Rougier P, Escudier B, Duvillard P, Pessayre D: Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. Biochem Pharmacol. 1999 Apr 15;57(8):951-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10086330\n# Sunman JA, Hawke RL, LeCluyse EL, Kashuba AD: Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos. 2004 Mar;32(3):359-63. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14977871", "known-action": "unknown", "polypeptide": {"@id": "P08684", "@source": "Swiss-Prot", "name": "Cytochrome P450 3A4", "general-function": "Involved in monooxygenase activity", "specific-function": "Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4- hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. The enzyme also hydroxylates etoposide", "gene-name": "CYP3A4", "locus": "7q21.1", "cellular-location": "Endoplasmic reticulum", "transmembrane-regions": "2-22", "signal-regions": null, "theoretical-pi": "8.25", "molecular-weight": "57344.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2637"}, {"resource": "GenAtlas", "identifier": "CYP3A4"}, {"resource": "GenBank Gene Database", "identifier": "M18907"}, {"resource": "UniProtKB", "identifier": "P08684"}, {"resource": "UniProt Accession", "identifier": "CP3A4_HUMAN"}]}, "synonyms": {"synonym": ["CYPIIIA4", "EC 1.14.13.67", "EC 1.14.13.97", "NF-25", "Nifedipine oxidase", "P450-PCN1", "Quinine 3-monooxygenase", "Taurochenodeoxycholate 6-alpha- hydroxylase"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytochrome P450 3A4\nMALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF\nDMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI\nAEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS\nMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV\nFPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI\nIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV\nNETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS\nKKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG\nGLLQPEKPVVLKVESRDGTVSGA"}, "gene-sequence": {"@format": "FASTA", "#text": ">1512 bp\nATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG\nCTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG\nCCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT\nGACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT\nGTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT\nGTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA\nGCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA\nAAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG\nAGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC\nATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA\nGACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT\nCTCTCAATAACAGTCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTG\nTTTCCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGC\nCTCGAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAAT\nTCAAAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATT\nATCTTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAA\nCTGGCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCC\nAATAAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTG\nAATGAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGAT\nGTTGAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCT\nCTTCACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGC\nAAGAAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGA\nAACTGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTT\nCAGAACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGA\nGGACTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTA\nAGTGGAGCCTGA"}, "pfams": {"pfam": {"identifier": "PF00067", "name": "p450"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "iron ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "tetrapyrrole binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "heme binding"}, {"category": "function", "description": "monooxygenase activity"}, {"category": "function", "description": "oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "generation of precursor metabolites and energy"}, {"category": "process", "description": "electron transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}, {"@position": "4", "id": "BE0002204", "name": "Xanthine dehydrogenase/oxidase", "organism": "Human", "actions": {"action": "inducer"}, "references": "# Faggioni R, Allavena P, Cantoni L, Carelli M, Demitri MT, Delgado R, Gatti S, Gnocchi P, Isetta AM, Paganin C, et al.: Mechanisms of interleukin-2-induced hydrothoraxy in mice: protective effect of endotoxin tolerance and dexamethasone and possible role of reactive oxygen intermediates. J Immunother Emphasis Tumor Immunol. 1994 Apr;15(3):194-201. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8032542", "known-action": "unknown", "polypeptide": {"@id": "P47989", "@source": "Swiss-Prot", "name": "Xanthine dehydrogenase/oxidase", "general-function": "Nucleotide transport and metabolism", "specific-function": "This enzyme can be converted from the dehydrogenase form (D) to the oxidase form (O) irreversibly by proteolysis or reversibly through the oxidation of sulfhydryl groups", "gene-name": "XDH", "locus": "2p23.1", "cellular-location": "Peroxisome", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.7", "molecular-weight": "146426.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:12805"}, {"resource": "GenAtlas", "identifier": "XDH"}, {"resource": "GeneCards", "identifier": "XDH"}, {"resource": "GenBank Gene Database", "identifier": "D11456"}, {"resource": "GenBank Protein Database", "identifier": "10336525"}, {"resource": "UniProtKB", "identifier": "P47989"}, {"resource": "UniProt Accession", "identifier": "XDH_HUMAN"}]}, "synonyms": {"synonym": ["EC 1.17.1.4", "EC 1.17.3.2", "Xanthine oxidase", "XD", "XO"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Xanthine dehydrogenase/oxidase [Includes: Xanthine dehydrogenase\nMTADKLVFFVNGRKVVEKNADPETTLLAYLRRKLGLSGTKLGCGEGGCGACTVMLSKYDR\nLQNKIVHFSANACLAPICSLHHVAVTTVEGIGSTKTRLHPVQERIAKSHGSQCGFCTPGI\nVMSMYTLLRNQPEPTMEEIENAFQGNLCRCTGYRPILQGFRTFARDGGCCGGDGNNPNCC\nMNQKKDHSVSLSPSLFKPEEFTPLDPTQEPIFPPELLRLKDTPRKQLRFEGERVTWIQAS\nTLKELLDLKAQHPDAKLVVGNTEIGIEMKFKNMLFPMIVCPAWIPELNSVEHGPDGISFG\nAACPLSIVEKTLVDAVAKLPAQKTEVFRGVLEQLRWFAGKQVKSVASVGGNIITASPISD\nLNPVFMASGAKLTLVSRGTRRTVQMDHTFFPGYRKTLLSPEEILLSIEIPYSREGEYFSA\nFKQASRREDDIAKVTSGMRVLFKPGTTEVQELALCYGGMANRTISALKTTQRQLSKLWKE\nELLQDVCAGLAEELHLPPDAPGGMVDFRCTLTLSFFFKFYLTVLQKLGQENLEDKCGKLD\nPTFASATLLFQKDPPADVQLFQEVPKGQSEEDMVGRPLPHLAADMQASGEAVYCDDIPRY\nENELSLRLVTSTRAHAKIKSIDTSEAKKVPGFVCFISADDVPGSNITGICNDETVFAKDK\nVTCVGHIIGAVVADTPEHTQRAAQGVKITYEELPAIITIEDAIKNNSFYGPELKIEKGDL\nKKGFSEADNVVSGEIYIGGQEHFYLETHCTIAVPKGEAGEMELFVSTQNTMKTQSFVAKM\nLGVPANRIVVRVKRMGGGFGGKETRSTVVSTAVALAAYKTGRPVRCMLDRDEDMLITGGR\nHPFLARYKVGFMKTGTVVALEVDHFSNVGNTQDLSQSIMERALFHMDNCYKIPNIRGTGR\nLCKTNLPSNTAFRGFGGPQGMLIAECWMSEVAVTCGMPAEEVRRKNLYKEGDLTHFNQKL\nEGFTLPRCWEECLASSQYHARKSEVDKFNKENCWKKRGLCIIPTKFGISFTVPFLNQAGA\nLLHVYTDGSVLLTHGGTEMGQGLHTKMVQVASRALKIPTSKIYISETSTNTVPNTSPTAA\nSVSADLNGQAVYAACQTILKRLEPYKKKNPSGSWEDWVTAAYMDTVSLSATGFYRTPNLG\nYSFETNSGNPFHYFSYGVACSEVEIDCLTGDHKNLRTDIVMDVGSSLNPAIDIGQVEGAF\nVQGLGLFTLEELHYSPEGSLHTRGPSTYKIPAFGSIPIEFRVSLLRDCPNKKAIYASKAV\nGEPPLFLAASIFFAIKDAIRAARAQHTGNNVKELFRLDSPATPEKIRNACVDKFTTLCVT\nGVPENCKPWSVRV"}, "gene-sequence": {"@format": "FASTA", "#text": ">4002 bp\nATGACAGCAGACAAATTGGTTTTCTTTGTGAATGGCAGAAAGGTGGTGGAGAAAAATGCA\nGATCCAGAGACAACCCTTTTGGCCTACCTGAGAAGAAAGTTGGGGCTGAGTGGAACCAAG\nCTCGGCTGTGGAGAGGGGGGCTGCGGGGCTTGCACAGTGATGCTCTCCAAGTATGATCGT\nCTGCAGAACAAGATCGTCCACTTTTCTGCCAATGCCTGCCTGGCCCCCATCTGCTCCTTG\nCACCATGTTGCAGTGACAACTGTGGAAGGAATAGGAAGCACCAAGACGAGGCTGCATCCT\nGTGCAGGAGAGAATTGCCAAAAGCCACGGCTCCCAGTGCGGGTTCTGCACCCCTGGCATC\nGTCATGAGTATGTACACACTGCTCCGGAATCAGCCCGAGCCCACCATGGAGGAGATTGAG\nAATGCCTTCCAAGGAAATCTGTGCCGCTGCACAGGCTACAGACCCATCCTCCAGGGCTTC\nCGGACCTTTGCCAGGGATGGTGGATGCTGTGGAGGAGATGGGAATAATCCAAATTGCTGC\nATGAACCAGAAGAAAGACCACTCAGTCAGCCTCTCGCCATCTTTATTCAAACCAGAGGAG\nTTCACGCCCCTGGATCCAACCCAGGAGCCCATTTTTCCCCCAGAGTTGCTGAGGCTGAAA\nGACACTCCTCGGAAGCAGCTGCGATTTGAAGGGGAGCGTGTGACGTGGATACAGGCCTCA\nACCCTCAAGGAGCTGCTGGACCTCAAGGCTCAGCACCCTGACGCCAAGCTGGTCGTGGGG\nAACACGGAGATTGGCATTGAGATGAAGTTCAAGAATATGCTGTTTCCTATGATTGTCTGC\nCCAGCCTGGATCCCTGAGCTGAATTCGGTAGAACATGGACCCGACGGTATCTCCTTTGGA\nGCTGCTTGCCCCCTGAGCATTGTGGAAAAAACCCTGGTGGATGCTGTTGCTAAGCTTCCT\nGCCCAAAAGACAGAGGTGTTCAGAGGGGTCCTGGAGCAGCTGCGCTGGTTTGCTGGGAAG\nCAAGTCAAGTCTGTGGCGTCCGTTGGAGGGAACATCATCACTGCCAGCCCCATCTCCGAC\nCTCAACCCCGTGTTCATGGCCAGTGGGGCCAAGCTGACACTTGTGTCCAGAGGCACCAGG\nAGAACTGTCCAGATGGACCACACCTTCTTCCCTGGCTACAGAAAGACCCTGCTGAGCCCG\nGAGGAGATACTGCTCTCCATAGAGATCCCCTACAGCAGGGAGGGGGAGTATTTCTCAGCA\nTTCAAGCAGGCCTCCCGGAGAGAAGATGACATTGCCAAGGTAACCAGTGGCATGAGAGTT\nTTATTCAAGCCAGGAACCACAGAGGTACAGGAGCTGGCCCTTTGCTATGGTGGAATGGCC\nAACAGAACCATCTCAGCCCTCAAGACCACTCAGAGGCAGCTTTCCAAGCTCTGGAAGGAG\nGAGCTGCTGCAGGACGTGTGTGCAGGACTGGCAGAGGAGCTGCATCTGCCTCCCGATGCC\nCCTGGTGGCATGGTGGACTTCCGGTGCACCCTCACCCTCAGCTTCTTCTTCAAGTTCTAC\nCTGACAGTCCTTCAGAAGCTGGGCCAAGAGAACCTGGAAGACAAGTGTGGTAAACTGGAC\nCCCACTTTCGCCAGTGCAACTTTACTGTTTCAGAAAGACCCCCCAGCCGATGTCCAGCTC\nTTCCAAGAGGTGCCCAAGGGTCAGTCTGAGGAGGACATGGTGGGCCGGCCCCTGCCCCAC\nCTGGCAGCGGACATGCAGGCCTCTGGTGAGGCCGTGTACTGTGACGACATTCCTCGCTAC\nGAGAATGAGCTGTCTCTCCGGCTGGTCACCAGCACCCGGGCCCACGCCAAGATCAAGTCC\nATAGATACATCAGAAGCTAAGAAGGTTCCAGGGTTTGTTTGTTTCATTTCCGCTGATGAT\nGTTCCTGGGAGTAACATAACTGGAATTTGTAATGATGAGACAGTCTTTGCGAAGGATAAG\nGTTACTTGTGTTGGGCATATCATTGGTGCTGTGGTTGCTGACACCCCGGAACACACACAG\nAGAGCTGCCCAAGGGGTGAAAATCACCTATGAAGAACTACCAGCCATTATCACAATTGAG\nGATGCTATAAAGAACAACTCCTTTTATGGACCTGAGCTGAAGATCGAGAAAGGGGACCTA\nAAGAAGGGGTTTTCCGAAGCAGATAATGTTGTGTCAGGGGAGATATACATCGGTGGCCAA\nGAGCACTTCTACCTGGAGACTCACTGCACCATTGCTGTTCCAAAAGGCGAGGCAGGGGAG\nATGGAGCTCTTTGTGTCTACACAGAACACCATGAAGACCCAGAGCTTTGTTGCAAAAATG\nTTGGGGGTTCCAGCAAACCGGATTGTGGTTCGAGTGAAGAGAATGGGAGGAGGCTTTGGA\nGGCAAGGAGACCCGGAGCACTGTGGTGTCCACGGCAGTGGCCCTGGCTGCATATAAGACC\nGGCCGCCCTGTGCGATGCATGCTGGACCGTGATGAGGACATGCTGATAACTGGTGGCAGA\nCATCCCTTCCTGGCCAGATACAAGGTTGGCTTCATGAAGACTGGGACAGTTGTGGCTCTT\nGAGGTGGACCACTTCAGCAATGTGGGGAACACCCAGGATCTCTCTCAGAGTATTATGGAA\nCGAGCTTTATTCCACATGGACAACTGCTATAAAATCCCCAACATCCGGGGCACTGGGCGG\nCTGTGCAAAACCAACCTTCCCTCCAACACGGCCTTCCGGGGCTTTGGGGGGCCCCAGGGG\nATGCTCATTGCCGAGTGCTGGATGAGTGAAGTTGCAGTGACCTGTGGGATGCCTGCAGAG\nGAGGTGCGGAGAAAAAACCTGTACAAAGAAGGGGACCTGACACACTTCAACCAGAAGCTT\nGAGGGTTTCACCTTGCCCAGATGCTGGGAAGAATGCCTAGCAAGCTCTCAGTATCATGCT\nCGGAAGAGTGAGGTTGACAAGTTCAACAAGGAGAATTGTTGGAAAAAGAGAGGATTGTGC\nATAATTCCCACCAAGTTTGGAATAAGCTTCACAGTTCCTTTTCTGAATCAGGCAGGAGCC\nCTACTTCATGTGTACACAGATGGCTCTGTGCTGCTGACCCACGGGGGGACTGAGATGGGC\nCAAGGCCTTCATACCAAAATGGTCCAGGTGGCCAGTAGAGCTCTGAAAATCCCCACCTCT\nAAGATTTATATCAGCGAGACAAGCACTAACACTGTGCCCAACACCTCTCCCACGGCTGCC\nTCTGTCAGCGCTGACCTCAATGGACAGGCCGTCTATGCGGCTTGTCAGACCATCTTGAAA\nAGGCTGGAACCCTACAAGAAGAAGAATCCCAGTGGCTCCTGGGAAGACTGGGTCACAGCT\nGCCTACATGGACACAGTGAGCTTGTCTGCCACTGGGTTTTATAGAACACCCAATCTGGGC\nTACAGCTTTGAGACTAACTCAGGGAACCCCTTCCACTACTTCAGCTATGGGGTGGCTTGC\nTCTGAAGTAGAAATCGACTGCCTAACAGGAGATCATAAGAACCTCCGCACAGATATTGTC\nATGGATGTTGGCTCCAGTCTAAACCCTGCCATTGATATTGGACAGGTGGAAGGGGCATTT\nGTCCAGGGCCTTGGCCTCTTCACCCTAGAGGAGCTACACTATTCCCCCGAGGGGAGCCTG\nCACACCCGTGGCCCTAGCACCTACAAGATCCCGGCATTTGGCAGCATCCCCATTGAGTTC\nAGGGTGTCCCTGCTCCGCGACTGCCCCAACAAGAAGGCCATCTATGCATCGAAGGCTGTT\nGGAGAGCCGCCCCTCTTCCTGGCTGCTTCTATCTTCTTTGCCATCAAAGATGCCATCCGT\nGCAGCTCGAGCTCAGCACACAGGTAATAACGTGAAGGAACTCTTCCGGCTAGACAGCCCT\nGCCACCCCGGAGAAGATCCGCAATGCCTGCGTGGACAAGTTCACCACCCTGTGTGTCACT\nGGTGTCCCAGAAAACTGCAAACCCTGGTCTGTGAGGGTCTAA"}, "pfams": {"pfam": [{"identifier": "PF00111", "name": "Fer2"}, {"identifier": "PF01315", "name": "Ald_Xan_dh_C"}, {"identifier": "PF02738", "name": "Ald_Xan_dh_C2"}, {"identifier": "PF01799", "name": "Fer2_2"}, {"identifier": "PF03450", "name": "CO_deh_flav_C"}, {"identifier": "PF00941", "name": "FAD_binding_5"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "iron ion binding"}, {"category": "function", "description": "transporter activity"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "electron transporter activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "metal ion binding"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "generation of precursor metabolites and energy"}, {"category": "process", "description": "electron transport"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}, {"@position": "5", "id": "BE0003533", "name": "Cytochrome P450 2E1", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Elkahwaji J, Robin MA, Berson A, Tinel M, Letteron P, Labbe G, Beaune P, Elias D, Rougier P, Escudier B, Duvillard P, Pessayre D: Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. Biochem Pharmacol. 1999 Apr 15;57(8):951-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10086330", "known-action": "unknown", "polypeptide": {"@id": "P05181", "@source": "Swiss-Prot", "name": "Cytochrome P450 2E1", "general-function": "Secondary metabolites biosynthesis, transport and catabolism", "specific-function": "Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms", "gene-name": "CYP2E1", "locus": "10q24.3-qter", "cellular-location": "Endoplasmic reticulum membrane", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.22", "molecular-weight": "56848.4", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "GNC:2631"}, {"resource": "GeneCards", "identifier": "CYP2E1"}, {"resource": "GenBank Gene Database", "identifier": "J02625"}, {"resource": "GenBank Protein Database", "identifier": "181360"}, {"resource": "UniProtKB", "identifier": "P05181"}, {"resource": "UniProt Accession", "identifier": "CP2E1_HUMAN"}]}, "synonyms": {"synonym": ["4-nitrophenol 2-hydroxylase", "CYPIIE1", "P450-J"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytochrome P450 2E1\nMSALGVTVALLVWAAFLLLVSMWRQVHSSWNLPPGPFPLPIIGNLFQLELKNIPKSFTRL\nAQRFGPVFTLYVGSQRMVVMHGYKAVKEALLDYKDEFSGRGDLPAFHAHRDRGIIFNNGP\nTWKDIRRFSLTTLRNYGMGKQGNESRIQREAHFLLEALRKTQGQPFDPTFLIGCAPCNVI\nADILFRKHFDYNDEKFLRLMYLFNENFHLLSTPWLQLYNNFPSFLHYLPGSHRKVIKNVA\nEVKEYVSERVKEHHQSLDPNCPRDLTDCLLVEMEKEKHSAERLYTMDGITVTVADLFFAG\nTETTSTTLRYGLLILMKYPEIEEKLHEEIDRVIGPSRIPAIKDRQEMPYMDAVVHEIQRF\nITLVPSNLPHEATRDTIFRGYLIPKGTVVVPTLDSVLYDNQEFPDPEKFKPEHFLNENGK\nFKYSDYFKPFSTGKRVCAGEGLARMELFLLLCAILQHFNLKPLVDPKDIDLSPIHIGFGC\nIPPRYKLCVIPRS"}, "gene-sequence": {"@format": "FASTA", "#text": ">1482 bp\nCCCAGCGCACCATGTCTGCCCTCGGAGTGACCGTGGCCCTGCTGGTGTGGGCGGCCTTCC\nTCCTGCTGGTGTCCATGTGGAGGCAGGTGCACAGCAGCTGGAATCTGCCCCCAGGTCCTT\nTCCCGCTTCCCATCATCGGGAACCTCTTCCAGTTGGAATTGAAGAATATTCCCAAGTCCT\nTCACCCGGTTGGCCCAGCGCTTCGGGCCGGTGTTCACGCTGTACGTGGGCTCGCAGCGCA\nTGGTGGTGATGCACGGCTACAAGGCGGTGAAGGAAGCGCTGCTGGACTACAAGGACGAGT\nTCTCGGGCAGAGGCGACCTCCCCGCGTTCCATGCGCACAGGGACAGGGGAATCATTTTTA\nATAATGGACCTACCTGGAAGGACATCCGGCGGTTTTCCCTGACCACCCTCCGGAACTATG\nGGATGGGGAAACAGGGCAATGAGAGCCGGATCCAGAGGGAGGCCCACTTCCTGCTGGAAG\nCACTCAGGAAGACCCAAGGCCAGCCTTTCGACCCCACCTTCCTCATCGGCTGCGCGCCCT\nGCAACGTCATAGCCGACATCCTCTTCCGCAAGCATTTTGACTACAATGATGAGAAGTTTC\nTAAGGCTGATGTATTTGTTTAATGAGAACTTCCACCTACTCAGCACTCCCTGGCTCCAGC\nTTTACAATAATTTTCCCAGCTTTCTACACTACTTGCCTGGAAGCCACAGAAAAGTCATAA\nAAAATGTGGCTGAAGTAAAAGAGTATGTGTCTGAAAGGGTGAAGGAGCACCATCAATCTC\nTGGACCCCAACTGTCCCCGGGACCTCACCGACTGCCTGCTCGTGGAAATGGAGAAGGAAA\nAGCACAGTGCAGAGCGCTTGTACACAATGGACGGTATCACCGTGACTGTGGCCGACCTGT\nTCTTTGCGGGGACAGAGACCACCAGCACAACTCTGAGATATGGGCTCCTGATTCTCATGA\nAATACCCTGAGATCGAAGAGAAGCTCCATGAAGAAATTGACAGGGTGATTGGGCCAAGCC\nGAATCCCTGCCATCAAGGATAGGCAAGAGATGCCCTACATGGATGCTGTGGTGCATGAGA\nTTCAGCGGTTCATCACCCTCGTGCCCTCCAACCTGCCCCATGAAGCAACCCGAGACACCA\nTTTTCAGAGGATACCTCATCCCCAAGGGCACAGTCGTAGTGCCAACTCTGGACTCTGTTT\nTGTATGACAACCAAGAATTTCCTGATCCAGAAAAGTTTAAGCCAGAACACTTCCTGAATG\nAAAATGGAAAGTTCAAGTACAGTGACTATTTCAAGCCATTTTCCACAGGAAAACGAGTGT\nGTGCTGGAGAAGGCCTGGCTCGCATGGAGTTGTTTCTTTTGTTGTGTGCCATTTTGCAGC\nATTTTAATTTGAAGCCTCTCGTTGACCCAAAGGATATCGACCTCAGCCCTATACATATTG\nGGTTTGGCTGTATCCCACCACGTTACAAACTCTGTGTCATTC"}, "pfams": {"pfam": {"identifier": "PF00067", "name": "p450"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "iron ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "tetrapyrrole binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "heme binding"}, {"category": "function", "description": "monooxygenase activity"}, {"category": "function", "description": "oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "generation of precursor metabolites and energy"}, {"category": "process", "description": "electron transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}]}, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2015-09-22", "drugbank-id": [{"@primary": "true", "#text": "DB00042"}, "BIOD00070", "BTD00070"], "name": "Botulinum Toxin Type B", "description": "Neurotoxin produced by fermentation of clostridium botulinum type B. The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex. The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation and chromatography steps.", "cas-number": "93384-44-2", "groups": {"group": "approved"}, "general-references": "# Montecucco C, Molgo J: Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005 Jun;5(3):274-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15907915\n# Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M: Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999 Oct 22;53(7):1431-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10534247\n# Shukla HD, Sharma SK: Clostridium botulinum: a bug with beauty and weapon. Crit Rev Microbiol. 2005;31(1):11-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15839401\n# Eisenach JH, Atkinson JL, Fealey RD: Hyperhidrosis: evolving therapies for a well-established phenomenon. Mayo Clin Proc. 2005 May;80(5):657-66. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15887434\n# Schurch B, Corcos J: Botulinum toxin injections for paediatric incontinence. Curr Opin Urol. 2005 Jul;15(4):264-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15928517", "synthesis-reference": null, "indication": "For the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.", "pharmacodynamics": "Botulinum Toxin Type B inhibits acetylcholine release at the neuromuscular junction via a three stage process: 1) Heavy Chain mediated neurospecific binding of the toxin, 2) internalization of the toxin by receptor-mediated endocytosis, and 3) ATP and pH dependent translocation of the Light Chain to the neuronal cytosol where it acts as a zinc-dependent endoprotease cleaving polypeptides essential for neurotransmitter release.", "mechanism-of-action": "Botulinum Toxin Type B binds to and cleaves the synaptic Vesicle Associated Membrane Protein (VAMP, also known as synaptobrevin) which is a component of the protein complex responsible for docking and fusion of the synaptic vesicle to the presynaptic membrane, a necessary step to neurotransmitter release.", "toxicity": "One unit of Botulinum Toxin Type B corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice.", "metabolism": null, "absorption": "Though pharmacokinetic or ADME studies were not performed, Botulinum Toxin Type B is not expected to be present in the peripheral blood at measurable levels following IM injection at the recommended doses.", "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Botulinum neurotoxin type B precursor"}, {"@language": "", "@coder": "", "#text": "BTX-B"}, {"@language": "", "@coder": "", "#text": "RimabotulinumtoxinB"}]}, "products": {"product": [{"name": "Myobloc", "ndc-id": "10454-710_fe96358c-e490-47bd-b992-3783022b7aff", "ndc-product-code": "10454-710", "dpd-id": null, "started-marketing-on": "2000-12-08", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "2500 [USP'U]/.5mL", "route": "intramuscular", "fda-application-number": "BLA103846", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Myobloc", "ndc-id": "10454-711_fe96358c-e490-47bd-b992-3783022b7aff", "ndc-product-code": "10454-711", "dpd-id": null, "started-marketing-on": "2000-12-08", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "5000 [USP'U]/mL", "route": "intramuscular", "fda-application-number": "BLA103846", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Myobloc", "ndc-id": "10454-712_fe96358c-e490-47bd-b992-3783022b7aff", "ndc-product-code": "10454-712", "dpd-id": null, "started-marketing-on": "2000-12-08", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "10000 [USP'U]/2mL", "route": "intramuscular", "fda-application-number": "BLA103846", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Myobloc", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02252295", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "5000 unit", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": {"name": "Neurobloc", "company": "Solstice Neurosciences"}}, "mixtures": {"mixture": [{"name": "Myobloc", "ingredients": "Botulinum Toxin Type B"}, {"name": "Myobloc", "ingredients": "Botulinum Toxin Type B"}, {"name": "Myobloc", "ingredients": "Botulinum Toxin Type B"}, {"name": "Myobloc", "ingredients": "Botulinum Toxin Type B"}]}, "packagers": {"packager": {"name": "Solstice Neurosciences", "url": "http://www.solsticeneuro.com"}}, "manufacturers": null, "prices": {"price": [{"description": "Myobloc 2500 unit/0.5 ml vial", "cost": {"@currency": "USD", "#text": "299.4"}, "unit": "vial"}, {"description": "Myobloc 10000 unit/2ml Solution 2ml Vial", "cost": {"@currency": "USD", "#text": "1245.5"}, "unit": "vial"}]}, "categories": {"category": {"category": "Antidystonic Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, solution", "route": "intramuscular", "strength": "10000 [USP'U]/2mL"}, {"form": "Injection, solution", "route": "intramuscular", "strength": "2500 [USP'U]/.5mL"}, {"form": "Injection, solution", "route": "intramuscular", "strength": "5000 [USP'U]/mL"}, {"form": "Solution", "route": "intramuscular", "strength": "5000 unit"}]}, "atc-codes": null, "ahfs-codes": null, "patents": null, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB08897", "name": "Aclidinium", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00479", "name": "Amikacin", "description": "Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00321", "name": "Amitriptyline", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00543", "name": "Amoxapine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00732", "name": "Atracurium besylate", "description": "Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00572", "name": "Atropine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00972", "name": "Azelastine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00245", "name": "Benzatropine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00083", "name": "Botulinum Toxin Type A", "description": "AbobotulinumtoxinA may enhance the adverse neuromuscular effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00835", "name": "Brompheniramine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00748", "name": "Carbinoxamine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00341", "name": "Cetirizine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01114", "name": "Chlorphenamine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00477", "name": "Chlorpromazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00565", "name": "Cisatracurium besylate", "description": "Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00283", "name": "Clemastine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00771", "name": "Clidinium", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01242", "name": "Clomipramine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00363", "name": "Clozapine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00318", "name": "Codeine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01176", "name": "Cyclizine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00924", "name": "Cyclobenzaprine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00979", "name": "Cyclopentolate", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00434", "name": "Cyproheptadine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00496", "name": "Darifenacin", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01151", "name": "Desipramine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00967", "name": "Desloratadine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00405", "name": "Dexbrompheniramine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00804", "name": "Dicyclomine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01501", "name": "Difenoxin", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00985", "name": "Dimenhydrinate", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01075", "name": "Diphenhydramine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01081", "name": "Diphenoxylate", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00280", "name": "Disopyramide", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01142", "name": "Doxepin", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00366", "name": "Doxylamine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00450", "name": "Droperidol", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01288", "name": "Fenoterol", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB06702", "name": "Fesoterodine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00950", "name": "Fexofenadine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01148", "name": "Flavoxate", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00875", "name": "Flupentixol", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00623", "name": "Fluphenazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00588", "name": "Fluticasone Propionate", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00798", "name": "Gentamicin", "description": "Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00986", "name": "Glycopyrrolate", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00502", "name": "Haloperidol", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00557", "name": "Hydroxyzine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00424", "name": "Hyoscyamine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00458", "name": "Imipramine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00332", "name": "Ipratropium bromide", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01247", "name": "Isocarboxazid", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01172", "name": "Kanamycin", "description": "Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01106", "name": "Levocabastine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB06282", "name": "Levocetirizine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00455", "name": "Loratadine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00408", "name": "Loxapine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00934", "name": "Maprotiline", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00737", "name": "Meclizine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB04843", "name": "Mepenzolate", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01403", "name": "Methotrimeprazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01171", "name": "Moclobemide", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00994", "name": "Neomycin", "description": "Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00540", "name": "Nortriptyline", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00334", "name": "Olanzapine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00768", "name": "Olopatadine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01173", "name": "Orphenadrine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01062", "name": "Oxybutynin", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01337", "name": "Pancuronium", "description": "Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00850", "name": "Perphenazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00780", "name": "Phenelzine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01100", "name": "Pimozide", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB06153", "name": "Pizotifen", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00433", "name": "Prochlorperazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00387", "name": "Procyclidine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00420", "name": "Promazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01069", "name": "Promethazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00782", "name": "Propantheline", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00344", "name": "Protriptyline", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01224", "name": "Quetiapine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00734", "name": "Risperidone", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00728", "name": "Rocuronium", "description": "Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00747", "name": "Scopolamine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01591", "name": "Solifenacin", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01082", "name": "Streptomycin", "description": "Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00202", "name": "Succinylcholine", "description": "Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00679", "name": "Thioridazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01623", "name": "Thiothixene", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01409", "name": "Tiotropium", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00684", "name": "Tobramycin", "description": "Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01036", "name": "Tolterodine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00752", "name": "Tranylcypromine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00831", "name": "Trifluoperazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00376", "name": "Trihexyphenidyl", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00662", "name": "Trimethobenzamide", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00726", "name": "Trimipramine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00427", "name": "Triprolidine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00209", "name": "Trospium", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB09076", "name": "Umeclidinium", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01339", "name": "Vecuronium", "description": "Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB01624", "name": "Zuclopenthixol", "description": "Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">Botulinum neurotoxin type B - Clostridium botulinum\nMPVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFN\nKSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLG\nDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNH\nFASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLY\nGIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIV\nDRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETN\nIAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQA\nYEEISKEHLAVYKIQMCKSVKAPGICIDVDNEDLFFIADKNSFSDDLSKNERIEYNTQSN\nYIENDFPINELILDTDLISKIELPSENTESLTDFNVDVPVYEKQPAIKKIFTDENTIFQY\nLYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVND\nFVIEANKSNTMDKIADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLI\nPVVGAFLLESYIDNKNKIIKTIDNALTKRNEKWSDMYGLIVAQWLSTVNTQFYTIKEGMY\nKALNYQAQALEEIIKYRYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINGCSV\nSYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVNKYLKTIMPFDL\nSIYTNDTILIEMFNKYNSEILNNIILNLRYKDNNLIDLSGYGAKVEVYDGVELNDKNQFK\nLTSSANSKIRVTQNQNIIFNSVFLDFSVSFWIRIPKYKNDGIQNYIHNEYTIINCMKNNS\nGWKISIRGNRIIWTLIDINGKTKSVFFEYNIREDISEYINRWFFVTITNNLNNAKIYING\nKLESNTDIKDIREVIANGEIIFKLDGDIDRTQFIWMKYFSIFNTELSQSNIEERYKIQSY\nSEYLKDFWGNPLMYNKEYYMFNAGNKNSYIKLKKDSPVGEILTRSKYNQNSKYINYRDLY\nIGEKFIIRRKSNSQSINDDIVRKEDYIYLDFFNLNQEWRVYTYKYFKKEEEKLFLAPISD\nSDEFYNTIQIKEYDEQPTYSCQLLFKKDEESTDEIGLIGIHRFYESGIVFEEYKDYFCIS\nKWYLKEVKRKPYNLKLGCNWQFIPKDEGWTE"}}, "experimental-properties": {"property": {"kind": "Molecular Weight", "value": "150804.0000", "source": null}}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "12854"}, {"resource": "KEGG Drug", "identifier": "D02735"}, {"resource": "GenBank", "identifier": "M81186"}, {"resource": "PharmGKB", "identifier": "PA164747061"}, {"resource": "UniProtKB", "identifier": "P10844"}, {"resource": "Wikipedia", "identifier": "Botulinum_toxin"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/botulinumtoxin.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/botulinum-toxin-type-b.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0002137", "name": "Vesicle-associated membrane protein 2", "organism": "Human", "actions": {"action": "binder"}, "references": "# Liu W, Montana V, Chapman ER, Mohideen U, Parpura V: Botulinum toxin type B micromechanosensor. Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13621-5. Epub 2003 Oct 22. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14573702\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P63027", "@source": "Swiss-Prot", "name": "Vesicle-associated membrane protein 2", "general-function": null, "specific-function": "Involved in the targeting and/or fusion of transport vesicles to their target membrane", "gene-name": "VAMP2", "locus": "17p13.1", "cellular-location": "Cytoplasmic vesicle", "transmembrane-regions": "95-114", "signal-regions": null, "theoretical-pi": "8.48", "molecular-weight": "12649.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:12643"}, {"resource": "GenAtlas", "identifier": "VAMP2"}, {"resource": "GeneCards", "identifier": "VAMP2"}, {"resource": "GenBank Gene Database", "identifier": "M36205"}, {"resource": "GenBank Protein Database", "identifier": "338632"}, {"resource": "UniProtKB", "identifier": "P63027"}, {"resource": "UniProt Accession", "identifier": "VAMP2_HUMAN"}]}, "synonyms": {"synonym": ["Synaptobrevin-2", "VAMP-2"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Vesicle-associated membrane protein 2\nMSATAATAPPAAPAGEGGPPAPPPNLTSNRRLQQTQAQVDEVVDIMRVNVDKVLERDQKL\nSELDDRADALQAGASQFETSAAKLKRKYWWKNLKMMIILGVICAIILIIIIVYFSS"}, "gene-sequence": {"@format": "FASTA", "#text": ">351 bp\nATGTCTGCTACCGCTGCCACGGCCCCCCCTGCTGCCCCGGCTGGGGAGGGTGGTCCCCCT\nGCACCCCCTCCAAACCTCACCAGTAACAGGAGACTGCAGCAGACCCAGGCCCAGGTGGAT\nGAGGTGGTGGACATCATGAGGGTGAACGTGGACAAGGTCCTGGAGCGAGACCAGAAGCTG\nTCGGAGCTGGACGACCGTGCAGATGCACTCCAGGCGGGGGCCTCCCAGTTTGAAACAAGC\nGCAGCCAAGCTCAAGCGCAAATACTGGTGGAAAAACCTCAAGATGATGATCATCTTGGGA\nGTGATTTGCGCCATCATCCTCATCATCATCATAGTTTACTTCAGCTCTTAA"}, "pfams": {"pfam": {"identifier": "PF00957", "name": "Synaptobrevin"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "vesicle-mediated transport"}]}}}, {"@position": "2", "id": "BE0002136", "name": "Vesicle-associated membrane protein 1", "organism": "Human", "actions": {"action": "binder"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P23763", "@source": "Swiss-Prot", "name": "Vesicle-associated membrane protein 1", "general-function": null, "specific-function": "Involved in the targeting and/or fusion of transport vesicles to their target membrane", "gene-name": "VAMP1", "locus": "12p", "cellular-location": "Cytoplasmic vesicle", "transmembrane-regions": "97-116", "signal-regions": null, "theoretical-pi": "6.59", "molecular-weight": "12902.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:12642"}, {"resource": "GenAtlas", "identifier": "VAMP1"}, {"resource": "GeneCards", "identifier": "VAMP1"}, {"resource": "GenBank Gene Database", "identifier": "M36200"}, {"resource": "GenBank Protein Database", "identifier": "338625"}, {"resource": "UniProtKB", "identifier": "P23763"}, {"resource": "UniProt Accession", "identifier": "VAMP1_HUMAN"}]}, "synonyms": {"synonym": ["Synaptobrevin-1", "VAMP-1"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Vesicle-associated membrane protein 1\nMSAPAQPPAEGTEGTAPGGGPPGPPPNMTSNRRLQQTQAQVEEVVDIIRVNVDKVLERDQ\nKLSELDDRADALQAGASQFESSAAKLKRKYWWKNCKMMIMLGAICAIIVVVIVIYFFT"}, "gene-sequence": {"@format": "FASTA", "#text": ">357 bp\nATGTCTGCTCCAGCTCAGCCACCTGCTGAAGGGACAGAAGGGACTGCCCCAGGTGGGGGT\nCCCCCTGGCCCTCCTCCTAACATGACCAGTAACAGACGACTACAGCAAACCCAGGCACAA\nGTGGAGGAGGTGGTGGACATCATACGTGTGAACGTGGACAAGGTCCTGGAGAGGGACCAG\nAAGCTGTCAGAGCTGGATGACCGAGCTGATGCCTTGCAGGCAGGAGCATCACAATTTGAG\nAGCAGTGCTGCCAAGCTAAAGAGGAAGTATTGGTGGAAAAACTGCAAGATGATGATCATG\nCTGGGAGCCATCTGTGCCATCATCGTGGTAGTTATTGTAATCTACTTTTTTACTTGA"}, "pfams": {"pfam": {"identifier": "PF00957", "name": "Synaptobrevin"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "vesicle-mediated transport"}]}}}, {"@position": "3", "id": "BE0002138", "name": "Synaptotagmin-2", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Poulain B, Lonchamp E, Jover E, Popoff MR, Molgo J: [Mechanisms of action of botulinum toxins and neurotoxins] Ann Dermatol Venereol. 2009 May;136 Suppl 4:S73-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19576489", "known-action": "yes", "polypeptide": {"@id": "Q8N9I0", "@source": "Swiss-Prot", "name": "Synaptotagmin-2", "general-function": null, "specific-function": "May have a regulatory role in the membrane interactions during trafficking of synaptic vesicles at the active zone of the synapse. It binds acidic phospholipids with a specificity that requires the presence of both an acidic head group and a diacyl backbone", "gene-name": "SYT2", "locus": "1q32.1", "cellular-location": "Cytoplasmic vesicle", "transmembrane-regions": "63-83", "signal-regions": null, "theoretical-pi": "8.12", "molecular-weight": "46873.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:11510"}, {"resource": "GenAtlas", "identifier": "SYT2"}, {"resource": "GeneCards", "identifier": "SYT2"}, {"resource": "GenBank Gene Database", "identifier": "AK090672"}, {"resource": "GenBank Protein Database", "identifier": "21748879"}, {"resource": "UniProtKB", "identifier": "Q8N9I0"}, {"resource": "UniProt Accession", "identifier": "SYT2_HUMAN"}]}, "synonyms": {"synonym": ["Synaptotagmin II", "SytII"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Synaptotagmin-2\nMRNIFKRNQEPIVAPATTTATMPIGPVDNSTESGGAGESQEDMFAKLKEKLFNEINKIPL\nPPWALIAIAVVAGLLLLTCCFCICKKCCCKKKKNKKEKGKGMKNAMNMKDMKGGQDDDDA\nETGLTEGEGEGEEEKEPENLGKLQFSLDYDFQANQLTVGVLQAAELPALDMGGTSDPYVK\nVFLLPDKKKKYETKVHRKTLNPAFNETFTFKVPYQELGGKTLVMAIYDFDRFSKHDIIGE\nVKVPMNTVDLGQPIEEWRDLQGGEKEEPEKLGDICTSLRYVPTAGKLTVCILEAKNLKKM\nDVGGLSDPYVKIHLMQNGKRLKKKKTTVKKKTLNPYFNESFSFEIPFEQIQKVQVVVTVL\nDYDKLGKNEAIGKIFVGSNATGTELRHWSDMLANPRRPIAQWHSLKPEEEVDALLGKNK"}, "gene-sequence": {"@format": "FASTA", "#text": ">1260 bp\nATGAGGAACATTTTCAAGAGGAACCAGGAGCCTATTGTGGCTCCTGCCACCACCACCGCC\nACGATGCCCATTGGACCCGTGGACAACTCCACTGAGAGTGGGGGTGCTGGGGAGAGTCAG\nGAGGACATGTTTGCCAAACTGAAGGAGAAGTTATTCAATGAGATAAACAAGATTCCCTTA\nCCACCCTGGGCACTGATCGCCATTGCTGTGGTTGCTGGGCTCCTGCTTCTCACCTGCTGC\nTTCTGCATCTGCAAGAAATGCTGCTGCAAGAAGAAGAAGAACAAGAAGGAGAAGGGCAAA\nGGCATGAAGAATGCCATGAACATGAAGGACATGAAAGGGGGTCAGGATGACGACGACGCA\nGAGACAGGCCTGACTGAGGGGGAAGGTGAAGGGGAGGAGGAGAAAGAGCCAGAGAACCTG\nGGCAAACTGCAGTTTTCCCTGGACTATGATTTTCAGGCTAATCAGCTTACTGTGGGCGTT\nCTGCAGGCTGCTGAACTGCCTGCCCTGGACATGGGAGGCACCTCAGACCCTTATGTCAAG\nGTCTTCCTCCTTCCTGACAAGAAGAAGAAATATGAGACCAAAGTCCATCGGAAGACACTG\nAACCCTGCCTTCAATGAAACCTTCACCTTCAAGGTGCCATACCAGGAGCTTGGGGGCAAA\nACTCTGGTGATGGCCATCTATGACTTTGACCGCTTCTCCAAACATGACATCATTGGAGAG\nGTAAAGGTGCCTATGAACACAGTGGACCTCGGCCAGCCCATTGAGGAGTGGAGAGACCTG\nCAAGGCGGGGAAAAGGAGGAGCCGGAGAAGCTGGGCGACATCTGCACCTCCCTGCGCTAT\nGTGCCCACGGCCGGGAAGCTCACTGTCTGCATCCTGGAGGCTAAGAACCTCAAGAAGATG\nGACGTGGGCGGCCTTTCAGACCCGTACGTGAAGATCCACCTGATGCAGAATGGCAAGAGG\nCTCAAGAAGAAGAAGACAACCGTGAAGAAGAAGACCCTGAACCCATACTTCAACGAGTCC\nTTCAGCTTTGAGATCCCCTTCGAGCAGATTCAGAAAGTCCAGGTAGTGGTCACCGTGCTG\nGACTATGACAAGCTGGGCAAGAACGAAGCCATAGGCAAGATCTTCGTGGGCAGCAATGCC\nACGGGCACAGAGCTGCGGCACTGGTCCGACATGCTGGCCAACCCCCGGAGGCCCATCGCC\nCAGTGGCACTCGCTCAAGCCTGAGGAGGAGGTGGATGCACTCCTGGGCAAGAACAAGTAG"}, "pfams": {"pfam": {"identifier": "PF00168", "name": "C2"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cytoplasmic vesicle"}, {"category": "component", "description": "cytoplasmic membrane-bound vesicle"}, {"category": "component", "description": "coated vesicle"}, {"category": "component", "description": "clathrin-coated vesicle"}, {"category": "component", "description": "synaptic vesicle"}, {"category": "component", "description": "cell"}, {"category": "component", "description": "organelle"}, {"category": "component", "description": "membrane"}, {"category": "component", "description": "vesicle"}, {"category": "function", "description": "transporter activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}, {"category": "process", "description": "transport"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-01-22", "drugbank-id": [{"@primary": "true", "#text": "DB00043"}, "BIOD00081", "BTD00081"], "name": "Omalizumab", "description": "A recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair is produced by a Chinese hamster ovary cell suspension culture in a nutrient medium containing the antibiotic gentamicin.", "cas-number": "242138-07-4", "groups": {"group": ["approved", "investigational"]}, "general-references": "# Karagiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, Thompson RG, Durham SR, Schwartz LB, Balkwill FR, Gould HJ: Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol. 2003 Apr;33(4):1030-40. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12672069", "synthesis-reference": null, "indication": "For treatment of asthma caused by allergies", "pharmacodynamics": "Xolair inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits the degree of release of mediators of the allergic response. Xolair is used to treat severe, persisten asthma.", "mechanism-of-action": "Xolair binds to IgE (a class of antibodies normally secreted in allergic responses), which prevents their binding to mast cells and basophils.", "toxicity": null, "metabolism": "Most likely removed by opsonization via the reticuloendothelial system.", "absorption": null, "half-life": "26 days", "protein-binding": null, "route-of-elimination": "Liver elimination of IgG includes degradation in the liver reticuloendothelial system (RES) and endothelial cells. Intact IgG is also excreted in bile.", "volume-of-distribution": "* 78 \u00b1 32 mL/kg", "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": {"@language": "", "@coder": "", "#text": "Ig gamma-1 chain C region"}}, "products": {"product": [{"name": "Xolair", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02260565", "started-marketing-on": "2005-02-03", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "150 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Xolair", "ndc-id": "50242-040_7fa51469-9f7e-4823-a160-93f04f2a55b4", "ndc-product-code": "50242-040", "dpd-id": null, "started-marketing-on": "2003-06-20", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "202.5 mg/1.4mL", "route": "subcutaneous", "fda-application-number": "BLA103976", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Xolair", "ingredients": "Omalizumab"}, {"name": "Xolair", "ingredients": "Omalizumab"}]}, "packagers": {"packager": [{"name": "Genentech Inc.", "url": "http://www.gene.com"}, {"name": "Novartis AG", "url": "http://www.novartis.com"}]}, "manufacturers": null, "prices": {"price": {"description": "Xolair 150 mg vial", "cost": {"@currency": "USD", "#text": "715.42"}, "unit": "vial"}}, "categories": {"category": [{"category": "Anti-Allergic Agents", "mesh-id": null}, {"category": "Anti-Asthmatic Agents", "mesh-id": null}, {"category": "Immunosuppressive Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, solution", "route": "subcutaneous", "strength": "202.5 mg/1.4mL"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "150 mg"}]}, "atc-codes": {"atc-code": {"@code": "R03DX05", "level": [{"@code": "R", "#text": "RESPIRATORY SYSTEM"}, {"@code": "R03", "#text": "DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES"}, {"@code": "R03D", "#text": "OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES"}, {"@code": "R03DX", "#text": "Other systemic drugs for obstructive airway diseases"}]}}, "ahfs-codes": {"ahfs-code": "48:92.00"}, "patents": {"patent": [{"number": "1340233", "country": "Canada", "approved": "1998-12-15", "expires": "2015-12-15"}, {"number": "2113813", "country": "Canada", "approved": "2005-04-12", "expires": "2012-08-14"}]}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB08879", "name": "Belimumab", "description": "Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab."}, {"drugbank-id": "DB00408", "name": "Loxapine", "description": "Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine."}]}, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">Omalizumab heavy chain\nEVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNY\nADSVKGRFTISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVS\nSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY\nSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSV\nFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY\nRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK\nNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG\nNVFSCSVMHEALHNHYTQKSLSLSPGK"}, {"@format": "FASTA", "#text": ">Omalizumab light chain\nDIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLES\nGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIKRTVAAPSVF\nIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS\nSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "61 \u00b0C (FAB fragment), 71 \u00b0C (whole mAb)", "source": "Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)"}, {"kind": "Hydrophobicity", "value": "-0.432", "source": null}, {"kind": "Isoelectric Point", "value": "7.03", "source": null}, {"kind": "Molecular Weight", "value": "145058.2000", "source": null}, {"kind": "Molecular Formula", "value": "C6450H9916N1714O2023S38", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "13365"}, {"resource": "National Drug Code Directory", "identifier": "50242-040-62"}, {"resource": "GenBank", "identifier": "J00228"}, {"resource": "PharmGKB", "identifier": "PA164752253"}, {"resource": "UniProtKB", "identifier": "P01857"}, {"resource": "Wikipedia", "identifier": "Omalizumab"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/xolair.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/omalizumab.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000015", "name": "High affinity immunoglobulin epsilon receptor subunit alpha", "organism": "Human", "actions": null, "references": "# Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S: Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol. 2004 Sep;114(3):527-30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15356552\n# Mirkina I, Schweighoffer T, Kricek F: Inhibition of human cord blood-derived mast cell responses by anti-Fc epsilon RI mAb 15/1 versus anti-IgE Omalizumab. Immunol Lett. 2007 Apr 15;109(2):120-8. Epub 2007 Mar 1. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17368811", "known-action": "yes", "polypeptide": {"@id": "P12319", "@source": "Swiss-Prot", "name": "High affinity immunoglobulin epsilon receptor subunit alpha", "general-function": null, "specific-function": "Binds to the Fc region of immunoglobulins epsilon. High affinity receptor. Responsible for initiating the allergic response. Binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators (such as histamine) responsible for the manifestations of allergy. The same receptor also induces the secretion of important lymphokines", "gene-name": "FCER1A", "locus": "1q23", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "206-224", "signal-regions": null, "theoretical-pi": "6.67", "molecular-weight": "29596.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3609"}, {"resource": "GenAtlas", "identifier": "FCER1A"}, {"resource": "GeneCards", "identifier": "FCER1A"}, {"resource": "GenBank Gene Database", "identifier": "X06948"}, {"resource": "GenBank Protein Database", "identifier": "31318"}, {"resource": "UniProtKB", "identifier": "P12319"}, {"resource": "UniProt Accession", "identifier": "FCERA_HUMAN"}]}, "synonyms": {"synonym": ["Fc-epsilon RI-alpha", "FcERI", "High affinity immunoglobulin epsilon receptor subunit alpha precursor", "IgE Fc receptor, alpha-subunit"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">High affinity immunoglobulin epsilon receptor alpha-subunit precursor\nMAPAMESPTLLCVALLFFAPDGVLAVPQKPKVSLNPPWNRIFKGENVTLTCNGNNFFEVS\nSTKWFHNGSLSEETNSSLNIVNAKFEDSGEYKCQHQQVNESEPVYLEVFSDWLLLQASAE\nVVMEGQPLFLRCHGWRNWDVYKVIYYKDGEALKYWYENHNISITNATVEDSGTYYCTGKV\nWQLDYESEPLNITVIKAPREKYWLQFFIPLLVVILFAVDTGLFISTQQQVTFLLKIKRTR\nKGFRLLNPHPKPNPKNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">774 bp\nATGGCTCCTGCCATGGAATCCCCTACTCTACTGTGTGTAGCCTTACTGTTCTTCGCTCCA\nGATGGCGTGTTAGCAGTCCCTCAGAAACCTAAGGTCTCCTTGAACCCTCCATGGAATAGA\nATATTTAAAGGAGAGAATGTGACTCTTACATGTAATGGGAACAATTTCTTTGAAGTCAGT\nTCCACCAAATGGTTCCACAATGGCAGCCTTTCAGAAGAGACAAATTCAAGTTTGAATATT\nGTGAATGCCAAATTTGAAGACAGTGGAGAATACAAATGTCAGCACCAACAAGTTAATGAG\nAGTGAACCTGTGTACCTGGAAGTCTTCAGTGACTGGCTGCTCCTTCAGGCCTCTGCTGAG\nGTGGTGATGGAGGGCCAGCCCCTCTTCCTCAGGTGCCATGGTTGGAGGAACTGGGATGTG\nTACAAGGTGATCTATTATAAGGATGGTGAAGCTCTCAAGTACTGGTATGAGAACCACAAC\nATCTCCATTACAAATGCCACAGTTGAAGACAGTGGAACCTACTACTGTACGGGCAAAGTG\nTGGCAGCTGGACTATGAGTCTGAGCCCCTCAACATTACTGTAATAAAAGCTCCGCGTGAG\nAAGTACTGGCTACAATTTTTTATCCCATTGTTGGTGGTGATTCTGTTTGCTGTGGACACA\nGGATTATTTATCTCAACTCAGCAGCAGGTCACATTTCTCTTGAAGATTAAGAGAACCAGG\nAAAGGCTTCAGACTTCTGAACCCACATCCTAAGCCAAACCCCAAAAACAACTGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"id": "BE0002139", "name": "High affinity immunoglobulin epsilon receptor subunit beta", "organism": "Human", "actions": {"action": "antagonist"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# DuBuske LM: IgE, allergic diseases, and omalizumab. Curr Pharm Des. 2006;12(30):3929-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17073688", "known-action": "yes", "polypeptide": {"@id": "Q01362", "@source": "Swiss-Prot", "name": "High affinity immunoglobulin epsilon receptor subunit beta", "general-function": null, "specific-function": "Binds to the Fc region of immunoglobulins epsilon. High affinity receptor. Responsible for initiating the allergic response. Binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators (such as histamine) responsible for the manifestations of allergy. The same receptor also induces the secretion of important lymphokines", "gene-name": "MS4A2", "locus": "11q13", "cellular-location": "Membrane", "transmembrane-regions": "60-79\n98-117\n131-150\n181-200", "signal-regions": null, "theoretical-pi": "4.78", "molecular-weight": "26534.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:7316"}, {"resource": "GenAtlas", "identifier": "MS4A2"}, {"resource": "GeneCards", "identifier": "MS4A2"}, {"resource": "GenBank Gene Database", "identifier": "D10583"}, {"resource": "GenBank Protein Database", "identifier": "219882"}, {"resource": "UniProtKB", "identifier": "Q01362"}, {"resource": "UniProt Accession", "identifier": "FCERB_HUMAN"}]}, "synonyms": {"synonym": ["Fc epsilon receptor I beta-chain", "FcERI", "IgE Fc receptor subunit beta", "Membrane-spanning 4-domains subfamily A member 2"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">High affinity immunoglobulin epsilon receptor subunit beta\nMDTESNRRANLALPQEPSSVPAFEVLEISPQEVSSGRLLKSASSPPLHTWLTVLKKEQEF\nLGVTQILTAMICLCFGTVVCSVLDISHIEGDIFSSFKAGYPFWGAIFFSISGMLSIISER\nRNATYLVRGSLGANTASSIAGGTGITILIINLKKSLAYIHIHSCQKFFETKCFMASFSTE\nIVVMMLFLTILGLGSAVSLTICGAGEELKGNKVPEDRVYEELNIYSATYSELEDPGEMSP\nPIDL"}, "gene-sequence": {"@format": "FASTA", "#text": ">735 bp\nATGGACACAGAAAGTAATAGGAGAGCAAATCTTGCTCTCCCACAGGAGCCTTCCAGTGTG\nCCTGCATTTGAAGTCTTGGAAATATCTCCCCAGGAAGTATCTTCAGGCAGACTATTGAAG\nTCGGCCTCATCCCCACCACTGCATACATGGCTGACAGTTTTGAAAAAAGAGCAGGAGTTC\nCTGGGGGTAACACAAATTCTGACTGCTATGATATGCCTTTGTTTTGGAACAGTTGTCTGC\nTCTGTACTTGATATTTCACACATTGAGGGAGACATTTTTTCATCATTTAAAGCAGGTTAT\nCCATTCTGGGGAGCCATATTTTTTTCTATTTCTGGAATGTTGTCAATTATATCTGAAAGG\nAGAAATGCAACATATCTGGTGAGAGGAAGCCTGGGAGCAAACACTGCCAGCAGCATAGCT\nGGGGGAACGGGAATTACCATCCTGATCATCAACCTGAAGAAGAGCTTGGCCTATATCCAC\nATCCACAGTTGCCAGAAATTTTTTGAGACCAAGTGCTTTATGGCTTCCTTTTCCACTGAA\nATTGTAGTGATGATGCTGTTTCTCACCATTCTGGGACTTGGTAGTGCTGTGTCACTCACA\nATCTGTGGAGCTGGGGAAGAACTCAAAGGAAACAAGGTTCCAGAGGATCGTGTTTATGAA\nGAATTAAACATATATTCAGCTACTTACAGTGAGTTGGAAGACCCAGGGGAAATGTCTCCT\nCCCATTGATTTATAA"}, "pfams": {"pfam": {"identifier": "PF04103", "name": "CD20"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-11-10", "drugbank-id": [{"@primary": "true", "#text": "DB00044"}, "BIOD00056", "BTD00056"], "name": "Lutropin alfa", "description": "Lutropin alfa is a recombinant human luteinizing hormone produced in yeast with 2 subunits, alpha = 92 residues, beta = 121 residues. It is a heterodimeric glycoprotein. Each monomeric unit is a glycoprotein molecule. In females, an acute rise of LH (\"LH surge\") triggers ovulation and the development of the corpus luteum. In males, it stimulates Leydig cell production of testosterone. Lutropin alfa was the first and only recombinant human form of luteinizing hormone (LH) developed for use in the stimulation of follicular development.", "cas-number": "152923-57-4", "groups": {"group": "approved"}, "general-references": "# Blanchard J: Gastrointestinal absorption. I. Mechanisms. Am J Pharm Sci Support Public Health. 1975 Sep-Oct;147(5):135-46. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/3972\n# Louvet JP, Harman SM, Ross GT: Effects of human chorionic gonadotropin, human interstitial cell stimulating hormone and human follicle-stimulating hormone on ovarian weights in estrogen-primed hypophysectomized immature female rats. Endocrinology. 1975 May;96(5):1179-86. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1122882\n# Nielsen MS, Barton SD, Hatasaka HH, Stanford JB: Comparison of several one-step home urinary luteinizing hormone detection test kits to OvuQuick. Fertil Steril. 2001 Aug;76(2):384-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11476792\n# Gibreel A, Bhattacharya S: Recombinant follitropin alfa/lutropin alfa in fertility treatment. Biologics. 2010 Feb 4;4:5-17. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20161981\n# Dhillon S, Keating GM: Lutropin alfa. Drugs. 2008;68(11):1529-40. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18627209\n#Lutropin Alfa. In DynaMed [database online]. EBSCO Information Services.\nhttp://search.ebscohost.com/login.aspx?direct=true&site=DynaMed&id=233015. Updated January 18, 2013. Accessed October 1, 2014.\n#Lexicomp. Lutropin alfa. N.p., 2014. Web. 11 Nov. 2014.\n#EMD Serono, A Division of EMD Inc., Canada. Lutropin Alfa. Mississauga, Ontario: N.p., 2012.", "synthesis-reference": null, "indication": "For treatment of infertility in women with hypothalamic or pituitary insufficiency (hypogonadotropic hypogonadism) and profound LH deficiency (LH <1.2 international units [IU]/L)", "pharmacodynamics": "Used to facilitate female conception, lutropin alfa performs the same actions as luteinizing hormone (LH), which is normally produced in the pituitary gland. Lutropin is usually given in combination with follitropin alfa. Together they stimulate the development of a follicle to prepare the reproductive tract for implementation and pregnancy. Lutropin alfa also stimulates the theca cells to produce androgens and the secretion of estradiol by the follicles. Lutropin alfa and follitropin alfa are discontinued once ultrasound assessment and serum estradiol concentrations show sufficient follicular maturation. hCG is then administered to complete follicular maturation and induce ovulation. In females, a LH surge about halfway through the menstrual cycle triggers the onset of ovulation. Lutropin alfa substitutes for endogenous LH and induces rupture of the preovulatory ovarian follicle and oocyte expulsion. Lutropin alfa induces and maintains the corpus luteum, which then secretes progesterone.", "mechanism-of-action": "Luteinizing hormone binds to a receptor shared with the human chorionic gonadotropin hormone (hCG) on the ovarian theca (and granulosa) cells and testicular Leydig cells. This LH/CG transmembrane receptor is a member of the super-family of G protein-coupled receptors. Adenylate cyclase then activates many other pathways leading to steroid hormone production and other follicle maturation processes.", "toxicity": "Lutropin alfa is not indicated for people under 16 and over 60, pregnant and lactating women, patients with uncontrolled thyroid and adrenal failure, patients with active, untreated tumours of the hypothalamus and pituitary gland, and in any patient with a condition that makes a normal pregnancy possible such as primary ovarian failure or fibroid tumors of the uterus.", "metabolism": "<5% of dose excreted renally as unchanged drug.", "absorption": "Mean absolute bioavailability is 56%, following sub-Q administration, maximum serum concentrations reached after 4\u201316 hours. Time to peak, serum: 9 hours", "half-life": "Biphasic; terminal half-life is approximately 18 hours.", "protein-binding": null, "route-of-elimination": "Total body clearance is approximately 2 to 3 L/h with less than 5 percent of the dose being excreted unchanged renally.", "volume-of-distribution": "The steady state volume of distribution is around 10-14 L.", "clearance": "* 2 \u2013 3 L/h [healthy female following subcutaneous administration]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "ICSH"}, {"@language": "", "@coder": "", "#text": "Insterstiial cell-stimulating hormone"}, {"@language": "", "@coder": "", "#text": "LH"}, {"@language": "", "@coder": "", "#text": "LH-B"}, {"@language": "", "@coder": "", "#text": "LSH- beta"}, {"@language": "", "@coder": "", "#text": "LSH-B"}, {"@language": "", "@coder": "", "#text": "Luteinizing hormone"}, {"@language": "", "@coder": "", "#text": "Luteinizing hormone beta subunit"}, {"@language": "", "@coder": "", "#text": "Lutrophin"}, {"@language": "", "@coder": "", "#text": "Lutropin alpha"}, {"@language": "", "@coder": "", "#text": "Lutropin beta chain precursor"}]}, "products": {"product": [{"name": "Humegon Inj 75 I.U.", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01958992", "started-marketing-on": "1993-12-31", "ended-marketing-on": "2006-08-17", "dosage-form": "liquid; powder for solution", "strength": ".9 %", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Luveris", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02269066", "started-marketing-on": "2005-06-28", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "75 unit", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Pergonal 75 I.U.", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00254916", "started-marketing-on": "1979-12-31", "ended-marketing-on": "2007-05-07", "dosage-form": "powder for solution", "strength": "75 unit", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Pergoveris", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02445301", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "kit; powder for solution", "strength": "150 unit", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Luveris", "ingredients": "Lutropin alfa"}, {"name": "Pergoveris", "ingredients": "Follitropin Alpha + Lutropin alfa"}, {"name": "Humegon Inj 75 I.U.", "ingredients": "Sodium Chloride + Lutropin alfa + Urofollitropin"}, {"name": "Pergonal 75 I.U.", "ingredients": "Lutropin alfa + Urofollitropin"}]}, "packagers": {"packager": [{"name": "EMD Canada Inc.", "url": "http://www.emdcanada.com"}, {"name": "Merck Serono SPA", "url": "http://www.merckserono.net"}]}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Emd serono inc"}}, "prices": {"price": {"description": "Luveris 75 unit vial", "cost": {"@currency": "USD", "#text": "38.88"}, "unit": "vial"}}, "categories": {"category": {"category": "Fertility Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Liquid; powder for solution", "route": "intramuscular", "strength": ".9 %"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "75 unit"}, {"form": "Powder for solution", "route": "intramuscular", "strength": "75 unit"}, {"form": "Kit; powder for solution", "route": "subcutaneous", "strength": "150 unit"}]}, "atc-codes": {"atc-code": {"@code": "G03GA07", "level": [{"@code": "G", "#text": "GENITO URINARY SYSTEM AND SEX HORMONES"}, {"@code": "G03", "#text": "SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM"}, {"@code": "G03G", "#text": "GONADOTROPINS AND OTHER OVULATION STIMULANTS"}, {"@code": "G03GA", "#text": "Gonadotropins"}]}}, "ahfs-codes": {"ahfs-code": "68:18.00"}, "patents": {"patent": {"number": "5767251", "country": "United States", "approved": "1995-06-16", "expires": "2015-06-16"}}, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">Alpha Chain\nAPDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC\nVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS"}, {"@format": "FASTA", "#text": ">Beta Chain (LH)\nSREPLRPWCHPINAILAVEKEGCPVCITVNTTICAGYCPTMMRVLQAVLPPLPQVVCTYR\nDVRFESIRLPGCPRGVDPVVSFPVALSCRCGPCRRSTSDCGGPKDHPLTCDHPQLSGLLF\nL"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "55 \u00b0C", "source": "Forastieri, H., Ingham, K.C. J. Biol. Chem. 257:7976-7981 (1982)"}, {"kind": "Hydrophobicity", "value": "-0.063", "source": null}, {"kind": "Isoelectric Point", "value": "8.44", "source": null}, {"kind": "Molecular Weight", "value": "30,000", "source": null}, {"kind": "Molecular Formula", "value": "C1014H1609N287O294S27", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "15875"}, {"resource": "Drugs Product Database (DPD)", "identifier": "7347"}, {"resource": "National Drug Code Directory", "identifier": "44087-1375-1"}, {"resource": "GenBank", "identifier": "X00264"}, {"resource": "PharmGKB", "identifier": "PA164750539"}, {"resource": "UniProtKB", "identifier": "P01229"}, {"resource": "Wikipedia", "identifier": "Lutropin_alfa"}]}, "external-links": {"external-link": {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/lutropin-alfa.html"}}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0000134", "name": "Lutropin-choriogonadotropic hormone receptor", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Gibreel A, Bhattacharya S: Recombinant follitropin alfa/lutropin alfa in fertility treatment. Biologics. 2010 Feb 4;4:5-17. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20161981\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P22888", "@source": "Swiss-Prot", "name": "Lutropin-choriogonadotropic hormone receptor", "general-function": "Involved in rhodopsin-like receptor activity", "specific-function": "Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase", "gene-name": "LHCGR", "locus": "2p21", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "364-385\n396-416\n440-462\n483-505\n526-549\n571-594\n606-627", "signal-regions": null, "theoretical-pi": "8.58", "molecular-weight": "78617.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6585"}, {"resource": "GenAtlas", "identifier": "LHCGR"}, {"resource": "GeneCards", "identifier": "LHCGR"}, {"resource": "GenBank Gene Database", "identifier": "M73746"}, {"resource": "GenBank Protein Database", "identifier": "903746"}, {"resource": "IUPHAR", "identifier": "254"}, {"resource": "Guide to Pharmacology", "identifier": "30"}, {"resource": "UniProtKB", "identifier": "P22888"}, {"resource": "UniProt Accession", "identifier": "LSHR_HUMAN"}]}, "synonyms": {"synonym": ["LH/CG-R", "LHR", "LSH- R", "Luteinizing hormone receptor", "Lutropin-choriogonadotropic hormone receptor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Lutropin-choriogonadotropic hormone receptor precursor\nMKQRFSALQLLKLLLLLQPPLPRALREALCPEPCNCVPDGALRCPGPTAGLTRLSLAYLP\nVKVIPSQAFRGLNEVIKIEISQIDSLERIEANAFDNLLNLSEILIQNTKNLRYIEPGAFI\nNLPRLKYLSICNTGIRKFPDVTKVFSSESNFILEICDNLHITTIPGNAFQGMNNESVTLK\nLYGNGFEEVQSHAFNGTTLTSLELKENVHLEKMHNGAFRGATGPKTLDISSTKLQALPSY\nGLESIQRLIATSSYSLKKLPSRETFVNLLEATLTYPSHCCAFRNLPTKEQNFSHSISENF\nSKQCESTVRKVSNKTLYSSMLAESELSGWDYEYGFCLPKTPRCAPEPDAFNPCEDIMGYD\nFLRVLIWLINILAIMGNMTVLFVLLTSRYKLTVPRFLMCNLSFADFCMGLYLLLIASVDS\nQTKGQYYNHAIDWQTGSGCSTAGFFTVFASELSVYTLTVITLERWHTITYAIHLDQKLRL\nRHAILIMLGGWLFSSLIAMLPLVGVSNYMKVSICFPMDVETTLSQVYILTILILNVVAFF\nIICACYIKIYFAVRNPELMATNKDTKIAKKMAILIFTDFTCMAPISFFAISAAFKVPLIT\nVTNSKVLLVLFYPINSCANPFLYAIFTKTFQRDFFLLLSKFGCCKRRAELYRRKDFSAYT\nSNCKNGFTGSNKPSQSTLKLSTLHCQGTALLDKTRYTEC"}, "gene-sequence": {"@format": "FASTA", "#text": ">2058 bp\nATGAAGCAGCGGTTCTCGCCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGGCGCCG\nCTGCCACGAGCGCTGCGCAGGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGCGCC\nCTGCGTGCCCCGGCCCCACGGCCGTCCACTCGACTATCACTTGCCTACCTCCCTGTCAAA\nGTGATCCCATCTCAAAGTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATCTCTCAG\nATTGATTCCCTGGAAAGGATAGAAGCTAATGCCTTTGACAACCTCCTCAATTTGTCTGAA\nATACTGATCCAGAACACCAAAAATCTGAGATACATTGAGCCCGGAGCATTTATAAATCTT\nCCCCGATTAAAATACTTGAGCATCTGTAACACAGGCATCAGAAAGTTTCCAGATGTTACG\nAAGGTCTTCTCCTCTGAATCAAATTTCATTCTGGAAATTTGTGATAACTTACACATAACC\nACCATACCAGGAAATGCTTTTCAAGGGATGAATAATGAATCTGTAACACTCAAACTATAT\nGGAAATGGATTTGAAGAAGTACAAAGTCATGCATTCAATGGGACGACACTGACTTCACTG\nGAGCTAAAGGAAAACGTACATCTGGAGAAGATGCACAATGGAGCCTTCCGTGGGGCCACA\nGGGCCGAAAACCTTGGATATTTCTTCCACCAAATTGCAGGCCCTGCCGAGCTATGGCCTA\nGAGTCCATTCAGAGGCTAATTGCCACGTCATCCTATTCTCTAAAAAAATTGCCATCAAAA\nCAAACATTTGTCAATCTCCTGAGGGCCACGCTTCATTACCCCAGCCACTGCTGTGCATTT\nAGAAACTTGCCAACGAAAGAGCTAAACTTCTCACATTCCATTTCTGAAAACTTTTCCAAA\nCAATGTGAAAGCACAGTAAGGAAAAGTGAACTGAGTGGCTGGGACTATGAATATGGTTTC\nTGCTTACCCAAGACACCCCGATGTGCTCCTGAACCAGATGCTTTTAATCCCTGTGAAGAC\nATTATGGGCTATGACTTCCTTAGGGTCCTGATTTGGCTGATTAATATTCTAGCCATCATG\nGGAAACATGACTGTTCTTTTTGTTCTCCTGACAAGTCGTTACAAACTTACAGTGCCTCGT\nTTTCTCATGTGCAATCTCTCCTTTGCAGACTTTTGCATGGGGCTCTATCTGCTGCTCATA\nGCCTCAGTTGATTCCCAAACCAAGGGCCAGTACTATAACCATGCCATAGACTGGCAGACA\nGGGAGTGGGTGCAGCACTGCTGGCTTTTTCACTGTATTAGCAAGTGAACTTTCTGTCTAC\nACCCTCACCGTCATCACTCTAGAAAGATGGCACACCATCACCTATGCTATTCACCTGGAC\nCAAAAGCTGCGATTAAGACATGCCATTCTGATTATGCTTGGAGGCTGGCTCTTTTCTTCT\nCTAATTGCTATGTTGCCCCTTGTCGGGGTCAGCAATTACATGAAGGTCAGTATTTGCTTC\nCCCATGGATGTGGAAACCACTCTCTCACAAGTCTATATATTAACCATCCTGATTCTCAAT\nGTGGTGGCCTTCTTAATAATTTGTGCTTGCTACATTAAAATTTATTTTGCAGTTCGAAAC\nCCAGAATTAATGGCTACCAATAAAGATACAAAGATTGCTAAGAAAATGGCAATCCTCATC\nTTCACCGATTTTACCTGCATGGCACCTATCTCTTTTTTTGCCATCTCAGCTGCCTTCAAA\nGTACCTCTTATCACAGTAACCAACTCTAAAGTTTTACTGGTTCTTTTTTATCCCATCAAT\nTCTTGTGCCAATCCATTTCTGTATGCAATATTCACTAAGACATTCCAAAGAGATTTCTTT\nCTTTTGCTGAGCAAATTTGGCTGCTGTAAACGTCGGGCTGATCCTCTTTATAGAAGGAAA\nGATTTTTCAGCTTACACCTCCAACTGCAAAAATGGCTTCACTGGATCAAATAAGCCTTCT\nCAATCCACCTTGAAGTTGTCCACATTGCACTGTCAAGGTACAGCTCTCCTAGACAAGACT\nCGCTACACAGAGTGTTAA"}, "pfams": {"pfam": {"identifier": "PF00001", "name": "7tm_1"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "function", "description": "lutropin-choriogonadotropic hormone receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "protein-hormone receptor activity"}, {"category": "function", "description": "receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}]}}}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-01-27", "drugbank-id": [{"@primary": "true", "#text": "DB00045"}, "BIOD00054", "BTD00054"], "name": "OspA lipoprotein", "description": "Vaccine against Lyme disease that contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli. Lipoprotein OspA is a single polypeptide chain of 257 amino acids with lipids covalently bonded to the N terminus. It is conjugated with alum (aluminum hydroxide) as an adjuvant.", "cas-number": null, "groups": {"group": ["approved", "withdrawn"]}, "general-references": null, "synthesis-reference": null, "indication": "For prophylactic treatment of Lyme Disease", "pharmacodynamics": "OspA lipoprotein is a single polypeptide chain of 270 amino acids. It is a vaccination used to prevent Lyme Disease.", "mechanism-of-action": "OspA lipoprotein, an outer surface protein of the bacteria Borrelia burgdorferi sensu stricto ZS7, is used to stimulate the production of specific antibodies against B. burgdorferi. It is used as a vaccination against Lyme Disease, a disease carried by ticks.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": "1.2 hours (mammalian reticulocytes, in vitro).", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": {"@language": "", "@coder": "", "#text": "Outer surface protein A precursor"}}, "products": null, "international-brands": {"international-brand": {"name": "LYMErix", "company": "SmithKline Beecham"}}, "mixtures": null, "packagers": null, "manufacturers": null, "prices": null, "categories": {"category": {"category": "Vaccines", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": null, "atc-codes": null, "ahfs-codes": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": {"@format": "FASTA", "#text": "> OspA lipoprotein\nMKKYLLGIGLILALIACKQNVSSLDEKNSVSVDVPGGMKVLVSKEKNKDGKYDLMATVDN\nVDLKGTSDKNNGSGILEGVKADKSKVKLTVADDLSKTTLEVLKEDGTVVSRKVTSKDKST\nTEAKFNEKGELSEKTMTRANGTTLEYSQMTNEDNAAKAVETLKNGIKFEGNLASGKTAVE\nIKEGTVTLKREIDKNGKVTVSLNDTASGSKKTASWQESTSTLTISANSKKTKDLVFLTNG\nTITVQNYDSAGTKLEGSAAEIKKLDELKNALR"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.652", "source": null}, {"kind": "Isoelectric Point", "value": "6.72", "source": null}, {"kind": "Molecular Weight", "value": "27743.1000", "source": null}, {"kind": "Molecular Formula", "value": "C1198H2012N322O422S2", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "GenBank", "identifier": "X16467"}, {"resource": "PharmGKB", "identifier": "PA164743058"}, {"resource": "UniProtKB", "identifier": "P14013"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"@position": "1", "id": "BE0001164", "name": "Toll-like receptor 2", "organism": "Human", "actions": {"action": "other/unknown"}, "references": "# Welty DM, Snyder DS: Internalization of OspA in rsCD14 complex and aggregated forms. Mol Microbiol. 2003 Nov;50(3):835-43. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14617145", "known-action": "yes", "polypeptide": {"@id": "O60603", "@source": "Swiss-Prot", "name": "Toll-like receptor 2", "general-function": "Involved in transmembrane receptor activity", "specific-function": "Cooperates with LY96 to mediate the innate immune response to bacterial lipoproteins and other microbial cell wall components. Acts via MyD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. May also promote apoptosis in response to lipoproteins. Recognizes mycoplasmal macrophage-activating lipopeptide-2kD (MALP-2), soluble tuberculosis factor (STF), phenol-soluble modulin (PSM) and B.burgdorferi outer surface protein A lipoprotein (OspA-L) cooperatively with TLR6", "gene-name": "TLR2", "locus": "4q32", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "589-609", "signal-regions": null, "theoretical-pi": "6.59", "molecular-weight": "89839.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:11848"}, {"resource": "GenAtlas", "identifier": "TLR2"}, {"resource": "GeneCards", "identifier": "TLR2"}, {"resource": "GenBank Gene Database", "identifier": "AF051152"}, {"resource": "GenBank Protein Database", "identifier": "3132528"}, {"resource": "UniProtKB", "identifier": "O60603"}, {"resource": "UniProt Accession", "identifier": "TLR2_HUMAN"}]}, "synonyms": {"synonym": ["CD282 antigen", "Toll-like receptor 2 precursor", "Toll/interleukin 1 receptor-like protein 4"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Toll-like receptor 2 precursor\nMPHTLWMVWVLGVIISLSKEESSNQASLSCDRNGICKGSSGSLNSIPSGLTEAVKSLDLS\nNNRITYISNSDLQRCVNLQALVLTSNGINTIEEDSFSSLGSLEHLDLSYNYLSNLSSSWF\nKPLSSLTFLNLLGNPYKTLGETSLFSHLTKLQILRVGNMDTFTKIQRKDFAGLTFLEELE\nIDASDLQSYEPKSLKSIQNVSHLILHMKQHILLLEIFVDVTSSVECLELRDTDLDTFHFS\nELSTGETNSLIKKFTFRNVKITDESLFQVMKLLNQISGLLELEFDDCTLNGVGNFRASDN\nDRVIDPGKVETLTIRRLHIPRFYLFYDLSTLYSLTERVKRITVENSKVFLVPCLLSQHLK\nSLEYLDLSENLMVEEYLKNSACEDAWPSLQTLILRQNHLASLEKTGETLLTLKNLTNIDI\nSKNSFHSMPETCQWPEKMKYLNLSSTRIHSVTGCIPKTLEILDVSNNNLNLFSLNLPQLK\nELYISRNKLMTLPDASLLPMLLVLKISRNAITTFSKEQLDSFHTLKTLEAGGNNFICSCE\nFLSFTQEQQALAKVLIDWPANYLCDSPSHVRGQQVQDVRLSVSECHRTALVSGMCCALFL\nLILLTGVLCHRFHGLWYMKMMWAWLQAKRKPRKAPSRNICYDAFVSYSERDAYWVENLMV\nQELENFNPPFKLCLHKRDFIPGKWIIDNIIDSIEKSHKTVFVLSENFVKSEWCKYELDFS\nHFRLFDENNDAAILILLEPIEKKAIPQRFCKLRKIMNTKTYLEWPMDEAQREGFWVNLRA\nAIKS"}, "gene-sequence": {"@format": "FASTA", "#text": ">2355 bp\nATGCCACATACTTTGTGGATGGTGTGGGTCCTGGGGGTCATCATCAGCCTCTCCAAGGAA\nGAATCCTCCAATCAGGCTTCTCTGTCTTGTGACCGCAATGGTATCTGCAAGGGCAGCTCA\nGGATCTTTAAACTCCATTCCCTCAGGGCTCACAGAAGCTGTAAAAAGCCTTGACCTGTCC\nAACAACAGGATCACCTACATTAGCAACAGTGACCTACAGAGGTGTGTGAACCTCCAGGCT\nCTGGTGCTGACATCCAATGGAATTAACACAATAGAGGAAGATTCTTTTTCTTCCCTGGGC\nAGTCTTGAACATTTAGACTTATCCTATAATTACTTATCTAATTTATCGTCTTCCTGGTTC\nAAGCCCCTTTCTTCTTTAACATTCTTAAACTTACTGGGAAATCCTTACAAAACCCTAGGG\nGAAACATCTCTTTTTTCTCATCTCACAAAATTGCAAATCCTGAGAGTGGGAAATATGGAC\nACCTTCACTAAGATTCAAAGAAAAGATTTTGCTGGACTTACCTTCCTTGAGGAACTTGAG\nATTGATGCTTCAGATCTACAGAGCTATGAGCCAAAAAGTTTGAAGTCAATTCAGAATGTA\nAGTCATCTGATCCTTCATATGAAGCAGCATATTTTACTGCTGGAGATTTTTGTAGATGTT\nACAAGTTCCGTGGAATGTTTGGAACTGCGAGATACTGATTTGGACACTTTCCATTTTTCA\nGAACTATCCACTGGTGAAACAAATTCATTGATTAAAAAGTTTACATTTAGAAATGTGAAA\nATCACCGATGAAAGTTTGTTTCAGGTTATGAAACTTTTGAATCAGATTTCTGGATTGTTA\nGAATTAGAGTTTGATGACTGTACCCTTAATGGAGTTGGTAATTTTAGAGCATCTGATAAT\nGACAGAGTTATAGATCCAGGTAAAGTGGAAACGTTAACAATCCGGAGGCTGCATATTCCA\nAGGTTTTACTTATTTTATGATCTGAGCACTTTATATTCACTTACAGAAAGAGTTAAAAGA\nATCACAGTAGAAAACAGTAAAGTTTTTCTGGTTCCTTGTTTACTTTCACAACATTTAAAA\nTCATTAGAATACTTGGATCTCAGTGAAAATTTGATGGTTGAAGAATACTTGAAAAATTCA\nGCCTGTGAGGATGCCTGGCCCTCTCTACAAACTTTAATTTTAAGGCAAAATCATTTGGCA\nTCATTGGAAAAAACCGGAGAGACTTTGCTCACTCTGAAAAACTTGACTAACATTGATATC\nAGTAAGAATAGTTTTCATTCTATGCCTGAAACTTGTCAGTGGCCAGAAAAGATGAAATAT\nTTGAACTTATCCAGCACACGAATACACAGTGTAACAGGCTGCATTCCCAAGACACTGGAA\nATTTTAGATGTTAGCAACAACAATCTCAATTTATTTTCTTTGAATTTGCCGCAACTCAAA\nGAACTTTATATTTCCAGAAATAAGTTGATGACTCTACCAGATGCCTCCCTCTTACCCATG\nTTACTAGTATTGAAAATCAGTAGGAATGCAATAACTACGTTTTCTAAGGAGCAACTTGAC\nTCATTTCACACACTGAAGACTTTGGAAGCTGGTGGCAATAACTTCATTTGCTCCTGTGAA\nTTCCTCTCCTTCACTCAGGAGCAGCAAGCACTGGCCAAAGTCTTGATTGATTGGCCAGCA\nAATTACCTGTGTGACTCTCCATCCCATGTGCGTGGCCAGCAGGTTCAGGATGTCCGCCTC\nTCGGTGTCGGAATGTCACAGGACAGCACTGGTGTCTGGCATGTGCTGTGCTCTGTTCCTG\nCTGATCCTGCTCACGGGGGTCCTGTGCCACCGTTTCCATGGCCTGTGGTATATGAAAATG\nATGTGGGCCTGGCTCCAGGCCAAAAGGAAGCCCAGGAAAGCTCCCAGCAGGAACATCTGC\nTATGATGCATTTGTTTCTTACAGTGAGCGGGATGCCTACTGGGTGGAGAACCTTATGGTC\nCAGGAGCTGGAGAACTTCAATCCCCCCTTCAAGTTGTGTCTTCATAAGCGGGACTTCATT\nCCTGGCAAGTGGATCATTGACAATATCATTGACTCCATTGAAAAGAGCCACAAAACTGTC\nTTTGTGCTTTCTGAAAACTTTGTGAAGAGTGAGTGGTGCAAGTATGAACTGGACTTCTCC\nCATTTCCGTCTTTTTGATGAGAACAATGATGCTGCCATTCTCATTCTTCTGGAGCCCATT\nGAGAAAAAAGCCATTCCCCAGCGCTTCTGCAAGCTGCGGAAGATAATGAACACCAAGACC\nTACCTGGAGTGGCCCATGGACGAGGCTCAGCGGGAAGGATTTTGGGTAAATCTGAGAGCT\nGCGATAAAGTCCTAG"}, "pfams": {"pfam": [{"identifier": "PF00560", "name": "LRR_1"}, {"identifier": "PF01463", "name": "LRRCT"}, {"identifier": "PF01582", "name": "TIR"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}]}}}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-06-24", "drugbank-id": [{"@primary": "true", "#text": "DB00046"}, "BIOD00065", "BTD00065", "DB01310"], "name": "Insulin Lispro", "description": "Insulin lispro is a recombinant human insulin analogue produced in a specialized laboratory strain of Escherischia coli. Plasmid DNA transfected into the bacteria encodes for an analogue of human insulin that has a lysine at residuce B28 and proline at B29; these residues are reversed in endogenous human insulin. Reversal of these amino acid residues produces a rapid-acting insulin analogue. FDA approved on 1996.", "cas-number": "133107-64-9", "groups": {"group": "approved"}, "general-references": "# Miles HL, Acerini CL: Insulin analog preparations and their use in children and adolescents with type 1 diabetes mellitus. Paediatr Drugs. 2008;10(3):163-76. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18454569\n# Zib I, Raskin P: Novel insulin analogues and its mitogenic potential. Diabetes Obes Metab. 2006 Nov;8(6):611-20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17026485", "synthesis-reference": null, "indication": "For the treatment of Type 1 or 2 diabetes mellitus. To be used in conjunction with an intermediate or long-acting insulin except when used in a continuous insulin infusion pump.", "pharmacodynamics": "Insulin is a natural hormone produced by beta cells of the pancreas. In non-diabetic individuals, a basal level of insulin is supplemented with insulin spikes following meals. Increased insulin secretion following meals is responsible for the metabolic changes that occur as the body transitions from a postabsorptive to absorptive state. Insulin promotes cellular uptake of glucose, particularly in muscle and adipose tissues, promotes energy storage via glycogenesis, opposes catabolism of energy stores, increases DNA replication and protein synthesis by stimulating amino acid uptake by liver, muscle and adipose tissue, and modifies the activity of numerous enzymes involved in glycogen synthesis and glycolysis. Insulin also promotes growth and is required for the actions of growth hormone (e.g. protein synthesis, cell division, DNA synthesis). Insulin lispro is a rapid-acting insulin analogue used to mimic postprandial insulin spikes in diabetic individuals. The onset of action of insulin lispro is 10-15 minutes. Its activity peaks 60 minutes following subcutaneous injection and its duration of action is 4-5 hours. Compared to regular human insulin, insulin lispro  has a more rapid onset of action and a shorter duration of action. Insulin lispro is also shown to be equipotent to human insulin on a molar basis.", "mechanism-of-action": "Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Reversal of the proline and lysine residues at positions B28 and B29 of native insulin eliminates hydrophobic interactions and weakens some of the hydrogen bonds that contribute to the stability of the insulin dimers that comprise insulin hexamers. Hexamers of insulin lispro are produced in the presence of zinc and <i>m</i>-cresol. These weakly associated hexamers quickly dissociate upon subcutaneous injection and are absorbed as monomers through vascular endothelial cells. These properties give insulin lispro its fast-acting properties.", "toxicity": "Inappropriately high dosages relative to food intake and/or energy expenditure may result in severe and sometimes prolonged and life-threatening hypoglycemia. Neurogenic (autonomic) signs and symptoms of hypoglycemia include trembling, palpitations, sweating, anxiety, hunger, nausea and tingling. Neuroglycopenic signs and symptoms of hypoglycemia include difficulty concentrating, lethargy/weakness, confusion, drowsiness, vision changes, difficulty speaking, headache, and dizziness. Mild hypoglycemia is characterized by the presence of autonomic symptoms. Moderate hypoglycemia is characterized by the presence of autonomic and neuroglycopenic symptoms. Individuals may become unconscious in severe cases of hypoglycemia. Rare cases of lipoatrophy or lipohypertrophy reactions have been observed.", "metabolism": "Insulin is predominantly cleared by metabolic degradation via a receptor-mediated process.", "absorption": "Rapidly absorbed following subcutaneous administration. It is also absorbed more quickly than regular human insulin. Peak serum levels occur 30-90 minutes after injection in healthy subjects. Absorption also differs depending on the site of injection. After insulin lispro was administered in the abdomen, serum drug levels were higher and the duration of action was slightly shorter than after deltoid or thigh administration.\nBioavailability, 0.1 - 0.2 unit/kg = 55% - 77%.", "half-life": "SubQ administration = 1 hour", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": "When administered intravenously as bolus injections of 0.1 and 0.2 U/kg dose in two separate groups of healthy subjects, the mean volume of distribution of insulin lispro appeared to decrease with increase in dose (1.55 and 0.72 L/kg, respectively).", "clearance": "Clearance is dose dependent. When a dose of 0.1 unit/kg and 0.2 unit/kg were administered intravenously, the mean clearance was 21.0 mL/min/kg and 9.6 mL/min/kg respectively.", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": {"@language": "", "@coder": "", "#text": "Insulin Lispro Recombinant"}}, "products": {"product": [{"name": "Humalog", "ndc-id": "0002-7510_30b67795-62b2-45cc-9bb1-d570d38207a7", "ndc-product-code": "0002-7510", "dpd-id": null, "started-marketing-on": "1996-07-24", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 [iU]/mL", "route": "intravenous; subcutaneous", "fda-application-number": "NDA020563", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humalog", "ndc-id": "0002-7516_30b67795-62b2-45cc-9bb1-d570d38207a7", "ndc-product-code": "0002-7516", "dpd-id": null, "started-marketing-on": "1998-02-20", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 [iU]/mL", "route": "intravenous; subcutaneous", "fda-application-number": "NDA020563", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humalog", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02229704", "started-marketing-on": "1996-11-15", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 unit", "route": "intramuscular; intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Humalog", "ndc-id": "54868-5108_199662a5-c92a-43ca-88ff-38e30bc6c3b9", "ndc-product-code": "54868-5108", "dpd-id": null, "started-marketing-on": "2005-05-02", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA020563", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humalog", "ndc-id": "55045-3602_0b67b87e-09b2-4469-846e-52ea3f962018", "ndc-product-code": "55045-3602", "dpd-id": null, "started-marketing-on": "1996-07-24", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA020563", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humalog  (cartridge)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02229705", "started-marketing-on": "1996-11-27", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 unit", "route": "intramuscular; intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Humalog  (kwikpen)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02403412", "started-marketing-on": "2013-08-14", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 unit", "route": "intramuscular; intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Humalog 200 Units/ml Kwikpen", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02439611", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "200 unit", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Humalog Cartridge", "ndc-id": "54868-5836_199662a5-c92a-43ca-88ff-38e30bc6c3b9", "ndc-product-code": "54868-5836", "dpd-id": null, "started-marketing-on": "2007-12-03", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA020563", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humalog KwikPen", "ndc-id": "0002-7712_30b67795-62b2-45cc-9bb1-d570d38207a7", "ndc-product-code": "0002-7712", "dpd-id": null, "started-marketing-on": "2015-05-26", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "200 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA205747", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humalog KwikPen", "ndc-id": "0002-8799_30b67795-62b2-45cc-9bb1-d570d38207a7", "ndc-product-code": "0002-8799", "dpd-id": null, "started-marketing-on": "2008-01-16", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 [iU]/mL", "route": "intravenous; subcutaneous", "fda-application-number": "NDA020563", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humalog Mix50/50", "ndc-id": "0002-7512_a9613057-f8d7-4566-aecf-89d4dc6cbb50", "ndc-product-code": "0002-7512", "dpd-id": null, "started-marketing-on": "2006-02-07", "ended-marketing-on": null, "dosage-form": "injection, suspension", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA021018", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humalog Mix50/50 KwikPen", "ndc-id": "0002-8798_a9613057-f8d7-4566-aecf-89d4dc6cbb50", "ndc-product-code": "0002-8798", "dpd-id": null, "started-marketing-on": "2006-02-07", "ended-marketing-on": null, "dosage-form": "injection, suspension", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA021018", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humalog Mix75/25", "ndc-id": "0002-7511_8a709ede-6322-4c32-84ae-1812f5d716f7", "ndc-product-code": "0002-7511", "dpd-id": null, "started-marketing-on": "1999-12-22", "ended-marketing-on": null, "dosage-form": "injection, suspension", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA021017", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humalog Mix75/25", "ndc-id": "54868-4381_d1df2bf7-621c-4b96-b2fb-1634fe9053e9", "ndc-product-code": "54868-4381", "dpd-id": null, "started-marketing-on": "2005-02-22", "ended-marketing-on": null, "dosage-form": "injection, suspension", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA021017", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humalog Mix75/25 KwikPen", "ndc-id": "0002-8797_8a709ede-6322-4c32-84ae-1812f5d716f7", "ndc-product-code": "0002-8797", "dpd-id": null, "started-marketing-on": "2008-01-16", "ended-marketing-on": null, "dosage-form": "injection, suspension", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA021017", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humalog Pen", "ndc-id": "54868-5899_199662a5-c92a-43ca-88ff-38e30bc6c3b9", "ndc-product-code": "54868-5899", "dpd-id": null, "started-marketing-on": "2008-05-12", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA020563", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Humalog Pen", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02241283", "started-marketing-on": "2000-01-10", "ended-marketing-on": "2011-04-29", "dosage-form": "liquid", "strength": "100 unit", "route": "intramuscular; intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Humalog", "ingredients": "Insulin Lispro"}, {"name": "Humalog Mix75/25", "ingredients": "Insulin Lispro"}, {"name": "Humalog Mix50/50", "ingredients": "Insulin Lispro"}, {"name": "Humalog", "ingredients": "Insulin Lispro"}, {"name": "Humalog KwikPen", "ingredients": "Insulin Lispro"}, {"name": "Humalog Mix75/25 KwikPen", "ingredients": "Insulin Lispro"}, {"name": "Humalog Mix50/50 KwikPen", "ingredients": "Insulin Lispro"}, {"name": "Humalog KwikPen", "ingredients": "Insulin Lispro"}, {"name": "Humalog Mix75/25", "ingredients": "Insulin Lispro"}, {"name": "Humalog", "ingredients": "Insulin Lispro"}, {"name": "Humalog Cartridge", "ingredients": "Insulin Lispro"}, {"name": "Humalog Pen", "ingredients": "Insulin Lispro"}, {"name": "Humalog", "ingredients": "Insulin Lispro"}, {"name": "Humalog", "ingredients": "Insulin Lispro"}, {"name": "Humalog  (cartridge)", "ingredients": "Insulin Lispro"}, {"name": "Humalog  (kwikpen)", "ingredients": "Insulin Lispro"}, {"name": "Humalog Pen", "ingredients": "Insulin Lispro"}, {"name": "Humalog 200 Units/ml Kwikpen", "ingredients": "Insulin Lispro"}]}, "packagers": {"packager": [{"name": "Eli Lilly & Co.", "url": "http://www.lilly.com"}, {"name": "Hospira Inc.", "url": "http://www.hospira.com"}, {"name": "Lilly Del Caribe Inc.", "url": null}, {"name": "Midwest IV and Home Care", "url": "http://midwestmed.org/iv"}, {"name": "Physicians Total Care Inc.", "url": "http://www.physicianstotalcare.com"}]}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Eli lilly and co"}}, "prices": {"price": [{"description": "Humalog 100 unit/ml", "cost": {"@currency": "USD", "#text": "2.95"}, "unit": "cartridge"}, {"description": "Humalog 100 unit/ml Cartridge", "cost": {"@currency": "USD", "#text": "9.37"}, "unit": "cartridge"}, {"description": "Humalog mix 50/50 kwikpen", "cost": {"@currency": "USD", "#text": "11.83"}, "unit": "ml"}, {"description": "Humalog 100 unit/ml kwikpen", "cost": {"@currency": "USD", "#text": "15.4"}, "unit": "ml"}, {"description": "Humalog 100 unit/ml pen", "cost": {"@currency": "USD", "#text": "15.4"}, "unit": "ml"}, {"description": "Humalog mix 50-50 kwikpen", "cost": {"@currency": "USD", "#text": "15.4"}, "unit": "ml"}, {"description": "Humalog mix 50-50 pen", "cost": {"@currency": "USD", "#text": "15.4"}, "unit": "ml"}, {"description": "HumaLOG 100 unit/ml Solution 10ml Vial", "cost": {"@currency": "USD", "#text": "124.36"}, "unit": "vial"}, {"description": "HumaLOG 100 unit/ml Solution 1 Box = Five 3ml Cartridges = 15ml", "cost": {"@currency": "USD", "#text": "231.0"}, "unit": "box"}, {"description": "HumaLOG KwikPen 100 unit/ml Solution (1box = 5 Pens = 15ml)", "cost": {"@currency": "USD", "#text": "240.18"}, "unit": "box"}, {"description": "HumaLOG Mix 50/50 KwikPen 50-50% Suspension Five 3ml Pens Per Box = 15ml", "cost": {"@currency": "USD", "#text": "240.18"}, "unit": "box"}, {"description": "HumaLOG Mix 75/25 KwikPen 75-25% Suspension Five 3ml Pen Per Box = 15ml", "cost": {"@currency": "USD", "#text": "240.18"}, "unit": "box"}, {"description": "HumaLOG Mix 75/25 Pen 75-25% Suspension 15ml Box", "cost": {"@currency": "USD", "#text": "240.18"}, "unit": "box"}, {"description": "HumaLOG Pen (five 3ml Pens Per Box) 15ml Box", "cost": {"@currency": "USD", "#text": "240.18"}, "unit": "box"}]}, "categories": {"category": [{"category": "Hypoglycemic Agents", "mesh-id": null}, {"category": "Antidiabetic Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, solution", "route": "intravenous; subcutaneous", "strength": "100 [iU]/mL"}, {"form": "Injection, solution", "route": "subcutaneous", "strength": "100 [iU]/mL"}, {"form": "Solution", "route": "intramuscular; intravenous; subcutaneous", "strength": "100 unit"}, {"form": "Solution", "route": "subcutaneous", "strength": "200 unit"}, {"form": "Injection, solution", "route": "subcutaneous", "strength": "200 [iU]/mL"}, {"form": "Injection, suspension", "route": "subcutaneous", "strength": "100 [iU]/mL"}, {"form": "Liquid", "route": "intramuscular; intravenous; subcutaneous", "strength": "100 unit"}]}, "atc-codes": {"atc-code": [{"@code": "A10AB04", "level": [{"@code": "A", "#text": "ALIMENTARY TRACT AND METABOLISM"}, {"@code": "A10", "#text": "DRUGS USED IN DIABETES"}, {"@code": "A10A", "#text": "INSULINS AND ANALOGUES"}, {"@code": "A10AB", "#text": "Insulins and analogues for injection, fast-acting"}]}, {"@code": "A10AC04", "level": [{"@code": "A", "#text": "ALIMENTARY TRACT AND METABOLISM"}, {"@code": "A10", "#text": "DRUGS USED IN DIABETES"}, {"@code": "A10A", "#text": "INSULINS AND ANALOGUES"}, {"@code": "A10AC", "#text": "Insulins and analogues for injection, intermediate-acting"}]}, {"@code": "A10AD04", "level": [{"@code": "A", "#text": "ALIMENTARY TRACT AND METABOLISM"}, {"@code": "A10", "#text": "DRUGS USED IN DIABETES"}, {"@code": "A10A", "#text": "INSULINS AND ANALOGUES"}, {"@code": "A10AD", "#text": "Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting"}]}]}, "ahfs-codes": {"ahfs-code": "68:20.08"}, "patents": {"patent": [{"number": "2151560", "country": "Canada", "approved": "2000-05-09", "expires": "2015-06-12"}, {"number": "2151564", "country": "Canada", "approved": "2003-02-11", "expires": "2015-06-12"}, {"number": "5474978", "country": "United States", "approved": "1994-06-16", "expires": "2014-06-16"}, {"number": "5514646", "country": "United States", "approved": "1993-05-07", "expires": "2013-05-07"}]}, "food-interactions": {"food-interaction": "Inject subcutaneuosly 15 minutes before meal"}, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00414", "name": "Acetohexamide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00945", "name": "Acetylsalicylic acid", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB06203", "name": "Alogliptin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01238", "name": "Aripiprazole", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01169", "name": "Arsenic trioxide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB09009", "name": "Articaine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06216", "name": "Asenapine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01072", "name": "Atazanavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00436", "name": "Bendroflumethiazide", "description": "Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00443", "name": "Betamethasone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB09128", "name": "Brexpiprazole", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00887", "name": "Bumetanide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06719", "name": "Buserelin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB08907", "name": "Canagliflozin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB09063", "name": "Ceritinib", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00880", "name": "Chlorothiazide", "description": "Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00672", "name": "Chlorpropamide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00310", "name": "Chlorthalidone", "description": "Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00363", "name": "Clozapine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01285", "name": "Corticotropin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01380", "name": "Cortisone acetate", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB04839", "name": "Cyproterone acetate", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB08912", "name": "Dabrafenib", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01406", "name": "Danazol", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01264", "name": "Darunavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00304", "name": "Desogestrel", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01234", "name": "Dexamethasone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01119", "name": "Diazoxide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB09123", "name": "Dienogest", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB02901", "name": "Dihydrotestosterone", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00280", "name": "Disopyramide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01395", "name": "Drospirenone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00974", "name": "Edetic Acid", "description": "May enhance the hypoglycemic effect of Insulin."}, {"drugbank-id": "DB00974", "name": "Edetic Acid", "description": "May enhance the hypoglycemic effect of Insulin."}, {"drugbank-id": "DB00668", "name": "Epinephrine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00783", "name": "Estradiol", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB04574", "name": "Estropipate", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00903", "name": "Ethacrynic acid", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00977", "name": "Ethinyl Estradiol", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00823", "name": "Ethynodiol", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00294", "name": "Etonogestrel", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01590", "name": "Everolimus", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00687", "name": "Fludrocortisone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01319", "name": "Fosamprenavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00695", "name": "Furosemide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01120", "name": "Gliclazide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00222", "name": "Glimepiride", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01067", "name": "Glipizide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01251", "name": "Gliquidone", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01016", "name": "Glyburide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00014", "name": "Goserelin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06788", "name": "Histrelin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00999", "name": "Hydrochlorothiazide", "description": "Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00741", "name": "Hydrocortisone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06789", "name": "Hydroxyprogesterone caproate", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB04946", "name": "Iloperidone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00808", "name": "Indapamide", "description": "Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00224", "name": "Indinavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB05278", "name": "inhaled insulin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01306", "name": "Insulin Aspart", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01307", "name": "Insulin Detemir", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00047", "name": "Insulin Glargine", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01309", "name": "Insulin Glulisine", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00030", "name": "Insulin Regular", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB08914", "name": "Insulin, isophane", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB06791", "name": "Lanreotide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00007", "name": "Leuprolide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00367", "name": "Levonorgestrel", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB08882", "name": "Linagliptin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00166", "name": "Lipoic Acid", "description": "May enhance the hypoglycemic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06655", "name": "Liraglutide", "description": "May enhance the hypoglycemic effect of Insulin."}, {"drugbank-id": "DB01601", "name": "Lopinavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB08815", "name": "Lurasidone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01277", "name": "Mecasermin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00603", "name": "Medroxyprogesterone Acetate", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00351", "name": "Megestrol acetate", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01357", "name": "Mestranol", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00331", "name": "Metformin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01403", "name": "Methotrimeprazine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00232", "name": "Methyclothiazide", "description": "Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00959", "name": "Methylprednisolone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00524", "name": "Metolazone", "description": "Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB09046", "name": "Metreleptin", "description": "May enhance the hypoglycemic effect of Insulin."}, {"drugbank-id": "DB00834", "name": "Mifepristone", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00731", "name": "Nateglinide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00220", "name": "Nelfinavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00627", "name": "Niacin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB04868", "name": "Nilotinib", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00717", "name": "Norethindrone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00957", "name": "Norgestimate", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00104", "name": "Octreotide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00334", "name": "Olanzapine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00621", "name": "Oxandrolone", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB01267", "name": "Paliperidone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06663", "name": "Pasireotide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00082", "name": "Pegvisomant", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00738", "name": "Pentamidine", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01132", "name": "Pioglitazone", "description": "May enhance the adverse/toxic effect of Insulin. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination."}, {"drugbank-id": "DB00592", "name": "Piperazine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01621", "name": "Pipotiazine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01278", "name": "Pramlintide", "description": "May enhance the hypoglycemic effect of Insulin."}, {"drugbank-id": "DB00860", "name": "Prednisolone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00635", "name": "Prednisone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00396", "name": "Progesterone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01224", "name": "Quetiapine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00468", "name": "Quinine", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00912", "name": "Repaglinide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00734", "name": "Risperidone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00503", "name": "Ritonavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00412", "name": "Rosiglitazone", "description": "Insulin may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination."}, {"drugbank-id": "DB01398", "name": "Salicylate-sodium", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB01232", "name": "Saquinavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06335", "name": "Saxagliptin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00877", "name": "Sirolimus", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00359", "name": "Sulfadiazine", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01015", "name": "Sulfamethoxazole", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00263", "name": "Sulfisoxazole", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01268", "name": "Sunitinib", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00864", "name": "Tacrolimus", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06287", "name": "Temsirolimus", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00624", "name": "Testosterone", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00932", "name": "Tipranavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00839", "name": "Tolazamide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01124", "name": "Tolbutamide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00214", "name": "Torasemide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00620", "name": "Triamcinolone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06825", "name": "Triptorelin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB04876", "name": "Vildagliptin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB02546", "name": "Vorinostat", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00246", "name": "Ziprasidone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}]}, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">A chain\nGIVEQCCTSICSLYQLENYCN"}, {"@format": "FASTA", "#text": ">B chain\nFVNQHLCGSHLVEALYLVCGERGFFYTKPT"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "81 \u00b0C", "source": "Khachidze, D.G. et al., J. Biol. Phys. Chem. 1:64-67 (2001)"}, {"kind": "Hydrophobicity", "value": "0.218", "source": null}, {"kind": "Isoelectric Point", "value": "5.39", "source": null}, {"kind": "Molecular Weight", "value": "5808.0000", "source": null}, {"kind": "Molecular Formula", "value": "C257H387N65O76S6", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "11115"}, {"resource": "KEGG Drug", "identifier": "D04477"}, {"resource": "National Drug Code Directory", "identifier": "0002-7510-01"}, {"resource": "PharmGKB", "identifier": "PA164747059"}, {"resource": "Wikipedia", "identifier": "Insulin_lispro"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/insulinlispro.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/mtm/insulin-lispro.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000033", "name": "Insulin receptor", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352\n# Jehle PM, Fussgaenger RD, Kunze U, Dolderer M, Warchol W, Koop I: The human insulin analog insulin lispro improves insulin binding on circulating monocytes of intensively treated insulin-dependent diabetes mellitus patients. J Clin Endocrinol Metab. 1996 Jun;81(6):2319-27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8964871\n# Jehle PM, Fussganger RD, Seibold A, Luttke B, Bohm BO: Pharmacodynamics of insulin Lispro in 2 patients with type II diabetes mellitus. Int J Clin Pharmacol Ther. 1996 Nov;34(11):498-503. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8937933\n# Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, Squatrito S, Vigneri R: Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia. 2010 Apr 28. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20424816", "known-action": "yes", "polypeptide": {"@id": "P06213", "@source": "Swiss-Prot", "name": "Insulin receptor", "general-function": "Involved in transmembrane receptor protein tyrosine kinase activity", "specific-function": "This receptor binds insulin and has a tyrosine-protein kinase activity. Isoform Short has a higher affinity for insulin. Mediates the metabolic functions of insulin. Binding to insulin stimulates association of the receptor with downstream mediators including IRS1 and phosphatidylinositol 3'-kinase (PI3K). Can activate PI3K either directly by binding to the p85 regulatory subunit, or indirectly via IRS1", "gene-name": "INSR", "locus": "19p13.3-p13.2", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "957-979", "signal-regions": null, "theoretical-pi": "6.18", "molecular-weight": "156308.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6091"}, {"resource": "GenAtlas", "identifier": "INSR"}, {"resource": "GeneCards", "identifier": "INSR"}, {"resource": "GenBank Gene Database", "identifier": "M10051"}, {"resource": "GenBank Protein Database", "identifier": "307070"}, {"resource": "UniProtKB", "identifier": "P06213"}, {"resource": "UniProt Accession", "identifier": "INSR_HUMAN"}]}, "synonyms": {"synonym": ["CD220 antigen", "EC 2.7.10.1", "Insulin receptor precursor", "IR"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Insulin receptor precursor\nMGTGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHL\nQILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYAL\nVIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNE\nECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECL\nGNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQG\nCHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGC\nTVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETL\nEIGNYSFYALDNQNLRQLWDWSKHNLTTTQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQE\nRNDIALKTNGDKASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQ\nNVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFS\nDERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWE\nRQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQIL\nKELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAF\nPNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYV\nSARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCV\nSRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIG\nPLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSR\nEKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKG\nFTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMA\nAEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPV\nRWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDN\nCPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEME\nFEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSN\nPS"}, "gene-sequence": {"@format": "FASTA", "#text": ">4149 bp\nATGGGCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCG\nCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATC\nCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTG\nCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAA\nCTCATCATGATCACTGATTACTTGCTGCTCTTCCGGGTCTATGGGCTCGAGAGCCTGAAG\nGACCTGTTCCCCAACCTCACGGTCATCCGGGGATCACGACTGTTCTTTAACTACGCGCTG\nGTCATCTTCGAGATGGTTCACCTCAAGGAACTCGGCCTCTACAACCTGATGAACATCACC\nCGGGGTTCTGTCCGCATCGAGAAGAACAATGAGCTCTGTTACTTGGCCACTATCGACTGG\nTCCCGTATCCTGGATTCCGTGGAGGATAATCACATCGTGTTGAACAAAGATGACAACGAG\nGAGTGTGGAGACATCTGTCCGGGTACCGCGAAGGGCAAGACCAACTGCCCCGCCACCGTC\nATCAACGGGCAGTTTGTCGAACGATGTTGGACTCATAGTCACTGCCAGAAAGTTTGCCCG\nACCATCTGTAAGTCACACGGCTGCACCGCCGAAGGCCTCTGTTGCCACAGCGAGTGCCTG\nGGCAACTGTTCTCAGCCCGACGACCCCACCAAGTGCGTGGCCTGCCGCAACTTCTACCTG\nGACGGCAGGTGTGTGGAGACCTGCCCGCCCCCGTACTACCACTTCCAGGACTGGCGCTGT\nGTGAACTTCAGCTTCTGCCAGGACCTGCACCACAAATGCAAGAACTCGCGGAGGCAGGGC\nTGCCACCAATACGTCATTCACAACAACAAGTGCATCCCTGAGTGTCCCTCCGGGTACACG\nATGAATTCCAGCAACTTGCTGTGCACCCCATGCCTGGGTCCCTGTCCCAAGGTGTGCCAC\nCTCCTAGAAGGCGAGAAGACCATCGACTCGGTGACGTCTGCCCAGGAGCTCCGAGGATGC\nACCGTCATCAACGGGAGTCTGATCATCAACATTCGAGGAGGCAACAATCTGGCAGCTGAG\nCTAGAAGCCAACCTCGGCCTCATTGAAGAAATTTCAGGGTATCTAAAAATCCGCCGATCC\nTACGCTCTGGTGTCACTTTCCTTCTTCCGGAAGTTACGTCTGATTCGAGGAGAGACCTTG\nGAAATTGGGAACTACTCCTTCTATGCCTTGGACAACCAGAACCTAAGGCAGCTCTGGGAC\nTGGAGCAAACACAACCTCACCACCACTCAGGGGAAACTCTTCTTCCACTATAACCCCAAA\nCTCTGCTTGTCAGAAATCCACAAGATGGAAGAAGTTTCAGGAACCAAGGGGCGCCAGGAG\nAGAAACGACATTGCCCTGAAGACCAATGGGGACAAGGCATCCTGTGAAAATGAGTTACTT\nAAATTTTCTTACATTCGGACATCTTTTGACAAGATCTTGCTGAGATGGGAGCCGTACTGG\nCCCCCCGACTTCCGAGACCTCTTGGGGTTCATGCTGTTCTACAAAGAGGCCCCTTATCAG\nAATGTGACGGAGTTCGATGGGCAGGATGCGTGTGGTTCCAACAGTTGGACGGTGGTAGAC\nATTGACCCACCCCTGAGGTCCAACGACCCCAAATCACAGAACCACCCAGGGTGGCTGATG\nCGGGGTCTCAAGCCCTGGACCCAGTATGCCATCTTTGTGAAGACCCTGGTCACCTTTTCG\nGATGAACGCCGGACCTATGGGGCCAAGAGTGACATCATTTATGTCCAGACAGATGCCACC\nAACCCCTCTGTGCCCCTGGATCCAATCTCAGTGTCTAACTCATCATCCCAGATTATTCTG\nAAGTGGAAACCACCCTCCGACCCCAATGGCAACATCACCCACTACCTGGTTTTCTGGGAG\nAGGCAGGCGGAAGACAGTGAGCTGTTCGAGCTGGATTATTGCCTCAAAGGGCTGAAGCTG\nCCCTCGAGGACCTGGTCTCCACCATTCGAGTCTGAAGATTCTCAGAAGCACAACCAGAGT\nGAGTATGAGGATTCGGCCGGCGAATGCTGCTCCTGTCCAAAGACAGACTCTCAGATCCTG\nAAGGAGCTGGAGGAGTCCTCGTTTAGGAAGACGTTTGAGGATTACCTGCACAACGTGGTT\nTTCGTCCCCAGAAAAACCTCTTCAGGCACTGGTGCCGAGGACCCTAGGCCATCTCGGAAA\nCGCAGGTCCCTTGGCGATGTTGGGAATGTGACGGTGGCCGTGCCCACGGTGGCAGCTTTC\nCCCAACACTTCCTCGACCAGCGTGCCCACGAGTCCGGAGGAGCACAGGCCTTTTGAGAAG\nGTGGTGAACAAGGAGTCGCTGGTCATCTCCGGCTTGCGACACTTCACGGGCTATCGCATC\nGAGCTGCAGGCTTGCAACCAGGACACCCCTGAGGAACGGTGCAGTGTGGCAGCCTACGTC\nAGTGCGAGGACCATGCCTGAAGCCAAGGCTGATGACATTGTTGGCCCTGTGACGCATGAA\nATCTTTGAGAACAACGTCGTCCACTTGATGTGGCAGGAGCCGAAGGAGCCCAATGGTCTG\nATCGTGCTGTATGAAGTGAGTTATCGGCGATATGGTGATGAGGAGCTGCATCTCTGCGTC\nTCCCGCAAGCACTTCGCTCTGGAACGGGGCTGCAGGCTGCGTGGGCTGTCACCGGGGAAC\nTACAGCGTGCGAATCCGGGCCACCTCCCTTGCGGGCAACGGCTCTTGGACGGAACCCACC\nTATTTCTACGTGACAGACTATTTAGACGTCCCGTCAAATATTGCAAAAATTATCATCGGC\nCCCCTCATCTTTGTCTTTCTCTTCAGTGTTGTGATTGGAAGTATTTATCTATTCCTGAGA\nAAGAGGCAGCCAGATGGGCCGCTGGGACCGCTTTACGCTTCTTCAAACCCTGAGTATCTC\nAGTGCCAGTGATGTGTTTCCATGCTCTGTGTACGTGCCGGACGAGTGGGAGGTGTCTCGA\nGAGAAGATCACCCTCCTTCGAGAGCTGGGGCAGGGCTCCTTCGGCATGGTGTATGAGGGC\nAATGCCAGGGACATCATCAAGGGTGAGGCAGAGACCCGCGTGGCGGTGAAGACGGTCAAC\nGAGTCAGCCAGTCTCCGAGAGCGGATTGAGTTCCTCAATGAGGCCTCGGTCATGAAGGGC\nTTCACCTGCCATCACGTGGTGCGCCTCCTGGGAGTGGTGTCCAAGGGCCAGCCCACGCTG\nGTGGTGATGGAGCTGATGGCTCACGGAGACCTGAAGAGCTACCTCCGTTCTCTGCGGCCA\nGAGGCTGAGAATAATCCTGGCCGCCCTCCCCCTACCCTTCAAGAGATGATTCAGATGGCG\nGCAGAGATTGCTGACGGGATGGCCTACCTGAACGCCAAGAAGTTTGTGCATCGGGACCTG\nGCAGCGAGAAACTGCATGGTCGCCCATGATTTTACTGTCAAAATTGGAGACTTTGGAATG\nACCAGAGACATCTATGAAACGGATTACTACCGGAAAGGGGGCAAGGGTCTGCTCCCTGTA\nCGGTGGATGGCACCGGAGTCCCTGAAGGATGGGGTCTTCACCACTTCTTCTGACATGTGG\nTCCTTTGGCGTGGTCCTTTGGGAAATCACCAGCTTGGCAGAACAGCCTTACCAAGGCCTG\nTCTAATGAACAGGTGTTGAAATTTGTCATGGATGGAGGGTATCTGGATCAACCCGACAAC\nTGTCCAGAGAGAGTCACTGACCTCATGCGCATGTGCTGGCAATTCAACCCCAAGATGAGG\nCCAACCTTCCTGGAGATTGTCAACCTGCTCAAGGACGACCTGCACCCCAGCTTTCCAGAG\nGTGTCGTTCTTCCACAGCGAGGAGAACAAGGCTCCCGAGAGTGAGGAGCTGGAGATGGAG\nTTTGAGGACATGGAGAATGTGCCCCTGGACCGTTCCTCGCACTGTCAGAGGGAGGAGGCG\nGGGGGCCGGGATGGAGGGTCCTCGCTGGGTTTCAAGCGGAGCTACGAGGAACACATCCCT\nTACACACACATGAACGGAGGCAAGAAAAACGGGCGGATTCTGACCTTGCCTCGGTCCAAT\nCCTTCCTAA"}, "pfams": {"pfam": [{"identifier": "PF07714", "name": "Pkinase_Tyr"}, {"identifier": "PF00041", "name": "fn3"}, {"identifier": "PF00757", "name": "Furin-like"}, {"identifier": "PF01030", "name": "Recep_L_domain"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "protein-tyrosine kinase activity"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "transferase activity, transferring phosphorus-containing groups"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "function", "description": "kinase activity"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "transferase activity"}, {"category": "function", "description": "protein kinase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "transmembrane receptor protein tyrosine kinase activity"}, {"category": "function", "description": "epidermal growth factor receptor activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "protein amino acid phosphorylation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "enzyme linked receptor protein signaling pathway"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "transmembrane receptor protein tyrosine kinase signaling pathway"}, {"category": "process", "description": "biopolymer metabolism"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "biopolymer modification"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "protein modification"}]}}}, {"@position": "2", "id": "BE0000858", "name": "Insulin-like growth factor 1 receptor", "organism": "Human", "actions": null, "references": "# Smith TJ: Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev. 2010 Jun;62(2):199-236. Epub 2010 Apr 14. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20392809", "known-action": "unknown", "polypeptide": {"@id": "P08069", "@source": "Swiss-Prot", "name": "Insulin-like growth factor 1 receptor", "general-function": "Involved in transmembrane receptor protein tyrosine kinase activity", "specific-function": "This receptor binds insulin-like growth factor 1 (IGF1) with a high affinity and IGF2 with a lower affinity. It has a tyrosine-protein kinase activity, which is necessary for the activation of the IGF1-stimulated downstream signaling cascade", "gene-name": "IGF1R", "locus": "15q26.3", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "936-959", "signal-regions": null, "theoretical-pi": "5.54", "molecular-weight": "154795.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5465"}, {"resource": "GenAtlas", "identifier": "IGF1R"}, {"resource": "GeneCards", "identifier": "IGF1R"}, {"resource": "GenBank Gene Database", "identifier": "X04434"}, {"resource": "GenBank Protein Database", "identifier": "804990"}, {"resource": "UniProtKB", "identifier": "P08069"}, {"resource": "UniProt Accession", "identifier": "IGF1R_HUMAN"}]}, "synonyms": {"synonym": ["CD221 antigen", "EC 2.7.10.1", "IGF-I receptor", "Insulin-like growth factor 1 receptor precursor", "Insulin-like growth factor I receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Insulin-like growth factor 1 receptor precursor\nMKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLH\nILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIF\nEMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGD\nLCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCS\nAPDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHD\nGECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNL\nLINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSF\nYVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTR\nNNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDG\nQDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSE\nILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRH\nNYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRK\nVFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFES\nRVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTW\nEPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGN\nYTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHR\nKRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKG\nVVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIME\nLMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARN\nCMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGV\nVLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFL\nEIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRH\nSGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC"}, "gene-sequence": {"@format": "FASTA", "#text": ">4104 bp\nATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCC\nGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGC\nAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCAC\nATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTC\nATTACCGAGTACTTGCTGCTGTTCCGAGTGGCTGGCCTCGAGAGCCTCGGAGACCTCTTC\nCCCAACCTCACGGTCATCCGCGGCTGGAAACTCTTCTACAACTACGCCCTGGTCATCTTC\nGAGATGACCAATCTCAAGGATATTGGGCTTTACAACCTGAGGAACATTACTCGGGGGGCC\nATCAGGATTGAGAAAAATGCTGACCTCTGTTACCTCTCCACTGTGGACTGGTCCCTGATC\nCTGGATGCGGTGTCCAATAACTACATTGTGGGGAATAAGCCCCCAAAGGAATGTGGGGAC\nCTGTGTCCAGGGACCATGGAGGAGAAGCCGATGTGTGAGAAGACCACCATCAACAATGAG\nTACAACTACCGCTGCTGGACCACAAACCGCTGCCAGAAAATGTGCCCAAGCACGTGTGGG\nAAGCGGGCGTGCACCGAGAACAATGAGTGCTGCCACCCCGAGTGCCTGGGCAGCTGCAGC\nGCGCCTGACAACGACACGGCCTGTGTAGCTTGCCGCCACTACTACTATGCCGGTGTCTGT\nGTGCCTGCCTGCCCGCCCAACACCTACAGGTTTGAGGGCTGGCGCTGTGTGGACCGTGAC\nTTCTGCGCCAACATCCTCAGCGCCGAGAGCAGCGACTCCGAGGGGTTTGTGATCCACGAC\nGGCGAGTGCATGCAGGAGTGCCCCTCGGGCTTCATCCGCAACGGCAGCCAGAGCATGTAC\nTGCATCCCTTGTGAAGGTCCTTGCCCGAAGGTCTGTGAGGAAGAAAAGAAAACAAAGACC\nATTGATTCTGTTACTTCTGCTCAGATGCTCCAAGGATGCACCATCTTCAAGGGCAATTTG\nCTCATTAACATCCGACGGGGGAATAACATTGCTTCAGAGCTGGAGAACTTCATGGGGCTC\nATCGAGGTGGTGACGGGCTACGTGAAGATCCGCCATTCTCATGCCTTGGTCTCCTTGTCC\nTTCCTAAAAAACCTTCGCCTCATCCTAGGAGAGGAGCAGCTAGAAGGGAATTACTCCTTC\nTACGTCCTCGACAACCAGAACTTGCAGCAACTGTGGGACTGGGACCACCGCAACCTGACC\nATCAAAGCAGGGAAAATGTACTTTGCTTTCAATCCCAAATTATGTGTTTCCGAAATTTAC\nCGCATGGAGGAAGTGACGGGGACTAAAGGGCGCCAAAGCAAAGGGGACATAAACACCAGG\nAACAACGGGGAGAGAGCCTCCTGTGAAAGTGACGTCCTGCATTTCACCTCCACCACCACG\nTCGAAGAATCGCATCATCATAACCTGGCACCGGTACCGGCCCCCTGACTACAGGGATCTC\nATCAGCTTCACCGTTTACTACAAGGAAGCACCCTTTAAGAATGTCACAGAGTATGATGGG\nCAGGATGCCTGCGGCTCCAACAGCTGGAACATGGTGGACGTGGACCTCCCGCCCAACAAG\nGACGTGGAGCCCGGCATCTTACTACATGGGCTGAAGCCCTGGACTCAGTACGCCGTTTAC\nGTCAAGGCTGTGACCCTCACCATGGTGGAGAACGACCATATCCGTGGGGCCAAGAGTGAG\nATCTTGTACATTCGCACCAATGCTTCAGTTCCTTCCATTCCCTTGGACGTTCTTTCAGCA\nTCGAACTCCTCTTCTCAGTTAATCGTGAAGTGGAACCCTCCCTCTCTGCCCAACGGCAAC\nCTGAGTTACTACATTGTGCGCTGGCAGCGGCAGCCTCAGGACGGCTACCTTTACCGGCAC\nAATTACTGCTCCAAAGACAAAATCCCCATCAGGAAGTATGCCGACGGCACCATCGACATT\nGAGGAGGTCACAGAGAACCCCAAGACTGAGGTGTGTGGTGGGGAGAAAGGGCCTTGCTGC\nGCCTGCCCCAAAACTGAAGCCGAGAAGCAGGCCGAGAAGGAGGAGGCTGAATACCGCAAA\nGTCTTTGAGAATTTCCTGCACAACTCCATCTTCGTGCCCAGACCTGAAAGGAAGCGGAGA\nGATGTCATGCAAGTGGCCAACACCACCATGTCCAGCCGAAGCAGGAACACCACGGCCGCA\nGACACCTACAACATCACCGACCCGGAAGAGCTGGAGACAGAGTACCCTTTCTTTGAGAGC\nAGAGTGGATAACAAGGAGAGAACTGTCATTTCTAACCTTCGGCCTTTCACATTGTACCGC\nATCGATATCCACAGCTGCAACCACGAGGCTGAGAAGCTGGGCTGCAGCGCCTCCAACTTC\nGTCTTTGCAAGGACTATGCCCGCAGAAGGAGCAGATGACATTCCTGGGCCAGTGACCTGG\nGAGCCAAGGCCTGAAAACTCCATCTTTTTAAAGTGGCCGGAACCTGAGAATCCCAATGGA\nTTGATTCTAATGTATGAAATAAAATACGGATCACAAGTTGAGGATCAGCGAGAATGTGTG\nTCCAGACAGGAATACAGGAAGTATGGAGGGGCCAAGCTAAACCGGCTAAACCCGGGGAAC\nTACACAGCCCGGATTCAGGCCACATCTCTCTCTGGGAATGGGTCGTGGACAGATCCTGTG\nTTCTTCTATGTCCAGGCCAAAACAGGATATGAAAACTTCATCCATCTGATCATCGCTCTG\nCCCGTCGCTGTCCTGTTGATCGTGGGAGGGTTGGTGATTATGCTGTACGTCTTCCATAGA\nAAGAGAAATAACAGCAGGCTGGGGAATGGAGTGCTGTATGCCTCTGTGAACCCGGAGTAC\nTTCAGCGCTGCTGATGTGTACGTTCCTGATGAGTGGGAGGTGGCTCGGGAGAAGATCACC\nATGAGCCGGGAACTTGGGCAGGGGTCGTTTGGGATGGTCTATGAAGGAGTTGCCAAGGGT\nGTGGTGAAAGATGAACCTGAAACCAGAGTGGCCATTAAAACAGTGAACGAGGCCGCAAGC\nATGCGTGAGAGGATTGAGTTTCTCAACGAAGCTTCTGTGATGAAGGAGTTCAATTGTCAC\nCATGTGGTGCGATTGCTGGGTGTGGTGTCCCAAGGCCAGCCAACACTGGTCATCATGGAA\nCTGATGACACGGGGCGATCTCAAAAGTTATCTCCGGTCTCTGAGGCCAGAAATGGAGAAT\nAATCCAGTCCTAGCACCTCCAAGCCTGAGCAAGATGATTCAGATGGCCGGAGAGATTGCA\nGACGGCATGGCATACCTCAACGCCAATAAGTTCGTCCACAGAGACCTTGCTGCCCGGAAT\nTGCATGGTAGCCGAAGATTTCACAGTCAAAATCGGAGATTTTGGTATGACGCGAGATATC\nTATGAGACAGACTATTACCGGAAAGGAGGCAAAGGGCTGCTGCCCGTGCGCTGGATGTCT\nCCTGAGTCCCTCAAGGATGGAGTCTTCACCACTTACTCGGACGTCTGGTCCTTCGGGGTC\nGTCCTCTGGGAGATCGCCACACTGGCCGAGCAGCCCTACCAGGGCTTGTCCAACGAGCAA\nGTCCTTCGCTTCGTCATGGAGGGCGGCCTTCTGGACAAGCCAGACAACTGTCCTGACATG\nCTGTTTGAACTGATGCGCATGTGCTGGCAGTATAACCCCAAGATGAGGCCTTCCTTCCTG\nGAGATCATCAGCAGCATCAAAGAGGAGATGGAGCCTGGCTTCCGGGAGGTCTCCTTCTAC\nTACAGCGAGGAGAACAAGCTGCCCGAGCCGGAGGAGCTGGACCTGGAGCCAGAGAACATG\nGAGAGCGTCCCCCTGGACCCCTCGGCCTCCTCGTCCTCCCTGCCACTGCCCGACAGACAC\nTCAGGACACAAGGCCGAGAACGGCCCCGGCCCTGGGGTGCTGGTCCTCCGCGCCAGCTTC\nGACGAGAGACAGCCTTACGCCCACATGAACGGGGGCCGCAAGAACGAGCGGGCCTTGCCG\nCTGCCCCAGTCTTCGACCTGCTGA"}, "pfams": {"pfam": [{"identifier": "PF07714", "name": "Pkinase_Tyr"}, {"identifier": "PF00041", "name": "fn3"}, {"identifier": "PF00757", "name": "Furin-like"}, {"identifier": "PF01030", "name": "Recep_L_domain"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "protein-tyrosine kinase activity"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "transferase activity, transferring phosphorus-containing groups"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "function", "description": "kinase activity"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "transferase activity"}, {"category": "function", "description": "protein kinase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "transmembrane receptor protein tyrosine kinase activity"}, {"category": "function", "description": "epidermal growth factor receptor activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "protein amino acid phosphorylation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "enzyme linked receptor protein signaling pathway"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "transmembrane receptor protein tyrosine kinase signaling pathway"}, {"category": "process", "description": "biopolymer metabolism"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "biopolymer modification"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "protein modification"}]}}}]}, "enzymes": {"enzyme": {"id": "BE0002433", "name": "Cytochrome P450 1A2", "organism": "Human", "actions": {"action": "inducer"}, "references": "# Flockhart DA. \"Drug Interactions: Cytochrome P450 Drug Interaction Table\":http://medicine.iupui.edu/clinpharm/ddis/table.asp. Indiana University School of Medicine (2007). Accessed May 28, 2010.", "known-action": "unknown", "polypeptide": {"@id": "P05177", "@source": "Swiss-Prot", "name": "Cytochrome P450 1A2", "general-function": "Involved in monooxygenase activity", "specific-function": "Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen", "gene-name": "CYP1A2", "locus": "15q24", "cellular-location": "Endoplasmic reticulum", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.43", "molecular-weight": "58295.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2596"}, {"resource": "GenAtlas", "identifier": "CYP1A2"}, {"resource": "GenBank Gene Database", "identifier": "Z00036"}, {"resource": "UniProtKB", "identifier": "P05177"}, {"resource": "UniProt Accession", "identifier": "CP1A2_HUMAN"}]}, "synonyms": {"synonym": ["CYPIA2", "EC 1.14.14.1", "P(3)450", "P450 4", "P450-P3"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytochrome P450 1A2\nMALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN\nPHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG\nQSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM\nAGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP\nILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN\nLIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS\nDRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL\nWEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE\nFSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN"}, "gene-sequence": {"@format": "FASTA", "#text": ">1548 bp\nATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCTGCCATC\nTTCTGCCTGGTATTCTGGGTGCTCAAGGGTTTGAGGCCTCGGGTCCCCAAAGGCCTGAAA\nAGTCCACCAGAGCCATGGGGCTGGCCCTTGCTCGGGCATGTGCTGACCCTGGGGAAGAAC\nCCGCACCTGGCACTGTCAAGGATGAGCCAGCGCTACGGGGACGTCCTGCAGATCCGCATT\nGGCTCCACGCCCGTGCTGGTGCTGAGCCGCCTGGACACCATCCGGCAGGCCCTGGTGCGG\nCAGGGCGACGATTTCAAGGGCCGGCCTGACCTCTACACCTCCACCCTCATCACTGATGGC\nCAGAGCTTGACCTTCAGCACAGACTCTGGACCGGTGTGGGCTGCCCGCCGGCGCCTGGCC\nCAGAATGCCCTCAACACCTTCTCCATCGCCTCTGACCCAGCTTCCTCATCCTCCTGCTAC\nCTGGAGGAGCATGTGAGCAAGGAGGCTAAGGCCCTGATCAGCAGGTTGCAGGAGCTGATG\nGCAGGGCCTGGGCACTTCGACCCTTACAATCAGGTGGTGGTGTCAGTGGCCAACGTCATT\nGGTGCCATGTGCTTCGGACAGCACTTCCCTGAGAGTAGCGATGAGATGCTCAGCCTCGTG\nAAGAACACTCATGAGTTCGTGGAGACTGCCTCCTCCGGGAACCCCCTGGACTTCTTCCCC\nATCCTTCGCTACCTGCCTAACCCTGCCCTGCAGAGGTTCAAGGCCTTCAACCAGAGGTTC\nCTGTGGTTCCTGCAGAAAACAGTCCAGGAGCACTATCAGGACTTTGACAAGAACAGTGTC\nCGGGACATCACGGGTGCCCTGTTCAAGCACAGCAAGAAGGGGCCTAGAGCCAGCGGCAAC\nCTCATCCCACAGGAGAAGATTGTCAACCTTGTCAATGACATCTTTGGAGCAGGATTTGAC\nACAGTCACCACAGCCATCTCCTGGAGCCTCATGTACCTTGTGACCAAGCCTGAGATACAG\nAGGAAGATCCAGAAGGAGCTGGACACTGTGATTGGCAGGGAGCGGCGGCCCCGGCTCTCT\nGACAGACCCCAGCTGCCCTACTTGGAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCC\nTTCTTGCCCTTCACCATCCCCCACAGCACAACAAGGGACACAACGCTGAATGGCTTCTAC\nATCCCCAAGAAATGCTGTGTCTTCGTAAACCAGTGGCAGGTCAACCATGACCCAGAGCTG\nTGGGAGGACCCCTCTGAGTTCCGGCCTGAGCGGTTCCTCACCGCCGATGGCACTGCCATT\nAACAAGCCCTTGAGTGAGAAGATGATGCTGTTTGGCATGGGCAAGCGCCGGTGTATCGGG\nGAAGTCCTGGCCAAGTGGGAGATCTTCCTCTTCCTGGCCATCCTGCTACAGCAACTGGAG\nTTCAGCGTGCCGCCGGGCGTGAAAGTCGACCTGACCCCCATCTACGGGCTGACCATGAAG\nCACGCCCGCTGTGAACATGTCCAGGCGCGGCGCTTCTCCATCAATTGA"}, "pfams": {"pfam": {"identifier": "PF00067", "name": "p450"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "iron ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "tetrapyrrole binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "heme binding"}, {"category": "function", "description": "monooxygenase activity"}, {"category": "function", "description": "oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "generation of precursor metabolites and energy"}, {"category": "process", "description": "electron transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}}, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-06-27", "drugbank-id": [{"@primary": "true", "#text": "DB00047"}, "BIOD00045", "BTD00045", "DB01308"], "name": "Insulin Glargine", "description": "Insulin glargine is produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism. It is an analogue of human insulin made by replacing the asparagine residue at position A21 of the A-chain with glycine and adding two arginines to the C-terminus (positions B31 and 32) of the B-chain. The resulting protein is soluble at pH 4 and forms microprecipitates at physiological pH 7.4. Small amounts of insulin glargine are slowly released from microprecipitates giving the drug a long duration of action (up to 24 hours) and no pronounced peak concentration.", "cas-number": "160337-95-1", "groups": {"group": "approved"}, "general-references": "# Chatterjee S, Tringham JR, Davies MJ: Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus. Expert Opin Pharmacother. 2006 Jul;7(10):1357-71. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16805721\n# Dunn CJ, Plosker GL, Keating GM, McKeage K, Scott LJ: Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs. 2003;63(16):1743-78. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12904090\n# Home PD, Ashwell SG: An overview of insulin glargine. Diabetes Metab Res Rev. 2002 Sep-Oct;18 Suppl 3:S57-63. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12324987\n# Jones R: Insulin glargine (Aventis Pharma). IDrugs. 2000 Sep;3(9):1081-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16049868\n# Wang F, Carabino JM, Vergara CM: Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther. 2003 Jun;25(6):1541-77, discussion 1539-40. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12860485\n# Warren E, Weatherley-Jones E, Chilcott J, Beverley C: Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess. 2004 Nov;8(45):iii, 1-57. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15525480\n# Owens DR, Bolli GB: Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther. 2008 Oct;10(5):333-49. doi: 10.1089/dia.2008.0023. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18715209", "synthesis-reference": null, "indication": "For the treatment of Type 1 or 2 diabetes mellitus in patients over 17 years old who require a long-acting (basal) insulin for the control of hyperglycemia. May be used in pediatric patients with Type 1 diabetes mellitus who require a long-acting (basal) insulin for glycemic control.", "pharmacodynamics": "Insulin is a natural hormone produced by beta cells of the pancreas. In non-diabetic individuals, a basal level of insulin is supplemented with insulin spikes following meals. Increased insulin secretion following meals is responsible for the metabolic changes that occur as the body transitions from a postabsorptive to absorptive state. Insulin promotes cellular uptake of glucose, particularly in muscle and adipose tissues, promotes energy storage via glycogenesis, opposes catabolism of energy stores, increases DNA replication and protein synthesis by stimulating amino acid uptake by liver, muscle and adipose tissue, and modifies the activity of numerous enzymes involved in glycogen synthesis and glycolysis. Insulin also promotes growth and is required for the actions of growth hormone (e.g. protein synthesis, cell division, DNA synthesis). Insulin glargine is a long-acting insulin analogue with a flat and predictable action profile. It is used to mimic the basal levels of insulin in diabetic individuals. The onset of action of insulin glargine is approximately 90 minutes and its duration of action is up to 24 hours. The action profile of insulin glargine is peakless. The significance of this finding is that insulin glargine has a lower chance of nocturnal hypoglycemia.", "mechanism-of-action": "Insulin glargine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism. Insulin glargine is completely soluble at pH 4, the pH of administered solution, and has low solubility at physiological pH 7.4. Upon subcuteous injection, the solution is neutralized resulting in the formation of microprecipitates. Small amounts of insulin glargine are released from microprecipitates giving the drug a relatively constant concentration over time profile over 24 hours with no pronounced peak. This release mechanism allows the drug to mimic basal insulin levels within the body.", "toxicity": "Inappropriately high dosages relative to food intake and/or energy expenditure may result in severe and sometimes prolonged and life-threatening hypoglycemia. Neurogenic (autonomic) signs and symptoms of hypoglycemia include trembling, palpitations, sweating, anxiety, hunger, nausea and tingling. Neuroglycopenic signs and symptoms of hypoglycemia include difficulty concentrating, lethargy/weakness, confusion, drowsiness, vision changes, difficulty speaking, headache, and dizziness. Mild hypoglycemia is characterized by the presence of autonomic symptoms. Moderate hypoglycemia is characterized by the presence of autonomic and neuroglycopenic symptoms. Individuals may become unconscious in severe cases of hypoglycemia. Other adverse events that may occur include allergic reaction, injection site reaction, lipodystrophy, pruritis, and rash.", "metabolism": "Partly metabolized to two active metabolites with similar <i>in vitro</i> activity to insulin: A21-Gly-insulin and A21-Gly-des-B30-Thr-insulin.", "absorption": "Because of the modifications to the A and B chain, the isoelectric point shifts towards a neutral pH and insulin glargine is more stable in acidic conditions than regular insulin. As insulin glargine is less soluble at neutral pH, once injected, forms microprecipitates. Slow release of insulin glargine from microprecipitates provides a relatively constant concentration of insulin over 24 hours. Onset of action is approximately 1.1 hours.", "half-life": "Not reported in humans; 30 hours <i>in vitro</i> in mammalian reticulocytes.", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": {"@language": "", "@coder": "", "#text": "Insulin Glargine (rDNA origin)"}}, "products": {"product": [{"name": "Basaglar", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02444844", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 unit", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Basaglar", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02444852", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 unit", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Lantus", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02294338", "started-marketing-on": "2007-09-24", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 unit", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Lantus", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02251930", "started-marketing-on": "2006-05-04", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 unit", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Lantus", "ndc-id": "52125-416_0c92b3d0-8c26-42ff-8788-7e050db63038", "ndc-product-code": "52125-416", "dpd-id": null, "started-marketing-on": "2013-11-21", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA021081", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Lantus", "ndc-id": "52125-416_add8d95a-6943-4dc5-bc75-5d0c2d458aef", "ndc-product-code": "52125-416", "dpd-id": null, "started-marketing-on": "2013-06-12", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA021081", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Lantus", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02276410", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 unit", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Lantus", "ndc-id": "55045-3685_71907ed5-ee95-471a-8d7d-f72dcbbdfb60", "ndc-product-code": "55045-3685", "dpd-id": null, "started-marketing-on": "2009-09-23", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA021081", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Lantus", "ndc-id": "54868-4626_929a6a1f-8668-425d-aec4-15793be80ea7", "ndc-product-code": "54868-4626", "dpd-id": null, "started-marketing-on": "2002-06-04", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA021081", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Lantus", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02280418", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 unit", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Lantus", "ndc-id": "64725-2220_7d9b3b09-2b30-40a4-8b37-38d2e6af3abf", "ndc-product-code": "64725-2220", "dpd-id": null, "started-marketing-on": "2009-09-23", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA021081", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Lantus", "ndc-id": "54868-5765_929a6a1f-8668-425d-aec4-15793be80ea7", "ndc-product-code": "54868-5765", "dpd-id": null, "started-marketing-on": "2007-04-04", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA021081", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Lantus", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02245689", "started-marketing-on": "2002-07-24", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 unit", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Lantus", "ndc-id": "0088-2220_0dd5b537-70f4-45d3-8003-8ce600908e96", "ndc-product-code": "0088-2220", "dpd-id": null, "started-marketing-on": "2009-09-23", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA021081", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Lantus", "ndc-id": "54868-6231_929a6a1f-8668-425d-aec4-15793be80ea7", "ndc-product-code": "54868-6231", "dpd-id": null, "started-marketing-on": "2011-02-07", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA021081", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Lantus Solostar", "ndc-id": "0088-2219_0dd5b537-70f4-45d3-8003-8ce600908e96", "ndc-product-code": "0088-2219", "dpd-id": null, "started-marketing-on": "2009-09-23", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 [iU]/mL", "route": "subcutaneous", "fda-application-number": "NDA021081", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Toujeo", "ndc-id": "0024-5869_ab5b1a7c-6eaf-4a3c-8886-28dfed0e4e49", "ndc-product-code": "0024-5869", "dpd-id": null, "started-marketing-on": "2015-02-25", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "300 U/mL", "route": "subcutaneous", "fda-application-number": "NDA206538", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Toujeo Solostar", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02441829", "started-marketing-on": "2015-07-15", "ended-marketing-on": null, "dosage-form": "solution", "strength": "300 unit", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": {"name": "Lantus OptiSet", "company": null}}, "mixtures": {"mixture": [{"name": "Toujeo", "ingredients": "Insulin Glargine"}, {"name": "Lantus Solostar", "ingredients": "Insulin Glargine"}, {"name": "Lantus", "ingredients": "Insulin Glargine"}, {"name": "Lantus", "ingredients": "Insulin Glargine"}, {"name": "Lantus", "ingredients": "Insulin Glargine"}, {"name": "Lantus", "ingredients": "Insulin Glargine"}, {"name": "Lantus", "ingredients": "Insulin Glargine"}, {"name": "Lantus", "ingredients": "Insulin Glargine"}, {"name": "Lantus", "ingredients": "Insulin Glargine"}, {"name": "Lantus", "ingredients": "Insulin Glargine"}, {"name": "Lantus", "ingredients": "Insulin Glargine"}, {"name": "Lantus", "ingredients": "Insulin Glargine"}, {"name": "Lantus", "ingredients": "Insulin Glargine"}, {"name": "Toujeo Solostar", "ingredients": "Insulin Glargine"}, {"name": "Lantus", "ingredients": "Insulin Glargine"}, {"name": "Lantus", "ingredients": "Insulin Glargine"}, {"name": "Basaglar", "ingredients": "Insulin Glargine"}, {"name": "Basaglar", "ingredients": "Insulin Glargine"}]}, "packagers": {"packager": [{"name": "Gruppo Lepetit SPA", "url": null}, {"name": "Physicians Total Care Inc.", "url": "http://www.physicianstotalcare.com"}, {"name": "Sanofi-Aventis Inc.", "url": "http://www.sanofi-aventis.com"}]}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Sanofi aventis us llc"}}, "prices": {"price": [{"description": "Lantus 100 unit/ml cartridge", "cost": {"@currency": "USD", "#text": "14.35"}, "unit": "ml"}, {"description": "Lantus solostar 100 unit/ml", "cost": {"@currency": "USD", "#text": "14.35"}, "unit": "ml"}, {"description": "Lantus for OptiClik 100 unit/ml Solution 3ml Cartridge", "cost": {"@currency": "USD", "#text": "44.78"}, "unit": "cartridge"}, {"description": "Lantus 100 unit/ml Solution 10ml Vial", "cost": {"@currency": "USD", "#text": "111.88"}, "unit": "vial"}, {"description": "Lantus SoloStar 100 unit/ml Solution 1 Box = Five 3ml Syringes", "cost": {"@currency": "USD", "#text": "223.89"}, "unit": "box"}]}, "categories": {"category": [{"category": "Hypoglycemic Agents", "mesh-id": null}, {"category": "Antidiabetic Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Solution", "route": "subcutaneous", "strength": "100 unit"}, {"form": "Injection, solution", "route": "subcutaneous", "strength": "100 [iU]/mL"}, {"form": "Injection, solution", "route": "subcutaneous", "strength": "300 U/mL"}, {"form": "Solution", "route": "subcutaneous", "strength": "300 unit"}]}, "atc-codes": {"atc-code": {"@code": "A10AE04", "level": [{"@code": "A", "#text": "ALIMENTARY TRACT AND METABOLISM"}, {"@code": "A10", "#text": "DRUGS USED IN DIABETES"}, {"@code": "A10A", "#text": "INSULINS AND ANALOGUES"}, {"@code": "A10AE", "#text": "Insulins and analogues for injection, long-acting"}]}}, "ahfs-codes": {"ahfs-code": "68:20.08"}, "patents": {"patent": [{"number": "1339044", "country": "Canada", "approved": "1997-04-01", "expires": "2014-04-01"}, {"number": "6100376", "country": "United States", "approved": "1992-11-06", "expires": "2009-11-06"}, {"number": "7476652", "country": "United States", "approved": "2004-01-23", "expires": "2024-01-23"}]}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00414", "name": "Acetohexamide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00945", "name": "Acetylsalicylic acid", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB06203", "name": "Alogliptin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01238", "name": "Aripiprazole", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01169", "name": "Arsenic trioxide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB09009", "name": "Articaine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06216", "name": "Asenapine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01072", "name": "Atazanavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00436", "name": "Bendroflumethiazide", "description": "Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00443", "name": "Betamethasone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB09128", "name": "Brexpiprazole", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00887", "name": "Bumetanide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06719", "name": "Buserelin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB08907", "name": "Canagliflozin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB09063", "name": "Ceritinib", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00880", "name": "Chlorothiazide", "description": "Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00672", "name": "Chlorpropamide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00310", "name": "Chlorthalidone", "description": "Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00363", "name": "Clozapine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01285", "name": "Corticotropin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01380", "name": "Cortisone acetate", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB04839", "name": "Cyproterone acetate", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB08912", "name": "Dabrafenib", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01406", "name": "Danazol", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01264", "name": "Darunavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00304", "name": "Desogestrel", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01234", "name": "Dexamethasone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01119", "name": "Diazoxide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB09123", "name": "Dienogest", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB02901", "name": "Dihydrotestosterone", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00280", "name": "Disopyramide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01395", "name": "Drospirenone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00974", "name": "Edetic Acid", "description": "May enhance the hypoglycemic effect of Insulin."}, {"drugbank-id": "DB00974", "name": "Edetic Acid", "description": "May enhance the hypoglycemic effect of Insulin."}, {"drugbank-id": "DB00668", "name": "Epinephrine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00783", "name": "Estradiol", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB04574", "name": "Estropipate", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00903", "name": "Ethacrynic acid", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00977", "name": "Ethinyl Estradiol", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00823", "name": "Ethynodiol", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00294", "name": "Etonogestrel", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01590", "name": "Everolimus", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00687", "name": "Fludrocortisone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01319", "name": "Fosamprenavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00695", "name": "Furosemide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01120", "name": "Gliclazide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00222", "name": "Glimepiride", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01067", "name": "Glipizide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01251", "name": "Gliquidone", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01016", "name": "Glyburide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00014", "name": "Goserelin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06788", "name": "Histrelin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00999", "name": "Hydrochlorothiazide", "description": "Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00741", "name": "Hydrocortisone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06789", "name": "Hydroxyprogesterone caproate", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB04946", "name": "Iloperidone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00808", "name": "Indapamide", "description": "Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00224", "name": "Indinavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB05278", "name": "inhaled insulin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01306", "name": "Insulin Aspart", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01307", "name": "Insulin Detemir", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01309", "name": "Insulin Glulisine", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00046", "name": "Insulin Lispro", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00030", "name": "Insulin Regular", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB08914", "name": "Insulin, isophane", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB06791", "name": "Lanreotide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00007", "name": "Leuprolide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00367", "name": "Levonorgestrel", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB08882", "name": "Linagliptin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00166", "name": "Lipoic Acid", "description": "May enhance the hypoglycemic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06655", "name": "Liraglutide", "description": "May enhance the hypoglycemic effect of Insulin."}, {"drugbank-id": "DB01601", "name": "Lopinavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB08815", "name": "Lurasidone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01277", "name": "Mecasermin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00603", "name": "Medroxyprogesterone Acetate", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00351", "name": "Megestrol acetate", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01357", "name": "Mestranol", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00331", "name": "Metformin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01403", "name": "Methotrimeprazine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00232", "name": "Methyclothiazide", "description": "Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00959", "name": "Methylprednisolone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00524", "name": "Metolazone", "description": "Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB09046", "name": "Metreleptin", "description": "May enhance the hypoglycemic effect of Insulin."}, {"drugbank-id": "DB00834", "name": "Mifepristone", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00731", "name": "Nateglinide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00220", "name": "Nelfinavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00627", "name": "Niacin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB04868", "name": "Nilotinib", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00717", "name": "Norethindrone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00957", "name": "Norgestimate", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00104", "name": "Octreotide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00334", "name": "Olanzapine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00621", "name": "Oxandrolone", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB01267", "name": "Paliperidone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06663", "name": "Pasireotide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00082", "name": "Pegvisomant", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00738", "name": "Pentamidine", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01132", "name": "Pioglitazone", "description": "May enhance the adverse/toxic effect of Insulin. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination."}, {"drugbank-id": "DB00592", "name": "Piperazine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01621", "name": "Pipotiazine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01278", "name": "Pramlintide", "description": "May enhance the hypoglycemic effect of Insulin."}, {"drugbank-id": "DB00860", "name": "Prednisolone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00635", "name": "Prednisone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00396", "name": "Progesterone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB01224", "name": "Quetiapine", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00468", "name": "Quinine", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00912", "name": "Repaglinide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00734", "name": "Risperidone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00503", "name": "Ritonavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00412", "name": "Rosiglitazone", "description": "Insulin may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination."}, {"drugbank-id": "DB01398", "name": "Salicylate-sodium", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB01232", "name": "Saquinavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06335", "name": "Saxagliptin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00877", "name": "Sirolimus", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00359", "name": "Sulfadiazine", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01015", "name": "Sulfamethoxazole", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00263", "name": "Sulfisoxazole", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01268", "name": "Sunitinib", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00864", "name": "Tacrolimus", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06287", "name": "Temsirolimus", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00624", "name": "Testosterone", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00932", "name": "Tipranavir", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00839", "name": "Tolazamide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01124", "name": "Tolbutamide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00214", "name": "Torasemide", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00620", "name": "Triamcinolone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB06825", "name": "Triptorelin", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB04876", "name": "Vildagliptin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB02546", "name": "Vorinostat", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}, {"drugbank-id": "DB00246", "name": "Ziprasidone", "description": "Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents."}]}, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">A chain\nGIVEQCCTSICSLYQLENYCG"}, {"@format": "FASTA", "#text": ">B chain\nFVNQHLCGSHLVEALYLVCGERGFFYTPKTRR"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "81 \u00b0C", "source": "Khachidze, D.G. et al., J. Biol. Phys. Chem. 1:64-67 (2001)"}, {"kind": "Hydrophobicity", "value": "0.098", "source": null}, {"kind": "Isoelectric Point", "value": "6.88", "source": null}, {"kind": "Molecular Weight", "value": "6063 Daltons", "source": null}, {"kind": "Molecular Formula", "value": "C267H404N72O78S6", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "12724"}, {"resource": "KEGG Drug", "identifier": "D03250"}, {"resource": "National Drug Code Directory", "identifier": "0088-2220-60"}, {"resource": "PharmGKB", "identifier": "PA449992"}, {"resource": "Wikipedia", "identifier": "Insulin_glargine"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic2/lantus.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/insulin-glargine-cartridge-systems.html"}]}, "pathways": null, "reactions": {"reaction": [{"sequence": "1", "left-element": {"drugbank-id": "DB00047", "name": "Insulin Glargine"}, "right-element": {"drugbank-id": "DBMET00786", "name": "A21-Gly-des-B30-Thr-insulin"}, "enzymes": null}, {"sequence": "1", "left-element": {"drugbank-id": "DB00047", "name": "Insulin Glargine"}, "right-element": {"drugbank-id": "DBMET00787", "name": "A21-Gly-insulin"}, "enzymes": null}]}, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000033", "name": "Insulin receptor", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352\n# Le Roith D: Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes. Diabetes Metab Res Rev. 2007 Nov;23(8):593-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17922476\n# Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, Squatrito S, Vigneri R: Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia. 2010 Apr 28. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20424816\n# Wada T, Azegami M, Sugiyama M, Tsuneki H, Sasaoka T: Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin. Diabetes Res Clin Pract. 2008 Sep;81(3):269-77. Epub 2008 Jun 27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18585815", "known-action": "yes", "polypeptide": {"@id": "P06213", "@source": "Swiss-Prot", "name": "Insulin receptor", "general-function": "Involved in transmembrane receptor protein tyrosine kinase activity", "specific-function": "This receptor binds insulin and has a tyrosine-protein kinase activity. Isoform Short has a higher affinity for insulin. Mediates the metabolic functions of insulin. Binding to insulin stimulates association of the receptor with downstream mediators including IRS1 and phosphatidylinositol 3'-kinase (PI3K). Can activate PI3K either directly by binding to the p85 regulatory subunit, or indirectly via IRS1", "gene-name": "INSR", "locus": "19p13.3-p13.2", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "957-979", "signal-regions": null, "theoretical-pi": "6.18", "molecular-weight": "156308.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6091"}, {"resource": "GenAtlas", "identifier": "INSR"}, {"resource": "GeneCards", "identifier": "INSR"}, {"resource": "GenBank Gene Database", "identifier": "M10051"}, {"resource": "GenBank Protein Database", "identifier": "307070"}, {"resource": "UniProtKB", "identifier": "P06213"}, {"resource": "UniProt Accession", "identifier": "INSR_HUMAN"}]}, "synonyms": {"synonym": ["CD220 antigen", "EC 2.7.10.1", "Insulin receptor precursor", "IR"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Insulin receptor precursor\nMGTGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHL\nQILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYAL\nVIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNE\nECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECL\nGNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQG\nCHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGC\nTVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETL\nEIGNYSFYALDNQNLRQLWDWSKHNLTTTQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQE\nRNDIALKTNGDKASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQ\nNVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFS\nDERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWE\nRQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQIL\nKELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAF\nPNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYV\nSARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCV\nSRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIG\nPLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSR\nEKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKG\nFTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMA\nAEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPV\nRWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDN\nCPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEME\nFEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSN\nPS"}, "gene-sequence": {"@format": "FASTA", "#text": ">4149 bp\nATGGGCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCG\nCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATC\nCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTG\nCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAA\nCTCATCATGATCACTGATTACTTGCTGCTCTTCCGGGTCTATGGGCTCGAGAGCCTGAAG\nGACCTGTTCCCCAACCTCACGGTCATCCGGGGATCACGACTGTTCTTTAACTACGCGCTG\nGTCATCTTCGAGATGGTTCACCTCAAGGAACTCGGCCTCTACAACCTGATGAACATCACC\nCGGGGTTCTGTCCGCATCGAGAAGAACAATGAGCTCTGTTACTTGGCCACTATCGACTGG\nTCCCGTATCCTGGATTCCGTGGAGGATAATCACATCGTGTTGAACAAAGATGACAACGAG\nGAGTGTGGAGACATCTGTCCGGGTACCGCGAAGGGCAAGACCAACTGCCCCGCCACCGTC\nATCAACGGGCAGTTTGTCGAACGATGTTGGACTCATAGTCACTGCCAGAAAGTTTGCCCG\nACCATCTGTAAGTCACACGGCTGCACCGCCGAAGGCCTCTGTTGCCACAGCGAGTGCCTG\nGGCAACTGTTCTCAGCCCGACGACCCCACCAAGTGCGTGGCCTGCCGCAACTTCTACCTG\nGACGGCAGGTGTGTGGAGACCTGCCCGCCCCCGTACTACCACTTCCAGGACTGGCGCTGT\nGTGAACTTCAGCTTCTGCCAGGACCTGCACCACAAATGCAAGAACTCGCGGAGGCAGGGC\nTGCCACCAATACGTCATTCACAACAACAAGTGCATCCCTGAGTGTCCCTCCGGGTACACG\nATGAATTCCAGCAACTTGCTGTGCACCCCATGCCTGGGTCCCTGTCCCAAGGTGTGCCAC\nCTCCTAGAAGGCGAGAAGACCATCGACTCGGTGACGTCTGCCCAGGAGCTCCGAGGATGC\nACCGTCATCAACGGGAGTCTGATCATCAACATTCGAGGAGGCAACAATCTGGCAGCTGAG\nCTAGAAGCCAACCTCGGCCTCATTGAAGAAATTTCAGGGTATCTAAAAATCCGCCGATCC\nTACGCTCTGGTGTCACTTTCCTTCTTCCGGAAGTTACGTCTGATTCGAGGAGAGACCTTG\nGAAATTGGGAACTACTCCTTCTATGCCTTGGACAACCAGAACCTAAGGCAGCTCTGGGAC\nTGGAGCAAACACAACCTCACCACCACTCAGGGGAAACTCTTCTTCCACTATAACCCCAAA\nCTCTGCTTGTCAGAAATCCACAAGATGGAAGAAGTTTCAGGAACCAAGGGGCGCCAGGAG\nAGAAACGACATTGCCCTGAAGACCAATGGGGACAAGGCATCCTGTGAAAATGAGTTACTT\nAAATTTTCTTACATTCGGACATCTTTTGACAAGATCTTGCTGAGATGGGAGCCGTACTGG\nCCCCCCGACTTCCGAGACCTCTTGGGGTTCATGCTGTTCTACAAAGAGGCCCCTTATCAG\nAATGTGACGGAGTTCGATGGGCAGGATGCGTGTGGTTCCAACAGTTGGACGGTGGTAGAC\nATTGACCCACCCCTGAGGTCCAACGACCCCAAATCACAGAACCACCCAGGGTGGCTGATG\nCGGGGTCTCAAGCCCTGGACCCAGTATGCCATCTTTGTGAAGACCCTGGTCACCTTTTCG\nGATGAACGCCGGACCTATGGGGCCAAGAGTGACATCATTTATGTCCAGACAGATGCCACC\nAACCCCTCTGTGCCCCTGGATCCAATCTCAGTGTCTAACTCATCATCCCAGATTATTCTG\nAAGTGGAAACCACCCTCCGACCCCAATGGCAACATCACCCACTACCTGGTTTTCTGGGAG\nAGGCAGGCGGAAGACAGTGAGCTGTTCGAGCTGGATTATTGCCTCAAAGGGCTGAAGCTG\nCCCTCGAGGACCTGGTCTCCACCATTCGAGTCTGAAGATTCTCAGAAGCACAACCAGAGT\nGAGTATGAGGATTCGGCCGGCGAATGCTGCTCCTGTCCAAAGACAGACTCTCAGATCCTG\nAAGGAGCTGGAGGAGTCCTCGTTTAGGAAGACGTTTGAGGATTACCTGCACAACGTGGTT\nTTCGTCCCCAGAAAAACCTCTTCAGGCACTGGTGCCGAGGACCCTAGGCCATCTCGGAAA\nCGCAGGTCCCTTGGCGATGTTGGGAATGTGACGGTGGCCGTGCCCACGGTGGCAGCTTTC\nCCCAACACTTCCTCGACCAGCGTGCCCACGAGTCCGGAGGAGCACAGGCCTTTTGAGAAG\nGTGGTGAACAAGGAGTCGCTGGTCATCTCCGGCTTGCGACACTTCACGGGCTATCGCATC\nGAGCTGCAGGCTTGCAACCAGGACACCCCTGAGGAACGGTGCAGTGTGGCAGCCTACGTC\nAGTGCGAGGACCATGCCTGAAGCCAAGGCTGATGACATTGTTGGCCCTGTGACGCATGAA\nATCTTTGAGAACAACGTCGTCCACTTGATGTGGCAGGAGCCGAAGGAGCCCAATGGTCTG\nATCGTGCTGTATGAAGTGAGTTATCGGCGATATGGTGATGAGGAGCTGCATCTCTGCGTC\nTCCCGCAAGCACTTCGCTCTGGAACGGGGCTGCAGGCTGCGTGGGCTGTCACCGGGGAAC\nTACAGCGTGCGAATCCGGGCCACCTCCCTTGCGGGCAACGGCTCTTGGACGGAACCCACC\nTATTTCTACGTGACAGACTATTTAGACGTCCCGTCAAATATTGCAAAAATTATCATCGGC\nCCCCTCATCTTTGTCTTTCTCTTCAGTGTTGTGATTGGAAGTATTTATCTATTCCTGAGA\nAAGAGGCAGCCAGATGGGCCGCTGGGACCGCTTTACGCTTCTTCAAACCCTGAGTATCTC\nAGTGCCAGTGATGTGTTTCCATGCTCTGTGTACGTGCCGGACGAGTGGGAGGTGTCTCGA\nGAGAAGATCACCCTCCTTCGAGAGCTGGGGCAGGGCTCCTTCGGCATGGTGTATGAGGGC\nAATGCCAGGGACATCATCAAGGGTGAGGCAGAGACCCGCGTGGCGGTGAAGACGGTCAAC\nGAGTCAGCCAGTCTCCGAGAGCGGATTGAGTTCCTCAATGAGGCCTCGGTCATGAAGGGC\nTTCACCTGCCATCACGTGGTGCGCCTCCTGGGAGTGGTGTCCAAGGGCCAGCCCACGCTG\nGTGGTGATGGAGCTGATGGCTCACGGAGACCTGAAGAGCTACCTCCGTTCTCTGCGGCCA\nGAGGCTGAGAATAATCCTGGCCGCCCTCCCCCTACCCTTCAAGAGATGATTCAGATGGCG\nGCAGAGATTGCTGACGGGATGGCCTACCTGAACGCCAAGAAGTTTGTGCATCGGGACCTG\nGCAGCGAGAAACTGCATGGTCGCCCATGATTTTACTGTCAAAATTGGAGACTTTGGAATG\nACCAGAGACATCTATGAAACGGATTACTACCGGAAAGGGGGCAAGGGTCTGCTCCCTGTA\nCGGTGGATGGCACCGGAGTCCCTGAAGGATGGGGTCTTCACCACTTCTTCTGACATGTGG\nTCCTTTGGCGTGGTCCTTTGGGAAATCACCAGCTTGGCAGAACAGCCTTACCAAGGCCTG\nTCTAATGAACAGGTGTTGAAATTTGTCATGGATGGAGGGTATCTGGATCAACCCGACAAC\nTGTCCAGAGAGAGTCACTGACCTCATGCGCATGTGCTGGCAATTCAACCCCAAGATGAGG\nCCAACCTTCCTGGAGATTGTCAACCTGCTCAAGGACGACCTGCACCCCAGCTTTCCAGAG\nGTGTCGTTCTTCCACAGCGAGGAGAACAAGGCTCCCGAGAGTGAGGAGCTGGAGATGGAG\nTTTGAGGACATGGAGAATGTGCCCCTGGACCGTTCCTCGCACTGTCAGAGGGAGGAGGCG\nGGGGGCCGGGATGGAGGGTCCTCGCTGGGTTTCAAGCGGAGCTACGAGGAACACATCCCT\nTACACACACATGAACGGAGGCAAGAAAAACGGGCGGATTCTGACCTTGCCTCGGTCCAAT\nCCTTCCTAA"}, "pfams": {"pfam": [{"identifier": "PF07714", "name": "Pkinase_Tyr"}, {"identifier": "PF00041", "name": "fn3"}, {"identifier": "PF00757", "name": "Furin-like"}, {"identifier": "PF01030", "name": "Recep_L_domain"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "protein-tyrosine kinase activity"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "transferase activity, transferring phosphorus-containing groups"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "function", "description": "kinase activity"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "transferase activity"}, {"category": "function", "description": "protein kinase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "transmembrane receptor protein tyrosine kinase activity"}, {"category": "function", "description": "epidermal growth factor receptor activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "protein amino acid phosphorylation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "enzyme linked receptor protein signaling pathway"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "transmembrane receptor protein tyrosine kinase signaling pathway"}, {"category": "process", "description": "biopolymer metabolism"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "biopolymer modification"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "protein modification"}]}}}, {"@position": "1", "id": "BE0000858", "name": "Insulin-like growth factor 1 receptor", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Smith TJ: Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev. 2010 Jun;62(2):199-236. Epub 2010 Apr 14. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20392809", "known-action": "unknown", "polypeptide": {"@id": "P08069", "@source": "Swiss-Prot", "name": "Insulin-like growth factor 1 receptor", "general-function": "Involved in transmembrane receptor protein tyrosine kinase activity", "specific-function": "This receptor binds insulin-like growth factor 1 (IGF1) with a high affinity and IGF2 with a lower affinity. It has a tyrosine-protein kinase activity, which is necessary for the activation of the IGF1-stimulated downstream signaling cascade", "gene-name": "IGF1R", "locus": "15q26.3", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "936-959", "signal-regions": null, "theoretical-pi": "5.54", "molecular-weight": "154795.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5465"}, {"resource": "GenAtlas", "identifier": "IGF1R"}, {"resource": "GeneCards", "identifier": "IGF1R"}, {"resource": "GenBank Gene Database", "identifier": "X04434"}, {"resource": "GenBank Protein Database", "identifier": "804990"}, {"resource": "UniProtKB", "identifier": "P08069"}, {"resource": "UniProt Accession", "identifier": "IGF1R_HUMAN"}]}, "synonyms": {"synonym": ["CD221 antigen", "EC 2.7.10.1", "IGF-I receptor", "Insulin-like growth factor 1 receptor precursor", "Insulin-like growth factor I receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Insulin-like growth factor 1 receptor precursor\nMKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLH\nILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIF\nEMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGD\nLCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCS\nAPDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHD\nGECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNL\nLINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSF\nYVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTR\nNNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDG\nQDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSE\nILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRH\nNYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRK\nVFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFES\nRVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTW\nEPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGN\nYTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHR\nKRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKG\nVVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIME\nLMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARN\nCMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGV\nVLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFL\nEIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRH\nSGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC"}, "gene-sequence": {"@format": "FASTA", "#text": ">4104 bp\nATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCC\nGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGC\nAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCAC\nATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTC\nATTACCGAGTACTTGCTGCTGTTCCGAGTGGCTGGCCTCGAGAGCCTCGGAGACCTCTTC\nCCCAACCTCACGGTCATCCGCGGCTGGAAACTCTTCTACAACTACGCCCTGGTCATCTTC\nGAGATGACCAATCTCAAGGATATTGGGCTTTACAACCTGAGGAACATTACTCGGGGGGCC\nATCAGGATTGAGAAAAATGCTGACCTCTGTTACCTCTCCACTGTGGACTGGTCCCTGATC\nCTGGATGCGGTGTCCAATAACTACATTGTGGGGAATAAGCCCCCAAAGGAATGTGGGGAC\nCTGTGTCCAGGGACCATGGAGGAGAAGCCGATGTGTGAGAAGACCACCATCAACAATGAG\nTACAACTACCGCTGCTGGACCACAAACCGCTGCCAGAAAATGTGCCCAAGCACGTGTGGG\nAAGCGGGCGTGCACCGAGAACAATGAGTGCTGCCACCCCGAGTGCCTGGGCAGCTGCAGC\nGCGCCTGACAACGACACGGCCTGTGTAGCTTGCCGCCACTACTACTATGCCGGTGTCTGT\nGTGCCTGCCTGCCCGCCCAACACCTACAGGTTTGAGGGCTGGCGCTGTGTGGACCGTGAC\nTTCTGCGCCAACATCCTCAGCGCCGAGAGCAGCGACTCCGAGGGGTTTGTGATCCACGAC\nGGCGAGTGCATGCAGGAGTGCCCCTCGGGCTTCATCCGCAACGGCAGCCAGAGCATGTAC\nTGCATCCCTTGTGAAGGTCCTTGCCCGAAGGTCTGTGAGGAAGAAAAGAAAACAAAGACC\nATTGATTCTGTTACTTCTGCTCAGATGCTCCAAGGATGCACCATCTTCAAGGGCAATTTG\nCTCATTAACATCCGACGGGGGAATAACATTGCTTCAGAGCTGGAGAACTTCATGGGGCTC\nATCGAGGTGGTGACGGGCTACGTGAAGATCCGCCATTCTCATGCCTTGGTCTCCTTGTCC\nTTCCTAAAAAACCTTCGCCTCATCCTAGGAGAGGAGCAGCTAGAAGGGAATTACTCCTTC\nTACGTCCTCGACAACCAGAACTTGCAGCAACTGTGGGACTGGGACCACCGCAACCTGACC\nATCAAAGCAGGGAAAATGTACTTTGCTTTCAATCCCAAATTATGTGTTTCCGAAATTTAC\nCGCATGGAGGAAGTGACGGGGACTAAAGGGCGCCAAAGCAAAGGGGACATAAACACCAGG\nAACAACGGGGAGAGAGCCTCCTGTGAAAGTGACGTCCTGCATTTCACCTCCACCACCACG\nTCGAAGAATCGCATCATCATAACCTGGCACCGGTACCGGCCCCCTGACTACAGGGATCTC\nATCAGCTTCACCGTTTACTACAAGGAAGCACCCTTTAAGAATGTCACAGAGTATGATGGG\nCAGGATGCCTGCGGCTCCAACAGCTGGAACATGGTGGACGTGGACCTCCCGCCCAACAAG\nGACGTGGAGCCCGGCATCTTACTACATGGGCTGAAGCCCTGGACTCAGTACGCCGTTTAC\nGTCAAGGCTGTGACCCTCACCATGGTGGAGAACGACCATATCCGTGGGGCCAAGAGTGAG\nATCTTGTACATTCGCACCAATGCTTCAGTTCCTTCCATTCCCTTGGACGTTCTTTCAGCA\nTCGAACTCCTCTTCTCAGTTAATCGTGAAGTGGAACCCTCCCTCTCTGCCCAACGGCAAC\nCTGAGTTACTACATTGTGCGCTGGCAGCGGCAGCCTCAGGACGGCTACCTTTACCGGCAC\nAATTACTGCTCCAAAGACAAAATCCCCATCAGGAAGTATGCCGACGGCACCATCGACATT\nGAGGAGGTCACAGAGAACCCCAAGACTGAGGTGTGTGGTGGGGAGAAAGGGCCTTGCTGC\nGCCTGCCCCAAAACTGAAGCCGAGAAGCAGGCCGAGAAGGAGGAGGCTGAATACCGCAAA\nGTCTTTGAGAATTTCCTGCACAACTCCATCTTCGTGCCCAGACCTGAAAGGAAGCGGAGA\nGATGTCATGCAAGTGGCCAACACCACCATGTCCAGCCGAAGCAGGAACACCACGGCCGCA\nGACACCTACAACATCACCGACCCGGAAGAGCTGGAGACAGAGTACCCTTTCTTTGAGAGC\nAGAGTGGATAACAAGGAGAGAACTGTCATTTCTAACCTTCGGCCTTTCACATTGTACCGC\nATCGATATCCACAGCTGCAACCACGAGGCTGAGAAGCTGGGCTGCAGCGCCTCCAACTTC\nGTCTTTGCAAGGACTATGCCCGCAGAAGGAGCAGATGACATTCCTGGGCCAGTGACCTGG\nGAGCCAAGGCCTGAAAACTCCATCTTTTTAAAGTGGCCGGAACCTGAGAATCCCAATGGA\nTTGATTCTAATGTATGAAATAAAATACGGATCACAAGTTGAGGATCAGCGAGAATGTGTG\nTCCAGACAGGAATACAGGAAGTATGGAGGGGCCAAGCTAAACCGGCTAAACCCGGGGAAC\nTACACAGCCCGGATTCAGGCCACATCTCTCTCTGGGAATGGGTCGTGGACAGATCCTGTG\nTTCTTCTATGTCCAGGCCAAAACAGGATATGAAAACTTCATCCATCTGATCATCGCTCTG\nCCCGTCGCTGTCCTGTTGATCGTGGGAGGGTTGGTGATTATGCTGTACGTCTTCCATAGA\nAAGAGAAATAACAGCAGGCTGGGGAATGGAGTGCTGTATGCCTCTGTGAACCCGGAGTAC\nTTCAGCGCTGCTGATGTGTACGTTCCTGATGAGTGGGAGGTGGCTCGGGAGAAGATCACC\nATGAGCCGGGAACTTGGGCAGGGGTCGTTTGGGATGGTCTATGAAGGAGTTGCCAAGGGT\nGTGGTGAAAGATGAACCTGAAACCAGAGTGGCCATTAAAACAGTGAACGAGGCCGCAAGC\nATGCGTGAGAGGATTGAGTTTCTCAACGAAGCTTCTGTGATGAAGGAGTTCAATTGTCAC\nCATGTGGTGCGATTGCTGGGTGTGGTGTCCCAAGGCCAGCCAACACTGGTCATCATGGAA\nCTGATGACACGGGGCGATCTCAAAAGTTATCTCCGGTCTCTGAGGCCAGAAATGGAGAAT\nAATCCAGTCCTAGCACCTCCAAGCCTGAGCAAGATGATTCAGATGGCCGGAGAGATTGCA\nGACGGCATGGCATACCTCAACGCCAATAAGTTCGTCCACAGAGACCTTGCTGCCCGGAAT\nTGCATGGTAGCCGAAGATTTCACAGTCAAAATCGGAGATTTTGGTATGACGCGAGATATC\nTATGAGACAGACTATTACCGGAAAGGAGGCAAAGGGCTGCTGCCCGTGCGCTGGATGTCT\nCCTGAGTCCCTCAAGGATGGAGTCTTCACCACTTACTCGGACGTCTGGTCCTTCGGGGTC\nGTCCTCTGGGAGATCGCCACACTGGCCGAGCAGCCCTACCAGGGCTTGTCCAACGAGCAA\nGTCCTTCGCTTCGTCATGGAGGGCGGCCTTCTGGACAAGCCAGACAACTGTCCTGACATG\nCTGTTTGAACTGATGCGCATGTGCTGGCAGTATAACCCCAAGATGAGGCCTTCCTTCCTG\nGAGATCATCAGCAGCATCAAAGAGGAGATGGAGCCTGGCTTCCGGGAGGTCTCCTTCTAC\nTACAGCGAGGAGAACAAGCTGCCCGAGCCGGAGGAGCTGGACCTGGAGCCAGAGAACATG\nGAGAGCGTCCCCCTGGACCCCTCGGCCTCCTCGTCCTCCCTGCCACTGCCCGACAGACAC\nTCAGGACACAAGGCCGAGAACGGCCCCGGCCCTGGGGTGCTGGTCCTCCGCGCCAGCTTC\nGACGAGAGACAGCCTTACGCCCACATGAACGGGGGCCGCAAGAACGAGCGGGCCTTGCCG\nCTGCCCCAGTCTTCGACCTGCTGA"}, "pfams": {"pfam": [{"identifier": "PF07714", "name": "Pkinase_Tyr"}, {"identifier": "PF00041", "name": "fn3"}, {"identifier": "PF00757", "name": "Furin-like"}, {"identifier": "PF01030", "name": "Recep_L_domain"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "protein-tyrosine kinase activity"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "transferase activity, transferring phosphorus-containing groups"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "function", "description": "kinase activity"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "transferase activity"}, {"category": "function", "description": "protein kinase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "transmembrane receptor protein tyrosine kinase activity"}, {"category": "function", "description": "epidermal growth factor receptor activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "protein amino acid phosphorylation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "enzyme linked receptor protein signaling pathway"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "transmembrane receptor protein tyrosine kinase signaling pathway"}, {"category": "process", "description": "biopolymer metabolism"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "biopolymer modification"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "protein modification"}]}}}]}, "enzymes": {"enzyme": {"id": "BE0002433", "name": "Cytochrome P450 1A2", "organism": "Human", "actions": {"action": "inducer"}, "references": "# Flockhart DA. \"Drug Interactions: Cytochrome P450 Drug Interaction Table\":http://medicine.iupui.edu/clinpharm/ddis/table.asp. Indiana University School of Medicine (2007). Accessed May 28, 2010.", "known-action": "unknown", "polypeptide": {"@id": "P05177", "@source": "Swiss-Prot", "name": "Cytochrome P450 1A2", "general-function": "Involved in monooxygenase activity", "specific-function": "Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen", "gene-name": "CYP1A2", "locus": "15q24", "cellular-location": "Endoplasmic reticulum", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.43", "molecular-weight": "58295.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2596"}, {"resource": "GenAtlas", "identifier": "CYP1A2"}, {"resource": "GenBank Gene Database", "identifier": "Z00036"}, {"resource": "UniProtKB", "identifier": "P05177"}, {"resource": "UniProt Accession", "identifier": "CP1A2_HUMAN"}]}, "synonyms": {"synonym": ["CYPIA2", "EC 1.14.14.1", "P(3)450", "P450 4", "P450-P3"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytochrome P450 1A2\nMALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN\nPHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG\nQSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM\nAGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP\nILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN\nLIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS\nDRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL\nWEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE\nFSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN"}, "gene-sequence": {"@format": "FASTA", "#text": ">1548 bp\nATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCTGCCATC\nTTCTGCCTGGTATTCTGGGTGCTCAAGGGTTTGAGGCCTCGGGTCCCCAAAGGCCTGAAA\nAGTCCACCAGAGCCATGGGGCTGGCCCTTGCTCGGGCATGTGCTGACCCTGGGGAAGAAC\nCCGCACCTGGCACTGTCAAGGATGAGCCAGCGCTACGGGGACGTCCTGCAGATCCGCATT\nGGCTCCACGCCCGTGCTGGTGCTGAGCCGCCTGGACACCATCCGGCAGGCCCTGGTGCGG\nCAGGGCGACGATTTCAAGGGCCGGCCTGACCTCTACACCTCCACCCTCATCACTGATGGC\nCAGAGCTTGACCTTCAGCACAGACTCTGGACCGGTGTGGGCTGCCCGCCGGCGCCTGGCC\nCAGAATGCCCTCAACACCTTCTCCATCGCCTCTGACCCAGCTTCCTCATCCTCCTGCTAC\nCTGGAGGAGCATGTGAGCAAGGAGGCTAAGGCCCTGATCAGCAGGTTGCAGGAGCTGATG\nGCAGGGCCTGGGCACTTCGACCCTTACAATCAGGTGGTGGTGTCAGTGGCCAACGTCATT\nGGTGCCATGTGCTTCGGACAGCACTTCCCTGAGAGTAGCGATGAGATGCTCAGCCTCGTG\nAAGAACACTCATGAGTTCGTGGAGACTGCCTCCTCCGGGAACCCCCTGGACTTCTTCCCC\nATCCTTCGCTACCTGCCTAACCCTGCCCTGCAGAGGTTCAAGGCCTTCAACCAGAGGTTC\nCTGTGGTTCCTGCAGAAAACAGTCCAGGAGCACTATCAGGACTTTGACAAGAACAGTGTC\nCGGGACATCACGGGTGCCCTGTTCAAGCACAGCAAGAAGGGGCCTAGAGCCAGCGGCAAC\nCTCATCCCACAGGAGAAGATTGTCAACCTTGTCAATGACATCTTTGGAGCAGGATTTGAC\nACAGTCACCACAGCCATCTCCTGGAGCCTCATGTACCTTGTGACCAAGCCTGAGATACAG\nAGGAAGATCCAGAAGGAGCTGGACACTGTGATTGGCAGGGAGCGGCGGCCCCGGCTCTCT\nGACAGACCCCAGCTGCCCTACTTGGAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCC\nTTCTTGCCCTTCACCATCCCCCACAGCACAACAAGGGACACAACGCTGAATGGCTTCTAC\nATCCCCAAGAAATGCTGTGTCTTCGTAAACCAGTGGCAGGTCAACCATGACCCAGAGCTG\nTGGGAGGACCCCTCTGAGTTCCGGCCTGAGCGGTTCCTCACCGCCGATGGCACTGCCATT\nAACAAGCCCTTGAGTGAGAAGATGATGCTGTTTGGCATGGGCAAGCGCCGGTGTATCGGG\nGAAGTCCTGGCCAAGTGGGAGATCTTCCTCTTCCTGGCCATCCTGCTACAGCAACTGGAG\nTTCAGCGTGCCGCCGGGCGTGAAAGTCGACCTGACCCCCATCTACGGGCTGACCATGAAG\nCACGCCCGCTGTGAACATGTCCAGGCGCGGCGCTTCTCCATCAATTGA"}, "pfams": {"pfam": {"identifier": "PF00067", "name": "p450"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "iron ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "tetrapyrrole binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "heme binding"}, {"category": "function", "description": "monooxygenase activity"}, {"category": "function", "description": "oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "generation of precursor metabolites and energy"}, {"category": "process", "description": "electron transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}}, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2015-09-22", "drugbank-id": [{"@primary": "true", "#text": "DB00048"}, "BIOD00010", "BTD00010"], "name": "Collagenase clostridium histolyticum", "description": "Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum that dismantles collagen. It is used as a powder-and-solvent injection kit for the treatment of Dupuytren's contracture, a condition where the fingers bend towards the palm and cannot be fully straightened, and Peyronie's disease, a connective tissue disorder involving the growth of fibrous plaques in the soft tissue of the penis. BioSpecifics Technologies developed the preparation, which is manufactured and marketed by Auxilium Pharmaceuticals as Xiaflex in the US and by Sobi as Xiapex in Europe.", "cas-number": "9001-12-1", "groups": {"group": ["approved", "investigational"]}, "general-references": "# Norris DB, Trudgill PW: Multiple forms of cyclohexanone oxygenase from Nocardia globerula CL1. Eur J Biochem. 1976 Mar 16;63(1):193-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/4312\n# Pajot P: Fluroescence of proteins in 6-M guanidine hydrochloride. A method for the quantitative determination of tryptophan. Eur J Biochem. 1976 Mar 16;63(1):263-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/4317", "synthesis-reference": "Hun-Chi Lin, Shau-Ping Lei, \"Molecular cloning of the genes responsible for collagenase production from Clostridium histolyticum.\" U.S. Patent US5177017, issued December, 1972.", "indication": "Used to promote debridement of necrotic tissue in the treatment of severe burns and dermal ulcers including decubitus ulcers.", "pharmacodynamics": "Used in the treatment of skin ulcers and sever burns, collagenase is able to digest collagen in necrotic tissue at physiological pH by hydrolyzing the peptide bonds of undenatured and denatured collagen. Collagenase thus contributes towards the formation of granulation tissue and subsequent epithelization of dermal ulcers and severely burned areas. The action of collagenase may remove substrates necessary for bacterial proliferation or may permit antibodies, leukocytes, and antibiotics better access to the infected area.", "mechanism-of-action": "Collagenase is a protease that is specific to collagen. The triple helical region of interstitial collagens is highly resistant to most cell proteinases. However, during remodeling of the connective tissue in such processes as wound healing and metastasis, collagen becomes susceptible to cleavage by collagenases. Collagenase cleaves all 3 alpha helical chains of native Types I, II and III collagens at a single locus by hydrolyzing the peptide bond following the Gly residue of the sequence: Gly 775-(Ile or Leu) 776-(Ala or Leu) 777 located approximately three-fourths of the chain length from each N-terminus", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": {"product": [{"name": "Collagenase Santyl", "ndc-id": "50484-010_02a922f5-5f34-4784-95ed-fd20dcfe5cfb", "ndc-product-code": "50484-010", "dpd-id": null, "started-marketing-on": "2012-12-21", "ended-marketing-on": null, "dosage-form": "ointment", "strength": "250 [arb'U]/g", "route": "topical", "fda-application-number": "BLA101995", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Collagenase Santyl", "ndc-id": "0064-5010_4a7d5058-59c6-410e-8dec-e30d05a072ca", "ndc-product-code": "0064-5010", "dpd-id": null, "started-marketing-on": "2006-10-18", "ended-marketing-on": null, "dosage-form": "ointment", "strength": "250 [arb'U]/g", "route": "topical", "fda-application-number": "BLA101995", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Xiaflex", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02388316", "started-marketing-on": "2012-11-14", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "0.9 mg", "route": "intralesional", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": [{"name": "Cordase", "company": null}, {"name": "Santyl", "company": "Advance Biofactures Corp"}, {"name": "Xiapex", "company": "Sobi"}]}, "mixtures": {"mixture": [{"name": "Collagenase Santyl", "ingredients": "Collagenase clostridium histolyticum"}, {"name": "Collagenase Santyl", "ingredients": "Collagenase clostridium histolyticum"}, {"name": "Xiaflex", "ingredients": "Collagenase clostridium histolyticum"}]}, "packagers": {"packager": [{"name": "Abbott Laboratories Ltd.", "url": "http://www.abbott.com"}, {"name": "Advance Biofactures Corp.", "url": null}, {"name": "Auxilium Pharmaceuticals", "url": "http://www.auxilium.com"}, {"name": "BASF Corp.", "url": "http://BASF Corp."}, {"name": "Dispensing Solutions", "url": "http://www.drxdispensing.com"}, {"name": "Healthpoint Ltd.", "url": "http://www.healthpoint.com"}, {"name": "Medisca Inc.", "url": "http://www.medisca.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Santyl ointment", "cost": {"@currency": "USD", "#text": "4.13"}, "unit": "g"}, {"description": "Santyl 250 unit/gm Ointment 15 gm Tube", "cost": {"@currency": "USD", "#text": "62.98"}, "unit": "tube"}, {"description": "Collagenase powder", "cost": {"@currency": "USD", "#text": "2432.7"}, "unit": "g"}, {"description": "Xiaflex 0.9 mg vial", "cost": {"@currency": "USD", "#text": "3900.0"}, "unit": "vial"}]}, "categories": null, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Ointment", "route": "topical", "strength": "250 [arb'U]/g"}, {"form": "Powder for solution", "route": "intralesional", "strength": "0.9 mg"}]}, "atc-codes": {"atc-code": [{"@code": "M09AB02", "level": [{"@code": "M", "#text": "MUSCULO-SKELETAL SYSTEM"}, {"@code": "M09", "#text": "OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM"}, {"@code": "M09A", "#text": "OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM"}, {"@code": "M09AB", "#text": "Enzymes"}]}, {"@code": "D03BA02", "level": [{"@code": "D", "#text": "DERMATOLOGICALS"}, {"@code": "D03", "#text": "PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS"}, {"@code": "D03B", "#text": "ENZYMES"}, {"@code": "D03BA", "#text": "Proteolytic enzymes"}]}]}, "ahfs-codes": {"ahfs-code": "84:92.00"}, "patents": null, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00054", "name": "Abciximab", "description": "May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased."}, {"drugbank-id": "DB01418", "name": "Acenocoumarol", "description": "May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased."}, {"drugbank-id": "DB04272", "name": "Citric Acid", "description": "May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased."}, {"drugbank-id": "DB06779", "name": "Dalteparin", "description": "May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased."}, {"drugbank-id": "DB00266", "name": "Dicoumarol", "description": "May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased."}, {"drugbank-id": "DB00974", "name": "Edetic Acid", "description": "May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased."}, {"drugbank-id": "DB01225", "name": "Enoxaparin", "description": "May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased."}, {"drugbank-id": "DB08794", "name": "Ethyl biscoumacetate", "description": "May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased."}, {"drugbank-id": "DB00569", "name": "Fondaparinux sodium", "description": "May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased."}, {"drugbank-id": "DB01109", "name": "Heparin", "description": "May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased."}, {"drugbank-id": "DB00498", "name": "Phenindione", "description": "May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased."}, {"drugbank-id": "DB00946", "name": "Phenprocoumon", "description": "May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased."}, {"drugbank-id": "DB06271", "name": "Sulodexide", "description": "May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased."}, {"drugbank-id": "DB00374", "name": "Treprostinil", "description": "May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased."}, {"drugbank-id": "DB00682", "name": "Warfarin", "description": "May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": "> Collagenase Sequence \nMKRKCLSKRLMLAITMATIFTVNSTLPIYAAVDKNNATAAVQNESKRYTVSYLKTLNYYD\nLVDLLVKTEIENLPDLFQYSSDAKEFYGNKTRMSFIMDEIGRRAPQYTEIDHKGIPTLVE\nVVRAGFYLGFHNKELNEINKRSFKERVIPSILAIQKNPNFKLGTEVQDKIVSATGLLAGN\nETAPPEVVNNFTPILQDCIKNIDRYALDDLKSKALFNVLAAPTYDITEYLRATKEKPENT\nPWYGKIDGFINELKKLALYGKINDNNSWIIDNGIYHIAPLGKLHSNNKIGIETLTEVMKV\nYPYLSMQHLQSADQIKRHYDSKDAEGNKIPLDKFKKEGKEKYCPKTYTFDDGKVIIKAGA\nRVEEEKVKRLYWASKEVNSQFFRVYGIDKPLEEGNPDDILTMVIYNSPEEYKLNSVLYGY\nDTNNGGMYIEPEGTFFTYEREAQESTYTLEELFRHEYTHYLQGRYAVPGQWGRTKLYDND\nRLTWYEEGGAELFAGSTRTSGILPRKSIVSNIHNTTRNNRYKLSDTVHSKYGASFEFYNY\nACMFMDYMYNKDMGILNKLNDLAKNNDVDGYDNYIRDLSSNYALNDKYQDHMQERIDNYE\nNLTVPFVADDYLVRHAYKNPNEIYSEISEVAKLKDAKSEVKKSQYFSTFTLRGSYTGGAS\nKGKLEDQKAMNKFIDDSLKKLDTYSWSGYKTLTAYFTNYKVDSSNRVTYDVVFHGYLPNE\nGDSKNSLPYGKINGTYKGTEKEKIKFSSEGSFDPDGKIVSYEWDFGDGNKSNEENPEHSY\nDKVGTYTVKLKVTDDKGESSVSTTTAEIKDLSENKLPVIYMHVPKSGALNQKVVFYGKGT\nYDPDGSIAGYQWDFGDGSDFSSEQNPSHVYTKKGEYTVTLRVMDSSGQMSEKTMKIKITD\nPVYPIGTEKEPNNSKETASGPIVPGIPVSGTIENTSDQDYFYFDVITPGEVKIDINKLGY\nGGATWVVYDENNNAVSYATDDGQNLSGKFKADKPGRYYIHLYMFNGSYMPYRINIEGSVG\nR"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.714", "source": null}, {"kind": "Isoelectric Point", "value": "5.58", "source": null}, {"kind": "Molecular Weight", "value": "112023.2000", "source": null}, {"kind": "Molecular Formula", "value": "C5028H7666N1300O1564S21", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "21378"}, {"resource": "KEGG Compound", "identifier": "C00816"}, {"resource": "PharmGKB", "identifier": "PA449107"}, {"resource": "Wikipedia", "identifier": "Collagenase"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/collagenase.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/collagenase-ointment.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000025", "name": "Collagen alpha-1(I) chain", "organism": "Human", "actions": null, "references": "# Egeblad M, Shen HC, Behonick DJ, Wilmes L, Eichten A, Korets LV, Kheradmand F, Werb Z, Coussens LM: Type I collagen is a genetic modifier of matrix metalloproteinase 2 in murine skeletal development. Dev Dyn. 2007 Jun;236(6):1683-93. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17440987\n# Lindsey ML, Yoshioka J, MacGillivray C, Muangman S, Gannon J, Verghese A, Aikawa M, Libby P, Krane SM, Lee RT: Effect of a cleavage-resistant collagen mutation on left ventricular remodeling. Circ Res. 2003 Aug 8;93(3):238-45. Epub 2003 Jul 10. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12855673\n# Beare AH, O'Kane S, Krane SM, Ferguson MW: Severely impaired wound healing in the collagenase-resistant mouse. J Invest Dermatol. 2003 Jan;120(1):153-63. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12535212\n# Chiu CJ, Chang ML, Chiang CP, Hahn LJ, Hsieh LL, Chen CJ: Interaction of collagen-related genes and susceptibility to betel quid-induced oral submucous fibrosis. Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):646-53. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12101112\n# Beare AH, Krane SM, Ferguson MW: Variable impairment of wound healing in the heterozygous collagenase-resistant mouse. Wound Repair Regen. 2005 Jan-Feb;13(1):27-40. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15659034", "known-action": "unknown", "polypeptide": {"@id": "P02452", "@source": "Swiss-Prot", "name": "Collagen alpha-1(I) chain", "general-function": "Carbohydrate transport and metabolism", "specific-function": "Type I collagen is a member of group I collagen (fibrillar forming collagen)", "gene-name": "COL1A1", "locus": "17q21.33", "cellular-location": null, "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.56", "molecular-weight": "138885.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2197"}, {"resource": "GenAtlas", "identifier": "COL1A1"}, {"resource": "GeneCards", "identifier": "COL1A1"}, {"resource": "GenBank Gene Database", "identifier": "Z74615"}, {"resource": "GenBank Protein Database", "identifier": "1418928"}, {"resource": "UniProtKB", "identifier": "P02452"}, {"resource": "UniProt Accession", "identifier": "CO1A1_HUMAN"}]}, "synonyms": {"synonym": ["Alpha-1 type I collagen", "Collagen alpha-1(I) chain precursor", "I"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Collagen alpha-1(I) chain precursor\nMFSFVDLRLLLLLAATALLTHGQEEGQVEGQDEDIPPITCVQNGLRYHDRDVWKPEPCRI\nCVCDNGKVLCDDVICDETKNCPGAEVPEGECCPVCPDGSESPTDQETTGVEGPKGDTGPR\nGPRGPAGPPGRDGIPGQPGLPGPPGPPGPPGPPGLGGNFAPQLSYGYDEKSTGGISVPGP\nMGPSGPRGLPGPPGAPGPQGFQGPPGEPGEPGASGPMGPRGPPGPPGKNGDDGEAGKPGR\nPGERGPPGPQGARGLPGTAGLPGMKGHRGFSGLDGAKGDAGPAGPKGEPGSPGENGAPGQ\nMGPRGLPGERGRPGAPGPAGARGNDGATGAAGPPGPTGPAGPPGFPGAVGAKGEAGPQGP\nRGSEGPQGVRGEPGPPGPAGAAGPAGNPGADGQPGAKGANGAPGIAGAPGFPGARGPSGP\nQGPGGPPGPKGNSGEPGAPGSKGDTGAKGEPGPVGVQGPPGPAGEEGKRGARGEPGPTGL\nPGPPGERGGPGSRGFPGADGVAGPKGPAGERGSPGPAGPKGSPGEAGRPGEAGLPGAKGL\nTGSPGSPGPDGKTGPPGPAGQDGRPGPPGPPGARGQAGVMGFPGPKGAAGEPGKAGERGV\nPGPPGAVGPAGKDGEAGAQGPPGPAGPAGERGEQGPAGSPGFQGLPGPAGPPGEAGKPGE\nQGVPGDLGAPGPSGARGERGFPGERGVQGPPGPAGPRGANGAPGNDGAKGDAGAPGAPGS\nQGAPGLQGMPGERGAAGLPGPKGDRGDAGPKGADGSPGKDGVRGLTGPIGPPGPAGAPGD\nKGESGPSGPAGPTGARGAPGDRGEPGPPGPAGFAGPPGADGQPGAKGEPGDAGAKGDAGP\nPGPAGPAGPPGPIGNVGAPGAKGARGSAGPPGATGFPGAAGRVGPPGPSGNAGPPGPPGP\nAGKEGGKGPRGETGPAGRPGEVGPPGPPGPAGEKGSPGADGPAGAPGTPGPQGIAGQRGV\nVGLPGQRGERGFPGLPGPSGEPGKQGPSGASGERGPPGPMGPPGLAGPPGESGREGAPGA\nEGSPGRDGSPGAKGDRGETGPAGPPGAPGAPGAPGPVGPAGKSGDRGETGPAGPAGPVGP\nAGARGPAGPQGPRGDKGETGEQGDRGIKGHRGFSGLQGPPGPPGSPGEQGPSGASGPAGP\nRGPPGSAGAPGKDGLNGLPGPIGPPGPRGRTGDAGPVGPPGPPGPPGPPGPPSAGFDFSF\nLPQPPQEKAHDGGRYYRADDANVVRDRDLEVDTTLKSLSQQIENIRSPEGSRKNPARTCR\nDLKMCHSDWKSGEYWIDPNQGCNLDAIKVFCNMETGETCVYPTQPSVAQKNWYISKNPKD\nKRHVWFGESMTDGFQFEYGGQGSDPADVAIQLTFLRLMSTEASQNITYHCKNSVAYMDQQ\nTGNLKKALLLKGSNEIEIRAEGNSRFTYSVTVDGCTSHTGAWGKTVIEYKTTKTSRLPII\nDVAPLDVGAPDQEFGFDVGPVCFL"}, "gene-sequence": {"@format": "FASTA", "#text": ">4395 bp\nATGTTCAGCTTTGTGGACCTCCGGCTCCTGCTCCTCTTAGCGGCCACCGCCCTCCTGACG\nCACGGCCAAGAGGAAGGCCAAGTCGAGGGCCAAGACGAAGACATCCCACCAATCACCTGC\nGTACAGAACGGCCTCAGGTACCATGACCGAGACGTGTGGAAACCCGAGCCCTGCCGGATC\nTGCGTCTGCGACAACGGCAAGGTGTTGTGCGATGACGTGATCTGTGACGAGACCAAGAAC\nTGCCCCGGCGCCGAAGTCCCCGAGGGCGAGTGCTGTCCCGTCTGCCCCGACGGCTCAGAG\nTCACCCACCGACCAAGAAACCACCGGCGTCGAGGGACCCAAGGGAGACACTGGCCCCCGA\nGGCCCAAGGGGACCCGCAGGCCCCCCTGGCCGAGATGGCATCCCTGGACAGCCTGGACTT\nCCCGGACCCCCCGGACCCCCCGGACCTCCCGGACCCCCTGGCCTCGGAGGAAACTTTGCT\nCCCCAGCTGTCTTATGGCTATGATGAGAAATCAACCGGAGGAATTTCCGTGCCTGGCCCC\nATGGGTCCCTCTGGTCCTCGTGGTCTCCCTGGCCCCCCTGGTGCACCTGGTCCCCAAGGC\nTTCCAAGGTCCCCCTGGTGAGCCTGGCGAGCCTGGAGCTTCAGGTCCCATGGGTCCCCGA\nGGTCCCCCAGGTCCCCCTGGAAAGAATGGAGATGATGGGGAAGCTGGAAAACCTGGTCGT\nCCTGGTGAGCGTGGGCCTCCTGGGCCTCAGGGTGCTCGAGGATTGCCCGGAACAGCTGGC\nCTCCCTGGAATGAAGGGACACAGAGGTTTCAGTGGTTTGGATGGTGCCAAGGGAGATGCT\nGGTCCTGCTGGTCCTAAGGGTGAGCCTGGCAGCCCTGGTGAAAATGGAGCTCCTGGTCAG\nATGGGCCCCCGTGGCCTGCCTGGTGAGAGAGGTCGCCCTGGAGCCCCTGGCCCTGCTGGT\nGCTCGTGGAAATGATGGTGCTACTGGTGCTGCCGGGCCCCCTGGTCCCACCGGCCCCGCT\nGGTCCTCCTGGCTTCCCTGGTGCTGTTGGTGCTAAGGGTGAAGCTGGTCCCCAAGGGCCC\nCGAGGCTCTGAAGGTCCCCAGGGTGTGCGTGGTGAGCCTGGCCCCCCTGGCCCTGCTGGT\nGCTGCTGGCCCTGCTGGAAACCCTGGTGCTGATGGACAGCCTGGTGCTAAAGGTGCCAAT\nGGTGCTCCTGGTATTGCTGGTGCTCCTGGCTTCCCTGGTGCCCGAGGCCCCTCTGGACCC\nCAGGGCCCCGGCGGCCCTCCTGGTCCCAAGGGTAACAGCGGTGAACCTGGTGCTCCTGGC\nAGCAAAGGAGACACTGGTGCTAAGGGAGAGCCTGGCCCTGTTGGTGTTCAAGGACCCCCT\nGGCCCTGCTGGAGAGGAAGGAAAGCGAGGAGCTCGAGGTGAACCCGGACCCACTGGCCTG\nCCCGGACCCCCTGGCGAGCGTGGTGGACCTGGTAGCCGTGGTTTCCCTGGCGCAGATGGT\nGTTGCTGGTCCCAAGGGTCCCGCTGGTGAACGTGGTTCTCCTGGCCCCGCTGGCCCCAAA\nGGATCTCCTGGTGAAGCTGGTCGTCCCGGTGAAGCTGGTCTGCCTGGTGCCAAGGGTCTG\nACTGGAAGCCCTGGCAGCCCTGGTCCTGATGGCAAAACTGGCCCCCCTGGTCCCGCCGGT\nCAAGATGGTCGCCCCGGACCCCCAGGCCCACCTGGTGCCCGTGGTCAGGCTGGTGTGATG\nGGATTCCCTGGACCTAAAGGTGCTGCTGGAGAGCCCGGCAAGGCTGGAGAGCGAGGTGTT\nCCCGGACCCCCTGGCGCTGTCGGTCCTGCTGGCAAAGATGGAGAGGCTGGAGCTCAGGGA\nCCCCCTGGCCCTGCTGGTCCCGCTGGCGAGAGAGGTGAACAAGGCCCTGCTGGCTCCCCC\nGGATTCCAGGGTCTCCCTGGTCCTGCTGGTCCTCCAGGTGAAGCAGGCAAACCTGGTGAA\nCAGGGTGTTCCTGGAGACCTTGGCGCCCCTGGCCCCTCTGGAGCAAGAGGCGAGAGAGGT\nTTCCCTGGCGAGCGTGGTGTGCAAGGTCCCCCTGGTCCTGCTGGACCCCGAGGGGCCAAC\nGGTGCTCCCGGCAACGATGGTGCTAAGGGTGATGCTGGTGCCCCTGGAGCTCCCGGTAGC\nCAGGGCGCCCCTGGCCTTCAGGGAATGCCTGGTGAACGTGGTGCAGCTGGTCTTCCAGGG\nCCTAAGGGTGACAGAGGTGATGCTGGTCCCAAAGGTGCTGATGGCTCTCCTGGCAAAGAT\nGGCGTCCGTGGTCTGACCGGCCCCATTGGTCCTCCTGGCCCTGCTGGTGCCCCTGGTGAC\nAAGGGTGAAAGTGGTCCCAGCGGCCCTGCTGGTCCCACTGGAGCTCGTGGTGCCCCCGGA\nGACCGTGGTGAGCCTGGTCCCCCCGGCCCTGCTGGCTTTGCTGGCCCCCCTGGTGCTGAC\nGGCCAACCTGGTGCTAAAGGCGAACCTGGTGATGCTGGTGCCAAAGGCGATGCTGGTCCC\nCCTGGGCCTGCCGGACCCGCTGGACCCCCTGGCCCCATTGGTAATGTTGGTGCTCCTGGA\nGCCAAAGGTGCTCGCGGCAGCGCTGGTCCCCCTGGTGCTACTGGTTTCCCTGGTGCTGCT\nGGCCGAGTCGGTCCTCCTGGCCCCTCTGGAAATGCTGGACCCCCTGGCCCTCCTGGTCCT\nGCTGGCAAAGAAGGCGGCAAAGGTCCCCGTGGTGAGACTGGCCCTGCTGGACGTCCTGGT\nGAAGTTGGTCCCCCTGGTCCCCCTGGCCCTGCTGGCGAGAAAGGATCCCCTGGTGCTGAT\nGGTCCTGCTGGTGCTCCTGGTACTCCCGGGCCTCAAGGTATTGCTGGACAGCGTGGTGTG\nGTCGGCCTGCCTGGTCAGAGAGGAGAGAGAGGCTTCCCTGGTCTTCCTGGCCCCTCTGGT\nGAACCTGGCAAACAAGGTCCCTCTGGAGCAAGTGGTGAACGTGGTCCCCCCGGTCCCATG\nGGCCCCCCTGGATTGGCTGGACCCCCTGGTGAATCTGGACGTGAGGGGGCTCCTGCTGCC\nGAAGGTTCCCCTGGACGAGACGGTTCTCCTGGCGCCAAGGGTGACCGTGGTGAGACCGGC\nCCCGCTGGACCCCCTGGTGCTCCTGGTGCTCCTGGTGCCCCTGGCCCCGTTGGCCCTGCT\nGGCAAGAGTGGTGATCGTGGTGAGACTGGTCCTGCTGGTCCCGCCGGTCCCGTCGGCCCC\nGTCGGCGCCCGTGGCCCCGCCGGACCCCAAGGCCCCCGTGGTGACAAGGGTGAGACAGGC\nGAACAGGGCGACAGAGGCATAAAGGGTCACCGTGGCTTCTCTGGCCTCCAGGGTCCCCCT\nGGCCCTCCTGGCTCTCCTGGTGAACAAGGTCCCTCTGGAGCCTCTGGTCCTGCTGGTCCC\nCGAGGTCCCCCTGGCTCTGCTGGTGCTCCTGGCAAAGATGGACTCAACGGTCTCCCTGGC\nCCCATTGGGCCCCCTGGTCCTCGCGGTCGCACTGGTGATGCTGGTCCTGTTGGTCCCCCC\nGGCCCTCCTGGACCTCCTGGTCCCCCTGGTCCTCCCAGCGCTGGTTTCGACTTCAGCTTC\nCTGCCCCAGCCACCTCAAGAGAAGGCTCACGATGGTGGCCGCTACTACCGGGCTGATGAT\nGCCAATGTGGTTCGTGACCGTGACCTCGAGGTGGACACCACCCTCAAGAGCCTGAGCCAG\nCAGATCGAGAACATCCGGAGCCCAGAGGGAAGCCGCAAGAACCCCGCCCGCACCTGCCGT\nGACCTCAAGATGTGCCACTCTGACTGGAAGAGTGGAGAGTACTGGATTGACCCCAACCAA\nGGCTGCAACCTGGATGCCATCAAAGTCTTCTGCAACATGGAGACTGGTGAGACCTGCGTG\nTACCCCACTCAGCCCAGTGTGGCCCAGAAGAACTGGTACATCAGCAAGAACCCCAAGGAC\nAAGAGGCATGTCTGGTTCGGCGAGAGCATGACCGATGGATTCCAGTTCGAGTATGGCGGC\nCAGGGCTCCGACCCTGCCGATGTGGCCATCCAGCTGACCTTCCTGCGCCTGATGTCCACC\nGAGGCCTCCCAGAACATCACCTACCACTGCAAGAACAGCGTGGCCTACATGGACCAGCAG\nACTGGCAACCTCAAGAAGGCCCTGCTCCTCAAGGGCTCCAACGAGATCGAGATCCGCGCC\nGAGGGCAACAGCCGCTTCACCTACAGCGTCACTGTCGATGGCTGCACGAGTCACACCGGA\nGCCTGGGGCAAGACAGTGATTGAATACAAAACCACCAAGTCCTCCCGCCTGCCCATCATC\nGATGTGGCCCCCTTGGACGTTGGTGCCCCAGACCAGGAATTCGGCTTCGACGTTGGCCCT\nGTCTGCTTCCTGTAA"}, "pfams": {"pfam": [{"identifier": "PF01410", "name": "COLFI"}, {"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00093", "name": "VWC"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular matrix"}, {"category": "component", "description": "extracellular matrix (sensu Metazoa)"}, {"category": "component", "description": "cell"}, {"category": "component", "description": "collagen"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "function", "description": "extracellular matrix structural constituent"}, {"category": "function", "description": "structural molecule activity"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "cellular physiological process"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}]}}}, {"id": "BE0002140", "name": "Collagen alpha-1(II) chain", "organism": "Human", "actions": null, "references": "# Fraser A, Fearon U, Billinghurst RC, Ionescu M, Reece R, Barwick T, Emery P, Poole AR, Veale DJ: Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthritis Rheum. 2003 Nov;48(11):3085-95. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14613270\n# Imai K, Dalal SS, Hambor J, Mitchell P, Okada Y, Horton WC, D'Armiento J: Bone growth retardation in mouse embryos expressing human collagenase 1. Am J Physiol Cell Physiol. 2007 Oct;293(4):C1209-15. Epub 2007 Jul 25. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17652426\n# Verstappen SM, Poole AR, Ionescu M, King LE, Abrahamowicz M, Hofman DM, Bijlsma JW, Lafeber FP: Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. Arthritis Res Ther. 2006;8(1):R31. Epub 2006 Jan 10. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16507130\n# Martin G, Bogdanowicz P, Domagala F, Ficheux H, Pujol JP: Articular chondrocytes cultured in hypoxia: their response to interleukin-1beta and rhein, the active metabolite of diacerhein. Biorheology. 2004;41(3-4):549-61. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15299286\n# Pratta MA, Yao W, Decicco C, Tortorella MD, Liu RQ, Copeland RA, Magolda R, Newton RC, Trzaskos JM, Arner EC: Aggrecan protects cartilage collagen from proteolytic cleavage. J Biol Chem. 2003 Nov 14;278(46):45539-45. Epub 2003 Jul 30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12890681", "known-action": "unknown", "polypeptide": {"@id": "P02458", "@source": "Swiss-Prot", "name": "Collagen alpha-1(II) chain", "general-function": "Carbohydrate transport and metabolism", "specific-function": "Collagen type II is specific for cartilaginous tissues. It is essential for the normal embryonic development of the skeleton, for linear growth and for the ability of cartilage to resist compressive forces", "gene-name": "COL2A1", "locus": "12q13.11-q13.2", "cellular-location": null, "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.89", "molecular-weight": "141787.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2200"}, {"resource": "GenAtlas", "identifier": "COL2A1"}, {"resource": "GeneCards", "identifier": "COL2A1"}, {"resource": "GenBank Gene Database", "identifier": "X16468"}, {"resource": "GenBank Protein Database", "identifier": "29516"}, {"resource": "UniProtKB", "identifier": "P02458"}, {"resource": "UniProt Accession", "identifier": "CO2A1_HUMAN"}]}, "synonyms": {"synonym": ["Alpha-1 type II collagen", "Collagen alpha-1(II) chain precursor", "II"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Collagen alpha-1(II) chain\nMIRLGAPQTLVLLTLLVAAVLRCQGQDVQEAGSCVQDGQRYNDKDVWKPEPCRICVCDTG\nTVLCDDIICEDVKDCLSPEIPFGECCPICPTDLATASGQPGPKGQKGEPGDIKDIVGPKG\nPPGPQGPAGEQGPRGDRGDKGEKGAPGPRGRDGEPGTPGNPGPPGPPGPPGPPGLGGNFA\nAQMAGGFDEKAGGAQLGVMQGPMGPMGPRGPPGPAGAPGPQGFQGNPGEPGEPGVSGPMG\nPRGPPGPPGKPGDDGEAGKPGKAGERGPPGPQGARGFPGTPGLPGVKGHRGYPGLDGAKG\nEAGAPGVKGESGSPGENGSPGPMGPRGLPGERGRTGPAGAAGARGNDGQPGPAGPPGPVG\nPAGGPGFPGAPGAKGEAGPTGARGPEGAQGPRGEPGTPGSPGPAGASGNPGTDGIPGAKG\nSAGAPGIAGAPGFPGPRGPPGPQGATGPLGPKGQTGEPGIAGFKGEQGPKGEPGPAGPQG\nAPGPAGEEGKRGARGEPGGVGPIGPPGERGAPGNRGFPGQDGLAGPKGAPGERGPSGLAG\nPKGANGDPGRPGEPGLPGARGLTGRPGDAGPQGKVGPSGAPGEDGRPGPPGPQGARGQPG\nVMGFPGPKGANGEPGKAGEKGLPGAPGLRGLPGKDGETGAAGPPGPAGPAGERGEQGAPG\nPSGFQGLPGPPGPPGEGGKPGDQGVPGEAGAPGLVGPRGERGFPGERGSPGAQGLQGPRG\nLPGTPGTDGPKGASGPAGPPGAQGPPGLQGMPGERGAAGIAGPKGDRGDVGEKGPEGAPG\nKDGGRGLTGPIGPPGPAGANGEKGEVGPPGPAGSAGARGAPGERGETGPPGPAGFAGPPG\nADGQPGAKGEQGEAGQKGDAGAPGPQGPSGAPGPQGPTGVTGPKGARGAQGPPGATGFPG\nAAGRVGPPGSNGNPGPPGPPGPSGKDGPKGARGDSGPPGRAGEPGLQGPAGPPGEKGEPG\nDDGPSGAEGPPGPQGLAGQRGIVGLPGQRGERGFPGLPGPSGEPGKQGAPGASGDRGPPG\nPVGPPGLTGPAGEPGREGSPGADGPPGRDGAAGVKGDRGETGAVGAPGAPGPPGSPGPAG\nPTGKQGDRGEAGAQGPMGPSGPAGARGIQGPQGPRGDKGEAGEPGERGLKGHRGFTGLQG\nLPGPPGPSGDQGASGPAGPSGPRGPPGPVGPSGKDGANGIPGPIGPPGPRGRSGETGPAG\nPPGNPGPPGPPGPPGPGIDMSAFAGLGPREKGPDPLQYMRADQAAGGLRQHDAEVDATLK\nSLNNQIESIRSPEGSRKNPARTCRDLKLCHPEWKSGDYWIDPNQGCTLDAMKVFCNMETG\nETCVYPNPANVPKKNWWSSKSKEKKHIWFGETINGGFHFSYGDDNLAPNTANVQMTFLRL\nLSTEGSQNITYHCKNSIAYLDEAAGNLKKALLIQGSNDVEIRAEGNSRFTYTALKDGCTK\nHTGKWGKTVIEYRSQKTSRLPIIDIAPMDIGGPEQEFGVDIGPVCFL"}, "gene-sequence": {"@format": "FASTA", "#text": ">4464 bp\nATGATTCGCCTCGGGGCTCCCCAGTCGCTGGTGCTGCTGACGCTGCTCGTCGCCGCTGTC\nCTTCGGTGTCAGGGCCAGGATGTCCAGGAGGCTGGCAGCTGTGTGCAGGATGGGCAGAGG\nTATAATGATAAGGATGTGTGGAAGCCGGAGCCCTGCCGGATCTGTGTCTGTGACACTGGG\nACTGTCCTCTGCGACGACATAATCTGTGAAGACGTGAAAGACTGCCTCAGCCCTGAGATC\nCCCTTCGGAGAGTGCTGCCCCATCTGCCCAACTGACCTCGCCACTGCCAGTGGGCAACCA\nGGACCAAAGGGACAGAAAGGAGAACCTGGAGACATCAAGGATATTGTAGGACCCAAAGGA\nCCTCCTGGGCCTCAGGGACCTGCAGGGGAACAAGGACCCAGAGGGGATCGTGGTGACAAA\nGGTGAAAAAGGTGCCCCTGGACCTCGTGGCAGAGATGGAGAACCTGGGACCCCTGGAAAT\nCCTGGCCCCCCTGGTCCTCCCGGCCCCCCTGGTCCCCCTGGTCTTGGTGGAAACTTTGCT\nGCCCAGATGGCTGGAGGATTTGATGAAAAGGCTGGTGGCGCCCAGTTGGGAGTAATGCAA\nGGACCAATGGGCCCCATGGGACCTCGAGGACCTCCAGGCCCTGCAGGTGCTCCTGGGCCT\nCAAGGATTTCAAGGCAATCCTGGTGAACCTGGTGAACCTGGTGTCTCTGGTCCCATGGGT\nCCCCGTGGTCCTCCTGGTCCCCCTGGAAAGCCTGGTGATGATGGTGAAGCTGGAAAACCT\nGGAAAAGCTGGTGAAAGGGGTCCGCCTGGTCCTCAGGGTGCTCGTGGTTTCCCAGGAACC\nCCAGGCCTTCCTGGTGTCAAAGGTCACAGAGGTTATCCAGGCCTGGACGGTGCTAAGGGA\nGAGGCGGGTGCTCCTGGTGTGAAGGGTGAGAGTGGTTCCCCGGGTGAGAACGGATCTCCG\nGGCCCAATGGGTCCTCGTGGCCTGCCTGGTGAAAGAGGACGGACTGGCCCTGCTGGCGCT\nGCGGGTGCCCGAGGCAACGATGGTCAGCCAGGCCCCGCAGGTCCTCCGGGTCCTGTCGGT\nCCTGCTGGTGGTCCTGGCTTCCCTGGTGCTCCTGGAGCCAAGGGTGAAGCCGGCCCCACT\nGGTGCCCGTGGTCCTGAAGGTGCTCAAGGTCCTCGCGGTGAACCTGGTACTCCTGGGTCC\nCCTGGGCCTGCTGGTGCCTCCGGTAACCCTGGAACAGATGGAATTCCTGGAGCCAAAGGA\nTCTGCTGGTGCTCCTGGCATTGCTGGTGCTCCTGGCTTCCCTGGGCCACGGGGTCCTCCT\nGGCCCTCAAGGTGCAACTGGTCCTCTGGGCCCGAAAGGTCAGACGGGTGAACCTGGTATT\nGCTGGCTTCAAAGGTGAACAAGGCCCCAAGGGAGAACCTGGCCCTGCTGGCCCCCAGGGA\nGCCCCTGGACCCGCTGGTGAAGAAGGCAAGAGAGGTGCCCGTGGAGAGCCTGGTGGCGTT\nGGGCCCATCGGTCCCCCTGGAGAAAGAGGTGCTCCCGGAAACCGCGGTTTCCCAGGTCAA\nGATGGTCTGGCAGGTCCCAAGGGAGCCCCTGGAGAGCGAGGGCCCAGTGGTCTTGCTGGC\nCCCAAGGGAGCCAACGGTGACCCTGGCCGTCCTGGAGAACCTGGCCTTCCTGGAGCCCGG\nGGTCTCACTGGCCGCCCTGGTGATGCTGGTCCTCAAGGCAAAGTTGGCCCTTCTGGAGCC\nCCTGGTGAAGATGGTCGTCCTGGACCTCCAGGTCCTCAGGGGGCTCGTGGGCAGCCTGGT\nGTCATGGGTTTCCCTGGCCCCAAAGGTGCCAACGGTGAGCCTGGCAAAGCTGGTGAGAAG\nGGACTGCCTGGTGCTCCTGGTCTGAGGGGTCTTCCTGGCAAAGATGGTGAGACAGGTGCT\nGCAGGACCCCCTGGCCCTGCTGGACCTGCTGGTGAACGAGGCGAGCAGGGTGCTCCTGGG\nCCATCTGGGTTCCAGGGACTTCCTGGCCCTCCTGGTCCCCCAGGTGAAGGTGGAAAACCA\nGGTGACCAGGGTGTTCCCGGTGAAGCTGGAGCCCCTGGCCTCGTGGGTCCCAGGGGTGAA\nCGAGGTTTCCCAGGTGAACGTGGCTCTCCCGGTGCCCAGGGCCTCCAGGGTCCCCGTGGC\nCTCCCCGGCACTCCTGGCACTGATGGTCCCAAAGGTGCATCTGGCCCAGCAGGCCCCCCT\nGGCGCACAGGGCCCTCCAGGTCTTCAGGGAATGCCTGGCGAGAGGGGAGCAGCTGGTATC\nGCTGGGCCCAAAGGCGACAGGGGTGACGTTGGTGAGAAAGGCCCTGAGGGAGCCCCTGGA\nAAGGATGGTGGACGAGGCCTGACAGGTCCCATTGGCCCCCCTGGCCCAGCTGGTGCTAAC\nGGCGAGAAGGGAGAAGTTGGACCTCCTGGTCCTGCAGGAAGTGCTGGTGCTCGTGGCGCT\nCCGGGTGAACGTGGAGAGACTGGCCCCCCCGGACCAGCGGGATTTGCTGGGCCTCCTGGT\nGCTGATGGCCAGCCTGGGGCCAAGGGTGAGCAAGGAGAGGCCGGCCAGAAAGGCGATGCT\nGGTGCCCCTGGTCCTCAGGGCCCCTCTGGAGCACCTGGGCCTCAGGGTCCTACTGGAGTG\nACTGGTCCTAAAGGAGCCCGAGGTGCCCAAGGCCCCCCGGGAGCCACTGGATTCCCTGGA\nGCTGCTGGCCGCGTTGGACCCCCAGGCTCCAATGGCAACCCTGGACCCCCTGGTCCCCCT\nGGTCCTTCTGGAAAAGATGGTCCCAAAGGTGCTCGAGGAGACAGCGGCCCCCCTGGCCGA\nGCTGGTGAACCCGGCCTCCAAGGTCCTGCTGGACCCCCTGGCGAGAAGGGAGAGCCTGGA\nGATGACGGTCCCTCTGGTGCCGAAGGTCCACCAGGTCCCCAGGGTCTGGCTGGTCAGAGA\nGGCATCGTCGGTCTGCCTGGGCAACGTGGTGAGAGAGGATTCCCTGGCTTGCCTGGCCCA\nTCGGGTGAGCCCGGCAAGCAGGGTGCTCCTGGAGCATCTGGAGACAGAGGTCCTCCTGGC\nCCCGTGGGTCCTCCTGGCCTGACGGGTCCTGCAGGTGAACCCGGACGAGAGGGAAGCCCC\nGGTGCTGATGGCCCCCCTGGCAGAGATGGCGCTGCTGGAGTCAAGGGTGATCGTGGTGAG\nACTGGTGCTGTGGGAGCTCCTGGAGCCCCTGGGCCCCCTGGCTCCCCTGGCCCCGCTGGT\nCCAACTGGCAAGCAAGGAGACAGAGGAGAAGCTGGTGCACAAGGCCCCATGGGACCCTCA\nGGACCAGCTGGAGCCCGGGGAATCCAGGGTCCTCAAGGCCCCAGAGGTGACAAAGGAGAG\nGCTGGAGAGCCTGGCGAGAGAGGCCTGAAGGGACACCGTGGCTTCACTGGTCTGCAGGGT\nCTGCCCGGCCCTCCTGGTCCTTCTGGAGACCAAGGTGCTTCTGGTCCTGCTGGTCCTTCT\nGGCCCTAGAGGTCCTCCTGGCCCCGTCGGTCCCTCTGGCAAAGATGGTGCTAATGGAATC\nCCTGGCCCCATTGGGCCTCCTGGTCCCCGTGGACGATCAGGCGAAACCGGTCCTGCTGGT\nCCTCCTGGAAATCCTGGGCCCCCTGGTCCTCCAGGTCCCCCTGGCCCTGGCATCGACATG\nTCCGCCTTTGCTGGCTTAGGCCCGAGAGAGAAGGGCCCCGACCCCCTGCAGTACATGCGG\nGCCGACCAGGCAGCCGGTGGCCTGAGACAGCATGACGCCGAGGTGGATGCCACACTCAAG\nTCCCTCAACAACCAGATTGAGAGCATCCGCAGCCCCGAGGGCTCCCGCAAGAACCCTGCT\nCGCACCTGCAGAGACCTGAAACTCTGCCACCCTGAGTGGAAGAGTGGAGACTACTGGATT\nGACCCCAACCAAGGCTGCACCTTGGACGCCATGAAGGTTTTCTGCAACATGGAGACTGGC\nGAGACTTGCGTCTACCCCAATCCAGCAAACGTTCCCAAGAAGAACTGGTGGAGCAGCAAG\nAGCAAGGAGAAGAAACACATCTGGTTTGGAGAAACCATCAATGGTGGCTTCCATTTCAGC\nTATGGAGATGACAATCTGGCTCCCAACACTGCCAACGTCCAGATGACCTTCCTACGCCTG\nCTGTCCACGGAAGGCTCCCAGAACATCACCTACCACTGCAAGAACAGCATTGCCTATCTG\nGACGAAGCAGCTGGCAACCTCAAGAAGGCCCTGCTCATCCAGGGCTCCAATGACGTGGAG\nATCCGGGCAGAGGGCAATAGCAGGTTCACGTACACTGCCCTGAAGGATGGCTGCACGAAA\nCATACCGGTAAGTGGGGCAAGACTGTTATCGAGTACCGGTCACAGAAGACCTCACGCCTC\nCCCATCATTGACATTGCACCCATGGACATAGGAGGGCCCGAGCAGGAATTCGGTGTGGAC\nATAGGGCCGGTCTGCTTCTTGTAA"}, "pfams": {"pfam": [{"identifier": "PF01410", "name": "COLFI"}, {"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00093", "name": "VWC"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular matrix"}, {"category": "component", "description": "extracellular matrix (sensu Metazoa)"}, {"category": "component", "description": "cell"}, {"category": "component", "description": "collagen"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "function", "description": "extracellular matrix structural constituent"}, {"category": "function", "description": "structural molecule activity"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "cellular physiological process"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}]}}}, {"id": "BE0002130", "name": "Collagen alpha-1(III) chain", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Cole WG, Chiodo AA, Lamande SR, Janeczko R, Ramirez F, Dahl HH, Chan D, Bateman JF: A base substitution at a splice site in the COL3A1 gene causes exon skipping and generates abnormal type III procollagen in a patient with Ehlers-Danlos syndrome type IV. J Biol Chem. 1990 Oct 5;265(28):17070-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2145268", "known-action": "unknown", "polypeptide": {"@id": "P02461", "@source": "Swiss-Prot", "name": "Collagen alpha-1(III) chain", "general-function": "Carbohydrate transport and metabolism", "specific-function": "Collagen type III occurs in most soft connective tissues along with type I collagen", "gene-name": "COL3A1", "locus": "2q31", "cellular-location": null, "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.57", "molecular-weight": "138566.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2201"}, {"resource": "GenAtlas", "identifier": "COL3A1"}, {"resource": "GeneCards", "identifier": "COL3A1"}, {"resource": "GenBank Gene Database", "identifier": "X14420"}, {"resource": "GenBank Protein Database", "identifier": "30058"}, {"resource": "UniProtKB", "identifier": "P02461"}, {"resource": "UniProt Accession", "identifier": "CO3A1_HUMAN"}]}, "synonyms": {"synonym": ["Collagen alpha-1(III) chain precursor", "III"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Collagen alpha-1(III) chain\nMMSFVQKGSWLLLALLHPTIILAQQEAVEGGCSHLGQSYADRDVWKPEPCQICVCDSGSV\nLCDDIICDDQELDCPNPEIPFGECCAVCPQPPTAPTRPPNGQGPQGPKGDPGPPGIPGRN\nGDPGIPGQPGSPGSPGPPGICESCPTGPQNYSPQYDSYDVKSGVAVGGLAGYPGPAGPPG\nPPGPPGTSGHPGSPGSPGYQGPPGEPGQAGPSGPPGPPGAIGPSGPAGKDGESGRPGRPG\nERGLPGPPGIKGPAGIPGFPGMKGHRGFDGRNGEKGETGAPGLKGENGLPGENGAPGPMG\nPRGAPGERGRPGLPGAAGARGNDGARGSDGQPGPPGPPGTAGFPGSPGAKGEVGPAGSPG\nSNGAPGQRGEPGPQGHAGAQGPPGPPGINGSPGGKGEMGPAGIPGAPGLMGARGPPGPAG\nANGAPGLRGGAGEPGKNGAKGEPGPRGERGEAGIPGVPGAKGEDGKDGSPGEPGANGLPG\nAAGERGAPGFRGPAGPNGIPGEKGPAGERGAPGPAGPRGAAGEPGRDGVPGGPGMRGMPG\nSPGGPGSDGKPGPPGSQGESGRPGPPGPSGPRGQPGVMGFPGPKGNDGAPGKNGERGGPG\nGPGPQGPPGKNGETGPQGPPGPTGPGGDKGDTGPPGPQGLQGLPGTGGPPGENGKPGEPG\nPKGDAGAPGAPGGKGDAGAPGERGPPGLAGAPGLRGGAGPPGPEGGKGAAGPPGPPGAAG\nTPGLQGMPGERGGLGSPGPKGDKGEPGGPGADGVPGKDGPRGPTGPIGPPGPAGQPGDKG\nEGGAPGLPGIAGPRGSPGERGETGPPGPAGFPGAPGQNGEPGGKGERGAPGEKGEGGPPG\nVAGPPGGSGPAGPPGPQGVKGERGSPGGPGAAGFPGARGLPGPPGSNGNPGPPGPSGSPG\nKDGPPGPAGNTGAPGSPGVSGPKGDAGQPGEKGSPGAQGPPGAPGPLGIAGITGARGLAG\nPPGMPGPRGSPGPQGVKGESGKPGANGLSGERGPPGPQGLPGLAGTAGEPGRDGNPGSDG\nLPGRDGSPGGKGDRGENGSPGAPGAPGHPGPPGPVGPAGKSGDRGESGPAGPAGAPGPAG\nSRGAPGPQGPRGDKGETGERGAAGIKGHRGFPGNPGAPGSPGPAGQQGAIGSPGPAGPRG\nPVGPSGPPGKDGTSGHPGPIGPPGPRGNRGERGSEGSPGHPGQPGPPGPPGAPGPCCGGV\nGAAAIAGIGGEKAGGFAPYYGDEPMDFKINTDEIMTSLKSVNGQIESLISPDGSRKNPAR\nNCRDLKFCHPELKSGEYWVDPNQGCKLDAIKVFCNMETGETCISANPLNVPRKHWWTDSS\nAEKKHVWFGESMDGGFQFSYGNPELPEDVLDVHLAFLRLLSSRASQNITYHCKNSIAYMD\nQASGNVKKALKLMGSNEGEFKAEGNSKFTYTVLEDGCTKHTGEWSKTVFEYRTRKAVRLP\nIVDIAPYDIGGPDQEFGVDVGPVCFL"}, "gene-sequence": {"@format": "FASTA", "#text": ">4401 bp\nATGATGAGCTTTGTGCAAAAGGGGAGCTGGCTACTTCTCGCTCTGCTTCATCCCACTATT\nATTTTGGCACAACAGGAAGCTGTTGAAGGAGGATGTTCCCATCTTGGTCAGTCCTATGCG\nGATAGAGATGTCTGGAAGCCAGAACCATGCCAAATATGTGTCTGTGACTCAGGATCCGTT\nCTCTGCGATGACATAATATGTGACGATCAAGAATTAGACTGCCCCAACCCAGAAATTCCA\nTTTGGAGAATGTTGTGCAGTTTGCCCACAGCCTCCAACTGCTCCTACTCGCCCTCCTAAT\nGGTCAAGGACCTCAAGGCCCCAAGGGAGATCCAGGCCCTCCTGGTATTCCTGGGAGAAAT\nGGTGACCCTGGTATTCCAGGACAACCAGGGTCCCCTGGTTCTCCTGGCCCCCCTGGAATC\nTGTGAATCATGCCCTACTGGTCCTCAGAACTATTCTCCCCAGTATGATTCATATGATGTC\nAAGTCTGGAGTAGCAGTAGGAGGACTCGCAGGCTATCCTGGACCAGCTGGCCCCCCAGGC\nCCTCCCGGTCCCCCTGGTACATCTGGTCATCCTGGTTCCCCTGGATCTCCAGGATACCAA\nGGACCCCCTGGTGAACCTGGGCAAGCTGGTCCTTCAGGCCCTCCAGGACCTCCTGGTGCT\nATAGGTCCATCTGGTCCTGCTGGAAAAGATGGAGAATCAGGTAGACCCGGACGACCTGGA\nGAGCGAGGATTGCCTGGACCTCCAGGTATCAAAGGTCCAGCTGGGATACCTGGATTCCCT\nGGTATGAAAGGACACAGAGGCTTCGATGGACGAAATGGAGAAAAGGGTGAAACAGGTGCT\nCCTGGATTAAAGGGTGAAAATGGTCTTCCAGGCGAAAATGGAGCTCCTGGACCCATGGGT\nCCAAGAGGGGCTCCTGGTGAGCGAGGACGGCCAGGACTTCCTGGGGCTGCAGGTGCTCGG\nGGTAATGACGGTGCTCGAGGCAGTGATGGTCAACCAGGCCCTCCTGGTCCTCCTGGAACT\nGCCGGATTCCCTGGATCCCCTGGTGCTAAGGGTGAAGTTGGACCTGCAGGGTCTCCTGGT\nTCAAATGGTGCCCCTGGACAAAGAGGAGAACCTGGACCTCAGGGACACGCTGGTGCTCAA\nGGTCCTCCTGGCCCTCCTGGGATTAATGGTAGTCCTGGTGGTAAAGGCGAAATGGGTCCC\nGCTGGCATTCCTGGAGCTCCTGGACTGATGGGAGCCCGGGGTCCTCCAGGACCAGCCGGT\nGCTAATGGTGCTCCTGGACTGCGAGGTGGTGCAGGTGAGCCTGGTAAGAATGGTGCCAAA\nGGAGAGCCCGGACCACGTGGTGAACGCGGTGAGGCTGGTATTCCAGGTGTTCCAGGAGCT\nAAAGGCGAAGATGGCAAGGATGGATCACCTGGAGAACCTGGTGCAAATGGGCTTCCAGGA\nGCTGCAGGAGAAAGGGGTGCCCCTGGGTTCCGAGGACCTGCTGGACCAAATGGCATCCCA\nGGAGAAAAGGGTCCTGCTGGAGAGCGTGGTGCTCCAGGCCCTGCAGGGCCCAGAGGAGCT\nGCTGGAGAACCTGGCAGAGATGGCGTCCCTGGAGGTCCAGGAATGAGGGGCATGCCCGGA\nAGTCCAGGAGGACCAGGAAGTGATGGGAAACCAGGGCCTCCCGGAAGTCAAGGAGAAAGT\nGGTCGACCAGGTCCTCCTGGGCCATCTGGTCCCCGAGGTCAGCCTGGTGTCATGGGCTTC\nCCCGGTCCTAAAGGAAATGATGGTGCTCCTGGTAAGAATGGAGAACGAGGTGGCCCTGGA\nGGACCTGGCCCTCAGGGTCCTCCTGGAAAGAATGGTGAAACTGGACCTCAAGGACCCCCA\nGGGCCTACTGGGCCTGGTGGTGACAAAGGAGACACAGGACCCCCTGGTCCACAAGGATTA\nCAAGGCTTGCCTGGTACAGGTGGTCCTCCAGGAGAAAATGGAAAACCTGGGGAACCAGGT\nCCAAAGGGTGATGCCGGTGCACCTGGAGCTCCAGGAGGCAAGGGTGATGCTGGTGCCCCT\nGGTGAACGTGGACCTCCTGGATTGGCAGGGGCCCCAGGACTTAGAGGTGGAGCTGGTCCC\nCCTGGTCCCGAAGGAGGAAAGGGTGCTGCTGGTCCTCCTGGGCCACCTGGTGCTGCTGGT\nACTCCTGGTCTGCAAGGAATGCCTGGAGAAAGAGGAGGTCTTGGAAGTCCTGGTCCAAAG\nGGTGACAAGGGTGAACCAGGCGGCCCAGGTGCTGATGGTGTCCCAGGGAAAGATGGCCCA\nAGGGGTCCTACTGGTCCTATTGGTCCTCCTGGCCCAGCTGGCCAGCCTGGAGATAAGGGT\nGAAGGTGGTGCCCCCGGACTTCCAGGTATAGCTGGACCTCGTGGTAGCCCTGGTGAGAGA\nGGTGAAACTGGCCCTCCAGGACCTGCTGGTTTCCCTGGTGCTCCTGGACAGAATGGTGAA\nCCTGGTGGTAAAGGAGAAAGAGGGGCTCCGGGTGAGAAAGGTGAAGGAGGCCCTCCTGGA\nGTTGCAGGACCCCCTGGAGGTTCTGGACCTGCTGGTCCTCCTGGTCCCCAAGGTGTCAAA\nGGTGAACGTGGCAGTCCTGGTGGACCTGGTGCTGCTGGCTTCCCTGGTGCTCGTGGTCTT\nCCTGGTCCTCCTGGTAGTAATGGTAACCCAGGACCCCCAGGTCCCAGCGGTTCTCCAGGC\nAAGGATGGGCCCCCAGGTCCTGCGGGTAACACTGGTGCTCCTGGCAGCCCTGGAGTGTCT\nGGACCAAAAGGTGATGCTGGCCAACCAGGAGAGAAGGGATCGCCTGGTGCCCAGGGCCCA\nCCAGGAGCTCCAGGCCCACTTGGGATTGCTGGGATCACTGGAGCACGGGGTCTTGCAGGA\nCCACCAGGCATGCCAGGTCCTAGGGGAAGCCCTGGCCCTCAGGGTGTCAAGGGTGAAAGT\nGGGAAACCAGGAGCTAACGGTCTCAGTGGAGAACGTGGTCCCCCTGGACCCCAGGGTCTT\nCCTGGTCTGGCTGGTACAGCTGGTGAACCTGGAAGAGATGGAAACCCTGGATCAGATGGT\nCTTCCAGGCCGAGATGGATCTCCTGGTGGCAAGGGTGATCGTGGTGAAAATGGCTCTCCT\nGGTGCCCCTGGCGCTCCTGGTCATCCAGGCCCACCTGGTCCTGTCGGTCCAGCTGGAAAG\nAGTGGTGACAGAGGAGAAAGTGGCCCTGCTGGCCCTGCTGGTGCTCCCGGTCCTGCTGGT\nTCCCGAGGTGCTCCTGGTCCTCAAGGCCCACGTGGTGACAAAGGTGAAACAGGTGAACGT\nGGAGCTGCTGGCATCAAAGGACATCGAGGATTCCCTGGTAATCCAGGTGCCCCAGGTTCT\nCCAGGCCCTGCTGGTCAGCAGGGTGCAATCGGCAGTCCAGGACCTGCAGGCCCCAGAGGA\nCCTGTTGGACCCAGTGGACCTCCTGGCAAAGATGGAACCAGTGGACATCCAGGTCCCATT\nGGACCACCAGGGCCTCGAGGTAACAGAGGTGAAAGAGGATCTGAGGGCTCCCCAGGCCAC\nCCAGGGCAACCAGGCCCTCCTGGACCTCCTGGTGCCCCTGGTCCTTGCTGTGGTGGTGTT\nGGAGCCGCTGCCATTGCTGGGATTGGAGGTGAAAAAGCTGGCGGTTTTGCCCCGTATTAT\nGGAGATGAACCAATGGATTTCAAAATCAACACCGATGAGATTATGACTTCACTCAAGTCT\nGTTAATGGACAAATAGAAAGCCTCATTAGTCCTGATGGTTCTCGTAAAAACCCCGCTAGA\nAACTGCAGAGACCTGAAATTCTGCCATCCTGAACTCAAGAGTGGAGAATACTGGGTTGAC\nCCTAACCAAGGATGCAAATTGGATGCTATCAAGGTATTCTGTAATATGGAAACTGGGGAA\nACATGCATAAGTGCCAATCCTTTGAATGTTCCACGGAAACACTGGTGGACAGATTCTAGT\nGCTGAGAAGAAACACGTTTGGTTTGGAGAGTCCATGGATGGTGGTTTTCAGTTTAGCTAC\nGGCAATCCTGAACTTCCTGAAGATGTCCTTGATGTGCAGCTGGCATTCCTTCGACTTCTC\nTCCAGCCGAGCTTCCCAGAACATCACATATCACTGCAAAAATAGCATTGCATACATGGAT\nCAGGCCAGTGGAAATGTAAAGAAGGCCCTGAAGCTGATGGGGTCAAATGAAGGTGAATTC\nAAGGCTGAAGGAAATAGCAAATTCACCTACACAGTTCTGGAGGATGGTTGCACGAAACAC\nACTGGGGAATGGAGCAAAACAGTCTTTGAATATCGAACACGCAAGGCTGTGAGACTACCT\nATTGTAGATATTGCACCCTATGACATTGGTGGTCCTGATCAAGAATTTGGTGTGGACGTT\nGGCCCTGTTTGCTTTTTATAA"}, "pfams": {"pfam": [{"identifier": "PF01410", "name": "COLFI"}, {"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00093", "name": "VWC"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular matrix"}, {"category": "component", "description": "extracellular matrix (sensu Metazoa)"}, {"category": "component", "description": "cell"}, {"category": "component", "description": "collagen"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "function", "description": "extracellular matrix structural constituent"}, {"category": "function", "description": "structural molecule activity"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "cellular physiological process"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}]}}}, {"id": "BE0002141", "name": "Collagen alpha-2(I) chain", "organism": "Human", "actions": null, "references": "# Chiu CJ, Chang ML, Chiang CP, Hahn LJ, Hsieh LL, Chen CJ: Interaction of collagen-related genes and susceptibility to betel quid-induced oral submucous fibrosis. Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):646-53. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12101112", "known-action": "unknown", "polypeptide": {"@id": "P08123", "@source": "Swiss-Prot", "name": "Collagen alpha-2(I) chain", "general-function": "Carbohydrate transport and metabolism", "specific-function": "Type I collagen is a member of group I collagen (fibrillar forming collagen)", "gene-name": "COL1A2", "locus": "7q22.1", "cellular-location": null, "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.36", "molecular-weight": "129289.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2198"}, {"resource": "GenAtlas", "identifier": "COL1A2"}, {"resource": "GeneCards", "identifier": "COL1A2"}, {"resource": "GenBank Gene Database", "identifier": "J03464"}, {"resource": "GenBank Protein Database", "identifier": "179596"}, {"resource": "UniProtKB", "identifier": "P08123"}, {"resource": "UniProt Accession", "identifier": "CO1A2_HUMAN"}]}, "synonyms": {"synonym": ["Alpha-2 type I collagen", "Collagen alpha-2(I) chain precursor", "I"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Collagen alpha-2(I) chain\nMLSFVDTRTLLLLAVTLCLATCQSLQEETVRKGPAGDRGPRGERGPPGPPGRDGEDGPTG\nPPGPPGPPGPPGLGGNFAAQYDGKGVGLGPGPMGLMGPRGPPGAAGAPGPQGFQGPAGEP\nGEPGQTGPAGARGPAGPPGKAGEDGHPGKPGRPGERGVVGPQGARGFPGTPGLPGFKGIR\nGHNGLDGLKGQPGAPGVKGEPGAPGENGTPGQTGARGLPGERGRVGAPGPAGARGSDGSV\nGPVGPAGPIGSAGPPGFPGAPGPKGEIGAVGNAGPAGPAGPRGEVGLPGLSGPVGPPGNP\nGANGLTGAKGAAGLPGVAGAPGLPGPRGIPGPVGAAGATGARGLVGEPGPAGSKGESGNK\nGEPGSAGPQGPPGPSGEEGKRGPNGEAGSAGPPGPPGLRGSPGSRGLPGADGRAGVMGPP\nGSRGASGPAGVRGPNGDAGRPGEPGLMGPRGLPGSPGNIGPAGKEGPVGLPGIDGRPGPI\nGPAGARGEPGNIGFPGPKGPTGDPGKNGDKGHAGLAGARGAPGPDGNNGAQGPPGPQGVQ\nGGKGEQGPAGPPGFQGLPGPSGPAGEVGKPGERGLHGEFGLPGPAGPRGERGPPGESGAA\nGPTGPIGSRGPSGPPGPDGNKGEPGVVGAVGTAGPSGPSGLPGERGAAGIPGGKGEKGEP\nGLRGEIGNPGRDGARGAPGAVGAPGPAGATGDRGEAGAAGPAGPAGPRGSPGERGEVGPA\nGPNGFAGPAGAAGQPGAKGERGAKGPKGENGVVGPTGPVGAAGPAGPNGPPGPAGSRGDG\nGPPGMTGFPGAAGRTGPPGPSGISGPPGPPGPAGKEGLRGPRGDQGPVGRTGEVGAVGPP\nGFAGEKGPSGEAGTAGPPGTPGPQGLLGAPGILGLPGSRGERGLPGVAGAVGEPGPLGIA\nGPPGARGPPGAVGSPGVNGAPGEAGRDGNPGNDGPPGRDGQPGHKGERGYPGNIGPVGAA\nGAPGPHGPVGPAGKHGNRGETGPSGPVGPAGAVGPRGPSGPQGIRGDKGEPGEKGPRGLP\nGLKGHNGLQGLPGIAGHHGDQGAPGSVGPAGPRGPAGPSGPAGKDGRTGHPGTVGPAGIR\nGPQGHQGPAGPPGPPGPPGPPGVSGGGYDFGYDGDFYRADQPRSAPSLRPKDYEVDATLK\nSLNNQIETLLTPEGSRKNPARTCRDLRLSHPEWSSGYYWIDPNQGCTMDAIKVYCDFSTG\nETCIRAQPENIPAKNWYRSSKDKKHVWLGETINAGSQFEYNVEGVTSKEMATQLAFMRLL\nANYASQNITYHCKNSIAYMDEETGNLKKAVILQGSNDVELVAEGNSRFTYTVLVDGCSKK\nTNEWGKTIIEYKTNKPSRLPFLDIAPLDIGGADQEFFVDIGPVCFK"}, "gene-sequence": {"@format": "FASTA", "#text": ">4101 bp\nATGCTCAGCTTTGTGGATACGCGGACTTTGTTGCTGCTTGCAGTAACCTTATGCCTAGCA\nACATGCCAATCTTTACAAGAGGAAACTGTAAGAAAGGGCCCAGCCGGAGATAGAGGACCA\nCGTGGAGAAAGGGGTCCACCAGGCCCCCCAGGCAGAGATGGTGAAGATGGTCCCACAGGC\nCCTCCTGGTCCACCTGGTCCTCCTGGCCCCCCTGGTCTCGGTGGGAACTTTGCTGCTCAG\nTATGATGGAAAAGGAGTTGGACTTGGCCCTGGACCAATGGGCTTAATGGGACCTAGAGGC\nCCACCTGGTGCAGCTGGAGCCCCAGGCCCTCAAGGTTTCCAAGGACCTGCTGGTGAGCCT\nGGTGAACCTGGTCAAACTGGTCCTGCAGGTGCTCGTGGTCCAGCTGGCCCTCCTGGCAAG\nGCTGGTGAAGATGGTCACCCTGGAAAACCCGGACGACCTGGTGAGAGAGGAGTTGTTGGA\nCCACAGGGTGCTCGTGGTTTCCCTGGAACTCCTGGACTTCCTGGCTTCAAAGGCATTAGG\nGGACACAATGGTCTGGATGGATTGAAGGGACAGCCCGGTGCTCCTGGTGTGAAGGGTGAA\nCCTGGTGCCCCTGGTGAAAATGGAACTCCAGGTCAAACAGGAGCCCGTGGTCTTCCTGGT\nGAGAGAGGACGTGTTGGTGCCCCTGGTCCAGCTGGTGCCCGTGGAAGTGATGGAAGTGTG\nGGTCCCGTAGGTCCTGCTGGTCCTAATGGGTCTGCTGGCCCTCCAGGTTTCCCAGGTGCC\nCCTGGTCCCAAGGGTGAAATTGGAGCTGTTGGTAACGCTGGTCCTACTGGACCCGCCGGT\nCCCCGTGGTGAAGTGGGTCTTCCAGGCCTCTCCGGCCCCGTTGGACCTCCTGGTAATCCT\nGGAGCAAACGGCCTTACTGGTGCCAAGGGTGCTGCTGGCCTTCCCGGCGTTGCTGGGGCT\nCCCGGCCTCCCTGGACCCCGCGGTATTCCTGGCCCTCCTGGTGCTGCCGGTACTACTGGT\nGCCAGAGGACTTGTTGGTGAGCCTGGTCCAGCTGGCTCCAAAGGAGAGAGCGGTAACAAG\nGGTGAGCCCGGCTCCGCTGGTCCCCAAGGTCCTCCTGGTCCCAGTGGTGAAGAAGGAAAG\nAGAGGCCCTAATGGGGAAGCTGGATCTGCCGGCCCTCCAGGACCTCCTGGGCTGAGAGGT\nAGTCCTGGTTCTCGTGGTCTTCCTGGAGCTGATGGCAGAGCTGGCGTCATGGGCCCTCCT\nGGTAGTCGTGGTGCAAGTGGCCCTGCTGGAGTCCGAGGACCTAATGGAGATGCTGGTCGC\nCCTGGGGAGCCTGGTCTCATGGGACCCAGAGGTCTTCCTGGTTCCCCTGGAAATATCGGC\nCCCGCTGGAAAAGAAGGTCCTGTCGGCCTCCCTGGCATCGACGGCAGGCCTGGCCCAATT\nGGCCCCGTTGGAGCAAGAGGAGAGCCTGGCAACATTGGATTCCCTGGACCCAAAGGCCCC\nACTGGTGACCCTGGCAAAAACGGTGATAAAGGTCATGCTGGTCTTGCTGGTGCTCGGGGT\nGCTCCAGGTCCTGATGGAAACAATGGTGCTCAGGGACCTCCTGGACCACAGGGTGTTCAA\nGGTGGAAAAGGTGAACAGGGTCCCGCTGGTCCTCCAGGCTTCCAGGGTCTGCCTGGCCCC\nTCAGGTCCCGCTGGTGAAGTTGGCAAACCAGGAGAAAGGGGTCTCCATGGTGAGTTTGGT\nCTCCCTGGTCCTGCTGGTCCAAGAGGGGAACGCGGTCCCCCAGGTGAGAGTGGTGCTGCC\nGGTCCTACTGGTCCTATTGGAAGCCGAGGTCCTTCTGGACCCCCAGGGCCTGATGGAAAC\nAAGGGTGAACCTGGTGTGGTTGGTGCTGTGGGCACTGCTGGTCCATCTGGTCCTAGTGGA\nCTCCCAGGAGAGAGGGGTGCTGCTGGCATACCTGGAGGCAAGGGAGAAAAGGGTGAACCT\nGGTCTCAGAGGTGAAATTGGTAACCCTGGCAGAGATGGTGCTCGTGGTGCTCATGGTGCT\nGTAGGTGCCCCTGGTCCTGCTGGAGCCACAGGTGACCGGGGCGAAGCTGGGGCTGCTGGT\nCCTGCTGGTCCTGCTGGTCCTCGGGGAAGCCCTGGTGAACGTGGCGAGGTCGGTCCTGCT\nGGCCCCAACGGATTTGCTGGTCCGGCTGGTGCTGCTGGTCAACCGGGTGCTAAAGGAGAA\nAGAGGAGGCAAAGGGCCTAAGGGTGAAAACGGTGTTGTTGGTCCCACAGGCCCCGTTGGA\nGCTGCTGGCCCAGCTGGTCCAAATGGTCCCCCCGGTCCTGCTGGAAGTCGTGGTGATGGA\nGGCCCCCCTGGTATGACTGGTTTCCCTGGTGCTGCTGGACGGACTGGTCCCCCAGGACCC\nTCTGGTATTTCTGGCCCTCCTGGTCCCCCTGGTCCTGCTGGGAAAGAAGGGCTTCGTGGT\nCCTCGTGGTGACCAAGGTCCAGTTGGCCGAACTGGAGAAGTAGGTGCAGTTGGTCCCCCT\nGGCTTCGCTGGTGAGAAGGGTCCCTCTGGAGAGGCTGGTACTGCTGGACCTCCTGGCACT\nCCAGGTCCTCAGGGTCTTCTTGGTGCTCCTGGTATTCTGGGTCTCCCTGGCTCGAGAGGT\nGAACGTGGTCTACCTGGTGTTGCTGGTGCTGTGGGTGAACCTGGTCCTCTTGGCATTGCC\nGGCCCTCCTGGGGCCCGTGGTCCTCCTGGTGCTGTGGGTAGTCCTGGAGTCAACGGTGCT\nCCTGGTGAAGCTGGTCGTGATGGCAACCCTGGGAACGATGGTCCCCCAGGTCGCGATGGT\nCAACCCGGACACAAGGGAGAGCGCGGTTACCCTGGCAATATTGGTCCCGTTGGTGCTGCA\nGGTGCACCTGGTCCTCATGGCCCCGTGGGTCCTGCTGGCAAACATGGAAACCGTGGTGAA\nACTGGTCCTTCTGGTCCTGTTGGTCCTGCTGGTGCTGTTGGCCCAAGAGGTCCTAGTGGC\nCCACAAGGCATTCGTGGCGATAAGGGAGAGCCCGGTGAAAAGGGGCCCAGAGGTCTTCCT\nGGCTTCAAGGGACACAATGGATTGCAAGGTCTGCCTGGTATCGCTGGTCACCATGGTGAT\nCAAGGTGCTCCTGGCTCCGTGGGTCCTGCTGGTCCTAGGGGCCCTGCTGGTCCTTCTGGC\nCCTGCTGGAAAAGATGGTCGCACTGGACATCCTGGTACGGTTGGACCTGCTGGCATTCGA\nGGCCCTCAGGGTCACCAAGGCCCTGCTGGCCCCCCTGGTCCCCCTGGCCCTCCTGGACCT\nCCAGGTGTAAGCGGTGGTGGTTATGACTTTGGTTACGATGGAGACTTCTACAGGGCTGAC\nCAGCCTCGCTCAGCACCTTCTCTCAGACCCAAGGACTATGAAGTTGATGCTACTCTGAAG\nTCTCTCAACAACCAGATTGAGACCCTTCTTACTCCTGAAGGCTCTAGAAAGAACCCAGCT\nCGCACATGCCGTGACTTGAGACTCAGCCACCCAGAGTGGAGCAGCGGTTACTACTGGATT\nGACCCCAACCAAGGATGCACTATGGAAGCCATCAAAGTATACTGTGATTTCCCTACCGGC\nGAAACCTGTATCCGGGCCCAACCTGAAAACATCCCAGCCAAGAACTGGTATAGGAGCTCC\nAAGGACAAGAAACACGTCTGGCTAGGAGAAACTATCAATGCTGGCAGCCAGTTTGAATAT\nAATGTTGAAGGAGTGACTTCCAAGGAAATGGCTACCCAACTTGCCTTCATGCGCCTGCTG\nGCCAACTATGCCTCTCAGAACATCACCTACCACTGCAAGAACAGCATTGCATACATGGAT\nGAGGAGACTGGCAACCTGAAAAAGGCTGTCATTCTACAGGGCTCTAATGATGTTGAACTT\nGTTGCTGAGGGCAACAGCAGGTTCACTTACACTGTTCTTGTAGATGGCTGCTCTAAAAAG\nACAAATGAATGGGGAAAGACAATCATTGAATACAAAACAAATAAGCCATCACGCCTGCCC\nTTCCTTGATATTGCACCTTTGGACATCGGTGGTGCTGACCATGAATTCTTTGTGGACATT\nGGCCCAGTCTGTTTCAAATAA"}, "pfams": {"pfam": [{"identifier": "PF01410", "name": "COLFI"}, {"identifier": "PF01391", "name": "Collagen"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular matrix"}, {"category": "component", "description": "extracellular matrix (sensu Metazoa)"}, {"category": "component", "description": "cell"}, {"category": "component", "description": "collagen"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "function", "description": "extracellular matrix structural constituent"}, {"category": "function", "description": "structural molecule activity"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "cellular physiological process"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-09-13", "drugbank-id": [{"@primary": "true", "#text": "DB00049"}, "BIOD00090", "BTD00090"], "name": "Rasburicase", "description": "Rasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified <i>Saccharomyces cerevisiae</i> strain. The cDNA coding for rasburicase was cloned from a strain of <i>Aspergillus flavus</i>.", "cas-number": "134774-45-1", "groups": {"group": ["approved", "investigational"]}, "general-references": "# Giraldez M: A single, fixed dose of Rasburicase (6 mg maximum) for Treatment of Tumor Lysis Syndrome in Adults. Eur J Haematol. 2010 Apr 12. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/ 20394650\n# Collings I, Watier Y, Giffard M, Dagogo S, Kahn R, Bonnete F, Wright JP, Fitch AN, Margiolaki I: Polymorphism of microcrystalline urate oxidase from Aspergillus flavus. Acta Crystallogr D Biol Crystallogr. 2010 May;66(Pt 5):539-48. Epub 2010 Apr 21. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20445229", "synthesis-reference": "Roy Eugene Snoke, Hugh Arthur Risley, Charles Thomas Goodhue, \"Production of uricase from micrococcus luteus.\" U.S. Patent US4062731, issued May, 1974.", "indication": "For treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy)", "pharmacodynamics": "Drugs used to treat lympohoid leukemia, non-Hodgkin's lymphoma and acute myelogenous leukemia often lead to the accumulation of toxic plasma levels of purine metabolites (i.e. uric acid). The injection of rasburicase reduces levels of uric acid and mitigates the toxic effects of chemotherapy induced tumor lysis.", "mechanism-of-action": "Rasburicase catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin).", "toxicity": null, "metabolism": null, "absorption": null, "half-life": "18 hours", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": "* 110 to 127 mL/kg [pediatric patients]\n* 75.8 to 138 mL/kg [adult patients]", "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Urate oxidase"}, {"@language": "", "@coder": "", "#text": "Uricase"}]}, "products": {"product": [{"name": "Fasturtec", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02271397", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "7.5 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Fasturtec", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02248416", "started-marketing-on": "2004-09-21", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "1.5 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Fasturtec", "ingredients": "Rasburicase"}, {"name": "Fasturtec", "ingredients": "Rasburicase"}]}, "packagers": {"packager": [{"name": "GlaxoSmithKline Inc.", "url": "http://www.gsk.com"}, {"name": "Sanofi-Aventis Inc.", "url": "http://www.sanofi-aventis.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Elitek 1.5 mg vial", "cost": {"@currency": "USD", "#text": "627.23"}, "unit": "vial"}, {"description": "Elitek 7.5 mg vial", "cost": {"@currency": "USD", "#text": "3136.18"}, "unit": "vial"}]}, "categories": {"category": [{"category": "Gout Suppressants", "mesh-id": null}, {"category": "Antihyperuricemic Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Powder for solution", "route": "intravenous", "strength": "1.5 mg"}, {"form": "Powder for solution", "route": "intravenous", "strength": "7.5 mg"}]}, "atc-codes": {"atc-code": {"@code": "V03AF07", "level": [{"@code": "V", "#text": "VARIOUS"}, {"@code": "V03", "#text": "ALL OTHER THERAPEUTIC PRODUCTS"}, {"@code": "V03A", "#text": "ALL OTHER THERAPEUTIC PRODUCTS"}, {"@code": "V03AF", "#text": "Detoxifying agents for antineoplastic treatment"}]}}, "ahfs-codes": {"ahfs-code": "44:00.00"}, "patents": {"patent": [{"number": "2148537", "country": "Canada", "approved": "2002-07-16", "expires": "2015-05-03"}, {"number": "2175971", "country": "Canada", "approved": "2003-12-30", "expires": "2016-05-07"}]}, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00049 sequence\nSAVKAARYGKDNVRVYKVHKDEKTGVQTVYEMTVCVLLEGEIETSYTKADNSVIVATDSI\nKNTIYITAKQNPVTPPELFGSILGTHFIEKYNHIHAAHVNIVCHRWTRMDIDGKPHPHSF\nIRDSEEKRNVQVDVVEGKGIDIKSSLSGLTVLKSTNSQFWGFLRDEYTTLKETWDRILST\nDVDATWQWKNFSGLQEVRSHVPKFDATWATAREVTLKTFAEDNSASVQATMYKMAEQILA\nRQQLIETVEYSLPNKHYFEIDLSWHKGLQNTGKNAEVFAPQSDPNGLIKCTVGRSSLKSK\nL"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.465", "source": null}, {"kind": "Isoelectric Point", "value": "7.16", "source": null}, {"kind": "Molecular Weight", "value": "34109.5000", "source": null}, {"kind": "Molecular Formula", "value": "C1521H2381N417O461S7", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "13268"}, {"resource": "National Drug Code Directory", "identifier": "0024-5150-10"}, {"resource": "GenBank", "identifier": "X61766"}, {"resource": "PharmGKB", "identifier": "PA10176"}, {"resource": "UniProtKB", "identifier": "Q00511"}, {"resource": "Wikipedia", "identifier": "Rasburicase"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/elitek.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/rasburicase.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0004823", "name": "Uric acid", "organism": "Human", "actions": {"action": "metabolizer"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Cete S, Yasar A, Arslan F: An amperometric biosensor for uric acid determination prepared from uricase immobilized in polypyrrole film. Artif Cells Blood Substit Immobil Biotechnol. 2006;34(3):367-80. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16809136\n# Gabison L, Chiadmi M, Colloc'h N, Castro B, El Hajji M, Prange T: Recapture of [S]-allantoin, the product of the two-step degradation of uric acid, by urate oxidase. FEBS Lett. 2006 Apr 3;580(8):2087-91. Epub 2006 Mar 10. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16545381\n# Zhao Y, Zhao L, Yang G, Tao J, Bu Y, Liao F: Characterization of a uricase from Bacillus fastidious A.T.C.C. 26904 and its application to serum uric acid assay by a patented kinetic uricase method. Biotechnol Appl Biochem. 2006 Sep;45(Pt 2):75-80. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16689679\n# Giraldez M: A single, fixed dose of Rasburicase (6 mg maximum) for Treatment of Tumor Lysis Syndrome in Adults. Eur J Haematol. 2010 Apr 12. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20394650", "known-action": "yes"}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2005-06-13", "@updated": "2013-09-16", "drugbank-id": [{"@primary": "true", "#text": "DB00050"}, "APRD00686", "BIOD00115", "BTD00115"], "name": "Cetrorelix", "description": "Cetrorelix is a man-made hormone that blocks the effects of Gonadotropin Releasing Hormone (GnRH). GnRH controls another hormone that is called luteinizing hormone (LH), which is the hormone that starts ovulation during the menstrual cycle. When undergoing hormone treatment sometimes premature ovulation can occur, leading to eggs that are not ready for fertilization to be released. Cetrorelix does not allow the premature release of these eggs to occur.", "cas-number": "120287-85-6", "groups": {"group": ["approved", "investigational"]}, "general-references": null, "synthesis-reference": null, "indication": "For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation", "pharmacodynamics": "Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity. GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol (E2) feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This LH-surge induces the ovulation of the dominant follicle, resumption of oocyte meiosis and subsequently luteinization as indicated by rising progesterone levels. Cetrorelix competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner.", "mechanism-of-action": "Cetrorelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion. It competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner.", "toxicity": null, "metabolism": "In in vitro studies, cetrorelix was stable against phase I- and phase II-metabolism. Cetrorelix was transformed by peptidases, and the (1-4) peptide was the predominant metabolite.", "absorption": "Rapidly absorbed following subcutaneous injection. The mean absolute bioavailability following subcutaneous administration to healthy female subjects is 85%.", "half-life": "~62.8 hours", "protein-binding": "86%", "route-of-elimination": "Following subcutaneous administration of 10 mg cetrorelix to males and females, only unchanged cetrorelix was detected in urine.", "volume-of-distribution": "* 1.16 L/kg", "clearance": "* 1.28 ml/min\u00b7kg [adult healthy female with 3 mg single SC administration]", "classification": {"description": "This compound belongs to the class of organic compounds known as polypeptides. These are peptides containing ten or more amino acid residues.", "direct-parent": "Polypeptides", "kingdom": "Organic compounds", "superclass": "Organic Polymers", "class": "Polypeptides", "subclass": null, "alternative-parent": ["Acetamides", "Alpha amino acid amides", "Amphetamines and derivatives", "Aryl chlorides", "Azacyclic compounds", "Carbonyl compounds", "Carboximidamides", "Chlorobenzenes", "Guanidines", "Heteroaromatic compounds", "Hydrocarbon derivatives", "Imines", "N-acyl amines", "N-acyl-alpha amino acids and derivatives", "N-acylpyrrolidines", "Naphthalenes", "Organochlorides", "Peptides", "Phenols and derivatives", "Phenylpropylamines", "Primary alcohols", "Primary carboxylic acid amides", "Pyridines and derivatives", "Pyrrolidinecarboxamides", "Secondary carboxylic acid amides", "Tertiary amines", "Tertiary carboxylic acid amides", "Ureas"], "substituent": ["Acetamide", "Alcohol", "Alpha peptide", "Alpha-amino acid amide", "Amine", "Amphetamine or derivatives", "Aromatic heteropolycyclic compound", "Aryl chloride", "Aryl halide", "Azacycle", "Benzenoid", "Carbonyl group", "Carboxamide group", "Carboximidamide", "Carboxylic acid amide", "Carboxylic acid derivative", "Chlorobenzene", "Fatty acyl", "Fatty amide", "Guanidine", "Halobenzene", "Heteroaromatic compound", "Hydrocarbon derivative", "Imine", "Monocyclic benzene moiety", "N-acyl-alpha amino acid or derivatives", "N-acyl-amine", "N-acylpyrrolidine", "N-substituted-alpha-amino acid", "Naphthalene", "Organochloride", "Organohalogen compound", "Organoheterocyclic compound", "Organonitrogen compound", "Organooxygen compound", "Phenol", "Phenylpropylamine", "Polypeptide", "Primary alcohol", "Primary carboxylic acid amide", "Pyridine", "Pyrrolidine", "Pyrrolidine carboxylic acid or derivatives", "Pyrrolidine-2-carboxamide", "Secondary carboxylic acid amide", "Tertiary amine", "Tertiary carboxylic acid amide", "Urea"]}, "salts": {"salt": {"drugbank-id": {"@primary": "true", "#text": "DBSALT000021"}, "name": "Cetrorelix Acetate", "cas-number": "145672-81-7", "inchikey": "InChIKey=KFEFLCOCAHJBEA-ANRVCLKPSA-N"}}, "synonyms": {"synonym": {"@language": "Latin", "@coder": "INN", "#text": "Cetrorelixum"}}, "products": {"product": [{"name": "Cetrotide", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02247766", "started-marketing-on": "2004-03-03", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "0.25 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Cetrotide", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02247767", "started-marketing-on": "2004-02-25", "ended-marketing-on": "2014-10-20", "dosage-form": "powder for solution", "strength": "3 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Cetrotide", "ingredients": "Cetrorelix"}, {"name": "Cetrotide", "ingredients": "Cetrorelix"}]}, "packagers": {"packager": [{"name": "Baxter International Inc.", "url": "http://www.baxter.com"}, {"name": "EMD Canada Inc.", "url": "http://www.emdcanada.com"}, {"name": "Solvay Pharmaceuticals", "url": "http://global.abbottgrowth.com"}]}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Emd serono inc"}}, "prices": {"price": [{"description": "Cetrotide 0.25 mg kit", "cost": {"@currency": "USD", "#text": "137.99"}, "unit": "kit"}, {"description": "Cetrotide 3 mg kit", "cost": {"@currency": "USD", "#text": "689.92"}, "unit": "kit"}]}, "categories": {"category": [{"category": "Hormone Antagonists", "mesh-id": null}, {"category": "Fertility Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Powder for solution", "route": "subcutaneous", "strength": "0.25 mg"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "3 mg"}]}, "atc-codes": {"atc-code": {"@code": "H01CC02", "level": [{"@code": "H", "#text": "SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS"}, {"@code": "H01", "#text": "PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES"}, {"@code": "H01C", "#text": "HYPOTHALAMIC HORMONES"}, {"@code": "H01CC", "#text": "Anti-gonadotropin-releasing hormones"}]}}, "ahfs-codes": {"ahfs-code": "92:00.00"}, "patents": {"patent": [{"number": "2115943", "country": "Canada", "approved": "2003-08-05", "expires": "2014-02-18"}, {"number": "5198533", "country": "United States", "approved": "1993-10-24", "expires": "2010-10-24"}, {"number": "6319192", "country": "United States", "approved": "1998-04-23", "expires": "2018-04-23"}]}, "food-interactions": null, "drug-interactions": null, "calculated-properties": {"property": [{"kind": "logP", "value": "1.33", "source": "ALOGPS"}, {"kind": "logS", "value": "-5.3", "source": "ALOGPS"}, {"kind": "Water Solubility", "value": "6.94e-03 g/l", "source": "ALOGPS"}, {"kind": "logP", "value": "-1.7", "source": "ChemAxon"}, {"kind": "IUPAC Name", "value": "(2S)-N-[(2S)-5-carbamimidamido-1-[(2S)-2-{[(1R)-1-carbamoylethyl]carbamoyl}pyrrolidin-1-yl]-1-oxopentan-2-yl]-2-[(2R)-5-(carbamoylamino)-2-[(2S)-2-[(2S)-2-[(2R)-2-[(2R)-3-(4-chlorophenyl)-2-[(2R)-2-acetamido-3-(naphthalen-2-yl)propanamido]propanamido]-3-(pyridin-3-yl)propanamido]-3-hydroxypropanamido]-3-(4-hydroxyphenyl)propanamido]pentanamido]-4-methylpentanamide", "source": "ChemAxon"}, {"kind": "Traditional IUPAC Name", "value": "cetrorelix", "source": "ChemAxon"}, {"kind": "Molecular Weight", "value": "1431.038", "source": "ChemAxon"}, {"kind": "Monoisotopic Weight", "value": "1429.669818444", "source": "ChemAxon"}, {"kind": "SMILES", "value": "CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CN=CC=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O", "source": "ChemAxon"}, {"kind": "Molecular Formula", "value": "C70H92ClN17O14", "source": "ChemAxon"}, {"kind": "InChI", "value": "InChI=1S/C70H92ClN17O14/c1-39(2)31-52(61(94)82-51(15-9-28-77-69(73)74)68(101)88-30-10-16-58(88)67(100)79-40(3)59(72)92)83-60(93)50(14-8-29-78-70(75)102)81-63(96)54(34-43-20-25-49(91)26-21-43)86-66(99)57(38-89)87-65(98)56(36-45-11-7-27-76-37-45)85-64(97)55(33-42-18-23-48(71)24-19-42)84-62(95)53(80-41(4)90)35-44-17-22-46-12-5-6-13-47(46)32-44/h5-7,11-13,17-27,32,37,39-40,50-58,89,91H,8-10,14-16,28-31,33-36,38H2,1-4H3,(H2,72,92)(H,79,100)(H,80,90)(H,81,96)(H,82,94)(H,83,93)(H,84,95)(H,85,97)(H,86,99)(H,87,98)(H4,73,74,77)(H3,75,78,102)/t40-,50-,51+,52+,53-,54+,55-,56-,57+,58+/m1/s1", "source": "ChemAxon"}, {"kind": "InChIKey", "value": "InChIKey=SBNPWPIBESPSIF-MHWMIDJBSA-N", "source": "ChemAxon"}, {"kind": "Polar Surface Area (PSA)", "value": "495.67", "source": "ChemAxon"}, {"kind": "Refractivity", "value": "384.16", "source": "ChemAxon"}, {"kind": "Polarizability", "value": "148.09", "source": "ChemAxon"}, {"kind": "Rotatable Bond Count", "value": "38", "source": "ChemAxon"}, {"kind": "H Bond Acceptor Count", "value": "18", "source": "ChemAxon"}, {"kind": "H Bond Donor Count", "value": "17", "source": "ChemAxon"}, {"kind": "pKa (strongest acidic)", "value": "9.49", "source": "ChemAxon"}, {"kind": "pKa (strongest basic)", "value": "11.11", "source": "ChemAxon"}, {"kind": "Physiological Charge", "value": "1", "source": "ChemAxon"}, {"kind": "Number of Rings", "value": "6", "source": "ChemAxon"}, {"kind": "Bioavailability", "value": "0", "source": "ChemAxon"}, {"kind": "Rule of Five", "value": "0", "source": "ChemAxon"}, {"kind": "Ghose Filter", "value": "0", "source": "ChemAxon"}, {"kind": "MDDR-Like Rule", "value": "1", "source": "ChemAxon"}]}, "experimental-properties": null, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "13224"}, {"resource": "ChEBI", "identifier": "59224"}, {"resource": "KEGG Drug", "identifier": "D01685"}, {"resource": "National Drug Code Directory", "identifier": "44087-1225-1"}, {"resource": "PharmGKB", "identifier": "PA164764506"}, {"resource": "Wikipedia", "identifier": "Cetrorelix"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic2/cetrorelix.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/cetrorelix-acetate.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000203", "name": "Gonadotropin-releasing hormone receptor", "organism": "Human", "actions": {"action": "antagonist"}, "references": "# Volker P, Grundker C, Schmidt O, Schulz KD, Emons G: Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am J Obstet Gynecol. 2002 Feb;186(2):171-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11854630\n# Zapatero-Caballero H, Sanchez-Franco F, Guerra-Perez N, Fernandez-Mendez C, Fernandez-Vazquez G: Gonadotropin-releasing hormone receptor gene expression during pubertal development of male rats. Biol Reprod. 2003 May;68(5):1764-70. Epub 2002 Dec 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12606421\n# Zapatero-Caballero H, Sanchez-Franco F, Fernandez-Mendez C, Garcia-San Frutos M, Botella-Cubells LM, Fernandez-Vazquez G: Gonadotropin-releasing hormone receptor gene expression during pubertal development of female rats. Biol Reprod. 2004 Feb;70(2):348-55. Epub 2003 Oct 15. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14561652\n# Roth C, Hegemann F, Hildebrandt J, Balzer I, Witt A, Wuttke W, Jarry H: Pituitary and gonadal effects of GnRH (gonadotropin releasing hormone) analogues in two peripubertal female rat models. Pediatr Res. 2004 Jan;55(1):126-33. Epub 2003 Nov 6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14605254\n# Castellon E, Clementi M, Hitschfeld C, Sanchez C, Benitez D, Saenz L, Contreras H, Huidobro C: Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest. 2006 Apr-May;24(3):261-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16809153\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P30968", "@source": "Swiss-Prot", "name": "Gonadotropin-releasing hormone receptor", "general-function": "Involved in rhodopsin-like receptor activity", "specific-function": "Receptor for gonadotropin releasing hormone (GnRH) that mediate the action of GnRH to stimulate the secretion of the gonadotropic hormones (LH and FSH). This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Isoform 2 may act a an inhibitor of GnRH-R signaling", "gene-name": "GNRHR", "locus": "4q21.2", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "39-58\n78-97\n116-137\n165-184\n213-232\n282-300\n307-326", "signal-regions": null, "theoretical-pi": "9.93", "molecular-weight": "37731.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:4421"}, {"resource": "GenAtlas", "identifier": "GNRHR"}, {"resource": "GeneCards", "identifier": "GNRHR"}, {"resource": "GenBank Gene Database", "identifier": "L03380"}, {"resource": "GenBank Protein Database", "identifier": "183422"}, {"resource": "IUPHAR", "identifier": "256"}, {"resource": "Guide to Pharmacology", "identifier": "31"}, {"resource": "UniProtKB", "identifier": "P30968"}, {"resource": "UniProt Accession", "identifier": "GNRHR_HUMAN"}]}, "synonyms": {"synonym": ["GnRH receptor", "GnRH-R"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Gonadotropin-releasing hormone receptor\nMANSASPEQNQNHCSAINNSIPLMQGNLPTLTLSGKIRVTVTFFLFLLSATFNASFLLKL\nQKWTQKKEKGKKLSRMKLLLKHLTLANLLETLIVMPLDGMWNITVQWYAGELLCKVLSYL\nKLFSMYAPAFMMVVISLDRSLAITRPLALKSNSKVGQSMVGLAWILSSVFAGPQLYIFRM\nIHLADSSGQTKVFSQCVTHCSFSQWWHQAFYNFFTFSCLFIIPLFIMLICNAKIIFTLTR\nVLHQDPHELQLNQSKNNIPRARLKTLKMTVAFATSFTVCWTPYYVLGIWYWFDPEMLNRL\nSDPVNHFFFLFAFLNPCFDPLIYGYFSL"}, "gene-sequence": {"@format": "FASTA", "#text": ">987 bp\nATGGCAAACAGTGCCTCTCCTGAACAGAATCAAAATCACTGTTCAGCCATCAACAACAGC\nATCCCACTGATGCAGGGCAACCTCCCCACTCTGACCTTGTCTGGAAAGATCCGAGTGACG\nGTTACTTTCTTCCTTTTTCTGCTCTCTGCGACCTTTAATGCTTCTTTCTTGTTGAAACTT\nCAGAAGTGGACACAGAAGAAAGAGAAAGGGAAAAAGCTCTCAAGAATGAAGCTGCTCTTA\nAAACATCTGACCTTAGCCAACCTGTTGGAGACTCTGATTGTCATGCCACTGGATGGGATG\nTGGAACATTACAGTCCAATGGTATGCTGGAGAGTTACTCTGCAAAGTTCTCAGTTATCTA\nAAGCTTTTCTCCATGTATGCCCCAGCCTTCATGATGGTGGTGATCAGCCTGGACCGCTCC\nCTGGCTATCACGAGGCCCCTAGCTTTGAAAAGCAACAGCAAAGTCGGACAGTCCATGGTT\nGGCCTGGCCTGGATCCTCAGTAGTGTCTTTGCAGGACCACAGTTATACATCTTCAGGATG\nATTCATCTAGCAGACAGCTCTGGACAGACAAAAGTTTTCTCTCAATGTGTAACACACTGC\nAGTTTTTCACAATGGTGGCATCAAGCATTTTATAACTTTTTCACCTTCAGCTGCCTCTTC\nATCATCCCTCTTTTCATCATGCTGATCTGCAATGCAAAAATCATCTTCACCCTGACACGG\nGTCCTTCATCAGGACCCCCACGAACTACAACTGAATCAGTCCAAGAACAATATACCAAGA\nGCACGGCTGAAGACTCTAAAAATGACGGTTGCATTTGCCACTTCATTTACTGTCTGCTGG\nACTCCCTACTATGTCCTAGGAATTTGGTATTGGTTTGATCCTGAAATGTTAAACAGGTTG\nTCAGACCCAGTAAATCACTTCTTCTTTCTCTTTGCCTTTTTAAACCCATGCTTTGATCCA\nCTTATCTATGGATATTTTTCTCTGTGA"}, "pfams": {"pfam": {"identifier": "PF00001", "name": "7tm_1"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "function", "description": "protein-hormone receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "gonadotropin-releasing hormone receptor activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}]}}}, {"id": "BE0000134", "name": "Lutropin-choriogonadotropic hormone receptor", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Ascoli M, Fanelli F, Segaloff DL: The lutropin/choriogonadotropin receptor, a 2002 perspective. Endocr Rev. 2002 Apr;23(2):141-74. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11943741", "known-action": "unknown", "polypeptide": {"@id": "P22888", "@source": "Swiss-Prot", "name": "Lutropin-choriogonadotropic hormone receptor", "general-function": "Involved in rhodopsin-like receptor activity", "specific-function": "Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase", "gene-name": "LHCGR", "locus": "2p21", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "364-385\n396-416\n440-462\n483-505\n526-549\n571-594\n606-627", "signal-regions": null, "theoretical-pi": "8.58", "molecular-weight": "78617.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6585"}, {"resource": "GenAtlas", "identifier": "LHCGR"}, {"resource": "GeneCards", "identifier": "LHCGR"}, {"resource": "GenBank Gene Database", "identifier": "M73746"}, {"resource": "GenBank Protein Database", "identifier": "903746"}, {"resource": "IUPHAR", "identifier": "254"}, {"resource": "Guide to Pharmacology", "identifier": "30"}, {"resource": "UniProtKB", "identifier": "P22888"}, {"resource": "UniProt Accession", "identifier": "LSHR_HUMAN"}]}, "synonyms": {"synonym": ["LH/CG-R", "LHR", "LSH- R", "Luteinizing hormone receptor", "Lutropin-choriogonadotropic hormone receptor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Lutropin-choriogonadotropic hormone receptor precursor\nMKQRFSALQLLKLLLLLQPPLPRALREALCPEPCNCVPDGALRCPGPTAGLTRLSLAYLP\nVKVIPSQAFRGLNEVIKIEISQIDSLERIEANAFDNLLNLSEILIQNTKNLRYIEPGAFI\nNLPRLKYLSICNTGIRKFPDVTKVFSSESNFILEICDNLHITTIPGNAFQGMNNESVTLK\nLYGNGFEEVQSHAFNGTTLTSLELKENVHLEKMHNGAFRGATGPKTLDISSTKLQALPSY\nGLESIQRLIATSSYSLKKLPSRETFVNLLEATLTYPSHCCAFRNLPTKEQNFSHSISENF\nSKQCESTVRKVSNKTLYSSMLAESELSGWDYEYGFCLPKTPRCAPEPDAFNPCEDIMGYD\nFLRVLIWLINILAIMGNMTVLFVLLTSRYKLTVPRFLMCNLSFADFCMGLYLLLIASVDS\nQTKGQYYNHAIDWQTGSGCSTAGFFTVFASELSVYTLTVITLERWHTITYAIHLDQKLRL\nRHAILIMLGGWLFSSLIAMLPLVGVSNYMKVSICFPMDVETTLSQVYILTILILNVVAFF\nIICACYIKIYFAVRNPELMATNKDTKIAKKMAILIFTDFTCMAPISFFAISAAFKVPLIT\nVTNSKVLLVLFYPINSCANPFLYAIFTKTFQRDFFLLLSKFGCCKRRAELYRRKDFSAYT\nSNCKNGFTGSNKPSQSTLKLSTLHCQGTALLDKTRYTEC"}, "gene-sequence": {"@format": "FASTA", "#text": ">2058 bp\nATGAAGCAGCGGTTCTCGCCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGGCGCCG\nCTGCCACGAGCGCTGCGCAGGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGCGCC\nCTGCGTGCCCCGGCCCCACGGCCGTCCACTCGACTATCACTTGCCTACCTCCCTGTCAAA\nGTGATCCCATCTCAAAGTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATCTCTCAG\nATTGATTCCCTGGAAAGGATAGAAGCTAATGCCTTTGACAACCTCCTCAATTTGTCTGAA\nATACTGATCCAGAACACCAAAAATCTGAGATACATTGAGCCCGGAGCATTTATAAATCTT\nCCCCGATTAAAATACTTGAGCATCTGTAACACAGGCATCAGAAAGTTTCCAGATGTTACG\nAAGGTCTTCTCCTCTGAATCAAATTTCATTCTGGAAATTTGTGATAACTTACACATAACC\nACCATACCAGGAAATGCTTTTCAAGGGATGAATAATGAATCTGTAACACTCAAACTATAT\nGGAAATGGATTTGAAGAAGTACAAAGTCATGCATTCAATGGGACGACACTGACTTCACTG\nGAGCTAAAGGAAAACGTACATCTGGAGAAGATGCACAATGGAGCCTTCCGTGGGGCCACA\nGGGCCGAAAACCTTGGATATTTCTTCCACCAAATTGCAGGCCCTGCCGAGCTATGGCCTA\nGAGTCCATTCAGAGGCTAATTGCCACGTCATCCTATTCTCTAAAAAAATTGCCATCAAAA\nCAAACATTTGTCAATCTCCTGAGGGCCACGCTTCATTACCCCAGCCACTGCTGTGCATTT\nAGAAACTTGCCAACGAAAGAGCTAAACTTCTCACATTCCATTTCTGAAAACTTTTCCAAA\nCAATGTGAAAGCACAGTAAGGAAAAGTGAACTGAGTGGCTGGGACTATGAATATGGTTTC\nTGCTTACCCAAGACACCCCGATGTGCTCCTGAACCAGATGCTTTTAATCCCTGTGAAGAC\nATTATGGGCTATGACTTCCTTAGGGTCCTGATTTGGCTGATTAATATTCTAGCCATCATG\nGGAAACATGACTGTTCTTTTTGTTCTCCTGACAAGTCGTTACAAACTTACAGTGCCTCGT\nTTTCTCATGTGCAATCTCTCCTTTGCAGACTTTTGCATGGGGCTCTATCTGCTGCTCATA\nGCCTCAGTTGATTCCCAAACCAAGGGCCAGTACTATAACCATGCCATAGACTGGCAGACA\nGGGAGTGGGTGCAGCACTGCTGGCTTTTTCACTGTATTAGCAAGTGAACTTTCTGTCTAC\nACCCTCACCGTCATCACTCTAGAAAGATGGCACACCATCACCTATGCTATTCACCTGGAC\nCAAAAGCTGCGATTAAGACATGCCATTCTGATTATGCTTGGAGGCTGGCTCTTTTCTTCT\nCTAATTGCTATGTTGCCCCTTGTCGGGGTCAGCAATTACATGAAGGTCAGTATTTGCTTC\nCCCATGGATGTGGAAACCACTCTCTCACAAGTCTATATATTAACCATCCTGATTCTCAAT\nGTGGTGGCCTTCTTAATAATTTGTGCTTGCTACATTAAAATTTATTTTGCAGTTCGAAAC\nCCAGAATTAATGGCTACCAATAAAGATACAAAGATTGCTAAGAAAATGGCAATCCTCATC\nTTCACCGATTTTACCTGCATGGCACCTATCTCTTTTTTTGCCATCTCAGCTGCCTTCAAA\nGTACCTCTTATCACAGTAACCAACTCTAAAGTTTTACTGGTTCTTTTTTATCCCATCAAT\nTCTTGTGCCAATCCATTTCTGTATGCAATATTCACTAAGACATTCCAAAGAGATTTCTTT\nCTTTTGCTGAGCAAATTTGGCTGCTGTAAACGTCGGGCTGATCCTCTTTATAGAAGGAAA\nGATTTTTCAGCTTACACCTCCAACTGCAAAAATGGCTTCACTGGATCAAATAAGCCTTCT\nCAATCCACCTTGAAGTTGTCCACATTGCACTGTCAAGGTACAGCTCTCCTAGACAAGACT\nCGCTACACAGAGTGTTAA"}, "pfams": {"pfam": {"identifier": "PF00001", "name": "7tm_1"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "function", "description": "lutropin-choriogonadotropic hormone receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "protein-hormone receptor activity"}, {"category": "function", "description": "receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2015-04-20", "drugbank-id": [{"@primary": "true", "#text": "DB00051"}, "BIOD00049", "BTD00049"], "name": "Adalimumab", "description": "Adalimumab is a human monoclonal antibody against TNF-alpha. It is produced by recombinant DNA technology using a mammalian cell expression system. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.", "cas-number": "331731-18-1", "groups": {"group": "approved"}, "general-references": "# PDB sequence \"Link\":http://www.rcsb.org/pdb/download/downloadFile.do?fileFormat=FASTA&compression=NO&structureId=1IGT\n# Patent Information \"Link\":http://www.freepatentsonline.com/6090382.html", "synthesis-reference": null, "indication": "For treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.", "pharmacodynamics": "Used in the treatment of immune system mediated diseases, adalimumab binds specifically to TNF-alpha and blocks its general cytokine effects, thereby reducing TNF-induced inflammation and halting tissue destruction.", "mechanism-of-action": "Adalimumab binds to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement.", "toxicity": null, "metabolism": "Most likely removed by opsonization via the reticuloendothelial system.", "absorption": null, "half-life": "10-20 days.", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": "* 12 mL/hr [RA patients with dose 0.25-10 mg/kg]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": {"@language": "", "@coder": "", "#text": "Ig gamma-1 chain C region"}}, "products": {"product": [{"name": "Humira", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02258595", "started-marketing-on": "2004-09-24", "ended-marketing-on": null, "dosage-form": "solution", "strength": "40 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Humira", "ndc-id": "0074-3797_aa6f7aea-ddd9-b203-263b-0daad92b0ee4", "ndc-product-code": "0074-3797", "dpd-id": null, "started-marketing-on": "2002-12-30", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "40 mg/.8mL", "route": "subcutaneous", "fda-application-number": "BLA125057", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}]}, "international-brands": {"international-brand": {"name": "Humira Pen", "company": "Abbott Laboratories"}}, "mixtures": {"mixture": [{"name": "Humira", "ingredients": "Adalimumab"}, {"name": "Humira", "ingredients": "Adalimumab"}]}, "packagers": {"packager": [{"name": "Abbott Laboratories Ltd.", "url": "http://www.abbott.com"}, {"name": "Vetter Pharma Fertigung GmbH and Co. KG", "url": "http://www.vetter-pharma.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Humira 20 mg/0.4 ml syringe", "cost": {"@currency": "USD", "#text": "959.19"}, "unit": "syringe"}, {"description": "Humira 40 mg/0.8 ml pen", "cost": {"@currency": "USD", "#text": "959.19"}, "unit": "pen"}, {"description": "Humira crohn's starter pack", "cost": {"@currency": "USD", "#text": "959.19"}, "unit": "each"}, {"description": "Humira psoriasis starter pack", "cost": {"@currency": "USD", "#text": "959.19"}, "unit": "each"}, {"description": "Humira (1 Box = Two 40 mg/0.8ml Syringes) Box", "cost": {"@currency": "USD", "#text": "1995.1"}, "unit": "box"}, {"description": "Humira 2 20 mg/0.4ml Kit 1 Box = Two 20 mg/0.4ml Syringes", "cost": {"@currency": "USD", "#text": "1995.1"}, "unit": "box"}, {"description": "Humira Pen 2 40 mg/0.8ml Kit (1 Box = 1 Kit Containing Two 40 mg/0.8ml Pens)", "cost": {"@currency": "USD", "#text": "1995.1"}, "unit": "box"}]}, "categories": {"category": [{"category": "Antirheumatic Agents", "mesh-id": null}, {"category": "Anti-Inflammatory Agents", "mesh-id": null}, {"category": "Immunosuppressive Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, solution", "route": "subcutaneous", "strength": "40 mg/.8mL"}, {"form": "Solution", "route": "subcutaneous", "strength": "40 mg"}]}, "atc-codes": {"atc-code": {"@code": "L04AB04", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L04", "#text": "IMMUNOSUPPRESSANTS"}, {"@code": "L04A", "#text": "IMMUNOSUPPRESSANTS"}, {"@code": "L04AB", "#text": "Tumor necrosis factor alpha (TNF-\u03b1) inhibitors"}]}}, "ahfs-codes": {"ahfs-code": "92:00.00"}, "patents": {"patent": {"number": "2243459", "country": "Canada", "approved": "2002-09-17", "expires": "2017-02-10"}}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB01281", "name": "Abatacept", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported."}, {"drugbank-id": "DB01223", "name": "Aminophylline", "description": "May decrease the serum concentration of Theophylline Derivatives."}, {"drugbank-id": "DB00026", "name": "Anakinra", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported."}, {"drugbank-id": "DB08879", "name": "Belimumab", "description": "Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab."}, {"drugbank-id": "DB06168", "name": "Canakinumab", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased."}, {"drugbank-id": "DB08904", "name": "Certolizumab pegol", "description": "Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab pegol."}, {"drugbank-id": "DB00091", "name": "Cyclosporine", "description": "May decrease the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB06643", "name": "Denosumab", "description": "May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased."}, {"drugbank-id": "DB00065", "name": "Infliximab", "description": "Adalimumab may enhance the immunosuppressive effect of Infliximab."}, {"drugbank-id": "DB01097", "name": "Leflunomide", "description": "Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased."}, {"drugbank-id": "DB00108", "name": "Natalizumab", "description": "Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased."}, {"drugbank-id": "DB00337", "name": "Pimecrolimus", "description": "May enhance the adverse/toxic effect of Immunosuppressants."}, {"drugbank-id": "DB06372", "name": "Rilonacept", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept."}, {"drugbank-id": "DB01656", "name": "Roflumilast", "description": "May enhance the immunosuppressive effect of Immunosuppressants."}, {"drugbank-id": "DB06688", "name": "Sipuleucel-T", "description": "Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T."}, {"drugbank-id": "DB00277", "name": "Theophylline", "description": "May decrease the serum concentration of Theophylline Derivatives."}, {"drugbank-id": "DB06273", "name": "Tocilizumab", "description": "May enhance the immunosuppressive effect of Anti-TNF Agents."}, {"drugbank-id": "DB08895", "name": "Tofacitinib", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib."}, {"drugbank-id": "DB08895", "name": "Tofacitinib", "description": "Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib."}, {"drugbank-id": "DB00072", "name": "Trastuzumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB09033", "name": "Vedolizumab", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab."}, {"drugbank-id": "DB00682", "name": "Warfarin", "description": "Adalimumab may decrease the serum concentration of Warfarin."}]}, "sequences": {"sequence": [{"@format": "FASTA", "#text": "> Light chain:\nDIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPS\nRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIKRTVAAPSVFIFPP\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT\nLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC"}, {"@format": "FASTA", "#text": "> Heavy chain:\nEVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDY\nADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVS\nSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS\nSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC"}]}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.441", "source": null}, {"kind": "Isoelectric Point", "value": "8.25", "source": null}, {"kind": "Molecular Weight", "value": "144190.3000", "source": null}, {"kind": "Molecular Formula", "value": "C6428H9912N1694O1987S46", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "13356"}, {"resource": "National Drug Code Directory", "identifier": "0074-3799-02"}, {"resource": "GenBank", "identifier": "J00228"}, {"resource": "PharmGKB", "identifier": "PA10004"}, {"resource": "UniProtKB", "identifier": "P01857"}, {"resource": "Wikipedia", "identifier": "Adalimumab"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/humira.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/adalimumab.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000704", "name": "Tumor necrosis factor", "organism": "Human", "actions": {"action": "antibody"}, "references": "# Lorenz HM: Technology evaluation: adalimumab, Abbott laboratories. Curr Opin Mol Ther. 2002 Apr;4(2):185-90. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12044041\n# Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL: Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii30-3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14532145\n# Aguillon JC, Contreras J, Dotte A, Cruzat A, Catalan D, Salazar L, Molina MC, Guerrero J, Lopez M, Soto L, Salazar-Onfray F, Cuchacovich M: [New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies] Rev Med Chil. 2003 Dec;131(12):1445-53. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15022409\n# Bang LM, Keating GM: Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs. 2004;18(2):121-39. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15046527\n# Klinkhoff A: Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. Drugs. 2004;64(12):1267-83. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15200343\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P01375", "@source": "Swiss-Prot", "name": "Tumor necrosis factor", "general-function": "Involved in tumor necrosis factor receptor binding", "specific-function": "Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin 1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation", "gene-name": "TNF", "locus": "6p21.3", "cellular-location": "Cell membrane; single-pass type II membrane protein. Processed form:Secreted protein. Also exists as", "transmembrane-regions": "36-56", "signal-regions": null, "theoretical-pi": "6.92", "molecular-weight": "25645.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:11892"}, {"resource": "GenAtlas", "identifier": "TNF"}, {"resource": "GeneCards", "identifier": "TNF"}, {"resource": "GenBank Gene Database", "identifier": "M16441"}, {"resource": "GenBank Protein Database", "identifier": "339741"}, {"resource": "UniProtKB", "identifier": "P01375"}, {"resource": "UniProt Accession", "identifier": "TNFA_HUMAN"}]}, "synonyms": {"synonym": ["Cachectin", "TNF-a", "TNF-alpha", "Tumor necrosis factor ligand superfamily member 2", "Tumor necrosis factor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Tumor necrosis factor precursor\nMSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQR\nEEFPRDLSLISPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELR\nDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRE\nTPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL"}, "gene-sequence": {"@format": "FASTA", "#text": ">702 bp\nATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAG\nACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATC\nGTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGG\nGAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCT\nTCTCGAACCCCGAGTGACAAGCCTGTAGCCCATGTTGTAGCAAACCCTCAAGCTGAGGGG\nCAGCTCCAGTGGCTGAACCGCCGGGCCAATGCCCTCCTGGCCAATGGCGTGGAGCTGAGA\nGATAACCAGCTGGTGGTGCCATCAGAGGGCCTGTACCTCATCTACTCCCAGGTCCTCTTC\nAAGGGCCAAGGCTGCCCCTCCACCCATGTGCTCCTCACCCACACCATCAGCCGCATCGCC\nGTCTCCTACCAGACCAAGGTCAACCTCCTCTCTGCCATCAAGAGCCCCTGCCAGAGGGAG\nACCCCAGAGGGGGCTGAGGCCAAGCCCTGGTATGAGCCCATCTATCTGGGAGGGGTCTTC\nCAGCTGGAGAAGGGTGACCGACTCAGCGCTGAGATCAATCGGCCCGACTATCTCGACTTT\nGCCGAGTCTGGGCAGGTCTACTTTGGGATCATTGCCCTGTGA"}, "pfams": {"pfam": {"identifier": "PF00229", "name": "TNF"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor binding"}, {"category": "function", "description": "cytokine activity"}, {"category": "function", "description": "tumor necrosis factor receptor binding"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "immune response"}]}}}, {"id": "BE0000901", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "O75015", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "general-function": null, "specific-function": "Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils", "gene-name": "FCGR3B", "locus": "1q23", "cellular-location": "Cell membrane; lipid-anchor; GPI-anchor. Secreted protein. Note=Secreted after cleavage", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.71", "molecular-weight": "26216.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3620"}, {"resource": "GenAtlas", "identifier": "FCGR3B"}, {"resource": "GeneCards", "identifier": "FCGR3B"}, {"resource": "GenBank Gene Database", "identifier": "X16863"}, {"resource": "GenBank Protein Database", "identifier": "31322"}, {"resource": "UniProtKB", "identifier": "O75015"}, {"resource": "UniProt Accession", "identifier": "FCG3B_HUMAN"}]}, "synonyms": {"synonym": ["CD16b antigen", "Fc-gamma RIII", "Fc-gamma RIII-beta", "Fc-gamma RIIIb", "FcR-10", "FcRIII", "FcRIIIb", "IgG Fc receptor III-1", "Low affinity immunoglobulin gamma Fc region receptor III-B precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-B precursor\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI"}, "gene-sequence": {"@format": "FASTA", "#text": ">702 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"id": "BE0002093", "name": "Complement C1r subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P00736", "@source": "Swiss-Prot", "name": "Complement C1r subcomponent", "general-function": null, "specific-function": "C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system", "gene-name": "C1R", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.24", "molecular-weight": "80174.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1246"}, {"resource": "GenAtlas", "identifier": "C1R"}, {"resource": "GeneCards", "identifier": "C1R"}, {"resource": "GenBank Gene Database", "identifier": "X04701"}, {"resource": "GenBank Protein Database", "identifier": "29539"}, {"resource": "UniProtKB", "identifier": "P00736"}, {"resource": "UniProt Accession", "identifier": "C1R_HUMAN"}]}, "synonyms": {"synonym": ["Complement C1r subcomponent precursor", "Complement component 1, r subcomponent", "EC 3.4.21.41"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1r subcomponent\nMWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF\nQQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF\nSNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY\nELQEDRHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF\nDIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL\nRYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD\nDGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR\nESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF\nTNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV\nSVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME\nEKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV\nRDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2118 bp\nATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC\nATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC\nAACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC\nCAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT\nGATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG\nGGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC\nTCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT\nGTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG\nTGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT\nGAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG\nGCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC\nAACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT\nGATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC\nGGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC\nAATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG\nCGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC\nATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA\nGGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT\nGATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA\nAACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC\nCGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG\nGAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG\nGGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG\nAGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC\nACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT\nGCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC\nCTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC\nAGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG\nCTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC\nAACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG\nGAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT\nGAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT\nGGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA\nAGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC\nAGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG\nATGGAGGAGGAGGACTGA"}, "pfams": {"pfam": [{"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF07645", "name": "EGF_CA"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"id": "BE0002094", "name": "Complement C1q subcomponent subunit A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02745", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit A", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QA", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.45", "molecular-weight": "26017.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1241"}, {"resource": "GenAtlas", "identifier": "C1QA"}, {"resource": "GeneCards", "identifier": "C1QA"}, {"resource": "GenBank Gene Database", "identifier": "AF135157"}, {"resource": "GenBank Protein Database", "identifier": "4894854"}, {"resource": "UniProtKB", "identifier": "P02745"}, {"resource": "UniProt Accession", "identifier": "C1QA_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit A precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit A\nMEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR\nTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI\nRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR\nGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL\nIFPSA"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG\nGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC\nAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG\nACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC\nAAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGGGCCCGTGGCATCCCGGGAATTAAA\nGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT\nCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG\nGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC\nTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG\nGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG\nGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC\nCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC\nATCTTCCCATCTGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"id": "BE0002095", "name": "Complement C1q subcomponent subunit B", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02746", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit B", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QB", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.87", "molecular-weight": "26460.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1242"}, {"resource": "GenAtlas", "identifier": "C1QB"}, {"resource": "GeneCards", "identifier": "C1QB"}, {"resource": "GenBank Gene Database", "identifier": "X03084"}, {"resource": "GenBank Protein Database", "identifier": "573114"}, {"resource": "UniProtKB", "identifier": "P02746"}, {"resource": "UniProt Accession", "identifier": "C1QB_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit B precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit B\nMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEK\nGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKI\nAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCV\nNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANSIF\nSGFLLFPDMEA"}, "gene-sequence": {"@format": "FASTA", "#text": ">688 bp\nCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGG\nGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCC\nAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAA\nTCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGCCCAGGGGCCCCTGG\nAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAGAAAATCGCCTTCTC\nTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATCCGCTTCGACCACGT\nGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTCACCTGCAAGGTGCC\nCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTGTGCGTGAACCTCAT\nGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTATGCCTACAACACCTT\nCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAGAACGTCTTCCTGCA\nGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGCATCTTTTCCGGGTT\nCCTGCTCTTTCCAGATATGGAGGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"id": "BE0002096", "name": "Complement C1q subcomponent subunit C", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02747", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit C", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QC", "locus": "1p36.11", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.58", "molecular-weight": "25774.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1245"}, {"resource": "GenAtlas", "identifier": "C1QC"}, {"resource": "GeneCards", "identifier": "C1QC"}, {"resource": "GenBank Gene Database", "identifier": "AF087892"}, {"resource": "GenBank Protein Database", "identifier": "33150626"}, {"resource": "UniProtKB", "identifier": "P02747"}, {"resource": "UniProt Accession", "identifier": "C1QC_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit C precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit C\nMDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP\nGIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS\nVFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV\nLLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF\nLLFPD"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG\nCTGCTGCCCCTCAGGGCCAAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC\nCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA\nGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA\nCCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC\nCCCATGGGATTCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA\nGTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC\nAACGCGGTCCTCACCAACCCGCAGGAGGATTATGACACGAGCACTGGCAAGTTCACCTGC\nAAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG\nCTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT\nCAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT\nGTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC\nCTGCTCTTCCCCGACTAG"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"id": "BE0002097", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P08637", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "general-function": null, "specific-function": "Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis", "gene-name": "FCGR3A", "locus": "1q23", "cellular-location": "Cell membrane", "transmembrane-regions": "209-229", "signal-regions": null, "theoretical-pi": "8.21", "molecular-weight": "29089.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3619"}, {"resource": "GenAtlas", "identifier": "FCGR3A"}, {"resource": "GeneCards", "identifier": "FCGR3A"}, {"resource": "GenBank Gene Database", "identifier": "X52645"}, {"resource": "GenBank Protein Database", "identifier": "31324"}, {"resource": "UniProtKB", "identifier": "P08637"}, {"resource": "UniProt Accession", "identifier": "FCG3A_HUMAN"}]}, "synonyms": {"synonym": ["CD16a antigen", "Fc-gamma RIII", "Fc-gamma RIII-alpha", "Fc-gamma RIIIa", "FcR-10", "FcRIII", "FcRIIIa", "IgG Fc receptor III-2", "Low affinity immunoglobulin gamma Fc region receptor III-A precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK"}, "gene-sequence": {"@format": "FASTA", "#text": ">765 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCGACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCA\nAAAGCCACACTCAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTTTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGG\nAAGGACCATAAATTTAAATGGAGAAAGGACCCTCAAGACAAATGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"id": "BE0001529", "name": "Complement C1s subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P09871", "@source": "Swiss-Prot", "name": "Complement C1s subcomponent", "general-function": "Involved in calcium ion binding", "specific-function": "C1s B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4", "gene-name": "C1S", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "4.59", "molecular-weight": "76685.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1247"}, {"resource": "GenAtlas", "identifier": "C1S"}, {"resource": "GeneCards", "identifier": "C1S"}, {"resource": "GenBank Gene Database", "identifier": "X06596"}, {"resource": "GenBank Protein Database", "identifier": "763110"}, {"resource": "UniProtKB", "identifier": "P09871"}, {"resource": "UniProt Accession", "identifier": "C1S_HUMAN"}]}, "synonyms": {"synonym": ["C1 esterase", "Complement C1s subcomponent precursor", "EC 3.4.21.42"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1s subcomponent precursor\nMWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIE\nLSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERF\nTGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVF\nTALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVF\nVAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTP\nNSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCG\nIPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPK\nCVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGN\nREPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVK\nMGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKV\nEKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCG\nTYGLYTRVKNYVDWIMKTMQENSTPRED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2067 bp\nATGTGGTGCATTGTCCTGTTTTCACTTTTGGCATGGGTTTATGCTGAGCCTACCATGTAT\nGGGGAGATCCTGTCCCCTAACTATCCTCAGGCATATCCCAGTGAGGTAGAGAAATCTTGG\nGACATAGAAGTTCCTGAAGGGTATGGGATTCACCTCTACTTCACCCATCTGGACATTGAG\nCTGTCAGAGAACTGTGCGTATGACTCAGTGCAGATAATCTCAGGAGACACTGAAGAAGGG\nAGGCTCTGTGGACAGAGGAGCAGTAACAATCCCCACTCTCCAATTGTGGAAGAGTTCCAA\nGTCCCATACAACAAACTCCAGGTGATCTTTAAGTCAGACTTTTCCAATGAAGAGCGTTTT\nACGGGGTTTGCTGCATACTATGTTGCCACAGACATAAATGAATGCACAGATTTTGTAGAT\nGTCCCTTGTAGCCACTTCTGCAACAATTTCATTGGTGGTTACTTCTGCTCCTGCCCCCCG\nGAATATTTCCTCCATGATGACATGAAGAATTGCGGAGTTAATTGCAGTGGGGATGTATTC\nACTGCACTGATTGGGGAGATTGCAAGTCCCAATTATCCCAAACCATATCCAGAGAACTCA\nAGGTGTGAATACCAGATCCGGTTGGAGAAAGGGTTCCAAGTGGTGGTGACCTTGCGGAGA\nGAAGATTTTGATGTGGAAGCAGCTGACTCAGCGGGAAACTGCCTTGACAGTTTAGTTTTT\nGTTGCAGGAGATCGGCAATTTGGTCCTTACTGTGGTCATGGATTCCCTGGGCCTCTAAAT\nATTGAAACCAAGAGTAATGCTCTTGATATCATCTTCCAAACTGATCTAACAGGGCAAAAA\nAAGGGCTGGAAACTTCGCTATCATGGAGATCCAATGCCCTGCCCTAAGGAAGACACTCCC\nAATTCTGTTTGGGAGCCTGCGAAGGCAAAATATGTCTTTAGAGATGTGGTGCAGATAACC\nTGTCTGGATGGGTTTGAAGTTGTGGAGGGACGTGTTGGTGCAACATCTTTCTATTCGACT\nTGTCAAAGCAATGGAAAGTGGAGTAATTCCAAACTGAAATGTCAACCTGTGGACTGTGGC\nATTCCTGAATCCATTGAGAATGGTAAAGTTGAAGACCCAGAGAGCACTTTGTTTGGTTCT\nGTCATCCGCTACACTTGTGAGGAGCCATATTACTACATGGAAAATGGAGGAGGTGGGGAG\nTATCACTGTGCTGGTAACGGGAGCTGGGTGAATGAGGTGCTGGGCCCGGAGCTGCCGAAA\nTGTGTTCCAGTCTGTGGAGTCCCCAGAGAACCCTTTGAAGAAAAACAGAGGATAATTGGA\nGGATCCGATGCAGATATTAAAAACTTCCCCTGGCAAGTCTTCTTTGACAACCCATGGGCT\nGGTGGAGCGCTCATTAATGAGTACTGGGTGCTGACGGCTGCTCATGTTGTGGAGGGAAAC\nAGGGAGCCAACAATGTATGTTGGGTCCACCTCAGTGCAGACCTCACGGCTGGCAAAATCC\nAAGATGCTCACTCCTGAGCATGTGTTTATTCATCCGGGATGGAAGCTGCTGGAAGTCCCA\nGAAGGACGAACCAATTTTGATAATGACATTGCACTGGTGCGGCTGAAAGACCCAGTGAAA\nATGGGACCCACCGTCTCTCCCATCTGCCTACCAGGCACCTCTTCCGACTACAACCTCATG\nGATGGGGACCTGGGACTGATCTCAGGCTGGGGCCGAACAGAGAAGAGAGATCGTGCTGTT\nCGCCTCAAGGCGGCAAGGTTACCTGTAGCTCCTTTAAGAAAATGCAAAGAAGTGAAAGTG\nGAGAAACCCACAGCAGATGCAGAGGCCTATGTTTTCACTCCTAACATGATCTGTGCTGGA\nGGAGAGAAGGGCATGGATAGCTGTAAAGGGGACAGTGGTGGGGCCTTTGCTGTACAGGAT\nCCCAATGACAAGACCAAATTCTACGCAGCTGGCCTGGTGTCCTGGGGGCCCCAGTGTGGG\nACCTATGGGCTCTACACACGGGTAAAGAACTATGTTGACTGGATAATGAAGACTATGCAG\nGAAAATAGCACCCCCCGTGAGGACTAA"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"id": "BE0000710", "name": "High affinity immunoglobulin gamma Fc receptor I", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P12314", "@source": "Swiss-Prot", "name": "High affinity immunoglobulin gamma Fc receptor I", "general-function": "Involved in receptor signaling protein activity", "specific-function": "Binds to the Fc region of immunoglobulins gamma. High affinity receptor", "gene-name": "FCGR1A", "locus": "1q21.2-q21.3", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "293-313", "signal-regions": null, "theoretical-pi": "8.08", "molecular-weight": "42632.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3613"}, {"resource": "GenAtlas", "identifier": "FCGR1A"}, {"resource": "GeneCards", "identifier": "FCGR1A"}, {"resource": "GenBank Gene Database", "identifier": "X14356"}, {"resource": "GenBank Protein Database", "identifier": "31332"}, {"resource": "UniProtKB", "identifier": "P12314"}, {"resource": "UniProt Accession", "identifier": "FCGR1_HUMAN"}]}, "synonyms": {"synonym": ["CD64 antigen", "Fc-gamma RI", "FcRI", "High affinity immunoglobulin gamma Fc receptor I precursor", "IgG Fc receptor I"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">High affinity immunoglobulin gamma Fc receptor I precursor\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1125 bp\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCTCTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAACTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"id": "BE0002098", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P12318", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "general-function": null, "specific-function": "Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens", "gene-name": "FCGR2A", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.78", "molecular-weight": "34990.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3616"}, {"resource": "GenAtlas", "identifier": "FCGR2A"}, {"resource": "GeneCards", "identifier": "FCGR2A"}, {"resource": "GenBank Gene Database", "identifier": "M31932"}, {"resource": "GenBank Protein Database", "identifier": "182474"}, {"resource": "UniProtKB", "identifier": "P12318"}, {"resource": "UniProt Accession", "identifier": "FCG2A_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-a", "Fc-gamma-RIIa", "FcRII-a", "IgG Fc receptor II-a", "Low affinity immunoglobulin gamma Fc region receptor II-a precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-a\nMAMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSRLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">954 bp\nATGGCTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"id": "BE0002099", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31994", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "general-function": null, "specific-function": "Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B- cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis", "gene-name": "FCGR2B", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.12", "molecular-weight": "34044.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3618"}, {"resource": "GenAtlas", "identifier": "FCGR2B"}, {"resource": "GeneCards", "identifier": "FCGR2B"}, {"resource": "GenBank Gene Database", "identifier": "U87560"}, {"resource": "GenBank Protein Database", "identifier": "4099445"}, {"resource": "UniProtKB", "identifier": "P31994"}, {"resource": "UniProt Accession", "identifier": "FCG2B_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-b", "Fc-gamma-RIIb", "FcRII-b", "IgG Fc receptor II-b", "Low affinity immunoglobulin gamma Fc region receptor II-b precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI"}, "gene-sequence": {"@format": "FASTA", "#text": ">930 bp\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCTCTCCCAGGATACCCTGAG\nTGCAGGGAAATGGGAGAGACCCTCCCTGAGAAACCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATT"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"id": "BE0002100", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31995", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "general-function": null, "specific-function": "Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells", "gene-name": "FCGR2C", "locus": "1q23.3", "cellular-location": "Cell membrane", "transmembrane-regions": "224-246", "signal-regions": null, "theoretical-pi": "6.9", "molecular-weight": "35578.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:15626"}, {"resource": "GenAtlas", "identifier": "FCGR2C"}, {"resource": "GeneCards", "identifier": "FCGR2C"}, {"resource": "GenBank Gene Database", "identifier": "X17652"}, {"resource": "GenBank Protein Database", "identifier": "32074"}, {"resource": "UniProtKB", "identifier": "P31995"}, {"resource": "UniProt Accession", "identifier": "FCG2C_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-c", "Fc-gamma-RIIc", "FcRII-c", "IgG Fc receptor II-c", "Low affinity immunoglobulin gamma Fc region receptor II-c precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-c\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR\nAPTDDDKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">972 bp\nATGGGAATCCTGTCATTTTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACAGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCATTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCTGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG\nAAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT\nGAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG\nGCACCTACTGACGATGATAAAAACATCTACTTGACTCTTCCTCCCAACGACCATGTCAAC\nAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-09-13", "drugbank-id": [{"@primary": "true", "#text": "DB00052"}, "BIOD00086", "BTD00086"], "name": "Somatropin recombinant", "description": "Recombinant human growth hormone (somatotropin) 191 residues, MW 22.1 kD, synthesized in E. coli", "cas-number": "12629-01-5", "groups": {"group": ["approved", "investigational"]}, "general-references": "# Seltzer V, Tonge SR: Proceedings: Methylamphetamine withdrawal as a model for the depressive state: antagonism of post-amphetamine depression by imipramine. J Pharm Pharmacol. 1975 Dec;27 Suppl?-2:16P. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2688\n# Alba-Roth J, Muller OA, Schopohl J, von Werder K: Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion. J Clin Endocrinol Metab. 1988 Dec;67(6):1186-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2903866\n# Scarth JP: Modulation of the growth hormone-insulin-like growth factor (GH-IGF) axis by pharmaceutical, nutraceutical and environmental xenobiotics: an emerging role for xenobiotic-metabolizing enzymes and the transcription factors regulating their expression. A review. Xenobiotica. 2006 Feb-Mar;36(2-3):119-218. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16702112\n# Takahashi Y, Kipnis DM, Daughaday WH: Growth hormone secretion during sleep. J Clin Invest. 1968 Sep;47(9):2079-90. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/5675428", "synthesis-reference": "Mandayam J. Narasimhan, John A. Anderson, \"Process for the large scale production of human growth hormone by serial secondary suspension culture.\" U.S. Patent US4124448, issued January, 1963.", "indication": "For treatment of dwarfism, acromegaly and prevention of HIV-induced weight loss", "pharmacodynamics": "Used in the treatment of dwarfism and growth failure, growth hormone (hGH) stimulates skeletal growth in pediatric patients with growth failure due to a lack of adequate secretion of endogenous GH. Skeletal growth is accomplished at the epiphyseal plates at the ends of a growing bone. Growth and metabolism of epiphyseal plate cells are directly stimulated by GH and one of its mediators, IGF-I (insulin-like growth factor).", "mechanism-of-action": "hGH binds to the human growth hormone receptor (GHR). Upon binding, hGH causes dimerization of GHR, activation of the GHR-associated JAK2 tyrosine kinase, and tyrosyl phosphorylation of both JAK2 and GHR. These events recruit and/or activate a variety of signaling molecules, including MAP kinases, insulin receptor substrates, phosphatidylinositol 3' phosphate kinase, diacylglycerol, protein kinase C, intracellular calcium, and Stat transcription factors. These signaling molecules contribute to the GH-induced changes in enzymatic activity, transport function, and gene expression that ultimately culminate in changes in growth and metabolism.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": "Although calcium excretion in the urine is increased, there is a simultaneous increase in calcium absorption from the intestine. Somatropin stimulates the synthesis of chondroitin sulfate and collagen, and increases the urinary excretion of hydroxyproline.", "volume-of-distribution": null, "clearance": "* 2.3 +/- 1.8 mL/min/kg [GHD patients (IV 33 ng/kg/min)]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "GH"}, {"@language": "", "@coder": "", "#text": "GH-N"}, {"@language": "", "@coder": "", "#text": "Growth hormone"}, {"@language": "", "@coder": "", "#text": "Growth hormone 1"}, {"@language": "", "@coder": "", "#text": "Pituitary growth hormone"}, {"@language": "", "@coder": "", "#text": "Somatotropin precursor"}, {"@language": "", "@coder": "", "#text": "Somatropin"}]}, "products": {"product": [{"name": "Bio-tropin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02231515", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "liquid; powder for solution", "strength": "10 ml", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Bio-tropin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02231516", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "liquid; powder for solution", "strength": "10 ml", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Genotropin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02401681", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "5 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Genotropin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02401746", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "0.2 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Genotropin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02401754", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "0.4 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Genotropin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02401703", "started-marketing-on": "2013-09-18", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "5.3 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Genotropin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02401711", "started-marketing-on": "2013-09-18", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "12 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Genotropin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02401762", "started-marketing-on": "2013-09-18", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "0.6 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Genotropin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02401770", "started-marketing-on": "2013-09-18", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "0.8 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Genotropin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02401789", "started-marketing-on": "2013-09-18", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "1.0 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Genotropin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02401797", "started-marketing-on": "2013-09-18", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "1.2 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Genotropin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02401800", "started-marketing-on": "2013-09-18", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "1.4 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Genotropin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02401819", "started-marketing-on": "2013-09-18", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "1.6 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Genotropin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02401827", "started-marketing-on": "2013-09-18", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "1.8 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Genotropin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02401835", "started-marketing-on": "2013-09-18", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "2.0 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Humatrope Inj 1mg/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00745626", "started-marketing-on": "1987-12-31", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "1 mg", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Norditropin", "ndc-id": "0169-7703_d3cd279e-c599-4d0c-b2e7-bf52e97fba13", "ndc-product-code": "0169-7703", "dpd-id": null, "started-marketing-on": "2009-03-30", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "30 mg/3mL", "route": "subcutaneous", "fda-application-number": "NDA021148", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Norditropin", "ndc-id": "0169-7704_d3cd279e-c599-4d0c-b2e7-bf52e97fba13", "ndc-product-code": "0169-7704", "dpd-id": null, "started-marketing-on": "2005-01-03", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "5 mg/1.5mL", "route": "subcutaneous", "fda-application-number": "NDA021148", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Norditropin", "ndc-id": "0169-7705_d3cd279e-c599-4d0c-b2e7-bf52e97fba13", "ndc-product-code": "0169-7705", "dpd-id": null, "started-marketing-on": "2006-01-02", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "10 mg/1.5mL", "route": "subcutaneous", "fda-application-number": "NDA021148", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Norditropin", "ndc-id": "0169-7708_d3cd279e-c599-4d0c-b2e7-bf52e97fba13", "ndc-product-code": "0169-7708", "dpd-id": null, "started-marketing-on": "2005-01-03", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "15 mg/1.5mL", "route": "subcutaneous", "fda-application-number": "NDA021148", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Norditropin", "ndc-id": "54868-6146_7af60e76-41ca-4324-8f44-c6cc00fdd694", "ndc-product-code": "54868-6146", "dpd-id": null, "started-marketing-on": "2010-08-10", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "5 mg/1.5mL", "route": "subcutaneous", "fda-application-number": "NDA021148", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Norditropin Nordiflex", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02334852", "started-marketing-on": "2014-08-15", "ended-marketing-on": null, "dosage-form": "solution", "strength": "5 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Norditropin Nordiflex", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02334860", "started-marketing-on": "2014-08-15", "ended-marketing-on": null, "dosage-form": "solution", "strength": "10 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Norditropin Nordiflex", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02334879", "started-marketing-on": "2014-08-15", "ended-marketing-on": null, "dosage-form": "solution", "strength": "15 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Norditropin Simplexx", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02334968", "started-marketing-on": "2010-05-04", "ended-marketing-on": "2015-06-19", "dosage-form": "solution", "strength": "15 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Norditropin Simplexx", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02334941", "started-marketing-on": "2010-05-04", "ended-marketing-on": "2015-06-19", "dosage-form": "solution", "strength": "10 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Norditropin Simplexx", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02334925", "started-marketing-on": "2010-05-04", "ended-marketing-on": "2015-06-19", "dosage-form": "solution", "strength": "5 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Nutropin - Kit  Pws(10mg) & Liq(10ml) Im Sc", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02216191", "started-marketing-on": "2002-10-08", "ended-marketing-on": "2013-12-02", "dosage-form": "kit; powder for solution", "strength": "10 mg", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Nutropin - Kit  Pws(5mg) & Liq(10ml) Im Sc", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02216183", "started-marketing-on": "1997-01-20", "ended-marketing-on": "2011-07-19", "dosage-form": "kit; powder for solution", "strength": "5 mg", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Nutropin Aq - Sc 5mg/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02229722", "started-marketing-on": "1997-10-14", "ended-marketing-on": "2013-04-16", "dosage-form": "liquid", "strength": "5 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Nutropin Aq Nuspin 10", "ndc-id": "50242-074_e18cba5f-c533-4435-83ea-9cf3867ad56f", "ndc-product-code": "50242-074", "dpd-id": null, "started-marketing-on": "1995-12-29", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "10 mg/2mL", "route": "subcutaneous", "fda-application-number": "NDA020522", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Nutropin Aq Nuspin 10", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02376393", "started-marketing-on": "2012-05-18", "ended-marketing-on": null, "dosage-form": "solution", "strength": "10 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Nutropin Aq Nuspin 20", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02399083", "started-marketing-on": "2013-09-09", "ended-marketing-on": null, "dosage-form": "solution", "strength": "20 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Nutropin Aq Nuspin 20", "ndc-id": "50242-076_e18cba5f-c533-4435-83ea-9cf3867ad56f", "ndc-product-code": "50242-076", "dpd-id": null, "started-marketing-on": "1995-12-29", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "20 mg/2mL", "route": "subcutaneous", "fda-application-number": "NDA020522", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Nutropin Aq Nuspin 5", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02399091", "started-marketing-on": "2013-09-09", "ended-marketing-on": null, "dosage-form": "solution", "strength": "5 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Nutropin Aq Nuspin 5", "ndc-id": "50242-075_e18cba5f-c533-4435-83ea-9cf3867ad56f", "ndc-product-code": "50242-075", "dpd-id": null, "started-marketing-on": "1995-12-29", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "5 mg/2mL", "route": "subcutaneous", "fda-application-number": "NDA020522", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Nutropin Aq Pen 10", "ndc-id": "50242-043_e18cba5f-c533-4435-83ea-9cf3867ad56f", "ndc-product-code": "50242-043", "dpd-id": null, "started-marketing-on": "1995-12-29", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "10 mg/2mL", "route": "subcutaneous", "fda-application-number": "NDA020522", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Nutropin Aq Pen 20", "ndc-id": "50242-073_e18cba5f-c533-4435-83ea-9cf3867ad56f", "ndc-product-code": "50242-073", "dpd-id": null, "started-marketing-on": "1995-12-29", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "20 mg/2mL", "route": "subcutaneous", "fda-application-number": "NDA020522", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Nutropin Aq Pen Cartridge", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02249002", "started-marketing-on": "2004-08-09", "ended-marketing-on": null, "dosage-form": "solution", "strength": "10 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Omnitrope", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02325063", "started-marketing-on": "2009-04-20", "ended-marketing-on": null, "dosage-form": "solution", "strength": "5.0 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Omnitrope", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02325071", "started-marketing-on": "2009-04-20", "ended-marketing-on": null, "dosage-form": "solution", "strength": "10.0 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Omnitrope", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02325055", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "kit; powder for solution", "strength": "5.8 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Omnitrope", "ndc-id": "0781-3001_27a5c992-5724-4ed9-a72c-d7d7e1953fc9", "ndc-product-code": "0781-3001", "dpd-id": null, "started-marketing-on": "2006-05-30", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "5 mg/1.5mL", "route": "subcutaneous", "fda-application-number": "NDA021426", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Omnitrope", "ndc-id": "0781-3004_27a5c992-5724-4ed9-a72c-d7d7e1953fc9", "ndc-product-code": "0781-3004", "dpd-id": null, "started-marketing-on": "2006-05-30", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "10 mg/1.5mL", "route": "subcutaneous", "fda-application-number": "NDA021426", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Saizen", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02350122", "started-marketing-on": "2010-12-02", "ended-marketing-on": null, "dosage-form": "solution", "strength": "5.83 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Saizen", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02350130", "started-marketing-on": "2010-12-02", "ended-marketing-on": null, "dosage-form": "solution", "strength": "8 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Saizen", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02350149", "started-marketing-on": "2010-12-02", "ended-marketing-on": null, "dosage-form": "solution", "strength": "8 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Saizen", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02237971", "started-marketing-on": "1999-10-26", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "5 mg", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Saizen 10iu  -  Kit", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02215136", "started-marketing-on": "1996-10-17", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "5 ml", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Saizen 8.8mg (5.83mg/ml)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02272083", "started-marketing-on": "2006-01-23", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "8.8 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Serostim", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02239046", "started-marketing-on": "1999-07-28", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "5 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Serostim", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02239047", "started-marketing-on": "1999-06-30", "ended-marketing-on": "2013-07-15", "dosage-form": "powder for solution", "strength": "6 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": [{"name": "BioTropin", "company": "Biotech General"}, {"name": "NutropinAQ", "company": "Genentech Inc."}]}, "mixtures": {"mixture": [{"name": "Norditropin", "ingredients": "Somatropin recombinant"}, {"name": "Norditropin", "ingredients": "Somatropin recombinant"}, {"name": "Norditropin", "ingredients": "Somatropin recombinant"}, {"name": "Norditropin", "ingredients": "Somatropin recombinant"}, {"name": "Omnitrope", "ingredients": "Somatropin recombinant"}, {"name": "Omnitrope", "ingredients": "Somatropin recombinant"}, {"name": "Nutropin Aq Pen 10", "ingredients": "Somatropin recombinant"}, {"name": "Nutropin Aq Pen 20", "ingredients": "Somatropin recombinant"}, {"name": "Nutropin Aq Nuspin 10", "ingredients": "Somatropin recombinant"}, {"name": "Nutropin Aq Nuspin 5", "ingredients": "Somatropin recombinant"}, {"name": "Nutropin Aq Nuspin 20", "ingredients": "Somatropin recombinant"}, {"name": "Norditropin", "ingredients": "Somatropin recombinant"}, {"name": "Saizen 10iu  -  Kit", "ingredients": "Sodium Chloride + Somatropin recombinant"}, {"name": "Saizen", "ingredients": "Somatropin recombinant"}, {"name": "Serostim", "ingredients": "Somatropin recombinant + Water"}, {"name": "Nutropin Aq Pen Cartridge", "ingredients": "Somatropin recombinant"}, {"name": "Saizen 8.8mg (5.83mg/ml)", "ingredients": "Somatropin recombinant"}, {"name": "Omnitrope", "ingredients": "Somatropin recombinant"}, {"name": "Omnitrope", "ingredients": "Somatropin recombinant"}, {"name": "Humatrope Inj 1mg/ml", "ingredients": "Somatropin recombinant"}, {"name": "Norditropin Nordiflex", "ingredients": "Somatropin recombinant"}, {"name": "Norditropin Nordiflex", "ingredients": "Somatropin recombinant"}, {"name": "Norditropin Nordiflex", "ingredients": "Somatropin recombinant"}, {"name": "Saizen", "ingredients": "Somatropin recombinant"}, {"name": "Saizen", "ingredients": "Somatropin recombinant"}, {"name": "Saizen", "ingredients": "Somatropin recombinant"}, {"name": "Nutropin Aq Nuspin 10", "ingredients": "Somatropin recombinant"}, {"name": "Nutropin Aq Nuspin 20", "ingredients": "Somatropin recombinant"}, {"name": "Nutropin Aq Nuspin 5", "ingredients": "Somatropin recombinant"}, {"name": "Genotropin", "ingredients": "Somatropin recombinant"}, {"name": "Genotropin", "ingredients": "Somatropin recombinant"}, {"name": "Genotropin", "ingredients": "Somatropin recombinant"}, {"name": "Genotropin", "ingredients": "Somatropin recombinant"}, {"name": "Genotropin", "ingredients": "Somatropin recombinant"}, {"name": "Genotropin", "ingredients": "Somatropin recombinant"}, {"name": "Genotropin", "ingredients": "Somatropin recombinant"}, {"name": "Genotropin", "ingredients": "Somatropin recombinant"}, {"name": "Genotropin", "ingredients": "Somatropin recombinant"}, {"name": "Genotropin", "ingredients": "Somatropin recombinant"}, {"name": "Nutropin - Kit  Pws(5mg) & Liq(10ml) Im Sc", "ingredients": "Somatropin recombinant + Water"}, {"name": "Nutropin - Kit  Pws(10mg) & Liq(10ml) Im Sc", "ingredients": "Somatropin recombinant + Water"}, {"name": "Nutropin Aq - Sc 5mg/ml", "ingredients": "Somatropin recombinant"}, {"name": "Serostim", "ingredients": "Somatropin recombinant + Water"}, {"name": "Norditropin Simplexx", "ingredients": "Somatropin recombinant"}, {"name": "Norditropin Simplexx", "ingredients": "Somatropin recombinant"}, {"name": "Norditropin Simplexx", "ingredients": "Somatropin recombinant"}, {"name": "Bio-tropin", "ingredients": "Sodium Chloride + Somatropin recombinant"}, {"name": "Bio-tropin", "ingredients": "Sodium Chloride + Somatropin recombinant"}, {"name": "Omnitrope", "ingredients": "Somatropin recombinant + Water"}, {"name": "Genotropin", "ingredients": "Somatropin recombinant"}, {"name": "Genotropin", "ingredients": "Somatropin recombinant"}, {"name": "Genotropin", "ingredients": "Somatropin recombinant"}]}, "packagers": {"packager": [{"name": "Bio Technology General Ltd.", "url": null}, {"name": "Bristol-Myers Squibb Co.", "url": "http://www.bms.com"}, {"name": "BTG Pharmaceuticals Corp.", "url": "http://www.btgplc.com"}, {"name": "Ebewe Pharma", "url": "http://www.ebewe.at"}, {"name": "Eli Lilly & Co.", "url": "http://www.lilly.com"}, {"name": "EMD Canada Inc.", "url": "http://www.emdcanada.com"}, {"name": "F Hoffmann-La Roche Ltd.", "url": "http://www.roche.com"}, {"name": "First KJM Corporation", "url": null}, {"name": "Gate Pharmaceuticals", "url": null}, {"name": "Genentech Inc.", "url": "http://www.gene.com"}, {"name": "Hospira Inc.", "url": "http://www.hospira.com"}, {"name": "Merck KGaA", "url": "http://www.merck.de"}, {"name": "Merck Serono SPA", "url": "http://www.merckserono.net"}, {"name": "Novartis AG", "url": "http://www.novartis.com"}, {"name": "Novo Nordisk Inc.", "url": "http://www.novonordisk.com"}, {"name": "Pfizer Inc.", "url": "http://www.pfizer.com"}, {"name": "Pharmacia Inc.", "url": "http://www.pharmaciaupjohn.com"}, {"name": "Physicians Total Care Inc.", "url": "http://www.physicianstotalcare.com"}, {"name": "Sandoz", "url": "http://www.sandoz.ca"}, {"name": "Serono SA", "url": "http://www.merckserono.net"}, {"name": "Vetter Pharma Fertigung GmbH and Co. KG", "url": "http://www.vetter-pharma.com"}, {"name": "Wasserburger Arzneimittelwerk GmbH", "url": null}]}, "manufacturers": {"manufacturer": [{"@generic": "false", "#text": "Genentech inc"}, {"@generic": "false", "#text": "Serono laboratories inc"}, {"@generic": "false", "#text": "Cangene corp"}, {"@generic": "false", "#text": "Ferring pharmaceuticals inc"}, {"@generic": "false", "#text": "Pharmacia and upjohn co"}, {"@generic": "false", "#text": "Eli lilly and co"}, {"@generic": "false", "#text": "Novo nordisk inc"}, {"@generic": "false", "#text": "Sandoz inc"}, {"@generic": "false", "#text": "Emd serono inc"}, {"@generic": "false", "#text": "Lg life sciences ltd"}]}, "prices": {"price": [{"description": "Genotropin miniquick 0.2 mg", "cost": {"@currency": "USD", "#text": "15.05"}, "unit": "each"}, {"description": "Genotropin miniquick 0.4 mg", "cost": {"@currency": "USD", "#text": "30.09"}, "unit": "each"}, {"description": "Genotropin miniquick 0.6 mg", "cost": {"@currency": "USD", "#text": "45.14"}, "unit": "each"}, {"description": "Genotropin miniquick 0.8 mg", "cost": {"@currency": "USD", "#text": "60.19"}, "unit": "each"}, {"description": "Genotropin miniquick 1 mg", "cost": {"@currency": "USD", "#text": "75.23"}, "unit": "each"}, {"description": "Genotropin MiniQuick 1 mg (7 Cartridges Per Box)", "cost": {"@currency": "USD", "#text": "77.36"}, "unit": "cartridge"}, {"description": "Genotropin miniquick 1.2 mg", "cost": {"@currency": "USD", "#text": "90.28"}, "unit": "each"}, {"description": "Genotropin MiniQuick 1.2 mg (7 Cartridges Per Box)", "cost": {"@currency": "USD", "#text": "92.83"}, "unit": "cartridge"}, {"description": "Genotropin miniquick 1.4 mg", "cost": {"@currency": "USD", "#text": "105.32"}, "unit": "each"}, {"description": "Genotropin MiniQuick 1.4 mg (7 Cartridges Per Box)", "cost": {"@currency": "USD", "#text": "108.78"}, "unit": "cartridge"}, {"description": "Genotropin MiniQuick 0.2 mg (7 Cartridges Per Box)", "cost": {"@currency": "USD", "#text": "110.52"}, "unit": "box"}, {"description": "Genotropin miniquick 1.6 mg", "cost": {"@currency": "USD", "#text": "120.37"}, "unit": "each"}, {"description": "Genotropin MiniQuick 1.6 mg (7 Cartridges Per Box)", "cost": {"@currency": "USD", "#text": "123.78"}, "unit": "cartridge"}, {"description": "Genotropin miniquick 1.8 mg", "cost": {"@currency": "USD", "#text": "135.41"}, "unit": "each"}, {"description": "Genotropin miniquick 2 mg", "cost": {"@currency": "USD", "#text": "150.46"}, "unit": "each"}, {"description": "Genotropin MiniQuick 2 mg (7 Cartridges Per Box)", "cost": {"@currency": "USD", "#text": "154.72"}, "unit": "cartridge"}, {"description": "Serostim 4 mg vial", "cost": {"@currency": "USD", "#text": "221.9"}, "unit": "vial"}, {"description": "Genotropin MiniQuick 0.4 mg (7 Cartridges Per Box)", "cost": {"@currency": "USD", "#text": "228.45"}, "unit": "box"}, {"description": "Tev-tropin 5 mg vial", "cost": {"@currency": "USD", "#text": "239.51"}, "unit": "vial"}, {"description": "Tev-Tropin 5 mg Solution Vial", "cost": {"@currency": "USD", "#text": "259.45"}, "unit": "vial"}, {"description": "Protropin 5 mg Solution Vial", "cost": {"@currency": "USD", "#text": "274.95"}, "unit": "vial"}, {"description": "Serostim 5 mg vial", "cost": {"@currency": "USD", "#text": "277.38"}, "unit": "vial"}, {"description": "Omnitrope 5.8 mg Solution Vial", "cost": {"@currency": "USD", "#text": "283.38"}, "unit": "vial"}, {"description": "Genotropin MiniQuick 0.6 mg (7 Cartridges Per Box)", "cost": {"@currency": "USD", "#text": "326.67"}, "unit": "box"}, {"description": "Serostim 6 mg vial", "cost": {"@currency": "USD", "#text": "332.86"}, "unit": "vial"}, {"description": "Saizen 5 mg vial", "cost": {"@currency": "USD", "#text": "376.26"}, "unit": "vial"}, {"description": "Norditropin 5 mg/1.5ml Solution 1.5ml Cartridge", "cost": {"@currency": "USD", "#text": "389.44"}, "unit": "cartridge"}, {"description": "Norditropin NordiFlex Pen 5 mg/1.5ml Solution 1 Syringe = 1.5ml", "cost": {"@currency": "USD", "#text": "389.44"}, "unit": "pen"}, {"description": "Genotropin 5.8 mg Cartridge", "cost": {"@currency": "USD", "#text": "391.21"}, "unit": "cartridge"}, {"description": "Saizen 5 mg Solution Vial", "cost": {"@currency": "USD", "#text": "391.31"}, "unit": "vial"}, {"description": "Nutropin 5 mg vial", "cost": {"@currency": "USD", "#text": "392.35"}, "unit": "vial"}, {"description": "Serostim 8.8 mg vial", "cost": {"@currency": "USD", "#text": "418.66"}, "unit": "vial"}, {"description": "Genotropin MiniQuick 0.8 mg (7 Cartridges Per Box)", "cost": {"@currency": "USD", "#text": "433.56"}, "unit": "box"}, {"description": "Humatrope 6 mg cartridge", "cost": {"@currency": "USD", "#text": "455.72"}, "unit": "cartridge"}, {"description": "Protropin 10 mg Solution Vial", "cost": {"@currency": "USD", "#text": "549.9"}, "unit": "vial"}, {"description": "Saizen 8.8 mg vial", "cost": {"@currency": "USD", "#text": "602.02"}, "unit": "vial"}, {"description": "Saizen 8.8 mg Solution Vial", "cost": {"@currency": "USD", "#text": "626.1"}, "unit": "vial"}, {"description": "Saizen Click.Easy 8.8 mg Solution Vial", "cost": {"@currency": "USD", "#text": "626.1"}, "unit": "vial"}, {"description": "Norditropin nordiflex 30 mg/3", "cost": {"@currency": "USD", "#text": "748.92"}, "unit": "ml"}, {"description": "Norditropin NordiFlex Pen 10 mg/1.5ml Solution 1 Syringe = 1.5ml", "cost": {"@currency": "USD", "#text": "753.86"}, "unit": "pen"}, {"description": "Nutropin aq 20 mg/2ml pen cart", "cost": {"@currency": "USD", "#text": "759.55"}, "unit": "ml"}, {"description": "Nutropin aq nuspin 20 pen cart", "cost": {"@currency": "USD", "#text": "759.55"}, "unit": "ml"}, {"description": "Nutropin 10 mg vial", "cost": {"@currency": "USD", "#text": "784.7"}, "unit": "vial"}, {"description": "Humatrope 12 mg cartridge", "cost": {"@currency": "USD", "#text": "911.45"}, "unit": "cartridge"}, {"description": "Genotropin 12 mg Solution", "cost": {"@currency": "USD", "#text": "928.36"}, "unit": "each"}, {"description": "Norditropin 15 mg/1.5 ml cartridge", "cost": {"@currency": "USD", "#text": "1123.38"}, "unit": "ml"}, {"description": "Norditropin nordiflx 15 mg/1.5", "cost": {"@currency": "USD", "#text": "1123.38"}, "unit": "ml"}, {"description": "Norditropin 15 mg/1.5ml Solution 1.5ml Cartridge", "cost": {"@currency": "USD", "#text": "1168.32"}, "unit": "cartridge"}, {"description": "Norditropin NordiFlex Pen 15 mg/1.5ml Solution 1 Syringe = 1.5ml", "cost": {"@currency": "USD", "#text": "1168.32"}, "unit": "pen"}, {"description": "Norditropin flexpro 15 mg/1.5", "cost": {"@currency": "USD", "#text": "1179.54"}, "unit": "ml"}, {"description": "Humatrope 24 mg cartridge", "cost": {"@currency": "USD", "#text": "1822.9"}, "unit": "cartridge"}]}, "categories": {"category": {"category": "Hormone Replacement Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Liquid; powder for solution", "route": "subcutaneous", "strength": "10 ml"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "0.2 mg"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "0.4 mg"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "0.6 mg"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "0.8 mg"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "1.0 mg"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "1.2 mg"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "1.4 mg"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "1.6 mg"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "1.8 mg"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "12 mg"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "2.0 mg"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "5 mg"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "5.3 mg"}, {"form": "Powder for solution", "route": "intramuscular; subcutaneous", "strength": "1 mg"}, {"form": "Injection, solution", "route": "subcutaneous", "strength": "10 mg/1.5mL"}, {"form": "Injection, solution", "route": "subcutaneous", "strength": "15 mg/1.5mL"}, {"form": "Injection, solution", "route": "subcutaneous", "strength": "30 mg/3mL"}, {"form": "Injection, solution", "route": "subcutaneous", "strength": "5 mg/1.5mL"}, {"form": "Solution", "route": "subcutaneous", "strength": "15 mg"}, {"form": "Solution", "route": "subcutaneous", "strength": "5 mg"}, {"form": "Kit; powder for solution", "route": "intramuscular; subcutaneous", "strength": "10 mg"}, {"form": "Kit; powder for solution", "route": "intramuscular; subcutaneous", "strength": "5 mg"}, {"form": "Liquid", "route": "subcutaneous", "strength": "5 mg"}, {"form": "Solution", "route": "subcutaneous", "strength": "20 mg"}, {"form": "Injection, solution", "route": "subcutaneous", "strength": "5 mg/2mL"}, {"form": "Injection, solution", "route": "subcutaneous", "strength": "10 mg/2mL"}, {"form": "Injection, solution", "route": "subcutaneous", "strength": "20 mg/2mL"}, {"form": "Solution", "route": "subcutaneous", "strength": "10 mg"}, {"form": "Kit; powder for solution", "route": "subcutaneous", "strength": "5.8 mg"}, {"form": "Solution", "route": "subcutaneous", "strength": "10.0 mg"}, {"form": "Solution", "route": "subcutaneous", "strength": "5.0 mg"}, {"form": "Powder for solution", "route": "intramuscular; subcutaneous", "strength": "5 mg"}, {"form": "Solution", "route": "subcutaneous", "strength": "5.83 mg"}, {"form": "Solution", "route": "subcutaneous", "strength": "8 mg"}, {"form": "Powder for solution", "route": "intramuscular; subcutaneous", "strength": "5 ml"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "8.8 mg"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "5 mg"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "6 mg"}]}, "atc-codes": {"atc-code": {"@code": "H01AC01", "level": [{"@code": "H", "#text": "SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS"}, {"@code": "H01", "#text": "PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES"}, {"@code": "H01A", "#text": "ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES"}, {"@code": "H01AC", "#text": "Somatropin and somatropin agonists"}]}}, "ahfs-codes": null, "patents": {"patent": [{"number": "1326439", "country": "Canada", "approved": "1994-01-25", "expires": "2011-01-25"}, {"number": "2252535", "country": "Canada", "approved": "2009-06-23", "expires": "2017-04-24"}, {"number": "5288703", "country": "United States", "approved": "1994-10-07", "expires": "2011-10-07"}, {"number": "6152897", "country": "United States", "approved": "1998-11-20", "expires": "2018-11-20"}]}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB01380", "name": "Cortisone acetate", "description": "May diminish the therapeutic effect of Cortisone. Growth hormone may reduce the conversion of cortisone to the active cortisol metabolite."}, {"drugbank-id": "DB01395", "name": "Drospirenone", "description": "Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women."}, {"drugbank-id": "DB00783", "name": "Estradiol", "description": "Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women."}, {"drugbank-id": "DB04574", "name": "Estropipate", "description": "Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women."}, {"drugbank-id": "DB00957", "name": "Norgestimate", "description": "Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women."}, {"drugbank-id": "DB00592", "name": "Piperazine", "description": "Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women."}, {"drugbank-id": "DB00635", "name": "Prednisone", "description": "May diminish the therapeutic effect of Prednisone. Growth hormone may reduce the conversion of Prednisone to the active prednisolone metabolite."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00052 sequence\nFPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPT\nPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEG\nIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIV\nQCRSVEGSCGF"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "76 \u00b0C at pH 3.5", "source": "Gomez-Orellana, I. et al., Protein Sci. 7:1352-1358 (1998)"}, {"kind": "Hydrophobicity", "value": "-0.411", "source": null}, {"kind": "Isoelectric Point", "value": "5.27", "source": null}, {"kind": "Molecular Weight", "value": "22129.0000", "source": null}, {"kind": "Molecular Formula", "value": "C990H1532N262O300S7", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "7364"}, {"resource": "National Drug Code Directory", "identifier": "0169-7704-21"}, {"resource": "GenBank", "identifier": "AF374232"}, {"resource": "PharmGKB", "identifier": "PA451446"}, {"resource": "UniProtKB", "identifier": "P58756"}, {"resource": "Wikipedia", "identifier": "Somatropin_recombinant"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/nutropin.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/somatropin-rdna-origin-nonrefrigerated.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000075", "name": "Growth hormone receptor", "organism": "Human", "actions": {"action": "binder"}, "references": "# Walenkamp MJ, Wit JM: Genetic disorders in the growth hormone - insulin-like growth factor-I axis. Horm Res. 2006;66(5):221-30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16917171\n# Wu XY, Xu Z, Chen C, Liu FK, Li JS: [Correlation of growth hormone receptor expression to preoperative radiosensitivity of rectal cancer patients] Ai Zheng. 2006 Sep;25(9):1162-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16965663\n# Adriani M, Garbi C, Amodio G, Russo I, Giovannini M, Amorosi S, Matrecano E, Cosentini E, Candotti F, Pignata C: Functional interaction of common gamma-chain and growth hormone receptor signaling apparatus. J Immunol. 2006 Nov 15;177(10):6889-95. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17082603\n# Choi JH, Kim HS, Kim SH, Yang YR, Bae YS, Chang JS, Kwon HM, Ryu SH, Suh PG: Phospholipase Cgamma1 negatively regulates growth hormone signalling by forming a ternary complex with Jak2 and protein tyrosine phosphatase-1B. Nat Cell Biol. 2006 Dec;8(12):1389-97. Epub 2006 Nov 26. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17128263\n# Bernstein RM, Leigh SR, Donovan SM, Monaco MH: Hormones and body size evolution in papionin primates. Am J Phys Anthropol. 2007 Feb;132(2):247-60. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17133434\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P10912", "@source": "Swiss-Prot", "name": "Growth hormone receptor", "general-function": "Involved in hematopoietin/interferon-class (D200-domain) cytokine receptor activity", "specific-function": "Isoform 2 up-regulates the production of GHBP and acts as a negative inhibitor of GH signaling", "gene-name": "GHR", "locus": "5p13-p12", "cellular-location": "Cell membrane; single-pass type I membrane protein. GHBP:Secreted protein. On growth hormone binding", "transmembrane-regions": "265-288", "signal-regions": null, "theoretical-pi": "4.51", "molecular-weight": "71500.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:4263"}, {"resource": "GenAtlas", "identifier": "GHR"}, {"resource": "GeneCards", "identifier": "GHR"}, {"resource": "GenBank Gene Database", "identifier": "X06562"}, {"resource": "GenBank Protein Database", "identifier": "31738"}, {"resource": "UniProtKB", "identifier": "P10912"}, {"resource": "UniProt Accession", "identifier": "GHR_HUMAN"}]}, "synonyms": {"synonym": ["GH receptor", "Growth hormone receptor precursor", "Somatotropin receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Growth hormone receptor precursor\nMDLWQLLLTLALAGSSDAFSGSEATAAILSRAPWSLQSVNPGLKTNSSKEPKFTKCRSPE\nRETFSCHWTDEVHHGTKNLGPIQLFYTRRNTQEWTQEWKECPDYVSAGENSCYFNSSFTS\nIWIPYCIKLTSNGGTVDEKCFSVDEIVQPDPPIALNWTLLNVSLTGIHADIQVRWEAPRN\nADIQKGWMVLEYELQYKEVNETKWKMMDPILTTSVPVYSLKVDKEYEVRVRSKQRNSGNY\nGEFSEVLYVTLPQMSQFTCEEDFYFPWLLIIIFGIFGLTVMLFVFLFSKQQRIKMLILPP\nVPVPKIKGIDPDLLKEGKLEEVNTILAIHDSYKPEFHSDDSWVEFIELDIDEPDEKTEES\nDTDRLLSSDHEKSHSNLGVKDGDSGRTSCCEPDILETDFNANDIHEGTSEVAQPQRLKGE\nADLLCLDQKNQNNSPYHDACPATQQPSVIQAEKNKPQPLPTEGAESTHQAAHIQLSNPSS\nLSNIDFYAQVSDITPAGSVVLSPGQKNKAGMSQCDMHPEMVSLCQENFLMDNAYFCEADA\nKKCIPVAPHIKVESHIQPSLNQEDIYITTESLTTAAGRPGTGEHVPGSEMPVPDYTSIHI\nVQSPQGLILNATALPLPDKEFLSSCGYVSTDQLNKIMP"}, "gene-sequence": {"@format": "FASTA", "#text": ">1917 bp\nATGGATCTCTGGCAGCTGCTGTTGACCTTGGCACTGGCAGGATCAAGTGATGCTTTTTCT\nGGAAGTGAGGCCACAGCAGCTATCCTTAGCAGAGCACCCTGGAGTCTGCAAAGTGTTAAT\nCCAGGCCTAAAGACAAATTCTTCTAAGGAGCCTAAATTCACCAAGTGCCGTTCACCTGAG\nCGAGAGACTTTTTCATGCCACTGGACAGATGAGGTTCATCATGGTACAAAGAACCTAGGA\nCCCATACAGCTGTTCTATACCAGAAGGAACACTCAAGAATGGACTCAAGAATGGAAAGAA\nTGCCCTGATTATGTTTCTGCTGGGGAAAACAGCTGTTACTTTAATTCATCGTTTACCTCC\nATCTGGATACCTTATTGTATCAAGCTAACTAGCAATGGTGGTACAGTGGATGAAAAGTGT\nTTCTCTGTTGATGAAATAGTGCAACCAGATCCACCCATTGCCCTCAACTGGACTTTACTG\nAACGTCAGTTTAACTGGGATTCATGCAGATATCCAAGTGAGATGGGAAGCACCACGCAAT\nGCAGATATTCAGAAAGGATGGATGGTTCTGGAGTATGAACTTCAATACAAAGAAGTAAAT\nGAAACTAAATGGAAAATGATGGACCCTATATTGACAACATCAGTTCCAGTGTACTCATTG\nAAAGTGGATAAGGAATATGAAGTGCGTGTGAGATCCAAACAACGAAACTCTGGAAATTAT\nGGCGAGTTCAGTGAGGTGCTCTATGTAACACTTCCTCAGATGAGCCAATTTACATGTGAA\nGAAGATTTCTACTTTCCATGGCTCTTAATTATTATCTTTGGAATATTTGGGCTAACAGTG\nATGCTATTTGTATTCTTATTTTCTAAACAGCAAAGGATTAAAATGCTGATTCTGCCCCCA\nGTTCCAGTTCCAAAGATTAAAGGAATCGATCCAGATCTCCTCAAGGAAGGAAAATTAGAG\nGAGGTGAACACAATCTTAGCCATTCATGATAGCTATAAACCCGAATTCCACAGTGATGAC\nTCTTGGGTTGAATTTATTGAGCTAGATATTGATGAGCCAGATGAAAAGACTGAGGAATCA\nGACACAGACAGACTTCTAAGCAGTGACCATGAGAAATCACATAGTAACCTAGGGGTGAAG\nGATGGCGACTCTGGACGTACCAGCTGTTGTGAACCTGACATTCTGGAGACTGATTTCAAT\nGCCAATGACATACATGAGGGTACCTCAGAGGTTGCTCAGCCACAGAGGTTAAAAGGGGAA\nGCAGATCTCTTATGCCTTGACCAGAAGAATCAAAATAACTCACCTTATCATGATGCTTGC\nCCTGCTACTCAGCAGCCCAGTGTTATCCAAGCAGAGAAAAACAAACCACAACCACTTCCT\nACTGAAGGAGCTGAGTCAACTCACCAAGCTGCCCATATTCAGCTAAGCAATCCAAGTTCA\nCTGTCAAACATCGACTTTTATGCCCAGGTGAGCGACATTACACCAGCAGGTAGTGTGGTC\nCTTTCCCCGGGCCAAAAGAATAAGGCAGGGATGTCCCAATGTGACATGCACCCGGAAATG\nGTCTCACTCTGCCAAGAAAACTTCCTTATGGACAATGCCTACTTCTGTGAGGCAGATGCC\nAAAAAGTGCATCCCTGTGGCTCCTCACATCAAGGTTGAATCACACATACAGCCAAGCTTA\nAACCAAGAGGACATTTACATCACCACAGAAAGCCTTACCACTGCTGCTGGGAGGCCTGGG\nACAGGAGAACATGTTCCAGGTTCTGAGATGCCTGTCCCAGACTATACCTCCATTCATATA\nGTACAGTCCCCACAGGGCCTCATACTCAATGCGACTGCCTTGCCCTTGCCTGACAAAGAG\nTTTCTCTCATCATGTGGCTATGTGAGCACAGACCAACTGAACAAAATCATGCCTTAG"}, "pfams": {"pfam": {"identifier": "PF00041", "name": "fn3"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "hematopoietin/interferon-class (D200-domain) cytokine receptor activity"}]}}}, {"id": "BE0000345", "name": "Prolactin receptor", "organism": "Human", "actions": null, "references": "# Keeler C, Jablonski EM, Albert YB, Taylor BD, Myszka DG, Clevenger CV, Hodsdon ME: The kinetics of binding human prolactin, but not growth hormone, to the prolactin receptor vary over a physiologic pH range. Biochemistry. 2007 Mar 6;46(9):2398-410. Epub 2007 Feb 6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17279774\n# Ahmed TA, Buzzelli MD, Lang CH, Capen JB, Shumate ML, Navaratnarajah M, Nagarajan M, Cooney RN: Interleukin-6 inhibits growth hormone-mediated gene expression in hepatocytes. Am J Physiol Gastrointest Liver Physiol. 2007 Jun;292(6):G1793-803. Epub 2007 Mar 29. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17395896\n# Moderscheim TA, Gorba T, Pathipati P, Kokay IC, Grattan DR, Williams CE, Scheepens A: Prolactin is involved in glial responses following a focal injury to the juvenile rat brain. Neuroscience. 2007 Mar 30;145(3):963-73. Epub 2007 Feb 20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17317019\n# Cunningham BC, Bass S, Fuh G, Wells JA: Zinc mediation of the binding of human growth hormone to the human prolactin receptor. Science. 1990 Dec 21;250(4988):1709-12. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2270485", "known-action": "yes", "polypeptide": {"@id": "P16471", "@source": "Swiss-Prot", "name": "Prolactin receptor", "general-function": "Involved in hematopoietin/interferon-class (D200-domain) cytokine receptor activity", "specific-function": "This is a receptor for the anterior pituitary hormone prolactin", "gene-name": "PRLR", "locus": "5p14-p13", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "235-258", "signal-regions": null, "theoretical-pi": "5.08", "molecular-weight": "69506.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9446"}, {"resource": "GenAtlas", "identifier": "PRLR"}, {"resource": "GeneCards", "identifier": "PRLR"}, {"resource": "GenBank Gene Database", "identifier": "M31661"}, {"resource": "GenBank Protein Database", "identifier": "190362"}, {"resource": "UniProtKB", "identifier": "P16471"}, {"resource": "UniProt Accession", "identifier": "PRLR_HUMAN"}]}, "synonyms": {"synonym": ["PRL-R", "Prolactin receptor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Prolactin receptor precursor\nMKENVASATVFTLLLFLNTCLLNGQLPPGKPEIFKCRSPNKETFTCWWRPGTDGGLPTNY\nSLTYHREGETLMHECPDYITGGPNSCHFGKQYTSMWRTYIMMVNATNQMGSSFSDELYVD\nVTYIVQPDPPLELAVEVKQPEDRKPYLWIKWSPPTLIDLKTGWFTLLYEIRLKPEKAAEW\nEIHFAGQQTEFKILSLHPGQKYLVQVRCKPDHGYWSAWSPATFIQIPSDFTMNDTTVWIS\nVAVLSAVICLIIVWAVALKGYSMVTCIFPPVPGPKIKGFDAHLLEKGKSEELLSALGCQD\nFPPTSDYEDLLVEYLEVDDSEDQHLMSVHSKEHPSQGMKPTYLDPDTDSGRGSCDSPSLL\nSEKCEEPQANPSTFYDPEVIEKPENPETTHTWDPQCISMEGKIPYFHAGGSKCSTWPLPQ\nPSQHNPRSSYHNITDVCELAVGPAGAPATLLNEAGKDALKSSQTIKSREEGKATQQREVE\nSFHSETDQDTPWLLPQEKTPFGSAKPLDYVEIHKVNKDGALSLLPKQRENSGKPKKPGTP\nENNKEYAKVSGVMDNNILVLVPDPHAKNVACFEESAKEAPPSLEQNQAEKALANFTATSS\nKCRLQLGGLDYLDPACFTHSFH"}, "gene-sequence": {"@format": "FASTA", "#text": ">1869 bp\nATGAAGGAAAATGTGGCATCTGCAACCGTTTTCACTCTGCTACTTTTTCTCAACACCTGC\nCTTCTGAATGGACAGTTACCTCCTGGAAAACCTGAGATCTTTAAATGTCGTTCTCCCAAT\nAAGGAAACATTCACCTGCTGGTGGAGGCCTGGGACAGATGGAGGACTTCCTACCAATTAT\nTCACTGACTTACCACAGGGAAGGAGAGACACTCATGCATGAATGTCCAGACTACATAACC\nGGTGGCCCCAACTCCTGCCACTTTGGCAAGCAGTACACCTCCATGTGGAGGACATACATC\nATGATGGTCAATGCCACTAACCAGATGGGAAGCAGTTTCTCGGATGAACTTTATGTGGAC\nGTGACTTACATAGTTCAGCCAGACCCTCCTTTGGAGCTGGCTGTGGAAGTAAAACAGCCA\nGAAGACAGAAAACCCTACCTGTGGATTAAATGGTCTCCACCTACCCTGATTGACTTAAAA\nACTGGTTGGTTCACGCTCCTGTATGAAATTCGATTAAAACCCGAGAAAGCAGCTGAGTGG\nGAGATCCATTTTGCTGGGCAGCAAACAGAGTTTAAGATTCTCAGCCTACATCCAGGACAG\nAAATACCTTGTCCAGGTTCGCTGCAAACCAGACCATGGATACTGGAGTGCATGGAGTCCA\nGCGACCTTCATTCAGATACCTAGTGACTTCACCATGAATGATACAACCGTGTGGATCTCT\nGTGGCTGTCCTTTCTGCTGTCATCTGTTTGATTATTGTCTGGGCAGTGGCTTTGAAGGGC\nTATAGCATGGTGACCTGCATCTTTCCGCCAGTTCCTGGGCCAAAAATAAAAGGATTTGAT\nGCTCATCTGTTGGAGAAGGGCAAGTCTGAAGAACTACTGAGTGCCTTGGGATGCCAAGAC\nTTTCCTCCCACTTCTGACTATGAGGACTTGCTGGTGGAGTATTTAGAAGTAGATGATAGT\nGAGGACCAGCATCTAATGTCAGTCCATTCAAAAGAACACCCAAGTCAAGGTATGAAACCC\nACATACCTGGATCCTGACACTGACTCAGGCCGGGGGAGCTGTGACAGCCCTTCCCTTTTG\nTCTGAAAAGTGTGAGGAACCCCAGGCCAATCCCTCCACATTCTATGATCCTGAGGTCATT\nGAGAAGCCAGAGAATCCTGAAACAACCCACACCTGGGACCCCCAGTGCATAAGCATGGAA\nGGCAAAATCCCCTATTTTCATGCTGGTGGATCCAAATGTTCAACATGGCCCTTACCACAG\nCCCAGCCAGCACAACCCCAGATCCTCTTACCACAATATTACTGATGTGTGTGAGCTGGCT\nGTGGGCCCTGCAGGTGCACCGGCCACTCTGTTGAATGAAGCAGGTAAAGATGCTTTAAAA\nTCCTCTCAAACCATTAAGTCTAGAGAAGAGGGAAAGGCAACCCAGCAGAGGGAGGTAGAA\nAGCTTCCATTCTGAGACTGACCAGGATACGCCCTGGCTGCTGCCCCAGGAGAAAACCCCC\nTTTGGCTCCGCTAAACCCTTGGATTATGTGGAGATTCACAAGGTCAACAAAGATGGTGCA\nTTATCATTGCTACCAAAACAGAGAGAGAACAGCGGCAAGCCCAAGAAGCCCGGGACTCCT\nGAGAACAATAAGGAGTATGCCAAGGTGTCCGGGGTCATGGATAACAACATCCTGGTGTTG\nGTGCCAGATCCACATGCTAAAAACGTGGCTTGCTTTGAAGAATCAGCCAAAGAGGCCCCA\nCCATCACTTGAACAGAATCAAGCTGAGAAAGCCCTGGCCAACTTCACTGCAACATCAAGC\nAAGTGCAGGCTCCAGCTGGGTGGTTTGGATTACCTGGATCCCGCATGTTTTACACACTCC\nTTTCACTGA"}, "pfams": {"pfam": {"identifier": "PF00041", "name": "fn3"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "hematopoietin/interferon-class (D200-domain) cytokine receptor activity"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2011-08-04", "drugbank-id": [{"@primary": "true", "#text": "DB00053"}, "BIOD00026", "BTD00026"], "name": "Imiglucerase", "description": "Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues", "cas-number": "143003-46-7", "groups": {"group": "approved"}, "general-references": "# Pastores GM, Hughes DA: Gaucher Disease  \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20301446", "synthesis-reference": null, "indication": "For the treatment of Gaucher's disease (deficiency in glucocerebrosidase)", "pharmacodynamics": "Gaucher disease is characterized by a functional deficiency in Beta-glucocerebrosidase enzymatic activity and the resultant accumulation of lipid glucocerebroside in tissue macrophages which become engorged and are termed Gaucher cells. Gaucher cells are typically found in liver, spleen and bone marrow. This can lead to an enlarged spleen and liver (hepatosplenomegaly). Secondary hematologic sequelae include severe anemia and thrombocytopenia. Injections of imiglucerase into Gaucher disease patients leads to elevated serum levels of the enzyme and reduction in the accumulation of glucocerebroside leading to reduced anemia and thrombocytopenia, reduced spleen and liver size, and decreased cachexia", "mechanism-of-action": "Imiglucerase catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": "3.6-10.4 min", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": "* 0.09 to 0.15 L/kg", "clearance": "* 14.5 +/- 4.0 mL/min/kg", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": {"product": [{"name": "Cerezyme", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02230694", "started-marketing-on": "1997-05-01", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "200 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Cerezyme", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02241751", "started-marketing-on": "2000-06-14", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "400 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Cerezyme", "ndc-id": "58468-1983_c07ea20e-36bc-4f7b-a218-d79927f7c77e", "ndc-product-code": "58468-1983", "dpd-id": null, "started-marketing-on": "1994-05-23", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "40 U/mL", "route": "intravenous", "fda-application-number": "NDA020367", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Cerezyme", "ndc-id": "58468-4663_c07ea20e-36bc-4f7b-a218-d79927f7c77e", "ndc-product-code": "58468-4663", "dpd-id": null, "started-marketing-on": "1994-05-23", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "40 U/mL", "route": "intravenous", "fda-application-number": "NDA020367", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Cerezyme", "ingredients": "Imiglucerase"}, {"name": "Cerezyme", "ingredients": "Imiglucerase"}, {"name": "Cerezyme", "ingredients": "Imiglucerase"}, {"name": "Cerezyme", "ingredients": "Imiglucerase"}]}, "packagers": {"packager": {"name": "Genzyme Inc.", "url": "http://www.genzyme.ca"}}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Genzyme corp"}}, "prices": {"price": [{"description": "Ceredase 80 unit/ml vial", "cost": {"@currency": "USD", "#text": "380.64"}, "unit": "ml"}, {"description": "Cerezyme 200 unit vial", "cost": {"@currency": "USD", "#text": "951.6"}, "unit": "vial"}, {"description": "Cerezyme 400 unit vial", "cost": {"@currency": "USD", "#text": "1903.2"}, "unit": "vial"}]}, "categories": {"category": {"category": "Enzyme Replacement Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, powder, lyophilized, for solution", "route": "intravenous", "strength": "40 U/mL"}, {"form": "Powder for solution", "route": "intravenous", "strength": "200 unit"}, {"form": "Powder for solution", "route": "intravenous", "strength": "400 unit"}]}, "atc-codes": {"atc-code": {"@code": "A16AB02", "level": [{"@code": "A", "#text": "ALIMENTARY TRACT AND METABOLISM"}, {"@code": "A16", "#text": "OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS"}, {"@code": "A16A", "#text": "OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS"}, {"@code": "A16AB", "#text": "Enzymes"}]}}, "ahfs-codes": {"ahfs-code": "44:00.00"}, "patents": {"patent": {"number": "5549892", "country": "United States", "approved": "1993-08-27", "expires": "2013-08-27"}}, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00053 sequence\nARPCIPKSFGYSSVVCVCNATYCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANH\nTGTGLLLTLQPEQKFQKVKGFGGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIR\nVPMASCDFSIRTYTYADTPDDFQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWT\nSPTWLKTNGAVNGKGSLKGQPGDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGL\nLSGYPFQCLGFTPEHQRDFIARDLGPTLANSTHHNVRLLMLDDQRLLLPHWAKVVLTDPE\nAAKYVHGIAVHWYLDFLAPAKATLGETHRLFPNTMLFASEACVGSKFWEQSVRLGSWDRG\nMQYSHSIITNLLYHVVGWTDWNLALNPEGGPNWVRNFVDSPIIVDITKDTFYKQPMFYHL\nGHFSKFIPEGSQRVGLVASQKNDLDAVALMHPDGSAVVVVLNRSSKDVPLTIKDPAVGFL\nETISPGYSIHTYLWRRQ"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.168", "source": null}, {"kind": "Isoelectric Point", "value": "7.41", "source": null}, {"kind": "Molecular Weight", "value": "55597.4000", "source": null}, {"kind": "Molecular Formula", "value": "C2532H3854N672O711S16", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "11365"}, {"resource": "KEGG Drug", "identifier": "D02810"}, {"resource": "National Drug Code Directory", "identifier": "58468-4663-1"}, {"resource": "GenBank", "identifier": "M16328"}, {"resource": "PharmGKB", "identifier": "PA164742934"}, {"resource": "UniProtKB", "identifier": "P04062"}, {"resource": "Wikipedia", "identifier": "Imiglucerase"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic2/imiglucerase.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/imiglucerase.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"@position": "1", "id": "BE0004806", "name": "Glucocerebroside", "organism": "Human", "actions": {"action": "other/unknown"}, "references": "# Pastores GM, Hughes DA: Gaucher Disease  \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20301446", "known-action": "yes"}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-07-08", "drugbank-id": [{"@primary": "true", "#text": "DB00054"}, "BIOD00041", "BTD00041"], "name": "Abciximab", "description": "Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (\u03b1v\u03b23) receptor found on platelets and vessel wall endothelial and smooth muscle cells.", "cas-number": "143653-53-6", "groups": {"group": "approved"}, "general-references": "# Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. 1994 Apr 7;330(14):956-61. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8121459\n# Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW: Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 2003 Sep 16;108(11):1316-23. Epub 2003 Aug 25. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12939213\n# FDA label", "synthesis-reference": null, "indication": "Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and \nin patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab is intended for use with aspirin and heparin and has been studied only in that setting.", "pharmacodynamics": "Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets. A single intravenous bolus dose from 0.15 mg/kg to 0.30 mg/kg produced rapid dose-dependent inhibition of platelet function. After two hours post-injection with a dose of 0.25 - 0.30 mg/kg, 80% of the GPIIb/IIIa receptors were blocked and platelet aggregation was prevented. GPIIb/IIIa is the major surface receptor involved in the final pathway of platelet aggregation. Bleeding time increases to over 30 minutes at the aforementioned doses. To compare, baseline values were five minutes.", "mechanism-of-action": "Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPIIb/IIIa. By binding to the vitronectin receptor (also known as the \u03b1v\u03b23 integrin), abciximab blocks effects mediated by this integrin which include cell adhesion. Furthermore, abciximab blocks Mac-1 receptor on monocytes and neutrophils thus inhibiting monocyte adhesion.", "toxicity": null, "metabolism": "Most likely removed by opsonization via the reticuloendothelial system when bound to platelets, or by human antimurine antibody production. Excreted renally.", "absorption": null, "half-life": "Following intravenous bolus administration, free plasma concentrations of Abciximab decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors.", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "7E3"}, {"@language": "", "@coder": "", "#text": "7E3 antibody"}, {"@language": "", "@coder": "", "#text": "antiGPIIBIIIa"}, {"@language": "", "@coder": "", "#text": "C7E3"}]}, "products": {"product": [{"name": "Reopro", "ndc-id": "0002-7140_da423d8f-0105-410f-8384-43b5df8603b4", "ndc-product-code": "0002-7140", "dpd-id": null, "started-marketing-on": "1993-12-16", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "2 mg/mL", "route": "intravenous", "fda-application-number": "BLA103575", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Reopro", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02216973", "started-marketing-on": "1996-10-30", "ended-marketing-on": null, "dosage-form": "solution", "strength": "2 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Reopro", "ingredients": "Abciximab"}, {"name": "Reopro", "ingredients": "Abciximab"}]}, "packagers": {"packager": [{"name": "Centocor Ortho Biotech Inc.", "url": "http://www.centocororthobiotech.com"}, {"name": "Eli Lilly & Co.", "url": "http://www.lilly.com"}, {"name": "Hospira Inc.", "url": "http://www.hospira.com"}, {"name": "JHP Pharmaceuticals LLC", "url": "http://www.jhppharma.com"}]}, "manufacturers": null, "prices": {"price": {"description": "Reopro 2 mg/ml vial", "cost": {"@currency": "USD", "#text": "155.77"}, "unit": "ml"}}, "categories": {"category": [{"category": "Anticoagulants", "mesh-id": null}, {"category": "Platelet Aggregation Inhibitors", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, solution", "route": "intravenous", "strength": "2 mg/mL"}, {"form": "Solution", "route": "intravenous", "strength": "2 mg"}]}, "atc-codes": {"atc-code": {"@code": "B01AC13", "level": [{"@code": "B", "#text": "BLOOD AND BLOOD FORMING ORGANS"}, {"@code": "B01", "#text": "ANTITHROMBOTIC AGENTS"}, {"@code": "B01A", "#text": "ANTITHROMBOTIC AGENTS"}, {"@code": "B01AC", "#text": "Platelet aggregation inhibitors excl. heparin"}]}}, "ahfs-codes": {"ahfs-code": "92:00.00"}, "patents": {"patent": {"number": "1341357", "country": "Canada", "approved": "2002-05-07", "expires": "2019-05-07"}}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB01418", "name": "Acenocoumarol", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00945", "name": "Acetylsalicylic acid", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result."}, {"drugbank-id": "DB00009", "name": "Alteplase", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00233", "name": "Aminosalicylic Acid", "description": "Salicylates may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00261", "name": "Anagrelide", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00029", "name": "Anistreplase", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06605", "name": "Apixaban", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased."}, {"drugbank-id": "DB00278", "name": "Argatroban", "description": "May enhance the anticoagulant effect of other Anticoagulants."}, {"drugbank-id": "DB08879", "name": "Belimumab", "description": "Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab."}, {"drugbank-id": "DB01294", "name": "Bismuth Subsalicylate", "description": "Salicylates may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00006", "name": "Bivalirudin", "description": "May enhance the anticoagulant effect of other Anticoagulants."}, {"drugbank-id": "DB06441", "name": "Cangrelor", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00482", "name": "Celecoxib", "description": "Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01166", "name": "Cilostazol", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00215", "name": "Citalopram", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB04272", "name": "Citric Acid", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00758", "name": "Clopidogrel", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00048", "name": "Collagenase clostridium histolyticum", "description": "May enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased."}, {"drugbank-id": "DB04839", "name": "Cyproterone acetate", "description": "Progestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects."}, {"drugbank-id": "DB06695", "name": "Dabigatran etexilate", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran etexilate. This mechanism applies specifically to clopidogrel."}, {"drugbank-id": "DB06779", "name": "Dalteparin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06754", "name": "Danaparoid", "description": "May enhance the anticoagulant effect of other Anticoagulants."}, {"drugbank-id": "DB01254", "name": "Dasatinib", "description": "May enhance the anticoagulant effect of Agents with Antiplatelet Properties."}, {"drugbank-id": "DB01609", "name": "Deferasirox", "description": "May enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased."}, {"drugbank-id": "DB03619", "name": "Deoxycholic Acid", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased."}, {"drugbank-id": "DB00304", "name": "Desogestrel", "description": "Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects."}, {"drugbank-id": "DB06700", "name": "Desvenlafaxine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00586", "name": "Diclofenac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00266", "name": "Dicoumarol", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB09123", "name": "Dienogest", "description": "Progestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects."}, {"drugbank-id": "DB00861", "name": "Diflunisal", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01551", "name": "Dihydrocodeine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00975", "name": "Dipyridamole", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01395", "name": "Drospirenone", "description": "Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects."}, {"drugbank-id": "DB00476", "name": "Duloxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00974", "name": "Edetic Acid", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB09075", "name": "Edoxaban", "description": "Edoxaban may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01225", "name": "Enoxaparin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01240", "name": "Epoprostenol", "description": "Prostacyclin Analogues may enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination."}, {"drugbank-id": "DB00063", "name": "Eptifibatide", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01175", "name": "Escitalopram", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00783", "name": "Estradiol", "description": "Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects."}, {"drugbank-id": "DB04574", "name": "Estropipate", "description": "Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects."}, {"drugbank-id": "DB00977", "name": "Ethinyl Estradiol", "description": "Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects."}, {"drugbank-id": "DB08794", "name": "Ethyl biscoumacetate", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00823", "name": "Ethynodiol", "description": "Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects."}, {"drugbank-id": "DB00749", "name": "Etodolac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00294", "name": "Etonogestrel", "description": "Progestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects."}, {"drugbank-id": "DB00573", "name": "Fenoprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB08976", "name": "Floctafenine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00472", "name": "Fluoxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00712", "name": "Flurbiprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00176", "name": "Fluvoxamine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00569", "name": "Fondaparinux sodium", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01296", "name": "Glucosamine", "description": "May enhance the antiplatelet effect of Agents with Antiplatelet Properties."}, {"drugbank-id": "DB01109", "name": "Heparin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06789", "name": "Hydroxyprogesterone caproate", "description": "Progestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects."}, {"drugbank-id": "DB00078", "name": "Ibritumomab", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB09053", "name": "Ibrutinib", "description": "May enhance the adverse/toxic effect of Agents with Antiplatelet Properties."}, {"drugbank-id": "DB01050", "name": "Ibuprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00159", "name": "Icosapent", "description": "Omega-3 Fatty Acids may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB08887", "name": "Icosapent ethyl", "description": "Omega-3 Fatty Acids may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01088", "name": "Iloprost", "description": "Prostacyclin Analogues may enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination."}, {"drugbank-id": "DB00328", "name": "Indomethacin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01009", "name": "Ketoprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00465", "name": "Ketorolac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB08918", "name": "Levomilnacipran", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00367", "name": "Levonorgestrel", "description": "Progestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects."}, {"drugbank-id": "DB01397", "name": "Magnesium salicylate", "description": "Salicylates may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00603", "name": "Medroxyprogesterone Acetate", "description": "Progestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects."}, {"drugbank-id": "DB00784", "name": "Mefenamic acid", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00351", "name": "Megestrol acetate", "description": "Progestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects."}, {"drugbank-id": "DB00814", "name": "Meloxicam", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01357", "name": "Mestranol", "description": "Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects."}, {"drugbank-id": "DB04896", "name": "Milnacipran", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00461", "name": "Nabumetone", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB08813", "name": "Nadroparin", "description": "May enhance the anticoagulant effect of other Anticoagulants."}, {"drugbank-id": "DB00788", "name": "Naproxen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB09079", "name": "Nintedanib", "description": "May enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased."}, {"drugbank-id": "DB00717", "name": "Norethindrone", "description": "Progestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects."}, {"drugbank-id": "DB00957", "name": "Norgestimate", "description": "Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects."}, {"drugbank-id": "DB08935", "name": "Obinutuzumab", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased."}, {"drugbank-id": "DB00991", "name": "Oxaprozin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00715", "name": "Paroxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00686", "name": "Pentosan Polysulfate", "description": "May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents."}, {"drugbank-id": "DB00806", "name": "Pentoxifylline", "description": "May enhance the antiplatelet effect of Agents with Antiplatelet Properties."}, {"drugbank-id": "DB00498", "name": "Phenindione", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00946", "name": "Phenprocoumon", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00592", "name": "Piperazine", "description": "Estrogen Derivatives may diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects."}, {"drugbank-id": "DB00554", "name": "Piroxicam", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06209", "name": "Prasugrel", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00396", "name": "Progesterone", "description": "Progestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects."}, {"drugbank-id": "DB00015", "name": "Reteplase", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01207", "name": "Ridogrel", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06228", "name": "Rivaroxaban", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban."}, {"drugbank-id": "DB01398", "name": "Salicylate-sodium", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result."}, {"drugbank-id": "DB01399", "name": "Salsalate", "description": "Salicylates may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01104", "name": "Sertraline", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00086", "name": "Streptokinase", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00605", "name": "Sulindac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06271", "name": "Sulodexide", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00031", "name": "Tenecteplase", "description": "Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01600", "name": "Tiaprofenic acid", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB08816", "name": "Ticagrelor", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00208", "name": "Ticlopidine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06822", "name": "Tinzaparin", "description": "May enhance the anticoagulant effect of other Anticoagulants."}, {"drugbank-id": "DB00932", "name": "Tipranavir", "description": "May enhance the antiplatelet effect of Agents with Antiplatelet Properties."}, {"drugbank-id": "DB00775", "name": "Tirofiban", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00500", "name": "Tolmetin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00081", "name": "Tositumomab", "description": "May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased."}, {"drugbank-id": "DB00374", "name": "Treprostinil", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00013", "name": "Urokinase", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00285", "name": "Venlafaxine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06684", "name": "Vilazodone", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00163", "name": "Vitamin E", "description": "May enhance the antiplatelet effect of Agents with Antiplatelet Properties."}, {"drugbank-id": "DB09030", "name": "Vorapaxar", "description": "Vorapaxar may enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding."}, {"drugbank-id": "DB09068", "name": "Vortioxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00682", "name": "Warfarin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}]}, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">1TXV:H ReoPro-like antibody Heavy Chain 1\nEVQLQQSGAELVKPGASVKLSCTASGFNIKDTYVHWVKQRPEQGLEWIGRIDPANGYTKY\nDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCVRPLYDYYAMDYWGQGTSVTVSSA\nKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDL\nYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRPKSCDKTHTCPPCPAPELLGG\nPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN\nSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE\nLTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW\nQQGNVFSCSVMHEALHNHYTQKSLSLSPGK"}, {"@format": "FASTA", "#text": ">1TXV:L ReoPro-like antibody Light Chain 1\nDILMTQSPSSMSVSLGDTVSITCHASQGISSNIGWLQQKPGKSFMGLIYYGTNLVDGVPS\nRFSGSGSGADYSLTISSLDSEDFADYYCVQYAQLPYTFGGGTKLEIKRADAAPTVSIFPP\nSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLT\nLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC"}, {"@format": "FASTA", "#text": ">1TXV:H ReoPro-like antibody Heavy Chain 2\nEVQLQQSGAELVKPGASVKLSCTASGFNIKDTYVHWVKQRPEQGLEWIGRIDPANGYTKY\nDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCVRPLYDYYAMDYWGQGTSVTVSSA\nKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDL\nYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRPKSCDKTHTCPPCPAPELLGG\nPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN\nSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE\nLTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW\nQQGNVFSCSVMHEALHNHYTQKSLSLSPGK"}, {"@format": "FASTA", "#text": ">1TXV:L ReoPro-like antibody Light Chain 2\nDILMTQSPSSMSVSLGDTVSITCHASQGISSNIGWLQQKPGKSFMGLIYYGTNLVDGVPS\nRFSGSGSGADYSLTISSLDSEDFADYYCVQYAQLPYTFGGGTKLEIKRADAAPTVSIFPP\nSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLT\nLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "61 \u00b0C (FAB fragment), 71 \u00b0C (whole mAb)", "source": "Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)"}, {"kind": "Hydrophobicity", "value": "-0.424", "source": null}, {"kind": "Isoelectric Point", "value": "6.16", "source": null}, {"kind": "Molecular Weight", "value": "145651.1000", "source": null}, {"kind": "Molecular Formula", "value": "C6462H9964N1690O2049S48", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "61"}, {"resource": "KEGG Drug", "identifier": "D02778"}, {"resource": "National Drug Code Directory", "identifier": "0002-7140-01"}, {"resource": "PharmGKB", "identifier": "PA448006"}, {"resource": "Wikipedia", "identifier": "Abciximab"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/reopro-drug.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/abciximab.html"}]}, "pathways": {"pathway": {"smpdb-id": "SMP00265", "name": "Abciximab Action Pathway", "drugs": {"drug": {"drugbank-id": "DB00054", "name": "Abciximab"}}, "enzymes": {"uniprot-id": ["P08514", "P05106"]}}}, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": {"reaction": {"protein-name": "Integrin beta-3", "gene-symbol": "ITGB3", "uniprot-id": "P05106", "rs-id": null, "allele": "GPIIIa PlA2", "adverse-reaction": "A2 Allele", "description": "Associated with greater restenosis and risk for subacute coronary thrombosis in patients administered antiplatelet therapy.", "pubmed-id": "10732888"}}, "targets": {"target": [{"@position": "1", "id": "BE0001155", "name": "Integrin beta-3", "organism": "Human", "actions": {"action": "antagonist"}, "references": "# Amoroso G, van Boven AJ, van Veldhuisen DJ, Tio RA, Balje-Volkers CP, Petronio AS, van Oeveren W: Eptifibatide and abciximab exhibit equivalent antiplatelet efficacy in an experimental model of stenting in both healthy volunteers and patients with coronary artery disease. J Cardiovasc Pharmacol. 2001 Oct;38(4):633-41. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11588534\n# Weber AA, Meila D, Jacobs C, Weber S, Kelm M, Strauer BE, Zotz RB, Scharf RE, Schror K: Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors. Thromb Res. 2002 Apr 1;106(1):25-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12165285\n# Hall PR, Malone L, Sillerud LO, Ye C, Hjelle BL, Larson RS: Characterization and NMR solution structure of a novel cyclic pentapeptide inhibitor of pathogenic hantaviruses. Chem Biol Drug Des. 2007 Mar;69(3):180-90. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17441904\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352\n# Mazzaferri EL Jr, Young JJ: Abciximab: a review and update for clinicians. Expert Rev Cardiovasc Ther. 2008 Jun;6(5):609-18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18510478\n# Ibbotson T, McGavin JK, Goa KL: Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs. 2003;63(11):1121-63. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12749745", "known-action": "yes", "polypeptide": {"@id": "P05106", "@source": "Swiss-Prot", "name": "Integrin beta-3", "general-function": "Involved in cell adhesion and blood clotting", "specific-function": "Integrin alpha-V/beta-3 is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha- IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions", "gene-name": "ITGB3", "locus": "17q21.32", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "719-741", "signal-regions": null, "theoretical-pi": "4.85", "molecular-weight": "87058.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6156"}, {"resource": "GenAtlas", "identifier": "ITGB3"}, {"resource": "GeneCards", "identifier": "ITGB3"}, {"resource": "GenBank Gene Database", "identifier": "J02703"}, {"resource": "GenBank Protein Database", "identifier": "306786"}, {"resource": "UniProtKB", "identifier": "P05106"}, {"resource": "UniProt Accession", "identifier": "ITB3_HUMAN"}]}, "synonyms": {"synonym": ["CD61 antigen", "GPIIIa", "Integrin beta-3 precursor", "Platelet membrane glycoprotein IIIa"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Integrin beta-3 precursor\nMRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLG\nSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRP\nDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFG\nAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSR\nNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCH\nVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLS\nMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDT\nVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGT\nFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFG\nKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLL\nCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRY\nCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDIL\nVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTF\nTNITYRGT"}, "gene-sequence": {"@format": "FASTA", "#text": ">2367 bp\nATGCGAGCGCGGCCGCGGCCCCGGCCGCTCTGGGTGACTGTGCTGGCGCTGGGGGCGCTG\nGCGGGCGTTGGCGTAGGAGGGCCCAACATCTGTACCACGCGAGGTGTGAGCTCCTGCCAG\nCAGTGCCTGGCTGTGAGCCCCATGTGTGCCTGGTGCTCTGATGAGGCCCTGCCTCTGGGC\nTCACCTCGCTGTGACCTGAAGGAGAATCTGCTGAAGGATAACTGTGCCCCAGAATCCATC\nGAGTTCCCAGTGAGTGAGGCCCGAGTACTAGAGGACAGGCCCCTCAGCGACAAGGGCTCT\nGGAGACAGCTCCCAGGTCACTCAAGTCAGTCCCCAGAGGATTGCACTCCGGCTCCGGCCA\nGATGATTCGAAGAATTTCTCCATCCAAGTGCGGCAGGTGGAGGATTACCCTGTGGACATC\nTACTACTTGATGGACCTGTCTTACTCCATGAAGGATGATCTGTGGAGCATCCAGAACCTG\nGGTACCAAGCTGGCCACCCAGATGCGAAAGCTCACCAGTAACCTGCGGATTGGCTTCGGG\nGCATTTGTGGACAAGCCTGTGTCACCATACATGTATATCTCCCCACCAGAGGCCCTCGAA\nAACCCCTGCTATGATATGAAGACCACCTGCTTGCCCATGTTTGGCTACAAACACGTGCTG\nACGCTAACTGACCAGGTGACCCGCTTCAATGAGGAAGTGAAGAAGCAGAGTGTGTCACGG\nAACCGAGATGCCCCAGAGGGTGGCTTTGATGCCATCATGCAGGCTACAGTCTGTGATGAA\nAAGATTGGCTGGAGGAATGATGCATCCCACTTGCTGGTGTTTACCACTGATGCCAAGACT\nCATATAGCATTGGACGGAAGGCTGGCAGGCATTGTCCAGCCTAATGACGGGCAGTGTCAT\nGTTGGTAGTGACAATCATTACTCTGCCTCCACTACCATGGATTATCCCTCTTTGGGGCTG\nATGACTGAGAAGCTATCCCAGAAAAACATCAATTTGATCTTTGCAGTGACTGAAAATGTA\nGTCAATCTCTATCAGAACTATAGTGAGCTCATCCCAGGGACCACAGTTGGGGTTCTGTCC\nATGGATTCCAGCAATGTCCTCCAGCTCATTGTTGATGCTTATGGGAAAATCCGTTCTAAA\nGTCGAGCTGGAAGTGCGTGACCTCCCTGAAGAGTTGTCTCTATCCTTCAATGCCACCTGC\nCTCAACAATGAGGTCATCCCTGGCCTCAAGTCTTGTATGGGACTCAAGATTGGAGACACG\nGTGAGCTTCAGCATTGAGGCCAAGGTGCGAGGCTGTCCCCAGGAGAAGGAGAAGTCCTTT\nACCATAAAGCCCGTGGGCTTCAAGGACAGCCTGATCGTCCAGGTCACCTTTGATTGTGAC\nTGTGCCTGCCAGGCCCAAGCTGAACCTAATAGCCATCGCTGCAACAATGGCAATGGGACC\nTTTGAGTGTGGGGTATGCCGTTGTGGGCCTGGCTGGCTGGGATCCCAGTGTGAGTGCTCA\nGAGGAGGACTATCGCCCTTCCCAGCAGGACGAGTGCAGCCCCCGAGAGGGTCAGCCCGTC\nTGCAGCCAGCGGGGCGAGTGCCTCTGTGGTCAATGTGTCTGCCACAGCAGTGACTTTGGC\nAAGATCACGGGCAAGTACTGCGAGTGTGACGACTTCTCCTGTGTCCGCTACAAGGGGGAG\nATGTGCTCAGGCCATGGCCAGTGCAGCTGTGGGGACTGCCTGTGTGACTCCGACTGGACC\nGGCTACTACTGCAACTGTACCACGCGTACTGACACCTGCATGTCCAGCAATGGGCTGCTG\nTGCAGCGGCCGCGGCAAGTGTGAATGTGGCAGCTGTGTCTGTATCCAGCCGGGCTCCTAT\nGGGGACACCTGTGAGAAGTGCCCCACCTGCCCAGATGCCTGCACCTTTAAGAAAGAATGT\nGTGGAGTGTAAGAAGTTTGACCGGGAGCCCTACATGACCGAAAATACCTGCAACCGTTAC\nTGCCGTGACGAGATTGAGTCAGTGAAAGAGCTTAAGGACACTGGCAAGGATGCAGTGAAT\nTGTACCTATAAGAATGAGGATGACTGTGTCGTCAGATTCCAGTACTATGAAGATTCTAGT\nGGAAAGTCCATCCTGTATGTGGTAGAAGAGCCAGAGTGTCCCAAGGGCCCTGACATCCTG\nGTGGTCCTGCTCTCAGTGATGGGGGCCATTCTGCTCATTGGCCTTGCCGCCCTGCTCATC\nTGGAAACTCCTCATCACCATCCACGACCGAAAAGAATTCGCTAAATTTGAGGAAGAACGC\nGCCAGAGCAAAATGGGACACAGCCAACAACCCACTGTATAAAGAGGCCACGTCTACCTTC\nACCAATATCACGTACCGGGGCACTTAA"}, "pfams": {"pfam": [{"identifier": "PF07974", "name": "EGF_2"}, {"identifier": "PF00362", "name": "Integrin_beta"}, {"identifier": "PF08725", "name": "Integrin_b_cyt"}, {"identifier": "PF07965", "name": "Integrin_B_tail"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "protein complex"}, {"category": "component", "description": "receptor complex"}, {"category": "component", "description": "integrin complex"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell adhesion"}, {"category": "process", "description": "cell-substrate adhesion"}, {"category": "process", "description": "cell-matrix adhesion"}, {"category": "process", "description": "development"}]}}}, {"@position": "2", "id": "BE0000439", "name": "Integrin alpha-IIb", "organism": "Human", "actions": {"action": "antagonist"}, "references": "# Gibbs NM: Point-of-care assessment of antiplatelet agents in the perioperative period: a review. Anaesth Intensive Care. 2009 May;37(3):354-69. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19499855\n# Mazzaferri EL Jr, Young JJ: Abciximab: a review and update for clinicians. Expert Rev Cardiovasc Ther. 2008 Jun;6(5):609-18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18510478\n# Ibbotson T, McGavin JK, Goa KL: Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs. 2003;63(11):1121-63. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12749745", "known-action": "yes", "polypeptide": {"@id": "P08514", "@source": "Swiss-Prot", "name": "Integrin alpha-IIb", "general-function": "Involved in cell adhesion", "specific-function": "Integrin alpha-IIb/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. It recognizes the sequence R-G-D in a wide array of ligands. It recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha- IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial cell surface", "gene-name": "ITGA2B", "locus": "17q21.32", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "994-1019", "signal-regions": null, "theoretical-pi": "5.03", "molecular-weight": "113392.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6138"}, {"resource": "GenAtlas", "identifier": "ITGA2B"}, {"resource": "GeneCards", "identifier": "ITGA2B"}, {"resource": "GenBank Gene Database", "identifier": "J02764"}, {"resource": "GenBank Protein Database", "identifier": "190068"}, {"resource": "UniProtKB", "identifier": "P08514"}, {"resource": "UniProt Accession", "identifier": "ITA2B_HUMAN"}]}, "synonyms": {"synonym": ["CD41 antigen", "GPalpha IIb", "GPIIb", "Integrin alpha-IIb precursor", "Platelet membrane glycoprotein IIb"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Integrin alpha-IIb precursor\nMARALCPLQALWLLEWVLLLLGPCAAPPAWALNLDPVQLTFYAGPNGSQFGFSLDFHKDS\nHGRVAIVVGAPRTLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVGSQTLQTFKA\nRQGLGASVVSWSDVIVACAPWQHWNVLEKTEEAEKTPVGSCFLAQPESGRRAEYSPCRGN\nTLSRIYVENDFSWDKRYCEAGFSSVVTQAGELVLGAPGGYYFLGLLAQAPVADIFSSYRP\nGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTTEYVVGAPTWSWTLGAVEI\nLDSYYQRLHRLRAEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKLAEVGRVY\nLFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDRDGYNDIAVAAPYGGPSGRGQV\nLVFLGQSEGLRSRPSQVLDSPFPTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYR\nAQPVVKASVQLLVQDSLNPAVKSCVLPQTKTPVSCFNIQMCVGATGHNIPQKLSLNAELQ\nLDRQKPRQGRRVLLLGSQQAGTTLNLDLGGKHSPICHTTMAFLRDEADFRDKLSPIVLSL\nNVSLPPTEAGMAPAVVLHGDTHVQEQTRIVLDCGEDDVCVPQLQLTASVTGSPLLVGADN\nVLELQMDAANEGEGAYEAELAVHLPQGAHYMRALSNVEGFERLICNQKKENETRVVLCEL\nGNPMKKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLLDVPVRAEAQVE\nLRGNSFPASLVVAAEEGEREQNSLDSWGPKVEHTYELHNNGPGTVNGLHLSIHLPGQSQP\nSDLLYILDIQPQGGLQCFPQPPVNPLKVDWGLPIPSPSPIHPAHHKRDRRQIFLPEPEQP\nSRLQDPVLVSCDSAPCTVVQCDLQEMARGQRAMVTVLAFLWLPSLYQRPLDQFVLQSHAW\nFNVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAIPIWWVLVGVLGGLLLLTILVLAMWK\nVGFFKRNRPPLEEDDEEGE"}, "gene-sequence": {"@format": "FASTA", "#text": ">3120 bp\nATGGCCAGAGCTTTGTGTCCACTGCAAGCCCTCTGGCTTCTGGAGTGGGTGCTGCTGCTC\nTTGGGACCTTGTGCTGCCCCTCCAGCCTGGGCCTTGAACCTGGACCCAGTGCAGCTCACC\nTTCTATGCAGGCCCCAATGGCAGCCAGTTTGGATTTTCACTGGACTTCCACAAGGACAGC\nCATGGGAGAGTGGCCATCGTGGTGGGCGCCCCGCGGACCCTGGGCCCCAGCCAGGAGGAG\nACGGGCGGCGTGTTCCTGTGCCCCTGGAGGGCCGAGGGCGGCCAGTGCCCCTCGCTGCTC\nTTTGACCTCCGTGATGAGACCCGAAATGTAGGCTCCCAAACTTTACAAACCTTCAAGGCC\nCGCCAAGGACTGGGGGCGTCGGTCGTCAGCTGGAGCGACGTCATTGTGGCCTGCGCCCCC\nTGGCAGCACTGGAACGTCCTAGAAAAGACTGAGGAGGCTGAGAAGACGCCCGTAGGTAGC\nTGCTTTTTGGCTCAGCCAGAGAGCGGCCGCCGCGCCGAGTACTCCCCCTGTCGCGGGAAC\nACCCTGAGCCGCATTTACGTGGAAAATGATTTTAGCTGGGACAAGCGTTACTGTGAAGCG\nGGCTTCAGCTCCGTGGTCACTCAGGCCGGAGAGCTGGTGCTTGGGGCTCCTGGCGGCTAT\nTATTTCTTAGGTCTCCTGGCCCAGGCTCCAGTTGCGGATATTTTCTCGAGTTACCGCCCA\nGGCATCCTTTTGTGGCACGTGTCCTCCCAGAGCCTCTCCTTTGACTCCAGCAACCCAGAG\nTACTTCGACGGCTACTGGGGGTACTCGGTGGCCGTGGGCGAGTTCGACGGGGATCTCAAC\nACTACAGAATATGTCGTCGGTGCCCCCACTTGGAGCTGGACCCTGGGAGCGGTGGAAATT\nTTGGATTCCTACTACCAGAGGCTGCATCGGCTGCGCGCAGAGCAGATGGCGTCGTATTTT\nGGGCATTCAGTGGCTGTCACTGACGTCAACGGGGATGGGAGGCATGATCTGCTGGTGGGC\nGCTCCACTGTATATGGAGAGCCGGGCAGACCGAAAACTGGCCGAAGTGGGGCGTGTGTAT\nTTGTTCCTGCAGCCGCGAGGCCCCCACGCGCTGGGTGCCCCCAGCCTCCTGCTGACTGGC\nACACAGCTCTATGGGCGATTCGGCTCTGCCATCGCACCCCTGGGCGACCTCGACCGGGAT\nGGCTACAATGACATTGCAGTGGCTGCCCCCTACGGGGGTCCCAGTGGCCGGGGCCAAGTG\nCTGGTGTTCCTGGGTCAGAGTGAGGGGCTGAGGTCACGTCCCTCCCAGGTCCTGGACAGC\nCCCTTCCCCACAGGCTCTGCCTTTGGCTTCTCCCTTCGAGGTGCCGTAGACATCGATGAC\nAACGGATACCCAGACCTGATCGTGGGAGCTTACGGGGCCAACCAGGTGGCTGTGTACAGA\nGCTCAGCCAGTGGTGAAGGCCTCTGTCCAGCTACTGGTGCAAGATTCACTGAATCCTGCT\nGTGAAGAGCTGTGTCCTACCTCAGACCAAGACACCCGTGAGCTGCTTCAACATCCAGATG\nTGTGTTGGAGCCACTGGGCACAACATTCCTCAGAAGCTATCCCTAAATGCCGAGCTGCAG\nCTGGACCGGCAGAAGCCCCGCCAGGGCCGGCGGGTGCTGCTGCTGGGCTCTCAACAGGCA\nGGCACCACCCTGAACCTGGATCTGGGCGGAAAGCACAGCCCCATCTGCCACACCACCATG\nGCCTTCCTTCGAGATGAGGCAGACTTCCGGGACAAGCTGAGCCCCATTGTGCTCAGCCTC\nAATGTGTCCCTACCGCCCACGGAGGCTGGAATGGCCCCTGCTGTCGTGCTGCATGGAGAC\nACCCATGTGCAGGAGCAGACACGAATCGTCCTGGACTCTGGGGAAGATGACGTATGTGTG\nCCCCAGCTTCAGCTCACTGCCAGCGTGACGGGCTCCCCGCTCCTAGTTGGGGCAGATAAT\nGTCCTGGAGCTGCAGATGGACGCAGCCAACGAGGGCGAGGGGGCCTATGAAGCAGAGCTG\nGCCGTGCACCTGCCCCAGGGCGCCCACTACATGCGGGCCCTAAGCAATGTCGAGGGCTTT\nGAGAGACTCATCTGTAATCAGAAGAAGGAGAATGAGACCAGGGTGGTGCTGTGTGAGCTG\nGGCAACCCCATGAAGAAGAACGCCCAGATAGGAATCGCGATGTTGGTGAGCGTGGGGAAT\nCTGGAAGAGGCTGGGGAGTCTGTGTCCTTCCAGCTGCAGATACGGAGCAAGAACAGCCAG\nAATCCAAACAGCAAGATTGTGCTGCTGGACGTGCCGGTCCGGGCAGAGGCCCAAGTGGAG\nCTGCGAGGGAACTCCTTTCCAGCCTCCCTGGTGGTGGCAGCAGAAGAAGGTGAGAGGGAG\nCAGAACAGCTTGGACAGCTGGGGACCCAAAGTGGAGCACACCTATGAGCTCCACAACAAT\nGGCCCTGGGACTGTGAATGGTCTTCACCTCAGCATCCACCTTCCGGGACAGTCCCAGCCC\nTCCGACCTGCTCTACATCCTGGATATACAGCCCCAGGGGGGCCTTCAGTGCTTCCCACAG\nCCTCCTGTCAACCCTCTCAAGGTGGACTGGGGGCTGCCCATCCCCAGCCCCTCCCCCATT\nCACCCGGCCCATCACAAGCGGGATCGCAGACAGATCTTCCTGCCAGAGCCCGAGCAGCCC\nTCGAGGCTTCAGGATCCAGTTCTCGTAAGCTGCGACTCGGCGCCCTGTACTGTGGTGCAG\nTGTGACCTGCAGGAGATGGCGCGCGGGCAGCGGGCCATGGTCACGGTGCTGGCCTTCCTG\nTGGCTGCCCAGCCTCTACCAGAGGCCTCTGGATCAGTTTGTGCTGCAGTCGCACGCATGG\nTTCAACGTGTCCTCCCTCCCCTATGCGGTGCCCCCGCTCAGCCTGCCCCGAGGGGAAGCT\nCAGGTGTGGACACAGCTGCTCCGGGCCTTGGAGGAGAGGGCCATTCCAATCTGGTGGGTG\nCTGGTGGGTGTGCTGGGTGGCCTGCTGCTGCTCACCATCCTGGTCCTGGCCATGTGGAAG\nGTCGGCTTCTTCAAGCGGAACCGGCCACCCCTGGAAGAAGATGATGAAGAGGGGGAGTGA"}, "pfams": {"pfam": [{"identifier": "PF01839", "name": "FG-GAP"}, {"identifier": "PF00357", "name": "Integrin_alpha"}, {"identifier": "PF08441", "name": "Integrin_alpha2"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "protein complex"}, {"category": "component", "description": "receptor complex"}, {"category": "component", "description": "integrin complex"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell adhesion"}, {"category": "process", "description": "cell-substrate adhesion"}, {"category": "process", "description": "cell-matrix adhesion"}]}}}, {"@position": "3", "id": "BE0000901", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "O75015", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "general-function": null, "specific-function": "Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils", "gene-name": "FCGR3B", "locus": "1q23", "cellular-location": "Cell membrane; lipid-anchor; GPI-anchor. Secreted protein. Note=Secreted after cleavage", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.71", "molecular-weight": "26216.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3620"}, {"resource": "GenAtlas", "identifier": "FCGR3B"}, {"resource": "GeneCards", "identifier": "FCGR3B"}, {"resource": "GenBank Gene Database", "identifier": "X16863"}, {"resource": "GenBank Protein Database", "identifier": "31322"}, {"resource": "UniProtKB", "identifier": "O75015"}, {"resource": "UniProt Accession", "identifier": "FCG3B_HUMAN"}]}, "synonyms": {"synonym": ["CD16b antigen", "Fc-gamma RIII", "Fc-gamma RIII-beta", "Fc-gamma RIIIb", "FcR-10", "FcRIII", "FcRIIIb", "IgG Fc receptor III-1", "Low affinity immunoglobulin gamma Fc region receptor III-B precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-B precursor\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI"}, "gene-sequence": {"@format": "FASTA", "#text": ">702 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "4", "id": "BE0002093", "name": "Complement C1r subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P00736", "@source": "Swiss-Prot", "name": "Complement C1r subcomponent", "general-function": null, "specific-function": "C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system", "gene-name": "C1R", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.24", "molecular-weight": "80174.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1246"}, {"resource": "GenAtlas", "identifier": "C1R"}, {"resource": "GeneCards", "identifier": "C1R"}, {"resource": "GenBank Gene Database", "identifier": "X04701"}, {"resource": "GenBank Protein Database", "identifier": "29539"}, {"resource": "UniProtKB", "identifier": "P00736"}, {"resource": "UniProt Accession", "identifier": "C1R_HUMAN"}]}, "synonyms": {"synonym": ["Complement C1r subcomponent precursor", "Complement component 1, r subcomponent", "EC 3.4.21.41"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1r subcomponent\nMWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF\nQQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF\nSNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY\nELQEDRHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF\nDIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL\nRYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD\nDGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR\nESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF\nTNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV\nSVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME\nEKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV\nRDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2118 bp\nATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC\nATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC\nAACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC\nCAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT\nGATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG\nGGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC\nTCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT\nGTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG\nTGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT\nGAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG\nGCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC\nAACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT\nGATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC\nGGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC\nAATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG\nCGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC\nATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA\nGGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT\nGATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA\nAACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC\nCGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG\nGAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG\nGGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG\nAGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC\nACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT\nGCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC\nCTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC\nAGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG\nCTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC\nAACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG\nGAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT\nGAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT\nGGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA\nAGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC\nAGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG\nATGGAGGAGGAGGACTGA"}, "pfams": {"pfam": [{"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF07645", "name": "EGF_CA"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "5", "id": "BE0002094", "name": "Complement C1q subcomponent subunit A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02745", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit A", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QA", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.45", "molecular-weight": "26017.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1241"}, {"resource": "GenAtlas", "identifier": "C1QA"}, {"resource": "GeneCards", "identifier": "C1QA"}, {"resource": "GenBank Gene Database", "identifier": "AF135157"}, {"resource": "GenBank Protein Database", "identifier": "4894854"}, {"resource": "UniProtKB", "identifier": "P02745"}, {"resource": "UniProt Accession", "identifier": "C1QA_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit A precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit A\nMEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR\nTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI\nRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR\nGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL\nIFPSA"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG\nGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC\nAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG\nACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC\nAAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGGGCCCGTGGCATCCCGGGAATTAAA\nGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT\nCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG\nGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC\nTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG\nGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG\nGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC\nCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC\nATCTTCCCATCTGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "6", "id": "BE0002095", "name": "Complement C1q subcomponent subunit B", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02746", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit B", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QB", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.87", "molecular-weight": "26460.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1242"}, {"resource": "GenAtlas", "identifier": "C1QB"}, {"resource": "GeneCards", "identifier": "C1QB"}, {"resource": "GenBank Gene Database", "identifier": "X03084"}, {"resource": "GenBank Protein Database", "identifier": "573114"}, {"resource": "UniProtKB", "identifier": "P02746"}, {"resource": "UniProt Accession", "identifier": "C1QB_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit B precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit B\nMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEK\nGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKI\nAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCV\nNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANSIF\nSGFLLFPDMEA"}, "gene-sequence": {"@format": "FASTA", "#text": ">688 bp\nCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGG\nGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCC\nAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAA\nTCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGCCCAGGGGCCCCTGG\nAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAGAAAATCGCCTTCTC\nTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATCCGCTTCGACCACGT\nGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTCACCTGCAAGGTGCC\nCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTGTGCGTGAACCTCAT\nGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTATGCCTACAACACCTT\nCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAGAACGTCTTCCTGCA\nGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGCATCTTTTCCGGGTT\nCCTGCTCTTTCCAGATATGGAGGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "7", "id": "BE0002096", "name": "Complement C1q subcomponent subunit C", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02747", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit C", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QC", "locus": "1p36.11", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.58", "molecular-weight": "25774.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1245"}, {"resource": "GenAtlas", "identifier": "C1QC"}, {"resource": "GeneCards", "identifier": "C1QC"}, {"resource": "GenBank Gene Database", "identifier": "AF087892"}, {"resource": "GenBank Protein Database", "identifier": "33150626"}, {"resource": "UniProtKB", "identifier": "P02747"}, {"resource": "UniProt Accession", "identifier": "C1QC_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit C precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit C\nMDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP\nGIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS\nVFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV\nLLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF\nLLFPD"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG\nCTGCTGCCCCTCAGGGCCAAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC\nCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA\nGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA\nCCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC\nCCCATGGGATTCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA\nGTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC\nAACGCGGTCCTCACCAACCCGCAGGAGGATTATGACACGAGCACTGGCAAGTTCACCTGC\nAAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG\nCTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT\nCAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT\nGTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC\nCTGCTCTTCCCCGACTAG"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "8", "id": "BE0002097", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P08637", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "general-function": null, "specific-function": "Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis", "gene-name": "FCGR3A", "locus": "1q23", "cellular-location": "Cell membrane", "transmembrane-regions": "209-229", "signal-regions": null, "theoretical-pi": "8.21", "molecular-weight": "29089.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3619"}, {"resource": "GenAtlas", "identifier": "FCGR3A"}, {"resource": "GeneCards", "identifier": "FCGR3A"}, {"resource": "GenBank Gene Database", "identifier": "X52645"}, {"resource": "GenBank Protein Database", "identifier": "31324"}, {"resource": "UniProtKB", "identifier": "P08637"}, {"resource": "UniProt Accession", "identifier": "FCG3A_HUMAN"}]}, "synonyms": {"synonym": ["CD16a antigen", "Fc-gamma RIII", "Fc-gamma RIII-alpha", "Fc-gamma RIIIa", "FcR-10", "FcRIII", "FcRIIIa", "IgG Fc receptor III-2", "Low affinity immunoglobulin gamma Fc region receptor III-A precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK"}, "gene-sequence": {"@format": "FASTA", "#text": ">765 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCGACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCA\nAAAGCCACACTCAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTTTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGG\nAAGGACCATAAATTTAAATGGAGAAAGGACCCTCAAGACAAATGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "9", "id": "BE0001529", "name": "Complement C1s subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P09871", "@source": "Swiss-Prot", "name": "Complement C1s subcomponent", "general-function": "Involved in calcium ion binding", "specific-function": "C1s B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4", "gene-name": "C1S", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "4.59", "molecular-weight": "76685.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1247"}, {"resource": "GenAtlas", "identifier": "C1S"}, {"resource": "GeneCards", "identifier": "C1S"}, {"resource": "GenBank Gene Database", "identifier": "X06596"}, {"resource": "GenBank Protein Database", "identifier": "763110"}, {"resource": "UniProtKB", "identifier": "P09871"}, {"resource": "UniProt Accession", "identifier": "C1S_HUMAN"}]}, "synonyms": {"synonym": ["C1 esterase", "Complement C1s subcomponent precursor", "EC 3.4.21.42"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1s subcomponent precursor\nMWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIE\nLSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERF\nTGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVF\nTALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVF\nVAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTP\nNSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCG\nIPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPK\nCVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGN\nREPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVK\nMGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKV\nEKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCG\nTYGLYTRVKNYVDWIMKTMQENSTPRED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2067 bp\nATGTGGTGCATTGTCCTGTTTTCACTTTTGGCATGGGTTTATGCTGAGCCTACCATGTAT\nGGGGAGATCCTGTCCCCTAACTATCCTCAGGCATATCCCAGTGAGGTAGAGAAATCTTGG\nGACATAGAAGTTCCTGAAGGGTATGGGATTCACCTCTACTTCACCCATCTGGACATTGAG\nCTGTCAGAGAACTGTGCGTATGACTCAGTGCAGATAATCTCAGGAGACACTGAAGAAGGG\nAGGCTCTGTGGACAGAGGAGCAGTAACAATCCCCACTCTCCAATTGTGGAAGAGTTCCAA\nGTCCCATACAACAAACTCCAGGTGATCTTTAAGTCAGACTTTTCCAATGAAGAGCGTTTT\nACGGGGTTTGCTGCATACTATGTTGCCACAGACATAAATGAATGCACAGATTTTGTAGAT\nGTCCCTTGTAGCCACTTCTGCAACAATTTCATTGGTGGTTACTTCTGCTCCTGCCCCCCG\nGAATATTTCCTCCATGATGACATGAAGAATTGCGGAGTTAATTGCAGTGGGGATGTATTC\nACTGCACTGATTGGGGAGATTGCAAGTCCCAATTATCCCAAACCATATCCAGAGAACTCA\nAGGTGTGAATACCAGATCCGGTTGGAGAAAGGGTTCCAAGTGGTGGTGACCTTGCGGAGA\nGAAGATTTTGATGTGGAAGCAGCTGACTCAGCGGGAAACTGCCTTGACAGTTTAGTTTTT\nGTTGCAGGAGATCGGCAATTTGGTCCTTACTGTGGTCATGGATTCCCTGGGCCTCTAAAT\nATTGAAACCAAGAGTAATGCTCTTGATATCATCTTCCAAACTGATCTAACAGGGCAAAAA\nAAGGGCTGGAAACTTCGCTATCATGGAGATCCAATGCCCTGCCCTAAGGAAGACACTCCC\nAATTCTGTTTGGGAGCCTGCGAAGGCAAAATATGTCTTTAGAGATGTGGTGCAGATAACC\nTGTCTGGATGGGTTTGAAGTTGTGGAGGGACGTGTTGGTGCAACATCTTTCTATTCGACT\nTGTCAAAGCAATGGAAAGTGGAGTAATTCCAAACTGAAATGTCAACCTGTGGACTGTGGC\nATTCCTGAATCCATTGAGAATGGTAAAGTTGAAGACCCAGAGAGCACTTTGTTTGGTTCT\nGTCATCCGCTACACTTGTGAGGAGCCATATTACTACATGGAAAATGGAGGAGGTGGGGAG\nTATCACTGTGCTGGTAACGGGAGCTGGGTGAATGAGGTGCTGGGCCCGGAGCTGCCGAAA\nTGTGTTCCAGTCTGTGGAGTCCCCAGAGAACCCTTTGAAGAAAAACAGAGGATAATTGGA\nGGATCCGATGCAGATATTAAAAACTTCCCCTGGCAAGTCTTCTTTGACAACCCATGGGCT\nGGTGGAGCGCTCATTAATGAGTACTGGGTGCTGACGGCTGCTCATGTTGTGGAGGGAAAC\nAGGGAGCCAACAATGTATGTTGGGTCCACCTCAGTGCAGACCTCACGGCTGGCAAAATCC\nAAGATGCTCACTCCTGAGCATGTGTTTATTCATCCGGGATGGAAGCTGCTGGAAGTCCCA\nGAAGGACGAACCAATTTTGATAATGACATTGCACTGGTGCGGCTGAAAGACCCAGTGAAA\nATGGGACCCACCGTCTCTCCCATCTGCCTACCAGGCACCTCTTCCGACTACAACCTCATG\nGATGGGGACCTGGGACTGATCTCAGGCTGGGGCCGAACAGAGAAGAGAGATCGTGCTGTT\nCGCCTCAAGGCGGCAAGGTTACCTGTAGCTCCTTTAAGAAAATGCAAAGAAGTGAAAGTG\nGAGAAACCCACAGCAGATGCAGAGGCCTATGTTTTCACTCCTAACATGATCTGTGCTGGA\nGGAGAGAAGGGCATGGATAGCTGTAAAGGGGACAGTGGTGGGGCCTTTGCTGTACAGGAT\nCCCAATGACAAGACCAAATTCTACGCAGCTGGCCTGGTGTCCTGGGGGCCCCAGTGTGGG\nACCTATGGGCTCTACACACGGGTAAAGAACTATGTTGACTGGATAATGAAGACTATGCAG\nGAAAATAGCACCCCCCGTGAGGACTAA"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "10", "id": "BE0000710", "name": "High affinity immunoglobulin gamma Fc receptor I", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P12314", "@source": "Swiss-Prot", "name": "High affinity immunoglobulin gamma Fc receptor I", "general-function": "Involved in receptor signaling protein activity", "specific-function": "Binds to the Fc region of immunoglobulins gamma. High affinity receptor", "gene-name": "FCGR1A", "locus": "1q21.2-q21.3", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "293-313", "signal-regions": null, "theoretical-pi": "8.08", "molecular-weight": "42632.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3613"}, {"resource": "GenAtlas", "identifier": "FCGR1A"}, {"resource": "GeneCards", "identifier": "FCGR1A"}, {"resource": "GenBank Gene Database", "identifier": "X14356"}, {"resource": "GenBank Protein Database", "identifier": "31332"}, {"resource": "UniProtKB", "identifier": "P12314"}, {"resource": "UniProt Accession", "identifier": "FCGR1_HUMAN"}]}, "synonyms": {"synonym": ["CD64 antigen", "Fc-gamma RI", "FcRI", "High affinity immunoglobulin gamma Fc receptor I precursor", "IgG Fc receptor I"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">High affinity immunoglobulin gamma Fc receptor I precursor\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1125 bp\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCTCTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAACTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "11", "id": "BE0002098", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P12318", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "general-function": null, "specific-function": "Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens", "gene-name": "FCGR2A", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.78", "molecular-weight": "34990.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3616"}, {"resource": "GenAtlas", "identifier": "FCGR2A"}, {"resource": "GeneCards", "identifier": "FCGR2A"}, {"resource": "GenBank Gene Database", "identifier": "M31932"}, {"resource": "GenBank Protein Database", "identifier": "182474"}, {"resource": "UniProtKB", "identifier": "P12318"}, {"resource": "UniProt Accession", "identifier": "FCG2A_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-a", "Fc-gamma-RIIa", "FcRII-a", "IgG Fc receptor II-a", "Low affinity immunoglobulin gamma Fc region receptor II-a precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-a\nMAMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSRLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">954 bp\nATGGCTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "12", "id": "BE0002099", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31994", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "general-function": null, "specific-function": "Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B- cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis", "gene-name": "FCGR2B", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.12", "molecular-weight": "34044.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3618"}, {"resource": "GenAtlas", "identifier": "FCGR2B"}, {"resource": "GeneCards", "identifier": "FCGR2B"}, {"resource": "GenBank Gene Database", "identifier": "U87560"}, {"resource": "GenBank Protein Database", "identifier": "4099445"}, {"resource": "UniProtKB", "identifier": "P31994"}, {"resource": "UniProt Accession", "identifier": "FCG2B_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-b", "Fc-gamma-RIIb", "FcRII-b", "IgG Fc receptor II-b", "Low affinity immunoglobulin gamma Fc region receptor II-b precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI"}, "gene-sequence": {"@format": "FASTA", "#text": ">930 bp\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCTCTCCCAGGATACCCTGAG\nTGCAGGGAAATGGGAGAGACCCTCCCTGAGAAACCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATT"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "13", "id": "BE0002100", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31995", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "general-function": null, "specific-function": "Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells", "gene-name": "FCGR2C", "locus": "1q23.3", "cellular-location": "Cell membrane", "transmembrane-regions": "224-246", "signal-regions": null, "theoretical-pi": "6.9", "molecular-weight": "35578.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:15626"}, {"resource": "GenAtlas", "identifier": "FCGR2C"}, {"resource": "GeneCards", "identifier": "FCGR2C"}, {"resource": "GenBank Gene Database", "identifier": "X17652"}, {"resource": "GenBank Protein Database", "identifier": "32074"}, {"resource": "UniProtKB", "identifier": "P31995"}, {"resource": "UniProt Accession", "identifier": "FCG2C_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-c", "Fc-gamma-RIIc", "FcRII-c", "IgG Fc receptor II-c", "Low affinity immunoglobulin gamma Fc region receptor II-c precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-c\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR\nAPTDDDKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">972 bp\nATGGGAATCCTGTCATTTTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACAGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCATTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCTGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG\nAAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT\nGAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG\nGCACCTACTGACGATGATAAAAACATCTACTTGACTCTTCCTCCCAACGACCATGTCAAC\nAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "14", "id": "BE0001068", "name": "Vitronectin", "organism": "Human", "actions": null, "references": "# Romagnoli E, Burzotta F, Trani C, Biondi-Zoccai GG, Giannico F, Crea F: Rationale for intracoronary administration of abciximab. J Thromb Thrombolysis. 2007 Feb;23(1):57-63. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17160551\n# Ibbotson T, McGavin JK, Goa KL: Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs. 2003;63(11):1121-63. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12749745", "known-action": "unknown", "polypeptide": {"@id": "P04004", "@source": "Swiss-Prot", "name": "Vitronectin", "general-function": "Involved in protein binding and cell adhesion", "specific-function": "Somatomedin B is a growth hormone-dependent serum factor with protease-inhibiting activity", "gene-name": "VTN", "locus": "17q11", "cellular-location": "Secreted protein; extracellular space", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.54", "molecular-weight": "54306.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:12724"}, {"resource": "GenAtlas", "identifier": "VTN"}, {"resource": "GeneCards", "identifier": "VTN"}, {"resource": "GenBank Gene Database", "identifier": "X03168"}, {"resource": "GenBank Protein Database", "identifier": "36575"}, {"resource": "UniProtKB", "identifier": "P04004"}, {"resource": "UniProt Accession", "identifier": "VTNC_HUMAN"}]}, "synonyms": {"synonym": ["S-protein", "Serum-spreading factor", "V75", "Vitronectin precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Vitronectin precursor\nMAPLRPLLILALLAWVALADQESCKGRCTEGFNVDKKCQCDELCSYYQSCCTDYTAECKP\nQVTRGDVFTMPEDEYTVYDDGEEKNNATVHEQVGGPSLTSDLQAQSKGNPEQTPVLKPEE\nEAPAPEVGASKPEGIDSRPETLHPGRPQPPAEEELCSGKPFDAFTDLKNGSLFAFRGQYC\nYELDEKAVRPGYPKLIRDVWGIEGPIDAAFTRINCQGKTYLFKGSQYWRFEDGVLDPDYP\nRNISDGFDGIPDNVDAALALPAHSYSGRERVYFFKGKQYWEYQFQHQPSQEECEGSSLSA\nVFEHFAMMQRDSWEDIFELLFWGRTSAGTRQPQFISRDWHGVPGQVDAAMAGRIYISGMA\nPRPSLAKKQRFRHRNRKGYRSQRGHSRGRNQNSRRPSRATWLSLFSSEESNLGANNYDDY\nRMDWLVPATCEPIQSVFFFSGDKYYRVNLRTRRVDTVDPPYPRSIAQYWLGCPAPGHL"}, "gene-sequence": {"@format": "FASTA", "#text": ">1437 bp\nATGGCACCCCTGAGACCCCTTCTCATACTGGCCCTGCTGGCATGGGTTGCTCTGGCTGAC\nCAAGAGTCATGCAAGGGCCGCTGCACTGAGGGCTTCAACGTGGACAAGAAGTGCCAGTGT\nGACGAGCTCTGCTCTTACTACCAGAGCTGCTGCACAGACTATACGGCTGAGTGCAAGCCC\nCAAGTGACTCGCGGGGATGTGTTCACTATGCCGGAGGATGAGTACACGGTCTATGACGAT\nGGCGAGGAGAAAAACAATGCCACTGTCCATGAACAGGTGGGGGGCCCCTCCCTGACCTCT\nGACCTCCAGGCCCAGTCCAAAGGGAATCCTGAGCAGACACCTGTTCTGAAACCTGAGGAA\nGAGGCCCCTGCGCCTGAGGTGGGCGCCTCTAAGCCTGAGGGGATAGACTCAAGGCCTGAG\nACCCTTCATCCAGGGAGACCTCAGCCCCCAGCAGAGGAGGAGCTGTGCAGTGGGAAGCCC\nTTCGACGCCTTCACCGACCTCAAGAACGGTTCCCTCTTTGCCTTCCGAGGGCAGTACTGC\nTATGAACTGGACGAAAAGGCAGTGAGGCCTGGGTACCCCAAGCTCATCCGAGATGTCTGG\nGGCATCGAGGGCCCCATCGATGCCGCCTTCACCCGCATCAACTGTCAGGGGAAGACCTAC\nCTCTTCAAGGGTAATCAGTACTGGCGCTTTGAGGATGGTGTCCTGGACCCTGATTACCCC\nCGAAATATCTCTGACGGCTTCGATGGCATCCCGGACAACGTGGATGCAGCCTTGGCCCTC\nCCTGCCCATAGCTACAGTGGCCGGGAGCGGGTCTACTTCTTCAAGGGGAAACAGTACTGG\nGAGTACCAGTTCCAGCACCAGCCCAGTCAGGAGGAGTGTGAAGGCAGCTCCCTGTCGGCT\nGTGTTTGAACACTTTGCCATGATGCAGCGGGACAGCTGGGAGGACATCTTCGAGCTTCTC\nTTCTGGGGCAGAACCTCTGCTGGTACCAGACAGCCCCAGTTCATTAGCCGGGACTGGCAC\nGGTGTGCCAGGGCAAGTGGACGCAGCCATGGCTGGCCGCATCTACATCTCAGGCATGGCA\nCCCCGCCCCTCCTTGACCAAGAAACAAAGGTTTAGGCATCGCAACCGCAAAGGCTACCGT\nTCACAACGAGGCCACAGCCGTGGCCGCAACCAGAACTCCCGCCGGCCATCCCGCGCCATG\nTGGCTGTCCTTGTTCTCCAGTGAGGAGAGCAACTTGGGAGCCAACAACTATGATGACTAC\nAGGATGGACTGGCTTGTGCCTGCCACCTGTGAACCCATCCAGAGTGTCTTCTTCTTCTCT\nGGAGACAAGTACTACCGAGTCAATCTTCGCACACGGCGAGTGGACACTGTGGACCCTCCC\nTACCCACGCTCCATCGCTCACTACTGGCTGGGCTGCCCAGCTCCTGGCCATCTGTAG"}, "pfams": {"pfam": [{"identifier": "PF00045", "name": "Hemopexin"}, {"identifier": "PF01033", "name": "Somatomedin_B"}]}, "go-classifiers": null}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-01-29", "drugbank-id": [{"@primary": "true", "#text": "DB00055"}, "BIOD00068", "BTD00068"], "name": "Drotrecogin alfa", "description": "Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis.", "cas-number": "60202-16-6", "groups": {"group": ["approved", "investigational", "withdrawn"]}, "general-references": null, "synthesis-reference": null, "indication": "For reduction of mortality in patients with severe sepsis.", "pharmacodynamics": "Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond.\nDrotrecogin alfa inhibits factor Va and VIIIa, thereby reducing the coagulability of blood.", "mechanism-of-action": "Activated protein C combines with protein S on platelet surfaces and then degrades factor Va and factor VIIIa, thereby reducing blood coagulability.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": "5.5 hours (mammalian reticulocytes, in vitro).", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": "* 40 L/hr [severe sepsis adults]\n* 30\u00a0+/-\u00a08 L/hr [patients without sepsis undergoing hemodialysis]\n* 28\u00a0+/-\u00a09 L/hr [heathy]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Anticoagulant protein C"}, {"@language": "", "@coder": "", "#text": "Autoprothrombin IIA"}, {"@language": "", "@coder": "", "#text": "Blood coagulation factor XIV"}, {"@language": "", "@coder": "", "#text": "Vitamin K-dependent protein C precursor"}]}, "products": {"product": [{"name": "Xigris  (20mg/vial)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02247130", "started-marketing-on": "2003-03-25", "ended-marketing-on": "2011-11-14", "dosage-form": "powder for solution", "strength": "20 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Xigris (5mg/vial)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02247129", "started-marketing-on": "2003-02-20", "ended-marketing-on": "2011-11-14", "dosage-form": "powder for solution", "strength": "5 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": {"name": "Xigris", "company": "Eli Lilly & Co"}}, "mixtures": {"mixture": [{"name": "Xigris (5mg/vial)", "ingredients": "Drotrecogin alfa"}, {"name": "Xigris  (20mg/vial)", "ingredients": "Drotrecogin alfa"}]}, "packagers": {"packager": [{"name": "DSM Corp.", "url": "http://www.dsm.com"}, {"name": "Eli Lilly & Co.", "url": "http://www.lilly.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Xigris 5 mg vial", "cost": {"@currency": "USD", "#text": "370.42"}, "unit": "vial"}, {"description": "Xigris 20 mg vial", "cost": {"@currency": "USD", "#text": "1481.66"}, "unit": "vial"}]}, "categories": {"category": {"category": "Antisepsis", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Powder for solution", "route": "intravenous", "strength": "20 mg"}, {"form": "Powder for solution", "route": "intravenous", "strength": "5 mg"}]}, "atc-codes": null, "ahfs-codes": {"ahfs-code": "20:12.20"}, "patents": {"patent": [{"number": "2036894", "country": "Canada", "approved": "2002-01-15", "expires": "2011-02-22"}, {"number": "2139468", "country": "Canada", "approved": "2007-08-21", "expires": "2015-01-03"}]}, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">Heavy chain\nLIDGKMTRRGDSPWQVVLLDSKKKLACGAVLIHPSWVLTAAHCMDESKKLLVRLGEYDLR\nRWEKWELDLDIKEVFVHPNYSKSTTDNDIALLHLAQPATLSQTIVPICLPDSGLAERELN\nQAGQETLVTGWGYHSSREKEAKRNRTFVLNFIKIPVVPHNECSEVMSNMVSENMLCAGIL\nGDRQDACEGDSGGPMVASFHGTWFLVGLVSWGEGCGLLHNYGVYTKVSRYLDWIHGHIRD\nKEAPQKSWAP"}, {"@format": "FASTA", "#text": ">Light chain\nSKHVDGDQCLVLPLEHPCASLCCGHGTCIXGIGSFSCDCRSGWEGRFCQREVSFLNCSLD\nNGGCTHYCLEEVGWRRCSCAPGYKLGDDLLQCHPAVKFPCGRPWKRMEKKRSHL"}]}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.291", "source": null}, {"kind": "Isoelectric Point", "value": "6.78", "source": null}, {"kind": "Molecular Weight", "value": "55000.0000", "source": null}, {"kind": "Molecular Formula", "value": "C1786H2779N509O519S29", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "12084"}, {"resource": "National Drug Code Directory", "identifier": "0002-7559-01"}, {"resource": "GenBank", "identifier": "M11228"}, {"resource": "PharmGKB", "identifier": "PA131548935"}, {"resource": "UniProtKB", "identifier": "P04070"}, {"resource": "Wikipedia", "identifier": "Drotrecogin_alfa"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/drotrecogin.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/drotrecogin-alfa.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000016", "name": "Coagulation factor VIII", "organism": "Human", "actions": {"action": "multitarget"}, "references": "# Geng JP, Castellino FJ: Properties of a recombinant chimeric protein in which the gamma-carboxyglutamic acid and helical stack domains of human anticoagulant protein C are replaced by those of human coagulation factor VII. Thromb Haemost. 1997 May;77(5):926-33. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9184404\n# Colin G, Annane D: Corticosteroids and human recombinant activated protein C for septic shock. Clin Chest Med. 2008 Dec;29(4):705-12, x. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18954704\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P00451", "@source": "Swiss-Prot", "name": "Coagulation factor VIII", "general-function": "Involved in oxidoreductase activity", "specific-function": "Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa", "gene-name": "F8", "locus": "Xq28", "cellular-location": "Secreted protein; extracellular space", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.37", "molecular-weight": "267012.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3546"}, {"resource": "GenAtlas", "identifier": "F8"}, {"resource": "GeneCards", "identifier": "F8"}, {"resource": "GenBank Gene Database", "identifier": "M14113"}, {"resource": "GenBank Protein Database", "identifier": "182818"}, {"resource": "UniProtKB", "identifier": "P00451"}, {"resource": "UniProt Accession", "identifier": "FA8_HUMAN"}]}, "synonyms": {"synonym": ["AHF", "Antihemophilic factor", "Coagulation factor VIII precursor", "Procoagulant component"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Coagulation factor VIII precursor\nMQIELSTCFFLCLLRFCFSATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFN\nTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAV\nGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSH\nVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRD\nAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNH\nRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNE\nEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLA\nPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTL\nLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGP\nTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDE\nNRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILS\nIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRG\nMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNSRHPSTRQKQFNATTI\nPENDIEKTDPWFAHRTPMPKIQNVSSSDLLMLLRQSPTPHGLSLSDLQEAKYETFSDDPS\nPGAIDSNNSLSEMTHFRPQLHHSGDMVFTPESGLQLRLNEKLGTTAATELKKLDFKVSST\nSNNLISTIPSDNLAAGTDNTSSLGPPSMPVHYDSQLDTTLFGKKSSPLTESGGPLSLSEE\nNNDSKLLESGLMNSQESSWGKNVSSTESGRLFKGKRAHGPALLTKDNALFKVSISLLKTN\nKTSNNSATNRKTHIDGPSLLIENSPSVWQNILESDTEFKKVTPLIHDRMLMDKNATALRL\nNHMSNKTTSSKNMEMVQQKKEGPIPPDAQNPDMSFFKMLFLPESARWIQRTHGKNSLNSG\nQGPSPKQLVSLGPEKSVEGQNFLSEKNKVVVGKGEFTKDVGLKEMVFPSSRNLFLTNLDN\nLHENNTHNQEKKIQEEIEKKETLIQENVVLPQIHTVTGTKNFMKNLFLLSTRQNVEGSYD\nGAYAPVLQDFRSLNDSTNRTKKHTAHFSKKGEEENLEGLGNQTKQIVEKYACTTRISPNT\nSQQNFVTQRSKRALKQFRLPLEETELEKRIIVDDTSTQWSKNMKHLTPSTLTQIDYNEKE\nKGAITQSPLSDCLTRSHSIPQANRSPLPIAKVSSFPSIRPIYLTRVLFQDNSSHLPAASY\nRKKDSGVQESSHFLQGAKKNNLSLAILTLEMTGDQREVGSLGTSATNSVTYKKVENTVLP\nKPDLPKTSGKVELLPKVHIYQKDLFPTETSNGSPGHLDLVEGSLLQGTEGAIKWNEANRP\nGKVPFLRVATESSAKTPSKLLDPLAWDNHYGTQIPKEEWKSQEKSPEKTAFKKKDTILSL\nNACESNHAIAAINEGQNKPEIEVTWAKQGRTERLCSQNPPVLKRHQREITRTTLQSDQEE\nIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNR\nAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASR\nPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDV\nDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRA\nPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGH\nVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKC\nQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMII\nHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFN\nPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFA\nTWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFL\nISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRM\nEVLGCEAQDLY"}, "gene-sequence": {"@format": "FASTA", "#text": ">7056 bp\nATGCAAATAGAGCTCTCCACCTGCTTCTTTCTGTGCCTTTTGCGATTCTGCTTTAGTGCC\nACCAGAAGATACTACCTGGGTGCAGTGGAACTGTCATGGGACTATATGCAAAGTGATCTC\nGGTGAGCTGCCTGTGGACGCAAGATTTCCTCCTAGAGTGCCAAAATCTTTTCCATTCAAC\nACCTCAGTCGTGTACAAAAAGACTCTGTTTGTAGAATTCACGGATCACCTTTTCAACATC\nGCTAAGCCAAGGCCACCCTGGATGGGTCTGCTAGGTCCTACCATCCAGGCTGAGGTTTAT\nGATACAGTGGTCATTACACTTAAGAACATGGCTTCCCATCCTGTCAGTCTTCATGCTGTT\nGGTGTATCCTACTGGAAAGCTTCTGAGGGAGCTGAATATGATGATCAGACCAGTCAAAGG\nGAGAAAGAAGATGATAAAGTCTTCCCTGGTGGAAGCCATACATATGTCTGGCAGGTCCTG\nAAAGAGAATGGTCCAATGGCCTCTGACCCACTGTGCCTTACCTACTCATATCTTTCTCAT\nGTGGACCTGGTAAAAGACTTGAATTCAGGCCTCATTGGAGCCCTACTAGTATGTAGAGAA\nGGGAGTCTGGCCAAGGAAAAGACACAGACCTTGCACAAATTTATACTACTTTTTGCTGTA\nTTTGATGAAGGGAAAAGTTGGCACTCAGAAACAAAGAACTCCTTGATGCAGGATAGGGAT\nGCTGCATCTGCTCGGGCCTGGCCTAAAATGCACACAGTCAATGGTTATGTAAACAGGTCT\nCTGCCAGGTCTGATTGGATGCCACAGGAAATCAGTCTATTGGCATGTGATTGGAATGGGC\nACCACTCCTGAAGTGCACTCAATATTCCTCGAAGGTCACACATTTCTTGTGAGGAACCAT\nCGCCAGGCGTCCTTGGAAATCTCGCCAATAACTTTCCTTACTGCTCAAACACTCTTGATG\nGACCTTGGACAGTTTCTACTGTTTTGTCATATCTCTTCCCACCAACATGATGGCATGGAA\nGCTTATGTCAAAGTAGACAGCTGTCCAGAGGAACCCCAACTACGAATGAAAAATAATGAA\nGAAGCGGAAGACTATGATGATGATCTTACTGATTCTGAAATGGATGTGGTCAGGTTTGAT\nGATGACAACTCTCCTTCCTTTATCCAAATTCGCTCAGTTGCCAAGAAGCATCCTAAAACT\nTGGGTACATTACATTGCTGCTGAAGAGGAGGACTGGGACTATGCTCCCTTAGTCCTCGCC\nCCCGATGACAGAAGTTATAAAAGTCAATATTTGAACAATGGCCCTCAGCGGATTGGTAGG\nAAGTACAAAAAAGTCCGATTTATGGCATACACAGATGAAACCTTTAAGACTCGTGAAGCT\nATTCAGCATGAATCAGGAATCTTGGGACCTTTACTTTATGGGGAAGTTGGAGACACACTG\nTTGATTATATTTAAGAATCAAGCAAGCAGACCATATAACATCTACCCTCACGGAATCACT\nGATGTCCGTCCTTTGTATTCAAGGAGATTACCAAAAGGTGTAAAACATTTGAAGGATTTT\nCCAATTCTGCCAGGAGAAATATTCAAATATAAATGGACAGTGACTGTAGAAGATGGGCCA\nACTAAATCAGATCCTCGGTGCCTGACCCGCTATTACTCTAGTTTCGTTAATATGGAGAGA\nGATCTAGCTTCAGGACTCATTGGCCCTCTCCTCATCTGCTACAAAGAATCTGTAGATCAA\nAGAGGAAACCAGATAATGTCAGACAAGAGGAATGTCATCCTGTTTTCTGTATTTGATGAG\nAACCGAAGCTGGTACCTCACAGAGAATATACAACGCTTTCTCCCCAATCCAGCTGGAGTG\nCAGCTTGAGGATCCAGAGTTCCAAGCCTCCAACATCATGCACAGCATCAATGGCTATGTT\nTTTGATAGTTTGCAGTTGTCAGTTTGTTTGCATGAGGTGGCATACTGGTACATTCTAAGC\nATTGGAGCACAGACTGACTTCCTTTCTGTCTTCTTCTCTGGATATACCTTCAAACACAAA\nATGGTCTATGAAGACACACTCACCCTATTCCCATTCTCAGGAGAAACTGTCTTCATGTCG\nATGGAAAACCCAGGTCTATGGATTCTGGGGTGCCACAACTCAGACTTTCGGAACAGAGGC\nATGACCGCCTTACTGAAGGTTTCTAGTTGTGACAAGAACACTGGTGATTATTACGAGGAC\nAGTTATGAAGATATTTCAGCATACTTGCTGAGTAAAAACAATGCCATTGAACCAAGAAGC\nTTCTCCCAGAATTCAAGACACCCTAGCACTAGGCAAAAGCAATTTAATGCCACCACAATT\nCCAGAAAATGACATAGAGAAGACTGACCCTTGGTTTGCACACAGAACACCTATGCCTAAA\nATACAAAATGTCTCCTCTAGTGATTTGTTGATGCTCTTGCGACAGAGTCCTACTCCACAT\nGGGCTATCCTTATCTGATCTCCAAGAAGCCAAATATGAGACTTTTTCTGATGATCCATCA\nCCTGGAGCAATAGACAGTAATAACAGCCTGTCTGAAATGACACACTTCAGGCCACAGCTC\nCATCACAGTGGGGACATGGTATTTACCCCTGAGTCAGGCCTCCAATTAAGATTAAATGAG\nAAACTGGGGACAACTGCAGCAACAGAGTTGAAGAAACTTGATTTCAAAGTTTCTAGTACA\nTCAAATAATCTGATTTCAACAATTCCATCAGACAATTTGGCAGCAGGTACTGATAATACA\nAGTTCCTTAGGACCCCCAAGTATGCCAGTTCATTATGATAGTCAATTAGATACCACTCTA\nTTTGGCAAAAAGTCATCTCCCCTTACTGAGTCTGGTGGACCTCTGAGCTTGAGTGAAGAA\nAATAATGATTCAAAGTTGTTAGAATCAGGTTTAATGAATAGCCAAGAAAGTTCATGGGGA\nAAAAATGTATCGTCAACAGAGAGTGGTAGGTTATTTAAAGGGAAAAGAGCTCATGGACCT\nGCTTTGTTGACTAAAGATAATGCCTTATTCAAAGTTAGCATCTCTTTGTTAAAGACAAAC\nAAAACTTCCAATAATTCAGCAACTAATAGAAAGACTCACATTGATGGCCCATCATTATTA\nATTGAGAATAGTCCATCAGTCTGGCAAAATATATTAGAAAGTGACACTGAGTTTAAAAAA\nGTGACACCTTTGATTCATGACAGAATGCTTATGGACAAAAATGCTACAGCTTTGAGGCTA\nAATCATATGTCAAATAAAACTACTTCATCAAAAAACATGGAAATGGTCCAACAGAAAAAA\nGAGGGCCCCATTCCACCAGATGCACAAAATCCAGATATGTCGTTCTTTAAGATGCTATTC\nTTGCCAGAATCAGCAAGGTGGATACAAAGGACTCATGGAAAGAACTCTCTGAACTCTGGG\nCAAGGCCCCAGTCCAAAGCAATTAGTATCCTTAGGACCAGAAAAATCTGTGGAAGGTCAG\nAATTTCTTGTCTGAGAAAAACAAAGTGGTAGTAGGAAAGGGTGAATTTACAAAGGACGTA\nGGACTCAAAGAGATGGTTTTTCCAAGCAGCAGAAACCTATTTCTTACTAACTTGGATAAT\nTTACATGAAAATAATACACACAATCAAGAAAAAAAAATTCAGGAAGAAATAGAAAAGAAG\nGAAACATTAATCCAAGAGAATGTAGTTTTGCCTCAGATACATACAGTGACTGGCACTAAG\nAATTTCATGAAGAACCTTTTCTTACTGAGCACTAGGCAAAATGTAGAAGGTTCATATGAC\nGGGGCATATGCTCCAGTACTTCAAGATTTTAGGTCATTAAATGATTCAACAAATAGAACA\nAAGAAACACACAGCTCATTTCTCAAAAAAAGGGGAGGAAGAAAACTTGGAAGGCTTGGGA\nAATCAAACCAAGCAAATTGTAGAGAAATATGCATGCACCACAAGGATATCTCCTAATACA\nAGCCAGCAGAATTTTGTCACGCAACGTAGTAAGAGAGCTTTGAAACAATTCAGACTCCCA\nCTAGAAGAAACAGAACTTGAAAAAAGGATAATTGTGGATGACACCTCAACCCAGTGGTCC\nAAAAACATGAAACATTTGACCCCGAGCACCCTCACACAGATAGACTACAATGAGAAGGAG\nAAAGGGGCCATTACTCAGTCTCCCTTATCAGATTGCCTTACGAGGAGTCATAGCATCCCT\nCAAGCAAATAGATCTCCATTACCCATTGCAAAGGTATCATCATTTCCATCTATTAGACCT\nATATATCTGACCAGGGTCCTATTCCAAGACAACTCTTCTCATCTTCCAGCAGCATCTTAT\nAGAAAGAAAGATTCTGGGGTCCAAGAAAGCAGTCATTTCTTACAAGGAGCCAAAAAAAAT\nAACCTTTCTTTAGCCATTCTAACCTTGGAGATGACTGGTGATCAAAGAGAGGTTGGCTCC\nCTGGGGACAAGTGCCACAAATTCAGTCACATACAAGAAAGTTGAGAACACTGTTCTCCCG\nAAACCAGACTTGCCCAAAACATCTGGCAAAGTTGAATTGCTTCCAAAAGTTCACATTTAT\nCAGAAGGACCTATTCCCTACGGAAACTAGCAATGGGTCTCCTGGCCATCTGGATCTCGTG\nGAAGGGAGCCTTCTTCAGGGAACAGAGGGAGCGATTAAGTGGAATGAAGCAAACAGACCT\nGGAAAAGTTCCCTTTCTGAGAGTAGCAACAGAAAGCTCTGCAAAGACTCCCTCCAAGCTA\nTTGGATCCTCTTGCTTGGGATAACCACTATGGTACTCAGATACCAAAAGAAGAGTGGAAA\nTCCCAAGAGAAGTCACCAGAAAAAACAGCTTTTAAGAAAAAGGATACCATTTTGTCCCTG\nAACGCTTGTGAAAGCAATCATGCAATAGCAGCAATAAATGAGGGACAAAATAAGCCCGAA\nATAGAAGTCACCTGGGCAAAGCAAGGTAGGACTGAAAGGCTGTGCTCTCAAAACCCACCA\nGTCTTGAAACGCCATCAACGGGAAATAACTCGTACTACTCTTCAGTCAGATCAAGAGGAA\nATTGACTATGATGATACCATATCAGTTGAAATGAAGAAGGAAGATTTTGACATTTATGAT\nGAGGATGAAAATCAGAGCCCCCGCAGCTTTCAAAAGAAAACACGACACTATTTTATTGCT\nGCAGTGGAGAGGCTCTGGGATTATGGGATGAGTAGCTCCCCACATGTTCTAAGAAACAGG\nGCTCAGAGTGGCAGTGTCCCTCAGTTCAAGAAAGTTGTTTTCCAGGAATTTACTGATGGC\nTCCTTTACTCAGCCCTTATACCGTGGAGAACTAAATGAACATTTGGGACTCCTGGGGCCA\nTATATAAGAGCAGAAGTTGAAGATAATATCATGGTAACTTTCAGAAATCAGGCCTCTCGT\nCCCTATTCCTTCTATTCTAGCCTTATTTCTTATGAGGAAGATCAGAGGCAAGGAGCAGAA\nCCTAGAAAAAACTTTGTCAAGCCTAATGAAACCAAAACTTACTTTTGGAAAGTGCAACAT\nCATATGGCACCCACTAAAGATGAGTTTGACTGCAAAGCCTGGGCTTATTTCTCTGATGTT\nGACCTGGAAAAAGATGTGCACTCAGGCCTGATTGGACCCCTTCTGGTCTGCCACACTAAC\nACACTGAACCCTGCTCATGGGAGACAAGTGACAGTACAGGAATTTGCTCTGTTTTTCACC\nATCTTTGATGAGACCAAAAGCTGGTACTTCACTGAAAATATGGAAAGAAACTGCAGGGCT\nCCCTGCAATATCCAGATGGAAGATCCCACTTTTAAAGAGAATTATCGCTTCCATGCAATC\nAATGGCTACATAATGGATACACTACCTGGCTTAGTAATGGCTCAGGATCAAAGGATTCGA\nTGGTATCTGCTCAGCATGGGCAGCAATGAAAACATCCATTCTATTCATTTCAGTGGACAT\nGTGTTCACTGTACGAAAAAAAGAGGAGTATAAAATGGCACTGTACAATCTCTATCCAGGT\nGTTTTTGAGACAGTGGAAATGTTACCATCCAAAGCTGGAATTTGGCGGGTGGAATGCCTT\nATTGGCGAGCATCTACATGCTGGGATGAGCACACTTTTTCTGGTGTACAGCAATAAGTGT\nCAGACTCCCCTGGGAATGGCTTCTGGACACATTAGAGATTTTCAGATTACAGCTTCAGGA\nCAATATGGACAGTGGGCCCCAAAGCTGGCCAGACTTCATTATTCCGGATCAATCAATGCC\nTGGAGCACCAAGGAGCCCTTTTCTTGGATCAAGGTGGATCTGTTGGCACCAATGATTATT\nCACGGCATCAAGACCCAGGGTGCCCGTCAGAAGTTCTCCAGCCTCTACATCTCTCAGTTT\nATCATCATGTATAGTCTTGATGGGAAGAAGTGGCAGACTTATCGAGGAAATTCCACTGGA\nACCTTAATGGTCTTCTTTGGCAATGTGGATTCATCTGGGATAAAACACAATATTTTTAAC\nCCTCCAATTATTGCTCGATACATCCGTTTGCACCCAACTCATTATAGCATTCGCAGCACT\nCTTCGCATGGAGTTGATGGGCTGTGATTTAAATAGTTGCAGCATGCCATTGGGAATGGAG\nAGTAAAGCAATATCAGATGCACAGATTACTGCTTCATCCTACTTTACCAATATGTTTGCC\nACCTGGTCTCCTTCAAAAGCTCGACTTCACCTCCAAGGGAGGAGTAATGCCTGGAGACCT\nCAGGTGAATAATCCAAAAGAGTGGCTGCAAGTGGACTTCCAGAAGACAATGAAAGTCACA\nGGAGTAACTACTCAGGGAGTAAAATCTCTGCTTACCAGCATGTATGTGAAGGAGTTCCTC\nATCTCCAGCAGTCAAGATGGCCATCAGTGGACTCTCTTTTTTCAGAATGGCAAAGTAAAG\nGTTTTTCAGGGAAATCAAGACTCCTTCACACCTGTGGTGAACTCTCTAGACCCACCGTTA\nCTGACTCGCTACCTTCGAATTCACCCCCAGAGTTGGGTGCACCAGATTGCCCTGAGGATG\nGAGGTTCTGGGCTGCGAGGCACAGGACCTCTACTGA"}, "pfams": {"pfam": [{"identifier": "PF00394", "name": "Cu-oxidase"}, {"identifier": "PF07731", "name": "Cu-oxidase_2"}, {"identifier": "PF07732", "name": "Cu-oxidase_3"}, {"identifier": "PF00754", "name": "F5_F8_type_C"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "copper ion binding"}, {"category": "process", "description": "cell adhesion"}, {"category": "process", "description": "cellular process"}]}}}, {"id": "BE0000041", "name": "Coagulation factor V", "organism": "Human", "actions": {"action": "multitarget"}, "references": "# Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001 Mar 8;344(10):699-709. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11236773\n# Kanji S, Devlin JW, Piekos KA, Racine E: Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis. Pharmacotherapy. 2001 Nov;21(11):1389-402. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11714212\n# Lyseng-Williamson KA, Perry CM: Drotrecogin alfa (activated). Drugs. 2002;62(4):617-30; discussion 631-2. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11893230\n# Joyce DE, Grinnell BW: Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit Care Med. 2002 May;30(5 Suppl):S288-93. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12004250\n# Poe K: Drotrecogin alfa (activated) approved for treatment of severe sepsis. J Am Pharm Assoc (Wash). 2002 May-Jun;42(3):520-2. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12030642\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P12259", "@source": "Swiss-Prot", "name": "Coagulation factor V", "general-function": "Involved in copper ion binding", "specific-function": "Coagulation factor V is a cofactor that participates with factor Xa to activate prothrombin to thrombin", "gene-name": "F5", "locus": "1q23", "cellular-location": null, "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.95", "molecular-weight": "251673.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3542"}, {"resource": "GenAtlas", "identifier": "F5"}, {"resource": "GeneCards", "identifier": "F5"}, {"resource": "GenBank Gene Database", "identifier": "M16967"}, {"resource": "GenBank Protein Database", "identifier": "182412"}, {"resource": "UniProtKB", "identifier": "P12259"}, {"resource": "UniProt Accession", "identifier": "FA5_HUMAN"}]}, "synonyms": {"synonym": ["Activated protein C cofactor", "Coagulation factor V precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Coagulation factor V precursor\nMFPGCPRLWVLVVLGTSWVGWGSQGTEAAQLRQFYVAAQGISWSYRPEPTNSSLNLSVTS\nFKKIVYREYEPYFKKEKPQSTISGLLGPTLYAEVGDIIKVHFKNKADKPLSIHPQGIRYS\nKLSEGASYLDHTFPAEKMDDAVAPGREYTYEWSISEDSGPTHDDPPCLTHIYYSHENLIE\nDFNSGLIGPLLICKKGTLTEGGTQKTFDKQIVLLFAVFDESKSWSQSSSLMYTVNGYVNG\nTMPDITVCAHDHISWHLLGMSSGPELFSIHFNGQVLEQNHHKVSAITLVSATSTTANMTV\nGPEGKWIISSLTPKHLQAGMQAYIDIKNCPKKTRNLKKITREQRRHMKRWEYFIAAEEVI\nWDYAPVIPANMDKKYRSQHLDNFSNQIGKHYKKVMYTQYEDESFTKHTVNPNMKEDGILG\nPIIRAQVRDTLKIVFKNMASRPYSIYPHGVTFSPYEDEVNSSFTSGRNNTMIRAVQPGET\nYTYKWNILEFDEPTENDAQCLTRPYYSDVDIMRDIASGLIGLLLICKSRSLDRRGIQRAA\nDIEQQAVFAVFDENKSWYLEDNINKFCENPDEVKRDDPKFYESNIMSTINGYVPESITTL\nGFCFDDTVQWHFCSVGTQNEILTIHFTGHSFIYGKRHEDTLTLFPMRGESVTVTMDNVGT\nWMLTSMNSSPRSKKLRLKFRDVKCIPDDDEDSYEIFEPPESTVMATRKMHDRLEPEDEES\nDADYDYQNRLAAALGIRSFRNSSLNQEEEEFNLTALALENGTEFVSSNTDIIVGSNYSSP\nSNISKFTVNNLAEPQKAPSHQQATTAGSPLRHLIGKNSVLNSSTAEHSSPYSEDPIEDPL\nQPDVTGIRLLSLGAGEFKSQEHAKHKGPKVERDQAAKHRFSWMKLLAHKVGRHLSQDTGS\nPSGMRPWEDLPSQDTGSPSRMRPWKDPPSDLLLLKQSNSSKILVGRWHLASEKGSYEIIQ\nDTDEDTAVNNWLISPQNASRAWGESTPLANKPGKQSGHPKFPRVRHKSLQVRQDGGKSRL\nKKSQFLIKTRKKKKEKHTHHAPLSPRTFHPLRSEAYNTFSERRLKHSLVLHKSNETSLPT\nDLNQTLPSMDFGWIASLPDHNQNSSNDTGQASCPPGLYQTVPPEEHYQTFPIQDPDQMHS\nTSDPSHRSSSPELSEMLEYDRSHKSFPTDISQMSPSSEHEVWQTVISPDLSQVTLSPELS\nQTNLSPDLSHTTLSPELIQRNLSPALGQMPISPDLSHTTLSPDLSHTTLSLDLSQTNLSP\nELSQTNLSPALGQMPLSPDLSHTTLSLDFSQTNLSPELSHMTLSPELSQTNLSPALGQMP\nISPDLSHTTLSLDFSQTNLSPELSQTNLSPALGQMPLSPDPSHTTLSLDLSQTNLSPELS\nQTNLSPDLSEMPLFADLSQIPLTPDLDQMTLSPDLGETDLSPNFGQMSLSPDLSQVTLSP\nDISDTTLLPDLSQISPPPDLDQIFYPSESSQSLLLQEFNESFPYPDLGQMPSPSSPTLND\nTFLSKEFNPLVIVGLSKDGTDYIEIIPKEEVQSSEDDYAEIDYVPYDDPYKTDVRTNINS\nSRDPDNIAAWYLRSNNGNRRNYYIAAEEISWDYSEFVQRETDIEDSDDIPEDTTYKKVVF\nRKYLDSTFTKRDPRGEYEEHLGILGPIIRAEVDDVIQVRFKNLASRPYSLHAHGLSYEKS\nSEGKTYEDDSPEWFKEDNAVQPNSSYTYVWHATERSGPESPGSACRAWAYYSAVNPEKDI\nHSGLIGPLLICQKGILHKDSNMPVDMREFVLLFMTFDEKKSWYYEKKSRSSWRLTSSEMK\nKSHEFHAINGMIYSLPGLKMYEQEWVRLHLLNIGGSQDIHVVHFHGQTLLENGNKQHQLG\nVWPLLPGSFKTLEMKASKPGWWLLNTEVGENQRAGMQTPFLIMDRDCRMPMGLSTGIISD\nSQIKASEFLGYWEPRLARLNNGGSYNAWSVEKLAAEFASKPWIQVDMQKEVIITGIQTQG\nAKHYLKSCYTTEFYVAYSSNQINWQIFKGNSTRNVMYFNGNSDASTIKENQFDPPIVARY\nIRISPTRAYNRPTLRLELQGCEVNGCSTPLGMENGKIENKQITASSFKKSWWGDYWEPFR\nARLNAQGRVNAWQAKANNNKQWLEIDLLKIKKITAIITQGCKSLSSEMYVKSYTIHYSEQ\nGVEWKPYRLKSSMVDKIFEGNTNTKGHVKNFFNPPIISRFIRVIPKTWNQSIALRLELFG\nCDIY"}, "gene-sequence": {"@format": "FASTA", "#text": ">6675 bp\nATGTTCCCAGGCTGCCCACGCCTCTGGGTCCTGGTGGTCTTGGGCACCAGCTGGGTAGGC\nTGGGGGAGCCAAGGGACAGAAGCGGCACAGCTAAGGCAGTTCTACGTGGCTGCTCAGGGC\nATCAGTTGGAGCTACCGACCTGAGCCCACAAACTCAAGTTTGAATCTTTCTGTAACTTCC\nTTTAAGAAAATTGTCTACAGAGAGTATGAACCATATTTTAAGAAAGAAAAACCACAATCT\nACCATTTCAGGACTTCTTGGGCCTACTTTATATGCTGAAGTCGGAGACATCATAAAAGTT\nCACTTTAAAAATAAGGCAGATAAGCCCTTGAGCATCCATCCTCAAGGAATTAGGTACAGT\nAAATTATCAGAAGGTGCTTCTTACCTTGACCACACATTCCCTGCGGAGAAGATGGACGAC\nGCTGTGGCTCCAGGCCGAGAATACACCTATGAATGGAGTATCAGTGAGGACAGTGGACCC\nACCCATGATGACCCTCCATGCCTCACACACATCTATTACTCCCATGAAAATCTGATCGAG\nGATTTCAACTCGGGGCTGATTGGGCCCCTGCTTATCTGTAAAAAAGGGACCCTAACTGAG\nGGTGGGACACAGAAGACGTTTGACAAGCAAATCGTGCTACTATTTGCTGTGTTTGATGAA\nAGCAAGAGCTGGAGCCAGTCATCATCCCTAATGTACACAGTCAATGGATATGTGAATGGG\nACAATGCCAGATATAACAGTTTGTGCCCATGACCACATCAGCTGGCATCTGCTGGGAATG\nAGCTCGGGGCCAGAATTATTCTCCATTCATTTCAACGGCCAGGTCCTGGAGCAGAACCAT\nCATAAGGTCTCAGCCATCACCCTTGTCAGTGCTACATCCACTACCGCAAATATGACTGTG\nGGCCCAGAGGGAAAGTGGATCATATCTTCTCTCACCCCAAAACATTTGCAAGCTGGGATG\nCAGGCTTACATTGACATTAAAAACTGCCCAAAGAAAACCAGGAATCTTAAGAAAATAACT\nCGTGAGCAGAGGCGGCACATGAAGAGGTGGGAATACTTCATTGCTGCAGAGGAAGTCATT\nTGGGACTATGCACCTGTAATACCAGCGAATATGGACAAAAAATACAGGTCTCAGCATTTG\nGATAATTTCTCAAACCAAATTGGAAAACATTATAAGAAAGTTATGTACACACAGTACGAA\nGATGAGTCCTTCACCAAACATACAGTGAATCCCAATATGAAAGAAGATGGGATTTTGGGT\nCCTATTATCAGAGCCCAGGTCAGAGACACACTCAAAATCGTGTTCAAAAATATGGCCAGC\nCGCCCCTATAGCATTTACCCTCATGGAGTGACCTTCTCGCCTTATGAAGATGAAGTCAAC\nTCTTCTTTCACCTCAGGCAGGAACAACACCATGATCAGAGCAGTTCAACCAGGGGAAACC\nTATACTTATAAGTGGAACATCTTAGAGTTTGATGAACCCACAGAAAATGATGCCCAGTGC\nTTAACAAGACCATACTACAGTGACGTGGACATCATGAGAGACATCGCCTCTGGGCTAATA\nGGACTACTTCTAATCTGTAAGAGCAGATCCCTGGACAGGCGAGGAATACAGAGGGCAGCA\nGACATCGAACAGCAGGCTGTGTTTGCTGTGTTTGATGAGAACAAAAGCTGGTACCTTGAG\nGACAACATCAACAAGTTTTGTGAAAATCCTGATGAGGTGAAACGTGATGACCCCAAGTTT\nTATGAATCAAACATCATGAGCACTATCAATGGCTATGTGCCTGAGAGCATAACTACTCTT\nGGATTCTGCTTTGATGACACTGTCCAGTGGCACTTCTGTAGTGTGGGGACCCAGAATGAA\nATTTTGACCATCCACTTCACTGGGCACTCATTCATCTATGGAAAGAGGCATGAGGACACC\nTTGACCCTCTTCCCCATGCGTGGAGAATCTGTGACGGTCACAATGGATAATGTTGGAACT\nTGGATGTTAACTTCCATGAATTCTAGTCCAAGAAGCAAAAAGCTGAGGCTGAAATTCAGG\nGATGTTAAATGTATCCCAGATGATGATGAAGACTCATATGAGATTTTTGAACCTCCAGAA\nTCTACAGTCATGGCTACACGGAAAATGCATGATCGTTTAGAACCTGAAGATGAAGAGAGT\nGATGCTGACTATGATTACCAGAACAGACTGGCTGCAGCATTAGGAATTAGGTCATTCCGA\nAACTCATCATTGAACCAGGAAGAAGAAGAGTTCAATCTTACTGCCCTAGCTCTGGAGAAT\nGGCACTGAATTCGTTTCTTCGAACACAGATATAATTGTTGGTTCAAATTATTCTTCCCCA\nAGTAATATTAGTAAGTTCACTGTCAATAACCTTGCAGAACCTCAGAAAGCCCCTTCTCAC\nCAACAAGCCACCACAGCTGGTTCCCCACTGAGACACCTCATTGGCAAGAACTCAGTTCTC\nAATTCTTCCACAGCAGAGCATTCCAGCCCATATTCTGAAGACCCTATAGAGGATCCTCTA\nCAGCCAGATGTCACAGGGATACGTCTACTTTCACTTGGTGCTGGAGAATTCAGAAGTCAA\nGAACATGCTAAGCGTAAGGGACCCAAGGTAGAAAGAGATCAAGCAGCAAAGCACAGGTTC\nTCCTGGATGAAATTACTAGCACATAAAGTTGGGAGACACCTAAGCCAAGACACTGGTTCT\nCCTTCCGGAATGAGGCCCTGGGAGGACCTTCCTAGCCAAGACACTGGTTCTCCTTCCAGA\nATGAGGCCCTGGGAGGACCCTCCTAGTGATCTGTTACTCTTAAAACAAAGTAACTCATCT\nAAGATTTTGGTTGGGAGATGGCATTTGGCTTCTGAGAAAGGTAGCTATGAAATAATCCAA\nGATACTGATGAAGACACAGCTGTTAACAATTGGCTGATCAGCCCCCAGAATGCCTCACGT\nGCTTGGGGAGAAAGCACCCCTCTTGCCAACAAGCCTGGAAAGCAGAGTGGCCACCCAAAG\nTTTCCTAGAGTTAGACATAAATCTCTACAAGTAAGACAGGATGGAGGAAAGAGTAGACTG\nAAGAAAAGCCAGTTTCTCATTAAGACACGAAAAAAGAAAAAAGAGAAGCACACACACCAT\nGCTCCTTTATCTCCGAGGACCTTTCACCCTCTAAGAAGTGAAGCCTACAACACATTTTCA\nGAAAGAAGACTTAAGCATTCGTTGGTGCTTCATAAATCCAATGAAACATCTCTTCCCACA\nGACCTCAATCAGACATTGCCCTCTATGGATTTTGGCTGGATAGCCTCACTTCCTGACCAT\nAATCAGAATTCCTCAAATGACACTGGTCAGGCAAGCTGTCCTCCAGGTCTTTATCAGACA\nGTGCCCCCAGAGGAACACTATCAAACATTCCCCATTCAAGACCCTGATCAAATGCACTCT\nACTTCAGACCCCAGTCACAGATCCTCTTCTCCAGAGCTCAGTGAAATGCTTGAGTATGAC\nCGAAGTCACAAGTCCTTCCCCACAGATATAAGTCAAATGTCCCCTTCCTCAGAACATGAA\nGTCTGGCAGACAGTCATCTCTCCAGACCTCAGCCAGGTGACCCTCTCTCCAGAACTCAGC\nCAGACAAACCTCTCTCCAGACCTCAGCCACACGACTCTCTCTCCAGAACTCATTCAGAGA\nAACCTTTCCCCAGCCCTCGGTCAGATGCCCATTTCTCCAGACCTCAGCCATACAACCCTT\nTCTCCAGACCTCAGCCATACAACCCTTTCTTTAGACCTCAGCCAGACAAACCTCTCTCCA\nGAACTCAGTCAGACAAACCTTTCCCCAGCCCTCGGTCAGATGCCCCTTTCTCCAGACCTC\nAGCCATACAACCCTTTCTCTAGACTTCAGCCAGACAAACCTCTCTCCAGAACTCAGCCAT\nATGACTCTCTCTCCAGAACTCAGTCAGACAAACCTTTCCCCAGCCCTTGGTCAGATGCCC\nATTTCTCCAGACCTCAGCCATACAACCCTTTCTCTAGACTTCAGCCAGACAAACCTCTCT\nCCAGAACTCAGTCAAACAAACCTTTCCCCAGCCCTCGGTCAGATGCCCCTTTCTCCAGAC\nCCCAGCCATACAACCCTTTCTCTAGACCTCAGCCAGACAAACCTCTCTCCAGAACTCAGT\nCAGACAAACCTTTCCCCAGACCTCAGTGAGATGCCCCTCTTTGCAGATCTCAGTCAAATT\nCCCCTTACCCCAGACCTCGACCAGATGACACTTTCTCCAGACCTTGGTGAGACAGATCTT\nTCCCCAAACTTTGGTCAGATGTCCCTTTCCCCAGACCTCAGCCAGGTGACTCTCTCTCCA\nGACATCAGTGACACCACCCTTCTCCCGGATCTCAGCCAGATATCACCTCCTCCAGACCTT\nGATCAGATATTCTACCCTTCTGAATCTAGTCAGTCATTGCTTCTTCAAGAATTTAATGAG\nTCTTTTCCTTATCCAGACCTTGGTCAGATGCCATCTCCTTCATCTCCTACTCTCAATGAT\nACTTTTCTATCAAAGGAATTTAATCCACTGGTTATAGTGGGCCTCAGTAAAGATGGTACA\nGATTACATTGAGATCATTCCAAAGGAAGAGGTCCAGAGCAGTGAAGATGACTATGCTGAA\nATTGATTATGTGCCCTATGATGACCCCTACAAAACTGATGTTAGGACAAACATCAACTCC\nTCCAGAGATCCTGACAACATTGCAGCATGGTACCTCCGCAGCAACAATGGAAACAGAAGA\nAATTATTACATTGCTGCTGAAGAAATATCCTGGGATTATTCAGAATTTGTACAAAGGGAA\nACAGATATTGAAGACTCTGATGATATTCCAGAAGATACCACATATAAGAAAGTAGTTTTT\nCGAAAGTACCTCGACAGCACTTTTACCAAACGTGATCCTCGAGGGGAGTATGAAGAGCAT\nCTCGGAATTCTTGGTCCTATTATCAGAGCTGAAGTGGATGATGTTATCCAAGTTCGTTTT\nAAAAATTTAGCATCCAGACCGTATTCTCTACATGCCCATGGACTTTCCTATGAAAAATCA\nTCAGAGGGAAAGACTTATGAAGATGACTCTCCTGAATGGTTTAAGGAAGATAATGCTGTT\nCAGCCAAATAGCAGTTATACCTACGTATGGCATGCCACTGAGCGATCAGGGCCAGAAAGT\nCCTGGCTCTGCCTGTCGGGCTTGGGCCTACTACTCAGCTGTGAACCCAGAAAAAGATATT\nCACTCAGGCTTGATAGGTCCCCTCCTAATCTGCCAAAAAGGAATACTACATAAGGACAGC\nAACATGCCTGTGGACATGAGAGAATTTGTCTTACTATTTATGACCTTTGATGAAAAGAAG\nAGCTGGTACTATGAAAAGAAGTCCCGAAGTTCTTGGAGACTCACATCCTCAGAAATGAAA\nAAATCCCATGAGTTTCACGCCATTAATGGGATGATCTACAGCTTGCCTGGCCTGAAAATG\nTATGAGCAAGAGTGGGTGAGGTTACACCTGCTGAACATAGGCGGCTCCCAAGACATTCAC\nGTGGTTCACTTTCACGGCCAGACCTTGCTGGAAAATGGCAATAAACAGCACCAGTTAGGG\nGTCTGGCCCCTTCTGCCTGGTTCATTTAAAACTCTTGAAATGAAGGCATCAAAACCTGGC\nTGGTGGCTCCTAAACACAGAGGTTGGAGAAAACCAGAGAGCAGGGATGCAAACGCCATTT\nCTTATCATGGACAGAGACTGTAGGATGCCAATGGGACTAAGCACTGGTATCATATCTGAT\nTCACAGATCAAGGCTTCAGAGTTTCTGGGTTACTGGGAGCCCAGATTAGCAAGATTAAAC\nAATGGTGGATCTTATAATGCTTGGAGTGTAGAAAAACTTGCAGCAGAATTTGCCTCTAAA\nCCTTGGATCCAGGTGGACATGCAAAAGGAAGTCATAATCACAGGGATCCAGACCCAAGGT\nGCCAAACACTACCTGAAGTCCTGCTATACCACAGAGTTCTATGTAGCTTACAGTTCCAAC\nCAGATCAACTGGCAGATCTTCAAAGGGAACAGCACAAGGAATGTGATGTATTTTAATGGC\nAATTCAGATGCCTCTACAATAAAAGAGAATCAGTTTGACCCACCTATTGTGGCTAGATAT\nATTAGGATCTCTCCAACTCGAGCCTATAACAGACCTACCCTTCGATTGGAACTGCAAGGT\nTGTGAGGTAAATGGATGTTCCACACCCCTGGGTATGGAAAATGGAAAGATAGAAAACAAG\nCAAATCACAGCTTCTTCGTTTAAGAAATCTTGGTGGGGAGATTACTGGGAACCCTTCCGT\nGCCCGTCTGAATGCCCAGGGACGTGTGAATGCCTGGCAAGCCAAGGCAAACAACAATAAG\nCAGTGGCTAGAAATTGATCTACTCAAGATCAAGAAGATAACGGCAATTATAACACAGGGC\nTGCAAGTCTCTGTCCTCTGAAATGTATGTAAAGAGCTATACCATCCACTACAGTGAGCAG\nGGAGTGGAATGGAAACCATACAGGCTGAAATCCTCCATGGTGGACAAGATTTTTGAAGGA\nAATACTAATACCAAAGGACATGTGAAGAACTTTTTCAACCCCCCAATCATTTCCAGGTTT\nATCCGTGTCATTCCTAAAACATGGAATCAAAGTATTACACTTCGCCTGGAACTCTTTGGC\nTGTGATATTTACTAG"}, "pfams": {"pfam": [{"identifier": "PF07732", "name": "Cu-oxidase_3"}, {"identifier": "PF00754", "name": "F5_F8_type_C"}, {"identifier": "PF06049", "name": "LSPR"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "copper ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "transition metal ion binding"}, {"category": "process", "description": "cell adhesion"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "hemostasis"}, {"category": "process", "description": "blood coagulation"}, {"category": "process", "description": "cellular process"}]}}}, {"id": "BE0000240", "name": "Plasminogen activator inhibitor 1", "organism": "Human", "actions": null, "references": "# Carr ME: Diabetes mellitus: a hypercoagulable state. J Diabetes Complications. 2001 Jan-Feb;15(1):44-54. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11259926\n# Cerchiara E, Tirindelli MC, Giannetti B, Dicuonzo G, Avvisati G: [The numerous properties of the anticoagulant protein C] Clin Ter. 2007 Mar-Apr;158(2):181-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17566522\n# Idell S: Endothelium and disordered fibrin turnover in the injured lung: newly recognized pathways. Crit Care Med. 2002 May;30(5 Suppl):S274-80. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12004248\n# Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC, Spapen HD, Riess H, Basson B, Johnson G 3rd, Kinasewitz GT: Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost. 2003 Oct;90(4):642-53. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14515185", "known-action": "unknown", "polypeptide": {"@id": "P05121", "@source": "Swiss-Prot", "name": "Plasminogen activator inhibitor 1", "general-function": "Involved in serine-type endopeptidase inhibitor activity", "specific-function": "This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, and protein C. Its rapid interaction with TPA may function as a major control point in the regulation of fibrinolysis", "gene-name": "SERPINE1", "locus": "7q21.3-q22", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.22", "molecular-weight": "45061.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:8583"}, {"resource": "GenAtlas", "identifier": "SERPINE1"}, {"resource": "GeneCards", "identifier": "SERPINE1"}, {"resource": "GenBank Gene Database", "identifier": "X04429"}, {"resource": "GenBank Protein Database", "identifier": "35272"}, {"resource": "UniProtKB", "identifier": "P05121"}, {"resource": "UniProt Accession", "identifier": "PAI1_HUMAN"}]}, "synonyms": {"synonym": ["Endothelial plasminogen activator inhibitor", "PAI", "PAI-1", "Plasminogen activator inhibitor 1 precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Plasminogen activator inhibitor 1 precursor\nMQMSPALTCLVLGLALVFGEGSAVHHPPSYVAHLASDFGVRVFQQVAQASKDRNVVFSPY\nGVASVLAMLQLTTGGETQQQIQAAMGFKIDDKGMAPALRHLYKELMGPWNKDEISTTDAI\nFVQRDLKLVQGFMPHFFRLFRSTVKQVDFSEVERARFIINDWVKTHTKGMISNLLGKGAV\nDQLTRLVLVNALYFNGQWKTPFPDSSTHRRLFHKSDGSTVSVPMMAQTNKFNYTEFTTPD\nGHYYDILELPYHGDTLSMFIAAPYEKEVPLSALTNILSAQLISHWKGNMTRLPRLLVLPK\nFSLETEVDLRKPLENLGMTDMFRQFQADFTSLSDQEPLHVAQALQKVKIEVNESGTVASS\nSTAVIVSARMAPEEIIMDRPFLFVVRHNPTGTVLFMGQVMEP"}, "gene-sequence": {"@format": "FASTA", "#text": ">1209 bp\nATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAA\nGGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTG\nAGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTAT\nGGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAG\nATTCAAGCAGCTATGGGATTCAAGATTGATGACAAGGGCATGGCCCCCGCCCTCCGGCAT\nCTGTACAAGGAGCTCATGGGGCCATGGAACAAGGACGAGATCAGCACCACAGACGCGATC\nTTCGTCCAGCGGGATCTGAAGCTGGTCCAGGGCTTCATGCCCCACTTCTTCAGGCTGTTC\nCGGAGCACGGTCAAGCAAGTGGACTTTTCAGAGGTGGAGAGAGCCAGATTCATCATCAAT\nGACTGGGTGAAGACACACACAAAAGGTATGATCAGCAACTTGCTTGGGAAAGGAGCCGTG\nGACCAGCTGACACGGCTGGTGCTGGTGAATGCCCTCTACTTCAACGGCCAGTGGAAGACT\nCCCTTCCCCGACTCCAGCACCCACCGCCGCCTCTTCCACAAATCAGACGGCAGCACTGTC\nTCTGTGCCCATGATGGCTCAGACCAACAAGTTCAACTATACTGAGTTCACCACGCCCGAT\nGGCCATTACTACGACATCCTGGAACTGCCCTACCACGGGGACACCCTCAGCATGTTCATT\nGCTGCCCCTTATGAAAAAGAGGTGCCTCTCTCTGCCCTCACCAACATTCTGAGTGCCCAG\nCTCATCAGCCACTGGAAAGGCAACATGACCAGGCTGCCCCGCCTCCTGGTTCTGCCCAAG\nTTCTCCCTGGAGACTGAAGTCGACCTCAGGAAGCCCCTAGAGAACCTGGGAATGACCGAC\nATGTTCAGACAGTTTCAGGCTGACTTCACGAGTCTTTCAGACCAAGAGCCTCTCCACGTC\nGCGCAGGCGCTGCAGAAAGTGAAGATCGAGGTGAACGAGAGTGGCACGGTGGCCTCCTCA\nTCCACAGCTGTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCC\nTTCCTCTTTGTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCCAAGTGATG\nGAACCCTGA"}, "pfams": {"pfam": {"identifier": "PF00079", "name": "Serpin"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "protease inhibitor activity"}, {"category": "function", "description": "endopeptidase inhibitor activity"}, {"category": "function", "description": "serine-type endopeptidase inhibitor activity"}, {"category": "function", "description": "enzyme regulator activity"}, {"category": "function", "description": "enzyme inhibitor activity"}]}}}, {"id": "BE0001151", "name": "Thrombomodulin", "organism": "Human", "actions": null, "references": "# Gresele P, Agnelli G: Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11804648\n# Pineda AO, Chen ZW, Caccia S, Cantwell AM, Savvides SN, Waksman G, Mathews FS, Di Cera E: The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket. J Biol Chem. 2004 Sep 17;279(38):39824-8. Epub 2004 Jul 13. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15252033\n# McCachren SS, Diggs J, Weinberg JB, Dittman WA: Thrombomodulin expression by human blood monocytes and by human synovial tissue lining macrophages. Blood. 1991 Dec 15;78(12):3128-32. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1660324\n# Shirai T, Shiojiri S, Ito H, Yamamoto S, Kusumoto H, Deyashiki Y, Maruyama I, Suzuki K: Gene structure of human thrombomodulin, a cofactor for thrombin-catalyzed activation of protein C. J Biochem (Tokyo). 1988 Feb;103(2):281-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2836377\n# Boffa MC, Burke B, Haudenschild C: [Different localization of thrombomodulin] Ann Biol Clin (Paris). 1987;45(2):191-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/3039877", "known-action": "unknown", "polypeptide": {"@id": "P07204", "@source": "Swiss-Prot", "name": "Thrombomodulin", "general-function": "Involved in calcium ion binding", "specific-function": "Thrombomodulin is a specific endothelial cell receptor that forms a 1:1 stoichiometric complex with thrombin. This complex is responsible for the conversion of protein C to the activated protein C (protein Ca). Once evolved, protein Ca scissions the activated cofactors of the coagulation mechanism, factor Va and factor VIIIa, and thereby reduces the amount of thrombin generated", "gene-name": "THBD", "locus": "20p12-cen", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "516-539", "signal-regions": null, "theoretical-pi": "4.54", "molecular-weight": "60330.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:11784"}, {"resource": "GenAtlas", "identifier": "THBD"}, {"resource": "GeneCards", "identifier": "THBD"}, {"resource": "GenBank Gene Database", "identifier": "X05495"}, {"resource": "GenBank Protein Database", "identifier": "736251"}, {"resource": "UniProtKB", "identifier": "P07204"}, {"resource": "UniProt Accession", "identifier": "TRBM_HUMAN"}]}, "synonyms": {"synonym": ["CD141 antigen", "Fetomodulin", "Thrombomodulin precursor", "TM"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Thrombomodulin precursor\nMLGVLVLGALALAGLGFPAPAEPQPGGSQCVEHDCFALYPGPATFLNASQICDGLRGHLM\nTVRSSVAADVISLLLNGDGGVGRRRLWIGLQLPPGCGDPKRLGPLRGFQWVTGDNNTSYS\nRWARLDLNGAPLCGPLCVAVSAAEATVPSEPIWEEQQCEVKADGFLCEFHFPATCRPLAV\nEPGAAAAAVSITYGTPFAARGADFQALPVGSSAAVAPLGLQLMCTAPPGAVQGHWAREAP\nGAWDCSVENGGCEHACNAIPGAPRCQCPAGAALQADGRSCTASATQSCNDLCEHFCVPNP\nDQPGSYSCMCETGYRLAADQHRCEDVDDCILEPSPCPQRCVNTQGGFECHCYPNYDLVDG\nECVEPVDPCFRANCEYQCQPLNQTSYLCVCAEGFAPIPHEPHRCQMFCNQTACPADCDPN\nTQASCECPEGYILDDGFICTDIDECENGGFCSGVCHNLPGTFECICGPDSALARHIGTDC\nDSGKVDGGDSGSGEPPPSPTPGSTLTPPAVGLVHSGLLIGISIASLCLVVALLALLCHLR\nKKQGAARAKMEYKCAAPSKEVVLQHVRTERTPQRL"}, "gene-sequence": {"@format": "FASTA", "#text": ">1728 bp\nATGCTTGGGGTCCTGGTCCTTGGCGCGCTGGCCCTGGCCGGCCTGGGGTTCCCCGCACCC\nGCAGAGCCGCAGCCGGGTGGCAGCCAGTGCGTCGAGCACGACTGCTTCGCGCTCTACCCG\nGGCCCCGCGACCTTCCTCAATGCCAGTCAGATCTGCGACGGACTGCGGGGCCACCTAATG\nACAGTGCGCTCCTCGGTGGCTGCCGATGTCATTTCCTTGCTACTGAACGGCGACGGCGGC\nGTTGGCCGCCGGCGCCTCTGGATCGGCCTGCAGCTGCCACCCGGCTGCGGCGACCCCAAG\nCGCCTCGGGCCCCTGCGCGGCTTCCAGTGGGTTACGGGAGACAACAACACCAGCTATAGC\nAGGTGGGCACGGCTCGACCTCAATGGGGCTCCCCTCTGCGGCCCGTTGTGCGTCGCTGTC\nTCCGCTGCTGAGGCCACTGTGCCCAGCGAGCCGATCTGGGAGGAGCAGCAGTGCGAAGTG\nAAGGCCGATGGCTTCCTCTGCGAGTTCCACTTCCCAGCCACCTGCAGGCCACTGGCTGTG\nGAGCCCGGCGCCGCGGCTGCCGCCGTCTCGATCACCTACGGCACCCCGTTCGCGGCCCGC\nGGAGCGGACTTCCAGGCGCTGCCGGTGGGCAGCTCCGCCGCGGTGGCTCCCCTCGGCTTA\nCAGCTAATGTGCACCGCGCCGCCCGGAGCGGTCCAGGGGCACTGGGCCAGGGAGGCGCCG\nGGCGCTTGGGACTGCAGCGTGGAGAACGGCGGCTGCGAGCACGCGTGCAATGCGATCCCT\nGGGGCTCCCCGCTGCCAGTGCCCAGCCGGCGCCGCCCTGCAGGCAGACGGGCGCTCCTGC\nACCGCATCCGCGACGCAGTCCTGCAACGACCTCTGCGAGCACTTCTGCGTTCCCAACCCC\nGACCAGCCGGGCTCCTACTCGTGCATGTGCGAGACCGGCTACCGGCTGGCGGCCGACCAA\nCACCGGTGCGAGGACGTGGATGACTGCATACTGGAGCCCAGTCCGTGTCCGCAGCGCTGT\nGTCAACACACAGGGTGGCTTCGAGTGCCACTGCTACCCTAACTACGACCTGGTGGACGGC\nGAGTGTGTGGAGCCCGTGGACCCGTGCTTCAGAGCCAACTGCGAGTACCAGTGCCAGCCC\nCTGAACCAAACTAGCTACCTCTGCGTCTGCGCCGAGGGCTTCGCGCCCATTCCCCACGAG\nCCGCACAGGTGCCAGATGTTTTGCAACCAGACTGCCTGTCCAGCCGACTGCGACCCCAAC\nACCCAGGCTAGCTGTGAGTGCCCTGAAGGCTACATCCTGGACGACGGTTTCATCTGCACG\nGACATCGACGAGTGCGAAAACGGCGGCTTCTGCTCCGGGGTGTGCCACAACCTCCCCGGT\nACCTTCGAGTGCATCTGCGGGCCCGACTCGGCCCTTGTCCGCCACATTGGCACCGACTGT\nGACTCCGGCAAGGTGGACGGTGGCGACAGCGGCTCTGGCGAGCCCCCGCCCAGCCCGACG\nCCCGGCTCCACCTTGACTCCTCCGGCCGTGGGGCTCGTGCATTCGGGCTTGCTCATAGGC\nATCTCCATCGCGAGCCTGTGCCTGGTGGTGGCGCTTTTGGCGCTCCTCTGCCACCTGCGC\nAAGAAGCAGGGCGCCGCCAGGGCCAAGATGGAGTACAAGTGCGCGGCCCCTTCCAAGGAG\nGTAGTGCTGCAGCACGTGCGGACCGAGCGGACGCCGCAGAGACTCTGA"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF07645", "name": "EGF_CA"}, {"identifier": "PF00059", "name": "Lectin_C"}, {"identifier": "PF09064", "name": "Tme5_EGF_like"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "carbohydrate binding"}, {"category": "function", "description": "sugar binding"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "hemostasis"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "blood coagulation"}]}}}, {"id": "BE0000943", "name": "Vitamin K-dependent protein S", "organism": "Human", "actions": null, "references": "# Cvirn G, Gallistl S, Koestenberger M, Kutschera J, Leschnik B, Muntean W: Alpha 2-macroglobulin enhances prothrombin activation and thrombin potential by inhibiting the anticoagulant protein C/protein S system in cord and adult plasma. Thromb Res. 2002 Mar 1;105(5):433-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12062545\n# Hesselvik JF, Malm J, Dahlback B, Blomback M: Protein C, protein S and C4b-binding protein in severe infection and septic shock. Thromb Haemost. 1991 Feb 12;65(2):126-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1828915\n# Cosio FG, Harker C, Batard MA, Brandt JT, Griffin JH: Plasma concentrations of the natural anticoagulants protein C and protein S in patients with proteinuria. J Lab Clin Med. 1985 Aug;106(2):218-22. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/3160800", "known-action": "unknown", "polypeptide": {"@id": "P07225", "@source": "Swiss-Prot", "name": "Vitamin K-dependent protein S", "general-function": "Involved in calcium ion binding", "specific-function": "Anticoagulant plasma protein; it is a cofactor to activated protein C in the degradation of coagulation factors Va and VIIIa. It helps to prevent coagulation and stimulating fibrinolysis", "gene-name": "PROS1", "locus": "3q11.2", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.37", "molecular-weight": "75123.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9456"}, {"resource": "GenAtlas", "identifier": "PROS1"}, {"resource": "GeneCards", "identifier": "PROS1"}, {"resource": "GenBank Gene Database", "identifier": "M15036"}, {"resource": "GenBank Protein Database", "identifier": "190289"}, {"resource": "UniProtKB", "identifier": "P07225"}, {"resource": "UniProt Accession", "identifier": "PROS_HUMAN"}]}, "synonyms": {"synonym": "Vitamin K-dependent protein S precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Vitamin K-dependent protein S precursor\nMRVLGGRCGALLACLLLVLPVSEANFLSKQQASQVLVRKRRANSLLEETKQGNLERECIE\nELCNKEEAREVFENDPETDYFYPKYLVCLRSFQTGLFTAARQSTNAYPDLRSCVNAIPDQ\nCSPLPCNEDGYMSCKDGKASFTCTCKPGWQGEKCEFDINECKDPSNINGGCSQICDNTPG\nSYHCSCKNGFVMLSNKKDCKDVDECSLKPSICGTAVCKNIPGDFECECPEGYRYNLKSKS\nCEDIDECSENMCAQLCVNYPGGYTCYCDGKKGFKLAQDQKSCEVVSVCLPLNLDTKYELL\nYLAEQFAGVVLYLKFRLPEISRFSAEFDFRTYDSEGVILYAESIDHSAWLLIALRGGKIE\nVQLKNEHTSKITTGGDVINNGLWNMVSVEELEHSISIKIAKEAVMDINKPGPLFKPENGL\nLETKVYFAGFPRKVESELIKPINPRLDGCIRSWNLMKQGASGIKEIIQEKQNKHCLVTVE\nKGSYYPGSGIAQFHIDYNNVSSAEGWHVNVTLNIRPSTGTGVMLALVSGNNTVPFAVSLV\nDSTSEKSQDILLSVENTVIYRIQALSLCSDQQSHLEFRVNRNNLELSTPLKIETISHEDL\nQRQLAVLDKAMKAKVATYLGGLPDVPFSATPVNAFYNGCMEVNINGVQLDLDEAISKHND\nIRAHSCPSVWKKTKNS"}, "gene-sequence": {"@format": "FASTA", "#text": ">2031 bp\nATGAGGGTCCTGGGTGGGCGCTGCGGGGCGCCGCTGGCGTGTCTCCTCCTAGTGCTTCCC\nGTCTCAGAGGCAAACCTTCTGTCAAAGCAACAGGCTTCACAAGTCCTGGTTAGGAAGCGT\nCGTGCAAATTCTTTACTTGAAGAAACCAAACAGGGTAATCTTGAAAGAGAATGCATCGAA\nGAACTGTGCAATAAAGAAGAAGCCAGGGAGGTCTTTGAAAATGACCCGGAAACGGATTAT\nTTTTATCCAAAATACTTAGTTTGTCTTCGCTCTTTTCAAACTGGGTTATTCACTGCTGCA\nCGTCAGTCAACTAATGCTTATCCTGACCTAAGAAGCTGTGTCAATGCCATTCCAGACCAG\nTGTAGTCCTCTGCCATGCAATGAAGATGGATATATGAGCTGCAAAGATGGAAAAGCTTCT\nTTTACTTGCACTTGTAAACCAGGTTGGCAAGGAGAAAAGTGTGAATTTGACATAAATGAA\nTGCAAAGATCCCTCAAATATAAATGGAGGTTGCAGTCAAATTTGTGATAATACACCTGGA\nAGTTACCACTGTTCCTGTAAAAATGGTTTTGTTATGCTTTCAAATAAGAAAGATTGTAAA\nGATGTGGATGAATGCTCTTTGAAGCCAAGCATTTGTGGCACAGCTGTGTGCAAGAACATC\nCCAGGAGATTTTGAATGTGAATGCCCCGAAGGCTACAGATATAATCTCAAATCAAAGTCT\nTGTGAAGATATAGATGAATGCTCTGAGAACATGTGTGCTCAGCTTTGTGTCAATTACCCT\nGGAGGTTACACTTGCTATTGTGATGGGAAGAAAGGATTCAAACTTGCCCAAGATCAGAAG\nAGTTGTGAGGTTGTTTCAGTGTGCCTTCCCTTGAACCTTGACACAAAGTATGAATTACTT\nTACTTGGCGGAGCAGTTTGCAGGGGTTGTTTTATATTTAAAATTTCGTTTGCCAGAAATC\nAGCAGATTTTCAGCAGAATTTGATTTCCGGACATATGATTCAGAAGGCGTGATACTGTAC\nGCAGAATCTATCGATCACTCAGCGTGGCTCCTGATTGCACTTCGTGGTGGAAAGATTGAA\nGTTCAGCTTAAGAATGAACATACATCCAAAATCACAACTGGAGGTGATGTTATTAATAAT\nGGTCTATGGAATATGGTGTCTGTGGAAGAATTAGAACATAGTATTAGCATTAAAATAGCT\nAAAGAAGCTGTGATGGATATAAATAAACCTGGACCCCTTTTTAAGCCGGAAAATGGATTG\nCTGGAAACCAAAGTATACTTTGCAGGATTCCCTCGGAAAGTGGAAAGTGAACTCATTAAA\nCCGATTAACCCTCGTCTAGATGGATGTATACGAAGCTGGAATTTGATGAAGCAAGGAGCT\nTCTGGAATAAAGGAAATTATTCAAGAAAAACAAAATAAGCATTGCCTGGTTACTGTGGAG\nAAGGGCTCCTACTATCCTGGTTCTGGAATTGCTCAATTTCACATAGATTATAATAATGTA\nTCCAGTGCTGAGGGTTGGCATGTAAATGTGACCTTGAATATTCGTCCATCCACGGGCACT\nGGTGTTATGCTTGCCTTGGTTTCTGGTAACAACACAGTGCCCTTTGCTGTGTCCTTGGTG\nGACTCCACCTCTGAAAAATCACAGGATATTCTGTTATCTGTTGAAAATACTGTAATATAT\nCGGATACAGGCCCTAAGTCTATGTTCCGATCAACAATCTCATCTGGAATTTAGAGTCAAC\nAGAAACAATCTGGAGTTGTCGACACCACTTAAAATAGAAACCATCTCCCATGAAGACCTT\nCAAAGACAACTTGCCGTCTTGGACAAAGCAATGAAAGCAAAAGTGGCCACATACCTGGGT\nGGCCTTCCAGATGTTCCATTCAGTGCCACACCAGTGAATGCCTTTTATAATGGCTGCATG\nGAAGTGAATATTAATGGTGTACAGTTGGATCTGGATGAAGCCATTTCTAAACATAATGAT\nATTAGAGCTCACTCATGTCCATCAGTTTGGAAAAAGACAAAGAATTCTTAA"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF00594", "name": "Gla"}, {"identifier": "PF07645", "name": "EGF_CA"}, {"identifier": "PF00054", "name": "Laminin_G_1"}, {"identifier": "PF02210", "name": "Laminin_G_2"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}]}}}, {"id": "BE0001140", "name": "Ceruloplasmin", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P00450", "@source": "Swiss-Prot", "name": "Ceruloplasmin", "general-function": "Secondary metabolites biosynthesis, transport and catabolism", "specific-function": "Ceruloplasmin is a blue, copper-binding (6-7 atoms per molecule) glycoprotein. It has ferroxidase activity oxidizing iron(II) to iron(III) without releasing radical oxygen species. It is involved in iron transport across the cell membrane", "gene-name": "CP", "locus": "3q23-q25", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.5", "molecular-weight": "122206.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2295"}, {"resource": "GenAtlas", "identifier": "CP"}, {"resource": "GeneCards", "identifier": "CP"}, {"resource": "GenBank Gene Database", "identifier": "M13699"}, {"resource": "GenBank Protein Database", "identifier": "180256"}, {"resource": "UniProtKB", "identifier": "P00450"}, {"resource": "UniProt Accession", "identifier": "CERU_HUMAN"}]}, "synonyms": {"synonym": ["Ceruloplasmin precursor", "EC 1.16.3.1", "Ferroxidase"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Ceruloplasmin precursor\nMKILILGIFLFLCSTPAWAKEKHYYIGIIETTWDYASDHGEKKLISVDTEHSNIYLQNGP\nDRIGRLYKKALYLQYTDETFRTTIEKPVWLGFLGPIIKAETGDKVYVHLKNLASRPYTFH\nSHGITYYKEHEGAIYPDNTTDFQRADDKVYPGEQYTYMLLATEEQSPGEGDGNCVTRIYH\nSHIDAPKDIASGLIGPLIICKKDSLDKEKEKHIDREFVVMFSVVDENFSWYLEDNIKTYC\nSEPEKVDKDNEDFQESNRMYSVNGYTFGSLPGLSMCAEDRVKWYLFGMGNEVDVHAAFFH\nGQALTNKNYRIDTINLFPATLFDAYMVAQNPGEWMLSCQNLNHLKAGLQAFFQVQECNKS\nSSKDNIRGKHVRHYYIAAEEIIWNYAPSGIDIFTKENLTAPGSDSAVFFEQGTTRIGGSY\nKKLVYREYTDASFTNRKERGPEEEHLGILGPVIWAEVGDTIRVTFHNKGAYPLSIEPIGV\nRFNKNNEGTYYSPNYNPQSRSVPPSASHVAPTETFTYEWTVPKEVGPTNADPVCLAKMYY\nSAVDPTKDIFTGLIGPMKICKKGSLHANGRQKDVDKEFYLFPTVFDENESLLLEDNIRMF\nTTAPDQVDKEDEDFQESNKMHSMNGFMYGNQPGLTMCKGDSVVWYLFSAGNEADVHGIYF\nSGNTYLWRGERRDTANLFPQTSLTLHMWPDTEGTFNVECLTTDHYTGGMKQKYTVNQCRR\nQSEDSTFYLGERTYYIAAVEVEWDYSPQREWEKELHHLQEQNVSNAFLDKGEFYIGSKYK\nKVVYRQYTDSTFRVPVERKAEEEHLGILGPQLHADVGDKVKIIFKNMATRPYSIHAHGVQ\nTESSTVTPTLPGETLTYVWKIPERSGAGTEDSACIPWAYYSTVDQVKDLYSGLIGPLIVC\nRRPYLKVFNPRRKLEFALLFLVFDENESWYLDDNIKTYSDHPEKVNKDDEEFIESNKMHA\nINGRMFGNLQGLTMHVGDEVNWYLMGMGNEIDLHTVHFHGHSFQYKHRGVYSSDVFDIFP\nGTYQTLEMFPRTPGIWLLHCHVTDHIHAGMETTYTVLQNEDTKSG"}, "gene-sequence": {"@format": "FASTA", "#text": ">3198 bp\nATGAAGATTTTGATACTTGGTATTTTTCTGTTTTTATGTAGTACCCCAGCCTGGGCGAAA\nGAAAAGCATTATTACATTGGAATTATTGAAACGACTTGGGATTATGCCTCTGACCATGGG\nGAAAAGAAACTTATTTCTGTTGACACGGAACATTCCAATATCTATCTTCAAAATGGCCCA\nGATAGAATTGGGAGACTATATAAGAAGGCCCTTTATCTTCAGTACACAGATGAAACCTTT\nAGGACAACTATAGAAAAACCGGTCTGGCTTGGGTTTTTAGGCCCTATTATCAAAGCTGAA\nACTGGAGATAAAGTTTATGTACACTTAAAAAACCTTGCCTCTAGGCCCTACACCTTTCAT\nTCACATGGAATAACTTACTATAAGGAACATGAGGGGGCCATCTACCCTGATAACACCACA\nGATTTTCAAAGAGCAGATGACAAAGTATATCCAGGAGAGCAGTATACATACATGTTGCTT\nGCCACTGAAGAACAAAGTCCTGGGGAAGGAGATGGCAATTGTGTGACTAGGATTTACCAT\nTCCCACATTGATGCTCCAAAAGATATTGCCTCAGGACTCATCGGACCTTTAATAATCTGT\nAAAAAAGATTCTCTAGATAAAGAAAAAGAAAAACATATTGACCGAGAATTTGTGGTGATG\nTTTTCTGTGGTGGATGAAAATTTCAGCTGGTACCTAGAAGACAACATTAAAACCTACTGC\nTCAGAACCAGAGAAAGTTGACAAAGACAACGAAGACTTCCAGGAGAGTAACAGAATGTAT\nTCTGTGAATGGATACACTTTTGGAAGTCTCCCAGGACTCTCCATGTGTGCTGAAGACAGA\nGTAAAATGGTACCTTTTTGGTATGGGTAATGAAGTTGATGTGCACGCAGCTTTCTTTCAC\nGGGCAAGCACTGACTAACAAGAACTACCGTATTGACACAATCAACCTCTTTCCTGCTACC\nCTGTTTGATGCTTATATGGTGGCCCAGAACCCTGGAGAATGGATGCTCAGCTGTCAGAAT\nCTAAACCATCTGAAAGCCGGTTTGCAAGCCTTTTTCCAGGTCCAGGAGTGTAACAAGTCT\nTCATCAAAGGATAATATCCGTGGGAAGCATGTTAGACACTACTACATTGCCGCTGAGGAA\nATCATCTGGAACTATGCTCCCTCTGGTATAGACATCTTCACTAAAGAAAACTTAACAGCA\nCCTGGAAGTGACTCAGCGGTGTTTTTTGAACAAGGTACCACAAGAATTGGAGGCTCTTAT\nAAAAAGCTGGTTTATCGTGAGTACACAGATGCCTCCTTCACAAATCGAAAGGAGAGAGGC\nCCTGAAGAAGAGCATCTTGGCATCCTGGGTCCTGTCATTTGGGCAGAGGTGGGAGACACC\nATCAGAGTAACCTTCCATAACAAAGGAGCATATCCCCTCAGTATTGAGCCGATTGGGGTG\nAGATTCAATAAGAACAACGAGGGCACATACTATTCCCCAAATTACAACCCCCAGAGCAGA\nAGTGTGCCTCCTTCAGCCTCCCATGTGGCACCCACAGAAACATTCACCTATGAATGGACT\nGTCCCCAAAGAAGTAGGACCCACTAATGCAGATCCTGTGTGTCTAGCTAAGATGTATTAT\nTCTGCTGTGGATCCCACTAAAGATATATTCACTGGGCTTATTGGGCCAATGAAAATATGC\nAAGAAAGGAAGTTTACATGCAAATGGGAGACAGAAAGATGTAGACAAGGAATTCTATTTG\nTTTCCTACAGTATTTGATGAGAATGAGAGTTTACTCCTGGAAGATAATATTAGAATGTTT\nACAACTGCACCTGATCAGGTGGATAAGGAAGATGAAGACTTTCAGGAATCTAATAAAATG\nCACTCCATGAATGGATTCATGTATGGGAATCAGCCGGGTCTCACTATGTGCAAAGGAGAT\nTCGGTCGTGTGGTACTTATTCAGCGCCGGAAATGAGGCCGATGTACATGGAATATACTTT\nTCAGGAAACACATATCTGTGGAGAGGAGAACGGAGAGACACAGCAAACCTCTTCCCTCAA\nACAAGTCTTACGCTCCACATGTGGCCTGACACAGAGGGGACTTTTAATGTTGAATGCCTT\nACAACTGATCATTACACAGGCGGCATGAAGCAAAAATATACTGTGAACCAATGCAGGCGG\nCAGTCTGAGGATTCCACCTTCTACCTGGGAGAGAGGACATACTATATCGCAGCAGTGGAG\nGTGGAATGGGATTATTCCCCACAAAGGGAGTGGGAAAAGGAGCTGCATCATTTACAAGAG\nCAGAATGTTTCAAATGCATTTTTAGATAAGGGAGAGTTTTACATAGGCTCAAAGTACAAG\nAAAGTTGTGTATCGGCAGTATACTGATAGCACATTCCGTGTTCCAGTGGAGAGAAAAGCT\nGAAGAAGAACATCTGGGAATTCTAGGTCCACAACTTCATGCAGATGTTGGAGACAAAGTC\nAAAATTATCTTTAAAAACATGGCCACAAGGCCCTACTCAATACATGCCCATGGGGTACAA\nACAGAGAGTTCTACAGTTACTCCAACATTACCAGGTGAAACTCTCACTTACGTATGGAAA\nATCCCAGAAAGATCTGGAGCTGGAACAGAGGATTCTGCTTGTATTCCATGGGCTTATTAT\nTCAACTGTGGATCAAGTTAAGGACCTCTACAGTGGATTAATTGGCCCCCTGATTGTTTGT\nCGAAGACCTTACTTGAAAGTATTCAATCCCAGAAGGAAGCTGGAATTTGCCCTTCTGTTT\nCTAGTTTTTGATGAGAATGAATCTTGGTACTTAGATGACAACATCAAAACATACTCTGAT\nCACCCCGAGAAAGTAAACAAAGATGATGAGGAATTCATAGAAAGCAATAAAATGCATGCT\nATTAATGGAAGAATGTTTGGAAACCTACAAGGCCTCACAATGCACGTGGGAGATGAAGTC\nAACTGGTATCTGATGGGAATGGGCAATGAAATAGACTTACACACTGTACATTTTCACGGC\nCATAGCTTCCAATACAAGCACAGGGGAGTTTATAGTTCTGATGTCTTTGACATTTTCCCT\nGGAACATACCAAACCCTAGAAATGTTTCCAAGAACACCTGGAATTTGGTTACTCCACTGC\nCATGTGACCGACCACATTCATGCTGGAATGGAAACCACTTACACCGTTCTACAAAATGAA\nGACACCAAATCTGGCTGA"}, "pfams": {"pfam": [{"identifier": "PF00394", "name": "Cu-oxidase"}, {"identifier": "PF07731", "name": "Cu-oxidase_2"}, {"identifier": "PF07732", "name": "Cu-oxidase_3"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "copper ion binding"}]}}}, {"id": "BE0000048", "name": "Prothrombin", "organism": "Human", "actions": null, "references": "# Omar MN, Shouk TA, Khaleq MA: Activity of blood coagulation and fibrinolysis during and after hydroxyethyl starch (HES) colloidal volume replacement. Clin Biochem. 1999 Jun;32(4):269-74. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10463819\n# Cvirn G, Gallistl S, Koestenberger M, Kutschera J, Leschnik B, Muntean W: Alpha 2-macroglobulin enhances prothrombin activation and thrombin potential by inhibiting the anticoagulant protein C/protein S system in cord and adult plasma. Thromb Res. 2002 Mar 1;105(5):433-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12062545\n# Gruber A, Cantwell AM, Di Cera E, Hanson SR: The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo. J Biol Chem. 2002 Aug 2;277(31):27581-4. Epub 2002 Jun 17. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12070133\n# Conway EM, Van de Wouwer M, Pollefeyt S, Jurk K, Van Aken H, De Vriese A, Weitz JI, Weiler H, Hellings PW, Schaeffer P, Herbert JM, Collen D, Theilmeier G: The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med. 2002 Sep 2;196(5):565-77. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12208873\n# Levi M, De Jonge E, van der Poll T: Recombinant human activated protein C (Xigris). Int J Clin Pract. 2002 Sep;56(7):542-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12296618", "known-action": "unknown", "polypeptide": {"@id": "P00734", "@source": "Swiss-Prot", "name": "Prothrombin", "general-function": "Involved in blood clotting cascade", "specific-function": "Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C", "gene-name": "F2", "locus": "11p11-q12", "cellular-location": "Secreted protein; extracellular space", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.7", "molecular-weight": "70037.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3535"}, {"resource": "GenAtlas", "identifier": "F2"}, {"resource": "GeneCards", "identifier": "F2"}, {"resource": "GenBank Gene Database", "identifier": "M17262"}, {"resource": "GenBank Protein Database", "identifier": "339641"}, {"resource": "UniProtKB", "identifier": "P00734"}, {"resource": "UniProt Accession", "identifier": "THRB_HUMAN"}]}, "synonyms": {"synonym": ["Activated Factor II [IIa]", "Coagulation factor II", "EC 3.4.21.5", "Prothrombin precursor", "Thrombin"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Prothrombin precursor\nMAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC\nVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV\nNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE\nCSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA\nQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG\nDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI\nDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN\nDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP\nVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST\nRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY\nGFYTHVFRLKKWIQKVIDQFGE"}, "gene-sequence": {"@format": "FASTA", "#text": ">1869 bp\nATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC\nCTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG\nGTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTAGAGCGAGAGTGC\nGTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG\nGATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT\nGCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG\nAACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT\nGAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC\nGACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA\nTGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA\nGGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG\nTACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA\nCAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC\nTTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT\nGGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA\nGATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC\nCAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT\nCTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC\nGACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG\nCTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG\nGTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT\nGACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACAAGGTACGAGCGAAACATTGAAAAG\nATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC\nCGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT\nGTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG\nGTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC\nAGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC\nCGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA\nGGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC\nCGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT\nGGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT\nGGAGAGTAG"}, "pfams": {"pfam": [{"identifier": "PF00594", "name": "Gla"}, {"identifier": "PF00051", "name": "Kringle"}, {"identifier": "PF00089", "name": "Trypsin"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "thrombin activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "binding"}, {"category": "process", "description": "hemostasis"}, {"category": "process", "description": "blood coagulation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "physiological process"}]}}}, {"id": "BE0001129", "name": "Platelet factor 4", "organism": "Human", "actions": null, "references": "# Carr ME: Diabetes mellitus: a hypercoagulable state. J Diabetes Complications. 2001 Jan-Feb;15(1):44-54. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11259926", "known-action": "unknown", "polypeptide": {"@id": "P02776", "@source": "Swiss-Prot", "name": "Platelet factor 4", "general-function": "Involved in cytokine activity", "specific-function": "Platelet factor 4, non-covalently bound to a proteoglycan molecule, is released during platelet aggregation. PF4 neutralizes the anticoagulant effect of heparin because it binds more strongly to heparin than to the chondroitin-4-sulfate chains of the carrier molecule. Chemotactic for neutrophils and monocytes", "gene-name": "PF4", "locus": "4q12-q21", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.78", "molecular-weight": "10845.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:8861"}, {"resource": "GenAtlas", "identifier": "PF4"}, {"resource": "GeneCards", "identifier": "PF4"}, {"resource": "GenBank Gene Database", "identifier": "M25897"}, {"resource": "GenBank Protein Database", "identifier": "189851"}, {"resource": "UniProtKB", "identifier": "P02776"}, {"resource": "UniProt Accession", "identifier": "PLF4_HUMAN"}]}, "synonyms": {"synonym": ["CXCL4", "Iroplact", "Oncostatin A", "PF-4", "Platelet factor 4 precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Platelet factor 4 precursor\nMSSAAGFCASRPGLLFLGLLLLPLVVAFASAEAEEDGDLQCLCVKTTSQVRPRHITSLEV\nIKAGPHCPTAQLIATLKNGRKICLDLQAPLYKKIIKKLLES"}, "gene-sequence": {"@format": "FASTA", "#text": ">306 bp\nATGAGCTCCGCAGCCGGGTTCTGCGCCTCACGCCCCGGGCTGCTGTTCCTGGGGTTGCTG\nCTCCTGCCACTTGTGGTCGCCTTCGCCAGCGCTGAAGCTGAAGAAGATGGGGACCTGCAG\nTGCCTGTGTGTGAAGACCACCTCCCAGGTCCGTCCCAGGCACATCACCAGCCTGGAGGTG\nATCAAGGCCGGACCCCACTGCCCCACTGCCCAACTGATAGCCACGCTGAAGAATGGAAGG\nAAAATTTGCTTGGACCTGCAAGCCCCGCTGTACAAGAAAATAATTAAGAAACTTTTGGAG\nAGTTAG"}, "pfams": {"pfam": {"identifier": "PF00048", "name": "IL8"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "chemokine activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor binding"}, {"category": "function", "description": "cytokine activity"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "immune response"}]}}}, {"id": "BE0002112", "name": "Plasma serine protease inhibitor", "organism": "Human", "actions": null, "references": "# Shen L, Villoutreix BO, Dahlback B: Involvement of Lys 62(217) and Lys 63(218) of human anticoagulant protein C in heparin stimulation of inhibition by the protein C inhibitor. Thromb Haemost. 1999 Jul;82(1):72-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10456457\n# He X, Shen L, Bjartell A, Malm J, Lilja H, Dahlback B: The gene encoding vitamin K-dependent anticoagulant protein C is expressed in human male reproductive tissues. J Histochem Cytochem. 1995 Jun;43(6):563-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7769227\n# Kobayashi H, Gabazza EC, Taguchi O, Wada H, Takeya H, Nishioka J, Yasui H, Kobayashi T, Hataji O, Suzuki K, Adachi Y: Protein C anticoagulant system in patients with interstitial lung disease. Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1850-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9620917\n# Hayashi T, Suzuki K: [Molecular biology of protein C-thrombomodulin pathway. Structure and function, and basic studies on its clinical application] Nippon Rinsho. 1993 Jun;51(6):1610-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8391599\n# Berg DT, Gerlitz B, Shang J, Smith T, Santa P, Richardson MA, Kurz KD, Grinnell BW, Mace K, Jones BE: Engineering the proteolytic specificity of activated protein C improves its pharmacological properties. Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4423-8. Epub 2003 Apr 1. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12671072", "known-action": "unknown", "polypeptide": {"@id": "P05154", "@source": "Swiss-Prot", "name": "Plasma serine protease inhibitor", "general-function": null, "specific-function": "Inhibits activated protein C as well as plasminogen activators", "gene-name": "SERPINA5", "locus": "14q32.1", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.76", "molecular-weight": "45702.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:8723"}, {"resource": "GenAtlas", "identifier": "SERPINA5"}, {"resource": "GeneCards", "identifier": "SERPINA5"}, {"resource": "GenBank Gene Database", "identifier": "J02639"}, {"resource": "GenBank Protein Database", "identifier": "180550"}, {"resource": "UniProtKB", "identifier": "P05154"}, {"resource": "UniProt Accession", "identifier": "IPSP_HUMAN"}]}, "synonyms": {"synonym": ["Acrosomal serine protease inhibitor", "PAI-3", "PAI3", "PCI", "Plasma serine protease inhibitor precursor", "Plasminogen activator inhibitor 3", "Protein C inhibitor", "Serpin A5"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Plasma serine protease inhibitor\nMQLFLLLCLVLLSPQGASLHRHHPREMKKRVEDLHVGATVAPSSRRDFTFDLYRALASAA\nPSQNIFFSPVSISMSLAMLSLGAGSSTKMQILEGLGLNLQKSSEKELHRGFQQLLQELNQ\nPRDGFQLSLGNALFTDLVVDLQDTFVSAMKTLYLADTFPTNFRDSAGAMKQINDYVAKQT\nKGKIVDLLKNLDSNAVVIMVNYIFFKAKWETSFNHKGTQEQDFYVTSETVVRVPMMSRED\nQYHYLLDRNLSCRVVGVPYQGNATALFILPSEGKMQQVENGLSEKTLRKWLKMFKKRQLE\nLYLPKFSIEGSYQLEKVLPSLGISNVFTSHADLSGISNHSNIQVSEMVHKAVVEVDESGT\nRAAAATGTIFTFRSARLNSQRLVFNRPFLMFIVDNNILFLGKVNRP"}, "gene-sequence": {"@format": "FASTA", "#text": ">1221 bp\nATGCAGCTCTTCCTCCTCTTGTGCCTGGTGCTTCTCAGCCCTCAGGGGGCCTCCCTTCAC\nCGCCACCACCCCCGGGAGATGAAGAAGAGAGTCGAGGACCTCCATGTAGGTGCCACGGTG\nGCCCCCAGCAGCAGAAGGGACTTTACCTTTGACCTCTACAGGGCCTTGGCTTCCGCTGCC\nCCCAGCCAGAACATCTTCTTCTCCCCTGTGAGCATCTCCATGAGCCTGGCCATGCTCTCC\nCTGGGGGCTGGGTCCAGCACAAAGATGCAGATCCTGGAGGGCCTGGGCCTCAACCTCCAG\nAAAAGCTCAGAGAAGGAGCTGCACAGAGGCTTTCAGCAGCTCCTTCAGGAACTCAACCAG\nCCCAGAGATGGCTTCCAGCTGAGCCTCGGCAATGCCCTTTTCACCGACCTGGTGGTAGAC\nCTGCAGGACACCTTCGTAAGTGCCATGAAGACGCTGTACCTGGCAGACACTTTCCCCACC\nAACTTTAGGGACTCTGCAGGGGCCATGAAGCAGATCAATGATTATGTGGCAAAGCAAACG\nAAGGGCAAGATTGTGGACTTGCTTAAGAACCTCGATAGCAATGCGGTCGTGATCATGGTG\nAATTACATCTTCTTTAAAGCTAAGTGGGAGACAAGCTTCAACCACAAAGGCACCCAAGAG\nCAAGACTTCTACGTGACCTCGGAGACTGTGGTGCGGGTACCCATGATGAGCCGCGAGGAT\nCAGTATCACTACCTCCTGGACCGGAACCTCTCCTGCAGGGTGGTGGGGGTCCCCTACCAA\nGGCAATGCCACGGCTTTGTTCATTCTCCCCAGTGAGGGAAAGATGCAGCAGGTGGAGAAT\nGGACTGAGTGAGAAAACGCTGAGGAAGTGGCTTAAGATGTTCAAAAAGAGGCAGCTCGAG\nCTTTACCTTCCCAAATTCTCCATTGAGGGCTCCTATCAGCTGGAGAAAGTCCTCCCCAGT\nCTGGGGATCAGTAACGTCTTCACCTCCCATGCTGATCTGTCCCGCATCAGCAACCACTCA\nAATATCCAGGTGTCTGAGATGGTGCACAAAGCTGTGGTGGAGGTGGACGAGTCGGGAACC\nAGAGCAGCGGCAGCCACGGGGACAATCTTCACTTTCAGGTCGGCCCGCCTGAACTCTCAG\nAGGCTAGTGTTCAACAGGCCCTTTCTGATGTTCATTGTGGATAACAACATCCTCTTCCTT\nGGCAAAGTGAACCGCCCCTGA"}, "pfams": {"pfam": {"identifier": "PF00079", "name": "Serpin"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "enzyme regulator activity"}, {"category": "function", "description": "enzyme inhibitor activity"}, {"category": "function", "description": "protease inhibitor activity"}, {"category": "function", "description": "endopeptidase inhibitor activity"}, {"category": "function", "description": "serine-type endopeptidase inhibitor activity"}]}}}, {"id": "BE0002142", "name": "Serpin B6", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P35237", "@source": "Swiss-Prot", "name": "Serpin B6", "general-function": null, "specific-function": "Inhibits thrombin", "gene-name": "SERPINB6", "locus": "6p25", "cellular-location": "Cytoplasm", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "4.93", "molecular-weight": "42590.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:8950"}, {"resource": "GenAtlas", "identifier": "SERPINB6"}, {"resource": "GeneCards", "identifier": "SERPINB6"}, {"resource": "GenBank Gene Database", "identifier": "Z22658"}, {"resource": "GenBank Protein Database", "identifier": "297412"}, {"resource": "UniProtKB", "identifier": "P35237"}, {"resource": "UniProt Accession", "identifier": "SPB6_HUMAN"}]}, "synonyms": {"synonym": ["CAP", "Cytoplasmic antiproteinase", "PI-6", "Placental thrombin inhibitor", "Protease inhibitor 6"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Serpin B6\nMDVLAEANGTFALNLLKTLGKDNSKNVFFSPMSMSCALAMVYMGAKGNTAAQMAQILSFN\nKSGGGGDIHQGFQSLLTEVNKTGTQYLLRVANRLFGEKSCDFLSSFRDSCQKFYQAEMEE\nLDFISAVEKSRKHINTWVAEKTEGKIAELLSPGSVDPLTRLVLVNAVYFRGNWDEQFDKE\nNTEERLFKVSKNEEKPVQMMFKQSTFKKTYIGEIFTQILVLPYVGKELNMIIMLPDETTD\nLRTVEKELTYEKFVEWTRLDMMDEEEVEVSLPRFKLEESYDMESVLRNLGMTDAFELGKA\nDFSGMSQTDLSLSKVVHKSFVEVNEEGTEAAAATAAIMMMRCARFVPRFCADHPFLFFIQ\nHSKTNGILFCGRFSSP"}, "gene-sequence": {"@format": "FASTA", "#text": ">1131 bp\nATGGATGTTCTCGCAGAGGCAAATGGCACCTTTGCCTTAAACCTTTTGAAAACGCTGGGT\nAAAGACAACTCGAAGAATGTGTTTTTCTCACCCATGAGCATGTCCTGTGCCCTGGCCATG\nGTCTACATGGGGGCAAAGGGAAACACCGCTGCACAGATGGCCCAGATACTTTCTTTCAAT\nAAAAGTGGCGGTGGTGGAGACATCCACCAGGGCTTCCAGTCTCTTCTCACCGAAGTGAAC\nAAGACTGGCACGCAGTACTTGCTTAGGGTGGCCAACAGGCTCTTTGGGGAAAAGTCTTGT\nGATTTCCTCTCATCTTTTAGAGATTCCTGCCAAAAATTCTACCAAGCAGAGATGGAGGAG\nCTTGACTTTATCAGCGCCGTAGAGAAGTCCAGAAAACACATAAACACCTGGGTAGCTGAA\nAAGACAGAAGGTAAAATTGCGGAGTTGCTCTCTCCGGGCTCAGTGGATCCATTGACAAGG\nCTGGTTCTGGTGAATGCTGTCTATTTCAGAGGAAACTGGGATGGACAGTTTGACAAGGAG\nAACACCGAGGAGAGACTGTTTAAAGTCAGCAAGAATGAGGAGAAACCTGTGCAAATGATG\nTTTAAGCAATCTACTTTTAAGAAGACCTATATAGGAGAAATATTTACCCAAATCTTGGTG\nCTTCCATATGTTGGCAAGGAACTGAATATGATCATCATGCTTCCGGACGAGACCACTGAC\nTTGAGAACGGTGGAGAAAGAACTCACTTACGAGAAGTTCGTAGAATGGACGAGGCTGGAC\nATGATGGATGAAGAGGAGGTGGAAGTGTCCCTCCCGCGGTTTAAACTAGAGGAAAGCTAC\nGACATGGAGAGTGTCCTGCGCAACCTGGGCATGACTGATGCCTTCGAGCTGGGCAAGGCA\nGACTTCTCTGGAATGTCCCAGACAGACCTGTCTCTGTCCAAGGTCGTGCACAAGTCTTTT\nGTGGAGGTCAATGAGGAAGGCACGGAGGCTGCAGCCGCCACAGCTGCCATCATGATGATG\nCGGTGTGCCAGATTCGTCCCCCGCTTCTGCGCCGACCACCCCTTCCTTTTCTTCATCCAG\nCACAGAAAGACCAACGGGATTCTCTTCTGCGGCCGCTTTTCCTCTCCGTGA"}, "pfams": {"pfam": {"identifier": "PF00079", "name": "Serpin"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "enzyme regulator activity"}, {"category": "function", "description": "enzyme inhibitor activity"}, {"category": "function", "description": "protease inhibitor activity"}, {"category": "function", "description": "endopeptidase inhibitor activity"}, {"category": "function", "description": "serine-type endopeptidase inhibitor activity"}]}}}, {"id": "BE0000403", "name": "Vitamin K-dependent gamma-carboxylase", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P38435", "@source": "Swiss-Prot", "name": "Vitamin K-dependent gamma-carboxylase", "general-function": "Involved in gamma-glutamyl carboxylase activity", "specific-function": "Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium binding gamma-carboxyglutamate (Gla) residues with the concomitant convertion of the reduced hydroquinone form of vitamin K to vitamin K epoxide", "gene-name": "GGCX", "locus": "2p12", "cellular-location": "Endoplasmic reticulum; endoplasmic reticulum membrane; multi-pass membrane protein", "transmembrane-regions": "61-81\n114-134\n137-157\n293-313\n362-382", "signal-regions": null, "theoretical-pi": "8.1", "molecular-weight": "87562.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:4247"}, {"resource": "GenAtlas", "identifier": "GGCX"}, {"resource": "GeneCards", "identifier": "GGCX"}, {"resource": "GenBank Gene Database", "identifier": "M81592"}, {"resource": "GenBank Protein Database", "identifier": "184028"}, {"resource": "UniProtKB", "identifier": "P38435"}, {"resource": "UniProt Accession", "identifier": "VKGC_HUMAN"}]}, "synonyms": {"synonym": ["EC 6.4.-.-", "Gamma-glutamyl carboxylase", "Vitamin K gamma glutamyl carboxylase"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Vitamin K-dependent gamma-carboxylase\nMAVSAGSARTSPSSDKVQKDKAELISGPRQDSRIGKLLGFEWTDLSSWRRLVTLLNRPTD\nPASLAVFRFLFGFLMVLDIPQERGLSSLDRKYLDGLDVCRFPLLDALRPLPLDWMYLVYT\nIMFLGALGMMLGLCYRISCVLFLLPYWYVFLLDKTSWNNHSYLYGLLAFQLTFMDANHYW\nSVDGLLNAHRRNAHVPLWNYAVLRGQIFIVYFIAGVKKLDADWVEGYSMEYLSRHWLFSP\nFKLLLSEELTSLLVVHWGGLLLDLSAGFLLFFDVSRSIGLFFVSYFHCMNSQLFSIGMFS\nYVMLASSPLFCSPEWPRKLVSYCPRRLQQLLPLKAAPQPSVSCVYKRSRGKSGQKPGLRH\nQLGAAFTLLYLLEQLFLPYSHFLTQGYNNWTNGLYGYSWDMMVHSRSHQHVKITYRDGRT\nGELGYLNPGVFTQSRRWKDHADMLKQYATCLSRLLPKYNVTEPQIYFDIWVSINDRFQQR\nIFDPRVDIVQAAWSPFQRTSWVQPLLMDLSPWRAKLQEIKSSLDNHTEVVFIADFPGLHL\nENFVSEDLGNTSIQLLQGEVTVELVAEQKNQTLREGEKMQLPAGEYHKVYTTSPSPSCYM\nYVYVNTTELALEQDLAYLQELKEKVENGSETGPLPPELQPLLEGEVKGGPEPTPLVQTFL\nRRQQRLQEIERRRNTPFHERFFRFLLRKLYVFRRSFLMTCISLRNLILGRPSLEQLAQEV\nTYANLRPFEAVGELNPSNTDSSHSNPPESNPDPVHSEF"}, "gene-sequence": {"@format": "FASTA", "#text": ">2277 bp\nATGGCGGTGTCTGCCGGGTCCGCGCGGACCTCGCCCAGCTCAGATAAAGTACAGAAAGAC\nAAGGCTGAACTGATCTCAGGGCCCAGGCAGGACAGCCGAATAGGGAAACTCTTGGGTTTT\nGAGTGGACAGATTTGTCCAGTTGGCGGAGGCTGGTGACCCTGCTGAATCGACCAACGGAC\nCCTGCAAGCTTAGCTGTCTTTCGTTTTCTTTTTGGGTTCTTGATGGTGCTAGACATTCCC\nCAGGAGCGGGGGCTCAGCTCTCTGGACCGGAAATACCTTGATGGGCTGGATGTGTGCCGC\nTTCCCCTTGCTGGATGCCCTACGCCCACTGCCACTTGACTGGATGTATCTTGTCTACACC\nATCATGTTTCTGGGGGCACTGGGCATGATGCTGGGCCTGTGCTACCGGATAAGCTGTGTG\nTTATTCCTGCTGCCATACTGGTATGTGTTTCTCCTGGACAAGACATCATGGAACAACCAC\nTCCTATCTGTATGGGTTGTTGGCCTTTCAGCTAACATTCATGGATGCAAACCACTACTGG\nTCTGTGGACGGTCTGCTGAATGCCCATAGGAGGAATGCCCACGTGCCCCTTTGGAACTAT\nGCAGTGCTCCGTGGCCAGATCTTCATTGTGTACTTCATTGCGGGTGTGAAAAAGCTGGAT\nGCAGACTGGGTTGAAGGCTATTCCATGGAATATTTGTCCCGGCACTGGCTCTTCAGTCCC\nTTCAAACTGCTGTTGTCTGAGGAGCTGACTAGCCTGCTGGTCGTGCACTGGGGTGGGCTG\nCTGCTTGACCTCTCAGCTGGTTTCCTGCTCTTTTTTGATGTCTCAAGATCCATTGGCCTG\nTTCTTTGTGTCCTACTTCCACTGCATGAATTCCCAGCTTTTCAGCATTGGTATGTTCTCC\nTACGTCATGCTGGCCAGCAGCCCTCTCTTCTGCTCCCCTGAGTGGCCTCGGAAGCTGGTG\nTCCTACTGCCCCCAAAGGTTGCAACAACTGTTGCCCCTCAAGGCAGCCCCTCAGCCCAGT\nGTTTCCTGTGTGTATAAGAGGAGCCGGGGCAAAAGTGGCCAGAAGCCAGGGCTGCGCCAT\nCAGCTGGGAGCTGCCTTCACCCTGCTCTACCTCCTGGAGCAGCTATTCCTGCCCTATTCT\nCATTTTCTCACCCAGGGCTATAACAACTGGACAAATGGGCTGTATGGCTATTCCTGGGAC\nATGATGGTGCACTCCCGTTCCCACCAGCACGTGAAGATCACCTACCGTGATGGCCGCACT\nGGCGAACTGGGCTACCTTAACCCTGGGGTATTTACACAGAGTCGGCGATGGAAGGATCAT\nGCAGACATGCTGAAGCAATATGCCACTTGCCTGAGCCGCCTGCTTCCCAAGTATAATGTC\nACTGAGCCCCAGATCTACTTTGATATTTGGGTCTCCATCAATGACCGCTTCCAGCAGAGG\nATTTTTGACCCTCGTGTGGACATCGTGCAGGCCGCTTGGTCACCCTTTCAGCGCACATCC\nTGGGTGCAACCACTCTTGATGGACCTGTCTCCCTGGAGGGCCAAGTTACAGGAAATCAAG\nAGCAGCCTAGACAACCACACTGAGGTGGTCTTCATTGCAGATTTCCCTGGACTGCACTTG\nGAGAATTTTGTGAGTGAAGACCTGGGCAACACTAGCATCCAGCTGCTGCAGGGGGAAGTG\nACTGTGGAGCTTGTGGCAGAACAGAAGAACCAGACTCTTCGAGAGGGAGAAAAAATGCAG\nTTGCCTGCTGGTGAGTACCATAAGGTGTATACGACATCACCTAGCCCTTCTTGCTACATG\nTACGTCTATGTCAACACTACAGAGCTTGCACTGGAGCAAGACCTGGCATATCTGCAAGAA\nTTAAAGGAAAAGGTGGAGAATGGAAGTGAAACAGGGCCTCTACCCCCAGAGCTGCAGCCT\nCTGTTGGAAGGGGAAGTAAAAGGGGGCCCTGAGCCAACACCTCTGGTTCAGACCTTTCTT\nAGACGCCAACAAAGGCTCCAGGAGATTGAACGCCGGCGAAATACTCCTTTCCATGAGCGA\nTTCTTCCGCTTCTTGTTGCGAAAGCTCTATGTCTTTCGCCGCAGCTTCCTGATGACTTGT\nATCTCACTTCGAAATCTGATATTAGGCCGTCCTTCCCTGGAGCAGCTGGCCCAGGAGGTG\nACTTATGCAAACTTGAGACCCTTTGAGGCAGTTGGAGAACTGAATCCCTCAAACACGGAT\nTCTTCACATTCTAATCCTCCTGAGTCAAATCCTGATCCTGTCCACTCAGAGTTCTGA"}, "pfams": {"pfam": {"identifier": "PF05090", "name": "VKG_Carbox"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "gamma-glutamyl carboxylase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "lyase activity"}, {"category": "function", "description": "carbon-carbon lyase activity"}, {"category": "function", "description": "carboxy-lyase activity"}, {"category": "process", "description": "biopolymer modification"}, {"category": "process", "description": "protein modification"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "peptidyl-amino acid modification"}, {"category": "process", "description": "peptidyl-glutamic acid modification"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "peptidyl-glutamic acid carboxylation"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "biopolymer metabolism"}]}}}, {"id": "BE0001161", "name": "Endothelial protein C receptor", "organism": "Human", "actions": null, "references": "# Fukudome K, Ye X, Tsuneyoshi N, Tokunaga O, Sugawara K, Mizokami H, Kimoto M: Activation mechanism of anticoagulant protein C in large blood vessels involving the endothelial cell protein C receptor. J Exp Med. 1998 Apr 6;187(7):1029-35. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9529319\n# Ruf W, Dorfleutner A, Riewald M: Specificity of coagulation factor signaling. J Thromb Haemost. 2003 Jul;1(7):1495-503. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12871285\n# Castellino FJ, Liang Z, Volkir SP, Haalboom E, Martin JA, Sandoval-Cooper MJ, Rosen ED: Mice with a severe deficiency of the endothelial protein C receptor gene develop, survive, and reproduce normally, and do not present with enhanced arterial thrombosis after challenge. Thromb Haemost. 2002 Sep;88(3):462-72. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12353077\n# Cerchiara E, Tirindelli MC, Giannetti B, Dicuonzo G, Avvisati G: [The numerous properties of the anticoagulant protein C] Clin Ter. 2007 Mar-Apr;158(2):181-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17566522\n# Liaw PC: Endogenous protein C activation in patients with severe sepsis. Crit Care Med. 2004 May;32(5 Suppl):S214-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15118520", "known-action": "unknown", "polypeptide": {"@id": "Q9UNN8", "@source": "Swiss-Prot", "name": "Endothelial protein C receptor", "general-function": "Involved in protein C biniding activity and blood coagulation", "specific-function": "Binds activated protein C. Enhances protein C activation by the thrombin-thrombomodulin complex; plays a role in the protein C pathway controlling blood coagulation", "gene-name": "PROCR", "locus": "20q11.2", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "211-231", "signal-regions": null, "theoretical-pi": "7.2", "molecular-weight": "26672.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9452"}, {"resource": "GenAtlas", "identifier": "PROCR"}, {"resource": "GeneCards", "identifier": "PROCR"}, {"resource": "GenBank Gene Database", "identifier": "L35545"}, {"resource": "GenBank Protein Database", "identifier": "565268"}, {"resource": "UniProtKB", "identifier": "Q9UNN8"}, {"resource": "UniProt Accession", "identifier": "EPCR_HUMAN"}]}, "synonyms": {"synonym": ["Activated protein C receptor", "APC receptor", "CD201 antigen", "Endothelial cell protein C receptor", "Endothelial protein C receptor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Endothelial protein C receptor precursor\nMLTTLLPILLLSGWAFCSQDASDGLQRLHMLQISYFRDPYHVWYQGNASLGGHLTHVLEG\nPDTNTTIIQLQPLQEPESWARTQSGLQSYLLQFHGLVRLVHQERTLAFPLTIRCFLGCEL\nPPEGSRAHVFFEVAVNGSSFVSFRPERALWQADTQVTSGVVTFTLQQLNAYNRTRYELRE\nFLEDTCVQYVQKHISAENTKGSQTSRSYTSLVLGVLVGSFIIAGVAVGIFLCTGGRRC"}, "gene-sequence": {"@format": "FASTA", "#text": ">717 bp\nATGTTGACAACATTGCTGCCGATACTGCTGCTGTCTGGCTGGGCCTTTTGTAGCCAAGAC\nGCCTCAGATGGCCTCCAAAGACTTCATATGCTCCAGATCTCCTACTTCCGCGACCCCTAT\nCACGTGTGGTACCAGGGCAACGCGTCGCTGGGGGGACACCTAACGCACGTGCTGGAAGGC\nCCAGACACCAACACCACGATCATTCAGCTGCAGCCCTTGCAGGAGCCCGAGAGCTGGGCG\nCGCACGCAGAGTGGCCTGCAGTCCTACCTGCTCCAGTTCCACGGCCTCGTGCGCCTGGTG\nCACCAGGAGCGGACCTTGGCCTTTCCTCTGACCATCCGCTGCTTCCTGGGCTGTGAGCTG\nCCTCCCGAGGGCTCTAGAGCCCATGTCTTCTTCGAAGTGGCTGTGAATGGGAGCTCCTTT\nGTGAGTTTCCGGCCGGAGAGAGCCTTGTGGCAGGCAGACACCCAGGTCACCTCCGGAGTG\nGTCACCTTCACCCTGCAGCAGCTCAATGCCTACAACCGCACTCGGTATGAACTGCGGGAA\nTTCCTGGAGGACACCTGTGTGCAGTATGTGCAGAAACATATTTCCGCGGAAAACACGAAA\nGGGAGCCAAACAAGCCGCTCCTACACTTCGCTGGTCCTGGGCGTCCTGGTGGGCGGTTTC\nATCATTGCTGGTGTGGCTGTAGGCATCTTCCTGTGCACAGGTGGACGGCGATGTTAA"}, "pfams": null, "go-classifiers": null}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-01-29", "drugbank-id": [{"@primary": "true", "#text": "DB00056"}, "BIOD00077", "BTD00077"], "name": "Gemtuzumab ozogamicin", "description": "Recombinant humanized IgG4, kappa antibody conjugated with a cytotoxic antitumor antibiotic, calicheamicin, isolated from fermentation of a bacterium, Micromonospora echinospora ssp. calichensis. The antibody portion of Mylotarg binds specifically to the CD33 antigen, The anti-CD33 hP67.6 antibody is produced by mammalian cell suspension culture using a myeloma NS0 cell line. Gemtuzumab ozogamicin (trade name Mylotarg) was withdrawn in 2010 when a clinical trial showed the drug increased patient death and exhibited no advantages over traditional cancer therapies.", "cas-number": "220578-59-6", "groups": {"group": ["approved", "investigational", "withdrawn"]}, "general-references": "# Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R: Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001 Jun;7(6):1490-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11410481\n# Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH: Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001 Jul 15;92(2):406-13. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11466696\n# Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Alyea EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ: Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003 Sep 1;102(5):1578-82. Epub 2003 May 8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12738663", "synthesis-reference": null, "indication": "For treatment of CD33-positive acute myeloid leukemia in patients 60 and over who are not candidates for other chemotherapy.", "pharmacodynamics": "Used for the treatment of acute myeloid leukemia (AML), mylotarg binds to the CD33 antigen, which is expressed on the surface of leukemic cells in more than 80% of patients with AML. The CD33 antigen is not expressed on pluripotent hematopoietic stem cells or nonhematopoietic cells. This gives mylotarg the selectivity needed to target leukemic cells.", "mechanism-of-action": "Mylotarg is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin derivative binds to DNA in the minor groove resulting in DNA double strand breaks and cell death.", "toxicity": "The most frequently reported toxicities are myelosuppression and hepatic veno-occlusive disorder.", "metabolism": "Most likely removed by opsonization via the reticuloendothelial system.", "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": null, "international-brands": {"international-brand": {"name": "Mylotarg", "company": "Wyeth"}}, "mixtures": null, "packagers": {"packager": [{"name": "Ben Venue Laboratories Inc.", "url": "http://www.benvenue.com"}, {"name": "Wyeth Pharmaceuticals", "url": "http://www.wyeth.com"}]}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Wyeth pharmaceuticals inc"}}, "prices": {"price": {"description": "Mylotarg 5 mg vial", "cost": {"@currency": "USD", "#text": "3104.82"}, "unit": "vial"}}, "categories": {"category": [{"category": "Antineoplastic Agents", "mesh-id": null}, {"category": "Immunotoxins", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": null, "atc-codes": null, "ahfs-codes": null, "patents": {"patent": [{"number": "5585089", "country": "United States", "approved": "1993-12-17", "expires": "2013-12-17"}, {"number": "5773001", "country": "United States", "approved": "1995-06-30", "expires": "2015-06-30"}]}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB08879", "name": "Belimumab", "description": "Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab."}, {"drugbank-id": "DB00363", "name": "Clozapine", "description": "Myelosuppressive Agents may enhance the adverse/toxic effect of Clozapine. Specifically, the risk for agranulocytosis may be increased."}, {"drugbank-id": "DB06643", "name": "Denosumab", "description": "May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased."}, {"drugbank-id": "DB01097", "name": "Leflunomide", "description": "Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased."}, {"drugbank-id": "DB04817", "name": "Metamizole", "description": "May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased"}, {"drugbank-id": "DB00108", "name": "Natalizumab", "description": "Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased."}, {"drugbank-id": "DB00337", "name": "Pimecrolimus", "description": "May enhance the adverse/toxic effect of Immunosuppressants."}, {"drugbank-id": "DB01656", "name": "Roflumilast", "description": "May enhance the immunosuppressive effect of Immunosuppressants."}, {"drugbank-id": "DB06688", "name": "Sipuleucel-T", "description": "Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T."}, {"drugbank-id": "DB08895", "name": "Tofacitinib", "description": "Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib."}, {"drugbank-id": "DB00072", "name": "Trastuzumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}]}, "sequences": {"sequence": [{"@format": "FASTA", "#text": "> Light Chain No. 1\nQIVLTQSPAIMSASPGEKVTITCSASSSISYMHWFQQKPGTSPKLWIYTTSNLASGVPAR\nFSGSGSGTSYSLTISRMEAEDAATYYCHQRSTYPLTFGSGTKLELK"}, {"@format": "FASTA", "#text": "> Light Chain No. 2\nDIQMTQSPSTLSASVGDRVTITCRASQSINTWLAWYQQKPGKAPKLLMYKASSLESGVPS\nRFIGSGSGTEFTLTISSLQPDDFATYYCQQYNSDSKMFGQGTKVEVK"}, {"@format": "FASTA", "#text": "> Heavy Chain No. 1\nQVQLQQSGAELAKPGASVKMSCKASGYTFTSYRMHWVKQRPGQGLEWIGYINPSTGYTEY\nNQKFKDKATLTADKSSSTAYMQLSSLTFEDSAVYYCARGGGVFDYWGQGTTLTVSS"}, {"@format": "FASTA", "#text": "> Heavy Chain No. 2\nQVQLVQSGAEVKKPGSSVKVSCKASGGTFSRSAIIWVRQAPGQGLEWMGGIVPMFGPPNY\nAQKFQGRVTITADESTNTAYMELSSLRSEDTAFYFCAGGYGIYSPEEYNGGLVTVSS"}]}, "experimental-properties": {"property": {"kind": "Melting Point", "value": "61 \u00b0C (FAB fragment), 71 \u00b0C (whole mAb)", "source": "Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)"}}, "external-identifiers": {"external-identifier": [{"resource": "National Drug Code Directory", "identifier": "0008-4510-01"}, {"resource": "PharmGKB", "identifier": "PA164749431"}, {"resource": "Wikipedia", "identifier": "Gemtuzumab_ozogamicin"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic2/gemtuzumab.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/gemtuzumab-ozogamicin.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000674", "name": "Myeloid cell surface antigen CD33", "organism": "Human", "actions": {"action": "antibody"}, "references": "# Naito K, Takeshita A, Shigeno K, Nakamura S, Fujisawa S, Shinjo K, Yoshida H, Ohnishi K, Mori M, Terakawa S, Ohno R: Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia. 2000 Aug;14(8):1436-43. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10942240\n# Niculescu-Duvaz I: Technology evaluation: gemtuzumab ozogamicin, Celltech Group. Curr Opin Mol Ther. 2000 Dec;2(6):691-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11249747\n# van Der Velden VH, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS, van Dongen JJ: Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood. 2001 May 15;97(10):3197-204. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11342449\n# Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R: Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001 Jun;7(6):1490-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11410481\n# Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001 Jul 1;19(13):3244-54. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11432892\n# McHayleh W, Foon K, Redner R, Sehgal R, Raptis A, Agha M, Luong TM, Schlesselman JJ, Boyiadzis M: Gemtuzumab ozogamicin as first-line treatment in patients aged 70 years or older with acute myeloid leukemia. Cancer. 2010 Jun 15;116(12):3001-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20564405\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P20138", "@source": "Swiss-Prot", "name": "Myeloid cell surface antigen CD33", "general-function": "Involved in receptor activity", "specific-function": "Putative adhesion molecule of myelomonocytic-derived cells that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. Induces apoptosis in acute myeloid leukemia (in vitro)", "gene-name": "CD33", "locus": "19q13.3", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "260-282", "signal-regions": null, "theoretical-pi": "8.48", "molecular-weight": "39826.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1659"}, {"resource": "GenAtlas", "identifier": "CD33"}, {"resource": "GeneCards", "identifier": "CD33"}, {"resource": "GenBank Gene Database", "identifier": "M23197"}, {"resource": "GenBank Protein Database", "identifier": "180098"}, {"resource": "UniProtKB", "identifier": "P20138"}, {"resource": "UniProt Accession", "identifier": "CD33_HUMAN"}]}, "synonyms": {"synonym": ["gp67", "Myeloid cell surface antigen CD33 precursor", "Sialic acid-binding Ig- like lectin 3", "Siglec-3"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Myeloid cell surface antigen CD33 precursor\nMPLLLLLPLLWAGALAMDPNFWLQVQESVTVQEGLCVLVPCTFFHPIPYYDKNSPVHGYW\nFREGAIISRDSPVATNKLDQEVQEETQGRFRLLGDPSRNNCSLSIVDARRRDNGSYFFRM\nERGSTKYSYKSPQLSVHVTDLTHRPKILIPGTLEPGHSKNLTCSVSWACEQGTPPIFSWL\nSAAPTSLGPRTTHSSVLIITPRPQDHGTNLTCQVKFAGAGVTTERTIQLNVTYVPQNPTT\nGIFPGDGSGKQETRAGVVHGAIGGAGVTALLALCLCLIFFIVKTHRRKAARTAVGRNDTH\nPTTGSASPKHQKKSKLHGPTETSSCSGAAPTVEMDEELHYASLNFHGMNPSKDTSTEYSE\nVRTQ"}, "gene-sequence": {"@format": "FASTA", "#text": ">1095 bp\nATGCCGCTGCTGCTACTGCTGCCCCTGCTGTGGGCAGGGGCCCTGGCTATGGATCCAAAT\nTTCTGGCTGCAAGTGCAGGAGTCAGTGACGGTACAGGAGGGTTTGTGCGTCCTCGTGCCC\nTGCACTTTCTTCCATCCCATACCCTACTACGACAAGAACTCCCCAGTTCATGGTTACTGG\nTTCCGGGAAGGAGCCATTATATCCGGGGACTCTCCAGTGGCCACAAACAAGCTAGATCAA\nGAAGTACAGGAGGAGACTCAGGGCAGATTCCGCCTCCTTGGGGATCCCAGTAGGAACAAC\nTGCTCCCTGAGCATCGTAGACGCCAGGAGGAGGGATAATGGTTCATACTTCTTTCGGATG\nGAGAGAGGAAGTACCAAATACAGTTACAAATCTCCCCAGCTCTCTGTGCATGTGACAGAC\nTTGACCCACAGGCCCAAAATCCTCATCCCTGGCACTCTAGAACCCGGCCACTCCAAAAAC\nCTTACCTGCTCTGTGTCCTGGGCCTGTGAGCAGGGAACACCCCCGATCTTCTCCTGGTTG\nTCAGCTGCCCCCACCTCCCTGGGCCCCAGGACTACTCACTCCTCGGTGCTCATAATCACC\nCCACGGCCCCAGGACCACGGCACCAACCTGACCTGTCAGGTGAAGTTCGCTGGAGCTGGT\nGTGACTACGGAGAGAACCATCCAGCTCAACGTCACCTATGTTCCACAGAACCCAACAACT\nGGTATCTTTCCAGGAGATGGCTCAGGGAAACAAGAGACCAGAGCAGGACTGGTTCATGGG\nGCCATTGGAGGAGCTGGTGTTACAGCCCTGCTCGCTCTTTGTCTCTGCCTCATCTTCTTC\nATAGTGAAGACCCACAGGAGGAAAGCAGCCAGGACAGCAGTGGGCAGCAATGACACCCAC\nCCTACCACAGGGTCAGCCTCCCCGAAACACCAGAAGAACTCCAAGTTACATGGCCCCACT\nGAAACCTCAAGCTGTTCAGGTGCCGCCCCTACTGTGGAGATGGATGAGGAGCTGCATTAT\nGCTTCCCTCAACTTTCATGGGATGAATCCTTCCAAGGACACCTCCACCGAATACTCAGAG\nGTCAGGACCCAGTGA"}, "pfams": {"pfam": [{"identifier": "PF00047", "name": "ig"}, {"identifier": "PF07686", "name": "V-set"}]}, "go-classifiers": null}}, {"id": "BE0000901", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "organism": "Human", "actions": null, "references": "# Caron PC, Lai LT, Scheinberg DA: Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia. Clin Cancer Res. 1995 Jan;1(1):63-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9815888\n# Rogler G, Hausmann M, Vogl D, Aschenbrenner E, Andus T, Falk W, Andreesen R, Scholmerich J, Gross V: Isolation and phenotypic characterization of colonic macrophages. Clin Exp Immunol. 1998 May;112(2):205-15. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9649182\n# Ericson SG, Benoit NE, Mills LE, Fanger MW: The effect of recombinant human interleukin-3 and recombinant human granulocyte-macrophage colony-stimulating factor on Fc gamma receptor expression and antibody-dependent cellular cytotoxicity of hematopoietic progenitor cells during in vitro myeloid maturation. Exp Hematol. 1994 Mar;22(3):283-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7509291", "known-action": "unknown", "polypeptide": {"@id": "O75015", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "general-function": null, "specific-function": "Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils", "gene-name": "FCGR3B", "locus": "1q23", "cellular-location": "Cell membrane; lipid-anchor; GPI-anchor. Secreted protein. Note=Secreted after cleavage", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.71", "molecular-weight": "26216.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3620"}, {"resource": "GenAtlas", "identifier": "FCGR3B"}, {"resource": "GeneCards", "identifier": "FCGR3B"}, {"resource": "GenBank Gene Database", "identifier": "X16863"}, {"resource": "GenBank Protein Database", "identifier": "31322"}, {"resource": "UniProtKB", "identifier": "O75015"}, {"resource": "UniProt Accession", "identifier": "FCG3B_HUMAN"}]}, "synonyms": {"synonym": ["CD16b antigen", "Fc-gamma RIII", "Fc-gamma RIII-beta", "Fc-gamma RIIIb", "FcR-10", "FcRIII", "FcRIIIb", "IgG Fc receptor III-1", "Low affinity immunoglobulin gamma Fc region receptor III-B precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-B precursor\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI"}, "gene-sequence": {"@format": "FASTA", "#text": ">702 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"id": "BE0002093", "name": "Complement C1r subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P00736", "@source": "Swiss-Prot", "name": "Complement C1r subcomponent", "general-function": null, "specific-function": "C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system", "gene-name": "C1R", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.24", "molecular-weight": "80174.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1246"}, {"resource": "GenAtlas", "identifier": "C1R"}, {"resource": "GeneCards", "identifier": "C1R"}, {"resource": "GenBank Gene Database", "identifier": "X04701"}, {"resource": "GenBank Protein Database", "identifier": "29539"}, {"resource": "UniProtKB", "identifier": "P00736"}, {"resource": "UniProt Accession", "identifier": "C1R_HUMAN"}]}, "synonyms": {"synonym": ["Complement C1r subcomponent precursor", "Complement component 1, r subcomponent", "EC 3.4.21.41"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1r subcomponent\nMWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF\nQQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF\nSNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY\nELQEDRHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF\nDIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL\nRYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD\nDGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR\nESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF\nTNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV\nSVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME\nEKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV\nRDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2118 bp\nATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC\nATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC\nAACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC\nCAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT\nGATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG\nGGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC\nTCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT\nGTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG\nTGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT\nGAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG\nGCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC\nAACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT\nGATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC\nGGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC\nAATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG\nCGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC\nATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA\nGGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT\nGATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA\nAACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC\nCGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG\nGAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG\nGGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG\nAGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC\nACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT\nGCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC\nCTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC\nAGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG\nCTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC\nAACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG\nGAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT\nGAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT\nGGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA\nAGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC\nAGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG\nATGGAGGAGGAGGACTGA"}, "pfams": {"pfam": [{"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF07645", "name": "EGF_CA"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"id": "BE0002094", "name": "Complement C1q subcomponent subunit A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02745", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit A", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QA", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.45", "molecular-weight": "26017.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1241"}, {"resource": "GenAtlas", "identifier": "C1QA"}, {"resource": "GeneCards", "identifier": "C1QA"}, {"resource": "GenBank Gene Database", "identifier": "AF135157"}, {"resource": "GenBank Protein Database", "identifier": "4894854"}, {"resource": "UniProtKB", "identifier": "P02745"}, {"resource": "UniProt Accession", "identifier": "C1QA_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit A precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit A\nMEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR\nTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI\nRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR\nGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL\nIFPSA"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG\nGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC\nAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG\nACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC\nAAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGGGCCCGTGGCATCCCGGGAATTAAA\nGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT\nCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG\nGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC\nTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG\nGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG\nGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC\nCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC\nATCTTCCCATCTGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"id": "BE0002095", "name": "Complement C1q subcomponent subunit B", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02746", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit B", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QB", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.87", "molecular-weight": "26460.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1242"}, {"resource": "GenAtlas", "identifier": "C1QB"}, {"resource": "GeneCards", "identifier": "C1QB"}, {"resource": "GenBank Gene Database", "identifier": "X03084"}, {"resource": "GenBank Protein Database", "identifier": "573114"}, {"resource": "UniProtKB", "identifier": "P02746"}, {"resource": "UniProt Accession", "identifier": "C1QB_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit B precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit B\nMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEK\nGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKI\nAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCV\nNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANSIF\nSGFLLFPDMEA"}, "gene-sequence": {"@format": "FASTA", "#text": ">688 bp\nCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGG\nGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCC\nAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAA\nTCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGCCCAGGGGCCCCTGG\nAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAGAAAATCGCCTTCTC\nTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATCCGCTTCGACCACGT\nGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTCACCTGCAAGGTGCC\nCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTGTGCGTGAACCTCAT\nGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTATGCCTACAACACCTT\nCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAGAACGTCTTCCTGCA\nGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGCATCTTTTCCGGGTT\nCCTGCTCTTTCCAGATATGGAGGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"id": "BE0002096", "name": "Complement C1q subcomponent subunit C", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02747", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit C", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QC", "locus": "1p36.11", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.58", "molecular-weight": "25774.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1245"}, {"resource": "GenAtlas", "identifier": "C1QC"}, {"resource": "GeneCards", "identifier": "C1QC"}, {"resource": "GenBank Gene Database", "identifier": "AF087892"}, {"resource": "GenBank Protein Database", "identifier": "33150626"}, {"resource": "UniProtKB", "identifier": "P02747"}, {"resource": "UniProt Accession", "identifier": "C1QC_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit C precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit C\nMDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP\nGIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS\nVFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV\nLLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF\nLLFPD"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG\nCTGCTGCCCCTCAGGGCCAAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC\nCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA\nGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA\nCCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC\nCCCATGGGATTCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA\nGTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC\nAACGCGGTCCTCACCAACCCGCAGGAGGATTATGACACGAGCACTGGCAAGTTCACCTGC\nAAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG\nCTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT\nCAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT\nGTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC\nCTGCTCTTCCCCGACTAG"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"id": "BE0002097", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Ericson SG, Benoit NE, Mills LE, Fanger MW: The effect of recombinant human interleukin-3 and recombinant human granulocyte-macrophage colony-stimulating factor on Fc gamma receptor expression and antibody-dependent cellular cytotoxicity of hematopoietic progenitor cells during in vitro myeloid maturation. Exp Hematol. 1994 Mar;22(3):283-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7509291", "known-action": "unknown", "polypeptide": {"@id": "P08637", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "general-function": null, "specific-function": "Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis", "gene-name": "FCGR3A", "locus": "1q23", "cellular-location": "Cell membrane", "transmembrane-regions": "209-229", "signal-regions": null, "theoretical-pi": "8.21", "molecular-weight": "29089.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3619"}, {"resource": "GenAtlas", "identifier": "FCGR3A"}, {"resource": "GeneCards", "identifier": "FCGR3A"}, {"resource": "GenBank Gene Database", "identifier": "X52645"}, {"resource": "GenBank Protein Database", "identifier": "31324"}, {"resource": "UniProtKB", "identifier": "P08637"}, {"resource": "UniProt Accession", "identifier": "FCG3A_HUMAN"}]}, "synonyms": {"synonym": ["CD16a antigen", "Fc-gamma RIII", "Fc-gamma RIII-alpha", "Fc-gamma RIIIa", "FcR-10", "FcRIII", "FcRIIIa", "IgG Fc receptor III-2", "Low affinity immunoglobulin gamma Fc region receptor III-A precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK"}, "gene-sequence": {"@format": "FASTA", "#text": ">765 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCGACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCA\nAAAGCCACACTCAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTTTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGG\nAAGGACCATAAATTTAAATGGAGAAAGGACCCTCAAGACAAATGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"id": "BE0001529", "name": "Complement C1s subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P09871", "@source": "Swiss-Prot", "name": "Complement C1s subcomponent", "general-function": "Involved in calcium ion binding", "specific-function": "C1s B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4", "gene-name": "C1S", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "4.59", "molecular-weight": "76685.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1247"}, {"resource": "GenAtlas", "identifier": "C1S"}, {"resource": "GeneCards", "identifier": "C1S"}, {"resource": "GenBank Gene Database", "identifier": "X06596"}, {"resource": "GenBank Protein Database", "identifier": "763110"}, {"resource": "UniProtKB", "identifier": "P09871"}, {"resource": "UniProt Accession", "identifier": "C1S_HUMAN"}]}, "synonyms": {"synonym": ["C1 esterase", "Complement C1s subcomponent precursor", "EC 3.4.21.42"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1s subcomponent precursor\nMWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIE\nLSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERF\nTGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVF\nTALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVF\nVAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTP\nNSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCG\nIPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPK\nCVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGN\nREPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVK\nMGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKV\nEKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCG\nTYGLYTRVKNYVDWIMKTMQENSTPRED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2067 bp\nATGTGGTGCATTGTCCTGTTTTCACTTTTGGCATGGGTTTATGCTGAGCCTACCATGTAT\nGGGGAGATCCTGTCCCCTAACTATCCTCAGGCATATCCCAGTGAGGTAGAGAAATCTTGG\nGACATAGAAGTTCCTGAAGGGTATGGGATTCACCTCTACTTCACCCATCTGGACATTGAG\nCTGTCAGAGAACTGTGCGTATGACTCAGTGCAGATAATCTCAGGAGACACTGAAGAAGGG\nAGGCTCTGTGGACAGAGGAGCAGTAACAATCCCCACTCTCCAATTGTGGAAGAGTTCCAA\nGTCCCATACAACAAACTCCAGGTGATCTTTAAGTCAGACTTTTCCAATGAAGAGCGTTTT\nACGGGGTTTGCTGCATACTATGTTGCCACAGACATAAATGAATGCACAGATTTTGTAGAT\nGTCCCTTGTAGCCACTTCTGCAACAATTTCATTGGTGGTTACTTCTGCTCCTGCCCCCCG\nGAATATTTCCTCCATGATGACATGAAGAATTGCGGAGTTAATTGCAGTGGGGATGTATTC\nACTGCACTGATTGGGGAGATTGCAAGTCCCAATTATCCCAAACCATATCCAGAGAACTCA\nAGGTGTGAATACCAGATCCGGTTGGAGAAAGGGTTCCAAGTGGTGGTGACCTTGCGGAGA\nGAAGATTTTGATGTGGAAGCAGCTGACTCAGCGGGAAACTGCCTTGACAGTTTAGTTTTT\nGTTGCAGGAGATCGGCAATTTGGTCCTTACTGTGGTCATGGATTCCCTGGGCCTCTAAAT\nATTGAAACCAAGAGTAATGCTCTTGATATCATCTTCCAAACTGATCTAACAGGGCAAAAA\nAAGGGCTGGAAACTTCGCTATCATGGAGATCCAATGCCCTGCCCTAAGGAAGACACTCCC\nAATTCTGTTTGGGAGCCTGCGAAGGCAAAATATGTCTTTAGAGATGTGGTGCAGATAACC\nTGTCTGGATGGGTTTGAAGTTGTGGAGGGACGTGTTGGTGCAACATCTTTCTATTCGACT\nTGTCAAAGCAATGGAAAGTGGAGTAATTCCAAACTGAAATGTCAACCTGTGGACTGTGGC\nATTCCTGAATCCATTGAGAATGGTAAAGTTGAAGACCCAGAGAGCACTTTGTTTGGTTCT\nGTCATCCGCTACACTTGTGAGGAGCCATATTACTACATGGAAAATGGAGGAGGTGGGGAG\nTATCACTGTGCTGGTAACGGGAGCTGGGTGAATGAGGTGCTGGGCCCGGAGCTGCCGAAA\nTGTGTTCCAGTCTGTGGAGTCCCCAGAGAACCCTTTGAAGAAAAACAGAGGATAATTGGA\nGGATCCGATGCAGATATTAAAAACTTCCCCTGGCAAGTCTTCTTTGACAACCCATGGGCT\nGGTGGAGCGCTCATTAATGAGTACTGGGTGCTGACGGCTGCTCATGTTGTGGAGGGAAAC\nAGGGAGCCAACAATGTATGTTGGGTCCACCTCAGTGCAGACCTCACGGCTGGCAAAATCC\nAAGATGCTCACTCCTGAGCATGTGTTTATTCATCCGGGATGGAAGCTGCTGGAAGTCCCA\nGAAGGACGAACCAATTTTGATAATGACATTGCACTGGTGCGGCTGAAAGACCCAGTGAAA\nATGGGACCCACCGTCTCTCCCATCTGCCTACCAGGCACCTCTTCCGACTACAACCTCATG\nGATGGGGACCTGGGACTGATCTCAGGCTGGGGCCGAACAGAGAAGAGAGATCGTGCTGTT\nCGCCTCAAGGCGGCAAGGTTACCTGTAGCTCCTTTAAGAAAATGCAAAGAAGTGAAAGTG\nGAGAAACCCACAGCAGATGCAGAGGCCTATGTTTTCACTCCTAACATGATCTGTGCTGGA\nGGAGAGAAGGGCATGGATAGCTGTAAAGGGGACAGTGGTGGGGCCTTTGCTGTACAGGAT\nCCCAATGACAAGACCAAATTCTACGCAGCTGGCCTGGTGTCCTGGGGGCCCCAGTGTGGG\nACCTATGGGCTCTACACACGGGTAAAGAACTATGTTGACTGGATAATGAAGACTATGCAG\nGAAAATAGCACCCCCCGTGAGGACTAA"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"id": "BE0000710", "name": "High affinity immunoglobulin gamma Fc receptor I", "organism": "Human", "actions": null, "references": "# Ericson SG, Benoit NE, Mills LE, Fanger MW: The effect of recombinant human interleukin-3 and recombinant human granulocyte-macrophage colony-stimulating factor on Fc gamma receptor expression and antibody-dependent cellular cytotoxicity of hematopoietic progenitor cells during in vitro myeloid maturation. Exp Hematol. 1994 Mar;22(3):283-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7509291", "known-action": "unknown", "polypeptide": {"@id": "P12314", "@source": "Swiss-Prot", "name": "High affinity immunoglobulin gamma Fc receptor I", "general-function": "Involved in receptor signaling protein activity", "specific-function": "Binds to the Fc region of immunoglobulins gamma. High affinity receptor", "gene-name": "FCGR1A", "locus": "1q21.2-q21.3", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "293-313", "signal-regions": null, "theoretical-pi": "8.08", "molecular-weight": "42632.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3613"}, {"resource": "GenAtlas", "identifier": "FCGR1A"}, {"resource": "GeneCards", "identifier": "FCGR1A"}, {"resource": "GenBank Gene Database", "identifier": "X14356"}, {"resource": "GenBank Protein Database", "identifier": "31332"}, {"resource": "UniProtKB", "identifier": "P12314"}, {"resource": "UniProt Accession", "identifier": "FCGR1_HUMAN"}]}, "synonyms": {"synonym": ["CD64 antigen", "Fc-gamma RI", "FcRI", "High affinity immunoglobulin gamma Fc receptor I precursor", "IgG Fc receptor I"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">High affinity immunoglobulin gamma Fc receptor I precursor\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1125 bp\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCTCTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAACTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"id": "BE0002098", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P12318", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "general-function": null, "specific-function": "Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens", "gene-name": "FCGR2A", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.78", "molecular-weight": "34990.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3616"}, {"resource": "GenAtlas", "identifier": "FCGR2A"}, {"resource": "GeneCards", "identifier": "FCGR2A"}, {"resource": "GenBank Gene Database", "identifier": "M31932"}, {"resource": "GenBank Protein Database", "identifier": "182474"}, {"resource": "UniProtKB", "identifier": "P12318"}, {"resource": "UniProt Accession", "identifier": "FCG2A_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-a", "Fc-gamma-RIIa", "FcRII-a", "IgG Fc receptor II-a", "Low affinity immunoglobulin gamma Fc region receptor II-a precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-a\nMAMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSRLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">954 bp\nATGGCTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"id": "BE0002099", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31994", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "general-function": null, "specific-function": "Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B- cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis", "gene-name": "FCGR2B", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.12", "molecular-weight": "34044.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3618"}, {"resource": "GenAtlas", "identifier": "FCGR2B"}, {"resource": "GeneCards", "identifier": "FCGR2B"}, {"resource": "GenBank Gene Database", "identifier": "U87560"}, {"resource": "GenBank Protein Database", "identifier": "4099445"}, {"resource": "UniProtKB", "identifier": "P31994"}, {"resource": "UniProt Accession", "identifier": "FCG2B_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-b", "Fc-gamma-RIIb", "FcRII-b", "IgG Fc receptor II-b", "Low affinity immunoglobulin gamma Fc region receptor II-b precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI"}, "gene-sequence": {"@format": "FASTA", "#text": ">930 bp\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCTCTCCCAGGATACCCTGAG\nTGCAGGGAAATGGGAGAGACCCTCCCTGAGAAACCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATT"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"id": "BE0002100", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31995", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "general-function": null, "specific-function": "Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells", "gene-name": "FCGR2C", "locus": "1q23.3", "cellular-location": "Cell membrane", "transmembrane-regions": "224-246", "signal-regions": null, "theoretical-pi": "6.9", "molecular-weight": "35578.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:15626"}, {"resource": "GenAtlas", "identifier": "FCGR2C"}, {"resource": "GeneCards", "identifier": "FCGR2C"}, {"resource": "GenBank Gene Database", "identifier": "X17652"}, {"resource": "GenBank Protein Database", "identifier": "32074"}, {"resource": "UniProtKB", "identifier": "P31995"}, {"resource": "UniProt Accession", "identifier": "FCG2C_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-c", "Fc-gamma-RIIc", "FcRII-c", "IgG Fc receptor II-c", "Low affinity immunoglobulin gamma Fc region receptor II-c precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-c\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR\nAPTDDDKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">972 bp\nATGGGAATCCTGTCATTTTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACAGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCATTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCTGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG\nAAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT\nGAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG\nGCACCTACTGACGATGATAAAAACATCTACTTGACTCTTCCTCCCAACGACCATGTCAAC\nAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-01-29", "drugbank-id": [{"@primary": "true", "#text": "DB00057"}, "BIOD00108", "BTD00108"], "name": "Satumomab Pendetide", "description": "Tumor associated glycoprotein (TAG) 72 (B72.3) monoclonal antibody conjugated with Indium 111 for radioimaging colon tumors. Satumomab Pendetide (trade name: OncoScint\u00ae) is no longer commercially available.", "cas-number": "138955-26-7", "groups": {"group": ["approved", "withdrawn"]}, "general-references": "# Artiko V, Obradovic V, Davidovic B, Petrovic N, Petrovic M, Krivokapic Z, Kecmanovic D, Pesko P, Djukic V, Milosavljevic T, Adanja G, Vlajkovic M: Radioimmunodetection of colorectal carcinoma. Hepatogastroenterology. 2003 Jul-Aug;50(52):1029-31. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12845972\n# Bohdiewicz PJ: Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging. J Nucl Med Technol. 1998 Sep;26(3):155-63; quiz 170-1. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/ 9755434", "synthesis-reference": null, "indication": "For diagnosis of extrahepatic malignant cancers", "pharmacodynamics": "Binds to the tumor associated glycoprotein 72 antigen, which is a cell surface protein generally over-expressed in colorectal cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of TAG-72 expressing cells and tumors.", "mechanism-of-action": "Satumomab Pendetide is a monoclonal antibody which is attached to the chelator pentetic acid (DTPA) linked to the tripeptide  glycine  (G) \u2013 L-tyrosine (Y) \u2013 L-lysine (K), which chelates Indium 111. Satumomab pendetide binds selectively to cell-surface TAG-72 expressed on colorectal tumors.", "toxicity": null, "metabolism": "Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production", "absorption": null, "half-life": "0.8 hours (mammalian reticulocytes, in vitro)", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Indium (111In) satumomab pendetide"}, {"@language": "", "@coder": "", "#text": "Indium-111 satumomab pendetide"}]}, "products": null, "international-brands": {"international-brand": {"name": "OncoScint", "company": "Cytogen Corp, Lonza Biologics"}}, "mixtures": null, "packagers": {"packager": {"name": "EUSA Pharma Inc.", "url": "http://www.eusapharma.com"}}, "manufacturers": null, "prices": null, "categories": {"category": {"category": "Diagnostic Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": null, "atc-codes": null, "ahfs-codes": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">Heavy chain 1 B72.3 (murine)\nQVQLQQSDAELVKPGASVKISCKASGYTFTDHAIHWAKQKPEQGLEWIGYISPGNDDIKY\nNEKFKGKATLTADKSSSTAYMQLNSLTSEDSAVYFCKRSYYGHWGQGTTLTVSSASTKGP\nSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS\nSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVCPPCKCPAPNLLGGPSVFIFPPKIKDVL\nMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQ\nDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTD\nFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEG\nLHNHHTTKSFSR"}, {"@format": "FASTA", "#text": ">Light chain 1 B72.3 (murine)\nDIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYAATNLADGVPS\nRFSGSGSGTQYSLKINSLQSEDFGSYYCQHFWGTPYTFGGGTRLEIKRADAAPTVFIFPP\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT\nLSKADYEKHKVYACEVTHQGLSSPVTKSFN"}, {"@format": "FASTA", "#text": ">Heavy chain 2 B72.3 (murine)\nQVQLQQSDAELVKPGASVKISCKASGYTFTDHAIHWAKQKPEQGLEWIGYISPGNDDIKY\nNEKFKGKATLTADKSSSTAYMQLNSLTSEDSAVYFCKRSYYGHWGQGTTLTVSSASTKGP\nSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS\nSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVCPPCKCPAPNLLGGPSVFIFPPKIKDVL\nMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQ\nDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTD\nFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEG\nLHNHHTTKSFSR"}, {"@format": "FASTA", "#text": ">Light chain 2 B72.3 (murine)\nDIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYAATNLADGVPS\nRFSGSGSGTQYSLKINSLQSEDFGSYYCQHFWGTPYTFGGGTRLEIKRADAAPTVFIFPP\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT\nLSKADYEKHKVYACEVTHQGLSSPVTKSFN"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "61 \u00b0C (FAB fragment), 71 \u00b0C (whole mAb)", "source": "Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)"}, {"kind": "Hydrophobicity", "value": "-0.427", "source": null}, {"kind": "Isoelectric Point", "value": "7.02", "source": null}, {"kind": "Molecular Weight", "value": "141478.9000", "source": null}, {"kind": "Molecular Formula", "value": "C6268H9708N1666O1971S48", "source": null}]}, "external-identifiers": {"external-identifier": {"resource": "PharmGKB", "identifier": "PA164745371"}}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"@position": "1", "id": "BE0004842", "name": "Tumor-associated glycoprotein 72 (TAG-72)", "organism": "Human", "actions": {"action": "other/unknown"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Muxi A, Pons F, Vidal-Sicart S, Setoain FJ, Herranz R, Novell F, Fernandez RM, Trias M, Setoain J: Radioimmunoguided surgery of colorectal carcinoma with an 111In-labelled anti-TAG72 monoclonal antibody. Nucl Med Commun. 1999 Feb;20(2):123-30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10088160", "known-action": "yes"}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-09-13", "drugbank-id": [{"@primary": "true", "#text": "DB00058"}, "BIOD00002", "BTD00002"], "name": "Alpha-1-proteinase inhibitor", "description": "Human alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation.", "cas-number": "9041-92-3", "groups": {"group": "approved"}, "general-references": "# Karnaukhova E, Ophir Y, Golding B: Recombinant human alpha-1 proteinase inhibitor: towards therapeutic use. Amino Acids. 2006 Jun;30(4):317-32. Epub 2006 May 26. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16773239", "synthesis-reference": "Michael H. Coan, William J. Brockway, \"Method of preparing alpha-1-proteinase inhibitor.\" U.S. Patent US4379087, issued December, 1968.", "indication": "For treatment of panacinar emphysema", "pharmacodynamics": "Prevents excessive accumulation of active neutrophil elastase and consequent proteolysis of elastin tissues in alveolar lung structures. This prevents the development of emphysema.", "mechanism-of-action": "Alpha-1 proteinase inhibitor is a serine protease inhibitor (Serpin). Its primary mechanism is inhibiting the action of the serine protease called elastase (also plasmin and thrombin) in the lungs. The reactive center loop (RCL) of alpha-1 proteinase inhibitor extends out from the body of the protein and directs binding to the target protease. The protease cleaves the serpin at the reactive site, establishing a covalent linkage between the carboxyl group of the serpin reactive site and the serine hydroxyl of the protease. The resulting inactive serpin-protease complex is highly stable.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": "* 5632 \u00b1 2006 mL [ARALAST NP]\n* 5618 \u00b1 1618 mL [Aralast]", "clearance": "* 940 +/- 275 mL/day [Patients with congenital \u03b11-PI deficiency with single IV infusion of 60\u00a0mg/kg]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Alpha 1-antitrypsin"}, {"@language": "", "@coder": "", "#text": "Alpha-1 protease inhibitor"}, {"@language": "", "@coder": "", "#text": "Alpha-1-antiproteinase"}, {"@language": "", "@coder": "", "#text": "Alpha-1-antitrypsin precursor"}]}, "products": null, "international-brands": {"international-brand": [{"name": "Aralast", "company": "Baxter"}, {"name": "Prolastin", "company": "Talecris Biotherapeutics C formerly Bayer"}]}, "mixtures": null, "packagers": {"packager": [{"name": "Baxter International Inc.", "url": "http://www.baxter.com"}, {"name": "CSL Behring LLC", "url": "http://www.cslbehring.com"}, {"name": "Talecris Biotherapeutics", "url": "http://www.talecris.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Prolastin 1000 mg vial", "cost": {"@currency": "USD", "#text": "0.46"}, "unit": "vial"}, {"description": "Prolastin 500 mg vial", "cost": {"@currency": "USD", "#text": "0.46"}, "unit": "vial"}, {"description": "Prolastin c 1000 mg vial", "cost": {"@currency": "USD", "#text": "0.46"}, "unit": "vial"}, {"description": "Aralast 500 mg vial", "cost": {"@currency": "USD", "#text": "0.5"}, "unit": "vial"}, {"description": "Zemaira 1000 mg vial", "cost": {"@currency": "USD", "#text": "0.5"}, "unit": "vial"}, {"description": "Aralast 1000 mg vial", "cost": {"@currency": "USD", "#text": "0.52"}, "unit": "vial"}, {"description": "Aralast np 1000 mg vial", "cost": {"@currency": "USD", "#text": "0.52"}, "unit": "vial"}, {"description": "Aralast np 500 mg vial", "cost": {"@currency": "USD", "#text": "0.52"}, "unit": "vial"}]}, "categories": {"category": [{"category": "Serine Proteinase Inhibitors", "mesh-id": null}, {"category": "Trypsin Inhibitors", "mesh-id": null}, {"category": "Enzyme Replacement Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": null, "atc-codes": null, "ahfs-codes": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00058 sequence\nEDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNIFFSPVSIATA\nFAMLSLGTKADTHDEILEGLNFNLTEIPEAQIHEGFQELLRTLNQPDSQLQLTTGNGLFL\nSEGLKLVDKFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLVKELDRDT\nVFALVNYIFFKGKWERPFEVKDTEEEDFHVDQVTTVKVPMMKRLGMFNIQHCKKLSSWVL\nLMKYLGNATAIFFLPDEGKLQHLENELTHDIITKFLENEDRRSASLHLPKLSITGTYDLK\nSVLGQLGITKVFSNGADLSGVTEEAPLKLSKAVHKAVLTIDEKGTEAAGAMFLEAIPMSI\nPPEVKFNKPFVFLMIEQNTKSPLFMGKVVNPTQK"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "59 \u00b0C at pH 7.8", "source": "Tew D.J., Bottomley, S.P. J. Mol. Biol. 313:1161-1169 (2001)"}, {"kind": "Hydrophobicity", "value": "-0.302", "source": null}, {"kind": "Isoelectric Point", "value": "5.37", "source": null}, {"kind": "Molecular Weight", "value": "44324.5000", "source": null}, {"kind": "Molecular Formula", "value": "C2001H3130N514O601S10", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "National Drug Code Directory", "identifier": "0944-2802-01"}, {"resource": "GenBank", "identifier": "K01396"}, {"resource": "PharmGKB", "identifier": "PA10308"}, {"resource": "UniProtKB", "identifier": "P01009"}, {"resource": "Wikipedia", "identifier": "Alpha_1-antitrypsin"}]}, "external-links": {"external-link": {"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/zemaira.htm"}}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0000394", "name": "Neutrophil elastase", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Topic A, Ljujic M, Nikolic A, Petrovic-Stanojevic N, Dopudja-Pantic V, Mitic-Milikic M, Radojkovic D: Alpha-1-antitrypsin Phenotypes and Neutrophil Elastase Gene Promoter Polymorphisms in Lung Cancer. Pathol Oncol Res. 2010 Jun 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20521180\n# Karnaukhova E, Ophir Y, Golding B: Recombinant human alpha-1 proteinase inhibitor: towards therapeutic use. Amino Acids. 2006 Jun;30(4):317-32. Epub 2006 May 26. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16773239\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P08246", "@source": "Swiss-Prot", "name": "Neutrophil elastase", "general-function": "Involved in elastase activity and cytokine binding", "specific-function": "Modifies the functions of natural killer cells, monocytes and granulocytes. Inhibits C5a-dependent neutrophil enzyme release and chemotaxis", "gene-name": "ELANE", "locus": "19p13.3", "cellular-location": "Cytoplasmic", "transmembrane-regions": "7-26", "signal-regions": null, "theoretical-pi": "9.41", "molecular-weight": "28518.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3309"}, {"resource": "GenAtlas", "identifier": "ELA2"}, {"resource": "GeneCards", "identifier": "ELA2"}, {"resource": "GenBank Gene Database", "identifier": "Y00477"}, {"resource": "GenBank Protein Database", "identifier": "296665"}, {"resource": "UniProtKB", "identifier": "P08246"}, {"resource": "UniProt Accession", "identifier": "ELNE_HUMAN"}]}, "synonyms": {"synonym": ["Bone marrow serine protease", "EC 3.4.21.37", "Elastase-2", "HLE", "Human leukocyte elastase", "Leukocyte elastase precursor", "Medullasin", "Neutrophil elastase", "PMN elastase"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Leukocyte elastase precursor\nMTLGRRLACLFLACVLPALLLGGTALASEIVGGRRARPHAWPFMVSLQLRGGHFCGATLI\nAPNFVMSAAHCVANVNVRAVRVVLGAHNLSRREPTRQVFAVQRIFENGYDPVNLLNDIVI\nLQLNGSATINANVQVAQLPAQGRRLGNGVQCLAMGWGLLGRNRGIASVLQELNVTVVTSL\nCRRSNVCTLVRGRQAGVCFGDSGSPLVCNGLIHGIASFVRGGCASGLYPDAFAPVAQFVN\nWIDSIIQRSEDNPCPHPRDPDPASRTH"}, "gene-sequence": {"@format": "FASTA", "#text": ">804 bp\nATGACCCTCGGCCGCCGACTCGCGTGTCTTTTCCTCGCCTGTGTCCTGCCGGCCTTGCTG\nCTGGGGGGCACCGCGCTGGCCTCGGAGATTGTGGGGGGCCGGCGAGCGCGGCCCCACGCG\nTGGCCCTTCATGGTGTCCCTGCAGCTGCGCGGAGGCCACTTCTGCGGCGCCACCCTGATT\nGCGCCCAACTTCGTCATGTCGGCCGCGCACTGCGTGGCGAATGTAAACGTCCGCGCGGTG\nCGGGTGGTCCTGGGAGCCCATAACCTCTCGCGGCGGGAGCCCACCCGGCAGGTGTTCGCC\nGTGCAGCGCATCTTCGAAAACGGCTACGACCCCGTAAACTTGCTCAACGACATCGTGATT\nCTCCAGCTCAACGGGTCGGCCACCATCAACGCCAACGTGCAGGTGGCCCAGCTGCCGGCT\nCAGGGACGCCGCCTGGGCAACGGGGTGCAGTGCCTGGCCATGGGCTGGGGCCTTCTGGGC\nAGGAACCGTGGGATCGCCAGCGTCCTGCAGGAGCTCAACGTGACGGTGGTGACGTCCCTC\nTGCCGTCGCAGCAACGTCTGCACTCTCGTGAGGGGCCGGCAGGCCGGCGTCTGTTTCGGG\nGACTCCGGCAGCCCCTTGGTCTGCAACGGGCTAATCCACGGAATTGCCTCCTTCGTCCGG\nGGAGGCTGCGCCTCAGGGCTCTACCCCGATGCCTTTGCCCCGGTGGCACAGTTTGTAAAC\nTGGATCGACTCTATCATCCAACGCTCCGAGGACAACCCCTGTCCCCACCCCCGGGACCCG\nGACCCGGCCAGCAGGACCCACTGA"}, "pfams": {"pfam": {"identifier": "PF00089", "name": "Trypsin"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}]}}}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-11-12", "drugbank-id": [{"@primary": "true", "#text": "DB00059"}, "BIOD00079", "BTD00079"], "name": "Pegaspargase", "description": "Pegylated L-asparagine amidohydrolase from E. coli. Pegylation substantially (by a factor of 4) extends the protein half life.", "cas-number": "130167-69-0", "groups": {"group": ["approved", "investigational"]}, "general-references": "# Graham ML: Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev. 2003 Sep 26;55(10):1293-302. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14499708\n#Lexicomp Online (2014). Pegaspargase.  Available at:http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7445#f_adverse-reactions [Accessed 12 Nov. 2014].\n#American Society of Health System Pharmacists, Inc., DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995. Pegaspargase; [updated 2013 Jan 18; cited 2014 Nov 12]. Available from http://search.ebscohost.com/login.aspx?direct=true&site=DynaMed&id=233015.", "synthesis-reference": null, "indication": "For treatment of acute lymphoblastic leukemia", "pharmacodynamics": "In a significant number of patients with acute leukemia, the malignant cells are dependent on an exogenous source of asparagine for survival. Normal cells, however, are able to synthesize asparagine and thus are affected less by the rapid depletion produced by treatment with the enzyme asparaginase. Oncaspar exploits a metabolic defect in asparagine synthesis of some malignant cells.", "mechanism-of-action": "Pegaspargase, more effective than asparaginase, converts asparagine to aspartic acid and ammonia. It facilitates production of oxaloacetate which is needed for general cellular metabolism. Some malignant cells lose the ability to produce asparagine and so the loss of exogenous sources of asparagine leads to cell death.", "toxicity": "Adverse effects that occur more than 10% of the time include hepatotoxicity as it is known to increase serum transaminases (ALT, AST). Also known to induce hypersensitivity reactions including anaphylaxis, erythema and bronchospasm.", "metabolism": null, "absorption": "Onset of Asparagine depletion by IM is within 4 days \nTime to peak: IM: 3 to 4 days", "half-life": "IM: ~6 days; half-life decreased to ~3 days (range: 1.4 to 5 days) in patients with previous hypersensitivity to native L-asparaginase; IV: Adults (asparaginase naive): 7 days", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": "IV: Adults (asparaginase naive): 2.4 L/m2\nDistributes into CSF (reportedly reducing CSF asparagine concentrations to a similar extent as asparaginase", "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "L-asparagine amidohydrolase"}, {"@language": "", "@coder": "", "#text": "Putative L-asparaginase precursor"}]}, "products": {"product": [{"name": "Oncaspar", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02236849", "started-marketing-on": "1998-10-13", "ended-marketing-on": "2004-01-02", "dosage-form": "liquid", "strength": "750 unit", "route": "intramuscular; intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Oncaspar", "ndc-id": "54482-301_9abd8f67-34cb-4ab7-b2ba-0745c25fdfd2", "ndc-product-code": "54482-301", "dpd-id": null, "started-marketing-on": "1994-02-01", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "750 [iU]/mL", "route": "intramuscular; intravenous", "fda-application-number": "BLA103411", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Oncaspar", "ingredients": "Pegaspargase"}, {"name": "Oncaspar", "ingredients": "Pegaspargase"}]}, "packagers": {"packager": [{"name": "Ben Venue Laboratories Inc.", "url": "http://www.benvenue.com"}, {"name": "Enzon Inc.", "url": "http://www.enzon.com"}]}, "manufacturers": null, "prices": {"price": {"description": "Oncaspar 750 unit/ml vial", "cost": {"@currency": "USD", "#text": "656.0"}, "unit": "ml"}}, "categories": {"category": {"category": "Antineoplastic Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, solution", "route": "intramuscular; intravenous", "strength": "750 [iU]/mL"}, {"form": "Liquid", "route": "intramuscular; intravenous", "strength": "750 unit"}]}, "atc-codes": {"atc-code": {"@code": "L01XX24", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L01", "#text": "ANTINEOPLASTIC AGENTS"}, {"@code": "L01X", "#text": "OTHER ANTINEOPLASTIC AGENTS"}, {"@code": "L01XX", "#text": "Other antineoplastic agents"}]}}, "ahfs-codes": null, "patents": null, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB06643", "name": "Denosumab", "description": "May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased."}, {"drugbank-id": "DB01097", "name": "Leflunomide", "description": "Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased."}, {"drugbank-id": "DB00108", "name": "Natalizumab", "description": "Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased."}, {"drugbank-id": "DB00337", "name": "Pimecrolimus", "description": "May enhance the adverse/toxic effect of Immunosuppressants."}, {"drugbank-id": "DB01656", "name": "Roflumilast", "description": "May enhance the immunosuppressive effect of Immunosuppressants."}, {"drugbank-id": "DB06688", "name": "Sipuleucel-T", "description": "Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T."}, {"drugbank-id": "DB08895", "name": "Tofacitinib", "description": "Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib."}, {"drugbank-id": "DB00072", "name": "Trastuzumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00059 sequence\nMEFFKKTALAALVMGFSGAALALPNITILATGGTIAGGGDSATKSNYTVGKVGVENLVNA\nVPQLKDIANVKGEQVVNIGSQDMNDNVWLTLAKKINTDCDKTDGFVITHGTDTMEETAYF\nLDLTVKCDKPVVMVGAMRPSTSMSADGPFNLYNAVVTAADKASANRGVLVVMNDTVLDGR\nDVTKTNTTDVATFKSVNYGPLGYIHNGKIDYQRTPARKHTSDTPFDVSKLNELPKVGIVY\nNYANASDLPAKALVDAGYDGIVSAGVGNGNLYKSVFDTLATAAKTGTAVVRSSRVPTGAT\nTQDAEVDDAKYGFVASGTLNPQKARVLLQLALTQTKDPQQIQQIFNQY"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "0.059", "source": null}, {"kind": "Isoelectric Point", "value": "4.67", "source": null}, {"kind": "Molecular Weight", "value": "31731.9000", "source": null}, {"kind": "Molecular Formula", "value": "C1377H2208N382O442S17", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "11706"}, {"resource": "National Drug Code Directory", "identifier": "57665-002-02"}, {"resource": "GenBank", "identifier": "U00096"}, {"resource": "PharmGKB", "identifier": "PA164760860"}, {"resource": "UniProtKB", "identifier": "P37595"}, {"resource": "Wikipedia", "identifier": "Pegaspargase"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic2/pegaspargase.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/pegaspargase.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0004798", "name": "L-asparagine", "organism": "Human", "actions": {"action": "other/unknown"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Douer D, Yampolsky H, Cohen LJ, Watkins K, Levine AM, Periclou AP, Avramis VI: Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007 Apr 1;109(7):2744-50. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17132721\n# Wetzler M, Sanford BL, Kurtzberg J, DeOliveira D, Frankel SR, Powell BL, Kolitz JE, Bloomfield CD, Larson RA: Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood. 2007 May 15;109(10):4164-7. Epub 2007 Jan 30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17264295\n# Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R: FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist. 2007 Aug;12(8):991-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17766659", "known-action": "yes"}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2015-09-23", "drugbank-id": [{"@primary": "true", "#text": "DB00060"}, "BIOD00093", "BTD00093"], "name": "Interferon beta-1a", "description": "Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.", "cas-number": "145258-61-3", "groups": {"group": ["approved", "investigational"]}, "general-references": null, "synthesis-reference": "Heinz-Jurgen Friesen, Sidney Pestka, \"Preparation of homogeneous human fibroblast interferon.\" U.S. Patent US4289689, issued December, 1968.", "indication": "For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum", "pharmacodynamics": "Interferon beta upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Type I interferons also induce the synthesis of several key antiviral mediators including 2'-5' oligoadenylate synthetase (2'-5' A synthetase), beta-2 microglobulin and neopterin.", "mechanism-of-action": "Interferon beta binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon beta binds more stably to type I interferon receptors than interferon alpha.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": "10 hrs", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": "* 33-55 L/hour [Healthy SC injection of 60 mcg]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Fibroblast interferon"}, {"@language": "", "@coder": "", "#text": "IFN-beta"}, {"@language": "", "@coder": "", "#text": "Interferon beta precursor"}]}, "products": {"product": [{"name": "Avonex", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02237770", "started-marketing-on": "1998-06-19", "ended-marketing-on": "2010-10-30", "dosage-form": "powder for solution", "strength": "30 mcg", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Avonex", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02267594", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "60 mcg", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Avonex", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02269201", "started-marketing-on": "2005-12-02", "ended-marketing-on": null, "dosage-form": "solution", "strength": "30 mcg", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Avonex", "ndc-id": "59627-001_4c6158f1-ef8f-417c-b6b3-66ed94fe8f01", "ndc-product-code": "59627-001", "dpd-id": null, "started-marketing-on": "1996-05-17", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "30 ug/mL", "route": "intramuscular", "fda-application-number": "BLA103628", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Avonex", "ndc-id": "59627-002_4c6158f1-ef8f-417c-b6b3-66ed94fe8f01", "ndc-product-code": "59627-002", "dpd-id": null, "started-marketing-on": "2003-05-23", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "30 ug/.5mL", "route": "intramuscular", "fda-application-number": "BLA103628", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Avonex Pen", "ndc-id": "59627-003_4c6158f1-ef8f-417c-b6b3-66ed94fe8f01", "ndc-product-code": "59627-003", "dpd-id": null, "started-marketing-on": "2003-05-23", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "30 ug/.5mL", "route": "intramuscular", "fda-application-number": "BLA103628", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Rebif", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02318288", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "132 mcg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Rebif", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02237319", "started-marketing-on": "1998-02-23", "ended-marketing-on": null, "dosage-form": "solution", "strength": "22 mcg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Rebif", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02237320", "started-marketing-on": "1998-02-24", "ended-marketing-on": null, "dosage-form": "solution", "strength": "44 mcg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Rebif", "ndc-id": "44087-0022_36fcc6cb-ac58-40ab-9ab7-15dcefafd73b", "ndc-product-code": "44087-0022", "dpd-id": null, "started-marketing-on": "2002-03-07", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "22 ug/.5mL", "route": "subcutaneous", "fda-application-number": "BLA103780", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Rebif", "ndc-id": "44087-0044_36fcc6cb-ac58-40ab-9ab7-15dcefafd73b", "ndc-product-code": "44087-0044", "dpd-id": null, "started-marketing-on": "2002-03-07", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "44 ug/.5mL", "route": "subcutaneous", "fda-application-number": "BLA103780", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Rebif", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02318253", "started-marketing-on": "2009-05-14", "ended-marketing-on": null, "dosage-form": "solution", "strength": "66 mcg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Rebif", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02318261", "started-marketing-on": "2009-05-14", "ended-marketing-on": null, "dosage-form": "solution", "strength": "132 mcg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Rebif", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02277492", "started-marketing-on": "2006-05-30", "ended-marketing-on": "2013-08-09", "dosage-form": "solution", "strength": "8.8 mcg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Rebif", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02237317", "started-marketing-on": "1998-04-03", "ended-marketing-on": "2011-05-09", "dosage-form": "kit; liquid; powder", "strength": "11 mcg", "route": "intralesional; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Rebif Rebidose", "ndc-id": "44087-3322_36fcc6cb-ac58-40ab-9ab7-15dcefafd73b", "ndc-product-code": "44087-3322", "dpd-id": null, "started-marketing-on": "2012-12-21", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "22 ug/.5mL", "route": "subcutaneous", "fda-application-number": "BLA103780", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Rebif Rebidose", "ndc-id": "44087-3344_36fcc6cb-ac58-40ab-9ab7-15dcefafd73b", "ndc-product-code": "44087-3344", "dpd-id": null, "started-marketing-on": "2012-12-21", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "44 ug/.5mL", "route": "subcutaneous", "fda-application-number": "BLA103780", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}]}, "international-brands": {"international-brand": [{"name": "Betaferon", "company": "Bayer"}, {"name": "Blastoferon", "company": "Sidus"}, {"name": "Uribeta", "company": "Probiomed"}]}, "mixtures": {"mixture": [{"name": "Rebif", "ingredients": "Interferon beta-1a"}, {"name": "Rebif", "ingredients": "Interferon beta-1a"}, {"name": "Rebif Rebidose", "ingredients": "Interferon beta-1a"}, {"name": "Rebif Rebidose", "ingredients": "Interferon beta-1a"}, {"name": "Avonex", "ingredients": "Interferon beta-1a"}, {"name": "Avonex", "ingredients": "Interferon beta-1a"}, {"name": "Avonex Pen", "ingredients": "Interferon beta-1a"}, {"name": "Rebif", "ingredients": "Interferon beta-1a"}, {"name": "Rebif", "ingredients": "Interferon beta-1a"}, {"name": "Avonex", "ingredients": "Interferon beta-1a"}, {"name": "Rebif", "ingredients": "Interferon beta-1a"}, {"name": "Rebif", "ingredients": "Interferon beta-1a"}, {"name": "Rebif", "ingredients": "Interferon beta-1a + Sodium Chloride"}, {"name": "Avonex", "ingredients": "Interferon beta-1a + Water"}, {"name": "Rebif", "ingredients": "Interferon beta-1a"}, {"name": "Avonex", "ingredients": "Interferon beta-1a"}, {"name": "Rebif", "ingredients": "Interferon beta-1a"}]}, "packagers": {"packager": [{"name": "Biogen Idec Inc.", "url": "http://www.biogenidec.com"}, {"name": "EMD Canada Inc.", "url": "http://www.emdcanada.com"}, {"name": "Merck KGaA", "url": "http://www.merck.de"}, {"name": "Merck Serono SPA", "url": "http://www.merckserono.net"}, {"name": "Pierre Fabre", "url": "http://www.pierre-fabre.com"}, {"name": "Vetter Pharma Fertigung GmbH and Co. KG", "url": "http://www.vetter-pharma.com"}]}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Biogen Idec"}}, "prices": {"price": [{"description": "Rebif 22 mcg/0.5 ml syringe", "cost": {"@currency": "USD", "#text": "247.79"}, "unit": "syringe"}, {"description": "Rebif 44 mcg/0.5 ml syringe", "cost": {"@currency": "USD", "#text": "247.79"}, "unit": "syringe"}, {"description": "Avonex admin pack 30 mcg vial", "cost": {"@currency": "USD", "#text": "781.8"}, "unit": "vial"}, {"description": "Avonex 4 30 mcg/vial Kit 1 Box = 4 Vials ( 0.5ml Per Vial)", "cost": {"@currency": "USD", "#text": "3252.29"}, "unit": "box"}, {"description": "Avonex Prefilled (1 Box = 1 Kit = Four 30 mcg/0.5ml Syringes) Box", "cost": {"@currency": "USD", "#text": "3252.29"}, "unit": "box"}]}, "categories": {"category": [{"category": "Antineoplastic Agents", "mesh-id": null}, {"category": "Antiviral Agents", "mesh-id": null}, {"category": "Immunologic Factors", "mesh-id": null}, {"category": "Immunosuppressive Agents", "mesh-id": null}]}, "affected-organisms": null, "dosages": {"dosage": [{"form": "Injection, powder, lyophilized, for solution", "route": "intramuscular", "strength": "30 ug/mL"}, {"form": "Injection, solution", "route": "intramuscular", "strength": "30 ug/.5mL"}, {"form": "Powder for solution", "route": "intramuscular", "strength": "30 mcg"}, {"form": "Powder for solution", "route": "intramuscular", "strength": "60 mcg"}, {"form": "Solution", "route": "intramuscular", "strength": "30 mcg"}, {"form": "Injection, solution", "route": "subcutaneous", "strength": "22 ug/.5mL"}, {"form": "Injection, solution", "route": "subcutaneous", "strength": "44 ug/.5mL"}, {"form": "Kit; liquid; powder", "route": "intralesional; subcutaneous", "strength": "11 mcg"}, {"form": "Solution", "route": "subcutaneous", "strength": "132 mcg"}, {"form": "Solution", "route": "subcutaneous", "strength": "22 mcg"}, {"form": "Solution", "route": "subcutaneous", "strength": "44 mcg"}, {"form": "Solution", "route": "subcutaneous", "strength": "66 mcg"}, {"form": "Solution", "route": "subcutaneous", "strength": "8.8 mcg"}]}, "atc-codes": {"atc-code": {"@code": "L03AB07", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L03", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03A", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03AB", "#text": "Interferons"}]}}, "ahfs-codes": {"ahfs-code": "92:00.00"}, "patents": {"patent": {"number": "1341604", "country": "Canada", "approved": "2010-05-04", "expires": "2027-05-04"}}, "food-interactions": null, "drug-interactions": {"drug-interaction": {"drugbank-id": "DB00495", "name": "Zidovudine", "description": "Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine."}}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00060 sequence\nMSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIY\nEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSL\nHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.427", "source": null}, {"kind": "Isoelectric Point", "value": "8.93", "source": null}, {"kind": "Molecular Weight", "value": "20027.0000", "source": null}, {"kind": "Molecular Formula", "value": "C908H1408N246O252S7", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "11746"}, {"resource": "National Drug Code Directory", "identifier": "44087-8822-1"}, {"resource": "GenBank", "identifier": "V00534"}, {"resource": "PharmGKB", "identifier": "PA450037"}, {"resource": "UniProtKB", "identifier": "P01574"}, {"resource": "Wikipedia", "identifier": "Interferon_beta-1a"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/rebif.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/interferon-beta-1a.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000661", "name": "Interferon alpha/beta receptor 1", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Russell-Harde D, Wagner TC, Perez HD, Croze E: Formation of a uniquely stable type I interferon receptor complex by interferon beta is dependent upon particular interactions between interferon beta and its receptor and independent of tyrosine phosphorylation. Biochem Biophys Res Commun. 1999 Feb 16;255(2):539-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10049744\n# van Koetsveld PM, Vitale G, de Herder WW, Feelders RA, van der Wansem K, Waaijers M, van Eijck CH, Speel EJ, Croze E, van der Lely AJ, Lamberts SW, Hofland LJ: Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth. J Clin Endocrinol Metab. 2006 Nov;91(11):4537-43. Epub 2006 Aug 15. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16912135\n# Dupont SA, Goelz S, Goyal J, Green M: Mechanisms for regulation of cellular responsiveness to human IFN-beta1a. J Interferon Cytokine Res. 2002 Apr;22(4):491-501. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12034032\n# Runkel L, De Dios C, Karpusas M, Baker D, Li Z, Zafari M, Betzenhauser M, Muldowney C, Miller S, Redlich PN, Grossberg SE, Whitty A, Hochman PS: Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis. J Interferon Cytokine Res. 2001 Nov;21(11):931-41. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11747625", "known-action": "yes", "polypeptide": {"@id": "P17181", "@source": "Swiss-Prot", "name": "Interferon alpha/beta receptor 1", "general-function": "Involved in interferon-alpha/beta receptor activity", "specific-function": "Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta- subunits themselves", "gene-name": "IFNAR1", "locus": null, "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "437-457", "signal-regions": null, "theoretical-pi": "5.56", "molecular-weight": "63526.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5432"}, {"resource": "GenAtlas", "identifier": "IFNAR1"}, {"resource": "GeneCards", "identifier": "IFNAR1"}, {"resource": "GenBank Gene Database", "identifier": "J03171"}, {"resource": "GenBank Protein Database", "identifier": "306914"}, {"resource": "UniProtKB", "identifier": "P17181"}, {"resource": "UniProt Accession", "identifier": "INAR1_HUMAN"}]}, "synonyms": {"synonym": ["IFN-alpha-REC", "Interferon-alpha/beta receptor alpha chain precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interferon-alpha/beta receptor alpha chain precursor\nMMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT\nFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF\nTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI\nENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ\nNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK\nGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP\nVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV\nFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE\nYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN\nEDESESKTSEELQQDFV"}, "gene-sequence": {"@format": "FASTA", "#text": ">1674 bp\nATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGGCCCATGGGTG\nTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC\nATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT\nTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG\nAATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT\nAAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT\nACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG\nGCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT\nTTAAGCTTTACATATAGCTTACTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT\nGAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA\nAAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT\nATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA\nAATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG\nTGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA\nCCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA\nGGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA\nGAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA\nTCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT\nGTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT\nGAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT\nGTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT\nTTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA\nGTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC\nTTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG\nTATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA\nAAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT\nGATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT\nGAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA"}, "pfams": null, "go-classifiers": null}}, {"@position": "2", "id": "BE0000385", "name": "Interferon alpha/beta receptor 2", "organism": "Human", "actions": null, "references": "# van Koetsveld PM, Vitale G, de Herder WW, Feelders RA, van der Wansem K, Waaijers M, van Eijck CH, Speel EJ, Croze E, van der Lely AJ, Lamberts SW, Hofland LJ: Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth. J Clin Endocrinol Metab. 2006 Nov;91(11):4537-43. Epub 2006 Aug 15. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16912135\n# Runkel L, De Dios C, Karpusas M, Baker D, Li Z, Zafari M, Betzenhauser M, Muldowney C, Miller S, Redlich PN, Grossberg SE, Whitty A, Hochman PS: Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis. J Interferon Cytokine Res. 2001 Nov;21(11):931-41. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11747625", "known-action": "yes", "polypeptide": {"@id": "P48551", "@source": "Swiss-Prot", "name": "Interferon alpha/beta receptor 2", "general-function": "Involved in interferon-alpha/beta receptor activity", "specific-function": "Receptor for interferons alpha and beta. Isoform 1 and isoform 3 are directly involved in signal transduction due to their interaction with the TYR kinase, JAK1. Isoform 1 also interacts with the transcriptional factors, STAT1 and STAT2. Both forms are potent inhibitors of type I IFN activity", "gene-name": "IFNAR2", "locus": null, "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "244-264", "signal-regions": null, "theoretical-pi": "4.11", "molecular-weight": "57759.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5433"}, {"resource": "GenAtlas", "identifier": "IFNAR2"}, {"resource": "GeneCards", "identifier": "IFNAR2"}, {"resource": "GenBank Gene Database", "identifier": "L42243"}, {"resource": "GenBank Protein Database", "identifier": "995300"}, {"resource": "UniProtKB", "identifier": "P48551"}, {"resource": "UniProt Accession", "identifier": "INAR2_HUMAN"}]}, "synonyms": {"synonym": ["IFN-alpha-REC", "IFN-R", "Interferon alpha/beta receptor 2", "Interferon-alpha/beta receptor beta chain precursor", "Type I interferon receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interferon-alpha/beta receptor beta chain precursor\nMLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS\nIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF\nSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK\nHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE\nSAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD\nMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI\nDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR\nITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT\nFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR"}, "gene-sequence": {"@format": "FASTA", "#text": ">1548 bp\nATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT\nATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT\nTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC\nATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG\nGTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA\nAGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC\nAGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG\nATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA\nGAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG\nCATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA\nATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA\nATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA\nTCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC\nATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG\nAATTTTCATAACTTTTTAGCCTGGCCATTTCCTAACCTGCCACCGTTGGAAGCCATGGAT\nATGGTGGAGGTCATTTACATCAACAGAAAGAAGAAAGTGTGGGATTATAATTATGATGAT\nGAAAGTGATAGCGATACTGAGGCAGCGCCCAGGACAAGTGGCGGTGGCTATACCATGCAT\nGGACTGACTGTCAGGCCTCTGGGTCAGGCCTCTGCCACCTCTACAGAATCCCAGTTGATA\nGACCCGGAGTCCGAGGAGGAGCCTGACCTGCCTGAGGTTGATGTGGAGCTCCCCACGATG\nCCAAAGGACAGCCCTCAGCAGTTGGAACTCTTGAGTGGGCCCTGTGAGAGGAGAAAGAGT\nCCACTCCAGGACCCTTTTCCCGAAGAGGACTACAGCTCCACGGAGGGGTCTGGGGGCAGA\nATTACCTTCAATGTGGACTTAAACTCTGTGTTTTTGAGAGTTCTTGATGACGAGGACAGT\nGACGACTTAGAAGCCCCTCTGATGCTATCGTCTCATCTGGAAGAGATGGTTGACCCAGAG\nGATCCTGATAATGTGCAATCAAACCATTTGCTGGCCAGCGGGGAAGGGACACAGCCAACC\nTTTCCCAGCCCCTCTTCAGAGGGCCTGTGGTCCGAAGATGCTCCATCTGATCAAAGTGAC\nACTTCTGAGTCAGATGTTGACCTTGGGGATGGTTATATAATGAGATGA"}, "pfams": null, "go-classifiers": null}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-11-12", "drugbank-id": [{"@primary": "true", "#text": "DB00061"}, "BIOD00100", "BTD00100"], "name": "Pegademase bovine", "description": "Bovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life.", "cas-number": "9026-93-1", "groups": {"group": "approved"}, "general-references": "#Lexicomp Online (2014). Pegademase Bovine. Available at:http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7443#f_pharmacology-and-pharmacokinetics [Accessed 12 Nov. 2014].", "synthesis-reference": "Paul Skonezny, \"Process for preparing dideoxyinosine using adenosine deaminase enzyme.\" U.S. Patent US20040175804, issued September 09, 2004.", "indication": "For treatment of adenosine deaminase deficiency", "pharmacodynamics": "Used to replace deficient or inactive adenosine deaminase which leads to severe combined immunodeficiency disease (SCID). The enzyme is responsible for converting adenosine to inosine. In the absence of adenosine deaminase, the purine substrates adenosine, 2'-deoxyadenosine and their metabolites are actually toxic to lymphocytes thereby leading to diminished immune function.", "mechanism-of-action": "Pegademase converts adenosine (toxic) to inosine (less toxic) by deamination. It also converts 2'-deoxyadenosine to 2'-deoxyinosine via deamination.", "toxicity": null, "metabolism": null, "absorption": "Time to peak for plasma adenosine deaminase is 2 to 3 days", "half-life": "plasma adenosine deaminase elimination half-life is 3 to >6 days", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Adenosine aminohydrolase"}, {"@language": "", "@coder": "", "#text": "Adenosine deaminase"}]}, "products": {"product": {"name": "Adagen", "ndc-id": "57665-001_cf871fdf-06a3-4f26-b80b-d3d9b7846072", "ndc-product-code": "57665-001", "dpd-id": null, "started-marketing-on": "2010-10-18", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "250 [iU]/mL", "route": "intramuscular", "fda-application-number": "NDA019818", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}}, "international-brands": null, "mixtures": {"mixture": {"name": "Adagen", "ingredients": "Pegademase bovine"}}, "packagers": {"packager": [{"name": "Ben Venue Laboratories Inc.", "url": "http://www.benvenue.com"}, {"name": "Enzon Inc.", "url": "http://www.enzon.com"}]}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Sigma tau pharmaceuticals inc"}}, "prices": {"price": {"description": "Adagen 250 unit/ml vial", "cost": {"@currency": "USD", "#text": "4375.0"}, "unit": "ml"}}, "categories": {"category": {"category": "Enzyme Replacement Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": {"form": "Injection, solution", "route": "intramuscular", "strength": "250 [iU]/mL"}}, "atc-codes": null, "ahfs-codes": null, "patents": null, "food-interactions": null, "drug-interactions": {"drug-interaction": {"drugbank-id": "DB00552", "name": "Pentostatin", "description": "Pegademase bovine may diminish the therapeutic effect of Pentostatin. Pentostatin may diminish the therapeutic effect of Pegademase bovine."}}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00061 sequence\nMAQTPAFNKPKVELHVHLDGAIKPETILYYGRKRGIALPADTPEELQNIIGMDKPLSLPE\nFLAKFDYYMPAIAGCREAVKRIAYEFVEMKAKDGVVYVEVRYSPHLLANSKVEPIPWNQA\nEGDLTPDEVVSLVNQGLQEGERDFGVKVRSILCCMRHQPSWSSEVVELCKKYREQTVVAI\nDLAGDETIEGSSLFPGHVKAYAEAVKSGVHRTVHAGEVGSANVVKEAVDTLKTERLGHGY\nHTLEDATLYNRLRQENMHFEVCPWSSYLTGAWKPDTEHPVVRFKNDQVNYSLNTDDPLIF\nKSTLDTDYQMTKNEMGFTEEEFKRLNINAAKSSFLPEDEKKELLDLLYKAYGMPSPASAE\nQCL"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.428", "source": null}, {"kind": "Isoelectric Point", "value": "5.33", "source": null}, {"kind": "Molecular Weight", "value": "40788.2000", "source": null}, {"kind": "Molecular Formula", "value": "C1821H2834N484O552S14", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "National Drug Code Directory", "identifier": "57665-001-01"}, {"resource": "GenBank", "identifier": "AF280603"}, {"resource": "PharmGKB", "identifier": "PA450831"}, {"resource": "UniProtKB", "identifier": "P56658"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic2/pegademase.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/pegademase-bovine.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0004828", "name": "Adenosine", "organism": "Human", "actions": {"action": "metabolizer"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Van Linden A, Eltzschig HK: Role of pulmonary adenosine during hypoxia: extracellular generation, signaling and metabolism by surface adenosine deaminase/CD26. Expert Opin Biol Ther. 2007 Sep;7(9):1437-47. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17727332\n# Kemeny-Beke A, Jakab A, Zsuga J, Vecsernyes M, Karsai D, Pasztor F, Grenczer M, Szentmiklosi AJ, Berta A, Gesztelyi R: Adenosine deaminase inhibition enhances the inotropic response mediated by A(1) adenosine receptor in hyperthyroid guinea pig atrium. Pharmacol Res. 2007 Aug;56(2):124-31. Epub 2007 May 10. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17574432\n# Mohsenin A, Mi T, Xia Y, Kellems RE, Chen JF, Blackburn MR: Genetic removal of the A2A adenosine receptor enhances pulmonary inflammation, mucin production, and angiogenesis in adenosine deaminase-deficient mice. Am J Physiol Lung Cell Mol Physiol. 2007 Sep;293(3):L753-61. Epub 2007 Jun 29. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17601796", "known-action": "yes"}, {"id": "BE0000917", "name": "Growth factor receptor-bound protein 2", "organism": "Human", "actions": {"action": "binder"}, "references": "# Ramos-Morales F, Dominguez A, Rios RM, Barroso SI, Infante C, Schweighoffer F, Tocque B, Pintor-Toro JA, Tortolero M: Adenosine deaminase is a specific partner for the Grb2 isoform Grb3-3. Biochem Biophys Res Commun. 1997 Aug 28;237(3):735-40. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9299436", "known-action": "unknown", "polypeptide": {"@id": "P62993", "@source": "Swiss-Prot", "name": "Growth factor receptor-bound protein 2", "general-function": "Involved in epidermal growth factor receptor binding", "specific-function": "Isoform GRB3-3 does not bind to phosphorylated epidermal growth factor receptor (EGFR) but inhibits EGF-induced transactivation of a RAS-responsive element. Isoform GRB3-3 acts as a dominant negative protein over GRB2 and by suppressing proliferative signals, may trigger active programmed cell death", "gene-name": "GRB2", "locus": "17q24-q25", "cellular-location": null, "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.25", "molecular-weight": "25207.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:4566"}, {"resource": "GenAtlas", "identifier": "GRB2"}, {"resource": "GeneCards", "identifier": "GRB2"}, {"resource": "GenBank Gene Database", "identifier": "M96995"}, {"resource": "GenBank Protein Database", "identifier": "181976"}, {"resource": "UniProtKB", "identifier": "P62993"}, {"resource": "UniProt Accession", "identifier": "GRB2_HUMAN"}]}, "synonyms": {"synonym": ["Adapter protein GRB2", "Protein Ash", "SH2/SH3 adapter GRB2"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Growth factor receptor-bound protein 2\nMEAIAKYDFKATADDELSFKRGDILKVLNEECDQNWYKAELNGKDGFIPKNYIEMKPHPW\nFFGKIPRAKAEEMLSKQRHDGAFLIRESESAPGDFSLSVKFGNDVQHFKVLRDGAGKYFL\nWVVKFNSLNELVDYHRSTSVSRNQQIFLRDIEQVPQQPTYVQALFDFDPQEDGELGFRRG\nDFIHVMDNSDPNWWKGACHGQTGMFPRNYVTPVNRNV"}, "gene-sequence": {"@format": "FASTA", "#text": ">654 bp\nATGGAAGCCATCGCCAAATATGACTTCAAAGCTACTGCAGACGACGAGCTGAGCTTCAAA\nAGGGGGGACATCCTCAAGGTTTTGAACGAAGAATGTGATCAGAACTGGTACAAGGCAGAG\nCTTAATGGAAAAGACGGCTTCATTCCCAAGAACTACATAGAAATGAAACCACATCCGTGG\nTTTTTTGGCAAAATCCCCAGAGCCAAGGCAGAAGAAATGCTTAGCAAACAGCGGCACGAT\nGGGGCCTTTCTTATCCGAGAGAGTGAGAGCGCTCCTGGGGACTTCTCCCTCTCTGTCAAG\nTTTGGAAACGATGTGCAGCACTTCAAGGTGCTCCGAGATGGAGCCGGGAAGTACTTCCTC\nTGGGTGGTGAAGTTCAATTCTTTGAATGAGCTGGTGGATTATCACAGATCTACATCTGTC\nTCCAGAAACCAGCAGATATTCCTGCGGGACATAGAACAGGTGCCACAGCAGCCGACATAC\nGTCCAGGCCCTCTTTGACTTTGATCCCCAGGAGGATGGAGAGCTGGGCTTCCGCCGGGGA\nGATTTTATCCATGTCATGGATAACTCAGACCCCAACTGGTGGAAAGGAGCTTGCCACGGG\nCAGACCGGCATGTTTCCCCGCAATTATGTCACCCCCGTGAACCGGAACGTCTAA"}, "pfams": {"pfam": [{"identifier": "PF00017", "name": "SH2"}, {"identifier": "PF00018", "name": "SH3_1"}]}, "go-classifiers": {"go-classifier": [{"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "intracellular signaling cascade"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-09-13", "drugbank-id": [{"@primary": "true", "#text": "DB00062"}, "BIOD00059", "BTD00059"], "name": "Human Serum Albumin", "description": "Human serum albumin isolated from expired blood plasma", "cas-number": "9048-49-1", "groups": {"group": "approved"}, "general-references": null, "synthesis-reference": "Robert A. Tenold, \"Preparing essentially monomeric normal human serum albumin.\" U.S. Patent USRE0362590, issued July, 1976.", "indication": "For treatment of severe blood loss, hypervolemia, hypoproteinemia", "pharmacodynamics": "Regulates the colloidal osmotic pressure of blood. It is used to increase the circulating plasma volume, thereby reducing hemoconcentrtion and blood viscosity. Also used as a transport protein that binds naturally occurring, therapeutic and toxic materials in circulation.", "mechanism-of-action": "Acts as a high molecular weight, very soluble osmolyte", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": {"@language": "", "@coder": "", "#text": "Serum albumin precursor"}}, "products": {"product": {"name": "Albuminar-5", "ndc-id": "0053-7670_de8fa40b-f8c2-47c3-bb34-554701d154af", "ndc-product-code": "0053-7670", "dpd-id": null, "started-marketing-on": "2009-01-06", "ended-marketing-on": null, "dosage-form": "solution", "strength": "2.5 g/50mL", "route": "intravenous", "fda-application-number": "BLA103955", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}}, "international-brands": null, "mixtures": {"mixture": {"name": "Albuminar-5", "ingredients": "Human Serum Albumin"}}, "packagers": {"packager": [{"name": "ALK-Abello Inc.", "url": "http://www.alk-abello.com"}, {"name": "Alpha Therapeutic Corp.", "url": null}, {"name": "Alpine Biologics Inc.", "url": null}, {"name": "American Red Cross", "url": "http://www.redcross.org"}, {"name": "Baxter International Inc.", "url": "http://www.baxter.com"}, {"name": "CSL Behring LLC", "url": "http://www.cslbehring.com"}, {"name": "Grifols SA", "url": "http://www.grifols.com"}, {"name": "Massbiologics", "url": "http://www.massbio.org"}, {"name": "Octapharma USA", "url": "http://www.octapharma.com"}, {"name": "Sanofi-Aventis Inc.", "url": "http://www.sanofi-aventis.com"}, {"name": "Talecris Biotherapeutics", "url": "http://www.talecris.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Albutein 25% vial", "cost": {"@currency": "USD", "#text": "1.32"}, "unit": "ml"}, {"description": "Albumin 25% iv solution", "cost": {"@currency": "USD", "#text": "1.97"}, "unit": "ml"}, {"description": "Buminate 25% iv solution", "cost": {"@currency": "USD", "#text": "2.22"}, "unit": "ml"}, {"description": "Albumin (human) 5% iv solution", "cost": {"@currency": "USD", "#text": "0.3"}, "unit": "ml"}, {"description": "Albutein 5% iv solution", "cost": {"@currency": "USD", "#text": "0.43"}, "unit": "ml"}, {"description": "Buminate 5% iv solution", "cost": {"@currency": "USD", "#text": "0.44"}, "unit": "ml"}]}, "categories": {"category": {"category": "Serum substitutes", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": {"form": "Solution", "route": "intravenous", "strength": "2.5 g/50mL"}}, "atc-codes": null, "ahfs-codes": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": {"@format": "FASTA", "#text": "> Human Serum Albumin Sequence\nMKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF\nEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEP\nERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF\nFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV\nARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK\nECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYAR\nRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFE\nQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV\nLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTL\nSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV\nAASQAALGL"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "62 \u00b0C", "source": "Flora, K. et al., Biophys J. 75:1084-1096 (1998)"}, {"kind": "Hydrophobicity", "value": "-0.395", "source": null}, {"kind": "Isoelectric Point", "value": "5.67", "source": null}, {"kind": "Molecular Weight", "value": "66472.2000", "source": null}, {"kind": "Molecular Formula", "value": "C2936H4624N786O889S41", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "National Drug Code Directory", "identifier": "0053-7670-06"}, {"resource": "GenBank", "identifier": "M12523"}, {"resource": "PharmGKB", "identifier": "PA164743293"}, {"resource": "UniProtKB", "identifier": "P02768"}]}, "external-links": {"external-link": {"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/albumin.htm"}}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0001119", "name": "Apolipoprotein E", "organism": "Human", "actions": null, "references": "# Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, Michaelis M, Kreuter J, Langer K: Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther. 2006 Jun;317(3):1246-53. Epub 2006 Mar 22. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16554356\n# Yamashita T, Kawashima S, Hirase T, Shinohara M, Takaya T, Sasaki N, Takeda M, Tawa H, Inoue N, Hirata K, Yokoyama M: Xenogenic macrophage immunization reduces atherosclerosis in apolipoprotein E knockout mice. Am J Physiol Cell Physiol. 2007 Sep;293(3):C865-73. Epub 2007 Jun 6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17553935\n# Yuan ZY, Liu Y, Kishimoto C, Shioji K, Yokode M, Liu ZQ: [The Fc region of immunoglobulin suppresses atherosclerosis in apolipoprotein E knockout mice] Zhonghua Yi Xue Za Zhi. 2003 Mar 25;83(6):489-93. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12887764\n# Mojzisova H, Bonneau S, Vever-Bizet C, Brault D: The pH-dependent distribution of the photosensitizer chlorin e6 among plasma proteins and membranes: a physico-chemical approach. Biochim Biophys Acta. 2007 Feb;1768(2):366-74. Epub 2006 Oct 25. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17141733\n# Yuan Z, Kishimoto C, Sano H, Shioji K, Xu Y, Yokode M: Immunoglobulin treatment suppresses atherosclerosis in apolipoprotein E-deficient mice via the Fc portion. Am J Physiol Heart Circ Physiol. 2003 Aug;285(2):H899-906. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12860569", "known-action": "unknown", "polypeptide": {"@id": "P02649", "@source": "Swiss-Prot", "name": "Apolipoprotein E", "general-function": "Replication, recombination and repair", "specific-function": "Mediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues", "gene-name": "APOE", "locus": "19q13.2", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.42", "molecular-weight": "36155.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:613"}, {"resource": "GenAtlas", "identifier": "APOE"}, {"resource": "GeneCards", "identifier": "APOE"}, {"resource": "GenBank Gene Database", "identifier": "M12529"}, {"resource": "GenBank Protein Database", "identifier": "178849"}, {"resource": "UniProtKB", "identifier": "P02649"}, {"resource": "UniProt Accession", "identifier": "APOE_HUMAN"}]}, "synonyms": {"synonym": ["Apo-E", "Apolipoprotein E precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Apolipoprotein E precursor\nMKVLWAALLVTFLAGCQAKVEQAVETEPEPELRQQTEWQSGQRWELALGRFWDYLRWVQT\nLSEQVQEELLSSQVTQELRALMDETMKELKAYKSELEEQLTPVAEETRARLSKELQAAQA\nRLGADMEDVCGRLVQYRGEVQAMLGQSTEELRVRLASHLRKLRKRLLRDADDLQKRLAVY\nQAGAREGAERGLSAIRERLGPLVEQGRVRAATVGSLAGQPLQERAQAWGERLRARMEEMG\nSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEK\nVQAAVGTSAAPVPSDNH"}, "gene-sequence": {"@format": "FASTA", "#text": ">954 bp\nATGAAGGTTCTGTGGGCTGCGTTGCTGGTCACATTCCTGGCAGGATGCCAGGCCAAGGTG\nGAGCAAGCGGTGGAGACAGAGCCGGAGCCCGAGCTGCGCCAGCAGACCGAGTGGCAGAGC\nGGCCAGCGCTGGGAACTGGCACTGGGTCGCTTTTGGGATTACCTGCGCTGGGTGCAGACA\nCTGTCTGAGCAGGTGCAGGAGGAGCTGCTCAGCTCCCAAGTCACCCAAGAACTGAGGGCG\nCTGATGGACGAGACCATGAAGGAGTTGAAGGCCTACAAATCGGAACTGGAGGAACAACTG\nACCCCGGTAGCGGAGGAGACGCGGGCACGGCTGTCCAAGGAGCTGCAGACGGCGCAGGCC\nCGGCTGGGCGCGGACATGGAGGACGTGTGCGGCCGCCTGGTGCAGTACCGCGGCGAGGTG\nCAGGCCATGCTCGGCCAGAGCACCGAGGAGCTGCGGGTGCGCCTCGCCTCCCACCTGCGC\nAAGCTGCGTAAGCGGCTCCTCCGCGATCCCGATGACCTGCAGAAGCGCCTGGCAGTGTAC\nCAGGCCGGGGCCCGCGAGGGCGCCGAGCGCGGCCTCAGCGCCATCCGCGAGCGCCTGGGG\nCCCCTGGTGGAACAGGGCCGCGTGCGGGCCGCCACTGTGGGCTCCCTGGCCGGCCAGCCG\nCTACAGGAGCGGGCCCAGGCCTGGGGCGAGCGGCTGCGCGCGCGGATGGAGGAGATGGGC\nAGTCGGACCCGCGACCGCCTGGACGAGGTGAAGGAGCAGGTGGCGGAGGTGCGCGCCAAG\nCTGGAGGAGCAGGCCCAGCAGATACGCCTGCAGGCCGAGGCCTTCCAGGCCCGCCTCAAG\nAGCTGGTTCGAGCCCCTGGTGGAAGACATGCAGCGCCAGTGGGCCGGGCTGGTGGAGAAG\nGTGCAGGCTGCCGTGGGCACCAGCGCCGCCCCTGTGCCCAGCGACAATCACTGA"}, "pfams": {"pfam": {"identifier": "PF01442", "name": "Apolipoprotein"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "lipid binding"}, {"category": "function", "description": "binding"}, {"category": "process", "description": "lipid transport"}, {"category": "process", "description": "lipoprotein metabolism"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}]}}}, {"id": "BE0004795", "name": "Serum amyloid A-1 protein", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P0DJI8", "@source": "Swiss-Prot", "name": "Serum amyloid A-1 protein", "general-function": null, "specific-function": "Major acute phase reactant. Apolipoprotein of the HDL complex", "gene-name": "SAA1", "locus": "11p15.1", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.79", "molecular-weight": "13532.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:10513"}, {"resource": "GenAtlas", "identifier": "SAA1"}, {"resource": "GeneCards", "identifier": "SAA1"}, {"resource": "GenBank Gene Database", "identifier": "M10906"}, {"resource": "GenBank Protein Database", "identifier": "337748"}, {"resource": "UniProtKB", "identifier": "P0DJI8"}, {"resource": "UniProt Accession", "identifier": "SAA1_HUMAN"}]}, "synonyms": null, "amino-acid-sequence": {"@format": "FASTA"}, "gene-sequence": {"@format": "FASTA"}, "pfams": null, "go-classifiers": null}}, {"id": "BE0000932", "name": "Protein AMBP", "organism": "Human", "actions": null, "references": "# Sala A, Campagnoli M, Perani E, Romano A, Labo S, Monzani E, Minchiotti L, Galliano M: Human alpha-1-microglobulin is covalently bound to kynurenine-derived chromophores. J Biol Chem. 2004 Dec 3;279(49):51033-41. Epub 2004 Sep 27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15452109", "known-action": "unknown", "polypeptide": {"@id": "P02760", "@source": "Swiss-Prot", "name": "Protein AMBP", "general-function": "Involved in transporter activity", "specific-function": "Inter-alpha-trypsin inhibitor, present in plasma and urine, inhibits trypsin, plasmin, and lysosomal granulocytic elastase", "gene-name": "AMBP", "locus": "9q32-q33", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.15", "molecular-weight": "39000.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:453"}, {"resource": "GenAtlas", "identifier": "AMBP"}, {"resource": "GeneCards", "identifier": "AMBP"}, {"resource": "GenBank Gene Database", "identifier": "X54816"}, {"resource": "GenBank Protein Database", "identifier": "825614"}, {"resource": "UniProtKB", "identifier": "P02760"}, {"resource": "UniProt Accession", "identifier": "AMBP_HUMAN"}]}, "synonyms": {"synonym": "AMBP protein precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">AMBP protein precursor [Contains: Alpha-1-microglobulin\nMRSLGALLLLLSACLAVSAGPVPTPPDNIQVQENFNISRIYGKWYNLAIGSTCPWLKKIM\nDRMTVSTLVLGEGATEAEISMTSTRWRKGVCEETSGAYEKTDTDGKFLYHKSKWNITMES\nYVVHTNYDEYAIFLTKKFSRHHGPTITAKLYGRAPQLRETLLQDFRVVAQGVGIPEDSIF\nTMADRGECVPGEQEPEPILIPRVRRAVLPQEEEGSGGGQLVTEVTKKEDSCQLGYSAGPC\nMGMTSRYFYNGTSMACETFQYGGCMGNGNNFVTEKECLQTCRTVAACNLPIVRGPCRAFI\nQLWAFDAVKGKCVLFPYGGCQGNGNKFYSEKECREYCGVPGDGDEELLRFSN"}, "gene-sequence": {"@format": "FASTA", "#text": ">1059 bp\nATGAGGAGCCTCGGGGCCCTGCTCTTGCTGCTGAGCGCCTGCCTGGCGGTGAGCGCTGGC\nCCTGTGCCAACGCCGCCCGACAACATCCAAGTGCAGGAAAACTTCAATATCTCTCGGATC\nTATGGGAAGTGGTACAACCTGGCCATCGGTTCCACCTGCCCCTGGCTGAAGAAGATCATG\nGACAGGATGACAGTGAGCACGCTGGTGCTGGGAGAGGGCGCTACAGAGGCGGAGATCAGC\nATGACCAGCACTCGTTGGCGGAAAGGTGTCTGTGAGGAGACGTCTGGAGCTTATGAGAAA\nACAGATACTGATGGGAAGTTTCTCTATCACAAATCCAAATGGAACATAACCATGGAGTCC\nTATGTGGTCCACACCAACTATGATGAGTATGCCATTTTCCTGACCAAGAAATTCAGCCGC\nCATCATGGACCCACCATTACTGCCAAGCTCTACGGGCGGGCGCCGCAGCTGAGGGAAACT\nCTCCTGCAGGACTTCAGAGTGGTTGCCCAGGGTGTGGGCATCCCTGAGGACTCCATCTTC\nACCATGGCTGACCGAGGTGAATGTGTCCCTGGGGAGCAGGAACCAGAGCCCATCTTAATC\nCCGAGAGTCCGGAGGGCTGTGCTACCCCAAGAAGAGGAAGGATCAGGGGGTGGGCAACTG\nGTAACTGAAGTCACCAAGAAAGAAGATTCCTGCCAGCTGGGCTACTCGGCCGGTCCCTGC\nATGGGAATGACCAGCAGGTATTTCTATAATGGTACATCCATGGCCTGTGAGACTTTCCAG\nTACGGCGGCTGCATGGGCAACGGTAACAACTTCGTCACAGAAAAGGAGTGTCTGCAGACC\nTGCCGAACTGTGGCGGCCTGCAATCTCCCCATAGTCCGGGGCCCCTGCCGAGCCTTCATC\nCAGCTCTGGGCATTTGATGCTGTCAAGGGGAAGTGCGTCCTCTTCCCCTACGGGGGCTGC\nCAGGGCAACGGGAACAAGTTCTACTCAGAGAAGGAGTGCAGAGAGTACTGCGGTGTCCCT\nGGTGATGGTGATGAGGAGCTGCTGCGCTTCTCCAACTGA"}, "pfams": {"pfam": [{"identifier": "PF00061", "name": "Lipocalin"}, {"identifier": "PF00014", "name": "Kunitz_BPTI"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "endopeptidase inhibitor activity"}, {"category": "function", "description": "serine-type endopeptidase inhibitor activity"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "transporter activity"}, {"category": "function", "description": "enzyme regulator activity"}, {"category": "function", "description": "enzyme inhibitor activity"}, {"category": "function", "description": "protease inhibitor activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}, {"category": "process", "description": "transport"}]}}}]}, "enzymes": {"enzyme": [{"@position": "1", "id": "BE0002793", "name": "Cytochrome P450 2C9", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Zhou Q, Matsumoto S, Ding LR, Fischer NE, Inaba T: The comparative interaction of human and bovine serum albumins with CYP2C9 in human liver microsomes. Life Sci. 2004 Sep 17;75(18):2145-55. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15325841[uid]", "known-action": "unknown", "polypeptide": {"@id": "P11712", "@source": "Swiss-Prot", "name": "Cytochrome P450 2C9", "general-function": "Involved in monooxygenase activity", "specific-function": "Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S- warfarin, diclofenac, phenytoin, tolbutamide and losartan", "gene-name": "CYP2C9", "locus": "10q24", "cellular-location": "Endoplasmic reticulum", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.99", "molecular-weight": "55629.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2623"}, {"resource": "GenAtlas", "identifier": "CYP2C9"}, {"resource": "GenBank Gene Database", "identifier": "AY341248"}, {"resource": "UniProtKB", "identifier": "P11712"}, {"resource": "UniProt Accession", "identifier": "CP2C9_HUMAN"}]}, "synonyms": {"synonym": ["(R)-limonene 6-monooxygenase", "(S)- limonene 7-monooxygenase", "(S)-limonene 6-monooxygenase", "CYPIIC9", "EC 1.14.13.48", "EC 1.14.13.49", "EC 1.14.13.80", "P-450MP", "P450 MP-4/MP-8", "P450 PB-1", "S- mephenytoin 4-hydroxylase"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytochrome P450 2C9\nMDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV\nYGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW\nKEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS\nIIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM\nKSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE\nTTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID\nLLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK\nKSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP\nPFYQLCFIPV"}, "gene-sequence": {"@format": "FASTA", "#text": ">1473 bp\nATGGATTCTCTTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTTCACTCTGG\nAGACAGAGCTCTGGGAGAGGAAAACTCCCTCCTGGCCCCACTCCTCTCCCAGTGATTGGA\nAATATCCTACAGATAGGTATTAAGGACATCAGCAAATCCTTAACCAATCTCTCAAAGGTC\nTATGGCCCTGTGTTCACTCTGTATTTTGGCCTGAAACCCATAGTGGTGCTGCATGGATAT\nGAAGCAGTGAAGGAAGCCCTGATTGATCTTGGAGAGGAGTTTTCTGGAAGAGGCATTTTC\nCCACTGGCTGAAAGAGCTAACAGAGGATTTGGAATTGTTTTCAGCAATGGAAAGAAATGG\nAAGGAGATCCGGCGTTTCTCCCTCATGACGCTGCGGAATTTTGGGATGGGGAAGAGGAGC\nATTGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAAG\nGCCTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC\nATTATTTTCCATAAACGTTTTGATTATAAAGATCAGCAATTTCTTAACTTAATGGAAAAG\nTTGAATGAAAACATCAAGATTTTGAGCAGCCCCTGGATCCAGATCTGCAATAATTTTTCT\nCCTATCATTGATTACTTCCCGGGAACTCACAACAAATTACTTAAAAACGTTGCTTTTATG\nAAAAGTTATATTTTGGAAAAAGTAAAAGAACACCAAGAATCAATGGACATGAACAACCCT\nCAGGACTTTATTGATTGCTTCCTGATGAAAATGGAGAAGGAAAAGCACAACCAACCATCT\nGAATTTACTATTGAAAGCTTGGAAAACACTGCAGTTGACTTGTTTGGAGCTGGGACAGAG\nACGACAAGCACAACCCTGAGATATGCTCTCCTTCTCCTGCTGAAGCACCCAGAGGTCACA\nGCTAAAGTCCAGGAAGAGATTGAACGTGTGATTGGCAGAAACCGGAGCCCCTGCATGCAA\nGACAGGAGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGAGATACATTGAC\nCTTCTCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACATTAAATTCAGAAACTATCTC\nATTCCCAAGGGCACAACCATATTAATTTCCCTGACTTCTGTGCTACATGACAACAAAGAA\nTTTCCCAACCCAGAGATGTTTGACCCTCATCACTTTCTGGATGAAGGTGGCAATTTTAAG\nAAAAGTAAATACTTCATGCCTTTCTCAGCAGGAAAACGGATTTGTGTGGGAGAAGCCCTG\nGCCGGCATGGAGCTGTTTTTATTCCTGACCTCCATTTTACAGAACTTTAACCTGAAATCT\nCTGGTTGACCCAAAGAACCTTGACACCACTCCAGTTGTCAATGGATTTGCCTCTGTGCCG\nCCCTTCTACCAGCTGTGCTTCATTCCTGTCTGA"}, "pfams": {"pfam": {"identifier": "PF00067", "name": "p450"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "iron ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "tetrapyrrole binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "heme binding"}, {"category": "function", "description": "monooxygenase activity"}, {"category": "function", "description": "oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "generation of precursor metabolites and energy"}, {"category": "process", "description": "electron transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}, {"@position": "2", "id": "BE0001075", "name": "Myeloperoxidase", "organism": "Human", "actions": {"action": "substrate"}, "references": "# Salavej P, Spalteholz H, Arnhold J: Modification of amino acid residues in human serum albumin by myeloperoxidase. Free Radic Biol Med. 2006 Feb 1;40(3):516-25. Epub 2005 Nov 9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16443167\n# Senthilmohan R, Kettle AJ: Bromination and chlorination reactions of myeloperoxidase at physiological concentrations of bromide and chloride. Arch Biochem Biophys. 2006 Jan 15;445(2):235-44. Epub 2005 Aug 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16125131", "known-action": "unknown", "polypeptide": {"@id": "P05164", "@source": "Swiss-Prot", "name": "Myeloperoxidase", "general-function": "Involved in peroxidase activity", "specific-function": "Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity", "gene-name": "MPO", "locus": "17q23.1", "cellular-location": "Lysosome", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.14", "molecular-weight": "83870.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:7218"}, {"resource": "GenAtlas", "identifier": "MPO"}, {"resource": "GeneCards", "identifier": "MPO"}, {"resource": "GenBank Gene Database", "identifier": "J02694"}, {"resource": "GenBank Protein Database", "identifier": "189040"}, {"resource": "UniProtKB", "identifier": "P05164"}, {"resource": "UniProt Accession", "identifier": "PERM_HUMAN"}]}, "synonyms": {"synonym": ["EC 1.11.1.7", "MPO", "Myeloperoxidase precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Myeloperoxidase precursor\nMGVPFFSSLRCMVDLGPCWAGGLTAEMKLLLALAGLLAILATPQPSEGAAPAVLGEVDTS\nLVLSSMEEAKQLVDKAYKERRESIKQRLRSGSASPMELLSYFKQPVAATRTAVRAADYLH\nVALDLLERKLRSLWRRPFNVTDVLTPAQLNVLSKSSGCAYQDVGVTCPEQDKYRTITGMC\nNNRRSPTLGASNRAFVRWLPAEYEDGFSLPYGWTPGVKRNGFPVALARAVSNEIVRFPTD\nQLTPDQERSLMFMQWGQLLDHDLDFTPEPAARASFVTGVNCETSCVQQPPCFPLKIPPND\nPRIKNQADCIPFFRSCPACPGSNITIRNQINALTSFVDASMVYGSEEPLARNLRNMSNQL\nGLLAVNQRFQDNGRALLPFDNLHDDPCLLTNRSARIPCFLAGDTRSSEMPELTSMHTLLL\nREHNRLATELKSLNPRWDGERLYQEARKIVGAMVQIITYRDYLPLVLGPTAMRKYLPTYR\nSYNDSVDPRIANVFTNAFRYGHTLIQPFMFRLDNRYQPMEPNPRVPLSRVFFASWRVVLE\nGGIDPILRGLMATPAKLNRQNQIAVDEIRERLFEQVMRIGLDLPALNMQRSRDHGLPGYN\nAWRRFCGLPQPETVGQLGTVLRNLKLARKLMEQYGTPNNIDIWMGGVSEPLKRKGRVGPL\nLACIIGTQFRKLRDGDRFWWENEGVFSMQQRQALAQISLPRIICDNTGITTVSKNNIFMS\nNSYPRDFVNCSTLPALNLASWREAS"}, "gene-sequence": {"@format": "FASTA", "#text": ">2238 bp\nATGGGGGTTCCCTTCTTCTCTTCTCTCAGATGCATGGTGGACTTAGGACCTTGCTGGGCT\nGGGGGTCTCACTGCAGAGATGAAGCTGCTTCTGGCCCTAGCAGGGCTCCTGGCCATTCTG\nGCCACGCCCCAGCCCTCTGAAGGTGCTGCTCCAGCTGTCCTGGGGGAGGTGGACACCTCG\nTTGGTGCTGAGCTCCATGGAGGAGGCCAAGCAGCTGGTGGACAAGGCCTACAAGGAGCGG\nCGGGAAAGCATCAAGCAGCGGCTTCGCAGCGGCTCAGCCAGCCCCATGGAACTCCTATCC\nTACTTCAAGCAGCCGGTGGCAGCCACCAGGACGGCGGTGAGGGCCGCTGACTACCTGCAC\nGTGGCTCTAGACCTGCTGGAGAGGAAGCTGCGGTCCCTGTGGCGAAGGCCATTCAATGTC\nACTGATGTGCTGACGCCCGCCCAGCTGAATGTGTTGTCCAAGTCAAGCGGCTGCGCCTAC\nCAGGACGTGGGGGTGACTTGCCCGGAGCAGGACAAATACCGCACCATCACCGGGATGTGC\nAACAACAGACGCAGCCCCACGCTGGGGGCCTCCAACCGTGCCTTTGTGCGCTGGCTGCCG\nGCGGAGTATGAGGACGGCTTCTCTCTTCCCTACGGCTGGACGCCCGGGGTCAAGCGCAAC\nGGCTTCCCGGTGGCTCTGGCTCGCGCGGTCTCCAACGAGATCGTGCGCTTCCCCACTGAT\nCAGCTGACTCCGGACCAGGAGCGCTCACTCATGTTCATGCAATGGGGCCAGCTGTTGGAC\nCACGACCTCGACTTCACCCCTGAGCCGGCCGCCCGGGCCTCCTTCGTCACTGGCGTCAAC\nTGCGAGACCAGCTGCGTTCAGCAGCCGCCCTGCTTCCCGCTCAAGATCCCGCCCAATGAC\nCCCCGCATCAAGAACCAAGCCGACTGCATCCCGTTCTTCCGCTCCTGCCCGGCTTGCCCC\nGGGAGCAACATCACCATCCGCAACCAGATCAACGCGCTCACTTCCTTCGTGGACGCCAGC\nATGGTGTACGGCAGCGAGGAGCCCCTGGCCAGGAACCTGCGCAACATGTCCAACCAGCTG\nGGGCTGCTGGCCGTCAACCAGCGCTTCCAAGACAACGGCCGGGCCCTGCTGCCCTTTGAC\nAACCTGCACGATGACCCCTGTCTCCTCACCAACCGCTCAGCGCGCATCCCCTGCTTCCTG\nGCAGGGGACACCCGTTCCAGTGAGATGCCCGAGCTCACCTCCATGCACACCCTCTTACTT\nCGGGAGCACAACCGGCTGGCCACAGAGCTCAAGAGCCTGAACCCTAGGTGGGATGGGGAG\nAGGCTCTACCAGGAAGCCCGGAAGATCGTGGGGGCCATGGTCCAGATCATCACTTACCGG\nGACTACCTGCCCCTGGTGCTGGGGCCAACGGCCATGAGGAAGTACCTGCCCACGTACCGT\nTCCTACAATGACTCAGTGGACCCACGCATCGCCAACGTCTTCACCAATGCCTTCCGCTAC\nGGCCACACCCTCATCCAACCCTTCATGTTCCGCCTGGACAATCGGTACCAGCCCATGGAA\nCCCAACCCCCGTGTCCCCCTCAGCAGGGTCTTTTTTGCCTCCTGGAGGGTCGTGCTGGAA\nGGTGGCATTGACCCCATCCTCCGGGGCCTCATGGCCACCCCTGCCAAGCTGAATCGTCAG\nAACCAAATTGCAGTGGATGAGATCCGGGAGCGATTGTTTGAGCAGGTCATGAGGATTGGG\nCTGGACCTGCCTGCTCTGAACATGCAGCGCAGCAGGGACCACGGCCTCCCAGGATACAAT\nGCCTGGAGGCGCTTCTGTGGGCTCCCGCAGCCTGAAACTGTGGGCCAGCTGGGCACGGTG\nCTGAGGAACCTGAAATTGGCGAGGAAACTGATGGAGCAGTATGGCACGCCCAACAACATC\nGACATCTGGATGGGCGGCGTGTCCGAGCCTCTGAAGCGCAAAGGCCGCGTGGGCCCACTC\nCTCGCCTGCATCATCGGTACCCAGTTCAGGAAGCTCCGGGATGGTGATCGGTTTTGGTGG\nGAGAACGAGGGTGTGTTCAGCATGCAGCAGCGACAGGCCCTGGCCCAGATCTCATTGCCC\nCGGATCATCTGCGACAACACAGGCATCACCACCGTGTCTAAGAACAACATCTTCATGTCC\nAACTCATATCCCCGGGACTTTGTCAACTGCAGTACACTTCCTGCATTGAACCTGGCTTCC\nTGGAGGGAAGCCTCCTAG"}, "pfams": {"pfam": {"identifier": "PF03098", "name": "An_peroxidase"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "antioxidant activity"}, {"category": "function", "description": "peroxidase activity"}, {"category": "process", "description": "cellular metabolism"}, {"category": "process", "description": "oxygen and reactive oxygen species metabolism"}, {"category": "process", "description": "response to oxidative stress"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}, {"@position": "3", "id": "BE0003538", "name": "UDP-glucuronosyltransferase 1-9", "organism": "Human", "actions": {"action": "inducer"}, "references": "# Rowland A, Knights KM, Mackenzie PI, Miners JO: The \"albumin effect\" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos. 2008 Jun;36(6):1056-62. Epub 2008 Mar 24. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18362158", "known-action": "unknown", "polypeptide": {"@id": "O60656", "@source": "Swiss-Prot", "name": "UDP-glucuronosyltransferase 1-9", "general-function": "Carbohydrate transport and metabolism", "specific-function": "UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols", "gene-name": "UGT1A9", "locus": "2q37", "cellular-location": "Microsome. Endoplasmic reticulum membrane", "transmembrane-regions": "488-504", "signal-regions": null, "theoretical-pi": "7.96", "molecular-weight": "59940.5", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "GNC:12541"}, {"resource": "GeneCards", "identifier": "UGT1A9"}, {"resource": "GenBank Gene Database", "identifier": "S55985"}, {"resource": "GenBank Protein Database", "identifier": "7690346"}, {"resource": "UniProtKB", "identifier": "O60656"}, {"resource": "UniProt Accession", "identifier": "UD19_HUMAN"}]}, "synonyms": {"synonym": ["lugP4", "UDP-glucuronosyltransferase 1A9", "UDPGT", "UGT-1I", "UGT1-9", "UGT1.9", "UGT1*9", "UGT1I"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">UDP-glucuronosyltransferase 1-9\nMACTGWTSPLPLCVCLLLTCGFAEAGKLLVVPMDGSHWFTMRSVVEKLILRGHEVVVVMP\nEVSWQLGRSLNCTVKTYSTSYTLEDLDREFKAFAHAQWKAQVRSIYSLLMGSYNDIFDLF\nFSNCRSLFKDKKLVEYLKESSFDAVFLDPFDNCGLIVAKYFSLPSVVFARGILCHYLEEG\nAQCPAPLSYVPRILLGFSDAMTFKERVRNHIMHLEEHLLCHRFFKNALEIASEILQTPVT\nEYDLYSHTSIWLLRTDFVLDYPKPVMPNMIFIGGINCHQGKPLPMEFEAYINASGEHGIV\nVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGH\nPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTSEDL\nENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDLTW\nYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH"}, "gene-sequence": {"@format": "FASTA", "#text": ">1593 bp\nATGGCTTGCACAGGGTGGACCAGCCCCCTTCCTCTATGTGTGTGTCTGCTGCTGACCTGT\nGGCTTTGCCGAGGCAGGGAAGCTAGTGGTAGTGCCCATGGATGGGAGCCACTGGTTCACC\nATGAGGTCGGTGGTGGAGAAACTCATTCTCAGGGGGCATGAGGTGGTTGTAGTCAGTGCC\nAGAGGTGAGTTGGCAACTGGGAAGATCAATGAATTGCACAGTGAAGACTTATTCAACTTC\nATATACCTGGAGGATCTGGACCGGGAGTTCAAGGCTTTTGCCCATGCTCAATGGAAAGCA\nCAAGTACGAAGTATATATTCTCTATTAATGGGTTCATACAATGACATTTTTGACTTATTT\nTTTTCAAATTGCAGGAGTTTGTTTAAAGACAAAAAATTAGTAGAATACTTAAAGGAGAGT\nTCTTTTGATGCAGTGTTTCTCGATCCTTTTGATAACTGTGGCTTAATTGTTGCCAAATAT\nTTCTCCCTCCCCTCCGTGGTCTTCGCCAGGGGAATACTTTGCCACTATCTTGAAGAAGGT\nGCACAGTGCCCTGCTCCTCTTTCCTATGTCCCCAGAATTCTCTTAGGGTTCTCAGATGAC\nATGACTTTCAAGGAGAGAGTACGGAACCACATCATGCACTTGGAGGAACATTTATTATGC\nCACCGTTTTTTCAAAAATGCCCTAGAAATAGCCTCTGAAATTCTCCAAACACCTGTTACG\nGAGTATGATCTCTACAGCCACACATCAATTTGGTTGTTGCGAACGGACTTTGTTTTGGAC\nTATCCCAAACCCGTGATGCCCAACATGATCTTCATTGGTGGTATCAACTGCCATGAGAGG\nAAAGCGTTGCCTATGGAATTTGAAGCCTACATTAATGCTTCTGGAGAACATGGAATTGTG\nGGTTTCTCTTTGGGATCAATGGTCTCAGAAATTCCAGAGAAGAAAGCTATGGCAATTGCT\nGATGCTTTGGGCAAAATCCCTCAGACAGTCCTGTGGCGGTACACTGGAACCCGACCATGC\nAATCTTGCGAACAACACGATACTTGTTAAGTGGCTACCCCAAAACGATCTGCTTGGTCAC\nCCGATGACCAGTGCCTTTATCACCCATGCTGGTTCCCATGGTGTTTATGAAAGCATATGC\nAATGGCGTTCCCATGGTGATGATGCCCTTGTTTGGTGATCAGATGGACAATGCAAAGCGC\nATGGAGACTAAGGGAGCTGGAGTGACCATGAATGTTCTGGAAATGACTTCTGAAGAATTA\nGAAAATGCTCTAAAAGCAGTCATCAATGACAAAAGTTACAAGGAGAACATCATGCGCCTC\nTCCAGCCTTCACAAGGACCGCCCGGTGGAGCCGCTGGACCTGGCCGTGTTCTGGGTGGAG\nTTTGTTATGAGGCACAAGGGCGCGACACACCTGCGCCCCGCAGCCCACGACCTCACCTGG\nTACCAGTACCATTCCTTGGACGTGATTGGTTTCCTCTTGGCCGCCGTGCTGACAGTGGCC\nTTCATCACCTGTAAATGTTGTGCTTATGGCTACCGGAAATGCTTGGGGAAAAAAGGGCGA\nGTTAAGAAAGCCCACAAATCCAAGACCCATTGA"}, "pfams": {"pfam": {"identifier": "PF00201", "name": "UDPGT"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "transferase activity"}, {"category": "function", "description": "transferase activity, transferring glycosyl groups"}, {"category": "function", "description": "transferase activity, transferring hexosyl groups"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}]}, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-09-13", "drugbank-id": [{"@primary": "true", "#text": "DB00063"}, "BIOD00063", "BTD00063"], "name": "Eptifibatide", "description": "Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation.", "cas-number": "188627-80-7", "groups": {"group": ["approved", "investigational"]}, "general-references": "# Nguyen CM, Harrington RA: Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention. Am J Cardiovasc Drugs. 2003;3(6):423-36. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/ 14728062", "synthesis-reference": "Guojie Ho, Antoinette Paone, Luciano Forni, Catherine De Tollenaere, Brice Bonnet, Christine Devijver, \"Processes for preparing eptifibatide.\" U.S. Patent US20060036071, issued February 16, 2006.", "indication": "For treatment of myocardial infarction and acute coronary syndrome.", "pharmacodynamics": "Eptifibatide is an anti-coagulant that selectively blocks the platelet glycoprotein IIb/IIIa receptor. Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarus barbouri). It belongs to the class of the so called arginin-glycin-aspartat-mimetics and reversibly binds to platelets.", "mechanism-of-action": "Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. Inhibition of platelet aggregation occurs in a dose- and concentration-dependent manner.", "toxicity": "Eptifibatide was not lethal to rats, rabbits, or monkeys when administered by continuous intravenous infusion for 90 minutes at a total dose of 45 mg/kg (about 2 to 5 times the recommended maximum daily human dose on a body surface area basis)", "metabolism": "No major metabolites have been detected in human plasma. Deamidated eptifibatide and other, more polar metabolites have been detected in urine.", "absorption": null, "half-life": "Approximately 2.5 hours", "protein-binding": "Approximately 25%", "route-of-elimination": null, "volume-of-distribution": null, "clearance": "* 55 mL/kg/h [patients with coronary artery disease]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Integrelin"}, {"@language": "", "@coder": "", "#text": "Intrifiban"}]}, "products": {"product": [{"name": "Eptifibatide Injection", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02410109", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "0.75 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Eptifibatide Injection", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02410125", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "2 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Eptifibatide Injection", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02422840", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "0.75 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Eptifibatide Injection", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02422859", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "2 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Eptifibatide Injection", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02405083", "started-marketing-on": "2013-04-29", "ended-marketing-on": null, "dosage-form": "solution", "strength": "0.75 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Eptifibatide Injection", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02367858", "started-marketing-on": "2013-04-29", "ended-marketing-on": null, "dosage-form": "solution", "strength": "2 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Integrilin", "ndc-id": "0085-1136_09400257-b29a-4eb6-972b-25b966979db5", "ndc-product-code": "0085-1136", "dpd-id": null, "started-marketing-on": "2015-01-23", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": ".75 mg/mL", "route": "intravenous", "fda-application-number": "NDA020718", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Integrilin", "ndc-id": "0085-1136_0d4f321d-46bb-4789-a1a3-a6fbc08c61fa", "ndc-product-code": "0085-1136", "dpd-id": null, "started-marketing-on": "1998-05-18", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": ".75 mg/mL", "route": "intravenous", "fda-application-number": "NDA020718", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Integrilin", "ndc-id": "0085-1136_6b08d39d-179d-4099-8af4-efe0caefd812", "ndc-product-code": "0085-1136", "dpd-id": null, "started-marketing-on": "2014-08-18", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": ".75 mg/mL", "route": "intravenous", "fda-application-number": "NDA020718", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Integrilin", "ndc-id": "0085-1177_09400257-b29a-4eb6-972b-25b966979db5", "ndc-product-code": "0085-1177", "dpd-id": null, "started-marketing-on": "2015-01-23", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "2 mg/mL", "route": "intravenous", "fda-application-number": "NDA020718", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Integrilin", "ndc-id": "0085-1177_0d4f321d-46bb-4789-a1a3-a6fbc08c61fa", "ndc-product-code": "0085-1177", "dpd-id": null, "started-marketing-on": "1998-05-18", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "2 mg/mL", "route": "intravenous", "fda-application-number": "NDA020718", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Integrilin", "ndc-id": "0085-1177_6b08d39d-179d-4099-8af4-efe0caefd812", "ndc-product-code": "0085-1177", "dpd-id": null, "started-marketing-on": "2015-01-23", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "2 mg/mL", "route": "intravenous", "fda-application-number": "NDA020718", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Integrilin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02240351", "started-marketing-on": "1999-06-23", "ended-marketing-on": null, "dosage-form": "solution", "strength": "0.75 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Integrilin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02240352", "started-marketing-on": "1999-06-23", "ended-marketing-on": null, "dosage-form": "solution", "strength": "2 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Integrilin", "ingredients": "Eptifibatide"}, {"name": "Integrilin", "ingredients": "Eptifibatide"}, {"name": "Integrilin", "ingredients": "Eptifibatide"}, {"name": "Integrilin", "ingredients": "Eptifibatide"}, {"name": "Integrilin", "ingredients": "Eptifibatide"}, {"name": "Integrilin", "ingredients": "Eptifibatide"}, {"name": "Integrilin", "ingredients": "Eptifibatide"}, {"name": "Integrilin", "ingredients": "Eptifibatide"}, {"name": "Eptifibatide Injection", "ingredients": "Eptifibatide"}, {"name": "Eptifibatide Injection", "ingredients": "Eptifibatide"}, {"name": "Eptifibatide Injection", "ingredients": "Eptifibatide"}, {"name": "Eptifibatide Injection", "ingredients": "Eptifibatide"}, {"name": "Eptifibatide Injection", "ingredients": "Eptifibatide"}, {"name": "Eptifibatide Injection", "ingredients": "Eptifibatide"}]}, "packagers": {"packager": [{"name": "Assia Chemical Industries Ltd.", "url": null}, {"name": "Patheon Inc.", "url": "http://www.patheon.com"}, {"name": "Schering Corp.", "url": "http://www.schering.de"}, {"name": "Schering-Plough Inc.", "url": "http://www.schering-plough.ca"}, {"name": "Teva Pharmaceutical Industries Ltd.", "url": "http://www.tevapharm.com"}]}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Schering corp"}}, "prices": {"price": [{"description": "Integrilin 75 mg/100 ml vial", "cost": {"@currency": "USD", "#text": "3.88"}, "unit": "ml"}, {"description": "Integrilin 200 mg/100 ml vial", "cost": {"@currency": "USD", "#text": "10.74"}, "unit": "ml"}, {"description": "Integrilin 20 mg/10 ml vial", "cost": {"@currency": "USD", "#text": "12.41"}, "unit": "ml"}]}, "categories": {"category": {"category": "Platelet Aggregation Inhibitors", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, solution", "route": "intravenous", "strength": ".75 mg/mL"}, {"form": "Injection, solution", "route": "intravenous", "strength": "2 mg/mL"}, {"form": "Solution", "route": "intravenous", "strength": "0.75 mg"}, {"form": "Solution", "route": "intravenous", "strength": "2 mg"}]}, "atc-codes": {"atc-code": {"@code": "B01AC16", "level": [{"@code": "B", "#text": "BLOOD AND BLOOD FORMING ORGANS"}, {"@code": "B01", "#text": "ANTITHROMBOTIC AGENTS"}, {"@code": "B01A", "#text": "ANTITHROMBOTIC AGENTS"}, {"@code": "B01AC", "#text": "Platelet aggregation inhibitors excl. heparin"}]}}, "ahfs-codes": {"ahfs-code": "20:12.18"}, "patents": {"patent": [{"number": "2133205", "country": "Canada", "approved": "2007-04-17", "expires": "2013-04-27"}, {"number": "5686570", "country": "United States", "approved": "1994-11-11", "expires": "2014-11-11"}, {"number": "5807825", "country": "United States", "approved": "1995-09-15", "expires": "2015-09-15"}]}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00054", "name": "Abciximab", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01418", "name": "Acenocoumarol", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00945", "name": "Acetylsalicylic acid", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result."}, {"drugbank-id": "DB00009", "name": "Alteplase", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00029", "name": "Anistreplase", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06605", "name": "Apixaban", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased."}, {"drugbank-id": "DB04272", "name": "Citric Acid", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06695", "name": "Dabigatran etexilate", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran etexilate. This mechanism applies specifically to clopidogrel."}, {"drugbank-id": "DB06779", "name": "Dalteparin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01254", "name": "Dasatinib", "description": "May enhance the anticoagulant effect of Agents with Antiplatelet Properties."}, {"drugbank-id": "DB03619", "name": "Deoxycholic Acid", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased."}, {"drugbank-id": "DB00266", "name": "Dicoumarol", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00974", "name": "Edetic Acid", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01225", "name": "Enoxaparin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB08794", "name": "Ethyl biscoumacetate", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00569", "name": "Fondaparinux sodium", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01296", "name": "Glucosamine", "description": "May enhance the antiplatelet effect of Agents with Antiplatelet Properties."}, {"drugbank-id": "DB01109", "name": "Heparin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00078", "name": "Ibritumomab", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB09053", "name": "Ibrutinib", "description": "May enhance the adverse/toxic effect of Agents with Antiplatelet Properties."}, {"drugbank-id": "DB08935", "name": "Obinutuzumab", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased."}, {"drugbank-id": "DB00686", "name": "Pentosan Polysulfate", "description": "May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents."}, {"drugbank-id": "DB00806", "name": "Pentoxifylline", "description": "May enhance the antiplatelet effect of Agents with Antiplatelet Properties."}, {"drugbank-id": "DB00498", "name": "Phenindione", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00946", "name": "Phenprocoumon", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00015", "name": "Reteplase", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01207", "name": "Ridogrel", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06228", "name": "Rivaroxaban", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban."}, {"drugbank-id": "DB01398", "name": "Salicylate-sodium", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result."}, {"drugbank-id": "DB00086", "name": "Streptokinase", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06271", "name": "Sulodexide", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00031", "name": "Tenecteplase", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00932", "name": "Tipranavir", "description": "May enhance the antiplatelet effect of Agents with Antiplatelet Properties."}, {"drugbank-id": "DB00374", "name": "Treprostinil", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00013", "name": "Urokinase", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase."}, {"drugbank-id": "DB00163", "name": "Vitamin E", "description": "May enhance the antiplatelet effect of Agents with Antiplatelet Properties."}, {"drugbank-id": "DB00682", "name": "Warfarin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants."}]}, "sequences": null, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-2.3", "source": null}, {"kind": "Molecular Weight", "value": "831.9620", "source": null}, {"kind": "Molecular Formula", "value": "C35H49N11O9S2", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "11891"}, {"resource": "National Drug Code Directory", "identifier": "0085-1177-01"}, {"resource": "PharmGKB", "identifier": "PA449483"}, {"resource": "Wikipedia", "identifier": "Eptifibatide"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/eptifibatide.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/eptifibatide.html"}]}, "pathways": {"pathway": {"smpdb-id": "SMP00266", "name": "Eptifibatide Action Pathway", "drugs": {"drug": {"drugbank-id": "DB00063", "name": "Eptifibatide"}}, "enzymes": {"uniprot-id": ["P08514", "P05106"]}}}, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0001155", "name": "Integrin beta-3", "organism": "Human", "actions": null, "references": "# Amoroso G, van Boven AJ, van Veldhuisen DJ, Tio RA, Balje-Volkers CP, Petronio AS, van Oeveren W: Eptifibatide and abciximab exhibit equivalent antiplatelet efficacy in an experimental model of stenting in both healthy volunteers and patients with coronary artery disease. J Cardiovasc Pharmacol. 2001 Oct;38(4):633-41. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11588534\n# Schror K, Weber AA: Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis. 2003 Apr;15(2):71-80. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14618072\n# Fischer TH, Thatte HS, Nichols TC, Bender-Neal DE, Bellinger AD, Vournakis JN: Synergistic platelet integrin signaling and factor XII activation in poly-N-acetyl glucosamine fiber-mediated hemostasis. Biomaterials. 2005 Sep;26(27):5433-43. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15860200\n# Weber AA, Jacobs C, Meila D, Weber S, Zotz RB, Scharf RE, Kelm M, Strauer BE, Schror K: No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein IIb/IIIa inhibitors. Pharmacogenetics. 2002 Oct;12(7):581-3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12360110\n# Schwarz M, Katagiri Y, Kotani M, Bassler N, Loeffler C, Bode C, Peter K: Reversibility versus persistence of GPIIb/IIIa blocker-induced conformational change of GPIIb/IIIa (alphaIIbbeta3, CD41/CD61). J Pharmacol Exp Ther. 2004 Mar;308(3):1002-11. Epub 2003 Nov 14. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14617694\n# Auer J, Berent R, Lassnig E, Weber T, Maurer E, Eber B: [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease] Herz. 2003 Aug;28(5):393-403. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12928738\n# Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10592235", "known-action": "yes", "polypeptide": {"@id": "P05106", "@source": "Swiss-Prot", "name": "Integrin beta-3", "general-function": "Involved in cell adhesion and blood clotting", "specific-function": "Integrin alpha-V/beta-3 is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha- IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions", "gene-name": "ITGB3", "locus": "17q21.32", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "719-741", "signal-regions": null, "theoretical-pi": "4.85", "molecular-weight": "87058.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6156"}, {"resource": "GenAtlas", "identifier": "ITGB3"}, {"resource": "GeneCards", "identifier": "ITGB3"}, {"resource": "GenBank Gene Database", "identifier": "J02703"}, {"resource": "GenBank Protein Database", "identifier": "306786"}, {"resource": "UniProtKB", "identifier": "P05106"}, {"resource": "UniProt Accession", "identifier": "ITB3_HUMAN"}]}, "synonyms": {"synonym": ["CD61 antigen", "GPIIIa", "Integrin beta-3 precursor", "Platelet membrane glycoprotein IIIa"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Integrin beta-3 precursor\nMRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLG\nSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRP\nDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFG\nAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSR\nNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCH\nVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLS\nMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDT\nVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGT\nFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFG\nKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLL\nCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRY\nCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDIL\nVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTF\nTNITYRGT"}, "gene-sequence": {"@format": "FASTA", "#text": ">2367 bp\nATGCGAGCGCGGCCGCGGCCCCGGCCGCTCTGGGTGACTGTGCTGGCGCTGGGGGCGCTG\nGCGGGCGTTGGCGTAGGAGGGCCCAACATCTGTACCACGCGAGGTGTGAGCTCCTGCCAG\nCAGTGCCTGGCTGTGAGCCCCATGTGTGCCTGGTGCTCTGATGAGGCCCTGCCTCTGGGC\nTCACCTCGCTGTGACCTGAAGGAGAATCTGCTGAAGGATAACTGTGCCCCAGAATCCATC\nGAGTTCCCAGTGAGTGAGGCCCGAGTACTAGAGGACAGGCCCCTCAGCGACAAGGGCTCT\nGGAGACAGCTCCCAGGTCACTCAAGTCAGTCCCCAGAGGATTGCACTCCGGCTCCGGCCA\nGATGATTCGAAGAATTTCTCCATCCAAGTGCGGCAGGTGGAGGATTACCCTGTGGACATC\nTACTACTTGATGGACCTGTCTTACTCCATGAAGGATGATCTGTGGAGCATCCAGAACCTG\nGGTACCAAGCTGGCCACCCAGATGCGAAAGCTCACCAGTAACCTGCGGATTGGCTTCGGG\nGCATTTGTGGACAAGCCTGTGTCACCATACATGTATATCTCCCCACCAGAGGCCCTCGAA\nAACCCCTGCTATGATATGAAGACCACCTGCTTGCCCATGTTTGGCTACAAACACGTGCTG\nACGCTAACTGACCAGGTGACCCGCTTCAATGAGGAAGTGAAGAAGCAGAGTGTGTCACGG\nAACCGAGATGCCCCAGAGGGTGGCTTTGATGCCATCATGCAGGCTACAGTCTGTGATGAA\nAAGATTGGCTGGAGGAATGATGCATCCCACTTGCTGGTGTTTACCACTGATGCCAAGACT\nCATATAGCATTGGACGGAAGGCTGGCAGGCATTGTCCAGCCTAATGACGGGCAGTGTCAT\nGTTGGTAGTGACAATCATTACTCTGCCTCCACTACCATGGATTATCCCTCTTTGGGGCTG\nATGACTGAGAAGCTATCCCAGAAAAACATCAATTTGATCTTTGCAGTGACTGAAAATGTA\nGTCAATCTCTATCAGAACTATAGTGAGCTCATCCCAGGGACCACAGTTGGGGTTCTGTCC\nATGGATTCCAGCAATGTCCTCCAGCTCATTGTTGATGCTTATGGGAAAATCCGTTCTAAA\nGTCGAGCTGGAAGTGCGTGACCTCCCTGAAGAGTTGTCTCTATCCTTCAATGCCACCTGC\nCTCAACAATGAGGTCATCCCTGGCCTCAAGTCTTGTATGGGACTCAAGATTGGAGACACG\nGTGAGCTTCAGCATTGAGGCCAAGGTGCGAGGCTGTCCCCAGGAGAAGGAGAAGTCCTTT\nACCATAAAGCCCGTGGGCTTCAAGGACAGCCTGATCGTCCAGGTCACCTTTGATTGTGAC\nTGTGCCTGCCAGGCCCAAGCTGAACCTAATAGCCATCGCTGCAACAATGGCAATGGGACC\nTTTGAGTGTGGGGTATGCCGTTGTGGGCCTGGCTGGCTGGGATCCCAGTGTGAGTGCTCA\nGAGGAGGACTATCGCCCTTCCCAGCAGGACGAGTGCAGCCCCCGAGAGGGTCAGCCCGTC\nTGCAGCCAGCGGGGCGAGTGCCTCTGTGGTCAATGTGTCTGCCACAGCAGTGACTTTGGC\nAAGATCACGGGCAAGTACTGCGAGTGTGACGACTTCTCCTGTGTCCGCTACAAGGGGGAG\nATGTGCTCAGGCCATGGCCAGTGCAGCTGTGGGGACTGCCTGTGTGACTCCGACTGGACC\nGGCTACTACTGCAACTGTACCACGCGTACTGACACCTGCATGTCCAGCAATGGGCTGCTG\nTGCAGCGGCCGCGGCAAGTGTGAATGTGGCAGCTGTGTCTGTATCCAGCCGGGCTCCTAT\nGGGGACACCTGTGAGAAGTGCCCCACCTGCCCAGATGCCTGCACCTTTAAGAAAGAATGT\nGTGGAGTGTAAGAAGTTTGACCGGGAGCCCTACATGACCGAAAATACCTGCAACCGTTAC\nTGCCGTGACGAGATTGAGTCAGTGAAAGAGCTTAAGGACACTGGCAAGGATGCAGTGAAT\nTGTACCTATAAGAATGAGGATGACTGTGTCGTCAGATTCCAGTACTATGAAGATTCTAGT\nGGAAAGTCCATCCTGTATGTGGTAGAAGAGCCAGAGTGTCCCAAGGGCCCTGACATCCTG\nGTGGTCCTGCTCTCAGTGATGGGGGCCATTCTGCTCATTGGCCTTGCCGCCCTGCTCATC\nTGGAAACTCCTCATCACCATCCACGACCGAAAAGAATTCGCTAAATTTGAGGAAGAACGC\nGCCAGAGCAAAATGGGACACAGCCAACAACCCACTGTATAAAGAGGCCACGTCTACCTTC\nACCAATATCACGTACCGGGGCACTTAA"}, "pfams": {"pfam": [{"identifier": "PF07974", "name": "EGF_2"}, {"identifier": "PF00362", "name": "Integrin_beta"}, {"identifier": "PF08725", "name": "Integrin_b_cyt"}, {"identifier": "PF07965", "name": "Integrin_B_tail"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "protein complex"}, {"category": "component", "description": "receptor complex"}, {"category": "component", "description": "integrin complex"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell adhesion"}, {"category": "process", "description": "cell-substrate adhesion"}, {"category": "process", "description": "cell-matrix adhesion"}, {"category": "process", "description": "development"}]}}}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2011-09-03", "drugbank-id": [{"@primary": "true", "#text": "DB00064"}, "BIOD00089", "BTD00089"], "name": "Serum albumin iodonated", "description": "A diagnostic radiopharmaceutical containing iodinated I 131 albumin for intravenous imaging. Following intravenous injection, radioiodinated albumin human is uniformly distributed throughout the intravascular pool within 10 minutes; extravascular distribution takes place more slowly (2 days). Indicated for use in determinations of total blood and plasma volumes, cardiac output, cardiac and pulmonary blood volumes and circulation times", "cas-number": "9048-49-1", "groups": {"group": "approved"}, "general-references": null, "synthesis-reference": null, "indication": "For determination of total blood and plasma volumes", "pharmacodynamics": "Regulates the colloidal osmotic pressure of blood. It is used to increase the circulating plasma volume, thereby reducing hemoconcentrtion and blood viscosity. Also used as a transport protein that binds naturally occurring, therapeutic and toxic materials in circulation.", "mechanism-of-action": "Serum albumin acts as a high molecular weight, very soluble osmolyte", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": {"@language": "", "@coder": "", "#text": "Serum albumin precursor"}}, "products": {"product": {"name": "Volumex", "ndc-id": "50914-7720_4ae21854-e93b-4550-b544-1e0a093d0e47", "ndc-product-code": "50914-7720", "dpd-id": null, "started-marketing-on": "1993-08-01", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": ".025 mCi/mL", "route": "intravenous", "fda-application-number": "NDA017837", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}}, "international-brands": null, "mixtures": {"mixture": {"name": "Volumex", "ingredients": "Serum albumin iodonated"}}, "packagers": null, "manufacturers": {"manufacturer": [{"@generic": "false", "#text": "Iso tex diagnostics inc"}, {"@generic": "false", "#text": "Bayer pharmaceuticals corp"}, {"@generic": "false", "#text": "Mallinckrodt medical inc"}]}, "prices": null, "categories": {"category": {"category": "Diagnostic Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": {"form": "Injection, solution", "route": "intravenous", "strength": ".025 mCi/mL"}}, "atc-codes": null, "ahfs-codes": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": {"@format": "FASTA", "#text": "> Human Serum Albumin Sequence\nMKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF\nEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEP\nERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF\nFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQGLKCASLQKFGERAFKAWAV\nARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK\nECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVGSKDVCKNYAEAKDVFLGMFLYEYAR\nRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFE\nQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDCLSVF\nLNQLCVLHEKTPVSDRVTKCCTESLVNGRPCFSALEVDETYVPKEFNAETFTFHADICTL\nSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "62 \u00b0C", "source": "Flora, K. et al., Biophys J. 75:1084-1096 (1998)"}, {"kind": "Hydrophobicity", "value": "-0.395", "source": null}, {"kind": "Isoelectric Point", "value": "5.67", "source": null}, {"kind": "Molecular Weight", "value": "66472.2000", "source": null}, {"kind": "Molecular Formula", "value": "C2936H4624N786O889S41", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "National Drug Code Directory", "identifier": "50914-7720"}, {"resource": "GenBank", "identifier": "M12523"}, {"resource": "PharmGKB", "identifier": "PA164752827"}, {"resource": "UniProtKB", "identifier": "P02768"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0001119", "name": "Apolipoprotein E", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Wang L, Li CM, Rudolf M, Curcio CA, Peng D, Liu X, Zeng S: [Gene expression of apolipoprotein and lipids synthesis and secretion in RPE-J cells] Yan Ke Xue Bao. 2006 Dec;22(4):244-51. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17378158\n# Cano NJ, Saingra Y, Dupuy AM, Lorec-Penet AM, Portugal H, Lairon D, Cristol JP, Come A, Le Brun A, Atlan P, Leverve XM: Intradialytic parenteral nutrition: comparison of olive oil versus soybean oil-based lipid emulsions. Br J Nutr. 2006 Jan;95(1):152-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16441928", "known-action": "unknown", "polypeptide": {"@id": "P02649", "@source": "Swiss-Prot", "name": "Apolipoprotein E", "general-function": "Replication, recombination and repair", "specific-function": "Mediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues", "gene-name": "APOE", "locus": "19q13.2", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.42", "molecular-weight": "36155.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:613"}, {"resource": "GenAtlas", "identifier": "APOE"}, {"resource": "GeneCards", "identifier": "APOE"}, {"resource": "GenBank Gene Database", "identifier": "M12529"}, {"resource": "GenBank Protein Database", "identifier": "178849"}, {"resource": "UniProtKB", "identifier": "P02649"}, {"resource": "UniProt Accession", "identifier": "APOE_HUMAN"}]}, "synonyms": {"synonym": ["Apo-E", "Apolipoprotein E precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Apolipoprotein E precursor\nMKVLWAALLVTFLAGCQAKVEQAVETEPEPELRQQTEWQSGQRWELALGRFWDYLRWVQT\nLSEQVQEELLSSQVTQELRALMDETMKELKAYKSELEEQLTPVAEETRARLSKELQAAQA\nRLGADMEDVCGRLVQYRGEVQAMLGQSTEELRVRLASHLRKLRKRLLRDADDLQKRLAVY\nQAGAREGAERGLSAIRERLGPLVEQGRVRAATVGSLAGQPLQERAQAWGERLRARMEEMG\nSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEK\nVQAAVGTSAAPVPSDNH"}, "gene-sequence": {"@format": "FASTA", "#text": ">954 bp\nATGAAGGTTCTGTGGGCTGCGTTGCTGGTCACATTCCTGGCAGGATGCCAGGCCAAGGTG\nGAGCAAGCGGTGGAGACAGAGCCGGAGCCCGAGCTGCGCCAGCAGACCGAGTGGCAGAGC\nGGCCAGCGCTGGGAACTGGCACTGGGTCGCTTTTGGGATTACCTGCGCTGGGTGCAGACA\nCTGTCTGAGCAGGTGCAGGAGGAGCTGCTCAGCTCCCAAGTCACCCAAGAACTGAGGGCG\nCTGATGGACGAGACCATGAAGGAGTTGAAGGCCTACAAATCGGAACTGGAGGAACAACTG\nACCCCGGTAGCGGAGGAGACGCGGGCACGGCTGTCCAAGGAGCTGCAGACGGCGCAGGCC\nCGGCTGGGCGCGGACATGGAGGACGTGTGCGGCCGCCTGGTGCAGTACCGCGGCGAGGTG\nCAGGCCATGCTCGGCCAGAGCACCGAGGAGCTGCGGGTGCGCCTCGCCTCCCACCTGCGC\nAAGCTGCGTAAGCGGCTCCTCCGCGATCCCGATGACCTGCAGAAGCGCCTGGCAGTGTAC\nCAGGCCGGGGCCCGCGAGGGCGCCGAGCGCGGCCTCAGCGCCATCCGCGAGCGCCTGGGG\nCCCCTGGTGGAACAGGGCCGCGTGCGGGCCGCCACTGTGGGCTCCCTGGCCGGCCAGCCG\nCTACAGGAGCGGGCCCAGGCCTGGGGCGAGCGGCTGCGCGCGCGGATGGAGGAGATGGGC\nAGTCGGACCCGCGACCGCCTGGACGAGGTGAAGGAGCAGGTGGCGGAGGTGCGCGCCAAG\nCTGGAGGAGCAGGCCCAGCAGATACGCCTGCAGGCCGAGGCCTTCCAGGCCCGCCTCAAG\nAGCTGGTTCGAGCCCCTGGTGGAAGACATGCAGCGCCAGTGGGCCGGGCTGGTGGAGAAG\nGTGCAGGCTGCCGTGGGCACCAGCGCCGCCCCTGTGCCCAGCGACAATCACTGA"}, "pfams": {"pfam": {"identifier": "PF01442", "name": "Apolipoprotein"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "lipid binding"}, {"category": "function", "description": "binding"}, {"category": "process", "description": "lipid transport"}, {"category": "process", "description": "lipoprotein metabolism"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}]}}}, {"id": "BE0004795", "name": "Serum amyloid A-1 protein", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Danesh J, Muir J, Wong YK, Ward M, Gallimore JR, Pepys MB: Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J. 1999 Jul;20(13):954-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10361047\n# Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB: Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000 Jul 22;321(7255):199-204. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10903648\n# Grehan S, Uhlar CM, Sim RB, Herbert J, Whitehead AS: Expression of a biologically active recombinant mouse IL-1 receptor antagonist and its use in vivo to modulate aspects of the acute phase response. J Immunol. 1997 Jul 1;159(1):369-78. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9200475", "known-action": "unknown", "polypeptide": {"@id": "P0DJI8", "@source": "Swiss-Prot", "name": "Serum amyloid A-1 protein", "general-function": null, "specific-function": "Major acute phase reactant. Apolipoprotein of the HDL complex", "gene-name": "SAA1", "locus": "11p15.1", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.79", "molecular-weight": "13532.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:10513"}, {"resource": "GenAtlas", "identifier": "SAA1"}, {"resource": "GeneCards", "identifier": "SAA1"}, {"resource": "GenBank Gene Database", "identifier": "M10906"}, {"resource": "GenBank Protein Database", "identifier": "337748"}, {"resource": "UniProtKB", "identifier": "P0DJI8"}, {"resource": "UniProt Accession", "identifier": "SAA1_HUMAN"}]}, "synonyms": null, "amino-acid-sequence": {"@format": "FASTA"}, "gene-sequence": {"@format": "FASTA"}, "pfams": null, "go-classifiers": null}}, {"id": "BE0000932", "name": "Protein AMBP", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02760", "@source": "Swiss-Prot", "name": "Protein AMBP", "general-function": "Involved in transporter activity", "specific-function": "Inter-alpha-trypsin inhibitor, present in plasma and urine, inhibits trypsin, plasmin, and lysosomal granulocytic elastase", "gene-name": "AMBP", "locus": "9q32-q33", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.15", "molecular-weight": "39000.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:453"}, {"resource": "GenAtlas", "identifier": "AMBP"}, {"resource": "GeneCards", "identifier": "AMBP"}, {"resource": "GenBank Gene Database", "identifier": "X54816"}, {"resource": "GenBank Protein Database", "identifier": "825614"}, {"resource": "UniProtKB", "identifier": "P02760"}, {"resource": "UniProt Accession", "identifier": "AMBP_HUMAN"}]}, "synonyms": {"synonym": "AMBP protein precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">AMBP protein precursor [Contains: Alpha-1-microglobulin\nMRSLGALLLLLSACLAVSAGPVPTPPDNIQVQENFNISRIYGKWYNLAIGSTCPWLKKIM\nDRMTVSTLVLGEGATEAEISMTSTRWRKGVCEETSGAYEKTDTDGKFLYHKSKWNITMES\nYVVHTNYDEYAIFLTKKFSRHHGPTITAKLYGRAPQLRETLLQDFRVVAQGVGIPEDSIF\nTMADRGECVPGEQEPEPILIPRVRRAVLPQEEEGSGGGQLVTEVTKKEDSCQLGYSAGPC\nMGMTSRYFYNGTSMACETFQYGGCMGNGNNFVTEKECLQTCRTVAACNLPIVRGPCRAFI\nQLWAFDAVKGKCVLFPYGGCQGNGNKFYSEKECREYCGVPGDGDEELLRFSN"}, "gene-sequence": {"@format": "FASTA", "#text": ">1059 bp\nATGAGGAGCCTCGGGGCCCTGCTCTTGCTGCTGAGCGCCTGCCTGGCGGTGAGCGCTGGC\nCCTGTGCCAACGCCGCCCGACAACATCCAAGTGCAGGAAAACTTCAATATCTCTCGGATC\nTATGGGAAGTGGTACAACCTGGCCATCGGTTCCACCTGCCCCTGGCTGAAGAAGATCATG\nGACAGGATGACAGTGAGCACGCTGGTGCTGGGAGAGGGCGCTACAGAGGCGGAGATCAGC\nATGACCAGCACTCGTTGGCGGAAAGGTGTCTGTGAGGAGACGTCTGGAGCTTATGAGAAA\nACAGATACTGATGGGAAGTTTCTCTATCACAAATCCAAATGGAACATAACCATGGAGTCC\nTATGTGGTCCACACCAACTATGATGAGTATGCCATTTTCCTGACCAAGAAATTCAGCCGC\nCATCATGGACCCACCATTACTGCCAAGCTCTACGGGCGGGCGCCGCAGCTGAGGGAAACT\nCTCCTGCAGGACTTCAGAGTGGTTGCCCAGGGTGTGGGCATCCCTGAGGACTCCATCTTC\nACCATGGCTGACCGAGGTGAATGTGTCCCTGGGGAGCAGGAACCAGAGCCCATCTTAATC\nCCGAGAGTCCGGAGGGCTGTGCTACCCCAAGAAGAGGAAGGATCAGGGGGTGGGCAACTG\nGTAACTGAAGTCACCAAGAAAGAAGATTCCTGCCAGCTGGGCTACTCGGCCGGTCCCTGC\nATGGGAATGACCAGCAGGTATTTCTATAATGGTACATCCATGGCCTGTGAGACTTTCCAG\nTACGGCGGCTGCATGGGCAACGGTAACAACTTCGTCACAGAAAAGGAGTGTCTGCAGACC\nTGCCGAACTGTGGCGGCCTGCAATCTCCCCATAGTCCGGGGCCCCTGCCGAGCCTTCATC\nCAGCTCTGGGCATTTGATGCTGTCAAGGGGAAGTGCGTCCTCTTCCCCTACGGGGGCTGC\nCAGGGCAACGGGAACAAGTTCTACTCAGAGAAGGAGTGCAGAGAGTACTGCGGTGTCCCT\nGGTGATGGTGATGAGGAGCTGCTGCGCTTCTCCAACTGA"}, "pfams": {"pfam": [{"identifier": "PF00061", "name": "Lipocalin"}, {"identifier": "PF00014", "name": "Kunitz_BPTI"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "endopeptidase inhibitor activity"}, {"category": "function", "description": "serine-type endopeptidase inhibitor activity"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "transporter activity"}, {"category": "function", "description": "enzyme regulator activity"}, {"category": "function", "description": "enzyme inhibitor activity"}, {"category": "function", "description": "protease inhibitor activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}, {"category": "process", "description": "transport"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-11-12", "drugbank-id": [{"@primary": "true", "#text": "DB00065"}, "BIOD00004", "BTD00004"], "name": "Infliximab", "description": "Tumor necrosis factor (TNF-alpha) binding antibody (chimeric IgG1). It is composed of human constant and murine variable regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion", "cas-number": "170277-31-3", "groups": {"group": "approved"}, "general-references": "# Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, et al.: Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993 Nov;30(16):1443-53. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8232330\n#American Society of Health System Pharmacists, Inc., DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995. Infliximab; [updated 2014 Aug 27; cited 2014 Nov 12]. Available fromhttp://web.b.ebscohost.com/dynamed/detail?vid=15&sid=c9ea9657-342a-4b9b-a3bb-bf363d5d58c4%40sessionmgr112&hid=110&bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BlPXNpdGU%3d#db=dme&AN=232803&anchor=Mechanism-of-Action-Pharmacokinetics\n# Dubinsky MC, Fleshner PP: Treatment of Crohn's Disease of Inflammatory, Stenotic, and Fistulizing Phenotypes. Curr Treat Options Gastroenterol. 2003 Jun;6(3):183-200. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12744819\n# Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999 May 6;340(18):1398-405. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10228190\n# Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ: Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004 Feb 26;350(9):876-85. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14985485\n# Hanauer SB: Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol. 2003 Feb;17(1):131-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12617888\n# http://www.google.co.in/patents/US8524217\n#Lexicomp Online (2014). Infliximab Available at: http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7084#f_pharmacology-and-pharmacokinetics [Accessed 12 Nov. 2014].", "synthesis-reference": null, "indication": "To manage the signs and symptoms, as well as to induce and maintain clinical remission in adults with moderate to severe active Crohn's disease or ulcerative colitis. Also used to manage signs and symptoms of rheumatoid arthritis (in conjunction with methotrexate), ankylosing spondylitis, psoriatic arthritis, and juvenile arthritis.", "pharmacodynamics": "Infliximab is a chimeric human-murine anti-human tumor necrosis factor (TNF) monoclonal antibody. It binds to tumor necrosis factor alpha (TNFa) and inhibits binding of TNFa with its receptors. This reduces production of pro-inflammatory cytokines such as interleukins (IL) 1 and 6. This also limits leukocyte migration and expression of adhesion molecules by endothelial cells and leukocytes. Infliximab also limits the activation of neutrophil and eosinophil functional activity, reduces production of tissue degrading enzymes produced by synoviocytes and/or chondrocytes. Infliximab decreases synovitis and joint erosions in collagen-induced arthritis and allows eroded joints to heal.", "mechanism-of-action": "Infliximab neutralizes the biological activity of TNFa by binding with high affinity to the soluble and transmembrane forms of TNFa and inhibits binding of TNFa with its receptors. Infliximab does not neutralize TNFb (lymphotoxin a), a related cytokine that utilizes the same receptors as TNFa. TNFa activation normally induces the release of proinflammatory cytokines, the enhancement of leukocyte migration and activation of neutrophils among others. Neutralization of the biological activity of TNFa leads to an overall reduction in inflammation.", "toxicity": null, "metabolism": "Most likely removed by opsonization via the reticuloendothelial system when bound to T lymphocytes, or by human antimurine antibody production. Not metabolized by the CYP enzymes.", "absorption": "Onset of action occurs in about 2 weeks in Crohn's disease.", "half-life": "9.5 days (7-12 days) in patients with Crohn's disease, plaque psoriasis and rheumatoid arthritis", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": "3-6 L", "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": {"@language": "", "@coder": "", "#text": "Ig gamma-1 chain C region"}}, "products": {"product": [{"name": "Inflectra", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02419475", "started-marketing-on": "2014-09-04", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "100 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Remicade", "ndc-id": "57894-030_52ab743e-5e8f-40ba-8981-05826b0a750e", "ndc-product-code": "57894-030", "dpd-id": null, "started-marketing-on": "1998-08-24", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "100 mg/10mL", "route": "intravenous", "fda-application-number": "BLA103772", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Remicade", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02244016", "started-marketing-on": "2001-06-14", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "100 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Remsima", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02419483", "started-marketing-on": "2014-09-18", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "100 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Remicade", "ingredients": "Infliximab"}, {"name": "Remicade", "ingredients": "Infliximab"}, {"name": "Inflectra", "ingredients": "Infliximab"}, {"name": "Remsima", "ingredients": "Infliximab"}]}, "packagers": {"packager": [{"name": "Centocor Ortho Biotech Inc.", "url": "http://www.centocororthobiotech.com"}, {"name": "Hospira Inc.", "url": "http://www.hospira.com"}]}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "J&J and Mitsubisi Tanabe"}}, "prices": {"price": [{"description": "Remicade 100 mg vial", "cost": {"@currency": "USD", "#text": "789.44"}, "unit": "vial"}, {"description": "Remicade 100 mg Solution Vial", "cost": {"@currency": "USD", "#text": "821.02"}, "unit": "vial"}]}, "categories": {"category": [{"category": "Antirheumatic Agents", "mesh-id": null}, {"category": "Anti-Inflammatory Agents, Non-Steroidal", "mesh-id": null}, {"category": "Dermatologic Agents", "mesh-id": null}, {"category": "Gastrointestinal Agents", "mesh-id": null}, {"category": "Immunosuppressive Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, powder, lyophilized, for solution", "route": "intravenous", "strength": "100 mg/10mL"}, {"form": "Powder for solution", "route": "intravenous", "strength": "100 mg"}]}, "atc-codes": {"atc-code": {"@code": "L04AB02", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L04", "#text": "IMMUNOSUPPRESSANTS"}, {"@code": "L04A", "#text": "IMMUNOSUPPRESSANTS"}, {"@code": "L04AB", "#text": "Tumor necrosis factor alpha (TNF-\u03b1) inhibitors"}]}}, "ahfs-codes": {"ahfs-code": "92:00.00"}, "patents": {"patent": {"number": "2106299", "country": "Canada", "approved": "2001-02-06", "expires": "2012-03-18"}}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB01281", "name": "Abatacept", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported."}, {"drugbank-id": "DB00051", "name": "Adalimumab", "description": "May enhance the immunosuppressive effect of Infliximab."}, {"drugbank-id": "DB00026", "name": "Anakinra", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported."}, {"drugbank-id": "DB08879", "name": "Belimumab", "description": "Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab."}, {"drugbank-id": "DB06168", "name": "Canakinumab", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased."}, {"drugbank-id": "DB08904", "name": "Certolizumab pegol", "description": "Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab pegol."}, {"drugbank-id": "DB06643", "name": "Denosumab", "description": "May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased."}, {"drugbank-id": "DB00005", "name": "Etanercept", "description": "May enhance the immunosuppressive effect of Infliximab."}, {"drugbank-id": "DB06674", "name": "golimumab", "description": "May enhance the immunosuppressive effect of Infliximab."}, {"drugbank-id": "DB01097", "name": "Leflunomide", "description": "Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased."}, {"drugbank-id": "DB00108", "name": "Natalizumab", "description": "Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased."}, {"drugbank-id": "DB00337", "name": "Pimecrolimus", "description": "May enhance the adverse/toxic effect of Immunosuppressants."}, {"drugbank-id": "DB06372", "name": "Rilonacept", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept."}, {"drugbank-id": "DB01656", "name": "Roflumilast", "description": "May enhance the immunosuppressive effect of Immunosuppressants."}, {"drugbank-id": "DB06688", "name": "Sipuleucel-T", "description": "Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T."}, {"drugbank-id": "DB06273", "name": "Tocilizumab", "description": "May enhance the immunosuppressive effect of Anti-TNF Agents."}, {"drugbank-id": "DB08895", "name": "Tofacitinib", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib."}, {"drugbank-id": "DB08895", "name": "Tofacitinib", "description": "Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib."}, {"drugbank-id": "DB00072", "name": "Trastuzumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB05679", "name": "Ustekinumab", "description": "May enhance the immunosuppressive effect of Infliximab."}, {"drugbank-id": "DB09033", "name": "Vedolizumab", "description": "Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab."}]}, "sequences": null, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "61 \u00b0C (FAB fragment), 71 \u00b0C (whole mAb)", "source": "Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)"}, {"kind": "Hydrophobicity", "value": "-0.441", "source": null}, {"kind": "Isoelectric Point", "value": "8.25", "source": null}, {"kind": "Molecular Weight", "value": "144190.3000", "source": null}, {"kind": "Molecular Formula", "value": "C6428H9912N1694O1987S46", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "12094"}, {"resource": "GenBank", "identifier": "J00228"}, {"resource": "PharmGKB", "identifier": "PA452639"}, {"resource": "UniProtKB", "identifier": "P01857"}, {"resource": "Wikipedia", "identifier": "Infliximab"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/infliximab.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/infliximab.html"}]}, "pathways": null, "reactions": null, "snp-effects": {"effect": {"protein-name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "gene-symbol": "FCGR3A", "uniprot-id": "P08637", "rs-id": "rs1801274", "allele": null, "defining-change": "CC Allele (homozygous)", "description": "Better ACR20 response", "pubmed-id": "18930989"}}, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0000704", "name": "Tumor necrosis factor", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352\n# Mimura T: [Selection of one of the TNF blockers; infliximab and etanercept] Nippon Rinsho. 2007 Jul;65(7):1282-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17642244\n# Braun J, Baraliakos X, Listing J, Sieper J: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005 Aug;52(8):2447-51. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16052578\n# Danese S, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cittadini A, Pique JM, Panes J, Katz JA, Gasbarrini A, Fiocchi C: TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol. 2006 Feb 15;176(4):2617-24. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16456024\n# Magro F, Pereira P, Carneiro F, Veloso FT: Reactive hepatitis in a patient with Crohn's disease successfully treated with infliximab: does tumor necrosis factor alpha play a role in reactive hepatitis? Inflamm Bowel Dis. 2005 Jan;11(1):88-90. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15674127\n# Mori S, Imamura F, Kiyofuji C, Ito K, Koga Y, Honda I, Sugimoto M: Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody. Mod Rheumatol. 2006;16(1):58-62. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16622728\n# Maini RN, Feldmann M: How does infliximab work in rheumatoid arthritis? Arthritis Res. 2002;4 Suppl 2:S22-8. Epub 2002 Mar 27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12110154\n# Sapienza MS, Cohen S, Dimarino AJ: Treatment of pyoderma gangrenosum with infliximab in Crohn's disease. Dig Dis Sci. 2004 Sep;49(9):1454-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15481318\n# Tobin AM, Kirby B: TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs. 2005;19(1):47-57. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15691217\n# Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeerts P, Ceuppens JL: Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther. 2005 Feb 1;21(3):251-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15691299\n# Popa C, Netea MG, Barrera P, Radstake TR, van Riel PL, Kullberg BJ, Van der Meer JW: Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy. Cytokine. 2005 Apr 21;30(2):72-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15804598", "known-action": "yes", "polypeptide": {"@id": "P01375", "@source": "Swiss-Prot", "name": "Tumor necrosis factor", "general-function": "Involved in tumor necrosis factor receptor binding", "specific-function": "Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin 1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation", "gene-name": "TNF", "locus": "6p21.3", "cellular-location": "Cell membrane; single-pass type II membrane protein. Processed form:Secreted protein. Also exists as", "transmembrane-regions": "36-56", "signal-regions": null, "theoretical-pi": "6.92", "molecular-weight": "25645.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:11892"}, {"resource": "GenAtlas", "identifier": "TNF"}, {"resource": "GeneCards", "identifier": "TNF"}, {"resource": "GenBank Gene Database", "identifier": "M16441"}, {"resource": "GenBank Protein Database", "identifier": "339741"}, {"resource": "UniProtKB", "identifier": "P01375"}, {"resource": "UniProt Accession", "identifier": "TNFA_HUMAN"}]}, "synonyms": {"synonym": ["Cachectin", "TNF-a", "TNF-alpha", "Tumor necrosis factor ligand superfamily member 2", "Tumor necrosis factor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Tumor necrosis factor precursor\nMSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQR\nEEFPRDLSLISPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELR\nDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRE\nTPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL"}, "gene-sequence": {"@format": "FASTA", "#text": ">702 bp\nATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAG\nACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATC\nGTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGG\nGAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCT\nTCTCGAACCCCGAGTGACAAGCCTGTAGCCCATGTTGTAGCAAACCCTCAAGCTGAGGGG\nCAGCTCCAGTGGCTGAACCGCCGGGCCAATGCCCTCCTGGCCAATGGCGTGGAGCTGAGA\nGATAACCAGCTGGTGGTGCCATCAGAGGGCCTGTACCTCATCTACTCCCAGGTCCTCTTC\nAAGGGCCAAGGCTGCCCCTCCACCCATGTGCTCCTCACCCACACCATCAGCCGCATCGCC\nGTCTCCTACCAGACCAAGGTCAACCTCCTCTCTGCCATCAAGAGCCCCTGCCAGAGGGAG\nACCCCAGAGGGGGCTGAGGCCAAGCCCTGGTATGAGCCCATCTATCTGGGAGGGGTCTTC\nCAGCTGGAGAAGGGTGACCGACTCAGCGCTGAGATCAATCGGCCCGACTATCTCGACTTT\nGCCGAGTCTGGGCAGGTCTACTTTGGGATCATTGCCCTGTGA"}, "pfams": {"pfam": {"identifier": "PF00229", "name": "TNF"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor binding"}, {"category": "function", "description": "cytokine activity"}, {"category": "function", "description": "tumor necrosis factor receptor binding"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "immune response"}]}}}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-07-29", "drugbank-id": [{"@primary": "true", "#text": "DB00066"}, "BIOD00064", "BIOD00099", "BTD00064", "BTD00099"], "name": "Follitropin beta", "description": "Follitropin beta is a human follicle stimulating hormone (FSH) preparation of recombinant DNA origin, which consists of two non-covalently linked, non-identical glycoproteins designated as the alpha- and beta- subunits. The alpha- and beta- subunits have 92 and 111 amino acids. The alpha subunit is glycosylated at Asn 51 and Asn 78 while the beta subunit is glycosylated at Asn 7 and Asn 24. Follitropin beta is produced in genetically engineered Chinese hamster cell lines (CHO). The nomenclature \u201cbeta\u201d differentiates it from another recombinant human FSH product that was marketed earlier as follitropin alpha. Follitropin is important in the development of follicles produced by the ovaries. Given by subcutaneous injection, it is used in combination with human chorionic gonadotropin (hCG) to assist in ovulation and fertility. Follitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF).  Numerous physio-chemical tests and bioassays indicate that follitropin beta and follitropin alpha are indistinguishable. However, a more recent study showed there is may be a slight clinical difference, with the alpha form tending towards a higher pregnancy rate and the beta form tending towards a lower pregnancy rate, but with significantly higher estradiol (E2) levels.  Structural analysis shows that the amino acid sequence of follitropin beta is identical to that of natural human follicle stimulating hormone (FSH). Further, the ogliosaccharide side chains are very similar, but not completely identical to that of natural FSH. However, these small differences do not affect the bioactivity compared to natural FSH.", "cas-number": "9002-68-0", "groups": {"group": "approved"}, "general-references": "# Goa KL, Wagstaff AJ: Follitropin alpha in infertility: a review. BioDrugs. 1998 Mar;9(3):235-60. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18020563", "synthesis-reference": null, "indication": "For treatment of female infertility", "pharmacodynamics": "Used for the treatment of female infertility, Follitropin beta or follicle stimulating hormone (FSH) stimulates ovarian follicular growth in women who do not have primary ovarian failure. FSH, the active component of Follitropin beta is the primary hormone responsible for follicular recruitment and development.", "mechanism-of-action": "Follitropin alpha is a recombinant form of endogenous follicle stimulating hormone (FSH). FSH binds to the follicle stimulating hormone receptor which is a G-coupled transmembrane receptor. Binding of the FSH to its receptor seems to induce phosphorylation and activation of the PI3K (Phosphatidylinositol-3-kinase) and Akt signaling pathway, which is known to regulate many other metabolic and related survival/maturation functions in cells.", "toxicity": null, "metabolism": null, "absorption": "74%", "half-life": "Circulation half life of 3-4 hours, elimination half life of 35-40 hours", "protein-binding": null, "route-of-elimination": "Via liver and kidneys", "volume-of-distribution": "* 8 L [female subjects following intravenous administration of a 300 IU dose]", "clearance": "* 0.01 1*h-1kg-1 [European women with a single intramuscular dose of 300 IU]\n* 0.01 1*h-1kg-1 [Japanese women with a single intramuscular dose of 300 IU]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Follicle stimulating hormone beta"}, {"@language": "", "@coder": "", "#text": "Follicle-stimulating hormone beta subunit"}, {"@language": "", "@coder": "", "#text": "Follitrophin beta"}, {"@language": "", "@coder": "", "#text": "Follitropin beta"}, {"@language": "", "@coder": "", "#text": "Follitropin beta chain precursor"}, {"@language": "", "@coder": "", "#text": "FSH-b"}, {"@language": "", "@coder": "", "#text": "FSH-B"}, {"@language": "", "@coder": "", "#text": "FSH-beta"}]}, "products": {"product": [{"name": "Puregon", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02242439", "started-marketing-on": "2001-10-24", "ended-marketing-on": null, "dosage-form": "solution", "strength": "50 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Puregon", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02242441", "started-marketing-on": "2001-10-24", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Puregon", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02243948", "started-marketing-on": "2001-10-18", "ended-marketing-on": null, "dosage-form": "solution", "strength": "833 unit", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Puregon  (600 Iu)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02243949", "started-marketing-on": "2001-10-18", "ended-marketing-on": "2005-07-07", "dosage-form": "solution", "strength": "737 unit", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Puregon 100 I.U.", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02231656", "started-marketing-on": "1997-10-08", "ended-marketing-on": "2006-08-17", "dosage-form": "liquid; powder for solution", "strength": "100 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Puregon 50 I.U.", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02231655", "started-marketing-on": "1997-10-08", "ended-marketing-on": "2006-08-17", "dosage-form": "liquid; powder for solution", "strength": "50 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": {"name": "Follistim", "company": "Organon"}}, "mixtures": {"mixture": [{"name": "Puregon", "ingredients": "Follitropin beta"}, {"name": "Puregon", "ingredients": "Follitropin beta"}, {"name": "Puregon", "ingredients": "Follitropin beta"}, {"name": "Puregon 50 I.U.", "ingredients": "Follitropin beta + Sodium Chloride"}, {"name": "Puregon 100 I.U.", "ingredients": "Follitropin beta + Sodium Chloride"}, {"name": "Puregon  (600 Iu)", "ingredients": "Follitropin beta"}]}, "packagers": {"packager": [{"name": "EMD Canada Inc.", "url": "http://www.emdcanada.com"}, {"name": "Organon Pharmaceuticals", "url": "http://www.organonshop.com"}, {"name": "Vetter Pharma Fertigung GmbH and Co. KG", "url": "http://www.vetter-pharma.com"}]}, "manufacturers": {"manufacturer": [{"@generic": "false", "#text": "Organon usa inc"}, {"@generic": "false", "#text": "Emd serono inc"}]}, "prices": {"price": [{"description": "Follistim aq 75 unit vial", "cost": {"@currency": "USD", "#text": "109.51"}, "unit": "vial"}, {"description": "Gonal-f rff 75 unit vial", "cost": {"@currency": "USD", "#text": "117.47"}, "unit": "vial"}, {"description": "Follistim aq 150 unit vial", "cost": {"@currency": "USD", "#text": "219.02"}, "unit": "vial"}, {"description": "Follistim aq 300 unit cartridge", "cost": {"@currency": "USD", "#text": "438.05"}, "unit": "cartridge"}, {"description": "Follistim AQ 300unt/0.36ml Solution 0.42ml Cartridge", "cost": {"@currency": "USD", "#text": "455.57"}, "unit": "cartridge"}, {"description": "Gonal-f rff 300 unit pen", "cost": {"@currency": "USD", "#text": "469.87"}, "unit": "pen"}, {"description": "Gonal-f rff 450 unit pen", "cost": {"@currency": "USD", "#text": "704.81"}, "unit": "pen"}, {"description": "Gonal-f 450 unit Solution Vial", "cost": {"@currency": "USD", "#text": "733.0"}, "unit": "vial"}, {"description": "Follistim AQ 600unt/0.72ml Solution 0.78ml Cartridge", "cost": {"@currency": "USD", "#text": "911.14"}, "unit": "cartridge"}, {"description": "Follistim AQ 900unt/1.08ml Solution 1 Cartridge = 1.17ml", "cost": {"@currency": "USD", "#text": "1366.71"}, "unit": "cartridge"}, {"description": "Gonal-f rff 900 unit pen", "cost": {"@currency": "USD", "#text": "1409.62"}, "unit": "ml"}]}, "categories": {"category": {"category": "Fertility Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Solution", "route": "intramuscular; subcutaneous", "strength": "100 unit"}, {"form": "Solution", "route": "intramuscular; subcutaneous", "strength": "50 unit"}, {"form": "Solution", "route": "subcutaneous", "strength": "833 unit"}, {"form": "Solution", "route": "subcutaneous", "strength": "737 unit"}, {"form": "Liquid; powder for solution", "route": "intramuscular; subcutaneous", "strength": "100 unit"}, {"form": "Liquid; powder for solution", "route": "intramuscular; subcutaneous", "strength": "50 unit"}]}, "atc-codes": {"atc-code": {"@code": "G03GA06", "level": [{"@code": "G", "#text": "GENITO URINARY SYSTEM AND SEX HORMONES"}, {"@code": "G03", "#text": "SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM"}, {"@code": "G03G", "#text": "GONADOTROPINS AND OTHER OVULATION STIMULANTS"}, {"@code": "G03GA", "#text": "Gonadotropins"}]}}, "ahfs-codes": null, "patents": {"patent": [{"number": "2037884", "country": "Canada", "approved": "2003-10-21", "expires": "2011-03-08"}, {"number": "5270057", "country": "United States", "approved": "1994-03-20", "expires": "2011-03-20"}, {"number": "7741268", "country": "United States", "approved": "2004-04-02", "expires": "2024-04-02"}]}, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">Alpha chain\nAPDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC\nVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS"}, {"@format": "FASTA", "#text": ">Beta chain\nNSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYET\nVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "55 \u00b0C", "source": "Forastieri, H., Ingham, K.C. J. Biol. Chem. 257:7976-7981 (1982)"}, {"kind": "Hydrophobicity", "value": "-0.330", "source": null}, {"kind": "Isoelectric Point", "value": "7.50", "source": null}, {"kind": "Molecular Weight", "value": "22672.9000", "source": null}, {"kind": "Molecular Formula", "value": "C975H1513N267O304S26", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "11463"}, {"resource": "National Drug Code Directory", "identifier": "0052-0306-31"}, {"resource": "GenBank", "identifier": "M16647"}, {"resource": "PharmGKB", "identifier": "PA449693"}, {"resource": "UniProtKB", "identifier": "P01225"}, {"resource": "Wikipedia", "identifier": "Follicle-stimulating_hormone"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/follitrop.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/follitropin-alfa-powder.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0000387", "name": "Follicle-stimulating hormone receptor", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Layman LC: Mutations in the follicle-stimulating hormone-beta (FSH beta) and FSH receptor genes in mice and humans. Semin Reprod Med. 2000;18(1):5-10. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11299519\n# Leng N, Dattatreyamurty B, Reichert LE Jr: Identification of amino acid residues 300-315 of the rat FSH receptor as a hormone binding domain: evidence for its interaction with specific regions of FSH beta-subunit. Biochem Biophys Res Commun. 1995 May 16;210(2):392-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7755615\n# Santa Coloma TA, Dattatreyamurty B, Reichert LE Jr: A synthetic peptide corresponding to human FSH beta-subunit 33-53 binds to FSH receptor, stimulates basal estradiol biosynthesis, and is a partial antagonist of FSH. Biochemistry. 1990 Feb 6;29(5):1194-200. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2108722\n# Dattatreyamurty B, Reichert LE Jr: Identification of regions of the follitropin (FSH) beta-subunit that interact with the N-terminus region (residues 9-30) of the FSH receptor. Mol Cell Endocrinol. 1993 May;93(1):39-46. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8319832\n# Lindau-Shepard B, Roth KE, Dias JA: Identification of amino acids in the C-terminal region of human follicle-stimulating hormone (FSH) beta-subunit involved in binding to human FSH receptor. Endocrinology. 1994 Sep;135(3):1235-40. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8070368\n# Goa KL, Wagstaff AJ: Follitropin alpha in infertility: a review. BioDrugs. 1998 Mar;9(3):235-60. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18020563\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P23945", "@source": "Swiss-Prot", "name": "Follicle-stimulating hormone receptor", "general-function": "Involved in follicle-stimulating hormone receptor activity", "specific-function": "Receptor for follicle-stimulating hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase", "gene-name": "FSHR", "locus": "2p21-p16", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "367-387\n399-421\n444-465\n486-508\n529-550\n574-597\n609-630", "signal-regions": null, "theoretical-pi": "7.19", "molecular-weight": "78296.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3969"}, {"resource": "GenAtlas", "identifier": "FSHR"}, {"resource": "GeneCards", "identifier": "FSHR"}, {"resource": "GenBank Gene Database", "identifier": "M65085"}, {"resource": "GenBank Protein Database", "identifier": "182771"}, {"resource": "IUPHAR", "identifier": "253"}, {"resource": "Guide to Pharmacology", "identifier": "30"}, {"resource": "UniProtKB", "identifier": "P23945"}, {"resource": "UniProt Accession", "identifier": "FSHR_HUMAN"}]}, "synonyms": {"synonym": ["Follicle-stimulating hormone receptor precursor", "Follitropin receptor", "FSH-R"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Follicle-stimulating hormone receptor precursor\nMALLLVSLLAFLSLGSGCHHRICHCSNRVFLCQESKVTEIPSDLPRNAIELRFVLTKLRV\nIQKGAFSGFGDLEKIEISQNDVLEVIEADVFSNLPKLHEIRIEKANNLLYINPEAFQNLP\nNLQYLLISNTGIKHLPDVHKIHSLQKVLLDIQDNINIHTIERNSFVGLSFESVILWLNKN\nGIQEIHNCAFNGTQLDELNLSDNNNLEELPNDVFHGASGPVILDISRTRIHSLPSYGLEN\nLKKLRARSTYNLKKLPTLEKLVALMEASLTYPSHCCAFANWRRQISELHPICNKSILRQE\nVDYMTQTRGQRSSLAEDNESSYSRGFDMTYTEFDYDLCNEVVDVTCSPKPDAFNPCEDIM\nGYNILRVLIWFISILAITGNIIVLVILTTSQYKLTVPRFLMCNLAFADLCIGIYLLLIAS\nVDIHTKSQYHNYAIDWQTGAGCDAAGFFTVFASELSVYTLTAITLERWHTITHAMQLDCK\nVQLRHAASVMVMGWIFAFAAALFPIFGISSYMKVSICLPMDIDSPLSQLYVMSLLVLNVL\nAFVVICGCYIHIYLTVRNPNIVSSSSDTRIAKRMAMLIFTDFLCMAPISFFAISASLKVP\nLITVSKAKILLVLFHPINSCANPFLYAIFTKNFRRDFFILLSKCGCYEMQAQIYRTETSS\nTVHNTHPRNGHCSSAPRVTNGSTYILVPLSHLAQN"}, "gene-sequence": {"@format": "FASTA", "#text": ">2088 bp\nATGGCCCTGCTCCTGGTCTCTTTGCTGGCATTCCTGAGCTTGGGCTCAGGATGTCATCAT\nCGGATCTGTCACTGCTCTAACAGGGTTTTTCTCTGCCAAGAGAGCAAGGTGACAGAGATT\nCCTTCTGACCTCCCGAGGAATGCCATTGAACTGAGGTTTGTCCTCACCAAGCTTCGAGTC\nATCCAAAAAGGTGCATTTTCAGGATTTGGGGACCTGGAGAAAATAGAGATCTCTCAGAAT\nGATGTCTTGGAGGTGATAGAGGCAGATGTGTTCTCCAACCTTCCCAAATTACATGAAATT\nAGAATTGAAAAGGCCAACAACCTGCTCTACATCACCCCTGAGGCCTTCCAGAACCTTCCC\nAACCTTCAATATCTGTTAATATCCAACACAGGTATTAAGCACCTTCCAGATGTTCACAAG\nATTCATTCTCTCCAAAAGGTTTTACTTGACATTCAAGATAACATAAACATCCACACAATT\nGAAAGAAATTCTTTCGTGGGGCTGAGCTTTGAAAGTGTGATTCTATGGCTGAATAAGAAT\nGGGATTCAAGAAATACACAACTGTGCATTCAATGGAACCCAACTAGATGCAGTGAATCTA\nAGCGATAATAATAATTTAGAAGAATTGCCTAATGATGTTTTCCACGGAGCCTCTGGACCA\nGTCATTCTAGATATTTCAAGAACAAGGATCCATTCCCTGCCTAGCTATGGCTTAGAAAAT\nCTTAAGAAGCTGAGGGCCAGGTCGACTTACAACTTAAAAAAGCTGCCTACTCTGGAAAAG\nCTTGTCGCCCTCATGGAAGCCAGCCTCACCTATCCCAGCCATTGCTGTGCCTTTGCAAAC\nTGGAGACGGCAAATCTCTGAGCTTCATCCAATTTGCAACAAATCTATTTTAAGGCAAGAA\nGTTGATTATATGACTCAGGCTAGGGGTCAGAGATCCTCTCTGGCAGAAGACAATGAGTCC\nAGCTACAGCAGAGGATTTGACATGACGTACACTGAGTTTGACTATGACTTATGCAATGAA\nGTGGTTGACGTGACCTGCTCCCCTAAGCCAGATGCATTCAACCCATGTGAAGATATCATG\nGGGTACAACATCCTCAGAGTCCTGATATGGTTTATCAGCATCCTGGCCATCACTGGGAAC\nATCATAGTGCTAGTGATCCTAACTACCAGCCAATATAAACTCACAGTCCCCAGGTTCCTT\nATGTGCAACCTGGCCTTTGCTGATCTCTGCATTGGAATCTACCTGCTGCTCATTGCATCA\nGTTGATATCCATACCAAGAGCCAATATCACAACTATGCCATTGACTGGCAAACTGGGGCA\nGGCTGTGATGCTGCTGGCTTTTTCACTGTCTTTGCCAGTGAGCTGTCAGTCTACACTCTG\nACAGCTATCACCTTGGAAAGATGGCATACCATCACGCATGCCATGCAGCTGGACTGCAAG\nGTGCAGCTCCGCCATGCTGCCAGTGTCATGGTGATGGGCTGGATTTTTGCTTTTGCAGCT\nGCCCTCTTTCCCATCTTTGGCATCAGCAGCTACATGAAGGTGAGCATCTGCCTGCCCATG\nGATATTGACAGCCCTTTGTCACAGCTGTATGTCATGTCCCTCCTTGTGCTCAATGTCCTG\nGCCTTTGTGGTCATCTGTGGCTGCTATATCCACATCTACCTCACAGTGCGGAACCCCAAC\nATCGTGTCCTCCTCTAGTGACACCAGGATCGCCAAGCGCATGGCCATGCTCATCTTCACT\nGACTTCCTCTGCATGGCACCCATTTCTTTCTTTGCCATTTCTGCCTCCCTCAAGGTGCCC\nCTCATCACTGTGTCCAAAGCAAAGATTCTGCTGGTTCTGTTTCACCCCATCAACTCCTGT\nGCCAACCCCTTCCTCTATGCCATCTTTACCAAAAACTTTCGCAGAGATTTCTTCATTCTG\nCTGAGCAAGTGTGGCTGCTATGAAATGCAAGCCCAAATTTATAGGACAGAAACTTCATCC\nACTGTCCACAACACCCATCCAAGGAATGGCCACTGCTCTTCAGCTCCCAGAGTCACCAGT\nGGTTCCACTTACATACTTGTCCCTCTAAGTCATTTAGCCCAAAACTAA"}, "pfams": {"pfam": [{"identifier": "PF00001", "name": "7tm_1"}, {"identifier": "PF00560", "name": "LRR_1"}, {"identifier": "PF01462", "name": "LRRNT"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "function", "description": "protein-hormone receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "follicle stimulating hormone receptor activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}]}}}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-09-13", "drugbank-id": [{"@primary": "true", "#text": "DB00067"}, "BIOD00110", "BTD00110"], "name": "Vasopressin", "description": "Antidiuretic hormone, also known as vasopressin, is a nine amino acid peptide secreted from the posterior pituitary. Antidiuretic hormone binds to receptors in the distal or collecting tubules of the kidney and promotes reabsorbtion of water back into the circulation", "cas-number": "11000-17-2", "groups": {"group": "approved"}, "general-references": "# Bielsky IF, Hu SB, Szegda KL, Westphal H, Young LJ: Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology. 2004 Mar;29(3):483-93. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14647484\n# Wersinger SR, Caldwell HK, Martinez L, Gold P, Hu SB, Young WS 3rd: Vasopressin 1a receptor knockout mice have a subtle olfactory deficit but normal aggression. Genes Brain Behav. 2007 Aug;6(6):540-51. Epub 2006 Nov 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17083331\n# Lolait SJ, Stewart LQ, Jessop DS, Young WS 3rd, O'Carroll AM: The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. Endocrinology. 2007 Feb;148(2):849-56. Epub 2006 Nov 22. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17122081\n# Wersinger SR, Kelliher KR, Zufall F, Lolait SJ, O'Carroll AM, Young WS 3rd: Social motivation is reduced in vasopressin 1b receptor null mice despite normal performance in an olfactory discrimination task. Horm Behav. 2004 Dec;46(5):638-45. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15555506\n# Kanwar S, Woodman RC, Poon MC, Murohara T, Lefer AM, Davenpeck KL, Kubes P: Desmopressin induces endothelial P-selectin expression and leukocyte rolling in postcapillary venules. Blood. 1995 Oct 1;86(7):2760-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7545469", "synthesis-reference": "Nedumparambil A. Abraham, Hans U. Immer, Kazimir Sestanj, \"Process for producing triglycyl-lysine vasopressin and intermediates therefor.\" U.S. Patent US4093610, issued June, 1963.", "indication": "For the treatment of enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding", "pharmacodynamics": "Vasopressin is an antidiuretic hormone indicated for the prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows, and in diabetes insipidus. Vasopressin can cause contraction of smooth muscle of the gastrointestinal tract and of all parts of the vascular bed, especially the capillaries, small arterioles and venules. It has less effect on the smooth musculature of the large veins. Vasopressin may also be used to control bleeding in some forms of von Willebrand disease and to treat extreme cases of bed wetting in children. It may also play a role in memory formation although the mechanism is unknown.", "mechanism-of-action": "Vasopressin acts on three different receptors, vasopressin receptor V1a (which initiates vasoconstriction, liver gluconeogenesis, platelet aggregation and release of factor VIII), vasopressin receptor V1b (which mediates corticotrophin secretion from the pituitary) and vasopressin receptor V2 which controls free water reabsorption in the renal medullar. The binding of vasopressin to the V2 receptor activates adenylate cyclase which causes the release of aquaporin 2 channels into the cells lining the renal medullar duct. This allows water to be reabsorbed down an osmotic gradient so the urine is more concentrated.", "toxicity": null, "metabolism": "The majority of a dose of vasopressin is metabolized and rapidly destroyed in the liver and kidneys.", "absorption": null, "half-life": "10-20 minutes", "protein-binding": "1%", "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "ADH"}, {"@language": "", "@coder": "", "#text": "Antidiuretic hormone"}, {"@language": "", "@coder": "", "#text": "Arginine vasopressin"}, {"@language": "", "@coder": "", "#text": "Argipressin"}, {"@language": "", "@coder": "", "#text": "AVP"}]}, "products": {"product": [{"name": "Pitressin Inj 10 Unit/0.5ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00222577", "started-marketing-on": "1971-12-31", "ended-marketing-on": "1997-08-25", "dosage-form": "liquid", "strength": "10 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Pressyn Ar", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02246133", "started-marketing-on": "2002-11-04", "ended-marketing-on": null, "dosage-form": "liquid", "strength": "20 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Vasopressin Inj 20unit/ml USP", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01944800", "started-marketing-on": "1992-12-31", "ended-marketing-on": "1996-09-10", "dosage-form": "liquid", "strength": "20 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Vasopressin Inj 20unit/ml USP", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00693820", "started-marketing-on": "1988-12-31", "ended-marketing-on": "2015-07-22", "dosage-form": "liquid", "strength": "20 unit", "route": "intramuscular; nasal; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Vasopressin Injection", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02139502", "started-marketing-on": "1996-08-14", "ended-marketing-on": null, "dosage-form": "solution", "strength": "20 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Vasopressin Injection USP", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02247938", "started-marketing-on": "2003-12-10", "ended-marketing-on": null, "dosage-form": "solution", "strength": "20 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Vasostrict", "ndc-id": "42023-164_e1bc7c2b-a536-49a4-97e4-dfac673f393b", "ndc-product-code": "42023-164", "dpd-id": null, "started-marketing-on": "2014-11-12", "ended-marketing-on": null, "dosage-form": "injection", "strength": "20 [USP'U]/mL", "route": "intravenous", "fda-application-number": "NDA204485", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}]}, "international-brands": {"international-brand": [{"name": "Pitressin", "company": null}, {"name": "Pressyn", "company": null}]}, "mixtures": {"mixture": [{"name": "Vasostrict", "ingredients": "Vasopressin"}, {"name": "Vasopressin Injection", "ingredients": "Vasopressin"}, {"name": "Pressyn Ar", "ingredients": "Vasopressin"}, {"name": "Vasopressin Injection USP", "ingredients": "Vasopressin"}, {"name": "Pitressin Inj 10 Unit/0.5ml", "ingredients": "Vasopressin"}, {"name": "Vasopressin Inj 20unit/ml USP", "ingredients": "Vasopressin"}, {"name": "Vasopressin Inj 20unit/ml USP", "ingredients": "Vasopressin"}]}, "packagers": {"packager": [{"name": "American Regent", "url": "http://www.americanregent.com"}, {"name": "APP Pharmaceuticals", "url": "http://www.apppharma.com"}, {"name": "APPD", "url": null}, {"name": "A-S Medication Solutions LLC", "url": "http://orders.a-smeds.com"}, {"name": "Cardinal Health", "url": "http://www.cardinal.com"}, {"name": "JHP Pharmaceuticals LLC", "url": "http://www.jhppharma.com"}, {"name": "Luitpold Pharmaceuticals Inc.", "url": "http://www.luitpold.com"}, {"name": "Monarch Pharmacy", "url": "http://www.monarch-pharmacy.co.uk"}, {"name": "PD-Rx Pharmaceuticals Inc.", "url": "http://www.pdrx.com"}]}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Parke davis div warner lambert co"}}, "prices": {"price": [{"description": "Vasopressin 20 unit/ml vial", "cost": {"@currency": "USD", "#text": "1.86"}, "unit": "ml"}, {"description": "Vasopressin 10 unit/0.5 ml vial", "cost": {"@currency": "USD", "#text": "2.88"}, "unit": "vial"}, {"description": "Pitressin 20 unit/ml vial", "cost": {"@currency": "USD", "#text": "7.68"}, "unit": "ml"}]}, "categories": {"category": {"category": "Antidiuretic Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Liquid", "route": "intramuscular; subcutaneous", "strength": "10 unit"}, {"form": "Liquid", "route": "intramuscular; subcutaneous", "strength": "20 unit"}, {"form": "Liquid", "route": "intramuscular; nasal; subcutaneous", "strength": "20 unit"}, {"form": "Solution", "route": "intramuscular; subcutaneous", "strength": "20 unit"}, {"form": "Injection", "route": "intravenous", "strength": "20 [USP'U]/mL"}]}, "atc-codes": {"atc-code": {"@code": "H01BA01", "level": [{"@code": "H", "#text": "SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS"}, {"@code": "H01", "#text": "PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES"}, {"@code": "H01B", "#text": "POSTERIOR PITUITARY LOBE HORMONES"}, {"@code": "H01BA", "#text": "Vasopressin and analogues"}]}}, "ahfs-codes": {"ahfs-code": "68:28.00"}, "patents": null, "food-interactions": {"food-interaction": "Ethanol"}, "drug-interactions": null, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DE = Vasopressin\nCYFQNCPRG"}}, "experimental-properties": {"property": [{"kind": "Water Solubility", "value": "Soluble", "source": null}, {"kind": "Hydrophobicity", "value": "-4.9", "source": null}, {"kind": "Molecular Weight", "value": "1050.2150", "source": null}, {"kind": "Molecular Formula", "value": "C43H67N15O12S2", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "7387"}, {"resource": "KEGG Compound", "identifier": "C00840"}, {"resource": "KEGG Drug", "identifier": "D00101"}, {"resource": "PharmGKB", "identifier": "PA451858"}, {"resource": "Wikipedia", "identifier": "Vasopressin"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/vasopressin.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/mtm/vasopressin.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000293", "name": "Vasopressin V2 receptor", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Boson WL, Della Manna T, Damiani D, Miranda DM, Gadelha MR, Liberman B, Correa H, Romano-Silva MA, Friedman E, Silva FF, Ribeiro PA, De Marco L: Novel vasopressin type 2 (AVPR2) gene mutations in Brazilian nephrogenic diabetes insipidus patients. Genet Test. 2006 Fall;10(3):157-62. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17020465\n# Slusarz MJ, Slusarz R, Ciarkowski J: Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system. Biopolymers. 2006 Apr 5;81(5):321-38. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16333859\n# Bouley R, Hawthorn G, Russo LM, Lin HY, Ausiello DA, Brown D: Aquaporin 2 (AQP2) and vasopressin type 2 receptor (V2R) endocytosis in kidney epithelial cells: AQP2 is located in 'endocytosis-resistant' membrane domains after vasopressin treatment. Biol Cell. 2006 Apr;98(4):215-32. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16563128\n# Yi X, Bouley R, Lin HY, Bechoua S, Sun TX, Del Re E, Shioda T, Raychowdhury MK, Lu HA, Abou-Samra AB, Brown D, Ausiello DA: Alix (AIP1) is a vasopressin receptor (V2R)-interacting protein that increases lysosomal degradation of the V2R. Am J Physiol Renal Physiol. 2007 May;292(5):F1303-13. Epub 2007 Feb 6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17287200\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P30518", "@source": "Swiss-Prot", "name": "Vasopressin V2 receptor", "general-function": "Involved in rhodopsin-like receptor activity", "specific-function": "Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate adenylate cyclase", "gene-name": "AVPR2", "locus": "Xq28", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "39-63\n78-98\n114-135\n160-180\n201-220\n272-293\n309-328", "signal-regions": null, "theoretical-pi": "9.41", "molecular-weight": "40279.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:897"}, {"resource": "GenAtlas", "identifier": "AVPR2"}, {"resource": "GeneCards", "identifier": "AVPR2"}, {"resource": "GenBank Gene Database", "identifier": "U04357"}, {"resource": "GenBank Protein Database", "identifier": "28418"}, {"resource": "IUPHAR", "identifier": "368"}, {"resource": "Guide to Pharmacology", "identifier": "66"}, {"resource": "UniProtKB", "identifier": "P30518"}, {"resource": "UniProt Accession", "identifier": "V2R_HUMAN"}]}, "synonyms": {"synonym": ["Antidiuretic hormone receptor", "AVPR V2", "Renal-type arginine vasopressin receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Vasopressin V2 receptor\nMLMASTTSAVPGHPSLPSLPSNSSQERPLDTRDPLLARAELALLSIVFVAVALSNGLVLA\nALARRGRRGHWAPIHVFIGHLCLADLAVALFQVLPQLAWKATDRFRGPDALCRAVKYLQM\nVGMYASSYMILAMTLDRHRAICRPMLAYRHGSGAHWNRPVLVAWAFSLLLSLPQLFIFAQ\nRNVEGGSGVTDCWACFAEPWGRRTYVTWIALMVFVAPTLGIAACQVLIFREIHASLVPGP\nSERPGGRRRGRRTGSPGEGAHVSAAVAKTVRMTLVIVVVYVLCWAPFFLVQLWAAWDPEA\nPLEGAPFVLLMLLASLNSCTNPWIYASFSSSVSSELRSLLCCARGRTPPSLGPQDESCTT\nASSSLAKDTSS"}, "gene-sequence": {"@format": "FASTA", "#text": ">1116 bp\nATGCTCATGGCGTCCACCACTTCCGCTGTGCCTGGGCATCCCTCTCTGCCCAGCCTGCCC\nAGCAACAGCAGCCAGGAGAGGCCACTGGACACCCGGGACCCGCTGCTAGCCCGGGCGGAG\nCTGGCGCTGCTCTCCATAGTCTTTGTGGCTGTGGCCCTGAGCAATGGCCTGGTGCTGGCG\nGCCCTAGCTCGGCGGGGCCGGCGGGGCCACTGGGCACCCATACACGTCTTCATTGGCCAC\nTTGTGCCTGGCCGACCTGGCCGTGGCTCTGTTCCAAGTGCTGCCCCAGCTGGCCTGGAAG\nGCCACCGACCGCTTCCGTGGGCCAGATGCCCTGTGTCGGGCCGTGAAGTATCTGCAGATG\nGTGGGCATGTATGCCTCCTCCTACATGATCCTGGCCATGACGCTGGACCGCCACCGTGCC\nATCTGCCGTCCCATGCTGGCGTACCGCCATGGAAGTGGGGCTCACTGGAACCGGCCGGTG\nCTAGTGGCTTGGGCCTTCTCGCTCCTTCTCAGCCTGCCCCAGCTCTTCATCTTCGCCCAG\nCGCAACGTGGAAGGTGGCAGCGGGGTCACTGACTGCTGGGCCTGCTTTGCGGAGCCCTGG\nGGCCGTCGCACCTATGTCACCTGGATTGCCCTGATGGTGTTCGTGGCACCTACCCTGGGT\nATCGCCGCCTGCCAGGTGCTCATCTTCCGGGAGATTCATGCCAGTCTGGTGCCAGGGCCA\nTCAGAGAGGCCTGGGGGGCGCCGCAGGGGACGCCGGACAGGCAGCCCCGGTGAGGGAGCC\nCACGTGTCAGCAGCTGTGGCCAAGACTGTGAGGATGACGCTAGTGATTGTGGTCGTCTAT\nGTGCTGTGCTGGGCACCCTTCTTCCTGGTGCAGCTGTGGGCCGCGTGGGACCCGGAGGCA\nCCTCTGGAAGGGGCGCCCTTTGTGCTACTCATGTTGCTGGCCAGCCTCAACAGCTGCACC\nAACCCCTGGATCTATGCATCTTTCAGCAGCAGCGTGTCCTCAGAGCTGCGAAGCTTGCTC\nTGCTGTGCCCGGGGACGCACCCCACCCAGCCTGGGTCCCCAAGATGAGTCCTGCACCACC\nGCCAGCTCCTCCCTGGCCAAGGACACTTCATCGTGA"}, "pfams": {"pfam": {"identifier": "PF00001", "name": "7tm_1"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "function", "description": "peptide receptor activity, G-protein coupled"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "vasopressin-like receptor activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "vasopressin receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}]}}}, {"@position": "2", "id": "BE0000165", "name": "Vasopressin V1a receptor", "organism": "Human", "actions": null, "references": "# Hiroyama M, Wang S, Aoyagi T, Oikawa R, Sanbe A, Takeo S, Tanoue A: Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice. Eur J Pharmacol. 2007 Mar 22;559(2-3):89-97. Epub 2006 Dec 29. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17275806\n# Liedman R, Grant L, Igidbashian S, James I, McLeod A, Skillern L, Akerlund M: Intrauterine pressure, ischemia markers, and experienced pain during administration of a vasopressin V1a receptor antagonist in spontaneous and vasopressin-induced dysmenorrhea. Acta Obstet Gynecol Scand. 2006;85(2):207-11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16532916\n# Adikesavan NV, Mahmood SS, Stanley N, Xu Z, Wu N, Thibonnier M, Shoham M: A C-terminal segment of the V1R vasopressin receptor is unstructured in the crystal structure of its chimera with the maltose-binding protein. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005 Apr 1;61(Pt 4):341-5. Epub 2005 Mar 24. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16511036\n# Hammock EA, Lim MM, Nair HP, Young LJ: Association of vasopressin 1a receptor levels with a regulatory microsatellite and behavior. Genes Brain Behav. 2005 Jul;4(5):289-301. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16011575\n# Aoyagi T, Birumachi J, Hiroyama M, Fujiwara Y, Sanbe A, Yamauchi J, Tanoue A: Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology. 2007 May;148(5):2075-84. Epub 2007 Feb 15. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17303660", "known-action": "yes", "polypeptide": {"@id": "P37288", "@source": "Swiss-Prot", "name": "Vasopressin V1a receptor", "general-function": "Involved in rhodopsin-like receptor activity", "specific-function": "Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl- inositol-calcium second messenger system. Has been involved in social behaviors, including affiliation and attachment", "gene-name": "AVPR1A", "locus": "12q14-q15", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "53-76\n89-110\n126-147\n169-190\n219-239\n294-313\n332-351", "signal-regions": null, "theoretical-pi": "9.67", "molecular-weight": "46800.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:895"}, {"resource": "GenAtlas", "identifier": "AVPR1A"}, {"resource": "GeneCards", "identifier": "AVPR1A"}, {"resource": "GenBank Gene Database", "identifier": "L25615"}, {"resource": "GenBank Protein Database", "identifier": "667068"}, {"resource": "IUPHAR", "identifier": "366"}, {"resource": "Guide to Pharmacology", "identifier": "66"}, {"resource": "UniProtKB", "identifier": "P37288"}, {"resource": "UniProt Accession", "identifier": "V1AR_HUMAN"}]}, "synonyms": {"synonym": ["Antidiuretic hormone receptor 1a", "AVPR V1a", "V1aR", "Vascular/hepatic-type arginine vasopressin receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Vasopressin V1a receptor\nMRLSAGPDAGPSGNSSPWWPLATGAGNTSREAEALGEGNGPPRDVRNEELAKLEIAVLAV\nTFAVAVLGNSSVLLALHRTPRKTSRMHLFIRHLSLADLAVAFFQVLPQMCWDITYRFRGP\nDWLCRVVKHLQVFGMFASAYMLVVMTADRYIAVCHPLKTLQQPARRSRLMIAAAWVLSFV\nLSTPQYFVFSMIEVNNVTKARDCWATFIQPWGSRAYVTWMTGGIFVAPVVILGTCYGFIC\nYNIWCNVRGKTASRQSKGAEQAGVAFQKGFLLAPCVSSVKSISRAKIRTVKMTFVIVTAY\nIVCWAPFFIIQMWSVWDPMSVWTESENPTITITALLGSLNSCCNPWIYMFFSGHLLQDCV\nQSFPCCQNMKEKFNKEDTDSMSRRQTFYSNNRSPTNSTGMWKDSPKSSKSIKFIPVST"}, "gene-sequence": {"@format": "FASTA", "#text": ">1257 bp\nATGCGTCTCTCCGCCGGTCCCGACGCGGGGCCCTCGGGCAACTCCAGCCCATGGTGGCCT\nCTGGCCACCGGCGCTGGCAACACAAGCCGGGAGGCCGAAGCCCTCGGGGAGGGCAACGGC\nCCACCGAGGGACGTGCGCAACGAGGAGCTGGCCAAACTGGAGATCGCCGTGCTGGCGGTG\nACTTTCGCGGTGGCCGTGCTGGGCAACAGCAGCGTACTGCTGGCTCTGCACCGGACGCCG\nCGCAAGACGTCCCGCATGCACCTCTTCATCCGACACCTCAGCCTGGCCGACCTGGCCGTG\nGCATTCTTCCAGGTGCTGCCGCAAATGTGCTGGGACATCACCTACCGCTTCCGCGGCCCC\nGACTGGCTGTGCCGCGTGGTGAAGCACCTGCAGGTGTTCGGCATGTTTGCGTCGGCCTAC\nATGCTGGTAGTCATGACAGCCGACCGCTACATCGCGGTGTGCCACCCGCTCAAGACTCTG\nCAACAGCCCGCGCGCCGCTCGCGCCTCATGATCGCGGCCGCCTGGGTGCTGAGCTTCGTG\nCTGAGCACGCCGCAGTACTTCGTCTTCTCCATGATCGAGGTGAACAATGTCACCAAGGCC\nCGCGACTGCTGGGCCACCTTCATCCAGCCCTGGGGTTCTCGTGCCTACGTGACCTGGATG\nACGGGCGGCATCTTTGTGGCGCCCGTGGTCATCTTGGGTACCTGCTACGGCTTCATCTGC\nTACAACATCTGGTGCAACGTCCGCGGGAAGACGGCGTCGCGCCAGAGCAAGGGTGCAGAG\nCAAGCGGGTGTGGCCTTCCAAAAGGGGTTCCTGCTCGCACCCTGTGTCAGCAGCGTGAAG\nTCCATTTCCCGGGCCAAGATCCGCACGGTGAAGATGACTTTTGTGATCGTGACGGCTTAC\nATCGTCTGCTGGGCGCCTTTCTTCATCATCCAGATGTGGTCTGTCTGGGATCCCATGTCC\nGTCTGGACCGAATCGGAAAACCCTACCATCACCATCACTGCATTACTGGGTTCCTTGAAT\nAGCTGCTGTAATCCCTGGATATACATGTTTTTTAGTGGCCATCTCCTTCAAGACTGTGTT\nCAAAGCTTCCCATGCTGCCAAAACATGAAGGAAAAATTCAACAAAGAAGATACTGACAGT\nATGAGCAGAAGACAGACTTTTTATTCTAACAATCGAAGCCCAACAAACAGTACGGGTATG\nTGGAAGGACTCGCCTAAATCTTCCAAGTCCATCAAATTCATTCCTGTTTCAACTTGA"}, "pfams": {"pfam": {"identifier": "PF00001", "name": "7tm_1"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "function", "description": "peptide receptor activity, G-protein coupled"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "vasopressin-like receptor activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "vasopressin receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}]}}}, {"@position": "3", "id": "BE0000773", "name": "Vasopressin V1b receptor", "organism": "Human", "actions": null, "references": "# Young WS, Li J, Wersinger SR, Palkovits M: The vasopressin 1b receptor is prominent in the hippocampal area CA2 where it is unaffected by restraint stress or adrenalectomy. Neuroscience. 2006 Dec 28;143(4):1031-9. Epub 2006 Oct 4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17027167\n# Volpi S, Liu Y, Aguilera G: Vasopressin increases GAGA binding activity to the V1b receptor promoter through transactivation of the MAP kinase pathway. J Mol Endocrinol. 2006 Jun;36(3):581-90. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16720725\n# Wersinger SR, Caldwell HK, Christiansen M, Young WS 3rd: Disruption of the vasopressin 1b receptor gene impairs the attack component of aggressive behavior in mice. Genes Brain Behav. 2007 Oct;6(7):653-60. Epub 2006 Dec 20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17284170\n# Slusarz MJ, Gieldon A, Slusarz R, Ciarkowski J: Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptors-molecular dynamics study of the activated receptor-vasopressin-G(alpha) systems. J Pept Sci. 2006 Mar;12(3):180-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16114100\n# Jurkevich A, Berghman LR, Cornett LE, Kuenzel WJ: Characterization and immunohistochemical visualization of the vasotocin VT2 receptor in the pituitary gland of the chicken, Gallus gallus. Gen Comp Endocrinol. 2005 Aug;143(1):82-91. Epub 2005 Mar 23. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15993108", "known-action": "yes", "polypeptide": {"@id": "P47901", "@source": "Swiss-Prot", "name": "Vasopressin V1b receptor", "general-function": "Involved in rhodopsin-like receptor activity", "specific-function": "Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl- inositol-calcium second messenger system", "gene-name": "AVPR1B", "locus": "1q32", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "36-59\n72-93\n109-130\n152-173\n202-222\n284-303\n322-341", "signal-regions": null, "theoretical-pi": "9.05", "molecular-weight": "46971.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:896"}, {"resource": "GenAtlas", "identifier": "AVPR1B"}, {"resource": "GeneCards", "identifier": "AVPR1B"}, {"resource": "GenBank Gene Database", "identifier": "D31833"}, {"resource": "GenBank Protein Database", "identifier": "563982"}, {"resource": "IUPHAR", "identifier": "367"}, {"resource": "Guide to Pharmacology", "identifier": "66"}, {"resource": "UniProtKB", "identifier": "P47901"}, {"resource": "UniProt Accession", "identifier": "V1BR_HUMAN"}]}, "synonyms": {"synonym": ["Antidiuretic hormone receptor 1b", "AVPR V1b", "AVPR V3", "V1bR", "Vasopressin V3 receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Vasopressin V1b receptor\nMDSGPLWDANPTPRGTLSAPNATTPWLGRDEELAKVEIGVLATVLVLATGGNLAVLLTLG\nQLGRKRSRMHLFVLHLALTDLAVALFQVLPQLLWDITYRFQGPDLLCRAVKYLQVLSMFA\nSTYMLLAMTLDRYLAVCHPLRSLQQPGQSTYLLIAAPWLLAAIFSLPQVFIFSLREVIQG\nSGVLDCWADFGFPWGPRAYLTWTTLAIFVLPVTMLTACYSLICHEICKNLKVKTQAWRVG\nGGGWRTWDRPSPSTLAATTRGLPSRVSSINTISRAKIRTVKMTFVIVLAYIACWAPFFSV\nQMWSVWDKNAPDEDSTNVAFTISMLLGNLNSCCNPWIYMGFNSHLLPRPLRHLACCGGPQ\nPRMRRRLSDGSLSSRHTTLLTRSSCPATLSLSLSLTLSGRPRPEESPRDLELADGEGTAE\nTIIF"}, "gene-sequence": {"@format": "FASTA", "#text": ">1275 bp\nATGGATTCTGGGCCTCTGTGGGATGCCAACCCCACCCCTCGGGGCACCCTCTCTGCCCCC\nAATGCCACAACACCCTGGCTGGGCCGGGATGAGGAGCTGGCCAAGGTGGAGATCGGAGTC\nCTGGCCACTGTCCTGGTGCTGGCGACCGGGGGCAACCTGGCTGTGCTGCTGACCCTGGGC\nCAGCTGGGCCGCAAGCGCTCCCGCATGCACCTGTTCGTGCTGCACTTAGCCCTGACAGAC\nCTGGCCGTGGCGCTCTTCCAGGTGCTGCCACAGCTGCTGTGGGACATCACCTACCGCTTC\nCAGGGCCCCGACCTCCTGTGCAGGGCCGTCAAGTACCTGCAGGTGCTCAGCATGTTTGCC\nTCCACCTACATGCTGCTGGCCATGACGCTGGACCGCTACCTGGCTGTCTGTCACCCCCTG\nCGCAGCCTCCAGCAGCCAGGCCAGTCCACCTACCTGCTCATCGCTGCTCCCTGGCTGCTG\nGCCGCCATCTTCAGCCTCCCTCAAGTCTTCATTTTTTCCCTGCGGGAGGTGATCCAGGGC\nTCAGGGGTGCTGGACTGCTGGGCAGACTTCGGCTTCCCTTGGGGGCCACGGGCCTACCTC\nACCTGGACCACCCTGGCTATCTTCGTTCTGCCGGTGACCATGCTCACGGCCTGCTACAGC\nCTCATCTGCCATGAGATCTGTAAAAACCTAAAAGTCAAGACACAGGCCTGGCGGGTGGGA\nGGAGGGGGCTGGAGGACTTGGGACAGGCCCTCACCTTCCACCTTAGCTGCCACCACTCGG\nGGGCTGCCATCTCGGGTCAGCAGCATCAACACCATCTCACGGGCCAAGATCCGAACAGTG\nAAGATGACCTTTGTCATCGTGCTGGCCTACATCGCTTGCTGGGCTCCCTTCTTCAGTGTC\nCAGATGTGGTCCGTGTGGGACAAGAATGCCCCTGATGAAGATTCCACCAATGTGGCTTTC\nACCATCTCTATGCTTTTGGGCAACCTCAACAGCTGCTGCAACCCCTGGATCTACATGGGC\nTTCAACAGCCACCTGTTACCGCGGCCCCTGCGTCACCTTGCCTGCTGTGGGGGTCCCCAG\nCCCAGGATGCGCCGGCGGCTCTCCGACGGCAGCCTCTCGAGCCGCCACACCACGCTGCTG\nACCCGCTCCAGCTGCCCGGCCACCCTCAGCCTCAGCCTCAGCCTAACCCTCAGTGGGAGG\nCCCAGGCCTGAAGAGTCACCAAGGGACTTGGAGCTGGCAGATGGGGAAGGCACCGCTGAG\nACCATCATCTTTTAG"}, "pfams": {"pfam": {"identifier": "PF00001", "name": "7tm_1"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "function", "description": "peptide receptor activity, G-protein coupled"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "vasopressin-like receptor activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "vasopressin receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}]}}}]}, "enzymes": null, "carriers": null, "transporters": {"transporter": {"@position": "4", "id": "BE0001069", "name": "Canalicular multispecific organic anion transporter 1", "organism": "Human", "actions": {"action": "substrate"}, "references": "# Madon J, Hagenbuch B, Landmann L, Meier PJ, Stieger B: Transport function and hepatocellular localization of mrp6 in rat liver. Mol Pharmacol. 2000 Mar;57(3):634-41. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10692506", "known-action": "unknown", "polypeptide": {"@id": "Q92887", "@source": "Swiss-Prot", "name": "Canalicular multispecific organic anion transporter 1", "general-function": "Defense mechanisms and drug export", "specific-function": "Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter", "gene-name": "ABCC2", "locus": "10q24", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "28-48\n69-89\n94-114\n127-147\n166-186\n314-334\n361-381\n438-458\n462-482\n545-565\n588-608\n972-992\n1034-1054\n1098-1118\n1120-1140\n1212-1232\n1235-1255", "signal-regions": null, "theoretical-pi": "8.46", "molecular-weight": "174194.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:53"}, {"resource": "GenAtlas", "identifier": "ABCC2"}, {"resource": "GeneCards", "identifier": "ABCC2"}, {"resource": "GenBank Gene Database", "identifier": "U63970"}, {"resource": "GenBank Protein Database", "identifier": "1764162"}, {"resource": "UniProtKB", "identifier": "Q92887"}, {"resource": "UniProt Accession", "identifier": "MRP2_HUMAN"}]}, "synonyms": {"synonym": ["ATP-binding cassette sub-family C member 2", "Canalicular multidrug resistance protein", "Multidrug resistance-associated protein 2"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Canalicular multispecific organic anion transporter 1\nMLEKFCNSTFWNSSFLDSPEADLPLCFEQTVLVWIPLGFLWLLAPWQLLHVYKSRTKRSS\nTTKLYLAKQVFVGFLLILAAIELALVLTEDSGQATVPAVRYTNPSLYLGTWLLVLLIQYS\nRQWCVQKNSWFLSLFWILSILCGTFQFQTLIRTLLQGDNSNLAYSCLFFISYGFQILILI\nFSAFSENNESSNNPSSIASFLSSITYSWYDSIILKGYKRPLTLEDVWEVDEEMKTKTLVS\nKFETHMKRELQKARRALQRRQEKSSQQNSGARLPGLNKNQSQSQDALVLEDVEKKKKKSG\nTKKDVPKSWLMKALFKTFYMVLLKSFLLKLVNDIFTFVSPQLLKLLISFASDRDTYLWIG\nYLCAILLFTAALIQSFCLQCYFQLCFKLGVKVRTAIMASVYKKALTLSNLARKEYTVGET\nVNLMSVDAQKLMDVTNFMHMLWSSVLQIVLSIFFLWRELGPSVLAGVGVMVLVIPINAIL\nSTKSKTIQVKNMKNKDKRLKIMNEILSGIKILKYFAWEPSFRDQVQNLRKKELKNLLAFS\nQLQCVVIFVFQLTPVLVSVVTFSVYVLVDSNNILDAQKAFTSITLFNILRFPLSMLPMMI\nSSMLQASVSTERLEKYLGGDDLDTSAIRHDCNFDKAMQFSEASFTWEHDSEATVRDVNLD\nIMAGQLVAVIGPVGSGKSSLISAMLGEMENVHGHITIKGTTAYVPQQSWIQNGTIKDNIL\nFGTEFNEKRYQQVLEACALLPDLEMLPGGDLAEIGEKGINLSGGQKQRISLARATYQNLD\nIYLLDDPLSAVDAHVGKHIFNKVLGPNGLLKGKTRLLVTHSMHFLPQVDEIVVLGNGTIV\nEKGSYSALLAKKGEFAKNLKTFLRHTGPEEEATVHDGSEEEDDDYGLISSVEEIPEDAAS\nITMRRENSFRRTLSRSSRSNGRHLKSLRNSLKTRNVNSLKEDEELVKGQKLIKKEFIETG\nKVKFSIYLEYLQAIGLFSIFFIILAFVMNSVAFIGSNLWLSAWTSDSKIFNSTDYPASQR\nDMRVGVYGALGLAQGIFVFIAHFWSAFGFVHASNILHKQLLNNILRAPMRFFDTTPTGRI\nVNRFAGDISTVDDTLPQSLRSWITCFLGIISTLVMICMATPVFTIIVIPLGIIYVSVQMF\nYVSTSRQLRRLDSVTRSPIYSHFSETVSGLPVIRAFEHQQRFLKHNEVRIDTNQKCVFSW\nITSNRWLAIRLELVGNLTVFFSALMMVIYRDTLSGDTVGFVLSNALNITQTLNWLVRMTS\nEIETNIVAVERITEYTKVENEAPWVTDKRPPPDWPSKGKIQFNNYQVRYRPELDLVLRGI\nTCDIGSMEKIGVVGRTGAGKSSLTNCLFRILEAAGGQIIIDGVDIASIGLHDLREKLTII\nPQDPILFSGSLRMNLDPFNNYSDEEIWKALELAHLKSFVASLQLGLSHEVTEAGGNLSIG\nQRQLLCLGRALLRKSKILVLDEATAAVDLETDNLIQTTIQNEFAHCTVITIAHRLHTIMD\nSDKVMVLDNGKIIECGSPEELLQIPGPFYFMAKEAGIENVNSTKF"}, "gene-sequence": {"@format": "FASTA", "#text": ">4638 bp\nATGCTGGAGAAGTTCTGCAACTCTACTTTTTGGAATTCCTCATTCCTGGACAGTCCGGAG\nGCAGACCTGCCACTTTGTTTTGAGCAAACTGTTCTGGTGTGGATTCCCTTGGGCTTCCTA\nTGGCTCCTGGCCCCCTGGCAGCTTCTCCACGTGTATAAATCCAGGACCAAGAGATCCTCT\nACCACCAAACTCTATCTTGCTAAGCAGGTATTCGTTGGTTTTCTTCTTATTCTAGCAGCC\nATAGAGCTGGCCCTTGTACTCACAGAAGACTCTGGACAAGCCACAGTCCCTGCTGTTCGA\nTATACCAATCCAAGCCTCTACCTAGGCACATGGCTCCTGGTTTTGCTGATCCAATACAGC\nAGACAATGGTGTGTACAGAAAAACTCCTGGTTCCTGTCCCTATTCTGGATTCTCTCGATA\nCTCTGTGGCACTTTCCAATTTCAGACTCTGATCCGGACACTCTTACAGGGTGACAATTCT\nAATCTAGCCTACTCCTGCCTGTTCTTCATCTCCTACGGATTCCAGATCCTGATCCTGATC\nTTTTCAGCATTTTCAGAAAATAATGAGTCATCAAATAATCCATCATCCATAGCTTCATTC\nCTGAGTAGCATTACCTACAGCTGGTATGACAGCATCATTCTGAAAGGCTACAAGCGTCCT\nCTGACACTCGAGGATGTCTGGGAAGTTGATGAAGAGATGAAAACCAAGACATTAGTGAGC\nAAGTTTGAAACGCACATGAAGAGAGAGCTGCAGAAAGCCAGGCGGGCACTCCAGAGACGG\nCAGGAGAAGAGCTCCCAGCAGAACTCTGGAGCCAGGCTGCCTGGCTTGAACAAGAATCAG\nAGTCAAAGCCAAGATGCCCTTGTCCTGGAAGATGTTGAAAAGAAAAAAAAGAAGTCTGGG\nACCAAAAAAGATGTTCCAAAATCCTGGTTGATGAAGGCTCTGTTCAAAACTTTCTACATG\nGTGCTCCTGAAATCATTCCTACTGAAGCTAGTGAATGACATCTTCACGTTTGTGAGTCCT\nCAGCTGCTGAAATTGCTGATCTCCTTTGCAAGTGACCGTGACACATATTTGTGGATTGGA\nTATCTCTGTGCAATCCTCTTATTCACTGCGGCTCTCATTCAGTCTTTCTGCCTTCAGTGT\nTATTTCCAACTGTGCTTCAAGCTGGGTGTAAAAGTACGGACAGCTATCATGGCTTCTGTA\nTATAAGAAGGCATTGACCCTATCCAACTTGGCCAGGAAGGAGTACACCGTTGGAGAAACA\nGTGAACCTGATGTCTGTGGATGCCCAGAAGCTCATGGATGTGACCAACTTCATGCACATG\nCTGTGGTCAAGTGTTCTACAGATTGTCTTATCTATCTTCTTCCTATGGAGAGAGTTGGGA\nCCCTCAGTCTTAGCAGGTGTTGGGGTGATGGTGCTTGTAATCCCAATTAATGCGATACTG\nTCCACCAAGAGTAAGACCATTCAGGTCAAAAATATGAAGAATAAAGACAAACGTTTAAAG\nATCATGAATGAGATTCTTAGTGGAATCAAGATCCTGAAATATTTTGCCTGGGAACCTTCA\nTTCAGAGACCAAGTACAAAACCTCCGGAAGAAAGAGCTCAAGAACCTGCTGGCCTTTAGT\nCAACTACAGTGTGTAGTAATATTCGTCTTCCAGTTAACTCCAGTCCTGGTATCTGTGGTC\nACATTTTCTGTTTATGTCCTGGTGGATAGCAACAATATTTTGGATGCACAAAAGGCCTTC\nACCTCCATTACCCTCTTCAATATCCTGCGCTTTCCCCTGAGCATGCTTCCCATGATGATC\nTCCTCCATGCTCCAGGCCAGTGTTTCCACAGAGCGGCTAGAGAAGTACTTGGGAGGGGAT\nGACTTGGACACATCTGCCATTCGACATGACTGCAATTTTGACAAAGCCATGCAGTTTTCT\nGAGGCCTCCTTTACCTGGGAACATGATTCGGAAGCCACAGTCCGAGATGTGAACCTGGAC\nATTATGGCAGGCCAACTTGTGGCTGTGATAGGCCCTGTCGGCTCTGGGAAATCCTCCTTG\nATATCAGCCATGCTGGGAGAAATGGAAAATGTCCACGGGCACATCACCATCAAGGGCACC\nACTGCCTATGTCCCACAGCAGTCCTGGATTCAGAATGGCACCATAAAGGACAACATCCTT\nTTTGGAACAGAGTTTAATGAAAAGAGGTACCAGCAAGTACTGGAGGCCTGTGCTCTCCTC\nCCAGACTTGGAAATGCTGCCTGGAGGAGATTTGGCTGAGATTGGAGAGAAGGGTATAAAT\nCTTAGTGGGGGTCAGAAGCAGCGGATCAGCCTGGCCAGAGCTACCTACCAAAATTTAGAC\nATCTATCTTCTAGATGACCCCCTGTCTGCAGTGGATGCTCATGTAGGAAAACATATTTTT\nAATAAGGTCTTGGGCCCCAATGGCCTGTTGAAAGGCAAGACTCGACTCTTGGTTACACAT\nAGCATGCACTTTCTTCCTCAAGTGGATGAGATTGTAGTTCTGGGGAATGGAACAATTGTA\nGAGAAAGGATCCTACAGTGCTCTCCTGGCCAAAAAAGGAGAGTTTGCTAAGAATCTGAAG\nACATTTCTAAGACATACAGGCCCTGAAGAGGAAGCCACAGTCCATGATGGCAGTGAAGAA\nGAAGACGATGACTATGGGCTGATATCCAGTGTGGAAGAGATCCCCGAAGATGCAGCCTCC\nATAACCATGAGAAGAGAGAACAGCTTTCGTCGAACACTTAGCCGCAGTTCTAGGTCCAAT\nGGCAGGCATCTGAAGTCCCTGAGAAACTCCTTGAAAACTCGGAATGTGAATAGCCTGAAG\nGAAGACGAAGAACTAGTGAAAGGACAAAAACTAATTAAGAAGGAATTCATAGAAACTGGA\nAAGGTGAAGTTCTCCATCTACCTGGAGTACCTACAAGCAATAGGATTGTTTTCGATATTC\nTTCATCATCCTTGCGTTTGTGATGAATTCTGTGGCTTTTATTGGATCCAACCTCTGGCTC\nAGTGCTTGGACCAGTGACTCTAAAATCTTCAATAGCACCGACTATCCAGCATCTCAGAGG\nGACATGAGAGTTGGAGTCTACGGAGCTCTGGGATTAGCCCAAGGTATATTTGTGTTCATA\nGCACATTTCTGGAGTGCCTTTGGTTTCGTCCATGCATCAAATATCTTGCACAAGCAACTG\nCTGAACAATATCCTTCGAGCACCTATGAGATTTTTTGACACAACACCCACAGGCCGGATT\nGTGAACAGGTTTGCCGGCGATATTTCCACAGTGGATGACACCCTGCCTCAGTCCTTGCGC\nAGCTGGATTACATGCTTCCTGGGGATAATCAGCACCCTTGTCATGATCTGCATGGCCACT\nCCTGTCTTCACCATCATCGTCATTCCTCTTGGCATTATTTATGTATCTGTTCAGATGTTT\nTATGTGTCTACCTCCCGCCAGCTGAGGCGTCTGGACTCTGTCACCAGGTCCCCAATCTAC\nTCTCACTTCAGCGAGACCGTATCAGGTTTGCCAGTTATCCGTGCCTTTGAGCACCAGCAG\nCGATTTCTGAAACACAATGAGGTGAGGATTGACACCAACCAGAAATGTGTCTTTTCCTGG\nATCACCTCCAACAGGTGGCTTGCAATTCGCCTGGAGCTGGTTGGGAACCTGACTGTCTTC\nTTTTCAGCCTTGATGATGGTTATTTATAGAGATACCCTAAGTGGGGACACTGTTGGCTTT\nGTTCTGTCCAATGCACTCAATATCACACAAACCCTGAACTGGCTGGTGAGGATGACATCA\nGAAATAGAGACCAACATTGTGGCTGTTGAGCGAATAACTGAGTACACAAAAGTGGAAAAT\nGAGGCACCCTGGGTGACTGATAAGAGGCCTCCGCCAGATTGGCCCAGCAAAGGCAAGATC\nCAGTTTAACAACTACCAAGTGCGGTACCGACCTGAGCTGGATCTGGTCCTCAGAGGGATC\nACTTGTGACATCGGTAGCATGGAGAAGATTGGTGTGGTGGGCAGGACAGGAGCTGGAAAG\nTCATCCCTCACAAACTGCCTCTTCAGAATCTTAGAGGCTGCCGGTGGTCAGATTATCATT\nGATGGAGTAGATATTGCTTCCATTGGGCTCCACGACCTCCGAGAGAAGCTGACCATCATC\nCCCCAGGACCCCATCCTGTTCTCTGGAAGCCTGAGGATGAATCTCGACCCTTTCAACAAC\nTACTCAGATGAGGAGATTTGGAAGGCCTTGGAGCTGGCTCACCTCAAGTCTTTTGTGGCC\nAGCCTGCAACTTGGGTTATCCCACGAAGTGACAGAGGCTGGTGGCAACCTGAGCATAGGC\nCAGAGGCAGCTGCTGTGCCTGGGCAGGGCTCTGCTTCGGAAATCCAAGATCCTGGTCCTG\nGATGAGGCCACTGCTGCGGTGGATCTAGAGACAGACAACCTCATTCAGACGACCATCCAA\nAACGAGTTCGCCCACTGCACAGTGATCACCATCGCCCACAGGCTGCACACCATCATGGAC\nAGTGACAAGGTAATGGTCCTAGACAACGGGAAGATTATAGAGTGCGGCAGCCCTGAAGAA\nCTGCTACAAATCCCTGGACCCTTTTACTTTATGGCTAAGGAAGCTGGCATTGAGAATGTG\nAACAGCACAAAATTCTAG"}, "pfams": {"pfam": [{"identifier": "PF00005", "name": "ABC_tran"}, {"identifier": "PF00664", "name": "ABC_membrane"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "nucleoside-triphosphatase activity"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "function", "description": "ATPase activity"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substances"}, {"category": "function", "description": "ATPase activity, coupled to transmembrane movement of substances"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides"}, {"category": "function", "description": "transporter activity"}, {"category": "function", "description": "pyrophosphatase activity"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}}}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-09-13", "drugbank-id": [{"@primary": "true", "#text": "DB00068"}, "BIOD00078", "BTD00078"], "name": "Interferon beta-1b", "description": "Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD", "cas-number": "145155-23-3", "groups": {"group": "approved"}, "general-references": null, "synthesis-reference": "Heinz-Jurgen Friesen, Sidney Pestka, \"Preparation of homogeneous human fibroblast interferon.\" U.S. Patent US4289689, issued December, 1968.", "indication": "Interferon beta-1b is a drug used for the treatment of relapsing/remitting multiple sclerosis. It has been shown to slow the advance of the disease as well as to decrease the frequency of attacks.", "pharmacodynamics": "Interferon beta upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Type I interferons also induce the synthesis of several key antiviral mediators including 2'-5' oligoadenylate synthetase (2'-5' A synthetase), beta-2 microglobulin, neopterin and protein kinase R.", "mechanism-of-action": "Interferon beta binds to type I interferon receptors (IFNAR1 and IFNAR2c) which activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon beta binds more stably to type I interferon receptors than interferon alpha.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": "* 0.25 to 2,88 L/kg", "clearance": "* 9.4 \u2013 28.9 mL/min\u2022kg-1 [patients with diseases other than MS receiving single intravenous doses up to 2.0 mg]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Fibroblast interferon"}, {"@language": "", "@coder": "", "#text": "IFN-beta"}, {"@language": "", "@coder": "", "#text": "Interferon beta precursor"}]}, "products": {"product": [{"name": "Betaseron", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02169649", "started-marketing-on": "1995-12-31", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "0.3 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Extavia", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02337819", "started-marketing-on": "2010-05-05", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "0.3 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Betaseron", "ingredients": "Interferon beta-1b"}, {"name": "Extavia", "ingredients": "Interferon beta-1b"}]}, "packagers": {"packager": [{"name": "Bayer Healthcare", "url": "http://www.bayerhealthcare.com"}, {"name": "Berlex Labs", "url": "http://www.berlex.com"}, {"name": "Chiron Corp.", "url": "http://www.chiron.com"}, {"name": "InterMune Inc.", "url": "http://www.intermune.com"}, {"name": "Novartis AG", "url": "http://www.novartis.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Extavia 0.3 mg kit", "cost": {"@currency": "USD", "#text": "196.76"}, "unit": "kit"}, {"description": "Betaseron 0.3 mg kit", "cost": {"@currency": "USD", "#text": "227.69"}, "unit": "kit"}, {"description": "Betaseron 14 0.3 mg Solution 1 Box Contains Fourteen .3 mg Vials.", "cost": {"@currency": "USD", "#text": "3315.06"}, "unit": "box"}]}, "categories": {"category": [{"category": "Adjuvants, Immunologic", "mesh-id": null}, {"category": "Immunosuppressive Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": {"form": "Powder for solution", "route": "subcutaneous", "strength": "0.3 mg"}}, "atc-codes": {"atc-code": {"@code": "L03AB08", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L03", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03A", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03AB", "#text": "Interferons"}]}}, "ahfs-codes": null, "patents": {"patent": [{"number": "1339707", "country": "Canada", "approved": "1998-03-10", "expires": "2015-03-10"}, {"number": "1340861", "country": "Canada", "approved": "1999-12-28", "expires": "2016-12-28"}]}, "food-interactions": null, "drug-interactions": {"drug-interaction": {"drugbank-id": "DB00495", "name": "Zidovudine", "description": "Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine."}}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00068 sequence\nMSYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIY\nEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSL\nHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.447", "source": null}, {"kind": "Isoelectric Point", "value": "9.02", "source": null}, {"kind": "Molecular Weight", "value": "20011.0000", "source": null}, {"kind": "Molecular Formula", "value": "C908H1408N246O253S6", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "172"}, {"resource": "KEGG Compound", "identifier": "C07901"}, {"resource": "KEGG Drug", "identifier": "D00746"}, {"resource": "National Drug Code Directory", "identifier": "50419-523-35"}, {"resource": "GenBank", "identifier": "V00534"}, {"resource": "PharmGKB", "identifier": "PA450039"}, {"resource": "UniProtKB", "identifier": "P01574"}, {"resource": "Wikipedia", "identifier": "Interferon_beta-1b"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/interferon_beta.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/interferon-beta-1b-solution.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000661", "name": "Interferon alpha/beta receptor 1", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Russell-Harde D, Wagner TC, Perez HD, Croze E: Formation of a uniquely stable type I interferon receptor complex by interferon beta is dependent upon particular interactions between interferon beta and its receptor and independent of tyrosine phosphorylation. Biochem Biophys Res Commun. 1999 Feb 16;255(2):539-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10049744\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P17181", "@source": "Swiss-Prot", "name": "Interferon alpha/beta receptor 1", "general-function": "Involved in interferon-alpha/beta receptor activity", "specific-function": "Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta- subunits themselves", "gene-name": "IFNAR1", "locus": null, "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "437-457", "signal-regions": null, "theoretical-pi": "5.56", "molecular-weight": "63526.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5432"}, {"resource": "GenAtlas", "identifier": "IFNAR1"}, {"resource": "GeneCards", "identifier": "IFNAR1"}, {"resource": "GenBank Gene Database", "identifier": "J03171"}, {"resource": "GenBank Protein Database", "identifier": "306914"}, {"resource": "UniProtKB", "identifier": "P17181"}, {"resource": "UniProt Accession", "identifier": "INAR1_HUMAN"}]}, "synonyms": {"synonym": ["IFN-alpha-REC", "Interferon-alpha/beta receptor alpha chain precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interferon-alpha/beta receptor alpha chain precursor\nMMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT\nFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF\nTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI\nENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ\nNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK\nGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP\nVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV\nFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE\nYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN\nEDESESKTSEELQQDFV"}, "gene-sequence": {"@format": "FASTA", "#text": ">1674 bp\nATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGGCCCATGGGTG\nTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC\nATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT\nTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG\nAATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT\nAAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT\nACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG\nGCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT\nTTAAGCTTTACATATAGCTTACTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT\nGAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA\nAAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT\nATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA\nAATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG\nTGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA\nCCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA\nGGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA\nGAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA\nTCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT\nGTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT\nGAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT\nGTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT\nTTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA\nGTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC\nTTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG\nTATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA\nAAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT\nGATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT\nGAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA"}, "pfams": null, "go-classifiers": null}}, {"id": "BE0000385", "name": "Interferon alpha/beta receptor 2", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Russell-Harde D, Wagner TC, Perez HD, Croze E: Formation of a uniquely stable type I interferon receptor complex by interferon beta is dependent upon particular interactions between interferon beta and its receptor and independent of tyrosine phosphorylation. Biochem Biophys Res Commun. 1999 Feb 16;255(2):539-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10049744\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P48551", "@source": "Swiss-Prot", "name": "Interferon alpha/beta receptor 2", "general-function": "Involved in interferon-alpha/beta receptor activity", "specific-function": "Receptor for interferons alpha and beta. Isoform 1 and isoform 3 are directly involved in signal transduction due to their interaction with the TYR kinase, JAK1. Isoform 1 also interacts with the transcriptional factors, STAT1 and STAT2. Both forms are potent inhibitors of type I IFN activity", "gene-name": "IFNAR2", "locus": null, "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "244-264", "signal-regions": null, "theoretical-pi": "4.11", "molecular-weight": "57759.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5433"}, {"resource": "GenAtlas", "identifier": "IFNAR2"}, {"resource": "GeneCards", "identifier": "IFNAR2"}, {"resource": "GenBank Gene Database", "identifier": "L42243"}, {"resource": "GenBank Protein Database", "identifier": "995300"}, {"resource": "UniProtKB", "identifier": "P48551"}, {"resource": "UniProt Accession", "identifier": "INAR2_HUMAN"}]}, "synonyms": {"synonym": ["IFN-alpha-REC", "IFN-R", "Interferon alpha/beta receptor 2", "Interferon-alpha/beta receptor beta chain precursor", "Type I interferon receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interferon-alpha/beta receptor beta chain precursor\nMLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS\nIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF\nSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK\nHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE\nSAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD\nMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI\nDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR\nITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT\nFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR"}, "gene-sequence": {"@format": "FASTA", "#text": ">1548 bp\nATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT\nATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT\nTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC\nATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG\nGTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA\nAGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC\nAGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG\nATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA\nGAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG\nCATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA\nATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA\nATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA\nTCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC\nATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG\nAATTTTCATAACTTTTTAGCCTGGCCATTTCCTAACCTGCCACCGTTGGAAGCCATGGAT\nATGGTGGAGGTCATTTACATCAACAGAAAGAAGAAAGTGTGGGATTATAATTATGATGAT\nGAAAGTGATAGCGATACTGAGGCAGCGCCCAGGACAAGTGGCGGTGGCTATACCATGCAT\nGGACTGACTGTCAGGCCTCTGGGTCAGGCCTCTGCCACCTCTACAGAATCCCAGTTGATA\nGACCCGGAGTCCGAGGAGGAGCCTGACCTGCCTGAGGTTGATGTGGAGCTCCCCACGATG\nCCAAAGGACAGCCCTCAGCAGTTGGAACTCTTGAGTGGGCCCTGTGAGAGGAGAAAGAGT\nCCACTCCAGGACCCTTTTCCCGAAGAGGACTACAGCTCCACGGAGGGGTCTGGGGGCAGA\nATTACCTTCAATGTGGACTTAAACTCTGTGTTTTTGAGAGTTCTTGATGACGAGGACAGT\nGACGACTTAGAAGCCCCTCTGATGCTATCGTCTCATCTGGAAGAGATGGTTGACCCAGAG\nGATCCTGATAATGTGCAATCAAACCATTTGCTGGCCAGCGGGGAAGGGACACAGCCAACC\nTTTCCCAGCCCCTCTTCAGAGGGCCTGTGGTCCGAAGATGCTCCATCTGATCAAAGTGAC\nACTTCTGAGTCAGATGTTGACCTTGGGGATGGTTATATAATGAGATGA"}, "pfams": null, "go-classifiers": null}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-11-12", "drugbank-id": [{"@primary": "true", "#text": "DB00069"}, "BIOD00062", "BTD00062"], "name": "Interferon alfacon-1", "description": "Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional amino acid changes were made to facilitate the molecular construction, and a corresponding synthetic DNA sequence was constructed using chemical synthesis methodology. Interferon alfacon-1 differs from interferon alfa-2b at 20/166 amino acids (88% homology), and comparison with interferon-beta shows identity at over 30% of the amino acid positions. Interferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1. Prior to final purification, Interferon alfacon-1 is allowed to oxidize to its native state, and its final purity is achieved by sequential passage over a series of chromatography columns. This protein has a molecular weight of 19,434 daltons.", "cas-number": "118390-30-0", "groups": {"group": "approved"}, "general-references": "# Blatt LM, Davis JM, Klein SB, Taylor MW: The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res. 1996 Jul;16(7):489-99. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8836913\n# http://www.google.com/patents/EP0422697A1?cl=en\n# Lexicomp Online (2014). Interferon Alfacon-1. Available at: http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7093#f_pharmacology-and-pharmacokinetics [Accessed 12 Nov. \n2014].", "synthesis-reference": "Lin Wang, \" NEW TYPE OF CONSENSUS INTERFERON AND PREPARATION METHOD THEREOF.\" U.S. Patent US20100266536, issued October 21, 2010.", "indication": "For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma", "pharmacodynamics": "Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.", "mechanism-of-action": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta. The resulting actions include gene transcription, inhibition of cellular growth, alteration of the state of cellular differentiation, interference with oncogene expression, alteration of cell surface antigen expression, increasing phagocytic activity of macrophages, and augmentation of the cytotoxicity of lymphocytes for target cells.", "toxicity": "Reproductive toxicity studies in pregnant rhesus monkeys and golden Syrian hamsters demonstrated an increase in fetal loss in hamsters treated with Interferon alfacon-1 at doses of > 150 mcg/kg/day, and in rhesus monkeys at doses of 3 and 10 mcg/kg/day. The Interferon alfacon-1 toxicity profile described is consistent with the known toxicity profile of other alpha interferons.", "metabolism": null, "absorption": "Subcutaneous bioavailability averages 99% in golden Syrian hamsters and 83% to 104% in rhesus monkeys.", "half-life": "The terminal half-life following subcutaneous dosing was 1.3 hours in golden Syrian hamsters and 3.4 hours in rhesus monkeys.", "protein-binding": null, "route-of-elimination": "Due predominantly to catabolism and excretion by the kidneys.", "volume-of-distribution": null, "clearance": "Clearance,  averaging 1.99 mL/minute/kg in golden Syrian hamsters and 0.71 to 0.92 mL/minute/kg in rhesus monkeys", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "CIFN"}, {"@language": "", "@coder": "", "#text": "consensus interferon"}, {"@language": "", "@coder": "", "#text": "IFN Alfacon-1"}, {"@language": "", "@coder": "", "#text": "Interferon Consensus, Methionyl"}, {"@language": "", "@coder": "", "#text": "methionyl interferon consensus"}, {"@language": "", "@coder": "", "#text": "methionyl-interferon-consensus"}, {"@language": "", "@coder": "", "#text": "rCon-IFN"}, {"@language": "", "@coder": "", "#text": "Recombinant Consensus Interferon"}, {"@language": "", "@coder": "", "#text": "Recombinant methionyl human consensus interferon"}]}, "products": {"product": {"name": "Infergen", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02239832", "started-marketing-on": "1999-07-12", "ended-marketing-on": "2012-10-31", "dosage-form": "solution", "strength": "0.03 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}}, "international-brands": {"international-brand": {"name": "Advaferon", "company": null}}, "mixtures": {"mixture": {"name": "Infergen", "ingredients": "Interferon alfacon-1"}}, "packagers": {"packager": [{"name": "Amgen Inc.", "url": "http://www.amgen.com"}, {"name": "InterMune Inc.", "url": "http://www.intermune.com"}, {"name": "Three Rivers Pharmaceuticals LLC", "url": "http://www.3riverspharma.com"}, {"name": "Valeant Ltd.", "url": "http://www.valeant.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Infergen 9 mcg/0.3 ml vial", "cost": {"@currency": "USD", "#text": "129.08"}, "unit": "vial"}, {"description": "Infergen 15 mcg/0.5ml Injectable 0.5ml Vial", "cost": {"@currency": "USD", "#text": "134.24"}, "unit": "vial"}]}, "categories": {"category": [{"category": "Antiviral Agents", "mesh-id": null}, {"category": "Immunosuppressive Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": {"form": "Solution", "route": "subcutaneous", "strength": "0.03 mg"}}, "atc-codes": {"atc-code": {"@code": "L03AB09", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L03", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03A", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03AB", "#text": "Interferons"}]}}, "ahfs-codes": {"ahfs-code": "10:00.00"}, "patents": null, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00041", "name": "Aldesleukin", "description": "Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination."}, {"drugbank-id": "DB00363", "name": "Clozapine", "description": "Myelosuppressive Agents may enhance the adverse/toxic effect of Clozapine. Specifically, the risk for agranulocytosis may be increased."}, {"drugbank-id": "DB04817", "name": "Metamizole", "description": "May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased"}, {"drugbank-id": "DB00333", "name": "Methadone", "description": "Interferons (Alfa) may increase the serum concentration of Methadone."}, {"drugbank-id": "DB00811", "name": "Ribavirin", "description": "Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin. Hemolytic anemia has been observed."}, {"drugbank-id": "DB00495", "name": "Zidovudine", "description": "Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": "> Interferon alfacon-1\nMCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHE\nMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILA\nVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "61 \u00b0C", "source": "Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)"}, {"kind": "Hydrophobicity", "value": "-0.336", "source": null}, {"kind": "Isoelectric Point", "value": "5.99", "source": null}, {"kind": "Molecular Weight", "value": "19343.0000", "source": null}, {"kind": "Molecular Formula", "value": "C860H1353N227O255S9", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "11856"}, {"resource": "National Drug Code Directory", "identifier": "0187-2007-06"}, {"resource": "GenBank", "identifier": "J00207"}, {"resource": "PharmGKB", "identifier": "PA164749376"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic2/infergen.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/interferon-alfacon-1.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000661", "name": "Interferon alpha/beta receptor 1", "organism": "Human", "actions": {"action": "binder"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Yasuda S, Miyata K: [Interferon alfacon-1 (Advaferon): a novel synthetic interferon for the treatment of hepatitis C, its pharmacological and clinical profile] Nippon Yakurigaku Zasshi. 2002 Dec;120(6):421-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12528473\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P17181", "@source": "Swiss-Prot", "name": "Interferon alpha/beta receptor 1", "general-function": "Involved in interferon-alpha/beta receptor activity", "specific-function": "Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta- subunits themselves", "gene-name": "IFNAR1", "locus": null, "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "437-457", "signal-regions": null, "theoretical-pi": "5.56", "molecular-weight": "63526.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5432"}, {"resource": "GenAtlas", "identifier": "IFNAR1"}, {"resource": "GeneCards", "identifier": "IFNAR1"}, {"resource": "GenBank Gene Database", "identifier": "J03171"}, {"resource": "GenBank Protein Database", "identifier": "306914"}, {"resource": "UniProtKB", "identifier": "P17181"}, {"resource": "UniProt Accession", "identifier": "INAR1_HUMAN"}]}, "synonyms": {"synonym": ["IFN-alpha-REC", "Interferon-alpha/beta receptor alpha chain precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interferon-alpha/beta receptor alpha chain precursor\nMMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT\nFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF\nTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI\nENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ\nNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK\nGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP\nVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV\nFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE\nYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN\nEDESESKTSEELQQDFV"}, "gene-sequence": {"@format": "FASTA", "#text": ">1674 bp\nATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGGCCCATGGGTG\nTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC\nATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT\nTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG\nAATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT\nAAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT\nACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG\nGCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT\nTTAAGCTTTACATATAGCTTACTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT\nGAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA\nAAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT\nATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA\nAATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG\nTGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA\nCCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA\nGGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA\nGAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA\nTCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT\nGTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT\nGAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT\nGTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT\nTTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA\nGTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC\nTTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG\nTATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA\nAAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT\nGATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT\nGAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA"}, "pfams": null, "go-classifiers": null}}, {"id": "BE0000385", "name": "Interferon alpha/beta receptor 2", "organism": "Human", "actions": {"action": "binder"}, "references": "# Blatt LM, Davis JM, Klein SB, Taylor MW: The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res. 1996 Jul;16(7):489-99. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8836913\n# Yasuda S, Miyata K: [Interferon alfacon-1 (Advaferon): a novel synthetic interferon for the treatment of hepatitis C, its pharmacological and clinical profile] Nippon Yakurigaku Zasshi. 2002 Dec;120(6):421-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12528473\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P48551", "@source": "Swiss-Prot", "name": "Interferon alpha/beta receptor 2", "general-function": "Involved in interferon-alpha/beta receptor activity", "specific-function": "Receptor for interferons alpha and beta. Isoform 1 and isoform 3 are directly involved in signal transduction due to their interaction with the TYR kinase, JAK1. Isoform 1 also interacts with the transcriptional factors, STAT1 and STAT2. Both forms are potent inhibitors of type I IFN activity", "gene-name": "IFNAR2", "locus": null, "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "244-264", "signal-regions": null, "theoretical-pi": "4.11", "molecular-weight": "57759.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5433"}, {"resource": "GenAtlas", "identifier": "IFNAR2"}, {"resource": "GeneCards", "identifier": "IFNAR2"}, {"resource": "GenBank Gene Database", "identifier": "L42243"}, {"resource": "GenBank Protein Database", "identifier": "995300"}, {"resource": "UniProtKB", "identifier": "P48551"}, {"resource": "UniProt Accession", "identifier": "INAR2_HUMAN"}]}, "synonyms": {"synonym": ["IFN-alpha-REC", "IFN-R", "Interferon alpha/beta receptor 2", "Interferon-alpha/beta receptor beta chain precursor", "Type I interferon receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interferon-alpha/beta receptor beta chain precursor\nMLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS\nIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF\nSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK\nHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE\nSAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD\nMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI\nDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR\nITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT\nFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR"}, "gene-sequence": {"@format": "FASTA", "#text": ">1548 bp\nATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT\nATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT\nTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC\nATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG\nGTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA\nAGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC\nAGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG\nATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA\nGAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG\nCATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA\nATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA\nATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA\nTCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC\nATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG\nAATTTTCATAACTTTTTAGCCTGGCCATTTCCTAACCTGCCACCGTTGGAAGCCATGGAT\nATGGTGGAGGTCATTTACATCAACAGAAAGAAGAAAGTGTGGGATTATAATTATGATGAT\nGAAAGTGATAGCGATACTGAGGCAGCGCCCAGGACAAGTGGCGGTGGCTATACCATGCAT\nGGACTGACTGTCAGGCCTCTGGGTCAGGCCTCTGCCACCTCTACAGAATCCCAGTTGATA\nGACCCGGAGTCCGAGGAGGAGCCTGACCTGCCTGAGGTTGATGTGGAGCTCCCCACGATG\nCCAAAGGACAGCCCTCAGCAGTTGGAACTCTTGAGTGGGCCCTGTGAGAGGAGAAAGAGT\nCCACTCCAGGACCCTTTTCCCGAAGAGGACTACAGCTCCACGGAGGGGTCTGGGGGCAGA\nATTACCTTCAATGTGGACTTAAACTCTGTGTTTTTGAGAGTTCTTGATGACGAGGACAGT\nGACGACTTAGAAGCCCCTCTGATGCTATCGTCTCATCTGGAAGAGATGGTTGACCCAGAG\nGATCCTGATAATGTGCAATCAAACCATTTGCTGGCCAGCGGGGAAGGGACACAGCCAACC\nTTTCCCAGCCCCTCTTCAGAGGGCCTGTGGTCCGAAGATGCTCCATCTGATCAAAGTGAC\nACTTCTGAGTCAGATGTTGACCTTGGGGATGGTTATATAATGAGATGA"}, "pfams": null, "go-classifiers": null}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-12-02", "drugbank-id": [{"@primary": "true", "#text": "DB00070"}, "BIOD00022", "BTD00022"], "name": "Hyaluronidase", "description": "Highly purified sheep hyaluronidase for administration by injection into the vitreous of the eye.", "cas-number": "488712-31-8", "groups": {"group": ["approved", "investigational"]}, "general-references": "# Csoka AB, Scherer SW, Stern R: Expression analysis of six paralogous human hyaluronidase genes clustered on chromosomes 3p21 and 7q31. Genomics. 1999 Sep 15;60(3):356-61. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10493834", "synthesis-reference": "Yasuhiro Mima, Masaaki Yamada, \"Preparation of human placental hyaluronidase.\" U.S. Patent US3945889, issued October, 1957.", "indication": "For increase of absorption and distribution of other injected drugs and for rehydration.", "pharmacodynamics": "Hyaluronidase hydrolyzes hyaluronic acid and increase diffusion of injected drugs, thus facilitating their absorption. Hyaluronidase is used for enhancing absorption and distribution of other injected drugs.", "mechanism-of-action": "Hyaluronidase is a spreading or diffusing substance. It increase the permeability of connective tissue through the hydrolysis of hyaluronic acid. Hyaluronidase hydrolyzes hyaluronic acid by splitting the glucosaminidic bond between C1 of the glucosamine moiety and C4 of glucuronic acid. This temporarily decreases the viscosity of the cellular cement and increases diffusion of injected fluids or of localized transudates or exudates, thus facilitating their absorption.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "HYAL-1"}, {"@language": "", "@coder": "", "#text": "Hyaluronidase 1 precursor"}, {"@language": "", "@coder": "", "#text": "Hyaluronidase PH-20"}, {"@language": "", "@coder": "", "#text": "Sperm adhesion molecule 1"}, {"@language": "", "@coder": "", "#text": "Sperm surface protein PH-20"}]}, "products": {"product": [{"name": "Amphadase", "ndc-id": "0548-9090_23cf2b43-e737-4b7d-abe4-fc1a5fd93733", "ndc-product-code": "0548-9090", "dpd-id": null, "started-marketing-on": "2004-10-26", "ended-marketing-on": null, "dosage-form": "injection", "strength": "150 [USP'U]/mL", "route": "subcutaneous", "fda-application-number": "NDA021665", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Wydase Inj 150unit/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00036307", "started-marketing-on": "1954-12-31", "ended-marketing-on": "1996-09-10", "dosage-form": "liquid", "strength": "150 unit", "route": "block/infiltration; subcutaneous; surgical", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Wydase Injection Liq 150 Units/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02041278", "started-marketing-on": "1994-12-31", "ended-marketing-on": "2002-06-10", "dosage-form": "liquid", "strength": "150 unit", "route": "block/infiltration; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": {"name": "Vitragan", "company": null}}, "mixtures": {"mixture": [{"name": "Amphadase", "ingredients": "Hyaluronidase"}, {"name": "Wydase Inj 150unit/ml", "ingredients": "Hyaluronidase"}, {"name": "Wydase Injection Liq 150 Units/ml", "ingredients": "Hyaluronidase"}]}, "packagers": {"packager": [{"name": "Akorn Inc.", "url": "http://www.akorn.com"}, {"name": "Amphastar Pharmaceuticals", "url": "http://www.amphastar.com"}, {"name": "Bausch & Lomb Inc.", "url": "http://www.bausch.com"}, {"name": "Baxter International Inc.", "url": "http://www.baxter.com"}, {"name": "Cardinal Health", "url": "http://www.cardinal.com"}, {"name": "Halozyme Therapeutics Inc.", "url": "http://www.halozyme.com"}, {"name": "ISTA Pharmaceuticals", "url": "http://www.istavision.com"}, {"name": "Oso Biopharmaceuticals Manufacturing LLC", "url": null}, {"name": "Primapharm Inc.", "url": "http://www.primapharm.net"}, {"name": "Professional Co.", "url": null}]}, "manufacturers": {"manufacturer": [{"@generic": "false", "#text": "Amphastar pharmaceutical inc"}, {"@generic": "false", "#text": "Primapharm inc"}, {"@generic": "false", "#text": "Ista pharmaceuticals"}, {"@generic": "false", "#text": "Baxter healthcare corp anesthesia and critical care"}]}, "prices": {"price": [{"description": "Hylenex 150 unit/ml vial", "cost": {"@currency": "USD", "#text": "108.0"}, "unit": "ml"}, {"description": "Hyaluronidase powder", "cost": {"@currency": "USD", "#text": "900.0"}, "unit": "g"}, {"description": "Vitrase 6200 unit vial", "cost": {"@currency": "USD", "#text": "967.2"}, "unit": "vial"}, {"description": "Vitrasert 4.5 mg implant", "cost": {"@currency": "USD", "#text": "19200.0"}, "unit": "implant"}]}, "categories": {"category": [{"category": "Adjuvants, Anesthesia", "mesh-id": null}, {"category": "Permeabilizing Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection", "route": "subcutaneous", "strength": "150 [USP'U]/mL"}, {"form": "Liquid", "route": "block/infiltration; subcutaneous; surgical", "strength": "150 unit"}, {"form": "Liquid", "route": "block/infiltration; subcutaneous", "strength": "150 unit"}]}, "atc-codes": {"atc-code": {"@code": "B06AA03", "level": [{"@code": "B", "#text": "BLOOD AND BLOOD FORMING ORGANS"}, {"@code": "B06", "#text": "OTHER HEMATOLOGICAL AGENTS"}, {"@code": "B06A", "#text": "OTHER HEMATOLOGICAL AGENTS"}, {"@code": "B06AA", "#text": "Enzymes"}]}}, "ahfs-codes": null, "patents": null, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00945", "name": "Acetylsalicylic acid", "description": "Salicylates may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00240", "name": "Alclometasone", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00288", "name": "Amcinonide", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00233", "name": "Aminosalicylic Acid", "description": "Salicylates may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB09009", "name": "Articaine", "description": "May enhance the vasoconstricting effect of Alpha-/Beta-Agonists."}, {"drugbank-id": "DB00972", "name": "Azelastine", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00394", "name": "Beclomethasone", "description": "May diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00443", "name": "Betamethasone", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB01294", "name": "Bismuth Subsalicylate", "description": "Salicylates may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00835", "name": "Brompheniramine", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB01222", "name": "Budesonide", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00297", "name": "Bupivacaine", "description": "May enhance the adverse/toxic effect of Local Anesthetics."}, {"drugbank-id": "DB02300", "name": "Calcipotriol", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00748", "name": "Carbinoxamine", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00341", "name": "Cetirizine", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB01161", "name": "Chloroprocaine", "description": "May enhance the adverse/toxic effect of Local Anesthetics."}, {"drugbank-id": "DB01114", "name": "Chlorphenamine", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00283", "name": "Clemastine", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB01013", "name": "Clobetasol propionate", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00838", "name": "Clocortolone", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00318", "name": "Codeine", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB01285", "name": "Corticotropin", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB01380", "name": "Cortisone acetate", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB01176", "name": "Cyclizine", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00434", "name": "Cyproheptadine", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00967", "name": "Desloratadine", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00304", "name": "Desogestrel", "description": "Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00547", "name": "Desoximetasone", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB01234", "name": "Dexamethasone", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00405", "name": "Dexbrompheniramine", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00223", "name": "Diflorasone", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB01551", "name": "Dihydrocodeine", "description": "Salicylates may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00985", "name": "Dimenhydrinate", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB01075", "name": "Diphenhydramine", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00988", "name": "Dopamine", "description": "Hyaluronidase may enhance the adverse/toxic effect of Dopamine."}, {"drugbank-id": "DB00366", "name": "Doxylamine", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB01395", "name": "Drospirenone", "description": "Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB01364", "name": "Ephedrine", "description": "May enhance the vasoconstricting effect of Alpha-/Beta-Agonists."}, {"drugbank-id": "DB00668", "name": "Epinephrine", "description": "May enhance the vasoconstricting effect of Alpha-/Beta-Agonists."}, {"drugbank-id": "DB00783", "name": "Estradiol", "description": "Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB04574", "name": "Estropipate", "description": "Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00977", "name": "Ethinyl Estradiol", "description": "Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00823", "name": "Ethynodiol", "description": "Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00950", "name": "Fexofenadine", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00687", "name": "Fludrocortisone", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00591", "name": "Fluocinolone Acetonide", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB01047", "name": "Fluocinonide", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00324", "name": "Fluorometholone", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00846", "name": "Flurandrenolide", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB08906", "name": "Fluticasone furoate", "description": "May diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00588", "name": "Fluticasone Propionate", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB06786", "name": "Halcinonide", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00596", "name": "Halobetasol Propionate", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00769", "name": "Hydrocortamate", "description": "May diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00741", "name": "Hydrocortisone", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00557", "name": "Hydroxyzine", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB01106", "name": "Levocabastine", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB06282", "name": "Levocetirizine", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB06707", "name": "Levonordefrin", "description": "May enhance the vasoconstricting effect of Alpha-/Beta-Agonists."}, {"drugbank-id": "DB00281", "name": "Lidocaine", "description": "May enhance the adverse/toxic effect of Local Anesthetics."}, {"drugbank-id": "DB00455", "name": "Loratadine", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB01397", "name": "Magnesium salicylate", "description": "Salicylates may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00737", "name": "Meclizine", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00961", "name": "Mepivacaine", "description": "May enhance the adverse/toxic effect of Local Anesthetics."}, {"drugbank-id": "DB01357", "name": "Mestranol", "description": "Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00959", "name": "Methylprednisolone", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00764", "name": "Mometasone", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00368", "name": "Norepinephrine", "description": "May enhance the vasoconstricting effect of Alpha-/Beta-Agonists."}, {"drugbank-id": "DB00957", "name": "Norgestimate", "description": "Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00768", "name": "Olopatadine", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00388", "name": "Phenylephrine", "description": "May enhance the vasoconstricting effect of Phenylephrine (Systemic)."}, {"drugbank-id": "DB00592", "name": "Piperazine", "description": "Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB06153", "name": "Pizotifen", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB01130", "name": "Prednicarbate", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00860", "name": "Prednisolone", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00635", "name": "Prednisone", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00750", "name": "Prilocaine", "description": "May enhance the adverse/toxic effect of Local Anesthetics."}, {"drugbank-id": "DB00896", "name": "Rimexolone", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00296", "name": "Ropivacaine", "description": "May enhance the adverse/toxic effect of Local Anesthetics."}, {"drugbank-id": "DB01398", "name": "Salicylate-sodium", "description": "May diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB01399", "name": "Salsalate", "description": "Salicylates may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB09085", "name": "Tetracaine", "description": "May enhance the adverse/toxic effect of Local Anesthetics."}, {"drugbank-id": "DB00620", "name": "Triamcinolone", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB00427", "name": "Triprolidine", "description": "Antihistamines may diminish the therapeutic effect of Hyaluronidase."}, {"drugbank-id": "DB09082", "name": "Vilanterol", "description": "Corticosteroids may diminish the therapeutic effect of Hyaluronidase."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": "> Hyaluronidase Sequence\nMWTGLGPAVTLALVLVVAWATELKPTAPPIFTGRPFVVAWDVPTQDCGPRHKMPLDPKDM\nKAFDVQASPNEGFVNQNITIFYRDRLGMYPHFNSVGGSVHGGVPQNGSLWVHLEMLKGHV\nEHYIRTQEPAGLAVIDWEDWRPVWVRNWQDKDVYRRLSRQLVASHHPDWPPERIVKEAQY\nEFEFAARQFMLETLRFVKAFRPRHLWGFYLFPDCYNHDYVQNWETYTGRCPDVEVSRNDQ\nLSWLWAESTALFPSVYLEETLASSTHGRNFVSFRVQEALRVADVHHANHALPVYVFTRPT\nYSRGLTGLSEMDLISTIGESAALGAAGVILWGDAGFTTSNETCRRLKDYLTRSLVPYVVN\nVSWAAQYCSWAQCHGHGRCVRRDPNAHTFLHLSASSFRLVPSHAPDEPRLRPEGELSWAD\nRNHLQTHFRCQCYLGWGGEQCQWDRRRAAGGASGAWAGFHLTGLLAVAVLAFTWTS"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.117", "source": null}, {"kind": "Isoelectric Point", "value": "5.73", "source": null}, {"kind": "Molecular Weight", "value": "53870.9000", "source": null}, {"kind": "Molecular Formula", "value": "C2455H3775N617O704S21", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "6039"}, {"resource": "National Drug Code Directory", "identifier": "0548-9090-10"}, {"resource": "GenBank", "identifier": "L13781"}, {"resource": "PharmGKB", "identifier": "PA164745713"}, {"resource": "UniProtKB", "identifier": "P38567"}, {"resource": "Wikipedia", "identifier": "Hyaluronidase"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/hylenex.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/hyaluronidase.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0004821", "name": "Hyaluronan", "organism": "Human", "actions": {"action": "other"}, "references": "# Nelson, D.L., & Cox, M.M. (2005). _Lehninger principles of biochemistry_ (4 ^th^ ed). New York, NY: W.H. Freeman and Company. \"doi:10.1002/bmb.2005.494033010419\":http://dx.doi.org/10.1002/bmb.2005.494033010419", "known-action": "yes"}, {"@position": "2", "id": "BE0000984", "name": "Transforming growth factor beta-1", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Chang NS: Hyaluronidase activation of c-Jun N-terminal kinase is necessary for protection of L929 fibrosarcoma cells from staurosporine-mediated cell death. Biochem Biophys Res Commun. 2001 May 4;283(2):278-86. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11327694\n# Locci P, Marinucci L, Lilli C, Martinese D, Becchetti E: Transforming growth factor beta 1-hyaluronic acid interaction. Cell Tissue Res. 1995 Aug;281(2):317-24. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7648625\n# Chang NS: Hyaluronidase enhancement of TNF-mediated cell death is reversed by TGF-beta 1. Am J Physiol. 1997 Dec;273(6 Pt 1):C1987-94. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9435505\n# Chang NS: Transforming growth factor-beta protection of cancer cells against tumor necrosis factor cytotoxicity is counteracted by hyaluronidase (review). Int J Mol Med. 1998 Dec;2(6):653-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9850732", "known-action": "unknown", "polypeptide": {"@id": "P01137", "@source": "Swiss-Prot", "name": "Transforming growth factor beta-1", "general-function": "Involved in transforming growth factor beta receptor binding", "specific-function": "Multifunctional protein that control proliferation, differentiation, and other functions in many cell types. Many cells synthesize TGFB1 and essentially all of them have specific receptors for this protein. It regulates the actions of many other growth factors and determines a positive or negative direction of their effects. It plays an important role in bone remodelling. It is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts", "gene-name": "TGFB1", "locus": "19q13.2|19q13.1", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.63", "molecular-weight": "44342.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:11766"}, {"resource": "GenAtlas", "identifier": "TGFB1"}, {"resource": "GeneCards", "identifier": "TGFB1"}, {"resource": "GenBank Gene Database", "identifier": "X05839"}, {"resource": "GenBank Protein Database", "identifier": "1212989"}, {"resource": "UniProtKB", "identifier": "P01137"}, {"resource": "UniProt Accession", "identifier": "TGFB1_HUMAN"}]}, "synonyms": {"synonym": ["TGF-beta-1", "Transforming growth factor beta-1 precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Transforming growth factor beta-1 precursor\nMPPSGLRLLLLLLPLLWLLVLTPGRPAAGLSTCKTIDMELVKRKRIEAIRGQILSKLRLA\nSPPSQGEVPPGPLPEAVLALYNSTRDRVAGESAEPEPEPEADYYAKEVTRVLMVETHNEI\nYDKFKQSTHSIYMFFNTSELREAVPEPVLLSRAELRLLRLKLKVEQHVELYQKYSNNSWR\nYLSNRLLAPSDSPEWLSFDVTGVVRQWLSRGGEIEGFRLSAHCSCDSRDNTLQVDINGFT\nTGRRGDLATIHGMNRPFLLLMATPLERAQHLQSSRHRRALDTNYCFSSTEKNCCVRQLYI\nDFRKDLGWKWIHEPKGYHANFCLGPCPYIWSLDTQYSKVLALYNQHNPGASAAPCCVPQA\nLEPLPIVYYVGRKPKVEQLSNMIVRSCKCS"}, "gene-sequence": {"@format": "FASTA", "#text": ">1173 bp\nATGCCGCCCTCCGGGCTGCGGCTGCTGCTGCTGCTGCTACCGCTGCTGTGGCTACTGGTG\nCTGACGCCTGGCCGGCCGGCCGCGGGACTATCCACCTGCAAGACTATCGACATGGAGCTG\nGTGAAGCGGAAGCGCATCGAGGCCATCCGCGGCCAGATCCTGTCCAAGCTGCGGCTCGCC\nAGCCCCCCGAGCCAGGGGGAGGTGCCGCCCGGCCCGCTGCCCGAGGCCGTGCTCGCCCTG\nTACAACAGCACCCGCGACCGGGTGGCCGGGGAGAGTGCAGAACCGGAGCCCGAGCCTGAG\nGCCGACTACTACGCCAAGGAGGTCACCCGCGTGCTAATGGTGGAAACCCACAACGAAATC\nTATGACAAGTTCAAGCAGAGTACACACAGCATATATATGTTCTTCAACACATCAGAGCTC\nCGAGAAGCGGTACCTGAACCCGTGTTGCTCTCCCGGGCAGAGCTGCGTCTGCTGAGGCTC\nAAGTTAAAAGTGGAGCAGCACGTGGAGCTGTACCAGAAATACAGCAACAATTCCTGGCGA\nTACCTCAGCAACCGGCTGCTGGCACCCAGCGACTCGCCAGAGTGGTTATCTTTTGATGTC\nACCGGAGTTGTGCGGCAGTGGTTGAGCCGTGGAGGGGAAATTGAGGGCTTTCGCCTTAGC\nGCCCACTGCTCCTGTGACAGCAGGGATAACACACTGCAAGTGGACATCAACGGGTTCACT\nACCGGCCGCCGAGGTGACCTGGCCACCATTCATGGCATGAACCGGCCTTTCCTGCTTCTC\nATGGCCACCCCGCTGGAGAGGGCCCAGCATCTGCAAAGCTCCCGGCACCGCCGAGCCCTG\nGACACCAACTATTGCTTCAGCTCCACGGAGAAGAACTGCTGCGTGCGGCAGCTGTACATT\nGACTTCCGCAAGGACCTCGGCTGGAAGTGGATCCACGAGCCCAAGGGCTACCATGCCAAC\nTTCTGCCTCGGGCCCTGCCCCTACATTTGGAGCCTGGACACGCAGTACAGCAAGGTCCTG\nGCCCTGTACAACCAGCATAACCCGGGCGCCTCGGCGGCGCCGTGCTGCGTGCCGCAGGCG\nCTGGAGCCGCTGCCCATCGTGTACTACGTGGGCCGCAAGCCCAAGGTGGAGCAGCTGTCC\nAACATGATCGTGCGCTCCTGCAAGTGCAGCTAG"}, "pfams": {"pfam": [{"identifier": "PF00019", "name": "TGF_beta"}, {"identifier": "PF00688", "name": "TGFb_propeptide"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "growth factor activity"}, {"category": "function", "description": "receptor binding"}, {"category": "function", "description": "transforming growth factor beta receptor binding"}, {"category": "process", "description": "growth"}, {"category": "process", "description": "cell growth"}]}}}]}, "enzymes": null, "carriers": {"carrier": {"@position": "5", "id": "BE0000530", "name": "Serum albumin", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Maingonnat C, Victor R, Bertrand P, Courel MN, Maunoury R, Delpech B: Activation and inhibition of human cancer cell hyaluronidase by proteins. Anal Biochem. 1999 Mar 1;268(1):30-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10036158\n# Parameswaran S, Brown LV, Ibbott GS, Lai-Fook SJ: Effect of concentration and hyaluronidase on albumin diffusion across rabbit mesentery. Microcirculation. 1999 Jun;6(2):117-26. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10466114", "known-action": "unknown", "polypeptide": {"@id": "P02768", "@source": "Swiss-Prot", "name": "Serum albumin", "general-function": "Involved in antioxidant activity", "specific-function": "Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood", "gene-name": "ALB", "locus": "4q11-q13", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.21", "molecular-weight": "69367.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:399"}, {"resource": "GenAtlas", "identifier": "ALB"}, {"resource": "GeneCards", "identifier": "ALB"}, {"resource": "GenBank Gene Database", "identifier": "V00494"}, {"resource": "GenBank Protein Database", "identifier": "28590"}, {"resource": "UniProtKB", "identifier": "P02768"}, {"resource": "UniProt Accession", "identifier": "ALBU_HUMAN"}]}, "synonyms": {"synonym": "Serum albumin precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Serum albumin precursor\nMKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF\nEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEP\nERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF\nFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV\nARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK\nECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYAR\nRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFE\nQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV\nLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTL\nSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV\nAASQAALGL"}, "gene-sequence": {"@format": "FASTA", "#text": ">1830 bp\nATGAAGTGGGTAACCTTTATTTCCCTTCTTTTTCTCTTTAGCTCGGCTTATTCCAGGGGT\nGTGTTTCGTCGAGATGCACACAAGAGTGAGGTTGCTCATCGGTTTAAAGATTTGGGAGAA\nGAAAATTTCAAAGCCTTGGTGTTGATTGCCTTTGCTCAGTATCTTCAGCAGTGTCCATTT\nGAAGATCATGTAAAATTAGTGAATGAAGTAACTGAATTTGCAAAAACATGTGTTGCTGAT\nGAGTCAGCTGAAAATTGTGACAAATCACTTCATACCCTTTTTGGAGACAAATTATGCACA\nGTTGCAACTCTTCGTGAAACCTATGGTGAAATGGCTGACTGCTGTGCAAAACAAGAACCT\nGGGAGAAATGAATGCTTCTTGCAACACAAAGATGACAACCCAAACCTCCCCCGATTGGTG\nAGACCAGAGGTTGATGTGATGTGCACTGCTTTTCATGACAATGAAGAGACATTTTTGAAA\nAAATACTTATATGAAATTGCCAGAAGACATCCTTACTTTTATGCCCCGGAACTCCTTTTC\nTTTGCTAAAAGGTATAAAGCTGCTTTTACAGAATGTTGCCAAGCTGCTGATAAAGCTGCC\nTGCCTGTTGCCAAAGCTCGATGAACTTCGGGATGAAGGGAAGGCTTCGTCTGCCAAACAG\nAGACTCAAGTGTGCCAGTCTCCAAAAATTTGGAGAAAGAGCTTTCAAAGCATGGGCAGTA\nGCTCGCCTGAGCCAGAGATTTCCCAAAGCTGAGTTTGCAGAAGTTTCCAAGTTAGTGACA\nGATCTTACCAAAGTCCACACGGAATGCTGCCATGGAGATCTGCTTGAATGTGCTGATGAC\nAGGGCGGACCTTGCCAAGTATATCTGTGAAAATCAAGATTCGATCTCCAGTAAACTGAAG\nGAATGCTGTGAAAAACCTCTGTTGGAAAAATCCCACTGCATTGCCGAAGTGGAAAATGAT\nGAGATGCCTGCTGACTTGCCTTCATTAGCTGCTGATTTTGTTGAAAGTAAGGATGTTTGC\nAAAAACTATGCTGAGGCAAAGGATGTCTTCTTGGGCATGTTTTTGTATGAATATGCAAGA\nAGGCATCCTGATTACTCTGTCGTGCTGCTGCTGAGACTTGCCAAGACATATGAAACCACT\nCTAGAGAAGTGCTGTGCCGCTGCAGATCCTCATGAATGCTATGCCAAAGTGTTCGATGAA\nTTTAAACCTCTTGTGGAAGAGCCTCAGAATTTAATCAAACAAAATTGTGAGCTTTTTGAG\nCAGCTTGGAGAGTACAAATTCCAGAATGCGCTGTTAGTTCGTTACACCAAGAAAGTACCC\nGAAGTGTCAACTCCAACTCTTGTAGAGGTCTCAAGAAACCTAGGAAAAGTGGGCAGCAAA\nTGTTGTAAACATCCTGAAGCAAAAAGAATGCCCTGTGCAGAAGACTATCTATCCGTGGTC\nCTGAACCAGTTATGTGTGTTGCATGAGAAAACGCCAGTAAGTGACAGAGTCACCAAATGC\nTGCACAGAATCCTTGGTGAACAGGCGACCATGCTTTTCAGCTCTGGAAGTCGATGAAACA\nTACGTTCCCAAAGAGTTTAATGCTGAAACATTCACCTTCCATGCAGATATATGCACACTT\nTCTGAGAAGGAGAGACAAATCAAGAAACAAACTGCACTTGTTGAGCTCGTGAAACACAAG\nCCCAAGGCAACAAAAGAGCAACTGAAAGCTGTTATGGATGATTTCGCTGCTTTTGTAGAG\nAAGTGCTGCAAGGCTGACGATAAGGAGACCTGCTTTGCCGAGGAGGGTAAAAAACTTGTT\nGCTGCAAGTCAAGCTGCCTTAGGCTTATAA"}, "pfams": {"pfam": {"identifier": "PF00273", "name": "Serum_albumin"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "component", "description": "extracellular space"}, {"category": "function", "description": "transporter activity"}, {"category": "function", "description": "carrier activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}, {"category": "process", "description": "transport"}]}}}}, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-10-03", "drugbank-id": [{"@primary": "true", "#text": "DB00071"}, "BIOD00031", "BTD00031"], "name": "Insulin, porcine", "description": "Insulin isolated from pig pancreas. Composed of alpha and beta chains, processed from pro-insulin. Forms a hexameric structure.", "cas-number": "9004-14-2", "groups": {"group": "approved"}, "general-references": null, "synthesis-reference": "Bruce H. Frank, \"Process for producing an insulin precursor.\" U.S. Patent US4430266, issued November, 1974.", "indication": "For the treatment of type I and II diabetes mellitus.", "pharmacodynamics": "Insulin is used in the treatment of type I and type II diabetes. The primary activity of insulin is the regulation of glucose metabolism. In muscle and other tissues (except the brain), insulin causes rapid transport of glucose and amino acids intracellularly. It also promotes anabolism, and inhibits protein catabolism. In the liver, insulin promotes the uptake and storage of glucose in the form of glycogen, inhibits gluconeogenesis, and promotes the conversion of excess glucose into fat.", "mechanism-of-action": "Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism.", "toxicity": null, "metabolism": "Insulin is predominantly cleared by metabolic degradation via a receptor-mediated process.", "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": null, "international-brands": {"international-brand": {"name": "Iletin II", "company": "Lilly"}}, "mixtures": null, "packagers": null, "manufacturers": {"manufacturer": [{"@generic": "false", "#text": "Eli lilly and co"}, {"@generic": "false", "#text": "Novo nordisk inc"}]}, "prices": null, "categories": {"category": {"category": "Hypoglycemic Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": null, "atc-codes": null, "ahfs-codes": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">A chain\nGIVEQCCTSICSLYQLENYCN"}, {"@format": "FASTA", "#text": ">B chain\nFVNQHLCGSHLVEALYLVCGERGFFYTPKT"}]}, "experimental-properties": {"property": [{"kind": "Water Solubility", "value": "Slightly soluble", "source": null}, {"kind": "Hydrophobicity", "value": "0.218", "source": null}, {"kind": "Isoelectric Point", "value": "5.39", "source": null}, {"kind": "Molecular Weight", "value": "5795.6000", "source": null}, {"kind": "Molecular Formula", "value": "C257H387N65O76S6", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "GenBank", "identifier": "AY137503"}, {"resource": "PharmGKB", "identifier": "PA164781053"}, {"resource": "UniProtKB", "identifier": "Q8HXV2"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000033", "name": "Insulin receptor", "organism": "Human", "actions": {"action": "binder"}, "references": "# Chen LM, Yang XW, Tang JG: Acidic residues on the N-terminus of proinsulin C-Peptide are important for the folding of insulin precursor. J Biochem (Tokyo). 2002 Jun;131(6):855-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12038982\n# Desbuquois B, Chauvet G, Kouach M, Authier F: Cell itinerary and metabolic fate of proinsulin in rat liver: in vivo and in vitro studies. Endocrinology. 2003 Dec;144(12):5308-21. Epub 2003 Sep 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12970169\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P06213", "@source": "Swiss-Prot", "name": "Insulin receptor", "general-function": "Involved in transmembrane receptor protein tyrosine kinase activity", "specific-function": "This receptor binds insulin and has a tyrosine-protein kinase activity. Isoform Short has a higher affinity for insulin. Mediates the metabolic functions of insulin. Binding to insulin stimulates association of the receptor with downstream mediators including IRS1 and phosphatidylinositol 3'-kinase (PI3K). Can activate PI3K either directly by binding to the p85 regulatory subunit, or indirectly via IRS1", "gene-name": "INSR", "locus": "19p13.3-p13.2", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "957-979", "signal-regions": null, "theoretical-pi": "6.18", "molecular-weight": "156308.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6091"}, {"resource": "GenAtlas", "identifier": "INSR"}, {"resource": "GeneCards", "identifier": "INSR"}, {"resource": "GenBank Gene Database", "identifier": "M10051"}, {"resource": "GenBank Protein Database", "identifier": "307070"}, {"resource": "UniProtKB", "identifier": "P06213"}, {"resource": "UniProt Accession", "identifier": "INSR_HUMAN"}]}, "synonyms": {"synonym": ["CD220 antigen", "EC 2.7.10.1", "Insulin receptor precursor", "IR"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Insulin receptor precursor\nMGTGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHL\nQILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYAL\nVIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNE\nECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECL\nGNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQG\nCHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGC\nTVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETL\nEIGNYSFYALDNQNLRQLWDWSKHNLTTTQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQE\nRNDIALKTNGDKASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQ\nNVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFS\nDERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWE\nRQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQIL\nKELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAF\nPNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYV\nSARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCV\nSRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIG\nPLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSR\nEKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKG\nFTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMA\nAEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPV\nRWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDN\nCPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEME\nFEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSN\nPS"}, "gene-sequence": {"@format": "FASTA", "#text": ">4149 bp\nATGGGCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCG\nCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATC\nCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTG\nCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAA\nCTCATCATGATCACTGATTACTTGCTGCTCTTCCGGGTCTATGGGCTCGAGAGCCTGAAG\nGACCTGTTCCCCAACCTCACGGTCATCCGGGGATCACGACTGTTCTTTAACTACGCGCTG\nGTCATCTTCGAGATGGTTCACCTCAAGGAACTCGGCCTCTACAACCTGATGAACATCACC\nCGGGGTTCTGTCCGCATCGAGAAGAACAATGAGCTCTGTTACTTGGCCACTATCGACTGG\nTCCCGTATCCTGGATTCCGTGGAGGATAATCACATCGTGTTGAACAAAGATGACAACGAG\nGAGTGTGGAGACATCTGTCCGGGTACCGCGAAGGGCAAGACCAACTGCCCCGCCACCGTC\nATCAACGGGCAGTTTGTCGAACGATGTTGGACTCATAGTCACTGCCAGAAAGTTTGCCCG\nACCATCTGTAAGTCACACGGCTGCACCGCCGAAGGCCTCTGTTGCCACAGCGAGTGCCTG\nGGCAACTGTTCTCAGCCCGACGACCCCACCAAGTGCGTGGCCTGCCGCAACTTCTACCTG\nGACGGCAGGTGTGTGGAGACCTGCCCGCCCCCGTACTACCACTTCCAGGACTGGCGCTGT\nGTGAACTTCAGCTTCTGCCAGGACCTGCACCACAAATGCAAGAACTCGCGGAGGCAGGGC\nTGCCACCAATACGTCATTCACAACAACAAGTGCATCCCTGAGTGTCCCTCCGGGTACACG\nATGAATTCCAGCAACTTGCTGTGCACCCCATGCCTGGGTCCCTGTCCCAAGGTGTGCCAC\nCTCCTAGAAGGCGAGAAGACCATCGACTCGGTGACGTCTGCCCAGGAGCTCCGAGGATGC\nACCGTCATCAACGGGAGTCTGATCATCAACATTCGAGGAGGCAACAATCTGGCAGCTGAG\nCTAGAAGCCAACCTCGGCCTCATTGAAGAAATTTCAGGGTATCTAAAAATCCGCCGATCC\nTACGCTCTGGTGTCACTTTCCTTCTTCCGGAAGTTACGTCTGATTCGAGGAGAGACCTTG\nGAAATTGGGAACTACTCCTTCTATGCCTTGGACAACCAGAACCTAAGGCAGCTCTGGGAC\nTGGAGCAAACACAACCTCACCACCACTCAGGGGAAACTCTTCTTCCACTATAACCCCAAA\nCTCTGCTTGTCAGAAATCCACAAGATGGAAGAAGTTTCAGGAACCAAGGGGCGCCAGGAG\nAGAAACGACATTGCCCTGAAGACCAATGGGGACAAGGCATCCTGTGAAAATGAGTTACTT\nAAATTTTCTTACATTCGGACATCTTTTGACAAGATCTTGCTGAGATGGGAGCCGTACTGG\nCCCCCCGACTTCCGAGACCTCTTGGGGTTCATGCTGTTCTACAAAGAGGCCCCTTATCAG\nAATGTGACGGAGTTCGATGGGCAGGATGCGTGTGGTTCCAACAGTTGGACGGTGGTAGAC\nATTGACCCACCCCTGAGGTCCAACGACCCCAAATCACAGAACCACCCAGGGTGGCTGATG\nCGGGGTCTCAAGCCCTGGACCCAGTATGCCATCTTTGTGAAGACCCTGGTCACCTTTTCG\nGATGAACGCCGGACCTATGGGGCCAAGAGTGACATCATTTATGTCCAGACAGATGCCACC\nAACCCCTCTGTGCCCCTGGATCCAATCTCAGTGTCTAACTCATCATCCCAGATTATTCTG\nAAGTGGAAACCACCCTCCGACCCCAATGGCAACATCACCCACTACCTGGTTTTCTGGGAG\nAGGCAGGCGGAAGACAGTGAGCTGTTCGAGCTGGATTATTGCCTCAAAGGGCTGAAGCTG\nCCCTCGAGGACCTGGTCTCCACCATTCGAGTCTGAAGATTCTCAGAAGCACAACCAGAGT\nGAGTATGAGGATTCGGCCGGCGAATGCTGCTCCTGTCCAAAGACAGACTCTCAGATCCTG\nAAGGAGCTGGAGGAGTCCTCGTTTAGGAAGACGTTTGAGGATTACCTGCACAACGTGGTT\nTTCGTCCCCAGAAAAACCTCTTCAGGCACTGGTGCCGAGGACCCTAGGCCATCTCGGAAA\nCGCAGGTCCCTTGGCGATGTTGGGAATGTGACGGTGGCCGTGCCCACGGTGGCAGCTTTC\nCCCAACACTTCCTCGACCAGCGTGCCCACGAGTCCGGAGGAGCACAGGCCTTTTGAGAAG\nGTGGTGAACAAGGAGTCGCTGGTCATCTCCGGCTTGCGACACTTCACGGGCTATCGCATC\nGAGCTGCAGGCTTGCAACCAGGACACCCCTGAGGAACGGTGCAGTGTGGCAGCCTACGTC\nAGTGCGAGGACCATGCCTGAAGCCAAGGCTGATGACATTGTTGGCCCTGTGACGCATGAA\nATCTTTGAGAACAACGTCGTCCACTTGATGTGGCAGGAGCCGAAGGAGCCCAATGGTCTG\nATCGTGCTGTATGAAGTGAGTTATCGGCGATATGGTGATGAGGAGCTGCATCTCTGCGTC\nTCCCGCAAGCACTTCGCTCTGGAACGGGGCTGCAGGCTGCGTGGGCTGTCACCGGGGAAC\nTACAGCGTGCGAATCCGGGCCACCTCCCTTGCGGGCAACGGCTCTTGGACGGAACCCACC\nTATTTCTACGTGACAGACTATTTAGACGTCCCGTCAAATATTGCAAAAATTATCATCGGC\nCCCCTCATCTTTGTCTTTCTCTTCAGTGTTGTGATTGGAAGTATTTATCTATTCCTGAGA\nAAGAGGCAGCCAGATGGGCCGCTGGGACCGCTTTACGCTTCTTCAAACCCTGAGTATCTC\nAGTGCCAGTGATGTGTTTCCATGCTCTGTGTACGTGCCGGACGAGTGGGAGGTGTCTCGA\nGAGAAGATCACCCTCCTTCGAGAGCTGGGGCAGGGCTCCTTCGGCATGGTGTATGAGGGC\nAATGCCAGGGACATCATCAAGGGTGAGGCAGAGACCCGCGTGGCGGTGAAGACGGTCAAC\nGAGTCAGCCAGTCTCCGAGAGCGGATTGAGTTCCTCAATGAGGCCTCGGTCATGAAGGGC\nTTCACCTGCCATCACGTGGTGCGCCTCCTGGGAGTGGTGTCCAAGGGCCAGCCCACGCTG\nGTGGTGATGGAGCTGATGGCTCACGGAGACCTGAAGAGCTACCTCCGTTCTCTGCGGCCA\nGAGGCTGAGAATAATCCTGGCCGCCCTCCCCCTACCCTTCAAGAGATGATTCAGATGGCG\nGCAGAGATTGCTGACGGGATGGCCTACCTGAACGCCAAGAAGTTTGTGCATCGGGACCTG\nGCAGCGAGAAACTGCATGGTCGCCCATGATTTTACTGTCAAAATTGGAGACTTTGGAATG\nACCAGAGACATCTATGAAACGGATTACTACCGGAAAGGGGGCAAGGGTCTGCTCCCTGTA\nCGGTGGATGGCACCGGAGTCCCTGAAGGATGGGGTCTTCACCACTTCTTCTGACATGTGG\nTCCTTTGGCGTGGTCCTTTGGGAAATCACCAGCTTGGCAGAACAGCCTTACCAAGGCCTG\nTCTAATGAACAGGTGTTGAAATTTGTCATGGATGGAGGGTATCTGGATCAACCCGACAAC\nTGTCCAGAGAGAGTCACTGACCTCATGCGCATGTGCTGGCAATTCAACCCCAAGATGAGG\nCCAACCTTCCTGGAGATTGTCAACCTGCTCAAGGACGACCTGCACCCCAGCTTTCCAGAG\nGTGTCGTTCTTCCACAGCGAGGAGAACAAGGCTCCCGAGAGTGAGGAGCTGGAGATGGAG\nTTTGAGGACATGGAGAATGTGCCCCTGGACCGTTCCTCGCACTGTCAGAGGGAGGAGGCG\nGGGGGCCGGGATGGAGGGTCCTCGCTGGGTTTCAAGCGGAGCTACGAGGAACACATCCCT\nTACACACACATGAACGGAGGCAAGAAAAACGGGCGGATTCTGACCTTGCCTCGGTCCAAT\nCCTTCCTAA"}, "pfams": {"pfam": [{"identifier": "PF07714", "name": "Pkinase_Tyr"}, {"identifier": "PF00041", "name": "fn3"}, {"identifier": "PF00757", "name": "Furin-like"}, {"identifier": "PF01030", "name": "Recep_L_domain"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "protein-tyrosine kinase activity"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "transferase activity, transferring phosphorus-containing groups"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "function", "description": "kinase activity"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "transferase activity"}, {"category": "function", "description": "protein kinase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "transmembrane receptor protein tyrosine kinase activity"}, {"category": "function", "description": "epidermal growth factor receptor activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "protein amino acid phosphorylation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "enzyme linked receptor protein signaling pathway"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "transmembrane receptor protein tyrosine kinase signaling pathway"}, {"category": "process", "description": "biopolymer metabolism"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "biopolymer modification"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "protein modification"}]}}}, {"@position": "2", "id": "BE0000858", "name": "Insulin-like growth factor 1 receptor", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Fottner C, Engelhardt D, Weber MM: Regulation of steroidogenesis by insulin-like growth factors (IGFs) in adult human adrenocortical cells: IGF-I and, more potently, IGF-II preferentially enhance androgen biosynthesis through interaction with the IGF-I receptor and IGF-binding proteins. J Endocrinol. 1998 Sep;158(3):409-17. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9846170\n# Zhang Q, Berggren PO, Hansson A, Tally M: Insulin-like growth factor-I-induced DNA synthesis in insulin-secreting cell line RINm5F is associated with phosphorylation of the insulin-like growth factor-I receptor and the insulin receptor substrate-2. J Endocrinol. 1998 Mar;156(3):573-81. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9582514\n# Sowers JR, Jacobs DB, Simpson L, al-Homsi B, Grunberger G, Sokol R: Erythrocyte insulin and insulin-like growth factor-I receptor tyrosine kinase activity in hypertension in pregnancy. Metabolism. 1995 Oct;44(10):1308-13. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7476290", "known-action": "unknown", "polypeptide": {"@id": "P08069", "@source": "Swiss-Prot", "name": "Insulin-like growth factor 1 receptor", "general-function": "Involved in transmembrane receptor protein tyrosine kinase activity", "specific-function": "This receptor binds insulin-like growth factor 1 (IGF1) with a high affinity and IGF2 with a lower affinity. It has a tyrosine-protein kinase activity, which is necessary for the activation of the IGF1-stimulated downstream signaling cascade", "gene-name": "IGF1R", "locus": "15q26.3", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "936-959", "signal-regions": null, "theoretical-pi": "5.54", "molecular-weight": "154795.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5465"}, {"resource": "GenAtlas", "identifier": "IGF1R"}, {"resource": "GeneCards", "identifier": "IGF1R"}, {"resource": "GenBank Gene Database", "identifier": "X04434"}, {"resource": "GenBank Protein Database", "identifier": "804990"}, {"resource": "UniProtKB", "identifier": "P08069"}, {"resource": "UniProt Accession", "identifier": "IGF1R_HUMAN"}]}, "synonyms": {"synonym": ["CD221 antigen", "EC 2.7.10.1", "IGF-I receptor", "Insulin-like growth factor 1 receptor precursor", "Insulin-like growth factor I receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Insulin-like growth factor 1 receptor precursor\nMKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLH\nILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIF\nEMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGD\nLCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCS\nAPDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHD\nGECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNL\nLINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSF\nYVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTR\nNNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDG\nQDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSE\nILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRH\nNYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRK\nVFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFES\nRVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTW\nEPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGN\nYTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHR\nKRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKG\nVVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIME\nLMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARN\nCMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGV\nVLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFL\nEIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRH\nSGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC"}, "gene-sequence": {"@format": "FASTA", "#text": ">4104 bp\nATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCC\nGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGC\nAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCAC\nATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTC\nATTACCGAGTACTTGCTGCTGTTCCGAGTGGCTGGCCTCGAGAGCCTCGGAGACCTCTTC\nCCCAACCTCACGGTCATCCGCGGCTGGAAACTCTTCTACAACTACGCCCTGGTCATCTTC\nGAGATGACCAATCTCAAGGATATTGGGCTTTACAACCTGAGGAACATTACTCGGGGGGCC\nATCAGGATTGAGAAAAATGCTGACCTCTGTTACCTCTCCACTGTGGACTGGTCCCTGATC\nCTGGATGCGGTGTCCAATAACTACATTGTGGGGAATAAGCCCCCAAAGGAATGTGGGGAC\nCTGTGTCCAGGGACCATGGAGGAGAAGCCGATGTGTGAGAAGACCACCATCAACAATGAG\nTACAACTACCGCTGCTGGACCACAAACCGCTGCCAGAAAATGTGCCCAAGCACGTGTGGG\nAAGCGGGCGTGCACCGAGAACAATGAGTGCTGCCACCCCGAGTGCCTGGGCAGCTGCAGC\nGCGCCTGACAACGACACGGCCTGTGTAGCTTGCCGCCACTACTACTATGCCGGTGTCTGT\nGTGCCTGCCTGCCCGCCCAACACCTACAGGTTTGAGGGCTGGCGCTGTGTGGACCGTGAC\nTTCTGCGCCAACATCCTCAGCGCCGAGAGCAGCGACTCCGAGGGGTTTGTGATCCACGAC\nGGCGAGTGCATGCAGGAGTGCCCCTCGGGCTTCATCCGCAACGGCAGCCAGAGCATGTAC\nTGCATCCCTTGTGAAGGTCCTTGCCCGAAGGTCTGTGAGGAAGAAAAGAAAACAAAGACC\nATTGATTCTGTTACTTCTGCTCAGATGCTCCAAGGATGCACCATCTTCAAGGGCAATTTG\nCTCATTAACATCCGACGGGGGAATAACATTGCTTCAGAGCTGGAGAACTTCATGGGGCTC\nATCGAGGTGGTGACGGGCTACGTGAAGATCCGCCATTCTCATGCCTTGGTCTCCTTGTCC\nTTCCTAAAAAACCTTCGCCTCATCCTAGGAGAGGAGCAGCTAGAAGGGAATTACTCCTTC\nTACGTCCTCGACAACCAGAACTTGCAGCAACTGTGGGACTGGGACCACCGCAACCTGACC\nATCAAAGCAGGGAAAATGTACTTTGCTTTCAATCCCAAATTATGTGTTTCCGAAATTTAC\nCGCATGGAGGAAGTGACGGGGACTAAAGGGCGCCAAAGCAAAGGGGACATAAACACCAGG\nAACAACGGGGAGAGAGCCTCCTGTGAAAGTGACGTCCTGCATTTCACCTCCACCACCACG\nTCGAAGAATCGCATCATCATAACCTGGCACCGGTACCGGCCCCCTGACTACAGGGATCTC\nATCAGCTTCACCGTTTACTACAAGGAAGCACCCTTTAAGAATGTCACAGAGTATGATGGG\nCAGGATGCCTGCGGCTCCAACAGCTGGAACATGGTGGACGTGGACCTCCCGCCCAACAAG\nGACGTGGAGCCCGGCATCTTACTACATGGGCTGAAGCCCTGGACTCAGTACGCCGTTTAC\nGTCAAGGCTGTGACCCTCACCATGGTGGAGAACGACCATATCCGTGGGGCCAAGAGTGAG\nATCTTGTACATTCGCACCAATGCTTCAGTTCCTTCCATTCCCTTGGACGTTCTTTCAGCA\nTCGAACTCCTCTTCTCAGTTAATCGTGAAGTGGAACCCTCCCTCTCTGCCCAACGGCAAC\nCTGAGTTACTACATTGTGCGCTGGCAGCGGCAGCCTCAGGACGGCTACCTTTACCGGCAC\nAATTACTGCTCCAAAGACAAAATCCCCATCAGGAAGTATGCCGACGGCACCATCGACATT\nGAGGAGGTCACAGAGAACCCCAAGACTGAGGTGTGTGGTGGGGAGAAAGGGCCTTGCTGC\nGCCTGCCCCAAAACTGAAGCCGAGAAGCAGGCCGAGAAGGAGGAGGCTGAATACCGCAAA\nGTCTTTGAGAATTTCCTGCACAACTCCATCTTCGTGCCCAGACCTGAAAGGAAGCGGAGA\nGATGTCATGCAAGTGGCCAACACCACCATGTCCAGCCGAAGCAGGAACACCACGGCCGCA\nGACACCTACAACATCACCGACCCGGAAGAGCTGGAGACAGAGTACCCTTTCTTTGAGAGC\nAGAGTGGATAACAAGGAGAGAACTGTCATTTCTAACCTTCGGCCTTTCACATTGTACCGC\nATCGATATCCACAGCTGCAACCACGAGGCTGAGAAGCTGGGCTGCAGCGCCTCCAACTTC\nGTCTTTGCAAGGACTATGCCCGCAGAAGGAGCAGATGACATTCCTGGGCCAGTGACCTGG\nGAGCCAAGGCCTGAAAACTCCATCTTTTTAAAGTGGCCGGAACCTGAGAATCCCAATGGA\nTTGATTCTAATGTATGAAATAAAATACGGATCACAAGTTGAGGATCAGCGAGAATGTGTG\nTCCAGACAGGAATACAGGAAGTATGGAGGGGCCAAGCTAAACCGGCTAAACCCGGGGAAC\nTACACAGCCCGGATTCAGGCCACATCTCTCTCTGGGAATGGGTCGTGGACAGATCCTGTG\nTTCTTCTATGTCCAGGCCAAAACAGGATATGAAAACTTCATCCATCTGATCATCGCTCTG\nCCCGTCGCTGTCCTGTTGATCGTGGGAGGGTTGGTGATTATGCTGTACGTCTTCCATAGA\nAAGAGAAATAACAGCAGGCTGGGGAATGGAGTGCTGTATGCCTCTGTGAACCCGGAGTAC\nTTCAGCGCTGCTGATGTGTACGTTCCTGATGAGTGGGAGGTGGCTCGGGAGAAGATCACC\nATGAGCCGGGAACTTGGGCAGGGGTCGTTTGGGATGGTCTATGAAGGAGTTGCCAAGGGT\nGTGGTGAAAGATGAACCTGAAACCAGAGTGGCCATTAAAACAGTGAACGAGGCCGCAAGC\nATGCGTGAGAGGATTGAGTTTCTCAACGAAGCTTCTGTGATGAAGGAGTTCAATTGTCAC\nCATGTGGTGCGATTGCTGGGTGTGGTGTCCCAAGGCCAGCCAACACTGGTCATCATGGAA\nCTGATGACACGGGGCGATCTCAAAAGTTATCTCCGGTCTCTGAGGCCAGAAATGGAGAAT\nAATCCAGTCCTAGCACCTCCAAGCCTGAGCAAGATGATTCAGATGGCCGGAGAGATTGCA\nGACGGCATGGCATACCTCAACGCCAATAAGTTCGTCCACAGAGACCTTGCTGCCCGGAAT\nTGCATGGTAGCCGAAGATTTCACAGTCAAAATCGGAGATTTTGGTATGACGCGAGATATC\nTATGAGACAGACTATTACCGGAAAGGAGGCAAAGGGCTGCTGCCCGTGCGCTGGATGTCT\nCCTGAGTCCCTCAAGGATGGAGTCTTCACCACTTACTCGGACGTCTGGTCCTTCGGGGTC\nGTCCTCTGGGAGATCGCCACACTGGCCGAGCAGCCCTACCAGGGCTTGTCCAACGAGCAA\nGTCCTTCGCTTCGTCATGGAGGGCGGCCTTCTGGACAAGCCAGACAACTGTCCTGACATG\nCTGTTTGAACTGATGCGCATGTGCTGGCAGTATAACCCCAAGATGAGGCCTTCCTTCCTG\nGAGATCATCAGCAGCATCAAAGAGGAGATGGAGCCTGGCTTCCGGGAGGTCTCCTTCTAC\nTACAGCGAGGAGAACAAGCTGCCCGAGCCGGAGGAGCTGGACCTGGAGCCAGAGAACATG\nGAGAGCGTCCCCCTGGACCCCTCGGCCTCCTCGTCCTCCCTGCCACTGCCCGACAGACAC\nTCAGGACACAAGGCCGAGAACGGCCCCGGCCCTGGGGTGCTGGTCCTCCGCGCCAGCTTC\nGACGAGAGACAGCCTTACGCCCACATGAACGGGGGCCGCAAGAACGAGCGGGCCTTGCCG\nCTGCCCCAGTCTTCGACCTGCTGA"}, "pfams": {"pfam": [{"identifier": "PF07714", "name": "Pkinase_Tyr"}, {"identifier": "PF00041", "name": "fn3"}, {"identifier": "PF00757", "name": "Furin-like"}, {"identifier": "PF01030", "name": "Recep_L_domain"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "protein-tyrosine kinase activity"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "transferase activity, transferring phosphorus-containing groups"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "function", "description": "kinase activity"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "transferase activity"}, {"category": "function", "description": "protein kinase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "transmembrane receptor protein tyrosine kinase activity"}, {"category": "function", "description": "epidermal growth factor receptor activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "protein amino acid phosphorylation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "enzyme linked receptor protein signaling pathway"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "transmembrane receptor protein tyrosine kinase signaling pathway"}, {"category": "process", "description": "biopolymer metabolism"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "biopolymer modification"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "protein modification"}]}}}, {"@position": "3", "id": "BE0001183", "name": "Insulin-degrading enzyme", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Harada S, Smith RM, Smith JA, Jarett L: Inhibition of insulin-degrading enzyme increases translocation of insulin to the nucleus in H35 rat hepatoma cells: evidence of a cytosolic pathway. Endocrinology. 1993 Jun;132(6):2293-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8504733\n# Hsu MC, Bai JP: Investigation into the presence of insulin-degrading enzyme in cultured type II alveolar cells and the effects of enzyme inhibitors on pulmonary bioavailability of insulin in rats. J Pharm Pharmacol. 1998 May;50(5):507-14. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9643444\n# MARIGO S, PANELLI G: [Insulinase and its inhibition by hypoglycemic sulfonamides; data on insulin sensitivity during tolbutamide therapy.] Arch Sci Med (Torino). 1958 Jun;105(6):587-609. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/13560210", "known-action": "unknown", "polypeptide": {"@id": "P14735", "@source": "Swiss-Prot", "name": "Insulin-degrading enzyme", "general-function": "Posttranslational modification, protein turnover, chaperones", "specific-function": "May play a role in the cellular processing of insulin. May be involved in intercellular peptide signaling", "gene-name": "IDE", "locus": "10q23-q25", "cellular-location": "Cytoplasm", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.74", "molecular-weight": "118023.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5381"}, {"resource": "GenAtlas", "identifier": "IDE"}, {"resource": "GeneCards", "identifier": "IDE"}, {"resource": "GenBank Gene Database", "identifier": "M21188"}, {"resource": "GenBank Protein Database", "identifier": "184556"}, {"resource": "UniProtKB", "identifier": "P14735"}, {"resource": "UniProt Accession", "identifier": "IDE_HUMAN"}]}, "synonyms": {"synonym": ["EC 3.4.24.56", "Insulin protease", "Insulinase", "Insulysin"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Insulin-degrading enzyme\nMRYRLAWLLHPALPSTFRSVLGARLPPPERLCGFQKKTYSKMNNPAIKRIGNHITKSPED\nKREYRGLELANGIKVLLMSDPTTDKSSAALDVHIGSLSDPPNIAGLSHFCEHMLFLGTKK\nYPKENEYSQFLSEHAGSSNAFTSGEHTNYYFDVSHEHLEGALDRFAQFFLCPLFDESCKD\nREVNAVDSEHEKNVMNDAWRLFQLEKATGNPKHPFSKFGTGNKYTLETRPNQEGIDVRQE\nLLKFHSAYYSSNLMAVCVLGRESLDDLTNLVVKLFSEVENKNVPLPEFPEHPFQEEHLKQ\nLYKIVPIKDIRNLYVTFPIPDLQKYYKSNPGHYLGHLIGHEGPGSLLSELKSKGWVNTLV\nGGQKEGARGFMFFIINVDLTEEGLLHVEDIILHMFQYIQKLRAEGPQEWVFQECKDLNAV\nAFRFKDKERPRGYTSKIAGILHYYPLEEVLTAEYLLEEFRPDLIEMVLDKLRPENVRVAI\nVSKSFEGKTDRTEEWYGTQYKQEAIPDEVIKKWQNADLNGKFKLPTKNEFIPTNFEILPL\nEKEATPYPALIKDTVMSKLWFKQDDKKKKPKACLNFEFFSPFAYVDPLHCNMAYLYLELL\nKDSLNEYAYAAELAGLSYDLQNTIYGMYLSVKGYNDKQPILLKKIIEKMATFEIDEKRFE\nIIKEAYMRSLNNFRAEQPHQHAMYYLRLLMTEVAWTKDELKEALDDVTLPRLKAFIPQLL\nSRLHIEALLHGNITKQAALGIMQMVEDTLIEHAHTKPLLPSQLVRYREVQLPDRGWFVYQ\nQRNEVHNNCGIEIYYQTDMQSTSENMFLELFCQIISEPCFNTLRTKEQLGYIVFSGPRRA\nNGIQSLRFIIQSEKPPHYLESRVEAFLITMEKSIEDMTEEAFQKHIQALAIRRLDKPKKL\nSAECAKYWGEIISQQYNFDRDNTEVAYLKTLTKEDIIKFYKEMLAVDAPRRHKVSVHVLA\nREMDSCPVVGEFPCQNDINLSQAPALPQPEVIQNMTEFKRGLPLFPLVKPHINFMAAKL"}, "gene-sequence": {"@format": "FASTA", "#text": ">3060 bp\nATGCGGTACCGGCTAGCGTGGCTTCTGCACCCCGCACTGCCCAGCACCTTCCGCTCAGTC\nCTCGGCGCCCGCCTGCCGCCTCCGGAGCGCCTGTGTGGTTTCCAAAAAAAGACTTACAGC\nAAAATGAATAATCCAGCCATCAAGAGAATAGGAAATCACATTACCAAGTCTCCTGAAGAC\nAAGCGAGAATATCGAGGGCTAGAGCTGGCCAATGGTATCAAAGTACTTCTTATGAGTGAT\nCCCACCACGGATAAGTCATCAGCAGCACTTGATGTGCACATAGGTTCATTGTCGGATCCT\nCCAAATATTGCTGGCTTAAGTCATTTTTGTGAACATATGCTTTTTTTGGGAACAAAGAAA\nTACCCTAAAGAAAATGAATACAGCCAGTTTCTCAGTGAGCATGCAGGAAGTTCAAATGCC\nTTTACTAGTGGAGAGCATACCAATTACTATTTTGATGTTTCTCATGAACACCTAGAAGGT\nGCCCTAGACAGGTTTGCACAGTTTTTTCTGTGCCCCTTGTTCGATGAAAGTTGCAAAGAC\nAGAGAGGTGAATGCAGTTGATTCAGAACATGAGAAGAATGTGATGAATGATGCCTGGAGA\nCTCTTTCAATTGGAAAAAGCTACAGGGAATCCTAAACACCCCTTCAGTAAATTTGGGACA\nGGTAACAAATATACTCTGGAGACTAGACCAAACCAAGAAGGCATTGATGTAAGACAAGAG\nCTACTGAAATTCCATTCTGCTTACTATTCATCCAACTTAATGGCTGTTTGTGTTTTAGGT\nCGAGAATCTTTAGATGACTTGACTAATCTGGTGGTAAAGTTATTTTCTGAAGTAGAGAAC\nAAAAATGTTCCATTGCCAGAATTTCCTGAACACCCTTTCCAAGAAGAACATCTTAAACAA\nCTTTACAAAATAGTACCCATTAAAGATATTAGGAATCTCTATGTGACATTTCCCATACCT\nGACCTTCAGAAATACTACAAATCAAATCCTGGTCATTATCTTGGTCATCTCATTGGGCAT\nGAAGGTCCTGGAAGTCTGTTATCAGAACTTAAGTCAAAGGGCTGGGTTAATACTCTTGTT\nGGTGGGCAGAAGGAAGGAGCCCGAGGTTTTATGTTTTTTATCATTAATGTGGACTTGACC\nGAGGAAGGATTATTACATGTTGAAGATATAATTTTGCACATGTTTCAATACATTCAGAAG\nTTACGTGCAGAAGGACCTCAAGAATGGGTTTTCCAAGAGTGCAAGGACTTGAATGCTGTT\nGCTTTTAGGTTTAAAGACAAAGAGAGGCCACGGGGCTATACATCTAAGATTGCAGGAATA\nTTGCATTATTATCCCCTAGAAGAGGTGCTCACAGCGGAATATTTACTGGAAGAATTTAGA\nCCTGACTTAATAGAGATGGTTCTCGATAAACTCAGACCAGAAAATGTCCGGGTTGCCATA\nGTTTCTAAATCTTTTGAAGGAAAAACTGATCGCACAGAAGAGTGGTATGGAACCCAGTAC\nAAACAAGAAGCTATACCGGATGAAGTCATCAAGAAATGGCAAAATGCTGACCTGAATGGG\nAAATTTAAACTTCCTACAAAGAATGAATTTATTCCTACGAATTTTGAGATTTTACCGTTA\nGAAAAAGAGGCGACACCATACCCTGCTCTTATTAAGGATACAGTCATGAGCAAACTTTGG\nTTCAAACAAGATGATAAGAAAAAAAAGCCGAAGGCTTGTCTCAACTTTGAATTTTTCAGC\nCCATTTGCTTATGTGGACCCCTTGCACTGTAACATGGCCTATTTGTACCTTGAGCTCCTC\nAAAGACTCACTCAACGAGTATGCATATGCAGCAGAGCTAGCAGGCTTGAGCTATGATCTC\nCAAAATACCATCTATGGGATGTATCTTTCAGTGAAAGGTTACAATGACAAGCAGCCAATT\nTTACTAAAGAAGATTATTGAGAAAATGGCTACCTTTGAGATTGATGAAAAAAGATTTGAA\nATTATCAAAGAAGCATATATGCGATCTCTTAACAATTTCCGGGCTGAACAGCCTCACCAG\nCATGCCATGTACTACCTCCGCTTGCTGATGACTGAAGTGGCCTGGACTAAAGATGAGTTA\nAAAGAAGCTCTGGATGATGTAACCCTTCCTCGCCTTAAGGCCTTCATACCTCAGCTCCTG\nTCACGGCTGCACATTGAAGCCCTTCTCCATGGAAACATAACAAAGCAGGCTGCATTAGGA\nATTATGCAGATGGTTGAAGACACCCTCATTGAACATGCTCATACCAAACCTCTCCTTCCA\nAGTCAGCTGGTTCGGTATAGAGAAGTTCAGCTCCCTGACAGAGGATGGTTTGTTTATCAG\nCAGAGAAATGAAGTTCACAATAACTGTGGCATCGAGATATACTACCAAACAGACATGCAA\nAGCACCTCAGAGAATATGTTTCTGGAGCTCTTCTGTCAGATTATCTCGGAACCTTGCTTC\nAACACCCTGCGCACCAAGGAGCAGTTGGGCTATATCGTCTTCAGCGGGCCACGTCGAGCT\nAATGGCATACAGAGCTTGAGATTCATCATCCAGTCAGAAAAGCCACCTCACTACCTAGAA\nAGCAGAGTGGAAGCTTTCTTAATTACCATGGAAAAGTCCATAGAGGACATGACAGAAGAG\nGCCTTCCAAAAACACATTCAGGCATTAGCAATTCGTCGACTAGACAAACCAAAGAAGCTA\nTCTGCTGAGTGTGCTAAATACTGGGGAGAAATCATCTCCCAGCAATATAATTTTGACAGA\nGATAACACTGAGGTTGCATATTTAAAGACACTTACCAAGGAAGATATCATCAAATTCTAC\nAAGGAAATGTTGGCAGTAGATGCTCCAAGGAGACATAAGGTATCCGTCCATGTTCTTGCC\nAGGGAAATGGATTCTTGTCCTGTTGTTGGAGAGTTCCCATGTCAAAATGACATAAATTTG\nTCACAAGCACCAGCCTTGCCACAACCTGAAGTGATTCAGAACATGACCGAATTCAAGCGT\nGGTCTGCCACTGTTTCCCCTTGTGAAACCACATATTAACTTCATGGCTGCAAAACTCTGA"}, "pfams": {"pfam": [{"identifier": "PF00675", "name": "Peptidase_M16"}, {"identifier": "PF05193", "name": "Peptidase_M16_C"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "metalloendopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}]}}}, {"@position": "4", "id": "BE0002122", "name": "HLA class II histocompatibility antigen, DQ alpha 2 chain", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Pugliese A, Bugawan T, Moromisato R, Awdeh ZL, Alper CA, Jackson RA, Erlich HA, Eisenbarth GS: Two subsets of HLA-DQA1 alleles mark phenotypic variation in levels of insulin autoantibodies in first degree relatives at risk for insulin-dependent diabetes. J Clin Invest. 1994 Jun;93(6):2447-52. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8200980\n# Hermann R, Soltesz G: [Pathogenesis and types of neonatal diabetes] Orv Hetil. 2000 Aug 20;141(34):1855-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11006709\n# Donner H, Rau H, Braun J, Herwig J, Usadel KH, Badenhoop K: Highly polymorphic promoter regions of HLA DQA1 and DQB1 genes do not help to further define disease susceptibility in insulin-dependent diabetes mellitus. Tissue Antigens. 1997 Dec;50(6):642-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9458118", "known-action": "unknown", "polypeptide": {"@id": "P01906", "@source": "Swiss-Prot", "name": "HLA class II histocompatibility antigen, DQ alpha 2 chain", "general-function": null, "specific-function": null, "gene-name": "HLA-DQA2", "locus": "6p21.3", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "4.53", "molecular-weight": "28033.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:4943"}, {"resource": "GenAtlas", "identifier": "HLA-DQA2"}, {"resource": "GeneCards", "identifier": "HLA-DQA2"}, {"resource": "GenBank Gene Database", "identifier": "M29615"}, {"resource": "GenBank Protein Database", "identifier": "493166"}, {"resource": "UniProtKB", "identifier": "P01906"}, {"resource": "UniProt Accession", "identifier": "DQA2_HUMAN"}]}, "synonyms": {"synonym": ["6", "DX alpha chain", "HLA class II histocompatibility antigen, DQ(6) alpha chain precursor", "HLA-DQA1"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">HLA class II histocompatibility antigen, DQ(6) alpha chain\nMILNKALLLGALALTAVMSPCGGEDIVADHVASYGVNFYQSHGPSGQYTHEFDGDEEFYV\nDLETKETVWQLPMFSKFISFDPQSALRNMAVGKHTLEFMMRQSNSTAATNEVPEVTVFSK\nFPVTLGQPNTLICLVDNIFPPVVNITWLSNGHSVTEGVSETSFLSKSDHSFFKISYLTFL\nPSADEIYDCKVEHWGLDEPLLKHWEPEIPAPMSELTETLVCALGLSVGLMGIVVGTVFII\nQGLRSVGASRHQGLL"}, "gene-sequence": {"@format": "FASTA", "#text": ">768 bp\nATGATCCTAAACAAAGCTCTGCTGCTGGGGGCCCTCGCCCTGACTGCCGTGATGAGCCCC\nTGTGGAGGTGAAGACATTGTGGCTGACCATGTTGCCTCCTATGGTGTGAACTTCTACCAG\nTCTCACGGTCCCTCTGGCCAGTACACCCATGAATTTGATGGAGACGAGGAGTTCTATGTG\nGACCTGGAGACGAAAGAGACTGTCTGGCAGTTGCCTATGTTTAGCAAATTTATAAGTTTT\nGACCCGCAGACTGCACTGAGAAATATGGCTGTGGGAAAACACACCTTGGAATTCATGATG\nAGACAGTCCAACTCTACCGCTGCCACCAATGAGGTTCCTGAGGTCACAGTGTTTTCCAAG\nTTTCCTGTGACGCTGGGTCAGCCCAACACCCTCATCTGTCTTGTGGACAACATCTTTCCT\nCCTGTGGTCAACATCACCTGGCTGAGCAATGGGCACTCAGTCACAGAAGGTGTTTCTGAG\nACCAGCTTCCTCTCCAAGAGTGATCATTCCTTCTTCAAGATCAGTTACCTCACCTTCCTC\nCCTTCTGCTGATGAGATTTATGACTGCAAGGTGGAGCACTGGGGCCTGGACGAGCCTCTT\nCTGAAACACTGGGAGCCTGAGATTCCAGCCCCTATGTCAGAGCTCACAGAGACTTTGGTC\nTGCGCCCTGGGGTTGTCTGTGGGCCTCATGGGCATTGTGGTGGGCACTGTCTTCATCATC\nCAAGGCCTGCGTTCAGTTGGTGCTTCCAGACACCAAGGGCTCTTATGA"}, "pfams": {"pfam": [{"identifier": "PF07654", "name": "C1-set"}, {"identifier": "PF00993", "name": "MHC_II_alpha"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "immune response"}]}}}, {"@position": "5", "id": "BE0004466", "name": "HLA class II histocompatibility antigen, DQ beta 1 chain", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Mahran MZ, Ross DG, Sadeghi-Nejad A, Rabson AR: Use of the polymerase chain reaction mismatch technique to identify the HLA-DQw8 allele in patients with insulin-dependent diabetes mellitus. Am J Clin Pathol. 1992 Jan;97(1):29-33. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1728861\n# Levy-Marchal C, Tichet J, Fajardy I, Gu XF, Dubois F, Czernichow P: Islet cell antibodies in normal French schoolchildren. Diabetologia. 1992 Jun;35(6):577-82. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1612232\n# Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10592235", "known-action": "unknown", "polypeptide": {"@id": "P01920", "@source": "Swiss-Prot", "name": "HLA class II histocompatibility antigen, DQ beta 1 chain", "general-function": "Involved in T cell receptor signaling pathway", "specific-function": "Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.", "gene-name": "HLA-DQB1", "locus": null, "cellular-location": null, "transmembrane-regions": null, "signal-regions": null, "theoretical-pi": null, "molecular-weight": "29991.02", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "UniProtKB", "identifier": "P01920"}, {"resource": "UniProt Accession", "identifier": "DQB1_HUMAN"}]}, "synonyms": null, "amino-acid-sequence": {"@format": "FASTA", "#text": ">HLA class II histocompatibility antigen, DQ beta 1 chain\nMSWKKALRIPGGLRAATVTLMLAMLSTPVAEGRDSPEDFVYQFKAMCYFTNGTERVRYVT\nRYIYNREEYARFDSDVEVYRAVTPLGPPDAEYWNSQKEVLERTRAELDTVCRHNYQLELR\nTTLQRRVEPTVTISPSRTEALNHHNLLVCSVTDFYPAQIKVRWFRNDQEETTGVVSTPLI\nRNGDWTFQILVMLEMTPQHGDVYTCHVEHPSLQNPITVEWRAQSESAQSKMLSGIGGFVL\nGLIFLGLGLIIHHRSQKGLLH"}, "gene-sequence": {"@format": "FASTA"}, "pfams": null, "go-classifiers": null}}, {"@position": "6", "id": "BE0002123", "name": "Retinoblastoma-associated protein", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Biener Y, Zick Y: Basic polycations activate the insulin receptor kinase and a tightly associated serine kinase. Eur J Biochem. 1990 Nov 26;194(1):243-50. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1701386", "known-action": "unknown", "polypeptide": {"@id": "P06400", "@source": "Swiss-Prot", "name": "Retinoblastoma-associated protein", "general-function": null, "specific-function": "Key regulator of entry into cell division that acts as a tumor suppressor. Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation. Recruits and targets histone methyltransferases SUV39H1, SUV420H1 and SUV420H2, leading to epigenetic transcriptional repression. Controls histone H4 'Lys-20' trimethylation. Also acts as a transcription repressor of E2F target genes by recruiting chromatin-modifying enzymes to promoters. Inhibits the intrinsic kinase activity of TAF1. Forms a complex with adenovirus E1A and with SV40 large T antigen. May bind and modulate functionally certain cellular proteins with which T and E1A compete for pocket binding", "gene-name": "RB1", "locus": "13q14.2", "cellular-location": "Nucleus", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.04", "molecular-weight": "106161.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9884"}, {"resource": "GenAtlas", "identifier": "RB1"}, {"resource": "GeneCards", "identifier": "RB1"}, {"resource": "GenBank Gene Database", "identifier": "M15400"}, {"resource": "GenBank Protein Database", "identifier": "190959"}, {"resource": "UniProtKB", "identifier": "P06400"}, {"resource": "UniProt Accession", "identifier": "RB_HUMAN"}]}, "synonyms": {"synonym": ["P105-RB", "PP110", "RB"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Retinoblastoma-associated protein\nMPPKTPRKTAATAAAAAAEPPAPPPPPPPEEDPEQDSGPEDLPLVRLEFEETEEPDFTAL\nCQKLKIPDHVRERAWLTWEKVSSVDGVLGGYIQKKKELWGICIFIAAVDLDEMSFTFTEL\nQKNIEISVHKFFNLLKEIDTSTKVDNAMSRLLKKYDVLFALFSKLERTCELIYLTQPSSS\nISTEINSALVLKVSWITFLLAKGEVLQMEDDLVISFQLMLCVLDYFIKLSPPMLLKEPYK\nTAVIPINGSPRTPRRGQNRSARIAKQLENDTRIIEVLCKEHECNIDEVKNVYFKNFIPFM\nNSLGLVTSNGLPEVENLSKRYEEIYLKNKDLDARLFLDHDKTLQTDSIDSFETQRTPRKS\nNLDEEVNVIPPHTPVRTVMNTIQQLMMILNSASDQPSENLISYFNNCTVNPKESILKRVK\nDIGYIFKEKFAKAVGQGCVEIGSQRYKLGVRLYYRVMESMLKSEEERLSIQNFSKLLNDN\nIFHMSLLACALEVVMATYSRSTSQNLDSGTDLSFPWILNVLNLKAFDFYKVIESFIKAEG\nNLTREMIKHLERCEHRIMESLAWLSDSPLFDLIKQSKDREGPTDHLESACPLNLPLQNNH\nTAADMYLSPVRSPKKKGSTTRVNSTANAETQATSAFQTQKPLKSTSLSLFYKKVYRLAYL\nRLNTLCERLLSEHPELEHIIWTLFQHTLQNEYELMRDRHLDQIMMCSMYGICKVKNIDLK\nFKIIVTAYKDLPHAVQETFKRVLIKEEEYDSIIVFYNSVFMQRLKTNILQYASTRPPTLS\nPIPHIPRSPYKFPSSPLRIPGGNIYISPLKSPYKISEGLPTPTKMTPRSRILVSIGESFG\nTSEKFQKINQMVCNSDRVLKRSAEGSNPPKPLKKLRFDIEGSDEADGSKHLPGESKFQQK\nLAEMTSTRTRMQKQKMNDSMDTSNKEEK"}, "gene-sequence": {"@format": "FASTA", "#text": ">2787 bp\nATGCCGCCCAAAACCCCCCGAAAAACGGCCGCCACCGCCGCCGCTGCCGCCGCGGAACCC\nCCGGCACCGCCGCCGCCGCCCCCTCCTGAGGAGGACCCAGAGCAGGACAGCGGCCCGGAG\nGACCTGCCTCTCGTCAGGCTTGAGTTTGAAGAAACAGAAGAACCTGATTTTACTGCATTA\nTGTCAGAAATTAAAGATACCAGATCATGTCAGAGAGAGAGCTTGGTTAACTTGGGAGAAA\nGTTTCATCTGTGGATGGAGTATTGGGAGGTTATATTCAAAAGAAAAAGGAACTGTGGGGA\nATCTGTATCTTTATTGCACGAGTTGACCTAGATGAGATGTCGTTCACTTTACTGAGCTAC\nAGAAAAACATACGAAATCAGTGTCCATAAATTCTTTAACTTACTAAAAGAAATTGATACC\nAGTACCAAAGTTGATAATGCTATGTCAAGACTGTTGAAGAAGTATGATGTATTGTTTGCA\nCTCTTCAGCAAATTGGAAAGGACATGTGAACTTATATATTTGACACAACCCAGCAGTTCG\nATATCTACTGAAATAAATTCTGCATTGGTGCTAAAAGTTTCTTGGATCACATTTTTATTA\nGCTAAAGGGGAAGTATTACAAATGGAAGATGATCTGGTGATTTCATTTCAGTTAATGCTA\nTGTGTCCTTGACTATTTTATTAAACTCTCACCTCCCATGTTGCTCAAAGAACCATATAAA\nACAGCTGTTATACCCATTAATGGTTCACCTCGAACACCCAGGCGAGGTCAGAACAGGAGT\nGCACGGATAGCAAAACAACTAGAAAATGATACAAGAATTATTGAAGTTCTCTGTAAAGAA\nCATGAATGTAATATAGATGAGGTGAAAAATGTTTATTTCAAAAATTTTATACCTTTTATG\nAATTCTCTTGGACTTGTAACATCTAATGGACTTCCAGAGGTTGAAAATCTTTCTAAACGA\nTACGAAGAAATTTATCTTAAAAATAAAGATCTAGATCGAAGATTATTTTTGGATCATGAT\nAAAACTCTTCAGACTGATTCTATAGACAGTTTTGAAACACAGAGAACACCACGAAAAAGT\nAACCTTGATGAAGAGGTGAATATAATTCCTCCACACACTCCAGTTAGGACTGTTATGAAC\nACTATCCAACAATTAATGATGATTTTAAATTCTGCAAGTGATCAACCTTCAGAAAATCTG\nATTTCCTATTTTAACAACTGCACAGTGAATCCAAAAGAAAGTATACTGAAAAGAGTGAAG\nGATATAGGATACATCTTTAAAGAGAAATTTGCTAAAGCTGTGGGACAGGGTTGTGTCGAA\nATTGGATCACAGCGATACAAACTTGGAGTTCGCTTGTATTACCGAGTAATGGAATCCATG\nCTTAAATCAGAAGAAGAACGATTATCCATTCAAAATTTTAGCAAACTTCTGAATGACAAC\nATTTTTCATATGTCTTTATTGGCGTGCGCTCTTGAGGTTGTAATGGCCACATATAGCAGA\nAGTACATCTCAGAATCTTGATTCTGGAACAGATTTGTCTTTCCCATGGATTCTGAATGTG\nCTTAATTTAAAAGCCTTTGATTTTTACAAAGTGATCGAAAGTTTTATCAAAGCAGAAGGC\nAACTTGACAAGAGAAATGATAAAACATTTAGAACGATGTGAACATCGAATCATGGAATCC\nCTTGCATGGCTCTCAGATTCACCTTTATTTGATCTTATTAAACAATCAAAGGACCGAGAA\nGGACCAACTGATCACCTTGAATCTGCTTGTCCTCTTAATCTTCCTCTCCAGAATAATCAC\nACTGCAGCAGATATGTATCTTTCTCCTGTAAGATCTCCAAAGAAAAAAGGTTCAACTACG\nCGTGTAAATTCTACTGCAAATGCAGAGACACAAGCAACCTCAGCCTTCCAGACCCAGAAG\nCCATTGAAATCTACCTCTCTTTCACTGTTTTATAAAAAAGTGTATCGGCTAGCCTATCTC\nCGGCTAAATACACTTTGTGAACGCCTTCTGTCTGAGCACCCAGAATTAGAACATATCATC\nTGGACCCTTTTCCAGCACACCCTGCAGAATGAGTATGAACTCATGAGAGACAGGCATTTG\nGACCAAATTATGATGTGTTCCATGTATGGCATATGCAAAGTGAAGAATATAGACCTTAAA\nTTCAAAATCATTGTAACAGCATACAAGGATCTTCCTCATGCTGTTCAGGAGACATTCAAA\nCGTGTTTTGATCAAAGAAGAGGAGTATGATTCTATTATAGTATTCTATAACTCGGTCTTC\nATGCAGAGACTGAAAACAAATATTTTGCAGTATGCTTCCACCAGGCCCCCTACCTTGTCA\nCCAATACCTCACATTCCTCGAAGCCCTTACAAGTTTCCTAGTTCACCCTTACGGATTCCT\nGGAGGGAACATCTATATTTCACCCCTGAAGAGTCCATATAAAATTTCAGAAGGTCTGCCA\nACACCAACAAAAATGACTCCAAGATCAAGAATCTTAGTATCAATTGGTGAATCATTCGGG\nACTTCTGAGAAGTTCCAGAAAATAAATCAGATGGTATGTAACAGCGACCGTGTGCTCAAA\nAGAAGTGCTGAAGGAAGCAACCCTCCTAAACCACTGAAAAAACTACGCTTTGATATTGAA\nGGATCAGATGAAGCAGATGGAAGTAAACATCTCCCAGGAGAGTCCAAATTTCAGCAGAAA\nCTGGCAGAAATGACTTCTACTCGAACACGAATGCAAAAGCAGAAAATGAATGATAGCATG\nGATACCTCAAACAAGGAAGAGAAATGA"}, "pfams": {"pfam": [{"identifier": "PF01858", "name": "RB_A"}, {"identifier": "PF01857", "name": "RB_B"}, {"identifier": "PF08934", "name": "Rb_C"}]}, "go-classifiers": null}}, {"@position": "7", "id": "BE0000941", "name": "Cathepsin D", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Authier F, Metioui M, Fabrega S, Kouach M, Briand G: Endosomal proteolysis of internalized insulin at the C-terminal region of the B chain by cathepsin D. J Biol Chem. 2002 Mar 15;277(11):9437-46. Epub 2002 Jan 4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11779865\n# Ogino S, Cohen ML, Abdul-Karim FW: Atypical teratoid/rhabdoid tumor of the CNS: cytopathology and immunohistochemistry of insulin-like growth factor-II, insulin-like growth factor receptor type 1, cathepsin D, and Ki-67. Mod Pathol. 1999 Apr;12(4):379-85. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10229502\n# Nunn SE, Peehl DM, Cohen P: Acid-activated insulin-like growth factor binding protein protease activity of cathepsin D in normal and malignant prostatic epithelial cells and seminal plasma. J Cell Physiol. 1997 May;171(2):196-204. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9130467", "known-action": "unknown", "polypeptide": {"@id": "P07339", "@source": "Swiss-Prot", "name": "Cathepsin D", "general-function": "Involved in aspartic-type endopeptidase activity", "specific-function": "Acid protease active in intracellular protein breakdown. Involved in the pathogenesis of several diseases such as breast cancer and possibly Alzheimer disease", "gene-name": "CTSD", "locus": "11p15.5", "cellular-location": "Lysosome. Melanosome. Note=Identified by mass spectrometry in melanosome fractions from stage I to s", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.5", "molecular-weight": "44553.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2529"}, {"resource": "GenAtlas", "identifier": "CTSD"}, {"resource": "GeneCards", "identifier": "CTSD"}, {"resource": "GenBank Gene Database", "identifier": "M11233"}, {"resource": "GenBank Protein Database", "identifier": "181180"}, {"resource": "UniProtKB", "identifier": "P07339"}, {"resource": "UniProt Accession", "identifier": "CATD_HUMAN"}]}, "synonyms": {"synonym": ["Cathepsin D precursor", "EC 3.4.23.5"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cathepsin D precursor\nMQPSSLLPLALCLLAAPASALVRIPLHKFTSIRRTMSEVGGSVEDLIAKGPVSKYSQAVP\nAVTEGPIPEVLKNYMDAQYYGEIGIGTPPQCFTVVFDTGSSNLWVPSIHCKLLDIACWIH\nHKYNSDKSSTYVKNGTSFDIHYGSGSLSGYLSQDTVSVPCQSASSASALGGVKVERQVFG\nEATKQPGITFIAAKFDGILGMAYPRISVNNVLPVFDNLMQQKLVDQNIFSFYLSRDPDAQ\nPGGELMLGGTDSKYYKGSLSYLNVTRKAYWQVHLDQVEVASGLTLCKEGCEAIVDTGTSL\nMVGPVDEVRELQKAIGAVPLIQGEYMIPCEKVSTLPAITLKLGGKGYKLSPEDYTLKVSQ\nAGKTLCLSGFMGMDIPPPSGPLWILGDVFIGRYYTVFDRDNNRVGFAEAARL"}, "gene-sequence": {"@format": "FASTA", "#text": ">1239 bp\nATGCAGCCCTCCAGCCTTCTGCCGCTCGCCCTCTGCCTGCTGGCTGCACCCGCCTCCGCG\nCTCGTCAGGATCCCGCTGCACAAGTTCACGTCCATCCGCCGGACCATGTCGGAGGTTGGG\nGGCTCTGTGGAGGACCTGATTGCCAAAGGCCCCGTCTCAAAGTACTCCCAGGCGGTGCCA\nGCCGTGACCGAGGGGCCCATTCCCGAGGTGCTCAAGAACTACATGGACGCCCAGTACTAC\nGGGGAGATTGGCATCGGGACGCCCCCCCAGTGCTTCACAGTCGTCTTCGACACGGGCTCC\nTCCAACCTGTGGGTCCCCTCCATCCACTGCAAACTGCTGGACATCGCTTGCTGGATCCAC\nCACAAGTACAACAGCGACAAGTCCAGCACCTACGTGAAGAATGGTACCTCGTTTGACATC\nCACTATGGCTCGGGCAGCCTCTCCGGGTACCTGAGCCAGGACACTGTGTCGGTGCCCTGC\nCAGTCAGCGTCGTCAGCCTCTGCCCTGGGCGGTGTCAAAGTGGAGAGGCAGGTCTTTGGG\nGAGGCCACCAAGCAGCCAGGCATCACCTTCATCGCAGCCAAGTTCGATGGCATCCTGGGC\nATGGCCTACCCCCGCATCTCCGTCAACAACGTGCTGCCCGTCTTCGACAACCTGATGCAG\nCAGAAGCTGGTGGACCAGAACATCTTCTCCTTCTACCTGAGCAGGGACCCAGATGCGCAG\nCCTGGGGGTGAGCTGATGCTGGGTGGCACAGACTCCAAGTATTACAAGGGTTCTCTGTCC\nTACCTGAATGTCACCCGCAAGGCCTACTGGCAGGTCCACCTGGACCAGGTGGAGGTGGCC\nAGCGGGCTGACCCTGTGCAAGGAGGGCTGTGAGGCCATTGTGGACACAGGCACTTCCCTC\nATGGTGGGCCCGGTGGATGAGGTGCGCGAGCTGCAGAAGGCCATCGGGGCCGTGCCGCTG\nATTCAGGGCGAGTACATGATCCCCTGTGAGAAGGTGTCCACCCTGCCCGCGATCACACTG\nAAGCTGGGAGGCAAAGGCTACAAGCTGTCCCCAGAGGACTACACGCTCAAGGTGTCGCAG\nGCCGGGAAGACCCTCTGCCTGAGCGGCTTCATGGGCATGGACATCCCGCCACCCAGCGGG\nCCACTCTGGATCCTGGGCGACGTCTTCATCGGCCGCTACTACACTGTGTTTGACCGTGAC\nAACAACAGGGTGGGCTTCGCCGAGGCTGCCCGCCTCTAG"}, "pfams": {"pfam": [{"identifier": "PF07966", "name": "A1_Propeptide"}, {"identifier": "PF00026", "name": "Asp"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "pepsin A activity"}, {"category": "function", "description": "aspartic-type endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}]}}}, {"@position": "8", "id": "BE0001123", "name": "Carboxypeptidase E", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Polastri L, Galbiati F, Folli F, Davalli AM: Effects of carboxypeptidase E overexpression on insulin mRNA levels, regulated insulin secretion, and proinsulin processing of pituitary GH3 cells transfected with a furin-cleavable human proinsulin cDNA. Cell Transplant. 2002;11(8):803-11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12588113\n# Guest PC, Pipeleers D, Rossier J, Rhodes CJ, Hutton JC: Co-secretion of carboxypeptidase H and insulin from isolated rat islets of Langerhans. Biochem J. 1989 Dec 1;264(2):503-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2481446\n# Furuta M, Carroll R, Martin S, Swift HH, Ravazzola M, Orci L, Steiner DF: Incomplete processing of proinsulin to insulin accompanied by elevation of Des-31,32 proinsulin intermediates in islets of mice lacking active PC2. J Biol Chem. 1998 Feb 6;273(6):3431-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9452465", "known-action": "unknown", "polypeptide": {"@id": "P16870", "@source": "Swiss-Prot", "name": "Carboxypeptidase E", "general-function": "Amino acid transport and metabolism", "specific-function": "Removes residual C-terminal Arg or Lys remaining after initial endoprotease cleavage during prohormone processing. Processes proinsulin", "gene-name": "CPE", "locus": "4q32.3", "cellular-location": "Secreted protein. Note=Secretory granules of pancreatic islets, adrenal gland, pituitary and brain", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "4.78", "molecular-weight": "53151.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2303"}, {"resource": "GenAtlas", "identifier": "CPE"}, {"resource": "GeneCards", "identifier": "CPE"}, {"resource": "GenBank Gene Database", "identifier": "X51405"}, {"resource": "GenBank Protein Database", "identifier": "29667"}, {"resource": "UniProtKB", "identifier": "P16870"}, {"resource": "UniProt Accession", "identifier": "CBPE_HUMAN"}]}, "synonyms": {"synonym": ["Carboxypeptidase E precursor", "Carboxypeptidase H", "CPE", "CPH", "EC 3.4.17.10", "Enkephalin convertase", "Prohormone-processing carboxypeptidase"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Carboxypeptidase E precursor\nMAGRGGSALLALCGALAACGWLLGAEAQEPGAPAAGMRRRRRLQQEDGISFEYHRYPELR\nEALVSVWLQCTAISRIYTVGRSFEGRELLVIELSDNPGVHEPGEPEFKYIGNMHGNEAVG\nRELLIFLAQYLCNEYQKGNETIVNLIHSTRIHIMPSLNPDGFEKAASQPGELKDWFVGRS\nNAQGIDLNRNFPDLDRIVYVNEKEGGPNNHLLKNMKKIVDQNTKLAPETKAVIHWIMDIP\nFVLSANLHGGDLVANYPYDETRSGSAHEYSSSPDDAIFQSLARAYSSFNPAMSDPNRPPC\nRKNDDDSSFVDGTTNGGAWYSVPGGMQDFNYLSSNCFEITVELSCEKFPPEETLKTYWED\nNKNSLISYLEQIHRGVKGFVRDLQGNPIANATISVEGIDHDVTSAKDGDYWRLLIPGNYK\nLTASAPGYLAITKKVAVPYSPAAGVDFELESFSERKEEEKEELMEWWKMMSETLNF"}, "gene-sequence": {"@format": "FASTA", "#text": ">1431 bp\nATGGCCGGGCGAGGGGGCAGCGCGCTGCTGGCTCTGTGCGGGGCACTGGCTGCCTGCGGG\nTGGCTCCTGGGCGCCGAAGCCCAGGAGCCCGGGGCGCCCGCGGCGGGCATGAGGCGGCGC\nCGGCGGCTGCAGCAAGAGGACGGCATCTCCTTCGAGTACCACCGCTACCCCGAGCTGCGC\nGAGGCGCTCGTGTCCGTGTGGCTGCAGTGCACCGCCATCAGCAGGATTTACACGGTGGGG\nCGCAGCTTCGAGGGCCGGGAGCTCCTGGTCATCGAGCTGTCCGACAACCCTGGCGTCCAT\nGAGCCTGGTGAGCCTGAATTTAAATACATTGGGAATATGCATGGGAATGAGGCTGTTGGA\nCGAGAACTGCTCATTTTCTTGGCCCAGTACCTATGCAACGAATACCAGAAGGGGAACGAG\nACAATTGTCAACCTGATCCACAGTACCCGCATTCACATCATGCCTTCCCTGAACCCAGAT\nGGCTTTGAGAAGGCAGCGTCTCAGCCTGGTGAACTCAAGGACTGGTTTGTGGGTCGAAGC\nAATGCCCAGGGAATAGATCTGAACCGGAACTTTCCAGACCTGGATAGGATAGTGTACGTG\nAATGAGAAAGAAGGTGGTCCAAATAATCATCTGTTGAAAAATATGAAGAAAATTGTGGAT\nCAAAACACAAAGCTTGCTCCTGAGACCAAGGCTGTCATTCATTGGATTATGGATATTCCT\nTTTGTGCTTTCTGCCAATCTCCATGGAGGAGACCTTGTGGCCAATTATCCATATGATGAG\nACGCGGAGTGGTAGTGCTCACGAATACAGCTCCTCCCCAGATGACGCCATTTTCCAAAGC\nTTGGCCCGGGCATACTCTTCTTTCAACCCGGCCATGTCTGACCCCAATCGGCCACCATGT\nCGCAAGAATGATGATGACAGCAGCTTTGTAGATGGAACCACCAACGGTGGTGCTTGGTAC\nAGCGTACCTGGAGGGATGCAAGACTTCAATTACCTTAGCAGCAACTGTTTTGAGATCACC\nGTGGAGCTTAGCTGTGAGAAGTTCCCACCTGAAGAGACTCTGAAGACCTACTGGGAGGAT\nAACAAAAACTCCCTCATTAGCTACCTTGAGCAGATACACCGAGGAGTTAAAGGATTTGTC\nCGAGACCTTCAAGGTAACCCAATTGCGAATGCCACCATCTCCGTGGAAGGAATAGACCAC\nGATGTTACATCCGCAAAGGATGGTGATTACTGGAGATTGCTTATACCTGGAAACTATAAA\nCTTACAGCCTCAGCTCCAGGCTATCTGGCAATAACAAAGAAAGTGGCAGTTCCTTACAGC\nCCTGCTGCTGGGGTTGATTTTGAACTGGAGTCATTTTCTGAAAGGAAAGAAGAGGAGAAG\nGAAGAATTGATGGAATGGTGGAAAATGATGTCAGAAACTTTAAATTTTTAA"}, "pfams": {"pfam": {"identifier": "PF00246", "name": "Peptidase_M14"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "exopeptidase activity"}, {"category": "function", "description": "carboxypeptidase activity"}, {"category": "function", "description": "metallocarboxypeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "carboxypeptidase A activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}]}}}, {"@position": "9", "id": "BE0002124", "name": "Neuroendocrine convertase 2", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Zertal-Zidani S, Bounacer A, Scharfmann R: Regulation of pancreatic endocrine cell differentiation by sulphated proteoglycans. Diabetologia. 2007 Mar;50(3):585-95. Epub 2007 Jan 13. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17221210\n# Utsunomiya N, Ohagi S, Sanke T, Tatsuta H, Hanabusa T, Nanjo K: Organization of the human carboxypeptidase E gene and molecular scanning for mutations in Japanese subjects with NIDDM or obesity. Diabetologia. 1998 Jun;41(6):701-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9662053\n# Ohagi S, Sakaguchi H, Sanke T, Tatsuta H, Hanabusa T, Nanjo K: Human prohormone convertase 3 gene: exon-intron organization and molecular scanning for mutations in Japanese subjects with NIDDM. Diabetes. 1996 Jul;45(7):897-901. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8666140", "known-action": "unknown", "polypeptide": {"@id": "P16519", "@source": "Swiss-Prot", "name": "Neuroendocrine convertase 2", "general-function": "Posttranslational modification, protein turnover, chaperones", "specific-function": "Involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues", "gene-name": "PCSK2", "locus": "20p11.2", "cellular-location": "Cytoplasmic vesicle", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.47", "molecular-weight": "70566.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:8744"}, {"resource": "GenAtlas", "identifier": "PCSK2"}, {"resource": "GeneCards", "identifier": "PCSK2"}, {"resource": "GenBank Gene Database", "identifier": "J05252"}, {"resource": "GenBank Protein Database", "identifier": "189652"}, {"resource": "UniProtKB", "identifier": "P16519"}, {"resource": "UniProt Accession", "identifier": "NEC2_HUMAN"}]}, "synonyms": {"synonym": ["EC 3.4.21.94", "KEX2-like endoprotease 2", "NEC 2", "Neuroendocrine convertase 2 precursor", "PC2", "Prohormone convertase 2", "Proprotein convertase 2"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Neuroendocrine convertase 2\nMKGGCVSQWKAAAGFLFCVMVFASAERPVFTNHFLVELHKGGEDKARQVAAEHGFGVRKL\nPFAEGLYHFYHNGLAKAKRRRSLHHKQQLERDPRVKMALQQEGFDRKKRGYRDINEIDIN\nMNDPLFTKQWYLINTGQADGTPGLDLNVAEAWELGYTGKGVTIGIMDDGIDYLHPDLASN\nYNAEASYDFSSNDPYPYPRYTDDWFNSHGTRCAGEVSAAANNNICGVGVAYNSKVAGIRM\nLDQPFMTDIIEASSISHMPQLIDIYSASWGPTDNGKTVDGPRELTLQAMADGVNKGRGGK\nGSIYVWASGDGGSYDDCNCDGYASSMWTISINSAINDGRTALYDESCSSTLASTFSNGRK\nRNPEAGVATTDLYGNCTLRHSGTSAAAPEAAGVFALALEANLGLTWRDMQHLTVLTSKRN\nQLHDEVHQWRRNGVGLEFNHLFGYGVLDAGAMVKMAKDWKTVPERFHCVGGSVQDPEKIP\nSTGKLVLTLTTDACEGKENFVRYLEHVQAVITVNATRRGDLNINMTSPMGTKSILLSRRP\nRDDDSKVGFDKWPFMTTHTWGEDARGTWTLELGFVGSAPQKGVLKEWTLMLHGTQSAPYI\nDQVVRDYQSKLAMSKKEELEEELDEAVERSLKSILNKN"}, "gene-sequence": {"@format": "FASTA", "#text": ">1917 bp\nATGAAGGGTGGTTGTGTCTCCCAGTGGAAGGCGGCCGCCGGGTTCCTCTTCTGTGTCATG\nGTTTTTGCATCTGCTGAGCGACCGGTCTTCACGAATCATTTTCTTGTGGAGTTGCATAAA\nGGGGGAGAGGACAAAGCTCGCCAAGTTGCAGCAGAACACGGCTTTGGAGTCCGAAAGCTT\nCCCTTTGCTGAAGGTCTGTACCACTTTTATCACAATGGCCTTGCAAAGGCCAAGAGAAGA\nCGCAGCCTACACCACAAGCAGCAGCTGGAGAGAGACCCCAGGGTAAAGATGGCTTTGCAG\nCAGGAAGGATTTGACCGAAAAAAGCGAGGTTACAGAGACATCAATGAGATCGACATCAAC\nATGAACGATCCTCTTTTTACAAAGCAGTGGTATCTGATCAATACTGGGCAAGCTGATGGC\nACTCCTGGCCTTGATTTGAATGTGGCTGAAGCCTGGGAGCTGGGATACACAGGGAAAGGT\nGTTACCATTGGAATTATGGATGATGGGATTGACTATCTCCACCCGGACCTGGCCTCCAAC\nTATAATGCCGAAGCAAGTTACGACTTCAGCAGCAACGACCCCTATCCTTACCCTCGGTAC\nACAGATGACTGGTTTAACAGCCACGGGACCCGATGTGCAGGAGAAGTTTCTGCTGCCGCC\nAACAACAATATCTGTGGAGTTGGAGTAGCATACAACTCCAAGGTTGCAGGCATCCGGATG\nCTGGACCAGCCATTCATGACAGACATCATCGAGGCCTCCTCCATCAGTCATATGCCACAG\nCTGATTGACATCTACAGCGCCAGCTGGGGCCCCACAGACAACGGCAAGACAGTGGATGGG\nCCCCGGGACGTCACGCTGCAGGCCATGGCCGATGGCGTGAACAAGGGCCGCGGCGGCAAA\nGGCAGCATCTACGTGTGGGCCTCCGGGGACGGCGGCAGCTATGACGACTGCAACTGCGAC\nGGCTACGCCTCCAGCATGTGGACCATCTCCATCAACTCAGCCATCAACGACGGCAGGACT\nGCCCTGTACGACGAGAGCTGCTCTTCCACCTTGGCTTCCACCTTCAGCAACGGGAGGAAA\nAGGAACCCCGAGGCCGGTGTGGCAACCACAGATTTGTACGGCAACTGCACTCTGAGGCAT\nTCTGGGACATCTGCAGCTGCCCCCGAGGCAGCTGGTGTGTTTGCACTGGCTCTGGAGGCT\nAACCTGGGTCTGACCTGGCGGGACATGCAGCATCTGACTGTGCTCACCTCCAAACGGAAC\nCAGCTTCACGACGAGGTCCATCAGTGGCGGCGCAATGGGGTCGGCCTGGAATTTAATCAC\nCTCTTTGGCTACGGGGTCCTTGATGCAGGTGCCATGGTGAAAATGGCTAAAGACTGGAAA\nACCGTGCCTGAGAGATTCCACTGTGTGGGAGGCTCCGTGCAGGACCCTGAGAAAATACCA\nTCCACTGGCAAGTTGGTGCTGACACTCACAACCGACGCCTGTGAGGGGAAGGAAAATTTT\nGTCCGCTACCTGGAGCATGTCCAGGCTGTCATCACGGTCAACGCAACCAGAAGAGGAGAC\nCTGAACATCAACATGACTTCCCCTATGGGCACCAAGTCCATTTTGCTGAGCCGGCGTCCA\nAGGGATGACGACTCCAAGGTGGGCTTTGACAAGTGGCCTTTCATGACCACTCACACGTGG\nGGGGAAGACGCCCGAGGCACCTGGACCCTGGAGCTGGGATTTGTCGGCAGCGCCCCGCAG\nAAGGGGGTGCTGAAGGAGTGGACCCTGATGCTGCATGGCACTCAGAGTGCCCCGTACATC\nGACCAGGTGGTGCGGGATTACCAGTCCAAGTTGGCCATGTCCAAGAAAGAGGAGCTGGAG\nGAAGAGCTGGACGAAGCCGTGGAGAGAAGCCTGAAAAGCATCCTTAACAAGAACTAG"}, "pfams": {"pfam": [{"identifier": "PF00082", "name": "Peptidase_S8"}, {"identifier": "PF01483", "name": "P_proprotein"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "subtilase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}]}}}, {"@position": "10", "id": "BE0002125", "name": "Neuroendocrine convertase 1", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Marriott D, Gillece-Castro B, Gorman CM: Prohormone convertase-1 will process prorelaxin, a member of the insulin family of hormones. Mol Endocrinol. 1992 Sep;6(9):1441-50. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1435788\n# Zhu X, Orci L, Carroll R, Norrbom C, Ravazzola M, Steiner DF: Severe block in processing of proinsulin to insulin accompanied by elevation of des-64,65 proinsulin intermediates in islets of mice lacking prohormone convertase 1/3. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10299-304. Epub 2002 Jul 22. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12136131\n# Kuwahata M, Tomoe Y, Harada N, Amano S, Segawa H, Tatsumi S, Ito M, Oka T, Miyamoto K: Characterization of the molecular mechanisms involved in the increased insulin secretion in rats with acute liver failure. Biochim Biophys Acta. 2007 Jan;1772(1):60-5. Epub 2006 Oct 4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17097861", "known-action": "unknown", "polypeptide": {"@id": "P29120", "@source": "Swiss-Prot", "name": "Neuroendocrine convertase 1", "general-function": "Posttranslational modification, protein turnover, chaperones", "specific-function": "Involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues. Substrates include POMC, renin, enkephalin, dynorphin, somatostatin and insulin", "gene-name": "PCSK1", "locus": "5q15-q21", "cellular-location": "Cytoplasmic vesicle", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.84", "molecular-weight": "84152.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:8743"}, {"resource": "GenAtlas", "identifier": "PCSK1"}, {"resource": "GeneCards", "identifier": "PCSK1"}, {"resource": "GenBank Gene Database", "identifier": "X64810"}, {"resource": "GenBank Protein Database", "identifier": "35318"}, {"resource": "UniProtKB", "identifier": "P29120"}, {"resource": "UniProt Accession", "identifier": "NEC1_HUMAN"}]}, "synonyms": {"synonym": ["EC 3.4.21.93", "NEC 1", "Neuroendocrine convertase 1 precursor", "PC1", "Prohormone convertase 1", "Proprotein convertase 1"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Neuroendocrine convertase 1\nMERRAWSLQCTAFVLFCAWCALNSAKAKRQFVNEWAAEIPGGPEAASAIAEELGYDLLGQ\nIGSLENHYLFKHKNHPRRSRRSAFHITKRLSDDDRVIWAEQQYEKERSKRSALRDSALNL\nFNDPMWNQQWYLQDTRMTAALPKLDLHVIPVWQKGITGKGVVITVLDDGLEWNHTDIYAN\nYDPEASYDFNDNDHDPFPRYDPTNENKHGTRCAGEIAMQANNHKCGVGVAYNSKVGGIRM\nLDGIVTDAIEASSIGFNPGHVDIYSASWGPNDDGKTVEGPGRLAQKAFEYGVKQGRQGKG\nSIFVWASGNGGRQGDNCDCDGYTDSIYTISISSASQQGLSPWYAEKCSSTLATSYSSGDY\nTDQRITSADLHNDCTETHTGTSASAPLAAGIFALALEANPNLTWRDMQHLVVWTSEYDPL\nANNPGWKKNGAGLMVNSRFGFGLLNAKALVDLADPRTWRSVPEKKECVVKDNDFEPRALK\nANGEVIIEIPTRACEGQENAIKSLEHVQFEATIEYSRRGDLHVTLTSAAGTSTVLLAERE\nRDTSPNGFKNWDFMSVHTWGENPIGTWTLRITDMSGRIQNEGRIVNWKLILHGTSSQPEH\nMKQPRVYTSYNTVQNDRRGVEKMVDPGEEQPTQENPKENTLVSKSPSSSSVGGRRDELEE\nGAPSQAMLRLLQSAFSKNSPPKQSPKKSPSAKLNIPYENFYEALEKLNKPSQLKDSEDSL\nYNDYVDVFYNTKPYKHRDDRLLQALVDILNEEN"}, "gene-sequence": {"@format": "FASTA", "#text": ">2262 bp\nATGGAGCGAAGAGCCTGGAGTCTGCAGTGCACTGCTTTCGTCCTCTTTTGCGCTTGGTGT\nGCACTGAACAGTGCAAAAGCGAAAAGGCAATTTGTCAATGAATGGGCAGCGGAGATCCCC\nGGGGGCCCGGAAGCAGCCTCGGCCATCGCCGAGGAGCTGGGCTATGACCTTTTGGGTCAG\nATTGGTTCACTTGAAAATCACTACTTATTCAAACATAAAAACCACCCCAGAAGGTCTCGA\nAGGAGTGCCTTTCATATCACTAAGAGATTATCTGATGATGATCGTGTGATATGGGCTGAA\nCAACAGTATGAAAAAGAAAGAAGTAAACGTTCAGCTCTAAGGGACTCAGCACTAAATCTC\nTTCAATGATCCCATGTGGAATCAGCAATGGTACTTGCAAGATACCAGGATGACGGCAGCC\nCTGCCCAAGCTGGACCTTCATGTGATACCTGTTTGGCAAAAAGGCATTACGGGCAAAGGA\nGTTGTTATCACCGTACTGGATGATGGTTTGGAGTGGAATCACACGGACATTTATGCCAAC\nTATGATCCAGAGGCTAGCTATGATTTTAATGATAATGACCATGATCCATTTCCCCGATAT\nGATCCCACAAACGAGAACAAACACGGGACCAGATGTGCAGGAGAAATTGCCATGCAAGCA\nAATAATCACAAATGCGGGGTTGGAGTTGCATACAATTCCAAAGTTGGAGGCATAAGAATG\nCTGGATGGCATTGTGACGGATGCTATTGAGGCCAGTTCAATTGGATTCAATCCTGGACAC\nGTGGATATTTACAGTGCAAGCTGGGGCCCTAATGATGATGGGAAAACTGTGGAGGGGCCT\nGGCCGGCTAGCCCAGAAGGCTTTTGAATATGGTGTCAAACAGGGGAGACAGGGGAAGGGG\nTCCATCTTCGTCTGGGCTTCGGGAAACGGGGGGCGTCAGGGAGATAATTGTGACTGTGAT\nGGCTACACAGACAGCATCTACACCATCTCCATCAGCAGTGCCTCCCAGCAAGGCCTATCC\nCCCTGGTACGCTGAGAAGTGCTCCTCCACACTGGCCACCTCTTACAGCGGCGGAGATTAC\nACCGACCAGAGAATCACGAGCGCTGACCTGCACAATGACTGCACGGAGACGCACACAGGC\nACCTCGGCCTCTGCACCTCTGGCTGCTGGCATCTTCGCTCTGGCCCTGGAAGCAAACCCA\nAATCTCACCTGGCGAGATATGCAGCACCTGGTTGTCTGGACCTCTGAGTATGACCCGCTG\nGCCAATAACCCTGGATGGAAAAAGAATGGAGCAGGCTTGATGGTGAATAGTCGATTTGGA\nTTTGGCTTGCTAAATGCCAAAGCTCTGGTGGATTTAGCTGACCCCAGGACCTGGAGGAGC\nGTGCCTGAGAAGAAAGAGTGTGTTGTAAAGGACAATGACTTTGAGCCCAGAGCCCTGAAA\nGCTAATGGAGAAGTTATCATTGAAATTCCAACAAGAGCTTGTGAAGGACAAGAAAATGCT\nATCAAGTCCCTGGAGCATGTACAATTTGAAGCAACAATTGAATATTCCCGAAGAGGAGAC\nCTTCATGTCACACTTACTTCTGCTGCTGGAACTAGCACTGTGCTCTTGGCTGAAAGAGAA\nCGGGATACATCTCCTAATGGCTTTAAGAACTGGGACTTCATGTCTGTTCACACATGGGGA\nGAGAACCCTATAGGTACTTGGACTTTGAGAATTACAGACATGTCTGGAAGAATTCAAAAT\nGAAGGAAGAATTGTGAACTGGAAGCTGATTTTGCACGGGACCTCTTCTCAGCCAGAGCAT\nATGAAGCAGCCTCGTGTGTACACGTCCTACAACACTGTTCAGAATGACAGAAGAGGGGTG\nGAGAAGATGGTGGATCCAGGGGAGGAGCAGCCCACACAAGAGAACCCTAAGGAGAACACC\nCTGGTGTCCAAAAGCCCCAGCAGCAGCAGCGTAGGGGGCCGGAGGGATGAGTTGGAGGAG\nGGAGCCCCTTCCCAGGCCATGCTGCGACTCCTGCAAAGTGCTTTCAGTAAAAACTCACCG\nCCAAAGCAATCACCAAAGAAGTCCCCAAGTGCAAAGCTCAACATCCCTTATGAAAACTTC\nTACGAAGCCCTGGAAAAGCTGAACAAACCTTCCCAGCTTAAAGACTCTGAAGACAGTCTG\nTATAATGACTATGTTGATGTTTTTTATAACACTAAACCTTACAAGCACAGAGACGACCGG\nCTGCTTCAAGCTCTGGTGGACATTCTGAATGAGGAAAATTAA"}, "pfams": {"pfam": [{"identifier": "PF00082", "name": "Peptidase_S8"}, {"identifier": "PF01483", "name": "P_proprotein"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "subtilase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}]}}}, {"@position": "11", "id": "BE0001147", "name": "Protein NOV homolog", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Burren CP, Wilson EM, Hwa V, Oh Y, Rosenfeld RG: Binding properties and distribution of insulin-like growth factor binding protein-related protein 3 (IGFBP-rP3/NovH), an additional member of the IGFBP Superfamily. J Clin Endocrinol Metab. 1999 Mar;84(3):1096-103. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10084601\n# Lafont J, Laurent M, Thibout H, Lallemand F, Le Bouc Y, Atfi A, Martinerie C: The expression of novH in adrenocortical cells is down-regulated by TGFbeta 1 through c-Jun in a Smad-independent manner. J Biol Chem. 2002 Oct 25;277(43):41220-9. Epub 2002 Jul 30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12149257\n# Martinerie C, Chevalier G, Rauscher FJ 3rd, Perbal B: Regulation of nov by WT1: a potential role for nov in nephrogenesis. Oncogene. 1996 Apr 4;12(7):1479-92. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8622864", "known-action": "unknown", "polypeptide": {"@id": "P48745", "@source": "Swiss-Prot", "name": "Protein NOV homolog", "general-function": "Involved in insulin-like growth factor binding", "specific-function": "Immediate-early protein likely to play a role in cell growth regulation", "gene-name": "NOV", "locus": "8q24.1", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.74", "molecular-weight": "39162.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:7885"}, {"resource": "GenAtlas", "identifier": "NOV"}, {"resource": "GeneCards", "identifier": "NOV"}, {"resource": "GenBank Gene Database", "identifier": "X78351"}, {"resource": "GenBank Protein Database", "identifier": "825696"}, {"resource": "UniProtKB", "identifier": "P48745"}, {"resource": "UniProt Accession", "identifier": "NOV_HUMAN"}]}, "synonyms": {"synonym": ["Nephroblastoma overexpressed gene protein homolog", "NovH", "Protein NOV homolog precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Protein NOV homolog precursor\nMQSVQSTSFCLRKQCLCLTFLLLHLLGQVAATQRCPPQCPGRCPATPPTCAPGVRAVLDG\nCSCCLVCARQRGESCSDLEPCDESSGLYCDRSADPSNQTGICTAVEGDNCVFDGVIYRSG\nEKFQPSCKFQCTCRDGQIGCVPRCQLDVLLPEPNCPAPRKVEVPGECCEKWICGPDEEDS\nLGGLTLAAYRPEATLGVEVSDSSVNCIEQTTEWTACSKSCGMGFSTRVTNRNRQCEMLKQ\nTRLCMVRPCEQEPEQPTDKKGKKCLRTKKSLKAIHLQFKNCTSLHTYKPRFCGVCSDGRC\nCTPHNTKTIQAEFQCSPGQIVKKPVMVIGTCTCHTNCPKNNEAFLQELELKTTRGKM"}, "gene-sequence": {"@format": "FASTA", "#text": ">1074 bp\nATGCAGAGTGTGCAGAGCACGAGCTTTTGTCTCCGAAAGCAGTGCCTTTGCCTGACCTTC\nCTGCTTCTCCATCTCCTGGGACAGGTCGCTGCGACTCAGCGCTGCCCTCCCCAGTGCCCG\nGGCCGGTGCCCTGCGACGCCGCCGACCTGCGCCCCCGGGGTGCGCGCGGTGCTGGACGGC\nTGCTCATGCTGTCTGGTGTGTGCCCGCCAGCGTGGCGAGAGCTGCTCAGATCTGGAGCCA\nTGCGACGAGAGCAGTGGCCTCTACTGTGATCGCAGCGCGGACCCCAGCAACCAGACTGGC\nATCTGCACGGCGGTAGAGGGAGATAACTGTGTGTTCGATGGGGTCATCTACCGCAGTGGA\nGAGAAATTTCAGCCAAGCTGCAAATTCCAGTGCACCTGCAGAGATGGGCAGATTGGCTGT\nGTGCCCCGCTGTCAGCTGGATGTGCTACTGCCTGAGCCTAACTGCCCAGCTCCAAGAAAA\nGTTGAGGTGCCTGGAGAGTGCTGTGAAAAGTGGATCTGTGGCCCAGATGAGGAGGATTCA\nCTGGGAGGCCTTACCCTTGCAGCTTACAGGCCAGAAGCCACCCTAGGAGTAGAAGTCTCT\nGACTCAAGTGTCAACTGCATTGAACAGACCACAGAGTGGACAGCATGCTCCAAGAGCTGT\nGGTATGGGGTTCTCCACCCGGGTCACCAATAGGAACCGTCAATGTGAGATGCTGAAACAG\nACTCGGCTCTGCATGGTGCGGCCCTGTGAACAAGAGCCAGAGCAGCCAACAGATAAGAAA\nGGAAAAAAGTGTCTCCGCACCAAGAAGTCACTCAAAGCCATCCACCTGCAGTTCAAGAAC\nTGCACCAGCCTGCACACCTACAAGCCCAGGTTCTGTGGGGTCTGCAGTGATGGCCGCTGC\nTGCACTCCCCACAATACCAAAACCATCCAGGCAGAGTTTCAGTGCTCCCCAGGGCAAATA\nGTCAAGAAGCCAGTGATGGTCATTGGGACCTGCACCTGTCACACCAACTGTCCTAAGAAC\nAATGAGGCCTTCCTCCAGGAGCTGGAGCTGAAGACTACCAGAGGGAAAATGTAA"}, "pfams": {"pfam": [{"identifier": "PF00093", "name": "VWC"}, {"identifier": "PF00219", "name": "IGFBP"}, {"identifier": "PF00007", "name": "Cys_knot"}, {"identifier": "PF00090", "name": "TSP_1"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "protein binding"}, {"category": "function", "description": "growth factor binding"}, {"category": "function", "description": "insulin-like growth factor binding"}, {"category": "process", "description": "regulation of biological process"}, {"category": "process", "description": "regulation of growth"}, {"category": "process", "description": "regulation of cell growth"}]}}}, {"@position": "12", "id": "BE0000942", "name": "Low-density lipoprotein receptor-related protein 2", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Orlando RA, Rader K, Authier F, Yamazaki H, Posner BI, Bergeron JJ, Farquhar MG: Megalin is an endocytic receptor for insulin. J Am Soc Nephrol. 1998 Oct;9(10):1759-66. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9773776\n# Christensen EI, Birn H: Hormone, growth factor, and vitamin handling by proximal tubule cells. Curr Opin Nephrol Hypertens. 1997 Jan;6(1):20-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9051350\n# Fuster DG, Bobulescu IA, Zhang J, Wade J, Moe OW: Characterization of the regulation of renal Na+/H+ exchanger NHE3 by insulin. Am J Physiol Renal Physiol. 2007 Feb;292(2):F577-85. Epub 2006 Oct 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17018843", "known-action": "unknown", "polypeptide": {"@id": "P98164", "@source": "Swiss-Prot", "name": "Low-density lipoprotein receptor-related protein 2", "general-function": "Involved in calcium ion binding", "specific-function": "May participate in regulation of parathyroid-hormone and para-thyroid-hormone-related protein release", "gene-name": "LRP2", "locus": "2q24-q31", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "4424-4446", "signal-regions": null, "theoretical-pi": "4.68", "molecular-weight": "521933.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6694"}, {"resource": "GenAtlas", "identifier": "LRP2"}, {"resource": "GeneCards", "identifier": "LRP2"}, {"resource": "GenBank Gene Database", "identifier": "U33837"}, {"resource": "GenBank Protein Database", "identifier": "1809240"}, {"resource": "UniProtKB", "identifier": "P98164"}, {"resource": "UniProt Accession", "identifier": "LRP2_HUMAN"}]}, "synonyms": {"synonym": ["Glycoprotein 330", "gp330", "Low-density lipoprotein receptor-related protein 2 precursor", "Megalin"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low-density lipoprotein receptor-related protein 2 precursor\nMDRGPAAVACTLLLALVACLAPASGQECDSAHFRCGSGHCIPADWRCDGTKDCSDDADEI\nGCAVVTCQQGYFKCQSEGQCIPSSWVCDQDQDCDDGSDERQDCSQSTCSSHQITCSNGQC\nIPSEYRCDHVRDCPDGADENDCQYPTCEQLTCDNGACYNTSQKCDWKVDCRDSSDEINCT\nEICLHNEFSCGNGECIPRAYVCDHDNDCQDGSDEHACNYPTCGGYQFTCPSGRCIYQNWV\nCDGEDDCKDNGDEDGCESGPHDVHKCSPREWSCPESGRCISIYKVCDGILDCPGREDENN\nTSTGKYCSMTLCSALNCQYQCHETPYGGACFCPPGYIINHNDSRTCVEFDDCQIWGICDQ\nKCESRPGRHLCHCEEGYILERGQYCKANDSFGEASIIFSNGRDLLIGDIHGRSFRILVES\nQNRGVAVGVAFHYHLQRVFWTDTVQNKVFSVDINGLNIQEVLNVSVETPENLAVDWVNNK\nIYLVETKVNRIDMVNLDGSYRVTLITENLGHPRGIAVDPTVGYLFFSDWESLSGEPKLER\nAFMDGSNRKDLVKTKLGWPAGVTLDMISKRVYWVDSRFDYIETVTYDGIQRKTVVHGGSL\nIPHPFGVSLFEGQVFFTDWTKMAVLKANKFTETNPQVYYQASLRPYGVTVYHSLRQPYAT\nNPCKDNNGGCEQVCVLSHRTDNDGLGFRCKCTFGFQLDTDERHCIAVQNFLIFSSQVAIR\nGIPFTLSTQEDVMVPVSGNPSFFVGIDFDAQDSTIFFSDMSKHMIFKQKIDGTGREILAA\nNRVENVESLAFDWISKNLYWTDSHYKSISVMRLADKTRRTVVQYLNNPRSVVVHPFAGYL\nFFTDWFRPAKIMRAWSDGSHLLPVINTTLGWPNGLAIDWAASRLYWVDAYFDKIEHSTFD\nGLDRRRLGHIEQMTHPFGLAIFGEHLFFTDWRLGAIIRVRKADGGEMTVIRSGIAYILHL\nKSYDVNIQTGSNACNQPTHPNGDCSHFCFPVPNFQRVCGCPYGMRLASNHLTCEGDPTNE\nPPTEQCGLFSFPCKNGRCVPNYYLCDGVDDCHDNSDEQLCGTLNNTCSSSAFTCGHGECI\nPAHWRCDKRNDCVDGSDEHNCPTHAPASCLDTQYTCDNHQCISKNWVCDTDNDCGDGSDE\nKNCNSTETCQPSQFNCPNHRCIDLSFVCDGDKDCVDGSDEVGCVLNCTASQFKCASGDKC\nIGVTNRCDGVFDCSDNSDEAGCPTRPPGMCHSDEFQCQEDGICIPNFWECDGHPDCLYGS\nDEHNACVPKTCPSSYFHCDNGNCIHRAWLCDRDNDCGDMSDEKDCPTQPFRCPSWQWQCL\nGHNICVNLSVVCDGIFDCPNGTDESPLCNGNSCSDFNGGCTHECVQEPFGAKCLCPLGFL\nLANDSKTCEDIDECDILGSCSQHCYNMRGSFRCSCDTGYMLESDGRTCKVTASESLLLLV\nASQNKIIADSVTSQVHNIYSLVENGSYIVAVDFDSISGRIFWSDATQGKTWSAFQNGTDR\nRVVFDSSIILTETIAIDWVGRNLYWTDYALETIEVSKIDGSHRTVLISKNLTNPRGLALD\nPRMNEHLLFWSDWGHHPRIERASMDGSMRTVIVQDKIFWPCGLTIDYPNRLLYFMDSYLD\nYMDFCDYNGHHRRQVIASDLIIRHPYALTLFEDSVYWTDRATRRVMRANKWHGGNQSVVM\nYNIQWPLGIVAVHPSKQPNSVNPCAFSRCSHLCLLSSQGPHFYSCVCPSGWSLSPDLLNC\nLRDDQPFLITVRQHIIFGISLNPEVKSNDAMVPIAGIQNGLDVEFDDAEQYIYWVENPGE\nIHRVKTDGTNRTVFASISMVGPSMNLALDWISRNLYSTNPRTQSIEVLTLHGDIRYRKTL\nIANDGTALGVGFPIGITVDPARGKLYWSDQGTDSGVPAKIASANMDGTSVKTLFTGNLEH\nLECVTLDIEEQKLYWAVTGRGVIERGNVDGTDRMILVHQLSHPWGIAVHDSFLYYTDEQY\nEVIERVDKATGANKIVLRDNVPNLRGLQVYHRRNAAESSNGCSNNMNACQQICLPVPGGL\nFSCACATGFKLNPDNRSCSPYNSFIVVSMLSAIRGFSLELSDHSETMVPVAGQGRNALHV\nDVDVSSGFIYWCDFSSSVASDNAIRRIKPDGSSLMNIVTHGIGENGVRGIAVDWVAGNLY\nFTNAFVSETLIEVLRINTTYRRVLLKVTVDMPRHIVVDPKNRYLFWADYGQRPKIERSFL\nDCTNRTVLVSEGIVTPRGLAVDRSDGYVYWVDDSLDIIARIRINGENSEVIRYGSRYPTP\nYGITVFENSIIWVDRNLKKIFQASKEPENTEPPTVIRDNINWLRDVTIFDKQVQPRSPAE\nVNNNPCLENNGGCSHLCFALPGLHTPKCDCAFGTLQSDGKNCAISTENFLIFALSNSLRS\nLHLDPENHSPPFQTINVERTVMSLDYDSVSDRIYFTQNLASGVGQISYATLSSGIHTPTV\nIASGIGTADGIAFDWITRRIYYSDYLNQMINSMAEDGSNRTVIARVPKPRAIVLDPCQGY\nLYWADWDTHAKIERATLGGNFRVPIVNSSLVMPSGLTLDYEEDLLYWVDASLQRIERSTL\nTGVDREVIVNAAVHAFGLTLYGQYIYWTDLYTQRIYRANKYDGSGQIAMTTNLLSQPRGI\nNTVVKNQKQQCNNPCEQFNGGCSHICAPGPNGAECQCPHEGNWYLANNRKHCIVDNGERC\nGASSFTCSNGRCISEEWKCDNDNDCGDGSDEMESVCALHTCSPTAFTCANGRCVQYSYRC\nDYYNDCGDGSDEAGCLFRDCNATTEFMCNNRRCIPREFICNGVDNCHDNNTSDEKNCPDR\nTCQSGYTKCHNSNICIPRVYLCDGDNDCGDNSDENPTYCTTHTCSSSEFQCASGRCIPQH\nWYCDQETDCFDASDEPASCGHSERTCLADEFKCDGGRCIPSEWICDGDNDCGDMSDEDKR\nHQCQNQNCSDSEFLCVNDRPPDRRCIPQSWVCDGDVDCTDGYDENQNCTRRTCSENEFTC\nGYGLCIPKIFRCDRHNDCGDYSDERGCLYQTCQQNQFTCQNGRCISKTFVCDEDNDCGDG\nSDELMHLCHTPEPTCPPHEFKCDNGRCIEMMKLCNHLDDCLDNSDEKGCGINECHDPSIS\nGCDHNCTDTLTSFYCSCRPGYKLMSDKRTCVDIDECTEMPFVCSQKCENVIGSYICKCAP\nGYLREPDGKTCRQNSNIEPYLIFSNRYYLRNLTIDGYFYSLILEGLDNVVALDFDRVEKR\nLYWIDTQRQVIERMFLNKTNKETIINHRLPAAESLAVDWVSRKLYWLDARLDGLFVSDLN\nGGHRRMLAQHCVDANNTFCFDNPRGLALHPQYGYLYWADWGHRAYIGRVGMDGTNKSVII\nSTKLEWPNGITIDYTNDLLYWADAHLGYIEYSDLEGHHRHTVYDGALPHPFAITIFEDTI\nYWTDWNTRTVEKGNKYDGSNRQTLVNTTHRPFDIHVYHPYRQPIVSNPCGTNNGGCSHLC\nLIKPGGKGFTCECPDDFRTLQLSGSTYCMPMCSSTQFLCANNEKCIPIWWKCDGQKDCSD\nGSDELALCPQRFCRLGQFQCSDGNCTSPQTLCNAHQNCPDGSDEDRLLCENHHCDSNEWQ\nCANKRCIPESWQCDTFNDCEDNSDEDSSHCASRTCRPGQFRCANGRCIPQAWKCDVDNDC\nGDHSDEPIEECMSSAHLCDNFTEFSCKTNYRCIPKWAVCNGVDDCRDNSDEQGCEERTCH\nPVGDFRCKNHHCIPLRWQCDGQNDCGDNSDEENCAPRECTESEFRCVNQQCIPSRWICDH\nYNDCGDNSDERDCEMRTCHPEYFQCTSGHCVHSELKCDGSADCLDASDEADCPTRFPDGA\nYCQATMFECKNHVCIPPYWKCDGDDDCGDGSDEELHLCLDVPCNSPNRFRCDNNRCIYSH\nEVCNGVDDCGDGTDETEEHCRKPTPKPCTEYEYKCGNGHCIPHDNVCDDADDCGDWSDEL\nGCNKGKERTCAENICEQNCTQLNEGGFICSCTAGFETNVFDRTSCLDINECEQFGTCPQH\nCRNTKGSYECVCADGFTSMSDRPGKRCAAEGSSPLLLLPDNVRIRKYNLSSERFSEYLQD\nEEYIQAVDYDWDPKDIGLSVVYYTVRGEGSRFGAIKRAYIPNFESGRNNLVQEVDLKLKY\nVMQPDGIAVDWVGRHIYWSDVKNKRIEVAKLDGRYRKWLISTDLDQPAAIAVNPKLGLMF\nWTDWGKEPKIESAWMNGEDRNILVFEDLGWPTGLSIDYLNNDRIYWSDFKEDVIETIKYD\nGTDRRVIAKEAMNPYSLDIFEDQLYWISKEKGEVWKQNKFGQGKKEKTLVVNPWLTQVRI\nFHQLRYNKSVPNLCKQICSHLCLLRPGGYSCACPQGSSFIEGSTTECDAAIELPINLPPP\nCRCMHGGNCYFDETDLPKCKCPSGYTGKYCEMAFSKGISPGTTAVAVLLTILLIVVIGAL\nAIAGFFHYRRTGSLLPALPKLPSLSSLVKPSENGNGVTFRSGADLNMDIGVSGFGPETAI\nDRSMAMSEDFVMEMGKQPIIFENPMYSARDSAVKVVQPIQVTVSENVDNKNYGSPINPSE\nIVPETNPTSPAADGTQVTKWNLFKRKSKQTTNFENPIYAQMENEQKESVAATPPPSPSLP\nAKPKPPSRRDPTPTYSATEDTFKDTANLVKEDSEV"}, "gene-sequence": {"@format": "FASTA", "#text": ">13968 bp\nATGGATCGCGGGCCGGCAGCAGTGGCGTGCACGCTGCTCCTGGCTCTCGTCGCCTGCCTA\nGCGCCGGCCAGTGGCCAAGAATGTGACAGTGCGCATTTTCGCTGTGGAAGTGGGCATTGC\nATCCCTGCAGACTGGAGGTGTGATGGGACCAAAGACTGTTCAGATGACGCGGATGAAATT\nGGCTGCGCTGTTGTGACCTGCCAGCAGGGCTATTTCAAGTGCCAGAGTGAGGGACAATGC\nATCCCCAGCTCCTGGGTGTGTGACCAAGATCAAGACTGTGATGATGGCTCAGATGAACGT\nCAAGATTGCTCACAAAGTACATGCTCAAGTCATCAGATAACATGCTCCAATGGTCAGTGT\nATCCCAAGTGAATACAGGTGCGACCACGTCAGAGACTGCCCCGATGGAGCTGATGAGAAT\nGACTGCCAGTACCCAACATGTGAGCAGCTTACTTGTGACAATGGGGCCTGCTATAACACC\nAGTCAGAAGTGTGATTGGAAAGTTGATTGCAGGGACTCCTCAGATGAAATCAACTGCACT\nGAGATATGCTTGCACAATGAGTTTTCATGTGGCAATGGAGAGTGTATCCCTCGTGCTTAT\nGTCTGTGACCATGACAATGATTGCCAAGACGGCAGTGATGAACATGCTTGCAACTATCCG\nACCTGCGGTGGTTACCAGTTCACTTGCCCCAGTGGCCGATGCATTTATCAAAACTGGGTT\nTGTGATGGAGAAGATGACTGTAAAGATAATGGAGATGAAGATGGATGTGAAAGCGGTCCT\nCATGATGTTCATAAATGTTCCCCAAGAGAATGGTCTTGCCCAGAGTCGGGACGATGCATC\nTCCATTTATAAAGTTTGTGATGGGATTTTAGATTGCCCAGGAAGAGAAGATGAAAACAAC\nACTAGTACCGGAAAATACTGTAGTATGACTCTGTGCTCTGCCTTGAACTGCCAGTACCAG\nTGCCATGAGACGCCGTATGGAGGAGCGTGTTTTTGTCCCCCAGGTTATATCATCAACCAC\nAATGACAGCCGTACCTGTGTTGAGTTTGATGATTGCCAGATATGGGGAATTTGTGACCAG\nAAGTGTGAAAGCCGACCTGGCCGTCACCTGTGCCACTGTGAAGAAGGGTATATCTTGGAG\nCGTGGACAGTATTGCAAAGCTAATGATTCCTTTGGCGAGGCCTCCATTATCTTCTCCAAT\nGGTCGGGATTTGTTAATTGGTGATATTCATGGAAGGAGCTTCCGGATCCTAGTGGAGTCT\nCAGAATCGTGGAGTGGCCGTGGGTGTGGCTTTCCACTATCACCTGCAAAGAGTTTTTTGG\nACAGACACCGTGCAAAATAAGGTTTTTTCAGTTGACATTAATGGTTTAAATATCCAAGAG\nGTTCTCAATGTTTCTGTTGAAACCCCAGAGAACCTGGCTGTGGACTGGGTTAATAATAAA\nATCTATCTAGTGGAAACCAAGGTCAACCGCATAGATATGGTAAATTTGGATGGAAGCTAT\nCGGGTTACCCTTATAACTGAAAACTTGGGGCATCCTAGAGGAATTGCCGTGGACCCAACT\nGTTGGTTATTTATTTTTCTCAGATTGGGAGAGCCTTTCTGGGGAACCTAAGCTGGAAAGG\nGCATTCATGGATGGCAGCAACCGTAAAGACTTGGTGAAAACAAAGCTGGGATGGCCTGCT\nGGGGTAACTCTGGATATGATATCGAAGCGTGTTTACTGGGTTGACTCTCGGTTTGATTAC\nATTGAAACTGTAACTTATGATGGAATTCAAAGGAAGACTGTAGTTCATGGAGGCTCCCTC\nATTCCTCATCCCTTTGGAGTAAGCTTATTTGAAGGTCAGGTGTTCTTTACAGATTGGACA\nAAGATGGCCGTGCTGAAGGCAAACAAGTTCACAGAGACCAACCCACAAGTGTACTACCAG\nGCTTCCCTGAGGCCCTATGGAGTGACTGTTTACCATTCCCTCAGACAGCCCTATGCTACC\nAATCCGTGTAAAGATAACAATGGGGGCTGTGAGCAGGTCTGTGTTCTCAGCCACAGAACA\nGATAATGATGGTTTGGGTTTCCGTTGCAAGTGCACATTCGGCTTCCAACTGGATACAGAT\nGAGCGCCACTGCATTGCTGTTCAGAATTTCCTCATTTTTTCATCCCAAGTTGCTATTCGT\nGGGATCCCGTTCACCTTGTCTACCCAGGAAGATGTCATGGTTCCAGTTTCGGGGAATCCT\nTCTTTCTTTGTCGGGATTGATTTTGACGCCCAGGACAGCACTATCTTTTTTTCAGATATG\nTCAAAACACATGATTTTTAAGCAAAAGATTGATGGCACAGGAAGAGAAATTCTCGCAGCT\nAACAGGGTGGAAAATGTTGAAAGTTTGGCTTTTGATTGGATTTCAAAGAATCTCTATTGG\nACAGACTCTCATTACAAGAGTATCAGTGTCATGAGGCTAGCTGATAAAACGAGACGCACA\nGTAGTTCAGTATTTAAATAACCCACGGTCGGTGGTAGTTCATCCTTTTGCCGGGTATCTA\nTTCTTCACTGATTGGTTCCGTCCTGCTAAAATTATGAGAGCATGGAGTGACGGATCTCAC\nCTCTTGCCTGTAATAAACACTACTCTTGGATGGCCCAATGGCTTGGCCATCGATTGGGCT\nGCTTCACGATTGTACTGGGTAGATGCCTATTTTGATAAAATTGAGCACAGCACCTTTGAT\nGGTTTAGACAGAAGAAGACTGGGCCATATAGAGCAGATGACACATCCGTTTGGACTTGCC\nATCTTTGGAGAGCATTTATTTTTTACTGACTGGAGACTGGGTGCCATTATTCGAGTCAGG\nAAAGCAGATGGTGGAGAAATGACAGTTATCCGAAGTGGCATTGCTTACATACTGCATTTG\nAAATCGTATGATGTCAACATCCAGACTGGTTCTAACGCCTGTAATCAACCCACGCATCCT\nAACGGTGACTGCAGCCACTTCTGCTTCCCGGTGCCAAATTTCCAGCGAGTGTGTGGGTGC\nCCTTATGGAATGAGGCTGGCTTCCAATCACTTGACATGCGAGGGGGACCCAACCAATGAA\nCCACCCACGGAGCAGTGTGGCTTATTTTCCTTCCCCTGTAAAAATGGCAGATGTGTGCCC\nAATTACTATCTCTGTGATGGAGTCGATGATTGTCATGATAACAGTGATGAGCAACTATGT\nGGCACACTTAATAATACCTGTTCATCTTCGGCGTTCACCTGTGGCCATGGGGAGTGCATT\nCCTGCACACTGGCGCTGTGACAAACGCAACGACTGTGTGGATGGCAGTGATGAGCACAAC\nTGCCCCACCCACGCACCTGCTTCCTGCCTTGACACCCAATACACCTGTGATAATCACCAG\nTGTATCTCAAAGAACTGGGTCTGTGACACAGACAATGATTGTGGGGATGGATCTGATGAA\nAAGAACTGCAATTCGACAGAGACATGCCAACCTAGTCAGTTTAATTGCCCCAATCATCGA\nTGTATTGACCTATCGTTTGTCTGTGATGGTGACAAGGATTGTGTTGATGGATCTGATGAG\nGTTGGTTGTGTATTAAACTGTACTGCTTCTCAATTCAAGTGTGCCAGTGGGGATAAATGT\nATTGGCGTCACAAATCGTTGTGATGGTGTTTTTGATTGCAGTGACAACTCGGATGAAGCG\nGGCTGTCCAACCAGGCCTCCTGGTATGTGCCACTCAGATGAATTTCAGTGCCAAGAAGAT\nGGTATCTGCATCCCGAACTTCTGGGAATGTGATGGGCATCCAGACTGCCTCTATGGATCT\nGATGAGCACAATGCCTGTGTCCCCAAGACTTGCCCTTCATCATATTTCCACTGTGACAAC\nGGAAACTGCATCCACAGGGCATGGCTCTGTGATCGGGACAATGACTGCGGGGATATGAGT\nGATGAGAAGGACTGCCCTACTCAGCCCTTTCGCTGTCCTAGTTGGCAATGGCAGTGTCTT\nGGCCATAACATCTGTGTGAATCTGAGTGTAGTGTGTGATGGCATCTTTGACTGCCCCAAT\nGGGACAGATGAGTCCCCACTTTGCAATGGGAACAGCTGCTCAGATTTCAATGGTGGTTGT\nACTCACGAGTGTGTTCAAGAGCCCTTTGGGGCTAAATGCCTATGTCCATTGGGATTCTTA\nCTTGCCAATGATTCTAAGACCTGTGAAGACATAGATGAATGTGATATTCTAGGCTCTTGT\nAGCCAGCACTGTTACAATATGAGAGGTTCTTTCCGGTGCTCGTGTGATACAGGCTACATG\nTTAGAAAGTGATGGGAGGACTTGCAAAGTTACAGCATCTGAGAGTCTGCTGTTACTTGTG\nGCAAGTCAGAACAAAATTATTGCCGACAGTGTCACCTCCCAGGTCCACAATATCTATTCA\nTTGGTCGAGAATGGTTCTTACATTGTAGCTGTTGATTTTGATTCAATTAGTGGTCGTATC\nTTTTGGTCTGATGCAACTCAGGGTAAAACCTGGAGTGCGTTTCAAAATGGAACGGACAGA\nAGAGTGGTATTTGACAGTAGCATCATCTTGACTGAAACTATTGCAATAGATTGGGTAGGT\nCGTAATCTTTACTGGACAGACTATGCTCTGGAAACAATTGAAGTCTCCAAAATTGATGGG\nAGCCACAGGACTGTGCTGATTAGTAAAAACCTAACAAATCCAAGAGGACTAGCATTAGAT\nCCCAGAATGAATGAGCATCTACTGTTCTGGTCTGACTGGGGCCACCACCCTCGCATCGAG\nCGAGCCAGCATGGACGGCAGCATGCGCACTGTCATTGTCCAGGACAAGATCTTCTGGCCC\nTGCGGCTTAACTATTGACTACCCCAACAGACTGCTCTACTTCATGGACTCCTATCTTGAT\nTACATGGACTTTTGCGATTATAATGGACACCATCGGAGACAGGTGATAGCCAGTGATTTG\nATTATACGGCACCCCTATGCCCTAACTCTCTTTGAAGACTCTGTGTACTGGACTGACCGT\nGCTACTCGTCGGGTTATGCGAGCCAACAAGTGGCATGGAGGGAACCAGTCAGTTGTAATG\nTATAATATTCAATGGCCCCTTGGGATTGTTGCGGTTCATCCTTCGAAACAACCAAATTCC\nGTGAATCCATGTGCCTTTTCCCGCTGCAGCCATCTCTGCCTGCTTTCCTCACAGGGGCCT\nCATTTTTACTCCTGTGTTTGTCCTTCAGGATGGAGTCTGTCTCCTGATCTCCTGAATTGC\nTTGAGAGATGATCAACCTTTCTTAATAACTGTAAGGCAACATATAATTTTTGGAATCTCC\nCTTAATCCTGAGGTGAAGAGCAATGATGCTATGGTCCCCATAGCAGGGATACAGAATGGT\nTTAGATGTTGAATTTGATGATGCTGAGCAATACATCTATTGGGTTGAAAATCCAGGTGAA\nATTCACAGAGTGAAGACAGATGGCACCAACAGGACAGTATTTGCTTCTATATCTATGGTG\nGGGCCTTCTATGAACCTGGCCTTAGATTGGATTTCAAGAAACCTTTATTCTACCAATCCT\nAGAACTCAGTCAATCGAGGTTTTGACACTCCACGGAGATATCAGATACAGAAAAACATTG\nATTGCCAATGATGGGACAGCTCTTGGAGTTGGCTTTCCAATTGGCATAACTGTTGATCCT\nGCTCGTGGGAAGCTGTACTGGTCAGACCAAGGAACTGACAGTGGGGTTCCTGCCAAGATC\nGCCAGTGCTAACATGGATGGCACATCTGTGAAAACTCTCTTTACTGGGAACCTCGAACAC\nCTGGAGTGTGTCACTCTTGACATCGAAGAGCAGAAACTCTACTGGGCAGTCACTGGAAGA\nGGAGTGATTGAAAGAGGAAACGTGGATGGAACAGATCGGATGATCCTGGTACACCAGCTT\nTCCCACCCCTGGGGAATTGCAGTCCATGATTCTTTCCTTTATTATACTGATGAACAGTAT\nGAGGTCATTGAAAGAGTTGATAAGGCCACTGGGGCCAACAAAATAGTCTTGAGAGATAAT\nGTTCCAAATCTGAGGGGTCTTCAAGTTTATCACAGACGCAATGCCGCCGAATCCTCAAAT\nGGCTGTAGCAACAACATGAATGCCTGTCAGCAGATTTGCCTGCCTGTACCAGGAGGATTG\nTTTTCCTGCGCCTGTGCCACTGGATTTAAACTCAATCCTGATAATCGGTCCTGCTCTCCA\nTATAACTCTTTCATTGTTGTTTCAATGCTGTCTGCAATCAGAGGCTTTAGCTTGGAATTG\nTCAGATCATTCAGAAACCATGGTGCCGGTGGCAGGCCAAGGACGAAACGCACTGCATGTG\nGATGTGGATGTGTCCTCTGGCTTTATTTATTGGTGTGATTTTAGCAGCTCAGTGGCATCT\nGATAATGCGATCCGTAGAATTAAACCAGATGGATCTTCTCTGATGAACATTGTGACACAT\nGGAATAGGAGAAAATGGAGTCCGGGGTATTGCAGTGGATTGGGTAGCAGGAAATCTTTAT\nTTCACCAATGCCTTTGTTTCTGAAACACTGATAGAAGTTCTGCGGATCAATACTACTTAC\nCGCCGTGTTCTTCTTAAAGTCACAGTGGACATGCCTAGGCATATTGTTGTAGATCCCAAG\nAACAGATACCTCTTCTGGGCTGACTATGGGCAGAGACCAAAGATTGAGCGTTCTTTCCTT\nGACTGTACCAATCGAACAGTGCTTGTGTCAGAGGGCATTGTCACACCACGGGGCTTGGCA\nGTGGACCGAAGTGATGGCTACGTTTATTGGGTTGATGATTCTTTAGATATAATTGCAAGG\nATTCGTATCAATGGAGAGAACTCTGAAGTGATTCGTTATGGCAGTCGTTACCCAACTCCT\nTATGGCATCACTGTTTTTGAAAATTCTATCATATGGGTAGATAGGAATTTGAAAAAGATC\nTTCCAAGCCAGCAAGGAACCAGAGAACACAGAGCCACCCACAGTGATAAGAGACAATATC\nAACTGGCTAAGAGATGTGACCATCTTTGACAAGCAAGTCCAGCCCCGGTCACCAGCAGAG\nGTCAACAACAACCCTTGCTTGGAAAACAATGGTGGGTGCTCTCATCTCTGCTTTGCTCTG\nCCTGGATTGCACACCCCAAAATGTGACTGTGCCTTTGGGACCCTGCAAAGTGATGGCAAG\nAATTGTGCCATTTCAACAGAAAATTTCCTCATCTTTGCCTTGTCTAATTCCTTGAGAAGC\nTTACACTTGGACCCTGAAAACCATAGCCCACCTTTCCAAACAATAAATGTGGAAAGAACT\nGTCATGTCTCTAGACTATGACAGTGTAAGTGATAGAATCTACTTCACACAAAATTTAGCC\nTCTGGAGTTGGACAGATTTCCTATGCCACCCTGTCTTCAGGGATCCATACTCCAACTGTC\nATTGCTTCAGGTATAGGGACTGCTGATGGCATTGCCTTTGACTGGATTACTAGAAGAATT\nTATTACAGTGACTACCTCAACCAGATGATTAATTCCATGGCTGAAGATGGGTCTAACCGC\nACTGTGATAGCCCGCGTTCCAAAACCAAGAGCAATTGTGTTAGATCCCTGCCAAGGGTAC\nCTGTACTGGGCTGACTGGGATACACATGCCAAAATCGAGAGAGCCACATTGGGAGGAAAC\nTTCCGGGTACCCATTGTGAACAGCAGTCTGGTCATGCCCAGTGGGCTGACTCTGGACTAT\nGAAGAGGACCTTCTCTACTGGGTGGATGCTAGTCTGCAGAGGATTGAACGCAGCACTCTG\nACGGGCGTGGATCGTGAAGTCATTGTCAATGCAGCCGTTCATGCTTTTGGCTTGACTCTC\nTATGGCCAGTATATTTACTGGACTGACTTGTACACACAAAGAATTTACCGAGCTAACAAA\nTATGACGGGTCAGGTCAGATTGCAATGACCACAAATTTGCTCTCCCAGCCCAGGGGAATC\nAACACTGTTGTGAAGAACCAGAAACAACAGTGTAACAATCCTTGTGAACAGTTTAATGGG\nGGCTGCAGCCATATCTGTGCACCAGGTCCAAATGGTGCCGAGTGCCAGTGTCCACATGAG\nGGCAACTGGTATTTGGCCAACAACAGGAAGCACTGCATTGTGGACAATGGTGAACGATGT\nGGTGCATCTTCCTTCACCTGCTCCAATGGGCGCTGCATCTCGGAAGAGTGGAAGTGTGAT\nAATGACAACGACTGTGGGGATGGCAGTGATGAGATGGAAAGTGTCTGTGCACTTCACACC\nTGCTCACCGACAGCCTTCACCTGTGCCAATGGGCGATGTGTCCAATACTCTTACCGCTGT\nGATTACTACAATGACTGTGGTGATGGCAGTGATGAGGCAGGGTGCCTGTTCAGGGACTGC\nAATGCCACCACGGAGTTTATGTGCAATAACAGAAGGTGCATACCTCGTGAGTTTATCTGC\nAATGGTGTAGACAACTGCCATGATAATAACACTTCAGATGAGAAAAATTGCCCTGATCGC\nACTTGCCAGTCTGGATACACAAAATGTCATAATTCAAATATTTGTATTCCTCGCGTTTAT\nTTGTGTGACGGAGACAATGACTGTGGAGATAACAGTGATGAAAACCCTACTTATTGCACC\nACTCACACATGCAGCAGCAGTGAGTTCCAATGCGCATCTGGGCGCTGTATTCCTCAACAT\nTGGTATTGTGATCAAGAAACAGATTGTTTTGATGCCTCTGATGAACCTGCCTCTTGTGGT\nCACTCTGAGCGAACATGCCTAGCTGATGAGTTCAAGTGTGATGGTGGGAGGTGCATCCCA\nAGCGAATGGATCTGTGACGGTGATAATGACTGTGGGGATATGAGTGACGAGGATAAAAGG\nCACCAGTGTCAGAATCAAAACTGCTCGGATTCCGAGTTTCTCTGTGTAAATGACAGACCT\nCCGGACAGGAGGTGCATTCCCCAGTCTTGGGTCTGTGATGGCGATGTGGATTGTACTGAC\nGGCTACGATGAGAATCAGAATTGCACCAGGAGAACTTGCTCTGAAAATGAATTCACCTGT\nGGTTACGGACTGTGTATCCCAAAGATATTCAGGTGTGACCGGCACAATGACTGTGGTGAC\nTATAGCGACGAGAGGGGCTGCTTATACCAGACTTGCCAACAGAATCAGTTTACCTGTCAG\nAACGGGCGCTGCATTAGTAAAACCTTCGTCTGTGATGAGGATAATGACTGTGGAGACGGA\nTCTGATGAGCTGATGCACCTGTGCCACACCCCAGAACCCACGTGTCCACCTCACGAGTTC\nAAGTGTGACAATGGGCGCTGCATCGAGATGATGAAACTCTGCAACCACCTAGATGACTGT\nTTGGACAACAGCGATGAGAAAGGCTGTGGCATTAATGAATGCCATGACCCTTCAATCAGT\nGGCTGCGATCACAACTGCACAGACACCTTAACCAGTTTCTATTGTTCCTGTCGTCCTGGT\nTACAAGCTCATGTCTGACAAGCGGACTTGTGTTGATATTGATGAATGCACAGAGATGCCT\nTTTGTCTGTAGCCAGAAGTGTGAGAATGTAATAGGCTCCTACATCTGTAAGTGTGCCCCA\nGGCTACCTCCGAGAACCAGATGGAAAGACCTGCCGGCAAAACAGTAACATCGAACCCTAT\nCTCATTTTTAGCAACCGTTACTATTTGAGAAATTTAACTATAGATGGCTATTTTTACTCC\nCTCATCTTGGAAGGACTGGACAATGTTGTGGCATTAGATTTTGACCGAGTAGAGAAGAGA\nTTGTATTGGATTGATACACAGAGGCAAGTCATTGAGAGAATGTTTCTGAATAAGACAAAC\nAAGGAGACAATCATAAACCACAGACTACCAGCTGCAGAAAGTCTGGCTGTAGACTGGGTT\nTCCAGAAAGCTCTACTGGTTGGATGCCCGCCTGGATGGCCTCTTTGTCTCTGACCTCAAT\nGGTGGACACCGCCGCATGCTGGCCCAGCACTGTGTGGATGCCAACAACACCTTCTGCTTT\nGATAATCCCAGAGGACTTGCCCTTCACCCTCAATATGGGTACCTCTACTGGGCAGACTGG\nGGTCACCGCGCATACATTGGGAGAGTAGGCATGGATGGAACCAACAAGTCTGTGATAATC\nTCCACCAAGTTAGAGTGGCCTAATGGCATCACCATTGATTACACCAATGATCTACTCTAC\nTGGGCAGATGCCCACCTGGGTTACATAGAGTACTCTGATTTGGAGGGCCACCATCGACAC\nACGGTGTATGATGGGGCACTGCCTCACCCTTTCGCTATTACCATTTTTGAAGACACTATT\nTATTGGACAGATTGGAATACAAGGACAGTGGAAAAGGGAAACAAATATGATGGATCAAAT\nAGACAGACACTGGTGAACACAACACACAGACCATTTGACATCCATGTGTACCATCCATAT\nAGGCAGCCCATTGTGAGCAATCCCTGTGGTACCAACAATGGTGGCTGTTCTCATCTCTGC\nCTCATCAAGCCAGGAGGAAAAGGGTTCACTTGCGAGTGTCCAGATGACTTCCGCACCCTT\nCAACTGAGTGGCAGCACCTACTGCATGCCCATGTGCTCCAGCACCCAGTTCCTGTGCGCT\nAACAATGAAAAGTGCATTCCTATCTGGTGGAAATGTGATGGACAGAAAGACTGCTCAGAT\nGGCTCTGATGAACTGGCCCTTTGCCCGCAGCGCTTCTGCCGACTGGGACAGTTCCAGTGC\nAGTGACGGCAACTGCACCAGCCCGCAGACTTTATGCAATGCTCACCAAAATTGCCCTGAT\nGGGTCTGATGAAGACCGTCTTCTTTGTGAGAATCACCACTGTGACTCCAATGAATGGCAG\nTGCGCCAACAAACGTTGCATCCCAGAATCCTGGCAGTGTGACACATTTAACGACTGTGAG\nGATAACTCAGATGAAGACAGTTCCCACTGTGCCAGCAGGACCTGCCGGCCGGGCCAGTTT\nCGGTGTGCTAATGGCCGCTGCATCCCGCAGGCCTGGAAGTGTGATGTGGATAATGATTGT\nGGAGACCACTCGGATGAGCCCATTGAAGAATGCATGAGCTCTGCCCATCTCTGTGACAAC\nTTCACAGAATTCAGCTGCAAAACAAATTACCGCTGCATCCCAAAGTGGGCCGTGTGCAAT\nGGTGTAGATGACTGCAGGGACAACAGTGATGAGCAAGGCTGTGAGGAGAGGACATGCCAT\nCCTGTGGGGGATTTCCGCTGTAAAAATCACCACTGCATCCCTCTTCGTTGGCAGTGTGAT\nGGGCAAAATGACTGTGGAGATAACTCAGATGAGGAAAACTGTGCTCCCCGGGAGTGCACA\nGAGAGCGAGTTTCGATGTGTCAATCAGCAGTGCATTCCCTCGCGATGGATCTGTGACCAT\nTACAACGACTGTGGGGACAACTCAGATGAACGGGACTGTGAGATGAGGACCTGCCATCCT\nGAATATTTTCAGTGTACAAGTGGACATTGTGTACACAGTGAACTGAAATGCGATGGATCC\nGCTGACTGTTTGGATGCGTCTGATGAAGCTGATTGTCCCACACGCTTTCCTGATGGTGCA\nTACTGCCAGGCTACTATGTTCGAATGCAAAAACCATGTTTGTATCCCGCCATATTGGAAA\nTGTGATGGCGATGATGACTGTGGCGATGGTTCAGATGAAGAACTTCACCTGTGCTTGGAT\nGTTCCCTGTAATTCACCAAACCGTTTCCGGTGTGACAACAATCGCTGCATTTATAGTCAT\nGAGGTGTGCAATGGTGTGGATGACTGTGGAGATGGAACTGATGAGACAGAGGAGCACTGT\nAGAAAACCGACCCCTAAACCTTGTACAGAATATGAATATAAGTGTGGCAATGGGCATTGC\nATTCCACATGACAATGTGTGTGATGATGCCGATGACTGTGGTGACTGGTCCGATGAACTG\nGGTTGCAATAAAGGAAAAGAAAGAACATGTGCTGAAAATATATGCGAGCAAAATTGTACC\nCAATTAAATGAAGGAGGATTTATCTGCTCCTGTACAGCTGGGTTCGAAACCAATGTTTTT\nGACAGAACCTCCTGTCTAGATATCAATGAATGTGAACAATTTGGGACTTGTCCCCAGCAC\nTGCAGAAATACCAAAGGAAGTTATGAGTGTGTCTGTGCTGATGGCTTCACGTCTATGAGT\nGACCGCCCTGGAAAACGATGTGCAGCTGAGGGTAGCTCTCCTTTGTTGCTACTGCCTGAC\nAATGTCCGAATTCGAAAATATAATCTCTCATCTGAGAGGTTCTCAGAGTATCTTCAAGAT\nGAGGAATATATCCAAGCTGTTGATTATGATTGGGATCCCAAGGACATAGGCCTCAGTGTT\nGTGTATTACACTGTGCGAGGGGAGGGCTCTAGGTTTGGTGCTATCAAACGTGCCTACATC\nCCCAACTTTGAATCCGGCCGCAATAATCTTGTGCAGGAAGTTGACCTGAAACTGAAATAC\nGTAATGCAGCCAGATGGAATAGCAGTGGACTGGGTTGGAAGGCATATTTACTGGTCAGAT\nGTCAAGAATAAACGCATTGAGGTGGCTAAACTTGATGGAAGGTACAGAAAGTGGCTGATT\nTCCACTGACCTGGACCAACCAGCTGCTATTGCTGTGAATCCCAAACTAGGGCTTATGTTC\nTGGACTGACTGGGGAAAGGAACCTAAAATCGAGTCTGCCTGGATGAATGGAGAGGACCGC\nAACATCCTGGTTTTCGAGGACCTTGGTTGGCCAACTGGCCTTTCTATCGATTATTTGAAC\nAATGACCGAATCTACTGGAGTGACTTCAAGGAGGACGTTATTGAAACCATAAAATATGAT\nGGGACTGATAGGAGAGTCATTGCAAAGGAAGCAATGAACCCTTACAGCCTGGACATCTTT\nGAAGACCAGTTATACTGGATATCTAAGGAAAAGGGAGAAGTATGGAAACAAAATAAATTT\nGGGCAAGGAAAGAAAGAGAAAACGCTGGTAGTGAACCCTTGGCTCACTCAAGTTCGAATC\nTTTCATCAACTCAGATACAATAAGTCAGTGCCCAACCTTTGCAAACAGATCTGCAGCCAC\nCTCTGCCTTCTGAGACCTGGAGGATACAGCTGTGCCTGTCCCCAAGGCTCCAGCTTTATA\nGAGGGGAGCACCACTGAGTGTGATGCAGCCATCGAACTGCCTATCAACCTGCCCCCCCCA\nTGCAGGTGCATGCACGGAGGAAATTGCTATTTTGATGAGACTGACCTCCCCAAATGCAAG\nTGTCCTAGCGGCTACACCGGAAAATATTGTGAAATGGCGTTTTCAAAAGGCATCTCTCCA\nGGAACAACCGCAGTAGCTGTGCTGTTGACAATCCTCTTGATCGTCGTAATTGGAGCTCTG\nGCAATTGCAGGATTCTTCCACTATAGAAGGACCGGCTCCCTTTTGCCTGCTCTGCCCAAG\nCTGCCAAGCTTAAGCAGTCTCGTCAAGCCCTCTGAAAATGGGAATGGGGTGACCTTCAGA\nTCAGGGGCAGATCTTAACATGGATATTGGAGTGTCTGGTTTTGGACCTGAGACTGCTATT\nGACAGGTCAATGGCAATGAGTGAAGACTTTGTCATGGAAATGGGGAAGCAGCCCATAATA\nTTTGAAAACCCAATGTACTCAGCCAGAGACAGTGCTGTCAAAGTGGTTCAGCCAATCCAG\nGTGACTGTATCTGAAAATGTGGATAATAAGAATTATGGAAGTCCCATAAACCCTTCTGAG\nATAGTTCCAGAGACAAACCCAACTTCACCAGCTGCTGATGGAACTCAGGTGACAAAATGG\nAATCTCTTCAAACGAAAATCTAAACAAACTACCAACTTTGAAAATCCAATCTATGCACAG\nATGGAGAACGAGCAAAAGGAAAGTGTTGCTGCGACACCACCTCCATCACCTTCGCTCCCT\nGCTAAGCCTAAGCCTCCTTCGAGAAGAGACCCAACTCCAACCTATTCTGCAACAGAAGAC\nACTTTTAAAGACACCGCAAATCTTGTTAAAGAAGACTCTGAAGTATAG"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF07645", "name": "EGF_CA"}, {"identifier": "PF00057", "name": "Ldl_recept_a"}, {"identifier": "PF00058", "name": "Ldl_recept_b"}, {"identifier": "PF07974", "name": "EGF_2"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}]}}}, {"@position": "13", "id": "BE0002126", "name": "Insulin-like growth factor-binding protein 7", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Lopez-Bermejo A, Buckway CK, Devi GR, Hwa V, Plymate SR, Oh Y, Rosenfeld RG: Characterization of insulin-like growth factor-binding protein-related proteins (IGFBP-rPs) 1, 2, and 3 in human prostate epithelial cells: potential roles for IGFBP-rP1 and 2 in senescence of the prostatic epithelium. Endocrinology. 2000 Nov;141(11):4072-80. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11089538\n# Radulescu RT: One for all and all for one: RB defends the cell while IDE, PTEN and IGFBP-7 antagonize insulin and IGFs to protect RB. Med Hypotheses. 2007;69(5):1018-20. Epub 2007 May 1. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17475416\n# Degeorges A, Wang F, Frierson HF Jr, Seth A, Chung LW, Sikes RA: Human prostate cancer expresses the low affinity insulin-like growth factor binding protein IGFBP-rP1. Cancer Res. 1999 Jun 15;59(12):2787-90. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10383131", "known-action": "unknown", "polypeptide": {"@id": "Q16270", "@source": "Swiss-Prot", "name": "Insulin-like growth factor-binding protein 7", "general-function": null, "specific-function": "Binds IGF-I and IGF-II with a relatively low affinity. Stimulates prostacyclin (PGI2) production", "gene-name": "IGFBP7", "locus": "4q12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.94", "molecular-weight": "29131.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5476"}, {"resource": "GenAtlas", "identifier": "IGFBP7"}, {"resource": "GeneCards", "identifier": "IGFBP7"}, {"resource": "GenBank Gene Database", "identifier": "L19182"}, {"resource": "GenBank Protein Database", "identifier": "307151"}, {"resource": "UniProtKB", "identifier": "Q16270"}, {"resource": "UniProt Accession", "identifier": "IBP7_HUMAN"}]}, "synonyms": {"synonym": ["IBP- 7", "IGF-binding protein 7", "IGFBP-7", "IGFBP-rP1", "Insulin-like growth factor-binding protein 7 precursor", "MAC25 protein", "PGI2-stimulating factor", "Prostacyclin-stimulating factor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Insulin-like growth factor-binding protein 7\nMERPSLRALLLGAAGLLLLLLPLSSSSSSDTCGPCEPASCPPLPPLGCLLGETRDACGCC\nPMCARGEGEPCGGGGAGRGYCAPGMECVKSRKRRKGKAGAAAGGPGVSGVCVCKSRYPVC\nGSDGTTYPSGCQLRAASQRAESRGEKAITQVSKGTCEQGPSIVTPPKDIWNVTGAQVYLS\nCEVIGIPTPVLIWNKVKRGHYGVQRTELLPGDRDNLAIQTRGGPEKHEVTGWVLVSPLSK\nEDAGEYECHASNSQGQASASAKITVVDALHEIPVKKGEGAEL"}, "gene-sequence": {"@format": "FASTA", "#text": ">834 bp\nATGGAGCGCGCGTCGCTGCGCGCCCTGCTCTTCGGCCCCGCTGGGCTGCTGCTCCTGCTC\nCTGCCCCTCTCCTCTTCCTCCTCTTCGGACACCTGCGGCCCCTGCGAGCCGGCCTCCTGC\nCCGCCCCTGCCCCCGCTGGGCTGCCTGCTGGGCGAGACCCGCGACGCGTGCGGCTGCTGC\nCCTATGTGCGCCCGCGGCGAGGGCGAGCCGTGCGGGGGTGGCGGCGCCGGCAGGGGGTAC\nTGCGCGCCGGGCATGGAGTGCGTGAAGAGCCGCAAGAGGCGGAGGGGTAAAGCCGGGGCA\nGCAGCCGGCGGTCCGGGTGTAAGCGGCGTGTGCGTGTGCAAGAGCCGCTACCCGGTGTGC\nGGCAGCGACGGCACCACCTACCCGAGCGGCTGCCAGCTGCGCGCCGCCAGCCAGAGGGCC\nGAGAGCCGCGGGGAGAAGGCCATCACCCAGGTCAGCAAGGGCACCTGCGAGCAAGGTCCT\nTCCATAGTGACGCCCCCCAAGGACATCTGGAATGTCACTGGTGCCCAGGTGTACTTGAGC\nTGTGAGGTCATCGGAATCCCGACACCTGTCCTCATCTGGAACAAGGTAAAAAGGGGTCAC\nTATGGAGTTCAAAGGACAGAACTCCTGCCTGGTGACCGGGACAACCTGGCCATTCAGACC\nCGGGGTGGCCCAGAAAAGCATGAAGTAACTGGCTGGGTGCTGGTATCTCCTCTAAGTAAG\nGAAGATGCTGGAGAATATGAGTGCCATGCATCCAATTCCCAAGGACAGGCTTCAGCATCA\nGCAAAAATTACAGTGGTTGATGCCTTACATGAAATAGCCAGTGAAAAAAGGTGA"}, "pfams": {"pfam": [{"identifier": "PF07679", "name": "I-set"}, {"identifier": "PF07648", "name": "Kazal_2"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "protein binding"}, {"category": "function", "description": "growth factor binding"}, {"category": "function", "description": "insulin-like growth factor binding"}, {"category": "process", "description": "regulation of biological process"}, {"category": "process", "description": "regulation of growth"}, {"category": "process", "description": "regulation of cell growth"}]}}}, {"@position": "14", "id": "BE0002127", "name": "Synaptotagmin-like protein 4", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Gomi H, Mizutani S, Kasai K, Itohara S, Izumi T: Granuphilin molecularly docks insulin granules to the fusion machinery. J Cell Biol. 2005 Oct 10;171(1):99-109. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16216924\n# Plaisance V, Abderrahmani A, Perret-Menoud V, Jacquemin P, Lemaigre F, Regazzi R: MicroRNA-9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells. J Biol Chem. 2006 Sep 15;281(37):26932-42. Epub 2006 Jul 10. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16831872\n# Torii S, Takeuchi T, Nagamatsu S, Izumi T: Rab27 effector granuphilin promotes the plasma membrane targeting of insulin granules via interaction with syntaxin 1a. J Biol Chem. 2004 May 21;279(21):22532-8. Epub 2004 Mar 17. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15028737", "known-action": "unknown", "polypeptide": {"@id": "Q96C24", "@source": "Swiss-Prot", "name": "Synaptotagmin-like protein 4", "general-function": null, "specific-function": "Modulates exocytosis of dense-core granules and secretion of hormones in the pancreas and the pituitary. Interacts with vesicles containing negatively charged phospholipids in a Ca(2+)-independent manner", "gene-name": "SYTL4", "locus": "-", "cellular-location": "Membrane", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.42", "molecular-weight": "76010.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:15588"}, {"resource": "GenAtlas", "identifier": "SYTL4"}, {"resource": "GeneCards", "identifier": "SYTL4"}, {"resource": "GenBank Gene Database", "identifier": "AK094110"}, {"resource": "GenBank Protein Database", "identifier": "21753104"}, {"resource": "UniProtKB", "identifier": "Q96C24"}, {"resource": "UniProt Accession", "identifier": "SYTL4_HUMAN"}]}, "synonyms": {"synonym": ["Exophilin-2", "Granuphilin"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Synaptotagmin-like protein 4\nMSELLDLSFLSEEEKDLILSVLQRDEEVRKADEKRIRRLKNELLEIKRKGAKRGSQHYSD\nRTCARCQESLGRLSPKTNTCRGCNHLVCRDCRIQESNGTWRCKVCAKEIELKKATGDWFY\nDQKVNRFAYRTGSEIIRMSLRHKPAVSKRETVGQSLLHQTQMGDIWPGRKIIQERQKEPS\nVLFEVPKLKSGKSALEAESESLDSFTADSDSTSRRDSLDKSGLFPEWKKMSAPKSQVEKE\nTQPGGQNVVFVDEGEMIFKKNTRKILRPSEYTKSVIDLRPEDVVHESGSLGDRSKSVPGL\nNVDMEEEEEEEDIDHLVKLHRQKLARSSMQSGSSMSTIGSMMSIYSEAGDFGNIFVTGRI\nAFSLKYEQQTQSLVVHVKECHQLAYADEAKKRSNPYVKTYLLPDKSRQGKRKTSIKRDTV\nNPLYDETLRYEIPESLLAQRTLQFSVWHHGRFGRNTFLGEAEIQMDSWKLDKKLDHCLPL\nHGKISAESPTGLPSHKGELVVSLKYIPASKTPVGGDRKKSKGGEGGELQVWIKEAKNLTA\nAKAGGTSDSFVKGYLLPMRNKASKRKTPVMKKTLNPHYNHTFVYNGVRLEDLQHMCLELT\nVWDREPLASNDFLGGVRLGVGTGISNGEVVDWMDSTGEEVSLWQKMRQYPGSWAEGTLQL\nRSSMAKQKLGL"}, "gene-sequence": {"@format": "FASTA", "#text": ">2016 bp\nATGTCGGAGTTACTGGACCTTTCTTTTCTGTCTGAGGAGGAAAAGGATTTGATTCTCAGT\nGTTCTACAGCGAGATGAAGAGGTCCGGAAAGCAGATGAGAAAAGGATTAGGCGACTAAAG\nAATGAGTTACTGGAGATAAAAAGGAAAGGGGCCAAGAGGGGCAGCCAACACTACAGTGAT\nCGGACCTGTGCCCGGTGCCAGGAGAGCCTGGGCCGTTTGAGTCCCAAAACCAATACTTGT\nCGGGGTTGTAATCACCTGGTGTGTCGGGACTGCCGCATACAGGAAAGCAATGGTACCTGG\nAGGTGCAAGGTGTGCGCCAAGGAAATAGAGTTGAAGAAAGCAACTGGGGACTGGTTTTAT\nGACCAGAAAGTGAATCGCTTTGCTTACCGCACAGGTAGTGAGATAATCAGGATGTCCCTG\nCGCCACAAACCTGCAGTGAGTAAAAGAGAGACAGTGGGACAGTCCCTCCTTCATCAGGCA\nCAGATGGGTGACATCTGGCCAGGAAGAAAGATCATTCAGGAGCGGCAGAAGGAGCCCAGT\nGTGCTATTTGAAGTGCCAAAGCTGAAAAGTGGAAAGAGTGCATTGGAAGCTGAGAGTGAG\nAGTCTGGATAGCTTCACAGCTGACTCGGATAGCACCTCCAGGAGAGACTCTCTGGATAAA\nTCTGGCCTCTTTCCAGAATGGAAGAAGATGTCTGCTCCCAAATCTCAAGTAGAAAAGGAA\nACTCAGCCTGGAGGTCAAAATGTGGTATTTGTGGATGAGGGTGAGATGATATTTAAGAAG\nAACACCAGAAAAATCCTCAGGCCTTCAGAGTACACTAAATCTGTGATAGATCTTCGCCCA\nGAAGATGTGGTACATGAAGGTGGCTCCTTGGGAGACAGAAGCAAATCCGTCCCAGGCCTC\nAATGTGGATATGGAAGAGGAAGAAGAAGAAGAAGACATTGACCACCTAGTGAAGTTACAT\nCGCCAGAAGCTAGCCAGAAGCAGCATGCAAAGTGGCTCCTCCATGAGTACGATCGGCAGC\nATGATGAGCATCTACAGTGAAGCTGGTGATTTCGGGAACATCTTTGTGACTGGCAGGATT\nGCCTTTTCCCTGAAGTATGAGCAGCAAACCCAGAGTCTGGTTGTCCATGTGAAGGAGTGC\nCATCAGCTGGCCTATGCTGATGAAGCCAAGAAGCGCTCTAACCCATATGTGAAGACTTAC\nCTTCTGCCTGACAAGTCCCGCCAAGGAAAAAGAAAAACCAGCATCAAGCGGGACACTGTT\nAATCCACTATATGATGAGACGCTGAGGTATGAGATCCCAGAATCTCTCCTGGCCCAGAGG\nACCCTGCAGTTCTCAGTTTGGCATCATGGTCGTTTTGGCAGAAACACTTTCCTTGGAGAG\nGCAGAGATCCAGATGGATTCCTGGAAGCTTGATAAGAAACTGGATCATTGCCTCCCTTTA\nCATGGAAAGATCAGTGCTGAGTCCCCGACTGGCTTGCCATCACACAAAGGCGAGTTGGTG\nGTTTCATTGAAATACATCCCAGCCTCCAAAACCCCTGTTGGAGGTGACCGGAAAAAGAGT\nAAAGGTGGGGAAGGGGGAGAGCTCCAGGTGTGGATCAAAGAAGCCAAGAACTTGACGGCT\nGCCAAAGCAGGAGGGACTTCAGACAGCTTTGTCAAGGGATACCTCCTTCCCATGAGGAAC\nAAGGCCAGTAAACGTAAAACTCCTGTGATGAAGAAGACCCTGAATCCTCACTACAACCAT\nACATTTGTCTACAATGGTGTGAGGCTGGAAGATCTACAGCATATGTGCCTGGAACTGACT\nGTGTGGGACCGGGAGCCCCTGGCCAGCAATGACTTCCTGGGAGGGGTCAGGCTGGGTGTT\nGGCACTGGGATCAGTAATGGGGAAGTGGTGGACTGGATGGACTCGACTGGGGAAGAAGTG\nAGCCTGTGGCAGAAGATGCGACAGTACCCAGGGTCTTGGGCAGAAGGGACTCTGCAGCTC\nCGTTCCTCAATGGCCAAGCAGAAGCTGGGTTTATGA"}, "pfams": {"pfam": [{"identifier": "PF00168", "name": "C2"}, {"identifier": "PF02318", "name": "RPH3A_effector"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "membrane"}, {"category": "component", "description": "vesicle"}, {"category": "component", "description": "protein complex"}, {"category": "component", "description": "cytoplasmic vesicle"}, {"category": "component", "description": "cytoplasmic membrane-bound vesicle"}, {"category": "component", "description": "coated vesicle"}, {"category": "component", "description": "clathrin-coated vesicle"}, {"category": "component", "description": "synaptic vesicle"}, {"category": "component", "description": "cell"}, {"category": "component", "description": "organelle"}, {"category": "component", "description": "ubiquitin ligase complex"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "ligase activity"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "transporter activity"}, {"category": "function", "description": "ligase activity, forming carbon-nitrogen bonds"}, {"category": "function", "description": "protein binding"}, {"category": "function", "description": "acid-amino acid ligase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "enzyme binding"}, {"category": "function", "description": "ubiquitin-protein ligase activity"}, {"category": "function", "description": "GTPase binding"}, {"category": "function", "description": "zinc ion binding"}, {"category": "function", "description": "small GTPase binding"}, {"category": "function", "description": "Rab GTPase binding"}, {"category": "process", "description": "protein modification"}, {"category": "process", "description": "protein transport"}, {"category": "process", "description": "intracellular protein transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "ubiquitin cycle"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein ubiquitination"}, {"category": "process", "description": "biopolymer metabolism"}, {"category": "process", "description": "biopolymer modification"}]}}}]}, "enzymes": {"enzyme": {"id": "BE0002433", "name": "Cytochrome P450 1A2", "organism": "Human", "actions": {"action": "inducer"}, "references": "# Flockhart DA. \"Drug Interactions: Cytochrome P450 Drug Interaction Table\":http://medicine.iupui.edu/clinpharm/ddis/table.asp. Indiana University School of Medicine (2007). Accessed May 28, 2010.", "known-action": "unknown", "polypeptide": {"@id": "P05177", "@source": "Swiss-Prot", "name": "Cytochrome P450 1A2", "general-function": "Involved in monooxygenase activity", "specific-function": "Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen", "gene-name": "CYP1A2", "locus": "15q24", "cellular-location": "Endoplasmic reticulum", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.43", "molecular-weight": "58295.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2596"}, {"resource": "GenAtlas", "identifier": "CYP1A2"}, {"resource": "GenBank Gene Database", "identifier": "Z00036"}, {"resource": "UniProtKB", "identifier": "P05177"}, {"resource": "UniProt Accession", "identifier": "CP1A2_HUMAN"}]}, "synonyms": {"synonym": ["CYPIA2", "EC 1.14.14.1", "P(3)450", "P450 4", "P450-P3"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytochrome P450 1A2\nMALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN\nPHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG\nQSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM\nAGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP\nILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN\nLIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS\nDRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL\nWEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE\nFSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN"}, "gene-sequence": {"@format": "FASTA", "#text": ">1548 bp\nATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCTGCCATC\nTTCTGCCTGGTATTCTGGGTGCTCAAGGGTTTGAGGCCTCGGGTCCCCAAAGGCCTGAAA\nAGTCCACCAGAGCCATGGGGCTGGCCCTTGCTCGGGCATGTGCTGACCCTGGGGAAGAAC\nCCGCACCTGGCACTGTCAAGGATGAGCCAGCGCTACGGGGACGTCCTGCAGATCCGCATT\nGGCTCCACGCCCGTGCTGGTGCTGAGCCGCCTGGACACCATCCGGCAGGCCCTGGTGCGG\nCAGGGCGACGATTTCAAGGGCCGGCCTGACCTCTACACCTCCACCCTCATCACTGATGGC\nCAGAGCTTGACCTTCAGCACAGACTCTGGACCGGTGTGGGCTGCCCGCCGGCGCCTGGCC\nCAGAATGCCCTCAACACCTTCTCCATCGCCTCTGACCCAGCTTCCTCATCCTCCTGCTAC\nCTGGAGGAGCATGTGAGCAAGGAGGCTAAGGCCCTGATCAGCAGGTTGCAGGAGCTGATG\nGCAGGGCCTGGGCACTTCGACCCTTACAATCAGGTGGTGGTGTCAGTGGCCAACGTCATT\nGGTGCCATGTGCTTCGGACAGCACTTCCCTGAGAGTAGCGATGAGATGCTCAGCCTCGTG\nAAGAACACTCATGAGTTCGTGGAGACTGCCTCCTCCGGGAACCCCCTGGACTTCTTCCCC\nATCCTTCGCTACCTGCCTAACCCTGCCCTGCAGAGGTTCAAGGCCTTCAACCAGAGGTTC\nCTGTGGTTCCTGCAGAAAACAGTCCAGGAGCACTATCAGGACTTTGACAAGAACAGTGTC\nCGGGACATCACGGGTGCCCTGTTCAAGCACAGCAAGAAGGGGCCTAGAGCCAGCGGCAAC\nCTCATCCCACAGGAGAAGATTGTCAACCTTGTCAATGACATCTTTGGAGCAGGATTTGAC\nACAGTCACCACAGCCATCTCCTGGAGCCTCATGTACCTTGTGACCAAGCCTGAGATACAG\nAGGAAGATCCAGAAGGAGCTGGACACTGTGATTGGCAGGGAGCGGCGGCCCCGGCTCTCT\nGACAGACCCCAGCTGCCCTACTTGGAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCC\nTTCTTGCCCTTCACCATCCCCCACAGCACAACAAGGGACACAACGCTGAATGGCTTCTAC\nATCCCCAAGAAATGCTGTGTCTTCGTAAACCAGTGGCAGGTCAACCATGACCCAGAGCTG\nTGGGAGGACCCCTCTGAGTTCCGGCCTGAGCGGTTCCTCACCGCCGATGGCACTGCCATT\nAACAAGCCCTTGAGTGAGAAGATGATGCTGTTTGGCATGGGCAAGCGCCGGTGTATCGGG\nGAAGTCCTGGCCAAGTGGGAGATCTTCCTCTTCCTGGCCATCCTGCTACAGCAACTGGAG\nTTCAGCGTGCCGCCGGGCGTGAAAGTCGACCTGACCCCCATCTACGGGCTGACCATGAAG\nCACGCCCGCTGTGAACATGTCCAGGCGCGGCGCTTCTCCATCAATTGA"}, "pfams": {"pfam": {"identifier": "PF00067", "name": "p450"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "iron ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "tetrapyrrole binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "heme binding"}, {"category": "function", "description": "monooxygenase activity"}, {"category": "function", "description": "oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "generation of precursor metabolites and energy"}, {"category": "process", "description": "electron transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}}, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2015-06-24", "drugbank-id": [{"@primary": "true", "#text": "DB00072"}, "BIOD00098", "BTD00098"], "name": "Trastuzumab", "description": "A recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein. Produced in CHO cell culture.*", "cas-number": "180288-69-1", "groups": {"group": ["approved", "investigational"]}, "general-references": "# Bange J, Zwick E, Ullrich A: Molecular targets for breast cancer therapy and prevention. Nat Med. 2001 May;7(5):548-52. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11329054\n# Menard S, Pupa SM, Campiglio M, Tagliabue E: Biologic and therapeutic role of HER2 in cancer. Oncogene. 2003 Sep 29;22(42):6570-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14528282\n# Kute T, Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, Mitchell T, Vaughn JP: Development of Herceptin resistance in breast cancer cells. Cytometry A. 2004 Feb;57(2):86-93. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14750129\n# Albanell J, Codony J, Rovira A, Mellado B, Gascon P: Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol. 2003;532:253-68. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12908564\n# Tan AR, Swain SM: Ongoing adjuvant trials with trastuzumab in breast cancer. Semin Oncol. 2003 Oct;30(5 Suppl 16):54-64. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14613027\n# IGMT \"Link\":http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=7637\n# IGMT \"Link\":http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=1N8Z\n# Nebija D, Kopelent-Frank H, Urban E, Noe CR, Lachmann B: Comparison of two-dimensional gel electrophoresis patterns and MALDI-TOF MS analysis of therapeutic recombinant monoclonal antibodies trastuzumab and rituximab. J Pharm Biomed Anal. 2011 Dec 5;56(4):684-91. doi: 10.1016/j.jpba.2011.07.006. Epub 2011 Jul 18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/21813259\n#American Society of Health System Pharmacists, Inc., DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995.Trastuzumab; [updated 2014 Nov 05; cited 2014 Nov 12.Available fromhttp://web.b.ebscohost.com/dynamed/detail?vid=2&sid=c9ea9657-342a-4b9b-a3bb-bf363d5d58c4%40sessionmgr112&hid=110&bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BlPXNpdGU%3d#db=dme&AN=233586", "synthesis-reference": null, "indication": "For treatment of early stage HER2-positive breast cancer, or metastatic breast cancer that substantially overexpress HER2.", "pharmacodynamics": "Used in the treatment of HER2-positive breast cancer. HER2 protein overexpression is observed in 25%-30% of primary breast cancers.Trastuzumab has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumorcells that overexpress HER2. It is a mediator of antibody dependent cellular cytotoxicity, in that the binding of the antibody to HER2 overexpressing cells leads to preferential cell death.", "mechanism-of-action": "Trastuzumab binds to the HER2 (or c-erbB2) proto-oncogene, an EGF receptor-like protein found on 20-30% of breast cancer cells. The binding leads to antibody mediated (complement mediated) killing of the HER2 positive cells.", "toxicity": "Administration of trastuzumab can result in ventricular dysfunction and congestive heart failure. Risk of cardiotocity is especially elevated in patients recieving concurrent anthracycline or cyclophosphamide therapy.", "metabolism": "Most likely removed by opsonization via the reticuloendothelial system.", "absorption": "Peak and trough plasma concentrations at steady state (between weeks 16 and 32) approximately 123 and 79 mcg/mL, respectively.", "half-life": "average 28.5 days. Pharmacokinetics are nonlinear; increased doses are associated with increased mean half-life and decreased clearance.", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": "* 44 mL/kg", "clearance": "Elimination may involve clearance of IgG through the reticuloendothelial system.", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Anti HER2"}, {"@language": "", "@coder": "", "#text": "Ig gamma-1 chain C region"}]}, "products": {"product": [{"name": "Herceptin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02240692", "started-marketing-on": "1999-08-23", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "440 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Perjeta-herceptin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02405024", "started-marketing-on": "2013-05-09", "ended-marketing-on": null, "dosage-form": "solution; kit; powder for solution", "strength": "440 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Herceptin", "ingredients": "Trastuzumab"}, {"name": "Perjeta-herceptin", "ingredients": "Trastuzumab + Pertuzumab"}]}, "packagers": {"packager": [{"name": "DSM Corp.", "url": "http://www.dsm.com"}, {"name": "F Hoffmann-La Roche Ltd.", "url": "http://www.roche.com"}, {"name": "Genentech Inc.", "url": "http://www.gene.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Herceptin 440 mg vial", "cost": {"@currency": "USD", "#text": "3443.46"}, "unit": "vial"}, {"description": "Herceptin 440 mg Solution Vial", "cost": {"@currency": "USD", "#text": "3581.2"}, "unit": "vial"}]}, "categories": {"category": {"category": "Antineoplastic Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Powder for solution", "route": "intravenous", "strength": "440 mg"}, {"form": "Solution; kit; powder for solution", "route": "intravenous", "strength": "440 mg"}]}, "atc-codes": {"atc-code": {"@code": "L01XC03", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L01", "#text": "ANTINEOPLASTIC AGENTS"}, {"@code": "L01X", "#text": "OTHER ANTINEOPLASTIC AGENTS"}, {"@code": "L01XC", "#text": "Monoclonal antibodies"}]}}, "ahfs-codes": null, "patents": {"patent": {"number": "2103059", "country": "Canada", "approved": "2005-03-22", "expires": "2012-06-15"}}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB01281", "name": "Abatacept", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00051", "name": "Adalimumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB05773", "name": "ado-trastuzumab emtansine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00087", "name": "Alemtuzumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00488", "name": "Altretamine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00276", "name": "Amsacrine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00026", "name": "Anakinra", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00098", "name": "Anti-thymocyte Globulin (Rabbit)", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00928", "name": "Azacitidine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00993", "name": "Azathioprine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00074", "name": "Basiliximab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB06681", "name": "Belatacept", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB08879", "name": "Belimumab", "description": "Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab."}, {"drugbank-id": "DB00443", "name": "Betamethasone", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00290", "name": "Bleomycin", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB09052", "name": "Blinatumomab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB08870", "name": "Brentuximab vedotin", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01222", "name": "Budesonide", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01008", "name": "Busulfan", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB06772", "name": "Cabazitaxel", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB06168", "name": "Canakinumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01101", "name": "Capecitabine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00958", "name": "Carboplatin", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00262", "name": "Carmustine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB08904", "name": "Certolizumab pegol", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00291", "name": "Chlorambucil", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00515", "name": "Cisplatin", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00242", "name": "Cladribine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00631", "name": "Clofarabine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01285", "name": "Corticotropin", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01380", "name": "Cortisone acetate", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00531", "name": "Cyclophosphamide", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00091", "name": "Cyclosporine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00987", "name": "Cytarabine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00851", "name": "Dacarbazine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00970", "name": "Dactinomycin", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01254", "name": "Dasatinib", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00694", "name": "Daunorubicin", "description": "May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic)."}, {"drugbank-id": "DB01234", "name": "Dexamethasone", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB09077", "name": "Dinutuximab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01248", "name": "Docetaxel", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00997", "name": "Doxorubicin", "description": "May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic)."}, {"drugbank-id": "DB01257", "name": "Eculizumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00445", "name": "Epirubicin", "description": "May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic)."}, {"drugbank-id": "DB01196", "name": "Estramustine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00005", "name": "Etanercept", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00773", "name": "Etoposide", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01590", "name": "Everolimus", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB08868", "name": "Fingolimod", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00322", "name": "Floxuridine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01073", "name": "Fludarabine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00687", "name": "Fludrocortisone", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00544", "name": "Fluorouracil", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00441", "name": "Gemcitabine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00056", "name": "Gemtuzumab ozogamicin", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB05259", "name": "Glatiramer Acetate", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB06674", "name": "golimumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00741", "name": "Hydrocortisone", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01005", "name": "Hydroxyurea", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00078", "name": "Ibritumomab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB09053", "name": "Ibrutinib", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01177", "name": "Idarubicin", "description": "May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic)."}, {"drugbank-id": "DB09054", "name": "Idelalisib", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01181", "name": "Ifosfamide", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00619", "name": "Imatinib", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00724", "name": "Imiquimod", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00065", "name": "Infliximab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00762", "name": "Irinotecan", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00120", "name": "L-Phenylalanine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01097", "name": "Leflunomide", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00480", "name": "Lenalidomide", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01206", "name": "Lomustine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00888", "name": "Mechlorethamine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01042", "name": "Melphalan", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01033", "name": "Mercaptopurine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00563", "name": "Methotrexate", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00959", "name": "Methylprednisolone", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00305", "name": "Mitomycin", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01204", "name": "Mitoxantrone", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00688", "name": "Mycophenolate mofetil", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01024", "name": "Mycophenolic acid", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00108", "name": "Natalizumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01280", "name": "Nelarabine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB04868", "name": "Nilotinib", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB08935", "name": "Obinutuzumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00526", "name": "Oxaliplatin", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01229", "name": "Paclitaxel", "description": "May decrease the serum concentration of Paclitaxel (Conventional). Paclitaxel (Conventional) may increase the serum concentration of Trastuzumab."}, {"drugbank-id": "DB09073", "name": "Palbociclib", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB06603", "name": "Panobinostat", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB06589", "name": "Pazopanib", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00059", "name": "Pegaspargase", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00642", "name": "Pemetrexed", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00552", "name": "Pentostatin", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB08910", "name": "Pomalidomide", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB06813", "name": "Pralatrexate", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00860", "name": "Prednisolone", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00635", "name": "Prednisone", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01168", "name": "Procarbazine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB06372", "name": "Rilonacept", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00073", "name": "Rituximab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB08877", "name": "Ruxolitinib", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB09029", "name": "Secukinumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB09036", "name": "Siltuximab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00877", "name": "Sirolimus", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00398", "name": "Sorafenib", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00428", "name": "Streptozocin", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01268", "name": "Sunitinib", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00864", "name": "Tacrolimus", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00853", "name": "Temozolomide", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB06287", "name": "Temsirolimus", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00444", "name": "Teniposide", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB08880", "name": "Teriflunomide", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01041", "name": "Thalidomide", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB04572", "name": "Thiotepa", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00352", "name": "Tioguanine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB06273", "name": "Tocilizumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB08895", "name": "Tofacitinib", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB01030", "name": "Topotecan", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00081", "name": "Tositumomab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB05109", "name": "Trabectedin", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00755", "name": "Tretinoin", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00620", "name": "Triamcinolone", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB05679", "name": "Ustekinumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB09033", "name": "Vedolizumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB09082", "name": "Vilanterol", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00570", "name": "Vinblastine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00541", "name": "Vincristine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00309", "name": "Vindesine", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00361", "name": "Vinorelbine", "description": "May enhance the neutropenic effect of Immunosuppressants."}]}, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">Anti-HER2 Light chain 1\nDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPS\nRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPP\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT\nLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC"}, {"@format": "FASTA", "#text": ">Anti-HER2 Heavy chain 1\nEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRY\nADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS\nASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS\nGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPPKSCDKTHTCPPCPAPELLG\nGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY\nNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD\nELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR\nWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK"}, {"@format": "FASTA", "#text": ">Anti-HER2 Light chain 2\nDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPS\nRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPP\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT\nLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC"}, {"@format": "FASTA", "#text": ">Anti-HER2 Heavy chain 2\nEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRY\nADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS\nASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS\nGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPPKSCDKTHTCPPCPAPELLG\nGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY\nNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD\nELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR\nWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK"}, {"@format": "FASTA", "#text": ">1n8z_A|Herceptin|||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23443.1|MW 23443.1|\nDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPS\nRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPP\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT\nLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC"}, {"@format": "FASTA", "#text": ">1n8z_B|Herceptin|||VH-CH1 (VH(1-120)+CH1(121-218))|||||||220||||MW 23404.2|MW 23404.2|\nEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRY\nADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS\nASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS\nGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP"}, {"@format": "FASTA", "#text": ">7637_H|trastuzumab|||H-GAMMA-1 (VH(1-120)+CH1(121-218)+HINGE-REGION(219-233)+CH2(234-343)+CH3(344-450))|||||||450||||MW 49236.5|MW 49236.5|\nEPKSCDKTHTCPPCP"}, {"@format": "FASTA", "#text": ">7637_L|trastuzumab|||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23443.1|MW 23443.1|\nDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPS\nRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPP\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT\nLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "61 \u00b0C (FAB fragment), 71 \u00b0C (whole mAb)", "source": "Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)"}, {"kind": "Hydrophobicity", "value": "-0.415", "source": null}, {"kind": "Isoelectric Point", "value": "8.45", "source": null}, {"kind": "Molecular Weight", "value": "145531.5000", "source": null}, {"kind": "Molecular Formula", "value": "C6470H10012N1726O2013S42", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "11905"}, {"resource": "National Drug Code Directory", "identifier": "50242-134-68"}, {"resource": "GenBank", "identifier": "J00228"}, {"resource": "PharmGKB", "identifier": "PA451743"}, {"resource": "UniProtKB", "identifier": "P01857"}, {"resource": "Wikipedia", "identifier": "Trastuzumab"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/trastuz.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/trastuzumab.html"}]}, "pathways": {"pathway": {"smpdb-id": "SMP00476", "name": "Trastuzumab Action Pathway", "drugs": {"drug": {"drugbank-id": "DB00072", "name": "Trastuzumab"}}, "enzymes": {"uniprot-id": "P00533"}}}, "reactions": null, "snp-effects": {"effect": {"protein-name": "Fibroblast growth factor receptor 4", "gene-symbol": "FGFR4", "uniprot-id": "P22455", "rs-id": "rs351855", "allele": null, "defining-change": "C Allele", "description": "Reduced response to herceptin", "pubmed-id": "16822847"}}, "snp-adverse-drug-reactions": {"reaction": {"protein-name": "Receptor tyrosine-protein kinase erbB-2", "gene-symbol": "ERBB2", "uniprot-id": "P04626", "rs-id": "rs1801200", "allele": null, "adverse-reaction": "G Allele, heterozygote", "description": "Cardiotoxicity", "pubmed-id": "17693647"}}, "targets": {"target": [{"@position": "1", "id": "BE0000511", "name": "Receptor tyrosine-protein kinase erbB-2", "organism": "Human", "actions": {"action": "antibody"}, "references": "# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352\n# Leveque D, Gigou L, Bergerat JP: Clinical pharmacology of trastuzumab. Curr Clin Pharmacol. 2008 Jan;3(1):51-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18690878\n# Lin A, Rugo HS: The role of trastuzumab in early stage breast cancer: current data and treatment recommendations. Curr Treat Options Oncol. 2007 Feb;8(1):47-60. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17660958\n# Treish I, Schwartz R, Lindley C: Pharmacology and therapeutic use of trastuzumab in breast cancer. Am J Health Syst Pharm. 2000 Nov 15;57(22):2063-76; quiz 2077-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11098307", "known-action": "yes", "polypeptide": {"@id": "P04626", "@source": "Swiss-Prot", "name": "Receptor tyrosine-protein kinase erbB-2", "general-function": "Involved in transmembrane receptor protein tyrosine kinase activity", "specific-function": "Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Not activated by EGF, TGF- alpha and amphiregulin", "gene-name": "ERBB2", "locus": "17q11.2-q12|17q21.1", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "653-675", "signal-regions": null, "theoretical-pi": "5.76", "molecular-weight": "137912.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3430"}, {"resource": "GenAtlas", "identifier": "ERBB2"}, {"resource": "GeneCards", "identifier": "ERBB2"}, {"resource": "GenBank Gene Database", "identifier": "M11767"}, {"resource": "GenBank Protein Database", "identifier": "553282"}, {"resource": "UniProtKB", "identifier": "P04626"}, {"resource": "UniProt Accession", "identifier": "ERBB2_HUMAN"}]}, "synonyms": {"synonym": ["C-erbB-2", "CD340 antigen", "EC 2.7.10.1", "MLN 19", "NEU proto-oncogene", "p185erbB2", "Receptor tyrosine-protein kinase erbB-2 precursor", "Tyrosine kinase-type cell surface receptor HER2"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Receptor tyrosine-protein kinase erbB-2 precursor\nMELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNL\nELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNG\nDPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLA\nLTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQC\nAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACP\nYNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSAN\nIQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLP\nDLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTV\nPWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQEC\nVEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARC\nPSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVG\nILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETEL\nRKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSP\nYVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVR\nLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFT\nHQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWM\nIDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDA\nEEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEG\nAGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYV\nNQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQ\nGGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV"}, "gene-sequence": {"@format": "FASTA", "#text": ">3768 bp\nATGGAGCTGGCGGCCTTGTGCCGCTGGGGGCTCCTCCTCGCCCTCTTGCCCCCCGGAGCC\nGCGAGCACCCAAGTGTGCACCGGCACAGACATGAAGCTGCGGCTCCCTGCCAGTCCCGAG\nACCCACCTGGACATGCTCCGCCACCTCTACCAGGGCTGCCAGGTGGTGCAGGGAAACCTG\nGAACTCACCTACCTGCCCACCAATGCCAGCCTGTCCTTCCTGCAGGATATCCAGGAGGTG\nCAGGGCTACGTGCTCATCGCTCACAACCAAGTGAGGCAGGTCCCACTGCAGAGGCTGCGG\nATTGTGCGAGGCACCCAGCTCTTTGAGGACAACTATGCCCTGGCCGTGCTAGACAATGGA\nGACCCGCTGAACAATACCACCCCTGTCACAGGGGCCTCCCCAGGAGGCCTGCGGGAGCTG\nCAGCTTCGAAGCCTCACAGAGATCTTGAAAGGAGGGGTCTTGATCCAGCGGAACCCCCAG\nCTCTGCTACCAGGACACGATTTTGTGGAAGGACATCTTCCACAAGAACAACCAGCTGGCT\nCTCACACTGATAGACACCAACCGCTCTCGGGCCTGCCACCCCTGTTCTCCGATGTGTAAG\nGGCTCCCGCTGCTGGGGAGAGAGTTCTGAGGATTGTCAGAGCCTGACGCGCACTGTCTGT\nGCCGGTGGCTGTGCCCGCTGCAAGGGGCCACTGCCCACTGACTGCTGCCATGAGCAGTGT\nGCTGCCGGCTGCACGGGCCCCAAGCACTCTGACTGCCTGGCCTGCCTCCACTTCAACCAC\nAGTGGCATCTGTGAGCTGCACTGCCCAGCCCTGGTCACCTACAACACAGACACGTTTGAG\nTCCATGCCCAATCCCGAGGGCCGGTATACATTCGGCGCCAGCTGTGTGACTGCCTGTCCC\nTACAACTACCTTTCTACGGACGTGGGATCCTGCACCCTCGTCTGCCCCCTGCACAACCAA\nGAGGTGACAGCAGAGGATGGAACACAGCGGTGTGAGAAGTGCAGCAAGCCCTGTGCCCGA\nGTGTGCTATGGTCTGGGCATGGAGCACTTGCGAGAGGTGAGGGCAGTTACCAGTGCCAAT\nATCCAGGAGTTTGCTGGCTGCAAGAAGATCTTTGGGAGCCTGGCATTTCTGCCGGAGAGC\nTTTGATGGGGACCCAGCCTCCAACACTGCCCCGCTCCAGCCAGAGCAGCTCCAAGTGTTT\nGAGACTCTGGAAGAGATCACAGGTTACCTATACATCTCAGCATGGCCGGACAGCCTGCCT\nGACCTCAGCGTCTTCCAGAACCTGCAAGTAATCCGGGGACGAATTCTGCACAATGGCGCC\nTACTCGCTGACCCTGCAAGGGCTGGGCATCAGCTGGCTGGGGCTGCGCTCACTGAGGGAA\nCTGGGCAGTGGACTGGCCCTCATCCACCATAACACCCACCTCTGCTTCGTGCACACGGTG\nCCCTGGGACCAGCTCTTTCGGAACCCGCACCAAGCTCTGCTCCACACTGCCAACCGGCCA\nGAGGACGAGTGTGTGGGCGAGGGCCTGGCCTGCCACCAGCTGTGCGCCCGAGGGCACTGC\nTGGGGTCCAGGGCCCACCCAGTGTGTCAACTGCAGCCAGTTCCTTCGGGGCCAGGAGTGC\nGTGGAGGAATGCCGAGTACTGCAGGGGCTCCCCAGGGAGTATGTGAATGCCAGGCACTGT\nTTGCCGTGCCACCCTGAGTGTCAGCCCCAGAATGGCTCAGTGACCTGTTTTGGACCGGAG\nGCTGACCAGTGTGTGGCCTGTGCCCACTATAAGGACCCTCCCTTCTGCGTGGCCCGCTGC\nCCCAGCGGTGTGAAACCTGACCTCTCCTACATGCCCATCTGGAAGTTTCCAGATGAGGAG\nGGCGCATGCCAGCCTTGCCCCATCAACTGCACCCACTCCTGTGTGGACCTGGATGACAAG\nGGCTGCCCCGCCGAGCAGAGAGCCAGCCCTCTGACGTCCATCGTCTCTGCGGTGGTTGGC\nATTCTGCTGGTCGTGGTCTTGGGGGTGGTCTTTGGGATCCTCATCAAGCGACGGCAGCAG\nAAGATCCGGAAGTACACGATGCGGAGACTGCTGCAGGAAACGGAGCTGGTGGAGCCGCTG\nACACCTAGCGGAGCGATGCCCAACCAGGCGCAGATGCGGATCCTGAAAGAGACGGAGCTG\nAGGAAGGTGAAGGTGCTTGGATCTGGCGCTTTTGGCACAGTCTACAAGGGCATCTGGATC\nCCTGATGGGGAGAATGTGAAAATTCCAGTGGCCATCAAAGTGTTGAGGGAAAACACATCC\nCCCAAAGCCAACAAAGAAATCTTAGACGAAGCATACGTGATGGCTGGTGTGGGCTCCCCA\nTATGTCTCCCGCCTTCTGGGCATCTGCCTGACATCCACGGTGCAGCTGGTGACACAGCTT\nATGCCCTATGGCTGCCTCTTAGACCATGTCCGGGAAAACCGCGGACGCCTGGGCTCCCAG\nGACCTGCTGAACTGGTGTATGCAGATTGCCAAGGGGATGAGCTACCTGGAGGATGTGCGG\nCTCGTACACAGGGACTTGGCCGCTCGGAACGTGCTGGTCAAGAGTCCCAACCATGTCAAA\nATTACAGACTTCGGGCTGGCTCGGCTGCTGGACATTGACGAGACAGAGTACCATGCAGAT\nGGGGGCAAGGTGCCCATCAAGTGGATGGCGCTGGAGTCCATTCTCCGCCGGCGGTTCACC\nCACCAGAGTGATGTGTGGAGTTATGGTGTGACTGTGTGGGAGCTGATGACTTTTGGGGCC\nAAACCTTACGATGGGATCCCAGCCCGGGAGATCCCTGACCTGCTGGAAAAGGGGGAGCGG\nCTGCCCCAGCCCCCCATCTGCACCATTGATGTCTACATGATCATGGTCAAATGTTGGATG\nATTGACTCTGAATGTCGGCCAAGATTCCGGGAGTTGGTGTCTGAATTCTCCCGCATGGCC\nAGGGACCCCCAGCGCTTTGTGGTCATCCAGAATGAGGACTTGGGCCCAGCCAGTCCCTTG\nGACAGCACCTTCTACCGCTCACTGCTGGAGGACGATGACATGGGGGACCTGGTGGATGCT\nGAGGAGTATCTGGTACCCCAGCAGGGCTTCTTCTGTCCAGACCCTGCCCCGGGCGCTGGG\nGGCATGGTCCACCACAGGCACCGCAGCTCATCTACCAGGAGTGGCGGTGGGGACCTGACA\nCTAGGGCTGGAGCCCTCTGAAGAGGAGGCCCCCAGGTCTCCACTGGCACCCTCCGAAGGG\nGCTGGCTCCGATGTATTTGATGGTGACCTGGGAATGGGGGCAGCCAAGGGGCTGCAAAGC\nCTCCCCACACATGACCCCAGCCCTCTACAGCGGTACAGTGAGGACCCCACAGTACCCCTG\nCCCTCTGAGACTGATGGCTACGTTGCCCCCCTGACCTGCAGCCCCCAGCCTGAATATGTG\nAACCAGCCAGATGTTCGGCCCCAGCCCCCTTCGCCCCGAGAGGGCCCTCTGCCTGCTGCC\nCGACCTGCTGGTGCCACTCTGGAAAGGGCCAAGACTCTCTCCCCAGGGAAGAATGGGGTC\nGTCAAAGACGTTTTTGCCTTTGGGGGTGCCGTGGAGAACCCCGAGTACTTGACACCCCAG\nGGAGGAGCTGCCCCTCAGCCCCACCCTCCTCCTGCCTTCAGCCCAGCCTTCGACAACCTC\nTATTACTGGGACCAGGACCCACCAGAGCGGGGGGCTCCACCCAGCACCTTCAAAGGGACA\nCCTACGGCAGAGAACCCAGAGTACCTGGGTCTGGACGTGCCAGTGTGA"}, "pfams": {"pfam": [{"identifier": "PF07714", "name": "Pkinase_Tyr"}, {"identifier": "PF00757", "name": "Furin-like"}, {"identifier": "PF01030", "name": "Recep_L_domain"}, {"identifier": "PF02757", "name": "YLP"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "protein-tyrosine kinase activity"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "transferase activity, transferring phosphorus-containing groups"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "function", "description": "kinase activity"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "transferase activity"}, {"category": "function", "description": "protein kinase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "transmembrane receptor protein tyrosine kinase activity"}, {"category": "function", "description": "epidermal growth factor receptor activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "protein amino acid phosphorylation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "enzyme linked receptor protein signaling pathway"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "transmembrane receptor protein tyrosine kinase signaling pathway"}, {"category": "process", "description": "biopolymer metabolism"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "biopolymer modification"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "protein modification"}]}}}, {"@position": "2", "id": "BE0000767", "name": "Epidermal growth factor receptor", "organism": "Human", "actions": null, "references": "# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "unknown", "polypeptide": {"@id": "P00533", "@source": "Swiss-Prot", "name": "Epidermal growth factor receptor", "general-function": "Involved in transmembrane receptor protein tyrosine kinase activity", "specific-function": "Isoform 2/truncated isoform may act as an antagonist", "gene-name": "EGFR", "locus": "7p12", "cellular-location": "Cell membrane; single-pass type I membrane protein. Isoform 2:Secreted protein", "transmembrane-regions": "646-668", "signal-regions": null, "theoretical-pi": "6.67", "molecular-weight": "134279.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3236"}, {"resource": "GenAtlas", "identifier": "EGFR"}, {"resource": "GeneCards", "identifier": "EGFR"}, {"resource": "GenBank Gene Database", "identifier": "X00588"}, {"resource": "GenBank Protein Database", "identifier": "757924"}, {"resource": "UniProtKB", "identifier": "P00533"}, {"resource": "UniProt Accession", "identifier": "EGFR_HUMAN"}]}, "synonyms": {"synonym": ["EC 2.7.10.1", "Epidermal growth factor receptor precursor", "Receptor tyrosine-protein kinase ErbB-1"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Epidermal growth factor receptor precursor\nMRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEV\nVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALA\nVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDF\nQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGC\nTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYV\nVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFK\nNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAF\nENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKL\nFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCN\nLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM\nGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVV\nALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGS\nGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGI\nCLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAA\nRNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSY\nGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPK\nFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQ\nQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTED\nSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLN\nTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRV\nAPQSSEFIGA"}, "gene-sequence": {"@format": "FASTA", "#text": ">3633 bp\nATGCGACCCTCCGGGACGGCCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCG\nGCGAGTCGGGCTCTGGAGGAAAAGAAAGTTTGCCAAGGCACGAGTAACAAGCTCACGCAG\nTTGGGCACTTTTGAAGATCATTTTCTCAGCCTCCAGAGGATGTTCAATAACTGTGAGGTG\nGTCCTTGGGAATTTGGAAATTACCTATGTGCAGAGGAATTATGATCTTTCCTTCTTAAAG\nACCATCCAGGAGGTGGCTGGTTATGTCCTCATTGCCCTCAACACAGTGGAGCGAATTCCT\nTTGGAAAACCTGCAGATCATCAGAGGAAATATGTACTACGAAAATTCCTATGCCTTAGCA\nGTCTTATCTAACTATGATGCAAATAAAACCGGACTGAAGGAGCTGCCCATGAGAAATTTA\nCAGGAAATCCTGCATGGCGCCGTGCGGTTCAGCAACAACCCTGCCCTGTGCAACGTGGAG\nAGCATCCAGTGGCGGGACATAGTCAGCAGTGACTTTCTCAGCAACATGTCGATGGACTTC\nCAGAACCACCTGGGCAGCTGCCAAAAGTGTGATCCAAGCTGTCCCAATGGGAGCTGCTGG\nGGTGCAGGAGAGGAGAACTGCCAGAAACTGACCAAAATCATCTGTGCCCAGCAGTGCTCC\nGGGCGCTGCCGTGGCAAGTCCCCCAGTGACTGCTGCCACAACCAGTGTGCTGCAGGCTGC\nACAGGCCCCCGGGAGAGCGACTGCCTGGTCTGCCGCAAATTCCGAGACGAAGCCACGTGC\nAAGGACACCTGCCCCCCACTCATGCTCTACAACCCCACCACGTACCAGATGGATGTGAAC\nCCCGAGGGCAAATACAGCTTTGGTGCCACCTGCGTGAAGAAGTGTCCCCGTAATTATGTG\nGTGACAGATCACGGCTCGTGCGTCCGAGCCTGTGGGGCCGACAGCTATGAGATGGAGGAA\nGACGGCGTCCGCAAGTGTAAGAAGTGCGAAGGGCCTTGCCGCAAAGTGTGTAACGGAATA\nGGTATTGGTGAATTTAAAGACTCACTCTCCATAAATGCTACGAATATTAAACACTTCAAA\nAACTGCACCTCCATCAGTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCC\nTTCACACATACTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAA\nATCACAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCTTT\nGAGAACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTCTTGCAGTC\nGTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGATAAGTGATGGAGAT\nGTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATACAATAAACTGGAAAAAACTG\nTTTGGGACCTCCGGTCAGAAAACCAAAATTATAAGCAACAGAGGTGAAAACAGCTGCAAG\nGCCACAGGCCAGGTCTGCCATGCCTTGTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCC\nAGGGACTGCGTCTCTTGCCGGAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAAG\nCTTCTGGAGGGTGAGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCA\nGAGTGCCTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATC\nCAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGAGTCATG\nGGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGTGTGCCACCTGTGC\nCATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGAAGGCTGTCCAACGAATGGG\nCCTAAGATCCCGTCCATCGCCACTGGGATGGTGGGGGCCCTCCTCTTGCTGCTGGTGGTG\nGCCCTGGGGATCGGCCTCTTCATGCGAAGGCGCCACATCGTTCGGAAGCGCACGCTGCGG\nAGGCTGCTGCAGGAGAGGGAGCTTGTGGAGCCTCTTACACCCAGTGGAGAAGCTCCCAAC\nCAAGCTCTCTTGAGGATCTTGAAGGAAACTGAATTCAAAAAGATCAAAGTGCTGGGCTCC\nGGTGCGTTCGGCACGGTGTATAAGGGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATT\nCCCGTCGCTATCAAGGAATTAAGAGAAGCAACATCTCCGAAAGCCAACAAGGAAATCCTC\nGATGAAGCCTACGTGATGGCCAGCGTGGACAACCCCCACGTGTGCCGCCTGCTGGGCATC\nTGCCTCACCTCCACCGTGCAACTCATCACGCAGCTCATGCCCTTCGGCTGCCTCCTGGAC\nTATGTCCGGGAACACAAAGACAATATTGGCTCCCAGTACCTGCTCAACTGGTGTGTGCAG\nATCGCAAAGGGCATGAACTACTTGGAGGACCGTCGCTTGGTGCACCGCGACCTGGCAGCC\nAGGAACGTACTGGTGAAAACACCGCAGCATGTCAAGATCACAGATTTTGGGCTGGCCAAA\nCTGCTGGGTGCGGAAGAGAAAGAATACCATGCAGAAGGAGGCAAAGTGCCTATCAAGTGG\nATGGCATTGGAATCAATTTTACACAGAATCTATACCCACCAGAGTGATGTCTGGAGCTAC\nGGGGTGACCGTTTGGGAGTTGATGACCTTTGGATCCAAGCCATATGACGGAATCCCTGCC\nAGCGAGATCTCCTCCATCCTGGAGAAAGGAGAACGCCTCCCTCAGCCACCCATATGTACC\nATCGATGTCTACATGATCATGGTCAAGTGCTGGATGATAGACGCAGATAGTCGCCCAAAG\nTTCCGTGAGTTGATCATCGAATTCTCCAAAATGGCCCGAGACCCCCAGCGCTACCTTGTC\nATTCAGGGGGATGAAAGAATGCATTTGCCAAGTCCTACAGACTCCAACTTCTACCGTGCC\nCTGATGGATGAAGAAGACATGGACGACGTGGTGGATGCCGACGAGTACCTCATCCCACAG\nCAGGGCTTCTTCAGCAGCCCCTCCACGTCACGGACTCCCCTCCTGAGCTCTCTGAGTGCA\nACCAGCAACAATTCCACCGTGGCTTGCATTGATAGAAATGGGCTGCAAAGCTGTCCCATC\nAAGGAAGACAGCTTCTTGCAGCGATACAGCTCAGACCCCACAGGCGCCTTGACTGAGGAC\nAGCATAGACGACACCTTCCTCCCAGTGCCTGAATACATAAACCAGTCCGTTCCCAAAAGG\nCCCGCTGGCTCTGTGCAGAATCCTGTCTATCACAATCAGCCTCTGAACCCCGCGCCCAGC\nAGAGACCCACACTACCAGGACCCCCACAGCACTGCAGTGGGCAACCCCGAGTATCTCAAC\nACTGTCCAGCCCACCTGTGTCAACAGCACATTCGACAGCCCTGCCCACTGGGCCCAGAAA\nGGCAGCCACCAAATTAGCCTGGACAACCCTGACTACCAGCAGGACTTCTTTCCCAAGGAA\nGCCAAGCCAAATGGCATCTTTAAGGGCTCCACAGCTGAAAATGCAGAATACCTAAGGGTC\nGCGCCACAAAGCAGTGAATTTATTGGAGCATGA"}, "pfams": {"pfam": [{"identifier": "PF07714", "name": "Pkinase_Tyr"}, {"identifier": "PF00757", "name": "Furin-like"}, {"identifier": "PF01030", "name": "Recep_L_domain"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "transmembrane receptor protein tyrosine kinase activity"}, {"category": "function", "description": "epidermal growth factor receptor activity"}, {"category": "function", "description": "protein-tyrosine kinase activity"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "transferase activity, transferring phosphorus-containing groups"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "function", "description": "kinase activity"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "transferase activity"}, {"category": "function", "description": "protein kinase activity"}, {"category": "process", "description": "protein amino acid phosphorylation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "enzyme linked receptor protein signaling pathway"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "transmembrane receptor protein tyrosine kinase signaling pathway"}, {"category": "process", "description": "biopolymer metabolism"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "biopolymer modification"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "protein modification"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "3", "id": "BE0002093", "name": "Complement C1r subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P00736", "@source": "Swiss-Prot", "name": "Complement C1r subcomponent", "general-function": null, "specific-function": "C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system", "gene-name": "C1R", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.24", "molecular-weight": "80174.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1246"}, {"resource": "GenAtlas", "identifier": "C1R"}, {"resource": "GeneCards", "identifier": "C1R"}, {"resource": "GenBank Gene Database", "identifier": "X04701"}, {"resource": "GenBank Protein Database", "identifier": "29539"}, {"resource": "UniProtKB", "identifier": "P00736"}, {"resource": "UniProt Accession", "identifier": "C1R_HUMAN"}]}, "synonyms": {"synonym": ["Complement C1r subcomponent precursor", "Complement component 1, r subcomponent", "EC 3.4.21.41"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1r subcomponent\nMWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF\nQQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF\nSNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY\nELQEDRHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF\nDIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL\nRYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD\nDGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR\nESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF\nTNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV\nSVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME\nEKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV\nRDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2118 bp\nATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC\nATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC\nAACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC\nCAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT\nGATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG\nGGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC\nTCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT\nGTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG\nTGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT\nGAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG\nGCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC\nAACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT\nGATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC\nGGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC\nAATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG\nCGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC\nATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA\nGGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT\nGATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA\nAACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC\nCGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG\nGAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG\nGGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG\nAGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC\nACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT\nGCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC\nCTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC\nAGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG\nCTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC\nAACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG\nGAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT\nGAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT\nGGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA\nAGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC\nAGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG\nATGGAGGAGGAGGACTGA"}, "pfams": {"pfam": [{"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF07645", "name": "EGF_CA"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "4", "id": "BE0002094", "name": "Complement C1q subcomponent subunit A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02745", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit A", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QA", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.45", "molecular-weight": "26017.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1241"}, {"resource": "GenAtlas", "identifier": "C1QA"}, {"resource": "GeneCards", "identifier": "C1QA"}, {"resource": "GenBank Gene Database", "identifier": "AF135157"}, {"resource": "GenBank Protein Database", "identifier": "4894854"}, {"resource": "UniProtKB", "identifier": "P02745"}, {"resource": "UniProt Accession", "identifier": "C1QA_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit A precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit A\nMEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR\nTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI\nRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR\nGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL\nIFPSA"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG\nGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC\nAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG\nACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC\nAAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGGGCCCGTGGCATCCCGGGAATTAAA\nGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT\nCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG\nGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC\nTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG\nGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG\nGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC\nCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC\nATCTTCCCATCTGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "5", "id": "BE0002095", "name": "Complement C1q subcomponent subunit B", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02746", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit B", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QB", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.87", "molecular-weight": "26460.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1242"}, {"resource": "GenAtlas", "identifier": "C1QB"}, {"resource": "GeneCards", "identifier": "C1QB"}, {"resource": "GenBank Gene Database", "identifier": "X03084"}, {"resource": "GenBank Protein Database", "identifier": "573114"}, {"resource": "UniProtKB", "identifier": "P02746"}, {"resource": "UniProt Accession", "identifier": "C1QB_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit B precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit B\nMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEK\nGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKI\nAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCV\nNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANSIF\nSGFLLFPDMEA"}, "gene-sequence": {"@format": "FASTA", "#text": ">688 bp\nCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGG\nGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCC\nAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAA\nTCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGCCCAGGGGCCCCTGG\nAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAGAAAATCGCCTTCTC\nTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATCCGCTTCGACCACGT\nGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTCACCTGCAAGGTGCC\nCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTGTGCGTGAACCTCAT\nGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTATGCCTACAACACCTT\nCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAGAACGTCTTCCTGCA\nGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGCATCTTTTCCGGGTT\nCCTGCTCTTTCCAGATATGGAGGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "6", "id": "BE0002096", "name": "Complement C1q subcomponent subunit C", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02747", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit C", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QC", "locus": "1p36.11", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.58", "molecular-weight": "25774.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1245"}, {"resource": "GenAtlas", "identifier": "C1QC"}, {"resource": "GeneCards", "identifier": "C1QC"}, {"resource": "GenBank Gene Database", "identifier": "AF087892"}, {"resource": "GenBank Protein Database", "identifier": "33150626"}, {"resource": "UniProtKB", "identifier": "P02747"}, {"resource": "UniProt Accession", "identifier": "C1QC_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit C precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit C\nMDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP\nGIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS\nVFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV\nLLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF\nLLFPD"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG\nCTGCTGCCCCTCAGGGCCAAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC\nCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA\nGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA\nCCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC\nCCCATGGGATTCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA\nGTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC\nAACGCGGTCCTCACCAACCCGCAGGAGGATTATGACACGAGCACTGGCAAGTTCACCTGC\nAAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG\nCTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT\nCAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT\nGTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC\nCTGCTCTTCCCCGACTAG"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "7", "id": "BE0001529", "name": "Complement C1s subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P09871", "@source": "Swiss-Prot", "name": "Complement C1s subcomponent", "general-function": "Involved in calcium ion binding", "specific-function": "C1s B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4", "gene-name": "C1S", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "4.59", "molecular-weight": "76685.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1247"}, {"resource": "GenAtlas", "identifier": "C1S"}, {"resource": "GeneCards", "identifier": "C1S"}, {"resource": "GenBank Gene Database", "identifier": "X06596"}, {"resource": "GenBank Protein Database", "identifier": "763110"}, {"resource": "UniProtKB", "identifier": "P09871"}, {"resource": "UniProt Accession", "identifier": "C1S_HUMAN"}]}, "synonyms": {"synonym": ["C1 esterase", "Complement C1s subcomponent precursor", "EC 3.4.21.42"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1s subcomponent precursor\nMWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIE\nLSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERF\nTGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVF\nTALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVF\nVAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTP\nNSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCG\nIPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPK\nCVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGN\nREPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVK\nMGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKV\nEKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCG\nTYGLYTRVKNYVDWIMKTMQENSTPRED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2067 bp\nATGTGGTGCATTGTCCTGTTTTCACTTTTGGCATGGGTTTATGCTGAGCCTACCATGTAT\nGGGGAGATCCTGTCCCCTAACTATCCTCAGGCATATCCCAGTGAGGTAGAGAAATCTTGG\nGACATAGAAGTTCCTGAAGGGTATGGGATTCACCTCTACTTCACCCATCTGGACATTGAG\nCTGTCAGAGAACTGTGCGTATGACTCAGTGCAGATAATCTCAGGAGACACTGAAGAAGGG\nAGGCTCTGTGGACAGAGGAGCAGTAACAATCCCCACTCTCCAATTGTGGAAGAGTTCCAA\nGTCCCATACAACAAACTCCAGGTGATCTTTAAGTCAGACTTTTCCAATGAAGAGCGTTTT\nACGGGGTTTGCTGCATACTATGTTGCCACAGACATAAATGAATGCACAGATTTTGTAGAT\nGTCCCTTGTAGCCACTTCTGCAACAATTTCATTGGTGGTTACTTCTGCTCCTGCCCCCCG\nGAATATTTCCTCCATGATGACATGAAGAATTGCGGAGTTAATTGCAGTGGGGATGTATTC\nACTGCACTGATTGGGGAGATTGCAAGTCCCAATTATCCCAAACCATATCCAGAGAACTCA\nAGGTGTGAATACCAGATCCGGTTGGAGAAAGGGTTCCAAGTGGTGGTGACCTTGCGGAGA\nGAAGATTTTGATGTGGAAGCAGCTGACTCAGCGGGAAACTGCCTTGACAGTTTAGTTTTT\nGTTGCAGGAGATCGGCAATTTGGTCCTTACTGTGGTCATGGATTCCCTGGGCCTCTAAAT\nATTGAAACCAAGAGTAATGCTCTTGATATCATCTTCCAAACTGATCTAACAGGGCAAAAA\nAAGGGCTGGAAACTTCGCTATCATGGAGATCCAATGCCCTGCCCTAAGGAAGACACTCCC\nAATTCTGTTTGGGAGCCTGCGAAGGCAAAATATGTCTTTAGAGATGTGGTGCAGATAACC\nTGTCTGGATGGGTTTGAAGTTGTGGAGGGACGTGTTGGTGCAACATCTTTCTATTCGACT\nTGTCAAAGCAATGGAAAGTGGAGTAATTCCAAACTGAAATGTCAACCTGTGGACTGTGGC\nATTCCTGAATCCATTGAGAATGGTAAAGTTGAAGACCCAGAGAGCACTTTGTTTGGTTCT\nGTCATCCGCTACACTTGTGAGGAGCCATATTACTACATGGAAAATGGAGGAGGTGGGGAG\nTATCACTGTGCTGGTAACGGGAGCTGGGTGAATGAGGTGCTGGGCCCGGAGCTGCCGAAA\nTGTGTTCCAGTCTGTGGAGTCCCCAGAGAACCCTTTGAAGAAAAACAGAGGATAATTGGA\nGGATCCGATGCAGATATTAAAAACTTCCCCTGGCAAGTCTTCTTTGACAACCCATGGGCT\nGGTGGAGCGCTCATTAATGAGTACTGGGTGCTGACGGCTGCTCATGTTGTGGAGGGAAAC\nAGGGAGCCAACAATGTATGTTGGGTCCACCTCAGTGCAGACCTCACGGCTGGCAAAATCC\nAAGATGCTCACTCCTGAGCATGTGTTTATTCATCCGGGATGGAAGCTGCTGGAAGTCCCA\nGAAGGACGAACCAATTTTGATAATGACATTGCACTGGTGCGGCTGAAAGACCCAGTGAAA\nATGGGACCCACCGTCTCTCCCATCTGCCTACCAGGCACCTCTTCCGACTACAACCTCATG\nGATGGGGACCTGGGACTGATCTCAGGCTGGGGCCGAACAGAGAAGAGAGATCGTGCTGTT\nCGCCTCAAGGCGGCAAGGTTACCTGTAGCTCCTTTAAGAAAATGCAAAGAAGTGAAAGTG\nGAGAAACCCACAGCAGATGCAGAGGCCTATGTTTTCACTCCTAACATGATCTGTGCTGGA\nGGAGAGAAGGGCATGGATAGCTGTAAAGGGGACAGTGGTGGGGCCTTTGCTGTACAGGAT\nCCCAATGACAAGACCAAATTCTACGCAGCTGGCCTGGTGTCCTGGGGGCCCCAGTGTGGG\nACCTATGGGCTCTACACACGGGTAAAGAACTATGTTGACTGGATAATGAAGACTATGCAG\nGAAAATAGCACCCCCCGTGAGGACTAA"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "8", "id": "BE0000710", "name": "High affinity immunoglobulin gamma Fc receptor I", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Curnow RT: Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):210-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9435876", "known-action": "unknown", "polypeptide": {"@id": "P12314", "@source": "Swiss-Prot", "name": "High affinity immunoglobulin gamma Fc receptor I", "general-function": "Involved in receptor signaling protein activity", "specific-function": "Binds to the Fc region of immunoglobulins gamma. High affinity receptor", "gene-name": "FCGR1A", "locus": "1q21.2-q21.3", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "293-313", "signal-regions": null, "theoretical-pi": "8.08", "molecular-weight": "42632.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3613"}, {"resource": "GenAtlas", "identifier": "FCGR1A"}, {"resource": "GeneCards", "identifier": "FCGR1A"}, {"resource": "GenBank Gene Database", "identifier": "X14356"}, {"resource": "GenBank Protein Database", "identifier": "31332"}, {"resource": "UniProtKB", "identifier": "P12314"}, {"resource": "UniProt Accession", "identifier": "FCGR1_HUMAN"}]}, "synonyms": {"synonym": ["CD64 antigen", "Fc-gamma RI", "FcRI", "High affinity immunoglobulin gamma Fc receptor I precursor", "IgG Fc receptor I"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">High affinity immunoglobulin gamma Fc receptor I precursor\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1125 bp\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCTCTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAACTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "9", "id": "BE0002098", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17704420", "known-action": "unknown", "polypeptide": {"@id": "P12318", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "general-function": null, "specific-function": "Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens", "gene-name": "FCGR2A", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.78", "molecular-weight": "34990.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3616"}, {"resource": "GenAtlas", "identifier": "FCGR2A"}, {"resource": "GeneCards", "identifier": "FCGR2A"}, {"resource": "GenBank Gene Database", "identifier": "M31932"}, {"resource": "GenBank Protein Database", "identifier": "182474"}, {"resource": "UniProtKB", "identifier": "P12318"}, {"resource": "UniProt Accession", "identifier": "FCG2A_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-a", "Fc-gamma-RIIa", "FcRII-a", "IgG Fc receptor II-a", "Low affinity immunoglobulin gamma Fc region receptor II-a precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-a\nMAMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSRLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">954 bp\nATGGCTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "10", "id": "BE0002099", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31994", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "general-function": null, "specific-function": "Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B- cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis", "gene-name": "FCGR2B", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.12", "molecular-weight": "34044.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3618"}, {"resource": "GenAtlas", "identifier": "FCGR2B"}, {"resource": "GeneCards", "identifier": "FCGR2B"}, {"resource": "GenBank Gene Database", "identifier": "U87560"}, {"resource": "GenBank Protein Database", "identifier": "4099445"}, {"resource": "UniProtKB", "identifier": "P31994"}, {"resource": "UniProt Accession", "identifier": "FCG2B_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-b", "Fc-gamma-RIIb", "FcRII-b", "IgG Fc receptor II-b", "Low affinity immunoglobulin gamma Fc region receptor II-b precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI"}, "gene-sequence": {"@format": "FASTA", "#text": ">930 bp\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCTCTCCCAGGATACCCTGAG\nTGCAGGGAAATGGGAGAGACCCTCCCTGAGAAACCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATT"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "11", "id": "BE0002100", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31995", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "general-function": null, "specific-function": "Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells", "gene-name": "FCGR2C", "locus": "1q23.3", "cellular-location": "Cell membrane", "transmembrane-regions": "224-246", "signal-regions": null, "theoretical-pi": "6.9", "molecular-weight": "35578.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:15626"}, {"resource": "GenAtlas", "identifier": "FCGR2C"}, {"resource": "GeneCards", "identifier": "FCGR2C"}, {"resource": "GenBank Gene Database", "identifier": "X17652"}, {"resource": "GenBank Protein Database", "identifier": "32074"}, {"resource": "UniProtKB", "identifier": "P31995"}, {"resource": "UniProt Accession", "identifier": "FCG2C_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-c", "Fc-gamma-RIIc", "FcRII-c", "IgG Fc receptor II-c", "Low affinity immunoglobulin gamma Fc region receptor II-c precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-c\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR\nAPTDDDKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">972 bp\nATGGGAATCCTGTCATTTTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACAGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCATTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCTGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG\nAAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT\nGAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG\nGCACCTACTGACGATGATAAAAACATCTACTTGACTCTTCCTCCCAACGACCATGTCAAC\nAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "12", "id": "BE0000901", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "organism": "Human", "actions": null, "references": "# Bowles JA, Weiner GJ: CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods. 2005 Sep;304(1-2):88-99. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16109421\n# Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM: Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem. 2004 Dec 24;279(52):53907-14. Epub 2004 Oct 7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15471859\n# Kubo M, Morisaki T, Kuroki H, Tasaki A, Yamanaka N, Matsumoto K, Nakamura K, Onishi H, Baba E, Katano M: Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer. Anticancer Res. 2003 Nov-Dec;23(6a):4443-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14666732\n# Yamaguchi Y, Hironaka K, Okawaki M, Okita R, Matsuura K, Ohshita A, Toge T: HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab. Anticancer Res. 2005 Mar-Apr;25(2A):827-32. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15868915\n# Xie Z, Guo N, Yu M, Hu M, Shen B: A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis. J Immunol Methods. 2005 Jan;296(1-2):95-101. Epub 2004 Nov 19. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15680154", "known-action": "unknown", "polypeptide": {"@id": "O75015", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "general-function": null, "specific-function": "Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils", "gene-name": "FCGR3B", "locus": "1q23", "cellular-location": "Cell membrane; lipid-anchor; GPI-anchor. Secreted protein. Note=Secreted after cleavage", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.71", "molecular-weight": "26216.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3620"}, {"resource": "GenAtlas", "identifier": "FCGR3B"}, {"resource": "GeneCards", "identifier": "FCGR3B"}, {"resource": "GenBank Gene Database", "identifier": "X16863"}, {"resource": "GenBank Protein Database", "identifier": "31322"}, {"resource": "UniProtKB", "identifier": "O75015"}, {"resource": "UniProt Accession", "identifier": "FCG3B_HUMAN"}]}, "synonyms": {"synonym": ["CD16b antigen", "Fc-gamma RIII", "Fc-gamma RIII-beta", "Fc-gamma RIIIb", "FcR-10", "FcRIII", "FcRIIIb", "IgG Fc receptor III-1", "Low affinity immunoglobulin gamma Fc region receptor III-B precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-B precursor\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI"}, "gene-sequence": {"@format": "FASTA", "#text": ">702 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "13", "id": "BE0002097", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "organism": "Human", "actions": null, "references": "# Suzuki E, Niwa R, Saji S, Muta M, Hirose M, Iida S, Shiotsu Y, Satoh M, Shitara K, Kondo M, Toi M: A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. Clin Cancer Res. 2007 Mar 15;13(6):1875-82. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17363544", "known-action": "unknown", "polypeptide": {"@id": "P08637", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "general-function": null, "specific-function": "Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis", "gene-name": "FCGR3A", "locus": "1q23", "cellular-location": "Cell membrane", "transmembrane-regions": "209-229", "signal-regions": null, "theoretical-pi": "8.21", "molecular-weight": "29089.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3619"}, {"resource": "GenAtlas", "identifier": "FCGR3A"}, {"resource": "GeneCards", "identifier": "FCGR3A"}, {"resource": "GenBank Gene Database", "identifier": "X52645"}, {"resource": "GenBank Protein Database", "identifier": "31324"}, {"resource": "UniProtKB", "identifier": "P08637"}, {"resource": "UniProt Accession", "identifier": "FCG3A_HUMAN"}]}, "synonyms": {"synonym": ["CD16a antigen", "Fc-gamma RIII", "Fc-gamma RIII-alpha", "Fc-gamma RIIIa", "FcR-10", "FcRIII", "FcRIIIa", "IgG Fc receptor III-2", "Low affinity immunoglobulin gamma Fc region receptor III-A precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK"}, "gene-sequence": {"@format": "FASTA", "#text": ">765 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCGACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCA\nAAAGCCACACTCAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTTTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGG\nAAGGACCATAAATTTAAATGGAGAAAGGACCCTCAAGACAAATGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}]}, "enzymes": {"enzyme": {"@position": "14", "id": "BE0002090", "name": "Cytochrome P450 19A1", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19934256", "known-action": "unknown", "polypeptide": {"@id": "P11511", "@source": "Swiss-Prot", "name": "Cytochrome P450 19A1", "general-function": "Secondary metabolites biosynthesis, transport and catabolism", "specific-function": "Catalyzes the formation of aromatic C18 estrogens from C19 androgens", "gene-name": "CYP19A1", "locus": "15q21.1", "cellular-location": "Membrane; peripheral membrane protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.56", "molecular-weight": "57884.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2594"}, {"resource": "GenAtlas", "identifier": "CYP19A1"}, {"resource": "GeneCards", "identifier": "CYP19A1"}, {"resource": "GenBank Gene Database", "identifier": "M22246"}, {"resource": "GenBank Protein Database", "identifier": "179002"}, {"resource": "UniProtKB", "identifier": "P11511"}, {"resource": "UniProt Accession", "identifier": "CP19A_HUMAN"}]}, "synonyms": {"synonym": ["Aromatase", "CYPXIX", "EC 1.14.14.1", "Estrogen synthetase", "P-450AROM"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytochrome P450 19A1\nMVLEMLNPIHYNITSIVPEAMPAATMPVLLLTGLFLLVWNYEGTSSIPGPGYCMGIGPLI\nSHGRFLWMGIGSACNYYNRVYGEFMRVWISGEETLIISKSSSMFHIMKHNHYSSRFGSKL\nGLQCIGMHEKGIIFNNNPELWKTTRPFFMKALSGPGLVRMVTVCAESLKTHLDRLEEVTN\nESGYVDVLTLLRRVMLDTSNTLFLRIPLDESAIVVKIQGYFDAWQALLIKPDIFFKISWL\nYKKYEKSVKDLKDAIEVLIAEKRRRISTEEKLEECMDFATELILAEKRGDLTRENVNQCI\nLEMLIAAPDTMSVSLFFMLFLIAKHPNVEEAIIKEIQTVIGERDIKIDDIQKLKVMENFI\nYESMRYQPVVDLVMRKALEDDVIDGYPVKKGTNIILNIGRMHRLEFFPKPNEFTLENFAK\nNVPYRYFQPFGFGPRGCAGKYIAMVMMKAILVTLLRRFHVKTLQGQCVESIQKIHDLSLH\nPDETKNMLEMIFTPRNSDRCLEH"}, "gene-sequence": {"@format": "FASTA", "#text": ">1512 bp\nATGGTTTTGGAAATGCTGAACCCGATACATTATAACATCACCAGCATCGTGCCTGAAGCC\nATGCCTGCTGCCACCATGCCAGTCCTGCTCCTCACTGGCCTTTTTCTCTTGGTGTGGAAT\nTATGAGGGCACATCCTCAATACCAGGTCCTGGCTACTGCATGGGAATTGGACCCCTCATC\nTCCCACGGCAGATTCCTGTGGATGGGGATCGGCAGTGCCTGCAACTACTACAACCGGGTA\nTATGGAGAATTCATGCGAGTCTGGATCTCTGGAGAGGAAACACTCATTATCAGCAAGTCC\nTCAAGTATGTTCCACATAATGAAGCACAATCATTACAGCTCTCGATTCGGCAGCAAACTT\nGGGCTGCAGTGCATCGGTATGCATGAGAAAGGCATCATATTTAACAACAATCCAGAGCTC\nTGGAAAACAACTCGACCCTTCTTTATGAAAGCTCTGTCAGGCCCCGGCCTTGTTCGTATG\nGTCACAGTCTGTGCTGAATCCCTCAAAACACATCTGGACAGGTTGGAGGAGGTGACCAAT\nGAATCGGGCTATGTGGACGTGTTGACCCTTCTGCGTCGTGTCATGCTGGACACCTCTAAC\nACGCTCTTCTTGAGGATCCCTTTGGACGAAAGTGCTATCGTGGTTAAAATCCAAGGTTAT\nTTTGATGCATGGCAAGCTCTCCTCATCAAACCAGACATCTTCTTTAAGATTTCTTGGCTA\nTACAAAAAGTATGAGAAGTCTGTCAAGGATTTGAAAGATGCCATAGAAGTTCTGATAGCA\nGAAAAAAGACGCAGGATTTCCACAGAAGAGAAACTGGAAGAATGTATGGACTTTGCCACT\nGAGTTGATTTTAGCAGAGAAACGTGGTGACCTGACAAGAGAGAATGTGAACCAGTGCATA\nTTGGAAATGCTGATCGCAGCTCCTGACACCATGTCTGTCTCTTTGTTCTTCATGCTATTT\nCTCATTGCAAAGCACCCTAATGTTGAAGAGGCAATAATAAAGGAAATCCAGACTGTTATT\nGGTGAGAGAGACATAAAGATTGATGATATACAAAAATTAAAAGTGATGGAAAACTTCATT\nTATGAGAGCATGCGGTACCAGCCTGTCGTGGACTTGGTCATGCGCAAAGCCTTAGAAGAT\nGATGTAATCGATGGCTACCCAGTGAAAAAGGGGACAAACATTATCCTGAATATTGGAAGG\nATGCACAGACTCGAGTTTTTCCCCAAACCCAATGAATTTACTCTTGAAAATTTTGCAAAG\nAATGTTCCTTATAGGTACTTTCAGCCATTTGGCTTTGGGCCCCGTGGCTGTGCAGGAAAG\nTACATCGCCATGGTGATGATGAAAGCCATCCTCGTTACACTTCTGAGACGATTCCACGTG\nAAGACATTGCAAGGACAGTGTGTTGAGAGCATACAGAAGATACACGACTTGTCCTTGCAC\nCCAGATGAGACTAAAAACATGCTGGAAATGATCTTTACCCCAAGAAGCTCAGACAGGTGT\nCTGGAACACTAG"}, "pfams": {"pfam": {"identifier": "PF00067", "name": "p450"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "iron ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "tetrapyrrole binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "heme binding"}, {"category": "function", "description": "monooxygenase activity"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "generation of precursor metabolites and energy"}, {"category": "process", "description": "electron transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}}, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-01-31", "drugbank-id": [{"@primary": "true", "#text": "DB00073"}, "BIOD00014", "BTD00014"], "name": "Rituximab", "description": "Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids", "cas-number": "174722-31-7", "groups": {"group": "approved"}, "general-references": "# McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9704735\n# Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004 Jun 17;350(25):2572-81. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15201414\n# Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC: Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol. 2005 Apr;78(4):275-80. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15795920\n# Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M: The epitope recognized by rituximab. Blood. 2006 Sep 15;108(6):1975-8. Epub 2006 May 16. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16705086\n# Burton C, Kaczmarski R, Jan-Mohamed R: Interstitial pneumonitis related to rituximab therapy. N Engl J Med. 2003 Jun 26;348(26):2690-1; discussion 2690-1. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12826649\n# http://www.google.com/patents/EP2231183A2?cl=en\n# http://planetorbitrap.com/data/uploads/528fce2e395be.pdf", "synthesis-reference": null, "indication": "For treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.", "pharmacodynamics": "Rituximab binds to the CD20 antigen, which is predominantly expressed on mature B cells and on >90% of B-cell\nnon-Hodgkin's lympohomas. The antibody leads to selective killing of B-cells.", "mechanism-of-action": "The Fab regions of rituximab binds to the CD20 antigen on B lymphocytes, while the Fc domain recruits antibodies and complements to mediate cell lysis.", "toxicity": null, "metabolism": "Most likely removed by opsonization via the reticuloendothelial system when bound to B lymphocytes, or by human antimurine antibody production", "absorption": null, "half-life": "0.8 hours (mammalian reticulocytes, in vitro)", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": "* 3.1 L", "clearance": "* 0.34 L/day [RA patients]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "AntiCD20"}, {"@language": "", "@coder": "", "#text": "Ig gamma-1 chain C region"}]}, "products": {"product": [{"name": "Rituxan", "ndc-id": "50242-051_c909e297-c14a-4c71-bc5d-9c3ee815de15", "ndc-product-code": "50242-051", "dpd-id": null, "started-marketing-on": "1997-11-26", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "10 mg/mL", "route": "intravenous", "fda-application-number": "BLA103705", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Rituxan", "ndc-id": "50242-053_c909e297-c14a-4c71-bc5d-9c3ee815de15", "ndc-product-code": "50242-053", "dpd-id": null, "started-marketing-on": "1997-11-26", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "10 mg/mL", "route": "intravenous", "fda-application-number": "BLA103705", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Rituxan", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02241927", "started-marketing-on": "2000-03-20", "ended-marketing-on": null, "dosage-form": "solution", "strength": "10 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": {"name": "MabThera", "company": "Roche"}}, "mixtures": {"mixture": [{"name": "Rituxan", "ingredients": "Rituximab"}, {"name": "Rituxan", "ingredients": "Rituximab"}, {"name": "Rituxan", "ingredients": "Rituximab"}]}, "packagers": {"packager": [{"name": "Biogen Idec Inc.", "url": "http://www.biogenidec.com"}, {"name": "F Hoffmann-La Roche Ltd.", "url": "http://www.roche.com"}, {"name": "Genentech Inc.", "url": "http://www.gene.com"}]}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Roche"}}, "prices": {"price": [{"description": "Rituxan 10 mg/ml vial", "cost": {"@currency": "USD", "#text": "68.09"}, "unit": "ml"}, {"description": "Rituxan 10 mg/ml Concentrate 10ml Vial", "cost": {"@currency": "USD", "#text": "708.17"}, "unit": "vial"}]}, "categories": {"category": [{"category": "Antineoplastic Agents", "mesh-id": null}, {"category": "Immunologic Factors", "mesh-id": null}, {"category": "Antirheumatic Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, solution", "route": "intravenous", "strength": "10 mg/mL"}, {"form": "Solution", "route": "intravenous", "strength": "10 mg"}]}, "atc-codes": {"atc-code": {"@code": "L01XC02", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L01", "#text": "ANTINEOPLASTIC AGENTS"}, {"@code": "L01X", "#text": "OTHER ANTINEOPLASTIC AGENTS"}, {"@code": "L01XC", "#text": "Monoclonal antibodies"}]}}, "ahfs-codes": {"ahfs-code": "10:00.00"}, "patents": {"patent": [{"number": "1336826", "country": "Canada", "approved": "1995-08-29", "expires": "2012-08-29"}, {"number": "2149329", "country": "Canada", "approved": "2008-07-15", "expires": "2013-11-12"}, {"number": "5736137", "country": "United States", "approved": "1998-04-07", "expires": "2015-04-07"}]}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB01281", "name": "Abatacept", "description": "Rituximab may enhance the adverse/toxic effect of Abatacept."}, {"drugbank-id": "DB01193", "name": "Acebutolol", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB09026", "name": "Aliskiren", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00594", "name": "Amiloride", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00381", "name": "Amlodipine", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00335", "name": "Atenolol", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB08822", "name": "Azilsartan medoxomil", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB08879", "name": "Belimumab", "description": "Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab."}, {"drugbank-id": "DB00542", "name": "Benazepril", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00436", "name": "Bendroflumethiazide", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00195", "name": "Betaxolol", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00612", "name": "Bisoprolol", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00887", "name": "Bumetanide", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00796", "name": "Candesartan", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB01197", "name": "Captopril", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB01136", "name": "Carvedilol", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB08904", "name": "Certolizumab pegol", "description": "Rituximab may enhance the immunosuppressive effect of Certolizumab pegol."}, {"drugbank-id": "DB00880", "name": "Chlorothiazide", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00310", "name": "Chlorthalidone", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB01340", "name": "Cilazapril", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB04920", "name": "Clevidipine", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00575", "name": "Clonidine", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00363", "name": "Clozapine", "description": "Myelosuppressive Agents may enhance the adverse/toxic effect of Clozapine. Specifically, the risk for agranulocytosis may be increased."}, {"drugbank-id": "DB06643", "name": "Denosumab", "description": "May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased."}, {"drugbank-id": "DB00343", "name": "Diltiazem", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00590", "name": "Doxazosin", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00584", "name": "Enalapril", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00700", "name": "Eplerenone", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00876", "name": "Eprosartan", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00187", "name": "Esmolol", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00903", "name": "Ethacrynic acid", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB01023", "name": "Felodipine", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00492", "name": "Fosinopril", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00695", "name": "Furosemide", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB01018", "name": "Guanfacine", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB01275", "name": "Hydralazine", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00999", "name": "Hydrochlorothiazide", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00808", "name": "Indapamide", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB01029", "name": "Irbesartan", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00270", "name": "Isradipine", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00598", "name": "Labetalol", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB01097", "name": "Leflunomide", "description": "Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased."}, {"drugbank-id": "DB00722", "name": "Lisinopril", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00678", "name": "Losartan", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00742", "name": "Mannitol", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00657", "name": "Mecamylamine", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB04817", "name": "Metamizole", "description": "May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased"}, {"drugbank-id": "DB00232", "name": "Methyclothiazide", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00968", "name": "Methyldopa", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00524", "name": "Metolazone", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00264", "name": "Metoprolol", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00350", "name": "Minoxidil", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00691", "name": "Moexipril", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB01203", "name": "Nadolol", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00108", "name": "Natalizumab", "description": "Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased."}, {"drugbank-id": "DB04861", "name": "Nebivolol", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00622", "name": "Nicardipine", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB01115", "name": "Nifedipine", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00393", "name": "Nimodipine", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00401", "name": "Nisoldipine", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00325", "name": "Nitroprusside", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00275", "name": "Olmesartan", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB01359", "name": "Penbutolol", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00790", "name": "Perindopril", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00925", "name": "Phenoxybenzamine", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00692", "name": "Phentolamine", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00337", "name": "Pimecrolimus", "description": "May enhance the adverse/toxic effect of Immunosuppressants."}, {"drugbank-id": "DB00960", "name": "Pindolol", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00457", "name": "Prazosin", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00571", "name": "Propranolol", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00881", "name": "Quinapril", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00178", "name": "Ramipril", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00206", "name": "Reserpine", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB01656", "name": "Roflumilast", "description": "May enhance the immunosuppressive effect of Immunosuppressants."}, {"drugbank-id": "DB06688", "name": "Sipuleucel-T", "description": "Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T."}, {"drugbank-id": "DB00489", "name": "Sotalol", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00421", "name": "Spironolactone", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00966", "name": "Telmisartan", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB01162", "name": "Terazosin", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00373", "name": "Timolol", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB08895", "name": "Tofacitinib", "description": "Rituximab may enhance the adverse/toxic effect of Tofacitinib."}, {"drugbank-id": "DB00214", "name": "Torasemide", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00519", "name": "Trandolapril", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00072", "name": "Trastuzumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00384", "name": "Triamterene", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00177", "name": "Valsartan", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}, {"drugbank-id": "DB00661", "name": "Verapamil", "description": "Antihypertensives may enhance the hypotensive effect of Rituximab."}]}, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">Rituximab heavy chain chimeric\nQVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSY\nNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVS\nAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS\nSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLG\nGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY\nNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD\nELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR\nWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK"}, {"@format": "FASTA", "#text": ">Rituximab light chain chimeric\nQIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVR\nFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKRTVAAPSVFIFPPS\nDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL\nSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "61 \u00b0C (FAB fragment), 71 \u00b0C (whole mAb)", "source": "Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)"}, {"kind": "Hydrophobicity", "value": "-0.414", "source": null}, {"kind": "Isoelectric Point", "value": "8.68", "source": null}, {"kind": "Molecular Weight", "value": "143859.7000", "source": null}, {"kind": "Molecular Formula", "value": "C6416H9874N1688O1987S44", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "11982"}, {"resource": "National Drug Code Directory", "identifier": "50242-053-06"}, {"resource": "GenBank", "identifier": "J00228"}, {"resource": "PharmGKB", "identifier": "PA451261"}, {"resource": "UniProtKB", "identifier": "P01857"}, {"resource": "Wikipedia", "identifier": "Rituximab"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/ritux.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/rituximab.html"}]}, "pathways": null, "reactions": null, "snp-effects": {"effect": {"protein-name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "gene-symbol": "FCGR3A", "uniprot-id": "P08637", "rs-id": "rs396991", "allele": null, "defining-change": "A > C", "description": "Better response to drug therapy (compared to allele A)", "pubmed-id": "16609067"}}, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000066", "name": "B-lymphocyte antigen CD20", "organism": "Human", "actions": {"action": "antibody"}, "references": "# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352\n# van Meerten T, Hagenbeek A: CD20-targeted therapy: the next generation of antibodies. Semin Hematol. 2010 Apr;47(2):199-210. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20350667\n# Jaglowski SM, Byrd JC: Rituximab in chronic lymphocytic leukemia. Semin Hematol. 2010 Apr;47(2):156-69. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20350663", "known-action": "yes", "polypeptide": {"@id": "P11836", "@source": "Swiss-Prot", "name": "B-lymphocyte antigen CD20", "general-function": "Involved in immune function and regulation", "specific-function": "This protein may be involved in the regulation of B-cell activation and proliferation", "gene-name": "MS4A1", "locus": "11q12", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "64-84\n85-105\n121-141\n189-209", "signal-regions": null, "theoretical-pi": "4.73", "molecular-weight": "33078.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:7315"}, {"resource": "GenAtlas", "identifier": "MS4A1"}, {"resource": "GeneCards", "identifier": "MS4A1"}, {"resource": "GenBank Gene Database", "identifier": "X12530"}, {"resource": "GenBank Protein Database", "identifier": "29774"}, {"resource": "UniProtKB", "identifier": "P11836"}, {"resource": "UniProt Accession", "identifier": "CD20_HUMAN"}]}, "synonyms": {"synonym": ["B-lymphocyte surface antigen B1", "Bp35", "Leu-16", "Membrane-spanning 4-domains subfamily A member 1"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">B-lymphocyte antigen CD20\nMTTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRRMSSLVGPTQSFFMRESKTLGAVQIMNG\nLFHIALGGLLMIPAGIYAPICVTVWYPLWGGIMYIISGSLLAATEKNSRKCLVKGKMIMN\nSLSLFAAISGMILSIMDILNIKISHFLKMESLNFIRAHTPYINIYNCEPANPSEKNSPST\nQYCYSIQSLFLGILSVMLIFAFFQELVIAGIVENEWKRTCSRPKSNIVLLSAEEKKEQTI\nEIKEEVVGLTETSSQPKNEEDIEIIPIQEEEEEETETNFPEPPQDQESSPIENDSSP"}, "gene-sequence": {"@format": "FASTA", "#text": ">894 bp\nATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCT\nATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCC\nACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGG\nCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATC\nTGTGTGACTGTGTGGTACCCTCTCTGGGGAGGCATTATGTATATTATTTCCGGATCACTC\nCTGGCAGCAACGGAGAAAAACTCCAGGAAGTGTTTGGTCAAAGGAAAAATGATAATGAAT\nTCATTGAGCCTCTTTGCTGCCATTTCTGGAATGATTCTTTCAATCATGGACATACTTAAT\nATTAAAATTTCCCATTTTTTAAAAATGGAGAGTCTGAATTTTATTAGAGCTCACACACCA\nTATATTAACATATACAACTGTGAACCAGCTAATCCCTCTGAGAAAAACTCCCCATCTACC\nCAATACTGTTACAGCATACAATCTCTGTTCTTGGGCATTTTGTCAGTGATGCTGATCTTT\nGCCTTCTTCCAGGAACTTGTAATAGCTGGCATCGTTGAGAATGAATGGAAAAGAACGTGC\nTCCAGACCCAAATCTAACATAGTTCTCCTGTCAGCAGAAGAAAAAAAAGAACAGACTATT\nGAAATAAAAGAAGAAGTGGTTGGGCTAACTGAAACATCTTCCCAACCAAAGAATGAAGAA\nGACATTGAAATTATTCCAATCCAAGAAGAGGAAGAAGAAGAAACAGAGACGAACTTTCCA\nGAACCTCCCCAAGATCAGGAATCCTCACCAATAGAAAATGACAGCTCTCCTTAA"}, "pfams": {"pfam": {"identifier": "PF04103", "name": "CD20"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}]}}}, {"id": "BE0000901", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "organism": "Human", "actions": null, "references": "# Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, Maloney DG, Fox EA: Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol. 2005 Jan 20;23(3):474-81. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15659493\n# Bowles JA, Weiner GJ: CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods. 2005 Sep;304(1-2):88-99. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16109421\n# Bowles JA, Wang SY, Link BK, Allan B, Beuerlein G, Campbell MA, Marquis D, Ondek B, Wooldridge JE, Smith BJ, Breitmeyer JB, Weiner GJ: Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood. 2006 Oct 15;108(8):2648-54. Epub 2006 Jul 6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16825493\n# Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, Dimmock EA, Kortsaris A, Mitsiades C, Anderson KC, Fox EA, Treon SP: Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood. 2007 Oct 1;110(7):2561-4. Epub 2007 May 2. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17475906", "known-action": "unknown", "polypeptide": {"@id": "O75015", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "general-function": null, "specific-function": "Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils", "gene-name": "FCGR3B", "locus": "1q23", "cellular-location": "Cell membrane; lipid-anchor; GPI-anchor. Secreted protein. Note=Secreted after cleavage", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.71", "molecular-weight": "26216.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3620"}, {"resource": "GenAtlas", "identifier": "FCGR3B"}, {"resource": "GeneCards", "identifier": "FCGR3B"}, {"resource": "GenBank Gene Database", "identifier": "X16863"}, {"resource": "GenBank Protein Database", "identifier": "31322"}, {"resource": "UniProtKB", "identifier": "O75015"}, {"resource": "UniProt Accession", "identifier": "FCG3B_HUMAN"}]}, "synonyms": {"synonym": ["CD16b antigen", "Fc-gamma RIII", "Fc-gamma RIII-beta", "Fc-gamma RIIIb", "FcR-10", "FcRIII", "FcRIIIb", "IgG Fc receptor III-1", "Low affinity immunoglobulin gamma Fc region receptor III-B precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-B precursor\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI"}, "gene-sequence": {"@format": "FASTA", "#text": ">702 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"id": "BE0002093", "name": "Complement C1r subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P00736", "@source": "Swiss-Prot", "name": "Complement C1r subcomponent", "general-function": null, "specific-function": "C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system", "gene-name": "C1R", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.24", "molecular-weight": "80174.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1246"}, {"resource": "GenAtlas", "identifier": "C1R"}, {"resource": "GeneCards", "identifier": "C1R"}, {"resource": "GenBank Gene Database", "identifier": "X04701"}, {"resource": "GenBank Protein Database", "identifier": "29539"}, {"resource": "UniProtKB", "identifier": "P00736"}, {"resource": "UniProt Accession", "identifier": "C1R_HUMAN"}]}, "synonyms": {"synonym": ["Complement C1r subcomponent precursor", "Complement component 1, r subcomponent", "EC 3.4.21.41"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1r subcomponent\nMWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF\nQQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF\nSNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY\nELQEDRHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF\nDIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL\nRYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD\nDGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR\nESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF\nTNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV\nSVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME\nEKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV\nRDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2118 bp\nATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC\nATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC\nAACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC\nCAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT\nGATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG\nGGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC\nTCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT\nGTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG\nTGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT\nGAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG\nGCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC\nAACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT\nGATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC\nGGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC\nAATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG\nCGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC\nATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA\nGGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT\nGATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA\nAACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC\nCGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG\nGAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG\nGGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG\nAGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC\nACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT\nGCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC\nCTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC\nAGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG\nCTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC\nAACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG\nGAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT\nGAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT\nGGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA\nAGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC\nAGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG\nATGGAGGAGGAGGACTGA"}, "pfams": {"pfam": [{"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF07645", "name": "EGF_CA"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"id": "BE0002094", "name": "Complement C1q subcomponent subunit A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, Botto M, Introna M, Golay J: Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol. 2003 Aug 1;171(3):1581-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12874252", "known-action": "unknown", "polypeptide": {"@id": "P02745", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit A", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QA", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.45", "molecular-weight": "26017.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1241"}, {"resource": "GenAtlas", "identifier": "C1QA"}, {"resource": "GeneCards", "identifier": "C1QA"}, {"resource": "GenBank Gene Database", "identifier": "AF135157"}, {"resource": "GenBank Protein Database", "identifier": "4894854"}, {"resource": "UniProtKB", "identifier": "P02745"}, {"resource": "UniProt Accession", "identifier": "C1QA_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit A precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit A\nMEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR\nTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI\nRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR\nGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL\nIFPSA"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG\nGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC\nAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG\nACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC\nAAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGGGCCCGTGGCATCCCGGGAATTAAA\nGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT\nCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG\nGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC\nTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG\nGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG\nGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC\nCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC\nATCTTCCCATCTGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"id": "BE0002095", "name": "Complement C1q subcomponent subunit B", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02746", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit B", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QB", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.87", "molecular-weight": "26460.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1242"}, {"resource": "GenAtlas", "identifier": "C1QB"}, {"resource": "GeneCards", "identifier": "C1QB"}, {"resource": "GenBank Gene Database", "identifier": "X03084"}, {"resource": "GenBank Protein Database", "identifier": "573114"}, {"resource": "UniProtKB", "identifier": "P02746"}, {"resource": "UniProt Accession", "identifier": "C1QB_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit B precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit B\nMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEK\nGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKI\nAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCV\nNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANSIF\nSGFLLFPDMEA"}, "gene-sequence": {"@format": "FASTA", "#text": ">688 bp\nCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGG\nGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCC\nAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAA\nTCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGCCCAGGGGCCCCTGG\nAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAGAAAATCGCCTTCTC\nTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATCCGCTTCGACCACGT\nGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTCACCTGCAAGGTGCC\nCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTGTGCGTGAACCTCAT\nGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTATGCCTACAACACCTT\nCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAGAACGTCTTCCTGCA\nGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGCATCTTTTCCGGGTT\nCCTGCTCTTTCCAGATATGGAGGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"id": "BE0002096", "name": "Complement C1q subcomponent subunit C", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02747", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit C", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QC", "locus": "1p36.11", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.58", "molecular-weight": "25774.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1245"}, {"resource": "GenAtlas", "identifier": "C1QC"}, {"resource": "GeneCards", "identifier": "C1QC"}, {"resource": "GenBank Gene Database", "identifier": "AF087892"}, {"resource": "GenBank Protein Database", "identifier": "33150626"}, {"resource": "UniProtKB", "identifier": "P02747"}, {"resource": "UniProt Accession", "identifier": "C1QC_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit C precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit C\nMDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP\nGIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS\nVFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV\nLLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF\nLLFPD"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG\nCTGCTGCCCCTCAGGGCCAAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC\nCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA\nGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA\nCCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC\nCCCATGGGATTCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA\nGTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC\nAACGCGGTCCTCACCAACCCGCAGGAGGATTATGACACGAGCACTGGCAAGTTCACCTGC\nAAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG\nCTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT\nCAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT\nGTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC\nCTGCTCTTCCCCGACTAG"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"id": "BE0002097", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "organism": "Human", "actions": null, "references": "# Niwa R, Hatanaka S, Shoji-Hosaka E, Sakurada M, Kobayashi Y, Uehara A, Yokoi H, Nakamura K, Shitara K: Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6248-55. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15448014\n# Hatjiharissi E, Hansen M, Santos DD, Xu L, Leleu X, Dimmock EW, Ho AW, Hunter ZR, Branagan AR, Patterson CJ, Kortsaris A, Verselis S, Fox E, Treon SP: Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma. 2007 Jan;7(4):286-90. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17324336\n# Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Kim MK, Hyun MS, Sohn SK: FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 2006 Oct 15;108(8):2720-5. Epub 2006 Apr 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16609067", "known-action": "unknown", "polypeptide": {"@id": "P08637", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "general-function": null, "specific-function": "Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis", "gene-name": "FCGR3A", "locus": "1q23", "cellular-location": "Cell membrane", "transmembrane-regions": "209-229", "signal-regions": null, "theoretical-pi": "8.21", "molecular-weight": "29089.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3619"}, {"resource": "GenAtlas", "identifier": "FCGR3A"}, {"resource": "GeneCards", "identifier": "FCGR3A"}, {"resource": "GenBank Gene Database", "identifier": "X52645"}, {"resource": "GenBank Protein Database", "identifier": "31324"}, {"resource": "UniProtKB", "identifier": "P08637"}, {"resource": "UniProt Accession", "identifier": "FCG3A_HUMAN"}]}, "synonyms": {"synonym": ["CD16a antigen", "Fc-gamma RIII", "Fc-gamma RIII-alpha", "Fc-gamma RIIIa", "FcR-10", "FcRIII", "FcRIIIa", "IgG Fc receptor III-2", "Low affinity immunoglobulin gamma Fc region receptor III-A precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK"}, "gene-sequence": {"@format": "FASTA", "#text": ">765 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCGACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCA\nAAAGCCACACTCAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTTTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGG\nAAGGACCATAAATTTAAATGGAGAAAGGACCCTCAAGACAAATGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"id": "BE0001529", "name": "Complement C1s subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P09871", "@source": "Swiss-Prot", "name": "Complement C1s subcomponent", "general-function": "Involved in calcium ion binding", "specific-function": "C1s B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4", "gene-name": "C1S", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "4.59", "molecular-weight": "76685.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1247"}, {"resource": "GenAtlas", "identifier": "C1S"}, {"resource": "GeneCards", "identifier": "C1S"}, {"resource": "GenBank Gene Database", "identifier": "X06596"}, {"resource": "GenBank Protein Database", "identifier": "763110"}, {"resource": "UniProtKB", "identifier": "P09871"}, {"resource": "UniProt Accession", "identifier": "C1S_HUMAN"}]}, "synonyms": {"synonym": ["C1 esterase", "Complement C1s subcomponent precursor", "EC 3.4.21.42"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1s subcomponent precursor\nMWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIE\nLSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERF\nTGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVF\nTALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVF\nVAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTP\nNSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCG\nIPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPK\nCVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGN\nREPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVK\nMGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKV\nEKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCG\nTYGLYTRVKNYVDWIMKTMQENSTPRED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2067 bp\nATGTGGTGCATTGTCCTGTTTTCACTTTTGGCATGGGTTTATGCTGAGCCTACCATGTAT\nGGGGAGATCCTGTCCCCTAACTATCCTCAGGCATATCCCAGTGAGGTAGAGAAATCTTGG\nGACATAGAAGTTCCTGAAGGGTATGGGATTCACCTCTACTTCACCCATCTGGACATTGAG\nCTGTCAGAGAACTGTGCGTATGACTCAGTGCAGATAATCTCAGGAGACACTGAAGAAGGG\nAGGCTCTGTGGACAGAGGAGCAGTAACAATCCCCACTCTCCAATTGTGGAAGAGTTCCAA\nGTCCCATACAACAAACTCCAGGTGATCTTTAAGTCAGACTTTTCCAATGAAGAGCGTTTT\nACGGGGTTTGCTGCATACTATGTTGCCACAGACATAAATGAATGCACAGATTTTGTAGAT\nGTCCCTTGTAGCCACTTCTGCAACAATTTCATTGGTGGTTACTTCTGCTCCTGCCCCCCG\nGAATATTTCCTCCATGATGACATGAAGAATTGCGGAGTTAATTGCAGTGGGGATGTATTC\nACTGCACTGATTGGGGAGATTGCAAGTCCCAATTATCCCAAACCATATCCAGAGAACTCA\nAGGTGTGAATACCAGATCCGGTTGGAGAAAGGGTTCCAAGTGGTGGTGACCTTGCGGAGA\nGAAGATTTTGATGTGGAAGCAGCTGACTCAGCGGGAAACTGCCTTGACAGTTTAGTTTTT\nGTTGCAGGAGATCGGCAATTTGGTCCTTACTGTGGTCATGGATTCCCTGGGCCTCTAAAT\nATTGAAACCAAGAGTAATGCTCTTGATATCATCTTCCAAACTGATCTAACAGGGCAAAAA\nAAGGGCTGGAAACTTCGCTATCATGGAGATCCAATGCCCTGCCCTAAGGAAGACACTCCC\nAATTCTGTTTGGGAGCCTGCGAAGGCAAAATATGTCTTTAGAGATGTGGTGCAGATAACC\nTGTCTGGATGGGTTTGAAGTTGTGGAGGGACGTGTTGGTGCAACATCTTTCTATTCGACT\nTGTCAAAGCAATGGAAAGTGGAGTAATTCCAAACTGAAATGTCAACCTGTGGACTGTGGC\nATTCCTGAATCCATTGAGAATGGTAAAGTTGAAGACCCAGAGAGCACTTTGTTTGGTTCT\nGTCATCCGCTACACTTGTGAGGAGCCATATTACTACATGGAAAATGGAGGAGGTGGGGAG\nTATCACTGTGCTGGTAACGGGAGCTGGGTGAATGAGGTGCTGGGCCCGGAGCTGCCGAAA\nTGTGTTCCAGTCTGTGGAGTCCCCAGAGAACCCTTTGAAGAAAAACAGAGGATAATTGGA\nGGATCCGATGCAGATATTAAAAACTTCCCCTGGCAAGTCTTCTTTGACAACCCATGGGCT\nGGTGGAGCGCTCATTAATGAGTACTGGGTGCTGACGGCTGCTCATGTTGTGGAGGGAAAC\nAGGGAGCCAACAATGTATGTTGGGTCCACCTCAGTGCAGACCTCACGGCTGGCAAAATCC\nAAGATGCTCACTCCTGAGCATGTGTTTATTCATCCGGGATGGAAGCTGCTGGAAGTCCCA\nGAAGGACGAACCAATTTTGATAATGACATTGCACTGGTGCGGCTGAAAGACCCAGTGAAA\nATGGGACCCACCGTCTCTCCCATCTGCCTACCAGGCACCTCTTCCGACTACAACCTCATG\nGATGGGGACCTGGGACTGATCTCAGGCTGGGGCCGAACAGAGAAGAGAGATCGTGCTGTT\nCGCCTCAAGGCGGCAAGGTTACCTGTAGCTCCTTTAAGAAAATGCAAAGAAGTGAAAGTG\nGAGAAACCCACAGCAGATGCAGAGGCCTATGTTTTCACTCCTAACATGATCTGTGCTGGA\nGGAGAGAAGGGCATGGATAGCTGTAAAGGGGACAGTGGTGGGGCCTTTGCTGTACAGGAT\nCCCAATGACAAGACCAAATTCTACGCAGCTGGCCTGGTGTCCTGGGGGCCCCAGTGTGGG\nACCTATGGGCTCTACACACGGGTAAAGAACTATGTTGACTGGATAATGAAGACTATGCAG\nGAAAATAGCACCCCCCGTGAGGACTAA"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"id": "BE0000710", "name": "High affinity immunoglobulin gamma Fc receptor I", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P12314", "@source": "Swiss-Prot", "name": "High affinity immunoglobulin gamma Fc receptor I", "general-function": "Involved in receptor signaling protein activity", "specific-function": "Binds to the Fc region of immunoglobulins gamma. High affinity receptor", "gene-name": "FCGR1A", "locus": "1q21.2-q21.3", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "293-313", "signal-regions": null, "theoretical-pi": "8.08", "molecular-weight": "42632.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3613"}, {"resource": "GenAtlas", "identifier": "FCGR1A"}, {"resource": "GeneCards", "identifier": "FCGR1A"}, {"resource": "GenBank Gene Database", "identifier": "X14356"}, {"resource": "GenBank Protein Database", "identifier": "31332"}, {"resource": "UniProtKB", "identifier": "P12314"}, {"resource": "UniProt Accession", "identifier": "FCGR1_HUMAN"}]}, "synonyms": {"synonym": ["CD64 antigen", "Fc-gamma RI", "FcRI", "High affinity immunoglobulin gamma Fc receptor I precursor", "IgG Fc receptor I"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">High affinity immunoglobulin gamma Fc receptor I precursor\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1125 bp\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCTCTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAACTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"id": "BE0002098", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "organism": "Human", "actions": null, "references": "# Hatjiharissi E, Hansen M, Santos DD, Xu L, Leleu X, Dimmock EW, Ho AW, Hunter ZR, Branagan AR, Patterson CJ, Kortsaris A, Verselis S, Fox E, Treon SP: Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma. 2007 Jan;7(4):286-90. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17324336\n# Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Kim MK, Hyun MS, Sohn SK: FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 2006 Oct 15;108(8):2720-5. Epub 2006 Apr 11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16609067", "known-action": "unknown", "polypeptide": {"@id": "P12318", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "general-function": null, "specific-function": "Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens", "gene-name": "FCGR2A", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.78", "molecular-weight": "34990.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3616"}, {"resource": "GenAtlas", "identifier": "FCGR2A"}, {"resource": "GeneCards", "identifier": "FCGR2A"}, {"resource": "GenBank Gene Database", "identifier": "M31932"}, {"resource": "GenBank Protein Database", "identifier": "182474"}, {"resource": "UniProtKB", "identifier": "P12318"}, {"resource": "UniProt Accession", "identifier": "FCG2A_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-a", "Fc-gamma-RIIa", "FcRII-a", "IgG Fc receptor II-a", "Low affinity immunoglobulin gamma Fc region receptor II-a precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-a\nMAMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSRLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">954 bp\nATGGCTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"id": "BE0002099", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31994", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "general-function": null, "specific-function": "Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B- cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis", "gene-name": "FCGR2B", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.12", "molecular-weight": "34044.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3618"}, {"resource": "GenAtlas", "identifier": "FCGR2B"}, {"resource": "GeneCards", "identifier": "FCGR2B"}, {"resource": "GenBank Gene Database", "identifier": "U87560"}, {"resource": "GenBank Protein Database", "identifier": "4099445"}, {"resource": "UniProtKB", "identifier": "P31994"}, {"resource": "UniProt Accession", "identifier": "FCG2B_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-b", "Fc-gamma-RIIb", "FcRII-b", "IgG Fc receptor II-b", "Low affinity immunoglobulin gamma Fc region receptor II-b precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI"}, "gene-sequence": {"@format": "FASTA", "#text": ">930 bp\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCTCTCCCAGGATACCCTGAG\nTGCAGGGAAATGGGAGAGACCCTCCCTGAGAAACCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATT"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"id": "BE0002100", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31995", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "general-function": null, "specific-function": "Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells", "gene-name": "FCGR2C", "locus": "1q23.3", "cellular-location": "Cell membrane", "transmembrane-regions": "224-246", "signal-regions": null, "theoretical-pi": "6.9", "molecular-weight": "35578.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:15626"}, {"resource": "GenAtlas", "identifier": "FCGR2C"}, {"resource": "GeneCards", "identifier": "FCGR2C"}, {"resource": "GenBank Gene Database", "identifier": "X17652"}, {"resource": "GenBank Protein Database", "identifier": "32074"}, {"resource": "UniProtKB", "identifier": "P31995"}, {"resource": "UniProt Accession", "identifier": "FCG2C_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-c", "Fc-gamma-RIIc", "FcRII-c", "IgG Fc receptor II-c", "Low affinity immunoglobulin gamma Fc region receptor II-c precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-c\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR\nAPTDDDKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">972 bp\nATGGGAATCCTGTCATTTTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACAGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCATTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCTGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG\nAAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT\nGAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG\nGCACCTACTGACGATGATAAAAACATCTACTTGACTCTTCCTCCCAACGACCATGTCAAC\nAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2012-06-14", "drugbank-id": [{"@primary": "true", "#text": "DB00074"}, "BIOD00073", "BTD00073"], "name": "Basiliximab", "description": "A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha.", "cas-number": "152923-56-3", "groups": {"group": ["approved", "investigational"]}, "general-references": null, "synthesis-reference": null, "indication": "For prophylactic treatment of kidney transplant rejection", "pharmacodynamics": "Basiliximab functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.", "mechanism-of-action": "Basiliximab binds with high-affinity to the alpha-subunit (CD25) of the high-affinity IL-2 receptor. This inhibits IL-2 binding, which inhibits T-cell activation and prevents the body from mounting an immune response against the foreign kidney.", "toxicity": null, "metabolism": "Most likely removed by opsonization via the reticuloendothelial system when bound to lymphocytes, or by human antimurine antibody production", "absorption": null, "half-life": "7.2 +/- 3.2 days (adults)", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": "* 7.8 \u00b1 5.1 L [Pediatric]\n* 4.8 \u00b1 2.1 L [Adult]", "clearance": "* 41 +/- 19 mL/h [Adult patients undergoing first kidney transplantation]\n* 17 +/- 6 mL/h [pediatric patients undergoing renal transplantation]\n* 31 +/- 19 mL/h [adolescent patients undergoing renal transplantation]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "chimeric mouse-human antiCD25"}, {"@language": "", "@coder": "", "#text": "Ig gamma-1 chain C region"}]}, "products": {"product": [{"name": "Simulect", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02242815", "started-marketing-on": "2000-10-23", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "20 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Simulect", "ndc-id": "0078-0393_88e1d8f7-be69-4d69-b417-0125a8a6b4b9", "ndc-product-code": "0078-0393", "dpd-id": null, "started-marketing-on": "1998-05-12", "ended-marketing-on": null, "dosage-form": "injection, powder, for solution", "strength": "10 mg/2.5mL", "route": "intravenous", "fda-application-number": "BLA103764", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Simulect", "ndc-id": "0078-0331_88e1d8f7-be69-4d69-b417-0125a8a6b4b9", "ndc-product-code": "0078-0331", "dpd-id": null, "started-marketing-on": "1998-05-12", "ended-marketing-on": null, "dosage-form": "injection, powder, for solution", "strength": "20 mg/5mL", "route": "intravenous", "fda-application-number": "BLA103764", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Simulect", "ingredients": "Basiliximab"}, {"name": "Simulect", "ingredients": "Basiliximab"}, {"name": "Simulect", "ingredients": "Basiliximab"}]}, "packagers": {"packager": {"name": "Novartis AG", "url": "http://www.novartis.com"}}, "manufacturers": null, "prices": {"price": [{"description": "Simulect 10 mg vial", "cost": {"@currency": "USD", "#text": "1883.11"}, "unit": "vial"}, {"description": "Simulect 20 mg vial", "cost": {"@currency": "USD", "#text": "2471.6"}, "unit": "vial"}]}, "categories": {"category": {"category": "Immunosuppressive Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, powder, for solution", "route": "intravenous", "strength": "10 mg/2.5mL"}, {"form": "Injection, powder, for solution", "route": "intravenous", "strength": "20 mg/5mL"}, {"form": "Powder for solution", "route": "intravenous", "strength": "20 mg"}]}, "atc-codes": {"atc-code": {"@code": "L04AC02", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L04", "#text": "IMMUNOSUPPRESSANTS"}, {"@code": "L04A", "#text": "IMMUNOSUPPRESSANTS"}, {"@code": "L04AC", "#text": "Interleukin inhibitors"}]}}, "ahfs-codes": {"ahfs-code": "92:00.00"}, "patents": {"patent": {"number": "2038279", "country": "Canada", "approved": "1999-03-09", "expires": "2011-03-11"}}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB08879", "name": "Belimumab", "description": "Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab."}, {"drugbank-id": "DB06643", "name": "Denosumab", "description": "May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased."}, {"drugbank-id": "DB01097", "name": "Leflunomide", "description": "Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased."}, {"drugbank-id": "DB00108", "name": "Natalizumab", "description": "Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased."}, {"drugbank-id": "DB00337", "name": "Pimecrolimus", "description": "May enhance the adverse/toxic effect of Immunosuppressants."}, {"drugbank-id": "DB01656", "name": "Roflumilast", "description": "May enhance the immunosuppressive effect of Immunosuppressants."}, {"drugbank-id": "DB06688", "name": "Sipuleucel-T", "description": "Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T."}, {"drugbank-id": "DB08895", "name": "Tofacitinib", "description": "Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib."}, {"drugbank-id": "DB00072", "name": "Trastuzumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}]}, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">Basiliximab heavy chain\nQLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQ\nKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSSASTKG\nPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL\nSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPPKSCDKTHTCPPCPAPELLGGPSVF\nLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR\nVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN\nQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN\nVFSCSVMHEALHNHYTQKSLSLSPGK"}, {"@format": "FASTA", "#text": ">Basiliximab light chain\nQIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPAR\nFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIKRTVAAPSVFIFPPSDE\nQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSK\nADYEKHKVYACEVTHQGLSSPVTKSFNRGE"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "61 \u00b0C (FAB fragment), 71 \u00b0C (whole mAb)", "source": "Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)"}, {"kind": "Hydrophobicity", "value": "-0.473", "source": null}, {"kind": "Isoelectric Point", "value": "8.68", "source": null}, {"kind": "Molecular Weight", "value": "143801.3000", "source": null}, {"kind": "Molecular Formula", "value": "C6378H9844N1698O1997S48", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "12027"}, {"resource": "National Drug Code Directory", "identifier": "0078-0393-61"}, {"resource": "GenBank", "identifier": "J00228"}, {"resource": "PharmGKB", "identifier": "PA164747126"}, {"resource": "UniProtKB", "identifier": "P01857"}, {"resource": "Wikipedia", "identifier": "Basiliximab"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic2/basiliximab.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/basiliximab.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000658", "name": "Interleukin-2 receptor subunit alpha", "organism": "Human", "actions": {"action": "antibody"}, "references": "# Choy BY, Chan TM, Li FK, Lui SL, Lo WK, Yip T, Tse KC, Lai KN: IL2-receptor antagonist (basiliximab) induction therapy is associated with lower morbidity and mortality in renal transplant recipients. Transplant Proc. 2003 Feb;35(1):195. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12591363\n# Kovarik J, Breidenbach T, Gerbeau C, Korn A, Schmidt AG, Nashan B: Disposition and immunodynamics of basiliximab in liver allograft recipients. Clin Pharmacol Ther. 1998 Jul;64(1):66-72. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9695721\n# Garcia CD, Bittencourt VB, Tumelero A, Antonello JS, Malheiros D, Garcia VD: Plasmapheresis for recurrent posttransplant focal segmental glomerulosclerosis. Transplant Proc. 2006 Jul-Aug;38(6):1904-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16908318\n# Berard JL, Velez RL, Freeman RB, Tsunoda SM: A review of interleukin-2 receptor antagonists in solid organ transplantation. Pharmacotherapy. 1999 Oct;19(10):1127-37. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10512062\n# Mentre F, Kovarik J, Gerbeau C: Constructing a prediction interval for time to reach a threshold concentration based on a population pharmacokinetic analysis: an application to basiliximab in renal transplantation. J Pharmacokinet Biopharm. 1999 Apr;27(2):213-30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10567956\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P01589", "@source": "Swiss-Prot", "name": "Interleukin-2 receptor subunit alpha", "general-function": "Involved in interleukin-2 receptor activity", "specific-function": "Receptor for interleukin-2", "gene-name": "IL2RA", "locus": "10p15-p14", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "241-259", "signal-regions": null, "theoretical-pi": "6.49", "molecular-weight": "30819.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6008"}, {"resource": "GenAtlas", "identifier": "IL2RA"}, {"resource": "GeneCards", "identifier": "IL2RA"}, {"resource": "GenBank Gene Database", "identifier": "X01057"}, {"resource": "GenBank Protein Database", "identifier": "33813"}, {"resource": "UniProtKB", "identifier": "P01589"}, {"resource": "UniProt Accession", "identifier": "IL2RA_HUMAN"}]}, "synonyms": {"synonym": ["CD25 antigen", "IL-2 receptor alpha subunit", "IL-2-RA", "IL2-RA", "Interleukin-2 receptor alpha chain precursor", "p55", "TAC antigen"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interleukin-2 receptor alpha chain precursor\nMDSYLLMWGLLTFIMVPGCQAELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKS\nGSLYMLCTGNSSHSSWDNQCQCTSSATRNTTKQVTPQPEEQKERKTTEMQSPMQPVDQAS\nLPGHCREPPPWENEATERIYHFVVGQMVYYQCVQGYRALHRGPAESVCKMTHGKTRWTQP\nQLICTGEMETSQFPGEEKPQASPEGRPESETSCLVTTTDFQIQTEMAATMETSIFTTEYQ\nVAVAGCVFLLISVLLLSGLTWQRRQRKSRRTI"}, "gene-sequence": {"@format": "FASTA", "#text": ">819 bp\nATGGATTCATACCTGCTGATGTGGGGACTGCTCACGTTCATCATGGTGCCTGGCTGCCAG\nGCAGAGCTCTGTGACGATGACCCGCCAGAGATCCCACACGCCACATTCAAAGCCATGGCC\nTACAAGGAAGGAACCATGTTGAACTGTGAATGCAAGAGAGGTTTCCGCAGAATAAAAAGC\nGGGTCACTCTATATGCTCTGTACAGGAAACTCTAGCCACTCGTCCTGGGACAACCAATGT\nCAATGCACAAGCTCTGCCACTCGGAACACAACGAAACAAGTGACACCTCAACCTGAAGAA\nCAGAAAGAAAGGAAAACCACAGAAATGCAAAGTCCAATGCAGCCAGTGGACCAAGCGAGC\nCTTCCAGGTCACTGCAGGGAACCTCCACCATGGGAAAATGAAGCCACAGAGAGAATTTAT\nCATTTCGTGGTGGGGCAGATGGTTTATTATCAGTGCGTCCAGGGATACAGGGCTCTACAC\nAGAGGTCCTGCTGAGAGCGTCTGCAAAATGACCCACGGGAAGACAAGGTGGACCCAGCCC\nCAGCTCATATGCACAGGTGAAATGGAGACCAGTCAGTTTCCAGGTGAAGAGAAGCCTCAG\nGCAAGCCCCGAAGGCCGTCCTGAGAGTGAGACTTCCTGCCTCGTCACAACAACAGATTTT\nCAAATACAGACAGAAATGGCTGCAACCATGGAGACGTCCATATTTACAACAGAGTACCAG\nGTAGCAGTGGCCGGCTGTGTTTTCCTGCTGATCAGCGTCCTCCTCCTGAGTGGGCTCACC\nTGGCAGCGGAGACAGAGGAAGAGTAGAAGAACAATCTAG"}, "pfams": {"pfam": {"identifier": "PF00084", "name": "Sushi"}}, "go-classifiers": null}}, {"@position": "2", "id": "BE0000651", "name": "Interleukin-2 receptor subunit beta", "organism": "Human", "actions": {"action": "antibody"}, "references": "# Onrust SV, Wiseman LR: Basiliximab. Drugs. 1999 Feb;57(2):207-13; discussion 214. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10188761\n# Hausen B, Gummert J, Berry GJ, Christians U, Serkova N, Ikonen T, Hook L, Legay F, Schuler W, Schreier MH, Morris RE: Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin. Transplantation. 2000 Feb 27;69(4):488-96. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10708100\n# Schmitz K, Hitzer S, Behrens-Baumann W: [Immune suppression by combination therapy with basiliximab and cyclosporin in high risk keratoplasty. A pilot study] Ophthalmologe. 2002 Jan;99(1):38-45. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11840795\n# Warle MC, Kwekkeboom J, Tilanus HW, Metselaar HJ: Basiliximab interferes with the detection of soluble IL-2 receptor by the Immulite Immunoassay system. J Immunol Methods. 2003 Apr 1;275(1-2):133-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12667677\n# Emparan C, Laukotter M, Wolters H, Dame C, Heidenreich S, Senninger N: Calcineurin-free protocols with basiliximab induction allow patients included in \"old to old\" programs achieve standard kidney transplant function. Transplant Proc. 2003 Jun;35(4):1326-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12826150\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "unknown", "polypeptide": {"@id": "P14784", "@source": "Swiss-Prot", "name": "Interleukin-2 receptor subunit beta", "general-function": "Involved in hematopoietin/interferon-class (D200-domain) cytokine receptor activity", "specific-function": "Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2", "gene-name": "IL2RB", "locus": "22q13|22q13.1", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "241-265", "signal-regions": null, "theoretical-pi": "4.68", "molecular-weight": "61118.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6009"}, {"resource": "GenAtlas", "identifier": "IL2RB"}, {"resource": "GeneCards", "identifier": "IL2RB"}, {"resource": "GenBank Gene Database", "identifier": "M26062"}, {"resource": "GenBank Protein Database", "identifier": "307048"}, {"resource": "UniProtKB", "identifier": "P14784"}, {"resource": "UniProt Accession", "identifier": "IL2RB_HUMAN"}]}, "synonyms": {"synonym": ["CD122 antigen", "High affinity IL-2 receptor subunit beta", "IL-2 receptor", "Interleukin-2 receptor subunit beta precursor", "P70-75", "p75"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interleukin-2 receptor beta chain precursor\nMAAPALSWRLPLLILLLPLATSWASAAVNGTSQFTCFYNSRANISCVWSQDGALQDTSCQ\nVHAWPDRRRWNQTCELLPVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMA\nIQDFKPFENLRLMAPISLQVVHVETHRCNISWEISQASHYFERHLEFEARTLSPGHTWEE\nAPLLTLKQKQEWICLETLTPDTQYEFQVRVKPLQGEFTTWSPWSQPLAFRTKPAALGKDT\nIPWLGHLLVGLSGAFGFIILVYLLINCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDV\nQKWLSSPFPSSSFSPGGLAPEISPLEVLERDKVTQLLLQQDKVPEPASLSSNHSLTSCFT\nNQGYFFFHLPDALEIEACQVYFTYDPYSEEDPDEGVAGAPTGSSPQPLQPLSGEDDAYCT\nFPSRDDLLLFSPSLLGGPSPPSTAPGGSGAGEERMPPSLQERVPRDWDPQPLGPPTPGVP\nDLVDFQPPPELVLREAGEEVPDAGPREGVSFPWSRPPGQGEFRALNARLPLNTDAYLSLQ\nELQGQDPTHLV"}, "gene-sequence": {"@format": "FASTA", "#text": ">1656 bp\nATGGCGGCCCCTGCTCTGTCCTGGCGTCTGCCCCTCCTCATCCTCCTCCTGCCCCTGGCT\nACCTCTTGGGCATCTGCAGCGGTGAATGGCACTTCCCAGTTCACATGCTTCTACAACTCG\nAGAGCCAACATCTCCTGTGTCTGGAGCCAAGATGGGGCTCTGCAGGACACTTCCTGCCAA\nGTCCATGCCTGGCCGGACAGACGGCGGTGGAACCAAACCTGTGAGCTGCTCCCCGTGAGT\nCAAGCATCCTGGGCCTGCAACCTGATCCTCGGAGCCCCAGATTCTCAGAAACTGACCACA\nGTTGACATCGTCACCCTGAGGGTGCTGTGCCGTGAGGGGGTGCGATGGAGGGTGATGGCC\nATCCAGGACTTCAAGCCCTTTGAGAACCTTCGCCTGATGGCCCCCATCTCCCTCCAAGTT\nGTCCACGTGGAGACCCACAGATGCAACATAAGCTGGGAAATCTCCCAAGCCTCCCACTAC\nTTTGAAAGACACCTGGAGTTCGAGGCCCGGACGCTGTCCCCAGGCCACACCTGGGAGGAG\nGCCCCCCTGCTGACTCTCAAGCAGAAGCAGGAATGGATCTGCCTGGAGACGCTCACCCCA\nGACACCCAGTATGAGTTTCAGGTGCGGGTCAAGCCTCTGCAAGGCGAGTTCACGACCTGG\nAGCCCCTGGAGCCAGCCCCTGGCCTTCAGGACAAAGCCTGCAGCCCTTGGGAAGGACACC\nATTCCGTGGCTCGGCCACCTCCTCGTGGGCCTCAGCGGGGCTTTTGGCTTCATCATCTTA\nGTGTACTTGCTGATCAACTGCAGGAACACCGGGCCATGGCTGAAGAAGGTCCTGAAGTGT\nAACACCCCAGACCCCTCGAAGTTCTTTTCCCAGCTGAGCTCAGAGCATGGAGGAGACGTC\nCAGAAGTGGCTCTCTTCGCCCTTCCCCTCATCGTCCTTCAGCCCTGGCGGCCTGGCACCT\nGAGATCTCGCCACTAGAAGTGCTGGAGAGGGACAAGGTGACGCAGCTGCTCCTGCAGCAG\nGACAAGGTGCCTGAGCCCGCATCCTTAAGCAGCAACCACTCGCTGACCAGCTGCTTCACC\nAACCAGGGTTACTTCTTCTTCCACCTCCCGGATGCCTTGGAGATAGAGGCCTGCCAGGTG\nTACTTTACTTACGACCCCTACTCAGAGGAAGACCCTGATGAGGGTGTGGCCGGGGCACCC\nACAGGGTCTTCCCCCCAACCCCTGCAGCCTCTGTCAGGGGAGGACGACGCCTACTGCACC\nTTCCCCTCCAGGGATGACCTGCTGCTCTTCTCCCCCAGTCTCCTCGGTGGCCCCAGCCCC\nCCAAGCACTGCCCCTGGGGGCAGTGGGGCCGGTGAAGAGAGGATGCCCCCTTCTTTGCAA\nGAAAGAGTCCCCAGAGACTGGGACCCCCAGCCCCTGGGGCCTCCCACCCCAGGAGTCCCA\nGACCTGGTGGATTTTCAGCCACCCCCTGAGCTGGTGCTGCGAGAGGCTGGGGAGGAGGTC\nCCTGACGCTGGCCCCAGGGAGGGAGTCAGTTTCCCCTGGTCCAGGCCTCCTGGGCAGGGG\nGAGTTCAGGGCCCTTAATGCTCGCCTGCCCCTGAACACTGATGCCTACTTGTCCCTCCAA\nGAACTCCAGGGTCAGGACCCAACTCACTTGGTGTAG"}, "pfams": null, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "hematopoietin/interferon-class (D200-domain) cytokine receptor activity"}]}}}, {"@position": "3", "id": "BE0000710", "name": "High affinity immunoglobulin gamma Fc receptor I", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P12314", "@source": "Swiss-Prot", "name": "High affinity immunoglobulin gamma Fc receptor I", "general-function": "Involved in receptor signaling protein activity", "specific-function": "Binds to the Fc region of immunoglobulins gamma. High affinity receptor", "gene-name": "FCGR1A", "locus": "1q21.2-q21.3", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "293-313", "signal-regions": null, "theoretical-pi": "8.08", "molecular-weight": "42632.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3613"}, {"resource": "GenAtlas", "identifier": "FCGR1A"}, {"resource": "GeneCards", "identifier": "FCGR1A"}, {"resource": "GenBank Gene Database", "identifier": "X14356"}, {"resource": "GenBank Protein Database", "identifier": "31332"}, {"resource": "UniProtKB", "identifier": "P12314"}, {"resource": "UniProt Accession", "identifier": "FCGR1_HUMAN"}]}, "synonyms": {"synonym": ["CD64 antigen", "Fc-gamma RI", "FcRI", "High affinity immunoglobulin gamma Fc receptor I precursor", "IgG Fc receptor I"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">High affinity immunoglobulin gamma Fc receptor I precursor\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1125 bp\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCTCTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAACTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "4", "id": "BE0002097", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P08637", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "general-function": null, "specific-function": "Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis", "gene-name": "FCGR3A", "locus": "1q23", "cellular-location": "Cell membrane", "transmembrane-regions": "209-229", "signal-regions": null, "theoretical-pi": "8.21", "molecular-weight": "29089.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3619"}, {"resource": "GenAtlas", "identifier": "FCGR3A"}, {"resource": "GeneCards", "identifier": "FCGR3A"}, {"resource": "GenBank Gene Database", "identifier": "X52645"}, {"resource": "GenBank Protein Database", "identifier": "31324"}, {"resource": "UniProtKB", "identifier": "P08637"}, {"resource": "UniProt Accession", "identifier": "FCG3A_HUMAN"}]}, "synonyms": {"synonym": ["CD16a antigen", "Fc-gamma RIII", "Fc-gamma RIII-alpha", "Fc-gamma RIIIa", "FcR-10", "FcRIII", "FcRIIIa", "IgG Fc receptor III-2", "Low affinity immunoglobulin gamma Fc region receptor III-A precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK"}, "gene-sequence": {"@format": "FASTA", "#text": ">765 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCGACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCA\nAAAGCCACACTCAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTTTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGG\nAAGGACCATAAATTTAAATGGAGAAAGGACCCTCAAGACAAATGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "5", "id": "BE0002098", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P12318", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "general-function": null, "specific-function": "Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens", "gene-name": "FCGR2A", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.78", "molecular-weight": "34990.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3616"}, {"resource": "GenAtlas", "identifier": "FCGR2A"}, {"resource": "GeneCards", "identifier": "FCGR2A"}, {"resource": "GenBank Gene Database", "identifier": "M31932"}, {"resource": "GenBank Protein Database", "identifier": "182474"}, {"resource": "UniProtKB", "identifier": "P12318"}, {"resource": "UniProt Accession", "identifier": "FCG2A_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-a", "Fc-gamma-RIIa", "FcRII-a", "IgG Fc receptor II-a", "Low affinity immunoglobulin gamma Fc region receptor II-a precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-a\nMAMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSRLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">954 bp\nATGGCTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "6", "id": "BE0002099", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31994", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "general-function": null, "specific-function": "Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B- cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis", "gene-name": "FCGR2B", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.12", "molecular-weight": "34044.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3618"}, {"resource": "GenAtlas", "identifier": "FCGR2B"}, {"resource": "GeneCards", "identifier": "FCGR2B"}, {"resource": "GenBank Gene Database", "identifier": "U87560"}, {"resource": "GenBank Protein Database", "identifier": "4099445"}, {"resource": "UniProtKB", "identifier": "P31994"}, {"resource": "UniProt Accession", "identifier": "FCG2B_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-b", "Fc-gamma-RIIb", "FcRII-b", "IgG Fc receptor II-b", "Low affinity immunoglobulin gamma Fc region receptor II-b precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI"}, "gene-sequence": {"@format": "FASTA", "#text": ">930 bp\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCTCTCCCAGGATACCCTGAG\nTGCAGGGAAATGGGAGAGACCCTCCCTGAGAAACCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATT"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "7", "id": "BE0002100", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31995", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "general-function": null, "specific-function": "Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells", "gene-name": "FCGR2C", "locus": "1q23.3", "cellular-location": "Cell membrane", "transmembrane-regions": "224-246", "signal-regions": null, "theoretical-pi": "6.9", "molecular-weight": "35578.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:15626"}, {"resource": "GenAtlas", "identifier": "FCGR2C"}, {"resource": "GeneCards", "identifier": "FCGR2C"}, {"resource": "GenBank Gene Database", "identifier": "X17652"}, {"resource": "GenBank Protein Database", "identifier": "32074"}, {"resource": "UniProtKB", "identifier": "P31995"}, {"resource": "UniProt Accession", "identifier": "FCG2C_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-c", "Fc-gamma-RIIc", "FcRII-c", "IgG Fc receptor II-c", "Low affinity immunoglobulin gamma Fc region receptor II-c precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-c\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR\nAPTDDDKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">972 bp\nATGGGAATCCTGTCATTTTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACAGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCATTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCTGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG\nAAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT\nGAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG\nGCACCTACTGACGATGATAAAAACATCTACTTGACTCTTCCTCCCAACGACCATGTCAAC\nAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "8", "id": "BE0000901", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "O75015", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "general-function": null, "specific-function": "Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils", "gene-name": "FCGR3B", "locus": "1q23", "cellular-location": "Cell membrane; lipid-anchor; GPI-anchor. Secreted protein. Note=Secreted after cleavage", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.71", "molecular-weight": "26216.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3620"}, {"resource": "GenAtlas", "identifier": "FCGR3B"}, {"resource": "GeneCards", "identifier": "FCGR3B"}, {"resource": "GenBank Gene Database", "identifier": "X16863"}, {"resource": "GenBank Protein Database", "identifier": "31322"}, {"resource": "UniProtKB", "identifier": "O75015"}, {"resource": "UniProt Accession", "identifier": "FCG3B_HUMAN"}]}, "synonyms": {"synonym": ["CD16b antigen", "Fc-gamma RIII", "Fc-gamma RIII-beta", "Fc-gamma RIIIb", "FcR-10", "FcRIII", "FcRIIIb", "IgG Fc receptor III-1", "Low affinity immunoglobulin gamma Fc region receptor III-B precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-B precursor\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI"}, "gene-sequence": {"@format": "FASTA", "#text": ">702 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "9", "id": "BE0001529", "name": "Complement C1s subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P09871", "@source": "Swiss-Prot", "name": "Complement C1s subcomponent", "general-function": "Involved in calcium ion binding", "specific-function": "C1s B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4", "gene-name": "C1S", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "4.59", "molecular-weight": "76685.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1247"}, {"resource": "GenAtlas", "identifier": "C1S"}, {"resource": "GeneCards", "identifier": "C1S"}, {"resource": "GenBank Gene Database", "identifier": "X06596"}, {"resource": "GenBank Protein Database", "identifier": "763110"}, {"resource": "UniProtKB", "identifier": "P09871"}, {"resource": "UniProt Accession", "identifier": "C1S_HUMAN"}]}, "synonyms": {"synonym": ["C1 esterase", "Complement C1s subcomponent precursor", "EC 3.4.21.42"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1s subcomponent precursor\nMWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIE\nLSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERF\nTGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVF\nTALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVF\nVAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTP\nNSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCG\nIPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPK\nCVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGN\nREPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVK\nMGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKV\nEKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCG\nTYGLYTRVKNYVDWIMKTMQENSTPRED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2067 bp\nATGTGGTGCATTGTCCTGTTTTCACTTTTGGCATGGGTTTATGCTGAGCCTACCATGTAT\nGGGGAGATCCTGTCCCCTAACTATCCTCAGGCATATCCCAGTGAGGTAGAGAAATCTTGG\nGACATAGAAGTTCCTGAAGGGTATGGGATTCACCTCTACTTCACCCATCTGGACATTGAG\nCTGTCAGAGAACTGTGCGTATGACTCAGTGCAGATAATCTCAGGAGACACTGAAGAAGGG\nAGGCTCTGTGGACAGAGGAGCAGTAACAATCCCCACTCTCCAATTGTGGAAGAGTTCCAA\nGTCCCATACAACAAACTCCAGGTGATCTTTAAGTCAGACTTTTCCAATGAAGAGCGTTTT\nACGGGGTTTGCTGCATACTATGTTGCCACAGACATAAATGAATGCACAGATTTTGTAGAT\nGTCCCTTGTAGCCACTTCTGCAACAATTTCATTGGTGGTTACTTCTGCTCCTGCCCCCCG\nGAATATTTCCTCCATGATGACATGAAGAATTGCGGAGTTAATTGCAGTGGGGATGTATTC\nACTGCACTGATTGGGGAGATTGCAAGTCCCAATTATCCCAAACCATATCCAGAGAACTCA\nAGGTGTGAATACCAGATCCGGTTGGAGAAAGGGTTCCAAGTGGTGGTGACCTTGCGGAGA\nGAAGATTTTGATGTGGAAGCAGCTGACTCAGCGGGAAACTGCCTTGACAGTTTAGTTTTT\nGTTGCAGGAGATCGGCAATTTGGTCCTTACTGTGGTCATGGATTCCCTGGGCCTCTAAAT\nATTGAAACCAAGAGTAATGCTCTTGATATCATCTTCCAAACTGATCTAACAGGGCAAAAA\nAAGGGCTGGAAACTTCGCTATCATGGAGATCCAATGCCCTGCCCTAAGGAAGACACTCCC\nAATTCTGTTTGGGAGCCTGCGAAGGCAAAATATGTCTTTAGAGATGTGGTGCAGATAACC\nTGTCTGGATGGGTTTGAAGTTGTGGAGGGACGTGTTGGTGCAACATCTTTCTATTCGACT\nTGTCAAAGCAATGGAAAGTGGAGTAATTCCAAACTGAAATGTCAACCTGTGGACTGTGGC\nATTCCTGAATCCATTGAGAATGGTAAAGTTGAAGACCCAGAGAGCACTTTGTTTGGTTCT\nGTCATCCGCTACACTTGTGAGGAGCCATATTACTACATGGAAAATGGAGGAGGTGGGGAG\nTATCACTGTGCTGGTAACGGGAGCTGGGTGAATGAGGTGCTGGGCCCGGAGCTGCCGAAA\nTGTGTTCCAGTCTGTGGAGTCCCCAGAGAACCCTTTGAAGAAAAACAGAGGATAATTGGA\nGGATCCGATGCAGATATTAAAAACTTCCCCTGGCAAGTCTTCTTTGACAACCCATGGGCT\nGGTGGAGCGCTCATTAATGAGTACTGGGTGCTGACGGCTGCTCATGTTGTGGAGGGAAAC\nAGGGAGCCAACAATGTATGTTGGGTCCACCTCAGTGCAGACCTCACGGCTGGCAAAATCC\nAAGATGCTCACTCCTGAGCATGTGTTTATTCATCCGGGATGGAAGCTGCTGGAAGTCCCA\nGAAGGACGAACCAATTTTGATAATGACATTGCACTGGTGCGGCTGAAAGACCCAGTGAAA\nATGGGACCCACCGTCTCTCCCATCTGCCTACCAGGCACCTCTTCCGACTACAACCTCATG\nGATGGGGACCTGGGACTGATCTCAGGCTGGGGCCGAACAGAGAAGAGAGATCGTGCTGTT\nCGCCTCAAGGCGGCAAGGTTACCTGTAGCTCCTTTAAGAAAATGCAAAGAAGTGAAAGTG\nGAGAAACCCACAGCAGATGCAGAGGCCTATGTTTTCACTCCTAACATGATCTGTGCTGGA\nGGAGAGAAGGGCATGGATAGCTGTAAAGGGGACAGTGGTGGGGCCTTTGCTGTACAGGAT\nCCCAATGACAAGACCAAATTCTACGCAGCTGGCCTGGTGTCCTGGGGGCCCCAGTGTGGG\nACCTATGGGCTCTACACACGGGTAAAGAACTATGTTGACTGGATAATGAAGACTATGCAG\nGAAAATAGCACCCCCCGTGAGGACTAA"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "10", "id": "BE0002093", "name": "Complement C1r subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P00736", "@source": "Swiss-Prot", "name": "Complement C1r subcomponent", "general-function": null, "specific-function": "C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system", "gene-name": "C1R", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.24", "molecular-weight": "80174.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1246"}, {"resource": "GenAtlas", "identifier": "C1R"}, {"resource": "GeneCards", "identifier": "C1R"}, {"resource": "GenBank Gene Database", "identifier": "X04701"}, {"resource": "GenBank Protein Database", "identifier": "29539"}, {"resource": "UniProtKB", "identifier": "P00736"}, {"resource": "UniProt Accession", "identifier": "C1R_HUMAN"}]}, "synonyms": {"synonym": ["Complement C1r subcomponent precursor", "Complement component 1, r subcomponent", "EC 3.4.21.41"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1r subcomponent\nMWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF\nQQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF\nSNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY\nELQEDRHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF\nDIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL\nRYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD\nDGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR\nESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF\nTNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV\nSVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME\nEKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV\nRDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2118 bp\nATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC\nATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC\nAACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC\nCAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT\nGATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG\nGGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC\nTCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT\nGTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG\nTGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT\nGAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG\nGCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC\nAACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT\nGATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC\nGGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC\nAATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG\nCGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC\nATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA\nGGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT\nGATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA\nAACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC\nCGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG\nGAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG\nGGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG\nAGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC\nACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT\nGCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC\nCTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC\nAGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG\nCTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC\nAACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG\nGAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT\nGAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT\nGGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA\nAGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC\nAGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG\nATGGAGGAGGAGGACTGA"}, "pfams": {"pfam": [{"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF07645", "name": "EGF_CA"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "11", "id": "BE0002094", "name": "Complement C1q subcomponent subunit A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02745", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit A", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QA", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.45", "molecular-weight": "26017.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1241"}, {"resource": "GenAtlas", "identifier": "C1QA"}, {"resource": "GeneCards", "identifier": "C1QA"}, {"resource": "GenBank Gene Database", "identifier": "AF135157"}, {"resource": "GenBank Protein Database", "identifier": "4894854"}, {"resource": "UniProtKB", "identifier": "P02745"}, {"resource": "UniProt Accession", "identifier": "C1QA_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit A precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit A\nMEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR\nTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI\nRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR\nGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL\nIFPSA"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG\nGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC\nAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG\nACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC\nAAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGGGCCCGTGGCATCCCGGGAATTAAA\nGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT\nCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG\nGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC\nTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG\nGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG\nGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC\nCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC\nATCTTCCCATCTGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "12", "id": "BE0002095", "name": "Complement C1q subcomponent subunit B", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02746", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit B", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QB", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.87", "molecular-weight": "26460.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1242"}, {"resource": "GenAtlas", "identifier": "C1QB"}, {"resource": "GeneCards", "identifier": "C1QB"}, {"resource": "GenBank Gene Database", "identifier": "X03084"}, {"resource": "GenBank Protein Database", "identifier": "573114"}, {"resource": "UniProtKB", "identifier": "P02746"}, {"resource": "UniProt Accession", "identifier": "C1QB_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit B precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit B\nMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEK\nGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKI\nAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCV\nNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANSIF\nSGFLLFPDMEA"}, "gene-sequence": {"@format": "FASTA", "#text": ">688 bp\nCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGG\nGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCC\nAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAA\nTCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGCCCAGGGGCCCCTGG\nAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAGAAAATCGCCTTCTC\nTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATCCGCTTCGACCACGT\nGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTCACCTGCAAGGTGCC\nCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTGTGCGTGAACCTCAT\nGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTATGCCTACAACACCTT\nCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAGAACGTCTTCCTGCA\nGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGCATCTTTTCCGGGTT\nCCTGCTCTTTCCAGATATGGAGGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "13", "id": "BE0002096", "name": "Complement C1q subcomponent subunit C", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02747", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit C", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QC", "locus": "1p36.11", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.58", "molecular-weight": "25774.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1245"}, {"resource": "GenAtlas", "identifier": "C1QC"}, {"resource": "GeneCards", "identifier": "C1QC"}, {"resource": "GenBank Gene Database", "identifier": "AF087892"}, {"resource": "GenBank Protein Database", "identifier": "33150626"}, {"resource": "UniProtKB", "identifier": "P02747"}, {"resource": "UniProt Accession", "identifier": "C1QC_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit C precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit C\nMDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP\nGIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS\nVFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV\nLLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF\nLLFPD"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG\nCTGCTGCCCCTCAGGGCCAAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC\nCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA\nGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA\nCCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC\nCCCATGGGATTCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA\nGTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC\nAACGCGGTCCTCACCAACCCGCAGGAGGATTATGACACGAGCACTGGCAAGTTCACCTGC\nAAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG\nCTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT\nCAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT\nGTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC\nCTGCTCTTCCCCGACTAG"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-01-31", "drugbank-id": [{"@primary": "true", "#text": "DB00075"}, "BIOD00005", "BTD00005"], "name": "Muromonab", "description": "Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type 2a (IgG2a).", "cas-number": "140608-64-6", "groups": {"group": ["approved", "investigational"]}, "general-references": null, "synthesis-reference": null, "indication": "For treatment of organ transplant recipients, prevention of organ rejection", "pharmacodynamics": "Used in organ transplant prophylaxis, Muromonab or OKT-3 binds specifically to the CD-3 complex, which is involved in antigen recognition and cell stimulation, on the surface of T lymphocytes. Immediately after administration CD-3-positive T lymphocytes are abruptly removed from circulation. It has been effective in reversing corticosteroid-resistant acute rejection in renal, liver, and cardiac transplant recipients.", "mechanism-of-action": "Muromonab binds to the T-cell surface glycoprotein CD3 epsilon chain. It appears to kill CD-3 positive cells by inducing Fc mediated apoptosis, antibody mediated cytotoxicity and complement-dependent cytotoxicity.", "toxicity": null, "metabolism": "Most likely removed by opsonization via the reticuloendothelial system when bound to T lymphocytes, or by human antimurine antibody production", "absorption": null, "half-life": "0.8 hours (mammalian reticulocytes, in vitro)", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Anti-CD3"}, {"@language": "", "@coder": "", "#text": "Muromonab-CD3"}]}, "products": {"product": [{"name": "Okt3", "ndc-id": "59676-101_0993081a-81b0-43c7-a8dc-a21b2f7dcaea", "ndc-product-code": "59676-101", "dpd-id": null, "started-marketing-on": "1986-07-19", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "5 mg/5mL", "route": "intravenous", "fda-application-number": "BLA103463", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Orthoclone Okt 3 Sterile Solution  IV 1mg/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02015978", "started-marketing-on": "1987-12-31", "ended-marketing-on": "2007-07-09", "dosage-form": "solution", "strength": "1 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": {"name": "Orthoclone OKT3", "company": "Janssen-Cilag"}}, "mixtures": {"mixture": [{"name": "Okt3", "ingredients": "Muromonab"}, {"name": "Orthoclone Okt 3 Sterile Solution  IV 1mg/ml", "ingredients": "Muromonab"}]}, "packagers": {"packager": {"name": "Centocor Ortho Biotech Inc.", "url": "http://www.centocororthobiotech.com"}}, "manufacturers": null, "prices": {"price": {"description": "Orthoclone okt-3 5 mg/5 ml", "cost": {"@currency": "USD", "#text": "261.75"}, "unit": "ml"}}, "categories": {"category": [{"category": "Immunologic Factors", "mesh-id": null}, {"category": "Immunosuppressive Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, solution", "route": "intravenous", "strength": "5 mg/5mL"}, {"form": "Solution", "route": "intravenous", "strength": "1 mg"}]}, "atc-codes": {"atc-code": {"@code": "L04AA02", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L04", "#text": "IMMUNOSUPPRESSANTS"}, {"@code": "L04A", "#text": "IMMUNOSUPPRESSANTS"}, {"@code": "L04AA", "#text": "Selective immunosuppressants"}]}}, "ahfs-codes": {"ahfs-code": "92:00.00"}, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">Muromonab-CD3 light chain\nQIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAH\nFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEINRADTAPTVSIFPPS\nSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTL\nTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC"}, {"@format": "FASTA", "#text": ">Muromonab-CD3 heavy chain\nQVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNY\nNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSA\nKTTAPSVYPLAPVCGGTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDL\nYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRPKSCDKTHTCPPCPAPELLGG\nPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN\nSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE\nLTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW\nQQGNVFSCSVMHEALHNHYTQKSLSLSPGK"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "61 \u00b0C (FAB fragment), 71 \u00b0C (whole mAb)", "source": "Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)"}, {"kind": "Hydrophobicity", "value": "-0.513", "source": null}, {"kind": "Isoelectric Point", "value": "8.31", "source": null}, {"kind": "Molecular Weight", "value": "146189.7000", "source": null}, {"kind": "Molecular Formula", "value": "C6460H9946N1720O2043S56", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "7680"}, {"resource": "KEGG Drug", "identifier": "D05092"}, {"resource": "National Drug Code Directory", "identifier": "59676-101-01"}, {"resource": "PharmGKB", "identifier": "PA164743097"}, {"resource": "Wikipedia", "identifier": "Muromonab"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0003456", "name": "T-cell surface glycoprotein CD3 delta chain", "organism": "Human", "actions": null, "references": "# Todd PA, Brogden RN: Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs. 1989 Jun;37(6):871-99. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2503348\n# Wilde MI, Goa KL: Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs. 1996 May;51(5):865-94. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8861551", "known-action": "yes", "polypeptide": {"@id": "P04234", "@source": "Swiss-Prot", "name": "T-cell surface glycoprotein CD3 delta chain", "general-function": null, "specific-function": "The CD3 complex mediates signal transduction", "gene-name": "CD3D", "locus": null, "cellular-location": "Membrane", "transmembrane-regions": "106-126", "signal-regions": null, "theoretical-pi": "5.21", "molecular-weight": "18930.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1673"}, {"resource": "GenAtlas", "identifier": "CD3D"}, {"resource": "GenBank Gene Database", "identifier": "X01451"}, {"resource": "UniProtKB", "identifier": "P04234"}, {"resource": "UniProt Accession", "identifier": "CD3D_HUMAN"}]}, "synonyms": {"synonym": ["T-cell receptor T3 delta chain", "T-cell surface glycoprotein CD3 delta chain precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">T-cell surface glycoprotein CD3 delta chain\nMEHSTFLSGLVLATLLSQVSPFKIPIEELEDRVFVNCNTSITWVEGTVGTLLSDITRLDL\nGKRILDPRGIYRCNGTDIYKDKESTVQVHYRMCQSCVELDPATVAGIIVTDVIATLLLAL\nGVFCFAGHETGRLSGAADTQALLRNDQVYQPLRDRDDAQYSHLGGNWARNK"}, "gene-sequence": {"@format": "FASTA"}, "pfams": {"pfam": {"identifier": "PF02189", "name": "ITAM"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}]}}}, {"@position": "2", "id": "BE0000274", "name": "T-cell surface glycoprotein CD3 epsilon chain", "organism": "Human", "actions": {"action": "binder"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P07766", "@source": "Swiss-Prot", "name": "T-cell surface glycoprotein CD3 epsilon chain", "general-function": "Involved in transmembrane receptor activity", "specific-function": "The CD3 complex mediates signal transduction", "gene-name": "CD3E", "locus": "11q23", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "127-152", "signal-regions": null, "theoretical-pi": "6.75", "molecular-weight": "23148.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1674"}, {"resource": "GenAtlas", "identifier": "CD3E"}, {"resource": "GeneCards", "identifier": "CD3E"}, {"resource": "GenBank Gene Database", "identifier": "X03884"}, {"resource": "GenBank Protein Database", "identifier": "469945"}, {"resource": "UniProtKB", "identifier": "P07766"}, {"resource": "UniProt Accession", "identifier": "CD3E_HUMAN"}]}, "synonyms": {"synonym": ["T-cell surface antigen T3/Leu-4 epsilon chain", "T-cell surface glycoprotein CD3 epsilon chain precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">T-cell surface glycoprotein CD3 epsilon chain precursor\nMQSGTHWRVLGLCLLSVGVWGQDGNEEMGGITQTPYKVSISGTTVILTCPQYPGSEILWQ\nHNDKNIGGDEDDKNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRARVCE\nNCMEMDVMSVATIVIVDICITGGLLLLVYYWSKNRKAKAKPVTRGAGAGGRQRGQNKERP\nPPVPNPDYEPIRKGQRDLYSGLNQRRI"}, "gene-sequence": {"@format": "FASTA", "#text": ">624 bp\nATGCAGTCGGGCACTCACTGGAGAGTTCTGGGCCTCTGCCTCTTATCAGTTGGCGTTTGG\nGGGCAAGATGGTAATGAAGAAATGGGTGGTATTACACAGACACCATATAAAGTCTCCATC\nTCTGGAACCACAGTAATATTGACATGCCCTCAGTATCCTGGATCTGAAATACTATGGCAA\nCACAATGATAAAAACATAGGCGGTGATGAGGATGATAAAAACATAGGCAGTGATGAGGAT\nCACCTGTCACTGAAGGAATTTTCAGAATTGGAGCAAAGTGGTTATTATGTCTGCTACCCC\nAGAGGAAGCAAACCAGAAGATGCGAACTTTTATCTCTACCTGAGGGCAAGAGTGTGTGAG\nAACTGCATGGAGATGGATGTGATGTCGGTGGCCACAATTGTCATAGTGGACATCTGCATC\nACTGGGGGCTTGCTGCTGCTGGTTTACTACTGGAGCAAGAATAGAAAGGCCAAGGCCAAG\nCCTGTGACACGAGGAGCGGGTGCTGGCGGCAGGCAAAGGGGACAAAACAAGGAGAGGCCA\nCCACCTGTTCCCAACCCAGACTATGAGCCCATCCGGAAAGGCCAGCGGGACCTGTATTCT\nGGCCTGAATCAGAGACGCATCTGA"}, "pfams": {"pfam": {"identifier": "PF02189", "name": "ITAM"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}]}}}, {"@position": "3", "id": "BE0003457", "name": "T-cell surface glycoprotein CD3 gamma chain", "organism": "Human", "actions": null, "references": "# Todd PA, Brogden RN: Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs. 1989 Jun;37(6):871-99. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2503348\n# Wilde MI, Goa KL: Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs. 1996 May;51(5):865-94. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8861551", "known-action": "yes", "polypeptide": {"@id": "P09693", "@source": "Swiss-Prot", "name": "T-cell surface glycoprotein CD3 gamma chain", "general-function": null, "specific-function": "The CD3 complex mediates signal transduction", "gene-name": "CD3G", "locus": null, "cellular-location": "Membrane", "transmembrane-regions": "117-137", "signal-regions": null, "theoretical-pi": "8.59", "molecular-weight": "20470.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1675"}, {"resource": "GenAtlas", "identifier": "CD3G"}, {"resource": "GenBank Gene Database", "identifier": "BC113830"}, {"resource": "UniProtKB", "identifier": "P09693"}, {"resource": "UniProt Accession", "identifier": "CD3G_HUMAN"}]}, "synonyms": {"synonym": ["T-cell receptor T3 gamma chain", "T-cell surface glycoprotein CD3 gamma chain precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">T-cell surface glycoprotein CD3 gamma chain\nMEQGKGLAVLILAIILLQGTLAQSIKGNHLVKVYDYQEDGSVLLTCDAEAKNITWFKDGK\nMIGFLTEDKKKWNLGSNAKDPRGMYQCKGSQNKSKPLQVYYRMCQNCIELNAATISGFLF\nAEIVSIFVLAVGVYFIAGQDGVRQSRASDKQTLLPNDQLYQPLKDREDDQYSHLQGNQLR\nRN"}, "gene-sequence": {"@format": "FASTA"}, "pfams": {"pfam": {"identifier": "PF02189", "name": "ITAM"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}]}}}, {"@position": "4", "id": "BE0003458", "name": "T-cell surface glycoprotein CD3 zeta chain", "organism": "Human", "actions": null, "references": "# Todd PA, Brogden RN: Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs. 1989 Jun;37(6):871-99. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2503348\n# Wilde MI, Goa KL: Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs. 1996 May;51(5):865-94. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8861551", "known-action": "yes", "polypeptide": {"@id": "P20963", "@source": "Swiss-Prot", "name": "T-cell surface glycoprotein CD3 zeta chain", "general-function": null, "specific-function": "Probable role in assembly and expression of the TCR complex as well as signal transduction upon antigen triggering", "gene-name": "CD247", "locus": null, "cellular-location": "Membrane", "transmembrane-regions": "31-51", "signal-regions": null, "theoretical-pi": "9.65", "molecular-weight": "18697.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1677"}, {"resource": "GenAtlas", "identifier": "CD247"}, {"resource": "GenBank Gene Database", "identifier": "BC025703"}, {"resource": "UniProtKB", "identifier": "P20963"}, {"resource": "UniProt Accession", "identifier": "CD3Z_HUMAN"}]}, "synonyms": {"synonym": ["CD247 antigen", "T-cell receptor T3 zeta chain", "T-cell surface glycoprotein CD3 zeta chain precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">T-cell surface glycoprotein CD3 zeta chain\nMKWKALFTAAILQAQLPITEAQSFGLLDPKLCYLLDGILFIYGVILTALFLRVKFSRSAD\nAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMA\nEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR"}, "gene-sequence": {"@format": "FASTA"}, "pfams": {"pfam": {"identifier": "PF02189", "name": "ITAM"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}]}}}, {"@position": "5", "id": "BE0000901", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "organism": "Human", "actions": null, "references": "# Pellegrini P, Berghella AM, Del Beato T, Adorno D, Casciani CU: Immunological directives for biotherapy improvement in the treatment of colorectal cancer. Cancer Biother Radiopharm. 1996 Apr;11(2):113-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10851527\n# Contasta I, Pellegrini P, Berghella AM, Del Beato T, Canossi A, Di Rocco M, Adorno D, Casciani CU: Necessity of biotherapeutic treatments inducing TH1 cell functions in colorectal cancer. Cancer Biother Radiopharm. 1996 Dec;11(6):373-83. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10851498", "known-action": "unknown", "polypeptide": {"@id": "O75015", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "general-function": null, "specific-function": "Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils", "gene-name": "FCGR3B", "locus": "1q23", "cellular-location": "Cell membrane; lipid-anchor; GPI-anchor. Secreted protein. Note=Secreted after cleavage", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.71", "molecular-weight": "26216.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3620"}, {"resource": "GenAtlas", "identifier": "FCGR3B"}, {"resource": "GeneCards", "identifier": "FCGR3B"}, {"resource": "GenBank Gene Database", "identifier": "X16863"}, {"resource": "GenBank Protein Database", "identifier": "31322"}, {"resource": "UniProtKB", "identifier": "O75015"}, {"resource": "UniProt Accession", "identifier": "FCG3B_HUMAN"}]}, "synonyms": {"synonym": ["CD16b antigen", "Fc-gamma RIII", "Fc-gamma RIII-beta", "Fc-gamma RIIIb", "FcR-10", "FcRIII", "FcRIIIb", "IgG Fc receptor III-1", "Low affinity immunoglobulin gamma Fc region receptor III-B precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-B precursor\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI"}, "gene-sequence": {"@format": "FASTA", "#text": ">702 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "6", "id": "BE0002093", "name": "Complement C1r subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P00736", "@source": "Swiss-Prot", "name": "Complement C1r subcomponent", "general-function": null, "specific-function": "C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system", "gene-name": "C1R", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.24", "molecular-weight": "80174.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1246"}, {"resource": "GenAtlas", "identifier": "C1R"}, {"resource": "GeneCards", "identifier": "C1R"}, {"resource": "GenBank Gene Database", "identifier": "X04701"}, {"resource": "GenBank Protein Database", "identifier": "29539"}, {"resource": "UniProtKB", "identifier": "P00736"}, {"resource": "UniProt Accession", "identifier": "C1R_HUMAN"}]}, "synonyms": {"synonym": ["Complement C1r subcomponent precursor", "Complement component 1, r subcomponent", "EC 3.4.21.41"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1r subcomponent\nMWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF\nQQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF\nSNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY\nELQEDRHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF\nDIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL\nRYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD\nDGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR\nESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF\nTNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV\nSVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME\nEKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV\nRDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2118 bp\nATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC\nATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC\nAACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC\nCAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT\nGATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG\nGGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC\nTCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT\nGTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG\nTGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT\nGAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG\nGCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC\nAACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT\nGATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC\nGGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC\nAATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG\nCGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC\nATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA\nGGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT\nGATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA\nAACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC\nCGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG\nGAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG\nGGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG\nAGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC\nACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT\nGCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC\nCTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC\nAGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG\nCTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC\nAACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG\nGAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT\nGAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT\nGGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA\nAGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC\nAGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG\nATGGAGGAGGAGGACTGA"}, "pfams": {"pfam": [{"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF07645", "name": "EGF_CA"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "7", "id": "BE0002094", "name": "Complement C1q subcomponent subunit A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02745", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit A", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QA", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.45", "molecular-weight": "26017.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1241"}, {"resource": "GenAtlas", "identifier": "C1QA"}, {"resource": "GeneCards", "identifier": "C1QA"}, {"resource": "GenBank Gene Database", "identifier": "AF135157"}, {"resource": "GenBank Protein Database", "identifier": "4894854"}, {"resource": "UniProtKB", "identifier": "P02745"}, {"resource": "UniProt Accession", "identifier": "C1QA_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit A precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit A\nMEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR\nTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI\nRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR\nGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL\nIFPSA"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG\nGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC\nAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG\nACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC\nAAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGGGCCCGTGGCATCCCGGGAATTAAA\nGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT\nCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG\nGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC\nTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG\nGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG\nGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC\nCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC\nATCTTCCCATCTGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "8", "id": "BE0002095", "name": "Complement C1q subcomponent subunit B", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02746", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit B", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QB", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.87", "molecular-weight": "26460.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1242"}, {"resource": "GenAtlas", "identifier": "C1QB"}, {"resource": "GeneCards", "identifier": "C1QB"}, {"resource": "GenBank Gene Database", "identifier": "X03084"}, {"resource": "GenBank Protein Database", "identifier": "573114"}, {"resource": "UniProtKB", "identifier": "P02746"}, {"resource": "UniProt Accession", "identifier": "C1QB_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit B precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit B\nMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEK\nGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKI\nAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCV\nNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANSIF\nSGFLLFPDMEA"}, "gene-sequence": {"@format": "FASTA", "#text": ">688 bp\nCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGG\nGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCC\nAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAA\nTCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGCCCAGGGGCCCCTGG\nAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAGAAAATCGCCTTCTC\nTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATCCGCTTCGACCACGT\nGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTCACCTGCAAGGTGCC\nCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTGTGCGTGAACCTCAT\nGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTATGCCTACAACACCTT\nCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAGAACGTCTTCCTGCA\nGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGCATCTTTTCCGGGTT\nCCTGCTCTTTCCAGATATGGAGGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "9", "id": "BE0002096", "name": "Complement C1q subcomponent subunit C", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02747", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit C", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QC", "locus": "1p36.11", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.58", "molecular-weight": "25774.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1245"}, {"resource": "GenAtlas", "identifier": "C1QC"}, {"resource": "GeneCards", "identifier": "C1QC"}, {"resource": "GenBank Gene Database", "identifier": "AF087892"}, {"resource": "GenBank Protein Database", "identifier": "33150626"}, {"resource": "UniProtKB", "identifier": "P02747"}, {"resource": "UniProt Accession", "identifier": "C1QC_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit C precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit C\nMDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP\nGIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS\nVFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV\nLLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF\nLLFPD"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG\nCTGCTGCCCCTCAGGGCCAAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC\nCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA\nGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA\nCCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC\nCCCATGGGATTCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA\nGTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC\nAACGCGGTCCTCACCAACCCGCAGGAGGATTATGACACGAGCACTGGCAAGTTCACCTGC\nAAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG\nCTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT\nCAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT\nGTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC\nCTGCTCTTCCCCGACTAG"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "10", "id": "BE0002097", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P08637", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "general-function": null, "specific-function": "Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis", "gene-name": "FCGR3A", "locus": "1q23", "cellular-location": "Cell membrane", "transmembrane-regions": "209-229", "signal-regions": null, "theoretical-pi": "8.21", "molecular-weight": "29089.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3619"}, {"resource": "GenAtlas", "identifier": "FCGR3A"}, {"resource": "GeneCards", "identifier": "FCGR3A"}, {"resource": "GenBank Gene Database", "identifier": "X52645"}, {"resource": "GenBank Protein Database", "identifier": "31324"}, {"resource": "UniProtKB", "identifier": "P08637"}, {"resource": "UniProt Accession", "identifier": "FCG3A_HUMAN"}]}, "synonyms": {"synonym": ["CD16a antigen", "Fc-gamma RIII", "Fc-gamma RIII-alpha", "Fc-gamma RIIIa", "FcR-10", "FcRIII", "FcRIIIa", "IgG Fc receptor III-2", "Low affinity immunoglobulin gamma Fc region receptor III-A precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK"}, "gene-sequence": {"@format": "FASTA", "#text": ">765 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCGACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCA\nAAAGCCACACTCAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTTTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGG\nAAGGACCATAAATTTAAATGGAGAAAGGACCCTCAAGACAAATGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "11", "id": "BE0001529", "name": "Complement C1s subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P09871", "@source": "Swiss-Prot", "name": "Complement C1s subcomponent", "general-function": "Involved in calcium ion binding", "specific-function": "C1s B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4", "gene-name": "C1S", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "4.59", "molecular-weight": "76685.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1247"}, {"resource": "GenAtlas", "identifier": "C1S"}, {"resource": "GeneCards", "identifier": "C1S"}, {"resource": "GenBank Gene Database", "identifier": "X06596"}, {"resource": "GenBank Protein Database", "identifier": "763110"}, {"resource": "UniProtKB", "identifier": "P09871"}, {"resource": "UniProt Accession", "identifier": "C1S_HUMAN"}]}, "synonyms": {"synonym": ["C1 esterase", "Complement C1s subcomponent precursor", "EC 3.4.21.42"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1s subcomponent precursor\nMWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIE\nLSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERF\nTGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVF\nTALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVF\nVAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTP\nNSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCG\nIPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPK\nCVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGN\nREPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVK\nMGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKV\nEKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCG\nTYGLYTRVKNYVDWIMKTMQENSTPRED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2067 bp\nATGTGGTGCATTGTCCTGTTTTCACTTTTGGCATGGGTTTATGCTGAGCCTACCATGTAT\nGGGGAGATCCTGTCCCCTAACTATCCTCAGGCATATCCCAGTGAGGTAGAGAAATCTTGG\nGACATAGAAGTTCCTGAAGGGTATGGGATTCACCTCTACTTCACCCATCTGGACATTGAG\nCTGTCAGAGAACTGTGCGTATGACTCAGTGCAGATAATCTCAGGAGACACTGAAGAAGGG\nAGGCTCTGTGGACAGAGGAGCAGTAACAATCCCCACTCTCCAATTGTGGAAGAGTTCCAA\nGTCCCATACAACAAACTCCAGGTGATCTTTAAGTCAGACTTTTCCAATGAAGAGCGTTTT\nACGGGGTTTGCTGCATACTATGTTGCCACAGACATAAATGAATGCACAGATTTTGTAGAT\nGTCCCTTGTAGCCACTTCTGCAACAATTTCATTGGTGGTTACTTCTGCTCCTGCCCCCCG\nGAATATTTCCTCCATGATGACATGAAGAATTGCGGAGTTAATTGCAGTGGGGATGTATTC\nACTGCACTGATTGGGGAGATTGCAAGTCCCAATTATCCCAAACCATATCCAGAGAACTCA\nAGGTGTGAATACCAGATCCGGTTGGAGAAAGGGTTCCAAGTGGTGGTGACCTTGCGGAGA\nGAAGATTTTGATGTGGAAGCAGCTGACTCAGCGGGAAACTGCCTTGACAGTTTAGTTTTT\nGTTGCAGGAGATCGGCAATTTGGTCCTTACTGTGGTCATGGATTCCCTGGGCCTCTAAAT\nATTGAAACCAAGAGTAATGCTCTTGATATCATCTTCCAAACTGATCTAACAGGGCAAAAA\nAAGGGCTGGAAACTTCGCTATCATGGAGATCCAATGCCCTGCCCTAAGGAAGACACTCCC\nAATTCTGTTTGGGAGCCTGCGAAGGCAAAATATGTCTTTAGAGATGTGGTGCAGATAACC\nTGTCTGGATGGGTTTGAAGTTGTGGAGGGACGTGTTGGTGCAACATCTTTCTATTCGACT\nTGTCAAAGCAATGGAAAGTGGAGTAATTCCAAACTGAAATGTCAACCTGTGGACTGTGGC\nATTCCTGAATCCATTGAGAATGGTAAAGTTGAAGACCCAGAGAGCACTTTGTTTGGTTCT\nGTCATCCGCTACACTTGTGAGGAGCCATATTACTACATGGAAAATGGAGGAGGTGGGGAG\nTATCACTGTGCTGGTAACGGGAGCTGGGTGAATGAGGTGCTGGGCCCGGAGCTGCCGAAA\nTGTGTTCCAGTCTGTGGAGTCCCCAGAGAACCCTTTGAAGAAAAACAGAGGATAATTGGA\nGGATCCGATGCAGATATTAAAAACTTCCCCTGGCAAGTCTTCTTTGACAACCCATGGGCT\nGGTGGAGCGCTCATTAATGAGTACTGGGTGCTGACGGCTGCTCATGTTGTGGAGGGAAAC\nAGGGAGCCAACAATGTATGTTGGGTCCACCTCAGTGCAGACCTCACGGCTGGCAAAATCC\nAAGATGCTCACTCCTGAGCATGTGTTTATTCATCCGGGATGGAAGCTGCTGGAAGTCCCA\nGAAGGACGAACCAATTTTGATAATGACATTGCACTGGTGCGGCTGAAAGACCCAGTGAAA\nATGGGACCCACCGTCTCTCCCATCTGCCTACCAGGCACCTCTTCCGACTACAACCTCATG\nGATGGGGACCTGGGACTGATCTCAGGCTGGGGCCGAACAGAGAAGAGAGATCGTGCTGTT\nCGCCTCAAGGCGGCAAGGTTACCTGTAGCTCCTTTAAGAAAATGCAAAGAAGTGAAAGTG\nGAGAAACCCACAGCAGATGCAGAGGCCTATGTTTTCACTCCTAACATGATCTGTGCTGGA\nGGAGAGAAGGGCATGGATAGCTGTAAAGGGGACAGTGGTGGGGCCTTTGCTGTACAGGAT\nCCCAATGACAAGACCAAATTCTACGCAGCTGGCCTGGTGTCCTGGGGGCCCCAGTGTGGG\nACCTATGGGCTCTACACACGGGTAAAGAACTATGTTGACTGGATAATGAAGACTATGCAG\nGAAAATAGCACCCCCCGTGAGGACTAA"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "12", "id": "BE0000710", "name": "High affinity immunoglobulin gamma Fc receptor I", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P12314", "@source": "Swiss-Prot", "name": "High affinity immunoglobulin gamma Fc receptor I", "general-function": "Involved in receptor signaling protein activity", "specific-function": "Binds to the Fc region of immunoglobulins gamma. High affinity receptor", "gene-name": "FCGR1A", "locus": "1q21.2-q21.3", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "293-313", "signal-regions": null, "theoretical-pi": "8.08", "molecular-weight": "42632.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3613"}, {"resource": "GenAtlas", "identifier": "FCGR1A"}, {"resource": "GeneCards", "identifier": "FCGR1A"}, {"resource": "GenBank Gene Database", "identifier": "X14356"}, {"resource": "GenBank Protein Database", "identifier": "31332"}, {"resource": "UniProtKB", "identifier": "P12314"}, {"resource": "UniProt Accession", "identifier": "FCGR1_HUMAN"}]}, "synonyms": {"synonym": ["CD64 antigen", "Fc-gamma RI", "FcRI", "High affinity immunoglobulin gamma Fc receptor I precursor", "IgG Fc receptor I"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">High affinity immunoglobulin gamma Fc receptor I precursor\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1125 bp\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCTCTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAACTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "13", "id": "BE0002098", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P12318", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "general-function": null, "specific-function": "Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens", "gene-name": "FCGR2A", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.78", "molecular-weight": "34990.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3616"}, {"resource": "GenAtlas", "identifier": "FCGR2A"}, {"resource": "GeneCards", "identifier": "FCGR2A"}, {"resource": "GenBank Gene Database", "identifier": "M31932"}, {"resource": "GenBank Protein Database", "identifier": "182474"}, {"resource": "UniProtKB", "identifier": "P12318"}, {"resource": "UniProt Accession", "identifier": "FCG2A_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-a", "Fc-gamma-RIIa", "FcRII-a", "IgG Fc receptor II-a", "Low affinity immunoglobulin gamma Fc region receptor II-a precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-a\nMAMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSRLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">954 bp\nATGGCTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "14", "id": "BE0002099", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31994", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "general-function": null, "specific-function": "Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B- cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis", "gene-name": "FCGR2B", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.12", "molecular-weight": "34044.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3618"}, {"resource": "GenAtlas", "identifier": "FCGR2B"}, {"resource": "GeneCards", "identifier": "FCGR2B"}, {"resource": "GenBank Gene Database", "identifier": "U87560"}, {"resource": "GenBank Protein Database", "identifier": "4099445"}, {"resource": "UniProtKB", "identifier": "P31994"}, {"resource": "UniProt Accession", "identifier": "FCG2B_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-b", "Fc-gamma-RIIb", "FcRII-b", "IgG Fc receptor II-b", "Low affinity immunoglobulin gamma Fc region receptor II-b precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI"}, "gene-sequence": {"@format": "FASTA", "#text": ">930 bp\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCTCTCCCAGGATACCCTGAG\nTGCAGGGAAATGGGAGAGACCCTCCCTGAGAAACCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATT"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "15", "id": "BE0002100", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31995", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "general-function": null, "specific-function": "Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells", "gene-name": "FCGR2C", "locus": "1q23.3", "cellular-location": "Cell membrane", "transmembrane-regions": "224-246", "signal-regions": null, "theoretical-pi": "6.9", "molecular-weight": "35578.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:15626"}, {"resource": "GenAtlas", "identifier": "FCGR2C"}, {"resource": "GeneCards", "identifier": "FCGR2C"}, {"resource": "GenBank Gene Database", "identifier": "X17652"}, {"resource": "GenBank Protein Database", "identifier": "32074"}, {"resource": "UniProtKB", "identifier": "P31995"}, {"resource": "UniProt Accession", "identifier": "FCG2C_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-c", "Fc-gamma-RIIc", "FcRII-c", "IgG Fc receptor II-c", "Low affinity immunoglobulin gamma Fc region receptor II-c precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-c\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR\nAPTDDDKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">972 bp\nATGGGAATCCTGTCATTTTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACAGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCATTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCTGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG\nAAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT\nGAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG\nGCACCTACTGACGATGATAAAAACATCTACTTGACTCTTCCTCCCAACGACCATGTCAAC\nAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-10-03", "drugbank-id": [{"@primary": "true", "#text": "DB00076"}, "BIOD00027", "BIOD00046", "BTD00027", "BTD00046"], "name": "Digoxin Immune Fab (Ovine)", "description": "Digoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative Digoxindicarboxymethylamine. It is used as an antidote for overdose of digoxin.", "cas-number": null, "groups": {"group": "approved"}, "general-references": null, "synthesis-reference": null, "indication": "For treatment of digitoxin overdose or digitalis glycoside toxicity.", "pharmacodynamics": "DigiFab binds molecules of digoxin, making them unavailable for binding at their site of action on cells in the body. The Fab fragment-digoxin complex accumulates in the blood, from which it is excreted by the kidney. The net effect is to shift the equilibrium away from binding of digoxin to its receptors in the body, thereby reversing its effects.", "mechanism-of-action": "Binds excess digoxin or digitoxin molecules circulating in the blood.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": "15-20 hrs", "protein-binding": null, "route-of-elimination": "Cumulative urinary excretion of digoxin was comparable for both products and exceeded 40% of the administered dose by 24 hours.", "volume-of-distribution": "* 0.3 L/kg [DigiFab]\n* 0.4 L/kg [Digibind]", "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": {"product": [{"name": "Digibind", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02146967", "started-marketing-on": "1995-12-31", "ended-marketing-on": "2013-02-06", "dosage-form": "powder for solution", "strength": "38 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Digifab", "ndc-id": "0281-0365_e4b895ab-8a6f-46b0-ad84-f4cae6158049", "ndc-product-code": "0281-0365", "dpd-id": null, "started-marketing-on": "2001-08-31", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "38 mg", "route": "intravenous", "fda-application-number": "BLA103910", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Digifab", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02361043", "started-marketing-on": "2011-11-04", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "40 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Digifab", "ingredients": "Digoxin Immune Fab (Ovine)"}, {"name": "Digifab", "ingredients": "Digoxin Immune Fab (Ovine)"}, {"name": "Digibind", "ingredients": "Digoxin Immune Fab (Ovine)"}]}, "packagers": {"packager": [{"name": "GlaxoSmithKline Inc.", "url": "http://www.gsk.com"}, {"name": "Savage Labs", "url": "http://www.savagelabs.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Digifab 40 mg vial", "cost": {"@currency": "USD", "#text": "615.6"}, "unit": "vial"}, {"description": "Digibind 38 mg vial", "cost": {"@currency": "USD", "#text": "727.91"}, "unit": "vial"}]}, "categories": {"category": {"category": "Antidotes", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Powder for solution", "route": "intravenous", "strength": "38 mg"}, {"form": "Injection, powder, lyophilized, for solution", "route": "intravenous", "strength": "38 mg"}, {"form": "Powder for solution", "route": "intravenous", "strength": "40 mg"}]}, "atc-codes": null, "ahfs-codes": {"ahfs-code": "80:04.00"}, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">26-10 Heavy chain (murine)\nEVQLQQSGPELVKPGASVRMSCKSSGYIFTDFYMNWVRQSHGKSLDYIGYISPYSGVTGY\nNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCAGSSGNKWAMDYWGHGASVTVSSA\nKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDL\nYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEP"}, {"@format": "FASTA", "#text": ">26-10 Light chain (murine)\nDVVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLNWYLQKAGQSPKLLIYKVSNRF\nSGVPDRFSGSGSGTDFTLKISRVEAEDLGIYFCSQTTHVPPTFGGGTKLEIKRADAAPTV\nSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSM\nSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "61 \u00b0C (FAB fragment)", "source": "Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)"}, {"kind": "Hydrophobicity", "value": "-0.343", "source": null}, {"kind": "Isoelectric Point", "value": "8.01", "source": null}, {"kind": "Molecular Weight", "value": "47301.7000", "source": null}, {"kind": "Molecular Formula", "value": "C2085H3223N553O672S16", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "7676"}, {"resource": "National Drug Code Directory", "identifier": "0281-0365-10"}, {"resource": "PharmGKB", "identifier": "PA164769030"}, {"resource": "Wikipedia", "identifier": "Digoxin_Immune_Fab"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/digoxinfab.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/digoxin-immune-fab.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0004837", "name": "Digoxin", "organism": "Human", "actions": {"action": "other/unknown"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# McMillin GA, Owen WE, Lambert TL, De BK, Frank EL, Bach PR, Annesley TM, Roberts WL: Comparable effects of DIGIBIND and DigiFab in thirteen digoxin immunoassays. Clin Chem. 2002 Sep;48(9):1580-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12194938\n# Chhatre S, Thillaivinayagalingam P, Francis R, Titchener-Hooker NJ, Newcombe AR, Keshavarz-Moore E: Decision-support software for the industrial-scale chromatographic purification of antibodies. Biotechnol Prog. 2007 Jul-Aug;23(4):888-94. Epub 2007 Jul 13. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17630695\n# Thillaivinayagalingam P, Newcombe AR, O'donovan K, Francis R, Keshavarz-Moore E: Detection and quantification of affinity ligand leaching and specific antibody fragment concentration within chromatographic fractions using surface plasmon resonance. Biotechnol Appl Biochem. 2007 May 22;. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17516918\n# Betten DP, Vohra RB, Cook MD, Matteucci MJ, Clark RF: Antidote use in the critically ill poisoned patient. J Intensive Care Med. 2006 Sep-Oct;21(5):255-77. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16946442", "known-action": "yes"}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-11-24", "drugbank-id": [{"@primary": "true", "#text": "DB00078"}, "BIOD00069", "BTD00069"], "name": "Ibritumomab", "description": "Indium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.", "cas-number": "174722-31-7", "groups": {"group": "approved"}, "general-references": "#American Society of Health System Pharmacists, Inc., DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995. Ibritumomab; [updated 2013 Jan 18; cited 2014 Nov 24]. Available from http://web.b.ebscohost.com/dynamed/detail?vid=6&sid=48a6db20-234e-4280-b18e-dcd0e2fed388%40sessionmgr198&hid=102&bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BlPXNpdGU%3d#db=dme&AN=232878\n#Lexicomp Online (2014). Ibritumomab. Available at:http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7065#f_pharmacology-and-pharmacokinetics [Accessed 24 Nov. 2014].", "synthesis-reference": null, "indication": "For treatment of non-Hodgkin's lymphoma", "pharmacodynamics": "Ibritumomab is a murine monoclonal antibody against CD20 that has been radiolabeled with yttrium-90.", "mechanism-of-action": "The Fab segment of the antibody targets the CD20 epitope on B-cells, allowing the radioactive yttrium to destroy the cell via production of beta particles.", "toxicity": null, "metabolism": "Most likely removed by opsonization via the reticuloendothelial system when bound to B cells, or by human antimurine antibody production", "absorption": null, "half-life": "0.8 hours (mammalian reticulocytes, in vitro)", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": "Binding observed on lymphoid cells of the bone marrow, lymph node, thymus, red and white pulp of the spleen, lymphoid follicles of the tonsil, and lymphoid nodules of other organs (e.g., large and small intestines)", "clearance": "Approximately 7.2% of injected dose of yttrium Y 90 ibritumomab tiuxetan is excreted in urine within 7 days.", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Ig gamma-2A chain C region, membrane-bound form"}, {"@language": "", "@coder": "", "#text": "radiolabeled murine anti-CD20"}]}, "products": null, "international-brands": null, "mixtures": null, "packagers": {"packager": {"name": "Spectrum Pharmaceuticals", "url": "http://www.spectrumpharm.com"}}, "manufacturers": null, "prices": {"price": [{"description": "Zevalin in-111 kit", "cost": {"@currency": "USD", "#text": "4200.0"}, "unit": "kit"}, {"description": "Zevalin y-90 kit", "cost": {"@currency": "USD", "#text": "37800.0"}, "unit": "kit"}]}, "categories": null, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": null, "atc-codes": null, "ahfs-codes": null, "patents": {"patent": {"number": "2149329", "country": "Canada", "approved": "2008-07-15", "expires": "2013-11-12"}}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00054", "name": "Abciximab", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB01418", "name": "Acenocoumarol", "description": "Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}, {"drugbank-id": "DB00945", "name": "Acetylsalicylic acid", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00261", "name": "Anagrelide", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB06605", "name": "Apixaban", "description": "Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}, {"drugbank-id": "DB00278", "name": "Argatroban", "description": "Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}, {"drugbank-id": "DB08879", "name": "Belimumab", "description": "Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab."}, {"drugbank-id": "DB00006", "name": "Bivalirudin", "description": "Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}, {"drugbank-id": "DB06441", "name": "Cangrelor", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB01166", "name": "Cilostazol", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00215", "name": "Citalopram", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB04272", "name": "Citric Acid", "description": "May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}, {"drugbank-id": "DB00758", "name": "Clopidogrel", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00363", "name": "Clozapine", "description": "Myelosuppressive Agents may enhance the adverse/toxic effect of Clozapine. Specifically, the risk for agranulocytosis may be increased."}, {"drugbank-id": "DB06695", "name": "Dabigatran etexilate", "description": "Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}, {"drugbank-id": "DB06779", "name": "Dalteparin", "description": "Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}, {"drugbank-id": "DB06754", "name": "Danaparoid", "description": "Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}, {"drugbank-id": "DB06643", "name": "Denosumab", "description": "May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased."}, {"drugbank-id": "DB06700", "name": "Desvenlafaxine", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00586", "name": "Diclofenac", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00266", "name": "Dicoumarol", "description": "May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}, {"drugbank-id": "DB00861", "name": "Diflunisal", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB01551", "name": "Dihydrocodeine", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00975", "name": "Dipyridamole", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00476", "name": "Duloxetine", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00974", "name": "Edetic Acid", "description": "May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}, {"drugbank-id": "DB09075", "name": "Edoxaban", "description": "Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}, {"drugbank-id": "DB01225", "name": "Enoxaparin", "description": "Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}, {"drugbank-id": "DB00063", "name": "Eptifibatide", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB01175", "name": "Escitalopram", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB08794", "name": "Ethyl biscoumacetate", "description": "May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}, {"drugbank-id": "DB00749", "name": "Etodolac", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00573", "name": "Fenoprofen", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB08976", "name": "Floctafenine", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00472", "name": "Fluoxetine", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00712", "name": "Flurbiprofen", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00176", "name": "Fluvoxamine", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00569", "name": "Fondaparinux sodium", "description": "Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}, {"drugbank-id": "DB01109", "name": "Heparin", "description": "Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}, {"drugbank-id": "DB01050", "name": "Ibuprofen", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00328", "name": "Indomethacin", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB01009", "name": "Ketoprofen", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00465", "name": "Ketorolac", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB01097", "name": "Leflunomide", "description": "Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased."}, {"drugbank-id": "DB08918", "name": "Levomilnacipran", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00784", "name": "Mefenamic acid", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00814", "name": "Meloxicam", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB04817", "name": "Metamizole", "description": "May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased"}, {"drugbank-id": "DB04896", "name": "Milnacipran", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00461", "name": "Nabumetone", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB08813", "name": "Nadroparin", "description": "Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}, {"drugbank-id": "DB00788", "name": "Naproxen", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00108", "name": "Natalizumab", "description": "Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased."}, {"drugbank-id": "DB00991", "name": "Oxaprozin", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00715", "name": "Paroxetine", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00498", "name": "Phenindione", "description": "May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}, {"drugbank-id": "DB00946", "name": "Phenprocoumon", "description": "May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}, {"drugbank-id": "DB00337", "name": "Pimecrolimus", "description": "May enhance the adverse/toxic effect of Immunosuppressants."}, {"drugbank-id": "DB00554", "name": "Piroxicam", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB06209", "name": "Prasugrel", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB06228", "name": "Rivaroxaban", "description": "Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}, {"drugbank-id": "DB01656", "name": "Roflumilast", "description": "May enhance the immunosuppressive effect of Immunosuppressants."}, {"drugbank-id": "DB01104", "name": "Sertraline", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB06688", "name": "Sipuleucel-T", "description": "Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T."}, {"drugbank-id": "DB00605", "name": "Sulindac", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB06271", "name": "Sulodexide", "description": "May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}, {"drugbank-id": "DB01600", "name": "Tiaprofenic acid", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB08816", "name": "Ticagrelor", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00208", "name": "Ticlopidine", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB06822", "name": "Tinzaparin", "description": "Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}, {"drugbank-id": "DB00775", "name": "Tirofiban", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB08895", "name": "Tofacitinib", "description": "Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib."}, {"drugbank-id": "DB00500", "name": "Tolmetin", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00072", "name": "Trastuzumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00374", "name": "Treprostinil", "description": "May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}, {"drugbank-id": "DB00285", "name": "Venlafaxine", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB06684", "name": "Vilazodone", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB09030", "name": "Vorapaxar", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB09068", "name": "Vortioxetine", "description": "Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding."}, {"drugbank-id": "DB00682", "name": "Warfarin", "description": "Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding."}]}, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">Ibritumomab tiuxetan heavy chain\nQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSY\nNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTV\nSAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYT\nLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSV\nFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTL\nRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTK\nKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVER\nNSYSCSVVHEGLHNHHTTKSFSR"}, {"@format": "FASTA", "#text": ">Ibritumomab tiuxetan light chain\nQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPAR\nFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRADAAPTVFIFPPS\nDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL\nSKADYEKHKVYACEVTHQGLSSPVTKSFN"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "61 \u00b0C (FAB fragment), 71 \u00b0C (whole mAb)", "source": "Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)"}, {"kind": "Hydrophobicity", "value": "-0.359", "source": null}, {"kind": "Isoelectric Point", "value": "7.91", "source": null}, {"kind": "Molecular Weight", "value": "143375.5000", "source": null}, {"kind": "Molecular Formula", "value": "C6382H9830N1672O1979S54", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "GenBank", "identifier": "J00470"}, {"resource": "PharmGKB", "identifier": "PA164781375"}, {"resource": "UniProtKB", "identifier": "P01865"}, {"resource": "Wikipedia", "identifier": "Ibritumomab"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/zevalin.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/ibritumomab-tiuxetan-with-indium-111.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000066", "name": "B-lymphocyte antigen CD20", "organism": "Human", "actions": {"action": "antibody"}, "references": "# Wiseman GA, White CA, Witzig TE, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Grillo-Lopez AJ: Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res. 1999 Oct;5(10 Suppl):3281s-3286s. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10541376\n# Goldenberg DM: The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):195-201. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11418316\n# Dillman RO: Monoclonal antibody therapy for lymphoma: an update. Cancer Pract. 2001 Mar-Apr;9(2):71-80. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11879282\n# Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002 May 15;20(10):2453-63. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12011122\n# Witzig TE: Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma. Drugs Today (Barc). 2004 Feb;40(2):111-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15045033\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352\n# Goldsmith SJ: Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med. 2010 Mar;40(2):122-35. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20113680", "known-action": "yes", "polypeptide": {"@id": "P11836", "@source": "Swiss-Prot", "name": "B-lymphocyte antigen CD20", "general-function": "Involved in immune function and regulation", "specific-function": "This protein may be involved in the regulation of B-cell activation and proliferation", "gene-name": "MS4A1", "locus": "11q12", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "64-84\n85-105\n121-141\n189-209", "signal-regions": null, "theoretical-pi": "4.73", "molecular-weight": "33078.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:7315"}, {"resource": "GenAtlas", "identifier": "MS4A1"}, {"resource": "GeneCards", "identifier": "MS4A1"}, {"resource": "GenBank Gene Database", "identifier": "X12530"}, {"resource": "GenBank Protein Database", "identifier": "29774"}, {"resource": "UniProtKB", "identifier": "P11836"}, {"resource": "UniProt Accession", "identifier": "CD20_HUMAN"}]}, "synonyms": {"synonym": ["B-lymphocyte surface antigen B1", "Bp35", "Leu-16", "Membrane-spanning 4-domains subfamily A member 1"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">B-lymphocyte antigen CD20\nMTTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRRMSSLVGPTQSFFMRESKTLGAVQIMNG\nLFHIALGGLLMIPAGIYAPICVTVWYPLWGGIMYIISGSLLAATEKNSRKCLVKGKMIMN\nSLSLFAAISGMILSIMDILNIKISHFLKMESLNFIRAHTPYINIYNCEPANPSEKNSPST\nQYCYSIQSLFLGILSVMLIFAFFQELVIAGIVENEWKRTCSRPKSNIVLLSAEEKKEQTI\nEIKEEVVGLTETSSQPKNEEDIEIIPIQEEEEEETETNFPEPPQDQESSPIENDSSP"}, "gene-sequence": {"@format": "FASTA", "#text": ">894 bp\nATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCT\nATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCC\nACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGG\nCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATC\nTGTGTGACTGTGTGGTACCCTCTCTGGGGAGGCATTATGTATATTATTTCCGGATCACTC\nCTGGCAGCAACGGAGAAAAACTCCAGGAAGTGTTTGGTCAAAGGAAAAATGATAATGAAT\nTCATTGAGCCTCTTTGCTGCCATTTCTGGAATGATTCTTTCAATCATGGACATACTTAAT\nATTAAAATTTCCCATTTTTTAAAAATGGAGAGTCTGAATTTTATTAGAGCTCACACACCA\nTATATTAACATATACAACTGTGAACCAGCTAATCCCTCTGAGAAAAACTCCCCATCTACC\nCAATACTGTTACAGCATACAATCTCTGTTCTTGGGCATTTTGTCAGTGATGCTGATCTTT\nGCCTTCTTCCAGGAACTTGTAATAGCTGGCATCGTTGAGAATGAATGGAAAAGAACGTGC\nTCCAGACCCAAATCTAACATAGTTCTCCTGTCAGCAGAAGAAAAAAAAGAACAGACTATT\nGAAATAAAAGAAGAAGTGGTTGGGCTAACTGAAACATCTTCCCAACCAAAGAATGAAGAA\nGACATTGAAATTATTCCAATCCAAGAAGAGGAAGAAGAAGAAACAGAGACGAACTTTCCA\nGAACCTCCCCAAGATCAGGAATCCTCACCAATAGAAAATGACAGCTCTCCTTAA"}, "pfams": {"pfam": {"identifier": "PF04103", "name": "CD20"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}]}}}, {"@position": "2", "id": "BE0000901", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "O75015", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "general-function": null, "specific-function": "Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils", "gene-name": "FCGR3B", "locus": "1q23", "cellular-location": "Cell membrane; lipid-anchor; GPI-anchor. Secreted protein. Note=Secreted after cleavage", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.71", "molecular-weight": "26216.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3620"}, {"resource": "GenAtlas", "identifier": "FCGR3B"}, {"resource": "GeneCards", "identifier": "FCGR3B"}, {"resource": "GenBank Gene Database", "identifier": "X16863"}, {"resource": "GenBank Protein Database", "identifier": "31322"}, {"resource": "UniProtKB", "identifier": "O75015"}, {"resource": "UniProt Accession", "identifier": "FCG3B_HUMAN"}]}, "synonyms": {"synonym": ["CD16b antigen", "Fc-gamma RIII", "Fc-gamma RIII-beta", "Fc-gamma RIIIb", "FcR-10", "FcRIII", "FcRIIIb", "IgG Fc receptor III-1", "Low affinity immunoglobulin gamma Fc region receptor III-B precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-B precursor\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI"}, "gene-sequence": {"@format": "FASTA", "#text": ">702 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "3", "id": "BE0002093", "name": "Complement C1r subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P00736", "@source": "Swiss-Prot", "name": "Complement C1r subcomponent", "general-function": null, "specific-function": "C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system", "gene-name": "C1R", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.24", "molecular-weight": "80174.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1246"}, {"resource": "GenAtlas", "identifier": "C1R"}, {"resource": "GeneCards", "identifier": "C1R"}, {"resource": "GenBank Gene Database", "identifier": "X04701"}, {"resource": "GenBank Protein Database", "identifier": "29539"}, {"resource": "UniProtKB", "identifier": "P00736"}, {"resource": "UniProt Accession", "identifier": "C1R_HUMAN"}]}, "synonyms": {"synonym": ["Complement C1r subcomponent precursor", "Complement component 1, r subcomponent", "EC 3.4.21.41"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1r subcomponent\nMWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF\nQQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF\nSNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY\nELQEDRHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF\nDIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL\nRYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD\nDGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR\nESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF\nTNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV\nSVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME\nEKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV\nRDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2118 bp\nATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC\nATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC\nAACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC\nCAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT\nGATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG\nGGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC\nTCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT\nGTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG\nTGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT\nGAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG\nGCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC\nAACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT\nGATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC\nGGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC\nAATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG\nCGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC\nATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA\nGGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT\nGATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA\nAACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC\nCGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG\nGAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG\nGGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG\nAGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC\nACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT\nGCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC\nCTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC\nAGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG\nCTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC\nAACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG\nGAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT\nGAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT\nGGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA\nAGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC\nAGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG\nATGGAGGAGGAGGACTGA"}, "pfams": {"pfam": [{"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF07645", "name": "EGF_CA"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "4", "id": "BE0002094", "name": "Complement C1q subcomponent subunit A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02745", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit A", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QA", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.45", "molecular-weight": "26017.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1241"}, {"resource": "GenAtlas", "identifier": "C1QA"}, {"resource": "GeneCards", "identifier": "C1QA"}, {"resource": "GenBank Gene Database", "identifier": "AF135157"}, {"resource": "GenBank Protein Database", "identifier": "4894854"}, {"resource": "UniProtKB", "identifier": "P02745"}, {"resource": "UniProt Accession", "identifier": "C1QA_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit A precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit A\nMEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR\nTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI\nRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR\nGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL\nIFPSA"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG\nGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC\nAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG\nACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC\nAAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGGGCCCGTGGCATCCCGGGAATTAAA\nGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT\nCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG\nGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC\nTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG\nGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG\nGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC\nCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC\nATCTTCCCATCTGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "5", "id": "BE0002095", "name": "Complement C1q subcomponent subunit B", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02746", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit B", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QB", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.87", "molecular-weight": "26460.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1242"}, {"resource": "GenAtlas", "identifier": "C1QB"}, {"resource": "GeneCards", "identifier": "C1QB"}, {"resource": "GenBank Gene Database", "identifier": "X03084"}, {"resource": "GenBank Protein Database", "identifier": "573114"}, {"resource": "UniProtKB", "identifier": "P02746"}, {"resource": "UniProt Accession", "identifier": "C1QB_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit B precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit B\nMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEK\nGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKI\nAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCV\nNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANSIF\nSGFLLFPDMEA"}, "gene-sequence": {"@format": "FASTA", "#text": ">688 bp\nCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGG\nGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCC\nAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAA\nTCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGCCCAGGGGCCCCTGG\nAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAGAAAATCGCCTTCTC\nTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATCCGCTTCGACCACGT\nGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTCACCTGCAAGGTGCC\nCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTGTGCGTGAACCTCAT\nGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTATGCCTACAACACCTT\nCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAGAACGTCTTCCTGCA\nGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGCATCTTTTCCGGGTT\nCCTGCTCTTTCCAGATATGGAGGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "6", "id": "BE0002096", "name": "Complement C1q subcomponent subunit C", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02747", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit C", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QC", "locus": "1p36.11", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.58", "molecular-weight": "25774.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1245"}, {"resource": "GenAtlas", "identifier": "C1QC"}, {"resource": "GeneCards", "identifier": "C1QC"}, {"resource": "GenBank Gene Database", "identifier": "AF087892"}, {"resource": "GenBank Protein Database", "identifier": "33150626"}, {"resource": "UniProtKB", "identifier": "P02747"}, {"resource": "UniProt Accession", "identifier": "C1QC_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit C precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit C\nMDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP\nGIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS\nVFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV\nLLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF\nLLFPD"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG\nCTGCTGCCCCTCAGGGCCAAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC\nCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA\nGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA\nCCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC\nCCCATGGGATTCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA\nGTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC\nAACGCGGTCCTCACCAACCCGCAGGAGGATTATGACACGAGCACTGGCAAGTTCACCTGC\nAAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG\nCTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT\nCAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT\nGTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC\nCTGCTCTTCCCCGACTAG"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "7", "id": "BE0002097", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P08637", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "general-function": null, "specific-function": "Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis", "gene-name": "FCGR3A", "locus": "1q23", "cellular-location": "Cell membrane", "transmembrane-regions": "209-229", "signal-regions": null, "theoretical-pi": "8.21", "molecular-weight": "29089.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3619"}, {"resource": "GenAtlas", "identifier": "FCGR3A"}, {"resource": "GeneCards", "identifier": "FCGR3A"}, {"resource": "GenBank Gene Database", "identifier": "X52645"}, {"resource": "GenBank Protein Database", "identifier": "31324"}, {"resource": "UniProtKB", "identifier": "P08637"}, {"resource": "UniProt Accession", "identifier": "FCG3A_HUMAN"}]}, "synonyms": {"synonym": ["CD16a antigen", "Fc-gamma RIII", "Fc-gamma RIII-alpha", "Fc-gamma RIIIa", "FcR-10", "FcRIII", "FcRIIIa", "IgG Fc receptor III-2", "Low affinity immunoglobulin gamma Fc region receptor III-A precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK"}, "gene-sequence": {"@format": "FASTA", "#text": ">765 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCGACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCA\nAAAGCCACACTCAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTTTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGG\nAAGGACCATAAATTTAAATGGAGAAAGGACCCTCAAGACAAATGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "8", "id": "BE0001529", "name": "Complement C1s subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P09871", "@source": "Swiss-Prot", "name": "Complement C1s subcomponent", "general-function": "Involved in calcium ion binding", "specific-function": "C1s B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4", "gene-name": "C1S", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "4.59", "molecular-weight": "76685.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1247"}, {"resource": "GenAtlas", "identifier": "C1S"}, {"resource": "GeneCards", "identifier": "C1S"}, {"resource": "GenBank Gene Database", "identifier": "X06596"}, {"resource": "GenBank Protein Database", "identifier": "763110"}, {"resource": "UniProtKB", "identifier": "P09871"}, {"resource": "UniProt Accession", "identifier": "C1S_HUMAN"}]}, "synonyms": {"synonym": ["C1 esterase", "Complement C1s subcomponent precursor", "EC 3.4.21.42"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1s subcomponent precursor\nMWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIE\nLSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERF\nTGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVF\nTALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVF\nVAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTP\nNSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCG\nIPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPK\nCVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGN\nREPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVK\nMGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKV\nEKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCG\nTYGLYTRVKNYVDWIMKTMQENSTPRED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2067 bp\nATGTGGTGCATTGTCCTGTTTTCACTTTTGGCATGGGTTTATGCTGAGCCTACCATGTAT\nGGGGAGATCCTGTCCCCTAACTATCCTCAGGCATATCCCAGTGAGGTAGAGAAATCTTGG\nGACATAGAAGTTCCTGAAGGGTATGGGATTCACCTCTACTTCACCCATCTGGACATTGAG\nCTGTCAGAGAACTGTGCGTATGACTCAGTGCAGATAATCTCAGGAGACACTGAAGAAGGG\nAGGCTCTGTGGACAGAGGAGCAGTAACAATCCCCACTCTCCAATTGTGGAAGAGTTCCAA\nGTCCCATACAACAAACTCCAGGTGATCTTTAAGTCAGACTTTTCCAATGAAGAGCGTTTT\nACGGGGTTTGCTGCATACTATGTTGCCACAGACATAAATGAATGCACAGATTTTGTAGAT\nGTCCCTTGTAGCCACTTCTGCAACAATTTCATTGGTGGTTACTTCTGCTCCTGCCCCCCG\nGAATATTTCCTCCATGATGACATGAAGAATTGCGGAGTTAATTGCAGTGGGGATGTATTC\nACTGCACTGATTGGGGAGATTGCAAGTCCCAATTATCCCAAACCATATCCAGAGAACTCA\nAGGTGTGAATACCAGATCCGGTTGGAGAAAGGGTTCCAAGTGGTGGTGACCTTGCGGAGA\nGAAGATTTTGATGTGGAAGCAGCTGACTCAGCGGGAAACTGCCTTGACAGTTTAGTTTTT\nGTTGCAGGAGATCGGCAATTTGGTCCTTACTGTGGTCATGGATTCCCTGGGCCTCTAAAT\nATTGAAACCAAGAGTAATGCTCTTGATATCATCTTCCAAACTGATCTAACAGGGCAAAAA\nAAGGGCTGGAAACTTCGCTATCATGGAGATCCAATGCCCTGCCCTAAGGAAGACACTCCC\nAATTCTGTTTGGGAGCCTGCGAAGGCAAAATATGTCTTTAGAGATGTGGTGCAGATAACC\nTGTCTGGATGGGTTTGAAGTTGTGGAGGGACGTGTTGGTGCAACATCTTTCTATTCGACT\nTGTCAAAGCAATGGAAAGTGGAGTAATTCCAAACTGAAATGTCAACCTGTGGACTGTGGC\nATTCCTGAATCCATTGAGAATGGTAAAGTTGAAGACCCAGAGAGCACTTTGTTTGGTTCT\nGTCATCCGCTACACTTGTGAGGAGCCATATTACTACATGGAAAATGGAGGAGGTGGGGAG\nTATCACTGTGCTGGTAACGGGAGCTGGGTGAATGAGGTGCTGGGCCCGGAGCTGCCGAAA\nTGTGTTCCAGTCTGTGGAGTCCCCAGAGAACCCTTTGAAGAAAAACAGAGGATAATTGGA\nGGATCCGATGCAGATATTAAAAACTTCCCCTGGCAAGTCTTCTTTGACAACCCATGGGCT\nGGTGGAGCGCTCATTAATGAGTACTGGGTGCTGACGGCTGCTCATGTTGTGGAGGGAAAC\nAGGGAGCCAACAATGTATGTTGGGTCCACCTCAGTGCAGACCTCACGGCTGGCAAAATCC\nAAGATGCTCACTCCTGAGCATGTGTTTATTCATCCGGGATGGAAGCTGCTGGAAGTCCCA\nGAAGGACGAACCAATTTTGATAATGACATTGCACTGGTGCGGCTGAAAGACCCAGTGAAA\nATGGGACCCACCGTCTCTCCCATCTGCCTACCAGGCACCTCTTCCGACTACAACCTCATG\nGATGGGGACCTGGGACTGATCTCAGGCTGGGGCCGAACAGAGAAGAGAGATCGTGCTGTT\nCGCCTCAAGGCGGCAAGGTTACCTGTAGCTCCTTTAAGAAAATGCAAAGAAGTGAAAGTG\nGAGAAACCCACAGCAGATGCAGAGGCCTATGTTTTCACTCCTAACATGATCTGTGCTGGA\nGGAGAGAAGGGCATGGATAGCTGTAAAGGGGACAGTGGTGGGGCCTTTGCTGTACAGGAT\nCCCAATGACAAGACCAAATTCTACGCAGCTGGCCTGGTGTCCTGGGGGCCCCAGTGTGGG\nACCTATGGGCTCTACACACGGGTAAAGAACTATGTTGACTGGATAATGAAGACTATGCAG\nGAAAATAGCACCCCCCGTGAGGACTAA"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "9", "id": "BE0000710", "name": "High affinity immunoglobulin gamma Fc receptor I", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P12314", "@source": "Swiss-Prot", "name": "High affinity immunoglobulin gamma Fc receptor I", "general-function": "Involved in receptor signaling protein activity", "specific-function": "Binds to the Fc region of immunoglobulins gamma. High affinity receptor", "gene-name": "FCGR1A", "locus": "1q21.2-q21.3", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "293-313", "signal-regions": null, "theoretical-pi": "8.08", "molecular-weight": "42632.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3613"}, {"resource": "GenAtlas", "identifier": "FCGR1A"}, {"resource": "GeneCards", "identifier": "FCGR1A"}, {"resource": "GenBank Gene Database", "identifier": "X14356"}, {"resource": "GenBank Protein Database", "identifier": "31332"}, {"resource": "UniProtKB", "identifier": "P12314"}, {"resource": "UniProt Accession", "identifier": "FCGR1_HUMAN"}]}, "synonyms": {"synonym": ["CD64 antigen", "Fc-gamma RI", "FcRI", "High affinity immunoglobulin gamma Fc receptor I precursor", "IgG Fc receptor I"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">High affinity immunoglobulin gamma Fc receptor I precursor\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1125 bp\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCTCTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAACTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "10", "id": "BE0002098", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P12318", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "general-function": null, "specific-function": "Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens", "gene-name": "FCGR2A", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.78", "molecular-weight": "34990.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3616"}, {"resource": "GenAtlas", "identifier": "FCGR2A"}, {"resource": "GeneCards", "identifier": "FCGR2A"}, {"resource": "GenBank Gene Database", "identifier": "M31932"}, {"resource": "GenBank Protein Database", "identifier": "182474"}, {"resource": "UniProtKB", "identifier": "P12318"}, {"resource": "UniProt Accession", "identifier": "FCG2A_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-a", "Fc-gamma-RIIa", "FcRII-a", "IgG Fc receptor II-a", "Low affinity immunoglobulin gamma Fc region receptor II-a precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-a\nMAMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSRLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">954 bp\nATGGCTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "11", "id": "BE0002099", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31994", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "general-function": null, "specific-function": "Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B- cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis", "gene-name": "FCGR2B", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.12", "molecular-weight": "34044.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3618"}, {"resource": "GenAtlas", "identifier": "FCGR2B"}, {"resource": "GeneCards", "identifier": "FCGR2B"}, {"resource": "GenBank Gene Database", "identifier": "U87560"}, {"resource": "GenBank Protein Database", "identifier": "4099445"}, {"resource": "UniProtKB", "identifier": "P31994"}, {"resource": "UniProt Accession", "identifier": "FCG2B_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-b", "Fc-gamma-RIIb", "FcRII-b", "IgG Fc receptor II-b", "Low affinity immunoglobulin gamma Fc region receptor II-b precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI"}, "gene-sequence": {"@format": "FASTA", "#text": ">930 bp\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCTCTCCCAGGATACCCTGAG\nTGCAGGGAAATGGGAGAGACCCTCCCTGAGAAACCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATT"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "12", "id": "BE0002100", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31995", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "general-function": null, "specific-function": "Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells", "gene-name": "FCGR2C", "locus": "1q23.3", "cellular-location": "Cell membrane", "transmembrane-regions": "224-246", "signal-regions": null, "theoretical-pi": "6.9", "molecular-weight": "35578.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:15626"}, {"resource": "GenAtlas", "identifier": "FCGR2C"}, {"resource": "GeneCards", "identifier": "FCGR2C"}, {"resource": "GenBank Gene Database", "identifier": "X17652"}, {"resource": "GenBank Protein Database", "identifier": "32074"}, {"resource": "UniProtKB", "identifier": "P31995"}, {"resource": "UniProt Accession", "identifier": "FCG2C_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-c", "Fc-gamma-RIIc", "FcRII-c", "IgG Fc receptor II-c", "Low affinity immunoglobulin gamma Fc region receptor II-c precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-c\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR\nAPTDDDKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">972 bp\nATGGGAATCCTGTCATTTTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACAGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCATTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCTGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG\nAAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT\nGAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG\nGCACCTACTGACGATGATAAAAACATCTACTTGACTCTTCCTCCCAACGACCATGTCAAC\nAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-11-12", "drugbank-id": [{"@primary": "true", "#text": "DB00080"}, "BIOD00111", "BTD00111"], "name": "Daptomycin", "description": "Daptomycin is a lipopeptide antibiotic that kills susceptible gram positive bacteria by disrupting their membrane potential. It is a naturally-occurring compound found in the soil bacterium <i>Streptomyces roseosporus</i>. Antibiotics are used in the treatment of infections caused by bacteria. They work by killing bacteria or preventing their growth. Daptomycin will not work for colds, flu, or other virus infections. It was approved in September 2003 for the treatment of complicated skin and soft tissue infections. It has a safety profile similar to other agents commonly administered to treat gram-positive infections.", "cas-number": "103060-53-3", "groups": {"group": ["approved", "investigational"]}, "general-references": "# Woodworth JR, Nyhart EH Jr, Brier GL, Wolny JD, Black HR: Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother. 1992 Feb;36(2):318-25. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1318678\n# Tally FP, DeBruin MF: Development of daptomycin for gram-positive infections. J Antimicrob Chemother. 2000 Oct;46(4):523-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11020247\n# Charles PG, Grayson ML: The dearth of new antibiotic development: why we should be worried and what we can do about it. Med J Aust. 2004 Nov 15;181(10):549-53. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15540967\n# Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fatkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE: Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006 Aug 17;355(7):653-65. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16914701\n# Lee SY, Fan HW, Kuti JL, Nicolau DP: Update on daptomycin: the first approved lipopeptide antibiotic. Expert Opin Pharmacother. 2006 Jul;7(10):1381-97. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16805723\n# http://www.google.com/patents/WO2002059322A2?cl=en\n#Lexicomp\n#Dynamed", "synthesis-reference": "Dennis Keith, \"Methods for preparing purified daptomycin.\" U.S. Patent US20030045484, issued March 06, 2003.", "indication": "For the treatment of complicated skin and skin structure infections caused by susceptible strains of Gram-positive microorganisms.", "pharmacodynamics": "Daptomycin is a 13 member amino acid cyclic lipopeptide antibiotic active against Gram-positive bacteria only. It has proven in vitro activity against enterococci (including glycopeptide-resistant Enterococci (GRE)), staphylococci (including methicillin-resistant <i>Staphylococcus aureus</i>), streptococci and corynebacteria. Daptomycin is derived from the fermentation product of Streptomyces roseosporus.", "mechanism-of-action": "Daptomycin appears to bind or insert into the outer membrane of gram positive bacteria. The binding and integration of daptomycin into the cell membrane is calcium dependent. Calcium ions cause a conformational change in daptomycin, augmenting its amphipathicity (hydrophilic head group and hydrophobic tail group), leading to incorporation into the cell membrane.\nThis binding causes rapid depolarisation, resulting in a loss of membrane potential leading to inhibition of protein, DNA and RNA synthesis, which results in bacterial cell death. The bactericidal activity of daptomycin is concentration-dependent. There is in vitro evidence of synergy with \u03b2-lactam antibiotics.", "toxicity": null, "metabolism": "Minor amounts of three oxidative metabolites and one unidentified compound have been detected in urine. The site of metabolism has not been identified.", "absorption": "Generally exhibits linear and time-independent pharmacokinetics at a dosage of 4\u201312 mg/kg IV once every 24 hours. Steady-state trough serum concentrations are achieved by the third daily dose.", "half-life": "Half-life elimination: 8-9 hours (up to 28 hours in renal impairment)", "protein-binding": "Daptomycin is reversibly bound to human plasma proteins, primarily to serum albumin, in a concentration-independent manner. The overall mean binding ranged from 90 to 93%.", "route-of-elimination": "Daptomycin is excreted primarily by the kidney.\u00c2  In a mass balance study of 5 healthy subjects using radiolabeled daptomycin, approximately 78% of the administered dose was recovered from urine based on total radioactivity (approximately 52% of the dose based on microbiologically active concentrations) and 5.7% of the dose was recovered from feces (collected for up to 9 days) based on total radioactivity. Because renal excretion is the primary route of elimination, dosage adjustment is necessary in patients with severe renal insufficiency (CLCR <30 mL/min)", "volume-of-distribution": "* 0.1 L/Kg [healthy adult subjects]", "clearance": "Excreted primarily in the urine as unchanged drug (78%) and in the feces (6%)", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": {"product": [{"name": "Cubicin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02299909", "started-marketing-on": "2007-12-03", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "500 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Cubicin", "ndc-id": "67919-011_5ef7e6fe-5dca-4939-9f21-2e07ad3236ad", "ndc-product-code": "67919-011", "dpd-id": null, "started-marketing-on": "2003-09-12", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "500 mg/10mL", "route": "intravenous", "fda-application-number": "NDA021572", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Daptomycin", "ndc-id": "0409-0106_d86d83cb-30cf-47fa-bb0c-18ce2179677f", "ndc-product-code": "0409-0106", "dpd-id": null, "started-marketing-on": "2014-09-12", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "50 mg/mL", "route": "intravenous", "fda-application-number": "ANDA202857", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Daptomycin", "ingredients": "Daptomycin"}, {"name": "Cubicin", "ingredients": "Daptomycin"}, {"name": "Cubicin", "ingredients": "Daptomycin"}]}, "packagers": {"packager": [{"name": "Cardinal Health", "url": "http://www.cardinal.com"}, {"name": "Catalent Pharma Solutions", "url": "http://www.catalent.com"}, {"name": "Cubist Pharmaceuticals Inc.", "url": "http://www.cubist.com"}, {"name": "Hospira Inc.", "url": "http://www.hospira.com"}, {"name": "Oso Biopharmaceuticals Manufacturing LLC", "url": null}, {"name": "Sepracor Pharmaceuticals Inc.", "url": "http://www.sepracor.com"}]}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Cubist pharmaceuticals inc"}}, "prices": {"price": {"description": "Cubicin 500 mg vial", "cost": {"@currency": "USD", "#text": "272.7"}, "unit": "vial"}}, "categories": null, "affected-organisms": {"affected-organism": "Enteric bacteria and other eubacteria"}, "dosages": {"dosage": [{"form": "Injection, powder, lyophilized, for solution", "route": "intravenous", "strength": "500 mg/10mL"}, {"form": "Powder for solution", "route": "intravenous", "strength": "500 mg"}, {"form": "Injection, powder, lyophilized, for solution", "route": "intravenous", "strength": "50 mg/mL"}]}, "atc-codes": {"atc-code": {"@code": "J01XX09", "level": [{"@code": "J", "#text": "ANTIINFECTIVES FOR SYSTEMIC USE"}, {"@code": "J01", "#text": "ANTIBACTERIALS FOR SYSTEMIC USE"}, {"@code": "J01X", "#text": "OTHER ANTIBACTERIALS"}, {"@code": "J01XX", "#text": "Other antibacterials"}]}}, "ahfs-codes": null, "patents": {"patent": [{"number": "2344318", "country": "Canada", "approved": "2006-07-04", "expires": "2019-09-24"}, {"number": "6468967", "country": "United States", "approved": "1999-09-24", "expires": "2019-09-24"}, {"number": "RE39071", "country": "United States", "approved": "1996-06-15", "expires": "2016-06-15"}]}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB01076", "name": "Atorvastatin", "description": "HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of Daptomycin. Specifically, the risk of skeletal muscle toxicity may be increased."}, {"drugbank-id": "DB01095", "name": "Fluvastatin", "description": "HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of Daptomycin. Specifically, the risk of skeletal muscle toxicity may be increased."}, {"drugbank-id": "DB00227", "name": "Lovastatin", "description": "HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of Daptomycin. Specifically, the risk of skeletal muscle toxicity may be increased."}, {"drugbank-id": "DB08860", "name": "Pitavastatin", "description": "HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of Daptomycin. Specifically, the risk of skeletal muscle toxicity may be increased."}, {"drugbank-id": "DB00175", "name": "Pravastatin", "description": "HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of Daptomycin. Specifically, the risk of skeletal muscle toxicity may be increased."}, {"drugbank-id": "DB01098", "name": "Rosuvastatin", "description": "HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of Daptomycin. Specifically, the risk of skeletal muscle toxicity may be increased."}, {"drugbank-id": "DB00641", "name": "Simvastatin", "description": "HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of Daptomycin. Specifically, the risk of skeletal muscle toxicity may be increased."}]}, "sequences": null, "experimental-properties": {"property": [{"kind": "Molecular Weight", "value": "1620.6706", "source": null}, {"kind": "Molecular Formula", "value": "C72H101N17O26", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "20161"}, {"resource": "KEGG Compound", "identifier": "C12013"}, {"resource": "KEGG Drug", "identifier": "D01080"}, {"resource": "National Drug Code Directory", "identifier": "67919-011-01"}, {"resource": "PharmGKB", "identifier": "PA164768820"}, {"resource": "Wikipedia", "identifier": "Daptomycin"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/cubicin.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/daptomycin.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0004833", "name": "Bacterial outer membrane", "organism": null, "actions": {"action": "incorporation into and destabilization"}, "references": "# Jerala R: Synthetic lipopeptides: a novel class of anti-infectives. Expert Opin Investig Drugs. 2007 Aug;16(8):1159-69. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17685866\n# Lee SY, Fan HW, Kuti JL, Nicolau DP: Update on daptomycin: the first approved lipopeptide antibiotic. Expert Opin Pharmacother. 2006 Jul;7(10):1381-97. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16805723\n# Guay DR: Daptomycin: the first approved lipopeptide antimicrobial. Consult Pharm. 2004 Jul;19(7):614-28. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16553491\n# Jung D, Rozek A, Okon M, Hancock RE: Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol. 2004 Jul;11(7):949-57. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15271353", "known-action": "yes"}, {"id": "BE0004832", "name": "Lipoteichoic acid synthesis", "organism": "Gram positive bacteria", "actions": {"action": "inhibitor"}, "references": "# Canepari P, Boaretti M: Lipoteichoic acid as a target for antimicrobial action. Microb Drug Resist. 1996 Spring;2(1):85-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9158727\n# Canepari P, Boaretti M, Lleo MM, Satta G: Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032). Antimicrob Agents Chemother. 1990 Jun;34(6):1220-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2168145", "known-action": "unknown"}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2010-09-29", "drugbank-id": [{"@primary": "true", "#text": "DB00081"}, "BIOD00085", "BTD00085"], "name": "Tositumomab", "description": "Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine).", "cas-number": "192391-48-3", "groups": {"group": "approved"}, "general-references": null, "synthesis-reference": null, "indication": "For treatment of non-Hodgkin's lymphoma (CD20 positive, follicular)", "pharmacodynamics": "Tositumomab binds to the CD20 antigen, which is predominantly expressed on mature B cells and on >90% of B-cell non-Hodgkin's lympohomas. The antibody leads to selective killing of B-cells.", "mechanism-of-action": "Binds to the CD20 antigen which is found on mature B lymphocytes. The antibody binding appears to induce apoptosis, complement-dependent cytotoxicity and cell death through ionizing radiation.", "toxicity": null, "metabolism": "Most likely removed by opsonization via the reticuloendothelial system when bound to B lymphocytes, or by human antimurine antibody production", "absorption": null, "half-life": "0.8 hours (mammalian reticulocytes, in vitro)", "protein-binding": null, "route-of-elimination": "Elimination of Iodine-131 occurs by decay and excretion in the urine.", "volume-of-distribution": null, "clearance": "* 68.2 mg/hr [patients with NHL]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": {"@language": "", "@coder": "", "#text": "Ig gamma-1 chain C region"}}, "products": {"product": {"name": "Bexxar Therapy", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02270471", "started-marketing-on": "2006-04-10", "ended-marketing-on": "2014-07-31", "dosage-form": "solution; kit", "strength": "14 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}}, "international-brands": {"international-brand": {"name": "Bexxar", "company": "Corixa Corp"}}, "mixtures": {"mixture": {"name": "Bexxar Therapy", "ingredients": "Tositumomab"}}, "packagers": {"packager": [{"name": "GlaxoSmithKline Inc.", "url": "http://www.gsk.com"}, {"name": "MDS Nordion", "url": "http://www.mds.nordion.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Bexxar 14 mg/ml dosimetric", "cost": {"@currency": "USD", "#text": "100.43"}, "unit": "ml"}, {"description": "Bexxar 131 iodine dosimetric", "cost": {"@currency": "USD", "#text": "180.77"}, "unit": "ml"}]}, "categories": null, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": {"form": "Solution; kit", "route": "intravenous", "strength": "14 mg"}}, "atc-codes": null, "ahfs-codes": {"ahfs-code": "10:00.00"}, "patents": null, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00054", "name": "Abciximab", "description": "May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased."}, {"drugbank-id": "DB01418", "name": "Acenocoumarol", "description": "May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased."}, {"drugbank-id": "DB08879", "name": "Belimumab", "description": "Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab."}, {"drugbank-id": "DB04272", "name": "Citric Acid", "description": "May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased."}, {"drugbank-id": "DB00363", "name": "Clozapine", "description": "Myelosuppressive Agents may enhance the adverse/toxic effect of Clozapine. Specifically, the risk for agranulocytosis may be increased."}, {"drugbank-id": "DB06779", "name": "Dalteparin", "description": "May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased."}, {"drugbank-id": "DB06643", "name": "Denosumab", "description": "May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased."}, {"drugbank-id": "DB00266", "name": "Dicoumarol", "description": "May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased."}, {"drugbank-id": "DB00974", "name": "Edetic Acid", "description": "May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased."}, {"drugbank-id": "DB01225", "name": "Enoxaparin", "description": "May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased."}, {"drugbank-id": "DB08794", "name": "Ethyl biscoumacetate", "description": "May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased."}, {"drugbank-id": "DB00569", "name": "Fondaparinux sodium", "description": "May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased."}, {"drugbank-id": "DB01109", "name": "Heparin", "description": "May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased."}, {"drugbank-id": "DB01097", "name": "Leflunomide", "description": "Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased."}, {"drugbank-id": "DB04817", "name": "Metamizole", "description": "May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased"}, {"drugbank-id": "DB00108", "name": "Natalizumab", "description": "Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased."}, {"drugbank-id": "DB00498", "name": "Phenindione", "description": "May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased."}, {"drugbank-id": "DB00946", "name": "Phenprocoumon", "description": "May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased."}, {"drugbank-id": "DB00337", "name": "Pimecrolimus", "description": "May enhance the adverse/toxic effect of Immunosuppressants."}, {"drugbank-id": "DB01656", "name": "Roflumilast", "description": "May enhance the immunosuppressive effect of Immunosuppressants."}, {"drugbank-id": "DB06688", "name": "Sipuleucel-T", "description": "Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T."}, {"drugbank-id": "DB06271", "name": "Sulodexide", "description": "May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased."}, {"drugbank-id": "DB08895", "name": "Tofacitinib", "description": "Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib."}, {"drugbank-id": "DB00072", "name": "Trastuzumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00374", "name": "Treprostinil", "description": "May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased."}, {"drugbank-id": "DB00682", "name": "Warfarin", "description": "May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased."}]}, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">Mouse-Human chimeric Anti-CD20 Heavy Chain 1\nQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSY\nNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTV\nSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY\nSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSV\nFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY\nRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK\nNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG\nNVFSCSVMHEALHNHYTQKSLSLSPGK"}, {"@format": "FASTA", "#text": ">Mouse-Human chimeric Anti-CD20 Light Chain 1\nQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPAR\nFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRTVAAPSVFIFPPS\nDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL\nSKADYEKHKVYACEVTHQGLSSPVTKSFNR"}, {"@format": "FASTA", "#text": ">Mouse-Human chimeric Anti-CD20 Heavy Chain 2\nQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSY\nNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTV\nSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY\nSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSV\nFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY\nRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK\nNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG\nNVFSCSVMHEALHNHYTQKSLSLSPGK"}, {"@format": "FASTA", "#text": ">Mouse-Human chimeric Anti-CD20 Light Chain 2\nQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPAR\nFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRTVAAPSVFIFPPS\nDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL\nSKADYEKHKVYACEVTHQGLSSPVTKSFNR"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "61 \u00b0C (FAB fragment), 71 \u00b0C (whole mAb)", "source": "Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)"}, {"kind": "Hydrophobicity", "value": "-0.414", "source": null}, {"kind": "Isoelectric Point", "value": "8.68", "source": null}, {"kind": "Molecular Weight", "value": "143859.7000", "source": null}, {"kind": "Molecular Formula", "value": "C6416H9874N1688O1987S44", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "16096"}, {"resource": "National Drug Code Directory", "identifier": "0007-3260-31"}, {"resource": "GenBank", "identifier": "J00228"}, {"resource": "PharmGKB", "identifier": "PA164748364"}, {"resource": "UniProtKB", "identifier": "P01857"}, {"resource": "Wikipedia", "identifier": "Tositumomab"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/bexxar.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/iodine-i-131-tositumomab.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000066", "name": "B-lymphocyte antigen CD20", "organism": "Human", "actions": {"action": "antibody"}, "references": "# Goldenberg DM: The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):195-201. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11418316\n# Dillman RO: Monoclonal antibody therapy for lymphoma: an update. Cancer Pract. 2001 Mar-Apr;9(2):71-80. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11879282\n# Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab. BioDrugs. 2003;17(4):290-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12899647\n# Friedberg JW, Fisher RI: Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther. 2004 Feb;4(1):18-26. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14748653\n# Silverman DH, Delpassand ES, Torabi F, Goy A, McLaughlin P, Murray JL: Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues. Cancer Treat Rev. 2004 Apr;30(2):165-72. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15023434\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352\n# Beeson C, Butrynski JE, Hart MJ, Nourigat C, Matthews DC, Press OW, Senter PD, Bernstein ID: Conditionally cleavable radioimmunoconjugates: a novel approach for the release of radioisotopes from radioimmunoconjugates. Bioconjug Chem. 2003 Sep-Oct;14(5):927-33. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/13129395", "known-action": "yes", "polypeptide": {"@id": "P11836", "@source": "Swiss-Prot", "name": "B-lymphocyte antigen CD20", "general-function": "Involved in immune function and regulation", "specific-function": "This protein may be involved in the regulation of B-cell activation and proliferation", "gene-name": "MS4A1", "locus": "11q12", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "64-84\n85-105\n121-141\n189-209", "signal-regions": null, "theoretical-pi": "4.73", "molecular-weight": "33078.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:7315"}, {"resource": "GenAtlas", "identifier": "MS4A1"}, {"resource": "GeneCards", "identifier": "MS4A1"}, {"resource": "GenBank Gene Database", "identifier": "X12530"}, {"resource": "GenBank Protein Database", "identifier": "29774"}, {"resource": "UniProtKB", "identifier": "P11836"}, {"resource": "UniProt Accession", "identifier": "CD20_HUMAN"}]}, "synonyms": {"synonym": ["B-lymphocyte surface antigen B1", "Bp35", "Leu-16", "Membrane-spanning 4-domains subfamily A member 1"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">B-lymphocyte antigen CD20\nMTTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRRMSSLVGPTQSFFMRESKTLGAVQIMNG\nLFHIALGGLLMIPAGIYAPICVTVWYPLWGGIMYIISGSLLAATEKNSRKCLVKGKMIMN\nSLSLFAAISGMILSIMDILNIKISHFLKMESLNFIRAHTPYINIYNCEPANPSEKNSPST\nQYCYSIQSLFLGILSVMLIFAFFQELVIAGIVENEWKRTCSRPKSNIVLLSAEEKKEQTI\nEIKEEVVGLTETSSQPKNEEDIEIIPIQEEEEEETETNFPEPPQDQESSPIENDSSP"}, "gene-sequence": {"@format": "FASTA", "#text": ">894 bp\nATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCT\nATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCC\nACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGG\nCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATC\nTGTGTGACTGTGTGGTACCCTCTCTGGGGAGGCATTATGTATATTATTTCCGGATCACTC\nCTGGCAGCAACGGAGAAAAACTCCAGGAAGTGTTTGGTCAAAGGAAAAATGATAATGAAT\nTCATTGAGCCTCTTTGCTGCCATTTCTGGAATGATTCTTTCAATCATGGACATACTTAAT\nATTAAAATTTCCCATTTTTTAAAAATGGAGAGTCTGAATTTTATTAGAGCTCACACACCA\nTATATTAACATATACAACTGTGAACCAGCTAATCCCTCTGAGAAAAACTCCCCATCTACC\nCAATACTGTTACAGCATACAATCTCTGTTCTTGGGCATTTTGTCAGTGATGCTGATCTTT\nGCCTTCTTCCAGGAACTTGTAATAGCTGGCATCGTTGAGAATGAATGGAAAAGAACGTGC\nTCCAGACCCAAATCTAACATAGTTCTCCTGTCAGCAGAAGAAAAAAAAGAACAGACTATT\nGAAATAAAAGAAGAAGTGGTTGGGCTAACTGAAACATCTTCCCAACCAAAGAATGAAGAA\nGACATTGAAATTATTCCAATCCAAGAAGAGGAAGAAGAAGAAACAGAGACGAACTTTCCA\nGAACCTCCCCAAGATCAGGAATCCTCACCAATAGAAAATGACAGCTCTCCTTAA"}, "pfams": {"pfam": {"identifier": "PF04103", "name": "CD20"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}]}}}, {"@position": "2", "id": "BE0000901", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "O75015", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "general-function": null, "specific-function": "Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils", "gene-name": "FCGR3B", "locus": "1q23", "cellular-location": "Cell membrane; lipid-anchor; GPI-anchor. Secreted protein. Note=Secreted after cleavage", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.71", "molecular-weight": "26216.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3620"}, {"resource": "GenAtlas", "identifier": "FCGR3B"}, {"resource": "GeneCards", "identifier": "FCGR3B"}, {"resource": "GenBank Gene Database", "identifier": "X16863"}, {"resource": "GenBank Protein Database", "identifier": "31322"}, {"resource": "UniProtKB", "identifier": "O75015"}, {"resource": "UniProt Accession", "identifier": "FCG3B_HUMAN"}]}, "synonyms": {"synonym": ["CD16b antigen", "Fc-gamma RIII", "Fc-gamma RIII-beta", "Fc-gamma RIIIb", "FcR-10", "FcRIII", "FcRIIIb", "IgG Fc receptor III-1", "Low affinity immunoglobulin gamma Fc region receptor III-B precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-B precursor\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI"}, "gene-sequence": {"@format": "FASTA", "#text": ">702 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "3", "id": "BE0002093", "name": "Complement C1r subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P00736", "@source": "Swiss-Prot", "name": "Complement C1r subcomponent", "general-function": null, "specific-function": "C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system", "gene-name": "C1R", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.24", "molecular-weight": "80174.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1246"}, {"resource": "GenAtlas", "identifier": "C1R"}, {"resource": "GeneCards", "identifier": "C1R"}, {"resource": "GenBank Gene Database", "identifier": "X04701"}, {"resource": "GenBank Protein Database", "identifier": "29539"}, {"resource": "UniProtKB", "identifier": "P00736"}, {"resource": "UniProt Accession", "identifier": "C1R_HUMAN"}]}, "synonyms": {"synonym": ["Complement C1r subcomponent precursor", "Complement component 1, r subcomponent", "EC 3.4.21.41"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1r subcomponent\nMWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF\nQQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF\nSNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY\nELQEDRHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF\nDIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL\nRYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD\nDGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR\nESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF\nTNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV\nSVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME\nEKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV\nRDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2118 bp\nATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC\nATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC\nAACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC\nCAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT\nGATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG\nGGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC\nTCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT\nGTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG\nTGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT\nGAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG\nGCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC\nAACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT\nGATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC\nGGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC\nAATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG\nCGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC\nATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA\nGGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT\nGATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA\nAACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC\nCGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG\nGAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG\nGGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG\nAGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC\nACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT\nGCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC\nCTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC\nAGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG\nCTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC\nAACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG\nGAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT\nGAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT\nGGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA\nAGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC\nAGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG\nATGGAGGAGGAGGACTGA"}, "pfams": {"pfam": [{"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF07645", "name": "EGF_CA"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "4", "id": "BE0002094", "name": "Complement C1q subcomponent subunit A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02745", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit A", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QA", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.45", "molecular-weight": "26017.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1241"}, {"resource": "GenAtlas", "identifier": "C1QA"}, {"resource": "GeneCards", "identifier": "C1QA"}, {"resource": "GenBank Gene Database", "identifier": "AF135157"}, {"resource": "GenBank Protein Database", "identifier": "4894854"}, {"resource": "UniProtKB", "identifier": "P02745"}, {"resource": "UniProt Accession", "identifier": "C1QA_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit A precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit A\nMEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR\nTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI\nRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR\nGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL\nIFPSA"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG\nGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC\nAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG\nACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC\nAAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGGGCCCGTGGCATCCCGGGAATTAAA\nGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT\nCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG\nGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC\nTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG\nGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG\nGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC\nCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC\nATCTTCCCATCTGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "5", "id": "BE0002095", "name": "Complement C1q subcomponent subunit B", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02746", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit B", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QB", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.87", "molecular-weight": "26460.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1242"}, {"resource": "GenAtlas", "identifier": "C1QB"}, {"resource": "GeneCards", "identifier": "C1QB"}, {"resource": "GenBank Gene Database", "identifier": "X03084"}, {"resource": "GenBank Protein Database", "identifier": "573114"}, {"resource": "UniProtKB", "identifier": "P02746"}, {"resource": "UniProt Accession", "identifier": "C1QB_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit B precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit B\nMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEK\nGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKI\nAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCV\nNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANSIF\nSGFLLFPDMEA"}, "gene-sequence": {"@format": "FASTA", "#text": ">688 bp\nCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGG\nGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCC\nAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAA\nTCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGCCCAGGGGCCCCTGG\nAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAGAAAATCGCCTTCTC\nTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATCCGCTTCGACCACGT\nGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTCACCTGCAAGGTGCC\nCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTGTGCGTGAACCTCAT\nGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTATGCCTACAACACCTT\nCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAGAACGTCTTCCTGCA\nGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGCATCTTTTCCGGGTT\nCCTGCTCTTTCCAGATATGGAGGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "6", "id": "BE0002096", "name": "Complement C1q subcomponent subunit C", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02747", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit C", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QC", "locus": "1p36.11", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.58", "molecular-weight": "25774.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1245"}, {"resource": "GenAtlas", "identifier": "C1QC"}, {"resource": "GeneCards", "identifier": "C1QC"}, {"resource": "GenBank Gene Database", "identifier": "AF087892"}, {"resource": "GenBank Protein Database", "identifier": "33150626"}, {"resource": "UniProtKB", "identifier": "P02747"}, {"resource": "UniProt Accession", "identifier": "C1QC_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit C precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit C\nMDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP\nGIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS\nVFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV\nLLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF\nLLFPD"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG\nCTGCTGCCCCTCAGGGCCAAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC\nCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA\nGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA\nCCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC\nCCCATGGGATTCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA\nGTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC\nAACGCGGTCCTCACCAACCCGCAGGAGGATTATGACACGAGCACTGGCAAGTTCACCTGC\nAAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG\nCTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT\nCAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT\nGTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC\nCTGCTCTTCCCCGACTAG"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "7", "id": "BE0002097", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P08637", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "general-function": null, "specific-function": "Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis", "gene-name": "FCGR3A", "locus": "1q23", "cellular-location": "Cell membrane", "transmembrane-regions": "209-229", "signal-regions": null, "theoretical-pi": "8.21", "molecular-weight": "29089.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3619"}, {"resource": "GenAtlas", "identifier": "FCGR3A"}, {"resource": "GeneCards", "identifier": "FCGR3A"}, {"resource": "GenBank Gene Database", "identifier": "X52645"}, {"resource": "GenBank Protein Database", "identifier": "31324"}, {"resource": "UniProtKB", "identifier": "P08637"}, {"resource": "UniProt Accession", "identifier": "FCG3A_HUMAN"}]}, "synonyms": {"synonym": ["CD16a antigen", "Fc-gamma RIII", "Fc-gamma RIII-alpha", "Fc-gamma RIIIa", "FcR-10", "FcRIII", "FcRIIIa", "IgG Fc receptor III-2", "Low affinity immunoglobulin gamma Fc region receptor III-A precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK"}, "gene-sequence": {"@format": "FASTA", "#text": ">765 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCGACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCA\nAAAGCCACACTCAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTTTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGG\nAAGGACCATAAATTTAAATGGAGAAAGGACCCTCAAGACAAATGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "8", "id": "BE0000710", "name": "High affinity immunoglobulin gamma Fc receptor I", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P12314", "@source": "Swiss-Prot", "name": "High affinity immunoglobulin gamma Fc receptor I", "general-function": "Involved in receptor signaling protein activity", "specific-function": "Binds to the Fc region of immunoglobulins gamma. High affinity receptor", "gene-name": "FCGR1A", "locus": "1q21.2-q21.3", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "293-313", "signal-regions": null, "theoretical-pi": "8.08", "molecular-weight": "42632.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3613"}, {"resource": "GenAtlas", "identifier": "FCGR1A"}, {"resource": "GeneCards", "identifier": "FCGR1A"}, {"resource": "GenBank Gene Database", "identifier": "X14356"}, {"resource": "GenBank Protein Database", "identifier": "31332"}, {"resource": "UniProtKB", "identifier": "P12314"}, {"resource": "UniProt Accession", "identifier": "FCGR1_HUMAN"}]}, "synonyms": {"synonym": ["CD64 antigen", "Fc-gamma RI", "FcRI", "High affinity immunoglobulin gamma Fc receptor I precursor", "IgG Fc receptor I"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">High affinity immunoglobulin gamma Fc receptor I precursor\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1125 bp\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCTCTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAACTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "9", "id": "BE0002098", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P12318", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "general-function": null, "specific-function": "Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens", "gene-name": "FCGR2A", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.78", "molecular-weight": "34990.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3616"}, {"resource": "GenAtlas", "identifier": "FCGR2A"}, {"resource": "GeneCards", "identifier": "FCGR2A"}, {"resource": "GenBank Gene Database", "identifier": "M31932"}, {"resource": "GenBank Protein Database", "identifier": "182474"}, {"resource": "UniProtKB", "identifier": "P12318"}, {"resource": "UniProt Accession", "identifier": "FCG2A_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-a", "Fc-gamma-RIIa", "FcRII-a", "IgG Fc receptor II-a", "Low affinity immunoglobulin gamma Fc region receptor II-a precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-a\nMAMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSRLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">954 bp\nATGGCTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "10", "id": "BE0002099", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31994", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "general-function": null, "specific-function": "Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B- cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis", "gene-name": "FCGR2B", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.12", "molecular-weight": "34044.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3618"}, {"resource": "GenAtlas", "identifier": "FCGR2B"}, {"resource": "GeneCards", "identifier": "FCGR2B"}, {"resource": "GenBank Gene Database", "identifier": "U87560"}, {"resource": "GenBank Protein Database", "identifier": "4099445"}, {"resource": "UniProtKB", "identifier": "P31994"}, {"resource": "UniProt Accession", "identifier": "FCG2B_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-b", "Fc-gamma-RIIb", "FcRII-b", "IgG Fc receptor II-b", "Low affinity immunoglobulin gamma Fc region receptor II-b precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI"}, "gene-sequence": {"@format": "FASTA", "#text": ">930 bp\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCTCTCCCAGGATACCCTGAG\nTGCAGGGAAATGGGAGAGACCCTCCCTGAGAAACCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATT"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "11", "id": "BE0002100", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31995", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "general-function": null, "specific-function": "Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells", "gene-name": "FCGR2C", "locus": "1q23.3", "cellular-location": "Cell membrane", "transmembrane-regions": "224-246", "signal-regions": null, "theoretical-pi": "6.9", "molecular-weight": "35578.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:15626"}, {"resource": "GenAtlas", "identifier": "FCGR2C"}, {"resource": "GeneCards", "identifier": "FCGR2C"}, {"resource": "GenBank Gene Database", "identifier": "X17652"}, {"resource": "GenBank Protein Database", "identifier": "32074"}, {"resource": "UniProtKB", "identifier": "P31995"}, {"resource": "UniProt Accession", "identifier": "FCG2C_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-c", "Fc-gamma-RIIc", "FcRII-c", "IgG Fc receptor II-c", "Low affinity immunoglobulin gamma Fc region receptor II-c precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-c\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR\nAPTDDDKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">972 bp\nATGGGAATCCTGTCATTTTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACAGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCATTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCTGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG\nAAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT\nGAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG\nGCACCTACTGACGATGATAAAAACATCTACTTGACTCTTCCTCCCAACGACCATGTCAAC\nAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-09-13", "drugbank-id": [{"@primary": "true", "#text": "DB00082"}, "BIOD00044", "BTD00044"], "name": "Pegvisomant", "description": "Pegvisomant is a highly selective growth hormone (GH) receptor antagonist.  It is used to treat acromegaly.  Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.", "cas-number": "218620-50-9", "groups": {"group": "approved"}, "general-references": null, "synthesis-reference": "Mandayam J. Narasimhan, John A. Anderson, \"Process for the large scale production of human growth hormone by serial secondary suspension culture.\" U.S. Patent US4124448, issued January, 1963.", "indication": "Pegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly.", "pharmacodynamics": "Somavert is used for the treatment of acromegaly, which arises from excessive IGF-1 levels. Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH, and thus interferes with GH signal transduction. Inhibition of GH action results in decreased serum concentrations of insulin-like growth factor-I (IGF-I), and IGF binding protein-3 (IGFBP-3). This reduces the symptoms of acromegaly.", "mechanism-of-action": "Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH. This leads to the normalization of serum IGF-1 levels.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": "~6 days", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": "* 7 L", "clearance": "* 36 - 28 mL/h [SC doses ranging from 10 to 20 mg/day]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "GH"}, {"@language": "", "@coder": "", "#text": "GH-N"}, {"@language": "", "@coder": "", "#text": "Growth hormone"}, {"@language": "", "@coder": "", "#text": "Growth hormone 1"}, {"@language": "", "@coder": "", "#text": "Pituitary growth hormone"}, {"@language": "", "@coder": "", "#text": "Somatotropin precursor"}]}, "products": {"product": [{"name": "Somavert", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02272199", "started-marketing-on": "2006-01-24", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "10 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Somavert", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02272202", "started-marketing-on": "2006-01-24", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "15 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Somavert", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02272210", "started-marketing-on": "2006-01-24", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "20 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Somavert", "ingredients": "Pegvisomant"}, {"name": "Somavert", "ingredients": "Pegvisomant"}, {"name": "Somavert", "ingredients": "Pegvisomant"}]}, "packagers": {"packager": [{"name": "Hospira Inc.", "url": "http://www.hospira.com"}, {"name": "Pfizer Inc.", "url": "http://www.pfizer.com"}, {"name": "Pharmacia Inc.", "url": "http://www.pharmaciaupjohn.com"}]}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Pharmacia and upjohn co"}}, "prices": {"price": [{"description": "Somavert 10 mg vial", "cost": {"@currency": "USD", "#text": "104.18"}, "unit": "vial"}, {"description": "Somavert 15 mg vial", "cost": {"@currency": "USD", "#text": "156.29"}, "unit": "vial"}, {"description": "Somavert 20 mg vial", "cost": {"@currency": "USD", "#text": "208.38"}, "unit": "vial"}]}, "categories": {"category": {"category": "Hormone Replacement Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Powder for solution", "route": "subcutaneous", "strength": "10 mg"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "15 mg"}, {"form": "Powder for solution", "route": "subcutaneous", "strength": "20 mg"}]}, "atc-codes": {"atc-code": {"@code": "H01AX01", "level": [{"@code": "H", "#text": "SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS"}, {"@code": "H01", "#text": "PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES"}, {"@code": "H01A", "#text": "ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES"}, {"@code": "H01AX", "#text": "Other anterior pituitary lobe hormones and analogues"}]}}, "ahfs-codes": {"ahfs-code": "68:30.08"}, "patents": {"patent": [{"number": "2102129", "country": "Canada", "approved": "2003-04-01", "expires": "2012-05-01"}, {"number": "2230492", "country": "Canada", "approved": "2009-05-26", "expires": "2016-09-20"}, {"number": "5350836", "country": "United States", "approved": "1994-09-27", "expires": "2011-09-27"}, {"number": "5849535", "country": "United States", "approved": "1997-03-25", "expires": "2017-03-25"}]}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00284", "name": "Acarbose", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB09043", "name": "Albiglutide", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00802", "name": "Alfentanil", "description": "Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant."}, {"drugbank-id": "DB06203", "name": "Alogliptin", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB01200", "name": "Bromocriptine", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00921", "name": "Buprenorphine", "description": "Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant."}, {"drugbank-id": "DB00611", "name": "Butorphanol", "description": "Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant."}, {"drugbank-id": "DB08907", "name": "Canagliflozin", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00672", "name": "Chlorpropamide", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00318", "name": "Codeine", "description": "Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant."}, {"drugbank-id": "DB06292", "name": "Dapagliflozin", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB01551", "name": "Dihydrocodeine", "description": "Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant."}, {"drugbank-id": "DB00280", "name": "Disopyramide", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB09045", "name": "Dulaglutide", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB09038", "name": "Empagliflozin", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB01276", "name": "Exenatide", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00813", "name": "Fentanyl", "description": "Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant."}, {"drugbank-id": "DB01120", "name": "Gliclazide", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00222", "name": "Glimepiride", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB01067", "name": "Glipizide", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB01016", "name": "Glyburide", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00956", "name": "Hydrocodone", "description": "Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant."}, {"drugbank-id": "DB00327", "name": "Hydromorphone", "description": "Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant."}, {"drugbank-id": "DB05278", "name": "inhaled insulin", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB01306", "name": "Insulin Aspart", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB01307", "name": "Insulin Detemir", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00047", "name": "Insulin Glargine", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB01309", "name": "Insulin Glulisine", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00046", "name": "Insulin Lispro", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00030", "name": "Insulin Regular", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB06791", "name": "Lanreotide", "description": "Somatostatin Analogs may enhance the adverse/toxic effect of Pegvisomant. Specifically, this combination may increase the risk for significant elevations of liver enzymes."}, {"drugbank-id": "DB06791", "name": "Lanreotide", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00854", "name": "Levorphanol", "description": "Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant."}, {"drugbank-id": "DB06655", "name": "Liraglutide", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB01277", "name": "Mecasermin", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00331", "name": "Metformin", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00333", "name": "Methadone", "description": "Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant."}, {"drugbank-id": "DB00834", "name": "Mifepristone", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00491", "name": "Miglitol", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00295", "name": "Morphine", "description": "Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant."}, {"drugbank-id": "DB00844", "name": "Nalbuphine", "description": "Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant."}, {"drugbank-id": "DB00731", "name": "Nateglinide", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00104", "name": "Octreotide", "description": "Somatostatin Analogs may enhance the adverse/toxic effect of Pegvisomant. Specifically, this combination may increase the risk for significant elevations of liver enzymes."}, {"drugbank-id": "DB00104", "name": "Octreotide", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00497", "name": "Oxycodone", "description": "Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant."}, {"drugbank-id": "DB01192", "name": "Oxymorphone", "description": "Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant."}, {"drugbank-id": "DB06663", "name": "Pasireotide", "description": "Somatostatin Analogs may enhance the adverse/toxic effect of Pegvisomant. Specifically, this combination may increase the risk for significant elevations of liver enzymes."}, {"drugbank-id": "DB06663", "name": "Pasireotide", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00738", "name": "Pentamidine", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00652", "name": "Pentazocine", "description": "Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant."}, {"drugbank-id": "DB00454", "name": "Pethidine", "description": "Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant."}, {"drugbank-id": "DB01132", "name": "Pioglitazone", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB01278", "name": "Pramlintide", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00468", "name": "Quinine", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00899", "name": "Remifentanil", "description": "Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant."}, {"drugbank-id": "DB00912", "name": "Repaglinide", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00412", "name": "Rosiglitazone", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB06335", "name": "Saxagliptin", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB01261", "name": "Sitagliptin", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00708", "name": "Sufentanil", "description": "Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant."}, {"drugbank-id": "DB00359", "name": "Sulfadiazine", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB01015", "name": "Sulfamethoxazole", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00263", "name": "Sulfisoxazole", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB01268", "name": "Sunitinib", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB06204", "name": "Tapentadol", "description": "Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant."}, {"drugbank-id": "DB00839", "name": "Tolazamide", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB01124", "name": "Tolbutamide", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00193", "name": "Tramadol", "description": "Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00082 sequence\nFPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPT\nPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEG\nIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIV\nQCRSVEGSCGF"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "76 \u00b0C at pH 3.5", "source": "Gomez-Orellana, I. et al., Protein Sci. 7:1352-1358 (1998)"}, {"kind": "Hydrophobicity", "value": "-0.411", "source": null}, {"kind": "Isoelectric Point", "value": "5.27", "source": null}, {"kind": "Molecular Weight", "value": "22129.0000", "source": null}, {"kind": "Molecular Formula", "value": "C990H1532N262O300S7", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "16581"}, {"resource": "National Drug Code Directory", "identifier": "0009-5176-01"}, {"resource": "GenBank", "identifier": "AF374232"}, {"resource": "PharmGKB", "identifier": "PA164749630"}, {"resource": "UniProtKB", "identifier": "P58756"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/somavert.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/pegvisomant.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"@position": "1", "id": "BE0000075", "name": "Growth hormone receptor", "organism": "Human", "actions": {"action": "antagonist"}, "references": "# Moller L, Norrelund H, Jessen N, Flyvbjerg A, Pedersen SB, Gaylinn BD, Liu J, Thorner MO, Moller N, Lunde Jorgensen JO: Impact of growth hormone receptor blockade on substrate metabolism during fasting in healthy subjects. J Clin Endocrinol Metab. 2009 Nov;94(11):4524-32. Epub 2009 Oct 9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19820031\n# Paisley AN, Hayden K, Ellis A, Anderson J, Wieringa G, Trainer PJ: Pegvisomant interference in GH assays results in underestimation of GH levels. Eur J Endocrinol. 2007 Mar;156(3):315-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17322491\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352\n# De Martino MC, Auriemma RS, Brevetti G, Vitale G, Schiano V, Galdiero M, Grasso L, Lombardi G, Colao A, Pivonello R: THE TREATMENT WITH GROWTH HORMONE RECEPTOR ANTAGONIST IN ACROMEGALY: EFFECT ON VASCULAR STRUCTURE AND FUNCTION IN PATIENTS RESISTANT TO SOMATOSTATIN ANALOGUES. J Endocrinol Invest. 2010 Jul 1. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20595800", "known-action": "yes", "polypeptide": {"@id": "P10912", "@source": "Swiss-Prot", "name": "Growth hormone receptor", "general-function": "Involved in hematopoietin/interferon-class (D200-domain) cytokine receptor activity", "specific-function": "Isoform 2 up-regulates the production of GHBP and acts as a negative inhibitor of GH signaling", "gene-name": "GHR", "locus": "5p13-p12", "cellular-location": "Cell membrane; single-pass type I membrane protein. GHBP:Secreted protein. On growth hormone binding", "transmembrane-regions": "265-288", "signal-regions": null, "theoretical-pi": "4.51", "molecular-weight": "71500.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:4263"}, {"resource": "GenAtlas", "identifier": "GHR"}, {"resource": "GeneCards", "identifier": "GHR"}, {"resource": "GenBank Gene Database", "identifier": "X06562"}, {"resource": "GenBank Protein Database", "identifier": "31738"}, {"resource": "UniProtKB", "identifier": "P10912"}, {"resource": "UniProt Accession", "identifier": "GHR_HUMAN"}]}, "synonyms": {"synonym": ["GH receptor", "Growth hormone receptor precursor", "Somatotropin receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Growth hormone receptor precursor\nMDLWQLLLTLALAGSSDAFSGSEATAAILSRAPWSLQSVNPGLKTNSSKEPKFTKCRSPE\nRETFSCHWTDEVHHGTKNLGPIQLFYTRRNTQEWTQEWKECPDYVSAGENSCYFNSSFTS\nIWIPYCIKLTSNGGTVDEKCFSVDEIVQPDPPIALNWTLLNVSLTGIHADIQVRWEAPRN\nADIQKGWMVLEYELQYKEVNETKWKMMDPILTTSVPVYSLKVDKEYEVRVRSKQRNSGNY\nGEFSEVLYVTLPQMSQFTCEEDFYFPWLLIIIFGIFGLTVMLFVFLFSKQQRIKMLILPP\nVPVPKIKGIDPDLLKEGKLEEVNTILAIHDSYKPEFHSDDSWVEFIELDIDEPDEKTEES\nDTDRLLSSDHEKSHSNLGVKDGDSGRTSCCEPDILETDFNANDIHEGTSEVAQPQRLKGE\nADLLCLDQKNQNNSPYHDACPATQQPSVIQAEKNKPQPLPTEGAESTHQAAHIQLSNPSS\nLSNIDFYAQVSDITPAGSVVLSPGQKNKAGMSQCDMHPEMVSLCQENFLMDNAYFCEADA\nKKCIPVAPHIKVESHIQPSLNQEDIYITTESLTTAAGRPGTGEHVPGSEMPVPDYTSIHI\nVQSPQGLILNATALPLPDKEFLSSCGYVSTDQLNKIMP"}, "gene-sequence": {"@format": "FASTA", "#text": ">1917 bp\nATGGATCTCTGGCAGCTGCTGTTGACCTTGGCACTGGCAGGATCAAGTGATGCTTTTTCT\nGGAAGTGAGGCCACAGCAGCTATCCTTAGCAGAGCACCCTGGAGTCTGCAAAGTGTTAAT\nCCAGGCCTAAAGACAAATTCTTCTAAGGAGCCTAAATTCACCAAGTGCCGTTCACCTGAG\nCGAGAGACTTTTTCATGCCACTGGACAGATGAGGTTCATCATGGTACAAAGAACCTAGGA\nCCCATACAGCTGTTCTATACCAGAAGGAACACTCAAGAATGGACTCAAGAATGGAAAGAA\nTGCCCTGATTATGTTTCTGCTGGGGAAAACAGCTGTTACTTTAATTCATCGTTTACCTCC\nATCTGGATACCTTATTGTATCAAGCTAACTAGCAATGGTGGTACAGTGGATGAAAAGTGT\nTTCTCTGTTGATGAAATAGTGCAACCAGATCCACCCATTGCCCTCAACTGGACTTTACTG\nAACGTCAGTTTAACTGGGATTCATGCAGATATCCAAGTGAGATGGGAAGCACCACGCAAT\nGCAGATATTCAGAAAGGATGGATGGTTCTGGAGTATGAACTTCAATACAAAGAAGTAAAT\nGAAACTAAATGGAAAATGATGGACCCTATATTGACAACATCAGTTCCAGTGTACTCATTG\nAAAGTGGATAAGGAATATGAAGTGCGTGTGAGATCCAAACAACGAAACTCTGGAAATTAT\nGGCGAGTTCAGTGAGGTGCTCTATGTAACACTTCCTCAGATGAGCCAATTTACATGTGAA\nGAAGATTTCTACTTTCCATGGCTCTTAATTATTATCTTTGGAATATTTGGGCTAACAGTG\nATGCTATTTGTATTCTTATTTTCTAAACAGCAAAGGATTAAAATGCTGATTCTGCCCCCA\nGTTCCAGTTCCAAAGATTAAAGGAATCGATCCAGATCTCCTCAAGGAAGGAAAATTAGAG\nGAGGTGAACACAATCTTAGCCATTCATGATAGCTATAAACCCGAATTCCACAGTGATGAC\nTCTTGGGTTGAATTTATTGAGCTAGATATTGATGAGCCAGATGAAAAGACTGAGGAATCA\nGACACAGACAGACTTCTAAGCAGTGACCATGAGAAATCACATAGTAACCTAGGGGTGAAG\nGATGGCGACTCTGGACGTACCAGCTGTTGTGAACCTGACATTCTGGAGACTGATTTCAAT\nGCCAATGACATACATGAGGGTACCTCAGAGGTTGCTCAGCCACAGAGGTTAAAAGGGGAA\nGCAGATCTCTTATGCCTTGACCAGAAGAATCAAAATAACTCACCTTATCATGATGCTTGC\nCCTGCTACTCAGCAGCCCAGTGTTATCCAAGCAGAGAAAAACAAACCACAACCACTTCCT\nACTGAAGGAGCTGAGTCAACTCACCAAGCTGCCCATATTCAGCTAAGCAATCCAAGTTCA\nCTGTCAAACATCGACTTTTATGCCCAGGTGAGCGACATTACACCAGCAGGTAGTGTGGTC\nCTTTCCCCGGGCCAAAAGAATAAGGCAGGGATGTCCCAATGTGACATGCACCCGGAAATG\nGTCTCACTCTGCCAAGAAAACTTCCTTATGGACAATGCCTACTTCTGTGAGGCAGATGCC\nAAAAAGTGCATCCCTGTGGCTCCTCACATCAAGGTTGAATCACACATACAGCCAAGCTTA\nAACCAAGAGGACATTTACATCACCACAGAAAGCCTTACCACTGCTGCTGGGAGGCCTGGG\nACAGGAGAACATGTTCCAGGTTCTGAGATGCCTGTCCCAGACTATACCTCCATTCATATA\nGTACAGTCCCCACAGGGCCTCATACTCAATGCGACTGCCTTGCCCTTGCCTGACAAAGAG\nTTTCTCTCATCATGTGGCTATGTGAGCACAGACCAACTGAACAAAATCATGCCTTAG"}, "pfams": {"pfam": {"identifier": "PF00041", "name": "fn3"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "hematopoietin/interferon-class (D200-domain) cytokine receptor activity"}]}}}}, "enzymes": {"enzyme": [{"@position": "2", "id": "BE0000549", "name": "Sterol 26-hydroxylase, mitochondrial", "organism": "Human", "actions": {"action": "inducer"}, "references": "# Araya Z, Tang W, Wikvall K: Hormonal regulation of the human sterol 27-hydroxylase gene CYP27A1. Biochem J. 2003 Jun 1;372(Pt 2):529-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12597773", "known-action": "unknown", "polypeptide": {"@id": "Q02318", "@source": "Swiss-Prot", "name": "Sterol 26-hydroxylase, mitochondrial", "general-function": "Secondary metabolites biosynthesis, transport and catabolism", "specific-function": "Catalyzes the first step in the oxidation of the side chain of sterol intermediates; the 27-hydroxylation of 5-beta- cholestane-3-alpha,7-alpha,12-alpha-triol. Has also a vitamin D3- 25-hydroxylase activity", "gene-name": "CYP27A1", "locus": "2q33-qter", "cellular-location": "Mitochondrion", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.16", "molecular-weight": "60236.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2605"}, {"resource": "GenAtlas", "identifier": "CYP27A1"}, {"resource": "GeneCards", "identifier": "CYP27A1"}, {"resource": "GenBank Gene Database", "identifier": "M62401"}, {"resource": "GenBank Protein Database", "identifier": "181292"}, {"resource": "UniProtKB", "identifier": "Q02318"}, {"resource": "UniProt Accession", "identifier": "CP27A_HUMAN"}]}, "synonyms": {"synonym": ["5-beta-cholestane-3- alpha,7-alpha,12-alpha-triol 27-hydroxylase", "Cytochrome P-450C27/25", "Cytochrome P450 27, mitochondrial precursor", "EC 1.14.13.15", "Sterol 26-hydroxylase", "Sterol 27- hydroxylase", "Vitamin D(3) 25-hydroxylase"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytochrome P450 27, mitochondrial precursor\nMAALGCARLRWALRGAGRGLCPHGARAKAAIPAALPSDKATGAPGAGPGVRRRQRSLEEI\nPRLGQLRFFFQLFVQGYALQLHQLQVLYKAKYGPMWMSYLGPQMHVNLASAPLLEQVMRQ\nEGKYPVRNDMELWKEHRDQHDLTYGPFTTEGHHWYQLRQALNQRLLKPAEAALYTDAFNE\nVIDDFMTRLDQLRAESASGNQVSDMAQLFYYFALEAICYILFEKRIGCLQRSIPEDTVTF\nVRSIGLMFQNSLYATFLPKWTRPVLPFWKRYLDGWNAIFSFGKKLIDEKLEDMEAQLQAA\nGPDGIQVSGYLHFLLASGQLSPREAMGSLPELLMAGVDTTSNTLTWALYHLSKDPEIQEA\nLHEEVVGVVPAGQVPQHKDFAHMPLLKAVLKETLRLYPVVPTNSRIIEKEIEVDGFLFPK\nNTQFVFCHYVVSRDPTAFSEPESFQPHRWLRNSQPATPRIQHPFGSVPFGYGVRACLGRR\nIAELEMQLLLARLIQKYKVVLAPETGELKSVARIVLVPNKKVGLQFLQRQC"}, "gene-sequence": {"@format": "FASTA", "#text": ">1596 bp\nATGGCTGCGCTGGGCTGCGCGAGGCTGAGGTGGGCGCTGCGAGGGGCCGGCCGTGGCCTC\nTGCCCCCACGGGGCCAGAGCCAAGGCCGCGATCCCTGCCGCCCTCCCCTCGGACAAGGCC\nACCGGAGCTCCCGGAGCCGGGCCTGGTGTCCGGCGGCGGCAACGGAGCTTAGAGGAGATT\nCCACGTCTAGGACAGCTGCGCTTCTTCTTTCAGCTGTTCGTTCAAGGCTATGCCCTGCAA\nCTGCACCAGTTACAGGTGCTTTACAAGGCCAAGTACGGTCCAATGTGGATGTCCTACTTA\nGGGCCTCAGATGCACGTGAACCTGGCCAGTGCCCCGCTCTTGGAGCAAGTGATGCGGCAA\nGAGGGAAAGTACCCAGTACGGAACGACATGGAGCTATGGAAGGAGCACCGGGACCAGCAC\nGACCTGACCTATGGGCCGTTCACCACGGAAGGACACCACTGGTACCAGCTGCGCCAGGCT\nCTGAACCAGCGGTTGCTGAAGCCAGCGGAAGCAGCGCTCTATACGGATGCTTTCAATGAG\nGTGATTGATGACTTTATGACTCGACTGGACCAGCTGCGGGCAGAGAGTGCTTCGGGGAAC\nCAGGTGTCGGACATGGCTCAACTCTTCTACTACTTTGCCTTGGAAGCTATTTGCTACATC\nCTGTTCGAGAAACGCATTGGCTGCCTGCAGCGATCCATCCCCGAGGACACCGTGACCTTC\nGTCAGATCCATCGGGTTAATGTTCCAGAACTCACTCTATGCCACCTTCCTCCCCAAGTGG\nACTCGCCCCGTGCTGCCTTTCTGGAAGCGATACCTGGATGGTTGGAATGCCATCTTTTCC\nTTTGGGAAGAAGCTGATTGATGAGAAGCTCGAAGATATGGAGGCCCAACTGCAGGCAGCA\nGGGCCAGATGGCATCCAGGTGTCTGGCTACCTGCACTTCTTACTGGCCAGTGGACAGCTC\nAGTCCTCGGGAGGCCATGGGCAGCCTGCCTGAGCTGCTCATGGCTGGAGTGGACACGACA\nTCCAACACGCTGACATGGGCCCTGTACCACCTCTCAAAGGACCCTGAGATCCAGGAGGCC\nTTGCACGAGGAAGTGGTGGGTGTGGTGCCAGCCGGGCAAGTGCCCCAGCACAAGGACTTT\nGCCCACATGCCGTTGCTCAAAGCTGTGCTTAAGGAGACTCTGCGTCTCTACCCTGTGGTC\nCCCACAAACTCCCGGATCATAGAAAAGGAAATTGAAGTTGATGGCTTCCTCTTCCCCAAG\nAACACCCAGTTTGTGTTCTGCCACTATGTGGTGTCCCGGGACCCCACTGCCTTCTCTGAG\nCCTGAAAGCTTCCAGCCCCACCGCTGGCTGAGAAACAGCCAGCCTGCTACCCCCAGGATC\nCAGCACCCATTTGGCTCTGTGCCCTTTGGCTATGGGGTCCGGGCCTGCCTGGGCCGCAGG\nATTGCAGAGCTGGAGATGCAGCTACTCCTCGCAAGGCTGATCCAGAAGTACAAGGTGGTC\nCTGGCCCCGGAGACGGGGGAGTTGAAGAGTGTGGCCCGCATTGTCCTGGTTCCCAATAAG\nAAAGTGGGCCTGCAGTTCCTGCAGAGACAGTGCTGA"}, "pfams": {"pfam": {"identifier": "PF00067", "name": "p450"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "iron ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "tetrapyrrole binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "heme binding"}, {"category": "function", "description": "monooxygenase activity"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "generation of precursor metabolites and energy"}, {"category": "process", "description": "electron transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}, {"@position": "3", "id": "BE0002240", "name": "Glutamine synthetase", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Nolan EM, Masters JN, Dunn A: Growth hormone regulation of hepatic glutamine synthetase mRNA levels in rats. Mol Cell Endocrinol. 1990 Mar 5;69(2-3):101-10. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1970314", "known-action": "unknown", "polypeptide": {"@id": "P15104", "@source": "Swiss-Prot", "name": "Glutamine synthetase", "general-function": "Amino acid transport and metabolism", "specific-function": "ATP + L-glutamate + NH(3) = ADP + phosphate + L-glutamine", "gene-name": "GLUL", "locus": "1q31", "cellular-location": "Cytoplasm", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.88", "molecular-weight": "42065.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:4341"}, {"resource": "GenAtlas", "identifier": "GLUL"}, {"resource": "GeneCards", "identifier": "GLUL"}, {"resource": "GenBank Gene Database", "identifier": "Y00387"}, {"resource": "GenBank Protein Database", "identifier": "31833"}, {"resource": "UniProtKB", "identifier": "P15104"}, {"resource": "UniProt Accession", "identifier": "GLNA_HUMAN"}]}, "synonyms": {"synonym": ["EC 6.3.1.2", "Glutamate--ammonia ligase", "GS"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Glutamine synthetase\nMTTSASSHLNKGIKQVYMSLPQGEKVQAMYIWIDGTGEGLRCKTRTLDSEPKCVEELPEW\nNFDGSSTLQSEGSNSDMYLVPAAMFRDPFRKDPNKLVLCEVFKYNRRPAETNLRHTCKRI\nMDMVSNQHPWFGMEQEYTLMGTDGHPFGWPSNGFPGPQGPYYCGVGADRAYGRDIVEAHY\nRACLYAGVKIAGTNAEVMPAQWEFQIGPCEGISMGDHLWVARFILHRVCEDFGVIATFDP\nKPIPGNWNGAGCHTNFSTKAMREENGLKYIEEAIEKLSKRHQYHIRAYDPKGGLDNARRL\nTGFHETSNINDFSAGVANRSASIRIPRTVGQEKKGYFEDRRPSANCDPFSVTEALIRTCL\nLNETGDEPFQYKN"}, "gene-sequence": {"@format": "FASTA", "#text": ">1122 bp\nATGACCACCTCAGCAAGTTCCCACTTAAATAAAGGCATCAAGCAGGTGTACATGTCCCTG\nCCTCAGGGTGAGAAAGTCCAGGCCATGTATATCTGGATCGATGGTACTGGAGAAGGACTG\nCGCTGCAAGACCCGGACCCTGGACAGTGAGCCCAAGTGTGTGGAAGAGTTGCCTGAGTGG\nAATTTCGATGGCTCCAGTACTTTACAGTCTGAGGGTTCCAACAGTGACATGTATCTCGTG\nCCTGCTGCCATGTTTCGGGACCCCTTCCGTAAGGACCCTAACAAGCTGGTGTTATGTGAA\nGTTTTCAAGTACAATCGAAGGCCTGCAGAGACCAATTTGAGGCACACCTGTAAACGGATA\nATGGACATGGTGAGCAACCAGCACCCCTGGTTTGGCATGGAGCAGGAGTATACCCTCATG\nGGGACAGATGGGCACCCCTTTGGTTGGCCTTCCAACGGCTTCCCAGGGCCCCAGGGTCCA\nTATTACTGTGGTGTGGGAGCAGACAGAGCCTATGGCAGGGACATCGTGGAGGCCCATTAC\nCGGGCCTGCTTGTATGCTGGAGTCAAGATTGCGGGGACTAATGCCGAGGTCATGCCTGCC\nCAGTGGGAATTTCAGATTGGACCTTGTGAAGGAATCAGCATGGGAGATCATCTCTGGGTG\nGCCCGTTTCATCTTGCATCGTGTGTGTGAAGACTTTGGAGTGATAGCAACCTTTGATCCT\nAAGCCCATTCCTGGGAACTGGAATGGTGCAGGCTGCCATACCAACTTCAGCACCAAGGCC\nATGCGGGAGGAGAATGGTCTGAAGTACATCGAGGAGGCCATTGAGAAACTAAGCAAGCGG\nCACCAGTACCACATCCGTGCCTATGATCCCAAGGGAGGCCTGGACAATGCCCGACGTCTA\nACTGGATTCCATGAAACCTCCAACATCAACGACTTTTCTGGTGGTGTAGCCAATCGTAGC\nGCCAGCATACGCATTCCCCGGACTGTTGGCCAGGAGAAGAAGGGTTACTTTGAAGATCGT\nCGCCCCTCTGCCAACTGCGACCCCTTTTCGGTGACAGAAGCCCTCATCCGCACGTGTCTT\nCTCAATGAAACCGGCGATGAGCCCTTCCAGTACAAAAATTAA"}, "pfams": {"pfam": [{"identifier": "PF00120", "name": "Gln-synt_C"}, {"identifier": "PF03951", "name": "Gln-synt_N"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "ligase activity"}, {"category": "function", "description": "ligase activity, forming carbon-nitrogen bonds"}, {"category": "function", "description": "acid-ammonia (or amide) ligase activity"}, {"category": "function", "description": "ammonia ligase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "glutamate-ammonia ligase activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "nitrogen compound metabolism"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular metabolism"}, {"category": "process", "description": "glutamine biosynthesis"}, {"category": "process", "description": "amino acid metabolism"}, {"category": "process", "description": "amino acid and derivative metabolism"}, {"category": "process", "description": "glutamine family amino acid metabolism"}, {"category": "process", "description": "glutamine metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}, {"@position": "4", "id": "BE0003611", "name": "Cytochrome P450 2C18", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Lofgren S, Baldwin RM, Carleros M, Terelius Y, Fransson-Steen R, Mwinyi J, Waxman DJ, Ingelman-Sundberg M: Regulation of human CYP2C18 and CYP2C19 in transgenic mice: influence of castration, testosterone, and growth hormone. Drug Metab Dispos. 2009 Jul;37(7):1505-12. Epub 2009 Apr 1. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19339376", "known-action": "unknown", "polypeptide": {"@id": "P33260", "@source": "Swiss-Prot", "name": "Cytochrome P450 2C18", "general-function": "Secondary metabolites biosynthesis, transport and catabolism", "specific-function": "Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics", "gene-name": "CYP2C18", "locus": "10q24", "cellular-location": "Endoplasmic reticulum membrane", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.22", "molecular-weight": "55710.1", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "GNC:2620"}, {"resource": "GeneCards", "identifier": "CYP2C18"}, {"resource": "GenBank Gene Database", "identifier": "M61853"}, {"resource": "UniProtKB", "identifier": "P33260"}, {"resource": "UniProt Accession", "identifier": "CP2CI_HUMAN"}]}, "synonyms": {"synonym": ["CYPIIC18", "P450-6B/29C"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytochrome P450 2C18\nMDPAVALVLCLSCLFLLSLWRQSSGRGRLPSGPTPLPIIGNILQLDVKDMSKSLTNFSKV\nYGPVFTVYFGLKPIVVLHGYEAVKEALIDHGEEFSGRGSFPVAEKVNKGLGILFSNGKRW\nKEIRRFCLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTNASPCDPTFILGCAPCNVICS\nVIFHDRFDYKDQRFLNLMEKFNENLRILSSPWIQVCNNFPALIDYLPGSHNKIAENFAYI\nKSYVLERIKEHQESLDMNSARDFIDCFLIKMEQEKHNQQSEFTVESLIATVTDMFGAGTE\nTTSTTLRYGLLLLLKYPEVTAKVQEEIECVVGRNRSPCMQDRSHMPYTDAVVHEIQRYID\nLLPTNLPHAVTCDVKFKNYLIPKGTTIITSLTSVLHNDKEFPNPEMFDPGHFLDKSGNFK\nKSDYFMPFSAGKRMCMGEGLARMELFLFLTTILQNFNLKSQVDPKDIDITPIANAFGRVP\nPLYQLCFIPV"}, "gene-sequence": {"@format": "FASTA"}, "pfams": {"pfam": {"identifier": "PF00067", "name": "p450"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "iron ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "tetrapyrrole binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "heme binding"}, {"category": "function", "description": "monooxygenase activity"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "generation of precursor metabolites and energy"}, {"category": "process", "description": "electron transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}, {"@position": "5", "id": "BE0002638", "name": "Cytochrome P450 3A4", "organism": "Human", "actions": {"action": "inducer"}, "references": "# Liddle C, Goodwin BJ, George J, Tapner M, Farrell GC: Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes. J Clin Endocrinol Metab. 1998 Jul;83(7):2411-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9661620\n# Cheung C, Yu AM, Chen CS, Krausz KW, Byrd LG, Feigenbaum L, Edwards RJ, Waxman DJ, Gonzalez FJ: Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice. J Pharmacol Exp Ther. 2006 Mar;316(3):1328-34. Epub 2005 Nov 16. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16291874", "known-action": "unknown", "polypeptide": {"@id": "P08684", "@source": "Swiss-Prot", "name": "Cytochrome P450 3A4", "general-function": "Involved in monooxygenase activity", "specific-function": "Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4- hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. The enzyme also hydroxylates etoposide", "gene-name": "CYP3A4", "locus": "7q21.1", "cellular-location": "Endoplasmic reticulum", "transmembrane-regions": "2-22", "signal-regions": null, "theoretical-pi": "8.25", "molecular-weight": "57344.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2637"}, {"resource": "GenAtlas", "identifier": "CYP3A4"}, {"resource": "GenBank Gene Database", "identifier": "M18907"}, {"resource": "UniProtKB", "identifier": "P08684"}, {"resource": "UniProt Accession", "identifier": "CP3A4_HUMAN"}]}, "synonyms": {"synonym": ["CYPIIIA4", "EC 1.14.13.67", "EC 1.14.13.97", "NF-25", "Nifedipine oxidase", "P450-PCN1", "Quinine 3-monooxygenase", "Taurochenodeoxycholate 6-alpha- hydroxylase"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytochrome P450 3A4\nMALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF\nDMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI\nAEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS\nMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV\nFPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI\nIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV\nNETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS\nKKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG\nGLLQPEKPVVLKVESRDGTVSGA"}, "gene-sequence": {"@format": "FASTA", "#text": ">1512 bp\nATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG\nCTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG\nCCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT\nGACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT\nGTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT\nGTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA\nGCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA\nAAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG\nAGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC\nATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA\nGACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT\nCTCTCAATAACAGTCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTG\nTTTCCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGC\nCTCGAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAAT\nTCAAAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATT\nATCTTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAA\nCTGGCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCC\nAATAAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTG\nAATGAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGAT\nGTTGAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCT\nCTTCACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGC\nAAGAAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGA\nAACTGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTT\nCAGAACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGA\nGGACTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTA\nAGTGGAGCCTGA"}, "pfams": {"pfam": {"identifier": "PF00067", "name": "p450"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "iron ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "tetrapyrrole binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "heme binding"}, {"category": "function", "description": "monooxygenase activity"}, {"category": "function", "description": "oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "generation of precursor metabolites and energy"}, {"category": "process", "description": "electron transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}, {"@position": "6", "id": "BE0002180", "name": "Cholinesterase", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Lamartiniere CA: Growth hormone modulates serum cholinesterase. Endocrinology. 1986 Mar;118(3):1252-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/3948777", "known-action": "unknown", "polypeptide": {"@id": "P06276", "@source": "Swiss-Prot", "name": "Cholinesterase", "general-function": "Lipid transport and metabolism", "specific-function": "An acylcholine + H(2)O = choline + a carboxylate", "gene-name": "BCHE", "locus": "3q26.1-q26.2", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.47", "molecular-weight": "68419.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:983"}, {"resource": "GenAtlas", "identifier": "BCHE"}, {"resource": "GeneCards", "identifier": "BCHE"}, {"resource": "GenBank Gene Database", "identifier": "M32391"}, {"resource": "GenBank Protein Database", "identifier": "1311630"}, {"resource": "UniProtKB", "identifier": "P06276"}, {"resource": "UniProt Accession", "identifier": "CHLE_HUMAN"}]}, "synonyms": {"synonym": ["Acylcholine acylhydrolase", "Butyrylcholine esterase", "Choline esterase II", "Cholinesterase precursor", "EC 3.1.1.8", "Pseudocholinesterase"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cholinesterase\nMHSKVTIICIRFLFWFLLLCMLIGKSHTEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIP\nYAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDC\nLYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALG\nFLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPG\nSHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEI\nLLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVY\nGAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDV\nVGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLER\nRDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMT\nKLRAQQCRFWTSFFPKVLEMTGNIDEAEWEWKAGFHRWNNYMMDWKNQFNDYTSKKESCV\nGL"}, "gene-sequence": {"@format": "FASTA", "#text": ">1809 bp\nATGCATAGCAAAGTCACAATCATATGCATCAGATTTCTCTTTTGGTTTCTTTTGCTCTGC\nATGCTTATTGGGAAGTCACATACTGAAGATGACATCATAATTGCAACAAAGAATGGAAAA\nGTCAGAGGGATGAACTTGACAGTTTTTGGTGGCACGGTAACAGCCTTTCTTGGAATTCCC\nTATGCACAGCCACCTCTTGGTAGACTTCGATTCAAAAAGCCACAGTCTCTGACCAAGTGG\nTCTGATATTTGGAATGCCACAAAATATGCAAATTCTTGCTGTCAGAACATAGATCAAAGT\nTTTCCAGGCTTCCATGGATCAGAGATGTGGAACCCAAACACTGACCTCAGTGAAGACTGT\nTTATATCTAAATGTATGGATTCCAGCACCTAAACCAAAAAATGCCACTGTATTGATATGG\nATTTATGGTGGTGGTTTTCAAACTGGAACATCATCTTTACATGTTTATGATGGCAAGTTT\nCTGGCTCGGGTTGAAAGAGTTATTGTAGTGTCAATGAACTATAGGGTGGGTGCCCTAGGA\nTTCTTAGCTTTGCCAGGAAATCCTGAGGCTCCAGGGAACATGGGTTTATTTGATCAACAG\nTTGGCTCTTCAGTGGGTTCAAAAAAATATAGCAGCCTTTGGTGGAAATCCTAAAAGTGTA\nACTCTCTTTGGAGAAAGTGCAGGAGCAGCTTCAGTTAGCCTGCATTTGCTTTCTCCTGGA\nAGCCATTCATTGTTCACCAGAGCCATTCTGCAAAGTGGATCCTTTAATGCTCCTTGGGCG\nGTAACATCTCTTTATGAAGCTAGGAACAGAACGTTGAACTTAGCTAAATTGACTGGTTGC\nTCTAGAGAGAATGAGACTGAAATAATCAAGTGTCTTAGAAATAAAGATCCCCAAGAAATT\nCTTCTGAATGAAGCATTTGTTGTCCCCTATGGGACTCCTTTGTCAGTAAACTTTGGTCCG\nACCGTGGATGGTGATTTTCTCACTGACATGCCAGACATATTACTTGAACTTGGACAATTT\nAAAAAAACCCAGATTTTGGTGGGTGTTAATAAAGATGAAGGGACAGCTTTTTTAGTCTAT\nGGTGCTCCTGGCTTCAGCAAAGATAACAATAGTATCATAACTAGAAAAGAATTTCAGGAA\nGGTTTAAAAATATTTTTTCCAGGAGTGAGTGAGTTTGGAAAGGAATCCATCCTTTTTCAT\nTACACAGACTGGGTAGATGATCAGAGACCTGAAAACTACCGTGAGGCCTTGGGTGATGTT\nGTTGGGGATTATAATTTCATATGCCCTGCCTTGGAGTTCACCAAGAAGTTCTCAGAATGG\nGGAAATAATGCCTTTTTCTACTATTTTGAACACCGATCCTCCAAACTTCCGTGGCCAGAA\nTGGATGGGAGTGATGCATGGCTATGAAATTGAATTTGTCTTTGGTTTACCTCTGGAAAGA\nAGAGATAATTACACAAAAGCCGAGGAAATTTTGAGTAGATCCATAGTGAAACGTTGGGCA\nAATTTTGCAAAATATGGGAATCCAAATGAGACTCAGAACAATAGCACAAGCTGGCCTGTC\nTTCAAAAGCACTGAACAAAAATATCTAACCTTGAATACAGAGTCAACAAGAATAATGACG\nAAACTACGTGCTCAACAATGTCGATTCTGGACATCATTTTTTCCAAAAGTCTTGGAAATG\nACAGGAAATATTGATGAAGCAGAATGGGAGTGGAAAGCAGGATTCCATCGCTGGAACAAT\nTACATGATGGACTGGAAAAATCAATTTAACGATTACACTAGCAAGAAAGAAAGTTGTGTG\nGGTCTCTAA"}, "pfams": {"pfam": [{"identifier": "PF00135", "name": "COesterase"}, {"identifier": "PF08674", "name": "AChE_tetra"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "hydrolase activity, acting on ester bonds"}, {"category": "function", "description": "carboxylic ester hydrolase activity"}, {"category": "function", "description": "cholinesterase activity"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}, {"@position": "7", "id": "BE0003536", "name": "Cytochrome P450 2C19", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Lofgren S, Baldwin RM, Carleros M, Terelius Y, Fransson-Steen R, Mwinyi J, Waxman DJ, Ingelman-Sundberg M: Regulation of human CYP2C18 and CYP2C19 in transgenic mice: influence of castration, testosterone, and growth hormone. Drug Metab Dispos. 2009 Jul;37(7):1505-12. Epub 2009 Apr 1. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19339376", "known-action": "unknown", "polypeptide": {"@id": "P33261", "@source": "Swiss-Prot", "name": "Cytochrome P450 2C19", "general-function": "Secondary metabolites biosynthesis, transport and catabolism", "specific-function": "Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine", "gene-name": "CYP2C19", "locus": "10q24.1-q24.3", "cellular-location": "Endoplasmic reticulum membrane", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.42", "molecular-weight": "55930.5", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "GNC:2621"}, {"resource": "GeneCards", "identifier": "CYP2C19"}, {"resource": "GenBank Gene Database", "identifier": "M61854"}, {"resource": "GenBank Protein Database", "identifier": "181344"}, {"resource": "UniProtKB", "identifier": "P33261"}, {"resource": "UniProt Accession", "identifier": "CP2CJ_HUMAN"}]}, "synonyms": {"synonym": ["(R)-limonene 6-monooxygenase", "(S)-limonene 6-monooxygenase", "(S)-limonene 7-monooxygenase", "CYPIIC17", "CYPIIC19", "Mephenytoin 4-hydroxylase", "P450-11A", "P450-254C"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytochrome P450 2C19\nMDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI\nYGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW\nKEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS\nIIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM\nESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE\nTTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID\nLIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK\nKSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP\nPFYQLCFIPV"}, "gene-sequence": {"@format": "FASTA", "#text": ">1473 bp\nATGGATCCTTTTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTTCAATCTGG\nAGACAGAGCTCTGGGAGAGGAAAACTCCCTCCTGGCCCCACTCCTCTCCCAGTGATTGGA\nAATATCCTACAGATAGATATTAAGGATGTCAGCAAATCCTTAACCAATCTCTCAAAAATC\nTATGGCCCTGTGTTCACTCTGTATTTTGGCCTGGAACGCATGGTGGTGCTGCATGGATAT\nGAAGTGGTGAAGGAAGCCCTGATTGATCTTGGAGAGGAGTTTTCTGGAAGAGGCCATTTC\nCCACTGGCTGAAAGAGCTAACAGAGGATTTGGAATCGTTTTCAGCAATGGAAAGAGATGG\nAAGGAGATCCGGCGTTTCTCCCTCATGACGCTGCGGAATTTTGGGATGGGGAAGAGGAGC\nATTGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAAG\nGCTTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC\nATTATTTTCCAGAAACGTTTCGATTATAAAGATCAGCAATTTCTTAACTTGATGGAAAAA\nTTGAATGAAAACATCAGGATTGTAAGCACCCCCTGGATCCAGATATGCAATAATTTTCCC\nACTATCATTGATTATTTCCCGGGAACCCATAACAAATTACTTAAAAACCTTGCTTTTATG\nGAAAGTGATATTTTGGAGAAAGTAAAAGAACACCAAGAATCGATGGACATCAACAACCCT\nCGGGACTTTATTGATTGCTTCCTGATCAAAATGGAGAAGGAAAAGCAAAACCAACAGTCT\nGAATTCACTATTGAAAACTTGGTAATCACTGCAGCTGACTTACTTGGAGCTGGGACAGAG\nACAACAAGCACAACCCTGAGATATGCTCTCCTTCTCCTGCTGAAGCACCCAGAGGTCACA\nGCTAAAGTCCAGGAAGAGATTGAACGTGTCATTGGCAGAAACCGGAGCCCCTGCATGCAG\nGACAGGGGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGAGATACATCGAC\nCTCATCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACGTTAAATTCAGAAACTACCTC\nATTCCCAAGGGCACAACCATATTAACTTCCCTCACTTCTGTGCTACATGACAACAAAGAA\nTTTCCCAACCCAGAGATGTTTGACCCTCGTCACTTTCTGGATGAAGGTGGAAATTTTAAG\nAAAAGTAACTACTTCATGCCTTTCTCAGCAGGAAAACGGATTTGTGTGGGAGAGGGCCTG\nGCCCGCATGGAGCTGTTTTTATTCCTGACCTTCATTTTACAGAACTTTAACCTGAAATCT\nCTGATTGACCCAAAGGACCTTGACACAACTCCTGTTGTCAATGGATTTGCTTCTGTCCCG\nCCCTTCTATCAGCTGTGCTTCATTCCTGTCTGA"}, "pfams": {"pfam": {"identifier": "PF00067", "name": "p450"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "iron ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "tetrapyrrole binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "heme binding"}, {"category": "function", "description": "monooxygenase activity"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "generation of precursor metabolites and energy"}, {"category": "process", "description": "electron transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}, {"@position": "8", "id": "BE0000421", "name": "Cytochrome P450 4A11", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Savas U, Machemer DE, Hsu MH, Gaynor P, Lasker JM, Tukey RH, Johnson EF: Opposing roles of peroxisome proliferator-activated receptor alpha and growth hormone in the regulation of CYP4A11 expression in a transgenic mouse model. J Biol Chem. 2009 Jun 12;284(24):16541-52. Epub 2009 Apr 14. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19366684[uid]", "known-action": "unknown", "polypeptide": {"@id": "Q02928", "@source": "Swiss-Prot", "name": "Cytochrome P450 4A11", "general-function": "Secondary metabolites biosynthesis, transport and catabolism", "specific-function": "Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity towards prostaglandins A1 and E1", "gene-name": "CYP4A11", "locus": "1p33", "cellular-location": "Endoplasmic reticulum; endoplasmic reticulum membrane; peripheral membrane protein", "transmembrane-regions": "15-32; 118-140", "signal-regions": null, "theoretical-pi": "8.99", "molecular-weight": "59349.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2642"}, {"resource": "GenAtlas", "identifier": "CYP4A11"}, {"resource": "GeneCards", "identifier": "CYP4A11"}, {"resource": "GenBank Gene Database", "identifier": "L04751"}, {"resource": "GenBank Protein Database", "identifier": "181397"}, {"resource": "UniProtKB", "identifier": "Q02928"}, {"resource": "UniProt Accession", "identifier": "CP4AB_HUMAN"}]}, "synonyms": {"synonym": ["CYP4AII", "CYPIVA11", "Cytochrome P450 4A11 precursor", "EC 1.14.15.3", "Fatty acid omega-hydroxylase", "Lauric acid omega-hydroxylase", "P-450 HK omega", "P450-HL-omega"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytochrome P450 4A11 precursor\nMSVSVLSPSRLLGDVSGILQAASLLILLLLLIKAVQLYLHRQWLLKALQQFPCPPSHWLF\nGHIQELQQDQELQRIQKWVETFPSACPHWLWGGKVRVQLYDPDYMKVILGRSDPKSHGSY\nRFLAPWIGYGLLLLNGQTWFQHRRMLTPAFHYDILKPYVGLMADSVRVMLDKWEELLGQD\nSPLEVFQHVSLMTLDTIMKCAFSHQGSIQVDRNSQSYIQAISDLNNLVFSRVRNAFHQND\nTIYSLTSAGRWTHRACQLAHQHTDQVIQLRKAQLQKEGELEKIKRKRHLDFLDILLLAKM\nENGSILSDKDLRAEVDTFMFEGHDTTASGISWILYALATHPKHQERCREEIHSLLGDGAS\nITWNHLDQMPYTTMCIKEALRLYPPVPGIGRELSTPVTFPDGRSLPKGIMVLLSIYGLHH\nNPKVWPNPEVFDPFRFAPGSAQHSHAFLPFSGGSRNCIGKQFAMNELKVATALTLLRFEL\nLPDPTRIPIPIARLVLKSKNGIHLRLRRLPNPCEDKDQL"}, "gene-sequence": {"@format": "FASTA", "#text": ">1560 bp\nATGAGTGTCTCTGTGCTGAGCCCCAGCAGACTCCTGGGTGATGTCTCTGGAATCCTCCAA\nGCGGCCTCCCTGCTCATTCTGCTTCTGCTGCTGATCAAGGCAGTTCAGCTCTACCTGCAC\nAGGCAGTGGCTGCTCAAAGCCCTCCAGCAGTTCCCGTGCCCTCCCTCCCACTGGCTCTTC\nGGGCACATCCAGGAGCTCCAACAGGACCAGGAGCTACAACGGATTCAGAAATGGGTGGAG\nACATTCCCAAGTGCCTGTCCTCATTGGCTATGGGGAGGCAAAGTTCGTGTCCAGCTCTAT\nGACCCTGACTATATGAAGGTGATTCTGGGGAGATCAGACCCGAAATCCCATGGTTCCTAC\nAGATTCCTGGCTCCATGGATTGGGTACGGCTTGCTCCTGTTGAATGGGCAGACATGGTTC\nCAGCATCGACGGATGCTGACCCCAGCCTTCCACTATGACATCCTGAAGCCCTATGTGGGG\nCTCATGGCAGACTCTGTACGAGTGATGCTGGACAAATGGGAAGAGCTCCTTGGCCAGGAT\nTCCCCTCTGGAGGTCTTTCAGCACGTCTCCTTGATGACCCTGGACACCATCATGAAGTGT\nGCCTTCAGCCATCAGGGCAGCATCCAGGTGGACAGGAATTCTCAGTCCTACATACAGGCC\nATTAGTGACCTGAACAACCTGGTTTTTTCCCGTGTGAGGAATGCCTTTCACCAGAATGAC\nACCATCTACAGCCTGACCTCTGCTGGCCGCTGGACACACCGCGCCTGCCAGCTGGCCCAT\nCAGCACACAGACCAAGTGATCCAACTGAGGAAGGCTCAACTACAGAAGGAGGGGGAGCTG\nGAGAAGATCAAGAGGAAGAGGCATTTGGATTTTCTGGATATCCTCCTCTTGGCCAAAATG\nGAGAATGGGAGCATCTTGTCAGACAAGGACCTCCGTGCTGAGGTGGACACGTTCATGTTT\nGAGGGCCACGACACCACAGCCAGTGGGATCTCCTGGATCCTCTATGCTCTGGCCACACAC\nCCCAAGCATCAGGAGAGGTGCCGGGAGGAGATCCACAGCCTCCTGGGTGATGGAGCCTCC\nATCACCTGGAACCACCTGGACCAGATGCCCTACACCACCATGTGCATTAAGGAGGCACTG\nAGGCTCTACCCACCGGTGCCAGGCATTGGCAGAGAGCTCAGCACTCCCGTCACCTTCCCT\nGATGGGCGCTCCTTGCCCAAAGGTATCATGGTCCTCCTCTCCATTTATGGCCTTCACCAC\nAACCCAAAAGTGTGGCCCAACCCAGAGGTGTTTGACCCTTTCCGTTTTGCACCGGGTTCT\nGCTCAACACAGCCACGCTTTCCTGCCCTTCTCAGGAGGATCAAGGAACTGCATTGGGAAA\nCAATTTGCCATGAACGAGCTGAAGGTGGCCACGGCCCTGACCCTGCTCCGCTTTGAGCTG\nCTGCCTGATCCCACCAGGATCCCCATCCCCATTGCACGACTTGTGTTGAAATCCAAAAAT\nGGAATCCACCTGCGTCTCAGGAGGCTCCCTAACCCTTGTGAAGACAAGGACCAGCTTTGA"}, "pfams": {"pfam": {"identifier": "PF00067", "name": "p450"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "iron ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "tetrapyrrole binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "heme binding"}, {"category": "function", "description": "monooxygenase activity"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "generation of precursor metabolites and energy"}, {"category": "process", "description": "electron transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}]}, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-02-03", "drugbank-id": [{"@primary": "true", "#text": "DB00083"}, "BIOD00092", "BTD00092"], "name": "Botulinum Toxin Type A", "description": "Purified botulinum toxin from Clostridium botulinum, purified from culture via dialysis and acid precipitation.", "cas-number": "93384-43-1", "groups": {"group": ["approved", "investigational"]}, "general-references": "# Montecucco C, Molgo J: Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005 Jun;5(3):274-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15907915\n# Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M: Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999 Oct 22;53(7):1431-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10534247\n# Shukla HD, Sharma SK: Clostridium botulinum: a bug with beauty and weapon. Crit Rev Microbiol. 2005;31(1):11-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15839401\n# Eisenach JH, Atkinson JL, Fealey RD: Hyperhidrosis: evolving therapies for a well-established phenomenon. Mayo Clin Proc. 2005 May;80(5):657-66. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15887434\n# Schurch B, Corcos J: Botulinum toxin injections for paediatric incontinence. Curr Opin Urol. 2005 Jul;15(4):264-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15928517", "synthesis-reference": null, "indication": "For the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia. Also for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents and for the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and above. Also used cosmetically to temporarily improve the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines) as well as for the treatment of excessive underarm sweating.", "pharmacodynamics": "A 150 kDa neurotoxic protein produced from fermentation of Hall strain Clostridium botulinum type A grown in a medium containing casein hydrolysate, glucose and yeast extract. It is purified from the culture solution by dialysis and a series of acid precipitations to a complex consisting of the neurotoxin, and several accessory proteins. Botulinum Toxin Type A is not expected to be present in the peripheral blood at measurable levels following IM or intradermal injection at the recommended doses. The recommended quantities of neurotoxin administered at each treatment session are not expected to result in systemic, overt distant clinical effects, i.e. muscle weakness, in patients without other neuromuscular dysfunction. However, sub-clinical systemic effects have been shown by single-fiber electromyography after IM doses of botulinum toxins appropriate to produce clinically observable local muscle weakness.", "mechanism-of-action": "Botulinum Toxin Type A blocks neuromuscular transmission by binding to acceptor sites on motor or sympathetic nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings.", "toxicity": "Based on toxicological studies, it has been estimated that the human LD50 \nby injection is approximately 2800 Units, equivalent to 28 individual vials of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex (100 Units) for a 70 kg adult. When injected intramuscularly, Botulinum Toxin Type A has been shown to be teratogenic or to have embryocidal effects in some animal species.", "metabolism": null, "absorption": "The chemical complexity of Botulinum Toxin Type A combined with its extreme potency limits the opportunity to study its pharmacokinetic profile in humans. Therefore, no human pharmacokinetic studies have been performed. Botulinum Toxin Type A is injected directly into the target organ, a skeletal muscle. Thus, bioavailability of the intravenous or oral route is not of clinical relevance.", "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "AbobotulinumtoxinA"}, {"@language": "", "@coder": "", "#text": "BoNT/A"}, {"@language": "", "@coder": "", "#text": "Bontoxilysin A"}, {"@language": "", "@coder": "", "#text": "Botulinum neurotoxin type A precursor"}, {"@language": "", "@coder": "", "#text": "BTX-A"}, {"@language": "", "@coder": "", "#text": "OnabotulinumtoxinA"}]}, "products": {"product": [{"name": "Botox", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01981501", "started-marketing-on": "1992-12-31", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "100 unit", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Botox", "ndc-id": "0023-1145_fa99cac9-09b5-45a3-8f9c-c67930b2a270", "ndc-product-code": "0023-1145", "dpd-id": null, "started-marketing-on": "1989-12-15", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "100 [USP'U]", "route": "intradermal; intramuscular", "fda-application-number": "BLA103000", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Botox", "ndc-id": "0023-3921_fa99cac9-09b5-45a3-8f9c-c67930b2a270", "ndc-product-code": "0023-3921", "dpd-id": null, "started-marketing-on": "2010-01-11", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "200 [USP'U]", "route": "intradermal; intramuscular", "fda-application-number": "BLA103000", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Botox Cosmetic", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02243721", "started-marketing-on": "2001-05-07", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "100 unit", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Botox Cosmetic", "ndc-id": "0023-3919_c69b1bba-a805-4511-9a24-91c6608a03a4", "ndc-product-code": "0023-3919", "dpd-id": null, "started-marketing-on": "2008-07-15", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "50 [USP'U]", "route": "intramuscular", "fda-application-number": "BLA103000", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Botox Cosmetic", "ndc-id": "0023-9232_c69b1bba-a805-4511-9a24-91c6608a03a4", "ndc-product-code": "0023-9232", "dpd-id": null, "started-marketing-on": "2008-05-20", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "100 [USP'U]", "route": "intramuscular", "fda-application-number": "BLA103000", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Dysport", "ndc-id": "15054-0500_c81096ce-077e-4723-b20a-8afc27ae19a6", "ndc-product-code": "15054-0500", "dpd-id": null, "started-marketing-on": "2009-11-02", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "500 U", "route": "intramuscular", "fda-application-number": "BLA125274", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Dysport", "ndc-id": "15054-0530_c81096ce-077e-4723-b20a-8afc27ae19a6", "ndc-product-code": "15054-0530", "dpd-id": null, "started-marketing-on": "2009-11-02", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "300 U", "route": "intramuscular", "fda-application-number": "BLA125274", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Dysport", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02387735", "started-marketing-on": "2013-02-19", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "300 unit", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Dysport", "ndc-id": "0299-5962_fca1011f-d605-4a53-843a-a9e031f94c65", "ndc-product-code": "0299-5962", "dpd-id": null, "started-marketing-on": "2009-11-02", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "300 U", "route": "intramuscular", "fda-application-number": "BLA125274", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Xeomin", "ndc-id": "46783-160_53000540-4a5b-427c-8257-3fe1177d2d62", "ndc-product-code": "46783-160", "dpd-id": null, "started-marketing-on": "2011-08-01", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "100 [USP'U]", "route": "intramuscular", "fda-application-number": "BLA125360", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Xeomin", "ndc-id": "46783-161_53000540-4a5b-427c-8257-3fe1177d2d62", "ndc-product-code": "46783-161", "dpd-id": null, "started-marketing-on": "2011-08-01", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "50 [USP'U]", "route": "intramuscular", "fda-application-number": "BLA125360", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Xeomin", "ndc-id": "46783-165_53000540-4a5b-427c-8257-3fe1177d2d62", "ndc-product-code": "46783-165", "dpd-id": null, "started-marketing-on": "2011-08-01", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "50 [USP'U]", "route": "intramuscular", "fda-application-number": "BLA125360", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Xeomin", "ndc-id": "0259-1605_c3deea37-b97e-4aea-bec1-bbb2afd2e8d9", "ndc-product-code": "0259-1605", "dpd-id": null, "started-marketing-on": "2010-09-01", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "50 [USP'U]", "route": "intramuscular", "fda-application-number": "BLA125360", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Xeomin", "ndc-id": "0259-1610_c3deea37-b97e-4aea-bec1-bbb2afd2e8d9", "ndc-product-code": "0259-1610", "dpd-id": null, "started-marketing-on": "2010-09-01", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "100 [USP'U]", "route": "intramuscular", "fda-application-number": "BLA125360", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Xeomin", "ndc-id": "0259-4110_c3deea37-b97e-4aea-bec1-bbb2afd2e8d9", "ndc-product-code": "0259-4110", "dpd-id": null, "started-marketing-on": "2010-09-01", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "100 [USP'U]", "route": "intramuscular", "fda-application-number": "BLA125360", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Xeomin", "ndc-id": "0259-4150_c3deea37-b97e-4aea-bec1-bbb2afd2e8d9", "ndc-product-code": "0259-4150", "dpd-id": null, "started-marketing-on": "2010-09-01", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "50 [USP'U]", "route": "intramuscular", "fda-application-number": "BLA125360", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Botox", "ingredients": "Botulinum Toxin Type A"}, {"name": "Botox Cosmetic", "ingredients": "Botulinum Toxin Type A"}, {"name": "Botox", "ingredients": "Botulinum Toxin Type A"}, {"name": "Botox Cosmetic", "ingredients": "Botulinum Toxin Type A"}, {"name": "Xeomin", "ingredients": "Botulinum Toxin Type A"}, {"name": "Xeomin", "ingredients": "Botulinum Toxin Type A"}, {"name": "Xeomin", "ingredients": "Botulinum Toxin Type A"}, {"name": "Xeomin", "ingredients": "Botulinum Toxin Type A"}, {"name": "Dysport", "ingredients": "Botulinum Toxin Type A"}, {"name": "Dysport", "ingredients": "Botulinum Toxin Type A"}, {"name": "Dysport", "ingredients": "Botulinum Toxin Type A"}, {"name": "Xeomin", "ingredients": "Botulinum Toxin Type A"}, {"name": "Xeomin", "ingredients": "Botulinum Toxin Type A"}, {"name": "Xeomin", "ingredients": "Botulinum Toxin Type A"}, {"name": "Botox", "ingredients": "Botulinum Toxin Type A"}, {"name": "Botox Cosmetic", "ingredients": "Botulinum Toxin Type A"}, {"name": "Dysport", "ingredients": "Botulinum Toxin Type A"}]}, "packagers": {"packager": [{"name": "Allergan Inc.", "url": "http://www.allergan.com"}, {"name": "Tercica Inc.", "url": "http://www.tercica.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Botox (100 - 200 unit/Vial)", "cost": {"@currency": "USD", "#text": "3.74"}, "unit": "vial"}, {"description": "Botox cosmetic 50 unit vial", "cost": {"@currency": "USD", "#text": "346.8"}, "unit": "vial"}, {"description": "Botox 100 unit vial", "cost": {"@currency": "USD", "#text": "630.0"}, "unit": "vial"}, {"description": "Botox cosmetic 100 unit vial", "cost": {"@currency": "USD", "#text": "630.0"}, "unit": "vial"}, {"description": "Botox 100 unit", "cost": {"@currency": "USD", "#text": "655.2"}, "unit": "vial"}, {"description": "Dysport 500 unit vial", "cost": {"@currency": "USD", "#text": "852.0"}, "unit": "vial"}, {"description": "Botox 200 unit vial", "cost": {"@currency": "USD", "#text": "1260.0"}, "unit": "vial"}]}, "categories": {"category": [{"category": "Neuromuscular Blocking Agents", "mesh-id": null}, {"category": "Anti-Wrinkle Agents", "mesh-id": null}, {"category": "Antidystonic Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, powder, lyophilized, for solution", "route": "intradermal; intramuscular", "strength": "100 [USP'U]"}, {"form": "Injection, powder, lyophilized, for solution", "route": "intradermal; intramuscular", "strength": "200 [USP'U]"}, {"form": "Powder for solution", "route": "intramuscular", "strength": "100 unit"}, {"form": "Injection, powder, lyophilized, for solution", "route": "intramuscular", "strength": "100 [USP'U]"}, {"form": "Injection, powder, lyophilized, for solution", "route": "intramuscular", "strength": "50 [USP'U]"}, {"form": "Injection, powder, lyophilized, for solution", "route": "intramuscular", "strength": "300 U"}, {"form": "Injection, powder, lyophilized, for solution", "route": "intramuscular", "strength": "500 U"}, {"form": "Powder for solution", "route": "intramuscular", "strength": "300 unit"}]}, "atc-codes": null, "ahfs-codes": {"ahfs-code": "92:00.00"}, "patents": {"patent": [{"number": "2280565", "country": "Canada", "approved": "2005-11-15", "expires": "2019-08-20"}, {"number": "2310845", "country": "Canada", "approved": "2001-05-15", "expires": "2014-06-07"}]}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB08897", "name": "Aclidinium", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB08897", "name": "Aclidinium", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00479", "name": "Amikacin", "description": "Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00479", "name": "Amikacin", "description": "Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00321", "name": "Amitriptyline", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00321", "name": "Amitriptyline", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00543", "name": "Amoxapine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00543", "name": "Amoxapine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB06696", "name": "Arbekacin", "description": "May enhance the neuromuscular-blocking effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00732", "name": "Atracurium besylate", "description": "May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents."}, {"drugbank-id": "DB00732", "name": "Atracurium besylate", "description": "Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00572", "name": "Atropine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00572", "name": "Atropine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00972", "name": "Azelastine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00972", "name": "Azelastine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00245", "name": "Benzatropine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00245", "name": "Benzatropine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00042", "name": "Botulinum Toxin Type B", "description": "AbobotulinumtoxinA may enhance the adverse neuromuscular effect of RimabotulinumtoxinB."}, {"drugbank-id": "DB00835", "name": "Brompheniramine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00835", "name": "Brompheniramine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00748", "name": "Carbinoxamine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00748", "name": "Carbinoxamine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00341", "name": "Cetirizine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00341", "name": "Cetirizine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01114", "name": "Chlorphenamine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01114", "name": "Chlorphenamine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00477", "name": "Chlorpromazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00477", "name": "Chlorpromazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00565", "name": "Cisatracurium besylate", "description": "May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents."}, {"drugbank-id": "DB00565", "name": "Cisatracurium besylate", "description": "Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00283", "name": "Clemastine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00283", "name": "Clemastine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00771", "name": "Clidinium", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00771", "name": "Clidinium", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01242", "name": "Clomipramine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01242", "name": "Clomipramine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00363", "name": "Clozapine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00363", "name": "Clozapine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00318", "name": "Codeine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00318", "name": "Codeine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01176", "name": "Cyclizine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01176", "name": "Cyclizine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00924", "name": "Cyclobenzaprine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00924", "name": "Cyclobenzaprine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00979", "name": "Cyclopentolate", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00979", "name": "Cyclopentolate", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00434", "name": "Cyproheptadine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00434", "name": "Cyproheptadine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00496", "name": "Darifenacin", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00496", "name": "Darifenacin", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01151", "name": "Desipramine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01151", "name": "Desipramine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00967", "name": "Desloratadine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00967", "name": "Desloratadine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00405", "name": "Dexbrompheniramine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00405", "name": "Dexbrompheniramine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00804", "name": "Dicyclomine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00804", "name": "Dicyclomine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01501", "name": "Difenoxin", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01501", "name": "Difenoxin", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00985", "name": "Dimenhydrinate", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00985", "name": "Dimenhydrinate", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01075", "name": "Diphenhydramine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01075", "name": "Diphenhydramine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01081", "name": "Diphenoxylate", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01081", "name": "Diphenoxylate", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00280", "name": "Disopyramide", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00280", "name": "Disopyramide", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01142", "name": "Doxepin", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01142", "name": "Doxepin", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00366", "name": "Doxylamine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00366", "name": "Doxylamine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00450", "name": "Droperidol", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00450", "name": "Droperidol", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01288", "name": "Fenoterol", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01288", "name": "Fenoterol", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB06702", "name": "Fesoterodine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB06702", "name": "Fesoterodine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00950", "name": "Fexofenadine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00950", "name": "Fexofenadine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01148", "name": "Flavoxate", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01148", "name": "Flavoxate", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00875", "name": "Flupentixol", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00875", "name": "Flupentixol", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00623", "name": "Fluphenazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00623", "name": "Fluphenazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00588", "name": "Fluticasone Propionate", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00588", "name": "Fluticasone Propionate", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00452", "name": "Framycetin", "description": "May enhance the neuromuscular-blocking effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00798", "name": "Gentamicin", "description": "Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00798", "name": "Gentamicin", "description": "Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00986", "name": "Glycopyrrolate", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00986", "name": "Glycopyrrolate", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00502", "name": "Haloperidol", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00502", "name": "Haloperidol", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00557", "name": "Hydroxyzine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00557", "name": "Hydroxyzine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00424", "name": "Hyoscyamine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00424", "name": "Hyoscyamine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00458", "name": "Imipramine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00458", "name": "Imipramine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00332", "name": "Ipratropium bromide", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00332", "name": "Ipratropium bromide", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01247", "name": "Isocarboxazid", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01247", "name": "Isocarboxazid", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01172", "name": "Kanamycin", "description": "Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01172", "name": "Kanamycin", "description": "Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01106", "name": "Levocabastine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01106", "name": "Levocabastine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB06282", "name": "Levocetirizine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB06282", "name": "Levocetirizine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00455", "name": "Loratadine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00455", "name": "Loratadine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00408", "name": "Loxapine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00408", "name": "Loxapine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00934", "name": "Maprotiline", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00934", "name": "Maprotiline", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00737", "name": "Meclizine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00737", "name": "Meclizine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB04843", "name": "Mepenzolate", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB04843", "name": "Mepenzolate", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01403", "name": "Methotrimeprazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01403", "name": "Methotrimeprazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01171", "name": "Moclobemide", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01171", "name": "Moclobemide", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00994", "name": "Neomycin", "description": "Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00994", "name": "Neomycin", "description": "Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00955", "name": "Netilmicin", "description": "May enhance the neuromuscular-blocking effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00540", "name": "Nortriptyline", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00540", "name": "Nortriptyline", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00334", "name": "Olanzapine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00334", "name": "Olanzapine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00768", "name": "Olopatadine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00768", "name": "Olopatadine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01173", "name": "Orphenadrine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01173", "name": "Orphenadrine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01062", "name": "Oxybutynin", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01062", "name": "Oxybutynin", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01337", "name": "Pancuronium", "description": "May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents."}, {"drugbank-id": "DB01337", "name": "Pancuronium", "description": "Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00850", "name": "Perphenazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00850", "name": "Perphenazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00780", "name": "Phenelzine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00780", "name": "Phenelzine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01100", "name": "Pimozide", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01100", "name": "Pimozide", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB06153", "name": "Pizotifen", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB06153", "name": "Pizotifen", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00433", "name": "Prochlorperazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00433", "name": "Prochlorperazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00387", "name": "Procyclidine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00387", "name": "Procyclidine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00420", "name": "Promazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00420", "name": "Promazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01069", "name": "Promethazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01069", "name": "Promethazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00782", "name": "Propantheline", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00782", "name": "Propantheline", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00344", "name": "Protriptyline", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00344", "name": "Protriptyline", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01224", "name": "Quetiapine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01224", "name": "Quetiapine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB03615", "name": "Ribostamycin", "description": "May enhance the neuromuscular-blocking effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00734", "name": "Risperidone", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00734", "name": "Risperidone", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00728", "name": "Rocuronium", "description": "May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents."}, {"drugbank-id": "DB00728", "name": "Rocuronium", "description": "Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00747", "name": "Scopolamine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00747", "name": "Scopolamine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01591", "name": "Solifenacin", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01591", "name": "Solifenacin", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00919", "name": "Spectinomycin", "description": "May enhance the neuromuscular-blocking effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01082", "name": "Streptomycin", "description": "Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01082", "name": "Streptomycin", "description": "Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00202", "name": "Succinylcholine", "description": "May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents."}, {"drugbank-id": "DB00202", "name": "Succinylcholine", "description": "Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00679", "name": "Thioridazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00679", "name": "Thioridazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01623", "name": "Thiothixene", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01623", "name": "Thiothixene", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01409", "name": "Tiotropium", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01409", "name": "Tiotropium", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00684", "name": "Tobramycin", "description": "Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00684", "name": "Tobramycin", "description": "Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01036", "name": "Tolterodine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01036", "name": "Tolterodine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00752", "name": "Tranylcypromine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00752", "name": "Tranylcypromine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00831", "name": "Trifluoperazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00831", "name": "Trifluoperazine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00376", "name": "Trihexyphenidyl", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00376", "name": "Trihexyphenidyl", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00662", "name": "Trimethobenzamide", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00662", "name": "Trimethobenzamide", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00726", "name": "Trimipramine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00726", "name": "Trimipramine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00427", "name": "Triprolidine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00427", "name": "Triprolidine", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB00209", "name": "Trospium", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB00209", "name": "Trospium", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB09076", "name": "Umeclidinium", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB09076", "name": "Umeclidinium", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01339", "name": "Vecuronium", "description": "May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents."}, {"drugbank-id": "DB01339", "name": "Vecuronium", "description": "Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA."}, {"drugbank-id": "DB01624", "name": "Zuclopenthixol", "description": "Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA."}, {"drugbank-id": "DB01624", "name": "Zuclopenthixol", "description": "Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">Botulinum Toxin Type A Sequence\nMPFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLN\nPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGG\nSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGY\nGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPN\nRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKA\nKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKV\nLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFT\nGLFEFYKLLCVRGIITSKTKSLDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEE\nITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNG\nKKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEA\nAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSG\nAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAK\nVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKA\nMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDK\nVNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINI\nGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNN\nEYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTIT\nNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELN\nEKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPR\nGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQA\nGVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAK\nLVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL"}}, "experimental-properties": {"property": [{"kind": "Water Solubility", "value": "Soluble", "source": null}, {"kind": "Hydrophobicity", "value": "-0.368", "source": null}, {"kind": "Isoelectric Point", "value": "6.06", "source": null}, {"kind": "Molecular Weight", "value": "149322.7000", "source": null}, {"kind": "Molecular Formula", "value": "C6760H10447N1743O2010S32", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "17056"}, {"resource": "Drugs Product Database (DPD)", "identifier": "21617"}, {"resource": "KEGG Compound", "identifier": "C07946"}, {"resource": "KEGG Drug", "identifier": "D00783"}, {"resource": "National Drug Code Directory", "identifier": "99207-500-30"}, {"resource": "GenBank", "identifier": "X52066"}, {"resource": "PharmGKB", "identifier": "PA164754825"}, {"resource": "UniProtKB", "identifier": "P10845"}, {"resource": "Wikipedia", "identifier": "Botox"}]}, "external-links": {"external-link": {"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/botox.htm"}}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000390", "name": "Synaptosomal-associated protein 25", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Zhou JY, Wang ZF, Ren XM, Tang MZ, Shi YL: Antagonism of botulinum toxin type A-induced cleavage of SNAP-25 in rat cerebral synaptosome by toosendanin. FEBS Lett. 2003 Dec 4;555(2):375-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14644446\n# Flynn TC: Myobloc. Dermatol Clin. 2004 Apr;22(2):207-11, vii. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15222581\n# Okada M, Yoshida S, Zhu G, Kaneko S: [Methodological consideration in studying the exocytosis mechanisms using microdialysis] Nihon Shinkei Seishin Yakurigaku Zasshi. 2004 Aug;24(4):165-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15484814\n# Frassoni C, Inverardi F, Coco S, Ortino B, Grumelli C, Pozzi D, Verderio C, Matteoli M: Analysis of SNAP-25 immunoreactivity in hippocampal inhibitory neurons during development in culture and in situ. Neuroscience. 2005;131(4):813-23. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15749336\n# Straughan D: Progress in applying the Three Rs to the potency testing of Botulinum toxin type A. Altern Lab Anim. 2006 Jun;34(3):305-13. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16831062\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P60880", "@source": "Swiss-Prot", "name": "Synaptosomal-associated protein 25", "general-function": "Involved in regulation of insulin secretion", "specific-function": "t-SNARE involved in the molecular regulation of neurotransmitter release. May play an important role in the synaptic function of specific neuronal systems. Associates with proteins involved in vesicle docking and membrane fusion", "gene-name": "SNAP25", "locus": "20p12-p11.2", "cellular-location": null, "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "4.39", "molecular-weight": "23315.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:11132"}, {"resource": "GenAtlas", "identifier": "SNAP25"}, {"resource": "GeneCards", "identifier": "SNAP25"}, {"resource": "GenBank Gene Database", "identifier": "L19760"}, {"resource": "GenBank Protein Database", "identifier": "307426"}, {"resource": "UniProtKB", "identifier": "P60880"}, {"resource": "UniProt Accession", "identifier": "SNP25_HUMAN"}]}, "synonyms": {"synonym": ["SNAP-25", "SUP", "Super protein", "Synaptosomal-associated 25 kDa protein"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Synaptosomal-associated protein 25\nMAEDADMRNELEEMQRRADQLADESLESTRRMLQLVEESKDAGIRTLVMLDEQGEQLERI\nEEGMDQINKDMKEAEKNLTDLGKFCGLCVCPCNKLKSSDAYKKAWGNNQDGVVASQPARV\nVDEREQMAISGGFIRRVTNDARENEMDENLEQVSGIIGNLRHMALDMGNEIDTQNRQIDR\nIMEKADSNKTRIDEANQRATKMLGSG"}, "gene-sequence": {"@format": "FASTA", "#text": ">621 bp\nATGGCCGAAGACGCAGACATGCGCAATGAGCTGGAGGAGATGCAGCGAAGGGCTGACCAG\nTTGGCTGATGAGTCGCTGGAAAGCACCCGTCGTATGCTGCAACTGGTTGAAGAGAGTAAA\nGATGCTGGTATCAGGACTTTGGTTATGTTGGATGAACAAGGAGAACAACTCGATCGTGTC\nGAAGAAGGCATGAACCATATCAACCAAGACATGAAGGAGGCTGAGAAAAATTTAAAAGAT\nTTAGGGAAATGCTGTGGCCTTTTCATATGTCCTTGTAACAAGCTTAAATCAAGTGATGCT\nTACAAAAAAGCCTGGGGCAATAATCAGGATGGAGTGGTGGCCAGCCAGCCTGCTCGTGTA\nGTGGACGAACGGGAGCAGATGGCCATCAGTGGCGGCTTCATCCGCAGGGTAACAAATGAT\nGCCCGAGAAAATGAAATGGATGAAAACCTAGAGCAGGTGAGCGGCATCATCGGGAACCTC\nCGTCACATGGCCCTGGATATGGGCAATGAGATCGATACACAGAATCGCCAGATCGACAGG\nATCATGGAGAAGGCTGATTCCAACAAAACCAGAATTGATGAGGCCAACCAACGTGCAACA\nAAGATGCTGGGAAGTGGTTAA"}, "pfams": {"pfam": [{"identifier": "PF00835", "name": "SNAP-25"}, {"identifier": "PF05739", "name": "SNARE"}]}, "go-classifiers": null}}, {"@position": "1", "id": "BE0003572", "name": "Rho-related GTP-binding protein RhoB", "organism": "Human", "actions": null, "references": "# Ishida H, Zhang X, Erickson K, Ray P: Botulinum toxin type A targets RhoB to inhibit lysophosphatidic acid-stimulated actin reorganization and acetylcholine release in nerve growth factor-treated PC12 cells. J Pharmacol Exp Ther. 2004 Sep;310(3):881-9. Epub 2004 May 12. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15140914", "known-action": "unknown", "polypeptide": {"@id": "P62745", "@source": "Swiss-Prot", "name": "Rho-related GTP-binding protein RhoB", "general-function": "Involved in GTP binding", "specific-function": "Mediates apoptosis in neoplastically transformed cells after DNA damage. Not essential for development but affects cell adhesion and growth factor signaling in transformed cells. Plays a negative role in tumorigenesis as deletion causes tumor formation. Involved in intracellular protein trafficking of a number of proteins. Targets PKN1 to endosomes and is involved in trafficking of the EGF receptor from late endosomes to lysosomes. Also required for stability and nuclear trafficking of AKT1/AKT which promotes endothelial cell survival during vascular development", "gene-name": "RHOB", "locus": "2p24", "cellular-location": "Late endosome membrane", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "4.85", "molecular-weight": "22123.2", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "GNC:668"}, {"resource": "GeneCards", "identifier": "RHOB"}, {"resource": "GenBank Gene Database", "identifier": "X06820"}, {"resource": "GenBank Protein Database", "identifier": "36032"}, {"resource": "UniProtKB", "identifier": "P62745"}, {"resource": "UniProt Accession", "identifier": "RHOB_HUMAN"}]}, "synonyms": {"synonym": "H6"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Rho-related GTP-binding protein RhoB\nMAAIRKKLVVVGDGACGKTCLLIVFSKDEFPEVYVPTVFENYVADIEVDGKQVELALWDT\nAGQEDYDRLRPLSYPDTDVILMCFSVDSPDSLENIPEKWVPEVKHFCPNVPIILVANKKD\nLRSDEHVRTELARMKQEPVRTDDGRAMAVRIQAYDYLECSAKTKEGVREVFETATRAALQ\nKRYGSQNGCINCCKVL"}, "gene-sequence": {"@format": "FASTA"}, "pfams": {"pfam": {"identifier": "PF00071", "name": "Ras"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "GTP binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "guanyl nucleotide binding"}, {"category": "process", "description": "small GTPase mediated signal transduction"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "intracellular signaling cascade"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-05-19", "drugbank-id": [{"@primary": "true", "#text": "DB00085"}, "BIOD00067", "BTD00067"], "name": "Pancrelipase", "description": "Pancrelipase is an enzyme mixture isolated from porcine or bovine pancreas, sometimes called pancreatin. It contains 3 enzymes: amylase, lipase, and a protease (chymotrypsin). Pancrelipase is marketed under several brand names such as Ultresa\u2122 and Viokace\u2122.", "cas-number": "53608-75-6", "groups": {"group": "approved"}, "general-references": null, "synthesis-reference": null, "indication": "For treatment of exocrine pancreatic insufficiency in cystic fibrosis (Ultresa\u2122), chronic pancreatitis (Viokace\u2122 in combination with a proton pump inhibitor), and pancreatectomy (Viokace\u2122 in combination with a proton pump inhibitor).", "pharmacodynamics": "Used in the treatment of cystic fibrosis or pancreatic dysfunction, pancrelipase helps improve fat digestion in the small intestine. Specifically, the lipase, protease and amylase components break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. Pancreatic enzymes are used to correct maldigestion, malabsorption and pain associated with pancreatic insufficiency. The major maldigestion/malabsorption problems arise from incomplete fat digestion. Exogenous pancrelipase reduces the amount of nitrogen and fat excreted in the stool.", "mechanism-of-action": "The lipase, protease and amylase components of pancrelipase break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars.", "toxicity": "Overdose symptoms may include diarrhea or stomach upset. The most common adverse reactions seen are ear, neck, and abdominal pain; headache, nasal congestion, and beta-hemolytic streptococcal infection.", "metabolism": "Pancrelipase acts locally, so there is minimal metabolism.", "absorption": "Pancrelipase is not significantly absorbed from the gastrointestinal tract.", "half-life": "Pancrelipase is not significantly absorbed from the gastrointestinal tract and acts locally, so there is no terminal elimination half life.", "protein-binding": "Pancrelipase acts locally, so there is minimal plasma protein binding.", "route-of-elimination": "Pancrelipase is eliminated in the feces.", "volume-of-distribution": "Pancrelipase acts locally, so there is no volume of distribution.", "clearance": "Pancrelipase is not significantly absorbed, so there is minimal clearance from the body.", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "1,4-alpha-D- glucan glucanohydrolase"}, {"@language": "", "@coder": "", "#text": "PA"}, {"@language": "", "@coder": "", "#text": "Pancreatic alpha-amylase precursor"}]}, "products": null, "international-brands": {"international-brand": [{"name": "Cotazym", "company": "Organon"}, {"name": "Ku-Zyme", "company": "Koichi"}, {"name": "Pancrease", "company": "Ortho-McNeil"}, {"name": "Ultrase", "company": "Axcan Scandipharm"}, {"name": "Ultresa (delayed-release enteric coated capsules)", "company": "APTALIS PHARMA US"}, {"name": "Viokace (tablets)", "company": "APTALIS PHARMA US"}, {"name": "Zymase", "company": "Organon"}]}, "mixtures": null, "packagers": {"packager": [{"name": "Axcan Pharma Inc.", "url": "http://www.axcan.com"}, {"name": "Confab Laboratories Inc.", "url": "http://www.confab.ca"}, {"name": "Eurand Pharmaceuticals Inc.", "url": "http://www.eurand.com"}, {"name": "Global Pharmaceuticals", "url": "http://www.globalphar.com"}, {"name": "Kaiser Foundation Hospital", "url": null}, {"name": "Ortho Mcneil Janssen Pharmaceutical Inc.", "url": "http://www.ortho-mcneil.com"}, {"name": "Ortho-McNeil-Janssen Pharmaceuticals Inc.", "url": "http://www.ortho-mcneil.com"}, {"name": "Physicians Total Care Inc.", "url": "http://www.physicianstotalcare.com"}, {"name": "Schwarz Pharma Inc.", "url": null}, {"name": "Solvay Pharmaceuticals", "url": "http://global.abbottgrowth.com"}, {"name": "X-Gen Pharmaceuticals", "url": "http://www.x-gen.us"}, {"name": "Yung Shin Pharmaceutical Industry Ltd.", "url": "http://www.ysp.com.cn"}]}, "manufacturers": null, "prices": {"price": [{"description": "Pancrelipase MST-16 48-16-48mu Enteric Coated Capsule", "cost": {"@currency": "USD", "#text": "1.03"}, "unit": "capsule"}, {"description": "Pancrelipase 10000 30-10-30mu Enteric Coated Capsule", "cost": {"@currency": "USD", "#text": "1.38"}, "unit": "capsule"}, {"description": "Pancrease MT 10 30-10-30mu Enteric Coated Capsule", "cost": {"@currency": "USD", "#text": "1.49"}, "unit": "capsule"}, {"description": "Creon 10 33.2-10-37.5mu Enteric Coated Capsule", "cost": {"@currency": "USD", "#text": "1.54"}, "unit": "capsule"}, {"description": "Ultrase MT 12 39-12-39mu Enteric Coated Capsule", "cost": {"@currency": "USD", "#text": "1.65"}, "unit": "capsule"}, {"description": "Pancrelipase 16000 48-16-48mu Enteric Coated Capsule", "cost": {"@currency": "USD", "#text": "2.02"}, "unit": "capsule"}, {"description": "Pancrease MT 16 48-16-48mu Enteric Coated Capsule", "cost": {"@currency": "USD", "#text": "2.4"}, "unit": "capsule"}, {"description": "Ultrase MT 18 58.5-18-58.5mu Enteric Coated Capsule", "cost": {"@currency": "USD", "#text": "2.65"}, "unit": "capsule"}, {"description": "Creon 20 66.4-20-75mu Enteric Coated Capsule", "cost": {"@currency": "USD", "#text": "2.83"}, "unit": "capsule"}, {"description": "Pancrease MT 20 56-20-44mu Enteric Coated Capsule", "cost": {"@currency": "USD", "#text": "2.99"}, "unit": "capsule"}, {"description": "Ultrase MT 20 65-20-65mu Enteric Coated Capsule", "cost": {"@currency": "USD", "#text": "3.06"}, "unit": "capsule"}, {"description": "Creon 24000 unit Enteric Coated Capsule", "cost": {"@currency": "USD", "#text": "3.32"}, "unit": "capsule"}, {"description": "Pancrelipase ec 4500 capsule", "cost": {"@currency": "USD", "#text": "0.64"}, "unit": "capsule"}, {"description": "Pancrease ec capsule", "cost": {"@currency": "USD", "#text": "0.76"}, "unit": "capsule"}, {"description": "Ultrase 4500 unit Enteric Coated Capsule", "cost": {"@currency": "USD", "#text": "0.8"}, "unit": "capsule"}, {"description": "Creon 5 16.6-5-18.75mu Enteric Coated Capsule", "cost": {"@currency": "USD", "#text": "0.86"}, "unit": "capsule"}, {"description": "Pancrease 4500 unit Enteric Coated Capsule", "cost": {"@currency": "USD", "#text": "0.87"}, "unit": "capsule"}]}, "categories": {"category": [{"category": "Gastrointestinal Agents", "mesh-id": null}, {"category": "Enzyme Replacement Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": null, "atc-codes": null, "ahfs-codes": null, "patents": null, "food-interactions": {"food-interaction": ["Delayed release capsules should not be broken or crushed, but for those patients who cannot swallow the capsules, sprinkle the contents of the capsule onto soft acidic foods (pH of \u22644.5). Alkaline foods with a higher pH will promote early release of pancrelipase followed by enzyme inactivation in the stomach.", "Multivitamins/minerals which have vitamins ADEK, folate, or iron: If pancrelipase is used in combination with multivitamins/minerals that have vitamins ADEK, folate, or iron then monitor therapy because pancrelipase may decrease absorption of iron in these multivitamin/mineral products.", "Take pancrelipase with meals and a sufficient amount of water."]}, "drug-interactions": null, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">Pancreatic alpha amylase\nQYSPNTQQGRTSIVHLFEWRWVDIALECERYLAPKGFGGVQVSPPNENVAIYNPFRPWWE\nRYQPVSYKLCTRSGNEDEFRNMVTRCNNVGVRIYVDAVINHMCGNAVSAGTSSTCGSYFN\nPGSRDFPAVPYSGWDFNDGKCKTGSGDIENYNDATQVRDCRLTGLLDLALEKDYVRSKIA\nEYMNHLIDIGVAGFRLDASKHMWPGDIKAILDKLHNLNSNWFPAGSKPFIYQEVIDLGGE\nPIKSSDYFGNGRVTEFKYGAKLGTVIRKWNGEKMSYLKNWGEGWGFVPSDRALVFVDNHD\nNQRGHGAGGASILTFWDARLYKMAVGFMLAHPYGFTRVMSSYRWPRQFQNGNDVNDWVGP\nPNNNGVIKEVTINPDTTCGNDWVCEHRWRQIRNMVIFRNVVDGQPFTNWYDNGSNQVAFG\nRGNRGFIVFNNDDWSFSLTLQTGLPAGTYCDVISGDKINGNCTGIKIYVSDDGKAHFSIS\nNSAEDPFIAIHAESKL"}, {"@format": "FASTA", "#text": ">Chymotrypsin B\nGVPAIHPVLSGLSRIVNGEDAVPGSWPWQVSLQDKTGFHFCGGSLISEDWVVTAAHCGVR\nTSDVVVAGEFDQGSDEENIQVLKIAKVFKNPKFSILTVNNDITLLKLATPARFSQTVSAV\nCLPSADDDFPAGTLCATTGWGKTKYNANKTPDKLQQAALPLLSNAECKKSWGRRITDVMI\nCAGASGVSSCMGDSGGPLVCQKDGAWTLVGIVSWGSDTCSTSSPGVYARVTKLIPWVQKI\nLAAN"}, {"@format": "FASTA", "#text": ">pancreatic triacylglycerol lipase\nMLPLWTLSLLLGAVAGKEVCYERLGCFSDDSPWSGITERPLHILPWSPKDVNTRFLLYTN\nENPNNFQEVAADSSSISGSNFKTNRKTRFIIHGFIDKGEENWLANVCKNLFKVESVNCIC\nVDWKGGSRTGYTQASQNIRIVGAEVAYFVEFLQSAFGYSPSNVHVIGHSLGAHAAGEAGR\nRTNGTIGRITGLDPAEPCFQGTPELVRLDPSDAKFVDVIHTDGAPIVPNLGFGMSQVVGH\nLDFFPNGGVEMPGCKKNILSQIVDIDGIWEGTRDFAACNHLRSYKYYTDSIVNPDGFAGF\nPCASYNVFTANKCFPCPSGGCPQMGHYADRYPGKTNDVGQKFYLDTGDASNFARWRYKVS\nVTLSGKKVTGHILVSLFGNKGNSKQYEIFKGTLKPDSTHSNEFDSDVDVGDLQMVKFIWY\nNNVINPTLPRVGASKIIVETNVGKQFNFCSPETVREEVLLTLTPC"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "48-50 \u00b0C", "source": "Vinogradov, A.A. et al., Protein Eng. 14:683-689 (2001)"}, {"kind": "Isoelectric Point", "value": "6.44", "source": null}, {"kind": "Molecular Weight", "value": "131125.6000", "source": null}, {"kind": "Molecular Formula", "value": "C5850H8902N1606O1739S49", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "3173"}, {"resource": "KEGG Drug", "identifier": "D05349"}, {"resource": "National Drug Code Directory", "identifier": "54868-6067-0"}, {"resource": "GenBank", "identifier": "M18785"}, {"resource": "PharmGKB", "identifier": "PA448428"}, {"resource": "UniProtKB", "identifier": "P04746"}, {"resource": "Wikipedia", "identifier": "Pancrelipase"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic2/pancrel.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/amylase-lipase-protease.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0004834", "name": "Dietary fat", "organism": "Human", "actions": {"action": "cleavage"}, "references": "# Svendsen A: Lipase protein engineering. Biochim Biophys Acta. 2000 Dec 29;1543(2):223-238. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11150608", "known-action": "yes"}, {"@position": "2", "id": "BE0004835", "name": "Dietary protein", "organism": "Human", "actions": {"action": "cleavage"}, "references": "# Rawlings ND, Barrett AJ: Families of serine peptidases. Methods Enzymol. 1994;244:19-61. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7845208", "known-action": "yes"}, {"@position": "3", "id": "BE0004836", "name": "Dietary starch", "organism": "Human", "actions": {"action": "cleavage"}, "references": "# Udani J, Hardy M, Madsen DC: Blocking carbohydrate absorption and weight loss: a clinical trial using Phase 2 brand proprietary fractionated white bean extract. Altern Med Rev. 2004 Mar;9(1):63-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15005645", "known-action": "yes"}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-09-13", "drugbank-id": [{"@primary": "true", "#text": "DB00086"}, "BIOD00028", "BTD00028"], "name": "Streptokinase", "description": "Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci.", "cas-number": "9002-01-1", "groups": {"group": "approved"}, "general-references": null, "synthesis-reference": "Lawrence Isaac Galler, \"Streptokinase derivatives with high affinity for activated platelets and methods of their production and use in thrombolytic therapy.\" U.S. Patent US6087332, issued July, 1997.", "indication": "For the treatment of acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis or emolism and occlusion of arteriovenous cannulae", "pharmacodynamics": "Streptokinase creates an active complex which promotes the cleavage of the Arg/Val bond in plasminogen to form the proteolytic enzyme plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.", "mechanism-of-action": "Plasminogen is an inactive molecule that becomes activated to plasmin when the Arg/Val bond is cleaved. Plasmin breaks down fibrin clots created by the blood clotting cascade. Streptokinase forms a highly specific 1:1 enzymatic complex with plasminogen which converts inactive plasminogen molecules into active plasmin. Plasmin degrades fibrin clots as well as fibrinogen and other plasma proteins. This in turn leads to the degradation of blood clots.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": {"@language": "", "@coder": "", "#text": "Streptokinase C precursor"}}, "products": {"product": [{"name": "Kabikinase - Pws 1500000units/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02126141", "started-marketing-on": "1995-12-31", "ended-marketing-on": "2001-07-30", "dosage-form": "powder for solution", "strength": "1500000 unit", "route": "intravenous; intracoronary", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kabikinase - Pws 250000 Unit/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02126125", "started-marketing-on": "1995-12-31", "ended-marketing-on": "1999-08-12", "dosage-form": "powder for solution", "strength": "250000 unit", "route": "intravenous; intracoronary", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Kabikinase - Pws 750000units/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02126133", "started-marketing-on": "1995-12-31", "ended-marketing-on": "2001-07-30", "dosage-form": "powder for solution", "strength": "750000 unit", "route": "intravenous; intracoronary", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Streptase", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02018993", "started-marketing-on": "1994-12-31", "ended-marketing-on": "2012-02-22", "dosage-form": "powder for solution", "strength": "250000 unit", "route": "intravenous; intracoronary", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Streptase", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02019000", "started-marketing-on": "1994-12-31", "ended-marketing-on": "2012-02-22", "dosage-form": "powder for solution", "strength": "750000 unit", "route": "intravenous; intracoronary", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Streptase", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02019019", "started-marketing-on": "1994-12-31", "ended-marketing-on": "2012-02-22", "dosage-form": "powder for solution", "strength": "1500000 unit", "route": "intravenous; intracoronary", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Streptase Inj 1500000 Unit/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00881686", "started-marketing-on": "1991-12-31", "ended-marketing-on": "1996-08-29", "dosage-form": "powder for solution", "strength": "1500000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Streptase Inj 250000unit/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00527157", "started-marketing-on": "1981-12-31", "ended-marketing-on": "1996-08-29", "dosage-form": "powder for solution", "strength": "250000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Streptase Inj 750000unit/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00527149", "started-marketing-on": "1981-12-31", "ended-marketing-on": "1996-08-29", "dosage-form": "powder for solution", "strength": "750000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Streptase Inj 1500000 Unit/vial", "ingredients": "Streptokinase"}, {"name": "Streptase", "ingredients": "Streptokinase"}, {"name": "Streptase", "ingredients": "Streptokinase"}, {"name": "Streptase", "ingredients": "Streptokinase"}, {"name": "Kabikinase - Pws 1500000units/vial", "ingredients": "Streptokinase"}, {"name": "Kabikinase - Pws 750000units/vial", "ingredients": "Streptokinase"}, {"name": "Kabikinase - Pws 250000 Unit/vial", "ingredients": "Streptokinase"}, {"name": "Streptase Inj 750000unit/vial", "ingredients": "Streptokinase"}, {"name": "Streptase Inj 250000unit/vial", "ingredients": "Streptokinase"}]}, "packagers": {"packager": {"name": "Pfizer Inc.", "url": "http://www.pfizer.com"}}, "manufacturers": null, "prices": null, "categories": {"category": [{"category": "Fibrinolytic Agents", "mesh-id": null}, {"category": "Thrombolytic Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Powder for solution", "route": "intravenous; intracoronary", "strength": "1500000 unit"}, {"form": "Powder for solution", "route": "intravenous; intracoronary", "strength": "250000 unit"}, {"form": "Powder for solution", "route": "intravenous; intracoronary", "strength": "750000 unit"}, {"form": "Powder for solution", "route": "intravenous", "strength": "1500000 unit"}, {"form": "Powder for solution", "route": "intravenous", "strength": "250000 unit"}, {"form": "Powder for solution", "route": "intravenous", "strength": "750000 unit"}]}, "atc-codes": {"atc-code": {"@code": "B01AD01", "level": [{"@code": "B", "#text": "BLOOD AND BLOOD FORMING ORGANS"}, {"@code": "B01", "#text": "ANTITHROMBOTIC AGENTS"}, {"@code": "B01A", "#text": "ANTITHROMBOTIC AGENTS"}, {"@code": "B01AD", "#text": "Enzymes"}]}}, "ahfs-codes": {"ahfs-code": "20:12.20"}, "patents": null, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00054", "name": "Abciximab", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01418", "name": "Acenocoumarol", "description": "May enhance the anticoagulant effect of Vitamin K Antagonists."}, {"drugbank-id": "DB00945", "name": "Acetylsalicylic acid", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00233", "name": "Aminosalicylic Acid", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB00261", "name": "Anagrelide", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06605", "name": "Apixaban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06692", "name": "Aprotinin", "description": "Aprotinin may diminish the therapeutic effect of Thrombolytic Agents."}, {"drugbank-id": "DB00278", "name": "Argatroban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01294", "name": "Bismuth Subsalicylate", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB00006", "name": "Bivalirudin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06441", "name": "Cangrelor", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01166", "name": "Cilostazol", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00215", "name": "Citalopram", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00758", "name": "Clopidogrel", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06695", "name": "Dabigatran etexilate", "description": "May enhance the anticoagulant effect of Dabigatran etexilate."}, {"drugbank-id": "DB06779", "name": "Dalteparin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06754", "name": "Danaparoid", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB06700", "name": "Desvenlafaxine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00586", "name": "Diclofenac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00861", "name": "Diflunisal", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01551", "name": "Dihydrocodeine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00975", "name": "Dipyridamole", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00476", "name": "Duloxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB09075", "name": "Edoxaban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01225", "name": "Enoxaparin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01240", "name": "Epoprostenol", "description": "May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents."}, {"drugbank-id": "DB00063", "name": "Eptifibatide", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01175", "name": "Escitalopram", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00749", "name": "Etodolac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00573", "name": "Fenoprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB08976", "name": "Floctafenine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00472", "name": "Fluoxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00712", "name": "Flurbiprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00176", "name": "Fluvoxamine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00569", "name": "Fondaparinux sodium", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01109", "name": "Heparin", "description": "May enhance the anticoagulant effect of Heparin."}, {"drugbank-id": "DB01050", "name": "Ibuprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01088", "name": "Iloprost", "description": "May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents."}, {"drugbank-id": "DB00328", "name": "Indomethacin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01009", "name": "Ketoprofen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00465", "name": "Ketorolac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB08918", "name": "Levomilnacipran", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01397", "name": "Magnesium salicylate", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB00784", "name": "Mefenamic acid", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00814", "name": "Meloxicam", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB04896", "name": "Milnacipran", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00461", "name": "Nabumetone", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB08813", "name": "Nadroparin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00788", "name": "Naproxen", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00991", "name": "Oxaprozin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00715", "name": "Paroxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00554", "name": "Piroxicam", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06209", "name": "Prasugrel", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06228", "name": "Rivaroxaban", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB01399", "name": "Salsalate", "description": "Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur."}, {"drugbank-id": "DB01104", "name": "Sertraline", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00605", "name": "Sulindac", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB01600", "name": "Tiaprofenic acid", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB08816", "name": "Ticagrelor", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00208", "name": "Ticlopidine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06822", "name": "Tinzaparin", "description": "May enhance the anticoagulant effect of Anticoagulants."}, {"drugbank-id": "DB00775", "name": "Tirofiban", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00500", "name": "Tolmetin", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00374", "name": "Treprostinil", "description": "May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents."}, {"drugbank-id": "DB00285", "name": "Venlafaxine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB06684", "name": "Vilazodone", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB09030", "name": "Vorapaxar", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB09068", "name": "Vortioxetine", "description": "Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents."}, {"drugbank-id": "DB00682", "name": "Warfarin", "description": "May enhance the anticoagulant effect of Vitamin K Antagonists."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">Streptokinase Sequence DB00086\nMKNYLSFGMFALLFALTFGTVNSVQAIAGPEWLLDRPSVNNSQLVVSVAGTVEGTNQDIS\nLKFFEIDLTSRPAHGGKTEQGLSPKSKPFATDSGAMSHKLEKADLLKAIQEQLIANVHSN\nDDYFEVIDFASDATITDRNGKVYFADKDGSVTLPTQPVQEFLLSGHVRVRPYKEKPIQNQ\nAKSVDVEYTVQFTPLNPDDDFRPGLKDTKLLKTLAIGDTITSQELLAQAQSILNKNHPGY\nTIYERDSSIVTHDNDIFRTILPMDQEFTYRVKNREQAYRINKKSGLNEEINNTDLISEKY\nYVLKKGEKPYDPFDRSHLKLFTIKYVDVDTNELLKSEQLLTASERNLDFRDLYDPRDKAK\nLLYNNLDAFGIMDYTLTGKVEDNHDDTNRIITVYMGKRPEGENASYHLAYDKDRYTEEER\nEVYSYLRYTGTPIPDNPNDK"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.728", "source": null}, {"kind": "Isoelectric Point", "value": "5.12", "source": null}, {"kind": "Molecular Weight", "value": "47286.7000", "source": null}, {"kind": "Molecular Formula", "value": "C2100H3278N566O669S4", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "5991"}, {"resource": "GenBank", "identifier": "K02986"}, {"resource": "PharmGKB", "identifier": "PA164754919"}, {"resource": "UniProtKB", "identifier": "P00779"}, {"resource": "Wikipedia", "identifier": "Streptokinase"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic2/streptokinase.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cons/streptokinase-intravenous-intracoronary.html"}]}, "pathways": {"pathway": {"smpdb-id": "SMP00282", "name": "Streptokinase Action Pathway", "drugs": {"drug": [{"drugbank-id": "DB00086", "name": "Streptokinase"}, {"drugbank-id": "DB01022", "name": "Phylloquinone"}, {"drugbank-id": "DB01373", "name": "Calcium"}]}, "enzymes": {"uniprot-id": ["P00747", "P00748", "P02452", "P03952", "P03951", "P00740", "P00451", "P00734", "P12259", "P00742", "P02671", "P02675", "P02679", "P00488", "P05160", "P00750", "P08709", "P13726", "Q9BQB6", "P38435"]}}}, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000211", "name": "Plasminogen", "organism": "Human", "actions": {"action": "activator"}, "references": "# Caballero AR, Lottenberg R, Johnston KH: Cloning, expression, sequence analysis, and characterization of streptokinases secreted by porcine and equine isolates of Streptococcus equisimilis. Infect Immun. 1999 Dec;67(12):6478-86. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10569766\n# Alessi MC, Juhan-Vague I: [Thrombolytics and their use] Rev Prat. 1999 Oct 1;49(15):1654-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10581996\n# Chaudhary A, Vasudha S, Rajagopal K, Komath SS, Garg N, Yadav M, Mande SC, Sahni G: Function of the central domain of streptokinase in substrate plasminogen docking and processing revealed by site-directed mutagenesis. Protein Sci. 1999 Dec;8(12):2791-805. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10631997\n# Parry MA, Zhang XC, Bode I: Molecular mechanisms of plasminogen activation: bacterial cofactors provide clues. Trends Biochem Sci. 2000 Feb;25(2):53-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10664583\n# Korol'chuk VI, Makohonenko IeM, Sederkhol'm-Vil'iams SA: [Plasminogen binding with decapeptide and polypeptide fragments of streptokinase] Ukr Biokhim Zh. 1999 Sep-Oct;71(5):51-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10726310\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P00747", "@source": "Swiss-Prot", "name": "Plasminogen", "general-function": "Involved in plasmin activity", "specific-function": "Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo", "gene-name": "PLG", "locus": "6q26", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.25", "molecular-weight": "90569.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9071"}, {"resource": "GenAtlas", "identifier": "PLG"}, {"resource": "GeneCards", "identifier": "PLG"}, {"resource": "GenBank Gene Database", "identifier": "X05199"}, {"resource": "GenBank Protein Database", "identifier": "387026"}, {"resource": "UniProtKB", "identifier": "P00747"}, {"resource": "UniProt Accession", "identifier": "PLMN_HUMAN"}]}, "synonyms": {"synonym": ["EC 3.4.21.7", "Plasminogen precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Plasminogen precursor\nMEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT\nCRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN\nGITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE\nCEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE\nLRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS\nAQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE\nQLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG\nLTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED\nCMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG\nPWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT\nRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE\nPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ\nLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW\nGLGCARPNKPGVYVRVSRFVTWIEGVMRNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">2433 bp\nATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG\nCCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG\nCTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC\nTGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG\nAAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC\nTCAGAGTGCAAGACTGGGAATGGAAAGAATTACAGAGGGACGATGTCCAAAACAAAAAAT\nGGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT\nACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG\nGGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG\nTGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC\nATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT\nCCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG\nCTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGCGACATCCCC\nCGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT\nGAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT\nGCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTTCCCTGCAAAAATTTGGAT\nGAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC\nCAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA\nCAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT\nGATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT\nTGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC\nCTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA\nGACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT\nGTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAAATGTAGAGACTCCTTCCGAAGAAGAC\nTGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG\nCCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA\nAATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT\nCCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT\nGCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG\nGTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA\nAGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT\nGCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC\nCAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG\nCCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA\nGTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC\nATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG\nCTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA\nTCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT\nGGAGGGCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG\nGGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT\nACTTGGATTGAGGGAGTGATGAGAAATAATTAA"}, "pfams": {"pfam": [{"identifier": "PF00051", "name": "Kringle"}, {"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00024", "name": "PAN_1"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "plasmin activity"}, {"category": "function", "description": "binding"}, {"category": "process", "description": "hemostasis"}, {"category": "process", "description": "blood coagulation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "physiological process"}]}}}, {"id": "BE0000928", "name": "Proteinase-activated receptor 1", "organism": "Human", "actions": {"action": "cleavage"}, "references": "# McRedmond JP, Harriott P, Walker B, Fitzgerald DJ: Streptokinase-induced platelet activation involves antistreptokinase antibodies and cleavage of protease-activated receptor-1. Blood. 2000 Feb 15;95(4):1301-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10666203", "known-action": "unknown", "polypeptide": {"@id": "P25116", "@source": "Swiss-Prot", "name": "Proteinase-activated receptor 1", "general-function": "Involved in rhodopsin-like receptor activity", "specific-function": "High affinity receptor for activated thrombin coupled to G proteins that stimulate phosphoinositide hydrolysis. May play a role in platelets activation and in vascular development", "gene-name": "F2R", "locus": "5q13", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "103-128\n138-157\n177-198\n219-239\n269-288\n312-334\n351-374", "signal-regions": null, "theoretical-pi": "8.33", "molecular-weight": "47441.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3537"}, {"resource": "GenAtlas", "identifier": "F2R"}, {"resource": "GeneCards", "identifier": "F2R"}, {"resource": "GenBank Gene Database", "identifier": "M62424"}, {"resource": "GenBank Protein Database", "identifier": "339677"}, {"resource": "IUPHAR", "identifier": "347"}, {"resource": "Guide to Pharmacology", "identifier": "59"}, {"resource": "UniProtKB", "identifier": "P25116"}, {"resource": "UniProt Accession", "identifier": "PAR1_HUMAN"}]}, "synonyms": {"synonym": ["Coagulation factor II receptor", "PAR-1", "Proteinase-activated receptor 1 precursor", "Thrombin receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Proteinase-activated receptor 1 precursor\nMGPRRLLLVAACFSLCGPLLSARTRARRPESKATNATLDPRSFLLRNPNDKYEPFWEDEE\nKNESGLTEYRLVSINKSSPLQKQLPAFISEDASGYLTSSWLTLFVPSVYTGVFVVSLPLN\nIMAIVVFILKMKVKKPAVVYMLHLATADVLFVSVLPFKISYYFSGSDWQFGSELCRFVTA\nAFYCNMYASILLMTVISIDRFLAVVYPMQSLSWRTLGRASFTCLAIWALAIAGVVPLLLK\nEQTIQVPGLNITTCHDVLNETLLEGYYAYYFSAFSAVFFFVPLIISTVCYVSIIRCLSSS\nAVANRSKKSRALFLSAAVFCIFIICFGPTNVLLIAHYSFLSHTSTTEAAYFAYLLCVCVS\nSISCCIDPLIYYYASSECQRYVYSILCCKESSDPSSYNSSGQLMASKMDTCSSNLNNSIY\nKKLLT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1278 bp\nATGGGGCCGCGGCGGCTGCTGCTGGTGGCCGCCTGCTTCAGTCTGTGCGGCCCGCTGTTG\nTCTGCCCGCACCCGGGCCCGCAGGCCAGAATCAAAAGCAACAAATGCCACCTTAGATCCC\nCGGTCATTTCTTCTCAGGAACCCCAATGATAAATATGAACCATTTTGGGAGGATGAGGAG\nAAAAATGAAAGTGGGTTAACTGAATACAGATTAGTCTCCATCAATAAAAGCAGTCCTCTT\nCAAAAACAACTTCCTGCATTCATCTCAGAAGATGCCTCCGGATATTTGACCAGCTCCTGG\nCTGACACTCTTTGTCCCATCTGTGTACACCGGAGTGTTTGTAGTCAGCCTCCCACTAAAC\nATCATGGCCATCGTTGTGTTCATCCTGAAAATGAAGGTCAAGAAGCCGGCGGTGGTGTAC\nATGCTGCACCTGGCCACGGCAGATGTGCTGTTTGTGTCTGTGCTCCCCTTTAAGATCAGC\nTATTACTTTTCCGGCAGTGATTGGCAGTTTGGGTCTGAATTGTGTCGCTTCGTCACTGCA\nGCATTTTACTGTAACATGTACGCCTCTATCTTGCTCATGACAGTCATAAGCATTGACCGG\nTTTCTGGCTGTGGTGTATCCCATGCAGTCCCTCTCCTGGCGTACTCTGGGAAGGGCTTCC\nTTCACTTGTCTGGCCATCTGGGCTTTGGCCATCGCAGGGGTAGTGCCTCTCGTCCTCAAG\nGAGCAAACCATCCAGGTGCCCGGGCTCAACATCACTACCTGTCATGATGTGCTCAATGAA\nACCCTGCTCGAAGGCTACTATGCCTACTACTTCTCAGCCTTCTCTGCTGTCTTCTTTTTT\nGTGCCGCTGATCATTTCCACGGTCTGTTATGTGTCTATCATTCGATGTCTTAGCTCTTCC\nGCAGTTGCCAACCGCAGCAAGAAGTCCCGGGCTTTGTTCCTGTCAGCTGCTGTTTTCTGC\nATCTTCATCATTTGCTTCGGACCCACAAACGTCCTCCTGATTGCGCATTACTCATTCCTT\nTCTCACACTTCCACCACAGAGGCTGCCTACTTTGCCTACCTCCTCTGTGTCTGTGTCAGC\nAGCATAAGCTCGTGCATCGACCCCCTAATTTACTATTACGCTTCCTCTGAGTGCCAGAGG\nTACGTCTACAGTATCTTATGCTGCAAAGAAAGTTCCGATCCCAGCAGTTATAACAGCAGT\nGGGCAGTTGATGGCAAGTAAAATGGATACCTGCTCTAGTAACCTGAATAACAGCATATAC\nAAAAAGCTGTTAACTTAG"}, "pfams": {"pfam": {"identifier": "PF00001", "name": "7tm_1"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "function", "description": "peptide receptor activity, G-protein coupled"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "function", "description": "thrombin receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "process", "description": "blood coagulation"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "hemostasis"}]}}}]}, "enzymes": {"enzyme": {"@position": "1", "id": "BE0000657", "name": "Cytosolic phospholipase A2", "organism": "Human", "actions": {"action": "inducer"}, "references": "# Kawaguchi H, Iizuka K, Sano H, Yasuda H: Effect of streptokinase on prostacyclin synthesis and phospholipase activity in cultured pulmonary artery endothelial cells. Biochim Biophys Acta. 1990 Dec 10;1055(3):223-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2265209", "known-action": "unknown", "polypeptide": {"@id": "P47712", "@source": "Swiss-Prot", "name": "Cytosolic phospholipase A2", "general-function": "Involved in phospholipase activity", "specific-function": "Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory response", "gene-name": "PLA2G4A", "locus": "1q25", "cellular-location": "Cytoplasm. Cytoplasmic vesicle. Translocates to membrane vesicles in a calcium-dependent fashion", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.03", "molecular-weight": "85212.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9035"}, {"resource": "GenAtlas", "identifier": "PLA2G4A"}, {"resource": "GeneCards", "identifier": "PLA2G4A"}, {"resource": "GenBank Gene Database", "identifier": "M72393"}, {"resource": "GenBank Protein Database", "identifier": "190007"}, {"resource": "UniProtKB", "identifier": "P47712"}, {"resource": "UniProt Accession", "identifier": "PA24A_HUMAN"}]}, "synonyms": {"synonym": ["cPLA2", "EC 3.1.1.4", "Phospholipase A2 group IVA"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytosolic phospholipase A2\nMSFIDPYQHIIVEHQYSHKFTVVVLRATKVTKGAFGDMLDTPDPYVELFISTTPDSRKRT\nRHFNNDINPVWNETFEFILDPNQENVLEITLMDANYVMDETLGTATFTVSSMKVGEKKEV\nPFIFNQVTEMVLEMSLEVCSCPDLRFSMALCDQEKTFRQQRKEHIRESMKKLLGPKNSEG\nLHSARDVPVVAILGSGGGFRAMVGFSGVMKALYESGILDCATYVAGLSGSTWYMSTLYSH\nPDFPEKGPEEINEELMKNVSHNPLLLLTPQKVKRYVESLWKKKSSGQPVTFTDIFGMLIG\nETLIHNRMNTTLSSLKEKVNTAQCPLPLFTCLHVKPDVSELMFADWVEFSPYEIGMAKYG\nTFMAPDLFGSKFFMGTVVKKYEENPLHFLMGVWGSAFSILFNRVLGVSGSQSRGSTMEEE\nLENITTKHIVSNDSSDSDDESHEPKGTENEDAGSDYQSDNQASWIHRMIMALVSDSALFN\nTREGRAGKVHNFMLGLNLNTSYPLSPLSDFATQDSFDDDELDAAVADPDEFERIYEPLDV\nKSKKIHVVDSGLTFNLPYPLILRPQRGVDLIISFDFSARPSDSSPPFKELLLAEKWAKMN\nKLPFPKIDPYVFDREGLKECYVFKPKNPDMEKDCPTIIHFVLANINFRKYKAPGVPRETE\nEEKEIADFDIFDDPESPFSTFNFQYPNQAFKRLHDLMHFNTLNNIDVIKEAMVESIEYRR\nQNPSRCSVSLSNVEARRFFNKEFLSKPKA"}, "gene-sequence": {"@format": "FASTA", "#text": ">2250 bp\nATGTCATTTATAGATCCTTACCAGCACATTATAGTGGAGCACCAGTATTCCCACAAGTTT\nACGGTAGTGGTGTTACGTGCCACCAAAGTGACAAAGGGGGCCTTTGGTGACATGCTTGAT\nACTCCAGATCCCTATGTGGAACTTTTTATCTCTACAACCCCTGACAGCAGGAAGAGAACA\nAGACATTTCAATAATGACATAAACCCTGTGTGGAATGAGACCTTTGAATTTATTTTGGAT\nCCTAATCAGGAAAATGTTTTGGAGATTACGTTAATGGATGCCAATTATGTCATGGATGAA\nACTCTAGGGACAGCAACATTTACTGTATCTTCTATGAAGGTGGGAGAAAAGAAAGAAGTT\nCCTTTTATTTTCAACCAAGTCACTGAAATGGTTCTAGAAATGTCTCTTGAAGTTTGCTCA\nTGCCCAGACCTACGATTTAGTATGGCTCTGTGTGATCAGGAGAAGACTTTCAGACAACAG\nAGAAAAGAACACATAAGGGAGAGCATGAAGAAACTCTTGGGTCCAAAGAATAGTGAAGGA\nTTGCATTCTGCACGTGATGTGCCTGTGGTAGCCATATTGGGTTCAGGTGGGGGTTTCCGA\nGCCATGGTGGGATTCTCTGGTGTGATGAAGGCATTATACGAATCAGGAATTCTGGATTGT\nGCTACCTACGTTGCTGGTCTTTCTGGCTCCACCTGGTATATGTCAACCTTGTATTCTCAC\nCCTGATTTTCCAGAGAAAGGGCCAGAGGAGATTAATGAAGAACTAATGAAAAATGTTAGC\nCACAATCCCCTTTTACTTCTCACACCACAGAAAGTTAAAAGATATGTTGAGTCTTTATGG\nAAGAAGAAAAGCTCTGGACAACCTGTCACCTTTACTGATATCTTTGGGATGTTAATAGGA\nGAAACACTAATTCATAATAGAATGAATACTACTCTGAGCAGTTTGAAGGAAAAAGTTAAT\nACTGCACAATGCCCTTTACCTCTTTTCACCTGTCTTCATGTCAAACCTGACGTTTCAGAG\nCTGATGTTTGCAGATTGGGTTGAATTTAGTCCATACGAAATTGGCATGGCTAAATATGGT\nACTTTTATGGCTCCCGACTTATTTGGAAGCAAATTTTTTATGGGAACAGTCGTTAAGAAG\nTATGAAGAAAACCCCTTGCATTTCTTAATGGGTGTCTGGGGCAGTGCCTTTTCCATATTG\nTTCAACAGAGTTTTGGGCGTTTCTGGTTCACAAAGCAGAGGCTCCACAATGGAGGAAGAA\nTTAGAAAATATTACCACAAAGCATATTGTGAGTAATGATAGCTCGGACAGTGATGATGAA\nTCACACGAACCCAAAGGCACTGAAAATGAAGATGCTGGAAGTGACTATCAAAGTGATAAT\nCAAGCAAGTTGGATTCATCGTATGATAATGGCCTTGGTGAGTGATTCAGCTTTATTCAAT\nACCAGAGAAGGACGTGCTGGGAAGGTACACAACTTCATGCTGGGCTTGAATCTCAATACA\nTCTTATCCACTGTCTCCTTTGAGTGACTTTGCCACACAGGACTCCTTTGATGATGATGAA\nCTGGATGCAGCTGTAGCAGATCCTGATGAATTTGAGCGAATATATGAGCCTCTGGATGTC\nAAAAGTAAAAAGATTCATGTAGTGGACAGTGGGCTCACATTTAACCTGCCGTATCCCTTG\nATACTGAGACCTCAGAGAGGGGTTGATCTCATAATCTCCTTTGACTTTTCTGCAAGGCCA\nAGTGACTCTAGTCCTCCGTTCAAGGAACTTCTACTTGCAGAAAAGTGGGCTAAAATGAAC\nAAGCTCCCCTTTCCAAAGATTGATCCTTATGTGTTTGATCGGGAAGGGCTGAAGGAGTGC\nTATGTCTTTAAACCCAAGAATCCTGATATGGAGAAAGATTGCCCAACCATCATCCACTTT\nGTTCTGGCCAACATCAACTTCAGAAAGTACAAGGCTCCAGGTGTTCCAAGGGAAACTGAG\nGAAGAGAAAGAAATCGCTGACTTTGATATTTTTGATGACCCAGAATCACCATTTTCAACC\nTTCAATTTTCAATATCCAAATCAAGCATTCAAAAGACTACATGATCTTATGCACTTCAAT\nACTCTGAACAACATTGATGTGATAAAAGAAGCCATGGTTGAAAGCATTGAATATAGAAGA\nCAGAATCCATCTCGTTGCTCTGTTTCCCTTAGTAATGTTGAGGCAAGAAGATTTTTCAAC\nAAGGAGTTTCTAAGTAAACCCAAAGCATAG"}, "pfams": {"pfam": [{"identifier": "PF00168", "name": "C2"}, {"identifier": "PF01735", "name": "PLA2_B"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "carboxylic ester hydrolase activity"}, {"category": "function", "description": "lipase activity"}, {"category": "function", "description": "phospholipase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "hydrolase activity, acting on ester bonds"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "membrane lipid metabolism"}, {"category": "process", "description": "phospholipid metabolism"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "phospholipid catabolism"}, {"category": "process", "description": "primary metabolism"}, {"category": "process", "description": "lipid metabolism"}, {"category": "process", "description": "cellular lipid metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}}, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2010-09-29", "drugbank-id": [{"@primary": "true", "#text": "DB00087"}, "BIOD00109", "BTD00109"], "name": "Alemtuzumab", "description": "Humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin.", "cas-number": "216503-57-0", "groups": {"group": ["approved", "investigational"]}, "general-references": "# Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro AJ, Waldmann H: Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood. 1983 Oct;62(4):873-82. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/6349718\n# Riechmann L, Clark M, Waldmann H, Winter G: Reshaping human antibodies for therapy. Nature. 1988 Mar 24;332(6162):323-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/3127726\n# IGMT \"Link\":http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=1BEY\n# IGMT \"Link\":http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=1CE1\n# IGMT \"Link\":http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=8005", "synthesis-reference": null, "indication": "Alemtuzumab (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia.", "pharmacodynamics": "Campath is used to treat leukemia by exploiting antibody mediated lysis of CD52 presenting cells. The CD52 antigen is a cell surface protein found on essentially all B and T lymphocytes, a majority of monocytes, macrophages and most granulocytes. The CD52 antigen is not present on erythrocytes or hematopoetic stem cells. In leukemia there is an excess of B and T cells, so Campath permits selective reduction of lymphocyte populations.", "mechanism-of-action": "Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells.", "toxicity": null, "metabolism": "Most likely removed by opsonization via the reticuloendothelial system when bound to B or T lymphocytes", "absorption": null, "half-life": "~288 hrs", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": "* 0.18 L/kg", "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": {"product": [{"name": "Campath", "ndc-id": "58468-0357_d986d7b0-b2f5-48d7-af39-f01669bc674f", "ndc-product-code": "58468-0357", "dpd-id": null, "started-marketing-on": "2009-11-30", "ended-marketing-on": null, "dosage-form": "injection", "strength": "30 mg/mL", "route": "intravenous", "fda-application-number": "BLA103948", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Lemtrada", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02418320", "started-marketing-on": "2014-01-29", "ended-marketing-on": null, "dosage-form": "solution", "strength": "12 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Lemtrada", "ndc-id": "58468-0200_26ec6adb-b2a1-4480-80f6-2d81311ddb5f", "ndc-product-code": "58468-0200", "dpd-id": null, "started-marketing-on": "2014-11-18", "ended-marketing-on": null, "dosage-form": "injection, solution, concentrate", "strength": "12 mg/1.2mL", "route": "intravenous", "fda-application-number": "BLA103948", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Mabcampath", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02273993", "started-marketing-on": "2006-05-01", "ended-marketing-on": "2008-08-07", "dosage-form": "solution", "strength": "10 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Mabcampath", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02290960", "started-marketing-on": "2007-09-07", "ended-marketing-on": null, "dosage-form": "solution", "strength": "30 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Lemtrada", "ingredients": "Alemtuzumab"}, {"name": "Campath", "ingredients": "Alemtuzumab"}, {"name": "Mabcampath", "ingredients": "Alemtuzumab"}, {"name": "Lemtrada", "ingredients": "Alemtuzumab"}, {"name": "Mabcampath", "ingredients": "Alemtuzumab"}]}, "packagers": {"packager": [{"name": "Bayer Healthcare", "url": "http://www.bayerhealthcare.com"}, {"name": "Boehringer Ingelheim Ltd.", "url": "http://www.boehringer-ingelheim.com"}, {"name": "Genzyme Inc.", "url": "http://www.genzyme.ca"}, {"name": "ILEX Pharmaceuticals LP", "url": null}]}, "manufacturers": null, "prices": {"price": [{"description": "Campath 30 mg/ml vial", "cost": {"@currency": "USD", "#text": "2042.18"}, "unit": "ml"}, {"description": "Campath 30 mg/ml Solution (1 Box Contains Three 1ml Vials)", "cost": {"@currency": "USD", "#text": "6179.24"}, "unit": "box"}]}, "categories": null, "affected-organisms": null, "dosages": {"dosage": [{"form": "Injection", "route": "intravenous", "strength": "30 mg/mL"}, {"form": "Injection, solution, concentrate", "route": "intravenous", "strength": "12 mg/1.2mL"}, {"form": "Solution", "route": "intravenous", "strength": "12 mg"}, {"form": "Solution", "route": "intravenous", "strength": "10 mg"}, {"form": "Solution", "route": "intravenous", "strength": "30 mg"}]}, "atc-codes": {"atc-code": {"@code": "L04AA34", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L04", "#text": "IMMUNOSUPPRESSANTS"}, {"@code": "L04A", "#text": "IMMUNOSUPPRESSANTS"}, {"@code": "L04AA", "#text": "Selective immunosuppressants"}]}}, "ahfs-codes": {"ahfs-code": "10:00.00"}, "patents": {"patent": {"number": "1339198", "country": "Canada", "approved": "1997-08-05", "expires": "2014-08-05"}}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB08879", "name": "Belimumab", "description": "Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab."}, {"drugbank-id": "DB00363", "name": "Clozapine", "description": "Myelosuppressive Agents may enhance the adverse/toxic effect of Clozapine. Specifically, the risk for agranulocytosis may be increased."}, {"drugbank-id": "DB06643", "name": "Denosumab", "description": "May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased."}, {"drugbank-id": "DB01097", "name": "Leflunomide", "description": "Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased."}, {"drugbank-id": "DB04817", "name": "Metamizole", "description": "May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased"}, {"drugbank-id": "DB00108", "name": "Natalizumab", "description": "Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased."}, {"drugbank-id": "DB00337", "name": "Pimecrolimus", "description": "May enhance the adverse/toxic effect of Immunosuppressants."}, {"drugbank-id": "DB01656", "name": "Roflumilast", "description": "May enhance the immunosuppressive effect of Immunosuppressants."}, {"drugbank-id": "DB06688", "name": "Sipuleucel-T", "description": "Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T."}, {"drugbank-id": "DB08895", "name": "Tofacitinib", "description": "Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib."}, {"drugbank-id": "DB00072", "name": "Trastuzumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}]}, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">1CE1:H CAMPATH-1H:Heavy Chain 1\nQVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTT\nEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVS\nSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS\nSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLG\nGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY\nNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD\nELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR\nWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK"}, {"@format": "FASTA", "#text": ">1CE1:L CAMPATH-1H:Light Chain 1\nDIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPS\nRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPP\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT\nLSKADYEKHKVYACEVTHQGLSSPVTKSFNR"}, {"@format": "FASTA", "#text": ">1CE1:H CAMPATH-1H:Heavy Chain 2\nQVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTT\nEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVS\nSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS\nSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLG\nGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY\nNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD\nELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR\nWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK"}, {"@format": "FASTA", "#text": ">1CE1:L CAMPATH-1H:Light Chain 2\nDIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPS\nRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPP\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT\nLSKADYEKHKVYACEVTHQGLSSPVTKSFNR"}, {"@format": "FASTA", "#text": ">1bey_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-210))|||||||219||||MW 23397.3|MW 23397.3|\nQVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTT\nEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVS\nSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS\nSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV"}, {"@format": "FASTA", "#text": ">1bey_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|\nDIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPS\nRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPP\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT\nLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC"}, {"@format": "FASTA", "#text": ">8005_H|alemtuzumab|||H-GAMMA-1 (VH(1-121)+CH1(122-219)+HINGE-REGION(220-220)+CH2(221-330)+CH3(331-437))|||||||437||||MW 47976.2|MW 47976.2|\nQVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTT\nEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVS\nSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS\nSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEAPELLGGPSVFLFPPKPKDT\nLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH\nQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVK\nGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE\nALHNHYTQKSLSLSPGK"}, {"@format": "FASTA", "#text": ">8005_L|alemtuzumab|||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|\nDIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPS\nRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPP\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT\nLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC"}, {"@format": "FASTA", "#text": ">1ce1_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-219))|||||||220||||MW 23526.4|MW 23526.4|\nQVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTT\nEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVS\nSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS\nSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE"}, {"@format": "FASTA", "#text": ">1ce1_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-211))|||||||211||||MW 23282.0|MW 23282.0|\nDIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPS\nRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPP\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT\nLSKADYEKHKVYACEVTHQGLSSPVTKSFNR"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "61 \u00b0C (FAB fragment), 71 \u00b0C (whole mAb)", "source": "Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)"}, {"kind": "Hydrophobicity", "value": "-0.431", "source": null}, {"kind": "Isoelectric Point", "value": "8.76", "source": null}, {"kind": "Molecular Weight", "value": "145453.8000", "source": null}, {"kind": "Molecular Formula", "value": "C6468H10066N1732O2005S40", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "12491"}, {"resource": "National Drug Code Directory", "identifier": "50419-357-03"}, {"resource": "PharmGKB", "identifier": "PA164783958"}, {"resource": "Wikipedia", "identifier": "Alemtuzumab"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/campath.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/alemtuzumab.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000083", "name": "CAMPATH-1 antigen", "organism": "Human", "actions": {"action": "antibody"}, "references": "# Gilliland LK, Walsh LA, Frewin MR, Wise MP, Tone M, Hale G, Kioussis D, Waldmann H: Elimination of the immunogenicity of therapeutic antibodies. J Immunol. 1999 Mar 15;162(6):3663-71. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10092828\n# James LC, Hale G, Waldmann H, Bloomer AC: 1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen. J Mol Biol. 1999 Jun 4;289(2):293-301. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10366506\n# Rawstron AC, Rollinson SJ, Richards S, Short MA, English A, Morgan GJ, Hale G, Hillmen P: The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment. Br J Haematol. 1999 Oct;107(1):148-53. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10520035\n# Rebello PR, Hale G, Friend PJ, Cobbold SP, Waldmann H: Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection. Transplantation. 1999 Nov 15;68(9):1417-20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10573085\n# Hederer RA, Guntermann C, Miller N, Nagy P, Szollosi J, Damjanovich S, Hale G, Alexander DR: The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells. Int Immunol. 2000 Apr;12(4):505-16. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10744652\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352\n# Geissinger E, Bonzheim I, Roth S, Rosenwald A, Muller-Hermelink HK, Rudiger T: CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies. Leuk Lymphoma. 2009 Jun;50(6):1010-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19479612\n# Quintas-Cardama A, O'Brien S: Targeted therapy for chronic lymphocytic leukemia. Target Oncol. 2009 Jan;4(1):11-21. Epub 2009 Jan 27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19343298", "known-action": "yes", "polypeptide": {"@id": "P31358", "@source": "Swiss-Prot", "name": "CAMPATH-1 antigen", "general-function": null, "specific-function": "May play a role in carrying and orienting carbohydrate, as well as having a more specific role", "gene-name": "CD52", "locus": "1p36", "cellular-location": "Cell membrane; lipid-anchor; GPI-anchor", "transmembrane-regions": "5-23; 38-60", "signal-regions": null, "theoretical-pi": "8.56", "molecular-weight": "6614.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1804"}, {"resource": "GenAtlas", "identifier": "CD52"}, {"resource": "GeneCards", "identifier": "CD52"}, {"resource": "GenBank Gene Database", "identifier": "X62466"}, {"resource": "GenBank Protein Database", "identifier": "29646"}, {"resource": "UniProtKB", "identifier": "P31358"}, {"resource": "UniProt Accession", "identifier": "CD52_HUMAN"}]}, "synonyms": {"synonym": ["Cambridge pathology 1 antigen", "CAMPATH-1 antigen precursor", "CD52 antigen", "CDw52", "Epididymal secretory protein E5"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">CAMPATH-1 antigen precursor\nMKRFLFLLLTISLLVMVQIQTGLSGQNDTSQTSSPSASSNISGGIFLFFVANAIIHLFCF\nS"}, "gene-sequence": {"@format": "FASTA", "#text": ">186 bp\nATGAAGCGCTTCCTCTTCCTCCTACTCACCATCAGCCTCCTGGTTATGGTACAGATACAA\nACTGGACTCTCAGGACAAAACGACACCAGCCAAACCAGCAGCCCCTCAGCATCCAGCAAC\nATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACCTCTTCTGCTTC\nAGTTGA"}, "pfams": null, "go-classifiers": null}}, {"@position": "2", "id": "BE0000901", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "organism": "Human", "actions": null, "references": "# Nagler A, Condiotti R, Lubina A, Deutsch VR: Enhancement of megakaryocytopoiesis by Campath-1G-treated natural killer cells. Bone Marrow Transplant. 1997 Oct;20(7):525-31. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9337053\n# Brett S, Baxter G, Cooper H, Johnston JM, Tite J, Rapson N: Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H. Immunology. 1996 May;88(1):13-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8707338\n# Osterborg A, Werner A, Halapi E, Lundin J, Harmenberg U, Wigzell H, Mellstedt H: Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52). Eur J Haematol. 1997 Jan;58(1):5-13. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9020367", "known-action": "unknown", "polypeptide": {"@id": "O75015", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "general-function": null, "specific-function": "Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils", "gene-name": "FCGR3B", "locus": "1q23", "cellular-location": "Cell membrane; lipid-anchor; GPI-anchor. Secreted protein. Note=Secreted after cleavage", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.71", "molecular-weight": "26216.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3620"}, {"resource": "GenAtlas", "identifier": "FCGR3B"}, {"resource": "GeneCards", "identifier": "FCGR3B"}, {"resource": "GenBank Gene Database", "identifier": "X16863"}, {"resource": "GenBank Protein Database", "identifier": "31322"}, {"resource": "UniProtKB", "identifier": "O75015"}, {"resource": "UniProt Accession", "identifier": "FCG3B_HUMAN"}]}, "synonyms": {"synonym": ["CD16b antigen", "Fc-gamma RIII", "Fc-gamma RIII-beta", "Fc-gamma RIIIb", "FcR-10", "FcRIII", "FcRIIIb", "IgG Fc receptor III-1", "Low affinity immunoglobulin gamma Fc region receptor III-B precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-B precursor\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI"}, "gene-sequence": {"@format": "FASTA", "#text": ">702 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "3", "id": "BE0002093", "name": "Complement C1r subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P00736", "@source": "Swiss-Prot", "name": "Complement C1r subcomponent", "general-function": null, "specific-function": "C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system", "gene-name": "C1R", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.24", "molecular-weight": "80174.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1246"}, {"resource": "GenAtlas", "identifier": "C1R"}, {"resource": "GeneCards", "identifier": "C1R"}, {"resource": "GenBank Gene Database", "identifier": "X04701"}, {"resource": "GenBank Protein Database", "identifier": "29539"}, {"resource": "UniProtKB", "identifier": "P00736"}, {"resource": "UniProt Accession", "identifier": "C1R_HUMAN"}]}, "synonyms": {"synonym": ["Complement C1r subcomponent precursor", "Complement component 1, r subcomponent", "EC 3.4.21.41"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1r subcomponent\nMWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF\nQQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF\nSNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY\nELQEDRHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF\nDIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL\nRYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD\nDGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR\nESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF\nTNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV\nSVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME\nEKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV\nRDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2118 bp\nATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC\nATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC\nAACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC\nCAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT\nGATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG\nGGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC\nTCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT\nGTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG\nTGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT\nGAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG\nGCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC\nAACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT\nGATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC\nGGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC\nAATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG\nCGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC\nATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA\nGGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT\nGATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA\nAACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC\nCGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG\nGAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG\nGGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG\nAGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC\nACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT\nGCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC\nCTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC\nAGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG\nCTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC\nAACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG\nGAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT\nGAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT\nGGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA\nAGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC\nAGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG\nATGGAGGAGGAGGACTGA"}, "pfams": {"pfam": [{"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF07645", "name": "EGF_CA"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "4", "id": "BE0002094", "name": "Complement C1q subcomponent subunit A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02745", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit A", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QA", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.45", "molecular-weight": "26017.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1241"}, {"resource": "GenAtlas", "identifier": "C1QA"}, {"resource": "GeneCards", "identifier": "C1QA"}, {"resource": "GenBank Gene Database", "identifier": "AF135157"}, {"resource": "GenBank Protein Database", "identifier": "4894854"}, {"resource": "UniProtKB", "identifier": "P02745"}, {"resource": "UniProt Accession", "identifier": "C1QA_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit A precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit A\nMEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR\nTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI\nRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR\nGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL\nIFPSA"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG\nGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC\nAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG\nACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC\nAAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGGGCCCGTGGCATCCCGGGAATTAAA\nGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT\nCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG\nGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC\nTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG\nGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG\nGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC\nCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC\nATCTTCCCATCTGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "5", "id": "BE0002095", "name": "Complement C1q subcomponent subunit B", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02746", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit B", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QB", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.87", "molecular-weight": "26460.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1242"}, {"resource": "GenAtlas", "identifier": "C1QB"}, {"resource": "GeneCards", "identifier": "C1QB"}, {"resource": "GenBank Gene Database", "identifier": "X03084"}, {"resource": "GenBank Protein Database", "identifier": "573114"}, {"resource": "UniProtKB", "identifier": "P02746"}, {"resource": "UniProt Accession", "identifier": "C1QB_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit B precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit B\nMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEK\nGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKI\nAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCV\nNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANSIF\nSGFLLFPDMEA"}, "gene-sequence": {"@format": "FASTA", "#text": ">688 bp\nCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGG\nGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCC\nAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAA\nTCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGCCCAGGGGCCCCTGG\nAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAGAAAATCGCCTTCTC\nTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATCCGCTTCGACCACGT\nGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTCACCTGCAAGGTGCC\nCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTGTGCGTGAACCTCAT\nGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTATGCCTACAACACCTT\nCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAGAACGTCTTCCTGCA\nGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGCATCTTTTCCGGGTT\nCCTGCTCTTTCCAGATATGGAGGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "6", "id": "BE0002096", "name": "Complement C1q subcomponent subunit C", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02747", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit C", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QC", "locus": "1p36.11", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.58", "molecular-weight": "25774.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1245"}, {"resource": "GenAtlas", "identifier": "C1QC"}, {"resource": "GeneCards", "identifier": "C1QC"}, {"resource": "GenBank Gene Database", "identifier": "AF087892"}, {"resource": "GenBank Protein Database", "identifier": "33150626"}, {"resource": "UniProtKB", "identifier": "P02747"}, {"resource": "UniProt Accession", "identifier": "C1QC_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit C precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit C\nMDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP\nGIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS\nVFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV\nLLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF\nLLFPD"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG\nCTGCTGCCCCTCAGGGCCAAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC\nCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA\nGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA\nCCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC\nCCCATGGGATTCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA\nGTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC\nAACGCGGTCCTCACCAACCCGCAGGAGGATTATGACACGAGCACTGGCAAGTTCACCTGC\nAAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG\nCTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT\nCAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT\nGTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC\nCTGCTCTTCCCCGACTAG"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "7", "id": "BE0002097", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "organism": "Human", "actions": null, "references": "# Lin TS, Flinn IW, Modali R, Lehman TA, Webb J, Waymer S, Moran ME, Lucas MS, Farag SS, Byrd JC: FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood. 2005 Jan 1;105(1):289-91. Epub 2004 Jun 24. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15217834", "known-action": "unknown", "polypeptide": {"@id": "P08637", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "general-function": null, "specific-function": "Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis", "gene-name": "FCGR3A", "locus": "1q23", "cellular-location": "Cell membrane", "transmembrane-regions": "209-229", "signal-regions": null, "theoretical-pi": "8.21", "molecular-weight": "29089.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3619"}, {"resource": "GenAtlas", "identifier": "FCGR3A"}, {"resource": "GeneCards", "identifier": "FCGR3A"}, {"resource": "GenBank Gene Database", "identifier": "X52645"}, {"resource": "GenBank Protein Database", "identifier": "31324"}, {"resource": "UniProtKB", "identifier": "P08637"}, {"resource": "UniProt Accession", "identifier": "FCG3A_HUMAN"}]}, "synonyms": {"synonym": ["CD16a antigen", "Fc-gamma RIII", "Fc-gamma RIII-alpha", "Fc-gamma RIIIa", "FcR-10", "FcRIII", "FcRIIIa", "IgG Fc receptor III-2", "Low affinity immunoglobulin gamma Fc region receptor III-A precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK"}, "gene-sequence": {"@format": "FASTA", "#text": ">765 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCGACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCA\nAAAGCCACACTCAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTTTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGG\nAAGGACCATAAATTTAAATGGAGAAAGGACCCTCAAGACAAATGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "8", "id": "BE0000710", "name": "High affinity immunoglobulin gamma Fc receptor I", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P12314", "@source": "Swiss-Prot", "name": "High affinity immunoglobulin gamma Fc receptor I", "general-function": "Involved in receptor signaling protein activity", "specific-function": "Binds to the Fc region of immunoglobulins gamma. High affinity receptor", "gene-name": "FCGR1A", "locus": "1q21.2-q21.3", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "293-313", "signal-regions": null, "theoretical-pi": "8.08", "molecular-weight": "42632.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3613"}, {"resource": "GenAtlas", "identifier": "FCGR1A"}, {"resource": "GeneCards", "identifier": "FCGR1A"}, {"resource": "GenBank Gene Database", "identifier": "X14356"}, {"resource": "GenBank Protein Database", "identifier": "31332"}, {"resource": "UniProtKB", "identifier": "P12314"}, {"resource": "UniProt Accession", "identifier": "FCGR1_HUMAN"}]}, "synonyms": {"synonym": ["CD64 antigen", "Fc-gamma RI", "FcRI", "High affinity immunoglobulin gamma Fc receptor I precursor", "IgG Fc receptor I"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">High affinity immunoglobulin gamma Fc receptor I precursor\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1125 bp\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCTCTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAACTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "9", "id": "BE0002098", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "organism": "Human", "actions": null, "references": "# Lin TS, Flinn IW, Modali R, Lehman TA, Webb J, Waymer S, Moran ME, Lucas MS, Farag SS, Byrd JC: FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood. 2005 Jan 1;105(1):289-91. Epub 2004 Jun 24. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15217834", "known-action": "unknown", "polypeptide": {"@id": "P12318", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "general-function": null, "specific-function": "Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens", "gene-name": "FCGR2A", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.78", "molecular-weight": "34990.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3616"}, {"resource": "GenAtlas", "identifier": "FCGR2A"}, {"resource": "GeneCards", "identifier": "FCGR2A"}, {"resource": "GenBank Gene Database", "identifier": "M31932"}, {"resource": "GenBank Protein Database", "identifier": "182474"}, {"resource": "UniProtKB", "identifier": "P12318"}, {"resource": "UniProt Accession", "identifier": "FCG2A_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-a", "Fc-gamma-RIIa", "FcRII-a", "IgG Fc receptor II-a", "Low affinity immunoglobulin gamma Fc region receptor II-a precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-a\nMAMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSRLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">954 bp\nATGGCTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "10", "id": "BE0002099", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31994", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "general-function": null, "specific-function": "Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B- cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis", "gene-name": "FCGR2B", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.12", "molecular-weight": "34044.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3618"}, {"resource": "GenAtlas", "identifier": "FCGR2B"}, {"resource": "GeneCards", "identifier": "FCGR2B"}, {"resource": "GenBank Gene Database", "identifier": "U87560"}, {"resource": "GenBank Protein Database", "identifier": "4099445"}, {"resource": "UniProtKB", "identifier": "P31994"}, {"resource": "UniProt Accession", "identifier": "FCG2B_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-b", "Fc-gamma-RIIb", "FcRII-b", "IgG Fc receptor II-b", "Low affinity immunoglobulin gamma Fc region receptor II-b precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI"}, "gene-sequence": {"@format": "FASTA", "#text": ">930 bp\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCTCTCCCAGGATACCCTGAG\nTGCAGGGAAATGGGAGAGACCCTCCCTGAGAAACCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATT"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "11", "id": "BE0002100", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31995", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "general-function": null, "specific-function": "Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells", "gene-name": "FCGR2C", "locus": "1q23.3", "cellular-location": "Cell membrane", "transmembrane-regions": "224-246", "signal-regions": null, "theoretical-pi": "6.9", "molecular-weight": "35578.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:15626"}, {"resource": "GenAtlas", "identifier": "FCGR2C"}, {"resource": "GeneCards", "identifier": "FCGR2C"}, {"resource": "GenBank Gene Database", "identifier": "X17652"}, {"resource": "GenBank Protein Database", "identifier": "32074"}, {"resource": "UniProtKB", "identifier": "P31995"}, {"resource": "UniProt Accession", "identifier": "FCG2C_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-c", "Fc-gamma-RIIc", "FcRII-c", "IgG Fc receptor II-c", "Low affinity immunoglobulin gamma Fc region receptor II-c precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-c\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR\nAPTDDDKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">972 bp\nATGGGAATCCTGTCATTTTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACAGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCATTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCTGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG\nAAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT\nGAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG\nGCACCTACTGACGATGATAAAAACATCTACTTGACTCTTCCTCCCAACGACCATGTCAAC\nAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2011-09-03", "drugbank-id": [{"@primary": "true", "#text": "DB00088"}, "BIOD00037", "BTD00037"], "name": "Alglucerase", "description": "Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues", "cas-number": "37228-64-1", "groups": {"group": "approved"}, "general-references": "# Grabowski GA, Kacena K, Cole JA, Hollak CE, Zhang L, Yee J, Mistry PK, Zimran A, Charrow J, vom Dahl S: Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genet Med. 2009 Feb;11(2):92-100. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19265748", "synthesis-reference": null, "indication": "For the treatment of Gaucher's disease (deficiency in glucocerebrosidase)", "pharmacodynamics": "Gaucher disease is characterized by a functional deficiency in Beta-glucocerebrosidase enzymatic activity and the resultant accumulation of lipid glucocerebroside in tissue macrophages which become engorged and are termed Gaucher cells. Gaucher cells are typically found in liver, spleen and bone marrow. This can lead to an enlarged spleen and liver (hepatosplenomegaly). Secondary hematologic sequelae include severe anemia and thrombocytopenia. Injections of alglucerase into Gaucher disease patients leads to elevated serum levels of the enzyme and reduction in the accumulation of glucocerebroside", "mechanism-of-action": "Alglucerase catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": "3.6-10.4 min", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": "* 49.4 to 282.1 mL/kg", "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": null, "products": null, "international-brands": {"international-brand": {"name": "Ceredase", "company": "Genzyme"}}, "mixtures": null, "packagers": {"packager": [{"name": "Cardinal Health", "url": "http://www.cardinal.com"}, {"name": "Genzyme Inc.", "url": "http://www.genzyme.ca"}, {"name": "Oso Biopharmaceuticals Manufacturing LLC", "url": null}]}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Genzyme corp"}}, "prices": {"price": {"description": "Ceredase 80 unit/ml vial", "cost": {"@currency": "USD", "#text": "380.64"}, "unit": "ml"}}, "categories": {"category": {"category": "Enzyme Replacement Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": null, "atc-codes": {"atc-code": {"@code": "A16AB01", "level": [{"@code": "A", "#text": "ALIMENTARY TRACT AND METABOLISM"}, {"@code": "A16", "#text": "OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS"}, {"@code": "A16A", "#text": "OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS"}, {"@code": "A16AB", "#text": "Enzymes"}]}}, "ahfs-codes": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00088 sequence\nARPCIPKSFGYSSVVCVCNATYCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANH\nTGTGLLLTLQPEQKFQKVKGFGGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIR\nVPMASCDFSIRTYTYADTPDDFQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWT\nSPTWLKTNGAVNGKGSLKGQPGDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGL\nLSGYPFQCLGFTPEHQRDFIARDLGPTLANSTHHNVRLLMLDDQRLLLPHWAKVVLTDPE\nAAKYVHGIAVHWYLDFLAPAKATLGETHRLFPNTMLFASEACVGSKFWEQSVRLGSWDRG\nMQYSHSIITNLLYHVVGWTDWNLALNPEGGPNWVRNFVDSPIIVDITKDTFYKQPMFYHL\nGHFSKFIPEGSQRVGLVASQKNDLDAVALMHPDGSAVVVVLNRSSKDVPLTIKDPAVGFL\nETISPGYSIHTYLWRRQ"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.168", "source": null}, {"kind": "Isoelectric Point", "value": "7.41", "source": null}, {"kind": "Molecular Weight", "value": "55597.4000", "source": null}, {"kind": "Molecular Formula", "value": "C2532H3854N672O711S16", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "KEGG Drug", "identifier": "D09675"}, {"resource": "National Drug Code Directory", "identifier": "58468-1060-1"}, {"resource": "GenBank", "identifier": "M16328"}, {"resource": "PharmGKB", "identifier": "PA164748093"}, {"resource": "UniProtKB", "identifier": "P04062"}, {"resource": "Wikipedia", "identifier": "Alglucerase"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/ceredase.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/alglucerase.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"@position": "1", "id": "BE0004806", "name": "Glucocerebroside", "organism": "Human", "actions": {"action": "other/unknown"}, "references": "# Pastores GM, Hughes DA: Gaucher Disease  \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20301446", "known-action": "yes"}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2015-10-28", "drugbank-id": [{"@primary": "true", "#text": "DB00089"}, "BIOD00080", "BTD00080"], "name": "Capromab", "description": "Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA \u2013 also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA. Pendetide acts as a chelating agent for the radionuclide indium-111. Capromab is used to image the extent of prostate cancer.", "cas-number": "145464-28-4", "groups": {"group": "approved"}, "general-references": "# http://www.google.com/patents/WO2013006706A1?cl=en\n# http://www.lens.org/lens/patent/US_4671958_A\n# http://www.google.ca/patents/US4741900\n# http://www.google.com/patents/US5162504", "synthesis-reference": null, "indication": "For diagnosis of prostate cancer and detection of intra-pelvic metastases.", "pharmacodynamics": "Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors.", "mechanism-of-action": "Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors.", "toxicity": null, "metabolism": "Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production", "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": "Approximately 10% of the administered radioisotope dose is excreted in the urine during the 72 hours following intravenous infusion.", "volume-of-distribution": "* 4 \u00b1 2.1 L", "clearance": "* 42 +/- 22 mL/hr", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Capromab pendetide"}, {"@language": "", "@coder": "", "#text": "In 111 Capromab pendetide"}, {"@language": "", "@coder": "", "#text": "Indium (111In) capromab pendetide"}, {"@language": "", "@coder": "", "#text": "Indium 111 Capromab Pendetide"}]}, "products": null, "international-brands": {"international-brand": {"name": "ProstaScint", "company": "Cytogen Corp."}}, "mixtures": null, "packagers": {"packager": {"name": "EUSA Pharma Inc.", "url": "http://www.eusapharma.com"}}, "manufacturers": null, "prices": {"price": {"description": "Prostascint kit", "cost": {"@currency": "USD", "#text": "1584.0"}, "unit": "kit"}}, "categories": {"category": [{"category": "Indicators and Reagents", "mesh-id": null}, {"category": "Diagnostic Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": null, "atc-codes": null, "ahfs-codes": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": null, "experimental-properties": {"property": {"kind": "Melting Point", "value": "61 \u00b0C (FAB fragment), 71 \u00b0C (whole mAb)", "source": "Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)"}}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "20500"}, {"resource": "National Drug Code Directory", "identifier": "57902-817-01"}, {"resource": "PharmGKB", "identifier": "PA164745489"}, {"resource": "Wikipedia", "identifier": "Indium_(111In)_capromab_pendetide"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0000568", "name": "Glutamate carboxypeptidase 2", "organism": "Human", "actions": {"action": "other/unknown"}, "references": "# Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH: In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000 Sep 15;60(18):5237-43. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11016653\n# Sodee DB, Nelson AD, Faulhaber PF, Maclennan GT, Resnick MI, Bakale G: Update on fused capromab pendetide imaging of prostate cancer. Clin Prostate Cancer. 2005 Mar;3(4):230-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15882479\n# Gregorakis AK, Holmes EH, Murphy GP: Prostate-specific membrane antigen: current and future utility. Semin Urol Oncol. 1998 Feb;16(1):2-12. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9508077\n# Sodee DB, Ellis RJ, Samuels MA, Spirnak JP, Poole WF, Riester C, Martanovic DM, Stonecipher R, Bellon EM: Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results. Prostate. 1998 Nov 1;37(3):140-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9792131\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "Q04609", "@source": "Swiss-Prot", "name": "Glutamate carboxypeptidase 2", "general-function": "Involved in peptidase activity", "specific-function": "Also exhibits a dipeptidyl-peptidase IV type activity. In vitro, cleaves Gly-Pro-AMC", "gene-name": "FOLH1", "locus": "11p11.2", "cellular-location": "Cell membrane; single-pass type II membrane protein. Isoform PSMA':Cytoplasm", "transmembrane-regions": "20-43", "signal-regions": null, "theoretical-pi": "6.97", "molecular-weight": "84331.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3788"}, {"resource": "GenAtlas", "identifier": "FOLH1"}, {"resource": "GeneCards", "identifier": "FOLH1"}, {"resource": "GenBank Gene Database", "identifier": "M99487"}, {"resource": "GenBank Protein Database", "identifier": "190664"}, {"resource": "UniProtKB", "identifier": "Q04609"}, {"resource": "UniProt Accession", "identifier": "FOLH1_HUMAN"}]}, "synonyms": {"synonym": ["EC 3.4.17.21", "FGCP", "Folate hydrolase 1", "Folylpoly-gamma- glutamate carboxypeptidase", "Glutamate carboxypeptidase II", "Membrane glutamate carboxypeptidase", "mGCP", "N- acetylated-alpha-linked acidic dipeptidase I", "NAALADase I", "Prostate- specific membrane antigen", "PSM", "PSMA", "Pteroylpoly-gamma-glutamate carboxypeptidase"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Glutamate carboxypeptidase 2\nMWNLLHETDSAVATARRPRWLCAGALVLAGGFFLLGFLFGWFIKSSNEATNITPKHNMKA\nFLDELKAENIKKFLYNFTQIPHLAGTEQNFQLAKQIQSQWKEFGLDSVELAHYDVLLSYP\nNKTHPNYISIINEDGNEIFNTSLFEPPPPGYENVSDIVPPFSAFSPQGMPEGDLVYVNYA\nRTEDFFKLERDMKINCSGKIVIARYGKVFRGNKVKNAQLAGAKGVILYSDPADYFAPGVK\nSYPDGWNLPGGGVQRGNILNLNGAGDPLTPGYPANEYAYRRGIAEAVGLPSIPVHPIGYY\nDAQKLLEKMGGSAPPDSSWRGSLKVPYNVGPGFTGNFSTQKVKMHIHSTNEVTRIYNVIG\nTLRGAVEPDRYVILGGHRDSWVFGGIDPQSGAAVVHEIVRSFGTLKKEGWRPRRTILFAS\nWDAEEFGLLGSTEWAEENSRLLQERGVAYINADSSIEGNYTLRVDCTPLMYSLVHNLTKE\nLKSPDEGFEGKSLYESWTKKSPSPEFSGMPRISKLGSGNDFEVFFQRLGIASGRARYTKN\nWETNKFSGYPLYHSVYETYELVEKFYDPMFKYHLTVAQVRGGMVFELANSIVLPFDCRDY\nAVVLRKYADKIYSISMKHPQEMKTYSVSFDSLFSAVKNFTEIASKFSERLQDFDKSNPIV\nLRMMNDQLMFLERAFIDPLGLPDRPFYRHVIYAPSSHNKYAGESFPGIYDALFDIESKVD\nPSKAWGEVKRQIYVAAFTVQAAAETLSEVA"}, "gene-sequence": {"@format": "FASTA", "#text": ">2253 bp\nATGTGGAATCTCCTTCACGAAACCGACTCGGCTGTGGCCACCGCGCGCCGCCCGCGCTGG\nCTGTGCGCTGGGGCGCTGGTGCTGGCGGGTGGCTTCTTTCTCCTCGGCTTCCTCTTCGGG\nTGGTTTATAAAATCCTCCAATGAAGCTACTAACATTACTCCAAAGCATAATATGAAAGCA\nTTTTTGGATGAATTGAAAGCTGAGAACATCAAGAAGTTCTTATATAATTTTACACAGATA\nCCACATTTAGCAGGAACAGAACAAAACTTTCAGCTTGCAAAGCAAATTCAATCCCAGTGG\nAAAGAATTTGGCCTGGATTCTGTTGAGCTAGCACATTATGATGTCCTGTTGTCCTACCCA\nAATAAGACTCATCCCAACTACATCTCAATAATTAATGAAGATGGAAATGAGATTTTCAAC\nACATCATTATTTGAACCACCTCCTCCAGGATATGAAAATGTTTCGGATATTGTACCACCT\nTTCAGTGCTTTCTCTCCTCAAGGAATGCCAGAGGGCGATCTAGTGTATGTTAACTATGCA\nCGAACTGAAGACTTCTTTAAATTGGAACGGGACATGAAAATCAATTGCTCTGGGAAAATT\nGTAATTGCCAGATATGGGAAAGTTTTCAGAGGAAATAAGGTTAAAAATGCCCAGCTGGCA\nGGGGCCAAAGGAGTCATTCTCTACTCCGACCCTGCTGACTACTTTGCTCCTGGGGTGAAG\nTCCTATCCAGATGGTTGGAATCTTCCTGGAGGTGGTGTCCAGCGTGGAAATATCCTAAAT\nCTGAATGGTGCAGGAGACCCTCTCACACCAGGTTACCCAGCAAATGAATATGCTTATAGG\nCGTGGAATTGCAGAGGCTGTTGGTCTTCCAAGTATTCCTGTTCATCCAATTGGATACTAT\nGATGCACAGAAGCTCCTAGAAAAAATGGGTGGCTCAGCACCACCAGATAGCAGCTGGAGA\nGGAAGTCTCAAAGTGCCCTACAATGTTGGACCTGGCTTTACTGGAAACTTTTCTACACAA\nAAAGTCAAGATGCACATCCACTCTACCAATGAAGTGACAAGAATTTACAATGTGATAGGT\nACTCTCAGAGGAGCAGTGGAACCAGACAGATATGTCATTCTGGGAGGTCACCGGGACTCA\nTGGGTGTTTGGTGGTATTGACCCTCAGAGTGGAGCAGCTGTTGTTCATGAAATTGTGAGG\nAGCTTTGGAACACTGAAAAAGGAAGGGTGGAGACCTAGAAGAACAATTTTGTTTGCAAGC\nTGGGATGCAGAAGAATTTGGTCTTCTTGGTTCTACTGAGTGGGCAGAGGAGAATTCAAGA\nCTCCTTCAAGAGCGTGGCGTGGCTTATATTAATGCTGACTCATCTATAGAAGGAAACTAC\nACTCTGAGAGTTGATTGTACACCGCTGATGTACAGCTTGGTACACAACCTAACAAAAGAG\nCTGAAAAGCCCTGATGAAGGCTTTGAAGGCAAATCTCTTTATGAAAGTTGGACTAAAAAA\nAGTCCTTCCCCAGAGTTCAGTGGCATGCCCAGGATAAGCAAATTGGGATCTGGAAATGAT\nTTTGAGGTGTTCTTCCAACGACTTGGAATTGCTTCAGGCAGAGCACGGTATACTAAAAAT\nTGGGAAACAAACAAATTCAGCGGCTATCCACTGTATCACAGTGTCTATGAAACATATGAG\nTTGGTGGAAAAGTTTTATGATCCAATGTTTAAATATCACCTCACTGTGGCCCAGGTTCGA\nGGAGGGATGGTGTTTGAGCTAGCCAATTCCATAGTGCTCCCTTTTGATTGTCGAGATTAT\nGCTGTAGTTTTAAGAAAGTATGCTGACAAAATCTACAGTATTTCTATGAAACATCCACAG\nGAAATGAAGACATACAGTGTATCATTTGATTCACTTTTTTCTGCAGTAAAGAATTTTACA\nGAAATTGCTTCCAAGTTCAGTGAGAGACTCCAGGACTTTGACAAAAGCAACCCAATAGTA\nTTAAGAATGATGAATGATCAACTCATGTTTCTGGAAAGAGCATTTATTGATCCATTAGGG\nTTACCAGACAGGCCTTTTTATAGGCATGTCATCTATGCTCCAAGCAGCCACAACAAGTAT\nGCAGGGGAGTCATTCCCAGGAATTTATGATGCTCTGTTTGATATTGAAAGCAAAGTGGAC\nCCTTCCAAGGCCTGGGGAGAAGTGAAGAGACAGATTTATGTTGCAGCCTTCACAGTGCAG\nGCAGCTGCAGAGACTTTGAGTGAAGTAGCCTAA"}, "pfams": {"pfam": [{"identifier": "PF02225", "name": "PA"}, {"identifier": "PF04389", "name": "Peptidase_M28"}, {"identifier": "PF04253", "name": "TFR_dimer"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}]}}}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2011-08-04", "drugbank-id": [{"@primary": "true", "#text": "DB00090"}, "BIOD00008", "BTD00008"], "name": "Laronidase", "description": "Human recombinant alpha-L-iduronidase, 628 residues (mature form), produced by recombinant DNAtechnology in a Chinese hamster ovary cell line. Laronidase is a glycoprotein with a molecular weight of approximately 83 kD. The predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human a-L-iduronidase. It contains 6 N-linked oligosaccharide modification sites.", "cas-number": "210589-09-6", "groups": {"group": "approved"}, "general-references": "# Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Sidman M, Kakkis ED, Cox GF: Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009 Jan;123(1):229-40. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19117887\n# Landry Y, Gies JP: Drugs and their molecular targets: an updated overview. Fundam Clin Pharmacol. 2008 Feb;22(1):1-18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18251718", "synthesis-reference": null, "indication": "For the treatment of mucopolysaccharidosis", "pharmacodynamics": "Laronidase is used to treat mucopolysaccharide storage disorders (specifically mucopolysaccharidosis 1 or Hurlers syndrome) caused by deficiencies of alpha-L-iduronidase. Reduced or absent a-L-iduronidase activity results in the accumulation of the GAG substrates, dermatan sulfate and heparan sulfate, throughout the body and leads to widespread cellular, tissue, and organ dysfunction.", "mechanism-of-action": "Laronidase catalyses the hydrolysis of terminal alpha-L-iduronic acid residues of dermatan sulfate and heparin sulfate.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": "1.5-3.6 hrs", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": {"@language": "", "@coder": "", "#text": "Alpha-L-iduronidase precursor"}}, "products": {"product": [{"name": "Aldurazyme", "ndc-id": "58468-0070_f4bd8179-7bb2-455d-93dd-651cc11b1f5b", "ndc-product-code": "58468-0070", "dpd-id": null, "started-marketing-on": "2003-04-30", "ended-marketing-on": null, "dosage-form": "injection, solution, concentrate", "strength": "2.9 mg/5mL", "route": "intravenous", "fda-application-number": "BLA125058", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Aldurazyme", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02254506", "started-marketing-on": "2004-08-12", "ended-marketing-on": null, "dosage-form": "solution", "strength": "0.58 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Aldurazyme", "ingredients": "Laronidase"}, {"name": "Aldurazyme", "ingredients": "Laronidase"}]}, "packagers": {"packager": [{"name": "BioMarin Pharmaceuticals Inc.", "url": "http://www.bmrn.com"}, {"name": "Genzyme Inc.", "url": "http://www.genzyme.ca"}, {"name": "Hollister-Stier Laboratories LLC", "url": "http://www.hollisterstier.com"}]}, "manufacturers": null, "prices": {"price": {"description": "Aldurazyme 2.9 mg/5 ml vial", "cost": {"@currency": "USD", "#text": "168.0"}, "unit": "ml"}}, "categories": {"category": {"category": "Enzyme Replacement Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, solution, concentrate", "route": "intravenous", "strength": "2.9 mg/5mL"}, {"form": "Solution", "route": "intravenous", "strength": "0.58 mg"}]}, "atc-codes": {"atc-code": {"@code": "A16AB05", "level": [{"@code": "A", "#text": "ALIMENTARY TRACT AND METABOLISM"}, {"@code": "A16", "#text": "OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS"}, {"@code": "A16A", "#text": "OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS"}, {"@code": "A16AB", "#text": "Enzymes"}]}}, "ahfs-codes": {"ahfs-code": "44:00.00"}, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00090 sequence\nAPHLVQVDAARALWPLRRFWRSTGFCPPLPHSQADQYVLSWDQQLNLAYVGAVPHRGIKQ\nVRTHWLLELVTTRGSTGRGLSYNFTHLDGYLDLLRENQLLPGFELMGSASGHFTDFEDKQ\nQVFEWKDLVSSLARRYIGRYGLAHVSKWNFETWNEPDHHDFDNVSMTMQGFLNYYDACSE\nGLRAASPALRLGGPGDSFHTPPRSPLSWGLLRHCHDGTNFFTGEAGVRLDYISLHRKGAR\nSSISILEQEKVVAQQIRQLFPKFADTPIYNDEADPLVGWSLPQPWRADVTYAAMVVKVIA\nQHQNLLLANTTSAFPYALLSNDNAFLSYHPHPFAQRTLTARFQVNNTRPPHVQLLRKPVL\nTAMGLLALLDEEQLWAEVSQAGTVLDSNHTVGVLASAHRPQGPADAWRAAVLIYASDDTR\nAHPNRSVAVTLRLRGVPPGPGLVYVTRYLDNGLCSPDGEWRRLGRPVFPTAEQFRRMRAA\nEDPVAAAPRPLPAGGRLTLRPALRLPSLLLVHVCARPEKPPGQVTRLRALPLTQGQLVLV\nWSDEHVGSKCLWTYEIQFSQDGKAYTPVSRKPSTFNLFVFSPDTGAVSGSYRVRALDYWA\nRPGPFSDPVPYLEVPVPRGPPSPGNP"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.300", "source": null}, {"kind": "Isoelectric Point", "value": "9.09", "source": null}, {"kind": "Molecular Weight", "value": "69899.4000", "source": null}, {"kind": "Molecular Formula", "value": "C3160H4848N898O881S12", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "13106"}, {"resource": "GenBank", "identifier": "M74715"}, {"resource": "PharmGKB", "identifier": "PA164776670"}, {"resource": "UniProtKB", "identifier": "P35475"}, {"resource": "Wikipedia", "identifier": "Laronidase"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/aldurazyme.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/laronidase.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0004822", "name": "Iduronic acid", "organism": "Human", "actions": {"action": "other/unknown"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Kloska A, Bohdanowicz J, Konopa G, Tylki-Szymnska A, Jakobkiewicz-Banecka J, Czartoryska B, Liberek A, Wegrzyn A, Wegrzyn G: Changes in hair morphology of mucopolysaccharidosis I patients treated with recombinant human alpha-L-iduronidase (laronidase, Aldurazyme). Am J Med Genet A. 2005 Dec 15;139(3):199-203. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16283671\n# Bach G, Eisenberg F Jr, Cantz M, Neufeld EF: The defect in the Hunter syndrome: deficiency of sulfoiduronate sulfatase. Proc Natl Acad Sci U S A. 1973 Jul;70(7):2134-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/4269173\n# Freeman C, Hopwood JJ: Human alpha-L-iduronidase. Catalytic properties and an integrated role in the lysosomal degradation of heparan sulphate. Biochem J. 1992 Mar 15;282 ( Pt 3):899-908. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1554373", "known-action": "yes"}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2005-06-13", "@updated": "2013-09-16", "drugbank-id": [{"@primary": "true", "#text": "DB00091"}, "BIOD00003", "BTD00003"], "name": "Cyclosporine", "description": "A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. Cyclosporine is produced as a metabolite by the fungus species Cordyceps militaris. (From Martindale, The Extra Pharmacopoeia, 30th ed).", "cas-number": "59865-13-3", "groups": {"group": ["approved", "investigational"]}, "general-references": "# Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994 Jun 30;330(26):1841-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8196726\n# Synthesis Information \"Link\":http://www.patentgenius.com/patent/6927208.html\n#  \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9323029", "synthesis-reference": "Hans Dietl, \"Pharmaceutical preparation containing cyclosporine(s) for intravenous administration and a process for its production.\" U.S. Patent US5527537, issued October, 1990.", "indication": "For treatment of transplant (kidney, liver, and heart) rejection, rheumatoid arthritis, severe psoriasis.", "pharmacodynamics": "Used in immunosuppression for prophylactic treatment of organ transplants, cyclosporine exerts specific and reversible inhibition of immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited. The T1-helper cell is the main target, although the T1-suppressor cell may also be suppressed. Sandimmune (cyclosporine) also inhibits lymphokine production and release including interleukin-2.", "mechanism-of-action": "Cyclosporine binds to cyclophilin. The complex then inhibits calcineurin which is normally responsible for activating transcription of interleukin 2. Cyclosporine also inhibits lymphokine production and interleukin release. In ophthalmic applications, the precise mechanism of action is not known. Cyclosporine emulsion is thought to act as a partial immunomodulator in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.", "toxicity": "The oral LD<sub>50</sub> is 2329 mg/kg in mice, 1480 mg/kg in rats, and > 1000 mg/kg in rabbits. The I.V. LD<sub>50</sub> is 148 mg/kg in mice, 104 mg/kg in rats, and 46 mg/kg in rabbits.", "metabolism": "Hepatic, extensively metabolized by the cytochrome P450 3A enzyme system in the liver. It is also metabolized in the gastrointestinal tract and kidney to a lesser degree. The metabolites are significantly less potent than the parent compound. The major metabolites (M1, M9, and M4N) result from oxidation at the 1-beta, 9-gamma, and 4-N-demethylated positions, respectively.", "absorption": "The absorption of cyclosporine from the gastrointestinal tract is incomplete and variable. The extent of absorption is dependent on the individual patient, the patient population, and the formulation. The absolute bioavailability of cyclosproine administered as Sandimmune\u00ae is dependent on the patient population, estimated to be less than 10% in liver transplant patients and as great as 89% in some renal transplant patients. Compared to an intravenous infusion, the absolute bioavailability of the oral solution is approximately 30% based upon the results in 2 patients. The cyclosporine capsules and oral solution are bioequivalent. The time of peak blood concentrations (Tmax) following oral administration of cyclosporine [modified] ranged from 1.5 - 2.0 hours.", "half-life": "Biphasic and variable, approximately 7 hours (range 7 to 19 hours) in children and approximately 19 hours (range 10 to 27 hours) in adults.", "protein-binding": "In the plasma, approximately 90% is bound to proteins, primarily lipoproteins. In blood, the distribution is concentration dependent. Approximately 33% to 47% is in plasma, 4% to 9% in lymphocytes, 5% to 12% in granulocytes, and 41% to 58% in erythrocytes.", "route-of-elimination": "Elimination is primarily biliary with only 6% of the dose (parent drug and metabolites) excreted in the urine. Only 0.1% of the dose is excreted in the urine as unchanged drug.", "volume-of-distribution": "The steady state volume of distribution during intravenous dosing has been reported as 3 to 5 L/kg in solid organ transplant recipients. Cyclosporine is excreted in human milk.", "clearance": "Following intravenous administration, the blood clearance of cyclosporine (assay: HPLC) is approximately 5 to 7 mL/min/kg in adult recipients of renal or liver allografts. Blood cyclosporine clearance appears to be slightly slower in cardiac transplant patients. The following are clearance parameters (CL/F) for select patient populations:\n * 593 \u00b1 204 mL/min [De novo renal transplant patients, 597\u00b1174 mg/day] \n * 492 \u00b1 140 mL/min [Stable renal transplant patients, 344\u00b1122 mg/day] \n * 577 \u00b1 309 mL/min [De novo liver transplant, 458\u00b1190 mg/day] \n * 613 \u00b1 196 mL/min [De novo rheumatoid arthritis, 182\u00b155.6 mg/day] \n * 723 \u00b1 186 mL/min [De novo psoriasis, 189\u00b169.8 mg/day] \t\n * 285 \u00b1 94 mL/min [Stable Liver Transplant, Age 2 - 8, Dosed T.I.D 101\u00b125 mg/day] \n * 378 \u00b1 80 mL/min [Stable Liver Transplant, Age 8 - 15, Dosed B.I.D 188\u00b155 mg/day] \t \n * 171 mL/min [Stable liver transplant, Age 3, Dosed B.I.D 120 mg/day]\n * 328 \u00b1 121 mL/min [Stable liver transplant, Age 8 - 15, Dosed B.I.D 158\u00b155 mg/day] \t\n * 418 \u00b1 143 mL/min [Stable renal transplant, Age 7 - 15, Dosed B.I.D 328\u00b183 mg/day]", "classification": {"description": "This compound belongs to the class of organic compounds known as polypeptides. These are peptides containing ten or more amino acid residues.", "direct-parent": "Polypeptides", "kingdom": "Organic compounds", "superclass": "Organic Polymers", "class": "Polypeptides", "subclass": null, "alternative-parent": ["Azacyclic compounds", "Carbonyl compounds", "Cyclosporins", "Hydrocarbon derivatives", "Lactams", "Macrolactams", "Secondary alcohols", "Secondary carboxylic acid amides", "Tertiary amines", "Tertiary carboxylic acid amides"], "substituent": ["Alcohol", "Aliphatic heteromonocyclic compound", "Amine", "Azacycle", "Carbonyl group", "Carboxamide group", "Carboxylic acid amide", "Carboxylic acid derivative", "Cyclic peptoid/peptide", "Cyclosporin-backbone", "Hydrocarbon derivative", "Lactam", "Macrolactam", "Organoheterocyclic compound", "Organonitrogen compound", "Organooxygen compound", "Polypeptide", "Secondary alcohol", "Secondary carboxylic acid amide", "Tertiary amine", "Tertiary carboxylic acid amide"]}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "INN", "#text": "Ciclosporin"}, {"@language": "", "@coder": "", "#text": "CsA"}, {"@language": "", "@coder": "", "#text": "CyA"}, {"@language": "", "@coder": "", "#text": "Cyclosporin A"}]}, "products": {"product": [{"name": "Apo-cyclosporine Oral Solution", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02244324", "started-marketing-on": "2002-07-30", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 mg", "route": "oral", "fda-application-number": null, "generic": "true", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Cyclosporine", "ndc-id": "68084-921_58143bf0-1f65-471b-a084-73a6927f1d5a", "ndc-product-code": "68084-921", "dpd-id": null, "started-marketing-on": "2015-03-30", "ended-marketing-on": null, "dosage-form": "capsule, liquid filled", "strength": "100 mg", "route": "oral", "fda-application-number": "ANDA065040", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Cyclosporine", "ndc-id": "0591-2222_55d1009c-3332-4712-81e9-6ebcb0650e55", "ndc-product-code": "0591-2222", "dpd-id": null, "started-marketing-on": "2008-12-01", "ended-marketing-on": null, "dosage-form": "capsule, liquid filled", "strength": "25 mg", "route": "oral", "fda-application-number": "ANDA065044", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Cyclosporine", "ndc-id": "0591-2223_55d1009c-3332-4712-81e9-6ebcb0650e55", "ndc-product-code": "0591-2223", "dpd-id": null, "started-marketing-on": "2008-12-01", "ended-marketing-on": null, "dosage-form": "capsule, liquid filled", "strength": "100 mg", "route": "oral", "fda-application-number": "ANDA065044", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Cyclosporine", "ndc-id": "0591-2224_55d1009c-3332-4712-81e9-6ebcb0650e55", "ndc-product-code": "0591-2224", "dpd-id": null, "started-marketing-on": "2008-12-01", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 mg/mL", "route": "oral", "fda-application-number": "ANDA065054", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Cyclosporine", "ndc-id": "60432-140_4e33a7bf-17b9-4a58-8a92-1efd3d3b59ac", "ndc-product-code": "60432-140", "dpd-id": null, "started-marketing-on": "2005-02-09", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 mg/mL", "route": "oral", "fda-application-number": "ANDA065133", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Cyclosporine", "ndc-id": "0185-0932_724d0555-2d54-434f-a5e9-0cb3b24d7b4a", "ndc-product-code": "0185-0932", "dpd-id": null, "started-marketing-on": "2000-01-13", "ended-marketing-on": null, "dosage-form": "capsule", "strength": "25 mg", "route": "oral", "fda-application-number": "ANDA065017", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Cyclosporine", "ndc-id": "0185-0933_724d0555-2d54-434f-a5e9-0cb3b24d7b4a", "ndc-product-code": "0185-0933", "dpd-id": null, "started-marketing-on": "2000-01-13", "ended-marketing-on": null, "dosage-form": "capsule", "strength": "100 mg", "route": "oral", "fda-application-number": "ANDA065017", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Cyclosporine", "ndc-id": "54868-5522_db323395-0dbc-47bd-bc21-85b754faa472", "ndc-product-code": "54868-5522", "dpd-id": null, "started-marketing-on": "2006-02-10", "ended-marketing-on": null, "dosage-form": "capsule, liquid filled", "strength": "100 mg", "route": "oral", "fda-application-number": "ANDA065040", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Cyclosporine", "ndc-id": "62584-827_770b1c29-2e06-4627-b8a1-d3f8078288c3", "ndc-product-code": "62584-827", "dpd-id": null, "started-marketing-on": "2009-12-11", "ended-marketing-on": null, "dosage-form": "capsule", "strength": "100 mg", "route": "oral", "fda-application-number": "ANDA065040", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Cyclosporine", "ndc-id": "60505-0133_d8bb0ab1-432e-3540-4adf-4d038b2d7d7d", "ndc-product-code": "60505-0133", "dpd-id": null, "started-marketing-on": "2002-05-29", "ended-marketing-on": null, "dosage-form": "capsule, gelatin coated", "strength": "25 mg", "route": "oral", "fda-application-number": "ANDA065040", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Cyclosporine", "ndc-id": "60505-0134_d8bb0ab1-432e-3540-4adf-4d038b2d7d7d", "ndc-product-code": "60505-0134", "dpd-id": null, "started-marketing-on": "2002-05-29", "ended-marketing-on": null, "dosage-form": "capsule, gelatin coated", "strength": "100 mg", "route": "oral", "fda-application-number": "ANDA065040", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Cyclosporine", "ndc-id": "0574-0866_d93def6b-d783-4cc4-aa61-091ebc74ac65", "ndc-product-code": "0574-0866", "dpd-id": null, "started-marketing-on": "2003-10-07", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "50 mg/mL", "route": "intravenous", "fda-application-number": "ANDA065151", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Cyclosporine", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02334763", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "capsule", "strength": "25 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Cyclosporine", "ndc-id": "0172-7313_ebbd1abb-1ce7-422a-a5b3-b01abcc4ab39", "ndc-product-code": "0172-7313", "dpd-id": null, "started-marketing-on": "2005-03-29", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 mg/mL", "route": "oral", "fda-application-number": "ANDA065078", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Cyclosporine", "ndc-id": "55154-6349_b5580eb5-2f1c-44fb-aca6-138b872f249f", "ndc-product-code": "55154-6349", "dpd-id": null, "started-marketing-on": "2010-09-01", "ended-marketing-on": null, "dosage-form": "capsule, liquid filled", "strength": "100 mg", "route": "oral", "fda-application-number": "ANDA065110", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Cyclosporine", "ndc-id": "54868-6232_fedee476-b4b4-47d3-93d4-8d9665ee3c64", "ndc-product-code": "54868-6232", "dpd-id": null, "started-marketing-on": "2011-02-10", "ended-marketing-on": null, "dosage-form": "capsule, liquid filled", "strength": "100 mg", "route": "oral", "fda-application-number": "ANDA065110", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Cyclosporine", "ndc-id": "68084-879_58143bf0-1f65-471b-a084-73a6927f1d5a", "ndc-product-code": "68084-879", "dpd-id": null, "started-marketing-on": "2014-12-15", "ended-marketing-on": null, "dosage-form": "capsule, liquid filled", "strength": "25 mg", "route": "oral", "fda-application-number": "ANDA065040", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Cyclosporine Modified", "ndc-id": "0093-5740_c6858d6c-2773-4d8d-a08c-19d69d2f67cb", "ndc-product-code": "0093-5740", "dpd-id": null, "started-marketing-on": "2015-06-01", "ended-marketing-on": null, "dosage-form": "capsule, liquid filled", "strength": "25 mg", "route": "oral", "fda-application-number": "ANDA065110", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Cyclosporine Modified", "ndc-id": "0093-5741_c6858d6c-2773-4d8d-a08c-19d69d2f67cb", "ndc-product-code": "0093-5741", "dpd-id": null, "started-marketing-on": "2015-06-01", "ended-marketing-on": null, "dosage-form": "capsule, liquid filled", "strength": "50 mg", "route": "oral", "fda-application-number": "ANDA065110", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Cyclosporine Modified", "ndc-id": "0093-5742_c6858d6c-2773-4d8d-a08c-19d69d2f67cb", "ndc-product-code": "0093-5742", "dpd-id": null, "started-marketing-on": "2015-06-01", "ended-marketing-on": null, "dosage-form": "capsule, liquid filled", "strength": "100 mg", "route": "oral", "fda-application-number": "ANDA065110", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Cyclosporine Modified", "ndc-id": "0172-7310_dc5b6a50-4d6d-4cba-8ad3-8821bc7f0be9", "ndc-product-code": "0172-7310", "dpd-id": null, "started-marketing-on": "2005-03-29", "ended-marketing-on": "2017-03-31", "dosage-form": "capsule, liquid filled", "strength": "25 mg", "route": "oral", "fda-application-number": "ANDA065110", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Cyclosporine Modified", "ndc-id": "0172-7311_dc5b6a50-4d6d-4cba-8ad3-8821bc7f0be9", "ndc-product-code": "0172-7311", "dpd-id": null, "started-marketing-on": "2005-04-28", "ended-marketing-on": "2017-02-28", "dosage-form": "capsule, liquid filled", "strength": "50 mg", "route": "oral", "fda-application-number": "ANDA065110", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Cyclosporine Modified", "ndc-id": "0172-7312_dc5b6a50-4d6d-4cba-8ad3-8821bc7f0be9", "ndc-product-code": "0172-7312", "dpd-id": null, "started-marketing-on": "2005-03-29", "ended-marketing-on": "2017-03-31", "dosage-form": "capsule, liquid filled", "strength": "100 mg", "route": "oral", "fda-application-number": "ANDA065110", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Gengraf", "ndc-id": "55154-2395_1daa75c5-5e4f-4af8-8f40-3002151e4815", "ndc-product-code": "55154-2395", "dpd-id": null, "started-marketing-on": "2010-05-24", "ended-marketing-on": null, "dosage-form": "capsule", "strength": "100 mg", "route": "oral", "fda-application-number": "ANDA065003", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Gengraf", "ndc-id": "55154-2396_1daa75c5-5e4f-4af8-8f40-3002151e4815", "ndc-product-code": "55154-2396", "dpd-id": null, "started-marketing-on": "2010-05-24", "ended-marketing-on": null, "dosage-form": "capsule", "strength": "25 mg", "route": "oral", "fda-application-number": "ANDA065003", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Gengraf", "ndc-id": "0074-6463_ffbf7d49-160e-d6cd-744e-948dbd628e14", "ndc-product-code": "0074-6463", "dpd-id": null, "started-marketing-on": "2010-05-24", "ended-marketing-on": null, "dosage-form": "capsule", "strength": "25 mg", "route": "oral", "fda-application-number": "ANDA065003", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Gengraf", "ndc-id": "0074-6479_ffbf7d49-160e-d6cd-744e-948dbd628e14", "ndc-product-code": "0074-6479", "dpd-id": null, "started-marketing-on": "2010-05-24", "ended-marketing-on": null, "dosage-form": "capsule", "strength": "100 mg", "route": "oral", "fda-application-number": "ANDA065003", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Gengraf", "ndc-id": "0074-7269_d146b6df-a46e-c6d0-114f-744e407d57e9", "ndc-product-code": "0074-7269", "dpd-id": null, "started-marketing-on": "2010-05-25", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 mg/mL", "route": "oral", "fda-application-number": "ANDA065025", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Neoral", "ndc-id": "55154-3418_139cec0c-481d-4a41-89dd-d51f236cc5cc", "ndc-product-code": "55154-3418", "dpd-id": null, "started-marketing-on": "1995-07-14", "ended-marketing-on": null, "dosage-form": "capsule, liquid filled", "strength": "25 mg", "route": "oral", "fda-application-number": "NDA050715", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Neoral", "ndc-id": "0078-0246_1140e0e4-7cd5-443e-b3c3-bf5d50befde1", "ndc-product-code": "0078-0246", "dpd-id": null, "started-marketing-on": "1995-07-14", "ended-marketing-on": null, "dosage-form": "capsule, liquid filled", "strength": "25 mg", "route": "oral", "fda-application-number": "NDA050715", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Neoral", "ndc-id": "0078-0248_1140e0e4-7cd5-443e-b3c3-bf5d50befde1", "ndc-product-code": "0078-0248", "dpd-id": null, "started-marketing-on": "1995-07-14", "ended-marketing-on": null, "dosage-form": "capsule, liquid filled", "strength": "100 mg", "route": "oral", "fda-application-number": "NDA050715", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Neoral", "ndc-id": "0078-0274_1140e0e4-7cd5-443e-b3c3-bf5d50befde1", "ndc-product-code": "0078-0274", "dpd-id": null, "started-marketing-on": "1995-07-14", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 mg/mL", "route": "oral", "fda-application-number": "NDA050716", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Neoral 100mg", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02150670", "started-marketing-on": "1995-12-31", "ended-marketing-on": null, "dosage-form": "capsule", "strength": "100 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Neoral 10mg", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02237671", "started-marketing-on": "1998-10-02", "ended-marketing-on": null, "dosage-form": "capsule", "strength": "10 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Neoral 25mg", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02150689", "started-marketing-on": "1995-12-31", "ended-marketing-on": null, "dosage-form": "capsule", "strength": "25 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Neoral 50mg", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02150662", "started-marketing-on": "1995-12-31", "ended-marketing-on": null, "dosage-form": "capsule", "strength": "50 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Neoral Oral Solution 100mg/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02150697", "started-marketing-on": "1995-12-31", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Restasis", "ndc-id": "0023-9163_73857d5a-73ee-4c27-9232-68e54f174893", "ndc-product-code": "0023-9163", "dpd-id": null, "started-marketing-on": "2003-04-01", "ended-marketing-on": null, "dosage-form": "emulsion", "strength": ".5 mg/mL", "route": "ophthalmic", "fda-application-number": "NDA050790", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Restasis", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02355655", "started-marketing-on": "2010-09-29", "ended-marketing-on": null, "dosage-form": "emulsion", "strength": "0.05 %", "route": "ophthalmic", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Restasis", "ndc-id": "54868-4793_10aaf531-4033-442c-821d-69292ccf5f85", "ndc-product-code": "54868-4793", "dpd-id": null, "started-marketing-on": "2009-03-27", "ended-marketing-on": null, "dosage-form": "emulsion", "strength": ".5 mg/mL", "route": "ophthalmic", "fda-application-number": "NDA050790", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Sandimmune", "ndc-id": "0078-0109_44916161-f61e-4dd9-8d68-d088fdbcfcec", "ndc-product-code": "0078-0109", "dpd-id": null, "started-marketing-on": "1983-11-14", "ended-marketing-on": null, "dosage-form": "injection", "strength": "50 mg/mL", "route": "intravenous", "fda-application-number": "NDA050573", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Sandimmune", "ndc-id": "0078-0110_44916161-f61e-4dd9-8d68-d088fdbcfcec", "ndc-product-code": "0078-0110", "dpd-id": null, "started-marketing-on": "1983-11-14", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 mg/mL", "route": "oral", "fda-application-number": "NDA050574", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Sandimmune", "ndc-id": "0078-0240_44916161-f61e-4dd9-8d68-d088fdbcfcec", "ndc-product-code": "0078-0240", "dpd-id": null, "started-marketing-on": "1990-03-02", "ended-marketing-on": null, "dosage-form": "capsule, liquid filled", "strength": "25 mg", "route": "oral", "fda-application-number": "NDA050625", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Sandimmune", "ndc-id": "0078-0241_44916161-f61e-4dd9-8d68-d088fdbcfcec", "ndc-product-code": "0078-0241", "dpd-id": null, "started-marketing-on": "1990-03-02", "ended-marketing-on": null, "dosage-form": "capsule, liquid filled", "strength": "100 mg", "route": "oral", "fda-application-number": "NDA050625", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Sandimmune Cap 50mg", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01907182", "started-marketing-on": "1991-12-31", "ended-marketing-on": "1996-11-14", "dosage-form": "capsule", "strength": "50 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Sandimmune IV 50mg/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00593257", "started-marketing-on": "1984-12-31", "ended-marketing-on": null, "dosage-form": "liquid", "strength": "50 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Sandimmune Oral Sol 100mg/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00593249", "started-marketing-on": "1984-12-31", "ended-marketing-on": "1997-04-15", "dosage-form": "liquid", "strength": "100 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Sandimmune Soft Gelatin Cap 100mg", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00755605", "started-marketing-on": "1988-12-31", "ended-marketing-on": "1997-04-15", "dosage-form": "capsule", "strength": "100 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Sandimmune Soft Gelatine Cap 25mg", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00755591", "started-marketing-on": "1988-12-31", "ended-marketing-on": "1997-04-15", "dosage-form": "capsule", "strength": "25 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Sandoz Cyclosporine", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02242821", "started-marketing-on": "2001-12-27", "ended-marketing-on": null, "dosage-form": "capsule", "strength": "100 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Sandoz Cyclosporine", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02247073", "started-marketing-on": "2005-05-16", "ended-marketing-on": null, "dosage-form": "capsule", "strength": "25 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Sandoz Cyclosporine", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02247074", "started-marketing-on": "2006-10-18", "ended-marketing-on": null, "dosage-form": "capsule", "strength": "50 mg", "route": "oral", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": {"name": "Sangcya", "company": null}}, "mixtures": {"mixture": [{"name": "Restasis", "ingredients": "Cyclosporine"}, {"name": "Gengraf", "ingredients": "Cyclosporine"}, {"name": "Gengraf", "ingredients": "Cyclosporine"}, {"name": "Gengraf", "ingredients": "Cyclosporine"}, {"name": "Sandimmune", "ingredients": "Cyclosporine"}, {"name": "Sandimmune", "ingredients": "Cyclosporine"}, {"name": "Sandimmune", "ingredients": "Cyclosporine"}, {"name": "Sandimmune", "ingredients": "Cyclosporine"}, {"name": "Neoral", "ingredients": "Cyclosporine"}, {"name": "Neoral", "ingredients": "Cyclosporine"}, {"name": "Neoral", "ingredients": "Cyclosporine"}, {"name": "Cyclosporine Modified", "ingredients": "Cyclosporine"}, {"name": "Cyclosporine Modified", "ingredients": "Cyclosporine"}, {"name": "Cyclosporine Modified", "ingredients": "Cyclosporine"}, {"name": "Cyclosporine Modified", "ingredients": "Cyclosporine"}, {"name": "Cyclosporine Modified", "ingredients": "Cyclosporine"}, {"name": "Cyclosporine Modified", "ingredients": "Cyclosporine"}, {"name": "Cyclosporine", "ingredients": "Cyclosporine"}, {"name": "Cyclosporine", "ingredients": "Cyclosporine"}, {"name": "Cyclosporine", "ingredients": "Cyclosporine"}, {"name": "Cyclosporine", "ingredients": "Cyclosporine"}, {"name": "Cyclosporine", "ingredients": "Cyclosporine"}, {"name": "Cyclosporine", "ingredients": "Cyclosporine"}, {"name": "Cyclosporine", "ingredients": "Cyclosporine"}, {"name": "Restasis", "ingredients": "Cyclosporine"}, {"name": "Cyclosporine", "ingredients": "Cyclosporine"}, {"name": "Cyclosporine", "ingredients": "Cyclosporine"}, {"name": "Gengraf", "ingredients": "Cyclosporine"}, {"name": "Gengraf", "ingredients": "Cyclosporine"}, {"name": "Neoral", "ingredients": "Cyclosporine"}, {"name": "Cyclosporine", "ingredients": "Cyclosporine"}, {"name": "Cyclosporine", "ingredients": "Cyclosporine"}, {"name": "Cyclosporine", "ingredients": "Cyclosporine"}, {"name": "Cyclosporine", "ingredients": "Cyclosporine"}, {"name": "Cyclosporine", "ingredients": "Cyclosporine"}, {"name": "Cyclosporine", "ingredients": "Cyclosporine"}, {"name": "Cyclosporine", "ingredients": "Cyclosporine"}, {"name": "Neoral 100mg", "ingredients": "Cyclosporine"}, {"name": "Neoral Oral Solution 100mg/ml", "ingredients": "Cyclosporine"}, {"name": "Neoral 25mg", "ingredients": "Cyclosporine"}, {"name": "Neoral 50mg", "ingredients": "Cyclosporine"}, {"name": "Sandimmune IV 50mg/ml", "ingredients": "Cyclosporine"}, {"name": "Neoral 10mg", "ingredients": "Cyclosporine"}, {"name": "Sandoz Cyclosporine", "ingredients": "Cyclosporine"}, {"name": "Apo-cyclosporine Oral Solution", "ingredients": "Cyclosporine"}, {"name": "Sandoz Cyclosporine", "ingredients": "Cyclosporine"}, {"name": "Sandoz Cyclosporine", "ingredients": "Cyclosporine"}, {"name": "Restasis", "ingredients": "Cyclosporine"}, {"name": "Sandimmune Cap 50mg", "ingredients": "Cyclosporine"}, {"name": "Sandimmune Oral Sol 100mg/ml", "ingredients": "Cyclosporine"}, {"name": "Sandimmune Soft Gelatine Cap 25mg", "ingredients": "Cyclosporine"}, {"name": "Sandimmune Soft Gelatin Cap 100mg", "ingredients": "Cyclosporine"}, {"name": "Cyclosporine", "ingredients": "Cyclosporine"}]}, "packagers": {"packager": [{"name": "Abbott Laboratories Ltd.", "url": "http://www.abbott.com"}, {"name": "Allergan Inc.", "url": "http://www.allergan.com"}, {"name": "Amerisource Health Services Corp.", "url": "http://www.amerisourcebergen.com"}, {"name": "Apotex Inc.", "url": "http://www.apotex.com"}, {"name": "Banner Pharmacaps Inc.", "url": "http://www.banpharm.com"}, {"name": "Bedford Labs", "url": "http://www.bedfordlabs.com"}, {"name": "Ben Venue Laboratories Inc.", "url": "http://www.benvenue.com"}, {"name": "Cardinal Health", "url": "http://www.cardinal.com"}, {"name": "Catalent Pharma Solutions", "url": "http://www.catalent.com"}, {"name": "Draxis Specialty Pharmaceuticals Inc.", "url": "http://www.draxispharma.com"}, {"name": "Eon Labs", "url": null}, {"name": "Ivax Pharmaceuticals", "url": null}, {"name": "Lake Erie Medical and Surgical Supply", "url": null}, {"name": "Medisca Inc.", "url": "http://www.medisca.com"}, {"name": "Murfreesboro Pharmaceutical Nursing Supply", "url": "http://www.unitdosesupply.com"}, {"name": "Novartis AG", "url": "http://www.novartis.com"}, {"name": "Paddock Labs", "url": "http://www.paddocklabs.com"}, {"name": "Physicians Total Care Inc.", "url": "http://www.physicianstotalcare.com"}, {"name": "Pliva Inc.", "url": "http://www.pliva.com"}, {"name": "R.P. Scherer GmbH and Co. KG", "url": "http://www.rpscherer.de"}, {"name": "Sandhills Packaging Inc.", "url": "http://www.sandhillspackaging.com"}, {"name": "Sangstat Medical Corp.", "url": null}, {"name": "Santec Chemicals Corp.", "url": "http://www.santecchemcorp.com"}, {"name": "Swiss Caps Ag", "url": "http://www.swisscaps.com"}, {"name": "Teva Pharmaceutical Industries Ltd.", "url": "http://www.tevapharm.com"}, {"name": "Torpharm Inc.", "url": null}, {"name": "Watson Pharmaceuticals", "url": "http://www.watson.com"}, {"name": "Wockhardt Ltd.", "url": "http://www.wockhardtin.com"}]}, "manufacturers": {"manufacturer": [{"@generic": "true", "#text": "Apotex inc"}, {"@generic": "true", "#text": "Ivax pharmaceuticals inc sub teva pharmaceuticals usa"}, {"@generic": "true", "#text": "Pliva inc"}, {"@generic": "true", "#text": "Sandoz inc"}, {"@generic": "false", "#text": "Abbott laboratories"}, {"@generic": "false", "#text": "Novartis pharmaceuticals corp"}, {"@generic": "false", "#text": "Allergan inc"}, {"@generic": "true", "#text": "Bedford laboratories div ben venue laboratories inc"}, {"@generic": "true", "#text": "Pharmaforce inc"}, {"@generic": "true", "#text": "Novex pharma"}, {"@generic": "true", "#text": "Watson laboratories inc"}, {"@generic": "true", "#text": "Wockhardt eu operations (swiss) ag"}]}, "prices": {"price": [{"description": "Gengraf 25 mg capsule", "cost": {"@currency": "USD", "#text": "1.32"}, "unit": "capsule"}, {"description": "Cyclosporine 25 mg softgel", "cost": {"@currency": "USD", "#text": "1.38"}, "unit": "softgel capsule"}, {"description": "Neoral 25 mg gelatin capsule", "cost": {"@currency": "USD", "#text": "1.53"}, "unit": "capsule"}, {"description": "Cyclosporine 25 mg capsule", "cost": {"@currency": "USD", "#text": "1.56"}, "unit": "capsule"}, {"description": "Sandimmune 25 mg capsule", "cost": {"@currency": "USD", "#text": "2.48"}, "unit": "capsule"}, {"description": "Cyclosporine 50 mg softgel", "cost": {"@currency": "USD", "#text": "2.74"}, "unit": "softgel capsule"}, {"description": "Restasis 0.05% eye emulsion", "cost": {"@currency": "USD", "#text": "4.49"}, "unit": "each"}, {"description": "Cyclosporine 50 mg/ml vial", "cost": {"@currency": "USD", "#text": "5.28"}, "unit": "ml"}, {"description": "Gengraf 100 mg capsule", "cost": {"@currency": "USD", "#text": "5.28"}, "unit": "capsule"}, {"description": "Cyclosporine 50 mg/ml amp", "cost": {"@currency": "USD", "#text": "5.45"}, "unit": "ml"}, {"description": "Cyclosporine modif 100 mg capsule", "cost": {"@currency": "USD", "#text": "5.49"}, "unit": "capsule"}, {"description": "Cyclosporine 100 mg softgel", "cost": {"@currency": "USD", "#text": "5.5"}, "unit": "softgel capsule"}, {"description": "Cyclosporine modif 100 mg softgel", "cost": {"@currency": "USD", "#text": "5.5"}, "unit": "softgel capsule"}, {"description": "Neoral 100 mg gelatn capsule", "cost": {"@currency": "USD", "#text": "6.11"}, "unit": "capsule"}, {"description": "Cyclosporine 100 mg capsule", "cost": {"@currency": "USD", "#text": "6.46"}, "unit": "capsule"}, {"description": "Sandimmune 50 mg/ml ampul", "cost": {"@currency": "USD", "#text": "7.71"}, "unit": "ml"}, {"description": "Sandimmune 100 mg capsule", "cost": {"@currency": "USD", "#text": "9.89"}, "unit": "capsule"}, {"description": "Cyclosporine a powder", "cost": {"@currency": "USD", "#text": "25.2"}, "unit": "g"}, {"description": "CycloSPORINE Modified 30 25 mg capsule Box", "cost": {"@currency": "USD", "#text": "42.9"}, "unit": "box"}, {"description": "Gengraf 30 25 mg capsule Box", "cost": {"@currency": "USD", "#text": "42.99"}, "unit": "box"}, {"description": "SandIMMUNE 50 mg/ml Solution 5ml Ampule", "cost": {"@currency": "USD", "#text": "46.38"}, "unit": "ampule"}, {"description": "Neoral 30 25 mg capsule Box", "cost": {"@currency": "USD", "#text": "47.69"}, "unit": "box"}, {"description": "SandIMMUNE 30 25 mg capsule Box", "cost": {"@currency": "USD", "#text": "77.33"}, "unit": "box"}, {"description": "Gengraf 30 100 mg capsule Box", "cost": {"@currency": "USD", "#text": "159.94"}, "unit": "box"}, {"description": "CycloSPORINE Modified 30 100 mg capsule Box", "cost": {"@currency": "USD", "#text": "171.48"}, "unit": "box"}, {"description": "Neoral 30 100 mg capsule Box", "cost": {"@currency": "USD", "#text": "190.54"}, "unit": "box"}, {"description": "Restasis 30 0.05% Emulsion 1 Box = 30 Containers", "cost": {"@currency": "USD", "#text": "205.99"}, "unit": "box"}, {"description": "SandIMMUNE 30 100 mg capsule Box", "cost": {"@currency": "USD", "#text": "308.69"}, "unit": "box"}, {"description": "CycloSPORINE Modified 100 mg/ml Solution 50ml Bottle", "cost": {"@currency": "USD", "#text": "311.53"}, "unit": "bottle"}, {"description": "Neoral 100 mg/ml Solution 50ml Bottle", "cost": {"@currency": "USD", "#text": "346.14"}, "unit": "bottle"}, {"description": "SandIMMUNE 100 mg/ml Solution 50ml Bottle", "cost": {"@currency": "USD", "#text": "499.62"}, "unit": "bottle"}]}, "categories": {"category": [{"category": "Antirheumatic Agents", "mesh-id": null}, {"category": "Dermatologic Agents", "mesh-id": null}, {"category": "Immunosuppressive Agents", "mesh-id": null}, {"category": "Antifungal Agents", "mesh-id": null}, {"category": "Enzyme Inhibitors", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Capsule, gelatin coated", "route": "oral", "strength": "100 mg"}, {"form": "Capsule, gelatin coated", "route": "oral", "strength": "25 mg"}, {"form": "Injection, solution", "route": "intravenous", "strength": "50 mg/mL"}, {"form": "Capsule, liquid filled", "route": "oral", "strength": "50 mg"}, {"form": "Capsule", "route": "oral", "strength": "100 mg"}, {"form": "Capsule", "route": "oral", "strength": "25 mg"}, {"form": "Solution", "route": "oral", "strength": "100 mg/mL"}, {"form": "Capsule", "route": "oral", "strength": "10 mg"}, {"form": "Capsule", "route": "oral", "strength": "50 mg"}, {"form": "Solution", "route": "oral", "strength": "100 mg"}, {"form": "Emulsion", "route": "ophthalmic", "strength": ".5 mg/mL"}, {"form": "Emulsion", "route": "ophthalmic", "strength": "0.05 %"}, {"form": "Capsule, liquid filled", "route": "oral", "strength": "100 mg"}, {"form": "Capsule, liquid filled", "route": "oral", "strength": "25 mg"}, {"form": "Injection", "route": "intravenous", "strength": "50 mg/mL"}, {"form": "Liquid", "route": "intravenous", "strength": "50 mg"}, {"form": "Liquid", "route": "oral", "strength": "100 mg"}]}, "atc-codes": {"atc-code": [{"@code": "L04AD01", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L04", "#text": "IMMUNOSUPPRESSANTS"}, {"@code": "L04A", "#text": "IMMUNOSUPPRESSANTS"}, {"@code": "L04AD", "#text": "Calcineurin inhibitors"}]}, {"@code": "S01XA18", "level": [{"@code": "S", "#text": "SENSORY ORGANS"}, {"@code": "S01", "#text": "OPHTHALMOLOGICALS"}, {"@code": "S01X", "#text": "OTHER OPHTHALMOLOGICALS"}, {"@code": "S01XA", "#text": "Other ophthalmologicals"}]}]}, "ahfs-codes": {"ahfs-code": "92:00.00"}, "patents": {"patent": [{"number": "1332150", "country": "Canada", "approved": "1994-09-27", "expires": "2011-09-27"}, {"number": "2108018", "country": "Canada", "approved": "2003-04-15", "expires": "2012-04-16"}, {"number": "4839342", "country": "United States", "approved": "1992-08-02", "expires": "2009-08-02"}, {"number": "5985321", "country": "United States", "approved": "1994-09-26", "expires": "2014-09-26"}]}, "food-interactions": {"food-interaction": ["Avoid salt substitutes containing potassium.", "Avoid taking with grapefruit or grapefruit juice as grapefruit can significantly increase serum levels of this product.", "Red wine may reduce cyclosporine levels due to increased metabolism, therefore it appears prudent  to avoid red wine (white wine does not appear to affect cyclosporine metabolism).", "When taken with a meal, AUC and Cmax of cyclosporine modified decreased."]}, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00819", "name": "Acetazolamide", "description": "May increase the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00051", "name": "Adalimumab", "description": "May decrease the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB08916", "name": "Afatinib", "description": "P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib."}, {"drugbank-id": "DB09026", "name": "Aliskiren", "description": "Cyclosporine (Systemic) may increase the serum concentration of Aliskiren."}, {"drugbank-id": "DB06403", "name": "ambrisentan", "description": "Cyclosporine (Systemic) may increase the serum concentration of ambrisentan."}, {"drugbank-id": "DB00479", "name": "Amikacin", "description": "May enhance the nephrotoxic effect of Cyclosporine (Systemic)."}, {"drugbank-id": "DB01118", "name": "Amiodarone", "description": "May decrease the metabolism of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00681", "name": "Amphotericin B", "description": "May enhance the nephrotoxic effect of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00673", "name": "Aprepitant", "description": "May increase the serum concentration of CYP3A4 Substrates."}, {"drugbank-id": "DB06696", "name": "Arbekacin", "description": "May enhance the nephrotoxic effect of Cyclosporine (Systemic)."}, {"drugbank-id": "DB01238", "name": "Aripiprazole", "description": "CYP3A4 Inhibitors (Weak) may increase the serum concentration of Aripiprazole."}, {"drugbank-id": "DB06413", "name": "armodafinil", "description": "May decrease the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB01076", "name": "Atorvastatin", "description": "Cyclosporine (Systemic) may increase the serum concentration of Atorvastatin."}, {"drugbank-id": "DB03880", "name": "Batimastat", "description": "May increase the serum concentration of Cyclosporine (Systemic). Cyclosporine (Systemic) may increase the serum concentration of Protease Inhibitors."}, {"drugbank-id": "DB08873", "name": "Boceprevir", "description": "Cyclosporine (Systemic) may increase the serum concentration of Boceprevir. Boceprevir may increase the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00559", "name": "Bosentan", "description": "Cyclosporine (Systemic) may increase the serum concentration of Bosentan. Bosentan may decrease the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB06616", "name": "Bosutinib", "description": "P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib."}, {"drugbank-id": "DB08870", "name": "Brentuximab vedotin", "description": "P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased."}, {"drugbank-id": "DB01200", "name": "Bromocriptine", "description": "May increase the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00237", "name": "Butabarbital", "description": "May increase the metabolism of Cyclosporine (Systemic)."}, {"drugbank-id": "DB01353", "name": "Butethal", "description": "May increase the metabolism of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00564", "name": "Carbamazepine", "description": "May decrease the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB01136", "name": "Carvedilol", "description": "May increase the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00520", "name": "Caspofungin", "description": "Cyclosporine (Systemic) may enhance the adverse/toxic effect of Caspofungin. Cyclosporine (Systemic) may increase the serum concentration of Caspofungin."}, {"drugbank-id": "DB00446", "name": "Chloramphenicol", "description": "May increase the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB02659", "name": "Cholic Acid", "description": "BSEP/ABCB11 Inhibitors (Clinically Relevant) may decrease the excretion of Cholic Acid."}, {"drugbank-id": "DB01394", "name": "Colchicine", "description": "P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased."}, {"drugbank-id": "DB00930", "name": "Colesevelam", "description": "May decrease the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00872", "name": "Conivaptan", "description": "May increase the serum concentration of CYP3A4 Substrates."}, {"drugbank-id": "DB08865", "name": "Crizotinib", "description": "May increase the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00531", "name": "Cyclophosphamide", "description": "May enhance the immunosuppressive effect of Cyclosporine (Systemic). Cyclophosphamide may decrease the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB06695", "name": "Dabigatran etexilate", "description": "P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran etexilate."}, {"drugbank-id": "DB08912", "name": "Dabrafenib", "description": "May decrease the serum concentration of CYP3A4 Substrates."}, {"drugbank-id": "DB01254", "name": "Dasatinib", "description": "May increase the serum concentration of CYP3A4 Substrates."}, {"drugbank-id": "DB01609", "name": "Deferasirox", "description": "May decrease the serum concentration of CYP3A4 Substrates."}, {"drugbank-id": "DB06643", "name": "Denosumab", "description": "May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased."}, {"drugbank-id": "DB00390", "name": "Digoxin", "description": "Cyclosporine (Systemic) may increase the serum concentration of Digoxin."}, {"drugbank-id": "DB02901", "name": "Dihydrotestosterone", "description": "May enhance the hepatotoxic effect of Cyclosporine (Systemic). Androgens may increase the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00204", "name": "Dofetilide", "description": "CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide."}, {"drugbank-id": "DB04855", "name": "Dronedarone", "description": "Cyclosporine (Systemic) may increase the serum concentration of Dronedarone."}, {"drugbank-id": "DB09075", "name": "Edoxaban", "description": "P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Edoxaban."}, {"drugbank-id": "DB00625", "name": "Efavirenz", "description": "May decrease the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB08899", "name": "Enzalutamide", "description": "May decrease the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00700", "name": "Eplerenone", "description": "May enhance the hyperkalemic effect of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00773", "name": "Etoposide", "description": "Cyclosporine (Systemic) may decrease the metabolism of Etoposide."}, {"drugbank-id": "DB00773", "name": "Etoposide", "description": "Cyclosporine (Systemic) may increase the serum concentration of Etoposide Phosphate. Cyclosporine may decrease the metabolism, via CYP isoenzymes, and decrease the p-glycoprotein-mediated elimination of Etoposide Phosphate."}, {"drugbank-id": "DB01590", "name": "Everolimus", "description": "Cyclosporine (Systemic) may increase the serum concentration of Everolimus."}, {"drugbank-id": "DB00973", "name": "Ezetimibe", "description": "May increase the serum concentration of Cyclosporine (Systemic). Cyclosporine (Systemic) may increase the serum concentration of Ezetimibe."}, {"drugbank-id": "DB04908", "name": "Flibanserin", "description": "CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin."}, {"drugbank-id": "DB00196", "name": "Fluconazole", "description": "May increase the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB01095", "name": "Fluvastatin", "description": "Cyclosporine (Systemic) may increase the serum concentration of Fluvastatin."}, {"drugbank-id": "DB06717", "name": "Fosaprepitant", "description": "May increase the serum concentration of CYP3A4 Substrates."}, {"drugbank-id": "DB00529", "name": "Foscarnet", "description": "May enhance the nephrotoxic effect of Cyclosporine (Systemic)."}, {"drugbank-id": "DB01320", "name": "Fosphenytoin", "description": "May decrease the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00452", "name": "Framycetin", "description": "May enhance the nephrotoxic effect of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00798", "name": "Gentamicin", "description": "May enhance the nephrotoxic effect of Cyclosporine (Systemic)."}, {"drugbank-id": "DB01016", "name": "Glyburide", "description": "Cyclosporine (Systemic) may diminish the therapeutic effect of Glyburide. Glyburide may increase the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00400", "name": "Griseofulvin", "description": "May decrease the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB01354", "name": "Heptabarbital", "description": "May increase the metabolism of Cyclosporine (Systemic)."}, {"drugbank-id": "DB01355", "name": "Hexobarbital", "description": "May increase the metabolism of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00956", "name": "Hydrocodone", "description": "CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone."}, {"drugbank-id": "DB09054", "name": "Idelalisib", "description": "May increase the serum concentration of CYP3A4 Substrates."}, {"drugbank-id": "DB00619", "name": "Imatinib", "description": "May increase the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB01598", "name": "Imipenem", "description": "Cyclosporine (Systemic) may enhance the neurotoxic effect of Imipenem. Imipenem may decrease the serum concentration of Cyclosporine (Systemic). Imipenem may increase the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00677", "name": "Isoflurophate", "description": "May increase the serum concentration of Cyclosporine (Systemic). Cyclosporine (Systemic) may increase the serum concentration of Protease Inhibitors."}, {"drugbank-id": "DB08820", "name": "Ivacaftor", "description": "May increase the serum concentration of CYP3A4 Substrates."}, {"drugbank-id": "DB01172", "name": "Kanamycin", "description": "May enhance the nephrotoxic effect of Cyclosporine (Systemic)."}, {"drugbank-id": "DB09027", "name": "Ledipasvir", "description": "P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ledipasvir."}, {"drugbank-id": "DB01097", "name": "Leflunomide", "description": "Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased."}, {"drugbank-id": "DB00528", "name": "Lercanidipine", "description": "May increase the serum concentration of Cyclosporine (Systemic). Cyclosporine (Systemic) may increase the serum concentration of Lercanidipine."}, {"drugbank-id": "DB08827", "name": "Lomitapide", "description": "CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide."}, {"drugbank-id": "DB00227", "name": "Lovastatin", "description": "Cyclosporine (Systemic) may increase the serum concentration of Lovastatin."}, {"drugbank-id": "DB08933", "name": "Luliconazole", "description": "May increase the serum concentration of CYP3A4 Substrates."}, {"drugbank-id": "DB01042", "name": "Melphalan", "description": "May enhance the nephrotoxic effect of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00474", "name": "Methohexital", "description": "May increase the metabolism of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00563", "name": "Methotrexate", "description": "Cyclosporine (Systemic) may increase the serum concentration of Methotrexate. This may result in nausea, vomiting, oral ulcers, hepatotoxicity and/or nephrotoxicity. Methotrexate may increase the serum concentration of Cyclosporine (Systemic). This may result in nephrotoxicity."}, {"drugbank-id": "DB00959", "name": "Methylprednisolone", "description": "Cyclosporine (Systemic) may increase the serum concentration of Methylprednisolone. Methylprednisolone may increase the serum concentration of Cyclosporine (Systemic). Methylprednisolone may decrease the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB01233", "name": "Metoclopramide", "description": "May increase the absorption of Cyclosporine (Systemic)."}, {"drugbank-id": "DB09046", "name": "Metreleptin", "description": "May decrease the serum concentration of Cyclosporine (Systemic). Metreleptin may increase the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00834", "name": "Mifepristone", "description": "May increase the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00648", "name": "Mitotane", "description": "May decrease the serum concentration of CYP3A4 Substrates."}, {"drugbank-id": "DB01204", "name": "Mitoxantrone", "description": "Cyclosporine (Systemic) may increase the serum concentration of Mitoxantrone."}, {"drugbank-id": "DB00745", "name": "Modafinil", "description": "May decrease the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB01024", "name": "Mycophenolic acid", "description": "Cyclosporine (Systemic) may decrease the serum concentration of Mycophenolate. Specifically, Cyclosporine may decrease concentrations of the active metabolite Mycophenolic acid."}, {"drugbank-id": "DB00607", "name": "Nafcillin", "description": "May increase the metabolism of Cyclosporine (Systemic)."}, {"drugbank-id": "DB09049", "name": "Naloxegol", "description": "P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naloxegol."}, {"drugbank-id": "DB00108", "name": "Natalizumab", "description": "Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased."}, {"drugbank-id": "DB00994", "name": "Neomycin", "description": "May enhance the nephrotoxic effect of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00955", "name": "Netilmicin", "description": "May enhance the nephrotoxic effect of Cyclosporine (Systemic)."}, {"drugbank-id": "DB09048", "name": "Netupitant", "description": "May increase the serum concentration of CYP3A4 Substrates."}, {"drugbank-id": "DB00393", "name": "Nimodipine", "description": "CYP3A4 Inhibitors (Weak) may increase the serum concentration of Nimodipine."}, {"drugbank-id": "DB01059", "name": "Norfloxacin", "description": "May decrease the metabolism of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00338", "name": "Omeprazole", "description": "May increase the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB01083", "name": "Orlistat", "description": "May decrease the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00621", "name": "Oxandrolone", "description": "May enhance the hepatotoxic effect of Cyclosporine (Systemic). Androgens may increase the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB09073", "name": "Palbociclib", "description": "May increase the serum concentration of CYP3A4 Substrates."}, {"drugbank-id": "DB06589", "name": "Pazopanib", "description": "P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pazopanib."}, {"drugbank-id": "DB00312", "name": "Pentobarbital", "description": "May increase the metabolism of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00252", "name": "Phenytoin", "description": "May increase the metabolism of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00337", "name": "Pimecrolimus", "description": "May enhance the adverse/toxic effect of Immunosuppressants."}, {"drugbank-id": "DB01100", "name": "Pimozide", "description": "CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide."}, {"drugbank-id": "DB08860", "name": "Pitavastatin", "description": "Cyclosporine (Systemic) may increase the serum concentration of Pitavastatin."}, {"drugbank-id": "DB00175", "name": "Pravastatin", "description": "Cyclosporine (Systemic) may increase the serum concentration of Pravastatin. Pravastatin may increase the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00635", "name": "Prednisone", "description": "Cyclosporine (Systemic) may increase serum concentrations of the active metabolite(s) of Prednisone. Prednisone may decrease the serum concentration of Cyclosporine (Systemic). Prednisone may increase the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00794", "name": "Primidone", "description": "May increase the metabolism of Cyclosporine (Systemic)."}, {"drugbank-id": "DB06480", "name": "Prucalopride", "description": "P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of prucalopride."}, {"drugbank-id": "DB00339", "name": "Pyrazinamide", "description": "May increase the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB01369", "name": "Quinupristin", "description": "May increase the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00243", "name": "Ranolazine", "description": "P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ranolazine."}, {"drugbank-id": "DB00243", "name": "Ranolazine", "description": "May increase the serum concentration of P-glycoprotein/ABCB1 Substrates."}, {"drugbank-id": "DB00912", "name": "Repaglinide", "description": "Cyclosporine (Systemic) may increase the serum concentration of Repaglinide."}, {"drugbank-id": "DB03615", "name": "Ribostamycin", "description": "May enhance the nephrotoxic effect of Cyclosporine (Systemic)."}, {"drugbank-id": "DB01220", "name": "Rifaximin", "description": "Cyclosporine (Systemic) may increase the serum concentration of Rifaximin."}, {"drugbank-id": "DB00503", "name": "Ritonavir", "description": "May increase the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB01656", "name": "Roflumilast", "description": "May enhance the immunosuppressive effect of Immunosuppressants."}, {"drugbank-id": "DB01098", "name": "Rosuvastatin", "description": "Cyclosporine (Systemic) may increase the serum concentration of Rosuvastatin."}, {"drugbank-id": "DB00418", "name": "Secobarbital", "description": "May increase the metabolism of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00658", "name": "Sevelamer", "description": "May decrease the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB06207", "name": "Silodosin", "description": "P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin."}, {"drugbank-id": "DB09036", "name": "Siltuximab", "description": "May decrease the serum concentration of CYP3A4 Substrates."}, {"drugbank-id": "DB06290", "name": "Simeprevir", "description": "May increase the serum concentration of Cyclosporine (Systemic). Cyclosporine (Systemic) may increase the serum concentration of Simeprevir."}, {"drugbank-id": "DB00641", "name": "Simvastatin", "description": "Cyclosporine (Systemic) may increase the serum concentration of Simvastatin."}, {"drugbank-id": "DB06688", "name": "Sipuleucel-T", "description": "Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T."}, {"drugbank-id": "DB00877", "name": "Sirolimus", "description": "May enhance the adverse/toxic effect of Cyclosporine (Systemic). An increased risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA) has been described. Cyclosporine (Systemic) may increase the serum concentration of Sirolimus. This is of specific concern with Cyclosporine [MODIFIED]."}, {"drugbank-id": "DB06268", "name": "Sitaxentan", "description": "Cyclosporine (Systemic) may increase the serum concentration of Sitaxentan."}, {"drugbank-id": "DB00919", "name": "Spectinomycin", "description": "May enhance the nephrotoxic effect of Cyclosporine (Systemic)."}, {"drugbank-id": "DB09118", "name": "Stiripentol", "description": "May increase the serum concentration of CYP3A4 Substrates."}, {"drugbank-id": "DB01082", "name": "Streptomycin", "description": "May enhance the nephrotoxic effect of Cyclosporine (Systemic)."}, {"drugbank-id": "DB01138", "name": "Sulfinpyrazone", "description": "May decrease the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB05521", "name": "Telaprevir", "description": "May increase the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB06287", "name": "Temsirolimus", "description": "May enhance the adverse/toxic effect of Cyclosporine (Systemic). An increased risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA) has been described with concomitant sirolimus use."}, {"drugbank-id": "DB00624", "name": "Testosterone", "description": "May enhance the hepatotoxic effect of Cyclosporine (Systemic). Androgens may increase the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB08816", "name": "Ticagrelor", "description": "Cyclosporine (Systemic) may increase the serum concentration of Ticagrelor."}, {"drugbank-id": "DB00684", "name": "Tobramycin", "description": "May enhance the nephrotoxic effect of Cyclosporine (Systemic)."}, {"drugbank-id": "DB06273", "name": "Tocilizumab", "description": "May decrease the serum concentration of CYP3A4 Substrates."}, {"drugbank-id": "DB08895", "name": "Tofacitinib", "description": "Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib."}, {"drugbank-id": "DB01030", "name": "Topotecan", "description": "P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan."}, {"drugbank-id": "DB00072", "name": "Trastuzumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}, {"drugbank-id": "DB00126", "name": "Vitamin C", "description": "May decrease the serum concentration of Cyclosporine (Systemic)."}, {"drugbank-id": "DB00163", "name": "Vitamin E", "description": "May decrease the serum concentration of Cyclosporine (Systemic)."}]}, "calculated-properties": {"property": [{"kind": "logP", "value": "4.37", "source": "ALOGPS"}, {"kind": "logS", "value": "-5.3", "source": "ALOGPS"}, {"kind": "Water Solubility", "value": "5.81e-03 g/l", "source": "ALOGPS"}, {"kind": "logP", "value": "6.92", "source": "ChemAxon"}, {"kind": "IUPAC Name", "value": "30-ethyl-14,17,23,32-tetrahydroxy-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriaconta-13,16,22,31-tetraene-2,5,8,11,20,26,29-heptone", "source": "ChemAxon"}, {"kind": "Traditional IUPAC Name", "value": "30-ethyl-14,17,23,32-tetrahydroxy-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriaconta-13,16,22,31-tetraene-2,5,8,11,20,26,29-heptone", "source": "ChemAxon"}, {"kind": "Molecular Weight", "value": "1202.6112", "source": "ChemAxon"}, {"kind": "Monoisotopic Weight", "value": "1201.841368071", "source": "ChemAxon"}, {"kind": "SMILES", "value": "CCC1NC(=O)C(C(O)C(C)C\\C=C\\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C", "source": "ChemAxon"}, {"kind": "Molecular Formula", "value": "C62H111N11O12", "source": "ChemAxon"}, {"kind": "InChI", "value": "InChI=1/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+", "source": "ChemAxon"}, {"kind": "InChIKey", "value": "InChIKey=PMATZTZNYRCHOR-IMVLJIQENA-N", "source": "ChemAxon"}, {"kind": "Polar Surface Area (PSA)", "value": "292.76", "source": "ChemAxon"}, {"kind": "Refractivity", "value": "329.23", "source": "ChemAxon"}, {"kind": "Polarizability", "value": "131.92", "source": "ChemAxon"}, {"kind": "Rotatable Bond Count", "value": "15", "source": "ChemAxon"}, {"kind": "H Bond Acceptor Count", "value": "16", "source": "ChemAxon"}, {"kind": "H Bond Donor Count", "value": "5", "source": "ChemAxon"}, {"kind": "pKa (strongest acidic)", "value": "3.69", "source": "ChemAxon"}, {"kind": "pKa (strongest basic)", "value": "1.94", "source": "ChemAxon"}, {"kind": "Physiological Charge", "value": "0", "source": "ChemAxon"}, {"kind": "Number of Rings", "value": "1", "source": "ChemAxon"}, {"kind": "Bioavailability", "value": "0", "source": "ChemAxon"}, {"kind": "Rule of Five", "value": "0", "source": "ChemAxon"}, {"kind": "Ghose Filter", "value": "0", "source": "ChemAxon"}, {"kind": "MDDR-Like Rule", "value": "0", "source": "ChemAxon"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "148-151 \u00b0C", "source": null}, {"kind": "caco2 Permeability", "value": "-6.05", "source": "ADME Research, USCD"}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "11396"}, {"resource": "ChEBI", "identifier": "4031"}, {"resource": "KEGG Compound", "identifier": "C05086"}, {"resource": "KEGG Drug", "identifier": "D00184"}, {"resource": "National Drug Code Directory", "identifier": "0078-0240-15"}, {"resource": "PharmGKB", "identifier": "PA449167"}, {"resource": "Wikipedia", "identifier": "Cyclosporine"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/cyclosporine.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/cyclosporine-drops.html"}]}, "pathways": null, "reactions": {"reaction": {"sequence": "1", "left-element": {"drugbank-id": "DB00091", "name": "Cyclosporine"}, "right-element": {"drugbank-id": "DBMET00359", "name": "Metabolite AM1"}, "enzymes": {"enzyme": {"drugbank-id": "BE0002638", "name": "Cytochrome P450 3A4", "uniprot-id": "P08684"}}}}, "snp-effects": null, "snp-adverse-drug-reactions": {"reaction": {"protein-name": "Cytotoxic T-lymphocyte protein 4", "gene-symbol": "CTLA4", "uniprot-id": "P16410", "rs-id": "rs231775", "allele": null, "adverse-reaction": "A Allele", "description": "Gingival overgrowth, periodontal disease", "pubmed-id": "18021981"}}, "targets": {"target": [{"@position": "1", "id": "BE0000379", "name": "Calcium signal-modulating cyclophilin ligand", "organism": "Human", "actions": {"action": "binder"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Bernasconi R, Solda T, Galli C, Pertel T, Luban J, Molinari M: Cyclosporine a-sensitive, cyclophilin B-dependent endoplasmic reticulum-associated degradation. PLoS One. 2010 Sep 28;5(9). pii: e13008. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20927389\n# Yamashita H, Ito T, Kato H, Asai S, Tanaka H, Nagai H, Inagaki N: Comparison of the efficacy of tacrolimus and cyclosporine A in a murine model of dinitrofluorobenzene-induced atopic dermatitis. Eur J Pharmacol. 2010 Oct 25;645(1-3):171-6. Epub 2010 Aug 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20674565\n# Galat A, Bua J: Molecular aspects of cyclophilins mediating therapeutic actions of their ligands. Cell Mol Life Sci. 2010 Oct;67(20):3467-88. Epub 2010 Jul 4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20602248\n# Lee J, Kim SS: Current implications of cyclophilins in human cancers. J Exp Clin Cancer Res. 2010 Jul 19;29:97. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20637127", "known-action": "yes", "polypeptide": {"@id": "P49069", "@source": "Swiss-Prot", "name": "Calcium signal-modulating cyclophilin ligand", "general-function": "Involved in cyclophilin binding", "specific-function": "Likely involved in the mobilization of calcium as a result of the TCR/CD3 complex interaction. Binds to cyclophilin B", "gene-name": "CAMLG", "locus": "5q23", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "190-210\n241-257", "signal-regions": null, "theoretical-pi": "8.19", "molecular-weight": "32953.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1471"}, {"resource": "GenAtlas", "identifier": "CAMLG"}, {"resource": "GeneCards", "identifier": "CAMLG"}, {"resource": "GenBank Gene Database", "identifier": "U18242"}, {"resource": "GenBank Protein Database", "identifier": "619670"}, {"resource": "UniProtKB", "identifier": "P49069"}, {"resource": "UniProt Accession", "identifier": "CAMLG_HUMAN"}]}, "synonyms": {"synonym": "CAML"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Calcium signal-modulating cyclophilin ligand\nMESMAVATDGGERPGVPAGSGLSASQRRAELRRRKLLMNSEQRINRIMGFHRPGSGAEEE\nSQTKSKQQDSDKLNSLSVPSVSKRVVLGDSVSTGTTDQQGGVAEVKGTQLGDKLDSFIKP\nPECSSDVNLELRQRNRGDLTADSVQRGSRHGLEQYLSRFEEAMKLRKQLISEKPSQEDGN\nTTEEFDSFRIFRLVGCALLALGVRAFVCKYLSIFAPFLTLQLAYMGLYKYFPKSEKKIKT\nTVLTAALLLSGIPAEVINRSMDTYSKMGEVFTDLCVYFFTFIFCHELLDYWGSEVP"}, "gene-sequence": {"@format": "FASTA", "#text": ">891 bp\nATGGAGTCGATGGCCGTCGCTACCGACGGCGGGGAGAGGCCGGGGGTCCCAGCGGGCTCA\nGGTCTGTCGGCTTCCCAGCGTCGGGCGGAGCTGCGTCGGAGAAAGCTGCTCATGAACTCG\nGAACAGCGCATCAACCGGATCATGGGCTTTCACAGGCCCGGGAGCGGCGCGGAAGAAGAA\nAGTCAAACAAAATCAAAGCAGCAGGACAGTGATAAACTGAACTCCCTCAGCGTTCCTTCC\nGTTTCAAAGCGAGTAGTGCTGGGTGATTCAGTCAGTACAGGAACAACTGACCAGCAGGGT\nGGTGTGGCCGAGGTAAAGGGGACCCAACTGGGAGACAAATTGGACTCGTTCATTAAACCA\nCCTGAGTGCAGTAGTGATGTCAACCTTGAGCTCCGGCAGCGGAACAGAGGGGACCTGACA\nGCGGACTCGGTCCAGAGGGGTTCCCGCCATGGCCTAGAGCAGTACCTTTCCAGATTCGAA\nGAAGCAATGAAGCTAAGGAAACAGCTGATTAGTGAAAAACCCAGTCAAGAGGATGGAAAT\nACAACAGAAGAATTTGACTCTTTTCGAATATTTAGATTGGTGGGATGTGCTCTTCTTGCT\nCTTGGAGTCAGAGCTTTTGTTTGCAAATACTTGTCCATATTTGCTCCATTTCTTACTTTA\nCAACTTGCGTACATGGGATTATACAAATATTTTCCCAAGAGTGAAAAGAAGATAAAGACA\nACAGTACTAACAGCTGCACTTCTATTGTCGGGAATTCCTGCCGAAGTGATAAATCGATCA\nATGGATACCTATAGCAAAATGGGCGAAGTCTTCACAGATCTCTGTGTCTACTTTTTCACT\nTTTATCTTTTGTCATGAACTGCTTGATTATTGGGGCTCTGAAGTACCATGA"}, "pfams": null, "go-classifiers": null}}, {"@position": "2", "id": "BE0002143", "name": "Calcineurin subunit B type 2", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Yamashita H, Ito T, Kato H, Asai S, Tanaka H, Nagai H, Inagaki N: Comparison of the efficacy of tacrolimus and cyclosporine A in a murine model of dinitrofluorobenzene-induced atopic dermatitis. Eur J Pharmacol. 2010 Oct 25;645(1-3):171-6. Epub 2010 Aug 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20674565", "known-action": "yes", "polypeptide": {"@id": "Q96LZ3", "@source": "Swiss-Prot", "name": "Calcineurin subunit B type 2", "general-function": null, "specific-function": "Regulatory subunit of calcineurin, a calcium-dependent, calmodulin stimulated protein phosphatase. Confers calcium sensitivity", "gene-name": "PPP3R2", "locus": "9q31.1", "cellular-location": null, "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "4.49", "molecular-weight": "19533.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9318"}, {"resource": "GenAtlas", "identifier": "PPP3R2"}, {"resource": "GeneCards", "identifier": "PPP3R2"}, {"resource": "GenBank Gene Database", "identifier": "AF145026"}, {"resource": "GenBank Protein Database", "identifier": "33150800"}, {"resource": "UniProtKB", "identifier": "Q96LZ3"}, {"resource": "UniProt Accession", "identifier": "CANB2_HUMAN"}]}, "synonyms": {"synonym": ["Calcineurin B-like protein", "CBLP", "CNBII", "Protein phosphatase 2B regulatory subunit 2", "Protein phosphatase 3 regulatory subunit B beta isoform"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Calcineurin subunit B isoform 2\nMGNEASYPAEMCSHFDNDEIKRLGRRFKKLDLDKSGSLSVEEFMSLPELRHNPLVRRVID\nVFDTDGDGEVDFKEFILGTSQFSVKGDEEQKLRFAFSIYDMDKDGYISNGELFQVLKMMV\nGNNLTDWQLQQLVDKTIIILDKDGDGKISFEEFSAVVRDLEIHKKLVLIV"}, "gene-sequence": {"@format": "FASTA", "#text": ">513 bp\nATGGGAAACGAGGCCAGTTACCCGGCGGAGATGTGCTCCCACTTTGACAATGATGAAATT\nAAAAGGCTGGGCAGGAGGTTTAAGAAGTTGGACTTGGACAAATCAGGGTCTCTGAGCGTG\nGAGGAGTTCATGTCCCTGCCGGAGCTGCGCCACAACCCGTTGGTGCGGCGAGTGATCGAC\nGTCTTCGACACCGACGGTGATGGAGAAGTGGACTTCAAGGAATTCATCCTGGGGACCTCC\nCAGTTCAGCGTCAAGGGCGACGAGGAGCAGAAGTTGAGGTTTGCGTTCAGCATTTACGAC\nATGGATAAAGATGGCTACATTTCCAACGGGGAGCTCTTCCAGGTGCTGAAGATGATGGTG\nGGCAACAACCTGACGGACTGGCAGCTCCAGCAGCTGGTCGACAAAACCATCATCATCCTG\nGACAAGGATGGCGATGGGAAGATATCCTTTGAGGAATTCAGTGCTGTGGTCAGAGACCTG\nGAGATCCACAAGAAGCTGGTCCTCATCGTATGA"}, "pfams": {"pfam": {"identifier": "PF00036", "name": "efhand"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "binding"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}]}}}, {"@position": "3", "id": "BE0001014", "name": "Peptidyl-prolyl cis-trans isomerase A", "organism": "Human", "actions": null, "references": "# Keckesova Z, Ylinen LM, Towers GJ: Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity. J Virol. 2006 May;80(10):4683-90. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16641261\n# Patwardhan AM, Jeske NA, Price TJ, Gamper N, Akopian AN, Hargreaves KM: The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11393-8. Epub 2006 Jul 18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16849427\n# Redell JB, Zhao J, Dash PK: Acutely increased cyclophilin a expression after brain injury: a role in blood-brain barrier function and tissue preservation. J Neurosci Res. 2007 Jul;85(9):1980-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17461417\n# Schaller T, Ylinen LM, Webb BL, Singh S, Towers GJ: Fusion of cyclophilin A to Fv1 enables cyclosporine-sensitive restriction of human and feline immunodeficiency viruses. J Virol. 2007 Sep;81(18):10055-63. Epub 2007 Jul 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17609268\n# Lee J, Kim SS: Current implications of cyclophilins in human cancers. J Exp Clin Cancer Res. 2010 Jul 19;29:97. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20637127\n# Stegmann CM, Luhrmann R, Wahl MC: The crystal structure of PPIL1 bound to cyclosporine A suggests a binding mode for a linear epitope of the SKIP protein. PLoS One. 2010 Apr 2;5(4):e10013. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20368803", "known-action": "unknown", "polypeptide": {"@id": "P62937", "@source": "Swiss-Prot", "name": "Peptidyl-prolyl cis-trans isomerase A", "general-function": "Posttranslational modification, protein turnover, chaperones", "specific-function": "PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides", "gene-name": "PPIA", "locus": "7p13", "cellular-location": "Cytoplasm", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.97", "molecular-weight": "18013.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9253"}, {"resource": "GenAtlas", "identifier": "PPIA"}, {"resource": "GeneCards", "identifier": "PPIA"}, {"resource": "GenBank Gene Database", "identifier": "Y00052"}, {"resource": "GenBank Protein Database", "identifier": "30309"}, {"resource": "UniProtKB", "identifier": "P62937"}, {"resource": "UniProt Accession", "identifier": "PPIA_HUMAN"}]}, "synonyms": {"synonym": ["Cyclophilin A", "Cyclosporin A-binding protein", "EC 5.2.1.8", "PPIase A", "Rotamase A"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Peptidyl-prolyl cis-trans isomerase A\nMVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGF\nMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTE\nWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE"}, "gene-sequence": {"@format": "FASTA", "#text": ">498 bp\nATGGTCAACCCCACCGTGTTCTTCGACATTGCCGTCGACGGCGAGCCCTTGGGCCGCGTC\nTCCTTTGAGCTGTTTGCAGACAAGGTCCCAAAGACAGCAGAAAATTTTCGTGCTCTGAGC\nACTGGAGAGAAAGGATTTGGTTATAAGGGTTCCTGCTTTCACAGAATTATTCCAGGGTTT\nATGTGTCAGGGTGGTGACTTCACACGCCATAATGGCACTGGTGGCAAGTCCATCTATGGG\nGAGAAATTTGAAGATGAGAACTTCATCCTAAAGCATACGGGTCCTGGCATCTTGTCCATG\nGCAAATGCTGGACCCAACACAAATGGTTCCCAGTTTTTCATCTGCACTGCCAAGACTGAG\nTGGTTGGATGGCAAGCATGTGGTGTTTGGCAAAGTGAAAGAAGGCATGAATATTGTGGAG\nGCCATGGAGCGCTTTGGGTCCAGGAATGGCAAGACCAGCAAGAAGATCACCATTGCTGAC\nTGTGGACAACTCGAATAA"}, "pfams": {"pfam": {"identifier": "PF00160", "name": "Pro_isomerase"}}, "go-classifiers": {"go-classifier": [{"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "protein folding"}]}}}, {"@position": "20", "id": "BE0001399", "name": "Peptidyl-prolyl cis-trans isomerase F, mitochondrial", "organism": "Human", "actions": {"action": "binder"}, "references": "# Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW: Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science. 1984 Nov 2;226(4674):544-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/6238408", "known-action": "unknown", "polypeptide": {"@id": "P30405", "@source": "Swiss-Prot", "name": "Peptidyl-prolyl cis-trans isomerase F, mitochondrial", "general-function": "Posttranslational modification, protein turnover, chaperones", "specific-function": "PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides", "gene-name": "PPIF", "locus": "10q22-q23", "cellular-location": "Mitochondrion; mitochondrial matrix", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.95", "molecular-weight": "22040.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:9259"}, {"resource": "GenAtlas", "identifier": "PPIF"}, {"resource": "GeneCards", "identifier": "PPIF"}, {"resource": "GenBank Gene Database", "identifier": "M80254"}, {"resource": "GenBank Protein Database", "identifier": "181274"}, {"resource": "UniProtKB", "identifier": "P30405"}, {"resource": "UniProt Accession", "identifier": "PPIF_HUMAN"}]}, "synonyms": {"synonym": ["Cyclophilin F", "EC 5.2.1.8", "Peptidyl-prolyl cis-trans isomerase, mitochondrial precursor", "PPIase", "Rotamase"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Peptidyl-prolyl cis-trans isomerase, mitochondrial precursor\nMLALRCGSRWLGLLSVPRSVPLRLPAARACSKGSGDPSSSSSSGNPLVYLDVDANGKPLG\nRVVLELKADVVPKTAENFRALCTGEKGFGYKGSTFHRVIPSFMCQAGDFTNHNGTGGKSI\nYGSRFPDENFTLKHVGPGVLSMANAGPNTNGSQFFICTIKTDWLDGKHVVFGHVKEGMDV\nVKKIESFGSKSGRTSKKIVITDCGQLS"}, "gene-sequence": {"@format": "FASTA", "#text": ">624 bp\nATGCTGGCGCTGCGCTGCGGCTCCCGCTGGCTCGGCCTGCTCTCCGTCCCGCGCTCCGTG\nCCGCTGCGCCTCCCCGCGGCCCGCGCCTGCAGCAAGGGCTCCGGCGACCCGTCCTCTTCC\nTCCTCCTCCGGGAACCCGCTCGTGTACCTGGACGTGGACGCCAACGGGAAGCCGCTCGGC\nCGCGTGGTGCTGGAGCTGAAGGCAGATGTCGTCCCAAAGACAGCTGAGAACTTCAGAGCC\nCTGTGCACTGGTGAGAAGGGCTTCGGCTACAAAGGCTCCACCTTCCACAGGGTGATCCCT\nTCCTTCATGTGCCAGGCGGGCGACTTCACCAACCACAATGGCACAGGCGGGAAGTCCATC\nTACGGAAGCCGCTTTCCTGACGAGAACTTTACACTGAAGCACGTGGGGCCAGGTGTCCTG\nTCCATGGCTAATGCTGGTCCTAACACCAACGGCTCCCAGTTCTTCATCTGCACCATAAAG\nACAGACTGGTTGGATGGCAAGCATGTTGTGTTCGGTCACGTCAAAGAGGGCATGGACGTC\nGTGAAGAAAATAGAATCTTTCGGCTCTAAGAGTGGGAGGACATCCAAGAAGATTGTCATC\nACAGACTGTGGCCAGTTGAGCTAA"}, "pfams": {"pfam": {"identifier": "PF00160", "name": "Pro_isomerase"}}, "go-classifiers": {"go-classifier": [{"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "protein folding"}]}}}]}, "enzymes": {"enzyme": [{"id": "BE0003612", "name": "Cytochrome P450 3A7", "organism": "Human", "actions": {"action": ["substrate", "inducer"]}, "references": "# Flockhart DA. \"Drug Interactions: Cytochrome P450 Drug Interaction Table\":http://medicine.iupui.edu/clinpharm/ddis/table.asp. Indiana University School of Medicine (2007). Accessed May 28, 2010.\n# Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19934256", "known-action": "unknown", "polypeptide": {"@id": "P24462", "@source": "Swiss-Prot", "name": "Cytochrome P450 3A7", "general-function": "Secondary metabolites biosynthesis, transport and catabolism", "specific-function": "Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics", "gene-name": "CYP3A7", "locus": "7q21-q22.1", "cellular-location": "Endoplasmic reticulum membrane", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.59", "molecular-weight": "57525.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "GNC:2640"}, {"resource": "GeneCards", "identifier": "CYP3A7"}, {"resource": "GenBank Gene Database", "identifier": "D00408"}, {"resource": "GenBank Protein Database", "identifier": "220149"}, {"resource": "UniProtKB", "identifier": "P24462"}, {"resource": "UniProt Accession", "identifier": "CP3A7_HUMAN"}]}, "synonyms": {"synonym": ["CYPIIIA7", "P450-HFLA"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytochrome P450 3A7\nMDLIPNLAVETWLLLAVSLILLYLYGTRTHGLFKKLGIPGPTPLPFLGNALSFRKGYWTF\nDMECYKKYRKVWGIYDCQQPMLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKNAISI\nAEDEEWKRIRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKHVFGAYS\nMDVITSTSFGVSIDSLNNPQDPFVENTKKLLRFNPLDPFVLSIKVFPFLTPILEALNITV\nFPRKVISFLTKSVKQIKEGRLKETQKHRVDFLQLMIDSQNSKDSETHKALSDLELMAQSI\nIFIFAGYETTSSVLSFIIYELATHPDVQQKVQKEIDTVLPNKAPPTYDTVLQLEYLDMVV\nNETLRLFPVAMRLERVCKKDVEINGMFIPKGVVVMIPSYVLHHDPKYWREPEKFLPERFS\nKKNKDNIDPYIYTPFGSGPRNCIGMRFALVNMKLALVRVLQNFSFKPCKETQIPLKLRFG\nGLLLTEKPIVLKAESRDETVSGA"}, "gene-sequence": {"@format": "FASTA", "#text": ">1512 bp\nATGGATCTCATCCCAAACTTGGCCGTGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGATA\nCTCCTCTATCTATATGGAACCCGTACACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG\nCCCACACCTCTGCCTTTTTTGGGAAATGCTTTGTCCTTCCGTAAGGGCTATTGGACGTTT\nGACATGGAATGTTATAAAAAGTATAGAAAAGTCTGGGGTATTTATGACTGTCAACAGCCT\nATGCTGGCTATCACAGATCCCGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT\nGTCTTCACAAACCGGAGGCCTTTCGGGCCAGTGGGATTTATGAAAAATGCCATCTCTATA\nGCTGAGGATGAAGAATGGAAGAGAATACGATCATTGCTGTCTCCAACATTCACCAGCGGA\nAAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG\nAGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAACACGTCTTTGGGGCCTACAGC\nATGGATGTGATCACTAGCACATCATTTGGAGTGAGCATCGACTCTCTCAACAATCCACAA\nGACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTAATCCATTAGATCCATTCGTT\nCTCTCAATAAAAGTCTTTCCATTCCTTACCCCAATTCTTGAAGCATTAAATATCACTGTG\nTTTCCAAGAAAAGTTATAAGTTTTCTAACAAAATCTGTAAAACAGATAAAAGAAGGTCGC\nCTCAAAGAGACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAAT\nTCAAAAGACTCTGAGACCCACAAAGCTCTGTCTGATCTGGAGCTCATGGCCCAATCAATT\nATCTTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATATATGAA\nCTGGCCACTCACCCTGATGTCCAGCAGAAAGTGCAGAAGGAAATTGATACAGTTTTACCC\nAATAAGGCACCACCCACCTATGATACTGTGCTACAGTTGGAGTATCTTGACATGGTGGTG\nAATGAAACACTCAGATTATTCCCAGTTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGAT\nGTTGAAATCAATGGGATGTTTATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGTT\nCTTCATCATGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGGTTCAGT\nAAAAAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGA\nAACTGCATTGGCATGAGGTTTGCTCTCGTGAACATGAAACTTGCTCTAGTCAGAGTCCTT\nCAGAACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTACGCTTTGGA\nGGACTTCTTCTAACAGAAAAACCCATTGTTCTAAAGGCTGAGTCAAGGGATGAGACCGTA\nAGTGGAGCCTGA"}, "pfams": {"pfam": {"identifier": "PF00067", "name": "p450"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "iron ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "tetrapyrrole binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "heme binding"}, {"category": "function", "description": "monooxygenase activity"}, {"category": "function", "description": "oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "generation of precursor metabolites and energy"}, {"category": "process", "description": "electron transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}, {"id": "BE0002362", "name": "Cytochrome P450 3A5", "organism": "Human", "actions": {"action": ["substrate", "inducer"]}, "references": "# Flockhart DA. \"Drug Interactions: Cytochrome P450 Drug Interaction Table\":http://medicine.iupui.edu/clinpharm/ddis/table.asp. Indiana University School of Medicine (2007). Accessed May 28, 2010.\n# Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19934256", "known-action": "unknown", "polypeptide": {"@id": "P20815", "@source": "Swiss-Prot", "name": "Cytochrome P450 3A5", "general-function": "Secondary metabolites biosynthesis, transport and catabolism", "specific-function": "Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics", "gene-name": "CYP3A5", "locus": "7q21.1", "cellular-location": "Endoplasmic reticulum", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.09", "molecular-weight": "57109.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2638"}, {"resource": "GenAtlas", "identifier": "CYP3A5"}, {"resource": "GeneCards", "identifier": "CYP3A5"}, {"resource": "GenBank Gene Database", "identifier": "J04813"}, {"resource": "GenBank Protein Database", "identifier": "181346"}, {"resource": "UniProtKB", "identifier": "P20815"}, {"resource": "UniProt Accession", "identifier": "CP3A5_HUMAN"}]}, "synonyms": {"synonym": ["CYPIIIA5", "EC 1.14.14.1", "HLp2", "P450-PCN3"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytochrome P450 3A5\nMDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNVLSYRQGLWKF\nDTECYKKYGKMWGTYEGQLPVLAITDPDVIRTVLVKECYSVFTNRRSLGPVGFMKSAISL\nAEDEEWKRIRSLLSPTFTSGKLKEMFPIIAQYGDVLVRNLRREAEKGKPVTLKDIFGAYS\nMDVITGTSFGVNIDSLNNPQDPFVESTKKFLKFGFLDPLFLSIILFPFLTPVFEALNVSL\nFPKDTINFLSKSVNRMKKSRLNDKQKHRLDFLQLMIDSQNSKETESHKALSDLELAAQSI\nIFIFAGYETTSSVLSFTLYELATHPDVQQKLQKEIDAVLPNKAPPTYDAVVQMEYLDMVV\nNETLRLFPVAIRLERTCKKDVEINGVFIPKGSMVVIPTYALHHDPKYWTEPEEFRPERFS\nKKKDSIDPYIYTPFGTGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLDTQG\nLLQPEKPIVLKVDSRDGTLSGE"}, "gene-sequence": {"@format": "FASTA", "#text": ">1509 bp\nATGGACCTCATCCCAAATTTGGCGGTGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG\nCTCCTCTATCTATATGGGACCCGTACACATGGACTTTTTAAGAGACTGGGAATTCCAGGG\nCCCACACCTCTGCCTTTGTTGGGAAATGTTTTGTCCTATCGTCAGGGTCTCTGGAAATTT\nGACACAGAGTGCTATAAAAAGTATGGAAAAATGTGGGGAACGTATGAAGGTCAACTCCCT\nGTGCTGGCCATCACAGATCCCGACGTGATCAGAACAGTGCTAGTGAAAGAATGTTATTCT\nGTCTTCACAAATCGAAGGTCTTTAGGCCCAGTGGGATTTATGAAAAGTGCCATCTCTTTA\nGCTGAGGATGAAGAATGGAAGAGAATACGGTCATTGCTGTCTCCAACCTTCACCAGCGGA\nAAACTCAAGGAGATGTTCCCCATCATTGCCCAGTATGGAGATGTATTGGTGAGAAACTTG\nAGGCGGGAAGCAGAGAAAGGCAAGCCTGTCACCTTGAAAGACATCTTTGGGGCCTACAGC\nATGGATGTGATTACTGGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA\nGACCCCTTTGTGGAGAGCACTAAGAAGTTCCTAAAATTTGGTTTCTTAGATCCATTATTT\nCTCTCAATAATACTCTTTCCATTCCTTACCCCAGTTTTTGAAGCATTAAATGTCTCTCTG\nTTTCCAAAAGATACCATAAATTTTTTAAGTAAATCTGTAAACAGAATGAAGAAAAGTCGC\nCTCAACGACAAACAAAAGCACCGACTAGATTTCCTTCAGCTGATGATTGACTCCCAGAAT\nTCGAAAGAAACTGAGTCCCACAAAGCTCTGTCTGATCTGGAGCTCGCAGCCCAGTCAATA\nATCTTCATTTTTGCTGGCTATGAAACCACCAGCAGTGTTCTTTCCTTCACTTTATATGAA\nCTGGCCACTCACCCTGATGTCCAGCAGAAACTGCAAAAGGAGATTGATGCAGTTTTGCCC\nAATAAGGCACCACCTACCTATGATGCCGTGGTACAGATGGAGTACCTTGACATGGTGGTG\nAATGAAACACTCAGATTATTCCCAGTTGCTATTAGACTTGAGAGGACTTGCAAGAAAGAT\nGTTGAAATCAATGGGGTATTCATTCCCAAAGGGTCAATGGTGGTGATTCCAACTTATGCT\nCTTCACCATGACCCAAAGTACTGGACAGAGCCTGAGGAGTTCCGCCCTGAAAGGTTCAGT\nAAGAAGAAGGACAGCATAGATCCTTACATATACACACCCTTTGGAACTGGACCCAGAAAC\nTGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG\nAACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCTTGAAATTAGACACGCAAGGA\nCTTCTTCAACCAGAAAAACCCATTGTTCTAAAGGTGGATTCAAGAGATGGAACCCTAAGT\nGGAGAATGA"}, "pfams": {"pfam": {"identifier": "PF00067", "name": "p450"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "iron ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "tetrapyrrole binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "heme binding"}, {"category": "function", "description": "monooxygenase activity"}, {"category": "function", "description": "oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "generation of precursor metabolites and energy"}, {"category": "process", "description": "electron transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}, {"id": "BE0002638", "name": "Cytochrome P450 3A4", "organism": "Human", "actions": {"action": ["substrate", "inhibitor"]}, "references": "# Flockhart DA. \"Drug Interactions: Cytochrome P450 Drug Interaction Table\":http://medicine.iupui.edu/clinpharm/ddis/table.asp. Indiana University School of Medicine (2007). Accessed May 28, 2010.\n# Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19934256\n# Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10490933\n# Lexicomp.", "known-action": "unknown", "polypeptide": {"@id": "P08684", "@source": "Swiss-Prot", "name": "Cytochrome P450 3A4", "general-function": "Involved in monooxygenase activity", "specific-function": "Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4- hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. The enzyme also hydroxylates etoposide", "gene-name": "CYP3A4", "locus": "7q21.1", "cellular-location": "Endoplasmic reticulum", "transmembrane-regions": "2-22", "signal-regions": null, "theoretical-pi": "8.25", "molecular-weight": "57344.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2637"}, {"resource": "GenAtlas", "identifier": "CYP3A4"}, {"resource": "GenBank Gene Database", "identifier": "M18907"}, {"resource": "UniProtKB", "identifier": "P08684"}, {"resource": "UniProt Accession", "identifier": "CP3A4_HUMAN"}]}, "synonyms": {"synonym": ["CYPIIIA4", "EC 1.14.13.67", "EC 1.14.13.97", "NF-25", "Nifedipine oxidase", "P450-PCN1", "Quinine 3-monooxygenase", "Taurochenodeoxycholate 6-alpha- hydroxylase"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytochrome P450 3A4\nMALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF\nDMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI\nAEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS\nMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV\nFPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI\nIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV\nNETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS\nKKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG\nGLLQPEKPVVLKVESRDGTVSGA"}, "gene-sequence": {"@format": "FASTA", "#text": ">1512 bp\nATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG\nCTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG\nCCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT\nGACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT\nGTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT\nGTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA\nGCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA\nAAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG\nAGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC\nATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA\nGACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT\nCTCTCAATAACAGTCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTG\nTTTCCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGC\nCTCGAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAAT\nTCAAAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATT\nATCTTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAA\nCTGGCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCC\nAATAAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTG\nAATGAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGAT\nGTTGAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCT\nCTTCACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGC\nAAGAAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGA\nAACTGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTT\nCAGAACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGA\nGGACTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTA\nAGTGGAGCCTGA"}, "pfams": {"pfam": {"identifier": "PF00067", "name": "p450"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "iron ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "tetrapyrrole binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "heme binding"}, {"category": "function", "description": "monooxygenase activity"}, {"category": "function", "description": "oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "generation of precursor metabolites and energy"}, {"category": "process", "description": "electron transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular metabolism"}]}}, "inhibition-strength": "moderate", "induction-strength": "unknown"}, {"@position": "16", "id": "BE0003536", "name": "Cytochrome P450 2C19", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19934256", "known-action": "unknown", "polypeptide": {"@id": "P33261", "@source": "Swiss-Prot", "name": "Cytochrome P450 2C19", "general-function": "Secondary metabolites biosynthesis, transport and catabolism", "specific-function": "Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine", "gene-name": "CYP2C19", "locus": "10q24.1-q24.3", "cellular-location": "Endoplasmic reticulum membrane", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.42", "molecular-weight": "55930.5", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "GNC:2621"}, {"resource": "GeneCards", "identifier": "CYP2C19"}, {"resource": "GenBank Gene Database", "identifier": "M61854"}, {"resource": "GenBank Protein Database", "identifier": "181344"}, {"resource": "UniProtKB", "identifier": "P33261"}, {"resource": "UniProt Accession", "identifier": "CP2CJ_HUMAN"}]}, "synonyms": {"synonym": ["(R)-limonene 6-monooxygenase", "(S)-limonene 6-monooxygenase", "(S)-limonene 7-monooxygenase", "CYPIIC17", "CYPIIC19", "Mephenytoin 4-hydroxylase", "P450-11A", "P450-254C"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytochrome P450 2C19\nMDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI\nYGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW\nKEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS\nIIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM\nESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE\nTTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID\nLIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK\nKSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP\nPFYQLCFIPV"}, "gene-sequence": {"@format": "FASTA", "#text": ">1473 bp\nATGGATCCTTTTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTTCAATCTGG\nAGACAGAGCTCTGGGAGAGGAAAACTCCCTCCTGGCCCCACTCCTCTCCCAGTGATTGGA\nAATATCCTACAGATAGATATTAAGGATGTCAGCAAATCCTTAACCAATCTCTCAAAAATC\nTATGGCCCTGTGTTCACTCTGTATTTTGGCCTGGAACGCATGGTGGTGCTGCATGGATAT\nGAAGTGGTGAAGGAAGCCCTGATTGATCTTGGAGAGGAGTTTTCTGGAAGAGGCCATTTC\nCCACTGGCTGAAAGAGCTAACAGAGGATTTGGAATCGTTTTCAGCAATGGAAAGAGATGG\nAAGGAGATCCGGCGTTTCTCCCTCATGACGCTGCGGAATTTTGGGATGGGGAAGAGGAGC\nATTGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAAG\nGCTTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC\nATTATTTTCCAGAAACGTTTCGATTATAAAGATCAGCAATTTCTTAACTTGATGGAAAAA\nTTGAATGAAAACATCAGGATTGTAAGCACCCCCTGGATCCAGATATGCAATAATTTTCCC\nACTATCATTGATTATTTCCCGGGAACCCATAACAAATTACTTAAAAACCTTGCTTTTATG\nGAAAGTGATATTTTGGAGAAAGTAAAAGAACACCAAGAATCGATGGACATCAACAACCCT\nCGGGACTTTATTGATTGCTTCCTGATCAAAATGGAGAAGGAAAAGCAAAACCAACAGTCT\nGAATTCACTATTGAAAACTTGGTAATCACTGCAGCTGACTTACTTGGAGCTGGGACAGAG\nACAACAAGCACAACCCTGAGATATGCTCTCCTTCTCCTGCTGAAGCACCCAGAGGTCACA\nGCTAAAGTCCAGGAAGAGATTGAACGTGTCATTGGCAGAAACCGGAGCCCCTGCATGCAG\nGACAGGGGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGAGATACATCGAC\nCTCATCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACGTTAAATTCAGAAACTACCTC\nATTCCCAAGGGCACAACCATATTAACTTCCCTCACTTCTGTGCTACATGACAACAAAGAA\nTTTCCCAACCCAGAGATGTTTGACCCTCGTCACTTTCTGGATGAAGGTGGAAATTTTAAG\nAAAAGTAACTACTTCATGCCTTTCTCAGCAGGAAAACGGATTTGTGTGGGAGAGGGCCTG\nGCCCGCATGGAGCTGTTTTTATTCCTGACCTTCATTTTACAGAACTTTAACCTGAAATCT\nCTGATTGACCCAAAGGACCTTGACACAACTCCTGTTGTCAATGGATTTGCTTCTGTCCCG\nCCCTTCTATCAGCTGTGCTTCATTCCTGTCTGA"}, "pfams": {"pfam": {"identifier": "PF00067", "name": "p450"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "iron ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "tetrapyrrole binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "heme binding"}, {"category": "function", "description": "monooxygenase activity"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "generation of precursor metabolites and energy"}, {"category": "process", "description": "electron transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}, {"@position": "17", "id": "BE0002887", "name": "Cytochrome P450 2C8", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19934256", "known-action": "unknown", "polypeptide": {"@id": "P10632", "@source": "Swiss-Prot", "name": "Cytochrome P450 2C8", "general-function": "Involved in monooxygenase activity", "specific-function": "Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme responsible for the metabolism the anti- cancer drug paclitaxel (taxol)", "gene-name": "CYP2C8", "locus": "10q23.33", "cellular-location": "Endoplasmic reticulum", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.62", "molecular-weight": "55825.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2622"}, {"resource": "GenAtlas", "identifier": "CYP2C8"}, {"resource": "GenBank Gene Database", "identifier": "M17397"}, {"resource": "UniProtKB", "identifier": "P10632"}, {"resource": "UniProt Accession", "identifier": "CP2C8_HUMAN"}]}, "synonyms": {"synonym": ["CYPIIC8", "EC 1.14.14.1", "P450 form 1", "P450 IIC2", "P450 MP- 12/MP-20", "S-mephenytoin 4-hydroxylase"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytochrome P450 2C8\nMEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDICKSFTNFSKV\nYGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNGKRW\nKEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICS\nVVFQKRFDYKDQNFLTLMKRFNENFRILNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALT\nRSYIREKVKEHQASLDVNNPRDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFVAGTE\nTTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSD\nLVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDKEFPNPNIFDPGHFLDKNGNFK\nKSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIVSLP\nPSYQICFIPV"}, "gene-sequence": {"@format": "FASTA", "#text": ">1473 bp\nATGGAACCTTTTGTGGTCCTGGTGCTGTGTCTCTCTTTTATGCTTCTCTTTTCACTCTGG\nAGACAGAGCTGTAGGAGAAGGAAGCTCCCTCCTGGCCCCACTCCTCTTCCTATTATTGGA\nAATATGCTACAGATAGATGTTAAGGACATCTGCAAATCTTTCACCAATTTCTCAAAAGTC\nTATGGTCCTGTGTTCACCGTGTATTTTGGCATGAATCCCATAGTGGTGTTTCATGGATAT\nGAGGCAGTGAAGGAAGCCCTGATTGATAATGGAGAGGAGTTTTCTGGAAGAGGCAATTCC\nCCAATATCTCAAAGAATTACTAAAGGACTTGGAATCATTTCCAGCAATGGAAAGAGATGG\nAAGGAGATCCGGCGTTTCTCCCTCACAAACTTGCGGAATTTTGGGATGGGGAAGAGGAGC\nATTGAGGACCGTGTTCAAGAGGAAGCTCACTGCCTTGTGGAGGAGTTGAGAAAAACCAAG\nGCTTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC\nGTTGTTTTCCAGAAACGATTTGATTATAAAGATCAGAATTTTCTCACCCTGATGAAAAGA\nTTCAATGAAAACTTCAGGATTCTGAACTCCCCATGGATCCAGGTCTGCAATAATTTCCCT\nCTACTCATTGATTGTTTCCCAGGAACTCACAACAAAGTGCTTAAAAATGTTGCTCTTACA\nCGAAGTTACATTAGGGAGAAAGTAAAAGAACACCAAGCATCACTGGATGTTAACAATCCT\nCGGGACTTTATGGATTGCTTCCTGATCAAAATGGAGCAGGAAAAGGACAACCAAAAGTCA\nGAATTCAATATTGAAAACTTGGTTGGCACTGTAGCTGATCTATTTGTTGCTGGAACAGAG\nACAACAAGCACCACTCTGAGATATGGACTCCTGCTCCTGCTGAAGCACCCAGAGGTCACA\nGCTAAAGTCCAGGAAGAGATTGATCATGTAATTGGCAGACACAGGAGCCCCTGCATGCAG\nGATAGGAGCCACATGCCTTACACTGATGCTGTAGTGCACGAGATCCAGAGATACAGTGAC\nCTTGTCCCCACCGGTGTGCCCCATGCAGTGACCACTGATACTAAGTTCAGAAACTACCTC\nATCCCCAAGGGCACAACCATAATGGCATTACTGACTTCCGTGCTACATGATGACAAAGAA\nTTTCCTAATCCAAATATCTTTGACCCTGGCCACTTTCTAGATAAGAATGGCAACTTTAAG\nAAAAGTGACTACTTCATGCCTTTCTCAGCAGGAAAACGAATTTGTGCAGGAGAAGGACTT\nGCCCGCATGGAGCTATTTTTATTTCTAACCACAATTTTACAGAACTTTAACCTGAAATCT\nGTTGATGATTTAAAGAACCTCAATACTACTGCAGTTACCAAAGGGATTGTTTCTCTGCCA\nCCCTCATACCAGATCTGCTTCATCCCTGTCTGA"}, "pfams": {"pfam": {"identifier": "PF00067", "name": "p450"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "iron ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "tetrapyrrole binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "heme binding"}, {"category": "function", "description": "monooxygenase activity"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "generation of precursor metabolites and energy"}, {"category": "process", "description": "electron transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}, {"@position": "18", "id": "BE0002793", "name": "Cytochrome P450 2C9", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19934256\n# Lexicomp", "known-action": "unknown", "polypeptide": {"@id": "P11712", "@source": "Swiss-Prot", "name": "Cytochrome P450 2C9", "general-function": "Involved in monooxygenase activity", "specific-function": "Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S- warfarin, diclofenac, phenytoin, tolbutamide and losartan", "gene-name": "CYP2C9", "locus": "10q24", "cellular-location": "Endoplasmic reticulum", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.99", "molecular-weight": "55629.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2623"}, {"resource": "GenAtlas", "identifier": "CYP2C9"}, {"resource": "GenBank Gene Database", "identifier": "AY341248"}, {"resource": "UniProtKB", "identifier": "P11712"}, {"resource": "UniProt Accession", "identifier": "CP2C9_HUMAN"}]}, "synonyms": {"synonym": ["(R)-limonene 6-monooxygenase", "(S)- limonene 7-monooxygenase", "(S)-limonene 6-monooxygenase", "CYPIIC9", "EC 1.14.13.48", "EC 1.14.13.49", "EC 1.14.13.80", "P-450MP", "P450 MP-4/MP-8", "P450 PB-1", "S- mephenytoin 4-hydroxylase"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytochrome P450 2C9\nMDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV\nYGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW\nKEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS\nIIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM\nKSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE\nTTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID\nLLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK\nKSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP\nPFYQLCFIPV"}, "gene-sequence": {"@format": "FASTA", "#text": ">1473 bp\nATGGATTCTCTTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTTCACTCTGG\nAGACAGAGCTCTGGGAGAGGAAAACTCCCTCCTGGCCCCACTCCTCTCCCAGTGATTGGA\nAATATCCTACAGATAGGTATTAAGGACATCAGCAAATCCTTAACCAATCTCTCAAAGGTC\nTATGGCCCTGTGTTCACTCTGTATTTTGGCCTGAAACCCATAGTGGTGCTGCATGGATAT\nGAAGCAGTGAAGGAAGCCCTGATTGATCTTGGAGAGGAGTTTTCTGGAAGAGGCATTTTC\nCCACTGGCTGAAAGAGCTAACAGAGGATTTGGAATTGTTTTCAGCAATGGAAAGAAATGG\nAAGGAGATCCGGCGTTTCTCCCTCATGACGCTGCGGAATTTTGGGATGGGGAAGAGGAGC\nATTGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAAG\nGCCTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC\nATTATTTTCCATAAACGTTTTGATTATAAAGATCAGCAATTTCTTAACTTAATGGAAAAG\nTTGAATGAAAACATCAAGATTTTGAGCAGCCCCTGGATCCAGATCTGCAATAATTTTTCT\nCCTATCATTGATTACTTCCCGGGAACTCACAACAAATTACTTAAAAACGTTGCTTTTATG\nAAAAGTTATATTTTGGAAAAAGTAAAAGAACACCAAGAATCAATGGACATGAACAACCCT\nCAGGACTTTATTGATTGCTTCCTGATGAAAATGGAGAAGGAAAAGCACAACCAACCATCT\nGAATTTACTATTGAAAGCTTGGAAAACACTGCAGTTGACTTGTTTGGAGCTGGGACAGAG\nACGACAAGCACAACCCTGAGATATGCTCTCCTTCTCCTGCTGAAGCACCCAGAGGTCACA\nGCTAAAGTCCAGGAAGAGATTGAACGTGTGATTGGCAGAAACCGGAGCCCCTGCATGCAA\nGACAGGAGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGAGATACATTGAC\nCTTCTCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACATTAAATTCAGAAACTATCTC\nATTCCCAAGGGCACAACCATATTAATTTCCCTGACTTCTGTGCTACATGACAACAAAGAA\nTTTCCCAACCCAGAGATGTTTGACCCTCATCACTTTCTGGATGAAGGTGGCAATTTTAAG\nAAAAGTAAATACTTCATGCCTTTCTCAGCAGGAAAACGGATTTGTGTGGGAGAAGCCCTG\nGCCGGCATGGAGCTGTTTTTATTCCTGACCTCCATTTTACAGAACTTTAACCTGAAATCT\nCTGGTTGACCCAAAGAACCTTGACACCACTCCAGTTGTCAATGGATTTGCCTCTGTGCCG\nCCCTTCTACCAGCTGTGCTTCATTCCTGTCTGA"}, "pfams": {"pfam": {"identifier": "PF00067", "name": "p450"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "iron ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "tetrapyrrole binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "heme binding"}, {"category": "function", "description": "monooxygenase activity"}, {"category": "function", "description": "oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "generation of precursor metabolites and energy"}, {"category": "process", "description": "electron transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular metabolism"}]}}, "inhibition-strength": "moderate", "induction-strength": "unknown"}, {"@position": "19", "id": "BE0002363", "name": "Cytochrome P450 2D6", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19934256", "known-action": "unknown", "polypeptide": {"@id": "P10635", "@source": "Swiss-Prot", "name": "Cytochrome P450 2D6", "general-function": "Secondary metabolites biosynthesis, transport and catabolism", "specific-function": "Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants", "gene-name": "CYP2D6", "locus": "22q13.1", "cellular-location": "Endoplasmic reticulum", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.26", "molecular-weight": "55770.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2625"}, {"resource": "GenAtlas", "identifier": "CYP2D6"}, {"resource": "GeneCards", "identifier": "CYP2D6"}, {"resource": "GenBank Gene Database", "identifier": "M20403"}, {"resource": "GenBank Protein Database", "identifier": "181350"}, {"resource": "UniProtKB", "identifier": "P10635"}, {"resource": "UniProt Accession", "identifier": "CP2D6_HUMAN"}]}, "synonyms": {"synonym": ["CYPIID6", "Debrisoquine 4-hydroxylase", "EC 1.14.14.1", "P450-DB1"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Cytochrome P450 2D6\nMGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ\nLRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF\nLARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK\nAVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV\nLRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA\nDLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI\nHEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF\nLDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV\nFAFLVSPSPYELCAVPR"}, "gene-sequence": {"@format": "FASTA", "#text": ">1494 bp\nATGGGGCTAGAAGCACTGGTGCCCCTGGCCGTGATAGTGGCCATCTTCCTGCTCCTGGTG\nGACCTGATGCACCGGCGCCAACGCTGGGCTGCACGCTACCCACCAGGCCCCCTGCCACTG\nCCCGGGCTGGGCAACCTGCTGCATGTGGACTTCCAGAACACACCATACTGCTTCGACCAG\nTTGCGGCGCCGCTTCGGGGACGTGTTCAGCCTGCAGCTGGCCTGGACGCCGGTGGTCGTG\nCTCAATGGGCTGGCGGCCGTGCGCGAGGCGCTGGTGACCCACGGCGAGGACACCGCCGAC\nCGCCCGCCTGTGCCCATCACCCAGATCCTGGGTTTCGGGCCGCGTTCCCAAGGGGTGTTC\nCTGGCGCGCTATGGGCCCGCGTGGCGCGAGCAGAGGCGCTTCTCCGTGTCCACCTTGCGC\nAACTTGGGCCTGGGCAAGAAGTCGCTGGAGCAGTGGGTGACCGAGGAGGCCGCCTGCCTT\nTGTGCCGCCTTCGCCAACCACTCCGGACGCCCCTTTCGCCCCAACGGTCTCTTGGACAAA\nGCCGTGAGCAACGTGATCGCCTCCCTCACCTGCGGGCGCCGCTTCGAGTACGACGACCCT\nCGCTTCCTCAGGCTGCTGGACCTAGCTCAGGAGGGACTGAAGGAGGAGTCGGGCTTTCTG\nCGCGAGGTGCTGAATGCTGTCCCCGTCCTCCTGCATATCCCAGCGCTGGCTGGCAAGGTC\nCTACGCTTCCAAAAGGCTTTCCTGACCCAGCTGGATGAGCTGCTAACTGAGCACAGGATG\nACCTGGGACCCAGCCCAGCCCCCCCGAGACCTGACTGAGGCCTTCCTGGCAGAGATGGAG\nAAGGCCAAGGGGAACCCTGAGAGCAGCTTCAATGATGAGAACCTGCGCATAGTGGTGGCT\nGACCTGTTCTCTGCCGGGATGGTGACCACCTCGACCACGCTGGCCTGGGGCCTCCTGCTC\nATGATCCTACATCCGGATGTGCAGCGCCGTGTCCAACAGGAGATCGACGACGTGATAGGG\nCAGGTGCGGCGACCAGAGATGGGTGACCAGGCTCACATGCCCTACACCACTGCCGTGATT\nCATGAGGTGCAGCGCTTTGGGGACATCGTCCCCCTGGGTATGACCCATATGACATCCCGT\nGACATCGAAGTACAGGGCTTCCGCATCCCTAAGGGAACGACACTCATCACCAACCTGTCA\nTCGGTGCTGAAGGATGAGGCCGTCTGGGAGAAGCCCTTCCGCTTCCACCCCGAACACTTC\nCTGGATGCCCAGGGCCACTTTGTGAAGCCGGAGGCCTTCCTGCCTTTCTCAGCAGGCCGC\nCGTGCATGCCTCGGGGAGCCCCTGGCCCGCATGGAGCTCTTCCTCTTCTTCACCTCCCTG\nCTGCAGCACTTCAGCTTCTCGGTGCCCACTGGACAGCCCCGGCCCAGCCACCATGGTGTC\nTTTGCTTTCCTGGTGAGCCCATCCCCCTATGAGCTTTGTGCTGTGCCCCGCTAG"}, "pfams": {"pfam": {"identifier": "PF00067", "name": "p450"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "iron ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "tetrapyrrole binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "heme binding"}, {"category": "function", "description": "monooxygenase activity"}, {"category": "function", "description": "oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "generation of precursor metabolites and energy"}, {"category": "process", "description": "electron transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}]}, "carriers": null, "transporters": {"transporter": [{"@position": "4", "id": "BE0001032", "name": "Multidrug resistance protein 1", "organism": "Human", "actions": {"action": ["substrate", "inhibitor", "inducer"]}, "references": "# Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12387747\n# Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10820137\n# Tiberghien F, Kurome T, Takesako K, Didier A, Wenandy T, Loor F: Aureobasidins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC-transporter. J Med Chem. 2000 Jun 29;43(13):2547-56. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10891114\n# Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11405287\n# Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11716514\n# Leonessa F, Kim JH, Ghiorghis A, Kulawiec RJ, Hammer C, Talebian A, Clarke R: C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump. J Med Chem. 2002 Jan 17;45(2):390-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11784143\n# Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11961113\n# Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12134945\n# Kumar S, Kwei GY, Poon GK, Iliff SA, Wang Y, Chen Q, Franklin RB, Didolkar V, Wang RW, Yamazaki M, Chiu SH, Lin JH, Pearson PG, Baillie TA: Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein. J Pharmacol Exp Ther. 2003 Mar;304(3):1161-71. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12604693\n# Horie K, Tang F, Borchardt RT: Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res. 2003 Feb;20(2):161-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12636153\n# Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12699389\n# Atkinson DE, Greenwood SL, Sibley CP, Glazier JD, Fairbairn LJ: Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer. Am J Physiol Cell Physiol. 2003 Sep;285(3):C584-91. Epub 2003 Apr 30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12724138\n# Hamada A, Miyano H, Watanabe H, Saito H: Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther. 2003 Nov;307(2):824-8. Epub 2003 Sep 15. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12975485\n# Corea G, Fattorusso E, Lanzotti V, Taglialatela-Scafati O, Appendino G, Ballero M, Simon PN, Dumontet C, Di Pietro A: Modified jatrophane diterpenes as modulators of multidrug resistance from Euphorbia dendroides L. Bioorg Med Chem. 2003 Nov 17;11(23):5221-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14604686\n# Rao US, Scarborough GA: Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein. Mol Pharmacol. 1994 Apr;45(4):773-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7514263\n# Pouliot JF, L'Heureux F, Liu Z, Prichard RK, Georges E: Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem Pharmacol. 1997 Jan 10;53(1):17-25. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8960059\n# Kuhnel JM, Perrot JY, Faussat AM, Marie JP, Schwaller MA: Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe. Leukemia. 1997 Jul;11(7):1147-55. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9205004\n# Ito T, Yano I, Tanaka K, Inui KI: Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther. 1997 Aug;282(2):955-60. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9262363\n# Kim AE, Dintaman JM, Waddell DS, Silverman JA: Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther. 1998 Sep;286(3):1439-45. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9732409\n# Kusunoki N, Takara K, Tanigawara Y, Yamauchi A, Ueda K, Komada F, Ku Y, Kuroda Y, Saitoh Y, Okumura K: Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein. Jpn J Cancer Res. 1998 Nov;89(11):1220-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9914792\n# Golstein PE, Boom A, van Geffel J, Jacobs P, Masereel B, Beauwens R: P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch. 1999 Apr;437(5):652-60. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10087141\n# Wigler PW: PSC833, cyclosporin A, and dexniguldipine effects on cellular calcein retention and inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Biochem Biophys Res Commun. 1999 Apr 13;257(2):410-3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10198227\n# Hochman JH, Chiba M, Nishime J, Yamazaki M, Lin JH: Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J Pharmacol Exp Ther. 2000 Jan;292(1):310-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10604964\n# Asakura E, Nakayama H, Sugie M, Zhao YL, Nadai M, Kitaichi K, Shimizu A, Miyoshi M, Takagi K, Takagi K, Hasegawa T: Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats. Eur J Pharmacol. 2004 Jan 26;484(2-3):333-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14744620\n# D'Emanuele A, Jevprasesphant R, Penny J, Attwood D: The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control Release. 2004 Mar 24;95(3):447-53. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15023456\n# Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol. 2004 Dec;143(7):856-64. Epub 2004 Oct 25. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15504753\n# Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14985103\n# Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12235267\n# Kugawa F, Suzuki T, Miyata M, Tomono K, Tamanoi F: Construction of a model cell line for the assay of MDR1 (multi drug resistance gene-1) substrates/inhibitors using HeLa cells. Pharmazie. 2009 May;64(5):296-300. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19530439\n# Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. Epub 2009 Mar 25. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19319690\n# Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11602674\n# Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11785684\n# Seeballuck F, Ashford MB, O'Driscoll CM: The effects of pluronics block copolymers and Cremophor EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells. Pharm Res. 2003 Jul;20(7):1085-92. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12880295\n# Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12948019\n# Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T: Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993 Mar 25;268(9):6077-80. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7681059\n# Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C: Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol. 1996 Aug;118(7):1841-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8842452\n# Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB: Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 1997 Sep;62(3):248-60. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9333100\n# Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ: Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res. 1999 Apr;16(4):478-85. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10227700\n# Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17045309", "known-action": "unknown", "polypeptide": {"@id": "P08183", "@source": "Swiss-Prot", "name": "Multidrug resistance protein 1", "general-function": "Defense mechanisms and drug export", "specific-function": "Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells", "gene-name": "ABCB1", "locus": "7q21.1", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "52-72\n120-140\n189-209\n216-236\n297-317\n326-346\n711-731\n757-777\n833-853\n854-874\n937-957\n974-994", "signal-regions": null, "theoretical-pi": "9.44", "molecular-weight": "141464.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:40"}, {"resource": "GenAtlas", "identifier": "ABCB1"}, {"resource": "GeneCards", "identifier": "ABCB1"}, {"resource": "GenBank Gene Database", "identifier": "M14758"}, {"resource": "GenBank Protein Database", "identifier": "307180"}, {"resource": "UniProtKB", "identifier": "P08183"}, {"resource": "UniProt Accession", "identifier": "MDR1_HUMAN"}]}, "synonyms": {"synonym": ["ATP-binding cassette sub-family B member 1", "CD243 antigen", "EC 3.6.3.44", "P-glycoprotein 1"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Multidrug resistance protein 1\nMDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLYMVVGTLAAII\nHGAGLPLMMLVFGEMTDIFANAGNLEDLMSNITNRSDINDTGFFMNLEEDMTRYAYYYSG\nIGAGVLVAAYIQVSFWCLAAGRQIHKIRKQFFHAIMRQEIGWFDVHDVGELNTRLTDDVS\nKINEGIGDKIGMFFQSMATFFTGFIVGFTRGWKLTLVILAISPVLGLSAAVWAKILSSFT\nDKELLAYAKAGAVAEEVLAAIRTVIAFGGQKKELERYNKNLEEAKRIGIKKAITANISIG\nAAFLLIYASYALAFWYGTTLVLSGEYSIGQVLTVFFSVLIGAFSVGQASPSIEAFANARG\nAAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLEFRNVHFSYPSRKEVKILKGLNLKVQSG\nQTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVSQEPVLF\nATTIAENIRYGRENVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIA\nIARALVRNPKILLLDEATSALDTESEAVVQVALDKARKGRTTIVIAHRLSTVRNADVIAG\nFDDGVIVEKGNHDELMKEKGIYFKLVTMQTAGNEVELENAADESKSEIDALEMSSNDSRS\nSLIRKRSTRRSVRGSQAQDRKLSTKEALDESIPPVSFWRIMKLNLTEWPYFVVGVFCAII\nNGGLQPAFAIIFSKIIGVFTRIDDPETKRQNSNLFSLLFLALGIISFITFFLQGFTFGKA\nGEILTKRLRYMVFRSMLRQDVSWFDDPKNTTGALTTRLANDAAQVKGAIGSRLAVITQNI\nANLGTGIIISFIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGAGKIATEA\nIENFRTVVSLTQEQKFEHMYAQSLQVPYRNSLRKAHIFGITFSFTQAMMYFSYAGCFRFG\nAYLVAHKLMSFEDVLLVFSAVVFGAMAVGQVSSFAPDYAKAKISAAHIIMIIEKTPLIDS\nYSTEGLMPNTLEGNVTFGEVVFNYPTRPDIPVLQGLSLEVKKGQTLALVGSSGCGKSTVV\nQLLERFYDPLAGKVLLDGKEIKRLNVQWLRAHLGIVSQEPILFDCSIAENIAYGDNSRVV\nSQEEIVRAAKEANIHAFIESLPNKYSTKVGDKGTQLSGGQKQRIAIARALVRQPHILLLD\nEATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQL\nLAQKGIYFSMVSVQAGTKRQ"}, "gene-sequence": {"@format": "FASTA", "#text": ">3843 bp\nATGGATCTTGAAGGGGACCGCAATGGAGGAGCAAAGAAGAAGAACTTTTTTAAACTGAAC\nAATAAAAGTGAAAAAGATAAGAAGGAAAAGAAACCAACTGTCAGTGTATTTTCAATGTTT\nCGCTATTCAAATTGGCTTGACAAGTTGTATATGGTGGTGGGAACTTTGGCTGCCATCATC\nCATGGGGCTGGACTTCCTCTCATGATGCTGGTGTTTGGAGAAATGACAGATATCTTTGCA\nAATGCAGGAAATTTAGAAGATCTGATGTCAAACATCACTAATAGAAGTGATATCAATGAT\nACAGGGTTCTTCATGAATCTGGAGGAAGACATGACCAGGTATGCCTATTATTACAGTGGA\nATTGGTGCTGGGGTGCTGGTTGCTGCTTACATTCAGGTTTCATTTTGGTGCCTGGCAGCT\nGGAAGACAAATACACAAAATTAGAAAACAGTTTTTTCATGCTATAATGCGACAGGAGATA\nGGCTGGTTTGATGTGCACGATGTTGGGGAGCTTAACACCCGACTTACAGATGATGTCTCT\nAAGATTAATGAAGTTATTGGTGACAAAATTGGAATGTTCTTTCAGTCAATGGCAACATTT\nTTCACTGGGTTTATAGTAGGATTTACACGTGGTTGGAAGCTAACCCTTGTGATTTTGGCC\nATCAGTCCTGTTCTTGGACTGTCAGCTGCTGTCTGGGCAAAGATACTATCTTCATTTACT\nGATAAAGAACTCTTAGCGTATGCAAAAGCTGGAGCAGTAGCTGAAGAGGTCTTGGCAGCA\nATTAGAACTGTGATTGCATTTGGAGGACAAAAGAAAGAACTTGAAAGGTACAACAAAAAT\nTTAGAAGAAGCTAAAAGAATTGGGATAAAGAAAGCTATTACAGCCAATATTTCTATAGGT\nGCTGCTTTCCTGCTGATCTATGCATCTTATGCTCTGGCCTTCTGGTATGGGACCACCTTG\nGTCCTCTCAGGGGAATATTCTATTGGACAAGTACTCACTGTATTCTTTTCTGTATTAATT\nGGGGCTTTTAGTGTTGGACAGGCATCTCCAAGCATTGAAGCATTTGCAAATGCAAGAGGA\nGCAGCTTATGAAATCTTCAAGATAATTGATAATAAGCCAAGTATTGACAGCTATTCGAAG\nAGTGGGCACAAACCAGATAATATTAAGGGAAATTTGGAATTCAGAAATGTTCACTTCAGT\nTACCCATCTCGAAAAGAAGTTAAGATCTTGAAGGGCCTGAACCTGAAGGTGCAGAGTGGG\nCAGACGGTGGCCCTGGTTGGAAACAGTGGCTGTGGGAAGAGCACAACAGTCCAGCTGATG\nCAGAGGCTCTATGACCCCACAGAGGGGATGGTCAGTGTTGATGGACAGGATATTAGGACC\nATAAATGTAAGGTTTCTACGGGAAATCATTGGTGTGGTGAGTCAGGAACCTGTATTGTTT\nGCCACCACGATAGCTGAAAACATTCGCTATGGCCGTGAAAATGTCACCATGGATGAGATT\nGAGAAAGCTGTCAAGGAAGCCAATGCCTATGACTTTATCATGAAACTGCCTCATAAATTT\nGACACCCTGGTTGGAGAGAGAGGGGCCCAGTTGAGTGGTGGGCAGAAGCAGAGGATCGCC\nATTGCACGTGCCCTGGTTCGCAACCCCAAGATCCTCCTGCTGGATGAGGCCACGTCAGCC\nTTGGACACAGAAAGCGAAGCAGTGGTTCAGGTGGCTCTGGATAAGGCCAGAAAAGGTCGG\nACCACCATTGTGATAGCTCATCGTTTGTCTACAGTTCGTAATGCTGACGTCATCGCTGGT\nTTCGATGATGGAGTCATTGTGGAGAAAGGAAATCATGATGAACTCATGAAAGAGAAAGGC\nATTTACTTCAAACTTGTCACAATGCAGACAGCAGGAAATGAAGTTGAATTAGAAAATGCA\nGCTGATGAATCCAAAAGTGAAATTGATGCCTTGGAAATGTCTTCAAATGATTCAAGATCC\nAGTCTAATAAGAAAAAGATCAACTCGTAGGAGTGTCCGTGGATCACAAGCCCAAGACAGA\nAAGCTTAGTACCAAAGAGGCTCTGGATGAAAGTATACCTCCAGTTTCCTTTTGGAGGATT\nATGAAGCTAAATTTAACTGAATGGCCTTATTTTGTTGTTGGTGTATTTTGTGCCATTATA\nAATGGAGGCCTGCAACCAGCATTTGCAATAATATTTTCAAAGATTATAGGGGTTTTTACA\nAGAATTGATGATCCTGAAACAAAACGACAGAATAGTAACTTGTTTTCACTATTGTTTCTA\nGCCCTTGGAATTATTTCTTTTATTACATTTTTCCTTCAGGGTTTCACATTTGGCAAAGCT\nGGAGAGATCCTCACCAAGCGGCTCCGATACATGGTTTTCCGATCCATGCTCAGACAGGAT\nGTGAGTTGGTTTGATGACCCTAAAAACACCACTGGAGCATTGACTACCAGGCTCGCCAAT\nGATGCTGCTCAAGTTAAAGGGGCTATAGGTTCCAGGCTTGCTGTAATTACCCAGAATATA\nGCAAATCTTGGGACAGGAATAATTATATCCTTCATCTATGGTTGGCAACTAACACTGTTA\nCTCTTAGCAATTGTACCCATCATTGCAATAGCAGGAGTTGTTGAAATGAAAATGTTGTCT\nGGACAAGCACTGAAAGATAAGAAAGAACTAGAAGGTGCTGGGAAGATCGCTACTGAAGCA\nATAGAAAACTTCCGAACCGTTGTTTCTTTGACTCAGGAGCAGAAGTTTGAACATATGTAT\nGCTCAGAGTTTGCAGGTACCATACAGAAACTCTTTGAGGAAAGCACACATCTTTGGAATT\nACATTTTCCTTCACCCAGGCAATGATGTATTTTTCCTATGCTGGATGTTTCCGGTTTGGA\nGCCTACTTGGTGGCACATAAACTCATGAGCTTTGAGGATGTTCTGTTAGTATTTTCAGCT\nGTTGTCTTTGGTGCCATGGCCGTGGGGCAAGTCAGTTCATTTGCTCCTGACTATGCCAAA\nGCCAAAATATCAGCAGCCCACATCATCATGATCATTGAAAAAACCCCTTTGATTGACAGC\nTACAGCACGGAAGGCCTAATGCCGAACACATTGGAAGGAAATGTCACATTTGGTGAAGTT\nGTATTCAACTATCCCACCCGACCGGACATCCCAGTGCTTCAGGGACTGAGCCTGGAGGTG\nAAGAAGGGCCAGACGCTGGCTCTGGTGGGCAGCAGTGGCTGTGGGAAGAGCACAGTGGTC\nCAGCTCCTGGAGCGGTTCTACGACCCCTTGGCAGGGAAAGTGCTGCTTGATGGCAAAGAA\nATAAAGCGACTGAATGTTCAGTGGCTCCGAGCACACCTGGGCATCGTGTCCCAGGAGCCC\nATCCTGTTTGACTGCAGCATTGCTGAGAACATTGCCTATGGAGACAACAGCCGGGTGGTG\nTCACAGGAAGAGATCGTGAGGGCAGCAAAGGAGGCCAACATACATGCCTTCATCGAGTCA\nCTGCCTAATAAATATAGCACTAAAGTAGGAGACAAAGGAACTCAGCTCTCTGGTGGCCAG\nAAACAACGCATTGCCATAGCTCGTGCCCTTGTTAGACAGCCTCATATTTTGCTTTTGGAT\nGAAGCCACGTCAGCTCTGGATACAGAAAGTGAAAAGGTTGTCCAAGAAGCCCTGGACAAA\nGCCAGAGAAGGCCGCACCTGCATTGTGATTGCTCACCGCCTGTCCACCATCCAGAATGCA\nGACTTAATAGTGGTGTTTCAGAATGGCAGAGTCAAGGAGCATGGCACGCATCAGCAGCTG\nCTGGCACAGAAAGGCATCTATTTTTCAATGGTCAGTGTCCAGGCTGGAACAAAGCGCCAG\nTGA"}, "pfams": {"pfam": [{"identifier": "PF00005", "name": "ABC_tran"}, {"identifier": "PF00664", "name": "ABC_membrane"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "ATPase activity"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substances"}, {"category": "function", "description": "ATPase activity, coupled to transmembrane movement of substances"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "pyrophosphatase activity"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "nucleoside-triphosphatase activity"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "5", "id": "BE0001061", "name": "Canalicular multispecific organic anion transporter 2", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11585759", "known-action": "unknown", "polypeptide": {"@id": "O15438", "@source": "Swiss-Prot", "name": "Canalicular multispecific organic anion transporter 2", "general-function": "Defense mechanisms and drug export", "specific-function": "May act as an inducible transporter in the biliary and intestinal excretion of organic anions", "gene-name": "ABCC3", "locus": "17q22", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "33-53\n74-94\n100-120\n133-153\n172-192\n303-323\n350-370\n427-447\n451-471\n534-554\n577-597\n964-984\n1022-1042\n1086-1106\n1108-1128\n1200-1220\n1223-1243", "signal-regions": null, "theoretical-pi": "7.2", "molecular-weight": "169345.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:54"}, {"resource": "GenAtlas", "identifier": "ABCC3"}, {"resource": "GeneCards", "identifier": "ABCC3"}, {"resource": "GenBank Gene Database", "identifier": "AB010887"}, {"resource": "GenBank Protein Database", "identifier": "3132270"}, {"resource": "UniProtKB", "identifier": "O15438"}, {"resource": "UniProt Accession", "identifier": "MRP3_HUMAN"}]}, "synonyms": {"synonym": ["ATP-binding cassette sub-family C member 3", "MOAT-D", "Multi-specific organic anion transporter-D", "Multidrug resistance-associated protein 3"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Canalicular multispecific organic anion transporter 2\nMDALCGSGELGSKFWDSNLSVHTENPDLTPCFQNSLLAWVPCIYLWVALPCYLLYLRHHC\nRGYIILSHLSKLKMVLGVLLWCVSWADLFYSFHGLVHGRAPAPVFFVTPLVVGVTMLLAT\nLLIQYERLQGVQSSGVLIIFWFLCVVCAIVPFRSKILLAKAEGEISDPFRFTTFYIHFAL\nVLSALILACFREKPPFFSAKNVDPNPYPETSAGFLSRLFFWWFTKMAIYGYRHPLEEKDL\nWSLKEEDRSQMVVQQLLEAWRKQEKQTARHKASAAPGKNASGEDEVLLGARPRPRKPSFL\nKALLATFGSSFLISACFKLIQDLLSFINPQLLSILIRFISNPMAPSWWGFLVAGLMFLCS\nMMQSLILQHYYHYIFVTGVKFRTGIMGVIYRKALVITNSVKRASTVGEIVNLMSVDAQRF\nMDLAPFLNLLWSAPLQIILAIYFLWQNLGPSVLAGVAFMVLLIPLNGAVAVKMRAFQVKQ\nMKLKDSRIKLMSEILNGIKVLKLYAWEPSFLKQVEGIRQGELQLLRTAAYLHTTTTFTWM\nCSPFLVTLITLWVYVYVDPNNVLDAEKAFVSVSLFNILRLPLNMLPQLISNLTQASVSLK\nRIQQFLSQEELDPQSVERKTISPGYAITIHSGTFTWAQDLPPTLHSLDIQVPKGALVAVV\nGPVGCGKSSLVSALLGEMEKLEGKVHMKGSVAYVPQQAWIQNCTLQENVLFGKALNPKRY\nQQTLEACALLADLEMLPGGDQTEIGEKGINLSGGQRQRVSLARAVYSDADIFLLDDPLSA\nVDSHVAKHIFDHVIGPEGVLAGKTRVLVTHGISFLPQTDFIIVLADGQVSEMGPYPALLQ\nRNGSFANFLCNYAPDEDQGHLEDSWTALEGAEDKEALLIEDTLSNHTDLTDNDPVTYVVQ\nKQFMRQLSALSSDGEGQGRPVPRRHLGPSEKVQVTEAKADGALTQEEKAAIGTVELSVFW\nDYAKAVGLCTTLAICLLYVGQSAAAIGANVWLSAWTNDAMADSRQNNTSLRLGVYAALGI\nLQGFLVMLAAMAMAAGGIQAARVLHQALLHNKIRSPQSFFDTTPSGRILNCFSKDIYVVD\nEVLAPVILMLLNSFFNAISTLVVIMASTPLFTVVILPLAVLYTLVQRFYAATSRQLKRLE\nSVSRSPIYSHFSETVTGASVIRAYNRSRDFEIISDTKVDANQRSCYPYIISNRWLSIGVE\nFVGNCVVLFAALFAVIGRSSLNPGLVGLSVSYSLQVTFALNWMIRMMSDLESNIVAVERV\nKEYSKTETEAPWVVEGSRPPEGWPPRGEVEFRNYSVRYRPGLDLVLRDLSLHVHGGEKVG\nIVGRTGAGKSSMTLCLFRILEAAKGEIRIDGLNVADIGLHDLRSQLTIIPQDPILFSGTL\nRMNLDPFGSYSEEDIWWALELSHLHTFVSSQPAGLDFQCSEGGENLSVGQRQLVCLARAL\nLRKSRILVLDEATAAIDLETDNLIQATIRTQFDTCTVLTIAHRLNTIMDYTRVLVLDKGV\nVAEFDSPANLIAARGIFYGMARDAGLA"}, "gene-sequence": {"@format": "FASTA", "#text": ">4584 bp\nATGGACGCCCTGTGCGGTTCCGGGGAGCTCGGCTCCAAGTTCTGGGACTCCAACCTGTCT\nGTGCACACAGAAAACCCGGACCTCACTCCCTGCTTCCAGAACTCCCTGCTGGCCTGGGTG\nCCCTGCATCTACCTGTGGGTCGCCCTGCCCTGCTACTTGCTCTACCTGCGGCACCATTGT\nCGTGGCTACATCATCCTCTCCCACCTGTCCAAGCTCAAGATGGTCCTGGGTGTCCTGCTG\nTGGTGCGTCTCCTGGGCAGACCTTTTTTACTCCTTCCATGGCCTGGTCCATGGCCGGGCC\nCCTGCCCCTGTTTTCTTTGTCACCCCCTTGGTGGTGGGGGTCACCATGCTGCTGGCCACC\nCTGCTGATACAGTATGAGCGGCTGCAGGGCGTACAGTCTTCGGGGGTCCTCATTATCTTC\nTGGTTCCTGTGTGTGGTCTGCGCCATCGTCCCATTCCGCTCCAAGATCCTTTTAGCCAAG\nGCAGAGGGTGAGATCTCAGACCCCTTCCGCTTCACCACCTTCTACATCCACTTTGCCCTG\nGTACTCTCTGCCCTCATCTTGGCCTGCTTCAGGGAGAAACCTCCATTTTTCTCCGCAAAG\nAATGTCGACCCTAACCCCTACCCTGAGACCAGCGCTGGCTTTCTCTCCCGCCTGTTTTTC\nTGGTGGTTCACAAAGATGGCCATCTATGGCTACCGGCATCCCCTGGAGGAGAAGGACCTC\nTGGTCCCTAAAGGAAGAGGACAGATCCCAGATGGTGGTGCAGCAGCTGCTGGAGGCATGG\nAGGAAGCAGGAAAAGCAGACGGCACGACACAAGGCTTCAGCAGCACCTGGGAAAAATGCC\nTCCGGCGAGGACGAGGTGCTGCTGGGTGCCCGGCCCAGGCCCCGGAAGCCCTCCTTCCTG\nAAGGCCCTGCTGGCCACCTTCGGCTCCAGCTTCCTCATCAGTGCCTGCTTCAAGCTTATC\nCAGGACCTGCTCTCCTTCATCAATCCACAGCTGCTCAGCATCCTGATCAGGTTTATCTCC\nAACCCCATGGCCCCCTCCTGGTGGGGCTTCCTGGTGGCTGGGCTGATGTTCCTGTGCTCC\nATGATGCAGTCGCTGATCTTACAACACTATTACCACTACATCTTTGTGACTGGGGTGAAG\nTTTCGTACTGGGATCATGGGTGTCATCTACAGGAAGGCTCTGGTTATCACCAACTCAGTC\nAAACGTGCGTCCACTGTGGGGGAAATTGTCAACCTCATGTCAGTGGATGCCCAGCGCTTC\nATGGACCTTGCCCCCTTCCTCAATCTGCTGTGGTCAGCACCCCTGCAGATCATCCTGGCG\nATCTACTTCCTCTGGCAGAACCTAGGTCCCTCTGTCCTGGCTGGAGTCGCTTTCATGGTC\nTTGCTGATTCCACTCAACGGAGCTGTGGCCGTGAAGATGCGCGCCTTCCAGGTAAAGCAA\nATGAAATTGAAGGACTCGCGCATCAAGCTGATGAGTGAGATCCTGAACGGCATCAAGGTG\nCTGAAGCTGTACGCCTGGGAGCCCAGCTTCCTGAAGCAGGTGGAGGGCATCAGGCAGGGT\nGAGCTCCAGCTGCTGCGCACGGCGGCCTACCTCCACACCACAACCACCTTCACCTGGATG\nTGCAGCCCCTTCCTGGTGACCCTGATCACCCTCTGGGTGTACGTGTACGTGGACCCAAAC\nAATGTGCTGGACGCCGAGAAGGCCTATGTGTCTGTGTCCTTGTTTAATATCTTAAGACTT\nCCCCTCAACATGCTGCCCCAGTTAATCAGCAACCTGACTCAGGCCAGTGTGTCTCTGAAA\nCGGATCCAGCAATTCCTGAGCCAAGAGGAACTTGACCCCCAGAGTGTGGAAAGAAAGACC\nATCTCCCCAGGCTATGCCATCACCATACACAGTGGCACCTTCACCTGGGCCCAGGACCTG\nCCCCCCACTCTGCACAGCCTAGACATCCAGGTCCCGAAAGGGGCACTGGTGGCCGTGGTG\nGGGCCTGTGGGCTGTGGGAAGTCCTCCCTGGTGTCTGCCCTGCTGGGAGAGATGGAGAAG\nCTAGAAGGCAAAGTGCACATGAAGGGCTCCGTGGCCTATGTGCCCCAGCAGGCATGGATC\nCAGAACTGCACTCTTCAGGAAAACGTGCTTTTCGGCAAAGCCCTGAACCCCAAGCGCTAC\nCAGCAGACTCTGGAGGCCTGTGCCTTGCTAGCTGACCTGGAGATGCTGCCTGGTGGGGAT\nCAGACAGAGATTGGAGAGAAGGGCATTAACCTGTCTGGGGGCCAGCGGCAGCGGGTCAGT\nCTGGCTCGAGCTGTTTACAGTGATGCCGATATTTTCTTGCTGGATGACCCACTGTCCGCG\nGTGGACTCTCATGTGGCCAAGCACATCTTTGACCACGTCATCGGGCCAGAAGGCGTGCTG\nGCAGGCAAGACGCGAGTGCTGGTGACGCACGGCATTAGCTTCCTGCCCCAGACAGACTTC\nATCATTGTGCTAGCTGATGGACAGGTGTCTGAGATGGGCCCGTACCCAGCCCTGCTGCAG\nCGCAACGGCTCCTTTGCCAACTTTCTCTGCAACTATGCCCCCGATGAGGACCAAGGGCAC\nCTGGAGGACAGCTGGACCGCGTTGGAAGGTGCAGAGGATAAGGAGGCACTGCTGATTGAA\nGACACACTCAGCAACCACACGGATCTGACAGACAATGATCCAGTCACCTATGTGGTCCAG\nAAGCAGTTTATGAGACAGCTGAGTGCCCTGTCCTCAGATGGGGAGGGACAGGGTCGGCCT\nGTACCCCGGAGGCACCTGGGTCCATCAGAGAAGGTGCAGGTGACAGAGGCGAAGGCAGAT\nGGGGCACTGACCCAGGAGGAGAAAGCAGCCATTGGCACTGTGGAGCTCAGTGTGTTCTGG\nGATTATGCCAAGGCCGTGGGGCTCTGTACCACGCTGGCCATCTGTCTCCTGTATGTGGGT\nCAAAGTGCGGCTGCCATTGGAGCCAATGTGTGGCTCAGTGCCTGGACAAATGATGCCATG\nGCAGACAGTAGACAGAACAACACTTCCCTGAGGCTGGGCGTCTATGCTGCTTTAGGAATT\nCTGCAAGGGTTCTTGGTGATGCTGGCAGCCATGGCCATGGCAGCGGGTGGCATCCAGGCT\nGCCCGTGTGTTGCACCAGGCACTGCTGCACAACAAGATACGCTCGCCACAGTCCTTCTTT\nGACACCACACCATCAGGCCGCATCCTGAACTGCTTCTCCAAGGACATCTATGTCGTTGAT\nGAGGTTCTGGCCCCTGTCATCCTCATGCTGCTCAATTCCTTCTTCAACGCCATCTCCACT\nCTTGTGGTCATCATGGCCAGCACGCCGCTCTTCACTGTGGTCATCCTGCCCCTGGCTGTG\nCTCTACACCTTAGTGCAGCGCTTCTATGCAGCCACATCACGGCAACTGAAGCGGCTGGAA\nTCAGTCAGCCGCTCACCTATCTACTCCCACTTTTCGGAGACAGTGACTGGTGCCAGTGTC\nATCCGGGCCTACAACCGCAGCCGGGATTTTGAGATCATCAGTGATACTAAGGTGGATGCC\nAACCAGAGAAGCTGCTACCCCTACATCATCTCCAACCGGTGGCTGAGCATCGGAGTGGAG\nTTCGTGGGGAACTGCGTGGTGCTCTTTGCTGCACTATTTGCCGTCATCGGGAGGAGCAGC\nCTGAACCCGGGGCTGGTGGGCCTTTCTGTGTCCTACTCCTTGCAGGTGACATTTGCTCTG\nAACTGGATGATACGAATGATGTCAGATTTGGAATCTAACATCGTGGCTGTGGAGAGGGTC\nAAGGAGTACTCCAAGACAGAGACAGAGGCGCCCTGGGTGGTGGAAGGCAGCCGCCCTCCC\nGAAGGTTGGCCCCCACGTGGGGAGGTGGAGTTCCGGAATTATTCTGTGCGCTACCGGCCG\nGGCCTAGACCTGGTGCTGAGAGACCTGAGTCTGCATGTGCATGGTGGCGAGAAGGTGGGG\nATCGTGGGCCGCACTGGGGCTGGCAAGTCTTCCATGACCCTTTGCCTGTTCCGCATCCTG\nGAGGCGGCAAAGGGTGAAATCCGCATTGATGGCCTCAATGTGGCAGACATCGGCCTCCAT\nGACCTGCGCTCTCAGCTGACCATCATCCCGCAGGACCCCATCCTGTTCTCGGGGACCCTG\nCGCATGAACCTGGACCCCTTCGGCAGCTACTCAGAGGAGGACATTTGGTGGGCTTTGGAG\nCTGTCCCACCTGCACACGTTTGTGAGCTCCCAGCCGGCAGGCCTGGACTTCCAGTGCTCA\nGAGGGCGGGGAGAATCTCAGCGTGGGCCAGAGGCAGCTCGTGTGCCTGGCCCGAGCCCTG\nCTCCGCAAGAGCCGCATCCTGGTTTTAGACGAGGCCACAGCTGCCATCGACCTGGAGACT\nGACAACCTCATCCAGGCTACCATCCGCACCCAGTTTGATACCTGCACTGTCCTGACCATC\nGCACACCGGCTTAACACTATCATGGACTACACCAGGGTCCTGGTCCTGGACAAAGGAGTA\nGTAGCTGAGTTTGATTCTCCAGCCAACCTCATTGCAGCTAGAGGCATCTTCTACGGGATG\nGCCAGAGATGCTGGACTTGCCTAA"}, "pfams": {"pfam": [{"identifier": "PF00005", "name": "ABC_tran"}, {"identifier": "PF00664", "name": "ABC_membrane"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "nucleoside-triphosphatase activity"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "function", "description": "ATPase activity"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substances"}, {"category": "function", "description": "ATPase activity, coupled to transmembrane movement of substances"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides"}, {"category": "function", "description": "transporter activity"}, {"category": "function", "description": "pyrophosphatase activity"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "6", "id": "BE0000703", "name": "Bile salt export pump", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ: The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002 Nov;123(5):1649-58. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12404239\n# Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12739759\n# Noe J, Hagenbuch B, Meier PJ, St-Pierre MV: Characterization of the mouse bile salt export pump overexpressed in the baculovirus system. Hepatology. 2001 May;33(5):1223-31. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11343252\n# Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10617675\n# Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ: Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology. 2000 Feb;118(2):422-30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10648470\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "unknown", "polypeptide": {"@id": "O95342", "@source": "Swiss-Prot", "name": "Bile salt export pump", "general-function": "Defense mechanisms", "specific-function": "Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes", "gene-name": "ABCB11", "locus": "2q24", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "63-83\n148-168\n216-236\n241-261\n320-340\n354-374\n756-776\n795-815\n870-890\n891-911\n980-1000\n1012-1032", "signal-regions": null, "theoretical-pi": "6.52", "molecular-weight": "146395.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:42"}, {"resource": "GenAtlas", "identifier": "ABCB11"}, {"resource": "GeneCards", "identifier": "ABCB11"}, {"resource": "GenBank Gene Database", "identifier": "AF091582"}, {"resource": "GenBank Protein Database", "identifier": "3873243"}, {"resource": "UniProtKB", "identifier": "O95342"}, {"resource": "UniProt Accession", "identifier": "ABCBB_HUMAN"}]}, "synonyms": {"synonym": "ATP-binding cassette sub-family B member 11"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Bile salt export pump\nMSDSVILRSIKKFGEENDGFESDKSYNNDKKSRLQDEKKGDGVRVGFFQLFRFSSSTDIW\nLMFVGSLCAFLHGIAQPGVLLIFGTMTDVFIDYDVELQELQIPGKACVNNTIVWTNSSLN\nQNMTNGTRCGLLNIESEMIKFASYYAGIAVAVLITGYIQICFWVIAAARQIQKMRKFYFR\nRIMRMEIGWFDCNSVGELNTRFSDDINKINDAIADQMALFIQRMTSTICGFLLGFFRGWK\nLTLVIISVSPLIGIGAATIGLSVSKFTDYELKAYAKAGVVADEVISSMRTVAAFGGEKRE\nVERYEKNLVFAQRWGIRKGIVMGFFTGFVWCLIFLCYAVAFWYGSTLVLDEGEYTPGTLV\nQIFLSVIVGALNLGNASPCLEAFATGRAAATSIFETIDRKPIIDCMSEDGYKLDRIKGEI\nEFHNVTFHYPSRPEVKILNDLNMVIKPGEMTALVGPSGAGKSTALQLIQRFYDPCEGMVT\nVDGHDIRSLNIQWLRDQIGIVEQEPVLFSTTIAENIRYGREDATMEDIVQAAKEANAYNF\nIMDLPQQFDTLVGEGGGQMSGGQKQRVAIARALIRNPKILLLDMATSALDNESEAMVQEV\nLSKIQHGHTIISVAHRLSTVRAADTIIGFEHGTAVERGTHEELLERKGVYFTLVTLQSQG\nNQALNEEDIKDATEDDMLARTFSRGSYQDSLRASIRQRSKSQLSYLVHEPPLAVVDHKST\nYEEDRKDKDIPVQEEVEPAPVRRILKFSAPEWPYMLVGSVGAAVNGTVTPLYAFLFSQIL\nGTFSIPDKEEQRSQINGVCLLFVAMGCVSLFTQFLQGYAFAKSGELLTKRLRKFGFRAML\nGQDIAWFDDLRNSPGALTTRLATDASQVQGAAGSQIGMIVNSFTNVTVAMIIAFSFSWKL\nSLVILCFFPFLALSGATQTRMLTGFASRDKQALEMVGQITNEALSNIRTVAGIGKERRFI\nEALETELEKPFKTAIQKANIYGFCFAFAQCIMFIANSASYRYGGYLISNEGLHFSYVFRV\nISAVVLSATALGRAFSYTPSYAKAKISAARFFQLLDRQPPISVYNTAGEKWDNFQGKIDF\nVDCKFTYPSRPDSQVLNGLSVSISPGQTLAFVGSSGCGKSTSIQLLERFYDPDQGKVMID\nGHDSKKVNVQFLRSNIGIVSQEPVLFACSIMDNIKYGDNTKEIPMERVIAAAKQAQLHDF\nVMSLPEKYETNVGSQGSQLSRGEKQRIAIARAIVRDPKILLLDEATSALDTESEKTVQVA\nLDKAREGRTCIVIAHRLSTIQNADIIAVMAQGVVIEKGTHEELMAQKGAYYKLVTTGSPI\nS"}, "gene-sequence": {"@format": "FASTA", "#text": ">3966 bp\nATGTCTGACTCAGTAATTCTTCGAAGTATAAAGAAATTTGGAGAGGAGAATGATGGTTTT\nGAGTCAGATAAATCATATAATAATGATAAGAAATCAAGGTTACAAGATGAGAAGAAAGGT\nGATGGCGTTAGAGTTGGCTTCTTTCAATTGTTTCGGTTTTCTTCATCAACTGACATTTGG\nCTGATGTTTGTGGGAAGTTTGTGTGCATTTCTCCATGGAATAGCCCAGCCAGGCGTGCTA\nCTCATTTTTGGCACAATGACAGATGTTTTTATTGACTACGACGTTGAGTTACAAGAACTC\nCAGATTCCAGGAAAAGCATGTGTGAATAACACCATTGTATGGACTAACAGTTCCCTCAAC\nCAGAACATGACAAATGGAACACGTTGTGGGTTGCTGAACATCGAGAGCGAAATGATCAAA\nTTTGCCAGTTACTATGCTGGAATTGCTGTCGCAGTACTTATCACAGGATATATTCAAATA\nTGCTTTTGGGTCATTGCCGCAGCTCGTCAGATACAGAAAATGAGAAAATTTTACTTTAGG\nAGAATAATGAGAATGGAAATAGGGTGGTTTGACTGCAATTCAGTGGGGGAGCTGAATACA\nAGATTCTCTGATGATATTAATAAAATCAATGATGCCATAGCTGACCAAATGGCCCTTTTC\nATTCAGCGCATGACCTCGACCATCTGTGGTTTCCTGTTGGGATTTTTCAGGGGTTGGAAA\nCTGACCTTGGTTATTATTTCTGTCAGCCCTCTCATTGGGATTGGAGCAGCCACCATTGGT\nCTGAGTGTGTCCAAGTTTACGGACTATGAGCTGAAGGCCTATGCCAAAGCAGGGGTGGTG\nGCTGATGAAGTCATTTCATCAATGAGAACAGTGGCTGCTTTTGGTGGTGAGAAAAGAGAG\nGTTGAAAGGTATGAGAAAAATCTTGTGTTCGCCCAGCGTTGGGGAATTAGAAAAGGAATA\nGTGATGGGATTCTTTACTGGATTCGTGTGGTGTCTCATCTTTTTGTGTTATGCAGTGGCC\nTTCTGGTACGGCTCCACACTTGTCCTGGATGAAGGAGAATATACACCAGGAACCCTTGTC\nCAGATTTTCCTCAGTGTCATAGTAGGAGCTTTAAATCTTGGCAATGCCTCTCCTTGTTTG\nGAAGCCTTTGCAACTGGACGTGCAGCAGCCACCAGCATTTTTGAGACAATAGACAGGAAA\nCCCATCATTGACTGCATGTCAGAAGATGGTTACAAGTTGGATCGAATCAAGGGTGAAATT\nGAATTCCATAATGTGACCTTCCATTATCCTTCCAGACCAGAGGTGAAGATTCTAAATGAC\nCTCAACATGGTCATTAAACCAGGGGAAATGACAGCTCTGGTAGGACCCAGTGGAGCTGGA\nAAAAGTACAGCACTGCAACTCATTCAGCGATTCTATGACCCCTGTGAAGGAATGGTGACC\nGTGGATGGCCATGACATTCGCTCTCTTAACATTCAGTGGCTTAGAGATCAGATTGGGATA\nGTGGAGCAAGAGCCAGTTCTGTTCTCTACCACCATTGCAGAAAATATTCGCTATGGCAGA\nGAAGATGCAACAATGGAAGACATAGTCCAAGCTGCCAAGGAGGCCAATGCCTACAACTTC\nATCATGGACCTGCCACAGCAATTTGACACCCTTGTTGGAGAAGGAGGAGGCCAGATGAGT\nGGTGGCCAGAAACAAAGGGTAGCTATCGCCAGAGCCCTCATCCGAAATCCCAAGATTCTG\nCTTTTGGACATGGCCACCTCAGCTCTGGACAATGAGAGTGAAGCCATGGTGCAAGAAGTG\nCTGAGTAAGATTCAGCATGGGCACACAATCATTTCAGTTGCTCATCGCTTGTCTACGGTC\nAGAGCTGCAGATACCATCATTGGTTTTGAACATGGCACTGCAGTGGAAAGAGGGACCCAT\nGAAGAATTACTGGAAAGGAAAGGTGTTTACTTCACTCTAGTGACTTTGCAAAGCCAGGGA\nAATCAAGCTCTTAATGAAGAGGACATAAAGGATGCAACTGAAGATGACATGCTTGCGAGG\nACCTTTAGCAGAGGGAGCTACCAGGATAGTTTAAGGGCTTCCATCCGGCAACGCTCCAAG\nTCTCAGCTTTCTTACCTGGTGCACGAACCTCCATTAGCTGTTGTAGATCATAAGTCTACC\nTATGAAGAAGATAGAAAGGACAAGGACATTCCTGTGCAGGAAGAAGTTGAACCTGCCCCA\nGTTAGGAGGATTCTGAAATTCAGTGCTCCAGAATGGCCCTACATGCTGGTAGGGTCTGTG\nGGTGCAGCTGTGAACGGGACAGTCACACCCTTGTATGCCTTTTTATTCAGCCAGATTCTT\nGGGACTTTTTCAATTCCTGATAAAGAGGAACAAAGGTCACAGATCAATGGTGTGTGCCTA\nCTTTTTGTAGCAATGGGCTGTGTATCTCTTTTCACCCAATTTCTACAGGGATATGCCTTT\nGCTAAATCTGGGGAGCTCCTAACAAAAAGGCTACGTAAATTTGGTTTCAGGGCAATGCTG\nGGGCAAGATATTGCCTGGTTTGATGACCTCAGAAATAGCCCTGGAGCATTGACAACAAGA\nCTTGCTACAGATGCTTCCCAAGTTCAAGGGGCTGCCGGCTCTCAGATCGGGATGATAGTC\nAATTCCTTCACTAACGTCACTGTGGCCATGATCATTGCCTTCTCCTTTAGCTGGAAGCTG\nAGCCTGGTCATCTTGTGCTTCTTCCCCTTCTTGGCTTTATCAGGAGCCACACAGACCAGG\nATGTTGACAGGATTTGCCTCTCGAGATAAGCAGGCCCTGGAGATGGTGGGACAGATTACA\nAATGAAGCCCTCAGTAACATCCGCACTGTTGCTGGAATTGGAAAGGAGAGGCGGTTCATT\nGAAGCACTTGAGACTGAGCTGGAGAAGCCCTTCAAGACAGCCATTCAGAAAGCCAATATT\nTACGGATTCTGCTTTGCCTTTGCCCAGTGCATCATGTTTATTGCGAATTCTGCTTCCTAC\nAGATATGGAGGTTACTTAATCTCCAATGAGGGGCTCCATTTCAGCTATGTGTTCAGGGTG\nATCTCTGCAGTTGTACTGAGTGCAACAGCTCTTGGAAGAGCCTTCTCTTACACCCCAAGT\nTATGCAAAAGCTAAAATATCAGCTGCACGCTTTTTTCAACTGCTGGACCGACAACCCCCA\nATCAGTGTATACAATACTGCAGGTGAAAAATGGGACAACTTCCAGGGGAAGATTGATTTT\nGTTGATTGTAAATTTACATATCCTTCTCGACCTGACTCGCAAGTTCTGAATGGTCTCTCA\nGTGTCGATTAGTCCAGGGCAGACACTGGCGTTTGTTGGGAGCAGTGGATGTGGCAAAAGC\nACTAGCATTCAGCTGTTGGAACGTTTCTATGATCCTGATCAAGGGAAGGTGATGATAGAT\nGGTCATGACAGCAAAAAAGTAAATGTCCAGTTCCTCCGCTCAAACATTGGAATTGTTTCC\nCAGGAACCAGTGTTGTTTGCCTGTAGCATAATGGACAATATCAAGTATGGAGACAACACC\nAAAGAAATTCCCATGGAAAGAGTCATAGCAGCTGCAAAACAGGCTCAGCTGCATGATTTT\nGTCATGTCACTCCCAGAGAAATATGAAACTAACGTTGGGTCCCAGGGGTCTCAACTCTCT\nAGAGGGGAGAAACAACGCATTGCTATTGCTCGGGCCATTGTACGAGATCCTAAAATCTTG\nCTACTAGATGAAGCCACTTCTGCCTTAGACACAGAAAGTGAAAAGACGGTGCAGGTTGCT\nCTAGACAAAGCCAGAGAGGGTCGGACCTGCATTGTCATTGCCCATCGCTTGTCCACCATC\nCAGAACGCGGATATCATTGCTGTCATGGCACAGGGGGTGGTGATTGAAAAGGGGACCCAT\nGAAGAACTGATGGCCCAAAAAGGAGCCTACTACAAACTAGTCACCACTGGATCCCCCATC\nAGTTGA"}, "pfams": {"pfam": [{"identifier": "PF00005", "name": "ABC_tran"}, {"identifier": "PF00664", "name": "ABC_membrane"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "ATPase activity"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substances"}, {"category": "function", "description": "ATPase activity, coupled to transmembrane movement of substances"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "pyrophosphatase activity"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "nucleoside-triphosphatase activity"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "7", "id": "BE0000785", "name": "Multidrug resistance-associated protein 1", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Pec MK, Aguirre A, Fernandez JJ, Souto ML, Dorta JF, Villar J: Dehydrothyrsiferol does not modulate multidrug resistance-associated protein 1 resistance: a functional screening system for MRP1 substrates. Int J Mol Med. 2002 Nov;10(5):605-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12373300\n# Leier I, Jedlitschky G, Buchholz U, Cole SP, Deeley RG, Keppler D: The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem. 1994 Nov 11;269(45):27807-10. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7961706", "known-action": "unknown", "polypeptide": {"@id": "P33527", "@source": "Swiss-Prot", "name": "Multidrug resistance-associated protein 1", "general-function": "Drug defense mechanisms", "specific-function": "May participate directly in the active transport of drugs into subcellular organelles or influence drug distribution indirectly. Confers resistance to anticancer drugs. Transports LTC4. May protect milk against xenobiotics", "gene-name": "ABCC1", "locus": "16p13.1", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "34-54\n75-95\n101-121\n134-154\n173-193\n317-337\n364-384\n441-461\n465-485\n548-568\n591-611\n968-988\n1026-1046\n1090-1110\n1112-1132\n1204-1224\n1227-1247", "signal-regions": null, "theoretical-pi": "7.11", "molecular-weight": "171563.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:51"}, {"resource": "GenAtlas", "identifier": "ABCC1"}, {"resource": "GeneCards", "identifier": "ABCC1"}, {"resource": "GenBank Gene Database", "identifier": "L05628"}, {"resource": "GenBank Protein Database", "identifier": "1835659"}, {"resource": "UniProtKB", "identifier": "P33527"}, {"resource": "UniProt Accession", "identifier": "MRP1_HUMAN"}]}, "synonyms": {"synonym": ["ATP-binding cassette sub- family C member 1", "Leukotriene C(4", "LTC4 transporter"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Multidrug resistance-associated protein 1\nMALRGFCSADGSDPLWDWNVTWNTSNPDFTKCFQNTVLVWVPCFYLWACFPFYFLYLSRH\nDRGYIQMTPLNKTKTALGFLLWIVCWADLFYSFWERSRGIFLAPVFLVSPTLLGITTLLA\nTFLIQLERRKGVQSSGIMLTFWLVALVCALAILRSKIMTALKEDAQVDLFRDITFYVYFS\nLLLIQLVLSCFSDRSPLFSETIHDPNPCPESSASFLSRITFWWITGLIVRGYRQPLEGSD\nLWSLNKEDTSEQVVPVLVKNWKKECAKTRKQPVKVVYSSKDPAQPKESSKVDANEEVEAL\nIVKSPQKEWNPSLFKVLYKTFGPYFLMSFFFKAIHDLMMFSGPQILKLLIKFVNDTKAPD\nWQGYFYTVLLFVTACLQTLVLHQYFHICFVSGMRIKTAVIGAVYRKALVITNSARKSSTV\nGEIVNLMSVDAQRFMDLATYINMIWSAPLQVILALYLLWLNLGPSVLAGVAVMVLMVPVN\nAVMAMKTKTYQVAHMKSKDNRIKLMNEILNGIKVLKLYAWELAFKDKVLAIRQEELKVLK\nKSAYLSAVGTFTWVCTPFLVALCTFAVYVTIDENNILDAQTAFVSLALFNILRFPLNILP\nMVISSIVQASVSLKRLRIFLSHEELEPDSIERRPVKDGGGTNSITVRNATFTWARSDPPT\nLNGITFSIPEGALVAVVGQVGCGKSSLLSALLAEMDKVEGHVAIKGSVAYVPQQAWIQND\nSLRENILFGCQLEEPYYRSVIQACALLPDLEILPSGDRTEIGEKGVNLSGGQKQRVSLAR\nAVYSNADIYLFDDPLSAVDAHVGKHIFENVIGPKGMLKNKTRILVTHSMSYLPQVDVIIV\nMSGGKISEMGSYQELLARDGAFAEFLRTYASTEQEQDAEENGVTGVSGPGKEAKQMENGM\nLVTDSAGKQLQRQLSSSSSYSGDISRHHNSTAELQKAEAKKEETWKLMEADKAQTGQVKL\nSVYWDYMKAIGLFISFLSIFLFMCNHVSALASNYWLSLWTDDPIVNGTQEHTKVRLSVYG\nALGISQGIAVFGYSMAVSIGGILASRCLHVDLLHSILRSPMSFFERTPSGNLVNRFSKEL\nDTVDSMIPEVIKMFMGSLFNVIGACIVILLATPIAAIIIPPLGLIYFFVQRFYVASSRQL\nKRLESVSRSPVYSHFNETLLGVSVIRAFEEQERFIHQSDLKVDENQKAYYPSIVANRWLA\nVRLECVGNCIVLFAALFAVISRHSLSAGLVGLSVSYSLQVTTYLNWLVRMSSEMETNIVA\nVERLKEYSETEKEAPWQIQETAPPSSWPQVGRVEFRNYCLRYREDLDFVLRHINVTINGG\nEKVGIVGRTGAGKSSLTLGLFRINESAEGEIIIDGINIAKIGLHDLRFKITIIPQDPVLF\nSGSLRMNLDPFSQYSDEEVWTSLELAHLKDFVSALPDKLDHECAEGGENLSVGQRQLVCL\nARALLRKTKILVLDEATAAVDLETDDLIQSTIRTQFEDCTVLTIAHRLNTIMDYTRVIVL\nDKGEIQEYGAPSDLLQQRGLFYSMAKDAGLV"}, "gene-sequence": {"@format": "FASTA", "#text": ">4596 bp\nATGGCGCTCCGGGGCTTCTGCAGCGCCGATGGCTCCGACCCGCTCTGGGACTGGAATGTC\nACGTGGAATACCAGCAACCCCGACTTCACCAAGTGCTTTCAGAACACGGTCCTCGTGTGG\nGTGCCTTGTTTTTACCTCTGGGCCTGTTTCCCCTTCTACTTCCTCTATCTCTCCCGACAT\nGACCGAGGCTACATTCAGATGACACCTCTCAACAAAACCAAAACTGCCTTGGGATTTTTG\nCTGTGGATCGTCTGCTGGGCAGACCTCTTCTACTCTTTCTGGGAAAGAAGTCGGGGCATA\nTTCCTGGCCCCAGTGTTTCTGGTCAGCCCAACTCTCTTGGGCATCACCACGCTGCTTGCT\nACCTTTTTAATTCAGCTGGAGAGGAGGAAGGGAGTTCAGTCTTCAGGGATCATGCTCACT\nTTCTGGCTGGTAGCCCTAGTGTGTGCCCTAGCCATCCTGAGATCCAAAATTATGACAGCC\nTTAAAAGAGGATGCCCAGGTGGACCTGTTTCGTGACATCACTTTCTACGTCTACTTTTCC\nCTCTTACTCATTCAGCTCGTCTTGTCCTGTTTCTCAGATCGCTCACCCCTGTTCTCGGAA\nACCATCCACGACCCTAATCCCTGCCCAGAGTCCAGCGCTTCCTTCCTGTCGAGGATCACC\nTTCTGGTGGATCACAGGGTTGATTGTCCGGGGCTACCGCCAGCCCCTGGAGGGCAGTGAC\nCTCTGGTCCTTAAACAAGGAGGACACGTCGGAACAAGTCGTGCCTGTTTTGGTAAAGAAC\nTGGAAGAAGGAATGCGCCAAGACTAGGAAGCAGCCGGTGAAGGTTGTGTACTCCTCCAAG\nGATCCTGCCCAGCCGAAAGAGAGTTCCAAGGTGGATGCGAATGAGGAGGTGGAGGCTTTG\nATCGTCAAGTCCCCACAGAAGGAGTGGAACCCCTCTCTGTTTAAGGTGTTATACAAGACC\nTTTGGGCCCTACTTCCTCATGAGCTTCTTCTTCAAGGCCATCCACGACCTGATGATGTTT\nTCCGGGCCGCAGATCTTAAAGTTGCTCATCAAGTTCGTGAATGACACGAAGGCCCCAGAC\nTGGCAGGGCTACTTCTACACCGTGCTGCTGTTTGTCACTGCCTGCCTGCAGACCCTCGTG\nCTGCACCAGTACTTCCACATCTGCTTCGTCAGTGGCATGAGGATCAAGACCGCTGTCATT\nGGGGCTGTCTATCGGAAGGCCCTGGTGATCACCAATTCAGCCAGAAAATCCTCCACGGTC\nGGGGAGATTGTCAACCTCATGTCTGTGGACGCTCAGAGGTTCATGGACTTGGCCACGTAC\nATTAACATGATCTGGTCAGCCCCCCTGCAAGTCATCCTTGCTCTCTACCTCCTGTGGCTG\nAATCTGGGCCCTTCCGTCCTGGCTGGAGTGGCGGTGATGGTCCTCATGGTGCCCGTCAAT\nGCTGTGATGGCGATGAAGACCAAGACGTATCAGGTGGCCCACATGAAGAGCAAAGACAAT\nCGGATCAAGCTGATGAACGAAATTCTCAATGGGATCAAAGTGCTAAAGCTTTATGCCTGG\nGAGCTGGCATTCAAGGACAAGGTGCTGGCCATCAGGCAGGAGGAGCTGAAGGTGCTGAAG\nAAGTCTGCCTACCTGTCAGCCGTGGGCACCTTCACCTGGGTCTGCACGCCCTTTCTGGTG\nGCCTTGTGCACATTTGCCGTCTACGTGACCATTGACGAGAACAACATCCTGGATGCCCAG\nACAGCCTTCGTGTCTTTGGCCTTGTTCAACATCCTCCGGTTTCCCCTGAACATTCTCCCC\nATGGTCATCAGCAGCATCGTGCAGGCGAGTGTCTCCCTCAAACGCCTGAGGATCTTTCTC\nTCCCATGAGGAGCTGGAACCTGACAGCATCGAGCGACGGCCTGTCAAAGACGGCGGGGGC\nACGAACAGCATCACCGTGAGGAATGCCACATTCACCTGGGCCAGGAGCGACCCTCCCACA\nCTGAATGGCATCACCTTCTCCATCCCCGAAGGTGCTTTGGTGGCCGTGGTGGGCCAGGTG\nGGCTGCGGAAAGTCGTCCCTGCTCTCAGCCCTCTTGGCTGAGATGGACAAAGTGGAGGGG\nCACGTGGCTATCAAGGGCTCCGTGGCCTATGTGCCACAGCAGGCCTGGATTCAGAATGAT\nTCTCTCCGAGAAAACATCCTTTTTGGATGTCAGCTGGAGGAACCATATTACAGGTCCGTG\nATACAGGCCTGTGCCCTCCTCCCAGACCTGGAAATCCTGCCCAGTGGGGATCGGACAGAG\nATTGGCGAGAAGGGCGTGAACCTGTCTGGGGGCCAGAAGCAGCGCGTGAGCCTGGCCCGG\nGCCGTGTACTCCAACGCTGACATTTACCTCTTCGATGATCCCCTCTCAGCAGTGGATGCC\nCATGTGGGAAAACACATCTTTGAAAATGTGATTGGCCCCAAGGGGATGCTGAAGAACAAG\nACGCGGATCTTGGTCACGCACAGCATGAGCTACTTGCCGCAGGTGGACGTCATCATCGTC\nATGAGTGGCGGCAAGATCTCTGAGATGGGCTCCTACCAGGAGCTGCTGGCTCGAGACGGC\nGCCTTCGCTGAGTTCCTGCGTACCTATGCCAGCACAGAGCAGGAGCAGGATGCAGAGGAG\nAACGGGGTCACGGGCGTCAGCGGTCCAGGGAAGGAAGCAAAGCAAATGGAGAATGGCATG\nCTGGTGACGGACAGTGCAGGGAAGCAACTGCAGAGACAGCTCAGCAGCTCCTCCTCCTAT\nAGTGGGGACATCAGCAGGCACCACAACAGCACCGCAGAACTGCAGAAAGCTGAGGCCAAG\nAAGGAGGAGACCTGGAAGCTGATGGAGGCTGACAAGGCGCAGACAGGGCAGGTCAAGCTT\nTCCGTGTACTGGGACTACATGAAGGCCATCGGACTCTTCATCTCCTTCCTCAGCATCTTC\nCTTTTCATGTGTAACCATGTGTCCGCGCTGGCTTCCAACTATTGGCTCAGCCTCTGGACT\nGATGACCCCATCGTCAACGGGACTCAGGAGCACACGAAAGTCCGGCTGAGCGTCTATGGA\nGCCCTGGGCATTTCACAAGGGATCGCCGTGTTTGGCTACTCCATGGCCGTGTCCATCGGG\nGGGATCTTGGCTTCCCGCTGTCTGCACGTGGACCTGCTGCACAGCATCCTGCGGTCACCC\nATGAGCTTCTTTGAGCGGACCCCCAGTGGGAACCTGGTGAACCGCTTCTCCAAGGAGCTG\nGACACAGTGGACTCCATGATCCCGGAGGTCATCAAGATGTTCATGGGCTCCCTGTTCAAC\nGTCATTGGTGCCTGCATCGTTATCCTGCTGGCCACGCCCATCGCCGCCATCATCATCCCG\nCCCCTTGGCCTCATCTACTTCTTCGTCCAGAGGTTCTACGTGGCTTCCTCCCGGCAGCTG\nAAGCGCCTCGAGTCGGTCAGCCGCTCCCCGGTCTATTCCCATTTCAACGAGACCTTGCTG\nGGGGTCAGCGTCATTCGAGCCTTCGAGGAGCAGGAGCGCTTCATCCACCAGAGTGACCTG\nAAGGTGGACGAGAACCAGAAGGCCTATTACCCCAGCATCGTGGCCAACAGGTGGCTGGCC\nGTGCGGCTGGAGTGTGTGGGCAACTGCATCGTTCTGTTTGCTGCCCTGTTTGCGGTGATC\nTCCAGGCACAGCCTCAGTGCTGGCTTGGTGGGCCTCTCAGTGTCTTACTCATTGCAGGTC\nACCACGTACTTGAACTGGCTGGTTCGGATGTCATCTGAAATGGAAACCAACATCGTGGCC\nGTGGAGAGGCTCAAGGAGTATTCAGAGACTGAGAAGGAGGCGCCCTGGCAAATCCAGGAG\nACAGCTCCGCCCAGCAGCTGGCCCCAGGTGGGCCGAGTGGAATTCCGGAACTACTGCCTG\nCGCTACCGAGAGGACCTGGACTTCGTTCTCAGGCACATCAATGTCACGATCAATGGGGGA\nGAAAAGGTCGGCATCGTGGGGCGGACGGGAGCTGGGAAGTCGTCCCTGACCCTGGGCTTA\nTTTCGGATCAACGAGTCTGCCGAAGGAGAGATCATCATCGATGGCATCAACATCGCCAAG\nATCGGCCTGCACGACCTCCGCTTCAAGATCACCATCATCCCCCAGGACCCTGTTTTGTTT\nTCGGGTTCCCTCCGAATGAACCTGGACCCATTCAGCCAGTACTCGGATGAAGAAGTCTGG\nACGTCCCTGGAGCTGGCCCACCTGAAGGACTTCGTGTCAGCCCTTCCTGACAAGCTAGAC\nCATGAATGTGCAGAAGGCGGGGAGAACCTCAGTGTCGGGCAGCGCCAGCTTGTGTGCCTA\nGCCCGGGCCCTGCTGAGGAAGACGAAGATCCTTGTGTTGGATGAGGCCACGGCAGCCGTG\nGACCTGGAAACGGACGACCTCATCCAGTCCACCATCCGGACACAGTTCGAGGACTGCACC\nGTCCTCACCATCGCCCACCGGCTCAACACCATCATGGACTACACAAGGGTGATCGTCTTG\nGACAAAGGAGAAATCCAGGAGTACGGCGCCCCATCGGACCTCCTGCAGCAGAGAGGTCTT\nTTCTACAGCATGGCCAAAGACGCCGGCTTGGTGTGA"}, "pfams": {"pfam": [{"identifier": "PF00005", "name": "ABC_tran"}, {"identifier": "PF00664", "name": "ABC_membrane"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "nucleoside-triphosphatase activity"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "function", "description": "ATPase activity"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substances"}, {"category": "function", "description": "ATPase activity, coupled to transmembrane movement of substances"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides"}, {"category": "function", "description": "transporter activity"}, {"category": "function", "description": "pyrophosphatase activity"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "8", "id": "BE0003642", "name": "Solute carrier organic anion transporter family member 1A2", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11883641", "known-action": "unknown", "polypeptide": {"@id": "P46721", "@source": "Swiss-Prot", "name": "Solute carrier organic anion transporter family member 1A2", "general-function": "Involved in bile acid transmembrane transporter activity", "specific-function": "Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity)", "gene-name": "SLCO1A2", "locus": "12p12", "cellular-location": "Membrane", "transmembrane-regions": "21-37\n86-106\n156-176\n194-214\n246-266\n316-336\n356-376\n390-410\n461-481\n513-533\n557-577\n603-623", "signal-regions": null, "theoretical-pi": "5.75", "molecular-weight": "74144.1", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "GNC:10956"}, {"resource": "GeneCards", "identifier": "SLCO1A2"}, {"resource": "GenBank Gene Database", "identifier": "U21943"}, {"resource": "GenBank Protein Database", "identifier": "885978"}, {"resource": "UniProtKB", "identifier": "P46721"}, {"resource": "UniProt Accession", "identifier": "SO1A2_HUMAN"}]}, "synonyms": {"synonym": ["OATP-A", "OATP1", "Organic anion-transporting polypeptide 1", "Sodium-independent organic anion transporter", "Solute carrier family 21 member 3"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Solute carrier organic anion transporter family member 1A2\nMGETEKRIETHRIRCLSKLKMFLLAITCAFVSKTLSGSYMNSMLTQIERQFNIPTSLVGF\nINGSFEIGNLLLIIFVSYFGTKLHRPIMIGIGCVVMGLGCFLKSLPHFLMNQYEYESTVS\nVSGNLSSNSFLCMENGTQILRPTQDPSECTKEVKSLMWVYVLVGNIVRGMGETPILPLGI\nSYIEDFAKFENSPLYIGLVETGAIIGPLIGLLLASFCANVYVDTGFVNTDDLIITPTDTR\nWVGAWWFGFLICAGVNVLTAIPFFFLPNTLPKEGLETNADIIKNENEDKQKEEVKKEKYG\nITKDFLPFMKSLSCNPIYMLFILVSVIQFNAFVNMISFMPKYLEQQYGISSSDAIFLMGI\nYNLPPICIGYIIGGLIMKKFKITVKQAAHIGCWLSLLEYLLYFLSFLMTCENSSVVGINT\nSYEGIPQDLYVENDIFADCNVDCNCPSKIWDPVCGNNGLSYLSACLAGCETSIGTGINMV\nFQNCSCIQTSGNSSAVLGLCDKGPDCSLMLQYFLILSAMSSFIYSLAAIPGYMVLLRCMK\nSEEKSLGVGLHTFCTRVFAGIPAPIYFGALMDSTCLHWGTLKCGESGACRIYDSTTFRYI\nYLGLPAALRGSSFVPALIILILLRKCHLPGENASSGTELIETKVKGKENECKDIYQKSTV\nLKDDELKTKL"}, "gene-sequence": {"@format": "FASTA", "#text": ">2013 bp\nATGGGAGAAACTGAGAAAAGAATTGAAACCCATAGAATAAGATGTCTTTCCAAGTTGAAG\nATGTTTCTGTTGGCAATAACATGTGCATTTGTATCCAAAACACTGTCTGGATCTTATATG\nAATTCCATGCTCACACAAATAGAGAGACAATTCAACATCCCAACATCTCTAGTTGGATTC\nATTAATGGAAGCTTTGAGATTGGAAATCTTTTGTTGATTATATTTGTGAGTTATTTTGGA\nACCAAACTGCATAGACCTATAATGATTGGCATTGGATGTGTGGTTATGGGCTTAGGCTGT\nTTCTTAAAATCACTACCTCATTTCCTCATGAACCAATATGAATATGAATCTACAGTTTCA\nGTTTCAGGCAACTTGTCCTCAAACAGTTTCTTGTGTATGGAAAATGGAACCCAGATTTTA\nAGACCAACGCAGGATCCATCAGAGTGTACAAAGGAAGTTAAATCATTAATGTGGGTGTAC\nGTCCTAGTAGGCAATATTGTACGTGGAATGGGTGAAACTCCCATCCTGCCTTTGGGTATT\nTCCTATATAGAAGATTTTGCCAAATTTGAAAATTCTCCTTTATATATTGGGCTTGTAGAA\nACAGGAGCTATTATTGGTCCTTTGATTGGACTTTTGTTGGCATCATTCTGTGCAAATGTT\nTATGTTGACACTGGATTTGTGAACACAGATGATCTGATCATAACTCCCACTGACACTCGT\nTGGGTCGGTGCATGGTGGTTTGGCTTTCTGATTTGTGCAGGAGTTAACGTGCTCACTGCC\nATTCCTTTTTTCTTTTTGCCCAACACACTTCCAAAGGAAGGACTAGAGACTAATGCTGAC\nATCATTAAAAATGAAAATGAAGACAAACAAAAAGAAGAGGTCAAGAAGGAAAAATATGGA\nATCACTAAAGATTTTCTACCTTTCATGAAAAGTCTTTCCTGCAATCCAATTTATATGCTT\nTTCATACTTGTAAGTGTGATACAGTTCAATGCATTCGTTAACATGATCTCCTTCATGCCT\nAAATACCTAGAACAGCAATATGGAATATCATCTTCAGATGCAATCTTTCTAATGGGTATT\nTATAACTTACCTCCAATATGTATTGGATATATAATTGGTGGTTTAATTATGAAGAAGTTC\nAAGATTACTGTCAAACAAGCTGCCCACATAGGATGTTGGTTATCCTTACTTGAGTATCTT\nCTCTATTTTTTATCTTTTCTCATGACTTGTGAAAATTCTTCAGTTGTTGGAATAAATACC\nTCTTATGAAGGAATTCCACAAGATTTATATGTGGAAAATGACATCTTTGCTGATTGCAAT\nGTGGATTGCAACTGTCCATCTAAAATATGGGATCCTGTGTGTGGAAACAATGGCTTGTCA\nTATCTGTCAGCTTGTCTTGCTGGTTGTGAGACATCCATTGGAACGGGAATAAACATGGTG\nTTCCAAAATTGCAGCTGTATTCAAACATCAGGAAATTCATCTGCAGTTCTTGGGCTGTGC\nGACAAAGGACCTGACTGTTCCTTGATGCTCCAGTACTTCCTAATCTTGTCAGCGATGAGC\nAGTTTCATTTATTCTTTGGCTGCCATACCTGGATATATGGTTCTCTTGAGGTGTATGAAA\nTCTGAAGAGAAGTCCCTTGGTGTGGGATTACATACATTTTGCACAAGAGTATTTGCTGGC\nATTCCTGCACCTATATATTTTGGCGCTTTAATGGATTCCACATGTTTACACTGGGGAACT\nTTGAAATGTGGTGAGTCAGGGGCATGCAGGATATATGATTCCACCACCTTCAGATACATC\nTACCTCGGATTGCCGGCAGCACTAAGAGGATCAAGCTTTGTTCCAGCCTTAATCATCTTA\nATTCTTTTGAGGAAGTGTCATCTACCTGGTGAAAATGCCTCTTCAGGAACAGAGCTTATA\nGAGACAAAAGTCAAAGGGAAGGAAAATGAGTGCAAAGATATATACCAAAAGTCCACGGTT\nTTGAAAGATGATGAATTGAAAACTAAATTGTAA"}, "pfams": {"pfam": [{"identifier": "PF07648", "name": "Kazal_2"}, {"identifier": "PF03137", "name": "OATP"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "transporter activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}, {"category": "process", "description": "transport"}]}}}, {"@position": "9", "id": "BE0003643", "name": "Ileal sodium/bile acid cotransporter", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Craddock AL, Love MW, Daniel RW, Kirby LC, Walters HC, Wong MH, Dawson PA: Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1 Pt 1):G157-69. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9458785", "known-action": "unknown", "polypeptide": {"@id": "Q12908", "@source": "Swiss-Prot", "name": "Ileal sodium/bile acid cotransporter", "general-function": "Involved in bile acid:sodium symporter activity", "specific-function": "Plays a critical role in the sodium-dependent reabsorption of bile acids from the lumen of the small intestine. Plays a key role in cholesterol metabolism", "gene-name": "SLC10A2", "locus": "13q33", "cellular-location": "Membrane", "transmembrane-regions": "29-49\n83-103\n127-147\n158-178\n196-216\n225-245\n285-305", "signal-regions": null, "theoretical-pi": "7.13", "molecular-weight": "37697.4", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "GNC:10906"}, {"resource": "GeneCards", "identifier": "SLC10A2"}, {"resource": "GenBank Gene Database", "identifier": "U10417"}, {"resource": "GenBank Protein Database", "identifier": "595399"}, {"resource": "UniProtKB", "identifier": "Q12908"}, {"resource": "UniProt Accession", "identifier": "NTCP2_HUMAN"}]}, "synonyms": {"synonym": ["Apical sodium-dependent bile acid transporter", "ASBT", "IBAT", "Ileal Na(+)/bile acid cotransporter", "Ileal sodium-dependent bile acid transporter", "ISBT", "Na(+)-dependent ileal bile acid transporter", "Sodium/taurocholate cotransporting polypeptide, ileal", "Solute carrier family 10 member 2"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Ileal sodium/bile acid cotransporter\nMNDPNSCVDNATVCSGASCVVPESNFNNILSVVLSTVLTILLALVMFSMGCNVEIKKFLG\nHIKRPWGICVGFLCQFGIMPLTGFILSVAFDILPLQAVVVLIIGCCPGGTASNILAYWVD\nGDMDLSVSMTTCSTLLALGMMPLCLLIYTKMWVDSGSIVIPYDNIGTSLVALVVPVSIGM\nFVNHKWPQKAKIILKIGSIAGAILIVLIAVVGGILYQSAWIIAPKLWIIGTIFPVAGYSL\nGFLLARIAGLPWYRCRTVAFETGMQNTQLCSTIVQLSFTPEELNVVFTFPLIYSIFQLAF\nAAIFLGFYVAYKKCHGKNKAEIPESKENGTEPESSFYKANGGFQPDEK"}, "gene-sequence": {"@format": "FASTA", "#text": ">1047 bp\nATGAATGATCCGAACAGCTGTGTGGACAATGCAACAGTTTGCTCTGGTGCATCCTGTGTG\nGTACCTGAGAGCAATTTCAATAACATCCTAAGTGTGGTCCTAAGTACGGTGCTGACCATC\nCTGTTGGCCTTGGTGATGTTCTCCATGGGATGCAACGTGGAAATCAAGAAATTTCTAGGG\nCACATAAAGCGGCCGTGGGGCATTTGTGTTGGCTTCCTCTGTCAGTTTGGAATCATGCCC\nCTCACAGGATTCATCCTGTCGGTGGCCTTTGACATCCTCCCGCTCCAGGCCGTAGTGGTG\nCTCATTATAGGATGCTGCCCTGGAGGAACTGCCTCCAATATCTTGGCCTATTGGGTCGAT\nGGCGACATGGACCTGAGCGTCAGCATGACCACATGCTCCACACTGCTTGCCCTCGGAATG\nATGCCGCTGTGCCTCCTTATCTATACCAAAATGTGGGTCGACTCTGGGAGCATCGTAATT\nCCCTATGATAACATAGGTACATCTCTGGTTGCTCTCGTTGTTCCTGTTTCCATTGGAATG\nTTTGTTAATCACAAATGGCCCCAAAAAGCAAAGATCATACTTAAAATTGGGTCCATCGCG\nGGCGCCATCCTCATTGTGCTCATAGCTGTGGTTGGAGGAATATTGTACCAAAGCGCCTGG\nATCATTGCTCCCAAACTGTGGATTATAGGAACAATATTTCCTGTGGCGGGTTACTCCCTG\nGGGTTTCTTCTGGCTAGAATTGCTGGTCTACCCTGGTACAGGTGCCGAACGGTTGCTTTT\nGAAACGGGGATGCAGAACACGCAGCTATGTTCCACCATCGTTCAGCTCTCCTTCACTCCT\nGAGGAGCTCAATGTCGTATTCACCTTCCCGCTCATCTACAGCATTTTCCAGCTCGCCTTT\nGCCGCAATATTCTTAGGATTTTATGTGGCATACAAGAAATGTCATGGAAAAAACAAGGCA\nGAAATTCCAGAGAGCAAAGAAAATGGAACGGAGCCAGAGTCATCGTTTTATAAGGCAAAT\nGGAGGATTTCAACCTGACGAAAAGTAG"}, "pfams": {"pfam": {"identifier": "PF01758", "name": "SBF"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "function", "description": "transporter activity"}, {"category": "function", "description": "organic acid transporter activity"}, {"category": "function", "description": "organic acid:sodium symporter activity"}, {"category": "function", "description": "bile acid:sodium symporter activity"}, {"category": "process", "description": "monovalent inorganic cation transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "sodium ion transport"}, {"category": "process", "description": "cellular physiological process"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "organic anion transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "cation transport"}]}}}, {"@position": "10", "id": "BE0003644", "name": "Sodium/bile acid cotransporter", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Schroeder A, Eckhardt U, Stieger B, Tynes R, Schteingart CD, Hofmann AF, Meier PJ, Hagenbuch B: Substrate specificity of the rat liver Na(+)-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells. Am J Physiol. 1998 Feb;274(2 Pt 1):G370-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9486191", "known-action": "unknown", "polypeptide": {"@id": "Q14973", "@source": "Swiss-Prot", "name": "Sodium/bile acid cotransporter", "general-function": "Involved in bile acid:sodium symporter activity", "specific-function": "The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presence of sodium", "gene-name": "SLC10A1", "locus": "14q24.1", "cellular-location": "Membrane", "transmembrane-regions": "25-45\n60-80\n91-111\n120-140\n156-176\n191-211\n220-240\n283-303", "signal-regions": null, "theoretical-pi": "8.94", "molecular-weight": "38118.6", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "GNC:10905"}, {"resource": "GeneCards", "identifier": "SLC10A1"}, {"resource": "GenBank Gene Database", "identifier": "L21893"}, {"resource": "GenBank Protein Database", "identifier": "410214"}, {"resource": "UniProtKB", "identifier": "Q14973"}, {"resource": "UniProt Accession", "identifier": "NTCP_HUMAN"}]}, "synonyms": {"synonym": ["Cell growth-inhibiting gene 29 protein", "Na(+)/bile acid cotransporter", "Na(+)/taurocholate transport protein", "Sodium/taurocholate cotransporting polypeptide", "Solute carrier family 10 member 1"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Sodium/bile acid cotransporter\nMEAHNASAPFNFTLPPNFGKRPTDLALSVILVFMLFFIMLSLGCTMEFSKIKAHLWKPKG\nLAIALVAQYGIMPLTAFVLGKVFRLKNIEALAILVCGCSPGGNLSNVFSLAMKGDMNLSI\nVMTTCSTFCALGMMPLLLYIYSRGIYDGDLKDKVPYKGIVISLVLVLIPCTIGIVLKSKR\nPQYMRYVIKGGMIIILLCSVAVTVLSAINVGKSIMFAMTPLLIATSSLMPFIGFLLGYVL\nSALFCLNGRCRRTVSMETGCQNVQLCSTILNVAFPPEVIGPLFFFPLLYMIFQLGEGLLL\nIAIFWCYEKFKTPKDKTKMIYTAATTEETIPGALGNGTYKGEDCSPCTA"}, "gene-sequence": {"@format": "FASTA", "#text": ">1050 bp\nATGGAGGCCCACAACGCGTCTGCCCCATTCAACTTCACCCTGCCACCCAACTTTGGCAAG\nCGCCCCACAGACCTGGCACTGAGCGTCATCCTGGTGTTCATGTTGTTCTTCATCATGCTC\nTCGCTGGGCTGCACCATGGAGTTCAGCAAGATCAAGGCTCACTTATGGAAGCCTAAAGGG\nCTGGCCATCGCCCTGGTGGCACAGTATGGCATCATGCCCCTCACGGCCTTTGTGCTGGGC\nAAGGTCTTCCGGCTGAAGAACATTGAGGCACTGGCCATCTTGGTCTGTGGCTGCTCACCT\nGGAGGGAACCTGTCCAATGTCTTCAGTCTGGCCATGAAGGGGGACATGAACCTCAGCATT\nGTGATGACCACCTGCTCCACCTTCTGTGCCCTTGGCATGATGCCTCTCCTCCTGTACATC\nTACTCCAGGGGGATCTATGATGGGGACCTGAAGGACAAGGTGCCCTATAAAGGCATCGTG\nATATCACTGGTCCTGGTTCTCATTCCTTGCACCATAGGGATCGTCCTCAAATCCAAACGG\nCCACAATACATGCGCTATGTCATCAAGGGAGGGATGATCATCATTCTCTTGTGCAGTGTG\nGCCGTCACAGTTCTCTCTGCCATCAATGTGGGGAAGAGCATCATGTTTGCCATGACACCA\nCTCTTGATTGCCACCTCCTCCCTGATGCCTTTTATTGGCTTTCTGCTGGGTTATGTTCTC\nTCTGCTCTCTTCTGCCTCAATGGACGGTGCAGACGCACTGTCAGCATGGAGACTGGATGC\nCAAAATGTCCAACTCTGTTCCACCATCCTCAATGTGGCCTTTCCACCTGAAGTCATTGGA\nCCACTTTTCTTCTTTCCCCTCCTCTACATGATTTTCCAGCTTGGAGAAGGGCTTCTCCTC\nATTGCCATATTTTGGTGCTATGAGAAATTCAAGACTCCCAAGGATAAAACAAAAATGATC\nTACACAGCTGCCACAACTGAAGAAACAATTCCAGGAGCTCTGGGAAATGGCACCTACAAA\nGGGGAGGACTGCTCCCCTTGCACAGCCTAG"}, "pfams": {"pfam": {"identifier": "PF01758", "name": "SBF"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "function", "description": "transporter activity"}, {"category": "function", "description": "organic acid transporter activity"}, {"category": "function", "description": "organic acid:sodium symporter activity"}, {"category": "function", "description": "bile acid:sodium symporter activity"}, {"category": "process", "description": "monovalent inorganic cation transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "sodium ion transport"}, {"category": "process", "description": "cellular physiological process"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "organic anion transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "cation transport"}]}}}, {"@position": "11", "id": "BE0001066", "name": "Solute carrier family 22 member 6", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Sweet DH, Wolff NA, Pritchard JB: Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney. J Biol Chem. 1997 Nov 28;272(48):30088-95. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9374486", "known-action": "unknown", "polypeptide": {"@id": "Q4U2R8", "@source": "Swiss-Prot", "name": "Solute carrier family 22 member 6", "general-function": "Carbohydrate transport and metabolism", "specific-function": null, "gene-name": "SLC22A6", "locus": null, "cellular-location": null, "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.78", "molecular-weight": "60353.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:10970"}, {"resource": "GenAtlas", "identifier": "hROAT1"}, {"resource": "GeneCards", "identifier": "hROAT1"}, {"resource": "GenBank Gene Database", "identifier": "AF057039"}, {"resource": "GenBank Protein Database", "identifier": "3831566"}, {"resource": "UniProtKB", "identifier": "Q4U2R8"}, {"resource": "UniProt Accession", "identifier": "S22A6_HUMAN"}]}, "synonyms": null, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Putative renal organic anion transporter 1\nMAFNDLLQQVGGVGRFQQIQVTLVVLPLLLMASHNTLQNFTAAIPTHHCRPPADANLSKN\nGGLEVWLPRDRQGQPESCLRFTSPQWGLPFLNGTEANGTGATEPCTDGWIYDNSTFPSTI\nVTEWDLVCSHRALRQLAQSLYMVGVLLGAMVFGYLADRLGRRKVLILNYLQTAVSGTCAA\nFAPNFPIYCAFRLLSGMALAGISLNCMTLNVEWMPIHTRACVGTLIGYVYSLGQFLLAGV\nAYAVPHWRHLQLLVSAPFFAFFIYSWFFIESARWHSSSGRLDLTLRALQRVARINGKREE\nGAKLSMEVLRASLQKELTMGKGQASAMELLRCPTLRHLFLCLSMLWFATSFAYYGLVMDL\nQGFGVSIYLIQVIFGAVDLPAKLVGFLVINSLGRRPAQMAALLLAGICILLNGVIPQDQS\nIVRTSLAVLGKGCLAASFNCIFLYTGELYPTMIRQTGMGMGSTMARVGSIVSPLVSMTAE\nLYPSMPLFIYGAVPVAASAVTVLLPETLGQPLPDTVQDLESRKGKQTRQQQEHQKYMVPL\nQASAQEKNGF"}, "gene-sequence": {"@format": "FASTA", "#text": ">1653 bp\nATGGCCTTTAATGACCTCCTGCAGCAGGTGGGGGGTGTCGGCCGCTTCCAGCAGATCCAG\nGTCACCCTGGTGGTCCTCCCCCTGCTCCTGATGGCTTCTCACAACACCCTGCAGAACTTC\nACTGCTGCCATCCCTACCCACCACTGCCGCCCGCCTGCCGATGCCAACCTCAGCAAGAAC\nGGGGGGCTGGAGGTCTGGCTGCCCCGGGACAGGCAGGGGCAGCCTGAGTCCTGCCTCCGC\nTTCACCTCCCCGCAGTGGGGACTGCCCTTTCTCAATGGCACAGAAGCCAATGGCACAGGG\nGCCACAGAGCCCTGCACCGATGGCTGGATCTATGACAACAGCACCTTCCCGTCTACCATC\nGTGACTGAGTGGGACCTTGTGTGCTCTCACAGGGCCCTACGCCAGCTGGCCCAGTCCTTG\nTACATGGTGGGGGTGCTGCTCGGAGCCATGGTGTTCGGCTACCTTGCAGACAGGCTAGGC\nCGCCGGAAGGTACTCATCTTGAACTACCTGCAGACAGCTGTGTCAGGGACCTGCGCAGCC\nTTCGCACCCAACTTCCCCATCTACTGCGCCTTCCGGCTCCTCTCGGGCATGGCTCTGGCT\nGGCATCTCCCTCAACTGCATGACACTGAATGTGGAGTGGATGCCCATTCACACACGGGCC\nTGCGTGGGCACCTTGATTGGCTATGTCTACAGCCTGGGCCAGTTCCTCCTGGCTGGTGTG\nGCCTACGCTGTGCCCCACTGGCGCCACCTGCAGCTACTGGTCTCTGCGCCTTTTTTTGCC\nTTCTTCATCTACTCCTGGTTCTTCATTGAGTCGGCCCGCTGGCACTCCTCCTCCGGGAGG\nCTGGACCTCACCCTGAGGGCCCTGCAGAGAGTCGCCCGGATCAATGGGAAGCGGGAAGAA\nGGAGCCAAATTGAGTATGGAGGTACTCCGGGCCAGTCTGCAGAAGGAGCTGACCATGGGC\nAAAGGCCAGGCATCGGCCATGGAGCTGCTGCGCTGCCCCACCCTCCGCCACCTCTTCCTC\nTGCCTCTCCATGCTGTGGTTTGCCACTAGCTTTGCATACTATGGGCTGGTCATGGACCTG\nCAGGGCTTTGGAGTCAGCATCTACCTAATCCAGGTGATCTTTGGTGCTGTGGACCTGCCT\nGCCAAGCTTGTGGGCTTCCTTGTCATCAACTCCCTGGGTCGCCGGCCTGCCCAGATGGCT\nGCACTGCTGCTGGCAGGCATCTGCATCCTGCTCAATGGGGTGATACCCCAGGACCAGTCC\nATTGTCCGAACCTCTCTTGCTGTGCTGGGGAAGGGTTGTCTGGCTGCCTCCTTCAACTGC\nATCTTCCTGTATACTGGGGAACTGTATCCCACAATGATCCGGCAGACAGGCATGGGAATG\nGGCAGCACCATGGCCCGAGTGGGCAGCATCGTGAGCCCACTGGTGAGCATGACTGCCGAG\nCTCTACCCCTCCATGCCTCTCTTCATCTACGGTGCTGTTCCTGTGGCCGCCAGCGCTGTC\nACTGTCCTCCTGCCAGAGACCCTGGGCCAGCCACTGCCAGACACGGTGCAGGACCTGGAG\nAGCAGGAAAGGGAAACAGACGCGACAGCAACAAGAGCACCAGAAGTATATGGTCCCACTG\nCAGGCCTCAGCACAAGAGAAGAATGGATTTTGA"}, "pfams": {"pfam": {"identifier": "PF07690", "name": "MFS_1"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "function", "description": "transporter activity"}, {"category": "function", "description": "ion transporter activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}]}}}, {"@position": "12", "id": "BE0003651", "name": "Multidrug resistance-associated protein 7", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12527806", "known-action": "unknown", "polypeptide": {"@id": "Q5T3U5", "@source": "Swiss-Prot", "name": "Multidrug resistance-associated protein 7", "general-function": "Defense mechanisms", "specific-function": "ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion", "gene-name": "ABCC10", "locus": "6p21.1", "cellular-location": "Cell membrane", "transmembrane-regions": "32-52\n70-90\n102-122\n133-153\n172-192\n293-313\n320-340\n391-411\n414-434\n507-527\n538-558\n875-895\n933-953\n974-994\n1051-1071\n1153-1173\n1182-1202", "signal-regions": null, "theoretical-pi": "7.07", "molecular-weight": "161627.4", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "GNC:52"}, {"resource": "GeneCards", "identifier": "ABCC10"}, {"resource": "GenBank Gene Database", "identifier": "AY032599"}, {"resource": "GenBank Protein Database", "identifier": "21103955"}, {"resource": "UniProtKB", "identifier": "Q5T3U5"}, {"resource": "UniProt Accession", "identifier": "MRP7_HUMAN"}]}, "synonyms": {"synonym": "ATP-binding cassette sub-family C member 10"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Multidrug resistance-associated protein 7\nMERLLAQLCGSSAAWPLPLWEGDTTGHCFTQLVLSALPHALLAVLSACYLGTPRSPDYIL\nPCSPGWRLRLAASFLLSVFPLLDLLPVALPPGAGPGPIGLEVLAGCVAAVAWISHSLALW\nVLAHSPHGHSRGPLALALVALLPAPALVLTVLWHCQRGTLLPPLLPGPMARLCLLILQLA\nALLAYALGWAAPGGPREPWAQEPLLPEDQEPEVAEDGESWLSRFSYAWLAPLLARGACGE\nLRQPQDICRLPHRLQPTYLARVFQAHWQEGARLWRALYGAFGRCYLALGLLKLVGTMLGF\nSGPLLLSLLVGFLEEGQEPLSHGLLYALGLAGGAVLGAVLQNQYGYEVYKVTLQARGAVL\nNILYCKALQLGPSRPPTGEALNLLGTDSERLLNFAGSFHEAWGLPLQLAITLYLLYQQVG\nVAFVGGLILALLLVPVNKVIATRIMASNQEMLQHKDARVKLVTELLSGIRVIKFCGWEQA\nLGARVEACRARELGRLRVIKYLDAACVYLWAALPVVISIVIFITYVLMGHQLTATKVFTA\nLALVRMLILPLNNFPWVINGLLEAKVSLDRIQLFLDLPNHNPQAYYSPDPPAEPSTVLEL\nHGALFSWDPVGTSLETFISHLEVKKGMLVGIVGKVGCGKSSLLAAIAGELHRLRGHVAVR\nGLSKGFGLATQEPWIQFATIRDNILFGKTFDAQLYKEVLEACALNDDLSILPAGDQTEVG\nEKGVTLSGGQRARIALARAVYQEKELYLLDDPLAAVDADVANHLLHRCILGMLSYTTRLL\nCTHRTEYLERADAVLLMEAGRLIRAGPPSEILPLVQAVPKAWAENGQESDSATAQSVQNP\nEKTKEGLEEEQSTSGRLLQEESKKEGAVALHVYQAYWKAVGQGLALAILFSLLLMQATRN\nAADWWLSHWISQLKAENSSQEAQPSTSPASMGLFSPQLLLFSPGNLYIPVFPLPKAAPNG\nSSDIRFYLTVYATIAGVNSLCTLLRAVLFAAGTLQAAATLHRRLLHRVLMAPVTFFNATP\nTGRILNRFSSDVACADDSLPFILNILLANAAGLLGLLAVLGSGLPWLLLLLPPLSIMYYH\nVQRHYRASSRELRRLGSLTLSPLYSHLADTLAGLSVLRATGATYRFEEENLRLLELNQRC\nQFATSATMQWLDIRLQLMGAAVVSAIAGIALVQHQQGLANPGLVGLSLSYALSLTGLLSG\nLVSSFTQTEAMLVSVERLEEYTCDLPQEPQGQPLQLGTGWLTQGGVEFQDVVLAYRPGLP\nNALDGVTFCVQPGEKLGIVGRTGSGKSSLLLVLFRLLEPSSGRVLLDGVDTSQLELAQLR\nSQLAIIPQEPFLFSGTVRENLDPQGLHKDRALWQALKQCHLSEVITSMGGLDGELGEGGR\nSLSLGQRQLLCLARALLTDAKILCIDEATASVDQKTDQLLQQTICKRFANKTVLTIAHRL\nNTILNSDRVLVLQAGRVVELDSPATLRNQPHSLFQQLLQSSQQGVPASLGGP"}, "gene-sequence": {"@format": "FASTA", "#text": ">4392 bp\nATGTGCCTCCTTGTCTTCCCCCTTGTCCCCAGGAGTCCAGATTACATCCTACCCTGCAGT\nCCTGGATGGCGCCTCCGACTTGCAGCTTCCTTCCTGCTTTCCGTCTTCCCGCTGCTAGAC\nCTTCTTCCAGTTGCTTTGCCACCAGGGGCAGGCCCAGGACCCATAGGGCTAGAGGTGTTG\nGCAGGGTGCGTGGCAGCTGTGGCCTGGATCAGCCACAGCCTGGCCCTGTGGGTGTTGGCA\nCATTCCCCTCATGGCCACTCCCGGGGTCCCTTGGCCTTGGCCCTGGTAGCCTTGCTGCCA\nGCTCCAGCCCTAGTGCTGACCGTGTTGTGGCATTGCCAGCGAGGCACACTTCTGCCCCCA\nCTTCTCCCAGGGCCCATGGCCCGCCTATGCTTGCTCATCCTGCAGCTGGCTGCACTCTTG\nGCCTATGCACTGGGATGGGCAGCTCCTGGGGGACCACGAGAACCCTGGGCTCAGGAGCCC\nCTCCTGCCCGAGGAGCAAGAACCTGAGGTGGCTGAAGATGGGGAGAGTCTGTCACGCTTT\nTCCTATGCCTGGCTGGCACCCTTGCTGGCCCGTGGGGCCTGTGGAGAGCTCCGGCAGCCT\nCAGGACATTTGCCGCCTCCCCCACAGACTGCAGCCAACCTACCTGGCTCGTGTCTTCCAG\nGCACACTGGCAGGAGGGGGCACGGCTGTGGAGGGCCTTGTATGGGGCCTTTGGACGGTGC\nTATCTGGCACTTGGACTGCTGAAGCTGGTGGGGACCATGTTGGGATTCTCAGGGCCCCTG\nTTGCTCTCCCTACTGGTGGGCTTCCTGGAAGAGGGGCAGGAGCCACTAAGCCACGGCCTG\nCTCTATGCTCTGGGGCTAGCCGGTGGGGCTGTGCTGGGTGCTGTGCTGCAGAATCAGTAT\nGGGTATGAGGTATATAAGGTAACACTTCAGGCACGGGGGGCTGTGCTGAACATCCTGTAC\nTGCAAGGCTTTACAGCTGGGGCCCAGCCGCCCTCCTACTGGGGAGGCCCTGAACCTACTA\nGGCACTGACTCTGAACGGCTGCTTAACTTTGCTGGGAGCTTCCATGAAGCCTGGGGCCTG\nCCCCTGCAACTGGCCATCACCCTCTACCTGCTGTACCAGCAGGTAGGCGTGGCCTTCGTG\nGGTGGTCTCATCTTGGCACTGCTGCTGGTACCCGTCAACAAAGTGATTGCCACCCGCATC\nATGGCCAGCAACCAGGAAATGCTACAGCACAAGGATGCGCGGGTTAAGCTTGTGACAGAG\nCTGCTGAGTGGCATTCGGGTCATCAAGTTCTGCGGGTGGGAGCAGGCACTGGGAGCCCGA\nGTAGAGGCCTGCCGGGCTCGAGAGCTGGGGCGACTCCGGGTCATCAAATACCTGGATGCG\nGCCTGTGTATACCTGTGGGCTGCCCTACCGGTTGTCATCTCCATCGTTATCTTCATCACC\nTATGTCCTCATGGGGCACCAGCTCACTGCCACCAAGGTGTTCACGGCCCTGGCACTGGTG\nCGAATGCTCATTCTTCCTCTCAACAACTTCCCTTGGGTGATCAATGGTCTCCTGGAGGCC\nAAAGTGTCCTTGGACCGGATCCAGCTTTTCCTCGACCTTCCAAACCACAACCCCCAGGCC\nTACTACAGCCCAGATTGTGGTAGATTAGGAGCCCAAATCAAGTGGCTTCTCTGTTCAGAT\nCCCCCTGCAGAGCCATCTACAGTATTGGAGCTGCATGGAGCCTTGTTCTCCTGGGACCCA\nGTTGGAACCAGCCTGGAGACCTTCATCAGTCATCTCGAAGTGAAAAAGGGTATGCTGGTG\nGGCACCGTGGGGAAGGTCGGCTGTGGGAAGAGCTCCCTGCTGGCTGCCATCGCTGGAGAG\nCTCCACAGGCTGCGTGGGCATGTGGCAGTGCGGGGGCTGTCCAAGGGCTTTGGCCTGGCC\nACCCAGGAACCCTGGATCCAGTTTGCCACCATCCGAGACAACATCCTCTTTGGGAAGACA\nTTTGATGCACAGCTGTACAAGGAGGTGCTAGAAGCCTGCGCCCTCAATGATGACCTCAGT\nATCCTGCCTGCTGGAGACCAGACAGAGGTGGGGGAGAAGGGTGTCACCCTTAGCGGAGGA\nCAGCGTGCCCGGATTGCCCTTGCTCGTGCTGTCTACCAGGAAAAGGAGCTCTATCTCCTC\nGATGACCCTCTGGCCGCTGTGGATGCAGATGTGGCCAACCACCCGCTGCACAGGTGCATC\nCTGGGCATGCTGAGCTACACCACACGGCTGCTCTGCACCCACCGCACTGAGTACCTGGAG\nAGGGCTGACGCGGTGCTGCTGATGGAGGCCGGGCGCCTCATCCGGGCTGGACCTCCCCCT\nGAGATTCTGCCACTGGTACAAGCTGTCCCCAAAGCCTGGGCTGAGAATGGACAAGAGTCT\nGACTCAGCCACAGCCCAGTCAGTACAGAACCCAGAGAAAACAAAGGAGGGGCTGGAGGAG\nGAGCAGAGCACATCTGGTCGCCTGCTGCAGGAAGAAAGCAAGAAGGAGGGCGCCGTGGCC\nTTGCACGTGTACCAAGCTTACTGGAAGGCCGTGGGCCAGGGCTTGGCCTTAGCCACCCTC\nTTCTCTCTGCTTCTCATGCAAGCCACGCGGAACGCTGCTGACTGGTGGCTCTCCCACTGG\nATCTCTCAGCTGAAGGCTGAGAATAGCTCCCAGGAGGCGCAACCCTCCACCAGCCCAGCT\nTCTATGGGGCTCTTCTCTCCGCAGCTGCTCCTCTTTTCCCCTGGAAACCTCTACATCCCA\nGTGTTCCCACTGCCCAAAGCTGCCCCCAATGGCTCGTCAGACATCCGTTTCTACCTCACC\nGTGTATGCGACCATTGCTGGTGTAAATTCCCTCTGCACCCTTCTCCGGGCAGTGCTCTTT\nGCAGCAGGCACCCTTCAAGCAGCTGCCACTCTGCATCGCCGCCTGCTGCATCGAGTCCTT\nATGGCACCAGTGACTTTCTTCAATGCCACACCCACGGGCCGGATCCTAAACCGCTTCTCC\nTTTGATGTGGCCTGTGCGGATGACAGCCTGCCCTTCATCCTCAACATCCTCCTGGCCAAC\nGCGGCAGGCCTGCTGGGGCTCCTGGCCGTGCTGGGCTCTGGCCTGCCCTGGCTGCTGCTC\nCTGCTGCCGCCTTTGAGCATCATGTACTATCACGTGCAGCGCCACTACAGGGCCTCCTCA\nCGGGAGCTGCGGCGCCTGGGCAGCCTCACCCTGTCTCCACTGTATAGCCATCTGGCCGAT\nACCTTGGCTGGCCTCTCTGTGCTCCGGGCCACAGGGGCCACCTACAGGTTTGAGGAGGAG\nAACCTGCGACTCCTTGAGCTAAACCAGAGGTGCCAGTTTGCCACCAGTGCCACAATGCAG\nTGGCTGGACATTCGGCTACAGCTCATGGGGGCGGCTGTGGTCAGCGCTATCGCAGGCATC\nGCTCTGGTGCAGCACCAGCAGGGCCTCGCTAACCCAGGGCTGGTGGGCTTGTCGCTGTCT\nTATGCCCTGTCCCTGACGGGCCTGCTCTCGGGCCTGGTGAGCAGCTTCACACAGACAGAG\nGCCATGCTGGTGAGCGTCGAGCGGCTGGAAGAGTACACCTGTGACCTGCCCCAGGAACCC\nCAGGGCCAGCCACTGCAGCTGGGCACCGGCTGGCTGACCCAGGGGGGCGTGGAGTTCCAG\nGACGTGGTGTTGGCGTACCGGCCAGGGCTGCCGAATGCCCTGGATGGAGTGACCTTCTGC\nGTGCAGCCTGGAGAGAAGGTCGGCATCGTGGGACGGACCGGCTCCGGCAAGTCTTCCCTG\nTTGTTGGTGCTCTTCCGGCTGCTAGAGCCCAGTTCAGGGCGAGTGCTGCTGGACGGCGTG\nGACACCAGCCAGCTGGAGCTGGCCCAGCTCAGATCCCAGTTGGCTATCATCCCCCAGGAG\nCCCTTTTTGTTCAGTGGGACTGTTCGGGAAAACCTGGACCCCCAGGGCCTACATAAGGAC\nAGGGCCTTGTGGCAGGCCCTGAAGCAGTGCCACCTGAGTGAGGTGATTACATCCATGGGT\nGGTCTGGATGGTGAGCTGGGTGAGGGGGGCCGGAGCTTATCTCTTGGGCAGAGGCAGCTG\nTTGTGTTTGGCCAGGGCTCTCCTCACAGATGCCAAGATCCTGTGTATCGATGAGGCCACA\nGCAAGTGTGGACCAGAAGACAGACCAGCTGCTCCAGCAGACCATCTGCAAACGCTTTGCC\nAACAAGACAGTGCTGACCATTGCCCATAGGCTCAACACGATCCTGAACTCAGACCGGGTG\nCTGGTGCTACAAGCGGAGAGAGTGGTAGAGCTGGACTCCCCGGCCACCCTGCGCAACCAG\nCCCCACTCCCTGTTCCAGCAGCTGCTGCAGAGCTGCCAGCAGGGAGTCCCTGCCTCACTC\nAGAGGTCCCTGA"}, "pfams": {"pfam": [{"identifier": "PF00005", "name": "ABC_tran"}, {"identifier": "PF00664", "name": "ABC_membrane"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "ATPase activity"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substances"}, {"category": "function", "description": "ATPase activity, coupled to transmembrane movement of substances"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "pyrophosphatase activity"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "nucleoside-triphosphatase activity"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "13", "id": "BE0001069", "name": "Canalicular multispecific organic anion transporter 1", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12134946\n# Hong J, Lambert JD, Lee SH, Sinko PJ, Yang CS: Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem Biophys Res Commun. 2003 Oct 10;310(1):222-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14511674\n# Kamisako T, Leier I, Cui Y, Konig J, Buchholz U, Hummel-Eisenbeiss J, Keppler D: Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology. 1999 Aug;30(2):485-90. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10421658\n# Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T, Uchiumi T, Wada M, Kuwano M, Akiyama SI: Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol. 1999 Dec;56(6):1219-28. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10570049\n# Horikawa M, Kato Y, Tyson CA, Sugiyama Y: The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab Pharmacokinet. 2002;17(1):23-33. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15618649", "known-action": "unknown", "polypeptide": {"@id": "Q92887", "@source": "Swiss-Prot", "name": "Canalicular multispecific organic anion transporter 1", "general-function": "Defense mechanisms and drug export", "specific-function": "Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter", "gene-name": "ABCC2", "locus": "10q24", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "28-48\n69-89\n94-114\n127-147\n166-186\n314-334\n361-381\n438-458\n462-482\n545-565\n588-608\n972-992\n1034-1054\n1098-1118\n1120-1140\n1212-1232\n1235-1255", "signal-regions": null, "theoretical-pi": "8.46", "molecular-weight": "174194.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:53"}, {"resource": "GenAtlas", "identifier": "ABCC2"}, {"resource": "GeneCards", "identifier": "ABCC2"}, {"resource": "GenBank Gene Database", "identifier": "U63970"}, {"resource": "GenBank Protein Database", "identifier": "1764162"}, {"resource": "UniProtKB", "identifier": "Q92887"}, {"resource": "UniProt Accession", "identifier": "MRP2_HUMAN"}]}, "synonyms": {"synonym": ["ATP-binding cassette sub-family C member 2", "Canalicular multidrug resistance protein", "Multidrug resistance-associated protein 2"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Canalicular multispecific organic anion transporter 1\nMLEKFCNSTFWNSSFLDSPEADLPLCFEQTVLVWIPLGFLWLLAPWQLLHVYKSRTKRSS\nTTKLYLAKQVFVGFLLILAAIELALVLTEDSGQATVPAVRYTNPSLYLGTWLLVLLIQYS\nRQWCVQKNSWFLSLFWILSILCGTFQFQTLIRTLLQGDNSNLAYSCLFFISYGFQILILI\nFSAFSENNESSNNPSSIASFLSSITYSWYDSIILKGYKRPLTLEDVWEVDEEMKTKTLVS\nKFETHMKRELQKARRALQRRQEKSSQQNSGARLPGLNKNQSQSQDALVLEDVEKKKKKSG\nTKKDVPKSWLMKALFKTFYMVLLKSFLLKLVNDIFTFVSPQLLKLLISFASDRDTYLWIG\nYLCAILLFTAALIQSFCLQCYFQLCFKLGVKVRTAIMASVYKKALTLSNLARKEYTVGET\nVNLMSVDAQKLMDVTNFMHMLWSSVLQIVLSIFFLWRELGPSVLAGVGVMVLVIPINAIL\nSTKSKTIQVKNMKNKDKRLKIMNEILSGIKILKYFAWEPSFRDQVQNLRKKELKNLLAFS\nQLQCVVIFVFQLTPVLVSVVTFSVYVLVDSNNILDAQKAFTSITLFNILRFPLSMLPMMI\nSSMLQASVSTERLEKYLGGDDLDTSAIRHDCNFDKAMQFSEASFTWEHDSEATVRDVNLD\nIMAGQLVAVIGPVGSGKSSLISAMLGEMENVHGHITIKGTTAYVPQQSWIQNGTIKDNIL\nFGTEFNEKRYQQVLEACALLPDLEMLPGGDLAEIGEKGINLSGGQKQRISLARATYQNLD\nIYLLDDPLSAVDAHVGKHIFNKVLGPNGLLKGKTRLLVTHSMHFLPQVDEIVVLGNGTIV\nEKGSYSALLAKKGEFAKNLKTFLRHTGPEEEATVHDGSEEEDDDYGLISSVEEIPEDAAS\nITMRRENSFRRTLSRSSRSNGRHLKSLRNSLKTRNVNSLKEDEELVKGQKLIKKEFIETG\nKVKFSIYLEYLQAIGLFSIFFIILAFVMNSVAFIGSNLWLSAWTSDSKIFNSTDYPASQR\nDMRVGVYGALGLAQGIFVFIAHFWSAFGFVHASNILHKQLLNNILRAPMRFFDTTPTGRI\nVNRFAGDISTVDDTLPQSLRSWITCFLGIISTLVMICMATPVFTIIVIPLGIIYVSVQMF\nYVSTSRQLRRLDSVTRSPIYSHFSETVSGLPVIRAFEHQQRFLKHNEVRIDTNQKCVFSW\nITSNRWLAIRLELVGNLTVFFSALMMVIYRDTLSGDTVGFVLSNALNITQTLNWLVRMTS\nEIETNIVAVERITEYTKVENEAPWVTDKRPPPDWPSKGKIQFNNYQVRYRPELDLVLRGI\nTCDIGSMEKIGVVGRTGAGKSSLTNCLFRILEAAGGQIIIDGVDIASIGLHDLREKLTII\nPQDPILFSGSLRMNLDPFNNYSDEEIWKALELAHLKSFVASLQLGLSHEVTEAGGNLSIG\nQRQLLCLGRALLRKSKILVLDEATAAVDLETDNLIQTTIQNEFAHCTVITIAHRLHTIMD\nSDKVMVLDNGKIIECGSPEELLQIPGPFYFMAKEAGIENVNSTKF"}, "gene-sequence": {"@format": "FASTA", "#text": ">4638 bp\nATGCTGGAGAAGTTCTGCAACTCTACTTTTTGGAATTCCTCATTCCTGGACAGTCCGGAG\nGCAGACCTGCCACTTTGTTTTGAGCAAACTGTTCTGGTGTGGATTCCCTTGGGCTTCCTA\nTGGCTCCTGGCCCCCTGGCAGCTTCTCCACGTGTATAAATCCAGGACCAAGAGATCCTCT\nACCACCAAACTCTATCTTGCTAAGCAGGTATTCGTTGGTTTTCTTCTTATTCTAGCAGCC\nATAGAGCTGGCCCTTGTACTCACAGAAGACTCTGGACAAGCCACAGTCCCTGCTGTTCGA\nTATACCAATCCAAGCCTCTACCTAGGCACATGGCTCCTGGTTTTGCTGATCCAATACAGC\nAGACAATGGTGTGTACAGAAAAACTCCTGGTTCCTGTCCCTATTCTGGATTCTCTCGATA\nCTCTGTGGCACTTTCCAATTTCAGACTCTGATCCGGACACTCTTACAGGGTGACAATTCT\nAATCTAGCCTACTCCTGCCTGTTCTTCATCTCCTACGGATTCCAGATCCTGATCCTGATC\nTTTTCAGCATTTTCAGAAAATAATGAGTCATCAAATAATCCATCATCCATAGCTTCATTC\nCTGAGTAGCATTACCTACAGCTGGTATGACAGCATCATTCTGAAAGGCTACAAGCGTCCT\nCTGACACTCGAGGATGTCTGGGAAGTTGATGAAGAGATGAAAACCAAGACATTAGTGAGC\nAAGTTTGAAACGCACATGAAGAGAGAGCTGCAGAAAGCCAGGCGGGCACTCCAGAGACGG\nCAGGAGAAGAGCTCCCAGCAGAACTCTGGAGCCAGGCTGCCTGGCTTGAACAAGAATCAG\nAGTCAAAGCCAAGATGCCCTTGTCCTGGAAGATGTTGAAAAGAAAAAAAAGAAGTCTGGG\nACCAAAAAAGATGTTCCAAAATCCTGGTTGATGAAGGCTCTGTTCAAAACTTTCTACATG\nGTGCTCCTGAAATCATTCCTACTGAAGCTAGTGAATGACATCTTCACGTTTGTGAGTCCT\nCAGCTGCTGAAATTGCTGATCTCCTTTGCAAGTGACCGTGACACATATTTGTGGATTGGA\nTATCTCTGTGCAATCCTCTTATTCACTGCGGCTCTCATTCAGTCTTTCTGCCTTCAGTGT\nTATTTCCAACTGTGCTTCAAGCTGGGTGTAAAAGTACGGACAGCTATCATGGCTTCTGTA\nTATAAGAAGGCATTGACCCTATCCAACTTGGCCAGGAAGGAGTACACCGTTGGAGAAACA\nGTGAACCTGATGTCTGTGGATGCCCAGAAGCTCATGGATGTGACCAACTTCATGCACATG\nCTGTGGTCAAGTGTTCTACAGATTGTCTTATCTATCTTCTTCCTATGGAGAGAGTTGGGA\nCCCTCAGTCTTAGCAGGTGTTGGGGTGATGGTGCTTGTAATCCCAATTAATGCGATACTG\nTCCACCAAGAGTAAGACCATTCAGGTCAAAAATATGAAGAATAAAGACAAACGTTTAAAG\nATCATGAATGAGATTCTTAGTGGAATCAAGATCCTGAAATATTTTGCCTGGGAACCTTCA\nTTCAGAGACCAAGTACAAAACCTCCGGAAGAAAGAGCTCAAGAACCTGCTGGCCTTTAGT\nCAACTACAGTGTGTAGTAATATTCGTCTTCCAGTTAACTCCAGTCCTGGTATCTGTGGTC\nACATTTTCTGTTTATGTCCTGGTGGATAGCAACAATATTTTGGATGCACAAAAGGCCTTC\nACCTCCATTACCCTCTTCAATATCCTGCGCTTTCCCCTGAGCATGCTTCCCATGATGATC\nTCCTCCATGCTCCAGGCCAGTGTTTCCACAGAGCGGCTAGAGAAGTACTTGGGAGGGGAT\nGACTTGGACACATCTGCCATTCGACATGACTGCAATTTTGACAAAGCCATGCAGTTTTCT\nGAGGCCTCCTTTACCTGGGAACATGATTCGGAAGCCACAGTCCGAGATGTGAACCTGGAC\nATTATGGCAGGCCAACTTGTGGCTGTGATAGGCCCTGTCGGCTCTGGGAAATCCTCCTTG\nATATCAGCCATGCTGGGAGAAATGGAAAATGTCCACGGGCACATCACCATCAAGGGCACC\nACTGCCTATGTCCCACAGCAGTCCTGGATTCAGAATGGCACCATAAAGGACAACATCCTT\nTTTGGAACAGAGTTTAATGAAAAGAGGTACCAGCAAGTACTGGAGGCCTGTGCTCTCCTC\nCCAGACTTGGAAATGCTGCCTGGAGGAGATTTGGCTGAGATTGGAGAGAAGGGTATAAAT\nCTTAGTGGGGGTCAGAAGCAGCGGATCAGCCTGGCCAGAGCTACCTACCAAAATTTAGAC\nATCTATCTTCTAGATGACCCCCTGTCTGCAGTGGATGCTCATGTAGGAAAACATATTTTT\nAATAAGGTCTTGGGCCCCAATGGCCTGTTGAAAGGCAAGACTCGACTCTTGGTTACACAT\nAGCATGCACTTTCTTCCTCAAGTGGATGAGATTGTAGTTCTGGGGAATGGAACAATTGTA\nGAGAAAGGATCCTACAGTGCTCTCCTGGCCAAAAAAGGAGAGTTTGCTAAGAATCTGAAG\nACATTTCTAAGACATACAGGCCCTGAAGAGGAAGCCACAGTCCATGATGGCAGTGAAGAA\nGAAGACGATGACTATGGGCTGATATCCAGTGTGGAAGAGATCCCCGAAGATGCAGCCTCC\nATAACCATGAGAAGAGAGAACAGCTTTCGTCGAACACTTAGCCGCAGTTCTAGGTCCAAT\nGGCAGGCATCTGAAGTCCCTGAGAAACTCCTTGAAAACTCGGAATGTGAATAGCCTGAAG\nGAAGACGAAGAACTAGTGAAAGGACAAAAACTAATTAAGAAGGAATTCATAGAAACTGGA\nAAGGTGAAGTTCTCCATCTACCTGGAGTACCTACAAGCAATAGGATTGTTTTCGATATTC\nTTCATCATCCTTGCGTTTGTGATGAATTCTGTGGCTTTTATTGGATCCAACCTCTGGCTC\nAGTGCTTGGACCAGTGACTCTAAAATCTTCAATAGCACCGACTATCCAGCATCTCAGAGG\nGACATGAGAGTTGGAGTCTACGGAGCTCTGGGATTAGCCCAAGGTATATTTGTGTTCATA\nGCACATTTCTGGAGTGCCTTTGGTTTCGTCCATGCATCAAATATCTTGCACAAGCAACTG\nCTGAACAATATCCTTCGAGCACCTATGAGATTTTTTGACACAACACCCACAGGCCGGATT\nGTGAACAGGTTTGCCGGCGATATTTCCACAGTGGATGACACCCTGCCTCAGTCCTTGCGC\nAGCTGGATTACATGCTTCCTGGGGATAATCAGCACCCTTGTCATGATCTGCATGGCCACT\nCCTGTCTTCACCATCATCGTCATTCCTCTTGGCATTATTTATGTATCTGTTCAGATGTTT\nTATGTGTCTACCTCCCGCCAGCTGAGGCGTCTGGACTCTGTCACCAGGTCCCCAATCTAC\nTCTCACTTCAGCGAGACCGTATCAGGTTTGCCAGTTATCCGTGCCTTTGAGCACCAGCAG\nCGATTTCTGAAACACAATGAGGTGAGGATTGACACCAACCAGAAATGTGTCTTTTCCTGG\nATCACCTCCAACAGGTGGCTTGCAATTCGCCTGGAGCTGGTTGGGAACCTGACTGTCTTC\nTTTTCAGCCTTGATGATGGTTATTTATAGAGATACCCTAAGTGGGGACACTGTTGGCTTT\nGTTCTGTCCAATGCACTCAATATCACACAAACCCTGAACTGGCTGGTGAGGATGACATCA\nGAAATAGAGACCAACATTGTGGCTGTTGAGCGAATAACTGAGTACACAAAAGTGGAAAAT\nGAGGCACCCTGGGTGACTGATAAGAGGCCTCCGCCAGATTGGCCCAGCAAAGGCAAGATC\nCAGTTTAACAACTACCAAGTGCGGTACCGACCTGAGCTGGATCTGGTCCTCAGAGGGATC\nACTTGTGACATCGGTAGCATGGAGAAGATTGGTGTGGTGGGCAGGACAGGAGCTGGAAAG\nTCATCCCTCACAAACTGCCTCTTCAGAATCTTAGAGGCTGCCGGTGGTCAGATTATCATT\nGATGGAGTAGATATTGCTTCCATTGGGCTCCACGACCTCCGAGAGAAGCTGACCATCATC\nCCCCAGGACCCCATCCTGTTCTCTGGAAGCCTGAGGATGAATCTCGACCCTTTCAACAAC\nTACTCAGATGAGGAGATTTGGAAGGCCTTGGAGCTGGCTCACCTCAAGTCTTTTGTGGCC\nAGCCTGCAACTTGGGTTATCCCACGAAGTGACAGAGGCTGGTGGCAACCTGAGCATAGGC\nCAGAGGCAGCTGCTGTGCCTGGGCAGGGCTCTGCTTCGGAAATCCAAGATCCTGGTCCTG\nGATGAGGCCACTGCTGCGGTGGATCTAGAGACAGACAACCTCATTCAGACGACCATCCAA\nAACGAGTTCGCCCACTGCACAGTGATCACCATCGCCCACAGGCTGCACACCATCATGGAC\nAGTGACAAGGTAATGGTCCTAGACAACGGGAAGATTATAGAGTGCGGCAGCCCTGAAGAA\nCTGCTACAAATCCCTGGACCCTTTTACTTTATGGCTAAGGAAGCTGGCATTGAGAATGTG\nAACAGCACAAAATTCTAG"}, "pfams": {"pfam": [{"identifier": "PF00005", "name": "ABC_tran"}, {"identifier": "PF00664", "name": "ABC_membrane"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "nucleoside-triphosphatase activity"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "function", "description": "ATPase activity"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substances"}, {"category": "function", "description": "ATPase activity, coupled to transmembrane movement of substances"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides"}, {"category": "function", "description": "transporter activity"}, {"category": "function", "description": "pyrophosphatase activity"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "14", "id": "BE0001067", "name": "ATP-binding cassette sub-family G member 2", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, Sarkadi B: Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11437380", "known-action": "unknown", "polypeptide": {"@id": "Q9UNQ0", "@source": "Swiss-Prot", "name": "ATP-binding cassette sub-family G member 2", "general-function": "Defense mechanisms and xenobiotic export", "specific-function": "Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from the brain. May be involved in brain-to-blood efflux. Appears to play a major role in the multidrug resistance phenotype of several cancer cell lines. When overexpressed, the transfected cells become resistant to mitoxantrone, daunorubicin and doxorubicin, display diminished intracellular accumulation of daunorubicin, and manifest an ATP- dependent increase in the efflux of rhodamine 123", "gene-name": "ABCG2", "locus": "4q22", "cellular-location": "Cell membrane; multi-pass membrane protein", "transmembrane-regions": "396-416\n429-449\n478-498\n507-527\n536-556\n631-651", "signal-regions": null, "theoretical-pi": "8.9", "molecular-weight": "72315.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:74"}, {"resource": "GenAtlas", "identifier": "ABCG2"}, {"resource": "GeneCards", "identifier": "ABCG2"}, {"resource": "GenBank Gene Database", "identifier": "AF103796"}, {"resource": "GenBank Protein Database", "identifier": "4185796"}, {"resource": "UniProtKB", "identifier": "Q9UNQ0"}, {"resource": "UniProt Accession", "identifier": "ABCG2_HUMAN"}]}, "synonyms": {"synonym": ["Breast cancer resistance protein", "CD338 antigen", "CDw338", "Mitoxantrone resistance-associated protein", "Placenta-specific ATP- binding cassette transporter"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">ATP-binding cassette sub-family G member 2\nMSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKSGFLPCRKPVE\nKEILSNINGIMKPGLNAILGPTGGGKSSLLDVLAARKDPSGLSGDVLINGAPRPANFKCN\nSGYVVQDDVVMGTLTVRENLQFSAALRLATTMTNHEKNERINRVIQELGLDKVADSKVGT\nQFIRGVSGGERKRTSIGMELITDPSILFLDEPTTGLDSSTANAVLLLLKRMSKQGRTIIF\nSIHQPRYSIFKLFDSLTLLASGRLMFHGPAQEALGYFESAGYHCEAYNNPADFFLDIING\nDSTAVALNREEDFKATEIIEPSKQDKPLIEKLAEIYVNSSFYKETKAELHQLSGGEKKKK\nITVFKEISYTTSFCHQLRWVSKRSFKNLLGNPQASIAQIIVTVVLGLVIGAIYFGLKNDS\nTGIQNRAGVLFFLTTNQCFSSVSAVELFVVEKKLFIHEYISGYYRVSSYFLGKLLSDLLP\nMRMLPSIIFTCIVYFMLGLKPKADAFFVMMFTLMMVAYSASSMALAIAAGQSVVSVATLL\nMTICFVFMMIFSGLLVNLTTIASWLSWLQYFSIPRYGFTALQHNEFLGQNFCPGLNATGN\nNPCNYATCTGEEYLVKQGIDLSPWGLWKNHVALACMIVIFLTIAYLKLLFLKKYS"}, "gene-sequence": {"@format": "FASTA", "#text": ">1968 bp\nATGTCTTCCAGTAATGTCGAAGTTTTTATCCCAGTGTCACAAGGAAACACCAATGGCTTC\nCCCGCGACAGTTTCCAATGACCTGAAGGCATTTACTGAAGGAGCTGTGTTAAGTTTTCAT\nAACATCTGCTATCGAGTAAAACTGAAGAGTGGCTTTCTACCTTGTCGAAAACCAGTTGAG\nAAAGAAATATTATCGAATATCAATGGGATCATGAAACCTGGTCTCAACGCCATCCTGGGA\nCCCACAGGTGGAGGCAAATCTTCGTTATTAGATGTCTTAGCTGCAAGGAAAGATCCAAGT\nGGATTATCTGGAGATGTTCTGATAAATGGAGCACCGCGACCTGCCAATTTCAAATGTAAT\nTCAGGTTACGTGGTACAAGATGATGTTGTGATGGGCACTCTGACGGTGAGAGAAAACTTA\nCAGTTCTCAGCAGCTCTTCGGCTTGCAACAACTATGACGAATCATGAAAAAAACGAACGG\nATTAACAGGGTCATTGAAGAGTTAGGTCTGGATAAAGTGGCAGACTCCAAGGTTGGAACT\nCAGTTTATCCGTGGTGTGTCTGGAGGAGAAAGAAAAAGGACTAGTATAGGAATGGAGCTT\nATCACTGATCCTTCCATCTTGTCCTTGGATGAGCCTACAACTGGCTTAGACTCAAGCACA\nGCAAATGCTGTCCTTTTGCTCCTGAAAAGGATGTCTAAGCAGGGACGAACAATCATCTTC\nTCCATTCATCAGCCTCGATATTCCATCTTCAAGTTGTTTGATAGCCTCACCTTATTGGCC\nTCAGGAAGACTTATGTTCCACGGGCCTGCTCAGGAGGCCTTGGGATACTTTGAATCAGCT\nGGTTATCACTGTGAGGCCTATAATAACCCTGCAGACTTCTTCTTGGACATCATTAATGGA\nGATTCCACTGCTGTGGCATTAAACAGAGAAGAAGACTTTAAAGCCACAGAGATCATAGAG\nCCTTCCAAGCAGGATAAGCCACTCATAGAAAAATTAGCGGAGATTTATGTCAACTCCTCC\nTTCTACAAAGAGACAAAAGCTGAATTACATCAACTTTCCGGGGGTGAGAAGAAGAAGAAG\nATCACAGTCTTCAAGGAGATCAGCTACACCACCTCCTTCTGTCATCAACTCAGATGGGTT\nTCCAAGCGTTCATTCAAAAACTTGCTGGGTAATCCCCAGGCCTCTATAGCTCAGATCATT\nGTCACAGTCGTACTGGGACTGGTTATAGGTGCCATTTACTTTGGGCTAAAAAATGATTCT\nACTGGAATCCAGAACAGAGCTGGGGTTCTCTTCTTCCTGACGACCAACCAGTGTTTCAGC\nAGTGTTTCAGCCGTGGAACTCTTTGTGGTAGAGAAGAAGCTCTTCATACATGAATACATC\nAGCGGATACTACAGAGTGTCATCTTATTTCCTTGGAAAACTGTTATCTGATTTATTACCC\nATGAGGATGTTACCAAGTATTATATTTACCTGTATAGTGTACTTCATGTTAGGATTGAAG\nCCAAAGGCAGATGCCTTCTTCGTTATGATGTTTACCCTTATGATGGTGGCTTATTCAGCC\nAGTTCCATGGCACTGGCCATAGCAGCAGGTCAGAGTGTGGTTTCTGTAGCAACACTTCTC\nATGACCATCTGTTTTGTGTTTATGATGATTTTTTCAGGTCTGTTGGTCAATCTCACAACC\nATTGCATCTTGGCTGTCATGGCTTCAGTACTTCAGCATTCCACGATATGGATTTACGGCT\nTTGCAGCATAATGAATTTTTGGGACAAAACTTCTGCCCAGGACTCAATGCAACAGGAAAC\nAATCCTTGTAACTATGCAACATGTACTGGCGAAGAATATTTGGTAAAGCAGGGCATCGAT\nCTCTCACCCTGGGGCTTGTGGAAGAATCACGTGGCCTTGGCTTGTATGATTGTTATTTTC\nCTCACAATTGCCTACCTGAAATTGTTATTTCTTAAAAAATATTCTTAA"}, "pfams": {"pfam": [{"identifier": "PF00005", "name": "ABC_tran"}, {"identifier": "PF01061", "name": "ABC2_membrane"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides"}, {"category": "function", "description": "pyrophosphatase activity"}, {"category": "function", "description": "nucleoside-triphosphatase activity"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "ATPase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "hydrolase activity, acting on acid anhydrides"}]}}}, {"@position": "15", "id": "BE0001004", "name": "Solute carrier organic anion transporter family member 1B1", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Tirona RG, Leake BF, Wolkoff AW, Kim RB: Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003 Jan;304(1):223-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12490595\n# Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y: Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther. 2003 Feb;304(2):610-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12538813\n# Nozawa T, Tamai I, Sai Y, Nezu J, Tsuji A: Contribution of organic anion transporting polypeptide OATP-C to hepatic elimination of the opioid pentapeptide analogue [D-Ala2, D-Leu5]-enkephalin. J Pharm Pharmacol. 2003 Jul;55(7):1013-20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12906759\n# Fehrenbach T, Cui Y, Faulstich H, Keppler D: Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn Schmiedebergs Arch Pharmacol. 2003 Nov;368(5):415-20. Epub 2003 Oct 3. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14530907", "known-action": "unknown", "polypeptide": {"@id": "Q9Y6L6", "@source": "Swiss-Prot", "name": "Solute carrier organic anion transporter family member 1B1", "general-function": "Carbohydrate transport and metabolism", "specific-function": "Mediates the Na(+)-independent transport of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. May play an important role in the clearance of bile acids and organic anions from the liver", "gene-name": "SLCO1B1", "locus": "12p", "cellular-location": "Cell membrane; basolateral cell membrane; multi-pass membrane protein. Note=Detected in basolateral", "transmembrane-regions": "97-117\n207-227\n259-279\n336-356\n376-396\n410-430\n575-595", "signal-regions": null, "theoretical-pi": "8.68", "molecular-weight": "76450.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:10959"}, {"resource": "GenAtlas", "identifier": "SLCO1B1"}, {"resource": "GeneCards", "identifier": "SLCO1B1"}, {"resource": "GenBank Gene Database", "identifier": "AF060500"}, {"resource": "GenBank Protein Database", "identifier": "5051630"}, {"resource": "UniProtKB", "identifier": "Q9Y6L6"}, {"resource": "UniProt Accession", "identifier": "SO1B1_HUMAN"}]}, "synonyms": {"synonym": ["Liver-specific organic anion transporter 1", "LST-1", "OATP 2", "OATP-C", "Sodium-independent organic anion- transporting polypeptide 2", "Solute carrier family 21 member 6"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Solute carrier organic anion transporter family member 1B1\nMDQNQHLNKTAEAQPSENKKTRYCNGLKMFLAALSLSFIAKTLGAIIMKSSIIHIERRFE\nISSSLVGFIDGSFEIGNLLVIVFVSYFGSKLHRPKLIGIGCFIMGIGGVLTALPHFFMGY\nYRYSKETNINSSENSTSTLSTCLINQILSLNRASPEIVGKGCLKESGSYMWIYVFMGNML\nRGIGETPIVPLGLSYIDDFAKEGHSSLYLGILNAIAMIGPIIGFTLGSLFSKMYVDIGYV\nDLSTIRITPTDSRWVGAWWLNFLVSGLFSIISSIPFFFLPQTPNKPQKERKASLSLHVLE\nTNDEKDQTANLTNQGKNITKNVTGFFQSFKSILTNPLYVMFVLLTLLQVSSYIGAFTYVF\nKYVEQQYGQPSSKANILLGVITIPIFASGMFLGGYIIKKFKLNTVGIAKFSCFTAVMSLS\nFYLLYFFILCENKSVAGLTMTYDGNNPVTSHRDVPLSYCNSDCNCDESQWEPVCGNNGIT\nYISPCLAGCKSSSGNKKPIVFYNCSCLEVTGLQNRNYSAHLGECPRDDACTRKFYFFVAI\nQVLNLFFSALGGTSHVMLIVKIVQPELKSLALGFHSMVIRALGGILAPIYFGALIDTTCI\nKWSTNNCGTRGSCRTYNSTSFSRVYLGLSSMLRVSSLVLYIILIYAMKKKYQEKDINASE\nNGSVMDEANLESLNKNKHFVPSAGADSETHC"}, "gene-sequence": {"@format": "FASTA", "#text": ">2076 bp\nATGGACCAAAATCAACATTTGAATAAAACAGCAGAGGCACAACCTTCAGAGAATAAGAAA\nACAAGATACTGCAATGGATTGAAGATGTTCTTGGCAGCTCTGTCACTCAGCTTTATTGCT\nAAGACACTAGGTGCAATTATTATGAAAAGTTCCATCATTCATATAGAACGGAGATTTGAG\nATATCCTCTTCTCTTGTTGGTTTTATTGACGGAAGCTTTGAAATTGGAAATTTGCTTGTG\nATTGTATTTGTGAGTTACTTTGGATCCAAACTACATAGACCAAAGTTAATTGGAATCGGT\nTGTTTCATTATGGGAATTGGAGGTGTTTTGACTGCTTTGCCACATTTCTTCATGGGATAT\nTACAGGTATTCTAAAGAAACTAATATCAATTCATCAGAAAATTCAACATCGACCTTATCC\nACTTGTTTAATTAATCAAATTTTATCACTCAATAAAGCATCACCTGAGATAGTGGGAAAA\nGGTTGTTTAAAGGAATCTGGGTCATACATGTGGATATATGTGTTCATGGGTAATATGCTT\nCGTGGAATAGGGGAGACTCCCATAGTACCACTGGGGCTTTCTTACATTGATGATTTCGCT\nAAAGAAGGACATTCTTCTTTGTATTTAGGTATATTGAATGCAATAGCAATGATTGGTCCA\nATCATTGGCTTTACCCTGGGATCTCTGTTTTCTAAAATGTACGTGGATATTGGATATGTT\nAATCTAAGCACTATCAGGATAACTCCTACTGATTCTCGATGGGTTGGAGCTTGGTGGCTT\nAATTTCCTTGTGTCTGGACTATTCTCCATTATTTCTTCCATACCATTCTTTTTCTTGCCC\nCAAACTCCAAATAAACCACAAAAAGAAAGAAAAGCTTCACTGTCTTTGCATGTGCTGGAA\nACAAATGATGAAAAGGATCAAACAGCTAATTTGACCAATCAAGGAAAAAATATTACCAAA\nAATGTGACTGGTTTTTTCCAGTCTTTTAAAAGCATCCTTACTAATCCCCTGTATGTTATG\nTTTGTGCTTTTGACGTTGTTACAAGTAAGCAGCTATATTGGTGCTTTTACTTATGTCTTC\nAAATACGTAGAGCAACAGTATGGTCAGCCTTCATCTAAGGCTAACATCTTATTGGGAGTC\nATAACCATACCTATTTTTGCAAGTGGAATGTTTTTAGGAGGATATATCATTAAAAAATTC\nAAACTGAACACCGTTGGAATTGCCAAATTCTCATGTTTTACTGCTGTGATGTCATTGTCC\nTTTTACCTATTATATTTTTTCATACTCTGTGAAAACAAATCAGTTGCCGGACTAACCATG\nACCTATGATGGAAATAATCCAGTGACATCTCATAGAGATGTACCACTTTCTTATTGCAAC\nTCAGACTGCAATTGTGATGAAAGTCAATGGGAACCAGTCTGTGGAAACAATGGAATAACT\nTACATCTCACCCTGTCTAGCAGGTTGCAAATCTTCAAGTGGCAATAAAAAGCCTATAGTG\nTTTTACAACTGCAGTTGTTTGGAAGTAACTGGTCTCCAGAACAGAAATTACTCAGCCCAT\nTTGGGTGAATGCCCAAGAGATGATGCTTGTACAAGGAAATTTTACTTTTTTGTTGCAATA\nCAAGTCTTGAATTTATTTTTCTCTGCACTTGGAGGCACCTCACATGTCATGCTGATTGTT\nAAAATTGTTCAACCTGAATTGAAATCACTTGCACTGGGTTTCCACTCAATGGTTATACGA\nGCACTAGGAGGAATTCTAGCTCCTATATATTTTGGGGCTCTGATTGATACAACGTGTATA\nAAGTGGTCCACCAACAACTGTGGCACACGTGGGTCATGTAGGACATATAATTCCACATCA\nTTTTCAAGGGTCTACTTGGGCTTGTCTTCAATGTTAAGAGTCTCATCACTTGTTTTATAT\nATTATATTAATTTATGCCATGAAGAAAAAATATCAAGAGAAAGATATCAATGCATCAGAA\nAATGGAAGTGTCATGGATGAAGCAAACTTAGAATCCTTAAATAAAAATAAACATTTTGTC\nCCTTCTGCTGGGGCAGATAGTGAAACACATTGTTAA"}, "pfams": {"pfam": [{"identifier": "PF07648", "name": "Kazal_2"}, {"identifier": "PF03137", "name": "OATP"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "transporter activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}, {"category": "process", "description": "transport"}]}}}]}}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-11-11", "drugbank-id": [{"@primary": "true", "#text": "DB00092"}, "BIOD00055", "BTD00055"], "name": "Alefacept", "description": "Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.", "cas-number": "222535-22-0", "groups": {"group": ["approved", "withdrawn"]}, "general-references": "# Koo JY, Bagel J, Sweetser MT, Ticho BS: Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study. J Drugs Dermatol. 2006 Jul-Aug;5(7):623-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16865867\n# Krell JM: Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept. J Am Acad Dermatol. 2006 Jun;54(6):1099-101. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16713481\n# Parrish CA, Sobera JO, Robbins CM, Cantrell WC, Desmond RA, Elewski BE: Alefacept in the treatment of psoriatic nail disease: a proof of concept study. J Drugs Dermatol. 2006 Apr;5(4):339-40. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16673801\n# American Society of Health System Pharmacists, Inc., DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995. Alefacept; [updated 2014 Jan 30; cited 2014 Nov 11]. Available from http://web.b.ebscohost.com.login.ezproxy.library.ualberta.ca/dynamed/detail?vid=9&sid=78010ea4-6f9c-4d5a-a7df-a148b3891321%40sessionmgr110&hid=123&bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BlPXNpdGU%3d#db=dme&AN=232900", "synthesis-reference": null, "indication": "As an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis", "pharmacodynamics": "Interferes with lymphocyte activation by specifically binding to the lymphocyte antigen, CD2, and inhibiting LFA-3/CD2 interaction. Activation of T lymphocytes involving the interaction between LFA-3 on antigen-presenting cells and CD2 on T lymphocytes plays a role in the pathophysiology of chronic plaque psoriasis. Also causes a reduction in subsets of CD2+ T lymphocytes as well as CD4+ and CD8+ T lymphocytes.", "mechanism-of-action": "Inhibits T-lymphocyte activation and production by binding to the CD2 lymphocyte antigen.", "toxicity": "While it has been found to cross the placenta in monkeys, it is not yet known if it also diffuses into breast milk.", "metabolism": null, "absorption": "Bioavailability after IM administration is 63%.", "half-life": "~270 hours", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": {"@language": "", "@coder": "", "#text": "ASP0485"}}, "products": {"product": {"name": "Amevive", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02259052", "started-marketing-on": "2004-10-12", "ended-marketing-on": "2012-12-01", "dosage-form": "powder for solution", "strength": "15 mg", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}}, "international-brands": null, "mixtures": {"mixture": {"name": "Amevive", "ingredients": "Alefacept"}}, "packagers": {"packager": [{"name": "Astellas Pharma Inc.", "url": "http://www.astellas.com"}, {"name": "Ben Venue Laboratories Inc.", "url": "http://www.benvenue.com"}, {"name": "Pierre Fabre", "url": "http://www.pierre-fabre.com"}]}, "manufacturers": null, "prices": {"price": {"description": "Amevive 15 mg vial", "cost": {"@currency": "USD", "#text": "1190.4"}, "unit": "vial"}}, "categories": {"category": [{"category": "Dermatologic Agents", "mesh-id": null}, {"category": "Immunosuppressive Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": {"form": "Powder for solution", "route": "intramuscular", "strength": "15 mg"}}, "atc-codes": {"atc-code": {"@code": "L04AA15", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L04", "#text": "IMMUNOSUPPRESSANTS"}, {"@code": "L04A", "#text": "IMMUNOSUPPRESSANTS"}, {"@code": "L04AA", "#text": "Selective immunosuppressants"}]}}, "ahfs-codes": {"ahfs-code": "84:92.00"}, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">Alefacept heavy chain \nCFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVAELENSEFRAFSSFKNRVYLDTVS\nGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYVLESLPSPTLTCALTNGSIEVQCMIPEH\nYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIP\nSSGHSRHRYALIPIPLAVITTCIVLYMNGILKCDRKPDRTNSNRVEPKSCDKTHTCPPCP\nAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPQVKFNWYVDGVQVHNAKTK\nPREQQYNSTYRVVSVLTVLHQNWLDGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYT\nLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKL\nTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK"}, {"@format": "FASTA", "#text": ">Alefacept light chain\nMVAGSDAGRALGVLSVVCLLHCFGFISCFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQK\nDKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYV\nLESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMEND\nLPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKC\nDRKPDRTNSN"}]}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.432", "source": null}, {"kind": "Isoelectric Point", "value": "7.86", "source": null}, {"kind": "Molecular Weight", "value": "51801.1000", "source": null}, {"kind": "Molecular Formula", "value": "C2306H3594N610O694S26", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "12559"}, {"resource": "PharmGKB", "identifier": "PA164748040"}, {"resource": "Wikipedia", "identifier": "Alefacept"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/amevive.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/alefacept.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000719", "name": "T-cell surface antigen CD2", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Chamian F, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Cardinale I, Khatcherian A, Novitskaya I, Wittkowski KM, Krueger JG, Lowes MA: Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis. J Transl Med. 2007 Jun 7;5:27. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17555598\n# da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu YM, Hochman PS: Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol. 2002 May 1;168(9):4462-71. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11970990\n# Larsen R, Ryder LP, Svejgaard A, Gniadecki R: Changes in circulating lymphocyte subpopulations following administration of the leucocyte function-associated antigen-3 (LFA-3)/IgG1 fusion protein alefacept. Clin Exp Immunol. 2007 Jul;149(1):23-30. Epub 2007 Apr 2. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17403057\n# Goedkoop AY, de Rie MA, Picavet DI, Kraan MC, Dinant HJ, van Kuijk AW, Tak PP, Bos JD, Teunissen MB: Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch Dermatol Res. 2004 Apr;295(11):465-73. Epub 2004 Feb 14. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14968366\n# Ortonne JP: Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2003 Jul;17 Suppl 2:12-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12795770\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P06729", "@source": "Swiss-Prot", "name": "T-cell surface antigen CD2", "general-function": "Involved in cell-cell adhesion", "specific-function": "CD2 interacts with lymphocyte function-associated antigen (LFA-3) and CD48/BCM1 to mediate adhesion between T-cells and other cell types. CD2 is implicated in the triggering of T- cells, the cytoplasmic domain is implicated in the signaling function", "gene-name": "CD2", "locus": "1p13", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "210-235", "signal-regions": null, "theoretical-pi": "10.3", "molecular-weight": "39440.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1639"}, {"resource": "GenAtlas", "identifier": "CD2"}, {"resource": "GeneCards", "identifier": "CD2"}, {"resource": "GenBank Gene Database", "identifier": "M19806"}, {"resource": "GenBank Protein Database", "identifier": "180081"}, {"resource": "UniProtKB", "identifier": "P06729"}, {"resource": "UniProt Accession", "identifier": "CD2_HUMAN"}]}, "synonyms": {"synonym": ["Erythrocyte receptor", "LFA-2", "LFA-3 receptor", "Rosette receptor", "T-cell surface antigen CD2 precursor", "T-cell surface antigen T11/Leu- 5"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">T-cell surface antigen CD2 precursor\nMSFPCKFVASFLLIFNVSSKGAVSKEITNALETWGALGQDINLDIPSFQMSDDIDDIKWE\nKTSDKKKIAQFRKEKETFKEKDTYKLFKNGTLKIKHLKTDDQDIYKVSIYDTKGKNVLEK\nIFDLKIQERVSKPKISWTCINTTLTCEVMNGTDPELNLYQDGKHLKLSQRVITHKWTTSL\nSAKFKCTAGNKVSKESSVEPVSCPEKGLDIYLIIGICGGGSLLMVFVALLVFYITKRKKQ\nRSRRNDEELETRAHRVATEERGRKPQQIPASTPQNPATSQHPPPPPGHRSQAPSHRPPPP\nGHRVQHQPQKRPPAPSGTQVHQQKGPPLPRPRVQPKPPHGAAENSLSPSSN"}, "gene-sequence": {"@format": "FASTA", "#text": ">1056 bp\nATGAGCTTTCCATGTAAATTTGTAGCCAGCTTCCTTCTGATTTTCAATGTTTCTTCCAAA\nGGTGCAGTCTCCAAAGAGATTACGAATGCCTTGGAAACCTGGGGTGCCTTGGGTCAGGAC\nATCAACTTGGACATTCCTAGTTTTCAAATGAGTGATGATATTGACGATATAAAATGGGAA\nAAAACTTCAGACAAGAAAAAGATTGCACAATTCAGAAAAGAGAAAGAGACTTTCAAGGAA\nAAAGATACATATAAGCTATTTAAAAATGGAACTCTGAAAATTAAGCATCTGAAGACCGAT\nGATCAGGATATCTACAAGGTATCAATATATGATACAAAAGGAAAAAATGTGTTGGAAAAA\nATATTTGATTTGAAGATTCAAGAGAGGGTCTCAAAACCAAAGATCTCCTGGACTTGTATC\nAACACAACCCTGACCTGTGAGGTAATGAATGGAACTGACCCCGAATTAAACCTGTATCAA\nGATGGGAAACATCTAAAACTTTCTCAGAGGGTCATCACACACAAGTGGACCACCAGCCTG\nAGTGCAAAATTCAAGTGCACAGCAGGGAACAAAGTCAGCAAGGAATCCAGTGTCGAGCCT\nGTCAGCTGTCCAGAGAAAGGTCTGGACATCTATCTCATCATTGGCATATGTGGAGGAGGC\nAGCCTCTTGATGGTCTTTGTGGCACTGCTCGTTTTCTATATCACCAAAAGGAAAAAACAG\nAGGAGTCGGAGAAATGATGAGGAGCTGGAGACAAGAGCCCACAGAGTAGCTACTGAAGAA\nAGGGGCCGGAAGCCCCACCAAATTCCAGCTTCAACCCCTCAGAATCCAGCAACTTCCCAA\nCATCCTCCTCCACCACCTGGTCATCGTTCCCAGGCACCTAGTCATCGTCCCCCGCCTCCT\nGGACACCGTGTTCAGCACCAGCCTCAGAAGAGGCCTCCTGCTCCGTCGGGCACACAAGTT\nCACCAGCAGAAAGGCCCGCCCCTCCCCAGACCTCGAGTTCAGCCAAAACCTCCCCATGGG\nGCAGCAGAAAACTCATTGTCCCCTTCCTCTAATTAA"}, "pfams": {"pfam": [{"identifier": "PF07686", "name": "V-set"}, {"identifier": "PF05790", "name": "C2-set"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell adhesion"}]}}}, {"@position": "2", "id": "BE0002093", "name": "Complement C1r subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P00736", "@source": "Swiss-Prot", "name": "Complement C1r subcomponent", "general-function": null, "specific-function": "C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system", "gene-name": "C1R", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.24", "molecular-weight": "80174.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1246"}, {"resource": "GenAtlas", "identifier": "C1R"}, {"resource": "GeneCards", "identifier": "C1R"}, {"resource": "GenBank Gene Database", "identifier": "X04701"}, {"resource": "GenBank Protein Database", "identifier": "29539"}, {"resource": "UniProtKB", "identifier": "P00736"}, {"resource": "UniProt Accession", "identifier": "C1R_HUMAN"}]}, "synonyms": {"synonym": ["Complement C1r subcomponent precursor", "Complement component 1, r subcomponent", "EC 3.4.21.41"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1r subcomponent\nMWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF\nQQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF\nSNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY\nELQEDRHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF\nDIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL\nRYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD\nDGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR\nESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF\nTNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV\nSVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME\nEKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV\nRDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2118 bp\nATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC\nATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC\nAACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC\nCAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT\nGATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG\nGGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC\nTCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT\nGTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG\nTGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT\nGAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG\nGCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC\nAACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT\nGATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC\nGGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC\nAATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG\nCGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC\nATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA\nGGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT\nGATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA\nAACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC\nCGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG\nGAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG\nGGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG\nAGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC\nACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT\nGCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC\nCTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC\nAGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG\nCTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC\nAACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG\nGAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT\nGAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT\nGGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA\nAGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC\nAGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG\nATGGAGGAGGAGGACTGA"}, "pfams": {"pfam": [{"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF07645", "name": "EGF_CA"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "3", "id": "BE0002094", "name": "Complement C1q subcomponent subunit A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02745", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit A", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QA", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.45", "molecular-weight": "26017.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1241"}, {"resource": "GenAtlas", "identifier": "C1QA"}, {"resource": "GeneCards", "identifier": "C1QA"}, {"resource": "GenBank Gene Database", "identifier": "AF135157"}, {"resource": "GenBank Protein Database", "identifier": "4894854"}, {"resource": "UniProtKB", "identifier": "P02745"}, {"resource": "UniProt Accession", "identifier": "C1QA_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit A precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit A\nMEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR\nTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI\nRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR\nGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL\nIFPSA"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG\nGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC\nAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG\nACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC\nAAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGGGCCCGTGGCATCCCGGGAATTAAA\nGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT\nCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG\nGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC\nTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG\nGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG\nGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC\nCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC\nATCTTCCCATCTGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "4", "id": "BE0002095", "name": "Complement C1q subcomponent subunit B", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02746", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit B", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QB", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.87", "molecular-weight": "26460.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1242"}, {"resource": "GenAtlas", "identifier": "C1QB"}, {"resource": "GeneCards", "identifier": "C1QB"}, {"resource": "GenBank Gene Database", "identifier": "X03084"}, {"resource": "GenBank Protein Database", "identifier": "573114"}, {"resource": "UniProtKB", "identifier": "P02746"}, {"resource": "UniProt Accession", "identifier": "C1QB_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit B precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit B\nMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEK\nGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKI\nAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCV\nNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANSIF\nSGFLLFPDMEA"}, "gene-sequence": {"@format": "FASTA", "#text": ">688 bp\nCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGG\nGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCC\nAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAA\nTCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGCCCAGGGGCCCCTGG\nAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAGAAAATCGCCTTCTC\nTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATCCGCTTCGACCACGT\nGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTCACCTGCAAGGTGCC\nCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTGTGCGTGAACCTCAT\nGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTATGCCTACAACACCTT\nCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAGAACGTCTTCCTGCA\nGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGCATCTTTTCCGGGTT\nCCTGCTCTTTCCAGATATGGAGGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "5", "id": "BE0002096", "name": "Complement C1q subcomponent subunit C", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02747", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit C", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QC", "locus": "1p36.11", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.58", "molecular-weight": "25774.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1245"}, {"resource": "GenAtlas", "identifier": "C1QC"}, {"resource": "GeneCards", "identifier": "C1QC"}, {"resource": "GenBank Gene Database", "identifier": "AF087892"}, {"resource": "GenBank Protein Database", "identifier": "33150626"}, {"resource": "UniProtKB", "identifier": "P02747"}, {"resource": "UniProt Accession", "identifier": "C1QC_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit C precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit C\nMDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP\nGIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS\nVFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV\nLLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF\nLLFPD"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG\nCTGCTGCCCCTCAGGGCCAAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC\nCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA\nGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA\nCCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC\nCCCATGGGATTCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA\nGTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC\nAACGCGGTCCTCACCAACCCGCAGGAGGATTATGACACGAGCACTGGCAAGTTCACCTGC\nAAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG\nCTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT\nCAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT\nGTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC\nCTGCTCTTCCCCGACTAG"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"@position": "6", "id": "BE0002097", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu YM, Hochman PS: Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol. 2002 May 1;168(9):4462-71. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11970990\n# Vaishnaw AK, TenHoor CN: Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. J Pharmacokinet Pharmacodyn. 2002 Dec;29(5-6):415-26. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12795239", "known-action": "unknown", "polypeptide": {"@id": "P08637", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "general-function": null, "specific-function": "Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis", "gene-name": "FCGR3A", "locus": "1q23", "cellular-location": "Cell membrane", "transmembrane-regions": "209-229", "signal-regions": null, "theoretical-pi": "8.21", "molecular-weight": "29089.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3619"}, {"resource": "GenAtlas", "identifier": "FCGR3A"}, {"resource": "GeneCards", "identifier": "FCGR3A"}, {"resource": "GenBank Gene Database", "identifier": "X52645"}, {"resource": "GenBank Protein Database", "identifier": "31324"}, {"resource": "UniProtKB", "identifier": "P08637"}, {"resource": "UniProt Accession", "identifier": "FCG3A_HUMAN"}]}, "synonyms": {"synonym": ["CD16a antigen", "Fc-gamma RIII", "Fc-gamma RIII-alpha", "Fc-gamma RIIIa", "FcR-10", "FcRIII", "FcRIIIa", "IgG Fc receptor III-2", "Low affinity immunoglobulin gamma Fc region receptor III-A precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK"}, "gene-sequence": {"@format": "FASTA", "#text": ">765 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCGACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCA\nAAAGCCACACTCAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTTTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGG\nAAGGACCATAAATTTAAATGGAGAAAGGACCCTCAAGACAAATGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "7", "id": "BE0000710", "name": "High affinity immunoglobulin gamma Fc receptor I", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P12314", "@source": "Swiss-Prot", "name": "High affinity immunoglobulin gamma Fc receptor I", "general-function": "Involved in receptor signaling protein activity", "specific-function": "Binds to the Fc region of immunoglobulins gamma. High affinity receptor", "gene-name": "FCGR1A", "locus": "1q21.2-q21.3", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "293-313", "signal-regions": null, "theoretical-pi": "8.08", "molecular-weight": "42632.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3613"}, {"resource": "GenAtlas", "identifier": "FCGR1A"}, {"resource": "GeneCards", "identifier": "FCGR1A"}, {"resource": "GenBank Gene Database", "identifier": "X14356"}, {"resource": "GenBank Protein Database", "identifier": "31332"}, {"resource": "UniProtKB", "identifier": "P12314"}, {"resource": "UniProt Accession", "identifier": "FCGR1_HUMAN"}]}, "synonyms": {"synonym": ["CD64 antigen", "Fc-gamma RI", "FcRI", "High affinity immunoglobulin gamma Fc receptor I precursor", "IgG Fc receptor I"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">High affinity immunoglobulin gamma Fc receptor I precursor\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1125 bp\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCTCTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAACTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "8", "id": "BE0002098", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P12318", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "general-function": null, "specific-function": "Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens", "gene-name": "FCGR2A", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.78", "molecular-weight": "34990.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3616"}, {"resource": "GenAtlas", "identifier": "FCGR2A"}, {"resource": "GeneCards", "identifier": "FCGR2A"}, {"resource": "GenBank Gene Database", "identifier": "M31932"}, {"resource": "GenBank Protein Database", "identifier": "182474"}, {"resource": "UniProtKB", "identifier": "P12318"}, {"resource": "UniProt Accession", "identifier": "FCG2A_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-a", "Fc-gamma-RIIa", "FcRII-a", "IgG Fc receptor II-a", "Low affinity immunoglobulin gamma Fc region receptor II-a precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-a\nMAMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSRLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">954 bp\nATGGCTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "9", "id": "BE0002099", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31994", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "general-function": null, "specific-function": "Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B- cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis", "gene-name": "FCGR2B", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.12", "molecular-weight": "34044.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3618"}, {"resource": "GenAtlas", "identifier": "FCGR2B"}, {"resource": "GeneCards", "identifier": "FCGR2B"}, {"resource": "GenBank Gene Database", "identifier": "U87560"}, {"resource": "GenBank Protein Database", "identifier": "4099445"}, {"resource": "UniProtKB", "identifier": "P31994"}, {"resource": "UniProt Accession", "identifier": "FCG2B_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-b", "Fc-gamma-RIIb", "FcRII-b", "IgG Fc receptor II-b", "Low affinity immunoglobulin gamma Fc region receptor II-b precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI"}, "gene-sequence": {"@format": "FASTA", "#text": ">930 bp\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCTCTCCCAGGATACCCTGAG\nTGCAGGGAAATGGGAGAGACCCTCCCTGAGAAACCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATT"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "10", "id": "BE0002100", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31995", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "general-function": null, "specific-function": "Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells", "gene-name": "FCGR2C", "locus": "1q23.3", "cellular-location": "Cell membrane", "transmembrane-regions": "224-246", "signal-regions": null, "theoretical-pi": "6.9", "molecular-weight": "35578.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:15626"}, {"resource": "GenAtlas", "identifier": "FCGR2C"}, {"resource": "GeneCards", "identifier": "FCGR2C"}, {"resource": "GenBank Gene Database", "identifier": "X17652"}, {"resource": "GenBank Protein Database", "identifier": "32074"}, {"resource": "UniProtKB", "identifier": "P31995"}, {"resource": "UniProt Accession", "identifier": "FCG2C_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-c", "Fc-gamma-RIIc", "FcRII-c", "IgG Fc receptor II-c", "Low affinity immunoglobulin gamma Fc region receptor II-c precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-c\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR\nAPTDDDKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">972 bp\nATGGGAATCCTGTCATTTTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACAGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCATTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCTGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG\nAAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT\nGAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG\nGCACCTACTGACGATGATAAAAACATCTACTTGACTCTTCCTCCCAACGACCATGTCAAC\nAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "11", "id": "BE0000901", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "organism": "Human", "actions": null, "references": "# da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu YM, Hochman PS: Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol. 2002 May 1;168(9):4462-71. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11970990", "known-action": "unknown", "polypeptide": {"@id": "O75015", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "general-function": null, "specific-function": "Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils", "gene-name": "FCGR3B", "locus": "1q23", "cellular-location": "Cell membrane; lipid-anchor; GPI-anchor. Secreted protein. Note=Secreted after cleavage", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.71", "molecular-weight": "26216.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3620"}, {"resource": "GenAtlas", "identifier": "FCGR3B"}, {"resource": "GeneCards", "identifier": "FCGR3B"}, {"resource": "GenBank Gene Database", "identifier": "X16863"}, {"resource": "GenBank Protein Database", "identifier": "31322"}, {"resource": "UniProtKB", "identifier": "O75015"}, {"resource": "UniProt Accession", "identifier": "FCG3B_HUMAN"}]}, "synonyms": {"synonym": ["CD16b antigen", "Fc-gamma RIII", "Fc-gamma RIII-beta", "Fc-gamma RIIIb", "FcR-10", "FcRIII", "FcRIIIb", "IgG Fc receptor III-1", "Low affinity immunoglobulin gamma Fc region receptor III-B precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-B precursor\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI"}, "gene-sequence": {"@format": "FASTA", "#text": ">702 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2005-06-13", "@updated": "2014-04-22", "drugbank-id": [{"@primary": "true", "#text": "DB00093"}, "BIOD00114", "BTD00114"], "name": "Felypressin", "description": "A synthetic nonapeptide comprising cysteinyl, phenylalanyl, phenylalanyl, glutaminyl, asparaginyl, cysteinyl, prolyl, lysyl, and glycinamide residues in sequence, with a disulfide bridge joining the two cysteine residues. Its antidiuretic effects are less than those of vasopressin. It is used as a vasoconstrictor in local anaesthetic injections for dental use, and is an ingredient of preparations that have been used for treatment of pain and inflammation of the mouth. [ChEBI]", "cas-number": "56-59-7", "groups": {"group": "approved"}, "general-references": "# Cecanho R, De Luca LA Jr, Ranali J: Cardiovascular effects of felypressin. Anesth Prog. 2006 Winter;53(4):119-25. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17177590", "synthesis-reference": "Boissonnas, R.and Guttmann, S.; U.S. Patent 3,232,923; February 1, 1966: assigned to Sandoz AG, Switzerland.", "indication": "For use as an alternative to adrenaline as a localising agent, provided that local ischaemia is not essential.", "pharmacodynamics": "Felypressin is a synthetic analog of lypressin or vasopressin with more vasoconstrictor activity than antidiuretic action. It is used primarily as a hemostatic. Felypressin is a non-catecholamine vasoconstrictor that is chemically related to vasopressin, the posterior pituitary hormone.", "mechanism-of-action": "Felypressin binds to the vasopressin receptor V1a. This causes contraction of the smooth muscle in the vascular bed, especially capillaries, small arterioles and venules.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": "This compound belongs to the class of organic compounds known as cyclic peptides. These are compounds containing a cyclic moiety bearing a peptide backbone.", "direct-parent": "Cyclic peptides", "kingdom": "Organic compounds", "superclass": "Organic acids and derivatives", "class": "Carboxylic acids and derivatives", "subclass": "Amino acids, peptides, and analogues", "alternative-parent": ["Alpha amino acid amides", "Azacyclic compounds", "Benzene and substituted derivatives", "Carbonyl compounds", "Cyclic alcohols and derivatives", "Hydrocarbon derivatives", "Lactams", "Macrolactams", "Monoalkylamines", "N-acyl amines", "N-acyl-alpha amino acids and derivatives", "N-acylpyrrolidines", "Organic disulfides", "Primary carboxylic acid amides", "Pyrrolidinecarboxamides", "Secondary carboxylic acid amides", "Tertiary amines", "Tertiary carboxylic acid amides"], "substituent": ["Alpha-amino acid amide", "Alpha-amino acid or derivatives", "Amine", "Aromatic heteromonocyclic compound", "Azacycle", "Benzenoid", "Carbonyl group", "Carboxamide group", "Carboxylic acid amide", "Cyclic alcohol", "Cyclic alpha peptide", "Fatty acyl", "Fatty amide", "Hydrocarbon derivative", "Lactam", "Macrolactam", "Monocyclic benzene moiety", "N-acyl-alpha amino acid or derivatives", "N-acyl-amine", "N-acylpyrrolidine", "N-substituted-alpha-amino acid", "Organic disulfide", "Organoheterocyclic compound", "Organonitrogen compound", "Organooxygen compound", "Primary aliphatic amine", "Primary amine", "Primary carboxylic acid amide", "Pyrrolidine", "Pyrrolidine carboxylic acid or derivatives", "Pyrrolidine-2-carboxamide", "Secondary carboxylic acid amide", "Tertiary amine", "Tertiary carboxylic acid amide"]}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "2-(L-phenylalanine)-8-L-lysinevasopressin"}, {"@language": "Spanish", "@coder": "INN", "#text": "Felipresina"}, {"@language": "", "@coder": "INN, BAN, USAN", "#text": "Felypressin"}, {"@language": "French", "@coder": "INN", "#text": "Felypressine"}, {"@language": "Latin", "@coder": "INN", "#text": "Felypressinum"}, {"@language": "", "@coder": "", "#text": "PLV-2"}]}, "products": null, "international-brands": {"international-brand": [{"name": "Colupressine", "company": "Joullie"}, {"name": "Octapressin", "company": "Sandoz"}]}, "mixtures": null, "packagers": null, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Novartis pharmaceuticals corp"}}, "prices": null, "categories": {"category": [{"category": "Vasoconstrictor Agents", "mesh-id": null}, {"category": "Renal Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": null, "atc-codes": null, "ahfs-codes": null, "patents": null, "food-interactions": null, "drug-interactions": null, "calculated-properties": {"property": [{"kind": "logP", "value": "-1.1", "source": "ALOGPS"}, {"kind": "logS", "value": "-4.4", "source": "ALOGPS"}, {"kind": "Water Solubility", "value": "4.53e-02 g/l", "source": "ALOGPS"}, {"kind": "logP", "value": "-5.8", "source": "ChemAxon"}, {"kind": "IUPAC Name", "value": "(2S)-6-amino-2-{[(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-13,16-dibenzyl-10-(2-carbamoylethyl)-7-(carbamoylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl]pyrrolidin-2-yl]formamido}-N-(carbamoylmethyl)hexanamide", "source": "ChemAxon"}, {"kind": "Traditional IUPAC Name", "value": "felypressin", "source": "ChemAxon"}, {"kind": "Molecular Weight", "value": "1040.219", "source": "ChemAxon"}, {"kind": "Monoisotopic Weight", "value": "1039.436791367", "source": "ChemAxon"}, {"kind": "SMILES", "value": "NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O", "source": "ChemAxon"}, {"kind": "Molecular Formula", "value": "C46H65N13O11S2", "source": "ChemAxon"}, {"kind": "InChI", "value": "InChI=1/C46H65N13O11S2/c47-18-8-7-14-29(40(64)52-23-38(51)62)54-45(69)35-15-9-19-59(35)46(70)34-25-72-71-24-28(48)39(63)55-31(20-26-10-3-1-4-11-26)43(67)56-32(21-27-12-5-2-6-13-27)42(66)53-30(16-17-36(49)60)41(65)57-33(22-37(50)61)44(68)58-34/h1-6,10-13,28-35H,7-9,14-25,47-48H2,(H2,49,60)(H2,50,61)(H2,51,62)(H,52,64)(H,53,66)(H,54,69)(H,55,63)(H,56,67)(H,57,65)(H,58,68)/t28-,29-,30-,31-,32-,33-,34-,35-/s2", "source": "ChemAxon"}, {"kind": "InChIKey", "value": "InChIKey=SFKQVVDKFKYTNA-YVGXZPIDNA-N", "source": "ChemAxon"}, {"kind": "Polar Surface Area (PSA)", "value": "405.32", "source": "ChemAxon"}, {"kind": "Refractivity", "value": "264.79", "source": "ChemAxon"}, {"kind": "Polarizability", "value": "103.93", "source": "ChemAxon"}, {"kind": "Rotatable Bond Count", "value": "19", "source": "ChemAxon"}, {"kind": "H Bond Acceptor Count", "value": "13", "source": "ChemAxon"}, {"kind": "H Bond Donor Count", "value": "12", "source": "ChemAxon"}, {"kind": "pKa (strongest acidic)", "value": "11.39", "source": "ChemAxon"}, {"kind": "pKa (strongest basic)", "value": "10.18", "source": "ChemAxon"}, {"kind": "Physiological Charge", "value": "2", "source": "ChemAxon"}, {"kind": "Number of Rings", "value": "4", "source": "ChemAxon"}, {"kind": "Bioavailability", "value": "0", "source": "ChemAxon"}, {"kind": "Rule of Five", "value": "0", "source": "ChemAxon"}, {"kind": "Ghose Filter", "value": "0", "source": "ChemAxon"}, {"kind": "MDDR-Like Rule", "value": "1", "source": "ChemAxon"}]}, "experimental-properties": {"property": {"kind": "Melting Point", "value": "222", "source": "Boissonnas, R.and Guttmann, S.; U.S. Patent 3,232,923; February 1, 1966: assigned to Sandoz AG, Switzerland."}}, "external-identifiers": {"external-identifier": [{"resource": "PharmGKB", "identifier": "PA164744374"}, {"resource": "Wikipedia", "identifier": "Felypressin"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0000165", "name": "Vasopressin V1a receptor", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G: Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18655903\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P37288", "@source": "Swiss-Prot", "name": "Vasopressin V1a receptor", "general-function": "Involved in rhodopsin-like receptor activity", "specific-function": "Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl- inositol-calcium second messenger system. Has been involved in social behaviors, including affiliation and attachment", "gene-name": "AVPR1A", "locus": "12q14-q15", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "53-76\n89-110\n126-147\n169-190\n219-239\n294-313\n332-351", "signal-regions": null, "theoretical-pi": "9.67", "molecular-weight": "46800.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:895"}, {"resource": "GenAtlas", "identifier": "AVPR1A"}, {"resource": "GeneCards", "identifier": "AVPR1A"}, {"resource": "GenBank Gene Database", "identifier": "L25615"}, {"resource": "GenBank Protein Database", "identifier": "667068"}, {"resource": "IUPHAR", "identifier": "366"}, {"resource": "Guide to Pharmacology", "identifier": "66"}, {"resource": "UniProtKB", "identifier": "P37288"}, {"resource": "UniProt Accession", "identifier": "V1AR_HUMAN"}]}, "synonyms": {"synonym": ["Antidiuretic hormone receptor 1a", "AVPR V1a", "V1aR", "Vascular/hepatic-type arginine vasopressin receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Vasopressin V1a receptor\nMRLSAGPDAGPSGNSSPWWPLATGAGNTSREAEALGEGNGPPRDVRNEELAKLEIAVLAV\nTFAVAVLGNSSVLLALHRTPRKTSRMHLFIRHLSLADLAVAFFQVLPQMCWDITYRFRGP\nDWLCRVVKHLQVFGMFASAYMLVVMTADRYIAVCHPLKTLQQPARRSRLMIAAAWVLSFV\nLSTPQYFVFSMIEVNNVTKARDCWATFIQPWGSRAYVTWMTGGIFVAPVVILGTCYGFIC\nYNIWCNVRGKTASRQSKGAEQAGVAFQKGFLLAPCVSSVKSISRAKIRTVKMTFVIVTAY\nIVCWAPFFIIQMWSVWDPMSVWTESENPTITITALLGSLNSCCNPWIYMFFSGHLLQDCV\nQSFPCCQNMKEKFNKEDTDSMSRRQTFYSNNRSPTNSTGMWKDSPKSSKSIKFIPVST"}, "gene-sequence": {"@format": "FASTA", "#text": ">1257 bp\nATGCGTCTCTCCGCCGGTCCCGACGCGGGGCCCTCGGGCAACTCCAGCCCATGGTGGCCT\nCTGGCCACCGGCGCTGGCAACACAAGCCGGGAGGCCGAAGCCCTCGGGGAGGGCAACGGC\nCCACCGAGGGACGTGCGCAACGAGGAGCTGGCCAAACTGGAGATCGCCGTGCTGGCGGTG\nACTTTCGCGGTGGCCGTGCTGGGCAACAGCAGCGTACTGCTGGCTCTGCACCGGACGCCG\nCGCAAGACGTCCCGCATGCACCTCTTCATCCGACACCTCAGCCTGGCCGACCTGGCCGTG\nGCATTCTTCCAGGTGCTGCCGCAAATGTGCTGGGACATCACCTACCGCTTCCGCGGCCCC\nGACTGGCTGTGCCGCGTGGTGAAGCACCTGCAGGTGTTCGGCATGTTTGCGTCGGCCTAC\nATGCTGGTAGTCATGACAGCCGACCGCTACATCGCGGTGTGCCACCCGCTCAAGACTCTG\nCAACAGCCCGCGCGCCGCTCGCGCCTCATGATCGCGGCCGCCTGGGTGCTGAGCTTCGTG\nCTGAGCACGCCGCAGTACTTCGTCTTCTCCATGATCGAGGTGAACAATGTCACCAAGGCC\nCGCGACTGCTGGGCCACCTTCATCCAGCCCTGGGGTTCTCGTGCCTACGTGACCTGGATG\nACGGGCGGCATCTTTGTGGCGCCCGTGGTCATCTTGGGTACCTGCTACGGCTTCATCTGC\nTACAACATCTGGTGCAACGTCCGCGGGAAGACGGCGTCGCGCCAGAGCAAGGGTGCAGAG\nCAAGCGGGTGTGGCCTTCCAAAAGGGGTTCCTGCTCGCACCCTGTGTCAGCAGCGTGAAG\nTCCATTTCCCGGGCCAAGATCCGCACGGTGAAGATGACTTTTGTGATCGTGACGGCTTAC\nATCGTCTGCTGGGCGCCTTTCTTCATCATCCAGATGTGGTCTGTCTGGGATCCCATGTCC\nGTCTGGACCGAATCGGAAAACCCTACCATCACCATCACTGCATTACTGGGTTCCTTGAAT\nAGCTGCTGTAATCCCTGGATATACATGTTTTTTAGTGGCCATCTCCTTCAAGACTGTGTT\nCAAAGCTTCCCATGCTGCCAAAACATGAAGGAAAAATTCAACAAAGAAGATACTGACAGT\nATGAGCAGAAGACAGACTTTTTATTCTAACAATCGAAGCCCAACAAACAGTACGGGTATG\nTGGAAGGACTCGCCTAAATCTTCCAAGTCCATCAAATTCATTCCTGTTTCAACTTGA"}, "pfams": {"pfam": {"identifier": "PF00001", "name": "7tm_1"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "function", "description": "peptide receptor activity, G-protein coupled"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "vasopressin-like receptor activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "vasopressin receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}]}}}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-11-11", "drugbank-id": [{"@primary": "true", "#text": "DB00094"}, "BIOD00104", "BTD00104"], "name": "Urofollitropin", "description": "Urofollitropin is a purified form of follicle-stimulating hormone (FSH) that is manufactured by extraction from human urine and then purified. It consists of two non-covalently linked, non-identical glycoproteins designated as the alpha- and beta- subunits. The alpha- and beta- subunits have 92 and 111 amino acids. The alpha subunit is glycosylated at Asn 51 and Asn 78 while the beta subunit is glycosylated at Asn 7 and Asn 24. Urofollitropin is important in the development of follicles produced by the ovaries. Given by subcutaneous injection, it is used in combination with human chorionic gonadotropin (hCG) to assist in ovulation and fertility. Urofollitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF).", "cas-number": "146479-72-3", "groups": {"group": "approved"}, "general-references": "# Goa KL, Wagstaff AJ: Follitropin alpha in infertility: a review. BioDrugs. 1998 Mar;9(3):235-60. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18020563\n#Lexicomp. Urofollitropin. N.p., 2014. Web. 11 Nov. 2014. http://online.lexi.com.login.ezproxy.library.ualberta.ca/lco/action/doc/retrieve/docid/patch_f/797#f_pharmacology-and-pharmacokinetics", "synthesis-reference": null, "indication": "For treatment of female infertility", "pharmacodynamics": "Used for the treatment of female infertility, urofollitropin or follicle stimulating hormone (FSH) stimulates ovarian follicular growth in women who do not have primary ovarian failure. FSH, the active component of urofollitropin is the primary hormone responsible for follicular recruitment and development.", "mechanism-of-action": "FSH binds to the follicle stimulating hormone receptor which is a G-coupled transmembrane receptor. Binding of the FSH to its receptor seems to induce phosphorylation and activation of the PI3K (Phosphatidylinositol-3-kinase) and Akt signaling pathway, which is known to regulate many other metabolic and related survival/maturation functions in cells.", "toxicity": null, "metabolism": null, "absorption": "74%", "half-life": "Circulation half life of 3-4 hours, elimination half life of 35-40 hours", "protein-binding": null, "route-of-elimination": "Via liver and kidneys", "volume-of-distribution": "Time to peak in plasma:\nIM: 17 hours (single dose), 11 hours (multiple doses)\nSubQ: 21 hours (single dose), 10 hours (multiple doses)", "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Follicle Stimulating Hormone"}, {"@language": "", "@coder": "", "#text": "Follicle-stimulating hormone beta subunit"}, {"@language": "", "@coder": "", "#text": "Follitropin beta chain precursor"}, {"@language": "", "@coder": "", "#text": "FSH"}, {"@language": "", "@coder": "", "#text": "FSH-B"}, {"@language": "", "@coder": "", "#text": "FSH-beta"}, {"@language": "", "@coder": "", "#text": "Urofollitrophin"}]}, "products": {"product": [{"name": "Bravelle", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02268140", "started-marketing-on": "2005-06-15", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "75 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Fertinorm Hp 150 - Pws Diluent Im Sc", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02125412", "started-marketing-on": "1994-12-31", "ended-marketing-on": "2007-05-07", "dosage-form": "kit; liquid; powder for solution", "strength": "150 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Fertinorm Hp 75 - Pws Diluent Im Sc", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02125404", "started-marketing-on": "1994-12-31", "ended-marketing-on": "2007-05-07", "dosage-form": "liquid; powder for solution", "strength": "75 unit", "route": "intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Humegon Inj 75 I.U.", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01958992", "started-marketing-on": "1993-12-31", "ended-marketing-on": "2006-08-17", "dosage-form": "liquid; powder for solution", "strength": ".9 %", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Metrodin 75 I.U.", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00755613", "started-marketing-on": "1988-12-31", "ended-marketing-on": "1999-08-11", "dosage-form": "powder for solution", "strength": "75 unit", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Pergonal 75 I.U.", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00254916", "started-marketing-on": "1979-12-31", "ended-marketing-on": "2007-05-07", "dosage-form": "powder for solution", "strength": "75 unit", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": [{"name": "Fertinex", "company": "Serono S.A."}, {"name": "Metrodin", "company": "Serum Inst."}]}, "mixtures": {"mixture": [{"name": "Bravelle", "ingredients": "Urofollitropin"}, {"name": "Humegon Inj 75 I.U.", "ingredients": "Sodium Chloride + Lutropin alfa + Urofollitropin"}, {"name": "Fertinorm Hp 75 - Pws Diluent Im Sc", "ingredients": "Urofollitropin + Sodium Chloride"}, {"name": "Fertinorm Hp 150 - Pws Diluent Im Sc", "ingredients": "Urofollitropin + Sodium Chloride"}, {"name": "Pergonal 75 I.U.", "ingredients": "Lutropin alfa + Urofollitropin"}, {"name": "Metrodin 75 I.U.", "ingredients": "Urofollitropin"}]}, "packagers": {"packager": [{"name": "Cardinal Health", "url": "http://www.cardinal.com"}, {"name": "Draxis Specialty Pharmaceuticals Inc.", "url": "http://www.draxispharma.com"}, {"name": "Ferring Pharmaceuticals Inc.", "url": "http://www.ferring.com"}, {"name": "Instituto Massone SA", "url": "http://www.massone.com"}, {"name": "Merck Serono SPA", "url": "http://www.merckserono.net"}, {"name": "North America Genescience LLC", "url": null}, {"name": "Organon Pharmaceuticals", "url": "http://www.organonshop.com"}, {"name": "Serono SA", "url": "http://www.merckserono.net"}, {"name": "Vetter Pharma Fertigung GmbH and Co. KG", "url": "http://www.vetter-pharma.com"}]}, "manufacturers": {"manufacturer": [{"@generic": "false", "#text": "Serono laboratories inc"}, {"@generic": "false", "#text": "Ferring pharmaceuticals inc"}]}, "prices": {"price": [{"description": "Bravelle 75 unit vial", "cost": {"@currency": "USD", "#text": "93.85"}, "unit": "vial"}, {"description": "Fertinex 75 unit Solution", "cost": {"@currency": "USD", "#text": "103.85"}, "unit": "vial"}]}, "categories": {"category": {"category": "Fertility Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Powder for solution", "route": "intramuscular; subcutaneous", "strength": "75 unit"}, {"form": "Kit; liquid; powder for solution", "route": "intramuscular; subcutaneous", "strength": "150 unit"}, {"form": "Liquid; powder for solution", "route": "intramuscular; subcutaneous", "strength": "75 unit"}, {"form": "Liquid; powder for solution", "route": "intramuscular", "strength": ".9 %"}, {"form": "Powder for solution", "route": "intramuscular", "strength": "75 unit"}, {"form": "Powder for solution", "route": "intramuscular", "strength": "75 unit"}]}, "atc-codes": {"atc-code": {"@code": "G03GA04", "level": [{"@code": "G", "#text": "GENITO URINARY SYSTEM AND SEX HORMONES"}, {"@code": "G03", "#text": "SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM"}, {"@code": "G03G", "#text": "GONADOTROPINS AND OTHER OVULATION STIMULANTS"}, {"@code": "G03GA", "#text": "Gonadotropins"}]}}, "ahfs-codes": {"ahfs-code": "68:18.00"}, "patents": {"patent": {"number": "5767067", "country": "United States", "approved": "1995-06-16", "expires": "2015-06-16"}}, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">Alpha chain\nAPDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC\nVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS"}, {"@format": "FASTA", "#text": ">Beta chain\nNSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYET\nVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "55 \u00b0C", "source": "Forastieri, H., Ingham, K.C. J. Biol. Chem. 257:7976-7981 (1982)"}, {"kind": "Hydrophobicity", "value": "-0.330", "source": null}, {"kind": "Isoelectric Point", "value": "7.50", "source": null}, {"kind": "Molecular Weight", "value": "980.1620", "source": null}, {"kind": "Molecular Formula", "value": "C42H65N11O12S2", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "306"}, {"resource": "Drugs Product Database (DPD)", "identifier": "7649"}, {"resource": "National Drug Code Directory", "identifier": "55566-8505-2"}, {"resource": "GenBank", "identifier": "M16647"}, {"resource": "PharmGKB", "identifier": "PA451835"}, {"resource": "UniProtKB", "identifier": "P01225"}, {"resource": "Wikipedia", "identifier": "Urofollitropin"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/urofollitropin.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/urofollitropin-purified.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"id": "BE0000387", "name": "Follicle-stimulating hormone receptor", "organism": "Human", "actions": {"action": "agonist"}, "references": "# Layman LC: Mutations in the follicle-stimulating hormone-beta (FSH beta) and FSH receptor genes in mice and humans. Semin Reprod Med. 2000;18(1):5-10. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11299519\n# Leng N, Dattatreyamurty B, Reichert LE Jr: Identification of amino acid residues 300-315 of the rat FSH receptor as a hormone binding domain: evidence for its interaction with specific regions of FSH beta-subunit. Biochem Biophys Res Commun. 1995 May 16;210(2):392-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7755615\n# Santa Coloma TA, Dattatreyamurty B, Reichert LE Jr: A synthetic peptide corresponding to human FSH beta-subunit 33-53 binds to FSH receptor, stimulates basal estradiol biosynthesis, and is a partial antagonist of FSH. Biochemistry. 1990 Feb 6;29(5):1194-200. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2108722\n# Dattatreyamurty B, Reichert LE Jr: Identification of regions of the follitropin (FSH) beta-subunit that interact with the N-terminus region (residues 9-30) of the FSH receptor. Mol Cell Endocrinol. 1993 May;93(1):39-46. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8319832\n# Lindau-Shepard B, Roth KE, Dias JA: Identification of amino acids in the C-terminal region of human follicle-stimulating hormone (FSH) beta-subunit involved in binding to human FSH receptor. Endocrinology. 1994 Sep;135(3):1235-40. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8070368\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P23945", "@source": "Swiss-Prot", "name": "Follicle-stimulating hormone receptor", "general-function": "Involved in follicle-stimulating hormone receptor activity", "specific-function": "Receptor for follicle-stimulating hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase", "gene-name": "FSHR", "locus": "2p21-p16", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "367-387\n399-421\n444-465\n486-508\n529-550\n574-597\n609-630", "signal-regions": null, "theoretical-pi": "7.19", "molecular-weight": "78296.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3969"}, {"resource": "GenAtlas", "identifier": "FSHR"}, {"resource": "GeneCards", "identifier": "FSHR"}, {"resource": "GenBank Gene Database", "identifier": "M65085"}, {"resource": "GenBank Protein Database", "identifier": "182771"}, {"resource": "IUPHAR", "identifier": "253"}, {"resource": "Guide to Pharmacology", "identifier": "30"}, {"resource": "UniProtKB", "identifier": "P23945"}, {"resource": "UniProt Accession", "identifier": "FSHR_HUMAN"}]}, "synonyms": {"synonym": ["Follicle-stimulating hormone receptor precursor", "Follitropin receptor", "FSH-R"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Follicle-stimulating hormone receptor precursor\nMALLLVSLLAFLSLGSGCHHRICHCSNRVFLCQESKVTEIPSDLPRNAIELRFVLTKLRV\nIQKGAFSGFGDLEKIEISQNDVLEVIEADVFSNLPKLHEIRIEKANNLLYINPEAFQNLP\nNLQYLLISNTGIKHLPDVHKIHSLQKVLLDIQDNINIHTIERNSFVGLSFESVILWLNKN\nGIQEIHNCAFNGTQLDELNLSDNNNLEELPNDVFHGASGPVILDISRTRIHSLPSYGLEN\nLKKLRARSTYNLKKLPTLEKLVALMEASLTYPSHCCAFANWRRQISELHPICNKSILRQE\nVDYMTQTRGQRSSLAEDNESSYSRGFDMTYTEFDYDLCNEVVDVTCSPKPDAFNPCEDIM\nGYNILRVLIWFISILAITGNIIVLVILTTSQYKLTVPRFLMCNLAFADLCIGIYLLLIAS\nVDIHTKSQYHNYAIDWQTGAGCDAAGFFTVFASELSVYTLTAITLERWHTITHAMQLDCK\nVQLRHAASVMVMGWIFAFAAALFPIFGISSYMKVSICLPMDIDSPLSQLYVMSLLVLNVL\nAFVVICGCYIHIYLTVRNPNIVSSSSDTRIAKRMAMLIFTDFLCMAPISFFAISASLKVP\nLITVSKAKILLVLFHPINSCANPFLYAIFTKNFRRDFFILLSKCGCYEMQAQIYRTETSS\nTVHNTHPRNGHCSSAPRVTNGSTYILVPLSHLAQN"}, "gene-sequence": {"@format": "FASTA", "#text": ">2088 bp\nATGGCCCTGCTCCTGGTCTCTTTGCTGGCATTCCTGAGCTTGGGCTCAGGATGTCATCAT\nCGGATCTGTCACTGCTCTAACAGGGTTTTTCTCTGCCAAGAGAGCAAGGTGACAGAGATT\nCCTTCTGACCTCCCGAGGAATGCCATTGAACTGAGGTTTGTCCTCACCAAGCTTCGAGTC\nATCCAAAAAGGTGCATTTTCAGGATTTGGGGACCTGGAGAAAATAGAGATCTCTCAGAAT\nGATGTCTTGGAGGTGATAGAGGCAGATGTGTTCTCCAACCTTCCCAAATTACATGAAATT\nAGAATTGAAAAGGCCAACAACCTGCTCTACATCACCCCTGAGGCCTTCCAGAACCTTCCC\nAACCTTCAATATCTGTTAATATCCAACACAGGTATTAAGCACCTTCCAGATGTTCACAAG\nATTCATTCTCTCCAAAAGGTTTTACTTGACATTCAAGATAACATAAACATCCACACAATT\nGAAAGAAATTCTTTCGTGGGGCTGAGCTTTGAAAGTGTGATTCTATGGCTGAATAAGAAT\nGGGATTCAAGAAATACACAACTGTGCATTCAATGGAACCCAACTAGATGCAGTGAATCTA\nAGCGATAATAATAATTTAGAAGAATTGCCTAATGATGTTTTCCACGGAGCCTCTGGACCA\nGTCATTCTAGATATTTCAAGAACAAGGATCCATTCCCTGCCTAGCTATGGCTTAGAAAAT\nCTTAAGAAGCTGAGGGCCAGGTCGACTTACAACTTAAAAAAGCTGCCTACTCTGGAAAAG\nCTTGTCGCCCTCATGGAAGCCAGCCTCACCTATCCCAGCCATTGCTGTGCCTTTGCAAAC\nTGGAGACGGCAAATCTCTGAGCTTCATCCAATTTGCAACAAATCTATTTTAAGGCAAGAA\nGTTGATTATATGACTCAGGCTAGGGGTCAGAGATCCTCTCTGGCAGAAGACAATGAGTCC\nAGCTACAGCAGAGGATTTGACATGACGTACACTGAGTTTGACTATGACTTATGCAATGAA\nGTGGTTGACGTGACCTGCTCCCCTAAGCCAGATGCATTCAACCCATGTGAAGATATCATG\nGGGTACAACATCCTCAGAGTCCTGATATGGTTTATCAGCATCCTGGCCATCACTGGGAAC\nATCATAGTGCTAGTGATCCTAACTACCAGCCAATATAAACTCACAGTCCCCAGGTTCCTT\nATGTGCAACCTGGCCTTTGCTGATCTCTGCATTGGAATCTACCTGCTGCTCATTGCATCA\nGTTGATATCCATACCAAGAGCCAATATCACAACTATGCCATTGACTGGCAAACTGGGGCA\nGGCTGTGATGCTGCTGGCTTTTTCACTGTCTTTGCCAGTGAGCTGTCAGTCTACACTCTG\nACAGCTATCACCTTGGAAAGATGGCATACCATCACGCATGCCATGCAGCTGGACTGCAAG\nGTGCAGCTCCGCCATGCTGCCAGTGTCATGGTGATGGGCTGGATTTTTGCTTTTGCAGCT\nGCCCTCTTTCCCATCTTTGGCATCAGCAGCTACATGAAGGTGAGCATCTGCCTGCCCATG\nGATATTGACAGCCCTTTGTCACAGCTGTATGTCATGTCCCTCCTTGTGCTCAATGTCCTG\nGCCTTTGTGGTCATCTGTGGCTGCTATATCCACATCTACCTCACAGTGCGGAACCCCAAC\nATCGTGTCCTCCTCTAGTGACACCAGGATCGCCAAGCGCATGGCCATGCTCATCTTCACT\nGACTTCCTCTGCATGGCACCCATTTCTTTCTTTGCCATTTCTGCCTCCCTCAAGGTGCCC\nCTCATCACTGTGTCCAAAGCAAAGATTCTGCTGGTTCTGTTTCACCCCATCAACTCCTGT\nGCCAACCCCTTCCTCTATGCCATCTTTACCAAAAACTTTCGCAGAGATTTCTTCATTCTG\nCTGAGCAAGTGTGGCTGCTATGAAATGCAAGCCCAAATTTATAGGACAGAAACTTCATCC\nACTGTCCACAACACCCATCCAAGGAATGGCCACTGCTCTTCAGCTCCCAGAGTCACCAGT\nGGTTCCACTTACATACTTGTCCCTCTAAGTCATTTAGCCCAAAACTAA"}, "pfams": {"pfam": [{"identifier": "PF00001", "name": "7tm_1"}, {"identifier": "PF00560", "name": "LRR_1"}, {"identifier": "PF01462", "name": "LRRNT"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "function", "description": "protein-hormone receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "follicle stimulating hormone receptor activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}]}}}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2010-09-29", "drugbank-id": [{"@primary": "true", "#text": "DB00095"}, "BIOD00074", "BTD00074"], "name": "Efalizumab", "description": "Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin.", "cas-number": "214745-43-4", "groups": {"group": ["approved", "investigational"]}, "general-references": "#  \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8943405\n# Descamps V: [Efalizumab] Ann Dermatol Venereol. 2006 Aug-Sep;133(8-9 Pt 1):666-78. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17053736", "synthesis-reference": null, "indication": "For the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy.", "pharmacodynamics": "Lymphocyte activation and trafficking to skin play a role in the pathophysiology of chronic plaque psoriasis. In psoriatic skin, ICAM-1 cell surface expression is upregulated on endothelium and keratinocytes. Raptiva inhibits the binding of LFA-1 to the intercellular adhesion molecule-1 (ICAM-1), thereby inhibiting the adhesion of leukocytes to other cell types.", "mechanism-of-action": "Efalizumab binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes. As a result efalizumab decreases cell surface expression of CD11a.", "toxicity": null, "metabolism": null, "absorption": "Average efalizumab bioavailability following subcutaneous administration was estimated at 30 to 50%.", "half-life": "5 days", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "anti alphaL integrin"}, {"@language": "", "@coder": "", "#text": "antiCD11 alpha"}, {"@language": "", "@coder": "", "#text": "hu1124"}, {"@language": "", "@coder": "", "#text": "Raptiva"}]}, "products": {"product": {"name": "Raptiva", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02272504", "started-marketing-on": "2005-10-26", "ended-marketing-on": "2009-06-08", "dosage-form": "powder for solution", "strength": "150 mg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}}, "international-brands": null, "mixtures": {"mixture": {"name": "Raptiva", "ingredients": "Efalizumab"}}, "packagers": {"packager": {"name": "Genentech Inc.", "url": "http://www.gene.com"}}, "manufacturers": null, "prices": null, "categories": {"category": {"category": "Immunosuppressive Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": {"form": "Powder for solution", "route": "subcutaneous", "strength": "150 mg"}}, "atc-codes": {"atc-code": {"@code": "L04AA21", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L04", "#text": "IMMUNOSUPPRESSANTS"}, {"@code": "L04A", "#text": "IMMUNOSUPPRESSANTS"}, {"@code": "L04AA", "#text": "Selective immunosuppressants"}]}}, "ahfs-codes": {"ahfs-code": "84:92.00"}, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">Heavy Chain Variable Region\nEVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGIMIHPSDSETR\nYNQKFKDIRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARIGIYFYGTTYFDYIWGQGTL\nVTVSS"}, {"@format": "FASTA", "#text": ">Light Chain Variable Region\nDIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWXQQKPGKAPKLLIYSGSTLQSGVPS\nRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIKR"}]}, "experimental-properties": {"property": {"kind": "Melting Point", "value": "61 \u00b0C (FAB fragment), 71 \u00b0C (whole mAb)", "source": "Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)"}}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "13093"}, {"resource": "PharmGKB", "identifier": "PA164748817"}, {"resource": "Wikipedia", "identifier": "Efalizumab"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/raptiva.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/efalizumab.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000516", "name": "Integrin alpha-L", "organism": "Human", "actions": {"action": "antibody"}, "references": "# Frampton JE, Plosker GL: Efalizumab: a review of its use in the management of chronic moderate-to-severe plaque psoriasis. Am J Clin Dermatol. 2009;10(1):51-72. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19170413\n# Descamps V: [Efalizumab] Ann Dermatol Venereol. 2006 Aug-Sep;133(8-9 Pt 1):666-78. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17053736\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P20701", "@source": "Swiss-Prot", "name": "Integrin alpha-L", "general-function": "Involved in cell adhesion and protein binding", "specific-function": "Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. It is involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes", "gene-name": "ITGAL", "locus": "16p11.2", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "1091-1111", "signal-regions": null, "theoretical-pi": "5.35", "molecular-weight": "128771.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6148"}, {"resource": "GenAtlas", "identifier": "ITGAL"}, {"resource": "GeneCards", "identifier": "ITGAL"}, {"resource": "GenBank Gene Database", "identifier": "Y00796"}, {"resource": "GenBank Protein Database", "identifier": "31422"}, {"resource": "UniProtKB", "identifier": "P20701"}, {"resource": "UniProt Accession", "identifier": "ITAL_HUMAN"}]}, "synonyms": {"synonym": ["CD11a antigen", "Integrin alpha-L precursor", "Leukocyte adhesion glycoprotein LFA-1 alpha chain", "Leukocyte function-associated molecule 1 alpha chain", "LFA-1A"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Integrin alpha-L precursor\nMKDSCITVMAMALLSGFFFFAPASSYNLDVRGARSFSPPRAGRHFGYRVLQVGNGVIVGA\nPGEGNSTGSLYQCQSGTGHCLPVTLRGSNYTSKYLGMTLATDPTDGSILACDPGLSRTCD\nQNTYLSGLCYLFRQNLQGPMLQGRPGFQECIKGNVDLVFLFDGSMSLQPDEFQKILDFMK\nDVMKKLSNTSYQFAAVQFSTSYKTEFDFSDYVKRKDPDALLKHVKHMLLLTNTFGAINYV\nATEVFREELGARPDATKVLIIITDGEATDSGNIDAAKDIIRYIIGIGKHFQTKESQETLH\nKFASKPASEFVKILDTFEKLKDLFTELQKKIYVIEGTSKQDLTSFNMELSSSGISADLSR\nGHAVVGAVGAKDWAGGFLDLKADLQDDTFIGNEPLTPEVRAGYLGYTVTWLPSRQKTSLL\nASGAPRYQHMGRVLLFQEPQGGGHWSQVQTIHGTQIGSYFGGELCGVDVDQDGETELLLI\nGAPLFYGEQRGGRVFIYQRRQLGFEEVSELQGDPGYPLGRFGEAITALTDINGDGLVDVA\nVGAPLEEQGAVYIFNGRHGGLSPQPSQRIEGTQVLSGIQWFGRSIHGVKDLEGDGLADVA\nVGAESQMIVLSSRPVVDMVTLMSFSPAEIPVHEVECSYSTSNKMKEGVNITICFQIKSLI\nPQFQGRLVANLTYTLQLDGHRTRRRGLFPGGRHELRRNIAVTTSMSCTDFSFHFPVCVQD\nLISPINVSLNFSLWEEEGTPRDQRAQGKDIPPILRPSLHSETWEIPFEKNCGEDKKCEAN\nLRVSFSPARSRALRLTAFASLSVELSLSNLEEDAYWVQLDLHFPPGLSFRKVEMLKPHSQ\nIPVSCEELPEESRLLSRALSCNVSSPIFKAGHSVALQMMFNTLVNSSWGDSVELHANVTC\nNNEDSDLLEDNSATTIIPILYPINILIQDQEDSTLYVSFTPKGPKIHQVKHMYQVRIQPS\nIHDHNIPTLEAVVGVPQPPSEGPITHQWSVQMEPPVPCHYEDLERLPDAAEPCLPGALFR\nCPVVFRQEILVQVIGTLELVGEIEASSMFSLCSSLSISFNSSKHFHLYGSNASLAQVVMK\nVDVVYEKQMLYLYVLSGIGGLLLLLLIFIVLYKVGFFKRNLKEKMEAGRGVPNGIPAEDS\nEQLASGQEAGDPGCLKPLHEKDSESGGGKD"}, "gene-sequence": {"@format": "FASTA", "#text": ">3513 bp\nATGAAGGATTCCTGCATCACTGTGATGGCCATGGCGCTGCTGTCTGGGTTCTTTTTCTTC\nGCGCCGGCCTCGAGCTACAACCTGGACGTGCGGGGCGCGCGGAGCTTCTCCCCACCGCGC\nGCCGGGAGGCACTTTGGATACCGCGTCCTGCAGGTCGGAAACGGGGTCATCGTGGGAGCT\nCCAGGGGAGGGGAACAGCACAGGAAGCCTCTATCAGTGCCAGTCGGGCACAGGACACTGC\nCTGCCAGTCACCCTGAGAGGTTCCAACTATACCTCCAAGTACTTGGGAATGACCTTGGCA\nACAGACCCCACAGATGGAAGCATTTTGGCCTGTGACCCTGGGCTGTCTCGAACGTGTGAC\nCAGAACACCTATCTGAGTGGCCTGTGTTACCTCTTCCGCCAGAATCTGCAGGGTCCCATG\nCTGCAGGGGCGCCCTGGTTTTCAGGAATGTATCAAGGGCAACGTAGACCTGGTATTTCTG\nTTTGATGGTTCGATGAGCTTGCAGCCAGATGAATTTCAGAAAATTCTGGACTTCATGAAG\nGATGTGATGAAGAAACTCAGCAACACTTCGTACCAGTTTGCTGCTGTTCAGTTTTCCACA\nAGCTACAAAACAGAATTTGATTTCTCAGATTATGTTAAATGGAAGGACCCTGATGCTCTG\nCTGAAGCATGTAAAGCACATGTTGCTGTTGACCAATACCTTTGGTGCCATCAATTATGTC\nGCGACAGAGGTGTTCCGGGAGGAGCTGGGGGCCCGGCCAGATGCCACCAAAGTGCTTATC\nATCATCACGGATGGGGAGGCCACTGACAGTGGCAACATCGATGCGGCCAAAGACATCATC\nCGCTACATCATCGGGATTGGAAAGCATTTTCAGACCAAGGAGAGTCAGGAGACCCTCCAC\nAAATTTGCATCAAAACCCGCGAGCGAGTTTGTGAAAATTCTGGACACATTTGAGAAGCTG\nAAAGATCTATTCACTGAGCTGCAGAAGAAGATCTATGTCATTGAGGGCACAAGCAAACAG\nGACCTGACTTCCTTCAACATGGAGCTGTCCTCCAGCGGCATCAGTGCTGACCTCAGCAGG\nGGCCATGCAGTCGTGGGGGCAGTAGGAGCCAAGGACTGGGCTGGGGGCTTTCTTGACCTG\nAAGGCAGACCTGCAGGATGACACATTTATTGGGAATGAACCATTGACACCAGAAGTGAGA\nGCAGGCTATTTGGGTTACACCGTGACCTGGCTGCCCTCCCGGCAAAAGACTTCGTTGCTG\nGCCTCGGGAGCCCCTCGATACCAGCACATGGGCCGAGTGCTGCTGTTCCAAGAGCCACAG\nGGCGGAGGACACTGGAGCCAGGTCCAGACAATCCATGGGACCCAGATTGGCTCTTATTTC\nGGTGGGGAGCTGTGTGGCGTCGACGTGGACCAAGATGGGGAGACAGAGCTGCTGCTGATT\nGGTGCCCCACTGTTCTATGGGGAGCAGAGAGGAGGCCGGGTGTTTATCTACCAGAGAAGA\nCAGTTGGGGTTTGAAGAAGTCTCAGAGCTGCAGGGGGACCCCGGCTACCCACTCGGGCGG\nTTTGGAGAAGCCATCACTGCTCTGACAGACATCAACGGCGATGGGCTGGTAGACGTGGCT\nGTGGGGGCCCCTCTGGAGGAGCAGGGGGCTGTGTACATCTTCAATGGGAGGCACGGGGGG\nCTTAGTCCCCAGCCAAGTCAGCGGATAGAAGGGACCCAAGTGCTCTCAGGAATTCAGTGG\nTTTGGACGCTCCATCCATGGGGTGAAGGACCTTGAAGGGGATGGCTTGGCAGATGTGGCT\nGTGGGGGCTGAGAGCCAGATGATCGTGCTGAGCTCCCGGCCCGTGGTGGATATGGTCACC\nCTGATGTCCTTCTCTCCAGCTGAGATCCCAGTGCATGAAGTGGAGTGCTCCTATTCAACC\nAGTAACAAGATGAAAGAAGGAGTTAATATCACAATCTGTTTCCAGATCAAGTCTCTCTAC\nCCCCAGTTCCAAGGCCGCCTGGTTGCCAATCTCACTTACACTCTGCAGCTGGATGGCCAC\nCGGACCAGAAGACGGGGGTTGTTCCCAGGAGGGAGACATGAACTCAGAAGGAATATAGCT\nGTCACCACCAGCATGTCATGCACTGACTTCTCATTTCATTTCCCGGTATGTGTTCAAGAC\nCTCATCTCCCCCATCAATGTTTCCCTGAATTTCTCTCTTTGGGAGGAGGAAGGGACACCG\nAGGGACCAAAGGGCGCAGGGCAAGGACATACCGCCCATCCTGAGACCCTCCCTGCACTCG\nGAAACCTGGGAGATCCCTTTTGAGAAGAACTGTGGGGAGGACAAGAAGTGTGAGGCAAAC\nTTGAGAGTGTCCTTCTCTCCTGCAAGATCCAGAGCCCTGCGTCTAACTGCTTTTGCCAGC\nCTCTCTGTGGAGCTGAGCCTGAGTAACTTGGAAGAAGATGCTTACTGGGTCCAGCTGGAC\nCTGCACTTCCCCCCGGGACTCTCCTTCCGCAAGGTGGAGATGCTGAAGCCCCATAGCCAG\nATACCTGTGAGCTGCGAGGAGCTTCCTGAAGAGTCCAGGCTTCTGTCCAGGGCATTATCT\nTGCAATGTGAGCTCTCCCATCTTCAAAGCAGGCCACTCGGTTGCTCTGCAGATGATGTTT\nAATACACTGGTAAACAGCTCCTGGGGGGACTCGGTTGAATTGCACGCCAATGTGACCTGT\nAACAATGAGGACTCAGACCTCCTGGAGGACAACTCAGCCACTACCATCATCCCCATCCTG\nTACCCCATCAACATCCTCATCCAGGACCAAGAAGACTCCACACTCTATGTCAGTTTCACC\nCCCAAAGGCCCCAAGATCCACCAAGTCAAGCACATGTACCAGGTGAGGATCCAGCCTTCC\nATCCACGACCACAACATACCCACCCTGGAGGCTGTGGTTGGGGTGCCACAGCCTCCCAGC\nGAGGGGCCCATCACACACCAGTGGAGCGTGCAGATGGAGCCTCCCGTGCCCTGCCACTAT\nGAGGATCTGGAGAGGCTCCCGGATGCAGCTGAGCCTTGTCTCCCCGGAGCCCTGTTCCGC\nTGCCCTGTTGTCTTCAGGCAGGAGATCCTCGTCCAAGTGATCGGGACTCTGGAGCTGGTG\nGGAGAGATCGAGGCCTCTTCCATGTTCAGCCTCTGCAGCTCCCTCTCCATCTCCTTCAAC\nAGCAGCAAGCATTTCCACCTCTATGGCAGCAACGCCTCCCTGGCCCAGGTTGTCATGAAG\nGTTGACGTGGTGTATGAGAAGCAGATGCTCTACCTCTACGTGCTGAGCGGCATCGGGGGG\nCTGCTGCTGCTGCTGCTCATTTTCATAGTGCTGTACAAGGTTGGTTTCTTCAAACGGAAC\nCTGAAGGAGAAGATGGAGGCTGGCAGAGGTGTCCCGAATGGAATCCCTGCAGAAGACTCT\nGAGCAGCTGGCATCTGGGCAAGAGGCTGGGGATCCCGGCTGCCTGAAGCCCCTCCATGAG\nAAGGACTCTGAGAGTGGTGGTGGCAAGGACTGA"}, "pfams": {"pfam": [{"identifier": "PF01839", "name": "FG-GAP"}, {"identifier": "PF00357", "name": "Integrin_alpha"}, {"identifier": "PF08441", "name": "Integrin_alpha2"}, {"identifier": "PF00092", "name": "VWA"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "integrin complex"}, {"category": "component", "description": "protein complex"}, {"category": "component", "description": "receptor complex"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell adhesion"}, {"category": "process", "description": "cell-substrate adhesion"}, {"category": "process", "description": "cell-matrix adhesion"}]}}}, {"id": "BE0000901", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "O75015", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-B", "general-function": null, "specific-function": "Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils", "gene-name": "FCGR3B", "locus": "1q23", "cellular-location": "Cell membrane; lipid-anchor; GPI-anchor. Secreted protein. Note=Secreted after cleavage", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.71", "molecular-weight": "26216.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3620"}, {"resource": "GenAtlas", "identifier": "FCGR3B"}, {"resource": "GeneCards", "identifier": "FCGR3B"}, {"resource": "GenBank Gene Database", "identifier": "X16863"}, {"resource": "GenBank Protein Database", "identifier": "31322"}, {"resource": "UniProtKB", "identifier": "O75015"}, {"resource": "UniProt Accession", "identifier": "FCG3B_HUMAN"}]}, "synonyms": {"synonym": ["CD16b antigen", "Fc-gamma RIII", "Fc-gamma RIII-beta", "Fc-gamma RIIIb", "FcR-10", "FcRIII", "FcRIIIb", "IgG Fc receptor III-1", "Low affinity immunoglobulin gamma Fc region receptor III-B precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-B precursor\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI"}, "gene-sequence": {"@format": "FASTA", "#text": ">702 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"id": "BE0002093", "name": "Complement C1r subcomponent", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P00736", "@source": "Swiss-Prot", "name": "Complement C1r subcomponent", "general-function": null, "specific-function": "C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system", "gene-name": "C1R", "locus": "12p13", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.24", "molecular-weight": "80174.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1246"}, {"resource": "GenAtlas", "identifier": "C1R"}, {"resource": "GeneCards", "identifier": "C1R"}, {"resource": "GenBank Gene Database", "identifier": "X04701"}, {"resource": "GenBank Protein Database", "identifier": "29539"}, {"resource": "UniProtKB", "identifier": "P00736"}, {"resource": "UniProt Accession", "identifier": "C1R_HUMAN"}]}, "synonyms": {"synonym": ["Complement C1r subcomponent precursor", "Complement component 1, r subcomponent", "EC 3.4.21.41"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1r subcomponent\nMWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF\nQQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF\nSNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY\nELQEDRHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF\nDIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL\nRYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD\nDGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR\nESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF\nTNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV\nSVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME\nEKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV\nRDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED"}, "gene-sequence": {"@format": "FASTA", "#text": ">2118 bp\nATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC\nATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC\nAACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC\nCAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT\nGATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG\nGGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC\nTCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT\nGTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG\nTGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT\nGAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG\nGCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC\nAACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT\nGATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC\nGGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC\nAATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG\nCGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC\nATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA\nGGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT\nGATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA\nAACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC\nCGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG\nGAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG\nGGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG\nAGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC\nACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT\nGCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC\nCTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC\nAGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG\nCTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC\nAACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG\nGAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT\nGAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT\nGGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA\nAGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC\nAGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG\nATGGAGGAGGAGGACTGA"}, "pfams": {"pfam": [{"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00084", "name": "Sushi"}, {"identifier": "PF07645", "name": "EGF_CA"}, {"identifier": "PF00431", "name": "CUB"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "humoral immune response"}, {"category": "process", "description": "complement activation"}, {"category": "process", "description": "physiological process"}]}}}, {"id": "BE0002094", "name": "Complement C1q subcomponent subunit A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02745", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit A", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QA", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.45", "molecular-weight": "26017.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1241"}, {"resource": "GenAtlas", "identifier": "C1QA"}, {"resource": "GeneCards", "identifier": "C1QA"}, {"resource": "GenBank Gene Database", "identifier": "AF135157"}, {"resource": "GenBank Protein Database", "identifier": "4894854"}, {"resource": "UniProtKB", "identifier": "P02745"}, {"resource": "UniProt Accession", "identifier": "C1QA_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit A precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit A\nMEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR\nTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI\nRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR\nGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL\nIFPSA"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG\nGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC\nAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG\nACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC\nAAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGGGCCCGTGGCATCCCGGGAATTAAA\nGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT\nCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG\nGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC\nTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG\nGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG\nGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC\nCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC\nATCTTCCCATCTGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"id": "BE0002095", "name": "Complement C1q subcomponent subunit B", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02746", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit B", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QB", "locus": "1p36.12", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.87", "molecular-weight": "26460.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1242"}, {"resource": "GenAtlas", "identifier": "C1QB"}, {"resource": "GeneCards", "identifier": "C1QB"}, {"resource": "GenBank Gene Database", "identifier": "X03084"}, {"resource": "GenBank Protein Database", "identifier": "573114"}, {"resource": "UniProtKB", "identifier": "P02746"}, {"resource": "UniProt Accession", "identifier": "C1QB_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit B precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit B\nMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEK\nGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKI\nAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCV\nNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANSIF\nSGFLLFPDMEA"}, "gene-sequence": {"@format": "FASTA", "#text": ">688 bp\nCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGG\nGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCC\nAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAA\nTCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGCCCAGGGGCCCCTGG\nAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAGAAAATCGCCTTCTC\nTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATCCGCTTCGACCACGT\nGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTCACCTGCAAGGTGCC\nCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTGTGCGTGAACCTCAT\nGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTATGCCTACAACACCTT\nCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAGAACGTCTTCCTGCA\nGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGCATCTTTTCCGGGTT\nCCTGCTCTTTCCAGATATGGAGGCCTGA"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"id": "BE0002096", "name": "Complement C1q subcomponent subunit C", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P02747", "@source": "Swiss-Prot", "name": "Complement C1q subcomponent subunit C", "general-function": null, "specific-function": "C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes", "gene-name": "C1QC", "locus": "1p36.11", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.58", "molecular-weight": "25774.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1245"}, {"resource": "GenAtlas", "identifier": "C1QC"}, {"resource": "GeneCards", "identifier": "C1QC"}, {"resource": "GenBank Gene Database", "identifier": "AF087892"}, {"resource": "GenBank Protein Database", "identifier": "33150626"}, {"resource": "UniProtKB", "identifier": "P02747"}, {"resource": "UniProt Accession", "identifier": "C1QC_HUMAN"}]}, "synonyms": {"synonym": "Complement C1q subcomponent subunit C precursor"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Complement C1q subcomponent subunit C\nMDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP\nGIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS\nVFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV\nLLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF\nLLFPD"}, "gene-sequence": {"@format": "FASTA", "#text": ">738 bp\nATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG\nCTGCTGCCCCTCAGGGCCAAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC\nCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA\nGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA\nCCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC\nCCCATGGGATTCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA\nGTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC\nAACGCGGTCCTCACCAACCCGCAGGAGGATTATGACACGAGCACTGGCAAGTTCACCTGC\nAAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG\nCTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT\nCAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT\nGTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC\nCTGCTCTTCCCCGACTAG"}, "pfams": {"pfam": [{"identifier": "PF01391", "name": "Collagen"}, {"identifier": "PF00386", "name": "C1q"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intracellular"}, {"category": "component", "description": "cytoplasm"}, {"category": "process", "description": "transport"}, {"category": "process", "description": "ion transport"}, {"category": "process", "description": "anion transport"}, {"category": "process", "description": "inorganic anion transport"}, {"category": "process", "description": "phosphate transport"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "cellular physiological process"}]}}}, {"id": "BE0002097", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P08637", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor III-A", "general-function": null, "specific-function": "Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis", "gene-name": "FCGR3A", "locus": "1q23", "cellular-location": "Cell membrane", "transmembrane-regions": "209-229", "signal-regions": null, "theoretical-pi": "8.21", "molecular-weight": "29089.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3619"}, {"resource": "GenAtlas", "identifier": "FCGR3A"}, {"resource": "GeneCards", "identifier": "FCGR3A"}, {"resource": "GenBank Gene Database", "identifier": "X52645"}, {"resource": "GenBank Protein Database", "identifier": "31324"}, {"resource": "UniProtKB", "identifier": "P08637"}, {"resource": "UniProt Accession", "identifier": "FCG3A_HUMAN"}]}, "synonyms": {"synonym": ["CD16a antigen", "Fc-gamma RIII", "Fc-gamma RIII-alpha", "Fc-gamma RIIIa", "FcR-10", "FcRIII", "FcRIIIa", "IgG Fc receptor III-2", "Low affinity immunoglobulin gamma Fc region receptor III-A precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK"}, "gene-sequence": {"@format": "FASTA", "#text": ">765 bp\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCGACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCA\nAAAGCCACACTCAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTTTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGG\nAAGGACCATAAATTTAAATGGAGAAAGGACCCTCAAGACAAATGA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"id": "BE0000710", "name": "High affinity immunoglobulin gamma Fc receptor I", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P12314", "@source": "Swiss-Prot", "name": "High affinity immunoglobulin gamma Fc receptor I", "general-function": "Involved in receptor signaling protein activity", "specific-function": "Binds to the Fc region of immunoglobulins gamma. High affinity receptor", "gene-name": "FCGR1A", "locus": "1q21.2-q21.3", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "293-313", "signal-regions": null, "theoretical-pi": "8.08", "molecular-weight": "42632.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3613"}, {"resource": "GenAtlas", "identifier": "FCGR1A"}, {"resource": "GeneCards", "identifier": "FCGR1A"}, {"resource": "GenBank Gene Database", "identifier": "X14356"}, {"resource": "GenBank Protein Database", "identifier": "31332"}, {"resource": "UniProtKB", "identifier": "P12314"}, {"resource": "UniProt Accession", "identifier": "FCGR1_HUMAN"}]}, "synonyms": {"synonym": ["CD64 antigen", "Fc-gamma RI", "FcRI", "High affinity immunoglobulin gamma Fc receptor I precursor", "IgG Fc receptor I"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">High affinity immunoglobulin gamma Fc receptor I precursor\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT"}, "gene-sequence": {"@format": "FASTA", "#text": ">1125 bp\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCTCTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAACTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"id": "BE0002098", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P12318", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-a", "general-function": null, "specific-function": "Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens", "gene-name": "FCGR2A", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.78", "molecular-weight": "34990.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3616"}, {"resource": "GenAtlas", "identifier": "FCGR2A"}, {"resource": "GeneCards", "identifier": "FCGR2A"}, {"resource": "GenBank Gene Database", "identifier": "M31932"}, {"resource": "GenBank Protein Database", "identifier": "182474"}, {"resource": "UniProtKB", "identifier": "P12318"}, {"resource": "UniProt Accession", "identifier": "FCG2A_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-a", "Fc-gamma-RIIa", "FcRII-a", "IgG Fc receptor II-a", "Low affinity immunoglobulin gamma Fc region receptor II-a precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-a\nMAMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSRLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">954 bp\nATGGCTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"id": "BE0002099", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31994", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "general-function": null, "specific-function": "Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B- cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis", "gene-name": "FCGR2B", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.12", "molecular-weight": "34044.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3618"}, {"resource": "GenAtlas", "identifier": "FCGR2B"}, {"resource": "GeneCards", "identifier": "FCGR2B"}, {"resource": "GenBank Gene Database", "identifier": "U87560"}, {"resource": "GenBank Protein Database", "identifier": "4099445"}, {"resource": "UniProtKB", "identifier": "P31994"}, {"resource": "UniProt Accession", "identifier": "FCG2B_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-b", "Fc-gamma-RIIb", "FcRII-b", "IgG Fc receptor II-b", "Low affinity immunoglobulin gamma Fc region receptor II-b precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI"}, "gene-sequence": {"@format": "FASTA", "#text": ">930 bp\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCTCTCCCAGGATACCCTGAG\nTGCAGGGAAATGGGAGAGACCCTCCCTGAGAAACCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATT"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"id": "BE0002100", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423", "known-action": "unknown", "polypeptide": {"@id": "P31995", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-c", "general-function": null, "specific-function": "Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells", "gene-name": "FCGR2C", "locus": "1q23.3", "cellular-location": "Cell membrane", "transmembrane-regions": "224-246", "signal-regions": null, "theoretical-pi": "6.9", "molecular-weight": "35578.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:15626"}, {"resource": "GenAtlas", "identifier": "FCGR2C"}, {"resource": "GeneCards", "identifier": "FCGR2C"}, {"resource": "GenBank Gene Database", "identifier": "X17652"}, {"resource": "GenBank Protein Database", "identifier": "32074"}, {"resource": "UniProtKB", "identifier": "P31995"}, {"resource": "UniProt Accession", "identifier": "FCG2C_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-c", "Fc-gamma-RIIc", "FcRII-c", "IgG Fc receptor II-c", "Low affinity immunoglobulin gamma Fc region receptor II-c precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-c\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR\nAPTDDDKNIYLTLPPNDHVNSNN"}, "gene-sequence": {"@format": "FASTA", "#text": ">972 bp\nATGGGAATCCTGTCATTTTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACAGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCATTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCTGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG\nAAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT\nGAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG\nGCACCTACTGACGATGATAAAAACATCTACTTGACTCTTCCTCCCAACGACCATGTCAAC\nAGTAATAACTAA"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2013-09-13", "drugbank-id": [{"@primary": "true", "#text": "DB00096"}, "BIOD00101", "BTD00101"], "name": "Serum albumin", "description": "A sterile non-pyrogenic suspension of microspheres of human serum albumin with perflutren (a highly fluorinated small molecule) for contrast enhancement during indicated ultrasound imaging procedures.", "cas-number": "9048-49-1", "groups": {"group": "approved"}, "general-references": "# Zunszain PA, Ghuman J, Komatsu T, Tsuchida E, Curry S: Crystal structural analysis of human serum albumin complexed with hemin and fatty acid. BMC Struct Biol. 2003 Jul 7;3:6. Epub 2003 Jul 7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12846933", "synthesis-reference": "Rene Fickat, Simon Benita, Francis Puisieux, \"Preparation of biodegradable microcapsules based on serum albumin.\" U.S. Patent US4666641, issued June, 1958.", "indication": "For treatment of severe blood loss, hypervolemia, hypoproteinemia.", "pharmacodynamics": "Serum albumin is a soluble, monomeric protein necessary for maintaining and regulating the colloidal osmotic pressure of blood. It is used to increase the circulating plasma volume, thereby reducing hemoconcentration and blood viscosity. Also used as a transport protein that binds naturally occurring, therapeutic and toxic materials in circulation.", "mechanism-of-action": "Serum albumin acts as a high molecular weight, very soluble osmolyte. Serum albumin also acts as a protein drug carrier in plasma, and transports hemin, steroids, thyroid hormones and fatty acids. It binds many other substances, such as unconjugated bilirubin, calcium ions, and other fat soluble hormones.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": {"@language": "", "@coder": "", "#text": "Serum albumin precursor"}}, "products": null, "international-brands": {"international-brand": [{"name": "Optison", "company": null}, {"name": "Perflutren Protein-Type A Microspheres", "company": null}]}, "mixtures": null, "packagers": {"packager": [{"name": "Draxis Specialty Pharmaceuticals Inc.", "url": "http://www.draxispharma.com"}, {"name": "GE Healthcare Inc.", "url": "http://www.gehealthcare.com"}, {"name": "Medi-Physics Inc.", "url": null}, {"name": "Pharmalucence Inc.", "url": "http://pharmalucence.com"}]}, "manufacturers": {"manufacturer": {"@generic": "false", "#text": "Ge healthcare"}}, "prices": {"price": {"description": "Optison vial", "cost": {"@currency": "USD", "#text": "56.16"}, "unit": "ml"}}, "categories": {"category": {"category": "Serum substitutes", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": null, "atc-codes": null, "ahfs-codes": null, "patents": {"patent": [{"number": "5558094", "country": "United States", "approved": "1995-02-28", "expires": "2012-02-28"}, {"number": "6723303", "country": "United States", "approved": "2001-04-20", "expires": "2021-04-20"}]}, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00096 sequence\nDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAE\nNCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEV\nDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLP\nKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTK\nVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA\nDLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKC\nCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVST\nPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTES\nLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKAT\nKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "62 \u00b0C", "source": "Flora, K. et al., Biophys J. 75:1084-1096 (1998)"}, {"kind": "Hydrophobicity", "value": "-0.395", "source": null}, {"kind": "Isoelectric Point", "value": "5.67", "source": null}, {"kind": "Molecular Weight", "value": "66472.2000", "source": null}, {"kind": "Molecular Formula", "value": "C2936H4624N786O889S41", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "National Drug Code Directory", "identifier": "0407-2707-03"}, {"resource": "GenBank", "identifier": "M12523"}, {"resource": "PharmGKB", "identifier": "PA164749380"}, {"resource": "UniProtKB", "identifier": "P02768"}, {"resource": "Wikipedia", "identifier": "Serum_albumin"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": null, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2015-09-23", "drugbank-id": [{"@primary": "true", "#text": "DB00097"}, "BIOD00034", "BTD00034"], "name": "Choriogonadotropin alfa", "description": "Recombinant human chorionic gonadotropin with 2 subunits, alpha = 92 residues, beta = 145 residues, each with N-and O-linked carbohydrate moieties linked to ASN-52 and ASN-78 (on alpha subunit) and ASN-13, ASN-30, SER-121, SER-127, SER-132 and SER-138 (on beta subunit). The primary structure of the alpha-chain of r-hCG is identical to that of the alpha-chain of hCG, FSH and LH.", "cas-number": "177073-44-8", "groups": {"group": "approved"}, "general-references": "# Kayisli UA, Selam B, Guzeloglu-Kayisli O, Demir R, Arici A: Human chorionic gonadotropin contributes to maternal immunotolerance and endometrial apoptosis by regulating Fas-Fas ligand system. J Immunol. 2003 Sep 1;171(5):2305-13. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12928375\n# Askling J, Erlandsson G, Kaijser M, Akre O, Ekbom A: Sickness in pregnancy and sex of child. Lancet. 1999 Dec 11;354(9195):2053. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10636378", "synthesis-reference": null, "indication": "For the treatment of female infertility", "pharmacodynamics": "Choriogonadotropin alfa is used to treat female infertility, Choriogonadotropin alfa stimulates late follicular maturation and resumption of oocyte meiosis, and initiates rupture of the pre-ovulatory ovarian follicle. Ovidrel is an analogue of Luteinizing Hormone (LH) and binds to the LH/hCG receptor of the granulosa and theca cells of the ovary to effect these changes in the absence of an endogenous LH surge.", "mechanism-of-action": "Choriogonadotropin alfa binds to the Follicle stimulating hormone receptor which results in ovulation in the absence of sufficient endogenous Luteinizing hormone.", "toxicity": null, "metabolism": null, "absorption": "The mean absolute bioavailability following a single subcutaneous injection to healthy female volunteers is about 40%.", "half-life": "The mean terminal half-life is about 29 \u00b1 6 hours (initial half-life is 4.5 \u00b1 0.5 hours).", "protein-binding": null, "route-of-elimination": "One-tenth of the dose is excreted in the urine.", "volume-of-distribution": "* 5.9 \u00b1 1.0 L", "clearance": "* 0.29 +/- 0.04 L/h [healthy down-regulated females]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "CG-beta"}, {"@language": "", "@coder": "", "#text": "Choriogonadotropin alpha"}, {"@language": "", "@coder": "", "#text": "Choriogonadotropin beta chain precursor"}, {"@language": "", "@coder": "", "#text": "Chorionic gonadotrophin beta subunit"}]}, "products": {"product": [{"name": "Ovidrel", "ndc-id": "44087-1150_c9252713-194c-41c9-b094-4fa8fd3caac8", "ndc-product-code": "44087-1150", "dpd-id": null, "started-marketing-on": "2003-10-06", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "250 ug/.5mL", "route": "subcutaneous", "fda-application-number": "NDA021149", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Ovidrel", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02262088", "started-marketing-on": "2004-12-20", "ended-marketing-on": null, "dosage-form": "solution", "strength": "250 mcg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Ovidrel", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02371588", "started-marketing-on": "2013-05-28", "ended-marketing-on": null, "dosage-form": "solution", "strength": "250 mcg", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": {"name": "Profasi", "company": "Serono S.A."}}, "mixtures": {"mixture": [{"name": "Ovidrel", "ingredients": "Choriogonadotropin alfa"}, {"name": "Ovidrel", "ingredients": "Choriogonadotropin alfa"}, {"name": "Ovidrel", "ingredients": "Choriogonadotropin alfa"}]}, "packagers": {"packager": [{"name": "EMD Canada Inc.", "url": "http://www.emdcanada.com"}, {"name": "Ferring Pharmaceuticals Inc.", "url": "http://www.ferring.com"}, {"name": "Merck KGaA", "url": "http://www.merck.de"}, {"name": "Organon Pharmaceuticals", "url": "http://www.organonshop.com"}]}, "manufacturers": {"manufacturer": [{"@generic": "false", "#text": "Emd serono inc"}, {"@generic": "false", "#text": "Ferring pharmaceuticals inc"}, {"@generic": "false", "#text": "App pharmaceuticals llc"}, {"@generic": "false", "#text": "Bel mar laboratories inc"}, {"@generic": "false", "#text": "Bristol myers squibb"}, {"@generic": "false", "#text": "Organon usa inc"}]}, "prices": {"price": [{"description": "Pregnyl 10000 unit vial", "cost": {"@currency": "USD", "#text": "57.23"}, "unit": "vial"}, {"description": "Pregnyl 10000 unit Solution", "cost": {"@currency": "USD", "#text": "60.7"}, "unit": "vial"}, {"description": "Ovidrel 250 mcg/0.5ml Injectable 0.5ml Syringe", "cost": {"@currency": "USD", "#text": "93.22"}, "unit": "syringe"}, {"description": "Novarel 10000 unit vial", "cost": {"@currency": "USD", "#text": "113.99"}, "unit": "vial"}, {"description": "Novarel 10000 unit/10ml Solution 1 Vial = 10ml", "cost": {"@currency": "USD", "#text": "118.55"}, "unit": "vial"}]}, "categories": {"category": [{"category": "Fertility Agents", "mesh-id": null}, {"category": "Gonadotropins", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, solution", "route": "subcutaneous", "strength": "250 ug/.5mL"}, {"form": "Solution", "route": "subcutaneous", "strength": "250 mcg"}]}, "atc-codes": {"atc-code": {"@code": "G03GA08", "level": [{"@code": "G", "#text": "GENITO URINARY SYSTEM AND SEX HORMONES"}, {"@code": "G03", "#text": "SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM"}, {"@code": "G03G", "#text": "GONADOTROPINS AND OTHER OVULATION STIMULANTS"}, {"@code": "G03GA", "#text": "Gonadotropins"}]}}, "ahfs-codes": null, "patents": {"patent": [{"number": "5767251", "country": "United States", "approved": "1995-06-16", "expires": "2015-06-16"}, {"number": "6706681", "country": "United States", "approved": "2001-03-16", "expires": "2021-03-16"}]}, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": [{"@format": "FASTA", "#text": ">Alpha chain\nAPDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCC\nVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS"}, {"@format": "FASTA", "#text": ">Beta chain\nSKEPLRPRCRPINATLAVEKEGCPVCITVNTTICAGYCPTMTRVLQGVLPALPQVVCNYR\nDVRFESIRLPGCPRGVNPVVSYAVALSCQCALCRRSTTDCGGPKDHPLTCDDPRFQDSSS\nSKAPPPSLPSPSRLPGPSDTPILPQ"}]}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "55 \u00b0C", "source": "Forastieri, H., Ingham, K.C. J. Biol. Chem. 257:7976-7981 (1982)"}, {"kind": "Hydrophobicity", "value": "-0.258", "source": null}, {"kind": "Isoelectric Point", "value": "8.61", "source": null}, {"kind": "Molecular Weight", "value": "25719.7000", "source": null}, {"kind": "Molecular Formula", "value": "C1105H1770N318O336S26", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "12389"}, {"resource": "National Drug Code Directory", "identifier": "44087-1150-1"}, {"resource": "GenBank", "identifier": "J00117"}, {"resource": "PharmGKB", "identifier": "PA164783947"}, {"resource": "UniProtKB", "identifier": "P01233"}, {"resource": "Wikipedia", "identifier": "Choriogonadotropin_alfa"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/ovidrel.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/choriogonadotropin-alfa.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000134", "name": "Lutropin-choriogonadotropic hormone receptor", "organism": "Human", "actions": null, "references": "# Bodek G, Vierre S, Rivero-Muller A, Huhtaniemi I, Ziecik AJ, Rahman NA: A novel targeted therapy of Leydig and granulosa cell tumors through the luteinizing hormone receptor using a hecate-chorionic gonadotropin beta conjugate in transgenic mice. Neoplasia. 2005 May;7(5):497-508. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15967102\n# Gromoll J, Wistuba J, Terwort N, Godmann M, Muller T, Simoni M: A new subclass of the luteinizing hormone/chorionic gonadotropin receptor lacking exon 10 messenger RNA in the New World monkey (Platyrrhini) lineage. Biol Reprod. 2003 Jul;69(1):75-80. Epub 2003 Feb 19. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12606382\n# Lin W, Bernard MP, Cao D, Myers RV, Kerrigan JE, Moyle WR: Follitropin receptors contain cryptic ligand binding sites. Mol Cell Endocrinol. 2007 Jan 2;260-262:83-92. Epub 2006 Oct 23. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17059863", "known-action": "yes", "polypeptide": {"@id": "P22888", "@source": "Swiss-Prot", "name": "Lutropin-choriogonadotropic hormone receptor", "general-function": "Involved in rhodopsin-like receptor activity", "specific-function": "Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase", "gene-name": "LHCGR", "locus": "2p21", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "364-385\n396-416\n440-462\n483-505\n526-549\n571-594\n606-627", "signal-regions": null, "theoretical-pi": "8.58", "molecular-weight": "78617.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6585"}, {"resource": "GenAtlas", "identifier": "LHCGR"}, {"resource": "GeneCards", "identifier": "LHCGR"}, {"resource": "GenBank Gene Database", "identifier": "M73746"}, {"resource": "GenBank Protein Database", "identifier": "903746"}, {"resource": "IUPHAR", "identifier": "254"}, {"resource": "Guide to Pharmacology", "identifier": "30"}, {"resource": "UniProtKB", "identifier": "P22888"}, {"resource": "UniProt Accession", "identifier": "LSHR_HUMAN"}]}, "synonyms": {"synonym": ["LH/CG-R", "LHR", "LSH- R", "Luteinizing hormone receptor", "Lutropin-choriogonadotropic hormone receptor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Lutropin-choriogonadotropic hormone receptor precursor\nMKQRFSALQLLKLLLLLQPPLPRALREALCPEPCNCVPDGALRCPGPTAGLTRLSLAYLP\nVKVIPSQAFRGLNEVIKIEISQIDSLERIEANAFDNLLNLSEILIQNTKNLRYIEPGAFI\nNLPRLKYLSICNTGIRKFPDVTKVFSSESNFILEICDNLHITTIPGNAFQGMNNESVTLK\nLYGNGFEEVQSHAFNGTTLTSLELKENVHLEKMHNGAFRGATGPKTLDISSTKLQALPSY\nGLESIQRLIATSSYSLKKLPSRETFVNLLEATLTYPSHCCAFRNLPTKEQNFSHSISENF\nSKQCESTVRKVSNKTLYSSMLAESELSGWDYEYGFCLPKTPRCAPEPDAFNPCEDIMGYD\nFLRVLIWLINILAIMGNMTVLFVLLTSRYKLTVPRFLMCNLSFADFCMGLYLLLIASVDS\nQTKGQYYNHAIDWQTGSGCSTAGFFTVFASELSVYTLTVITLERWHTITYAIHLDQKLRL\nRHAILIMLGGWLFSSLIAMLPLVGVSNYMKVSICFPMDVETTLSQVYILTILILNVVAFF\nIICACYIKIYFAVRNPELMATNKDTKIAKKMAILIFTDFTCMAPISFFAISAAFKVPLIT\nVTNSKVLLVLFYPINSCANPFLYAIFTKTFQRDFFLLLSKFGCCKRRAELYRRKDFSAYT\nSNCKNGFTGSNKPSQSTLKLSTLHCQGTALLDKTRYTEC"}, "gene-sequence": {"@format": "FASTA", "#text": ">2058 bp\nATGAAGCAGCGGTTCTCGCCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGGCGCCG\nCTGCCACGAGCGCTGCGCAGGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGCGCC\nCTGCGTGCCCCGGCCCCACGGCCGTCCACTCGACTATCACTTGCCTACCTCCCTGTCAAA\nGTGATCCCATCTCAAAGTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATCTCTCAG\nATTGATTCCCTGGAAAGGATAGAAGCTAATGCCTTTGACAACCTCCTCAATTTGTCTGAA\nATACTGATCCAGAACACCAAAAATCTGAGATACATTGAGCCCGGAGCATTTATAAATCTT\nCCCCGATTAAAATACTTGAGCATCTGTAACACAGGCATCAGAAAGTTTCCAGATGTTACG\nAAGGTCTTCTCCTCTGAATCAAATTTCATTCTGGAAATTTGTGATAACTTACACATAACC\nACCATACCAGGAAATGCTTTTCAAGGGATGAATAATGAATCTGTAACACTCAAACTATAT\nGGAAATGGATTTGAAGAAGTACAAAGTCATGCATTCAATGGGACGACACTGACTTCACTG\nGAGCTAAAGGAAAACGTACATCTGGAGAAGATGCACAATGGAGCCTTCCGTGGGGCCACA\nGGGCCGAAAACCTTGGATATTTCTTCCACCAAATTGCAGGCCCTGCCGAGCTATGGCCTA\nGAGTCCATTCAGAGGCTAATTGCCACGTCATCCTATTCTCTAAAAAAATTGCCATCAAAA\nCAAACATTTGTCAATCTCCTGAGGGCCACGCTTCATTACCCCAGCCACTGCTGTGCATTT\nAGAAACTTGCCAACGAAAGAGCTAAACTTCTCACATTCCATTTCTGAAAACTTTTCCAAA\nCAATGTGAAAGCACAGTAAGGAAAAGTGAACTGAGTGGCTGGGACTATGAATATGGTTTC\nTGCTTACCCAAGACACCCCGATGTGCTCCTGAACCAGATGCTTTTAATCCCTGTGAAGAC\nATTATGGGCTATGACTTCCTTAGGGTCCTGATTTGGCTGATTAATATTCTAGCCATCATG\nGGAAACATGACTGTTCTTTTTGTTCTCCTGACAAGTCGTTACAAACTTACAGTGCCTCGT\nTTTCTCATGTGCAATCTCTCCTTTGCAGACTTTTGCATGGGGCTCTATCTGCTGCTCATA\nGCCTCAGTTGATTCCCAAACCAAGGGCCAGTACTATAACCATGCCATAGACTGGCAGACA\nGGGAGTGGGTGCAGCACTGCTGGCTTTTTCACTGTATTAGCAAGTGAACTTTCTGTCTAC\nACCCTCACCGTCATCACTCTAGAAAGATGGCACACCATCACCTATGCTATTCACCTGGAC\nCAAAAGCTGCGATTAAGACATGCCATTCTGATTATGCTTGGAGGCTGGCTCTTTTCTTCT\nCTAATTGCTATGTTGCCCCTTGTCGGGGTCAGCAATTACATGAAGGTCAGTATTTGCTTC\nCCCATGGATGTGGAAACCACTCTCTCACAAGTCTATATATTAACCATCCTGATTCTCAAT\nGTGGTGGCCTTCTTAATAATTTGTGCTTGCTACATTAAAATTTATTTTGCAGTTCGAAAC\nCCAGAATTAATGGCTACCAATAAAGATACAAAGATTGCTAAGAAAATGGCAATCCTCATC\nTTCACCGATTTTACCTGCATGGCACCTATCTCTTTTTTTGCCATCTCAGCTGCCTTCAAA\nGTACCTCTTATCACAGTAACCAACTCTAAAGTTTTACTGGTTCTTTTTTATCCCATCAAT\nTCTTGTGCCAATCCATTTCTGTATGCAATATTCACTAAGACATTCCAAAGAGATTTCTTT\nCTTTTGCTGAGCAAATTTGGCTGCTGTAAACGTCGGGCTGATCCTCTTTATAGAAGGAAA\nGATTTTTCAGCTTACACCTCCAACTGCAAAAATGGCTTCACTGGATCAAATAAGCCTTCT\nCAATCCACCTTGAAGTTGTCCACATTGCACTGTCAAGGTACAGCTCTCCTAGACAAGACT\nCGCTACACAGAGTGTTAA"}, "pfams": {"pfam": {"identifier": "PF00001", "name": "7tm_1"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "function", "description": "lutropin-choriogonadotropic hormone receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "protein-hormone receptor activity"}, {"category": "function", "description": "receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}]}}}, {"@position": "2", "id": "BE0000387", "name": "Follicle-stimulating hormone receptor", "organism": "Human", "actions": {"action": "binder"}, "references": "# Jameson JL: Inherited disorders of the gonadotropin hormones. Mol Cell Endocrinol. 1996 Dec 20;125(1-2):143-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9027352\n# Lin W, Bernard MP, Cao D, Myers RV, Kerrigan JE, Moyle WR: Follitropin receptors contain cryptic ligand binding sites. Mol Cell Endocrinol. 2007 Jan 2;260-262:83-92. Epub 2006 Oct 23. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17059863\n# Tao YX, Segaloff DL: Chapter 5 Follicle Stimulating Hormone Receptor Mutations and Reproductive Disorders. Prog Mol Biol Transl Sci. 2009;89C:115-131. Epub 2009 Oct 7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20374735\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P23945", "@source": "Swiss-Prot", "name": "Follicle-stimulating hormone receptor", "general-function": "Involved in follicle-stimulating hormone receptor activity", "specific-function": "Receptor for follicle-stimulating hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase", "gene-name": "FSHR", "locus": "2p21-p16", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "367-387\n399-421\n444-465\n486-508\n529-550\n574-597\n609-630", "signal-regions": null, "theoretical-pi": "7.19", "molecular-weight": "78296.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3969"}, {"resource": "GenAtlas", "identifier": "FSHR"}, {"resource": "GeneCards", "identifier": "FSHR"}, {"resource": "GenBank Gene Database", "identifier": "M65085"}, {"resource": "GenBank Protein Database", "identifier": "182771"}, {"resource": "IUPHAR", "identifier": "253"}, {"resource": "Guide to Pharmacology", "identifier": "30"}, {"resource": "UniProtKB", "identifier": "P23945"}, {"resource": "UniProt Accession", "identifier": "FSHR_HUMAN"}]}, "synonyms": {"synonym": ["Follicle-stimulating hormone receptor precursor", "Follitropin receptor", "FSH-R"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Follicle-stimulating hormone receptor precursor\nMALLLVSLLAFLSLGSGCHHRICHCSNRVFLCQESKVTEIPSDLPRNAIELRFVLTKLRV\nIQKGAFSGFGDLEKIEISQNDVLEVIEADVFSNLPKLHEIRIEKANNLLYINPEAFQNLP\nNLQYLLISNTGIKHLPDVHKIHSLQKVLLDIQDNINIHTIERNSFVGLSFESVILWLNKN\nGIQEIHNCAFNGTQLDELNLSDNNNLEELPNDVFHGASGPVILDISRTRIHSLPSYGLEN\nLKKLRARSTYNLKKLPTLEKLVALMEASLTYPSHCCAFANWRRQISELHPICNKSILRQE\nVDYMTQTRGQRSSLAEDNESSYSRGFDMTYTEFDYDLCNEVVDVTCSPKPDAFNPCEDIM\nGYNILRVLIWFISILAITGNIIVLVILTTSQYKLTVPRFLMCNLAFADLCIGIYLLLIAS\nVDIHTKSQYHNYAIDWQTGAGCDAAGFFTVFASELSVYTLTAITLERWHTITHAMQLDCK\nVQLRHAASVMVMGWIFAFAAALFPIFGISSYMKVSICLPMDIDSPLSQLYVMSLLVLNVL\nAFVVICGCYIHIYLTVRNPNIVSSSSDTRIAKRMAMLIFTDFLCMAPISFFAISASLKVP\nLITVSKAKILLVLFHPINSCANPFLYAIFTKNFRRDFFILLSKCGCYEMQAQIYRTETSS\nTVHNTHPRNGHCSSAPRVTNGSTYILVPLSHLAQN"}, "gene-sequence": {"@format": "FASTA", "#text": ">2088 bp\nATGGCCCTGCTCCTGGTCTCTTTGCTGGCATTCCTGAGCTTGGGCTCAGGATGTCATCAT\nCGGATCTGTCACTGCTCTAACAGGGTTTTTCTCTGCCAAGAGAGCAAGGTGACAGAGATT\nCCTTCTGACCTCCCGAGGAATGCCATTGAACTGAGGTTTGTCCTCACCAAGCTTCGAGTC\nATCCAAAAAGGTGCATTTTCAGGATTTGGGGACCTGGAGAAAATAGAGATCTCTCAGAAT\nGATGTCTTGGAGGTGATAGAGGCAGATGTGTTCTCCAACCTTCCCAAATTACATGAAATT\nAGAATTGAAAAGGCCAACAACCTGCTCTACATCACCCCTGAGGCCTTCCAGAACCTTCCC\nAACCTTCAATATCTGTTAATATCCAACACAGGTATTAAGCACCTTCCAGATGTTCACAAG\nATTCATTCTCTCCAAAAGGTTTTACTTGACATTCAAGATAACATAAACATCCACACAATT\nGAAAGAAATTCTTTCGTGGGGCTGAGCTTTGAAAGTGTGATTCTATGGCTGAATAAGAAT\nGGGATTCAAGAAATACACAACTGTGCATTCAATGGAACCCAACTAGATGCAGTGAATCTA\nAGCGATAATAATAATTTAGAAGAATTGCCTAATGATGTTTTCCACGGAGCCTCTGGACCA\nGTCATTCTAGATATTTCAAGAACAAGGATCCATTCCCTGCCTAGCTATGGCTTAGAAAAT\nCTTAAGAAGCTGAGGGCCAGGTCGACTTACAACTTAAAAAAGCTGCCTACTCTGGAAAAG\nCTTGTCGCCCTCATGGAAGCCAGCCTCACCTATCCCAGCCATTGCTGTGCCTTTGCAAAC\nTGGAGACGGCAAATCTCTGAGCTTCATCCAATTTGCAACAAATCTATTTTAAGGCAAGAA\nGTTGATTATATGACTCAGGCTAGGGGTCAGAGATCCTCTCTGGCAGAAGACAATGAGTCC\nAGCTACAGCAGAGGATTTGACATGACGTACACTGAGTTTGACTATGACTTATGCAATGAA\nGTGGTTGACGTGACCTGCTCCCCTAAGCCAGATGCATTCAACCCATGTGAAGATATCATG\nGGGTACAACATCCTCAGAGTCCTGATATGGTTTATCAGCATCCTGGCCATCACTGGGAAC\nATCATAGTGCTAGTGATCCTAACTACCAGCCAATATAAACTCACAGTCCCCAGGTTCCTT\nATGTGCAACCTGGCCTTTGCTGATCTCTGCATTGGAATCTACCTGCTGCTCATTGCATCA\nGTTGATATCCATACCAAGAGCCAATATCACAACTATGCCATTGACTGGCAAACTGGGGCA\nGGCTGTGATGCTGCTGGCTTTTTCACTGTCTTTGCCAGTGAGCTGTCAGTCTACACTCTG\nACAGCTATCACCTTGGAAAGATGGCATACCATCACGCATGCCATGCAGCTGGACTGCAAG\nGTGCAGCTCCGCCATGCTGCCAGTGTCATGGTGATGGGCTGGATTTTTGCTTTTGCAGCT\nGCCCTCTTTCCCATCTTTGGCATCAGCAGCTACATGAAGGTGAGCATCTGCCTGCCCATG\nGATATTGACAGCCCTTTGTCACAGCTGTATGTCATGTCCCTCCTTGTGCTCAATGTCCTG\nGCCTTTGTGGTCATCTGTGGCTGCTATATCCACATCTACCTCACAGTGCGGAACCCCAAC\nATCGTGTCCTCCTCTAGTGACACCAGGATCGCCAAGCGCATGGCCATGCTCATCTTCACT\nGACTTCCTCTGCATGGCACCCATTTCTTTCTTTGCCATTTCTGCCTCCCTCAAGGTGCCC\nCTCATCACTGTGTCCAAAGCAAAGATTCTGCTGGTTCTGTTTCACCCCATCAACTCCTGT\nGCCAACCCCTTCCTCTATGCCATCTTTACCAAAAACTTTCGCAGAGATTTCTTCATTCTG\nCTGAGCAAGTGTGGCTGCTATGAAATGCAAGCCCAAATTTATAGGACAGAAACTTCATCC\nACTGTCCACAACACCCATCCAAGGAATGGCCACTGCTCTTCAGCTCCCAGAGTCACCAGT\nGGTTCCACTTACATACTTGTCCCTCTAAGTCATTTAGCCCAAAACTAA"}, "pfams": {"pfam": [{"identifier": "PF00001", "name": "7tm_1"}, {"identifier": "PF00560", "name": "LRR_1"}, {"identifier": "PF01462", "name": "LRRNT"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "function", "description": "protein-hormone receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "follicle stimulating hormone receptor activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2015-11-16", "drugbank-id": [{"@primary": "true", "#text": "DB00098"}, "BIOD00040", "BTD00040"], "name": "Anti-thymocyte Globulin (Rabbit)", "description": "Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.", "cas-number": null, "groups": {"group": "approved"}, "general-references": "#American Society of Health System Pharmacists, Inc., DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995. Antithymocyte globulin; [updated 2013 Jan 18; cited 2014 Nov 11]; Available http://web.b.ebscohost.com.login.ezproxy.library.ualberta.ca/dynamed/detail?vid=7&sid=78010ea4-6f9c-4d5a-a7df-a148b3891321%40sessionmgr110&hid=123&bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BlPXNpdGU%3d#db=dme&AN=356335", "synthesis-reference": null, "indication": "For prevention of renal transplant rejection", "pharmacodynamics": "Antithymocyte Globulin (ATG) is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line. ATG is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation. ATG reduces the host immune response against tissue transplants or organ allografts.", "mechanism-of-action": "Binds to multiple, T-cell specific antigens leading to T-lymphocyte cell death via complement mediated cytotoxicity or apoptosis.", "toxicity": "Not known whether ATG (rabbit) distributes into human milk; however, other immunoglobulins are distributed into human milk.", "metabolism": "Most likely removed by opsonization via the reticuloendothelial system when bound to T lymphocytes, or by human antimurine antibody production.", "absorption": "T-cell depletion usually observed within 1 day after initiating therapy. Average 21.5 and 87 mcg/mL 4\u20138 hours post-infusion after first and last IV doses, respectively, when given for 7\u201311 days.", "half-life": "2-3 days, may increase after multiple doses administration", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Anti-thymocyte globulin (rabbit)"}, {"@language": "", "@coder": "", "#text": "rabbit ATG"}, {"@language": "", "@coder": "", "#text": "rATG"}, {"@language": "", "@coder": "", "#text": "Thymoglobulin"}]}, "products": {"product": [{"name": "Thymoglobulin", "ndc-id": "58468-0080_14bd56fa-cdab-4b85-8b1c-a9f7aba03e54", "ndc-product-code": "58468-0080", "dpd-id": null, "started-marketing-on": "1998-12-30", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "5 mg/mL", "route": "intravenous", "fda-application-number": "BLA103869", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Thymoglobulin", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02246805", "started-marketing-on": "2003-05-06", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "25 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": [{"name": "ATG-Fresenius", "company": "Fresenius SE"}, {"name": "ATG-Fresenius S", "company": "Fresenius SE"}, {"name": "Genzyme", "company": null}, {"name": "Thymoglobulin SangStat Medical", "company": null}]}, "mixtures": {"mixture": [{"name": "Thymoglobulin", "ingredients": "Anti-thymocyte Globulin (Rabbit)"}, {"name": "Thymoglobulin", "ingredients": "Anti-thymocyte Globulin (Rabbit)"}]}, "packagers": {"packager": {"name": "Genzyme Inc.", "url": "http://www.genzyme.ca"}}, "manufacturers": null, "prices": {"price": {"description": "Thymoglobulin 25 mg vial", "cost": {"@currency": "USD", "#text": "636.48"}, "unit": "vial"}}, "categories": {"category": [{"category": "Immunologic Factors", "mesh-id": null}, {"category": "Immunosuppressive Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, powder, lyophilized, for solution", "route": "intravenous", "strength": "5 mg/mL"}, {"form": "Powder for solution", "route": "intravenous", "strength": "25 mg"}]}, "atc-codes": null, "ahfs-codes": null, "patents": null, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB06643", "name": "Denosumab", "description": "May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased."}, {"drugbank-id": "DB01097", "name": "Leflunomide", "description": "Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased."}, {"drugbank-id": "DB00108", "name": "Natalizumab", "description": "Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased."}, {"drugbank-id": "DB00337", "name": "Pimecrolimus", "description": "May enhance the adverse/toxic effect of Immunosuppressants."}, {"drugbank-id": "DB01656", "name": "Roflumilast", "description": "May enhance the immunosuppressive effect of Immunosuppressants."}, {"drugbank-id": "DB06688", "name": "Sipuleucel-T", "description": "Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T."}, {"drugbank-id": "DB08895", "name": "Tofacitinib", "description": "Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib."}, {"drugbank-id": "DB00072", "name": "Trastuzumab", "description": "May enhance the neutropenic effect of Immunosuppressants."}]}, "sequences": null, "experimental-properties": {"property": {"kind": "Melting Point", "value": "61 \u00b0C (FAB fragment), 71 \u00b0C (whole mAb)", "source": "Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)"}}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "12118"}, {"resource": "PharmGKB", "identifier": "PA164743704"}, {"resource": "Wikipedia", "identifier": "Anti-thymocyte_globulin"}]}, "external-links": null, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000598", "name": "T-cell surface glycoprotein CD1a", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "unknown", "polypeptide": {"@id": "P06126", "@source": "Swiss-Prot", "name": "T-cell surface glycoprotein CD1a", "general-function": null, "specific-function": "Not known", "gene-name": "CD1A", "locus": "1q22-q23", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "301-321", "signal-regions": null, "theoretical-pi": "6.79", "molecular-weight": "37173.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1634"}, {"resource": "GenAtlas", "identifier": "CD1A"}, {"resource": "GeneCards", "identifier": "CD1A"}, {"resource": "GenBank Gene Database", "identifier": "M28825"}, {"resource": "GenBank Protein Database", "identifier": "180036"}, {"resource": "UniProtKB", "identifier": "P06126"}, {"resource": "UniProt Accession", "identifier": "CD1A_HUMAN"}]}, "synonyms": {"synonym": ["CD1a antigen", "hTa1 thymocyte antigen", "T-cell surface antigen T6/Leu-6", "T-cell surface glycoprotein CD1a precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">T-cell surface glycoprotein CD1a precursor\nMLFLLLPLLAVLPGDGNADGLKEPLSFHVIWIASFYNHSWKQNLVSGWLSDLQTHTWDSN\nSSTIVFLWPWSRGNFSNEEWKELETLFRIRTIRSFEGIRRYAHELQFEYPFEIQVTGGCE\nLHSGKVSGSFLQLAYQGSDFVSFQNNSWLPYPVAGNMAKHFCKVLNQNQHENDITHNLLS\nDTCPRFILGLLDAGKAHLQRQVKPEAWLSHGPSPGPGHLQLVCHVSGFYPKPVWVMWMRG\nEQEQQGTQRGDILPSADGTWYLRATLEVAAGEAADLSCRVKHSSLEGQDIVLYWEHHSSV\nGFIILAVIVPLLLLIGLALWFRKRCFC"}, "gene-sequence": {"@format": "FASTA", "#text": ">984 bp\nATGCTGTTTTTGCTACTTCCATTGTTAGCTGTTCTCCCAGGTGATGGCAATGCAGACGGG\nCTCAAGGAGCCTCTCTCCTTCCATGTCATCTGGATCGCATCCTTTTACAACCATTCCTGG\nAAACAAAATCTGGTCTCAGGTTGGCTGAGTGATTTGCAGACTCATACCTGGGACAGCAAT\nTCCAGCACCATCGTTTTCCTGTGGCCCTGGTCCAGGGGAAACTTCAGCAATGAGGAGTGG\nAAGGAACTGGAAACATTATTCCGTATACGCACCATTCGGTCATTTGAGGGAATTCGTAGA\nTACGCCCATGAATTGCAGTTTGAATATCCTTTTGAGATACAGGTGACAGGAGGCTGTGAG\nCTGCACTCTGGAAAGGTCTCAGGAAGCTTCTTGCAGTTAGCTTATCAAGGATCAGACTTT\nGTGAGCTTCCAGAACAATTCATGGTTGCCATATCCAGTGGCTGGGAATATGGCCAAGCAT\nTTCTGCAAAGTGCTCAATCAGAATCAGCATGAAAATGACATAACACACAATCTTCTCAGT\nGACACCTGCCCACGTTTCATCTTGGGTCTTCTTGATGCAGGAAAGGCACATCTCCAGCGG\nCAAGTGAAGCCCGAGGCCTGGCTGTCCCATGGCCCCAGTCCTGGCCCTGGCCATCTGCAG\nCTTGTGTGCCATGTCTCAGGATTCTACCCAAAGCCCGTGTGGGTGATGTGGATGCGGGGT\nGAGCAGGAGCAGCAGGGCACTCAGCGAGGGGACATCTTGCCCAGTGCTGATGGGACATGG\nTATCTCCGCGCAACCCTGGAGGTGGCCGCTGGGGAGGCAGCTGACCTGTCCTGTCGGGTG\nAAGCACAGCAGTCTAGAGGGCCAGGACATCGTCCTCTACTGGGAGCATCACAGTTCCGTG\nGGCTTCATCATCTTGGCGGTGATAGTGCCTTTACTTCTTCTGATAGGTCTTGCGCTTTGG\nTTCAGGAAACGCTGTTTCTGTTAA"}, "pfams": {"pfam": [{"identifier": "PF07654", "name": "C1-set"}, {"identifier": "PF00129", "name": "MHC_I"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "MHC protein complex"}, {"category": "component", "description": "protein complex"}, {"category": "component", "description": "MHC class I protein complex"}, {"category": "function", "description": "MHC class I receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "antigen presentation"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}]}}}, {"@position": "1", "id": "BE0003573", "name": "Major histocompatibility complex class I-related gene protein", "organism": "Human", "actions": {"action": "antagonist"}, "references": "# Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12586600", "known-action": "yes", "polypeptide": {"@id": "Q95460", "@source": "Swiss-Prot", "name": "Major histocompatibility complex class I-related gene protein", "general-function": "Involved in MHC class I receptor activity", "specific-function": "Has antigen presentation function. Involved in the development and expansion of a small population of T cells expressing an invariant T cell receptor alpha chain called mucosal-associated invariant T cells (MAIT). MAIT cells are preferentially located in the gut lamina propria and therfore may be involed in monitoring commensal flora or serve as a distress signal. Expression and MAIT cell recognition seem to be ligand- dependent", "gene-name": "MR1", "locus": "1q25.3", "cellular-location": "Isoform 4:Secreted", "transmembrane-regions": "303-323", "signal-regions": null, "theoretical-pi": "6.27", "molecular-weight": "39365.8", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "GNC:4975"}, {"resource": "GeneCards", "identifier": "MR1"}, {"resource": "GenBank Gene Database", "identifier": "U22963"}, {"resource": "GenBank Protein Database", "identifier": "940354"}, {"resource": "UniProtKB", "identifier": "Q95460"}, {"resource": "UniProt Accession", "identifier": "HMR1_HUMAN"}]}, "synonyms": {"synonym": ["Class I histocompatibility antigen-like protein", "MHC class-I related-gene protein"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Major histocompatibility complex class I-related gene protein\nMGELMAFLLPLIIVLMVKHSDSRTHSLRYFRLGVSDPIHGVPEFISVGYVDSHPITTYDS\nVTRQKEPRAPWMAENLAPDHWERYTQLLRGWQQMFKVELKRLQRHYNHSGSHTYQRMIGC\nELLEDGSTTGFLQYAYDGQDFLIFNKDTLSWLAVDNVAHTIKQAWEANQHELLYQKNWLE\nEECIAWLKRFLEYGKDTLQRTEPPLVRVNRKETFPGVTALFCKAHGFYPPEIYMTWMKNG\nEEIVQEIDYGDILPSGDGTYQAWASIELDPQSSNLYSCHVEHCGVHMVLQVPQESETIPL\nVMKAVSGSIVLVIVLAGVGVLVWRRRPREQNGAIYLPTPDR"}, "gene-sequence": {"@format": "FASTA", "#text": ">1026 bp\nATGGGGGAACTGATGGCGTTCCTGTTACCTCTCATCATTGTGTTAATGGTGAAGCACAGC\nGATTCCCGGACGCACTCTCTGAGATATTTTCGCCTGGGCGTTTCGGATCCCATCCATGGG\nGTCCCTGAATTTATTTCGGTTGGGTACGTGGACTCGCACCCTATCACCACATATGACAGT\nGTCACTCGGCAGAAGGAGCCACGGGCCCCATGGATGGCAGAGAACCTCGCGCCTGATCAC\nTGGGAGAGGTACACTCAGCTGCTGAGGGGCTGGCAGCAGATGTTCAAGGTGGAACTGAAG\nCGCCTACAGAGGCACTACAATCACTCAGGGTCTCACACTTACCAGAGAATGATTGGCTGT\nGAGCTGCTGGAGGATGGAAGCACCACAGGATTTCTGCAGTATGCATATGACGGGCAGGAT\nTTCCTGATCTTCAATAAAGACACCCTCTCCTGGCTGGCTGTAGATAATGTGGCTCACACC\nATCAAGCAGGCATGGGAGGCCAATCAGCATGAGTTGCTGTATCAAAAGAATTGGCTGGAA\nGAAGAATGTATTGCCTGGCTAAAGAGATTCCTGGAGTATGGGAAAGACACCCTACAAAGA\nACAGAGCCCCCACTGGTCAGAGTAAATCGCAAAGAAACTTTTCCAGGGGTTACAGCTCTC\nTTCTGCAAAGCTCATGGCTTTTACCCCCCAGAAATTTACATGACATGGATGAAAAACGGG\nGAAGAAATTGTCCAAGAAATTGATTATGGAGACATTCTTCCCAGTGGGGATGGAACCTAT\nCAGGCGTGGGCATCAATTGAGCTTGATCCTCAGAGCAGCAACCTTTACTCCTGTCATGTG\nGAGCACTGCGGTGTCCACATGGTTCTTCAGGTCCCCCAGGAATCAGAAACTATCCCTCTT\nGTGATGAAAGCTGTCTCTGGGTCCATTGTCCTTGTCATTGTGCTGGCTGGAGTTGGTGTT\nCTAGTCTGGAGAAGAAGGCCCCGAGAGCAAAATGGAGCCATCTACCTTCCAACACCAGAT\nCGATGA"}, "pfams": {"pfam": [{"identifier": "PF07654", "name": "C1-set"}, {"identifier": "PF00129", "name": "MHC_I"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "MHC protein complex"}, {"category": "component", "description": "protein complex"}, {"category": "component", "description": "MHC class I protein complex"}, {"category": "function", "description": "MHC class I receptor activity"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "antigen presentation"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}]}}}, {"@position": "2", "id": "BE0000516", "name": "Integrin alpha-L", "organism": "Human", "actions": null, "references": "# Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12586600", "known-action": "yes", "polypeptide": {"@id": "P20701", "@source": "Swiss-Prot", "name": "Integrin alpha-L", "general-function": "Involved in cell adhesion and protein binding", "specific-function": "Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. It is involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes", "gene-name": "ITGAL", "locus": "16p11.2", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "1091-1111", "signal-regions": null, "theoretical-pi": "5.35", "molecular-weight": "128771.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6148"}, {"resource": "GenAtlas", "identifier": "ITGAL"}, {"resource": "GeneCards", "identifier": "ITGAL"}, {"resource": "GenBank Gene Database", "identifier": "Y00796"}, {"resource": "GenBank Protein Database", "identifier": "31422"}, {"resource": "UniProtKB", "identifier": "P20701"}, {"resource": "UniProt Accession", "identifier": "ITAL_HUMAN"}]}, "synonyms": {"synonym": ["CD11a antigen", "Integrin alpha-L precursor", "Leukocyte adhesion glycoprotein LFA-1 alpha chain", "Leukocyte function-associated molecule 1 alpha chain", "LFA-1A"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Integrin alpha-L precursor\nMKDSCITVMAMALLSGFFFFAPASSYNLDVRGARSFSPPRAGRHFGYRVLQVGNGVIVGA\nPGEGNSTGSLYQCQSGTGHCLPVTLRGSNYTSKYLGMTLATDPTDGSILACDPGLSRTCD\nQNTYLSGLCYLFRQNLQGPMLQGRPGFQECIKGNVDLVFLFDGSMSLQPDEFQKILDFMK\nDVMKKLSNTSYQFAAVQFSTSYKTEFDFSDYVKRKDPDALLKHVKHMLLLTNTFGAINYV\nATEVFREELGARPDATKVLIIITDGEATDSGNIDAAKDIIRYIIGIGKHFQTKESQETLH\nKFASKPASEFVKILDTFEKLKDLFTELQKKIYVIEGTSKQDLTSFNMELSSSGISADLSR\nGHAVVGAVGAKDWAGGFLDLKADLQDDTFIGNEPLTPEVRAGYLGYTVTWLPSRQKTSLL\nASGAPRYQHMGRVLLFQEPQGGGHWSQVQTIHGTQIGSYFGGELCGVDVDQDGETELLLI\nGAPLFYGEQRGGRVFIYQRRQLGFEEVSELQGDPGYPLGRFGEAITALTDINGDGLVDVA\nVGAPLEEQGAVYIFNGRHGGLSPQPSQRIEGTQVLSGIQWFGRSIHGVKDLEGDGLADVA\nVGAESQMIVLSSRPVVDMVTLMSFSPAEIPVHEVECSYSTSNKMKEGVNITICFQIKSLI\nPQFQGRLVANLTYTLQLDGHRTRRRGLFPGGRHELRRNIAVTTSMSCTDFSFHFPVCVQD\nLISPINVSLNFSLWEEEGTPRDQRAQGKDIPPILRPSLHSETWEIPFEKNCGEDKKCEAN\nLRVSFSPARSRALRLTAFASLSVELSLSNLEEDAYWVQLDLHFPPGLSFRKVEMLKPHSQ\nIPVSCEELPEESRLLSRALSCNVSSPIFKAGHSVALQMMFNTLVNSSWGDSVELHANVTC\nNNEDSDLLEDNSATTIIPILYPINILIQDQEDSTLYVSFTPKGPKIHQVKHMYQVRIQPS\nIHDHNIPTLEAVVGVPQPPSEGPITHQWSVQMEPPVPCHYEDLERLPDAAEPCLPGALFR\nCPVVFRQEILVQVIGTLELVGEIEASSMFSLCSSLSISFNSSKHFHLYGSNASLAQVVMK\nVDVVYEKQMLYLYVLSGIGGLLLLLLIFIVLYKVGFFKRNLKEKMEAGRGVPNGIPAEDS\nEQLASGQEAGDPGCLKPLHEKDSESGGGKD"}, "gene-sequence": {"@format": "FASTA", "#text": ">3513 bp\nATGAAGGATTCCTGCATCACTGTGATGGCCATGGCGCTGCTGTCTGGGTTCTTTTTCTTC\nGCGCCGGCCTCGAGCTACAACCTGGACGTGCGGGGCGCGCGGAGCTTCTCCCCACCGCGC\nGCCGGGAGGCACTTTGGATACCGCGTCCTGCAGGTCGGAAACGGGGTCATCGTGGGAGCT\nCCAGGGGAGGGGAACAGCACAGGAAGCCTCTATCAGTGCCAGTCGGGCACAGGACACTGC\nCTGCCAGTCACCCTGAGAGGTTCCAACTATACCTCCAAGTACTTGGGAATGACCTTGGCA\nACAGACCCCACAGATGGAAGCATTTTGGCCTGTGACCCTGGGCTGTCTCGAACGTGTGAC\nCAGAACACCTATCTGAGTGGCCTGTGTTACCTCTTCCGCCAGAATCTGCAGGGTCCCATG\nCTGCAGGGGCGCCCTGGTTTTCAGGAATGTATCAAGGGCAACGTAGACCTGGTATTTCTG\nTTTGATGGTTCGATGAGCTTGCAGCCAGATGAATTTCAGAAAATTCTGGACTTCATGAAG\nGATGTGATGAAGAAACTCAGCAACACTTCGTACCAGTTTGCTGCTGTTCAGTTTTCCACA\nAGCTACAAAACAGAATTTGATTTCTCAGATTATGTTAAATGGAAGGACCCTGATGCTCTG\nCTGAAGCATGTAAAGCACATGTTGCTGTTGACCAATACCTTTGGTGCCATCAATTATGTC\nGCGACAGAGGTGTTCCGGGAGGAGCTGGGGGCCCGGCCAGATGCCACCAAAGTGCTTATC\nATCATCACGGATGGGGAGGCCACTGACAGTGGCAACATCGATGCGGCCAAAGACATCATC\nCGCTACATCATCGGGATTGGAAAGCATTTTCAGACCAAGGAGAGTCAGGAGACCCTCCAC\nAAATTTGCATCAAAACCCGCGAGCGAGTTTGTGAAAATTCTGGACACATTTGAGAAGCTG\nAAAGATCTATTCACTGAGCTGCAGAAGAAGATCTATGTCATTGAGGGCACAAGCAAACAG\nGACCTGACTTCCTTCAACATGGAGCTGTCCTCCAGCGGCATCAGTGCTGACCTCAGCAGG\nGGCCATGCAGTCGTGGGGGCAGTAGGAGCCAAGGACTGGGCTGGGGGCTTTCTTGACCTG\nAAGGCAGACCTGCAGGATGACACATTTATTGGGAATGAACCATTGACACCAGAAGTGAGA\nGCAGGCTATTTGGGTTACACCGTGACCTGGCTGCCCTCCCGGCAAAAGACTTCGTTGCTG\nGCCTCGGGAGCCCCTCGATACCAGCACATGGGCCGAGTGCTGCTGTTCCAAGAGCCACAG\nGGCGGAGGACACTGGAGCCAGGTCCAGACAATCCATGGGACCCAGATTGGCTCTTATTTC\nGGTGGGGAGCTGTGTGGCGTCGACGTGGACCAAGATGGGGAGACAGAGCTGCTGCTGATT\nGGTGCCCCACTGTTCTATGGGGAGCAGAGAGGAGGCCGGGTGTTTATCTACCAGAGAAGA\nCAGTTGGGGTTTGAAGAAGTCTCAGAGCTGCAGGGGGACCCCGGCTACCCACTCGGGCGG\nTTTGGAGAAGCCATCACTGCTCTGACAGACATCAACGGCGATGGGCTGGTAGACGTGGCT\nGTGGGGGCCCCTCTGGAGGAGCAGGGGGCTGTGTACATCTTCAATGGGAGGCACGGGGGG\nCTTAGTCCCCAGCCAAGTCAGCGGATAGAAGGGACCCAAGTGCTCTCAGGAATTCAGTGG\nTTTGGACGCTCCATCCATGGGGTGAAGGACCTTGAAGGGGATGGCTTGGCAGATGTGGCT\nGTGGGGGCTGAGAGCCAGATGATCGTGCTGAGCTCCCGGCCCGTGGTGGATATGGTCACC\nCTGATGTCCTTCTCTCCAGCTGAGATCCCAGTGCATGAAGTGGAGTGCTCCTATTCAACC\nAGTAACAAGATGAAAGAAGGAGTTAATATCACAATCTGTTTCCAGATCAAGTCTCTCTAC\nCCCCAGTTCCAAGGCCGCCTGGTTGCCAATCTCACTTACACTCTGCAGCTGGATGGCCAC\nCGGACCAGAAGACGGGGGTTGTTCCCAGGAGGGAGACATGAACTCAGAAGGAATATAGCT\nGTCACCACCAGCATGTCATGCACTGACTTCTCATTTCATTTCCCGGTATGTGTTCAAGAC\nCTCATCTCCCCCATCAATGTTTCCCTGAATTTCTCTCTTTGGGAGGAGGAAGGGACACCG\nAGGGACCAAAGGGCGCAGGGCAAGGACATACCGCCCATCCTGAGACCCTCCCTGCACTCG\nGAAACCTGGGAGATCCCTTTTGAGAAGAACTGTGGGGAGGACAAGAAGTGTGAGGCAAAC\nTTGAGAGTGTCCTTCTCTCCTGCAAGATCCAGAGCCCTGCGTCTAACTGCTTTTGCCAGC\nCTCTCTGTGGAGCTGAGCCTGAGTAACTTGGAAGAAGATGCTTACTGGGTCCAGCTGGAC\nCTGCACTTCCCCCCGGGACTCTCCTTCCGCAAGGTGGAGATGCTGAAGCCCCATAGCCAG\nATACCTGTGAGCTGCGAGGAGCTTCCTGAAGAGTCCAGGCTTCTGTCCAGGGCATTATCT\nTGCAATGTGAGCTCTCCCATCTTCAAAGCAGGCCACTCGGTTGCTCTGCAGATGATGTTT\nAATACACTGGTAAACAGCTCCTGGGGGGACTCGGTTGAATTGCACGCCAATGTGACCTGT\nAACAATGAGGACTCAGACCTCCTGGAGGACAACTCAGCCACTACCATCATCCCCATCCTG\nTACCCCATCAACATCCTCATCCAGGACCAAGAAGACTCCACACTCTATGTCAGTTTCACC\nCCCAAAGGCCCCAAGATCCACCAAGTCAAGCACATGTACCAGGTGAGGATCCAGCCTTCC\nATCCACGACCACAACATACCCACCCTGGAGGCTGTGGTTGGGGTGCCACAGCCTCCCAGC\nGAGGGGCCCATCACACACCAGTGGAGCGTGCAGATGGAGCCTCCCGTGCCCTGCCACTAT\nGAGGATCTGGAGAGGCTCCCGGATGCAGCTGAGCCTTGTCTCCCCGGAGCCCTGTTCCGC\nTGCCCTGTTGTCTTCAGGCAGGAGATCCTCGTCCAAGTGATCGGGACTCTGGAGCTGGTG\nGGAGAGATCGAGGCCTCTTCCATGTTCAGCCTCTGCAGCTCCCTCTCCATCTCCTTCAAC\nAGCAGCAAGCATTTCCACCTCTATGGCAGCAACGCCTCCCTGGCCCAGGTTGTCATGAAG\nGTTGACGTGGTGTATGAGAAGCAGATGCTCTACCTCTACGTGCTGAGCGGCATCGGGGGG\nCTGCTGCTGCTGCTGCTCATTTTCATAGTGCTGTACAAGGTTGGTTTCTTCAAACGGAAC\nCTGAAGGAGAAGATGGAGGCTGGCAGAGGTGTCCCGAATGGAATCCCTGCAGAAGACTCT\nGAGCAGCTGGCATCTGGGCAAGAGGCTGGGGATCCCGGCTGCCTGAAGCCCCTCCATGAG\nAAGGACTCTGAGAGTGGTGGTGGCAAGGACTGA"}, "pfams": {"pfam": [{"identifier": "PF01839", "name": "FG-GAP"}, {"identifier": "PF00357", "name": "Integrin_alpha"}, {"identifier": "PF08441", "name": "Integrin_alpha2"}, {"identifier": "PF00092", "name": "VWA"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "integrin complex"}, {"category": "component", "description": "protein complex"}, {"category": "component", "description": "receptor complex"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell adhesion"}, {"category": "process", "description": "cell-substrate adhesion"}, {"category": "process", "description": "cell-matrix adhesion"}]}}}, {"@position": "3", "id": "BE0000846", "name": "T-lymphocyte activation antigen CD86", "organism": "Human", "actions": null, "references": "# Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12586600", "known-action": "yes", "polypeptide": {"@id": "P42081", "@source": "Swiss-Prot", "name": "T-lymphocyte activation antigen CD86", "general-function": "Involved in coreceptor activity", "specific-function": "Receptor involved in the costimulatory signal essential for T-lymphocyte proliferation and interleukin 2 production, by binding CD28 or CTLA-4. May play a critical role in the early events of T-cell activation and costimulation of naive T-cells, such as deciding between immunity and anergy that is made by T- cells within 24 hours after activation. Isoform 2 interferes with the formation of CD86 clusters, and thus acts as a negative regulator of T-cell activation", "gene-name": "CD86", "locus": "3q21", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "248-268", "signal-regions": null, "theoretical-pi": "6.91", "molecular-weight": "37697.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1705"}, {"resource": "GenAtlas", "identifier": "CD86"}, {"resource": "GeneCards", "identifier": "CD86"}, {"resource": "GenBank Gene Database", "identifier": "L25259"}, {"resource": "GenBank Protein Database", "identifier": "439839"}, {"resource": "UniProtKB", "identifier": "P42081"}, {"resource": "UniProt Accession", "identifier": "CD86_HUMAN"}]}, "synonyms": {"synonym": ["Activation B7-2 antigen", "B70", "BU63", "CTLA-4 counter-receptor B7.2", "FUN-1", "T-lymphocyte activation antigen CD86 precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">T-lymphocyte activation antigen CD86 precursor\nMDPQCTMGLSNILFVMAFLLSGAAPLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQ\nENLVLNEVYLGKEKFDSVHSKYMGRTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGM\nIRIHQMNSELSVLANFSQPEIVPISNITENVYINLTCSSIHGYPEPKKMSVLLRTKNSTI\nEYDGIMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCILETDKTRLLSSPFSIELEDPQ\nPPPDHIPWITAVLPTVIICVMVFCLILWKWKKKKRPRNSYKCGTNTMEREESEQTKKREK\nIHIPERSDEAQRVFKSSKTSSCDKSDTCF"}, "gene-sequence": {"@format": "FASTA", "#text": ">972 bp\nATGGGACTGAGTAACATTCTCTTTGTGATGGCCTTCCTGCTCTCTGGTGCTGCTCCTCTG\nAAGATTCAAGCTTATTTCAATGAGACTGCAGACCTGCCATGCCAATTTGCAAACTCTCAA\nAACCAAAGCCTGAGTGAGCTAGTAGTATTTTGGCAGGACCAGGAAAACTTGGTTCTGAAT\nGAGGTATACTTAGGCAAAGAGAAATTTGACAGTGTTCATTCCAAGTATATGGGCCGCACA\nAGTTTTGATTCGGACAGTTGGACCCTGAGACTTCACAATCTTCAGATCAAGGACAAGGGC\nTTGTATCAATGTATCATCCATCACAAAAAGCCCACAGGAATGATTCGCATCCACCAGATG\nAATTCTGAACTGTCAGTGCTTGCTAACTTCAGTCAACCTGAAATAGTACCAATTTCTAAT\nATAACAGAAAATGTGTACATAAATTTGACCTGCTCATCTATACACGGTTACCCAGAACCT\nAAGAAGATGAGTGTTTTGCTAAGAACCAAGAATTCAACTATCGAGTATGATGGTATTATG\nCAGAAATCTCAAGATAATGTCACAGAACTGTACGACGTTTCCATCAGCTTGTCTGTTTCA\nTTCCCTGATGTTACGAGCAATATGACCATCTTCTGTATTCTGGAAACTGACAAGACGCGG\nCTTTTATCTTCACCTTTCTCTATAGAGCTTGAGGACCCTCAGCCTCCCCCAGACCACATT\nCCTTGGATTACAGCTGTACTTCCAACAGTTATTATATGTGTGATGGTTTTCTGTCTAATT\nCTATGGAAATGGAAGAAGAAGAAGCGGCCTCGCAACTCTTATAAATGTGGAACCAACACA\nATGGAGAGGGAAGAGAGTGAACAGACCAAGAAAAGAGAAAAAATCCATATACCTGAAAGA\nTCTGATGAAGCCCAGCGTGTTTTTAAAAGTTCGAAGACATCTTCATGCGACAAAAGTGAT\nACATGTTTTTAA"}, "pfams": {"pfam": {"identifier": "PF07686", "name": "V-set"}}, "go-classifiers": null}}, {"@position": "4", "id": "BE0002099", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "organism": "Human", "actions": null, "references": "# Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12586600", "known-action": "yes", "polypeptide": {"@id": "P31994", "@source": "Swiss-Prot", "name": "Low affinity immunoglobulin gamma Fc region receptor II-b", "general-function": null, "specific-function": "Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B- cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis", "gene-name": "FCGR2B", "locus": "1q23", "cellular-location": "Membrane", "transmembrane-regions": "218-240", "signal-regions": null, "theoretical-pi": "6.12", "molecular-weight": "34044.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3618"}, {"resource": "GenAtlas", "identifier": "FCGR2B"}, {"resource": "GeneCards", "identifier": "FCGR2B"}, {"resource": "GenBank Gene Database", "identifier": "U87560"}, {"resource": "GenBank Protein Database", "identifier": "4099445"}, {"resource": "UniProtKB", "identifier": "P31994"}, {"resource": "UniProt Accession", "identifier": "FCG2B_HUMAN"}]}, "synonyms": {"synonym": ["CD32 antigen", "CDw32", "Fc-gamma RII-b", "Fc-gamma-RIIb", "FcRII-b", "IgG Fc receptor II-b", "Low affinity immunoglobulin gamma Fc region receptor II-b precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI"}, "gene-sequence": {"@format": "FASTA", "#text": ">930 bp\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCTCTCCCAGGATACCCTGAG\nTGCAGGGAAATGGGAGAGACCCTCCCTGAGAAACCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATT"}, "pfams": {"pfam": {"identifier": "PF00047", "name": "ig"}}, "go-classifiers": null}}, {"@position": "5", "id": "BE0003488", "name": "T-cell surface glycoprotein CD4", "organism": "Human", "actions": null, "references": "# Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12586600", "known-action": "yes", "polypeptide": {"@id": "P01730", "@source": "Swiss-Prot", "name": "T-cell surface glycoprotein CD4", "general-function": null, "specific-function": "Accessory protein for MHC class-II antigen/T-cell receptor interaction. May regulate T-cell activation. Induces the aggregation of lipid rafts", "gene-name": "CD4", "locus": null, "cellular-location": "Cell membrane", "transmembrane-regions": "397-418", "signal-regions": null, "theoretical-pi": "10.24", "molecular-weight": "51111.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:1678"}, {"resource": "GenAtlas", "identifier": "CD4"}, {"resource": "GenBank Gene Database", "identifier": "BC025782"}, {"resource": "UniProtKB", "identifier": "P01730"}, {"resource": "UniProt Accession", "identifier": "CD4_HUMAN"}]}, "synonyms": {"synonym": ["T-cell surface antigen T4/Leu-3", "T-cell surface glycoprotein CD4 precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">T-cell surface glycoprotein CD4\nMNRGVPFRHLLLVLQLALLPAATQGKKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIK\nILGNQGSFLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICEVEDQKEEVQL\nLVFGLTANSDTHLLQGQSLTLTLESPPGSSPSVQCRSPRGKNIQGGKTLSVSQLELQDSG\nTWTCTVLQNQKKVEFKIDIVVLAFQKASSIVYKKEGEQVEFSFPLAFTVEKLTGSGELWW\nQAERASSSKSWITFDLKNKEVSVKRVTQDPKLQMGKKLPLHLTLPQALPQYAGSGNLTLA\nLEAKTGKLHQEVNLVVMRATQLQKNLTCEVWGPTSPKLMLSLKLENKEAKVSKREKAVWV\nLNPEAGMWQCLLSDSGQVLLESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIGLGIFFCV\nRCRHRRRQAERMSQIKRLLSEKKTCQCPHRFQKTCSPI"}, "gene-sequence": {"@format": "FASTA"}, "pfams": {"pfam": [{"identifier": "PF00047", "name": "ig"}, {"identifier": "PF05790", "name": "C2-set"}, {"identifier": "PF09191", "name": "CD4-extracel"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "process", "description": "response to stimulus"}, {"category": "process", "description": "response to biotic stimulus"}, {"category": "process", "description": "defense response"}, {"category": "process", "description": "immune response"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell adhesion"}]}}}, {"@position": "6", "id": "BE0003575", "name": "Integrin beta-1", "organism": "Human", "actions": null, "references": "# Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12586600", "known-action": "yes", "polypeptide": {"@id": "P05556", "@source": "Swiss-Prot", "name": "Integrin beta-1", "general-function": "Involved in identical protein binding", "specific-function": "Integrins alpha-1/beta-1, alpha-2/beta-1, alpha-10/beta- 1 and alpha-11/beta-1 are receptors for collagen. Integrins alpha- 1/beta-1 and alpha-2/beta-2 recognize the proline-hydroxylated sequence G-F-P-G-E-R in collagen. Integrins alpha-2/beta-1, alpha- 3/beta-1, alpha-4/beta-1, alpha-5/beta-1, alpha-8/beta-1, alpha- 10/beta-1, alpha-11/beta-1 and alpha-V/beta-1 are receptors for fibronectin. Alpha-4/beta-1 recognizes one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. Integrin alpha-5/beta-1 is a receptor for fibrinogen. Integrin alpha-1/beta-1, alpha-2/beta-1, alpha-6/beta-1 and alpha-7/beta-1 are receptors for lamimin. Integrin alpha-4/beta-1 is a receptor for VCAM1. It recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha-9/beta-1 is a receptor for VCAM1, cytotactin and osteopontin. It recognizes the sequence A-E-I-D-G-I-E-L in cytotactin. Integrin alpha-3/beta-1 is a receptor for epiligrin, thrombospondin and CSPG4. Alpha-3/beta-1 may mediate with LGALS3 the stimulation by CSPG4 of endothelial cells migration. Integrin alpha-V/beta-1 is a receptor for vitronectin. Beta-1 integrins recognize the sequence R-G-D in a wide array of ligands. Isoform beta-1B interferes with isoform beta-1A resulting in a dominant negative effect on cell adhesion and migration (in vitro). In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. When associated with alpha-7/beta-1 integrin, regulates cell adhesion and laminin matrix deposition. Involved in promoting endothelial cell motility and angiogenesis. May be involved in up- regulation of the activity of kinases such as PKC via binding to KRT1. Together with KRT1 and GNB2L1/RACK1, serves as a platform for SRC activation or inactivation. Plays a mechanistic adhesive role during telophase, required for the successful completion of cytokinesis", "gene-name": "ITGB1", "locus": "10p11.2", "cellular-location": "Cell membrane", "transmembrane-regions": "729-751", "signal-regions": null, "theoretical-pi": "5.04", "molecular-weight": "88414.6", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "GNC:6153"}, {"resource": "GeneCards", "identifier": "ITGB1"}, {"resource": "GenBank Gene Database", "identifier": "X07979"}, {"resource": "GenBank Protein Database", "identifier": "31442"}, {"resource": "UniProtKB", "identifier": "P05556"}, {"resource": "UniProt Accession", "identifier": "ITB1_HUMAN"}]}, "synonyms": {"synonym": ["CD29 antigen", "Fibronectin receptor subunit beta", "Integrin VLA-4 subunit beta"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Integrin beta-1\nMNLQPIFWIGLISSVCCVFAQTDENRCLKANAKSCGECIQAGPNCGWCTNSTFLQEGMPT\nSARCDDLEALKKKGCPPDDIENPRGSKDIKKNKNVTNRSKGTAEKLKPEDITQIQPQQLV\nLRLRSGEPQTFTLKFKRAEDYPIDLYYLMDLSYSMKDDLENVKSLGTDLMNEMRRITSDF\nRIGFGSFVEKTVMPYISTTPAKLRNPCTSEQNCTSPFSYKNVLSLTNKGEVFNELVGKQR\nISGNLDSPEGGFDAIMQVAVCGSLIGWRNVTRLLVFSTDAGFHFAGDGKLGGIVLPNDGQ\nCHLENNMYTMSHYYDYPSIAHLVQKLSENNIQTIFAVTEEFQPVYKELKNLIPKSAVGTL\nSANSSNVIQLIIDAYNSLSSEVILENGKLSEGVTISYKSYCKNGVNGTGENGRKCSNISI\nGDEVQFEISITSNKCPKKDSDSFKIRPLGFTEEVEVILQYICECECQSEGIPESPKCHEG\nNGTFECGACRCNEGRVGRHCECSTDEVNSEDMDAYCRKENSSEICSNNGECVCGQCVCRK\nRDNTNEIYSGKFCECDNFNCDRSNGLICGGNGVCKCRVCECNPNYTGSACDCSLDTSTCE\nASNGQICNGRGICECGVCKCTDPKFQGQTCEMCQTCLGVCAEHKECVQCRAFNKGEKKDT\nCTQECSYFNITKVESRDKLPQPVQPDPVSHCKEKDVDDCWFYFTYSVNGNNEVMVHVVEN\nPECPTGPDIIPIVAGVVAGIVLIGLALLLIWKLLMIIHDRREFAKFEKEKMNAKWDTGEN\nPIYKSAVTTVVNPKYEGK"}, "gene-sequence": {"@format": "FASTA", "#text": ">2397 bp\nATGAATTTACAACCAATTTTCTGGATTGGACTGATCAGTTCAGTTTGCTGTGTGTTTGCT\nCAAACAGATGAAAATAGATGTTTAAAAGCAAATGCCAAATCATGTGGAGAATGTATACAA\nGCAGGGCCAAATTGTGGGTGGTGCACAAATTCAACATTTTTACAGGAAGGAATGCCTACT\nTCTGCACGATGTGATGATTTAGAAGCCTTAAAAAAGAAGGGTTGCCCTCCAGATGACATA\nGAAAATCCCAGAGGCTCCAAAGATATAAAGAAAAATAAAAATGTAACCAACCGTAGCAAA\nGGAACAGCAGAGAAGCTCAAGCCAGAGGATATTCATCAGATCCAACCACAGCAGTTGGTT\nTTGCGATTAAGATCAGGGGAGCCACAGACATTTACATTAAAATTCAAGAGAGCTGAAGAC\nTATCCCATTGACCTCTACTACCTTATGGACCTGTCTTATTCAATGAAAGACGATTTGGAG\nAATGTAAAAAGTCTTGGAACAGATCTGATGAATGAAATGAGGAGGATTACTTCGGACTTC\nAGAATTGGATTTGGCTCATTTGTGGAAAAGACTGTGATGCCTTACATTAGCACAACACCA\nGCTAAGCTCAGGAACCCTTGCACAAGTGAACAGAACTGCACCACCCCATTTAGCTACAAA\nAATGTGCTCAGTCTTACTAATAAAGGAGAAGTATTTAATGAACTTGTTGGAAAACAGCGC\nATATCTGGAAATTTGGATTCTCCAGAAGGTGGTTTCGATGCCATCATGCAAGTTGCAGTT\nTGTGGATCACTGATTGGCTGGAGGAATGTTACACGGCTGCTGGTGTTTTCCACAGATGCC\nGGGTTTCACTTTGCTGGAGATGGGAAACTTGGTGGCATTGTTTTACCAAATGATGGACAA\nTGTCACCTGGAAAATAATATGTACACAATGAGCCATTATTATGATTATCCTTCTATTGCT\nCACCTTGTCCAGAAACTGAGTGAAAATAATATTCAGACAATTTTTGCAGTTACTGAAGAA\nTTTCAGCCTGTTTACAAGGAGCTGAAAAACTTGATCCCTAAGTCAGCAGTAGGAACATTA\nTCTGCAAATTCTAGCAATGTAATTCAGTTGATCATTGATGCATACAATTCCCTTTCCTCA\nGAAGTCATTTTGGAAAACGGCAAATTGTCAGAAGGAGTAACAATAAGTTACAAATCTTAC\nTGCAAGAACGGGGTGAATGGAACAGGGGAAAATGGAAGAAAATGTTCCAATATTTCCATT\nGGAGATGAGGTTCAATTTGAAATTAGCATAACTTCAAATAAGTGTCCAAAAAAGGATTCT\nGACAGCTTTAAAATTAGGCCTCTGGGCTTTACGGAGGAAGTAGAGGTTATTCTTCAGTAC\nATCTGTGAATGTGAATGCCAAAGCGAAGGCATCCCTGAAAGTCCCAAGTGTCATGAAGGA\nAATGGGACATTTGAGTGTGGCGCGTGCAGGTGCAATGAAGGGCGTGTTGGTAGACATTGT\nGAATGCAGCACAGATGAAGTTAACAGTGAAGACATGGATGCTTACTGCAGGAAAGAAAAC\nAGTTCAGAAATCTGCAGTAACAATGGAGAGTGCGTCTGCGGACAGTGTGTTTGTAGGAAG\nAGGGATAATACAAATGAAATTTATTCTGGCAAATTCTGCGAGTGTGATAATTTCAACTGT\nGATAGATCCAATGGCTTAATTTGTGGAGGAAATGGTGTTTGCAAGTGTCGTGTGTGTGAG\nTGCAACCCCAACTACACTGGCAGTGCATGTGACTGTTCTTTGGATACTAGTACTTGTGAA\nGCCAGCAACGGACAGATCTGCAATGGCCGGGGCATCTGCGAGTGTGGTGTCTGTAAGTGT\nACAGATCCGAAGTTTCAAGGGCAAACGTGTGAGATGTGTCAGACCTGCCTTGGTGTCTGT\nGCTGAGCATAAAGAATGTGTTCAGTGCAGAGCCTTCAATAAAGGAGAAAAGAAAGACACA\nTGCACACAGGAATGTTCCTATTTTAACATTACCAAGGTAGAAAGTCGGGACAAATTACCC\nCAGCCGGTCCAACCTGATCCTGTGTCCCATTGTAAGGAGAAGGATGTTGACGACTGTTGG\nTTCTATTTTACGTATTCAGTGAATGGGAACAACGAGGTCATGGTTCATGTTGTGGAGAAT\nCCAGAGTGTCCCACTGGTCCAGACATCATTCCAATTGTAGCTGGTGTGGTTGCTGGAATT\nGTTCTTATTGGCCTTGCATTACTGCTGATATGGAAGCTTTTAATGATAATTCATGACAGA\nAGGGAGTTTGCTAAATTTGAAAAGGAGAAAATGAATGCCAAATGGGACACGGGTGAAAAT\nCCTATTTATAAGAGTGCCGTAACAACTGTGGTCAATCCGAAGTATGAGGGAAAATGA"}, "pfams": {"pfam": [{"identifier": "PF07974", "name": "EGF_2"}, {"identifier": "PF00362", "name": "Integrin_beta"}, {"identifier": "PF08725", "name": "Integrin_b_cyt"}, {"identifier": "PF07965", "name": "Integrin_B_tail"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "integrin complex"}, {"category": "component", "description": "protein complex"}, {"category": "component", "description": "receptor complex"}, {"category": "process", "description": "development"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell adhesion"}, {"category": "process", "description": "cell-substrate adhesion"}, {"category": "process", "description": "cell-matrix adhesion"}]}}}, {"@position": "7", "id": "BE0003576", "name": "Integrin alpha-V", "organism": "Human", "actions": null, "references": "# Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12586600", "known-action": "yes", "polypeptide": {"@id": "P06756", "@source": "Swiss-Prot", "name": "Integrin alpha-V", "general-function": "Involved in calcium ion binding", "specific-function": "The alpha-V integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. They recognize the sequence R-G-D in a wide array of ligands. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions", "gene-name": "ITGAV", "locus": "2q31-q32", "cellular-location": "Membrane", "transmembrane-regions": "993-1016", "signal-regions": null, "theoretical-pi": "5.36", "molecular-weight": "116036.9", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "GNC:6150"}, {"resource": "GeneCards", "identifier": "ITGAV"}, {"resource": "GenBank Gene Database", "identifier": "M14648"}, {"resource": "GenBank Protein Database", "identifier": "340307"}, {"resource": "UniProtKB", "identifier": "P06756"}, {"resource": "UniProt Accession", "identifier": "ITAV_HUMAN"}]}, "synonyms": {"synonym": ["CD51 antigen", "Integrin alpha-V heavy chain", "Integrin alpha-V light chain", "Vitronectin receptor subunit alpha"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Integrin alpha-V\nMAFPPRRRLRLGPRGLPLLLSGLLLPLCRAFNLDVDSPAEYSGPEGSYFGFAVDFFVPSA\nSSRMFLLVGAPKANTTQPGIVEGGQVLKCDWSSTRRCQPIEFDATGNRDYAKDDPLEFKS\nHQWFGASVRSKQDKILACAPLYHWRTEMKQEREPVGTCFLQDGTKTVEYAPCRSQDIDAD\nGQGFCQGGFSIDFTKADRVLLGGPGSFYWQGQLISDQVAEIVSKYDPNVYSIKYNNQLAT\nRTAQAIFDDSYLGYSVAVGDFNGDGIDDFVSGVPRAARTLGMVYIYDGKNMSSLYNFTGE\nQMAAYFGFSVAATDINGDDYADVFIGAPLFMDRGSDGKLQEVGQVSVSLQRASGDFQTTK\nLNGFEVFARFGSAIAPLGDLDQDGFNDIAIAAPYGGEDKKGIVYIFNGRSTGLNAVPSQI\nLEGQWAARSMPPSFGYSMKGATDIDKNGYPDLIVGAFGVDRAILYRARPVITVNAGLEVY\nPSILNQDNKTCSLPGTALKVSCFNVRFCLKADGKGVLPRKLNFQVELLLDKLKQKGAIRR\nALFLYSRSPSHSKNMTISRGGLMQCEELIAYLRDESEFRDKLTPITIFMEYRLDYRTAAD\nTTGLQPILNQFTPANISRQAHILLDCGEDNVCKPKLEVSVDSDQKKIYIGDDNPLTLIVK\nAQNQGEGAYEAELIVSIPLQADFIGVVRNNEALARLSCAFKTENQTRQVVCDLGNPMKAG\nTQLLAGLRFSVHQQSEMDTSVKFDLQIQSSNLFDKVSPVVSHKVDLAVLAAVEIRGVSSP\nDHVFLPIPNWEHKENPETEEDVGPVVQHIYELRNNGPSSFSKAMLHLQWPYKYNNNTLLY\nILHYDIDGPMNCTSDMEINPLRIKISSLQTTEKNDTVAGQGERDHLITKRDLALSEGDIH\nTLGCGVAQCLKIVCQVGRLDRGKSAILYVKSLLWTETFMNKENQNHSYSLKSSASFNVIE\nFPYKNLPIEDITNSTLVTTNVTWGIQPAPMPVPVWVIILAVLAGLLLLAVLVFVMYRMGF\nFKRVRPPQEEQEREQLQPHENGEGNSET"}, "gene-sequence": {"@format": "FASTA", "#text": ">3147 bp\nGCACTTCGGCGATGGCTTTTCCGCCGCGGCGACGGCTGCGCCTCGGTCCCCGCGGCCTCC\nCGCTTCTTCTCTCGGGACTCCTGCTACCTCTGTGCCGCGCCTTCAACCTAGACGTGGACA\nGTCCTGCCGAGTACTCTGGCCCCGAGGGAAGTTACTTCGGCTTCGCCGTGGATTTCTTCG\nTGCCCAGCGCGTCTTCCCGGATGTTTCTTCTCGTGGGAGCTCCCAAAGCAAACACCACCC\nAGCCTGGGATTGTGGAAGGAGGGCAGGTCCTCAAATGTGACTGGTCTTCTACCCGCCGGT\nGCCAGCCAATTGAATTTGATGCAACAGGCAATAGAGATTATGCCAAGGATGATCCATTGG\nAATTTAAGTCCCATCAGTGGTTTGGAGCATCTGTGAGGTCGAAACAGGATAAAATTTTGG\nCCTGTGCCCCATTGTACCATTGGAGAACTGAGATGAAACAGGAGCGAGAGCCTGTTGGAA\nCATGCTTTCTTCAAGATGGAACAAAGACTGTTGAGTATGCTCCATGTAGATCACAAGATA\nTTGATGCTGATGGACAGGGATTTTGTCAAGGAGGATTCAGCATTGATTTTACTAAAGCTG\nACAGAGTACTTCTTGGTGGTCCTGGTAGCTTTTATTGGCAAGGTCAGCTTATTTCGGATC\nAAGTGGCAGAAATCGTATCTAAATACGACCCCAATGTTTACAGCATCAAGTATAATAACC\nAATTAGCAACTCGGACTGCACAAGCTATTTTTGATGACAGCTATTTGGGTTATTCTGTGG\nCTGTCGGAGATTTCAATGGTGATGGCATAGATGACTTTGTTTCAGGAGTTCCAAGAGCAG\nCAAGGACTTTGGGAATGGTTTATATTTATGATGGGAAGAACATGTCCTCCTTATACAATT\nTTACTGGCGAGCAGATGGCTGCATATTTCGGATTTTCTGTAGCTGCCACTGACATTAATG\nGAGATGATTATGCAGATGTGTTTATTGGAGCACCTCTCTTCATGGATCGTGGCTCTGATG\nGCAAACTCCAAGAGGTGGGGCAGGTCTCAGTGTCTCTACAGAGAGCTTCAGGAGACTTCC\nAGACGACAAAGCTGAATGGATTTGAGGTCTTTGCACGGTTTGGCAGTGCCATAGCTCCTT\nTGGGAGATCTGGACCAGGATGGTTTCAATGATATTGCAATTGCTGCTCCATATGGGGGTG\nAAGATAAAAAAGGAATTGTTTATATCTTCAATGGAAGATCAACAGGCTTGAACGCAGTCC\nCATCTCAAATCCTTGAAGGGCAGTGGGCTGCTCGAAGCATGCCACCAAGCTTTGGCTATT\nCAATGAAAGGAGCCACAGATATAGACAAAAATGGATATCCAGACTTAATTGTAGGAGCTT\nTTGGTGTAGATCGAGCTATCTTATACAGGGCCAGACCAGTTATCACTGTAAATGCTGGTC\nTTGAAGTGTACCCTAGCATTTTAAATCAAGACAATAAAACCTGCTCACTGCCTGGAACAG\nCTCTCAAAGTTTCCTGTTTTAATGTTAGGTTCTGCTTAAAGGCAGATGGCAAAGGAGTAC\nTTCCCAGGAAACTTAATTTCCAGGTGGAACTTCTTTTGGATAAACTCAAGCAAAAGGGAG\nCAATTCGACGAGCACTGTTTCTCTACAGCAGGTCCCCAAGTCACTCCAAGAACATGACTA\nTTTCAAGGGGGGGACTGATGCAGTGTGAGGAATTGATAGCGTATCTGCGGGATGAATCTG\nAATTTAGAGACAAACTCACTCCAATTACTATTTTTATGGAATATCGGTTGGATTATAGAA\nCAGCTGCTGATACAACAGGCTTGCAACCCATTCTTAACCAGTTCACGCCTGCTAACATTA\nGTCGACAGGCTCACATTCTACTTGACTGTGGTGAAGACAATGTCTGTAAACCCAAGCTGG\nAAGTTTCTGTAGATAGTGATCAAAAGAAGATCTATATTGGGGATGACAACCCTCTGACAT\nTGATTGTTAAGGCTCAGAATCAAGGAGAAGGTGCCTACGAAGCTGAGCTCATCGTTTCCA\nTTCCACTGCAGGCTGATTTCATCGGGGTTGTCCGAAACAATGAAGCCTTAGCAAGACTTT\nCCTGTGCATTTAAGACAGAAAACCAAACTCGCCAGGTGGTATGTGACCTTGGAAACCCAA\nTGAAGGCTGGAACTCAACTCTTAGCTGGTCTTCGTTTCAGTGTGCACCAGCAGTCAGAGA\nTGGATACTTCTGTGAAATTTGACTTACAAATCCAAAGCTCAAATCTATTTGACAAAGTAA\nGCCCAGTTGTATCTCACAAAGTTGATCTTGCTGTTTTAGCTGCAGTTGAGATAAGAGGAG\nTCTCGAGTCCTGATCATATCTTTCTTCCGATTCCAAACTGGGAGCACAAGGAGAACCCTG\nAGACTGAAGAAGATGTTGGGCCAGTTGTTCAGCACATCTATGAGCTGAGAAACAATGGTC\nCAAGTTCATTCAGCAAGGCAATGCTCCATCTTCAGTGGCCTTACAAATATAATAATAACA\nCTCTGTTGTATATCCTTCATTATGATATTGATGGACCAATGAACTGCACTTCAGATATGG\nAGATCAACCCTTTGAGAATTAAGATCTCATCTTTGCAAACAACTGAAAAGAATGACACGG\nTTGCCGGGCAAGGTGAGCGGGACCATCTCATCACTAAGCGGGATCTTGCCCTCAGTGAAG\nGAGATATTCACACTTTGGGTTGTGGAGTTGCTCAGTGCTTGAAGATTGTCTGCCAAGTTG\nGGAGATTAGACAGAGGAAAGAGTGCAATCTTGTACGTAAAGTCATTACTGTGGACTGAGA\nCTTTTATGAATAAAGAAAATCAGAATCATTCCTATTCTCTGAAGTCGTCTGCTTCATTTA\nATGTCATAGAGTTTCCTTATAAGAATCTTCCAATTGAGGATATCACCAACTCCACATTGG\nTTACCACTAATGTCACCTGGGGCATTCAGCCAGCGCCCATGCCTGTGCCTGTGTGGGTGA\nTCATTTTAGCAGTTCTAGCAGGATTGTTGCTACTGGCTGTTTTGGTATTTGTAATGTACA\nGGATGGGCTTTTTTAAACGGGTCCGGCCACCTCAAGAAGAACAAGAAAGGGAGCAGCTTC\nAACCTCATGAAAATGGTGAAGGAAACT"}, "pfams": {"pfam": [{"identifier": "PF01839", "name": "FG-GAP"}, {"identifier": "PF00357", "name": "Integrin_alpha"}, {"identifier": "PF08441", "name": "Integrin_alpha2"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "integrin complex"}, {"category": "component", "description": "protein complex"}, {"category": "component", "description": "receptor complex"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell adhesion"}, {"category": "process", "description": "cell-substrate adhesion"}, {"category": "process", "description": "cell-matrix adhesion"}]}}}, {"@position": "8", "id": "BE0001155", "name": "Integrin beta-3", "organism": "Human", "actions": null, "references": "# Monti P, Allavena P, Di Carlo V, Piemonti L: Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003 Feb;3(2):189-96. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12586600", "known-action": "yes", "polypeptide": {"@id": "P05106", "@source": "Swiss-Prot", "name": "Integrin beta-3", "general-function": "Involved in cell adhesion and blood clotting", "specific-function": "Integrin alpha-V/beta-3 is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIb/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha- IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions", "gene-name": "ITGB3", "locus": "17q21.32", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "719-741", "signal-regions": null, "theoretical-pi": "4.85", "molecular-weight": "87058.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6156"}, {"resource": "GenAtlas", "identifier": "ITGB3"}, {"resource": "GeneCards", "identifier": "ITGB3"}, {"resource": "GenBank Gene Database", "identifier": "J02703"}, {"resource": "GenBank Protein Database", "identifier": "306786"}, {"resource": "UniProtKB", "identifier": "P05106"}, {"resource": "UniProt Accession", "identifier": "ITB3_HUMAN"}]}, "synonyms": {"synonym": ["CD61 antigen", "GPIIIa", "Integrin beta-3 precursor", "Platelet membrane glycoprotein IIIa"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Integrin beta-3 precursor\nMRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLG\nSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRP\nDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFG\nAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSR\nNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCH\nVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLS\nMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDT\nVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGT\nFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFG\nKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLL\nCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRY\nCRDEIESVKELKDTGKDAVNCTYKNEDDCVVRFQYYEDSSGKSILYVVEEPECPKGPDIL\nVVLLSVMGAILLIGLAALLIWKLLITIHDRKEFAKFEEERARAKWDTANNPLYKEATSTF\nTNITYRGT"}, "gene-sequence": {"@format": "FASTA", "#text": ">2367 bp\nATGCGAGCGCGGCCGCGGCCCCGGCCGCTCTGGGTGACTGTGCTGGCGCTGGGGGCGCTG\nGCGGGCGTTGGCGTAGGAGGGCCCAACATCTGTACCACGCGAGGTGTGAGCTCCTGCCAG\nCAGTGCCTGGCTGTGAGCCCCATGTGTGCCTGGTGCTCTGATGAGGCCCTGCCTCTGGGC\nTCACCTCGCTGTGACCTGAAGGAGAATCTGCTGAAGGATAACTGTGCCCCAGAATCCATC\nGAGTTCCCAGTGAGTGAGGCCCGAGTACTAGAGGACAGGCCCCTCAGCGACAAGGGCTCT\nGGAGACAGCTCCCAGGTCACTCAAGTCAGTCCCCAGAGGATTGCACTCCGGCTCCGGCCA\nGATGATTCGAAGAATTTCTCCATCCAAGTGCGGCAGGTGGAGGATTACCCTGTGGACATC\nTACTACTTGATGGACCTGTCTTACTCCATGAAGGATGATCTGTGGAGCATCCAGAACCTG\nGGTACCAAGCTGGCCACCCAGATGCGAAAGCTCACCAGTAACCTGCGGATTGGCTTCGGG\nGCATTTGTGGACAAGCCTGTGTCACCATACATGTATATCTCCCCACCAGAGGCCCTCGAA\nAACCCCTGCTATGATATGAAGACCACCTGCTTGCCCATGTTTGGCTACAAACACGTGCTG\nACGCTAACTGACCAGGTGACCCGCTTCAATGAGGAAGTGAAGAAGCAGAGTGTGTCACGG\nAACCGAGATGCCCCAGAGGGTGGCTTTGATGCCATCATGCAGGCTACAGTCTGTGATGAA\nAAGATTGGCTGGAGGAATGATGCATCCCACTTGCTGGTGTTTACCACTGATGCCAAGACT\nCATATAGCATTGGACGGAAGGCTGGCAGGCATTGTCCAGCCTAATGACGGGCAGTGTCAT\nGTTGGTAGTGACAATCATTACTCTGCCTCCACTACCATGGATTATCCCTCTTTGGGGCTG\nATGACTGAGAAGCTATCCCAGAAAAACATCAATTTGATCTTTGCAGTGACTGAAAATGTA\nGTCAATCTCTATCAGAACTATAGTGAGCTCATCCCAGGGACCACAGTTGGGGTTCTGTCC\nATGGATTCCAGCAATGTCCTCCAGCTCATTGTTGATGCTTATGGGAAAATCCGTTCTAAA\nGTCGAGCTGGAAGTGCGTGACCTCCCTGAAGAGTTGTCTCTATCCTTCAATGCCACCTGC\nCTCAACAATGAGGTCATCCCTGGCCTCAAGTCTTGTATGGGACTCAAGATTGGAGACACG\nGTGAGCTTCAGCATTGAGGCCAAGGTGCGAGGCTGTCCCCAGGAGAAGGAGAAGTCCTTT\nACCATAAAGCCCGTGGGCTTCAAGGACAGCCTGATCGTCCAGGTCACCTTTGATTGTGAC\nTGTGCCTGCCAGGCCCAAGCTGAACCTAATAGCCATCGCTGCAACAATGGCAATGGGACC\nTTTGAGTGTGGGGTATGCCGTTGTGGGCCTGGCTGGCTGGGATCCCAGTGTGAGTGCTCA\nGAGGAGGACTATCGCCCTTCCCAGCAGGACGAGTGCAGCCCCCGAGAGGGTCAGCCCGTC\nTGCAGCCAGCGGGGCGAGTGCCTCTGTGGTCAATGTGTCTGCCACAGCAGTGACTTTGGC\nAAGATCACGGGCAAGTACTGCGAGTGTGACGACTTCTCCTGTGTCCGCTACAAGGGGGAG\nATGTGCTCAGGCCATGGCCAGTGCAGCTGTGGGGACTGCCTGTGTGACTCCGACTGGACC\nGGCTACTACTGCAACTGTACCACGCGTACTGACACCTGCATGTCCAGCAATGGGCTGCTG\nTGCAGCGGCCGCGGCAAGTGTGAATGTGGCAGCTGTGTCTGTATCCAGCCGGGCTCCTAT\nGGGGACACCTGTGAGAAGTGCCCCACCTGCCCAGATGCCTGCACCTTTAAGAAAGAATGT\nGTGGAGTGTAAGAAGTTTGACCGGGAGCCCTACATGACCGAAAATACCTGCAACCGTTAC\nTGCCGTGACGAGATTGAGTCAGTGAAAGAGCTTAAGGACACTGGCAAGGATGCAGTGAAT\nTGTACCTATAAGAATGAGGATGACTGTGTCGTCAGATTCCAGTACTATGAAGATTCTAGT\nGGAAAGTCCATCCTGTATGTGGTAGAAGAGCCAGAGTGTCCCAAGGGCCCTGACATCCTG\nGTGGTCCTGCTCTCAGTGATGGGGGCCATTCTGCTCATTGGCCTTGCCGCCCTGCTCATC\nTGGAAACTCCTCATCACCATCCACGACCGAAAAGAATTCGCTAAATTTGAGGAAGAACGC\nGCCAGAGCAAAATGGGACACAGCCAACAACCCACTGTATAAAGAGGCCACGTCTACCTTC\nACCAATATCACGTACCGGGGCACTTAA"}, "pfams": {"pfam": [{"identifier": "PF07974", "name": "EGF_2"}, {"identifier": "PF00362", "name": "Integrin_beta"}, {"identifier": "PF08725", "name": "Integrin_b_cyt"}, {"identifier": "PF07965", "name": "Integrin_B_tail"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "protein complex"}, {"category": "component", "description": "receptor complex"}, {"category": "component", "description": "integrin complex"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell adhesion"}, {"category": "process", "description": "cell-substrate adhesion"}, {"category": "process", "description": "cell-matrix adhesion"}, {"category": "process", "description": "development"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2015-03-11", "drugbank-id": [{"@primary": "true", "#text": "DB00099"}, "BIOD00072", "BTD00072"], "name": "Filgrastim", "description": "Filgrastim is a recombinant, non-pegylated human granulocyte colony stimulating factor (G-CSF) analogue manufactured by recombinant DNA technology using a strain of E. coli. It is marketed as the brand name Neupogen by Amgen. Chemically, it consists of 175 amino acid residues. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal methionine necessary for expression in E coli. Tbo-filgrastim, which is marketed by Sicor Biotech and FDA approved on August 29, 2012, contains the same active ingredient as Neupogen and is biologically similar, but it is formulated to be short-acting. On March 6, 2015, the FDA approved the biosimilar Zarxio (filgrastim-sndz) and is indicated for use in the same conditions as Neupogen. Zarxio is marketed by Sandoz.", "cas-number": "121181-53-1", "groups": {"group": "approved"}, "general-references": "# Wang B, Ludden TM, Cheung EN, Schwab GG, Roskos LK: Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers. J Pharmacokinet Pharmacodyn. 2001 Aug;28(4):321-42. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11677930\n# FDA label for Neupogen and tbo-filgrastim", "synthesis-reference": "Tetsuro Kuga, Hiromasa Miyaji, Moriyuki Sato, Masami Okabe, Makoto Morimoto, Seiga Itoh, Motoo Yamasaki, Yoshiharu Yokoo, Kazuo Yamaguchi, Hajime Yoshida, Yoshinori Komatsu, \"Method of producing a polypeptide having human granulocyte colony stimulating factor activity.\" U.S. Patent US5994518, issued February, 1988.", "indication": "Filgrastim is used in patients with acute myeloid leukemia receiving induction or consolidation chemotherapy. It is also used in cancer patients receiving bone marrow transplant. In general, filgrastim increases neutrophil counts in order to decrease the risk of infection or duration of neutropenia in the aforementioned patient populations. Infection and neutropenia are adverse events associated with chemotherapy. Furthermore, filgrastim is also indicated for patients with severe chronic neutropenia. It mobilizes hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis to allow for a more rapid engraftment. Tbo-filgrastim has a narrower indication profile than Neupogen - it is a leukocyte growth factor indicated for the reduction in the duration of severe neutropenia in patients with non-myeloid malignancies.", "pharmacodynamics": "Used in the treatment of chemotherapy-induced neutropenia by enhancing the production of neutrophils. Filgrastim acts on hematopoietic cells by binding to specific cell surface receptors thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. When tbo-filgrastim is administered to cancer patients, it took 3-5 days to reach maximum absolute neutrophil count (ANC). Levels of neutrophils returned to baseline by 21 days following completion of chemotherapy. In the healthy volunteer trials, doubling the tbo-filgrastim subcutaneous dose from 5 to 10 mcg/kg resulted in a 16-19% increase in the ANCmax and a 33-36% increase in the area under the effect curve for ANC.", "mechanism-of-action": "Filgrastim binds to the G-CSF receptor and stimulates the production of neutrophils in the bone marrow. As a G-CSF analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Filgrastim also stimulates the release of neutrophils from bone marrow storage pools and reduces their maturation time. Filgrastim acts to increase the phagocytic activity of mature neutrophils. In patients receiving cytotoxic chemotherapy, Filgrastim can accelerate neutrophil recovery, leading to a reduction in duration of the neutropenic phase", "toxicity": null, "metabolism": null, "absorption": "Absorption and clearance of Neupogen follows first-order pharmacokinetic modeling without apparent concentration dependence. When 3.45 mcg/kg and 11.5 mcg/kg of Neupogen is subcutaneously administered, the maximum serum concentration is 4 and 49 ng/mL\u201a respectively\u201a within 2 to 8 hours. Neupogen does not accumulate. It is estimated that when filgrastim is subcutaneously administered, the absolute bioavailability is approximately 62% and 71% for 375 mcg and 750 mcg doses respectively. When 5 mcg/kg tbo-filgrastim is subcutaneously administered, the absolute bioavailability is 33%. It takes 4-6 hours for tho-filgrastim to reach maximum concentration. Like Neupogen, accumulation was not observed.", "half-life": "Elimination half-life, healthy subjects and cancer patients, Neopogen = 3.5 hours;\nElimination half-life, cancer patients, tbo-filgrastim = 3.2-3.8 hours", "protein-binding": null, "route-of-elimination": "Filgrastim is primarily eliminated by the kidney and neutrophils/neutrophil precursors; the latter presumably involves binding of the growth factor to the G-CSF receptor on the cell surface, internalization of the growth factor-receptor complexes via endocytosis, and subsequent degradation inside the cells.", "volume-of-distribution": "Vd, healthy subjects and cancer patients = 150 mL/kg", "clearance": "0.5 - 0.7 mL/minute/kg (SC administration of 3.45 mcg/kg and 11.5 mcg/kg in both normal subjects and cancer patients, Neupogen)", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "G-CSF"}, {"@language": "", "@coder": "", "#text": "Granulocyte Colony Stimulating Factor"}, {"@language": "", "@coder": "", "#text": "Tbo-filgrastim"}]}, "products": {"product": [{"name": "Granix", "ndc-id": "63459-910_e9b9666e-3099-4de8-b878-089d4fe1c429", "ndc-product-code": "63459-910", "dpd-id": null, "started-marketing-on": "2013-11-11", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "300 ug/.5mL", "route": "subcutaneous", "fda-application-number": "BLA125294", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Granix", "ndc-id": "63459-912_e9b9666e-3099-4de8-b878-089d4fe1c429", "ndc-product-code": "63459-912", "dpd-id": null, "started-marketing-on": "2013-11-11", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "480 ug/.8mL", "route": "subcutaneous", "fda-application-number": "BLA125294", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Neupogen", "ndc-id": "54868-2522_9166ec18-da24-4f12-b446-dcf2dcc9d3ca", "ndc-product-code": "54868-2522", "dpd-id": null, "started-marketing-on": "1994-06-08", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "300 ug/mL", "route": "intravenous", "fda-application-number": "BLA103353", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Neupogen", "ndc-id": "54868-5020_9166ec18-da24-4f12-b446-dcf2dcc9d3ca", "ndc-product-code": "54868-5020", "dpd-id": null, "started-marketing-on": "2004-03-11", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "300 ug/.5mL", "route": "intravenous", "fda-application-number": "BLA103353", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Neupogen", "ndc-id": "54868-3050_9166ec18-da24-4f12-b446-dcf2dcc9d3ca", "ndc-product-code": "54868-3050", "dpd-id": null, "started-marketing-on": "2006-08-14", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "480 ug/.8mL", "route": "intravenous", "fda-application-number": "BLA103353", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Neupogen", "ndc-id": null, "ndc-product-code": null, "dpd-id": "01968017", "started-marketing-on": "1992-12-31", "ended-marketing-on": null, "dosage-form": "solution", "strength": "300 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Neupogen", "ndc-id": "55513-209_d857f9eb-01d7-490f-8a54-2ea92eb3d044", "ndc-product-code": "55513-209", "dpd-id": null, "started-marketing-on": "2000-10-02", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "480 ug/.8mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103353", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Neupogen", "ndc-id": "55513-530_d857f9eb-01d7-490f-8a54-2ea92eb3d044", "ndc-product-code": "55513-530", "dpd-id": null, "started-marketing-on": "1997-05-19", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "300 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103353", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Neupogen", "ndc-id": "55513-546_d857f9eb-01d7-490f-8a54-2ea92eb3d044", "ndc-product-code": "55513-546", "dpd-id": null, "started-marketing-on": "1997-04-07", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "480 ug/1.6mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103353", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Neupogen", "ndc-id": "55513-924_d857f9eb-01d7-490f-8a54-2ea92eb3d044", "ndc-product-code": "55513-924", "dpd-id": null, "started-marketing-on": "2000-10-02", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "300 ug/.5mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA103353", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Neupogen", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02420104", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "600 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Neupogen", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02420112", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "600 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Zarxio", "ndc-id": "61314-304_dae317f4-9712-49d1-acad-f619702c0d71", "ndc-product-code": "61314-304", "dpd-id": null, "started-marketing-on": "2015-03-06", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "300 ug/.5mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA125553", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Zarxio", "ndc-id": "61314-312_dae317f4-9712-49d1-acad-f619702c0d71", "ndc-product-code": "61314-312", "dpd-id": null, "started-marketing-on": "2015-03-06", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "480 ug/.8mL", "route": "intravenous; subcutaneous", "fda-application-number": "BLA125553", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}]}, "international-brands": {"international-brand": [{"name": "Biocilin", "company": null}, {"name": "Biofigran", "company": null}, {"name": "Biofilgran", "company": null}, {"name": "Endufil", "company": null}, {"name": "Filatil", "company": null}, {"name": "Filgen", "company": null}, {"name": "Gran", "company": null}, {"name": "Granulokine", "company": null}, {"name": "Grimatin", "company": null}, {"name": "Inmunef", "company": null}, {"name": "Jiexin", "company": null}, {"name": "Leucogen", "company": null}, {"name": "Leucostim", "company": null}, {"name": "Macroleuco", "company": null}, {"name": "Neukine", "company": null}, {"name": "Neutromax", "company": null}, {"name": "Neutroval", "company": "Sicor Biotech"}, {"name": "Nivestim", "company": null}, {"name": "Recombicyte", "company": null}, {"name": "SciLocyte", "company": null}, {"name": "Tevagastrim", "company": null}, {"name": "White-C", "company": null}, {"name": "Zarzio", "company": null}]}, "mixtures": {"mixture": [{"name": "Neupogen", "ingredients": "Filgrastim"}, {"name": "Neupogen", "ingredients": "Filgrastim"}, {"name": "Neupogen", "ingredients": "Filgrastim"}, {"name": "Neupogen", "ingredients": "Filgrastim"}, {"name": "Neupogen", "ingredients": "Filgrastim"}, {"name": "Neupogen", "ingredients": "Filgrastim"}, {"name": "Neupogen", "ingredients": "Filgrastim"}, {"name": "Zarxio", "ingredients": "Filgrastim"}, {"name": "Zarxio", "ingredients": "Filgrastim"}, {"name": "Granix", "ingredients": "Filgrastim"}, {"name": "Granix", "ingredients": "Filgrastim"}, {"name": "Neupogen", "ingredients": "Filgrastim"}, {"name": "Neupogen", "ingredients": "Filgrastim"}, {"name": "Neupogen", "ingredients": "Filgrastim"}]}, "packagers": {"packager": [{"name": "Amgen Inc.", "url": "http://www.amgen.com"}, {"name": "Physicians Total Care Inc.", "url": "http://www.physicianstotalcare.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Neupogen 300 mcg/ml vial", "cost": {"@currency": "USD", "#text": "286.04"}, "unit": "vial"}, {"description": "Neupogen 480 mcg/1.6 ml vial", "cost": {"@currency": "USD", "#text": "437.94"}, "unit": "ml"}, {"description": "Neupogen 300 mcg/0.5ml Solution 1 Box Contains Ten 0.5ml Syringes", "cost": {"@currency": "USD", "#text": "3138.1"}, "unit": "box"}, {"description": "Neupogen 480 mcg/1.6ml Solution 1 Box Contains Ten 1.6ml Syringes", "cost": {"@currency": "USD", "#text": "4554.58"}, "unit": "box"}, {"description": "Neupogen 480 mcg/0.8ml Solution 1 Box Contains Ten 0.8ml Syringes", "cost": {"@currency": "USD", "#text": "4998.24"}, "unit": "box"}]}, "categories": {"category": [{"category": "Immunosuppressive Agents", "mesh-id": null}, {"category": "Antineutropenic Agents", "mesh-id": null}, {"category": "Hematopoietic Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, solution", "route": "subcutaneous", "strength": "300 ug/.5mL"}, {"form": "Injection, solution", "route": "subcutaneous", "strength": "480 ug/.8mL"}, {"form": "Injection, solution", "route": "intravenous", "strength": "300 ug/.5mL"}, {"form": "Injection, solution", "route": "intravenous", "strength": "300 ug/mL"}, {"form": "Injection, solution", "route": "intravenous", "strength": "480 ug/.8mL"}, {"form": "Injection, solution", "route": "intravenous; subcutaneous", "strength": "300 ug/.5mL"}, {"form": "Injection, solution", "route": "intravenous; subcutaneous", "strength": "300 ug/mL"}, {"form": "Injection, solution", "route": "intravenous; subcutaneous", "strength": "480 ug/.8mL"}, {"form": "Injection, solution", "route": "intravenous; subcutaneous", "strength": "480 ug/1.6mL"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "300 mcg"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "600 mcg"}]}, "atc-codes": {"atc-code": {"@code": "L03AA02", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L03", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03A", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03AA", "#text": "Colony stimulating factors"}]}}, "ahfs-codes": {"ahfs-code": "20:16.00"}, "patents": {"patent": [{"number": "1339071", "country": "Canada", "approved": "1997-07-29", "expires": "2014-07-29"}, {"number": "1341537", "country": "Canada", "approved": "2007-07-31", "expires": "2024-07-31"}]}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00290", "name": "Bleomycin", "description": "Filgrastim may enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased."}, {"drugbank-id": "DB00531", "name": "Cyclophosphamide", "description": "Filgrastim may enhance the adverse/toxic effect of Cyclophosphamide. Specifically, the risk of pulmonary toxicity may be enhanced."}, {"drugbank-id": "DB01030", "name": "Topotecan", "description": "Filgrastim may enhance the adverse/toxic effect of Topotecan."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">Amino acid sequence for filgrastim\nMTPLGPASSLPQSFLLKCLEQVRKIQGDGAALQEKLCATYKLCHPEELVLLGHSLGIPWA\nPLSSCPSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQ\nQMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLAQP"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "60 \u00b0C", "source": "Luo, P., Protein Science 11:1218-1226 (2002)"}, {"kind": "Hydrophobicity", "value": "0.209", "source": null}, {"kind": "Isoelectric Point", "value": "5.65", "source": null}, {"kind": "Molecular Weight", "value": "18.8 kDa", "source": null}, {"kind": "Molecular Formula", "value": "C845H1343N223O243S9", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "7657"}, {"resource": "KEGG Drug", "identifier": "D03235"}, {"resource": "National Drug Code Directory", "identifier": "55513-209-10"}, {"resource": "GenBank", "identifier": "X03438"}, {"resource": "PharmGKB", "identifier": "PA449626"}, {"resource": "UniProtKB", "identifier": "P09919"}, {"resource": "Wikipedia", "identifier": "Filgrastim"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/filgrastim.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/filgrastim.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000793", "name": "Granulocyte colony-stimulating factor receptor", "organism": "Human", "actions": {"action": "stimulator"}, "references": "# Erkeland SJ, Aarts LH, Irandoust M, Roovers O, Klomp A, Valkhof M, Gits J, Eyckerman S, Tavernier J, Touw IP: Novel role of WD40 and SOCS box protein-2 in steady-state distribution of granulocyte colony-stimulating factor receptor and G-CSF-controlled proliferation and differentiation signaling. Oncogene. 2007 Mar 29;26(14):1985-94. Epub 2006 Sep 25. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17001306\n# Link DC, Kunter G, Kasai Y, Zhao Y, Miner T, McLellan MD, Ries RE, Kapur D, Nagarajan R, Dale DC, Bolyard AA, Boxer LA, Welte K, Zeidler C, Donadieu J, Bellanne-Chantelot C, Vardiman JW, Caligiuri MA, Bloomfield CD, DiPersio JF, Tomasson MH, Graubert TA, Westervelt P, Watson M, Shannon W, Baty J, Mardis ER, Wilson RK, Ley TJ: Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood. 2007 Sep 1;110(5):1648-55. Epub 2007 May 9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17494858\n# Cao YR, Shao ZH, Liu H, Shi J, Bai J, Tu MF, Wang HQ, Xing LM, Cui ZZ, Sun J, Jia HR, Yang TY: [The response of bone marrow hematopoietic cells to G-CSF in paroxysmal nocturnal hemoglobinuria patients] Zhonghua Xue Ye Xue Za Zhi. 2005 Apr;26(4):235-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15949269\n# Ward AC: The role of the granulocyte colony-stimulating factor receptor (G-CSF-R) in disease. Front Biosci. 2007 Jan 1;12:608-18. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17127322\n# Zhuang D, Qiu Y, Haque SJ, Dong F: Tyrosine 729 of the G-CSF receptor controls the duration of receptor signaling: involvement of SOCS3 and SOCS1. J Leukoc Biol. 2005 Oct;78(4):1008-15. Epub 2005 Jul 20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16033816", "known-action": "yes", "polypeptide": {"@id": "Q99062", "@source": "Swiss-Prot", "name": "Granulocyte colony-stimulating factor receptor", "general-function": "Involved in hematopoietin/interferon-class (D200-domain) cytokine receptor activity", "specific-function": "Receptor for granulocyte colony-stimulating factor. In addition it may function in some adhesion or recognition events at the cell surface", "gene-name": "CSF3R", "locus": "1p35-p34.3", "cellular-location": "Cell membrane; single-pass type I membrane protein. Isoform GCSFR2:Secreted protein (Probable). Isof", "transmembrane-regions": "628-650", "signal-regions": null, "theoretical-pi": "6.14", "molecular-weight": "92157.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:2439"}, {"resource": "GenAtlas", "identifier": "CSF3R"}, {"resource": "GeneCards", "identifier": "CSF3R"}, {"resource": "GenBank Gene Database", "identifier": "X55721"}, {"resource": "GenBank Protein Database", "identifier": "31697"}, {"resource": "UniProtKB", "identifier": "Q99062"}, {"resource": "UniProt Accession", "identifier": "CSF3R_HUMAN"}]}, "synonyms": {"synonym": ["CD114 antigen", "G-CSF-R", "Granulocyte colony-stimulating factor receptor precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Granulocyte colony-stimulating factor receptor precursor\nMARLGNCSLTWAALIILLLPGSLEECGHISVSAPIVHLGDPITASCIIKQNCSHLDPEPQ\nILWRLGAELQPGGRQQRLSDGTQESIITLPHLNHTQAFLSCCLNWGNSLQILDQVELRAG\nYPPAIPHNLSCLMNLTTSSLICQWEPGPETHLPTSFTLKSFKSRGNCQTQGDSILDCVPK\nDGQSHCCIPRKHLLLYQNMGIWVQAENALGTSMSPQLCLDPMDVVKLEPPMLRTMDPSPE\nAAPPQAGCLQLCWEPWQPGLHINQKCELRHKPQRGEASWALVGPLPLEALQYELCGLLPA\nTAYTLQIRCIRWPLPGHWSDWSPSLELRTTERAPTVRLDTWWRQRQLDPRTVQLFWKPVP\nLEEDSGRIQGYVVSWRPSGQAGAILPLCNTTELSCTFHLPSEAQEVALVAYNSAGTSRPT\nPVVFSESRGPALTRLHAMARDPHSLWVGWEPPNPWPQGYVIEWGLGPPSASNSNKTWRME\nQNGRATGFLLKENIRPFQLYEIIVTPLYQDTMGPSQHVYAYSQEMAPSHAPELHLKHIGK\nTWAQLEWVPEPPELGKSPLTHYTIFWTNAQNQSFSAILNASSRGFVLHGLEPASLYHIHL\nMAASQAGATNSTVLTLMTLTPEGSELHIILGLFGLLLLLTCLCGTAWLCCSPNRKNPLWP\nSVPDPAHSSLGSWVPTIMEEDAFQLPGLGTPPITKLTVLEEDEKKPVPWESHNSSETCGL\nPTLVQTYVLQGDPRAVSTQPQSQSGTSDQVLYGQLLGSPTSPGPGHYLRCDSTQPLLAGL\nTPSPKSYENLWFQASPLGTLVTPAPSQEDDCVFGPLLNFPLLQGIRVHGMEALGSF"}, "gene-sequence": {"@format": "FASTA", "#text": ">2511 bp\nATGGCAAGGCTGGGAAACTGCAGCCTGACTTGGGCTGCCCTGATCATCCTGCTGCTCCCC\nGGAAGTCTGGAGGAGTGCGGGCACATCAGTGTCTCAGCCCCCATCGTCCACCTGGGGGAT\nCCCATCACAGCCTCCTGCATCATCAAGCAGAACTGCAGCCATCTGGACCCGGAGCCACAG\nATTCTGTGGAGACTGGGAGCAGAGCTTCAGCCCGGGGGCAGGCAGCAGCGTCTGTCTGAT\nGGGACCCAGGAATCTATCATCACCCTGCCCCACCTCAACCACACTCAGGCCTTTCTCTCC\nTGCTGCCTGAACTGGGGCAACAGCCTGCAGATCCTGGACCAGGTTGAGCTGCGCGCAGGC\nTACCCTCCAGCCATACCCCACAACCTCTCCTGCCTCATGAACCTCACAACCAGCAGCCTC\nATCTGCCAGTGGGAGCCAGGACCTGAGACCCACCTACCCACCAGCTTCACTCTGAAGAGT\nTTCAAGAGCCGGGGCAACTGTCAGACCCAAGGGGACTCCATCCTGGACTGCGTGCCCAAG\nGACGGGCAGAGCCACTGCTGCATCCCACGCAAACACCTGCTGTTGTACCAGAATATGGGC\nATCTGGGTGCAGGCAGAGAATGCGCTGGGGACCAGCATGTCCCCACAACTGTGTCTTGAT\nCCCATGGATGTTGTGAAACTGGAGCCCCCCATGCTGCGGACCATGGACCCCAGCCCTGAA\nGCGGCCCCTCCCCAGGCAGGCTGCCTACAGCTGTGCTGGGAGCCATGGCAGCCAGGCCTG\nCACATAAATCAGAAGTGTGAGCTGCGCCACAAGCCGCAGCGTGGAGAAGCCAGCTGGGCA\nCTGGTGGGCCCCCTCCCCTTGGAGGCCCTTCAGTATGAGCTCTGCGGGCTCCTCCCAGCC\nACGGCCTACACCCTGCAGATACGCTGCATCCGCTGGCCCCTGCCTGGCCACTGGAGCGAC\nTGGAGCCCCAGCCTGGAGCTGAGAACTACCGAACGGGCCCCCACTGTCAGACTGGACACA\nTGGTGGCGGCAGAGGCAGCTGGACCCCAGGACAGTGCAGCTGTTCTGGAAGCCAGTGCCC\nCTGGAGGAAGACAGCGGACGGATCCAAGGTTATGTGGTTTCTTGGAGACCCTCAGGCCAG\nGCTGGGGCCATCCTGCCCCTCTGCAACACCACAGAGCTCAGCTGCACCTTCCACCTGCCT\nTCAGAAGCCCAGGAGGTGGCCCTTGTGGCCTATAACTCAGCCGGGACCTCTCGCCCCACC\nCCGGTGGTCTTCTCAGAAAGCAGAGGCCCAGCTCTGACCAGACTCCATGCCATGGCCCGA\nGACCCTCACAGCCTCTGGGTAGGCTGGGAGCCCCCCAATCCATGGCCTCAGGGCTATGTG\nATTGAGTGGGGCCTGGGCCCCCCCAGCGCGAGCAATAGCAACAAGACCTGGAGGATGGAA\nCAGAATGGGAGAGCCACGGGGTTTCTGCTGAAGGAGAACATCAGGCCCTTTCAGCTCTAT\nGAGATCATCGTGACTCCCTTGTACCAGGACACCATGGGACCCTCCCAGCATGTCTATGCC\nTACTCTCAAGAAATGGCTCCCTCCCATGCCCCAGAGCTGCATCTAAAGCACATTGGCAAG\nACCTGGGCACAGCTGGAGTGGGTGCCTGAGCCCCCTGAGCTGGGGAAGAGCCCCCTTACC\nCACTACACCATCTTCTGGACCAACGCTCAGAACCAGTCCTTCTCCGCCATCCTGAATGCC\nTCCTCCCGTGGCTTTGTCCTCCATGGCCTGGAGCCCGCCAGTCTGTATCACATCCACCTC\nATGGCTGCCAGCCAGGCTGGGGCCACCAACAGTACAGTCCTCACCCTGATGACCTTGACC\nCCAGAGGGGTCGGAGCTACACATCATCCTGGGCCTGTTCGGCCTCCTGCTGTTGCTCACC\nTGCCTCTGTGGAACTGCCTGGCTCTGTTGCAGCCCCAACAGGAAGAATCCCCTCTGGCCA\nAGTGTCCCAGACCCAGCTCACAGCAGCCTGGGCTCCTGGGTGCCCACAATCATGGAGGAG\nGATGCCTTCCAGCTGCCCGGCCTTGGCACGCCACCCATCACCAAGCTCACAGTGCTGGAG\nGAGGATGAAAAGAAGCCGGTGCCCTGGGAGTCCCATAACAGCTCAGAGACCTGTGGCCTC\nCCCACTCTGGTCCAGACCTATGTGCTCCAGGGGGACCCAAGAGCAGTTTCCACCCAGCCC\nCAATCCCAGTCTGGCACCAGCGATCAGGTCCTTTATGGGCAGCTGCTGGGCAGCCCCACA\nAGCCCAGGGCCAGGGCACTATCTCCGCTGTGACTCCACTCAGCCCCTCTTGGCGGGCCTC\nACCCCCAGCCCCAAGTCCTATGAGAACCTCTGGTTCCAGGCCAGCCCCTTGGGGACCCTG\nGTAACCCCAGCCCCAAGCCAGGAGGACGACTGTGTCTTTGGGCCACTGCTCAACTTCCCC\nCTCCTGCAGGGGATCCGGGTCCATGGGATGGAGGCGCTGGGGAGCTTCTAG"}, "pfams": {"pfam": [{"identifier": "PF00041", "name": "fn3"}, {"identifier": "PF06328", "name": "Lep_receptor_Ig"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "hematopoietin/interferon-class (D200-domain) cytokine receptor activity"}]}}}, {"id": "BE0000394", "name": "Neutrophil elastase", "organism": "Human", "actions": {"action": "other/unknown"}, "references": "# Carter CR, Whitmore KM, Thorpe R: The significance of carbohydrates on G-CSF: differential sensitivity of G-CSFs to human neutrophil elastase degradation. J Leukoc Biol. 2004 Mar;75(3):515-22. Epub 2003 Dec 4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14657210\n# Jian MY, Koizumi T, Tsushima K, Fujimoto K, Kubo K: Effects of granulocyte colony-stimulating factor (G-CSF) and neutrophil elastase inhibitor (ONO-5046) on acid-induced lung injury in rats. Inflammation. 2004 Dec;28(6):327-36. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16245075\n# Donini M, Fontana S, Savoldi G, Vermi W, Tassone L, Gentili F, Zenaro E, Ferrari D, Notarangelo LD, Porta F, Facchetti F, Notarangelo LD, Dusi S, Badolato R: G-CSF treatment of severe congenital neutropenia reverses neutropenia but does not correct the underlying functional deficiency of the neutrophil in defending against microorganisms. Blood. 2007 Jun 1;109(11):4716-23. Epub 2007 Feb 20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17311988\n# Schepers H, Wierenga AT, van Gosliga D, Eggen BJ, Vellenga E, Schuringa JJ: Reintroduction of C/EBPalpha in leukemic CD34+ stem/progenitor cells impairs self-renewal and partially restores myelopoiesis. Blood. 2007 Aug 15;110(4):1317-25. Epub 2007 May 2. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17475913\n# Druhan LJ, Ai J, Massullo P, Kindwall-Keller T, Ranalli MA, Avalos BR: Novel mechanism of G-CSF refractoriness in patients with severe congenital neutropenia. Blood. 2005 Jan 15;105(2):584-91. Epub 2004 Sep 7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15353486\n# El Ouriaghli F, Fujiwara H, Melenhorst JJ, Sconocchia G, Hensel N, Barrett AJ: Neutrophil elastase enzymatically antagonizes the in vitro action of G-CSF: implications for the regulation of granulopoiesis. Blood. 2003 Mar 1;101(5):1752-8. Epub 2002 Oct 17. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12393522", "known-action": "unknown", "polypeptide": {"@id": "P08246", "@source": "Swiss-Prot", "name": "Neutrophil elastase", "general-function": "Involved in elastase activity and cytokine binding", "specific-function": "Modifies the functions of natural killer cells, monocytes and granulocytes. Inhibits C5a-dependent neutrophil enzyme release and chemotaxis", "gene-name": "ELANE", "locus": "19p13.3", "cellular-location": "Cytoplasmic", "transmembrane-regions": "7-26", "signal-regions": null, "theoretical-pi": "9.41", "molecular-weight": "28518.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3309"}, {"resource": "GenAtlas", "identifier": "ELA2"}, {"resource": "GeneCards", "identifier": "ELA2"}, {"resource": "GenBank Gene Database", "identifier": "Y00477"}, {"resource": "GenBank Protein Database", "identifier": "296665"}, {"resource": "UniProtKB", "identifier": "P08246"}, {"resource": "UniProt Accession", "identifier": "ELNE_HUMAN"}]}, "synonyms": {"synonym": ["Bone marrow serine protease", "EC 3.4.21.37", "Elastase-2", "HLE", "Human leukocyte elastase", "Leukocyte elastase precursor", "Medullasin", "Neutrophil elastase", "PMN elastase"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Leukocyte elastase precursor\nMTLGRRLACLFLACVLPALLLGGTALASEIVGGRRARPHAWPFMVSLQLRGGHFCGATLI\nAPNFVMSAAHCVANVNVRAVRVVLGAHNLSRREPTRQVFAVQRIFENGYDPVNLLNDIVI\nLQLNGSATINANVQVAQLPAQGRRLGNGVQCLAMGWGLLGRNRGIASVLQELNVTVVTSL\nCRRSNVCTLVRGRQAGVCFGDSGSPLVCNGLIHGIASFVRGGCASGLYPDAFAPVAQFVN\nWIDSIIQRSEDNPCPHPRDPDPASRTH"}, "gene-sequence": {"@format": "FASTA", "#text": ">804 bp\nATGACCCTCGGCCGCCGACTCGCGTGTCTTTTCCTCGCCTGTGTCCTGCCGGCCTTGCTG\nCTGGGGGGCACCGCGCTGGCCTCGGAGATTGTGGGGGGCCGGCGAGCGCGGCCCCACGCG\nTGGCCCTTCATGGTGTCCCTGCAGCTGCGCGGAGGCCACTTCTGCGGCGCCACCCTGATT\nGCGCCCAACTTCGTCATGTCGGCCGCGCACTGCGTGGCGAATGTAAACGTCCGCGCGGTG\nCGGGTGGTCCTGGGAGCCCATAACCTCTCGCGGCGGGAGCCCACCCGGCAGGTGTTCGCC\nGTGCAGCGCATCTTCGAAAACGGCTACGACCCCGTAAACTTGCTCAACGACATCGTGATT\nCTCCAGCTCAACGGGTCGGCCACCATCAACGCCAACGTGCAGGTGGCCCAGCTGCCGGCT\nCAGGGACGCCGCCTGGGCAACGGGGTGCAGTGCCTGGCCATGGGCTGGGGCCTTCTGGGC\nAGGAACCGTGGGATCGCCAGCGTCCTGCAGGAGCTCAACGTGACGGTGGTGACGTCCCTC\nTGCCGTCGCAGCAACGTCTGCACTCTCGTGAGGGGCCGGCAGGCCGGCGTCTGTTTCGGG\nGACTCCGGCAGCCCCTTGGTCTGCAACGGGCTAATCCACGGAATTGCCTCCTTCGTCCGG\nGGAGGCTGCGCCTCAGGGCTCTACCCCGATGCCTTTGCCCCGGTGGCACAGTTTGTAAAC\nTGGATCGACTCTATCATCCAACGCTCCGAGGACAACCCCTGTCCCCACCCCCGGGACCCG\nGACCCGGCCAGCAGGACCCACTGA"}, "pfams": {"pfam": {"identifier": "PF00089", "name": "Trypsin"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2015-02-01", "drugbank-id": [{"@primary": "true", "#text": "DB00100"}, "BIOD00038", "BTD00038"], "name": "Coagulation Factor IX", "description": "Human Factor IX protein, produced by recombinant DNA technology for use in therapy of factor IX deficiency, known as hemophilia B or Christmas disease. Coagulation Factor IX (Recombinant) is a glycoprotein with an approximate molecular mass of 55,000 Da consisting of 415 amino acids in a single chain. It has a primary amino acid sequence that is identical to the Ala 148 allelic form of plasma-derived factor IX.", "cas-number": "9001-28-9", "groups": {"group": "approved"}, "general-references": "# BIGGS R, DOUGLAS AS, MACFARLANE RG, DACIE JV, PITNEY WR, MERSKEY: Christmas disease: a condition previously mistaken for haemophilia. Br Med J. 1952 Dec 27;2(4799):1378-82. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12997790\n# Kurachi K, Davie EW: Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci U S A. 1982 Nov;79(21):6461-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/6959130", "synthesis-reference": "Volker Schellenberger, Joshua Silverman, Willem Stemmer, Chia-wei Wang, Benjamin Spink, Nathan Geething, Wayne To, \"Coagulation factor IX compositions and methods of making and using same.\" U.S. Patent US20110046060, issued February 24, 2011.", "indication": "For treatment of hemophilia (Christmas disease).", "pharmacodynamics": "Binds vitamin K and factor VIIIa. Cleaves the Arg-Ile bond in factor X to form active factor Xa. Plays a key role in blood coagulation and clotting. Injections of factor IX are used to treat hemophilia B, which is sometimes called Christmas disease. AlphaNine is injected to increase plasma levels of Factor IX and can temporarily correct this coagulation defect.", "mechanism-of-action": "Coagulation Factor IX is an important protein in the process of hemostasis and normal blood clotting. Factor IX is plays an important intermediate role in the blood coagulation cascade. It is located within the blood plasma as a zymogen, an antecedent to enzymatic function, in its inactivated state. Factor IX is dependent on the presence of Vitamin K, and is activated to a serine protease by the function of Coagulation Factor XIa. Factor XIa cleaves the peptide bond associated with protein activation in Factor IX, leaving Factor IX with two exposed chains, a light chain and a heavy chain. These two chains are held together by several disulfide bonds that reinforce the structure of Factor IX's activated form. After being activated, Factor IX forms a complex with calcium ions, membrane phospholipids and Coagulation Factor VIII to activate Coagulation Factor X. The activation of Factor X then performs a similarly integral step in the blood coagulation cascade. The ultimate result of phenotypically normal coagulation factors is the creation of platelets for normal blood clotting.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": "19.4 \u00b1 5.4 hours (range from 11 to 36 hours)", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Christmas factor"}, {"@language": "", "@coder": "", "#text": "Coagulation factor IX precursor"}, {"@language": "", "@coder": "", "#text": "Plasma thromboplastin component"}, {"@language": "", "@coder": "", "#text": "PTC"}]}, "products": {"product": [{"name": "Benefix", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02293765", "started-marketing-on": "2007-04-14", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "250 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Benefix", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02293773", "started-marketing-on": "2007-04-14", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "500 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Benefix", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02293781", "started-marketing-on": "2007-04-14", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "1000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Benefix", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02293803", "started-marketing-on": "2008-07-12", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "2000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Benefix", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02392984", "started-marketing-on": "2013-02-12", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "3000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Benefix  - (250iu)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02231018", "started-marketing-on": "1998-08-12", "ended-marketing-on": "2008-06-19", "dosage-form": "kit; liquid; powder for solution", "strength": "250 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Benefix  - (500iu)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02231019", "started-marketing-on": "1998-08-12", "ended-marketing-on": "2008-06-19", "dosage-form": "kit; liquid; powder for solution", "strength": "500 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Benefix  -(1000iu)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02231020", "started-marketing-on": "1998-08-12", "ended-marketing-on": "2008-06-19", "dosage-form": "kit; liquid; powder for solution", "strength": "1000 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Immunine Vh", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02206021", "started-marketing-on": "1996-10-18", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "720 unit", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Immunine Vh", "ingredients": "Coagulation Factor IX"}, {"name": "Benefix", "ingredients": "Coagulation Factor IX"}, {"name": "Benefix", "ingredients": "Coagulation Factor IX"}, {"name": "Benefix", "ingredients": "Coagulation Factor IX"}, {"name": "Benefix", "ingredients": "Coagulation Factor IX"}, {"name": "Benefix", "ingredients": "Coagulation Factor IX"}, {"name": "Benefix  - (250iu)", "ingredients": "Coagulation Factor IX + Water"}, {"name": "Benefix  - (500iu)", "ingredients": "Coagulation Factor IX + Water"}, {"name": "Benefix  -(1000iu)", "ingredients": "Coagulation Factor IX + Water"}]}, "packagers": {"packager": [{"name": "CSL Behring LLC", "url": "http://www.cslbehring.com"}, {"name": "Grifols SA", "url": "http://www.grifols.com"}, {"name": "Hospira Inc.", "url": "http://www.hospira.com"}, {"name": "Wyeth Pharmaceuticals", "url": "http://www.wyeth.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Benefix 1000 unit vial", "cost": {"@currency": "USD", "#text": "1.0"}, "unit": "vial"}, {"description": "Benefix 250 unit vial", "cost": {"@currency": "USD", "#text": "1.0"}, "unit": "vial"}, {"description": "Benefix 500 unit vial", "cost": {"@currency": "USD", "#text": "1.0"}, "unit": "vial"}, {"description": "Benefix 2000 unit vial", "cost": {"@currency": "USD", "#text": "1.12"}, "unit": "vial"}, {"description": "Mononine 1000 unit vial", "cost": {"@currency": "USD", "#text": "1.2"}, "unit": "vial"}, {"description": "Mononine 500 unit vial", "cost": {"@currency": "USD", "#text": "1.2"}, "unit": "vial"}, {"description": "Alphanine sd 250-1500 unit vial", "cost": {"@currency": "USD", "#text": "1.42"}, "unit": "vial"}]}, "categories": {"category": [{"category": "Coagulants", "mesh-id": null}, {"category": "Thrombotic Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Powder for solution", "route": "intravenous", "strength": "1000 unit"}, {"form": "Powder for solution", "route": "intravenous", "strength": "2000 unit"}, {"form": "Powder for solution", "route": "intravenous", "strength": "250 unit"}, {"form": "Powder for solution", "route": "intravenous", "strength": "3000 unit"}, {"form": "Powder for solution", "route": "intravenous", "strength": "500 unit"}, {"form": "Kit; liquid; powder for solution", "route": "intravenous", "strength": "250 unit"}, {"form": "Kit; liquid; powder for solution", "route": "intravenous", "strength": "500 unit"}, {"form": "Kit; liquid; powder for solution", "route": "intravenous", "strength": "1000 unit"}, {"form": "Powder for solution", "route": "intravenous", "strength": "720 unit"}]}, "atc-codes": {"atc-code": {"@code": "B02BD04", "level": [{"@code": "B", "#text": "BLOOD AND BLOOD FORMING ORGANS"}, {"@code": "B02", "#text": "ANTIHEMORRHAGICS"}, {"@code": "B02B", "#text": "VITAMIN K AND OTHER HEMOSTATICS"}, {"@code": "B02BD", "#text": "Blood coagulation factors"}]}}, "ahfs-codes": null, "patents": null, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00100 sequence\nYNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGG\nSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAEN\nQKSCEPAVPFPCGRVSVSQTSKLTRAEAVFPDVDYVNSTEAETILDNITQSTQSFNDFTR\nVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEE\nTEHTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFL\nKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDS\nCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "54 \u00b0C", "source": "Link, R.P., Castellino, F.J. Arch. Biochem. Biophsy. 227:259-265 (1983)"}, {"kind": "Hydrophobicity", "value": "-0.431", "source": null}, {"kind": "Isoelectric Point", "value": "5.20", "source": null}, {"kind": "Molecular Weight", "value": "46548.2000", "source": null}, {"kind": "Molecular Formula", "value": "C2041H3136N558O641S25", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "90"}, {"resource": "Drugs Product Database (DPD)", "identifier": "11417"}, {"resource": "KEGG Compound", "identifier": "C03101"}, {"resource": "National Drug Code Directory", "identifier": "0053-7668-02"}, {"resource": "GenBank", "identifier": "K02402"}, {"resource": "PharmGKB", "identifier": "PA164744952"}, {"resource": "UniProtKB", "identifier": "P00740"}, {"resource": "Wikipedia", "identifier": "Factor_IX"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic2/factorix.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/coagulation-factor-ix-injection-human.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000216", "name": "Coagulation factor X", "organism": "Human", "actions": {"action": "activator"}, "references": "# Worfolk LA, Robinson RA, Tracy PB: Factor Xa interacts with two sites on monocytes with different functional activities. Blood. 1992 Oct 15;80(8):1989-97. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1391956\n# Jones KC, Mann KG: A model for the tissue factor pathway to thrombin. II. A mathematical simulation. J Biol Chem. 1994 Sep 16;269(37):23367-73. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8083242\n# Ambrosini G, Plescia J, Chu KC, High KA, Altieri DC: Activation-dependent exposure of the inter-EGF sequence Leu83-Leu88 in factor Xa mediates ligand binding to effector cell protease receptor-1. J Biol Chem. 1997 Mar 28;272(13):8340-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9079657\n# London FS, Walsh PN: Zymogen factor IX potentiates factor IXa-catalyzed factor X activation. Biochemistry. 2000 Aug 15;39(32):9850-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10933803\n# Scandella DH: Properties of anti-factor VIII inhibitor antibodies in hemophilia A patients. Semin Thromb Hemost. 2000;26(2):137-42. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10919405\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352\n# Di Scipio RG, Kurachi K, Davie EW: Activation of human factor IX (Christmas factor). J Clin Invest. 1978 Jun;61(6):1528-38. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/659613", "known-action": "yes", "polypeptide": {"@id": "P00742", "@source": "Swiss-Prot", "name": "Coagulation factor X", "general-function": "Involved in calcium ion binding", "specific-function": "Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting", "gene-name": "F10", "locus": "13q34", "cellular-location": "Cytoplasmic", "transmembrane-regions": "7-26", "signal-regions": null, "theoretical-pi": "5.74", "molecular-weight": "54732.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3528"}, {"resource": "GenAtlas", "identifier": "F10"}, {"resource": "GeneCards", "identifier": "F10"}, {"resource": "GenBank Gene Database", "identifier": "K03194"}, {"resource": "GenBank Protein Database", "identifier": "182841"}, {"resource": "UniProtKB", "identifier": "P00742"}, {"resource": "UniProt Accession", "identifier": "FA10_HUMAN"}]}, "synonyms": {"synonym": ["Coagulation factor X precursor", "EC 3.4.21.6", "Stuart factor", "Stuart- Prower factor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Coagulation factor X precursor\nMGRPLHLVLLSASLAGLLLLGESLFIRREQANNILARVTRANSFLEEMKKGHLERECMEE\nTCSYEEAREVFEDSDKTNEFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKN\nCELFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLERR\nKRSVAQATSSSGEAPDSITWKPYDAADLDPTENPFDLLDFNQTQPERGDNNLTRIVGGQE\nCKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGE\nAVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGI\nVSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSG\nGPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPE\nVITSSPLK"}, "gene-sequence": {"@format": "FASTA", "#text": ">1433 bp\nCCTCCCTGGCTGGCCTCCTGCTGCTCGGGGAAAGTCTGTTCATCCGCAGGGAGCAGGCCA\nACAACATCCTGGCGAGGGTCACGAGGGCCAATTCCTTTCTTGAAGAGATGAAGAAAGGAC\nACCTCGAAAGAGAGTGCATGGAAGAGACCTGCTCATACGAAGAGGCCCGCGAGGTCTTTG\nAGGACAGCGACAAGACGAATGAATTCTGGAATAAATACAAAGATGGCGACCAGTGTGAGA\nCCAGTCCTTGCCAGAACCAGGGCAAATGTAAAGACGGCCTCGGGGAATACACCTGCACCT\nGTTTAGAAGGATTCGAAGGCAAAAACTGTGAATTATTCACACGGAAGCTCTGCAGCCTGG\nACAACGGGGACTGTGACCAGTTCTGCCACGAGGAACAGAACTCTGTGGTGTGCTCCTGCG\nCCCGCGGGTACACCCTGGCTGACAACGGCAAGGCCTGCATTCCCACAGGGCCCTACCCCT\nGTGGGAAACAGACCCTGGAACGCAGGAAGAGGTCAGTGGCCCAGGCCACCAGCAGCAGCG\nGGGAGGCCCCTGACAGCATCACATGGAAGCCATATGATGCAGCCGACCTGGACCCCACCG\nAGAACCCCTTCGACCTGCTTGACTTCAACCAGACGCAGCCTGAGAGGGGCGACAACAACC\nTCACCAGGATCGTGGGAGGCCAGGAATGCAAGGACGGGGAGTGTCCCTGGCAGGCCCTGC\nTCATCAATGAGGAAAACGAGGGTTTCTGTGGTGGAACTATTCTGAGCGAGTTCTACATCC\nTAACGGCAGCCCACTGTCTCTACCAAGCCAAGAGATTCAAGGTGAGGGTAGGGGACCGGA\nACACGGAGCAGGAGGAGGGCGGTGAGGCGGTGCACGAGGTGGAGGTGGTCATCAAGCACA\nACCGGTTCACAAAGGAGACCTATGACTTCGACATCGCCGTGCTCCGGCTCAAGACCCCCA\nTCACCTTCCGCATGAACGTGGCGCCTGCCTGCCTCCCCGAGCGTGACTGGGCCGAGTCCA\nCGCTGATGACGCAGAAGACGGGGATTGTGAGCGGCTTCGGGCGCACCCACGAGAAGGGCC\nGGCAGTCCACCAGGCTCAAGATGCTGGAGGTGCCCTACGTGGACCGCAACAGCTGCAAGC\nTGTCCAGCAGCTTCATCATCACCCAGAACATGTTCTGTGCCGGCTACGACACCAAGCAGG\nAGGATGCCTGCCAGGGGGACAGCGGGGGCCCGCACGTCACCCGCTTCAAGGACACCTACT\nTCGTGACAGGCATCGTCAGCTGGGGAGAGAGCTGTGCCCGTAAGGGGAAGTACGGGATCT\nACACCAAGGTCACCGCCTTCCTCAAGTGGATCGACAGGTCCATGAAAACCAGGGGCTTGC\nCCAAGGCCAAGAGCCATGCCCCGGAGGTCATAACGTCCTCTCCATTAAAGTGA"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF00594", "name": "Gla"}, {"identifier": "PF00089", "name": "Trypsin"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "hemostasis"}, {"category": "process", "description": "blood coagulation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}]}}}, {"@position": "2", "id": "BE0001021", "name": "Coagulation factor XI", "organism": "Human", "actions": {"action": "ligand"}, "references": "# Sun MF, Zhao M, Gailani D: Identification of amino acids in the factor XI apple 3 domain required for activation of factor IX. J Biol Chem. 1999 Dec 17;274(51):36373-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10593931\n# Gailani D, Ho D, Sun MF, Cheng Q, Walsh PN: Model for a factor IX activation complex on blood platelets: dimeric conformation of factor XIa is essential. Blood. 2001 May 15;97(10):3117-22. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11342438\n# Di Scipio RG, Kurachi K, Davie EW: Activation of human factor IX (Christmas factor). J Clin Invest. 1978 Jun;61(6):1528-38. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/659613", "known-action": "yes", "polypeptide": {"@id": "P03951", "@source": "Swiss-Prot", "name": "Coagulation factor XI", "general-function": "Involved in serine-type endopeptidase activity", "specific-function": "Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX", "gene-name": "F11", "locus": "4q35", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "8.14", "molecular-weight": "70110.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3529"}, {"resource": "GenAtlas", "identifier": "F11"}, {"resource": "GeneCards", "identifier": "F11"}, {"resource": "GenBank Gene Database", "identifier": "M13142"}, {"resource": "GenBank Protein Database", "identifier": "182833"}, {"resource": "UniProtKB", "identifier": "P03951"}, {"resource": "UniProt Accession", "identifier": "FA11_HUMAN"}]}, "synonyms": {"synonym": ["Coagulation factor XI precursor", "EC 3.4.21.27", "FXI", "Plasma thromboplastin antecedent", "PTA"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Coagulation factor XI precursor\nMIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFT\nFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDM\nKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITK\nLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFT\nFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTD\nFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKIL\nHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSI\nIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYD\nIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLV\nTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCA\nQRERPGVYTNVVEYVDWILEKTQAV"}, "gene-sequence": {"@format": "FASTA", "#text": ">1878 bp\nATGATTTTCTTATATCAAGTGGTACATTTCATTTTATTTACTTCAGTTTCTGGTGAATGT\nGTGACTCAGTTGTTGAAGGACACCTGCTTTGAAGGAGGGGACATTACTACGGTCTTCACA\nCCAAGCGCCAAGTACTGCCAGGTAGTCTGCACTTACCACCCAAGATGTTTACTCTTCACT\nTTCACGGCGGAATCACCATCTGAGGATCCCACCCGATGGTTTACTTGTGTCCTGAAAGAC\nAGTGTTACAGAAACACTGCCAAGAGTGAATAGGACAGCAGCGATTTCTGGGTATTCTTTC\nAAGCAATGCTCACACCAAATAAGCGCTTGCAACAAAGACATTTATGTGGACCTAGACATG\nAAGGGCATAAACTATAACAGCTCAGTTGCCAAGAGTGCTCAAGAATGCCAAGAAAGATGC\nACGGATGACGTCCACTGCCACTTTTTCACGTACGCCACAAGGCAGTTTCCCAGCCTGGAG\nCATCGTAACATTTGTCTACTGAAGCACACCCAAACAGGGACACCAACCAGAATAACGAAG\nCTCGATAAAGTGGTGTCTGGATTTTCACTGAAATCCTGTGCACTTTCTAATCTGGCTTGT\nATTAGGGACATTTTCCCTAATACGGTGTTTGCAGACAGCAACATCGACAGTGTCATGGCT\nCCCGATGCTTTTGTCTGTGGCCGAATCTGCACTCATCATCCCGGTTGCTTGTTTTTTACC\nTTCTTTTCCCAGGAATGGCCCAAAGAATCTCAAAGAAATCTTTGTCTCCTTAAAACATCT\nGAGAGTGGATTGCCCAGTACACGCATTAAAAAGAGCAAAGCTCTTTCTGGTTTCAGTCTA\nCAAAGCTGCAGGCACAGCATCCCAGTGTTCTGCCATTCTTCATTTTACCATGACACTGAT\nTTCTTGGGAGAAGAACTGGATATTGTTGCTGCAAAAAGTCACGAGGCCTGCCAGAAACTG\nTGCACCAATGCCGTCCGCTGCCAGTTTTTTACCTATACCCCAGCCCAAGCATCCTGCAAC\nGAAGGGAAGGGCAAGTGTTACTTAAAGCTTTCTTCAAACGGATCTCCAACTAAAATACTT\nCACGGGAGAGGAGGCATCTCTGGATACACATTAAGGTTGTGTAAAATGGATAATGAGTGT\nACCACCAAAATCAAGCCCAGGATCGTTGGAGGAACTGCGTCTGTTCGTGGTGAGTGGCCG\nTGGCAGGTGACCCTGCACACAACCTCACCCACTCAGAGACACCTGTGTGGAGGCTCCATC\nATTGGAAACCAGTGGATATTAACAGCCGCTCACTGTTTCTATGGGGTAGAGTCACCTAAG\nATTTTGCGTGTCTACAGTGGCATTTTAAATCAATCTGAAATAAAAGAGGACACATCTTTC\nTTTGGGGTTCAAGAAATAATAATCCATGATCAGTATAAAATGGCAGAAAGCGGGTATGAT\nATTGCCTTGTTGAAACTGGAAACCACAGTGAATTACACAGATTCTCAACGACCCATATGC\nCTGCCTTCCAAAGGAGATAGAAATGTAATATACACTGATTGCTGGGTGACTGGATGGGGG\nTACAGAAAACTAAGAGACAAAATACAAAATACTCTCCAGAAAGCCAAGATACCCTTAGTG\nACCAACGAAGAGTGCCAGAAGAGATACAGAGGACATAAAATAACCCATAAGATGATCTGT\nGCCGGCTACAGGGAAGGAGGGAAGGACGCTTGCAAGGGAGATTCGGGAGGCCCTCTGTCC\nTGCAAACACAATGAGGTCTGGCATCTGGTAGGCATCACGAGCTGGGGCGAAGGCTGTGCT\nCAAAGGGAGCGGCCAGGTGTTTACACCAACGTGGTCGAGTACGTGGACTGGATTCTGGAG\nAAAACTCAAGCAGTGTGA"}, "pfams": {"pfam": [{"identifier": "PF00089", "name": "Trypsin"}, {"identifier": "PF00024", "name": "PAN_1"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "peptidase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "hemostasis"}, {"category": "process", "description": "blood coagulation"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}]}}}, {"@position": "3", "id": "BE0000333", "name": "Coagulation factor VII", "organism": "Human", "actions": {"action": "ligand"}, "references": "# Baker DC, Robbe SL, Jacobson L, Manco-Johnson MJ, Holler L, Lefkowitz J: Hereditary deficiency of vitamin-K-dependent coagulation factors in Rambouillet sheep. Blood Coagul Fibrinolysis. 1999 Mar;10(2):75-80. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10192655\n# Hertzberg MS, Facey SL, Hogg PJ: An Arg/Ser substitution in the second epidermal growth factor-like module of factor IX introduces an O-linked carbohydrate and markedly impairs activation by factor XIa and factor VIIa/Tissue factor and catalytic efficiency of factor IXa. Blood. 1999 Jul 1;94(1):156-63. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10381508\n# Butenas S, van't Veer C, Mann KG: \"Normal\" thrombin generation. Blood. 1999 Oct 1;94(7):2169-78. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10498586\n# Celie PH, Lenting PJ, Mertens K: Hydrophobic contact between the two epidermal growth factor-like domains of blood coagulation factor IX contributes to enzymatic activity. J Biol Chem. 2000 Jan 7;275(1):229-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10617609\n# Shord SS, Lindley CM: Coagulation products and their uses. Am J Health Syst Pharm. 2000 Aug 1;57(15):1403-17; quiz 1418-20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10938981\n# Di Scipio RG, Kurachi K, Davie EW: Activation of human factor IX (Christmas factor). J Clin Invest. 1978 Jun;61(6):1528-38. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/659613", "known-action": "yes", "polypeptide": {"@id": "P08709", "@source": "Swiss-Prot", "name": "Coagulation factor VII", "general-function": "Involved in calcium ion binding", "specific-function": "Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X to factor Xa by limited proteolysis. Factor VIIa will also convert factor IX to factor IXa in the presence of tissue factor and calcium", "gene-name": "F7", "locus": "13q34", "cellular-location": "Cytoplasmic", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.23", "molecular-weight": "51594.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3544"}, {"resource": "GenAtlas", "identifier": "F7"}, {"resource": "GeneCards", "identifier": "F7"}, {"resource": "GenBank Gene Database", "identifier": "M13232"}, {"resource": "GenBank Protein Database", "identifier": "182801"}, {"resource": "UniProtKB", "identifier": "P08709"}, {"resource": "UniProt Accession", "identifier": "FA7_HUMAN"}]}, "synonyms": {"synonym": ["Coagulation factor VII precursor", "EC 3.4.21.21", "Eptacog alfa", "Proconvertin", "Serum prothrombin conversion accelerator", "SPCA"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Coagulation factor VII precursor\nMVSQALRLLCLLLGLQGCLAAGGVAKASGGETRDMPWKPGPHRVFVTQEEAHGVLHRRRR\nANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGS\nCKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSL\nLADGVSCTPTVEYPCGKIPILEKRNASKPQGRIVGGKVCPKGECPWQVLLLVNGAQLCGG\nTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTN\nHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVL\nNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTG\nIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP"}, "gene-sequence": {"@format": "FASTA", "#text": ">1401 bp\nATGGTCTCCCAGGCCCTCAGGCTCCTCTGCCTTCTGCTTGGGCTTCAGGGCTGCCTGGCT\nGCAGGCGGGGTCGCTAAGGCCTCAGGAGGAGAAACACGGGACATGCCGTGGAAGCCGGGG\nCCTCACAGAGTCTTCGTAACCCAGGAGGAAGCCCACGGCGTCCTGCACCGGCGCCGGCGC\nGCCAACGCGTTCCTGGAGGAGCTGCGGCCGGGCTCCCTGGAGAGGGAGTGCAAGGAGGAG\nCAGTGCTCCTTCGAGGAGGCCCGGGAGATCTTCAAGGACGCGGAGAGGACGAAGCTGTTC\nTGGATTTCTTACAGTGATGGGGACCAGTGTGCCTCAAGTCCATGCCAGAATGGGGGCTCC\nTGCAAGGACCAGCTCCAGTCCTATATCTGCTTCTGCCTCCCTGCCTTCGAGGGCCGGAAC\nTGTGAGACGCACAAGGATGACCAGCTGATCTGTGTGAACGAGAACGGCGGCTGTGAGCAG\nTACTGCAGTGACCACACGGGCACCAAGCGCTCCTGTCGGTGCCACGAGGGGTACTCTCTG\nCTGGCAGACGGGGTGTCCTGCACACCCACAGTTGAATATCCATGTGGAAAAATACCTATT\nCTAGAAAAAAGAAATGCCAGCAAACCCCAAGGCCGAATTGTGGGGGGCAAGGTGTGCCCC\nAAAGGGGAGTGTCCATGGCAGGTCCTGTTGTTGGTGAATGGAGCTCAGTTGTGTGGGGGG\nACCCTGATCAACACCATCTGGGTGGTCTCCGCGGCCCACTGTTTCGACAAAATCAAGAAC\nTGGAGGAACCTGATCGCGGTGCTGGGCGAGCACGACCTCAGCGAGCACGACGGGGATGAG\nCAGAGCCGGCGGGTGGCGCAGGTCATCATCCCCAGCACGTACGTCCCGGGCACCACCAAC\nCACGACATCGCGCTGCTCCGCCTGCACCAGCCCGTGGTCCTCACTGACCATGTGGTGCCC\nCTCTGCCTGCCCGAACGGACGTTCTCTGAGAGGACGCTGGCCTTCGTGCGCTTCTCATTG\nGTCAGCGGCTGGGGCCAGCTGCTGGACCGTGGCGCCACGGCCCTGGAGCTCATGGTGCTC\nAACGTGCCCCGGCTGATGACCCAGGACTGCCTGCAGCAGTCACGGAAGGTGGGAGACTCC\nCCAAATATCACGGAGTACATGTTCTGTGCCGGCTACTCGGATGGCAGCAAGGACTCCTGC\nAAGGGGGACAGTGGAGGCCCACATGCCACCCACTACCGGGGCACGTGGTACCTGACGGGC\nATCGTCAGCTGGGGCCAGGGCTGCGCAACCGTGGGCCACTTTGGGGTGTACACCAGGGTC\nTCCCAGTACATCGAGTGGCTGCAAAAGCTCATGCGCTCAGAGCCACGCCCAGGAGTCCTC\nCTGCGAGCCCCATTTCCCTAG"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF00594", "name": "Gla"}, {"identifier": "PF00089", "name": "Trypsin"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "peptidase activity"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "cation binding"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "hemostasis"}, {"category": "process", "description": "blood coagulation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}]}}}, {"@position": "4", "id": "BE0000016", "name": "Coagulation factor VIII", "organism": "Human", "actions": {"action": "cofactor"}, "references": "# Neels JG, Bovenschen N, van Zonneveld AJ, Lenting PJ: Interaction between factor VIII and LDL receptor-related protein. Modulation of coagulation? Trends Cardiovasc Med. 2000 Jan;10(1):8-14. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11150722\n# Carr ME Jr, Martin EJ, Kuhn JG, Seremetis SV: Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion. Thromb Haemost. 2003 May;89(5):803-11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12719776\n# Federici AB: The factor VIII/von Willebrand factor complex: basic and clinical issues. Haematologica. 2003 Jun;88(6):EREP02. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12826528\n# Kalashnikova LA, Berkovskii AL, Dobrynina LA, Sergeeva EV, Kozlov AA, Aleksandrova EN, Nasonov EL: [Clotting factor VIII in Sneddon syndrome] Klin Med (Mosk). 2003;81(9):42-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14598591\n# Johansen RF, Sorensen B, Ingerslev J: Acquired haemophilia: dynamic whole blood coagulation utilized to guide haemostatic therapy. Haemophilia. 2006 Mar;12(2):190-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16476097\n# Di Scipio RG, Kurachi K, Davie EW: Activation of human factor IX (Christmas factor). J Clin Invest. 1978 Jun;61(6):1528-38. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/659613", "known-action": "yes", "polypeptide": {"@id": "P00451", "@source": "Swiss-Prot", "name": "Coagulation factor VIII", "general-function": "Involved in oxidoreductase activity", "specific-function": "Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa", "gene-name": "F8", "locus": "Xq28", "cellular-location": "Secreted protein; extracellular space", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "7.37", "molecular-weight": "267012.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3546"}, {"resource": "GenAtlas", "identifier": "F8"}, {"resource": "GeneCards", "identifier": "F8"}, {"resource": "GenBank Gene Database", "identifier": "M14113"}, {"resource": "GenBank Protein Database", "identifier": "182818"}, {"resource": "UniProtKB", "identifier": "P00451"}, {"resource": "UniProt Accession", "identifier": "FA8_HUMAN"}]}, "synonyms": {"synonym": ["AHF", "Antihemophilic factor", "Coagulation factor VIII precursor", "Procoagulant component"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Coagulation factor VIII precursor\nMQIELSTCFFLCLLRFCFSATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFN\nTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAV\nGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSH\nVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRD\nAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNH\nRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNE\nEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLA\nPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTL\nLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGP\nTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDE\nNRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILS\nIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRG\nMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNSRHPSTRQKQFNATTI\nPENDIEKTDPWFAHRTPMPKIQNVSSSDLLMLLRQSPTPHGLSLSDLQEAKYETFSDDPS\nPGAIDSNNSLSEMTHFRPQLHHSGDMVFTPESGLQLRLNEKLGTTAATELKKLDFKVSST\nSNNLISTIPSDNLAAGTDNTSSLGPPSMPVHYDSQLDTTLFGKKSSPLTESGGPLSLSEE\nNNDSKLLESGLMNSQESSWGKNVSSTESGRLFKGKRAHGPALLTKDNALFKVSISLLKTN\nKTSNNSATNRKTHIDGPSLLIENSPSVWQNILESDTEFKKVTPLIHDRMLMDKNATALRL\nNHMSNKTTSSKNMEMVQQKKEGPIPPDAQNPDMSFFKMLFLPESARWIQRTHGKNSLNSG\nQGPSPKQLVSLGPEKSVEGQNFLSEKNKVVVGKGEFTKDVGLKEMVFPSSRNLFLTNLDN\nLHENNTHNQEKKIQEEIEKKETLIQENVVLPQIHTVTGTKNFMKNLFLLSTRQNVEGSYD\nGAYAPVLQDFRSLNDSTNRTKKHTAHFSKKGEEENLEGLGNQTKQIVEKYACTTRISPNT\nSQQNFVTQRSKRALKQFRLPLEETELEKRIIVDDTSTQWSKNMKHLTPSTLTQIDYNEKE\nKGAITQSPLSDCLTRSHSIPQANRSPLPIAKVSSFPSIRPIYLTRVLFQDNSSHLPAASY\nRKKDSGVQESSHFLQGAKKNNLSLAILTLEMTGDQREVGSLGTSATNSVTYKKVENTVLP\nKPDLPKTSGKVELLPKVHIYQKDLFPTETSNGSPGHLDLVEGSLLQGTEGAIKWNEANRP\nGKVPFLRVATESSAKTPSKLLDPLAWDNHYGTQIPKEEWKSQEKSPEKTAFKKKDTILSL\nNACESNHAIAAINEGQNKPEIEVTWAKQGRTERLCSQNPPVLKRHQREITRTTLQSDQEE\nIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNR\nAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASR\nPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDV\nDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRA\nPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGH\nVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKC\nQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMII\nHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFN\nPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFA\nTWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFL\nISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRM\nEVLGCEAQDLY"}, "gene-sequence": {"@format": "FASTA", "#text": ">7056 bp\nATGCAAATAGAGCTCTCCACCTGCTTCTTTCTGTGCCTTTTGCGATTCTGCTTTAGTGCC\nACCAGAAGATACTACCTGGGTGCAGTGGAACTGTCATGGGACTATATGCAAAGTGATCTC\nGGTGAGCTGCCTGTGGACGCAAGATTTCCTCCTAGAGTGCCAAAATCTTTTCCATTCAAC\nACCTCAGTCGTGTACAAAAAGACTCTGTTTGTAGAATTCACGGATCACCTTTTCAACATC\nGCTAAGCCAAGGCCACCCTGGATGGGTCTGCTAGGTCCTACCATCCAGGCTGAGGTTTAT\nGATACAGTGGTCATTACACTTAAGAACATGGCTTCCCATCCTGTCAGTCTTCATGCTGTT\nGGTGTATCCTACTGGAAAGCTTCTGAGGGAGCTGAATATGATGATCAGACCAGTCAAAGG\nGAGAAAGAAGATGATAAAGTCTTCCCTGGTGGAAGCCATACATATGTCTGGCAGGTCCTG\nAAAGAGAATGGTCCAATGGCCTCTGACCCACTGTGCCTTACCTACTCATATCTTTCTCAT\nGTGGACCTGGTAAAAGACTTGAATTCAGGCCTCATTGGAGCCCTACTAGTATGTAGAGAA\nGGGAGTCTGGCCAAGGAAAAGACACAGACCTTGCACAAATTTATACTACTTTTTGCTGTA\nTTTGATGAAGGGAAAAGTTGGCACTCAGAAACAAAGAACTCCTTGATGCAGGATAGGGAT\nGCTGCATCTGCTCGGGCCTGGCCTAAAATGCACACAGTCAATGGTTATGTAAACAGGTCT\nCTGCCAGGTCTGATTGGATGCCACAGGAAATCAGTCTATTGGCATGTGATTGGAATGGGC\nACCACTCCTGAAGTGCACTCAATATTCCTCGAAGGTCACACATTTCTTGTGAGGAACCAT\nCGCCAGGCGTCCTTGGAAATCTCGCCAATAACTTTCCTTACTGCTCAAACACTCTTGATG\nGACCTTGGACAGTTTCTACTGTTTTGTCATATCTCTTCCCACCAACATGATGGCATGGAA\nGCTTATGTCAAAGTAGACAGCTGTCCAGAGGAACCCCAACTACGAATGAAAAATAATGAA\nGAAGCGGAAGACTATGATGATGATCTTACTGATTCTGAAATGGATGTGGTCAGGTTTGAT\nGATGACAACTCTCCTTCCTTTATCCAAATTCGCTCAGTTGCCAAGAAGCATCCTAAAACT\nTGGGTACATTACATTGCTGCTGAAGAGGAGGACTGGGACTATGCTCCCTTAGTCCTCGCC\nCCCGATGACAGAAGTTATAAAAGTCAATATTTGAACAATGGCCCTCAGCGGATTGGTAGG\nAAGTACAAAAAAGTCCGATTTATGGCATACACAGATGAAACCTTTAAGACTCGTGAAGCT\nATTCAGCATGAATCAGGAATCTTGGGACCTTTACTTTATGGGGAAGTTGGAGACACACTG\nTTGATTATATTTAAGAATCAAGCAAGCAGACCATATAACATCTACCCTCACGGAATCACT\nGATGTCCGTCCTTTGTATTCAAGGAGATTACCAAAAGGTGTAAAACATTTGAAGGATTTT\nCCAATTCTGCCAGGAGAAATATTCAAATATAAATGGACAGTGACTGTAGAAGATGGGCCA\nACTAAATCAGATCCTCGGTGCCTGACCCGCTATTACTCTAGTTTCGTTAATATGGAGAGA\nGATCTAGCTTCAGGACTCATTGGCCCTCTCCTCATCTGCTACAAAGAATCTGTAGATCAA\nAGAGGAAACCAGATAATGTCAGACAAGAGGAATGTCATCCTGTTTTCTGTATTTGATGAG\nAACCGAAGCTGGTACCTCACAGAGAATATACAACGCTTTCTCCCCAATCCAGCTGGAGTG\nCAGCTTGAGGATCCAGAGTTCCAAGCCTCCAACATCATGCACAGCATCAATGGCTATGTT\nTTTGATAGTTTGCAGTTGTCAGTTTGTTTGCATGAGGTGGCATACTGGTACATTCTAAGC\nATTGGAGCACAGACTGACTTCCTTTCTGTCTTCTTCTCTGGATATACCTTCAAACACAAA\nATGGTCTATGAAGACACACTCACCCTATTCCCATTCTCAGGAGAAACTGTCTTCATGTCG\nATGGAAAACCCAGGTCTATGGATTCTGGGGTGCCACAACTCAGACTTTCGGAACAGAGGC\nATGACCGCCTTACTGAAGGTTTCTAGTTGTGACAAGAACACTGGTGATTATTACGAGGAC\nAGTTATGAAGATATTTCAGCATACTTGCTGAGTAAAAACAATGCCATTGAACCAAGAAGC\nTTCTCCCAGAATTCAAGACACCCTAGCACTAGGCAAAAGCAATTTAATGCCACCACAATT\nCCAGAAAATGACATAGAGAAGACTGACCCTTGGTTTGCACACAGAACACCTATGCCTAAA\nATACAAAATGTCTCCTCTAGTGATTTGTTGATGCTCTTGCGACAGAGTCCTACTCCACAT\nGGGCTATCCTTATCTGATCTCCAAGAAGCCAAATATGAGACTTTTTCTGATGATCCATCA\nCCTGGAGCAATAGACAGTAATAACAGCCTGTCTGAAATGACACACTTCAGGCCACAGCTC\nCATCACAGTGGGGACATGGTATTTACCCCTGAGTCAGGCCTCCAATTAAGATTAAATGAG\nAAACTGGGGACAACTGCAGCAACAGAGTTGAAGAAACTTGATTTCAAAGTTTCTAGTACA\nTCAAATAATCTGATTTCAACAATTCCATCAGACAATTTGGCAGCAGGTACTGATAATACA\nAGTTCCTTAGGACCCCCAAGTATGCCAGTTCATTATGATAGTCAATTAGATACCACTCTA\nTTTGGCAAAAAGTCATCTCCCCTTACTGAGTCTGGTGGACCTCTGAGCTTGAGTGAAGAA\nAATAATGATTCAAAGTTGTTAGAATCAGGTTTAATGAATAGCCAAGAAAGTTCATGGGGA\nAAAAATGTATCGTCAACAGAGAGTGGTAGGTTATTTAAAGGGAAAAGAGCTCATGGACCT\nGCTTTGTTGACTAAAGATAATGCCTTATTCAAAGTTAGCATCTCTTTGTTAAAGACAAAC\nAAAACTTCCAATAATTCAGCAACTAATAGAAAGACTCACATTGATGGCCCATCATTATTA\nATTGAGAATAGTCCATCAGTCTGGCAAAATATATTAGAAAGTGACACTGAGTTTAAAAAA\nGTGACACCTTTGATTCATGACAGAATGCTTATGGACAAAAATGCTACAGCTTTGAGGCTA\nAATCATATGTCAAATAAAACTACTTCATCAAAAAACATGGAAATGGTCCAACAGAAAAAA\nGAGGGCCCCATTCCACCAGATGCACAAAATCCAGATATGTCGTTCTTTAAGATGCTATTC\nTTGCCAGAATCAGCAAGGTGGATACAAAGGACTCATGGAAAGAACTCTCTGAACTCTGGG\nCAAGGCCCCAGTCCAAAGCAATTAGTATCCTTAGGACCAGAAAAATCTGTGGAAGGTCAG\nAATTTCTTGTCTGAGAAAAACAAAGTGGTAGTAGGAAAGGGTGAATTTACAAAGGACGTA\nGGACTCAAAGAGATGGTTTTTCCAAGCAGCAGAAACCTATTTCTTACTAACTTGGATAAT\nTTACATGAAAATAATACACACAATCAAGAAAAAAAAATTCAGGAAGAAATAGAAAAGAAG\nGAAACATTAATCCAAGAGAATGTAGTTTTGCCTCAGATACATACAGTGACTGGCACTAAG\nAATTTCATGAAGAACCTTTTCTTACTGAGCACTAGGCAAAATGTAGAAGGTTCATATGAC\nGGGGCATATGCTCCAGTACTTCAAGATTTTAGGTCATTAAATGATTCAACAAATAGAACA\nAAGAAACACACAGCTCATTTCTCAAAAAAAGGGGAGGAAGAAAACTTGGAAGGCTTGGGA\nAATCAAACCAAGCAAATTGTAGAGAAATATGCATGCACCACAAGGATATCTCCTAATACA\nAGCCAGCAGAATTTTGTCACGCAACGTAGTAAGAGAGCTTTGAAACAATTCAGACTCCCA\nCTAGAAGAAACAGAACTTGAAAAAAGGATAATTGTGGATGACACCTCAACCCAGTGGTCC\nAAAAACATGAAACATTTGACCCCGAGCACCCTCACACAGATAGACTACAATGAGAAGGAG\nAAAGGGGCCATTACTCAGTCTCCCTTATCAGATTGCCTTACGAGGAGTCATAGCATCCCT\nCAAGCAAATAGATCTCCATTACCCATTGCAAAGGTATCATCATTTCCATCTATTAGACCT\nATATATCTGACCAGGGTCCTATTCCAAGACAACTCTTCTCATCTTCCAGCAGCATCTTAT\nAGAAAGAAAGATTCTGGGGTCCAAGAAAGCAGTCATTTCTTACAAGGAGCCAAAAAAAAT\nAACCTTTCTTTAGCCATTCTAACCTTGGAGATGACTGGTGATCAAAGAGAGGTTGGCTCC\nCTGGGGACAAGTGCCACAAATTCAGTCACATACAAGAAAGTTGAGAACACTGTTCTCCCG\nAAACCAGACTTGCCCAAAACATCTGGCAAAGTTGAATTGCTTCCAAAAGTTCACATTTAT\nCAGAAGGACCTATTCCCTACGGAAACTAGCAATGGGTCTCCTGGCCATCTGGATCTCGTG\nGAAGGGAGCCTTCTTCAGGGAACAGAGGGAGCGATTAAGTGGAATGAAGCAAACAGACCT\nGGAAAAGTTCCCTTTCTGAGAGTAGCAACAGAAAGCTCTGCAAAGACTCCCTCCAAGCTA\nTTGGATCCTCTTGCTTGGGATAACCACTATGGTACTCAGATACCAAAAGAAGAGTGGAAA\nTCCCAAGAGAAGTCACCAGAAAAAACAGCTTTTAAGAAAAAGGATACCATTTTGTCCCTG\nAACGCTTGTGAAAGCAATCATGCAATAGCAGCAATAAATGAGGGACAAAATAAGCCCGAA\nATAGAAGTCACCTGGGCAAAGCAAGGTAGGACTGAAAGGCTGTGCTCTCAAAACCCACCA\nGTCTTGAAACGCCATCAACGGGAAATAACTCGTACTACTCTTCAGTCAGATCAAGAGGAA\nATTGACTATGATGATACCATATCAGTTGAAATGAAGAAGGAAGATTTTGACATTTATGAT\nGAGGATGAAAATCAGAGCCCCCGCAGCTTTCAAAAGAAAACACGACACTATTTTATTGCT\nGCAGTGGAGAGGCTCTGGGATTATGGGATGAGTAGCTCCCCACATGTTCTAAGAAACAGG\nGCTCAGAGTGGCAGTGTCCCTCAGTTCAAGAAAGTTGTTTTCCAGGAATTTACTGATGGC\nTCCTTTACTCAGCCCTTATACCGTGGAGAACTAAATGAACATTTGGGACTCCTGGGGCCA\nTATATAAGAGCAGAAGTTGAAGATAATATCATGGTAACTTTCAGAAATCAGGCCTCTCGT\nCCCTATTCCTTCTATTCTAGCCTTATTTCTTATGAGGAAGATCAGAGGCAAGGAGCAGAA\nCCTAGAAAAAACTTTGTCAAGCCTAATGAAACCAAAACTTACTTTTGGAAAGTGCAACAT\nCATATGGCACCCACTAAAGATGAGTTTGACTGCAAAGCCTGGGCTTATTTCTCTGATGTT\nGACCTGGAAAAAGATGTGCACTCAGGCCTGATTGGACCCCTTCTGGTCTGCCACACTAAC\nACACTGAACCCTGCTCATGGGAGACAAGTGACAGTACAGGAATTTGCTCTGTTTTTCACC\nATCTTTGATGAGACCAAAAGCTGGTACTTCACTGAAAATATGGAAAGAAACTGCAGGGCT\nCCCTGCAATATCCAGATGGAAGATCCCACTTTTAAAGAGAATTATCGCTTCCATGCAATC\nAATGGCTACATAATGGATACACTACCTGGCTTAGTAATGGCTCAGGATCAAAGGATTCGA\nTGGTATCTGCTCAGCATGGGCAGCAATGAAAACATCCATTCTATTCATTTCAGTGGACAT\nGTGTTCACTGTACGAAAAAAAGAGGAGTATAAAATGGCACTGTACAATCTCTATCCAGGT\nGTTTTTGAGACAGTGGAAATGTTACCATCCAAAGCTGGAATTTGGCGGGTGGAATGCCTT\nATTGGCGAGCATCTACATGCTGGGATGAGCACACTTTTTCTGGTGTACAGCAATAAGTGT\nCAGACTCCCCTGGGAATGGCTTCTGGACACATTAGAGATTTTCAGATTACAGCTTCAGGA\nCAATATGGACAGTGGGCCCCAAAGCTGGCCAGACTTCATTATTCCGGATCAATCAATGCC\nTGGAGCACCAAGGAGCCCTTTTCTTGGATCAAGGTGGATCTGTTGGCACCAATGATTATT\nCACGGCATCAAGACCCAGGGTGCCCGTCAGAAGTTCTCCAGCCTCTACATCTCTCAGTTT\nATCATCATGTATAGTCTTGATGGGAAGAAGTGGCAGACTTATCGAGGAAATTCCACTGGA\nACCTTAATGGTCTTCTTTGGCAATGTGGATTCATCTGGGATAAAACACAATATTTTTAAC\nCCTCCAATTATTGCTCGATACATCCGTTTGCACCCAACTCATTATAGCATTCGCAGCACT\nCTTCGCATGGAGTTGATGGGCTGTGATTTAAATAGTTGCAGCATGCCATTGGGAATGGAG\nAGTAAAGCAATATCAGATGCACAGATTACTGCTTCATCCTACTTTACCAATATGTTTGCC\nACCTGGTCTCCTTCAAAAGCTCGACTTCACCTCCAAGGGAGGAGTAATGCCTGGAGACCT\nCAGGTGAATAATCCAAAAGAGTGGCTGCAAGTGGACTTCCAGAAGACAATGAAAGTCACA\nGGAGTAACTACTCAGGGAGTAAAATCTCTGCTTACCAGCATGTATGTGAAGGAGTTCCTC\nATCTCCAGCAGTCAAGATGGCCATCAGTGGACTCTCTTTTTTCAGAATGGCAAAGTAAAG\nGTTTTTCAGGGAAATCAAGACTCCTTCACACCTGTGGTGAACTCTCTAGACCCACCGTTA\nCTGACTCGCTACCTTCGAATTCACCCCCAGAGTTGGGTGCACCAGATTGCCCTGAGGATG\nGAGGTTCTGGGCTGCGAGGCACAGGACCTCTACTGA"}, "pfams": {"pfam": [{"identifier": "PF00394", "name": "Cu-oxidase"}, {"identifier": "PF07731", "name": "Cu-oxidase_2"}, {"identifier": "PF07732", "name": "Cu-oxidase_3"}, {"identifier": "PF00754", "name": "F5_F8_type_C"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "binding"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "oxidoreductase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "transition metal ion binding"}, {"category": "function", "description": "copper ion binding"}, {"category": "process", "description": "cell adhesion"}, {"category": "process", "description": "cellular process"}]}}}, {"@position": "5", "id": "BE0000048", "name": "Prothrombin", "organism": "Human", "actions": null, "references": "# Butenas S, van't Veer C, Mann KG: \"Normal\" thrombin generation. Blood. 1999 Oct 1;94(7):2169-78. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10498586\n# Kohler M: Thrombogenicity of prothrombin complex concentrates. Thromb Res. 1999 Aug 15;95(4 Suppl 1):S13-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10499904\n# Seitz R, Dodt J: Virus safety of prothrombin complex concentrates and factor IX concentrates. Thromb Res. 1999 Aug 15;95(4 Suppl 1):S19-23. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10499905\n# Samis JA, Ramsey GD, Walker JB, Nesheim ME, Giles AR: Proteolytic processing of human coagulation factor IX by plasmin. Blood. 2000 Feb 1;95(3):943-51. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10648407\n# Bauer KA, Humphries S, Smillie B, Li L, Cooper JA, Barzegar S, Rosenberg RD, Miller GJ: Prothrombin activation is increased among asymptomatic carriers of the prothrombin G20210A and factor V Arg506Gln mutations. Thromb Haemost. 2000 Sep;84(3):396-400. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11019961", "known-action": "unknown", "polypeptide": {"@id": "P00734", "@source": "Swiss-Prot", "name": "Prothrombin", "general-function": "Involved in blood clotting cascade", "specific-function": "Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C", "gene-name": "F2", "locus": "11p11-q12", "cellular-location": "Secreted protein; extracellular space", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "5.7", "molecular-weight": "70037.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:3535"}, {"resource": "GenAtlas", "identifier": "F2"}, {"resource": "GeneCards", "identifier": "F2"}, {"resource": "GenBank Gene Database", "identifier": "M17262"}, {"resource": "GenBank Protein Database", "identifier": "339641"}, {"resource": "UniProtKB", "identifier": "P00734"}, {"resource": "UniProt Accession", "identifier": "THRB_HUMAN"}]}, "synonyms": {"synonym": ["Activated Factor II [IIa]", "Coagulation factor II", "EC 3.4.21.5", "Prothrombin precursor", "Thrombin"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Prothrombin precursor\nMAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC\nVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV\nNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE\nCSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA\nQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG\nDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI\nDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN\nDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP\nVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST\nRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY\nGFYTHVFRLKKWIQKVIDQFGE"}, "gene-sequence": {"@format": "FASTA", "#text": ">1869 bp\nATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC\nCTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG\nGTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTAGAGCGAGAGTGC\nGTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG\nGATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT\nGCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG\nAACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT\nGAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC\nGACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA\nTGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA\nGGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG\nTACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA\nCAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC\nTTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT\nGGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA\nGATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC\nCAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT\nCTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC\nGACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG\nCTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG\nGTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT\nGACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACAAGGTACGAGCGAAACATTGAAAAG\nATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC\nCGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT\nGTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG\nGTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC\nAGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC\nCGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA\nGGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC\nCGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT\nGGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT\nGGAGAGTAG"}, "pfams": {"pfam": [{"identifier": "PF00594", "name": "Gla"}, {"identifier": "PF00051", "name": "Kringle"}, {"identifier": "PF00089", "name": "Trypsin"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "extracellular region"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "thrombin activity"}, {"category": "function", "description": "hydrolase activity"}, {"category": "function", "description": "calcium ion binding"}, {"category": "function", "description": "peptidase activity"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "endopeptidase activity"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "serine-type endopeptidase activity"}, {"category": "function", "description": "binding"}, {"category": "process", "description": "hemostasis"}, {"category": "process", "description": "blood coagulation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "protein metabolism"}, {"category": "process", "description": "proteolysis"}, {"category": "process", "description": "cellular protein metabolism"}, {"category": "process", "description": "organismal physiological process"}, {"category": "process", "description": "regulation of body fluids"}, {"category": "process", "description": "physiological process"}]}}}, {"@position": "6", "id": "BE0002110", "name": "Prolow-density lipoprotein receptor-related protein 1", "organism": "Human", "actions": null, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Rohlena J, Kolkman JA, Boertjes RC, Mertens K, Lenting PJ: Residues Phe342-Asn346 of activated coagulation factor IX contribute to the interaction with low density lipoprotein receptor-related protein. J Biol Chem. 2003 Mar 14;278(11):9394-401. Epub 2003 Jan 9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12522212", "known-action": "unknown", "polypeptide": {"@id": "Q07954", "@source": "Swiss-Prot", "name": "Prolow-density lipoprotein receptor-related protein 1", "general-function": null, "specific-function": "Required for early embryonic development. Involved in the plasma clearance of chylomicron remnants and activated alpha 2-macroglobulin, as well as the local metabolism of complexes between plasminogen activators and their endogenous inhibitors. May modulate APP metabolism, kinase-dependent intracellular signaling, neuronal calcium signaling as well as neurotransmission", "gene-name": "LRP1", "locus": "12q13-q14", "cellular-location": "Cell membrane", "transmembrane-regions": "4420-4444", "signal-regions": null, "theoretical-pi": "5.02", "molecular-weight": "504578.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:6692"}, {"resource": "GenAtlas", "identifier": "LRP1"}, {"resource": "GeneCards", "identifier": "LRP1"}, {"resource": "GenBank Gene Database", "identifier": "X13916"}, {"resource": "GenBank Protein Database", "identifier": "34339"}, {"resource": "UniProtKB", "identifier": "Q07954"}, {"resource": "UniProt Accession", "identifier": "LRP1_HUMAN"}]}, "synonyms": {"synonym": ["A2MR", "Alpha-2-macroglobulin receptor", "APOER", "Apolipoprotein E receptor", "CD91 antigen", "Low-density lipoprotein receptor-related protein 1 precursor", "LRP"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Low-density lipoprotein receptor-related protein 1\nMLTPPLLLLLPLLSALVAAAIDAPKTCSPKQFACRDQITCISKGWRCDGERDCPDGSDEA\nPEICPQSKAQRCQPNEHNCLGTELCVPMSRLCNGVQDCMDGSDEGPHCRELQGNCSRLGC\nQHHCVPTLDGPTCYCNSSFQLQADGKTCKDFDECSVYGTCSQLCTNTDGSFICGCVEGYL\nLQPDNRSCKAKNEPVDRPPVLLIANSQNILATYLSGAQVSTITPTSTRQTTAMDFSYANE\nTVCWVHVGDSAAQTQLKCARMPGLKGFVDEHTINISLSLHHVEQMAIDWLTGNFYFVDDI\nDDRIFVCNRNGDTCVTLLDLELYNPKGIALDPAMGKVFFTDYGQIPKVERCDMDGQNRTK\nLVDSKIVFPHGITLDLVSRLVYWADAYLDYIEVVDYEGKGRQTIIQGILIEHLYGLTVFE\nNYLYATNSDNANAQQKTSVIRVNRFNSTEYQVVTRVDKGGALHIYHQRRQPRVRSHACEN\nDQYGKPGGCSDICLLANSHKARTCRCRSGFSLGSDGKSCKKPEHELFLVYGKGRPGIIRG\nMDMGAKVPDEHMIPIENLMNPRALDFHAETGFIYFADTTSYLIGRQKIDGTERETILKDG\nIHNVEGVAVDWMGDNLYWTDDGPKKTISVARLEKAAQTRKTLIEGKMTHPRAIVVDPLNG\nWMYWTDWEEDPKDSRRGRLERAWMDGSHRDIFVTSKTVLWPNGLSLDIPAGRLYWVDAFY\nDRIETILLNGTDRKIVYEGPELNHAFGLCHHGNYLFWTEYRSGSVYRLERGVGGAPPTVT\nLLRSERPPIFEIRMYDAQQQQVGTNKCRVNNGGCSSLCLATPGSRQCACAEDQVLDADGV\nTCLANPSYVPPPQCQPGEFACANSRCIQERWKCDGDNDCLDNSDEAPALCHQHTCPSDRF\nKCENNRCIPNRWLCDGDNDCGNSEDESNATCSARTCPPNQFSCASGRCIPISWTCDLDDD\nCGDRSDESASCAYPTCFPLTQFTCNNGRCININWRCDNDNDCGDNSDEAGCSHSCSSTQF\nKCNSGRCIPEHWTCDGDNDCGDYSDETHANCTNQATRPPGGCHTDEFQCRLDGLCIPLRW\nRCDGDTDCMDSSDEKSCEGVTHVCDPSVKFGCKDSARCISKAWVCDGDNDCEDNSDEENC\nESLACRPPSHPCANNTSVCLPPDKLCDGNDDCGDGSDEGELCDQCSLNNGGCSHNCSVAP\nGEGIVCSCPLGMELGPDNHTCQIQSYCAKHLKCSQKCDQNKFSVKCSCYEGWVLEPDGES\nCRSLDPFKPFIIFSNRHEIRRIDLHKGDYSVLVPGLRNTIALDFHLSQSALYWTDVVEDK\nIYRGKLLDNGALTSFEVVIQYGLATPEGLAVDWIAGNIYWVESNLDQIEVAKLDGTLRTT\nLLAGDIEHPRAIALDPRDGILFWTDWDASLPRIEAASMSGAGRRTVHRETGSGGWPNGLT\nVDYLEKRILWIDARSDAIYSARYDGSGHMEVLRGHEFLSHPFAVTLYGGEVYWTDWRTNT\nLAKANKWTGHNVTVVQRTNTQPFDLQVYHPSRQPMAPNPCEANGGQGPCSHLCLINYNRT\nVSCACPHLMKLHKDNTTCYEFKKFLLYARQMEIRGVDLDAPYYNYIISFTVPDIDNVTVL\nDYDAREQRVYWSDVRTQAIKRAFINGTGVETVVSADLPNAHGLAVDWVSRNLFWTSYDTN\nKKQINVARLDGSFKNAVVQGLEQPHGLVVHPLRGKLYWTDGDNISMANMDGSNRTLLFSG\nQKGPVGLAIDFPESKLYWISSGNHTINRCNLDGSGLEVIDAMRSQLGKATALAIMGDKLW\nWADQVSEKMGTCSKADGSGSVVLRNSTTLVMHMKVYDESIQLDHKGTNPCSVNNGDCSQL\nCLPTSETTRSCMCTAGYSLRSGQQACEGVGSFLLYSVHEGIRGIPLDPNDKSDALVPVSG\nTSLAVGIDFHAENDTIYWVDMGLSTISRAKRDQTWREDVVTNGIGRVEGIAVDWIAGNIY\nWTDQGFDVIEVARLNGSFRYVVISQGLDKPRAITVHPEKGYLFWTEWGQYPRIERSRLDG\nTERVVLVNVSISWPNGISVDYQDGKLYWCDARTDKIERIDLETGENREVVLSSNNMDMFS\nVSVFEDFIYWSDRTHANGSIKRGSKDNATDSVPLRTGIGVQLKDIKVFNRDRQKGTNVCA\nVANGGCQQLCLYRGRGQRACACAHGMLAEDGASCREYAGYLLYSERTILKSIHLSDERNL\nNAPVQPFEDPEHMKNVIALAFDYRAGTSPGTPNRIFFSDIHFGNIQQINDDGSRRITIVE\nNVGSVEGLAYHRGWDTLYWTSYTTSTITRHTVDQTRPGAFERETVITMSGDDHPRAFVLD\nECQNLMFWTNWNEQHPSIMRAALSGANVLTLIEKDIRTPNGLAIDHRAEKLYFSDATLDK\nIERCEYDGSHRYVILKSEPVHPFGLAVYGEHIFWTDWVRRAVQRANKHVGSNMKLLRVDI\nPQQPMGIIAVANDTNSCELSPCRINNGGCQDLCLLTHQGHVNCSCRGGRILQDDLTCRAV\nNSSCRAQDEFECANGECINFSLTCDGVPHCKDKSDEKPSYCNSRRCKKTFRQCSNGRCVS\nNMLWCNGADDCGDGSDEIPCNKTACGVGEFRCRDGTCIGNSSRCNQFVDCEDASDEMNCS\nATDCSSYFRLGVKGVLFQPCERTSLCYAPSWVCDGANDCGDYSDERDCPGVKRPRCPLNY\nFACPSGRCIPMSWTCDKEDDCEHGEDETHCNKFCSEAQFECQNHRCISKQWLCDGSDDCG\nDGSDEAAHCEGKTCGPSSFSCPGTHVCVPERWLCDGDKDCADGADESIAAGCLYNSTCDD\nREFMCQNRQCIPKHFVCDHDRDCADGSDESPECEYPTCGPSEFRCANGRCLSSRQWECDG\nENDCHDQSDEAPKNPHCTSPEHKCNASSQFLCSSGRCVAEALLCNGQDDCGDSSDERGCH\nINECLSRKLSGCSQDCEDLKIGFKCRCRPGFRLKDDGRTCADVDECSTTFPCSQRCINTH\nGSYKCLCVEGYAPRGGDPHSCKAVTDEEPFLIFANRYYLRKLNLDGSNYTLLKQGLNNAV\nALDFDYREQMIYWTDVTTQGSMIRRMHLNGSNVQVLHRTGLSNPDGLAVDWVGGNLYWCD\nKGRDTIEVSKLNGAYRTVLVSSGLREPRALVVDVQNGYLYWTDWGDHSLIGRIGMDGSSR\nSVIVDTKITWPNGLTLDYVTERIYWADAREDYIEFASLDGSNRHVVLSQDIPHIFALTLF\nEDYVYWTDWETKSINRAHKTTGTNKTLLISTLHRPMDLHVFHALRQPDVPNHPCKVNNGG\nCSNLCLLSPGGGHKCACPTNFYLGSDGRTCVSNCTASQFVCKNDKCIPFWWKCDTEDDCG\nDHSDEPPDCPEFKCRPGQFQCSTGICTNPAFICDGDNDCQDNSDEANCDIHVCLPSQFKC\nTNTNRCIPGIFRCNGQDNCGDGEDERDCPEVTCAPNQFQCSITKRCIPRVWVCDRDNDCV\nDGSDEPANCTQMTCGVDEFRCKDSGRCIPARWKCDGEDDCGDGSDEPKEECDERTCEPYQ\nFRCKNNRCVPGRWQCDYDNDCGDNSDEESCTPRPCSESEFSCANGRCIAGRWKCDGDHDC\nADGSDEKDCTPRCDMDQFQCKSGHCIPLRWRCDADADCMDGSDEEACGTGVRTCPLDEFQ\nCNNTLCKPLAWKCDGEDDCGDNSDENPEECARFVCPPNRPFRCKNDRVCLWIGRQCDGTD\nNCGDGTDEEDCEPPTAHTTHCKDKKEFLCRNQRCLSSSLRCNMFDDCGDGSDEEDCSIDP\nKLTSCATNASICGDEARCVRTEKAAYCACRSGFHTVPGQPGCQDINECLRFGTCSQLCNN\nTKGGHLCSCARNFMKTHNTCKAEGSEYQVLYIADDNEIRSLFPGHPHSAYEQAFQGDESV\nRIDAMDVHVKAGRVYWTNWHTGTISYRSLPPAAPPTTSNRHRRQIDRGVTHLNISGLKMP\nRGIAIDWVAGNVYWTDSGRDVIEVAQMKGENRKTLISGMIDEPHAIVVDPLRGTMYWSDW\nGNHPKIETAAMDGTLRETLVQDNIQWPTGLAVDYHNERLYWADAKLSVIGSIRLNGTDPI\nVAADSKRGLSHPFSIDVFEDYIYGVTYINNRVFKIHKFGHSPLVNLTGGLSHASDVVLYH\nQHKQPEVTNPCDRKKCEWLCLLSPSGPVCTCPNGKRLDNGTCVPVPSPTPPPDAPRPGTC\nNLQCFNGGSCFLNARRQPKCRCQPRYTGDKCELDQCWEHCRNGGTCAASPSGMPTCRCPT\nGFTGPKCTQQVCAGYCANNSTCTVNQGNQPQCRCLPGFLGDRCQYRQCSGYCENFGTCQM\nAADGSRQCRCTAYFEGSRCEVNKCSRCLEGACVVNKQSGDVTCNCTDGRVAPSCLTCVGH\nCSNGGSCTMNSKMMPECQCPPHMTGPRCEEHVFSQQQPGHIASILIPLLLLLLLVLVAGV\nVFWYKRRVQGAKGFQHQRMTNGAMNVEIGNPTYKMYEGGEPDDVGGLLDADFALDPDKPT\nNFTNPVYATLYMGGHGSRHSLASTDEKRELLGRGPEDEIGDPLA"}, "gene-sequence": {"@format": "FASTA", "#text": ">13635 bp\nATGCTGACCCCGCCGTTGCTCCTGCTGCTGCCCCTGCTCTCAGCTCTGGTCGCGGCGGCT\nATCGACGCCCCTAAGACTTGCAGCCCCAAGCAGTTTGCCTGCAGAGATCAAATAACCTGT\nATCTCAAAGGGCTGGCGGTGCGACGGTGAGAGGGACTGCCCAGACGGATCTGACGAGGCC\nCCTGAGATTTGTCCACAGAGTAAGGCCCAGCGATGCCAGCCAAACGAGCATAACTGCCTG\nGGTACTGAGCTGTGTGTTCCCATGTCCCGCCTCTGCAATGGGGTCCAGGACTGCATGGAC\nGGCTCAGATGAGGGGCCCCACTGCCGAGAGCTCCAAGGCAACTGCTCTCGCCTGGGCTGC\nCAGCACCATTGTGTCCCCACACTCGATGGGCCCACCTGCTACTGCAACAGCAGCTTTCAG\nCTTCAGGCAGATGGCAAGACCTGCAAAGATTTTGATGAGTGCTCAGTGTACGGCACCTGC\nAGCCAGCTATGCACCAACACAGACGGCTCCTTCATATGTGGCTGTGTTGAAGGATACCTC\nCTGCAGCCGGATAACCGCTCCTGCAAGGCCAAGAACGAGCCAGTAGACCGGCCCCCTGTG\nCTGTTGATAGCCAACTCCCAGAACATCTTGGCCACGTACCTGAGTGGGGCCCAGGTGTCT\nACCATCACACCTACGAGCACGCGGCAGACCACAGCCATGGACTTCAGCTATGCCAACGAG\nACCGTATGCTGGGTGCATGTTGGGGACAGTGCTGCTCAGACGCAGCTCAAGTGTGCCCGC\nATGCCTGGCCTAAAGGGCTTCGTGGATGAGCACACCATCAACATCTCCCTCAGTCTGCAC\nCACGTGGAACAGATGGCCATCGACTGGCTGACAGGCAACTTCTACTTTGTGGATGACATC\nGATGATAGGATCTTTGTCTGCAACAGAAATGGGGACACATGTGTCACATTGCTAGACCTG\nGAACTCTACAACCCCAAGGGCATTGCCCTGGACCCTGCCATGGGGAAGGTGTTTTTCACT\nGACTATGGGCAGATCCCAAAGGTGGAACGCTGTGACATGGATGGGCAGAACCGCACCAAG\nCTCGTCGACAGCAAGATTGTGTTTCCTCATGGCATCACGCTGGACCTGGTCAGCCGCCTT\nGTCTACTGGGCAGATGCCTATCTGGACTATATTGAAGTGGTGGACTATGAGGGCAAGGGC\nCGCCAGACCATCATCCAGGGCATCCTGATTGAGCACCTGTACGGCCTGACTGTGTTTGAG\nAATTATCTCTATGCCACCAACTCGGACAATGCCAATGCCCAGCAGAAGACGAGTGTGATC\nCGTGTGAACCGCTTTAACAGCACCGAGTACCAGGTTGTCACCCGGGTGGACAAGGGTGGT\nGCCCTCCACATCTACCACCAGAGGCGTCAGCCCCGAGTGAGGAGCCATGCCTGTGAAAAC\nGACCAGTATGGGAAGCCGGGTGGCTGCTCTGACATCTGCCTGCTGGCCAACAGCCACAAG\nGCGCGGACCTGCCGCTGCCGTTCCGGCTTCAGCCTGGGCAGTGACGGGAAGTCATGCAAG\nAAGCCGGAGCATGAGCTGTTCCTCGTGTATGGCAAGGGCCGGCCAGGCATCATCCGGGGC\nATGGATATGGGGGCCAAGGTCCCGGATGAGCACATGATCCCCATTGAAAACCTCATGAAC\nCCCCGAGCCCTGGACTTCCACGCTGAGACCGGCTTCATCTACTTTGCCGACACCACCAGC\nTACCTCATTGGCCGCCAGAAGATTGATGGCACTGAGCGGGAGACCATCCTGAAGGACGGC\nATCCACAATGTGGAGGGTGTGGCCGTGGACTGGATGGGAGACAATCTGTACTGGACGGAC\nGATGGGCCCAAAAAGACAATCAGCGTGGCCAGGCTGGAGAAAGCTGCTCAGACCCGCAAG\nACTTTAATCGAGGGCAAAATGACACACCCCAGGGCTATTGTGGTGGATCCACTCAATGGG\nTGGATGTACTGGACAGACTGGGAGGAGGACCCCAAGGACAGTCGGCGTGGGCGGCTGGAG\nAGGGCGTGGATGGATGGCTCACACCGAGACATCTTTGTCACCTCCAAGACAGTGCTTTGG\nCCCAATGGGCTAAGCCTGGACATCCCGGCTGGGCGCCTCTACTGGGTGGATGCCTTCTAC\nGACCGCATCGAGACGATACTGCTCAATGGCACAGACCGGAAGATTGTGTATGAAGGTCCT\nGAGCTGAACCACGCCTTTGGCCTGTGTCACCATGGCAACTACCTCTTCTGGACTGAGTAT\nCGGAGTGGCAGTGTCTACCGCTTGGAACGGGGTGTAGGAGGCGCACCCCCCACTGTGACC\nCTTCTGCGCAGTGAGCGGCCCCCCATCTTTGAGATCCGAATGTATGATGCCCAGCAGCAG\nCAAGTTGGCACCAACAAATGCCGGGTGAACAATGGCGGCTGCAGCAGCCTGTGCTTGGCC\nACCCCTGGGAGCCGCCAGTGCGCCTGTGCTGAGGACCAGGTGTTGGACGCAGACGGCGTC\nACTTGCTTGGCGAACCCATCCTACGTGCCTCCACCCCAGTGCCAGCCAGGCGAGTTTGCC\nTGTGCCAACAGCCGCTGCATCCAGGAGCGCTGGAAGTGTGACGGAGACAACGATTGCCTG\nGACAACAGTGATGAGGCCCCAGCCCTCTGCCATCAGCACACCTGCCCCTCGGACCGATTC\nAAGTGCGAGAACAACCGGTGCATCCCCAACCGCTGGCTCTGCGACGGGGACAATGACTGT\nGGGAACAGTGAAGATGAGTCCAATGCCACTTGTTCAGCCCGCACCTGCCCCCCCAACCAG\nTTCTCCTGTGCCAGTGGCCGCTGCATCCCCATCTCCTGGACGTGTGATCTGGATGACGAC\nTGTGGGGACCGCTCTGATGAGTCTGCTTCGTGTGCCTATCCCACCTGCTTCCCCCTGACT\nCAGTTTACCTGCAACAATGGCAGATGTATCAACATCAACTGGAGATGCGACAATGACAAT\nGACTGTGGGGACAACAGTGACGAAGCCGGCTGCAGCCACTCCTGTTCTAGCACCCAGTTC\nAAGTGCAACAGCGGGCGTTGCATCCCCGAGCACTGGACCTGCGATGGGGACAATGACTGC\nGGAGACTACAGTGATGAGACACACGCCAACTGCACCAACCAGGCCACGAGGCCCCCTGGT\nGGCTGCCACACTGATGAGTTCCAGTGCCGGCTGGATGGACTATGCATCCCCCTGCGGTGG\nCGCTGCGATGGGGACACTGACTGCATGGACTCCAGCGATGAGAAGAGCTGTGAGGGAGTG\nACCCACGTCTGCGATCCCAGTGTCAAGTTTGGCTGCAAGGACTCAGCTCGGTGCATCAGC\nAAAGCGTGGGTGTGTGATGGCGACAATGACTGTGAGGATAACTCGGACGAGGAGAACTGC\nGAGTCCCTGGCCTGCAGGCCACCCTCGCACCCTTGTGCCAACAACACCTCAGTCTGCCTG\nCCCCCTGACAAGCTGTGTGATGGCAACGACGACTGTGGCGACGGCTCAGATGAGGGCGAG\nCTCTGCGACCAGTGCTCTCTGAATAACGGTGGCTGCAGCCACAACTGCTCAGTGGCACCT\nGGCGAAGGCATTGTGTGTTCCTGCCCTCTGGGCATGGAGCTGGGGCCCGACAACCACACC\nTGCCAGATCCAGAGCTACTGTGCCAAGCATCTCAAATGCAGCCAAAAGTGCGACCAGAAC\nAAGTTCAGCGTGAAGTGCTCCTGCTACGAGGGCTGGGTCCTGGAACCTGACGGCGAGAGC\nTGCCGCAGCCTGGACCCCTTCAAGCCGTTCATCATTTTCTCCAACCGCCATGAAATCCGG\nCGCATCGATCTTCACAAAGGAGACTACAGCGTCCTGGTGCCCGGCCTGCGCAACACCATC\nGCCCTGGACTTCCACCTCAGCCAGAGCGCCCTCTACTGGACCGACGTGGTGGAGGACAAG\nATCTACCGCGGGAAGCTGCTGGACAACGGAGCCCTGACTAGTTTCGAGGTGGTGATTCAG\nTATGGCCTGGCCACACCCGAGGGCCTGGCTGTAGACTGGATTGCAGGCAACATCTACTGG\nGTGGAGAGTAACCTGGATCAGATCGAGGTGGCCAAGCTGGATGGGACCCTCCGGACCACC\nCTGCTGGCCGGTGACATTGAGCACCCAAGGGCAATCGCACTGGATCCCCGGGATGGGATC\nCTGTTTTGGACAGACTGGGATGCCAGCCTGCCCCGCATTGAGGCAGCCTCCATGAGTGGG\nGCTGGGCGCCGCACCGTGCACCGGGAGACCGGCTCTGGGGGCTGGCCCAACGGGCTCACC\nGTGGACTACCTGGAGAAGCGCATCCTTTGGATTGACGCCAGGTCAGATGCCATTTACTCA\nGCCCGTTACGACGGCTCTGGCCACATGGAGGTGCTTCGGGGACACGAGTTCCTGTCGCAC\nCCGTTTGCAGTGACGCTGTACGGGGGGGAGGTCTACTGGACTGACTGGCGAACAAACACA\nCTGGCTAAGGCCAACAAGTGGACCGGCCACAATGTCACCGTGGTACAGAGGACCAACACC\nCAGCCCTTTGACCTGCAGGTGTACCACCCCTCCCGCCAGCCCATGGCTCCCAATCCCTGT\nGAGGCCAATGGGGGCCAGGGCCCCTGCTCCCACCTGTGTCTCATCAACTACAACCGGACC\nGTGTCCTGCGCCTGCCCCCACCTCATGAAGCTCCACAAGGACAACACCACCTGCTATGAG\nTTTAAGAAGTTCCTGCTGTACGCACGTCAGATGGAGATCCGAGGTGTGGACCTGGATGCT\nCCCTACTACAACTACATCATCTCCTTCACGGTGCCCGACATCGACAACGTCACAGTGCTA\nGACTACGATGCCCGCGAGCAGCGTGTGTACTGGTCTGACGTGCGGACACAGGCCATCAAG\nCGGGCCTTCATCAACGGCACAGGCGTGGAGACAGTCGTCTCTGCAGACTTGCCAAATGCC\nCACGGGCTGGCTGTGGACTGGGTCTCCCGAAACCTGTTCTGGACAAGCTATGACACCAAT\nAAGAAGCAGATCAATGTGGCCCGGCTGGATGGCTCCTTCAAGAACGCAGTGGTGCAGGGC\nCTGGAGCAGCCCCATGGCCTTGTCGTCCACCCTCTGCGTGGGAAGCTCTACTGGACCGAT\nGGTGACAACATCAGCATGGCCAACATGGATGGCAGCAATCGCACCCTGCTCTTCAGTGGC\nCAGAAGGGCCCCGTGGGCCTGGCTATTGACTTCCCTGAAAGCAAACTCTACTGGATCAGC\nTCCGGGAACCATACCATCAACCGCTGCAACCTGGATGGGAGTGGGCTGGAGGTCATCGAT\nGCCATGCGGAGCCAGCTGGGCAAGGCCACCGCCCTGGCCATCATGGGGGACAAGCTGTGG\nTGGGCTGATCAGGTGTCGGAAAAGATGGGCACATGCAGCAAGGCTGACGGCTCGGGCTCC\nGTGGTCCTTCGGAACAGCACCACCCTGGTGATGCACATGAAGGTCTATGACGAGAGCATC\nCAGCTGGACCATAAGGGCACCAACCCCTGCAGTGTCAACAACGGTGACTGCTCCCAGCTC\nTGCCTGCCCACGTCAGAGACGACCCGCTCCTGCATGTGCACAGCCGGCTATAGCCTCCGG\nAGTGGCCAGCAGGCCTGCGAGGGCGTAGGTTCCTTTCTCCTGTACTCTGTGCATGAGGGA\nATCAGGGGAATTCCCCTGGATCCCAATGACAAGTCAGATGCCCTGGTCCCAGTGTCCGGG\nACCTCGCTGGCTGTCGGCATCGACTTCCACGCTGAAAATGACACCATCTACTGGGTGGAC\nATGGGCCTGAGCACGATCAGCCGGGCCAAGCGGGACCAGACGTGGCGTGAAGACGTGGTG\nACCAATGGCATTGGCCGTGTGGAGGGCATTGCAGTGGACTGGATCGCAGGCAACATCTAC\nTGGACAGACCAGGGCTTTGATGTCATCGAGGTCGCCCGGCTCAATGGCTCCTTCCGCTAC\nGTGGTGATCTCCCAGGGTCTAGACAAGCCCCGGGCCATCACCGTCCACCCGGAGAAAGGG\nTACTTGTTCTGGACTGAGTGGGGTCAGTATCCGCGTATTGAGCGGTCTCGGCTAGATGGC\nACGGAGCGTGTGGTGCTGGTCAACGTCAGCATCAGCTGGCCCAACGGCATCTCAGTGGAC\nTACCAGGATGGGAAGCTGTACTGGTGCGATGCACGGACAGACAAGATTGAACGGATCGAC\nCTGGAGACAGGTGAGAACCGCGAGGTGGTTCTGTCCAGCAACAACATGGACATGTTTTCA\nGTGTCTGTGTTTGAGGATTTCATCTACTGGAGTGACAGGACTCATGCCAACGGCTCTATC\nAAGCGCGGGAGCAAAGACAATGCCACAGACTCCGTGCCCCTGCGAACCGGCATCGGCGTC\nCAGCTTAAAGACATCAAAGTCTTCAACCGGGACCGGCAGAAAGGCACCAACGTGTGCGCG\nGTGGCCAATGGCGGGTGCCAGCAGCTGTGCCTGTACCGGGGCCGTGGGCAGCGGGCCTGC\nGCCTGTGCCCACGGGATGCTGGCTGAAGACGGAGCATCGTGCCGCGAGTATGCCGGCTAC\nCTGCTCTACTCAGAGCGCACCATTCTCAAGAGTATCCACCTGTCGGATGAGCGCAACCTC\nAATGCGCCCGTGCAGCCCTTCGAGGACCCTGAGCACATGAAGAACGTCATCGCCCTGGCC\nTTTGACTACCGGGCAGGCACCTCTCCGGGCACCCCCAATCGCATCTTCTTCAGCGACATC\nCACTTTGGGAACATCCAACAGATCAACGACGATGGCTCCAGGAGGATCACCATTGTGGAA\nAACGTGGGCTCCGTGGAAGGCCTGGCCTATCACCGTGGCTGGGACACTCTCTATTGGACA\nAGCTACACGACATCCACCATCACGCGCCACACAGTGGACCAGACCCGCCCAGGGGCCTTC\nGAGCGTGAGACCGTCATCACTATGTCTGGAGATGACCACCCACGGGCCTTCGTTTTGGAC\nGAGTGCCAGAACCTCATGTTCTGGACCAACTGGAATGAGCAGCATCCCAGCATCATGCGG\nGCGGCGCTCTCGGGAGCCAATGTCCTGACCCTTATCGAGAAGGACATCCGTACCCCCAAT\nGGCCTGGCCATCGACCACCGTGCCGAGAAGCTCTACTTCTCTGACGCCACCCTGGACAAG\nATCGAGCGGTGCGAGTATGACGGCTCCCACCGCTATGTGATCCTAAAGTCAGAGCCTGTC\nCACCCCTTCGGGCTGGCCGTGTATGGGGAGCACATTTTCTGGACTGACTGGGTGCGGCGG\nGCAGTGCAGCGGGCCAACAAGCACGTGGGCAGCAACATGAAGCTGCTGCGCGTGGACATC\nCCCCAGCAGCCCATGGGCATCATCGCCGTGGCCAACGACACCAACAGCTGTGAACTCTCT\nCCATGCCGAATCAACAACGGTGGCTGCCAGGACCTGTGTCTGCTCACTCACCAGGGCCAT\nGTCAACTGCTCATGCCGAGGGGGCCGAATCCTCCAGGATGACCTCACCTGCCGAGCGGTG\nAATTCCTCTTGCCGAGCACAAGATGAGTTTGAGTGTGCCAATGGCGAGTGCATCAACTTC\nAGCCTGACCTGCGACGGCGTCCCCCACTGCAAGGACAAGTCCGATGAGAAGCCATCCTAC\nTGCAACTCCCGCCGCTGCAAGAAGACTTTCCGGCAGTGCAGCAATGGGCGCTGTGTGTCC\nAACATGCTGTGGTGCAACGGGGCCGACGACTGTGGGGATGGCTCTGACGAGATCCCTTGC\nAACAAGACAGCCTGTGGTGTGGGCGAGTTCCGCTGCCGGGACGGGACCTGCATCGGGAAC\nTCCAGCCGCTGCAACCAGTTTGTGGATTGTGAGGACGCCTCAGATGAGATGAACTGCAGT\nGCCACCGACTGCAGCAGCTACTTCCGCCTGGGCGTGAAGGGCGTGCTCTTCCAGCCCTGC\nGAGCGGACCTCACTCTGCTACGCACCCAGCTGGGTGTGTGATGGCGCCAATGACTGTGGG\nGACTACAGTGATGAGCGCGACTGCCCAGGTGTGAAACGCCCCAGATGCCCTCTGAATTAC\nTTCGCCTGCCCTAGTGGGCGCTGCATCCCCATGAGCTGGACGTGTGACAAAGAGGATGAC\nTGTGAACATGGCGAGGACGAGACCCACTGCAACAAGTTCTGCTCAGAGGCCCAGTTTGAG\nTGCCAGAACCATCGCTGCATCTCCAAGCAGTGGCTGTGTGACGGCAGCGATGACTGTGGG\nGATGGCTCAGACGAGGCTGCTCACTGTGAAGGCAAGACGTGCGGCCCCTCCTCCTTCTCC\nTGCCCTGGCACCCACGTGTGCGTCCCCGAGCGCTGGCTCTGTGACGGTGACAAAGACTGT\nGCTGATGGTGCAGACGAGAGCATCGCAGCTGGTTGCTTGTACAACAGCACTTGTGACGAC\nCGTGAGTTCATGTGCCAGAACCGCCAGTGCATCCCCAAGCACTTCGTGTGTGACCACGAC\nCGTGACTGTGCAGATGGCTCTGATGAGTCCCCCGAGTGTGAGTACCCGACCTGCGGCCCC\nAGTGAGTTCCGCTGTGCCAATGGGCGCTGTCTGAGCTCCCGCCAGTGGGAGTGTGATGGC\nGAGAATGACTGCCACGACCAGAGTGACGAGGCTCCCAAGAACCCACACTGCACCAGCCCA\nGAGCACAAGTGCAATGCCTCGTCACAGTTCCTGTGCAGCAGTGGGCGCTGTGTGGCTGAG\nGCACTGCTCTGCAACGGCCAGGATGACTGTGGCGACAGCTCGGACGAGCGTGGCTGCCAC\nATCAATGAGTGTCTCAGCCGCAAGCTCAGTGGCTGCAGCCAGGACTGTGAGGACCTCAAG\nATCGGCTTCAAGTGCCGCTGTCGCCCTGGCTTCCGGCTGAAGGATGACGGCCGGACGTGT\nGCTGATGTGGACGAGTGCAGCACCACCTTCCCCTGCAGCCAGCGCTGCATCAACACCCAT\nGGCAGCTATAAGTGTCTGTGTGTGGAGGGCTATGCACCCCGCGGCGGCGACCCCCACAGC\nTGCAAGGCTGTGACTGACGAGGAACCGTTTCTGATCTTCGCCAACCGGTACTACCTGCGC\nAAGCTCAACCTGGACGGGTCCAACTACACGTTACTTAAGCAGGGCCTGAACAACGCCGTT\nGCCTTGGATTTTGACTACCGAGAGCAGATGATCTACTGGACAGATGTGACCACCCAGGGC\nAGCATGATCCGAAGGATGCACCTTAACGGGAGCAATGTGCAGGTCCTACACCGTACAGGC\nCTCAGCAACCCCGATGGGCTGGCTGTGGACTGGGTGGGTGGCAACCTGTACTGGTGCGAC\nAAAGGCCGGGACACCATCGAGGTGTCCAAGCTCAATGGGGCCTATCGGACGGTGCTGGTC\nAGCTCTGGCCTCCGTGAGCCCAGGGCTCTGGTGGTGGATGTGCAGAATGGGTACCTGTAC\nTGGACAGACTGGGGTGACCATTCACTGATCGGCCGCATCGGCATGGATGGGTCCAGCCGC\nAGCGTCATCGTGGACACCAAGATCACATGGCCCAATGGCCTGACGCTGGACTATGTCACT\nGAGCGCATCTACTGGGCCGACGCCCGCGAGGACTACATTGAATTTGCCAGCCTGGATGGC\nTCCAATCGCCACGTTGTGCTGAGCCAGGACATCCCGCACATCTTTGCACTGACCCTGTTT\nGAGGACTACGTCTACTGGACCGACTGGGAAACAAAGTCCATTAACCGAGCCCACAAGACC\nACGGGCACCAACAAAACGCTCCTCATCAGCACGCTGCACCGGCCCATGGACCTGCATGTC\nTTCCATGCCCTGCGCCAGCCAGACGTGCCCAATCACCCCTGCAAGGTCAACAATGGTGGC\nTGCAGCAACCTGTGCCTGCTGTCCCCCGGGGGAGGGCACAAATGTGCCTGCCCCACCAAC\nTTCTACCTGGGCAGCGATGGGCGCACCTGTGTGTCCAACTGCACGGCTAGCCAGTTTGTA\nTGCAAGAACGACAAGTGCATCCCCTTCTGGTGGAAGTGTGACACCGAGGACGACTGCGGG\nGACCACTCAGACGAGCCCCCGGACTGCCCTGAGTTCAAGTGCCGGCCCGGACAGTTCCAG\nTGCTCCACAGGTATCTGCACAAACCCTGCCTTCATCTGCGATGGCGACAATGACTGCCAG\nGACAACAGTGACGAGGCCAACTGTGACATCCACGTCTGCTTGCCCAGTCAGTTCAAATGC\nACCAACACCAACCGCTGTATTCCCGGCATCTTCCGCTGCAATGGGCAGGACAACTGCGGA\nGATGGGGAGGATGAGAGGGACTGCCCCGAGGTGACCTGCGCCCCCAACCAGTTCCAGTGC\nTCCATTACCAAACGGTGCATCCCCCGGGTCTGGGTCTGCGACCGGGACAATGACTGTGTG\nGATGGCAGTGATGAGCCCGCCAACTGCACCCAGATGACCTGTGGTGTGGACGAGTTCCGC\nTGCAAGGATTCGGGCCGCTGCATCCCAGCGCGTTGGAAGTGTGACGGAGAGGATGACTGT\nGGGGATGGCTCGGATGAGCCCAAGGAAGAGTGTGATGAACGCACCTGTGAGCCATACCAG\nTTCCGCTGCAAGAACAACCGCTGCGTGCCCGGCCGCTGGCAGTGCGACTACGACAACGAT\nTGCGGTGACAACTCCGATGAAGAGAGCTGCACCCCTCGGCCCTGCTCCGAGAGTGAGTTC\nTCCTGTGCCAACGGCCGCTGCATCGCGGGGCGCTGGAAATGCGATGGAGACCACGACTGC\nGCGGACGGCTCGGACGAGAAAGACTGCACCCCCCGCTGTGACATGGACCAGTTCCAGTGC\nAAGAGCGGCCACTGCATCCCCCTGCGCTGGCGCTGTGACGCAGACGCCGACTGCATGGAC\nGGCAGCGACGAGGAGGCCTGCGGCACTGGCGTGCGGACCTGCCCCCTGGACGAGTTCCAG\nTGCAACAACACCTTGTGCAAGCCGCTGGCCTGGAAGTGCGATGGCGAGGATGACTGTGGG\nGACAACTCAGATGAGAACCCCGAGGAGTGTGCCCGGTTCGTGTGCCCTCCCAACCGGCCC\nTTCCGTTGCAAGAATGACCGCGTCTGTCTGTGGATCGGGCGCCAATGCGATGGCACGGAC\nAACTGTGGGGATGGGACTGATGAAGAGGACTGTGAGCCCCCCACAGCCCACACCACCCAC\nTGCAAAGACAAGAAGGAGTTTCTGTGCCGGAACCAGCGCTGCCTCTCCTCCTCCCTGCGC\nTGCAACATGTTCGATGACTGCGGGGACGGCTCTGACGAGGAGGACTGCAGCATCGACCCC\nAAGCTGACCAGCTGCGCCACCAATGCCAGCATCTGTGGGGACGAGGCACGCTGCGTGCGC\nACCGAGAAAGCGGCCTACTGTGCCTGCCGCTCGGGCTTCCACACCGTGCCCGGCCAGCCC\nGGATGCCAAGACATCAACGAGTGCCTGCGCTTCGGCACCTGCTCCCAGCTCTGCAACAAC\nACCAAGGGCGGCCACCTCTGCAGCTGCGCTCGGAACTTCATGAAGACGCACAACACCTGC\nAAGGCCGAAGGCTCTGAGTACCAGGTCCTGTACATCGCTGATGACAATGAGATCCGCAGC\nCTGTTCCCCGGCCACCCCCATTCGGCTTACGAGCAGGCATTCCAGGGTGACGAGAGTGTC\nCGCATTGATGCTATGGATGTCCATGTCAAGGCTGGCCGTGTCTATTGGACCAACTGGCAC\nACGGGCACCATCTCCTACCGCAGCCTGCCACCTGCTGCGCCTCCTACCACTTCCAACCGC\nCACCGGCGACAGATTGACCGGGGTGTCACCCACCTCAACATTTCAGGGCTGAAGATGCCC\nAGAGGCATCGCCATCGACTGGGTGGCCGGAAACGTGTACTGGACCGACTCGGGCCGAGAT\nGTGATTGAGGTGGCGCAGATGAAGGGCGAGAACCGCAAGACGCTCATCTCGGGCATGATT\nGACGAGCCCCACGCCATTGTGGTGGACCCACTGAGGGGGACCATGTACTGGTCAGACTGG\nGGCAACCACCCCAAGATTGAGACGGCAGCGATGGATGGGACGCTTCGGGAGACACTGGTG\nCAGGACAACATTCAGTGGCCCACAGGCCTGGCCGTGGATTATCACAATGAGCGGCTGTAC\nTGGGCAGACGCCAAGCTTTCAGTCATCGGCAGCATCCGGCTCAATGGCACGGACCCCATT\nGTGGCTGCTGACAGCAAACGAGGCCTAAGTCACCCCTTCAGCATCGACGTCTTTGAGGAT\nTACATCTATGGTGTCACCTACATCAATAATCGTGTCTTCAAGATCCATAAGTTTGGCCAC\nAGCCCCTTGGTCAACCTGACAGGGGGCCTGAGCCACGCCTCTGACGTGGTCCTTTACCAT\nCAGCACAAGCAGCCCGAAGTGACCAACCCATGTGACCGCAAGAAATGCGAGTGGCTCTGC\nCTGCTGAGCCCCAGTGGGCCTGTCTGCACCTGTCCCAATGGGAAGCGGCTGGACAACGGC\nACATGCGTGCCTGTGCCCTCTCCAACGCCCCCCCCAGATGCTCCCCGGCCTGGAACCTGT\nAACCTGCAGTGCTTCAACGGTGGCAGCTGTTTCCTCAATGCACGGAGGCAGCCCAAGTGC\nCGCTGCCAACCCCGCTACACGGGTGACAAGTGTGAACTGGACCAGTGCTGGGAGCACTGT\nCGCAATGGGGGCACCTGTGCTGCCTCCCCCTCTGGCATGCCCACGTGCCGGTGCCCCACG\nGGCTTCACGGGCCCCAAATGCACCCAGCAGGTGTGTGCGGGCTACTGTGCCAACAACAGC\nACCTGCACTGTCAACCAGGGCAACCAGCCCCAGTGCCGATGCCTACCCGGCTTCCTGGGC\nGACCGCTGCCAGTACCGGCAGTGCTCTGGCTACTGTGAGAACTTTGGCACATGCCAGATG\nGCTGCTGATGGCTCCCGACAATGCCGCTGCACTGCCTACTTTGAGGGATCGAGGTGTGAG\nGTGAACAAGTGCAGCCGCTGTCTCGAAGGGGCCTGTGTGGTCAACAAGCAGAGTGGGGAT\nGTCACCTGCAACTGCACGGATGGCCGGGTGGCCCCCAGCTGTCTGACCTGCGTCGGCCAC\nTGCAGCAATGGCGGCTCCTGTACCATGAACAGCAAAATGATGCCTGAGTGCCAGTGCCCA\nCCCCACATGACAGGGCCCCGGTGTGAGGAGCACGTCTTCAGCCAGCAGCAGCCAGGACAT\nATAGCCTCCATCCTAATCCCTCTGCTGTTGCTGCTGCTGCTGGTTCTGGTGGCCGGAGTG\nGTATTCTGGTATAAGCGGCGAGTCCAAGGGGCTAAGGGCTTCCAGCACCAACGGATGACC\nAACGGGGCCATGAACGTGGAGATTGGAAACCCCACCTACAAGATGTACGAAGGCGGAGAG\nCCTGATGATGTGGGAGGCCTACTGGACGCTGACTTTGCCCTGGACCCTGACAAGCCCACC\nAACTTCACCAACCCCGTGTATGCCACACTCTACATGGGGGGCCATGGCAGTCGCCACTCC\nCTGGCCAGCACGGACGAGAAGCGAGAACTCCTGGGCCGGGGCCCTGAGGACGAGATAGGG\nGACCCCTTGGCATAG"}, "pfams": {"pfam": [{"identifier": "PF00008", "name": "EGF"}, {"identifier": "PF07645", "name": "EGF_CA"}, {"identifier": "PF00057", "name": "Ldl_recept_a"}, {"identifier": "PF00058", "name": "Ldl_recept_b"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "ion binding"}, {"category": "function", "description": "cation binding"}, {"category": "function", "description": "calcium ion binding"}]}}}, {"@position": "7", "id": "BE0000403", "name": "Vitamin K-dependent gamma-carboxylase", "organism": "Human", "actions": null, "references": "# Lin PJ, Straight DL, Stafford DW: Binding of the factor IX gamma-carboxyglutamic acid domain to the vitamin K-dependent gamma-glutamyl carboxylase active site induces an allosteric effect that may ensure processive carboxylation and regulate the release of carboxylated product. J Biol Chem. 2004 Feb 20;279(8):6560-6. Epub 2003 Dec 2. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14660587\n# Wu SM, Mutucumarana VP, Geromanos S, Stafford DW: The propeptide binding site of the bovine gamma-glutamyl carboxylase. J Biol Chem. 1997 May 2;272(18):11718-22. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9115224\n# Rehemtulla A, Roth DA, Wasley LC, Kuliopulos A, Walsh CT, Furie B, Furie BC, Kaufman RJ: In vitro and in vivo functional characterization of bovine vitamin K-dependent gamma-carboxylase expressed in Chinese hamster ovary cells. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4611-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8506307\n# Stanley TB, Wu SM, Houben RJ, Mutucumarana VP, Stafford DW: Role of the propeptide and gamma-glutamic acid domain of factor IX for in vitro carboxylation by the vitamin K-dependent carboxylase. Biochemistry. 1998 Sep 22;37(38):13262-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9748333\n# Stanley TB, Stafford DW, Olivera BM, Bandyopadhyay PK: Identification of a vitamin K-dependent carboxylase in the venom duct of a Conus snail. FEBS Lett. 1997 Apr 21;407(1):85-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9141486", "known-action": "unknown", "polypeptide": {"@id": "P38435", "@source": "Swiss-Prot", "name": "Vitamin K-dependent gamma-carboxylase", "general-function": "Involved in gamma-glutamyl carboxylase activity", "specific-function": "Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium binding gamma-carboxyglutamate (Gla) residues with the concomitant convertion of the reduced hydroquinone form of vitamin K to vitamin K epoxide", "gene-name": "GGCX", "locus": "2p12", "cellular-location": "Endoplasmic reticulum; endoplasmic reticulum membrane; multi-pass membrane protein", "transmembrane-regions": "61-81\n114-134\n137-157\n293-313\n362-382", "signal-regions": null, "theoretical-pi": "8.1", "molecular-weight": "87562.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:4247"}, {"resource": "GenAtlas", "identifier": "GGCX"}, {"resource": "GeneCards", "identifier": "GGCX"}, {"resource": "GenBank Gene Database", "identifier": "M81592"}, {"resource": "GenBank Protein Database", "identifier": "184028"}, {"resource": "UniProtKB", "identifier": "P38435"}, {"resource": "UniProt Accession", "identifier": "VKGC_HUMAN"}]}, "synonyms": {"synonym": ["EC 6.4.-.-", "Gamma-glutamyl carboxylase", "Vitamin K gamma glutamyl carboxylase"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Vitamin K-dependent gamma-carboxylase\nMAVSAGSARTSPSSDKVQKDKAELISGPRQDSRIGKLLGFEWTDLSSWRRLVTLLNRPTD\nPASLAVFRFLFGFLMVLDIPQERGLSSLDRKYLDGLDVCRFPLLDALRPLPLDWMYLVYT\nIMFLGALGMMLGLCYRISCVLFLLPYWYVFLLDKTSWNNHSYLYGLLAFQLTFMDANHYW\nSVDGLLNAHRRNAHVPLWNYAVLRGQIFIVYFIAGVKKLDADWVEGYSMEYLSRHWLFSP\nFKLLLSEELTSLLVVHWGGLLLDLSAGFLLFFDVSRSIGLFFVSYFHCMNSQLFSIGMFS\nYVMLASSPLFCSPEWPRKLVSYCPRRLQQLLPLKAAPQPSVSCVYKRSRGKSGQKPGLRH\nQLGAAFTLLYLLEQLFLPYSHFLTQGYNNWTNGLYGYSWDMMVHSRSHQHVKITYRDGRT\nGELGYLNPGVFTQSRRWKDHADMLKQYATCLSRLLPKYNVTEPQIYFDIWVSINDRFQQR\nIFDPRVDIVQAAWSPFQRTSWVQPLLMDLSPWRAKLQEIKSSLDNHTEVVFIADFPGLHL\nENFVSEDLGNTSIQLLQGEVTVELVAEQKNQTLREGEKMQLPAGEYHKVYTTSPSPSCYM\nYVYVNTTELALEQDLAYLQELKEKVENGSETGPLPPELQPLLEGEVKGGPEPTPLVQTFL\nRRQQRLQEIERRRNTPFHERFFRFLLRKLYVFRRSFLMTCISLRNLILGRPSLEQLAQEV\nTYANLRPFEAVGELNPSNTDSSHSNPPESNPDPVHSEF"}, "gene-sequence": {"@format": "FASTA", "#text": ">2277 bp\nATGGCGGTGTCTGCCGGGTCCGCGCGGACCTCGCCCAGCTCAGATAAAGTACAGAAAGAC\nAAGGCTGAACTGATCTCAGGGCCCAGGCAGGACAGCCGAATAGGGAAACTCTTGGGTTTT\nGAGTGGACAGATTTGTCCAGTTGGCGGAGGCTGGTGACCCTGCTGAATCGACCAACGGAC\nCCTGCAAGCTTAGCTGTCTTTCGTTTTCTTTTTGGGTTCTTGATGGTGCTAGACATTCCC\nCAGGAGCGGGGGCTCAGCTCTCTGGACCGGAAATACCTTGATGGGCTGGATGTGTGCCGC\nTTCCCCTTGCTGGATGCCCTACGCCCACTGCCACTTGACTGGATGTATCTTGTCTACACC\nATCATGTTTCTGGGGGCACTGGGCATGATGCTGGGCCTGTGCTACCGGATAAGCTGTGTG\nTTATTCCTGCTGCCATACTGGTATGTGTTTCTCCTGGACAAGACATCATGGAACAACCAC\nTCCTATCTGTATGGGTTGTTGGCCTTTCAGCTAACATTCATGGATGCAAACCACTACTGG\nTCTGTGGACGGTCTGCTGAATGCCCATAGGAGGAATGCCCACGTGCCCCTTTGGAACTAT\nGCAGTGCTCCGTGGCCAGATCTTCATTGTGTACTTCATTGCGGGTGTGAAAAAGCTGGAT\nGCAGACTGGGTTGAAGGCTATTCCATGGAATATTTGTCCCGGCACTGGCTCTTCAGTCCC\nTTCAAACTGCTGTTGTCTGAGGAGCTGACTAGCCTGCTGGTCGTGCACTGGGGTGGGCTG\nCTGCTTGACCTCTCAGCTGGTTTCCTGCTCTTTTTTGATGTCTCAAGATCCATTGGCCTG\nTTCTTTGTGTCCTACTTCCACTGCATGAATTCCCAGCTTTTCAGCATTGGTATGTTCTCC\nTACGTCATGCTGGCCAGCAGCCCTCTCTTCTGCTCCCCTGAGTGGCCTCGGAAGCTGGTG\nTCCTACTGCCCCCAAAGGTTGCAACAACTGTTGCCCCTCAAGGCAGCCCCTCAGCCCAGT\nGTTTCCTGTGTGTATAAGAGGAGCCGGGGCAAAAGTGGCCAGAAGCCAGGGCTGCGCCAT\nCAGCTGGGAGCTGCCTTCACCCTGCTCTACCTCCTGGAGCAGCTATTCCTGCCCTATTCT\nCATTTTCTCACCCAGGGCTATAACAACTGGACAAATGGGCTGTATGGCTATTCCTGGGAC\nATGATGGTGCACTCCCGTTCCCACCAGCACGTGAAGATCACCTACCGTGATGGCCGCACT\nGGCGAACTGGGCTACCTTAACCCTGGGGTATTTACACAGAGTCGGCGATGGAAGGATCAT\nGCAGACATGCTGAAGCAATATGCCACTTGCCTGAGCCGCCTGCTTCCCAAGTATAATGTC\nACTGAGCCCCAGATCTACTTTGATATTTGGGTCTCCATCAATGACCGCTTCCAGCAGAGG\nATTTTTGACCCTCGTGTGGACATCGTGCAGGCCGCTTGGTCACCCTTTCAGCGCACATCC\nTGGGTGCAACCACTCTTGATGGACCTGTCTCCCTGGAGGGCCAAGTTACAGGAAATCAAG\nAGCAGCCTAGACAACCACACTGAGGTGGTCTTCATTGCAGATTTCCCTGGACTGCACTTG\nGAGAATTTTGTGAGTGAAGACCTGGGCAACACTAGCATCCAGCTGCTGCAGGGGGAAGTG\nACTGTGGAGCTTGTGGCAGAACAGAAGAACCAGACTCTTCGAGAGGGAGAAAAAATGCAG\nTTGCCTGCTGGTGAGTACCATAAGGTGTATACGACATCACCTAGCCCTTCTTGCTACATG\nTACGTCTATGTCAACACTACAGAGCTTGCACTGGAGCAAGACCTGGCATATCTGCAAGAA\nTTAAAGGAAAAGGTGGAGAATGGAAGTGAAACAGGGCCTCTACCCCCAGAGCTGCAGCCT\nCTGTTGGAAGGGGAAGTAAAAGGGGGCCCTGAGCCAACACCTCTGGTTCAGACCTTTCTT\nAGACGCCAACAAAGGCTCCAGGAGATTGAACGCCGGCGAAATACTCCTTTCCATGAGCGA\nTTCTTCCGCTTCTTGTTGCGAAAGCTCTATGTCTTTCGCCGCAGCTTCCTGATGACTTGT\nATCTCACTTCGAAATCTGATATTAGGCCGTCCTTCCCTGGAGCAGCTGGCCCAGGAGGTG\nACTTATGCAAACTTGAGACCCTTTGAGGCAGTTGGAGAACTGAATCCCTCAAACACGGAT\nTCTTCACATTCTAATCCTCCTGAGTCAAATCCTGATCCTGTCCACTCAGAGTTCTGA"}, "pfams": {"pfam": {"identifier": "PF05090", "name": "VKG_Carbox"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "gamma-glutamyl carboxylase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "lyase activity"}, {"category": "function", "description": "carbon-carbon lyase activity"}, {"category": "function", "description": "carboxy-lyase activity"}, {"category": "process", "description": "biopolymer modification"}, {"category": "process", "description": "protein modification"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "peptidyl-amino acid modification"}, {"category": "process", "description": "peptidyl-glutamic acid modification"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "peptidyl-glutamic acid carboxylation"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "biopolymer metabolism"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2014-11-11", "drugbank-id": [{"@primary": "true", "#text": "DB00102"}, "BIOD00053", "BTD00053"], "name": "Becaplermin", "description": "Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae. Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together by disulfide bonds", "cas-number": "165101-51-9", "groups": {"group": ["approved", "investigational"]}, "general-references": "# http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000212/WC500050140.pdf\n#Lexicomp [Internet]. Becaplermin. 2014 [cited 12 November 2014]. Available from: http://online.lexi.com.login.ezproxy.library.ualberta.ca/lco/action/doc/retrieve/docid/patch_f/6420#f_pharmacology-and-pharmacokinetics", "synthesis-reference": null, "indication": "For topical treatment of skin ulcers (from diabetes)", "pharmacodynamics": "Used for the topical treatment of skin ulcers, Regranex has a biological activity similar to that of endogenous platelet-derived growth factor, which includes promoting the chemotactic recruitment and proliferation of cells involved in wound repair and enhancing the formation of granulation tissue.", "mechanism-of-action": "Binds to the beta platelet-derived growth factor (PDGF) receptor, a tyrosine kinase receptor. PDGF is known to exist as a dimer, and activates its signaling pathway by a ligand induced receptor dimerization and autophosphorylation. PDGF receptors also contain many auto-phosphorylation sites, which serve to mediate binding of SH2 sites and subsequently signal corresponding pathways. There are five different isoforms of PDGF that activate through two different receptors (alpha and beta).", "toxicity": null, "metabolism": null, "absorption": "very little systemic absorption. 15% of patients experienced complete healing within 8 weeks, while for 25% of patients, it was at 10 weeks.", "half-life": null, "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "c-sis"}, {"@language": "", "@coder": "", "#text": "PDGF B-chain"}, {"@language": "", "@coder": "", "#text": "PDGF-2"}, {"@language": "", "@coder": "", "#text": "Platelet-derived growth factor B chain precursor"}, {"@language": "", "@coder": "", "#text": "Platelet-derived growth factor beta polypeptide"}]}, "products": {"product": [{"name": "Regranex", "ndc-id": "50484-810_d16fc7c5-e6ad-4c29-a8f0-4b81b3c6a083", "ndc-product-code": "50484-810", "dpd-id": null, "started-marketing-on": "2011-11-01", "ended-marketing-on": null, "dosage-form": "gel", "strength": "100 ug/g", "route": "topical", "fda-application-number": "BLA103691", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Regranex", "ndc-id": "0064-0810_c080f728-52c4-4c59-a2b5-4959f144ccb0", "ndc-product-code": "0064-0810", "dpd-id": null, "started-marketing-on": "2011-11-01", "ended-marketing-on": null, "dosage-form": "gel", "strength": "100 ug/g", "route": "topical", "fda-application-number": "BLA103691", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Regranex (becaplermin) 0.01%", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02239405", "started-marketing-on": "1999-02-01", "ended-marketing-on": "2011-07-27", "dosage-form": "gel", "strength": "100 mcg", "route": "topical", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Regranex", "ingredients": "Becaplermin"}, {"name": "Regranex", "ingredients": "Becaplermin"}, {"name": "Regranex (becaplermin) 0.01%", "ingredients": "Becaplermin"}]}, "packagers": {"packager": [{"name": "Janssen-Ortho Inc.", "url": "http://www.janssen-ortho.com"}, {"name": "McNeil Laboratories", "url": null}, {"name": "OMJ Pharmaceuticals", "url": null}, {"name": "Ortho Mcneil Janssen Pharmaceutical Inc.", "url": "http://www.ortho-mcneil.com"}, {"name": "Ortho-McNeil-Janssen Pharmaceuticals Inc.", "url": "http://www.ortho-mcneil.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Regranex 0.01% gel", "cost": {"@currency": "USD", "#text": "46.4"}, "unit": "g"}, {"description": "Regranex 0.01% Gel 15 gm Tube", "cost": {"@currency": "USD", "#text": "723.82"}, "unit": "tube"}]}, "categories": {"category": {"category": "Angiogenesis Inducing Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Gel", "route": "topical", "strength": "100 ug/g"}, {"form": "Gel", "route": "topical", "strength": "100 mcg"}]}, "atc-codes": {"atc-code": [{"@code": "A01AD08", "level": [{"@code": "A", "#text": "ALIMENTARY TRACT AND METABOLISM"}, {"@code": "A01", "#text": "STOMATOLOGICAL PREPARATIONS"}, {"@code": "A01A", "#text": "STOMATOLOGICAL PREPARATIONS"}, {"@code": "A01AD", "#text": "Other agents for local oral treatment"}]}, {"@code": "D03AX06", "level": [{"@code": "D", "#text": "DERMATOLOGICALS"}, {"@code": "D03", "#text": "PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS"}, {"@code": "D03A", "#text": "CICATRIZANTS"}, {"@code": "D03AX", "#text": "Other cicatrizants"}]}]}, "ahfs-codes": {"ahfs-code": "84:16.00"}, "patents": {"patent": {"number": "1340846", "country": "Canada", "approved": "1999-12-07", "expires": "2015-12-15"}}, "food-interactions": null, "drug-interactions": null, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00102 sequence\nSLGSLTIAEPAMIAECKTRTEVFEISRRLIDRTNANFLVWPPCVEVQRCSGCCNNRNVQC\nRPTQVQLRPVQVRKIEIVRKKPIFKKATVTLEDHLACKCETVAAARPVT"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.160", "source": null}, {"kind": "Isoelectric Point", "value": "9.38", "source": null}, {"kind": "Molecular Weight", "value": "12294.4000", "source": null}, {"kind": "Molecular Formula", "value": "C532H892N162O153S9", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "11832"}, {"resource": "GenBank", "identifier": "K01401"}, {"resource": "PharmGKB", "identifier": "PA164749511"}, {"resource": "UniProtKB", "identifier": "P01127"}, {"resource": "Wikipedia", "identifier": "Becaplermin"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic2/becapler.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/becaplermin.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"@position": "1", "id": "BE0000205", "name": "Platelet-derived growth factor receptor beta", "organism": "Human", "actions": null, "references": "# Papanas N, Maltezos E: Becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Clin Interv Aging. 2008;3(2):233-40. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18686746", "known-action": "yes", "polypeptide": {"@id": "P09619", "@source": "Swiss-Prot", "name": "Platelet-derived growth factor receptor beta", "general-function": "Involved in protein kinase activity", "specific-function": "Receptor that binds specifically to PDGFB and PDGFD and has a tyrosine-protein kinase activity. Phosphorylates Tyr residues at the C-terminus of PTPN11 creating a binding site for the SH2 domain of GRB2", "gene-name": "PDGFRB", "locus": "5q31-q32", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "532-556", "signal-regions": null, "theoretical-pi": "4.62", "molecular-weight": "123969.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:8804"}, {"resource": "GenAtlas", "identifier": "PDGFRB"}, {"resource": "GeneCards", "identifier": "PDGFRB"}, {"resource": "GenBank Gene Database", "identifier": "J03278"}, {"resource": "GenBank Protein Database", "identifier": "189732"}, {"resource": "UniProtKB", "identifier": "P09619"}, {"resource": "UniProt Accession", "identifier": "PGFRB_HUMAN"}]}, "synonyms": {"synonym": ["Beta platelet-derived growth factor receptor precursor", "CD140b antigen", "EC 2.7.10.1", "PDGF-R-beta"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Beta platelet-derived growth factor receptor precursor\nMRLPGAMPALALKGELLLLSLLLLLEPQISQGLVVTPPGPELVLNVSSTFVLTCSGSAPV\nVWERMSQEPPQEMAKAQDGTFSSVLTLTNLTGLDTGEYFCTHNDSRGLETDERKRLYIFV\nPDPTVGFLPNDAEELFIFLTEITEITIPCRVTDPQLVVTLHEKKGDVALPVPYDHQRGFS\nGIFEDRSYICKTTIGDREVDSDAYYVYRLQVSSINVSVNAVQTVVRQGENITLMCIVIGN\nEVVNFEWTYPRKESGRLVEPVTDFLLDMPYHIRSILHIPSAELEDSGTYTCNVTESVNDH\nQDEKAINITVVESGYVRLLGEVGTLQFAELHRSRTLQVVFEAYPPPTVLWFKDNRTLGDS\nSAGEIALSTRNVSETRYVSELTLVRVKVAEAGHYTMRAFHEDAEVQLSFQLQINVPVRVL\nELSESHPDSGEQTVRCRGRGMPQPNIIWSACRDLKRCPRELPPTLLGNSSEEESQLETNV\nTYWEEEQEFEVVSTLRLQHVDRPLSVRCTLRNAVGQDTQEVIVVPHSLPFKVVVISAILA\nLVVLTIISLIILIMLWQKKPRYEIRWKVIESVSSDGHEYIYVDPMQLPYDSTWELPRDQL\nVLGRTLGSGAFGQVVEATAHGLSHSQATMKVAVKMLKSTARSSEKQALMSELKIMSHLGP\nHLNVVNLLGACTKGGPIYIITEYCRYGDLVDYLHRNKHTFLQHHSDKRRPPSAELYSNAL\nPVGLPLPSHVSLTGESDGGYMDMSKDESVDYVPMLDMKGDVKYADIESSNYMAPYDNYVP\nSAPERTCRATLINESPVLSYMDLVGFSYQVANGMEFLASKNCVHRDLAARNVLICEGKLV\nKICDFGLARDIMRDSNYISKGSTFLPLKWMAPESIFNSLYTTLSDVWSFGILLWEIFTLG\nGTPYPELPMNEQFYNAIKRGYRMAQPAHASDEIYEIMQKCWEEKFEIRPPFSQLVLLLER\nLLGEGYKKKYQQVDEEFLRSDHPAILRSQARLPGFHGLRSPLDTSSVLYTAVQPNEGDND\nYIIPLPDPKPEVADEGPLEGSPSLASSTLNEVNTSSTISCDSPLEPQDEPEPEPQLELQV\nEPEPELEQLPDSGCPAPRAEAEDSFL"}, "gene-sequence": {"@format": "FASTA", "#text": ">3321 bp\nATGCGGCTTCCGGGTGCGATGCCAGCTCTGGCCCTCAAAGGCGAGCTGCTGTTGCTGTCT\nCTCCTGTTACTTCTGGAACCACAGATCTCTCAGGGCCTGGTCGTCACACCCCCGGGGCCA\nGAGCTTGTCCTCAATGTCTCCAGCACCTTCGTTCTGACCTGCTCGGGTTCAGCTCCGGTG\nGTGTGGGAACGGATGTCCCAGGAGCCCCCACAGGAAATGGCCAAGGCCCAGGATGGCACC\nTTCTCCAGCGTGCTCACACTGACCAACCTCACTGGGCTAGACACGGGAGAATACTTTTGC\nACCCACAATGACTCCCGTGGACTGGAGACCGATGAGCGGAAACGGCTCTACATCTTTGTG\nCCAGATCCCACCGTGGGCTTCCTCCCTAATGATGCCGAGGAACTATTCATCTTTCTCACG\nGAAATAACTGAGATCACCATTCCATGCCGAGTAACAGACCCACAGCTGGTGGTGACACTG\nCACGAGAAGAAAGGGGACGTTGCACTGCCTGTCCCCTATGATCACCAACGTGGCTTTTCT\nGGTATCTTTGAGGACAGAAGCTACATCTGCAAAACCACCATTGGGGACAGGGAGGTGGAT\nTCTGATGCCTACTATGTCTACAGACTCCAGGTGTCATCCATCAACGTCTCTGTGAACGCA\nGTGCAGACTGTGGTCCGCCAGGGTGAGAACATCACCCTCATGTGCATTGTGATCGGGAAT\nGAGGTGGTCAACTTCGAGTGGACATACCCCCGCAAAGAAAGTGGGCGGCTGGTGGAGCCG\nGTGACTGACTTCCTCTTGGATATGCCTTACCACATCCGCTCCATCCTGCACATCCCCAGT\nGCCGAGTTAGAAGACTCGGGGACCTACACCTGCAATGTGACGGAGAGTGTGAATGACCAT\nCAGGATGAAAAGGCCATCAACATCACCGTGGTTGAGAGCGGCTACGTGCGGCTCCTGGGA\nGAGGTGGGCACACTACAATTTGCTGAGCTGCATCGGAGCCGGACACTGCAGGTAGTGTTC\nGAGGCCTACCCACCGCCCACTGTCCTGTGGTTCAAAGACAACCGCACCCTGGGCGACTCC\nAGCGCTGGCGAAATCGCCCTGTCCACGCGCAACGTGTCGGAGACCCGGTATGTGTCAGAG\nCTGACACTGGTTCGCGTGAAGGTGGCAGAGGCTGGCCACTACACCATGCGGGCCTTCCAT\nGAGGATGCTGAGGTCCAGCTCTCCTTCCAGCTACAGATCAATGTCCCTGTCCGAGTGCTG\nGAGCTAAGTGAGAGCCACCCTGACAGTGGGGAACAGACAGTCCGCTGTCGTGGCCGGGGC\nATGCCCCAGCCGAACATCATCTGGTCTGCCTGCAGAGACCTCAAAAGGTGTCCACGTGAG\nCTGCCGCCCACGCTGCTGGGGAACAGTTCCGAAGAGGAGAGCCAGCTGGAGACTAACGTG\nACGTACTGGGAGGAGGAGCAGGAGTTTGAGGTGGTGAGCACACTGCGTCTGCAGCACGTG\nGATCGGCCACTGTCGGTGCGCTGCACGCTGCGCAACGCTGTGGGCCAGGACACGCAGGAG\nGTCATCGTGGTGCCACACTCCTTGCCCTTTAAGGTGGTGGTGATCTCAGCCATCCTGGCC\nCTGGTGGTGCTCACCATCATCTCCCTTATCATCCTCATCATGCTTTGGCAGAAGAAGCCA\nCGTTACGAGATCCGATGGAAGGTGATTGAGTCTGTGAGCTCTGACGGCCATGAGTACATC\nTACGTGGACCCCATGCAGCTGCCCTATGACTCCACGTGGGAGCTGCCGCGGGACCAGCTT\nGTGCTGGGACGCACCCTCGGCTCTGGGGCCTTTGGGCAGGTGGTGGAGGCCACGGCTCAT\nGGCCTGAGCCATTCTCAGGCCACGATGAAAGTGGCCGTCAAGATGCTTAAATCCACAGCC\nCGCAGCAGTGAGAAGCAAGCCCTTATGTCGGAGCTGAAGATCATGAGTCACCTTGGGCCC\nCACCTGAACGTGGTCAACCTGTTGGGGGCCTGCACCAAAGGAGGACCCATCTATATCATC\nACTGAGTACTGCCGCTACGGAGACCTGGTGGACTACCTGCACCGCAACAAACACACCTTC\nCTGCAGCACCACTCCGACAAGCGCCGCCCGCCCAGCGCGGAGCTCTACAGCAATGCTCTG\nCCCGTTGGGCTCCCCCTGCCCAGCCATGTGTCCTTGACCGGGGAGAGCGACGGTGGCTAC\nATGGACATGAGCAAGGACGAGTCGGTGGACTATGTGCCCATGCTGGACATGAAAGGAGAC\nGTCAAATATGCAGACATCGAGTCCTCCAACTACATGGCCCCTTACGATAACTACGTTCCC\nTCTGCCCCTGAGAGGACCTGCCGAGCAACTTTGATCAACGAGTCTCCAGTGCTAAGCTAC\nATGGACCTCGTGGGCTTCAGCTACCAGGTGGCCAATGGCATGGAGTTTCTGGCCTCCAAG\nAACTGCGTCCACAGAGACCTGGCGGCTAGGAACGTGCTCATCTGTGAAGGCAAGCTGGTC\nAAGATCTGTGACTTTGGCCTGGCTCGAGACATCATGCGGGACTCGAATTACATCTCCAAA\nGGCAGCACCTTTTTGCCTTTAAAGTGGATGGCTCCGGAGAGCATCTTCAACAGCCTCTAC\nACCACCCTGAGCGACGTGTGGTCCTTCGGGATCCTGCTCTGGGAGATCTTCACCTTGGGT\nGGCACCCCTTACCCAGAGCTGCCCATGAACGAGCAGTTCTACAATGCCATCAAACGGGGT\nTACCGCATGGCCCAGCCTGCCCATGCCTCCGACGAGATCTATGAGATCATGCAGAAGTGC\nTGGGAAGAGAAGTTTGAGATTCGGCCCCCCTTCTCCCAGCTGGTGCTGCTTCTCGAGAGA\nCTGTTGGGCGAAGGTTACAAAAAGAAGTACCAGCAGGTGGATGAGGAGTTTCTGAGGAGT\nGACCACCCAGCCATCCTTCGGTCCCAGGCCCGCTTGCCTGGGTTCCATGGCCTCCGATCT\nCCCCTGGACACCAGCTCCGTCCTCTATACTGCCGTGCAGCCCAATGAGGGTGACAACGAC\nTATATCATCCCCCTGCCTGACCCCAAACCCGAGGTTGCTGACGAGGGCCCACTGGAGGGT\nTCCCCCAGCCTAGCCAGCTCCACCCTGAATGAAGTCAACACCTCCTCAACCATCTCCTGT\nGACAGCCCCCTGGAGCCCCAGGACGAACCAGAGCCAGAGCCCCAGCTTGAGCTCCAGGTG\nGAGCCGGAGCCAGAGCTGGAACAGTTGCCGGATTCGGGGTGCCCTGCGCCTCGGGCGGAA\nGCAGAGGATAGCTTCCTGTAG"}, "pfams": {"pfam": [{"identifier": "PF07714", "name": "Pkinase_Tyr"}, {"identifier": "PF00047", "name": "ig"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "protein-tyrosine kinase activity"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "transferase activity, transferring phosphorus-containing groups"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "function", "description": "kinase activity"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "transferase activity"}, {"category": "function", "description": "protein kinase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "vascular endothelial growth factor receptor activity"}, {"category": "function", "description": "transmembrane receptor protein tyrosine kinase activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "protein amino acid phosphorylation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "enzyme linked receptor protein signaling pathway"}, {"category": "process", "description": "biopolymer metabolism"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "transmembrane receptor protein tyrosine kinase signaling pathway"}, {"category": "process", "description": "biopolymer modification"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "protein modification"}]}}}, {"@position": "2", "id": "BE0000852", "name": "Platelet-derived growth factor receptor alpha", "organism": "Human", "actions": null, "references": "# Abdiu A, Walz TM, Nishikawa BK, Wingren S, Larsson SE, Wasteson A: Human malignant fibrous histiocytomas in vitro: growth characteristics and their association with expression of mRNA for platelet-derived growth factor, transforming growth factor-alpha and their receptors. Eur J Cancer. 1998 Dec;34(13):2094-100. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10070317\n# Ebert M, Yokoyama M, Friess H, Kobrin MS, Buchler MW, Korc M: Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int J Cancer. 1995 Sep 4;62(5):529-35. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7665222\n# Miller-Kasprzak E, Niemir ZI, Czekalski S: [Structure and function of PDGF-R-alpha and its expression in normal kidney and kidney diseases] Przegl Lek. 2002;59(10):826-31. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12632922\n# Heidaran MA, Pierce JH, Lombardi D, Ruggiero M, Gutkind JS, Matsui T, Aaronson SA: Deletion or substitution within the alpha platelet-derived growth factor receptor kinase insert domain: effects on functional coupling with intracellular signaling pathways. Mol Cell Biol. 1991 Jan;11(1):134-42. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1702511\n# Yu J, Liu XW, Kim HR: Platelet-derived growth factor (PDGF) receptor-alpha-activated c-Jun NH2-terminal kinase-1 is critical for PDGF-induced p21WAF1/CIP1 promoter activity independent of p53. J Biol Chem. 2003 Dec 5;278(49):49582-8. Epub 2003 Sep 23. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14506245", "known-action": "unknown", "polypeptide": {"@id": "P16234", "@source": "Swiss-Prot", "name": "Platelet-derived growth factor receptor alpha", "general-function": "Involved in protein kinase activity", "specific-function": "Receptor that binds both PDGFA and PDGFB and has a tyrosine-protein kinase activity", "gene-name": "PDGFRA", "locus": "4q11-q13", "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "525-549", "signal-regions": null, "theoretical-pi": "4.81", "molecular-weight": "122671.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:8803"}, {"resource": "GenAtlas", "identifier": "PDGFRA"}, {"resource": "GeneCards", "identifier": "PDGFRA"}, {"resource": "GenBank Gene Database", "identifier": "M21574"}, {"resource": "GenBank Protein Database", "identifier": "189734"}, {"resource": "UniProtKB", "identifier": "P16234"}, {"resource": "UniProt Accession", "identifier": "PGFRA_HUMAN"}]}, "synonyms": {"synonym": ["Alpha platelet-derived growth factor receptor precursor", "CD140a antigen", "EC 2.7.10.1", "PDGF-R-alpha"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Alpha platelet-derived growth factor receptor precursor\nMGTSHPAFLVLGCLLTGLSLILCQLSLPSILPNENEKVVQLNSSFSLRCFGESEVSWQYP\nMSEEESSDVEIRNEENNSGLFVTVLEVSSASAAHTGLYTCYYNHTQTEENELEGRHIYIY\nVPDPDVAFVPLGMTDYLVIVEDDDSAIIPCRTTDPETPVTLHNSEGVVPASYDSRQGFNG\nTFTVGPYICEATVKGKKFQTIPFNVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNN\nEVVDLQWTYPGEVKGKGITMLEEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVK\nEMKKVTISVHEKGFIEIKPTFSQLEAVNLHEVKHFVVEVRAYPPPRISWLKNNLTLIENL\nTEITTDVEKIQEIRYRSKLKLIRAKEEDSGHYTIVAQNEDAVKSYTFELLTQVPSSILDL\nVDDHHGSTGGQTVRCTAEGTPLPDIEWMICKDIKKCNNETSWTILANNVSNIITEIHSRD\nRSTVEGRVTFAKVEETIAVRCLAKNLLGAENRELKLVAPTLRSELTVAAAVLVLLVIVII\nSLIVLVVIWKQKPRYEIRWRVIESISPDGHEYIYVDPMQLPYDSRWEFPRDGLVLGRVLG\nSGAFGKVVEGTAYGLSRSQPVMKVAVKMLKPTARSSEKQALMSELKIMTHLGPHLNIVNL\nLGACTKSGPIYIITEYCFYGDLVNYLHKNRDSFLSHHPEKPKKELDIFGLNPADESTRSY\nVILSFENNGDYMDMKQADTTQYVPMLERKEVSKYSDIQRSLYDRPASYKKKSMLDSEVKN\nLLSDDNSEGLTLLDLLSFTYQVARGMEFLASKNCVHRDLAARNVLLAQGKIVKICDFGLA\nRDIMHDSNYVSKGSTFLPVKWMAPESIFDNLYTTLSDVWSYGILLWEIFSLGGTPYPGMM\nVDSTFYNKIKSGYRMAKPDHATSEVYEIMVKCWNSEPEKRPSFYHLSEIVENLLPGQYKK\nSYEKIHLDFLKSDHPAVARMRVDSDNAYIGVTYKNEEDKLKDWEGGLDEQRLSADSGYII\nPLPDIDPVPEEEDLGKRNRHSSQTSEESAIETGSSSSTFIKREDETIEDIDMMDDIGIDS\nSDLVEDSFL"}, "gene-sequence": {"@format": "FASTA", "#text": ">3270 bp\nATGGGGACTTCCCATCCGGCGTTCCTGGTCTTAGGCTGTCTTCTCACAGGGCTGAGCCTA\nATCCTCTGCCAGCTTTCATTACCCTCTATCCTTCCAAATGAAAATGAAAAGGTTGTGCAG\nCTGAATTCATCCTTTTCTCTGAGATGCTTTGGGGAGAGTGAAGTGAGCTGGCAGTACCCC\nATGTCTGAAGAAGAGAGCTCCGATGTGGAAATCAGAAATGAAGAAAACAACAGCGGCCTT\nTTTGTGACGGTCTTGGAAGTGAGCAGTGCCTCGGCGGCCCACACAGGGTTGTACACTTGC\nTATTACAACCACACTCAGACAGAAGAGAATGAGCTTGAAGGCAGGCACATTTACATCTAT\nGTGCCAGACCCAGATGTAGCCTTTGTACCTCTAGGAATGACGGATTATTTAGTCATCGTG\nGAGGATGATGATTCTGCCATTATACCTTGTCGCACAACTGATCCCGAGACTCCTGTAACC\nTTACACAACAGTGAGGGGGTGGTACCTGCCTCCTACGACAGCAGACAGGGCTTTAATGGG\nACCTTCACTGTAGGGCCCTATATCTGTGAGGCCACCGTCAAAGGAAAGAAGTTCCAGACC\nATCCCATTTAATGTTTATGCTTTAAAAGCAACATCAGAGCTGGATCTAGAAATGGAAGCT\nCTTAAAACCGTGTATAAGTCAGGGGAAACGATTGTGGTCACCTGTGCTGTTTTTAACAAT\nGAGGTGGTTGACCTTCAATGGACTTACCCTGGAGAAGTGAAAGGCAAAGGCATCACAATG\nCTGGAAGAAATCAAAGTCCCATCCATCAAATTGGTGTACACTTTGACGGTCCCCGAGGCC\nACGGTGAAAGACAGTGGAGATTACGAATGTGCTGCCCGCCAGGCTACCAGGGAGGTCAAA\nGAAATGAAGAAAGTCACTATTTCTGTCCATGAGAAAGGTTTCATTGAAATCAAACCCACC\nTTCAGCCAGTTGGAAGCTGTCAACCTGCATGAAGTCAAACATTTTGTTGTAGAGGTGCGG\nGCCTACCCACCTCCCAGGATATCCTGGCTGAAAAACAATCTGACTCTGATTGAAAATCTC\nACTGAGATCACCACTGATGTGGAAAAGATTCAGGAAATAAGGTATCGAAGCAAATTAAAG\nCTGATCCGTGCTAAGGAAGAAGACAGTGGCCATTATACTATTGTAGCTCAAAATGAAGAT\nGCTGTGAAGAGCTATACTTTTGAACTGTTAACTCAAGTTCCTTCATCCATTCTGGACTTG\nGTCGATGATCACCATGGCTCAACTGGGGGACAGACGGTGAGGTGCACAGCTGAAGGCACG\nCCGCTTCCTGATATTGAGTGGATGATATGCAAAGATATTAAGAAATGTAATAATGAAACT\nTCCTGGACTATTTTGGCCAACAATGTCTCAAACATCATCACGGAGATCCACTCCCGAGAC\nAGGAGTACCGTGGAGGGCCGTGTGACTTTCGCCAAAGTGGAGGAGACCATCGCCGTGCGA\nTGCCTGGCTAAGAATCTCCTTGGAGCTGAGAACCGAGAGCTGAAGCTGGTGGCTCCCACC\nCTGCGTTCTGAACTCACGGTGGCTGCTGCAGTCCTGGTGCTGTTGGTGATTGTGATCATC\nTCACTTATTGTCCTGGTTGTCATTTGGAAACAGAAACCGAGGTATGAAATTCGCTGGAGG\nGTCATTGAATCAATCAGCCCGGATGGACATGAATATATTTATGTGGACCCGATGCAGCTG\nCCTTATGACTCAAGATGGGAGTTTCCAAGAGATGGACTAGTGCTTGGTCGGGTCTTGGGG\nTCTGGAGCGTTTGGGAAGGTGGTTGAAGGAACAGCCTATGGATTAAGCCGGTCCCAACCT\nGTCATGAAAGTTGCAGTGAAGATGCTAAAACCCACGGCCAGATCCAGTGAAAAACAAGCT\nCTCATGTCTGAACTGAAGATAATGACTCACCTGGGGCCACATTTGAACATTGTAAACTTG\nCTGGGAGCCTGCACCAAGTCAGGCCCCATTTACATCATCACAGAGTATTGCTTCTATGGA\nGATTTGGTCAACTATTTGCATAAGAATAGGGATAGCTTCCTGAGCCACCACCCAGAGAAG\nCCAAAGAAAGAGCTGGATATCTTTGGATTGAACCCTGCTGATGAAAGCACACGGAGCTAT\nGTTATTTTATCTTTTGAAAACAATGGTGACTACATGGACATGAAGCAGGCTGATACTACA\nCAGTATGTCCCCATGCTAGAAAGGAAAGAGGTTTCTAAATATTCCGACATCCAGAGATCA\nCTCTATGATCGTCCAGCCTCATATAAGAAGAAATCTATGTTAGACTCAGAAGTCAAAAAC\nCTCCTTTCAGATGATAACTCAGAAGGCCTTACTTTATTGGATTTGTTGAGCTTCACCTAT\nCAAGTTGCCCGAGGAATGGAGTTTTTGGCTTCAAAAAATTGTGTCCACCGTGATCTGGCT\nGCTCGCAACGTCCTCCTGGCACAAGGAAAAATTGTGAAGATCTGTGACTTTGGCCTGGCC\nAGAGACATCATGCATGATTCGAACTATGTGTCGAAAGGCAGTACCTTTCTGCCCGTGAAG\nTGGATGGCTCCTGAGAGCATCTTTGACAACCTCTACACCACACTGAGTGATGTCTGGTCT\nTATGGCATTCTGCTCTGGGAGATCTTTTCCCTTGGTGGCACCCCTTACCCCGGCATGATG\nGTGGATTCTACTTTCTACAATAAGATCAAGAGTGGGTACCGGATGGCCAAGCCTGACCAC\nGCTACCAGTGAAGTCTACGAGATCATGGTGAAATGCTGGAACAGTGAGCCGGAGAAGAGA\nCCCTCCTTTTACCACCTGAGTGAGATTGTGGAGAATCTGCTGCCTGGACAATATAAAAAG\nAGTTATGAAAAAATTCACCTGGACTTCCTGAAGAGTGACCATCCTGCTGTGGCACGCATG\nCGTGTGGACTCAGACAATGCATACATTGGTGTCACCTACAAAAACGAGGAAGACAAGCTG\nAAGGACTGGGAGGGTGGTCTGGATGAGCAGAGACTGAGCGCTGACAGTGGCTACATCATT\nCCTCTGCCTGACATTGACCCTGTCCCTGAGGAGGAGGACCTGGGCAAGAGGAACAGACAC\nAGCTCGCAGACCTCTGAAGAGAGTGCCATTGAGACGGGTTCCAGCAGTTCCACCTTCATC\nAAGAGAGAGGACGAGACCATTGAAGACATCGACATGATGGACGACATCGGCATAGACTCT\nTCAGACCTGGTGGAAGACAGCTTCCTGTAA"}, "pfams": {"pfam": [{"identifier": "PF07714", "name": "Pkinase_Tyr"}, {"identifier": "PF00047", "name": "ig"}, {"identifier": "PF07679", "name": "I-set"}]}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "protein-tyrosine kinase activity"}, {"category": "function", "description": "nucleotide binding"}, {"category": "function", "description": "ATP binding"}, {"category": "function", "description": "purine nucleotide binding"}, {"category": "function", "description": "transferase activity, transferring phosphorus-containing groups"}, {"category": "function", "description": "adenyl nucleotide binding"}, {"category": "function", "description": "kinase activity"}, {"category": "function", "description": "binding"}, {"category": "function", "description": "transferase activity"}, {"category": "function", "description": "protein kinase activity"}, {"category": "function", "description": "catalytic activity"}, {"category": "function", "description": "vascular endothelial growth factor receptor activity"}, {"category": "function", "description": "transmembrane receptor protein tyrosine kinase activity"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "protein amino acid phosphorylation"}, {"category": "process", "description": "metabolism"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "macromolecule metabolism"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "enzyme linked receptor protein signaling pathway"}, {"category": "process", "description": "biopolymer metabolism"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "transmembrane receptor protein tyrosine kinase signaling pathway"}, {"category": "process", "description": "biopolymer modification"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "protein modification"}]}}}, {"@position": "3", "id": "BE0000910", "name": "Alpha-2-macroglobulin", "organism": "Human", "actions": null, "references": "# Lizonova A, Bizik J, Grofova M, Vaheri A: Coexpression of tumor-associated alpha 2-macroglobulin and growth factors in human melanoma cell lines. J Cell Biochem. 1990 Aug;43(4):315-25. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/1697862\n# Bonner JC, Osornio-Vargas AR: Differential binding and regulation of platelet-derived growth factor A and B chain isoforms by alpha 2-macroglobulin. J Biol Chem. 1995 Jul 7;270(27):16236-42. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7541796", "known-action": "unknown", "polypeptide": {"@id": "P01023", "@source": "Swiss-Prot", "name": "Alpha-2-macroglobulin", "general-function": "Involved in endopeptidase inhibitor activity", "specific-function": "Is able to inhibit all four classes of proteinases by a unique 'trapping' mechanism. This protein has a peptide stretch, called the 'bait region' which contains specific cleavage sites for different proteinases. When a proteinase cleaves the bait region, a conformational change is induced in the protein which traps the proteinase. The entrapped enzyme remains active against low molecular weight substrates (activity against high molecular weight substrates is greatly reduced). Following cleavage in the bait region a thioester bond is hydrolyzed and mediates the covalent binding of the protein to the proteinase", "gene-name": "A2M", "locus": "12p13.3-p12.3", "cellular-location": "Secreted protein", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "6.39", "molecular-weight": "163280.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:7"}, {"resource": "GenAtlas", "identifier": "A2M"}, {"resource": "GeneCards", "identifier": "A2M"}, {"resource": "GenBank Gene Database", "identifier": "M11313"}, {"resource": "GenBank Protein Database", "identifier": "177870"}, {"resource": "UniProtKB", "identifier": "P01023"}, {"resource": "UniProt Accession", "identifier": "A2MG_HUMAN"}]}, "synonyms": {"synonym": ["Alpha-2-M", "Alpha-2-macroglobulin precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Alpha-2-macroglobulin precursor\nMGKNKLLHPSLVLLLLVLLPTDASVSGKPQYMVLVPSLLHTETTEKGCVLLSYLNETVTV\nSASLESVRGNRSLFTDLEAENDVLHCVAFAVPKSSSNEEVMFLTVQVKGPTQEFKKRTTV\nMVKNEDSLVFVQTDKSIYKPGQTVKFRVVSMDENFHPLNELIPLVYIQDPKGNRIAQWQS\nFQLEGGLKQFSFPLSSEPFQGSYKVVVQKKSGGRTEHPFTVEEFVLPKFEVQVTVPKIIT\nILEEEMNVSVCGLYTYGKPVPGHVTVSICRKYSDASDCHGEDSQAFCEKFSGQLNSHGCF\nYQQVKTKVFQLKRKEYEMKLHTEAQIQEEGTVVELTGRQSSEITRTITKLSFVKVDSHFR\nQGIPFFGQVRLVDGKGVPIPNKVIFIRGNEANYYSNATTDEHGLVQFSINTTNVMGTSLT\nVRVNYKDRSPCYGYQWVSEEHEEAHHTAYLVFSPSKSFVHLEPMSHELPCGHTQTVQAHY\nILNGGTLLGLKKLSFYYLIMAKGGIVRTGTHGLLVKQEDMKGHFSISIPVKSDIAPVARL\nLIYAVLPTGDVIGDSAKYDVENCLANKVDLSFSPSQSLPASHAHLRVTAAPQSVCALRAV\nDQSVLLMKPDAELSASSVYNLLPEKDLTGFPGPLNDQDDEDCINRHNVYINGITYTPVSS\nTNEKDMYSFLEDMGLKAFTNSKIRKPKMCPQLQQYEMHGPEGLRVGFYESDVMGRGHARL\nVHVEEPHTETVRKYFPETWIWDLVVVNSAGVAEVGVTVPDTITEWKAGAFCLSEDAGLGI\nSSTASLRAFQPFFVELTMPYSVIRGEAFTLKATVLNYLPKCIRVSVQLEASPAFLAVPVE\nKEQAPHCICANGRQTVSWAVTPKSLGNVNFTVSAEALESQELCGTEVPSVPEHGRKDTVI\nKPLLVEPEGLEKETTFNSLLCPSGGEVSEELSLKLPPNVVEESARASVSVLGDILGSAMQ\nNTQNLLQMPYGCGEQNMVLFAPNIYVLDYLNETQQLTPEVKSKAIGYLNTGYQRQLNYKH\nYDGSYSTFGERYGRNQGNTWLTAFVLKTFAQARAYIFIDEAHITQALIWLSQRQKDNGCF\nRSSGSLLNNAIKGGVEDEVTLSAYITIALLEIPLTVTHPVVRNALFCLESAWKTAQEGDH\nGSHVYTKALLAYAFALAGNQDKRKEVLKSLNEEAVKKDNSVHWERPQKPKAPVGHFYEPQ\nAPSAEVEMTSYVLLAYLTAQPAPTSEDLTSATNIVKWITKQQNAQGGFSSTQDTVVALHA\nLSKYGAATFTRTGKAAQVTIQSSGTFSSKFQVDNNNRLLLQQVSLPELPGEYSMKVTGEG\nCVYLQTSLKYNILPEKEEFPFALGVQTLPQTCDEPKAHTSFQISLSVSYTGSRSASNMAI\nVDVKMVSGFIPLKPTVKMLERSNHVSRTEVSSNHVLIYLDKVSNQTLSLFFTVLQDVPVR\nDLKPAIVKVYDYYETDEFAIAEYNAPCSKDLGNA"}, "gene-sequence": {"@format": "FASTA", "#text": ">4425 bp\nATGGGGAAGAACAAACTCCTTCATCCAAGTCTGGTTCTTCTCCTCTTGGTCCTCCTGCCC\nACAGACGCCTCAGTCTCTGGAAAACCGCAGTATATGGTTCTGGTCCCCTCCCTGCTCCAC\nACTGAGACCACTGAGAAGGGCTGTGTCCTTCTGAGCTACCTGAATGAGACAGTGACTGTA\nAGTGCTTCCTTGGAGTCTGTCAGGGGAAACAGGAGCCTCTTCACTGACCTGGAGGCGGAG\nAATGACGTACTCCACTGTGTCGCCTTCGCTGTCCCAAAGTCTTCATCCAATGAGGAGGTA\nATGTTCCTCACTGTCCAAGTGAAAGGACCAACCCAAGAATTTAAGAAGCGGACCACAGTG\nATGGTTAAGAACGAGGACAGTCTGGTCTTTGTCCAGACAGACAAATCAATCTACAAACCA\nGGGCAGACAGTGAAATTTCGTGTTGTCTCCATGGATGAAAACTTTCACCCCCTGAATGAG\nTTGATTCCACTAGTATACATTCAGGATCCCAAAGGAAATCGCATCGCACAATGGCAGAGT\nTTCCAGTTAGAGGGTGGCCTCAAGCAATTTTCTTTTCCCCTCTCATCAGAGCCCTTCCAG\nGGCTCCTACAAGGTGGTGGTACAGAAGAAATCAGGTGGAAGGACAGAGCACCCTTTCACC\nGTGGAGGAATTTGTTCTTCCCAAGTTTGAAGTACAAGTAACAGTGCCAAAGATAATCACC\nATCTTGGAAGAAGAGATGAATGTATCAGTGTGTGGCCTATACACATATGGGAAGCCTGTC\nCCTGGACATGTGACTGTGAGCATTTGCAGAAAGTATAGTGACGCTTCCGACTGCCACGGT\nGAAGATTCACAGGCTTTCTGTGAGAAATTCAGTGGACAGCTAAACAGCCATGGCTGCTTC\nTATCAGCAAGTAAAAACCAAGGTCTTCCAGCTGAAGAGGAAGGAGTATGAAATGAAACTT\nCACACTGAGGCCCAGATCCAAGAAGAAGGAACAGTGGTGGAATTGACTGGAAGGCAGTCC\nAGTGAAATCACAAGAACCATAACCAAACTCTCATTTGTGAAAGTGGACTCACACTTTCGA\nCAGGGAATTCCCTTCTTTGGGCAGGTGCGCCTAGTAGATGGGAAAGGCGTCCCTATACCA\nAATAAAGTCATATTCATCAGAGGAAATGAAGCAAACTATTACTCCAATGCTACCACGGAT\nGAGCATGGCCTTGTACAGTTCTCTATCAACACCACCAACGTTATGGGTACCTCTCTTACT\nGTTAGGGTCAATTACAAGGATCGTAGTCCCTGTTACGGCTACCAGTGGGTGTCAGAAGAA\nCACGAAGAGGCACATCACACTGCTTATCTTGTGTTCTCCCCAAGCAAGAGCTTTGTCCAC\nCTTGAGCCCATGTCTCATGAACTACCCTGTGGCCATACTCAGACAGTCCAGGCACATTAT\nATTCTGAATGGAGGCACCCTGCTGGGGCTGAAGAAGCTCTCCTTTTATTATCTGATAATG\nGCAAAGGGAGGCATTGTCCGAACTGGGACTCATGGACTGCTTGTGAAGCAGGAAGACATG\nAAGGGCCATTTTTCCATCTCAATCCCTGTGAAGTCAGACATTGCTCCTGTCGCTCGGTTG\nCTCATCTATGCTGTTTTACCTACCGGGGACGTGATTGGGGATTCTGCAAAATATGATGTT\nGAAAATTGTCTGGCCAACAAGGTGGATTTGAGCTTCAGCCCATCACAAAGTCTCCCAGCC\nTCACACGCCCACCTGCGAGTCACAGCGGCTCCTCAGTCCGTCTGCGCCCTCCGTGCTGTG\nGACCAAAGCGTGCTGCTCATGAAGCCTGATGCTGAGCTCTCGGCGTCCTCGGTTTACAAC\nCTGCTACCAGAAAAGGACCTCACTGGCTTCCCTGGGCCTTTGAATGACCAGGACGATGAA\nGACTGCATCAATCGTCATAATGTCTATATTAATGGAATCACATATACTCCAGTATCAAGT\nACAAATGAAAAGGATATGTACAGCTTCCTAGAGGACATGGGCTTAAAGGCATTCACCAAC\nTCAAAGATTCGTAAACCCAAAATGTGTCCACAGCTTCAACAGTATGAAATGCATGGACCT\nGAAGGTCTACGTGTAGGTTTTTATGAGTCAGATGTAATGGGAAGAGGCCATGCACGCCTG\nGTGCATGTTGAAGAGCCTCACACGGAGACCGTACGAAAGTACTTCCCTGAGACATGGATC\nTGGGATTTGGTGGTGGTAAACTCAGCAGGGGTGGCTGAGGTAGGAGTAACAGTCCCTGAC\nACCATCACCGAGTGGAAGGCAGGGGCCTTCTGCCTGTCTGAAGATGCTGGACTTGGTATC\nTCTTCCACTGCCTCTCTCCGAGCCTTCCAGCCCTTCTTTGTGGAGCTTACAATGCCTTAC\nTCTGTGATTCGTGGAGAGGCCTTCACACTCAAGGCCACGGTCCTAAACTACCTTCCCAAA\nTGCATCCGGGTCAGTGTGCAGCTGGAAGCCTCTCCCGCCTTCCTTGCTGTCCCAGTGGAG\nAAGGAACAAGCGCCTCACTGCATCTGTGCAAACGGGCGGCAAACTGTGTCCTGGGCAGTA\nACCCCAAAGTCATTAGGAAATGTGAATTTCACTGTGAGCGCAGAGGCACTAGAGTCTCAA\nGAGCTGTGTGGGACTGAGGTGCCTTCAGTTCCTGAACACGGAAGGAAAGACACAGTCATC\nAAGCCTCTGTTGGTTGAACCTGAAGGACTAGAGAAGGAAACAACATTCAACTCCCTACTT\nTGTCCATCAGGTGGTGAGGTTTCTGAAGAATTATCCCTGAAACTGCCACCAAATGTGGTA\nGAAGAATCTGCCCGAGCTTCTGTCTCAGTTTTGGGAGACATATTAGGCTCTGCCATGCAA\nAACACACAAAATCTTCTCCAGATGCCCTATGGCTGTGGAGAGCAGAATATGGTCCTCTTT\nGCTCCTAACATCTATGTACTGGATTATCTAAATGAAACACAGCAGCTTACTCCAGAGGTC\nAAGTCCAAGGCCATTGGCTATCTCAACACTGGTTACCAGAGACAGTTGAACTACAAACAC\nTATGATGGCTCCTACAGCACCTTTGGGGAGCGATATGGCAGGAACCAGGGCAACACCTGG\nCTCACAGCCTTTGTTCTGAAGACTTTTGCCCAAGCTCGAGCCTACATCTTCATCGATGAA\nGCACACATTACCCAAGCCCTCATATGGCTCTCCCAGAGGCAGAAGGACAATGGCTGTTTC\nAGGAGCTCTGGGTCACTGCTCAACAATGCCATAAAGGGAGGAGTAGAAGATGAAGTGACC\nCTCTCCGCCTATATCACCATCGCCCTTCTGGAGATTCCTCTCACAGTCACTCACCCTGTT\nGTCCGCAATGCCCTGTTTTGCCTGGAGTCAGCCTGGAAGACAGCACAAGAAGGGGACCAT\nGGCAGCCATGTATATACCAAAGCACTGCTGGCCTATGCTTTTGCCCTGGCAGGTAACCAG\nGACAAGAGGAAGGAAGTACTCAAGTCACTTAATGAGGAAGCTGTGAAGAAAGACAACTCT\nGTCCATTGGGAGCGCCCTCAGAAACCCAAGGCACCAGTGGGGCATTTTTACGAACCCCAG\nGCTCCCTCTGCTGAGGTGGAGATGACATCCTATGTGCTCCTCGCTTATCTCACGGCCCAG\nCCAGCCCCAACCTCGGAGGACCTGACCTCTGCAACCAACATCGTGAAGTGGATCACGAAG\nCAGCAGAATGCCCAGGGCGGTTTCTCCTCCACCCAGGACACAGTGGTGGCTCTCCATGCT\nCTGTCCAAATATGGAGCCGCCACATTTACCAGGACTGGGAAGGCTGCACAGGTGACTATC\nCAGTCTTCAGGGACATTTTCCAGCAAATTCCAAGTGGACAACAACAATCGCCTGTTACTG\nCAGCAGGTCTCATTGCCAGAGCTGCCTGGGGAATACAGCATGAAAGTGACAGGAGAAGGA\nTGTGTCTACCTCCAGACCTCCTTGAAATACAATATTCTCCCAGAAAAGGAAGAGTTCCCC\nTTTGCTTTAGGAGTGCAGACTCTGCCTCAAACTTGTGATGAACCCAAAGCCCACACCAGC\nTTCCAAATCTCCCTAAGTGTCAGTTACACAGGGAGCCGCTCTGCCTCCAACATGGCGATC\nGTTGATGTGAAGATGGTCTCTGGCTTCATTCCCCTGAAGCCAACAGTGAAAATGCTTGAA\nAGATCTAACCATGTGAGCCGGACAGAAGTCAGCAGCAACCATGTCTTGATTTACCTTGAT\nAAGGTGTCAAATCAGACACTGAGCTTGTTCTTCACGGTTCTGCAAGATGTCCCAGTAAGA\nGATCTCAAACCAGCCATAGTGAAAGTCTATGATTACTACGAGACGGATGAGTTTGCAATC\nGCTGAGTACAATGCTCCTTGCAGCAAAGATCTTGGAAATGCTTGA"}, "pfams": {"pfam": [{"identifier": "PF00207", "name": "A2M"}, {"identifier": "PF07678", "name": "A2M_comp"}, {"identifier": "PF01835", "name": "A2M_N"}, {"identifier": "PF07703", "name": "A2M_N_2"}, {"identifier": "PF07677", "name": "A2M_recep"}]}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "enzyme regulator activity"}, {"category": "function", "description": "enzyme inhibitor activity"}, {"category": "function", "description": "protease inhibitor activity"}, {"category": "function", "description": "endopeptidase inhibitor activity"}]}}}]}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2011-01-06", "drugbank-id": [{"@primary": "true", "#text": "DB00103"}, "BIOD00075", "BTD00075"], "name": "Agalsidase beta", "description": "Recombinant human alpha-galactosidase A. The mature protein is composed of 2 subunits of 398 residues. Protein is glycosylated and produced by CHO cells", "cas-number": "104138-64-9", "groups": {"group": ["approved", "investigational"]}, "general-references": "# Schaefer RM, Tylki-Szymanska A, Hilz MJ: Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Drugs. 2009 Nov 12;69(16):2179-205. doi: 10.2165/11318300-000000000-00000. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19852524\n# El Dib RP, Pastores GM: Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev. 2010 May 12;(5):CD006663. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20464743\n# Lim-Melia ER, Kronn DF: Current enzyme replacement therapy for the treatment of lysosomal storage diseases. Pediatr Ann. 2009 Aug;38(8):448-55. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19725195", "synthesis-reference": null, "indication": "For treatment of Fabry's disease (alpha-galactosidase A deficiency)", "pharmacodynamics": "Used in the treatment of Fabry disease, an X-linked genetic disorder of glycosphingolipid metabolism. The disease is characterized by a deficiency of the lysosomal enzyme alpha-galactosidase A, which leads to progressive accumulation of glycosphingolipids, predominantly GL-3, in many body tissues. Clinical manifestations of Fabry disease include renal failure, cardiomyopathy, and cerebrovascular accidents. Fabrazyme is intended to provide an exogenous source of alpha-galactosidase A and to limit the accumulation of these glycolipids in the tissues. Studies show unconclusive evidence for the clinical efficacy of either agalasidase alfa or agalasidase beta in preventing morbidity.", "mechanism-of-action": "Alpha-galactosidase A catalyzes the hydrolysis of globotriaosylceramide (GL-3) and other a-galactyl-terminated neutral glycosphingolipids, such as galabiosylceramide and blood group B substances to ceramide dihexoside and galactose.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": "45-102 min", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": "* 4.1 +/- 1.2 mL/min/kg [adult patients with Fabry disease,0.3 mg/kg, 1 infusion]\n* 4.6 +/- 2.2 mL/min/kg [adult patients with Fabry disease, 0.3 mg/kg, 5 infusions]\n* 2.1 +/- 0.7 mL/min/kg [adult patients with Fabry disease, 1 mg/kg, 1 infusion]\n* 3.2 +/- 2.6 mL/min/kg [adult patients with Fabry disease, 1 mg/kg, 5 infusions]\n* 0.8 +/- 0.3 mL/min/kg [adult patients with Fabry disease, 3 mg/kg, 1 infusion]\n* 0.8 +/- 0.4 mL/min/kg [adult patients with Fabry disease, 3 mg/kg, 5 infusions]\n* 1.8 +/- 0.8 mL/min/kg [Pediatric Patients with Fabry Disease, 1 mg/kg, 1-3 infusions]\n* 4.9 +/- 5.6 mL/min/kg [Pediatric Patients with Fabry Disease, 1 mg/kg, 7 infusions]\n* 2.3 +/- 2.2 mL/min/kg [Pediatric Patients with Fabry Disease, 1 mg/kg, 11 infusions]", "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Agalsidase alfa"}, {"@language": "", "@coder": "", "#text": "Alpha-D- galactoside galactohydrolase"}, {"@language": "", "@coder": "", "#text": "Alpha-D-galactosidase A"}, {"@language": "", "@coder": "", "#text": "Alpha-galactosidase A precursor"}, {"@language": "", "@coder": "", "#text": "Melibiase"}]}, "products": {"product": [{"name": "Fabrazyme", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02248965", "started-marketing-on": "2004-09-17", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "5 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Fabrazyme", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02248966", "started-marketing-on": "2004-04-08", "ended-marketing-on": null, "dosage-form": "powder for solution", "strength": "35 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Fabrazyme", "ndc-id": "58468-0040_1062d32d-80a0-43eb-b5fa-78c3ea27504e", "ndc-product-code": "58468-0040", "dpd-id": null, "started-marketing-on": "2008-12-17", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "5 mg/mL", "route": "intravenous", "fda-application-number": "BLA103979", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Fabrazyme", "ndc-id": "58468-0041_1062d32d-80a0-43eb-b5fa-78c3ea27504e", "ndc-product-code": "58468-0041", "dpd-id": null, "started-marketing-on": "2008-12-17", "ended-marketing-on": null, "dosage-form": "injection, powder, lyophilized, for solution", "strength": "5 mg/mL", "route": "intravenous", "fda-application-number": "BLA103979", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Replagal", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02249057", "started-marketing-on": "2004-03-18", "ended-marketing-on": "2014-06-20", "dosage-form": "solution", "strength": "1 mg", "route": "intravenous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Fabrazyme", "ingredients": "Agalsidase beta"}, {"name": "Fabrazyme", "ingredients": "Agalsidase beta"}, {"name": "Fabrazyme", "ingredients": "Agalsidase beta"}, {"name": "Fabrazyme", "ingredients": "Agalsidase beta"}, {"name": "Replagal", "ingredients": "Agalsidase beta"}]}, "packagers": {"packager": [{"name": "Genzyme Inc.", "url": "http://www.genzyme.ca"}, {"name": "Shire Inc.", "url": "http://www.shire.com"}]}, "manufacturers": null, "prices": {"price": [{"description": "Fabrazyme 5 mg vial", "cost": {"@currency": "USD", "#text": "771.6"}, "unit": "vial"}, {"description": "Fabrazyme 35 mg vial", "cost": {"@currency": "USD", "#text": "5403.6"}, "unit": "vial"}]}, "categories": {"category": {"category": "Enzyme Replacement Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, powder, lyophilized, for solution", "route": "intravenous", "strength": "5 mg/mL"}, {"form": "Powder for solution", "route": "intravenous", "strength": "35 mg"}, {"form": "Powder for solution", "route": "intravenous", "strength": "5 mg"}, {"form": "Solution", "route": "intravenous", "strength": "1 mg"}]}, "atc-codes": {"atc-code": {"@code": "A16AB04", "level": [{"@code": "A", "#text": "ALIMENTARY TRACT AND METABOLISM"}, {"@code": "A16", "#text": "OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS"}, {"@code": "A16A", "#text": "OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS"}, {"@code": "A16AB", "#text": "Enzymes"}]}}, "ahfs-codes": {"ahfs-code": "44:00.00"}, "patents": {"patent": {"number": "2265464", "country": "Canada", "approved": "2007-06-26", "expires": "2017-09-12"}}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB01118", "name": "Amiodarone", "description": "May diminish the therapeutic effect of Agalsidase beta."}, {"drugbank-id": "DB00608", "name": "Chloroquine", "description": "May diminish the therapeutic effect of Agalsidase beta."}, {"drugbank-id": "DB00798", "name": "Gentamicin", "description": "Gentamicin (Systemic) may diminish the therapeutic effect of Agalsidase beta."}, {"drugbank-id": "DB00798", "name": "Gentamicin", "description": "Gentamicin (Systemic) may diminish the therapeutic effect of Agalsidase Alfa."}]}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00103 sequence\nLDNGLARTPTMGWLHWERFMCNLDCQEEPDSCISEKLFMEMAELMVSEGWKDAGYEYLCI\nDDCWMAPQRDSEGRLQADPQRFPHGIRQLANYVHSKGLKLGIYADVGNKTCAGFPGSFGY\nYDIDAQTFADWGVDLLKFDGCYCDSLENLADGYKHMSLALNRTGRSIVYSCEWPLYMWPF\nQKPNYTEIRQYCNHWRNFADIDDSWKSIKSILDWTSFNQERIVDVAGPGGWNDPDMLVIG\nNFGLSWNQQVTQMALWAIMAAPLFMSNDLRHISPQAKALLQDKDVIAINQDPLGKQGYQL\nRQGDNFEVWERPLSGLAWAVAMINRQEIGGPRSYTIAVASLGKGVACNPACFITQLLPVK\nRKLGFYEWTSRLRSHINPTGTVLLQLENTMQMSLKDLL"}}, "experimental-properties": {"property": [{"kind": "Hydrophobicity", "value": "-0.307", "source": null}, {"kind": "Isoelectric Point", "value": "5.17", "source": null}, {"kind": "Molecular Weight", "value": "45351.6000", "source": null}, {"kind": "Molecular Formula", "value": "C2029H3080N544O587S27", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "13296"}, {"resource": "Drugs Product Database (DPD)", "identifier": "13300"}, {"resource": "National Drug Code Directory", "identifier": "58468-0040-1"}, {"resource": "GenBank", "identifier": "X14448"}, {"resource": "PharmGKB", "identifier": "PA164746527"}, {"resource": "UniProtKB", "identifier": "P06280"}, {"resource": "Wikipedia", "identifier": "Agalsidase_beta"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic3/fabrazyme.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/agalsidase-beta.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": {"@position": "1", "id": "BE0004830", "name": "Globotriaosylceramide", "organism": "Human", "actions": {"action": "ligand"}, "references": "# Schaefer RM, Tylki-Szymanska A, Hilz MJ: Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Drugs. 2009 Nov 12;69(16):2179-205. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19852524\n# El Dib RP, Pastores GM: Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev. 2010 May 12;(5):CD006663. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20464743\n# Lim-Melia ER, Kronn DF: Current enzyme replacement therapy for the treatment of lysosomal storage diseases. Pediatr Ann. 2009 Aug;38(8):448-55. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19725195", "known-action": "yes"}}, "enzymes": null, "carriers": null, "transporters": null}, {"@type": "small molecule", "@created": "2005-06-13", "@updated": "2013-09-16", "drugbank-id": [{"@primary": "true", "#text": "DB00104"}, "BIOD00088", "BTD00088"], "name": "Octreotide", "description": "Octreotide is the acetate salt of a cyclic octapeptide. It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin.", "cas-number": "83150-76-9", "groups": {"group": ["approved", "investigational"]}, "general-references": "# Uhl W, Anghelacopoulos SE, Friess H, Buchler MW: The role of octreotide and somatostatin in acute and chronic pancreatitis. Digestion. 1999;60 Suppl 2:23-31. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10207228", "synthesis-reference": "Nishith Chaturvedi, \"Novel process for production of the somatostatin analog, octreotide.\" U.S. Patent US20040225108, issued November 11, 2004.", "indication": "For treatment of acromegaly and reduction of side effects from cancer chemotherapy", "pharmacodynamics": "Octreotide exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses leuteinizing hormone (LH) response to GnRH, decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide. Octreotide has been used to treat the symptoms associated with metastatic carcinoid tumors (flushing and diarrhea), and Vasoactive Intestinal Peptide (VIP) secreting adenomas (watery diarrhea). Octreotide substantially reduces and in many cases can normalize growth hormone and/or IGF-1 (somatomedin C) levels in patients with acromegaly.", "mechanism-of-action": "Octreotide binds to somatostatin receptors. These receptors are coupled via pertussis toxin sensitive G proteins which lead to inhibition of adenylyl cyclase. Octreotide binding to these receptors also stimulates phosphotyrosine phosphatase and activation of the Na(+)/H(+) exchanger via pertussis toxin insensitive G proteins.", "toxicity": null, "metabolism": null, "absorption": null, "half-life": null, "protein-binding": null, "route-of-elimination": "About 32% of the dose is excreted unchanged into the urine.", "volume-of-distribution": "* 13.6 L [healthy volunteers]\n* 21.6\u00b18.5 L [patients with acromegaly]", "clearance": "* 7 \u2013 10 L/hr [healthy after 100-mcg SC injection]\n* 18 L/hr [patients with acromegaly after 100-mcg SC injection]\n* 8.8 L/hr [mild renal impairment after 100-mcg SC injection]\n* 7.3 L/hr [moderate renal impairment after 100-mcg SC injection]\n* 7.6 L/hr [severe renal impairment after 100-mcg SC injection]\n* 4.5 L/hr [severe renal failure requiring dialysis after 100-mcg SC injection]\n* 5.9 L/hr [Patients with liver cirrhosis after 100-mcg SC injection]\n* 8.2 L/hr [patients with fatty liver disease after 100-mcg SC injection]", "classification": {"description": "This compound belongs to the class of organic compounds known as cyclic peptides. These are compounds containing a cyclic moiety bearing a peptide backbone.", "direct-parent": "Cyclic peptides", "kingdom": "Organic compounds", "superclass": "Organic acids and derivatives", "class": "Carboxylic acids and derivatives", "subclass": "Amino acids, peptides, and analogues", "alternative-parent": ["Alpha amino acid amides", "Amphetamines and derivatives", "Aralkylamines", "Azacyclic compounds", "Carbonyl compounds", "Fatty amides", "Heteroaromatic compounds", "Hydrocarbon derivatives", "Indoles", "Lactams", "Macrolactams", "Monoalkylamines", "N-acyl-alpha amino acids and derivatives", "Organic disulfides", "Phenylpropylamines", "Primary alcohols", "Secondary alcohols", "Secondary carboxylic acid amides", "Substituted pyrroles"], "substituent": ["Alcohol", "Alpha-amino acid amide", "Alpha-amino acid or derivatives", "Amine", "Amphetamine or derivatives", "Aralkylamine", "Aromatic heteropolycyclic compound", "Azacycle", "Benzenoid", "Carbonyl group", "Carboxamide group", "Carboxylic acid amide", "Cyclic alpha peptide", "Fatty acyl", "Fatty amide", "Heteroaromatic compound", "Hydrocarbon derivative", "Indole", "Indole or derivatives", "Lactam", "Macrolactam", "Monocyclic benzene moiety", "N-acyl-alpha amino acid or derivatives", "Organic disulfide", "Organoheterocyclic compound", "Organonitrogen compound", "Organooxygen compound", "Phenylpropylamine", "Primary alcohol", "Primary aliphatic amine", "Primary amine", "Pyrrole", "Secondary alcohol", "Secondary carboxylic acid amide", "Substituted pyrrole"]}, "salts": {"salt": {"drugbank-id": {"@primary": "true", "#text": "DBSALT000130"}, "name": "Octreotide acetate", "cas-number": null, "inchikey": "InChIKey=OKFJFPWFTVAWNK-AARKYNAGSA-N"}}, "synonyms": {"synonym": [{"@language": "Spanish", "@coder": "", "#text": "Octreotida"}, {"@language": "Latin", "@coder": "", "#text": "Octreotidum"}, {"@language": "", "@coder": "", "#text": "Octrotide"}]}, "products": {"product": [{"name": "Ocphyl", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02413191", "started-marketing-on": "2014-05-12", "ended-marketing-on": null, "dosage-form": "solution", "strength": "50 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Ocphyl", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02413205", "started-marketing-on": "2014-05-12", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Ocphyl", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02413213", "started-marketing-on": "2014-05-12", "ended-marketing-on": null, "dosage-form": "solution", "strength": "500 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Octreotide", "ndc-id": "63323-365_69f2e51d-126a-474c-ad51-771d7c58f8e7", "ndc-product-code": "63323-365", "dpd-id": null, "started-marketing-on": "2006-03-14", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "50 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA077457", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide", "ndc-id": "63323-365_c36b167e-77c9-492f-8ccb-d47a30360a54", "ndc-product-code": "63323-365", "dpd-id": null, "started-marketing-on": "2006-03-14", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "50 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA077457", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide", "ndc-id": "63323-376_69f2e51d-126a-474c-ad51-771d7c58f8e7", "ndc-product-code": "63323-376", "dpd-id": null, "started-marketing-on": "2006-03-14", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA077457", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide", "ndc-id": "63323-376_c36b167e-77c9-492f-8ccb-d47a30360a54", "ndc-product-code": "63323-376", "dpd-id": null, "started-marketing-on": "2006-03-14", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA077457", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide", "ndc-id": "63323-377_69f2e51d-126a-474c-ad51-771d7c58f8e7", "ndc-product-code": "63323-377", "dpd-id": null, "started-marketing-on": "2006-03-14", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "500 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA077457", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide", "ndc-id": "63323-377_c36b167e-77c9-492f-8ccb-d47a30360a54", "ndc-product-code": "63323-377", "dpd-id": null, "started-marketing-on": "2006-03-14", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "500 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA077457", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide", "ndc-id": "63323-378_69f2e51d-126a-474c-ad51-771d7c58f8e7", "ndc-product-code": "63323-378", "dpd-id": null, "started-marketing-on": "2006-03-14", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "200 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA077450", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide", "ndc-id": "63323-379_69f2e51d-126a-474c-ad51-771d7c58f8e7", "ndc-product-code": "63323-379", "dpd-id": null, "started-marketing-on": "2006-03-14", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "1000 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA077450", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "55648-632_3612a4d7-791d-4f11-aab1-4aefb5203bf1", "ndc-product-code": "55648-632", "dpd-id": null, "started-marketing-on": "2011-05-11", "ended-marketing-on": null, "dosage-form": "injection", "strength": "1000 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA090986", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "55648-633_3612a4d7-791d-4f11-aab1-4aefb5203bf1", "ndc-product-code": "55648-633", "dpd-id": null, "started-marketing-on": "2011-05-11", "ended-marketing-on": null, "dosage-form": "injection", "strength": "100 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA090985", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "55648-634_3612a4d7-791d-4f11-aab1-4aefb5203bf1", "ndc-product-code": "55648-634", "dpd-id": null, "started-marketing-on": "2011-05-11", "ended-marketing-on": null, "dosage-form": "injection", "strength": "200 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA090986", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "55648-635_3612a4d7-791d-4f11-aab1-4aefb5203bf1", "ndc-product-code": "55648-635", "dpd-id": null, "started-marketing-on": "2011-05-11", "ended-marketing-on": null, "dosage-form": "injection", "strength": "500 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA090985", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "55648-636_3612a4d7-791d-4f11-aab1-4aefb5203bf1", "ndc-product-code": "55648-636", "dpd-id": null, "started-marketing-on": "2011-05-11", "ended-marketing-on": null, "dosage-form": "injection", "strength": "50 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA090985", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "25021-451_8af84a7a-a879-4f2e-a1fe-7922ad3c7c59", "ndc-product-code": "25021-451", "dpd-id": null, "started-marketing-on": "2013-12-15", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "50 ug/mL", "route": "intramuscular; subcutaneous", "fda-application-number": "ANDA090834", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "25021-452_8af84a7a-a879-4f2e-a1fe-7922ad3c7c59", "ndc-product-code": "25021-452", "dpd-id": null, "started-marketing-on": "2013-12-15", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 ug/mL", "route": "intramuscular; subcutaneous", "fda-application-number": "ANDA090834", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "25021-453_8af84a7a-a879-4f2e-a1fe-7922ad3c7c59", "ndc-product-code": "25021-453", "dpd-id": null, "started-marketing-on": "2013-12-15", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "500 ug/mL", "route": "intramuscular; subcutaneous", "fda-application-number": "ANDA090834", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "0703-3301_87301f2d-48e4-44bb-a1ee-73ea6892ad37", "ndc-product-code": "0703-3301", "dpd-id": null, "started-marketing-on": "2005-11-14", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "50 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA075957", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "25021-454_8af84a7a-a879-4f2e-a1fe-7922ad3c7c59", "ndc-product-code": "25021-454", "dpd-id": null, "started-marketing-on": "2013-12-15", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "200 ug/mL", "route": "intramuscular; subcutaneous", "fda-application-number": "ANDA091041", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "0703-3311_87301f2d-48e4-44bb-a1ee-73ea6892ad37", "ndc-product-code": "0703-3311", "dpd-id": null, "started-marketing-on": "2005-11-14", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA075957", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "25021-455_8af84a7a-a879-4f2e-a1fe-7922ad3c7c59", "ndc-product-code": "25021-455", "dpd-id": null, "started-marketing-on": "2013-12-15", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "1000 ug/mL", "route": "intramuscular; subcutaneous", "fda-application-number": "ANDA091041", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "0703-3321_87301f2d-48e4-44bb-a1ee-73ea6892ad37", "ndc-product-code": "0703-3321", "dpd-id": null, "started-marketing-on": "2005-11-14", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "500 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA075957", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "0703-3333_87301f2d-48e4-44bb-a1ee-73ea6892ad37", "ndc-product-code": "0703-3333", "dpd-id": null, "started-marketing-on": "2005-11-23", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "200 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA075959", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "0703-3343_87301f2d-48e4-44bb-a1ee-73ea6892ad37", "ndc-product-code": "0703-3343", "dpd-id": null, "started-marketing-on": "2005-11-23", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "1000 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA075959", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "67457-239_17dd21b1-fe77-4ef6-b06f-e0d57be58d71", "ndc-product-code": "67457-239", "dpd-id": null, "started-marketing-on": "2013-04-25", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "50 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA079198", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "67457-245_17dd21b1-fe77-4ef6-b06f-e0d57be58d71", "ndc-product-code": "67457-245", "dpd-id": null, "started-marketing-on": "2013-04-25", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA079198", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "67457-246_17dd21b1-fe77-4ef6-b06f-e0d57be58d71", "ndc-product-code": "67457-246", "dpd-id": null, "started-marketing-on": "2013-04-25", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "500 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA079198", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "64679-632_ef0b005f-898a-4944-a983-72fe170ab7c7", "ndc-product-code": "64679-632", "dpd-id": null, "started-marketing-on": "2011-05-11", "ended-marketing-on": null, "dosage-form": "injection", "strength": "1000 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA090986", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "64679-633_ef0b005f-898a-4944-a983-72fe170ab7c7", "ndc-product-code": "64679-633", "dpd-id": null, "started-marketing-on": "2011-05-11", "ended-marketing-on": null, "dosage-form": "injection", "strength": "100 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA090985", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "64679-634_ef0b005f-898a-4944-a983-72fe170ab7c7", "ndc-product-code": "64679-634", "dpd-id": null, "started-marketing-on": "2011-05-11", "ended-marketing-on": null, "dosage-form": "injection", "strength": "200 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA090986", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "64679-635_ef0b005f-898a-4944-a983-72fe170ab7c7", "ndc-product-code": "64679-635", "dpd-id": null, "started-marketing-on": "2011-05-11", "ended-marketing-on": null, "dosage-form": "injection", "strength": "500 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA090985", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "64679-636_ef0b005f-898a-4944-a983-72fe170ab7c7", "ndc-product-code": "64679-636", "dpd-id": null, "started-marketing-on": "2011-05-11", "ended-marketing-on": null, "dosage-form": "injection", "strength": "50 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA090985", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "0781-3164_b02b276f-9007-4ec7-8bcd-40f14213d7f5", "ndc-product-code": "0781-3164", "dpd-id": null, "started-marketing-on": "1988-10-21", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "1000 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "NDA019667", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "0781-3165_b02b276f-9007-4ec7-8bcd-40f14213d7f5", "ndc-product-code": "0781-3165", "dpd-id": null, "started-marketing-on": "1988-10-21", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "200 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "NDA019667", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "0781-3166_4e5348ae-d032-4eea-babc-2cc54c66616e", "ndc-product-code": "0781-3166", "dpd-id": null, "started-marketing-on": "2014-02-04", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "50 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "NDA019667", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "0781-3167_4e5348ae-d032-4eea-babc-2cc54c66616e", "ndc-product-code": "0781-3167", "dpd-id": null, "started-marketing-on": "2014-02-04", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "NDA019667", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "0781-3168_4e5348ae-d032-4eea-babc-2cc54c66616e", "ndc-product-code": "0781-3168", "dpd-id": null, "started-marketing-on": "2014-02-04", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "500 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "NDA019667", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "62756-093_df56bfca-7af6-4bd7-afbc-d7f26b174b20", "ndc-product-code": "62756-093", "dpd-id": null, "started-marketing-on": "2012-08-31", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "50 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA077372", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "62756-094_df56bfca-7af6-4bd7-afbc-d7f26b174b20", "ndc-product-code": "62756-094", "dpd-id": null, "started-marketing-on": "2012-08-31", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA077372", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "62756-095_df56bfca-7af6-4bd7-afbc-d7f26b174b20", "ndc-product-code": "62756-095", "dpd-id": null, "started-marketing-on": "2012-08-31", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "500 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA077372", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "62756-348_df56bfca-7af6-4bd7-afbc-d7f26b174b20", "ndc-product-code": "62756-348", "dpd-id": null, "started-marketing-on": "2007-08-14", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "50 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA077372", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "62756-349_df56bfca-7af6-4bd7-afbc-d7f26b174b20", "ndc-product-code": "62756-349", "dpd-id": null, "started-marketing-on": "2007-08-14", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA077372", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "62756-350_df56bfca-7af6-4bd7-afbc-d7f26b174b20", "ndc-product-code": "62756-350", "dpd-id": null, "started-marketing-on": "2007-08-14", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "200 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA077373", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "62756-351_df56bfca-7af6-4bd7-afbc-d7f26b174b20", "ndc-product-code": "62756-351", "dpd-id": null, "started-marketing-on": "2007-08-14", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "500 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA077372", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate", "ndc-id": "62756-352_df56bfca-7af6-4bd7-afbc-d7f26b174b20", "ndc-product-code": "62756-352", "dpd-id": null, "started-marketing-on": "2007-08-14", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "1000 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "ANDA077373", "generic": "true", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Octreotide Acetate Injection   - 100mcg/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02263173", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Octreotide Acetate Injection   - 200mcg/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02263181", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "200 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Octreotide Acetate Injection   - 500mcg/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02263203", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "500 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Octreotide Acetate Injection  - 50mcg/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02263165", "started-marketing-on": null, "ended-marketing-on": null, "dosage-form": "solution", "strength": "50 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Octreotide Acetate Omega 100mcg/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02248640", "started-marketing-on": "2004-02-26", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Octreotide Acetate Omega 200mcg/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02248642", "started-marketing-on": "2004-03-11", "ended-marketing-on": null, "dosage-form": "solution", "strength": "200 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Octreotide Acetate Omega 500mcg/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02248641", "started-marketing-on": "2004-02-26", "ended-marketing-on": null, "dosage-form": "solution", "strength": "500 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Octreotide Acetate Omega 50mcg/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02248639", "started-marketing-on": "2004-02-26", "ended-marketing-on": null, "dosage-form": "solution", "strength": "50 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Octreotide Injection", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02299429", "started-marketing-on": "2014-04-18", "ended-marketing-on": null, "dosage-form": "solution", "strength": "50 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Octreotide Injection", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02299437", "started-marketing-on": "2008-03-06", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Octreotide Injection", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02299445", "started-marketing-on": "2008-03-06", "ended-marketing-on": null, "dosage-form": "solution", "strength": "200 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Octreotide Injection", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02299453", "started-marketing-on": "2008-03-06", "ended-marketing-on": null, "dosage-form": "solution", "strength": "500 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Sandostatin", "ndc-id": "0078-0180_99b5ec1c-b6bc-4b1c-b34f-413e36d6ce8c", "ndc-product-code": "0078-0180", "dpd-id": null, "started-marketing-on": "1988-10-21", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "50 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "NDA019667", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Sandostatin", "ndc-id": "0078-0181_99b5ec1c-b6bc-4b1c-b34f-413e36d6ce8c", "ndc-product-code": "0078-0181", "dpd-id": null, "started-marketing-on": "1988-10-21", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "100 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "NDA019667", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Sandostatin", "ndc-id": "0078-0182_99b5ec1c-b6bc-4b1c-b34f-413e36d6ce8c", "ndc-product-code": "0078-0182", "dpd-id": null, "started-marketing-on": "1988-10-21", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "500 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "NDA019667", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Sandostatin", "ndc-id": "0078-0183_99b5ec1c-b6bc-4b1c-b34f-413e36d6ce8c", "ndc-product-code": "0078-0183", "dpd-id": null, "started-marketing-on": "1998-10-21", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "200 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "NDA019667", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Sandostatin", "ndc-id": "0078-0184_99b5ec1c-b6bc-4b1c-b34f-413e36d6ce8c", "ndc-product-code": "0078-0184", "dpd-id": null, "started-marketing-on": "1988-10-21", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "1000 ug/mL", "route": "intravenous; subcutaneous", "fda-application-number": "NDA019667", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Sandostatin 100mcg/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00839205", "started-marketing-on": "1989-12-31", "ended-marketing-on": null, "dosage-form": "solution", "strength": "100 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Sandostatin 200mcg/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02049392", "started-marketing-on": "1996-12-31", "ended-marketing-on": null, "dosage-form": "solution", "strength": "200 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Sandostatin 500mcg/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00839213", "started-marketing-on": "1989-12-31", "ended-marketing-on": null, "dosage-form": "solution", "strength": "500 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Sandostatin 50mcg/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00839191", "started-marketing-on": "1989-12-31", "ended-marketing-on": null, "dosage-form": "solution", "strength": "50 mcg", "route": "intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Sandostatin Lar 10mg", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02239323", "started-marketing-on": "1999-01-27", "ended-marketing-on": null, "dosage-form": "powder", "strength": "10 mg", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Sandostatin Lar 20mg", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02239324", "started-marketing-on": "1999-01-27", "ended-marketing-on": null, "dosage-form": "powder", "strength": "20 mg", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Sandostatin Lar 30mg", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02239325", "started-marketing-on": "1999-01-27", "ended-marketing-on": null, "dosage-form": "powder", "strength": "30 mg", "route": "intramuscular", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": {"international-brand": {"name": "Sandostatin LAR", "company": "Novartis Pharmaceuticals"}}, "mixtures": {"mixture": [{"name": "Sandostatin", "ingredients": "Octreotide"}, {"name": "Sandostatin", "ingredients": "Octreotide"}, {"name": "Sandostatin", "ingredients": "Octreotide"}, {"name": "Sandostatin", "ingredients": "Octreotide"}, {"name": "Sandostatin", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide", "ingredients": "Octreotide"}, {"name": "Octreotide", "ingredients": "Octreotide"}, {"name": "Octreotide", "ingredients": "Octreotide"}, {"name": "Octreotide", "ingredients": "Octreotide"}, {"name": "Octreotide", "ingredients": "Octreotide"}, {"name": "Octreotide", "ingredients": "Octreotide"}, {"name": "Octreotide", "ingredients": "Octreotide"}, {"name": "Octreotide", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate", "ingredients": "Octreotide"}, {"name": "Sandostatin 200mcg/ml", "ingredients": "Octreotide"}, {"name": "Sandostatin Lar 10mg", "ingredients": "Octreotide"}, {"name": "Sandostatin Lar 20mg", "ingredients": "Octreotide"}, {"name": "Sandostatin Lar 30mg", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate Omega 50mcg/ml", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate Omega 100mcg/ml", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate Omega 500mcg/ml", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate Omega 200mcg/ml", "ingredients": "Octreotide"}, {"name": "Octreotide Injection", "ingredients": "Octreotide"}, {"name": "Octreotide Injection", "ingredients": "Octreotide"}, {"name": "Octreotide Injection", "ingredients": "Octreotide"}, {"name": "Octreotide Injection", "ingredients": "Octreotide"}, {"name": "Ocphyl", "ingredients": "Octreotide"}, {"name": "Ocphyl", "ingredients": "Octreotide"}, {"name": "Ocphyl", "ingredients": "Octreotide"}, {"name": "Sandostatin 50mcg/ml", "ingredients": "Octreotide"}, {"name": "Sandostatin 100mcg/ml", "ingredients": "Octreotide"}, {"name": "Sandostatin 500mcg/ml", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate Injection  - 50mcg/ml", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate Injection   - 100mcg/ml", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate Injection   - 200mcg/ml", "ingredients": "Octreotide"}, {"name": "Octreotide Acetate Injection   - 500mcg/ml", "ingredients": "Octreotide"}]}, "packagers": {"packager": [{"name": "APP Pharmaceuticals", "url": "http://www.apppharma.com"}, {"name": "Bachem Inc.", "url": "http://www.bachem.com"}, {"name": "Bedford Labs", "url": "http://www.bedfordlabs.com"}, {"name": "Ben Venue Laboratories Inc.", "url": "http://www.benvenue.com"}, {"name": "Novartis AG", "url": "http://www.novartis.com"}, {"name": "Polfa", "url": "http://www.polfa.pl"}, {"name": "Sandoz", "url": "http://www.sandoz.ca"}, {"name": "Sicor Pharmaceuticals", "url": null}, {"name": "Solvay Pharmaceuticals", "url": "http://global.abbottgrowth.com"}, {"name": "Sun Pharmaceutical Industries Ltd.", "url": "http://www.sunpharma.com"}, {"name": "Teva Pharmaceutical Industries Ltd.", "url": "http://www.tevapharm.com"}]}, "manufacturers": {"manufacturer": [{"@generic": "true", "#text": "App pharmaceuticals llc"}, {"@generic": "true", "#text": "Bedford laboratories div ben venue laboratories inc"}, {"@generic": "true", "#text": "Sun pharmaceutical industries ltd"}, {"@generic": "true", "#text": "Teva parenteral medicines inc"}, {"@generic": "false", "#text": "Novartis pharmaceuticals corp"}]}, "prices": {"price": [{"description": "Octreotide acet 50 mcg/ml vial", "cost": {"@currency": "USD", "#text": "3.6"}, "unit": "ml"}, {"description": "Sandostatin 0.05 mg/ml ampul", "cost": {"@currency": "USD", "#text": "11.92"}, "unit": "ml"}, {"description": "Octreotide acet 200 mcg/ml vial", "cost": {"@currency": "USD", "#text": "14.4"}, "unit": "ml"}, {"description": "Octreotide acet 100 mcg/ml vial", "cost": {"@currency": "USD", "#text": "15.36"}, "unit": "ml"}, {"description": "Sandostatin 0.1 mg/ml ampul", "cost": {"@currency": "USD", "#text": "23.11"}, "unit": "ml"}, {"description": "Octreotide acet 500 mcg/ml vial", "cost": {"@currency": "USD", "#text": "24.48"}, "unit": "ml"}, {"description": "Sandostatin 0.2 mg/ml vial", "cost": {"@currency": "USD", "#text": "47.66"}, "unit": "ml"}, {"description": "Octreotide 1000 mcg/ml vial", "cost": {"@currency": "USD", "#text": "67.2"}, "unit": "ml"}, {"description": "Sandostatin 0.5 mg/ml ampul", "cost": {"@currency": "USD", "#text": "111.48"}, "unit": "ml"}, {"description": "Sandostatin 1 mg/ml vial", "cost": {"@currency": "USD", "#text": "234.49"}, "unit": "ml"}, {"description": "Sandostatin lar 10 mg kit", "cost": {"@currency": "USD", "#text": "1967.81"}, "unit": "kit"}, {"description": "Sandostatin lar 20 mg kit", "cost": {"@currency": "USD", "#text": "2578.19"}, "unit": "kit"}, {"description": "Sandostatin lar 30 mg kit", "cost": {"@currency": "USD", "#text": "3860.62"}, "unit": "kit"}]}, "categories": {"category": [{"category": "Antineoplastic Agents, Hormonal", "mesh-id": null}, {"category": "Gastrointestinal Agents", "mesh-id": null}, {"category": "Hormone Replacement Agents", "mesh-id": null}]}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection", "route": "intravenous; subcutaneous", "strength": "100 ug/mL"}, {"form": "Injection", "route": "intravenous; subcutaneous", "strength": "1000 ug/mL"}, {"form": "Injection", "route": "intravenous; subcutaneous", "strength": "200 ug/mL"}, {"form": "Injection", "route": "intravenous; subcutaneous", "strength": "50 ug/mL"}, {"form": "Injection", "route": "intravenous; subcutaneous", "strength": "500 ug/mL"}, {"form": "Injection, solution", "route": "intramuscular; subcutaneous", "strength": "100 ug/mL"}, {"form": "Injection, solution", "route": "intramuscular; subcutaneous", "strength": "1000 ug/mL"}, {"form": "Injection, solution", "route": "intramuscular; subcutaneous", "strength": "200 ug/mL"}, {"form": "Injection, solution", "route": "intramuscular; subcutaneous", "strength": "50 ug/mL"}, {"form": "Injection, solution", "route": "intramuscular; subcutaneous", "strength": "500 ug/mL"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "100 mcg"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "500 mcg"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "50 mcg"}, {"form": "Injection, solution", "route": "intravenous; subcutaneous", "strength": "100 ug/mL"}, {"form": "Injection, solution", "route": "intravenous; subcutaneous", "strength": "1000 ug/mL"}, {"form": "Injection, solution", "route": "intravenous; subcutaneous", "strength": "200 ug/mL"}, {"form": "Injection, solution", "route": "intravenous; subcutaneous", "strength": "50 ug/mL"}, {"form": "Injection, solution", "route": "intravenous; subcutaneous", "strength": "500 ug/mL"}, {"form": "Solution", "route": "intravenous; subcutaneous", "strength": "200 mcg"}, {"form": "Powder", "route": "intramuscular", "strength": "10 mg"}, {"form": "Powder", "route": "intramuscular", "strength": "20 mg"}, {"form": "Powder", "route": "intramuscular", "strength": "30 mg"}]}, "atc-codes": {"atc-code": {"@code": "H01CB02", "level": [{"@code": "H", "#text": "SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS"}, {"@code": "H01", "#text": "PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES"}, {"@code": "H01C", "#text": "HYPOTHALAMIC HORMONES"}, {"@code": "H01CB", "#text": "Somatostatin and analogues"}]}}, "ahfs-codes": {"ahfs-code": "92:00.00"}, "patents": {"patent": [{"number": "1328402", "country": "Canada", "approved": "1994-04-12", "expires": "2011-04-12"}, {"number": "5538739", "country": "United States", "approved": "1993-07-23", "expires": "2013-07-23"}, {"number": "5922338", "country": "United States", "approved": "1997-01-13", "expires": "2017-01-13"}]}, "food-interactions": null, "drug-interactions": {"drug-interaction": [{"drugbank-id": "DB00414", "name": "Acetohexamide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00945", "name": "Acetylsalicylic acid", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB06203", "name": "Alogliptin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01158", "name": "Bretylium", "description": "May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents."}, {"drugbank-id": "DB01200", "name": "Bromocriptine", "description": "Somatostatin Analogs may increase the serum concentration of Bromocriptine. Somatostatin Analogs may also delay bromocriptine absorption and time to maximum plasma concentrations."}, {"drugbank-id": "DB08907", "name": "Canagliflozin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB09063", "name": "Ceritinib", "description": "Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib."}, {"drugbank-id": "DB00672", "name": "Chlorpropamide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00318", "name": "Codeine", "description": "Somatostatin Analogs may decrease the metabolism of Codeine. The formation of two major codeine metabolites (morphine and norcodeine) may be impaired by somatostatin analogs."}, {"drugbank-id": "DB02901", "name": "Dihydrotestosterone", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB01120", "name": "Gliclazide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00222", "name": "Glimepiride", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01251", "name": "Gliquidone", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01016", "name": "Glyburide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01306", "name": "Insulin Aspart", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01307", "name": "Insulin Detemir", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00047", "name": "Insulin Glargine", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB01309", "name": "Insulin Glulisine", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00046", "name": "Insulin Lispro", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00030", "name": "Insulin Regular", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB08914", "name": "Insulin, isophane", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB09083", "name": "Ivabradine", "description": "Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine."}, {"drugbank-id": "DB06218", "name": "Lacosamide", "description": "Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide."}, {"drugbank-id": "DB08882", "name": "Linagliptin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00331", "name": "Metformin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00834", "name": "Mifepristone", "description": "May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying)."}, {"drugbank-id": "DB00621", "name": "Oxandrolone", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00082", "name": "Pegvisomant", "description": "Somatostatin Analogs may enhance the adverse/toxic effect of Pegvisomant. Specifically, this combination may increase the risk for significant elevations of liver enzymes."}, {"drugbank-id": "DB00082", "name": "Pegvisomant", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB00912", "name": "Repaglinide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB08877", "name": "Ruxolitinib", "description": "May enhance the bradycardic effect of Bradycardia-Causing Agents."}, {"drugbank-id": "DB01398", "name": "Salicylate-sodium", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB06335", "name": "Saxagliptin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB00624", "name": "Testosterone", "description": "May enhance the hypoglycemic effect of Blood Glucose Lowering Agents."}, {"drugbank-id": "DB08895", "name": "Tofacitinib", "description": "May enhance the bradycardic effect of Bradycardia-Causing Agents."}, {"drugbank-id": "DB01124", "name": "Tolbutamide", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}, {"drugbank-id": "DB04876", "name": "Vildagliptin", "description": "May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents."}]}, "calculated-properties": {"property": [{"kind": "logP", "value": "0.42", "source": "ALOGPS"}, {"kind": "logS", "value": "-4.9", "source": "ALOGPS"}, {"kind": "Water Solubility", "value": "1.22e-02 g/l", "source": "ALOGPS"}, {"kind": "logP", "value": "-1.4", "source": "ChemAxon"}, {"kind": "IUPAC Name", "value": "(4R,7S,10S,13R,16S,19R)-19-[(2R)-2-amino-3-phenylpropanamido]-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide", "source": "ChemAxon"}, {"kind": "Traditional IUPAC Name", "value": "(4R,7S,10S,13R,16S,19R)-19-[(2R)-2-amino-3-phenylpropanamido]-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide", "source": "ChemAxon"}, {"kind": "Molecular Weight", "value": "1019.239", "source": "ChemAxon"}, {"kind": "Monoisotopic Weight", "value": "1018.440479762", "source": "ChemAxon"}, {"kind": "SMILES", "value": "C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(=O)N1", "source": "ChemAxon"}, {"kind": "Molecular Formula", "value": "C49H66N10O10S2", "source": "ChemAxon"}, {"kind": "InChI", "value": "InChI=1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29?,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1", "source": "ChemAxon"}, {"kind": "InChIKey", "value": "InChIKey=DEQANNDTNATYII-RRCPSWKPSA-N", "source": "ChemAxon"}, {"kind": "Polar Surface Area (PSA)", "value": "332.22", "source": "ChemAxon"}, {"kind": "Refractivity", "value": "269.77", "source": "ChemAxon"}, {"kind": "Polarizability", "value": "105.28", "source": "ChemAxon"}, {"kind": "Rotatable Bond Count", "value": "17", "source": "ChemAxon"}, {"kind": "H Bond Acceptor Count", "value": "12", "source": "ChemAxon"}, {"kind": "H Bond Donor Count", "value": "13", "source": "ChemAxon"}, {"kind": "pKa (strongest acidic)", "value": "11.4", "source": "ChemAxon"}, {"kind": "pKa (strongest basic)", "value": "10.17", "source": "ChemAxon"}, {"kind": "Physiological Charge", "value": "2", "source": "ChemAxon"}, {"kind": "Number of Rings", "value": "5", "source": "ChemAxon"}, {"kind": "Bioavailability", "value": "0", "source": "ChemAxon"}, {"kind": "Rule of Five", "value": "0", "source": "ChemAxon"}, {"kind": "Ghose Filter", "value": "0", "source": "ChemAxon"}, {"kind": "MDDR-Like Rule", "value": "1", "source": "ChemAxon"}]}, "experimental-properties": {"property": {"kind": "logP", "value": "1", "source": null}}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "1255"}, {"resource": "KEGG Compound", "identifier": "C07306"}, {"resource": "KEGG Drug", "identifier": "D00442"}, {"resource": "BindingDB", "identifier": "50175592"}, {"resource": "National Drug Code Directory", "identifier": "0078-0180-01"}, {"resource": "PharmGKB", "identifier": "PA450678"}, {"resource": "Wikipedia", "identifier": "Octreotide"}]}, "external-links": {"external-link": [{"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/octreotide.htm"}, {"resource": "Drugs.com", "url": "http://www.drugs.com/cdi/octreotide.html"}]}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000452", "name": "Somatostatin receptor type 1", "organism": "Human", "actions": null, "references": "# Wang ZZ, Qu W, Wang F, Li Y, Wang SK, Wang JQ: [Expression of somatostatin receptor reporter gene and its correlation with targeted imaging in vivo for detection of pancreas carcinoma] Zhonghua Zhong Liu Za Zhi. 2005 Nov;27(11):663-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16438887\n# Matrone C, Pivonello R, Colao A, Cappabianca P, Cavallo LM, Del Basso De Caro ML, Taylor JE, Culler MD, Lombardi G, Di Renzo GF, Annunziato L: Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Neuroendocrinology. 2004 Mar;79(3):142-8. Epub 2004 Apr 16. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15103227\n# Jaquet P, Gunz G, Saveanu A, Barlier A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Culler MD: BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest. 2005;28(11 Suppl International):21-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16625841\n# Schmid HA, Silva AP: Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats. J Endocrinol Invest. 2005;28(11 Suppl International):28-35. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16625842\n# Ruan W, Fahlbusch F, Clemmons DR, Monaco ME, Walden PD, Silva AP, Schmid HA, Kleinberg DL: SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3? Mol Endocrinol. 2006 Feb;20(2):426-36. Epub 2005 Oct 13. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16223973", "known-action": "yes", "polypeptide": {"@id": "P30872", "@source": "Swiss-Prot", "name": "Somatostatin receptor type 1", "general-function": "Involved in rhodopsin-like receptor activity", "specific-function": "Receptor for somatostatin with higher affinity for somatostatin-14 than -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphatase and Na(+)/H(+) exchanger via pertussis toxin insensitive G proteins", "gene-name": "SSTR1", "locus": "14q13", "cellular-location": "Membrane; multi-pass membrane protein", "transmembrane-regions": "57-84\n95-120\n132-153\n176-196\n220-244\n271-296\n304-327", "signal-regions": null, "theoretical-pi": "8.4", "molecular-weight": "42687.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:11330"}, {"resource": "GenAtlas", "identifier": "SSTR1"}, {"resource": "GeneCards", "identifier": "SSTR1"}, {"resource": "GenBank Gene Database", "identifier": "M81829"}, {"resource": "GenBank Protein Database", "identifier": "307434"}, {"resource": "IUPHAR", "identifier": "355"}, {"resource": "Guide to Pharmacology", "identifier": "61"}, {"resource": "UniProtKB", "identifier": "P30872"}, {"resource": "UniProt Accession", "identifier": "SSR1_HUMAN"}]}, "synonyms": {"synonym": ["SRIF-2", "SS1R"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Somatostatin receptor type 1\nMFPNGTASSPSSSPSPSPGSCGEGGGSRGPGAGAADGMEEPGRNASQNGTLSEGQGSAIL\nISFIYSVVCLVGLCGNSMVIYVILRYAKMKTATNIYILNLAIADELLMLSVPFLVTSTLL\nRHWPFGALLCRLVLSVDAVNMFTSIYCLTVLSVDRYVAVVHPIKAARYRRPTVAKVVNLG\nVWVLSLLVILPIVVFSRTAANSDGTVACNMLMPEPAQRWLVGFVLYTFLMGFLLPVGAIC\nLCYVLIIAKMRMVALKAGWQQRKRSERKITLMVMMVVMVFVICWMPFYVVQLVNVFAEQD\nDATVSQLSVILGYANSCANPILYGFLSDNFKRSFQRILCLSWMDNAAEEPVDYYATALKS\nRAYSVEDFQPENLESGGVFRNGTCTSRITTL"}, "gene-sequence": {"@format": "FASTA", "#text": ">1176 bp\nATGTTCCCCAATGGCACCGCCTCCTCTCCTTCCTCCTCTCCTAGCCCCAGCCCGGGCAGC\nTGCGGCGAAGGCGGCGGCAGCAGGGGCCCCGGGGCCGGCGCTGCGGACGGCATGGAGGAG\nCCAGGGCGAAATGCGTCCCAGAACGGGACCTTGAGCGAGGGCCAGGGCAGCGCCATCCTG\nATCTCTTTCATCTACTCCGTGGTGTGCCTGGTGGGGCTGTGTGGGAACTCTATGGTCATC\nTACGTGATCCTGCGCTATGCCAAGATGAAGACGGCCACCAACATCTACATCCTAAATCTG\nGCCATTGCTGATGAGCTGCTCATGCTCAGCGTGCCCTTCCTAGTCACCTCCACGTTGTTG\nCGCCACTGGCCCTTCGGTGCGCTGCTCTGCCGCCTCGTGCTCAGCGTGGACGCGGTCAAC\nATGTTCACCAGCATCTACTGTCTGACTGTGCTCAGCGTGGACCGCTACGTGGCCGTGGTG\nCATCCCATCAAGGCGGCCCGCTACCGCCGGCCCACCGTGGCCAAGGTAGTAAACCTGGGC\nGTGTGGGTGCTATCGCTGCTCGTCATCCTGCCCATCGTGGTCTTCTCTCGCACCGCGGCC\nAACAGCGACGGCACGGTGGCTTGCAACATGCTCATGCCAGAGCCCGCTCAACGCTGGCTG\nGTGGGCTTCGTGTTGTACACATTTCTCATGGGCTTCCTGCTGCCCGTGGGGGCTATCTGC\nCTGTGCTACGTGCTCATCATTGCTAAGATGCGCATGGTGGCCCTCAAGGCCGGCTGGCAG\nCAGCGCAAGCGCTCGGAGCGCAAGATCACCTTAATGGTGATGATGGTGGTGATGGTGTTT\nGTCATCTGCTGGATGCCTTTCTACGTGGTGCAGCTGGTTAACGTGTTTGCTGAGCAGGAC\nGACGCCACGGTGAGTCAGCTGTCGGTCATCCTCGGCTATGCCAACAGCTGCGCCAACCCC\nATCCTCTATGGCTTTCTCTCAGACAACTTCAAGCGCTCTTTCCAACGCATCCTATGCCTC\nAGCTGGATGGACAACGCCGCGGAGGAGCCGGTTGACTATTACGCCACCGCGCTCAAGAGC\nCGTGCCTACAGTGTGGAAGACTTCCAACCTGAGAACCTGGAGTCCGGCGGCGTCTTCCGT\nAATGGCACCTGCACGTCCCGGATCACGACGCTCTGA"}, "pfams": {"pfam": {"identifier": "PF00001", "name": "7tm_1"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "function", "description": "peptide receptor activity, G-protein coupled"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "neuropeptide receptor activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "somatostatin receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}]}}}, {"id": "BE0002147", "name": "Somatostatin receptor type 5", "organism": "Human", "actions": null, "references": "# Bronstein MD: Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome. Front Horm Res. 2006;35:129-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16809928\n# Xie Y, Tang CW, Wang CH: [Effect of HBV X gene transfection on octreotide-inhibited growth of hepatocellular carcinoma cell line HepG2] Ai Zheng. 2005 Aug;24(8):965-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16086874\n# Wang ZZ, Qu W, Wang F, Li Y, Wang SK, Wang JQ: [Expression of somatostatin receptor reporter gene and its correlation with targeted imaging in vivo for detection of pancreas carcinoma] Zhonghua Zhong Liu Za Zhi. 2005 Nov;27(11):663-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16438887\n# Jaquet P, Gunz G, Saveanu A, Barlier A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Culler MD: BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest. 2005;28(11 Suppl International):21-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16625841\n# Schmid HA, Silva AP: Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats. J Endocrinol Invest. 2005;28(11 Suppl International):28-35. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16625842", "known-action": "yes", "polypeptide": {"@id": "P35346", "@source": "Swiss-Prot", "name": "Somatostatin receptor type 5", "general-function": null, "specific-function": "Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase", "gene-name": "SSTR5", "locus": "16p13.3", "cellular-location": "Membrane", "transmembrane-regions": "39-66\n77-101\n114-135\n158-178\n198-222\n248-273\n284-308", "signal-regions": null, "theoretical-pi": "9.72", "molecular-weight": "39203.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:11334"}, {"resource": "GenAtlas", "identifier": "SSTR5"}, {"resource": "GeneCards", "identifier": "SSTR5"}, {"resource": "GenBank Gene Database", "identifier": "L14865"}, {"resource": "GenBank Protein Database", "identifier": "431095"}, {"resource": "IUPHAR", "identifier": "359"}, {"resource": "Guide to Pharmacology", "identifier": "61"}, {"resource": "UniProtKB", "identifier": "P35346"}, {"resource": "UniProt Accession", "identifier": "SSR5_HUMAN"}]}, "synonyms": {"synonym": "SS5R"}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Somatostatin receptor type 5\nMEPLFPASTPSWNASSPGAASGGGDNRTLVGPAPSAGARAVLVPVLYLLVCAAGLGGNTL\nVIYVVLRFAKMKTVTNIYILNLAVADVLYMLGLPFLATQNAASFWPFGPVLCRLVMTLDG\nVNQFTSVFCLTVMSVDRYLAVVHPLSSARWRRPRVAKLASAAAWVLSLCMSLPLLVFADV\nQEGGTCNASWPEPVGLWGAVFIIYTAVLGFFAPLLVICLCYLLIVVKVRAAGVRVGCVRR\nRSERKVTRMVLVVVLVFAGCWLPFFTVNIVNLAVALPQEPASAGLYFFVVILSYANSCAN\nPVLYGFLSDNFRQSFQKVLCLRKGSGAKDADATEPRPDRIRQQQEATPPAHRAAANGLMQ\nTSKL"}, "gene-sequence": {"@format": "FASTA", "#text": ">1092 bp\nATGGAGCCCCTGTTCCCAGCCTCCACGCCCAGCTGGAACGCCTCCTCCCCGGGGGCTGCC\nTCTGGAGGCGGTGACAACAGGACGCTGGTGGGGCCGGCGCCCTCGGCAGGGGCCCGGGCG\nGTGCTGGTGCCCGTGCTGTACCTGCTGGTGTGTGCGGCCGGGCTGGGCGGGAACACGCTG\nGTCATCTACGTGGTGCTGCGGTTCGCCAAGATGAAGACCGTCACCAACATCTACATTCTC\nAACCTGGCAGTGGCCGACGTCCTGTACATGCTGGGGCTGCCTTTCCTGGCCACGCAGAAC\nGCCGCGTCCTTCTGGCCCTTCGGCCCCGTCCTGTGCCGCCTGGTCATGACGCTGGACGGC\nGTCAACCAGTTCACCAGTGTCTTCTGCCTGACAGTCATGAGCGTGGACCGCTACCTGGCA\nGTGGTGCACCCGCTGAGCTCGGCCCGCTGGCGCCGCCCGCGTGTGGCCAAGCTGGCGAGC\nGCCGCCGCCTGGGTCCTGTCTCTGTGCATGTCGCTGCCGCTCTTGGTGTTCGCGGACGTG\nCAGGAGGGCGGTACCTGCAACGCCAGCTGGCCGGAGCCCGTGGGGCTGTGGGGCGCCGTC\nTTCATCATCTACACGGCCGTGCTGGGCTTCTTCGCGCCGCTGCTGGTCATCTGCCTGTGC\nTACCTGCTCATCGTGGTGAAGGTGAGGGCGGCGGGCGTGCGCGTGGGCTGCGTGCGGCGG\nCGCTCGGAGCGGAAGGTGACGCGCATGGTGTTGGTGGTGGTGCTGGTGTTTGCGGGATGT\nTGGCTGCCCTTCTTCACCGTCAACATCGTCAACCTGGCGGTTGCGCTGCCCCAGGAGCCC\nGCCTCCGCCGGCCTCTACTTCTTCGTGGTCATCCTCTCCTACGCCAACAGCTGTGCCAAC\nCCCGTCCTCTACGGCTTCCTCTCGGACAACTTCCGCCAGAGCTTCCAGAAGGTTCTGTGC\nCTCCGCAAGGGCTCTGGTGCCAAGGACGCTGACGCCACGGAGCCGCGTCCAGACAGGATC\nCGGCAGCAGCAGGAGGCCACGCGCCCGCGCACCGCCGCAGCCAACGGGCTTATGCAGACC\nAGCAAGCTGTGA"}, "pfams": {"pfam": {"identifier": "PF00001", "name": "7tm_1"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "function", "description": "peptide receptor activity, G-protein coupled"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "neuropeptide receptor activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "somatostatin receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}]}}}, {"@position": "1", "id": "BE0003528", "name": "Somatostatin receptor type 2", "organism": "Human", "actions": {"action": "binder"}, "references": "# Yim CB, Boerman OC, de Visser M, de Jong M, Dechesne AC, Rijkers DT, Liskamp RM: Versatile conjugation of octreotide to dendrimers by cycloaddition (\"click\") chemistry to yield high-affinity multivalent cyclic Peptide dendrimers. Bioconjug Chem. 2009 Jul;20(7):1323-31. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19537708\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P30874", "@source": "Swiss-Prot", "name": "Somatostatin receptor type 2", "general-function": null, "specific-function": "Receptor for somatostatins-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphatase and PLC via pertussis toxin insensitive as well as sensitive G proteins. In RIN-5F cells, this receptor inhibits calcium entry by suppressing voltage dependent calcium-channels", "gene-name": "SSTR2", "locus": null, "cellular-location": "Cell membrane", "transmembrane-regions": "44-67\n79-103\n119-138\n162-181\n208-229\n254-278\n289-303", "signal-regions": null, "theoretical-pi": "9.18", "molecular-weight": "41333.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:11331"}, {"resource": "GenAtlas", "identifier": "SSTR2"}, {"resource": "GenBank Gene Database", "identifier": "BC095495"}, {"resource": "IUPHAR", "identifier": "356"}, {"resource": "Guide to Pharmacology", "identifier": "61"}, {"resource": "UniProtKB", "identifier": "P30874"}, {"resource": "UniProt Accession", "identifier": "SSR2_HUMAN"}]}, "synonyms": {"synonym": ["SRIF-1", "SS2R"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Somatostatin receptor type 2\nMDMADEPLNGSHTWLSIPFDLNGSVVSTNTSNQTEPYYDLTSNAVLTFIYFVVCIIGLCG\nNTLVIYVILRYAKMKTITNIYILNLAIADELFMLGLPFLAMQVALVHWPFGKAICRVVMT\nVDGINQFTSIFCLTVMSIDRYLAVVHPIKSAKWRRPRTAKMITMAVWGVSLLVILPIMIY\nAGLRSNQWGRSSCTINWPGESGAWYTGFIIYTFILGFLVPLTIICLCYLFIIIKVKSSGI\nRVGSSKRKKSEKKVTRMVSIVVAVFIFCWLPFYIFNVSSVSMAISPTPALKGMFDFVVVL\nTYANSCANPILYAFLSDNFKKSFQNVLCLVKVSGTDDGERSDSKQDKSRLNETTETQRTL\nLNGDLQTSI"}, "gene-sequence": {"@format": "FASTA"}, "pfams": {"pfam": {"identifier": "PF00001", "name": "7tm_1"}}, "go-classifiers": {"go-classifier": [{"category": "component", "description": "cell"}, {"category": "component", "description": "intrinsic to membrane"}, {"category": "component", "description": "integral to membrane"}, {"category": "component", "description": "membrane"}, {"category": "function", "description": "rhodopsin-like receptor activity"}, {"category": "function", "description": "peptide receptor activity, G-protein coupled"}, {"category": "function", "description": "signal transducer activity"}, {"category": "function", "description": "neuropeptide receptor activity"}, {"category": "function", "description": "receptor activity"}, {"category": "function", "description": "somatostatin receptor activity"}, {"category": "function", "description": "transmembrane receptor activity"}, {"category": "function", "description": "G-protein coupled receptor activity"}, {"category": "process", "description": "cellular process"}, {"category": "process", "description": "cell communication"}, {"category": "process", "description": "signal transduction"}, {"category": "process", "description": "cell surface receptor linked signal transduction"}, {"category": "process", "description": "G-protein coupled receptor protein signaling pathway"}]}}}]}, "enzymes": {"enzyme": {"@position": "2", "id": "BE0001075", "name": "Myeloperoxidase", "organism": "Human", "actions": {"action": "inhibitor"}, "references": "# Alatas E, Alatas O, Colak O: Octreotide inhibits myeloperoxidase activity in rat uterus. Acta Obstet Gynecol Scand. 2000 Jul;79(7):524-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10929949\n# Alatas E, Gunal O, Alatas O, Colak O: Octreotide prevents postoperative adhesion formation by suppressing peritoneal myeloperoxidase activity. Hepatogastroenterology. 2000 Jul-Aug;47(34):1034-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11020872", "known-action": "unknown", "polypeptide": {"@id": "P05164", "@source": "Swiss-Prot", "name": "Myeloperoxidase", "general-function": "Involved in peroxidase activity", "specific-function": "Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity", "gene-name": "MPO", "locus": "17q23.1", "cellular-location": "Lysosome", "transmembrane-regions": "None", "signal-regions": null, "theoretical-pi": "9.14", "molecular-weight": "83870.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:7218"}, {"resource": "GenAtlas", "identifier": "MPO"}, {"resource": "GeneCards", "identifier": "MPO"}, {"resource": "GenBank Gene Database", "identifier": "J02694"}, {"resource": "GenBank Protein Database", "identifier": "189040"}, {"resource": "UniProtKB", "identifier": "P05164"}, {"resource": "UniProt Accession", "identifier": "PERM_HUMAN"}]}, "synonyms": {"synonym": ["EC 1.11.1.7", "MPO", "Myeloperoxidase precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Myeloperoxidase precursor\nMGVPFFSSLRCMVDLGPCWAGGLTAEMKLLLALAGLLAILATPQPSEGAAPAVLGEVDTS\nLVLSSMEEAKQLVDKAYKERRESIKQRLRSGSASPMELLSYFKQPVAATRTAVRAADYLH\nVALDLLERKLRSLWRRPFNVTDVLTPAQLNVLSKSSGCAYQDVGVTCPEQDKYRTITGMC\nNNRRSPTLGASNRAFVRWLPAEYEDGFSLPYGWTPGVKRNGFPVALARAVSNEIVRFPTD\nQLTPDQERSLMFMQWGQLLDHDLDFTPEPAARASFVTGVNCETSCVQQPPCFPLKIPPND\nPRIKNQADCIPFFRSCPACPGSNITIRNQINALTSFVDASMVYGSEEPLARNLRNMSNQL\nGLLAVNQRFQDNGRALLPFDNLHDDPCLLTNRSARIPCFLAGDTRSSEMPELTSMHTLLL\nREHNRLATELKSLNPRWDGERLYQEARKIVGAMVQIITYRDYLPLVLGPTAMRKYLPTYR\nSYNDSVDPRIANVFTNAFRYGHTLIQPFMFRLDNRYQPMEPNPRVPLSRVFFASWRVVLE\nGGIDPILRGLMATPAKLNRQNQIAVDEIRERLFEQVMRIGLDLPALNMQRSRDHGLPGYN\nAWRRFCGLPQPETVGQLGTVLRNLKLARKLMEQYGTPNNIDIWMGGVSEPLKRKGRVGPL\nLACIIGTQFRKLRDGDRFWWENEGVFSMQQRQALAQISLPRIICDNTGITTVSKNNIFMS\nNSYPRDFVNCSTLPALNLASWREAS"}, "gene-sequence": {"@format": "FASTA", "#text": ">2238 bp\nATGGGGGTTCCCTTCTTCTCTTCTCTCAGATGCATGGTGGACTTAGGACCTTGCTGGGCT\nGGGGGTCTCACTGCAGAGATGAAGCTGCTTCTGGCCCTAGCAGGGCTCCTGGCCATTCTG\nGCCACGCCCCAGCCCTCTGAAGGTGCTGCTCCAGCTGTCCTGGGGGAGGTGGACACCTCG\nTTGGTGCTGAGCTCCATGGAGGAGGCCAAGCAGCTGGTGGACAAGGCCTACAAGGAGCGG\nCGGGAAAGCATCAAGCAGCGGCTTCGCAGCGGCTCAGCCAGCCCCATGGAACTCCTATCC\nTACTTCAAGCAGCCGGTGGCAGCCACCAGGACGGCGGTGAGGGCCGCTGACTACCTGCAC\nGTGGCTCTAGACCTGCTGGAGAGGAAGCTGCGGTCCCTGTGGCGAAGGCCATTCAATGTC\nACTGATGTGCTGACGCCCGCCCAGCTGAATGTGTTGTCCAAGTCAAGCGGCTGCGCCTAC\nCAGGACGTGGGGGTGACTTGCCCGGAGCAGGACAAATACCGCACCATCACCGGGATGTGC\nAACAACAGACGCAGCCCCACGCTGGGGGCCTCCAACCGTGCCTTTGTGCGCTGGCTGCCG\nGCGGAGTATGAGGACGGCTTCTCTCTTCCCTACGGCTGGACGCCCGGGGTCAAGCGCAAC\nGGCTTCCCGGTGGCTCTGGCTCGCGCGGTCTCCAACGAGATCGTGCGCTTCCCCACTGAT\nCAGCTGACTCCGGACCAGGAGCGCTCACTCATGTTCATGCAATGGGGCCAGCTGTTGGAC\nCACGACCTCGACTTCACCCCTGAGCCGGCCGCCCGGGCCTCCTTCGTCACTGGCGTCAAC\nTGCGAGACCAGCTGCGTTCAGCAGCCGCCCTGCTTCCCGCTCAAGATCCCGCCCAATGAC\nCCCCGCATCAAGAACCAAGCCGACTGCATCCCGTTCTTCCGCTCCTGCCCGGCTTGCCCC\nGGGAGCAACATCACCATCCGCAACCAGATCAACGCGCTCACTTCCTTCGTGGACGCCAGC\nATGGTGTACGGCAGCGAGGAGCCCCTGGCCAGGAACCTGCGCAACATGTCCAACCAGCTG\nGGGCTGCTGGCCGTCAACCAGCGCTTCCAAGACAACGGCCGGGCCCTGCTGCCCTTTGAC\nAACCTGCACGATGACCCCTGTCTCCTCACCAACCGCTCAGCGCGCATCCCCTGCTTCCTG\nGCAGGGGACACCCGTTCCAGTGAGATGCCCGAGCTCACCTCCATGCACACCCTCTTACTT\nCGGGAGCACAACCGGCTGGCCACAGAGCTCAAGAGCCTGAACCCTAGGTGGGATGGGGAG\nAGGCTCTACCAGGAAGCCCGGAAGATCGTGGGGGCCATGGTCCAGATCATCACTTACCGG\nGACTACCTGCCCCTGGTGCTGGGGCCAACGGCCATGAGGAAGTACCTGCCCACGTACCGT\nTCCTACAATGACTCAGTGGACCCACGCATCGCCAACGTCTTCACCAATGCCTTCCGCTAC\nGGCCACACCCTCATCCAACCCTTCATGTTCCGCCTGGACAATCGGTACCAGCCCATGGAA\nCCCAACCCCCGTGTCCCCCTCAGCAGGGTCTTTTTTGCCTCCTGGAGGGTCGTGCTGGAA\nGGTGGCATTGACCCCATCCTCCGGGGCCTCATGGCCACCCCTGCCAAGCTGAATCGTCAG\nAACCAAATTGCAGTGGATGAGATCCGGGAGCGATTGTTTGAGCAGGTCATGAGGATTGGG\nCTGGACCTGCCTGCTCTGAACATGCAGCGCAGCAGGGACCACGGCCTCCCAGGATACAAT\nGCCTGGAGGCGCTTCTGTGGGCTCCCGCAGCCTGAAACTGTGGGCCAGCTGGGCACGGTG\nCTGAGGAACCTGAAATTGGCGAGGAAACTGATGGAGCAGTATGGCACGCCCAACAACATC\nGACATCTGGATGGGCGGCGTGTCCGAGCCTCTGAAGCGCAAAGGCCGCGTGGGCCCACTC\nCTCGCCTGCATCATCGGTACCCAGTTCAGGAAGCTCCGGGATGGTGATCGGTTTTGGTGG\nGAGAACGAGGGTGTGTTCAGCATGCAGCAGCGACAGGCCCTGGCCCAGATCTCATTGCCC\nCGGATCATCTGCGACAACACAGGCATCACCACCGTGTCTAAGAACAACATCTTCATGTCC\nAACTCATATCCCCGGGACTTTGTCAACTGCAGTACACTTCCTGCATTGAACCTGGCTTCC\nTGGAGGGAAGCCTCCTAG"}, "pfams": {"pfam": {"identifier": "PF03098", "name": "An_peroxidase"}}, "go-classifiers": {"go-classifier": [{"category": "function", "description": "antioxidant activity"}, {"category": "function", "description": "peroxidase activity"}, {"category": "process", "description": "cellular metabolism"}, {"category": "process", "description": "oxygen and reactive oxygen species metabolism"}, {"category": "process", "description": "response to oxidative stress"}, {"category": "process", "description": "physiological process"}, {"category": "process", "description": "metabolism"}]}}, "inhibition-strength": "unknown", "induction-strength": "unknown"}}, "carriers": null, "transporters": null}, {"@type": "biotech", "@created": "2005-06-13", "@updated": "2010-09-29", "drugbank-id": [{"@primary": "true", "#text": "DB00105"}, "BIOD00066", "BTD00066"], "name": "Interferon Alfa-2b, Recombinant", "description": "Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.", "cas-number": "99210-65-8", "groups": {"group": "approved"}, "general-references": "# Radhakrishnan R, Walter LJ, Hruza A, Reichert P, Trotta PP, Nagabhushan TL, Walter MR: Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography. Structure. 1996 Dec 15;4(12):1453-63. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8994971", "synthesis-reference": null, "indication": "For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.", "pharmacodynamics": "Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.", "mechanism-of-action": "Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which upon dimerization activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.", "toxicity": "There is limited experience with overdosage. Postmarketing surveillance includes reports of patients receiving a single dose as great as 10 times the recommended dose. In general, the primary effects of an overdose are consistent with the effects seen with therapeutic doses of interferon alfa-2b. Hepatic enzyme abnormalities, renal failure, hemorrhage, and myocardial infarction have been reported with single administration overdoses and/or with longer durations of treatment than prescribed. Toxic effects after ingestion of interferon alfa-2b are not expected because interferons are poorly absorbed orally.", "metabolism": null, "absorption": "Absorption is high (greater than 80%) when administered intramuscularly or subcutaneously.", "half-life": "The elimination half-life following both intramuscular and subcutaneous injections was approximately 2 to 3 hours. The elimination half-life was approximately 2 hours following intravenous injection.", "protein-binding": null, "route-of-elimination": null, "volume-of-distribution": null, "clearance": null, "classification": {"description": null, "direct-parent": "Peptides", "kingdom": "Organic Compounds", "superclass": "Organic Acids", "class": "Carboxylic Acids and Derivatives", "subclass": "Amino Acids, Peptides, and Analogues"}, "salts": null, "synonyms": {"synonym": [{"@language": "", "@coder": "", "#text": "Interferon alfa-2b"}, {"@language": "", "@coder": "", "#text": "rIFN-alpha-2b"}]}, "products": {"product": [{"name": "Intron A", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02223406", "started-marketing-on": "1997-03-12", "ended-marketing-on": null, "dosage-form": "liquid; powder for solution", "strength": "10000000 unit", "route": "intralesional; intramuscular; intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Intron A", "ndc-id": "0085-1133_a9acbb0a-5c41-4bc4-a158-c2c911e0f30a", "ndc-product-code": "0085-1133", "dpd-id": null, "started-marketing-on": "1986-06-04", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "19.2 ug/.5mL", "route": "intralesional; intramuscular; subcutaneous", "fda-application-number": "BLA103132", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Intron A", "ndc-id": "0085-1168_a9acbb0a-5c41-4bc4-a158-c2c911e0f30a", "ndc-product-code": "0085-1168", "dpd-id": null, "started-marketing-on": "1986-06-04", "ended-marketing-on": null, "dosage-form": "injection, solution", "strength": "11.6 ug/.5mL", "route": "intramuscular; subcutaneous", "fda-application-number": "BLA103132", "generic": "false", "over-the-counter": "false", "approved": "true", "country": "US", "source": "FDA NDC"}, {"name": "Intron A", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02231651", "started-marketing-on": "1998-03-11", "ended-marketing-on": null, "dosage-form": "kit; liquid; powder for solution", "strength": "18 miu", "route": "intralesional; intramuscular; intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Intron A", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02238674", "started-marketing-on": "1998-12-10", "ended-marketing-on": null, "dosage-form": "solution", "strength": "6000000 unit", "route": "intramuscular; intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Intron A", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02238675", "started-marketing-on": "1998-12-10", "ended-marketing-on": null, "dosage-form": "solution", "strength": "10000000 unit", "route": "intramuscular; intravenous; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Intron A", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02240693", "started-marketing-on": "1999-09-23", "ended-marketing-on": null, "dosage-form": "liquid", "strength": "15000000 unit", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Intron A", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02240694", "started-marketing-on": "1999-09-23", "ended-marketing-on": null, "dosage-form": "liquid", "strength": "25000000 unit", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Intron A", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02240695", "started-marketing-on": "1999-09-23", "ended-marketing-on": null, "dosage-form": "liquid", "strength": "50000000 unit", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Intron A - Kit (pws+diluent) 3000000iu/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02223384", "started-marketing-on": "1997-04-08", "ended-marketing-on": "2000-07-11", "dosage-form": "liquid; powder for solution", "strength": "3000000 unit", "route": "intralesional; intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Intron A - Kit (pws+diluent) 5000000iu/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02223392", "started-marketing-on": "1998-12-31", "ended-marketing-on": "2000-07-11", "dosage-form": "liquid; powder for solution", "strength": "5000000 unit", "route": "intralesional; intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Intron A - Liq 5000000iu/ml", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02223414", "started-marketing-on": "1997-09-25", "ended-marketing-on": "2001-07-18", "dosage-form": "liquid", "strength": "5000000 unit", "route": "intralesional; intramuscular; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Intron A Inj 10000000unit/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00705926", "started-marketing-on": "1986-12-31", "ended-marketing-on": "1999-07-22", "dosage-form": "liquid", "strength": "10000000 unit", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Intron A Inj 3000000unit/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00705896", "started-marketing-on": "1986-12-31", "ended-marketing-on": "1999-07-22", "dosage-form": "liquid", "strength": "3000000 unit", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Intron A Inj 5000000unit/vial", "ndc-id": null, "ndc-product-code": null, "dpd-id": "00705918", "started-marketing-on": "1986-12-31", "ended-marketing-on": "1999-07-22", "dosage-form": "liquid", "strength": "5000000 unit", "route": "subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Rebetron Ready To Use Solution (albumin(human)free) (6000000 Iu/ml and 200mg Capsules)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02239730", "started-marketing-on": "1999-03-31", "ended-marketing-on": "2004-10-27", "dosage-form": "kit; liquid; capsule", "strength": "6000000 unit", "route": "oral; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}, {"name": "Rebetron Solution (albumin (human) Free) (18 Miu Multi-dose Pen / 200mg Capsules)", "ndc-id": null, "ndc-product-code": null, "dpd-id": "02241159", "started-marketing-on": "1999-12-23", "ended-marketing-on": "2004-10-27", "dosage-form": "kit; liquid; capsule", "strength": "15000000 unit", "route": "oral; subcutaneous", "fda-application-number": null, "generic": "false", "over-the-counter": "false", "approved": "true", "country": "Canada", "source": "DPD"}]}, "international-brands": null, "mixtures": {"mixture": [{"name": "Intron A", "ingredients": "Interferon Alfa-2b, Recombinant"}, {"name": "Intron A", "ingredients": "Interferon Alfa-2b, Recombinant"}, {"name": "Intron A", "ingredients": "Interferon Alfa-2b, Recombinant + Water"}, {"name": "Intron A", "ingredients": "Interferon Alfa-2b, Recombinant + Water"}, {"name": "Intron A", "ingredients": "Interferon Alfa-2b, Recombinant"}, {"name": "Intron A", "ingredients": "Interferon Alfa-2b, Recombinant"}, {"name": "Intron A", "ingredients": "Interferon Alfa-2b, Recombinant"}, {"name": "Intron A", "ingredients": "Interferon Alfa-2b, Recombinant"}, {"name": "Intron A", "ingredients": "Interferon Alfa-2b, Recombinant"}, {"name": "Intron A - Kit (pws+diluent) 3000000iu/vial", "ingredients": "Interferon Alfa-2b, Recombinant + Water"}, {"name": "Intron A - Kit (pws+diluent) 5000000iu/vial", "ingredients": "Interferon Alfa-2b, Recombinant + Water"}, {"name": "Intron A - Liq 5000000iu/ml", "ingredients": "Interferon Alfa-2b, Recombinant"}, {"name": "Rebetron Ready To Use Solution (albumin(human)free) (6000000 Iu/ml and 200mg Capsules)", "ingredients": "Interferon Alfa-2b, Recombinant + Ribavirin"}, {"name": "Rebetron Solution (albumin (human) Free) (18 Miu Multi-dose Pen / 200mg Capsules)", "ingredients": "Interferon Alfa-2b, Recombinant + Ribavirin"}, {"name": "Intron A Inj 3000000unit/vial", "ingredients": "Interferon Alfa-2b, Recombinant"}, {"name": "Intron A Inj 5000000unit/vial", "ingredients": "Interferon Alfa-2b, Recombinant"}, {"name": "Intron A Inj 10000000unit/vial", "ingredients": "Interferon Alfa-2b, Recombinant"}]}, "packagers": {"packager": [{"name": "Physicians Total Care Inc.", "url": "http://www.physicianstotalcare.com"}, {"name": "Schering Corp.", "url": "http://www.schering.de"}, {"name": "Schering-Plough Inc.", "url": "http://www.schering-plough.ca"}]}, "manufacturers": null, "prices": {"price": [{"description": "Intron a 3 million unit/ml pen", "cost": {"@currency": "USD", "#text": "394.21"}, "unit": "pen"}, {"description": "Intron a 5 million unit/ml pen", "cost": {"@currency": "USD", "#text": "657.06"}, "unit": "pen"}, {"description": "Intron-A 5000000 unit/0.2ml Kit Box", "cost": {"@currency": "USD", "#text": "683.34"}, "unit": "box"}, {"description": "Intron a 10 million unit pen", "cost": {"@currency": "USD", "#text": "1068.12"}, "unit": "pen"}, {"description": "Intron-A 10000000 unit/0.2ml Kit (each Box Contains One 6 Dose 1.5ml Pen)", "cost": {"@currency": "USD", "#text": "1110.84"}, "unit": "box"}]}, "categories": {"category": {"category": "Immunosuppressive Agents", "mesh-id": null}}, "affected-organisms": {"affected-organism": "Humans and other mammals"}, "dosages": {"dosage": [{"form": "Injection, solution", "route": "intralesional; intramuscular; subcutaneous", "strength": "19.2 ug/.5mL"}, {"form": "Injection, solution", "route": "intramuscular; subcutaneous", "strength": "11.6 ug/.5mL"}, {"form": "Kit; liquid; powder for solution", "route": "intralesional; intramuscular; intravenous; subcutaneous", "strength": "18 miu"}, {"form": "Liquid", "route": "subcutaneous", "strength": "15000000 unit"}, {"form": "Liquid", "route": "subcutaneous", "strength": "25000000 unit"}, {"form": "Liquid", "route": "subcutaneous", "strength": "50000000 unit"}, {"form": "Liquid; powder for solution", "route": "intralesional; intramuscular; intravenous; subcutaneous", "strength": "10000000 unit"}, {"form": "Solution", "route": "intramuscular; intravenous; subcutaneous", "strength": "10000000 unit"}, {"form": "Solution", "route": "intramuscular; intravenous; subcutaneous", "strength": "6000000 unit"}, {"form": "Liquid; powder for solution", "route": "intralesional; intramuscular; subcutaneous", "strength": "3000000 unit"}, {"form": "Liquid; powder for solution", "route": "intralesional; intramuscular; subcutaneous", "strength": "5000000 unit"}, {"form": "Liquid", "route": "intralesional; intramuscular; subcutaneous", "strength": "5000000 unit"}, {"form": "Liquid", "route": "subcutaneous", "strength": "10000000 unit"}, {"form": "Liquid", "route": "subcutaneous", "strength": "3000000 unit"}, {"form": "Liquid", "route": "subcutaneous", "strength": "5000000 unit"}, {"form": "Kit; liquid; capsule", "route": "oral; subcutaneous", "strength": "6000000 unit"}, {"form": "Kit; liquid; capsule", "route": "oral; subcutaneous", "strength": "15000000 unit"}]}, "atc-codes": {"atc-code": {"@code": "L03AB05", "level": [{"@code": "L", "#text": "ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS"}, {"@code": "L03", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03A", "#text": "IMMUNOSTIMULANTS"}, {"@code": "L03AB", "#text": "Interferons"}]}}, "ahfs-codes": {"ahfs-code": "08:18.20"}, "patents": {"patent": [{"number": "1341567", "country": "Canada", "approved": "2008-02-19", "expires": "2025-02-19"}, {"number": "2201749", "country": "Canada", "approved": "1999-06-15", "expires": "2015-10-10"}]}, "food-interactions": {"food-interaction": "Avoid alcohol."}, "drug-interactions": {"drug-interaction": {"drugbank-id": "DB01265", "name": "Telbivudine", "description": "May enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased."}}, "sequences": {"sequence": {"@format": "FASTA", "#text": ">DB00105 sequence\nCDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI\nQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVR\nKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE"}}, "experimental-properties": {"property": [{"kind": "Melting Point", "value": "61 \u00b0C", "source": "Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)"}, {"kind": "Hydrophobicity", "value": "-0.339", "source": null}, {"kind": "Isoelectric Point", "value": "5.99", "source": null}, {"kind": "Molecular Weight", "value": "19271.0000", "source": null}, {"kind": "Molecular Formula", "value": "C860H1353N229O255S9", "source": null}]}, "external-identifiers": {"external-identifier": [{"resource": "Drugs Product Database (DPD)", "identifier": "1751"}, {"resource": "National Drug Code Directory", "identifier": "0085-0571-02"}, {"resource": "PharmGKB", "identifier": "PA164783990"}, {"resource": "UniProtKB", "identifier": "P01563"}]}, "external-links": {"external-link": {"resource": "RxList", "url": "http://www.rxlist.com/cgi/generic/introna.htm"}}, "pathways": null, "reactions": null, "snp-effects": null, "snp-adverse-drug-reactions": null, "targets": {"target": [{"id": "BE0000385", "name": "Interferon alpha/beta receptor 2", "organism": "Human", "actions": {"action": "binder"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Eid P, Tovey MG: Characterization of a domain of a human type I interferon receptor protein involved in ligand binding. J Interferon Cytokine Res. 1995 Mar;15(3):205-11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7584665\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P48551", "@source": "Swiss-Prot", "name": "Interferon alpha/beta receptor 2", "general-function": "Involved in interferon-alpha/beta receptor activity", "specific-function": "Receptor for interferons alpha and beta. Isoform 1 and isoform 3 are directly involved in signal transduction due to their interaction with the TYR kinase, JAK1. Isoform 1 also interacts with the transcriptional factors, STAT1 and STAT2. Both forms are potent inhibitors of type I IFN activity", "gene-name": "IFNAR2", "locus": null, "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "244-264", "signal-regions": null, "theoretical-pi": "4.11", "molecular-weight": "57759.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5433"}, {"resource": "GenAtlas", "identifier": "IFNAR2"}, {"resource": "GeneCards", "identifier": "IFNAR2"}, {"resource": "GenBank Gene Database", "identifier": "L42243"}, {"resource": "GenBank Protein Database", "identifier": "995300"}, {"resource": "UniProtKB", "identifier": "P48551"}, {"resource": "UniProt Accession", "identifier": "INAR2_HUMAN"}]}, "synonyms": {"synonym": ["IFN-alpha-REC", "IFN-R", "Interferon alpha/beta receptor 2", "Interferon-alpha/beta receptor beta chain precursor", "Type I interferon receptor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interferon-alpha/beta receptor beta chain precursor\nMLLSQNAFIFRSLNLVLMVYISLVFGISYDSPDYTDESCTFKISLRNFRSILSWELKNHS\nIVPTHYTLLYTIMSKPEDLKVVKNCANTTRSFCDLTDEWRSTHEAYVTVLEGFSGNTTLF\nSCSHNFWLAIDMSFEPPEFEIVGFTNHINVMVKFPSIVEEELQFDLSLVIEEQSEGIVKK\nHKPEIKGNMSGNFTYIIDKLIPNTNYCVSVYLEHSDEQAVIKSPLKCTLLPPGQESESAE\nSAKIGGIITVFLIALVLTSTIVTLKWIGYICLRNSLPKVLNFHNFLAWPFPNLPPLEAMD\nMVEVIYINRKKKVWDYNYDDESDSDTEAAPRTSGGGYTMHGLTVRPLGQASATSTESQLI\nDPESEEEPDLPEVDVELPTMPKDSPQQLELLSGPCERRKSPLQDPFPEEDYSSTEGSGGR\nITFNVDLNSVFLRVLDDEDSDDLEAPLMLSSHLEEMVDPEDPDNVQSNHLLASGEGTQPT\nFPSPSSEGLWSEDAPSDQSDTSESDVDLGDGYIMR"}, "gene-sequence": {"@format": "FASTA", "#text": ">1548 bp\nATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTAT\nATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACT\nTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCC\nATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAG\nGTGGTTAAGAACTGTGCAAATACCACAAGATCATTTTGTGACCTCACAGATGAGTGGAGA\nAGCACACACGAGGCCTATGTCACCGTCCTAGAAGGATTCAGCGGGAACACAACGTTGTTC\nAGTTGCTCACACAATTTCTGGCTGGCCATAGACATGTCTTTTGAACCACCAGAGTTTGAG\nATTGTTGGTTTTACCAACCACATTAATGTGATGGTGAAATTTCCATCTATTGTTGAGGAA\nGAATTACAGTTTGATTTATCTCTCGTCATTGAAGAACAGTCAGAGGGAATTGTTAAGAAG\nCATAAACCCGAAATAAAAGGAAACATGAGTGGAAATTTCACCTATATCATTGACAAGTTA\nATTCCAAACACGAACTACTGTGTATCTGTTTATTTAGAGCACAGTGATGAGCAAGCAGTA\nATAAAGTCTCCCTTAAAATGCACCCTCCTTCCACCTGGCCAGGAATCAGAATCAGCAGAA\nTCTGCCAAAATAGGAGGAATAATTACTGTGTTTTTGATAGCATTGGTCTTGACAAGCACC\nATAGTGACACTGAAATGGATTGGTTATATATGCTTAAGAAATAGCCTCCCCAAAGTCTTG\nAATTTTCATAACTTTTTAGCCTGGCCATTTCCTAACCTGCCACCGTTGGAAGCCATGGAT\nATGGTGGAGGTCATTTACATCAACAGAAAGAAGAAAGTGTGGGATTATAATTATGATGAT\nGAAAGTGATAGCGATACTGAGGCAGCGCCCAGGACAAGTGGCGGTGGCTATACCATGCAT\nGGACTGACTGTCAGGCCTCTGGGTCAGGCCTCTGCCACCTCTACAGAATCCCAGTTGATA\nGACCCGGAGTCCGAGGAGGAGCCTGACCTGCCTGAGGTTGATGTGGAGCTCCCCACGATG\nCCAAAGGACAGCCCTCAGCAGTTGGAACTCTTGAGTGGGCCCTGTGAGAGGAGAAAGAGT\nCCACTCCAGGACCCTTTTCCCGAAGAGGACTACAGCTCCACGGAGGGGTCTGGGGGCAGA\nATTACCTTCAATGTGGACTTAAACTCTGTGTTTTTGAGAGTTCTTGATGACGAGGACAGT\nGACGACTTAGAAGCCCCTCTGATGCTATCGTCTCATCTGGAAGAGATGGTTGACCCAGAG\nGATCCTGATAATGTGCAATCAAACCATTTGCTGGCCAGCGGGGAAGGGACACAGCCAACC\nTTTCCCAGCCCCTCTTCAGAGGGCCTGTGGTCCGAAGATGCTCCATCTGATCAAAGTGAC\nACTTCTGAGTCAGATGTTGACCTTGGGGATGGTTATATAATGAGATGA"}, "pfams": null, "go-classifiers": null}}, {"id": "BE0000661", "name": "Interferon alpha/beta receptor 1", "organism": "Human", "actions": {"action": "binder"}, "references": "# Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17139284\n# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17016423\n# Khine AA, Lingwood CA: Functional significance of globotriaosyl ceramide in interferon-alpha(2)/type 1 interferon receptor-mediated antiviral activity. J Cell Physiol. 2000 Jan;182(1):97-108. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10567921\n# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11752352", "known-action": "yes", "polypeptide": {"@id": "P17181", "@source": "Swiss-Prot", "name": "Interferon alpha/beta receptor 1", "general-function": "Involved in interferon-alpha/beta receptor activity", "specific-function": "Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta- subunits themselves", "gene-name": "IFNAR1", "locus": null, "cellular-location": "Membrane; single-pass type I membrane protein", "transmembrane-regions": "437-457", "signal-regions": null, "theoretical-pi": "5.56", "molecular-weight": "63526.0", "chromosome-location": null, "organism": {"@ncbi-taxonomy-id": "9606", "#text": "Human"}, "external-identifiers": {"external-identifier": [{"resource": "HUGO Gene Nomenclature Committee (HGNC)", "identifier": "HGNC:5432"}, {"resource": "GenAtlas", "identifier": "IFNAR1"}, {"resource": "GeneCards", "identifier": "IFNAR1"}, {"resource": "GenBank Gene Database", "identifier": "J03171"}, {"resource": "GenBank Protein Database", "identifier": "306914"}, {"resource": "UniProtKB", "identifier": "P17181"}, {"resource": "UniProt Accession", "identifier": "INAR1_HUMAN"}]}, "synonyms": {"synonym": ["IFN-alpha-REC", "Interferon-alpha/beta receptor alpha chain precursor"]}, "amino-acid-sequence": {"@format": "FASTA", "#text": ">Interferon-alpha/beta receptor alpha chain precursor\nMMVVLLGATTLVLVAVAPWVLSAAAGGKNLKSPQKVEVDIIDDNFILRWNRSDESVGNVT\nFSFDYQKTGMDNWIKLSGCQNITSTKCNFSSLKLNVYEEIKLRIRAEKENTSSWYEVDSF\nTPFRKAQIGPPEVHLEAEDKAIVIHISPGTKDSVMWALDGLSFTYSLVIWKNSSGVEERI\nENIYSRHKIYKLSPETTYCLKVKAALLTSWKIGVYSPVHCIKTTVENELPPPENIEVSVQ\nNQNYVLKWDYTYANMTFQVQWLHAFLKRNPGNHLYKWKQIPDCENVKTTQCVFPQNVFQK\nGIYLLRVQASDGNNTSFWSEEIKFDTEIQAFLLPPVFNIRSLSDSFHIYIGAPKQSGNTP\nVIQDYPLIYEIIFWENTSNAERKIIEKKTDVTVPNLKPLTVYCVKARAHTMDEKLNKSSV\nFSDAVCEKTKPGNTSKIWLIVGICIALFALPFVIYAAKVFLRCINYVFFPSLKPSSSIDE\nYFSEQPLKNLLLSTSEEQIEKCFIIENISTIATVEETNQTDEDHKKYSSQTSQDSGNYSN\nEDESESKTSEELQQDFV"}, "gene-sequence": {"@format": "FASTA", "#text": ">1674 bp\nATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGGCCCATGGGTG\nTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATC\nATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACT\nTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAG\nAATATTACTAGTACCAAATGCAACTTTTCTTCACTCAAGCTGAATGTTTATGAAGAAATT\nAAATTGCGTATAAGAGCAGAAAAAGAAAACACTTCTTCATGGTATGAGGTTGACTCATTT\nACACCATTTCGCAAAGCTCAGATTGGTCCTCCAGAAGTACATTTAGAAGCTGAAGATAAG\nGCAATAGTGATACACATCTCTCCTGGAACAAAAGATAGTGTTATGTGGGCTTTGGATGGT\nTTAAGCTTTACATATAGCTTACTTATCTGGAAAAACTCTTCAGGTGTAGAAGAAAGGATT\nGAAAATATTTATTCCAGACATAAAATTTATAAACTCTCACCAGAGACTACTTATTGTCTA\nAAAGTTAAAGCAGCACTACTTACGTCATGGAAAATTGGTGTCTATAGTCCAGTACATTGT\nATAAAGACCACAGTTGAAAATGAACTACCTCCACCAGAAAATATAGAAGTCAGTGTCCAA\nAATCAGAACTATGTTCTTAAATGGGATTATACATATGCAAACATGACCTTTCAAGTTCAG\nTGGCTCCACGCCTTTTTAAAAAGGAATCCTGGAAACCATTTGTATAAATGGAAACAAATA\nCCTGACTGTGAAAATGTCAAAACTACCCAGTGTGTCTTTCCTCAAAACGTTTTCCAAAAA\nGGAATTTACCTTCTCCGCGTACAAGCATCTGATGGAAATAACACATCTTTTTGGTCTGAA\nGAGATAAAGTTTGATACTGAAATACAAGCTTTCCTACTTCCTCCAGTCTTTAACATTAGA\nTCCCTTAGTGATTCATTCCATATCTATATCGGTGCTCCAAAACAGTCTGGAAACACGCCT\nGTGATCCAGGATTATCCACTGATTTATGAAATTATTTTTTGGGAAAACACTTCAAATGCT\nGAGAGAAAAATTATCGAGAAAAAAACTGATGTTACAGTTCCTAATTTGAAACCACTGACT\nGTATATTGTGTGAAAGCCAGAGCACACACCATGGATGAAAAGCTGAATAAAAGCAGTGTT\nTTTAGTGACGCTGTATGTGAGAAAACAAAACCAGGAAATACCTCTAAAATTTGGCTTATA\nGTTGGAATTTGTATTGCATTATTTGCTCTCCCGTTTGTCATTTATGCTGCGAAAGTCTTC\nTTGAGATGCATCAATTATGTCTTCTTTCCATCACTTAAACCTTCTTCCAGTATAGATGAG\nTATTTCTCTGAACAGCCATTGAAGAATCTTCTGCTTTCAACTTCTGAGGAACAAATCGAA\nAAATGTTTCATAATTGAAAATATAAGCACAATTGCTACAGTAGAAGAAACTAATCAAACT\nGATGAAGATCATAAAAAATACAGTTCCCAAACTAGCCAAGATTCAGGAAATTATTCTAAT\nGAAGATGAAAGCGAAAGTAAAACAAGTGAAGAACTACAGCAGGACTTTGTATGA"}, "pfams": null, "go-classifiers": null}}]}, "enzymes": null, "carriers": null, "transporters": null}]}}